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AMR in Gram-negatives
P553 Prevalence and molecular epidemiology of infections
caused by extended-spectrum and plasmid-mediated AmpC
b-lactamase producing Gram-negative bacteria in hospital
and community settings in Bosnia and Herzegovina
S. Uzunovic;-Kamberovic, A. Ibrahimagic*, B. Bedenic, F. Kamberovic,
T. Ille, S. Sivec, Zˇ. Zˇagar (Zenica, Travnik, Zenica, BA; Zagreb, HR;
Ljubljana, SI; Belgrade, RS)
Objectives: To investigate the prevalence of extended-spectrum
b-lactamase (ESBL) in Gram-negative bacteria obtained from various
clinical specimens of inpatients (from various departments, n = 247)
and outpatients (n = 265) in Cantonal Hospital Zenica, Bosnia and
Herzegovina during 2009.
Methods: Double-disk synergy test was used to detect ESBLs.
Minimum inihibitory concentrations (MICs) were determined by
broth microdilution method according to CLSI. The transferability of
ceftazidime resistance was tested by conjugation (broth mating method).
PCR was used to detect alleles encoding ESBL enzymes.
Results: ESBL was detected in 168 (68%) and 246 (93%) in- and
outpatient samples, respectively. ESBL prevalence was highest in non-
surgical departments, 59 (35%, p = 0.000). Both in- and outpatient
ESBLs were mostly isolated from urine and surgical wounds, 29%
and 78%, 27% and 14%, respectively. ESBL/non-ESBL prevalence was
highest in an inpatient Klebsiella spp. and in outpatient Escherichia
coli isolates, 36%/41% and 34%/42%, respectively. Inpatient urinary
isolates were more resistant to all antibiotic tested than outpatient
ones. Inpatient surgical wound isolates were more resistant to all
cephalosporins than outpatient ones, but lower to other antibiotics.
Cefuroxime, ceftazidime and cefotaxime were the least potent antibiotics
with MIC90 of 256mg/L. Forty nine (33.6%) of all isolates had
plasmid-mediated ampC ESBL by phenylboronic acid phenotypic test.
Conjugation frequency was in the range 10−4−10−7. Resistance to
gentamicin, chloramphenicol, sulphamethoxazole, trimethoprim and
tetracycline in most cases were co transferred alongside with cefotaxime
resistance. Thirty four of inpatient urine isolates yielded amplicons with
primers speciﬁc for TEM, and 33 were positive for CTX-M ESBL.
Multiplex PCR revealed group 1 of CTX-M b-lactamases. PCR reactions
with SHV-speciﬁc primers were positive for K. pneumoniae indicating
the presence of intrinsic SHV-1 ESBL. Twenty-one strains had both,
CTX-M combined with TEM type of ESBL.
Conclusion: The study demonstrated high prevalence of CTX-M
b-lactamase in an inpatient urinary isolates associated with high level
of resistance to cefotaxime and ceftriaxone. High resistance rates
observed for gentamicin and ciproﬂoxacin probably due to the fact that
plasmids encoding ESBLs also contain resistance genes for non b-lactam
antibiotics.
P554 High rates of multidrug resistance among Gram-negative
pathogens in Europe. Results from GLOBAL 6 Surveillance
(2009–2010)
C. Pillar*, J. Deane, D.F. Sahm (Chantilly, US)
Objective: The emergence and spread of b-lactamases and the
prevalence of multi-drug resistance (MDR) among Gram-negative
organisms has complicated selection of an appropriate empiric therapy.
Data from surveillance is useful for monitoring the activity of current
agents, and for any change in activity patterns as a result of emergence
or spread of resistance. Given the clinical impact of resistance among
Gram-negatives, this study evaluates resistance among common agents
for Enterobacteriaceae (EB), P. aeruginosa (PA), and Acinetobacter spp.
(AS) collected across Europe as part of the GLOBAL surveillance
initiative, both current resistance (2009–2010).
Methods: During GLOBAL 6 (2009–2010), clinical isolates of EB, PA
and AS from Belgium, France, Italy, Germany, Spain, and the United
Kingdom, were centrally tested for susceptibility by broth microdilution
(CLSI M7/M100). MDR was deﬁned as resistance to >3 different classes
of antibiotic.
Results: The current activity proﬁle from GLOBAL 6 is presented in the
table below. Of all evaluated agents, sitaﬂoxacin had the lowest MIC90s,
while MIC90s of 16mg/L and higher were commonly observed for other
evaluated agents. MDR rates were 8.7% among EB, 20.1% among PA,
and 39.6% among AS. 1.4% of evaluated K. pneumoniae were imipenem
resistant based on new CLSI breakpoints. Rates of MDR and resistance
to single agents varied across evaluated countries, with the highest degree
of resistance observed in Italy.
Conclusions: MDR was common among PA and AS in Europe. Based
on the degree of resistance among Gram-negatives, it is critical to
understand current levels resistance and continue to monitor for changes
in these patterns on a regional and local level when considering an
appropriate antimicrobial chemotherapy. This data also highlights the
need for agents with strong activity against resistant Gram-negative
isolates.
P555 Antimicrobial resistance of Citrobacter spp., Enterobacter
spp. and Klebsiella spp. strains isolated from meat samples
P. Gousia, E. Economou, H. Sakkas, S. Levidiotou*, C. Papadopoulou
(Ioannina, GR)
Objectives: The aim of the present study was to assess the antimicrobial
resistance of Citrobacter spp., Enterobacter spp. and Klebsiella spp.
isolated from raw and processed meat products.
Methods: During a 5 years period (2004 and 2009) there were examined
642 samples of different types of raw meat (pork, beef, goat and lamb)
and thermally processed meat products. The samples were collected from
restaurants, supermarkets and abattoirs of the greater area of Ioannina,
in Northwestern Greece. The antimicrobial resistance of the isolated
bacterial strains was tested using the disk diffusion method according to
Bauer-Kirby.
Results: From the raw meat samples, there were isolated 122 Citrobacter
spp strains, 19 Klebsiella spp strains and 76 Enterobacter spp strains.
No pathogenic bacteria were isolated from the thermally processed
meat samples. The Citrobacter spp. strains were resistant to ampicillin
(51%), cefuroxime (47%), nitrofurantoine (40%) and tetracycline (35%).
The Enterobacter spp. strains exhibited resistance to ampicillin (67%),
carbenicilline (54%) and tetracycline (41%) and the Klebsiella spp
strains were resistant to ampicillin (84%). The most tetracycline resistant
strains were isolated from pork meat samples and the most cefuraxime
resistant strains were isolated from ruminant’s meat samples (beef, goat,
lamb). Resistance to imipenem was always intermediate for all bacterial
strains.
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Conclusion: The results indicate that meat can be a source of resistant
bacteria which could be potentially transmitted to humans via the food
chain. The high frequency of tetracycline resistance of the pork strains is
related to the extended use of this antibiotic in pig breeding and the high
frequency of cefuraxime resistance of the ruminant strains is probably
due to the extended use of cephalosporins in the ruminant breeding
farms. The low occurrences of intermediate imipenem-resistance strains
is attributed to the no use of this antibiotic in the current veterinary
practice, emphasizing the fact that the prudent use of antibiotics in farm
animals is essential to limit the spread of antibiotic resistant bacteria and
to protect public health.
P556 Comparative antibacterial activity against E. coli from
paediatric patients in North America and Europe: 2006–2009
D. Hoban, S. Bouchillon, M. Hackel*, B. Johnson, R. Badal,
J. Johnson, S. Hawser, M. Dowzicky (Schaumburg, US; Epalinges,
CH; Collegeville, US)
Background: E. coli (Ec) remains a frequent cause of both community
and hospital infections. Increasingly these isolates are multi-drug
resistant and pose therapeutic challenges especially in pediatric
populations where ﬂuoroquinolones are generally contraindicated. The
Tigecycline Evaluation Surveillance Trial (TEST) has monitored trends
in susceptibility of tigecycline and comparators globally since 2004.
This report evaluates the in vitro activity of tigecycline and comparators
to E. coli isolated from pediatric patients in North America (NA) and
Europe (EU) utilizing continent-speciﬁc breakpoints (NA:FDA/CLSI,
EU:EUCAST).
Methods: In 2006–2010 1550 Ec (NA: 702, EU: 848) were collected
in NA (Mexico, USA, Canada) and EU (26 countries). MICs
were determined using supplied microdilution panels and interpreted
according to CLSI (NA) or EUCAST (EU) breakpoints (BPs).
Results: Summary data for tigecycline and comparators (% Susceptible)
are shown by year and continent.
Conclusions: Decreased susceptibility of Ec to cefepime, ceftriaxone,
minocycline and pip-tazo in EU vs NA in some study years may reﬂect
lower susceptible BPs in EU vs NA. Detailed analysis of resistant isolates
on both continents to conﬁrm isolate distributions is needed.
P557 Increase of polymicrobial infections and multi-resistant
pathogens causing prosthetic joint infections
S. Petersdorf*, T. Hoppe, A. Hoerauf, G. Pagenstert, D. Wirtz,
M. Wimmer, S. Gravius (Bonn, DE; Basel, CH)
Objectives: Prosthetic joint infections (PJI) are a serious complication
after total joint arthroplasty. Earlier descriptions of microorganisms
causing PJI revealed Gram-positive cocci in the majority of cases
and therapy guidelines were designed accordingly. Little information is
available about changes in distribution of pathogens causing PJI in an
era of increasing antibiotic resistance.
Methods: We conducted a retrospective analysis of all patients treated
for PJI at a center for revision total hip and knee arthroplasty
between 2006 and 2008 according to a modiﬁed “Liestaler treatment
algorithm”. Diagnosis of PJI was based on operative ﬁndings, subsequent
microbiological culture and histological examination. Pathogens were
identiﬁed by intraoperative and synovial culture. Superﬁcial wound
swaps or swaps from sinus tracts were not taken into account.
Results: 147 patients with PJI (total hip arthroplasty: n = 89 (60.5%),
total knee arthroplasty n = 58 (39.5%)) were included in the study.
19% (n = 28) presented with acute PJI, 81% (n = 119) with chronic
PJI. 26 patients (17.7%) were treated with debridement and retention,
121 (82.3%) with two-stage exchange. No pathogen could be detected
in 39 patients (26.5%). One or more pathogen could be identiﬁed in
108 patients (73.5%). 55 patients (50.9%) comprised monomicrobial, 53
patients (49.1%) polymicrobial PJI. In 32 patients two pathogens were
detected, three pathogens were found in 11 patients and four or more
pathogens in 10 patients respectively. 21 polymicrobial PJI included
only Gram-positive pathogens, 1 PJI only Gram-negative pathogens,
24 PJI consisted of Gram-positive and Gram-negative pathogens, 7
included fungi additionally. CoNS (n = 63) were the most commonly
isolated pathogen (MRSE: 59%, MSSE: 41%) followed by S. aureus
(n = 45) with 64% MSSA and 36% MRSA, and by Gram-negative rods
(n = 44). Infections caused by multiresistant pathogens (n = 50) were
found signiﬁcantly more often in polymicrobial (n = 36; 67.9%) than
in monomicrobial PJI (n = 14; 25%) (p< 0.05).
Conclusion: Distribution of pathogens causing PJI varies with time
and location. Earlier descriptions of pathogens causing PJI cannot
be conferred to centers specialized in revision arthroplasty. Our data
demonstrate a much more widespread range of pathogens, including
all kinds of multiresistant bacteria and a high number of polymicrobial
infections. Existing therapy regimens need to be adapted to this
development.
P558 Emerging quinolone resistance in typhoid outbreaks caused
by haplotype H58 in Kenya
S. Kariuki*, G. Revathi, R. Kingsley, K. Holt, G. Dougan (Nairobi,
KE; Cambridge, UK)
Objectives: To conduct surveillance for antimicrobial susceptibility and
determine molecular epidemiology of typhoid outbreaks in Kenya.
Methods: We characterised a total of 323 S. Typhi isolated from
outbreaks in Kenya over the period 1988–2008 for antimicrobial
susceptibility, and phylogenetic relationship using single nucleotide
polymorphism (SNP) analysis.
Results: Only 17.9% were fully sensitive while the majority (60.5%)
were multiply-resistant (MDR) to most commonly available drugs −
ampicillin, chloramphenicol, tetracycline (MICs >256mg/ml) and co-
trimoxazole (MIC >32mg/ml). Resistance to these antibiotics was
encoded on self-transferrable IncHI1 plasmids of the ST6 sequence type.
For MDR S. Typhi MICs for nalidixic acid and ciproﬂoxacin were
respectively 5- and 10-fold higher than for sensitive strains and the
proportion of MDR strains also resistant to nalidixic acid rose by a
factor of 20 between 1994 and 2005 to make up 25% of all strains.
Genotyping by pulsed-ﬁeld gel electrophoresis (PFGE) showed that the
MDR S. Typhi strains were closely related and were different from
the fully-susceptible strains. Of the 94 representative S. Typhi selected
for genome-wide haplotype analysis sensitive isolates fell into several
phylogenetically different groups whereas MDR isolates all belonged
to a single haplotype, H58, associated with MDR and ﬂuoroquinolone
resistance which is also dominant in many parts of SE Asia.
Conclusion: With the emergence of nalidixic acid resistant S. Typhi
with elevated MICs for ciproﬂoxacin more expensive and infrequently
available third generation cephalosporins may be required to effectively
treat most typhoid outbreaks in Kenya.
P559 Multilocus sequence typing of IncN plasmids
A. Garcı´a-Ferna´ndez*, L. Villa, A. Moodley, H. Hasman, V. Miriagou,
L. Guardabassi, A. Carattoli (Rome, IT; Frederiksberg, Lyngby, DK;
Athens, GR)
Objectives: IncN plasmids have been associated to the wide dissemina-
tion of antimicrobial resistance, including relevant b-lactamases genes
such as the blaVIM-1, blaCTX-M-1 and blaKPC. A plasmid Multilocus
Sequence Typing (pMLST) was developed on the DNA sequences of 12
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fully sequenced IncN plasmids available in the Genbank and applied to
a collection of 57 IncN plasmids from 6 European countries of human,
animal and environmental origin.
Methods: Fully sequenced IncN plasmids available in the Genbank were
analyzed in silico and the repA, traJ and korA genes were selected as
loci for the IncN speciﬁc pMLST. 57 plasmids of our collections were
all assigned to the IncN group by the Plasmid-Based Replicon Typing
(PBRT) method, transferred by conjugation in a recipient E. coli strain,
analyzed for b-lactamase genes and classiﬁed by DNA sequencing of the
amplicons obtained for the repA, traJ and korA loci.
Results: The repA, traJ and korA loci sequences were analyzed for 69
IncN plasmids, 12 available in Genbank and 57 from our collections.
Eleven Sequence Types (STs) were deﬁned on the basis of the loci
sequences and allele assortment, setting up a new pMLST scheme for
typing this plasmid family. ST1 and ST2 were included in the same
clonal complex (CC-1), since plasmids belonging to these STs were
highly related differing only for one mismatch in one allele. Similarly,
ST10 and ST11 were included in the clonal complex CC-10.
Plasmids carrying the blaCTX-M-1 gene, isolated in different countries
from food producing animals and humans were all but one assigned to the
clonal complex CC-1, suggesting the wide spread of an epidemic plasmid
carrying this ESBL through the food chain. Plasmids carrying blaVIM-1
from Klebsiella pneumoniae and Escherichia coli, isolated along a ﬁve
years period in Greece were all assigned to the clonal complex CC-10,
suggesting the spread and persistence of this particular IncN lineages in
this country.
Conclusions: The IncN plasmid family is successfully disseminating in
different environments linked to relevant resistance genes. This study
proposes the pMLST as a suitable and rapid method for identiﬁcation
of IncN epidemic plasmids.
P560 The ecology of major resistance plasmids in E. coli
J. Ellem, Z. Zong, S. Partridge, J. Iredell* (Sydney, AU)
Objectives: We wished to understand whether incoming globally
dominant resistance plasmids were displacing a native population of
similar type or integrating into it upon arrival by recombination.
Methods: At two geographically separated sites, we compared
IncI1 plasmids carrying blaCMY-2 with those carrying no resistance
phenotype at all (“sensitive”) and those carrying only ampicillin
resistance, in terms of plasmid size (S1 nuclease digestion) and RFLP
and in terms of published plasmid MLST alleles. We also compared
IncF1B plasmids carrying blaCTX-M-15 with IncF1B plasmids carrying
no resistance phenotype at all (“sensitive”) and those carrying only
ampicillin resistance, using the same approach except for an MLST.
Host strains were compared by PFGE and MLST as needed to establish
strain-plasmid associations.
Results: The local ‘sensitive’ plasmids were relatively diverse, and had
plasmid MLST alleles that had not previously been described. They were
quite different from each in the two sites, while established ‘resistance’
plasmids (eg IncI1/blaCMY-2 and IncF1B/blaCTX-M-15) were similar
to each other and at each site as well as to published plasmids from
around the world.
Conclusion: Whether this picture is unique to, say, IncI1/blaCMY-2
remains to be seen. However, the data suggest that E. coli plasmid
populations in the local microﬂora are displaced by invading resistance
plasmids. Known associations between plasmids and antibiotic resistance
genes and host strains (eg incF blaCTXM15 ST131) implies the
possibility of a long-term ecological risk which has not been considered
in detail and is deserving of closer scrutiny in these and other plasmid
populations. A more complete toolkit for characterisation of plasmid
populations and a clearer picture of the natural plasmid ecology of the
Enterobacteriaceae is needed.
P561 Who are the carriers of multi-resistant bacteria in the
community? A one-year prospective study in France
J. Caillon*, S. Thibaut, N. Foucher, S. Allorent, G. Grandjean,
F. Ollivier, F. Ballereau (Nantes, FR)
Background: To study the incidence of MRB in the community and to
deﬁne the characteristics of patients carrying MRB (medical history and
previous hospitalization, risk factors of colonization/infection).
Methods: This prospective epidemiological survey has been carried
out during 2009 with the MedQual network of 174 laboratories in
France. MRB strains − MRSA and 3rd-generation cephalosporins (3GC)-
resistant enterobacteria (EB)−, antibiograms and the socio-demographic
characteristics and risk factors were collected.
Results: 2198 MRB have been included: 762 (34.7%) MRSA, 1436
(65.3%) 3GC-resistant EB; the prevalence rate was 15,3% for MRSA
and 2,4% for 3GC-resistant EB.
EB were mainly isolated from urines (53.5% BLSE and 36.6%
cephalosporinase, 9 ND), with predominance of E. coli (75.9%).
78.3% patients were living at home. The carrying was unknown for
78.2%. The main FDR were antibiotics − ﬂuoroquinolones (28.7%),
blactamins (20.0%) and 3GC (17.3%) −, hospitalization, home care
on the year before (83.2%, 50.4% and 41.2% respectively). 71.5%
were resistant to nalidixic acid and 95.5% and 91% were susceptible
respectively to fosfomycin and nitrofuranes. Among 1436 patients, 411
(mean age 58) were without risk factors and carrying was unknown for
79.1%.
MRSA were isolated in skin and soft tissues (41.2%) and urines (34.6%).
64.7% patients were living at home; the carrying was unknown for
65.7%. 44.4% of them had chronic cutaneous lesions. The main FDR
were antibiotics − ﬂuoroquinolones (22.2%), blactamins (23.5%) and
3GC (17.4%), hospitalization and home care on the year before (80.2%,
62.1% and 70.2% respectively). Among 762 patients, 115 (mean age 49)
were without risk factors and carrying was unknown for 78.3%. 25% had
chronic cutaneous lesions.
Among 762 MRSA, 224 were susceptible to ﬂuoroquinolones. 6 MRSA
strains produced PVL and 15 produced TSST-1.
Conclusion: The incidence of EBSLE, mainly found in urine samples of
patients living at home, is increasing in the community. They are highly
resistant to ﬂuoroquinolones but are still susceptible to fosfomycine.
The most MRSA strains isolated in community don’t produce toxins
and have no co-resistance (resisting only to methicillin). The guidelines
of treatment of urinary tract infections must be applied. MedQual is
conducting a communication plan with Social Security alongside GPs
to adapt the prescription of antibiotics to the resistance proﬁle of the
community MRB.
P562 Epidemiology of plasmid-mediated quinolone resistance
determinants in bacterial isolates from animals and food
with co-resistance to several antibiotics
E. Ferreira, A.P. Francisco, D. Jones-Dias*, V. Manageiro, M. Canic¸a
(Lisbon, PT)
Objectives: The use of (ﬂuoro)quinolones both in humans and animals
has contributed to the selection of resistant bacteria, limiting the agents
available for treatment. This study aims to search for plasmid-mediated
quinolone resistance (PMQR) determinants to give information about
these expanding resistance mechanisms, their capacity of dissemination
among different bacteria by mobile elements, and the role that they play
in facilitating co-resistance to several antimicrobials.
Methods: In this work we investigated a collection of Escherichia
coli (n = 183) and Salmonella spp (n = 186) isolates recovered from
several types of consumable meat (n = 93) and from samples collected
from food-producing animals received from diagnostic (n = 276).
Antibiotic susceptibility testing against different classes of antibiotics
was performed by disk diffusion and MICs were determined by E-test
for PMQR-positive isolates. Molecular characterization of the isolates
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included PCR detection of PMQR determinants and of b-lactamase-
encoding genes (for putative producing isolates with diminished
susceptibility to b-lactams); the respective coding proteins were identiﬁed
through nucleotide sequencing. Class 1 integrons (int1 gene) were
searched by PCR.
Results: Overall, we detected 19/369 PMQR determinants, namely 11
QnrS1 in E. coli isolates from poultry. Two of these strains also carried
TEM-1 b-lactamase and one of them carried TEM-135 plus SHV-108
(ESBLs). Among the 6 QnrB detected, we identiﬁed 3 QnrB19: one
in an E. coli (from a pig) and 2 in Salmonella spp isolates (from
poultry), and 3 QnrB2 in Salmonella spp isolates (from embryonated
eggs). We also have detected 2 Aac-(6′)-Ib-cr in E. coli and Salmonella
spp isolates, from broiler and bovine origin, respectively. One isolate
carrying Aac-(6′)-Ib-cr was from consumable meat. Among PMQR-
negative isolates, we detected one DHA-type (plasmid-mediated AmpC
b-lactamase) Salmonella spp-producing isolate, as well as one SHV-12
and one TEM-135 (ESBLs) E. coli-producing isolates. Class 1 integrons
were detected among 8 out of 19 PMQR-positive isolates, but were not
always associated to multidrug-resistance (MDR).
Conclusions: This investigation has demonstrated that PMQR may act
additively with other plasmid-encoded resistance mechanisms in 16% of
studied isolates and in 42% may be disseminated by plasmids carrying
class 1 integrons, contributing to the scenario of MDR in animal
production facilities.
P563 Colistin therapy for multidrug-resistant Gram-negative
infection: clinical outcome and risk factors
Y. Jun*, H.J. Choi (Seoul, KR)
Objectives: As most antibiotics used in current Gram-negative bacterial
infection are ineffective, colistin has re-introduced in MDR treatment
strategy. Many questions regarding the clinical utility of colistin remain
unclear. The aim of this study is to evaluate the efﬁcacy of intravenous
colistin treatment for MDR Gram negative bacteria and understands the
risk factors for its therapy.
Methods: We retrospectively reviewed the medical records of patients
who had history of intravenous colistin for MDR Acinetobacter or
Pseudomonas which were sensitive to colistin. Patients were excluded if
they received <72h of colistin treatment. We analyzed the risk factors of
poor clinical response to colistin. The type of infection, characteristics of
patients including age, sex, underlying diseases, causative organism, co-
infection, antibiotics history before and after colistin treatment, duration
of colistin therapy, and treatment outcomes including 30-day mortality
were analyzed.
Results: Total 107 patient records were analyzed, 104 patients (97%)
were treated in the Intensive Care Unit. Good clinical responder was
60 (56%) and poor clinical responder was 47 (44%). Average age was
63.8±15.8 and average hospital stay was 124.5 days. Total duration of
colistin use was 14.7±12.1. In unvariate analysis, Age >64, Hospital
day >125days, ICU stay <7, Bacteremia, Diabetes Mellitus, Malignancy,
MDR pseudomonas infection, History of carbapenem or Glycopeptides
use are statistically meaningful. Antibiotic factors are not signiﬁcantly
meaningful. In logistic regression analysis, Hospital day >125 (OR: 1.12
CI= 1,090–8.555), Bacteremia (OR= 1.22, CI 0.066–1.438), Diabetes
Mellitus (OR: 1.07, CI: 0.198–2.043) were independent risk factors for
the outcome of colistin therapy.
Conclusion: Long term hospital patients, bacteremia, and Diabetes
Mellitus suggested poor outcome of the colistin therapy. The large
controlled prospective study on colistin should be considered in treatment
for MDR Gram-negative bacterial infection.
P564 Vibrio cholerae O1 Ogawa, a major aetiological agent of
diarrhoeal disease outbreak in Western Nepal
B.R. Adhikari*, G. Shakya, S. Shrestha, B. Upadhyay, K. Kc
(Kathmandu, NP)
Objectives: To investigate the causes and describe antimicrobial
susceptibility pattern of diarrhoea epidemic occurred in July to
September 2009, in Mid- and Far-Western Nepal.
Methods: All rectal swabs were collected in Cary Blair transport
medium from cases presented with diarrhoeal disease and received at
National Public Health Laboratory (NPHL) during the outbreak period
in July to September 2009 and processed both by conventional culture
and Real-time PCR methods. Antibiotic Susceptibility test of the isolates
was performed following Kirby-Bauer disc-diffusion method.
Results: Out of 158 rectal swabs tested by Conventional culture method,
V. cholerae (51.3%) was the most predominant bacterium followed by
E. coli (20.3%) and Aeromonas spp. (16.5%). All isolated V. cholerae
were of serogroup-O1, serotype-Ogawa and El Tor bio-type. Similarly
by Real-Time PCR also V. cholerae was the predominant (51.9%) one
followed by ETEC (31.6%) and Salmonella species (0.6%). Neither
rotavirus nor norovirus were identiﬁed. Sensitivity difference of isolation
of V. cholerae by conventional culture technique and detection by
molecular RT-PCR technique was not statistically signiﬁcant (P = 0.012).
Tetracycline, Oﬂoxacin and Norﬂoxacin were 100% sensitive for
V. cholerae isolates while cotri-moxazole and Furazolidone were 100%
resistant. 14.6% V. cholerae isolates showed intermediate susceptibility
while the rest were fully susceptible to ciproﬂoxacin. ETEC isolates were
resistant to most of the commonly used oral antibiotics.
Conclusion: Diarrhoea epidemic, 2009 in Nepal was primarily caused
by V. cholerae O1 biotype El Tor, serotype Ogawa. Majority of the
Vibrio cholerae were isolated from children of age group (0−10) years.
Tetracycline, oﬂoxacin and norﬂoxacin were found 100% sensitive for all
isolated V. cholerae. Approximately 15% of V. cholerae isolates showed
intermediate sensitivity to ciproﬂoxacin. All strains were multidrug
resistant. Increasing resistance of V. cholerae against commonly used
antibiotics signiﬁes that treatment options will become more problematic
in cases of severe diarrhoea. Drinking water source of the outbreak
regions were heavily contaminated with faecal coliform.
P565 Antimicrobial susceptibility trends of Enterobacteriaceae
from intra-abdominal infections in Europe: SMART
2002–2010
R. Badal*, S. Hawser, S. Bouchillon, D. Hoban, M. Hackel, A. Johnson
(Schaumburg, US; Epalinges, CH)
Objectives: The Study for Monitoring Antimicrobial Resistance
Trends (SMART) is a global longitudinal surveillance study that has
tracked activity of ertapenem and other drugs used to treat intra-
abdominal infections (IAI) since 2002. This report focuses on trends
in susceptibility of Enterobacteriaceae over 9 years in Europe.
Methods: 86 hospitals in 15 European countries each collected up to 100
consecutively isolated Gram-negative aerobic bacteria per year from IAI.
From 2002–2007, each site did susceptibility testing using MicroScan
broth microdilution panels, following Clinical and Laboratory Standards
Institute and MicroScan procedures and quality control. From 2008–2010
all susceptibility testing was done at a central lab (IHMA, Inc.), also
using MicroScan panels. Minimum inhibitory concentrations (MICs)
were interpreted using EUCAST guidelines. MIC frequency distributions
were analysed for trends using Spearman’s correlation coefﬁcient, and
geometric mean (GM) MICs calculated. Percent susceptibility from 2002
and 2010 was compared using Fisher’s exact test. Only drugs tested all
9 years of the study were evaluated.
Results: MICs of all drugs showed statistically signiﬁcant (p< 0.0001)
changes from 2002–2010: amikacin’s GM MIC declined, but all
other drugs increased. Percent susceptible values declined signiﬁcantly
(p< 0.05) from 2002–2010 except for ertapenem, imipenem, and
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amikacin. The table below compares GM MICs in 2002 and 2010 for
the 8 study drugs:
Conclusions: Although all drugs had statistically signiﬁcant changes in
MIC values over the course of the study, 3 (ertapenem, imipenem, and
amikacin) did not show signiﬁcant changes in their percent susceptible
values, with all remaining >94% in 2010. The other 5 drugs had
signiﬁcantly reduced levels of susceptibility. Among the drugs studied,
ertapenem, imipenem, and amikacin are the least affected by extended-
spectrum b-lactamases, and the loss of activity of the other study drugs is
probably due largely to increases in ESBL-producing Enterobacteriaceae
in Europe that have been documented in numerous reports.
P566 Comparison of antimicrobial susceptibility of Escherichia
coli from intra-abdominal and urinary tract infections in
Europe: SMART 2009–2010
R. Badal*, D. Hoban, S. Hawser, S. Bouchillon, M. Hackel, A. Johnson
(Schaumburg, US; Epalinges, CH)
Objectives: The Study for Monitoring Antimicrobial Resistance Trends
(SMART) has tracked susceptibility levels and incidence of extended-
spectrum b-lactamase producing (ESBL+) E. coli causing intra-
abdominal infections (IAI) since 2002. In late 2009 pathogens from
inpatient urinary tract infection (IAI) were added to the study. This report
compares susceptibility and ESBL+ rates of E. coli from IAI and UTI
in Europe in 2009–2010.
Methods: 21 hospitals in 12 European countries each collected up to 100
consecutive non-selected isolates from IAI and 50 from UTI. All isolates
were sent to a central laboratory (IHMA, Inc., USA) for conﬁrmation of
identiﬁcation, susceptibility testing, and ESBL determination; the latter
two were done following CLSI guidelines. Percent susceptibility was
determined using EUCAST breakpoints. Fisher’s exact test was used to
determine statistical signiﬁcance of differences between IAI and UTI
susceptibility levels.
Results: 2,726 isolates of E. coli were tested (IAI 2190, UTI 536).
ESBL+ rates were 11.1% in IAI and 18.8% in UTI. The following table
summarizes susceptibility of E. coli and ESBL+ E. coli from IAI and
UTI:
Conclusions: Although differences in susceptibility percentages between
IAI and UTI E. coli were generally small (all <10%), 7/11 drugs showed
signiﬁcantly lower susceptibility in UTI than in IAI (P< 0.05). This is
at least partially explained by the much higher ESBL+ rate seen in UTI
isolates (18.8%) than in IAI (11.1%). Imipenem, ertapenem, amikacin,
and piperacillin-tazobactam were the most active in vitro among the
drugs studied in SMART, but only ertapenem and imipenem inhibited
>90% of E. coli from both IAI and UTI. ESBL+ isolates were >92%
susceptible to both carbapenems, but <68% susceptible to all other study
drugs. The relatively high rate of ESBL+ E. coli in UTI in Europe
is concerning, as further increases may eventually render many drugs
commonly used to treat UTI ineffective.
P567 A 3-year study of Stenotrophomonas maltophilia
clinical isolates in a tertiary hospital. Emergence of
sulfamethoxazole/trimethoprim resistance
A. Stylianakis*, S. Tsiplakou, V. Papaioannou, P. Thomaidis,
A. Panagopoulou, C. Karra, A. Koutsoukou (Athens, GR)
Objectives: The purpose of this work was to study the Stenotrophomonas
maltophilia isolates derived from clinical samples and their resistance
proﬁle to the antibiotics used.
Methods: During a three year period (11/2007−10/2010) we examined
n = 123 non duplicated samples corresponding to n = 103 patients
hospitalized in all the wards of our hospital. The examined specimen
sources were pus (n = 64), bronchoalveolar excretions (n = 22), catheters
(n = 17), blood (n = 13), pleural liquid drainages (n = 5), and urine (n = 2).
The isolates identiﬁcation was performed using the automated system
VITEK 2 (Biomerieux, Marcy L’Etoile, France). The MIC values of
ticarcillin/clavulanic acid, sulfamethoxazole/trimethoprim, ceftazidime,
minocycline and levoﬂoxacin were determined by using the E-test system
following the manufacturer’s instructions (ABI Biodisk, Solna, Sweden),
and interpreted according to the CLSI guidelines (Vol. 28, No 1, M100 −
S18).
Results: The number and the resistance rate of the examined isolates
were as follows: ceftazidime (85/69,1%), ticarcillin/clavulanic acid
(84/68,3%), levoﬂoxacin (14/11,4%), sulfamethoxazole/trimethoprime
(6/4,9%). The sulfamethoxazole/trimethoprim-resistant isolates corre-
sponded to n = 4 patients hospitalized in the medical wards. These
isolates were detected during the last year period. No resistant isolates
were found to minocycline.
Conclusion: The examined Stenotrophomonas maltophilia clinical
isolates possessed a high resistance rate to ceftazidime and ticarcillin/
clavulanic in contrast to minocycline, sulfamethoxazole/trimethoprime
and levoﬂoxacin. The last three drugs remain in vitro, active
antimicrobial agents against Stenotrophomonas maltophilia isolates.
The emergence of sulfamethoxazole/trimethoprime resistance poses the
necessity strategies to be encouraged to prevent Stenotrophomonas
maltophilia infections and to restrict the dissemination of this resistance.
P568 Serotypes, antibiotic resistance, and class 1 integrons in
Salmonella isolates from paediatric cases of enteritis in
Tehran, Iran
R. Ranjbar*, G.M. Giammanco, S. Farshad, P. Owlia, A. Aleo,
N. Jonaidi, M. Izadi, N. Sadeghifard, C. Mammina (Tehran, IR;
Palermo, IT; Shiraz, IR; Ilam, IR)
Objectives: The present study was conducted to investigate serotype
distribution, antimicrobial resistance patterns, carriage of class 1
integron, and clonality of Salmonella strains isolated from patients aged
0−12 years in Tehran, Iran, during 2007–2008.
Methods: The study included all Salmonella isolates recovered from all
cases of enteritis in patients aged less than 12 years admitted to a major
children hospital in Tehran, Iran, during 2007–2008. Serotyping, drug
susceptibility testing, and analysis of class 1 integron were carried out
on 139 Salmonella isolates. Pulsed ﬁeld gel electrophoresis (PFGE) was
used to investigate genetic relatedness among the isolates.
Results: Salmonella serotypes Enteritidis, Infantis, and Typhimurium
included 84.9% of isolates, Enteritidis accounting for 41.7%. The
most prevalent resistances were to doxycycline (64.7%), nalidixic acid
(61.2%), tetracycline (51.8%), and streptomycin (42.8%). Fifty-three
(38.1%) isolates contained class 1 integron. Eight different gene cassettes
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were identiﬁed, aadA1 being the most frequently encountered. Pulsed-
ﬁeld gel electrophoresis showed that integron-positive Salmonella strains
belonging to serotypes Infantis, Enteritidis, and Typhimurium were
attributed to two, three, and ﬁve different pulsotypes, respectively.
Conclusions: The ﬁndings indicated that the distribution and drug
resistance pattern of most prevalent Salmonella serotypes were broadly
similar to that reported globally from human isolates. Presence of class
1 integrons was common among Salmonella serotypes in Tehran, Iran.
Concurrent clonal expansion and horizontal transmission events seem to
contribute to increase in drug resistance prevalence among Salmonella
serotypes.
P569 AAC(3)-II is the major aminoglycoside-modiﬁcation
enzyme in China, which leading to the obvious partial
cross-resistance in Escherichia coli to agents
Y. Xiao*, Y. Hu (Hangzhou, Beijing, CN)
Objectives: To study the aminoglycoside resistance and epidemiology of
aminoglcoside-modifying enzymes in Escherichia coli in China, evaluate
the clinical value of different aminoglycoside agents.
Methods: National wide clinical isolates of E. coli being resistant to
gentamycin or kanamycin were collected, antibacterial activity of 11
aminoglycoside agents were examined with agar dilution method, 12
aminoglycoside-modifying enzyme genes were detected with PCR and
conﬁrmed with DNA sequence.
Results: 205 bacterial strains of E. coli from 9 hospitals scattering
in cities were investigated. All the isolates were highly resistant to
gentamycin and kanmycin, followed by tobramycin, neltimicin and
etimicin, but less than 15% of the strains were resistant to amikacin
and isepamicin. 88.2% of gentamycin-resistant strains were susceptible
to isepamicin. 5 antibiotic modifying enzyme genes were detected in
191 bacterial strains. AAC(3)-II was the most common enzyme, which
was positive in 162 strains, the following enzymes were AAC(6′)-I
(50 strains), ANT(3′′)-I(28 strains), APH(3′)-II (20 strains), ANT(2′′)-I
(20 strains); the most common enzyme combinations were AAC(3)-
II(95 strains), AAC(6′)-I/AAC(3)-II(28 strains), AAC(3)-II/ANT(3′′)-
1(11 strains) and AAC(6′)-I(10 strains). The bacterial resistance and
antibiotic enzyme distribution in different cities were minor, but
the enzyme combination in Guangdong, Jinan and Dalian had some
difference with other cities, from which amikacin and ispamicin-resistant
strain were isolated mainly.
Conclusions: The major aminoglycoside-resitance in E. coli in China
is to gentamycin and kanamycin, rather than amikacin and isepamicin.
The aminglycoside-resistant phenotype in E. coli closely connects with
the antibiotic modifying enzymes. Amikacin and isepamicin keep high
antibacterial potency against E. coli, which is worthy for clinical
application.
P570 Surveillance of nosocomial and community-acquired enteric
pathogens shed in equine faeces and analysis of risk factors
associated with antibiotic resistant E. coli
M. Ahmed* (Tripoli, LY)
Antimicrobial-resistant bacteria represent a signiﬁcant threat to human
and animal health. The emergence of such resilient pathogens is
often associated with hospital settings, and faeces from horses in this
environment can be a source of community outbreaks. We compared
equine faecal samples (n = 264) from 138 horses from hospital and
non-hospital (livery stable and riding school) premises in North West
England to determine the prevalence of Escherichia coli, Salmonella,
and Campylobacter and the presence of antimicrobial-resistant strains.
All faecal samples were found to contain E. coli, while Campylobacter
jejuni was detected only in hospitalised horses (1.1%). No Salmonella
was identiﬁed. A total of 296 resistant E. coli strains were isolated. We
evaluated data of the horses’ management and veterinary treatment to
identify the risk factors associated with faecal shedding of antimicrobial-
resistant E. coli. Statistical analysis using multi-level logistic regression
revealed that the hospital was the major source of both resistant
and multiple drug resistant (MDR) E. coli. Moreover, shedding of
antimicrobial-resistant E. coli was correlated with hospitalization for
a gastrointestinal problem (odds ratio:+95%CI = 8.50: 1.79–40.32),
receipt of oral antimicrobial (odds = 3.52; 1.11–11.10 95%CI),
receipt of more than one antimicrobial in hospital (OR= 1.05: 1.01–
1.09), or gelding (OR= 4.62: 1.23–17.46). Interestingly, intraveneous
antimicrobial appeared to be negatively correlated with faecal shedding
of antimicrobial-resistant E. coli (OR= 0.18: 0.04–0.76). The presence of
MDR E. coli was positively correlated with hospitalization, antimicrobial
in hospital (OR/Tx = 3.65: 1.54–8.68), and increased age (odds
ratio:+95%CI = 1.11: 1.03–1.19 per year). Thus, equine hospitals appear
to be an important source of zoonotic antimicrobial-resistant and MDR
E. coli strains, but are unlikely reservoirs of zoonotic Salmonella or
Campylobacter, in this geographic location. It is important to control
the amount of antimicrobial Tx given to horses in hospital to lessen the
chance of zoonotic exposure in areas proximal to these facilities.
P571 Prevalence of carbapenem-resistant Enterobacteriaceae and
carbapenem-resistant Pseudomonas aeruginosa and Acine-
tobacter baumannii in routine ESBL surveillance samples
M. Pirs*, A. Andlovic, T. Cerar, T. Furlan, J. Guzej, K. Seme
(Ljubljana, SI)
Objective: The aim of our study was to determine the prevalence
of carbapenem-resistant (CR) Enterobacteriaceae, Pseudomonas aerugi-
nosa and Acinetobacter baumannii in routine ESBL surveillance samples
taken from patients in a tertiary hospital. Direct and enrichment protocol
were evaluated.
Methods: Samples were vortexed in tryptic soy broth (TSB), aliquots
were inoculated onto ChromID ESBL agar (bioMerieux), MacConkey
agar (MAC) onto which 10mg carbapenem discs were placed, and
TSB. TSB was subcultured following 24h incubation onto MAC agar
onto which carbapenem discs were placed. Reduced susceptibility to
carbapenems was suspected in any colony growing within the 23mm
inhibition zone for Enterobacteriaceae or 16mm for non-fermentative
gramnegative bacilli. Those colonies were subcultured followed by
antimicrobial susceptibility testing. Strains with reduced susceptibility
to carbapenems were identiﬁed and MICs were determined using Etest.
Phenotypical tests for detection of carbapenemases (modiﬁed Hodge
test (MHT) and inhibition tests) were performed as well as molecular
detection of blaKPC, blaVIM, blaIMP, blaOXA-48 and blaNDM-1.
Results: 343 surveillance samples from 269 patients were screened
(83.7% rectal swabs). CR Enterobacteriaceae were detected in 15 patients
(5.6%) (Table 1). Eight (44.4%) of CR isolates were not detected on
ESBL chromogenic agar, 2 (16.7%) of those were detected by enrichment
protocol only. Phenotypical tests for detection of carbapenemases were
negative. CR P. aeruginosa was detected in 22 patients (28 isolates);
63.6% of isolates had isolated resistance to carbapenems, 40.9% were
MDR strains; 10.7% of MDR CR P. aeruginosa isolates were detected
by enrichment protocol only (Table 1). Among MDR strains one had
positive inhibition test for class A and 2 for class B carbapenemases.
CR A. baumannii was detected in one patient by positive MHT and
inhibition test for class B carbapenemase (Table 1). Molecular screening
for 5 carbapenemase genes was negative in all isolates.
Conclusions: CR Enterobacteriaceae, CR P. aeruginosa and CR
A. baumannii were detected in 5.6%, 8.2% and 0.4% of routine
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ESBL surveillance samples taken from patients in a tertiary hospital,
respectively. We were not able to detect carbapenemase genes in our CR
isolates. Our study supports the use of MAC onto which carbapenem
discs are placed in combination with nonselective enrichment step for
detection of CR bacteria in surveillance samples.
P572 Evaluation of a new gradient-diffusion system for MIC
determination with Gram-negative pathogens
V. Conte, M.M. D’Andrea, T. Giani, G.M. Rossolini* (Siena, IT)
Objectives: Minimum Inhibitory Concentration (MIC) remains the
cornerstone parameter for evaluation of antimicrobial susceptibility.
MIC determination is crucial with some antimicrobial agents–pathogens
combinations, when disk diffusion testing is not reliable or when the MIC
value correlates with outcome. MIC determination has become important
also when dealing with multiresistant pathogens and treatment options
are seriously limited. However, most clinical laboratories cannot afford
the expensive and labor-intensive reference MIC testing or complex
automated systems for precise MIC determination, and a number of
products based on gradient-diffusion has been developed for easy
determination of MIC values. In this work we evaluated the performance
in MIC determination of a new gradient-diffusion system against a panel
of Gram-negative pathogens including several multiresistant strains with
emerging resistance mechanisms.
Methods: 100 bacterial isolates were studied, (70% Enterobacteriaceae
and 30% Gram negative non fermenters), including 30 reference strains
with known resistance mechanisms (acquired ampC, MBL, KPC and
ESBL producing Enterobacteriaceae, OXA-carbapenemase producing
Acinetobacter baumannii, MBL producing Pseudomonas aeruginosa),
determined by molecular methods, and 70 routine isolates. MIC deter-
minations were performed in parallel by MIC Test Strips (Lioﬁlchem
srl, Italy) and Etest (Biomerieux, France) on MHA (Becton-Dickinson,
USA) medium, according to EUCAST methods. The following strips
were evaluated: Ceftazime (CAZ), Cefotaxime (CTX), Colistin (COL),
Piperacillin/Tazobactam (PTZ), Imipenem (IMI), Meropenem (MEM).
Paper-strips containing CAZ or CTX, alone and in combination with
clavulanic acid, were used for the detection of ESBL. Comparator
MICs were obtained by broth microdilution (BMD), following EUCAST
guidelines.
Results:MIC determinations were considered concordant when obtained
results fell in the experimental error (±1 log2 dilution). Overall
agreement of MIC values between MIC test strips and BDM was 79,4%
(n = 467), with a speciﬁc agreement ranging from 89,5% of CAZ to
74,6% of CTX. Combination strips correctly detected ESBL in 24 cases
without any false positive. Similar values were obtained using the Etest
method.
Conclusions: The evaluated product gave overall good agreement with
BMD method, similar to that obtained with Etest. MIC test strips appear
therefore to be a valid alternatives to the Etest.
P573 In vitro activity of piperacillin-tazobactam and comparators
against P. aeruginosa in countries of Eastern Europe,
2006–2010
S. Lob, S. Bouchillon, R. Badal, D. Hoban*, S. Hawser, M. Hackel,
M. Dowzicky (Schaumburg, US; Epalinges, CH; Collegeville, US)
Objective: Pseudomonas aeruginosa infections continue to pose a
treatment challenge worldwide. The ongoing Tigecycline European
Surveillance Trial (T.E.S.T.), a comprehensive surveillance study, makes
possible the evaluation of regional differences in antibiotic susceptibility.
In this report, the antimicrobial activity of piperacillin-tazobactam (pip-
tazo) and several comparators was evaluated in Eastern European
countries.
Methods: Between 2006 and 2010, 1,351 P. aeruginosa isolates from
several specimen sources were collected in 11 countries in Eastern
Europe. The number of contributing sites per country ranged from 1
(Latvia) to 7 (Bulgaria). MICs were determined by each participating
laboratory using commercially-prepared microbroth panels. Results were
interpreted according to EUCAST breakpoints. The Fisher exact test
was used to determine the statistical signiﬁcance of differences in %
susceptible between the Eastern European average and each individual
country.
Results: Comparing 2006 to 2010, the in vitro activity of all ﬁve reported
antimicrobials was relatively stable with the MIC50 remaining the same
or changing by only one dilution; therefore, all P. aeruginosa isolates
collected during the ﬁve-year period were combined. The following
table shows the % susceptible (%S) and MIC50 for pip-tazo and four
comparators by country and all Eastern European data combined:
Conclusions: Piperacillin-tazobactam exhibited activity similar to that
of meropenem and ceftazidime against P. aeruginosa in Eastern Europe.
Only amikacin demonstrated signiﬁcantly better in vitro susceptibility
results than pip-tazo (72.8% vs. 58.1%). Variations in activity for all ﬁve
antimicrobials existed across countries. Romania (with 3 participating
sites) showed the highest MIC50 and lowest % susceptible for all reported
drugs. Overall, Slovenia (3 sites) exhibited the highest susceptibility
levels. The Czech Republic (3 sites), Hungary (4 sites), and the Slovak
Republic (2 sites) also reported susceptibility levels signiﬁcantly higher
than the Eastern European average for at least one reported drugs
(p< 0.05).
P574 Surveillance of antimicrobial susceptibility of Pseudomonas
aeruginosa isolates from a central hospital in central
Portugal: 7 years of evolution or involution?
S.G. Pereira*, H. Oliveira, L. Albuquerque, R. Leita˜o, O. Cardoso
on behalf of the Center for Pharmaceutical Studies
Objectives: Pseudomonas aeruginosa (PA) is an important nosocomial
pathogen causing a wide variety of infections, being at present the
fourth most common nosocomial pathogen. In order to apply optimal
therapeutic guidelines, physicians must be aware of recent resistance
surveillance and epidemiological data. The aim of this study was to
determine antimicrobial susceptibility of PA isolates in order to assist the
guidelines for empirical antibiotic prescription regimens and to evaluate
the infection control measures implemented in the hospital surveyed.
Methods: From April 2003 to April 2010, 2719 PA isolates were
collected in Centro Hospitalar de Coimbra: 1719 were nosocomial
isolates and 1000 from ambulatory. Isolates were obtained from sputum
(40.9%), urine (25.3%), exudates (12.4%), blood (4.7%) and other
sources (16.6%). Identiﬁcation and susceptibility patterns of the isolates
were performed with API32GN (BioMe´rieux) and MicroScan WalkAway
(Dadebehring). Susceptibilities to Piperacillin (PIP), Piperacillin plus
Tazobactam (TZP), Aztreonam (AZT), Ceftazidime (CAZ), Imipenem
(IP), Meropenem (MP), Amikacin (AMK), Gentamicin (GN), and
Ciproﬂoxacin (CIP) were guideline by CLSI.
Results: Considering all isolates, AMK was the best agent (86.5%),
and CIP was the worst (61.0%). The same result was observed in
nosocomial isolates, with AMK as the best agent (82.8%) and CIP the
worst (54.4%). In ambulatory isolates, MEM was the best agent (95.3%).
Since the beginning of the study, susceptibility rates have progressively
diminished in nosocomial and ambulatory isolates. In the year 2007–
2008, it was observed a small increase in the susceptibility rate of several
antimicrobials in all isolates (AZT, CAZ, GN, IP, MP, AMK, CIP), but
in the following years, it has decreased, being at present in the lowest
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level since the beginning of the study. Susceptibility rates of the most
important b-lactams IP, MP and CAZ have diminished in 16.5%, 21%
and 13.8%, respectively, in nosocomial isolates, and 10.9%, 8.9% and
9.9%, respectively, in ambulatory ones. Contrarily, the susceptibility rate
of TZP has increased (9.8%) since 2007–2008.
Conclusion: Appropriate empirical treatments based on knowledge of
particular resistance patterns are important determinants to the success
of therapeutics. Studies of surveillance can be helpful in ﬁghting the
development and spread of resistance among pathogenic agents.
P575 Resistance rates of Pseudomonas aeruginosa clinical isolates
in a tertiary hospital
S. Tsiplakou, A. Stylianakis, V. Papaioannou, P. Thomaidis,
E. Chatziandreou, C. Karra, A. Koutsoukou* (Athens, GR)
Objectives: The aim of the present study was to assess resistance rates
to various antimicrobials of Pseudomonas aeruginosa clinical isolates
for a period of three years in a tertiary hospital.
Methods: During a 3 year period from 2007 to 2009, a total of
1975 P. aeruginosa isolates, one per patient, were collected from
patients hospitalized in ICUs (730 isolates) and non-ICU wards (1245
isolates) of our hospital. P. aeruginosa was isolated from 736 pus, 464
urine, 324 respiratory, 238 catheter, 193 blood, and 20 pleural ﬂuid
cultures. Identiﬁcation and susceptibility testing were performed using
the Vitek 2 automated system (bioMe´rieux, Marcy l’E´toile, France) and
MICs were determined by E-test (AB Biodisk, Solna, Sweden) when
necessary, according to CLSI guidelines. The antimicrobials tested were
aztreonam (AZT), cefepime (FEP), ceftazidime (CAZ), imipenem (IMP),
meropenem (MER), piperacillin (PIP), piperacillin-tazobactam (TZP),
amikasin (AN), gentamicin (GM), tobramycin (TM), ciproﬂoxacin (CIP)
and colistin (CS).
Results: Higher resistance levels were observed for isolates that derived
from ICU patients, reaching up to 69% for AZT, 68% for FEP, 74%
for CAZ and CIP, 76% for IMP and 74% for MER, 60% for PIP, 50%
for TZP. Resistance rates to aminoglycosides varied from 68% for AN,
to 70% for GM and TM, and to 71% for NET. P. aeruginosa isolates
from non-ICU patients exhibited lower levels of resistance up to 50% for
AZT, 40% for FEP, 43% for CAZ, 47% for CIP, 42% for IMP and 38%
for MER, 33% for PIP, 20% for TZP. As for aminoglycosides resistance
was 38% for AN, 40% for GM and TM, and 44% for NET. Colistin
was the most active antimicrobial with resistance that reached 2,7% and
2,4% for isolates from ICU and non-ICU patients respectively. During
the 3 years of the study there was a gradual decrease of resistance to
gentamicin of 9% and to ceftazidime of 10%, which was not observed
for the rest of the antimicrobials tested.
Conclusion: Pseudomonas aeruginosa isolates from ICU patients
exhibited higher levels of resistance in contrast to those from non-ICU
patients. With most isolates being multidrug resistant the therapeutic
choices for these critically ill patients are restricted therefore the prudent
use of antibiotics along with the use of effective infection control
measures are necessary, in order to limit the development and spread
of resistance.
P576 Activity of colistin against European P. aeruginosa from the
TEST Study: 2009–2010
M. Hackel, D. Hoban*, B. Johnson, S. Bouchillon, J. Johnson, S. Hawser,
M. Dowzicky (Schaumburg, US; Epalinges, CH; Collegeville, US)
Background: Successful treatment of infections due to Pseudomonas
aeruginosa has become problematical due to widespread resistance to
currently available therapies. As many isolates exhibit resistance to
multiple antimicrobial agents, older agents, such as colistin (polymyxin
E), are being reexamined for their treatment potential. This study
investigated the activity of colistin against European clinical isolates
of P. aeruginosa collected during 2009–2010.
Methods: A subset of 504 isolates collected from 25 European
countries during the 2009–2010 TEST program (Tigecycline European
Surveillance Trial) from various infection sources were included in this
study. MICs were performed following CLSI guidelines and interpreted
according to EUCAST breakpoints.
Results: See the Table.
Conclusions: Colistin was the most active agent in vitro, with 80.6%
of the P. aeruginosa isolates, including multi-drug resistant strains,
susceptible by EUCAST criteria. Colistin represents a potential addition
to the treatment of drug-resistant P. aeruginosa. As usage of this agent
increases, careful monitoring of the incidence of resistance is warranted.
P577 Population structure of clinical and environmental Pseudo-
monas aeruginosa isolates from ﬁve Mediterranean countries
M. Maatallah, A. Bakhrouf, C. Giske* (Monastir, TN; Stockholm, SE)
Objectives: Based on various approaches, several studies in the last
years provided evidence that Pseudomonas aeruginosa has a non-clonal
population structure punctuated by highly successful epidemic clones
or clonal complexes. However, few studies have been conducted with
multilocus sequence typing (MLST). The role of recombination in the
diversiﬁcation of P. aeruginosa clones has been suggested, but too a little
extent demonstrated by using MLST-data.
Methods: Clinical (n = 124) and environmental (n = 19) isolates of
P. aeruginosa were subjected to pulsed-ﬁeld gel electrophoresis (PFGE),
MLST (n = 106, mostly with different SpeI macrorestriction proﬁles),
serotyping and PCR targeting the virulence genes exoS and exoU.
Susceptibility testing was performed with disk diffusion according to
EUCAST. The occurrence of multi-resistance (3 antipseudomonal
drugs) was analyzed. MLST data were analyzed with Bionumerics 6.0,
using minimal spanning tree analysis as well as eBURST. The inference
of clonal relationship was assessed with Clonal frame. The Neighbornet
algorithm was used to generate a phylogenetic network and to test for the
presence of recombination. Genetic diversity and linkage disequilibrium
was measured with the index of association with LIAN 3.5.
Results: Among the 143 isolates we identiﬁed 95 PFGE-types. The
MST connected 63 sequence types, among which ST235 was by far
the most common. ST235 was very frequently associated with the O11
serotype (21/23 O11), and very frequently displayed multi-resistance and
the virulence genotype exoS-/exoU+. The eBURST analysis revealed
a relatively high diversity among the isolates with some related STs.
Clonal frame linked several groups previously identiﬁed by eBURST and
provided insight to the evolutionary events occurring in the population.
A Neighbor net analysis based on the concatenated sequences revealed
a complex network, providing evidence of frequent recombination. The
index of association 0.351 when all the strains were considered indicated
a freely recombining population. The mean genetic diversity at all loci
was relatively high (0.8345±0.0245).
Conclusion: P. aeruginosa isolates from the Mediterranean countries
display an epidemic population structure, particularly dominated by
ST235-O11, which has earlier also been coupled to the spread of blaVIM
in many countries. ST235 was also frequently associated with exoU and
with multi-resistance. We found evidence of frequent recombination.
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Helicobacter pylori infections: from diagnosis
to pathogenesis
P578 Can Helicobacter pylori reside in the human oral cavity?
A. Al-Ahmad*, A. Ku¨rschner, A. Wittmer, E. Hellwig, M. Kist,
B. Waidner (Freiburg, DE)
Objectives: Helicobacter pylori is a Gram-negative, highly motile,
microaerophilic, spiral-shaped organism, which colonizes the stomachs
of at least half of the world’s population. Infection of humans results
in persistent gastritis, which can develop into peptic ulcer disease and
adenocarcinoma. The role of the oral cavity for the infection cycle of
this germ is still unclear. Published data are very contradictory and up
to now, there are no clear data demonstrating comprehensible isolation
of H. pylori from any of the different compartments of the oral cavity.
The aim of this study was to evaluate the prevalence of H. pylori in the
oral cavity of 15 H. pylori positive tested patients (stool antigen ELISA).
Methods: A comprehensive dental examination of all patients was
conducted by an experienced dentist. Thus samples were taken from
supragingival and subgingival plaque, saliva, periapical exudates and
tongue swabs. All samples were taken before antibiotic application. A
total of 163 oral samples were investigated by PCR using H. pylori
speciﬁc primers. PCR inhibition controls using a modiﬁed plasmid
were always enclosed. In addition culture technique was used to isolate
H. pylori from samples which showed positive PCR results.
Results: Despite a PCR detection limit of 102 bacteria per ml, in 14
patients H. pylori could not be detected in any sample taken (161 oral
samples). In one patient with bad periodontal status and oral hygiene as
well as with high gingival inﬂammation, H. pylori positive PCR signals
were obtained in two samples (periapical exudates and tongue swabs).
The PCR inhibition controls conducted in parallel conﬁrmed the validity
of the PCR reactions. H. pylori could not be cultivated from these two
PCR positive samples.
Conclusions: The results of this comprehensive study challenge the
depiction that H. pylori resides in the human oral cavity. Campylobacter
species which were frequently isolated from the oral cavity may cause
the contradictory results shown in literature.
Thus survival and proliferation of H. pylori in the oral cavity are still of
main concern and has to be veriﬁed.
P579 Assessment of peroxisome proliferator-activated receptor-g
polymorphisms in Helicobacter pylori infected patients
H. Goudarzi* (Tehran, IR)
Peroxisome proliferator-activated receptor-g (PPAR-g), is a member
of superfamily of nucleus hormones receptor which involved in cell
regulation. As demonstrated previously, two main function i.e inhibition
of growth of cancerous cells as well as induction of apoptosis are
attributed to PPAR-g. In the other hand, H. pylori can induce peptic
ulcer and gastric cancer. This study aimed to determine the PPAR-g
polymorphism in H. pylori infected patients.
A total of 200 H. pylori infected patients were included. The history of
H. pylori infection was conﬁrmed by detection of IgG using commercial
kit. DNA extraction was followed by PCR-RFLP of PPAR-g gene.
This study showed the polymorphic types as follows: 5% GG (Ala12Ala),
35% GC, and 60% CC. A statistical association was found between
GC polymorphism and duodenal ulcer (P = 0.03). In addition, GG
polymorphism associated with gastric cancer (P = 0.004).
Our study demonstrated that GG and GC polymorphism in PPAR-g
gene can be used as predictive factor for detection of high risk cases
of H. pylori infected patients.
P580 Detection of H. pylori and clarithromycin and/or
ﬂuoroquinolone resistance in gastric biopsies by Genotype®
HelicoDR
T. Alarcon*, A. Somodevilla, S. Agudo, P. Urruzuno, M.J. Martinez,
M. Lopez-Brea (Madrid, ES)
Clarithromycin susceptibility is an important factor to predict Heli-
cobacter pylori eradication failure. In addition, the resistance to this
antibiotic is high in Spain. Therefore, early detection of resistance is
important in treatment of H. pylori infection. The aim of this study was
to evaluate a commercially available kit Genotype® HelicoDR (Hain,
Diagnostika, Nehren, Germany) for detection of H. pylori strains that
are clarithromycin and/or ﬂuoroquinolone resistant and compare it with
conventional protocols.
A total of 146 biopsies were obtained from patients with gastric
symptoms. Standard procedures were used for H. pylori culture.
Clarithromycin and ciproﬂoxacin resistance was determined by E-test as
described before. DNA extraction was carried out by the NucliSens easy-
MAG platform (bioMe´rieux), and Genotype® HelicoDR was performed
as manufacturer recommended.
Results: 121 of the 146 biopsies were positive for H. pylori, 57 (47.1%)
of them were clarithromycin susceptible and 64 (52.9%) clarithromycin
resistant: 57 (89%) showed A2143G, 4 (6.2%) showed A2142G mutation
and 3 (4.7%) double mutations A21423C-A2143G. 17 of them showed
heteroresistance (wild type and mutation simultaneously).
114 (95%) of the biopsies were susceptible to ﬂuoroquinolones and 6
(5%) were resistant. The result in one biopsy was too light and was not
possible to deﬁne the presence of wild type or resistant genotype.
All negative biopsies, except one, were also negative by culture.
Conclusions: A high prevalence of clarithromycin resistance in H. pylori
from gastric biopsies from Spain was found. The use of a commercially
available kit is useful for rapid detection of both clarithromycin and
ﬂuoroquinolone resistance.
P581 Cytokine levels in serum of patients with gastric pathologic
infected with Helicobacter pylori cagA negative and cagA
positive
D. Ortiz Princz*, O. Rodrı´guez, M. Cavazza (Caracas, VE)
Helicobacter pylori is recognized as a human-speciﬁc gastric pathogen
and carcinogen type I that colonizes the mucus layer in the stomachs of at
least half of the world’s population. In some subjects, the infection causes
acute or chronic gastritis or peptic ulceration and plays an important
role in the development of peptic ulcer, gastric adenocarcinoma and
lymphoma MALT. The cagA gene is part of the cag pathogenicity island,
code for a putative H. pylori secretion system that is associated with
export of virulence factors to the extracellular compartment. Gastric
mucosal levels of proinﬂammatory cytokines have been reported to be
increased in H pylori infected subjects. In Venezuela there is a high
prevalence of H. pylori cagA positive and also a high incidence of gastric
cancer. The aim of this study was determine serum cytokine levels in
patients infected with H. pylori cagA positive and negative.
Methods: 42 adults male and female were evaluated in the Gastroen-
terology Service Jose´ Maria Vargas Hospital, Caracas, Venezuela. They
were carried out clinical evaluation, histopathological, determination
of serum cytokine levels for ﬂow cytometry, identiﬁcation and typing
of H. pylori by PCR. The serum cytokine levels (IFNg, TNF, IL-10,
IL-6, IL-4, and IL-2) were simultaneously quantiﬁed by cytometric bead
array. The procedure was carried out according to the manufacturer’s
instruction (CBA™, BD Biosciences), ﬁnally samples were analyzed
on FACS DIVA using the supplied cytometer setup beads. DNA from
H. pylori was extracted from culture obtained from gastric biopsies of
patients evaluated. The cagA gene was ampliﬁed by PCR using the
primers CAG1 and CAG2 (Yamaoka, 1998) were used to amplify the 3′
region of the cagA gene.
Results: 78% of patients tested were cagA positive. We found that
the values (pg/ml) of IFNg, TNF and IL-6 were signiﬁcantly higher
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(p< 0.001) in patients infected with of H. pylori cagA positive strains
than in those who were infected with H. pylori cagA negative.
Conclusion: These results can help us better understand the mechanism
by which H. pylori prevent a severe immune response and thereby
facilitates its stay in the stomach. The balance in the production of
anti-and pro-inﬂammatory cytokines may play an important role in
the development of severe gastric pathologies and the pathological
mechanisms of H. pylori infection in individuals at risk.
P582 Prevalence and distribution of virulence factor jhp0562 and
jhp0563 genes among Spanish Helicobacter pylori clinical
isolates
A´. Somodevilla*, T. Alarco´n, E. Aznar, M.J. Martı´nez, M. Lo´pez-Brea
(Madrid, ES)
Objective: The aim of this study was to determine the presence and
distribution of two glicosiltransferases encoded by jhp0562 and jhp0563
genes. These glicosiltransferases are involved in the lipopolysaccharide
(LPS) synthesis. The presence of jhp0562 has been recently related with
peptic ulcer disease.
Methods: Helicobacter pylori strains were obtained from biopsies of
symptomatic patients between 2008 and 2009. Biopsies were cultured in
Blood and Pylori Agar plates incubated at 37ºC in a 5% CO2 atmosphere.
DNA extraction of each strain was performed by using the automatic
system EasyMag (BioMe´rieux).
After conventional PCR with previously described primers, fragments
of 301 bp (jhp0562) and/or 602 bp (jhp0563) were detected by
electrophoresis with 1,2% agarose gel.
Results: 63 strains from symptomatic Spanish patients were studied.
Patients included 27 children (42,86%) and 36 adults (51,14%). The
prevalence of jhp0562 gene in the whole population was 53,9% (34 out
of 63) whereas for jhp0563 was 88,88% (56 out of 63).
Among pediatric patients results showed a 51,85% of positivity for
jhp0562 (14 out of 27), while the prevalence for adult patients was
58,33% (21 out of 36). Differences were not statistically signiﬁcant.
For jhp0563 results showed 96,3% of prevalence in children (26 out of
27) and 86,11% (31 out of 36) in adults. Differences were not statistically
signiﬁcant.
Distribution of CagA and Vacs1 genes was: 20 CagA (31,74%) and 20
vacs1 (%31,74) positive strains respectively.
Relationship between jhp0562 and jhp0563 with these two virulence
factors is presented in the table.
Conclusions: Jhp0562 was present in more than 50% of the population
studied whereas jhp0563 prevalence was almost 90%. Age seemed not to
be an important factor for the prevalence of any genes studied. However,
jhp0562 was statistically related with the presence of other important
virulence factor as Vac s1 and CagA.
P 0,01.
P583 Molecular characterisation of Helicobacter pylori associated
to different gastric pathology in adult Moroccan population:
prospective study
S. Alaoui, B. Bennani, M. Mahmoud*, M. Lahbabi, D. Benajah, M. El
Abkari, A. Ibrahimi, H. Belghiti, A. Amarti, K. El Ghazi, C. Nejjari,
A. Souleimani (Fez, MA)
Objective: The aim of our study is to determine the prevalence of
Helicobacter pylori (H. pylori) infection in our region and to deﬁne
the genotype diversity of identiﬁed strains and their association with
clinical presentation.
Methods: A prospective and randomized study has been conducted in
the gastroenterology department of university hospital Hassan II of Fez
from May 2009 to September 2010. A personal interview and a clinical
examination were conducted for all consenting patients enrolled in the
study. They had undergone endoscopy for diagnosis of abdominal pain or
discomfort and to collect gastric biopsies. For each patient, two biopsies
were examined by Polymerase Chain Reaction (PCR) to detect ure C
gene of H. pylori. The genotype characterization consists on the Cag A
status and Vac A sub-types determination, directly from biopsies. The
statistic analysis has been done using Epi-info.
Results: During the 16 months of the study, 330 patients have been
recruited. The mean age of the participants was 49 years. Clinical data
shows that 65.7%, 22% and 8% of patients have gastritis, peptic ulcer
disease and gastric cancer respectively. However, 4.3% of participants
present normal mucosa at endoscopy. PCR results showed that H. pylori
infection occurs in 68.4% of the cases. Genotypic analysis of 226
positives PCR showed that cag A gene has been found in 26.10%. Vac
A signal sequence genotypes s1 and s2 were detected in 35% and 42.3%
of the studied specimens respectively. The vac A middle region m1 has
been detected in 31.4% of the cases versus 55.9% for m2. All vac A
subtypes combination were founded with predominance of vacA m2-
s2 (33.2%) whereas, vacA m1-s2 was present with rang of 1.5%. A
multiple infection was detected in 9.4% of H. pylori positive cases. It is
also noticed that sub-type m1s1 was the most related genotype to cag A
(31%).
In the 14 patients with a normal endoscopy, 8 were H. pylori positives.
Determined genotypes of those specimens were vac A m2s2 (37.5%) or
one allele type of m or s region (62.5%). No signiﬁcant association has
been established between genotype and gastric pathology.
Conclusion: The primary results of our study showed that the sub-
type vacA m2-s2 is the most predominant in our series. No association
between H. pylori genotypes and clinical outcomes has been determined
in our region.
P584 Prevalence of virulence factor HomB among Spanish
Helicobacter pylori clinical isolates
A´. Somodevilla*, T. Alarco´n, M. Espı´nola, P. Urruzuno, M. Lo´pez-Brea
(Madrid, ES)
Objective: The aim of this study was to determine the prevalence and
distribution of gene HomB, recently proposed as new Helicobacter pylori
virulence factor. This gene encodes an outer membrane protein related
with adherence and proinﬂamatory Helicobacter pylori properties.
HomA gene, associated with non-ulcer disease, was also studied.
Methods: Helicobacter pylori strains were obtained from biopsies of
symptomatic patients between 2008 and 2009. Biopsies were cultured in
Blood and Pylori Agar plates incubated at 37ºC in a 5% CO2 atmosphere.
DNA extraction of each strain was performed by using the automatic
system EasyMag (BioMe´rieux). After conventional PCR with previously
described primers, fragments of 128 bp (HomA) and 161 bp (HomA)
were detected by electrophoresis with 1,2% agarose gel.
Results: 60 strains from symptomatic Spanish patients were studied.
Patients included 26 children (43,3%) and 34 adults (56,7%).
The prevalence of HomB gene in the whole population was 55% (33 out
of 60) whereas for HomA was 45% (27 out of 60).
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Among pediatric patients results showed a 55,69% of positivity for
HomB (15 out of 26), while the prevalence for adult patients was 47,05%
(16 out of 34). Differences were not statistically signiﬁcant.
Distribution of CagA and Vacs1 genes was: 18 CagA (30%) and 18
vacs1 (30%) positive strains respectively.
Relationship between HomB and HomA with these two virulence factors
is presented in the table.
Differences were not statistically signiﬁcant for both virulence factors.
Conclusions: HomB was present in more than a half of the population
studied. It seemed to follow an age pattern being more prevalent
among pediatric patients, although results in the population studied are
not statistically signiﬁcant. Differences in HomB distribution among
different genotypes had not been found in this study.
P585 Mice immune responses to UreB332-HpaA, a recombinant
fusion protein from Helicobacter pylori
B. Hajikhani*, S. Najar Peerayeh, H. Soleimanjahi, Z. Hassan (Tehran,
IR)
Objectives: Helicobacter pylori (H. pylori) is a spiral-shaped, mi-
croaerophilic, Gram-negative bacterium that colonizes the human gastric
and duodenal mucosa, where it induces chronic gastritis and peptic ulcer.
H. pylori infection is also associated with gastric MALT lymphoma
and gastric cancer. Current antibiotic therapies together with a proton-
pump inhibitor entail problems such as patient compliance, increasing
antibiotic resistance, recurrence, re-infection and high cost. Vaccination
is an attractive strategy, either as an alternative or a complementary to
antibiotic treatment, for clearance of H. pylori. In this way many of
H. pylori virulence factors have been tested to investigation their role in
different immune response induction.
Methods: At the current study a recombinant fusion protein from
H. pylori consisting of a fragment of B subunit from H. pylori urease
(UreB332) and helicobacter pylori adhesion A (HpaA) named UreB332-
HpaA have been produced and then the immune responses to this fusion
protein were tested in BALB/c mice.
Results: Subcutaneous administration of the fusion protein signiﬁcantly
induced immune responses in mice which were associated with H. pylori-
speciﬁc IgG1, IgG2a and sIgA antibodies production as well as IFN-g
and IL-4 cytokines which proposed a mix Th1/Th2 immune responses.
The Fusion antigens elicited stronger immune responses compare to each
single antigen (p< 0.001).
Conclusion: The results show that this bivalent fusion protein efﬁciently
elicited different types of immune responses and that an antigenic
fragment of the protein can be used instead of the whole protein to
construct a multivalent vaccine in further studies.
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P586 Prospective application of the Luminex xTAG®-GPP
multiplex PCR in diagnosing infectious gastroenteritis
E. Wessels, L. Rusman, M. van Bussel, L. Lan, D. Himsworth,
E. Claas* (Leiden, NL; Toronto, CA)
Objectives: Infectious gastro-enteritis (GE) is a major diagnostic
challenge as it can be caused by parasites, bacteria and viruses. The
Luminex Gastro-enteritis Pathogen Panel (xTAG®-GPP) detects 18 most
common GE causing pathogens including viruses (norovirus GI and
GII, adenovirus, and rotavirus), bacteria (Campylobacter, Salmonella,
Shigella, E. coli O157, Vibrio, and Yersinia), toxins (Clostridium toxins
A/B, Shiga toxins 1 and 2, and ETEC toxins) and parasites (Giardia,
Cryptosporidium and Entamoeba histolytica). This study shows the ﬁrst
prospective application of this assay.
Methods: From June to August 2010, 200 consecutive samples were
subjected to routine diagnostic procedures, i.e. culture for bacterial
pathogens and multiplex real-time PCR for viruses and parasites. The
samples were also analyzed by the xTAG®-GPP assay. In addition
77 positive (and 23 negative) samples were selected to include more
different pathogens in the analysis.
Results: 70 out of the 200 samples were positive in the xTAG®-
GPP assay. A total of 55/200 (27.5%) samples were positive for
Campylobacter sp., 4 for Shigella sp., 1 for Salmonella, 6 for Clostridium
difﬁcile, and 4 contained the ETEC ST toxin. Only six of these positives
were detected by bacterial culture. The diagnostic positive results for
parasites (4 Giardia lamblia, 1 Cryptosporidium parvum) and viruses
(4 Norovirus GII) were all detected by the xTAG®-GPP. Unresolved
inhibition was observed in 11 samples.
In the selected group, 39 Campylobacter sp. positive samples were
detected of which 17 were culture positive. Out of 37 virus positive
samples, 33 were conﬁrmed by the xTAG®-GPP assay and 4 with high
Ct values were not detected. Of 23 parasite positives, 17 were detected
by the xTAG®-GPP but three additional Giardia positive samples were
detected. Added value of the xTAG®-GPP assay is detection of additional
positive results, undetected in routine diagnostics mainly because the
analysis had not been requested by the clinician. For instance, in two
Cryptosporidium positive samples, E. coli O157 and ETEC-LT were
detected.
Conclusion: The 18-target multiplex of the xTAG®-GPP assay results
in a slight decrease of sensitivity for some targets. In general, the
concordance with current diagnostic molecular methods was good and
clearly superior to bacterial culture. Added value of the x-TAG®-GPP is
that pathogens not suspected in the infection are being detected, resulting
in improved diagnosis of gastro-enteritis.
P587 Screening for enteropathogenic Escherichia coli by an
eight-plex PCR of nucleic acids extracted directly from
human stools using the NorDiag Bullet stool DNA kit
J.K. Møller*, B. Kolmos, M.H. Dahl, L. Pødenphant, D. Ørnskov
(Vejle, DK)
Objectives: To evaluate the performance of an in-house eight-plex
PCR assay, amplifying eight speciﬁc virulence genes and one internal
control gene (16S rRNA) in a single reaction to screen for the ﬁve
main pathotypes of diarrheagenic E. coli. Three different approaches for
nucleic acids extraction were applied: (1) directly from stool samples,
(2) from a scrape across the primary culture plates after conventional
culture of the stool samples on the SSI Enteric Medium (Statens Serum
Institut, Copenhagen), (3) from E. coli representing different colony
morphology subcultured on chromID™ CPS® plates (bioMerieux).
Methods: Nucleic acids were extracted directly from stool specimens
using the Bullet stool DNA sample kit and protocol from NorDiag (Oslo,
Norway) and from culture plates by boiling and dilution of scrapings or
E. coli colonies. Primer sets for the eight virulence genes were used:
Stx1, Stx2, and eaeA for enterohemorrhagic E. coli (EHEC), eaeA for
enteropathogenic E. coli (EPEC), STIb, Sta, and LTI for enterotoxigenic
E. coli (ETEC), ipaH for enteroinvasive E. coli (EIEC), and aggR for
enteroaggregative E. coli (EAEC). Each forward primer was labelled
with a ﬂuorochrome and the PCR products were separated by multicolour
capillary electrophoresis on an ABI PRISM™3130 Genetic Analyzer
(Applied Biosystems). True positive samples were deﬁned as being PCR
positive in at least 2 of the 3 comparative assay protocols.
Results: A total of 387 randomly selected stool samples submitted
from patients with persistent diarrhoea were included during the study
period. Overall 102 (26.4%) stool samples contained one or more
of the seven virulence genes. The sensitivity of the eight-plex PCR
on direct stool material, culture scrapings, and E. coli colonies was
97.1% (99/102), 91.2% (93/102), 76.5% (78/102), respectively. The
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corresponding speciﬁcity was 98.2% (280/285), 98.6% (281/285), and
100% (285/285), respectively. The eaeA gene was the most commonly
found gene, 61.5% (64/104) of PCR-positive stools, 54.6% (53/97) of
PCR-positive scrapings, and 48.7% (38/78) of PCR-positive E. coli
colonies. Second most frequent gene was the aggR gene correspondingly
seen in 45.4%, 44.2%, and 52.6% of the PCR-positive samples.
Conclusion: Screening for virulence genes by PCR of DNA extracted
directly from stool samples followed by culture conﬁrmation of PCR-
positive samples may provide an effective and rapid alternative strategy
for detection of enteropathogenic E. coli.
P588 Microarray-based detection of virulence genes in verotoxic
Escherichia coli strains isolated from human, cattle and food
in Poland
A. Januszkiewicz*, J. Szych, J. Osek, W. Rastawicki (Warsaw, Pulawy, PL)
Objectives: Shiga toxin-producing Escherichia coli (STEC), is a one
amongst major causative agents of foodborne illness worldwide. That
emergance pathogens can cause diarrhea and hemorhagic colitis with
life-threatening complications, such as hemolytic uremic syndrome
(HUS). In Poland a few cases of human STEC infections are documented
per year among them so far only two patients developed HUS. There is
no data about prevalence of potential genetic virulence markers in STEC
strain in Poland. The aim of this study was to compare the distribution
of known virulence determinants in STEC strains isolated from human,
cattle and food in Poland.
Methods: We investigated 71 STEC strains from human (n = 45), cattle
(n = 16) and food (n = 10) isolated from 1999 to 2010. The isolates
were tested for verotoxin production by VTEC-RPLA (Oxoid) and
Vero cell cytotoxicity assay. Enterohemolytic phenotype (Ehly+) was
determined on blood agar plates containing 5% washed, deﬁbrinated
sheep erythrocytes (Oxoid). Presence of stx1, stx2, eae, ehly were
performed by convencional PCR. Sub-typing of the verotoxin genes were
determined by PCR. Microarray system (Identibac Ec) containing 92
virulence genes of various E. coli pathotypes, was used for detection of
virulence determinants.
Results: All of STEC strains produced active verotoxins which were
cytotoxic for Vero cell. STEC strains were positive for stx1 (n = 22),
stx2 (n = 27) or both (n = 22). The following variants of verotoxin
were detected: stx1a, sxt2a, sxt2b, sxt2c, sxt2d, sxt2g. All STEC
strains except 3 isolates from cattle (95,8%) were positive for the eae
gene. Enterohemolysin production (Ehly+) was detected in almost all
STEC strains (94,4%). The STEC strains were assigned to 40 different
virulotypes. We have found stable a core set of virulence genes in STEC
O26, O111 and O157. The core sets were serotype speciﬁc. In addition
to the cores there were strain speciﬁc determinants found in virulotypes.
STEC O157. isolates from human were similar to several STEC O157
isolates from cattle and food. While non-O157 STEC isolates from cattle
possesed virulence genes: subAB, saa, sta1, epeA, not detected in strains
from human and food.
Conclusion: The virulotyping microarray chip was able to distinguish
various virulotypes among STEC strains. STEC strains isolated in Poland
harboured serotype speciﬁc stable core of virulence genes which in some
strains was be extended by additional strain speciﬁc determinants.
P589 Evaluation of a new multiplex PCR as a tool for the identi-
ﬁcation of Campylobacter species in bacterial gastroenteritis
M.A. Lucien*, M. Boissinot, A. Huletsky, D. Boudreau, M.C. Helie,
M.G. Bergeron (Quebec City, CA)
Objectives: Bacteria belonging to the species Campylobacter represent
the most frequent etiological agent of human bacterial gastroenteritis in
the world. Their identiﬁcation can be made with phenotypical methods
which are time consuming, or with genotypic methods which are faster.
The aim of this study, was to develop a new PCR strategy to identify
Campylobacter species and compare the results to those obtained by the
phenotypic methods.
Material and Methods: We conducted a retrospective cohort study
on fecal isolates obtained at CHUL’s Hospital from 2007 to 2009. 242
consecutive isolates of campylobacteria that the microbiological lab had
identiﬁed with the hippurate test were submitted to PCR. Three pairs
of primers were combined in a triplex: one targets the tuf gene (this
study) of the Campylobacter jejuni subsp. jejuni and Campylobacter
jejuni subsp. doylei; and two others target napA and region ﬂanking
napA of C. jejuni jejuni and Campylobacter coli (W.G. Miller et al.
2007). With detection by agarose gel electrophoresis, C. jejuni jejuni
yields two bands: 836 pb and 1454 pb; C. jejuni doylei produces two
bands: 836 pb and 1240 pb; C. coli yields a single band at 1454 pb.
Based on this triplex PCR and conﬁrmation by sequencing, we should
be able to improve our ability to identify Campylobacter species and
subspecies.
Results: Among the 201 hippurate-positive isolates, 197 were conﬁrmed
by PCR as C. jejuni jejuni, and 4 were classiﬁed as other species. Within
the 41 hippurate-negative isolates, 31 were C. jejuni jejuni and 10 other
species by PCR. No C. jejuni doylei was found.
Conclusion: The results of the phenotypic methods have a good positive
predictive value when the hippurate test is positive; but when it is
negative, it misses a lot of C. jejuni jejuni. When the test for hippurate is
negative, it is essential to use the tuf-napA triplex PCR to have a better
representation of the real distribution of the Campylobacter species. This
new triplex PCR can help to precise the epidemiology and assist in the
choice for antibiotics in campylobacteriosis.
P590 Contrast-enhanced sonography for the diagnosis and therapy
of liver abscesses
R. Chiavaroli*, P. Grima, L. Gillini (Galatina, IT)
Objectives: Liver abscesses are often diagnosed by ultrasound detection
of focal liver lesion in patients with ﬂank pain and fever. Ultrasound
(US)guided drainage is useful to achieve an etiological diagnosis and to
speed up the clinical resolution after antibiotic therapy. Otherwise US
often underestimate small hepatic lesion while Computed Tomography
(CT) may fail to characterize necroting lesions mimicking liver
malignancy.
In our small study we showed how Contrast-Enhanced Sonography
(CES) can improve diagnosis and echo-guided therapy of liver focal
infections.
Methods: In our Department, from january to november 2010, we
admitted 10 patients (3 males and 7 females aged 11−65 years) with
fever and 29 total US detected focal lesions of the liver. All patients
were submitted to CT and CES using 2.4ml of second generation
US Contrast Medium (Sonovue − Bracco, Milan, Italy. Every patient
was also submitted to CES-guided drainage, pus and blood-colture,
serology for Bartonella henselae, Amoeba histolytica and Echinococcus
granulosus. The diagnosis of liver abscesses was achieved in all patients
and they were submitted to iv antibiothic therapy for 10 days. Monthly
follow up by CES was performed for a period of 3−9 months.
Results: In four out of ten patients pus and blood colture allowed to
achieve the ﬁnal diagnosis of pyogenic hepatic abscess by E. coli (2
patients), K. pneumoniae (1 patient) and S. bovis (1 patients). All patients
showed to be affected by underlying biliary or colonic diseases. In one
patient with a cat scratch disease serology for B. henselae allowed to
achieve the ﬁnal diagnosis. US examination detected only 18 out of 29
total liver abscesses while CES and TC were able to detect all 29 hepatic
lesions. CT fail to characterize 2 lesions mimicking liver metastatis while
CES allowed to characterize all liver lesions by detecting a rim arterial
enhancement in the early phase and a clear wash out in the portal and
late phase. Successfully pus-drainage and follow up was performed in
all patients by using CES to guide the procedures because of improved
detection of anechoic necrotic avascular areas.
Conclusions:
In our experience CES is a safe and effective tool in the management of
liver abscesses.
CES may improve and speed up the diagnosis of hepatic focal lesions
detected by US.
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CES is also usefull to characterize suspected liver malignancy after
inconclusive CT study and it is safe and effective to guide pus drainage
and clinical follow up.
P591 Distribution of Salmonella enteritidis and Salmonella
typhimurium phage types in Slovakia
L. Majta´nova´, V. Majta´n* (Bratislava, SK)
Objectives: The objectives of this study were to identify phage types of
both dominant Salmonella serovars, Enteritidis and Typhimurium, and to
ascertaine their distribution during the periode 1995–2009 in Slovakia.
Methods: The phage typing of 3900 S. Enteritidis isolates and 1741
S. Typhimurium isolates has been carried out in the periode 1995–2009.
A total of 3346 (85.8%) S. Enteritidis human isolates collected from
outbreaks or sporadic cases were isolated from faeces and 554 (14.2%)
strains originated from food. A total number of S. Typhimurium isolates
from human faeces was 1722 (98.9%) and only 19 (1.1%) strains were
isolated from food. For S. Enteritidis strains the phage typing system
described by Ward et al. (1987) has been used. The S. Typhimurium
strains were phage typed according to Callow (1959) and Anderson et al.
(1977) schemes.
Results: A total of 3802 (97.5%) S. Enteritidis isolates were typeable
and belonged to most frequent phage types PT8, PT4 and PT6. The
most predominant was PT8 over the period os study. In addition of these
observations, it was found that 183 S. Enteritidis strains with PT8 (67%
of the total PT8 food isolates), 58 strains with PT4 (59% of the total
PT4 food isolates) and 44 strains with PT6 (45% of the total PT6 food
isolates) were isolated from eggs and egg products. A total of 1343
S. Typhimurium strains (77.1%) were typaeble and belonged to different
PTs. Using the Callow typing scheme the most frequent phage type was
2b. According to Anderson’s typing scheme the most frequent PTs were
DT104, U302, DT193, DT20a, DT68, DT1 and DT2. The most dominant
phage type of isolates from food sources was PT U302.
Conclusion: Continual surveillance of both dominant Salmonella
serovars, Enteritidis and Typhimurium phage types monitors their
distribution during of large periods. The value of phage type information
is important for epidemiologic analysis salmonella infections, and in
following the emergence and spread of the important phage types such
as PT8, PT4 and DT104, U302 and relevant other.
P592 Comparison of two different Rappaport broths for the
detection of Salmonella in faecal specimens from patients
with gastroenteritis
L. Conter*, R. Vaiani, R. Botrugno, M. Reboldi, S. Missorini,
R. Colombo (Brescia, IT)
Objectives: In recent years automated instruments are available for
the microbiology laboratory that can be used only with samples in
liquid format. Copan is the ﬁrst company that introduced the Liquid
base microbiology (LBM) concept for samples collection followed by
the Walk Away Specimens Processor (WASP) to the microbiology
laboratory. Several specimens’ collection/transportation devices and
enrichment broths in a format suitable for automation are available
including a Rappaport Vassiliadis Soya (RVS) broth. The objective of
this study was to compare the performance of Copan RVS broth to the
Rappaport-T (RT) broth (bioMerieux) for the detection of Salmonella in
faecal specimens.
Methods: Clinical faecal specimens (253), received at the Fleming Labs
for the investigation of gastroenteritis, were used for this comparison.
Each sample was tested in duplicate, one as per routine method, 10mg
of sample was seeded into the 9mL RT broth in a glass tube, and a
same sample aliquot was seeded into the 2mL RVS broth in a plastic
tube. After 18−24h incubation at 37ºC inoculated 10 ul of each broth
were inoculated in SS and chromogenic SMID agar plates (bioMerieux).
After 24 incubation all positive colonies were tested with a latex poly
Salmonella antiserum (Oxoid) and serotyped with Salmonella group
speciﬁc antisera (DID/BioRad). Dubious culture were sub-cultured in
the same agar plates and identiﬁed as per above procedure.
Results: In the 253 tested 27 were salmonella positive and 224
salmonella negative in both RT and RVS broths. One sample was in
RVS was found salmonella positive on the 3rd passage and negative in
2nd passage in the Rappaport-T broth. The 20 Salmonellae positive were
identiﬁed eight serotypes O:9, 3, ﬁve serotypes O:6,7,8, six serotypes
O:4,5; eight were not identiﬁed.
Conclusions: Similar numbers of salmonella positive samples were
found in RVS broth compared to the RT broth. The 2ml RVS in plastic
tube demonstrate a good performance for the detection of salmonella in
faecal samples and was found as better device because is easy to use and
not prone to accidental breakage of during routine laboratory testing.
P593 Isolation of the emerging food-borne pathogen Arcobacter
from human stool
K. Houf*, S. Drieghe, A. Van den Abeele (Merelbeke, Ghent, BE)
Objectives: Arcobacters are Gram-negative slender curved bacteria
closely related to campylobacters. In humans, predominantly A. butzleri
has been associated with enteritis and occasionally septicaemia, but
also A. cryaerophilus and A. skirrowii have been isolated from stool
of diarrheic patients. Infection may occur by the consumption of
contaminated water and food or by direct contact. At present, for the
isolation of arcobacters from human specimens, Campylobacter, Yersinia
or Leptospira media are used. The aim of this study was to evaluate a
speciﬁc Arcobacter procedure (Houf et al., 2007) for the examination of
human stool from patients.
Methods: From January 2008 to November 2010, all stool samples
from out-patients and from in-patients admitted less than 72 hours to
a large secondary care hospital were included. Culture for all common
bacterial pathogens was performed. Arcobacter isolation was carried out
inoculating 1g faeces into 9ml of Arcobacter enrichment broth and
overnight incubation at 28ºC. Subsequently, 50ml was streaked onto
an Arcobacter selective agar plate. Plates were screened after 72 hours
microaerobic incubation at 28ºC by dark ﬁeld microscopy for typical
colonies and further identiﬁed by an Arcobacter species-speciﬁc PCR-
assay (Douidah et al., 2010). For patients with Arcobacter positive stools,
medical records were investigated for the presence of acute or recurrent
diarrhoea, abdominal pain and underlying disease.
Results: From 4868 eligible samples, 3597 (73.8%) were cultured for
arcobacters. In this group, Campylobacter spp. were on top of the
enteric bacterial pathogen list (5.4%) followed by Salmonella (3.0%) and
toxigenic C. difﬁcile (2,7%). Arcobacter was the fourth most common
isolated genus (1.3%), with almost equally isolation of A. butzleri and
A. cryaerophilus. Arcobacter butzleri positives tended to be in-patients
with diarrhoea and an underlying disease compared to A. cryaerophilus.
Arcobacter thereuis, recently isolated from aborted porcine foetuses
(Houf et al., 2009), was isolated for the ﬁrst time from a human patient.
Conclusion: Arcobacter was signiﬁcantly more isolated in this study
than in studies with other methods applied. Arcobacters were the fourth
most common organism isolated from stool in the study population and
A. thereuis was isolated for the ﬁrst time. Using the recently validated
veterinary isolation technique, routine recovery of arcobacters in humans
becomes feasible.
ESBL and AmpC in Enterobacteriaceae and
A. baumannii
P594 Acquisition of carbapenem resistance in multi-resistant
Klebsiella pneumoniae strains harbouring blactx-m-15, qnrs1
and aac(6′)-Ib-cr genes
E. Ruiz*, A. Ocampo-Sosa, A. Rezusta, M. Revillo, E. Roma´n,
C. Torres, L. Martı´nez-Martı´nez (La Rioja, Santander, Zaragoza, ES)
Objective: To characterize the acquisition of carbapenem resistance of
K. pneumoniae strains in a patient treated with carbapenems.
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Methods: Three K. pneumoniae isolates were recovered from two
clinical specimens from that patient. Presence of resistance genes, type
1 and 2 integrons and mutations in gyrA and parC genes was studied
by PCR and sequencing. The presence and mutations in ompK35,
ompK36 and ompK37 porin genes were analyzed by gene sequencing
and corresponding proteins were visualized by SDS-PAGE. Molecular
typing and phylogenetic group were determined by MLST and PCR-
RFLP, respectively. Genetic transfer of quinolone resistance genes was
carried out and the number and type of plasmids were analyzed by PFGE-
S1 and PCR-based replicon-typing (PBRT). Hybridization experiments
were performed with speciﬁc probes for blaCTX-M-15, qnrS1 and
aac(6′)-Ib-cr genes. The genetic environment of quinolone resistance
genes were studied by PCR-mapping and the aac(6′)-Ib gene expression
was determined by Real Time-PCR.
Results: The three isolates presented a close related PFGE pattern and
belonged to the KpI phylogenetic group and to a new MLST registered
as ST433. All of them showed the same resistance phenotype except
for the fact that only two of them were resistant to ertapenem, cefoxitin
and fosfomycin. The MICs to ertapenem, imipenem, meropenem and
doripenem in cabapenem susceptible/resistant isolates were 0.3/>32,
0.75/3−4, 0.13/8−12, and 0.19/8−32 g/L, respectively. All the strains
harboured qnrS1, aac(6′)-Ib-cr, blaCTX-M-15, blaOXA-1, blaSHV-11,
aac(3)-II, aph(3′)-Ia and oqxAB genes and wild type GyrA and
ParC proteins. The sequence of ompK35 and ompK36 genes showed
premature stop codons and the porins were not detected in the SDS-
PAGE gels of the ertapenem-resistant strains. The OmpK36 porin was
present in the SDS-PAGE gels of the ertapenem-susceptible strain. The
aac(6′)-Ib gene expression was three fold higher in one of the ertapenem-
resistant strains than in the susceptible one. Five plasmids were observed
by PFGE-S1 and colE and IncR plasmids were determined by PBRT.
Hybridization of blaCTX-M-15, qnrS1 and aac(6′)-Ib-cr probes was
detected in a plasmid of 30Kb in all the strains.
Conclusions: The use of carbapenems in the treatment of multiresistant
clinical isolates can cause the acquisition of carbapenem resistance due
to modiﬁcations in porin genes. This fact poses a serious health threat
due to the limited remaining options of treatment.
P595 Molecular characterisation of extended-spectrum b-lactamase
CTX-M-15 carrying Escherichia coli isolates from cattle
J.-Y. Madec*, A. Gourguechon, E. Saras, M. Haenni (Lyon, FR)
Introduction: Extended-Spectrum b-Lactamases (ESBLs) are a
widespread mechanism of resistance to antimicrobials in Gram-negative
bacteria. In the recent years, blaCTX-M-15 genes disseminated on a
pandemic way in humans, largely in association with the B2-O25b:H4-
ST131 clonal group of Escherichia coli. Interestingly, this clone has
been recently involved in the dissemination of blaCTX-M-15 among
companion animals, highlighting the possibility of a transmission from
their owners. Yet, blaCTX-M-15 genes were rarely reported in food-
producing animals and it was the aim of this work to characterize CTX-
M-15-producing E. coli isolates from cattle on a molecular basis.
Methods: Between 2007 and 2009, 77 non-duplicate E. coli clinical cat-
tle isolates collected in France were studied. Antimicrobial susceptibility
was tested by disk diffusion and ESBL production was determined by
double-disk synergy tests. The blaCTX-M, blaTEM, blaSHV, blaOXA,
aac(6′)-Ib-cr, qnrA, qnrB and qnrS genes were searched by PCR and
sequenced. Clonality was assessed by PFGE. Isolates were submitted to
phylogenetic grouping and O typing. Plasmids were rep typed on donor
strains and transconjugants and pMLST was performed where necessary.
Plasmid proﬁling was also carried out.
Results: All 77 E. coli isolates were ESBL producers and MIC for
ceftazidime ranged from 1 to 24mg/L. Nine isolates of MIC value equal
to or above 12mg/l of ceftazidime were further conﬁrmed as CTX-M-15-
producers. None of the qnr variants tested were found, but two isolates
contained the plasmid-mediated aac(6′)-Ib-cr gene. Isolates were mostly
unrelated and none of them was positive for the O25b:H4-ST131 clone.
Isolates belonged to the phylogenetic groups A, B1 or D, but never to
the B2 group. CTX-M-15-carrying plasmids were of the IncI1 or IncFII
groups.
Conclusion: This study showed that CTX-M-15-producing E. coli from
cattle did not belong to the pandemic B2-O25:H4-ST131 human virulent
clonal group, and that the blaCTX-M-15 genes were carried either on
IncI1 or IncFII plasmids. In particular, the same IncI1 plasmid circulated
among different backgrounds (A, B1 and D). Identical blaCTX-M-15-
carrying IncI1 plasmids were found in different farms and persisted over
years. These data reinforce the importance of plasmid versus clonal
dissemination in the transfer of resistance and question on the presence
of CTX-M-15-producing E. coli isolates in farms, where ceftazidime is
not prescribed.
P596 Genetic characterisation of CTX-M producing Proteus
mirabilis and Morganella morganii clinical strains with
association of resistance genes in Tunisia
S. Mahrouki, M. Ben-Moussa, O. Belhadj, M. Perilli*, G. Amicosante
(Tunis, Monﬂeury, TN; L’Aquila, IT)
Objectives: The aim of this study is to characterise the extended-
spectrum b-lactamases (ESBL) genes and their genetic environments
and the associated resistance genes in seven Proteus mirabilis and six
Morganella morganii ESBL-positive isolates recovered in the Military
Hospital of Tunisia.
Methods: From May 2005 to June 2009, 200 clinical isolates of Proteus
mirabilis and Morganella morganii were isolated from patients with
respiratory or urinary tract infections hospitalized at Military hospital
in Tunis (Tunisia). Antibiotic susceptibility was tested with the agar disk
diffusion method according to CASFM guidelines. ESBLs were detected
using a standard double-disk synergy test. Characterisation of ESBLs and
their genetic environments as well as integrons and their gene cassette
composition were performed by polymerase chain reaction (PCR) and
nucleotide sequencing. For the genotyping method, we used pulsed-ﬁeld
gel electrophoresis using SﬁI and SpeI restriction endonuclease.
Results: 21 of 200 (7%) strains exhibited non susceptibility to third
generation cephalosporins and among these strains the double-disk
synergy test conﬁrmed the phenotype of ESBLs in 13 isolates (62%).
These ESBLs producers were coresistant to chloramphenicol, tetracyclin
and oﬂoxacin, but remained susceptible to Ertapenem (MIC <0.25). By
PCR and nucleotide sequencing, we detected the presence of bla genes
as follows (number of isolates): blaCTX-M-15 (7), blaCTX-M-8 (1),
blaTEM-24 (10), blaTEM-1(4) and blaTEM-2 (4). ISEcp1, IS26 and
IS903, 0RF477 were located upstream and downstream, respectively,
of the blaCTX-M-15 gene in 7 strains. The intI1 gene was detected
respectively in four and one strains of M. morganii and P. mirabilis
including different gene cassettes: the combination dfrA1, orfC and aadB
were found, respectively, in 2 and 3 isolates. All CTX-M-15 producing
isolates showed unrelated PFGE patterns.
Conclusion: The emergence of mobile genetic elements like ISEcp1
carried blaCTX-M-15 gene in P. mirabilis and M. morganii was ﬁrst
discovered at the Military hospital in Tunisia. The incidence of these
strains invites continuous surveillance of the epidemiologic evolution of
these strains to prevent their dissemination.
P597 Biochemical characterisation of TEM-107 extended-spectrum
b-lactamase with an additional Arg164His substitution
compared to TEM-52
K. Lee, J. Yum, D. Yong, S.H. Jeong, J.D. Docquier, G.M. Rossolini,
Y. Chong* (Seoul, Busan, KR; Siena, IT)
Objectives: TEM-52 was a predominant TEM-type ESBL in Korea.
TEM-52 had the unusual feature of conferring decreased susceptibility to
moxalactam (MOX), and the enzyme hydrolyzed cefotaxime (CTX) more
efﬁciently than ceftazidime (CAZ). TEM-107 (GenBank accession No,
AY101764) is a novel ESBL found in a K. pneumoniae clinical isolate.
TEM-107 has an additional Arg164His change compared to TEM-52,
but the isolate was more resistant to CAZ than to CTX, and susceptible
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to MOX. Therefore, we investigated the biochemical characteristics of
TEM-107.
Methods: MICs were determined by an agar dilution method. The
recombinant plasmid (pET9a/blaTEM-107) was used to transform E. coli
XL1-blue, and BL21(DE3). TEM-107 was produced by culturing E. coli
BL21(DE3)-(pET9a/blaTEM-107) in ZYP-5052 medium. b-lactamase
was puriﬁed using two anion exchange chromatography steps. The
hydrolytic activity was determined at 30ºC, and the kinetic data were
analyzed using the Hanes-Woolf linearization of the Michaelis-Menten
equation.
Results: The MICs for K. pneumoniae isolate were CAZ 64mg/ml, and
CTX 2mg/ml. The resistance was transferred by conjugation. Arg164Ser
or Arg164His are frequently observed changes in TEM-type ESBLs,
which confer a higher level resistance to CAZ than to CTX. The MIC of
MOX was 1mg/ml. The puriﬁed TEM-107 protein preparation (puritiy,
>95% by SDS-PAGE analysis) showed an approximate pI of 6.0. The
turnover rate (kcat) of TEM-107 was higher for CAZ than for CTX.
Hydrolysis of MOX was not determinable. The catalytic efﬁciencies
(kcat/Km) of TEM-107 was slightly higher for CAZ than for CTX. The
IC50s of clavulanic acid was 0.61±0.1mM.
Conclusion: The MIC of CAZ was much higher than that of CTX for
a TEM-107-producing clinical isolate and the transconjugant, and the
isolate was susceptible to MOX. The kcat value of TEM-107 was much
higher for CAZ than for CTX, and the kcat/Km value was slightly higher
for CAZ than for CTX.
P598 Cephalosporin and clavulanic acid resistance mechanisms in
Escherichia coli isolates from cattle in Portugal
C. Pomba*, F. Louc¸a˜o, N. Couto, M. Delgado, J. Duarte Correia
(Lisbon, PT)
Objectives: To characterize the b-lactamase resistance mechanisms
involved in the resistance to oxyimino-cephalosporines, cephamycins and
clavulanic acid in E. coli isolated from cattle in Portugal.
Methods: Faecal samples were randomly selected by Veterinarians
participating in the study, between 2003 and 2006, and sent to
the Clinical Pathology Laboratory. E. coli isolates (n = 164) were
recovered from diarrhoeic calves (n = 100). MICs were determined by
the microdilution broth method. The presence of b-lactam resistance
genes, including plasmid-mediated AmpC b-lactamases was studied.
ESBL production was characterized by PCR using speciﬁc primers and
full-gene PCR products sequencing. TEM genes were fully sequenced
in isolates with MICs to amoxicillin/clavulante 32/16mg/ml. In E. coli
isolates with MICs to cefoxitin 32mg/ml, the promoter and the entire
reading frame of the chromosomal ampC gene were sequenced.
Results: From a total of 164 animal E. coli isolates 137 (84%) were
amoxicillin-resistant. Sixteen E. coli isolates out of 164 exhibited MICs
32/16mg/ml for amoxicillin/clavulante (Amc). From these, 6 isolates
had the blaTEM-1 gene (probably TEM-1 hyperproducers strains), 6
were IRT producers (3 IRT-2 and IRT-5), 3 were OXA-type, and 1 had
both TEM-1 and OXA-type enzymes. Nine E. coli isolates out of the
164 exhibited MICs 32mg/ml for cefoxitin. From these, 7 strains were
AmpC hyperproducers due to promoter mutations at positions −42, −18,
−1 and +58 (Group 1, n = 3) and +70 plus mutations in the attenuator
+22, +26, +27 and +32 (Group 2, n = 4). Group 2 strains had additional
mutations in the omega loop sequence, at positions Q180H, N185T and
P193S. Group 3 included 2 strains, which presented mutations only in the
ampC gene that corresponded to amino acid substitutions in the omega
loop (A220T) and in the helix H-11 (D351T). No plasmid-mediated
AmpC b-lactamases were detected. Seventeen E. coli isolates had MICs
128mg/ml for cefotaxime, of which 14 were CTX-M-32 and 3 were
CTX-M-14 producers.
Conclusions: Even though chromosomal ampC gene mutations and re-
sistance to clavulanic acid had emerged, extended-spectrum b-lactamases
were only ﬁrst detected in 2004. Our ﬁndings are of critical relevance,
as they show cattle as reservoirs for resistant bacteria that may enter
the food-chain. Furthermore, transfer of resistance markers and resistant
strains between animals and caretakers by direct contact is a strong
possibility.
P599 Genetic characterisation of an extended-spectrum
AmpC-cephalosporinase with hydrolysing activity against
fourth-generation cephalosporins in a clinical isolate of
Enterobacter aerogenes selected in vivo
J.M. Rodrı´guez-Martı´nez*, P. Ferna´ndez, F. Ferna´ndez-Cuenca, P. Diaz
de Alba, A. Briales, A´. Pascual (Seville, ES)
Objective: AmpC cephalosporinases with broadened substrate activity
(ESACs) have been reported in Enterobacteriaceae, Pseudomonas
aeruginosa and Acinetobacter baumannii, which mainly present changes
in four regions in the vicinity of the active site. Here, we characterized
a new AmpC variant selected in vivo from Enterobacter aerogenes
presenting a broadened substrate activity toward fourth generation
cephalosporins.
Methods: Two clonally-related consecutive isolates of E. aerogenes (Ea-
563 and Ea-595) obtained from a 74-year-old patient were evaluated.
Ea-595 presented high level of cefepime (FEP) resistance (MIC of
64mg/L) after 13 days of treatment with this agent. Screening for
ESAC production was performed using Mueller-Hinton agar plates
containing 200mg/L of cloxacillin (CXL). MICs were determined by
microdilution (CLSI guidelines). blaampC gene was characterized by
PCR and sequencing. blaampC genes were cloned in pCR-Blunt-TOPO
vector and expressed in E. coli Dh10B and E. coli HB4 (lacking
OmpC and OmpF porins). Speciﬁc activity against FEP was determined.
The structural changes in this ESAC b-lactamase were analysed by
modelization using Swiss-Pdb Viewer software.
Results: Isolate Ea-563 was resistant to ceftazidime (CAZ) and
susceptible to FEP (MIC of 0.5mg/L). Isolate Ea-595 was resistant
to fourth generation cephalosporins, both FEP and cefpirome (CPO)
(MIC of 64mg/L). Using CXL-containing plates, the susceptibility to
CAZ and FEP was restored in Ea-595, suggesting overproduction of an
ESAC AmpC. Sequencing identiﬁed a new AmpC b-lactamase variant
in Ea-595 presenting one amino acid substitution compared to Ea-563,
Val291Gly inside the H-10 helix. Recombinant plasmids harbouring this
ESAC AmpC conferred a broadened resistance proﬁle against CAZ,
cefotaxime, and more signiﬁcantly against FEP and CPO, increasing the
level of resistance of 4- to 64-fold in E. coli. MIC for FEP increased
up to 4mg/L for the ESAC variant, 64-folds higher compared to the
regular AmpC in E. coli Dh10B. The speciﬁc activity against FEP for
this cloned ESAC variant was 17-folds higher compared to the regular
AmpC. Homology model approach suggested that the active site size
was increased in the ESAC variant.
Conclusion: In vivo selection of an ESAC AmpC b-lactamase, confer-
ring high level of resistance against fourth generation cephalosporins in
E. aerogenes is described. This broaden spectrum is caused by a new
modiﬁcation in the H-10 helix of this gene.
P600 Evaluation of phenotypic methods for the detection of
AmpC b-lactamase producers and their differentiation from
extended-spectrum b-lactamases in Enterobacteriaceae
E.C. Coyle*, J. Kavanagh, D. Keating, K. Schaffer (Dublin, IE)
Objectives: Currently there is no gold-standard phenotypic method for
the detection of AmpC b-lactamase in Enterobacteriaceae, hence their
detection creates a challenge for microbiology laboratories. We evaluated
and compared three phenotypic methods to identify AmpC b-lactamase
producers and differentiate them from ESBL’s in Enterobacteriaceae.
Methods: Isolates (n = 64) exhibiting increased cephalosporin resistance
were included in this study. The phenotypic methods investigated were;
the Cica-B Test (Mast), AmpC-ESBL detection discs D68C (Mast) and
AmpC and ESBL Etests (ABbiodisks/bioMerieux). The presence of
b-lactamases was conﬁrmed by molecular methods (two ESBL multiplex
PCR’s and an AmpC multiplex PCR) and phenotypic methods in
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conjunction with organism identiﬁcation (by Vitek 2) for intrinsic AmpC
production.
Results: Mast’s AmpC-ESBL detection discs D68C were proven to be
the superior method with a sensitivity and speciﬁcity of 83.3% and 100%
respectively. It detected AmpC b-lactamase producers (deprepressed,
induced or hyperproducing mutants) and ESBL producers. This simple
over night method identiﬁes either the AmpC or ESBL enzyme by
5mm difference between the cefpodoxime disc and the corresponding
cefpodoxime-b-lactamse-inhibitor combination disc. Furthermore, a
combined AmpC-ESBL producer can be detected in the same test by a
difference of 5mm between the cefpodoxime disc and the cefpodoxime
disc combined with both AmpC and ESBL inhibitors.
Conclusion: Of the three methods investigated, Mast’s AmpC-ESBL
detection discs D68C was proven to be a very reliable indicator of
the presence of AmpC or ESBL b-lactamses. It also detects combined
b-lactmase producers, which are becoming more prevalent. The Cica-B
Test was not reliable, while 20% of the AmpC-Etests were non-
determinable.
P601 Role of IS30 in the expression of the blaADC gene in
Acinetobacter baumannii
B. Lopes, A. Hamouda, S. Amyes* (Edinburgh, UK)
Objective: Multidrug-resistant Acinetobacter baumannii is a major
nosocomial pathogen that is rapidly evolving and developing resistance
to all major classes of antibiotics. It is identiﬁed by the presence of
intrinsic blaoxa-51-like gene and restriction of 16S-23S rRNA intergenic
spacer sequences. The aim of this study was to investigate the role
of insertion sequences related to the expression of cephalosporinanses
present in A. baumannii.
Methods: A panel of 17 geographically diverse A. baumannii
isolates was screened for the presence of insertion sequence upstream
and downstream of blaADC gene. The isolates were conﬁrmed as
A. baumannii by blaoxa-51-like PCR and by restriction analysis using the
enzymes AluI and NdeII. The MICs of ceftazidime were determined by
the BSAC guidelines. The strains were checked for ESBL production
by synergy disc assay between cephalosporins and augmentin (co-
amoxiclav).
Results: The MICs for ceftazidime showed that 4 strains had an MIC
of >256mg/L, 7 strains had an MIC of 128mg/L, 1 strain had an
MIC of 64mg/L and 5 strains had an MIC of 32mg/L. None of
the strains produced ESBLs as tested by synergy between augmentin
and cephalosporins such as ceftazidime, cefotaxime, ceﬁpime and
cefpodoxime. PCR results showed that ISAba1 was present upstream
of blaADC gene in 12 strains (MICs ranging from 32–128mg/L). Out of
the ﬁve strains having MIC of 32mg/L one strain did not have ISAba1
present upstream of blaADC gene. The 4 strains with MICs >256mg/L
harboured IS30 upstream of blaADC gene. There was no insertion se-
quence detected downstream for all 17 strains making it a defunct trans-
poson. The IS30 insert was observed 126bp upstream of blaADC gene.
Although the region just upstream of blaADC had functional had a func-
tional promoter, the IS30 element also had a promoter for the transposase
it carries and this may also increase the expression of the blaADC gene.
Conclusions: These data indicate the presence of a novel insertion
element IS30 besides ISAba1 that can cause over-expression of blaadc
gene. The isolates with IS30 may encode novel ADC variants having
signiﬁcant hydrolysing activity against ceftazidime. The IS30 element
may also have a better promoter than ISAba1 to cause blaADC
overexpression.
Mechanisms of carbapenem-resistance in
Enterobacteriaceae and P. aeruginosa
P602 Investigation of carbapenem resistance in Klebsiella
pneumoniae isolates from St. James’s hospital, Dublin, Ireland
C. Roche* (Dublin, IE)
Objectives:
• To identify b-lactamases in a collection of K. pneumoniae isolates
with reduced susceptibility to carbapenems.
• To examine the role of altered permeability as a potential mechanism
of carbapenem resistance in K. pneumoniae.
• To investigate the contribution of efﬂux mechanisms to carbapenem
resistance.
Methods: Phenotypic detection of carbapenemases was performed
using the Modiﬁed Hodge test. Further phenotypic detection of KPC
carbapenemases was performed by measuring ertapenem MIC values in
the presence and absence of phenylboronic acid. Detection of metallo-
b-lactamases and class A ESBLs was performed using Etest methods.
Carbapenem MIC values were measured in the presence and absence of
phenyl-arginine b-naphthyl-amide dihydrochloride (PABN) to examine
the contribution of efﬂux to resistance. DNA ampliﬁcation of MBL genes
including blaVIM, blaIMP, blaGIM and blaSPM, serine carbapenemase
genes blaKPC, blaSME and blaOXA-48, blaAmpC genes and class
A blaCTX-M, blaTEM, blaSHV and blaOXA genes was performed.
DNA ampliﬁcation of ompK35 and ompK36 genes was performed to
examine the contribution of outer membrane impermeability. Expression
of OmpK35 and OmpK36 was examined using SDS-PAGE and mass
spectrometry techniques.
Results: Reduced susceptibility to carbapenems shown by nine
K. pneumoniae isolates in this study found that for eight isolates, this
was the result of class A ESBL production, predominantly CTX-M types,
in combination with lack of expression of both OmpK35 and OmpK36
porins. Porin loss was shown using SDS-PAGE analysis and the mass
spectrometry techniques, MALDI-MS and nanoLC-ESI MSMS. Lack
of expression was proposed to result from mutations in the regulatory
regions of the porin genes, since these regions could not be ampliﬁed
by PCR techniques. One isolate produced a KPC-2 carbapenemase. This
isolate did not express the OmpK35 porin, which probably contributed
to the resistant phenotype.
Conclusion: This study found resistance to carbapenems demonstrated
by either production of class A ESBLs in combination with a loss
of both OmpK35 and OmpK36, or by production of a class A serine
carbapenemase in combination with loss of OmpK35. In both cases,
carbapenem resistance was seen in conjunction with resistance to other
antibiotic classes.
P603 Lack of 37kDa outer membrane protein in Klebsiella
pneumoniae associated with decreased susceptibility to
imipenem in Japan
T. Sho*, T. Muratani, R. Hamasuna, H. Yakushiji, M. Honda,
T. Kobayashi, N. Fujimoto, T. Matsumoto (Kitakyushu, JP)
Objectives: Resistance to carbapenems is uncommon in Enterobac-
teriaceae except for Serratia marcescens. There are some reports of
carbapenem-resistant K. pneumoniae strains with the production of
b-lactamases that are capable of hydrolyzing carbapenems combined
with decreased drug permeability through the bacterial outer membrane
due to loss or alternation of porins. In 2006, we isolated imipenem-high-
resistant Klebsiella pneumoniae (imipenem MIC of 32mg/ml) harbouring
metallo-b-lactamase IMP-1 with lack of 37kDa outer membrane protein
from the urine of hospitalized patients for the ﬁrst time in Japan. And
since 2008, K. pneumoniae isolates showing decreased susceptibility
to imipenem have begun to emerge in our hospital. The purpose of
this study is to investigate the mechanisms of carbapenem-resistant
K. pneumoniae strains showing decreased susceptibility to imipenem.
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Methods: K. pneumoniae strains were isolated from clinical material
obtained from our hospital in 2008 to 2009. The MICs of various
antimicrobials were determined by agar dilution method in accordance
with CLSI. The presence of b-lactamases was conﬁrmed by PCR and
DNA sequence analysis. Outer membrane proteins (OMPs) were isolated
by Sarkosyl extraction and examined by SDS-PAGE.
Results: In the 1693 K. pneumoniae isolates collected in our hospital,
ﬁve isolates showed decreased susceptibility to imipenem (MICs of 2
to 4mg/ml). These ﬁve isolates, K. pneumoniae Lkp1008, Lkp1012,
Lkp1015, Lkp1026, and Lkp1027 had blaDHA-1 or blaSHV, but did
not have genes of carbapanemases like IMP-1, IMP-2, VIM-1, VIM-2,
NDM-1 or KPC-type b-lactamases. Strains showing imipenem MICs
under 2mg/ml had two OMPs of approximately 36 and 37kDa. Three
isolates, K. pneumoniae Lkp1012, Lkp1026, and Lkp1027 showing
imipenem MICs of 4mg/ml lacked OMPs of approximately 37kDa.
Conclusion: We reported K. pneumoniae isolates with lack of 37kDa
OMP showing decreased susceptibility to imipenem in Japan. Lack
of 37kDa OMP appeared to be one of the mechanisms of imipenem
resistance. In our knowledge, this is the ﬁrst report of carbapenem
resistance Klebsiella pneumoniae due to lack of outer membrane protein
of approximately 37kDa in Japan.
P604 KdgM a novel porin associated to carbapenem resistance in
Klebsiella pneumoniae
L. Garcia-Sureda*, A. Dome´nech-Sa´nchez, C. Juan, S. Albertı´ (Palma,
ES)
Objectives: In the last years, an increasing frequency of carbapenem-
resistant K. pneumoniae isolates has been reported world wide. In
some of these reports, resistance to carbapenems was caused by the
combination of different resistance mechanisms including loss of major
porins (OmpK35/36) expression. In this work, we investigated the
expression of alternative porins that might compensate the absence of
the major porins in the carbapenem resistant isolates.
Methods: Analysis of the outer membrane proteins from isogenic pairs
of carbapenem-susceptible and resistant strains isolated from different
hospitals was performed by SDS-PAGE and MALDI-TOF MS. Mutants
deﬁcients in the expression of those porins identiﬁed in the resistant
isolates and absent in the susceptible ones were constructed from
the resistant isolates by insertion-duplication mutagenesis. MICs were
determined following the manufacturer’s instructions. To investigate the
ﬁtness of the clinical isolates and their derived mutants, we conducted
competition experiments in vitro (growing the strains in Mueller Hinton)
and in vivo (in a murine model of systemic infection).
Results: A novel porin present in the carbapenem-resistant isolates
and absent in the susceptible ones was identiﬁed as KdgM, an
oligogalacturanate-speciﬁc monomeric porin that belongs to the KdgM
porin family. The structural features of the pore of this porin might
explain the low penetration of carbapenems and the resistant phenotype
of the isolates. Several attempts to mutate the KdgM coding gene, yjhA,
led to the reversion of the expression of the major porin OmpK36,
suggesting that KdgM expression compensates the loss of the major
porins in the resistant isolates. Finally, porin deﬁcient carbapenem-
resistant isolates expressing KdgM exhibited a reduced ﬁtness in vitro
and in vivo compared to their isogenic susceptible isolates expressing
the major porin OmpK36.
Conclusions: KdgM may represent an alternative porin for the
uptake of nutrients in the major porin-deﬁcient carbapenem-resistant
K. pneumoniae isolates.
P605 Accumulation of carbapenemase-producing Gram-negative
bacteria in a single patient linked to the acquisition of
multiple carbapenemase-producing strains and to the in vivo
transfer of a plasmid encoding VIM-1
L. Drieux*, N. Bourgeois-Nicolaos, J. Cremniter, C. Lawrence,
E. Macheras, V. Jarlier, F. Doucet-Populaire, W. Sougakoff (Paris,
Boulogne-Billancourt, Garches, FR)
Objectives: Six imipenem-resistant strains were successively isolated
from a single patient transferred from Greece to France in an
Intensive Care Unit (ICU). A few days after his admission, 2 MDR
Gram negative bacteria were isolated from rectal swab, Klebsiella
pneumoniae (Kp1) and Providencia stuartii (Ps), and an imipenem-
resistant Pseudomonas aeruginosa (Pa) was cultured from tibial wound
specimen. Two months later, a K. pneumoniae strain (Kp2), distinct from
Kp1, was isolated from wound drain ﬂuid. Two additional months later,
2 MDR Enterobacteriaceae, Proteus mirabilis (Pm) and Escherichia coli
(Ec),were isolated from rectal swabs. The molecular bases of resistance
to b-lactam antibiotics in these strains were investigated.
Methods and Results: The Kp1 strain showed a synergy between
imipenem and clavulanate, suggesting the production of a class A
carbapenemase identiﬁed by PCR and DNA sequencing as KPC-2.
Kp1 also harboured two bla genes encoding TEM-1 and the extended-
spectrum b-lactamase (ESBL) SHV-12. The Ps, Pm and Ec strains
were found to produce the metallo-b-lactamase (MBL) VIM-1 with an
additional ESBL, SHV-5, while both Pa and Kp2 strains had blaVIM-1
alone. Genes encoding VIM-1 and SHV-5 were co-transferred to E. coli
J53 by in vitro conjugation from Ps, Pm and Ec. Only blaVIM-1 was
transferred from Kp2. The ﬁngerprints obtained from plasmid DNA
digestions of the transconjugants TCPs, TCPm and TCEc were highly
similar, while the pattern obtained from TCKp2 was different. In all the
MBL producers, the blaVIM-1 gene was integrated in a class I integron.
PCR mapping of the variable region of the integron revealed three
distinct types of cassette arrays, of which one corresponded to a truncated
class-I integron shared by TCPs, TCPm and TCEc. In vivo conjugation
in a gnotobiotic mouse model permitted the transfer of the integron
carrying blaVIM-1 from the Ps strain to the recipient strain E. coli J53.
Conclusions: The time sequence of b-lactamase producers detection,
the molecular analysis of the genetic support of blaVIM-1 and the
conjugation results obtained in vivo in the gnotobiotic mouse model
strongly suggest the in-patient transfer between Ps, Pm and Ec of a
plasmid carrying a truncated class-I integron harbouring blaVIM-1.
This inter-species transfer, together with a probable acquisition of
multiple multidrug-resistant bacteria, led to a worrying accumulation
of carbapenemase-producing strains in a single patient.
P606 First detection of blaIMI-2 gene in a clinical Escherichia coli
strain
B. Rojo-Bezares*, C. Martı´n, C. Torres, Y. Sa´enz (Logron˜o, ES)
Objectives: To characterize the phenotype, and the genetic location of
the involved resistance genes in a clinical Escherichia coli strain resistant
to carbapenems.
Methods: A carbapenem-resistant E. coli W635 strain was obtained
from a faecal sample of an elderly patient who was admitted at a
Spanish hospital with fever and vomiting. Susceptibility testing to 33
antibiotics was performed by Microscan® system and by disc diffusion
method. Metallo-b-lactamase and class A carbapenemase phenotypes
were determined by E-test and double disc method, respectively. The
determination of class A carbapenemase, other involved antimicrobial
resistance mechanisms, class 1 and 2 integrons and multilocus sequence
typing (MLST) were performed by PCR and sequencing. Mating
experiments were assayed using E. coli CSH26 as recipient and plates
with meropenem (MEM) and rifampicin for transconjugant selection.
Characterization of plasmids in W635 strain and its transconjugants was
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performed by PCR-based replicon typing (PBRT), PFGE-S1, PFGE-
XbaI, southern blotting and hybridization (blaIMI-2, IncI1, IncF and
ColETP probes).
Results: E. coli W635 was ascribed to the new sequence type
ST1998, and showed resistance to imipenem, MEM, ertapenem,
ampicillin, ticarcillin, amoxicillin-clavulanic acid, cefazolin, cephalothin,
cefuroxime, streptomycin, nalidixic acid, ciproﬂoxacin, sulphonamides,
trimethoprim, fosfomycin; and intermediate resistance to aztreonam and
chloramphenicol. A class A carbapenemase positive phenotype was
found in E. coli W635 that harboured the blaIMI-2 gene with its LysR-
type regulator. In addition, this strain presented the blaTEM-1b gene, the
repC+sul2+strA+strB+ISCR2 structure, the S83L+D87N substitutions in
GyrA and the S80I in ParC, and harboured a class 1 integron with
dfrA1+aadA1 gene cassettes. E. coli W635 contained three typable
plasmids of IncI1 (ST26, CC-26), IncF and ColETP replicons. Three
different transconjugants from W635 strain were obtained (called TC1,
TC15 and TC18) that contained blaTEM-1b, the sul2 structure, the class
1 integron, and the IncI1 plasmid. TC1 and TC18 also harboured the
blaIMI-2 gene, IncF and ColETP plasmids. The blaIMI-2 gene in E. coli
W635 is related to IncF plasmid of approximately 48.5 Kb.
Conclusion: First report of a carbapenem-resistant E. coli strain carrying
the class A carbapenemase IMI-2. The blaIMI-2 gene was located in
a conjugative plasmid that contributes to the dissemination of these
enzymes.
P607 Emergence of OXA-181 carbapenemase-producing
Enterobacteriaceae
L. Poirel*, E. Lafeuille, S. Bernabeu, P. Nordmann (Le Kremlin-Biceˆtre,
FR)
Objectives: Recently, we identiﬁed an extensively drug resistant
Citrobacter freundii isolate in France from a patient who had
been transferred from India. That isolate co-expressed the metallo-
b-lactamases NDM-1 and VIM-1, but was also found positive for a
blaOXA-48-like gene, that latter encoding a carbapenem-hydrolysing
class D b-lactamase.
Methods: The genetic environnement of the blaOXA-48-like gene was
investigated by cloning experiments. Its mobility was evaluated by a
two-plasmid transposition assay. Expressions of OXA-48 and its variant
were compared in isogenic E. coli backgrounds.
Results: Sequencing revealed that the blaOXA-48-like gene identiﬁed in
C. freundii encoded a variant of OXA-48, namely OXA-181, differing
by four amino acid substitutions. Expression in E. coli showed that
both enzymes share the same susbstrate proﬁle, meaning that OXA-
181 hydrolyses carbapenems at low level but spares broad-spectrum
cephalosporins. The blaOXA-181-positive plasmid was transferred to
an E. coli recipient strain by mating-out assay. Identiﬁcation of the
genetic structures surrounding the blaOXA-181 gene showed that its
acquisition was linked to the insertion sequence ISEcp1, that may
mobilise adjacent sequences by a one-ended transposition mechanism,
and is also responsible for the mobilisation of many other resistance
genes, including the blaCTX-M and blaCMY b-lactamase genes. The
transposition of that ISEcp1-blaOXA-181 locus was demonstrated in
vitro. Screening of other isolates of our worldwide collection identiﬁed
blaOXA-181 in one K. pneumoniae from Sultanate of Oman and one
Providencia rettgeri from France. Noteworthy, the blaOXA-181 gene
was either plasmid- or chromosome-located in these two isolates.
Discussion: This study identiﬁed the spread of a novel carbapenemase
gene that has been found in different enterobacterial species. The
blaOXA-181 gene possessed similar hydrolytic properties compared to
OXA-48. Noteworthy, the association we evidenced between blaOXA-
181 and ISEcp1 suggests a high potency of dissemination. Interestingly,
these OXA-181-producing isolates were recovered from patients with a
link with India. Therefore, spread of OXA-181 may superimpose that of
NDM-1.
P608 Emergence of OXA-48-producing enterobacterial isolates in
France, with multiple importations from Turkey and North
Africa
L. Poirel*, N. Fortineau, P. Nordmann (Le Kremlin-Biceˆtre, FR)
Objectives: The aim of this study was to investigate the mechanisms
responsible for decreased susceptibility or resistance to carbapenems
from a collection of enterobacterial isolates of worldwide origin.
Methods: The genetic environnement of the blaOXA-48 gene was
studied by PCR combination using speciﬁc primers of IS1999 and
blaOXA-48 followed by sequencing. The plasmid scaffolds were typed
by a PCR speciﬁc for the RepP replicase featuring the blaOXA-
48-positive plasmid known to circulate at least in Turkey. Twenty
enterobacterial isolates exhibiting reduced susceptibility or resistance to
carbapenems were studied. They had been isolated in our hospital or in
other French hospitals.
Results: Six isolates produced the KPC-type or NDM-1 carbapenemases,
whereas fourteen were found positive for a blaOXA-48-like gene.
Most of these cases corresponded to patients transferred from foreign
hospitals, and corresponded to K. pneumoniae, E. coli, and E. cloacae
isolates from Turkey, but also E. cloacae from Morocco, E. coli from
Egypt, E. coli from Algeria. For some K. pneumoniae isolates, the
patients did not travel abroad. Most of these isolates showed only
decreased susceptibility to carbapenems according to the updated 2010
CLSI guidelines. In addition, some of them produced extended-spectrum
b-lactamases (ESBLs) being either of the CTX-M-14 or CTX-M-15
types, whereas others were not ESBL producers and therefore remained
susceptible to broad-spectrum cephalosporins. The same 70-kb plasmid,
that does not harbor other resistance determinants and possesses the
RepP backbone, was always identiﬁed in those OXA-48 producers.
Discussion: This study evidences a wide diffusion of OXA-48 producers
in France, with isolates recovered from patients with an expected link
to Turkey but more surprisingly to North African countries. Considering
the important size of the North African diaspora in France and cultural
relationships with that geographical area, it likely indicates that France
will face out a threatening dissemination of those carbapenemase
producers that need to be very early recognized in order to prevent their
further diffusion. Similar observations shall be observed in Germany,
Italy, and Spain in anear future.
P609 X-ray crystal structure of the Acinetobacter baumannii
OXA-24/40 Class D carbapenemase inhibited by NXL104
J.D. Docquier*, M. Benvenuti, J.M. Bruneau, G.M. Rossolini,
S. Mangani, C. Miossec, M.T. Black (Siena, IT; Romainville, FR)
Objectives: Class D carbapenem-hydrolysing b-lactamases represent an
emerging threat in clinically relevant Gram-negative pathogens. OXA-
24/40 is an acquired class D carbapenemase currently spreading in
carbapenem-resistant Acinetobacter baumannii clinical isolates, mainly
from Portugal and Spain. NXL104 is a new diazabicyclo-octanone
broad-spectrum non-b-lactam b-lactamase inhibitor presently in clinical
development. NXL104 was shown to inhibit the Klebsiella pneumoniae
OXA-48 carbapenemase, and the structure of the OXA-48/NXL104
complex was previously obtained. In order to investigate the potential of
NXL104 to inhibit divergent carbapenemase enzymes (such as OXA-48
and OXA-24), the structure of OXA-24 in complex with NXL104 was
determined.
Methods: OXA-24 b-lactamase was puriﬁed to homogeneity by
chromatography. Crystals of the inhibitor-b-lactamase complex were
obtained by co-crystallisation at pH 9.0. Diffraction data were collected
and the structure determined by molecular replacement, using the
coordinates of the native protein (PDB code, 2JC7) as the search model.
Results: The structure of OXA-24-NXL104 complex was determined at
2.4 angstroms resolution and expectedly shows the inhibitor molecule
covalently bound to Ser70. NXL104 interacts with conserved residues
of class D b-lactamases (including those of the SxV and KTG motifs)
essentially by means of polar contacts, although weak non-polar contacts
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were also observed. The typical tunnel-like entrance of the OXA-24
active site is observed in the complex structure and apparently does not
hinder inhibitor binding. As already observed in the OXA-48/NXL104
complex, the active site Lys73 remains carbamylated even in the presence
of the inhibitor.
Conclusions: This study provides structural insights on the interaction
between the new broad-spectrum non-b-lactam b-lactamase inhibitor
NXL104 and the OXA-24 class D carbapenemase. NXL104 is able to
inhibit OXA-24 in vitro by forming a stable covalent complex.
P610 Evaluation of a commercial microarray to detect
carbapenemase-producing Enterobacteriaceae
N. Woodford* (London, UK)
1 ARMRL, Microbiology Services Colindale, Health Protection Agency,
London, UK
2 Check-Point Health BV, Binnenhaven 5, 6709 PD Wageningen, The
Netherlands
Objectives: To evaluate a commercial microarray for detecting genes
encoding carbapenemases in clinical isolates of Enterobacteriaceae.
Methods: Sixty-four Enterobacteriaceae isolates were tested on the
Check-MDR CT102 ESBL-Carbapenemase Array (Check-Points): 41
were known to have a carbapenemase; 16 were carbapenem-resistant
through a combination of ESBL/AmpC activity plus impermeability
(porin loss), and 7 were carbapenem-susceptible controls. Total bacterial
DNA was extracted using a QIAGEN Blood and Tissue DNA puriﬁcation
kit and 10ml of undiluted DNA was used as template for the test. The
assays were undertaken according to the manufacturer’s instructions.
Image analysis and interpretation of the results used proprietary software
(Check-Points). Array results for carbapenemase genes were compared
with the carbapenem resistance mechanisms deﬁned previously by PCR
and sequencing.
Results: The correct carbapenemase gene was detected by the arrays in
all 41 carbapenemase-positive isolates, which included producers of KPC
(8), OXA-48 (11), IMP (12), NDM (7) and VIM (3) enzymes. There were
no false-negative results. The 16 carbapenem-resistant strains without
a carbapenemases were all negative by array. Six of the carbapenem-
susceptible controls were negative for all carbapenemase genes by the
array method, but one gave a false positive for blaVIM, though no such
gene was detectable by PCR.
Conclusion: This commercial array was easy to use and allowed accurate
detection of selected carbapenemases genes, including those emerging
or most prevalent in Europe and the USA. Simultaneous detection of
co-resident ESBL genes (not evaluated here) represents added value for
this method.
P611 Identiﬁcation of OXA-198, a novel carbapenem-hydrolysing
class D b-lactamase, in Pseudomonas aeruginosa
F. El Garch*, P. Bogaerts, C. Bebrone, Y. Glupczynski (Yvoir, Lie`ge, BE)
Objectives: To investigate an unusual enzymatic resistance mechanism
to carbapenems observed in a clinical isolate of P. aeruginosa.
Methods: Antimicrobial susceptibility was determined by Etests and
interpreted as recommended by CLSI. Class 1 integron, bla MBL, ESBL
and OXA-carba genes were sought by PCR-sequencing. Plasmid DNA
was extracted and electroporated in wild type P. aeruginosa PAO1 strain.
blaOXA-198 gene was cloned in Escherichia–Pseudomonas shuttle
vector pUCP24 and recombinant plasmid pOXA-198 was transferred
in E. coli TOP10 and in PAO1 by electroporation. b-lactamases activity
was observed by isoelectric focusing of crude sonicated cell extracts.
Hydrolysis of imipenem was followed on crude extracts at 300 nm and
with a modiﬁed Masuda’s phenotypical test.
Results: In April 2010, a multidrug carbapenem-resistant P. aeruginosa
(PA41437) but susceptible to expanded-spectrum cephalosporins was
recovered from lower respiratory tract specimen of an hospitalised 79-
yr old man. No synergy could be evidenced between imipenem and
EDTA, cloxacillin, boronic acid or clavulanic acid while a crude extract
clearly enhanced the growth of E. coli TOP10 near an imipenem disk
(Masuda test). By PCR none of the targeted b-lactamases genes were
detected but sequencing of a 3 kb amplicon obtained with primers
targeting class 1 integron revealed the presence of a novel blaOXA-
198 (HQ634775) in addition to aacA7 (encoding a aminoglycosides
modifying enzyme) and cmlA1 (encoding a chloramphenicol efﬂux
pump). OXA-198 shares 35%, 32%, 30% amino acid identity with
OXA-48, -58, -143 respectively and 29% with OXA-51, -23 and
OXA-40. blaOXA-198 was located on a non typable 50 kb plasmid
which, once transferred in P. aeruginosa PAO1, eventually led to a
reduced susceptibility to carbapenems. Cloning of blaOXA-198 gene
in pUCP24 in E. coli TOP10 and P. aeruginosa PAO1 also led to
transformants with reduced susceptibility to carbapenems. A slight
imipenem hydrolytic activity of an OXA-198 transformant crude extract
was observed by spectrophotometry (~7 nmole/min/mg).
Conclusion: We identiﬁed a novel class D carbapenem hydrolyzing
b-lactamase (CHDL) in P. aeruginosa responsible for a decreased sus-
ceptibility to carbapenems both in clinical strains and in transformants.
OXA-198 seems to be the ﬁrst representative of a new subgroup of
CHDL and the second CHDL recovered in P. aeruginosa.
P612 Characterisation of OprD in Pseudomonas aeruginosa
clinical strains showing high and intermediate levels of
resistance to imipenem and meropenem
A. Ocampo-Sosa*, C. Rodrı´guez, G. Cabot, E. Roman, F. Tubau,
M. Macia, B. Moya, L. Zamorano, C. Suarez, C. Pen˜a, A. Oliver,
L. Martinez-Martinez (Santander, Palma de Mallorca, Barcelona, ES)
Objective: To evaluate the impact of OprD inactivating mutations (IMs)
on the appearance of different resistance levels to imipenem (IMP) and
meropenem (MEP) in clinical strains of P. aeruginosa (Pa).
Methods: Fifty strains of Pa isolated from bacteremia in a multicenter
study and showing decreased susceptibility (MICs: 4−8mg/l) to IMP
and/or MEP (Pa-DS, n = 25) or resistance to these agents (MICs
16mg/l) (Pa-R, n = 25) were studied. MICs of IMP and MEP were
determined by microdilution, following the CLSI guidelines. The
presence of IMs in oprD was investigated by PCR ampliﬁcation followed
by sequencing of the entire gene. Nucleotide (nt) and amino acid (aa)
sequences were compared with those of the reference strain PAO1. OprD
expression was conﬁrmed by outer membrane protein (OMP) analysis.
OMPs were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). OprD proﬁles from clinical isolates were
compared with those of the reference strain PAO1 and a PAO1-
derivative oprD deﬁcient mutant. The presence of genes encoding
metalo-b-lactamases (MBLs) was also explored by PCR.
Results: Sequencing of the oprD gene showed that the studied strains
had several IMs resulting in the loss of porin OprD, as conﬁrmed by
analysis of their OMP proﬁles. The most frequent IMs were frameshift
mutations due to nt insertions or deletions (62%, including 12/25 Pa-R
and 19/25 Pa-DS), premature stop codon due to nt substitutions (24%;
9/25 Pa-R and 3/25 Pa-DS strains), several polymorphisms (10%, 2/25
Pa-R and 3/25 Pa-DS) and disruption of the coding sequence by an IS-
like element (4%; 2/25 Pa-R and 0/25 Pa-DS). A determined IM did not
directly correlate with the occurrence of a concrete level of resistance
to IMP and MEP. None of the isolates were found to produce MBLs.
Conclusion: IMs in oprD leading to OprD loss have been observed
in most Pa strains with either decreased susceptibility or resistance to
IMP and/or MEP. The level of resistance was independent of the IM
type, supporting the relevance of additional resistance mechanisms in
this phenotype.
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P613 Association of 16S rRNA methylases and NDM-1 in isolates
from Indian hospitals collected in 2006–2007
M. Castanheira*, L. Deshpande, R. Mendes, R. Jones (North Liberty, US)
Objective: To evaluate the association of 16S rRNA methylase genes
and NDM-1 metallo-b-lactamase among 15 Enterobacteriaceae isolates
collected in India during 2006 and 2007.
Methods: Fifteen NDM-1 producing Enterobacteriaceae (Escherichia
coli [EC; 6], Enterobacter cloacae [ECL; 3] and Klebsiella pneumoniae
[KPN; 6]) displaying resistant to amikacin (AMK), gentamicin (GEN)
and tobramycin (TOB; >32, >8, >16mg/L, respectively) were screened
for the presence of armA, rmtA, rmtB, rmtC, rmtD and npmA by PCR.
Amplicons were sequenced on both strands. Isolates were further tested
by CLSI reference broth microdilution MIC methods against arbekacin,
apramycin, kanamycin, neomycin, streptomycin and extended ranges for
AMK, GEN, TOB. Clonality was accessed by PFGE.
Results: Thirteen of the 15 (87.0%) NDM-1-producing isolates were
positive for 16S rRNA methylase-encoding genes (6 EC, 3 ECL
and 4 KPN; 2 KPN were negative). Isolates were collected in four
hospitals located in three cities (New Delhi, Mumbai, Pune). Nine
strains carried armA and three harboured additional genes: rmtC (2
EC) and rmtA (1 ECL). Three strains carried rmtC alone (1 each
species). Gene sequences showed 100% homology with armA, rmtA and
rmtC published sequences. Genetically identical EC and KPN carried
armA and ECL possessed rmtC. EC strains with similar PFGE proﬁles
harboured armA, rmtC or both. One ECL carried armA and rmtA.
Susceptibility proﬁles showed that all strains had AMK, GEN, TOB
and kanamycin MIC results at: 1024, 512, 512, 1024mg/L,
respectively. Arbekacin MIC results varied from 256 to 1024mg/L and
most isolates had streptomycin MIC values between 16 and 512mg/L;
however, one isolates had an MIC of only 4mg/L (rmtC-carrying ECL).
Apramycin and neomycin MIC results were lower compared to other
aminoglycosides tested (4−16 and 1−32mg/L, respectively).
Conclusions: 16S rRNA methlylases confer high-level of aminogly-
coside resistance, and the association of genes encoding 16S rRNA
methylases and b-lactamases have been reported. In this study, we expand
these results to large collection of strains producing NDM-1, showing
that these isolates carried one or two 16S rRNA methylases genes,
and displayed high levels of resistance to most aminoglycosides tested.
NDM-1-producing isolates were multidrug-resistant and the presence
of 16S rRNA methylases further limits the therapeutic options to treat
infections caused by these emerging pathogens.
P614 IMP-18-producing Klebsiella oxytoca, increasing genetic
diversity of metallo-b-lactamases in Mexican hospitals
M. Castanheira*, L. Deshpande, R. Morﬁn-Otero,
E. Rodriguez-Noriega, R. Jones (North Liberty, US; Guadalajara, MX)
Objectives: To characterize the carbapenem resistance (R) determinant
in a Klebsiella oxytoca (KOX) strain recovered from a wound infection
of an infant patient. IMP-18 was initially described from P. aeruginosa
(PSA) recovered from southwestern USA and the gene encoding this
MBL has been described more recently in PSA from Mexico, Puerto
Rico, Brazil, and France carried by distinct genetic contexts.
Methods: 183 Enterobacteriaceae strains collected in Mexican medical
centers during 2009 were susceptibility (S) tested by CLSI reference
broth microdilution MIC methods. Isolates displaying imipenem (IMI)
and/or meropenem (MER) MIC at 2mg/L were screened for
carbapenemase production using the Modiﬁed Hodge test (MHT) and
PCR reactions performed for genes encoding IMP-, VIM-, KPC-, OXA-
48, SME-variants, IMI/NMC-A, GES and NDM-1. Amplicons were
sequenced. Primers targeting the class 1 integron conserved structures
were used to reveal integron structure. S1 nuclease digest were resolved
in agarose and hybridized with blaIMP-18 probe.
Results: Three (1.6% overall) isolates showed carbapenem-R (one
of each: E. coli, K. pneumoniae and KOX). KOX (imipenem and
meropenem MIC values, 4 and 0.5mg/L, respectively) displayed a
positive MHT result and PCR followed by sequencing revealed the
presence of blaIMP-18. This isolate was recovered from a 2 y/o
female presenting with severe dysuria, latter diagnosed with a bladder
Rhabdomyosarcoma. After 13 months of chemotherapy a wound
infection developed. Vancomycin and meropenem were utilized after
poor initial response to ceftriaxone, amikacin and metronidazole.
Patient returned to the hospital with fever and bloodculture grew
KOX. Prolonged IV infusion of meropenem was initiated and 15
days later the patient was discharged. blaIMP-18 was located in
an integron with the follow cassette arrangement: intI1-blaIMP-18-
aacA4-aadA1-like(K201R and 235E236 insertion)-blaOXA-2-like(17
nucleotide insertion)-qacEdelta1/sul1. This MBL gene was located in
a 150-Kb plasmid.
Conclusions: A great variety of MBL enzymes have been described in
Mexico (VIM-2, VIM-23 in Enterobacteriaceae and IMP-15 and IMP-18
in PSA). Although IMP-18 was detected in several countries, this gene
was only reported in PSA. Our results demonstrate the mobilization
of blaIMP-18 to Enterobacteriaceae species (KOX) in a unique integron
structure, increasing the genetic diversity of MBLs in Mexican hospitals.
P615 Characterisation of Acinetobacter baumannii isolates causing
infections in animals
A. Endimiani*, K.M. Hujer, A.M. Hujer, I. Bertschy, A. Rossano,
C. Koch, V. Gerber, T. Francey, R.A. Bonomo, V. Perreten (Berne,
CH; Cleveland, US)
Objectives: A. baumannii (Ab) is emerging as a signiﬁcant human
opportunistic pathogen and is frequently responsible for hospital
outbreaks. Ab is also responsible for nosocomial infections in animals.
Presently, the molecular characterization of animal Ab isolates is lacking.
Here, we report the ﬁrst systematic analysis of resistance genes in Ab
strains obtained from clinical samples of veterinary origin.
Methods: Ab isolates from dogs (n = 12), cats (n = 3) and horses (n = 4)
were analyzed. Susceptibility tests were performed using Vitek 2 and
species identiﬁcation was obtained by MALDI-TOF. Rep-PCR was used
to study the clonality. MLST analysis and demonstration of the presence
of various blaOXA genes was carried out using PCR/ESI-MS on an Ibis
T5000 Biosensor. Aminoglycoside-modifying enzymes (AMEs), adeR
regulator of efﬂux pump AdeABC, gyrA, parC, b-lactamase genes, and
class 1−2 integrons were identiﬁed by PCR and sequenced. Expression
of b-lactamases was evaluated using the analytical isoelectric-focusing
(aIEF). Clinical data were retrospectively analyzed.
Results: All Ab isolates were susceptible to carbapenems and polymixin
B, but were resistant to cephalosporins. rep-PCR showed that the
majority of Ab belonged to 2 clonal lineages which are well known
as responsible for human infections. Clonal lineage A (n = 10) contained
strains of ST15 (European clone I) that were blaOXA69-positive and
harbored class 1 integrons carrying aacC1 and aadA1 AME genes.
Clonal lineage B (n = 7) included strains of ST12 (European clone II)
that were blaOXA51-positive and possessed the aacC2 AME gene. Two
isolates of ST10 and ST20 (one each) were also found. Twelve out of
the 19 Ab isolates were resistant to quinolones due to substitutions in
GyrA (Ser83Leu) and ParC (Ser80Leu or Glu84Lys). Carbapenemases
and extended-spectrum b-lactamase genes were not detected and only the
chromosomal ADC b-lactamase (pI of approximately 9.5) was observed
by aIEF. Ab strains were isolated from wound infections as well as
fasciitis, bloodstream and respiratory infections.
Conclusion: The two main Ab clonal lineages causing infection in
animals are similar to those frequently reported in human infections and
share a comparable molecular background of resistance. This analysis
suggests that antibiotic resistant strains of Ab may circulate between
human and animals.
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P616 Genotypic evaluation of a collection of Cfr-producing
staphylococcal clinical isolates from the SENTRY
Antimicrobial Surveillance Program
R. Mendes*, L. Deshpande, M. Castanheira, R. Jones (North Liberty, US)
Objectives: To evaluate the genotypic and phenotypic characteristics
of Cfr-producing staphylococcal clinical isolates submitted as part of
the SENTRY Antimicrobial Surveillance Program. Cfr-encoding gene is
often plasmid-located and therefore this recent linezolid (LZD) resistance
mechanism has the potential for mobilization.
Methods: Staphylococcal strains (76,303) submitted to the SENTRY
Program were tested for susceptibility (S) by reference CLSI methods
(M07-A8) and interpretations (M100-S20-U). Isolates with elevated
LZD MIC results (4mg/L) were screened for resistance mechanisms,
including cfr and mutations in the 23S rRNA-, L3- and L4-encoding
genes. cfr-positive strains were selected for this study and further
evaluated. Clonality was accessed by PFGE, spa (S. aureus [SA] only)
and MLST. Strains were identiﬁed by Vitek 2 and conﬁrmed by 16S
rRNA sequencing.
Results: Within 2006–2008, ﬁve cfr-positive strains were detected,
while nine and ﬁve Cfr-producing staphylococci were detected during
2009 and 2010, respectively (Table). Most (73.7%) cfr strains were
identiﬁed in coagulase-negative staphylococci (CoNS) and the LZD
MIC results in SA (4−16mg/L) were usually lower than those noted
in CoNS (8−>128mg/L). All SA were methicillin-resistant (MRSA)
and associated to internationally disseminated MRSA lineages, including
USA300 (isolate 1848). Among SA, no sequence type (ST) prevailed,
whereas ST23 was the commonest ST among CoNS. PFGE results
indicated the presence of CoNS strains with indistinguishable proﬁles
in medical centers in Guadalajara (Mexico), Tempe (USA) and Rome
(Italy). Overall, mutations in the 23S rRNA were not detected, except
in isolates 3147 (C2534T) and 27805 (G2576T), while alterations in the
L3 and L4 proteins were commonly observed, especially among CoNS.
Conclusions: Cfr-producing SA strains usually exhibited lower LZD
MIC values when compared with CoNS. This ﬁnding may be associated
with additional LZD resistance mechanisms in CoNS, such as mutations
in 23S rRNA, L3 and L4 proteins. Presence of cfr and 23S rRNA
alterations seems to be rare. The prevalence of cfr strains apprears to
be increasing slightly overyear in staphylococcal strains submitted to
this program; however, clonal dissemination was observed in several
medical sites, including the presence of a persistent clone (SEPI426A;
2007–2009) in a USA hospital.
P617 Prevalence of Tn6060-like transposons, harboured in a
pathogenicity island in Pseudomonas aeruginosa
E. Martinez*, A. Ingold, P. Roy Chowdhury, J. Merlino, C. Marquez,
H. Stokes (Sydney, AU; Montevideo, UY)
Introduction: Pseudomonas aeruginosa is a major opportunistic human
pathogen and is increasingly multi drug resistant and variable regions,
called pathogenic islands (PI), contribute to their antibiotic resistance
and virulence generally. Although, several PI have been identiﬁed in
P. aeruginosa, there has not been a detailed study of these regions
and the possible strain speciﬁc differences they provide, especially in
relation to the antibiotic resistance. We have reported a carbapeneme
resistant P. aeruginosa isolate from Sydney (Australia), which had two
class 1 integrons, one associated with a blaVIM-1 gene, and within a
new transposon, Tn6060. This transposon was inserted in a previously
identiﬁed PI, in the cystic ﬁbrosis P. aeruginosa strain PACS171b. Here,
we further assess the presence of this or related transposons in other
P. aeruginosa strains.
Methods: Isolates were collected from hospitals in Sydney, Australia
and Uruguay and screened by Polymerase Chain Reaction (PCR) for
intI1 and cassette arrays. Fosmid libraries were constructed from a
representative positive isolate from each country. These were CH79
(Australia) and, U09 (Uruguay). The sequences obtained were assembled
and identiﬁed using NCBI-BLAST. Pulsed-Field Gel-Electrophoresis
(PFGE) was performed to determine clonal relationships.
Results: Fosmid libraries from CH-79 and U-09 revealed that both have
the same Tn6060-like transposon seen previously but carrying different
cassettes which, in both isolates, comprised, aadA6-orfD. For both CH79
and U09 the point of insertion in the pathogenic island PACS171b was
the same as seen previously. Both of the isolates found here had a single
integron in the transposon at this location unlike the two seen in Tn6060.
However both CH-79 and U-09 had a second integron at a second
location in their respective genomes which had arrays that included a
blaGES in the former and a blaOXA gene in the latter. The location of
each of these two additional integrons was in different locations in the
chromosome. For CH-79 the integron was in a second PI and for U-09
it was in the chromosomal oprD gene. The two strains were different
based on PFGE analysis.
Conclusion: These results suggest that insertion of class 1 integrons in
PIs may be a global phenomenon with spread occurring via complex
mobile regions independent of clonal lines. More detailed analysis of P
aeruginosa strains with a broader geographic spread will be needed to
conﬁrm this.
P618 Provisional report of an association between the carbapen-
emase KPC and the pandemic clone E. coli 025b:ST131
I. Condon, C. Ludden, M. Corcoran, N. O’Connell, M. Cormican*,
T. Boo, D. Morris (Limerick, Galway, IE)
Objective: Escherichia coli 025b:ST131 is an extremely successful pan-
demic clone that has been implicated in the international dissemination of
CTX-M-15. The increasing emergence and dissemination of carbapenem
resistant (CR) Enterobacteriaceae is a major public health concern.
The association of carbapenemase enzymes with epidemic clones, such
as the recent association of KPC-2 and KPC-3 with the successful
K. pneumoniae ST258 clone represents a signiﬁcant public health threat.
The aim of this project was to characterise a CR E. coli (U490995.1)
identiﬁed during a project screening Enterobacteriaceae isolated at
the Mid-Western Regional Hospital in Ireland for carbapenemase
production.
Methods: All isolates of Enterobacteriaceae collected from all specimen
types since 25th January 2010 were screened for carbapenemase
production in accordance with Clinical Laboratory Standards Institute
(CLSI) screening and conﬁrmatory procedures. A single isolate of
carbapenemase-resistant E. coli was isolated from urine from a patient
co-infected with a CR K. pneumoniae. This isolate was examined for
susceptibility to 13 antimicrobial agents by disk diffusion and screened
for the presence of blaVIM, blaIMP and blaKPC by PCR as previously
described. A duplex PCR targeting the pabB and trpA genes was used to
determine if the isolate was a member of the 025b:ST131 clonal group.
Results: The isolate was susceptible to four of the thirteen antimicrobial
agents: streptomycin, chloramphenicol, minocycline and kanamycin.
PCR conﬁrmed the presence of blaKPC and indicated that the isolate
was 025b:ST131.
Conclusions: The identiﬁcation of an association between KPC and
E. coli 025b:ST131 is of major concern. CTX-M-15 is now the
Genetics of antimicrobial resistance S129
most widely reported extended spectrum b-lactamase worldwide. It’s
widespread dispersion is considered to be related at least in part to it’s
association with epidemic clones, predominately E. coli 025b: ST131.
Given the limited treatment options available for infection with KPC
and other carbapenemase producing strains, it’s association with the
successful E. coli 025b: ST131 clone is a cause for concern. Further
work to conﬁrm MLST type and characterise the plasmid from this
isolate is in progress.
P619 High incidence of horizontal transfer of ampicillin resistance
(pbp5) among CC17 Enterococcus faecium
C. Novais*, R. Escada, A.R. Freitas, E. Silveira, T.M. Coque, L. Peixe
(Porto, PT; Madrid, ES)
Objectives: Most CC17 E. faecium (Efm) are resistant to ampicillin
(AMPR). Transfer of AMPR has been linked to pbp5 mobilization
by conjugative transposons (CTn) Tn5382 or, more rarely, Tn916 and
Tn5386. We analyzed the occurrence of pbp5 transfer among Efm from
several sources in Portugal.
Methods: AMPR Efm (n = 80) from clinical samples (C, n = 39), Healthy
Humans (HH, n = 2), Hospital Sewage (S, n = 15), Animals (A, n = 22)
were studied. Transfer of pbp5 was screened by ﬁlter mating using recep-
tor strains lacking (EfmGE1) or containing (EfmBM4105RF/Efm64−3)
pbp5, and BHI with AMP, fusidic acid and rifampicin. Antibiotic
susceptibility was tested by disk diffusion/agar dilution methods (CLSI)
and clonality by PFGE/MLST. The stability of the acquired pbp5
[EfmGE1 transconjugants (TC)] was evaluated by serial passages (30x)
on BHI without AMP. Location of pbp5 was studied by hybridization
of genomic DNA (ICeu-I, SmaI) with 23S rRNA and/or pbp5 probes.
The presence of CTns (Tn5382, Tn916, Tn5386, Tn5397, Tn4453/4451,
Tn6000, Tn5801) was searched by PCR.
Results: pbp5 was transferred to EfmGE1 in 19% of the cases (n = 15;
1HH, 2A, 4S, 8C), all belonging to CC17 (8 PFGE types, 8 STs
comprising ST18, ST125, ST132, ST280, ST393, ST431, STnew).
All isolates presented a chromosomal location for pbp5 but none of
them carried any of the screened CTns. TCEfmGE1 were AMPR
(MIC=16−64mg/L) even after consecutive inoculations in AMP free
BHI. Resistance to glycopeptides, erythromycin and/or high level of
resistance to streptomycin was also observed in 6, 6 and 1 of TCEfmGE1,
respectively. Transfer of pbp5 to Efm64/3 (2/15) or EfmBM4105RF
(6/15) was also observed. EfmBM4105RF and Efm64/3 TC strains
increased their MICAMP values from 2mg/L to 8−16mg/L and 64mg/L,
respectively. pbp5 hybridized with SmaI DNA fragments of 290kb
and 250kb in EfmBM4105RF and Efm64/3 recipient strains while no
hybridization was seen in EfmGE1. In the TC, pbp5 was located on
bands of 180kb (1 TCEfmGE1), 200kb (2 TCEfmBM4105RF), 210kb
(32; 13 wild Efm, 13 TCEfmGE1, 5 TCEfmBM4105RF, 1 TCEfm64/3),
180kb +250kb (1TCEfm64/3) and 210kb+242kb (1 TCEfmBM4105RF).
Conclusions: AMPR is often transferable among CC17 Efm from
several origins and associated with pbp5 mobilization by conjugative
genetic elements different from those previously described. Further
studies to characterize the genetic context and to explain the variable
levels of AMPR on distinct genetic backgrounds (pbp5+/pbp5-) are in
process.
P620 Diversity of animal and human Tn1546-Enterococcus
faecium isolates belonging to CC9 and CC17 (ST78)
M. Lo´pez*, A.P. Tedim, F. Baquero, C. Torres, T.M. Coque (Logron˜o,
Madrid, ES)
Objective: E. faecium (Efm) host speciﬁc lineages recovered from
different sources are increasingly reported. CC17 and CC9 isolates
are involved in spread of vancomycin resistance in humans and
poultry, respectively but genetic elements carrying Tn1546 remain to
be addressed. Analysis of genetic context of Tn1546 of ST78 (a
predominant clone of CC17 worldwide spread in nosocomial setting)
and CC9 Efm isolates from different hosts is shown.
Methods: We analyzed vanA–Efm isolates belonging to ST78-CC17
(n = 13) and CC9 (n = 13, 2ST9, 2ST10, 2ST12, 3ST29, 1ST124,
1ST134, 1ST176) isolated from clinical, animal, food and healthy
human samples. Clonality was studied by PFGE and MLST. Plasmid
analysis included identiﬁcation of size and content (S1-PFGE), and
characterization of rep initiation proteins (rep), relaxases (rel), and
toxin-antitoxin systems (TA) by PCR-typing systems, hybridization and
sequencing. vanA location was determined by I-Ceu hybridization and
diversity of Tn1546 was searched by overlapping PCR.
Results: ST78 isolates were classiﬁed in 5 related PFGE types, 1 type
comprised clinical isolates from Spain and Italy; other corresponded to a
food and to a German clinical outbreak strain. CC9 strains were classiﬁed
in 12 different PFGE patterns, some STs being identiﬁed in animal
and human reservoirs from different locations. ST78-CC17 isolates
harboured higher number of plasmids than CC9 (1−6 vs. 1−3) ranging
from 20 to 350kb. All isolates contained pLG1-like megaplasmids
(100% reppLG1) and similar percentage of RCR (38/23% reppEF1071)
However, differences between CC9/ST78 isolates were found for rep of
small theta replicating plasmids (0/85% reppCIZ, 38/8% pEF418), and
those of Inc18 (100/62% rep1pInc18, 92/0% reppVEF, 54/0% rep2Inc18)
and RepA_N (0/100% reppRUM) families. Content in rel and TA was
consistent with that observed for rep sequences: 8/100% relpCIZ,and
23/85% relpJS42; 69/100% relpEF1 and 62/92% w-e-z (both linked to
Inc18 plasmids), and 0/100% of Axe-Tse (linked to pRUM). Tn1546
was mainly located on chromosome in ST78 isolates. Truncated variants
IS1216-Tn1546 were located on particular mosaic Inc18-like plasmids
in CC9 isolates.
Conclusion: Results show a intra/international spread of Efm ST78
and CC9 clones and/or their plasmids among animals and humans and
conﬁrm a possible debilitation of the species bottleneck for transmission
and adaptation of host-speciﬁc strains, as we recently reported for Efm
CC5 and CC17.
P621 Quantitation of bacteria in gastric biopsy specimen from
patients with gastrointestinal disorders: relationship between
counts and 23S rRNA point mutations
M. Kargar*, S. Ghorbani-Dalini, A. Doosti, N. Souod, P. Abbasi
(Jahrom, Shahrekord, IR)
Introduction and Objectives: H. pylori is the only bacteria that
infect humans gastric for which endoscopy examination is routinely
recommended. The risk of development of gastrointestinal disorders
(GIDs) and clinical features in the presence of H. pylori infection
depends on a variety of factors including bacterial, host, and
environmental ones that mostly relate to the pattern of bacterial load.
The aim of this study is the assessment of 4 types of 23S rRNA point
mutations affect on H. pylori count.
Methods: A prospective study of the concentrations of bacteria in the
gastric and their relationship to point mutations was conducted with 200
H. pylori suspected patients with GIDs. Initially, RUT and 16SrRNA
PCR were performed for identiﬁcation of H. pylori. Then, gastric biopsy
specimens were analyzed for bacterial count by using speciﬁc primers
and probe for wild type and 4 mutations of 23SrRNA by using Taq-Man
real-time PCR technology. Statistical analyses were performed using
the chi2 test. P-values less than 0.05 were taken to indicate statistical
signiﬁcance.
Results: Out of 200 samples, 164 (82%) had conﬁrmed H. pylori
positive. For 164 patients, the number of H. pylori CFU in gastric biopsy
sample were a value of 104 to 1012 CFU/ml. The results revealed that
more relationships between wild types and 104 (p = 0.026), 106 (p = 0.00)
and 107 (p = 0.00) CFU. Also, results showed more relationships between
106 and A2144G (p = 0.033), A2143G (p = 0.005), A2143C (p = 0.005),
and A2142G (p = 0.015) peptidyl transferase point mutations of 23S
rRNA gene.
Conclusion: This study has demonstrated a same relationship between
bacterial load and 4 types of 23S rRNA point mutations and wild
types. In conclusion, this ﬁnding supported the high prevalence of these
mutations in H. pylori population.
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P622 Prevalence and molecular characterisation of extended-
spectrum b-lactamase-producing Escherichia coli in
Moroccan community
A. Barguigua, K. Zerouali, M. Talmi, F. El Otmani, M. Timinouni*
(Casablanca, El Jadida, MA)
Objectives: The study aimed at the assessment of the prevalence of
ESBL-positive isolates of Escherichia coli collected from community
setting and their molecular biology analysis.
Methods: 1598 community E. coli strains responsible for urinary tract
infections were collected from ﬁve geographical areas of Morocco.
Antibiotic susceptibility testing and detection of ESBL production were
performed as recommended by the CA-SFM. The MICs were determined
using E-test method. The detection of the genes ESBL, AmpC, aac(6′)-
Ib qnr genes and class I integrons was performed by PCR ampliﬁcation.
Speciﬁc ISs and genes associated with blaCTX-M genetic environment
were investigated by PCR and sequencing. Conjugation experiments
were done to determine the mobility of blaCTX-M. The epidemiological
relationships between ESBL-producing E. coli strains were analysed by
PFGE.
Results: Forty nine isolates (3%) were deﬁned as ESBLs producers. All
were resistant to 6 or more antibiotics. ESBLs identiﬁed were CTX-M
group1 (63.2%), CTX-M group9 (2%), TEM (42.8%) and SHV (28.5%)
type. Eighteen strains expressed at least two types of b-lactamase. Genes
encoding acquired AmpC enzymes were detected in 7 isolates, AmpC
detected were DHA (n = 2), CIT (n = 1), EBC (n = 2) and CMY (n = 2)
type. The qnrB (n = 2) and qnrS (n = 1) genes were found in three isolates.
The class I integrons were detected in 28 isolates with amplicons ranging
from 0.4 to 2 kb in length. The PFGE analysis revealed the spread of
the strain in the community.
Ten CTX-M-type genes were sequenced and had amino acid sequences
indistinguishable from previously sequenced CTX-M-15 b-lactamases.
The blaCTX-M-15 gene presented the following genetic environment:
ISEcp1-blaCTX-M-15-orf477. We have shown that blaCTX-M-15,
blaOXA-30, aac(6′)-Ib-cr and qnrS1 were co-transferred and that these
genes are carried by a conjugative plasmid of high molecular weight.
Conclusion: 3% of E. coli isolates produced multiple b-lactamases
with predominance of CTX-M-15. Management and treatment of ESBL-
producing E. coli infections can be challenging. It is therefore essential
to include the molecular technique as part of the surveillance to monitor
the circulation of these resistance genes in a community setting.
P623 Mutations on the quinolone-resistant determining regions in
gyrA or parC gene of Mycoplasma genitalium
R. Hamasuna*, M. Matsumoto, T. Sho, N. Fujimoto, T. Matsumoto,
J.S. Jensen (Kitakyushu, JP; Copenhagen, DK)
Objectives: Mycoplasma genitalium is one of the pathogens of male
urethritis. Macrolides as azithromycin are effective against male urethritis
with M. genitalium, but macrolides-resistant M. genitalium strains were
found. Fluoroquinolones can be alternative agents against M. genitalium-
infection. However, efﬁcacies of ﬂuoroquinolones against M. genitalium-
infection are varied and there were some reports regarding to possibility
of ﬂuoroquinolone-resistant strains. To know the relationship between
the mutations on the quinolone-resistant determining regions (QRDR)
in gyrA or parC gene and ﬂuoroquinolone-resistance in M. genitalium,
genes of M. genitalium were analyzed.
Methods: The QRDR on gyrA and parC genes of M. genitalium were
sequenced and analyzed. DNA samples were puriﬁed from 23 M. geni-
talium strains which were determined antimicrobial susceptibilities and
M. genitalium-positive urine specimens collected before and after the
treatment with gatiﬂoxacin.
Results: Twenty-one M. genitalium gene from patients before the
treatment by gatiﬂoxacin and 4 genes from patients with treatment-failure
were examined. Regarding the QRDR in gyrA, all genes before treatment
were wild type. However, mutations including amino-change (Asp-99 to
Asn or Asp-99 to Gly) were found on 4 genes from the treatment-failure
cases. Regarding the QRDR in parC, 4 types of mutations (Ala-69 to
Thr, Asp-87 to His, Pro-72 to Ser and Ser-83 to Ile) were found on
M. genitalium genes from 5 patients before treatment. In these patients,
2 patients with mutatedM. genitalium-gene (Ala-69 to Thr, Pro-72 to Ser
and Ser-83 to Ile) failed to treat. From a patient with treatment-failure,
a mutation (Ser-83 to Ile) was found.
From M. genitalium strains, one strain has high MICs against
moxiﬂoxacin and gatiﬂoxacin. This strain has mutations on gyrA (Asp-
99 to Asn) and on parC (Ser 83 to Ile). Other M. genitalium strains have
some mutations on parC (Pro-62 to Ser, Ala-60 to Thr, Asn-87 to Tyr
and Ile-146 to Val), but these strains were sensitive to moxiﬂoxacin and
gatiﬂoxacin and other ﬂuoroquinolones.
Conclusion: In M. genitalium, mutations on QRDR in gyrA and parC
gene are also related to ﬂuoroquinolone-resistance as other bacteria.
P624 Association of virulence markers and antimicrobial
susceptibility in Escherichia coli clinical isolates
V. Calhau*, T. Lin, G. Ribeiro, N. Mendonc¸a, G. Da Silva (Coimbra,
PT; Ann Arbor, US)
Objective: Escherichia coli can cause a wide variety of infections and
is often resistant to multiple antibiotics. They fall into phylogroups A,
B1, B2 and D, with group B2 and D being more virulent and reported to
be more susceptible to quinolones. The main objective of the work was
to screen for the major pathogenicity islands (PAIs), to determine the
phylogeny and to associate the virulence markers with antibimicrobial
resistance proﬁle.
Methods: Between October and December 2007, 97 E. coli non-
duplicate isolates were collected from diverse wards and samples
of inpatients of a Portuguese hospital. Antibiotic susceptibility was
performed by Vitek2AES. ESBL production was conﬁrmed by the
disk diffusion synergy test. The screen of PAIs and the determination
of phylogenetic background were performed by Multiplex PCR. The
amplicons were sequenced.
Results: The majority of strains were recovered from urine (67%),
followed by the blood (17%), exsudates (12%) and other samples (4%).
All phylogenetic groups were represented in all the strains, but those
belonging to group B2 (39%) and A (32%) were prevalent. Urine isolates
were assigned mostly in B2 group (43%), while only 11% were from
group D. Septicaemic isolates were also predominantly from B2 lineage
(38%), but their distribution in the other groups was not signiﬁcantly
different (A, 25%; B1 and D, 19% each). None of the strains of A, B1
and D groups carried more than 3 PAIs, whereas 84% and 16% of B2
isolates showed 2 or 3 PAIs and 4 or 5 PAIs, respectively. PAI IV536
was the most prevalent pathogenicity island in all groups. PAI I536,
PAI IJ96 and PAI IIJ96 were not detected. The PAI ICTF073 and PAI
IICFT073 islands were distributed in all phylogenetic groups but were
more prevalent in groups B2 and D. Resistance to ciproﬂoxacin (CIPR)
was observed in 56% of all isolates and 16% were ESBL producers.
Among B2 group the combination of PAI IV536, PAI ICFT073 and
PAI IICFT073 was detected in 80% CIPR strains and in 75% of ESBL
producers. Of these 80% were collected from urines.
Conclusions: The phylogroup B2 was prevalent and showed the highest
number and variety of PAIs. The so-called commensal strains of
phylogroup A also carried several PAIs and were associated with urinary
infections and septicemia. A considerable number of CIPR strains were
also PAIs carriers (B2 group), some produced also ESBL, which may
indicate the emergence of a new sub-lineage among this phylogroup in
this clinical setting.
P625 Mutations in the dihydropteroate synthase gene in
Pneumocystis jirovecii isolates from children in Cape Town
S. Kumar, L. Ah Tow, C.M. Samuel, B. Morrow, M. Zampoli, H.J. Zar,
A.C. Whitelaw* (Cape Town, ZA)
Background: Pneumocystis jirovecii is a major cause of morbidity and
mortality in HIV infected children. Molecular analysis of the mito-
chondrial large subunit (mtLSU) rRNA locus and the dihydropteroate
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synthase (DHPS) gene has been used to study the epidemiology and co-
trimoxazole (CTX) resistance of this organism. Amino acid substitutions
T55A and P57S in DHPS have been associated with CTX exposure, but
the association with clinical resistance is unclear.
Aim: To characterise P. jirovecii isolates from children in Cape Town
by analysis of the DHPS gene and the mtLSU locus.
Materials & Methods: Respiratory samples from 101 children with
Pneumocystis pneumonia, diagnosed by PCR, were investigated.
Mutations in DHPS were analysed by PCR and restriction enzyme
digestion using AccI and HaeIII to detect mutations at amino acid
positions 55 and 57; mutations were conﬁrmed in a subset of isolates
by DNA sequencing. The mtLSU genotype was determined by PCR and
DNA sequencing. Presence of DHPS mutations was correlated to crude
mortality rate, ICU stay, and mtLSU genotype.
Results: The DHPS gene was ampliﬁed from 77 of 101 samples; 22
(28.6%) had DHPS mutations (Table 1). Most (13/22; 59.1%) were mixed
with wild type strains. No signiﬁcant association was found between
presence of mutations and ICU admission (54,5% vs 49,1%; RR 1.11;
95%CI 0.70–1.77; p = 0.66) or mortality (22.7% vs 43.6%; RR 0.52;
95%CI 0.23–1.19; p = 0.08). The mtLSU gene was ampliﬁed from 33
samples; sequence analysis suggested 15 (45.4%) were mixed. Of the
identiﬁable genotypes, genotype 3 was most common (n = 10, 30.3%).
90% of genotype 3 isolates had DHPS mutations, compared to 1 of 8
strains belonging to genotype 1 or 2 (OR= 63; 95%CI 3.32–1194.79).
Conclusion: Mutations in the DHPS gene are present in more than a
quarter of isolates, an increase from that previously reported in 2004 in
a similar patient population. Mixed infection appears common. DHPS
mutations may be associated with genotype 3, but larger studies are
needed to investigate both this and the association of genotype or DHPS
mutation with outcome.
Acknowledgements: NHLS Research Trust grant; National Research
Foundation South Africa; South African Thoracic Society; MRC
Southern Africa
P626 Characterisation of the penA mosaic gene in Neisseria
gonorrhoeae strains with decreased susceptibility to
cephalosporins in Amsterdam, Netherlands
R. Heymans*, S.M. Bruisten, H.J. de Vries, A.P. van Dam (Amsterdam,
NL)
Objectives: In 2006 to 2008, an increase in prevalence (7.3%) of
multidrug-resistant Neisseria gonorrhoeae (NG) strains with decreased
susceptibility to the extended-spectrum cephalosporin (ESC) cefotaxime
was observed among visitors of the STI clinic in Amsterdam, the Nether-
lands. To determine whether this was due to the rapid clonal expansion of
a NG strain harbouring a mosaic penA gene, polymorphisms in the penA
gene were correlated to the susceptibility to cefotaxime, ceﬁxime, and
ceftriaxone. Strain clonality and epidemiological concordance of mosaic
penA patterns were assessed by genotyping.
Methods: From 2006 to 2008, 74 NG isolates with a cefotaxime MIC
of >0.125mg/ml (group A), 54 with a cefotaxime MIC of 0.125mg/ml
(group B), and a control group of 74 with a cefotaxime MIC of
<0.125mg/ml (group C), were included in this study. All samples were
characterized using antibiograms, gel electrophoresis of the ampliﬁed
penA gene, and NG multiple-locus variable-number of tandem repeat
analysis (MLVA). Sequencing was used to identify and conﬁrm the
mosaic penA positive MLVA types.
Results: The proportion of NG isolates with decreased susceptibility
to ceﬁxime and ceftriaxone (MIC 0.016mg/ml) were higher in group
A (68% and 76%, respectively) than group B (11% and 57%), while
group C had slightly elevated ceftriaxone MICs only (5%). The mosaic
penA gene (n = 53) was identiﬁed only in group A (64%) and B (11%),
and showed a correlation with the higher ESC MICs. Hierarchical
cluster analysis of the MLVA data assigned all 53 patients with a
mosaic penA positive NG strain to the same large cluster (10
patients; n = 56). The presence of a mosaic penA gene in this NG
strain was conﬁrmed by sequencing and was shown to be identical to
a previously published sequence (GU723422). This cluster contained
Dutch homosexual men (66%), patients with frequent Chlamydia co-
infection (32%), and commercial sex workers (7%). A second large
cluster (n = 39) was identiﬁed that also contained isolates of group A
(21%) and B (67%), but no mosaic penA positive NG strains.
Conclusion: A correlation was found between the decreased suscepti-
bility to the ESCs and the introduction of a clonal mosaic penA positive
NG strain among visitors of the STI clinic Amsterdam. High-risk sexual
behaviour might facilitate the rapid spread of this multidrug-resistant
NG strain, posing new public health concerns.
P627 abaR3-like genomic resistance islands are associated with
Acinetobacter baumannii strains of European clone I
L. Krizova*, L. Dijkshoorn, A. Nemec (Prague, CZ; Leiden, NL)
Objective: Multidrug resistant (MDR) Acinetobacter baumannii strains
are mostly associated with several clonal lineages, three of which are
known as European (EU) clones I-III. It has been shown that a number
of resistance genes of EU clone I strains are located within genomic
resistance islands termed AbaR. Eight AbaR islands (AbaR1, 3, 5, 6−10)
have been described in this clone. They are integrated in the ATPase gene
and share the Tn6019 transposon. The aim of this study was to assess
the diversity of AbaR islands among a large set of archive EU clone I
isolates.
Methods: Twenty-eight MDR strains of EU clone I isolated in 24
hospitals of 12 countries in 1984–2005 were investigated. Strain HK302
from 1977 harboring AbaR3 was used as a positive control for structural
analysis of AbaR islands. The integrity of the ATPase gene and the
presence of 20 genes associated with AbaR3 were analyzed by PCR.
Long-range PCR mapping followed by RFLP analysis of amplicons was
used to reveal the structure of AbaR islands. The regions of AbaR islands
different from those of AbaR3 were sequenced.
Results: In all strains, the disrupted ATPase gene and the genes
associated with Tn6019 and Tn6018 transposons were detected using
PCR. Individual strains harbored from 5 to 20 AbaR3-associated genes in
13 different combinations. PCR mapping combined with RFLP analysis
and/or sequencing revealed that whereas 16 strains (isolated in eight
countries in 1984–2005) harbored AbaR3 islands with four different
class 1 integrons, 2 strains (isolated in 1992 and 1995) carried AbaR10
(30.5 kb), a less developed variant of AbaR3. In addition, nine novel
AbaR islands named AbaR11−19 were described. While AbaR11 (19.8
kb) only harbors Tn6019 and one copy of Tn6018, AbaR12−19 are
likely to be IS26-mediated deletion variants of AbaR3 varying in size
from 21.5 to 57.5 kb.
Conclusions: AbaR3-like structures have been generally associated with
MDR strains of EU clone I since at least 1977. AbaR11 seems to be a
progenitor of AbaR islands hitherto described in strains of this clonal
lineage.
Supported by the Czech Science Foundation (310/08/1747).
P628 CTX-M sequence types, plasmid replicon types, antimicrobial
resistance genes and virulence genes in Escherichia coli
isolates from cattle, chickens and turkeys in Great Britain
L.P. Randall*, M. Toszeghy, H. Wearing, R. Horton, G. Wu,
R.H. Davies, N. Coldham, C.J. Teale (New Haw, UK)
Objectives: Escherichia coli carrying the CTX-M gene are present
in some humans and animals worldwide. Of particular concern is the
pandemic CTX-M-15O25:H4-ST131 E. coli clone affecting man, which
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is predominantly involved in urinary tract infections and bacteraemia
and can cause signiﬁcant morbidity and mortality. We report here on the
characteristics of CTX-M isolates from cattle, chickens and turkeys from
Great Britain (GB) with respect to their CTX-M sequence type, plasmid
Inc group, conjugation rate, plasmid size and presence of antimicrobial
resistance and virulence genes.
Methods: Isolates from chicken (n = 27) and turkeys (n = 93) were
obtained as part of previous studies whilst isolates from cattle (n = 202)
were mainly from diagnostic samples submitted to the Veterinary
Laboratories Agency (VLA) since 2004. Most isolates were tested for
CTX-M sequence type, whilst representative isolates were tested for
conjugation rate to a Salmonella Typhimurium strain, Inc plasmid type,
plasmid size and the presence of antibiotic resistance and virulence genes
by micro-array.
Results: The predominant CTX-M sequence types from cattle were 15
(37.5%) and 14 (36%); from chickens were 1 (73%) and 15 (17%);
and from turkeys were 14 (45.1%) and 1 (36.5%) − Table 1. The
mean relative conjugation frequency mean and range were similar for
isolates from different animal species. The predominant plasmid Inc
group for isolates tested from cattle, chicken and turkeys was I1-g
(Table 1), although due to bias in the sample population, this may
not be representative of the general population for all these species.
Most CTX-M sequence type 14 isolates had an Inc K plasmid. Similar
size plasmids were present in isolates from all species (Table 1).
Antimicrobial resistance genes found included aadA1, aadA2, aadA4,
blaCTX-M, blaTEM, dfrA14, dfrA17, sul1, sul2, strA, strB, tetA, tetB
and tetG genes. Virulence genes included ireA (sidephore receptor),
lpfA (long polar ﬁmbriae), mchF (microcin transporter protein) and tsh
(temperature sensitive haemagglutinin).
Conclusion: The results show some diversity and some similarity
between isolates from different animal species on the basis of CTX-M
sequence type, replicon type and antimicrobial resistance and virulence
genes. This suggests that strains may be partly restricted to a particular
animal species, but it is possible that there is also some exchange of
strains and plasmids between different animal species.
P629 Comparison of genetic characteristics between Acinetobacter
baumannii and Acinetobacter genomospecies 3 and 13TU
isolated from Tae-jeon, Korea
S.H. Koo*, K. Kwon, G. Sung on behalf of the Korean Society of
Clinical Microbiologists
Objectives: Acinetobacter spp. are important opportunistic pathogens
and have given rise to signiﬁcant therapeutic challenges in the treatment
of nosocomial infections. For the difference of resistance genes between
the A. baumannii and A. genomospecies 3 and 13 TU, we investigated
integrons and the various genes involved in resistance to carbapenems
(blaOXA, blaIMP, blaVIM, and blaSIM), aminoglycosides (armA and
aminoglycoside modifying enzymes, AMEs), and ﬂuoroquinolones
(gyrA and parC) in 51 imipenem-nonsusceptible Acinetobacter spp.
isolates.
Methods: Thirty-nine imipenem-nonsusceptible A. baumannii and 12
A. genomospecies 3 and 13 TU isolated from Tae-jeon, Korea were
studied. The minimal inhibitory concentrations (MICs) of 10 antibiotics
were determined by the agar dilution method. PCR and DNA sequencing
were used to identify the genes that potentially contribute to each
resistance phenotype. Repetitive extragenic palindromic-PCR (REP-
PCR) was also performed to assess the clonality of the isolates.
Results: All A. baumannii isolates harbored OXA-51 and 18 (46.2%)
isolates co-produced OXA-23. In addition, ISAba1 was identiﬁed
upstream of the gene encoding OXA-51 and OXA-23. However, blaoxa
was not found in 12 A genomospecies 3 and 13TU isolates, which
contained blaIMP-1 or blaVIM-2. Most A. baumannii and genomo-
species 3 and 13TU (96.1%) showed the resistance to aminoglycoside
and harbored class 1 integrons, armA, and/or AMEs (aac(6′)-Ib, aph(3′)-
Ia, and/or aph(3′)-VI). armA and aph(3′)-Ia were detected only in
A. baumannii, whereas the frequency of aph(3′)-VI was signiﬁcantly
higher in A. genomospecies 3 and 13TU. In all 39 A. baumannii isolates,
resistance to ﬂuoroquinolones was conferred by sense mutations in the
gyrA and parC genes. However sense mutations in the parC were not
found in 12 A. genomospecies 3 and 13TU. While A. baumannii isolates
were clonally spread, clonal spread of A. genomospecies was not found
in the studied hospital.
Conclusion: Several differences of genes related to carbapenem,
aminoglycoside, and ﬂuoroquinolone resistance were detected in
A. baumannii and A. genomospecies. The co-occurrence of several
resistance determinants may also become a signiﬁcant threat. These
differences can give an inﬂuence on choosing antibiotics in clinical
setting.
P630 Genetics basis of antimicrobial resistance in clinical
multidrug-resistant strains of Salmonella typhimurium,
southern Italy
M. Legretto, F. Nuccio, R. Monno*, A. Pupillo, A. Dionisi, D. De
Vito, C. Pazzani (Bari, Rome, IT)
Objectives: The objective of this study was to assess both the genetic
basis of the antimicrobial resistance and the clonal relatedness in 88
multidrug-resistant (MDR) strains of Salmonella enterica subspecies
enterica serovar Typhimurium isolated in Southern Italy (2006–2008)
from clinical cases.
Methods: Antimicrobial susceptibility was determined by the disc
diffusion method. Detection of SGI, class 1 integrons and antimicrobial
resistance genes were performed by PCR. Resistance genes undetected
by PCR were identiﬁed by plasmid libraries: partial Sau3AI restrictions
of genomic DNA were separated by agarose gel electrophoresis, puriﬁed
and cloned into either plasmid pBluescript II SK(−) or pHSG396 and
transformed into JM83 competent cells. Plasmids isolated from each
candidate were characterized by restriction proﬁles and the suitable DNA
fragments were sequenced.
Genomic relatedness was established by Pulsed-ﬁeld gel electrophoresis
(PFGE) according to the standardized Salmonella protocol of the CDC
PulseNet.
Results: A total of 255 S. Typhimurium strains from clinical cases were
investigated. Eight-eight strains were multidrug-resistant (exhibiting
resistance to three o more antimicrobials). Two major restriction patterns
were detected. The ﬁrst was identiﬁed in 56 isolates (63,6) which
exhibited resistance to ACSSuT. rResistance was mainly encoded by SGI
detected in 85,7% of isolates. In strains SGI1 negative resistance was
encoded by catA1, sul1, tetB and blaOXA-30-aadA1 gene cassette array.
The second major resistance pattern was exhibited by 19 isolates (21,2%)
resistant to ACSSuTTm. The resistance was encoded by blaTEM-1,
strAB, sul2, tetA or tetB and dfrA12-aadA2 gene cassette array. Five
minor resistance proﬁles were identiﬁed mainly encoded by blaTEM-1,
strAB, sul2, tetA or tetB and by the dfrA12-aadA2 gene cassette array
integrated into an integron of class1.
Strain characterization by PFGE highlighted the prevalent identiﬁcation
of the pulse-type STYMXB.0061.
Conclusion: The study has highlighted the widespread of SGI among
MDR S. Typhimurium clinical strains isolated in Apulia. Strains positive
for SGI1 were largely identiﬁed with respect to place and date of
isolation; additionally these strains showed an indistinguishable PFGE
proﬁle (STYMXB.0061). Taken together, these data argue for a clonal
diffusion and persistence of this major group of MDR strains.
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P631 Point mutations associated with antibiotic resistance and
clonal relatedness of Pseudomonas aeruginosa clinical isolates
M. Straut*, S. Dinu, M. Surdeanu (Bucharest, RO)
Objectives: The incidence of Pseudomonas aeruginosa strains resistant
to carbapenems and ﬂuoroquinolones (FQ) is important in most of
hospitals in Bucharest. In order to examine the contribution of some
carbapenem resistance mechanisms in clinical isolates that lack metallo-
b-lactamase genes, our study aim was to investigate the prevalence of
extended-spectrum AmpC b-lactamases (ESAC) and of oprD mutants.
The same clinical isolates of P. aeruginosa were examined for alterations
in the quinolone resistance-determining regions (QRDR). An additional
interest was to search for a putative correlation between Multilocus
Sequence Typing (MLST) results and the distribution of QRDR silent
mutations and blaAmpC gene polymorphism, respectively.
Methods: Thirty-three imipenem- and FQ-resistant P. aeruginosa
clinical isolates, collected from ten Bucharest hospitals over an 11
year period, previously screened for blaPER-1 and class 1 integrons
occurrence, were selected for this study. PCR using blaAmpC, oprD
and gyrA, gyrB, parC, parE QRDR speciﬁc primers, followed by DNA
sequencing was performed. The resulting sequences were compared to
that of the reference strain PAO1. Clonal relationships were established
by MLST.
Results: The determination of the AmpC amino acid sequences
of all 33 isolates, allowed us to identify 8 Pseudomonas-derived
cephalosporinases (PDC) variants. Five of those were new variants,
submitted to EMBL/GenBank database. All variants contained T105A
substitution, consistent with an ESAC activity. For most of the studied
isolates, oprD sequence analysis revealed the presence of frame shift
mutations produced by one base pair insertions or deletions. Single
substitution T83I in GyrA was detected in all FQ-resistant isolates.
Twenty-two isolates contained equally a single substitution S87L in
ParC. Silent mutations were found in all QRDR, mainly in parE and
gyrB. Analysis of these silent mutations and of ESAC-type PDC variants
resulted in isolates clusters suggesting clonal relatedness, conﬁrmed by
MLST results. A cluster of 16 isolates is characterized by serotype O11,
sequence type ST235 and a new PDC-2-derived variant. A cluster of 8
isolates, mainly of serotype O12, belonging to ST111 displays PDC-3
variant.
Conclusion: This is the ﬁrst report about ESACs occurrence and speciﬁc
point mutations associated with FQ reduced susceptibility in multidrug
resistant P. aeruginosa clinical isolates from Romania.
P632 Molecular characteristics of extended-spectrum b-lactamase-
producing Escherichia coli in Japan: emergence of
CTX-M-15 in Japanese clinical isolates of E. coli ST131
H. Yano*, K. Hitoshi, Y. Hirakata, K. Arai, S. Endo, H. Kanamori,
M. Ogawa, M. Shimojima, N. Ishibashi, T. Aoyagi, M. Hatta,
M. Yamada, K. Nishimaki, K. Tokuda, M. Kitagawa, H. Kunishima,
M. Kaku (Sendai, Kawagoe, JP)
Objectives: The prevalence of extended-spectrum b-lactamase (ESBL)
has recently been increasing worldwide. In this study, we investigated
the molecular epidemiology and characteristics of ESBL-producing
Escherichia coli and plasmid-mediated quinolone resistance (PMQR)
determinants among these isolates in Japan.
Methods: A total of 101 clinical isolates of ESBL-positive E. coli
collected from 11 institutes in eastern Japan between June 2008 and
November 2009 were studied. Antimicrobial susceptibilities of the strains
were determined. PCR was performed to identify b-lactamase genes
blaTEM, blaSHV, and blaCTX-M. For CTX-M-positive strains, PCR
was performed to identify CTX-M-1, CTX-M-2, and CTX-M-9 group-
speciﬁc primers. PCR products of TEM, SHV, CTX-M-1 group, CTX-
M-2 group, and CTX-M-9 group genes were sequenced. These isolates
were also analyzed by multilocus sequence typing (MLST). Detection
of PMQR gene (qnrA, qnrB, qnrC, qnrS, and qepA) and aac(6′)-Ib gene
was performed by PCR. aac(6′)-Ib amplicons were sequenced to conﬁrm
the -cr variant.
Results: All 101 strains were intermediate or resistant to ampicillin,
piperacillin, cefpodoxime, cefotaxime, aztreonam, and cefepime, and 97
(96.0%) of them were to levoﬂoxacin. Of the 101 strains, 97 (96.0%)
were positive for CTX-M, while 47 (46.5%) and two (2.0%) were
positive for TEM and SHV, respectively. Among the 97 CTX-M-positive
strains, 18 were CTX-M-1 group; four were CTX-M-2 group; and 75
were CTX-M-9 group. Sequencing results revealed that CTX-M-14 was
the most prevalent (49/101: 48.5%), following by CTX-M-27 (22/101:
21.8%) and CTX-M-15 (8/101: 7.9%). Both of two CTX-M-2 group-
positive strains were CTX-M-2. All of the 47 TEM-positive strains
were TEM-1, and the two SHV-positive strains were SHV-12. Based
on MLST, seven of eight CTX-M-15-producing isolates belonged to
sequence typing (ST) 131. One and two isolates carried qnrB and
qnrS, respectively, while there were no qnrA nor qnrC-positive isolates.
Sequencing revealed that nine of 13 aac(6′)-Ib-positive strains were
-cr variant. Six of eight CTX-M-15-producing isolates were positive for
aac(6′)-Ib-cr.
Conclusion: Our results suggest that CTX-M-14 was the most prevalent
in ESBL-producing E. coli and ST131 producing CTX-M-15 has
emerged in Japan. To our knowledge, this is the ﬁrst report of CTX-
M-15-producing E. coli ST131 in Japan.
P633 Rapid detection system consisting of multiplex PCR and
melting curve analysis to amplify and identify blaTEM,
blaSHV and blaCTX-M genes in a single reaction
M. Chroma*, M. Kolar (Olomouc, CZ)
Objectives: Bacterial resistance to b-lactam antibiotics due to
b-lactamase production has become a serious global problem.
Methods: To develop and optimize a novel discrimination method,
a collection of 80 bacterial strains with known b-lactamases was
used. The multiplex PCR was run in the Rotor-Gene instrument using
speciﬁc primers and ﬂuorescent DNA-intercalating dye LCGreen for
ampliﬁcation of genes encoding TEM, SHV and CTX-M b-lactamases
in a single reaction. After ampliﬁcation a high resolution melting (HRM)
analysis was run using 0.1ºC increments from 75ºC to 99ºC at the same
instrument. A ﬂuorescent signal was obtained continuously during the
slow temperature rise.
Results: By multiplex PCR technique and agarose gel electrophoresis, all
control strains yielded a positive amplicon/amplicons with the expected
sizes (TEM − 1150 bp, SHV − 475 bp, CTX-M − 593 bp). After
normalization of ﬂuorescent data, the Tm shift for single genotypes
(blaTEM, blaSHV and blaCTX-M) was clearly distinguished (TEM
~86,5ºC, CTX-M-1 group ~89,5ºC, CTX-M-9 group ~90,5ºC, SHV
~92,5ºC). Because of the sequence variability within blaCTX-M, HRM
analysis could well discriminate between different clusters (CTX-M-1
and CTX-M-9 group). If two or three bla genes were ampliﬁed in one
reaction, the characteristic change in the shape of melting curve was
observed. HRM data were also interpreted using Rotor-Gene ScreenClust
HRM Software.
Conclusion: The aim of the study was to develop a new detection and
discrimination method for characterization of three b-lactamase genes
using HRM analysis. This technique could serve as a suitable and
helpfull tool for rapid identiﬁcation of present bla genes.
Supported by the Czech Ministry of Health grant no. IGA MZ CR
9950−3 and the Ministry of Education, Youth and Sports grant no.
MSM6198959205
P634 The oqxAB gene complex is present in all Klebsiella
pneumoniae clinical isolates
J. Yuan, X. Xu, Q. Guo, X. Ye, M. Wang* (Shanghai, CN)
Objectives: To investigate the prevalence of oqxAB, encoding a
multidrug efﬂux pump, in E. coli and K. pneumoniae clinical isolates.
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Methods: Antimicrobial susceptibility was determined by agar dilution
according to CLSI guidelines and the presence of the oqxA and oqxB
genes was evaluated by PCR in a total of 290 consecutive clinical isolates
of E. coli (n = 136) and K. pneumoniae (n = 154), collected at Huashan
Hospital in Shanghai, China from March 1st to May 31st, 2010.
Results: Of the E. coli strains, 89.1%, 71.3%, 73.5% and 70.6% were
nonsusceptible to nalidixic acid, ciproﬂoxacin, norﬂoxacin and lev-
oﬂoxacin, while 78.6%, 66.9%, 61.7% and 50.7% of the K. pneumoniae
strains tested nonsusceptible to the same agents. oqxA and oqxB were
present in 9 of 136 (6.6%) E. coli and all 154 K. pneumoniae strains.
The oqxA and oqxB PCR products of 9 E. coli and 74 randomly
selected K. pneumoniae strains were sequenced and showed 99% to
100% similar to the original oqxAB sequence of pOLA52 (EU370913).
Eight PCR primer pairs were designed to amplify the full-length of the
oqxAB genes from 9 strains of E. coli and 21 strains of K. pneumoniae.
Compared to the sequences encoded by pOLA52, one to 2 amino acid
substitutions were detected in the OqxA or OqxB sequences from two
E. coli strains and were temporarily designated as oqxA2, oqxB2 and
oqxB3. Among 21 OqxA and OqxB sequences from K. pneumoniae,
10 strains had 1 to 12 and 1 to 6 amino acid substitutions, respectively,
compared with four sequences of OqxA and OqxB or genomic sequences
from K. pneumoniae available in the GenBank (FJ975560, FJ975561,
CP000647, AP006725). I-CeuI digestion, transfer and hybridization with
speciﬁc probes for oqxA and 16S rRNA are being undertaken on
K. pneumoniae isolates to determine whether oqxAB is located on the
chromosome of K. pneumoniae or not.
Conclusion: New oqxAB genes, oqxA2, oqxB2and oqxB3 were
identiﬁed in two E. coli strains. The oqxAB gene is present in all
K. pneumoniae strains and may be locate on the chromosome, thus
identifying the genome of K. pneumoniae as a possible reservoir of
oqxAB.
P635 Genetic basis of expanded-spectrum cephalosporin resistance
in Salmonella from food animals detected by the Italian
Veterinary Monitoring System (ITAVARM)
A. Franco*, F. Feltrin, V. Donati, R. Amoruso, R. Lorenzetti, S. Tagliabue,
M. D’Incau, A. Lettini, A. Battisti (Rome, Brescia, Legnaro, IT)
Objective: The objective of the study is to describe the presence
and frequency of genes encoding resistance to Expanded-Spectrum
Cephalosporins (ESCs), in Salmonella from food animals detected
through a monitoring network (ITAVARM) of Veterinary Public Health
Institutes (IZSs). ESCs are among Critically Important Antimicrobials
for the treatment of invasive infections in humans caused by zoonotic
bacteria (WHO, 2008).
Methods: Isolates are collected following the guidelines issued by
the EFSA and by the EU Commission (Comm. Dec. 407/2007/EC).
Representativeness is obtained by the inclusion of isolates from baseline
studies and national control plans (Reg. 2160/2003/EC), along with
active monitoring and passive laboratory surveillance in food animals.
Isolates are tested by microdilution method (MICs) and interpreted
with the EUCAST epidemiologic cut-offs by the National Reference
laboratory for Antimicrobial Resistance, where also characterization of
resistance genes is conducted.
Results: ESC-resistance was detected in Salmonella from poultry
holdings, and was attributed to ESBL, AmpC-like, or TEM conferring
ESBL phenotype genes. In broiler chicken holdings, samples from
the 2008 EU harmonised baseline Survey (Comm. Dec. 2007/516/EC)
and passive surveillance yielded 13.2% (16/121) isolates resistant to
Cefotaxime (CTX-R). Among these isolates, 6.6% (8/121) were positive
for blaCTX-M group 1 or group 2, 2.5% (3/121) for blaSHV encoding
ESBLs, 1.7% (2/121) for blaTEM, and 2.5% (2/121) for blaCMY-2
genes, respectively. In holdings of fattening turkeys, samples from the
2007 EU baseline survey (Comm. Dec. 662/2006/EC), yielded 3.6%
(5/139) isolates CTX-R. All isolates were positive for blaCTX-M Group
2. Passive laboratory surveillance yielded 7% (3/43) isolates CTX-R, of
which 4.7% (2/43) were positive for blaCTX-M group 2, and 2.3% (1/43)
for blaSHV. PCR-based replicon typing of plasmids in these Salmonella
isolates detected the presence of different replicons such as HI2, P, I1,
N, FIA, A/C.
Conclusions: The veterinary monitoring system in place in Italy has
adequate sensitivity to detect emerging resistances and the underlying
mechanisms to some important antimicrobial classes such as ESCs in
food animals. In Italy ESC-resistance is mediated more frequently by
ESBL, otherwise by AmpC-like and blaTEM genes, and it is widespread
in Salmonella spp. from poultry although there is no medicinal product
registered for veterinary use in such animal species.
P636 Identiﬁcation of Inc plasmids types and its association
with plasmid-mediated quinolone resistance and extended-
spectrum b-lactamases determinants carried by Escherichia
coli clinical strains
V. Calhau*, M. Fois, G. Ribeiro, N. Mendonc¸a, G. Da Silva (Coimbra,
PT)
Objectives: Replicon typing plasmids is a useful tool to trace the
dissemination of plasmids conferring antimicrobial resistance. The
aim of the study was to classify and establish the frequency of the
Incompatibility (Inc) plasmids types among clinical Escherichia coli
strains and to identify the extended-spectrum b-lactamases (ESBLs) and
plasmid-mediated quinolone resistance (PMQRs).
Methods: During October-December 2007, 97 E. coli strains were
collected from patients of the University Hospital of Coimbra. The
Inc plasmid groups were identiﬁed by PCR-based replicon typing.
PMQR (qnr, aac(6′)-Ib-variant and qepA) and ESBL (blaTEM, blaSHV
and blaCTX-M) determinants were screened by PCR. Antimicrobial
susceptibility proﬁle and the identiﬁcation of ESBL-producing isolates
were determined using the Vitek2AES commercial system.
Results: Ninety nine percent of strains showed at least one plasmid type.
Forty three percent of strains presented at least 2 different plasmids, 25%
carried only 1 and 24% showed 3 different plasmids. The major Inc group
found was IncF (88%), followed by the IncK (60%). FIB, FIA and FIC
replicons were present in 57%, 40% and 17% of the strains, respectively.
Among the 67% of strains recovered from urine, the Inc plasmid mostly
identiﬁed were IncF, IncK and IncI (85%, 58% and 23% respectively).
We detected 15% of ESBL producers distributed by the clinical samples:
urine (n = 12), exudates (n = 2), and blood (n = 1). All ESBL producers
expressed a CTX-M-15 enzyme. An IncF plasmid was identiﬁed in
all ESBL strains and, of these, 20% also carried an IncK plasmid
and 7% an IncI plasmid. PMQR were detected in 44% of strains: 3%
QnrA, 3% QnrS and 38% aac(6′)-lb-cr. Of these, 64% were resistant to
ciproﬂoxacin, while 33% and 2% showed susceptibility or intermediate
level to this antibiotic. PMQR strains showed high plasmid diversity,
with 86% carrying an IncF, 43% an IncK and 21% an IncI. All strains
expressing simultaneously CTX-M-15 and a PMQR presented an IncF
plasmid, while 20% and 7% presented an IncK and IncI, respectively.
Conclusion: IncF was the prevalent group. It was present in all strains
expressing an ESBL and/or PMQR, suggesting its high association
with the spread of these determinants, namely the widely disseminated
CTX-M-15, and its capacity of mobility to other Enterobacteria.
The heterogeneity of plasmids seen in PMQR-strains may indicate
independent events of acquisition rather lateral transfer.
Molecular detection of antibiotic resistance
among Gram-negative bacteria
P637 Characterisation of carbapenemases in multidrug-resistant
Acinetobacter baumannii isolates from intensive care units
A. Uskudar Guclu*, A. Kilic, A.G. Gozen, O. Bedir, A. Basustaoglu
(Ankara, TR)
Objectives: Carbapenem resistance in Acinetobacter baumannii is a
growing public health concern and represents serious problems in
the treatment of related infection. Several carbapenem-hydrolysing
b-lactamases have been identiﬁed from A. baumannii so far. This study
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characterise carbapenem resistance in A. baumannii strains recovered
from intensive care units of Gulhane Military Medical Academy, Turkey.
Methods: From June 2006 to January 2010, 138 clinical A. baumannii
isolates were collected. Antimicrobial susceptibility tests of the isolates
were performed by using Phoenix™ 100 Instrument (Becton Dickinson,
USA). The MICs of imipenem and meropenem were also determined
by E-test method (AB Biodisk, Sweden). The 61 carbapenem resistant
A. baumannii strains were selected for further study. Firstly, to determine
the presence of carbapenemases, Modiﬁed Hodge test (MHT) was
performed. The presence of Metallo-b-lactamase (MBL) was investigated
by using MBL IP/IPI E-test strips (AB Biome´rieux, France). Detection
of the four groups of OXA carbapenemase (OXA-23, OXA-24, OXA-51
and OXA-58) was carried out using a multiplex PCR assay. Sequence
analysis was performed by using BigDye Cycle Sequencing Kit V3.1 on
ABI 3130 XL Genetic Analyzer.
Results: Non-duplicate, multidrug resistant 61 clinical A. baumannii
isolates were detected resistant to imipenem and meropenem. In the 61
isolates, the MIC50 of imipenem and meropenem were 16 and >32;
MIC90 were 192 and >32 respectively. MHT was positive for all 61
A. baumannii strains. None of these isolates showed MBL activity. All
of 61 isolates had blaOXA-51 genes, 50 isolates had blaOXA-23, and 11
isolated had blaOXA-58 genes. Alleles encoding OXA-24-like enzymes
were not detected in any isolates.
Conclusions: All of the 61 carbapenem resistant A. baumannii strains
showed OXA-type carbapenemase activity in this study. Ninety-ﬁve
percent (n = 58) of the isolates have two carbapenemases, one intrinsic
and the other acquired. OXA-51+OXA-23 was the most prevelant (77%).
P638 Evaluation of a low-density microarray for the identiﬁcation
of ESBL, AmpC and carbapenemase-producing
Enterobacteriaceae
U. Eigner*, D. Bertsch, K. Moskorz, M. Holfelder (Heidelberg, DE)
Objectives: We describe the validation of commercially available low
density microarrays (Check Arrays, Check-Points, Netherlands, Hain
Lifescience, Germany) for the reliable and highly speciﬁc identiﬁcation
of the most prevalent ESBL, AmpC and Carbapenemase-types.
Methods: The Check Arrays use speciﬁc DNA markers for the
detection of ESBL strains conferring TEM, SHV and the CTX-M
types, ampC and carbapenemases (NDM-1, KPC, VIM, OXA-48, IMP).
DNA was extracted from colonies grown on an agar plates using the
EasyMAG system (bioMerieux, Germany). Before PCR with biotin-
labelled primers, speciﬁc oligos containing a artiﬁcial 5′ sequence are
ligated when they are annealed to a complementary DNA-structure. PCR
products of up to three isolates can be pooled and hybridized to a low
density microarray (platform based on CLONDIAG chip technologies
GmbH). Detection was performed with a CP-Array tube reader and the
CP ESBL software. For validation a panel of 36 (19 ESBL-positive,
17 ESBL-negative) and 5 Carbapenemase-positive strains, genotypically
(sequencing, PCR) and phenotypically (Phoenix System, [BD Diagnostic
Systems, USA]) characterized Enterobacteriaceae-strains were used. In
addition to these reference strains 115 routine isolates characterized
by VITEK 2 and additional CLSI ESBL-disk diffusion test and the
AmpC&ESBL Detection set (Mast Diagnostika, UK) were analyzed with
the ESBL array.
Results: All (100%) of the 19 characterized ESBL-positive isolates (12
TEM, 7 SHV), were correctly identiﬁed with the Check-arrays. 3 of
the 17 ESBL reference strains were negative with the molecular test
and positive with the phenotypic methods. Of the 115 routine isolates
tested in total, 111 (96,5%) of the ESBL-positive and -negative strains
showed congruent results compared to phenotypic ESBL detection
methods. One routine isolate was ESBL-positive with the Check array
and negative with the phentotypic methods and one isolate was negative
with the molecular method and positive with the phenotypic method.
2 strains were invalid with the Check array. All strains characterized as
Carbapenemase-positive (n = 5) were correctly detected by the molecular
arrays.
Conclusions: The CP ESBL array showed accurate results for the
identiﬁcation of the TEM, SHV and CTX-M ESBL-types, AmpC and
Carbapenemases. The test can be performed within one workday (7−8h).
P639 Diversity of gene cassette promoters in antibiotic-resistant
bacteria from wastewater environments
A. Moura, T. Jove´*, M.C. Ploy, I. Henriques, A. Correia (Aveiro,
PT; Limoges, FR)
Objectives: To investigate the diversity of the Pc-P2 promoter
combinations involved in gene cassette transcription, in class 1 integrons
from wastewaters isolates.
Methods: Enterobacteriaceae and Aeromonadaceae were isolated from
two distinct environments: urban wastewaters, consisting mostly of
domestic efﬂuents and slaughterhouse wastewaters, consisting of
discharges with animal origin. Class 1 integrons-containing strains were
characterized in terms of phylogenetic afﬁliation and antimicrobial
resistance proﬁles. The Pc-P2 promoter region was ampliﬁed by PCR
and sequenced to identify the promoter variants.
Results: Among 47 integrons identiﬁed, the following 6 Pc-P2
conﬁgurations were detected: PcS, PcH2, PcH1, PcWTGN-10, PcW and
PcW+ P2. The promoter types were neither species- nor gene cassette
array-speciﬁc.
The diversity of Pc-P2 conﬁgurations differed according the origin of
the sample. In integrons from urban wastewaters (n = 23), the 6 Pc-P2
conﬁgurations were detected: PcH1 (44%), PcW (26%), PcWTGN-10
(13%), PcS (9%), PcW+Pc2 (4%) and PcH2 (4%), while in integrons
from slaughterhouses’ wastewaters (n = 24), only 3 conﬁgurations could
be detected: PcW (83%), PcH1 (13%) and PcW+Pc2 (4%).
Conclusions: Results obtained showed the predominance of the weak
PcW and PcH1 variants in both types of efﬂuents. However, the PcW
variant largely prevailed in integrons from animal’s wastewaters, while
PcH1 was prevalent in domestic efﬂuents. Interestingly, these low
efﬁcient promoters are known to determine the most efﬁcient integrons
integrase for recombination of gene cassettes. Hence, their prevalences
provide insights into the gene cassette dynamic in integrons from
wastewater environments. Other environments should be investigated in
order to determine whether the Pc diversity correlate with some/speciﬁc
environmental conditions.
P640 Evaluation of a commercial miniaturised DNA microarray
for detection of b-lactamase genes in Gram-negative bacteria
M. Gazin*, J. Vervoort, L. Bryssinck, C. Lammens, M. Gniadkowski,
H. Goossens, S. Malhotra-Kumar on behalf of the MOSAR WP2 and
SATURN WP1 study groups
Objectives: We evaluated the Identibac AMR-VE Genotyping (Alere
GmbH, Germany), a miniaturized DNA array, for high-throughput
detection of clinically important b-lactamase (CTX-M, TEM, and SHV)
genes in various Gram-negative bacteria.
Methods: The array was validated on 30 well-characterized Gram-
negative organisms harbouring b-lactamases and belonging to the
following species: Escherichia coli (n = 15); Klebsiella pneumoniae
(n = 5); Klebsiella oxytoca (n = 1); Proteus mirabilis (n = 4); Serratia
marcescens (n = 2); Enterobacter cloacae (n = 2); Citrobacter freundii
(n = 1). Strains were identiﬁed by mass spectrometry. Presence of
CTX-M, TEM, and SHV b-lactamase genes was conﬁrmed by PCR
and sequencing. For array testing, genomic DNA was extracted
with chloroform/isoamylalcohol, treated with RNase, and the required
concentration (0.1−0.3mg/ml) was calibrated spectrophotometrically.
Template DNA was biotin-labelled in a linear PCR followed by
hybridization (Array Hybridization Kit) to the microtube DNA array
system. Data was analyzed on the Array Tube Reader (ATR 03, 2.0)
using IconoClust software (Standard version) and normalised using 10
internal control probes. Mean signal intensities of two replicate spots
per probe were used for analysis. Intensities of 0.4 were considered
positive, <0.3 were negative, and 0.3−0.4 were ambiguous (manufacturer
recommendations).
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Results: Of the 30 strains tested, 19 harboured CTX-Ms and 12 (63%)
could be detected on the array. By PCR-sequencing, these were identiﬁed
as CTX-M-15 (n = 5), CTX-M-3 (n = 3), CTX-M-1, -27 (n = 2 each), and
CTX-M-2, -5, -9, -14, -32, -55, and a non-typeable CTX-M (n = 1 each)
(Table). Eight of the 12 array-positive CTX-Ms were present in E. coli,
3 in K. pneumoniae, and 1 in E. cloacae. However, 6 of the 7 CTX-
Ms that were not detected on the array were also present in E. coli
and of these, 3 were CTX-M-15 (Table). Of the 8 SHV genes detected
by PCR-sequencing, only 2 (25%, SHV-1 present in K. pneumoniae)
gave positive signals on the array. In contrast, all 23 TEM genes were
correctly detected. Array speciﬁcities for detection of CTX, SHV and
TEM were 100%.
Conclusion: Our data indicate that the Identibac AMR-VE array
is a high-throughput, easy-to-use method for detection of multiple
b-lactamase genes in Gram-negative bacteria, although iterative modi-
ﬁcations to increase its sensitivity for CTX-M and SHV detection are
required.
P641 Multiplex polymerase chain reactions for extended-spectrum
b-lactamases, AmpC b-lactamases and carbapenemases
G.M. Voets*, A.C. Fluit, J. Scharringa, J.W. Cohen Stuart, M. Leverstein-
van Hall on behalf of the ESBL National Surveillance Working Group
Objectives: Several multiplex PCRs for the detection of a broad range of
clinical important b-lactamase families have been published. However,
these PCRs use different ampliﬁcation protocols and do not cover the
wide range of clinically important Extended-Spectrum b-lactamases
(ESBLs), AmpC b-lactamases and carbapenemases. The aim of this
study was to develop a set of multiplex PCRs for the detection of the
majority of genes encoding clinically important b-lactamases causing
third-generation cephalosporin or carbapenem resistance using a single
ampliﬁcation protocol.
Methods: Twenty-six strains with sequenced b-lactamase genes were
used as positive controls. Primers used were either described by (Dallene
et al., JAC, 2010) or designed in this study and evaluated in the following
protocol. DNA was isolated using the NucleoSpin® Tissue kit according
to the instructions of the manufacturer. The DNA concentrations of the
samples were equalised to approximately 50 ng/ml and 1ml was added to
each multiplex PCR in a 25ml reaction mixture, containing 1x PCR
buffer (10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1% Triton X-100,
0.1% (w/v) stabilizer), 50mM of each deoxynucleotide triphospate,
1 U SuperTaq, and a variable concentration of primers and MgCl2.
Ampliﬁcation was carried out as follows: initial denaturation at 94ºC
for 1 min; 30 cycles of 30 sec at 94ºC, 40 sec 60ºC, 1 min 72ºC, and
a ﬁnal elongation step at 72ºC for 1 min. Ampliﬁcation products were
visualized after running at 100 V for 1 h on a 1% agarose gel containing
gel red. A 1 kb DNA ladder was used as a size marker.
Results: Ampliﬁcation products of the expected sizes were obtained with
all control strains, conﬁrming the speciﬁcity of the primers. This extends
the possibility to use multiplex PCRs for the detection of the following
b-lactamase genes: GIM, IMI, NDM, SIM, SME, SPM b-lactamase
families and the OXA-1, OXA-2, OXA-4, OXA-23, OXA-24, OXA-
51 and OXA-58 groups. These b-lactamase genes can be detected, along
with previously described b-lactamase genes by Dallene et al., using one
ampliﬁcation protocol.
Conclusion: We describe a set of multiplex PCRs that enables the
detection of the majority of clinically important b-lactamases causing
third-generation cephalosporin or carbapenem resistance using one
ampliﬁcation protocol.
P642 Development of a real-time multiplex PCR assay for the
detection of plasmid-mediated AmpC b-lactamases directly
from blood cultures
G.L. Vanstone*, L. Ramzi, B.M. Charalambous, I. Balakrishnan
(London, UK)
AmpC B-lactamase producing Enterobacteriaceae have a multi-drug
resistant phenotype and represent an infection control challenge.
The rapid detection of these organisms is critical to implementing
optimal antibiotic therapy and appropriate infection control procedures.
Currently, detection is based on phenotypic methods that can take 48
hours to complete.
Objectives:
• To convert a previously described conventional PCR that can detect
the six phylogenetic families of AmpC plasmids (CIT, DHA, ENT,
ACC, FOX and MOX) into a real-time multiplex PCR.
• To evaluate whether the real-time multiplex PCR can be used to detect
AmpC producing isolates directly from blood cultures within 4 hours.
Methods: The conventional PCR (Perez-Perez and Hanson, 2002) was
transferred onto a real-time platform (RotorGene 6000) using SYBR
Green chemistry. High Resolution Melt (HRM) analysis of the products
was evaluated as a method to distinguish between the different AmpC
families. Control organisms were then spiked into negative blood cultures
to give concentrations of 103 to 107 bacteria/ml. Bacterial DNA was
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extracted from the blood cultures using a rapid bead-beating extraction
method (BD Diagnostics) before performing the multiplex PCR.
Results: The real-time multiplex PCR was able to detect all of the
plasmidic AmpC genes and HRM analysis allowed each of the AmpC
genes to be distinguished. When performed on DNA extracts from the
spiked blood cultures this PCR was able to detect all control isolates
in less than 4 hours with a detection limit of 104 bacteria/ml. This is
signiﬁcantly lower than the average number of bacteria found in blood
cultures when they ﬂag positive (>107 bacteria/ml) on our currently used
automated blood culture detection system (Bactec FX, BD Diagnostics).
Conclusions: The detection time of AmpC producing organisms was
reduced by >10 fold compared to currently used routine methods. This
simple and rapid technique has the potential to dramatically improve
patient outcome and facilitate rationalisation of both antibiotic use and
infection control practices much earlier than currently possible. We are
currently evaluating this technique on clinical blood cultures and hope
to introduce it into routine service.
P643 Long-term evolution of hyper-mutable strains increases the
mutational cost of antibiotic resistance
M.C. Turrientes*, A. Ripoll, M.R. Baquero, R. Canto´n, F. Baquero,
J.C. Gala´n (Madrid, ES)
Objective: Increased mutation rate (m) should offer more opportunities
for antibiotic resistance, but simultaneously bacterial populations with
this trait might accumulate mutations affecting their replication rates.
These contradictory effects suggest that the overall success of strains
with increased m will be higher in the early stages after the emergence
of the hyper-mutable status. This work explores how the time-length
of established mutators inﬂuences the biological cost of newly acquired
antibiotic resistance mutations.
Methods: Four E. coli variants with different mutation rates (m) were
studied: i) a non-mutator E. coli strain (nA) with m= 1.07x10−9; ii)
its isogenic mutator variant (mA) with m= 5.37x10−8 and two evolved
variants from (mA) obtained after 1,500 generations in LB; iii) an
evolved mutator (mE) with m= 6.60x10−8; and iv) an evolved non-
mutator (nE) with m= 2.47x10−9. Quinolone- or rifampicin-resistant
variants of all these four strains were obtained in the lab, all of them
carrying the same single changes S83L (NalR) and D516N (RifR), which
do not affect to biological cost (W). Pairwise competition experiments
in LB-broth were performed between NalR or RifR versus wild-type
isogenic strains in order to measure W in mutator and non-mutator
backgrounds.
Results: 1) Competition experiments between strains (nA and nE) with
m close to modal value (m= 1x10−9) did not yield differences in W
independently from the number of generations (Wt0=0.99±0.06 and
Wt1500=0.97±0.06, respectively). However, in the ﬁrst generations,
the biological cost of mA strain was 15% higher than nA strain
(Wt0=0.85±0.05), signiﬁcantly rising in to 41% (Wt1500=0.59±0.09)
after 1,500 generations (mE). 2) Exposure to an SOS-inducing agent
(nalidixic acid) increased m of non-evolved mutator in 4.3-fold (mA,
2.31x10−7) and only 2.6-fold in the evolved mutator (mE, 1.76x10−7),
suggesting weaker activation of SOS system in evolved mutators. When
an antibiotic non-inductor of SOS system (rifampicin) was used no
signiﬁcant changes in m were observed.
Conclusions: In stable environments, mutator strains might reduce
their frequency in bacterial populations, because of the reduction of
their replicative capacities imposed by the new mutations. The possible
attenuation of SOS system in these strains might act as a compensatory
effect to decrease this mutational load, but also reducing their adaptive
opportunities.
P644 Rapid molecular detection of carbapenemase-producers in
Enterobacteriaceae including the newly described NDM-1
carbapenemase (TEST 2009–2010)
C. Lascols*, M. Hackel, S. Hawser, R. Badal, S. Bouchillon, D. Hoban,
M. Dowzicky (Schaumburg, US; Epalinges, CH; Collegeville, US)
Background: b-lactamases conferring resistance to carbapenems, such
as metallo-b-lactamases (MBLs), KPC and class D b-lactamases (e.g.
OXA-48) have emerged in Enterobacteriaceae. Moreover, the latest
threat in Gram-negative resistance is the recent emergence of NDM-1
multidrug-resistant isolates. A fast multiplex-PCR for the detection of
all these versatile enzymes was designed in this study.
Methods: A total of 343 recent carbapenem-resistant Enterobacteriaceae
isolates from 2009–2010 were investigated for the presence of KPC,
OXA-48, VIM and NDM-1. A rapid molecular test was developed using
multiplex-PCR and previously described primers for the KPC, OXA-48
and VIM genes. NDM-1 speciﬁc primers were designed for identiﬁcation
of the NDM-1 gene. Minimum inhibitory concentrations (MICs) were
determined using broth microdilution method following CLSI guidelines.
Results: The 343 isolates were collected from multiple infection sources
and originated from various countries in Europe (43.1%), Latin America
(30.3%), and North America (19%), the remaining were from Middle
East (5%), Asia (2.3%) and Africa (0.3%). The majority of isolates
included K. pneumoniae (74.3%), E. coli (16.3%), K. oxytoca (4.1%),
E. cloacae (4.1%), and E. aerogenes (1.2%). Of the 343 isolates, 135
isolates (39%) carrying at least one of these carbapenemases were
identiﬁed. Among the carbapenemase-producers, 114 (84.5%) were
KPC-positive isolates, followed by a signiﬁcantly lower proportion for
other genes: 13 (9.6%) VIM, 7 (5.2%) OXA-48 and 1 (0.7%) NDM-1
All the VIM and OXA-48-producers were isolated in Europe and in the
Middle East. KPC-producers were isolated in Europe (45.6%), North
America (28.1%), Latin America (15.8%) and Middle East (10.5%).
The new NDM-1 gene was identiﬁed in a K. pneumoniae isolate from
South Africa, from a urinary tract infection (UTI) in a 30-year old male
patient. This multi-drug resistant isolate, carrying an ESBL (CTX-M15)
and an AmpC b-lactamase (CMY-2), was only susceptible to tigecycline
and colistin.
Conclusions: Carbapenem resistance has become a major health care
issue, intensiﬁed by the rapid emergence of KPC carbapenemases and
the newly described NDM-1 carbapenemase. Molecular epidemiological
studies are crucial for monitoring the dissemination of all these
carbapenemase-producers worldwide.
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P645 Emergence of New Delhi metallo-b-lactamase (NDM-1)-
producing Enterobacteriaceae in Austria
A.J. Grisold*, G. Zarfel, M. Ho¨nigl, T. Valentin, H.J. Salzer, E. Leitner,
R. Krause (Graz, AT)
Objectives: Extended-spectrum b-lactamase-producing (ESBL) Enter-
obacteriaceae have emerged as major public health problem throughout
the world, in particular India and Pakistan. We report the emergence
of the newly described resistance mechanism conferred by New
Delhi metallo-b-lactamase 1 (NDM-1) in Austria. NDM-1 positive
Enterobacteriaceae (2x Klebsiella pneumoniae and 1x E. coli) has been
detected in three patients at the University Hospital of Graz, Austria,
with all three cases occurring within the last 6 months.
Methods: NDM-1 shares very little identity with other metallo-
b-lactamase (MBL) enzymes and Enterobacteriaceae with NDM-1
show high resistance to nearly all commonly used antibiotics.
Primers for PCR detection of NDM-1 were designed based on
GenBank (National Center for Biotechnology Information, National
Institutes of Health, Bethesda, MD) database entry AB571289.1
(http://www.ncbi.nlm.nih.gov/nuccore/300422615).
Results: NDM-1 was detected in isolates of three patients, in two cases
in K. pneumoniae, and one patient with NDM-1 positive E. coli. All three
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cases occurred between December 2009 and August 2010. Patient one
(NDM-1 K. pneumoniae), a 30-year-old Austrian male was admitted to
our University Hospital in November 2009. History revealed that he had
suffered multiple open fractures of his upper and lower left leg and rectal
laceration due to a motorcycle accident in Pakistan. In patient two the
NDM-1 K. pneumoniae was detected in August 2010, the patient being a
14-year-old Kosovarian boy transferred from Kosovo to the Department
of Pediatrics, University Hospital Graz, with multiple intraabdominal
abscess formations and peritonitis. He had undergone appendectomy in
Pristina, Kosovo, in April 2010 and had developed abdominal sepsis
consecutively. Patient number three (NDM-1 E. coli), a 56 year old
male developed a necrotizing fasciitis when being in India in January
2010, after a short admittance at a hospital in New Delhi the patient was
transferred to Austria.
Conclusion: Gram-negative Enterobacteriaceae with the newly described
resistance enzyme NDM-1 have been recently shown to pose the
potential of growing to a major public health problem worldwide.
We report the emergence of NDM-1 among Enterobacteriaceae in
Austria. During December 2009 and August 2010 two patients with
K. pneumoniae carrying NDM-1 and one patient with NDM-1 E. coli
were identiﬁed at the Medical University of Graz, Austria.
P646 Characterisation of the ﬁrst NDM-1 metallo b-lactamase
producing Escherichia coli isolates from an Italian hospital
T. Giani, M.M. D’Andrea, F. Arena, V. Conte, C. Venturelli, P. Bresciani,
F. Rumpianesi, F. Narni, G.M. Rossolini* (Siena, Modena, IT)
Objectives: Metallo b-lactamases (MBLs) are resistance determinants
of great clinical relevance, given their ability to hydrolyze almost all
b-lactams, including carbapenems. Among MBLs, NDM-1 is one of
the most worrisome due to its propensity to rapid dissemination among
Enterobacteriaceae. Here we report on the characterization of the ﬁrst
NDM-1 positive isolates from an Italian hospital.
Methods: A total of 8 NDM-1-positive E. coli isolates obtained during
2009–2010 from stool and wound-exudate samples of two Italian patients
were studied. Susceptibility testing were performed using Vitek2 system
(Biomerieux). MICs of carbapenems, amikacin, piperacillin-tazobactam,
colistin and tigecycline were conﬁrmed by Etest (Biomerieux). Detection
of resistance genes was performed using a custom microarray and all
positive signals were conﬁrmed by PCR. Clonality was investigated
by PFGE and MLST. Localization of blaNDM-1 was investigated by
Southern blot hybridizations. Gene transfer experiments were performed
both by electroporation and conjugation. The genetic environment of
blaNDM-1 was investigated by the inverse-PCR (iPCR) technique.
Results: Isolates showed a MDR phenotype being not susceptible to
all tested antibiotics, except colistin and, in 7 cases tigecycline. Car-
bapenem MICs were 4−8mg/L (imipenem), 8−>32mg/L (meropenem),
2−16mg/L (doripenem), and >32mg/L (ertapenem). Microarray, in
conjunction with PCR and sequencing, revealed the presence in all
isolates of blaNDM-1, blaTEM-1, blaOXA-1, blaOXA-9, blaCTX-
M-15, tetA(B), tetA(C), armA, aac(6′)-Ib-cr, aac(3)-II, catB3, and arr3
resistance determinants. PFGE and MLST demonstrated that isolates
were clonally related and belonged to ST405. blaNDM-1 was not
transferred either by electroporation or by conjugation using different
E. coli recipients. iPCR experiments revealed an original genetic
structure, characterized by an intact IS26 insertion sequence upstream
blaNDM-1. Results from Southern-Blot experiments revealed the likely
presence of 2 copies of blaNDM-1 in the investigated isolates, with one
plasmid-encoded.
Conclusions: Characterization of the genetic environment of the ﬁrst
NDM-1 positive Italian isolates revealed an original arrangement,
underscoring the promiscuity of genetic elements carrying blaNDM-1.
The presence of a plethora of different clinically relevant resistance
determinants in such isolates is a worrisome ﬁnding given the scarce
number of effective therapeutic options available.
P647 Emergence and epidemiology of New Delhi metallo-
b-lactamase 1-producing Klebsiella pneumoniae in a Korean
tertiary care hospital
M.N. Kim*, S.H. Park, D. Ahn, M. Lee (Seoul, KR)
Objectives: Acquired carbapenemases-producing Enterobacteriaceae has
been a legislative notiﬁable infectious disease in Korea since November
2010. For a month period of November 2010, four cases of a novel
acquired carbapenemase, New Delhi metallo-b-lactamase 1 (NDM-1)
was ﬁrst detected in a tertiary care hospital in Korea.
Methods: Species identiﬁcation and susceptibility testing of Enter-
obacteriaceae isolated from clinical and surveillance specimens was
performed with MicroScan NBC44 (Siemens, UK). Since November
2010, Nonsusceptible Enterobacteriaceae to one of ertapenem, imipenem
and meropenem have been tested with modiﬁed Hodge test and
disk diffusion testing using imipenem disks, meropenem disks,
EDTA-combined imipenem and meropenem disks, and boronic acid-
combined imipenem and meropenem disks. For the isolates revealing
carbapenem-hydrolyzing metallo-b-lactamase were submitted to NDM-
1-speciﬁc PCR and sequencing. All carbapenem-resistant K. pneumoniae
(CRKP) isolated in November 2010 was typed using pulsed ﬁeld gel
electrophoresis with Xba-1 restriction. Electronic medical records of
the patients infected or colonized with NDM-1 were reviewed for
demographic, clinical, and epidemiological data.
Results: Four NDM-1 producing K. pneumoniae were detected and three
of them were resistant to ertapenem, imipenem, and meropenem, but
one was susceptible to imipenem and intermediate to meropenem. Only
a few antimicrobials were remained active for those; colistin for all,
tigecylcine and amikacin for three, tobramycin for two, aztreonam for
one, and tetracycline for one. Two NDM-1 K. pneumoniae were isolated
from urine cultures and the others from stool surveillance. All patients
were hospitalized for 1 to 5 months and received meropenem for 8 to 47
days before isolation of NDM-1. One of them admitted and two had been
admitted to medical intensive care unit (MICU), but the periods staying
at MICU were not overlapped each other. The remaining one stayed
at a surgical ward after liver transplantation. There was no history of
traveling abroad and epidemiological linkage among the cases found.
Total of 8 CRKP including 4 NDM-1 were typed with PFGE, which
revealed clonality among two NDM-1 CRKPs from MICU and a medical
ward, and one CRKP other than NDM-1.
Conclusion: Nosocomial clustering of NDM-1 was emerged in a Korean
tertiary-care hospital. Careful surveillance of carbapenemase-producing
Enterobacteriaceae are required in Korea.
P648 Klebsiella pneumoniae harbouring NDM-1 metallo-
b-lactamase isolated in Croatia
A. Mazzariol*, Z. Bosnjak, P. Ballarini, A. Budimir, B. Bedenic,
S. Kalenic, G. Cornaglia (Verona, IT; Zagreb, HR)
Objectives: A K. pneumoniae strain, resistant to carbapenems, was
isolated in May 2009, from a blood culture of a 40-years-old man,
recovered in a surgical intensive care unit of the Clinical Hospital
Center in Zagreb, Croatia. The patient had been transferred from another
hospital of a neighbouring country after 5 days of hospitalization due to
a car accident. The clinical history mentioned antibiotic treatment not
including carbapenems (gentamicine, metronidazole and ceftriaxone),
and no link to India or Pakistan. We investigated the carbapenem
resistance mechanism.
Materials and Methods: Antimicrobial susceptibility testing was
performed by both Vitek2 and microdiluition, and interpreted according
to the latest EUCAST documents. The presence of a carbapenemase was
investigated by means of an MBL-etest, hydrolysis of carbapenems and
EDTA inhibition of hydrolysis. PCR and sequencing were carried out
by standard procedures. Resistance was transferred by conjugation to
E. coli J53.
Results: The strain was resistant to imipenem and meropenem (MICs
16mg/L and 64mg/L, respectively), and to all 3G-cephalosporins (MICs
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>128mg/L), and susceptible to ciproﬂoxacin (MIC 0.25mg/L) It also
harboured a qnrA and a ctx-m-15 genes. The presence of an MBL
was suggested by the MBL Etest and conﬁrmed spectrophotometric by
EDTA-inhibited imipenem hydrolysis.
PCR performed by using primers speciﬁc for blaIMP, blaVIM, blaSPM,
blaGIM, and blaSIM, did not yield any product. A product obtained
with NDM primers was conﬁrmed, after sequencing, to code for an
NDM-1 enzyme. The resistance to carbapenems and 3G-cephalosporins
was transferred to E. coli J53 by conjugation.
Conclusions: To our knowledge this is the ﬁrst report of an NDM-1-
producing K. pneumoniae in Croatia and in the Balkans. The patient had
no apparent link to the Indian subcontinent and the strain was isolated
before the recent outbreak of NDM-1 producing Enterobacteriaceae.
Although several cases reported by a recent pan-European survey
showed a clear link to the Balkan region, this is the ﬁrst documented
report of NDM-1 from that area, thus conﬁrming a possible multifocal
spread of this enzyme and prompting for a widespread epidemiological
surveillance.
P649 First description of an Escherichia coli strain producing
NDM-1 carbapenemase in Spain
M.M. Sole´*, C. Pitart, P. Salvador, L. Mun˜oz, I. Oliveira, J. Gasco´n,
I. Roca, A. Fa`brega, F. Marco, J. Vila (Barcelona, ES)
Objectives: Metallo-b-lactamases (MBL) are important enzymes that
hydrolyze all b-lactam antibiotics except aztreonam. Recently, a
Klebsiella pneumoniae isolate carrying a novel carbapenemase, named
NDM-1, was identiﬁed from a Swedish patient transferred from India.
In this study, we report the ﬁrst description of an E. coli strain producing
NDM-1 in Spain.
Methods: Antimicrobial susceptibility testing was performed by BD
Phoenix and Etest. Hodge and Imipenem-EDTA Etest synergy tests
were used to screen for MBL production. Detection of genes
encoding carbapenemases (VIM, IMP, NDM), ESBLs, plasmid-mediated
cephalosporinases, armA (to investigate aminoglycoside resistance)
as well as genes encoding heat-stable (ST), heat-labile (LT) toxins,
verotoxins (VT) and enteroaggregative E. coli virulence factors was
performed by PCR and sequence analysis. Conjugative transfer between
DVR22 and E. coli J53 was done by conventional biparental mating.
Plasmid analysis was performed both to the NDM-1 bearing strain
and selected transconjugants. After a four month period another stool
specimen from the same patient was screened to detect NDM-1 carriage.
Results: A carbapenem-resistant E. coli (DVR22) was recovered from
a stool specimen from a patient with traveller’s diarrhoea who had
travelled to India. The DVR22 strain was resistant to all antibiotics
tested except tigecycline, fosfomycin and colistin. MICs of carbapenems
were as follows: imipenem (8 mg/ml), meropenem (8mg/ml), ertapenem
(24mg/ml) and doripenem (6mg/ml). Hodge and Imipenem-EDTA Etest
synergy tests were positive. PCR and sequencing identiﬁed the presence
of genes encoding NDM-1, DHA, CTX-M-15, TEM-1 and armA
genes. E. coli transconjugants showed resistance to aminoglycosides
and all b-lactam antibiotics and were positive for NDM-1, CTX-M-15,
DHA, TEM-1 and armA genes. Plasmid analysis revealed that E. coli
transconjugants harboured a circa 180-kb plasmid. PCR screening of
genes encoding virulence factors of diarrhoeagenic E. coli was negative.
Four months later the DVR22 strain was no longer isolated from the
stool of this patient.
Conclusions: This is the ﬁrst isolation of an NDM-1 metallo-b-lactamase
in Spain. The location of NDM-1 in a conjugative plasmid increases the
risk of dissemination and transfer to other bacteria. Our results, however,
suggest that this strain does not persist long in the intestinal tract, most
likely due to the ﬁtness cost associated with the conjugative plasmid.
P650 First documented New Delhi metallo-b-lactamase 1 (NDM-1)
cases in Switzerland
C. Fankhauser*, A. Cherkaoui, G. Renzi, J. Schrenzel, S. Harbarth
(Geneva, CH)
Background: The rapid spread of New Delhi metallo-b-lactamase 1
(NDM-1) producing Enterobacteriaceae constitutes a global public health
threat.
Objective: To describe the clinical and epidemiological implications of
3 NDM-1 cases in Geneva.
Methods: Retrospective case review with molecular identiﬁcation.
MICs of ertapenem, meropenem and imipenem were determined with
Etests. ESBL production was tested using the cefotaxime-ceftazidime–
clavulanic acid double-disc method. The presence of blaNDM-1 was
determined by conventional PCR and DNA sequencing analysis with
primers speciﬁc for blaNDM-1. Inhibition of blaNDM-1 activity
was evaluated by disk approximation analysis. NDM-1 isolates were
further investigated by PCR ampliﬁcation to detect other resistance
determinants.
Results: Between December 2009 and January 2010, 3 NDM-1 isolates
were identiﬁed at HUG belonging to three patients that were repatriated
to Geneva after receiving medical treatment in India (1), Pakistan (2)
and Serbia (3). On admission, patient 1 was a digestive carrier of
E. coli blaNDM-1 and patient 3 had a urinary tract infection due
to K. pneumoniae blaNDM-1. Patient 2 was discovered a digestive
carrier of P. mirabilis blaNDM-1 only after extended hospitalization and
antibiotic therapy. All patients carried other multiresistant organisms
such as ESBL-producing Enterobacteria, Pseudomonas aeruginosa or
Acinetobacter baumannii. Patient 1 harbored a highly resistant strain of
E. coli blaNDM-1 showing in vitro susceptibility only to fosfomycine
and tigecycline and a pan-resistant Acinetobacter blaNDM-1. Proteus
blaNDM-1 (Patient 1) and K. pneumoniae blaNDM-1 (Patient 3) strains
were also sensitive to ciproﬂoxacin. The patients were hospitalized in
different wards; no cases of cross-transmission were identiﬁed due to
early screening and preemptive isolation. The presence of NDM-1 was
conﬁrmed retrospectively after patient discharge.
Conclusion: We report 3 imported cases of NDM-1 in Switzerland
and underline challenges related to clinical management and early
reliable identiﬁcation. The threat of NDM-1 points out the importance
of early detection, implementation of control measures and surveillance
of patients transferred from the Balkan region and South Asia.
P651 Characterisation of the ﬁrst NDM-1 producing
Enterobacteriaceae in Belgium
P. Bogaerts*, W. Bouchahrouf, A. Deplano, R. Rezende, C. Berhin,
O. Denis, Y. Glupczynski (Yvoir, Brussels, BE)
Objectives: To characterise the 5 ﬁrst NDM-1 metallo-b-lactamase
producing Enterobacteriaceae recovered in Belgium in 2010.
Methods: The isolates were identiﬁed to species level by MALDI-
TOF MS. Antibiotic susceptibilities were determined by disk diffusion,
VITEK2, and microdilution MIC determination. ESBL, AmpC and
carbapenemase were analyzed by PCR-sequencing. Puriﬁed plasmids
were electroporated in recipient TOP10 E. coli and their InC groups
were determined. The isolates were typed by PFGE and MLST.
Results: In 2010, 5 NDM-producing isolates (2 E. coli, 1 K. pneumoniae,
1 M. morganii, 1 E. cloacae) were identiﬁed in Belgium in 3 patients
admitted to different hospitals. Isolates were recovered upon admission
from necrotic wound infection, respiratory and fecal samples. One
patient died from severe sepsis while two others were colonized. Patients
were transferred from Pakistan, Montenegro and Kosovo. Enforced
barrier precautions were applied and no secondary nosocomial outbreaks
did occur. The E. coli isolates from 2 patients were genetically distinct by
PFGE and harbored different MLST sequence types (ST101 and ST782).
The K. pneumoniae presented a ST15 type (close to ST14)involved in
the spread of CTX-M-15 producing K. pneumoniae. All isolates were
extensively resistant and displayed a synergy between imipenem and
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EDTA. MICs against meropenem/imipenem/doripenem ranged from <1
to 8mg/L while MIC against ertapenem ranged between 4 and 16mg/L.
NDM-1 was borne on 1 IncFI, 1 IncA/C and 1 none typable plasmid.
NDM-1 in M. morganii and in E. cloacae could not be transferred
in recipient cells suggesting a chromosome location or very high size
plasmid. In E. coli TOP10, NDM-1 confers MICs 1mg/L against all
carbapenems. In addition, multiple resistance genes were associated with
NDM-1 on the same or on different plasmids including CMY-16, CMY-
58, CTX-M-15, SHV-12, TEM-1, OXA-30, OXA-9, RmtB, ArmA, QnrA
and QnrB.
Conclusion: NDM-1 is rapidly spreading worldwide mostly from the
Indian subcontinent. This is the ﬁrst characterization of NDM-1-
producing isolates in Belgium, two being isolated from patients with
no link with the Indian subcontinent but who received hospital care
in Balkan countries. The fact that NDM-1 was recovered in association
with a plethora of other resistance genes, in different species, on different
plasmids and possibly on the chromosome of unrelated species isolates,
underscores the high mobility of this gene.
P652 NDM-1 in Israel, evidence of travelling and carriage of
carbapenem-resistant organisms
M. Castanheira*, L. Deshpande, G. Smollan, R. Mendes, R. Jones,
D. Ben-David, M. Hindiyeh, S. Gefen-Halevi, N. Keller (North Liberty,
US; Tel-Hashomer, IL)
Objectives: To investigate the carbapenem (CARB) resistance (R)
mechanism in an Escherichia coli strain recovered from rectal swab of a
patient hospitalized in Israel that received medical care in India during a
vacation accident. NDM-1 was detected in several countries harboured
by various Gram-negative bacilli species and patient cases were closely
linked to receipt of medical care in India or Pakistan.
Methods: Gram-negative isolates from wound cultures were suscep-
tibility (S) tested by CLSI reference broth microdilution methods.
Isolates displaying imipenem (IMI) and/or meropenem (MER) MIC at
2mg/L were screened for CARBase production by Modiﬁed Hodge
test (MHT) and PCR for blaIMP, blaVIM, blaKPC and blaNDM-1.
Amplicons were sequenced. S1 nuclease digest were resolved in agarose
and hybridized with blaNDM-1 probe. Transformation was performed
by electroporation using E. coli DH5alfa and plating in selective media
(4mg/L of ceftazidime). Transformants were conﬁrmed by PCR and S
testing.
Results: A 52 year old female was transferred to Chaim Sheba Med
Center (CSMC; Tel-Hashomer, Israel) with an infected fracture of
the right ankle after a motorcycle accident followed by surgery while
vacationing in India. At CSMC, the patient underwent various surgical
procedures (ﬁve incisions and drainage). Three Aeromonas hydrophila/
caviae, two K. pneumoniae (one each of ESBL-positive and -negative)
and a methicillin-S S. aureus were recovered from wound cultures. One
K. pneumoniae was carbapenem-R (MIC, >8mg/L for IMI and MER)
and MHT and CARBase PCR negative. An E. coli R to carbapenems
(MIC, >8mg/L for IMI and MER) grew in rectal screen cultures. MHT
was positive and initial PCR for blaKPC was negative. PCR for and
sequencing conﬁrmed the presence of blaNDM-1. This MBL gene was
carried on a 150-kb plasmid that was transformed into an E. coli host.
Transformants displayed elevated MIC values for carbapenem (4 and
8mg/L for IMI and MER, respectively) and aminoglycosides (>32 and
>16mg/L for amikacin and tobramycin, respectively).
Conclusions: The infection control challenges posed by globalization
and easy travel are now being highlighted by clinical cases of infec-
tions caused by NDM-1-producing Enterobacteriaceae strains. NDM-1
appears to be easily transferred and well expressed in Enterobacteriaceae
and elevated carbapenem MIC values were demonstrated in this Israeli
clinical isolate and in our laboratory transformant strains.
P653 Nosocomial transmission of NDM-1-producing Klebsiella
pneumoniae in a tertiary care hospital, United Arab Emirates
A. Sonnevend*, T. Pal, R. Hashmey, M.B. Hamadeh, M. Al-Haj,
N. Akawi, A. Gazawi, A. Javad (Al Ain, AE)
Objectives: The aim of the study was to analyse the mechanisms
responsible for carbapenem resistance in Klebsiella pneumoniae isolates
recovered from sputum samples of two patients admitted to the same
ward in a tertiary care hospital of the United Arab Emirates.
Methods: Species identiﬁcation and antibiotic susceptibility testing were
performed using VITEK 2. MBL production was conﬁrmed by E-test.
The presence of blaNDM1 was detected by PCR and conﬁrmed by direct
sequencing of the amplicon. Plasmid analysis was conducted using the
alkaline lysis method. Conjugative transfer of b-lactam resistance genes
was carried out using an azide-resistant derivative of E. coli J53 as
recipient. Molecular ﬁngerprints of the isolates were obtained by ERIC
PCR and PFGE analysis.
Results: A 72-year old patient had transurethral prostate resection in
India one month prior being admitted to Tawam Hospital for treatment
of pulmonary oedema and sepsis. His sputum sample yielded an NDM-1
producer K. pneumoniae on admission (KP52). The 26-year old second
patient was admitted for the treatment of acute myeloid leukaemia 9 days
after the ﬁrst patient. He did not carry any multidrug resistant bacterium
on admission; neither did he travel outside of the UAE. He was treated at
the hospital’s ICU in a room adjacent to the ﬁrst patient’s for 7 days. By
the 9th day of his hospital stay, while being neutropenic, he developed
pneumonia caused by an NDM-1 producer K. pneumoniae (KP53). His
condition progressed to multi organ failure and he died on the 18th day
of hospitalization. Both isolates were resistant to all antibiotics tested
except tetracycline and colistin. A 379 bp long segment of blaNDM1
(identical to GenBank FN396876.1 sequence) was detected in both
isolates located on a 50kb conjugative plasmid conferring resistance to
b-lactam antibiotics, only. The identical molecular ﬁngerprint of the two
isolates suggests a direct link between the two cases and strains.
Conclusion: This is the ﬁrst description of blaNDM1 harbouring
bacterium in the United Arab Emirates. The study also demonstrates the
possibility of nosocomial spread of a NDM-1 producer K. pneumoniae.
Strict infection control practices should be enforced in order to limit the
nosocomial spread of this pathogen.
P654 Diversity of sequence types and serotypes among invasive
isolates of Klebsiella pneumoniae years 2007–2009, isolated
at a tertiary university hospital in Sweden
M. Andersson*, M. Kabir, A. Iversen, C. Giske (Stockholm, SE)
Objectives: The importance of particular serotypes and virulence genes
for the pathogenesis of K. pneumoniae has been investigated in a few
studies, but rarely in a deﬁned geographical area during a longer period.
The objective of this study was to characterize clinical invasive isolates
of K. pneumoniae from the Stockholm area to determine diversity of
sequence types, serotypes and virulence genes.
Methods: Clinical isolates of K. pneumoniae isolated from blood
(n = 148) or CSF (n = 3) cultures at Karolinska University Hospital,
Solna, years 2007–2009 were included. Only isolates from patients
>18 years were considered. Epidemiological typing was performed with
Pulsed-Field Gel Electrophoresis (PFGE) and representative isolates of
PFGE-clusters were subjected to Multi Locus Sequence Typing (MLST).
Serotyping and detection of virulence genes was carried out with real-
time PCR. The PCR targeted the serotypes K1, K2, K5, K20, K54
and K57 and the virulence genes rmpA and wcaG. Presence of mucoid
phenotype was evaluated with adherence of colonies to the inoculation
loop. Data from PFGE and MLST were analyzed with Bionumerics 6.0.
Results: Among the 153 isolates we identiﬁed 11 strains clusters
(Dice coefﬁcient >90%) containing 2−3 isolates each. If the relatedness
deﬁning strain clusters was reduced to 80% we could identify 45 strain
clusters comprising 2−5 isolates. Simpson’s diversity index was 99.89%
when considering 90% as the cut-off for assigning isolates to the same
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PFGE-type. Among the isolates subjected to MLST so far we identiﬁed
four new sequence types ST539–542, as well as ST111 and ST253, both
of which have been described in bovine mastitis. A mucoid phenotype
was detected in 11 isolates (4%); only two of these were serotypable
(K2). The most frequently encountered serotype was K2 (n = 8), followed
by K54 (n = 4), K57 (n = 4), K1 (n = 2) and K20 (n = 2). The virulence
genes wcaG and rmpA were found in 13 and 6 isolates, respectively. No
isolates featured both virulence genes.
Conclusion: The genetic diversity of invasive isolates of K. pneumoniae
was found to be very high according to PFGE. When considering
relatedness at 80% substantially more strains clusters were identiﬁed,
but none of them comprised more than 5 isolates. Two STs previously
described in bovine mastitis were identiﬁed among isolates subjected to
MLST so far. The most commonly encountered serotype was K2, and
the most frequent virulence gene was wcaG.
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P655 Dissemination of Salmonella enterica serovar enteritidis
sequence type 11 producing CTX-M-15 extended-spectrum
b-lactamase in Korea
I.K. Bae*, Y. Kim, S.H. Jeong, C. Lee, K. Lee (Seoul, Daegu, KR)
Objectives: The recent emergence and dissemination of Salmonella
strains producing CTX-M-type extended-spectrum b-lactamases (ES-
BLs) is now an important public health concern. This study was
performed to investigate the molecular epidemiology of Salmonella
enterica serovar Enteritidis producing CTX-M-15 in Korea.
Methods: A nationwide survey performed in July to September 2009
collected a total of 49 consecutive non-duplicate Salmonella isolates
from 15 hospitals at 11 cities in Korea. Genes encoding ESBLs were
detected by PCR experiments. The genetic organization of blaCTX-
M-15 was investigated by PCR and sequencing the regions surrounding
the gene. Southern blotting, pulse-ﬁeld gel electrophoresis (PFGE), and
multilocus sequence typing (MLST) were performed to characterize the
isolates carrying blaCTX-M-15.
Results: Six S. enterica serovar Enteritidis isolates resistant to both
ceftazidime and cefotaxime were found to carry the blaCTX-M-15
gene. The ISEcp1 element was identiﬁed upstream of the blaCTX-M-15
gene. The isolates shared a same sequence type (ST), ST11, however,
they showed two different XbaI-macrorestriction patterns by PFGE. The
blaCTX-M-15 gene was located on IncFIIs plasmids of an identical
replicon sequence type (RST), F1:A-:B-, in all six isolates.
Conclusion: The present data show that there were two clonal outbreaks
by S. enterica serovar Enteritidis producing CTX-M-15 in Korea in 2009.
Although two clones shared a same ST, ST11, they cannot be considered
to be a same clone because they showed a low genetic similarity of
<85% by PFGE experiments. Interestingly, they shared IncFIIs plasmids
of an identical RST, F1:A-:B-, suggesting the horizontal dissemination
of the plasmid carrying the blaCTX-M-15 gene among S. enterica
serovar Enteritidis isolates in Korea. Finally, IncFIIs plasmids carrying
the blaCTX-M-15 gene have never been described before.
P656 Susceptibility and incidence of extended-spectrum
b-lactamase producing Escherichia coli and Klebsiella
pneumoniae in intra-abdominal infections globally: SMART
2009–2010
R. Badal*, S. Hawser, S. Bouchillon, D. Hoban, M. Hackel, A. Johnson
(Schaumburg, US; Epalinges, CH)
Objectives: E. coli and K. pneumoniae together represent approximately
60−70% of all aerobic Gram-negative bacteria (GNB) from intra-
abdominal infections (IAI). It is therefore necessary to take their
antimicrobial susceptibility into account when treating IAI. One of the
goals of the Study for Monitoring Antimicrobial Resistance Trends
(SMART), which tracks susceptibility patterns of IAI GNB globally,
is to provide physicians with actionable data with which to tailor
empiric therapy of IAI. This report provides the latest (2009–2010)
susceptibility data and frequency of extended-spectrum b-lactamase-
producing (ESBL+) isolates for these two species.
Methods: Approximately 170 hospitals in 39 countries each collected up
to 100 consecutive non-selected GNB from IAI; conﬁrmation of iden-
tiﬁcation, susceptibility testing, and phenotypic ESBL determinations
were done at a central laboratory (IHMA, Inc.) using custom MicroScan
dehydrated MIC panels, following CLSI and manufacturer procedures
and quality control guidelines. CLSI M100-S20-U breakpoints were used
to determine susceptibility.
Results: The following table summarizes ESBL+ rates and susceptibility
of E. coli, K. pneumoniae, and their respective ESBL+ sub-populations.
Conclusions: The two most commonly isolated pathogens of IAI, E. coli
and K. pneumoniae, remain very susceptible to ertapenem, imipenem,
and amikacin; even these drugs, however, showed diminished activity
against ESBL+ K. pneumoniae. The high proportion (roughly 20%) of
each of these species that is ESBL+ renders most of the comparators in
this study <90% effective in vitro, with susceptibility to several <80%.
In areas where ESBL+ rates exceed the global average (e.g., Asia and
Latin America, data not shown), susceptibility rates are even lower,
potentially leaving only the carbapenems and possibly amikacin among
drugs studied in SMART as options for empiric therapy of IAI.
P657 Temporal trends of Enterobacteriaceae with resistance to
higher generation cephalosporins in Switzerland, 2004 to 2010
A. Kronenberg*, K. Mu¨hlemann (Berne, CH)
Objectives: Multidrug resistant Gram-negative Enterobacteriaceae, are
increasing world-wide in hospital and community-settings due to rapid
spread of extended spectum blactamase (ESBL).
Methods: Data from a laboratory-based nation-wide surveillance
system (www.anresis.ch) were used to describe the temporal trends
of Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis with
resistance to third generation cephalosporines (3GR) in the ambulatory
and hospital setting between 2004 and 2010. Only one isolate per patient
and year was included in the analysis.
Results: Resistance data for total 172′535 isolates (82% E. coli, 11%
K. pneumoniae, 7% Proteus mirabilis) were analyzed. 27% of isolates
were from outpatients, 82% from urinary samples, 11% from children
below the age of 15 years old and 20% from women aged 15 to 45 years.
The prevalence of isolates with 3GR increased between 2004 and 2010:
in E. coli from 1.0% to 4.3% (p< 0.001), for K. pneumoniae from 1.1%
to 4.3% (p< 0.001), and for P. mirabilis from 0.4% to 1.1% (p = 0.045).
For E. coli the increase of resistance was signiﬁcant in all age groups,
in all regions and in ambulatory and hospital samples.
In 2010, the prevalence of 3GR among E. coli isolates was somewhat
lower (3.8%) in the ambulatory setting than in hospitals (5.5%,
p< 0.001), it was signiﬁcantly higher in patients >45 years of age than
younger patients (5% vs. 3.6%, p< 0.001), and it was signiﬁcantly lower
in West-Switzerland than in the rest of Switzerland (3.6% vs. 4.9%,
p< 0.001). For K. pneumoniae and P. mirabilis there were no signiﬁcant
geographic or age dependant variations. 68% of 3GR E. coli were also
resistant to quinolones, 65% to trimethoprim-sulfamethoxazole, and 50%
to both of these antibiotics.
Conclusion: In Switzerland, resistance to 3rd generation cephalosporines
among E. coli, K. pneumoniae and P. mirabilis is increasing at low
but constant rates since 2004 in the hospital and outpatient setting.
Resistance rates are higher in the hospital setting and among older
patients.
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P658 Country-wide prevalence of ESBL-producing
Enterobacteriaceae in 2009
D.S. Hansen*, F. Hansen, H. Schumacher, K. Schønning, S.G.K. Hansen,
K. Fuursted, T. Højbjerg, H.K. Johansen, J.K. Møller, B.H. Kallesøe,
M. Arpi, E. Dzajic, B. Røder, O. Heltberg, A.M. Hammerum,
N. Frimodt-Møller (Hillerød, Copenhagen, Herning, Hvidovre, Odense,
A˚rhus, Aalborg, Vejle, Viborg, Herlev, Esbjerg, Slagelse, Næstved, DK)
Background: ESBL is increasing rapidly worldwide also in low
antibiotic use countries both in- and outside hospitals. We therefore
repeated a national prevalence study of ESBL producing E. coli,
K. pneumoniae and P. mirabilis from 2007, where the overall prevalence
was 2.4%, during a one month period in 2009 in all samples from blood
and urine from hospitals and the community.
Methods: All E. coli, K. pneumoniae and P. mirabilis isolated from blood
cultures and urine samples including hospital and community samples
were screened for cephalosporin resistance with either cefpodoxime,
ceftriaxone, cefotaxime or ceftazidime. Resistant strains were further
tested with conﬁrmatory ESBL tests based on synergy with clavulanic
acid and sent to the Statens Serum Institute for further conﬁrmatory
testing for ESBL or AmpC pheno- and genotype.
Results: A total of 29.110 urine and 11.353 blood cultures revealed 353
ESBL-producing isolates:
241 E. coli, 110 K. pneumoniae and 2 P. mirabilis, while 126 ESBL-
screening positive isolates were conﬁrmatory negative. The strain related
ESBL rates were (total/blood isolates): E. coli, 3.3/7%; K. pneumoniae:
9.9/14.6%; P. mirabilis, 0.6/0%, respectively.
Conclusion: Prevalence rates of ESBL producing E. coli and
K. pneumoniae have doubled since 2007, and this counts for both blood
and urine cultures including hospital and community. Prevalence rates for
K. pneumoniae in blood are highest in Scandinavia and similar to some
Southern European countries. The increase in ESBL is parallel to the
increase in broad spectrum antibiotics in Danish hospitals (DANMAP
2009), which is a clear warning to where intervention is needed.
P659 Clinical, epidemiological and microbiological features
of urinary tract infections caused by ESBL-producing
Enterobacteriaceae in hospitalised patients
A. Toumi*, Y. Kadri, H. Ben Abdallah, S. Noomen, M. Chakroun,
M. Mastouri (Monastir, TN)
Objective: Extended-spectrum b-lactamase-producing enterobacteri-
aceae (ESBLE) have been increasingly recognized in the community.
Little is known about epidemiology of ESBLE carries in Tunisia. The
aim of this study was to describe the epidemiology, clinical and antibiotic
susceptibility features of uropathogenic EBLSE at infectious diseases
service in a teaching hospital of Tunisia.
Methods: Retrospective study included all ESBLE isolated from urine
samples of patients admitted for community-acquired urinary tract
infections at infectious diseases department in the university hospital
of Monastir between January 2008 and august 2010. Clinical and
epidemiological features were collected. Urinary tract infection by
ESBLE was conﬁrmed, in the Laboratory of Microbiology in the same
hospital, by Kass criteria: bacteriuria 106/ml and leukocyte count
>104/ml. Identiﬁcation of enterobacteria was performed by API20E.
The study of antibiotic susceptibility was performed by agar diffusion
according to CA-SFM. Detection of ESBL was demonstrated by a
synergy test by placing a central disk of amoxicillin-clavulanic acid away
from 30mm disks of cefotaxime and ceftazidime.
Results: Twenty six ESBLE were collected. The number of strains
was increased from 7 in 2008 (27% of isolates) to 10 in 2010
(38.5%). The median age was 50 years (21−79 years). The odds
ratio was 1.36. Factors associated to ESBLE were: previous hospital
admission in the last year 73%, previous antibiotics uses 50%, recurrent
urinary tract infection 46%, diabetes mellitus 38.5%, suprapubic or
urinary catheter 23%, benign prostatic hyperplasia 15% and renal
lithiasis 11.5%. Pyelonephritis was diagnosed in 92%. Klebsiella
pneumoniae was isolated in 65.5% of cases, Escherichia coli in
15.5%, Enterobacter cloacae in 11.5% and Citrobacter freundii in
7.5%. The frequency of ESBLE resistance to gentamicin, amikacin,
tobramycin, ﬂuoroquinolones, cotrimoxazol and fosfomycin were 65.5%,
11.5%, 77%, 81%, 50% and 15% and respectively. Multiresistance
was noted in 11.5% of cases (ESBLE, ﬂuoroquinolones resistance and
aminoglycosides resistance). No strains were resistant to imipenem.
Conclusion: Community-acquired urinary tract infections due to ESBL-
producing enterobacteriaceae are increasing in Tunisia. It requires
a much better control of antibiotics prescriptions and therefore an
important multidisciplinary implication.
P660 Escherichia coli and Klebsiella pneumoniae ESBL genotype
distribution in Denmark: CTX-M-15 prevails countrywide,
also in hospital epidemics
R.F. Leihof, D.S. Hansen, F. Hansen, H. Schumacher, S.G. Kjær
Hansen, K. Fuursted, T. Højbjerg, H.K. Johansen, J.K. Møller,
J. Prag, M. Arpi, E. Dzajic, B. Røder, O. Heltberg, A.M. Hammerum*,
N. Frimodt-Møller (Copenhagen, Hillerød, Herning, Odense, Aarhus,
Aalborg, Vejle, Viborg, Herlev, Esbjerg, Slagelse, Næstved, DK)
Objectives: In Denmark, E. coli and K. pneumoniae isolates producing
ESBL have increased during the last ﬁve years. The aim of this study
was to determine possible changes in ESBL genotype prevalence from
2007 to 2009, the distribution of the ESBL genes across the country, as
well as the susceptibility pattern of the isolates.
Methods: During Sep. 2009 a nationwide search was conducted in
which Danish departments of clinical microbiology screened all E. coli,
K. pneumoniae, and Proteus mirabilis from blood and urine samples
for ESBL-enzyme production. Susceptibility testing was performed and
ESBL genotyping was conducted by PCR and sequencing.
Results: A total of 254 ESBL enzyme-producing isolates were collected;
E. coli (blood N= 15; urine N= 158), K. pneumoniae (blood N= 9; urine
N= 70), and P. mirabilis (urine N= 2). CTX-M enzymes were the most
dominant for E. coli, K. pneumoniae, and P. mirabilis with an occurrence
of 89%, 80% and 100%, respectively. The CTX-M-15 enzyme was the
most prevalent with 64% in E. coli, 73% in K. pneumoniae and 50% in
P. mirabilis. CTX-M-15 and CTX-M-1 were distributed equally around
the country, while the CTX-M-15/SHV 28 genotype in K. pneumoniae
was found on Zealand only. A combined CTX-M/SHV genotype was
most frequent in K. pneumoniae with 63% compared to only 2% in
E. coli.
Resistance towards gentamicin was 40% for E. coli and 68% for
K. pneumoniae. For ciproﬂoxacin resistance was >70% overall. E. coli
were >90% susceptible to the following antibiotics: amikacin 98%,
mecillinam 92%, nitrofurantoin 90%, fosfomycin 99% and colistin
100%. In K. pneumoniae >90% susceptibility was found towards
amikacin 95%, fosfomycin 95%, and colistin 100%. Both P. mirabilis
isolates were susceptible towards amikacin, tobramycin and colistin.
Conclusion: The distribution of ESBL enzymes did not change
signiﬁcantly from 2007 to 2009 in the two Danish prevalence studies.
CTX-M-15 continues to be the most prevalent enzyme.
P661 Prevalence of b-lactamase enzymes in bacteria from inanimate
surfaces in Hospital Infante D. Pedro, Aveiro, central Portugal
C. Santos, R. Diaz, E. Ramalheira, T. Caetano, S. Mendo* (Aveiro, PT)
Objective: The increasing use of b-lactams antibiotics leads to the
emergence of b-lactamases enzymes within the hospital environment.
We aimed to evaluate the presence of these enzymes in Gram-negative
bacteria isolated form inanimate surfaces in a comparative study
performed in 2005 and 2008.
Methods: Samples from different inanimate surfaces were collected,
during 1 month period in 2005 and the same period in 2008. Sterile swabs
were rubbed in the surfaces and then placed in rich medium (TSB), and
incubated overnight at 37ºC. Serial dilutions were plated in MacConkey
agar. Phenotypical different colonies were selected and their clonal
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relationship was evaluated by rep-PCR. Identiﬁcation to the species
level was determined by 16S ampliﬁcation. Presence of b-lactamases
enzymes (ESBL and metallo-b-lactamases) and their characterization
were performed by PCR, using appropriate primers. Nucleotide and
deduced aminoacid sequences were analyzed with Blast and ClustalW
programs.
Results: Escherichia coli, Klebsiella spp., Pseudomonas spp. and
Enterobacter cloacae strains were the most frequent microorganisms
isolated. In 2005 only 33% of the isolates possessed class 1 integrons.
In these isolates the presence of b-lactamases revealed a high percentage
of TEM (59%), VIM (18%) and SHV (14%), and lower percentages of
OXA (4%) and IMP (5%). CTX-M was not detected. In 2008, 46% of the
Gram-negative bacteria possessed class 1 integrons. Similar percentages
of all b-lactamases types were observed: TEM (28%), OXA (28%),
SHV (22%), CTX-M (17%) and VIM (5%). IMP was not present.
Carbapenemase KPC was described, for the ﬁrst time in Portugal, in
one Klebsiella oxytoca and one Klebsiella pneumoniae.
Conclusion: The results show the high prevalence of b-lactamases
in bacteria associated with inanimate surfaces within the hospital
environment. This aspect is preoccupant since these bacteria can also
infect compromised patients. The percentage of class 1 integrons and
some b-lactamases enzymes tends to increase due to excessive use of
b-lactams antibiotics, thus compromising the effective treatment of the
patients.
P662 Emergence of third-generation cephalosporin-resistant
Escherichia coli from bloodstream infections in Denmark:
this is due to both clonal and non-clonal spread of CTX-M-15
F. Hansen*, C. Lester, S.S. Olsen, O. Heltberg, U.S. Justesen,
T. Højbjerg, J. Knudsen, A.M. Hammerum (Copenhagen, Næstved,
Odense, Aalborg, Hvidovre, DK)
Objectives: Before 2007 the occurrence of third-generation cephalo-
sporin resistance was low among E. coli isolated from bloodstream
infections in Danish patients. However, the rate of resistance among
invasive E. coli in Denmark has increased from 2.5% in 2006 to 6.2%
in 2009 (EARS-Net report 2009). In the present study the spread of
third-generation cephalosporin resistant E. coli in Danish hospitals was
investigated by molecular characterisation of collected isolates.
Methods: In 2009, four Danish departments of clinical microbiology
(representing four regions in Denmark) collected all the third-generation
cephalosporin resistant E. coli isolated from bloodstream infections.
ESBL and/or AmpC phenotypes were tested with a combination
disk method using Rosco Neosensitabs (Rosco Diagnostica, Taastrup,
Denmark). Based upon the obtained phenotypes, PCR ampliﬁcation and
sequencing was performed to identify the ESBL- and plasmid mediated
AmpC present. All ESBL and/or AmpC genotype positive isolates were
PFGE typed and compared using Bionumerics 6.5 (Applied Maths, Sint-
Martens-Latem, Belgium).
Results: In total, 104 isolates were investigated, 71 of these were
ESBL positive and two isolates were plasmid mediated AmpC positive,
exclusively. In total, 55/71 (77%) ESBL positive isolates produced a
CTX-M-15 enzyme. In addition to this, six CTX-M-group 1-enzymes,
six CTX-M-group 9-enzymes, two (non-TEM-1) TEM-enzymes and one
SHV-enzyme were detected. The two AmpC-enzymes produced were
both CMY-22.
PFGE showed a pronounced degree of diversity with a total of 40
different PFGE types. However, 38% of the isolates (n = 28), belonged to
three relatively large clusters, including 12, 9 and 7 isolates, respectively.
The isolates in the second-largest cluster (n = 9), all originated from the
same hospital, while geographical origin of isolates in the other two
clusters appeared more diverse.
Conclusion: Third-generation cephalosporin resistant E. coli in Den-
mark is partly clonally unrelated. However, the presence of three large
clusters, strongly indicates that clonal spread of ESBL in Danish
hospitals does occur, within the same hospital as well as beyond regional
borders. CTX-M-15 remains by far the predominant ESBL enzyme-type
in E. coli in Denmark, representing 77% of all the ESBL-positive E. coli
detected in this study. The occurrence of plasmid mediated AmpC in
bloodstream infections is still low in Denmark.
P663 Signiﬁcant increase in antimicrobial co-resistance among
extended-spectrum b-lactamase-producing Escherichia coli
urinary isolates in Spain (2005–2009)
I. Rodriguez-Avial*, C. Rodrı´guez-Avial, E. Hernandez, J. Picazo
(Madrid, ES)
Objectives: The appearance of extended-spectrum b-lactamases (ESBL)-
producing E. coli in urinary tract infections (UTI) constitutes an
important therapeutic challenge that requires the study of its evolution
throughout time in order to establish a suitable empirical treatment.
Our aim was to determine the percentage of ESBL-producing E. coli
urinary isolates from 2005 and 2009. We also compared antimicrobial
coresistance to unrelated antimicrobial such as aminoglycosides,
cloramphenicol, trimethoprim-sufametoxazole, quinolones, fosfomycin
and nitrofurantoin, between ESBL-producing E. coli from 2005 with
that of 2009.
Methods: We analyzed 5053 and 6324 E. coli isolates obtained
from urine cultures in our laboratory in 2005 and 2009 respectively.
Duplicate isolates from the same patient were excluded. Antimicrobial
susceptibility was determined by the Wider microdilution system (Soria
Melguizo S.A.) and the phenotype pattern of resistance that indicated
a BLEE-producing E. coli was selected. The CLSI breakpoints of 2009
were applied.
Results: One hundred and ninety eight strains were ESBL producers
(3.9%) in 2005 and 463 (7.3%) in 2009. The resistance percentages of
ﬁve b-lactamic and nine non b-lactamic agents are shown in the table.
Conclusions: Our institution had a higher prevalence of ESBL-
producing E. coli in 2009. Other additional mechanisms of resistance to
b-lactamic agents could explain the increase in the resistance percentage
for all the b-lactamic analyzed. Resistance to carbapenems (imipenem,
meropenem and ertapenem) was detected in 2009. The increase of
resistance was signiﬁcant for amikacin and fosfomycin (p< 0.01). The
high level resistance to quinolones detected in 2005 indicated that they
were not suitable for the empirical treatment of uncomplicated UTI and
alternative agents like fosfomycin and nitrofuratoin were indicated. That
change in therapeutic options could explain the increase in the resistance
percentage to these antibiotics.
P664 Studying the urinary reservoir of extended-spectrum
b-lactamase-producing Enterobacteriaceae in a teaching
hospital
S. Le Fournis, C. Prouteau, F. Kowalczyk, M. Joly-Guillou,
M. Eveillard* (Angers, FR)
Objectives: Extended-spectrum b-lactamase producing Enterobacteri-
aceae (ESBLE) represent an important concern of public health. Our
objective was to assess the urinary reservoir of ESBLE by identifying
them in colonized urine samples.
Methods: The study was conducted during one month in a French
teaching hospital with a high prevalence of ESBLE. In the laboratory,
urine samples are plated in a chromogenic agar medium (UTI, Oxoid,
UK). The local usual practice is to not perform antibiograms and
bacterial identiﬁcations when there are more than two different types of
colonies in those plates. Bacterial identiﬁcations and strain conservation
are performed when two different types of colonies are visible or in
the absence of leucocytes. Otherwise, strains are identiﬁed and their
susceptibility to antibiotics is tested. During the study, all colonies
of Enterobacteriaceae visible onto the chromogenic agar plates were
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isolated onto a selective agar medium for Gram-negative bacteria
resistant to third-generation cephalosporins (BLSE, AES, France). In
case of positive subculture on this medium, the production of ESBL
was tested by the combined disk method on Mueller-Hinton agar plates.
ESBLE were identiﬁed thereafter with the API 20E system (bioMe´rieux,
France). Urines in which bacteria were studied (identiﬁcation +
antibiogram) according to our usual practice were considered as infected.
Urines in which ESBLE were sought according to the study protocol
were considered as colonized.
Results: During the study, 2312 urine samples were addressed to the
laboratory for identifying urinary-tract infections. Among them, 682
(29.5%) were infected and 114 (4.9%) were colonized with at least
one Enterobacteriaceae. Overall, 145 colonies were subcultured onto the
selective medium. Fourteen ESBLE were isolated in 13 colonized urines
(11.4%) and 36 were isolated in 35 infected urines (5.1%) (Prevalence
ratio = 2.12; P< 0.01). Among the 13 patients for whom an ESBLE
was identiﬁed in colonized urines, 10 had not been recorded as ESBLE
carriers in other samples. Lastly, the distribution of the three species
identiﬁed was similar in infected and colonized urines.
Conclusion: The prevalence of ESBLE is signiﬁcantly higher in
colonized urines than in infected urines. In hospitals where contact
precautions are implemented for ESBLE carriers, searching ESBLE in
urine samples could be a cheaper and less time-consuming alternative
to rectal swabbing for identifying carriers.
P665 Risk factors and outcome of bacteraemia due to cefotaxime-
resistant Enterobacteriaceae in a Japanese university hospital
Y. Matsumura*, K. Yasuma, M. Yamamoto, A. Matsushima, M. Nagao,
Y. Ito, S. Takakura, S. Ichiyama (Kyoto, JP)
Objectives: Cefotaxime is recommended as ﬁrst-line empirical therapy
for the treatment of bacteraemia due to enterobacteriaceae (En), however,
extended-spectrum b-lactamase (ESBL) and plasmid mediated-AmpC
b-lactamase (pAmpC) producing En is reported to be increasing. We
investigated the epidemiology, risk factors, and outcome of bacteraemia
due to cefotaxime-non-susceptible (CTXR)-En.
Methods: 249 Escherichia coli, 122 Klebsiella pneumoniae, 43
Klebsiella oxytoca, and 2 Proteus mirabilis were consecutively isolated
from blood cultures between April 2005 and March 2010. Only the
ﬁrst isolate for each patient was included. MICs were determined by
broth microdilution method and interpreted following CLSI (M100-
S20). All the isolates were tested by PCR and sequencing to detect
CTX-M, TEM, SHV, and pAmpC genes. A case control study was
performed: Cases were patients with CTXR-En, control patients with
cefotaxime-susceptible (CTXS)-En. Cases and controls were matched
1:2 based on species and isolated year. Children and patients with
polymicrobial bacteraemia were excluded. Variables with P-values <0.05
in univariate analysis were included in stepwise multivariate logistic
regression analysis.
Results: 58 of 59 CTXR-En had ESBL or pAmpC (41 CTX-M, 7
CMY-2, 4 CMY-2/CTX-M, 3 TEM, 2 SHV, and 1 SHV/CTX-M), while
only 1 of 357 CTXS-En had ESBL (TEM). CTXR-En increased from
6% in 2005 to 19% in 2009. Among CTXR-En, susceptibility rate
was the highest in imipenem (100%), followed by amikacin (95%). 52
cases and 104 controls were selected. Multivariate analysis identiﬁed
previous isolation of multidrug-resistant bacteria (OR 6.8, 95%CI 2.5–
18.6), neutropenia (OR 3.4, CI 1.3−8.8), and severe sepsis or septic shock
(OR 3.8, CI 1.8−8.2) as risk factors for CTXR-En. Cases more frequently
received inappropriate therapy over 24 hours (21% vs 4%, p = 0.001) and
died within 14 days (13% vs 3%, p = 0.02), but the durations between
appropriate therapy and treatment response were similar (median 3 days,
p = 0.9). 14-day mortality among patients with En bacteraemia was
associated with severe sepsis or inappropriate therapy (OR 9.3, CI 2.0–
43.2) and septic shock (OR 7.1, CI 1.3–38.3), irrespective of cefotaxime
susceptibility.
Conclusions: Bacteraemia due to CTXR-En has been increasing and had
higher mortality. Patients suspected of En bacteraemia with risk factors
for CTXR-En should be considered for treatment other than cefotaxime,
such as imipenem or amikacin.
P666 Risk factors for and laboratory detection time of ESBLs
A. Khan*, C.J. Collins, M. Morris Downes, D. Williams, H. Humphreys
(Dublin, IE)
Background: Extended-spectrum b-lactamase producing Gram negative
bacilli (ESBL) present challenges in laboratory detection, prevention
and treatment. We have recently started to actively monitor for ESBLs
to optimise their control.
Aims:
1. To assess the incidence of ESBLs in a Dublin tertiary referral hospital
which also serves the community
2. To determine risk factors for colonisation or infection
3. To compare reporting time using CLSI versus EUCAST methodolo-
gies
Methods: All ESBL producing isolates over 7 months, March-May &
August-November 2010, were included. Repeat isolates from the same
patient were excluded. We recorded: referral source, i.e. general
practitioner (GP), long term care facility (LTCF), outpatients and
inpatients, patient age, specimen site, i.e. MSU, CSU, blood culture,
sputum and swabs, organism, and reporting time, i.e. day of receipt to
day of reporting. For all inpatients, prior antibiotic use, the presence
of invasive medical devices, recent surgery and contact with healthcare
facilities within the previous 3 months were noted.
Results: 73 ESBL producing organisms were reported over the 7 months.
68 were E. coli and 5 were K. pneumoniae. 23 (31.5%) originated from
GPs, 10 (13.7%) from LTCFs, 15 (20.5%) from outpatients and 25
(34.3%) were from inpatients. The mean patient age was 64.2 years.
52 isolates originated from MSUs, 13 from CSUs, 4 from respiratory
specimens, 2 from blood cultures and 2 from swabs. There was no
difference in reporting time between CLSI and EUCAST methodologies
(3.4 days). All inpatients had been in a LTCF or hospital within the
previous 3 months, had invasive medical devices in situ (urinary catheter,
central lines, etc.) and all were on antibiotics at the time of the sampling.
75% had also been exposed to antibiotics within the previous 3 months.
Conclusions: 34.3% of ESBL producing organisms detected were in
inpatients with the remainder originating from the community, LTCF
or outpatients. ESBLs were most prevalent in E. coli, most commonly
from urine, and were associated with previous antibiotic exposure,
having medical devices in situ and in patients with frequent contact
with healthcare facilities. The reporting time was the same for both
methodologies tested; this is reassuring as this laboratory switched to
EUCAST in August 2010.
P667 Alarming rates of ﬂuoroquinolone resistance in CTX-M-15
harbouring Enterobacteriaceae recovered from patients with
hospital-associated diarrhoea
J. Vervoort*, M. Gazin, M. Kazma, T. Kotlovsky, C. Lammens,
Y. Carmeli, H. Goossens, S. Malhotra-Kumar on behalf of the SATURN
WP1 and MOSAR WP2 study groups
Objectives: We investigated the molecular epidemiology of ﬂuoro-
quinolone resistance (FQ-R) among ESBL-producing Enterobacteriaceae
(ESBL-EN) recovered from 120 hospitalized patients with diarrhea at the
Tel Aviv Sourasky Medical Center, Israel.
Methods: Seventy-four unique ESBL-EN were recovered from 44
(36.7%) of the 120 stools screened on MacConkey/Drigalski biplate
agar with ceftazidime and cefotaxime, respectively, and by the double
disk synergy test. ESBL-EN were identiﬁed by mass spectrometry,
and screened for CTX-M, TEM, and SHV genes by PCR-sequencing
and for FQ-R on blood agar with 0.12mg/ml ciproﬂoxacin (CIP).
Recovered ESBL-EN were tested for CIP-resistance (CIP-R, MIC
2mg/ml) by agar dilution. Topoisomerase (gyrA, parC) mutations and
plasmid mediated quinolone resistance (PMQR) genes (qnrA, qnrB,
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qnrS, qepA, aac(6′)-Ib-cr) were detected and characterized by PCR-
sequencing. Presence of aac(6′)-Ib-cr (AAC), the CIP modifying variant
of aac(6′)-Ib, was demonstrated by differential restriction with BseGI.
Results: Of the 74 ESBL-EN, 56 (75.7%) were CIP-R and 48 (85.7%)
showed MICs 4mg/ml (Table). PMQR genes were present in 42
(56.8%) ESBL-EN, of which 38, 16, and 2 carried AAC, qnrB, and
qnrA, respectively. qnrS and qepA were absent. Of the 74 ESBL-
EN, 52 (70.3%) harboured CTX-M, and 51 (68.9%) and 17 (23.0%)
TEM and SHV, respectively. Among CTX-M, CTX-M-15 was most
prevalent (n = 43, 82.7%). While presence of CTX-M-15 and AAC was
strongly correlated (0.82, Pearson’s correlation coefﬁcient) due to co-
carriage on one plasmid, overall carriage rates of PMQR genes were also
signiﬁcantly higher among CTX-M-15 ESBL-EN (88.4%) compared to
non-CTX-M-15 ESBL-EN (14.8%) (P< 0.001, c2 test) (Table). Of the
16 qnrB detected, 13 (81.3%) were present in CTX-M-15 ESBL-EN
with AAC, and 11 were subtyped as qnrB1. High-level CIP-R (MIC
32mg/ml) was also signiﬁcantly more frequent among CTX-M-15
ESBL-EN (n = 34, P< 0.001, c2 test); of the 7 strains harbouring 3
FQ-R determinants (AAC, qnrB, and topoisomerase mutations), 6 were
K. pneumoniae, while those with two FQ-R determinants were primarily
E. coli (n = 15).
Conclusion: We found a remarkably high prevalence of PMQR genes
and topoisomerase mutations associated with high-level FQ-R among
CTX-M-15 ESBL-EN recovered from hospitalized patients. Our data
underscore the need for stringent infection control to contain this
potentially infectious and multi-resistant reservoir.
P668 Molecular survey of b-lactamases conferring third-generation
cephalosporin resistance in Enterobacteriaceae from the
Netherlands
G.M. Voets*, T.N. Platteel, J.W. Cohen Stuart, J. Scharringa,
C.M. Schapendonk, M.J. Bonten, A.C. Fluit, M. Leverstein-van Hall
on behalf of the ESBL National Surveillance Working Group
Objectives: Despite increasing incidence of infections caused by
pathogens harbouring b-lactamases (BLs) conferring resistance to third-
generation cephalosporins (3gCeph) few large scale European surveys
on the molecular epidemiology of Extended-Spectrum BLs (ESBLs) and
AmpC BLs have been published. The aim of the study was to describe
the molecular epidemiology of BL genes causing 3gCeph resistance in
Enterobacteriaceae in the Netherlands.
Methods: From February 1st to May 1st 2009, 31 laboratories submitted
all E. coli, K. pneumoniae, K. oxytoca, P. mirabilis and Enterobacter
spp isolates with a positive ESBL screen test (ceftazidime/ceftriaxone
MIC >1mg). The ﬁrst 25 non-repeat isolates (if available) per lab,
were analysed using an ESBL array (Check-Points, Wageningen, NL)
detecting TEM, SHV and CTX-M genes. A random selection of 50%
was sequenced. Isolates negative in these analyses were investigated by
multiplex PCRs, detecting class A BLs, plasmid-borne AmpC and OXA
BLs. In addition, the presence of a plasmid-borne AmpC (pAmpC) was
tested in all isolates with a cefoxitin MIC 16mg/L, and if pAmpC
negative, the promotor of E. coli chromosomal AmpC was sequenced
to detect mutations associated with derepression. Genetic relatedness
of isolates (except P. mirabilis) was determined with DiversiLab
(bioMe´rieux, Marcy l’Etoile, France). 51 ESBL-positive E. coli were
genotyped by MLST.
Results: 558 (88%) of 633 isolates (75% E. coli) included carried a
plasmid-borne BL: 526 (83%) at least one ESBL, 52 (8%) a plasmid-
borne AmpC. The most prevalent ESBLs were CTX-M-15/28 (44%),
CTX-M-1 (18%), SHV-12 (8%), CTX-M-14 (8%), and TEM-52 (6%).
pAmpC’s belonged to the CMY-2 group (52%; all CMY-2/55), the
ACT/MIR group (46%), and DHA-1 (2%). Among the 75 (12%) isolates
without a plasmid-borne BL, 3gCeph resistance of 29 (5%) E. coli was
caused by AmpC promotor mutations, of 5 (1%) K. oxytoca by OXY
hyperproduction and for 22 (4%) E. cloacae likely by chromosomal
AmpC. For 19 (3%) isolates no resistance mechanism was detected.
DiversiLab showed no evidence of dissemination of a single strain,
nationally or locally. However, 22 E. coli isolates belonged to ST131.
Conclusions: The most prevalent BL genes causing 3gCeph resistance in
Enterobacteriaceae in the Netherlands were CTX-M ESBLs, especially
CTX-M-15. In comparison with other European surveys a relative high
prevalence of CTX-M-1 and TEM-52 genes was observed. CMY-2/-55
was the most prevalent AmpC.
P669 Real-time PCR typing of CTX-M and SHV family
genes of extended-spectrum b-lactamase-producing
Enterobacteriaceae clinical isolates from Vilnius University
Hospital Santariskiu Clinics, Lithuania
A. Macioniene, S. Kiveryte, Z. Kucinskiene, J. Gulbinovic,
L. Griskevicius, A. Jakubauskas* (Vilnius, LT)
Objective: ESBL producing Enterobacteriaceae is a growing clinical
problem. There is only limited information available on the type
and prevalence of genes that determine the ESBL phenotype of
Enterobacteriaceae in the Baltic region. Over a 2009–2010 year period
230 clinical isolates of Enterobacteriaceae species (132 Klebsiella
pneumoniae, 48 Escherichia coli, 32 Enterobacter spp, 8 Serratia
marcescens, 5 Citrobacter spp, 3 Klebsiella oxytoca, 2 Proteus mirabilis,
1 Morganella morganii) producing ESBLs were collected at Vilnius
University Hospital Santariskiu Clinics, one of the major tertiary multi-
proﬁle healthcare institutions in Lithuania. Bacteria were isolated from
urine (109), surgical infection sites (61), bronchial aspirates (29), blood
(28) and other samples (3). This study was conducted to determine the
prevalence of ESBLs that belong to CTX-M and SHV families.
Methods: Real-time PCR technique was used to detect alleles encoding
ﬁve phylogenetic groups of CTX-M family enzymes and SHV enzymes
harbouring mutations G238S, E240K.
Results: Typing for the presence of CTX-M family enzymes revealed
three families of blaCTX-M genes: blaCTX-M-group 1 (196 strains,
85.2%), blaCTX-M-group 2 (15 strains, 6.5%), blaCTX-M-group 9 (3
strains, 1.3%). Genes coding for CTX-M-group 8 and CTX-M-group
25 enzymes were not detected. The presence of SHV (G238S, E240K)
enzymes was detected in 18 isolates (7.8%): in 8 cases the only gene,
blaSHV(G238S, E240K), was detected, and in10 cases bacteria produced
two ESBLs coded by blaCTX-M-group 1 and blaSHV(G238S, E240K).
No genes coding for CTX-M and SHV (G238S, E240K) enzymes were
detected in 8 samples (3.5%) expressing ESBL phenotype. Therefore,
the presence of genes encoding b-lactamases from other families (e.g.
OXA, PER, VEB) was presumed.
Conclusion: This work showed high prevalence of CTX-M enzymes
that belong to phylogenetic group 1 among Enterobacteriaceae strains
expressing ESBL phenotype isolated at Vilnius University Hospital
Santariskiu Clinics.
P670 Monomicrobial bacteraemia caused by extended-spectrum
b-lactamase-producing Escherichia coli: predictors of
mortality and potential role of ertapenem
U.I. Wu*, H.M. Chang, W.C. Chen, C.S. Yang, J. Wang, F.C. Hu,
S.C. Chang, Y.C. Chen (Taipei, Taichung, TW)
Objectives: Carbapenems are recommended as the drug of choice
for infection of extended-spectrum b-lactamase (ESBL)-producing
organism. However, clinical studies to demonstrate or to compare the
effectiveness of different carbapenems are scarce.
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Methods: From January 1, 2005 to June 30, 2007, all adult patients
with the ﬁrst episode of monomicrobial ESBL-producing E. coli
bacteremia were included in this non-concurrent prospective study.
Logistic regression analysis and Cox’s regression model were used to
determine the predictors of early and 30-day mortality respectively.
Outcomes in patients treated with different carbapenems were compared
using propensity score.
Results: Of 97 patients with ESBL-producing E. coli bacteremia
reviewed, 71 patients met the study criteria. The early and 30-day
mortality rate were 12.7% and 29.6% respectively. Logistic regression
analysis identiﬁed ICU stay as the only predictor of early mortality.
Among 62 patients having received deﬁnitive antimicrobial therapy,
male gender, ICU stay at bacteremia onset, solid tumor and primary
bacteremia were independently associated with 30-day mortality, while
deﬁnitive antimicrobial therapy using carbapenem was found to be
protective by Cox’s regression analysis. Subgroup analysis using
propensity score demonstrated that ertapenem was non-inferior to other
carbapenems in terms of 30-day mortality.
Conclusions: Patient’s co-morbidities rather than initial choice of
empirical antimicrobial therapy were major predictors of early and 30-
day mortality. Using carbapenem as deﬁnitive therapy was a protective
factor of 30-day mortality. The choice of ertapenem is reasonable for less
severely ill patients who are at risk of ESBL-producing E. coli bacteremia
and unlikely to have infection due to Pseudomonas aeruginosa.
P671 Molecular characterisation of Escherichia coli and Klebsiella
pneumoniae producing CTX-M-type extended-spectrum
b-lactamase in O¨rebro County, Sweden
A. O¨nnberg*, P. Mo¨lling, B. So¨derquist (O¨rebro, SE)
Objectives: During the last decade an increasing prevalence of extended-
spectrum b-lactamase (ESBL) producing Enterobacteriaceae has been
detected worldwide, mainly due to dissemination of Escherichia coli and
Klebsiella pneumoniae producing CTX-M-type ESBLs. CTX-M-15 is
the most widespread CTX-M-type, and the predominant type in various
countries. The blaCTX-M gene is located on mobile genetic elements,
such as plasmids, and the dissemination of ESBL is not only caused by
clonal spread of epidemic strains, but also by horizontal gene transfer
between different strains and different species.
The aim of this study was to investigate the molecular epidemiology of
CTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated
during a ten year period in O¨rebro County, Sweden.
Methods: 200 clinical ESBLA-producing E. coli and K. pneumoniae
from the years 1999–2008 were included in the study. The majority were
isolated from urine, and the rest from blood, wounds, and the respiratory
tract. The entire genes for CTX-M, TEM, and SHV were ampliﬁed by
real-time PCR and the amplicons were sequenced in order to determine
CTX-M-, TEM-, or SHV-type.
Results: Out of the 200 ESBLA-producing isolates 87% were producing
CTX-M, belonging to subgroup CTX-M-1 (64%), CTX-M-9 (34%),
or CTX-M-2 (2%). The remaining isolates were producing variants
of SHV and TEM. Sequencing of the blaCTX-M genes revealed
ten different CTX-M-types, with a dominance of CTX-M-15 (E. coli
54%, K. pneumoniae 50%) followed by CTX-M-14 (E. coli 28%,
K. pneumoniae 27%).
Conclusion: As in most parts of the world a high proportion of the
ESBLA-producing E. coli and K. pneumoniae were producing ESBL
of CTX-M-type. In our county this appears to be mainly due to spread
of CTX-M-15 and CTX-M-14. Further analysis of the CTX-M-carrying
plasmids is ongoing in order to determine if the dissemination of CTX-
M-15 and CTX-M-14 is due to frequent horizontal transfer of a few
successful plasmids harbouring these genes.
P672 The clinical risk factors and susceptibility to fosfomycin
in community-acquired urinary tract infections caused by
extended-spectrum b-lactamase producing Escherichia coli
A. Gokcay Canpolat, P. Zarakolu, D. Turgut, S. Asioglu, M. Akova*
(Ankara, TR)
Objective: The choices of antimicrobial therapy for community-acquired
urinary tract infections (CA-UTIs) by extended-spectrum b-lactamase
(ESBL)-producing E. coli appear to be limited. Fosfomycin which can
be given by oral route could be effective against for this indication. We
attempted to evaluate the epidemiological features, resistance rates and
effect of fosfomycin in ESBL-producing E. coli isolated from patients
with uncomplicated CA-UTIs.
Methods: Single clinical isolates from 139 outpatients between May
2009-July 2010 at Hacettepe University Adult Hospital was included in
the study, (E. coli, 45% producing ESBL). Several potential clinical
risk factors and sociodemographic features of the study group were
evaluated. Susceptibility rates of ESBL-producing and non-producing
E. coli isolates to fosfomycin and other antibiotics were determined by
disc diffusion and Etest methods according to CLSI criteria. A two-sided
c2 test was used for statistical analysis.
Results: 75.5% of patients were female, mean age was 46.5 years.
Female gender (p = 0.01), recent hospitalization and/or antimicrobial
therapy in the last 3 months (<0.001), any surgical intervention
(p = 0.006), urological procedures (p = 0.033), previous UTI (p< 0.001),
intravascular device application (p< 0.001) all within the previous
year, malignancy history (p = 0.005), urinary catheter usage (p = 0.014)
and presence of renal disease (p = 0.028) were found as signiﬁcant
predisposing factors for CA-ESBL producing E. coli. The frequency
of infections were linearly associated with the severity of underlying
renal disease. The antimicrobial resistance rates in ESBL-producing
and non-producing isolates were as follows: piperacillin tazobactam
48.7% vs 0% (p< 0.001), amikacin 60.5% vs 0% (p< 0.001), ampicillin
98.7% vs 15.9% (p< 0.001), gentamicin 47.4% vs 7.9% (p< 0.001),
ciproﬂoxacin 100% vs 14.3% (p< 0.001), cefepim 78.9% vs 0%
(p< 0.001), ceftazidime 85.5% vs 0% (p< 0.001), nitrofurantoin 37.
3% vs 0% (p< 0.001), trimethoprim-sulphamethoxazol 64.5% vs 20.6%
(p< 0.001), and fosfomycin 19.4% vs 0% (p = 0.04).
Conclusion: Several risk factors were found to be related with increased
incidence of ESBL-producing E. coli for CA-UTIs. Antimicrobial
resistance and lack of oral options may compromise treatment in the
outpatient. Fosfomycin seems to be a possible oral alternative for this
indication.
P673 Healthcare-associated and hospital-acquired infections
caused by Enterobacteriaceae producing extended-spectrum
b-lactamases in hospitalised patients: are there any
signiﬁcant differences?
E. Tacconelli*, E. Mantengoli, C. Cadeddu, L. Attala, A. Bartoloni,
E. Bombana, G. Cologni, A. Pan, R. Cauda, G.M. Rossolini (Rome,
Siena, Florence, Bergamo, Cremona, IT)
Background: Information is limited on the epidemiology of health
care-associated (HCA) and community-acquired (CA) infections due to
ESBL+ Enterobacteriaceae (Ent.).
Objectives: To deﬁne differences in the epidemiology, treatments and
outcome of CA, HCA, and HA-infections due to ESBL+ Ent. in
hospitalised patients (pts).
Design: A prospective multicenter cohort study. All adult hospitalised
pts with infections due to ESBL+ Ent. were enrolled. Antibiotic therapy,
complications and outcome of infections were extracted. Mortality was
deﬁned as death occurring during hospitalization. Appropriate antibiotic
therapy was deﬁned as the initiation of therapy with activity against the
ESBL+ Ent. from the day before to 2 days after the initial positive clinical
culture result. HA, HCA and CA infections were deﬁned according to
established criteria.
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Results: Among 312 pts, 223 were diagnosed as having HA-ESBL+
Ent. infections (HAI); of the remaining 92 pts, 90 (98%) met the criteria
for HCA- infections and only 2 pts were diagnosed as having “true”
CA infections. Mean age (HCA vs HA: 69 vs 66 yrs) and male sex
(75% vs 66%) were not statistically different. Pts with HCA-ESBL+
Ent. (HCAI) were more likely to have had at least one hospitalisation in
the previous year (49%) and visiting nurse assistance (37%) while pts
with HAI were more likely to have urinary catheter (49%). A fourth of
pts in both groups received at least one antibiotic in the previous 30 days.
E. coli was equally represented in both groups (HCAI vs HAI: 69% vs
63%) while P. mirabilis was more frequent among HCAI (23% vs 16%)
than K. pneumoniae (8% vs 18%). For pts with HCAI compared with
HAI, UTIs were more frequent (71% vs 53%; RR 2.03, 95%CI:1.7−3.6;
p< 0.01) while PNE and SSI were less frequent (1% vs 20%, RR 9.74,
95%CI: 1.1–406, p< 0.01; 7% vs 13%, p = 0.08, respectively). BSI were
equally distributed (17% vs 20%). Overall mortality was not statistically
different (9% vs 7%). Therapy was changed more frequently in HAI than
HCAI infections (58% vs 65%). Rate of inappropriate therapy (41% vs
43%) and mortality (17% vs 20%) was not signiﬁcantly different between
HCAI and HAI.
Conclusions: HCAI are more frequent than CAI caused by ESBL+ Ent.
in hospitalised pts. Epidemiological differences as well as mortality
between HCA and HAI are minimum. Health care providers should
be aware about the clinical impact of HCA-ESBL+Ent. infections in
hospitalized pts.
P674 Multidrug-resistant chromosomal AmpC-producing
Enterobacteriaceae isolates carrying blaESBL, qnrB,
aac-(6)-Ib-cr, and armA
S. Sabtcheva*, T. Saga, T. Kantardjiev, M. Kaku (Soﬁa, BG; Tokyo,
JP; Sendai, JP)
Objectives: The aim of this study was to investigate the presence of 16S
rRNA methylases and plasmid-mediated quinolone resistance (PMQR)
determinants (qnr and aac-(6)-Ib-cr) in ESBL-producing inducible
Enterobacteriaceae isolated from cancer patients in Bulgaria.
Methods: A total of 511 clinically relevant enterobacterial isolates with
chromosomal AmpC b-lactamases, collected during 2002–2005, were
screened for ESBL production by the double-disk synergy method. The
b-lactamase genes (blaPER-1, blaTEM, blaSHV, blaCTX-M, blaVEB-1,
blaGES-1 and blaOXA-1) were detected by PCR ampliﬁcation with
speciﬁc primers. Search for16S rRNA methylase genes (armA, rmtA,
rmtB, rmtC, rmtD), qnr and aac(6′)-Ib genes was conducted by PCR
ampliﬁcation. Genotypes were determined by direct nucleotide sequence
analysis of the ampliﬁed products. Pulsed-ﬁeld gel electrophoresis
(PFGE) of SpeI-digested genomic DNA was used to compare isolates.
Results: Among the 511 inducible Enterobacteriaceae, 24 (4.7%) were
ESBL-producers. Of these, 9 (37.5%) carried armA methylase gene in
association with blaCTX-M-3 and blaTEM-1. Four isolates (16.7%) were
positive for aac(6′)-Ib-cr. Of these, 2 also carried blaCTX-M-15 and
blaOXA-1. qnrB was detected only in Citrobacter freundii strains (7
of 10). Among them, 4 had qnrB17, 2 had qnrB10 and 1 had qnrB12.
None of the isolates carried qnrA and qnrS. Among the qnrB17-carrying
isolates, 3 possessed blaTEM-3 alone and 1had both blaCTX-M-15 and
blaOXA-1 in association with aac(6′)-Ib-cr. The isolates with qnrB10
possessed blaTEM-3. The qnrB12-carrying isolate had simultaneously
blaCTX-M-15, blaOXA-1, blaTEM-1 and aac(6′)-Ib-cr. Most of the
isolates were genetically different according to PFGE.
Conclusion: The spread of multiresistant isolates expressing chro-
mosomal AmpC b-lactamase together with ESBLs, ArmA methylase
aminoglycoside resistance, Qnr and AAC(6′)-Ib-cr quinolone resistance
is a worrisome development requiring continuous monitoring.
P675 Ampliﬁcation of CTX-M-15-B2-ST131 and emergence of
A and D widespread clones producing different ESBLs in
Portuguese hospitals
Aˆ. Novais*, E. Machado, S. Amaral, T. Gonc¸alves, R. Canto´n,
T.M. Coque, L. Peixe (Porto, PT; Madrid, ES)
Objectives: In a previous survey (2003−05), isolates from a hospital in
the centre region of Portugal were mainly identiﬁed as Enterobacter
aerogenes producing TEM (-10, -24, -116) enzymes. We aim to
characterize population structure and epidemiological features of recent
E. coli isolates from this institution and a recently opened hospital
located nearby.
Methods: A total of 52 ESBL-producing E. coli isolates from
two Portuguese hospitals located in the Centre Interior region were
included (2006–2008). Species identiﬁcation and antibiotic susceptibility
testing were performed by standard methods. ESBL characterization
included DDST and searching of blaESBL genes (blaTEM, blaSHV and
blaCTX-M) by PCR and sequencing. Clonal relatedness was investigated
by XbaI-PFGE and MLST. E. coli phylogenetic groups were identiﬁed
by a multiplex PCR.
Results: Most isolates were recovered from urines (81%, 63% causing
UTI) produced mostly CTX-M enzymes (91%; CTX-M-1, -14, -15,
-32), although TEM (4%; TEM-52) and SHV (6%; SHV-12) types
were also detected, and belonged to particular clonal complexes.
A B2-ST131 E. coli clone was the most frequently identiﬁed in
both institutions (n = 42, 81%; 5 PFGE-types), exhibiting resistance to
kanamycin (93%), tobramycin (90%), gentamicin (83%), tetracyclines
(90%) and ciproﬂoxacin (88%). It harboured blaCTX-M-15 (n = 41) and
blaSHV-12 (1), frequently associated with blaOXA-1 and/or blaTEM-1,
and occasionally blaTEM-10 or blaTEM-116. E. coli isolates belonging
to phylogroup D were ST117 (n = 2, encoding CTX-M-1 plus TEM-116
or CTX-M-14) and ST648-like (n = 1, TEM-52). A-E. coli belonged to
ST10 complex (n = 2, CTX-M-15, CTX-M-32), ST23-like (n = 1, CTX-
M-1) and fumC11 (CTX-M-15). On the other hand, phylogroup B1
isolates were diverse (fumC4, fumC29, fumC65) and produced TEM-52,
CTX-M-14 and SHV-12. A, B1 and D clones were frequently resistant
to streptomycin, sulfonamides and tetracycline.
Conclusion: We demonstrated current widespread of B2-ST131 in dif-
ferent Portuguese hospitals, and the emergence of widespread A and B1
clones producing particular ESBL variants. The simultaneous detection
of additional TEM-10/-116 variants might indicate diversiﬁcation of pre-
existing blaTEM and/or recombination events.
P676 The occurrence of pandemic serotype ST131 in animal
Escherichia coli in Slovakia
V. Kmet, Z. Drugdova, D. Ohlasova, M. Niks* (Kosice, Bratislava, SK)
Objectives: A rapid dissemination of animal isolates producing CTX-
M-type extended-spectrum b-lactamases has recently been reported in
European countries (Carattoli, 2008). The occurence of animal E. coli
producing ESBL enzymes is increasing in Slovakia. The aim of the study
was to characterize the presence of ST131 in E. coli isolated in Slovakia.
Methods: During year 2010 129 faecal E. coli from calves and
100 E. coli from broilers representing different Slovakian regions
were collected and analysed. Antibiotic resistance was phenotypically
determined according to CLSI, M31-A3 (2008). The ST131 (Clermont
at al. 2009) and ESBL CTX-M (Woodford et al. 2006) were determined
by PCR. Also 9 human, phenotypically CTX-M positive clinical urinary
E. coli isolates, were analysed. Possible clonal relatedness of studied
isolates was determined by Maldi tof biotyper.
Results The ESBL phenotype was present in 11 (11%) of broiler and
in 16 (12, 4%) of calf E. coli isolates. The presence of CTX-M1 group
genes could be conﬁrmed in ten broilers and in eight calf isolates. The
ST131 pandemic clone was detected in one broiler and in three calf
isolates and was always accompanied by CTX-M gene. All ST 131
positive animal isolates originated from a single geographical region
in Slovakia. We could also conﬁrm ST131 in four of 9 human urinary,
S148 21st ECCMID/27th ICC, Posters
phenotypically ESBL CTX-M positive E. coli strains tested. The Maldi
biotyping of animal ST 131 E. coli could conﬁrm a clear relatedness
only between one poultry and one calf isolates. Human ST131 clinical
isolates were unrelated to animal ones.
Conclusions:
1. ESBL CTX-M1 group genes were detected in animal E. coli
frequently.
2. The ST131 pandemic E. coli clone was conﬁrmed for four animal
and also in four clinical human isolates. The ST131 type was always
accompanied by the CTX-M gene.
3. Just one poultry and one calf ST131 isolates showed a clonal
relatedness (Maldi tof biotyping). Animal ST 131 isolates were
unrelated to human clinical E. coli ST131 isolates.
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P677 Comparative in vitro activity of doripenem, imipenem and
meropenem against contemporary Gram-negative pathogens
from Portugal, Saudi Arabia, South Africa and Turkey
J. Laeuffer*, P. Cida´lia, M. Cassettari, I. Morrissey (Baar, CH; Porto,
PT; Fordham, UK)
Objective: In 2008/2009 (COMPACT phase 1 and 2), we determined the
MIC of contemporary Gram-negative pathogens (GNPs) causing serious
infections in hospitalised patients to doripenem (DPM), imipenem (IMP)
and meropenem (MEM) from 16 countries. This study is the 3rd phase
of COMPACT presenting data from 4 countries.
Methods: 558 Pseudomonas spp. [PS], 455 Enterobacteriaceae [E] and
115 other GNPs [OGNPs] were collected from 19 centres in Portugal,
Saudi Arabia, South Africa and Turkey in 2010. DPM, IMP and MEM
MICs were determined by Etest.
Results: Isolate source was: nosocomial pneumonia, 40.3%; blood
stream infections, 39.5%; and complicated Intra-Abdominal Infection,
20.2%. 48.4% of isolates were from ICU patients. Against all GNPs,
DPM (MIC50/90 = 0.12/32mg/L) was at least 2-fold more active than
MEM (MIC50/90 = 0.25/64mg/L or IMP (MIC50/90 = 1/64mg/L).
For PS, DPM was also more active than MEM and IMP (MIC50 of 0.5,
1 & 2mg/L and MIC90 of 16, 64 & 64mg/L, respectively). E were
highly susceptible to all 3 carbapenems, with DPM and MEM showing
similar activity (MIC50/90 of 0.03/0.12mg/L), IMI was 8-fold less active
at MIC50 (0.25mg/L) and 4-fold less active at MIC90 (0.5mg/L). All
three carbapenems were similar in activity against OGNPs with MIC50
and MIC90 of 64mg/L. However, a lower proportion of isolates had
DPM MIC of 64mg/L (58%) compared to IMI (72.2%) and MEM
(64%). There was a signiﬁcant increase in MIC50 for Acinetobacter
baumannii (AB) in phase 3 of this study compared to phase 1 and 2
where MIC50 was 4mg/L for all 3 carbapenems.
Conclusion: Overall, DPM showed excellent activity against GNPs
being generally similar or slightly better in activity to MEM and 2
to 8-fold more active than IMP against all GNPs combined, PS and
E. Against PS, DPM was more active than both IMP and MPM. However
carbapenem MIC against AB may be on the increase.
P678 Global evaluation of meropenem non-susceptible
Enterobacteriaceae: 2006/07 versus 2009/10
S. Lob, S. Hawser*, R. Badal, S. Bouchillon, D. Hoban, M. Hackel,
M. Dowzicky (Schaumburg, US; Epalinges, CH; Collegeville, US)
Objective: Carbapenemase-producing Enterobacteriaceae are spreading
globally. They are often resistant to all b-lactam antibiotics and
co-resistant to most other antibiotics, leaving very few treatment
options. Using surveillance data from the global, comprehensive
Tigecycline Evaluation Surveillance Trial (T.E.S.T.), we assessed
changes in incidence and susceptibility of meropenem non-susceptible
Enterobacteriaceae between the years 2006/07 and 2009/10.
Methods: A total of 1,220 meropenem non-susceptible Enterobac-
teriaceae were isolated in 46 countries from multiple infection
sources. MICs were determined by each participating laboratory using
commercially-prepared microbroth panels. Results were interpreted
according to CLSI breakpoints (including new meropenem breakpoints
published in June 2010) or FDA breakpoints (for tigecycline). The
difference in % susceptible values between 2006/07 and 2009/10 was
tested using the Fisher exact test, while the geometric mean MICs were
compared by t test of log-transformed MICs.
Results: 626 meropenem non-susceptible Enterobacteriaceae were
collected in 2006/07 and 594 isolates in 2009/10. These represented 2.1%
and 2.7% of all Enterobacteriaceae, respectively − a signiﬁcant increase
(p< 0.0001). The following table shows the MIC50, geometric mean
(GM) MIC, and % susceptible for tigecycline and several comparators,
as well as p values comparing both time periods.
Conclusions: While the MIC50 for tigecycline did not change between
2006/07 and 2009/10, the geometric mean increased signiﬁcantly,
demonstrating that this measure may offer better discrimination. The
increase in GM MIC for minocycline was also highly signiﬁcant, while
the decrease for cefepime was only marginally so. Despite tigecycline’s
increase in GM MIC and a statistically signiﬁcant decrease in %
susceptible, the agent continued to demonstrate the best in vitro activity
against meropenem non-susceptible Enterobacteriaceae. Almost 85% of
these usually multi-resistant pathogens remained susceptible, conﬁrming
tigecycline as an important therapeutic option, especially since most
other antimicrobials exhibited poor in vitro activity.
P679 Lack of ertapenem “MIC creep” in E. coli: data from
SMART 2002–2010
R. Badal*, S. Lob, S. Bouchillon, M. Hackel, D. Hoban, S. Hawser,
A. Johnson (Schaumburg, US; Epalinges, CH)
Objective: The Study for Monitoring Antimicrobial Resistance Trends
(SMART) has tracked susceptibility of intra-abdominal infection (IAI)
pathogens since 2002. As ertapenem is widely used against E. coli in
IAI, monitoring its activity over time is crucial. This report analyzes
ertapenem susceptibility trends of E. coli (including ESBL+ and ESBL−
isolates) over 9 years for evidence of “MIC creep”.
Methods: 28,687 IAI isolates of E. coli (23,857 ESBL−, 4,830
ESBL+) were collected from 732 cumulative sites in 44 countries from
2002–2010. Antimicrobial susceptibility and ESBL phenotypes were
determined using microdilution following CLSI and plate manufacturer
guidelines. MIC50, MIC90, and geometric mean (GM) MICs were
calculated for each year. MICs were evaluated for trend using Spearman’s
rank correlation coefﬁcient. Percent susceptibility was determined using
CLSI breakpoints.
Results: The following table summarizes ertapenem susceptibility data
from 2002–2010:
MIC90 increased from 0.03 to 0.12 in 2007, then returned to 0.06
the last 3 years. %S also declined slightly from 2001 until 2007, then
climbed back to 2002 levels. Spearman’s test showed a (P< 0.0001) trend
toward higher MICs over 9 years.
Conclusions:
• Ertapenem exhibited remarkably consistent activity vs. E. coli from
2002–2010. The MIC50 remained constant, the MIC90 rose from
0.03 to 0.12 in 2007 but then dropped back to 0.06, and geometric
mean MICs showed similar temporal trends.
• Although Spearman’s rank correlation showed a statistically signiﬁcant
trend (p< 0.0001) toward higher MICs from 2002–2010, the
coefﬁcient of 0.06 indicates that it was very weak. Furthermore, it
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is noteworthy that the last three years showed declining MICs, nearly
returning to 2002 levels.
P680 Surveillance of extended-spectrum cephalosporin- and
carbapenem-resistance in Escherichia coli from the Greater
Toronto Area, Ontario, Canada
O. Lastovetska*, N. Tijet, A. McGeer, R. Melano on behalf of the
Toronto Invasive Bacterial Network
Objective: The goal of this study is to investigate the prevalence of
extended-spectrum cephalosporin- (ESC) and carbapenem-resistance in
E. coli from the Greater Toronto Area (population ~13 million), as well
as the mechanisms involved in these phenotypes.
Methods: 526 non-duplicate E. coli clinical isolates were collected
during March 1−5, 2010 from 13 hospitals (TIBDN) in the GTA region.
Antimicrobial susceptibility proﬁles were determined using Vitek2 at
each participating laboratory, and agar dilution method (CLSI, 2009)
at the Public Health Lab. A sub-collection was selected for molecular
studies based in the following criteria: resistance (R) to ESC, R or
reduced susceptibility (rS) to carbapenems, and/or R or rS to cefoxitin
(FOX, marker for AmpC). Molecular screening of b-lactamase genes
(blaTEM, blaSHV, blaOXA-1-like, blaCTX-M groups 1, 2 and 9,
blaVEB, blaPER, blaGES, blaOXA-48-like, blaIMP, blaVIM, blaKPC,
blaNDM-1 and 6 groups of blaAmpC genes) was performed by PCR.
The 110 base pair-ampC promoter was sequenced and analyzed in the
chosen sub-collection. Their sequence types (ST) was determined by
Multi-Locus Sequence Typing (MLST).
Results: ESCR was detected in 64 isolates. Carbapenem rS or R was
not detected. rS or R to FOX was found in 11 strains, which were
added to make a ﬁnal sub-collection of 75 isolates. The most common
extended-spectrum b-lactamase (ESBL) found in that subset belonged to
the blaCTX-M family, groups 1 and 9 (n = 38, 51%). Other b-lactamases
detected were blaTEM, blaOXA-1-like and blaCMY-2. Some strains
harboured only one of the b-lactamase genes tested (30.7%) while other
strains had different combinations of them (42.6%). Twenty isolates
(26.7%) were negative for all b-lactamase genes tested. Analysis of ampC
promoter in these isolates revealed mutations in the −10 and −35 boxes
and attenuator region linked to AmpC hyperproduction. MLST results
revealed ST131 being the most predominant clone (n = 28), detected
in 11 of the 13 participant hospitals, harbouring blaCTX-M-15 and
blaCTX-M-14 genes.
Conclusion: 12.2% of the bacterial collection displayed ESCR. No
carbapenem rS or R had been detected. blaCTX-M genes (mainly
blaCTX-M-15) was the predominant ESBL detected in this surveillance,
generally harboured by a ST131 strain. Hyperproduction of the
chromosomal AmpC due to promoter mutations is playing a role in
the expression of ESCR in the GTA region.
P681 Resistance of Enterobacteriaceae to carbapenems in the
University Hospital Olomouc, Czech Republic
M. Htoutou Sedlakova*, V. Hanulik, M. Chroma, K. Hricova,
M. Senkyrikova, M. Kolar (Olomouc, CZ)
Objectives: Carbapenems are the drugs of choice for the treatment
of serious infections caused by ESBL- and AmpC-positive Enter-
obacteriaceae. An increasing trend of resistance to carbapenems has
been observed. The aim of the study was to determine resistance to
carbapenems in clinical isolates of the Enterobacteriaceae family and its
mechanism.
Methods: Between 1 April 2009 and 31 August 2010, Enterobac-
teriaceae were isolated from clinical samples obtained from patients
hospitalized in the University Hospital Olomouc, Czech Republic (1,406
beds incl. 155 ICU beds). The strains were identiﬁed using the
Phoenix automated system (Becton Dickinson) and their susceptibility to
meropenem was determined by the microdilution method and E-test. The
isolates were tested for carbapenemase production using the modiﬁed
Hodge test (mHodge test), a combined test with 3-aminophenylboronic
acid (3-APB) and EDTA, the combined-disk test (CD test) and modiﬁed
DDST for MBL (mDDST for MBL). ESBL and AmpC production
was determined by the mDDST and modiﬁed AmpC test, respectively.
Genes encoding production of serine carbapenemases, MBL, blaOXA-
23, blaOXA-48, ESBL and AmpC enzymes were detected with a
set of speciﬁc primers. TEM- and SHV-positive PCR products were
characterized by restriction analysis.
Results: From a total of 12,605 Enterobacteriaceae, 9 strains (7
Klebsiella pneumoniae and 2 Enterobacter cloacae) were isolates with
the minimum inhibitory concentration (MIC) of meropenem 2mg/L.
The MIC of meropenem for these strains ranged from 2 to 16mg/L.
The mHodge test, the combined test with 3-APB and EDTA, CD test,
mDDST for MBL and a series of PCR analyses did not detect production
of serine carbapenemases, MBL, OXA-23 or OXA-48 enzymes in any of
the tested strains. In 6 Klebsiella pneumoniae strains and 1 Enterobacter
cloacae strain, the mDDST test revealed ESBL production, and in 1
Klebsiella pneumoniae and 1 Enterobacter cloacae, AmpC production
was detected. Genetic analysis conﬁrmed the presence of CTX-M and
SHV types in ESBL strains and DHA and EBC types in AmpC strains.
Conclusion: The prevalence of the Enterobacteriaceae with the MIC of
meropenem 2mg/L in the University Hospital Olomouc was 0.07%.
None of the strains produced either serine carbapenemases or MBL.
Borderline resistance of the strains to carbapenems was determined by
the ESBL and AmpC production with another associated mechanism of
resistance.
Supported by the project IGA 9950−3.
P682 Prevalence and molecular characterisation of carbapenem-
resistant Enterobacteriaceae clinical isolates from a teaching
hospital in Shanghai, China
F. Hu*, S. Chen, X. Xu, W. Wu, Y. Liu, D. Zhu, Y. Zhang (Shanghai, CN)
Objective: To investigate the prevalence and molecular characteristics
of carbapenem-resistant Enterobacteriaceae clinical isolates.
Methods: Seventy-seven isolates resistance to at least one carbapenem
from 8254 Enterobacteriaceae clinical isolates were collected from
Jan. 2002 to Apr. 2009. Antimicrobial susceptibility testing and
molecular typing were performed by agar dilution and pulse-ﬁeld gel
electrophoresis (PFGE), respectively. Carbapenemases productions were
detected by modiﬁed Hodge test (MHT) according to the CLSI method.
b-lactamase genes were identiﬁed by PCR and DNA sequencing. Outer
membrane porin proteins (OmpK35, OmpK36 and OmpK37) were
investigated by SDS-PAGE.
Results: None of the Enterobacteriaceae clinical isolates were sus-
ceptible to ertapenem, and the susceptibility rates for imipenem and
meropenem were 6.5%, 1.3%, respectively. PFGE analysis revealed
four and 10 unrelated genotypes of Citrobacter freundii and Klebsiella
pneumoniae, respectively. Of the 77 isolates, 93.5% were found by PCR
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to be capable of carbapenemase genes production, and 92.2% were
classiﬁed as carbapenemase producers by the MHT. SDS-PAGE analysis
revealed that most isolates had lost at least one porin protein.
Conclusions: The resistance to carbapenems has increased dramaticaly
in our country and the predominant mechanism of resistance is attributed
to the production of various carbapenems-hydrolyzing b-lactamases
referred as carbapenamases, especially KPC-type carbapenamase.
P683 A simple phenotypic algorithm for direct and speciﬁc
detection of KPC and MBL carbapenemase-producing
Enterobacteriaceae in rectal screening
O. Zarkotou, I. Kristo, A. Poulou, G. Chrysos, K. Themeli-Digalaki,
S. Pournaras*, A. Tsakris (Athens, Larissa, Serres, GR)
Objectives: Carbapenemase-producing Enterobacteriaceae are rapidly
spreading. Early detection of carriers by faecal screening is crucial
for their restriction; it is performed by various non-speciﬁc tests
using carbapenem discs or selective agar plates supplemented with
carbapenems. We evaluated a simple phenotypic algorithm for speciﬁc
detection of MBL and KPC producers directly from rectal swabs.
Methods: Rectal swabs obtained from 55 hospitalized patients
during September-December 2010 were suspended in 1ml saline and
subsequently cultured onto two MacConkey agar plates (MC). A MC was
streaked for colony isolation and two ertapenem (ERT) discs were added
at the end of ﬁrst and second quadrant; an inhibition zone of 27mm
was applied for detection of carbapenemase producer. A second MC
was streaked for conﬂuent growth and four meropenem (MER) discs
were placed containing: i) MER alone, ii) MER plus 20 micro-L of
20mg/ml phenylboronic acid (PBA, KPC inhibitor), iii) MER plus 10
micro-L of 0.1M EDTA (MBL inhibitor), and iv) MER plus both PBA
and EDTA. Inhibition zone around MER disc alone of <23mm was
considered positive result for carbapenemase production. A difference
of 5mm in the inhibition zone between discs containing MER without
and with inhibitors (PBA, EDTA or both) was considered a positive
result for detection of KPC, MBL or both carbapenemases, respectively.
Rectal suspensions were further tested for carbapenemase genes by PCR.
Enterobacterial colonies grown at the edge of the inhibition halo around
MER plus inhibitors and ERT discs were identiﬁed by phenotypic tests
and PCR.
Results: 21 of the 55 screened patient-samples were PCR-positive for
carbapenemase genes (9 KPC, 3 VIM, 9 KPC and VIM). By ERT
disc test, 20 of the 21 PCR-positive samples (sensitivity 95%) were
carbapenemase-positive. By the combined MER disc test, 19/21 PCR-
positive samples (sensitivity 90%) were positive for carbapenemases,
while all 34 PCR-negative samples were negative (speciﬁcity 100%). In
all 19 cases the combined MER disc tests correctly differentiated KPC
producers from those producing MBL or both enzymes.
Conclusion: This simple combined disc algorithm enables direct and
speciﬁc detection of carbapenemase production from the ﬁrst day of
rectal screening without further testing, supporting the timely and costly
implementation of infection control measures. It could be effectively
used in hospitals with high rates of carbapenemase producers.
P684 Molecular characterisation of multidrug-resistant
Enterobacteriaceae producing carbapenemase OXA-48
Y. Pfeifer*, K. Schlatterer, E. Engelmann, R.A. Schiller, S.-H. Cho,
H.R. Frangenberg, W. Witte (Wernigerode, Greifswald, Berlin, DE;
Seoul, KR; Lu¨denscheid, DE)
Objectives: The rate of Carbapenem resistance in Enterobacteriaceae in
German hospitals is low (ca. 1%) compared to other European countries.
However, the number of carbapenem resistant isolates increased steadily
within the last three years. Several isolates develop reduced susceptibility
to carbapenems occur under antimicrobial therapy which is due to
increased production of efﬂux pumps or loss of porins (outer membrane
proteins, OMPs). Furthermore, carbapenem resistant strains occur as
colonizers or cause of infection in patients previously hospitalized
abroad. These strains acquired carbapenemases like KPC and OXA-48 or
metallo-b-lactamases like NDM-1 and VIM. Carbapenemase genes are
frequently located on plasmids which enable the fast transfer between
different enterobacterial species. Here we report on molecular analysis of
different Enterobacteriaceae isolates from German hospitals producing
OXA-48 carbapenemase.
Methods: Carbapenem resistant isolates of Klebsiella spp. (n = 5), E. coli
(n = 2), Citrobacter freundii (n = 1) and E. cloacae (n = 1) were collected
from ﬁve German hospitals from 2008–2010. b-Lactamase genes were
identiﬁed by PCR and sequencing. Conjugation experiments, plasmid
analyses and PFGE-typing were performed.
Results and Conclusion: Six isolates harboured gene blaOXA-48,
three isolates the related gene blaOXA-162. The majority of strains
also produce TEM-1, OXA-1 or OXA-9 b-lactamase. Furthermore ESBL
genes blaSHV-12 and blaCTX-M-15 were detected in all isolates with
exception of the two E. coli. XbaI-macrorestriction analysis revealed that
four K. pneumoniae isolates from two hospitals were identical.
The genes blaOXA-48 and blaOXA-162 were successfully transferred
into E. coli J53 and plasmids of ca. 60kb size were isolated from
transconjugants. Analyses of the genetic environment revealed the
location of blaOXA-48 on transposon Tn1999 in the K. pneumoniae
isolates as described previously in Turkish outbreak strains. In the
remaining isolates blaOXA-48 or blaOXA-162 was found within the
Tn1999.2 structure. The high MIC values for carbapenems in the
K. pneumoniae isolates were due to production of OXA-48 and a
porin loss as result of disruption of the ompK36 gene by an IS
insertion. The combination of ESBL and carbapenemases in multidrug-
resistant Enterobacteriaceae and the dissemination by speciﬁc clones
or acquisition of resistance plasmids are of special concern because of
limited therapeutic options and higher mortality.
P685 A study to identify risk factors for the acquisition of
carbapenemase-producing Gram-negative organisms in a
tertiary hospital serving a major international airport
C. MacDonald*, S. Thomas, C. Thornhill (Manchester, UK)
Objectives: To identify risk factors for acquisition of Carbapenemase
Producing Gram-Negative (CPGN) organisms in patients admitted to
the University Hospital South Manchester (UHSM), a tertiary referral
centre providing specialist care for areas such as Burns, Cystic Fibrosis
and serving a major international airport.
Methods: CPGNs were identiﬁed using automated sensitivity testing,
MIC conﬁrmation, a Modiﬁed Hodge Test for carbapenemase activity
and reference laboratory referral for PCR. Clinical data on all patients
with conﬁrmed CPGNs was collected from December 2009 to November
2010, by prospective case note analysis.
Results: 15 CPGNs were isolated from 14 patients from various
sample sites including urine (7, 50%) and blood (2, 14%). Various
carbapenemases were detected from a spectrum of Enterobacteriaceae.
1 patient had multiple carbapenemases. KPC-production was the most
common.
12 patients (86%) had prolonged hospital contact (>5days), 3 cases
(22%) had contact with a known outbreak of plasmid-mediated KPC
in a neighbouring hospital and 1 case was cross-contamination with a
VIM pseudomonas within UHSM Burns unit. 3 patients (21%) were
direct transfers following hospitalisation abroad (Egypt, India, Cyprus).
Exposure to broad-spectrum antibiotics was seen in 7 (50%). 1 patient
isolated a KPC which clustered with the neighbouring outbreak despite
no previous contact. 2 patients (14%) had no discernable risk factors.
Conclusions: Risk factors appear poorly deﬁned. Higher rates of CPGNs
in certain countries make contact with medical facilities abroad a risk,
as does contact with known outbreaks. Exposure to broad spectrum
antimicrobials appears signiﬁcant. Combinations of risk factors may be
important, e.g. acquisition of a resistant organism abroad combined with
exposure to broad spectrum agents, creating a selection pressure.
A lack of identiﬁable risk factors in 2 patients raises concern that
CPGNs are endemic in the community, impacting on efﬁcacy of
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empiric antimicrobial choices and creating signiﬁcant infection control
challenges.
Whilst numbers are small, risk factors may differ depending on the type
of carbapenemases. KPC appears more common in those with prolonged
hospital contact in the UK as well as contact with known outbreaks.
NDM-1 is associated with medical contact abroad. Further work around
community surveillance and awareness amongst health-care workers is
needed to accurately deﬁne the current situation and limit spread.
P686 Enterobacteriaceae producing VIM-1 metallo-b-lactamases
in England − a project for a EUPHEM fellow
K. Zakikhany*, R. Hill, R. Blackburn, J. Croall, N. Woodford, R. Jarvis,
D. Livermore, A. Efstratiou, E. Sheridan (London, Chester, Merseyside,
UK)
Objectives: The EUPHEM (European Public Health Microbiology
Training Programme) fellowship was aimed to undertake the formation
of a microbiological-epidemiological network, this most readily being
achieved through the investigation of a clinical problem linking
these two disciplines. This study investigates the epidemiology of
Enterobacteriaceae metallo-b-lactamase (MBL) producers from the
North West of England, which were submitted to the Antibiotic
Resistance Monitoring and Reference Laboratory (ARMRL).
Methods: Patient-isolates of Enterobacteriaceae with carbapenem-
resistance were initially submitted by a centre in North West England to
ARMRL for investigation of resistance mechanisms. MICs were obtained
for a wide range of cephalosporins and carbapenems by agar dilution
(BSAC method); isolates with EDTA potentiation of imipenem were
screened for the class B metallo-b-lactamases by PCR. Patient and
clinical data (including the date of sample collection) were collected
retrospectively for patients infected with these isolates. Based on these
ﬁndings, a questionnaire was developed to address wider epidemiological
questions.
Results: From March 2010 until November 2010, 18 patient-isolates
were identiﬁed as pan-cephalosporin and carbapenem-resistant, with
EDTA potentiation of imipenem. All were VIM-1-positive. Whilst 14
patients were inpatients, 4 were from the community. All Carbapenem-
producers were Klebsiella spp. and 11 (61%) cultures were isolated
from urine. Mean age was 72 years with nine (50%) of cases being
female. Cases were not obviously linked and appeared scattered in time,
at intervals of 1−10 weeks. Patients were not associated with any one
hospital ward or GP practice.
Conclusion: Klebsiella spp. with VIM metallo-carbapenemase have
become scattered across the region, both in terms of time and location,
with no clear connection between cases. More active community
surveillance is required to elucidate the links between cases and establish
routes of strain or plasmid transmission between hospitals and the
community.
P687 Risk factors for carbapenem-resistant Enterobacteriaceae
carriage on admission to a surgical unit and acquisition rate
during hospitalisation
G. Bouzala*, M. Psichogiou, L. Hadjihanas, V. Sypsa, M. Grammaticou,
D. Goukos, G. Daikos (Athens, GR)
Objectives: Carbapenem Resistant Enterobacteriaceae (CRE) are en-
demic in our geographic region and cause life threatening infections
in hospitalized patients. This study was conducted to identify the risk
factors for CRE colonization on admission to a surgical unit and the
acquisition rate during hospitalization.
Methods: A prospective study was conducted in a tertiary-care
hospital located in Athens, Greece, between May 2009 and June
2010. Surveillance cultures (pharynx, rectal, other sites when clinically
indicated) were obtained from all patients admitted to a surgical
unit within 48 hours upon admission and every 7 days afterwards.
The samples were inoculated on McConkey agar plates containing
0.5mg/L of meropenem and incubated at 37o C for 48h. All isolated
Enterobacteriaceae were examined for production of carbapenemases
by combined disk synergy test (meropenem-EDTA/-boronic acid) and
Hodge test. The presence of blaVIM, KPC genes were detected by PCR.
Pertinent information to identify risk factors for CRE colonization on
admission was collected in a pre-designed form.
Results: A total of 860 admissions of 750 patients were recorded
in the surgical unit during the study period. The median duration of
hospitalization was 8 days. The prevalence [95% conﬁdence interval
(CI)] of CRE colonization on admission was 3.02% (1.98%, 4.40%).
Prior stay in intensive care unit [odds ratio (OR): 8.5; 95%CI: 1.6,
44.9; p = 0.012] or in another hospital ward (OR: 8.0; 95%CI: 2.2,
29.4; p = 0.002) and antibiotic use in preceding three months (OR:
5.3; 95%CI: 1.3, 21.0; p = 0.019) were independently associated with
CRE colonization on admission. The incidence rate (95%CI) of CRE
acquisition in the surgical unit was 9.4 (6.9, 12.8) per 1,000 patient-days.
The probability of a patient to be colonized or infected in the ﬁrst week
of hospitalization was 1.3%.
Conclusion: Signiﬁcant transmission of CRE occurs in our hospital
setting. Enhanced infection control measures are urgently needed to
contain this transmission.
P688 Evaluation of the Dutch surveillance on carbapenemase
producing Enterobacteriaceae
J. Muilwijk*, J.W. Cohen Stuart, N. van de Sande, G. Voets, J. Scharringa,
A.C. Fluit, M. Leverstein-van Hall (Bilthoven, Utrecht, NL)
Objectives: There is a world-wide concern about the emergence
of carbapenemase producing Enterobacteriaceae. Local and national
surveillance is considered an important component of the strategy
to control these strains. Since March 2010 the surveillance on
carbapenemase producing Enterobacteriaceae (CPE) in the Netherlands
consists of three pillars: 1) a national guideline on the phenotypic
detection of CPE in the routine clinical setting, which recommends
to conﬁrm a non-wild-type carbapenemase MIC by Etest (IJAA 2010),
2) the national antimicrobial resistance surveillance system (ISIS-AR)
providing feedback alerts on isolates carbapenem I/R reported by the
participating labs but not yet conﬁrmed by Etest/disc, and 3) for this
study UMCU was available as reference laboratory for conﬁrming the
presence of carbapenemase genes in screen positive isolates. The aim
of this study was to evaluate this strategy and to estimate the possible
underreporting of CPE.
Methods: All E. coli (ECO), Klebsiella pneumoniae (KPN) and
Enterobacter spp (ENT) present in the ISIS-AR database from 1−1–
2009 to 11−12−10 were included. These were submitted by 22 labs,
serving general practitioners, long-term care facilities and 44% of the
Dutch hospital beds. Using this database we calculated: 1) the yearly
prevalence of I/R ECO, KPN and ENT, 2) the yearly number of cases
of screen positive ECO, KPN and ENB. Screen positive was deﬁned
as meropenem MIC 0.5mg/L or disk diameter 23mm or imipenem
S152 21st ECCMID/27th ICC, Posters
MIC 2 or a diameter 21mm, 3) the % of screen positive isolates
conﬁrmed by Etest/discs, and 4) the number of genotypic conﬁrmed
CPE isolates in the reference lab.
Results: The number of cases of screen positive isolates was around
600 per year (Table). The MIC of only 5% of the screen positive
isolates was conﬁrmed by an Etest or disc test. Of the screen positive
isolates conﬁrmed by Etest only the KPN with a MIC of 4mg/L were
carbapenemase positive by sequencing (KPC or VIM) (table).
Conclusion: Carbapenemase conﬁrmation tests were performed in only
a very small proportion of the screen positive isolates likely resulting in
an underestimation of the CRE prevalence. An increased awareness in the
clinical microbiology laboratories is required to improve carbapenemase
detection in Enterobacteriaceae in the Netherlands.
P689 Carbapenemases in Enterobacteriaceae − Report from the
Austrian National Reference Center
R. Hartl*, C. Luger, H. Kerschner, C. Mu¨llner, P. Apfalter (Linz, AT)
Objective: Increasing numbers of carbapenemase producing Enter-
obacteriaceae (CPEB) are reported from all over Europe. Following
London’s Health Protection Agency NDM-1 alert in summer 2010, the
Austrian ministry of health asked all microbiological laboratories to send
suspicious isolates to the NRZ for conﬁrmation. The presented data
(1) reﬂect the current Austrian situation and (2) compare a new molecular
biological tool for MDR-Gram negatives to conventional methods.
Methods: In 2010 thirty strains [K. pneumoniae (n = 16), K. oxytoca
(n = 7), E. coli (n = 3), Enterobacter sp. (n = 3), and C. freundii (n = 1)]
were referred from Vienna (n = 9), Tirol (n = 7), Upper Austria (n = 7),
Styria (n = 4), Salzburg (n = 2), and Carinthia (n = 1). Carbapenem
MICs and the MBL Etest-kit (AB Biodisk, Sweden), the modiﬁed
Hodge test (on MH and on McC), and the KPC + MBL Conﬁrm
ID kit (Rosco, Denmark) were performed. NAAT testing was done by
means of the Check-MDR CT102 Kit (Check-Points, The Netherlands),
a multiplex PCR hybridization platform, allowing for simultaneous
detection of KPC, VIM, IMP, OXA-48 and NDM-1 carbapenemases as
well as CTX-M, TEM and SHV derived extended spectrum b-lactamases
(ESBL).
Results: Fifteen of 30 strains (50%) were carbapenemase negative.
Thereof 8 were wildtypes, 4 carried an ESBL gene (CTX-M1 or M9)
and 3 were AmpC hyperproducers combined with reduced permeability
and/or efﬂux pumps. The other 15 (50%) were positive for blaVIM
(n = 8), blaKPC (n = 3), blaNDM-1 (n = 3) and blaOXA-48 (n = 1). Using
screening breakpoints for ertapenem (E; 0.5mg/L), meropenem, (M;
0.5mg/L), and imipenem (I; 2mg/L), E, M and I detected 13, 12;
and 6 of these 15 strains, respectively. The modiﬁed Hodge test detected
all blaKPC carrying strains, whereas only 2/12 of Ambler class B and D
enzymes. This was slightly improved when the Hodge test was done on
McConkey agar (5/12). The MBL Etest detected only 3 cases. Compared
with the Check-Points NAAT the KPC + MBL Conﬁrm ID kit revealed
excellent concordance (14/15 detected).
Conclusion: In Austria CPEB of heterogenous origin are present in
low numbers. Half of all Isolates referred to the NRZ did not carry
carbapenemase genes, stressing the importance of a conﬁrmation lab.
Although the number of strains analyzed is small, we suggest M and E
for screening in daily routine followed by the KPC + MBL Conﬁrm ID
kit. The Check-MDR CT102 is a promising tool allowing for detection
of several resistance mechanisms simultaneously.
P690 Carbapenemase-producing Enterobacteriaceae and
Pseudomonas aeruginosa strains in Finland
M. O¨sterblad*, J. Kirveskari, P. Tissari, K. Vuorenoja, M. Bergman,
A. Hakanen, S. Koskela, J. Jalava, M. Vaara (Turku, Helsinki, FI)
Objective: There has been an accelerating spread of carbapenemase-
producing strains globally during the last decade. Finland, similarly
to the other Nordic countries, has usually been spared from serious
epidemics of multiresistant bacteria; eg. ESBL prevalence is now rising
markedly, but is still only around 1−4%, depending on study material
and location. Despite the relatively small resistance problem, the global
carbapenemase epidemic can be seen also here.
Methods: Of strains referred to our laboratories, Enterobacteriaceae
strains nonsusceptible to imipenem or meropenem, and P. aeruginosa
strains nonsusceptible to meropenem and ceftazidime, using EUCAST
wild-type cutoffs, were further tested by showing hydrolysis of
imipenem, PCR detection of carbapenemase genes (KPC, VIM, IMP,
NDM, IMI/NMC-A, GES, PER, SPM, GIM, SIM, SME, SFC, CMY-
10, + OXA-23, -24, 48, -58), and sequencing. KPC-positive Klebsiella
strains were typed by MLST. Further susceptibility testing was done
using agar dilution (22 antibiotics representing 15 classes), and EUCAST
breakpoints.
Results: Between October 2008 and end of November 2010, 22
carbapenemase-producing strains with known genes have been found:
5 KPC+ Klebsiella pneumoniae, 3 VIM+ P. aeruginosa., 3 VIM+
K. pneumoniae, 6 IMP+ P. aeruginosa, one NDM+ K. pneumoniae, one
OXA-48+ K. pneumoniae, one OXA-48+ Escherichia coli, and 2 IMI+
Enterobacter cloacae. Fifteen of the strains were found in 2010. Of the
patients, 14 had been treated at hospitals abroad (Greece 4, Turkey 2,
Russia 2, and 6 countries with single isolates). One of the KPC isolates
was a contact of a patient with a travel history. Only the patients with
IMP isolates consequently had no previous travel history. No outbreaks
have been reported. Four of the K. pneumoniae strains belonged to the
international clone ST258. Susceptibility: The most active substances
were colistin which was active against 18/22 strains, and gentamicin
against 9/22. Two VIM+ P. aeruginosa strains were resistant against all
tested antibiotics, 7 P. aeruginosa and 2 K. pneumoniae strains were
resistant against all tested antibiotics except colistin.
Conclusion: Carbapenemase-producing strains have been isolated with
increasing frequency in Finland. A local epidemic in the near future is
not impossible. Most patients had contacts to hospitals outside Finland.
P691 Rapid emergence of carbapenemase-producing
Enterobacteriaceae isolates in Belgium
T.D. Huang*, P. Bogaerts, C. Berhin, B. Jans, O. Denis, Y. Glupczynski
(Yvoir, Brussels, BE)
Objectives: Carbapenemase-producing Enterobacteriaceae (CPE) iso-
lates are emerging worldwide and represent a serious threat for global
public health. We describe here the evolution of the epidemiology
of decreased carbapenem susceptibility in Enterobacteriaceae and the
increasing frequency of occurrence of CPE clinical isolates in Belgium.
Methods: Multidrug-resistant clinical Enterobacteriaceae isolated re-
ferred between Jan. 2007 and Dec. 2010 by Belgian laboratories to the
National Reference Centre were tested for antimicrobial susceptibility
by disk diffusion method according to CLSI guidelines. Isolates
showing decreased susceptibility to a carbapenem (meropenem inhibition
diameter <22mm) were tested for the presence of carbapenemase
encoding genes by PCR targeting blaVIM, IMP, KPC, NDM and
blaOXA-48. Case data were reviewed in CPE carriers for evidence of
recent travel or transfer from institution abroad.
Results: The number of Enterobacteriaceae isolates with decreased
susceptibility to a carbapenem increased from 8 (5% of all yearly
referred Enterobacteriaceae isolates), 11 (11%) and 14 (11%) in 2007,
2008 and 2009 respectively to 44 (47%) in year 2010. Of the 506
Enterobacteriaceae isolates received over the whole study period, 31 CPE
isolates were detected in 27 patients from 12 hospitals, carrying VIM-1
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(n = 15), NDM-1 (n = 5), KPC-2 (n = 5)and OXA-48 (n = 6) enzymes.
The majority (17/31) of the CPE isolates (including all 5 NDM-1 and 5
of 6 OXA-48 producing isolates) were recorded in 2010. K. pneumoniae
represented 65% (20/31) of CPE whereas all but one CPE isolates
belonging to 6 other species were reported in 2010. Among the 27
patients carrying CPE, 13 had travelled and had been hospitalized in a
foreign country during the three months before diagnosis, 6 had acquired
CPE through probable secondary nosocomial transmission, while for
8 carriers, no clear link to imported or epidemic strains could be
established.
Conclusion: Enterobacteriaceae isolates with decreased susceptibility
to carbapenems are increasingly reported and CPE are clearly more
frequently detected in Belgium since 2010. The rapid emergence of
CPE in Belgium including autochthonous strains and their dissemination
in different Enterobacteriaceae species are particularly worrisome and
warrants strengthened monitoring and epidemiological surveillance at
national level.
P692 Molecular epidemiology and mechanism of carbapenem-
resistant Enterobacteriaceae in a West China hospital
T. Wang*, C. Tao, Y. Xie, H. Ning, D. Li, M. Kang, L. Guo, H. Chen,
H. Fan (Chengdu, CN)
Objectives: Carbapenems have a broad spectrum of activity against
the drug-resistant Enterobacteriaceae. However, an increasing number
of Enterobacteriaceae producing Klebsiella pneumoniae carbapenemases
(KPC) were reported in the worldwide. In our study, we aimed to
investigate the molecular epidemiology and mechanism of carbapenem-
resistant Enterobacteriaceae isolates collected from West China Hospital,
Sichuan University.
Methods: 45 Enterobacteriaceae strains, resistant or with reduced
susceptibility to carbapenems were isolated from patients in West China
Hospital, and antimicrobial susceptibility were determined by the agar
dilution method. The modiﬁed Hodge test (MHT) and Boronic acid disk
tests were carried to screen the phenotype of carbapenemase-producing
bacteria. Speciﬁc PCR and DNA sequencing were performed to conﬁrm
the carbapenemase genotype.
Results: The resistant rates of the 45 isolates for imipenem, meropenem
and ertapenem were 20.0%, 15.6% and 75.6%, respectively. 35 of them
were positive in the MHT (77.8%, 35/45). BlaIMP, blaTEM, blaSHV
and blaCTX-M were detected in 48.9%, 60.0%, 53.3% and 15.6% of
these reduced susceptibility isolates. BlaKPC was identiﬁed in 4 (8.9%,
4/45) high-level resistant strains, of which one also carried blaCTX-M,
another one carried blaTEM, blaSHV and blaIMP, simultaneously. DNA
sequencing revealed that the 4 isolates encoded carbapenemase gene,
KPC-2. In the boronic acid disk test, by use of disks of imipenem,
meropenem, or cefepime, either alone or in combination with 400mg of
boronic acid, all 4 KPC producers gave positive results.
Conclusion: Production of KPC-2 carbapenemase contributes to reduced
susceptibility of carbapenems in Enterobacteriaceae, but the KPC-
producing isolates were still rare in southwestern China. The possessing
of MBLs and ESBLs, and possible alterations in outer membrane
proteins (OMPs) may be a main factor for carbapenem-resistance
or reduced susceptibility in Enterobacteriaceae. KPC-2 carbapenemase
gene were found being located on plasmids. Vertical and horizontal
transmission plasmid-mediated are probably the primary epidemical
mechanism. Further studies on plasmid are necessary to reveal the
perplexing mechanism of how the clone transmitted.
P693 Eradication of carbapenem-resistant Enterobacteriaceae
colonisation with non-absorbable oral antibiotic treatment
I. Oren*, H. Sprecher, R. Finkelstein, S. Hadad, N. Krivoy,
T. Zuckerman (Haifa, IL)
Objectives: Following a continuous outbreak of carbapenem resistant
Enterobacteriaceae (CRE) colonization and infection among inpatients
in our hospital, we conducted a randomized prospective trial aimed at
eradicating gastrointestinal tract CRE colonization, using oral antibiotic
administration of gentamicin (GM), collistin (COL), or both.
Methods: Consecutive hospitalized adult patients identiﬁed as CRE
carriers by rectal surveillance cultures, were included in the study.
Rectal isolates were tested for GM and COL susceptibility using E test.
Patients who did not consent, or whose isolates were resistant to both
drugs, were followed with repeated rectal swabs to asses spontaneous
eradication rate (control group). Patients whose rectal isolates were
GM-S but COL-R were treated with oral gentamicin sulphate 80mg qid.
Patients whose isolates were COL-S but GM-R were treated with oral
colistin sulphate 100mg qid. Patients whose isolates were sensitive to
both drugs were randomized to three groups of oral antibiotic treatment:
GM, COL, or both. Oral treatment was given until eradication, or for a
maximum of 60 days. Eradication was deﬁned by the presence of three
consecutive negative rectal swabs for CRE including PCR testing of the
third specimen. Failure was deﬁned when: 1) rectal swabs still positive
after 60 days of treatment or follow-up; 2) relapse occurred after apparent
eradication; 3) rectal isolates turned resistant to the administered drug.
Results: 83 patients were included in the study. 48 were followed
for spontaneous eradication (controls) for median of 87 days (range:
60–450). 35 patients received one of the 3 drug regimens: 21-GM;
9-COL; 5-both drugs. Eradication rates in these 3 groups were 38%,
33%, and 40%, respectively, each of them signiﬁcantly higher than the
4% spontaneous eradication rate in the control group (p< 0.001, 0.02
and 0.04, respectively) with no difference between the regimens. Also,
eradication rate among the 35 patients on any treatment − 37%, was
signiﬁcantly higher than 4% spontaneous eradication rate (p< 0.001;
OR 0.07; 95%CI, 0.01–0.39). No signiﬁcant side effects were observed,
to any of the treatment regimens.
Conclusions: Oral antibiotic treatment, with non-absorbable drugs that
CRE is susceptible to, appears to be an effective and safe measure for
eradication of CRE carrier state, and by that, may reduce patient to
patient transmission and the incidence of clinical infection with this
difﬁcult to treat organism.
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P694 Evaluation of a conﬁrmatory test for phenotypic detection
of acquired AmpC b-lactamases
F. Freitas*, R. Silva, A. Novais, T.M. Coque, R. Canto´n, L. Peixe,
E. Machado on behalf of The Portuguese Resistance Study Group
Objectives: Detection of acquired AmpC blactamases (qAmpC) should
be routinely performed in clinical laboratories, as this resistance
mechanism has been associated with false cephalosporin susceptibility
reports and therapeutic failures. Some inhibitors could be used in their
detection, but a standard method has not yet been recommended. We
evaluate the accuracy of a recently described test for phenotypic detection
of qAmpC producers based on the inhibitory activity of phenylboronic
acid (PBA) on these enzymes in a well characterized collection of
qAmpC-producing Enterobacteriaceae.
Methods: A total of 89 clinical isolates [29 E. coli (EC), 50
K. pneumoniae (KP), 9 K. oxytoca (KO), 1 P. mirabilis] resistant to
cefoxitin and intermediate/resistant to amoxicillin-clavulanic acid and
at least one oxyimino-cephalosporin (disk diffusion) were selected for
conﬁrmatory tests of qAmpC production. Isolates were recovered during
a 7 year period (2002−08) and included DHA-1 (n = 7), DHA-1+ESBL
(n = 40) and CMY-2 (n = 3) producers, as well as qAmpC(−)/ESBL(−)
(n = 6) and qAmpC(−)/ESBL(+) (n = 33) isolates. The PBA disk test was
performed in Mueller-Hinton agar using disks containing only cefotetan
(CTT) (30mg) and CTT plus PBA (30 mg/400mg). A DHA-1-producing
clinical isolate and EC ATCC 25922 were used as positive and negative
controls, respectively. A positive test for the presence of qAmpC was
considered if an increase of 5mm in the inhibition halo occurred after
the addition of PBA to CTT. Identiﬁcation of known blaqAmpC genes
was carried out by PCR and sequencing.
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Results: The PBA test was positive in 59 isolates (44 KP, 10 EC, 5 KO).
DHA-1-producing KP (n = 41) and KO (n = 4), and CMY-2-producing EC
were correctly detected, but the test failed for DHA-1-EC (n = 2). PBA
test was positive in 11 isolates (7 EC, 3 KP, 1 KO) which yield a negative
result in PCR assays for blaqAmpC, those from EC being attributable
to natural AmpC hyperproduction. Sensibility and speciﬁcity of this
method for this collection of isolates were 96% and 71.8%, respectively.
Positive and negative predictive values (NPV) were 81.4% and 93.3%,
respectively.
Conclusions: The PBA test combined with our screening method of
qAmpC phenotypes displayed a high sensitivity with a good NPV,
but only moderate speciﬁcity for detection of qAmpC producers.
Other cephalosporin/boronic acid combinations should be included
in the conﬁrmatory tests, especially to rule out EC natural AmpC
hyperproduction.
P695 Detection and differentiation of broad-spectrum b-lactamases
among carbapenem-resistant Klebsiella pneumoniae clinical
isolates
A. Poulou*, F. Markou, S. Pournaras, E. Voulgari, K. Ranellou,
G. Vrioni, A. Tsakris (Serres, Larissa, Athens, GR)
Objectives: The emergence of carbapenemase-producing Klebsiella
pneumoniae represents a major public health and infection control issue.
We present the use of a simple phenotypic algorithm for the early
detection and differentiation of broad-spectrum eta-lactamases among
carbapenem-resistant clinical isolates.
Methods: During Jan 2008-Sep 2010, 74 K. pneumoniae clinical
isolates with reduced susceptibility to imipenem and/or meropenem
(MIC >1mg/l) were recovered from hospitalized patients. Identiﬁcation
and susceptibility testing were performed with Microscan (Siemens) and
E-testing. b-lactamase genes were characterized by PCR and sequencing
analysis using speciﬁc primers for blaVIM, blaIMP, blaKPC, blaOXA-
48, blaTEM, blaSHV and blaCTX-M. For the detection of KPC, MBL or
both KPC and MBL genes 4 disks of meropenem 10mg were employed
without and with 10ml of 40mg/ml phenyl boronic acid (PBA), 10m
of 0.1 M EDTA or both PBA and EDTA. The interpretation of the
results was performed according to a previously proposed algorithm
(Tsakris et al., JAC 2010; 65: 1664−71). Additionally, a modiﬁed CLSI
conﬁrmatory test was used for the detection of ESBLs using disks of
ceftazidime (CAZ), CAZ plus clavulanate (CA), cefotaxime (CTX) and
CTX plus CA with the addition of PBA and EDTA.
Results: Molecular testing identiﬁed 41 KPC producers, 24 VIM
producers and 9 producers of both carbapenemases. ESBL production
was genotypically documented for 27, 13 and 3 of the KPC, VIM and
both KPC and VIM producers, respectively. Phenotypic tests succeeded
to detect and differentiate all KPC and VIM producers as well all isolates
that produced both KPC and VIM enzymes. The CLSI modiﬁed test,
using both PBA and EDTA, successfully detected ESBL production
among isolates possessing KPC, VIM or both carbapenemases. All
ESBL-negative isolates were also successfully documented as non-ESBL
producers.
Conclusion: Phenotypic tests using PBA, EDTA or both inhibitors
showed excellent sensitivity and speciﬁcity for the detection and
differentiation of carbapenemases. The newly modiﬁed CLSI test also
successfully detected isolates that co-produced ESBL genes, which is
very important for epidemiological purposes. The use of accurate and
low cost methods for the detection of various carbapenemases and other
broad-spectrum b-lactamases is essential for the early implementation of
infection control measures and adequate treatment.
P696 Rapid detection of ESBL-producing Enterobacteriaceae with
a new chromogenic medium: Colorex Orientation/Colorex
ESBL
P. Laudat*, C. Jouannet, V. Le ﬂoch, M. Deniau (Tours, FR)
Introduction: 1979, ﬁrst patent ﬁled by Alain Rambach for its
chromogenic medium for the detection of Escherichia coli. 2009, a
chromogenic medium for the detection of ESBL-producing Enterobac-
teriaceae (E) is available at the time when the emergence ESBLE in the
community becomes a major health concern.
A study by ONERBA in 2006 found that among a total of 6771 strains
of (E)isolated in the community, 72 (1.1%) were ESBL-producers, from
which 67% of the species E. coli.
Objective: Evaluation of the sensitivity and speciﬁcity of this new
medium for detection of ESBLE from clinical specimens, as well as
from a collection of 65 well-characterised strains.
Methods: ColorexOrientation/ColorexEBLSE (COCE) is a bi-plate for
the isolation and presumptive identiﬁcation of ESBLE.
Sensitivity test: a total of 65 isolates (from our collection and/or isolated
during the evaluation were plated in parallel on blood agar and on COCE
medium and incubated at 36ºC, and read after overnight incubation (18h-
24h): E. coli (n = 55), Proteus mirabilis (n = 5), Klebsiella pneumoniae
(n = 3), Enterobacter cloacae (n = 2).
Speciﬁcity: During 2 months, 500 samples from various specimen ori-
gins (including urine, sputum, gastric, pus) were seeded in parallel with
the media used in our laboratory routine (REMIC recommendations).
The identiﬁcation and susceptibility testing were carried (i) with the
MICROSCAN Walkaway (SIEMENS) and (ii) additional tests were also
carried as recommended by the CASFM-(France-2009).
Speciﬁcity: 159/500 clinical samples lead positive cultures: 135 on
the non-selective compartment only (0 ESBLE found), 24 on the 2
compartiments. 10/24 were not part of Enterobacteriaceae: Pseudomonas
spp. (8), Alcaligenes spp. (1) and Stenotrophomonas maltophilia (1),
which grew as colourless colonies. The speciﬁcity provided by the
chromogenic colour makes easy to differentiate the ESBLE from other
Gram(−) Oxidase (+) bacteria, known to be frequently multi-drug
resistant (MDR).
Among the Enterobacteriaceae 10/12 were conﬁrmed ESBLE.
Conclusion: COCE is particularly interesting for the screening of
ESBLE, particularly for E. coli ESBL+ (se = 100%) in clinical analysis
(urinalysis, colonization or carriage). This new medium, that we would
suggest for the use by hospital hygiene teams, could become a necessary
tool also for microbiologist dealing with the threat of community
acquired ESBLE.
P697 Phenotypic method for the detection of metallo-b-lactamases
and KPC carbapenemases in the same isolate of
Enterobacteriaceae
J.B. Casals*, M. Pandrup Duer-Jensen (Roskilde, Rosco, DK)
Objectives: Grundmann and a group of European National Experts
describe in Eurosurveillance, Nov 18th 2010 an algorithm for inter-
pretation of synergy tests using combined discs to detect carbapenem-
non-susceptible Enterobacteriaceae isolates. They recommend the use
of meropenem (MER) and their combinations with cloxacillin (CLOX),
boronic acid (BOR) and dipicolinic acid (DPA), permitting the differenti-
ation of KPC from AmpC+porin loss, from metallo-b-lactamases (MBL).
The appearence of isolates containing several carbapenemases (in
particular KPC+MBL)in Greece and elsewere, may complicate the
performance of the mentioned algorithm. The phenotypic traits of one
carbapenemase may mask the other.
The development of a disc/tablet containing: MER+BOR+DPA could
probably detect KPC and MBL in the same isolate.
Methods: 25 K. pneumoniae isolates comprising strains possessing
KPC-2 or VIM-1 and KPC-2+VIM-1 or AmpC+porin loss were tested
against disc (tablets) containing MER, MER+BOR, MER+CLOX,
MER+DPA and MER+DPA+BOR on Mueller Hinton agar using
McFarland 0.5 inoculum.
Synergism indicated by an inhibition zone 5mm larger around the
combined disc(tablet) compared to MER alone, was considered a positive
reaction. In the case of the triple combination (MER+DPA+BOR)the
zone was compared to MER+DPA and MER+BOR respectively.
An isolate possessing both KPC and MBL,would produce a zone around
the triple combination tablet 5mm than both around MER+BOR and
MER+DPA.
Detection of b-lactamases in Gram-negative rods S155
Results: Isolates with KPC-2 carbapenemase showed synergy with
MER+BOR,but not with MER+CLOX.
Isolates with AmpC+porin loss showed synergy with both MER+BOR
and MER+CLOX.
10 isolates with KPC-2+VIM-1 carbapenemases, showed aver-
age zones of 11mm around MER,14mm aroundMER+BOR,16mm
around MER+DPA and 21mm around the triple disc combination
(MER+DPA+BOR).
Conclusions: The triple combination tablet containing MER+DPA+BOR
detected both KPC-2 and VIM-1 carbapenemases in the same strain of
Klebsiella pneumoniae.
P698 Evaluation of Colorex C3Gr agar for the detection of
resistant Escherichia coli and Klebsiella sp. rectal colonisation
C. Vermerien*, E. Mak, K.C. Katz (Toronto, CA)
Objective: Evaluate the performance of Colorex C3Gr agar (Daylnn,
Canada) and MacConkey with 2mg/L cefpodoxime (CPD, Oxoid) for
detecting Class A extended-spectrum b-lactamase (ESBL), AmpC-type
b-lactamase (AmpC) and carbapenemase (CPM) producing Escherichia
coli (EC) and Klebsiella spp. (KS) rectal colonization. C3Gr agar is
a selective chromogenic agar allowing presumptive identiﬁcation of
ESBL, AmpC and CPM producing Enterobacteriaceae; EC colonies are
expected to appear red and KS, Enterobacter sp. (ES) and Citrobacter
sp. (CS) blue.
Method: 477 consecutive rectal swabs were inoculated to both media.
Oxidase negative colonies on CPD, and red or blue colonies on C3Gr
were investigated to conﬁrm species identiﬁcation and ESBL/AmpC/
CPM phenotype by standard methods. A true positive, for sensitivity
purposes, was deﬁned as ESBL/AmpC/CPM-producing EC or KS
detected on either medium.
Results: Growth was observed on 114 (24%) and 153 (32%) specimens
for CPD and C3Gr, respectively. 144 isolates grew on CPD and 181 on
C3Gr. Of the isolates growing on C3Gr, 70 appeared red with 69 (99%)
identiﬁed as EC and 60 (87%) conﬁrmed ESBL/AmpC producers. 111
isolates appeared blue on C3Gr, 101 (91%) were ES or CS, while 8
(7%) were KS. Of the 8 KS, 5 (63%) were conﬁrmed ESBL producers.
Of the 144 isolates recovered on CPD, 88 (61%) were either EC or KS
and 82 (93%) of these were conﬁrmed ESBL/AmpC producers. Overall,
the sensitivity was 94% and 90% for CPD and C3Gr, respectively, for
detecting EC or KS with one of the phenotypes of interest. On C3Gr,
the positive predictive value (PPV) of a red colony being EC was 99%.
The PPV of a red colony being an EC producing ESBL-A, AmpC or
CPM was 86%. The PPV of a blue colony being KS, ES or CS was
99%. The PPV of a blue colony being an ESBL/AmpC/CPD producing
KS was only 5%.
Conclusion: C3Gr performs according to the manufacturer’s speciﬁ-
cations. The ability to differentiate EC from other Enterobacteriaceae
has the potential to reduce turn-around time for detection of resistant
EC phenotypes. The poor PPV of a blue colony for very resistant KS
phenotypes, however, may limit the utility in some settings.
P699 Comparison of automated and phenotypic methods for
detection of extended-spectrum b-lactamases in a clinical
microbiology laboratory
S. Ferreira*, A. Paradela, S. Rocha, E. Ramalheira (Aveiro, PT)
Objective: Extended spectrum b-lactamases (ESBL) are an increasing
cause of resistance in nosocomial isolates of Enterobacteriaceae.
The laboratory detection of ESBLs can be complex and sometimes
misleading. The aim of this study is to compare the results obtained
using VITEK 2 AES and Etest strips.
Methods: A total of 1123 Gram-negative, were isolated from different
clinical specimens and were included in this study. The isolates were
identiﬁed by Vitek 2 system and Advanced Expert System tool (VITEK2
AES) (BioMe´rieux, Marcy L’E´toile, France). All the strains were
analysed by VITEK 2 system (AST-151 painel, BioMerieux, Portugal)
according to MIC breakpoint values of Cefotaxime/Cefotaxime +
Clavulanic acid and Ceftazidime/Ceftazidime + Clavulanic. Potential
ESBL producers were conﬁrmed by Etest® (AB Biodisk) ESBL
with Cefotaxime/Cefotaxime + Clavulanic acid and Ceftazidime/
Ceftazidime + Clavulanic acid strips, according to manufacturer’s
instructions. Also, Piperacillin/Tazobactam MIC was conﬁrmed by
Etest® (AB Biodisk) TZP strips, according to the manufacturer’s
instructions.
Results: Thirty out of 251 cases of potential ESBL producers, exhibited
a false resistance of TZP on AST-151 cards, major discrepancy of
a sensitive phenotype to resistant. The TZP overestimation lead to
an expertise error in favour of the OXA-30 phenotype, the MIC
128mg/L is out of range for the ESBL phenotype. Therefore the AES
demonstration tool did not corrected the sensitive phenotype of third
generation cephalosporins to resistant, as it was supposed, leading to a
wrong report to the clinician. In 12 cases, the report was manually altered
to resistant phenotype to third generation cephalosporins. Regarding to
ESBL production suggested by the AES, Etest conﬁrmed 248 isolates
as ESBL producers.
Conclusion: This study demonstrates errors of automated systems
that can lead to a misleading report of susceptibilities. Phenotypic
methods for determination of ESBL production have been widely used in
routine microbiology laboratories, however they have certain limitations.
The results in this study favour the use of automated antimicrobial
susceptibility system for this purpose, nevertheless CLSI phenotypic
conﬁrmation with these methods increases the reliability.
P700 Rapid strategy to detect colonisation by KPC-producing
Klebsiella pneumoniae during an outbreak
C. Tascini*, F. Menichetti, T. Giani, G. Gemignani, F. Arena, I. Ciullo,
A. Leonildi, M.M. D’Andrea, B. Casini, E. Tagliaferri, G. Privitera,
G.M. Rossolini (Pisa, Siena, IT)
Objectives: We aimed at developing a new direct screening method
(DSM), for rapid detection of Klebsiella pneumoniae carbapenemasi-
producing Klebsiella pneumoniae (KPC-KP) colonization to promptly
establish infection control measures.
Methods: Patients admitted in rehabilitation units and intensive care
units of the north-western area of Tuscany where cases of infection due
to KPC-KP had been observed, were screened for KPC-KP colonization,
from August to November 2010. Rectal swabs were inoculated on
McConkey agar and two paper disks, one containing meropenem (MER,
10mg) and the other containing MER plus phenylboronic acid (PB,
600mg), were placed on the seeded medium. DSM was considered
positive in presence of an inhibition zone lower than 16mm around MER
alone or larger than 5mm around the MER-PB disk with respect to
MER alone.
On the ﬁrst 82 samples a comparison between MER disk and imipenem
disk (IMP 10mg) was performed. For conﬁrmation, all the isolates
suspected to be KPC-KP were also tested with the same method on
Mueller-Hinton (MH) agar on a single colony. On 63 samples detection
of blaKPC genes was carried out by direct polymerase chain reaction
(PCR). Genotyping of KPC-KP by pulsed ﬁeld gel electrophoresis
(PFGE) of chromosomal DNA and multilocus sequence typing (MLST)
were also carried out.
Results: A total of 123 patients were screened and 27 tested positive.
The mean inhibition zone around MER±standard deviation (DS) was
7.6±7.5mm, signiﬁcantly lower (p< 0.001) of the mean inhibition
zone around MER-PB±SD that resulted 19.7±4.1mm. KPC production
was conﬁrmed by the phenotypic method on MH agar in all the
strains with a positive screening test. All these isolates were identiﬁed
as K. pneumoniae strains. MER resulted more effective than IMP
(p = 0.002) in screening KPC-KP: the mean inhibition zone around
MER±SD was 7.6±7.5mm while the mean inhibition zone around
IMP±SD was 13.3±6.8mm. Compared results of DSM and PCR are
reported in table 1. The sensitivity and speciﬁcity of DSM, compared
to PCR, were 81% and 90%, respectively. All isolates were clonally
related by PFGE typing, belonged to ST258 by MLST analysis, and were
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generally susceptible to gentamicin, fosfomicin and colistin; tigecycline
MIC ranged between 1 and 2mg/L.
Conclusion: DSM is a simple, rapid, cheap, sensitive and speciﬁc
method for the detection of KPC-KP colonization or infection.
Acinetobacter baumannii
P701 Acinetobacter baumannii in Italian hospitals: results from
a retrospective data analysis from the Micronet Network
laboratories
F. D Ancona*, A. Sisto, A. Raglio, M. Meledandri, A. Rocchetti and
the Micronet Network participants
Acinetobacter baumannii is a pathogen frequently isolated in hospital
that can survive for long period with different environmental condition.
This Gram Negative pathogen can cause outbreaks with clinical pictures
of sepsis, pneumonias, urinary and wound infections. Rarely it can cause
meningitis. It can be responsible of colonization in hospitalised patients.
Patients in intensive care units and surgeries are often affected by this
infection with an increased mortality.
In order to evaluate the circulation of this pathogen and describe the
phenotypic resistance to antimicrobial drugs, we conducted a retro-
spective descriptive analysis of the infections caused by A. baumannii,
A. calcoaceticus complex and Acinetobacter spp from 1st January 2010
to 30th June 2010 in 22 Italian hospitals participant to Italian Micronet
Network the largest nation-wide lab surveillance system.
The total number of ordinary hospitalization days in participating
hospitals is 2,012,521. The total number of bed in the hospitals included
in the study is 14066.
586 A. baumanniI (considering A. calcoaceticus complex, Acinetobacter
spp and A. baumannii) were isolated by culture (isolates from the same
patients before 30 days were excluded).
The range by hospital was 0 to 80 isolates (mean 25, median 20).
The most frequent specimen types of ﬁrst isolation were not protected
respiratory specimens (n: 254, 43.3%), Urine (n: 92, 15.7%), protected
respiratory specimens (n:63, 10.8%), blood culture (n:38, 6.5%).
272 were isolated from Intensive Care Units (46.4%), 57 (9.7%) from
surgeries, 180 (30.7%) from medicine ward.
Resistance to imipenem (539 samplings), meropenem (421), ampicillin
sulbactam (97) and ceftazidime (574) were respectively 73.5%, 72.9%,
30.9%, 77.7%.
307 (79.3%) of 387 isolates were non-susceptible both to imipenem
and meropenem. Considering the percentage of circulating multiresistant
A. baumannii circulating in hospital, it is a priority to activate control
measure in the hospitals to avoid outbreaks that, especially in ICU
where it can cause an excess of mortality. Surveillance of this events
and monitoring of the antimicrobial resistance should be taken in
consideration at national and local level.
P702 Epidemiology of multidrug- and carbapenem-resistant
Acinetobacter baumannii in Belgium: an emerging threat?
A. Verroken*, P. Bogaerts, T.D. Huang, A. Deplano, C. Bauraing,
O. Denis, Y. Glupczynski (Yvoir, Brussels, BE)
Objectives: To analyze the susceptibility, the genetic basis of resistance
and the molecular epidemiology of MDR Acinetobacter baumannii (Ab)
strains recently isolated in Belgian hospitals.
Methods: All Ab isolates referred on a voluntary basis to the National
Reference Centre from 09/2004 until 11/2010, were included in the study.
Identiﬁcation was performed by VITEK 2 and PCR for blaOXA-51 gene.
Antimicrobial susceptibility testing was performed by disk diffusion and
results were interpreted according to CLSI breakpoints. PCR-sequencing
targeting blaOXA-23,24,58-like, blaVIM,IMP, blaGES,PER,VEB and
blaADC were performed. Isolates were typed by PFGE (SpeI).
Results: Overall, 306 isolates (246 clinical, 12 environmental isolates
and 48 of unknown origin) were obtained from 30 Belgian hospitals.
Respiratory (34%), wound (18%) and urine (13%) were the most
common sites of isolation. 202 strains were found carbapenem
(imipenem or meropenem) resistant and among these, 158 isolates were
associated with 10 major nosocomial outbreaks. Carbapenem-resistant
Ab expressing the blaOXA-23 gene were at the source of 7 outbreaks
whereas the remaining outbreaks were caused by an Ab expressing an
OXA-24 group enzyme, an OXA-58 group enzyme or a GES extended-
spectrum b-lactamase (1 epidemic each). Index cases could be identiﬁed
in 7 outbreaks as initiated by medical transfers from North Africa (3),
France (2), Greece (1) and Thailand (1). Outbreak scales ranged from 3
to more than 50 patients, mainly affecting intensive care and burn unit
patients, and lasted up to several months in some cases.
Further, carbapenem-susceptible Ab strains were also associated with
outbreaks including 2 with OXA-58 group, 1 with PER-1 extended-
spectrum b-lactamase and 1 with overexpressed chromosomal ADC
cephalosporinase.
PFGE analysis performed on Ab strains from 8 outbreaks evidenced 2
major clones (PFGE type 12 and 39) genotypically related to European
clone (EC) I, and 3 unrelated to classical EC I, II and III (PFGE type
10, 42 and 44).
Conclusion: Ab is an emerging nosocomial pathogen in Belgium
associated with the occurrence of major nosocomial outbreaks. A
systematic screening, pre-emptive isolation and reinforced barrier
precaution measures should be adopted for patients undergoing sanitary
transfer from hospital in foreign countries. An active surveillance
programme is clearly needed.
P703 Strain diversity and antibiotic resistance including
carbapenem resistance in Acinetobacter baumannii in
Bulgarian hospitals
R. Vatcheva-Dobrevska*, T. van der Reijden, E. van Strijen,
E. Keuleyan, H. Hitkova, E. Savov, M. Lesseva, I. Ivanov, E. Dobreva,
M. Grigorova, A. Dimitrova, V. Tolekova, T. Yovcheva, T. Kantardjiev,
P. van den Broek, L. Dijkshoorn (Soﬁa, BG; Leiden, NL; Pleven,
Varna, Yambol, V. Tirnovo, Targovishte, BG)
Objectives: Since 2002, carbapenem resistant A. baumannii has emerged
in Bulgarian hospitals. The aim of our study was to assess type diversity
and antibiotic resistance including carbapenem resistance in multidrug-
resistant A. baumannii (MDRAB) isolates from nine Bulgarian hospitals
obtained between 2004 and 2008.
Methods: Investigated were 106 non-replicate MDRAB isolates
including 58 prospective isolates from the Military Medical Academy
(MMA) (2004–2006), 15 from from 3 other Bulgarian hospitals from
2005–2006, and 35 from 5 hospitals from 2008. Antibiotic susceptibility
was determined with VITEK-2. The organisms were identiﬁed to species
(similarity cut-off level 50%), to clone (80%) and to strain (90%) by
AFLP analysis. OXA-genes were detected by multiplex PCR.
Results: At the strain level (90%), isolates were allocated to 10 clusters
(i.e. types) and 2 single strains. Predominant types were no. 3 (47
isolates), 8 (13 isolates), 10 (12 isolates) and 12 (11 isolates). Isolates
from the MMA comprised two major types, no. 3 (34 isolates) and
12 (11 isolates). Although most hospitals had a particular predominant
type, several types were observed in multiple hospitals. With very few
exceptions, types from 2004–2006 were distinct from those of 2008.
Some clusters with isolates from multiple hospitals linked at ~80%,
indicating clonal lineages. One of these, comprising types 5−10, was
identiﬁed to EU clone I. Isolates were resistant to 8−15 out of 18 or
13−20 out of 21 antibiotics tested. Ninety-two isolates were carbapenem
resistant. All isolates had a positive OXA-51 PCR, 81 were OXA-23
positive and 5 (in type 3 isolates from 2006) OXA-58 positive.
Acinetobacter baumannii S157
Conclusion: Results indicated a wide endemic or epidemic presence of
different strains in the hospitals. Furthermore, there were indications
for interhospital spread. The high degree of resistance to antibiotics
including carbapenems is worrying.
P704 Preliminary results of the multicentre study on carbapenem
resistance of Acinetobacter baumannii in northern Croatia
B. Bedenic*, M. Vranic-Ladavac, A. Budimir, V. Rezo-Vranjes, S. Sivec,
D. Sijak, J. Vranes, N. Beader, S. Kalenic, Z. Bosnjak (Zagreb, Pula, HR)
Objectives: The aim of the study was to characterize the mechanisms of
carbapenem resistance in A. baumannii isolates collected in the frames
of a multicenter study and to study their molecular epidemiology.
Material and Methods: In total 115 A. baumannii isolates were
collected in 13 diagnostic laboratories located in Northern part of
Croatia in 2009. Antibiotic susceptibilities were determined by broth
microdilution method according to CLSI. E-test MBL strips were used
for detection of metallo-b-lactamases (MBLs). PCR was used to detect
the presence of oxacillinases (OXA-51, OXA-23, OXA-24 and OXA-
58) and MBLs of VIM, IMP and SIM series. The genetic context of
blaOXA-51 and blaOXA-58 genes was determined by PCR mapping with
the primers for ISAbaI and IsabaIII combined with forward and reverse
primers for blaOXA-51 and blaOXA-58. Genotyping of the isolates was
performed by PFGE.
Results: There were 97% of the strains resistant to piperacillin, 94%
to ceftriaxone, cefotaxime and gentamicin, 91% to ciproﬂoxacin, 89%
to ceftazidime, 68% to tobramycin, 60% to amikacin and 29% to
ampicillin/sulbactam. No resistance to colistin was observed. Colistin
was the most potent antibiotic with MIC90 of 2mg/L. Twelve isolates
were found to be resistant to both carbapenems. Nine of them were
shown to possess blaOXA58-like gene and three blaOXA-40 like gene.
The strains susceptible to carbapenems were positive only for naturally
ocurring OXA-51 b-lactamase whereas eight isolates with intermediate
susceptibility to one or both carbapenems were shown to possess
ISAbaI insertion sequence upstream of blaOXA-51 gene. No MBLs were
found. Only OXA-58 b-lactamase was inhibited by sodium chloride.
Chromosomal AmpC b-lactamases did not affect the susceptibility to
carbapenems. None of the isolates exhibited signiﬁcant synergy between
meropenem and CCCP, indicating that overexpression of proton-gradient
depended efﬂux pumps did not contribute to the meropenem resistance.
The strains producing only OXA-51 b-lactamase were found to belong
to EU clone I whereas OXA-40 and OXA-58 producers were asigned
to EU clone II. Three strains positive for blaOXA-40 like genes were
clonally related.
Conclusions: The emergence of carbapenem resistance in A. baumannii
in Northern Croatia is associated with the production of acquired
oxacillinases belonging to OXA-58 and OXA-40 like groups. Car-
bapenem resistant isolates producing acquired oxacillinases belonged to
EU clone II.
P705 OXA-carbapenemase-producing multidrug-resistant
Acinetobacter baumannii isolates from Sweden
N. Karah*, C. Giske, A. Sundsfjord, Ø. Samuelsen (Tromsø, NO;
Stockholm, SE)
Objectives: Multidrug- and carbapenem-resistant Acinetobacter bau-
mannii has increasingly emerged as a problematic pathogen responsible
for hospital-acquired infections worldwide. The aim of this project was
to characterise carbapenem-resistant A. baumannii isolates identiﬁed in
Sweden between 2004 and 2007.
Materials and Methods: The study included 14 carbapenem-resistant
A. baumannii isolates identiﬁed in Sweden from 11 patients, including
2 patients transferred to Sweden after the 2005 tsunami in Thailand.
Susceptibility testing was performed by Etest. PCR assays were
performed for detection of OXA-carbapenemase genes, 16S rRNA
methylase genes, ISAba1, intI1 and for determination of epidemic clonal
lineages. PFGE was performed using AbaI digested total genomic DNA.
Results: Epidemiological data showed that 7/11 patients had been
hospitalised abroad; Greece (n = 3), Thailand (tsunami victims, n = 2)
Poland (n = 1), and Serbia (n = 1). All 14 isolates expressed multidrug
resistance (MDR). OXA-carbapenemase genes were detected in all
isolates; blaOXA-23-like (n = 6), blaOXA-58-like (n = 7) and blaOXA-
24-like (n = 1). OXA-58-producing isolates showed lower MIC-values
against meropenem, with 1 isolate being susceptible and 5 isolates
intermediate susceptible. All OXA-23-/OXA-24-producing isolates were
resistant to meropenem. All isolates were resistant to imipenem.
ISAba1 was detected upstream of blaOXA-23-like in 6/6 isolates and
downstream in 5/6 isolates. Colistin resistance was observed in two
isolates. From one patient, two clonally related isolates were identiﬁed
of which only one was colistin resistant. The patient had been treated
with colistin, suggesting that colistin resistance has emerged during
treatment. All isolates were resistant to at least one aminoglycoside.
Two isolates showed high-level pan-aminoglycoside resistance. However,
no 16S rRNA methylase gene was detected. Six isolates belonged to
international clone II, including 4 clonally related isolates. No isolates
belonged to international clone I. The class 1 integrase gene (intI1) was
detected in 7/14 isolates.
Conclusion: MDR- and carbapenem-resistant A. baumannii isolates
from Sweden are mostly associated with import of OXA-carbapenemase
producing strains with some belonging to international clone II. MLST
and sequencing of integrons are ongoing.
P706 Molecular typing of multidrug-resistant Acinetobacter bau-
mannii from a tertiary care university hospital in Lithuania
J. Povilonis*, V. Sˇeputiene, A. Vitkauskiene, E. Suzˇiedeliene (Vilnius,
Kaunas, LT)
Objectives: The aim of this study was to perform genotypic and
phenotypic characterization of multidrug-resistant (MDR) Acinetobacter
baumannii isolates from largest country tertiary care medical center.
Methods: A total of 154 clinical A. baumannii isolates were obtained
from different units of Clinics of Kaunas University of Medicine
(2000 beds) during August-November of 2010 (intensive care units
(ICUs), n = 84; trauma (TUs) and surgery (SUs) units, n = 39; other
therapeutical units, n = 31). Antibiotic susceptibility testing to ten an-
tibiotics (cefoperazone/sulbactam, meropenem, tazobactam, ampicillin/
sulbactam, ceftazidime, gentamicin, amikacin, ciproﬂoxacin, imipenem,
piperacillin) was performed by disc diffusion method according to CLSI.
Molecular typing was performed by PFGE-ApaI and identiﬁcation of
European clonal lineages I-III (EC I-III) was carried out by multiplex-
PCR.
Results: Of 154 isolates, 137 (89%) were resistant to ﬁve or
more antibiotics. Majority of isolates were resistant to ciproﬂoxacin,
ceftazidime and piperacillin (138/154 90%, 138/154 90%, 137/154 89%,
respectively) while resistance to cefoperazone/sulbactam, meropenem
and imipenem was lower (51/154 33%, 48/154 31%, 45/154 29%,
respectively). All except three carbapenem resistant isolates conferred
resistance to both carbapenems − meropenem and imipenem.
Analysis of PFGE-ApaI macrorestriction patterns revealed that nearly all
MDR isolates (131 out of 137) belong to 28 genotypes which grouped
into two major clusters (I and II) at 80% Dice similarity cutoff and
with different resistance patterns. Notably, isolates from Cluster 2 were
signiﬁcantly more resistant to carbapenems while their resistance to
cefoperazone/sulbactam, ampicillin/sulbactam and aminoglycosides was
signiﬁcant lower (Table 1). Cluster 1 strains predominated among isolates
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from ICUs (44/84 52%) as well as among isolates from TUs/SUs (24/39
62%). Identiﬁcation of EC I-III showed that all isolates of Cluster 1 and
Cluster 2 belonged to EC I and EC II, respectively.
Conclusion: This study shows the high incidence of MDR phenotype
among A. baumannii isolates from tertiary care university hospital in
Lithuania. A close clonal relatedness was observed among these isolates
which were assigned to globally disseminated European clonal lineages
I and II.
P707 OXA-carbapenemase producing Acinetobacter baumannii in
tertiary care university hospital in Lithuania
V. Seputiene*, A. Bogdaite, J. Povilonis, R. Jusˇkaite, A. Vitkauskiene,
E. Suzˇiedeliene (Vilnius, Kaunas, LT)
Objectives: To perform ﬁrst phenotypic, genotyping and molecular
characterization of carbapenem-resistant clinical A. baumannii isolates
in Lithuania.
Methods: 44 nonduplicate clinical isolates resistant to carbapenems
were collected in the largest tertiary care medical center in Lithuania
(Clinics of Kaunas University of Medicine) during year 2010.
Their antimicrobial susceptibility was determined by disc diffusion.
The molecular characterization of carbapenem resistant isolates was
performed by using PFGE, PCR assays and sequencing.
Results: All isolates were resistant to meropenem, imipenem and
ciproﬂoxacin, 98% to piperacillin and ceftazidime, 95% to tazobactam/
piperacillin, 64% to amikacin, 43% to gentamicin, 20% to sulbactam/
ampicillin and 11% to sulbactam/cefoperazone. According to the PFGE-
ApaI macrorestriction pattern analysis, carbapenem-resistant isolates
showed 10 distinct genotype groups, which belonged to European clone
II. Carbapenem resistance was related to OXA-carbapenemases with
OXA-40-like the dominant enzyme OXA-72, found in 43 isolates.
OXA-23-like carbapenemase was identiﬁed in a single isolate. ADC
gene was linked to ISAbaA1 insertion sequence in all isolates resistant
to ceftazidime. The majority of carbapenem resistant isolates (96%)
contained strA and strB genes, while other aminoglycoside resistance
determinants (aacC1, aacC2, aacA4, aphA1, aphA6, aadA1) were rare.
16S rRNA methylase ArmA was present in OXA-23 producer. A
high incidence of tetracycline resistance genes was found with the
predominant tetB gene alone (86%) or in combinations with tetA (5%)
in one genotype group. catI and catB8 associated with chloramphenicol
resistance were found in three and one isolate, respectively. All isolates
were intI-positive whereas only the OXA-23 producer contained typical
(5‘CS-variable region-3‘CS) class-1 integron with gene casettes aacA4-
catB8-aadA1.
Conclusion: The ﬁrst molecular survey of carbapenem-resistant
A. baumannii in Lithuania showed that they were presented by OXA-72
and OXA-23 producers belonging to European clone II.
P708 Genetic basis of carbapenem resistance of Acinetobacter
baumannii in Belarus
Y. Gorbich*, I. Karpov, A. Martinovich (Minsk, BY; Smolensk, RU)
Objective: This study was designed to investigate the mechanisms
of carbapenem resistance among nosocomial isolates of Acinetobacter
baumannii in the Republic of Belarus.
Methods: The subject of inquiry was 47 patients (70.2% males; middle
age 50.7±4.6 years old) from 9 Minsk hospitals with clinical and
laboratory documented nosocomial infections caused by carbapenem-
resistant A. baumannii. Pathogen identiﬁcation and resistance surveil-
lance were performed at the Institute of Antimicrobial Chemotherapy
(Russian Federation). Strains collected from different specimen sources
of the same patient were excluded. The isolates were identiﬁed by
conventional methods. The presence of genes responsible for synthesis of
metallo-b-lactamases (IMP, VIM) and oxacillinases (OXA-23, OXA-58,
OXA-40) were established by real-time PCR. Additionally, carbapenem-
EDTA double disk synergy test was used to check presence of metallo-
b-lactamases.
Results: The majority (91.5%) of the examined A. baumannii strains
were recognized as producers of b-lactamases from oxacillinase-40
(OXA-40) subgroup. None of the tested isolates produced oxacillinases
from OXA-23 and OXA-58 subgpoups. Metallo-b-lactamases had not
been detected by both genotypic and phenotypic methods.
Unexpectedly, all b-lactamase-negative carbapenem-resistant strains
(8.5%) were resistant to meropenem but susceptible to imipenem, while
OXA-40-positive isolates showed resistance to both carbapenems.
Conclusion: Carbapenem resistance in A. baumannii isolates from
Belarusian hospitals is carried out through different ways. However, the
main mechanism is the production of OXA-40-type oxacillinases. The
diversity in carbapenem resistance among b-lactamase-negative isolates
indirectly supports the recent data that efﬂux pumps play the main role
in the meropenem-resistance.
P709 Resistance to antibiotics of Acinetobacter spp. in Saint
Petersburg, Russia
E.P. Barantsevich*, N.E. Barantsevich, N.S. Kozlova, V.G. Goik (Saint
Petersburg, RU)
Objectives: Resistance to antimicrobial preparations in Acinetobacter
spp., isolated from patients with nosocomial pyoseptic infections in
Saint-Petersburg, Russia, was studied.
Methods: Acinetobacter spp. were isolated from patients with noso-
comial pyoseptic infections in 4 major hospitals of Saint-Petersburg,
Russia. Identiﬁcation was performed by routine methods and/or
sequencing of 16sRNA gene (ABI Prism 3130, MicroSeq ID v2.0
Software, MicroSeq ID 16s rDNA500 Library v2.0). Susceptibility of
Acinetobacter spp. to 10 antibiotics was tested by dilution techniques in
Muller-Hinton agar (Oxoid, GB). The antibacterial preparations included
ampicillin (Amp), ceftazidime (Cz), imipenem (Im), meropenem (Mer),
ampicillin-sulbactam (Ams), cefoperazone-sulbactam (Cs), piperacillin-
tazobactam (Ppt), ciproﬂoxacin (Cip), amikacin (Amk), tigecycline (Tig).
Results: 83 strains of Acinetobacter spp. were isolated from bron-
choalveolar lavage, blood, wounds and pleural ﬂuid, including 79 strains
of A. baumannii, 2 − A. genospecies 3, 2 − A. genospecies 14.
The majority of strains were resistant to antibiotics (98.8%).
Resistance to Amp was observed in 98.8%, to Cz in 90.4%, to Ppt in
81.9%, to Cip in 73.5%, to Im in 65.1%, to Mer in 65.1%, to Amk
in 44.6%, to Ams 36.1% and Cs in 32.63% strains. All strains of
Acinetobacter spp. were susceptible to Tig. Only 1 strain of A. baumannii
was susceptible to all antibiotics tested.
Multiple drug resistance was revealed in 81.9% of the tested strains.
The majority of Acinetobacter spp. were resistant to 6 (31.3%) and 7
(28.9%) antibacterial preparations.
Acinetobacter spp. demonstrated 17 spectra of resistance. ApAmkCzPpt-
CipImMer was the most widespread and was observed in 24.1%
of the strains tested. Spectrum ApAmkCzCipImMer was revealed in
20.5%, ApAmkCzImMer in 9.6%. Other spectra were revealed with less
frequency.
Conclusions:
1. Multiple drug resistance prevailed in Acinetobacter spp., isolated
from patients with nosocomial pyoseptic infections in Saint-
Petersburg, Russia.
2. Resistance to antibiotics, claimed to be highly effective in the
treatment of nosocomial Acinetobacter infections, was revealed:
strains, resistant to carbapenems, comprised a major part (65.1%)
of the Acinetobacter spp.; resistance to cefoperazone-sulbactam was
registered in 1/3 of the tested strains.
3. All strains of Acinetobacter spp. in the present study were susceptible
to tigecycline.
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P710 Antibiotic resistance proﬁle in hospital-acquired
multidrug-resistant Acinetobacter spp.
A. Bu¨yu¨k, F.F. Yilmaz-Ko¨z*, S. Gu¨l-Yurtsever, M. Hosgo¨r-Limoncu
(Izmir, TR)
Objectives: Acinetobacter spp strains are most often responsible for
serious nosocomial infections, especially in the intensive care units.
Recent studies indicated a great increase in the antimicrobial resistance
against old and new aminoglycosides, ﬂuoroquinolones, carbapenems
and colistin (polymixin E). Today, researches on the resistance proﬁle
of multidrug resistant-MDR Acinetobacter spp have become important.
There are several phenotypic and molecular typing methods which used
for investigating the origin of infection, route of spread and prevalence of
the resistant strains. The aim of this study was to determine the resistance
proﬁle and antibiotypes of MDR Acinetobacter spp isolates.
Methods: Between 2009 and 2010, 79 MDR Acinetobacter spp
isolates were collected from different clinical specimens at the Clinical
Microbiology Laboratory of Izmir Atatu¨rk Training and Research
Hospital. Antibiotypes of Acinetobacter spp isolates were determined
by using the minimum inhibitory concentration-MIC values of amikacin,
ciproﬂoxacin, moxiﬂoxacin, colistin, meropenem, rifampicin. MICs were
analyzed by broth microdilution method according to the Clinical and
Laboratory Standards Institute standard criteria. Enterococcus faecalis
ATCC 29212 and Pseudomonas aeruginosa ATCC 27853 was used as
positive control.
Results: According to the results of antibiotic susceptibility tests, the
rates of resistance in 79 MDR Acinetobacter spp isolates are found
as 56,88%; 38,71%; 31,60%; 30,92%; 9,48%, 3,95% for ciproﬂoxacin,
meropenem, amikacin, rifampicin, moxiﬂoxacin, colistin, respectively.
All the resistant and intermediate isolates were evaluated as resistant.
Thus, it was obtained 15 different antibiotic resistance proﬁles. Only
one isolate was found as resistant against all the antibiotics tested, on
the other hand 5 isolates were found susceptible. When compared with
the other antibiotics, colistin was more inﬂuential. It was found clearly
that moxiﬂoxacin, the newer ﬂuoroquinolone, was more effective than
ciproﬂoxacin.
Conclusion: Acinetobacter spp are signiﬁcant problem worldwide
and increasingly responsible for numerous outbreaks and nosocomial
infections. It is known that several typing methods are in use for the
epidemiological investigation. Antibiotyping is one of the basic and
useful typing methods, however, it should be supported by molecular
techniques such as plasmid typing, ribotyping, etc. for the reliable
classiﬁcation.
P711 Prevalence of carbapenem-resistant Acinetobacter baumannii
isolated from symptomatic patients in two hospitals in Kuwait
N. Al-Sweih*, M. Al-Hubail, R. Joshi, V. Rotimi (Kuwait, KW)
Objectives: This study was conducted to evaluate the antimicrobial
susceptibility of Acinetobacter baumannii isolated from patients in two
major teaching hospitals in Kuwait and to investigate the mechanism of
carbapenem resistance and their clonal relatedness.
Materials and Methods: Consecutive clinical isolates of A. baumannii
were obtained from Mubarak hospital (36 isolates) and Al-Adan hospital
(58) over a period of 6 months and identiﬁed by PCR using the primers
speciﬁc for blaOXA-69 gene. Antimicrobial susceptibility testing was
performed using Etest method and genes mediating metallo-b-lactamase
(MBL) and oxacillinase production were characterized by PCR. Pulsed-
ﬁeld gel electrophoresis (PFGE) genotyping was used to determine their
clonality.
Results: Of the 94 isolates, 80 (85.1%) were multidrug-resistant, and
40 (42.6%) were resistant to the carbapenems; 17 (42.5%) were from
Mubarak and 23 (57.5%) from Al-Adan hospitals. blaIMP-1 was found
in 8 (27.8%) isolates, blaVIM-2 in 18 (62%), blaOXA-23 in two isolates
and blaVIM-1 in one isolate. The mechanism of resistance in 5 of 17
(29.4%) and 6 of 23 (26.1%) carbapenem-resistant isolates was not
known. Sixteen (94.1%) out of the 17 bla gene carrying strains from
Al-Adan hospital belonged to genotype A but only 5 (41.7%) of 12
from Mubarak hospital belonged to genotype A.
Conclusion: In this study, a high prevalence of carbapenem-resistant
A. baumannii was encountered in two Kuwait hospitals. The predominant
genes encoding MBL production were blaVIM-2 and blaIMP-1. There
is evidence of inter-hospital clonal spread of carbapenem-resistant
A. baumannii.
P712 Analysis of multidrug-resistant Acinetobacter baumannii
clinical isolates
V. Kasinathan, T. Drake, Y. Wang* (Atlanta, US)
Objectives: This study is to analyze the in vitro antimicrobial resistance
to antibiotics such as polymyxin B (POL), minocycline (MIN), and
tigecycline (TGC) among the multi-drug (MDR) resistant Acinetobacter
baumannii isolated from patients seen in a large hospital.
Methods: A total of 104 clinical isolates were used for the in vitro
antimicrobial susceptibility testing (AST). Of those non-duplicated
clinical isolates, 91 were isolated in 2010, 9 in 2009, and 4 in
2008. Among 104 isolates, 46 (47.1%) were isolated from respiratory
specimens, 33 (31.7%) from blood, 11 (10.6%) from wound and tissue,
and 11 (10.6%) from urine. Samples were collected from patients mostly
in the ICU and burn units. The MIC test methods by using Etest and
microbroth dilution method (the commercially available SENSITITRE
GNX2F panel) were performed for AST analysis.
Results: Of 104 isolates, 21 (20.2%) with MIC <4mg/mL were
susceptible to imipenem (IMP), and 83 (79.8%) resistant to IMP; 15
(14.4%) had MIC to doripenem (DOR) at <1mg/mL, 2 (1.9%) at 2, and
87 (83.7%) >2mg/mL to DOR. Among 104 isolates, 56 (53.8%) with
<4mg/mL were susceptible to MIN and 47 (45.2%) resistant to MIN;
102 (98.1%) susceptible to POL, and 2 (1.9%) with MIC >4mg/mL
were conﬁrmed by Etest at 6 and 8 to be resistant to POL. In addition,
97 (93.3%) isolates with MIC <2mg/mL were presumed susceptible to
TGC, and 7 (6.7%) had MIC at 4 and 8mg/mL to TGC. Among 83
IMP-resistant isolates, 38 (45.8%) were resistant to MIN, 4 (4.8%) to
TGC, and 2 (2.4%) to POL. Among 7 presumed TGC-resistant isolates,
3 were isolated from respiratory samples, 1 wound, and 3 from urine; all
were susceptible to POL. Of two POL-resistant isolates, one from blood
and one from urine, both isolates had MIC at 1 mg/mL to TGC.
Conclusion: GNX2F panel could be used routinely on testing MDR
Acinetobacter isolates. AST testing result demonstrated that many MDR
Acinetobacter clinical isolates were resistant to minocycline. A few
isolates were found to be resistant to tigecycline and to polymyxin B.
P713 Risk factors for acquisition of imipenem-resistant
Acinetobacter baumannii in Taiwan
H.Y. Lee*, R. Chang, L. Su, T.Y. Lin, C. Wu, C.-H. Chiu (Taoyuan, TW)
Objectives: To elucidate risk factors for acquiring imipenem-resistant
A. baumannii (IRAB), clinical data of case group (patients with IRAB)
and control group (patients with imipenem-sensitive A. baumannii,
ISAB) were compared.
Methods: Clinical presentations of patients infected with A. baumannii
from Chang Gung Memorial Hospital and Saint Paul’s Hospital in
December of 2009 were all collected and analyzed. Susceptibility of
the bacterial isolates to imipenem were determined by the standard disk
diffusion method and E-test analysis. Risk factors for acquiring IRAB
were analyzed by comparing data of 42 patients infected with IRAB and
20 patients with ISAB.
Results: The most common diagnosis was pneumonia (79% IRAB and
65% ISAB), followed by sepsis (11.3% IRAB and 10% ISAB), urinary
tract infection (4.8% IRAB and 10% ISAB) and soft tissue infection
(4.8% IRAB and 15% ISAB), such as cellulitis or abscess. There was
no signiﬁcant difference between case group and control group in their
sources, diagnosis, age, male gender, number of underlying diseases,
white cell count (WBC) or C-reactive protein (CRP) (all P> 0.05).
Patients infected with IRAB had signiﬁcantly higher mortality rate
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(P = 0.009), longer admitted days (P <0.001), and longer treated days
(P = 0.027) than those with ISAB. Comparing data of 21 mortal patients
and 41 alive ones, there was no signiﬁcant difference between these 2
groups in WBC, CRP or age (all P> 0.05). Results of the univariate
analysis revealed signiﬁcant differences between the patients with IRAB
or ISAB in terms of previous ICU stay at least 5 days, use of mechanical
ventilation at least 5 days, given carbapenems or extended-spectrum
cephalosporines for at least 5 days, and given carbapenem (Table 1).
However, only given carbapenems or extended-spectrum cephalosporines
for at least 5 days was the only independent risk factor for acquiring
imipenem resistance by multivariate logistic regression analysis (Odds
Ratio: 342.07, 95%CI: 2.07–56514.17). Any of other risk factors was
correlated with this independent risk factor (P< 0.001).
Conclusion: Patients infected with IRAB had higher mortality rate and
longer hospital stay than those with ISAB. Prior use of carbapenems
or extended-spectrum cephalosporines for at least 5 days was the only
independent risk factor signiﬁcantly correlated with IRAB infection.
Therefore, restricted use of carbapenems and extended-spectrum
cephalosporines is crucial to reduce acquisition of IRAB.
P714 Molecular epidemiology of clinical Acinetobacter baumannii
isolates in a Korean hospital
S.Y. Kim*, Y.J. Park, J.K. Yu, J.Y. Kim (Suwon, Seoul, Daejeon, KR)
Objectives: Acinetobacter baumannii are commonly associated with
nosocomial infections, and usually multiresistant. We investigated the
characteristics of 35 A. baumannii isolates by multilocus sequence
typing (MLST), pulsed-ﬁeld gel electrophoresis (PFGE), PCR of the
antimicrobial resistance determinants, and antimicrobial susceptibilities.
Methods: This study included 16 carbapenem-resistant A. baumannii
(CRAB) and 19 carbapenem-susceptible A. baumannii (CSAB) from a
secondary hospital in Daejeon, Korea between January and July 2009
without any selection criteria. PCR ampliﬁcation of genes for OXA-type
carbpenemases (OXA-23, 24, 51, and 58), metallo-b-lactamases (IMP
and VIM), ISCR1, aminoglycoside-modifying enzymes (AMEs), and
armA was performed. Susceptibility to imipenem, meropenem, amikacin,
tobramycin, gentamicin, trimethoprim-sulfamethoxazole, cefepime, and
ceftazidime were determined by an agar dilution method, and
interpretation was in accordance with the CLSI 2010 guidelines. To
elucidate the clonal relatedness, MLST and PFGE were carried out.
Results: CSAB showed more various genetic mechanisms than CRAB
because 9 STs were identiﬁed in CSAB while only 2 STs were identiﬁed
in CRAB. ST92 was the most prominent ST, accounting for 93.8%
(15/16) of CRAB and 21.1% (4/19) of CSAB isolates. A novel double-
locus variant of ST92 (STn1) was another major ST, which was detected
in 42.1% (8/19) of CSAB isolates and not detected in CRAB isolates.
The resistance rate to carbapenem was the highest (78.9%) in ST92
isolates while only one isolate had carbapenem resistance among isolates
of other STs. BlaOXA-23 was positive in 62.5% (10/16) of CRAB
isolates but negative in CSAB isolates. All blaOXA-23-bearing isolates
except one belonged to ST92. The resistance rates of CRAB isolates to
all antimicrobial agents tested were higher than those of CSAB isolates.
Conclusions: ST92 was dorminant sequence-type in a Korean hospital,
and it closely correlated with carbapenem resistance and the presence of
blaOXA-23.
P715 Evaluation of a novel selective medium, CHROMagar
acinetobacter with KPC supplement, for detection of
multidrug-resistant Acinetobacter baumannii from clinical
specimens in Japan
S. Kawakami*, M. Asahara, N. Matsunaga, Y. Ono, T. Hurukawa,
R. Kubo, M. Onozaki, T. Nakano, T. Kaneko, T. Teramoto, Y. Miyazawa
(Tokyo, JP)
Objectives: Multidrug-resistant A. baumannii (MRAB) has recently
been reported in both western countries and in China. However, cases
of such infections are very rare in Japan. Here, we report hospital-
acquired infection by A. baumannii blaOXA-51-like resistant to the
carbapenems imipenem or meropenem, the aminoglycoside amikacin and
the ﬂuoroquinolones levoﬂoxacin or ciproﬂoxacin. We also evaluated the
novel chromogenic medium, CHROMagar Acinetobacter (CHROMagar,
France) supplemented with KPC to detect MRAB.
Methods: KPC-supplemented CHROMagar Acinetobacter was used
for isolation of drug-resistant strains, such as E. coli blaCTX-M-2,
P. mirabilis blaCTX-M-2, K. pneumoniae blaIMP-1, E. cloacae blaIM-1,
Multidrug-resistant P. aeruginosa (MDRP) blaIMP-1, MDRP blaVIM-2,
permeability decreasing MDRP, MRAB blaIMP-1, MRAB blaOXA-
23, MRAB blaOXA-51-like and S. maltophilia. There were incubated
at 35ºC for 18−72 h. For the clinical trial, 5,740 specimens from the
pharyngeal swabs, urine and rectal swabs, and 6,617 swab specimens
from environmental materials were plated on this medium and incubated
at 35ºC for 18−72 h.
Results: In the trials of stock strains, three genotypes of MRAB showed
red and large colonies after cultivation for 18 h at 35ºC. ESBL-producing
enteric bacilli did not grow on the medium. However, K. pneumoniae
blaKPC and E. cloacae blaIPM-1 grew as small bluecolonies after 18 h of
cultivation. MDRP blaVIM-2 did not grow on the medium, permeability
decreasing MDRP showed small red colonies after 24 h of cultivation and
MDRP blaIMP-1 yielded small red colonies after 48 h of cultivation.
Twenty-one MRAB were detected from clinical and environmental
specimens.
Clinical and environmental isolates with carbapenems MIC 2 micro
g/ml (P. aeruginosa, P. ﬂuorescens, S. maltophilia, C. indologenes and
A. xylosoxidans) grew as small red colonies on this medium after
cultivation for 24−48 h. P. putida isolates with carbapenems MIC <1
micro g/ml yielded small red colonies on this medium after incubation
for 24 h.
Among red colonies suspected Acinetobacter were easily discriminated
from other genus by oxidase test and Gram staining.
Conclusion: The novel selective medium CHROMagar Acinetobacter
supplemented with KPC was useful for detecting our cases with MDRB
blaOXA-51-like. In addition, it was especially valuable for active
surveillance of specimens containing multiple bacteria, such as those
from the pharynx, urine, faeces and the environment.
P716 MDR Acinetobacter baumannii faecal colonisation of nursing
home residents of northern Portugal
D. Gonc¸alves*, H. Ferreira (Porto, PT)
Objectives: Our work, in fecal colonization with ESBL producers
in nursing home (NH) residents, showed that we could also ﬁnd
carbapenem-resistant isolates. The aim of our work was the detection of
carbapenem-resistant Gram negatives, in the fecal ﬂora of NH residents,
in the North of Portugal, including Porto metropolitan area.
Methods: Faecal samples of NH residents from two NH of Porto
Metropolitan area and one in the North of Portugal, were collected during
2008 and 2009. Samples were suspended in BHI. Isolates were selected
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in MacConkey agar with ceftazidime (2mg/l), cefotaxime (2mg/l),
aztreonam (2mg/l) and imipenem (1mg/l). Colonies were randomly
selected and susceptibility to antimicrobial agents was determined by
agar diffusion methods according to the CLSI guidelines. Carbapenem-
resistant isolates were obtained from imipenem containing plates and
also from other antibiotic selective media. Phenotypic identiﬁcation of
the selected isolates, was achieved by ID 32 GN. b-lactamases were
characterized by isoelectric focusing. MICs were determined by the
Etest methodology in Mueller-Hinton agar. Hodge test, was carried out
according to the CLSI guidelines, bioassays and inhibition studies were
done according to the literature.
Results: Our work showed the presence of 7 non fermenter isolates,
identiﬁed as Acinetobacter baumannii by ID 32 GN, from three different
nursing homes in the same region but geographically apart. Susceptibility
testing showed a multi-resistant phenotype including carbapenems and
ﬂuoroquinolones and susceptibility to amikacin. MICs to imipenem were
over 16mg/l, to meropenem were over 8mg/l and to cefotaxime were
over 32mg/l. Bioassays and Hodge test, showed carbapenem degradation
in representative isolates.
Conclusions: Hospitals of Porto urban area, have already experienced
the installation of outbreaks of MDR Acinetobacter baumannii of
difﬁcult resolution, by patients transferred from hospitals in the same
metropolitan area. NH of this area interchanging patients with local
hospitals, might function as reservoirs of MDRGN contributing for
outbreaks in particularly important hospital wards. This question should
be addressed as a relevant public health threat, once it might also
contribute for community spread of MDRGN via domiciliary care of
dependent people and dispersion to the healthy population. Our work
seems to suggest the utility of pre-admission screening of MDRGN in
the fecal ﬂora of nursing home residents.
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P717 RNase-mediated post-transcriptional regulation of gene
ompA seems to be the major mechanism of carbapenem
heteroresistance in A. baumannii
M. Samiotaki, M. Panopoulou, G. Panayotou, A. Ikonomidis* (Athens,
Alexandroupolis, GR)
Objectives: To investigate the molecular mechanism of carbapenem het-
eroresistance in characterized carbapenem heteroresistant Acinetobacter
baumannii (ChRAB) isolates.
Methods: Carbapenem Etest minimal inhibitory concentrations (MICs)
of the native and the respective meropenem heteroresistant populations
of 13 previously characterized ChRAB clinical isolates were tested
after defrosting from one year storage at −80ºC. Sodium-dodecyl-
sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) of protein
crude extract, in-gel protein digestion of bands of interest, nano-high
performance liquid chromatography and mass spectrometer (MS/MS)
analysis for protein identiﬁcation as well as quantitative real-time reverse
transcriptase PCR (qRT-PCR) for the quantiﬁcation of expression of gene
ompA were performed. All molecular techniques were applied to both the
native and the meropenem heteroresistant populations. Etest carbapenem
MICs of the native and the respective meropenem heteroresistant
populations were tested in Mueller-Hinton agar plates containing
30U/mL RNaseOUT RNase inhibitor, to investigate the putative role
of RNases in regulation of carbapenem resistance mechanisms.
Results: Only one isolate AB133 retained stable heteroresistant
subpopulations and was further investigated whereas the respective
heteroresistant subpopulations of the other isolates returned to the native
susceptible phenotype. SDS-PAGE showed a band of approximately
35 to 40kD to be of lower intensity in the heteroresistant population
versus the native population, and MS/MS analysis identiﬁed this
band as the outer membrane protein A (OmpA) when the amino
acid sequence was compared against ATCC17978 genome. qRT-PCR
showed that expression of gene ompA was 1.93 fold of change higher
in the heteroresistant population. For the heteroresistant population,
meropenem MIC in RNaseOUT inoculated Mueller-Hinton agar plates
was more than 3-fold lower (from >32 to 6mg/L) relative to the free-
of-RNaseOUT medium and imipenem MIC was 2-fold lower (from 6 to
1.5mg/L). Native population showed no variations in carbapenem MICs
when RNaseOUT was inoculated in the medium. When RNaseOUT
treated heteroresistant population was analyzed by SDS-PAGE, a band of
approx. 35 to 40kD was present and was identiﬁed as OmpA by MS/MS
analysis.
Conclusions: RNase-mediated post-transcriptional regulation of gene
ompA seems to be the major mechanism of carbapenem heteroresistance
in A. baumannii.
P718 Effect of Sub-MIC concentrations of biocides on the
expression of genes coding for efﬂux pumps and porins in
Acinetobacter baumannii ATCC 19606
F. Ferna´ndez-Cuenca*, M.C. Go´mez-Sa´nchez, F. Caballero, S. Ballesta,
J. Vila, L. Martı´nez-Martı´nez, G. Bou, J. Rodrı´guez-Ban˜o, A´. Pascual
(Seville, Barcelona, Santander, La Corun˜a, ES)
Objective: We analyzed the ability of sub-MICs concentrations of ﬁve
biocides commonly used in hospitals to affect the expression of genes
coding for efﬂux systems and porins related with antimicrobial resistance
and/or virulence in Acinetobacter baumannii ATCC 19606 (Ab).
Methods: The biocides evaluated were domestic bleach (DB), Sterillium
(ST; propan-2-ol, propan-1-ol, mecetronium ethyl sulfate), Bdine (BT;
povidone iodine), chlorhexidine digluconate (CHX) and benzalkonium
chloride (BKC). The Ab was grown in i) Mueller-Hinton broth
containing concentrations of biocides equivalent to the respective 0.25x
MIC and ii) Mueller-Hinton broth without biocides (control). Expression
of genes coding for adeB, adeJ, abeM, OmpA, CarO, OprD-like and
the Omp 33−36 kDa was determined by real time RT-PCR in a Light
Cycler 2.0 using speciﬁc oligonucleotides and SYBR Green I. Gene
expression was normalised with the 16S rDNA. Relative gene expression
was calculated using the 2(-DeltaDeltaCt) method. Expression of genes
in Ab grown with no biocides was set as 1 (reference).
Results: See table.
Conclusions:
1. Sub-MICs concentration of biocides increased the expression of most
of the efﬂux-related genes analysed, particularly adeB and abeM.
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2. For porin genes, there was also an increased expression, although it
was lower (except for oprD-like using BCK), than that observed with
the efﬂux genes.
3. Some biocides, like BKC, were stronger inducers of the expression
of eﬂux and porin genes than others.
P719 Effect of environmental factors on outer membrane proteins
expression and antimicrobial susceptibility of multi-resistant
clinical isolates of Escherichia coli
B. Ruiz Del Castillo*, E. Roma´n, L. Martı´nez-Martı´nez (Santander, ES)
Objectives: OmpF and OmpC porins represent a relevant component of
resistance in E. coli. Previous studies in E. coli K12 have shown that the
expression of these two porins is regulated in response to environmental
factors. We have studied several environmental factors on both porin
expression and antimicrobial susceptibility of clinical isolates of E. coli.
Methods: Twelve isolates, representative of the more frequent porin
patterns expressed by 112 clonally-unrelated (deﬁned by Rep-PCR)
multiresistant E. coli isolated from different patients were studied.
OMP expression and susceptibility to amoxicillin (Amx), ceftazidime
(Caz), ertapenem (Ert), gentamicin (Gm) and ciproﬂoxacin (Cip) were
evaluated in different conditions of osmolarity [Mueller-Hinton broth
(MH), Nutrient broth (NB) alone or NB plus 20% sorbitol], temperature
(MH or NB at 25ºC, 30ºC, 37ºC or 41ºC) and pH (MH or NB adjusted to
pH 8.5, 7.2, 5.5 or 5.0). OMPs were obtained from sonicated cells treated
with sarcosyl and separated in SDS-PAGE. MICs were determined by
microdilution (CLSI). In addition, RT-PCR was performed for measuring
the level of the efﬂux pump AcrB.
Results: None of the 12 isolates overexpressed AcrB. All of them
expressed both OmpC and OmpF when grown in standard conditions
(MH, 37ºC pH 7.2). None of the three factors we studied inﬂuenced
the MICs of Ert or Amx. No relevant changes in porin patterns were
observed when the organisms were grown in NB with or without sorbitol,
although the MICs of Gm were at least 4 times lower in NB alone than
in MH. At 41ºC, some isolates tested in MH lost OmpC and presented
increased Gm MICs. Variation in the expression of OmpF was also
observed when organisms were grown in media with pH of 5.5 or 5.0,
and in these pH conditions increased CMIs of Caz, Cip and Gm were
observed.
Conclusions: In the clinical isolates we have studied, the effects of
osmolarity, temperature or pH on porin expression are different from
those described for the laboratory strain E. coli-K12. High temperature or
low pH affect porin expression and have a moderate effect on the activity
of Caz, Cip or Gm. The increased activty of Gm in low-osmolarity
medium is unrelated to porin changes.
P720 Genome analysis of human multidrug-resistant strain of
Enterobacter aerogenes
S.M. Diene, C. Robert, A. El Filali, M. Henry, S. Azza, D. Raoult,
J.M. Rolain* (Marseille, FR)
Objective: Enterobacter aerogenes is a common and important human
opportunistic pathogen that may cause a wide variety of nosocomial
infections. In this study we report the complete genome sequence of an
E. aerogenes strain isolated in our institution which showed successive
resistance to all available antibiotics including imipenem and colistin in
a patient who died from this infection despite antibiotic treatment. The
aim of our study was to identify and decipher all resistance determinants
of this pan-resistant isolate using genome sequencing approach.
Method: Whole shotgun sequencing was used to fully sequence this
genome. The shotgun libraries of 4 and 9 kb generated were analyzed
and assembled using Phred_Phrap and Consed software suite. Genome
annotation was performed using online bioserver RAST server (Rapid
Annotations using Subsystems Technology). Standard PCR ampliﬁcation
and sequencing were used to improve sequence regions of low quality
on genomic contigs and to characterize putative mutations on candidate
genes involved in antibiotic resistance.
Principal ﬁndings: The genome of E. aerogenes comprises a
chromosomal DNA estimated at 5.37 Mb with a G+C content of 55% and
one circular plasmid of 162.182 bp in size. The functional annotation of
the chromosome gave a total of 5113 predicted coding sequences (CDS)
with 3197 (62.53%) being assigned to a biological function including
as many as 30 antibiotic resistance encoding genes, 49 antiseptic and
heavy-metal resistance encoding genes and more than 100 efﬂux pump
systems. Surprisingly, as compared to other available complete genomes,
E. aerogenes genome appears to be more closely related to Klebsiella
pneumoniae and not to E. cloacae species. Interestingly, the E. aerogenes
conjugative plasmid carries many mobile genetic elements including
antibiotic, antiseptics, and heavy metal resistance encoding genes.
Finally, we report here the potential molecular mechanism of colistin
resistance in this clinical isolate mediated by a single chromosome
mutation (G157A) on pmrA gene as compared to a parental susceptible
isolate in the PmrAB two-component regulatory system known to be
involved in polymyxin resistance.
Conclusion: Our study conﬁrms that whole genome sequence is a critical
approach to quickly decipher the resistome of any bacterium of clinical
relevance. To the best of our knowledge this is the ﬁrst complete genome
sequence of the E. aerogenes species.
P721 Exposure of Salmonella enterica serovar typhimurium to
high-level biocide challenge can select for novel-mechanism,
multidrug-resistant mutants in a single step
R.N. Whitehead*, T.W. Overton, C.L. Kemp, M.A. Webber (Birmingham,
UK)
Objectives: Biocides are used in a wide range of domestic and industrial
products to control microbial growth. There are concerns that biocide
exposure is helping drive selection of antibiotic resistant bacteria due to
common mechanisms of resistance. The aim of this study was to expose
S. enterica to working concentrations of biocides to identify if this single
step exposure can select for multidrug resistant (MDR) mutants.
Methods: Salmonella enterica serovar Typhimurium was challenged
with 4 biocides of differing modes of action at recommended-use
concentration. Flow cytometry was used to investigate the physiological
state of the cells after biocide challenge. After 5 hours in biocide,
live, viable cells were sorted and recovered after exposure to 2 of
the biocides. The recovered cells were tested for their drug resistance
proﬁle, real-time investigation of efﬂux activity was studied by the uptake
and accumulation of marker substrate dye and the expression of genes
responsible for efﬂux and stress response was assessed by QRT-PCR and
dHPLC analysis.
Results: Flow cytometry identiﬁed sub-populations of S. Typhimurium
capable of surviving working-level biocide challenge. The recovered cells
were multi-drug resistant and showed a marked increase in efﬂux activity.
The cells were found to over-express the efﬂux pump AcrEF and the
regulator protein MarA. However, compared to the parent strain, they
repressed the expression of AcrAB and RamA.
Conclusions: The data shows that high level biocide exposure can select
for MDR efﬂux mutants. Interestingly, it appears to be the AcrEF efﬂux
system not the AcrAB-TolC system that is facilitating this survival.
These data demonstrate the redundancy in MDR regulatory pathways
in Salmonella and show that Salmonella can survive extreme biocide
exposure if de-repression of MDR pumps has occurred.
P722 Evaluation of quinolone resistance determining region
mutations and efﬂux pump expression in Neisseria
meningitidis resistant to ﬂuoroquinolones
M. Castanheira*, L. Deshpande, R. Jones, D. Farrell (North Liberty, US)
Objectives: To evaluate additional ﬂuoroquinolone resistance (R)
mechanisms in N. meningitidis (NMEN) strains carrying a GyrA T91I
alteration and displaying elevated ciproﬂoxacin (CIP) MIC values (0.06
and 0.25mg/L). CIP-R in NMEN is rare in North America, and to date
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only three isolates with this phenotype have been described in the United
States (USA).
Methods: Serotype B NMEN strains (3; courtesy of Dr. Henry M. Wu,
CDC-USA) collected from USA hospitals (North Dakota [1 strain]
and Minnesota [2 strains]) displaying elevated CIP MICs and gyrA
mutation (T91I) were susceptibility tested by CLSI (M07-A8, 2009)
reference broth microdilution method. Quinolone R determining region
(QRDR) sequencing analysis of gyrA, gyrB, parC and parE was
performed. Mapping of the mtrCDE efﬂux system was carried out
using primers anchoring in the components of the pump, coverage
included intergenic regions. mRNA expression for pump components
was evaluated by quantitative reverse-transcriptase real-time PCR (qRT-
PCR) and comparing to NMEN ATCC 13102 control.
Results: Two strains showed CIP and levoﬂoxacin MIC values at
0.25mg/L and one strain had a CIP MIC at 0.06mg/L. parC mutations
causing alterations H141N and P186S were detected in all strains. In
addition to T91I, the two strains displaying higher MIC values also
possessed a T173A alteration on GyrA. All components of the efﬂux
pump mtrCDE (also associated to rifampin-R) were intact and had the
correct amplicon size, excluding the presence of insertions/deletions
and the Correia element within the pump operon. The promoter region
(mrtR) was fully sequenced and was distinct from the susceptible control.
Isolates 7782J and 7783J had identical promoter region, whereas isolate
7784J showing lower ciproﬂoxacin MIC values possessed a different
sequence. Expression experiments showed discrepancies in the mRNA
in pump components. The most remarkable difference was for the outer
membrane protein (OMP) encoded by mtrE that was hyperexpressed on
strain 7784J showing a 0.06mg/L CIP MIC (>3600X elevated compared
to control).
Conclusions: Our results indicate that T91I alteration on GyrA had
an important role in elevated CIP MIC values observed in these
NMEN strains. Additional R determinants were present, including other
gyrA and parC QRDR mutations. Alterations in expression of mtrCED
pump appear to have minimal contribution to CIP-R. This ﬁnding was
supported by low rifampin susceptibility results (MIC, 0.03mg/L).
P723 Phenotypic adaptation to isoniazid in Mycobacterium
tuberculosis: a pathway to multidrug-resistant tuberculosis
D. Machado*, I. Couto, L. Rodrigues, L. Amaral, M. Viveiros (Lisbon,
PT)
Objectives: Multidrug resistant tuberculosis (MDRTB) is caused by
M. tuberculosis strains resistant to isoniazid (INH) and rifampicin
(RIF). In this work, we studied the mechanism by which MDRTB
develops and how the differential expression of the main efﬂux pumps
in M. tuberculosis prior to, during and after the development of a MDR
phenotype interacts with the resistance by mutation.
Methods: The work was based on the in vitro inducement of an MDR
phenotype through the exposure to the critical concentrations of INH
and RIF, constant and independently, of 4 M. tuberculosis strains, 2 fully
susceptible (including the H37Rv reference strain) and 2 monoresistant
to RIF. Periodically, we assessed: (i) the susceptibility levels to INH
and RIF, with the aid of the new BACTEC MGIT 960 - TB eXIST
module; (ii) efﬂux pump inhibitors (EPIs), verapamil, thioridazine and
chlorpromazine, for their ability to inhibit/reduce the INH resistance
phenotype; (iii) the expression level of the efﬂux pump genes mmpL7,
mmr, tap, P55 and efpA by RT-qPCR and (iv) the efﬂux activity by a
semi-automated ﬂuorometric method.
Results: All the strains exposed to INH became resistant to INH after
3 weeks of exposure. The INH resistance was reversed or reduced by
EPIs in all strains. RT-qPCR analysis detected over-expression of all
efﬂux pump genes tested. Increased efﬂux activity was demonstrated
in all the INH exposed strains which was inhibited in the presence of
EPIs. The strains initially susceptible to INH became monoresistant to
this antibiotic. When the RIF resistant strains were exposed to INH,
they became MDR. Throughout the INH exposure process different
alterations in the katG gene were detected and characterized, namely
point mutations and deletions in the katG gene. No phenotypic or
genotypic alterations were detected during the exposure to RIF.
Conclusion: The results demonstrate the relevance of efﬂux as a
mechanism of resistance to INH in M. tuberculosis strengthening the
hypothesis that the activity of efﬂux pumps allows the maintenance of a
INH resistant population in a patient under a sub-optimal therapeutic
level, from which INH genetically resistant mutants emerge. These
results illustrate different strategies by which M. tuberculosis strains
respond when exposed to clinically relevant concentrations of the same
antibiotic, which may result in the emergence of MDRTB.
P724 Contribution of efﬂux activity to isoniazid resistance in
Mycobacterium tuberculosis complex
L. Rodrigues*, D. Machado, I. Couto, L. Amaral, M. Viveiros (Lisbon,
PT)
Objectives: Tuberculosis (TB) is still a major public health problem
worldwide and the increase of multi and extensively drug resistant TB
(MDRTB and XDRTB) is a threat to the success of the TB control
programmes. MDRTB is caused byMycobacterium tuberculosis resistant
to at least isoniazid (INH) and rifampicin (RIF), the main drugs used
in TB therapy. INH resistance is mainly due to mutations in the katG
and inhA genes. However, approximately 20−30% of INH resistant
M. tuberculosis isolates do not have mutations in any of the genes
associated with INH resistance. This suggests that other mechanism(s)
may be involved, namely efﬂux pump (EP) systems that extrude the drug
to the exterior of the cell. In a previous work, we have induced clinical
INH susceptible M. tuberculosis isolates and the H37Rv (ATCC27294)
reference strain to high-level resistance to INH, by gradual exposure to
increasing concentrations of this drug. In the present study, we have
characterized these strains with respect to their EP activity and its
contribution to INH resistance.
Methods: M. tuberculosis (H37Rv and two clinical isolates) and
M. bovis BCG strains induced to INH resistance were evaluated for their
susceptibility to INH in the presence and absence of the EP inhibitors
(EPIs) chlorpromazine (CPZ), thioridazine (TZ) and verapamil (VP),
using the BACTEC MGIT 960 system. EP activity was assessed by a
semi-automated ﬂuorometric method that uses ethidium bromide (EtBr)
as an EP substrate and the expression level of 5 genes coding for EPs
was quantiﬁed by real-time qRT-PCR.
Results: The INH induced strains presented an increased EtBr efﬂux
that was inhibited by CPZ, TZ and VP. Exposure to INH also promoted
the over-expression of the EP genes efpA, mmpL7, mmr, p55 and tap in
the induced strains. The EPIs decreased INH resistance in the induced
strains, in particular VP promoted a signiﬁcant reduction (at least 4-fold)
of the MIC of INH in all strains tested and caused reversal of resistance in
M. tuberculosis H37Rv(INH) and M. bovis BCG(INH). Altogether, these
results correlate efﬂux activity with INH resistance in M. tuberculosis.
Conclusion: This study demonstrates that EPs play an important role
in INH resistance in M. tuberculosis. The development of EPIs that can
restore the antimicrobial activity of the antibiotic subject to efﬂux is an
approach that can be useful in order to prevent the emergence of this
resistance and for the development of new effective anti-TB drugs.
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P725 Differential recognition of quinolones by efﬂux pumps in
Gram-positive (Staphylococcus aureus, Streptococcus pneumo-
niae) and Gram-negative (Pseudomonas aeruginosa) bacteria
C. Vallet*, J. Buyck, F. El Garch, P. Tulkens, F. Van Bambeke (Brussels,
BE)
Objectives: Active efﬂux may confer resistance to quinolones in both
Gram(+) and Gram(−) bacteria, but structural features determining their
recognition by transporters remain largely unknown. We have examined
the impact of typical representatives of 3 superfamilies of transporters,
each active in a main pathogen (NorA [MFS; S.a.]), PatA/B and PmrA
(ABC and MFS, respectively; S.p.), and MexAB-OprM, MexCD-OprJ,
MexEF-OprN, MexJK-OprM, and MexXY-OprM (RND; P.a.) on the
activity of 14 quinolones (see legend of the ﬁgure).
Methods: MICs were measured following CLSI recommendations using
isogenic strains differing in the level of expression of the corresponding
transporter(s) (S.a.: ATCC25923 vs. SA-1 overexpressing norA [Ba et al.
AAC 2006, 50:1931−6]; S.p.: SP295 overexpressing patA/B and pmrA
vs. its corresponding disruptants [El Garch et al. JAC 2010, 65:2076−82];
P.a.: PAO1 with basal expression of Mex efﬂux systems vs. PA509
[disruptant for 5 RND transporters; Mima et al. J Bacteriol. 2007,
189:7600−9]). The impact of efﬂux was expressed as the ratio of MIC
of the corresponding transporter(+)/transporter(−) isogenic strains (with
addition of 10mg/L reserpine to inhibit NorA in ATCC25923).
Results: The ﬁgure shows the correlation between the changes in
MIC observed between S.a. and S.p. (NorA vs PatA) and between
S.a. and P.a. (NorA vs Mex). There was a high degree of correlation
between efﬂux mediated by the two types of transporters in Gram(+)
bacteria (R2 = 0.8289 for PatA vs NorA and 0.7943 for PatB vs NorA
[not shown]) with PEF, SPX, GAR, DIF, and MXF being almost not
affected, and CIP and NOR (more hydrophilic ones) being most affected.
Disrupting pmrA was without effect on all quinolones (not shown).
Conversely, all quinolones were affected almost to the same level by
Mex transporters, making the correlation between NorA (or PatA [not
shown]) and Mex largely irrelevant.
Conclusion: Although belonging to very different superfamilies, NorA
and PatA/PatB show similar substrate speciﬁcities with respect to
quinolones, but mainly affect those that are least recommended today for
treating infections caused by these organisms. Of note, PmrA, although
also an MFS transporter, seems not to efﬂux any quinolone. Conversely,
Mex efﬂux systems transport all quinolones, including those that are
currently used in therapy, which contributes to reduce susceptibility, even
in wild-type strains.
P726 Rapid mutation of Staphylococcus aureus norA efﬂux pump
promoter after induction with ciproﬂoxacin is associated with
an increased norA expression and an increased ciproﬂoxacin
MIC
P. Wolffs*, I. Spyckerelle, E. Beuken, E. Stobberingh (Maastricht, NL)
Objectives: NorA is a chromosomally encoded efﬂux pump of S. aureus,
which is known to be involved in a.o. the efﬂux of ﬂuoroquinolones, such
as ciproﬂoxacin. In literature as well as in our previous work we showed
that mutations in the norA gene and promoter were associated with
an increased expression of norA. However, in several cases, sequences
that were associated with increased expression differed only in one
single base mutation from sequences associated with a wildtype (wt)
expression. The goal of this study was to observe whether mutations in
the norA gene or its promoter would occur in strains with a norA wt
expression after exposure to ciproﬂoxacin.
Methods: Three clinical S. aureus isolates with a ciproﬂoxacin MIC of
0.125–0.25mg/l and wt expression of norA were in duplicate subjected
to increasing concentrations of ciproﬂoxacin (starting at 0,5 MIC)
during two weeks. Antibiotic susceptibility proﬁles were determined
by microbroth dilution. The norA promoter and part of the norA gene
as well as gyrA and grlA were sequenced to determine the presence
of mutations, and relative gene expression experiments were performed
using 16S rDNA as a housekeeping gene.
Results: All three S. aureus strains (tested in duplicate) showed an
increase of the ciproﬂoxacin MIC to 8−32mg/l. Results showed that 3 out
of 6 replicates had obtained mutations in gyrA and grlA, of which 2 had
acquired a mutation in the norA promoter. Gene expression experiments
showed that the norA mutation was associated with an increase in norA
expression of >4-fold. The implications of this norA overexpression were
seen in one strain, of which one replicate showed only the mutations in
gyrA and grlA whereas the other showed additionally the mutation in
norA: the latter showed a 2 to 4-fold increase in ciproﬂoxacin MIC.
Retrospective analysis showed that norA mutation was obtained as
rapidly as within 5 days of the start of the experiment. All the acquired
mutations remained stable during daily subculturing for two more weeks
in the absence of ciproﬂoxacin.
Conclusion: In 2 S. aureus strains mutations in the norA promoter
were acquired after induction with ciproﬂoxacin. These mutations were
associated with an increase in norA expression and a 2 to 4-fold increase
in ciproﬂoxacin MIC. Future further studies will have to show which
mechanism was behind the increase in ciproﬂoxacin MIC in the strains
where no mutations were observed in either gyrA, grlA or norA.
P727 Total genome sequencing of multidrug and efﬂux pump
inhibitor resistant Streptococcus pneumoniae reveals new
roles for genes in PatAB-mediated antibiotic resistance
A. Baylay*, L.J. Piddock (Birmingham, UK)
Objectives: Over-expression of the ABC transporter genes patA and
patB has been shown to be associated with efﬂux-mediated multidrug
resistance in laboratory strains and clinical isolates of Streptococcus
pneumoniae. However, the cause of the over-expression of these genes
is unclear. The aim of this study was to use next-generation sequencing
techniques to identify candidate genes that affect expression of patA and
patB.
Methods: The complete genome sequences of a reserpine-resistant
laboratory mutant, M184, which over-expresses patA and patB, and
its parent strain, R6, were determined by Illumina Solexa sequencing
and compared to each other using the Xbase next-generation pipeline to
identify mutations. Genes containing mutations that affected their coding
sequences were counted as candidates for affecting expression of patA
and patB. The S. pneumoniae cluster analysis tool, ClusterSP, was used to
determine which of the candidate genes were part of the pneumococcal
core genome and therefore most likely to be involved in resistance.
To determine whether any of the observed mutations were natural
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polymorphisms, gene sequences from 17 published pneumococcal
genomes were aligned using ClustalW.
Results: Fourteen genes in M184 were found to contain mutations
that altered their protein coding sequence. By excluding natural
polymorphisms and only considering genes that are part of the core
genome of S. pneumoniae, the number of candidate genes was reduced
to ten. These ten genes belong to various functional groups including
metabolism (three genes), transcription (three genes), translation (one
gene), membrane transport (one gene) and regulation (one gene). One
candidate gene of unknown function was also identiﬁed. One gene
encoding a regulatory protein was truncated in M184, and this mutation
was conﬁrmed by PCR and sequencing. The same gene was also found
to contain a mutation in its putative DNA binding region in another
reserpine-resistant mutant strain, M168, which also over-expresses patA
and patB.
Conclusion: These data suggest that the regulatory protein identiﬁed
in this study could control patA and patB expression, and hence
susceptibility to antibiotics. This is the most promising candidate gene
in our set as regulatory proteins are known to regulate expression of
efﬂux pumps in other bacteria. This would constitute a novel role for
this protein in pneumococcal antibiotic resistance.
P728 Variability and inducibility of the mef(A)-msr(D) region in
erythromycin-resistant Streptococcus pyogenes
L.A. Vitali*, M.C. Di Luca, V. Iebba, D. Petrelli, I. Moltoni, W. Bahnan,
M. Prenna, S. Ripa (Camerino, Rome, IT)
Objectives: In streptococci, resistance towards 14- and 15-membered
macrolides may be due to efﬂux pumps belonging to the major facilitator
superfamily, encoded by mef(A) genes. mef(A) is associated with
msr(D), that codes for an ATP-dependent efﬂux pump. In Streptococcus
pyogenes this gene cluster is inserted in and carried by prophages or
transposons. We studied the variations in the sequence of the mef(A)-
msr(D) region, analysed their correlation with the level of macrolide
resistance, and we investigated the inducible expression of the efﬂux
system.
Methods: The 3,200 bp long mef(A)-msr(D) region of 28 S. pyogenes
strains with an M-phenotype of macrolide resistance was ampliﬁed
and sequenced. MICs for erythromycin were determined by the broth
microdilution method. Six out of 29 strains plus a reference strain (m46)
were cultured with or without sub-inhibitory inducing concentration
of erythromycin. After induction, the cultures were challenged with
erythromycin at different concentrations and the growth monitored. Total
RNA was extracted from induced and non induced cells of the reference
strain and analysed by northern blot and RT-PCR.
Results: The strains showed MICs for erythromycin ranging from 4
to 32mg/L. Cluster analysis showed an essential correlation between
the sequence of the mef(A)-msr(D) region and the MIC. In addition,
multivariate analysis indicated that the acquisition of the macrolide efﬂux
genes occurred prior to the divergence of the prophages carrying them.
The growth curves showed a pattern of induction of the macrolide
resistance that was more evident at the sub-inhibitory challenge
concentrations. In non-inducing conditions the amount of mef(A)-
speciﬁc transcript was below the detection limit of either the RT-PCR and
the Northern blot. On the contrary, in the induced samples a main band
3 Kb in size was visible. The transcript contained the sequences coding
for both mef(A) and msr(D), as conﬁrmed by Northern blot analysis
with an msr(D) speciﬁc probe.
Conclusion: In S. pyogenes, the increase in MICs for erythromycin could
be overall explained by the accumulation of mutation within the sequence
of the mef(A)-msr(D) region. Similarly to the case of pneumococci,
efﬂux-mediated macrolide resistance in S. pyogenes is inducible. In
agreement with previous genetic data suggesting that the product of
both genes contributes to the overall resistance to macrolides, mef(A)
and msr(D) are co-transcribed as a single bicistronic mRNA.
P729 Impact of inoculum on the antibacterial effect of levoﬂoxacin
and moxiﬂoxacin against S. pneumoniae strains with deﬁned
resistance mechanisms studied in an in vitro model of
infection
K.E. Bowker*, A.R. Noel, S. Tomaselli, H. Elliott, A. MacGowan
(Bristol, UK)
Objectives: S. pneumoniae (Sp) bacterial loads may be very high in
pneumonia. Fluoroquinolones (FQ) are thought to be unaffected by
bacterial inoculum, however, the long term impact on antibacterial effect
of high bacterial loads is rarely studied in pre-clinical models as it is
technically difﬁcult to sustain Sp growth over a period of days. We used
an in vitro pharmacokinetic model of infection to study the ABE of two
FQs at inocula of 106 CFU/ml (standard) and 108 CFU/ml (high) on a
range of Sp with deﬁned FQ resistance mechanisms over a 96h period.
Methods: Five Sp strains: a wild type levoﬂoxacin/moxiﬂoxacin
(levo/moxi) MIC 1.5/0.38mg/L; efﬂux phenotype levo/moxi MIC
0.75/0.38mg/L; parC mutation levo/moxi MIC 1.5/1.5mg/L; parC + gyrA
mutation levo/moxi MIC 6/2mg/L; parC + gyrA mutation levo/moxi MIC
6/4mg/L. Free drug concentrations associated with levo 750mg 24hly,
levo 500mg 12hly and moxi 400mg 24hly over 96h were simulated. A
standard (106 CFU/mL) and high inoculum (108 CFU/mL) were used.
Results: The log changes after 24h and 96h drug exposure are shown
in the table.
As 108 CFU/ml is the maximum sustainable bacterial density growth in
the in vitro model above this inoculum does not occur. High inoculum
resulted in slower clearance of wild type Sp from the model and regrowth
with levo 750 24h. With the efﬂux strain, kill was attenuated at high
inoculum and regrowth occurred with levo. With strains with mutation
in the QRDR, little or no killing occurred at high inocula, while at
standard inocula early reduction in count was noted with the parC strain
and one parC + gyrA strain.
Conclusion: Inoculum impacts on moxi and levo antibacterial effect.
Levo is more subject to inoculum effects against wild type and efﬂux
strains. Both moxi and levo show an inoculum effect with strains with
QRDR mutations.
K. pneumoniae: the worst threat amongst
Enterobacteriaceae?
P730 Closely related carbapenem-resistant K. pneumoniae from
hospital inpatients and community in Mid-West of Ireland
I. Condon, C. Ludden, M. Corcoran, N. O’Connell, M. Cormican*,
T. Boo, D. Morris (Limerick, Galway, IE)
Objectives: The worldwide emergence of carbapenem resistant Enter-
obacteriaceae is a major public health problem. Of particular concern
is the rapid international dissemination of KPC producing Klebsiella
pneumoniae. The aim of this project was to screen all Enterobacteriaceae
isolated at the Mid-Western Regional Hospital for carbapenemase
production and to characterise carbapenem resistant Enterobacteriaceae
(CRE) by phenotypic and molecular methods.
Methods: All Enterobacteriaceae collected from all specimen types
since January 25th 2010 were screened for carbapenemase production
in accordance with Clinical Laboratory Standards Institute (CLSI)
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screening and conﬁrmatory procedures. Carbapenemase production was
additionally conﬁrmed using commercially available tablets containing
meropenem and meropenem supplemented with dipicolinic acid,
boronic acid and cloxacillin in accordance with the manufacturers
instructions (Rosco Diagnostics, Taastrup, Denmark). Conﬁrmed CRE
were examined for susceptibility to 13 antimicrobial agents by disk
diffusion and screened for the presence of blaVIM, blaIMP and blaKPC
by PCR as previously described. Pulsed ﬁeld gel electroporesis (PFGE)
using Xba1 was performed on all CR K. pneumoniae isolates.
Results: Seven isolates of CRE were detected including 6 K. pneu-
moniae. Isolates were conﬁrmed as carbapenemase producers by both
phenotypic methods applied. These were collected from 5 patients over
a 9 month period. One of the K. pneumoniae was isolated from a non-
acute elderly-care facility from whom a CR E. coli was also isolated. All
CR K. pneumoniae were susceptible to 3/13 antimicrobial agents tested:
streptomycin, tetracycline and gentamicin. All 6 isolates harboured
blaKPC. PFGE analysis identiﬁed 5 individual pulsed ﬁeld proﬁles
(PFPs) although all were 81% similar by Bionumerics analysis. Two
isolates collected from the same patient had distinguishable but closely
related PFPs (86%). Two isolates had PFPs which were indistinguishable
from the PFP of a previously reported KPC producing K. pneumoniae
isolated at the same hospital in 2009.
Conclusions: There is evidence of clonal dissemination of KPC-
producing K. pneumoniae over an 18 month period in one region
of Ireland. It is possible that CR K. pneumoniae is more widely
disseminated and early detection in this region relates to a process of
active screening for CRE.
P731 Antimicrobial resistance in K. pneumoniae in hospitalised
and outpatients in Germany, 2009
I. Noll*, B. Schweickert, M. Feig, G. Krause, T. Eckmanns (Berlin, DE)
Objectives: A major ﬁnding of the European Antimicrobial Resistance
Surveillance Network (EARS-Net) Report 2009 is the high prevalence of
resistance in invasive K. pneumoniae isolates from hospitalised patients
to third-generation cephalosporins (3GC), ﬂuoroquinolones (FQ) and
aminoglycosides (AG) and the high level of combined resistance to these
classes in most European countries. Data from the German Antimicrobial
Resistance Surveillance (ARS) System are used to extend the study of
resistance to isolates from urine and respiratory samples as well as to
outpatients.
Methods: Analysis is based on non-duplicate isolates of K. pneumoniae
collected in 2009 by nine laboratories covering 160 hospitals and 865
practices. Species identiﬁcation and antimicrobial susceptibility testing
is performed by VITEK 2, results are evaluated according to CLSI
guidelines. Isolates are classiﬁed as resistant to an antibiotic class if they
show resistance to one of its agents: 3GC: ceftazidime or cefotaxime
or ceftriaxone, FQ: ciproﬂoxacin or levoﬂoxacin AG: gentamicin or
tobramicin or amikacin. The distinct class resistances are combined to
resistance patterns.
Results: The sample is composed of 5,548 non-duplicate K. pneumoniae
isolates from inpatients (blood: 299; respiratory samples: 1,118; urine:
4,131) and 2,666 isolates from outpatients (respiratory samples: 173;
urine: 2,493). Results are displayed in table 1. Proportions of resistance
are highest against FQ in all subsets ranging from 21.1% in blood
cultures from inpatients to 4.6% in respiratory samples from outpatients
followed by 3GC (16.4% to 3.5%) and AG (13.4% to 2.3%). Regarding
resistance against the three antibiotic classes simultaneously reveals that
triple resistance is the most frequent pattern in all inpatient subsets
reaching 10% in blood cultures, 9.3% in respiratory samples and 6.8%
in urines. In outpatient samples, single resistance against FQ is the most
frequent pattern followed by triple resistance in second place accounting
for 3.0% in urine samples and 1.2% in respiratory samples.
Conclusions: Surveillance limited to invasive isolates from hospitalised
patients like EARS-Net captures the sector with highest levels of
antimicrobial resistance in K. pneumoniae; the extended approach of
ARS reveals an emerging problem in outpatient care that physicians
should be aware of, even if resistance proportions might be overestimated
as samples are more likely to be taken from pre-treated patients.
P732 Antimicrobial susceptibility patterns associated with
European KPC producers
M. Hackel*, C. Lascols, S. Hawser, R. Badal, D. Hoban, S. Bouchillon,
B. Johnson, J. Johnson, M. Dowzicky (Schaumburg, US; Epalinges,
CH; Collegeville, US)
Background: In recent years carbapenem resistance has emerged among
Gram-negative isolates due to the acquisition of carbapenemases, which
usually belong to Ambler class B metallo-b-lactamases (MBLs) or to
KPC-type enzymes. Klebsiella pneumoniae carbapenemase (KPC) is
an Ambler class A b-lactamase that confers resistance to all b-lactam
agents, including carbapenems, cephalosporins, penicillins, and the
monobactam aztreonam Although this enzyme has been found primarily
in K. pneumoniae, it has also been identiﬁed in several other Gram-
negative bacilli. Because the blaKPC gene is carried on a plasmid,
the ease of mobility of this resistance mechanism is of concern and
represents a major threat to the antimicrobial treatment of infections
with Gram-negative organisms. As part of the Tigecycline European
Surveillance Trial (TEST), this study investigated the incidence and
susceptibility proﬁles of KPC producing Gram-negative isolates from
Europe during 2009−10.
Methods: 11,316 Enterobacteriaceae isolated in Europe in 2009−10
had minimum inhibitory concentrations (MICs) determined using broth
microdilution following CLSI guidelines and interpreted according to
EUCAST breakpoints where available. A total of 148 isolates with
meropenem MICs of 2mg/L were screened for the presence of KPC
genes using multiplex-PCR.
Results: Of 11,316 Enterobacteriaceae isolated in Europe in 2009−10,
148 (1.3%) had meropenem MICs of 2mg/L. 52 (35%) of these
148 meropenem non-susceptible isolates were positive for KPC genes.
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All KPC positive isolates were K. pneumoniae. Susceptibility of these
isolates is shown in the table.
Conclusions: The meropenem non-susceptible rate in European Enter-
obacteriaceae from the TEST study in 2009−10 was 1.3%, with 35%
of these (0.5%) positive for KPC. The most active antimicrobial against
these isolates in vitro was tigecycline with an MIC90 of 1mg/L, followed
by minocycline, with an MIC90 of 8mg/L. All other antimicrobials
exhibited susceptibilities of <20%.
P733 Ertapenem-resistant Escherichia coli and Klebsiella
pneumoniae bacteraemia: meropenem as an independent risk
factor, and potential efﬁcacy of imipenem and meropenem
K. Marimuthu*, T. Ng, D. Lye, T. Lim, T. Tan, P. Krishnan, L. Ling,
B. Ang, C. Teng (Singapore, SG)
Objective: We noted increasing ertapenem-resistant (ETP-R) extended-
spectrum b-lactamase (ESBL) positive Escherichia coli (EC) and
Klebsiella pneumoniae (KP) (ETP-R EC/KP) at our hospital. The
objective of this study is to assess risk factors for and treatment outcome
of ETP-R EC/KP.
Method: We conducted a retrospective case-control (1 to 3 ratio) from
1 January 2006 to 30 June 2009. Minimum inhibitory concentration
(MIC) by E-test, multiplex polymerase chain reaction for CTX-M, SHV,
TEM and AmpC, and genotyping for metalloblactamase and KPC were
performed.
Results: Of 12 cases, 10 were KP and 2 were EC. All 12 isolates
produced CTX-M ESBL (91% group 1); 41% carried SHV-11 and 33%
carried TEM-1 genes. Carbapenemases and clonality were not detected.
Compared with the 36 controls, the 12 cases were younger (median age,
64 vs 75 years, P = 0.03) than controls but had similar Pitt bacteraemia
(2.8 vs 3.2), Charlson’s (6.3 vs 6.6) and APACHE II (13.9 vs 14.9)
scores (P> 0.05). On univariate analysis, ETP-R cases were signiﬁcantly
associated with IPM (P = 0.008), MEM (P = 0.032) and ETP (P< 0.001)
exposure, and a history of multidrug-resistant organisms (P = 0.001) in
the preceding 3 months. On multivariate analysis, meropenem was the
only independent predictor of ETP-R EC/KP (adjusted OR 29.1, 95%CI
1.8–465.0, P = 0.017). There was no signiﬁcant difference in mortality
(0% vs 13.8%), mean days to defervescence (3.9 days vs 3.0 days) or
median length of hospital stay (3.9 days vs 3.0 days) between ETP-R
and ETP susceptible EC/KP isolates (P> 0.05). Of the cases, 41.7% were
treated with IPM or MEM only and 25% were treated with a combination
of IPM or MEM with amikacin or polymyxin B. Clinical response was
100% and mortality was 0% with IPM or MEM monotherapy with
MIC <1.
Conclusion: Meropenem use within 3 months was an independent
predictor for ETP-R EC/KP. Ertapenem resistance in KP/EC was
mediated by a combination of ESBL and AmpC enzymes. IPM or MEM
monotherapy remained effective for ETP-R KP/EC with MIC <1.
P734 The epidemiology of carbapenemases and extended-spectrum
b-lactamases among nosocomial Klebsiella isolates
M. Dizbay*, H.S. Ozger, U. Gaygisiz, O. Karasahin, G. Telli (Ankara, TR)
Objective: The aim of the study was to evaluate the epidemiology of
carbapenem resistant Klebsiella isolates in our hospital.
Methods: Consecutive Klebsiella isolates recovered between January
2009 and September 2010 were studied. Klebsiella isolates were
tested by cefotaxime and cefotaxime-clavulanat combined disk diffusion
method for ESBL detection. Ertapenem disks were used for screening
carbapenem resistance. Ertapenem E-test was used for conﬁrmation
of carbapenem resistance. A modiﬁed Hodge was performed in all
resistant isolates. MBL E-test (IPM/IPM-EDTA) was used to detect
metalloblactamase production, and imipenem − boronic acid double disk
synergy method was used to detect KPC carbapenemase production.
Results: Totally 283 Klebsiella spp. isolated from nosocomial infections
were enrolled in the study. ESBL positivity was detected in 61 (21.5)
strains. Overall, 31 of them (10.95%) were resistant to ertapenem. Only
two isolates were carrying both carbapenemase and ESBL type resistance
together. ESBL positivity was statistically higher among the ICU isolates,
but carbapenem resistance did not differ between the units. Among
the ertapenem resistant isolates, MBL production was determined in
15/31 (48.3%) isolates, and KPC carbapenemase in only one isolate
(3.2%). There was no statistical difference in carbapenem resistance
among the isolates regarding to units, clinical samples and type of
Klebsiella isolates. Carbapenem-resistant Klebsiella isolates were also
resistant to 3rd generation cephalosporins (96%), ciproﬂoxacin (96%)
and piperacillin-tazobactam (100%). Tigecycline resistance was detected
in 32% of the carbapenem resistant isolates. Colistin resistance was not
detected in the study.
Conclusions: Our results shows that carbapenem resistance among
Klebsiella isolates is an important problem in our hospital, and
requires urgent application of proper infection control measures. Major
carbapenem resistance mechanism among Klebsiella isolates was the
production of MBL in our study.
P735 Duration of colonisation with carbapenem-resistant Klebsiella
pneumoniae
D. Ben-David*, A. Barsist, I. Tal, Y. Maor, N. Keller, G. Smollan,
G. Rahav (Ramat-Gan, IL)
Background: Carbapenem resistant Klebsiella pneumoniae(CRKP) is
an emerging problem in several healthcare facilities worldwide. Several
studies have recently described the prevalence and risk factors for CRKP
infections. However, the time course of gastrointestinal tract colonization
has not been studied. The objective of this study was to determine the
persistence of CRKP carriage and the adequacy of three consecutive
negative cultures to determine clearance of colonization.
Methods: This study was performed at a 1600-bed tertiary care referral
center in central Israel. Between June 2007 and November 2010, all
CRKP-positive patients were prospectively evaluated for the persistence
or loss of CRKP colonization. On repeated re-admissions, rectal swabs
were obtained at least one week apart during hospitalization. The
likelihood of a negative culture was analyzed given prior culture results
and the time from the initial positive culture. To conﬁrm clearance
of CRKP, real-time PCR assay for blaKPC gene was performed after
three sequential negative cultures. Variables associated with duration of
colonization were documented from medical records.
Results: A total of 245 patients colonized with CRKP had 590 follow-
up cultures. The ﬁrst follow-up culture, collected after a median of 186
days (range 3–1282) following the initial positive isolate, was negative
in 69% (169/245) of cases. Among patients screened within 100 days
of the ﬁrst positive culture, 51% (35/68) were CRKP-negative compared
with 66% (62/94) of patients screened between 101–300 days and 87%
(68/78) screened after 300 days (P = 0.001). After one negative follow-up
culture, the next one was negative in 79% of patients (93/117).
After two negative cultures 84% remained culture-negative (57/68). After
three sequential negative cultures, PCR conﬁrmed clearance in 57 of 62
patients (92%). Residence in nursing home and antibiotic use decreased
the likelihood of clearing CRKP.
Conclusion: The percentage of patients who cleared CRKP colonization
increased signiﬁcantly over time. Three repeated cultures provide a good
estimate of CRKP clearance as compared with PCR testing. At least three
cultures are needed in order to conﬁrm clearance of CRKP colonization.
P736 Colistin-resistant Klebsiella pneumoniae in a tertiary hospital:
epidemiology and investigation of resistance mechanisms
H. Moraitou, S. Papadopoulos*, I. Galani, M. Makarona,
A. Mavrommati, P. Zarkadas, L. Kormali, I. Papazacharia (Athens, GR)
Objectives: The emergence of carbapenemase-producing Enterobacte-
riae is of great concern worldwide. These bacteria are resistant to all
b-lactams and most frequently co-resistant to most other antibiotics.
This fact has led to the revival of polymyxins, in clinical practice. The
aim of this study was to retrospectively record the colistin-resistant
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MDR K. pneumoniae strains (CRKP) isolated in a tertiary hospital
from January to October 2010 and investigate the epidemiology and
the additional resistance mechanisms present.
Material and Methods: From January to September 2010, fourteen
CRKP were isolated in our hospital, from different patients with hospital-
acquired infection, whose records were retrospectively investigated.
Bacterial identiﬁcation and antibiotic susceptibility testing were initially
performed using the Vitek2 automated system (BioMerieux). MICs of
colistin were carried out by Etest (AB, Biodisk). Resistance to colistin
was deﬁned as MIC >2mg/L. All isolates were phenotypically tested for
carbapenemase production, while the presence of blaVIM and blaKPC
was conﬁrmed by PCR. Detection of SHV-type ESBL production was
carried out by PCR. REP-PCR was performed to investigate the clonal
spread of isolates.
Results: All patients (n = 14) had received colistin iv, for at least 7 days
before CRKP isolation. Twelve were ICU patients (86%), whereas the
remaining two patients referred previous ICU hospitalization. Six CRKP
were isolated from blood culture, 4 from iv catheter, 2 from urine, 1
from bronchial secretions and 1 from pleuritic ﬂuid. All isolates showed
additional resistance to b-lactams and carbapenems. Forty-three percent
were susceptible to amikacin, 29% to gentamycin and 50% to tigecycline.
All strains were carbapenemase producers, with two isolates harboring
the blaVIM, eleven the blaKPC and one both genes. Four of the KPC-
positive strains were also ESBL-producers. REP-PCR proved the multi-
clonal proﬁle of CRKP isolates. However the four KPC(+) ESBL(+)
CRKP strains were of the same clone.
Conclusion: Colistin resistance proves to be most common among KPC
producing K. pneumoniae than in VIM (+) strains. The emergence of
colistin-resistant K. pneumoniae is most possibly the result of antibiotic
selective pressure. The excessive use of colistin, in addition to the
endemic spread of MDR K. pneumoniae, results to a serious threat of
infections. Measures should be taken to avoid further dissemination.
P737 KPC-producing Klebsiella pneumoniae in a cohort of urinary
tract infections: clinical features, molecular epidemiology
and outcomes
O. Zarkotou*, K. Stamatiou, D. Voutsinas, S. Pournaras, A. Tsakris,
K. Themeli-Digalaki (Athens, Larissa, GR)
Objectives: Klebsiella pneumoniae isolates producing KPC enzymes
(KPC-KP) have become increasingly prevalent in Greek hospitals.
These organisms, usually causing systemic infections, have been also
implicated in urinary tract infections. We present the results of a cohort
study regarding urinary acquisition of KPC-KP.
Methods: During a 2.5-year period (May 2008-October 2010) all
single-patient K. pneumoniae isolates recovered from urine cultures
and exhibiting elevated carbapenems’ MICs (>1mg/L) were screened
for carbapenemase production by phenotypic assays (EDTA and
phenylboronic acid combined-disc tests) and PCR. Clinical and
laboratory records were reviewed.
Results: A total of 48 patients (29 females, mean age 70.7±19.2
years) harbouring KPC-KP urinary isolates were identiﬁed. The majority
of patients were hospitalized at medical wards (31/48, 64.6%). The
mean time from admission to KPC-KP isolation was 9.7±13 days;
half of the patients (24/48) yielded KPC-KP within 48 hours of
hospitalization, indicating that KPC-KP was not acquired intrahospitally.
Of those patients, 20 had hospitalizations within the past 3 months,
three were hospitalized 4−9 months ago and one had no hospital
admissions but received prolonged quinolone treatment. Prior surgeries
were noted for 26/48 (54.2%) patients. Prior rectal colonization was
detected in 17 (35.4%) patients. Among comorbidities, urinary tract
diseases and diabetes mellitus prevailed (31/48 and 17/48, respectively).
Prior antibiotic exposure analysis revealed that most of the patients
had received b-lactams/b-lactamase inhibitors combinations (18/48) and
ﬂuoroquinolones (17/48). Most patients (41/48, 85.4%) had indwelling
catheters. Evidence of clinical infection was documented for 17
(35.4%) patients and 4 of them developed secondary bacteraemia.
Tigecycline was mostly used as treatment regimen, either alone or
in combinations. Overall mortality was 8.3% and infection mortality
23.5%. Co-production of both MBL and KPC was detected in two
cases. Susceptibility testing showed that 44 (91.7%) KPC-KP isolates
were susceptible to colistin, 37 (77.1%) to tigecycline and 41 (85.4%)
to gentamicin.
Conclusion: Urinary acquisition of KPC-KP was observed in patients
with prior hospitalizations, urinary tract comorbidities and indwelling
catheters. Regarding that it usually represents colonization, thorough
evaluation of clinical data is required before administration of
antimicrobial therapy.
P738 Spread of a plasmid-mediated carbapenem hydrolysing
OXA-48 b-lactamase in Klebsiella pneumoniae in a tertiary
teaching hospital, Spain
C. Pitart*, M.M. Sole´, J. Vila, F. Marco (Barcelona, ES)
Objectives: The most common mechanism for carbapenem resistance
in Klebsiella pneumoniae (KPNE) is the production of carbapenemases
belonging to Ambler class A, B or D. The oxacillinase OXA-48 was
ﬁrst identiﬁed in a KPNE isolate in Turkey. In this study we describe the
spread of a single clone of KPNE producing OXA-48 in our institution.
Methods: Twenty non-repetitive KPNE isolates with reduced suscepti-
bility to carbapenems were studied. Antimicrobial susceptibility testing
was performed by BD Phoenix and Etest. The Hodge test was used
to screen for carbapenemase production. PCR and sequence analysis for
carbapenemases (blaOXA-48 and blaKPC), ESBLs and plasmidic AmpC
cephalosporinases was performed. Clonality was evaluated by REP-PCR.
Conjugation experiments with E. coli J53 and plasmid analysis were
carried out. Outer membrane proteins (OMPs) proﬁles were analyzed to
study their contribution to carbapenem resistance.
Results: All strains were Hodge test positive. Eleven strains were
resistant to all antibiotics except cefoxitin, fosfomycin, tigecyclin and
colistin, and showed low level resistance to carbapenems: Imipenem
(IMI) (0,75−4 mcg/ml), meropenem (MER) (0.75−4 mcg/ml), ertapenem
(ETP) (3−>32 mcg/ml) and doripenem (DOR) (1−2 mcg/ml). Nine
strains were resistant to cefoxitin, and showed high level resistance to
carbapenems: IMI (12−>32 mcg/ml), MER (12−>32 mcg/ml), ETP (>32
mcg/ml) and DOR (8−>32 mcg/ml). PCR and sequencing identiﬁed the
presence of OXA-48, CTX-M-15 and SHV-1. E. coli transconjugant was
susceptible to all antibiotics except ampicillin, amoxicillin-clavulanate
and piperacilin-tazobactam and showed higher MIC of carbapenems:
IMI 0,5 mcg/ml, MER 0,125 mcg/ml, ETP 0,5 mcg/ml and DOR 0,125
mcg/ml compared to the recipient strain. Plasmid analysis revealed that
E. coli transconjugant harboured a circa 50-kb plasmid. Indistinguishable
REP-PCR patterns were found suggesting that all strains belong to the
same clone. OMP analysis revealed that low level resistant carbapenem
strains produced OmpK36, whereas high level resistant strains did not.
Conclusions: Our study identiﬁed the ﬁrst outbreak of OXA-48-
producing KPNE in Spain. This identiﬁcation of KPNE isolates carrying
the worldwide spread CTX-M-15 ESBL as well as the OXA-48
carbapenemase (and more importantly OmpK36 deﬁcient strains) is
worrisome since carbapenems are often the last resort for treating
infections caused by ESBL producing strains.
P739 Clinical and epidemiological study of an outbreak of
KPC-producing Klebsiella pneumoniae infection in Buenos
Aires, Argentina
E. Cordova, C. Rodriguez, F. Pasteran, N. Gomez, M. Badia, V. Oviedo,
M. Lespada* (Buenos Aires, AR)
Objectives: To describe an outbreak of KPC-producing Klebsiella
pneumoniae (Kpn-KPC) at the “Cosme Argerich” Hospital, Buenos
Aires, Argentina.
Methods: Prospective and descriptive study of an outbreak of Kpn-
KPC infection. Susceptibility tests were performed by disk diffusion
(CLSI) and MIC (Vitek 2-Biomerieux). Preliminary phenotypic detection
of KPC was based on the boronic acid disk synergy test. Presence of the
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blaKPC was conﬁrmed by PCR and DNA sequencing. Molecular typing
was performed by PFGE.
Results: From August 2009 through July 2010, 27 patients were infected
by KPC-2-producing K. pneumoniae (surgical care unit: n = 8, medical
care unit: n = 6, intensive care unit: n = 5, emergency care unit: n = 4,
and other: n = 4). All Kpn-KPC isolates belongs to a single clonal type.
Age (median): 67 years (range: 25−91 years). Female sex: 70%. All
the cases except the index one had a previous contact with a patient
with a Kpn-KPC infection or colonization. All infections except one
were nosocomially acquired, with the patients being hospitalized for
a median of 31 days (range 6–114 days) prior to isolation of the
organism. Site of infection: urinary tract (59%), respiratory tract (14%),
intraabdominal (14%), bloodstream (7%), bone (3%) and central venous
catheter (3%). Main comorbidities: diabetes mellitus (30%), malignancy
disease (23%), cardiopathy (23%) and malnutrition (19%). Most frequent
risk factors for Kpn-KPC infection: Urinary catheter (93%), chronic
wounds (52%), surgical wounds (46%), central venous catheter (33%)
and mechanical respiratory assistance (30%). All the patients had prior
exposure to antibiotics (median of 30 days; range 11−54 days), being
piperacillin-tazobactam (62%), cephalosporins (48%) and carbapenems
(44%) the most frequently antibiotics prescribed. All the isolates were
only susceptible to colistin and tigecycline.
Inappropriate empirical treatment was initiated in a 63%. Speciﬁc
treatment for Kpn-KPC infection: colistin (74%), tigecycline (4%),
tigecycline + colistin (22%). Global mortality: 59% (attributable
mortality: 26%).
Conclusions: A wide nosocomial spread of Kpn-KPC with a high
mortality rate was observed. A previous contact with a patient with
a Kpn-KPC infection or colonization, prior exposure to antibiotics and
the presence of comorbidities was seen in almost all cases. Kpn-KPC
infection creates an important challenge for clinicians to identify risk
factors in order to initiate an appropriated empirical treatment.
P740 Analysis of Klebsiella pneumoniae strains with non-enzymatic
carbapenem resistance isolated in the Czech Republic,
Poland and Russia
E. Chudackova*, T. Bergerova, H. Zemlickova, M. Edelstein,
M. Gniadkowski, J. Hrabak (Plzen, Prague, CZ; Smolensk, RU;
Warsaw, PL)
Objectives: The objectives of this study was to investigate the molecular
basis of carbapenem resistance in a set of carbapenemase-negative
Klebsiella pneumoniae strains collected in the Czech Republic, Poland
and Russia, and to assess their possible clonality in order to check
for eventual clone-associated risk factors of the development of this
resistance type.
Methods: The study was carried out on 30 K. pneumoniae strains
from the Czech Republic (n = 12), Poland (n = 7) and Russia (n = 11).
MICs of 24 antimicrobials were determined according to the EUCAST
methodology. Imipenem hydrolysis activity was assayed by spectropho-
tometry in crude protein extracts in order to exclude carbapenemase
activity. Isoelectric focusing and bioassay were performed to determine
b-lactamase content of the isolates, followed by PCR and sequencing
to identify the enzymes hydrolysing newer generation b-lactams. Major
outer membrane proteins (OMPs) were puriﬁed and separated by SDS-
PAGE. The expression of genes encoding OmpK35 and OmpK36
porins was analyzed by RT-PCR with speciﬁc primers and probes. Both
OmpK genes were ampliﬁed and sequenced. The strains were typed by
multilocus sequence typing (MLST).
Results: The MICs showed various patterns of resistance with
surprisingly good susceptibility of the Russian isolates to quinolones.
Each strain produced either an ESBL (of SHV or CTX-M type) or an
AmpC-like (DHA-1) b-lactamase. The porin OmpK35 was present in
the cell envelope extracts and RT-PCR did not show any signiﬁcant
quantitative changes in its expression. The expression of OmpK36 varied,
with a signiﬁcant decrease in most, though not all of the strains. In one
strain, another type of OmpK36 was detected. The MLST analysis is still
in progress, showing however high clonal diversity among the strains.
Conclusion: The non-enzymatic mechanisms remain a signiﬁcant source
of carbapenem resistance in enterobacteria. The results of the study
indicated the OmpK36 deﬁciency combined with the ESBL or AmpC
expression to be the major resistance mechanism. The non-signiﬁcant
decrease of OmpK36expression in some isolates suggested the rpesence
of other mechanism(s).
This work has been supported by the research project grants
NS9717−4/2008 and MSM 0021620819.
P741 DiversiLab analysis of a KPC-3-producing Klebsiella
pneumoniae outbreak in an Italian surgery unit
A. Mazzariol*, G. Lo Cascio, P. Ballarini, M. Ligozzi, F. Bercelli,
R. Fontana, G. Cornaglia (Verona, IT)
Objectives: From January to July 2010, eight strains of Klebsiella
pneumoniae resistant to ertapenem were isolated from different patients
recovered in a surgery unit of the Verona University Hospital. In addition
to ertapenem, the strains showed resistance to another carbapenem,
i.e. either meropenem or imipenem. The goal of this study was to
investigate these strains for carbapenemase production and to assess
the DiversiLab rep-PCR system as a rapid method for K. pneumoniae
outbreak investigations.
Methods: Antimicrobial susceptibility testing was performed by both
Vitek2 and broth microdilution. Results were interpreted according
to the latest EUCAST documents. The presence of carbapenemase
was investigated spectrophotometrically by following the hydrolysis of
imipenem with bacterial crude extracts. The presence of bla(KPC)
was investigated by PCR using published primers and amplicons
sequenced according to standard procedures. The strain clonality was
investigated by PFGE and by repetitive-sequence-based polymerase
chain reaction (rep-PCR) with a semiautomated instrument (DiversiLab
system) (Biomerieux).
Results: All strains proved resistant to all antibiotics tested apart from
tygecicline and colistin. Imipenem was hydrolysed with fast kinetics that
was not inﬂuenced by EDTA 2mM, thus suggesting the presence of a
class A carbapenemase. PCR performed with bla(KPC) primers yielded
positive results and amplicon sequencing revealed a 100% homology
with the kpc3 gene. Seven strains showed identical PFGE patterns and
REP-PCR proﬁles with more than 95% of similarity, whereas one was
not correlated.
Conclusions: Our work describes the outbreak of KPC-producing
K. pneumoniae in a surgery unit. The concordance between DiversiLab
and PFGE results showed the utility of rapid molecular techniques to
investigate outbreaks due to multidrug-resistant bacterial isolates. The
emergence of carbapenem-resistant Enterobacteriaceae is worrisome,
since the antimicrobial treatment options for infections due to multidrug-
resistant strains are very restricted.
P742 Nosocomial outbreak of Klebsiella pneumoniae harbouring
blaKPC-3 in France subsequent to a patient transfer from
Italy
G. Cuzon*, T. Naas, M. Demachy, H. Ittah-Desmeulles, P. Nordmann
(Le Kremlin-Biceˆtre, Meaux, FR)
Objectives: Klebsiella pneumoniae carbapenemases, KPCs, have rapi-
dely disseminated worldwide, likely linked to an efﬁcient Tn3-like
transposon, Tn4401. Several KPC-producing K. pneumoniae (KP-KPC)
clones have been described, but the most prevalent is of MLST type 258.
Single isolates of KP-KPC-2 or KPC-3 (differing by a single amino-
acid) have been reported from many countries in Europe, but outbreaks
of KP-KPC-2 have also been described in Greece, France, Germany and
in Spain. Here we describe a nosocomial outbreak of KP-KPC-3 in a
French hospital after strain importation from Italy.
Methods: Carbapenem-resistant K. pneumoniae isolates were charac-
terized by standard biochemical methods, disc diffusion susceptibility
testing, and E-tests. Genes coding for b-lactamases and the overall
structure of Tn4401 were sought by PCR and sequencing. Isolates were
compared by PFGE, MLST typing and by their plasmid content.
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Results: In August 2010, an 85-year-old woman was transferred from
an italian hospital to the cardiology ward of a south Paris hospital
(France) for heart failure syndrome. At her admission, bacteriological
culture identiﬁed from urines an extreme drug resistant (XDR) KP
isolates, susceptible only to gentamicin and colistin. Despite strict
infection control measures, three months later, two additional patients
were colonized or infected with isolates showing the same susceptibility
pattern. Patient 2 crossed the index patient in August in the cardiology
ward. PCR and sequencing identiﬁed blaKPC-3 and blaTEM-1 genes.
blaKPC-3 gene was associated with Tn4401a isoform and located on a
ca. 75-kb self-conjugative plasmid. The three isolates were genetically
related by PFGE and belonged to ST-258.
Conclusion: This study conﬁrms the worldwide spread of ST-258 clone
that has predominantly been identiﬁed among KPC-2 and KPC-3 KP-
producers. It underlines that even with strict hygiene precautions silent
spread of KP-KPC producing isolates may occur and lead to hospital-
acquired infections.
P743 Early stage of dissemination of KPC-producing
Enterobacteriaceae in Poland (2008–2009)
A. Baraniak, A. Grabowska, R. Izdebski*, J. Fiett, M. Herda,
A. Bojarska, D. Zabicka, G. Mlynarczyk, W. Hryniewicz,
M. Gniadkowski on behalf of the KPC-PL Study Group
Objectives: To characterize Enterobacteriaceae isolates producing KPC-
type carbapenemases identiﬁed in Poland in 2008–2009.
Methods: 119 non-repetitive KPC isolates of K. pneumoniae (n = 115),
K. oxytoca (n = 2) and E. coli (n = 2) from 2008–2009 were analyzed.
These were identiﬁed in 18 hospitals, including 12 in Warsaw. The
isolates were derived from infections, mainly UTIs (n = 61), invasive
infections (n = 22) and RTIs (n = 8), or from colonization (n = 22). KPCs
were detected phenotypically, followed by PCR. blaKPC-2- and blaKPC-
3-like genes were discerned by RsaI digestion of PCR products and
conﬁrmed by sequencing. The location of blaKPCs within Tn4401
transposons was analyzed by PCR mapping. b-Lactamases were proﬁled
by isoelectric focusing; genes coding for CTX-M-like and SHV-
like ESBLs, and TEM-1-like enzymes were analyzed by PCR and
sequencing. Typing was performed by PFGE and MLST. Plasmid
proﬁling was done by S1 nuclease analysis; blaKPC-carrying plasmids
were identiﬁed by hybridization and conjugation.
Results: After the 1st report in May 2008, by the end of 2008
33 KPC isolates were recovered in 5 Warsaw hospitals. Three of
these experienced non-controlled outbreaks which in 2009 converted
into endemic situations, being a source of transmission to other
sites. Altogether 86 isolates were collected in 2009, including 7 new
Warsaw hospitals and 6 in distant cities. MLST classiﬁed 97.4% of
K. pneumoniae isolates into the hyper-epidemic clone ST258; sporadic
isolates belonged to ST11 and ST23. The ST258 isolates revealed an
amazing internal diversity, with 28 PFGE subtypes, 27 plasmid proﬁles,
13 blaKPC-carrying plasmids and ﬁve b-lactamase patterns (including
those with CTX-M-3, CTX-M-15 and/or SHV-12). Most isolates carried
the blaKPC-2 gene in the Tn4401a element; one isolate had blaKPC-3
inside Tn4401b. The ~110kb blaKPC plasmid was present in 10 S1
proﬁles of 46 isolates and was conjugative. Another transferable plasmid,
of ~50kb, formed 2 S1 proﬁles in 46 isolates, including two pairs
of K. pneumoniae and E. coli isolates from single patients. In 6 S1
proﬁles two plasmids carried blaKPC genes, indicating likely Tn4401
transposition.
Conclusions: In a short time Poland has become one of the most
KPC-affected European countries, with Warsaw being the epicenter of
dissemination. Numerous actions were undertaken, including education,
and issuing guidelines for detection and infection control, aimed at
controlling the situation.
P744 In vivo transfer of OXA-48 during an outbreak of Klebsiella
pneumoniae with decreased susceptibility to carbapenems
S. Go¨ttig*, V.A. Kempf, T.A. Wichelhaus (Frankfurt, DE)
Objectives: We report an outbreak of Klebsiella pneumoniae with
carbapenem resistance or decreased susceptibility in seven patients at the
University Hospital of Frankfurt in 2010. Molecular and phenotypical
investigations of the clinical isolates were performed.
Methods: Antibiotic susceptibilites of K. pneumoniae were determined
by Vitek2 and E-test. DNA from K. pneumoniae were screened by PCR
for the presence of KPC, VIM, IMP, NDM-1 and Oxa-48 b-lactamases.
Transferability of Oxa-48 was tested by transformation of plasmid DNA
into E. coli.
Results: Ertapenem-resistant K. pneumoniae were isolated from rectal
swabs and urine samples from seven patients during an outbreak. Of
these seven patients, two were only colonized, three exhibited urinary
tract infections and two patients were severely ill suffering from sepsis
and/or pneumonia due to ertapenem-resistant K. pneumoniae. Infected
patients were successfully treated with high dose meropenem and
gentamicin, and, in case of pneumonia, in addition with inhalative
colistin. All K. pneumoniae were resistant to penicillins, cephalosporins,
ertapenem and ﬂuoroquinolones. Some of the strains exhibited elevated
MICs towards meropenem, doripenem or imipenem, but still remained
susceptible.
Oxa-48 was identiﬁed by PCR and sequencing in all K. pneumoniae
isolates from the seven patients. In one of these patients an Oxa-48
producing Escherichia coli was isolated from rectal swabs in addition
to the Oxa-48 producing K. pneumoniae. In vitro transfer of Oxa-
48 containing plasmid DNA from K. pneumoniae and E. coli into
highly susceptible E. coli resulted in resistance against penicillins,
cephalosporins and ertapenem.
Conclusion: To the best of our knowledge, this is the ﬁrst report
of an outbreak of Oxa-48 producing K. pneumoniae in Germany.
Epidemiological, molecular and phenotypical data suggest a horizontal
interspecies transfer of Oxa-48 containing plasmid in vivo.
P745 First outbreak of OXA-48-positive carbapenem-resistant
Klebsiella pneumoniae isolates in Western Europe, France
G. Cuzon*, J. Ouanich, H. Ahmed-Zaid, R. Gondret, T. Naas,
P. Nordmann (Le Kremlin-Biceˆtre, Villeneuve-Saint-Georges, FR)
Objectives: Emerging carbapenemases can be either metallo-
b-lactamases, Ambler class A enzymes or more rarely oxacillinases. The
class D b-lactamase OXA-48, initially identiﬁed from a carbapenem-
resistant K. pneumoniae isolate from Istanbul, Turkey, hydrolyzes
penicillins and imipenem but not expanded-spectrum cephalosporins.
Outbreaks of OXA-48-producing isolates have been described and
sporadic isolates are increasingly reported, especially in Mediterranean
countries. Here we describe a nosocomial outbreak of carbapenem-
resistant K. pneumoniae strains expressing OXA-48 in France.
Methods: Bacteria were characterized by standard biochemical methods,
disc diffusion susceptibility testing and E-tests. Genes coding for
class A, B and D carbapenemases were sought by PCR. Strains were
characterized by Pulse Field Gel Electrophoresis (PFGE), by MLST and
by plasmid analysis.
Results: Several Klebsiella pneumoniae isolates producing the OXA-
48 carbapenemase were analysed out of ten patients hospitalized from
May to June 2010 mostly in the medical Intensive Care Unit (ICU) of
the Villeneuve-Saint-Georges hospital, suburb of Paris, France. Seven
patients were infected, ﬁve of them were treated at least with a
carbapenem and ﬁve patients died. Isolates were multidrug resistant,
remaining susceptible to colistin, and exhibited heterogeneous decreased
susceptibility to carbapenems. Molecular analysis showed that the
isolates belonged to a single clone, harboring a 70-kb plasmid carrying
the blaOXA-48 gene and co-produced CTX-M-15, TEM-1 and OXA-1
b-lactamases.
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Conclusion: The present study identiﬁed the ﬁrst outbreak of
K. pneumoniae isolates producing the carbapenemase OXA-48 in France.
Isolates identiﬁed here were not clonally related to the previously
identiﬁed OXA-48-positive K. pneumoniae strains, but a very similar 70-
kb plasmid harboring blaOXA-48 was identiﬁed, underlying that spread
of the blaOXA-48 gene may be associated to spread of a single plasmid
type. Outbreaks of OXA-48 K. pneumoniae producers are now identiﬁed
in Western Europe after those producing other types of carbapenemases
(KPC-2, VIM-1 and NDM).
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P746 Correlation between EUCAST disk diffusion and the
standardised broth microdilution method
S. Bengtsson*, C. Bjelkenbrant, G. Kahlmeter (Va¨xjo¨, SE)
Objectives: To evaluate the correlation between zone diameters and MIC
values using EUCAST disk diffusion and broth microdilution for clinical
relevant species.
Methods: A collection of stored clinical strains comprising of 185 Gram
negatives and 177 Gram positive isolates (see table) were tested in
parallel with EUCAST disc diffusion and broth microdilution (TREK).
Seven to 14 antibiotics were evaluated for Enterobacteriaceae (n = 14),
Pseudomonas (n = 8), Staphylococci (n = 12) and Enterococci (n = 7).
Special attention was given to MRSA, ESBL, VRE and HLAR. Category
(SIR) interpretations of zone diameters and MIC were done according
to EUCAST clinical breakpoints (version 1.2, December 21, 2010).
Reference strains S. aureus ATCC 29213, ATCC 43300, E. faecalis
ATCC 29212, E. coli ATCC 25922, K. pneumoniae, ATCC 700603 and
P. aeruginosa ATCC 27853 were included as appropriate on each day of
testing.
Results: The results are summarised in the table. Overall category
agreement was 97.5% for 1641 tests of Gram positives and 95.5%
for 2374 tests of Gram negatives. Cefoxitin correctly identiﬁed all
S. aureus MRSA and MSSA. In Staphylococci one very major error
(VME) was seen for moxiﬂoxacin, ten VME for clindamycin (all were
inducible clindamycin resistance not detected by the MIC-test). For
E. faecium one VME was seen for gentamicin and ﬁve major error
(ME) for nitrofurantoin (all because the zone diameter breakpoint bisects
the natural distribution) and two ME for ampicillin. Among Gram
negatives one VME was obtained for piperacillin/tazobactam in an
ESBL-producing E. coli and one VME for cefuroxime in K. pneumoniae.
For P. aeruginosa two VME was shown for piperacillin/tazobactam
and mE were predominantly for aztreonam (n = 9) and piperacillin/
tazobactam (n = 5).
Conclusions: The EUCAST disk diffusion method could accurately
predict S, I and R-categorization based on standardized microbroth
dilution MIC-values and EUCAST clinical MIC-breakpoints. Minor
problems were mostly due to inducible clindamycin resistance in
Staphylococci not being detected by the MIC method and the fact that
the breakpoint for nitrofurantoin in E. faecium bisects the wild type
distribution of this species.
P747 EUCAST MIC breakpoints and inhibition zone diameter
correlates for staphylococci
E. Matuschek*, J. A˚hman, A. Petersen, R. Skov, R. Jones, G. Kahlmeter
(Va¨xjo¨, SE; Copenhagen, DK; Iowa, US)
Objectives: During 2009 and 2010, the European Committee on An-
timicrobial Susceptibility Testing (EUCAST) developed a disk diffusion
method calibrated to the harmonized EUCAST MIC breakpoints. Zone
diameter breakpoints were published at EUCAST website in December
2009, and have been tentative during 2010. The objective of this study
was to present correlates between MIC values and inhibition zone
diameters in Staphylococcus spp., and to present new breakpoints for
mupirocin and S. aureus.
Methods: For S. aureus, a total of 310 isolates with MIC values
close to EUCAST clinical MIC breakpoints were selected from the
SENTRY collection (JMI Laboratories, USA). For coagulase-negative
staphylococci (CoNS), 155 isolates were collected from several sites in
Europe and the USA, including S. epidermidis (68), S. capitis (30),
S. hominis (21), S. haemolyticus (16), S. cohnii (7), S. lugdunensis
(5), S. simulans (4) and S. warneri (4). Disk diffusion was performed
according to EUCAST methodology. MIC values were determined by
broth microdilution with custom panels from TREK Diagnostics for
S. aureus and with Etest (bioMe´rieux) for CoNS. All antibiotic agents
with clinical breakpoints in EUCAST tables were investigated (cefoxitin
is reported elsewhere). Mupirocin was tested using 5, 20 and 200 ug
disks.
Results: The correlation between inhibition zone diameters and MIC
values was excellent. Isolates categorized as wild type by MIC were
categorized as wild type by inhibition zone diameters. The median values
of the wild type zone distributions were 0−6mm lower for S. aureus
than for CoNS, but MIC correlates supported common zone diameter
breakpoints for most antibiotics (Table 1). However, for aminoglycosides,
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the zone/MIC correlates indicated a need for separate zone diameter
breakpoints for S. aureus and CoNS. Disk diffusion interpretation of
>2000 S. aureus zone/MIC determinations resulted in 4 very major
errors (mainly fusidic acid) and 10 major errors (mainly trim-sulfa). For
>150 CoNS correlates, there were 2 very major errors (tetracycline and
trimethoprim). For mupirocin, the 200 ug disk most reliably predicted
resistance in S. aureus (MIC >256mg/L).
Conclusion: For staphylococci, a review of the correlation between
MIC values and inhibition zone diameters resulted in minor revisions
of zone diameter breakpoints for several antibiotics. The EUCAST zone
diameter breakpoints are now well calibrated to the current EUCAST
MIC breakpoints for both S. aureus and CoNS.
P748 Screening for b-lactam resistance in Streptococcus viridans
group with the EUCAST disk diffusion method
E. Matuschek*, J. A˚hman, P. Littauer, G. Kahlmeter (Va¨xjo¨, SE;
Hvidovre, DK)
Objectives: Viridans (non b-haemolytic) streptococci are usually
considered weak pathogens but can cause invasive disease, in which
case b-lactam antibiotics, often in combination with an aminoglycoside,
are important therapeutic agents. The objective of this study was to
develop inhibition zone diameter breakpoints for viridans streptococci
and b-lactam antibiotics correlated to EUCAST harmonized MIC
breakpoints, and to evaluate the benzylpenicillin 1 unit disk as screen
for b-lactam resistance.
Methods: Antimicrobial susceptibility testing was performed on a
collection of 89 viridans streptococci, including S. anginosus (5), S. bovis
(1), S. gordonii (2), S. intermedius (1), S. mitis (30), S. mutans (1),
S. oralis (20), S. salivarius (7), S. sanguinis (7), S. vestibularis (1) and 14
non-speciated isolates. Disk diffusion was performed on Mueller-Hinton
agar with 5% deﬁbrinated horse blood and 20mg//L b-NAD (MH-F)
according to EUCAST methodology for benzylpenicillin (PCG) 1 unit,
ampicillin (AMP) 2 ug, cefotaxime (CTX) 5 ug, cefuroxime (CXM) 30
ug and meropenem (MER) 10 ug. MIC determination was performed
with Etest (bioMe´rieux) on Mueller-Hinton agar with 5% deﬁbrinated
horse blood.
Results: A PCG disk diffusion breakpoint of S 18mm and R <12mm
reported isolates with PCG MIC 2−8mg/L as resistant; S. mitis (2),
S. oralis (2) and S. vestibularis (1). Of these, four had elevated MIC
values for CTX and CXM and all ﬁve had MIC values above the ECOFF
for MER. For CTX and MER, all susceptible isolates were reported
susceptible with the PCG 1 unit disk. One isolate resistant to CXM (MIC
1mg/L) was reported as susceptible with both PCG and CXM disks,
and two isolates intermediate to PCG (MIC 0.5mg/L) were reported as
susceptible with the PCG disk.
Conclusion: EUCAST zone diameter breakpoints for Streptococcus
viridans group and b-lactam antibiotics are well calibrated to the MIC
breakpoints and can be used to predict susceptibility to b-lactam agents.
Benzylpenicillin 1 unit is a sensitive screening disk for the detection of
b-lactam resistance in viridans streptococci.
P749 EUCAST proposed new MIC breakpoints for Moraxella
catarrhalis and corresponding zone diameter breakpoints
J. A˚hman*, E. Matuschek, G. Kahlmeter (Va¨xjo¨, SE)
Objectives: Moraxella catarrhalis was long considered a harmless
commensal of the upper respiratory tract, but has been recognized
as a true pathogen in the last decades. The increasing prevalence of
b-lactamase producing strains has also renewed interest in this species.
Two types of b-lactamases have been identiﬁed, BRO-1 (90−95%
of isolates) and BRO-2. The BRO-1 enzyme is associated with a
higher level of penicillin resistance and higher MICs. Breakpoints for
M. catarrhalis were originally derived from Haemophilus inﬂuenzae,
but EUCAST has proposed separate breakpoints for M. catarrhalis in
2011. The objective of this study was to compare current and suggested
new MIC breakpoints and to establish corresponding zone diameter
breakpoints for M. catarrhalis.
Methods: A total of 106 consecutive clinical isolates of M. catarrhalis
were collected from Kronoberg County, Sweden. Species identiﬁcation
was conﬁrmed with MALDI-TOF analysis. All isolates were examined
for b-lactamase by using the nitroceﬁn disk. Disk diffusion was
performed on Mueller-Hinton agar supplemented with 5% horse blood
and 20mg/L b-NAD (MH-F) according to EUCAST methodology. MIC
determination using E-test (bioMe´rieux) was performed on isolates
with inhibition zones at the lower end of the wild-type distribution.
All antibiotic agents with clinical breakpoints in EUCAST tables and
benzylpenicillin and nalidixic acid were tested.
Results: Of the 106 M. catarrhalis isolates, 103 (97%) were
b-lactamase positive. Zone diameter distributions were bimodal for ben-
zylpenicillin, ampicillin, ampicillin-sulbactam, amoxicillin, amoxicillin-
clavulanate, ceﬁxime, cefotaxime, ceftibuten and ceftriaxone. For several
cephalosporins (cefaclor, cefepime, cefpodoxime and cefuroxime), the
current MIC breakpoints divided the wild-type distributions. An analysis
of all MIC breakpoints and wild-type distributions clearly showed that
species-speciﬁc breakpoints for M. catarrhalis are required. EUCAST
current and proposed breakpoints for M. catarrhalis are presented in
Table 1.
Conclusion: The EUCAST Steering Committee has proposed revised
MIC breakpoints for M. catarrhalis. These are currently (Dec 2010)
under consultation with national breakpoint committees in Europe. We
present proposed zone diameter breakpoints, correlated to the new MIC
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breakpoints. Revised clinical breakpoints for M. catarrhalis will be
presented as an addendum to the EUCAST breakpoint table during 2011.
P750 Methicillin resistance in Staphylococcus spp. Validation of
CLSI and EUCAST disk diffusion screen using cefoxitin
J. A˚hman*, E. Matuschek, R. Skov, G. Kahlmeter (Va¨xjo¨, SE;
Copenhagen, DK)
Objectives: Methicillin resistance in staphylococci is mediated by
the mecA gene. For S. aureus, several independent studies have
shown cefoxitin to be a reliable predictor of mecA status, and hence
methicillin resistance, both with MIC determination and disk diffusion.
For coagulase-negative staphylococci (CoNS), the cefoxitin disk has
been shown to be a better predictor of mecA status than MIC. Both
CLSI and EUCAST have published cefoxitin screen breakpoints for
S. aureus (R <22mm or MIC >4mg/L) and CoNS (R <25mm). The
speciﬁcity and sensitivity of the screen for CoNS has been questioned.
The objective of this study was to evaluate the cefoxitin disk as a
screen for methicillin resistance in Staphylococcus spp. using CLSI and
EUCAST zone diameter breakpoints.
Methods: A total of 102 S. aureus with cefoxitin MIC values >2mg/L
were selected from the SENTRY collection (JMI Laboratories, USA).
For CoNS, 150 species-identiﬁed isolates with known mecA status (85
mecA positive and 65 mecA negative) were collected from several sites
in Europe and the USA, including S. epidermidis (68), S. capitis (30),
S. hominis (21), S. haemolyticus (16), S. cohnii (7), S. simulans (4)
and S. warneri (4). Disk diffusion with cefoxitin 30 ug was performed
on all isolates according to EUCAST methodology and MIC values
were determined with broth microdilution on custom-panels from TREK
Diagnostics for S. aureus.
Results: Inhibition zone diameters for S. aureus isolates with MIC
values 8mg/L (n = 35) were 6−17mm and for isolates with MIC values
4mg/L (n = 67) 22−32mm. For CoNS, 64/65 mecA negative isolates
had inhibition zone diameters 25mm and 84/85 mecA positive isolates
had zone diameters <25mm. One mecA negative isolate (S. cohnii) had
a cefoxitin zone of 23mm and one mecA positive isolate (S. epidermidis)
had a cefoxitin zone of 27mm. Repeated testing of isolates close to the
breakpoint on Mueller-Hinton agar from different manufacturers showed
that misinterpretation was due to either too light inocula or the agar per
se. Discrepancies were not related to CoNS subspecies.
Conclusion: Disk diffusion with cefoxitin 30 ug and the use of separate
zone diameter breakpoints for S. aureus and CoNS is a reliable screening
method for the detection of mecA-mediated methicillin resistance in
staphylococci. However, CoNS with inhibition zones of 25−28mm must
be retested if the inoculum is too light.
P751 Inhibition zone diameter distributions and MIC correlates
for Pasteurella multocida on the EUCAST MH-F media
C. Karlsson*, J. A˚hman, E. Matuschek, G. Kahlmeter (Va¨xjo¨, SE)
Objectives: Pasteurella multocida is part of the normal respiratory
ﬂora of mammals and fowl. In humans it can cause serious soft tissue
infections. Treatment consists primarily of b-lactam antibiotics. b-lactam
resistance has been most frequently described in animal isolates, while
human isolates often remain susceptible to b-lactam antibiotics. The
European Committee on Antimicrobial susceptibility testing (EUCAST)
has not yet established clinical breakpoints for P. multocida, but MIC
epidemiological cut off (ECOFF) values are available for most relevant
antibiotics. The objective of this study was to establish inhibition zone
diameter ECOFF values as part of the EUCAST process to determine
clinical breakpoints during 2011.
Methods: A total of 89 P. multocida isolates were tested, 66 of animal
origin (31 bovine and 35 porcine) kindly provided by CVI, Wageningen,
NL, and 23 clinical isolates from bite wounds in humans (22 feline
and one canine). Species identiﬁcation was conﬁrmed with MALDI-
TOF analysis. Antibiotics tested were: benzylpenicillin (PCG) 1 unit,
ampicillin 2 ug, amoxicillin-clavulanic acid 20 + 10 ug, cefotaxime 5
ug, ciproﬂoxacin 5 ug, nalidixic acid 30 ug, tetracycline 30 ug and
trimethoprim-sulfamethoxazole 1.25–23.75 ug. Disk diffusion and MIC
determination, E-test® (bioMe´rieux), were performed on Mueller-Hinton
agar with 5% horse blood and 20mg/L b-NAD (MH-F) with an inoculum
of McFarland 0.5. Plates were incubated at 35ºC in 5% CO2 for 16−20 h.
Results: MIC values and inhibition zone diameters for P. multocida
from human and porcine origin were similar, whereas MIC values were
lower and inhibition zone diameters larger for bovine isolates. However,
there was excellent correlation between MIC values and inhibition zone
diameters, regardless of the origin of the isolates. Isolates belonging to
the wild-type zone diameter distribution showed good correlation with
data available in the literature and on the EUCAST website (Table 1).
b-lactamase positive strains (3/89) showed no ampicillin and PCG
inhibition zones.
Conclusion: We present inhibition zone diameter data and MIC
distributions as a basis for determining clinical breakpoints and zone
diameter correlates for P. multocida on MH-F media. EUCAST will
determine breakpoints for P. multocida during 2011.
P752 Comparison of two disk diffusion-based screening methods
for detection and classiﬁcation of b-lactam resistance in
Haemophilus inﬂuenzae
D. Skaare*, I.L. Anthonisen, A. Hannisdal, A. Jenkins, G. Kahlmeter,
A. Lia, E. Matuschek, Y. Tveten, B.-E. Kristiansen (Tønsberg, Skien,
NO; Va¨xjo¨, SE)
Objectives: b-lactam resistance in Haemophilus inﬂuenzae is most
commonly caused by b-lactamase and/or altered penicillin-binding
protein 3 (PBP3). Isolates with PBP3 alterations (N526K or R517H)
are denoted gBLNAR (genetic b-lactamase negative ampicillin resistant)
or gBLPACR (genetic b-lactamase positive amoxicillin-clavulanate
resistant), depending on b-lactamase status. Isolates without PBP3
alterations are denoted gBLNAS (genetic b-lactamase negative ampicillin
susceptible) or gBLPAR (genetic b-lactamase positive ampicillin
resistant).
The objectives of this study were to compare the reliability of two disk
diffusion-based screening methods for detection and classiﬁcation of
b-lactam resistant H inﬂuenzae according to resistance genotypes and
resistance phenotypes: phenoxymethylpenicillin 10 mcg (PCV10) and
benzylpenicillin 1 unit (PCG1), respectively, combined with b-lactamase
detection and cefaclor 30 mcg (CEC30).
Methods: A collection of 196 well-characterized respiratory tract
isolates comprising 109 gBLNAR, seven gBLPACR, nine gBLPAR and
71 gBLNAS isolates was tested by disk diffusion (PCV10, PCG1 and
CEC30; EUCAST methodology) and MIC-determination (ampicillin,
amoxicillin, piperacillin, cefuroxime, cefotaxime and meropenem;
microbroth dilution, CLSI methodology). For the penicillins, MIC
determination of b-lactamase positive isolates was performed in
combination with sulbactam, clavulanate and tazobactam, respectively.
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Disk diffusion results were interpreted for the two methods according to
the recommended test algorithms and compared to resistance genotypes
and resistance phenotypes, deﬁning resistant phenotype as resistant to
one or more agents according to EUCAST MIC breakpoints.
Results: A resistant phenotype was present in 94% of the
gBLNAR/gBLPACR isolates and 29% of the gBLNAS/gBLPAR isolates.
In general, gBLNAR/gBLPACR isolates with a resistant phenotype
expressed higher MICs and were resistant to a wider range of b-lactams
than gBLNAS/gBLPAR.
The PCG1-based method was superior to the PCV10-based method with
respect to categorization into genotypes (correct categorization 91% and
85%, respectively). Using resistance phenotype as the gold standard, the
PCG1- and PCV10-based methods correctly categorized 85% and 83%
of the isolates, respectively.
Conclusion: Replacement of the PCV10 disk by the PCG1 disk improves
performance of the screening method for detection of b-lactam resistance
in H inﬂuenzae.
P753 The EUCAST Mueller-Hinton fastidious agar for
antimicrobial susceptibility testing of anaerobic bacteria?
U.S. Justesen*, E. Matuschek, G. Kahlmeter (Odense C, DK; Va¨xjo¨, SE)
Objectives: The EUCAST disk diffusion antimicrobial susceptibility
testing method for fastidious organisms is based on the use of
the Mueller-Hinton fastidious agar, Mueller-Hinton agar with 5%
deﬁbrinated horse blood and 20mg/L b-NAD (MH-F). It is not known in
detail to what extent anaerobic bacteria will grow on MH-F. To evaluate
this further, the growth characteristics of seven anaerobic ATCC/NCTC
strains were tested on MH-F from different manufacturers.
Methods: MH-F plates from bioMerieux, the Department of Clinical
Microbiology, Va¨xjo¨ (Oxoid MH) and from Statens Serum Institut
(SSI), Copenhagen, Denmark (Oxoid MH and BBL II MH) were
tested. Supplemented MH-F (hemin and vitamin K) with Oxoid and
BBL II MH from SSI were also included. The six agars were
compared to the Brucella Blood Agar supplemented with hemin and
vitamin K and the anaerobe agar (modiﬁed chocolate agar containing
hemin and supplemented with vitamin K and cysteine) from SSI. The
following ATCC/NCTC strains were used: Bacteroides fragilis ATCC
25285, Bacteroides thetaiotaomicron ATCC 29741, Bacteroides vulgatus
ATCC 29327, Clostridium perfringens ATCC 13124, Clostridium
difﬁcile ATCC 700057, Fusobacterium necrophorum ATCC 25286
and Peptostreptococcus anaerobius NCTC 11460. A McFarland 1.0
suspension was prepared and diluted for CFU counting from spot test,
colony size, expressed as a growth value (0, no growth; 1, haze;
2, <0.5mm; 3, >0.5mm; and 4, >1mm), and summary of growth
characteristics (conﬂuent growth or not). All plates were incubated at
37ºC in an anaerobe environment for 24 hours.
Results: There was no difference in CFU counts between the eight
agars. The median growth value for the plates tested were as follows:
bioMerieux 2, Va¨xjo¨ 2, SSI (Oxoid) 2, SSI (BBL II) 2, SSI
(supplemented Oxoid) 2, SSI (supplemented BBL II) 3, supplemented
Brucella Blood Agar 4, anaerobe agar 4. Overall conﬂuent growth on
MH-F was only achieved with B. fragilis. Conﬂuent growth was achieved
with 4/7 strains on the supplemented Brucella Blood Agar and 6/7 strains
on the anaerobe agar.
Conclusion: The EUCAST MH-F agar is less favourable for antimicro-
bial susceptibility testing of anaerobic bacteria than the supplemented
Brucella Blood Agar or the anaerobe agar. Whether or not the MH-F
medium can be calibrated for antimicrobial susceptibility testing of
rapidly growing commonly isolated anaerobic bacteria remains to be
investigated.
P754 Feasibility of the E-test for susceptibility testing of doripenem
against Gram-negative and Gram-positive bacteria using
EUCAST breakpoints
M. Kresken*, B. Ko¨rber-Irrgang on behalf of the German Doripenem
Study Group
Objective: Doripenem (DOR), a member of the group of carbapenems,
has been shown to have in vitro activity against a wide range of Gram-
positive and Gram-negative pathogens, including P. aeruginosa. The
Etest methodology has been proposed as an alternative to the reference
broth microdilution (BMD) method (J Clin Microbiol 2010;483353−7),
but there is no comparative study on DOR using EUCAST interpretive
criteria. The aim of this study was to evaluate the Etest as an alternative
to the BMD method to establish its feasibility for routine susceptibility
testing of DOR.
Methods: A total of 1,796 clinical isolates were tested. Isolates
were collected from 15 medical microbiology laboratories during two
resistance surveillance studies conducted in Germany in 2007 and
2009. Organism groups tested were ceftriaxone (CRO)-susceptible
Enterobacteriaceae (n = 512), CRO-non-susceptible Enterobacteriaceae
(n = 349), A. baumannii group (n = 139), P. aeruginosa (n = 149), MSSA
(n = 151), MRSA (n = 147), CoNS (n = 135), E. faecalis (n = 148), and
S. pneumoniae (n = 66). Isolates were sent to a central laboratory
where species identiﬁcations were conﬁrmed using standard laboratory
methods, and tested for susceptibility by BMD according to the standard
ISO 20776−1:2006 (ISO BMD)and by Etest. Interpretive criteria were
those published by EUCAST. The categorical (breakpoint determination)
and essential (within one 2-fold dilution) agreement between the two
methods were assessed.
Results: As by EUCAST criteria, if available, the percentages of
DOR-susceptible isolates were 100% for CRO-susceptible Enterobac-
teriaceae, 98.3% for CRO-non-susceptible Enterobacteriaceae, 82.7%
for A. baumannii group isolates, 77.9% for P. aeruginosa and 100%
for S. pneumoniae. For the vast majority of organisms, Etest MICs
were 0.5 to 1.5 log2 dilution lower than ISO BMD MICs. The widest
difference detected was 2 log2 dilutions. The overall level of essential
and categorical agreement of Etest results as compared to BMD MICs
was 76.9% and 98.5%, respectively. Categorical discrepancies were
observed for 18 organisms, all of which were minor and related either to
P. aeruginosa (n = 11), the A. baumannii group (n = 5) or K. pneumoniae
(n = 2).
Conclusion: Our results suggest that the Etest is an acceptable
alternative to the reference BMD method for susceptibility testing of
DOR. However, organisms displaying Etest MICs around the clinical
breakpoints should be re-tested using the reference BMD method.
P755 Usefulness of Microscan System panels with EUCAST clinical
breakpoints to evaluate the antimicrobial susceptibility of
b-lactamase producing Gram-negative isolates
E. Nucleo*, G. Fugazza, M. Spalla, A. Piazza, L. Pagani,
R. Migliavacca (Pavia, IT)
Objectives: Evaluation of the ability of NBC45, NBC46 and NB40
Microscan (MS) panels, updated to 2010 EUCAST breakpoints,
to identify at species level and to correctly deﬁne the b-lactams
susceptibility of 61 b-lactamases (BLs) producing Gram-negative
isolates.
Methods: A collection of 73 fully identiﬁed strains was analyzed:
21 Klebsiella spp., 17 E. coli, 15 P. mirabilis, 9 A. baumannii-Ab,
7 P. aeruginosa and 4 Enterobacter spp.. 61/73 were BLs and/or
carbapenemases (CBs) producers: 15 CTX-M-1/-2/-14/-15, among them
2 were also VIM-1 positive, 4 TEM-52/-92, 3 PER-1, 2 SHV-12/-
18, 6 CMY-16 AmpC acquired, 11 KPC-2/-3, 9 OXA-51/-58/-23, 8
VIM-1 and 2 IMP-13 positive. One K-1 iperproducer K. oxytoca, 11
non-BL producers/ATCC control strains and a OprD2 porin lacking
P. aeruginosa were also included. All isolates were identiﬁed by Api-20E
and VITEK-2 Systems and antibiotic susceptibilities were obtained by
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broth microdilution method. Resistance genes were identiﬁed by PCR
and sequencing.
Results: All 73 isolates were correctly identiﬁed and a complete
agreement for susceptibility patterns was observed for both ATCC
control strains and non-BL clinical isolates.
MS failed to detect a BL/Extended-Spectrum-b-Lactamase (ESBL)
production in 5/61 cases: any ESBL alert was detected using NBC46
panel for 3/15 CTX-M positive strains and 2 VIM-1/CTX-M-15
producing K. pneumoniae isolates.
Intermediate resistance to cefoxitin (MIC 16mg/L), susceptibility to
cefepime (MIC 1mg/L) and to piperacillin/tazobactam (MIC8mg/L)
were correctly observed for CMY-16 producers.
KPC producers were always correctly detected, with MIC values of
1−8mg/L for ertapenem (ETP), according to previously results. All
VIM-1 producers resulted intermediate/resistant to IP and MP; decreased
MIC values were observed in 2/8 cases. Carbapenem MICs >8mg/L
were detected for IMP-13 P. aeruginosa producers; 6/9 OXA CBs
producing Ab showed IP MIC 8mg/L and 3/6 MER MIC 8mg/L. 3/9
Ab OXA-58/-51 producers, tested using NB40 panel, were intermediate
or resistant to doripenem and meropenem.
Conclusion: Regarding the detection of BLs overall agreement between
MS and reference methods was 91.9%. Carbapenems MIC values
resulted a fold lower than previously determined. Nevertheless using
2010 EUCAST breakpoints for ETP, MER and IP was possible to detect
all CBs producers. MS System represents a useful tool to perform
identiﬁcation of BL-producing Gram negative bacteria.
P756 Automating selection of epidemiological cut-off values using
a dedicated software tool: MicDat®
J. Turnidge*, J. Mouton, N. Punt (North Adelaide, AU; Nijmegen,
Maastricht, NL)
Objectives: Examination of MIC distributions and the setting of
epidemiological cutoff values (ECVs) are now recognised for their
contribution to clinical breakpoint setting and as deﬁning wild-type
versus non-wild-type phenotypes. We previously developed a statistical
method for selecting ECVs in an effort to eliminate any subjective
component to their selection. We wished to develop an easy-to-use
spreadsheet program that would automate the statistical method and
provide measures of dispersion of the ECV estimates.
Methods: We implemented the statistical method in Microsoft Excel®
using VBA-encoded macros, standard Excel functions and the Solver
add-in, and included a link to the EUCAST wild-type database. The
output includes a measure of error of the ﬁt. To validate the software
and compare the output to the currently published ECVs (determined
by visual inspection and group uniformity), we examined the published
EUCAST MIC distributions for ampicillin against 42 bacterial species.
Ampicillin was chosen as it was associated with a broad range
of distribution and resistance types, including bimodal and trimodal
distributions, common and rare “resistances” and intrinsic and acquired
resistance mechanisms.
Results: The software easily handled well-behaved MIC distributions,
including bimodal populations with small, similar and dominant upper
modes, and readily produced reliable estimates of ECVs. The software
produced results similar to those obtained by visual inspection when
the 97.5% of the modelled wild-type population was used to select the
ECV. It also demonstrated that applying group or genus ECVs may not
be appropriate. The software was also capable of determining a lower
cutoff value, a value of potential use in detecting strain misidentiﬁcation.
Problems estimating ECVs were experienced with M. catarrhalis due to
the low prevalence of the wild-type and 4 modes, and N. gonorrhoeae
due the lack of distinct wild-type mode. The software analysis also
highlighted some unusual MIC distributions, consistent with them
including strains with incorrect identiﬁcations.
Conclusions: MicDat® simpliﬁes the process of selecting ECVs, avoids
the subjectivity of selection by visual inspection, and offers potential
for on-line automation of ECVs initially and when MIC distribution
data are modiﬁed. It is also capable of identifying suspect distributions
which require review of data sources, susceptibility testing methods and
species identiﬁcation techniques.
P757 Amoxicillin-clavulanic acid susceptibility testing: ﬁxed ratio
versus ﬁxed concentration of clavulanic acid
T. Halaby*, N. Al Naiemi, T. van ’t Klooster, N. Koehorst, F. Heilmann
(Enschede, NL)
Introduction: In currently available susceptibility testing methods
amoxicillin-clavulanic acid (AC) is tested with a ﬁxed ratio of 2:1, while
according to the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) the inhibitor concentration should be ﬁxed at 2mg/L.
In this study, susceptibility testing using a ﬁxed concentration, as
advocated by the EUCAST, was examined, and compared to the routine
testing with a 2:1 ratio.
Materials and Methods: 100 Escherichia coli clinical strains from
routine urinary specimens with known susceptibility, as determined by
the agar-dilution method, were included. All were amoxicillin-resistent.
For quality control E. coli ATCC 25922 and E. coli ATCC 35218 (for
b lactam–blactamase inhibitor combination) were tested. Susceptibility
testing was performed by using 3 methods: 1. Mueller Hinton (HM) agar
plates containing the routinely used concentrations of AC with a ﬁxed
ratio (4:2, 8:4, 16:8 and 32:16mg/L), 2. HM agar plates with the same
amoxicillin concentrations but with a ﬁxed clavulnic acid concentration
at 2mg/L, 3. E-test for both amoxicillin and AC. Comparisons were
made using the c2 test.
Results: Fixed concentration of clavulanic acid at 2mg/L resulted in
a signiﬁcantly less inhibition than a ﬁxed amoxicillin/clavulanic acid
ratio of 2:1 (P = 0,02) (Fig 1). At an amoxicillin MIC of 8mg/L
(EUCAST breakpoint), 58% of strains are inhibited with the current used
methodology (ﬁxed ratio), whereas only 43% would have been inhibited,
should a 2mg/L ﬁxed concentration of clavulanic acid be used.
Conclusion: According to EUCAST the interpretative criteria for
amoxicillin-clavulanic acid susceptibility testing is based on a ﬁxed
concentration of clavulanic acid at 2mg/L. However, routinely used
susceptibility tests for AC, including Vitek, E-test, agar dilution- and
disc diffusion methods, are based on a ﬁxed ratio of 2:1, leading to
an underestimation of resistance rates. Therefore, such tests should be
modiﬁed by the manufacturers to meet EUCAST criteria.
P758 A rapid and functional assay for detection of resistance
against b-lactam antibiotics by MALDI-TOF mass
spectrometry
K. Sparbier, U. Weller, S. Schubert, C. Boogen, M. Kostrzewa*
(Bremen, Cologne, Munich, DE)
Objective: The growing number of antibiotic resistant microorganisms
is an increasing health care problem. b-lactam-resistant bacteria express
b-lactamases which destroy the b-lactam ring of b-lactam antibiotics by
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hydrolysis. A rapid MALDI-TOF MS based assay was set up to analyze
hydrolysis of different b-lactam antibiotics by certain bacteria.
Methods: Ampicillin and cephalosporins were tested with ESBL
E. coli strains and DH5a as negative control. Ertapenem, Imipenem
and Meropenem were tested with carbapenemase positive Klebsiella
pneumoniae strains and a sensitive strain as negative control. Antibiotics
were dissolved in water. 10ml of this solution were inoculated with 5
colonies of the corresponding bacteria and incubated for 3 h at 37ºC
under agitation. After centrifugation, 1ml of the supernatant was directly
applied to a MALDI sample carrier plate. Dried spots were overlaid with
MALDI matrix. MALDI-TOF MS spectra were acquired on a microﬂex
LT.
Results: The MS spectrum corresponding to DH5a revealed the
molecular peak of ampicillin at [M+H]+ 350 and the sodium adducts
[M+Na]+ at 372 and [M+2Na]+ at 394 Da. In contrast, the ESBL
derived spectra revealed clearly decreased peaks for ampicillin and
it’s adducts. Additional peaks at 368, 394, 412 and 324 Da appeared
corresponding to the hydrolyzed form of ampicillin, its sodium adducts
and the hydrolyzed, decarboxylated form of ampicillin, respectively. A
slight spontaneous hydrolysis of ampicillin was observed for DH5a.
Comparable results were achieved for Klebsiella pneumoniae and
carbapenems. Carbapenems did not tend to form sodium adducts.
Additionally, the hydrolyzed form of carbapenems is very labil and
decarboxylated immediately. A clear difference was observed between
the carbapenem sensitive strain and the carbapenamase positive strains.
For evaluation, the ratio of the sum of the areas of the non-hydrolyzed
forms and the sum of the enzymatically converted forms of the
antibiotics was calculated. The quotient is less than 1 for resistant
bacteria and exceeds 1 for antibiotics sensitive strains facilitating a
simple and easy detection of resistant bacterial strains.
The analysis of cephalosporin resistant bacteria resulted in the
disappearance of the antibiotic molecular peak without the appearance
of the corresponding hydrolysis products.
Conclusions: The developed approach provides a rapid method for the
detection of penicillin and carbapenem resistant bacteria within 4 h.
P759 Screening and conﬁrmation methods for carbapenemases in
Enterobacteriaceae
J.W. Cohen Stuart*, G. Voets, S. Voskuil, J. Scharringa, A.C. Fluit,
M. Leverstein-Van Hall (Utrecht, NL)
Objectives: In 2010, our group published a guideline for detection
of carbapenemases in Enterobacteriaceae (IJAA 2010). This guideline
recommends a meropenem screening breakpoint of 0.5mg/L or a
zone diameter of 23mm (10ug disk loading), or, alternatively, the less
speciﬁc ertapenem (0.5mg/L). Carbapenemase inhibition tests with
boronic acid (BA) were recommended for KPC and with EDTA or
dipicolinic acid (DPA) for metallo-carbapenemases (MBL). The aim
of this study was to evaluate meropenem and ertapenem as screening
carbapenems, and to compare our guideline breakpoints with EUCAST
clinical breakpoints. In addition, the inhibition tests with BA and DPA
for carbapenemase conﬁrmation were evaluated, and the CICA-B-Test
as MBL detection test.
Methods: 61 carbapenemase producers were included (44 K. pneumo-
niae, 7 E. coli, 5 Enterobacter spp., 3 S. marcescens, 2 P. mirabilis
of which 30 KPC, 25 MBL (16 VIM, 6 GIM, 3 NDM), 4 KPC/VIM
combined, 1 SME, 1 OXA-48) and 136 negative controls (32 AmpC,
84 ESBL, 3 ESBL/plasmid AmpC combined, 8 K1 hyperproducing
K. oxytoca, 2 non ESBL TEM/SHV, 7 E. coli without b-lactamase). MICs
of meropenem and ertapenem were determined using broth microdilution
(Merlin). Carbapenem zone diameters were determined using 10ug discs
(Mast) and tablets (Rosco). The conﬁrmation tests were obtained from
Rosco. Cica-B-Tests were obtained form Mast.
Results: Results of screening with meropenem and ertapenem are shown
in the Table. Conﬁrmation of KPC production using BA + meropenem
combination discs had a sensitivity of 85% and a speciﬁcity of 100%.
Conﬁrmation of MBL production had a sensitivity of 79% and a
speciﬁcity of 100%. When the KPC/VIM double positive isolates were
excluded, the sensitivity of APBA/meropenem for KPC production was
97%, and the sensitivity of DPA/meropenem for MBL production was
92%. The sensitivity of the Cica-B tests for MBL detection was 41%
and the speciﬁcity of 34%.
Conclusion: For carbapenemase detection, screening with meropenem
is more sensitive and speciﬁc than screening with ertapenem. The
meropenem 0.5mg/L screening breakpoint for carbapenemases was
100% sensitive versus 92% using the meropenem EUCAST clinical
breakpoint. The inhibition tests with BA for KPC and with DPA for
MBLs are sensitive and speciﬁc, although those tests failed to detect
isolates producing both VIM and KPC. Cica-B strips require further
development for detection of MBLs.
P760 Discrepancies in susceptibility testing of KPC-producing
Klebsiella pneumoniae using Vitek2
E. Cavassin, E. Sakagami, A. Fogagnoli, C. Santos, G. Von Konell,
K. Macedo, S. Sampaio, J. Sampaio* (Sao Paulo, BR)
Carbapenemase producing Klebsiella pneumoniae has become dissem-
inated in Brazilian hospitals during the last two years, restricting
the empirical therapeutic options for patients with severe nosocomial
infections potentially caused by Gram-negative rods.
Since automation is largely used in Brazilian hospitals we aimed at
evaluating the performance of Vitek2 system for detection of KPC
producing K. pneumoniae and evaluate the susceptibility to carbapenems,
tigecycline and colistin.
A total of 22 K. pneumoniae strains conﬁrmed to have the blaKPC gene,
one per patient, from ﬁve different private hospitals located in Sao Paulo,
Brazil, were tested with AST-N105 card using Vitek2 software version
4.02. All strain were also tested for polymyxin B, tigecycline, imipenem
and meropenem susceptibility using home made broth microdilution
panels (BMD) according to EUCAST and CLSI documents.
When tested with Vitek2, all isolates had MICs equal to or higher than 4
mcg/ml for ertapenem and would be classiﬁed as resistant by EUCAST
or CLSI criteria. Concerning imipenem, 31.8% had MICs equal to or
lower than 2 mcg/ml and were susceptible using EUCAST, but 9.9% had
MICs equal to or lower than 1 mcg/ml and were susceptible using CLSI
criteria. For meropenem, 63.6% of isolates had MICs equal to or lower
than 2 mcg/ml and were susceptible using EUCAST while 54.5% were
susceptible using CLSI criteria. Contrasting to this ﬁndings, all isolates
had MICs higher than 2 mcg/ml for imipenem and meropenem when
tested by BMD.
Concerning polymyxin B, 77.3% of isolates were susceptible by BMD
and there was a 95.4% category agreement with colistin results generated
by Vitek2. For tigecycline only 31.8% of isolates had MICs equal to or
lower than 1 mcg/ml by the Vitek2 system, contrasting to 95.4% by
BMD.
There was a high rate of false sensitivity to meropenem and a high rate
of false resistance to tigecycline when KPC producing K. pneumoniae
were tested with Vitek2. Strains resistant to tigecycline by Vitek2 must
be reevaluated by a reference method before results are released to
clinicians.
Antimicrobial susceptibility testing S177
P761 Evaluation of Alert™ PBP2a immunochromatographic assay
for detection of methicillin resistance in Staphylococcus
isolates
R. Selvarangan*, A. Nguyen, B. Doerge (Kansas City, US)
Objective: Penicillin-binding protein 2 a (PBP2a) mediates methicillin-
resistance in Staphylococcus spp. The aim of this study was to evaluate
the performance of Alere™ PBP2a assay; a rapid immunochromato-
graphic assay for the detection of PBP2a in isolates of Staphylococcus
spp., as a marker for methicillin-resistance.
Methods: A total of 175 Staphylococcus aureus (75 frozen retro-
spective isolates, 100 prospective isolates) and 75 coagulase-negative
staphylococcus (CoNS) isolates (prospective) grown on columbia agar
with 5% sheep blood (CA), tryptic soy agar with 5% sheep blood
(TSA) or Mueller-Hinton agar (MHA) with cefoxitin and oxacillin disks
were tested by the Alere™ PBP2a assay and results were compared
with the cefoxitin disk diffusion test (gold standard) per CLSI criteria.
Staphylococcus spp. was identiﬁed by Vitek 2 system.
Results: Methicillin-resistance was detected in 86/175 S. aureus isolates
(48 prospective, 38 retrospective) and 35/75 CoNS isolates by cefoxitin
disc testing. The performance of Alere™ PBP2a assay tested on
Staphylococcus isolates grown on different medium was calculated by
comparison with cefoxitin results. Overall sensitivity of Alere™ PBP2a
assay to detect methicillin-resistance was 98% for S. aureus and 83% for
CoNS. Testing CoNS isolates induced by exposure to oxacillin improved
sensitivity to 97%. No false positives were detected with the Alere™
PBP2a assay (see table).
Conclusion: The Alere™ PBP2a assay is a highly sensitive and
speciﬁc assay for rapid detection of methicillin-resistance in S. aureus
isolates. For CoNS isolates induction with oxacillin disk is necessary to
improve the sensitivity of the Alere™ PBP2a assay. Detecting methicllin-
resistance in Staphylococcus isolates in less than 10 minutes by using the
Alere™ PBP2a assay provides opportunity to tailor antibiotic therapy.
P762 The effects of varying susceptibility test parameters on
TP-434 activity in vitro
C. Pillar, D.F. Sahm, T. Grossman*, J. Sutcliffe (Chantilly, Watertown,
US)
Objective: TP-434 is a novel ﬂuorocycline entering Phase 2 clinical trials
for intra-abdominal infections. To support clinical development, a study
was run to evaluate the effects of various susceptibility test conditions on
TP-434 minimal inhibitory concentrations (MICs) for aerobic bacteria.
Tigecycline (TIG), a tetracycline with known sensitivities to media age
and divalent ion content, was used as the comparator (Peterson, et al.
2005. AAC 49:3910; Bradford, et al. 2005. AAC 49: 3903; Fernandez-
Mazarrasa et al. 2009. JCM 47:827).
Methods: Broth microdilution and agar dilution were performed
according to standard CLSI methodology. Varied assay parameters
evaluated included: fresh/frozen media, aged (2 weeks at room
temperature)media, added serum or blood, altered pH, added calcium,
added polysorbate, Haemophilus test medium (HTM), carbon dioxide
and altered inoculum size. A 4-fold difference in MICs was considered
potentially signiﬁcant.
Results: TP-434 MICs for Staphylococcus aureus (Sa) ATCC29213,
Enterococcus faecalis (Ef) ATCC29212, Streptococcus pneumoniae (Sp)
ATCC 49619, Escherichia coli (Ec) ATCC25922 and Haemophilus
inﬂuenzae (Hi) ATCC49247 were largely unaffected by most conditions.
A 2- to 4-fold decrease in MIC was observed for Sp at pH 6.0 and Ef at
pH 8.0. A 4-fold increase in MIC was observed only for Ef in 0.002%
polysorbate and 5% and 10% human serum. No signiﬁcant differences in
MICs were observed for inocula ranging from 5×104 to 5×106 CFU/mL.
A 4-fold increase in TIG MIC was noted for Ef in polysorbate. TP-434
MICs in aged media were unchanged or within one dilution of MICs
in fresh media for 92.3% of all tested clinical isolates (n = 30 isolates
+ Ec, Sa, Ef QC strains in triplicate); 7.6% of the MICs were elevated
4-fold in aged media. This was in contrast to TIG where MIC values
in aged media were unchanged (at or within one dilution of MICs in
fresh media) for 69.2% of all tested isolates, while 30.7% showed 4-
fold increases in MICs. Agar dilution and microdilution MICs for both
TP-434 and TIG were similar, suggesting no signiﬁcant interaction with
agar.
Conclusions: In contrast to TIG, in vitro antibacterial activity of TP-434
appears to be largely unaffected by media age and media additives.
P763 A pragmatic approach to blood culture isolate susceptibility
testing and ID on the fast track: direct E-test and
MALDI-TOF mass spectrometry
J.V. Bjørnholt*, P. Gaustad, A. Ingebretsen, T.M. Leegaard (Oslo,
Nordbyhagen, NO)
Objectives: Both valid susceptibility and identiﬁcation (ID) of a blood
culture isolate are of vital signiﬁcance for the clinician, guiding treatment
from only one of these parameters include serious caveats. We present
the evaluation of the application of direct Etest on positive blood cultures
and Maldi-Tof MS ID of the isolate when the Etest can be read.
Methods: Consecutive Bactec blood culture bottles (BD) positive
for bacteria (ﬂagged positive and positive on Gram/acridine orange
microscopy) were included. 2−3 drops were plated onto 140mm Mu¨ller-
Hinton plates with 5% sheep blood. Direct susceptibility testing by
Etest (bioMerieux) (5−6 Etest strips according to microscopy ﬁndings)
were read as early as possible (i.e. visible growth), and identiﬁed with
MALDI TOF MS using the MALDI Biotyper 2.0 software (Bruker
Daltonics). Early reading were compared to gold standard Etest and
VITEK2 (bioMerieux) susceptibility and ID results.
Results: 249 positive blood cultures were included. Mixed cultures were
excluded from the present analysis, as well as fastidious and anaerobic
isolates. 43% (103/239) had susceptibility from both Vitek2 and Etest
“gold standard” in addition to direct Etests. The early reading could be
performed at median time 6 hours, range 3−24 hours) and concomitant
Maldi-Tof MS ID were obtained on 100% of isolates to genus level
and 98% to species level. The MS procedure is completed within 15
min. Meropenem, TMX and gentamicin MIC’s are read too high by the
early reading for Enterobacteriaceae. Ampicillin, TMX, and clindamycin
are read too high or are difﬁcult to interpret for coagulase negative
staphylococci as well as ampicillin and clindamycin for Staphylococcus
aureus. There were no inconsistencies in susceptibility results between
early reading and gold standard Etest for Escherichia coli, Streptococcus
pneumoniae and Group A, B and C streptococci. For the enterococci one
major inconsistency for penicillin G was experienced in 1/23 isolates.
Conclusion: A practical approach consisting of direct application of
Etests on positive blood cultures and Maldi-Tof MS ID deliver both valid
antimicrobial susceptibility and ID for 66% (95%CI 60−72) of positive
blood cultures within 6 hours with minor workload. Antimicrobials tested
for should, however, be carefully chosen and cultures with more than one
species should receive special attention.
P764 Performance of the Dutch national phenotypic ESBL
detection guideline in clinical setting
T.N. Platteel*, J.W. Cohen Stuart, G.M. Voets, J. Scharringa, A.J. de
Neeling, N. van de Sande, M.J. Bonten, A.C. Fluit, M. Leverstein-van
Hall on behalf of the ESBL National Surveillance Working Group
Objectives: In 2008, the ESBL working party of the Dutch Society
for Medical Microbiology (NVMM) formulated and implemented a
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guideline for phenotypic screening and conﬁrmation of ESBLs in Enter-
obacteriaceae. This guideline recommends to conﬁrm ESBL production
with ESBL Etest or combination disc (CD) in Enterobacteriaceae with
a ceftazidime/ceftriaxone MIC >1mg/L or an ESBL alarm by Phoenix
or Vitek-2. The objectives of this study were to determine the accuracy
of phenotypic ESBL detection in Dutch clinical laboratories using this
guideline and to compare the performance of Etest and CD as ESBL
conﬁrmation tests in the clinical setting.
Methods: From February 1, 2009 to May 1, 2009, 20 laboratories
submitted all E. coli, K. pneumoniae, K. oxytoca, P. mirabilis and
Enterobacter spp. isolates with a positive ESBL screentest to a reference
laboratory. The ﬁrst 25 non-repeat isolates per laboratory were included.
Genotypic detection of ESBLs using microarray analysis and sequencing
was used as reference test. Phenotypic conﬁrmation tests were centrally
repeated in case of a discrepant result of the phenotype reported by the
participating laboratory and the ESBL genotype.
Results: Of 440 included isolates (74% E. coli, 12% E. cloacae, 8%
K. pneumoniae, 3% P. mirabilis and 2% K. oxytoca), 313 (71%) isolates
harboured an ESBL gene. The sensitivity of the phenotypic ESBL
conﬁrmation tests as performed in the participating laboratories was
95%, the speciﬁcity 72%, the positive predictive value (PPV) 93%, and
the negative predictive value (NPV) 89% (Table). When the phenotypic
conﬁrmation was repeated centrally, the phenotype of 6/11 (55%) false
negative and 14/21 (67%) false positive isolates was in agreement with
the genotype.
ESBL conﬁrmation was performed with Etest on 279 isolates, with CD
on 135 isolates and with both on 26 isolates. Sensitivities of Etest and
CD were not statistically different (96% and 92%, resp). The CD was
more speciﬁc than Etest (91% vs 61%, resp; p< 0.001). However, Etest
and CD did not have signiﬁcantly different PPV (94% vs 96%, resp) and
NPV (94% vs 83%, resp).
Conclusion: Implementation of a national guideline has resulted in
adequate phenotypic detection of ESBL-positive isolates, and generation
of reliable surveillance data in the Netherlands. Although the sensitivity,
PPV and NPV of CD and Etest as ESBL conﬁrmation tests were
comparable, Etests were less speciﬁc due to non-determinable and false
positive results.
P765 Vancomycin susceptibility trends in MRSA isolated from
blood cultures in Aberdeen Royal Inﬁrmary from 2006–2010.
Is vancomycin “creep” method dependent?
B. Edwards*, K. Milne, I. Cook, I.M. Gould (Aberdeen, UK)
Objectives: To assess the possibility of a vancomycin ‘creep’ among
all MRSA isolates from blood cultures from 2006 to 2010 in Aberdeen
Royal Inﬁrmary. Susceptibility testing was performed by E-tests.
Methods: All 208 MRSA bacteraemia isolates were identiﬁed from
microbiology laboratory records. Where available, original MIC values
performed by E-test were also obtained from laboratory records. All
other tests were performed on isolates recovered from storage in protekt
at −70 degrees. All isolates were subbed twice prior to any method
of susceptibility testing. E-tests were performed as per manufacturer’s
guidelines on Mueller-Hinton agar, and read blind by 2 people.
Results: Of 208 MRSA isolates, 88 had a vancomycin E-test performed
at the time of isolation, as this only became routine practice from
mid December 2007. 160/208 MRSA isolates were available in storage
in the Aberdeen laboratory for further susceptibility testing. On repeat
E-testing of these samples, there was usually (in 93.3% of isolates) a
lower MIC obtained in the isolates from storage than that obtained at
original testing. In some cases the MIC by E-test differed by as much
as 4 increments on the E-test strip. ‘Creep’ was observed in the original
E-test MICs (see graph), but not in those performed on stored isolates.
With the original MICs the highest proportion of isolates at 29% had an
MIC of 0.5 in 2006, as opposed to 55.3% with an MIC of 1.5 in 2010.
For the isolates taken out of storage, the highest proportion of isolates
all had an MIC of 0.5, except 2008 where the highest proportion had an
MIC of 0.75.
Conclusions: The MRSA isolates from storage were much more
susceptible to vancomycin than the samples when tested originally.
Raised MICs seem to be an unstable phenomenon. This may explain
why the vancomycin ‘creep’ is not consistently reported.
P766 MALDI-TOF mass spectrometry: detection of carbapenem
resistance within one hour
I. Burckhardt*, S. Zimmermann (Heidelberg, DE)
Objectives: Carbapenem resistance is the latest obstacle in the ﬁght
against bacterial infections. Fast and reliable detection of resistance
is indispensable. However, time to result for agar diffusion or MIC
determination is about 18 hours and sometimes resistance is not properly
expressed. PCR is reliable but costly and can only detect known
resistance mechanisms. We wanted to develop a method which is fast,
easy, low in cost and reliable.
Methods: We used MALDI-TOF MS (matrix assisted laser desorption
ionization time of ﬂight mass spectrometry) to determine carbapenem
resistance by monitoring the degradation of ertapenem through strains
carrying the following carbapenemases: IMP-1, IMP-2, KPC-2, VIM-1,
VIM-2 and NDM-1.
Results: Degradation of ertapenem was clearly visible within one hour
for NDM-1 and IMP-1. IMP-2, KPC-2 and VIM-1 needed about 1.5
hours for degradation and VIM-2 needed 2.5 hours. All controls were
negative (e.g. ESBL+ strains, K1+ strains).
Conclusions: We recommend this method as a fast conﬁrmation test for
carbapenem resistant bacterial isolates. This method is especially helpful
in an outbreak situation.
P767 A novel ﬂow cytometric method for rapid detection of
carbapenem-resistant Gram-negative bacteria
I. Faria-Ramos*, J. Santos-Antunes, A.G. Rodrigues, C. Pina-Vaz
(Porto, PT)
Objectives: Gram-negative pathogens are responsible for an increasing
number of serious nosocomial infections, including hospital-acquired
pneumonia, urinary tract infections, and bacteraemia. The increasing
frequency of Gram-negative clinical isolates resistant to carbapenems
makes its early detection a priority. Therefore, rapid reliable detection
is a prerequisite for successful infection control as well as accurate
therapeutic management. The aim of this study was to develop a new
detection methodology for carbapenem-resistant Gram-negative bacteria
using Flow Cytometry.
Methods: An antimicrobial susceptibility analysis was performed on
thirty four clinical isolates of Acinetobacter baumannii, Pseudomonas
aeruginosa and Enterobacteriaceae with known susceptibility proﬁle
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to carbapenems, previously performed by Vitek 2 automated system
(BioMe´rieux, Paris) and additionally by Etest (BioMe´rieux, Paris).
Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC
27853 were used as controls. For Flow Cytometry analysis, bacterial cells
were incubated in ﬁltered Muller-Hinton broth until exponential phase
and then exposed to different concentrations of meropenem, imipenem,
doripenem and ertapenem for 1 hour and 2 hours and afterwards stained
with Bis-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBAC4(3)), a
lipophilic anion able to diffuse across depolarized membranes. From
Flow Cytometry suspensions, conventional Colony-Forming Units (CFU)
assays were performed in order to establish a correlation between
depolarized cells quantiﬁed by Flow Cytometry.
Results: A clear discrimination between susceptible and resistant
strains was possible, soon after 1 hour of treatment with the studied
carbapenems. An excellent correlation was obtained between the
number of depolarized bacteria quantiﬁed by Flow Cytometry and the
conventional CFU assays.
Conclusions: A novel, simple and fast assay is now available to
detect carbapenem-resistant Gram-negative bacteria based upon Flow
Cytometry.
P768 Detection of carbapenemase enzymes in clinical isolates of
Pseudomonas aeruginosa by Re-modiﬁed Hodge Test and
other phenotypic methods
S. Jain*, S. Rai, K.N. Prasad, T.N. Dhole, A. Maurya (Lucknow, IN)
Objectives: Therapeutic failure to carbapenems is increasingly reported
in Pseudomonas aeruginosa due to emergence and rapid spread
of Metallo b Lactamase (MBL) enzymes which are present even
in carbapenem sensitive isolates. Presently no standard guidelines
for phenotypic testing are available for detection of carbapenemase
enzymes in Pseudomonas aeruginosa and previous reports are variable.
Timely and accurate laboratory detection and reporting of such
isolates harboring these enzymes will indicate their prevalence pattern
and will help advent appropriate and rational use of alternative
antimicrobials agents. Aim of present study was to detect the presence
of carbapenemase enzyme activity in carbapenem resistant and sensitive
isolates of Pseudomonas aeruginosa.
Methods: Study was conducted in Department of Microbiology at
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, a
1000 bedded tertiary care hospital in North India, over a 2 month period
(August–September 2008). We evaluated a Re-modiﬁed Hodge Test
and compared it with conventional Modiﬁed Hodge Test, Double Disc
Synergy Test (DDST) using ethylenediaminetetraacetic acid (EDTA)
with imipenem, meropenem and ceftazidime and EDTA Imipenem
Microbiological (EIM) assay among carbapenem resistant and sensitive
isolates of Pseudomonas aeruginosa. We also extended principle of three
dimensional enzyme extract test (3DT) for evaluation of MBL activity.
114 isolates of Pseudomonas aeruginosa were divided into two groups
(resistant and sensitive) based on minimum inhibitory concentration
values.
Results: 83 isolates were carbapenem resistant and 31 were sensitive.
Modiﬁed Hodge and re-modiﬁed Hodge tests were able to detect 58%
and 82% of MBLs in carbapenem resistant, and 19% and 32% of
carbapenem sensitive isolates respectively. Individually, EIM test and
ceftazidime/EDTA DDST were the most sensitive tests detecting MBLs
in 88% and 49% of carbapenem resistant, and 19% and 35.5% of
carbapenem sensitive isolates respectively. 3DT for MBL detection had a
poor sensitivity of 54% of carbapenem resistant and only 3% carbapenem
sensitive strains.
Conclusion: This study validates the use of Re-Modiﬁed Hodge Test for
routine detection of MBL activity in Pseudomonas aeruginosa as it is a
sensitive and technically easy to perform phenotypic test. Its routine
induction will maximize detection of MBL harboring Pseudomonas
aeruginosa resulting in proper and effective antimicrobial guidance.
P769 Application of ﬂuorescence in situ hybridisation using
peptide nucleic acid probes in gastric samples for detection
of Helicobacter pylori clarithromycin resistance
L. Cerqueira*, R. Fernandes, R. Ferreira, F. Carneiro, M. Dinis-Ribeiro,
C. Figueiredo, C.W. Keevil, N.F. Azevedo, M. Vieira (Braga, Porto,
PT; Southampton, UK)
Objectives: Microorganisms are responsible for several infectious
diseases that can cause severe problems to patients and their treatment
success is seriously correlated with the fast detection of the infectious
agent. Some of the standard methods used, such as culturing methods
are fastidious and time-consuming and do not give any information
about the antibiotic resistance proﬁle. Therefore, molecular methods have
been developed during the last several years in order to overcome these
shortcomings. In this work a new genotypic method that permits the
identiﬁcation of the microorganism in clinical samples in a prompt way
is proposed. This technique is based on Fluorescence in situ hybridization
with PNA probes that are synthetic molecules, complementary to a
speciﬁc rRNA sequence of the microorganism.
Methods: A set of PNA probes were designed concerning H. pylori
point mutations regarding clarithromycin resistance which is the
main problem of gastric diseases treatment failure. An additional
probe concerning susceptibility was also designed. After hybridization
conditions optimization, probes were applied to H. pylori smears to
achieve their practical sensitivity and speciﬁcity. At the end they were
applied to gastric biopsies in a retrospective study for method validation
in real samples. E-test and PCR-sequencing were used to evaluate the
results.
Results: The probes concerning clarithromycin resistance hybridized
only with the resistant strains that had the corresponding point mutations
and as such presented 100% sensitivity (95%CI, 79.9–100) and 100%
speciﬁcity (95%CI, 71.6–100). Results also showed that it is possible
to discriminate susceptible from resistant H. pylori strains in gastric
biopsy samples since it was presented similar results between the 3 tests
used. Overall, the PNA-FISH method was in full agreement with PCR-
sequencing although it was a little bit lower when compared to E-test that
it was used as gold standard method in this retrospective study (86%).
Conclusion: PNA-FISH proved to be an important in situ method for
detection of microorganisms in clinical samples in a more prompt way
than the standard methods. Due to high H. pylori probes sensitivity and
speciﬁcity it is proved the applicability of PNA-FISH methodology to
clinical material, thus overcoming the need of culturing steps and/or
PCR/sequencing procedures and enabling rapid initiation of appropriate
antibiotic therapy until culture conﬁrmation several days later.
P770 Comparison of the PBP2a latex agglutination assay, PBP2a
rapid immunochromatographic assay and chromogenic
medium for identifying methicillin-resistant Staphylococcus
aureus directly from positive blood cultures
S. Hong, B. Son, K. Shin* (Cheongwon, Cheongju, KR)
Objectives: Rapid and precise molecular methods (eg., real time-
PCR) have been developed for the detection of methicillin-resistant
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Staphylococcus aureus (MRSA) from blood cultures; however, molecular
testing often requires additional expertise and instrumentation that
in many clinical laboratories may be not readily available. This
study compared three non-molecular methods for the detection of
methicillin resistance directly from blood cultures containing clusters
of Gram positive cocci: penicillin-binding protein (PBP) 2a latex
agglutination (LA), PBP2a immunochromatographic assay (ICA) and
MRSA chromogenic medium (CM).
Methods: In total, 100 S. aureus (50 MRSA and 50 methicillin-
susceptible S. aureus (MSSA) conﬁrmed by mecA and nuc PCR)
were seeded into blood-culture bottles (Bact/Alert 3D, USA). When the
isolates gave a positive signal, 5mL of blood from the culture broth was
added to three serum separator tubes each and the tubes were centrifuged
at 1,300 g for 10 min. Two pellets were used as the inoculum for direct
PBP2a LA (Denka Seiken, Japan) and MRSA-CM (ChromID MRSA,
BioMe´rioux, France). Subsequently, PBP2a LA and MRSA-CM were
tested and interpreted following the manufacturer’s instructions. For a
novel PBP2a ICA (PBP2a MRSA Rapid kit, DiNona, Korea), a pellet
was inoculated in BHI broth containing 4mg/mL cefoxitin to induce more
much PBP2a for 4 h at 35ºC. Then, 0.1mL of lysis buffer and Tween 20
was added for 10 min and the lysate was tested using the MRSA rapid
kit, which was interpreted within 20 min.
Results: For the PBP2a LA, seven isolates of MRSA and ﬁve isolates of
MSSA showed the ambiguous agglutination and were scored as negative.
The respective sensitivities and speciﬁcities for the direct detection of
MRSA from positive blood culture were 78% and 100% for PBP2a LA,
98% and 100% for PBP2a ICA, and 100% and 100% for MRSA-CM
(Table 1).
Conclusions: MRSA-CM and PBP2a ICA gave superior results to
PBP2a LA. With PBP2a LA, it is necessary to use an isolated colony
rather than a pellet from blood culture broth directly. The accuracies of
the PBP2a ICA and MRSA-CM were comparable. MRSA-CM is more
effective than PBP2a ICA, based on the simplicity of the procedures and
ease of interpretation, but the turnaround time of PBP2a ICA is faster
than that of MRSA-CM. Thus, PBP2a ICA is a useful alternative method
for the early management of MRSA bacteraemic patients in hospitals that
do not have access to molecular methods for detecting MRSA.
P771 A comparative study of antibiotic gradient devices for the de-
termination of tigecycline minimum inhibitory concentration
S. Withey* (Basingstoke, UK)
Objectives: The ability to simply and accurately determine antimicrobial
susceptibility is of fundamental importance to the clinical microbiology
laboratory. The aim of this study was to compare the performance of the
tigecycline Oxoid M.I.C.Evaluator (M.I.C.E.) (Thermo Fisher Scientiﬁc)
with tigecycline Etest (bioMe´rieux) and the CLSI, BSAC and EUCAST
agar and/or broth dilution methods.
Methods: Two hundred and thirteen clinically signiﬁcant organisms were
tested, including staphylococci, streptococci, haemophilus, anaerobes
and Enterobacteriaceae. Overnight cultures were used to make a 0.5
McFarland suspension of each isolate (1.0 McFarland for anaerobic
organisms) for both the agar and/or broth dilutions and plate inoculation.
Inoculated plates and broths were incubated in appropriate conditions
according to CLSI, BSAC and EUCAST methods. Results were used
to determine the essential agreement (EA) of tigecycline M.I.C.E. strips
and tigecycline Etest strips.
Results: Tigecycline M.I.C.E. strips achieved an EA greater than 90%
across all groups of organisms for CLSI, BSAC and EUCAST methods.
Etest equivalents scored less than 90% in ﬁve out of twenty cases for
CLSI, three out of twenty cases for BSAC and four out of twenty cases
for EUCAST. Tigecycline M.I.C.E. strips had an EA equivalent to or
better than Etest in all groups and sub groups of organisms tested when
following the CLSI, BSAC and EUCAST methods.
Conclusion: Tigecycline M.I.C.E. strips are an effective and reliable
alternative to traditional agar/broth dilution methods for determination
of tigecycline MIC. Tigecycline M.I.C.E. strips performed consistently
better than tigecycline Etest strips and statistically signiﬁcantly better
than tigecycline Etest when following the CLSI (P = 0.032) and BSAC
(P = 0.014) methods.
P772 Comparison of Oxoid M.I.C. Evaluator® Strips to CLSI
broth microdilution method and E-test® with selected
antimicrobial agents
S.D. Munro*, C. Tau, N. Banaei, E.J. Baron, A. Hsiung, M.A. Silvius
(Palo Alto, Lenexa, US)
Objectives: The Oxoid M.I.C.Evaluator™ (M.I.C.E.™; Thermo Fisher
Scientiﬁc, Lenexa, KS, USA) incorporates a stable antimicrobial
gradient on a polymer strip. We compared results for penicillin (P),
amoxicillin-clavulanic acid (AMC), imipenem (IMP), vancomycin (VA),
ciproﬂoxacin (CIP) and linezolid (LZD) to Etest® (bioMe´rieux, Inc.,
Durham, NC, USA) and a reference method (CLSI broth microdilution).
Methods: Parallel testing was performed by M.I.C.E, Etest and broth
microdilution on Mueller Hinton agar/cation adjusted Mueller Hinton
broth (MHA/CAMHB), HTM agar/broth for Haemophilus spp. and
blood-supplemented MHA/CAMHB for streptococci. A total of 561 total
organism/strip combinations were tested by each method, using 159 fresh
or frozen stocked bacteria representing clinically important species.
Results: For this study, calculation of essential agreement (EA) of MIC
values (± one doubling dilution) included those values that were off-
scale if agreement was possible (e.g. strip MIC of >32 mcg/ml and
reference MIC of 32 mcg/ml). Overall EA for M.I.C.E. was 80.5%,
and for Etest was 83.8%. In some cases where EA was decreased, the
antimicrobial agent would not be routinely tested for the organism (e.g.
AMC vs. staphylococci). Categorical agreement (CA) was calculated
using CLSI breakpoints. Overall CA was 94.7% for M.I.C.E. and 92.3%
for Etest. Minor errors for all antimicrobial agents for both strips were
<10%, except CIP for Etest, which was 10.2%. Major errors were
observed for AMC for both strips (1.3%), and IMP for both strips (2%).
Very major errors were observed for AMC for both strips (1.3%). Both
M.I.C.E. and Etest results tended to be at least one dilution higher than
the reference method for AMC, VA, and LZD. M.I.C.E. P results and
Etest IMP results tended to run at least one dilution higher than the
reference method.
Conclusion: Both M.I.C.E. and Etest demonstrated very good CA
compared to the reference method. EA for both M.I.C.E. and Etest
was <90% for some organism/strip combinations when compared to
a reference method. M.I.C.E. was a useful alternative to Etest.
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P773 Advantages and limitations of tigecycline and fosfomycin
disk diffusion method for antimicrobial susceptibility testing
in multidrug-resistant strains, including KPC producers
F. Pasteran*, C. Lucero, M. Rapoport, L. Guerriero, I. Barreiro,
E. Albornoz, O. Veliz, A. Corso (Buenos Aires, AR)
The emergence of multidrug-resistant (MDR) strains, as KPC-possessing
Enterobacteriaceae (ENT), has resulted in extremely limited therapeutic
options. “Salvage” therapy includes fosfomycin (FOS) i.v., tigecycline
(TIG) and colistin. The evaluation of the sensitivity to FOS/TIG usually
requires performing a MIC as FOS i.v. breakpoints (BP) are only
available for this method or large proportion of errors has been reported
with the TIG disk.
Objectives: (i) to evaluate the accuracy of FOS and TIG disk
diffusion (DD) against MDR strains; (ii) to propose FOS i.v. DD BP;
(iii) to optimize TIG DD BP for a more reliable use in routine labs.
Methods: A panel of 168 ENT (140 Klebsiella pneumoniae, 20
Enterobacter spp, 5 Serratia marcescens, 2 Citrobacter freundii, 1
K. oxytoca) unique clinical isolates were included. Half of the strains
were KPC+ by PCR. MICs for TIG and FOS were obtained by
agar dilution (AD) (for FOS, Mueller-Hinton agar − MHA − was
supplemented with 25mg/ml of glucose-6-phosphate − G6P). DD was
carried out on MHA with TIG (15ug) and two FOS disks (200ug
FOS/50ug G6P and 50ug FOS/50ug G6P). Results were interpreted
according to EUCAST BP (FOS: S 32mg/ml, R 64mg/ml; TIG:
S 1mg/ml, R 4mg/ml and S 18mm, R 14mm). Categorical
interpretation agreement (CA), very mayor (VM), major (MA) and minor
(MI) errors were calculated.
Results: The DD BP obtained for FOS were: (i) S 17mm, R 15mm
for the 200ug FOS/50ug G6P disk (CA 94%, MI 6%); (ii) S 15mm,
R 12mm for the 50ug FOS/50ug G6P disk (CA 95%, MI 5%).
Colonies within FOS halos should not be considered. CA and errors
for TIG were: CA 42%, VM 3%, MI 55%. We did not ﬁnd DD BP that
could reduce errors to acceptable levels (VM 1%, MA 1.5%, MI 10%).
The best performance was achieved with a TIG BP of S 21mm and
R 16mm, which eliminated the VM errors (CA 64%, MI 36%).
Conclusions: The DD resulted highly reliable for assessing the
sensitivity to FOS i.v. using the BP proposed in this study. Both disks
(200ug FOS/50ug G6P and 50ug FOS/50ug G6P) tested similar. In
contrast, the DD for TIG showed unacceptable levels of errors. Using a
tentative BP of S 21mm and R 16mm, clinical labs could properly
categorize susceptible and resistant strains (VM and MA 0%). But due to
the high level of MI errors, strains with intermediate halos (20−17mm)
must be conﬁrmed by MIC, since these strains could be susceptible,
intermediate or resistant by the reference method. Targeting optimal TIG
therapy would require error minimization with the optimized DD BP
proposed in this study.
P774 Study of MIC results obtained with streptococci and
pristinamycin using a performance evaluation device
MicroScan MICroSTREP® plus panel
P. Schreckenberger, J. Tjhio, J. Hindler, M. Lewinski, F. Sooudipour,
M. Weinstein, J. Rothberg, K. Roshak, J. O’Connor, H. Boyd, B. Zimmer*
(Maywood, Los Angeles, New Brunswick, West Sacramento, US)
Objectives: Pristinamycin is a streptogramin compound that consists
of two components with synergistic antibacterial action against Gram-
positive bacteria. This study evaluated pristinamycin microdilution
with various streptococci on a Performance Evaluation Device (PED)
MicroScan MICroSTREP plus® panel. Panels were read with the
MicroScan® WalkAway System and visually. MIC results obtained from
both read methods were compared to results obtained with frozen broth
microdilution panels prepared according to CLSI methodology.
Methods: 217 streptococci, including 69 Streptococcus pneumoniae, 55
group B streptococci, 32 group A streptococci, 22 other b-hemolytic
streptococci, and 39 viridans group streptococci, were tested concur-
rently on a MicroScan PED Dried MICroSTREP plus Panel and a
frozen reference broth microdilution panel prepared according to CLSI
methodology. Both panels contained pristinamycin in doubling dilutions
from 0.25−8 mcg/ml that contained cation-adjusted Mueller-Hinton
Broth supplemented with lysed horse blood. Test panels were inoculated
using the turbidity standard method and read with the WalkAway System
at 20 hours followed by a visual read.
Results: The essential agreement for all 217 streptococcal isolates tested
was 97.7% (212/217) for the WalkAway System and 96.8% (210/217) for
the visual read when compared to the reference panel. The categorical
agreement was 100% (217/217) for the WalkAway System and 99.1%
(215/217) for the visual read. Categorical errors with the visual read
were 1 minor error with a S. pneumoniae isolate and 1 minor error with
a viridans group streptococcus isolate.
Conclusion: This study shows that testing of pristinamycin with the
MicroScan IUO MICroSTREP plus panel correlates well with a CLSI
reference broth microdilution panel when read both with the WalkAway
System and visually.
P775 Performance of the Vitek2 system for detection of inducible
clindamycin resistance in staphylococci
M. Lee, Y. Hwang*, M.K. Kim, J. Hong (Seoul, KR)
Background: Inducible clindamycin resistance of staphylococci cannot
be detected by the conventional antimicrobial susceptibility tests. The
Clinical and Laboratory Standards Institute (CLSI) recommends testing
for inducible clindamycin resistance in clindamycin non-resistant and
erythromycin resistant (CNR-ER) staphylococci by using a D-zone
test. Recently, the VITEK2 system was developed to detect inducible
clindamycin resistance in staphylococci. We evaluated the performance
of the VITEK2 system by comparing it with a D-zone test.
Methods: In detecting inducible clindamycin resistance, a total of 142
clinical isolates of staphylococci were tested by using the VITEK2
Antimicrobial Susceptibility Test (AST)-P601 card (bioMe´rieux, Marcy
l’Etoile, France) and the D-zone test. Of the 142 isolates of
staphylococci tested, 114 were CNR-ER staphylococci [40 coagulase-
negative staphylococci (CoNS), 74 Staphylococcus aureus] and 28
were staphylococci, either resistant or susceptible to clindamycin and
erythromycin (1 CoNS and 27 S. aureus).
Results: Of the 114 CNR-ER staphylococci, 98.6% (73/74) of S. aureus
and 32.5% (13/40) of CoNS were inducible clindamycin resistant
according to the D-zone test. Overall sensitivity and speciﬁcity of the
VITEK2 system were 98.8% (85/86) and 98.2% (55/56), respectively,
and the agreement between the VITEK2 system and the D-zone test was
98.6% (140/142).
Conclusions: The VITEK2 system shows high concordance with a
D-zone test. The inducible clindamycin resistance in staphylococci can
be detected easily and conveniently by the VITEK2 system.
P776 A new reliable screening method for the evaluation of VISA
and hVISA strains by “Vancomycin-Teicoplanin MIC Test
Strip” (Lioﬁlchem Srl, Italy)
F. Campanile, D. Bongiorno, M. Perez, C. Scuderi, G. Mongelli,
L. Sessa, S. Stefani* (Catania, IT)
Objectives: Heteroresistance to glycopeptides, in which subpopulations
with reduced susceptibility coexist in a seemingly susceptible phenotype,
have been recently associated with clinical failure.
Our objective was the validation of an alternative phenotypic test to
identify VISA and hVISA strains in parallel with other standardised
methods already described and conﬁrmed by population analysis
(PAP/AUC) considered the “gold-standard”.
Methods: The sample consisted of 23 MRSA strains already char-
acterised as hVISA and VISA by population analysis (PAP/AUC),
belonging to the main HA-MRSA and CA-MRSA clones diffused in
Italy. Mu50 and NRS403 (VISA), Mu3 and NRS22 (hVISA), ATCC
29213 and 9 clinical VSSA, were also included as control strains.
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Vancomycin-Teicoplanin MIC Test Strip (VTMTS) consists of a double-
sided gradient strip of VA 32−0.5mg/L and TP 32−0.5mg/L (Lioﬁlchem
srl, Italy). The screening was performed by macro-method (2 McFarland
inoculum) in BHI plates (BD, Diagnostic Systems), and tested in parallel
with the GRD macro-Etest (AB bioMe´rieux, France). The interpretive
MIC cutoffs used at 24 and 48h were used according to the international
guidelines (CLSI 2010; EAS 003).
Results: VTMTS and GRD were able to deﬁne hVISA and VISA strains
in all cases, conﬁrming that VTMTS is a reliable test, correlating well
with the PAP analysis. All VSSA were also conﬁrmed negative. The test
was replicated three times and by two different operators and was found
to be highly reproducible.
Conclusions: Our results demonstrated that the new VTMTS method
is a good alternative for the evaluation of hVISA and VISA strains for
clinical and epidemiological purposes.
P777 Evaluation of the MicroScan MICroSTREP plus
antimicrobial panel for testing b-haemolytic streptococci and
viridans group streptococci
Y. Uh*, I.H. Jang, K.S. Lee, S.D. Park, K.J. Yoon (Wonju, KR)
Objectives: To determine the clinical usefulness of MicroScan
(Siemens Healthcare Diagnostics, Sacramento, CA) MICroSTREP plus
antimicrobial panel (MICroSTREP) for the antimicrobial susceptibility
test of b-hemolytic streptococci (BHS) and viridans group streptococci
(VGS), we compared the MICroSTREP with the Clinical and Laboratory
Standard Institute (CLSI) reference method.
Methods: Seventy ﬁve BHS and ﬁfty nine VGS isolates were tested
for antimicrobial susceptibility to penicillin, ampicillin, cefotaxime,
meropenem, clindamycin, erythromycin, levoﬂoxacin, and vancomycin
with the MICroSTREP and CLSI agar dilution method.
Results: Overall essential agreement of MICs (within ±1 doubling dilu-
tion) and categorical agreement (CA) determined by the MICroSTREP
and CLSI reference method were 98.2% and 96.9%, respectively. For
the BHS isolates, the CAs of individual antimicrobial agents revealed
96.0% with erythromycin, and 100% with cefotaxime, meropenem,
levoﬂoxacin and vancomycin (ampicillin, penicillin, and clindamycin;
98.7%). For the VGS isolates, the CAs of individual antimicrobial agents
were 84.7% with penicillin, and 100% with erythromycin, clindamycin
and vancomycin (meropenem; 86.5%, ampicillin; 88.1%, cefotaxime and
levoﬂoxacin; 96.6%). All categorical errors of penicillin and ampicillin
in the VGS isolates were minor.
Conclusions: The MICroSTREP has an accuracy which is comparable
to CLSI reference method, suggesting that this panel can be effective for
antimicrobial susceptibility testing for BHS and VGS.
P778 Comparison of different methods for detection of methicillin
resistance in a challenge set of Staphylococcus aureus isolates
C. Nonhoff*, P. Buidin, G. Hay, N. Legros, C. Thiroux, M. Hallin,
S. Roisin, O. Denis (Brussels, BE)
Objectives: The detection of methicillin-resistant Staphylococcus aureus
(MRSA) is still a challenge, as isolates showing low-level (LL) resistance
may be misclassiﬁed as methicillin susceptible based on phenotypic
methods. The aim of this study was to compare disk diffusion, automated
system, imunochromatographic assay (ICA) and agglutination for the
detection of LL-MRSA.
Methods: MRSA isolates (n = 56) referred to the MRSA Reference
Laboratory or selected from national surveys were evaluated by
the cefoxitin disk diffusion method, the Vitek 2 card AST-P610
(bioMe´rieux), the MRSA Screen (bioMe´rieux) and the Clearview
Exact PBP2a according to the manufacture’s instructions. All isolates
harboured the mecA gene and showed oxacillin MICs ranging from 0.12
to 16mg/l.
Results: Half (50%) of the LL-MRSA isolates showed oxacillin MICs
ranging from 0.12 to 2mg/l by the agar dilution or the Etest methods
and were categorized as susceptible. The Slidex MRSA Screen and the
Clearview Exact PBP2a detected all MRSA strains. The disk diffusion
method using cefoxitin 30mg demonstrated a sensitivity of 87.5%. The
Vitek 2 system showed various performances: 28 (50%) LL-MRSA
isolates had oxacillin MICs above or equal to 4mg/l and were categorized
as resistant, 35 (62.5%) strains were positive by the cefoxitin screen
included in the panel. Finally, the Vitek Advanced Expert System
(AES) that combined the oxacillin MICs and the cefoxitin screen results
detected accurately only 38 (67.9%) LL-MRSA isolates. The difference
of sensitivity between the disk diffusion and the Vitek 2 was statistically
signiﬁcant (p = 0.003).
Conclusions: Routine phenotypic methods using disk diffusion and
automated system failed to detect LL-MRSA isolates. The best
performance was obtained by the cefoxitin disk diffusion method.
Automated systems need further optimisation for detection of low-level
MRSA strains. Detection of the PBP2a by the MRSA Screen or the
Clearview Exact PBP2a performed very well, the last test being a very
easy and rapid technique (<10 minutes). Accurate detection of LL-
MRSA may be increased by combining phenotypic methods.
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P779 Pharmacodynamic and pharmacogenomic proﬁling of
accessory gene regulator (agr) expression in Staphylococcus
aureus in response to linezolid
B. Tsuji*, T. Brown, D. Brazeau, S. Lanke, P. Holden, P. Kelchlin,
A. Forrest (Buffalo, US)
Objective: agr is the master regulator of virulence, exotoxins and
resistance in S. aureus. Dysfunction in agr, has been associated
with vancomycin heterogeneous resistance and persistence of MRSA
in bloodstream infection. Although the relationship between agr and
vancomycin has been investigated, there have been no studies on LZD
and agr. We evaluated the impact of agr function on LZD killing
activity and PD using isogenic knockout strains of S. aureus in time kill
experiments, a hollow ﬁber infection model (HFIM) over and utilized
PK-PD approaches to quantify response over a 10 day period.
Methods: 6 Strains of S. aureus were evaluated: 3 agr+ and 3 agr−
Group I, II, and IV. Time kill studies for were performed for LZD at 0
to 64mg/L vs. all 6 strains. A hollow ﬁber infection model was utilized
to simulate LZD 600mg q12h vs. agr+ and agr− Group II S. aureus
over 240h. PD analysis was completed using a Log Area Ratio approach
(AUCCFUdrug/AUCCFUControl) vs. drug concentration, ﬁt by a Hill-
type maximal effect mathematical model. From the HFIM, total RNA
was isolated, mRNA was enriched, reverse transcribed, and RNAIII, the
primary transcript of agr was ampliﬁed using quantitative real-time PCR
(qPCR).
Results: LZD displayed similar killing proﬁles against agr+ and agr−
Group I, II, and IV S. aureus, with a partially concentration dependant
response and 48h maximal reductions in Log Ratio Area of −3.7/−3.7,
−3.5/−3.9, and −3.6/−3.6. PD parameters were similar comparing
agr+/agr− Group II: Emax: 3.5/3.4, EC50:1.7/1.8, and Hills Constant:
6.3/4.9. All PD model ﬁts were excellent (R2> 0.98). In the HFIM, LZD
600mg q12h against both agr+ and agr− Group II displayed decreases of
>1.0 Log10 CFU/ml with suppression of all resistant subpopulations over
240h. LZD demonstrated a signiﬁcant decrease in RNAIII expression by
qPCR over 240h.
Conclusions: Dysfunction in agr did not alter LZD PD. These data have
may implications for the empiric choice of antimicrobial agents in MRSA
toxin mediated disease, and support the potential utility of linezolid to
impact virulence through alteration in agr expression.
P780 Intracellular activity of fusidic acid against clinical isolates
of Staphylococcus aureus of increasing MIC
S. Lemaire, D. Pie´rard, F. Van Bambeke, P. Tulkens* (Brussels, BE)
Background: Multiresistant S. aureus are of growing concern triggering
the reassessment of older antibiotic classes. Fusidic acid is currently
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being reinvestigated for systemic administration, based on the low level
of resistance observed in United States (Castanheira et al., AAC 2010,
54:3614−7), which is not the case in Europe (McLaws et al. AAC
2010 Dec 13. [Epub ahead of print]). Our aim was to examine the
activity of fusidic acid against intracellular S. aureus of increasing levels
of resistance to assess how extracellular and intracellular activities are
related.
Methods: MSSA ATCC 25923, MRSA ATCC 33591 (susceptible)
and 3 clinical isolates of increasing MIC (see Figure) were used for
(i) MIC determination (see values in the Figure); (ii) infection of
human THP-1 macrophages. For studies with infected cells, phagocytosis
was allowed for 1h at 37ºC (after opsonization with human serum),
extracellular bacteria were removed by washing and short term exposure
to gentamicin, and cells were thereafter exposed for 24 h to a wide
range of fusidic acid concentrations (from about 1/100 to 100× the
MIC) to obtain full concentration-effect relationships and determine
the static concentrations (Cs), relative potencies (EC50) and maximal
relative efﬁcacies (Emax) (see Barcia-Macay et al., AAC 50:841−51).
Results: The Figure shows that for all strains, dose-effect relationships
could be modeled using a sigmoidal function (Hill equation; R2 > 0.902).
When data are plotted against weight concentrations (mg/L), curves align
according to the MIC (increase in EC50 and in Cs). However, when data
are plotted against multiples of the MIC, all curves become essentially
indistinguishable, with non-signiﬁcant differences in EC50, Cs and Emax
(P> 0.05 [one-way ANOVA]).
Conclusions: Contrary to what we recently observed with moxiﬂoxacin,
for which the intracellular activity is markedly decreased (with signiﬁcant
loss of Emax) once the MIC of the target MRSA exceeds 0.125mg/L
(Lemaire et al. JAC in press), the intracellular activity of fusidic acid
is directly correlated to its extracellular activity as deﬁned by the MIC.
This shows that the intracellular growth of less susceptible intracellular
S. aureus can still be controlled by fusidic acid providing its extracellular
concentration is raised to reach an MIC/extracellular concentration ratio
similar to that of the susceptible ones.
P781 Activity of 9 antibiotics against intracellular forms of
S. pneumoniae
S. Lemaire*, P. Tulkens, F. Van Bambeke (Brussels, BE)
Objectives: Although often considered as an extracellular organism
only, S. pneumoniae has been shown to invade and survive within
eukaryotic cells in vitro (Jonsson et al., JID 1985, 152:4−13; Peppoloni
et al., Microbes infect 2010] 12:990–1001). Intracellular foci of
S. pneumoniae have also been observed in patients with persistent
streptococcal infections (Coates et al. Otolaryngol Head Neck Surg 2008,
138:778−81). We have set up an in vitro model of macrophages infected
by S. pneumoniae in order to quantitatively assess and compare the
activity of antibiotics against these intracellular forms.
Methods: S. pneumoniae ATCC 49619 and THP-1 myelomonocytic cells
were used throughout. MICs were determined in cation-adjusted Mueller
Hinton broth supplemented with 2.5% lysed horse blood. Infection of
THP-1 cells was performed with opsonized S. pneumoniae incubated for
2 h at 37ºC at a 10:1 bacteria:cell ratio. Non-phagocytized bacteria were
eliminated by incubation with gentamicin (50mg/L; 1 h) and 4 successive
washings with PBS. Infected cells were then transferred for 24 h in fresh
culture medium containing antibiotic concentrations ranging from about
1/100 to 100× the MIC (full concentration-dependent effects), collected,
lysed and used for cfu counting. The change in cfu was plotted against
antibiotic concentration and used for ﬁtting a Hill equation to determine
the static concentration (Cs) and the maximal relative efﬁcacy (Emax)
of each antibiotic (Barcia-Macay et al. AAC 2006 50:841−51).
Results: The table shows the MICs and the intracellular Cs and
Emax of the antibiotics ordered by increasing maximal relative efﬁcacy
(increasingly negative Emax). Cs varied from values close to the MIC
(LZD, MXF, DAP, Q-D) to large multiples of MIC (AZM, CEM-101,
RIF), and Emax from −1 log10 (AMX) to −3 log10 (Q-D).
Conclusions: This model shows that the intracellular activity of
antibiotics can only partially be predicted from the determination
of their MIC in broth, and that only one antibiotic (Q/D) yields
a truly intracellular bactericidal effect (deﬁned as 3 log10 cfu
decrease). Further studies examining the subcellular localization of the
phagocytized bacteria and of the antibiotics may help in rationalizing
these observations.
P782 Comparative pharmacodynamics of doripenem and
ciproﬂoxacin with Pseudomonas aeruginosa in an in vitro
dynamic model
S. Zinner*, D. Gilbert, Y. Portnoy, A. Firsov (Cambridge, US; Moscow,
RU)
Objective: To compare the pharmacodynamics of doripenem (DOR)
and ciproﬂoxacin (CIP) and their abilities to restrict the ampliﬁcation
of resistant P. aeruginosa, multiple dose pharmacokinetics of DOR and
CIP were simulated in vitro.
Methods: Three CIP-resistant isolates of P. aeruginosa (MIC of DOR
1mg/L, MIC of CIP 4mg/L) were exposed to thrice-daily DOR and
twice-daily CIP for three days at comparable ratios of the 24-hour
area under the concentration-time curve (AUC) to the MIC (50–170 h
with DOR and 55–180 h with CIP. Based on the mutant prevention
concentrations (MPCs) of DOR (8mg/L) and CIP (32mg/L), the
respective times inside the mutant selection window (Tmsw) varied from
39 to 46% (DOR) and from 77 to 90% of the dosing interval (CIP). The
antimicrobial effects of DOR and CIP were expressed by the area under
the bacterial concentration–time curve (AUBC) calculated from the
beginning of the simulated treatment to 72 h. Based on daily population
analyses (bacterial growth in the presence of 2×, 4×, 8× and 16×MIC
of DOR or CIP), areas under the bacterial mutant concentration–time
curve (AUBCm)s were calculated.
Results:With both DOR and CIP, an increase in the simulated AUC/MIC
ratio led to a systematic decrease in the AUBC (increase in the
antimicrobial effect). AUC/MIC relationships of the AUBC observed
with DOR and CIP were bacterial strain-independent and they were
practically superimposed. Therefore, the estimated AUC/MIC breakpoint
for DOR appeared similar to that for CIP (110 and 125 h, respectively).
DOR- and CIP-resistant mutants were enriched in all simulations, except
those at the highest AUC/MIC ratio with DOR. Unlike AUBC plots, a
speciﬁc AUBCm versus AUC/MIC relationship was established for each
antibiotic: at a given AUC/MIC ratio the effects of DOR on mutants
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resistant to 2× and 4×MIC were more pronounced than CIP. Less clear
AUC/MIC relationships of resistance were seen with mutants resistant
to 8× and 16×MIC of the antibiotics.
Conclusions: These data demonstrate similar antimicrobial effects of
DOR and CIP, but the greater ability of DOR compared to CIP to restrict
the enrichment of resistant P. aeruginosa that might be attributed to the
two-fold difference in Tmsw provided by the dosing regimens with DOR
and CIP simulated in this model.
P783 A pharmacokinetic-pharmacodynamic investigation of
MUT056399 against Staphylococcus aureus in an in vitro PD
model
B. Tsuji*, S. Lanke, D. Ngo, C. Soulama-Mouze, S. Fischer, A. Forrest
(Buffalo, US; Paris, FR)
Objective:MUT056399 is a novel fatty acid biosynthesis inhibitor which
acts on the unexploited target: FabI. The PK-PD proﬁle of MUT056399
has not been fully elucidated and optimal regimens in humans remain
unknown. The objective of this study was to investigate the PK-PD
proﬁle of MUT056399 against S. aureus using an IVPM simulating
human dosing PK and regimens.
Methods: MRSA USA300 was the bacterial isolate studied. MICs were
determined by microdilution according to CLSI. A one-compartment
IVPM was utilized to simulate the pharmacokinetics of MUT056399,
based on phase I PK data using a 0.666h terminal elimination half
life in plasma and a 5% free fraction, according to 95% binding
to Human Serum Albumin, against MRSA USA300, in log phase
growth, at 106 CFU/mL. Dose ranging experiments were performed
by simulating the following regimens of MUT056399: 300mg, 450mg,
600mg, 900mg and 1200mg administered either q6h, q8h and q8h
with a 2h prolonged infusion (PI). Continuous infusion (CI) regimens
of 1200mg/day, 2400mg/day, 3600mg/day and 4800mg/day were also
evaluated. Serial samples were obtained at 0, 1, 2, 4, 6, 8, 12, 24, 25, 26,
28, 30, 32, 36 and 48h to quantify bacterial burden over time. Changes in
Log10 CFU/mL at 48h versus ƒAUC/MIC, ƒCmax/MIC, and % T>MIC
were ﬁt to a Hill-type mathematical model.
Results: The MICs for MUT056399 was 0.06mg/L vs. USA300. By
48h, a dose dependant response for all of the MUT056399 dosing
regimens was evident, with greater exposure resulting in greater killing
activity. MUT056399 q6h regimens were most efﬁcacious compared to
other dosage regimens. Simulated regimens of 600mg q6h displayed
bactericidal killing activity, with rapid and sustainable killing. Complete
eradication of MRSA was evident at 900mg q6h and 1200mg q6h.
900mg and 1200mg q8h PI also resulted in eradication of MRSA. Q8h
and CI regimens were not as efﬁcacious as q6h and q8h PI regimens.
When analyzing only the q6h and the q8h PI regimens, ƒAUC/MIC
displayed r2 = 0.986 and % T>MIC r2 =0.915 for MUT056399.
Conclusions: MUT056399 demonstrated a dose-dependent response
using ƒAUC/MIC and % T>MIC as the predictive PD parameter, with
a high correlation to bacterial kill. Bactericidal activity of MUT056399
was achieved with regimens 600mg q6h or q8h PI. These data, along
with the low frequency of resistance and potent anti-staphyloccal activity
support MUT056399 as a novel candidate for further development.
P784 Colistin and doripenem combinations demonstrate synergy
and suppression of resistance against Acinetobacter
baumannii at multiple inocula in an in vitro PK/PD model
A. Poudyal, H. Yu, K. Davis, C. Ku, R. Nightingale, J. Jacob, B. Tsuji,
J. Bulitta, A. Forrest, J. Li, R. Nation* (Melbourne, AU; Buffalo,
Albany, US)
Background: Colistin (Col) is a last-line therapy for multidrug-resistant
(MDR) Acinetobacter baumannii (Ab). However, rapid emergence of Col
resistance due to monotherapy is worrying. Our aim was to evaluate the
activity of Col & doripenem (D) combinations (combos) against MDR
Ab using an in vitro PK/PD model (IVPM).
Methods: A one-compartment IVPM was used to simulate clinically
relevant Col & D regimens against Ab at two initial inocula of
~106 & ~108 cfu/mL. Three isolates were examined, one Col-susceptible
(ColS) D-resistant (DR) MDR clinical isolate FADDI Ab030 (MICCol
0.5mg/L, MICD 8mg/L) and two Col-heteroresistant isolates ATCC
19606 (MICCol 0.5mg/L, MICD 1mg/L) & FADDI Ab051 (DR MDR
clinical isolate, MICCol 0.5mg/L, MICD 16mg/L). Col was given alone
as 0.5 or 2mg/L (constant concentration) to simulate Col PK in critically-
ill patients, D was dosed alone every 8 h (Cmax 2.5 or 25mg/L, t1/2
1.5 h) & in combos. Viable counts were determined over 72 h & Col
population analysis proﬁles (PAPs) were conducted.
Results: At the 106 inoculum, Col alone (even with 0.5mg/L) resulted
in >3.1 log reduction in viable counts against all 3 isolates, followed
by extensive regrowth. ColR subpopulations growing at 8mg/L Col
increased from <10−6 at baseline to up to ~100% as early as 24 h.
D alone with Cmax 25mg/L showed initial killing (>1.4 log) against
all isolates but rapid & extensive regrowth similar to control values
even at 24 h (~7.5 log) except for ATCC 19606 (up to 2.2 log less than
control); subsequent doses showed no killing. While regrowth occurred
with the combo of 0.5mg/L Col and Cmax 2.5mg/L D, all other combos
showed signiﬁcant early killing (>4.8 log) & generally maintained the
antibacterial activity over 72 h (up to 6.3 log less than control). D
was highly active in suppression of ColR subpopulations as evident by
comparison of the 72-h PAPs of the combos with that of the control,
except in the combo of 0.5mg/L Col and Cmax 2.5mg/L D. Col alone,
D alone & the combos displayed a marked inoculum effect. However,
substantial synergy (up to 5 log kill within 6 h) was observed with the
combo of 2mg/L Col and 25mg/L D against all 3 isolates at the 108
inoculum, even with the DR FADDI Ab030 and 051.
Conclusions: Our data highlight that Col/D combos can be highly
synergistic against Ab & suppress Col and D resistance. Prospective
optimisation of Col and D combinations using a PK/PD approach is
essential for clinical utility.
P785 Activities of moxiﬂoxacin and ertapenem against E. coli,
E. cloacae, E. faecalis, and B. fragilis in mono- and mixed
cultures in an in vitro pharmacokinetic/pharmacodynamic
model simulating human pancreas concentration
S. Schubert*, A. Dalhoff (Kiel, DE)
Objective: Secondary polymicrobial infections caused by an-/aerobes
including E coli (Ec), E cloacae (Eb), E faecalis (Ef), and B fragilis
(Bf) are frequent in patients with severe necrotising pancreatitis.
Treatment with e.g. a carbapenem is indicated. Moxiﬂoxacin (MXF)
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may offer an alternative because of its antibacterial spectrum and its
pharmacokinetic (PK) proﬁle. Thus, we assessed MXF or ertapenem
(ERTA) pharmacokinetic/pharmacodynamic (PK/PD) against pathogens
causing severe necrotising pancreatitis.
Methods: Serum- and pancreas concentration vs time proﬁles of MXF
(400mg) or ERTA (1g) were deduced by log-linear regression from
published data; free drug concentrations were simulated. The pancreas
PK (MXF/ERTA Cmax=4.6/1.3mg/L; tmax=5/0.5h; t1/2=8/4h) was
simulated in a one compartment model acc to Grasso et al. Species
speciﬁc viable counts were monitored over 24h. Mono- and mixed (Ec
+ Eb, Ec + Ef, Ec + Bf) cultures of drug-susceptible ATCC strains were
exposed. Pre- and post-exposure MICs were determined acc to CLSI.
Cation adjusted Mueller Hinton broth or Brucella broth (Bf) was used.
Results: MXF eliminated in monocultures Ec + Eb within 4h and 10h,
and was bacteriostatic against Ef + Bf. ERTA reduced monoculture-
CFUs of Ec, Eb and Bf (−5.8 log10 in 8h each), whereas Ef was not
affected. Changes in viable counts of mixed cultures are shown in the
table. Pre- and post-exposure MICs did not differ in any case.
Conclusions: Both, MXF or ERTA were bactericidal against mono- and
mixed cultures of Ec + Eb, whereas ERTA exerted no effect against Ef.
Furthermore, MXF was more active against Ec + Eb, Ec + Ef and Ec +
Bf in mixed cultures. Thus, MXF may be superior over ERTA and may
offer a therapeutic alternative for an antibacterial treatment in patients
with severe necrotising pancreatitis.
P786 Pharmacodynamic effects of serum on in vitro activities of
echinocandins against Aspergillus spp.
A. Elefanti*, R. Al-Saigh, L. Zerva, J. Meletiadis (Athens, GR)
Objectives: Echinocandins are highly bound to serum proteins which
may alter their antifungal activity. In the present study, we investigated
the pharmacodynamic effects of human serum on the in vitro activities of
caspofungin (CAS), micafungin (MIF) and anidulafungin (ANI) against
5 clinical isolates Aspergillus spp.
Methods: Five clinical isolates of each A. fumigatus (AFM), A. ﬂavus
(AFL) and A. terreus (AT) were included. The minimal effective
concentrations (MEC) of CAS, MIF and ANI against these isolates were
0.5−1, 0.06–0.12 and 0.03mg/l, respectively. The in vitro activities of the
echinocandins were studied with a broth microdilution method based on
the CLSI M38-A2 using standard medium (RPMI 1640, 0.165 M MOPS,
pH 7.0) with and without 50% (v/v) pooled human serum. Twofold serial
dilutions of each agent ranging from 8 to 0.03mg/l were prepared in ﬂat-
bottom 96-well microtitration plates and inoculated with 2x104 CFU/ml.
The plates were incubated at 37ºC for 48h and fungal growth was
assessed using the XTT methodology previously described (Meletiadis
J. et al JCM 2008). The % of growth inhibition (E) were analyzed using
nonlinear regression analysis based on sigmoidal with variable slope
Emax model described by the equation E = Emax×Cn/(Cn+IC50n)
where Emax is maximal growth inhibition, C the drug concentration
and IC50 is the drug concentration corresponding to 50% of growth
inhibition and n is the Hillslope. The IC50 and Emax were determined
for each drug and isolate in absence of human serum and compared with
those values in presence of human serum.
Results: The IC50s of all three echinocandins ranged from 0.01–
0.06mg/l without serum and 0.09–0.36mg/l in presence of serum
showing a signiﬁcant 1−5 two-fold increase. The largest increase was
found with AL and ANI. The epsilon max of all three echinocandins
was 65 (31−80)% for AFM, 62 (0−72)% for AFL and 67 (42–100)%
for AT without serum and 90 (76−98)% for AFM, 94 (78–100)% for
AFL and 86 (74−95)% for AT. The addition of human serum increased
the Emax of echinocandins by 46 (21−90)% for AFM, 20 (0−37)% for
AFL and 16 (6−32)% for AT, resulting complete growth inhibition at
concentrations 1−8mg/l.
Conclusion: The activity of all echinocandins was increased at high
concentrations and decreased at lower near-MEC concentrations in the
presence of human serum.
P787 Mutant prevention concentration values for linezolid against
contemporary methicillin-resistant Staphylococcus aureus
clinical isolates with elevated MPC values to vancomycin
J.M. Blondeau*, K. MacKenzie (Saskatoon, CA)
Objective: Globally, community and hospital acquired MRSA strains
compromises the use of many antimicrobials against this important/
virulent human pathogen. MPC deﬁnes antimicrobial drug concentra-
tions preventing growth of bacterial subpopulations, from high density
inocula, that have inhibitory values above the susceptibility breakpoint.
MPC testing applies to bacterial strains susceptible to the drug by
minimum inhibitory susceptibility testing (MIC). We determined MPC
values for linezolid against contemporary MRSA clinical isolates with
elevated MPC values to vancomycin.
Methods: MIC testing was as per the recommended procedure of the
Clinical and Laboratory Standards Institute (CLSI) utilizing 105 cfu/ml
exposed to doubling drug dilutions by microbroth dilution in Mueller-
Hinton Broth. For MPC testing, >1010 bacteria were exposed to varying
drug concentrations incorporated into agar plates. Following incubation
under ambient conditions in O2, the MIC or MPC was the lowest drug
concentration preventing growth.
Results: A total of 50 MRSA clinical strains were tested. MIC50/90
(mg/ml) values for linezolid and vancomycin respectively were 2/4 and
0.5/1. By MPC testing, MPC50/90 (mg/ml) for linezolid and vancomycin
against MRSA respectively were 4/4 and 8/8. No isolates had an
MPC value >4 to linezolid or >8 to vancomycin. For organisms with
MPC values to vancomycin of 8 mg/ml, MPC values to linezolid were
<4mg/ml. The Mutant selection window (MSW) is deﬁned by the
MIC and MPC values and plotting for each drug against serum drug
concentrations showed time above MSW to be >12 hours for L and
~6.5 hours for V. The MIC90/MPC90 ratio for linezolid was 1 and for
vancomycin was 8.
Conclusion: Limited data exists on linezolid MPC testing against
MRSA. MIC/MPC ratios were higher for vancomycin at 8 as compared
to 1 for liunezolid. Linezolid serum drug concentrations remained in
excess of the MSW over the duration of the dose but not for vancomycin.
MPC values of 8mg/ml for vancomycin is a concern and the mechanism
remains unknown. Linezolid had serum drug concentrations in excess of
the MSW over the duration of the dose. This observation may have an
important therapeutic implication for using linezolid or vancomycin for
MRSA infections.
P788 The impact of pancreatic enzymes on the in vitro activity
of cefotaxime, ciproﬂoxacin, meropenem and moxiﬂoxacin
against organisms associated with intra-abdominal infections
A. Malawski, M. Moser, J.M. Blondeau* (Saskatoon, CA)
Objective: Some controversy exists regarding the potential interaction
and impact that pancreatic enzymes might have on the in vitro or in vivo
activity of antimicrobial agents used to treat intra-abdominal infections.
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To date, this topic remains largely unanswered. We tested cefotaxime,
ciproﬂoxacin, meropenem and moxiﬂoxacin against pathogens associated
with intra-abdominal infections with and without pancreatic enzymes.
Methods: The following clinical and American Type Culture Collection
(ATCC) control strains were tested: Staphylococcus aureus (SA) (ATCC
29213), E. coli (EC) (ATCC 25222), Pseudomonas aeruginosa (PA)
(ATCC 27853) and Enterococcus faecalis (EF) (ATCC 29212) and
clinical isolates of Klebsiella pneumoniae (KP), Klebsiella oxytoca
(KO) and Enterobacter cloacae (ECL). Enzymes tested alone or in
combination included: trypsin (porcine), amylase (hog) and lipase
(porcine). MIC testing (with and without enzyme (s)) was performed
using 105 cfu/ml of organism exposed to doubling drug concentration
of each drug in Mueller-Hinton (MH) broth; following incubation under
ambient conditions, the MIC was the lowest concentration preventing
growth.
Results: MIC values (mg/ml) for cefotaxime respectively against
SA, EC, PA,EF, KP, KO, ECL ranged from 2−4, 0.031–0.125,
>8, >8,0.016–0.031, 1−2, 0.125–0.25;ciproﬂoxacin, 0.125−0.5, 0.008–
0.016, 0.125−0.5, 0.25−0.5, 0.008–0.031, <0.002–0.004, 0.008–
0.031;meropenem, 0.063–0.125, <0.008–0.016, 0.25−1,2−8, 0.016–
0.031, 0.016–0.031, 0.016–0.031:moxiﬂoxacin, 0.016–0.031, <0.004–
0.031, 1−2, 0.063–0.125, 0.031–0.063, 0.016–0.031, 0.031−0,063. The
addition of the enzymes (10,000−1million units per liter) trypsin,
amylase and lipase alone (10,000−1million units per liter) or in all
combinations yielded MIC values that were within 1 doubling dilution
of the MIC values without enzyme added.
Conclusion: Against ATCC and clinical isolates of pathogens associated
with intra-abdominal infections, the in vitro activity of cefotaxime,
cirpﬂoxacin, meropenem and moxiﬂoxacin was not signiﬁcantly affected
(within 1 doubling dilution) by the addition of trypsin, amylase or lipase
(alone or in combinations) as determined by MIC measurements. This
data suggests that a mixture of enzymes that may be present during some
infections does not appear to impact antimicrobial activity.
P789 Time-kill effect of doripenem against multidrug-resistant
pathogens for ventilator-associated pneumonia
D. Carrer, A. Savva, M. Raftogiannis, G. Damoraki,
E.J. Giamarellos-Bourboulis* (Athens, GR)
Objectives: Ventilator-associated pneumonia (VAP) by multidrug-
resistant (MDR) isolates is a common worldwide situation in Intensive
Care Units. Most of these isolates appear resistant to carbapenems.
However, doripenem may be active against these isolates at concen-
trations equal to those achieved in serum after prolonged infusion. This
hypothesis was investigated.
Methods: A total of 21 genetically-distinct isolates were tested; nine of
Pseudomonas aeruginosa and 12 of Acinetobacter baumannii. All were
isolated from different patients at a count greater than 106 cfu/ml from
the tracheobronchial secretions within the ﬁrst 24 hours from advent of
diagnosis of VAP; all were MDR to cephalosporins, carbapenems and
quinolones. A 5×106 cfu/ml log-phase inoculum of each isolate was
exposed over-time to 5, 15 and 30 microg/ml of doripenem and to 18
microg/ml of meropenem. Concentrations of doripenem were selected
based on published ﬁndings for achieved serum concentrations after
infusion of 1g within 1 and 4 hours. Those of meropenem were selected
based on the reported serum levels.
Bacterial growth was measured at serial times of growth. Any equal to or
more than 3log10 decrease of starting inoculum was considered killing
effect.
Results: MICs of doripenem against P. aeruginosa isolates ranged
within 4 and >256 microg/ml and of meropenem within 32 and >256
microg/ml; those against A. baumannii ranged within 8 and 32 microg/ml
and within 16 and 64 microg/ml respectively. Limited killing effect
was found by both carbapenems against P. aeruginosa; of doripenem
against two isolates and of meropenem against one isolate. However,
doripenem had impressive killing effect against all studied A. baumannii
isolates mainly when tested at 15 and 30 microg/ml achieving signiﬁcant
decreases of bacterial growth. Meropenem retained a limited killing
effect against four isolates (Figure 1).
Conclusions: Doripenem retains considerable time-kill effect against
MDR A. baumannii at concentrations equal to 15 and 30 microg/ml.
These ﬁndings favor the administration of doripenem for infections
caused by that species at regimens delivering these concentrations.
P790 Combined activity of MK-7655 and imipenem against
carbapenem-resistant Pseudomonas aeruginosa
E.B. Hirsch*, K.R. Ledesma, K.T. Chang, M.S. Schwartz, M.R. Motyl,
V. Tam (Houston, Rahway, US)
Objectives: Carbapenem resistant bacteria pose a signiﬁcant treatment
dilemma given that carbapenems are often the last line of therapy
against resistant Gram-negative infections. MK-7655 is a novel
b-lactamase inhibitor under clinical development. We investigated the
combined killing activity of IPM/MK-7655 against three IPM-resistant
P. aeruginosa isolates.
Methods: Time-kill studies (TKS) using approximately 1–5×105
CFU/ml were conducted with IPM and MK-7655 against three
strains of AmpC-overproducing, oprD-deleted P. aeruginosa (PA24226,
PA24227, PA24228). TKS were performed using 25 clinically achievable
concentration combinations in a 5×5 array. Bacterial burden at 24h
was determined in triplicate by quantitative culture and mathematically
modeled using a three-dimensional response surface. Synergy and antag-
onism were deﬁned as an interaction index (VUPobserved/VUPexpected)
of <1 and >1, respectively. Mathematical model assessments were
validated using various clinically relevant dosing regimens of IPM±MK-
7655 in a hollow-ﬁber infection model (HFIM) over 72h.
Results: IPM MICs were reduced at least eightfold in 4mg/L of MK-
7655: PA24226 (32 to 2mg/L), PA24227 (16 to 2mg/L), and PA24228
(32 to 4mg/L). The combination of IPM/MK-7655 was synergistic for all
strains investigated. Interaction indices were found as follows: PA24226
= 0.60 (95%CI, 0.58–0.62), PA24227 = 0.70 (95%CI, 0.66–0.74),
and PA24228 = 0.55 (95%CI, 0.49–0.61). In HFIM, IPM/MK-7655
considerably reduced bacterial burden at 24h while failure with IPM
alone was seen against all 3 isolates. Sustained suppression of bacterial
growth was achieved with simulated doses of 500/500mg IPM/MK-7655
in 1 (PA24227) out of 3 strains, and 2 (PA24227, PA24228) out of
3 strains when IPM was increased to 1000mg. Post-HFIM (high-dose)
MICs of 3 randomly selected colonies of PA24226 were not signiﬁcantly
elevated.
Conclusions: The combination of IPM/MK-7655 considerably reduced
growth of IPM-resistant P. aeruginosa at 24h in HFIM. Suppression at
72h was achieved for 2 of 3 isolates studied. Additional studies are being
conducted to explore optimal dosing combinations for maximal killing
in P. aeruginosa.
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P791 Evaluation of a supratherapeutic dose of intravenous
ceftaroline fosamil on the QTc interval
T. Riccobene*, D. Rank, L. Rekeda, L. Llorens, D. Thye (Jersey City,
Oakland, US)
Objectives: Ceftaroline (CPT) fosamil (prodrug of the active component
CPT) is a new, parenteral, broad-spectrum cephalosporin. This study
assessed the effects of a single supratherapeutic dose of intravenous
(IV) CPT fosamil vs placebo (PBO) on the QT interval corrected for
heart rate (QTc) using an individual subject correction formula based on
the baseline QT-RR slope (QTcIb).
Methods: This was a randomized, double-blind, PBO-controlled,
3-period crossover study of single 1-h IV doses of CPT fosamil
(1500mg), PBO (negative control), and moxiﬂoxacin (MOX; 400mg;
positive control), each separated by a 5-day washout period, in 54 healthy
subjects. Continuous digital ECG recording began before study drug
administration and continued until 24.5 h after infusion. Three ECG
replicates separated by at least 1 min were extracted within the 15-min
period before administration (mean of these replicates deﬁned as predose
baseline) and at 1, 1.25, 1.5, 2, 4, 8, 12, and 24.5 h after the start of
administration. The primary ECG measure was change in QTcIb from
predose baseline for each postdose time point. The potential for QTc
prolongation was based on comparison of CPT with PBO. Two-sided
90% CIs were calculated for the time-matched difference between CPT
and PBO in the mean change in QTcIb using the SE from linear mixed
effects repeated measures model. Plasma samples for PK analysis were
collected over 24 h after the start of dosing.
Results: The supratherapeutic dose of CPT fosamil resulted in
substantially greater systemic exposure to CPT than observed with the
standard therapeutic dose (600mg q12h). The largest between-treatment
least-squares difference in change in QTcIb from baseline for CPT vs
PBO was 0.66 msec (90% CI: −2.1, 3.4ms) occurring 1.5 h postdose.
The upper 90% CI limit at every time point postdose was <10 msec,
indicating that CPT did not cause a clinically meaningful increase in
QTc. CPT plasma concentrations were not correlated with time-matched
between-treatment differences in change in QTcIb from baseline for CPT
vs PBO. The largest difference in change in QTcIb from baseline for
MOX vs placebo was 15.7 msec (90% CI: 12.8, 18.5 msec) occurring
1 h postdose. For MOX, the lower 90% CI limit was >5 msec at 5 time
points, demonstrating assay sensitivity.
Conclusion: A single supratherapeutic dose of IV CPT fosamil did
not cause a clinically meaningful increase in QTcIb at peak plasma
concentration or any other time.
P792 Evaluation of the effect of protein on the antibacterial
activity and pharmacodynamics of ceftaroline
S. Schubert*, A. Dalhoff (Kiel, DE)
Objective: To evaluate the effect of serum proteins on the MICs
and bactericidal activity of ceftaroline (CPT), a new broad-spectrum
cephalosporin that is minimally bound to human serum proteins after
conversion of the parenterally administered prodrug, CPT fosamil.
Ceftriaxone (CRO) and vancomycin (VAN) were comparators.
Methods: Serum-resistant strains of Staphylococcus aureus (including
MRSA), Streptococcus pneumoniae, enterococci, Escherichia coli,
Klebsiella pneumoniae, and Haemophilus inﬂuenzae were selected from
a collection based on antibiotic resistance patterns; antibiotic-susceptible
strains served as controls. Bacteria were cultivated in: 1) cation-adjusted
Mueller Hinton Broth (CAMHB); 2) CAMHB plus 50% active human
serum; 3) CAMHB plus 50% heat-inactivated serum; or 4) CAMHB plus
45 g/L albumin. MICs were determined using CLSI broth microdilution
methods; VAN was tested against S. aureus isolates only. Time-kill
experiments were performed; single-point and normalised kill rates
and times to reduce the inocula colony-forming unit (CFU) counts by
3log(10) CFU/mL were calculated at up to 8-fold MIC.
Results: CPT MICs for all strains were unaffected by presence of active
or inactive serum or albumin. CRO MICs were similar to CPT for Gram-
negative but higher than CPT for Gram-positive isolates. CRO MICs
increased up to 8-fold and VAN MICs increased up to 4-fold in the
presence of active or inactive serum or albumin, consistent with the
higher protein binding of these agents. CPT was bactericidal against all
strains tested except K. pneumoniae. Active serum enhanced bactericidal
activity by CPT and VAN, and to a lesser extent CRO. Times needed to
reduce viable counts of inocula by 3log(10) CFU/mL were signiﬁcantly
reduced in the presence of active serum. In the absence of active serum,
times were 11−12 h, 9.3–10.5 h, and 20.45 h for CPT, CRO, and VAN,
respectively, which were reduced to 3.3−3.9 h, 3.6−4.0 h, and 3.4 h, in
the presence of active serum.
Conclusion: CPT is bactericidal against difﬁcult-to-treat pathogens
with deﬁned resistance mechanisms and genotypes. CPT MICs were
unaffected in the presence of serum as would be predicted by its low
afﬁnity for serum proteins. Serum enhanced the bactericidal activity of
CPT, CRO, and VAN against the complement resistant strains used in
this study. These results suggest the possible presence of other serum
components that enhance the bactericidal activity of these cell wall active
agents.
P793 Plasma concentrations and occurrence of drug-related toxic
effects in patients treated with linezolid
G. Orlando*, E. Clementi, D. Cattaneo, L. Cordier, S. Merli,
C. Gulisano (Milan, IT)
Objectives: The pharmacokinetics and pharmacodynamics of linezolid
have been exensively studied in healthy volunteers and in patients
with Gram-positive bacterial infections. Evidences from retrospective
observations and single case reports have suggested the linezolid plasma
concentrations and length of treatment may be related to the risk of bone
marrow toxicity. However, no deﬁnitive data are available on the value of
linezolid plasma concentration in predicting drug-related adverse events.
The primary aim of this prospective observational study was to compare
linezolid trough plasma concentrations in patients developing drug-
related side effects with those measured in patients not experiencing
clinical signs of linezolid toxicity throughout the treatment period.
Methods: On day 3 after starting therapy with linezolid, eligible
patients underwent a basal evaluation of renal, hepatic and hematologic
status, together with the assessment of trough drug concentrations.
These evaluations were repeated at day 7, 14, 21 and periodically
till the treatment end. Any relevant information on the clinical status
of the patient was collected throughout the study. Plasma linezolid
concentrations were determined by a validated HPLC method. The
safety outcome was composite and included episodes of anemia
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(RBC <3.0×106/microL) leukopenia (WBC count <2.5×103/microL)
or thrombocytopenia (PLT count <125×103/microL).
Results: Twelve patients (for a total of 33 linezolid trough concentra-
tions) were included in this ad interim analysis. Four out of the 12
patients reached the safety outcome with episodes of haematological
toxicity. These episodes were associated with signiﬁcantly higher mean
linezolid concentrations compared with values measured in the subjects
with good tolerability to linezolid therapy (Fig 1). Conversely, the length
of treatment did not signiﬁcantly impact on the safety outcome (7±4 vs
10±6 treatment days in patients that developed or not haematological
adverse events − p 0.37).
Conclusion: Preliminary results of this prospective study suggest
a causal relationship between linezolid concentrations and the risk
to develop drug-related haematological toxicity. Accordingly, the
application of a stringent monitoring of linezolid plasma concentrations
may help to deﬁne concentration-based therapeutic windows for linezolid
associated with optimal drug tolerability.
P794 Linezolid plasma levels in long-term treatment of osteoar-
ticular infections: relationship with haematologic toxicity
N. Berenguer*, S. Luque, L. Sorli, L. Puig, F. A´lvarez-Lerma,
J.P. Horcajada, S. Grau (Barcelona, ES)
Objectives: Linezolid (LZD) exhibits an excellent penetration in all
tissues, including bone, joint and deep-seated soft-tissue, and also
shows a high bioavailability. These characteristics makes LZD an
attractive antibiotic in the treatment of osteoarticular infections caused by
multidrug-resistant Gram-positive microorganisms. Haematological side
effects related to LZD seem to be associated with plasma concentrations
and with the length of the LZD therapy. The objective of the study is
to assess the factors that could inﬂuence the haematologic toxicity in
patients with osteoarticular infections treated with LZD.
Methods: Prospective observational study carried out in ambula-
tory patients with osteoarticular infections treated with LZD for a
period longer than 1 month. Linezolid plasma concentrations were
analysed using a validated HPLC method. Measures: demographics;
duration of LZD treatment (days); maximum plasma concentration
(Cmax); minimum plasma concentration (Cmin); glomerular ﬁltration
rate (ml/min)(GFR)(mL/min), serum human albumin (g/dL)(Alb),
haemoglobin (g/dL) (HbB) and platelet counts (PtB)(x103 cells/mcL),
all at the beginning of the LZD therapy; haemoglobin (g/dL) (HbE)
and platelet counts (PtE) (x103 cells/mcL), both at the end of the
LZD therapy, presence of anaemia (haemoglobin less than 9.5 g/dL) or
thrombocytopenia (platelet count less than 150x103 cells/mcL) related
to LZD treatment and interruption of the LZD treatment due to
haematological toxicity.
c2 and Fischer exact test for dichotomic variables and t-Student and “U”
Mann-Whitney test for continuous variables were employed.
Results: Differences between patients with thrombocytopenia (TCP) at
the end of the LZD treatment and without it (Non_TCP), and anaemia at
the end of the LZD treatment and without it (Non_Anaemia) are shown
in table 1.
Conclusions: A lower platelet count at the beginnig of the treatment
was identiﬁed as a risk factor to develop thrombocytopenia in patients
with osteoarticular infections caused by multidrug resistant grampositive
microorganisms receiving long-term LZD therapy. Duration of LZD
therapy and LZD Cmin could be related to thrombocytopenia. LZD
should be avoided in patients with low GFR at the beginning of therapy
due to a higher risk of these patients to develop anaemia.
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P795 Antibacterial effect of ceftaroline against MRSA and VISA
strains studied in an in vitro pharmacokinetic model of
infection
A.R. Noel, S. Tomaselli, H. Elliott, K.E. Bowker, A. MacGowan*
(Bristol, UK)
Objectives: Ceftaroline (CPT) is a broad spectrum, cephalosporin with
bactericidal activity against methicillin-resistant Staphylococcus aureus
(MRSA) with MIC50/MIC90/maximum MIC of 0.5−1/1−2/2mg/L. MICs
for vancomycin intermediate (VISA) strains are 2mg/L. In healthy
volunteers, CPT fosamil (the prodrug of the active compound CPT)
dosed at 600mg 12 hrly produces a Cmax of about 20mg/L, half life of
2.5h and an AUC12 of 56mg/L·h. We used an in vitro pharmacokinetic
(IVPK) model to study the antibacterial effect of simulated CPT serum
concentrations on a range of MRSA and VISA strains.
Methods: A dilutional single compartment IVPK model was used to
simulate serum concentrations of CPT associated with CPT fosamil
dosing of 600mg 12 hrly for 48h (Cmax 23mg/L, half life 2.5h, 4 doses).
Three strains of vancomycin susceptible MRSA (CPT MICs 0.25, 0.5
and 1.5mg/L) and three VISA strains (CPT MICs 0.5 or 1.0mg/L) were
used at an initial inoculum of 106 CFU/mL. Antibacterial effect was
measured by change in viable count and the area under the bacterial kill
curve to 24h (AUBKC24, log CFU/mL·h) or 48h (AUBKC48). Risk of
emergence of resistance was assessed by changes in population analysis
proﬁles (PAP) measured at 24h and 48h post exposure.
Results: CPT produced a >2 log reduction in viable count after 6hr with
all strains and a >3.5 log reduction at 12h with 5 of the 6 strains. The
maximum kill was >4 logs. Bacterial growth suppression was maintained
over the 48h simulations. There was no relationship between strain CPT
MIC and antibacterial effect as measured by AUBKC24 or 48 (ANOVA,
p> 0.05). CPT was more bactericidal against VISA strains than MRSA
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in terms of AUBKC48 (p< 0.05) but not AUBKC24. There was no
emergence of resistance measured by PAP with any strain.
Conclusion: At simulated serum concentrations associated with doses of
600mg 12hrly, CPT has a marked bactericidal effect on MRSA strains
with MICs in the range 0.25−1.5mg/L. CPT was more active against
VISA strains than MRSA strains as assessed by some effect measures.
P796 Interspecies scaling for prediction of human intravenous
pharmacokinetics of GSK2251052, a novel boron-based
antimicrobial against Gram-negative bacteria
L. Liu*, L.T. Zane, A. Wu, W. Bu, M.R. Alley, V. Hernandez, H. Sexton,
X.Q. Fan, L. Feng, S. Baker, K. Maples, I. Heyman (Palo Alto, US)
Objectives: GSK2251052 (formerly AN3365), is a novel boron-based
antimicrobial which speciﬁcally targets bacterial leucyl-tRNA synthetase,
an essential enzyme in protein synthesis. This study evaluated the
interspecies scaling on pharmacokinetics (PK) from four mammalian
preclinical species to predict human PK proﬁle.
Methods: Pharmacokinetic parameters, including plasma clearance
(CLp), volume of distribution at central compartment (Vc) and at steady
state (Vss), and mean residence time (MRT), were determined following
intravenous (IV) administration of GSK2251052 in female CD-1 mouse,
male Sprague-Dawley rat, male Cynomolgus monkey, and male Beagle
dog at 30, 10, 10, and 10mg/kg, respectively. Plasma concentration-time
proﬁles following IV administration were analysed with compartmental
analysis using WinNonlin Pro version 5.2, and the bi-exponential decline
was deﬁned by the equation: C =A exp(−a·t) + B exp(−b·t). Secondary
PK parameters, including CLp, Vc, Vss, and MRT, were computed
and transformed appropriately, based on total body weights of the
species. The interspecies scaling based on the allometric equations
describing the relationships between body weight (W), CLp, Vc, Vss,
MRT, and primary parameters (A, B,a, b), was determined by ﬁtting
variable parameters Y to the standard power equation: Y = aWb.
Results: Applying the interspecies scaling on PK parameters from
mouse, rat, monkey and dog, the allometric equations were demonstrated
as CLp (mL/h) = 1153.6W0.74 (r2 = 0.999), Vc (mL) = 595.8W0.87
(r2 = 0.990), Vss (mL) = 3637W0.95 (r2 = 0.997), MRT (h) = 3.12W0.21
(r2 = 0.944). The predicted values of CLp, Vc, Vss, and MRT for a 70-
kg human were, 26.7 L/h, 23.7 L, 204 L, and 7.5 h, respectively, which
was less than 50% error from actual human PK parameters reported in
recent phase-I trial following IV infusion in male subjects.
Conclusions: Interspecies scaling successfully described pharmacoki-
netic parameters of GSK2251052 from four mammalian preclinical
species, more importantly, for the ﬁrst time, which applicability has
been proven to predict the pharmacokinetics of a novel boron-based
antimicrobial in human. Allometric scaling also allows the simulation of
concentration-time proﬁles following various dose regimens in human.
P797 Pharmacokinetic variability of clarithromycin is due to
differences in CYP3A4 activity in patients with cystic
ﬁbrosis − a reason for treatment failure?
C.S. Dalbøge*, X.C. Nielsen, K. Dalhoff, M. Dunø, A. Buchard,
J.W. Alffenaar, A.G. Jensen, T. Pressler, N. Høiby, H.K. Johansen
(Copenhagen, Slagelse, DK; Groningen, NL)
Objectives: Chronic lung infections increase the morbidity and mortality
in Cystic Fibrosis (CF) patients. Clarithromycin (CLA) is used to treat CF
patients and is mainly metabolised in the liver by the enzyme CYP3A4.
Multiple SNP’s in the gene coding CYP3A4 have been described, and
some of these may lead to increased or decreased enzyme activity, which
may lead to therapeutic failure or toxic side effects. The Erythromycin
Breath Test (ERMBT) measures CYP3A4 activity in vivo and may be
used to identify patients needing larger doses of an antibiotic to avoid
therapeutic failure or smaller doses to avoid toxicity. We investigated
the correlation between CYP3A4 enzyme activity and the metabolism
of CLA and if the activity could be predicted from the CYP3A genotype.
Methods: We included 22 CF patients (21−53 yr) with chronic
P. aeruginosa lung infections. ERMBT was measured by giving 0.15
MBq [14C-N-methyl] erythromycin i.v. Every 10 min for 1 h the patients
expired in a glass with 4ml hyamine liquid collecting the exhaled CO2.
The 14C activity was measured by the use of liquid scintillation. 500mg
CLA was given orally and blood samples were collected every half hour
for the ﬁrst 3 h and at 6 and 12 h. The concentration of CLA and the
metabolite 14-hydroxyCLA were measured by HPLC, and AUC, Tmax
and Cmax were calculated.
Results: We found a 10-fold variation in AUC for CLA, median
881mg/ml×min (range 247–2831), a 12-fold variation in AUC for
14-hydroxyCLA median 366mg/ml×min (range 84–1041), a 16-fold
variation in Cmax for CLA median 3.4 (mg/ml) (range 0.5−7.8) and a
11-fold variation in Cmax for 14-hydroxyCLA median 0.9(mg/ml) (range
0.2−2.2).
We found an 8-fold variation in the CYP3A4 activity (ERMBT
%14C/h), median 0.8 (range 0.3−2.0). A linear correlation between the
CYP3A4 activity and the metabolism of CLA expressed as the CLA/14-
hydroxyCLA ratio was demonstrated (P< 0.05).
Only two patients had another genotype of CYP3A4 than the general
population. It was therefore not possible to test for genotype-phenotype
correlations.
Conclusion: The large variation in the pharmacokinetic proﬁle of CLA
in CF patients may course treatment failure. Similar problems may
involve other antibiotics which are metabolised by CYP3A4. ERMBT
can be used to indentify CF patients who may be in risk of developing
therapeutic failure or drug toxicity.
P798 Minimal sampling colistin pharmacokinetics in critically ill
patients
P. Menna*, F. Battistoni, F. Crea, G. Minotti, E. Salvatorelli,
G. Dicuonzo (Rome, IT)
Objective: Colistin is used to treat infections by MDR Gram-
negative bacteria. Patients receive colistin methanesulfonate (CMS) that
hydrolyses to active colistin A or B. Pharmacokinetic (PK) correlates
of activity or toxicity (nephrotoxicity attributed to CMS) are poorly
understood because of heterogeneity of pharmaceutical formulations,
uncertainties on the concentration- or time-dependence of activity/
nephrotoxicity, limitations of methods to distinguish CMS from colistin,
unfeasibility of multiple blood sampling in clinical practice. This study
aimed at characterizing minimal sampling colistin PK in critically ill
patients.
Methods: CMS was given to 7 patients for a minimum of 4 consecutive
infusions (3x106 units over 1 h every 8 h). Blood was collected at the
end and before infusional cycles to determine peak or steady state (SS)
drug levels. Plasma was extracted and assayed unmodiﬁed (to measure
circulating colistin A and B) or after thermo-acid hydrolysis (to release
colistin A and B from residual CMS). Differences between hydrolyzed
or unmodiﬁed plasma extracts gave a measure of CMS. Colistin was
assayed by LC-MS-MS in ESI (−)/MRM modality. Colistin A (LOD
= 0.02mg/L) and B (LOD = 0.014mg/L) were quantiﬁed vs standard
curves built with hydrolyzed residues of the same CMS solution infused
to patients. Data were expressed as [colistin A + colistin B].
Results: Plasma peak and SS concentrations of CMS and colistin
increased with the number of infusional cycles but in the early about
10 cycles colistin peak and SS averaged below MIC determined in most
of patients (0.5−2mg/L). CMS accumulation at SS, but not at peak,
correlated inversely with Glomerular Filtration Rate (GFR); for colistin,
both peak and SS levels correlated inversely with GFR.
Conclusions: Colistin peak and SS levels below MIC over 10 infusional
cycles denote that current regimens/schedules are suboptimal for
achieving concentration and/or time-dependent antimicobrial activity.
Infusional cycle-dependent/GFR-independent accumulation of CMS
at peak denotes altered CMS distribution, while GFR-dependent
accumulation of CMS at SS denotes impaired renal elimination of CMS.
Infusional cycle- and GFR-dependent accumulation of colistin at both
peak and SS unravels that in critically ill patients kidney elimination is
important for colistin too. Minimal sampling colistin PK in critically ill
patients is feasible and informative.
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P799 Pharmacokinetics of daptomycin in critically ill patients
B. Preiswerk*, A. Rudiger, J. Fehr, N. Corti (Zurich, CH)
Objectives: Daptomycin dosing recommendations for critically ill
patients undergoing continuous renal replacement therapy (CRRT)
are scarce. For patients with renal impairment (creatinine-clearance
<30ml/min.) the recommended daptomycin dose is 6mg/kg every 48 hrs.
At our Intensive Care Unit (ICU) high volume renal replacement therapy
(35ml/kg/h) is performed (Multiﬁltrate, Fresenius Medical Care, Bad
Homburg, Germany). Insufﬁcient plasma concentrations were observed
when daptomycin was given every 48 hrs. Accordingly, the dosing-
interval was changed to once-daily and intensiﬁed drug monitoring was
performed to detect potential overdosing.
Methods: We retrospectively gathered daptomycin peak (Cmax) and
trough (Cmin) levels for 14 critically ill patients between 2008–
2010 exposed to once daily regimen. Seven of these patients required
CRRT. Daptomycin plasma levels were compared with data from
healthy volunteers receiving an equivalent daily dose at steady state.
Microbiological data, laboratory values and outcome data were collected.
Results:We analyzed 14 patients with sepsis (n = 9), endocarditis (n = 2),
wound infection (n = 2) and catheter-related bloodstream infection
(n = 1). Causative agent were Enterococcus faecium (n = 9), coagulase
negative staphylococcus (n = 2) and staphylococcus aureus (n = 2).
Microbiological eradication was successful in 9 of 14 patients. Five
patients died during the ICU stay.
Daptomycin dose ranged from 3 to 8mg/kg/24h in patients undergoing
CRRT and 6 to 10 10mg/kg/24h in patients without CRRT. Exposure was
comparable in CRRT patients to those without CRRT. Cmax and Cmin
showed high intra- and interpatient variability in both groups. A possible
correlation between dose (mg/kg) and Cmin values but no correlation
with Cmax values could be found. Cmin values in ICU patients were
comparable with plasma levels in healthy volunteers, whereas Cmax
values were substantially lower.
Conclusion: In ICU patients undergoing CRRT, daptomycin once daily
led to equivalent Cmin and lower Cmax values compared to healthy
volunteers, possibly as a result of the higher volume of distribution in
critically ill patients. We conclude that daptomycin clearance in critically
ill patients undergoing CRRT is probably equivalent to the clearance in
patients with a normal renal function.
P800 Linezolid pharmacokinetics in children: validation of a new
method with dried blood spots
A. Novelli*, M.I. Cassetta, S. Fallani, G. la Marca, F. Villanelli, M. De
Gaudio, L. Galli (Florence, IT)
Objectives: Linezolid has been shown to be a valid therapeutic
alternative to glycopeptides against multiresistant Gram-positive strains.
This antibiotic has time-dependent activity and the T>MIC, is the
PK/PD parameter which best predicts its efﬁcacy. However, serum
levels ﬂuctuate widely in septic subjects, leading to high intra-
individual variability. This may provide the rationale for therapeutic
drug monitoring. Up to now linezolid has been mostly assayed by Liquid
Chromatography (HPLC). However this approach is time demanding and
blood sample volumes must be at least 0.5mL, which may represent a
limitation in very young babies. The analysis performed in LC-tandem
mass spectrometry (LC-MS/MS) on dried blood spots (DBS) allows a
great advantage in terms of costs, affordability, and ease of sampling,
especially in infants. Since there are limited results for antimicrobials
with these method we evaluated linezolid kinetics in paediatric patients,
comparing these two methods in order to validate the DBS technique.
Methods: Linezolid was assayed either in HPLC with UV detection
at 254 nm (stationary phase: C18 5ODS, 100×4.6mm; mobile phase:
1% orthophosphoric acid, 30% methanol, 2 g/L heptane sulphonic acid,
adjusted to pH 5; ﬂow rate 1.0mL/min) using 0.5mL serum samples,
or by LC-MS/MS both in serum and DBS. The calibration curves were
obtained by spiking previously analyzed linezolid-free blood and serum
samples at 6 concentration levels and the quantitation were performed
using a API4000, in multiple reaction monitoring (MRM) mode.
Results: At present 5 hospitalized children with infection due to
sensitive strains, aged between 9 mo and 12 yr, were included in
the study. Mean±SD peak values were 15.3±1.7mg/L for HPLC and
17.6±3.5mg/L for DBS. Mean±SD trough levels were 0.64±0.39mg/L
for HPLC and 0.71±0.39 for DBS, with a variation ranging from
6.4% to −15.9% for single individual samples. These preliminary data
demonstrated a high correlation between the two methods (R square
0.97) for both low and high concentrations.
Conclusion: On the basis of our preliminary data the DBS technique
was well correlated with a standard analytical method such as HPLC. In
conclusion, the minimal sample preparation, with no derivatization steps,
high sensitivity/speciﬁcity, high throughput and minimal instrument
maintenance make this method a good candidate for a large-scale routine
task.
P801 Monitoring plasma voriconazole levels may be necessary to
avoid sub-therapeutic levels in lung transplant recipients
H. Lyster*, N. Leaver, A. Hall, A. Simon, M. Carby (Hareﬁeld, UK)
Background: Voriconazole is commonly used to treat fungal infections
(in particular, infections caused by Aspergillus spp) after lung
transplantation. There are no manufacturers’ recommendations for
therapeutic drug monitoring due to its favourable pharmacokinetic
proﬁle. However, a correlation between outcome and voriconazole levels
has been shown; with a lack of response to voriconazole with low levels
(<1mcg/ml).
Method: Pharmacy records were used to identify all lung transplant
recipients who had received voriconazole for at least 7 days and had
trough plasma voriconazole levels measured between May and December
2010 using validated methods based on high performance liquid
chromatography with mass detection (HPLC-MS/MS). Voriconazole was
commenced with an initial loading dose of 400mg twice daily orally for
24 hours followed by 200mg twice daily orally thereafter. Trough levels
were measured at a minimum of 3−5 days after commencing treatment,
a therapeutic level was deﬁned as >1.3mcg/ml (range 1.3−5.7mcg/ml).
Cystic ﬁbrosis (CF) lung transplant recipients were compared with
non-CF to determine whether this sub-group showed potentially lower
absorption of the drug and thus plasma levels.
Results: Twenty-four lung transplant recipients were included in the
study (21 bilateral lung transplant, 14 for Cystic Fibrosis, 45.8%
male, mean age of 40.3±13 years, at a median of 0.7 months after
lung transplantation (range 0.1–262.9). Levels were measured at a
median of 10 (range 3–336) days after commencing voriconazole
treatment. 12 patients (50%) achieved therapeutic levels with a mean of
2.5±1.0mcg/ml, the remaining 12 patients failed to achieve therapeutic
levels with a mean of 0.5±0.3mcg/ml. Of the 14 cystic ﬁbrosis lung
transplant recipients only 6 achieved the target level (43%), this was
similar to the non-CF group where 6 of 10 (60%) achieved target level
(p = 0.68).
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Conclusion: This study found that in adult lung transplant recipients
receiving standard dose of voriconazole orally, the levels are highly
variable between recipients with 50% of patients not achieving the
required target level of 1.3mcg/ml. There was no difference between CF
and non-CF patients. We conclude that monitoring plasma voriconazole
levels is necessary to avoid subtherapeutic levels in lung transplant
recipients. However, further study is required to evaluate clinical
outcomes and intra-subject variability in drug levels over time.
P802 Caspofungin: is standard dosing optimal or inadequate?
Pharmacokinetic description in a cohort of patients
F.G. De Rosa, L. Baietto*, A. D’Avolio, D. Pasero, S. Raviolo,
C. Marra, S. Pace, V.M. Ranieri, G. Di Perri (Turin, IT)
Objectives: Caspofungin is an echinocandin used in treatment of
Candida and Aspergillus infections. It has a concentration-dependent
fungicidal activity against Candida species and concentration dependent
fungistatic vs Aspergillus. Previous study showed that the Cmax/MIC and
AUC0-24h/MIC are the best PK/PD parameters associated with effective
therapy. In vivo studies showed that fungicidal activity was not observed
until the Cmax/MIC >4 for Candida species and AUC0-24h/MIC >250.
Aim of the study was to calculate PK parameters in a cohort of patients
with different candidemia with MIC of 0.25, 0.5, 1 and 2mg/L and to
compare them with those in healthy volunteers.
Methods: Patients treated with intravenous caspofungin at standard
dosages were analysed. Plasma samples were obtained after multiple
dosing at steady state conditions immediately before the infusion, at 1,
2, 5, 12±4 h and 24 h. Plasma concentrations of total caspofungin were
measured using a validated method on ultra-performance liquid chro-
matography coupled with ﬂuorescence detector system. PK parameters
were determined by non compartmental analysis.
Results: 17 patients were studied, 9 men and 8 women. Median
[IQR] age was 55 years [45−67]. Patients in therapy with concomitant
cyclosporine, tacrolimus, rifampicin were excluded from the study.
Median [IQR] weight and height were 62.5 [55.5–77.5] kg and
170 [160.5–180.0] cm, respectively. Median [IQR] Cmax and Cmin,
AUC0−24, Clearance, Distribution Volume and elimination half-life were
respectively 7.5 [7.0−8.7] mg/L and 1.7 [1.0−2.4] mg/L; 71.8 [58.2–
109.9] mg/L*h, 0.7 [0.4−0.8] L/h, 15.2 [10.5–20.7] L and 13.2 [10.5–
15.2] h.
We observed that for MIC 0.25, 0.5 and 1, all patients had Cmax/MIC
>4, while for MIC =2 only 17.6% had ratio >4. An AUC0−24h/MIC
>250 was achieved in 70.6% and 11.8% of patients with theoretical
Candida MIC of 0.25 and 0.5mg/L, respectively.
Conclusion: Data were similar to those reported in healthy volunteers.
These data showed that the dosage achieves adequate PK/PD parameters
to treat candidemia in a wide variety of clinical settings, including
critically ill patients with septic shock, if the Candida MIC is
0.25mg/L, as it is observed in 80% of blood isolates in our hospital.
P803 Anidulafungin pharmacokinetic evaluation in a cohort of
patients
F.G. De Rosa, L. Baietto*, A. D’Avolio, D. Pasero, S. Raviolo, S. Pace,
C. Marra, V.M. Ranieri, G. Di Perri (Turin, IT)
Objectives: Anidulafungin is a new echinocandin that plays an important
role in the treatment of invasive candidiasis and candidemia. Anidula-
fungin is concentration-dependent and fungicidal against Candida spp
and has peculiar pharmacokinetics with spontaneous degradation and no
metabolic interactions. Pharmacokinetic (PK) parameters associated with
success include area under the curve (AUC) at steady state >35mg/L*h
and minimum plasma concentration at steady state (Cmin) >1mg/L.
In animal models the best PK/PD parameter asssociated with success
was the AUC/MIC ratio of 250. Aim of the study was to calculate PK
parameters in a cohort of critically ill patients undergoing treatment
with anidulafungin for candidemia and to describe the AUC compared
to different MICs of Candida.
Methods: Patients treated with intravenous anidulafungin at standard
dosages were analysed. Plasma samples were obtained after achieving
the steady state conditions immediately before the infusion, at 1,2, 5,
12±4 h and 24 h. Plasma concentrations were measured using a validated
method on ultra-performance liquid chromatography coupled with PDA
detector system. PK parameters were determined by non compartmental
analysis.
Results: 8 critically ill patients were studied; 6 with severe sepsis and
2 with septic shock. Median [IQR] age was 56 years [46−68]. Median
[IQR] weight and height were 65 kg [52.0–68.7] and 170 cm [158–
173]. Patients in therapy with concomitant cyclosporine were excluded
from the study. Median [IQR] Cmax and Cmin, AUC0−24, Clearance,
Distribution Volume and half-life were respectively 6.3 [4.7−9.9] mg/L
and 2.4 [1.3–3.18] mg/L; 89.7 [62.2–111.9] mg/L*h, 1.1 [0.9−1.6] L/h,
33.5 [27.7–47.4] L and 20.0 [14.5–27.5] h. All patients had AUC
>35mg/L*h, 1 patient had Cmin <1mg/L.
Considering MIC values for Candida of 0.25 and 0.5mg/L, respectively,
75% and 12.5% of patients had AUC/MIC >250. Considering the MIC
1 and 2 no patients had AUC/MIC >250.
Conclusion: Data were similar to those reported in healthy volunteers.
Nonetheless, PK parameters may not be satisﬁed in critically ill patients
with Candida MIC >0.25mg/L. Further studies are needed to better
describe PK/PD abnormalities in critically ill patients.
P804 Population pharmacokinetic study of colistin in combined
healthy volunteers and patients with severe Gram-negative
multidrug-resistant infections
N. Gre´goire, B. Me´garbane, P. Gobin, D. Balayn, W. Couet*, O. Mimoz
(Poitiers, Paris, FR)
Objectives: Colistin appears frequently as last line defense therapy
against severe Gram(−) MDR infections and it is administered as an
inactive prodrug (CMS). Therefore complex pharmacokinetics (PK)
alterations in critical care patients must be investigated in order to
propose rational dosing guidelines, which was the aim of this study.
Methods: PK data in healthy volunteers (n = 12) and in critically ill
patients (n = 32) were combined for analysis. Healthy volunteers had
received 1 MIU of CMS as a single dose and plasma and urine samples
were collected for CMS and colistin concentrations determinations
using a chromatographic assay. Critically ill patients received multiple
doses ranging from 0.3 to 4 MIU of CMS and blood samples were
drawn after the ﬁrst dose and at steady-state for CMS and colistin
plasma concentrations determinations. Patients under haemodialysis or
haemoﬁltration were excluded for analysis. Population PK analysis was
performed with Nonmem VI software.
Results: Grouping healthy volunteers and critically ill patients, 29
males (15 females) median (range) age 52 (21–101) yr, weight 73 (40–
106) kg, creatinin clearance 94 (30–204) mL/min have been modeled.
A PK model with two-compartments for CMS and one for colistin,
distinguishing between renal (CLr) and non renal (CLnr) clearances
for CMS, successfully described the experimental data. CMS renal
clearance was related to creatinin clearance (CLcreat) according to
CLr=0.85xCLcreat in mL/min. Typical values for CMS non renal
clearance were 48mL/min in healthy volunteers and 27mL/min in
patients. Colistin clearance was almost exclusively non-renal with
relatively close typical values in healthy volunteers (CLcoli=49mL/min)
and in patients (CLcoli=35mL/min).
Conclusion: Most inter-patient variability in CMS disposition and
therefore colistin plasma concentrations is due to differences in renal
function and can be predicted from CLcreat. CMS initial dosing regimen
in patients should therefore be adjusted to creatinin clearance.
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P805 Population pharmacokinetics of doripenem in Japanese
subjects and Monte Carlo simulation for patients with renal
impairment
Y. Matsuo*, T. Ishibashi, R. Kubota, T. Wajima (Osaka, JP)
Objectives: Doripenem (DRPM), a parenteral carbapenem antibiotic,
exhibits broad spectrum of anti-bacterial activity against any aerobic
Gram-positive and Gram-negative bacteria and anaerobes. The aim of
this study was to evaluate the pharmacokinetics (PK) of DRPM using
plasma concentrations in the clinical studies by means of population PK
analysis. In addition, dosing regimens for patients with renal impairment
were investigated by Monte-Carlo simulation.
Methods: A total of 921 plasma concentration data from 92 subjects
from 8 phase 1 studies (including studies for subjects with renal
impairment and elderly subjects) were used for population PK analysis.
Age, body weight and renal function (creatinine clearance, CLcr)
were evaluated as covariates on PK of DRPM. Model evaluation was
performed using conventional diagnostic plots and a visual predictive
check. Final model was used to predict plasma concentration proﬁles
in patients using their covariates to conﬁrm whether the model would
be applied to patients. The ﬁnal model was also employed to simulate
the effect of renal function on PK and PK/PD parameters by means of
Monte-Carlo simulations.
Results: The two compartment model well described the observed
DRPM plasma concentrations. CLcr and age were found to be predictors
of DRPM clearance and CLcr was the most important inﬂuencing
factor on PK of DRPM, which was consistent with the previous
ﬁnding that DRPM is mainly eliminated via kidney. The plasma
concentration proﬁles simulated for patients based on the ﬁnal model
parameters estimated from the phase 1 data were consistent with
observed data, suggesting that DRPM PK can be explained by CLcr
and age, and that there was no signiﬁcant PK difference between non-
infected subjects and patients. Simulations suggest that 1 g every 12
hours (q12h), 0.5 g every 8 hours (q8h) and 0.25 g q8h for patients
with mild, moderate and severe renal impairment, respectively, give
similar exposures (AUC) and sufﬁcient the percentage of time above
minimum inhibitory concentration derived from free drug concentration
(%T>MIC) in comparison with 1 g q8h for patients with normal renal
function.
Conclusion: Our population PK model conﬁrmed renal function is the
most important inﬂuencing factor on PK of DRPM. Dose adjustment
based on CLcr is recommended for patients with renal impairment.
P806 Lean body weight explains variability in clearance and
absorption rate constant of linezolid in cystic ﬁbrosis patients
A. Schaeftlein*, R. Keel, J.L. Kuti, C. Kloft (Halle/Saale, DE; Hartford,
US)
Objectives: In cystic ﬁbrosis patients (CFP), a relation between body
weight and disease state1 has often been described, the latter known to
impact the pharmacokinetics (PK) of antibiotics2. Therefore, one might
hypothesize that body size could affect the PK of linezolid, a widely
used antibacterial treatment option in CFP. The objective of this analysis
was to compare different body size descriptors (BSD) as patient speciﬁc
factors (covariates) in a population PK model to determine the optimal
BSD to explain observed variability in PK parameters.
Methods: Based on a study of 8 adult CFP exposed to multiple 600mg
twice daily doses, population PK was applied to describe concentration-
time proﬁles using a two-compartment model with concentration-time-
dependent clearance inhibition3. The following BSDs [body weight
(BW), body surface area (BSA), fat free mass (FFM), lean body weight
(LBW), and body mass index (BMI)] were tested on a model without
covariates (base model) for their effect on volumes of distribution,
clearance (CL), intercompartmental clearance, absorption rate constant
(ka), and bioavailibility. All modelling and simulation processes were
carried out using the nonlinear mixed-effect modelling approach in
NONMEMTM. Selection of the model was guided by goodness-of-ﬁt
plots, objective function value (OFV), plausibility and ability to explain
variability in parameters.
Results: Compared with the base model, incorporation of BSD covariate
relations on CL and ka signiﬁcantly improved the model performance
leading to a decrease in the OFV >10.83 (df=1, p< 0.001). FFM and
LBW exhibited a positive relation with CL and ka while signiﬁcantly
and plausibly explaining interpatient variability. But only LBW almost
completely explained interpatient variability of ka, stabilized the entire
model, and demonstrated a statistically signiﬁcant inﬂuence on the PK
of linezolid. For clinical routine, in order to assess only a single BSD in
a patient, LBW was incorporated in the ﬁnal PK model.
Conclusion: Body size does have an impact on linezolid PK in CFP,
speciﬁcally on CL and ka. Adaptation of the linezolid dose to LBW
as marker for the disease status might have an impact on safety and
tolerability in this special population.
P807 Population pharmacokinetics of temocillin in intensive care
patients and Monte Carlo simulations to evaluate resistance
breakpoints
A.E. Muller*, P.F. Laterre, T. Dugernier, X. Wittebole, N. Couwenbergh,
P. Tulkens, S. Carryn, J. Mouton (Rotterdam, NL; Brussels, Manage,
BE; Nijmegen, NL)
Objectives: Temocillin (TMO) is a narrow spectrum penicillin with good
activity against Gram negative micro-organisms including ESBL and
AmpC producers. Previous studies indicated that the commonly used
dose of 2gr every 12 hours could be too low to cover the WildType
distributions of Enterobacteriaceae if variation of pharmacokinetics in a
patient population was taken into account. Data from a pharmacokinetic
study in 11 ICU patients receiving TMO 2g q8h were used to
establish a population model and perform Monte Carlo Simulations
(MCS) to determine Probabilities of Target Attainment (PTAs) for
pharmacodynamic indices (PDI) in order to evaluate and suggest clinical
resistance breakpoints.
Methods: Blood samples were taken from ICU patients after (t = 0.5,
1, 2, 8 h) a 30 m infusion of 2 g TMO (n = 11) and afterwards cooled,
centrifuged and stored at −70ºC until analysis by HPLC. Protein binding
was determined using an ultraﬁltration method. Results were used to
estimate population pharmacokinetic parameters by NONMEM (version
VI, ICON development solutions, USA) and Miclab2.36 (Medimatics,
NL) was used to perform MCS (10000 cycles) and obtain PTAs for
the unbound fraction including 95% conﬁdence intervals (CI) for the
target concentrations. fT>MIC was chosen as the PDI because of the
pharmacodynamic properties of TMO.
Results: Protein binding was 61%. A two-compartment model best ﬁtted
to the data, with estimates (se) of V1 =14.0 (2.5) L, Cl 3.69 L/h,
(0.46), V2 21.7 (4.5) L and Q= 8.45 (1.06) L/h, and omega’s for V1
and Cl of 0.34 and 0.13 respectively. The breakpoint MIC for a mean
fT>MIC of 50% was 32mg/L. However, MCS − taking the variation in
the population into account − and a 95%CI at 50% fT>MIC indicated
a clinical breakpoint of 16mg/L.
Conclusion: The population model described the data well. The
MCS using population pharmacokinetic estimates indicate a resistance
breakpoint for temocillin of >16mg/L provided an administration of 2
g q8h is used.
P808 Pharmacodynamics of three carbapenems against drug-
resistant Gram-negative pathogens isolated from hospitalised
patients in Germany using Monte Carlo simulation
M. Kresken*, B. Ko¨rber-Irrgang, S. Decker-Burgard, D. Hafner
(Rheinbach, Neuss, Du¨sseldorf, DE)
Objective: The carbapenems (CARBA) are widely used for empiric ther-
apy of serious infections involving drug-resistant Gram-neg. pathogens
like P. aeruginosa, A. baumannii or Enterobacteriaceae expressing an
ESBL phenotype or a stably de-repressed AmpC b-lactamase. The
objective of this study was to predict the probabilities of attaining
Antimicrobial pharmacokinetics S193
targeted pharmacodynamic exposure for clinically used dosing regimens
of doripenem (DOR), imipenem/cilastatin (IPM), and meropenem
(MEM) against a German collection of contemporary drug-resistant
Gram-neg. pathogens using Monte Carlo simulation (MCS).
Methods: Isolates from hospitalised patients were collected in 15
medical microbiology laboratories during two resistance surveillance
studies conducted in 2007 and 2009. Bacterial groups investigated were
P. aeruginosa (n = 149), A. baumannii group (n = 139), and ceftriaxone
(CRO)-resistant Enterobacteriaceae (n = 349). MCS modelled 5,000
patients receiving the following dosing regimens: DOR 500mg every
8 hours (1-h infusions), DOR 500mg every 8 hours (4-h infusions),
IPM 1,000mg every 8 hours (1-h-infusions), IPM 500mg every 6
hours (1-h-infusions), MEM 1,000mg every 8 hours (1-h-infusions),
and MEM 2,000mg every 8 hours (1-h-infusions). Pharmacodynamic
targets to predict efﬁcacy were the free drug concentrations above the
MIC for 40% of the dosing interval. Simulations were based upon a
normal distribution of volume of distribution and total body clearance.
Mean pharmacokinetic parameters and their distribution were taken
from published studies. The cumulative fraction of response (CFR) was
calculated considering the MIC distribution data for each of the three
groups of organisms.
Results: All CARBA regimens achieved CFR rates of >95% against
CRO-resistant Enterobacteriaceae, but varied between 80% and 88%
against A. baumannii group isolates (see Table). Against P. aeruginosa,
the highest CFR (91.9%) was obtained with DOR 500mg every 8 hours
(4-h infusions) and the lowest (72.7%) with IPM 500mg every 6 hours.
Conclusion: Considering the current susceptibility patterns of drug-
resistant Gram-neg. pathogens in Germany, all clinically used dosing
regimens of CARBA are sufﬁcient to achieve a probability of 98% or
greater success against CRO-resistant Enterobacteriaceae. In contrast,
only the DOR prolonged-infusion and MEM 2,000mg dosing regimens
achieved at least 90% CFR against P. aeruginosa. None of the CARBA
regimens achieved 90% CFR against A. baumannii group.
P809 Population pharmacokinetics of peramivir and dose
adjustment for inﬂuenza patients with renal impairment
T. Ishibashi*, T. Wajima, Y. Matsuo, A. Hollister, S. Kohno, J. Shimada
(Osaka, JP; Durham, US; Nagasaki, Tokyo, JP)
Background and Objectives: Peramivir is a selective inhibitor of
neuraminidases produced by inﬂuenza A and B viruses, and is the ﬁrst
injectable agent for treatment of inﬂuenza infection which was approved
in Japan and Korea in 2010 and is under development elsewhere.
The aim of this study was to evaluate the pharmacokinetics (PK) of
peramivir based on plasma concentration data in clinical trials by means
of population PK analysis. Furthermore, dose adjustment for special
populations was investigated by a simulation approach.
Methods: Population PK analysis of peramivir was performed using data
from 3199 plasma concentration samples in 332 subjects from 6 clinical
studies in Japan and the US, including studies in subjects with renal
impairment, elderly subjects and inﬂuenza patients. Age, body weight,
renal function (creatinine clearance, CLcr) and gender were tested as
covariates. PK differences between the Japanese and US subjects and
between inﬂuenza patients and uninfected subjects were investigated.
The ﬁnal model was evaluated by using conventional diagnostic plots
and a visual predictive check. Monte-Carlo simulation was applied to
evaluate the effect of inﬂuencing factors on the area under the plasma
concentration-time curve (AUC) based on the ﬁnal model.
Results: A three-compartment model described the observed plasma
concentration data of peramivir well, and CLcr was found to be the
most important inﬂuencing factor on clearance (CL). Age and body
weight were also found to be the covariates on CL and volume of
distribution, respectively. No PK differences were suggested between
genders and between Japanese and US subjects. Small PK differences
were observed between uninfected subjects and inﬂuenza patients.
Monte-Carlo simulations indicated that the 1/3-fold and 1/6-fold dose
adjustment for patients with moderate (CLcr: 30−50mL/min) and
severe renal impairment (CLcr: 10−30mL/min), respectively, would give
similar AUCs to those in patients with normal renal function. The need
for an additional dose after hemodialysis for patients on intermittent
hemodialysis was suggested.
Conclusion: A population PK model of peramivir was developed. CLcr
was found to be the most important inﬂuencing factor on the PK of
peramivir. The simulation studies suggested the usefulness of the dose
adjustment based on renal function.
P810 Usefulness of therapeutic drug monitoring of posaconazole
in haematological adult patients
L. Baietto*, F.G. De Rosa, A. D’Avolio, E. Biasin, F. Nesi, F. Saglio,
C. Marra, S. Pace, G. Di Perri (Turin, IT)
Objectives: Invasive fungal infections (IFI) are major causes of death
in high-risk haematological patients. Posaconazole and voriconazole
are second generation compounds more active than ﬂuconazole and
itraconazole against Candida species. Many individual factors have
been demonstrated to impact posaconazole absorption and cause high
pharmacokinetic variability: food, gastric pH, co-administration of
proton pump inhibitors (PPI) and frequency of administration. Aim of
our study was to describe posaconazole Ctrough levels in a cohort of
haematological adult patients and to compare them with the proposed
target plasma concentration >0.5mg/L.
Methods: Patients treated with oral posaconazole (200, 400mg; BID
or TID) were analysed. Plasma samples were obtained after multiple
dosing at steady state conditions immediately before the drug intake.
Plasma concentrations of posaconazole were measured by a validated
HPLC-MS method. Univariate and multivariate linear regression were
performed.
Results: 19 patients were considered in the study. 13 men and 6 women.
9 in therapy with 200mg/TID, 4 at 200mg/BID and 6 at 400mg/BID.
Median [IQR] age (years), weight (kg), dose/weight (mg/kg) were 26
[21−56], 75 [68.0–80.0] and 8.6 [7.1–10.3], respectively. Median [IQR]
Ctrough levels were 0.68mg/L [0.44–1.08]. Univariate and multivariate
linear regression showed absence of statistically signiﬁcance correlation
between individual factors (age, sex, weight, dose/weight, concomitant
PPI administration) and posaconazole Ctrough. A Ctrough >0.5mg/L,
was observed in 68% of our patients.
Conclusion: Therapeutic Drug Monitoring (TDM) of azoles has growing
importance in clinical practice. Our preliminary experience in a series
of haematological patients shows that 68% of patients have Ctrough
>0.5mg/L, with a high percentage of PPI treatment. TDM is extremely
useful to optimize antifungal prophylaxis in haematological patients,
according to the available published strategies. TDM of azoles should
be implemented in the routine clinical practice.
P811 Intra-ocular pharmacokinetics of doripenem in rabbits
O. Semoun, S. Marchand, I. Lamarche, C. Adier, N. Gre´goire,
L. Laroche, P. Goldschmidt, W. Couet* (Paris, Poitiers, FR)
Objectives: The aim of this study was to investigate intraocular
penetration of doripenem in rabbits.
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Methods: Nineteen New Zealand rabbits received a single 20mg (close
to 10mg/kg) dose of doripenem intravenously in a marginal ear vein
over 60 minutes. Specimens of aqueous humor (AH), vitreous ﬂuid
(VF) and blood were obtained at either 30 min. (n = 5), 1 h (n = 5), 2 h
(n = 5) or 3 h (n = 4) after starting infusion. Doripenem concentrations
in plasma, plasma ultraﬁltrates (UF), AH and VF were analyzed
by (HPLC). A naı¨ve pool data pharmacokinetic (PK) analysis was
conducted in UF and HA (n = 19), with the software WinNonLin (version
5.3 Pharsight Corporation, Mountain View, CA, U.S.A.). In a ﬁrst step
UF concentration-time data were analyzed using a one compartment
model with IV infusion. Owing to its small volume, HA will not affect
UF data and therefore a forcing function was used in a second step to
estimate HA input (CLin,HA). Elimination from the HA compartment
was added to estimate output (CLout,HA) clearance responsible for the
lower AUC than in UF. HA volume (VHA) in rabbits was set at 0.3ml.
Results: Doripenem peak concentration in UF was equal to 10.4
±2.1mg/ml. Its clearance (CLu) and volume of distribution (Vu) were
respectively equal to 1.7±1.1 L/h and 0.754 L. Corresponding half-life
was of 0.31±0.03h (18.4 min). Doripenem was not detected in any of the
VF samples, but was measured in HA with a peak at 0.49±0.08mg/mL
and a CLin,HA/CLout,HA ratio, equivalent to AUCHA/AUCU ratio,
equal to 8.3%.
Conclusion: Doripenem distribution is negligible in VF and limited
in AH after systemic administration in healthy rabbits, from which
it can be concluded that doripenem is likely to be substrate of still
undetermined efﬂux transporters at the blood-aqueous barrier. Clinical
trials are no warranted to assess AH penetration of doripenem in patients
with endophthalmitis and to compare AH concentrations with bacteria
MICs.
P812 Serum and urine concentrations of antibiotics in patients
implanted with gentamycin and vancomycin PMMA spacers:
data from the ﬁrst 50 patients (multi-centre study)
E. Bertazzoni Minelli*, A. Benini, T. Della Bora (Verona, IT)
Objectives: The resistance to aminoglycosides is increasing and the
combination with vancomycin (V) is useful in orthopaedic infections.
Gentamicin (G) and V are known to have a potential nephrotoxic effect,
especially when administered in combination. Toxic serum levels are
>10mg/l for G and >60mg/l for V, respectively.
Industrial spacers loaded with gentamicin and vancomycin (1.9% +
1.9%) were studied in an international multicenter clinical trial (Italy,
Spain, Switzerland). The primary endpoint was to assess their safety
when implanted in patients with prosthetic joint infection (two-stage
revision), also when the devices are utilized along with the systemic
antimicrobial therapy. The secondary endpoints were related to the
mechanical safety and to the functional effectiveness (joint mobility and
re-implantation).
Methods: Fourteen centres specialized in Orthopaedics and Traumatol-
ogy were involved in the study. G and V concentrations in serum and
urine were determined at different time (24, 48, 72 hours for serum
and 24, 72, 120 hours for urine) after spacer implant; renal function
parameters (renal clearance, serum creatinine, and BUN), inﬂammatory
markers (CRP, ESR) and clinical examination (X-ray, etc.) were also
considered during and after the study. Serum and urine concentrations
of G and V were determined by FPIA method.
Results: Fifty patients (mean age 67.0 ±5.0 yrs, mean ±SD) were
implanted with 34 knee spacers and 16 hip spacers. The serum
concentrations of G and V ranged from <0.1 to 1.8mg/l and from <1.0
to 49.3mg/l, respectively at all time considered. Urine concentrations
ranged from 0.13 to 60mg/L and <1.0 to 974.9mg/l for G and
V, respectively. Four patients showed high concentrations of V in
serum (range from 11.00 to 49.3mg/l) because of the parenteral co-
administration of V; however these values are in the therapeutic range.
72.5% of patients showed serum levels of V below sensitivity limits
(2.0mg/l). Renal parameters were in normal range during the study.
Conclusions: The implant of industrial spacers loaded with G and V
determined very low concentrations of both antibiotics in patients serum,
below the risk of renal toxicity. The release of G and V from spacers
exerted synergistic local antimicrobial activity, without toxic systemic
effects.
Therefore, the use of industrial spacers loaded with G and V in two-stage
revision surgery for the treatment of prosthetic joint infections should
be considered generally safe.
P813 Penetration of moxiﬂoxacin into liver tissue of patients
undergoing liver resection
C. Justinger, O. Kollmar, M.G. Kees*, F. Kees, M.K. Schilling
(Homburg, Berlin, Regensburg, DE)
Objective: Moxiﬂoxacin (MXF) may be a candidate for antibiotic
prophylaxis in the case of hepatobiliary interventions as well as for
treatment of bacterial liver abscesses. The aim of the study was to provide
data on the pharmacokinetics (PK) of MXF in serum and liver tissue of
patients undergoing liver resection due to primary or secondary tumour
of the liver.
Methods: After given informed consent, patients scheduled for planned
liver resection were enrolled into the study. The patients received MXF
400mg as one hour intravenous infusion at randomized timed intervals
prior to liver resection. Blood and healthy liver tissue was sampled in
34 patients (21 m/13 f, age 22−79 years, body weight 56–125 kg, height
155–187 cm) 1.5−26 h after administration of MXF. Plasma was sampled
concomitantly. In a subgroup of 19 patients, additional serum specimens
were obtained after 2, 4, 8, 12, 24, 36 and 48 h to establish the PK.
The pharmacokinetic parameters of MXF were calculated applying a
two-compartment model.
Results: The mean (SD) pharmacokinetic parameter were as follows:
Cmax 6.06 (1.93) mg/L, AUC 50.1 (15.1) mg*h/L, t1/2 11.9 (2.7) h, Vd
133 (36) L, Vd/kg 1.55 (0.21) L/kg, CL 8.73 (2.77) L/h. Compared with
historical data (SmPC, AVELOX, Nov 2009), mean Cmax and AUC were
25% higher, Vd normalized to body weight and CL 25% lower. The PK
parameters were signiﬁcantly correlated with weight and height, best Vd
R2 = 0.80, p< 0.001 and R2 = 0.55, p< 0.001, respectively. The mean
(SD) tissue concentrations were 9.13 (4,15, n = 13) mg/kg after 1.6−2.4 h,
7.62 (2,54, n = 9) mg/kg after 2.6−4.9 h, 7.48 (2.76, n = 7) mg/kg after
5.6–10.0 h, and 6.24 (3.66, n = 5) mg/kg after 22.9–26.5 h. The mean
tissue to serum quotients were 2.9, 3.4, 5.0 and 12.3, respectively. The
apparent half-life in tissue was 47 h, almost fourfold compared to serum
half-life. This difference indicates non-linear PK, most likely due to
saturated excretion of MXF into bile which contaminates the tissue
homogenate.
Conclusion: The PK parameters of MXF in patients undergoing
liver surgery were moderately altered compared to healthy volunteers.
Disposition of MXF into liver tissue apparently follows non-linear
kinetics.
P814 Pharmacokinetic evaluation of colistin in cerebrospinal
ﬂuid after endoventricular administration of colistin
methanesulfonate at different regimens in patients with
multidrug-resistant CNS infections
M. Cusato*, R. Imberti, P. Villani, L. Carnevale, G. Iotti, G. Accetta,
M. Regazzi (Pavia, IT)
Objectives: The increasing multidrug resistance to Gram-negative
bacteria and the lack of new active antibiotics have forced clinicians
to reconsider the use of colistin. Due to poor penetration through
the blood brain barrier, colistin methanesulfonate (CMS) is used via
endoventricular or intrathecal route. We evaluated the pharmacokinetic
of colistin in cerebrospinal ﬂuid (CSF) after endoventricular CMS
administration.
Methods: Six critically ill patients (5M, 1F, aged 26−70 years) were
investigated. CSF samples from each patient were collected at the steady-
state (sampling day range 3−23) before dosing and at time intervals after
the end administration. Patients no. 1, 5 and 6 received concomitant
CMS intravenously, not signiﬁcantly inﬂuencing our data. Colistin
concentrations were measured by HPLC with ﬂuorescence detector.
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Results: Patient no. 1 receiving CMS 30000 IU/24h had a Cmax and
Ctrough CSF level of 7.9 and 0.99 mcg/ml, respectively. Patients no. 2
and no. 3 receiving 60000 IU/24h had a mean [±SD] Cmax and Ctrough
CSF level of 14.1[±6.5] and 2.2[±1.1] mcg/ml, respectively. Patients
no. 4 and no. 5 receiving 30000 IU/12h had a mean [±SD] Cmax and
Ctrough CSF level of 12.8 [±0.4] and 5.8 [±0.4] mcg/ml, respectively.
Patient no. 6 receiving 60000 IU/12h had a Cmax and Ctrough CSF level
of 16.8 and 7.6 mcg/ml, respectively. Mean clearance and Vd were 0.025
L/h (range:0.018–0.033 L/h) and 0.44L (range:0.20–0.54L), respectively.
Interpatient variability (CV%) of clearance and Vd were about 20.7%
and 28.6%, respectively. The different amount of CSF spontaneously
drained during the study period is in part responsible for such variability.
Patients’ positive response to therapy was demonstrated by the decrease
in the CSF white blood cell count over the following days and by
subsequent sterilization of CSF.
Conclusions: Intraventricular administration of colistin in critically ill
patients was effective in the eradication of the Gram-negative bacteria
from the central nervous system.
Since the AUC/MIC ratio seems to be the most relevant surrogate
parameter of efﬁcacy (assuming a MIC value 1mcg/mL), our data
suggest that the 60000 IU/24h (AUC/MIC=209.2), 30000 IU/12h
(AUC/MIC=269.4) and 60000 IU/12h (AUC/MIC=316.4) dose regimens
achieved the optimal exposure, while the administration of CMS 30000
IU/24h (AUC/MIC=99.6) did not. Further studies are needed to clarify
which is the optimal regimen to use when CMS is administered
endoventricularly to treat CNS infections.
P815 Microdialysis study of metronidazole cerebral distribution
in patients with acute brain injury
D. Frasca, C. Dahyot-Fizelier, O. Mimoz, B. Debaene, W. Couet*,
S. Marchand (Poitiers, FR)
Objectives: Metronidazole is part of the standard therapy of bacterial
brain abscess and considered to penetrate well blood-brain barrier (BBB)
[1]. However dosing regimens are based on plasma and few cerebral
spinal ﬂuid (CSF) pharmacokinetic (PK) studies [2,3]. As infections
mainly occur in tissue extracellular ﬂuid (ECF), corresponding unbound
ECF antibiotic concentrations are responsible for the antimicrobial effect.
This study aims to explore metronidazole distribution in patients with
acute brain injury, by comparing their unbound concentrations in brain
and plasma.
Methods: After local ethic approval and written informed consent, four
brain injured patients, sedated, mechanically ventilated, monitored by
cerebral microdialysis (CMA 71, membrane lenght 10mm, membrane
diameter 0.6mm, molecular cut-off 100 kDa; CMA, Stockholm, Sweden)
and receiving metronidazole for an infection or prophylaxis, were
enrolled. PK study succeeded to 500mg of metronidazole over 30
minutes and brain dialysates and blood samples were collected over
400 minutes. In vivo probes recoveries were evaluated individually by
retrodialysis. Metronidazole was assayed by HPLC.
Results: Mean metronidazole brain to plasma AUC ratio was 0.86±0.14
(range from 0.74 to 1.06). All patients had metronidazole concentrations
versus time curves in brain delayed (mean time-to-peak = 69±30 min)
and peaks were smoother than corresponding curves in plasma with
mean Cmax in brain and plasma of 14.5±1.2 and 19.1±2.4mg/mL,
respectively. Mean half-lives was 379±131 min in plasma; Cmin were
7.2±4.0mg/mL in plasma and 5.5±1.3mg/mL in brain. Mean probe
recovery was 78.8±1.3%.
Conclusion: Our ﬁndings conﬁrm previous studies in CSF, metronida-
zole penetrates well BBB. Indeed, in acute brain injury patients, unbound
metronidazole AUCs in brain and plasma are close. Therefore unbound
metronidazole concentration in plasma could be a good surrogate of
metronidazole active concentration in brain for PK monitoring in routine.
P816 Study on the penetration of levoﬂoxacin into the prostatic
tissue
K. Takahashi*, S. Ishihara, T. Matsumoto (Onga-gun, Minokamo,
Kitakyushu, JP)
Background: Levoﬂoxacin (LVFX), a ﬂuoroquinolone marketed by
Daiichi Sankyo Co., Ltd., has been widely used in Japan, Europe and
the United States. The recommended dosage of LVFX was originally
100mg two to three times daily in Japan. After a review, based on the
PK-PD theory, the regimen was changed to 500mg once daily in July
2009.
Objective: The efﬁcacy of ﬂuoroquinolones for genitourinary tract
infection has been widely recognized. In the treatment of acute bacterial
prostatitis (ABP), however, both excellent penetration of a drug into
prostatic tissues and strong antimicrobial activity against the causative
pathogens are needed. In order to investigate the penetration of LVFX
into prostatic tissues, we conducted the present post-marketing clinical
study in compliance with GCP and measured the drug concentration in
prostatic tissues after administration of 500mg.
Subjects and Methods: Among the patients with prostatic hyperplasia
who presented to participating institutions during the period from
December 2009 to September 2010, 10 who fulﬁlled the following two
conditions were enrolled: 1) transurethral prostatectomy (TUR-P) was
judged to be necessary and 2) they gave written informed consent. The
subjects had a mean age of 73.9±9.09 years (mean±SD), while their
body weight was 59.12±8.02 kg and CLcr was 62.01±20.66mL/min.
After preoperative administration of one 500-mg LVFX tablet 3hours
prior to the surgery, each patient underwent TUR-P and 1−2 g of
prostatic tissue was obtained. At the same time, a blood sample was
collected from each patient to determine the ratio of the tissue drug
concentration to that in the plasma, which was separated from the blood
sample. LVFX concentrations in the prostatic tissues and plasma were
measured by liquid chromatography tandem mass spectrometry and by
high-performance liquid chromatography respectively.
Results: The concentration of LVFX in prostatic tissues was
6.44±1.79mg/g (mean±SD) and the tissue/plasma concentration ratio
was 1.16±0.26 (mean±SD).
Conclusions: It was demonstrated that LVFX, when administered orally
at 500mg, showed good penetration into prostatic tissues. Improper use
of ﬂuoroquinolones may promote the development of ﬂuoroquinolones
resistance in Escherichia coli, which is a current problem in the clinical
ﬁeld. LVFX (500mg once daily) promises to be effective for ABP both
in terms of its good antimicrobial activity and also by inhibiting the
emergence of resistant bacteria.
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P817 Clinical long-term microdialysis study with voriconazole in
healthy volunteers
C. Kirbs*, F. Simmel, M. Zeitlinger, E. Lackner, C. Rimmbach, C. Kloft
(Halle, DE; Vienna, AT; Greifswald, DE)
Objectives: Interstitial ﬂuid (ISF) concentrations of voriconazole (VRC)
were to be investigated representing the target site drug disposition
after sequence dosing of the antifungal drug. Microdialysis (MD), as a
minimally invasive method to facilitate the direct access to the unbound
ISF concentrations, was employed in a long-term setting with extensive
sampling over several days. Plasma ultraﬁltrate (UF) sampling was also
planned in order to determine the distribution to the target site by
comparing unbound plasma and tissue concentrations.
Methods: 6 healthy volunteers (age 21−46 yrs) were entered into the
study after giving written informed consent. VRC was administered as iv
infusion of 6mg/kg over 2 h (2 loading doses, dosing interval tau=12 h)
followed by 4mg/kg over 1.3 h (2 doses, tau=12 h) and 200mg VRC
tablets (tau=12 h). MD sampling over 84 h was performed in abdominal
subcutaneous adipose tissue using concentric catheters (CMA60, cut-
off 20 kDa) at a ﬂow rate of 2.0 mL/min. Relative recovery (RR) was
determined by retrodialysis. Plasma samples were ultraﬁltrated (cut-
off 30 kDa). MD and UF VRC concentrations were determined by a
validated HPLC assay. The genotype analysis of blood samples of the
study individuals with regard to the CYP isoenzymes 2C9(*2/*3) and
2C19(*2) was carried out.[1]
Results: Continuous MD was successfully applied over 84 h (except
in 1 individual: 60 h). RR revealed low intra- (0.7%-5.8%CV) and
interindividual variability (1.8%-3.2%CV) across all samples and showed
an overall high RR of 85.3%.
UF (n = 309 > lower limit of quantiﬁcation (LLOQ); n = 19 <LLOQ) and
ISF concentrations (n = 328 >LLOQ; n = 10 <LLOQ) were calculated:
UF ranging from 0.17–3.27mg/L and ISF from 0.17–3.13mg/L.
Individual concentration-time proﬁles revealed that variability between
individuals signiﬁcantly increased over time with one individual
displaying the highest concentrations (genotype: homozygous mutant for
CYP2C19*2). VRC showed favourable distribution to the target site with
predominately AUC ratios between ISF and UF of 1.
Conclusion: The concentration-time proﬁles of VRC in ISF, determined
by the use of MD, and in plasma allowed characterisation of the
pharmacokinetic behaviour and future assessment of pharmacokinetic-
pharmacodynamic relationships both in circulation and at the target site.
P818 Microdialysis for the study of ertapenem muscle distribution
and protein binding in healthy volunteers
T. Loupec, L. Laksiri, C. Adier, P. Saulnier, O. Mimoz, W. Couet*,
S. Marchand (Poitiers, FR)
Objective: Evaluate the relevance of microdialysis to assess muscle
distribution and plasma protein binding of ertapenem, as a representative
drug with extensive binding.
Methods: CMA 60 and CMA 64 IView microdialysis probes were
respectively inserted in the quadriceps and arm vein of young healthy
volunteers (n = 6). Probes recoveries were determined individually
by retrodialysis by drug. Ertapenem (1g) was then administrated
intravenously over 30 min and assayed by HPLC at various time
points (n = 13) in plasma before (total concentrations) and after
ultraﬁltration (free concentrations) with Centrifree® devices. Free
ertapenem concentrations were also determined in blood and muscle
dialysates (n = 14) and corrected for probes recoveries.
Results: Probes recoveries varied between 22.8±8.7% and 77.8±4.9%
in blood and 39.2±2.3% and 86.0±3.3% in muscle. Mean±SD unbound
muscle to plasma AUC ratio was equal to 3.1±1.2 [1.7−3.9] using
free plasma concentrations estimated by ultraﬁltration, but to 1.5±0.5
[0.8−2.0] with values obtained by blood microdialysis. Accordingly
ertapenem unbound fraction in plasma was equal to 3.2±1.6% on
average when derived from concentrations measured in ultraﬁltrates, and
more than twice higher (7.8±6.5%) when free plasma concentrations
were determined by blood microdialysis. These discrepancies could be
due to limited non speciﬁc adsorption of ertapenem on the ultraﬁltration
membranes.
Conclusion: For extensively bound drugs, small but unavoidable
experimental errors may have quite important consequences on free con-
centrations estimates and therefore tissue distribution characterization.
In such circumstances blood microdialysis may be preferred to plasma
ultraﬁltration, or at least used as a complementary method.
P819 Concentration of moxiﬂoxacin in plasma and tissue in
morbidly obese patients
S. Weber, M.G. Kees*, F. Kees, T. Horbach (Schwabach, Berlin,
Regensburg, Erlangen, DE)
Objective: The most appropriate dosage regimens for antibacterials in
obese individuals are often unknown. An accurate estimation of Vd and
CL is required to determine the appropriate loading and maintenance
doses of a drug regimen. The aim of the study was to determine the
pharmacokinetics (PK) of moxiﬂoxacin (MXF) in serum and adipose
tissue in morbidly obese patients undergoing gastric bypass surgery, and
to derive dosing recommendations for adipose patients.
Methods: After given informed consent, patients scheduled for planned
gastric bypass surgery were enrolled into the study. The patients were
treated with oral MXF 400mg qd for 3 days and with intravenous
MXF 400mg on day 4 (day of surgery). Venous blood was sampled
on day 1 up to 24 hours and on day 4 up to 72 hours to determine
the serum concentration-time course (area under the curve, AUC) of
MXF. Specimens of small intestine, omentum majus and subcutaneous
adipose tissue were collected on day 4 intraoperatively 1.8−3.7 (median
2.4) hours after administration of MXF.
Results: A total of 12 patients (2m/12f, age 25−61 years; body weight
98–166 kg, height 151–183 cm, BMI 43.0–58.2 kg/m2) completed the
study. The oral bioavailability (F) was 78.5 (11.5) %. The mean (SD) PK
were on day 1/day 4: AUCoo/AUCss 34.4 (8.9)/45.0 (12.2)mg·h/L, t1/2
9.9 (2.8)/12.3 (2.2) h, Vd/FVd 169 (34)/162 (29) L, CL/F/CL 12.3 (2.8)/
9.4 (2.0) L/h. Compared with historical data from healthy subjects
(Stass & Kubitza. J Antimicrob Chemother. 1999;43 Suppl B:83−90)
AUC was 30% higher, CL 25% lower. Absolute Vd was like in healthy
subjects, but halved when normalized to body weight (1.04 L/kg vs
2 L/kg in normal weight subjects). Accordingly, Vd was correlated
with height (R2 p.o/i.v. = 0.84/0.61; p< 0.01) more than with weight
(R2 p.o/i.v. = 0.64/0.50; p< 0.01). The quotient (SD) of the tissue to the
concomitant plasma concentrations was 2.22 (0.44) in small intestine, but
only 0.267 (0.064) in omentum majus and 0.224 (0.044) in subcutaneous
fat, indicating that adipose tissue is not a relevant compartment for MXF.
Conclusion: Surprisingly, the PK of MXF were not substantially altered
in adult morbidly obese patients compared to subjects with normal
weight, and no dose adjustments seem to be required for obese patients.
P820 Penetration of moxiﬂoxacin into wound tissue and wound
exudate obtained during topical negative pressure therapy
M. Sedigh, E. Polykandriotis, M. Jost, M.G. Kees, F. Kees*, R.E. Horch
(Erlangen, Berlin, Regensburg, DE)
Objective: Measurements regarding penetration of antibiotics into third
space ﬂuids (TSF) are of paramount importance for assessment of drug
exposure. Different experimental methods exist, including microdialysis
and skin blister ﬂuids, but their use is limited in patients. Topical
Negative Pressure (TNP) therapy is a convenient and ethical approach to
obtain interstitial ﬂuid under clinical conditions. Moxiﬂoxacin (MXF) is
approved for treatment of soft tissue infections, but data on its penetration
into the site of infection are limited.
Methods: After given informed consent, 21 patients treated with TNP
because of chronic wound healing disturbances or decubitus ulcer were
enrolled into the study. The patients received MXF 400mg intravenously
over 1 hour. In 18 patients (median, range: 51, 21−70 years; 75, 60−98
kg; 170, 160–180 cm) plasma and TNP wound exudate (WE) could be
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sampled before and 1−3, 12 and 24 hours after drug administration. The
pharmacokinetic parameters were determined in plasma using a one-
compartment model. WE data were evaluated descriptively.
Results: The mean (SD) pharmacokinetic parameters were similar to
data obtained from healthy subjects as described in the SmPC AVELOX
Nov 2009: Cmax 3.27 (0.90) mg/L, AUCoo 39.0 (16.7) mg*h/L, t1/2
8.1 (3.8) h, Vd/kg body weight 1.64 (0.42) L, CL 12.6 (6.7) L/h. Half-
life and Vd/kg were somewhat lower, but this may be due to the short
sampling period of only 24 hours. Penetration of MXF into the WE as
expressed by AUC was 62%, the quotient (mean (SD)) of ﬂuid to plasma
concentrations was 0.76 (0.56, n = 14) after 1−3 hours, 0.74 (0.34, n = 12)
after 8.6–13.8 hours and 0.69 (0.48, n = 14) after 24−30h.
Conclusion: The concentrations of MXF in WE were similar to the
unbound fraction in plasma (60%) and could be indicative for the
concentrations in interstitial ﬂuid in a clinical setting.
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P821 The emergence of novel and composite SCCmec element
types into Western Australian community S. aureus
G. Coombs*, J. Pearson, S. Monecke, F.G. O’Brien, K. Christiansen
(Perth, AU; Dresden, DE)
Objective: The earliest reports of community associated methicillin
resistant Staphylococcus aureus (CA-MRSA) involved indigenous
people living in remote Western Australian communities. Although
genetically diverse, these early strains primarily carried the type IV or
type V SCCmec element. Internationally a variety of “atypical” SCCmec
elements have recently been reported. The aim of this study was to
determine if novel SCCmec element types have been acquired by S
aureus isolated in the Western Australian community.
Methods: Since 1989, 84 pulsed-ﬁeld gel electrophoresis (PFGE) CA-
MRSA strains with 46 multilocus sequence types (MLST) have been
identiﬁed in Western Australia (WA). These sequence types are from
19 MLST clonal complexes and two singleton lineages. SCCmec typing
was performed on these strains by PCR and microarray DNA, and the
nomenclature as proposed by the International Working Group on the
Classiﬁcation of Staphylococcal Cassette Chromosome Elements was
used.
Results: The 84 PFGE CA-MRSA strains correspond to 67 CA-MRSA
MLST/SCCmec clones. Several SCCmec types and subtypes, novel
SCCmecs, and composite SCCmecs were identiﬁed. Forty six PFGE
strains carried SCCmec IVa-d [2B] (31 IVa, 2 IVb, 9 IVc, 4 IVd), 12
strains SCCmec V [5C2] and two strains SCCmec VIII [4A]. Two strains
had non typeable SCCmec IV subtypes and four strains had a SCCmec
element with a novel ccr gene complex including three with a class B
mec gene complex and one with a class A mec complex. Eighteen strains
carried SCCmec elements with composite ccr gene complexes including
twelve with SCCmec V [5C2&5] (5C2 plus ccrC1 allele 8), three with
SCCmec IVa [2B] & 5 (2B plus a type 5 ccr gene complex), one with
SCCmec V (5C2) & 2 (5C2 plus a type 2 ccr gene complex) and two
with SCCmec V [5C2&5] & 2 (a composite SCCmec V element plus a
type 2 ccr gene complex).
Conclusion: Although SCCmec IV and V are the predominant SCCmec
element types isolated in the Western Australian community, 30% of
strains carry novel or composite SCCmec elements. Although several
SCCmec elements have been acquired by multiple S aureus lineages
from which many CA-MRSA clones have emerged, only a few of these
clones have successfully adapted to the Western Australian community
environment.
P822 MRSA: different methods to predict healthcare or
community genotype
A. Charitakis*, C. Dimoulas, Z. Archontakis, S. Kanaki,
M. Kleisarchaki, S. Foyntoylakis, A. Xydaki, V. Liakou (Heraklion, GR)
Objectives: Aim of this study was to predict the frequency of healthcare
and community genotypes of MRSA strains isolated within a 3 year
period, using different methods.
Methods: Information on patients seen at Venizelio General Hospital
of Heraklion, Greece with MRSA infections were collected from
January 2008 to November 2010. MRSA infections were classiﬁed
as either healthcare associated (HA) or community associated (CA)
using an epidemiologic deﬁnition and an antibiotic susceptibility
phenotype rule to predict genotype. We considered CA-MRSA strains
isolated from outpatients and inpatients within 48 hours of hospital
admission and without previous history of hospitalization or dialysis
within the previous year (epidemiologic analysis, according to the
Centre for Disease Control and Prevention deﬁnition). Isolates were
considered as CA phenotype if they had a resistance proﬁle that
included the absence of gentamicin/trimethoprim-sulfa resistance and
the absence of ciproﬂoxacin/clindamycin/erythromycin coresistance
(phenotypic testing). Resistance testing and interpretation of the results
were performed according to CLSI criteria.
Results: The study consisted of 399 MRSA isolates. Using the
epidemiologic deﬁnition we found 308 CA-MRSA (77%) and 91 HA-
MRSA (23%) and using the phenotypic prediction rule 280 CA-MRSA
(67%) and 119 HA-MRSA (33%). Using a combination of both methods
we found 249 CA-MRSA (62.5%), 44 HA-MRSA (11%) and 106
(26.5%) strains which could not be classiﬁed.
Conclusion: As CA-MRSA enters the health care system and HA-
MRSA gets out into the community, it becomes more difﬁcult to
distinguish between HA- and CA-MRSA by epidemiologic or phenotypic
methods, but they can be used to describe the trend in MRSA infections.
Further work-up is necessary for conﬁrmation with pulsed-ﬁeld gel
electrophoresis (PFGE) or other molecular techniques. Nevertheless,
CA-MRSA genotype appears to be more frequent than the HA-MRSA
genotype.
P823 Evolving trends in treatment outcome of S. aureus
bacteraemia in Aberdeen Royal Inﬁrmary, 2006–2009
B. Edwards*, J. Abdel-Moneim, K. Girvan, B. Cosgrove, G. Edwards,
I.M. Gould (Aberdeen, Glasgow, UK)
Objectives: This study aimed to review patient outcomes and laboratory
characteristics from all S. aureus bacteraemias in Aberdeen Royal
Inﬁrmary over a four year period from 2006–2009.
Methods: All S. aureus bacteraemias were identiﬁed from laboratory
records over the four year period. Patient admission and discharge data
was accessed using the hospital’s patient management system (PAS). Any
antibiotic susceptibility data was also obtained from laboratory records.
Results: A total of 810 episodes of S. aureus bacteraemia were identiﬁed
from 2006–2009, 518 MSSA and 192 MRSA. For MSSA/MRSA over
the study period: 156/62 in 2006, 141/48 in 2007, 100/51 in 2008 and
121/31 in 2009. The age range was large (0−92, median 41 for MSSA;
0−98, median 69 for MRSA), with most MSSA bacteraemias occurring
in those 50−90 years old and MRSA in those 60−90 years old. For
MSSA/MRSA there was a male preponderance of 64.74/71.35%. For
MSSA/MRSA 41.51/61.98% of bacteraemias were hospital acquired
(cultures taken >48 hours after admission). The median length of stay
for MSSA/MRSA was 21/27.5 days, and remained stable over the
study period. For MRSA 30 day mortality rates over the four year
period declined, from 32.26% in 2006 to 19.35% in 2009. MSSA
30 day mortality remained stable. MRSA colonisation rates in those
with subsequent MRSA bacteraemia were 39.58%. There was no
evidence of an association between MIC and mortality. Therapeutic
monitoring showed vancomycin drug trough levels increase from 11.59
to 14.25mg/L over the study period. The level of vancomycin use
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remained constant over the study period, used in an average 62.99%
of episodes. Most MRSA bacteraemias are community strains, and
antibiotic susceptibility/strain types will be reported.
Conclusion: S. aureus bacteraemia still represents a huge burden in both
patient morbidity and ﬁnancially. While a large proportion of S. aureus
bacteraemias are still hospital acquired, MRSA and possibly MSSA case
ascertainment through admission screening, with appropriate isolation
and decolonisation, remains critical.
P824 Genotypic characterisation of Staphylococcus aureus isolates
causing bacteraemia at Tygerberg Hospital, Western Cape
Province, South Africa
H. Orth*, Z. Salaam-Dreyer, E. Makgotlho, B. Sinha, E. Wasserman
(Cape Town, ZA; Wu¨rzburg, DE)
Objectives: There is a paucity of studies on the genotypic character-
isation of invasive S. aureus strains and the incidence of community-
acquired methicillin resistant S. aureus (CA-MRSA) infections in
South Africa. In this study we characterized S. aureus isolates
from bacteraemia episodes using molecular methods and prospectively
collected demographic and clinical data on these patients.
Methods: Consecutive non-duplicate S. aureus blood culture isolates
were prospectively collected over one year. A multiplex PCR was used
for the detection of the spa, mecA and pvl genes. The spa gene was
sequenced and Ridom StaphType® used to determine spa-types and
spa clonal complexes (spa-CC). All cases were categorised by clinical
data as either hospital acquired (HA), health-care associated (HCA) or
community acquired (CA) S. aureus infections. Data were analysed by
using the Statistica® c2 test. A p value less than 0.05 was considered to
be statistically signiﬁcant.
Results: 113 S. aureus isolates (70% MSSA, 30% MRSA) were
collected from 104 patients. 86 bacteraemia episodes were classiﬁed
as HA (58%), HCA (27%) and CA (15%). According to clinical data,
all CA infections were due to MSSA and no CA-MRSA was detected in
our study. In the MSSA subgroup, 45% of cases were classiﬁed as HA,
33% HCA and 22% CA. Furthermore, all PVL-positive isolates were
MSSA (22.7% of all MSSA). MRSA strains clustered mainly in CC701
and CC012, whereas CC002 only consisted of MSSA (p = 0.0016).
The predominant source for S. aureus bacteraemia was catheter-related
sepsis (39%). Skin and soft tissue infections and pneumonia were
predominantly associated with MSSA strains.
Conclusion: Approximately one third of S. aureus bloodstream isolates
were MRSA in our setting, a rate comparable to the University Hospital
of Wu¨rzburg, Germany. None of the isolates were clinically categorised
as CA-MRSA; the majority of isolates were derived from cases deﬁned
as HA and the major source was catheter-related sepsis. This information
is useful for more targeted infection control and prevention practices to
reduce S. aureus bacteraemia.
P825 MALDI-TOF mass spectrometry: a useful tool for typing
Staphylococcus aureus strains in the context of cystic ﬁbrosis
N. Murillo, F. Bittar, M. Reynaud-Gaubert, J.C. Dubus, N. Stremler,
D. Raoult, J.M. Rolain* (Marseille, FR)
Objectives: Respiratory infections remain a major threat to cystic
ﬁbrosis (CF) patients and lungs represent a speciﬁc ecological niche that
is chronically colonized by various bacteria especially Staphylococcus
aureus that are known to be highly adapted to this microenvironment
during evolution of the disease. In this study, we used MALDI-TOF MS
on whole cells as a typing method to look for the possibility of a speciﬁc
clustering of S. aureus isolates recovered from sputum samples of CF
patients as compared to non-CF clinical isolates of S. aureus.
Methods: A total of 523 S. aureus isolates were analyzed including
324 isolates from CF patients collected from 2006 to 2010 at Marseille
(CF group), as well as 195 isolates from other patients in Marseille
and four reference strains (non-CF group). All strains were cultivated
on COS petri dishes at 37ºC overnight before analysis by MALDI-
TOF MS (AutoFlex apparatus, Brucker Daltonics®). Each of four
replicates of spectra was used to create proﬁles that were compared and
analyzed using Biotyper 2.0 software (Brucker Daltonics®) to generate
a dendrogram.
Results: All isolates were correctly identiﬁed by MALDI-TOF MS with
scores >1.9. The dendrogram obtained using Biotyper software clustered
the strains in ﬁve different clusters with an arbitrary distance level >500.
Statistical analysis revealed that cluster 1, 2 and 3 were signiﬁcantly
associated to isolates recovered from the CF group (p< 10−3) (Figure).
Cluster 4 was composed of 42 strains both from CF and non-CF group.
Conversely, cluster 5 was signiﬁcantly composed of isolates recovered
from the non-CF group (p< 10−6) (Figure). Looking more precisely at
the composition of these clusters for the CF group we found that cluster
3 was signiﬁcantly associated to isolates from adults (age >18 years,
p = 0.007) (Figure).
Conclusion: Our results suggest that MALDI-TOF MS may be useful
for the differentiation of isolates of S. aureus isolates from CF patients.
This should be compared with isolates from other CF centers to exclude
the possibility of a speciﬁc epidemiology of strains in our region. The
difference of clustering of isolates observed between children and adults
CF patients may be due to selective pressures in the CF patient’s lungs
during chronic infection, such as host responses and repeated antibiotic
treatment that may act as a driver for microevolution.
P826 Methicillin-resistant staphylococci in the Republic of Belarus:
results of the National Surveillance System (2008–2010)
L. Titov, T. Ermakova, V. Gorbunov, F. Lebedev*, I. Kazakov,
S. Glazkova (Minsk, BY)
Background: Staphylococcus aureus, especially its oxacillin-resistant
variant (MRSA), is the most important cause of multidrug resistant
health care-associated infections and mortality. In Belarus the national
antimicrobial resistance (AMR) surveillance program was established
in 2003 on the base of Laboratory for Clinical and Experimental
Microbiology (LCEM).
Objectives: To investigate the prevalence and levels of an antimicrobial
resistance of MRSA circulating in hospitals at the Republic of Belarus.
Materials and Methods: LCEM collects routine antimicrobial
susceptibility results of MRSA strains, isolated in regional laboratories
of the ministry of health. The data from the database of Vitek 2 Compact
(BioMerieux) of 943 isolates were also used. Minimal inhibitory
concentrations (MIC) for 15 antibiotics were detected automaticaly.
Results were analyzed using OBSERVA software (BioMerieux) and
biological statistics methods.
Results: The prevalence of MRSA isolates in hospitals varied from
20 to 45% and depends on the size of hospital, antibiotics prescribing
and consumption policy. MICs 90% (mg/l) for next antibiotics were de-
tected: benzylpenicillin (>0.25−0.5), oxacillin (>2.0−<4.0), tetracycline
(>8.0−<16.0), erythromycin (>4.0−<8.0), ciproﬂoxacin (>4.0−<8.0),
levoﬂoxacin (>2.0−<4.0), moxiﬂoxacin (>1.0−<2.0), gentamicin (8.0),
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clindamycin (>4.0−<8.0), fusidic acid (0.5), rifampicin (0.5), teicoplanin
(>2.0−<4.0) and vancomycin (2.0).
All isolates were susceptible to linezolid. Levels of susceptibility to
moxiﬂoxacin and fusidic acid were high − 96%, to teicoplanin − over
98%. Glycopeptide antibiotics, such as teicoplanin and vancomycin, have
been the mainstay of antimicrobial therapy in the treatment of serious
infections caused by MRSA. We found reduced susceptibility of MRSA
strains to vancomycin.
Conclusions and future prospects: 1. Resistance to antimicrobial drugs
is a recognized threat to public health and patient safety in Belarus.
Rational use of antimicrobials also plays a key role in bacteria resistance
preventing and controlling. 2. MRSA prevalence at the hospitals in
Belarus varied from 20% to 45%. 3. Collection of MRSA strains from
patients will be used for molecular-genetic typing (such as sequence
typing and SCCmec types determination).
P827 HA-MRSA epidemiology in an Italian paediatric ICU: an
outbreak caused by the Southern Germany clone
P. Cocchi*, G. Taccetti, M. Tanganelli, C. Braggion, M. de Martino,
G. Fognani, S. Campana (Florence, IT)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is
increasingly isolated in healthcare associated (HA-MRSA) and
community-acquired (CA-MRSA) infections. The aim of the present
study was to detect the presence of MRSA clones in the Intensive Care
Unit (ICU) of a Pediatric Hospital.
Methods: Nasal swabs were collected from 60 patients and 88 healthcare
workers in the ICU during a 7 months period of time. All putative isolates
were identiﬁed as Staphylococcus aureus by selective culture media and
positive results of the Slidex Staph Plus. MRSA isolates were identiﬁed
using Oxa Screen Test Agar and Brilliance MRSA medium. SCCmec
typing was performed in order to properly characterize CA-MRSA and
HA-MRSA, and all strains were analyzed with Multi Locus Sequence
Typing (MLST) in order to identify known epidemic clones (Oliveira DC
et al. 2002, Enright MC et al., 2000). The antibiotic susceptibility proﬁle
of MRSA strains was evaluated by disk diffusion test on Mueller-Hinton
agar and E-test.
Results: Twenty-four out of 148 (16.2%) nasal swabs were positive for
the presence of MRSA. Fifteen out of 24 (62.5%) isolates were HA-
MRSA. Three different clones were delineated, ST228-MRSA-I shared
by three patients, ST30-MRSA-III shared by two healthcare workers,
and ST45-MRSA-III shared by a healthcare worker and a patient.
Our attention was focused particularly on ST228-MRSA-I, the Southern
Germany clone.
This clone characterized by high rifampicin resistance has been described
in different European countries. MRSA strains isolated in Italian hospital
since 1990 were sensible to rifampicin. The Southern Germany clone
responsible of this Italian outbreak showed a susceptibility to rifampicin
characteristic of Italian isolates.
Conclusion: ST228-MRSA-I has not been previously highlighted
as responsible of outbreaks in Italy. This ﬁnding suggest that the
epidemiology of MRSA infections in critical care units need to be
carefully monitored, in order to detect and prevent the spreading of new
epidemic strains.
P828 An interaction between clone type and vancomycin MIC
inﬂuences risk of endocarditis associated with MRSA
bloodstream infection
C. Miller, O. Tosas, R. Batra, J. Otter, G. French, J. Edgeworth*
(London, UK)
Objectives: Bacterial virulence mechanisms and antimicrobial suscepti-
bilities may impact on risk of complications during treatment of MRSA
bloodstream infection. Isolates with a vancomycin minimum inhibitory
concentration (MIC) at the upper end of the susceptible range (1.5−2
microg/ml) have been associated with treatment failure, and some single
centre studies report an increase in population vancomycin MIC proﬁle
towards 1.5−2microg/ml: a phenomenon called MIC creep.
Methods: Spa typing, staphylococcal cassette chromosome mec allo-
typing and vancomycin and teicoplanin E-test-susceptibility testing were
performed on ﬁrst-isolates from 821 consecutive MRSA bloodstream
infection episodes occurring between 1999 and 2009. This period
overlapped with implementation of a successful hospital-wide MRSA
control programme leading to a 90% reduction in MRSA bacteremias.
Clinical and demographic data including focus of infection were
available for 695 clinically signiﬁcant episodes. Bayesian model
averaging (BMA) for multinomial logistic regression was used to
determine associations between clone type, MIC and focus of infection.
Results: Typing placed isolates in three groups; clonal complex (CC)
22 (n = 273), CC30 [n = 349] and non-CC22/30 [n = 198]. Over 11
years there was a signiﬁcant increase in proportion due to CC22
and non-CC22/30 and a decrease due to CC30, although the absolute
number decreased for all groups. Vancomycin MIC of all isolates
was 2microg/ml, however there was a signiﬁcant trend increase in
vancomycin MIC for each clonal group (CC22, OR 1.50 (95%CI
1.28–1.80), p< 0.001; CC30, 0R 2.08 (95%CI 1.56–2.96), p< 0.001;
non-CC22/CC30, OR 1.21 (95%CI 1.05–1.41), p = 0.024), which was
not observed for teicoplanin. BMA indicated that a vancomycin MIC
of 1.5−2microg/ml (n = 111), was associated with endocarditis with a
posterior probability of 96% depending on clone type. Speciﬁcally,
endocarditis was at least three times more likely in patients with a
bacteremia due to CC22 with an MIC of 1.5−2microg/ml (95%CI 2.99–
58.0) than other clone types. Clone and/or MIC did not predict bone and
joint or other infection foci.
Conclusion: Vancomycin creep has occurred on the background of an
effective MRSA control programme. In this setting clones have emerged
that have a strong association with endocarditis. The link between clone
type, higher MIC and a single distal focus site suggests that treatment
parameters alone are unlikely to account for this phenomenon.
P829 Genetic characterisation of early MRSA isolates in England
B. Pichon*, M. Ganner, R. Hill, R. Ehricht, B. Cookson, A.M. Kearns
(London, UK; Jena, DE)
Objectives: Since their emergence in the UK in the early 1960s,
Methicillin-Resistant Staphylococcus aureus (MRSA) have spread
rapidly worldwide. Fifty years on, they remain a major cause of hospital
acquired infection. To provide a benchmark for MRSA evolution in
hospitals in the UK, we have characterised some of the ﬁrst MSRA
isolates collected in England.
Methods: 29 MRSA recovered from hospitalised patients during
1960−61 in South London and the surrounding area, were selected
for genetic analyses including pulsed-ﬁeld gel electrophoresis (PFGE)
proﬁling, Multilocus Sequence Typing (MLST), spa and agr typing, toxin
gene proﬁling and Staphylococcus cassette chromosome mec (SCCmec)
typing. Microarray analyses were carried out on a subset of eight isolates
using StaphyType kit (Alere Technologies). MICs of a wide range
of antibiotics were determined and susceptibility interpreted according
to British Society for Antimicrobial Chemotherapy (BSAC)/European
Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria.
Results: Multiple pulsotypes were identiﬁed, but were closely related
and belonged to MLST CC8. ST250-SCCmec I (belonging to spa types
t008 and t121) was predominant (n = 27) and was recovered from each
hospital studied. A second lineage, ST247-SCCmec I (single locus
variant of ST250) was associated with spa t051. All isolates were positive
for enterotoxin B and were agr type 1. Microarray analyses highlighted
divergences in the SCCmec element, antimicrobial resistance traits and
virulence-associated markers. All isolates were resistant to b-lactams, as
the MIC of oxacillin 16mg/L, plus tetracycline (tetK-positive); two
isolates were non-susceptible to erythromycin (ermA).
Conclusion: Collectively, these data support the clonal expansion of two
closely related early ancestral MRSA strains, ST247 and ST250. Two
decades following their emergence, they were dubbed UK EMRSA-5
and -8 in recognition of their epidemic potential in UK hospitals.
Understanding the emergence, epidemiology and evolutionary biology
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of these resistant clones will provide important insights into the driving
force behind the expansion of MRSA clones.
P830 Temporal trends in the incidence of Staphylococcus aureus
bacteraemia. A multi-national population-based study
K. Laupland*, O. Lyytikainen, M. Søgaard, K. Kennedy, J. Knudsen,
C. Ostergaard, H. Schonheyder for the International Bacteremia
Surveillance Collaborative
Objectives: The epidemiology of Staphylococcus aureus bacteremia
has been changing in recent years especially with the emergence of
methicillin-resistant (MRSA) strains. However, it is unclear whether the
overall incidence of S. aureus bacteremia is increasing. The objective
of this study was to determine the population incidence of S. aureus
bacteremia and assess trends in incidence over time.
Methods: Population-based surveillance for all incident S. aureus
bacteremias was conducted nationally in Finland and in Calgary, Canada,
Canberra, Australia, and three regions in Denmark (North Denmark
Region, Copenhagen County, and Copenhagen City) during 2000–2008.
Incidence rates were age- and gender-standardized to the European
Union 27-country 2007 population.
Results: During 76,300,753 person-years of surveillance 17,046
episodes of S. aureus bacteremia were identiﬁed of which 16,364
(96.0%) were methicillin-sensitive (MSSA) and 682 (4.0%) were MRSA.
The very young and the elderly were at highest risk. Overall males were
at signiﬁcantly increased risk for development of S. aureus bacteremia
[crude incidence 27.9 vs. 17.0 per 100,000; incidence rate ratio (RR)
1.63; 95% conﬁdence interval (CI) 1.59–1.69]. The overall age- and
gender-standardized incidence rate was 27.0 per 100,000 and was 24.9
and 2.0 per 100,000 for MSSA and MRSA, respectively. The overall
standardized incidence rates (per 100,000) were 20.3 in Finland, 28.6 in
Calgary, 29.9 in Canberra, 31.0 in North Denmark, 33.1 in Copenhagen
County, and 32.1 in Copenhagen City. During the 9 years of the study,
the overall incidence (per 100,000) gradually decreased (29.8 in 2000 vs.
27.0 in 2008) and this was attributable to a reduction in disease due to
MSSA (28.5 in 2000 vs. 24.9 in 2008). However, MRSA increased from
1.3 per 100,000 in 2000 to 2.0 per 100,000 in 2008, and this increase
was marked in some regions.
Conclusions: The overall incidence of S. aureus bacteremia is
decreasing. However, ongoing surveillance is needed to assess regional
differences and whether this trend may be reversed in the coming years
due to the emergence of MRSA.
P831 The changing molecular epidemiology of methicillin-resistant
Staphylococcus aureus bacteraemia at a London teaching
hospital, 1999–2009
J.A. Otter*, J. Edgeworth, C. Miller, G. French (Andover, UK)
Objectives: Against a background of decreasing incidence, we sought to
determine the changing molecular epidemiology of methicillin-resistant
Staphylococcus aureus (MRSA) bacteraemia at Guy’s & St Thomas’
Trust (GSTT), a large London teaching hospital.
Methods: We investigated isolates of MRSA bacteraemia recovered
at GSTT from 1999–2009. The ﬁrst MRSA isolate from each patient
was characterised by spa type, staphylococcal cassette chromosome mec
(SCCmec) allotype and resistance to a range of antimicrobial agents.
Clones were deﬁned by using Based Upon Repeat Pattern (BURP)
clustering with a stringent calculated cost between lineages of 1. Analysis
of contingency tables was performed using c2 tests.
Results: 820 episodes of MRSA bacteraemia were reported during the
study period. Annual numbers decreased from 137 in 2000 to 13 in 2009.
The mean age of affected patients was 62 years (standard deviation 17),
84% were white, 34% were female and 30% of patients died. Epidemic
MRSA-15 (E15) and E16 accounted for 76% of cases overall. There
appeared to be a clonal replacement of E16 by E15 and other types
(chart). E15, other types and E16 accounted for 29%, 13% and 46%
of 634 cases during 1999–2004 compared with 46%, 24% and 22%
of 186 cases during 2005–2009, respectively (p< 0.001 comparing the
proportion of E15, other types and E16 in these two periods). E15
were SCCmec IV (100%), predominantly t032 (89%) and 65% were
resistant to <3 classes of non-b-lactams. E16 were SCCmec II (99%),
predominantly t018 (91%), 91% were resistant to >2 classes of non-
b-lactams and 40% were mupirocin resistant. t037 was classiﬁed as a
singleton lineage by BURP; it accounted for 9% of isolates and was
associated with a previously reported line-associated outbreak, peaking
in 2003 (chart). t037 isolates were SCCmec III (84%) and 86% were
resistant to >4 classes of non-b-lactams. The remaining 15% of isolates
were a heterogeneous group comprising 42 different spa types. There
were signiﬁcant differences in clonal distribution of all types in terms of
the focus of bacteraemia, patient specialty and antimicrobial resistance.
Conclusion: During a signiﬁcant decline in MRSA bacteraemias, the
relatively drug-susceptible E15 appears to have replaced the multidrug-
resistant E16 lineage as the commonest type of isolate and the proportion
of clonally heterogenous and singleton isolates has increased. The
reasons for these clonal replacements are unknown and warrant further
investigation.
P832 Mechanisms of adaptation of successful methicillin-resistant
Staphylococcus aureus clones
R. Baldan*, F. Testa, P. Cichero, C. Ossi, M. Moro, A. Biancardi,
P. Nizzero, D. Cirillo (Milan, IT)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is a
major cause of healthcare-associated (HA) infections. Most HA-MRSA
infections are due to few epidemic successful MRSA clones.
Since 2006, we collected and characterized the MRSA strains from
infected patients, admitted at the hSR, for infection control purposes
and to identify and characterize the major clones. We compared the
genetic background and the physiological characteristics of MRSAs
of “epidemic” and “sporadic” clones to investigate the adaptation
mechanisms and the genetic-phenotypic factors involved in the epidemic
behaviour of MRSA.
Methods: MRSA strains were characterized by SCCmec-typing, PFGE,
spa-typing and detection of Panton-Valentine leukocidin (PVL) genes.
Based on PFGE patterns, MLST was performed on selected strains.
Bioﬁlm production of isolates belonging to major clones and competitive
growth experiments were performed.
Results: We identiﬁed 3 major epidemic HA-MRSA clones and we
report here, for the ﬁrst time in Italy, the replacement of the ST228-
SCCmecI Southern German clone, still the most prevalent clone in Italy,
by the gentamicin- susceptible (GS) ST22-SCCmecIV EMRSA-15, that
became the leading clone in hSR.
We noticed a strong correlation between the ability to produce bioﬁlm
and the capacity of spreading and persistence of clones: during the study
period, the ST22 predominant type modiﬁed its bioﬁlm production from
weak to strong producer (p< 0.01). In hSR, there were no particular
restrictions on antibiotic use that could explain the replacement of a
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resistant clone (ST228) by a susceptible one (ST22). We observed that
GS-ST22 and ST228 clones have similar growth rate when grown in pure
culture, but in mixed culture they interfere each other and modify their
behavior: GS-ST22 reduces its generation time and outgrows ST228,
whose growth is signiﬁcantly slowed down.
Conclusion: We could improve infection control practices by under-
standing the mechanisms underlying the spreading abilities of MRSA
and factors inﬂuencing clones competition. Our data show that the
ability of an MRSA clone to modify its phenotypic and physiological
characteristics, such as bioﬁlm production and behaviour in presence of
a competitor clone, contributes to determine its epidemiological success.
P833 The risk factors of mortality for nosocomial Staphylococcus
aureus
A. Bastug*, G.R. Yilmaz, B. Kayaaslan, H. Bodur (Ankara, TR)
Objectives: Bloodstream infections (BSI) due to Staphylococcus aureus
have become increasingly common in hospitals worldwide. S. aureus
continues to be an important cause of nosocomial bacteremia. The aim
of this study was to evaluate the risk factors for mortality of nosocomial
BSI due to S. aureus.
Methods: We analyzed risk factors for mortality of methicillin-resistant
S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA)
bacteremia in a prospective case control study in an 1196-bed tertiary
referral medical center. One hundred and seventy six patients were
identiﬁed with clinically signiﬁcant and microbiologically conﬁrmed
nosocomial bacteremia due to S. aureus between July 2006 and January
2009. Logistic regression analyses were used to determine risk factors
of mortality.
Results: A total of 176 episodes of S. aureus BSI were identiﬁed:
102 MRSA BSI and 74 MSSA BSI. The crude mortality rate of
S. aureus bacteremia was 50.6%. The difference between the mortality
rates of MRSA (62.7%) and MSSA bacteremia (31.0%) was 31.7%.
Upon multivariate logistic regression analysis, the mortality with
MRSA bacteremia was revealed to be 3.02 times higher (p = 0.008,
RR=3.02, 95%CI= 1.34−6.8). Other signiﬁcant variables were found
as potential risk factors for mortality on multivariate logistic regression
analysis as follow; age equal or greater than 60 (p = 0.015, RR:2.13,
95%CI:1.1–3.39), hospitalization in intensive care unit (p = 0.000,
RR:5.6, 95%CI:2.9–10.9), total parenteral nutrition (p = 0.017, RR:
3.29, 95%CI: 1.24–8.76) and methicillin resistance (p = 0.008, RR:3.02,
95%CI: 1.34−6.8).
Conclusion: Methicillin resistance lead to higher mortality rates in
S. aureus BSI. As a consequence of this study we aimed decreasing total
parenteral nutrition usage. In additition, we planned to look over infection
control precautions and to apply strictly. For decreasing methicillin
resistance, we decided to evaluate rational antibiotic usage.
P834 BASALOMB: the Lombardy regional Staphylococcus aureus
bacteraemia surveillance system, Italy
A. Pan*, M. Arghittu, V. Bettamio, P. Casella, V. Cattolico, E. Costa,
C. Farina, F. Franzetti, M. Moro, G. Ortisi, A. Russo, E. Vigano` on
behalf of the Lombardy Group of Technical Assessment (GTA) for
Surveillance from Microbiological Data
Objectives: In 2005 the region Lombardy, implemented a prospective
regional surveillance system to monitor alert organisms (SENTILOMB),
antimicrobial resistance (RESILOMB) and Staphylococcus aureus
bacteremia − SAB (BASALOMB). We present data regarding the period
2007–2009 of the BASALOMB program.
Methods: A case record form was prepared to record data regarding
S. aureus bacteremia (SAB). Data were sent to a regional reference
centre, their quality was controlled, and analysis regarding incidence
and proportion resistance, performed and published on the website. The
trend of the incidence rates was deﬁned for a subset of 26 out of 122
microbiology laboratories participating in the surveillance program since
2007.
Results: During the period 2007–2009 we recorded 2,833 SAB, with a
38% methicillin-resistance (MR) rate. MR is stable: it was 37% in 2007
and 2008. The wards with the highest rates of SAB are coronary units
(17.1/10,000 patient days − PD), nephrology (10.2), infectious disease
(7.8) and intensive care unit (ICU) (7.3). MR SAB were more often
observed in neonatal ICU (4.0/10,000 PD), nephrology (3.8), ICU (3.6)
and medicine (2.3). SAB were due to MR strains in 27% of cases within
the ﬁrst 3 days from admission, 51% between 11−20 days and 61%
>20 days. The median patient age was 73 for MR and 68 for MS strains.
The median time from admission of SAB was 7 days for MR and 2 for
MS strains. Sensitivity of MR strains (n = ???) was: vancomycin=100%,
TMP-SXT and tetracycline =93%, gentamycin=53%, levoﬂoxacin=8%.
Among the 26 hospital subset the SAB incidence rate increased from
1.36 to 1.64/1000 admissions (+17%) and from 1.85 to 2.23/10,000 PD
(+21%). Methicillin-sensitive SAB increased from 1.23 to 1.32/10,000
PD (+7%), while methicillin-resistant SAB passed from 0.62 to
0.91/10,000 PD (+47%).
Conclusion: The incidence of SAB has progressively increased over the
study period. Although the proportion of MR has remained stable over
the study period, a relevant increase in the incidence of MR SAB has
been observed. Interventions to limit MR SAB should be implemented
especially in wards at higher risk, i.e. neonatal ICU, nephrology, ICU and
medicine. A high proportion (27%) of SAB diagnosed upon admission is
due to MR strains with important implication in terms of antimicrobial
choice.
P835 MRSA CC398 as an emerging cause of human infections in
Germany
R. Ko¨ck, A. Mellmann, A.W. Friedrich, K. Becker* (Mu¨nster, DE)
Objectives: Methicillin resistant Staphylococcus aureus (MRSA) of the
clonal complex (CC) 398 have emerged in European livestock and among
persons with a direct contact to these animals. Here we describe the
emergence of MRSA CC398 as a cause of human infections in a north-
western German university hospital located in an area with a high density
of pig production.
Methods: All patients admitted to the hospital between 2008 and
October 2010 were screened for nasal MRSA carriage at admission.
Every ﬁrst MRSA isolate of each patient case as well as every isolate
from clinical specimens was typed using S. aureus protein A gene (spa)
sequence typing. Isolates were grouped into spa clonal complexes (spa-
CC) by the Based Upon Repeat Pattern Algorithm (BURP). Isolates
clustering in the same spa-CC with spa types t011, t034 and t108
(known as the predominant spa types associated with MRSA CC398
from livestock) were considered to represent potential livestock-related
MRSA CC398 isolates. If MRSA isolates were detected in material
obtained within 72 h after admission, the cases were deﬁned as imported.
Results: In total, 1,748 MRSA isolates were characterized. Among
these, 1,378 isolates were from screening specimens, 31 from blood
cultures, 45 from respiratory secretions, 134 from wound swabs, 10 from
abscesses, 13 from urine and 137 from clinical varia. The proportion of
MRSA CC398 on all MRSA found was 21% in 2008, 23% in 2009 and
28% in 2010. Among isolates from screening specimens, this proportion
increased from 24% in 2008 to 33% in 2010. MRSA isolates from blood
cultures were associated with MRSA CC398 in 6%, from abscesses in
10%, from wound swabs in 8%, from respiratory secretions in 16%, from
urine in 0% and from clinical varia in 15%. Overall MRSA CC398 was
found in 14%, 9% and 11% of all clinical specimens in 2008 to 2010,
respectively. Ninety four % of all MRSA CC398 cases were classiﬁed
as imported. The distribution of spa types among isolates considered to
belong to CC398 was t011 (52%), t034 (34%), t108 (6%), t1451 and
t2011 (each 2%), t1197, t1250, t1255, t1457, t2346, t2576, t2582, t2741,
t3934 and t5095 (each less than 1%).
Conclusion: MRSA CC398 is going to become the predominant MRSA
clonal lineage in a German university hospital located in a rural area
representing one third of all MRSA isolates from screenings in 2010. Of
utmost interest, MRSA CC398 isolates have also emerged as frequent
causes of infections.
S202 21st ECCMID/27th ICC, Posters
P836 Persistent methicillin-resistant Staphylococcus aureus
bacteraemia: risk factors analysis and clinical outcomes
Y.M. Wi*, K.R. Peck, S.S. Yoon, K.W. Lee, J.M. Kim (Changwon-si,
Seoul, KR)
Background: The high mortality attributable to persistent MRSA
bacteremia despite glycopeptide treatment has heightened the need for
early detection and intervention with alternative agents. The purpose of
this study was to determine the clinical characteristics and risk factors
of persistent MRSA bacteremia.
Methods: All ﬁrst episodes of signiﬁcant MRSA bacteremia were
collected at a 710-bed academic medical center during the period
November 2009 through August 2010. Blood culture was done at 3rd
days and 7th days after initiation of glycopeptide treatment. Clinical
characteristics and outcomes were compared between persistent MRSA
bacteremia (7 days) and non-persistent MRSA bacteremia (3 days).
Time to blood culture positivity (TTP) is deﬁned as time between onset
of incubation and growth detection using an automated blood culture
system.
Results: Of 84 patients with MRSA bacteremia during the study
period, 33 patients (39.3%) had persisitent MRSA bactermeia. Persistent
MRSA bacteremia group had a signiﬁcantly higher 30-day mortality
than non-persistent MRSA bacteremia group group (OR, 17.60; 95%CI,
3.58–86.45: p< 0.001). Multivariate analysis indicated that catheter
retention in catheter-related infection (CRI) (OR, 5.48; 95%CI, 1.38–
21.86; p = 0.016) and metastatic complication at presentation (OR,
24.36; 95%CI, 4.63–128.21; p = 0.001) were independent predictors for
persistent MRSA bacteremia. Patients who had early TTP <12 hours
were at an increased risk of persistent MRSA bacteremia (32.2% versus
11.4%, p = 0.039).
Conclusions: High mortality of persistent MRSA bacteremia is noted in
patients with glycopeptides. Early removal of catheter and evaluation of
metastatic infection should be taken into consideration for reducing the
risk of persistent MRSA bacteremia. Further large studies are needed
to evaluate the efﬁcacy of early intervention with appropriate alternate
agents in MRSA bacteremia of earlier TTP.
P837 Distribution of the arginine catabolic mobile element in
staphylococci
S. Monecke*, D. Coleman, G. Coombs, E. Deasy, R. Ehricht, M. Ip,
A. Shore (Dresden, DE; Dublin, IE; Perth, AU; Jena, DE; Hong Kong,
HK)
Objectives: The SCCmec-associated arginine catabolic mobile element
(ACME) has been recently found in the MRSA strain ST8-MRSA-IVa,
“USA300” (Diep, 2006). This element was thought to contribute to the
pandemic spread of this strain, e.g., by enhancing survival on human
skin. ACME was also described in ST1-MRSA-IVa, ST5-MRSA-II and-
IVa, ST22-MRSA-IV, ST59-MRSA-IVa, ST97-MRSA-V and ST239-
MRSA-III isolates (Goering, 2007; Diep 2008; Ellington, 2008; Ellis,
2009; Shore, ISSSI 2010; Ghaznavi-Rad, 2010). Aim of the study was
to detect ACME in a large collection of staphylococcal isolates.
Methods: Approximately 6,400 S. aureus isolates (including ca. 3,700
MRSA) from diverse geographic locations were genotyped using DNA
microarrays (Alere Technologies, Germany) which assigned isolates
to MLST clonal complexes and detected virulence-associated genes
including the ACME genes arcA/B/C/D. This assay was also applied to
185 methicillin-resistant coagulase-negative staphylococci (MR-CoNS)
recovered from blood cultures from one Irish and two German hospitals.
Results: ACME was identiﬁed in 3.5% of S. aureus isolates tested. The
most common and widespread ACME-positive strain was “USA300”,
although one-third (57/182 isolates) lacked ACME. Other ACME-
positive MRSA strains included two clones, which appear to be restricted
to Hong Kong (ST1048-MRSA-IV, ST1774-MRSA-IV), and the above-
mentioned ST22-MRSA-IV from Ireland. ACME was found to occur
sporadically in several CC45-MRSA strains as well as in CC5-MRSA-II,
-IV, -V and ST239-MRSA-III isolates. The only methicillin-susceptible
S. aureus harbouring ACME were epidemiologically linked, hospital-
acquired CC8-MSSA from South-Eastern Saxony. ACME was also
detected in methicillin-resistant S. epidermidis and S. capitis as well
as in methicillin-susceptible S. warneri. Among blood culture isolates
of MR-CoNS, 28.6% (53/185) were ACME-positive with no signiﬁcant
difference between German and Irish isolates. The highest prevalence of
ACME was noted for S. epidermidis (47.3%).
Conclusion: ACME was identiﬁed in a small proportion of the S. aureus
population but it was more common among CoNS. While it still needs
to be clariﬁed whether the presence of ACME really confers a selective
advantage to S. aureus, it can be speculated that intra-species transfer
of ACME is a rare event and that it may confer some disadvantage or
ﬁtness cost which limits its spread within S. aureus.
P838 Is our hospital environment clean enough for the
containment of methicillin-resistant Staphylococcus aureus?
Y. Gan*, M.K. Yeung, M. Chan, P.L. Ho (Hong Kong, HK)
Objective: Transmission of multi-drug resistant pathogens has been
associated with hospital hygiene. One of the common hospital acquired
infection is methicillin-resistant Staphylococcus aureus (MRSA). This
study aimed at examining the level of environmental MRSA contamina-
tion in a public hospital in Hong Kong.
Methods: 32 patients with MRSA were randomly selected over one
month and each of these cases was matched with one control patient
presenting with no MRSA who resided in the same ward. 15 sites in
close proximity of the patient bed were selected where environmental
samples were obtained with contact slides and swabs. All the MRSA
isolates were characterized by molecular tests.
Results: There was signiﬁcantly higher chance of identifying MRSA
at the near-to-patient sites of infected patients than control patients
(53% vs 28%, p-value <0.05). Each MRSA patient had an average of
2.1 sites present with MRSA, compared with only 0.5 sites for each
control. Hand-touched sites, such as locker handle bar (23%) and bed
tilt adjustment handles (19%), most frequently harbored the microbe.
Fomites that were often omitted from routine cleaning, for instance,
cubical partition ledge and curtain, had substantial contamination of
MRSA. Molecular studies showed that most of the isolates belonged
to sequence type (ST) 45 (with spa t1081, Staphylococcus cassette
chromosome mec (SCCmec) V, agr IV). It constituted 40% (36 out of
90 isolates) of total near-to-patient MRSA. The second largest group
comprising 31% (28 isolates) was ST 8/239 (spa t037, SCCmec III/IIIA,
agr I).
Conclusions: It is found that MRSA ST45 is the most prevalent in
the hospital environment in Hong Kong. The higher rate of MRSA
isolated around the infected patients suggests a possible route of
MRSA transmission from the patients to their proximal environment.
Enhanced and audited cleaning should be advocated to reduce the risk
of nosocomial infection.
P839 First report of methicillin-resistant Staphylococcus aureus
Cordobes/Chilean clone involved in nosocomial infections in
Brazil
A.P. Becker, C. Dias*, P.A. d’Azevedo (Porto Alegre, BR)
The objective of this study was to describe the molecular epidemiology
of methicillin-resistant Staphylococcus aureus (MRSA) involved in
nosocomial infections in the city of Porto Alegre, Southern Brazil,
and its metropolitan area. We studied patients with MRSA infections
identiﬁed at a hospital complex from April to December, 2008. The
SCCmec complex type was determined by Polymerase Chain Reaction
(PCR). Representative isolates were typed by chromosomal DNA
macrorestriction followed by pulsed ﬁeld gel electrophoresis (PFGE).
A total of thirty MRSA isolates were obtained from inpatients. Eighteen
(60%) of MRSA isolates showed SSCmec type-III and PFGE analysis
of representative isolates revealed a pulsotype which corresponds to
the Brazilian Epidemic Clone (BEC). Eleven (36.7%) isolates showed
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SCCmec type-I, all belonging to the same clonal group which was
related to the Cordobes/Chilean clone by PFGE analysis. Finally, we
observed one isolate exhibiting SCCmec type IV that, according to
PFGE analysis was not similar to any of the international clones tested.
Isolates presenting SCCmec type I were typically multidrug resistant,
except for trimethoprim-sulfamethoxazole (TMP-SMX), vancomycin
and rifampin, whereas isolates presenting SCCmec type III had a variable
pattern of resistance. The rise of the now called Cordobes/Chilean
clone was documented in Cordoba, Argentina, more than a decade ago
and this clone quickly became predominant over BEC in Argentina
in 2001 (53% versus 23% in hospital-acquired infections). In Brazil,
besides BEC, the presence of different clones was described, however
the occurrence of Cordobes/Chilean clone was not reported so far.
All isolates of this study exhibited susceptibility to TMP-SMX and
this may be a useful phenotypic marker in the clinical microbiology
laboratory as a preliminary criterion to differentiate it from BEC in a
suspected outbreak. Our study is the ﬁrst report of Cordobes/Chilean
clone involved in nosocomial infections in Brazil. Considering that this
clone successfully replaced BEC in hospitals in Argentina and in other
countries, it is important to emphasize the need of surveillance studies
based on molecular epidemiology tools allowing us to trace the spread
of Cordobes/Chilean clone.
Financial support: CNPq
P840 Molecular characterisation of methicillin-resistant
Staphylococcus aureus: ST239 isolates collected over a
12-year period in Hong Kong
S. Shabir*, M. Ip, K. Hardy, P. Hawkey (Birmingham, UK; Shatin, HK)
Objectives: To determine the usefulness and discriminatory ability of
an extended panel of published VNTR primers when investigating the
molecular characterisation of a longitudinal collection of Methicillin
Resistant Staphylococcus aureus (MRSA); ST239 isolates from Hong
Kong.
Methods: Seventy-six non duplicate patient MRSA isolates collected
between 1988–2000 from blood culture and non blood culture samples
were conﬁrmed as sequence type 239 (ST239) using multiplex PCR.
Three multi locus variable number tandem (VNTR) analysis (MLVA)
typing schemes (A, B, C) were used to epidemiologically characterise
these isolates. The published methods utilised twenty-eight VNTR
regions on the S. aureus genome, of which twenty-three loci were
ampliﬁed. The ﬁve omitted loci were duplicated targets between all three
schemes.
Amplicons were analysed using the QIAxcel capillary gel electrophoresis
platform to determine size and repeat number of speciﬁc products at each
locus.
Results: Variability was seen in 20/23 loci. Scheme A, utilised 7 VNTRs
with 3 variable loci and resolved 76 isolates into 14 unique molecular
ﬁngerprints. Scheme B and C with 5 and 11 VNTRs respectively were
variable at all loci and resolved the isolates into 20 and 75 speciﬁc
proﬁles respectively.
When combining all 23 VNTRs all isolates were deemed unique through
a single repeat change at any loci. Overall similarity of all 76 isolates
using 23 loci differentiation was 24%, with 69 isolates clustering
within 85% similarity as determined by BioNumerics.
Conclusion: This study has demonstrated that by increasing the
number of VNTRs from a possible seven to 23 loci to characterise
S. aureus isolates for molecular ﬁngerprinting, further enhances its
discrimination as an epidemiological tool. However, opting for a 23
loci typing method potentially may have cost implications, thus further
work on identifying the optimal loci within this extended panel for
epidemiological differentiation or sub-typing is warranted.
P841 Clinical features of Staphylococcus aureus resistant to
linezolid at the Hospital Universitario Infanta Cristina,
Badajoz, Spain
E. Gardun˜o*, M. Fajardo, S. Rodrı´guez-Garrido, R. Hidalgo, N. Calvo
Sanchez, N. Gutie´rrez-Zuﬁaurre (Badajoz, Salamanca, ES)
Objective: To report the isolation of methicillin-resistant Staphylococcus
aureus resistant to linezolid (L-MRSA) in six patients at the Hospital
Universitario Infanta Cristina in Badajoz.
Methods: Descriptive analysis of clinical features of infections caused
by L-MRSA. At laboratory, susceptibility testing was performed using
the WalkAway System (Siemens Healthcare Diagnostics). Resistance
to Linezolid (Lz) was conﬁrmed with the method of E-test (AB
Biodisk, Solna, Sweden); interpretation of MICs was according to CLSI
guidelines.
Results: Between May and October 2009, ﬁve patients admitted to the
intensive care unit (ICU) and one to the Neurosurgery unit in our center
had severe infections caused by L-MRSA: two septic shocks (secondary
to nosocomial and to community-adquired pneumonia, respectively), a
post-quirurgical meningitis, a cranium encephalic trauma, a cerebral
hematoma and an encephalophaty secondary to cardiac arrest. All the
patient were men, with ages in a range 47−75 years (mean=56); all them
had central catheter in place, 4 of them (57%) had prior surgery; the
lenght of hospitalization were 10−44 days (mean=23), all them stayed at
ICU between 1−23 days (mean=9). The patients treated with linezolid
received it for 5−14 days (mean=7). L-MRSA was isolated in blood
cultures in three cases, in tracheal aspirate in one case, from CSF in one
case and from an eschar in another case. 2 patients were coinfected with
A. baumannii and one with extended-spectrum b-lactamase producing
Escherichia coli. All the patients except that from the Neurosurgery
unit had been treated with Lz prior to the isolation of L-MRSA. All
the isolates had resistance to Lz with MIC values between 16 and
>>258mg/ml conﬁrmed by E-test. L-MRSA isolates were found resistant
to oxacillin, ciproﬂoxacin, clindamycin, erythromycin, chloramphenicol,
and susceptible to teicoplanin, trimethoprim/sulfamethoxazole and
vancomycin. Plasmidic cfr gene was detected by PCR and conﬁrmed
by sequencing, but plasmids harboring this gene are under study.
The two patients with L-MRSA septic shock and the one with cranium
encephalic trauma died. No new cases were observed after reinforcing
infection control practices.
Conclusions: Lz-resistant MRSA isolates affected critically ill patients
with and without previous Lz treatment. High MICs of linezolid
suggest additional resistance mechanisms and are currently under further
investigation.
P842 Community-acquired methicillin-resistant Staphylococcus
aureus in Spain: present situation and evolution over the last
7 years in a general hospital
E. Cercenado*, A. Vindel, M. Marı´n, B. Gama, O. Cuevas, E. Bouza
(Madrid, ES)
Objectives: Since the ﬁrst description in 2003 of community-acquired
methicillin-resistant Staphylococcus aureus (CA-MRSA) isolates pro-
ducing the Panton-Valentine leukocidin (PVL+) in Spain, their incidence
seems to have increased. We describe the evolution of PVL+ CA-MRSA
over a period of 7 years in our institution, the molecular characteristics
of the isolates and analyze the clinical features of patients infected with
these isolates.
Methods: From September 2004 to November 2010, we collected 48
PVL-positive MRSA isolates corresponding to patients attending to the
emergency department. The isolates were genotyped by pulsed-ﬁeld
gel electrophoresis, SCCmec typing, agr polymorphism, and multilocus
sequence typing. Susceptibility to 29 antimicrobials was determined
by the broth microdilution method. In addition, the susceptibility to
linezolid, tigecycline and daptomycin was determined by the Etest
method. Methicillin-resistance was conﬁrmed by the detection of the
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mecA gene by PCR and pvl genes were detected by PCR ampliﬁcation
of the lukS-PV and lukF-PV genes.
Results: Over the period of study the number of isolates recovered
(year/number) was: 2004/4; 2005/2; 2006/4; 2007/10; 2008/8; 2009/11;
2010/10. The isolates belonged to the genotypes: ST8-SCCmec IVc
(n = 38); ST8-SCCmec IVa (USA300; n = 3); ST30-SCCmec IVc (n = 3);
ST5-SCCmec IVa (n = 1); ST80-SCCmec IVc (n = 1); and 2 singletons.
The corresponding agr types were I, I, III, II, III, and I, respectively.
In addition to methicilllin-resistance, 10 isolates were resistant to
tetracycline and doxycycline; 4 to erythromycin and clindamycin; 3
to erythromycin and ciproﬂoxacin; and 2 to fusidic acid. All isolates
were fully susceptible to the new antimicrobials linezolid, tigecycline
and daptomycin. The isolates were from children (n = 24) and adults
(n = 24), and were associated with skin and soft tissue infections
(pyogenic abscesses; n = 44), otitis (n = 2), and secondary bacteremia
(n = 2). Twenty-eight patients were from South America and one from
Africa. All patients recovered after surgical drainage and/or antimicrobial
treatment.
Conclusions: CA-MRSA infections are emerging in Spain although their
incidence is still low. Half of the patients were not Spanish-native. CA-
MRSA isolates belong to different lineages, although the majority of the
isolates belong to genotype ST8-SCCmec IVc. At present, the presence
of the USA300 clone is anecdotal in our area.
P843 Hospital-onset of “community-associated” methicillin-
resistant Staphylococcus aureus USA300 strain in Vancouver,
Canada
A. Wilmer*, E. Lloyd-Smith, M. Romney, L. Hoang, M. Hull,
S. Champagne (Vancouver, CA)
Objectives: USA300 is the predominant “community-associated”
methicillin-resistant Staphylococcus aureus (CA-MRSA) strain in the
USA, and has spread to Canada, Spain, Germany and other countries
worldwide. The epidemiology of CA-MRSA has recently changed and
USA300 appears to be emerging as a cause of serious, hospital-onset
infections in large American cities. The aim of this study was to
determine if transmission of USA300 MRSA was occurring within two
Canadian hospitals.
Methods: All new MRSA cases detected by a hospital-based
laboratory over a 12-month period in 2008/2009 were included in the
study. Microbiological specimens submitted for testing included both
surveillance and clinical specimens. Chart review was performed and
cases were deﬁned as hospital-onset MRSA (HO-MRSA) if positive
specimens were collected more than 72 hours after admission. Bacterial
isolates from these cases underwent PCR testing for the Panton-Valentine
leukocidin (PVL) genes. All HO-MRSA isolates that were PVL positive
underwent pulsed ﬁeld gel electrophoresis (PFGE) ﬁngerprinting.
Results: In total, 841 new MRSA cases were detected over the study
period. Of these,126 were HO-MRSA isolates and underwent testing for
PVL. Overall, 39 of 126 (31%) HO-MRSA isolates were found to be
PVL positive, and were conﬁrmed as the USA300 strain by PFGE.
Conclusion: Our ﬁndings indicate that transmission of HO-MRSA
USA300 amongst hospitalized patients is common in two Canadian
hospitals. This study represents the ﬁrst known documented report of
extensive transmission of HO-MRSA USA300 in Canada. Further, our
ﬁndings indicate that “community-associated” MRSA may not be an
appropriate classiﬁcation when molecular-based deﬁnitions of MRSA
are available.
P844 Epidemiology and antibiotic resistance of MRSA isolated in
Hospital Bologhine Ibn Ziri, Algiers
W. Amhis*, Y. Beroual, N. Amrar, S. Benmesbah, L. Benbetka, N. Sahel,
W. Hamzi (Algiers, DZ)
Objectives: To evaluate the epidemiology and the antiotic resistance of
the MRSA strains isolated in our university hospital.
Method: We analyzed the strains isolated from different samples
from outpatients and inpatient from January ﬁrst 2007 to September
30th 2010. The culture and identiﬁcation were performed according
to the standards techniques. The susceptibility test was performed
according to the disk diffusion CLSI technique against 15 antimicrobial
agents; Oxacillin (Oxa), kanamycin (Ka), Fucidic acid (FA), Tetra-
cycline (Te), Cotrimoxazole (SXT), Gentamicin (Gen), Erythromycin
(E), Oﬂoxacin (Oﬂ), Clindamycin (DA), Amikacin (Amk), Fosfomycin
(Fos), Levoﬂoxacin (Levo), Pristinamycine (Pris), Rifampicin (RiF),
Chloramphenicol (C) and Tobramycin (Tob), Teicoplanin (Tei) and
Vancomycin (Va). MRSA was deﬁned by Cefoxitin resistance (Cefoxitin
disk diameter <19mm).
Results: 76 strains were isolated from 71 patients. The sexe ratio
was 1.73. 63.38% were female and 36.6% were male. MRSA was
isolated more frequently from children under the age of 10 years and
the age groups of 31−40 years. 37.5% of MRSA was isolated from
outpatient samples. In the hospital, MRSA was frequently isolated from
patients’ samples from the surgery department 15.5%, followed by the
pediatrics and the intensive care unit 12.5%. Skin and soft tissue samples
were the most frequent 55.26%, followed by bacteremia 15.78%. The
susceptibility test showed a high resistance to Ka (74%), FA (61%), and
Te (51.9%). MRSA was also resistant to SXT (29.9%), Ge (24,7%),
E (18.2%), Oﬂ (18.2%), DA (14.9%), Amk (10.4%), Fos (5.2%), Levo
(5.2%), Prist (2.6%), RIF (1.3%), C and TOB (1.3%). 36 different
biotypes were identiﬁed. The most frequent was K.Te.FA 21% (with
37.5% in the outpatients and 16.66% in the inpatients). It was followed
by the antibiotype K.FA (5.26%)which was isolated essentially from
outpatient samples. The other antibiotype were <3.94%. One Strain of
MRSA was susceptible to all antibiotics.
Conclusion: This study showed that MRSA is most frequently isolated
from soft and skin infections. The biotype K.Te.FA which is usually
isolated from community infections is the most frequent biotype isolated
in our hospital. It seems that it had spread in our hospital. However it is
difﬁcult to determine the origin of its acquisition, in the community or in
the hospital. Further studies on the carriage of MRSA at the admission
are needed.
P845 Clonal lineages of tetracycline-resistant MRSA strains
isolated in a Spanish hospital during 2009. Detection of
MRSA ST398
C. Lozano*, A. Rezusta, E. Go´mez-Sanz, C. Colmenarejo, R. Ba´ez,
D. Benito, M. Revillo, M. Zarazaga, C. Torres (Logron˜o, Zaragoza, ES)
Objective: To study the clonal lineages, resistance mechanisms and
virulence traits of tetracycline resistant (TetR) MRSA strains isolated
in a Spanish Hospital during 2009.
Methods: 34 TetR MRSA were detected from unrelated patients in
Miguel Servet Hospital during 2009, representing 9.5% of MRSA
recovered in that period, and 27 of them were included in this study.
The antibiotic susceptibility proﬁle to 23 antibiotics was determined
by Microscan® system. Presence of ermA, ermB, ermC, ermT, ermF,
msrA/msrB, mphC, cfr, lsa(B), tetK, tetL, tetM, tetO, aac(6′)aph(2′′),
mupA, dfrA, dfrD, drfG, and dfrK genes was studied by PCR. Sequences
of grlA and gyrA genes were analysed in some of the strains.
Determination of SCCmec- and agr-typing was implemented on all
MRSA isolates. Spa-typing was performed by PCR and sequencing.
Presence of virulence factor genes lukF/lukS, tst, eta, etb, etd and cna
was investigated by PCR.
Results: The spa-types identiﬁed among the 27 TetR MRSA isolates
were (no strains): t011 (12), t1197 (1), t3934 (2), t002 (1), t008 (1),
t067 (3), t127 (2), t1381 (1), t2220 (2), and 2 new spa-types (t7613,
t7577). Fifteen strains (55.6%) were included in spa types related to
the livestock-associated sequence type ST398 (t011, t1197 and t3934).
These strains and one strain with a new spa-type (t7577) were typed
as SCCmecV and agrI. The other strain with a new spa-type (t7613)
presented a non-typable SCCmec and agrI. The remaining 10 MRSA
strains were typed as SCCmecIV and agrI, agrII or agrIII. The following
genes were detected (no strains): ermB (7), ermC (13), ermT (2),
msrA/msrB (4), mphC (5), tetK (16), tetM (27), aac(6′)aph(2′′) (5),
dfrA (2) and mupA (3). Mutation in quinolone targets were studied in 10
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ciproﬂoxacin resistant ST398 strains and all of them showed S80F amino
acid change in GrlA, six also presented S84L, two S84A, one E84G and
one no mutation in GyrA. Two strains were PVL positive (t7613 and
t008) and 20 strains were cna positive. None of them presented tst, eta,
etb and etd genes.
Conclusion: More than half of TetR MRSA studied corresponded to spa
types associated to the genetic lineage ST398. Tetracycline resistance
could be a good initial marker to think about potential ST398, although
this resistance can also be detected in other lineages. In addition, PVL
positive MRSA were also detected in this collection.
P846 Clinical outcomes and risk factors for mortality in patients
with invasive infection caused by ST72-MRSA-SCCmec type
IV strains in South Korea
E.J. Joo*, Y.E. Ha, J. Kim, S.J. Kang, S.Y. Park, C.I. Kang, K.R. Peck,
N. Lee, J.H. Song, D.R. Chung (Seoul, KR)
Objectives: Even though CA-MRSA in South Korea were known to be
the predominance of SCCmec type IV with sequence type (ST) 72 and
PVL-negative, the clinical outcomes and risk factors for mortality in
patients with CA-MRSA infection have been rarely exploited.
Methods: Retrospective cohort study was designed to identify ST72-
MRSA-SCCmec type IV from 3417 MRSA isolates stored in Samsung
Medical Center from 2007 to 2009. SCCmec typing and multilocus
sequence typing (MLST) was performed in selected MRSA infection
cases which had been susceptible to ﬂuoroquinolones (FQ), gentamicin
(GM), rifampin (RFP) and sulfamethoxazole/trimethoprim (SMX/TMP).
Finally, patients who had infection caused by ST72-MRSA-SCCmec type
IV were enrolled in this study.
Results: A total of 124 patients were identiﬁed to have ST72-MRSA-
SCCmec type IV infection from 452 MRSA isolates susceptible to FQ,
GM, RFP and SMX/TMP. The most common primary focus of infection
was skin and soft tissue infection (SSTI) (51/124, 41%) when it included
surgical site infection (27/124, 21.8%), and followed by pneumonia
(34/124, 27.4%) and bone and joint infection (13/124, 10.5%). Eighty-
four patients (67.3%) had community-onset (CO) infection with 61
(49.2%) healthcare-association, whereas 40 (32.3%) had hospital-
onset (HO) infection. In comparison of patients between community-
and hospital-onset infection, complicated SSTI had been related to
community (16/84 vs. 1/40; P = 0.002) and pneumonia to hospital
(16/84 vs. 18/40; P = 0.005). The univariate analysis showed that factors
associated with morality were the presence of hematologic malignancy
and pneumonia. By multivariate analysis, underlying hematologic
malignancy and pneumonia still showed a signiﬁcant association with
mortality (OR, 11.93; 95%CI, 1.41–101.07; P = 0.023 and OR, 37.74;
95%CI 6.64–214.65; P< 0.001).
Conclusions: Community-genotype strains which were deﬁned as
ST72- MRSA -SCCmec type IV, have been commonly observed
in healthcare and hospital-settings. Pneumonia was more related to
hospital-onset infection compared to community, whereas SSTI to
community compared to hospital. Underlying hematologic malignancy
and pneumonia were signiﬁcantly associated with mortality in patients
with ST72-MRSA infection.
P847 Comparison of mortality-associated bacteraemia due
to methicillin-resistant and methicillin-susceptible
Staphylococcus aureus
M. Cameo, M. Palacian, M. Marco, C. Marne, M. Aı´sa, A. Rezusta*,
M. Revillo (Zaragoza, ES)
Objectives:
1. Study of the prevalence and evolution of methicillin-resistant
Staphylococcus aureus (MRSA) in our hospital.
2. Comparison of the mortality risk associated with bacteremia due to
MRSA and methicillin-susceptible S. aureus (MSSA).
Methods: Retrospective study of MRSA and MSSA strains isolated
from clinical samples of patients attended in the Hospital Universitario
Miguel Servet from 2005 to 2009. Isolates were identiﬁed and tested for
antibiotic susceptibility by microdilution system (MicroScan Walkaway®
Siemens). Data from outcome of patients with S. aureus bacteremia were
collected for the study.
Results: The total isolates of SAMS were 1242 (65.78%) in 2005, 1342
(69.14%) in 2006, 1441 (67.49%) in 2007, 1520 (64.82%) in 2008 and
1466 (68.05%) in 2009. The isolates of MRSA were 646 (34.22%),
599 (30.86%), 694 (32.51%), 825 (35.18%) and 688 (31. 94%) The
total isolates of SAMS in blood samples were 99 (7.90%) in 2005, 143
(10.60%) in 2006, 153 (10.61%) in 2007, 136 (8.94%) in 2008 and 122
(8.32%) in 2009. The isolates of MRSA were 43 (6.65%), 39 (6.51%),
69 (9.94%), 40 (4.84%) and 38 (5.52%) respectively. The percentages of
patients affected by MRSA and MSSA bacteremia are shown in the table
below (table 1). The outcome was studied in the patients with S. aureus
bacteremia. We found that mortality was 66.6% in patients with MRSA
bacteremia, in 2005 (n = 6), 40% in 2006 (n = 4), 46.6% in 2007 (n = 7),
37.5% in 2008 (n = 6) and 50% in 2009 (n = 14). In comparison mortality
in patients with MSSA bacteremia data were 31.2% in 2005 (n = 15),
37.5% in 2006 (n = 27), 28.3% in 2007 (n = 19), 37.7% in 2008 (n = 24)
and 41.8% in 2009 (n = 36).
Conclusions:
• The prevalence of MRSA doesn’t change, although the number of
patients with MRSA bacteremia increases slightly in the period study.
• Patients with MRSA infection had higher mortality risk, compared
with patients with MSSA.
• Increased effort in the infection control measures and in reliable
laboratory screening for resistance is necesary, as MRSA infections
are still a cause of concern in our hospitals.
P848 Genetic lineages, virulence and antimicrobial resistance
mechanisms detected in methicillin-resistant Staphylococcus
aureus of blood origin in a Spanish hospital
N. Porres-Osante*, J. Crettaz, C. Martin, Y. Sa´enz, C. Torres (Logron˜o,
ES)
Objectives: To characterize the molecular epidemiology, resistance
and virulence in all meticillin-resistant Staphylococcus aureus (MRSA)
recovered from blood cultures of unrelated patients at a Spanish hospital
(period November 2008 to 2010).
Methods: Thirty-one MRSA isolates were included in this study.
Identiﬁcation was carried out by Microscan and by PCR ampliﬁcation
of nuc gene. The susceptibility testing to vancomycin (VAN),
teicoplanin (TEC), streptomycin, gentamicin (GEN), netilmicin (NET),
tobramycin (TOB), kanamycin (KAN), trimethoprim-sulfamethoxazole
(SXT), ciproﬂoxacin (CIP), tetracycline (TET), chloramphenicol (CHL),
linezolid (LZD), mupirocin (MUP), quinupristin-dalfopristin (Q-D),
erythromycin (ERY), and clindamycin (CLI) was tested by disc diffusion
method. The presence of resistance genes (e. g. mup, mecA, ant(4′)-Ia,
aac(6′)-Ie-aph(2”)-Ia) and virulence factors (e. g. tsst-1, pvl, eta and
etb) was determined by PCR. The clonal relationship was determined by
PFGE/SmaI and the genetic lineages by spa, SCCmec, and agr typing.
Results: The percentages of resistance detected in the MRSA isolates
were as follows: CIP (100%), GEN (16%), TOB (81%), KAN (90%),
ERY (35%), CLI (16%) and MUP (16%). Three strains presented
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inducible CLI resistance. All the studied MRSA were susceptible to
VAN, TEC, NET, SXT, TET, CHL, LZD and Q-D. A high diversity of
PFGE patterns was observed in the 31 MRSA. SCCmec type IV was
detected in 97% of strains, and the SCCmec type II in the remaining
ones. The agrII was identiﬁed in 84% of the strains, all of them spa type
t067, with exception of one strain that was t1094. The agrI was detected
in four strains; three of them were typed as t008 and the other one as
t2032. The spa type t021 was found in the only one agrIII strain. The
mup, ant(4′)-Ia, and aac(6′)-Ie-aph(2”)-Ia genes were found in all the
MUP-, TOB- and GEN-resistant strains, respectively. Two strains (spa
type t2032 and t021) ampliﬁed the toxic shock syndrome gene, whereas
none of the 31 MRSA strains were positive for pvl, eta or etb genes.
Conclusion: The spa t067 and agrII were the predominant types among
the MRSA of blood origin, although other types classically community-
associated were also found (t008, t021). High antimicrobial resistance
percentages have been observed, including mupirocin, that could reduce
the therapeutic options to treat MRSA.
P849 Molecular analysis of Staphylococcus aureus strains isolated
in a newborns unit in 2010
I. Codita*, E.C. Dragulescu, B.E. Lixandru, I.L. Coldea, S. Dinu
(Bucharest, RO)
Objective: To characterize Staphylococcus aureus strains circulating
in a new-born unit during the summer of 2010, in order to provide
information for infection containment.
Methods: Identiﬁcation of strains was done by using conventional
methods, authomated VITEK2 system and PCR nuc gene detection. We
included nuc gene detection in a triplex in house PCR, together with
mecA and luk S/F genes detection. For spa typing we used the SeqNet
protocol and the Ridom StaphType software (Ridom GmbH). Pulsed
Field Gel Electrophoresis was performed according to the HARMONY
protocol (Stephen Murchan et al.) and SCCmec typing according to the
PCR multiplex updated method (C. Milheirico et al. − AAC, 2007). Disc
diffusion was used for antimicrobial susceptibility testing, according to
the EUCAST method. For cefoxitin and vancomycin MIC detection we
used the E-test.
Results: Bacterial cultures received by our national reference laboratory
from a new-born unit were isolated during two summer months, in 2010,
from umbilical wounds (nr. = 13), nasal exsudate (nr. = 7), and two other
body sites. We identiﬁed 22 S. aureus strains, from which 2 MSSA and
20 MRSA. All MRSA belongged to the t127 spa type. The 20 MRSA
strains were equally distributted between 2 PFGE patterns, with a Dice
index of similarity of 87.5%. All MRSA strains were SCCmec type
VI or a type VI variant and PVL negative. The MSSA strains were
of spa type t616 and t1556, respectively, showing a low similarity index
with the MRSA strains. All MRSA strains, except one, showed the same
antimicrobial resistance pattern, with resistance to FOX, E, DA (MLSBi),
CN and TE. One strain was aditionally resistant to Ciproﬂoxacin.
Conclusion: Molecular analysis of MRSA strains isolated from a new-
born unit revealed a cluster of strongly related strains, supporting the
hypothesis that a success clone is evolving in this care unit. Besides
local measures, further studies are needed for deeper understanding the
origin of the evolving strain.
P850 Characterisation of oxacillin-susceptible mecA-positive
Staphylococcus aureus: could this be a new type of MRSA?
S. Al Johani*, A. Al Awaji (Riyadh, SA)
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) has
been deﬁned as S. aureus having the mecA gene or showing a minimum
inhibitory concentration (MIC) of oxacillin higher than 4mg/l. However,
some clinical isolates are mecA-positive and oxacillin-susceptible.
Therefore, we surveyed the occurrence of S. aureus having the mecA
gene and an MIC of oxacillin of less than 2mg/l (oxacillin-susceptible
MRSA; OS-MRSA).
Method: Between August and November 2010; a total of 2835 samples
of nasal swabs submitted for MRSA screening. Tests carried out by
Xpert MRSA (Cepheid®); all positive samples by Xpert system that
exhibit low Ct endpoint (<31) conﬁrmed by routine culture method using
Mannitol salt Agar (MSA) and all conﬁrmed staphylococcus aureus
samples examined by its susceptibility to cefoxitin disc (30ug; Oxoid®)
as per CLSI guidelines. All strains that susceptible to cefoxitin tested
by a third method, Penicillin binding protein 2a (PBP2a) which directly
detects the PBP2 protein encoded by the mec A gene.
Results: Of the 2835 nasal swabs screened by Xpert MRSA; there were
195 samples reported as positive for MRSA. Of the 195 there were
156 (80%) true positive conﬁrmed by culture and cefoxitin resistance,
19 (9.74%) were false positive and there were 20 (10.26%) samples that
has both Xpert MRSA positive, PBP2a positive and Cefoxitin susceptible
with a zone diameter of 25−31mm. Oxacillin MIC for all 20 isolates
were below 2mg/L.
These OS-MRSAs were least resistant to oxacillin among the MRSAs
tested and they were within the susceptible range to seven other b-lactam
antibiotics tested. Thus, OS-MRSA may become a high-resistant MRSA
upon the treatment of patients with b-lactam antibiotics.
Conclusion: We notice a prevalence of 10% of all positive MRSA,
exhibit new type of resistance. These results questioning the presence
of new mecA positive, Cefoxitin susceptible type of Staphylococcus
aureus that may be classiﬁed as a new type of MRSA. In this study, the
occurrence of OS-MRSA at a certain frequency was noted; precautions
are called for in the classiﬁcation of oxacillin-resistant S. aureus and in
the treatment of OS-MRSA infection. Further studies needed to genotype
these isolates.
P851 Hospital strains of methicillin-resistant Staphylococcus
aureus in Saint Petersburg, Russia
A. Goncharov*, T. Suborova, V. Kolodzieva, L. Zueva (Saint Petersburg,
RU)
Objectives: By the beginning the 21 st century, a considerable amount
of data about the fast geographical (and transnational) spread of the
international epidemic clones of nosocomial pathogens was accumulated.
In particular, the most serious medical and social problem is the spread
of international epidemic clones of methicillin-resistant Staphylococcus
aureus (MRSA). Meticillin-resistant S. aureus (MRSA) strains currently
belong to six of these lineages (CC1, CC5, CC8, CC22, CC30 and
CC45), each of which has independently acquired mobile genetic
elements (MGEs) carrying antibiotic resistance genes.
There is no enough data (in contrast to the EU countries) about
the genotypes (clonal types) prevailing and genetic basis of MRSA
population in Russia. A restriction-modiﬁcation (RM) test (Cockﬁeld JD,
Pathak S, Edgeworth JD, Lindsay JA., 2007) has now been developed
that is rapid, simple, inexpensive and accurately determines lineage of
hospital-acquired MRSA.
The aim of this study was to investigate the clonal structure of MRSA
population in St. Petersburg (Russia).
Methods: Using MLVA (Sabat A et al. 2003), RM-test the genotypic
structure of a 75 hospital-acquired methicillin-resistant Staphylococcus
aureus strains circulated in 5 specialized St-Petersburg hospitals has been
studied.
Results: The MRSA epidemic clone (spa-type t008, MLVA-type 1) is
revealed in two medical centers in St-Petersburg (North-West region of
Russia). The most (71 from 75) of hospital strains (including epidemic
isolates) were attributed as clonal complec CC8/239.
Conclusion: We suggest that several uniﬁed molecular techniques
including MLVA and CM-test will improve epidemiological surveillance
of staphylococcal infections by tracking geographical distribution of
epidemic clones and evaluation of the local epidemic situation. Simple
and accurate typing methods could lead to greater understanding of the
changes in genetic background of the current MRSA population.
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P852 Distribution of virulence factors and clonal complexes in
Staphylococcus aureus isolates from nosocomial bloodstream
infections
D. Jonas*, S. Rieg, C. Schneider, A.J. Kaasch, H. Seifert, W.V. Kern
(Freiburg, Cologne, DE)
The aim of this study was to analyse the genodiversity and presence
of virulence factors in Staphylococcus aureus isolated from patients
with nosocomial blood stream infections irrespective of Methicillin-
resistance.
Strains were isolated from patients at two university hospitals
participating in the Invasive Staphylococcus aureus Infections Cohort
(INSTINCT). One-hundred and forty-one strains were clinically
evaluated as originating from patients suffering from nosocomial blood
stream infections. Strains were analyzed by spa-typing and diagnostic
DNA microarrays (Arraymate, Clondiag) for detection of virulence
factors encoding DNA-sequences. Use of a manufacturers’ algorithm
deduces the most probable clonal complex (CC) assignation, which was
in accordance with known data about spa-types and their mapping with
MLST S. aureus database.
This investigation, which included 132 Methicillin-susceptible and nine
resistant isolates, revealed a large genetic heterogeneity of these strains
including 20 different CC. Strains of each CC were assigned to varying
spa-types, except of two CC59 isolates (both t216). MRSA included
ﬁve CC5-II (Rhine-Hesse EMRSA), two CC22-IV (Barnim EMRSA)
and one CC398-V (Dutch Pig Strain).
The predicted CC ranked in the order CC5 (n = 21), CC30 and CC45
(both 20), CC7 and CC15 (both 13), CC101 (9), C22 and CC8 (both
8). Fifty-eight (41%) of the isolates belonged to 13 CC, which rarely or
never give rise to MRSA; in particular, CC7 (13), CC15 (13) and CC101
(9). More than one isolate originated from the clonal complexes 1, 9,
12, 25, 59, 97, 121 and 398. One isolate each was assigned to CC78,
80, 182 and 395.
The most prevalent superantigens were the egc-cluster toxins (n = 79)
including seg/sei/sem/sen/seo/seu enterotoxins in strains of eight
different CC. Following entA (51) in eight CC, entC (21), entL (18)
and tst (17) were detected. Fifteen out of these latter 17 cases originated
from CC30 strains. No isolate was tested Panton-Valentine-toxin positive.
This study about nosocomial blood stream isolates revealed a high
diversity of 20 CC, which even again included a large number of
different spa-types. Even if about half of the isolates had a MRSA-
related genetic background, a considerable proportion belongs to CC
with genetic proﬁles different to MRSA-lineages. Knowledge about
prevailing proﬁles of virulence factors can be crucial for studying of
the epidemiology of S. aureus.
P853 Methicillin-resistant Staphylococcus aureus control in Italy:
the ProSA study, a questionnaire-based survey
A. Pan*, E. Bombana, G. Tura, C. Curti, S. Lorenzotti, P. Mondello,
M. Rosina, L. Signorini, M. Vizio, V. Rigobello, A. Goglio on behalf
of SIMPIOS (the Italian Multidisciplinary Society for Prevention of
Health Care Associated Infections) and ANIPIO (the Nurses National
Association for Prevention of Hospital Infections)
Objectives: MRSA control guidelines have been available in the
literature for over 2 decades and many hospital worldwide have
implemented local recommandations to control MRSA health-care
associated infections. We present the data of a questionnaire that was
sent to the Italian hospitals to evaluate the state of the art of MRSA
control in Italy.
Methods: A board from 2 infection control Italian societies, SIMPIOS
and ANIPIO, prepared a closed answer questionnaire that was sent
in February 2009 to all Italian hospitals. The questionnaire was
divided in 5 areas: general characteristics and infection control,
MRSA control, hand hygiene, antimicrobial stewardship, microbiological
data. The coordinating committee received, recorded, and elaborated
the questionnaires. An adherence evaluation to the Italian MRSA
bundle (draft, unpublished; (1) hand hygiene, (2) contact precautions,
(3) surveillance, (4) screening high risk patients, (5) decolonization, and
(6) antimicrobial stewardship) was performed.
Results:We received 205 questionnaires, representing 16.8% of the 1217
Italian hospitals, and 39% of the hospitals 200 beds, from 19/20 Italian
regions, accounting for 42% of the national admissions. 74 hospitals
(36%) had written guidelines, and further 17 hospitals referred to CDC
or WHO guidelines on multi-resistant microorganisms, for a total of 91
centres (44%). Local guidelines were based mostly on CDC guidelines
(78 hospitals, 86%), WHO (48, 53%), and/or SHEA (30, 33%). A hand
hygiene program was ongoing in 95 hospitals (46%), 33 (16%) had
indications on contact precautions, 87 (43%) analysed and fed back
surveillance data, 66 (32%) screened for MRSA high risk wards and/or
patients, 42 hospitals (20%) performed MRSA decolonization, and 41
(20%) had an ongoing antimicrobial stewardship program. One hospital
(0.5%) was compliant with all indications, while in 59 facilities (29%)
no intervention has yet been organized. Thirteen hospitals (6%) adhered
to 5 indications, 15 (7%) to 4, 39 (19%) to 3, and 78 (39%) to 1 or 2.
Conclusion: Although some level of MRSA control within hospitals
has been implemented in over 40% of the participating hospitals, a well
organized system, adhering to 4 interventions recommended by the
Italian MRSA bundle is available in 1 out of 7 hospitals in the country.
A higher level of organization is needed, and the forthcoming national
Italian MRSA recommendations are welcome.
P854 MRSA-Surveillance in Germany: ﬁrst data from the Antibi-
otic Resistance Surveillance System (ARS) and the mandatory
surveillance of MRSA in blood and cerebrospinal ﬂuid
B. Schweickert, I. Noll, M. Feig, H. Claus, G. Krause, T. Eckmanns*
(Berlin, DE)
Objectives: Surveillance is an indispensible component of most
strategies for control and prevention of MRSA. First data from ARS,
the German Antibiotic Resistance Surveillance system, and mandatory
reporting of MRSA in blood cultures are presented.
Methods: ARS: Within a framework of a voluntary laboratory based
surveillance system resistance data of all clinical pathogens and sample
types from hospital and ambulatory care are transmitted electronically
to the central data-base of the national public health institute (Robert
Koch Institute, RKI).
Notiﬁcations of MRSA: Since the 1st July 2009, all microbiological
laboratories are obliged to report the detection of MRSA in blood
and cerebrospinal ﬂuid to the local public health authority from where
it is reported to the RKI via the state health department. MRSA-
incidences have been calculated by using denominators based on the
German population 2009. The relationship between regional incidences
and MRSA-rates of eight federal states has been assessed by application
of spearman rank correlation.
Results: ARS: In 2009, 10 laboratories supplying 226 hospitals and 3222
medical practices provided resistance data from 37076 Staphylococcus
aureus isolates. MRSA-rates stratiﬁed by hospital and outpatient care
are presented in table 1.
Mandatory reporting: From 01.07.2009 to the 30.06.2010 3504 cases,
accounting for an incidence of MRSA-bacteraemia of 4.2/100,000
inhabitants/year, were reported. Males >65 years present with the highest
incidence (23.5/100,000 inhabitants/year). Stratiﬁcation by federal
states shows considerable regional differences (range:1.8−6.4/100,000
inhabitants/year), which were positively correlated to regional MRSA-
rates (6.7–27.3%) generated in ARS (spearman correlation coefﬁcient:
0.74; p = 0.04).
Conclusion: While mandatory reporting of MRSA-bacteraemia serves
as an indicator of the situation in hospital care, ARS additionally provides
a view on the outpatient setting. Expectedly, in ambulatory care MRSA-
rates are considerably lower compared to hospital care. Nevertheless,
the results indicate that in Germany MRSA plays a relevant role in
the outpatient setting as well. Particularly, high resistance rates in urine
samples suggest that further investigations about the epidemiological
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context in which infections occur and patient characteristics are
necessary to assess possible consequences for antibiotic management.
Travel medicine: tropical and parasitic
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P855 Liver dysfunction and its outcome in patients with Dengue
infection
S. Kumarasena, A. De Silva, R. Premaratna*, J. de Silva (Ragama, LK)
Objective: To describe the spectrum of liver dysfunction, identify
possible predictors of acute liver failure, and outcome in patients with
dengue infections.
Methods: All serologically conﬁrmed dengue patients admitted from
January 2009 to March 2010 were included in the study. Relevant
clinical and other details were obtained by analyzing their patient
records. Patients with DHF and DSS were managed in according to
WHO guidelines. Management of acute liver failure included supportive
management and intravenous N-acetyl-cysteine (NAC).
Results: Of 349 patients [54.6% female, mean age 36 years] with
serologically conﬁrmed dengue, 187 (53.6%) had dengue fever, 113
(32.4%) Dengue haemorrhagic fever (DHF) and 49 (14%) Dengue
shock syndrome (DSS). Deranged aspartate transaminase (AST), alanine
transaminase (ALT), total serum bilirubin, alkaline phosphatase (ALP),
g-glutamyl transpeptide, and International Normalized Ratio (INR) were
observed in 81.9%, 75.9%, 7.7%, 5.4%, 9.7%, and 17.7% of patients
respectively. 299 (85.6%) patients had elevated hepatic transaminases,
and 278 (93.9%) of them had an AST:ALT>1. Most (54.8%) had
elevated transaminases3 times the upper limit of normal (ULN), 31.4%
>3 to <25 ULN, and 41 (13.7%) had elevations above 1000 IU/l. Of these
41 patients, 16 developed acute liver failure (ALF). Early predictors ALF
among patients with transaminase levels above 1000 IU/l were presence
of nausea and vomiting, elevated bilirubin, elevated INR and elevated
ALP. There were three deaths; two had ALF and one had dengue shock
syndrome and multi-organ failure without ALF.
Conclusions: Liver function is commonly impaired in dengue fever, and
severe liver dysfunction does not seem to be uncommon. The presence
of nausea and vomiting, elevated bilirubin, elevated INR and elevated
ALP in patients with very high hepatic transaminases should alert the
physician to the possibility of impending acute liver failure.
P856 The effects of benznidazol treatment in the autonomical and
immunological response in chronic Chagas disease
M. Llaguno*, M. Silva, V. Rodrigues, V. Silva, D. Correa (Uberaba, BR)
Evidences of cardiac autonomic dyautonomia and the main immuno-
logical response in Chagas’ disease (ChD) are still controversial, and
factors that determine the different clinical outcomes, leading to a mild
or to severe forms of the disease are not fully understood. Benznidazole
treatment (Bz) induces parasite destruction and antigenic spreading
resulting in immune and autonomic changes that may have beneﬁcial
or detrimental effects on prognosis of Chagas’ disease. In order to
elucidate this issue, we performed a longitudinal study to evaluate
the parasitological, immunological and cardiac autonomic proﬁle before
and during Bz-treatment. Three groups were selected, 17 patients with
indeterminate ChD (IChD), 12 patients with a determinate ChD (DChD)
(7 cardiac, 1 digestive and 4 cardio-digestive) and 29 healthy control
subjects. All chagasic patients received speciﬁc treatment and were
follow-up for 60 days. Cardiac autonomic condition was assessed by a
short-term heart rate variability analysis (HRV) during basal conditions,
cold face test (parasympathetic stimulus) and passive orthostatism –Tilt
Test − (sympathetic stimulus) analyzing temporal, geometrical, spectral
and non-linear indices by Kubios HRV 2.0 software. The production
of plasmatic cytokines was evaluated by ELISA. HRV parameters were
signiﬁcantly decreased in basal conditions in both chagasic groups when
compared to the control group. During the cold face test, the IChD
group presented a lower variation and the DChD a higher variation of the
sympathetic parameters. Tilt tests did not showed any alteration. During
Bz-treatment was observed an unbalanced sı´mpato-vagal modulation,
and a subsequent relative sympathetic and parasympathetic modulation
at the end of the treatment. During Bz-treatment, was observed an
increased expression of pro-inﬂammatory cytokines in both chagasic
groups, but at the end of the treatment the IChD group expressed
a predominant proinﬂammatory proﬁle modulated by a subsequent
production of antinﬂammatory cytokines. In summary, both chagasic
groups present abnormal vagal modulation with similar but not equal
cytokine proﬁles before speciﬁc treatment, and during Bz-administration
each group present a different modulation of the cytokine/autonomic
proﬁles, probably, by an inﬂammatory response triggered by parasite
antigens or by a drug side effect.
P857 Severity of conﬁrmed adult Dengue in Singapore: comparison
of World Health Organization 1997 and 2009 criteria
V. Gan*, T.L. Thein, W.W. Lin, D. Lye, Y.S. Leo (Singapore, SG)
Objectives: In 2009, World Health Organisation (WHO) published new
guidelines on the classiﬁcation of dengue, using non-severe dengue
with and without warning signs, and severe dengue. We evaluated its
correlation with WHO 1997 criteria of dengue fever (DF), dengue
haemorrhagic fever (DHF) and dengue shock syndrome (DSS).
Methods: This is a retrospective study of 1278 adults with polymerase
chain reaction-conﬁrmed dengue at our centre managed with a
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standardised clinical pathway in 2004 (predominantly dengue serotype
1) and 2007 (predominantly dengue serotype 2).
Results: The two WHO criteria identiﬁed signiﬁcantly different
subpopulations (Bhapkar test for marginal homogeneity p< 0.001). The
new criteria classiﬁed more cases as severe (McNemar test of overall bias
p< 0.001), with 2.7% (0.7−7.8%) DSS vs. 16% (11.5–27.4%) severe
dengue. Isolated bleeding or organ failure without evidence of plasma
leakage accounted for the increase in severe dengue. A majority of cases
classiﬁed as severe by one set of criteria are classiﬁed as mild by the
other, indicating signiﬁcant disagreement between the two classiﬁcations:
60% (30−85%) of DHF were classiﬁed as non-severe by WHO 2009.
Conversely 56.3% (56−68%) of severe dengue by WHO 2009 were
classiﬁed as DF. Difference in deﬁnition of plasma leakage and shock
led to 45% of DSS being classiﬁed as non-severe dengue.
Conclusion: The two WHO criteria are signiﬁcantly different. The 2009
criteria rely on clinical judgment more than 1997. Further work is needed
to standardise the case deﬁnitions in WHO 2009, as subjective judgement
will undermine its value in surveillance and comparison. The WHO 1997
criteria are less useful in assessing clinical severity but may be better in
surveillance. More extensive and rigorous evaluation of the new criteria
should be undertaken before abandonment of WHO 1997 criteria.
P858 The utility of warning signs in predicting Dengue severity
in conﬁrmed adult Dengue: number needed to diagnose
V. Gan*, T.L. Thein, W.W. Lin, D. Lye, Y.S. Leo (Singapore, SG)
Objectives:World Health Organisation (WHO) proposed new guidelines
for dengue management in 2009, including using warning signs to
identify patients at risk of severe dengue. These criteria, derived from
expert consensus, differ substantially from previous guideline (WHO
1997) and require validation.
Methods: All adult dengue patients with positive dengue polymerase
chain reaction managed with a standardised clinical pathway at our
centre in 2004 and 2007 were retrospectively studied. Dengue serotype
1 predominated in 2004, and dengue serotype 2 in 2007.
Results: Using the six of seven warning signs identiﬁed by WHO 2009
that we were able to analyse, having any one warning sign had sensitivity
of 88–100% and speciﬁcity of 25−67% in predicting subsequent dengue
haemorrhagic fever (DHF) (WHO 1997). The sensitivity was 74−97%
and speciﬁcity 63−68% for progression to severe dengue (WHO 2009).
The three gastrointestinal warning signs (abdominal pain, persistent
vomiting and hepatomegaly) were each not signiﬁcantly associated with
either DHF or severe dengue (p> 0.05). The number needed to diagnose
(NND) is the number of patients that need to be tested to give one
correct result. Mucosal bleeding was the best predictor for DHF, with
NND=1.1−2.6 (p< 0.001). Concurrent rise in haematocrit with a drop
in platelet count was next best with NND=6.74–8.80 (p< 0.01). In
predicting severe dengue (WHO 2009), haematocrit rise with platelet
drop had a lower NND=2.5−2.9 (p< 0.001) with mucosal bleeding
next best with NND=3.0−6.1 (p< 0.001). Cases with clinical ﬂuid
accumulation were too few to provide meaningful quantitative estimates.
Conclusion: Both mucosal bleeding and a rapid concurrent haematocrit
rise with a drop in platelet count are good predictors of dengue severity
using WHO 1997 classiﬁcation of DHF and WHO 2009 category of
severe dengue. Using the presence of any one warning sign to identify
at-risk patients, the NND ranges from 1.4−7.3. While warning signs
are associated with dengue severity, there is scope for increasing the
speciﬁcity of criteria to reduce the burden on healthcare systems, as the
presence of warning signs is an admission criterion in the new WHO
2009 guideline.
P859 Echinococcus multilocularis in the Netherlands: what about
humans?
L.M. Kortbeek*, M. Harms, W. van Pelt, J. van der Giessen, E. Pinelli
Ortiz (Bilthoven, NL)
Introduction: In 2008 the ﬁrst autochthonous case of alveolar
echinococcosis was diagnosed using Em speciﬁc PCR and serology.
The patient lived in an area in the South of the Netherlands where the
prevalence of infection in foxes was determined to be more than 12%
and where the wormload is increasing. The incidence of Echinococcus
multilocularis (Em) in foxes in neighbouring countries is increasing. Em
is not a reportable disease in the Netherlands and it is not known if the
diagnosis in patients is missed.
Objective: To determine the seroprevalence of Echinococcus multilocu-
laris antibodies in areas at risk in the Netherlands.
Methods: 1581 human serum samples of 6 municipalities in areas
at risk and 5 control municipalities were tested. Antibodies against
Echinococcus spp.were detected using a commercial available Em2plus
ELISA (Bordier) and an in house E. granulosus IgG ELISA. All positive
samples were tested in an in house Immunoblot E. granulosus IgG1 to
conﬁrm the reactivity.
Results: 169 out of 1581 sera tested positive in the ELISA, 6 were
positive in both ELISAs. The reactivity of the ELISA positive samples
(Eg or Em or both) could not be conﬁrmed by westernblot.
An unexplained high reactivity was seen in children of 1−4 years and
5−9 years: 4.8−23.5% were positive, depending on the cut off level. This
reactivity was strongest in the E. multilocularis serology. 36 of 48 Em
seropositive children are autochtoneous Dutch.
Conclusion: We have found no evidence for speciﬁc antibodies in
this selection of the dutch population. The seroprevalence is still low
(<1:1581). Serology alone, without imaging or clinical examination
is not a good tool to determine if E. multilocularis is a threat for a
population. We advise not to study the population but to investigate
people at risk that live in regions with infected foxes.
P860 Burden of anaemia associated to helminthiases: partial
results from an ongoing Venezuelan survey
J. Flores*, C. Navarro, M. Montero, R. Nino-Incani, J. Cortez,
S. Jime´nez, M. Dı´az, D. Ortega, M. Cachare, L. Go´mez, A. Marı´n,
E. Sanz, M. Ga´mez, Y. Sandoval, E. Villegas, N. Bricen˜o, N. Carrillo,
E. Salazar-Labori, V. Gonza´lez, M. Echeverrı´a-Ortega, J. Mendoza,
C. Albano, G. Hidalgo, A. Rodriguez-Morales (Caracas, VE)
Objective: Helminthiases are known aetiological factors in tropical
anemia; however the extent to which their presence might interact to
further enhance the risk of anaemia is poorly understood. The aim of
this study was to determine the prevalence of helminthiases-associated
anemia in asymptomatic individuals from 11 states in the context of a
national survey of growth and development (2007–2009).
Methods: In the context of a Venezuelan Study on Human Growth
and Development (SENACREDH), a cross-sectional, probabilistic study,
of 4,779 asymptomatic children and adults (<60 y-old) was done.
Sampling was random, adjusted for age, sex and location. Results
represented population weighted estimates (5,295,762 pop.), 2,935,070
male, 2,360,692 female. Study area was 71 municipalities in 11 states of
North Central Coastal, South and Andean Venezuelan regions. Intestinal
parasites were diagnosed in stool samples after being preserved in MIF
media. Anemia was classiﬁed according WHO criteria after measure
haemoglobin in blood samples.
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Results: Hookworms (Necator americanus/Ancylostoma duodenale)
and whipworm (Trichuris trichiura) were signiﬁcantly associated
with anemia. Whipworm prevalence was 1.35% (71,540) (95%CI
1.34–1.36%). Hookworms was 0.57% (30,153) (95%CI 0.56–0.58%).
Anemia prevalence was 12.92% (684,054) (95%CI 12.88–12.95%),
being signiﬁcantly higher in those with hookworm infection (26.9%,
95%CI 26.86–26.93%) (p< 0.001) (OR=2.5, 95%CI 2.4−2.6). Similarly
was found for whipworm (16.4%, 95%CI 16.36–16.43%) (p< 0.001)
(OR=1.3, 95%CI 1.2−1.4).
Conclusions: Anemia is one of the most widespread and common health
conditions afﬂicting individuals living in the tropics. The consequences
of anemia are particularly severe for children and pregnant women. For
these reasons multiple level preventive interventions at national scope
should consider intestinal parasite surveys as this study shown.
P861 The comparison of microscopy, antigen detection and
real-time polymerase chain reaction tests for the diagnosis
of Pneumocystis jirovecii pneumonia: evaluation of clinical
parameters
S. Ozensoy Toz*, C. Gu¨ndu¨z, A. Tetik, H. Pullukc¸u, M. Tasbakan,
F. Bacakoglu, M. Sezai Tasbakan, F. Gulen, A. Unver Yolasigmaz,
N. Turgay (Izmir, TR)
Pneumocystis jirovecii pneumonia (PCP) causes serious infections,
especially in patients with immunosuppressive diseases. We aimed to
evaluate the results of bronchoalveolar lavage (BAL) samples of PCP
suspected patients with three different methods. The BAL samples sent to
the our Parasitology Laboratory were investigated with microscopically
examination using Gram Weigert and Giemsa stains, direct ﬂuorescent
antigen detection test (DFA, Pneumo Cel Indirect®) and Real Time
Polymerase Chain Reaction (PCR) tests. We designed speciﬁc primers
and probes according to partial sequence of PCP mitochondrial large
subunit ribosomal RNA gene and DNA samples were analysed by
Real Time PCR & melting curve analyses methods, respectively.
Demographic, clinical and laboratory data were recorded. The BAL
samples were studied in 42 patients (24 male, age: 31.29±26.43). There
were totally 17 positives either one of the tests. Sixteen, 3 and 2 samples
were detected positive by PCR, microscopically and DFA, respectively.
Tests were positive in one case by all three methods, whereas only DFA
test was positive in one case and only PCR test was positive in 13
cases. Clinical data is shown in the table. HRCT analyses were showed
ﬁne noduler pattern in 1, pulmonary inﬁltration in 12 and ground-glass
appearance in 6 cases. In comparison of positive and negative groups,
HRCT results were found to have a supportive affect on the clinical
evaluation of PCP patients. Co-trimoxazole was prescribed in 11 PCP
cases diagnosed by laboratory test and 6 of them died. Besides this,
PCR positive 6 cases were not treated with no clinical signs compatible
with PCP and they diagnosed as foreign body aspiration (n = 3), fungal
pneumonia (n = 1), alveolar carcinoma (n = 1) and H1N1 pneumonia
(n = 1).
Multidisciplinary approach is required for early PCP diagnosis. The
amount and intensity of samples affects the success of laboratory tests.
It’s important for deﬁnitive diagnosis of PCP to see parasites directly
as well as detection of speciﬁc antigen and DNA. It’s shown that DNA
ampliﬁed by PCR increases the sensitivity of diagnosis in our study.
However, high PCP carrier rate in the society should take in consideration
and clinical ﬁndings must be evaluated carefully for treatments in cases
have PCR-positive samples. In our study we concluded that at least one
diagnostic method besides PCR should be applied in PCP pneumonia
suspected cases and disease symptoms should be evaluated carefully for
treatment.
P862 Rich monotherpenic hydrocarbon plant extracts as potential
anti-protozoa agents: effects of Juniperus oxycedrus (berries
and leaves extracts), a-pinene and b-myrcene on Giardia
lamblia, Leishmania infantum, L. tropica and L. major
M. Machado*, C. Cavaleiro, G. Santori, A. Dinis, L. Salgueiro,
M.C. Sousa (Coimbra, PT; Rio de Janeiro, BR)
Giardiasis and leishmaniasis are re-emergent protozoa infections, often
considered as neglected diseases. Its treatment is limited and considering
toxicity, side effects, rate of relapse, cost, length and resistance to
available drugs, more attention should be given to the search of new
chemotherapeutic options.
The present work focused on the activity of Juniperus oxycedrus essential
oil, berries and leaves, a-pinene and b-myrcene on Giardia lamblia
trophozoites and L. infantum, L. tropica and L. major promastigotes.
Essential oils composition were analysed by GC and GC-MS. The
anti-Giardia activity was evaluated on basis of parasite growth assay.
Antileishmanial activity was performed on promastigotes of L. infantum,
L. tropica and L. major by tetrazolium-dye colorimetric method. Effects
on L. infantum promastigotes were analyzed by ﬂow cytometry in
order to assess mitochondrial transmembrane electrochemical gradient
(JC-1), to analyze phosphatidylserine externalization (annexin V-FITC,
propidium iodide) and to evaluate cell cycle (DNase-free RNase, PI).
Morphological and ultrastructural alterations were evaluated by light,
scanning and transmission electron microscopy.
Juniperus oxycedrus oil (leaves and berries) did not exhibit anti-Giardia
activity. Otherwise, tested essential oils and compounds revealed activity
against Leishmania promastigotes: IC50 values ranging from 21 to 51
microg/ml on the presence of J. oxycedrus berries oil, 127 microg/ml
on leave extract and around 160 microg/ml on a-pinene and b-myrcene.
Modiﬁcations on normal cell shape, mitochondrial swelling, increase
number of autophagosomal and myelin structures and cytoplasmatic
vacuolizations, electrondensity lost and membrane disruption were
ultrastructural alterations induced by J. oxycedrus berries oil. The
leishmanicidal activity was associated with mitochondrial membrane
depolarization and cell-cycle arrest at the G(0)/G(1) phase. No toxicity
was seen on mammalian cells. Taken together, these data indicate that
J. oxycedrus berries oil has promising anti-leishmanial activity and might
be a source for new leading drugs. The major compounds, a-pinene
and b-myrcene, do not seems to be responsible for the essential oil
activity so, minor compounds should be investigated. The results provide
new perspectives on the development of drugs with activities against
Leishmania.
This work was supported FCT POCTI (FEDER).
P863 Preparedness for malaria prevention in relief camps for
ﬂood affectees − a cross-sectional survey from Pakistan
B. Ahmed*, K. Nanji (Karachi, PK)
Objectives: The monsoon ﬂoods in Pakistan have caused massive
destructions and affected about 3.2 million people, including 1.4
million children and 133,000 pregnant women (UNICEF 2010). And
approximately 1.3 million people were internally displaced. Flood waters
had spread beyond the rivers and irrigation channels into poorly-drained,
low-lying areas, creating stagnant pools that form a breeding ground for
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mosquitoes. This poses a serious threat to the ﬂood affected people.
Reports to assess the vigilance of malaria prevention of the relief camps
are not available. We therefore, conducted a survey in the relief camps
serving the ﬂood affected internally displaced persons (IDP’s) to evaluate
the malaria prevention preparedness.
Methods: A cross sectional study was conducted in the camps identiﬁed
from the government registered lists during October to November 2010.
Face to face interviews were conducted with 500 eligible individuals (of
each family), recruited through multi-stage cluster sampling, by a team of
trained health care professional. The study comprised of two phases. In
the 1st phase the camps were visited and a complete checklist containing
the information regarding the availability of bed nets, insecticidal sprays,
mosquito repellents, coils were collected. Besides this, camps and
its surrounding were also observed for water and sanitary conditions
(uncovered latrines, stagnant water). In the 2nd phase of the study,
the administrations of these camps were also interviewed regarding the
measure taken for malaria prevention.
Results: Five hundred (13.5%) families out of 3700 IDPs were
interviewed. Average number of children 5 years of age per family was
4. Pregnant women were 110. None of the family reported to receive any
preventive intervention. Only 20 families use bed nets, bought by their
own. Sanitary conditions were poor with open drainage system, majorly
of the camps areas were surrounded by stagnant water. Accessibility to
clean water was difﬁcult. 96% individuals reported not practicing any
preventive measure for malaria. Inadequate Chloroquine was available
in the medical camps, arthremeter was not available. The doctors at the
medical camps reported, visiting of 8−10 patients daily with malaria
symptoms.
Conclusion: Malaria is a major epidemic and public health concern
particularly during ﬂood catastrophe. Transparent legislative and policy
making is required to design strategies for the preparedness of malaria
in Pakistan.
P864 Cryptosporidiosis in Iranian immunocompromised patients:
prevalence, molecular characteristics and risk factors
N. Jonaidi Jafari*, M. Izadi, M.R. Rezaiemanesh, M. Fazel,
M. Mohammad Jonaidi, R. Ranjbar (Tehran, IR)
Objective: Cryptosporidium spp. is a major cause of diarrhea in
developing countries mainly affecting people with compromised immune
system especially HIV-infected individuals with low CD4+ T-cell
counts. The infection is self-limiting in immunocompetent hosts, but
can be severe and persistent in the immunocompromised. There are
limited studies about cryptosporidiosis and Cryptosporidium genotypes
in Iranian immunocompromised patients. Also no information on risk
factors for disease exists. We undertook this study to identify prevalence,
genotypes and risk factors for cryptosporidiosis in immunocompromised
patients.
Methods: 183 patients was sampled three times and processed with
modiﬁed Ziehl-Neelsen staining methods and 18S ribosomal RNA gene
ampliﬁcation and sequencing.
Results: The overall infection prevalence was 6%. C. parvum was
identiﬁed in isolates from ﬁve HIV-infected patients, one patient with
Bone Marrow Transplantation and one with CLL, forand C. hominis
was identiﬁed in isolates from two HIV-infected patients and two
ALL patients. In the univariate analysis factors statistically signiﬁcant
were diarrhea (OR=21.7, CI=2.83–78.4, P< 0.003), CD4+ cells less
than 100 cells/mm3 (OR=41.3, CI=13.45–114.82.83–78.4, P< 0.0001),
other microbial infections (OR=7.1321.7, CI=1.97–25.732, P = 0.006),
Weight loss (OR=73.7821.7, CI=15.5–35083–78.4, P< 0.0001), Ab-
dominal pain (OR=10.29, CI=2.81–37.74.4, P = 0.001), Dehydration
(OR=72.1, CI=17.6–341.5.4, P< 0.0001), Vomiting (OR=4.87, CI=1.4–
16.9.4, P = 0.015), Nausea (OR=9.4, CI=2.38–37.2.4, P< 0.001), Highly
Active Antiretroviral Therapy (HAART) (OR=0.089, CI=0.01−0.8,
P = 0.015) and Diarrhea of household members (OR=7.37, CI=2.04–
26.66, P = 0.001). After multivariate analysis and a back ward deletion
process, only CD4+ cells less than 100 cells/mm3 maintained a
signiﬁcant association with infection.
Conclusion: We surmise that the presence of this infection should be
suspected in patients with diarrhea, weight loss, and dehydration and
especially diarrheal individual with CD4+ T-lymphocytes counts less
than 100 cell/mm3.
P865 Tropical infections in Coventry, UK
K. Lipas*, A. Illychysn, R. Gowda (Coventry, UK)
Objectives: We present 3 fascinating tropical cases masquerading as
other diagnoses. The diagnostic conundrum lead to delays in diagnosis.
We also treat 2 of the patients with unconventional therapy.
Methods and Results: Case 1: A 56 year old man returned from his
holiday in Majorca with multiple ’insect bites’ over his body. He failed to
improve with steroids, however a skin biopsy several months later showed
granulomas. Although special stains for mycobacteria were negative, a
Leishmania donovani PCR was eventually positive. As he was a pilot
instructor, conventional therapy with systemic Sodium Stibogluconate
was contraindicated. We thus administered miltefosine and the lesions
are now resolving.
Case 2: A 43 year old man from Nigeria presented to the acute medical
team with fever and painful legs. He had an elevated white cell count
and C-reactive protein. IV antibiotics were commenced for ’cellulitis’.
A more extensive cutaneous assessment revealed hyperpigmented skin
lesions on both legs, thickened auricular, ulnar and peroneal nerves,
and nodular lesions on the face. A slit-skin smear of the earlobe showed
numerous acid-fast bacilli and conﬁrmed our suspicions of multibacillary
leprosy. It became apparent that he had been previously treated and in
fact the skin lesions on his legs were consistent with Erythema nodosum
leprosum He is now being treated with dapsone and clofazimine.
Case 3: An 85 year old Englishman presented with a 3 week history
of fever and pancytopaenia. He had travelled to Portugal for an 8 day
holiday, 4 months prior to his presentation. A peripheral ﬁlm and a bone
marrow showed possible myelodysplasia and haemophagocytosis. He
therefore was commenced on systemic steroids with partial resolution of
his symptoms. 6 weeks after the initial presentation, a delayed leishmania
serology eventually came back positive. A retrospective analysis of the
bone marrow showed deﬁnite leishmania-donovani bodies and the PCR
was positive for Leishmania donovani. In view of his age and impaired
renal function, he was given a single dose of Ambisome 5mg/kg and a
test of cure bone marrow biopsy will be performed at 6 months.
Conclusions:
These cases show that:
1. A thorough history is paramount in considering tropical infections in
the differential
2. Migration and increasing world travel means rare conditions may
present in Northern Europe
3. A high index of suspicion is required
The outcome of the unusual treatment in Case 1 and 3 will be presented.
P866 Neurocysticercosis in Italy
M.T. Giordani*, R. Binazzi, F. Tamarozzi, E. Brunetti (Vicenza,
Bolzano, Pavia, IT)
Objectives and Methods: To report two cases of imported
neurocysticercosis (NCC) recently hospitalised in our department and
to stress the importance of NCC outside endemic areas.
Results: The two patients were male African immigrants, strict Muslims,
living in Italy for several years. Both patients were admitted with fever
and pleural and pericardial effusions and reported previous episodes
of seizure. One patient was HIV2 positive and on HAART, but
had treatment failure and severe immunosuppression (CD4 24/mcl).
Laboratory analysis revealed increased IgE titers and mild eosinophilia in
both cases. A tubercular etiology of the pleuro-pericardial effusion was
ruled out (direct acid-fast bacilli examination, polymerase-chain reaction
and culture of ﬂuid resulted negatives). MRI of the brain revealed the
presence of hypointense cystic lesions in the frontal lobes. In the HIV-
negative patient, NCC was diagnosed by histological examination of a
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bioptic sample. In the HIV-positive patient, brain biopsy was avoided
because of a very low platelets count (5000 plt/mmc). The diagnosis of
NCC was made instead on the basis of MRI results, failure of anti-
toxoplasma, anti-TB and antifungal therapy, and regression of the cystic
lesion upon empiric therapy with albendazole. In both patients, ova and
parasites stools examination, colonoscopy and speciﬁc serological tests
for cestode infection were negative.
Conclusion: NCC should be taken into account as a possible diagnosis
in all patients born and raised in endemic areas showing seizures and
compatible lesions in brain imaging. The lack of dietary intake of
pork meat should not be considered a valid epidemiological criterion
to exclude taenia solium infection, inter-human transmission having
been proven in African countries. A negative serology does not exclude
the diagnosis of NCC, and when a direct diagnosis is not obtainable,
the response to empiric treatment should be taken into consideration
(Dal Brutto et al. Neurology 2001). The possible correlation of pleural
effusions with the parasitic infection reported in the literature as response
to the reactivation of the infection, requires further study.
P867 Loa Loa African eye worm: two cases in a non-endemic
country, Italy
G. Giuliani*, L. Chenal, M. De Filippis, A. Tosoni, M. Corbellino,
L. Galimberti, S. Antinori, M.R. Gismondo (Milan, IT)
Objectives: Loa Loa is a subcutaneous nematode that causes loiasis.
Microﬁlariae, although not demonstrable in all patients, are characteristic
for each of the ﬁlariae and may be used in the identiﬁcation of the worm.
We describe two cases of ocular loiasis with the aim to discuss the aspects
of the diagnosis.
Methods and Results: First case: a 27-years-old woman, who had
migrated to Italy from Cameroon since 2002, presented complaining with
the sensation of something crawling over her left eye. On examination
a worm-like body was seen moving in the inferior fornix. Physical
examination demonstrated as an healthy pregnant woman at 16 weeks of
gestational age. Blood, urine and stool investigations were unremarkable
except for a mild eosinophilia (9%). Fresh peripheral blood examination
revealed the presence of highly motile microﬁlariae. Examination of
a Giemsa-stained peripheral blood smear revealed the presence of
a moderate number of sheathed microﬁlariae. During the pregnancy
woman was not treated. She gave birth an healthy baby girl. The
microscopic examination of both umbilical cord’s blood and neonate’s
peripheral blood demonstrated no circulating microﬁlariae. Second case:
a 25-years-old female from Cameroon. She has been living in Italy
since 2003. She presented complaining of a foreign body sensation
in her left eye. On ophthalmological examination a motile worm
was visualized subconjunctivally. Repeated samples of blood for fresh
peripheral blood examinations, Giemsa-stained peripheral blood smears
and Knott concentration technique were demonstrated negative for the
presence of microﬁlariae.
Conclusion: One of the main characteristics of human infection with
Loa is that a certain proportion of subjects remain amicroﬁlaremic. The
diagnosis of second case was made in an amicroﬁlaremic woman who
had a history of either living in an endemic area and eye worm migration.
In microﬁlaremic patients such as ﬁrst case, the diagnosis of loiasis may
be made by microscopic examination of Giemsa or hamatoxylin stains
of peripheral blood. The microﬁlariae may stain poorly and not to be
identiﬁed correctly, since Giemsa stain does not stain the microﬁlarial
sheath adequately. The appearance of “halos” around the microﬁlariae
does not always indicate the presence of a sheath because this effect
might be due to shrinkage. The Knott concentration technique and
ﬁltration of blood are also useful techniques to make this diagnosis.
P868 Argas persicus Ethiopian soft ticks as disease vectors
S. Cutler*, H. Adamu, A. Abdissa, T. Tolosa, A. Gashaw (London,
UK; Jimma, ET)
Objectives: We investigated the role of the poultry soft tick Argas
persicus for their ability to serve as vectors of disease in an Ethiopian
village.
Methods: Ticks were collected around poultry areas, but also under the
bark of many trees. These ticks were found feeding on various livestock
and importantly on humans dwelling in this village. Ticks were recovered
from cracks and crevices within traditional human dwellings were the
occupants reported regular bites during the night. Ticks were pooled
by similar collection sites in groups of 10−20 ticks per pool. These
were stored in guanidine hydrochloride prior to transport under licence.
Following DNA extraction with DNeasy (Qiagen) using a standard rodent
tail and tissue protocol, puriﬁed DNA was assessed by real-time PCR.
Pools were screened using a pan-rickettsial citrate synthase assay; the
IS1111 insertion sequence for Coxiella burnetii; and primers speciﬁc for
relapsing fever spirochaetes. They were also screened using conventional
PCR primers speciﬁc for spirochaetes.
Results: Preliminary screening of these ticks for pathogens revealed that
among 40 DNA extracted pools, 28 (70%) were positive for Rickettsia
using a real-time PCR for the citrate synthase gene. Furthermore, one of
these pools positive for Rickettsia, was additionally positive for Borrelia
with relapsing fever speciﬁc primers (2.5%). None of these pooled DNA
extracts were found to harbour Coxiella burnetii using IS1111 as a gene
target. A total of 16 pooled DNA extracts from hard ticks (predominantly
Ambloyomma variegatum) collected from this village and elsewhere in
Ethiopia, were also found positive with the above primers, with 4 (25%)
yielding evidence of Rickettsia and 2 (12.5%) with Borrelia (one dual
infection).
Conclusion: The lessons learned from this study are that A. persicus
ticks are not conﬁned to being a poultry pathogen, however, whether
alternative hosts will sustain their numbers in the absence of poultry
was not assessed. The regular exposure of the human population
to Rickettsial antigens is likely to complicate use of conventional
serological diagnostics in this population. These ticks are known vectors
of B. anserina, but these primers should not amplify this spirochaete.
The possibility of these ticks harbouring a novel spirochaete will be
discussed.
P869 Molecular investigation of Cryptosporidium spp. using the
TRAP-C2 gene
A. Keshavarz, N. Taghipour, E. Nazemalhosseini-Mojarad*,
M. Rostami-Nejad, A. Haghighi, M. Zali (Tehran, IR)
Objectives: At present 18 Cryptosporidium species are identiﬁed as valid
but Cryptosporidium parvum and C. hominis are the common species
in human. The aim of this study was to establish the genotypes of
Cryptosporidium spp. among children with diarrhea using the TRAP-
C2 gene.
Methods: Fecal samples were collected from 1263 children less than 12
years with diarrhea. After determine the presence of Cryptosporidium
oocysts by Ziehl-Neelsen acid fast staining, genomic DNA was extracted
of positive samples and nested PCR-RFLP was performed to amplify the
TRAP-C2 gene.
Results: Out of 1263 samples, Cryptosporidium oocysts were found in
31 (2.5%) sample. RFLP analysis showed C. parvum in 25 (80.6%)
isolates, C. hominis in 5 (16.1%) and mix infection pattern of both
C. parvum and C. hominis in 1 (3.2%).
Conclusion: In conclusion the use of TRAP-C2 primers could be
sensitive enough to conduct a routine detection study. The nested
PCR method using the TRAP-C2 gene sequence can be an alternative
diagnostic method to identify human infected with Cryptosporidium and
its genetic diversity.
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P870 Epidemiology of intestinal parasitosis in eleven states of
Venezuela: partial results of an ongoing national survey
E. Salazar-Labori*, C. Navarro, M. Montero, R. Nino-Incani, J. Cortez,
S. Jime´nez, M. Dı´az, D. Ortega, M. Cachare, L. Go´mez, A. Marı´n,
E. Sanz, M. Ga´mez, Y. Sandoval, E. Villegas, N. Bricen˜o, N. Carrillo,
J. Flores, V. Gonza´lez, M. Echeverrı´a-Ortega, C. Albano, G. Hidalgo,
A. Rodriguez-Morales (Caracas, VE)
Objective: Last national survey of prevalence of intestinal parasites in
Venezuela was held 2 decades ago (1989−92). The aim of this study
was to determine the prevalence of intestinal parasite species isolated
from faeces samples in asymptomatic individuals from 11 states in the
context of a national survey of growth and development (2007–2009).
Methods: In the context of a Venezuelan Study on Human Growth and
Development (SENACREDH), a cross-sectional, probabilistic study, of
6,437 asymptomatic children and adults (<60 y-old) was done. Sampling
was random, adjusted for age, sex and location. Results represented
population weighted estimates (7,120,744 pop.). Study area was 71
municipalities in 11 states of North Central Coastal, South and Andean
Venezuelan regions. Intestinal parasites were diagnosed in stool samples
after being preserved in MIF media.
Results: We found prevalences, for pathogen parasite infections, ranging
0.257–7.426% (see Table). However opportunistic parasite Blastocystis
hominis was found in 45.632%. Highest protozoan infection prevalence
was found for Giardia intestinalis, 7.246% (being higher in those <6 y-
old, 12.9%). Highest helminthic infection prevalence was found for
Ascaris lumbricoides, 3.974% (being higher in those <6 y-old, 6.7%).
Conclusions: Intestinal parasitoses continue to be one of the most
common infections worldwidely spread, especially in tropical countries.
In 1992 national prevalence was 20% whilst in this study, for 11 states
(of 24) it was less than 10% for pathogenic infections. During last years
a signiﬁcant reduction would be linked to improvement in housing, tap-
water access and in general, to the country development.
P871 Splenic abscess due to Salmonella enteritidis
H. C¸abadak*, A. Erbay, K. Karaman, S. Sen, Y. Tezer Tekc¸e (Ankara,
Yozgat, TR)
Objectives: Splenic abscess is a very rare complication of nontyphoid
fever since the advent of antibiotics. Risk of invasive salmonellosis is
increased in persons with comorbidities.
Case: A 63-year-old woman from east part of Turkey was admitted
with the complaint of back pain, vomiting and nausea since 20 days.
She had not any other complaint. Physical examination was normal.
She had diabetes mellitus and hypertension. In Laboratory examination
White blood cell (WBC) count was 14,670/mm3 (Neutrophils 88.9%)
and C-reactive protein (CRP) level was 58mg/L (normal value <5mg/L).
Erythrocyte sedimentation rate was 76mm/h. An abdominal ultrasound
revealed a hypoechogenic cystic structure of 61×72mm in the upper
part of the spleen with calciﬁcations, conﬁrmed on abdominal CT
scan compatible with abscess. The patient underwent an exploratory
laparotomy and splenectomy was performed. Salmonella enteritidis
was yielded from the culture of the abscess obtained during the
operation. After the isolation of Salmonella enteritidis, the patient
questioned in detail, it was learned that the patient had diarhoea and
fever existed 2 days and recovered without antibiotic treatment one
month ago. Ciproﬂoxacin was administered 500mg bid po for 10 days
postoperatively. The patient recovered well after surgery. There were no
recurrent symptoms during the follow up.
Conclusion: Salmonella gastroenteritis is usually a self limiting disease.
Although bacteraemia develops in less than 5% of all patients with
Salmonella enteritidis, patients with comorbities are at increased risk of
invasive infection. The treatment of splenic abscess includes antibiotic
treatment and surgery. Splenectomy is still the most accepted standard
surgical treatment of a splenic abscess.
P872 A case of Alkhurma haemorrhagic fever virus infection in
an Italian traveller returning from Egypt
F. Carletti*, C. Castilletti, A. Di Caro, M. Rosaria, C. Nisii, F. Suter,
M. Rizzi, A. Tebaldi, A. Goglio, C. Passerini Tosi, G. Ippolito (Rome, IT)
Objectives: The Alkhurma haemorrhagic fever virus (AHFV) is a
recently described member of the tick-borne haemorrhagic fever group
of the genus Flavivirus. To date, AHFV has been detected only in
Saudi Arabia, it is an emerging pathogen causing symptoms such as
fever, headache, thrombocytopaenia; severe cases may present with
haemorrhagic fever manifestations and encephalitis which can result in
death (case fatality rate as high as 25%).
Methods: A traveller, who spent one week in a touristic village in
southern Egypt, while visiting a camel and dromedary market, was bitten
by an unidentiﬁed arthropod. Two days after, the patient developed high
fever, shaking chills, anorexia, malaise, nausea and vomiting, and blurred
vision. Over the following 5 days his symptoms worsened and he was
admitted to the department of infectious diseases in the Ospedali Riuniti
di Bergamo.
Results: Laboratory test results showed leucopaenia, thrombocytopaenia
and increased liver enzymes. The patient was started on paracetamol, and
fever and general malaise progressively decreased over the following 5
days. He was discharged 11 days after hospitalization in good general
condition despite persistence of asthenia. Acute and convalescent sera
sent to the virology laboratory of the ’L. Spallanzani’ in Rome to be
tested for Dengue and West Nile virus infection. IgG and IgM for both
viruses were detected by immunoﬂuorescence, with a titre of 1:640
and 1:20 respectively, in both serum samples. There was no evidence
of rising antibody titers in the convalescent serum sample, arising the
suspicion of a cross-reactivity due to a previous Flavivirus infection or
to the Yellow Fever vaccination. A genus-speciﬁc RT-PCR targeted to
the NS5 gene of Flaviviruses was positive in the acute serum and the
sequence analysis of the amplicon showed high similarity with AHFV
sequences posted in GenBank This unexpected result called for further
investigations to conﬁrm the diagnosis of an AHFV infection. To this
aim, an AHFV-speciﬁc nested RT-PCR targeted to a wider region of a
different gene (E) was performed.
Conclusions: The ﬁnding that the distribution of the causing agent
is wider than previously thought should prompt further investigations
to better assess the real danger for local populations and international
travellers. Veterinary and entomological investigations are also necessary
to further understand the geographic distribution of AHFV.
P873 Two cases of visceral leishmaniasis treated with a single-dose
of liposomal amphotericin B
F. Brillo*, G. Cattani, B. Del Pin, F. Bragantini, M. Merelli, G. Villa,
A. Pagotto, D. Pecori, M. Gramiccia, A. Beltrame (Udine, Rome, IT)
Objectives: Liposomal Amphotericin B (LAmB) is the ﬁrst line
therapy for Visceral Leishmaniasis (VL). The standard treatment in
immunocompetent patients are: 3mg/kg/day at days 1−5 and 10 in
Mediterranean area; 2mg/kg/day for 5 days in India. Recent trials
indicate that high dose and shorter duration regimes of LAmB
therapy show comparable results to conventional treatment and are not
associated to higher rates of renal toxicity. We report two VL cases in
immunocompetent patients treated with single-dose of LAmB.
Case 1: A 35-year-old Angolan man presented with remitting fever
(39−40ºC) and acute renal failure. The histological examination of
the renal biopsy revealed a collapsing variant of focal segmental
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glomerulosclerosis (FSGS). Microscopic examination of thin blood
smears demonstrated the presence of Leishmania amastigotes.
Case 2: A 20-years-old Afghan man presented with weight loss (20
Kg in 3 months), pancitopenie, hepato-splenomegaly and apyrexia.
Microscopic examination of bone marrow aspirate demonstrated the
presence of Leishmania amastigotes.
Methods: Diagnosis was based on microscopic examination, microbial
culture and PCR of samples (blood, bone marrow and renal biopsy)
and serology (IFAT) performed by a National reference centre (Istituto
Superiore di Sanita`, Rome, Italy); abdomen sonography (spleen size) was
performed. Patients were treated with a single dose of LAmB 10mg/Kg.
Clinical examination and blood analysis were performed at the baseline
and 10, 20, 30, 60, 90, 180 days after therapy. At day 180 microbiological
examination of bone marrow aspirate, serology and ultrasound were
repeated. Deﬁnitive cure, assessed 180 days later, required being healthy
with no signs or symptoms of relapse.
Results: All sampled tissue resulted positive for Leishmania infantum
to culture and PCR. Both patients presented fever responsive to
paracetamole within 24 hours of LAmB infusion, without any evidence
of haematological and renal toxicity. The ﬁrst case showed progressive
improvement of the kidney function. Both patients after 180-days
evaluation have shown a deﬁnitive cure response (Table 1).
Conclusion: A single high dose of LAmB is an effective therapy for VL;
it is associated with high compliance and safety, without any evidence of
renal toxicity also in patients with moderate renal impairment. Moreover,
a single dose of LAmB is less expensive than conventional therapy with
multiple dose (2058 Euro vs 3740 Euro).
P874 Fatal melioidosis diagnosed by mass spectrometry in a
tourist returning from Martinique Island
L. Getaz, M. Abbas, L. Loutan, A. Iten, F. Simon, A. Decosterd,
R. Studer, P. Sudre, Y. Michel, P. Merlani, S. Emonet* (Geneva, CH)
Case report: A 35-year-old healthy man visited Martinique from 2010,
November 13th to 23rd. To practise surﬁng, he crossed recently ﬂooded
areas, while having multiple scratched mosquito bites on his legs. He
presented to our hospital on the 25th with fever, chills, headache,
abdominal cramps, mild diarrhea and lower back pain evolving for 48
hours. Suspecting typhoid fever, he received ceftriaxone, which was
changed after 24h to high dose imipenem-cilastatine. Indeed, blood
cultures were positive. Two hours after subculturing, Mass spectrometry
(MS) was performed on a very thin layer of material growing on
the blood agar, allowing the identiﬁcation of Burkholderia sp and
ledding to the presumption of melioidosis. MS was performed later
the same day on a well-grown colony and allowed the identiﬁcation
of B. thailandensis (score >2, MS cannot distinguish B. thailandensis
from B. mallei or pseudomallei. While breathing normally at admission,
the patient developed severe bilateral abscess-forming pneumonia, and
died on the 27th from septic shock with multi-organ failure and ARDS
(acute respiratory distress syndrome), despite the addition of granulocyte
colony-stimulating factor (G-CSF), low-dose steroids and intensive care
support including extracorporeal membrane ventilation. Sequencing of
the16S-rDNA conﬁrmed the presence of B. pseudomallei in all blood
cultures. Epidemiological data obtained from the patient was transmitted
on November 26th to the local clinicians and international medical
information networks, along with the diagnosis of melioidosis. Following
our immediate reporting to local hospitals, two additional cases were
suspected with immediate adaptation of antibiotic therapy.
Discussion: Melioidosis is endemic in South-East Asia and Northern
Australia, but cases are increasingly recognised in other parts of
the world. Burkholderia pseudomallei is a non-fermenting saprophyte
living in soil and surface water, usually transmitted percutaneously
with an incubation period of 1−21 days. Clinical presentation can
range from fulminant sepsis to chronic disease. The most common
manifestations are pneumonia, sepsis along with abscess of the prostatic
gland and others organs. Prognosis is poor in cases with severe
sepsis (30−50% mortality). Known predisposing medical conditions,
are diabetes, cirrhosis, alcoholism or renal failure. Mass spectrometry
provides rapid identiﬁcation, with the potential to improve prognosis of
fulminant melioidosis.
P875 Cutaneous and visceral tropisms of Leishmania tropica
strains isolated in Turkey in murine model
A. O¨zbilgin*, G. Culha, F. Yildiz Zeyrek, S. O¨zensoy To¨z, C. Gu¨ndu¨z,
O¨. Kurt, F. Pratlong, Y. O¨zbel (Manisa, Hatay, Sanliurfa, Izmir, TR;
Montpellier, FR)
Objectives: Visceral leishmaniasis (VL) caused by Leishmania (L)
infantum, and cutaneous leishmaniasis (CL) by L. tropica and
L. infantum have been recorded in Turkey. The possibility of genetic
exchanges between Leishmania species that may lead to the formation
of hybrid strains has recently been suggested. The aim of this study was
to examine tissue tropisms and clinical manifestations of Leishmania
isolates obtained from 5 CL and 1 VL patients from different endemic
areas of Turkey on a murine model. All were identiﬁed as L. tropica by
isoenzyme analysis.
Methods: After the preparation of suspensions (1×108 promastig-
otes/ml), 15 and 10 microl of each suspension were injected into the left
footpads of Balb/C mice subcutaneously (SC Group, 6 groups, 36 mice)
and into another mice group (IV Group, 6 groups, 36 mice) intravenously.
Footpads of SC Group were followed for 6 months and checked for the
presence of amastigotes in every 15 days. IV Group was sacriﬁced after
30 days, livers and spleens were removed. All samples were stained with
Giemsa and inoculated to NNN medium.
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Results: After 30 days, lesions with erythema and swelling were seen
on footpads of all mice in SC Group; microscopy and cultures were
positive after 45 days. No lesion occured on mice of VL isolate in
SC Group. All mice of VL isolate in IV Group showed visceralization
with symptoms, and 4 of 5 CL isolates showed visceralization in IV
Group. Real-time PCR on ITS-1 gene region was conducted, followed
by melting curve analyses for genotype identiﬁcation. All 6 isolates
showed peaks speciﬁc to L. tropica, similar to isoenzyme analysis, while
lesion aspiration smear samples obtained from the same patients showed
two peaks speciﬁc to both species, L. tropica and L. infantum, or one
peak speciﬁc to L. infantum.
Conclusion: In this study, murine models were established using local
Leishmania strains. Four isolates that presented dermo/viscerotropism
in murine model were evaluated as hybrid Leishmania strains. This is
the ﬁrst study that reports clinical manifestations and different tropisms
of Leishmania isolates in murine model using local strains. We further
plan; (a) advanced molecular analyses on different gene regions and
proteomics analyses, (b) detailed assessments of clinical manifestations
in animal models, (c) advanced examinations of clinical conditions of
patients.
[This study is partially supported by The Scientiﬁc and Technological
Research Council of Turkey (Project No: 107S154)].
P876 Not just Lake Malawi. Katayama fever at the Hospital of
Tropical Diseases, London, UK, over the last 12 years
S.A. Logan*, G. Nebbia, M. Armstrong, C. Whitty, T. Doherty (London,
UK)
Objectives: Our objective was to describe epidemiological and clinical
features of Katayama Fever in the era of improved serological testing
for Schistosomiasis.
Methods: We performed a retrospective review of cases of Katayama
Fever that have been seen over the last 12 years at the Hospital
for Tropical Diseases, London, UK. We identiﬁed patients from a
speciﬁcally designed database of all cases of Schistosomiasis as well
as searching through the hospital inpatient and outpatient databases and
our own personal records.
Results: We have complete data on 57 patients from 1998 to 2008.
We will have further data on at least a further 8 patients prior to
May 2011. 73% (42) are male and the median age at presentation
was 27 years (range 19−60 years). Only 38% had been to Malawi
though all reported freshwater exposure. With the exception of one
all had been to Africa. Swimming on holiday was the main reason
for exposure in 56% of patients. The others were either expatriates or
on business trips. Time from exposure to symptoms was established in
32 patients and the median was 6 weeks. The diagnosis was made on
the clinical presentation. Eosinophilia was present in 79% of patients
though interestingly 12 patients presented with a normal count which
subsequently increased. Schistosomal serology was positive in 91% of
patients. This was tested in all patients within 12 weeks of their exposure.
The majority were tested at the time they had symptoms of Katayama
fever. Only 10% of patients had detectable ova in their urine or stool.
All were treated appropriately with praziquantel and had a good clinical
outcome.
Conclusions: Exposure to Schistosomiasis occurs thoughout Africa, not
just Lake Malawi. Katayama Fever should be considered in patients
presenting with any of the typical features. A normal eosinophil account
does not preclude the diagnosis. The serology is positive in the majority
of patients at the time of their symptoms.
Maps, tabular presentation of the clinical features with the additional
patient data incorporated and a graphic of the Schistosomiasis life cycle
will form part of the poster presentation.
P877 Laboratory diagnosis of malaria and leishmaniasis:
conventional or molecular methods?
A. Calderaro*, C. Gorrini, S. Montecchini, G. Piccolo, C. Chezzi
(Parma, IT)
Objectives: The application of molecular methods for the laboratory
diagnosis of malaria and leishmaniasis was evaluated in our laboratory
as compared to conventional methods.
Methods: Malaria: Blood samples (1,467) from 928 patients with
clinical suspicion of imported malaria were subjected to thin-ﬁlm
microscopy (acridine orange and Giemsa stain) and to different 18S-
rDNA PCRs alternatively used during the period 2000–2010, including
nested- and real-time PCR assays.
Leishmaniasis: Different samples (27 bone marrow, 13 cutaneous and 1
splenic biopsies) from 36 patients with clinical suspicion of leishmaniasis
were subjected to conventional methods (microscopy and culture) and a
18S-rDNA real-time PCR assay, during 2006–2010.
Results: Malaria: By microscopy 208 cases of malaria were diagnosed
[173 Plasmodium falciparum (Pf) (83.2%), 11 P. ovale (Po) (5.3%), 12
P. vivax (Pv) (5.8%), 9 P. species (4.3%) and 3 mixed infection (1.4%)],
whilst 215 were diagnosed by PCRs [174 Pf (80.9%), 21 Po (9.8%), 8
Pv (3.7%), 3 P. malariae (1.4%) and 9 mixed infections (4.2%)].
Leishmaniasis: A total of 2 cases of leishmaniasis (1 cutaneous and
1 visceral) were diagnosed by both conventional methods and PCR.
Regarding the cutaneous case, 2 biopsies were collected including 1
negative by conventional methods.
Conclusion: Malaria: Despite microscopy remains the reference
diagnostic method (rapid and inexpensive), in some cases molecular
assays are the only ones allowing a correct diagnosis of malaria,
particularly to detect infections by species other than Pf and mixed
infections. PCR proved to be more sensitive and speciﬁc than microscopy
and changed malaria epidemiology in our area detecting 7 single
and 6 mixed infections missed by microscopy, revealing 5 single and
2 mixed infections incorrectly diagnosed by microscopy and giving
speciation in 9 cases in which microscopy had limited the result to
genus identiﬁcation. Then, the association of microscopic and molecular
assays demonstrated to be essential for an accurate diagnosis of malaria
and to administer a targeted therapy.
Leishmaniasis: The application of the real-time PCR did not lead in our
study to a dramatic improvement in the accuracy of the diagnosis of
leishmaniasis, even if the number of the analysed samples was limited.
However, real-time PCR is very rapid and speciﬁc and it could be
successfully associated to the conventional methods in particular in order
to improve the diagnosis of visceral leishmaniasis.
P878 Serological screening for Chagas disease in Latin American
pregnant women in Barcelona South Metropolitan Area
E. Dopico, M. Aguilar*, E. Grenzner, L. Guerrero, B. Allende,
R. Navarro, J. Ros (Barcelona, ES)
Introduction: Chagas disease was almost unknown in our country until
recent migratory ﬂow coming from Latin America. The risk of vertical
transmission by pregnant women represents a new challenge in public
health because the ﬁrst cases of congenital Trypanosoma cruzi infection
in Spain have already been described.
Since 2010 serological diagnosis of Chagas disease in pregnant women
coming from Latin America has been included in the serological
screening in Catalonia (Spain).
Objective: The aim of this study was to evaluate the results after the
implementation in 2010 of the serological screening for Chagas disease
in pregnant women coming from Latin America in the Barcelona South
Metropolitan area.
Methods: The Laboratori Clinic L’Hospitalet of the Catalan Institute of
Health in the Barcelona South Metropolitan area attends around 700.000
inhabitants with a 5.6% of Latin American population. From May to
December 2010, pregnant women from Latin America, who received
prenatal care in the public health system, were tested for the presence of
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T. cruzi antibodies. The screening assay performed was a recombinant
enzyme immunoassay (r-EIA, Bioelisa Chagas Biokit®) using antigens
with four immunodominant epitopes of T. cruzi. Positive serums were
conﬁrmed by a second assay, a native enzyme immunoassay (n-EIA,
Ortho® T. cruzi Elisa Test System) using a lysate of antigens prepared
from T. cruzi. According to the manufacturers sensitivity and speciﬁcity
of both methods were respectively >95% and 95−98%.
Results: From a total of 804 pregnant women tested, 17 (2.1%) were
positive by r-EIA and all were conﬁrmed by the n-EIA. The level of
antibodies by de r-EIA technique was three times greater than the cut-
off value in all the positive serums.
Most of the Latin American pregnant women studied were from Ecuador,
Colombia and Bolivia. However, all the infected women were Bolivian.
None of the 17 women with positive tests were known previously to
suffer from Chagas disease.
Conclusions: The presence of pregnant women with Chagas disease
justiﬁes the performance of this test during pregnancy in women coming
from endemic areas.
There is a good agreement between recombinant and native EIA
techniques used.
It is important to identify the infected pregnant women in order to
achieve a prompt diagnose and treatment of the children with congenital
Chagas disease.
P879 May immunochromatographic assay allow accurate detection
of antibodies against Echinococcus granulosus?
G. Sonmez Tamer* (Kocaeli, TR)
Objectives: Echinococcus granulosus (E. granulosus) is the causal
agent of cystic echinococcosis (CE). Serologic assays, together with
imaging techniques, are most frequently used for diagnosis. The indirect
hemagglutination test (IHA) and enzyme-linked immunosorbent assay
(ELISA) seem most satisfactory. In this study, a new immunochro-
matographic assay (ICA) for total E. granulosus antibodies, VIRapid®
HYDATIDOSIS, has been evaluated.
Methods: Two main groups of samples were analyzed to check the test
performance: 137 sero-negative serum samples from Turkish hospitals
and 85 sero-positive serum samples from different areas. A new ICA,
VIRapid® HYDATIDOSIS, (Vircell, Spain) designed for the qualitative
detection of antibodies against E. granulosus both in serum and plasma
samples. It is a single strip assay two lines, test and control. The test
performance was visually read out after incubation for 20 min at room
temperature. An IgG ELISA (DRG, Germany) and an IHA (Fumouze,
France) tests were used as references methods.
Results: 81 out of 85. positive sera displayed a distinct red test line in the
ICA. 137 out of 136 negative sera showed no reactivity on the test line
in the ICA. Sensitivity, speciﬁcity, positive predictive value and negative
predictive value were calculated for the new VIRapid® HYDATIDOSIS
assay as 95,29%, 99,27%, 98,78% and 97,14% respectively.
Conclusion: We obtained good predictive values in detection of anti-CE
antibodies in human serum samples. The test offered a fast and easy to
use performance with high sensitivity and speciﬁcity. There is no need
for elaborate instrumentation, special storage condition and the results
are easy to interpret.
P880 The pinworm: a Trojan horse for Dientamoeba fragilis?
O¨. Kurt*, N. Turgay, A. Bart, S. O¨zensoy To¨z, N. Verhaar, T. van
Gool (Manisa, Izmir, TR; Amsterdam, NL)
Objective: Despite over 90 years have passed since its ﬁrst description,
the mysterious journey of Dientamoeba fragilis trophozoites through
human gastric juice before reaching their target site, the colonic lumen,
and their survival outside the human body are yet to be deﬁned.
Helminths may play a role in its transmission and the pinworm,
Enterobius vermicularis, has been blamed for its transmission to humans.
We previously reported that 9.6% of pinworm-infected patients were
coinfected with D. fragilis, whereas 2.4% of the non-pinworm infected
patients had a D. fragilis infection. Similarly, 25.4% of D. fragilis-
infected patients were coinfected with the pinworm as compared to
10.1% in non-D. fragilis infected patients in our study group.
Real-time (RT) PCR is a sensitive and speciﬁc method for the
identiﬁcation of intestinal parasites, compared to conventional methods.
Recent reports indicate that it is also highly sensitive in the identiﬁcation
of D. fragilis in stool samples, which is rather difﬁcult with microscopy
as it requires examination of permanent-stained smears.
Methods: To assess the correlation between the pinworm and D. fragilis
infections with RT-PCR, a total of 11 stool samples of 10 pinworm-
infected patients diagnosed with cellophane tape method were collected
and kept at −20ºC until examination. Two samples were obtained from a
patient, initially and after anti-helminthic therapy, and both were positive
for pinworms. DNA isolation was done with the Magnapure system
(Roche) according to the manufacturer’s instructions. RT-PCR was done
as previously described by Verweij. Sequence analysis was conducted
with the amplicons in “BigDyeTerminator (Applied Biosystems)” and
the results were analysed with ABI 3900. Obtained DNA sequences
were assembled and compared to reference sequences using “CodonCode
Aligner” (Codon Code Corporation) and MEGA 4.0®.
Results: D. fragilis DNA was identiﬁed in 5 of 10 patients (50%) with
RT-PCR. Interestingly, a follow-up sample of one patient after treatment
remained positive for both pinworm and D. fragilis.
Conclusion: These initial results suggest a much higher percentage of
co-infection with D. fragilis in pinworm positive patients than previously
found in our population. Therefore, pinworm positive patients with
symptoms suggestive of D. fragilis coinfection should be thoroughly
examined for D. fragilis.
P881 Occurrence and genotype characterisation of Giardia lamblia
in wolves (Canis lupus L. 1758) from Portugal
M.C. Sousa*, M. Machado, A. Loureiro, A. Bra´s, R. Godinho, H. Rio-
Maior, F. A´lvares, P.J. Esteves (Coimbra, Porto, Viana do Castelo, PT)
The protozoan parasite Giardia lamblia (synonym G. duodenalis,
G. intestinalis) is recognised as one of the most important non-viral
infectious agents causing diarrhoeal illness in humans around the world.
Human giardiasis is considered a zoonotic infection, although the role
of animals in the transmission to humans is still unclear.
G. lamblia is the most frequent form of Giardia found in mammals
and represents a species complex comprising genotypes/assemblages that
are host speciﬁc (assemblages C to G), and those that affect humans
and a range of other mammalian species (assemblages A and B) and
are thus considered to have zoonotic potential. Assemblages A and B
show genetic sub-structuring and some subgroups appear to have more
zoonotic potential than others. Genotyping data from wild animals are
scarce, but some recent studies have revealed infection with assemblages
A and B in wild carnivores and wild ruminants, suggesting a potential
role of those animals as source of cysts infectious to other animals or to
humans.
The aims of the present work are to detect and molecular characterize
the isolates of Giardia obtained from wolves, in order to determine
the existence of new or previously described species/genotypes and to
establish their potential zoonotic character.
Wolves DNA was obtained from faecal samples (n = 38) collected in the
National Park of Peneda-Gereˆs, North of Portugal. The b-giardin locus
gene was ampliﬁed by nested-PCR and PCR products were sequenced
with dRodamina Terminator Cycle Sequencing kit. The reading was
performed using an ABI PRISM 310XL automatic DNA Sequencer and
the obtained sequences were aligned with those available in Genbank
using Clustal X program.
Results showed that a total of nineteen DNA faecal samples were positive
to the b-giardin locus gene (50.0%). The sequencing analysis showed
that the Giardia isolates belonged to the assemblage A1. Phylogenetic
analysis revealed a close relationship between animal assemblage A and
human isolates (Portland-1 and AY072723).
This is the ﬁrst genetic characterization of Giardia in wild animals
from Portugal. The results showed the high prevalence of Giardia in
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wolves and that the zoonotic Assemblage A was common in this wild
animal. These ﬁndings suggest that wolves may play an important role
in zoonotic transmission cycles of the parasite in north of Portugal.
This work was supported by FCT POCTI (FEDER) and by VentoMinho-
Energias Renova´veis, S.A.
P882 Detection of Acinetobacter sp. in human lice from Ethiopia
M. Kempf*, E. Angelakis, A. Abdissa, G. Diatta, J.F. Trape, D. Raoult
(Marseille, FR; Jimma, ET)
Objective: The human body louse (Pediculus humanus humanus) and
the head louse (P. h. capitis) are closely related obligate parasites
that feed exclusively on human blood. Acinetobacter baumannii readily
infect, multiply and proliferate in body lice, producing a generalized
infection1. The objective of this study was to assess the rate of infection
to Acinetobacter sp. of body and head lice collected in Ethiopia.
Methods: We collected head and body lice from seven locations with
different altitudes (from 1450 to 2400 meters) in Ethiopia. Total genomic
DNA of each louse was extracted and used as a template in a real-time
PCR assay targeting the rpoB gene of Acinetobacter sp.2. In order to
identify the genotype of body and head lice, the mitochondrial gene, cytB
(cytochrome b) was ampliﬁed and sequenced3. For data comparison,
EpiInfo version 6.0 software was used (Centers for Disease Control
and Prevention, Atlanta, GA, USA). A p value <0.05 was considered
signiﬁcant.
Results: A total of 115 head and 113 body lice were collected from
134 patients (109 females and 25 males) and tested. All body lice were
grouped in phylotype A and all the head lice, which were all black,
belonged to phylotype C. Acinetobacter sp. was found in 62 head (53%)
and 69 body (69%) lice. No difference was found in the presence of
Acinetobacter sp. between head and body lice (p = 0.58) or between
males and females patients (p = 0.34).
Conclusion: Our study is the ﬁrst showing presence of Acinetobacter
sp. in head and body lice in Ethiopia. The percentage of lice infection in
Ethiopia was much higher than in other countries such as in France or
the Netherlands where respectively 18% and 32% of body lice presented
A. baumannii, or than in Rwanda where 58% of body lice were infected
with A. baumannii [3]. Head and body lice can be differentiated into 3
deeply divergent mitochondrial clades, each having unique geographic
distribution. The ﬁrst contains both head and body lice and is worldwide
in distribution; the second occurs only in head lice and has been found
in the New World, Europe, and Australia; and the third has been found
only in black head lice from Nepal and Ethiopia [4]. In our study, we
have shown that all head lice presented the phylotype C and all body
lice presented the phylotype A.
P883 Performance of a multiplex PCR to identify diarrhoeagenic
Escherichia coli: experience from a tropical medicine hospital
A. Palmeiro*, C. Toro, A. Amor, N. Iglesias, P. Trevisi, M. Subirats,
A. Olaiz, M. Baquero (Madrid, ES)
Objectives: Accurate diagnosis of diarrhoeagenic Escherichia coli
(DEC) in patients with diarrhoea is hindered by standard detection
methods. This is particularly outstanding in subjects with traveller’s
diarrhoea in whom DEC is the main enteropathogen bacteria involved.
Our objective was to analyze the prevalence of DEC by a new multiplex
PCR (E. coli DEC PCR, Statens Serum Institut) in our Hospital
specialized in Tropical Medicine.
Methods: From June 2009 to October 2010, stool samples from patients
suffering acute or persistent diarrhoea were investigated. Samples were
analyzed for enteropathogen bacteria by standard procedures. In addition,
a commercial multiplex PCR was performed to detect genes associated
with DEC: verocytotoxins 1 (vtx1) and 2 (vtx2), intimin (eae), heat-
stable enterotoxin (estA) and heat-labile enterotoxin (eltA) and invasive
plasmid antigen (ipaH). Epidemiological data, including recent travels
and country of destination was also recorded.
Results: A total of 105 samples corresponding to 100 patients were
included. Most patients were travellers: 38 came from Africa, 15 from
Central America, 15 from Asia and 12 from South America. The
remaining 20 subjects did not report any travel in the last weeks.
The mean age of the study population was 38±14 years and 5% of
patients were children (<15 years old). The gender distribution was
equal. The main enteropathogen bacteria identiﬁed were DEC (7 patients)
followed by Salmonella spp (5 patients), Campylobacter spp (3 patients,
2 Campylobacter jejuni y 1 Campylobacter coli), Shigella sonnei (2
patients) and Plesiomonas shigelloides (1 patient). eae gen was the only
found in subjects with DEC strains. All of them were adults travellers
from Asia (4 patients), Africa (2 patients) and South America (1
patient). Three of them presented coinfection with other enteropathogens
(Campylobacter jejuni, rotavirus and Giardia lamblia in each case). Of
note, ipaH was detected in two patients in whom Shigella sonnei was
cultured. These subjects did not report any travel in recent weeks and
one of them was coinfected with HIV-1.
Conclusion: DEC was the main enterophatogen bacteria responsible of
traveller’s diarrhoea with a remarkable prevalence (7%). The multiplex
PCR is an useful and simple tool for detecting these strains. Our data
supports that investigation of DEC should be recommended as a routine
diagnostic test for patients in this clinical setting.
P884 Disseminated Penicillium marneffei infection in a
non-HIV-infected woman
R. Plongla*, K. Asvametha, P. Leethong, A. Chaindamporn,
C. Saunkratay (Bangkok, TH)
Objectives: Penicillium marneffei is a dimorphic fungal infection
endemic in Southeast Asia. It is one of the commonest opportunistic
infection in AIDS patients in Thailand, especially in the northern part.
Infection in non-HIV-infected patients is uncommon.
Figure: A: multiple discrete erythematous painless subcutaneous nodules dis-
tributed on her face. B and C: arthritis and redness at the ﬁfth PIP joint of
left hand and the ulnar side of right wrist without deformities. Bone radiographs
showed juxta-articular osteopenia, multiple osteolytic lesions at bilateral ﬁbula
shafts, erosions and osteolytic lesions at styloid process of right ulnar bone (long
arrow) and left ﬁfth PIP joint (short arrow) with soft tissue swelling without
periosteal reaction. A and B: Wright stain from pus showed multiple 2−4mm
yeast-like organisms with transverse septum. C: Silver stain. D: cultures of pus
from right wrist grew the fungal colonies which formation of a soluble red pigment
of Penicillium marneffei.
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Methods and Results:We described a 48-year-old HIV-negative woman
who presented with fever, multiple painless subcutaneous nodules,
multiple osteolytic lesions, and alteration of consciousness due to severe
hypercalcemia. Penicillium marneffei was isolated from the pus of her
subcutaneous nodules (see Figures). She recovered following eight-week
treatment with amphotericin B.
Conclusion: Penicillium marneffei infection in non-HIV-infected
patients presented differently from HIV-infected patients. Clinical
manifestations can be vary from mild skin papules to severe disseminated
infection. However, common ﬁndings included fever, weight loss, skin
manifestation, and osteoarticular involvement. Although, Penicilliosis in
non-HIV-infected patients is uncommon. By reporting this case, we hope
to raise the awareness of this fungus in the clinical practice.
P885 Occupational outbreak of tropical rat mite (Ornithonyssus
bacoti) dermatitis in laboratory personnel, in southern Italy
(Apulia region)
M.A. Caﬁero, D. Galante*, N. Cavaliere, C. Nardella La Porta,
M. Caiazzo, M. Lomuto (Foggia, IT)
Objectives: The tropical rat mite (TRM,) Ornithonyssus bacoti is
a non-burrowing, temporary blood-sucker mite infesting a variety of
domesticated and wild mammals worldwide, including rodents. It can
also bite humans and cause a non-speciﬁc dermatitis. We report an
occupational outbreak of TRM-dermatitis in laboratory personnel and
discuss the failed parasitological diagnosis.
Methods: Five researchers (4 women, 1 man) working in the animal
facility of a local University complained of pruritus and sporadic, tiny
papulae of two weeks’ duration involving mainly arms and hands.
They had also experienced the sensation of “bites and stings” at work
when handling the laboratory mice. Due to intense itching, one of
the researchers inspected her body and collected arthropods from her
underclothes similar to those previously observed on the rodents’ cages.
Inspection of the vivarium revealed several parasites which were then
sent to the Istituto Zooproﬁlattico of Foggia for the identiﬁcation.
Results: The mites were identiﬁed as O.b. The animal room and
the rodents’ cages were disinfested using pyrethroids. A professional
exterminator was recommended. There was no evidence of mites or
dermatitis during the follow-up.
Conclusions: Medical and parasitological textbooks rarely describe
O.b. outbreaks and only sparse information was found in manuals
on laboratory rodents maintenance and their infestations. Due to
the difﬁculty of achieving correct identiﬁcation and to the lack of
information on this mite in several European countries, personnel
working with laboratory rodents may be unaware of the existence
of TRM infestation and therefore fail to implement any preventive/
control measures. The mite often gains access to the animal research
building on feral rats and then lives in crevices adjacent to laboratory
cages. Laboratory rodents and man then become a food source. TRM
should therefore be listed as a zoonotic biological agent in all European
regulations regarding occupational safety, while TRM dermatitis should
be listed as an occupational risk for individuals working with laboratory
rodents. This study also highlights the need to train personnel working
in animal facilities about the zoonotic ectoparasites of laboratory
rodents with particular emphasis on TRM. As pet rodents have also
been implicated as sources of human infestation and dermatitis, TRM
dermatitis remains a relevant diagnosis for occupational medicine doctors
and also for dermatologists.
P886 Molecular analysis applied to mitochondrial DNA from the
family Planorbidae (Pulmonata: Basommatophora) snails,
potential intermediate hosts of trematode
M. Calado, D. Correia, A. Afonso, P. Ferreira, C. Ferreira, A. Pinto,
I. Maurı´cio, S. Beato*, M.A. Gra´cio (Lisbon, PT)
Introduction: The family Planorbidae (Pulmonata: Basommatophora),
a group of freshwater hermaphroditic snails, includes intermediate
hosts of trematode parasites of great importance in human health
and/or veterinary medicine. For example, the snail hosts of Schistosoma
spp. belong to the genera Biomphalaria, Bulinus and Planorbarius
(Gra´cio, 1983, 1981). The schistosomes cause considerable morbility
and mortality in humans, and schistosomiasis is considered a neglected
disease. Our objective was to compare populations of family Planorbidae
snails, from different geographical areas of Portugal (Mainland and
Madeira Island) and Cape Verde, a former Portuguese colony, through
molecular analysis of mitochondrial DNA.
Material and Methods: The snails were collected in the Alentejo
and Coimbra regions, and Madeira Island, all in Portugal, and Cape
Verde, and were morphologically identiﬁed as Planorbarius metidjensis.
Genomic DNA was extracted according to Stothard (1996). Two
mitochondrial genes, COI and 16S, and the nuclear ITS region
were ampliﬁed by PCR and sequenced in both directions. The
sequences obtained were edited with BioEdit version 7.0.0, aligned with
homologous sequences, obtained from GenBank and phylogenetic trees
were produced using MEGA 3.1.
Results: On a BLAST search the most similar sequences were of
Helisoma sp. All sequences were very similar to each other, but it was
possible to identify separate robust clusters on the rooted phylogenetic
trees. Speciﬁcally, one cluster included samples from Cape Verde, which
were very closely related, another samples from Madeira, which were
more diverse, and two separate clusters from mainland Portugal.
Conclusions: Snails morphologically identiﬁed as P. metidjensis were
genetically characterized using one nuclear and two mitochondrial
regions, which suggested a higher similarity to the genus Helisoma.
The population from Cape Verde was very homogeneous, suggesting a
recent bottle neck or founder effect. Conversely, that from Madeira was
polymorphic, suggesting multiple introductions from the same region or
an ancient introduction. Although these seemed related to the populations
from mainland Portugal, it was much more polymorphic. Mainland
Portugal samples did not show geographical patterns, but were divided
into two populations, which may have distinct biological characteristics
and, thus, implications for current and future transmission of helminth
parasites.
Funding: UPMM
P887 Ocular parasitosis: diagnosis and treatment
G.L. Popa*, C.M. Cretu, C. Chiotan, S. Cilievici, F. Balta, S. Radulescu
(Bucharest, RO)
Objectives: Our aim was to establish the parasitic aetiology for ocular
pathological developments, to monitor the evolution as well as to set out
the most efﬁcient therapy.
Methods: We collaborated with different clinics and laboratories and we
investigated 76 patients with ocular affections, between 2001 and 2009.
To establish the diagnosis we used ophthalmological and serological
methods as well as ocular echography and angioﬂuorography for several
cases. The treatment included the association of pyrimethamine and
sulfadiazine, or pyrimethamine and azithromycin for toxoplasmosis as
well as other schedules that will be presented, detailed and discussed.
Results: Common clinical features were blurred vision, scotoma, ocular
pain, photophobia and epiphora. Most ocular parasitosis were produced
by Toxoplasma gondii (89.47%). We identiﬁed one case of each
cysticercosis, orbital hydatid cyst, dyroﬁlariasis (periocular granuloma),
and the rest were determined by Toxocara spp. The most frequent cases
of toxoplasmosis were chorioretinitis.
For most of our patients we used 2 or 3 courses of treatment as presented
in methods. We would like to underline the efﬁcacy of azithromycin.
Systemic corticosteroids were used when lesions involved the macula,
optic nerve or papillomacular bundle.
Conclusions: The collaboration between clinicians of different specialty
is of outstanding importance. In larva migrans ocularis syndrome the
antibody levels are decreased in comparison with larva migrans visceralis
syndrome. ELISA results are not a sufﬁcient argument in order to
start the treatment. It is extremely important to have a precocious
diagnosis and treatment to obtain good results in ocular toxoplasmosis.
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The corticotherapy is essential in ocular damages with important
inﬂammatory reaction.
P888 Visceral leishmaniasis in a patient on haemodialysis
T. Exiara*, A. Konstantis, A. Risggits, M. Kouroupi, E. Filippidou,
L. Mporgi, S. Saridou, S. Papanastasiou, L. Papazoglou,
D. Papadopoulou (Komotini, Alexandroupolis, GR)
Introduction: Leishmaniasis is an endemic disease in many un-
derdeveloped countries and also in some Mediterranean countries.
Leishmaniasis is recognized as a serious opportunistic infection in
some immunosuppresed patients. We report a rare case of Visceral
Leishmaniasis (VL) in a hemodialyzed patient successfully treated with
amphotericin B.
Case report: A 78-year-old male with end-stage renal failure due
to diabetes mellitus on haemodialysis for the past nine years, was
admitted in our department with one-month history of anorexia,
fatique, malaise and weight loss. Physical examination revealed only
splenomegaly. Laboratory tests revealed pancytopenia (hemoglobin
8.4 gr/dl, total leucocytes 3.9×103 c/dl, platelets 90×103 c/dl) and hyper-
g-globulinaemia The prothrombin, activated partial thromboplastin time
and ﬁbrinogen were normal. The liver transaminases and total bilirubin
were normal. Mantoux and sputum test for acid-fast bacilli were negative.
HIV test was also negative. Thoracic radiographs were normal and
an abdominal ultrasound study showed splenomegaly (16 cm in its
maximum diameter). Platelets dropped further up to 50×103 c/dl on the
next days and a bone marrow aspirate was performed and demonstrated
amastigotes of Leishmania donovani. Peripheral blood smear showed
no parasites. Liposomal Amphotericin B was initiated at doses of
150mg/day intravenously for 5 continues day with no side effects.
A short course of treatment repeated ﬁve days later. Bone marrow
aspiration and bone marrow culture 3 months after the end of the
treatment were negative. One year later there has been no relapse.
Conclusion: Visceral Leishmaniasis has been reported as a complicating
infection in some immunosuppresed patients. However, to the best of
our knowledge, only three cases of VL in a haemodialysis patient
have been reported. It has been suggested that impaired cell-mediated
immunity and inhibition of macrophage function which are important
in the elimination of intercellular microorganisms may be predisposing
factors for this kind of infection. Pentavalent antimonials remain the
drug of choice for VL. However, the trend in southern Europe is shifting
towards using liposomal amphotericin B as the preferred treatment, even
though the response rate is still around 90% for antimonials. VL should
be considered in the differential diagnosis of patients who present with
fever, hematological abnormalities or hyper-g-globulinemia, especially
in endemic areas.
P889 Development of new anti-Leishmania drugs: activity of
heterocyclic derivates, pyrroles and porphyrin synthetic
compounds on L. infantum and L. tropica promastigotes
M.C. Sousa*, E. Bonifa´cio, J. Dias, J. Vitorino, K. Silva, M. Machado,
A. Sobral, A.T. Cabral (Coimbra, PT)
Protozoan parasites of the genus Leishmania cause visceral, cutaneous
and mucosal diseases in humans, which are collectively referred to
as leishmaniasis. These diseases affect more than 12 million people
worldwide with approximately 350 million people at risk. Considering
the toxicity, side effects, rate of relapse, cost, length of the treatment and
the resistance that parasites develop against drugs, more attention should
be given to the development of new compounds for leishmaniasis.
In the present work we focused on the activity of heterocyclic
derivates, thieno pyrroles and porphyrin synthetic compounds. Some of
these compounds seem to have pharmaceutical potential: heterocyclic
derivates have cytotoxicity for cancer cell lines by apoptosis mechanisms
associated with caspases signalling and DNA topoisomerases inhibition
and porphyrins showed good properties as a sensitizer in photodynamic
therapy. Inducers of apoptosis, anticancer drugs and inhibitors of DNA
topoisomerases seem to be an advantageous approach to the development
of leishmanicidal drugs.
The antileishmanial assays was performed on promastigotes cultures
of L. infantum and L. tropica incubated in growth medium, RPMI
1640 medium enriched with 10% fetal bovine serum, with different
concentrations of compounds. The promastigotes proliferation was
assessed by counting the total cells in haemocytometer and the viability
by the tetrazolium-dye colorimetric method (MTT). The experiments
were performed in triplicate and in at least six independent assays.
Results were expressed as concentrations that inhibit parasite growth
or viability by 50% (IC50).
For the all tested compounds (19) only two heterocyclic derivates and
one porphyrin revealed activity against Leishmania promastigotes with
IC50 values ranging from 22 mg/ml to 130mg/ml. There were distinct
and considerable differences in molecular structure of compounds
that showed activity against Leishmania. The 4-dimethylaminophenyl
substitute present on of the heterocyclic derivate and the Cl atom that
bind to methyl group on the other heterocyclic compound seems to be
responsible for the biological activity. In relation to the porphyrins, the
presence of carboxyl substitutes was crucial to the anti-protozoa activity.
The results suggest that the active synthetic compounds may serve as
models for the design of new active molecules for leishmaniasis therapy,
including cutaneous and visceral forms.
This work was supported FCT POCTI (FEDER)
P890 Increased level of interleukin-10 and tumour necrosis
factor-a associated with severe scrub typhus
Y.S. Kim*, S.J. Park (Daejeon, KR)
Objectives: Scrub typhus is a chigger-borne illness caused by Orientia
tsutsugamushi that causes a systemic infection with various severity
degrees. We aimed to identify the risk factors associated with severe
scrub typhus and compare the cytokine levels between severe and non-
severe scrub typhus groups.
Methods: We conducted a prospective study from September to Decem-
ber 2009. Scrub typhus was conﬁrmed using indirect immunoﬂuorescent
assay. We developed scrub typhus severity index (STSI) to evaluate
the severity of illness and deﬁned patients with STSI 3 as having
severe scrub typhus. The concentrations of cytokines were measured
using enzyme-linked immuosorbent assays.
Results: A total of 63 patients were conﬁrmed with scrub typhus and
13 patients were denoted as severe scrub typhus. Thrombocytopenia,
hypoalbuminemia and hyponatremia were more frequently associated
with severe than with non-severe scrub typhus. Mean age and CRP
increased more in severe scrub typhus group. However, multivariate
analysis demonstrated no factors were signiﬁcantly associated with
severe scrub typhus. The concentrations of interleukin (IL)-6, IL-10,
IL-12p40, interferon (INF) − g, and tumor necrosis factor (TNF) − a
increased in patients with scrub typhus compared with those of normal
control. IL-10 and TNF-a increased signiﬁcantly more in severe than in
non-severe scrub typhus group (p = 0.006).
Conclusion: Whereas there were no clinical features indicative of severe
scrub typhus, measuring the concentrations of IL-10 and TNF-a may
predict disease severity in adults with scrub typhus.
P891 Clinical and epidemiological peculiarities of severe
leptospirosis in Georgia
E. Vashakidze*, T. Megrelishvili, T. Khuchua, T. Tkhilaishvili,
P. Imnadze, N. Mamuchishvili (Tbilisi, GE)
Objectives: Leptospirosis is a zoonotic diseases of a worldwide
distribution. Frequent circulating serotypes of Leptospira interrogans as
an etiological agent in Georgia are: L. icterohaemorrhagiae, L. canicola,
L. grippotyphosa, L. ballum. During recent years new serotypes have
been identiﬁed: L. mankarso, L. wolfﬁi, L. autumnalis. Incidence during
last 5 years is 0.63. Overall lethality is 7−14%. This research aimed to
identify clinical and epidemiological aspects of severe leptospirosis.
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Methods: The research retrospectively studied the cases of severe
leptospirosis admitted at the emergency department of the Infectious
disease, aids and clinical immunology scientiﬁc practical centre of
Georgia, Tbilisi during 2005–2010. Serological conﬁrmation included:
ELISA, MAT.
Results: Totally 13 patients (11 males, 2 females) were registered, among
them 4 cases (31%) were lethal (3 males, 1 female). Age of the patients
were from 26 to 71 years. Source of infection were: contact with a natural
water reservoir-54%, ground contaminated with rodent excretions-8%,
cattle-raising activity-8%, unknown source − 15,5%.
Clinical ﬁnding: fever − 100%, jaundice − 100%, hepatomegaly −
100%, myalgia − 85%, increased creatinin − 85%, oligo-anuria −
77%, pneumonia − 69%, chills − 61,5%, cutaneous and mucosal
haemoragies − 61,5%, splenomegaly − 54%, infectious toxic shock −
46%, oedema − 38,5%, proteinuria − 38,5%, conuctivities − 31%,
macrohaematuria − 23%, haemoptoae − 16%, haematomesis − 8%,
cutaneous rush − 8%. Mortality was induced: severe infectious toxic
shock, acute renal failure, hepato-cellular failure, acute lung injury,
thombo-haemoragic syndrome. Such important comorbidities as HCV
chronic carrier, oncological pathology, body mass deﬁcit with lung
TB and atopic dermatitis in non-lethal cases were noticed to induce
prolonged course of illness and afterwards − reconvalescence.
Conclusion: Leptospirosis remains as an important problem for Georgia.
Severe leptospirosis is characterized with high mortality in Georgia.
Most frequent signs are: fever, jaundice, herapatomegaly, myalgia, oligo-
anuria, elevated creatinin, pneumonia, chills, cutanoeus and mucosal
haemoragies. During recent years new serovars have been registerd in
Georgia, which have not been circulating before.
P892 Severe Mediterranean spotted fever complicated by bilirubin
nephropathy
M. Sonmezoglu*, G. Kantarci, O. Akin, I. Dogan Ekici, G. Yilmaz
Celik (Istanbul, TR)
Mediterranean spotted fever (MSF) is a tick-borne acute febrile
disease caused by Rickettsia conorii. Recently, complicated cases have
been more frequently reported. We describe the case of severe MSF
complicated by bilurubin nephropathy and liver function test anomalies.
53-year-old male patient presented at hospital with a 7-day history
of chills, shivering, fever (40ºC), severe fronto-occipital headaches,
fatigue, generalized maculopapular rash, and muscle weakness. He
conﬁrmed having a dog in his garden and ticks on it, but denies
any tick bite on himself. His noticed maculopapular rash ﬁrst on the
forearms and extended to the whole body involving palms and soles.
An inoculation scar (“tache noire”) was noticed on the stomache. He
had currently medicated with cefuroxime and ampicilline, but had
no relief. On physical examination, he had painful abdomen on the
epigastric region with hepatomegaly and splenomegaly, sonographically
conﬁrmed. Based on a presumptive diagnosis of rickettsiosis, he was
put on doxicycline 100mg bid PO. On day 3, the patient presented
mental confusion, agitation, hallucination, disorientation, nausea and
vomiting. The presence of meningitis signs led to a lumbar puncture,
which revealed no pleocytosis and a normal protein count. Cranial MRI
ﬁnding was not correlated with meningoencephalitis. Due to urinary
retention, the patient was undergone to catheterization, revealing a
yellowish urine and had no urine for the following 6 hours. Urine
specimen showed bilurubin containing hyaline slenders. Laboratory
analyses showed the leukocytosis with predominant neutrophils; liver
transaminase level increase; aspartate aminotransferase (AST): 87 IU/L;
alanine aminotransferase, 89 IU/L; lactate dehydrogenase (LDH), 438
IU/L; serum creatinine (Cre), 4.12mg/dL; C-reactive protein (CRP),
304 (<5). Patient was given intravenous NAHCO3 solution and diuresis
started. Liver enzymes, Cre and CRP levels returned to normal in
three days. Biopsy of the papular lesion revealed a dense inﬂammatory
inﬁltrate, composed by histiocytes, lymphocytes and neutrophils, with
diffuse and perivascular distribution, present in a “tache noire”. Weil-
Felix test was negative on day 0 but positive on day 7. Seven days
after initiation of the antibiotic therapy, clinical conditions, including the
headache, nausea and rash started to ameliorate. The antibiotic treatment
continued for 10 days, and eventually the patient was discharged without
any complaint.
P893 Two cases of Toscana virus meningitis in Algarve, Portugal
A. Proenca*, R. Pereira, A. Mingo, M.J. Alves (Faro, Lisbon, PT)
Since the discovery of Toscana virus (TOSV) in 1971 in Tuscany,
sandﬂy-borne TOSV has become recognized as a leading cause of
acute meningitis in central Italy during the summer months from May
to October, far exceeding enteroviruses. France, Spain, Greece, and
Cyprus have also reported cases of TOSV infection. In Portugal there
are 2 cases reported in travellers to Algarve and 2 more others cases
from authors personal experience in the last 5 years. These 2 new
concomitant cases reported here alert clinicians to the possible emerging
of this agent in the region of Algarve. TOSV should be included in the
differential list of viral pathogens among patients who seek treatment
with symptoms consistent with meningitis or encephalitis living or
having recently travelled to Mediterranean areas, including Portugal.
Patients 1 is a previous healthy 32 years old male and patient 2 is a
healthy 58 years old woman. Both were admitted in Faro Hospital in
last October. They live in the country side and have contact with dogs.
Clinical disease was very similar with acute beginning of headache,
fever, myalgia, agitation and confusion. Clinical examination showed
photophobia, conjunctivitis and stiff neck. Skin and abdomen were
normal. Results of a complete blood count showed thrombocytopenia,
elevation of liver enzymes and high C-reactive protein levels. CSF
analysis showed lymphocytic pleocytosis and elevated proteins. Aseptic
meningitis of viral origin was suspected. Computed tomographic scan
and magnetic resonance imaging of the brain and EEG were normal. Test
results for acute-phase serum specimens performed at Centro de Estudos
e Vectores de Doenc¸as Infecciosas (CEVDI) in Lisbon were negative for
West Nile virus and positive Ig G and Ig M (IFA) for Toscana virus. The
patients received supportive care only and recovered without sequels.
Patient 2 had a longer recovery period reporting headache, memory
problems and asthenia 1 month after the initiation of symptoms.
Although to our knowledge there is no evidence yet of isolation of TOSV
from sandﬂys from the area, entomologic and epidemiologic surveys,
will have to be conducted in the near future to determine the risk for the
people living and visiting this area.
P894 Visceral leishmaniasis: a ﬁnal diagnosis of an intermittent
febrile syndrome with 3 years of evolution. Case report
M. Ribeiro*, J. Louro, L. Riem (Barcelos, PT)
Background and Objectives: Visceral Leishmaniasis (VL) caused by
the intracellular protozoan Leishmania infantum is an endemic infection
in Portugal with 15 to 20 cases diagnosed a year in immunocompetent
patients. Dogs are considered the main reservoir for human visceral
infection and parasites are transmitted by the bite of phlebotomine sand
ﬂies, being Phlebotomus perniciosus and P. ariasi the provenvectors in
Portugal. Onset of symptoms may be insidious or subacute weight loss,
enlargement of the spleen and liver, and decreases in the production of
blood cells that can lead to anemia, bleeding and infections with other
microorganisms. Without treatment, this form of the disease is nearly
always fatal. The objectives of this study are to report a VL case in a
patient that initiated his condition with an intermittent febrile syndrome
and liver involvement and to review the aspects related to this disease.
Case report: A 38 years old male patient. His past medical history
includes psoriatic arthritis, hypertension and 2 previous admissions
(in 2006, May and 2007, October) for fever of unknown origin: he
had increased liver enzymes and negative microbiological/immunologic
studies. In 2006 his abdominal ultrasound (US) showed hepatic steatosis
and in 2007 had evidencied hepatomegaly. Liver biopsy performed at
that time was compatible with chronic liver disease. In both times
fever broke only with steroids and the cause was not found. In 2009,
October our patient presented with fever and weight loss. Work up
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revealed pancytopenia, raised ESR and liver enzymes. He had hepatic
steatosis and splenomegaly in abdominal US. After three bone marrow
biopsies performed was possible to visualize amastigotes in the last one,
ensuring the diagnosis of leishmaniasis. He had responded well to the
administration of liposomal amphotericin, without recurrence of fever
up to date.
Discussion: The chronicity of complaints and the existence of prolonged
fever periods for which it was not possible to determine the etiology and
which were not repeated after treatment with amphotericin lead us to
think about the possibility if it is a chronic leishmaniasis.
Conclusion: Symptomatic disease is subacute or chronic and diverse in
presentation and outcome. Deﬁnitive diagnosis requires the demonstra-
tion of parasite by smear or culture in tissue.
P895 Evaluation of therapeutic potential of methanolic extract
of stem bark of Acacia nilotica (Linn) for the treatment of
African trypanosomiasis
E.O. Ogbadoyi*, M. Garba, A.Y. Kabir, J. Okogun (Minna, Abuja, NG)
Objectives: The objective of this work was to evaluate the therapeutic
potential of methanolic extract of stem bark of Acacia nilotica (Linn) in
the treatment of human African trypanosomiasis (sleeping sickness).
Methods: Powdered stem bark of A. nilotica was extracted in
70% v/v (Methanol/Water) and partially puriﬁed using column and
thin layer chromatography. Both crude and partially puriﬁed extracts
were then evaluated for their therapeutic effects in experimental
Trypanosoma brucei brucei infection in mice. Blood and cerebrospinal
ﬂuid infectivity tests were done by drawing blood from the cured mice,
sub inoculating each into healthy mice, and then monitoring inoculated
mice for establishment of infection. Acute toxicity studies was done by
administering 2000mg/kg bw to a group of four healthy mice which
were then observed for 48 hours for motality.
Results: The crude extract at a dose of 400mg/kg bw per day completely
cured experimental Trypanosoma brucei brucei infection in mice within
eight days, while a dose of 50mg/kg bw per day of the partially
puriﬁed extract completely cured experimental Trypanosoma brucei
brucei infection in mice within two days. Sub inoculation of blood
and cerebrospinal ﬂuid drawn from the cured mice and inoculated
into healthy mice failed to produce infection within 28 days of post
inoculation. Administration of 2000mgkg-1bw of the partially puriﬁed
extract led to the death of half the number of the experimental animals
used in the acute toxicity studies.
Conclusion: It is concluded that methanolic extract of A. nilotica stem
bark is sufﬁciently trypanocidal to allow further studies to pave way for
possible development of phytomedicine or synthetic safer drug through
modiﬁcation of isolated bioactive constituent for use in the treatment of
sleeping sickness.
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P896 Occurrence and characteristics of methicillin-resistant
Staphylococcus aureus in pig farming in the Czech Republic
J. Bardon*, M. Kolar, R. Karpiskova, H. Zemlickova, M. Fridrichova,
P. Sauer, Z. Stastkova, V. Hanulik (Olomouc, Prague, Brno, CZ)
Objectives: The aim was to carry out the ﬁrst nationwide survey on
the prevalence of methicillin-resistant Staphylococcus aureus (MRSA)
strains on Czech pig farms, in accordance with the Commission Decision
2008/55/EC. Presented are results of the study, including characteristics
of MRSA isolates.
Methods: On 283 selected Czech pig farms, samples of dust on
metal partitions separating pens were collected using special swabs.
Bacteriological analysis was performed using methods published in
the Commission Decision 2008/55/EC to obtain MRSA isolates. The
PCR method was used to study their ability to produce enterotoxins,
exfoliatins, PVL and TSST. Macrorestriction analysis using pulsed-
ﬁeld gel electrophoresis was carried out using the SmaI restriction
enzyme. MRSA isolates were characterized by SCCmec typing, spa
typing and MLST. The minimum inhibitory concentration values for
MRSA isolates to selected antibiotics were determined by the standard
broth microdilution method.
Results: MRSA was detected on 5 Czech farms localized in 5 different
districts. The prevalence of MRSA in herds of breeding pigs in the Czech
Republic was 1.8%. None of the MRSA strains carried a gene for the
production of the studied toxins. Using macrorestriction analysis, all the
isolates were classiﬁed as nontypeable. Molecular typing revealed that
all isolates belonged to ST398, showing 3 different, but closely related,
spa types (t034, t2346, and t4659). Two isolates sharing spa type t2346
differed by SCCmec types (types IV and V); the remaining 2 isolates
possessed SCCmec type V. The tested isolates were resistant to at least
4 types of antibiotics and all of them were resistant to tetracycline.
Conclusion: The prevalence of MRSA on Czech pig farms (1.8%) does
not pose a signiﬁcant general epidemiological epidemiological risk for
the human population. However, the colonization of pigs with MRSA
ST398 has been identiﬁed as an occupational health risk for farmers,
veterinarians and their families. Monitoring of the occurrence of MRSA
should be recommended in other commodities, in particular milk and
dairy products.
Acknowledgements: This study was supported by the Ministry of
Education project no. MSM 6198959223 and IGA grant no. 9642−4.
P897 Methicillin-resistant Staphylococcus aureus isolated from
swine and farm workers in Spain
C. Potel-Alvarellos, L. Constenla-Carames, A. Moreno-Flores,
C. Lopez-Coton, E. Comesan˜a-Da-Vila, L. Eiroa-De-La-Puente,
S. Perez-Castro, M. Alvarez-Fernandez* (Vigo, Pontevedra, ES)
Objectives: To determine the prevalence and molecular characteristics of
methicillin-resistant Staphylococcus aureus (MRSA) colonization among
swine and related workers.
Methods: The nares of 197 swine and 8 workers from four production
systems comprising 2,900 live pigs were sampled. The swabs were
cultured on CNA and MRSA selective agar (bioMerieux).
S. aureus strains were identiﬁed by the tube coagulase test. MRSA was
conﬁrmed by cefoxitin and oxacillin disk diffusion test. The MRSA
strains were characterized by pulsed ﬁeld electrophoresis (PFGE) using
EagI restriction enzyme, spa typing, and multilocus sequence typing
(MLST). PCR was used to determine the SCCmec type and the presence
of the mec and the pvl genes.
Results: The swine ages were 3 (n= 28, MRSA 21.4%), 8 (n = 45, MRSA
26.6%), 12 (n = 10, MRSA 30%), 16 (n = 75, none MRSA), and 24 (n=
25, MRSA 8%) weeks. Additionally 14 adult sows were studied being
the MRSA prevalence 14.3%.
A total of 25 (12.7%) MRSA isolates were recovered from swine and 6
(75%) MRSA were recovered from workers.
All the strains were ST398. The only SCCmec identiﬁed was type V. The
most common spa-type among pigs was t011 (84%), and it was the
only spa-type identiﬁed among workers (100%). The t1451 spa-type was
identiﬁed in the remainder of the pigs (16%), all of them belonged to
the same farm and were SCCmec V positive. PFGE classiﬁed the t011
strains in four types. The workers were colonized by the same PFGE
types than the related animals except in one case. All the strains were
pvl negative.
Conclusions: The results showed that the colonization of swine by
MRSA is common, being the nasal colonization among workers very
frequent.
PFGE results showed diversity within the spa t011 strains.
Swine could be an important reservoir for MRSA representing a
challenge for human health care systems.
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P898 Livestock-associated MRSA responsible for human
colonisation and infection in a northern region of Italy
M. Monaco, M. Pedroni, A. Sanchini, A. Bonomini, B. Milanesi,
A. Pantosti* (Rome, Manerbio, IT)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) has
become a pathogen of increasing importance in health-care settings (HA-
MRSA) and in community (CA-MRSA). Livestock-Associated MRSA
(LA-MRSA) belonging to ST398 lineage, common among pigs and other
animals, emerged in Central and Northern Europe, becoming a new risk
factor for MRSA among farm workers. Strains belonging to ST398 can
be responsible for human infections, mainly in areas with high livestock-
farming. The aim of this study was to investigate the occurrence of LA-
MRSA human colonization and infections in a Northern region of Italy
with high density of pig and cattle farming.
Methods: In the period March-April 2010, at Manerbio Hospital
(Lombardia Region) in the North of Italy, 879 nasal swabs were
sampled from patients submitted to a pre-admission screening. In the
period March-August 2010, at the same Hospital, MRSA isolated
from outpatients infections were collected. By PCR assays, the species
S. aureus, methicillin-resistance and the presence of Panton-Valentine
(PVL) toxin genes were conﬁrmed. Molecular characterization included
SCCmec typing, spa typing and, on selected strains, multi-locus sequence
typing (MLST).
Results: Out of 879 nasal swabs examined, 9 (1%) yielded MRSA.
No strains were positive for PVL toxin genes. Six isolates harboured
SCCmec type IV and 3 strains SCCmec type V. Five strains were
assigned to t899 (3 isolates), t108 (1 isolate) and t2922 (1 isolate),
all belonging to ST398 and therefore categorized as LA-MRSA. Three
strains were t008-ST8 and 1 strain was t688-ST5, likely of hospital
origin. A total of 10 MRSA were detected from outpatient infections
of which 9 were skin and soft tissue infections (SSTI). Of these, 4
strains were PVL positive CA-MRSA which harboured SCCmec type
IV (3 strains), type V (1 strain) and belonged to different clones (t005-
ST5, t008-ST8, t021-ST8 and t7445-ST772). Other 5 strains were PVL
negative, SCCmec type IV, t008 (2 strains), t127 (2 strains) and t515
(1 strain). One MRSA from ear infection was PVL negative, SCCmec
type IV, t899 and ST398, hence categorized as LA-MRSA.
Conclusion: In areas with high density of pig and cattle farming LA-
MRSA is able to colonize the population and also to produce infections
along with typical and more common CA-MRSA. Since animal contact
is an established risk factor for LA-MRSA, close surveillance combined
to appropriate control measures should be employed to avoid LA-MRSA
spread.
P899 Occurrence of methicillin-resistant Staphylococcus aureus in
dairy products of Apulia region Italy
E. Crisetti*, A. Cataleta, T. Onni, M.A. Caﬁero, S. Tola, G. La
Salandra (Foggia, Sassari, IT)
Objectives: Staphylococcus aureus is one of the most important
foodborne pathogens and its pathogenicity is related to the production
of staphyloccocal enterotoxins (SEs). The pathogenicity of some strains
is greatly increased by antimicrobial resistance. The use of antibiotics in
veterinary practices, could determine the selection of antibiotic-resistant
clones of S. aureus, including methicillin-resistant S. aureus (MRSA).
In this note are reported the results of the characterization of S. aureus
isolates from milk and cheeses produced in Italy.
Methods: 110 strains of S. aureus were isolated from dairy products
during 2008–2009 in Apulia (Italy). These strains were characterized in
order to determine the presence of staphylococcal enterotoxin(s) genes
(sea, seb, sec, sed, see, seg, seh, sei, sej, sem, sen, seo) by PCR, the
antibiotic-resistance proﬁle using the disc agar diffusion method (Kirby-
Bauer), and the detection of mecA gene by PCR. Different PCR were
used for Staphylococcal cassette chromosome mec (SCCmec) typing.
Results: Overall out of 110 analysed strains, 42 (38.2%) S. aureus
isolates were found to be positive for SE genes. Most of the isolated
strains carried, alone or in association, the sed gene (15.5%), followed
by ecg cluster: seg, sei, sem, sen, seo (13.6%), sej (10.9%), sea
(9.1%), seh (6.4%), sec (5.5%), seb (0.9%). Strains carrying see
gene were not found. A strong resistance to ampicillin/penicillin
G (40%), streptomycin (28.2%), erythromycin (17.3%), novobiocin
(16.4%), tetracycline (14.5%), kanamycin (11.8%) and bacitracin (10%)
was found in the analyzed S. aureus strains. Two S. aureus strains
resulted resistant to methicillin (1.8%) and mecA positive. These strains
carried the SCCmec type V.
Conclusion: The presence of enterotoxigenic strains of S. aureus in food
produced in Italy represents a potential risk for consumers. A remarkable
level of resistance to several antibiotics was found in the S. aureus strains
analyzed in this survey. The total percentage of multi-resistant strains
(resistance to three or more antibiotics) was found to be 31.8% and this
conﬁrms that dairy products still remain a major source of antibiotic
resistance in S. aureus. In our study two S. aureus presented methicillin
resistance (1.8%). Both strains were positive for the presence of mecA
and harboured the SCCmec typeV. The aim of this work was to contribute
to the knowledge on the prevalence of MRSA in dairy products. (Work
supported by IZSPB 06/08.)
P900 High prevalence of methicillin-resistant Staphylococcus
aureus in pigs and slaughterhouse workers
A. Morcillo*, B. Castro, J. Gonza´lez, C. Rodrı´guez-Alvarez, M. Novo,
A. Sierra, A. Arias (La Laguna, ES)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) strains
belonging to clonal lineage sequence type (ST) 398 are being reported at
an increasing frequency in Europe and other countries. This new MRSA
type has been isolated from colonized and infected animals and humans.
This study aimed to determine the prevalence of nasal MRSA carriage
in pig and slaughterhouse workers.
Methods: A total of 200 pigs and 25 workers of the slaughterhouse of
Tenerife (Canary Islands, Spain) was prospectively included in the study.
Animals were transported to the slaughter and placed in separate stalls
according to different farm origin. All of them were slaughtered within
12 hours.
Nasal samples were collected in the slaughter by using Amies-Rayon
swabs (Deltalab™). Swabs were enriched in Brain-Heart Infusion with
7% NaCl at 37ºC for 24 hours and subsequently streaked onto MRSA
chromID plates (BioMerieux). They were incubated at 37 ºC for 24−48
hours.
Suspected MRSA colonies were ﬁrst screened using Slidex™ Staph
Plus agglutination and subsequently conﬁrmed with PBP2 agglutination
(MRSA™ Screen). Molecular typing of microorganisms was performed
by pulsed ﬁeld gel electrophoresis (PFGE) using the restriction enzyme
ApaI (Promega™). Allele and sequence type (ST) designations were
made by using the MLST website.
Results: We found 91% (18/200) in pigs to carry MRSA in their nares.
The overall prevalence of nasal MRSA carriage in employees of pig
slaughterhouse was 8% (2/25) All the MRSA isolates belonged to the
swine strain ST398.
Conclusion: The prevalence of MRSA in nasal samples from pigs in
our area is even higher than those found in other studies. All the MRSA
isolates belonged to MRSA strain ST398. The high prevalence found in
our study suggests implementation of screening measures, surveillance
and control in livestock facilities. Further studies are needed to evaluate
the pig livestock as MRSA reservoir.
P901 Diversity of rep-families in Staphylococcus aureus of food,
animal and human origin
C. Lozano*, L. Garcia-Migura, C. Aspiroz, M. Zarazaga, C. Torres,
F.M. Aarestrup (Logron˜o, ES; Lyngby, DK; Zaragoza, ES)
Objective: To reveal the plasmid content of a collection of S. aureus
strains of human and animal origin by expanding the classiﬁcation
system for plasmids described for enterococci and other Gram-positive
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bacteria (Jensen et al., 2010). This classiﬁcation system was based on
PCR ampliﬁcation of conserved areas of rep genes encoding replication
initiating proteins.
Methods: A total of 112 rep sequences from S. aureus retrieved from
GeneBank were aligned using Bionumeric program. Nucleotide- and
protein-based phylogenetic trees were generated. A cut-off value of
75% identity was chosen to determine the rep-families. A total of15
rep-families and 10 unique sequences were deﬁned. A collection of
92 S. aureus with different antibiotic resistance pheno- and genotypes
and of different clonal lineages were included in this study. Forty-three
methicillin-resistant S. aureus (MRSA) were isolated in Spain from
human, animal and food origin. The remaining 49 strains (27 MRSA
and 22 methicillin-susceptible S. aureus [MSSA]) were from animal
origin obtained in Denmark. Primers were designed for new deﬁned rep-
families and unique sequences. Multiplex PCRs from the previous study
together with newly designed PCRs were performed in the 92 strains.
Some of the amplicons obtained were sequenced to conﬁrm ampliﬁcation
of the correct product.
Results: Positive amplicons were obtained from rep-families (no strains):
2 (1), 5 (6), 6 (1), 7 (49), 7b (5), 9 (2), 10 (35), 10b (2), 13 (4),
15 (2), 16 (2), 20 (5), 21 (31), 22 (28) and from unique sequences
pE194 (1) and pKKS825 (5). Eight strains did not yield amplicons for
any of the rep-families or unique sequences studied. The rep2, 6 and 9
families (speciﬁc of other Gram-positive genera) were detected in MRSA
CC398 strains from Denmark. Some rep-families and unique sequences
were only detected in strains from Spain (rep5, 7b, 10b, 15, 16, 20 and
pKKS825) or Denmark (rep2, 6, 9 and pE194). Only 3 rep-families were
identiﬁed in MSSA strains (rep7, 10 and 21).
Conclusion: A classiﬁcation system for plasmids from Gram-positive
bacteria has been expanded for S. aureus. Predominant rep-families
were identiﬁed. rep-families of other genera were found in S. aureus
strains demonstrating plasmid transfer between species. Differences in
rep family content were detected according to the origin. Association
between resistant phenotype and rep-families was often observed.
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P902 Presence of Panton-Valentine leukocidin, toxin genes and
Agr typing of methicillin-resistant Staphylococcus aureus
strains isolated from bloodstream infections at Hacettepe
University Adult Hospital, Ankara, Turkey
P. Zarakolu*, Z.C. Karahan, S. Unal (Ankara, TR)
Objectives: To investigate the presence of Panton Valentine leukocidin
(PVL), and toxin (enterotoxin A-J, staphylococcal toxic shock toxin-
TSST) genes, and accessory gene regulator (agr) types of mecA-positive
methicillin-resistant Staphylococcus aureus (MRSA) strains isolated
from hospital-acquired (HA) bloodstream infections.
Methods: A total of 111 non-duplicate MRSA strains isolated from HA-
bloodstream infections between January 2004-January 2010 at Hacettepe
University Adult Hospital were included in the study. Hospital acquisiton
was deﬁned on the basis of CDC deﬁnition criteria. The isolation and
identiﬁcation of the isolates were made by automated system (Phoenix,
Becton Dickinson, USA) at the central laboratory of the hospital and
then they were stored at −80ºC until the beginning of the study. They
were tested for methicillin resistance by sefoxitin (30mg, Oxoid, UK)
disk diffusion test according to the CLSI criteria and for the presence of
mecA, PVL, enterotoxin, TSST genes and agr types by PCR method.
Results: All MRSA isolates were mecA-positive. None of them were
positive for PVL or TSST genes. Eleven (10.1%) isolates was not
carrying any of the enterotoxin genes. Five isolates (4.5%) was carrying
sea gene alone. The remaining 95 isolates was positive for combination
of enterotoxin genes as follows: sea+see+sei (48 isolates, 50.5%), sea+sei
(35 isolates, 36.8%), and sea+sec+see+sei (6 isolates, 6.3%), other
combinations (6 isolates, 6.3%). Agr typing revealed that 36 (32.4%)
were type I, and four (3.6%) were type II. The remaining 66 isolates
(59.5%) was carrying two or three agr groups: 32 (28.8%) were types
I and III; 34 (30.6%) were types I, II, and III. In 5 isolates, agr groups
could not be identiﬁed.
Conclusion: Enterotoxin genes (especially sea) and complex agr types
were prevalent among HA-blood-stream MRSA isolates in our hospital.
Besides, none of them were positive for PVL or TSST genes.
P903 Identiﬁcation of methicillin-resistant staphylococci by PNA
FISH directly from positive blood cultures
A.K. Rasmussen*, H.K. Johansen, B. Kummerfeldt, A. Mortensen,
L. Bay, H. Stender (Vedbaek, Copenhagen, DK)
Background: In Denmark, the prevalence of methicillin resistant
Staphylococcus aureus (MRSA) is very low (1.6% in 2009) whereas the
prevalence of methicillin resistant coagulase negative Staphylococcus
(MR-CNS) is high. Rapid identiﬁcation (S. aureus vs. CNS) and
determination of resistance to methicillin (MR vs. MS) of positive
blood cultures containing staphylococci is important for optimal patient
therapy.
S. aureus/CNS PNA FISH is a rapid method for routine identiﬁcation
of S. aureus and CNS using rRNA as target. In this study, we evaluated
a novel assay − mecA PNA FISH − targeting mecA messenger RNA
(mRNA) in staphylococci performed in parallel with S. aureus/CNS PNA
FISH for rapid identiﬁcation of MRSA, MSSA, MR-CNS, and MS-CNS
within 2 hrs.
Method: Initially, 172 reference strains and clinical isolates spiked
into negative blood culture bottles were used to assess the analytical
sensitivity and speciﬁcity of mecA PNA FISH. Subsequently, the
clinical performance of mecA PNA FISH (prototype) in parallel with
S. aureus/CNS PNA FISH (AdvanDx) was assessed using 66 positive
blood cultures (Rigshospitalet, Copenhagen) containing Gram-positive
cocci in clusters (GPCC). Results were compared to routine identiﬁcation
obtained following subculture and determination of resistance to
methicillin using cefoxitin disk diffusion and mecA EVIGENE.
Results: 66 GPCC positive cultures comprised 49 CNS (33 S. epider-
midis, 11 S. haemolyticus, 1 S. hominis, 1 S. warneri, 3 mixed cultures
(2 CNS + E. faecium and one CNS + CNS)), 16 S. aureus and 1
M. luteus. As expected, 100% (16/16) of S. aureus were MSSA and 90%
(44/49) of CNS were MR-CNS. mecA PNA FISH showed 86% (38/44)
sensitivity and 100% (22/22) speciﬁcity compared to disk diffusion and
mecA EVIGENE.
Conclusions: mecA PNA FISH is a promising tool for identiﬁcation
of MR-CNS and potentially MRSA directly from positive blood cultures
(2 hrs). Less than 100% sensitivity for MR-CNS may be explained by low
or delayed expression of mecA. Low expression and potential link to low
level resistance is being studied and may be of therapeutic importance.
P904 Genotypic and phenotypic methods for detection of S. aureus,
coagulase-negative staphylococci and oxacillin resistance
B. Zaloudikova*, E. Nemcova´, M. Stechova´, F. Ruzicka, V. Hola´,
P. Nemec, T. Freiberger (Brno, CZ)
Objectives: An increasing resistance to oxacillin and other b-lactams
in staphylococci greatly complicates treatment of serious staphylococcal
infections. Here, we introduce a speciﬁc multiplex PCR for simultaneous
molecular detection of Staphylococcus aureus using the femB gene,
coagulase negative staphylococci (CoNS) using the 16S rDNA gene and
resistance to b-lactams using the mecA gene, and compare the results
with standard phenotypic approach.
Methods: We analyzed 14 reference staphylococcal strains and 173
clinical staphylococcal and non-staphylococcal isolates characterized
previously by conventional culture including oxacillin-sensitive CoNS
(MS-CoNS) (22), oxacillin-resistant CoNS (MR-CoNS) (31), oxacillin-
resistant S. aureus (MR-SA) (31), methicillin resistant S. aureus (MS-
SA) (33), non-staphylococcal isolates (49) and mixed staphylococcal
clinical isolates (7).
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Results: As compared to standard culture and oxacillin susceptibility
testing, speciﬁc multiplex PCR has shown total agreement with
phenotypic methods in detection of S. aureus and CoNS. All 32 MSSA
and 30/31 MRSA isolates as found by multiplex PCR were in accordance
with phenotypic oxacillin susceptibility tests. All 31 MR-CoNS isolates
showed presence of the mecA gene using multiplex PCR. Of the 22 MS-
CoNS isolates 10 isolates showed presence of the mecA gene. When
template DNA from any of the 49 nonstaphylococcal isolates was used,
no ampliﬁcation products on multiplex PCR were observed.
Conclusions: While detection of femB and 16S rDNA gene targets
showed full agreement with standard culture in identiﬁcation of S. aureus
and CoNS, detection of mecA gene target showed higher agreement with
phenotypic oxacillin susceptibility testing in S. aureus than in CoNS
isolates. The method proved particularly usefull in patients with infective
endocarditis or prosthetic joint infection of staphylococcal origin.
P905 Discrimination of staphylococci using an rpoB-consensus
PCR coupled with a microarray hybridisation assay
S. Monecke*, P. Slickers, E. Mu¨ller, H. Hotzel, R. Ehricht (Dresden,
Jena, DE)
Objectives: The objective of the study was to develop a DNA microarray
based assay for the molecular discrimination of staphylococci based on
rpoB sequences.
Methods: BLAST analysis revealed rpoB sequences of all available
staphylococci, additional isolates were sequenced. PCR primer and
microarray probes were designed using Clondiag Oligo design software.
Resulting 3′aminomodiﬁed oligonucleotides were synthesised and used
for the fabrication of ArrayStrip microarrays. A total set of 296 clinical
staphylococcal isolates and reference strains were characterised using
this assay. An automated algorithm for pattern recognition led to the
identiﬁcation of the species. Identiﬁcations were conﬁrmed by rpoB
sequencing, MALDI TOF and/or biochemical proﬁles (VITEK).
Results: All relevant rpoB sequences were annotated in a local database
and aligned. After alignment, the most conserved sequence windows
were calculated for primer design. The sequences between the primers
were used to produce all possible oligo sequences from these data
within a certain range of calculated melting temperatures. A set of
probe sequences was selected in order to achieve the strongest possible
discriminating power. In practical microarray experiments, the stringency
was adjusted to be as close as possible to theoretical experiments derived
from rpoB sequenced isolates. The assay was then applied to CNS or
S. aureus isolates which were identiﬁed by sequencing rpoB (n = 34,
concordance 100%), by MALDI TOF (n = 12, concordance 91.7%), by
VITEK-2 (n = 148, concordance 83.3%) or for which identiﬁcations have
been provided by strain collections (DSMZ, n = 29, concordance 89.7%
and NARSA, n = 7, concordance 100%).
Conclusion: Based on intensive bioinformatic calculations and optimisa-
tion of reaction conditions and stringencies, array hybridisation targeting
rpoB and subsequent pattern recognition rather than sequencing allows
identiﬁcation of staphylococcal species using the high throughput format
ArrayStrip/ArrayMate and adapted software. Despite an overall good
concordance, the methods for pheno- or genotypic species identiﬁcation
can differ in their results. This can be attributed to the presence of mis-
identiﬁed or atypical isolates in the available databases or to principal
discrepancies between geno- and phenotypic species deﬁnitions. Further
investigation, especially with regard to rare species, is warranted.
P906 Multicentre trial of the LightCycler® MRSA advanced test,
Xpert™ MRSA assay, and MRSASelect™ directly plated
culture for detection of methicillin-resistant Staphylococcus
aureus in nasal swabs
R. Arcenas, S. Spadoni, F. Kiechle, K. Walker, R. Fader,
F. Perdreau-Remington, J. Osiecki, O. Liesenfeld*, A. Rao (Hollywood,
Hines, Temple, San Francisco, Indianapolis, Pleasanton, US)
Objective: To compare the performance and workﬂow characteristics of
the LightCycler® MRSA Advanced test to the Xpert™ MRSA asay and
culture.
Method: One swab of a double headed nasal swab was plated directly
to Bio-Rad MRSASelect™ media and processed using the LightCycler®
MRSA Advanced test. The second swab head was plated directly onto a
separate MRSASelect™ plate and processed using Xpert™ MRSA asay.
Results: Among 1202 nasal swabs collected at 3 U.S. sites, 104 (11.6%)
grew MRSA. Compared to directly-plated culture the LightCycler®
MRSA Advanced and Xpert™ MRSA tests showed similar relative sen-
sitivities of 95.2 and 99.0%, and similar relative speciﬁcities of 95.5 and
95.5%, respectively. Following discrepancy analysis using sequencing
sensitivities and negative predictive values of the LightCycler® MRSA
Advanced and Xpert™ MRSA tests were signiﬁcantly higher than
that of directly-plated culture; speciﬁcities did not differ signiﬁcantly
between the LightCycler® MRSA Advanced test and culture but were
signiﬁcantly lower for the Xpert™ MRSA assay compared to culture.
Workﬂow analysis revealed average hands-on sample preparation times
of 1:40, 2:35, and 1:44 min/sample for the LightCycler® MRSA
Advanced, Xpert™ MRSA, and MRSASelect™ methods, respectively,
during routine clinical processing.
Conclusions: Molecular screening tests for nasal MRSA colonization
show signiﬁcantly increased sensitivities compared to directly-plated cul-
ture. Combined with high speciﬁcity, low hands-on sample preparation
time and efﬁciency gains using batching capabilities the LightCycler®
MRSA Advanced test is highly suitable for rapid screening of MRSA
colonization.
P907 Reduced delta-haemolysin activity and agr-expression
correlate with an hVISA/VISA phenotype
V. Caﬁso, T. Bertuccio, S. Purrello, D. Spina, F. Campanile,
D. Bongiorno, G. Blandino, S. Stefani* (Catania, IT)
Objectives: Glycopeptides are still the gold standard to treat serious
MRSA infections, but their widespread use has led to reduced
susceptibility to vancomycin (hVISA and VISA) in which different
genetic loci (agr-locus and genes involved in autolysis and cell-wall
turnover) have been implicated.
Therefore, to try to ﬁnd a novel screening method, we evaluated
the delta-hemolysin production of 30 S. aureus clinical isolates with
reduced vancomycin susceptibility, assigned by Macro E-Test and PAP
analysis, in comparison with those of prototype microorganisms, i.e.
NRS149 (VSSA), Mu3 (h-VISA), Mu50 (VISA). We also analyzed the
amount of hld RNAm (gene encoding delta-hemolysin) in the prototype
microorganisms.
Methods: Strains were cultured with or without sub-inhibitory
vancomycin concentrations. delta-hemolysin production was evaluated
on 5% sheep-blood-agar (Oxoid) and the expression levels of hld (agr-
functionality indicator) were quantiﬁed by real-time RT-PCR.
Results: Independently from the agr-genotypes, there was no delta-
hemolysin production in VISA and Mu50 strains, however there was a
strong production in VSSA and the control strain NRS149. hVISA and
Mu3 strains showed only a low delta-hemolysin production. In borderline
cases, the addition of vancomycin was able to resolve discrepancies
giving a deﬁnitive result in hVISA. These phenotypic data correlated
with molecular data in fact, in the presence and in the absence of
sub-inhibitory vancomycin concentrations, a gradual and substantial hld
down-regulation was found as follows: VISA < hVISA < VSSA.
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Conclusions: The correlation between our molecular and phenotypic
data supports the possibility of screening for delta-hemolysis, in the
presence of vancomycin, to quickly and accurately detect potential
hVISA or VISA isolates of diverse agr-genotypes. Studies are ongoing
using various sheep blood media.
P908 mecA expression in clinical MRSA strains upon cefoxitin
induction
T.Y. Wolff*, J. Lorenzen, T. Thomsen, H.S. Andersen, A.K. Rasmussen,
B. Kummerfeldt, L. Bay (Aarhus, Aalborg, Vedbæk, DK)
Objective: A clinically highly relevant diagnostic tool based on PNA
FISH on mRNA was developed for identiﬁcation of methicillin-resistant
Staphylococcus aureus (MRSA). This study examines the expression of
mecA in clinical MRSA strains upon cefoxitin induction by both PNA
FISH and reverse transcriptase quantitative polymerase chain reaction
(RT-qPCR).
Methods: Clinical isolates of MRSA and MSSA were grown with shake
at 35 ºC for 40 min with or without 3mg/mL cefoxitin. PNA FISH
slides were prepared, total RNA extracted from 1mL culture and cDNA
synthesized. cDNA was used in qPCRs targeting the mecA and 16S
rRNA genes respectively. Using qPCR data the baselines for cefoxitin
induced and uninduced cells and the mean fold changes (MFC) in mecA
expression were calculated (Shang et al., 2010). In order to evaluate the
effect of induction on mecA expression as measured with RT-qPCR
uninduced and induced baselines were compared by paired Students’
t-tests.
Results: Table 1 shows the cefoxitin minimum inhibitory concentrations,
baselines, P-values for t-tests, MFC and PNA FISH results obtained for
each strain. 7 strains showed signiﬁcantly increased mecA expression
upon cefoxitin induction (P< 0.05).
Conclusion: Even though inducability of the strains varied PNA FISH
detected all strains with MIC >12mg/mL. No correlation between the
SCCmec type and the mecA expression was observed. There was a
tendency for strains with a low cefoxitin MIC to have a low mecA
expression. The results of PNA FISH and RT-qPCR corresponded well.
P909 MRSA PCR screening and optimisation of laboratory
services: an innovative way for saving precious pennies in
times of ﬁnancial turbulence in NHS
D. Singleton*, K. Chandler, S. Williams, M. Przybylo, A. Guleri,
J. Carter Lindsay (Blackpool, UK)
Background: Blackpool Victoria Hospital introduced a PCR based
MRSA screening service in March 2008 for all emergency hospital
admissions. Service was offerred from 8am − midnight and 7days
a week. The rates of MRSA infections have since reduced by
78%[40/2007−08 to 9/2008−09]; 80%[8/2009−10]; 1 bacteraemia[Apr
2010 till date]. Since August 2010, this screening of emergency
admissions by PCR was extended to include MSSA and MRSA.
PCR is an integral part of any busy Microbiology department. During
times of serious ﬁnancial turbulence in NHS and subsequent budget cuts,
we have attempted to ﬁnd an innovative solution. We present a case for
optimisation of laboratory services and money savings by incorporation
of MRSA/MSSA PCR services from bacteriology to virology section of
the department.
Methods: Economic modelling based on quantum of work, shift patterns
and expected turn-around-times. This included the Virology department
stafﬁng structure of 5 dedicated technical members of staff [Band 4s
used where appropriate]. Extending working day to 8am till midnight.
Timing and ﬁne tuning batching of specimens for MRSA/MSSA PCR
to optimise the beneﬁts of 8am − midnight service, reducing costs
and reduce TAT. Planned spreading of work from 8am till midnight.
Serological tests conducted between MRSA PCR runs; Data analysis
[period before and after shift of MRSA PCR service to virology section].
Results: Between Aug-Nov 2010 [First 3 months of introducing dual
MRSA/MSSA PCR screening] reduction in MSSA positives from 27.3%
to 20.5%.
Since Jan 2010: MRSA positives reduced from 5% to 1.8%; reduction of
interminate results and 60% reduction in failed runs; optimal batching
permits 20% more tests from each kit.
Savings of upto £260K from bringing back in-house costly tests and
additional rapid tests which had been previously sent away and helped
reduce turnaround times.
Conclusions: Optimisation of services by economic modelling, service
and demand management can help maintain high quality of service
and reduce costs in these ﬁnancially challenging times. Cost beneﬁts
from reduction in MRSA/MSSA infections through saved bed-days &
bringing in-house expensive tests offsets the stafﬁng costs while reducing
TAT. Further cost saving/service optimisation options are open to explore
including splitting out-of-hours on call service between virology [dual
bacteriology/virology trained] between 8pm-midnight and bacteriology
from midnight-8am bringing a potential saving of £30K.
P910 Comparison of two molecular methods, Xpert MRSA
assay and MRSA Advanced Test, for methicillin-resistant
Staphylococcus aureus nasal screening
P. Stano*, M. Avolio, R. De Rosa, M. Modolo, A. Camporese
(Pordenone, IT)
Objectives: Colonization with methicillin resistant Staphylococcus
aureus (MRSA) is a risk factor for subsequent infections, leading to
increased morbidity and mortality, as well as healthcare costs, especially
in patients admitted to intensive care units (ICU). Infection control
guidelines recommend (Calfee DP et al. Infect Control Hosp Epidemiol.
2008) nasal screening for MRSA to prevent and limit the spread of
infections. Recently, the introduction of various molecular tests for
rapid identiﬁcation of MRSA carriers have improved infection control
procedures by providing results in hours rather than days, as the time
required for colture-based methods. In this study we evaluate the
accuracy of a rapid molecular test, MRSA Advanced Test (Roche), to
detect MRSA colonization among ICU patients, compared with the Xpert
MRSA Assay (Cepheid), FDA (Food and Drug Administration) approved
test and used routinely in our laboratory.
Methods: From December through April 2010, a total of 128 patients
were screened for MRSA carriage at admittance to ICU, by using a
double-shaft swab to sample both nostrils. All nasal swabs were analyzed
by GeneXpert MRSA (Cepheid) and, at the same time, with MRSA
Advanced Test (Roche). Both methods are able to amplify by real-time
PCR the target sequence for MRSA at the SCCmec-orfX junction.
Results: Among the 128 patients examined for MRSA, 12 had a positive
screening result by both molecular methods. Patients who had negative
results were 104 by MRSA Advanced Test and 106 by Xpert MRSA
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Assay. Initially 2 patients had invalid results in the MRSA Advanced
Test and conﬁrmed negative after repeat testing.
Conclusion: In conclusion we demonstrate here that MRSA Advanced
Test, compared to Xpert MRSA Assay, has similar sensitivity and
speciﬁcity. Both tests show high efﬁciency and efﬁcacy compared with
culture methods. In fact they requires few hours to complete the analysis
allowing a shorter turnaround time (TAT) and, by improving patient
management, a better clinical and therapeutic outcome. However the
Xpert MRSA Assay remains a real molecular point of care considering
its remarkable low complexity, the short time required to perform the
analysis and the best time-to-result (less than 70 minutes). This is a start
point for infection control strategies to prevent MRSA spread and for
developing more focused therapeutic measures in all colonized patients.
P911 Evaluation of the BD GeneOhm molecular assays as a
rapid screening tool for detection of methicillin-resistant
Staphylococcus aureus and vancomycin-resistant enterococci
in a tertiary hospital in Saudi Arabia
H. Hassan*, M. Shorman (Dammam, SA)
Objectives: KFSH-Dammam, a tertiary care hospital, has guidelines
for hospital wide screening of new hospital admission for Methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resistant
enterococci (VRE) to limit the spread of antimicrobial resistance within
certain high risk populations. The aim of this study was to evaluate
the diagnostic performance of BD GeneOhm VanR assay, a rapid real
time PCR test that detects the presence of vanA and/or vanB genes. We
evaluated also the performance of BD GeneOhm MRSA which detect the
staphylococcal cassette chromosome mec (SCCmec cassette) carrying
the mecA gene and Staphylococcus aureus speciﬁc sequence located
within the orfX gene.
Methods: Three hundred duplicate rectal swabs collected consecutively
between January 2009 & June 2009 were analyzed for the presence of
VRE by culture and BD GeneOhm VanR Assay PCR. 2267 duplicate
swabs were collected (728 nasal and 1539 groin swabs) between
January 2008 & June 2009 and analyzed for the presence of MRSA
by conventional cultured method and BD GeneOhm MRSA.
Results: Compared to culture, the BD GeneOhm vanR assay showed
a sensitivity, speciﬁcity, positive predictive value (PPV) and negative
predictive value (NPV) of 100%, 91,1%, 23.5% and 100% respectively.
The BD GeneOhm MRSA assay revealed sensitivity, speciﬁcity, PPV
and NPV of 97%, 99.4%, 89.5% & 99.9% respectively for nasal swabs.
For groin swabs, it was 100%, 98.4%, 60.9% and 100% respectively.
Conclusion: The BD GeneOhm vanR assay is a good screening test
for rapid exclusion of VRE carriers in hospitals. In our population
with predominantly vanB colonized patients and poor positive predictive
value, results of the assay should be conﬁrmed by another method for
the presence of VRE. The BD GeneOhm MRSA assay represents a
reliable screening test when applied to nasal and groin specimens. The
true strength of the BD GeneOhm assay for MRSA and VRE is its
exceptionally high NPV making the test an ideal tool for rapid exclusion
of MRSA and VRE carriers in hospitals. As a consequence, this would
dramatically shorten the patient isolation time.
P912 Development of a rapid and simple isothermal molecular
assay for the qualitative detection of Staphylococcus aureus
and methicillin-resistant Staphylococcus aureus directly from
blood culture on a non-instrumented platform
W. Tang, K. Cooper, T. Pack, N. Nasser, T. Ranalli*, R. Lollar,
H. Kong, T. Stenzel (Beverly, San Diego, US)
Background and Objectives: Staphylococcus aureus (SA) is responsible
for approximately 25% of all bloodstream infections, amongst those
26% to 47% are caused by Methicillin-resistant strains (MRSA). The
resulting bacteremia has a mortality rate of 25%-35%, thus the timely
identiﬁcation of SA and MRSA is necessary in order to provide
effective antibiotic therapy. Current traditional methods for identiﬁcation
of SA and MRSA include culture and agglutination testing followed by
oxacillin susceptibility testing, which takes between 16 to 48 hours in
order to obtain results. PCR based methods have been developed that
can be performed in less than two hours, however, these assays require
expensive instrumentation and must be performed in a highly-complex
molecular lab, rather than in a microbiology laboratory, a resource that
many small to medium hospitals do not have access to.
Methods and Results: Helicase dependent ampliﬁcation (HDA) is an
isothermal nucleic acid ampliﬁcation platform that utilizes a helicase
to separate strands of DNA or RNA, rather than heat, allowing for
efﬁcient ampliﬁcation of speciﬁc targets in the absence of thermocycling.
The SA/MRSA assay combines HDA with a disposable self-contained
detection device (BESt™ cassette) that allows for the rapid detection
of labeled amplicons generated by primers and probes speciﬁc for the
Esx A gene (SA) and Mec A cassette (MRSA) simultaneously in only
three pipetting steps. An aliquot from a positive blood culture tube is
diluted and heated to lyse the cells and transferred to a tube containing
the lyophilized HDA reagents. The sample is then incubated at 64ºC
for one hour and transferred to the BESt cassette wherein the result is
read via a lateral ﬂow strip. The entire assay is performed “on-demand”
in less than 1.5hrs without the need for batching of samples. Initial
analytical sensitivity testing determined that the assay can detect down
to 30 copies of both SA and MRSA, and does not cross-react with
any non-SA organisms that have been evaluated. Preliminary evaluation
of the assay with previously characterized clinical samples found that
18/18 MRSA samples and 18/18 SA positive/Mec A negative samples
were correctly identiﬁed.
Conclusion: The HDA-based SA/MRSA assay is a simple and sensitive
molecular assay that is capable of differentiating between SA and MRSA
infections and can be performed in a variety of laboratory settings
without the need for costly equipment.
P913 Evaluation of the impact of a rapid MRSA point-ofcare test
K. Desai, N. Baker, N.P. Brenwald, B. Oppenheim* (Birmingham, UK)
Objectives: MRSA screening of hospital admissions is now a
requirement of hospitals in England; however, the optimal methodology
for screening has not been deﬁned. Sandwell and West Birmingham
Hospitals NHS Trust have chosen to screen emergency admissions by a
rapid point of care PCR method and this study attempts to pull together
data on the impact of this approach on a number of outcomes.
Methods: Patients included in this study were those admitted to an
assessment unit and screened by MRSA POCT. Target patients eligible
for testing were either admitted for >24 hours or transferred to another
ward. During the period of study a total of 4797 screens were undertaken;
312 were positive. 250/312 MRSA positive patients were included in
an audit. Patients environments were screened for MRSA using broth
culture and compared to the environment of patients found to be MRSA
positive by routine culture.
Results: The screening programme has been accompanied by a steady
and sustained fall in MRSA bacteraemia, although many other initiatives
may also have contributed to this. An interesting ﬁnding has been a
steady decline in positivity rates from MRSA screening. Overall, 53%
of patients sampled had a screen result available within 12 hours of
admission and 91% within 24 hours. Overall, 76% of MRSA positive
patients received their ﬁrst dose of mupirocin within 24 hours of their
screen result and 65% received their ﬁrst application of chlorhexidine
within 24 hours. Most patients responded well to their experience of the
screening programme. A small study of environmental sampling suggests
that there might be less environmental contamination with MRSA in the
environment of patients identiﬁed as carriers by the POCT screening
compared with a group who had not been identiﬁed as carriers.
Conclusions: Our study has shown that the introduction of rapid
POCT MRSA screening was accompanied by a sustained fall in MRSA
bloodstream infections and an overall fall in positivity rates for screening.
This may be due to the rapid awareness of MRSA positivity status
and early institution of decolonisation treatment. Preliminary results
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also suggest a possible reduction in environmental contamination around
patients who have had this early intervention.
P914 Genotypic and phenotypic characteristics of methicillin-
resistant Staphylococcus aureus blood isolates with higher
MIC (3mg/L) of vancomycin in Taiwan
W.Y. Wang, S.M. Tsao, Y.L. Lee, T.S. Chiueh, J.J. Lu* (Taichung,
Miao-Li, Taipei, TW)
Background: Staphylococcus aureus, especially methicillin-resistant
S. aureus (MRSA), is a major pathogen that causes bacteraemia and
sepsis with signiﬁcant morbidity and mortality. Infections by MRSA
with higher minimal inhibitory concentration (MIC) of vancomycin (VA)
were reported with treatment failure.
Objectives: The goals of this study were to identify and delineate the
genotypes and phenotypes of MRSA isolates with higher VA MIC from
sterile tissue.
Methods: MRSA isolates from sterile sites were obtained from 2006 to
2009 collection of Tigecycline In-vitro Surveillance in Taiwan (TIST)
and tested of VA MIC with agar dilution. Isolates with higher VA MIC
(3mg/L) were selected for genotyping and phenotyping experiments
including pulse-ﬁeld gel electrophoresis (PFGE), staphylococcal cassette
chromosome mecA (SCCmec), multilocus sequence typing (MLST),
genes encoding protein A (spa) and accessory gene regulator (agr),
direct repeat unit (dru), E-test to daptomycin, disk diffusion to varied
antibiotics, D-test, gene encoding Panton-Valentine leucocidin (pvl), and
superantigenic toxins.
Results: A total of 596 MRSA isolates from sterile site were retrieved
with mean VA MIC of 1.46 (range: 1−3mg/L), in which most were
isolated from blood (551, 92.4%). Ten isolates with VA MIC 3mg/L
were selected, and all were multidrug resistance and negative pvl. Six
isolates were SCCmecIII-ST239-spa t037-agrI-dru7 (1 isolate) and dru14
(5 isolates), 2 isolates were SCCmecII-ST5-spa t586-agrII-dru4, and
one isolate was SCCmecII-ST89-spa t3520-agrIII-dru 7 and the other
isolates was SCCmecIV-ST59-spa t437-agrI-dru8, respectively. Only one
isolate had positive D-test and three isolates were insusceptible to
daptomycin (MIC 1mg/L). Five isolates possessed sea-selk-selq, in
which 4 belonged to SCCmecIII-ST239-spa t037-agrI. Five pulsotypes
were also identiﬁed in ten isolates.
Conclusions: Neither vancomycin-intermediate S. aureus (VISA) isolate
nor vancomycin creep was identiﬁed in the 4-year survey, but elevated
VA MIC in MRSA isolates was noted in Taiwan. MRSA isolates with
VA MIC 3mg/L were few with limited genotypes and corresponding
phenotypes.
P915 Detection of small colony variants among methicillin-resistant
Staphylococcus aureus blood isolates
S. Yagci, B. Sancak, G. Hascelik* (Ankara, TR)
Objectives: Staphylococcus aureus small colony variants (SCVs) are
associated with chronic and persistent infections. Methicillin-resistant
S. aureus SCVs cause more severe infections and mortality rates are
higher in comparison with infections caused by MRSA. Our objective
was to document the prevalence and phenotypical characteristics of
SCVs among MRSA blood isolates.
Methods: MRSA strains isolated from blood during 1999–2009 are
evaluated. Among 299 MRSA isolates, SCV suspected colonies were
inoculated onto Columbia blood agar and Schaedler agar. Columbia
blood agar was incubated in normal atmosphere and Schaedler agar in
5−10% CO2, both at 35ºC. If the small, non-pigmented, non-hemolytic
colonies on Columbia blood agar were seen as normal sized, hemolytic
and pigmented colonies on Schaedler agar, they were considered as
MRSA SCVs.
Results: Among 299 isolates evaluated, six MRSA SCVs are detected.
When subcultures are made, four of them reversed to phenotypically
normal S. aureus, but two isolates were stabile as SCV phenotype. As a
result, the prevalence of SCVs among MRSA blood isolates was found
as % 0,67 (2/299).
Conclusion: This is the ﬁrst report of detection of SCVs among MRSA
blood isolates from Turkey. As the clinical signiﬁcance of MRSA
infections is well documented, evaluation of MRSA SCVs in clinical
samples, especially from intensive care patients and those have chronic
and persistent infections is important to consider.
P916 Susceptibility patterns of S. aureus as predictors of
Panton-Valentine leukocidin positivity
A. Hamprecht*, A.J. Kaasch, P. Wiegel, G. Plum (Cologne, DE)
Objectives: Resistance to some antibiotics (e.g. fusidic acid) is
frequently used as an indicator for Panton-Valentine Leucocidin (PVL)
in Staphylococcus aureus. However its diagnostic value has not
been thoroughly evaluated. This study examines the usefulness of
antimicrobial susceptibility patterns in predicting PVL.
Methods: All S. aureus strains that were tested for PVL between
Sept. 2006 and Nov. 2010 at our institution were retrospectively
analysed. Susceptibility patterns of PVL positive and -negative strains
were compared to each other. Both methicillin-resistant (MRSA)
and methicillin-susceptible S. aureus (MSSA) strains were evaluated
separately. Identiﬁcation and susceptibility testing of S. aureus was
performed by Vitek-2. All isolates were furthermore tested for the
presence of SA442 (S. aureus speciﬁc gene), mecA and lukF gene
(encoding production of PVL) by PCR.
Results: Of 133 strains, mostly from abscesses and blood cultures
with clinical evidence of a possible role of PVL, the lukF gene was
detected in 47 (35.3%) strains (17 MRSA, 30 MSSA); 86 isolates were
negative for PVL (16 MRSA, 70 MSSA). PVL positive MRSA strains
were signiﬁcantly more often ciproﬂoxacin and clindamycin susceptible
(p< 0.05) and occurred more often in younger patients (median age
33 years for PVL+, 62 for PVL-), p< 0.001), mostly men (82.4%).
Sensitivity, speciﬁcity and positive predictive value of susceptibility
patterns (PPV) were 47.1%, 93.8% and 88.9% for ciproﬂoxacin and
52.9%, 81.3% and 75.0% for clindamycin. In MSSA, PVL was also
more common in younger patients (median age 28.5 years, p< 0.001),
regardless of gender.
Conclusion: PVL is an important virulence factor of S. aureus and was
frequently detected (35.3%) in strains which were selected for testing
based on clinical evidence. Most of the positive strains were from young
patients. In our setting, fusidic acid was not a good predictor of PVL,
in contrast to reports from other studies.
Susceptibility patterns such as ciproﬂoxacin and clindamycin susceptibil-
ity in MRSA may serve as an additional aid to initiate PVL testing when
there is an appropriate clinical context (PPV 88.9% and 75%). However,
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the sensitivity and negative predictive value of the described markers
is low and diagnostic algorithms based on antimicrobial susceptibility
patterns alone are therefore of limited utility for the detection of PVL.
P917 Measuring S. aureus exotoxin concentrations using protein
microarrays with antibodies generated by phage display
S. Monecke*, J. Buechler, R. Ehricht (Dresden, DE; San Diego, US;
Jena, DE)
Objectives: Objective of the study was to develop a multiplex microarray
based system for a fast and quantitative measurement of staphylococcal
toxins.
Methods: Puriﬁed native or overexpressed staphylococcal enterotoxins A
and B, toxic shock syndrome toxin, staphylococcal haemolysins a and b,
staphylokinase and Panton Valentine leukocidin (PVL, F-component)
were used to generate different speciﬁc sets of monoclonal antibodies
via phage display. These antibodies were puriﬁed after over-expression in
E. coli, characterised initially by ELISA and spotted in different dilutions
in microtiterstrip-mounted protein microarrays.
Results: For each toxin, all possible combinations of capture and
detection antibodies were tested with microarrays using different
protocols and antigen concentrations in order to ﬁnd the most speciﬁc
and sensitive antibody combination as well as the fastest possible
protocol. These arrays together with a speciﬁcally designed software
algorithm allow one to measure concentrations of single or multiple
staphylococcal toxins in culture supernatants after calibration using
recombinant and native toxins. In a ﬁrst series of experiments, the
expression of PVL by different S. aureus strains under uniform culture
conditions was targeted. PVL from human isolates yielded another
reaction pattern than leukocidin (lukM/lukF-P83) from bovine strains.
Generally, there was a correlation between clonal complex afﬁliation
and PVL yield. Collections of clinical isolates of USA300 (ST8-
MRSA-IV, with a mean of ca. 4,000 ng/mL PVL, F-component), the
Queensland Clone (ST93-MRSA-IV, ca. 5,000 ng/mL), ST93-MSSA
(ca. 6,500 ng/mL) and ST59-MRSA-VT (ca. 3,000 ng/mL) yielded on
average clearly more PVL than other PVL-positive MRSA or MSSA
strains such as, for instance, ST80-MRSA-IV (ca. 250 ng/mL), CC5-
MSSA (ca. 750 ng/mL). Isolates (CC30-MSSA and ST942-MSSA)
harbouring both, tst1 and PVL genes were found to produce no or only
very low amounts of PVL (ca. 140 ng/mL).
Conclusion: The simultaneous measurement of staphylococcal toxins in
high throughput format allows studying toxin gene regulation at different
experimental conditions, strain or clonal complex-speciﬁc variations and
a possible interference between different toxin genes. These issues as
well as, e.g., a potential clinical signiﬁcance of hyper-producing strains
warrant further study.
P918 Extending rapid PCR screening to all Staphylococcus aureus
(MSSA and MRSA): an innovative project at Blackpool
Victoria Teaching Hospital, UK
B. Lunt*, D. Singleton, J. Sycamore, S. Staff, S. Williams,
J. CarterLindsay, R. Palmer, A. Guleri (Blackpool, UK)
Background: Rapid and accurate identiﬁcation of Staphylococcus
aureus[SA]in hospital admissions is essential for timely decisions on
optimal treatment, isolation/bio-burden reduction, and reducing the po-
tential for cross transmission and self acquisition of healthcare-associated
infections (HCAI). Signiﬁcant reductions in MRSA bacteraemias have
been consistently reported from our hospital in previous 2-years. Here
we present the case for extending the PCR based screening programme
to MSSA and MRSA; evaluation of third year of MRSA screening
programme and the innovative trust investment tracking programme.
Methods: Retrospective analysis of infections with SA [MSSA/MRSA];
trends in pre & post 48h MRSA infections; evaluation of clinical/
collateral beneﬁts and hospital investment beneﬁt tracking programme.
Results: 40 MRSA bacteraemias were recorded in 2007−08 against
a target of 26. Reductions of 78% [9bacteraemias]2008−09; 80%
[8bacteraemias]2009−10; 1 bacteraemia [Apr–Nov 2010]. In 2009−10,
a 28% reduction [120/414] in MRSA wound infections.
The rates of MSSA infections including bacteraemia have remained static
over the previous years [2008–10] while consistent reductions in MRSA
infections.
Following from the phenomenal success with reductions in MRSA
infections in previous years, a case was made for extending the trust
screening programme to SA [MSSA and MRSA] since August 2010.
The trust has an innovative investment tracking programme to evaluate
the economic beneﬁts. 4-months is a short period for evaluation, however,
a consistent decline in MSSA bacteraemias [7, 6, 5 and 2] are recorded
during Aug–Nov10. Details to be presented.
Conclusions: Rapidly available SA [MSSA/MRSA] results are routinely
used to complement clinical decision making and optimise treatment in
our hospital. All emergency admissions to hospital are screened using
the PCR method and all electives using the chromogenic culture method.
The cost effectiveness of any HCAI programme is proportional to its
success. The key to success in this model is the teamwork between
CEO, infection control teams, laboratory services and clinical teams
(medical and nursing staff). The body of evidence which supports the
efﬁcacy of rapid screening is growing. A sound business case and return
on investment for the use of rapid diagnostic methods in our hospital
can be made. These technologies also enhance clinical quality, improve
patient safety and reduce the overall cost of SA infections.
P919 Emergence and distribution of Clostridium difﬁcile PCR
ribotype 027 in Hungarian hospitals
G. Terhes*, J. So´ki, K. Latko´czy, L. Szikra, M. Konkoly-Thege, G. Princz,
T. Nagy, H. Osztie, E. Urba´n (Szeged, Budapest, Sze´kesfehe´rva´r, HU)
Objectives: Since 2002, several countries have reported increased
prevalence of infection or outbreaks, which have been attributed to the
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emergent C. difﬁcile PCR ribotype 027. After the recognition of this, the
majority of the affected countries have developed surveillance studies to
monitor the spread of this strain and strict infection control measures
have been implemented. In Hungary, the ﬁrst recognized infection due
to C. difﬁcile PCR ribotype 027 was detected in 2007, after this case,
isolate belonging to this PCR ribotype could not be found among those
strains, which were sent to the Anaerobe Reference Laboratory for
further analysis.
Methods: Up to this time, 203 C. difﬁcile strains isolated from diarrhoeal
faeces of both inpatients and outpatients in 2010 were analysed. The
presence of toxins A and B was detected in local laboratories, while
PCRs were used to detect the presence of tcdA, tcdB and binary toxin
genes in the reference laboratory. If the binary toxin gene PCR gave
positive result, PCR ribotyping was performed.
Results and Conclusion: Until this time, among the examined 203
strains, 102 isolates proved to be positive for binary toxin genes. 100
of them were PCR ribotype 027. 79 strains carried the genes coding
toxins A and B, these strains did not harbour binary toxin genes. In
the case of 22 isolates, tcdA, tcdB and binary toxin genes could not
detected. The majority of strains belonging to PCR ribotype 027 were
isolated from inpatients (93 strains) and from patients over 60 years of
age (81 strains). On the basis of recent ﬁndings, increased prevalence of
hypervirulent PCR ribotype 027 could be observed in hospitals of North
and Northwest Hungary, but because of the lack of culture in several
laboratories and the low sensitivity of some commercial toxin assays,
the outbreak situation will go from bad to worse.
This work was supported by ESCMID/bioMe´rieux grant 2010.
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P920 Colonisation with vancomycin-resistant Enterococcus faecium
in a neonatal intensive care unit in Greece
A. Liakopoulos*, E. Lebessi, A. Mavroidi, A. Doudoulakis,
E. Charachousou, M. Papadimitriou, E. Petinaki (Larissa, Athens, GR)
Objectives: The aim of this study was to determine the incidence of
fecal colonization and the molecular characterization of vancomycin −
resistant Enterococcus faecium (VRE) in a 30-bed, university-afﬁliated,
level II-IV Neonatal Intensive Care Unit (NICU) at a large pediatric
hospital in Athens.
Methods: Routine surveillance rectal cultures of 312 neonates,
hospitalized in our NICU during one year period (from 1 December
2009 to 31 November 2010) were performed by using the campylosel
agar®. Fecal samples were obtained upon their admission and then
weekly, during their stay. The isolation and identiﬁcation were done
using conventional methods and antimicrobial susceptibility was tested
according to the CLSI criteria. The MICs to vancomycin and teicoplanin
were derermined by Etest®. The detection of van genes was assessed
by PCR, while the molecular identiﬁcation was based on Multi Locus
Sequence Typing.
Results: During the study period, a total of 390 neonates were admitted
in our NICU from various maternity hospitals. A total number of 12
Enterococcus faecium (VRE) isolates were recovered from respective
patients (3.08%). Four resistant patterns were observed. The individual
MICs for vancomycin were >256mg/l, whereas for teicoplanin ranged
from 16−64mg/l. All isolates carried the vanA gene. Molecular
identiﬁcation showed that the isolates belonged to two main clones; four
belonged to ST17, seven to ST192 and one to ST64. The strains of
ST17 were isolated from April to May 2010, while the strains of ST192
were isolated the ﬁrst week of September 2010. The strain of ST64 was
isolated upon admission of a neonate referred from a maternity hospital.
All but one strains belonging to two main clones, were NICU − acquired.
Environmental samples were negative for VRE. Strict infection control
measures, such as hand hygiene and patient cohorting, were established
during the two micro-outbreaks in order to eradicate the dissemination
of such strains.
Conclusion: Active surveillance cultures, together with implementation
of other infection control measures were instrumental in controlling VRE
transmission in our NICU.
P921 High-level aminoglycoside resistance in vancomycin-sensitive
and -resistant enterococci
B. Grabein, M. Hoeck, A. Toniolo, B. Wiedemann* for the EPICENTER
Network
Objectives: Despite the interpretation “resistant” for aminoglycosides
(AMGs) streptomycin (S) and gentamicin (G) can be used in
combination therapy for the treatment of infections with Enterococci,
like Endocarditis. However these strains can develop high level resistance
(HL), which renders the respective treatment useless. We wanted to
analyse the data of the EPICENTER network database to see the
development of resistance to vancomycin (VAN) and to aminoglycoside
high level resistance in vancomycin resistant and sensitive Enterococci.
Methods: All three Laboratories participate in the network using
the automated BD PHOENIX-systems measuring MICs. The BD
EPICENTER Data-Management-System is used for the evaluation of the
data in the laboratory and for the transfer of the data for join analysis.
Here the data are interpreted using, appropriate breakpoints. Copy strains
are excluded. Quality control is mandatory. We analysed the data of two
german and one italien laboratory. For this purpose we used EUCAST
break points. High level resistance was determined with gentamicin (G)
500 and streptomycin (S) 1000mg/L as selective criteria.
Results: We analysed 13930 E. faecalis and 4320 E. faecium isolates.
Vancomycin resistance was decreasing over the years from 2005 to
2010 in E. faecalis from 4.3% to 1.2%. 50% of the E. faecalis
VRE strains have high level AMG Resistance. 28% of the strains are
highly resistant to gentamycin and streptomycin (table). The data for
vancomycin sensitive strains are similar: 59 and 27% for high level
AMG and combined high level gentamicin and streptomycin resistance
respectively.
Vancomycin resistance in E. faecium decreased over the period from 15
to 9%. High level resistance in these strains is more common than in
E. faecalis. In VAN sensitive strains 77% of the strains had a high level
AMG resistance. In VAN resistant strains however the incidence of HL
AMG resistance was even 88%.
Conclusion: Vancomycin reistance in E. faecalis and E. faecium
is decreasing. A speciﬁc problem is the high level aminoglycoside
resistance in both VAN resistant and sensitive Enterococci. As high level
aminoglycoside resistance is similar in VAN sensitive and VAN resistant
strains both characters probably occur independently from each other.
P922 Focus and outcome for community-acquired Enterococcus
faecalis bacteraemia
M. Pinholt*, C.Ø. Andersen, M. Arpi, J. Knudsen (Herlev, Hvidovre, DK)
Objectives: To determine the epidemiology and outcome of community-
acquired bacteremia with Enterococcus faecalis.
Methods: We performed a retrospective population-based study of
all patients diagnosed with community-acquired bacteremia due to
E. faecalis at two departments of clinical microbiology in the
Copenhagen area (approximately 1,250,000 inhabitants or 25% of the
Danish population, serving nine public hospitals (3800 somatic beds))
during the period 2006–2009. If a patient had more than one episode,
only the ﬁrst episode was included. Also, Patients with cases of poly-
microbial bacteremia were excluded. Clinical data (age and sex of the
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patient, focus of infection, medical speciality) for patients with positive
blood cultures were collected prospectively and registered in a bacteremia
research database. Vital status and 30-day mortality were obtained from
the Danish Civil Registration System.
Results: During the 4 years study period, 169 patients were identiﬁed.
Twenty-nine percent were females. The median age of the patients was
79 years (range 22−98 years). The foci of infection were as follows:
Urinary tract was the focus in 43%, infectious endocarditis in 26%,
intra-abdominal infection in 5%, and 26% unknown focus. The total 30-
day mortality was 21%, signiﬁcantly highest for patients with unknown
focus 35% (OR: 2.4 (1.1−5.3), p = 0.036), followed by intra-abdominal
infections with 22%, focus in the urinary tract with 18%, and 11% for
patients with infective endocarditis. Two percent of the patients required
intensive care. Most of the patients, 77% were admitted to a medical
ward. Ten patients had relapse of the bacteremia. All the E. faecalis
isolated were susceptible to ampicillin. Two isolates were resistant to
vancomycin. and 28% of patients with infectious endocarditis had a
gentamicin high-level resistant isolate of E. faecalis.
Conclusion: Infective endocarditis was surprisingly often, in 26%, the
focus for the community-acquired E. faecalis bacteremia. From this
ﬁnding, we recommended that echocardiography to all patients with
community-acquired E. faecalis bacteremia should be performed. Most
of the patients were men, 71%, the median age was 79 years, and the
most frequent focus seen was the urinary tract. Our results show that it
is very important for the prognosis to identify the focus of infection, as
patients with, unknown focus have a signiﬁcant worse prognosis.
P923 Increased prevalence of high-level gentamycin resistance
in invasive Enterococcus faecium strains in Norway is
associated with hospital-adapted genetic lineages carrying
virulence determinants and aac(6′)-Ie-aph(2′′)-Ia containing
transferable megaplasmids
T. Pedersen, B. Langnes, K. Hegstad, T.C. Rosvoll, B. Aasnæs,
A.M. Hammerum, C. Lester, G.S. Simonsen, A. Sundsfjord* (Tromsø,
NO; Copenhagen, DK)
Objectives: During 2003–2008 a 10-fold increase in the prevalence
of high level gentamicin resistance (HLGR), to above 50%, in blood
culture isolates of E. faecium in Norway was reported by the Norwegian
Surveillance System for Antimicrobial Resistance (NORM). Here, we
present a molecular epidemiological study of representative invasive
E. faecium strains collected through the NORM system during 2008,
aiming molecular typing and mechanisms involved in the increased
prevalence of HLGR.
Methods: A total of 100 E. faecium strains were genotyped by PFGE
and multilocus sequence typing (MLST). Antimicrobial susceptibility
against clinically relevant antibiotics was determined by agar diffusion
and agar dilution (vancomycin) tests. The presence of HLGR encoding
genes, putative virulence determinants, plasmid replicon (rep) types and
plasmid stabilizing systems were examined by PCR and partial DNA
sequencing. Plasmid linkage of rep- and resistance genes was analysed
by Southern hybridization of S1 treated total DNA separated by PFGE.
In vitro conjugative transfer of HLGR was examined by ﬁlter mating
experiments.
Results: PFGE revealed the presence of a polyclonal collection of
E. faecium, although MLST-results showed that >90% of the strains
belonged to hospital adapted genetic lineages of E. faecium. A high
prevalence of ampicillin resistance (84%), HLGR (56%) and presence
of several virulence associated genes was detected. Neither vancomycin
nor linezolid resistance was observed. HLGR was strongly associated
with the presence of the aac(6′)-Ie-aph(2′′)-Ia gene. This resistance gene
was linked to non-rep-typable transferable megaplasmids (>200 kb) often
carrying the axe-txe plasmid stabilization system.
Conclusion: There is a signiﬁcant increased prevalence of hospital
adapted ampicillin resistant, HLGR E. faecium among invasive strains
in Norway. High level gentamicin resistance is present in 56% of the
strains and linked to transferable megaplasmids carrying the aac(6′)-
Ie-aph(2′′)-Ia gene encoding the bifunctional aminoglycoside modifying
enzyme.
P924 The widespread VRE outbreak in Swedish hospitals
2007–2009 was associated with clonal E. faecium CC17
genogroup strains harbouring several virulence traits and
transferable vanB pRUM-like repA plasmids
A. Sivertsen*, E.W. Lundblad, K.T. Wisell, B. Liljequist, H. Billstro¨m,
M. Ullberg, D. Heimer, I. Sjo¨gren, B. Aasnæs, A. Sundsfjord, K. Hegstad
(Tromso, NO; Stockholm, Huddinge, Halmstad, Va¨stera˚s, SE)
Objectives: To perform a molecular characterization of vancomycin
resistant (VRE) and susceptible (VSE) Enterococcus faecium isolates
from the dominant PFGE clone causing a widespread outbreak in
Swedish hospitals in 2007−09.
Materials and Methods: Outbreak isolates were analysed by PFGE.
Eighteen VRE isolates from 3 Swedish counties as well as two VSE
clinical isolates isolated before the outbreak belonging to the same
PFGE clone were included in the study. All isolates were analysed
by E-test, MLST, and PCRs speciﬁc for vanB2, Tn5382 and virulence
genes. VanB-transfer studies were performed by ﬁlter mating, and
transconjugants were analysed by SmaI and S1 nuclease PFGE and
Southern hybridization.
Results: All VRE-isolates showed vancomycin MICs ranging from 8 to
>256mg/L and susceptibility to teicoplanin, consistent with the vanB2
genotype. 18 isolates including the two VSE belonged to ST192 and
two isolates were single (ST78) and double (ST17) locus variants. Filter
mating with donors containing plasmids of 70 kb resulted in transfer of
larger sized (110–150 kb) pRUM-like repA plasmids harbouring vanB2
integrated in the conjugative transposon Tn5382. The VSE isolates
contained a plasmid with only pRUM-like repA. All isolates contained
8−11 virulence genes and were ampicillin and high-level ciproﬂoxacin
resistant, which all are traits associated with the CC17 genogroup.
Conclusion: The dominant vanB clone of the widespread VRE outbreak
in Swedish hospitals in 2007−09 belonged to the successful hospital
associated CC17 genogroup which contained several resistance and
virulence traits as well as transferable pRUM-like repA plasmids with
acquired vanB2 as part of the conjugative transposon Tn5382.
P925 Emergence of vancomycin-resistant Enterococcus gallinarum
strains carrying acquired glycopeptide resistance
determinants in Stockholm, Sweden
H. Fang*, G. Hedin, A. Ohlsson, A. Kahsai, M. Ullberg (Stockholm, SE)
Objectives: The emergence and spread of glycopeptide resistance
in enterococci has become a signiﬁcant clinical concern. VanA and
VanB are the most common types of the acquired glycopeptide
resistance. VanC-type glycopeptide resistance is intrinsic in Enterococcus
gallinarum, Enterococcus casseliﬂavus and Enterococcus ﬂavescens. The
acquisition of the vanA- or vanB-mediated glycopeptide resistance in
enterococcal species other than Enterococcus faecalis and Enterococcus
faecium has only been sporadically reported. Hereby we report the
detection of three vancomycin-resistant E. gallinarum isolates carrying
both the vanC1 gene and acquired glycopeptide resistance genes (vanA
or vanB) in Stockholm, Sweden.
Methods: The isolates were detected in our routine screening for
vancomycin-resistant enterococci (VRE) by a broth-PCR assay. The
strains were then isolated on the ChromID VRE plates, and further
identiﬁed by biochemical test, mobility test, Vitek 2 system and PCR
for the determination of species and resistance genes. Antimicrobial
susceptibilities were determined by disk-diffusion method or Etest. To
verify the vanA gene in one of isolates, DNA sequencing of the PCR
amplicons was performed. Pulsed-ﬁeld gel electrophoresis (PFGE) was
applied to investigate the clonal relationship of the isolates.
Results: Three vancomycin-resistant E. gallinarum were detected. Violet
colonies were observed on the ChromID VRE plates. In addition to the
vanC1 gene, the vanA determinants were detected in two of them and
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vanB in one isolate. Both vanA isolates were resistant to high levels
of gentamicin (MIC >256mg/L). One of the vanA-harbouring isolates
(EG08001) presented a phenotype otherwise typically seen in VanB-
type strains, with MICs of vancomycin and teicoplanin at 32mg/L and
4mg/L, respectively. The vanA identity of strain EG08001 was further
conﬁrmed by sequencing. The two vanA-carrying VRE isolates displayed
not identical but similar PFGE patterns.
Conclusion: This is the ﬁrst report of the detection of vancomycin-
resistant E. gallinarum strains carrying acquired glycopeptide resistance
determinants in Stockholm, Sweden. Coexistence of the vanC1 genotype
with the vanA or vanB genotype may represent an additional threat for
the control of enterococcal infections, which warrants further attention
for these microorganisms.
P926 Prevalence and rep-PCR typing of vancomycin-resistant
enterococci VanA-type recovered from sewage in Austria
J. Posch*, H. Galler, D. Haas, G. Zarfel, A. Melkes, G. Feierl,
L. Masoud, A.J. Grisold, E. Leitner, E. Marth, F.F. Reinthaler (Graz, AT)
Objectives: The importance of vancomycin-resistant enterococci (VRE)
as a nosocomial pathogene has increased globally in the last decade
in correlation with their ability to acquire high-level resistance against
glycopeptides. Enterococci are also able to reach the environment
persisting in sewage. The aim of the study was to determine the presence
of VRE VanA in sewage and to analyze their genetic relationships to
clinical isolates.
Methods: In 2009 a total of 115 sewage sludge samples from ﬁve
different treatment plants located in the region of Styria were screened
for the presence of VRE. All specimens were cultured on VRE Screen
Agar, after enrichment in Enterococcosel Broth. Routine methods for
identiﬁcation and susceptibility testing were employed. Eight clinical
isolates were recovered from feaces (n = 4) and wounds (n = 4) of
inpatients at the Institute of Hygiene/MU Graz. The detection of the
vanA-gene was done by PCR. To generate molecular ﬁngerprints of the
VanA-strains a semi-automated rep-PCR (DiversiLab®) was performed.
Isolates with >97.5% similarity and maximum one band difference were
characterized as indistinguishable.
Results: 70% of the sewage sludge samples were VRE positive whereas
the majority of the 228 isolated strains were E. gallinarum and
E. casseliﬂavus with intrinsic low level resistance to vancomycin. 9%
of the recovered strains were E. faecium and 7% were E. faecalis. A
total of 11 (5%) E. faecium strains, isolated from sewage sludge of three
treatment plants (A,B,C), harboured the vanA-gene.
Genotyping: Sewage and clinical isolates were discordant. For the 11
sewage isolates the rep-PCR distinguished two clusters including each
three strains from plant A, and one cluster including one strain from
plant A and two from plant B. Two strains were unique. The ﬁngerprints
of the clinical isolates showed minor concordance. They were distributed
in seven different patterns and only two strains had the same genotype.
Conclusion: In the present study no clonal relationships between sewage
and clinical VRE VanA isolates could be observed. Nevertheless we
could prove that VRE is able to persist in sewage. Environmental
spread via sewage sludge, disposed in agriculture, can not be excluded.
Therefore further surveillance of VRE is considered to be important.
P927 The vancomycin-resistant enterococci in drinking water
T. Konstantinidis, I. Alexandropoulou, M. Panopoulou*, E. Alepopoulou,
A. Varelas, A. Milona, T.C. Constantinidis (Alexandrupolis, GR)
Objectives: Enterococci are members of the normal intestinal micro ﬂora
in humans and animals. It has been suggested that the environmental
enterococcal strains could serve as a reservoir of the antimicrobial
resistance genes, which can be transferred to other potentially pathogenic
bacteria. The aim of study was to investigate the prevalence of
vancomycin resistant enterococci (VRE) in drinking water in our area.
Methods: 2000 samples of drinking water were analyzed in East
Macedonia-Thrace region of northern Greece from October 2009 to
November 2010. Water samples (100mL) were processed by a membrane
ﬁltration procedure and ﬁlters were placed in Slanetz-Bartley agar plates
for growth of Enterococcus spp. Membranes with typical colonies were
transferred into a plate of bile -aesculin-azide agar and incubated in
440C for 2 h (ISO 7899). For each positive sample, colonies were stored
at −80ºC in a medium containing 15% glycerol. The strains isolated
were identiﬁed by the automated system Vitek2 and antimicrobial
susceptibility testing was carried out by Vitek2 and E-test (Biomerieux).
Culture of enterococcal strains, grown in blood agar, were diluted in
saline to 0.5 McFarland and spread on Mueller Hinton agar (MHA).
Furthermore, VRE strains were diluted in broth to 2 McFarland and
spread on Brain Heart Infusion agar (CLSI M100-S20 Vol. 30 No 1).
Results: Enterococci (n = 121) were found in 6% of the samples. On
the basis of their biochemical proﬁles, 11 strains were identiﬁed as
E. faecium, 49 as E. faecalis, 10 as E. durans, 10 as E. hirae, 20
as E. gallinarum and 20 as E. casseliﬂavus. Resistance to vancomycin
according to results of Vitek2 was detected in 22 (18.2%) of the isolates
examined, 7 strains belonging to E. casseliﬂavus and 15 to E. gallinarum.
Only 4 strains on MH agar with 0.5 McFarland were found resistant with
MIC <8mg/dl. In contrary with 0.5 McFarland methods, all strains were
found resistant with MIC from 8 to 16mg/dl. Resistance to teicoplanin
was not detected in any of the isolates examined.
Conclusion: Consistent with these ﬁndings, VRE were detected in
samples from drinking water in our area. All VRE strains belonging
to E. casseliﬂavus and E. gallinarum with vanC phenotype according to
results of Vitek2.
P928 In vitro susceptibility of 104 vancomycin-resistant
Enterococcus faecium isolates from clinical specimen against
daptomycin, linezolid and tigecycline
S. Lemmen*, S. Scheithauer, G. Haase, H. Haefner (Aachen, DE)
Background: Vancomycin resistant Enterococcus faecium (VREF) has
become an important nosocomial pathogen world wide. Because of rising
infection rates and limited treatment options we compared the local in
vitro activity of Daptomycin (D), Linezolid (L) and Tigecycline (T)
against VREF.
Methods: 104 VREF were collected between 2004 and 2009 at the
University Hospital Aachen, Germany. The strains were isolated from
clinical specimens only (43 urine, 33 wounds, 15 blood-cultures, 12
catheter-tips, 1 respiratory secretion). Copy strains were excluded. For
identiﬁcation the Phoenix expert system (BD, Germany) was applied
and in vitro activity was detected by E-test-method. Because E. faecium
breakpoints for D and T do not exist, susceptibility values given by CLSI
and FDA for E. faecalis were adopted. Breakpoints for L for E. faecium
were applied according to CLSI.
Results: The MIC values are shown in Figure 1. All strains were
susceptible to D, 103 out of 104 strains (99%) were susceptible to L
and 99 out of 104 strains (95.2%) to T.
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MIC90 values for D were 3mg/mL, for L 1.5mg/mL and for T
0.19mg/mL, respectively. Strains with limited sensitivity to L and T had
MIC values only one step above the breakpoints.
Considering pharmacokinetic data we calculated the rates of Cmax to
MIC90 for the tested antibiotics. Values for Cmax were taken from
the literature (D dose 6mg/kg, L 600mg i.v. and T 100mg: 95mg/ml,
15mg/ml and 1,5mg/ml). The correlating Cmax: MIC90 values for D, L
and T were: 32, 15 and 8, respectively.
Conclusion: D, L and T had excellent in vitro activity against VREF
strains in our hospital. For D the correlation of Cmax:MIC90 was 2x and
4 times higher in comparison to L and T, respectively.
Considering the emergence of multiply resistant pathogen the local
epidemiological data are of importance.
Author Disclosure Information: This study was sponsored in part by
Novartis, Germany. S.L. is a member of the Advisory Board of Novartis.
P929 Susceptibility of 234 clinical isolates of vancomycin-resistant
Enterococcus spp. to teicoplanin, daptomycin, tigecycline,
doripenem and linezolid
M. Diab-El Schahawi*, C. Kratzer, A. Hirschl, V. Dosch, E. Presterl,
W. Graninger (Vienna, AT)
Background: Vancomycin-resistant enterococci are dreaded pathogens
of invasive infections in immunocompromised patients. The frequency
of the isolation of Vancomycin-resistant enterococci from clinical
specimens has been dramatically increasing during the last 5 years at
the University of Vienna.
Objective: The aim of this study was to investigate in vitro activity
of teicoplanin (TEI), daptomycin (DAP), tigecycline (TIG), doripenem
(DOR) and linezolid (LIN) against vancomycin-resistant Enterococcus
spp. (VRE) isolated at the University Hospital of Vienna during 2006–
2010.
Methods: Enterococcal strains, isolated from clinical specimens were
collected and saved at −80 degrees, and then tested against TEI, DAP,
TIG, DOR and LIN using the microdilution method. The minimal and
maximal minimal inhibitory concentration (MIC) (range) was measured,
along with MIC50 and MIC90.
Results: A total of 234 enterococcal isolates were tested against TEI,
DAP, TIG, DOR and LIN, the MIC were determined for each isolates.
For TEI, the MIC50 was 64mg/l (range 0.125–256) and the MIC90 was
128mg/l. For DAP, the MIC50 was 4mg/l (range 0.06–256) and the
MIC90 was 8mg/l. For TIG, the MIC50 was 0.5mg/l (range 0.03−32)
and the MIC90 was 2mg/l. For DOR, the MIC50 was 256mg/l (range
1–256) and the MIC90 was 256mg/l. For LIN, the MIC50 was 2mg/l
(range 0.25–256) and the MIC90 was 4mg/l.
Conclusion: Overall, nearly all isolates were resistant to TEI and
exhibited very high MIC against DAP and DOR. Fifty percent of isolates
exhibited MICs >0.5mg/l against TIG. LIN is still most active againts
VRE as 95.3% of the isolates exhibited a MIC 4mg/l.
P930 Antimicrobial susceptibility of enterococci and streptococci
from United States hospitals: a 9-year summary of the
Daptomycin Surveillance Program (2002–2010)
H. Sader*, P. Rhomberg, D. Farrell, R. Jones (North Liberty, US)
Objectives: To evaluate the activities of daptomycin (DAP) and com-
parator agents tested against enterococci and streptococci (b-haemolytic
[BHS] and viridans group [VGS]) collected from USA hospitals in 2002–
2010. DAP was ﬁrst approved by the USA-FDA in 2003 and by the
European Medicines Agency (EMEA) in 2005; and has increasingly
been used to treat bacteremia and acute bacterial skin and skin structure
infections (ABSSSI) worldwide.
Methods: Unique patient strains of clinical signiﬁcance were con-
secutively collected in 31 USA medical centers and susceptibility
(S) tested in a central reference laboratory against DAP and various
comparators by CLSI broth microdilution methods. Mueller-Hinton broth
was supplemented to 50mg/L of calcium when testing DAP.
Results: 14,044 strains were evaluated, including 5,977 E. faecalis (EF;
95.2% vancomycin [VAN]-S), 3,735 E. faecium (EFM; 79.6% VAN-S),
3,246 BHS and 1,086 VGS. Isolates were mostly from bacteremia
(62%), ABSSSI (15%) and urinary tract infections (13%). DAP-S rates
were 99.97, 99.60, 100.0 and 99.63% for EF, EFM, BHS and VGS,
respectively. VAN resistance (R; MIC, >4mg/L) increased progressively
from 64.9% in 2002 to 79.1% in 2010 among EFM, while VAN-R EF
increased from 2.8% in 2002 to 6.4% in 2008, but decreased to 2.9 and
3.3% in 2009 and 2010, respectively. Only 17 DAP-non-S enterococci
(0.18%) were observed, 2 EF (0.03%) and 17 EFM (0.40%). Importantly,
VAN-S and VAN-non-S enterococci exhibited very similar DAP MIC
distributions (Table). DAP was very active against VAN-non-S EF
(MIC50/90, 0.5/1mg/L) and EFM (MIC50/90, 2/4mg/L). Linezolid was
also very active against EF (MIC50/90, 1/2mg/L; 99.85% S) and EFM
(MIC50/90, 1/2mg/L; 98.5% S). BHS was very S to DAP (MIC50/90,
0.12/0.25mg/L; 100.0% S) and most other antimicrobials tested. DAP
was also highly active against VGS (MIC50/90, 0.25/0.5mg/L; 99.63%
S).
Conclusion: DAP demonstrated sustained activity against an extensive
sampling of clinical isolates of enterococci (including >3,000 VAN-R
strains) and streptococci from numerous USA medical centres over
the last 9 years (99.85% S overall). DAP activity was not adversely
inﬂuenced by R to other antimicrobial classes, including VAN among
enterococci.
P931 Evaluation of enterococcosel broth for detection of
vancomycin-resistant Enterococcus at Royal North Shore
Hospital Sydney, Australia
L.A. Fernandes*, P.G. Huntington, C. Fernandes, G. Kotsiou (St
Leonards, AU)
Objective: In Australia vancomycin-resistant enterococci are mainly
Enterococcus faecium of the vanB phenotype. Vancomycin MICs are
often low, and the sensitivity of detection is greatly improved using
enrichment techniques. Screening may be of value for particular at-risk
patients. Knowledge of VRE colonisation may also prevent subsequent
clinical VRE infection as well as avoid transmission to other patients.
Recent studies using VRE broth enrichment have used a 24-hour
incubation period. However would a 48-hour incubation protocol be more
effective in a routine clinical laboratory setting?
Methods: In this study a method using enterococcosel broth culture
containing 6mg/L vancomycin with up to 48-hour incubation was
evaluated retrospectively for 5156 specimens submitted for VRE
screening during 2009 at Royal North Shore Hospital in Sydney,
Australia.
Results: Patient specimens included faeces (n = 64), rectal swabs
(n = 1974) and swabs from other body sites (n = 31). Swabs collected
from the hospital environment were also screened (n = 2847). Overall
285 patient specimens and 44 environmental specimens were positive
for VRE. These included two E. faecalis vanB, three E. faecium vanA
and 289 E. faecium vanB as conﬁrmed by PCR. PCR was not performed
on 35 repeat positive isolates from patient specimens. Since sensitivity
testing of vancomycin is inﬂuenced by the test medium, MICs were
determined, by agar dilution, on six different media.
Of patient specimens that tested positive for VRE, 125 (43.9%) had
broth with black appearance following overnight incubation (up to 24
hours). An additional 160 (56.1%) had black appearance after a further
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overnight incubation (up to 48 hours). These isolates would have been
missed by a screening protocol that used only overnight incubation.
Of the 44 environmental specimens that tested positive for VRE, only one
(2.3%) had broth with black appearance following overnight incubation.
The rest (43; 97.7%) had black appearance after further overnight
incubation.
Conclusions: These results show that incubation of VRE screening
broths for up to 48 hours recovers a large number of additonal VRE
isolates that would be missed by an overnight incubation protocol.
Consideration should be given to extending broth incubation for VRE
screening in situations where a highly sensitive testing method offers
advantages over delay in results.
P932 In vitro activity of linezolid and comparators against
Enterococcus phenotypes: Europe, 2007–2010
D. Hoban*, B. Johnson, S. Hawser, R. Badal, M. Hackel, S. Bouchillon,
M. Dowzicky (Schaumburg, US; Epalinges, CH; Collegeville, US)
Background: Enterococcus faecium and E. faecalis are signiﬁcant
pathogens both in community and hospital patients causing infections
of the urinary tract, skin/skin structure and blood stream. The increasing
prevalence of vancomycin-resistant Enterococcus sp. worldwide dictates
the continued monitoring of these phenotypes in all countries. The
Tigecycline European Surveillance Trial (T.E.S.T.) evaluated the activity
of linezolid, tigecycline and comparators to over 4100 Enterococcus
isolates in 25 European countries 2007–2010.
Methods: In Europe 489 cumulative sites in 25 countries collected
4197 signiﬁcant Enterococcus species during 2007–2010. MICs were
performed at each site using prepared broth microdilution panels and
interpreted according to EUCAST guidelines.
Results: The % susceptible and MIC90 (mg/L) of tigecycline, linezolid
and comparators to Enterococcus sp. including vancomycin-susceptible
and -resistant phenotypes are shown in the following table.
Conclusions: In Europe 13.0% and 1.3% of E. faecium and E. faecalis,
respectively, were vancomycin resistant during 2007–2010. Linezolid
demonstrated potent in vitro activity against both vancomycin susceptible
and resistant isolates with percent susceptible ranging from 98.8–
100% and MIC90 of 2mg/L regardless of phenotype. Tigecycline
demonstrated percents susceptible ranging from 97.7–100% and MIC90
of 0.25mg/L regardless of phenotype. Tigecycline and linezolid continue
to demonstrate in vitro activity again all phenotypes of Enterococcus sp.
P933 First detection of the trimethoprim resistance gene dfrK in
Enterococcus isolates
M. Lo´pez*, K. Kadlec, S. Schwarz, C. Torres (Logron˜o, ES;
Neustadt-Mariensee, DE)
Objectives: The objectives of this study were to investigate a collection
of vancomycin-resistant and -susceptible enterococci of different species
and origins for the presence of trimethoprim resistance genes with
particular reference to the gene dfrK and its genetic environment.
Methods: In total, 166 Enterococcus isolates of different species
(88 E. faecium, 15 E. faecalis, 14 E. durans/E. hirae, and 49
E. gallinarum/E. casseliﬂavus), recovered from food (50), clinical (50)
and healthy human (34), animal (31) and sewage (1) samples, were
studied (vanA/vanB2: 93, vanC1/2: 59; susceptible: 24). Susceptibility
to trimethoprim and trimethoprim-sulfamethoxazole was assayed by disk
diffusion and agar dilution methods. The gene dfrK and the linkage
of the tetracycline resistance gene tet(L) with dfrK were detected by
PCR and sequencing. One E. faecium isolate was chosen for further
analysis to determine the dfrK environment by inverse PCR, cloning and
sequencing. Screening for other dfr genes known to occur in enterococci
(dfrF and dfrG) was done by PCR.
Results: The gene dfrK gene was detected in 89/166 isolates (54%),
including 41 E. faecium, 12 E. faecalis, 11 E. hirae/E. durans and 18
E. gallinarum/E. casseliﬂavus isolates. The linked tet(L)-dfrK genes were
detected in 17 isolates (19%) (7 E. faecium/vanA, 1 E. faecium/vanB2, 8
E. gallinarum/vanC1 and 1 E. hirae/vanA). Strain E. faecium C1723 was
selected for further analysis. This strain showed a MIC of trimethoprim
of 8mg/L and harboured the dfrK gene, but was negative for the
tet(L)-dfrK linkage. S1 nuclease digests and PFGE-ICeu-I hybridization
revealed the chromosomal location of dfrK. The genetic environment
of dfrK corresponded to a Tn559-like element integrated into the radC
gene. This dfrK-containing Tn559-like element was also detected in 14
other dfrK-positive enterococci. All possible combinations of dfr genes
were detected among the enterococci tested: dfrK, dfrG, dfrF, dfrK+dfrG,
dfrK+dfrF, dfrF+dfrG, dfrF+dfrG+dfrK.
Conclusion: This is the ﬁrst detection of the dfrK gene in Enterococcus.
These data suggest that enterococci may act as recipients of trimethoprim
resistance genes known to occur in other Gram-positive bacteria. The
presence of dfrK in enterococci of different origins and its association
with transposon Tn559 − recently identiﬁed in the chromosomal DNA of
Staphylococcus aureus ST3398 − underlines the resistance gene transfer
between enterococci and staphylococci.
P934 Emergence of tigecycline and linezolid resistance in a
vancomycin-resistant isolate of Enterococcus faecium
M. Hornsey*, D.W. Wareham, J.F. Turton, K. Martin, R. Pike, M. David,
D. Livermore, N. Woodford (London, UK)
Objectives: E. faecium is an opportunistic, nosocomial pathogen which
can cause infections of the urinary tract, wounds and bloodstream. Over
30% of UK isolates of E. faecium are resistant to glycopeptides; mostly
with the acquired VanA phenotype. Resistance to linezolid occurs but
is less common, whereas tigecycline resistance has not previously been
described in E. faecium. We investigated the emergence of linezolid
and tigecycline resistance in a clinical strain of vancomycin-resistant
E. faecium.
Methods: An isolate of E. faecium (designated EF082) was recovered
from the bloodstream of a post-second liver transplant patient who
presented septic with hepatic artery thrombosis and hepatic abscess.
Linezolid therapy was commenced two days later and continued for two
weeks. A second isolate was recovered from the same site one week
after the ﬁrst and was designated EF083. Three months later, after a
second episode of sepsis, the patient received a course of tigecycline.
After nine days of tigecycline therapy a third isolate (designated EF294)
was recovered from a hepatic abscess aspirate. MICs were determined by
agar dilution and Etest on IsoSensitest agar and interpreted according to
BSAC guidelines. PFGE was used to determine isolate relatedness. PCR
was used to screen for tetX and vanA genes. A G2576T mutation in 23S
rRNA genes was sought by PCR-RFLP analysis. Tigecycline resistance
in Staphylococcus aureus has been associated with up-regulation of the
MATE pump, MepA and expression of a mepA-like gene was examined
by real-time RT-PCR.
Results: MICs are detailed in Table 1. All isolates were: (i) indistin-
guishable by PFGE; (ii) PCR-positive for vanA, but negative for the
tigecycline-modifying determinant, tetX. Isolate EF294 had resistance
to tigecycline and linezolid, also to chloramphenicol and telavancin.
The G2576T mutation was identiﬁed in 23S rRNA genes of EF294,
explaining its linezolid resistance. RT-PCR identiﬁed a mean eight-fold
increase in mep-A-like transcript in EF294 compared with EF082 and
EF083.
Conclusions: We report the emergence of resistance to linezolid and
tigecycline, in a vancomycin-resistant clinical isolate of E. faecium, from
a patient treated with these drugs. The linezolid resistance was mediated
by a deﬁned mutation in 23S rRNA genes while tigecycline resistance
was associated with up-regulation of a MATE-type efﬂux pump. The
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mechanism(s) responsible for the reduced susceptibility to telavancin
remain undeﬁned.
P935 Characterising vancomycin-resistant Enterococcus strains
with varying daptomycin resistance developed in an in vitro
PK/PD model
M. Steed, C. Vidaillac*, R. Warren, P. Winterﬁeld, G. Kaatz, M. Rybak
(Detroit, Madison, US)
Objectives: Evaluate two DAP regimens (6 and 10mg/kg/day) in
a pharmacokinetic/pharmacodynamic (PK/PD) model and evaluate
recovered mutants for changes in phenotypic characteristics including
membrane surface charge, membrane depolarization, and cell wall
thickness.
Methods: Three Enterococcus faecium strains VRE ATCC 51559, VRE
12311, and VRE SF 12047 were evaluated in a 7 day 1-compartment in
vitro PK/PD model at a starting inoculum of 108 CFU/mL. Simulated
regimens were DAP 6mg/kg/day (fCmax=7.9mg/mL, T1/2=8 h), and
DAP 10mg/kg/day (fCmax=15.2mg/mL, T1/2=8 h). Samples were plated
daily on Mueller Hinton agar (MHA) supplemented with 50mg/L Ca2+
and containing DAP 16mg/mL to assess for the emergence of DAP
resistance. For each strain, the recovered mutant with the highest DAP
MIC value was then evaluated for changes in relative surface charge
(cytochrome c binding assay), cell wall thickness (transmission electron
microscopy), DAP induced potassium release and cytoplasmic membrane
depolarization (utilizing the membrane potential sensitive ﬂuorescent dye
DiSC3).
Results: DAP MIC values were 4 mg/mL for all 3 strains. A dose
dependent response and re-growth was observed for DAP 6 and DAP
10 against all 3 strains. Mutants of VRE ATCC 51559 (MIC =
128 & 64mg/mL) and VRE 12311 (MIC = 256 and 32mg/mL) were
recovered from DAP 6 and DAP 10, respectively. For VRE SF 12047,
a mutant (MIC = 32mg/mL) was recovered from the DAP 6 model.
All mutants displayed an increase in relative surface charge compared
to their respective parent strains. The DAP resistant mutants displayed
a signiﬁcant (p< 0.0001) increase in cell wall thickness from 30.3 nm
vs. 43.5 nm; 22.2 nm vs. 32.4 nm; 24.9nm vs. 39.5 nm for VRE SF
12047, VRE 12311, and VRE ATCC 51559, respectively. DAP induced
potassium release and membrane depolarization decreased by 10−36%
for the DAP resistant mutants compared to their parent strains.
Conclusion: VRE with elevated DAP MIC values displayed increased
surface charge, increased cell wall thickness, and decreased depo-
larization by DAP which is consistent with previous ﬁndings for
Staphylococcus aureus. Based on MIC values for enterococci, higher
dosages for invasive infections may be required to improve effective kill
and prevent the emergence of resistance.
Coagulase-negative staphylococci
P936 Coagulase-negative staphylococci carrying mecA and other
antibiotic resistance genes among healthy volunteers in the
UK
A. Endimiani*, I. Bertschy, J. Barford, A. Shamaei-Tousi, A. Coates,
B.J.F. Keijser, M. Wilson, V. Perreten (Berne, CH; London, UK; Zeist, NL)
Objectives: Coagulase-negative staphylococci (CNS) represent part of
the normal bacterial ﬂora that colonizes the nose and skin. Although
these bacteria are usually only opportunistic pathogens for immune-
compromised patients, they may serve as a reservoir of antibiotic
resistance genes for more important organisms that co-exist with them
(e.g., S. aureus). Data regarding the resistance genes in CNS strains
colonizing healthy people are lacking. Here, we present a systematic
analysis of antibiotic resistance genes of CNS collected from healthy
volunteers (HVs).
Methods: 5 HVs from UK who had not received antibiotics during the
last year were screened for the presence of CNS strains. Nasal samples
were collected using swabs with Amies-Charcoal transport medium.
Skin samples were obtained using a 2-mm slice of gelatine which was
pressed against the skin and transferred in to 2mL PYG buffer. Samples
were serially diluted in PBS buffer and plated on blood agar (BA)
plus amoxicillin [8mg/L] and BA plus minocycline [0.5mg/L]. Species
identiﬁcation was achieved using MALDI-TOF. Genomic extraction was
obtained using a bacterial DNA kit. A microarray platform was used to
analyze up to 110 antibiotic resistance genes already described among
Gram-positives. Genome sequencing was carried out using the 454
technology.
Results: All HVs were colonized in the nose with at least one CNS strain
harbouring multidrug-resistant (MDR) genotype (i.e., at least 3 genes
conferring resistance to different classes of antibiotics). In particular, 4
out of 5 subjects were colonized with isolates carrying the mecA gene.
These isolates also contained genes conferring resistance to penicillins
[blaZ], tetracyclines [tet(K)] and trimethoprim [dfr(A)]; association with
genes conferring resistance to macrolides [erm(C)] and aminoglycosides
[ant(4)-Ia] was also observed in isolates from 2 HVs. Colonization of
the skin by MDR CNS strains was seen in only 2 HVs; one of them
carried a mecA-positive S. hominis. The whole genome sequencing of
this isolate was obtained.
Conclusion: The present analysis is part of a larger study (ANTIRES-
DEV, 7th RTD Framework of the European Commission) that will
involve more HVs. These preliminary data indicate that healthy people in
the UK can harbour in the nose and skin CNS isolates with an extended
assortment of antibiotic resistance genes. The clinical impact of such a
reservoir of genes and their ability to be shared with other Gram-positives
remains to be evaluated.
P937 Methicillin-resistant Staphylococcus pseudintermedius from
healthy dogs in Spain: novel genotypic and phenotypic
characteristics of this emerging multi-resistant pathogen
E. Go´mez-Sanz*, C. Lozano, C. Aspiroz, C. Torres, M. Zarazaga
(Logron˜o, Zaragoza, ES)
Objectives: To identify the methicillin-resistant coagulase-positive
staphylococci (MRCPS) nasal carriage rate of dogs in Spain, to
determine their antimicrobial resistance and virulence traits, and to
characterize the recovered isolates by different molecular techniques.
Methods: 196 nasal samples from healthy dogs were obtained in
La Rioja (Spain). Following enrichment in nutrient broth with 6.5%
NaCl, samples were cultured on ORSAB plates (OXOID). Isolates
were identiﬁed by species-speciﬁc PCRs, PCR-RFLP (MboI) and
sequencing of sodA and hsp60 genes. All isolates were characterized
by spa-, SCCmec- and MLST/agr-typing, SmaI-PFGE, antimicrobial
susceptibility by disk-diffusion test to 16 antimicrobials, determination
of 33 antimicrobial resistance genes and toxin gene proﬁling (38 toxin
genes).
Results: Methicillin-resistant Staphylococcus pseudintermedius (MRSP)
were recovered from 9 of 196 samples (4.6%), being the only MR
isolates obtained. Seven isolates were typed as ST71(MLST)-III(agr)-
A(PFGE)-t02(spa)-II-III(SCCmec) and showed 4 closely-related SmaI-
PFGE proﬁles. One was typed as ST92-II-B-t06-V and the last one
was ST26-I-C and spa and SCCmec non typable. All ST71-MRSP
isolates presented an unusual inducible cefoxitin resistance phenotype
when placed next to oxacillin disk. MRSP were resistant to [resistance
gene/number isolates]: b-lactams [mecA+blaZ/9], tetracycline [tet(K)/7,
tet(M)/2], macrolides-lincosamides-streptogramins B [erm(B)/9], amino-
glycosides [aac(6)’-Ie-aph(2)-Ia+aph(3’)-III+ant(6′)-Ia/9], streptothricin
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[sat4/9], cotrimoxazole [dfr(G)/9], and cloramphenicol [catpC2217/1].
Eight MRSP isolates were also resistant to ﬂuoroquinolones and showed
amino acid changes at both GyrA [Ser84Leu/8] and GrlA [Ser80Ile/8]
proteins. An extra amino acid mutation [Glu714Lys/7] was detected in
GyrA protein. The presence of the antimicrobial resistance-gene-cluster
(rgc) ant(6′)-Ia-sat4-aph(3’)-III, and a linkage between this rgc and
erm(B) gene was revealed in all MRSP isolates. All isolates harboured
leukocidin genes lukS/F-I, exfoliatin gene siet, and enterotoxin gene
si-ent. Toxin gene hlg-v was only detected in ST26 and ST92 MRSP
isolates.
Conclusions: MRSP is a relatively common (4.6%) colonizer of healthy
dogs, with a major multidrug-resistant MRSP lineage detected (ST71).
Future investigations on the occurrence, pathogenic potential and human
health implications of this emerging spread multidrug-resistant clone are
warranted.
P938 Dissimilar distribution of cassette chromosome recombinase
allotypes among methicillin-susceptible coagulase-negative
staphylococci
M. Miragaia*, J. Rolo, O. Bouchami, H. de Lencastre (Oeiras, PT;
Tunis, TN; New York, US)
Objectives: The essential components of the mobile genetic element
Staphylococcal Cassette Chromosome mec (SCCmec) are the mec
complex and the cassette chromosome recombinases (ccr). The mec
complex contains the determinant of methicillin resistance, mecA (with
or without the regulators mecI and mecR1), and the genes of the ccr
complex are responsible for SCCmec mobility. Eight SCCmec types
have been described so far in S. aureus that result from the combination
of different ccr allotypes and mec complex classes. However, it is not
clear how SCCmec has been assembled and evolved.
In order to better understand the role of different CoNS species in the
evolutionary history of SCCmec, we compared the ccr allotype content
of some methicillin-resistant coagulase-negative staphylococci (MR-
CoNS) and methicillin-susceptible coagulase-negative staphylococci
(MS-CoNS).
Methods: A collection of 427 S. epidermidis (233 MRSE and 194
MSSE), 46 S. haemolyticus (36 MRSH and 10 MSSH) and 45 S. hominis
(34 MRSHo and 11 MSSHo and) were analyzed. The ccrAB and
ccrC presence was detected by Southern hybridization and the allotypes
determined by PCR. The nucleotide sequence of an internal region of
ccrB was determined. SCCmec type was obtained by the ampliﬁcation
of the mec and ccr complexes by PCR.
Results: SCCmec type IV (2B) was the most frequent among MRSE
(93/233, 40%), SCCmec 1A was the most common among MRSHo
(13/34, 38%) and SCCmec V (5C) (10/36, 28%) was the most
widespread among MRSH. Among the susceptible strains of the three
species analyzed 36% of MSSE (69/194), 73% (8/11) of MSSHo and
60% (6/10) of MSSH carried ccr genes. The ccrAB2 allotype was
almost exclusively found among MSSE and ccrAB4 and ccrAB1 were
exclusively found among MSSHo. The ccrC allotype was most frequently
identiﬁed among MSSH (50%, 5/10), but was also present among MSSE
(36%, 25/69) and MSSHo (27%, 3/11). The nucleotide sequence of
ccrB2 from MSSE and ccrB1 and ccrB4 from MSSHo had a very high
homology (>95%) with that of ccrB from SCCmec types IV, I, and
VI/VIII from S. aureus, respectively.
Conclusion: Our results suggest that methicillin susceptible S. hominis
might have been the donors of ccrAB1 and ccrAB4 for the assembly
of SCCmec types I, VI, and VIII in S. aureus, and that methicillin
susceptible S. epidermidis might have been the donors of ccrAB2 for
SCCmec IV.
P939 Prevalence of coagulase-positive staphylococci and
methicillin-resistant coagulase-negative staphylococci in
healthy humans and their companion animals: 6 cases of
interspecies transmission
E. Go´mez-Sanz*, C. Lozano, C. Aspiroz, C. Torres, M. Zarazaga
(Logron˜o, Zaragoza, ES)
Objectives: To detect and identify the CPS and/or MRCNS nasal
carriage rate of healthy humans and their pets and to determine the
potential staphylococcal interspecies transmission.
Materials: 32 unrelated pet-owning households were screened for CPS
and MRCNS nasal carriage in La Rioja (Spain) from June-2009/July-
2010. Forty-four owners and 46 pets (39 dogs, 7 cats) were sampled.
Following enrichment in nutrient broth with 6.5% NaCl, samples were
cultured on ORSAB and Mannitol-Salt-agar plates. Two colonies per
selective plate were analysed. Isolates were identiﬁed by species-speciﬁc
PCRs, PCR-RFLP, and sequencing of sodA gene. All MRCNS isolates
were tested for mecA gene by PCR. All S. aureus were characterized
by spa- and agr-typing. MLST and SmaI-PFGE was conducted in all
isolates suspected of interspecies transmission.
Results: 21 of the 32 households (66%) were positive for CPS and/or
MRCNS. A maximum of 3 distinct strains per individual were obtained.
Twenty owners of the 44 (46%) studied carried CPS and/or MRCNS
with 24 isolates obtained: 17 S. aureus; 2 S. pseudintermedius, and
5 MRCNS. Twenty-two of the 46 studied pets (48%) were positive
for CPS and/or MRCNS with 27 isolates obtained: 6 S. aureus; 12
S. pseudintermedius, and 9 MRCNS. In 11 of 21 positive-households
(52%), both owners and their pets were colonized by CPS and/or
MRCNS. All 14 MRCNS carried the mecA gene and only one
methicillin-resistant (MR) CPS (S. pseudintermedius) from a dog was
obtained. In 9 positive-households (43%) there were mecA-carrying
strains. The agr-types of S. aureus were: agrI (10 isolates), agrII (4),
agrIII (7), and agrIV (2). Sixteen different spa-types were obtained. (No
isolates when more than one): t073 (5), t021 (2), t002 (2), t209 (2),
t151, t440, t159, t015, t091, t1054, t148, t037, t3711, t3906, and a new
spa-type (2). In six cases identical strains by PFGE were isolated from
both owners and their pets: 1 S. aureus (spa)t073-(agr)I-(MLST)ST45-
(Clonal Complex)CC45; 1 S. aureus t209-II-ST109-CC9; 1 S. aureus
t021-III-ST1654(new)-singleton; 1 S. pseudintermedius; 1 MR S. lentus,
and 1 MR S. haemolyticus.
Conclusions: A high rate of households investigated (66%) carried CPS
and/or MRCNS. CPS and/or MRCNS are common colonizers of healthy
humans and their pets, although MR-CPS occurrence is low. In 6 pet-
owning households (19%) both owner and pet carried the same strain
what raises concerns on the potential interspecies transmission of these
microorganisms.
P940 High diversity of genetic backgrounds and SCCmec carried
by coagulase-negative staphylococci from a single host
N.A. Faria*, D.C. Oliveira, M. Miragaia, H. de Lencastre, H. Westh
(Oeiras, Caparica, PT; New York, US; Copenhagen, DK)
Objectives: Coagulase negative staphylococci (CoNS) are recognized
as one of the major causes of nosocomial infections. Isolates cross-
resistant to b-lactams, due to the presence of the staphylococcal cassette
chromosome mec (SCCmec), are of special concern. SCCmec can be
transferred among different isolates and different species; however, the
mechanism, conditions, and reservoirs involved are not known. CoNS
appear to play an important role in the SCCmec evolution, but their
contribution to this process is elusive.
In this study we aimed to contribute to elucidation of the privileged
pathways of SCCmec transmission among CoNS through the detailed
molecular characterization of the genetic background and the SCCmec
carried by CoNS populations inhabiting the same host.
Methods: Sixty-seven Danish volunteers were screened for CoNS
colonization in multiple body sites. Antibiotic susceptibility testing was
performed using the disc diffusion method. Species identiﬁcation was
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performed by VITEK2 system and internal transcribed spacer PCR;
species identiﬁcation was ascertained by RNA16S for speciﬁc cases. All
isolates were characterized by pulsed-ﬁeld gel electrophoresis, SCCmec
typing for the mec complex class and ccr allele by PCR and sequencing
strategies.
Results: Seventeen different Staphylococcus species were identiﬁed
among the 528 CoNS isolates collected. S. epidermidis, S. haemolyticus,
S. hominis, and S. saprophyticus, together, accounted for 70% of the
isolates. Methicillin resistance (MR) was observed in 11 out of 17
species identiﬁed, with an overall prevalence of c.a. 40%, ranging from
4 to 74%. The same individual could be colonized with as many as
5 different CoNS species and 8 different strains. Moreover, MR and
susceptible isolates of the same species could be isolated simultaneously
from the same host. SCCmec types 1A, 2A, 3A, 4B, 5A, 5C, and 7A were
identiﬁed and several isolates were non-typeable. At least 25 different ccr
alleles were found among 68 isolates. Interestingly, the great majority of
isolates colonizing the same individual did not share the same SCCmec
type.
Conclusion: CoNS isolates colonizing a single host were found to be
highly diverse in terms of genetic background and type of SCCmec
carried. The results suggest the absence of SCCmec transfer between
different CoNS strains and species during colonization of a single
individual and/or an extremely fast evolution of the SCCmec among
CoNS.
P941 Prevalence of mecA, clonal relation and linezolid
susceptibility of environmental Staphylococcus epidermidis
M. Hercun, L. Radtke, J. Knobloch* (Lu¨beck, DE)
Objective: S. epidermidis strains causing catheter-associated infections
are often resistant against Methicillin, whereas commensal isolates
from healthy individuals display low prevalence of mecA mediating
Methicillin resistance in staphylococci. The prevalence of mecA as well
as the clonal relation of S. epidermidis strains collected in hospital and
non-hospital environments was analyzed.
Methods: We isolated 1046 strains of coagulase-negative isolates
from hospital environments and non-hospital public environments and
investigated the prevalence of mecA in S. epidermidis strains (hospital:
H-SE; public: P-SE). Additionally the prevalence of the icaADBC gene
cluster was analyzed. The clonal relation of all icaADBC and/or mecA
positive isolates as well as 50 representative isolates of icaADBC- and
mecA-negative strains was determined by MLST. Susceptibility against
Linezolid was determined for all mecA-positive isolates.
Results: In H-SE a signiﬁcant (p< 0.01) higher prevalence of mecA
(19.0%) was observed compared to P-SE (3.2%). Thereby, 13 of
33 mecA-positive H-SE were also positive for icaADBC (39.4%).
In total 80 H-SE and 57 P-SE were characterized by MLST. The
majority of mecA-positive S. epidermidis isolates clustered in one clonal
complex with MLST ST6 as primary founder corresponding to the
epidemiology evaluated in different studies for S. epidermidis isolates
causing foreign body-associated infections. In contrast, the majority of
the mecA-negative STs were characterized as singletons. Interestingly, 6
H-SE with ST2 were mecA-positive, whereas the only P-SE with ST2
was icaADBC-positive and mecA-negative. All 7 H-SE of ST5 were
icaADBC-negative and mecA-positive. In contrast, one of two P-SE
with ST5 displayed a icaADBC-positive and mecA-negative genotype.
All mecA-positive isolates displayed a susceptible phenotype against
Linezolid.
Conclusion: Summarizing the epidemiological data as well as the clonal
relation of the investigated isolates it could be suggested that SCCmec
carrying the mecA-gene predominatly inserted into S. epidermidis clones
which are clonally related. A wide variety of S. epidermidis clones exist
which are not related to the major clonal complex. The rare prevalence
of mecA in these clones indicates that speciﬁc clones are successful to
be transmitted to patients within hospitals causing subsequent infection.
No Linezolid resistant strains were identiﬁed.
P942 Rapid colonisation by methicillin-resistant coagulase-negative
staphylococci of the nose upon hospitalisation
C. McMurray, K. Hardy, P. Hawkey* (Birmingham, UK)
Objectives: To establish the rate of colonisation by methicillin-resistance
coagulase negative staphylococci (MRCNS) of the nose of hospital
inpatients.
Methods: Daily nasal samples were taken from hospital inpatients for the
duration of their hospital admission. Samples were cultured on Columbia
horse blood agar containing Nalidixic acid and Colistin sulphate and
presumptively identiﬁed as coagulase negative staphylococci (CNS)
by colony morphology. Dependent on the number of colonies present
a representative number (1−10 colonies = 1, 10−50 colonies =
3, 50+ colonies = 5) were selected for further identiﬁcation. All
selected isolates were screened using a multiplex PCR to identify
Staphylococcus genus targeting 16S rRNA, Staphylococcus epidermidis,
Staphylococcus haemolyticus, Staphylococcus hominis species targeting
the hydroxymethylglutaryl-CoA reductase (mvaA) gene and the presence
of the mecA gene.
Results: Forty eight patients were included in the study, 24 female and
24 male, with a mean age of 64 years. The mean length of stay was 6.45
days (range 1−21). A total of 1059 isolates were selected for further
identiﬁcation and 1029 conﬁrmed as staphylococci, of which 38.91%,
58.3% and 69.23% were methicillin resistant (MR) S. epidermidis,
S. haemolyticus and S. hominis respectively. MRCNS were isolated from
72.92% (35/48) of patients during hospitalisation, with 34 (97.14%)
of these patients carrying methicllin-resistant S. epidermidis (MRSE).
S. haemolyticus and S. hominis were isolated from only 5 and 12 patients,
with MR strains in 80% (4/5) and 66.67% (8/12) of patients respectively.
Nasal carriage of MRCNS increased from 31.25% (15/48) of patients
on admission to 62.16% (23/37) on day 3 and 76.47% (13/17) on day 7.
After fourteen days of hospitalisation 83.33% (5/6) of patients carried
MRCNS.
Conclusion: Nasal colonisation of MRCNS rapidly increases during a
patient’s hospital admission and may act as a reservoir for resistance to
transfer to S. aureus. This is a unique observational longitudinal study
of MRCNS in the human nasal cavity.
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P943 Antimicrobial activity and spectrum of daptomycin tested
against Gram-positive strains collected in European
hospitals: results from 7 years of surveillance (2003–2009)
H. Sader*, D. Farrell, G. Moet, R. Jones (North Liberty, US)
Objective: To evaluate the in vitro activity and spectrum of daptomycin
(DAP) and comparators tested against clinical isolates from European
(EU) hospitals. DAP is a cyclic lipopeptide approved by EU Medicines
Agency (EMEA) for the treatment of complicated skin and skin structure
infections (cSSSI) and S. aureus (SA) bacteremia and endocarditis.
Methods: 36,759 consecutive strains were collected in 34 medical
centres located in 13 EU countries, Turkey and Israel, including S. aureus
(SA; 18,352; 27.2% MRSA); coagulase-negative staphylococci (CoNS;
6,874; 76.6% oxacillin [OXA]-resistant [R]), Enterococcus spp. (ENT;
7,241; 9.4% vancomycin [VAN]-R), b-haemolytic (BHS; 3,009) and
viridans group streptococci (VGS; 1,176), and S. bovis/gallolyticus (SB;
107). The organisms were isolated mainly from patients with bacteremia
(56%) or cSSSI (23%). The strains were tested for susceptibility (S)
against DAP and comparators by CLSI broth microdilution methods in
cation-adjusted Mueller-Hinton broth with 50mg/L of calcium for DAP
tests.
Results: DAP was very active against SA and CoNS (MIC50/90,
0.25/0.5mg/L for both organisms) and its activity was not adversely
inﬂuenced by OXA-R. MRSA varied from 1.3% in Sweden to as
high as 61.3% in Portugal and 55.9% in Greece. MRSA exhibited
high R rates to levoﬂoxacin (88.7) and clindamycin (40.2%), and
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high S rates to DAP (MIC50/90, 0.25/0.5mg/L; 100.0% S), linezolid
(LZD; MIC50/90, 1/2mg/L; 99.9% S), tigecycline (TIG; MIC50/90,
0.12/0.25mg/L; >99.9% S) and VAN (MIC50/90, 1/1mg/L; 100.0% S).
All E. faecalis were S to DAP. VAN-R E. faecium (VREFM) was
observed in 13 of 15 countries evaluated and was highest in Ireland
(62.4%) and UK (44.2%). DAP (MIC50/90, 2/2mg/L; 100.0% S), LZD
(MIC50/90, 1/2mg/L; 99.7% S) and TIG (MIC50/90, 0.06/0.12mg/L;
99.5% S) were the most active agents tested against VREFM. VAN-S
and -R ENT were equally S to DAP. DAP was also active against BHS
(MIC50/90, 0.06/0.25mg/L; 100.0% S), VGS (MIC50/90, 0.25/0.5mg/L;
99.8% S) and SB (MIC50/90, 0.06/0.12mg/L; 100.0% S).
Conclusions: DAP was highly active against a large collection (36,759)
of Gram-positive (GP) organisms isolated in European hospitals and
its activity remained stable across the 7-year period evaluated (2003–
2009) using reference methods. Decrease in DAP potency has not
been observed since EMEA approval and widespread clinical use, and
emerging R to other compounds did not adversely inﬂuence the DAP
potency against GP species.
P944 Fusidic acid activity and coverage of Gram-positive
pathogens associated with acute bacterial skin and skin
structure infections in the USA (2008–2010)
R. Jones*, D. Farrell, H. Sader, M. Castanheira (North Liberty, US)
Objectives: To determine the susceptibility (S) rates and activity of
fusidic acid (FA; CEM-102) tested against Gram-positive pathogens that
cause ABSSSI, isolated in the USA during 2008–2010 (16,033 strains)
using CLSI reference broth microdilution methods and the EUCAST
(1mg/L) S breakpoint concentration.
Methods: Staphylococcus aureus (SA; 12,062 strains, 52% MRSA),
coagulase-negative staphylococci (CoNS; 2,061 strains, 71% methicillin-
resistant [R]), and 1,910 b-haemolytic streptococci (BHS; 684 group A
and 933 group B). Totals of 4940, 5006 and 6087 strains were tested in
2008, 2009 and 2010, respectively from 65 medical centers in 37 states
including all nine Census Regions. Organisms were predominantly from
bacteremias (61%), ABSSSI (25%) and pneumonia (14%), and tested by
the CLSI M07-A8 method. Non-S SA strains were tested by molecular
methods to detect R mechanisms and by PFGE to determine possible
clonality.
Results: FA was consistently active against SA (MIC90, 0.12mg/L)
across all years (2008–2010) without signiﬁcant change in the S rate
(99.73% at 1mg/L). MRSA and methicillin-S SA had the same
FA-S rates and MIC50/90 results, but MR-CoNS were slightly less S
(90.76%) than MS-CoNS (97.28%) strains. BHS were less inhibited by
FA (MIC50/90, 8/16mg/L), however 99.42% of Group A (S. pyogenes)
isolates were inhibited at 8mg/L (FA PK trough concentration =
80mg/L). 21 SA strains had MIC values at 2−8mg/L with leading R
mechanisms detected of fusA (4; M453I, L461S, A471V + P404L),
fusB (3) fusC (12) and fusE (2; G78 to Q99 deletion). R-mechanisms
were found among all tested strains with FA MIC at 2mg/L or greater.
Clonal occurrences were noted within or between monitored years in 4
hospitals; 3 states (2 in New York).
Conclusions: FA remains highly active against SA (99.73% S) and
other ABSSSI pathogens isolated in the USA. CoNS were slightly less
S at 1mg/L (92.62%) and 99.42% of S. pyogenes were inhibited at
8mg/L. FA-R mechanisms were dominantly acquired (71% fusB or
C). FA appears to be an excellent, orally-administered (with a novel
loading-dose strategy), systemic drug candidate against the relatively
naı¨ve staphylococcal population in the USA.
P945 Antimicrobial activity of ceftaroline tested against common
pathogens causing complicated skin and soft tissue infections
in European medical centres in 2009
P. Rhomberg, D. Farrell, R. Jones, H. Sader* (North Liberty, US)
Objective: To assess the activity of ceftaroline and comparator agents
tested against pathogens responsible for complicated skin and skin
structure infections (cSSTI). Ceftaroline, the active component of the
prodrug ceftaroline fosamil, demonstrates bactericidal activity against
Gram-positive organisms, including methicillin-resistant S. aureus
(MRSA), and common Gram-negative pathogens associated with cSSTI.
Methods: Clinically signiﬁcant, unique (1 per patient) isolates of
S. aureus (n = 1985; 24.6% MRSA) and b-haemolytic streptococci
(BHS; n = 388) were collected consecutively from 27 medical centres
in 11 European (EU) countries, Turkey and Israel in 2009. Isolates
were tested and interpreted for susceptibility (S) by CLSI broth
microdilution methods (M07-A8; M100-S20-U) to ceftaroline and
numerous comparator antimicrobials currently available for cSSTI
treatment.
Results: Ceftaroline was very active against all S. aureus (24.6% MRSA;
highest MIC, 2mg/L). Oxacillin-S S. aureus (MSSA; MIC50 and MIC90,
0.25mg/L) had lower MICs than MRSA (MIC50/90, 1/2mg/L). Against
MSSA, ceftaroline was 2-, 4-, 8-, 16- and 16-fold more potent than
daptomycin (DAP), vancomycin (VAN), linezolid (LZD), ceftriaxone
(CRO) and cefepime (CPM), respectively. MRSA isolates demonstrated
100.0% S to LZD, VAN, DAP and tigecycline, but high resistance to
levoﬂoxacin (LEV; 89.4%), erythromycin (ERY; 65.6%) and clindamycin
(CLI; 32.1%). Against BHS, all isolates were inhibited at 0.03mg/L
of ceftaroline, with the greatest activity (MIC90; mg/L) observed against
group A (0.008mg/L), followed by other BHS (0.015mg/L) and group
B (0.03mg/L). Ceftaroline was 8-, 16-, 32- and 32-fold more potent
than DAP, VAN, LZD and LEV, respectively, against BHS. The lowest S
rates among BHS isolates were observed against CLI (90.2%) and ERY
(82.5%).
Conclusion: Ceftaroline demonstrated strong broad-spectrum activity
against the most common cSSTI pathogens (S. aureus, including MRSA
and BHS) isolated from patients in EU medical centres in 2009. These
data warrant continued clinical evaluation of ceftaroline as a therapeutic
agent for cSSTI.
P946 Analysis of linezolid in vitro activity against Gram-positive
species in Asia − TEST 2004–2010
S. Lob, R. Badal, D. Hoban, J. Johnson*, S. Bouchillon, M. Dowzicky
(Schaumburg, Collegeville, US)
Objectives: Linezolid has shown excellent activity against Gram-positive
organisms since its introduction over a decade ago. The Tigecycline
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Evaluation Surveillance Trial (TEST) examines the susceptibility of
pathogens isolated from a wide variety of infectious processes worldwide
to multiple antimicrobial agents. This report focuses on in vitro
susceptibility trends of Gram-positive pathogens to linezolid over the
past 7 years.
Methods: From 2004–2010, 3,164 Gram-positive isolates from multiple
infection sources were collected at 37 sites in 8 Asian countries.
MICs were performed at each site following CLSI guidelines using
commercially-prepared microbroth panels. Results were interpreted
according to CLSI breakpoints. MIC trends were assessed over time
using Spearman correlation.
Results: The % susceptible, MIC90, and p values for MIC trends for
linezolid are shown in the following table.
Conclusions: Linezolid was universally active against all Gram-positive
isolates collected in Asia between 2004 and 2010, including VRE,
MRSA, and PRSP. There was a slight but statistically signiﬁcant
(p< 0.05) trend toward increasing MICs for E. faecium, MRSA,
S. agalactiae, and penicillin-resistant S. pneumoniae. Since all isolates
were still susceptible, this has no practical consequence; however, the
trend should be monitored.
P947 Comparative in vitro potency of torezolid (TR-700) and
linezolid against key Gram-positive pathogens of European
origin (2009–2010)
C. Pillar, D.F. Sahm, K. Bartizal* (Chantilly, San Diego, US)
Objectives: Torezolid (TR-700) is an investigational oxazolidinone
currently under development for the treatment of acute bacterial skin
and skin structure infections (ABSSSI). Target ABSSSI pathogens of
torezolid include S. aureus, b-hemolytic streptococci, and enterococci.
As part of its development, it is important to establish the activity proﬁle
of torezolid relative to that of linezolid, the only currently marketed
oxazolidinone. This study was conducted to analyze such activity as it
pertains to European isolates of target skin pathogens.
Methods: Non-duplicate, non-consecutive clinical isolates of S. aureus
(N = 444), E. faecium (N = 33), S. pyogenes (GAS; N= 30), S. agalactiae
(GBS; N= 33), and Group C/F/G streptococci (C/F/G; N= 10) were
collected from 18 sites distributed across nine European countries from
2009–2010. Isolates underwent susceptibility testing against torezolid,
linezolid, and other relevant comparators in accordance with CLSI M7
and M100 guidelines at a central laboratory (Euroﬁns Medinet, Chantilly,
VA).
Results: The MIC50 and MIC90 (mg/L) of torezolid and linezolid against
the evaluated pathogens are presented in the table below. Torezolid had
an MIC50 and MIC90 4−8 fold lower than that of linezolid across Gram-
positive species. Among S. aureus, 19% were MRSA; 34% of MRSA had
torezolid MICs 4-fold lower than linezolid while 62% had torezolid MICs
8-fold lower than linezolid. Of the b-hemolytic streptococci resistant to
macrolides (15%), 91% had torezolid MICs 4-fold lower than linezolid.
Among E. faecium, of which 9% were vancomycin-resistant, 52% of
isolates had torezolid MICs that were 4-fold lower than linezolid and
48% of isolates had torezolid MICs that were 8-fold lower than linezolid.
Conclusions: These data demonstrate that the in vitro potency of
torezolid (based on MICs) against key Gram-positive pathogens is
several-fold greater than that of linezolid. It will be of interest to
determine the level of torezolid activity against linezolid non-susceptible
isolates, thus continued surveillance monitoring of oxazolidinone
susceptibility is essential.
P948 In vitro activity of telavancin and comparators against
Gram-positive bacteria isolated from bloodstream infections
H. Seifert*, D. Stefanik, A.J. Kaasch (Cologne, DE)
Objective: The antimicrobial activity of telavancin against 315 clinical
Gram-positive cocci obtained primarily from patients with bloodstream
infections hospitalized at the University of Cologne was evaluated and
compared with other anti-Gram-positive reference drugs.
Methods: Antimicrobial susceptibility testing was investigated by E-test
on 315 non-duplicate, Gram-positive bacterial isolates for telavancin,
vancomycin, teicoplanin, daptomycin, linezolid, and oxacillin. 89% of
isolates were obtained from bloodstream specimens between 2000 and
2010. Isolates included methicillin-susceptible Staphylococcus aureus
(MSSA) (n = 40); MRSA (57, including heteroVISA); vancomycin-
susceptible (VAN-S) Enterococcus faecalis (20); VAN-S E. faecium
(20); vancomycin-resistant (VAN-R) E. faecium with vanA pheno-
type (40); Van-R E. faecium with vanB phenotype (20); oxacillin-
susceptible coagulase-negative staphylococci (CoNS; 47); oxacillin-
resistant CoNS (41); penicillin-susceptible Streptococcus pneumoniae
(20); and penicillin-nonsusceptible S. pneumoniae (10).
Results: The MIC50 and MIC90 values (mg/ml) of the 315 Gram-positive
isolates are summarised in the table.
Conclusion: Telavancin is a promising agent that is highly active against
a wide range of Gram-positive cocci with various underlying resistance
mechanisms with the exception of VRE of the VanA phenotype.
P949 Prostate-derived Propionibacterium acnes isolates are
sensitive to potentially useful antibiotics
J. Olsson*, S. Davidsson, M. Unemo, P. Mo¨lling, S.-O. Andersson,
O. Andre´n, M. Sellin, B. So¨derqvist, F. Elgh (Umea˚, O¨rebro, SE)
Objectives: Bacterial infections of the prostate are increasingly
recognized as a potential risk factor for development of proliferative
diseases as benign prostate hyperplasia and cancer. We and others
have identiﬁed the Gram-positive facultative anaerobic bacterium
Propionibacterium acnes as a frequent inhabitant of prostate tissue.
Currently, we are investigating several aspects of this bacterial infection,
as: prevalence in prostatectomy tissue, genetic variance of isolates from
prostate contra other loci, and the inﬂammatory and proliferative effects
on prostate epithelium. Antibiotic treatment aimed to eradicate the
bacterium might be a therapeutic choice in an empiric strategy for
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prostate conditions. Antibiotic resistance is a signiﬁcant problem among
P. acnes isolated from skin and deep infections, while prostate isolates
are poorly investigated in this respect. The objective of the present study
is to determine antibiotics susceptibility patterns of P. acnes isolated
from prostate in relation to isolates from skin and other locals.
Methods: Prostate-derived Propionibacterium acnes strains and a
panel of control strains collected from skin and deep infections were
assessed, using Etest®, for susceptibility to ciproﬂoxacin, tetracy-
cline, azithromycin, clindamycin, sulfamethoxazole and trimethoprim,
penicillin G, metronidazole, fusidic acid, moxiﬂoxacin, linezolid,
vancomycin, imipenem, piperacillin/tazobactam, gentamicin, rifampicin,
daptomycin, tigecycline, erythromycin, and inducible clindamycin
resistance.
Results: In the reference panel, 5 out of 25 isolates had acquired
macrolide resistance with cross-resistance against azithromycin, clin-
damycine, and erythromycin. One of these was also resistant against
tetracycline. None of the 24 prostate derived P. acnes strains exhibited
acquired resistance to the tested antibiotics. All strains were resistant
against metronidazole, and poorly susceptible to ciproxine, fusidic acid,
moxiﬂoxacin, gentamicin and daptomycin.
Conclusions: P. acnes strains recovered from prostate exhibited less
acquired antibiotics resistance when compared with strains from other
locals.
P950 Determination of the postantibiotic and postantibiotic
sub-MIC effect of vancomycin and daptomycin on
Staphylococcus aureus and Enterococcus faecalis by
isothermal microcalorimetry
C. Zalila, A. Trampuz, A. Bizzini* (Lausanne, CH)
Objectives: The postantibiotic effect (PAE) and the postantibiotic sub-
MIC effect (PA-SME) are important pharmacodynamic parameters
helping to optimize dosing of antibiotics. The current gold standard
for the determination of PAE and PA-SME is the viable counts method,
which is laborious and time consuming. We developed and evaluated
a new method for determination of PAE and PA-SME based on the
measurement of bacterial growth-related heat production.
Methods: Methicillin-susceptible (ATCC 29213, SA1) or methicillin-
resistant (ATCC 43300, SA3) S. aureus strains as well as an E. faecalis
strain (ATCC 19433) were used. Exponential growth cultures (OD600
= 0.3) were exposed to 10 times the minimal inhibitory concentration
(MIC) of vancomycin or daptomycin for 1 hour. At the end of exposure,
antibiotic was removed by dilution. Microcalorimetry was performed in
triplicate on a 48-channel isothermal microcalorimeter (TAM III, TA
Instruments, USA) by adding 30 microliters of the antibiotic-exposed
cultures into ampoules containing 3ml of Mueller Hinton broth. For PA-
SME determination, subinhibitory concentrations of the tested drug at
0.3x the MIC was added to the ampoules after antibiotic removal. Heat
production (in microWatts) was followed at 37ºC. The PAE and PA-SME
was deﬁned as the time (in hours) required to reach 10 microWatts of
heat ﬂow.
Results: Table 1 summarizes the PAE and PA-SME of vancomycin and
daptomycin determined by microcalorimetry. In comparison with the
conventional viable count method, microcalorimetry showed excellent
repeatability, with vancomycin PAE of ca. 1.5 h for all strains. The
daptomycin PAE was signiﬁcantly higher, of ca. 4.5 h (for S. aureus
strains) and 13.2 h (for E. faecalis). The PA-SME increased with higher
sub-MIC concentrations.
Conclusion: Microcalorimetry allows an accurate determination of the
PAE and the PA-SME. In comparison with the conventional viable count
method, microcalorimetry is less labor-and time-consuming. Further
experiments will aim at determining the PAE and PA-SME of various
drug/pathogen combinations.
P951 In vitro development of high-level resistant Viridans group
streptococci upon exposure to daptomycin
R. Akins* (Shreveport, US)
Objectives: Viridans group streptococci (VGS) are a leading cause of
infective endocarditis and bacteraemia. Limited data exists regarding the
activity of newer antimicrobials against these organisms. We evaluated
daptomycin (DAP) 8mg/kg and 6mg/kg doses, linezolid (LZD) and
vancomycin (VAN) against four clinical strains of viridans group
streptococci in a pharmacodynamic simulated endocardial vegetation
model (SEVM) and in kill curves (KCs).
Methods: Four clinical isolates, Streptococcus mitis 1643, Streptococcus
oralis 1647 and 1648 and Streptococcus gordonii 1649, and 1 ATCC
strain, Streptococcus oralis 35037 were utilised. MICs were determined
by broth microdilution per CLSI guidelines. For SEVM, vegetations,
approximately 1010 CFU/g were used and samples were taken over 72
hours for colony counts. KCs assessed activity at 1/2, 1, 2, 4 and 8 times
MIC over 24 hours. Antibiotic peak/trough concentrations utilised: DAP
(8mg/kg) 133/17 and DAP (6mg/kg) 80/10mg/L; LZD 18/4.5mg/L;
VAN 40/15mg/L. Simulated half-life for DAP,LZD,VAN was 8,6,6
hours, respectively. Organism regrowth at 72 hours was assessed for
development of resistance by re-evaluating MICs and by plating samples
on 4 and 8 times DAP-containing plates.
Results: MICs (mg/L) for DAP were 1−2 for the clinical stains and 0.25
for 35037. MICs for LZD/VAN were 1/0.5 for all clinical isolates and
1/1 for 35037. Despite susceptible MICs all DAP and LZD regimens
in SEVM achieved approximately a 1−2 log kill for all clinical isolates
except DAP (8mg/kg) against 1649 (2.7 log kill). Two regimens/strains
increased in CFU/g at 72 hours (DAP 6mg/kg versus 1643 and DAP
8mg/kg versus 1648). VAN achieved approximately 2−>3 log kill for
all isolates. Initial reductions in CFU were noted at 8 hours but within
24−32 hours signiﬁcant regrowth was noted in all SEVM and KCs using
clinical strains except 1649 in DAP (8mg/kg) in SEVM. 35037 had
signiﬁcant regrowth by 48 hours in DAP 8 (mg/kg) with post-exposure
MIC >256mg/L but not in DAP (6mg/kg). Post-exposure MICs for
all clinical isolates except 1649 DAP (6mg/kg) SEVM increased to
>256mg/L.
Conclusions: Susceptible isolates achieved minimal in vitro kill for all
agents and were similar between the SEVM and KCs. There appears to
be high level resistance in VGS to DAP induced upon drug exposure.
Further characterisation of this phenomenon is warranted to determine
mechanism and clinical relevance.
P952 Linezolid resistance due to CFR in a clinical isolate of
methicillin-susceptible Staphylococcus aureus
J.P. Quinn*, G. Harrington, M.M. Lemmon, S. Bittner, M. Huband,
K.D. Ford (Groton, Battle Creek, US)
Objectives: To characterize the molecular mechanism of oxazolidinone
resistance in a linezolid resistant, methicillin-susceptible clinical
bloodstream isolate of Staphylococcus aureus (MSSA).
Methods: Identiﬁcation and susceptibility testing was done using BD
Phoenix®, Etest®, and CLSI broth microdilution. The cfr gene was
identiﬁed by PCR. G2576U mutation was explored by PCR.
Results: A 65 yr old man with pancreatitis underwent multiple
surgical procedures complicated by a perihepatic abscess. He received
multiple broad spectrum antibiotics. He developed line-associated VRE
bacteremia and received linezolid for 18 days. Recurrent fever led to
a second 14 day course of empiric linezolid. At the tail end of this,
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fever developed and he was treated with linezolid for an additional 8
days. Subsequent blood cultures grew MSSA resistant to linezolid (>4
mcg/mL by MicroScan, 8 mcg/mL by broth microdilution, but only
2 mcg/mL by Phoenix). Treatment was changed to nafcillin and the
bacteremia eventually cleared.
The isolate had a phenotype consistent with cfr, displaying resistance
(>64 mcg/mL) to chloramphenicol, clindamycin, erythromycin, and
tiamulin. PCR for cfr was positive. There was no evidence of G2576U
mutation.
Conclusion: To our knowledge this is the ﬁrst reported case of a
linezolid-resistant, cfr positive, clinical isolate of MSSA. All previous
cases have been in MRSA, presumably reﬂecting the selective use of
linezolid in this setting. As in most prior cases of linezolid resistance
in both staphylococci and enterococci, associated either with ribosomal
mutations or cfr, the case was associated with protracted therapy. It is
noteworthy that the BD Phoenix system missed the linezolid resistance.
As cfr is located on a mobile genetic element, future cases are assured.
Consequently, continued vigilance is warranted, especially in the context
of prolonged linezolid use, even in cases of infection due to MSSA.
P953 Study of frequency of metallo b-lactamase among
Pseudomonas aeruginosa strains isolated in clinical samples
in Ilam hospitals, Iran
N. Sadeghifard*, S. Ghafouryan, R. Mohebi, R. Ranjbar (Ilam, Tehran,
IR)
Objectives: Carbapenems are the most potent b-lactam agents with
a broad-spectrum activity against Gram-negative bacteria specially
P. aeruginosa. This study focus on frequency of metallo b-lactamase
including VIM and IMP among P. aeruginosa strains isolated in clinical
samples and positive strains which produced VIM or IMP and or both
of these genes has been affected against tannin.
Methods: Two hundred and forty isolates of P. aeruginosa were obtained
during one-year period from January 2008 to December 2009 in
Ilam Hospitals. Identiﬁcation of organisms was done by the standard
laboratory techniques. Detection of MBL was performed by phenotypic
and genotypic methods. P. aeruginosa producing MBL were tested
against tannin extract.
Results: Of two hundred and forty isolates of P. aeruginosa, 26.6% of
them were MBL positive by phenotypic method. Of sixty-four MBL
positive isolates, 3.1% (n = 2) and 28.1% (n = 18) were positive for
IMP and VIM genes respectively, moreover, 1.5% (n = 1) of them had
both IMP and VIM genes. P. aeruginosa producing VIM and IMP was
inhibited in 10mg/ml and 15mg/ml concentration of tannin respectively.
Conclusion: This study showed that frequency of MBL among clinical
strains of P. aeruginosa was high and most of MBL positive strains had
VIM genes.
P954 Microbiological characteristics of clinically signiﬁcant
Gram-positive bacilli from soft-tissue infections
S.Y. Ng*, J. Sim, L.C. Eng, T. Tan (Singapore, SG)
Objectives: This study was conducted to microbiologically characterize
aerobic Gram-positive bacilli obtained from surgically-acquired samples
in patients with soft-tissue infections.
Methods: Study isolates consisted of aerobic, Gram-positive bacilli
isolated from operative clinical samples in patients with soft-tissue
infections. Only isolates that grew in pure culture were included
in the study. Clinical data was collected from electronic medical
records. Conventional phenotypic identiﬁcation was initially performed
using a commercial identiﬁcation kit (API Coryne, bioMe´urieux).
Genotypic identiﬁcation was performed by comparing 400bp sequence
of the 16s ribosomal gene against datasets available in the BLAST
database (Pubmed). Antimicrobial susceptibility testing was performed
for penicillin, erythromycin, amoxicillin-clavulanate and moxiﬂoxacin
by Etest. Categorical susceptibility was determined by applying CLSI
breakpoints for Corynebacterium spp. or Staphylococcus aureus.
Results: Forty-two clinical isolates were available for inclusion in the
study over a two-year period. The most common isolates identiﬁed by
16sRNA sequencing were aerobically-growing Actinomyces spp. (n = 28,
67%), and Corynebacterium spp. (n = 8, 19%). 36% of isolates were not
identiﬁable by API Coryne, and a further 19% were mis-identiﬁed. Only
32% of Actinomyces spp. were successfully identiﬁed to genus level
by the API test kit, compared with 75% of Corynebacterium spp. The
commonest infections for Actinomyces spp. were pilonidal abscesses,
ischio-rectal and other cutaneous soft-tissue infections. Over two-thirds
of the infections with Actinomyces spp. and were located around
the waist, ischio-rectal and perineal regions. The range of infections
involving Corynebacterium spp. was more varied. Actinomyces spp. were
uniformly susceptible to penicillin and amoxicillin-clavulanate, but some
isolates were not susceptible to erythromycin (36%) and moxiﬂoxacin
(43%). Antibiotic susceptibilities were more varied for the other genera
isolated.
Conclusion: Aerobic Actinomyces species may be an under-reported
cause of bacterial soft-tissue infections, as they represented two-thirds
of all Gram-positive bacilli isolated from mono-microbial soft-tissue
infections and are poorly identiﬁed by phenotypic identiﬁcation kits.
Most study isolates remain susceptible to penicillin and amoxicillin-
clavulanate, while the activities of erythromycin and moxiﬂoxacin are
more variable.
P955 Incidence and spread of multi-resistant methicillin-susceptible
Staphylococcus aureus in southeastern Sweden
M. Lindqvist*, B. Isaksson, L. Nilsson, A. Wistedt, S. Lo¨fgren,
A. Ha¨llgren (Linko¨ping, Kalmar, Jo¨nko¨ping, SE)
Objectives: Since 2004, a multiresistant methicillin-susceptible Staphy-
lococcus aureus (MR-MSSA) strain has caused a clonal outbreak in
O¨stergo¨tland County, Sweden. The clone (spa type t002) was named
ECT-R since it shows resistance to erythromycin, clindamycin and
tobramycin. The objective of this study was to investigate the incidence
of MR-MSSA, and in particular spread of the ECT-R clone, in
southeastern Sweden, a region constituted by the three County Councils
of Jo¨nko¨ping, Kalmar and O¨stergo¨tland between which a high exchange
of patients occur.
Methods: From June 2009 to June 2010 consecutive clinical isolates
of S. aureus from patients within the County Councils of Jo¨nko¨ping,
Kalmar and O¨stergo¨tland were prospectively collected at the clinical
microbiology laboratories of Ryhov Hospital, Kalmar County Hospital
and Linko¨ping University Hospital, respectively. Three different groups
of isolates, with a maximum of 20 isolates/group and location, were
included: group 1: constitutively resistance to clindamycin, group 2:
resistance to tobramycin, and group 3: constitutively resistance to
clindamycin and tobramycin. The isolates were tested for antibiotic
susceptibility with E-test (for antibiotics tested, see table 1). Constitutive
or inducible resistance to clindamycin was determined with the disc
diffusion method. Genetic relatedness was investigated with sequence-
based typing of the polymorphic region X of the staphylococcal protein
A (spa).
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Results: The results of the antibiotic susceptibility tests are presented in
table 1. In total, multiresistance (i.e. resistance to 3 antibiotic classes)
was 24% in group1, 15% in group 2 and 100% in group 3. Whereas
no speciﬁc spa type dominated in group 1, t084 was commonly found
among the isolates in group 2 in all three counties. Combined resistance
to both clindamycin and tobramycin (group 3) was rare, except for in
O¨stergo¨tland County, where the majority of these isolates belonged to
spa type t002.
Conclusion: The ECT-R clone (t002) seemed to continuously have been
spread in O¨stergo¨tland County, but not have reached the other counties in
southeastern Sweden, in spite of the high exchange of patients. However,
isolates with tobramycin-resistance predominantly belonged to spa type
t084. This calls for further investigation.
P956 Streptococcus bovis infection: a comparative study of epidemi-
ology and clinical manifestations between biotypes I and II
R. Plongla*, C. Saunkratay, S. Ngamwongwan, T. Chatsuwan
(Bangkok, TH)
Objectives: There were 2 biotypes of Streptococcus bovis that cause
human infection. Our study was aimed to compare characteristics, risk
factors, and treatment outcomes of infection caused by the two biotypes
of S. bovis.
Methods: A 5-year case-control study was carried out at King Chu-
lalongkorn Memorial Hospital, Bangkok, Thailand. We retrospectively
reviewed all available medical records of adults older than 15 years who
had S. bovis infection from January 2005 to December 2009.
Results: One-hundred and ﬁfty-two patients had S. bovis infection during
the study period. Of this, 12 (7.9%) and 140 (92.1%) infections were
caused by S. bovis biotypes I and II, respectively. There was no difference
in the mean age between the 2 groups (65.8+17.95 and 61+17.00 years
in biotypes I and II, respectively). S. bovis biotype I infection was
signiﬁcantly associated with colonic cancer, compared to biotype II
infection (16.7% and 2.2% of biotypes I and II, respectively) (RR =
8.80, 95%CI 0.72–106.85, p = 0.046). In contrast, S. bovis biotype II
tended to be associated with hepatobiliary diseases (33.7% and 55.6% of
biotypes I and II, respectively) (RR = 2.5, 95%CI 0.66–9.51, p = 0.17).
The clinical spectrum of infections caused by the 2 biotypes was not
signiﬁcantly different: primary bacteremia (66.7% and 51.1% of biotypes
I and II), endocarditis (8.3% and 8.9%). Except spontaneous bacterial
peritonitis and biliary tract infection were only found in S. bovis type II
infection (15.6% and 8.9%, respectively). According to the MIC values,
all isolates were susceptible to penicillin, vancomycin, cefotaxime, and
meropenem. The mortality was comparable (25% and 20% in biotypes
I and II).
Conclusions: Our study showed that S. bovis infection is frequently
observed in the elderly. Each biotype has the unique features. S. bovis
biotype I infection is associated with colonic cancer, whereas S. bovis
biotype II infection tends to be associated with hepatobiliary disease.
Even though all isolates were susceptible to all available antibiotics, the
mortality was relatively high.
P957 Molecular characterisation of group B streptococci isolated
from invasive neonatal infections and colonised pregnant
women in Greece
A. Mavroidi*, S. Vourli, L. Zachariadou, K. Tsiveriotis, F. Kolonitsiou,
A. Liakopoulos, E. Papoutsidou, D. Kairis, M. Oeconomou, L. Zerva,
A. Pangalis, C. Koutsia-Carouzou, E. Malli, A. Vasdeki, S. Xytsas,
M. Panopoulou, S. Kartali-Ktenidou, E.D. Anastassiou, I. Spiliopoulou,
E. Petinaki (Larissa, Athens, Patras, Alexandroupolis, GR)
Objectives: Group B streptococci (Streptococcus agalactiae) is the
causative agent of neonatal meningitis and sepsis and colonise frequently
the genital track of women. The aim of the present study was
the determination and comparison of the genotypes of a nationwide
collection of group B streptococci isolated from invasive neonatal
infections and cervical smears of pregnant women.
Methods: A total of 214 group B streptococcal isolates were collected
from Greek hospitals during the period 2007–2010; 45 were isolated
from invasive neonatal infections and the rest from cervical smears of
pregnant women. Isolation and identiﬁcation of isolates was performed
at each hospital. Isolates accompanied with demographic and clinical
data were collected at the Department of Microbiology of the University
of Larissa, Greece. Serotyping was performed by agglutination test
with speciﬁc antiserum. The genetic relatedness of the isolates was
assessed by Multilocus sequence typing (MLST). Alleles and sequence
types (STs) were compared and determined with those deposited at the
international database (www.mlst.net). Clonal complexes were identiﬁed
by using the e-burst software (www.eburst.mlst.net).
Results: Group B streptococci isolated from invasive disease of neonatal
infections were of serotype III and belonged to distinct clonal complexes
of ST17 (62%) and ST19 (18%). Group B streptococci colonised
pregnant women belonged to STs 1 (31.5%), 23 (28%), 19 (14%),
12 (10.5%) 8 (9.5%) and 17 (6.5%). There were no differences in the
incidence of STs among different regions of the country.
Conclusions: Whereas ST17 is the most frequent ST isolated from
neonatal invasive infections, its prevalence among colonised pregnant
women is low. Therefore, there is no obvious correlation between
the colonisation of pregnant women and neonatal groupB neonatal
infections.
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P958 Pneumococcal serotype distribution in invasive pneumococcal
disease among adults >50 years old in Belgium in 2009
J. Verhaegen*, W. De Backer, B. Delaere, J. Flamaing, W. Peetermans,
P. Van Damme, K. Van Herck, Y. Van Laethem, F. Surmont on behalf
of the Adult IPD Study Group
Objectives: An ongoing Invasive Pneumococcal Disease (IPD) surveil-
lance network in Belgium started in 2009 aiming to:
• document the distribution and antibiotic susceptibility of Streptococ-
cus pneumoniae serotypes responsible for IPD in adults >50 y. of age
• document the mortality and morbidity of IPD in the same population
• estimate the potential coverage provided by the 13-valent conjugated
pneumococcal vaccine.
Methods: Prospective, active surveillance of IPD in hospitalized adults
older than 50 years of age.
Isolation of S. pneumoniae from culture of a normally sterile site
by hospital microbiological laboratories. Fifty hospitals (44% of
acute hospitals) participated in the surveillance network. The clinical
presentation, complications and death caused by an IPD was evaluated
and documented during hospital stay, at discharge and at 1 month
thereafter.
Results: A total of 551 patients older than 50 (mean age 71.7 range
50−88) with IPD were identiﬁed in 1 year. Of these, 442 patients were
evaluable. 340 (76.9%) had pneumonia with bacteremia, 39 (8.8%) had
empyema, 23 (5.2%) had meningitis, 21 (4.8%) had primary bacteremia.
The mean duration of hospitalization was 21 days. ICU admission was
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required for 31% of patients, with a mean duration of 12.6 days. 14%
of patients had sequellae that persisted more than 1 month in 50% of
patients. A total of 78 (18%) died during or within 1 month (6) after
hospitalization.
Serotypes 3 and 19A accounted for 22% of all IPD. The most frequent
types were 19A and 3 in pneumonia and 7F (15%) in empyema. Serotype
19A showed penicillin non susceptibility in 12% of isolates. The highest
mortality was found with serotypes 1, 3 and 5.
61% of the serotypes identiﬁed are included in the 13-valent conjugated
pneumococcal vaccine.
Conclusion: This study shows that serotypes 3 and 19A are the most
frequently isolated in invasive pneumococcal infections in Belgium. IPD
has a high morbidity and mortality with a case fatality rate of 1 in 5.
The serotypes present in the 13-valent pneumococcal vaccine account
for 61% of IPD’s.
P959 Distribution of Streptococcus pneumoniae serotype isolates
from invasive disease in Lombardy, northern Italy
M.L. Garlaschi*, L. Daprai, L. Cariani, M.C. Garlaschi, G. Clarizia,
M. D’Accico, G. Deﬁlippi, A. Bifﬁ, R. Rubini, A. Pavan, E. Torresani
(Milan, IT)
Objectives: Streptococcus pneumoniae is a commensal bacterium in
the human nasopharynx and is the most common cause of severe
infections, most of which may have strong epidemiological impacts,
such as meningitis, otitis media, pneumonia and sinusitis. More than
90 serotypes have been identiﬁed based on the antigenic composition of
the polysaccharide capsule. Some of these serotypes exhibit a distinctive
epidemiology with regard to their potential to cause invasive disease
when occurring in speciﬁc age groups or geographic regions. The aim
of this study is a regional surveillance on serotype distribution of invasive
pneumococci.
Methods: We studied 502 pneumococcal strains isolated from blood
and cerebrospinal ﬂuid, collected between March 2007 and February
2010, sent by clinical microbiology laboratories in Lombardy. The age
of patients ranged from 1 month to 102 yrs old.
Fresh culture of all isolates were sent on blood agar plates and in Amies
medium swab to our laboratory (Regional Pneumococcal Reference
Laboratory Milan, Italy) to be studied. To the reference laboratory, all
the isolates were conﬁrmed as S. pneumoniae by positive tests for alpha
haemolysis on blood agar, optochin susceptibility and bile solubility. The
serotype was determined by the capsular reaction test (Quellung reaction)
using speciﬁc antisera (Statens Serum Institut Copenhagen, Denmark).
Results: All 502 invasive S. pneumoniae isolates collected, were
analyzed. Invasive strains were isolated mainly from blood cultures
(74,8%) or cerebrospinal ﬂuid (25.2%). Age groups were: over 65 years
old (52.4%, GROUP1), 21−64 years old (28.5%, GROUP2), 6−20 years
old (1.0%, GROUP3), less than 5 years old (18.1%, GROUP4). The
serotype involved were 32. The prevalent serotypes, in descending order,
were: 19A (10.6%), 3 (9.4%), 7F (8.6%), 14 (8.4%). The distribution
of S. pneumoniae serotypes according to different patients age strata
was: GROUP1: 3, 19A, 7F, 14; GROUP2: 19A, 1, 7F, 14; GROUP3: not
evaluated (only 5 patients); GROUP4: 14, 19A, 7F, 23F.
Conclusion: The serotype coverage rate by 7-valent and 13-valent
pneumococcal conjugate vaccines among children less than 5 years old,
were 36.3% and 76% respectively. The serotype coverage rate by 23-
valent pneumococcal vaccine among adults over 65 years old and 21−64
years old, were respectively 80% and79%.
P960 Penicillin- and erythromycin-non-susceptible Streptococcus
pneumoniae serotypes in a Greek paediatric population,
2005–2009: replacement of 19F by 19A and 6A
I. Paraskakis, A. Pangalis, J. Papaparaskevas, P.T. Tassios*, H. Kirikou,
A. Charisiadou, L.S. Tzouvelekis, N.J. Legakis, A.Z. Tsakris (Athens, GR)
Objectives: Despite adoption of the heptavalent (7V) anti-pneumococcal
vaccine in 2004 for the <2yo paediatric population in Greece, the
‘Taiwan’ 19F-14/ST236 clone, largely penicillin-non-susceptible and
erythromycin-resistant, had persisted well into 2006 (Mavroidi et al.,
Clin Microbiol Infect 2007). Surveillance of Streptococcus pneumoniae
in children was continued, to assess whether this trend would eventually
change with time.
Methods: Over 2005–2009, 951 infection and carriage isolates from
children accessing two children’s hospitals in the Greater Athens
area (~3,500,000 total population) were serotyped by the Quellung
reaction using commercially available antisera (Statens Serum Institute,
Copenhagen, Denmark). Their susceptibility to antimicrobial drugs,
following 2009 CLSI breakpoints, was assessed by disk test (penicillin,
amoxicillin, cefotaxime, erythromycin, clindamycin, tetracycline, co-
trimoxazole, chloramphenicol, levoﬂoxacin, rifampicin) and, for selected
isolates and drugs, by the strip gradient method (Etest, bioMerieux).
MLSB phenotypes were characterized by the disk approximation
method (erythromycin-clindamycin). This study was conducted within
CAREPNEUMO (FP-Health-2007-B/22311).
Results: Of the 31 serotypes observed, six were represented by >5%
of the isolates: 19F (20.3%), 19A (8.3%), 6B (7.1%), 23F (6.7%), 14
(6.6%) and 6A (5.3). Comparing 2005 to 2009 across all serotypes,
the erythromycin resistance rate had remained relatively stable (from
42% to 47.6%), whilst that of non-susceptibility to penicillin showed
an upward trend (45% to 66.7%), entirely attributable to resistance
rather than intermediate susceptibility. During this period, the 7V vaccine
serotypes decreased, whilst non-7V serotypes increased: most notably,
19A from 2.7% to 24.8%, and 6A from 3.1% to 11.4%. The rate of
resistance to erythromycin was lower amongst 19A and 6A (17% and
55.3%, respectively) than in the initially dominant 19F (85%), as was
the rate of non-susceptibility to penicillin: 66.1% in 19A and 55.2% in
6A, compared to 88.8% in 19F.
Conclusion: Whilst the initially persisting 19F serotype declined from
2007, non-7V vaccine serotypes 6A and 19A increased. This trend was
accompanied overall by relatively stable resistance rates to erythromycin
but increased penicillin non-susceptibility rates, due to all serotypes’
contributions. Surveillance will be continued to monitor the effects of
introducing newer vaccines against more serotypes.
P961 Characteristics of invasive Streptococcus pneumoniae samples
A. Infante*, M.V. Garcia, V. Odero, C. Arana, I. Viciana, M.A. Sanchez
(Malaga, ES)
Objectives: To study evolution of the sensibility of Streptococcus
pneumoniae in the last 10 years, and analyze the presentation, clinical
course and serotypes.
Methods: Retrospective observational study of S. pneumoniae isolated
from invasive samples (blood and CSF) in the HCU Virgen de la
Victoria of Ma´laga, from January 2001 to November 2010. The blood
culture system used was the BD BACTEC 9600 (Becton-Dickinson). The
sensibility study was carried out by E-test method and the interpretation
of the cut-off points were used CLSI standards 2008. Serotyping was
performed on all isolates from 2004 (Instituto Salud Carlos III).
Pneumococci S243
Results: We can see the characteristics of the patients in Table 1. The
sensibility to penicillin was 99% for non-meningeal sites, presenting
a MIC50/90in 0.016 to 0.5 (range: <0016−3) and 99.7% for meningeal
location. As for cefotaxime 95.5% of the cases were sensible to locations
not meningeal, MIC50/90in 0.016 to 0.25 (range: <0016−2) and 93.5%
for meningeal infections. Sensibility to other antibiotics, erythromycin,
tetracycline, clindamycin, moxiﬂoxacin, levoﬂoxacin and cotrimoxazole
was 76.8%, 77.7%, 82.8%, 99.3% and 64.5% respectively.
The crude mortality was 25%, associated with sepsis and/or septic shock
57.6%, 24.3% with meningitis and 16.1% with CAP. Mortality in the
ﬁrst 48 hours was 48.2% and was due to sepsis and/or septic shock in
67% of cases and 25% CAP, however, if it occurred after 48 hours in
a 74.2% of the cases was due to CAP. As the most common serotypes
associated with mortality within 48 hours to 50% were not included in
the heptavalent vaccine (1, 14, 19A, 4, 7F, 3).
Conclusions:
1. S. pneumoniae bacteriemia are more common in men with a mean
age of 60 years, being the most common clinical presentation of CAP.
2. The high mortality (25%), especially in the ﬁrst 48 hours (50%) was
due to serotypes not included in the heptavalent vaccine.
3. b-lactams is still ﬁrst-line treatment at present for both meningeal and
not-meningeal infections.
P962 Serotype distribution and antimicrobial susceptibility of
Streptococcus pneumoniae isolated from children with
invasive pneumococcal infections in Turkey
S. Nar Otgun, R. Durmaz*, A. Gozalan, D. Guldemir, B. Acar,
M. Ertek for the Invasive Pneumococcal Diseases Study Group
Objectives: The aim of this study was to determine the serotype dis-
tribution and antimicrobial susceptibility of Streptococcus pneumoniae
strains isolated from invasive infections among children younger than
ﬁve years of age in Turkey after routine vaccination with seven-valent
conjugated pneumococcal vaccine (PCV-7).
Methods: In the scope of this multi-center study, a total of 287
clinical samples or strains isolated from the invasive infections were
examined in our laboratory from May 2009 to December 2010. Isolates
were serotyped by quellung reaction with the antisera panel (Statens
Serum Institute, Copenhagen, Denmark) and sequential multiplex PCR.
Susceptibilities to penicillin, cephotaxim, meropenem and vancomycin
of the isolates were determined by E-test (AB Biodisk, Solna, Sweden).
Results: A total of 60 pneumococcal strains were recovered from the all
study group. The most frequent serotypes were 19F (20%), 3 (8,3%), 14
(6,7%) and 1 (6,7%). Thirty two of these strains were isolated among
children 5 years old. And also pneumococcal DNA were detected by
sequential multiplex PCR directly from the cerebrospinal ﬂuid of three
cases in this age group. A total of 20 different serotypes/serogroups were
found among children 5 years old, the most frequent being 19F (20%
of the strains), Pool I (8,6%), 6A (8,6%), 18C (5,7%), 9L/N (5,7%), 5
(5,7%%), 3 (5,7%), 1 (5,7%). Vaccine serotype coverages were 34,4%,
48,7%, 65,9% for PCV-7, 10- and 13-valent pneumococcal conjugate
vaccines, respectively. Twenty two strains (68,75%) were susceptible to
penicillin, 7 (21,87%) were intermediate and 3 (9,37%) were resistant.
All strains were susceptible to cephotaxim, meropenem and vancomycin
except one isolate. This one was intermediate resistant to cephotaxim
and meropenem, resistant to penicillin although it was susceptible to
vancomycin.
Conclusions: We have gained some insight on the serotypes and
susceptibility of invasive S. pneumoniae strains in Turkey following to
PCV-7 vaccination. We consider that this multi-center study is a good
background for monitoring the epidemiology of invasive pneumococcal
diseases in Turkey.
P963 Temporal analysis of invasive pneumococcal serotypes from
patients attending a university hospital in Brazil
S.R. dos Santos, E.H. Takagi, L.F. Passadore, C.M. Fujii,
M.B. Martinez* (Sao Paulo, BR)
S. pneumoniae is among the most important pathogens in bacterial
pneumonia, sepsis, and meningitis worldwide. In March 2010, the ten-
valent pneumococcal conjugate vaccine (PCV-10) was introduced into
the childhood immunization schedule in the Brazilian Health Public
Service. This study monitored the population of invasive pneumococci
in University Hospital of University of Sao Paulo (HU-USP) in
the 5 years (2005–2009) preceding the introduction of PCV-10 by
using sequencial multiplex PCR typing, antimicrobial susceptibility and
multilocus sequence typing (MLST). A total of 213 isolates from patients
with invasive pneumococcal disease (IPD) were collected. We examined
pneumococcal isolates from the cerebrospinal ﬂuid (23) pleural ﬂuid
(15), and blood (143) of 181 patients attended at HU-USP. Statistical
analysis was performed using c2 or Fisher’s exact test. The patients’
ages ranged from 3 months to 95 years of age. Some 64.0% were from
children <15 years of age and 36.0% of the isolates originated from
adults >15 years of age. We carried out sequential multiplex PCR typing,
antibiotics sensibility, and multilocus sequence typing (MLST). The PCR
typing showed 23 serotypes, and the leading were 14 (28%), 5 (15%),
6 A/B/C (12%), 12 F/A (9%), 1 (5%), and 19F (4%). The serotypes
signiﬁcantly more common in children were 14, 6A/B/C, 5, and 1, while
among adults, serotypes 5 and 12F/A were predominant. Among children
<2 years old serotypes 14 and 6 A/B/C were signiﬁcantly more prevalent.
Among children aged >2 years and <5 years, serotypes 5 (35%), 14
(30%), and 1 (15%) occurred statistically more frequently; and among
children aged >5 years to <15 years, serotypes 1, 5, and 18A/B/C/F
were overrepresented. Serotypes 5 and 12F/A were statistically more
prevalent among adults aged >15months and <60 years old, while
among adults >60 years old, serotypes 14, 12 F/A, 10A and 23F
were predominant. Among the isolates, 59% showed Penicillin MIC
0,064mg/ml, 40% 0,12 2mg/ml, and 1% 4mg/ml. Moreover, 77%
showed Ceftriaxone MIC 0,5mg/ml, 22% equal to 1mg/ml, and 1%
2mg/ml. The serotype 14 showed the greatest tendency to resistance
to penicillin and ceftriaxone. So far, only one sequence type (156) by
MLST was found among isolates belonging to serotype 14.
Thanks to FAPESP
P964 Impact of pneumococcal vaccination in preventing invasive
pneumococcal disease in Cantabria (Spain)
C. Farin˜as-Alvarez*, M.A. Nun˜ez-Viejo, L. Ansorena-Pool, F. Rojo,
J.A. Sanz-Salanova, J. Llorca, M.C. Farin˜as (Santander, Laredo, ES)
Objectives: To asses the health beneﬁts associated with 23-
pneumococcal polysaccharide vaccine in reducing the risk of pneumoco-
cal invasive disease in a region in the north of Spain where this vaccine
is included in the public vaccination programme for persons aged 65
years and persons aged 2−64 years who have chronic illness from 2000.
Methods: A prospective matched 1:1 case-control study was done from
January 2003 to December 2008 in all National Health System hospitals
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in Cantabria (Spain), (3 hospitals, a total of 1500 beds). All patients 2
years old in whom S. pneumoniae was isolated from any normally sterile
site were identiﬁed by prospective surveillance in the microbiology
laboratories of the three National Health System hospitals in Cantabria.
Isolates of S. pneumoniae were serotiped by the Microbiology National
Center of Spain. For each case, one control was matched according to
age (+/-5 years), gender, site of hospitalization and admission date (+/-2
months) and the condition that constituted the indication for vaccination.
Matched OR, prevention fraction in exposed (etiologic fraction) and their
95% conﬁdence interval were calculated.
Results: From January, 2003 to December 2008, 144 cases and 144
controls were included in the study. The annual incidence was 8.7 cases
per 100,000 population, and the four serotypes more frecuently isolated
were 3, 14, 4 and 19A, all of them are included in polysaccharide vaccine.
In 13,2% of patients were isolated serotypes that were not included in
this vaccine. The pneumococcal polysaccharide vaccine effectiveness in
this case-control study was 11,7% (95%CI = −48,6% to 47,8%).
Conclusion: Pneumococcal polysaccharide vaccine effectiveness was
only 12%. Vaccine effectiveness increases in the months of December,
January and February (coincidence with inﬂuenza season) being 40%.
In addition in patients in whom inﬂuenza vaccine was administered
simultaneously the effectiveness of 23-pneumococcal polysaccharide
vaccine was 31%.
This study was partial ﬁnanced by the Fondo de Investigaciones
Sanitarias (FIS) of Spain, Project number PI021754
P965 Prognostic factors and mortality of invasive pneumococcal
disease in Cantabria (Spain)
C. Farin˜as-Alvarez*, M.A. Nun˜ez-Viejo, C. Fernandez-Mazarrasa,
M.P. Roiz, I. De-Benito, P. Mellado, J. Llorca, M.C. Farin˜as
(Torrelavega, Santander, Laredo, ES)
Objectives: S. pneumoniae infections are among the leading causes
of illness and death worldwide. The objective of this study was to
identify the main factors associated with mortality in patients with IPD
in Cantabria with special attention to the impact of the vaccination with
pneumococcal polysaccharide vaccine in mortality. Cantabria is a region
in the north of Spain, with a current immunization schedule since the
year 2000 that includes the pneumococcal polysaccharide vaccine.
Methods: A prospective multicenter community-based study was done
from January 2003 to December 2008 in the 3 National Health System
hospitals in Cantabria (Spain). All patients in whom S. pneumoniae
was isolated from any normally sterile site were included. They were
identiﬁed by prospective surveillance in the microbiology laboratories.
Data about risk factors, microbiology, clinical course, and mortality
were prospectively collected. Comparison of the means (Student’s t) for
continuous variables and Fisher’s exact test for categorical variables were
applied. Risk Ratios and their 95% Conﬁdence Intervals were calculated.
Results: During the study period, 335 cases of IPD were identiﬁed
(60.0% male). Underlying disease was presented in 65.4% of patients,
been diabetes (21.3%) and COPD (15.5%) the most frequent.
Pneumococcal Bacteremia occurred in 89.6% of cases and meningitis
in 8.1%. Attributable mortality of IPD occurred in 35 cases (10.4%).
Mortality related to bacteremia was 10.3%, whereas mortality in patients
with meningitis was 20.0% (p = 0.17). The pneumococcal polysaccharide
vaccine was administered in 22.1% of the cases, and there was not
signiﬁcant differences in mortality rate in this group compared with the
group of non-vaccinated patients (RR=1.2; 95%CI=0.6−2.5; p = 0.66).
Patients older than 65 years had higher mortality rate than younger
patients (RR= 3.0; 95%CI = 1.4−6.1; p = 0.002). The development of any
complication during hospitalization was the strongest factor associated
with mortality (p< 0.001).
Conclusions: The overall case-fatality rate of IPD was 10.4%, lower than
the reported in other countries. The highest mortality occurred among the
elderly and patients with any complication during hospitalization. The
use of polysaccharide vaccine was not associated with a lower mortality.
P966 Utility of Pneumotest-Latex in serotyping of Streptococcus
pneumoniae directly in clinical samples
A. Golebiewska*, A. Kuch, I. Wasko, P. Ronkiewicz, M. Markowska,
W. Hryniewicz, A. Skoczynska (Warsaw, PL)
Objective: Pneumotest-Latex is a rapid latex agglutination test intended
for serogruping or serotyping of Streptococcus pneumoniae isolates. This
study evaluated the usefulness of Pneumotest-Latex for serotyping of
S. pneumoniae directly in clinical samples from patients with invasive
pneumococcal diseases (IPD).
Methods: The study was performed on 31 clinical samples (CSF =16,
blood = 6, serum = 5, specimens drawn postmortem = 4) with presence
of pneumococcal DNA evaluated by species-speciﬁc PCR. In 12 cases
both clinical samples and isolates were available (CSF = 7, blood =
5). Additionally, 18 clinical samples (blood = 7, serum = 1, CSF = 6,
specimens drawn postmortem = 4) from patients with meningococcal
invasive diseases (IMD) were used for serotyping as negative controls.
Clinical samples and strain suspensions were heated at 100ºC and
centrifuged. Obtained supernatant were used for the Pneumotest-Latex
and performed according to the manufacturer’s instructions. For all
samples and strains the PCR with available primers, were run to establish
speciﬁc serotypes (1, 2, 3, 4, 5, 6A/B/C/D, 7, 8, 9V, 10A, 11A, 12 A/F,
14, 15A/B/C, 16F, 17F, 18C, 19A/F, 20, 22F, 23F, 24A/F, 31, 33, 34,
35 B/F and 38). Furthermore, serotypes of S. pneumoniae isolates were
conﬁrmed by the Quellung reaction.
Results: Pneumotest-Latex has given consistent results of serotype or
serogroup identiﬁcation with PCR reactions for 20 (65%) of the 31
samples tested. Four (13%) and two (6%) samples were typeable only by
one of the methods, Pneumotest-Latex or PCR, respectively. All 5 serum
samples were non typeable by any methods used. In the cases when we
have had both, clinical sample and isolate we noticed the complete results
compliance of Pneumotest-Latex and Quellung reaction. According to
its level of discrimination the technique was able to type (serogroup or
serotype) correctly 26 of 31 clinical samples (71%). If serum samples
would be excluded, the level of discrimination increases to 92%. All 18
samples from IMD cases were found to be negative by Pneumotest-Latex
and PCR serotyping.
Conclusion: Pneumotest-Latex may be a useful tool for serotyping of
S. pneumoniae directly in clinical samples from patients with IPD, with
the exception of blood serum samples. This is easy and rapid test
which can be used for epidemiological surveys of serotype distribution,
especially after the introduction of pneumococcal conjugate vaccines.
P967 Clinical and bacteriological efﬁcacies of sitaﬂoxacin against
community-acquired pneumonia caused by Streptococcus
pneumoniae: a multicentre clinical trial
J. Fujita*, S. Kohno (Okinawa, Nagasaki, JP)
Objectives: Fluoroquinolone-resistant Streptococcus pneumoniae is
increasing worldwide. It has been reported that a recently devel-
oped ﬂuoroquinolone; sitaﬂoxacin is effective against ﬂuoroquinolone-
resistant St. pneumoniae. Under this background, clinical efﬁcacy of
oral sitaﬂoxacin was evaluated against clinically-diagnosed community-
acquired pneumonia (CAP) caused by St. pneumoniae.
Methods: This study is a prospective and multicenter clinical trial.
The diagnostic criteria of CAP was as follows; acute appearance of
consolidation in chest x-ray and/or chest CT within 48 hours before
treatment, existence of purulent sputum, and increase of white blood
cells (more than ULN) or increase of C-reactive protein (more than
1.0mg/dL). In addition, existence of at least 1 ﬁnding among fever
more than 37ºC, respiratory symptom (cough, dyspnea or chest pain),
crackles, was also required. Among these CAP patients, the diagnosis
of St. pneumoniae pneumonia was performed with a positive urinary
antigen of St. pneumoniae and/or a positive culture of St. pneumoniae
from the sputum. Cases in whom respiratory pathogens other than
St. pneumoniae were cultured from sputum were excluded. After the
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diagnosis of CAP caused by St. pneumoniae, sitaﬂoxacin (50mg ×2, or
100mg ×1) was orally administered for 7 days.
Results: Sixty-three patients were eligible for this study. In 56
patients, St. pneumoniae was cultured from the sputum and only
urinary antigen was positive in 7 patients. The urinary antigen
test was positive in 46 patients among 62 patients (46/62, 74.2%,
urinary antigen test was not performed in 1 patient). Clinical
efﬁcacy of sitaﬂoxacin could be evaluated in 62 patients among
63 patients (clinical follow-up data could not be available in 1
patient). Clinical improvement of CAP was obtained in 60 patients
among 62 evaluable patients (60/62, 96.8%). Bacteriological effect
of sitaﬂoxacin could be evaluated in 56 patients, and eradica-
tion of St. pneumoniae was observed in 54 patients among 56
evaluable patients (54/56, 96.4%). In 2 patients, eradication of
St. pneumoniae was not achieved instead of clinical improvement of
CAP.
Conclusion: These ﬁndings demonstrated the clinical as well as
bacteriological effectiveness of sitaﬂoxacin in the treatment of CAP
caused by St. pneumoniae.
P968 FOCUS 1 and 2: Streptococcus pneumoniae subset analyses
from two phase III trials of ceftaroline fosamil vs ceftriaxone
in the treatment of community-acquired pneumonia
P.B. Eckburg*, I. Critchley, H.D. Friedland, L. Llorens, D. Thye
(Oakland, US)
Objectives: Ceftaroline fosamil (prodrug of the active component
ceftaroline [CPT]) is a novel, parenteral, broad-spectrum cephalosporin
that has previously demonstrated efﬁcacy and safety in the treatment of
community-acquired pneumonia (CAP) in the FOCUS trials (File et al.,
2010). Herein we present a subset analysis of those patients who had
Streptococcus pneumoniae identiﬁed as a baseline pathogen.
Methods: FOCUS 1 and FOCUS 2 were global, double-blind trials in
subjects who were hospitalised for moderate to severe CAP (Pneumonia
Outcomes Research Team [PORT] risk class III or IV) requiring
intravenous (IV) therapy. Subjects were randomised to receive IV CPT
fosamil 600mg q12h or ceftriaxone (CRO) 1 g q24h for 5 to 7
days. Treatment groups were comparable in terms of dosing days and
PORT scores; 51% of CPT and 47% of CRO subjects had CAP of
PORT Risk Class IV. Clinical cure and microbiological response were
evaluated 8 to 15 days post-therapy at the test-of-cure visit in the
CE and MITTE populations. This subset analysis further evaluated
results by S. pneumoniae baseline MIC, serotype, and bacteraemia.
Susceptibility testing was performed by broth microdilution and disk
diffusion tests.
Results: S. pneumoniae was identiﬁed among 69 of 182 baseline
pathogens from the CPT group (24 tested; MIC90, 0.06 mcg/mL; range,
0.004–0.25 mcg/mL) and 70 of 188 pathogens from the CRO group (27
tested; MIC90, 1 mcg/mL; range, 0.015−2 mcg/mL). S. pneumoniae
was identiﬁed by positive urine antigen alone for 40.6% (28/69) of
the isolates in the CPT group and 44.3% (31/70) of the isolates in
the CRO group. Rates of clinical cure and favourable microbiological
response in subjects with baseline S. pneumoniae were 85.5% and 87.0%,
respectively, in the CPT group compared with 68.6% and 72.9% in the
CRO group (Table). Clinical response was consistent across a range of
S. pneumoniaeMICs and diverse serotypes, including serotypes 10, 15A,
and 19A. Of the 29 cases of bacteraemia caused by S. pneumoniae, rates
of clinical cure were 82.4.% (14/17) in the CPT group and 66.7% (8/12)
in the CRO group.
Conclusion: CPT fosamil was associated with higher clinical cure
rates than those for ceftriaxone among subjects with CAP caused
by S. pneumoniae, including subjects infected with MDRSP. CPT
was efﬁcacious across the MIC distribution and diverse serotypes of
S. pneumoniae, including non-vaccine serotypes, and for patients with
S. pneumoniae bacteraemia in the FOCUS trials.
P969 Nasopharyngeal carriage of pneumococcal and other respi-
ratory bacteria in community-dwelling asymptomatic elderly
A.M. van Deursen*, M.R. van den Bergh, E. Hak, R.H. Veenhoven,
M.K. Sidhu, P. Zhao, M.J. Bonten, E.A. Sanders (Utrecht, Groningen,
Hoofddorp, NL; Pearl River, US)
Objective: Streptococcus pneumoniae is a common cause of pneumonia,
sepsis, and meningitis among the elderly. The aim of this study was to
evaluate the prevalence of nasopharyngeal carriage of S. pneumoniae
and its serotype distribution in asymptomatic non-institutionalized
elderly in the Netherlands prior to the introduction of the 7-valent
conjugate vaccine for infants in the national immunization programme
in June 2006. Additionally, carriage rates of other common respiratory
bacteria and possible risk factors for pneumococcal carriage were
evaluated.
Methods: A cross-sectional study was conducted in a random sample
of 330 community-dwelling subjects aged 65 years or older (median
age: 72.7; IQR: 68.7–79.0). Information on possible risk factors were
obtained by questionnaire. Both transnasal and transoral nasopharyngeal
samples were collected. Nasopharyngeal carriage of S. pneumoniae was
identiﬁed by conventional culture and PCR (lytA and ply). Pneumococci
identiﬁed by culture were serotyped by Quellung reaction. Pneumococci
detected by PCR were molecularly serotyped.
Results: Nasopharyngeal pneumococcal carriage rate, using both
conventional culture and PCR, was 22.8% (95%CI: 18.3–27.4).
Pneumococci were detected more frequently in transorally obtained
samples (18.8%; 95%CI: 14.6–23.1) than in transnasally obtained
samples (11.1%; 95%CI: 7.7–14.5). Pneumococcal carriage rates
detected with conventional cultures (25 positive isolates; 7.6%; 95%CI:
4.7–10.4) were lower than with PCR analyses (71 positive PCR-
results; 21.9%; 95%CI: 17.4–26.4). Strains covered by the 13-valent
pneumococcal conjugate vaccine were frequently carried (40.6% of
all serotyped isolates by Quellung reaction; 76.7% by PCR). Of all
potential risk factors, only regular contact with children under the age
of ﬁve appeared to increase nasopharyngeal pneumococcal carriage (OR
1.62; 95%CI: 0.95–2.78; p = 0.077). Carriage rates for S. aureus were
17.0% (95%CI: 12.9–21.0), H. inﬂuenzae 10.0% (95%CI: 6.8–13.2),
and M. catarrhalis 8.5% (95%CI: 5.5–11.5). Carriers of S. pneumoniae
were more likely to be co-colonized with S. aureus (OR 3.73; 95%CI:
1.59–8.87; p = 0.001) and H. inﬂuenzae (OR 6.59; 95%CI: 2.63–16.47;
p< 0.001).
Conclusions: Approximately one in ﬁve elderly carries S. pneumoniae
and those persons have increased risks of colonization with other
respiratory bacteria. Regular contact with children under ﬁve years of
age appears to increase pneumococcal carriage.
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P970 A pilot study of serotype distribution and antimicrobial
resistance of nasopharyngeal isolates of S. pneumoniae from
healthy toddlers in Evros, Greece
E. Mantadakis*, D. Themelidis, M. Panopoulou, S. Maraki,
E. Alepopoulou, S. Kartali, A. Chatzimichael (Alexandroupolis,
Heraklion, GR)
Objective: To study the serotype distribution and antibiotic suscepti-
bilities of nasopharyngeal (NP) isolates of Streptococcus pneumoniae
(SP) in children attending day care centres (DCC) in the area of
Alexandroupolis, Thrace, Greece.
Methods: From February 4 through March 17, 2010, we obtained NP
samplings from 184 healthy children aged 24 to 78 months (median age
65 months) attending 13 DCC. These children constituted 41% of the
total number of children enrolled in these DCC. Antibiotic susceptibility
testing was performed by E-test. Results were interpreted according
to the 2010 CLSI criteria, except for ciproﬂoxacin, where the Eucast
2010 breakpoints were used. Multi-resistance was deﬁned as resistance
to 3 classes of antibiotics. Pneumococcal isolates were serotyped by
the Quellung reaction using the 12 pooled antisera Pneumotest panel and
speciﬁc factor sera.
Results: Approximately 98% of the children had received 1 dose
of PCV7. Overall, 48 (26%) of the children sampled carried SP in
their nasopharynx. The percentage of SP carriers ranged between 0
and 69.2% among the DCC sampled. Among the 48 SP isolates, 16
belonged to PCV7 serotypes, i.e., 6B (4), 14 (2), 19F (3) and 23F
(7), 16 belonged to the 6 additional serotypes of PCV13, i.e., 3 (6),
7F (3), and 19A (7), while the remaining 16 serotypes were non-PCV
related, i.e., 9N (1), 10A (2), 11A (4), 15B (6), 17F (2), and 35A
(1). 20.8% of the isolates had decreased susceptibility to penicillin, but
no isolate had high level resistance. All isolates were susceptible to
amoxicillin, second and third generation cephalosporins, carbapenems,
chloramphenicol, vancomycin, linezolid and all quinolones tested except
ciproﬂoxacin. Macrolide resistance was seen in 31.3% of the isolates,
with the M phenotype being the most common (93.4% of macrolide-
resistant isolates). Some resistance to TMP/SMX was seen in 60.4%
being high level in 39.6% of the isolates. Eight SP isolates (16.7%) were
multi-drug resistant (MDR) and all these isolates except one (serotype
15B) were PCV-related.
Conclusion: PCV13 will cover against two thirds of pediatric NP isolates
in our area, where macrolide resistance (M phenotype) is prominent.
Continued serotyping and antimicrobial susceptibility surveillance of NP
carriage isolates of SP is essential for designing rational immunization
strategies and for providing guidance for appropriate treatment options
for pneumococcal infections.
P971 Evaluation of different techniques to detect S. pneumoniae
in hospitalised adults with community-acquired pneumonia
across Europe
K. Loens*, A. Vanderstraeten, K. Bergs, H. Goossens, M. Ieven
(Antwerp, BE)
Background: S. pneumoniae is the most common cause of community-
acquired pneumonia (CAP). Early and accurate diagnosis of pneumococ-
cal pneumonia remains difﬁcult due to the limitations of conventional
diagnostic methods. Several PCRs have been employed with varying
degrees of success, using primers speciﬁc to repetitive regions and
genes. In recent years, real-time quantitative PCR (Q-PCR) has improved
diagnosis.
Objectives: To compare the sensitivity and speciﬁcity of conventional
sputum culture, blood culture, S. pneumoniae urinary antigen test (uAg),
and qualitative and quantitative real-time PCR (Q-PCR) for the detection
of S. pneumoniae applied to a single throat swab (TS) from hospitalised
patients with CAP.
Methods: In a prospective study (November 2002-May 2003), 216
adult hospitalised patients with CAP collected all over Europe, were
enrolled. CAP was conﬁrmed by chest X-Ray. The following samples
were collected: sputum and blood for conventional culture, urine for
S. pneumoniae uAg-testing (Binax Now), and a TS for qualitative PCR
and Q-PCR. Samples were stored locally and batch-wise transported
to the central laboratory in Antwerp for analysis in 2003. Q-PCR was
applied in 2010. A sample was considered positive if positive by sputum
culture, blood culture and/or uAg-test.
Results: 20/216, 6/216, 39/216, 72/216, 44/216 patients were found to be
positive by sputum culture, blood culture, uAg test, qualitative PCR and
Q-PCR respectively. For 131 patients no S. pneumoniae positive result
was obtained. The bacterial load in the TS varied between 0.01 and 30500
DNA copies/ml. Samples with a Ct-value above 33.5 in qualitative PCR
were in general negative when analysed by Q-PCR. No clear correlation
was found between the results of Q-PCR and a positive sputum and/or
blood culture. Storage at −70ºC had little inﬂuence on the DNA quality,
generally resulting in a 0.5 Ct drop in the qualitative PCR. Sensitivities
and speciﬁcities are shown in the table.
Conclusion: In conclusion, S. pneumoniae may be rapidly diagnosed
by analyzing respiratory specimens by (Q) PCR and this may be
particularly valuable in patients in whom antibiotic therapy was initiated
before sampling. However, the main difﬁculty is the quality of the
sample, the TS in this study. Quality assessment of the sample is
needed. Q PCR warrants further evaluation in clinical settings and the
suitability of the test should be evaluated on different types of respiratory
specimens.
P972 The impact in Ireland of the 7-valent pneumococcal
conjugate vaccine on invasive pneumococcal disease within
two years of its introduction
I. Vickers*, M. Fitzgerald, S. Murchan, P. O’Lorcain, S. Cotter,
D. O’Flanagan, M. Cafferkey, H. Humphreys (Dublin, IE)
Aims: The Invasive Pneumococcal Disease (IPD) Typing Project was
established in April 2007. The primary aim was to determine the serotype
distribution of IPD isolates in Ireland before the introduction of the
7-valent pneumococcal conjugate vaccine (PCV7) and to subsequently
monitor its impact on the epidemiology of IPD.
Methods: Streptococcus pneumoniae isolates from blood and CSF were
serotyped using multiplex PCR and serology. Before PCV7 refers to
the time period from April 2007-September 2008, while post-PCV7
refers to the time period from April 2009-September 2010. Penicillin
susceptibility was assessed using the Etest method.
Results: Between April 2007 and September 2010, 1101 invasive
S. pneumoniae isolates were serotyped. Forty four different serotypes
were identiﬁed. The most common serotypes before PCV7 were 14, 4,
9V and 7F. Post-PCV7 serotype 14 was replaced by 7F as the commonest
cause of infection, 14 ranked second, followed by 19A and 8. A reduction
of 56% and 22% in the IPD burden (all serotypes included) occurred in
children <2 years of age and in all age groups, respectively. After PCV7
introduction nine serotypes were associated with reduced susceptibility to
penicillin (MIC >0.12mg/L), three of which were non-PCV7 serotypes.
The most common penicillin non-susceptible serotype was 14 followed
by 9V.
Conclusions: A dramatic reduction in IPD burden has occurred in
Ireland since 2007. However, the high prevalence of serotype 7F and
19A, contained in PCV13, supports the decision to introduce this vaccine
to the immunisation programme in December 2010.
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P973 Trends in serotypes causing invasive pneumococcal disease
in Canadian adults, 2000–2009
W. Rudnick*, A. McGeer, K. Green, S. Pong-Porter, A. Plevneshi,
M. Romilowych, D.E. Low on behalf of the Canadian Bacterial
Surveillance Network
Objectives: The Canadian Bacterial Surveillance Network (CBSN) is a
network of microbiology laboratories that submit bacterial isolates to a
central lab for serotyping and susceptibility testing. CBSN has monitored
(ST) trends in Streptococcus pneumoniae (SPN) since 1993. Routine
pediatric PCV7 was introduced in Canadian provinces between 2002
and 2005.
Methods: Labs submit one SPN isolate per invasive pneumococcal
disease (IPD) case for serotyping and susceptibility testing (CLSI
standards; non-mening R breakpoints: penicillin (pen) 8mg/mL,
ceftriaxone (ctr) 4mg/mL).
Results: From 2000−9, 6783 SPN isolates from adult (15y) IPD
cases were submitted from 80 microbiology labs in all 10 provinces
(blood:6246, CSF:173, pleural ﬂuid:167, other:197). During this time,
the percent of IPD due to ST in PCV7 decreased signiﬁcantly (56 to
18%), while the percent STs not in PCV7, but in PCV13 increased
(18−43%), as did the percent due to non-conjugate vaccine (NPCV) STs
(26−40%). The majority of the increase in PCV13 STs was due to 19A
(1 to 15%). In 2009, 19A, 7F and 3 were the most common STs in adult
IPD, representing 15%, 13% and 10% of isolates. The most common
NPCV STs, were 22F (16%), 23A (8%), and 9N (8%).
In 2007−09, 19A & 7F were the most common Trends in serotypes (STs)
from blood (11%,9%); 19A & 3 the most common in CSF (12%,12%);
22F & 3 were most common from pleural ﬂuid (9%,9%); and 6A & 3
from other sterile sites (12%,10%). Isolates from pleural ﬂuid were least
likely to be covered by PCV13 (33 v 60% for blood).
From 2000−09, resistance to at least one antibiotic class increased from
16 to 27%, and multidrug R (MDR (R to 3 classes) increased from 1 to
5%. In 2007−09, RSPN were more likely to be STs covered by PCV13
than non-R SPN isolates (RSPN: 67% due to PCV13; non-RSPN: 56%
PCV13; MDR: 90% due to STs in PCV13); STs 15A, 33A, 9V, and 19A
were most likely to be RSPN (69%,68%,53%,52%).
Conclusion: IPD due to PCV7 STs in adults decreased in association
with the introduction of pediatric PCV7 programs. The most common
STs in IPD in ’09 are included in PCV13. ST distribution differs from
blood, CSF, pleural ﬂuid and other sterile sites. Resistance continues to
increase. Sts 15A, 33A, 9V, and 19A are the most likely to be antibiotic
resistant.
P974 Serotype-speciﬁc trends in population-based surveillance for
invasive and respiratory pneumococcal disease in adults,
Toronto, 2000–2009
K. Green*, W. Rudnick, D.E. Low, S. Pong-Porter, A. Plevneshi,
M. Romilowych, A. McGeer on behalf of the Toronto Invasive Bacterial
Diseases Network
Objectives: TIBDN performs population-based surveillance for invasive
pneumococcal disease (IPD) in Toronto/Peel (pop 4M) since 1995. From
2002, respiratory tract isolates have been collected. PCV7 was licensed
for children in Canada in 2001 and publicly-funded routine vaccination
began 1/2005.
Methods: Serotyping and broth microdilution susceptibility testing to
CLSI standards is performed on one isolate per IPD/respiratory case.
Clinical data are collected from patient/physician interview and chart
review.
Results: From 2000−9, 7080 adult (15y) cases of respiratory disease
(RPD) and IPD were identiﬁed. Older adults (65y) accounted for 46%
of IPD (1585/3433) and 44% (1621/3647) of RPD. The rate of IPD in
adults 65y decreased from 34 to 21/100000/y between 2002 & 2005,
then increased to 25/100000/y in 2009. The rate of IPD stayed constant
for adults <65y (5.3/100000/y in 2002 & 2009). From 2002−9, the rate
of IPD due to PCV13/nonPCV7 serotypes (STs) has increased from
1.0 to 2.3/100000/y in adults <65y and from 5.3 to 9.6/1000000/y for
those 65y. Non-PCV (NPCV) ST disease has increased from 1.2 to
2.0/100000/y in adults <65y and from 9.7 to 12/100000/y in those 65y.
From 2002−9, the proportion of disease due to PCV7 STs decreased
from 57 to 17% for IPD and from 44 to 15% for RPD. The proportion
of isolates from STs not in PCV7 but in PCV13 increased from 17 to
44% in IPD and 18 to 27% in RPD. The ST distribution of IPD s differs
from RPD: 19F, 11A, & 23A/B are more likely isolated from RPD;
22F, 19A, & 7F are more likely isolated from IPD. ST distribution also
differs for nursing-home acquired (NH) and nosocomial (noso) cases.
From 2005−9, STs 19A/F, 6A, & 14 were more common in NH IPD
and STs 11A, 34 & 17F were more common in NH RPD compared to
community disease in other adults 65y. STs 35B and 6A/B are more
common in noso IPD and 19F is more common in noso RPD. Isolates
from noso/NH cases were also more likely antibiotic R (35% NH/noso
IPD R to at least one class vs 23% for community cases; 37 vs 30%
RPD isolates).
Conclusions: Since introduction of routine pediatric PCV7, the
incidence of adult IPD due to PCV7 STs has decreased while that
of PCV13 and NPCV isolates has increased. In 2009, STs in PCV7
comprised 17% of IPD and 15% of RPD isolates; STs in PCV13
comprised 61% of IPD and 41% of RPD. ST distribution differs for
IPD and RPD, as well as for nursing-home acquired and nosocomial
cases.
Streptococci: from diagnosis to pathogenesis
P975 Can we distinguish Streptococcus pneumoniae from other
streptococci in the mitis-group using the lytA gene?
A comparison of bacterial strains by real-time PCR and
phylogenetic analysis
T. Greve*, J.K. Møller (Skejby, Vejle, DK)
Objectives: The purpose of this study is to validate the use of the
lytA-gene in distinguishing S. pneumoniae from other streptococci.
S. pneumoniae, one of the most virulent human pathogens, is a part of
the mitis-group streptococci which otherwise consist of predominantly
avirulent commensals. The lytA-gene is found in a small group of the
streptococci belonging to the mitis-group. The introduction of rapid
molecular diagnostic tests has raised the question whether the commonly
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used lytA-gene primers and probes are exclusive to S. pneumoniae. We
have done a comprehensive work in the validation of the lytA-gene as a
PCR-target in the streptococci using a practical and theoretical approach.
Methods: The real-time-PCR used for the practical work was developed
for detection of S. pneumoniae using the lytA-gene (Sheppard et al.
2004). Three panels of bacteria were tested. (1) 31 strains not belonging
to the S. pneumoniae/mitis-group. (2) 41 strains of S. pneumoniae.
(3) 22 strains of the mitis-group (incl. ﬁve S. pneumoniae strains), which
were kindly provided by M. Kilian and blinded to us while working with
them. The theoretical work consisted of a lytA-gene sequence analysis of
orthologous gene clusters within the mitis-group. 52 sequences were left
for phylogenetic analysis after a primary reduction of the search result
by comparison of sequence similarities and gene function.
Results: The PCR found 45/46 S. pneumoniae strains positive (test
sensitivity, 97.9%). No positive test results were found in the non
S. pneumoniae strains (0/48) incl. the 17 mitis-group strains (test
speciﬁcity, 100%). The PPV was 100% and the NPV was 98%. The
theoretical approach showed that the lytA-gene is present in many of the
mitis-group strains. The gene is in general different in S. pneumoniae,
but a continuum of gene variants seems to be present in the mitis-group
(Figure 1). 1/44 S. pneumoniae strains was found within a mitis cluster
and did not match the primers and probes (theoretical sensitivity, 97.7%).
0/8 non-S. pneumoniae streptococci were found in the S. pneumoniae
clusters and none of them matched the primers and probes (theoretical
speciﬁcity, 100%). The theoretical PPV was 100% and the NPV was
89%.
Conclusion: It is possible to design sensitive and speciﬁc primers and
probes using the lytA-gene to distinguish S. pneumoniae from other
mitis-group streptococci. Differences within the gene are in general
larger between species than within a species in the mitis-group.
P976 Chromosomal drug efﬂux pumps in Streptococcus pneumoniae
N. Tocci*, A. Bidossi, M.L. Ciusa, F. Decorosi, C. Viti, G. Pozzi,
S. Ricci, M.R. Oggioni (Siena, Firenze, IT)
Objectives: Cross- and co-resistance between biocides and antibiotics
has been proposed to be a hazard for possible impact of biocide
utilization on selection of antimicrobial drug resistance. Scope of the
presented work was to construct a series of isogenic strains deleted for
possible chromosomal drug efﬂux pumps. As model organism we have
chosen the naturally transformable species Streptococcus pneumoniae.
Methods: Mutants for transporters were constructed by direct transfor-
mation of PCR ligated markers genes to chromosomal segments ﬂanking
the respective chromosomal loci. Mutant phenotypes were assayed by
disk diffusion, microdilution and phenotype microarray.
Results: Mutants for seven ABC transporters, three MATE efﬂux
pumps and one MFS transporters were obtained in S. pneumoniae.
The susceptibility of these eleven mutants were compared to the wild
type strain for over 250 substances. Out of the tested transporters
only the ABC transporter PatAB (SP2073−5) showed a clear MDR
proﬁle inasmuch its mutation increased signiﬁcantly the susceptibility
to noﬂoxacin, ethidium bromide, acriﬂavin and berberine. Upon the
other transporters tested, including the MFS DinF and the putative NorA
orthologue PmrA, only the mutant for the MATE efﬂux pump SP2065
showed an increase in susceptibility to novobiocin.
Conclusions: The ABC transporter PatAB has been conﬁrmed to be the
only MDR efﬂux pump of S. pneumoniae, with a surprising overlap
in substrate speciﬁcity to the classical Staphylococcus aureus MDR
antiporter NorA. The cross-speciﬁcity of PatAB for the quaternary
ammonium salt berberine, used as food additive, and the antibiotic
norﬂoxacin is an example of a possible selective mechanism form a
biocide for antibiotic resistance, even if epidemiological data do not
point to co-resistance in clinical strains has so far been shown.
P977 Detection of group B streptococci intrapartum using BD™
Max GBS assay
J.C. Nguyen Van*, E. Sauvanet, Y. Giovangrandi (Paris, FR)
Objective: The aim of this study was to evaluate the performance of
the BD ™ Max GBS assay for detection of Group B streptococcus in
intrapartum.
Method: During admission for delivery, paired vaginal swabs were
obtained: one was processed using the BD ™ Max GBS assay and
the other using microbiological culture. This prospective study was
undertaken from October to December 2010 including 246 parturients
admitted to the Paris Saint Joseph Hospital Group. From October 11
to November 18 (period 1) 107 samples were processed following the
method recommended by the manufacturer. Due to the high number of
indeterminate results by PCR, an additional step with needle Handylab
was incorporated to the procedure and 139 samples have been processed
from November 19 to December 17 (period 2).
Results: The results were as follows:
Period 1: sensitivity: 84.6%, speciﬁcity 98.4%, PPV = 91.7%, NPV =
96.8% with an undetermined results of 29.9%.
Period 2: sensitivity 69.5%, speciﬁcity 97.2%, PPV = 84.2%, NPV =
93.8% with an undetermined results of 5%.
Conclusion: We showed a signiﬁcant improvement in the number of
indeterminated results using an additional step to remove the inhibition
of PCR. The percentage of unresolved results is about 5%, a value that
is acceptable to a PCR technique of intrapartum screening.
P979 Streptococcus pneumoniae: a Multiplex-PCR challenged by
rough variants
R. Dargis, L. Lambertsen, M. Kemp, J.J. Christensen* (Copenhagen,
Odense, Slagelse, DK)
Objective: The three species Streptococcus pneumoniae, Streptococcus
mitis and Streptococcus oralis are phylogenetic closely related, especially
S. pneumoniae and S. mitis. Rough pneumococcal strains pose a
special challenge. A Multiplex-PCR test was attempted made, separating
pneumococcal strains from the other closely related species, based on
possible differences in presence of the ply gene and two distinct base
pairs on the 16S rRNA gene (16S) and applied on rough pneumococcal
strains using gdh sequence analysis as deﬁnite separation between
species.
Materials: Multiplex-PCR and gdh sequence comparisons: The
Multiplex-PCR tested for presence of the ply-gene and two previous
extensively BLAST screened differences at positions 220 and 641 (both
E. coli numbering) in the 16S rRNA gene; respectively base pair “C”
and “G” for S. pneumoniae. Partial gdh sequence analysis was used for
deﬁnite species identiﬁcation.
Strains: Eight collection strains (representing the species S. pneumoniae,
S. mitis, S. oralis and S. pseudopneumoniae) and all strains (n = 47)
received in 2008 as rough pneumococcal strains on the basis of optochin
sensitivity and bile solubility.
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Results: Collection strains were correctly identiﬁed by the Multiplex-
PCR. Of the 47 suspected rough pneumococcal strains 18 were identiﬁed
as S. pneumoniae by Multiplex-PCR and gdh sequence examination.
Nine-teen strains were non-S. pneumoniae strains by both genes in
the Multiplex-PCR and identiﬁed as S. mitis by the gdh sequence. Of
the remaining 10 strains, four strains being ply-gene positive by the
Multiplex-PCR were identiﬁed as S. mitis strains and six strains being
S. pneumoniae by the Multiplex-PCR were gdh-gene identiﬁed as S. mitis
(n = 3) and S. pseudopneumoniae (n = 3).
Conclusion: Only one S. pneumoniae strain could not be identiﬁed
by the 16S rRNA gene base positions, but six non-S. pneumoniae
strains were erroneously identiﬁed as S. pneumoniae. Seven S. mitis
strains harboured the ply-gene. Thus, both Multiplex-PCR markers were
not speciﬁc for S. pneumoniae. For the 16S base positions this was
further conﬁrmed by BLAST search showing variation on more recent
included sequences. Less than half of the suspected rough S. pneumoniae
strains were identiﬁed as S. pneumoniae by the Multiplex-PCR and gdh
sequence examination. Rough pneumococci therefore are not a well-
deﬁned entity. Deﬁnite species identiﬁcation is therefore important when
trying to compare their clinical importance.
P980 The streptokinase gene as a candidate target for
differentiation between Streptococcus dysgalactiae subsp.
equisimilis causing infections in humans and horses
S. Preziuso*, M. Pinho, A.R. Attili, J. Melo-Cristino, M. Ramirez,
V. Cuteri (Matelica, IT; Lisbon, PT)
Objectives: In humans, Streptococcus dysgalactiae subsp. equisimilis
(SDSE) causes a variety of infections ranging from mild to severe
diseases. In horses, SDSE is considered opportunistic, although recent
studies hypothesize a role for SDSE in causing mild respiratory disease.
A comparison between the characteristics of human and equine SDSE
is possible only if these can be accurately differentiated. The aim of this
work is to evaluate if the streptokinase gene (skg) of SDSE is a valid
target to develop PCR tests to distinguish between SDSE isolated from
humans and horses.
Methods: The sequences of the skg of SDSE isolated from humans
and horses deposited in GenBank have been aligned and compared.
Primers speciﬁc for the skg of human SDSE have been designed
and validated by BLAST. SDSE isolated from humans (n = 20), SDSE
isolated from horses (n = 30), S. pyogenes (n = 8), S. canis (n = 10) and
other Streptococcus spp. strains (n = 20) have been screened by PCR to
detect the species S. dysgalactiae, the skg of human SDSE (hskg), and
the skg of equine SDSE (eskg).
Results: All the 50 SDSE of human and animal origin resulted positive
for S. dysgalactiae by PCR. The 20 SDSE of human origin were also
positive for hskg but negative for eskg, while the 30 SDSE of equine
origin were positive for eskg but negative for hskg. All other streptococci
were negative for all three PCR products.
Conclusion: On the basis of these results, the skg gene is a valid target
to distinguish SDSE of human and equine origin. In the past, an SDSE
skg sequence similar to those of equine SDSE was found in the lung of
a human patient. The availability of a PCR protocol to speciﬁcally detect
human SDSE and to distinguish between human and animal strains has
not only a diagnostic value, but can also support further epidemiological
studies and can allow the evaluation of the zoonotic potential of animal
SDSE. The comparison between human and equine SDSE could increase
the knowledge about the pathogenic mechanisms of SDSE in their host
species and could help to explain the variability in disease severity
observed in different hosts.
P981 Distribution of pathogenicity island XII of group B
streptococci
E. Kuleshevich*, A. Savicheva, A. Suvorov (St. Petersburg, RU)
Objectives: Group B Streptococci (GBS) are the major cause of newborn
infections. It is well known that there are several pathogenicity islands
in the genomes of GBS which usually carry various the genes of various
virulence determinants. Pathogenicity island XII carries genes of several
virulence factors including scpB, lmb and sspB1. The latter gene was
previously shown to be common for the GBS invasive strains isolated
in Russia. The aim of the study was to further evaluate the distribution
of the island XII among GBS and to investigate the organization of the
putative virulence factor genes on this large genetic element.
Methods: The collection of 74 clinical GBS strains isolated in St.
Petersburg, Russia was investigated by PCR and hybridization. All the
strains were genetically typed employing multiplex PCR.
Results: 74 recently isolated in St. Petersburg Russia clinical GBS
strains have been studied for the presence of genes considered as
possible virulence factors. The following genes located on the virulence
island XII (PAI XII) have been tested: toxin, Zn-ﬁnger, helicase, sspB1,
transposon Tn5252, gene of type IV secretory system. The genes of
interest have been found only in 16 of 74 strains. Interestingly some of
the strains carried different number of the genes under study in their
genomes. Multiplex analysis for serotype afﬁliation allowed determining
only 56 strains in the collection. 16 strains belonged to the type Ia, 8 −
II, 11 − III, 16 − IV, 5 − V. Types of 18 strains could not be identiﬁed.
PAI XII was found in different types of GBS.
Conclusion: Pathogenicity island XII was found in 22% of clinical
strains of GBS under study. The genetic organization of the determinants
located on the island was found to be different. There was no correlation
between presence of pathogenicity island XII and type of GBS.
Work is supported by grants of the Government of Saint-Petersburg and
RFBR 10−04–00750a
P982 Non-haemolytic GBS on Granada medium: there might be
a solution for this problem!
S. Nickmans*, E. Verhoye, A. Boel, K. Van Vaerenbergh, H. De
Beenhouwer (Aalst, BE)
Objectives: Today, Group B streptococcus (GBS) still is an important
cause of neonatal sepsis. Screening for maternal GBS colonisation
is generally advised at 35−37 weeks gestation. One of the methods
recommended by the CDC (RR-10) for laboratory detection of GBS is
the chromogenic Granada medium, which utilizes the ability of GBS to
produce its unique orange carotenoid pigment. The reading of this plate
is easy and clear cut. However, approximately 5% of all GBS do not
produce this orange pigment, a characteristic closely linked to absence
of hemolysis. Therefore, we evaluated the addition of an oxacillin disk
in an attempt to pick up these challenging non-hemolytic GBS strains.
Methods: In a prospective study, 483 vulvo-rectal swabs from pregnant
women were tested for GBS by use of Granada medium® (bioMe´rieux)
and Lim Broth® (Beckton-Dickinson) enrichment. At arrival, the
samples were directly plated on Granada medium with addition of
an oxacillin disk (1 mg), and were inoculated in Lim Broth. After
overnight incubation, the Granada medium was evaluated. In case of
absence of orange colonies, the Lim Broth enrichment was plated onto
a second Granada medium with again addition of an oxacillin disk, and
another overnight incubation was performed. After this second overnight
incubation, the direct plated Granada media were evaluated again and
the media, plated after enrichment, were evaluated once. All white
colonies which were oxacillin-susceptible, were tested for catalase. If
catalase testing was negative, subsequent agglutination test with group
B antiserum (Diamondial Strep Kit®) was performed.
Results: After 48h of incubation, a total of 91 samples showed the
typical orange coloured colonies. Of the 392 white strains, 48 showed
an oxacillin-susceptibility zone. By means of catalase testing and
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subsequent agglutination with group B antiserum, 5 additional non-
hemolytic GBS were detected. So 5.2% (5/96) of all detected GBS were
non-hemolytic and were picked up solely by means of the additional
oxacillin disk. Taking into account the costs of personnel and required
reagents, this detection method represents a supplementary cost of about
0.18€/sample.
Conclusion: To overcome the Granada medium’s inability to detect
non-hemolytic GBS strains, addition of an oxacillin disk onto Granada
medium can provide a supplementary detection of approximately 5% of
all GBS strains. This is an efﬁcient and cost-effective method to intercept
these non-hemolytic strains.
P983 Rapid detection of Streptococcus pyogenes in peripheral
medical centres. A pilot custody assay
J.L. Ramos*, M.T. Fraile, M. Chanza´, N. Tormo, A. Lurbe, C. Gimeno
(Valencia, ES)
Objective: Respiratory infections are the most frequent cause of
consultation in the pediatric group. The clinical presumption diagnostic
of bacterial pharyngitis (Streptococcus pyogenes is the most common
bacterial cause of this disease), has low sensitivity and speciﬁcity. The
high percentage of false positives employing a presumption based on
clinical etiology, cause a misuse of antimicrobial treatment in general
clinical practice. The microbiological diagnosis is simple and fast, and
because of the difﬁculty involved in sending the child to hospital
emergency and/or Microbiology Unit for diagnosis, the vast majority
of clinical suspicion is treated empirically.
We conducted a custody pilot assay (Pediatrics and Microbiology) in the
pediatric services of four health peripherals centers, so that these centers
can perform rapid antigen detection of S. pyogenes, and thus:
1. Quickly diagnosing streptococcal pharyngitis in the same center.
2. Adequately treatment of acute pharyngitis.
3. Reduce spending on antibiotics.
Methods: The study included analysis of throat swabs from 165 children
using the rapid test and culture of the same sample. We made a working
protocol test OSROM Strep A Test, easy understanding and follow-up
for the sanitary staff of the peripheral centers, taking into account their
inexperience in laboratory testing. After a rapid screening test, they
showed in the culture request, the result and treatment given to patients
(antibiotic or symptomatic treatment). At the same time, they sent the
reactive strips with the analysis results to assess whether the reading was
done properly and monitor the reagents consumption.
Results: Of the 165 samples studied, 53 were positive for the rapid test,
3 with negative culture and 50 positive. Negative antigen was found in
112 samples; 110 were conﬁrmed by negative culture, and only 2 were
positive.
Conclusion: We diagnosed and treated quickly and effectively in the
peripheral medical centers 163 pharyngitis, 53 streptococcal pharyngitis
(with antibiotic treatment) and 110 pharyngitis of other etiology,
probably viral (symptomatic treatment). With this protocol we adecuate
the treatment in 110 patients. Only two patients of 165 patients (1,2%)
were untreated harboring S. pyogenes.
P984 Faster diagnosis by antigen detection for group B
Streptococcus carriage in pregnant women
A. Raglio*, P. Serna Ortega, S. Rampello, B. Pasini, M. Arosio,
F. Vailati, A. Grigis, A. Goglio (Bergamo, IT)
Objectives: In the new Revised Guidelines of 2010, CDC underlines
that more rapid techniques for identifying GBS directly from enrichment
broth have been developed. In a previous study we already veriﬁed the
possibility of avoiding plate subculture, by the detection of GBS antigen
within 24 hours directly from the enrichment broth after overnight
incubation. The aim of this study was to evaluate the chance of further
reducing the time of diagnosis within only 8−13 hours after incubation
in the enrichment broth.
Methods: Between 1 April and 30 October 2010, 265 pregnant women
were monitored at delivery, by placing into a Todd-Hewitt broth with
nalidixic acid and colistin (LIM, Copan) a rectal and a vaginal swab.
The samples were incubated at 35ºC immediately by the midwives in
the delivery room. Twice a day (8 am and 4 pm) and after at least 8
hours incubation, the broth was subcultured onto ChromId Agar strepto
B (Biomerieux) and the detection of GBS antigen was performed directly
from the enrichment broth, according to the kit procedure (Bio MK). The
samples were incubated again until 18−24 hours and the subculture and
the antigen research were repeated after the second incubation.
Results: We examined 265 pregnant women, 54 positive and 211
negative for GBS culture. Antigen after a mean of 13 (8−23) hours
conﬁrmed 50 of the culture positive results. The 4 cases with the
false-negative antigen showed less than 100 CFU/ml in the subcultures.
Among 211 negative cultures, 2 cases were positive by antigen. Taking as
reference the culture, antigen showed 92.6% sensitivity, 99% speciﬁcity,
NPV 98% and PPV 96%.
Conclusions: Clinicians ask for a rapid test for the detection of GBS that
can be used at the time of delivery. Currently, there are rapid molecular
methods, some even faster and simple but expensive. The detection of
GBS antigen allowed to identify 50/54 positive cases and showed a PPV
of 96%. Only in 4/54 cases the antigen was false-negative after shortened
incubation with the growth of only less than 100 CFU/ml. The reading
of antigen was always easy and the colorimetric reaction of sample-line
resulted weak with a risk of equivocal interpretation in 4 of 211 negative
cases. GBS antigen detection was rapid, reliable, easy-to-perform and
able to identify 92.6% of colonised pregnant women already within a
mean of 13 hours after sample collection.
AMR in fastidious micro-organisms
P985 Antimicrobial resistance in Helicobacter pylori positive
patients after therapy failure and in Helicobacter pylori
positive untreated patients
L. Franzin*, C. Avanzini, V. Demarie, A. Ferrari, A. Garripoli, P. Lerro,
C. Barbera (Turin, IT)
Objectives: Patients with peptic ulcers who are also infected by
Helicobacter pylori receive antimicrobial therapy, based on different an-
tibiotic combination including clarithromycin in addition to antisecretory
drugs. Eradication is however difﬁcult because of primary and secondary
resistance. The aim of the study is to evaluate in vitro susceptibility of
H. pylori strains isolated in a group of symptomatic patients with failure
of previous eradication treatments and the primary resistance in a group
of untreated symptomatic patients.
Methods: Group A:107 adult patients (36 males and 71 females, mean
age 53.5 years and range 25−77) with peptic ulcers and other gastric
disorders after failure of previous treatment regimens. Group B: 80
untreated patients. During endoscopy, four biopsies were taken from
antrum for histology, rapid urease test and culture and two from fundus
for histology and culture. The specimens for culture were homogenized
and streaked on fresh blood agar plates, incubated in a microaerophilic
atmosphere at 37ºC for 4 days up to 10−14. Fresh culture of 3 days were
tested by E-test method for susceptibility to clarithromycin, amoxicillin,
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metronidazole and tetracycline for group A and also for levoﬂoxacin and
rifabutin for group B.
Results: H. pylori susceptibility test was performed from 59/107 (55%)
patients of group A and from 33/80 (41%) patients of group B (14 males
and 19 females, mean age 29.7 years and range 4−66). In the other
subjects the culture showed no growth or contamination. Clarithromycin
resistance was found in 80%, metronidazole in 71% and amoxicillin in
2% of group A patients. Clarithromycin, metronidazole resistance was
respectively 19% and 15% in group B, where levoﬂoxacin resistance was
observed in only one patient. All strains were susceptible to tetracycline.
Resistance to at least one drug was observed in 95% of subjects of
group A and in 36% of group B, resistance to both clarithromycin and
metronidazole was found in 53% and 0% respectively.
Conclusion: The percentage of clarithromycin resistant strains from
patients with previous treatments failure is very high (80%), while
the primary resistance in untreated patient was 19%. Resistance to
tetracycline was never observed in both group. As clarythromycin
resistance affects the efﬁcacy of ﬁrst-line therapy and tetracycline should
be used in combined alternative treatment, this antibiotic should be
considered in susceptibility testing.
P986 Resistance of Helicobacter pylori to clarithromycin and
metronidazole in a tertiary hospital in the Netherlands
H.F. Wunderink*, P.E. Mourad-Baars, K.E. Veldkamp (Leiden, NL)
Objectives: The increasing antimicrobial resistance of Helicobacter
pylori (H. pylori) world-wide is one of the main reasons for eradication
failure. In the Netherlands data between 1993 and 2003 about the
resistance of H. pylori to clarithromycin and metronidazole in adults
are known. Since 2003 no further studies in adults have been published,
and there is no known data for H. pylori resistance in Dutch children.
As failure of ﬁrst eradication treatment has shown to diminish eradication
success in the future, we investigated the resistance prevalence of
H. pylori in children and adults to clarithromycin and metronidazole. Our
objective was to compare the results with known data from literature.
Methods: In the Leiden University Medical Centre (LUMC) a
retrospective database study from 1 January 2000 to 31 December 2009
was performed. All patients who had had an upper endoscopy with a
H. pylori positive culture from the antral and/or corpal biopsy were
included.
Antimicrobial susceptibility of the H. pylori strains was determined by
E-test. The cut-off values were 0.25mg/L = sensitive and >0.25mg/L
= resistant for clarithromycin and 8 = sensitive, >8 and 16mg/L =
intermediate and >16mg/L = resistant for metronidazole.
Results were compared to literature on Dutch adults until 2003 and to
data from a multicentre study of children in Europe in 2006.
Results: 1144 cultures from 1092 adults and 78 cultures from 77 children
were included. Resistance prevalence of H. pylori to clarithromycin in
adults was 10% and in children 7%. Resistance to metronidazole in
adults was 22% and in children 12%.
In earlier studies in the Netherlands the resistance of H. pylori in adults
to clarithromycin was 5% and to metronidazole 7−33%. Resistance of
H. pylori in children in the LUMC were compared to Koletzko et al.
Overall clarithromycin and metronidazole resistance in their multi-center
study were 24% and 25% respectively.
Conclusion: Comparing our resistance data of H. pylori in adults with
the data from earlier Dutch studies, clarithromycin resistance in the
LUMC is higher, while metronidazole resistance is equivalent. In our
study clarithromycin resistance in adults is higher than in children.
Resistance of H. pylori to clarithromycin and metronidazole in Dutch
children are lower when compared to European data. We believe that
surveillance of local H. pylori resistance is recommended in order to
increase the success of eradication treatment.
P987 High incidence of ciproﬂoxacin-resistant Neisseria gonor-
rhoeae in a tertiary hospital in Madrid, Spain (2005–2010)
A. Burillo*, E. Cercenado, M. Marı´n, M. Rivera, T. Vicente, E. Bouza
(Madrid, ES)
Objective: In recent years we have observed in our area an increase in the
incidence of sexually-transmitted diseases produced by N. gonorrhoeae
(NG). Resistance of gonococcal isolates to antimicrobials used for the
empirical treatment of gonorrhoea limits the therapeutic options. In order
to monitor local resistance patterns to guide treatment recommendations,
we studied the resistance patterns of 120 gonococcal isolates recovered
in our hospital over a period of 6 years.
Methods: From January 2005 to December 2010 we isolated a total of
124 gonococcal strains. Isolates were identiﬁed by standard biochemical
methods. Susceptibility testing was determined by the disk diffusion
and by the Etest methods and results were interpreted following the
CLSI 2010 guidelines. b-lactamase production was determined using
the nitrocephin test.
Results: The 124 isolates corresponded to 120 patients, 116 males and
4 females. Overall, the percentages of resistance to penicillin (PEN),
ciproﬂoxacin (CIP) and rifampin (RIF) were 15%, 48% and 39.5%,
respectively. No signiﬁcant increases in antimicrobial resistance were
detected over the study period (Table 1). Resistance to ciproﬂoxacin
ranged between 23% in 2007 to 56.5% in 2008. Among the penicillin-
resistant isolates, 9,7% were b-lactamase producers. All strains were fully
susceptible to cefotaxime (CTX) (MIC90 0.06mg/mL). One isolate
showed combined resistance to penicillin, ciproﬂoxacin and rifampicin.
Conclusion: The high resistance rate of NG to ciproﬂoxacin in our area
precludes the use of ﬂuoroquinolones for empiric therapy. Cefotaxime
remains a highly effective antimicrobial agent for the treatment of
gonorrhoea. Surveillance of antimicrobial resistance of NG isolates is
essential in order to prevent the spread of resistant isolates and to adjust
empirical treatments.
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P988 Ceﬁxime resistance in Neisseria gonorrhoeae isolates from
2006 to 2010: correlation of MIC values with target gene
alterations, the Italian experience
A. Carannante, I. Dal Conte, V. Ghisetti, S. Del Re, M. Cusini,
L. Scioccati, G. Prignano, G. Palamara, A. Di Carlo, V. Sambri,
A. D’Antuono, F. Cavrini, A. Matteelli, M. De Francesco, A. Di
Taranto, R. De Nittis, P. Stefanelli* (Rome, Turin, Milan, Bologna,
Brescia, Foggia, IT)
Objectives: Reduced susceptibility to cephalosporins, now recom-
mended as the mainstay of treatment, along with some treatment failures
with ceﬁxime have been reported for Neisseria gonorrhoeae.
Aim of this study was to test the ceﬁxime and ceftriaxone susceptibility
of strains isolated from 2006 to 2010 in Italy. Analyses of genetic
mechanisms for resistance and the genetic relationship among the
isolates have been also carried out looking for correlation with MICs.
Methods: Minimum inhibitory concentrations (MIC) for Ceftriaxone
and Ceﬁxime were determined by the E-test method (AB biodisk, Solna
Sweden) and agar dilution on 265 N. gonorrhoeae strains isolated from
2006–2010. The EUCAST 2010 (MIC R >0.12mg/L) and CLSI 2009
(MIC R 0.25mg/L) breakpoints were taken into account. PenA, mtrR,
porb1B and ponB sequences together with NGMAST analyses have been
also determined.
Results: The majority of the gonococci were susceptible to both
antibiotics. According to the EUCAST breakpoint 12% resulted resistant
to ceﬁxime compared to only 1% according to the CLSI reference
breakpoint. However, the number of gonococci with ceﬁxime MICs
of 0.125–0.25mg/L has increased in Italy during 2009–2010. These
MICs lie on the edge of the breakpoints. The complete nucleotide
sequence of penA from 45 isolates (either susceptible or with decreased
susceptibility/resistance) were determined. Five amino acid sequence
patterns in PBP2 were identiﬁed. These sequences were compared and
isolates with MIC 0.125mg/L all shared the sequence pattern XXXII.
The majority of strains with MIC 0.125mg/L belonged to ST1407
already described in ceﬁxime resistant strains worldwide. The other
target genes did not show any speciﬁc alterations compared to susceptible
strains. All the examined strains were fully susceptible to ceftriaxone.
Conclusions: An upward rate of ceﬁxime resistant or with decreased
susceptibility has been found among Italian gonococci isolated from
2006–2010. Our ﬁndings show that the PBP2 is involved in resistance
or reduced susceptibility equally. The remaining target genes do not
inﬂuence the genetic mechanism of resistance or decreased susceptibility
to ceﬁxime. These data underline once more the usefulness of individual
testing and local surveillance of N. gonorrhoeae in order to update
treatment recommendations and therefore help in disease control.
P989 Macrolide-resistant Mycoplasma pneumoniae in Japan
N. Miyashita*, Y. Kawai, K. Ouchi (Kurashiki City, JP)
Objectives: Recent epidemiological studies in Japan have demonstrated
that the incidence of macrolide-resistant M. pneumoniae is increasing
gradually in pediatric patients. The purpose of this study was to
clarify the frequency and clinical characteristics of macrolide-resistant
M. pneumoniae in adults.
Methods: A total of 30 children and 40 adults with M. pneumoniae
infection conﬁrmed by serology and PCR who visited to Kawasaki
Medical School hospital from June 2005 to April 2010 were enrolled
in this study. Primers for domain V of 23S rRNA were used as reported
by Lucier et al. DNA sequences of PCR products were compared to the
sequence of MP M129 (accession no. X68422).
Results: Among 30 children, 21 children were found to be infected
with macrolide-resistant M. pneumoniae. This macrolide resistance was
limited to point mutations of domain V of the M. pneumoniae 23S
rRNA gene, such as A2063G and A2064G. All of them were treated
with macrolides initially. Fever in nine children with M. pneumoniae
without point mutations at 2063, 2064, or 2617 disappeared within 48
hours of treatment; however, fever persisted for more than 48 hours after
treatment in 21 patients with M. pneumoniae. Minocycline was effective
in these patients with macrolide-resistant M. pneumoniae. In contrast to
pediatric patients, only three macrolide-resistant M. pneumoniae were
detected in adult patients.
Conclusion: Macrolide-resistance rate of M. pneumoniae may be
increasing to as high as 70% in children, but macrolide-resistance rate
was low in adult patients. However, monitoring of M. pneumoniae
strains seems to be necessary in order to recognize early changes in the
antibiotics resistance pattern of this important agent of human respiratory
tract infections. Tetracycline was effective to these macrolide-resistant
M. pneumoniae infections. Response of fever by antibiotics correlated
very well to response of reduction in number of M. pneumoniae at
nasopharynx.
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P990 Clinical epidemiology and manifestations of Campylobacter
concisus
H.L. Nielsen*, T. Ejlertsen, J. Engberg, H. Nielsen (Aalborg, Slagelse,
DK)
Objectives: Campylobacter jejuni is a major cause of bacterial diarrhoea
throughout the western world. After the acute gastroenteritis some
patients have sequelae like irritable bowel syndrome, reactive arthritis,
inﬂammatory bowel disease and Guillain Barre´ syndrome. Likewise,
Campylobacter concisus has been proposed to cause diarrhoea especially
among children and immunocompromised patients, but the epidemiology
and burden of disease in humans are not clariﬁed. In this community-
based study we describe the epidemiology and clinical manifestations
caused by C. concisus. We describe the differences and similarities of the
clinical presentations caused by C. jejuni and C. concisus respectively.
Methods: Campylobacter spp. was isolated from diarrhoeal stool
samples with use of the ﬁlter method. Patients with C. jejuni and
C. concisus were included in the study. The study period was two years
and started January 2009. Clinical data were reviewed by use of the
patient’s medical records as well as a questionnaire survey with a follow
up for six months.
Results: In the ﬁrst 22 months 10.388 faecal samples were cultivated
with use of the ﬁlter method as well as the routine methods for
cultivating pathogenic enteric bacteria. The most prevalent pathogenic
enteric bacteria was C. jejuni with 456 patients followed by C. concisus
with 378 patients (36/100,000/year). Clostridium difﬁcile and Salmonella
spp. were isolated from 349 and 206 patients, respectively. There was
an almost constant monthly prevalence of C. concisus during the study
period. The age-speciﬁc incidence showed that C. concisus was frequent
among small children and elderly patients. C. jejuni was most common
among young adults. Two third of the samples with C. concisus were
from general practice, the remaining were from hospitals. Patients with
C. concisus presented a more prolonged duration of diarrhoea compared
to C. jejuni.
Conclusion: C. concisus was frequently isolated from faeces from
patients suspected for bacterial gastroenteritis and suggest a pathogenic
potential of this Campylobacter spp. The infection occurs at any age,
but in contrary to C. jejuni, it is more frequently among infants
and the elderly. Many patients with C. concisus reported long-lasting
diarrhoea, especially among the elderly patients. Laboratory, as well as
clinical studies, are required to illuminate the molecular pathogenesis
by C. concisus and to describe if the patients may beneﬁt of antibiotic
treatment.
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P991 A study on Chikungunya virus infection in north India
J. Agarwal*, S. Srivastava, S. Malik, K.P. Singh, M. Singh (Lucknow, IN)
Objectives: Since re emergence of chikungunya virus (CKV) infection
in Indian subcontinent in 2005, it has become a major public health
threat.
Methods: Clinically suspected cases (as per NICD, New Delhi, India)
visiting outpatient or inpatient Departments of Pediatrics, Medicine and
Rheumatology and referred to Microbiology Department for diagnosis
of CKV were prospectively enrolled after obtaining written consent.
Detailed clinical history and examination ﬁndings were recorded in a pre
designed questionnaire from 248 such patients during September 2009
to May 2010. Results of hematological and other investigations were
extracted from medical records. IgM ELISA for CKV was done using
IgM antibody capture ELISA (NIV, Pune, India). Reverse Transcriptase
PCR for CKV was performed on 53 randomly selected samples. Tests for
Malaria antigen, IgM against Dengue, Japanese encephalitis (JE) virus
and typhoid were done as per referring clinician’s request.
Results: 12.1% (30/248; 21 true positives; 9 borderline cases) patients
were positive for CKV IgM and 17/53 were RT-PCR positive (14/45 IgM
negative; 1/2 IgM positive; 2/6 borderline IgM positive). Overall CKV
infection was present in 44/248 suspected patients. Mean duration of
fever was 6.68 + 1.83 days. Frequent clinical features were fever (100%);
arthralgia (95%); headache (85%); rash (57%); aphthous ulcers (36.5%);
arthritis (25%); lymphadenopathy (16%) and hemorrhagic manifestation
(15.9%). Involvement of elbow, wrist and hip joint, pain and redness in
eyes and photophobia had signiﬁcant association (p< 0.05) with CKV
positiviy. Clinical presentation was different in adults and pediatric age
groups. Neurological involvement with encephalitis and seizures was
present in 7 cases and was more common in young children. 16/44 cases
had co-infection by dengue virus, 4 with JE virus and 3 had concurrent
malaria. Mortality rate amongst CKV infected was 4.5% (2/248, both
children).
Conclusions: In absence of pathognomonic features, clinical overlap
with other infections prevalent in this part of the world; clinical diagnosis
becomes difﬁcult. Unusual features like encephalitis were present in
signiﬁcant proportion. Considerable number of patients had co-infection
with other pathogens hence even if patient is diagnosed with other
more prevalent infections, CKV should be tested for. Both, serology
and molecular diagnosis should be used in conjunction for better case
detection.
P992 The burden of invasive disease with non-b Haemophilus
inﬂuenzae serotypes in Alaska and Northern Canada,
2000–2009
M. Bruce*, T. Zulz, S. Desai, J. Lourenco, S. Kitka, D. Hurlburt,
D. Bruden, K. Rudolph, C. Debyle, R. Tsang (Anchorage, US; Ottawa,
Winnipeg, CA)
Background: Prior to introduction of the Haemophilus inﬂuenzae type
b (Hib) conjugate vaccines, rates of Hib disease among indigenous
people living in Alaska (AK) and Northern Canada (N Can) were among
the highest reported in the world. Routine vaccination has reduced
these rates; however, serotype replacement with non-type b strains is
of particular concern in the North American Arctic.
Methods: We identiﬁed cases of invasive Hi disease in AK and N
Can from 2000–2009 through the International Circumpolar Surveillance
(ICS) network. Medical charts were reviewed on laboratory-conﬁrmed
cases using standardized forms to verify clinical presentation. AK and
N Can estimated populations as of 2008 were 679,720 and 145,493
respectively; indigenous people comprised 20% of the population in AK
and 60% in N Can.
Results: During the study period, a total of 258 cases of invasive Hi
disease were reported from AK (152) and N Can (106). Among the
159 (62%) invasive Hi cases with serotype information available; 73
(46%) were serotype a, 47 (30%) were serotype b, 20 (13%) were
serotype f. Among Hia isolates, 63 (86%) occurred in indigenous people;
median age was 1.0 year (range 2 mo-74 years); 60% were male.
Four Hia cases (one adult/3 children) were fatal. Common clinical
presentations included: meningitis (32%), pneumonia (27%), and septic
arthritis (12%). There were no cases of epiglotitis. Overall annual Hia
incidence was 0.3, and 3.7 cases/100,000 population in AK and N
Can, respectively. Annual incidence rates among indigenous children
<2 years old in AK and N Can were 17 and 104 cases/100,000 persons,
respectively.
Conclusions: Serotype a is now the most common Hi serotype seen in
the North American Arctic, with the highest rates among indigenous
children. Further research is needed to investigate regional differences
in rates, and to determine sequelae, risk factors, and the utility of
chemoprophylaxis.
P993 Tertiary care hospital candidaemia: epidemiology and
emerging species
C. Ruiz de Alegria Puig*, M.A. Ballesteros Sanz, E. Roma´n Paucar,
J.L. Teja Barbero, C. Ferna´ndez-Mazarrasa, L. Martı´nez-Martı´nez
(Santander, ES)
Objectives: The present study was conducted in order to know the
epidemiology of candidemia and the characterization of some emerging
species of candida in a 5 years period in our hospital.
Methods: All candida blood culture isolates between 1 January 2005
and 31 December 2009 were included, in a 800-bed community
teaching hospital. Subsequent episodes one month before the ﬁrst
were not included. Blood cultures were processed using the Bactec
9240 system (Becton Dickinson, Franklin Lakes, USA). The yeasts
were inoculated in Sabouraud-Chloramphenicol agar and in Sabouraud-
Chloramphenicol-Actidiona agar (Bio-Rad, Hercules, CA, USA) and
also in a differential isolation medium CHROMagar Candida (Becton
Dickinson, Franklin Lakes, USA). Further identiﬁcation was performed
using the API ID 32C system (bioMe´rieux, Marcy l’Etoile, France).
C. albicans was differentiated from C. dubliniensis by PCR and
restrict digestion. Candida parapsilosis isolates were conﬁrmed as
C. parapsilosis, C. metapsilosis or C. orthopsilosis by RAPD-PCR.
C. glabrata was differentiated from its phylogenetically related species
C. nivariensis and C. bracarensis by a multiplex PCR.
Results: A total of 203 isolates of Candida were identiﬁed, that
accounted for 4.2% of all positive blood cultures, with a distribution
of 33 in 2005 (3.6%); 41 in 2006 (4.4%); 57 in 2007 (5.4%); 40 in 2008
(4.3%) and 32 in 2009 (3.3%). Males, 118 (58.1%), were more prevalent
than females, 85 (41.9%). The majority of the episodes were due to
C. albicans 36.9% and C. parapsilosis 34% followed by C. tropicalis
13.3%, C. glabrata 8.3%, C. krusei 2.5%, C. guilliermondii 2.9%,
C. lipolytica 1%, C. lusitaniae 0.5% and C. sake 0.5%. The prevalence
of parapsilosis group was as follows: 94.2% (65) for C. parapsilosis,
1.4% (1) for C. orthopsilosis and 4.3% (3) for C. metapsilosis. We did
not ﬁnd any C. dubliniensis, C. nivariensis nor C. bracarensis among
our isolates.
Conclusions: C. albicans was predominant in our hospital, followed very
closely by C. parapsilosis. This is in consonance with other countries
in Europe but not with data from USA where the more prevalent non-
candida species is C. glabrata. Though the number of isolates is limited,
the prevalence of the new species in parapsilosis group is very low and
they are in agreement with recent works in Spain and Portugal. The same
as C. nivariensis or C. bracarensis, that represented only the 0,2% of
C. glabrata isolates distributed globally.
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P994 Clinical and molecular epidemiology of emerging S. aureus
ST398 strains associated with bloodstream infections in
France
N.L. van der Mee-Marquet*, X. Bertrand, P.Y. Donnio, A.-S. Valentin-
Domelier, N. Girard, R. Quentin on behalf of the Bloodstream infection
Study Group of the Re´seau des Hygie´nistes du Centre, RHC
Since 2000, a survey of bloodstream infections (BSI) has been under way
in France (JCM,2009.47:2863−71,2007.45:851−7 & 2004.42:5650−7).
Since 2006, an increase with incidence involved methicillin-sensitive
S. aureus strains, associated since 2009 with emergence of ST398 strains
(CID.2011.52:152−3). In 2010, incidence of BSI associated with ST398
highly increased into short stay units (0.008/1000 PD in 2009, 0.015 in
2010) (Figure 1).
Our objective was to characterize the clinical and molecular epidemi-
ology of ST398 and non ST398 strains involved with 613 BSI cases
diagnosed since 2007.
Methods: Antibiotic susceptibility testing & PFGE were performed for
all strains. ST398 strains were further characterized (agr type, spa type &
MLST). Demographic and clinical data were collected for all patients:
age and sex, portal of entry (skin, surgical site, lungs, urine, intravascular
device, or digestion), community-associated/hospital-acquired BSI, death
within 7 days of BSI diagnosis, duration of hospital stay.
Results: Clinical & molecular epidemiology of ST398 and non-ST398
strains differed strongly. Microbiological characteristics. Compared with
non-ST398 strains, ST398 strains were more often susceptible to
meticillin (10/12, 83%, versus 446/601, 74%) and only resistant to
erythromycin (7/12, 58%, versus 40/601, 7%; p< 0.001). ST398 strains
were characterized by different spa-types mainly t571, a susceptibility
to tetracycline and a lack of PVL production, indicating that they
differed from European pig-borne strains (spa-types 011 or 034, TetR)
and shared similarity with Chinese-type (spa-type 571, TetS). Clinical
data. ST398 BSI cases were mostly hospital-acquired (11/12, 92%), but
observed in patients hospitalized in unrelated hospitals, thus excluding
an outbreak. Compared with non ST398, ST398 BSI cases were
signiﬁcantly diagnosed following surgery (5/12, 42% versus 56/601, 9%;
p = 0.004) or associated with a digestive portal of entry (3/12, 25% versus
15/601, 3%; p = 0.004). Examination of patient history revealed exposure
to animals in only one ST398 BSI case (a fatal idiopathic community-
acquired BSI in a 84-year old man living in a farm growing one pig),
thus questioning us how the present ST398 strains were transmitted.
Conclusions:We bring data over the emerging and rapid spreading clone
of ST398 strains in human infectious diseases.
P995 Low prevalence of Coxiella burnetii endocarditis in patients
with a history of valve surgery or cardiac valve prosthesis
in a Q-fever endemic area in the Netherlands
L.M. Kampschreur*, J.J. Oosterheert, P.J. Lestrade, N.H. Renders,
P. Elsman, P.C. Wever (Utrecht, ’s Hertogenbosch, NL)
Objectives: Q fever is a zoonosis, caused by Coxiella burnetii.
Following primary infection, which is often asymptomatic, 1−5%
of patients develop chronic Q fever, of which endocarditis is the
most common manifestation. Q fever endocarditis requires long-term
antibiotic treatment and has poor prognosis if untreated The estimated
risk of developing Q fever endocarditis after primary infection for
patients with pre-existent valvulopathy was 39% in a retrospective
study, with the highest risk for patients with prosthetic valves. In the
Netherlands there has been a large outbreak of acute Q fever with
over 4000 notiﬁed cases since 2007, which allows for a more precise
risk estimation of chronic Q fever in high-risk groups. We studied the
prevalence of chronic Q fever in an endemic area in patients with a
history of cardiac valve surgery, including valve prosthesis.
Methods:We selected all patients with a history of cardiac valve surgery
from our cardiology outpatient clinic and invited them by letter for
microbiological screening. IgG antibodies to phase I and II antigens
of C. burnetii were tested by immunoﬂuorescence assay. If phase I IgG
antibodies were positive, polymerase chain reaction (PCR) on blood for
C. burnetii DNA was also performed. Chronic Q fever was considered
probable if phase I IgG antibody titre was 1024 and deﬁnite in case
of positive C. burnetii PCR in blood.
Results: A total of 663 patients were identiﬁed with a history of valve
surgery and unknown Q fever serostatus. As of December 2010, 200
patients had been invited for screening. In total, 172 patients (86.0%)
responded and were available for serological screening. Of these, 31/172
patients (18.0%) had phase I and/or phase II IgG antibodies against
C. burnetii, indicating a previous C. burnetii infection. In this group, 2/31
patients (6.5%) had phase I antibodies titres 1024, indicating probable
chronic Q fever. C. burnetii PCR was negative for both patients.
Conclusion: Despite a seroprevalence of IgG antibodies against
C. burnetii of 18.0% in patients in an endemic area with a high risk
of developing chronic Q fever, only 6.5% of these patients had probable
chronic Q fever. Compared to the previously reported risk of 39% in case
of valvulopathy, we found a considerable lower percentage of patients
who progressed to chronic Q fever after C. burnetii infection. However,
as chronic Q fever can develop years after primary infection, further
follow-up of seropositive patients is warranted.
P996 The initial presentation of soft tissue anthrax
D. Hamilton*, G. Jones (Dumfries, UK)
Objectives: To describe the early clinical presentation of anthrax in a
cluster of cases related to recreational injected drug use.
Methods: Case notes and available laboratory data were accessed to
determine common features of ﬁve conﬁrmed anthrax cases.
Results: Five cases of anthrax were identiﬁed in Dumfries and Galloway
Royal Inﬁrmary during early 2010. The following features were common
to at least four patients. Mild soft tissue swelling close to a point of
injection. The swelling was painful, soft and diffuse but not associated
with erythema, eschar or discharge. On debridement these lesions had a
distinctive gelatinous appearance with fat necrosis. Fascia was affected
but bone and skin were not. The patients were either apyrexial or had a
borderline fever never above 38 degrees centigrade. The neutrophil count
and other blood cell indices were within normal ranges; Creatinine, Urea,
Sodium, Potassium and Liver Function Tests were normal. The CRP was
raised (median 60mg/L, range 48−70). Diagnosis was by PCR (5 cases),
culture (three cases) and serology (all ﬁve cases).
Each received four antimicrobials from: benzylpenicillin, ciproﬂoxacin,
clindamycin, metronidazole and ﬂucloxacillin, as per the Scottish
Guidelines. Following early debridement serous ﬂuid loss from the
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wounds was marked, requiring ﬂuid replacement. In three the serum
albumen dropped, in the worst case from 42 to 18g/l.
All cases showed worsening and local spread of the swelling for several
days (median 4) before recovery began. None developed further lesions
or classic cutaneous anthrax. One developed signiﬁcant respiratory
compromise. All recovered and at discharge were left with minimal
restriction.
Conclusion: Subcutaneous injection of heroin led to a cluster of
distinctive cases characterised by soft tissue swelling without erythema.
The tissue was gelatinous with fat necrosis. Electrolites and blood indices
were normal. The CRP was moderately raised. Post debridement ﬂuid
loss from the wounds was marked with dramatic falls in serum albumen.
Progress was marked by initial local spread then slow resolution.
Systemic signs were found in only one patient.
Early recognition of this distinctive pattern in patients with the
predisposition should alert the diagnosing clinician to the possibility
of soft tissue anthrax.
P997 Cryptosporidiosis in Kuwaiti children: association of clinical
characteristics with Cryptosporidium species and subtypes
J. Iqbal*, P.R. Hira, N. Khalid (Safat, KW)
Objectives: To determine the association of clinical characteristics with
Cryptosporidium types and subtypes.
Methods: Fecal specimens from 2548 children with diarrhea were
screened by microscopy for Cryptosporidium spp. and the positive
specimens were genotyped and subtyped by PCR-restriction fragment
length polymorphism.
Results: Eighty seven of 2548 (3.4%) children had cryptosporidial
diarrhea by microscopy and the majority (41.4%) of the infected children
were between 4−8 year-old age group. Molecular characterization
showed that C. parvum was the most commonly identiﬁed species
(72.5%) and consisted of 4 subtypes, IIa, IId were the commonest
(78.7%) followed by IIc and IIf. Twenty-two (26.5%) of the children had
C. hominis and showed three subtypes, Id was the most common (54.5%)
followed by Ia (36.4%) and Ie. Associated clinical manifestations varied
among different Cryptosporidium spp. Diarrhea associated with subtype
Id, the most commonly identiﬁed C. hominis subtype, was more severe
than that associated with other sub-types.
Conclusion: Our study conﬁrms a very different Cryptosporidium
genotype and subtype distribution, with a predominance of C. parvum
IIa and IId among the Kuwaiti children with diarrhea suggesting that
the anthroponotic transmission is likely to be an important mode in
the epidemiology of cryptosporidiosis in Kuwait. In addition, subtype
Id of C. hominis was associated with more diverse and severe clinical
manifestations in infected children suggesting that parasite genetics
may play an important role in the clinical manifestations of human
cryptosporidiosis.
P998 Deep-brain stimulation hardware related infection: an
emerging infectious disease
F. Fily, C. Haegelen, P. Tattevin*, S. Buffet-Bataillon, M. Revest,
A. Cady, P.Y. Donnio, H. Leroy, C. Arvieux, C. Michelet (Rennes, FR)
Background: Deep brain stimulation (DBS) is increasingly used for
the treatment of severe movement disorders. As a consequence, DBS
hardware-related infections have emerged as a challenging complication
of this medical progress. Better knowledge of DBS hardware-related
infections characteristics is required to optimize patients’ management.
Methods: DBS hardware-related infections diagnosed at Rennes
University Hospital were identiﬁed through computerized database
system. Data were retrospectively extracted from medical charts. We
performed a systematic review of the literature through MEDLINE
databases using the search terms brain stimulator AND infection,
hardware-related, device-related, or abscess.
Results: Eleven patients were diagnosed with DBS hardware-related
infections between October 2006 and December 2008. Sex ratio was
1/1 and mean age was 54 years [range 21−68]. Median delay between
DBS implantation and infection diagnosis was 28 days [range 8–820].
Infection sites included pulse generator (n = 8), retroauricular incision
and sub-cutaneous electrode (n = 5), frontal incision (n = 5), and brain
(n = 3). Initial surgical treatment consisted of total hardware removal
(n = 3), partial removal (pulse generator and electrode extender, n = 7),
or wound debridement (n = 1). Surgical samples yielded Staphylococcus
aureus (n = 6), S. epidermidis (n = 2), Propionibacterium acnes, and
Micrococcus sp. (one patient each). Despite prolonged intravenous
antibacterial treatment (median duration, 6 weeks), 3 patients initially
managed with partial hardware removal ultimately required total
hardware removal. All patients survived, and no disability was attributed
to DBS-related infections.
Conclusions: DBS hardware-related infections limited to pulse generator
can be successfully treated with partial hardware removal and
prolonged antibacterial treatment, while infections involving frontal or
retroauricular sites require total hardware removal.
P999 High-level gentamycin resistant Enterococcus faecalis isolated
from urinary tract infections and poultry in close contact
with the patient
L. Poulsen*, M. Bisgaard, A. Dalsgaard, N. Son, H. An, N. Trung
(Frederiksberg, DK; Hanoi, VN)
Enterococci represent commensals of the human and animal gastroin-
testinal tract but also opportunistic pathogens causing e. g. urinary tract
infections, endocarditis and sepsis. The role of Enterococcus spp. as
nosocomial pathogens has increased but the sources of community-
acquired and nosocomial infections are still unclear. In this study,
species-speciﬁc polymerase chain reaction (PCR) was used to identify
Enterococcus faecalis from patients suffering community-acquired
urinary tract infection (UTI) in Vietnam and from poultry living in
close contact with the patient. Isolates were characterized by multilocus
sequence typing (MLST) and pulsed-ﬁeld gel electrophoresis (PFGE) to
investigate whether poultry serve as a reservoir for human E. faecalis
infections. In addition, minimum inhibitory concentrations (MIC’s)
were determined for all urine isolates for the following antimicrobials:
ampicillin, avilamicin, chloramphenicol, daptomycin, erythromycin,
gentamicin, kanamycin, linezolid, moxiﬂoxacin, penicillin, salinomycin,
streptomycin, synercid, tetracycline, tigecycline and vancomycicn.
E. faecalis was identiﬁed from 19% (n = 57) of all UTI patients (n = 300).
In 54.4% (n = 31) of these cases E. faecalis was also isolated from cloacal
swabs from poultry raised at the patients household.
In seven cases, the same MLST type (ST 16 (4 isolates), ST 93, ST
141 and a new type with the alleles; 9, 6, 7, 16, 11, 11, 8) was isolated
from urine and poultry. PFGE typing showed identical patterns for urine
and poultry isolates suggesting that poultry seem to serve as a reservoir
of the human UTI E. faecalis infections. The majority of E. faecalis
isolated from urine belonged to the MLST type ST 16 (51.8%, n = 29).
17 (29.3%) of E. faecalis isolates demonstrated high-level gentamicin
resistance (MIC 1024mg/ml).
Demonstration of identical ST16 and PFGE types of E. faecalis from
human UTI patients and poultry in close contact provides further
evidence of the zoonotic potential and global spread of this clone which
recently was reported associated with endocarditis patients and pigs in
Denmark.
In conclusion: Poultry and pigs seem to represent a reservoir of
human E. faecalis infections including high-level gentamicin resistant
E. faecalis, the zoonotic potential of which should be further investigated.
P1000 Imported symptomatic Hantavirus infection in three family
members travelling from Cuba
F. Rovida*, E. Percivalle, A. Sarasini, G. Chichino, F. Baldanti (Pavia, IT)
Objectives: To monitor imported emerging and re-emerging viral
infections in order to prevent potential local outbreaks.
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Methods: Three imported cases of hantavirus pulmonary syndrome
(HPS) in three family members travelling from Cuba are reported.
Etiologic diagnosis was based upon detection of speciﬁc IgM and IgG
using ELISA and IFA commercial assays.
Results: From 13 to 30 August 2010 three family members (father,
59 yrs old, son, 29 yrs old and daughter, 28 yrs old) visited rural areas,
natural reserves and caves in Cuba. Following their return to Italy, on
September 13 the brother and the sister were hospitalized with high
fever, mild dyspnea and bilateral diffuse interstitial inﬁltrates. Laboratory
data, on admission, showed monocytosis, slightly alteration of aspartate
aminotransferase (AST), g-glutanyl transferase (GGT), erythrocyte
sedimentation rate (ESR) and C-reactive protein concentration. At the
same time, the father showed milder symptoms, which worsened some
days later, while the clinical picture of the two sons improved. When
admitted to hospital, chest radiography of the father showed diffuse
nodular inﬁltrates associated with lymphadenopathy and dyspnea. Search
of common respiratory bacterial and viral agents was unsuccessful. On
September 21 hantavirus IgG were detected in the two sons and both
IgG and IgM were detected in the father. IgG and IgM reactivity was
stronger against New World hantavirus strains. On September 22, the
brother and the sister were discharged from hospital in the absence of
a complete resolution of the chest radiological picture. At discharge at
the end of September, the father showed a better healing of radiologic
lesions.
Conclusion: Three imported hantanvirus infection cases are reported.
No information is available on hantaviruses infections in Cuba in WHO,
CDC and ECDC databases, while presence of hanta virus infection in
Southern USA, Central and Southern America is known. Thus, this the
ﬁrst report of human hantavirus infection imported from Cuba.
P1001 A severe H1N1 and Legionella co-infection necessitating
extracorporal membrane oxygenation treatment
P. Pongratz*, G. Hinterholzer, F. Thaller, M. Rosner, D. Schmid,
C. Wenisch, H. Laferl, J. Leitner (Vienna, AT)
The most common co-pathogens occurring among patients with
2009 pandemic inﬂuenza A (H1N1) are Streptococcus pneumoniae,
Staphylococcus aureus, Haemophilus inﬂuenzae, and occasionally other
Gram-negative bacilli. Here we describe the ﬁrst case of a co-infection
with inﬂuenza A (H1N1) plus Legionella pneumophila in Austria.
A 46-year-old male smoker with a history of chronic alcoholism was
admitted for 39ºC, sore throat, myalgia and headache. He had no sputum
production, no dyspnoea and no chest pain. Physical exam revealed
BMI 22 kg/m2, 39.4 ºC, HR 120 beats/min, BP 135/70mm Hg, RR
28 breaths/min, ﬁne basal crackles and was otherwise unremarkable.
Leukocytes were 13 G/L, CRP 347mg/L, procalcitonin 7,93 ng/ml.
Other remarkable diagnostic laboratory results were hyponatriaemia
(131mmol/L), and elevated creatinekinase (1869 U/l). The chest X-ray
showed extensive inﬁltrates and a small pleural effusion on the left lung.
Within hours after admission he was transferred to ICU for septic shock,
and mechanical ventilation. Microbiological assessments, results and the
clinical course are shown in the Figure.
This case highlights that also in the “inﬂuenza season” immediate testing
for legionella is clinically useful in patients at risk.
P1002 Lymphogranuloma venereum variant L2b-speciﬁc PCR:
insertion used to close an epidemiological gap
P. Verweij, A. Catsburg, S. Ouburg, A. Lombardi, R. Heijmans,
F. Dutly, R. Frei, S. Morre´, D. Goldenberger* (Amsterdam, NL; Milan,
IT; Zurich, Basel, CH)
Objectives: After the outbreak of Lymphogranuloma venereum (LGV)
in 2003 in The Netherlands, the disease appears to be endemic among
men who have sex with men in many industrialized countries. In most
cases, Chlamydia trachomatis serovariant L2b represents the causative
organism. We developed a new L2b-speciﬁc real-time PCR based on
the pmpH gene to circumvent time-concuming and laborious ompA
sequencing.
Methods: We sequenced the pmpH gene (2952bp) of two L2b-
containing clinical specimens. To our surprise several unique differences
compared to C. trachomatis L2 were detected (Table 1). We identiﬁed
a 9-bp insertion followed by a single mutation for L2b. These two
heterogeneities were exploited to develop a new L2b-speciﬁc PCR.
Speciﬁcity and sensitivity of the assay were then evaluated.
Additionally, one single-nucleotide polymorphism was found within the
previously developed MGB-probe of a widely used LGV-speciﬁc real-
time PCR assay.
Results: Our new L2b-speciﬁc real-time PCR using a MGB-probe
was tested for speciﬁcity with all known C. trachomatis reference
serovars, 31 micro-organisms found in the local body sites for
sampling, 10 rectal swabs from healthy men, and 60 ompA-based L2b-
positive clincal specimens from Switzerland, Italy and The Netherlands.
Only the samples which had been previously diagnosed as L2b by
ompA sequencing tested positive with the new assay. The general
C. trachomatis cryptic plasmid PCR was 10−50 times more sensitive
than the L2b-speciﬁc PCR.
Concerning LGV-speciﬁc PCR, we adjusted our previously published
probe using degenerated bases. Compared to the old LGV-speciﬁc PCR,
we observed a slightly increased analytical sensitivity of factor 2 to 20 for
detection of L2b. But as compared to the previous version no additional
positives were identiﬁed testing a collection of clinical samples with
suspicion of LGV organisms.
Conclusions: Mapping the spread and prevalence of C. trachomatis
variant L2b may answer important epidemiological questions needed
for disease control and prevention. Therefore, a fast and highly accurate
detection assay is a prerequisite. Our ﬁrst L2b-speciﬁc test fulﬁlls all
these requirements omitting the laborious ompA sequencing step.
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P1003 Infective endocarditis caused by Nocardia cyriacigeorgica,
the ﬁrst case reported
S. Nimitvilai*, N. Bumrungsri, A. Leelaporn, N. Angkasekwinai,
P. Koomanachai, M. Chayakulkeeree (Bangkok, TH)
Nocardia cyriacigeorgica was ﬁrst reported in 2001, and has been
described as an emerging pathogen in the United States. We present
a case of infective endocarditis (IE) caused by N. cyriacigeorgica
in idiopathic thrombocytopenic purpura (ITP) patient with prolonged
corticosteroid therapy.
Case report: A 62-year-old Thai female was admitted to a tertiary-care
university hospital with a 3-week history of high grade fever without
other symptoms. She was previously diagnosed of ITP for 1 year. The
patient was on prednisolone and had a reducing dose to 10mg/day
since 4 weeks after improvement of her condition. On examination,
the patient was alert with temperature 39C, heart rate 78/min, blood
pressure 82/57mmHg and respiratory rate 20/min. Heart sounds revealed
a pansystolic murmur grade III/VI over the apex radiate to axilla.
No vascular or immunological phenomenon was present. The rest of
physical examination was unremarkable. Transthoracic echocardiography
(TTE) revealed a 9.27*6.6mm oscillating mass attach to anterior
mitral valve leaﬂet. Four sets of blood cultures revealed Nocardia
spp. with subsequently identiﬁed as N. cyriacigeorgica by using
16S ribosomal DNA and secA1 gene sequencing. IE was diagnosed.
Imipenem, amikacin and trimethoprim-sulfamethoxazole (TMP-SMX)
were prescribed. TTE was follow-up after 4 weels amd revealed increased
in size of oscillating mass to 9.6*7.2mm. Mitral valve replacement was
performed. The patient responded well to therapy and discharged with
oral TMP-SMX and anticoagulants.
Discussion: From recent study in Thailand, N. cyriacigeorgica was the
third most common species (13.5%) after N. farcinica (35.4%) and
N. beijingensis (18.8%) by using 16S ribosomal DNA sequencing. The
organism has been reported from cases of septicemia, brain abscess,
pleuropulmonary infection and keratitis. Nocardia spp. are a rare cause of
endocarditis. Only 17 cases of Nocardia endocarditis have been reported
in the literature. There has been a reported case of N. cyriacigeorgica
isolated from abscess of thigh and anterior chest wall in patient with
suspected IE but negative blood culture. To our knowledge, this is the ﬁrst
case of deﬁnite IE caused by N. cyriacigeorgica that was successfully
treated with antibiotics and valve replacement.
P1004 Q fever across the Dutch border in Limburg province,
Belgium
R. Naesens*, K. Magerman, I. Gyssens, A. Leenders, J. Meekelenkamp,
M. Van Esbroeck, G. Coppens, E. Oris, J. Craeghs, I. Thoelen,
P. Gabrie¨ls, M. Vandevelde, A.-M. Forier, L. Waumans, R. Cartuyvels
(Hasselt, BE; ’s-Hertogenbosch, NL; Antwerp, Genk, Tongeren,
Sint-Truiden, Maaseik-Bree, BE)
Objective: Recently the Netherlands experienced a large outbreak of
human Q fever. We present the ﬁrst data on Q fever in Limburg, the
Belgian province which borders the outbreak area.
Methods: Data were compiled from three different sources. Firstly,
data (Jan.2003–Nov.2010) from the Belgian Q fever reference laboratory
were reviewed. Ratios of samples with elevated levels of IgM phase II
antibodies were determined. Secondly, a multi-centre prospective survey
was started in Limburg in April 2010. Five clinical hospital laboratories
each consecutively collected 20 serum samples from patients for whom
clinicians requested Mycoplasma pneumoniae but not Q fever serology.
Only samples with negative Mycoplasma IgM results were included.
Methods to detect C. burnetii exposure depended on the symptom
duration.
Thirdly, data (Nov.2009–Sept.2010) from the Belgian livestock screening
program, which started in winter 2009–2010, were analyzed. The
program 1. Investigated all compulsory reported abortions (RT-PCR);
2. Systematically tested tank milk on dairy sheep and goat farms of
>10 animals (RT-PCR and serology); 3. Randomly performed serological
screening of cattle farms.
Results: For 2003–2006, elevated IgM II antibody levels were found in
2%, 1%, 1%, and 1% of 1084, 1122, 1488, and 1447 human clinical
samples from the national reference laboratory respectively. In 2007,
an increase to 60 (4%) positive samples out of 1656 was notiﬁed.
In Limburg, 5% (4 out of 75) of samples were positive in that year.
The positive ratio dropped in 2008–2010 to 1% for both Belgium and
Limburg.
In the prospective provincial study, evidence of an acute C. burnetii
infection (positive PCR) was found in 3 out of 100 human clinical
samples.
Livestock screening in Limburg revealed a seroprevalence of 10%
in randomly selected cows; 42% of 45 tested cattle farms contained
seropositive cows. C. burnetii was detected in 17% of 129 cattle
abortions. In contrast, no Coxiella was found in the 4 goat and 3 sheep
abortions that were reported. Tank milk showed evidence for C. burnetii
in 0 out of 1 dairy sheep, and 1 out of 9 dairy goat farms.
Conclusion: C. burnetii is highly prevalent in Limburgian livestock,
especially in cattle, and is also causing human infections. The ratio of
positive human samples from the national reference centre has remained
stable over 7 years (1−2%), with just a temporary increase to 4−5% in
2007, the year of onset of the notorious outbreak in the Netherlands.
P1005 Prevalence of Borrelia burgdorferi sensu lato, Anaplasma
phagocytophilum, Rickettsia spp. and Babesia spp. in ticks
removed from humans in the area of Belluno, Italy
L. Brugnera Muraro, A. Tessari*, G. Del Giudice, G. Piccolin,
M. Battistel, E. Modolo, G. Bertiato (Belluno, IT)
Objectives: To investigate the prevalence of 4 human pathogens in
Ixodes ricinus hard ticks removed from humans, in order to asses the
potential risk of transmission of human pathogens vectored by ticks
resident in the mountain area of Belluno, close to Dolomites.
Methods: A total of 275 ticks were collected in 2009 (n = 102) and
2010 (n = 173) removed from patients at the emergency ambulatory
care of 3 hospitals in the area of Belluno, located in Belluno city,
Agordo and Pieve di Cadore. Ticks were collected during spring-
summer and counted 35% of adults, 65% of nynphae and 2% of
larvae. Each tick was individually processed for DNA extraction with
bioMe´rieux® NucliSens® miniMAG system. Extracts were preliminarily
checked with speciﬁc primers targeting Ixodes ricinus mithocondrial
DNA. Each sample was screened by Real-Time TaqMan PCR for
Borrelia burgdorferi sensu lato (ﬂa gene), Anaplasma phagocytophilum
(msp2 gene) and Rickettsia spp. (gltA gene), all performed on an Applied
Biosystems® 7300 Real-Time PCR system. A conventional PCR was
adopted for detection of Babesia spp.
Results: 19 of 102 of ticks collected in 2009 resulted positive for
B. burgdorferi sl, 4 for A. phagocytophilum, 8 for Rickettsia spp. and 3
for Babesia spp. In 2010 positive samples counted 14% of B. burgdorferi
sl (24/173), 3% of A. phagocytophilum, 16% of Rickettsia spp. and 9%
of Babesia spp. Four tick resulted co-infected with B. burgdorferi sl and
A. phagocytophilum, 3 with B. burgdorferi sl and Rickettsia spp., one
with B. burgdorferi sl and Babesia spp. and one with A. phagocytophilum
and Babesia spp. No sierological screening was included in the study but
one case of borreliosis acquired after the bite of a tick resulted positive
for Borrelia burgdorferi sl was documented clinically and serologically.
Conclusion: Residents of Belluno area are often exposed to ticks and
thus are at risk of acquiring infection with multiple tick-borne pathogens.
Epidemiological reports are mainly focused on Tick Borne Encephalitis
virus infection and borreliosis, endemic in the area of Belluno. Infections
caused by tick-vectored A. phagocytophilum, Rickettsia spp. and Babesia
spp. could be misdiagnosed because serological test are performed only
in reference centres and clinical diagnosis could be critical. Data obtained
from the study suggest that borreliosis is not the only diagnosis to be
considered along that could by transmitted to humans by hard tick bite.
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P1006 Intracellular growth and survival of Vibrio cholerae in
human macrophages
H. Abd* (Stockholm, SE)
Objectives: Vibrio cholerae is Gram-negative bacteria found in water
and it can be carried by sea living animals, such as shellﬁshes. V. cholerae
O1 and V. cholerae O139 produce cholera toxin and cause cholera in
humans. Despite that cholera infects millions and kills many thousands
patients under pandemics and thus causes a global health problem,
there is at present not enough information about how this bacterium
lives in human. The prevalence rate of infections caused by Vibrio
appears to be increasing globally. The combination of increased water
temperature and salinity may contribute to increased association rates of
the bacteria with sea living animals or protozoa. Author doctoral thesis
showed that V. cholerae O1 and O139 grew and survived inside the
protozoa Acanthamoeba castellanii. The current project is ﬁnanced by
the Swedish Civil Contingencies Agency (MSB), and is aimed to study
abilities of clinical isolates of V. cholerae O1 and O139 to grow/survive
inside human macrophages and disclose roles of bacterial capsule,
lipopolysaccaride O-side chain and outer membrane protein A on the
intracellular growth and survival of V. cholerae.
Methods and Microorganisms: Vibrio cholerae O1clasical, V. cholerae
El Tor wild type, V. cholerae El Tor outer membrane mutant, V. cholerae
O139 wild type, V. cholerae O139 capsule mutant, V. cholerae
O139 capsule/LPS O-side chain double mutant, human macrophage
TPH-1and human macrophage U937. An antibiotic assay used to
differentiate between extracellular and intracellular V. cholerae. Vibrio
species cultivated with human macrophages. Gentamicin used to kill
extracellular bacteria. Intracellular growth and survival examined by
viable count, ﬂuorescent microscopy and RNA detection. Intracellular
localisering visualized by confocal- and electron microscopy. Roles of
bacterial capsule, lipopolysaccaride O-side chain and outer membrane
protein A on the intracellular growth and survival of V. cholerae
examined by statistical veriﬁed comparison between growth of wild type
and mutant corresponded strain.
Results: The utilized methods showed that V. cholerae grew and survived
inside human macrophages. The antibiotic assay differentiated between
the extracellular and intracellular V. cholerae.
Conclusions: The intracellular behavior of V. cholerae may induce cell
mediated and humoral immunity and explains complexity of V. cholerae
and aids to new strategies for vaccination as well as treatment against
cholera.
P1007 Clinical and epidemiological features of Chikungunya fever
in returning travellers
P. Papineni*, M. Armstrong, T. Doherty (London, UK)
Objectives: Data on the epidemiology and clinical course of chikun-
gunya virus infection in returning travellers to the UK is scarce. The
Indian Ocean Islands, where outbreaks have been identiﬁed, are a popular
holiday destination for British travellers, and there is a large immigrant
population from the Indian sub-continent in London, who visit friends
and relatives in endemic areas. Here we present a case series from ten
years experience of managing patients diagnosed with chikungunya fever
at the Hospital for Tropical Diseases (HTD), London.
Methods: Patients were identiﬁed from a database of patients
presenting to the HTD inpatient and outpatient services from 2000
to 2009. Retrospective analysis of case notes to identify clinical
and epidemiological features was conducted. Serological testing was
performed by the Health Protection Agency’s (HPA) Special Pathogens
Reference Unit.
Results: 16 patients were identiﬁed with a mean age of 48.6 years (range
27−78). 11 patients were female. 9 patients gave the reason for travel as
visiting friends and relatives, 6 were on holiday and 1 travelled for work.
The majority of patients had visited Mauritius (56%). 4 had visited India
and 3 patients had travelled to Sri Lanka.
All patients reported symptoms of fever and arthralgia. In 44% of
patients, the clinical presentation included headache and 56% reported
macular erythematous rash. Only 2 patients had documented pyrexia
(greater than 38 degrees celcius) at presentation to HTD.
13 patients had full blood count performed and 15 patients had serologi-
cal testing. Thrombocytopenia (platelet count less than 150,000/microL)
was only present in one patient. Lymphopenia (lymphocyte count
less than 1.3/microL) was only observed in 2 patients; these were
both laboratory conﬁrmed cases by polymerase chain reaction (PCR).
11 patients had acute serology positive for chikungunya. 4 patients
had negative acute serology, but were conﬁrmed chikungunya by
PCR. Convalescent serology on 3 of these patients then demonstrated
seroconversion with chikungunya IgG detected.
Conclusions: There is a risk to British travellers to chikungunya-
endemic areas, particularly Mauritius. The absence of thrombocytopenia
and lymphopenia may help to distinguish chikungunya infection from
dengue and serological testing is useful in suspected cases.
P1008 Crimean-Congo haemorrhagic fever: six-year experience of
a secondary care hospital in the epidemic region
C. Kader*, A. Erbay, S. Bakir O¨zbey (Kastamonu, Yozgat, TR)
Objectives: Crimean-Congo hemorrhagic fever virus (CCHFV) is the
most widespread tick-borne virus that causes disease in humans. Since
2002, a rapid emergence of CCHF in the central, northern and eastern
regions of Turkey has occurred and CCHF has become a public health
problem in Turkey. The aim this study was to evaluate the patients
characteristics followed at a secondary care hospital at the CCHF
epidemic region.
Methods: Retrospective cohort study. Among the patients who were
followed up during the spring and summer of 2005–2010, patients with
IgM antibodies or PCR results positive for CCHFV in blood were
included in the study. The demographics, clinical and laboratory ﬁndings
were examined for each patient from the medical records.
Results: 281 patients were followed up between 2005 and 2010. Male
patients accounted for 121 (43.1%) of the patients and the mean age was
48.8±19.8 years. 251 (90%) of the patients were living in rural regions.
Husbandry and raising livestock were the most common occupations
(73%). Mean duration of symptoms were 1.6±1.2 (range 1−7) days
before hospital admission. Initial complaints were myalgia (79.7%),
headache (59.8%), nausea (57.1%), fever (38%), vomiting (12.5%)
and bleeding (2.1%). History of tick bite was present in 262 (93.6%)
cases. Time between tick bite and clinical symptoms were 3.9±1.6
days. Clinical ﬁndings were as follows; fever >38C (38.8%), epistaxis
(2.1%), splenomegaly (1.4%), somnolence (1.1%), melaena (1.1%),
gingival bleeding (0.7%) and ecchymosis (0.7%). Almost all of the
patients had leucopenia (99.6%), thrombocytopenia (100%), and elevated
AST (93.6%), ALT (93.6%), LDH (60.9%) and CPK (96.8%) levels
at admission. Thrombocyte level was <20000/mm3 in 20.6% of the
patients. Ribavirin was initiated 84.7% of the patients at the admission
day. 61.9% of the patients received platelets and 30.6% erythrocyte
infusions. 142 (50.5%) patients transferred to tertiary care facilities. The
main reason for transfer was deterioration of the clinical status (85.9%).
Overall fatality rate was 3.6%, mortality was seen only in transferred
patients.
Conclusion: Most of the reports about CCHF were from tertiary care
centers. Patient proﬁle, clinical symptoms, laboratory ﬁndings and case
fatality rate were much more milder in secondary care compared to
tertiary care centers.
P1009 All-cause mortality among hospitalised CDI patients is
associated with PCR-ribotype 027 but independent of the
presence of binary toxin
M.P. Hensgens*, A. Goorhuis, O.M. Dekkers, E. Kuijper (Leiden, NL)
Objectives: Incidence and mortality of patients with Clostridium difﬁcile
infections (CDI) have increased since the hypervirulent PCR ribotype
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027 emerged in 2002. CDI due to this type is associated with mortality
up to 25% after 30 days. This is often due to underlying comorbidities,
but estimated attributable mortality still accounts for about 4% or all
deaths. Since reliable mortality data are scarce, we performed a large
cohort study in an endemic setting in the Netherlands. A second aim
of this study was to determine the association of 30-day mortality with
C. difﬁcile PCR-ribotype.
Methods: From July 2006 to the end of April 2009, 13 Dutch hospitals
participated in a surveillance study investigating the incidence of CDI,
clinical course and outcome. All hospitalized patients with a ﬁrst episode
of diarrhoea and a positive assay for the toxin of Clostridium difﬁcile
were included. Survival status was obtained of all patients via the Dutch
Civil Registration System. We used a Cox-regression analysis to identify
determinants associated with death within 30 days.
Results: We identiﬁed 1367 patients with CDI, corresponding with an
incidence rate of 13 per 10,000 admissions. The cumulative all cause
mortality was 13% after 30 days, 30% after 6 months and 37% after
one year. Data on PCR-ribotype and the presence of binary toxin were
available for 685 patients (50%). 22% of the 55 patients with CDI due to
type 027 died within 30 days, compared to 15% of the 98 patients with
non-027/binary toxin positive CDI and 11% of the 399 patients with
the binary toxin negative CDI. Death within 30 days was signiﬁcantly
associated with age, Charlson comorbidity index and PCR ribotype 027
and remained associated after adjustment for age. The presence of binary
toxin in non-027 strains, was not signiﬁcantly associated with mortality.
Conclusion: Mortality among CDI patients is high, even in an endemic
situation. All cause mortality after 30 days was independent of the
presence of binary toxin, but depended on age, underlying diseases and
PCR ribotype 027.
P1010 Dutch patients, retail chicken meat and poultry share the
same ESBL genes, plasmids and strains
M. Leverstein-van Hall*, C.M. Dierikx, J.W. Cohen Stuart, G.M. Voets,
T.M. van den Munckhof, A. van Essen-Zandbergen, T.N. Platteel,
A.C. Fluit, N. van der Sande, J. Scharringa, M.J. Bonten, D. Mevius
on behalf of the ESBL national surveillance working group
Objectives: In the Netherlands, the incidence of infections with ESBL-
producing Enterobacteriaceae has increased in recent years despite low
levels of antibiotic use and stringent infection control policies. Antibiotic
use in the Dutch poultry industry is the highest in Europe and intestinal
carriage with ESBL-producing bacteria in food-producing animals has
been shown to result in contamination of retail meat. The aim of this
study was to quantify the proportion of human E. coli isolates with
ESBL genes, plasmids and genotypes that correspond to those found in
poultry or retail chicken meat.
Methods: The distribution of ESBL genes, plasmids and strain
genotypes in E. coli obtained from poultry and retail chicken meat in the
Netherlands was determined and deﬁned as “poultry-associated” (PA).
Subsequently, the proportion of E. coli isolates with PA ESBL genes,
plasmids and strains was quantiﬁed in a representative sample of clinical
isolates. E. coli were obtained from 96 non-frozen retail chicken meat
samples, a national prevalence survey among poultry, and 516 human
clinical samples from 31 laboratories collected during a 3 month period
in 2009. Isolates were analyzed using an ESBL-speciﬁc microarray,
sequencing of ESBL genes, PCR based Replicon Typing of plasmids,
plasmid Multi-Locus Sequence Typing (pMLST) and strain genotyping
(MLST).
Results: Six ESBL genes were deﬁned as PA (blaCTX-M-1, blaCTX-
M-2, blaSHV-2, blaSHV-12, blaTEM-20, blaTEM-52). Of the human
E. coli isolates, 35% (95%CI 30−39%) contained PA ESBL genes,
86% of which were either blaCTX-M-1 or blaTEM-52. These were also
the predominant ESBL genes in poultry (77%) and retail chicken meat
(75%). In 19% (95%CI 15−23%) of human E. coli, the PA ESBL genes
were located on IncI1 plasmids that were genetically indistinguishable
from those obtained from poultry (meat). In 11% (95%CI 8−14%) not
only the genes and plasmids but also the MLST genotypes were identical.
Of the retail meat samples, 94% contained ESBL producing isolates of
which 39% belonged to E. coli genotypes also present in human samples.
Conclusion: These ﬁndings are suggestive for transmission of ESBL
genes, plasmids and E. coli isolates from poultry to humans, most likely
through the food chain.
P1011 Characteristics of microsporidial keratoconjunctivitis in an
eastern Indian cohort: a case series
S. Saha*, A. Khetan, D. Banerjee, J. Sengupta (Midnapore West,
Kolkata, IN)
To determine the characteristics of microsporidial keratoconjunctivitis in
an otherwise immunocompetent group of patients attending the cornea
care unit of Kolkata (eastern India) based tertiary care eye hospital.
A retrospective, noncomparative, observational case series involving
patients with microsporidial keratoconjunctivitis from June 2009
to September 2009. Of the 24 patients identiﬁed, microbiological
conﬁrmation in direct smear was obtained in 22 cases and selected
for analysis. Standard microbiological workup was performed in all
cases. We studied the demographics, predisposing conditions, antecedent
treatment received before presentation, clinical characteristics, treatment
offered and resolution time with sequel. The management consisted of
simple debridement and application of chloramphenicol ointment (1%)
2 times a day till healing of epithelial defect.
Mean age of onset was 18.7 yrs (95%CI 15.7–21.7; range 11−36 years).
All patients gave history of wetting in the rains prior to episode.
Predisposing activities included playing soccer (54.5%), cricket (18.2%),
golf (13.6%) and rugby in 1 patient. Antecedent treatment comprised
of Acyclovir eye ointment (45.4%), antibiotic eye drop (27.3%) most
commonly. Microsporidia were identiﬁed in Grams stain (81.8%), KOH
(72.7%), Modiﬁed ZN staining (36.4%) and Giemsa (18.2%). Majority
presented as unilateral superﬁcial keratoconjunctivitis with punctate
epithelial keratitis except one with bilateral disease. Mean resolution
time was 9 days (95%CI 7.9–10.2).
Microsporidial keratoconjunctivitis can occur in normal patients with
exposure to rain and mud, related to outdoor activity often misdiagnosed
as viral ocular infections. Strong clinical suspicion with proper
microbiological evaluation helps to diagnose this commonly missed
condition.
P1012 Rapid recognition of Clostridium difﬁcile PCR ribotypes
027 and 078 using MALDI-TOF mass spectrometry
C.W. Knetsch, J. Corver, E. Kuijper* (Leiden, NL)
Objective: In the past decade, incidence of Clostridium difﬁcile
infections (CDI) with more severe disease increased and coincided with
the emergence of hypervirulent PCR ribotype 027. Recently, a new
virulent strain has been noticed in Europe which was characterized as
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PCR ribotype 078 and affected younger people with similar CDI severity
as type 027. The aim of this study was to explore the application of
matrix-assisted laser desorption ionization mass spectrometry (MALDI-
TOF MS) as a rapid technique to recognize these emerging C. difﬁcile
strains.
Methods: Since November 2009, MALDI-TOF MS has been validated
and implemented for routine bacterial identiﬁcation at the LUMC
clinical microbiology lab. The MALDI-TOF Microﬂex system (Bruker
Daltonics) is combined with the Bruker Biotyper database which
contains approximately 3.500 organisms, including (n= 10)reference
strains of C. difﬁcile. Bacterial identiﬁcation is performed using an
algorithm whereby scores above 2.3 are classiﬁed as identiﬁcation on
species level with high certainty.
Results: First, a separate database was build for C. difﬁcile using spectra
from over 50 different isolates belonging to 7 different PCR ribotypes
(001, 027, 078, 012, 014, 044 and 087). For this purpose only spectra
of high quality were used. Whole cell protein extracts were made
by performing an ethanol wash followed by a formic acid/acetonitril
extraction. 0.8 ul sample was transferred on a polished steel target
plate (Bruker Daltonics) and covered with a-Cyano-4-hydroxycinnamic
acid (HCCA) matrix. Reference spectra were obtained for 7 different
reference PCR ribotypes, namely 001, 027, 078, 012, 014, 044 and
087. Second, we typed over 50 clinical isolates obtained from the
National Reference Laboratory and belonging to the above mentioned
PCR ribotypes with the following results: 100% recognition of Type 027
(42 spectra from 7 isolates), 94.3% recognition of Type 078 (72 spectra
from 12 isolates), and 94.5% recognition of Type 001 (72 spectra from 12
isolates). The other PCR ribotypes (012, 014, 087 and 044) scored lower
ranging from (68.5% until 90.3%). All bacterial identiﬁcation scores
were high (>2.4).
Conclusion: MALDI-TOF MS is capable to recognize strains of
C. difﬁcile type 027 and 078, but improvement is needed for the other
types.
P1013 Invasive disease caused by Haemophilus inﬂuenzae serotypes
e and f in England and Wales
A. Vickers*, C. Crawford, D. Litt, S. Ladhani, M. Slack (London, UK)
Objectives: To analyse epidemiological data on invasive H. inﬂuenzae
disease caused by serotypes e and f (Hie and Hif) between 2000 and
2010, and to characterise the clinical bacterial isolates using multilocus
sequence typing (MLST).
Methods: The UK Health Protection Agency routinely collects
epidemiological data (patient’s age, sex and broad clinical presentation,
and the serotype of the bacterial isolate) for all cases of invasive
H. inﬂuenzae disease. After 2008, clinicians were asked to complete
a questionnaire for all invasive H. inﬂuenzae cases and provide detailed
clinical information relating to underlying co-morbidities, speciﬁc
clinical presentation, case fatality and cause of death. This study analysed
data on invasive Hie and Hif cases diagnosed between 2000 and 2010
inclusive. Clinical isolates were collected from the majority of cases.
MLST was performed using standard methods.
Results and Conclusions: The number of cases of invasive disease
caused by Hie and Hif has been increasing since 2000. Serotype b (Hib)
lost its position as the most common capsulated H. inﬂuenzae causing
invasive disease for the ﬁrst time in 2009 (8% of cases due to Hib, 4%
to Hie and 9% to Hif; 79% to nontypable Hi).
Detailed clinical follow-up of 22 Hie and 67 Hif cases from 2009−10
revealed that most cases occur in the older age groups, of whom
~80% had underlying co-morbidities. For both serotypes, ~50% of cases
presented with pneumonia, but Hie was more likely to present with
meningitis than Hif. Case fatality was associated with older age and the
presence of co-morbidities. Fatality within 7 days was higher among Hie
infections, suggesting that this serotype may directly have contributed to
the fatal outcome.
Characterisation of Hie and Hif bacterial isolates showed that they
possessed MLST types clustered around ST18 and ST124 respectively.
These clusters were distinct from each other and other H. inﬂuenzae
types, with the exception of type ST18, which had been seen previously
amongst Hib isolates from the 1990s. This suggests that at least some
Hie strains may have arisen from Hib strains via capsule switching.
P1014 Emergence of uncommon EMM types of Streptococcus
pyogenes among adult patients in southern Taiwan
C. Chiang-Ni, A.B. Wu, C.C. Liu, K.T. Chen, Y.S. Lin, W.J. Chuang,
H.Y. Fang, J.J. Wu* (Tainan, TW)
Objectives: Streptococcus pyogenes isolated from adult patients during
a 12-year period in southern Taiwan were analyzed to estimate
the distribution of emm types and their correlation with disease
manifestations and patient age.
Methods: Three hundred and thirty-four invasive and non-invasive
isolates collected from patients over 20 years old between 1997 and
2008 at National Cheng Kung University Hospital were included for
emm typing. A correlation between emm type, disease manifestations,
and patient ages was analyzed.
Results: The nine most prevalent types were emm11, emm12,
emm4, emm1, Sp9458/VT8, emm81, emm106, emm13 and emm75.
Formerly rare emm types, including emm11, emm81, and emm102,
emerged dramatically after 2004 in southern Taiwan. Type emm11 was
signiﬁcantly associated with both superﬁcial infections and cellulitis. In
addition, types emm13, emm81, and emm106 were more prevalent in
patients older than 50 years and signiﬁcantly associated with speciﬁc
invasive disease manifestation.
Conclusion: These results suggest new emm types (emm11, emm81,
and emm102) of Streptococcus pyogenes were introduced into the adult
population in southern Taiwan after 2004. The rarely reported emm
types, including emm13, emm81, and emm106, caused invasive diseases
more often in adult patients.
P1015 Phylogenetic and virulence analysis of tick-borne
encephalitis virus ﬁeld isolates from Switzerland
C.M. Beuret* (Spiez, CH)
Tick-borne encephalitis (TBE) is an endemic disease in Switzerland,
with about 110–120 reported human cases each year. Endemic areas
are evidentially present throughout the country. Despite this widespread
and increasing risk of infection, the viruses circulating in Switzerland
have not been characterized so far. Here we present complete envelope
(E) protein sequence analysis and phylogenetic classiﬁcation of 72 TBE
virus ﬁeld isolates recovered from Ixodes ricinus ticks sampled at 39
foci throughout Switzerland. All isolates were classiﬁed as members
of the European TBEV subtype and revealed to be conserved among
each other, showing a sequence identity of 84.9% at the nucleotide
and 94% at the amino acid level of the E protein, respectively.
Sixty-four isolates were characterized with respect to their virulence,
revealing a very heterogeneous population producing plaques of different
size and morphology in cell culture. Isolates frequently produced a
mixture of plaques, with phenotypes ranging from large to minute and
from sharp-edged and clear to barely visible and diffuse. Whereas all
isolates investigated in adult laboratory mice exhibited a high level of
neurovirulence (100% mortality), the neuroinvasiveness was relatively
low, with mouse survival rates ranging from 50 to 100%.
To summarize, here we describe the basic characterization of TBEV
isolates originating from established as well as emerging disease foci
throughout Switzerland. Whereas many endemic areas are characterized
by the presence of a heterogeneous population of TBEV variants
circulating in questing Ixodes ricinus ticks, some foci appear to be
more isolated, maintaining the circulation of phylogenetically closely
related strains. Among all isolates, a total of 30 different aa substitutions
were identiﬁed in the E protein, none of which however could clearly
be correlated with an attenuated virulence phenotype. The observed
relatively low virulence of most TBEV isolates could be in relation with
a number of asymptomatic or mild TBEV infections in Switzerland.
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P1016 Comparative genetic characterisation of human and animal
isolates of methicillin-resistant Staphylococcus aureus ST398
D. Jamrozy*, M. Sharma, M. Fielder, A.F. Kelly, P. Butaye, R. Ehricht,
S. Monecke, N. Coldham (New Haw, London, UK; Brussels, BE;
Jena, Dresden, DE)
Objectives: The recently emerged livestock-associated methicillin-
resistant Staphylococcus aureus ST398 poses a potentially signiﬁcant
risk to both farming industry as well as persons in contact with food-
producing animals. In this study a panel of MRSA ST398 strains were
subjected to comparative genetic characterisation to identify markers that
distinguish the strain from other lineages of S. aureus.
Methods: Fifty six strains were characterised consisting of: MRSA
ST398 (N= 18) and non-ST398 S. aureus: MSSA derived from cattle
(N = 18), MSSA and MRSA derived from humans (N= 20). All
isolates were subjected to PFGE, spa typing, and sequence type/clonal
complex assignment. Strains were characterised by Identibac MRSA
array tube (version pm5.5), which allows detection of S. aureus-
associated virulence and antimicrobial resistance genes. In addition
MRSA strains only were SCCmec typed, screened by PCR for presence
of additional antimicrobial resistance genes (ermT, dfrK, tetL) and
subjected to antimicrobial susceptibility testing by broth microdilution
method according to CLSI.
Results: Strains belonging to ST398 were found to harbour no lineage-
speciﬁc virulence determinants. The only genes detected in MRSA
ST398 panel were those found in all or majority of characterised strains:
hla, hld, hlgA, lukS, lukF, entX (SAV1601), entY and sarA. All MRSA
strains were found to carry at least one additional resistance gene other
than mecA. Previously described novel resistance genes such as dfrK
were detected among MRSA ST398 strains only. Erythromycin resistance
was common among all MRSA strains. All strains belonging to ST398
were resistant to tetracycline, with resistance to clindamycin (N= 14),
trimethoprim (N= 13) and gentamicin (N= 9) also being common.
Resistance to tiamulin (N= 4) and ﬂorfenicol (N = 3) was also detected.
Human MRSA strains belonged to CC22 and CC30, with all showing
resistance to ciproﬂoxacin and the majority being susceptible to the
remaining antimicrobials tested.
Conclusions: MRSA ST398 strains appear to lack major virulence
factors in comparison to other lineages of both animal and human
derived S. aureus strains. MRSA ST398 also displays high frequency of
antimicrobial resistance elements including presence of novel resistance
genes. While such multi-drug resistance would pose a considerable
therapeutic challenge the apparent lack of signiﬁcant virulence genes
would suggest low pathogenic potential.
P1017 Essentiality of dUTPase mediated by its Mycobacterium-
speciﬁc structural motif identiﬁes a novel TB drug target
I. Pecsi*, R. Hirmondo, A.C. Brown, A. Lopata, T. Parish, V.G. Beata,
J. Toth (Budapest, HU; London, UK)
Objectives: Thymidine biosynthesis is an essential metabolic pathway
in all cells. dTTP is synthesized via the uracil-containing nucleosides
dUTP and dUMP. To fulﬁll the task of dTTP synthesis, three major
pathways exist in humans, two de novo and one salvage pathway. In
mycobacteria, only one of these is present; this involves the action of
the enzyme dUTPase (dut) whose role is to eliminate excess dUTP.
dUTPase has been implicated as a potential drug target due to its central
role in mycobacterial thymidylate synthesis and to its essentiality in
E. coli and S. cerevisiae. All known mycobacterium genomes contain
dUTPases of 85% sequence identity which possess a mycobacterium-
speciﬁc motif that distinguishes them from the human dUTPase. The
purpose of this study was to obtain formal genetic proof of essentiality
of dut in mycobacteria and to assess the physiological role of the insert
present solely in mycobacterial genomes.
Methods: Experiments were performed in M. smegmatis to disrupt the
dut gene via two-step homologous recombination. Merodiploid strains
were generated to assay functional complementation of the wild-type
or mutant dut. The mutant contained a ﬁve-amino-acid deletion of the
mycobacterium-speciﬁc insert.
Results: Initial attempts to obtain mutant double crossover strains (DCO)
with the disrupted dut were unsuccessful. This provided preliminary
evidence that the gene might be essential. To prove this, we introduced
a functional copy of dut into a well-deﬁned chromosomal site and
screened for DCOs in this merodiploid background. Southern blot
analysis conﬁrmed that we could obtain the disrupted chromosomal copy
of dut in this background. Then we attempted to complement the lethal
mutant phenotype with the mutant dut gene lacking the mycobacterium-
speciﬁc insert. The screening procedures resulted in a wild type and a
spontaneous sucR single cross-over cell line; the remaining 86 colonies
were nonviable in the applied selection conditions.
Conclusions: These results provide formal genetic proof of dut
essentiality in M. smegmatis. Additionally, the mycobacterium-speciﬁc
motif exposed on the protein surface is necessary for complementation
of the dut function. As this genus-speciﬁc structural motif is not present
in the human dUTPase and is required for mycobacterium viability we
propose that targeting this site will potentially yield an efﬁcient and
speciﬁc antimycobacterial treatment.
P1018 West Nile fever outbreak in humans in northern Greece
D. Karabaxoglou*, A. Karabournidis, G. Kagkalou, E. Vassiliadou,
F. Kamaria, D. Chrysagis, A. Bakas, A. Kansouzidou (Thessaloniki, GR)
West Nile Fever (WNF) is a viral disease transmitted by mosquitoes and
is distributed worldwide. Sporadic human cases, clusters or outbreaks
have been reported from European countries. WNF usually is a febrile
illness characterized by fever, headache, manulopapular or roseolar
rash, lymphadenopathy and many other symptoms. Occasionally, aseptic
meningitis or encephalitis occurs.
Aim: The aim of the report is the recording and study of the WNV
outbreak that has been observed in Northern Greece, during the period
July-September 2010. Patients with febrile-rash illness (followed by
leucopenia and thrombocytopenia) or with Central Nervous System
infection were included in the study.
Methods: A total of 119 patients, 112 adults (56 males, 56 females)
aged 18−93 years old and 7 children (5 males, 2 females) aged 7−12
years old, were examined. Of the total patients, 35 were hospitalized with
central nervous system infection (34 adults, 1 child), 73 with febrile-rash
illness (67 adults, 6 children) and 11 with febrile illness (all adults). In
patients with suspected WNV infection serum samples were tested for
the presence of IgM and IgG antibodies against WNV. In 14 patients
a second serum sample was available. WNV speciﬁc antibodies were
detected with an indirect qualitative ELISA (Focus Diagnostics, USA).
The diagnosis of WNF was based on positive titers of IgM or/and IgG
speciﬁc antibodies.
Results: WNV neuroinvasive disease was conﬁrmed in 23 adult patients
and in 1 child (rate 68,6%). In these patients speciﬁc IgM and/or
IgG antibodies were detected in serum specimens. WNV neuroinvasive
infection was conﬁrmed in 17 patients older than 50 years and 8 of them
died (case-fatality rate 34,8%). In 33 patients (29 adults, 4 children) out
of the 73 patients with febrile-rash illness and in 5 out of 11 adult
patients with febrile illness speciﬁc WNV antibodies were detected, rate
45,2% and 45,6% respectively. In these patients speciﬁc IgM antibodies
were mainly detected in serum samples. WNV febrile-rash disease was
documented in 25 patients aged less than 50 years old. In patients in
which a second serum sample was examined both IgM and IgG WNV
antibodies were detected.
Conclusions: This is the ﬁrst time that WNV outbreak has been
documented in humans in Greece. Infection of CNS occurred mainly
in patients older than 50 years and febrile-rash disease in patients aged
less than 50 years. Most fatal cases have been observed in patients older
than 50 years.
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P1019 Using real-time PCR for detection of Yersinia pestis in ﬁeld
samples from Mountain Altai natural focus of plague
M. Afanas’ev*, E. Chipanin, V. Shestakov, A. Denisov, L. Fomina,
A. Ostyak, S. Balakhonov (Irkutsk, RU)
Objectives: Plague is an extremely dangerous infection disease caused
by Yersinia pestis. Presence in the Russian territory (particularly, in the
Siberia) active natural foci of plague needs effective monitoring measures
that based on modern diagnostic methods. The main goal of this study
was to construct and testing of real-time PCR (RT-PCR) for fast and
robust Y. pestis detection in ﬁeld laboratory condition during examination
of natural foci of plague.
Methods: For detection of Y. pestis in ﬁeld samples we constructed
SYBR green-based RT-PCR assay followed by melting curve analysis
for reaction’s speciﬁcity estimation adopted for programmed real-time
machine “Smart Cycler” (Cepheid, USA). Samples of ectoparasites
(ﬂeas and ticks) (n = 1206) and rodents and lagomorphs (n = 264) were
collected in September 2010 in Kuray and Sailugem range’s sectors of
Mountain Altai natural plague focus. Ectoparasites were obtained from
small mammals and its borrows and nests. Bacteriological testing of
samples was performed according to WHO recommendation.
DNA extraction from suspension of ectoparasites was carried out by
boiling. Same procedure for homogenate of small mammals organs
was performed by DNA-sorb Extraction Kit (ILS Ltd., Russia).
Strain Y. pestis EV was used as a control for all microbiological and
genetic procedures. Y. kristensenii, Y. intermedia, Y. pseudotuberculosis,
Y. enterocolitica, Y. frederiksenii were used for speciﬁcity control of
suggested assay.
Results: RT-PCR assay was constructed and tested in ﬁeld conditions.
Among ectoparasites included in the study Dermacentor nuttalli, Para-
monopsyllus scalonae, Paradoxopsyllus scorodumovi and Ctenophyllus
hirticrus were prevalent (24,2%, 292/1206; 22,8%, 275/1206; 18,4%,
222/1206 and 16,5%, 199/1206). Ochotona pricei was a dominating
species among studied small mammals (77,3%, 204/264). Eight Y. pestis
strains were isolated by traditional microbiological methods: six (66,7%,
6/9) − from ﬂeas and three (33,4%, 3/9) − from rodents and lagomorphs.
Eleven positive results were obtained by RT-PCR assay. These positive
samples included eight that were identiﬁed as Y. pestis positive by
microbiological methods.
Conclusion: Proposed RT-PCR assay demonstrated excellent sensitivity
and speciﬁcity and may be consider as a good, robust and simple method
for ﬁeld screening studies in natural foci of plague.
P1020 Coinfection of ticks with Borrelia burgdorferi sensu lato and
Rickettsia spp. in densely populated areas of the Po River
valley
M. Pajoro*, S. Epis, F. Comandatore, M. Montagna, N. Vicari,
M. Fabbi, D. Pistone, P. Marone, C. Bandi (Pavia, Milan, IT)
Objective: Several tick-borne rickettsiae cause diseases in humans and
animals. These bacteria circulate transtadially and transovarially in tick
populations, and are transmitted to vertebrates during the tick bite. The
recent description of micro-areas in the Po river valley where Lyme
borreliosis is endemic raises the needs for more accurate investigations
on the presence other pathogenic bacteria vectored by ticks. Here we
present a screening for the presence of Rickettsia spp. in these micro-
areas.
Methods: The same individual ticks investigated by the authors during
a survey for the presence of Borrelia burgdorferi sensu lato were further
analysed for the presence of bacteria belonging to the genus Rickettsia. A
subsample of 240 nymphs of Ixodes ricinus collected by dragging from
ﬁve rural and sub-urban micro-areas in the counties of Varese, Milano
and Pavia were subjected to DNA extraction. All samples were tested
for the quality of DNA with primers targeting mitochondrial 12S rRNA
gene and almost all of the examined nymphs (234/240) gave positive
ampliﬁcation. A sub-sample of the ampliﬁed 12S rRNA (20/234) were
sequenced to conﬁrm the identiﬁcation of the tick specimens as Ixodes
ricinus. To detect the presence of rickettsiae, a PCR for a 631-bp portion
of ompA gene was performed. Ten pools of ten larvae each and 11 adults
(4 female) were screened using the same procedure.
Results: Positive ampliﬁcation for Rickettsia spp. were obtained from
77 (33%) out of 234 nymphs, from 6 (2 females and 4 males) out of
11 adults and from all of the pools of larvae. Species identiﬁcation
through sequencing of the ampliﬁed portion of ompA is in progress. A
comparison with the data on the presence of B. burgdorferi s.l. in the
same ticks revealed that 13 (5.5%) out of 230 nymphs analyzed host
both pathogenic microorganisms, B. burgdorferi s.l. and Rickettsia spp.
Conclusions: Our study demonstrate the co-infection with two important
pathogenic microorganisms in ticks collected in a densely populated area,
where the risk of contracting tick-borne infection was not considered
prior to our work. This led the personnel of a natural park in the area
to require diagnostic exams for tick-borne diseases, and three subjects
were diagnosed as infected by Lyme borreliae and properly cured. The
risk of contracting Lyme and other tick-borne diseases is thus present
also in ﬂat areas of Italy, including the periphery of towns with over
40,000 inhabitants.
P1021 Clonal distribution of Streptococcus pneumoniae serotype
19A isolated in Malaysian hospitals
R.Md. Yasin*, K.N. Mohd Khalid, R. Issa, N. Ahmad (Kuala Lumpur, MY)
Objectives: Streptococcus pneumoniae serotype 19A has emerged all
over the world in recent years. In 2008–2009 we see a sudden
rise of this serotype in Malaysia representing second most common
(9.68%) serotype of all invasive isolate. The aim of this study was to
characterize pneumococcal strains of the 19A serotype received from
various hospitals.
Methods:Multilocus sequence typing (MLST) based on 7 housekeeping
genes aroE, gdh, gki, recP, spi, xpt and ddl were carried out to determine
the population structure of pneumococcal strains serotype 19A.
Penicillin, amoxi-clavulanic acid, ceftriaxone, erythromycin, meropenem
and levoﬂoxacin MICs were determined using the E-test method (AB
Biodisk, Solna, Sweden). MICs were interpreted using CLSI guidelines.
Serotyping was performed by latex agglutination (pool latex antisera and
factor sera; Staten Serum Institut, Copenhagen, Denmark).
Results: From a total of 31 pneumococcal isolates of serotype 19A
received at our laboratory between 2008 and 2009, 21 (67.74%) were
invasive isolates (bacteremia, meningitis, and pleural effusion). Only 25
including 17 invasive isolates were included in this study. Penicillin MIC
of the 25 strains ranged from 0.016−2 mg/ml and 17 (68%) were less-
susceptible to penicillin including 2 resistant strains (MICs 2mg/ml).
None of the isolates were resistant to levoﬂoxacin while resistant
(intermediate) to meropenem was 28% (n = 7), ceftriaxone 16% (n = 4),
and amoxi-clavulanic acid 20% (n = 5); and resistant to erythromycin
was 40% (n = 10). Five isolates belonged to multiresistant clones related
to sequence type ST320. The other penicillin less-susceptible strains are
related to sequence type ST172 (n = 4) and one of each ST15, ST166,
ST5817, ST5822, ST5818, ST276, ST2013 and ST 2855. Penicillin
sensitive strains belonged to sequence type ST3781 (n = 2) and one
of each ST5819, ST217, ST1848, ST5820, ST5821 and ST771. Ten
macrolide resistant strains related to sequence type ST320 (n = 5) and
one each ST15, ST1848, ST166, ST5820 and ST276.
Conclusions: Multiple clones were associated with serotype 19A. The
worldwide-disseminated multiresistant clones ST30, ST166 and ST276
were also present among our local strains. The clonality of the penicillin
less-susceptible strains also differs from the penicillin-sensitive strains.
P1022 Pacemaker-related endocarditis: clinical features and
microbiological spectrum of 43 consecutive cases
T. Exiara*, A. Konstantis, A. Risggits, A. Kalpaka, M. Kouroupi,
E. Gidaris, L. Mporgi, S. Papanastasiou, L. Papazoglou (Komotini,
Thessaloniki, Alexandroupolis, GR)
Introduction-aim: Pacemaker (PM) related endocarditis is a rare but
serious complication of permanent transvenous pacing. The reported
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incidence varies in the literature from 0.13% to 19.9%. The aim of
this study was to evaluate clinical features, microbiological spectrum,
echocardiographic ﬁndings and outcome of PM endocarditis in two
regional hospitals.
Material-methods: We studied retrospectively all the patients who
suffered a PM endocarditis in two hospitals between 2001 and 2009. All
the patients underwent clinical evaluation, blood and leads cultures and
transthoracic or/and transesophageal echocardiography. The diagnosis of
endocarditis was considered according to the Duke modiﬁed criteria for
PM endocarditis.
Results: 43 patients, 31 (72.1%) male and 12 (27.9%) female with
mean age of 64±13 years, were included in this study. The presentation
was acute in 11 (25.6%) patients (onset of symptoms <6 weeks after
implantation) and chronic in 32 (74.4%) patients (onset of symptoms
>6 weeks). Main comorbid conditions were: chronic heart failure
(67.4%), coronary artery disease (62.8%), diabetes mellitus (48.8%),
chronic obstructive pulmonary disease (37.2%), hemodialysis (20.9%)
and malignancy (9.3%). Most frequent clinical signs were fever (95.3%),
malaise (83.7%), anorexia (53.5%) and symptoms of heart failure
(48.8%). Local symptoms (erythema, pain, tenderness, skin ulceration)
were presented in 16 (37.2%) cases. A positive culture was obtained
in 39 out of 43 cases (90.7%), 32 times on blood culture, 27 times on
lead culture and 14 times on blood and lead culture: Staphylococcus
epidermidis in 24 (61.5%) cases, Staphylococcus aureus in 8 (20.5%),
Streptococcus viridans in 3 (7.7%), Enterobacter cloacae in 2 (5.1%),
Klebsiella oxytoca in 1 (2.6%) and Candida albicans in 1 (2.6%)
cases. 54.5% of staphylococci isolates in acute group were S. aureus
and 68.75% in chronic group were S. epidermidis. We found mixed
infections in 3 cases. 37.5% of the S. aureus isolates and 12.5% of the
S. epidermidis isolates were methicillin resistant. TTE showed vegetation
in 13 (30.2%) cases while TEE showed vegetation in 39 (90.7%) cases.
In all patients removal of the pacemaker and antibiotic treatment was
performed. Overall mortality was 18.6%.
Conclusion: Staphylococci were responsible for the vast majority of
PM endocarditis in our study, especially S. epidermidis in chronic group
and S. aureus in acute group. TTE was required for the diagnosis of
vegetations. Mortality was high.
P1023 H1N1 inﬂuenza pandemic from June 2010 to November
2010 at a single nodal centre in Hyderabad, India
F. Mohammad*, R. Paul, L. Nutankalva, S. Narreddy (Hyderabad, IN)
Objectives: H1N1 inﬂuenza began in spring/summer 2009 and spread
to all the continents. In India the second wave was between May and
November 2010. Here we report the characteristics and outcome of
patients at one teritiary care hospital. From June to November 2010,
H1N1 Inﬂuenza Pandemic emerged in Hyderabad and here we describe
the clinical characteristics, the progression, severity and the outcome of
87 Positive patients at one of the Nodal center in Hyderabad, India.
Methods: All the patients who presented with Flu like symtoms in an
outpatient as well as Inpatient setting were tested for H1N1 with the use
of reverese transcriptase polymerase chain reaction assay.
Results: There were 87 Positive patients with H1N1 Inﬂuenza, 62% were
in 20−40 year range, of which 67% were males. Twenty seven percent
were above 40 years of age. Out of the 84 patients, 93% had symptoms of
cough with only 30% showing chest Xray abnormalities. All the patients
with Pneumonia or Acute lung injury required Non-invasive Ventilation
and 10% of them needing Invasive Ventilation. Off 8 patients who were
mechanically intubated, 2 died of ARDS. There were 11% patients who
were health care providers from the hospital. Use of statins and steroids
along with anti-viral drugs were quite helpful in patients with severe
respiratory insufﬁciency.
Conclusions: Most of the patients presented with mild symptoms.
Patients with respiratory distress were admitted in isolation rooms. The
length of morbidity was reduced with early use of Anti-viral drugs.
Statins and Steroids remarkably decreased the duration of ventilation
and length of ICU Care. Non Invasive ventilation was sufﬁcient in
majority. The role of satins and steroids needs to be further studied. It
is also strongly advised for the health care providers to take preventive
vaccinations.
P1024 Serologic evidence of tick-borne aetiologies in Bulgaria
E. Taseva*, T. Gladnishka, I. Trifonova, V. Ivanova, I. Christova,
R. Refaat, E. Mohareb (Soﬁa, BG; Cairo, EG)
Bulgaria (7.5 million inhabitants) is known to be an endemic area for
Lyme borreliosis and Mediterranean spotted fever (MSF) with about
1000 cases reported per year. Less common are two other tick-borne
infections − Q-fever and Crimean-Congo hemorrhagic fever (CCHF).
Tick-borne encephalitis (TBE) has not been reported in Bulgaria. In
2008–2010, we have conducted a hospital-based surveillance survey
for acute febrile illness (AFI) in 5 different geographical regions in
Bulgaria. Acute and convalescent blood samples were collected from
422 AFI patients. Serum samples were tested by commercial ELISA
kits for speciﬁc IgM and IgG antibodies. Anti-TBE IgM antibodies were
found in acute serum samples from 5 patients by Euroimmun ELISA
(1.2%). Only one case appeared as meningitis, the other were febrile
diseases without neurological manifestation. In addition, 104 (24.6%)
cases had serologic evidence of other tick-borne etiologies, including
10 cases of CCHF (2.4%), 36 cases of Q-fever (8.5%) and 53 cases
of MSF (12.6%). Five (4.8%) of these 104 established cases of tick-
borne infections showed serologic evidence for co-infection with MSF
and Q-fever. Our results highlighted that tick-borne infections are more
widespread in Bulgaria than previously thought, especially rickettsioses.
Although TBE is believed to be common in North and Central part of
Europe, it is obviously not uncommon in Bulgaria, but most probably
often presents as unspeciﬁc febrile disease only. To our knowledge, this
study is the ﬁrst to provide serologic evidence of TBE in Bulgaria.
Further studies are ongoing to evaluate the disease burden of tick-borne
disease in Bulgaria using both clinical and other laboratory procedures.
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P1025 Strong relationship between total thiol status and
thrombocytopenia in patients with Crimean-Congo
haemorrhagic fever
R. Guner, M.A. Tasyaran*, S. Keske, I. Hasanoglu, D. Yapar, A. Kaya
Kalem, T. Arslan Gulen, S. Isikoglu, S. Neselioglu, O. Erel (Ankara, TR)
Objectives: To determine serum total thiol levels and total oxidant status
(TOS) in patients with Crimean-Congo hemorrhagic fever (CCHF) and
to investigate relationships of these parameters with thrombocytopenia.
Methods: Eighty three patients and 21 controls were enrolled in
the study. Serum thiol levels were measured by DTNB method
and total oxidant status (TOS) was measured by Erel’s method.
Thrombocytes were counted by automated hemocounter. Obtained results
were compared and relationships among the parameters were investigated
by correlation analysis.
Results: Serum thiol levels were signiﬁcantly lower in the patients
than those of the controls (220±78mmol/L and 542±51mmol/L,
p< 0.0001, respectively). Area under curve was 1.0 and, sensitivity
and speciﬁcity was 100% at 423mmol/L level. Serum TOS level was
signiﬁcantly higher in the patients (16.63±11.32mmol H2O2 equiv/L
and 7.86±3.59mmol H2O2 equiv/L, p = 0.001, respectively). There was
an important correlationship between serum total thiol levels and platelet
counts (r = 0.82, p< 0.0001).
Conclusion: Serum thiol levels are importantly decreased in the patients
with CCHF. This situation, which may be developed as primary
or secondary to the disease, may have a signiﬁcant role in the
etiopathogenesis of the thrombocyte dysfunction and bleeding in CCHF.
Thiol replacement might be helpful for treatment of CCHF.
P1026 Diagnosis of a case of Plasmodium vivax malaria in Arago´n,
Northern Spain. This is the ﬁrst autochthonous case since
its eradication in 1964
M. Ferrero*, P. Mairal, E. Latorre, A. Puy, J. Lucientes, J.M. Rubio
(Huesca, Zaragoza, Madrid, ES)
Objectives: Malaria is considered to be eradicated in Europe. Only
sporadic cases from travellers to endemic areas are occasionally reported
in Spain. A case of Plasmodium vivax malaria is reported about a patient
living in Huesca province.
Methods: The patient suffering from fever was hospitalized on 29
September 2010. Alarm trombocitopenia printed by automated Coulter
LH 50 from blood-EDTA led to a Giemsa staining. Further test (Rapid
BinaxNOW Malaria) and blood smears were carried out in other
blood samples. Conﬁrmation was made in the National Centre for
Microbiology in Madrid by Molecular characterization of Plasmodium
species, by multiplex Real time quantitative PCR and by conventional
Nested Multiplex Malaria PCR. At the same time, an epidemiological
investigation was made.
Results:Warning was alerted by COULTER LH 50 and just on the same
day the report of the Giemsa staining was unexpectedly identiﬁed as
Plasmodium spp. Then, the Test Binax malaria diagnosed Plasmodium
spp, no falciparum and by microscope examination Plasmodium spp.
Antimalaria treatment with cloroquina and primaquina was initiated, two
days later the patient was dismissed in good clinical conditions and the
Giemsa staining were aparasitaemic within a few days.
The real-time PCR of the initial sample in the National Reference
Laboratory was positive for Plasmodium vivax speciﬁc probe and
conﬁrmed by the Nested Multiplex malaria PCR.
The patient has never travelled to an endemic area. She had no surgeries
and never received any blood transfusion. She lives in an arid desert area
(Monegros) where A. atroparvus is present because of the climate change
and the artiﬁcial ﬂooding of the rice ﬁelds, which help the development
and permanence of the vector.
Conclusion: The situation in Spain since 1964 is deﬁned as anophelism
without malaria, but now, autochthonous cases may appear. The
diagnosis was possible because the Giemsa smears were made after the
alert of trombocitopenia in a blood automated study.
P. vivax was expected to be the agent of this autochthonous case because
the vectors present in this area, mainly A. atroparvus is refractory to
P. falciparum.
Clinicians in Southern Europe must be on alert in areas where competent
vectors for malaria are present.
P1027 Tularaemia outbreak in central Anatolia
A. Ulu Kilic*, E. Tutuncu, Y. Gurbuz, S. Kilic, G. Cicek Senturk,
G. Gulen, F. Sezen, I. Sencan (Ankara, TR)
Objective: An increase in the number of tularemia cases was observed
in Central Anatolia at the end of the year 2009. This study was aimed to
evaluate the clinical characteristics and the efﬁcacy of antibiotic therapy
in tularemia cases occured in six different provinces of Central Anatolia
in the last year.
Methods: Speciﬁc antibodies were screened by microagglutination test
(MAT). Throat swab and lymph node aspirate cultures were obtained
and PCR was performed from these specimens.
Results: A total of 63 cases were evaluated. Age of the patients
ranged from 6−83 (average 41.9), thirtysix of them (54.1%) were
females. 80.9% of cases were using spring water. Patients had clinical
presentations compatible with oropharyngeal (n = 45, 71%), glandular
(n = 12, 19%) and oculoglandular (n = 4, 6.3%) tularemia mostly. A
patient was presented with pneumonic form and another with laryngeal
mass. Initiating symptoms were sore throat (49.3%), fever (31.8%),
swollen neck (6.3%) and eye redness (6.3%). Cervical lymphadenopathy
(92.1%) and fever (77.2%) were the most common ﬁndings at admission.
MAT titers ranged from 1:160 to 1:5120. Francisella tularensis holarctica
was identiﬁed, providing a deﬁnitive diagnosis in 50% of the cases
who had tested by PCR. Causative agent recovered from cultures
in 5 clinical samples of 28 patients (17%). All the patients were
treated with antibiotics considered effective against F. tularensis; 45
with aminoglycosides (streptomycin, gentamicin, amikacin) and 18 with
quinolones (ciproﬂoxacin, levoﬂoxacin). However, therapeutic failure
was observed in 29% of the cases, which was found to be related
to the delay in the initiation of antibiotics. Although the success rate
in patients with early treatment (within 21 days after the onset of
symptoms) was signiﬁcantly better, no difference was found between
the effectiveness of aminoglycoside or quinolone treatments (p = 0.001
and p> 0.005 respectively).
Conclusion: This was the ﬁrst time emergence of tularemia epidemic
in Central Anatolia although small clusters of cases have been reported
before. Treatment was unsuccessful in patients with delayed diagnosis.
Tularemia is an emerging disease spreading to nonendemic regions
representing a signiﬁcant threat for public health.
P1028 Short-course high-dose rifaximin rescue treatment in CDI −
a single-centre experience
T. Marcello*, K. Schreiter, N. Schultheis, C. Hechler, I. Raila,
M. Lindner, A. Bethke, T. Gru¨newald (Leipzig, DE)
Objective: Clostridium (C.) difﬁcile infection (CDI) is commonly
encountered in hospitalized patients undergoing antimicrobial treatments.
Recent studies note an increase in disease severity and more often worse
outcomes than in earlier years. Metronidazole and/or local vancomycin
are still the drugs of choice, failures are increasingly seen in severly
compromised patients. Several antimicrobials are recommended in this
setting. Rifaximin as a non-absorbale ansamycin is probably useful
because of high stool concentrations and lack of resistance in C. difﬁcile.
Goal of this analysis was to examine efﬁcacy and tolerability of HD-
rifaximine (HD-RFX) in patients failing standard treatment regimes with
metronidazole or vancomycin.
Patients and Methods: All patients attending the infectious diseases
wards suffering from CDI in the years 2009 and 2010 were analyzed
for the presence of treatment failure while using metronidazole or
vancomycin with subsequent use of HD-RFX. CDI risk score as well as
stool frequency and consistency, vital signs and base labo values were
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estimated at presentation and treatment switch. Rifaximin was given after
individual informed consent orally 400mgs TID for one week. Patient’s
individual outcomes and overall in-hospital mortality were analyzed.
Results: During the observation period 107 patients presented with
CDI, 69 were treated with metronidazole, 31 using vancomycin. HD-
RFX was given to seven (6.5%). Complete resolution (clinically and
microbiologically) of CDI was seen in 7/7. HD-RFX failed in none
patient. Crude in-hospital mortality for the HD-RFX treated patients
was 12.15% (metronidazole 14.5%, vancomycin (6.5%).
Conclusions: Rifaximin given at high dosages for one week is safe and
efﬁcacious in the rescue treatment of CDI. Results from this and other
case series warrant larger trials regarding ﬁrst line treatment with HD-
RFX compared to standard medications.
P1029 Pyosalpinx and pelvic pain due to Brucella melitensis
A. Poulou*, F. Markou, G. Vrioni, A. Tsakris (Serres, Athens, GR)
Introduction: Brucellosis remains a worldwide health problem. In
Mediterranean countries, it is endemic and is caused primarily by
B. melitensis. Although there a lot of complications related to brucellosis,
soft tissue involvement is rare. In this case report a patient with
pyosalpinx caused by B. melitensis was presented.
Case report: A 21-year-old female patient was admitted to the
hospital complaining of abdominal pain and low-grade fever. Physical
examination conﬁrmed rebound tenderness in the right abdomen.
Laboratory evaluation revealed white cell count of 12500 with 78%
polymorphonuclear while C-reactive protein (CRP) was 13.5mg/dl.
There were no history of systemic complaints or other organ
involvement. A distended, pus-ﬁlled, right fallopian tube was detected
at ultrasonographic examination. The patient underwent an emergency
laparotomy. Fluid was sent to the laboratory and inoculated into
the standard aerobic and anaerobic Bactec bottles. Three days later
the sample of the positive bottles was subcultured and a Gram-
negative coccobacillus was grown on blood agar plates that was
catalase- and oxidase-positive. The microorganism was positive for
urease production and negative for carbohydrates fermentation, motility
and H2S production. Susceptibility testing was performed with E-test
method. The standard tube agglutination test was positive at a titer of
1:80 while the blood cultures were negative. The patient was treated with
oral doxycycline and rifampicin for 6 weeks. No history of contact with
infected animals or consumption of unpasteurised dairy products was
reported.
Conclusion: Although few cases of ovarian abscess due to B. melitensis
have been reported, this is the ﬁrst case of pyosalpinx due to this
pathogen. Brucellosis should be considered in the differential diagnosis
of pelvic pain and abscess especially in endemic areas.
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P1030 Validation of the new inducible clindamycin resistance test
on Vitek2 cards for staphylococci (AST-P610)
B. Van Meensel*, M. Lontie (Louvain, BE)
Objectives: For the detection of inducible macrolide-lincosamide-
streptogramine B (iMLSB) resistance in Staphylococcus spp., the
advanced expert system (AES) of Vitek 2 (bioMe´rieux) uses a recently
developed ‘Inducible Clindamycin Resistance’ (ICR)-test. Our aim was
to validate the ICR-test on AST-P610 cards, using the CLSI double disc
method (D-test) as reference test.
Methods: 95 consecutive patient samples with Staphylococcus spp. (54
S. aureus and 41 coagulase-negative staphylococci) were collected in
our laboratory (MCH Leuven). The strains were identiﬁed with the
GP card and tested for inducible clindamycin resistance by Vitek 2
ICR-test on the AST-P610 card. Disk diffusion using the D-zone test
was used as reference method (CLSI M100-S20, M02-A10). Based on
Cumitech 31 A, we used following validation criteria: very major errors
(VME) (D-test +, Vitek 2 ICR −) 3%; major errors (ME) (D-test −,
Vitek 2 ICR +) 3%; categorical agreement (CA) 90%.
Results: We noted a sensitivity of 100%, a speciﬁcity of 98.7%
and a categorical agreement of 98.9%. One major error (D-test −,
Vitek 2 ICR +) was noted but fell within our validation criteria
(ME 3%).
Conclusion: The Vitek 2 ICR-test on the AST-P610 card provided a
reliable method to detect iMLSB resistance in staphylococci and was
implemented in the daily routine of our laboratory.
P1031 Assessment of heteroresistance to vancomycin and other
antibiotics by broth macrodilution in Staphylococcus aureus
strains
F.F. Arhin*, I. Sarmiento, G. Moeck (Ville Saint Laurent, CA)
Objective: Heteroresistance (HR) to vancomycin (VAN), deﬁned as a
small subpopulation with elevated VAN MIC (>2mg/L) in a culture,
is becoming increasingly prevalent and has been linked to clinical
therapeutic failure. The most reliable procedure to detect VAN HR
is the agar-based population analysis proﬁle-area under curve (PAP-
AUC) method. This procedure is labour-intensive and cannot be applied
to agents for which agar-based assays are unsuitable. We developed
a broth macrodilution assay (Bmac) to assess HR to vancomycin.
The Bmac, with an increased number of cells relative to broth
microdilution assay (Bmic), increases the probability of identifying
rare resistant subpopulations while respecting the inoculum density
recommended by CLSI. This assay was used to assess HR to daptomycin
(DAP), teicoplanin (TEI), telavancin (TEL) and oritavancin (ORI) in
heterogeneous VAN-intermediate Staphylococcus aureus (SA) (hVISA)
strains.
Methods: 5 SA clinical strains (from NARSA or Euroﬁns Medinet) used
in this study exhibited VAN HR by PAP-AUC. MICs were determined
by Bmac and broth microdilution assay (Bmic) following CLSI M7-
A8. SA strains ATCC 29213 (VAN-susceptible) ATCC 700699 (VAN
intermediate SA [VISA]) and NRS2 (Mu3; hVISA) were used as
reference strains. Bmac was performed in 50mL polyproplylene screw
cap tubes containing 5×105 CFU/mL in a ﬁnal assay volume of 20mL
(total of 107 CFU). Bmac was read after 24 h at 37ºC. All experiments
were performed at least twice.
Results: By PAP-AUC, the 5 S. aureus test strains were VAN HR.
These isolates, along with NRS2 (hVISA reference strain), had VAN
MICs of 1 or 2mg/L by Bmic and 4mg/L by Bmac, indicating growth
of subpopulations at a VAN concentration of 2mg/mL in Bmac. In
contrast, the VSSA and VISA control strains showed MIC values that
were identical for both Bmic and Bmac. Two of the ﬁve VAN HR
isolates showed ORI and TEI Bmac MICs that were higher (2 doubling
dilutions) than the Bmic MICs, suggestive of HR to ORI and TEI. Bmac
and Bmic MICs for DAP and TEL were identical, suggesting lack of
HR in this set of isolates.
Conclusions: The Bmac assay described here provides a simple means
to identify the presence of rare HR isolates. The procedure is useful for
agents such as ORI for which agar-based assays are not possible. Two of
the 5 VAN HR strains of SA were identiﬁed by Bmac assay as possibly
HR to TEL and ORI. Clinical signiﬁcance of HR as identiﬁed by Bmac
remains to be determined.
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P1032 Evaluation of a rapid detection method for methicillin-
resistant coagulase-negative staphylococci, the Clearview®
Exact PBP2a test
E. De Witte, M. Ieven* (Edegem, BE)
Objectives: Conventional susceptibility methods take 24 hours and
identiﬁcation of the mecA gene is expensive and time-consuming. The
Clearview® Exact PBP2a test is a rapid immunochromatographic assay
that detects the penicillin binding protein 2a present in methicillin
resistant Staphylococcus aureus and has already been evaluated in these
isolates. However, methicillin resistant coagulase negative staphylococci
(MR-CNS) can also be an important cause of infection, especially of
bloodstream infections. As the performance of this test has not been
evaluated for this indication, we evaluated the test on CNS isolates.
Methods: The Clearview® Exact PBP2a test was evaluated on 200
CNS isolates out of a large collection stored at −80ºC in the University
Hospital of Antwerp (Ieven M et al. J Clin Microbiol 1995; 33:1060).
These isolates were selected taking into account the relative prevalence of
different CNS species in routine clinical samples. Methicillin resistance
was conﬁrmed by mecA detection with an in-house PCR. Among the
mecA positives 56% were Staphylococcus epidermidis isolates and 44%
non-S. epidermidis isolates. After thawing, isolates were cultured on
blood agars and incubated for 24 hours, which was repeated the next day
for again 24 hours. The third day cultures could be used to perform the
PBP2a test according to the instructions of the manufacturer. We used 10
methicillin sensitive (MSSA) and 15 methicillin resistant Staphylococcus
aureus (MRSA) isolates as controls. The presence of the mecA gene
using PCR was considered as the gold standard.
Results: Of the 200 isolates tested, 125 (63%) were methicillin resistant
conﬁrmed by PCR and 108 (86.4%) of these were correctly detected by
the PBP2a test. Sensitivity and speciﬁcity results for the PBP2a test on
CNS were 85.6% and 98.7% respectively. Within the most important
CNS species sensitivities were 80.0% for S. epidermidis, 94.9% for
S. haemolyticus and 85.7% for S. hominis (table 1). These differences
were not statistically signiﬁcant (P> 0.05).
Conclusion: Compared to the detection of PBP2a in MRSA, the
presence of PBP2a in MR-CNS is detected with a lower sensitivity by
the Clearview® Exact PBP2a test. Consequently, this rapid test has to
be used in combination with the conventional susceptibility methods.
However, the major advantage of this test for CNS is that, in case of a
positive result, it provides faster results to improve the patients’ outcome
and hospital costs.
P1033 Multicentre validation of the Clearview® Exact PBP2a test
B. Van Meensel*, J. Frans, W. Laffut, D. Van Kerkhoven, A. Lemmens,
J. Van Schaeren, E. De Laere (Louvain, Bonheiden, Lier, Sint-Truiden,
Mechelen, Antwerp, Roeselare-Menen, BE)
Objectives: To validate the Clearview® Exact PBP2a test, a qualitative
in vitro immunochromatographic assay for the detection of penicillin-
binding protein 2a (PBP2a) in isolates identiﬁed as Staphylococcus
aureus.
Methods: Seven Belgian laboratories (MCH Leuven, Imelda ziekenhuis
Bonheiden, H. Hartziekenhuis Lier, LKO-LMC Sint-Truiden, AZ Sint-
Maarten Mechelen, GZA Antwerpen, H. Hartziekenhuis Roeselare-
Menen) analysed a total of 151 S. aureus strains. Both clinical isolates
(n = 136) and QC-strains (n = 15) were cultured and identiﬁed following
local standard procedures in each lab. The Clearview® Exact PBP2a test
was performed in duplo with the currently used kit for PBP2a detection,
all requiring a boiling and centrifugation step (Slidex® MRSA detection
bioMe´rieux, MRSA-screen Denka Seiken, PBP2′ Oxoid). Discrepancies
were resolved using molecular testing.
Results: The S. aureus colonies were tested from different culture
media (blood agar, chromogenic SA agar, chromogenic MRSA agar,
Mueller Hinton agar). On a total of 151 S. aureus strains, only one
discrepant result was obtained. It concerned a S. aureus isolate positive
with Clearview® Exact PBP2a but negative with MRSA-screen (Denka
Seiken). The strain was conﬁrmed as MRSA using molecular testing
(Tuf, Nuc and MecA positive). In total, 116 MRSA-strains and 35
MSSA-strains were tested. All the labs mentioned the problem of weak
control lines, especially with positive isolates. When a smaller amount
of isolate was used, the strength of the control line increased.
Conclusion: The Clearview® Exact PBP2a test provides an accurate,
easy to use (no centrifugation or boiling stages required) and quick
(<6 minutes) method to detect the PBP2a protein in S. aureus isolates.
However, attention should be paid to over-inoculation of isolates positive
for PBP2a, resulting in weak or even negative (and therefore invalid)
control lines.
P1034 Evaluation of CHROMagar MRSA agar (E&O) and
brilliance MRSA 2 agar (Thermo Fisher Scientiﬁc)
D. Bangura* (Salisbury, UK)
Objectives: The need for accurate meticillin-resistant Staphylococcus
aureus (MRSA) screening methods is essential to a busy clinical
microbiology laboratory. This study evaluates the efﬁcacy of two MRSA
chromogenic media, CHROMagar MRSA Agar (E&O) and Brilliance™
MRSA (Thermo Fisher Scientiﬁc) for screening for MRSA from patient
samples.
Methods: Three hundred and eighty ﬁve patient samples collected
for routine MRSA screening (mostly nasal and groin swabs) were
inoculated onto Brilliance MRSA 2 Agar and CHROMagar MRSA Agar.
Plates were incubated at 36±2ºC for 22−24 hr. Any presumptive MRSA
colonies were conﬁrmed using DNase Agar, staphylococcus latex, PBP2′
latex and cefoxitin and oxacillin antibiotic sensitivity testing.
Results: Both chromogenic media successfully isolated MRSA from
twelve samples, giving a prevalence of 3% However, CHROMagar
MRSA Agar incorrectly identiﬁed three meticillin-sensitive Staphylo-
coccus aureus (MSSA) as MRSA, reducing the positive predictive value
(PPV) of the plate to 80% compared to 100% for Brilliance MRSA 2
Agar. The negative predictive value (NPV) for both chromogenic media
was 100%.
Conclusions: A high PPV and NPV are essential for any MRSA
screening method. Brilliance MRSA 2 Agar accurately detected MRSA
from patient samples, showing 100% PPV and NPV. Brilliance MRSA
2 Agar can be relied upon to correctly identify patients with MRSA
while remaining a highly speciﬁc chromogenic medium. Whilst the
CHROMagar MRSA Agar had a high NPV it misidentiﬁed three MSSAs
as MRSAs bringing its PPV down to 80%. This misidentiﬁcation resulted
in extra work being undertaken and therefore delaying the true negative
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result going out. Whilst both plates have a speciﬁc colour for the
identiﬁcation of MRSA the brighter blue colour of Brilliance MRSA
2 Agar was quicker and easier to spot on the plate, especially if the
plate was mixed.
P1035 Methicillin-resistant Staphylococcus aureus screening using
Brilliance MRSA 2 Agar
C. Sander*, W. Kalka-Moll, E. Scopes (Mo¨nchengladbach, DE;
Basingstoke, UK)
Objectives: To evaluate the performance of the newly formulated Bril-
liance MRSA 2 Agar (Thermo Fisher Scientiﬁc) and chromID MRSA
Agar (BioMe´rieux) for screening for meticillin-resistant Staphylococcus
aureus (MRSA) from patient samples.
Methods: One thousand and ﬁve patient samples collected for routine
MRSA screening, including nasal, perineum and wound swabs, plus
tracheal secretions, were inoculated onto Brilliance MRSA 2 Agar and
chromID MRSA Agar. Plates were incubated for 18 to 24 hr. Any
presumptive MRSA colonies were conﬁrmed using a coagulase test,
automated identiﬁcation and antimicrobial susceptibility testing, plus an
in-house PCR method detecting mecA, Sa442 and IS431 genes.
Results: One hundred and seven conﬁrmed MRSA were isolated on
one or both of the chromogenic media, giving a prevalence of 11%.
Sensitivity of Brilliance MRSA 2 Agar was statistically signiﬁcantly
higher (P = 0.04) than chromID MRSA Agar (96.3% and 85.5%
respectively). Speciﬁcity, positive predictive value (PPV) and negative
predictive value (NPV) of Brilliance MRSA 2 Agar were equal to or
higher than that of chromID MRSA Agar.
chromID MRSA Agar showed notably varied presumptive MRSA colony
colours, ranging from dark to light and transparent green. However, not
all of these were conﬁrmed as MRSA. In comparison, Brilliance MRSA
2 Agar showed a more consistent blue MRSA colony colour.
Conclusions: Brilliance MRSA 2 Agar detected considerably more
MRSA than chromID MRSA Agar while still showing excellent
speciﬁcity and NPV. Brilliance MRSA 2 Agar showed a more uniform,
distinctively blue MRSA colony colour compared to chromID, making
it reliable and straightforward to identify MRSA from patient samples.
P1036 Prospective evaluation of Brilliance VRE® and VRESelect®
Chromogenic Agars for detection of vancomycin-resistant
enterococci from surveillance specimens
B.M. Willey*, L. Louie, P. Gnanasuntharam, T. Fung, C. Watt,
P. Gnanasuntharam, C. Vermeiren, G. Ricci, P. Lo, K. Wong, A. Simor,
A. McGeer, T. Mazzulli, S.M. Poutanen (Toronto, CA)
Objectives: In an effort to improve turn-around-time (TAT) to
vancomycin-resistant enterococci (VRE) isolation without loss of
sensitivity, this study compared two newly available chromogenic agars
to commonly used non-chromogenic agars.
Methods: From Jul-Sep 2010, 3000 specimens from 18 Toronto
hospitals were screened prospectively for VRE using 4 agars: Brilliance
VRE (BRIL; Oxoid), VRESelect (SLCT; Bio-Rad), Bile Esculin
Azide Vancomycin (BEAV; Oxoid), and mEnterococcus with 6mg/L
vancomycin (mEV; BD, prep in-house). To avoid planting bias, agars
were arranged in rotating order, inoculated equally, streaked, incubated
simultaneously at 37C, and read independently every 24h for 48h (BRIL,
SLCT, and BEAV) and for 72h (mEV). While non-chromogenic colonies
were ignored, E. faecium (BRIL: purple, SLCT: pink) and E. faecalis
(BRIL: Demin-blue, SLCT: aquamarine) were identiﬁed (ID) directly
from agars when possible. Gram-positive cocci from mEV and black
colonies from BEAV were subbed to blood agar. Presumptive ID was by
PYR, arabinose, MGP, ampicillin disc, and CLSI BHI-vancomycin agar;
VRE were conﬁrmed by PCR.
Results: Overall, 141 VRE were isolated from 140 specimens [137/2926
(4.7%) rectal swabs, 3/74 (4.1%) stools]. These included 126 vanA
E. faecium (EFE), 11 vanB EFE and 4 vanB E. faecalis (EFC). Of
these, mEV detected 140, BRIL 137, SLCT 135 and BEAV 124; all 15
vanB were detected by each agar. Other isolates requiring 1 test to
rule out VRE included: 527 on BRIL [334 VS-EFC, 92 coagulase-neg
staphylococci (CNS), 87 VS-EFE, 8 yeast, 6 E. gallinarum (EGAL)];
646 on mEV [387 GPB/PYR-, 103 EGAL, 90 VS-EFE, 37 GNB,
16 VS-EFC, 12 yeast, 1 CNS]; 718 on BEAV [325 GPB/PYR-, 192
EGAL, 138 E. casseliﬂavus, 35 VS-EFC, 23 CNS, 4 VS-EFE, 1 yeast];
804 on SLCT [437 CNS, 169 VS-EFC, 161 GPB/PYR-, 19 EGAL,
12 VS-EFE, 6 yeast]. The daily % sensitivities, % speciﬁcities and
95% conﬁdence intervals for each medium are summarized in the table
below. No medium was highly speciﬁc or capable of detecting all VRE
within 24h. However, two tailed P values for 24h sensitivities found
a signiﬁcant improvement in TAT to VRE detection could be gained
by implementing the use of either chromogenic agar studied compared
the commonly used non-chromogenic media [BRIL versus mEV/BEAV
(0.0026/0.0010); SLCT versus mEV/BEAV (0.0288/0.0132)].
Conclusions: This evaluation found BRIL or SLCT would signiﬁcantly
reduce TAT to VRE detection but highlighted that both required 48h
incubation to avoid missing vanA VRE.
P1037 Retrospective evaluation of Brilliance VRE® and
VRESelect® Chromogenic agars for detection of
vancomycin-resistant enterococci using a diverse isolate
collection
B.M. Willey*, K. Prayitno, P. Gnanasuntharam, P. Gnanasuntharam,
T. Fung, L. Louie, P. Lo, K. Wong, T. Mazzulli, S.M. Poutanen (Toronto,
CA)
Objectives: Prospective evaluations of VRE selective agars have
limitations due to the small number of distinct clones in circulation at
one time. Using highly-characterized genetically diverse VRE and non-
VRE isolates, this study evaluated multiple lots of 2 chromogenic agars,
comparing them to 2 common non-chromogenic agars.
Methods: A total of 137 unique strains, selected for chromosomal and
VRE-genotype variation, were used to evaluate Brilliance VRE (BRIL,
Oxoid), VRESelect (SLCT, Bio-Rad), Bile Esculin Azide Vancomycin
(BEAV, Oxoid) and mEnterococcus with 6mg/L vancomycin (Difco
BD, prep in-house). Strains included: 49 E. faecium [EFE: 43 VRE −
23 vanA, 1 vanA-like, 12 vanB1, 5 vanB2/3, 1 vanD; 6 vancomycin-
susceptible (VSE)], 44 E. faecalis [EFC: 26 VRE − 2 vanA, 17
vanB1/vanB2/3, 6 vanE, 1 vanL; 18 VSE], 15 E. gallinarum (GAL),
8 E. casseliﬂavus (CAS), 10 Leuconostoc, 7 Pediococcus, and 4
Lactobacillus. Each lot was inoculated with 100uL of a 0.5 McFarland
STD equivalent suspension of each organism. Plates were streaked by
IsoPlater, incubated simultaneously at 37C, and independently read at
24h and 48h; mEV was also read at 72h. The number, size and colour
of colonies at each time point were noted. As an uneven number of lots
were tested, growth/inhibition of isolates per time point for all agar lots
was pooled and converted to % to be comparable.
Results: Ultimately, 548 isolates were tested on 4 BRIL lots, 411 isolates
on 3 lots ea of mEV and BEAV, and 274 isolates on 2 SLCT lots. The
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table summarizing overall % growth (95%CI) shows that no agar grew
100% of VRE at 24h or inhibited all non-VRE. While BRIL grew all but
2 vanB EFC by 24h, it failed to grow vanL, and 2 lots failed to grow
1 vanE. SLCT grew 108/120 vanA/B VRE by 24h, 11 at 48h, but 1
vanA EFE and 1 vanL EFC did not grow, and only 3/12 vanE EFC grew
overall. For BEAV, 168/180 vanA/B grew by 24h, 9 vanA/B and 3 vanE
grew by 48h, but 3 VRE (1 ea vanA EFC, vanB EFE, vanB EFC) failed
to grow, as did 2 vanE and the vanL EFC. While mEV isolated 100%
vanA/B VRE, only 120/180 grew by 24h, and 8 grew at 72h, and it grew
the least non-vanA/B VRE, missing 14/18 vanE and 2/3 vanL EFC. For
non-VRE, BRIL inhibited 261/276, SLCT 84/138, mEV 134/207, and
BEAV, 102/207 isolates tested.
Conclusions: This study found BRIL had a 24h sensitivity and
speciﬁcity that exceeded all other agars combined. However, even BRIL,
as with other VRE selective agars, required 48h to grow all VRE isolates.
P1038 External quality assessment of culture-based detection of
methicillin-resistant Staphylococcus aureus by a network of
European laboratories
M. Gazin*, C. Lammens, M. Ieven, H. Goossens, S. Malhotra-Kumar
on behalf of the MOSAR WP2 study team
Objectives: An external quality assessment (EQA) was carried out to
assess the culture-based methods utilized by 17 hospital laboratories
in 8 European countries and their proﬁciency in detecting methicillin-
resistant S. aureus (MRSA).
Methods: The EQA panel included 2 MRSA harbouring SCCmec IV
and I, and one strain each of MRCoNS (methicillin-resistant coagulase
negative S. epidermidis), MSSA (methicillin-sensitive S. aureus), and
Escherichia coli as pure strains or in mixtures at varying concentrations
(Table). All 17 participants analyzed the panel utilizing their in-house
culture protocol (IHP) for MRSA detection, and a standardized protocol
(SP) implemented as a diagnostic intervention in clinical trials as
part of the EU-FP6 project, MOSAR. SP included sample inoculation
on a chromogenic medium (BBL CHROMagar, BD Diagnostics) and
conﬁrmation of putative MRSA by 2 of the 3 suggested tests (slide
agglutination, coagulase test, and mannitol salt agar).
Results: Of the 17 participants, 16 (94%) could detect upto 10 colony
forming units (cfu) of absolute MRSA loads using both protocols (Table).
At 1 cfu absolute load, SCCmec I MRSA could be detected by a
larger no. of participants (82%, n = 14, and 88%, n = 15 by SP and IHP,
respectively) than SCCmec IV MRSA (53%, n = 9 and 76%, n = 13 by SP
and IHP, respectively). SP and IHP results showed 96.7% concordance
(kappa: 0.65, 95%CI: 0.44 to 0.86). One participant reported false-
negative results with 6 MRSA samples (pure strains: 1–100 cfu,
and mixtures) using both SP and IHP (Columbia agar with 6mg/ml
oxacillin; conﬁrmatory tests: coagulase, slide agglutination, and Vitek).
Another participant reported false-positive results with the MRCoNs as
a pure strain and mixed with MSSA using IHP (mannitol-salt agar;
conﬁrmatory test: not described). As IHP, 71% (n = 12) participants
utilized chromogenic media either alone (41%, n = 7) or combined with
conventional media (29%, n = 5). ChromID (BioMerieux) was the most
commonly employed chromogenic medium (35%, n = 6) followed by
BBL CHROMagar (29%, n = 5), and MRSASelect (Bio-Rad, 6%, n = 1).
Coagulase was the most commonly performed conﬁrmatory test (71%,
n = 12). ChromID combined with coagulase test was the preferred IHP
for 29% (n = 5) participants.
Conclusions: This is the ﬁrst EQA programme assessing culture-based
detection of MRSA. Performance of the participating laboratories was
generally high with the majority implementing ’rapid’ chromogenic
media as IHP for MRSA detection.
P1039 Improved sensitivity and reduction in MRSA surveillance
costs by using MRSA-B enrichment broth
C. Lee*, C. Rutherford, J. Korver (Hamilton, CA)
Objectives: Multiple body sites are swabbed when screening a patient
for MRSA colonization. Each swab is directly inoculated onto a selective
and differential agar plate, usually a Chromogenic-based plate, speciﬁc
for MRSA. A signiﬁcant portion of the laboratory budget is utilized for
this purpose, yet the sensitivity of direct plate inoculation is suboptimal
compared to the broth culture method.
The objectives of the study are as follows:
1. To determine whether MRSA-B broth [Copan, Italia SpA, Brescia
Italy], has superior sensitivity to conventional direct plate inoculation
method for isolation of MRSA.
2. To reduce laboratory costs by pooling multiple body site swabs and
inoculate into 1 tube of MRSA-B broth per patient.
Method: Using Amies® Transport Swab with charcoal [Copan, Italia
SpA, Brescia Italy], 372 swabs (multiple body sites) were collected
from 190 patients. As per clinical laboratory standard procedure, each
swab was directly inoculated onto CHROMagar MRSA® [CHROM agar
Microbiology, Paris, France] for isolation of MRSA. All swabs from
each patient were pooled and inoculated into a single tube of MRSA-B
broth and incubated for 5 hours at 37ºC and vortexed. 50 mL of broth
was plated onto a CHROMagar MRSA® plate. Plates were incubated
at 37ºC for 24 hours and examined. Presumptive MRSA colonies were
conﬁrmed by PCR for nuclease, PVL and mecA.
Results: The positive rate of MRSA was 11.05% (21/190 patients) using
the standard clinical laboratory method of direct plate inoculation of
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the swab. The MRSA-B broth method detected a total of 61 patients,
which included all 21 patients detected by the standard clinical laboratory
method and additional 40 patients, showing a positivity rate of 32.1%
(61/190). MRSA results using the MRSA-B broth method were reported
on the same day as the direct plate inoculation method. The MRSA-B
broth method also resulted in a 50% reduction in chromogenic MRSA
plate use.
Conclusions: The study shows that using MRSA-B enrichment broth
and pooling multiple body-site samples from the same patient results
in a statistically signiﬁcant superior sensitivity 11.05% Vs. 32.1%
(P = 00000.1) and reduction in laboratory cost. The improved sensitivity
will signiﬁcantly enhance patient care by identifying more colonized
patients and reduce nosocomial transmission.
P1040 Validation of new BinaxNow Staphylococcus aureus and
PBP2a tests performed directly from blood cultures
J. Montgomery* (Melbourne, AU)
Background: Rapid detection of both Methicillin-sensitive (SA)
Staphylococcus aureus and Methicillin-Resistant (MRSA) bacteraemia
signiﬁcantly improves patient outcome. Two rapid immunochromato-
graphic membrane assays using polyclonal antibodies to detect a SA
speciﬁc protein and penicillin binding protein 2a (BPBP) are now
available. This study compared the two tests with the routine in-house
protocol of direct tube coagulase (DTC) and modiﬁed direct PBP2a test
(PB) from blood cultures (BC) with Gram positive cocci resembling
staphylococci in the Gram stain.
Method: From October to December 2010, 85 BACTEC BC with GPC
resembling staphylococci in the Gram stain were included. Only the
ﬁrst positive bottle for each patient was tested. DTC, BSA, BPBP
and PB were done. There were 30 Staphylococcus aureus (STAU)
of which 7 were methicillin resistant (MRSA) and 55 Coagulase
negative Staphylococci (CNS). All isolates were conﬁrmed by routine
identiﬁcation and susceptibility testing.
S. aureus test (SAT): 1.0mL of solution A was mixed with 1.0mL of
BC broth, and centrifuged at 1500g for 5 minutes, supernatant removed
and washing repeated. 5 drops of reagent B were added to the deposit
and mixed, 25mL of reagent C was mixed in. 50mL of supernatant and
one drop of reagent D was added to the device. Four drops of reagent
D was then added to the left side of the device. The result was read at
10 minutes.
PBP2a test (PB): 1.5mL of solution 1 was mixed with 0.5mL of BC broth
and centrifuged at 1500g for 5 minutes. The supernatant was removed,
200mL of Reagent 2 was added, mixed thoroughly, 100mL of Reagent
3 was added and mixed then centrifuged at 1500g for 5 minutes. 75mL
of supernatant was added to the device and read at 10 minutes.
Results: Twenty two of 23 STAU and all seven MRSA were SAT
positive. All CNS were SAT negative. All seven MRSA were BPBP
positive and all SA negative. The sensitivity (SN) and speciﬁcity, (SP),
Positive Predictive Value (PPV) and Negative predictive Value (NPV) of
the SAT was 97%, 100%, 100% and 98% respectively. The SN, SP, PPV
and NPV of the PB test were all 100%.
Conclusion: The SAT and BPBP are fast and reliable alternatives for the
direct detection of SA and MRSA from BC. It is particularly useful for
those laboratories without molecular facilities for rapid detection. The
study should be expanded to include more patients, particularly those
with MRSA.
P1041 Detection of oxacillin resistance of S. aureus by whole
cell matrix assisted laser desorption time of ﬂight mass
spectrometry: the time has not yet come
F. Szabados*, M. Kaase, A. Anders, S. Gatermann (Bochum, DE)
Objectives: Several studies have been published that claimed to
identify oxacillin resistance of Staphylococcus aureus by whole cell
matrix assisted laser desorption time of ﬂight (MALDI-TOF) mass
spectrometry. In these studies selected methicillin susceptible S. aureus
isolates were compared to selected methicillin resistant S. aureus
(MRSA) isolates. Nevertheless, the study design in all of those studies
was not suitable to achieve this goal, because only mecA/SCCmec
“isogenic” strains could discriminate between strain speciﬁc- and “mecA/
SCCmec”-dependent peak variations.
It have been also described that strains speciﬁc peaks exist within
the species of S. aureus. We identiﬁed in our study mecA/SCCmec
“isogenic” strains of S. aureus and analysed their peak proﬁles by
MALDI-TOF MS.
Methods: A large MRSA strain collection was used containing 120
strains with molecular divergent backgrounds. The mecA gene was found
in only 104 out of 120 of these isolates after culturing the freezing
culture. The loss of the mecA gene during freezing culture has been
previously described. Single colonies of those isolates were identiﬁed
by the cefoxitin resistance phenotype and mecA PCR results. The
bacteria from freezing culture were submitted to LB media containing
increasing oxacillin concentrations in order to select the corresponding
mecA containing strain. In two out of 16 samples we could select a
mecA containing strain and a corresponding “isogenic” strain lacking
the mecA gene. These two pairs of molecularly characterised strains
were submitted for whole cell MALDI-TOF MS. In order to increase the
expression of the PBP2a, the oxacillin resistant strain was cultured in
LB medium containing NaCl and oxacillin. The corresponding oxacillin
susceptible strain was cultured in LB medium only.
Results: We do not found evidence for a difference in the peak proﬁles
in a mass-to-charge-ratio (Da) of 2000 to 15000 Da in two mecA-
“isogenic” pairs of S. aureus strains cultured on blood agar plates. The
protein peak proﬁles of the mecA positive strains, cultured on oxacillin
containing media, were also virtually identical compared to the mecA
negative corresponding isolates.
Conclusion: In contrast to several reports in literature, we could show
for the ﬁrst time that whole cell MALDI-TOF MS-derived peak proﬁles
are not suitable for the discrimination of mecA positive S. aureus strains
in the mass-to-charge-ratio of 2000 to 15000 Da.
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P1042 Antimicrobial resistance of H. pylori in Smolensk, Russia
N. Dekhnich, E. Kostykova, A. Punin, A. Alimov, N. Ivanchik,
R. Kozlov* (Smolensk, RU)
Objectives: To evaluate the susceptibility to antimicrobials of H. pylori
isolated from patients with H. pylori-associated gastrointestinal disorders
in Smolensk (Russia).
Methods: Overall 210 adult patients with H. pylori-associated
gastrointestinal disorders were included in the study in 2009–2010.
From each patient 2 antral and 2 corpus gastric biopsy samples were
taken for culture and placed in a phosphate buffer (Sigma, USA)
or Portagerm pylori (BioMerieux, France) for transportation to the
laboratory. Pylori agar (BioMerieux, France) plates were incubated for
3−5 days at 37ºC under microaerophilic conditions (9% CO2, 80%
N2, 11% O2). Antimicrobial susceptibility testing was performed on
Mueller-Hinton agar (BBL, USA) supplemented with 5% sheep blood
by the dilution method to amoxicillin, erythromycin, clarithromycin,
levoﬂoxacin, ciproﬂoxacin, tetracycline and metronidazole.
Results: H. pylori were isolated in 64% (n = 135) patients. Among
them 18% were resistant to one antimicrobial agent, 3% were resistant
to more than one antimicrobial agent. Seven (5.3%) isolates were
resistant to clarithromycin (MIC 1mg/L), 10 (7.6%) − to erythromycin
(MIC >4mg/L). The resistance rate of H. pylori to metronidazole was
3.8% (n = 5) (MIC >4mg/L). No strains resistant to amoxicillin and
tetracycline were found. Resistance to ciproﬂoxacin was detected in
12.8% (n = 17) (MIC >1mg/L) of strains, to levoﬂoxacin − in 8.3%
(n = 11) (MIC >1mg/L).
Conclusion: Our study highlights the importance of antibiotic resistance
surveillance to guide test and treat policies. In Smolensk we can use
current recommendations of the European H. pylori study group (proton
pump inhibitor + clarithromycin + amoxicillin or metronidazole) as
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the initial treatment for H. pylori infection. Quadruple therapy (proton
pump inhibitor + bismuth + metronidazole + tetracycline) could be an
alternative initial therapy.
P1043 Resistance and virulence characterisation of CTX-M15 and
KPC-3 Klebsiella pneumoniae clinical isolates
C. Caneiras, F. Calisto, A. Narciso, S. Arriaga, J. Melo Cristino,
A. Duarte* (Lisbon, PT)
Objectives: The aim of this study was to evaluate the relationship
between the type of ESBL produced and the resistance and virulence
determinants in Klebsiella pneumoniae clinical isolates recovered at the
1070-bed Hospital in Lisboa, Portugal.
Methods: This study included 41 representative clinical isolates of
K. pneumoniae ESBL producers that were collected between 2008 and
2010 in a terciary care hospital, Lisboa. It was included representatives
of CTX-M-15 (n = 24) as well as the novel carbapenemase KPC-3
K. pneumoniae (n = 17). The isolates were selected according to
antimicrobial and genetic proﬁle by disk diffusion disk and RAPD M13
DNA ﬁngerprint, respectively. Plasmid replicons were determined using
the PCR-based replicon typing scheme described by Carattoli et al.
(2005) with speciﬁc primers for 18 plasmid replicons. The isolates were
screened by PCR ampliﬁcation for gene markers of 8 virulence factors
genes: k2A, rmpA, magA, ﬁmH, mrkD2, mrKD3, khe and iucC.
Results: The most frequent virulence genes were the ﬁmbrial adhesins
ﬁmH (89%), mrKD2 (93%), and mrkD3 (68%). The gene khe, that
encodes a haemolysin, was found on 54% of the isolates and only 4% of
the isolates of have showed the iucC gene of the aerobactin system. 8%
of the isolates of K. pneumoniae belong to capsular serotypes K2. No
rmpA and magA genes were detected. The prevalence of the virulence
factors was comparable among all genetic groups, namely isolates
with endemic CTX-M15 enzyme and those with KPC-3 carbapenemase
ESBLs. In K. pneumoniae isolates producing CTX-M15 were found
only the IncHI1 plasmid incompatibility group although all the KPC-3
producers had plasmids belong to the Inc F incompatibility group.
Conclusions: Our results indicate a distribution of K. pneumoniae
isolates producing ESBLs, with abilities to simultaneously express
several virulence factors regardless the strain background. However,
ﬁmbrial adhesins seems to be an important virulence factor. The
K. pneumoniae CTX-M-15 ESBL isolates presented the plasmid
incompatibility group IncHI1 and none belonged to the IncF group.
Overall, it is important to note a high degree of variability in plasmid
proﬁle compared the recent KPC-3 isolates that showed the Inc F
group suggesting that these ESBL resistance genes cannot be readily
transmitted indistinctly between K. pneumoniae isolates.
P1044 In vitro assessment of the core/shell/extra-shell nanosystem
inﬂuence on the antibioﬁlm effect of usnic acid
C. Saviuc*, A. Grumezescu, M.C. Chiﬁriuc, L. Dascalu, M. Popa,
A. Cotar, A. Holban, C. Bleotu, E. Oprea, D. Mihaiescu, V. Lazar
(Bucharest, RO)
Objective: To investigate the inﬂuence of core/shell/extra shell − Fe3O4/
oleic acid/usnic acid nanosystem on the antibioﬁlm effect of usnic
acid (UA), known for its antimicrobial and especially its quorum-
sensing inhibitory activity, on the in vitro Staphylococcus aureus bioﬁlm
development.
Methods:Microscopic slides were coated with UA (1/2/3 layers), as free
substance and respectively, as extrashell of biocompatible nanostructures.
The Fe3O4/oleic acid-core/shell of 5−20 nm range have been synthesized
by Massart adapted method, under microwave conditions. Two controls,
represented by uncoated microscopical slides and respectively coated
with core/shell were used in the study. Each slide was immersed in 3ml
of liquid nutrient broth distributed in six-well polystirene plates and
inoculated with 300ml of 0.5 McFarland bacterial suspension prepared
from S. aureus ATCC 25923. The plates were incubated for 72 hrs under
stirring conditions (150 rpm). The temporal dynamic of S. aureus bioﬁlm
was studied by harvesting the slides at 24/48/72 hrs, washing them for
removing the non-adherent bacteria and discarding the adherent ones
by rigorously shaking for 30min in 10ml phosphate buffered saline.
The obtained suspensions were further ten-fold diluted and 5 ml of each
dilution were seeded in triplicates on brain heart agar, incubated for
24 hrs at 37ºC in order to perform the viable cell counts (VBCs) and
appreciate the number of bacterial cells embedded in bioﬁlms. The
bioﬁlm architecture was examined by CLSM.
Results: The free UA pelliculised on the microscopic slides exhibited an
antibioﬁlm activity, evidenced by the drastic decrease of VBCs recovered
from the coated slides at 24 and 48 hrs, comparatively with the bioﬁlm
developed on the uncoated glass support. At 72 hrs, the number of cells
was similar comparatively with the control. A similar bioﬁlm dynamic
was observed when S. aureus adhered to microscopic slides coated
with core/shell/adsorbtion-shell nanosystem. The core/shell exhibited an
anti-bioﬁlm activity evidenced only in the ﬁrst 24 hours of incubation,
thereafter the number of adherent bacterial cells being similar with the
control.
Conclusions: Our results are demonstrating that Fe3O4/oleic acid
nanoparticles could be used as successful coating agents for obtaining
antibioﬁlm pellicles on different devices, exhibiting the great advantage
of not affecting the antimicrobial properties of the absorbed substance.
P1045 Major genetic plasticity found in NDM-1 plasmids grown
under different conditions
S. Agouri*, J. Weeks, T. Walsh, M. Toleman (Cardiff, UK)
Objectives: Initially these experiments were set up in order to determine
how stable NDM-1 plasmids are in their host clinical isolates without
selection over a two week period and also the effect of the SOS system
on the mobilisation of NDM-1.
Methods: Nine clinical isolates that harboured NDM-1 on different sized
plasmids and different incompatibility groups were grown with daily
subculture at different temperatures (30ºC and 37ºC) without selection
and also at 37ºC with sub MIC amounts of ciproﬂoxacin (a known SOS
response inducer). Each day samples were taken and plugs were prepared
for pulsed ﬁeld electrophoresis (PFGE). At the end of the 14 days the
plugs were digested with S1 and the genomic DNA separated by PFGE.
Gels were then probed with 32P labelled blaNDM-1 to determine the
presence and location of NDM-1.
Results: All cultures were positive for NDM-1 throughout the two weeks
of growth without selection. The genomic location of the NDM-1 gene
varied markedly during the course of these experiments. The NDM-1
gene moved onto the chromosome in four isolates (IR25, IR26, IR18K
and IR29). For IR25 this was under all conditions and continued being
both on the chromosome and on a 350kb plasmid throughout the
experiment, in addition at day 12 NDM-1 also appeared on a plasmid
of ~100kb. However, for IR26 this movement occurred at day 1 at 30ºC
and at day 14 at 37ºC. In one Klebsiella isolate collected from the north
of India, the NDM-1 gene moved from being on a single plasmid of
100kb to being on four plasmids of different sizes ranging from 50kb
to 300kb in size when grown at 37ºC but not when ciproﬂoxacin was
present. In general the majority of the movement events appeared to
occur preferentially at 30ºC.
Conclusions: NDM-1 is a stable resistance gene being inherited over
a two week period without selection in 100% of the clinical isolates
tested in this study. NDM-1 also appears to be remarkably mobile and
able to move from plasmids to the chromosome of its host organism
in approaching 50% of the isolates over a 14 day period. Movement
and ampliﬁcation of NDM-1 copy number were common events during
the course of these experiments being observed in all isolates studied.
Interestingly growth at 30ºC appears to have the most dramatic effect on
these events and may indicate that movement of NDM-1 occurs rapidly
in the environment.
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P1046 Carbapenemase-2 producing Klebsiella pneumoniae
transmission in an Italian university hospital
M. Rossi*, G. Migliorino, E. Motta, G. Foti, F. Morini, G. Giltri,
E. Vigano`, R. Fumagalli, A. Gori (Monza, IT)
Objective: To describe the emergence of carbapenemase-2 (KPC-2)-
producing Klebsiella pneumoniae in an university hospital in Italy, focus-
ing on the epidemiological, microbiological, and clinical characteristics
of the KPC-2 spread and transmission.
Methods: All data and records for patients with a KPC-2-producing
K. pneumoniae infection were prospectively collected. All available
clinical KPC-2-producing K. pneumoniae strain were genotyped by
repPCR and PFGE. Species identiﬁcation of isolated bacteria and
MIC determinants were performed using an automated system (Vitek-2
bioMerieux); MICs of meropenem, colistin, gentamicin, tigeciclyne and
cotrimoxazole were evaluated with E test and were classiﬁed according
to Clinical and Laboratory Standards Institute (CLSI) breakpoints and
guidelines.
Results: From December 2009 through 20 October 2010, 50 patients
(40% female; mean age 70,2 years; range 19−94 years) were infected
by KPC-2-producing K. pneumoniae. Fingerprinting analysis showed a
cluster of 49 strains. 1 strain was not correlated. Eleven patients were
hospitalized in the ICU when the KPC-producing isolate was detected,
29 in medical ward and 10 in surgical ward. The total mean length of stay
in hospital before infection was 25,98 days (range 0–100 days). Twenty
ﬁve (50%) of the infected patients were receiving piperacillin/tazobactam
containing antimicrobial regimen when infection was diagnosed, 6 (12%)
were receiving meropenem. The prevalent strain tested was susceptible
to colistin, gentamicin, tigecycline and cotrimoxazole.
Sites of infection: 21 urinary tract infections, 16 lower tract respiratory
infections, 5 bacteremia, 7 surgical site infections, and 1 post-surgical
meningitis. Fifteen (30%) patients did not receive antimicrobial treatment
for KPC-2-producing K. pneumoniae: 7 (14%) patients died before
diagnosis of infection, 8 (16%) patients with urinary catheter related
infection were successfully treated only with catheter removal.
Infection was treated in 35 patients (70%): 27 patients received
antimicrobial regimen containing colistin either as the only active
antimicrobial (6 patients) or with other active antimicrobial (gentamicin,
cotrimoxazole, tigecycline. The crude mortality rate among the cohort
of infected patients was 34%, lower compared with recent literature
showing a mortality rate of 47%.
Conclusion: The emergence of KPC-2-producing K. pneumoniae create
an important challenge for clinicians and hospital epidemiologists.
P1047 A signiﬁcant impact on the rate of ESBL-producing
Klebsiella pneumoniae by changing the antibiotic policy and
consumption
J. Knudsen*, S.E. Andersen for the Bispebjerg Intervention Group
Background: In a 600-bed university hospital in Copenhagen, Denmark,
the extended spectrum b-lactamase (ESBL) producing Klebsiella
pneumoniae became a major problem, and the resistance rate among
patients with K. pneumoniae reached more than 40%, in spite of
numerous infection control initiatives as reintroducing choric cleaning
and focus on isolations precautions. The effect of an intervention
focusing on optimising diagnostics and a totally changed antimicrobial
policy was evaluated.
Methods: During 2009 all possible interventions were studied, and
an intervention, implying many different initiatives, was started in
January 2010. The antimicrobial policy was changed, and it was only
possible to use cephalosporin for surgical prophylaxis and in the
treatment of meningitis. The use of quinolone was diminished to only
certain indications. Focus was set on diagnostic initiatives and isolation
precautions and use of small spectrum antibiotics when possible.
Numerous teaching lectures were given, and written informations and
guidelines were distributed to all clinical working employees in brochures
and electronically.
Results: The rate of patients with ESBL producing K. pneumoniae
decreased from 43% in January 2010 to 16% in November 2010
(p = 0.007), and the rate for ESBL-producing E. coli patients were
unchanged app. 12%. The number of bed-days with patients under
isolation precautions for patients with ESBL producing K. pneumoniae
and E. coli were reduced from more than 260 per month to less than 50
(p< 0.001) The compliance to the new guidelines was almost complete,
the cephalosporin consumption decreased from 2409 to 581 DDD/month
(76%), and quinolones from 2859 to 2298 DDD/month (20%), from 2009
to 2010.
Conclusions: An intervention, implying many different initiatives
including changing antibiotic policy, reduced the rate of patients with
ESBL-producing Klebsiella pneumoniae signiﬁcantly. The number of
bed-days with patients under isolation precautions was also reduced
signiﬁcantly.
P1048 Chromosome-encoded extended-spectrum class A
b-lactamase MIN-1 from Minibacterium massiliensis
B. Bercot*, P. Nordmann, M. Drancourt, L. Poirel (Le Kremlin Bicetre,
Marseille, FR)
Objectives: Minibacterium massiliensis is a newly discovered water-
borne motile bacterium that has been isolated in Marseille from a 0.22-
micron ﬁltered water used for patients in the hospital. The genome of
the corresponding strain has been recently sequenced, and a putative
b-lactamase gene was identiﬁed. The aim of our study was to characterize
this novel b-lactamase.
Methods: MICs were determined by Etest method. The blaMIN-1
gene was ampliﬁed by PCR and then cloned into PCR-blunt vector
(Invitrogen). The resulting plasmid was sequenced and expressed in
Escherichia coli, and the MIN-1 protein was puriﬁed and kinetic
parameters determined by UV spectrophotometry.
Results: The M. massiliensis isolate was resistant to narrow-spectrum
b-lactams. The blaMIN-1 gene encoded MIN-1, a 300 amino-acid
Ambler class A b-lactamase with a pI value of 8.5 and a molecular
mass of ca. 29 kDa. MIN-1 shared 56%, 54% and 51% amino acid
identity respectively with the intrinsic extended spectrum b-lactamase
(ESBL) LUT-1 of Pseudomonas luteola and with the plasmid-
mediated b-lactamases KPC-2 and CTX-M-2. The hydrolysis spectrum
of the clavulanic acid-inhibited MIN-1 included expanded-spectrum
cephalosporins such as cefotaxime, ceftriaxone and aztreonam, but
not ceftazidime. The blaMIN-1 gene was chromosomally-located, as
indicated by analysis of the whole genome sequence. No putative
regulatory gene was identiﬁed upstream of the blaMIN-1 gene, in
accordance with the lack of induction of the b-lactamase expression
in M. massiliensis.
Conclusions: This work further illustrates the diversity of chromosome-
encoded Ambler class A ESBLs. This study further indicates that water-
living bacterial species are common sources of antibiotic resistance
genes.
New insights on mechanisms of resistance in
Staphylococcus aureus
P1049 Loss of activity of the GdpP protein leads to b-lactam
tolerance in Staphylococcus aureus
J. Grifﬁths*, A.J. O’Neill (Leeds, UK)
Objectives: Tolerance (TOL) describes a strain-speciﬁc phenomenon in
which the killing activity of a bactericidal antibiotic becomes attenuated.
It is most commonly observed in Gram-positive bacteria in response to
cell-wall active antibiotics. The presence of TOL Staphylococcus aureus
in deep-seated infections is reported to negatively impact treatment with
cell-wall active antibiotics and can lead to treatment failure. Despite this,
the genetic basis of TOL in S. aureus remains obscure. The objective
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of this study was to generate B-lactam-tolerant strains and use them to
elucidate the genetic basis of TOL.
Methods: Strains exhibiting tolerance to B-lactams were generated by
exposing S. aureus SH1000 to cycles of oxacillin (OXA) selection
(>100× minimum inhibitory concentration (MIC)). Genetic changes
were identiﬁed by comparative genome sequencing (CGS), and veriﬁed
by PCR and DNA sequencing. Disruption of a putative TOL locus was
performed using plasmid pMUTIN4 and complementation was carried
out using expression plasmid pEPSA5.
Results: TOL, deﬁned here as a 90% drop in viability after 6 h
challenge with 12.5mg OXA/L, was observed in SH1000 after 10−20
cycles of OXA exposure without a concomitant increase in OXA MIC.
CGS revealed that two independently-recovered TOL strains carried
two and ﬁve mutations per genome, respectively, with the majority
lying within, or in the vicinity of, genes of unknown function. Both
TOL strains harboured different missense mutations in gdpP, a gene
encoding a putative membrane-located signalling protein containing a
diguanylate cyclase (GGDEF) domain. The role of this gene in tolerance
was further examined by insertional inactivation, which resulted in a
stronger tolerance phenotype compared with that observed in the TOL
strains (<50% loss of viability after 6 h of OXA exposure vs. ~80%).
Complementation of the gdpP-disrupted mutant by providing wild-type
gdpP in trans resulted in loss of the TOL phenotype.
Conclusion: Two independently-selected TOL mutants both carried
missense mutations in gdpP. Since insertional inactivation of this gene
also resulted in TOL, we conclude that it is loss or reduction of
GdpP activity that underlies this phenotype. Bioinformatic analysis
suggests that GdpP is a signalling protein, potentially implicating altered
transduction of environmental signals in the reduced B-lactam killing
observed in TOL strains.
P1050 A novel mechanism of reduced susceptibility to vancomycin
in Staphylococcus aureus
A.Y. Peleg*, D. Cameron, D. Ward, R. Moellering, G.M. Eliopoulos
(Melbourne, AU; Boston, US)
Objectives: Staphylococcal strains with reduced susceptibility to
vancomycin (Vn) are being reported. This study aimed to elucidate the
genetic mechanisms of resistance.
Methods: Next generation whole genome sequencing was performed
on a unique collection of isogenic, clinical and laboratory derived pairs
that had been exposed to Vn and developed Vn non-susceptibility. Four
clinical pairs or series (11 strains) and 1 laboratory derived series
(3 strains) underwent comparative genomics. pKOR1 allelic exchange
was used for targeted mutagenesis and pL150 for complementation.
Gene expression analysis was performed using TIGR microarray chips.
Bioﬁlms on plastic surfaces, electron microscopy and population analysis
proﬁles (PAP) were also performed.
Results: An average of 5 single nucleotide polymorphisms, 2 deletions
and 1 insertion were identiﬁed in each Vn non-susceptible strain
compared to its Vn susceptible parent strain. Mutations in previously
described genes that control cell wall biosynthesis and autolysis were
identiﬁed including agr and dltA. However, mutations in new genes were
identiﬁed including in a sensor kinase, walK, and a serine/threonine
phosphatase, stp1, which also regulate cell wall metabolism. A clean
deletion of the stp1 gene conﬁrmed its importance to vancomycin
susceptibility, with an increase in MIC to vancomycin (from 1.5mg/ml to
2mg/ml) and an hVISA phenotype on PAP compared to its isogenic, Vn
susceptible parent strain. Cell wall thickness was also increased (from
26.32 nm to 30.34 nm, P< 0.05) and bioﬁlm formation was reduced 1.5
fold in the stp1 mutant (P< 0.05). These features returned to wild-type
with complementation of the stp1 gene. Apart from cell wall related
genes, microarray analysis showed that stp1 regulates virulence factors,
including hemolysins and phenol soluble modulins.
Conclusions: Mutation in stp1, a recently described serine/threonine
phosphatase, appears to be a novel genetic mechanism for reduced
susceptibility to vancomycin in S. aureus. Interestingly, this gene also
appears important for staphylococcal virulence.
P1051 Structural insights into fusidic acid resistance mediated by
FusB-type proteins in Staphylococcus aureus
G. Cox*, G.S. Thompson, H.T. Jenkins, S.W. Homans, T.A. Edwards,
A.J. O’Neill (Leeds, UK)
Objectives: The primary mechanism of fusidic acid (FA) resistance in
clinical strains of Staphylococcus aureus is expression of a FusB-type
protein (FusB or FusC). These proteins bind elongation factor G (EF-G),
the target of FA, and protect bacterial translation from FA-mediated
inhibition. However, the interaction of these proteins with EF-G is poorly
characterised, their structure has not been elucidated, and it is unknown
how protection from FA is mediated. Here we report the ﬁrst crystal
structure of a FusB-type protein, and deﬁne the binding interface between
these proteins and EF-G.
Methods: Proteins were over-expressed in E. coli BL21 (LambdaDE3),
and puriﬁed using nickel afﬁnity- and gel ﬁltration chromatography.
FusC crystals were grown using the hanging drop vapor diffusion
method. The structure was solved at 2.1 A˚ and reﬁned to 1.9 A˚ resolution.
NMR experiments were performed with perdeuterated 0.3 mM 13C
and 15N-labelled FusB. For chemical shift mapping, labelled FusB was
saturated with EF-GC3, a fragment of EF-G containing the FusB binding
site (domains 3−5). In silico protein-protein docking of FusC and EF-
GC3 was performed using ZDOCK.
Results: The 3D structure of FusC reveals a monomer composed of
two distinct domains. The N-terminal domain comprises a four-helix
bundle exhibiting similarity to existing protein structures. By contrast,
the C-terminal domain forms a novel fold of helices and b-sheet with four
conserved cysteine residues coordinating a central zinc ion. Chemical
shift mapping identiﬁed the C-terminal domain of FusC as the region of
the protein that interacts with EF-G. Molecular docking of EF-GC3 and
FusC indicate that FusB-type proteins speciﬁcally bind domains 3 and
4 of EF-G.
Conclusions: FusB-type proteins interact with EF-G via a novel protein
fold in the C-terminus that forms a zinc-binding domain. This interaction
occurs away from the FA binding site of EF-G, indicating that FusB-type
proteins do not likely mediate FA-resistance through steric-hindrance of
the interaction between FA and its target. Instead, these proteins interact
with the portion of EF-G known to make contact with the inside of the
ribosome, suggesting that binding of FusB-type proteins to EF-G may
trigger the release of FA-EF-G complexes from the ribosome.
P1052 Linezolid decreases exotoxin expression in Staphylococcus
aureus by early repressing agr, sarA and SAE regulators
O. Dumitrescu*, F. Forey, M. Bes, F. Vandenesch, J. Etienne, G. Lina
(Lyon, FR)
Objectives: Linezolid have been shown to decrease the expression
of several staphylococcal exotoxins (Panton-Valentine leukocidin PVL,
alpha toxin HLA and staphylococcal toxic shock toxin) suggesting that
linezolid might interfere with S. aureus virulence regulators. In this work
we explored linezolid effect on agr, sarA, rot and sae major virulence
regulators expression.
Methods: S. aureus RN6390 phiSLT was cultured to the mid exponential
phase and linezolid was added at sub-inhibitory concentration (1/2 of
the MIC). Aliquots of culture were taken after 1, 2 and 4 hours and
bacterial pellets were used for RNA extraction and subsequent RT-PCR
with speciﬁc gyrB, pvl, hla, agr, sarA, rot and seaP primers. The amounts
of amplicons speciﬁc for each gene were determined by quantitative
PCR relative to gyrB. The expression levels of investigated genes upon
linezolid treatment were expressed as n-fold difference relative to mRNA
expression levels of the growth control.
Results: After 1 hour incubation, no change was observed in mRNA
expression levels of explored genes. By contrast, after 2 hours incubation,
we observed signiﬁcant decrease upon linezolid treatment in agr (3.3 fold
decrease), sae (4.2 fold decrease), pvl (6.3 fold decrease) and hla (4.6
fold decrease) mRNA levels. Similar trends were observed after 4 hours:
4.2 fold decrease in agr, 14.6 fold decrease in sarA, 19 fold decrease in
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sae, 9.9 fold decrease in pvl, 8.7 fold decrease in hla mRNA levels.
Meanwhile, no change was observed in rot expression for linezolid
treated cultures at any time point explored.
Conclusions: In this work we show that linezolid decreases exotoxin
expression in S. aureus by promoting early reduction of PVL and
HLA mRNA levels. Our results show that linezolid represses three
major positive regulators of exotoxin expression: agr, sae and sarA.
Contrarily, the expression of rot “repressor of toxins” was not
modiﬁed. Therefore linezolid treatment induces an impaired expression
of virulence regulators: repressive regulators prevail thus leading to
decreased expression of exotoxins.
P1053 The effect of ermTR gene in isogenic conditions on
erythromycin and lincomycin susceptibilities of S. aureus
RN4220
E. Oryasin*, B. Bozdogan (Aydin, TR)
Introduction: ermTR is one of the most common gene that confers
resistance to macrolides especially in Streptococcus. The effect of ermTR
was never shown in isogenic conditions. The purpose of the present
study was to show the effect of ermTR in isogenic conditions by cloning
ermTR and transferring this gene to a Gram positive bacteria.
Material and Methods: Total DNA from S. pyogenes C1 was extracted
and was used for ampliﬁcation of ermTR gene. DNA extraction was
done using Instagene Matrix as described by manufacturer. To simplify
cloning modiﬁed primers with addition of restriction sites was used.
Amplicons as well as pUC18 were restricted with appropriate enzymes,
were ligated and transformants were selected after electrotransformation
of E. coli DH10B. Recombinant plasmids were puriﬁed and restricted
and subcloned in a shuttle plasmid pJIM2246 and were used for
transformation of E. coli DH10B. Recombinant pJIM2246 with ermTR
gene was introduced to S. aureus RN4220 by electroporation. MICs
for E. coli and S. aureus transformed with ermTR gene. The construct
contained no regulatory region to see the effect of ErmTR methylase
continuously synthesized.
Results: The initial erythromycin MICs of the recipient strains E. coli
DH10B and S. aureus RN4220 were 32 and 1mg/L, respectively. After
transformation MICs were increased 8 fold for E. coli and 32 fold for
S. aureus RN4220. The increase in lincomycin MIC was more important
in S. aureus and >128 fold increase was reached. The MICs obtained
are summarized in Table 1.
Conclusions: This study showed two main differences between ErmTR
and other methylases. i) Level of erythromycin resistance conferred by
ErmTR remains low. ii) Lincomycin resistance level conferred by ErmTR
methylation is higher than macrolide. Other methylases ermA, ermB
confer high level of macrolide resistance and high level lincomycin
resistance if the synthesis is permanent. These methylases methylates
adenine at position 2058 of 23S rRNA. Also mutations at that position
confer high level resistance. Further studies are necessary to determine
methylation site of ErmTR. ErmTR may methylate an other site than
A2058 at 23S rRNA.
P1054 Ultrastructural cell wall characteristics of clinical
gentamycin-resistant Staphylococcus aureus isolates
K. Fukutsuji*, S. Yamada, T. Harada (Kurashiki, JP)
Objectives: The frequent use of gentamycin (GM) ointment for treatment
of skin infections has led to an increase in the number of GM-resistant
strains of Staphylococcus aureus. We examined the ultrastructural
characteristics of clinical GM-resistant S. aureus strains by transmission
electron microscopy.
Methods: Fourteen S. aureus clinical isolates used in this study were
obtained from the Department of Laboratory Medicine, Kawasaki
Medical School Hospital, Japan. The minimal inhibitory concentrations
(MICs) were evaluated according to the standard agar dilution method
recommended by the Japan Society of Chemotherapy. It was recognized
that seven isolates were resistant and seven isolates were sensitive to
GM. Transmission electron microscopic analysis of each strain involved
measurement of cell wall thickness in more than 10 cells with equatorial
cut surfaces. We have genetically characterized these isolates using
polymerase chain reaction, targeting three genes of the aminoglycoside-
modifying enzyme, AAC(6′)-APH(2′′), APH(3′)-III and ANT(4′)-I.
Results: Electron microscopy indicated that the cell wall was
signiﬁcantly (P< 0.001) thicker in clinical GM-resistant strains
(32.24±5.99 nm) than in GM-sensitive strains (19.02±2.72 nm). Al-
though these ultrastructural characteristics were found in all GM-
resistant isolates, there was no clear correlation between these isolates
and the three known GM-resistance genes of S. aureus. Thus, the
mechanism of cell wall thickening does not appear to be dependent on
a particular GM-resistant gene. We also demonstrated that GM-resistant
mutant strains, derived in vitro from a GM-sensitive S. aureus parent
strain (209P), had a thickened cell wall.
Conclusion: These results strongly suggest that clinical GM-resistant
S. aureus strains have a thicker cell wall as a common ultrastructural
characteristic.
P1055 Antimicrobial activity of daptomycin tested against
S. aureus collected from osteoarticular infections
H. Sader*, D. Farrell, R. Jones (North Liberty, US)
Objectives: To evaluate the antimicrobial activity of daptomycin and
comparator agents tested against S. aureus from osteoarticular infections.
S. aureus is a major cause of osteoarticular infections and those caused
by oxacillin-resistant strains (MRSA) are particularly difﬁcult to treat
due to limited therapeutic options. MRSA ostearticular infections are a
primary indication for outpatient parenteral antimicrobial therapy.
Methods: As part of the Daptomycin Surveillance Program, 606
S. aureus causing osteoarticular infections were collected from 56
medical centers located in North America (NA; 29), Europe (EU; 17)
and Latin America (LA; 10) in 2002–2009. Isolates were tested for
susceptibility (S) against daptomycin and several comparators by CLSI
broth microdilution method. Calcium content of the broth was adjusted
(50mg/L) for testing daptomycin. S breakpoint approved by the USA-
FDA, CLSI and EUCAST (1mg/L) was applied.
Results: S to oxacillin was higher in EU (80.5%) and LA (76.0%)
compared to NA (51.7%). Daptomycin was very active against S. aureus
from osteaoarticular infections independent of geographic region.
Daptomycin activity was not adversely affected by resistance to oxacillin
or other antimicrobials (Table). All isolates were S to daptomycin
(MIC50/MIC90, 0.25/0.5mg/L) and 98.5% of strains were inhibited
at 0.5mg/L of daptomycin. Vancomycin (MIC50/90, 1/1mg/L) and
linezolid (MIC50/MIC90, 2/2mg/L) were also very active (both 100.0%
S), but were four- to eight-fold less potent than daptomycin. Among
MRSA, S to levoﬂoxacin (LEV; 27.1% overall) ranged from only 16.0%
in EU to 32.5% in NA; while S to clindamycin (CLI; 47.4% overall)
varied from 19.2% in LA to 62.7% in NA and 72.0% in EU.
Conclusion: Daptomycin was highly active against a large collection
of S. aureus from osteoarticular infections. Due to its excellent anti-
S. aureus spectrum, high potency and rapid bactericidal activity,
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daptomycin may represent an excellent option for treatment of S. aureus
osteoarticular infections, including those caused by MRSA.
P1056 Correlation of consumption and resistance in Staphylococcus
aureus in Lebanon
Z. Daoud*, M. Hajjar, E. Salem, E. Azar, C. Aﬁf (Beirut, LB)
Background: In this study, we attempt to correlate resistance of MRSA
and antibiotic consumption data and identify any association between
consumption and resistance within participating hospitals in Lebanon.
Methods: We determined antimicrobial susceptibility testing for
S. aureus isolated in the laboratories of 10 Lebanese hospitals. Oxacillin
susceptibility was determined by using an oxacillin screening plate at
6mg/L, an oxacillin (1mg) disc and a cefoxitin (10mg) disc, non-
susceptible isolates were conﬁrmed through oxacillin MIC. Susceptibility
testing of other antibiotics was also performed. Consumption data were
aggregated at the level of the active substance, in accordance with the
WHO’s ATC classiﬁcationand estimated in DDD/100BD.
Hospitals were sorted in an ascending order by resistance proportions and
the median was established. The sorted list was divided into above and
below median groups for MRSA. Mann Whitney analysis was performed
for the total levels of antibiotic consumption of the respective two
different clusters. Univariate regression analysis was performed for each
individual antibiotic group in order to identify individual correlations
between any one class and respective MRSA.
Results: A total of 855 isolates were studied for the 24 month study
period (Jan 2008-Jan 2010), by 10 hospital laboratories spread over the
Lebanese territories. The overall median MRSA proportion was 36%.
Over the 2-year duration of data collection, a statistically signiﬁcant
increasing trend (P, 0.05) was observed in 6 participating hospitals,
while signiﬁcant decreases were seen in the remaining 4 hospitals.
Resistance proportions were not related to the type or size of the hospital.
We also examined the distribution of single methicillin resistance and
multiresistance of S. aureus. The highest rate of multiresistance was
found in Beirut, reaching levels of 42% of all MRSA isolates reported.
Hospitals reporting lower MRSA proportions showed a median value for
total antibiotic use of 0.5 DDD/100BD, as compared to 1.3 DDD/100BD
in above median MRSA group. There were no evident differences in
the consumption of cephalosporins (ATC classes: J01DB − J01DE) by
hospitals in the below and above MRSA median arms.
Discussion: Our ﬁndings suggest that Lebanese hospitals with above-
median MRSA proportions tended to be associated with higher levels of
antibiotic consumption.
P1057 Susceptibility of S. aureus from inpatient vs outpatient
settings − a global analysis 2009–2010
S. Lob, D. Hoban, S. Bouchillon, R. Badal*, M. Hackel, J. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Objective: Staphylococcus aureus is a common cause of nosocomial and
community-acquired infections. Strains isolated from inpatients usually
exhibit higher resistance than community-acquired strains. In this study,
data from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) were
used to compare the in vitro activity of several antimicrobial agents
against MSSA and MRSA from inpatient and outpatient settings.
Methods: In 2009 and 2010, 5,124 S. aureus isolates from multiple
specimen sources were collected in 48 countries. MICs were performed
at each site following CLSI guidelines using commercially-prepared
microbroth panels. Results were interpreted according to CLSI
breakpoints (FDA breakpoints for tigecycline). % susceptible differences
between inpatients and outpatients were tested using the Fisher exact
test, while geometric mean MICs were compared by the non-parametric
Wilcoxon rank sum test.
Results: 2,740 and 658 MSSA and 1,424 and 302 MRSA from inpatients
and outpatients, respectively, were collected. The following table shows
the MIC50, geometric mean (GM) MIC, and % susceptible for several
antimicrobials, as well as p values comparing isolates from inpatient and
outpatient settings.
Conclusions: In 2009/10, amoxicillin-clavulanic acid, levoﬂoxacin,
meropenem, and minocycline exhibited signiﬁcantly higher MICs
(p< 0.05) in inpatient isolates than in outpatient specimens, mostly for
MRSA. Examining the GM MIC and testing for signiﬁcant differences
is often more sensitive for detecting changes in in vitro activity
than the MIC50 (e.g., minocycline vs MRSA) or the % susceptible
(e.g., levoﬂoxacin vs MSSA). Linezolid, tigecycline, and vancomycin
remained almost universally active against both MSSA and MRSA with
no signiﬁcant difference in the GM MIC (except vancomycin vs MSSA)
or % susceptible between inpatient and outpatient isolates.
P1058 Susceptibilities of antibiotics with activity against
methicillin-resistant Staphylococcus aureus from 2004–2008
T. Crawford*, L. Danziger, K. Rodvold, W. Janda (Chicago, US)
Objectives: Presence of subtle changes in vancomycin minimum
inhibitory concentrations (MICs) against Staphylococcus aureus (i.e.
MIC creep) has not been conclusively shown in scientiﬁc literature.
At the University of Illinois Medical Center at Chicago, vancomycin
MICs for methicillin-resistant Staphylococcus aureus (MRSA) obtained
by automated systems [Vitek Legacy (2004–2007) and Vitek 2 (2007–
2008)] decreased from 2004–2008. Objectives of this study are to
determine vancomycin MICs against MRSA utilizing E-test strips,
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compare vancomycin MICs obtained by Vitek 2 and E-test, and establish
daptomycin, trimethoprim/sulfamethoxazole, rifampin, linezolid, and
tigecycline MICs against MRSA.
Methods: 103 blood isolates were collected and stored at −70ºC.
Identiﬁcation of MRSA and initial vancomycin sensitivity testing were
performed by Vitek Legacy and Vitek 2. Blood isolates were tested for
susceptibility to six antibiotic agents (vancomycin, rifampin, daptomycin,
linezolid, tigecycline, and trimethoprim/sulfamethoxazole) by E-tests,
using Mueller Hinton agar plates (MHA) inoculated with inoculum
suspension with a turbidity equivalent to 0.5 McFarland standard. MHA
plates were incubated at 35ºC for 24 hours and read by a single reviewer.
Results: 31 isolates in 2004, 30 isolates in 2005, 19 isolates in 2006, 22
isolates in 2007, and 10 isolates in 2008 were identiﬁed. 18 isolates in
2004 and 2 isolates in 2008 reported a vancomycin MIC=2 obtained
by Vitek 2. Vancomycin MICs obtained by E-test report 3 isolates
with MICs=2 in both 2004 and 2008. All isolates were susceptible to
daptomycin during 2004–2006 however, 2 isolates in 2007 and 3 isolates
in 2008 were resistant. 1 isolate in 2005 and 3 isolates in 2007 were
resistant to trimethoprim/sulfamethoxazole. 1 isolate in both 2004 and
2006 and 2 isolates in both 2007 and 2008 were resistant to rifampin.
All isolates were susceptible to linezolid and tigecycline.
Conclusion: Vancomycin MICs obtained by E-test did not reﬂect a
decline in vancomycin MICs as reported by Vitek 2. Vancomycin
MICs remained fairly constant based on MIC reports obtained by
E-test. Small changes in the susceptibility of daptomycin, trimethoprim/
sulfamethoxazole and rifampin were reported while isolates remained
susceptible to linezolid and tigecycline.
P1059 Antimicrobial susceptibility phenotypes of vancomycin
intermediate Staphylococcus aureus isolates
R. Craven*, C. Doern, C. Burnham, C. Weber, S. Metzger, W.M. Dunne
(St. Louis, Dallas, Denver, US)
Objectives: The purpose of this study was to determine if evidence
of telavancin non-susceptibility existed among vancomycin intermediate
Staphylococcus aureus (VISA) isolates in our medical center.
Methods: S. aureus isolates that grew on a novel 3mg/L vancomycin
screening agar were subsequently tested for vancomycin susceptibility by
broth microdilution and VISA (MIC 4−8mg/mL) isolates were frozen at
−80ºC for future analysis. A collection of 148 consecutive VISA isolates
were then retrieved for characterization of telavancin susceptibility, and
repeat vancomycin and daptomycin MIC testing by broth microdilution.
Clonality of VISA isolates was determined by repPCR. A selection of
isolates was subjected to microdilution population analysis proﬁle (PAP)
and BACcel analyses to determine hVISA status.
Results: 141 of 148 isolates (95.2%) failed to maintain their VISA
phenotype, by MIC, upon retesting under non-selective conditions. 16
of these isolates were tested by population analysis (PAP) and BACcel −
a novel real-time growth analysis system, with concordant ﬁndings
between the two methods that 14/16 were hVISA. The remaining 2
isolates were identiﬁed as VSSA by PAP and hVISA by BACcel.
RepPCR analysis revealed that the 7 isolates that remained vancomycin
intermediate after thawing were not clonal, but fell into 5 distinct
clusters. 46% of S. aureus isolates that initially tested vancomycin
intermediate had also tested daptomycin non-susceptible. Upon retesting
after thawing, only 6% of isolates were daptomycin non-susceptible.
69% of the initial VISA isolates were methicillin resistant, while 31%
were methicillin susceptible. No isolates were telavancin non-susceptible
(MIC >1mg/L).
Conclusion: This study demonstrates that phenotypic expression of
vancomycin-intermediate status in S. aureus is unstable and likely to
be lost when selective pressure is removed. Retrospective studies of
stocked organisms to determine vancomycin susceptibility prevalence
may yield inaccurate results. The use of vancomycin screening agar
likely identiﬁes hVISA/VISA that would have been missed if broth
microdilution had been done directly from blood agar plates. There
is a correlation between reduced susceptibility to vancomycin and
daptomycin. Additionally, a signiﬁcant proportion of hVISA/VISA
isolates are methicillin susceptible. No evidence of telavancin non-
susceptibility was detected.
P1060 Present situation of antimicrobial resistance of
Staphylococcus in Spain (2010): seventh nationwide
prevalence study and emerging resistance to linezolid
E. Cercenado*, O. Cuevas, B. Gama, A. Vindel, M. Marı´n, E. Bouza
on behalf of the Staphylococcus Study Group
Objective: Data regarding the evolution of Staphylococcus resistance in
a whole country have a deﬁnite inﬂuence in the design of empirical
treatment regimens. For the last 25 years we have been performing
prevalence studies in order to ascertain the situation of the antimicrobial
resistance of Staphylococcus in our country. In this study we present the
results of the seventh point prevalence study performed in 2010.
Methods: In a selected day of June 2010, we collected all staphylococci
isolated in 152 Spanish hospitals. All microorganisms were sent
to a coordinating laboratory where identiﬁcation and antimicrobial
susceptibility testing was performed against 15 antimicrobial agents
using and automated microdilution method (MicroScan). Additional
E-test susceptibility testing was performed for vancomycin (VAN),
linezolid (LIN), daptomycin (DAP) and tigecycline (TG).
Results: We collected 542/438 S. aureus/coagulase negative staphylo-
cocci (CoNS) isolates. Percentages of resistance of S. aureus/CoNS
against selected antimicrobials (PEN = penicillin, OXA = oxacillin,
ERY = erythromycin, CLI = clindamycin, GEN = gentamicin, TOB =
tobramycin, CIP = ciproﬂoxacin, RIF = rifampin, T/S = trimethoprim/
sulfamethoxazole) in comparison with the results obtained in two
previous studies (2002 and 2006) are shown in the table.
No resistance to VAN, LIN, DAP, and TG was found among S. aureus.
However, among CoNS, resistance to LIN was 4,3%, and one isolate
showed decreased susceptibility to DAP (MIC 1.5mg/L). All strains
were susceptible to TG.
The most frequent phenotypes of resistance among methicillin-resistant
S. aureus were: ERY+CIP+TOB (21%); ERY+CIP (17.5%); CIP
(17.5%); and TOB+CIP (11.7%).
Conclusions: Methicillin-resistance of S. aureus and CoNS in Spain
seems to be stabilized (28%, and 60%, respectively) and strains are more
susceptible to GEN. However, emerging resistance of CoNS to linezolid
(4.3%) is a cause for concern.
Table. Percentages of resistance of S. aureus/CoNS to selected antimicrobials.
P1061 Thioridazine increases susceptibility to oxacillin in
methicillin-sensitive Staphylococcus aureus
K. Jacobsen*, M. Bonde, H. Kolmos, B. Kallipolitis, J.K. Klitgaard
(Odense, DK)
Objectives: The psycho-active drug, thioridazine, has been shown to
increase oxacillin (methicillin) susceptibility in MRSA. The underlying
mechanism is still unclear but seems to involve down regulation of
resistance and cell wall biosynthesis genes, while a number of surveyed
virulence factors are not induced by this drug combination. Now we ﬁnd
that thioridazine also can boost the susceptibility of Methicillin-sensitive
Staphylococcus aureus (MSSA) strains toward oxacillin and make them
even more sensitive to this b-lactam antibiotic. Although MSSAs are in
principle sensitive to oxacillin, recurring infections is a big issue with
staphylococcal infections. Subsequently, any increase in susceptibility of
the MSSA toward antibiotic treatment will possibly ease treatment.
Furthermore, we examined the effect of thioridazine with or without
oxacillin on the cell wall stimulon, vraSR and on a number of virulence
factors to verify that the treatment does not complicate the infection.
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Methods: Growth of four MSSA strains (ATCC 25923, Newman,
UAMS-1 and 8325−4) was examined in liquid media in the presence
of the methicillin analogue, oxacillin and the non-antibiotic, thioridazine
alone and in combination. We also used phase contrast microscopy to
examine the cells and analyzed transcription of vraSR and RNAIII by
northern blot and primer extension under the same conditions.
Results: We observed an increased susceptibility of all four MSSA
strains toward oxacillin in the presence of thioridazine compared to
bacteria grown with oxacillin or thioridazine alone. Phase contrast
microscopy reveals how cells treated with both oxacillin and thioridazine
become deformed and misshaped, their membranes are clearly affected
and many cells have lysed within 10 hours. We also observed
a concentration-dependent induction of vraSR by thioridazine alone
indicating that the cell wall is damaged by the treatment, which was also
noticed by microscopy. Notably, we do not ﬁnd an increase in expression
of the virulence marker, RNAIII, indicating that thioridazine does not
induce virulence.
Conclusion: Our study shows that addition of thioridazine can increase
oxacillin susceptibility in MSSAs. This important observation allows
treatment of recurring MSSA infections with lower concentrations of
oxacillin, which is of utterly importance in times where the world
consumption of antibiotics is alarmingly high leading to corresponding
high development of resistance.
P1062 Secondary metabolites from lichens: drug interaction of
usnic acid, lobaric acid and protolichesterinic acid with
antibiotics against MRSA clinical isolates
G. Celenza*, B. Segatore, D. Setacci, P. Bellio, F. Brisdelli, V. Petitto,
M. Perilli, M. Nicoletti, G. Amicosante (l’Aquila, Rome, IT)
Objectives: The objectives of this work were:
• to characterise the potential antibacterial activity of usnic acid,
protolichesterinic acid and lobaric acid secondary metabolites from
lichens against methicillin-resistant Staphylococcus aureus clinical
isolates;
• to investigate the interaction of the bioactive compounds from lichens
in combination with the antibiotics which susceptibility against MRSA
is reduced.
Methods: MICs of secondary metabolites from lichens were charac-
terised by microdiluton test in Mueller-Hinton broth, where bacteria
were grown at 37ºC 18 hours. MBCs were calculated by plating 100
uL of bacterial colture on MH agar medium from the determined
MIC value of each compounds up to eigthfold the MIC value. The
compounds were tested in combination with erythromycin, clindamycin,
gentamicin, levoﬂoxacin and oxacillin. All tested clinical isolates showed
resistance to those antibacterial agents. Drug interactions were assessed
by broth microdilution assays. The growth of each well was quantiﬁed by
microplate reader at 600 nm. FICI was calculated. Synergy was deﬁned
as FICI 0.5, antagonism as FICI 4, no-interaction for values of FICI
between 0.5 and 4.
Results:MIC performed on 10 clinical isolates of MRSA showed a value
ranging from 2−4mg/mL for usnic acid, 4−8 mg/mL for protolichesterinc
acid, 16−32mg/mL for lobaric acid. MBC for each compounds was
ranging from the MIC value to twofold the MIC value calculated for
each isolate. The checkerboard assay showed synergy between each
natural compound in combination with LVX and GEN (FIC 0.5), while
for ERY, CLI and OXA no-interactions were observed (FICI between
0.5 and 4). No antagonism has been observed. Beside the antibacterial
activity the cytotoxic effects of the secondary metabolites were evaluated
in human tumor celle lines (MCF-7, human breast adenocarcinoma;
HCT-116, human colon carcinoma; HeLa, human cervix carcinoma.
Usnic acid and protolichesterinic acid inhibited signiﬁcantly the growth
of HeLa and HCT-116 cells.
Conclusion: Although the antimicrobial activity of usnic acid against
Gram-positive bacteria is known, the interaction between secondary
metabolites from lichens in combination with antibiotics has been
investigated for the ﬁrst time in this study. This would pave the way for
the introduction of new classes of molecules in clinical practice from
natural sources. The potential biological activity of those compounds
might be extended to eukaryotic cells.
P1063 Genetic analysis of bacteriophages encoding virulence
factors among methicillin-resistant Staphylococcus aureus
isolated from clinical, animal and environmental samples
in Iran
F. Rahimi*, M. Bouzari, M. Katouli, M. Pourshaﬁe (Isfahan, IR;
Queensland, AU; Tehran, IR)
Introduction: Most of the Staphylococcus aureus isolates contain
lysogenic phages are responsible for production of various virulence
factors. All isolates are classiﬁed in 6 groups according to their
sensitivity to 27 known lysogenic phages. This study is done since 2008,
to detect genetic analysis of different bacteriophages encoding virulence
factors among S. aureus isolated from clinical, animal and environmental
samples.
Material and Methods: Totally 300 isolates of MRSA from human,
animal and sewage samples were collected from hospitals, farms and
sewage treatment plants in Tehran. All isolates were identiﬁed at the
species level using speciﬁc primers and typed using PFGE and Phene-
Plate system. Susceptibility to eighteen antibiotics was determined using
disc diffusion method and MIC of resistant isolates was also done using
Etest according to CLSI recommendation. Primers for identiﬁcation
of 6 classes of bacteriophages were used in Multiplex-PCR assay.
Different virulence factor genes were detected using PCR. All results
were conﬁrmed by sequencing.
Results: Using PCR all isolates were conﬁrmed as MRSA. 100%,
100%, 89%, 94%, 83%, 2%, 1%, 94%, 87%, 94%, 95%, 65%,
49%, 59%, 32%, 0% and 0% of isolates were resistant to oxacillin,
penicillin, clindamycin, tobramycin, tetracycline, nitrofurantoin, fusidic
acid, kanamycin, amikacin, erythromycin, ciproﬂoxacin, SXT, rifampin,
gentamycin, minocycline, synercid, linezolid and chloramphenicol
respectively. 90% of isolates were highly resistant to oxacillin. All
MRSA isolates contain at least one phage. Out of the total MRSA
isolates,95% and 3% of isolates contained 4 and 5 different classes of
phages, respectively. Only 2% of the total MRSA isolates had one class
of phage. 100%, 0%, 1.5%, 0%, 0%, 14%, 0%, 18%, 0%, 100%, 2%,
3%, 2%, 1%, 100%, 100%, 92%, 0%, 0% and 1% of isolates contained
seA, seB, seC, seD, seE, seG, seH, seI, seJ, seK, seL, seM, seN, seO,
seP, seQ, hlB, sak, et and tsst respectively. 6 single types and common
types were seen.
Conclusion: More diversity in the type of phages was found in human
MRSA isolated than in animals and environment. Prophage segments
from Phi-77-like phages were common in the isolates indicating the
ability of these isolates to produce enterotoxins and other virulence
factors. High prevalence of different classes of phages and also presence
of broad spectrum virulence factors and high oxacillin resistance provide
an important role of phages in the evolutionary development of virulence
factors and also diversity in methicillin resistance cassette in MRSA
isolates.
P1064 Comparison of MIC values of vancomycin, teicoplanin,
linezolid and daptomycin in methicillin-resistant
Staphylococcus aureus strains between 2007–2010
B. Dinc, A. Tezer-Tekc¸e*, S. Yagci, H. Cabadak, H. Kilic, S. Sen
(Ankara, TR)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) has
been emerging worldwide as one of the most important problems
in communities and hospitals. Vancomycin has been considered the
Standard for the treatment of MRSA infections. An increase of
vancomycin minimum inhibitory concentration (MIC) values in MRSA
strains has been noted in several reports. This increase is a concern,
since a growing number of studies have suggested that patients with
infections caused by MRSA with vancomycin MICs at the higher end of
susceptibility range are less responsive to vancomycin. Clinicians must
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have alternative therapies for such patients. Teicoplanin has demonstrated
similar efﬁcacy to vancomycin against S. aureus strains and is less toxic
than vancomycin. Linezolid is especially approved for the treatment
of nosocomial pneumonia caused by MRSA. Daptomycin is a new
lipopeptide antibiotic against MRSA and rare instances of resistance
have occurred. It is unclear whether the increase in vancomycin MICs
for MRSA is associated with similar shifts in MICs of other anti MRSA
agents. We aimed to examine the correlation between vancomycin MICs
and the MICs of teicoplanin, linezolid and daptomycin in MRSA strains.
Methods: A total of 200 MRSA strains isolated from clinical samples
were included in this study. The MICs for vancomycin, teicoplanin,
linezolid and daptomycin were determined with E test strips (AB
Biodisk, Sweden). The statistical analysis of the study was performed
by c2 test.
Results: All the MRSA strains were susceptible to the four antimicro-
bials. Table 1 shows the MIC range, MIC50 and MIC 90 values for
vancomycin, teicoplanin linezolid and daptomycin. Although there were
not statistically signiﬁcant differences among MIC values of teicoplanin
linezolid and daptomycin, there was a statistically signiﬁcant difference
in the MIC values of vancomycin between 2007 and 2010 (p< 0.05).
Conclusion: It is supported with our data that, the most common anti-
MRSA agents maintained their full spectrum of in vitro activity against
MRSA strains in our hospital. There are limited data on the association
between the MIC values of vancomycin and other anti-MRSA agents.
In our study, although there is an increase in vancomycin MIC values
between 2007 to 2010, there is no increase in MICs of other anti
MRSA agents like vancomycin. In order to prevent treatment failure
with vancomycin, MIC values must be determined during vancomycin
therapy.
P1065 Multisite evaluation of the daptomycin Neo-Sensitab
prediffusion method against 20 S. aureus
L. Koeth*, B. Katz, P. Bradford, J. Dallow, R. Skov (Westlake,
Lexington, Cambridge, US; Fordham, UK; Copenhagen, DK)
Objective: Neo-Sensitabs (NEO, Rosco Diagnostica, Copenhagen,
Denmark) were developed as an alternative method to disk diffusion,
providing the advantage of long-term room temperature storage. High
molecular weight antimicrobial agents like daptomycin diffuse slowly in
agar media, therefore, a prediffusion procedure has been established. The
purpose of this study performed at 5 sites was to compare daptomycin
(DAP) MIC results to NEO (prediffusion) inhibition zones sizes.
Methods: A set of 20 S. aureus were tested by all sites. The
strains included a range of DAP susceptible and non-susceptible strains
(including 1 hGISA and 5 GISA) and 2 QC strains (S. aureus ATCC
29213 and ATCC 25923). DAP MIC and categorical results (S, I, R)
for all strains were determined by each site by broth microdilution
using dried panels (Trek Diagnostics, E. Grinstead, UK) setup and read
according to EUCAST methods. All strains were tested in duplicate at
each site by DAP NEO 2+18 hour prediffusion utilizing the same lot
of BBL Mueller Hinton II agar. DAP NEO were placed on the non-
inoculated agar for 2 hours at room temperature, subsequently removed,
then held at room temperature for 18 hrs. After this prediffusion step,
plates were inoculated, incubated at 35ºC for 24 hrs and inhibition zones
measured. Categorical results (S, I, R) were interpreted according to the
manufacturer’s criteria. The category agreement (CA) and error rates
between the two methods (using mean MIC results from all sites) were
determined. In addition, the MIC results from each of the sites were
similarly compared to the mean MIC results.
Results: The correlation of DAP NEO and DAP MIC results by site
to mean DAP MIC results are shown in the table. Similar variation was
seen between site DAP MICs to DAP mean MICs (%CA 60−95%, %VM
0–10.5%, %MA 0% at 4 sites and 40% at 1 site).
Conclusion: Mean category agreement of DAP NEO to DAP mean
MICs was 85.7%. The mean category agreement of site DAP MICs
compared to DAP mean MICs was 81.9%. The result of this study are
promising given the use of a single MIC breakpoint and the use of a
biased small set of unique and infrequently isolated strains (80% with
DAP MICs >0.5mg/L). Additional testing with a larger set of strains
with a typical DAP MIC distribution (MIC90 = 0.5mg/L) is warranted.
P1066 An in vitro multisite study of vancomycin and daptomycin
MIC results and tolerance of contemporary Staphylococcus
aureus from Spain
L. Koeth*, E. Cercenado, F. Marco, C. Pitart, F. Linares,
E. Perez-Trallero, R. Canton, J.L. Perez Saenz (Westlake, US; Madrid,
Barcelona, San Sebastia´n, Mallorca, ES)
Objective: The purpose of this study was to determine daptomycin and
vancomycin MIC and MBC results for recent Staphylococcus aureus
clinical isolates at various medical centers in Spain.
Methods: A total of 6 medical centers from 4 distinct cities in Spain
tested 628 contemporary, clinically-signiﬁcant isolates MRSA (n = 516)
and MSSA (n = 112) isolates from various specimen sources. All isolates
were tested to determine MIC and MBC using dried broth microdilution
panels containing daptomycin and vancomycin (TREK Diagnostics, West
Sussex, England). With exception of dried panels, MIC procedures
followed EUCAST guidelines and MBC procedures followed CLSI and
ASM guidelines. MIC quality control was performed with S. aureus
ATCC 29213. MIC interpretative criteria were based on EUCAST
clinical breakpoints. No testing was performed to detect hVISA.
Results: The daptomycin MIC50/90for all S. aureus was 0.5mg/L, the
range of MIC’s was 0.12−2mg/L (MIC for 3 MRSA was 2mg/L). The
vancomycin MIC50/90 for all S. aureus was 1mg/L, the range of MIC’s
was 0.25−2mg/L (MIC for 17 MRSA and 3 MSSA was 2mg/L). The
percentage of vancomycin tolerant strains for all sites was 6.8% (43/628),
86% of which were MRSA. In comparison, 0.3% (2/628) of strains (both
MRSA) were considered daptomycin tolerant (See Table).
Conclusion: There were no VISA/VRSA strains detected and >99%
were susceptible to daptomycin. The higher level of vancomycin tolerant
strains compared to daptomycin suggests superior in vitro bactericidal
activity of daptomycin.
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P1067 Inﬂuence of telavancin sub-minimum inhibitory
concentration on methicillin-resistant Staphylococcus aureus
virulence factor expression
C. Teles*, C. Gemmell, S. Lang (Glasgow, St Andrews, UK)
Objectives: Telavancin is semi-synthetic lipoglycopeptide antibiotic
currently under review by the European Medicines Agency for treatment
of nosocomial pneumonia and complicated skin and soft tissue
infections caused by Gram positive bacteria, including methicillin-
resistant Staphylococcus aureus (MRSA). Despite the bactericidal
activity of this agent, evidence suggests that exposure of bacterial
cells to antibiotic sub-minimum inhibitory concentrations (sub-MICs)
can modulate virulence factors expression in a growth stage dependent
manner. This study aims to evaluate the temporal expression of virulence
factors by clinical isolates of hospital-acquired MRSA (HA-) and
community-acquired MRSA (CA-) after exposure to 0.25× MIC of
telavancin.
Methods: HA-MRSA 784 and CA-MRSA USA300 suspensions grown
in Mueller-Hinton broth at 37ºC were exposed to 0.25× MIC of
telavancin for 1h prior to harvesting in the mid-exponential, early- and
late-stationary growth phases, at which point bacterial cells RNA was
extracted using trizol. The effect of the antibiotic on the expression of
toxins (pvl and tst), adhesins (clfB and cna) as well as the quorum-
sensing intracellular effector molecule RNAIII, was determined through
qRT-PCR. The expression data were analysed using the 2−ddCt method
and the gene modulation threshold was deﬁned as a 2-fold change.
Results: Exposure of CA-MRSA USA300 to 0.25× MIC of telavancin
did not inﬂuence the expression of the virulence genes assessed at any
of the growth stages analysed. In contrast, the tst and clfB genes of HA-
MRSA 784 were down-regulated at the late-stationary phase of growth,
whilst the expression of the remaining genes examined was not subjected
to modulation. Additionally, the expression of the RNAIII encoding gene
of both CA- and HA-MRSA was not altered due to antibiotic exposure.
Conclusion: This study has demonstrated that CA- and HA-MRSA
respond differently to a sub-MIC of telavancin, however, the effect of
this antibiotic is independent of the quorum-sensing system of these
organisms, as demonstrated by the lack of modulation of the RNAIII
molecule. The suppression of the tst and clfB genes of the HA-
MRSA isolate is indicative of the positive effects of telavancin in the
management of MRSA infections.
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P1068 Ceftobiprole efﬁcacy in vitro on Panton-Valentine leukocidin
production and in vivo in a rabbit community-associated
methicillin-resistant Staphylococcus aureus osteomyelitis
model
A. Saleh Mghir, A. Dinh, O. Dumitrescu, G. Lina, Y. Boutrad,
F. Vandenesch, J. Etienne, A.C. Cre´mieux* (Garches, Lyon, FR)
Objectives: Community-Associated Methicillin-Resistant Staphylococ-
cus aureus (CA-MRSA) can cause osteomyelitis with severe sepsis
and/or local complications in which a Panton-Valentine Leukocidin
(PVL) role is suspected. In vitro Ceftobiprole (CEF) efﬁcacy against
3 major PVL+ CA-MRSA clones (USA300 (LAC), -400 and -1000)
was tested in time-kill analyses and for PVL production. In a rabbit
CA-MRSA osteomyelitis model, efﬁcacies of CEF (40mg/kg sc qid) or
vancomycin (VAN) (60mg/kg im bid) alone or combined with rifampin
(RIF) (10mg/kg bid) were compared.
Methods: Eleven CA-MRSA strains were cultured for 18 h in CCY broth
with SubMIC CEF. In parallel, CEF at its MIC time-kill analyses were
run with LAC, starting at 107 CFU/mL. A speciﬁc ELISA measured PVL
production. Intramedullary injection of a sclerosing agent into the tibia,
followed by inoculation of 4×107 LAC CFU (respective CEF, VAN and
RIF MIC: 0.75, 1.5 and 0.012mg/L) induced osteomyelitis. Treatment
was started 14 days postinoculation and lasted 14 days; 7 days later,
bacteria in crushed tibial bones were counted.
Results: PVL production by strains cultured with subMIC CEF was
1.6−4.8-fold above the control level for 6/11 strains tested, with no link
to speciﬁc clones. Time-kill analyses at the MIC showed a transient PVL-
production rise at 6 and 8 h. In vivo, CEF had signiﬁcantly lower mean
log10 CFU/g of bone (1.44±0.40) vs controls (4.33±0.91) (p< 0.01) and
sterilized 7/10 bones vs 0/6 controls. CEF was more effective than VAN
(2.37±1.22 CFU/g of bone (p< 0.05), 5/11 sterile bones). CEF+RIF
(1.16±0.04 CFU/g of bone, 11/11 sterile bones) was more effective than
CEF alone (p< 0.05).
Conclusions: In this CA-MRSA (USA300) model, in vivo CEF efﬁcacy
was enhanced by RIF adjunction. CEF bactericidal activity and the
known RIF anti-PVL effect could partly explain these ﬁndings, which
should be of interest for treating osteomyelitis.
P1069 Efﬁcacy of daptomycin versus vancomycin in an
experimental model of foreign body infection by bioﬁlm
producer Staphylococcus epidermidis
J. Domı´nguez-Herrera*, F. Docobo-Pe´rez, R. Lo´pez-Ro´jas, C. Pichardo,
J. Pacho´n (Seville, ES)
Objectives: Coagulase-negative staphylococci (CoNS) are frequent
causes of infections of prosthetic devices (?50% of cases). In addition,
CoNS cause more than 50% of infections in ventricle-peritoneal shunts
and 40% of prosthetic endocarditis. In 2009 (data from our hospital),
75% of 224 bacteraemic strains of S. epidermidis were resistant to
methicillin (MRSE). On the other hand, the emergence of strains with
reduced susceptibility to vancomycin (VAN) makes necessary to know
other therapeutic alternatives for this kind of infections.
The aim of this study is to compare the efﬁcacy of daptomycin
(DAP) versus VAN in an experimental model of foreign body infection
caused by bioﬁlm-producer MRSE strains, with reduced susceptibility
to vancomycin.
Methods: In vitro studies: MICs of DAP and VAN were determined in 2
isolates of MRSE (SE284 and SE385). Bioﬁlm production was assessed
by genotypic (ica genes) and phenotypic (Congo red and crystal violet)
methods. Bactericidal activity was assayed by time-kill curves (1xMIC
and Cmax). In vivo studies: a murine model of foreign body infection
(intraperitoneal catheter) in C57BL/6 neutropenic (cyclophosphamide
150mg/Kg) and bacterial inoculum of 8 to 8.5 Log CFU/mL was
performed.
Pharmacokinetic/Pharmacodynamic (PK/PD) studies (Cmax [mg/L],
AUC [mgoh/L], t1/2 [h], t>MIC [h], AUC/MIC) in serum after single
dose of DAP (50mg/Kg) and VAN (110mg/Kg) in healthy mice.
Therapeutic groups: untreated (CON), DAP (once daily) and VAN (four
times daily). Later, viable bacteria in liver (Log CFU/g) and catheter
(Log CFU/mL), survival (%), and qualitative blood culture (%) were
measured. Statistical analysis: ANOVA, post hoc test, and c2.
Results: MIC (mg/L): SE284: DAP = 1, VAN = 4; SE385: DAP
= 1, VAN = 2. Both strains were positive for bioﬁlm production.
Bactericidal activity: SE284, DAP (Cmax), VAN (1xMIC and Cmax);
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SE385, DAP (Cmax), VAN (1xMIC and Cmax). PK/PD parameters for
each antimicrobial are shown in the attached table.
The results of the experimental model are shown in the attached table.
Statistical signiﬁcance (p 0.05): [a] vs. the control group; [b] vs.
vancomycin group.
Conclusion: Daptomycin was more effective than vancomycin in the
treatment of experimental foreign body infection caused by MRSE with
reduced susceptibility to vancomycin and bioﬁlm-producer, in terms of
bacterial burden reduction in catheter and liver.
P1070 Meropenem treatment of experimental thigh infections
caused by meropenem-heteroresistant Acinetobacter
baumannii clinical isolates
G. Michail*, E. Neou, A. Tsakris, S. Pournaras (Larissa, Athens, GR)
Objectives:Meropenem heteroresistance was previously characterized in
Acinetobacter baumannii clinical isolates. The current study investigated
the efﬁciency of meropenem treatment in experimental infections caused
by meropenem-heteroresistant A. baumannii clinical isolates.
Materials: The study included 12 strains: native populations of ﬁve
meropenem-susceptible A. baumannii strains and the respective ﬁve
meropenem-heterogeneous subpopulations (colonies grown at highest
meropenem concentrations in population analyses), a non-heteroresistant
meropenem-susceptible isolate and Escherichia coli ATCC 25922 as
controls. Thighs of mice were infected in triplicate by approximately
7log10 CFU of each strain, animals were treated for 24 h with
meropenem at 20mg/kg/8h, 100mg/kg/12h or 400mg/kg/8h and equal
numbers of animals remained untreated as controls. Mice died from
infection or sacriﬁced at 24h, thighs excised, homogenized and cultured
serially diluted to enumerate bacterial counts. Growth curves were
performed for all study strains.
Results: All 15 untreated mice infected by the 5 native populations died
in <24h. Untreated mice infected by heterogeneous populations of 2
strains survived 24h in contrast with mice infected by 3 heterogeneous
populations. Mice infected by the non-heteroresistant and the E. coli
ATCC 25922 control strains survived 24h regardless of treatment. Using
20mg/kg and 100mg/kg meropenem treatment 27/30 mice infected by
the 5 native populations died in <24h; no signiﬁcant decrease in colonies
grown was observed for all 30 treated mice compared with untreated
ones (P> 0.05). In contrast, 24/30 mice infected with heterogeneous
populations survived for 24h receiving 20 and 100mg/kg meropenem,
although colony counts were similar in treated and untreated animals
(P> 0.05). With 400mg/kg meropenem regimen 28/30 infected mice
survived 24h; a signiﬁcant decrease (P< 0.05) in colony counts was
observed for 12/15 mice infected by native populations and all 15
mice infected by heterogeneous populations, compared with untreated
mice. The control strains responded sufﬁciently to 100 and 400mg/kg
meropenem regimens. Considerably lower growth rates were observed
among 4/5 heterogeneous populations compared with the native ones.
Conclusions: The results of the present study indicate that A. baumannii
isolates exhibiting heteroresistance are responsive to high meropenem
dosages. Heterogeneous seem to be less virulent than native populations.
P1071 In vivo activity of 22b-hydroxyoleanonic acid, against
Streptococcus pneumoniae in a mouse model
M. Sharma*, A. Rakhi, M. Janlav (Waknaghat, IN; Ulaanbaatar, MN)
Objective: The 22b-hydroxyoleanonic acid is a congener of pentacyclic
triterpenoid Lantadene A with potent activity against Gram-positive
pathogens. The in vivo activity of 22b-hydroxyoleanonic acid against
Streptococcus pneumoniae was compared with those of gatiﬂoxacin and
ciproﬂoxacin in a mouse model.
Methods: For study, two strains of S. pneumoniae were used [penicillin-
susceptible S. pneumoniae (PSSP) and penicillin-resistant S. pneumoniae
(PRSP)]. Five-week-old male CBA/J speciﬁc-pathogen-free mice (body
weight, 20 g) were used for in vivo studies. The MICs of antibiotics
were determined by a broth dilution method with Mueller-Hinton broth.
Mortality was recorded for 14 days, and the 50% effective dose (ED50)
of each drug was calculated by the probit method. For bacteriological
examination, the lungs (n = 7 for each group) were dissected under
aseptic conditions and suspended in saline (1ml). Lung tissue for
histological examination (n = 3 for each group) was ﬁxed in 10% buffered
formalin and stained with hematoxylin-eosin.
Results: The survival rates of mice infected with PSSP and PRSP at 14
days after infection were 80% in the 22b-hydroxyoleanonic acid-treated
group and 0 to 10% in the other three groups. In murine infections caused
by PSSP, the 50% effective doses (ED50s) of 22b-hydroxyoleanonic
acid, gatiﬂoxacin, and ciproﬂoxacin were 26.4, 40.3, and 136.2mg/kg,
respectively. Against PRSP-caused pneumonia in mice, the ED50s of
22b-hydroxyoleanonic acid, gatiﬂoxacin, and ciproﬂoxacin were 37.4,
62.5, and 124.2mg/kg, respectively. Compared with the other drugs,
22b-hydroxyoleanonic acid showed excellent therapeutic efﬁcacy and
eradicated viable bacteria in both PSSP- and PRSP-infected mice. The
means±standard errors of the means of viable bacterium counts in the
lungs of gatiﬂoxacin-treated, ciproﬂoxacin-treated, and untreated control
mice infected with PSSP were 2.90±0.34, 3.10±0.48 and 3.80±0.80
log10 CFU/ml, respectively. The same counts in mice infected with
PRSP treated with the same three agents were 6.50±0.99, 6.52±0.40,
and 7.12±0.42 log10 CFU/ml, respectively. 22b-Hydroxyoleanonic acid
signiﬁcantly decreased the number of viable bacteria in the lungs
compared with gatiﬂoxacin and ciproﬂoxacin.
Conclusion: From results it is inferred that 22b-hydroxyoleanonic acid
has potent in vivo efﬁcacy against both PSSP and PRSP.
P1072 Evaluation of combinational antimicrobial treatment using
rifampicin and gentamicin for Escherichia coli O157:H7 in
vitro and in vivo in BALB/c mice
E.A. Rahal*, N. Kazzi, A.M. Abdelnoor, G.M. Matar (Beirut, LB)
Objectives: Escherichia coli O157:H7 is the most commonly en-
countered member of the Enterohemorrhagic E. coli (EHEC) group.
Symptoms of infection with this organism include the potentially fatal
hemolytic uremic syndrome (HUS). Treatment of E. coli O157:H7
infections with antimicrobial agents is controversial due to an association
with inducing HUS. The production of Shiga-like toxins is believed to
be central to the pathogenesis of this organism. Therefore, decreasing the
expression and release of these toxins prior to bacterial eradication may
provide a safer course of therapy. In this study, the utility of decreasing
toxin expression with rifampicin prior to eradication with gentamicin
was evaluated.
Methods: The in vitro effect of rifampicin and gentamicin on the
expression of stx1 and stx2 genes, which code for SLT-I and SLT-
II respectively, was assessed using real time reverse transcriptase
polymerase chain reaction (RT-PCR). This was performed on samples
of E. coli O157:H7 treated with various regimens of rifampicin and
gentamicin. Effect of treatment on SLT-I and SLT-II release was assessed
using reversed passive latex agglutination (RPLA). To analyze the
efﬁcacy of this combinational antimicrobial treatment in vivo, BALB/c
mice were infected and then treated with these antimicrobial agents.
Results: Transcription of Shiga-like toxin genes was considerably
decreased as an effect of treating E. coli O157:H7 in vitro with the
minimum inhibitory concentration (MIC) of rifampicin followed by
the minimum bactericidal concentration (MBC) of gentamicin (>99%
decrease) compared to treatment with gentamicin alone (50−75%
decrease). RPLA-based detection of Shiga-like toxins released from
E. coli O157:H7 incubated with the MIC of rifampicin followed by
addition of the MBC of gentamicin conﬁrmed a decrease in toxin release
as well. The highest rate of survival in BALB/c mice infected with E. coli
O157:H7 was observed in those treated with the in vivo MIC equivalent
dose of rifampicin followed by the in vivo MBC equivalent dose of
gentamicin (50% survival) compared to mice treated with gentamicin
(0% survival) or rifampicin (25% survival) only.
Conclusions: The use of expression-inhibitory antimicrobial agents prior
to bactericidal doses in treating E. coli O157:H7 infection is effective
and may potentially be useful in human infections with this agent.
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P1073 Efﬁcacy of high doses of daptomycin in combination with
cloxacillin in an experimental foreign-body infection by
methicillin-resistant Staphylococcus aureus
C. Garrigo´s*, O. Murillo, J. Lora-Tamayo, M. Vivas, F. Tubau,
R. Verdaguer, X. Cabo, C. Cabellos, J. Ariza (Barcelona, ES)
Objectives: Clinical failures and emergence of resistance when using
daptomycin (D) in monotherapy against high bacterial inoculums and
foreign-body infection (FBI) could be avoided with high doses of D alone
or in combination. D plus cloxacillin (C) has shown in vitro synergism
and limited efﬁcacy in experimental endocarditis by D-nonsusceptible
MRSA. Herein, we studied the efﬁcacy of D (equivalent to 10mg/kg/d
in humans) in combination with C and compared with that of D plus
rifampin (R) in a FBI model by methicillin-resistant Staphylococcus
aureus (MRSA).
Methods: In vitro studies: MICs (mg/L): 1 (D), >256 (C), 0.03 (R).
MBCs and 24 h kill-curves were performed in the log- phase at inoculum
105 ufc/ml (5LP) and at high inoculum 107 ufc/ml (7LP), and in the
stationary-phase (SP). Animal studies: Two Teﬂon tissue-cages with a
cover-slip (CV) were subcutaneously implanted in rats; after 3 weeks,
tissue-cage ﬂuid (TCF) was infected with MRSA-HUSA 304 and, 72 h
later, therapy was given for 7 days. Criteria of efﬁcacy: Decreases in
TCF bacterial counts between the beginning and the end of treatment
(at 1 and 4 days after the end; d8 and d11, respectively); and bacterial
counts from CV at d11. Therapeutic groups (mg.kg/h): D (100/24), C
(200/12), D+C, D+R (25/12) and controls (CO).
Results:MBCs (mg/L) 5LP/7LP/SP: 4/16/24 (D), >256/>256/>256 (C),
0.5/>8/>8 (R). Kill-curves, the combination D+C achieved synergistic
effect especially in LP where it was bactericidal with D at 0.5mg/L (5LP)
and with D at 4mg/L (7LP); in SP, D (16mg/L)+C was bactericidal. In
vivo, all groups were better than CO (n = 10) (decreases in TCF bacterial
counts at d8 and d11, log CFU/ml: +0.80, +0.62, respectively, p< 0.05).
D+R (n = 11) (−4.99, −5.35) was signiﬁcantly the most active treatment
(p< 0.05). D+C (n = 19) (−3.27, −3.10) was also better (p = 0.06) than D
(n = 8) (−2.45, −2.51). Eradicating adherent bacteria from CV (bacterial
counts, log CFU/ml), all therapeutic groups were better than CO (4.65);
D+R (0.91) was signiﬁcantly the most effective treatment (p< 0.05) vs
D (1.62) and D+C (1.48).
Conclusions: D+C combination achieved higher bactericidal and
synergistic in vitro activity especially in the LP. D+C improved the
efﬁcacy of D against FBI but it was less effective than D+R. The potential
beneﬁts of adding C to anti-MRSA therapy with D alone could be in
the setting of infections with high bacterial inoculums mainly in the
log-phase or in FBI by R-resistant MRSA strains.
P1074 Comparative efﬁcacy of omadacycline (PTK796) in a
lethal Streptococcus pneumoniae and Staphylococcus aureus
pneumonia model
R.G. Leahy*, B. Hanley, A. Macone, M. Draper, S. Tanaka (Boston, US)
Objectives: Omadacycline is a novel aminomethylcycline with excellent
activity against pulmonary pathogens and overcomes tetracycline
resistance. The objective of these studies was to evaluate omadacycline
as a clinical candidate to treat Gram-positive pneumonias.
Methods: Neutropenic (cyclophosphamide treated) male CD-1 mice
were infected intranasally with 50 micro litres containing approximately
8×107 CFU of Staphylococcus aureus USA300 (SA) or 7.5×106 of
Streptococcus pneumoniae PBS1339 (SP) diluted in sterile PBS. Animals
were treated with omadacycline, tigecycline, vancomycin or saline at 2
hours post-infection (pi) with a single intravenous dose and survival
determined out to 7 days pi.
Results: Omadacycline was more effective than tigecycline and
vancomycin in preventing death in both the SA and SP pneumonia
models at all time points tested (Table 1). Omadacycline was over 3 fold
more effective than tigecycline at the early end points tested for both
SA and SP, and 1.5−2 fold more effective by 7 days pi. Vancomycin was
ineffective at any of the doses tested and at either of the time points for
both SA and SP infections. In addition, doxycycline was tested against
SA and daptomycin, linezolid, ceftriaxone, and levoﬂoxacin were tested
against SP. All these comparators failed by 7 days pi even at the highest
doses tested (>18mg/kg or higher).
Conclusion: Omadacycline was successful in protecting mice against a
lethal SA or SP pneumonia and was more effective than either tigecycline
or vancomycin. This data suggests that omadacycline may be considered
as a potential candidate for the treatment of Gram-positive pneumonias.
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P1075 Invasive pneumococcal disease in adults, Poland, 2006–2009
A. Skoczynska*, A. Kuch, A. Golebiewska, I. Wasko, W. Hryniewicz
(Warsaw, PL)
Objectives: Streptococcus pneumoniae is a major causative agent of
severe infections especially in children and elderly. Pneumococcal
conjugate vaccines (PCVs) offer a new possibility to reduce the incidence
of pneumococcal infections and there are plans to use them also in
adult population. Therefore, the aim of this study was to describe the
characteristics of invasive pneumococcal disease (IPD) among Polish
adults and to determine the coverage of the serotypes by different
pneumococcal vaccines.
Methods: The study was performed on all invasive S. pneumoniae
isolated from adults older than 54 in Poland between 2006 and 2009,
and collected in the National Reference Centre for Bacterial Meningitis
(NRCBM). All the strains were identiﬁed based on typical morphology,
Gram stain, susceptibility to optochin and bile solubility. Serotypes of
S. pneumoniae were determined by the Pneumotest-Latex kit, a PCR or
the the Quellung reaction. MICs were determined by the Etest method.
Results: Among 725 invasive pneumococcal isolates collected during
the study period, 260 (35.9%) were isolated from patients older than
54 years. Among them 37 different serotypes were identiﬁed along with
3 nontypeable isolates. The most common were isolates of serotype 3
(14.3%), 12F and 14 (8.9% each). Together with 1, 23F, 9V, 4 and 9N
they accounted for 65.3% of all serotypes.
The overall coverage rates of PCV7, PCV10, PCV13 and PPV23
of invasive isolates in adults over 54 years of age were 38.2%,
48.3%, 64.9%, and 87.6% respectively. When the studied patients were
divided into three age groups 55−64, 65−74 and 75plus, the cover-
age rates of PCV7/PCV10/PCV13/PPV23 were 36.1/44.3/67.0/88.7%,
34.2/48.7/61.8/86.8%, and 44.2/52.3/65.1/87.3%, respectively. The case
fatality ratios in these age groups were 15.5%, 26.3%, and 33.3%,
respectively. Penicillin MICs higher than 0.06mg/L were found in 42
isolates (16.2%) of which 12 were isolated from cerebro-spinal ﬂuid.
Such phenotypes were the most prevalent among isolates of serotype
14 (78.3%) and 9V (72.2%). PCV7, PCV10 and PCV13 covered 85.7,
88.1 and 95.2% of isolates with elevated MICs of penicillin, respectively.
Thirty-one (12%) isolates had MIC of cefotaxime higher than 0.5mg/L.
Conclusion: The registration of PCV for prophylaxis in adults could
have a considerable effect on limitation of IPD-associated morbidity and
mortality among Polish adults, especially of cases caused by bacteria
with decreased susceptibility to antibiotics.
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P1076 Incidence estimate of invasive pneumococcal disease in
Belgium in 2009 using the capture-recapture method
K. Van Herck*, T. Braeckman, P. Van Damme, J. Verhaegen, F. Surmont
(Ghent, Antwerp, Louvain, Brussels, BE)
Objectives: An ongoing prospective active IPD (Invasive Pneumococcal
Disease)surveillance network was set up in Belgium to estimate the
annual incidence of IPD in hospitalized adults older than 50 years of
age.
Methods: Cases were deﬁned as isolation of S. pneumoniae from culture
of a normally sterile site by hospital microbiological laboratories. The
network consisted of a convenience sample of 49 acute care hospitals.
The denominators are obtained from publicly available data sources
on the number of acute care hospitals/hospital beds and the Belgian
population older than 50 (mid-year 2009). The surveillance time frame
covers January to December 2009.
The annual incidence is estimated by the capture-recapture method,
which combines the information obtained through different existing
data sources. Data sources consist of the active adult IPD surveillance
network and the national reference laboratory for S. pneumoniae. Cases
are matched source by source (by age, gender, sampling date, hospital
code and postal code) and missing numbers are estimated using the
Lincoln-Petersen estimate.
Results: A total of 551 patients older than 50 (mean age 71,7 range
50−88) with IPD were detected in 1 year in the prospective IPD
surveillance in 49 acute care hospitals. The National reference laboratory
received 1172 samples from 99 laboratories. After matching cases from
both sources, the total number of IPD cases was estimated at about
1200 (Lincoln-Petersen estimate). This corresponds with an estimated
incidence just above 30 per 100.000 inhabitants older than 50 years of
age.
Conclusion: The capture-recapture method based on two data sources
estimated the incidence of IPD at just over 30/100.000 in persons
older than 50 in Belgium. Since both data sources showed a strong
interdependence, the incidence is likely to be underestimated; adding
the information from a third, less dependent, data source could lead to
a more precise incidence estimate.
P1077 Evolution of meningococcal disease incidence on Navarre’s
population (north of Spain)
D. Morales, F.J. Gil, M. Herranz, A. Barricarte, J. Castilla,
E. Bernaola* (Pamplona, Estella, ES)
Introduction: The meningococcal disease is a clinical feature of low
incidence but with a very important epidemiologic weihgt, because its
high morbimortality.
Objectives:
• Analysis about evolution of invasive meningococcal disease’s (IMD)
incidence on Navarre’s population.
• Stratiﬁed analysis about evolution of Neisseria meningitidis
serogroups.
• Evaluate changes on the IMD’s incidence on their different serogroups
and on different population groups after the introduction of the
systematic vaccination against meningococcal C at the last months
on 2000 year.
Methods: Population data was obtained from Ofﬁcial Census of Navarre.
Meningococcal disease data was obtained from the Navarre’s Institute
of Public Health through obligatory declaration diseases epidemiologyc
surveillance’s system, from january of 1987 to december of 2009.
Statistical analysis by SPSS 17.0 for Windows. We used independent
samples Student T test, c2 test and binary logistic regression analysis.
Results: We observed a global decrease in IMD’s incidence on our
population from prevaccinal period (1987–2000) to postvaccinal (2001–
2009), from 4,04 to 2,98 c/105 (OR: 0,749; CI95%: 0,617−0,908). This
fall was due to the drop in cases of serogroup C (SGC) from 1,13 to
0,42 c/105; OR: 0,376; CI95%: 0,234−0,6) and in non-grouped cases.
On the contrary, the cases of serogroup B (SGB) increased on the
postvaccination period (from 1,32 to 2,33 c/105; OR: 1,78; CI95%:
1,37−2,33). When we stratiﬁed by ages and serogroups, we observed
an increase of SGB on pediatric population (<15 years, OR: 1,57; IC:
1,13−2,19) and also on adult population (15 years, OR: 2,78; IC:
1,75−4,40). This rise was more signiﬁcant on teenagers and young adults.
SGC decreased on pediatric population (OR: 0,22; CI95%: 0,11−0,44),
mainly on the <5 years group, whereas on the adult population was
registered a non signiﬁcant increase. Concerning the sex, there were not
differences on the IMD’s incidence, but after stratiﬁcated analysis, the
fall of the SGC’s incidence was signiﬁcant only in men’s group and
not in women’s, where was showed a more important rise on the SGB’s
incidence.
Conclusions: After the introduction of vaccination, there was a decrease
in IMD’s incidence on general population. However, the important fall
of SGC cases on little children has been disguised by the increase of
SGB cases on olderer groups.
P1078 Increase of invasive meningococcal disease caused by
serogroup Y in Finland, 2010
M. Toropainen, A. Vainio, L. Saarinen, H. Ka¨yhty, M. Kuusi,
A. Virolainen* (Helsinki, FI)
Objectives: Since a serogroup A epidemic in the 1970’s, there have
been no major meningococcal epidemics or outbreaks in Finland. The
incidence of invasive meningococcal disease (IMD) in Finland has
ﬂuctuated at low levels between 0.6 to 1.5 per 100 000 inhabitants (29−79
notiﬁed cases annually) in 1995–2009. Most cases (73%) have been due
to group B, followed by group C (17%), and group Y (8%). Here we
report an increase of IMD caused by serogroup Y in Finland in 2010.
Methods: Reporting of IMD in Finland is obligatory and based
on notiﬁcations from clinical microbiology laboratories reporting all
positive CSF/blood culture, antigen detection and/or PCR ﬁndings and
clinicians reporting all laboratory-conﬁrmed cases. All case isolates are
requested to be sent to National Institute for Health and Welfare (THL),
for conﬁrmation and typing.
Results: In 2010, the overall number of IMD cases was comparable to
previous years, but both the number and the proportion of cases caused
by serogroup Y increased signiﬁcantly from an average of 4 cases (8%)
in 1995–2009 to 11 cases (36%) in 2010. Thus far, no epidemic link
between the cases has been recognized. The phenotype and genotype
distribution of the isolates will be presented.
Conclusion: Both the number and the proportion of IMD caused by
serogroup Y in Finland have increased during 2010. The possible
clonality of the serogroup Y isolates will be analysed by the use of
molecular typing methods, which have been introduced in 2010 in
Finland.
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P1079 Epidemiological characteristics of Q-fever in Vojvodina
Province, Serbia, from 1985 to 2009
J. Djekic*, G. Cosic, M. Petrovic (Novi Sad, RS)
Objective: The aim of this study was to give some data of Q-fever in
the Autonomous Province of Vojvodina, Serbia, which is known as an
area with a high degree of agricultural activity and cattle-breeding.
Materials and Methods: From 1985 to 2009 surveillance reports of the
serologically conﬁrmed Q-fever cases to Institute of Public Health of
Vojvodina were analyzed on demographic (age, sex, current residence),
seasonal and regional distribution of disease, clinical signs of the
disease and contact exposures, using standard statistical methods. For
comparative analysis of frequency, X2 test was used.
Results: In a 25-year period a total of 2154 serologically conﬁrmed
cases of Q-fever were reported, with an incidence rate ranged from
0.0 to 20.5/100,000 population in different local districts of Vojvodina
Province. Most of the cases were registered in outbreaks (76.6%).
The mean annual incidence rate signiﬁcantly decreased from
12.8/100,000 in 1980’s, 3.7/100,000 in 1990’s to 0.8/100,000 population
in the last decade (p< 0.01).
The male:female sex ratio of cases was 2.3:1.
The frequency of disease differed signiﬁcantly among age groups; it was
highest for the group from 30 to 39 years of age (p< 0.01).
Seasonal distribution indicated the lowest incidence rate from June
to December (range 0.6 to 6.3/100,000), while from January to May
incidence rate was 12.6 to 23.3/100,000 population (p< 0.01).
Overall, 75.4% patients had clinical symptoms of pneumonia. Among
cases with reported exposure risks, 77.1% were related to individual
household cattle handlers, and 23.9% to occupational exposure in food
industry (live stock farms, slaughterhouses, research facilities).
Conclusion: Vojvodina Province is an endemic area of Q fever. The
highest incidence rate in last 25 years was in 1988 (20.5/100,000
population), while it decreased signiﬁcantly further on with mean
rate of 0.8/100,000 population in the last decade. Cases of Q-fever
were registered as individual cases of interstitial pneumonia or, more
frequently, as outbreaks.
Decreased incidence of Q-fever from 1985 to 2009 can be attributed to
changes in farming practices from the nomadic cattle-breeding to live
stock farms and to overall reduction of the cattle herds.
P1080 Seroprevalence of whooping cough among Danish adults
T. Dalby*, A. Linneberg, K. Krogfelt (Copenhagen, Glostrup, DK)
Objectives: Several studies around the world on whooping cough
seroprevalence among adults have shown large discrepancies between
population based seroprevalence data and the number of diagnosed
whooping cough cases. The prevalence of whooping cough among adults
in the general Danish population was estimated by measurements of
Bordetella pertussis speciﬁc antibodies in serum.
Methods: Sera from the “Helbred 2006” population study conducted
in the vicinity of Copenhagen from 2006 to 2008 were studied for the
presence of pertussis toxin speciﬁc IgG antibodies. Sera were available
from 3440 individuals, 19 to 72 years old. The study population is
considered representative of the general adult Danish population.
Results: When using a diagnostic cut-off value of 75 IU/ml (IU/ml
according to the WHO international standard serum, NIBSC: 06/140),
the seroprevalence of whooping cough among the participants in the
study was 3.0% and the median concentration of pertussis toxin IgG
antibodies was 8.7 IU/ml. The serological results from each individual
are combined with data from a questionnaire on general health topics.
Conclusion: The seroprevalence of whooping cough among adults
19−72 years old in Denmark is estimated to be 3%. The prevalence of
laboratory-conﬁrmed whooping cough for the 19−72 age-group was 3.3
per 100.000 in 2008. Therefore, the true incidence of whooping cough
among adults in Denmark is probably a thousand fold higher than what
is currently detected in the laboratories.
P1081 Review of tetanus cases in England and Wales, 1984–2007.
Does administration of tetanus immunoglobulin and prior
vaccination status inﬂuence outcome?
J. Howard*, K. Wagner, J. White, N. Crowcroft (London, UK; Toronto,
CA)
Objectives:
• To describe the epidemiology of tetanus cases reported to the Health
Protection Agency (HPA) tetanus surveillance database between 1984
and 2007
• To determine whether administration of tetanus immunoglobulin (TIG)
inﬂuences the outcome of clinically diagnosed tetanus
• To determine whether prior vaccination status inﬂuences the outcome
of clinically diagnosed tetanus
Methods: Analysis of the HPA enhanced tetanus surveillance database
between 1984 and 2007 by age, sex and year. Logistic regression
was performed to determine whether prior vaccination status and
administration of tetanus immunoglobulin inﬂuenced outcome.
Results: 233 cases were reported to the HPA between 1st Jan 1984
and 30th October 2007. 56.7% were in females and 43.3% in males.
The highest number of cases was seen in the aged 65 and over age
group. Vaccination status was only recorded in 130/233 (55.8%) of cases.
60/233 (25.8%) were known to have received tetanus vaccination and
70/233 (30.0%) had not. In the remaining cases their vaccination status
was unknown. Only 3/60 (5%) were known to have received the full ﬁve
dose course. Most had low-risk injuries or could not recall a prior injury.
Information about whether TIG treatment was deﬁnitely given or not
was known for 115/233 (49.4%) of cases. For those with known disease
severity, there was a signiﬁcantly higher proportion of those who were
unvaccinated or of uncertain status who developed grade three disease
as compared with those who had a history of vaccination (p = 0.03).
Case severity and the number of vaccine doses received was known for
52/60 (86.7%) cases who had been vaccinated in the past. The case
fatality rate (CFR) was higher in those who only received one dose
at 24% (6/25). In those who received more than one dose, the CFR
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was lower at 14.8% (4/27) (Fisher’s exact test, p = 0.63, not statistically
signiﬁcant).
There were no deaths in those who were vaccinated and who had a
recorded dose of TIG given.
Conclusion:
• Individuals can get clinical tetanus following minor injuries despite
having had one or more tetanus vaccinations previously
• Clinicians should ensure that they ascertain patient’s tetanus vaccina-
tion history following all types of injuries
• Clinicians should take vaccination histories at every opportunity e.g.
in every health service or primary care visit
• England and Wales should consider adopting the World Health
Organisation’s recommendations for vaccination against tetanus
P1082 Epidemiological survey of diabetic foot infections in Lisbon
J.J. Mendes*, L. Prata, C. Vilela, J. Neves, N. Candeias, P. Cavaco
Silva, J. Melo Cristino (Lisbon, PT)
Objectives: Epidemiological survey of the infectious microbiota of the
diabetic foot in Lisbon Clinical Centers, stratifying it in relation to the
anamnesic data of patients, characteristics of the diabetic foot (using the
PEDIS classiﬁcation), time of evolution and current and previous (3
months) antibiotic therapy.
Methods: transversal observational study, with clinical data collection
using a structured questionnaire and microbiological products (swabs
collected by the Levine method, biopsies or aspirates) of clinically
infected diabetic feet ulcers of patients followed in Lisbon Clinical
Centers. Microbiological diagnosis (including aerobic and anaerobic
quantitative bacterial cultures) and antibiotic sensitivity proﬁles were
carried out and analyzed using standard procedures.
Results: 49 hospitalized and ambulatory patients were enrolled in this
study and 147 microbial isolates were cultured, comprising 43 species.
Systematized results are presented in the table. Staphylococcus spp. was
the main genus identiﬁed, with Staphylococcus aureus being present in
51% of the samples, in 96,6% of cases in quantities 105 CFU/g or mL.
In the clinical samples collected under antibiotic therapy, corresponding
mainly to hospitalized patients with osteomyelitis, 93% of the
antibiotic regimens were considered inadequate based on the antibiotic
susceptibility test results. Regarding theses samples, quantitative and
qualitatitive differences were found, with less microorganisms being
identiﬁed (2,1 vs 3,4), however with a higher prevalence of multi-drug
resistant (MDR) organisms (66,7% vs 26,5%). The average time of ulcer
evolution for the appearance of MDR organisms was 29 days, being
previous treatment with ciproﬂoxacin the only statistically signiﬁcant
risk factor. Methicillin-resistant Staphylococcus aureus (MRSA) was
identiﬁed in 24,5% of cases.
Conclusions: 1. Staphylococcus aureus is the most common cause of
diabetic foot infections in our area. 2. MDR organisms are frequent,
being MRSA the main pathogen. 3. Standard practice not to collect
products for microbiological examination in diabetic foot infections, as
advised by many clinical guidelines, should be discouraged because
of the high likelihood of infection by MDR not covered by the
recommended antibiotic regimens.
P1083 Rectal carriage and pyogenic liver abscess associated CPS
genotyping of Klebsiella pneumoniae in asymptomatic
diabetic patients in Taiwan
P.R. Hsueh, C. Liao, Y. Huang, J. Wang, C.Y. Liu* (Taipei, TW)
Background: Pyogenic liver abscess (PLA) caused by Klebsiella
pneumoniae (KP) is an emerging community acquired infectious disease
in Taiwan and certain serotypes are predominated in the causative
isolates. Diabetes mellitus (DM) has been identiﬁed as a risk factor of
KP related PLA infection. Rectal carriage of the PLA causing serotypes
in DM patients remained undetermined.
Methods: We prospectively followed rectal swab for KP culture in
asymptomatic DM patients attended for regular medication from March
2008 to June 2009. Patients with antibiotics usage or hospital admission
three months earlier were excluded. Diabetic control was evaluated by
their fasting blood glucose and glycosylated hemoglobin (HbA1C). The
swab was cultured on EMB agar and suspected isolates were identiﬁed by
Enterotube (Becton Dickinson, MD). Capsular serotype was determined
by polymerase chain reaction cps genotyping using primers speciﬁc for
most commonly encountered (>80%) capsular types associated with
PLA (K1, K2, K5, K20, K54, K57 and a new capsular type [N1]) as
previously described.
Results: There were 102 male and 64 female DM patients were enrolled
with a mean age of 56.7 year-old (S.D = 9.08). Eighty patients (48.2%)
had rectal KP colonization. The colonizer were elder than the non-
colonizer (58.4 v.s 55.1 y/o; p = 0.022). Gender, fasting blood glucose
and HbA1C were not different statistically signiﬁcant between colonizer
and non-colonizer (p = 0.364, 0.176, and 0.183, respectively). The results
of cps-genotyping for the 65 available isolates revealed that 22 isolates
(33.8%) belong to the 7 common serotypes identiﬁed in PLA. Serotype
K 57 was the most commonly identiﬁed serotype (N= 7, 10.8%) followed
by K1 (N= 6, 9.2%), K2 (N= 3, 4.6%), K20 (N= 3, 4.6%), K54 (N= 2,
3.1%) and K5 (N= 1, 1.5%). Serotypes of the remaining 43 isolates
(66.2%) could not be identiﬁed by the PCR cps genotyping.
Conclusions: KP strains of PLA associated capsular type could be found
in asymptomatic diabetic patients. Further follow up is mandated whether
these patients developed subsequent PLA.
P1084 Fever of unknown origin: a retrospective study of 52 cases
with evaluation of the diagnostic utility of PET/CT
T. Ingemann*, C. Roed, L.S. Knudsen, P. Skinhøj, S. Nielsen
(Copenhagen, DK)
Objectives: Fever of unknown origin (FUO) is a challenge to the
clinician. The diseases which comprise FUO may change in a given
geographical setting as a consequence of naturally occurring shifts
in disease epidemiology or as a consequence of the implementation
of disease curbing health care measures. Knowledge of the prevalent
spectrum of diseases and consequently use of the most rational diagnostic
approach is important. PET/CT is a non-invasive diagnostic tool
which may be of great beneﬁt in establishing a diagnosis in patients
with FUO.
Methods: Retrospective study of 52 cases of FUO. FUO was deﬁned
as fever higher than 38.3ºC recorded on several occasions and lasting at
least 3 weeks with no diagnosis in spite of at least 3 days of investigation.
Patients admitted during a ﬁve year period 2005–2010 and fulﬁlling
these criteria were included. Patients with known immunodeﬁciency,
HIV or nosocomial FUO were excluded. Clinical records, laboratory
data and radiographic ﬁndings were assessed. Follow-up on patients
was performed using a national registry database in order to identify
patients with recurrence of febrile episodes or death. Finally, the utility
of PET/CT in establishing a ﬁnal diagnosis was evaluated.
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FDG-PET/CT Final diagnosis Veriﬁed by
5 60 M Glandular uptake in
the neck, thorax and
mediastinum (TP)
Malignant lymphoma Lymph node
biopsy
19 65 M Multiple foci in the
lungs (TP)
Malignant lymphoma Lung biopsy
20 67 F Foci in the thyroid
gland (TP)
Autoimmune
thyreoiditis
Serology
24 61 F Multiple foci in the
lungs (TP)
Microscopic
polyangiitis
Renal biopsy
34 36 F Uptake in the
peripheral joints
(TP)
Systemic lupus
erythematosus
Fulﬁlling the
diagnostic
criteria for
systemic lupus
erythematosus
35 56 F Uptake in the aorta,
arteriae subclavia
and iliaca (TP)
Large vessel
vasculitis
PET/CT
38 62 F Uptake in the large
arteries (TP)
Large vessel
vasculitis
PET/CT
42 17 M Uptake in the spleen
(TP)
Rheumatologic
disease
Spleen
biopsy with
inﬂammation
no malignancy
44 33 F Uptake in the
mediastinum, liver,
retroperitoneum,
lungs and bones
(TP)
Metastatic
adenocarcinoma
Liver biopsy
28 28 F Glandular uptake
behind esophagus
(TP)
Bartonella infection Serology
43 31 F Sub-hepatic uptake
(FP)
Fever subsided
spontaneously
Clinical course
33 87 F Uptake in the
lumbar spinal
vertebra (FP)
Fever subsided
spontaneously
Clinical course
12 78 M Negative (FN) Died during
hospitalization with
continued fever
Autopsy
without any
particular
ﬁndings
15 68 F Negative (FN) Necrotizing vasculitis Renal biopsy
29 42 M Negative (FN) Treated in
rheumatological
department with
prednisolone and
TNF-alpha inhibitor
Clinical course
36 69 M Negative (FN) Continued to have
fever following
discharge, died
1 12 years later,
no autopsy was
performed
51 39 M Negative (FN) Adult-onset Mb Still.
8 65 M Negative (TN) ND. Fever subsided
spontaneously
Clinical course
11 66 M Negative (TN) ND. Fever subsided
spontaneously
Clinical course
31 33 M Negative (TN) ND. Fever subsided
spontaneously
Clinical course
41 65 F Negative (TN) ND. Fever subsided
spontaneously
Clinical course
52 34 M Negative (TN) ND. Fever subsided
spontaneously
Clinical course
Results: 52 patients fulﬁlled the criteria for FUO, 36 males and 16
females. Median age was 48 years and median duration of fever
before referral was 6 weeks. A ﬁnal diagnosis was achieved in 60%
(31/52) of the cases, and the most frequent diagnosis was non-infectious
inﬂammatory disease 55% (17/31) followed by infections 32% (10/31)
and malignancy 13% (4/31). Adult-onset Still’s disease and CMV
infection alone accounted for 29% of all cases. A PET/CT scanning
was performed for 24 patients. In 22 of these cases it was possible
to evaluate the diagnostic utility of PET/CT. PET/CT was considered
helpful in attaining a ﬁnal diagnosis in 10 of the cases (45%; 10/22). 2
cases were considered false positive.
Conclusion: In this study non-infectious inﬂammatory diseases com-
prised the majority of ﬁnal diagnoses in patients with fever of unknown
origin. PET/CT scanning proved to be a valuable aid in establishing the
diagnosis with a PPV of 0.83.
P1085 Risk factors and outcome of treatment in patients with
psoas abscesses
A. Kara*, M.C. Kizilarslanoglu, S. Alp, M. Akova (Ankara, TR)
Objectives: Although psoas abscesses (PAs) have not been reported
frequently in the literature, they remain a signiﬁcant therapeutic
challenge. We retrospectively evaluated demographic characteristics,
symptomatology, predisposing factors, microbiology and treatment
outcomes of patients with PAs in a large tertiary care university hospital.
Methods:We have electronically searched Hacettepe University Hospital
database. There were 83 patients who were diagnosed clinically and
radiologically with PA between 2003 and 2009. Individual patient
ﬁles were searched for detailed patient characteristics, possible risk
factors and underlying diseases, infecting microorganisms and treatment
outcomes.
Results: 37 (44.6%) of 83 patients were female. Median age was 51
years (range: 18−83). Mean abscess size was 6.4 centimeters (range:
1−25). Fever and pain were the most common symptoms. In 37 patients,
abscesses were localized at right psoas, in 40 patients at left and 6
patients had bilaterally. Multiple abscess formation were determined in
10 patients. The most common underlying diseases were malignancies
(16.9%) (4 with bladder carcinoma, 3 with colon cancer, 2 with multiple
myeloma and one of each with lung, breast, endometrium, ovarian and
prostate cancer), diabetes mellitus (13.2%), Crohn’s disease (4.8%), and
rheumatological diseases (4.8%). 13 patients (15.7%) had no underlying
disease and 46 (55.4%) of patients had a history of an abdominal
operation. 19 (22.9%) patients had previously and incompletely been
treated for PA. The most common isolated microorganisms were
Staphylococcus aureus (18 MSSA, 5 MRSA), Escherichia coli (n = 13;
3 of which with ESBL production) and Mycobacterium tuberculosis
(n = 11). 68 patients (81.9%) were treated successfully with percutaneous
drainage and with appropriate antimicrobial therapy. Four patients (4.8%)
died due to complications related to PA.
Conclusion: We report a high-rate of previous surgical intervention as
a predisposing factor for PAs. M. tuberculosis was also a frequent cause
of PAs which might be a consequence of intermediate-high prevalence
of tuberculosis in Turkey. High rates of treatment success were achieved
by a combination of drainage and antimicrobial treatment.
P1086 Clinical features and outcome of cardiovascular implantable
electronic device infections due to staphylococci
K. Le*, M. Sohail, P. Friedman, D. Uslan, S. Cha, D. Hayes, W. Wilson,
J. Steckelberg, L. Baddour (Rochester, Los Angeles, US)
Objective: To deﬁne the clinical features and outcome of staphylococcal
cardiovascular implantable electronic device (CIED) infections.
Methods: We retrospectively reviewed all cases of CIED infection seen
at Mayo Clinic Rochester between 1991 and 2008. Clinical features
including host and device characteristics, presenting symptoms/signs,
and laboratory parameters were identiﬁed using logistic regression.
Mortality was examined at 30-day and 1-year.
Results: Of the 416 patients with CIED infection, 129 (31.0%) were due
to Staphylococcus aureus, and 159 (38.2%) due to coagulase-negative
staphylococci (CoNS). S. aureus pocket infection generally occurred
closer to time of device implantation (<1 year); in contrast, S. aureus
bloodstream infection (BSI) and CIED-related infective endocarditis
(CIED-IE) often presented later (>1 year). In the multivariate setting,
S. aureus pocket infection was associated with high frequency of device
Miscellaneous infections S285
manipulation (OR 3.00, [1.30, 6.91]). However, S. aureus BSI or CIED-
IE more frequently involved originally implanted devices (OR 5.24 [1.73,
15.87]), patients receiving corticosteroid therapy (OR 7.95 [3.08, 20.53]),
or patients who had remote sources of infection (OR 4.48 [2.06, 9.71]).
They often presented with fever (OR 5.03 [1.79, 14.11]) or hypotension
(OR 2.55 [1.07, 6.05]), and had leukocytosis (OR 2.47 [1.23, 4.98])
or elevated serum creatinine (OR 1.37 [1.09, 1.77]). S. aureus BSI or
CIED-IE were associated with increased mortality at 30-day (OR 5.68
[2.10, 15.37]) and 1-year (OR 4.98 [2.41, 10.26]).
CoNS pocket infection was more frequent in patients with prior lead
revision (OR 3.30 [1.49, 7.30]) or prior device infections (OR 2.09
[1.10, 3.97]). CoNS BSI or CIED-IE was more common in patients
with implanted vascular grafts (OR 5.10 [1.08, 24.08]). There was no
increased mortality among patients with CoNS CIED infection.
Conclusion: CIED infections due to staphylococci have divergent
clinical features and mortality risks based on coagulase designation.
Recognition of the distinct characteristics that these two groups of
organisms manifest in patients with CIED infection could dramatically
impact management decisions.
P1087 Mortality risk factors in patients with prosthetic vascular
graft infection: a prospective cohort study
L. Legout*, P. Dhelia, B. Sarraz-Bournet, P. Devos, M. Caillaux,
F. Wallet, Y. Yazdanpanah, E. Senneville, O. Leroy (Tourcoing, Lille, FR)
Introduction: Prosthesis vascular graft infection is a devastating
complication with a signiﬁcant mortality up to 75%, especially in
intracavitary graft infection and mycotic aneurysm. The purpose of this
study was to evaluate factors associated to peri-operative mortality in
patients with deﬁnite graft infection.
Material and Methods: We reviewed the medical records of 85 patients
treated for early and late graft infection deﬁned as a positive bacterial
culture on intra-operative or blood culture and clinical, biological or
radiological signs of infection. Operative mortality was deﬁned as death
occurring within the same hospitalization as surgery and, cure as the
absence of evidence of infection during the follow-up period (minimum
one year).
Results: 85 patients with 54 intracavitary and 31 extracavitary graft
infection and treated with removal infected prosthesis (n = 41), surgical
debridment (n = 34) or medical treatment (n = 10) were included. Opera-
tive mortality rate was 16.5%. Three variables were independently associ-
ated to mortality: Age >70 years (HR 2.32;CI95%;0.87–7.01;p = 0.008),
intracavitary graft infection (HR 2.30;CI95%;0.86–7.11;p = 0.0007) and
admission in intensive care unit (HR1.98;CI95%;0.89–4.86;p = 0.02).
Cure was observed in 94% and 90% of evaluable patients treated
with removal prosthesis and replaced in situ and surgical debridement,
respectively. In patients with graft infection due to Gram positive Cocci,
rifampin use as adapted treatment is associated with a signiﬁcantly better
prognosis; p = 0.05).
Conclusion: Age >70 years, intracavitary graft infection and admission
in intensive care unit were associated to high operative mortality. To
limit the mortality risk, and for a better outcome, patients with graft
infection should be managed in referral center.
P1088 Spread of Corynebacterium diphtheriae in Ukraine during
post-epidemic period
T. Chumachenko*, A. Podavalenko, T. Glushkevich (Kharkiv, Kiev, UA)
Objective: The recent diphtheria epidemic in eastern Europe are a
warning that diphtheria can make a comeback in susceptible populations.
The aim of this study was to evaluate the diphtheria epidemiological
surveillance conducted in Ukraine based on an analysis of morbidity and
carriages by Corynebacterium diphtheriae (C.d.) in the population and to
characterize circulating human clinical isolates of C.d. in postepidemic
period.
Methods: The 898 cases of diphtheria, 11312 cases of C.d. carriages
during 2002–2009 in Ukraine were analyzed. Production of diphtheria
toxin in isolates of C.d. was assessed by Elek test. Carriage of the
diphtheria toxin gene tox in the 2058 isolates of nontoxigenic C.d. was
assessed by the polymerase chain reaction (PCR). Isolates were assigned
to biotypes based on biochemical characteristics.
Results: In postepidemic period incidence of diphtheria in Ukraine,
ranged from 0.57 (2002) to 0.05 (2009) per 100 000 population.
Toxigenic strains of C.d. from patients were isolated in 52.0% of cases,
there were in 26,5 times more toxigenic C.d. biotype gravis than C.d.
biotype mitis. Nontoxigenic strains of C.d. from patients with diphtheria
were isolated in 28.5% of cases, there were in 1,6 times more C.d.
biotype mitis than C.d. biotype gravis. Among C.d. isolates from carriers
of C.d. there were 931 (8,2%) toxigenic C.d. and 10381 nontoxigenic
C.d.
There were more prevalent biovar mitis (69,1%) among nontoxigenic,
and biovar gravis (88,1%) among the toxigenic. The study of the ratio of
toxigenic to nontoxigenic strain of C.d. which circulated in the territory
of Ukraine for the period of observation revealed a signiﬁcant increase
in nontoxigenic strains 1:6,6 (2002) to 1:14,6 (2009). The investigation
of 2258 nontoxigenic isolates of C.d. in PCR showed that 68 (3,0%) of
isolates carried the toxin genes but did not express them and 62 (91,2%)
isolates were biotype mitis.
Conclusion: Although vaccination has resulted in a low incidence
of diphtheria in Ukraine, isolates of C.d. which harbor and produce
the diphtheria toxin remain in circulation. It is necessary to enhance
the microbiological monitoring using molecular genetic techniques to
identify the nontoxigenic strains of C.d. The continued circulation of
toxigenic strains of C.d. and nontoxigenic strains of C.d. carried the
toxin genes but not express them highlights the importance of continuing
vaccination programs against diphtheria.
P1089 Measles among healthcare workers in Bulgaria
R. Komitova*, A. Kunchev, Z. Mihneva (Plovdiv, Soﬁa, BG)
Vaccine-preventable measles is highly infectious via airborne droplets.
Health care workers (HCWs) are at a higher risk of the disease than the
adult population. They may introduce measles in healthcare facilities,
leading to nosocomial spread and dire consequences. In 2009/2010,
8 years after the last indigenous cases, Bulgaria experienced a large
measles outbreak as a result of virus importation from Germany. Thirty-
eight HCWs at community hospitals and primary-care medical facilities
contracted the disease.
Objective: To assess the occupational risk of measles among HCWs and
describe the epidemiological characteristics of these cases.
Methods: A clinical case deﬁnition was deﬁned, using the revised
WHO/EURO criteria (2008). Cases were considered conﬁrmed if they
met clinical and laboratory criteria (positive ELISA IgM test) and
probable if they met clinical criteria and had epidemiological link. A
short questionnaire recording occupation, age, history of the present
disease and immunization status was distributed to the outpatients
participants. The same information was collected from the medical
records of hospitalized ones.
Results: Until mid April 2010 thirty-eight measles cases (age range
24−48 years) were notiﬁed among HCWs from 7 different regions
in Bulgaria. Twenty cases were deﬁned as conﬁrmed and eighteen as
probable. The largest groups of HCWs measles were physicians (n = 21,
55,5%) and nurses (n = 7, 19,4%). Thirty-seven HCWs acquired the
infection from patients and 1 physician from a colleague. Although
32 were eligible for vaccine all but one had no written evidence
of appropriate immunization. None transmitted measles to susceptible
patients or family members. Ten developed pneumonia but all recovered
uneventfully.
Conclusion: Prevention of future measles outbreaks will require
maintaining a high coverage with 2 doses measles-containing vaccine,
including HCWs and a high index of suspicion for measles among
travelers with unexplained rash.
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P1090 Transient bradycardia in patients with Crimean-Congo
haemorrhagic fever infection
S. Erol*, Z. Ozkurt, K. Ozden, M. Parlak (Erzurum, TR)
Objective: Crimean-Congo haemorrhagic fever (CCHF) is a fatal viral
infection described in parts of Africa, Asia, eastern Europe, and the
middle east. There is a variety of potential clinical manifestations
following infection, and not all patients develop the classic form
of the disease. The typical course of CCHF has been noted as
progressing through four distinct phases, i.e. incubation, prehemorrhagic,
hemorrhagic, and convalescence. Duration and associated symptoms of
the phases can vary greatly. Although some cardiovascular changes −
eg, bradycardia and low blood pressure-were emphasised in earlier
publications, these have not been reported in recent studies. To our
knowledge, there is no study detailing bradycardia in this patient group.
The main objective of this study was to determine the frequency and
clinical course of bradycardia in the patients with CCHF.
Patients and Methods: Between May 2002 and September 2010 a total
of 380 patients with CCHF were followed at the Department of Infectious
Diseases and Clinical Microbiology, Ataturk University Medical School.
All patients who had a transient bradycardia episode during this period
were included in this study. All CCHF patients who had cardiovascular
symptoms or signs were investigated by electrocardiogram, and in some
case by echography. Bradycardia (sinus bradycardia) was deﬁned as a
heart rate less than 60 beats per minute.
Results: During the study period, 14 patients (3 female, 11 male)
had an episode of bradycardia. The mean age was 46.2±19.8 years
(range:18−76). All patients were in sinus rhytm by electrocardiogram.
Three patients had clinical symptoms of bradycardia (dizziness, short-
ness of breath, hypotension), and intraveno¨z atropin was administered
to them. The patients were responsive to atropin. In the other patients,
bradycardia resolved spontaneously. No patient had underlying condition
for bradycardia such as electrolyte disorders, drug use, toxic exposure,
hypoglycemia, hypotiroidism, previous cardiac disorder, and increased
intracranial pressure. The onset of bradycardia appeared 7.0±1.7 days
(range:5−10) after ﬁrst clinical symptoms. In all patients, bradycardia
continued for 5. 1±1.6 days (range:2−8), and resolved without any
additional problem or sequelae. All patients had good prognosis.
Conclusions: Transient sinus bradycardia is a rare and benign clinical
manifestation of CCHF. This is the ﬁrst study detailing bradicardia on
this patients grouP.
P1091 Evaluation of cutaneous anthrax patients in eastern
Anatolia, Turkey
K. Ozden, Z. Ozkurt, S. Erol*, M.H. Uyanik, M. Parlak (Erzurum, TR)
Objectives: Anthrax is a zoonotic infectious disease that caused by
Bacillus anthracis.
The human is incidental host, they are infected with contaminated
animals and animal products directly or indirectly. Anthrax infectes
human by means of three major ways: Inhalation, gastrointestinal and
cutaneous. Cutaneous anthrax (CA) is the most common naturally
occuring form.
Sporadic cases and outbreaks of anthrax are still present worldwide
although they are relatively rare in developed countries. Anthrax is an
endemic infectious disease in the eastern part of Turkey. We investigated
epidemiologic properties of the cases of anthrax in our clinics for four
years period. In this study, we also evaluated the clinical histories, clinical
features, therapies and outcomes of 44 patients with cutaneous anthrax
followed up in our clinics in Ataturk University Faculty of Medicine.
Methods: The patients, who were thought as CA clinically and applied
to the clinic of infectious diseases in Ataturk University Faculty of
Medicine from January 2005 to December 2008, were included in our
study. The diagnosis of CA was based on a typical anthrax skin lesion
(dermatologic ﬁndings, including painless, pruritic ulcers covered by
a characteristic black eschar) and/or microbiologic methods, including
Gram stain and culture of samples obtained from the lesions.
Results: Twenty four patients (54.5%) were male and 20 (45.5%) were
female. All of patients almost were living in rural areas of Erzurum and
Kars province in eastern Anatolia, Turkey. The highest number (%79,5)
of presentations was seen in period of August-October.
All patients with a diagnosis of CA were followed up. Malignant oedema
was observed in 11 patients (25%) and malignant pustules in 33 (75%).
All of patients almost always had a history of close contact with sick
cows or sheep; slaughtering 34 (% 77,3), skin peeling 7 (% 15,9), cutting
of meat 36 (% 81,8), carrying contaminated packet 5 (%11,4).
The distribution of the lesions by site is; hand 24 (% 54,5), ﬁnger 11 (%
25), arm 18 (% 40,9), eyelids 3 (% 6,8), lips and surrounding area 3 (%
6,8), neck 4 (% 9,1) and face 5 (%11,4). There were 11 (%25) patients
with a total of two lesions and 5 (% 11,4) patients with a total of three
lesions from different body site.
Conclusion: There were not any complication (like anthrax sepsis and
respiratory tract obstruction) occur in our patients. All of the patients,
were discharged from the hospital after a full recovery.
P1092 Epidemiology and clinical aspects of murine typhus in
central Tunisia
A. Toumi*, A. Aouam, C. Loussaief, H. Ben Brahim, F. Ben Romdhane,
M. Chakroun (Monastir, TN)
Objective: Generally unrecognized, murine typhus continues to con-
found physicians because of its nonspeciﬁc clinical manifestations. In
an effort to update our knowledge on this poorly known disease we
describe the epidemiological, clinical, laboratory and treatment features
of murine typhus.
Patient and Methods: Retrospective study of 73 adult patients
hospitalized for murine typhus, in the department of infectious diseases,
university hospital Monastir, Tunisia, during the period 2005–2010.
Diagnosis was conﬁrmed by a four-fold rise in antibody titer, by a
single high titer 128 or by seroconversion to typhus group antigen by
indirect immunoﬂuorescent antibody assay (IFA). All sera cross-reacted
to Rickettsia conorii antigens were at lower titer.
Results: Mean age was 33 years (range, 13−68 years). Forty-seven
of the 73 patients were male (64%), and 26 were female (36%). A
seasonal pattern (87.6% from june to september) was observed. Thirty-
eight patients (52%) were from rural or suburban areas; neither ﬂea
bites nor exposure to rats were mentioned. The most common clinical
symptoms were fever in all patients, headache in 63 (86.3%), and myalgia
in 49 (67.1%). A maculopapular and non-conﬂuent rash was noted in
47 cases (64.4%). The eschar wasn’t found in any patient. There were
16 cases of pneumonia, with interstitial inﬁltrates on chest X-ray ﬁlm
in 8 cases. Meningitis was diagnosed in two cases and cerebrospinal
ﬂuid showed lymphocytic meningitis. Routine laboratory tests showed
thrombocytopenia was found in 38 cases (52%). C-reactive protein was
higher than 20mg/ml in 62 cases (mean = 67mg/l). Liver enzyme levels
were elevated in 60 cases (82.2%). Diagnosis was conﬁrmed by indirect
ﬂuorescence assay detecting speciﬁc R. typhi antibodies in all cases.
A single titer of these antibodies higher than 128 was found in 62
(84.9%) cases. The other 11 cases were diagnosed by a seroconversion.
All patients received antibiotics: 32 (43.8%) received tetracycline, 25
(34.2%) doxycycline, 13 ﬂuoroquinolone and 3 azithromycine. The
2 patients having meningitis were treated with ﬂuoroquinolone. The
outcome was favourable for all patients and no relapse was observed.
Conclusion: In our region, murine typhus is endemic. It is characterized
by benign prognosis. Doxycycline or tetracycline are considered the
drugs of choice against R. typhi.
P1093 A nosocomial outbreak of red mite (Dermanyssus gallinae)
dermatitis in Italy
D. Galante*, M. Lomuto, G. Totaro, G. Mancini, C. Nardella La Porta,
M.A. Caﬁero (Foggia, IT)
Objectives: The poultry red mite, Dermanyssus gallinae, is a widespread
blood-sucking ectoparasite of poultry and other birds. It can also bite
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mammals, including humans and cause a non-speciﬁc dermatitis with
intense itching. As a nest parasite it only comes to the host to feed. The
source of red mite infestation and its zoonotic role in urban environment
are presented.
Methods: In October 2010 the Istituto Zooproﬁlattico Sperimentale della
Puglia e della Basilicata (IZSPB) was contacted about an outbreak of
pruriginous dermatitis in patients/personnel in the maternity unit of a
hospital located in Apulia Region (Italy). For about four months, a not
reported number of employees and hospitalized women complained of
a itchy dermatitis in different body areas and referred to feel like if
they had been “bitten or stung”, but no deﬁnitive diagnosis had been
established. The symptoms disappeared or attenuated when employees
and patients left the hospital. In September, the health staff of the
hospital inspected the rooms and collected parasites initially identiﬁed as
probable ticks. The area was evacuated and three different interventions
of sanitation were effected using deltamethrin, but the infestation was
not solved. On the 6th of October other parasites were collected and sent
to IZSPB for a further identiﬁcation.
Results: The mites collected were identiﬁed as Dermanyssus gallinae
by the IZSPB, following morphological keys. Remains of a pigeon nest
were later found on the outside ledge, near a window of the infested
rooms. Removal of the nest and careful disinfestation using pyrethroids
led to the complete regression of the symptoms, and no more evidence
of mites or dermatites was observed during the follow-up period.
Conclusions: RMD is underestimated and often misdiagnosed even
though the growing number of synanthropic birds in our cities, ﬁrst
of all pigeons. We believe that the true incidence of this epizoonosis
in humans living in urban areas is much greater than that suggested
by the scarce number of reports in literature and can be considered an
emerging public health problem. A prompt identiﬁcation of the mite,
accurate disinfestations, nests removal and counter-measures to prevent
nests building are vital for the diagnosis and the management of the
RMD. So, it’s important to always consider this infestation in case of
single or massive episodes of non-speciﬁc dermatitis in places such as
schools, hospitals, ofﬁces or private habitations.
P1094 Increased incidence of invasive meningococcal disease
in Switzerland due to serogroup Y strains: a molecular
characterisation
B. Ninet*, R. Born, J. Schrenzel (Geneva, CH)
Objectives: The invasive meningococcal diseases (IMD) remain one of
the more severe infections due to Neisseria meningitidis of different
serogroups. In Europe, the majority of strains belong to the serogroup
B and C,strains; other serogroups are rarely isolated. Switzerland is a
country with very low IMD endemicity and the incidence continues to
decline since 2000s. However strains of serogroup Y have signiﬁcantly
emerged in the last two years. To improve the understanding of serogroup
Y IMD in Switzerland, we conducted a systematic typing of isolates.
Methods: All strains submitted to the Swiss National Center for
Meningococci in 2009 and 2010 (n = 98) were characterized by
serological assays, antimicrobial susceptibility testing and molecular
markers. The serogroup was deﬁned both by agglutination and by speciﬁc
PCR targets (siaD gene). The isolates were tested for antimicrobial
susceptibility proﬁle by the Minimal Inhibitory Concentration (MIC)
method. Genotyping was performed by multilocus sequence typing
(MLST), sequencing of the porA gene, and fetA allele determination.
Results: Among the ninety-three strains analyzed, 43 were of serogroup
B (46%), 27 of serogroup C (28%) and 20 of serogroup Y (21.5%). Three
additional strains were of serogroup W135 (n = 2) or non determined
serogroup (n = 1). The majority of serogroup Y strains (90%) belong
to the sequence type 23 (ST-23) clonal complex. One additional strain
was ST-1627 and one of ST-174. Among the 20 Y isolates, more than
half belonged the clone ST-23/P1.5−2,10−1 known to be commonly
distributed across all continents and correlated with invasiveness. No
speciﬁc resistance was detected for these strains. Sixty ﬁve percent of
infected patients (n = 13) were older than 40 years which is very rare for
IMD due to other serogroups.
Conclusion: An increase of the serogroup Y strains has been already
reported in the North America where one third of IMD cases are now
caused by this serogroup. In Europe, the proportion of IMD cases caused
by Y strains remains low (overall 5,8%). In the contrary, the percentage is
clearly increasing in Switzerland compared to other neighboring country
like in France (3% in 2009). The results of this study allow us to draw the
proﬁle of the invasive serogroup Y strains. The knowledge about these
emerging endemic strains will be helpful to follow the epidemiology and
pathology of IMD and can be an alarm for other European countries.
P1095 Epidemiologic study of bacterial gastroenteritis in Greek
children (2003–2009)
G. Kalogeras, N. Palaiologou, K. Giannakopoulou, F. Antonopoulou,
P. Xenos, M. Papadimitriou, D. Hatzaki, E. Vetouli, E. Lebessi*
(Athens, GR)
Objectives: Bacterial gastroenteritis is a common illness worldwide. A
seven-year study was conducted in a pediatric hospital in Athens, in
order to assess the isolation incidence and antimicrobial resistance of
pathogens involved in acute diarrhea in children younger than 14 years.
Methods: We retrospectively reviewed a total of 9,667 stool cultures
performed in our lab from children with acute gastroenteritis from Jan
2003 to Dec 2009.
Results: In total, 1783 samples from an equal number of children
yielded one or more enteropathogenic bacteria. During a seven-year
period, from 2003 to 2009, on a sequential, yearly basis starting
in 2003, the following bacteria, associated with acute diarrhea, were
isolated: Salmonella spp n = 708 (119;48.3% - 177;50.5% - 117;40.4%
- 100;36.7% - 82;31.2% - 67;29.5% - 46;23.8%), Campylobacter jejuni
n = 435 (17;6.9% - 62;17.7% - 42;14.5% - 58;21.3% - 81;30.9%
- 82;36.1% - 93;48.1%), enteropathogenic Escherichia coli n = 449
(69;28.1% - 76;21.7% - 71;24.5% - 80;29.4% - 67;25.5% - 52;22.9% -
34;17.6%), Aeromonas hydrophila n = 95 (16;6.5% - 13;3.7% - 16;5.5%
- 12;4.4% - 17;6.5% - 14;6.2% - 7;3.6%), Shigella spp n = 74 (18;7.3%
- 15;4.3% - 7;2.4% - 12;4.4% - 10;3.8% - 7;3.1% - 5;6.7%), Yersinia
enterocolitica n = 53 (7;2.8% - 7;2.0% - 11;3.8% - 10;3.7% - 5;1.9% -
5;2.2% - 8;4.1%). The predominant serovars among Salmonella isolates
were: Enteritidis (n = 525, 74.1%) and Typhimurium (n = 111, 15.8%).
Among Shigella isolates, the majority were S. sonnei (n = 32, 43.2%)
and S. ﬂexneri (n = 31, 41.9%). All but one, Y. enterocolitica isolates
belonged to O:3 (n = 52, 98.1%). A signiﬁcant increase was observed
in the resistance rates for Salmonella isolates to ampicillin (2.5% to
23.9%) and to cotrimoxazole (1.7% to 10.9%), as well as a dramatic
increase in the resistance for C. jejuni to ciproﬂoxacin (0% to 63%)
and to tetracycline (0% to 45.7%). All Salmonella isolates were found
susceptible to cefotaxime, and all C. jejuni strains were found susceptible
to erythromycin.
Conclusion: Salmonella spp and C. jejuni remain the most frequent
enteropathogens among children in Greece. It is of concern, that their
isolation rates have been reversed since 2008. A worrisome increase
in drug resistance was found for Salmonella spp and C. jejuni. This
phenomenon emphasize the need for a more restrictive policy on the use
of antibiotics in humans and animals.
P1096 Communicable diseases among Roma population in selected
district of Slovakia, 1997–2006
K. Rimarova*, M. Feckova, M. Rimar (Kosice, Bardejov, Bratislava, SK)
Objectives: The main aim of the study was to ﬁnd out and compare the
frequency of selected communicable diseases among Roma population
in comparison with non-Roma majority population in Bardejov district
(eastern Slovakia) in the period of 1997–2006.
Methods: Data about proportion of Roma population and majority
population demography in Bardejov district were obtained from regional
municipality statistics and from Statistical Ofﬁce of Slovak Republic.
Data about frequency of diseases were obtained through an information
system database EPIS from Regional Public Health Authority Bardejov.
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Reporting of infectious disease is mandatory through EPIS and it is duty
of local G.P. and pediatricians (any primary health care staff).
Results: Average annual salmonella morbidity of majority population
was 1.8 times higher than among Roma inhabitants (p< 0.001).
Salmonella morbidity has globally declining trend and balancing of
morbidity was noticed in observed population in district in recent years.
Average annual morbidity of dysentery diseases in Roma population
was 13.2 times higher than in majority population (p< 0.001). Age
speciﬁc morbidity of dysenteries was several times higher among Roma
population. Age distribution conﬁrmed that in 0 years old children it
was 16.8 times higher in Roma, in 1−4 years old 16.2 times higher
(p< 0.001). In older age-groups over 5 years was determined quite lower
morbidity and also smaller differences between Roma and non-Roma. In
Roma population more frequent (54.31%) was etiologic agent Shigella
ﬂexneri, while in majority population in 31.79%. In Bardejov district
from 1997 till 2006 were observed two cycles of outbreaks of viral
hepatitis type A, the both of them of epidemic origin and both occurred
in Roma settlements. Average annual morbidity in Roma population was
27.8 times higher than in majority.
Conclusion: Results conﬁrmed differences in health condition in
selected communicable diseases among Roma population and ma-
jority. These ﬁndings refer to the persisting problems, which have
negative inﬂuence on health and quality of life of Roma inhabitants,
particularly children. This paper is supported by grants CEMIO
NFP OPVaV-2009/2.1/03, Ministry of Education of Slovak Republic,
SORO − Centrum of excellence for research of factors inﬂuencing
health of marginalized and imunocompromised persons (50%), VEGA
1/0451/09 (25%), and KEGA 260–002UPJSˇ-4/2010 (25%).
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P1097 Susceptibility to antibacterial agents in Germany amongst
ocular isolates, 2004–2009: results of two laboratory
surveillance studies
M. Kresken*, B. Ko¨rber-Irrgang on behalf of the German
Ophthalmologic Study Group
Objectives: Antimicrobial resistance has increased over the past two
decades in Germany, as in many other countries. Data on the in vitro
susceptibility of pathogens isolated from ocular infections, however, are
scarce. Two multi-centre studies were carried out in order to assess the
occurrence of resistance amongst ocular isolates against antibacterial
agents used topically in the treatment of superﬁcial eye infections.
Methods: Bacterial isolates were prospectively collected in two
surveillance studies conducted in cooperation with the same 23 medical
laboratories in 2004 and 2009. Minimal inhibitory concentrations
were determined in a central laboratory using the broth microdilution
method according to the German DIN standard (now DIN-EN-ISO
20776−1:2006). Interpretive criteria applied were EUCAST clinical
breakpoints for systemic use of antibacterial agents as well as EUCAST
epidemiological cut-off values (ECOFFs) where available. Susceptibility
data of nine antibacterial agents were analysed: levoﬂoxacin (LVX),
moxiﬂoxacin (MXF), oﬂoxacin (OFX), gentamicin (GEN), kanamycin
(KAN), azithromycin (AZI), erythromycin (ERY), chloramphenicol
(CHL) and oxytetracycline (OTE). Additionally, the susceptibility of
staphylococci to oxacillin (OXA) was determined.
Results: A total of 2,006 ocular isolates (2004, n = 933; 2009, n = 1,073)
primarily recovered from conjunctival swabs were tested. S. aureus
was the predominant pathogen in either study (28−34%), followed by
H. inﬂuenzae (13−18%) and S. pneumoniae (15−16%). Patient related
data were comparable in both studies, with two third of the isolates
derived from out-patients and more than half of the patients being <10
years old. Of the S. aureus isolates collected in 2004 and 2009, 10.3%
and 9.8%, respectively, were OXA-resistant (i.e. MRSA). Resistance to
CHL, GEN and KAN among S. aureus decreased between 2004 and
2009, while resistance to ERY and the ﬂuoroquinolones (FQ) remained
unchanged (see Table). No signiﬁcant changes in the rates of resistance
were observed for S. pneumoniae and H. inﬂuenzae. In contrast, isolates
with reduced susceptibility to LVX and OFX among Enterobacteriaceae
increased from 0% and 1% in 2004 (n = 103) to 1.9% and 5.8% in 2009
(n = 104), respectively.
Conclusion: Overall, studied aminoglycosides and CHL displayed lower
resistance rates in 2009 as compared to 2004, while resistance rates of
FQ remained either unchanged or slightly increased.
P1098 Detection of antibiotic residues in pork and chicken meat
using the STAR test
M. Liousia, P. Gousia, E. Economou, H. Sakkas, S. Levidiotou*,
C. Papadopoulou (Ioannina, GR)
Objectives: The aim of the present study was the assessment of antibiotic
residues in pork and chicken meat using the STAR (Screening Test for
Antibiotic Resistance) test suggested by AFSSA Fouge`res Community
Reference Laboratory for Antimicrobial Residues in Food.
Methods: There were examined 59 chicken carcasses, from which
muscle and liver tissue was collected and 50 swine carcasses from
which muscle, liver and kidney tissue was collected. Tissue samples
of speciﬁed diameter were placed on solid agar and were inoculated
with the following microorganisms: Bacillus subtilis BGA (for testing
susceptibility to aminoglycosides), Kocuria varians ATCC 9341 (for
testing susceptibility to macrolides), Bacillus cereus ATCC 11778 (for
testing susceptibility to tetracyclines), Escherichia coli ATCC 11303
(for testing susceptibility to quinolones) and Bacillus stearothermophilus
ATCC 7953 (for testing susceptibility to sulfonamides and b-lactams).
The appearance of an inhibition zone radially to the sample indicates
the presence of antibiotic residues.
Results: 33.9% of the chicken samples and 26% of the pork samples
were found positive in one or more antibiotics. Of the positive chicken
and the pork samples 95% and 53.85% were found positive in the
detection of sulfonamides and b-lactams respectively, while 5% and
23.07% of the chicken and pork samples were found positive in the
detection of tetracyclines respectively. Concerning the detection of the
aminoglycosides and macrolides, only the pork samples were found
positive in 7.7% and 15.3% of the examined samples respectively, while
quinolone residues were not detected in any of the examined samples.
Conclusion: The STAR-Test is considered a cost-effective, easily applied
method, which can be used for screening potential antibiotic residues
in foods of animal origin. However, STAR test is neither a qualitative
or sensitive method for the detection of antibiotic residues and further
analytical methods (HPLC, GC-MS) are needed for conﬁrmation of
results. Nevertheless, the detection of positive samples for the presence
of antibiotic residues suggests the necessity of a continuous surveillance
in order to ensure the quality of the consumed foods.
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P1099 Surveillance of Aspergillus section Nigri in a general
hospital during two decades
T. Pelaez*, B. Gama, P. Lopez Roa, A. Espinel-Ingroff, P. Gijon,
P. Escribano, L. Alcala, J. Guinea, P. Mun˜oz, E. Bouza (Madrid, ES;
Richmond, US)
Background: Aspergillus fumigatus, A. ﬂavus and A. niger cause
>95% of invasive & non-invasive aspergillosis. However, antifungal
susceptibilities for most species within the section Nigri have been poorly
investigated; their identiﬁcation and susceptibility proﬁles have clinical
interest since 7 pts had invasive A. section Nigri aspergillosis at our
institution.
Methods: A total 211 Aspergillus section Nigri strains (collection
of the Hospital General Universitario Gregorio Maran˜o´n) were found
since 1988 by reviewing clinical data. MICs were determined by the
CLSI M38-A method with amphotericin B (AMB), itraconazole (IZ),
voriconazole (VZ), posaconazole (POS), terbinaﬁne (TB), caspofungin
(CAS) and micafungin (MF). Modal MICs & epidemiological cut-off
values (ECVs encompassing >95% of isolates) were obtained by deﬁning
wild-type (WT) distributions.
Results: The 211 Aspergillus section Nigri isolates were recovered
between 1988–2009 from 184 patients (respiratory tract [102], ear
[41], cutaneous [38], other sites [30]). MICs/MECs ranges/modes
(mg/ml) were: AMB (0.5−4/1), IZ (0.125−32/1), VZ (0.125−32/0.5),
POS (0.125−2/0.5), TB (0.03−0.5/0.03), CAS (0.06−1/(0.06) and MF
(0.06–0.125/0.06). ECVs & (% of isolates encompassed) were: AMB 2
(96.7%), IZ 2 (95.1%), VZ 2 (99.2%), POS 2 (99.2%), TB 0.25 (97.6),
CAS 0.5 (97.6%) and MF (98.4%). Azole values were slightly higher
than those for other Aspergillus spp. One strain of A. foetidus was highly
resistant to azole drugs, it was isolated from one patient with chronic
obstructive pulmonary disease.
Conclusions: During the study period, there was a signiﬁcant increase
of patients with Aspergillus of the Nigri group in our institution.
These isolates exhibited lower susceptibility to azoles than other
Aspergillus spp., but their susceptibilities were good to amphotericin B,
echinocandins and terbinaﬁne.
P1100 Twelve years of resistance monitoring in Salmonella from
healthy chickens in two EU regions
A. de Jong*, C. Ludwig, B. Stephan (Leverkusen, DE)
Objective: Non-typhoidal Salmonella is a main cause of food-borne
illness in man. For severe salmonellosis, antimicrobial treatment is used
with ﬂuoroquinolones (FQs) and 3rd generation cephalosporins (CPs)
as drugs of choice. A susceptibility survey with focus on FQs and
CPs was conducted in chickens, a major source of human Salmonella
infections, from 1998 to 2009. Both epidemiological cut-off values
(ECVs) and clinical breakpoints were applied to categorize antimicrobial
susceptibility.
Methods: Random, not-repetitive sampling was conducted in two
surveys. In one programme, caecal samples were taken at Belgian
abattoirs. In another, carcass samples were collected in various abattoirs
across Germany. Susceptibility testing to ciproﬂoxacin (CIP) and
cefotaxime (CTX), and various older molecules was done by agar
dilution (CLSI; M31-A3, 2008). E. coli ATCC was used as control strain
in each run. Clinical resistance was based on CLSI breakpoints (M100-
S20, 2010; decreased susceptibility (DS; % isolates with MICs  ECV
and < clinical breakpoint) was applicable to 4 compounds based on
ECVs as deﬁned by EUCAST and EFSA (2007).
Results: In all, 5673 Salmonella isolates (Belgium 752; Germany
4921) comprising 72 serovars were recovered. In both surveys, clinical
resistance to CIP was absent, but mean DS was 27.5 and 14.9%,
respectively. S. Hadar, S. Paratyphi B, S. SaintPaul, S. Virchow and
S. Newport were the most frequent serovars with DS to CIP. The presence
of DS to CIP was unrelated to CIP clinical resistance. Mean CTX
resistance was 6.0 and 0.1%, DS to CTX was 1.3 and 0.7%. In contrast,
resistance to ampicillin, chloramphenicol, nalidixic acid, streptomycin,
tetracycline and trimethoprim/sulfadiazine amounted to 39.9, 5.1, 27.4,
24.4, 28.0 and 20.6% in Belgium and 19.5, 5.6, 14.8, 11.9, 12.4 and
15.9% in Germany. Gentamicin resistance did not exceed 1% in either
programme. Overall DS for ampicillin amounted to 10.9% and for
gentamicin to 0.7%.
Conclusions: Clinical resistance among Salmonella from chickens was
absent for CIP and low for CTX, two essential drugs for treating
salmonellosis in humans. Decreased susceptibility to CIP and CTX,
however, varied from 1 to 28%. For most older drugs, notably higher
rates of clinical resistance were detected. Epidemiological cut-off values
are indispensable epidemiological tools to assess decreased susceptibility
to FQs and CPs, but questionable as predictor of clinical resistance.
P1101 Susceptibility to enroﬂoxacin of major bacterial pathogens
from dogs and cats in four EU countries
A. de Jong*, J.C. Do¨rner, C. Ludwig, A.T. Feßler, S. Schwarz,
B. Stephan (Leverkusen, Neustadt-Mariensee, DE)
Objective: International antimicrobial monitoring surveys are rare in
companion animal medicine. The aim of this survey was to study
enroﬂoxacin susceptibility of common bacterial pathogens from clinical
infections in dogs and cats across Europe. In addition, the prevalence
of meticillin-resistant Staphylococcus pseudintermedius (MRSP) and
S. aureus (MRSA) was assessed.
Methods: Isolates were obtained in 2004–2008 in Hungary, Poland,
Sweden, and the United Kingdom by local diagnostic laboratories
from skin/ear/wound, urogenital tract and respiratory tract infections
of non-pretreated animals. MIC values were assessed by agar dilution
(CLSI; M31-A3). Enroﬂoxacin resistance was calculated using the CLSI
breakpoint of 4mg/L. All S. pseudintermedius and S. aureus isolates
with oxacillin MICs 0.5 and 4mg/L, respectively, were screened by
PCR for the presence of the mecA gene.
Results: Totally 3424 isolates were tested: 2491 (73%) from skin/ear/
wound, 676 (19%) from urogenital and 257 (8%) from respiratory
infections. Of the isolates, 74% were from dogs and 26% from cats.
The following percentages of resistance were recorded (% resistant;
number of isolates tested): S. pseudintermedius (0.9%;n = 1187),
S. aureus (1.8%;n = 57), coagulase-negative (2.1%;n = 234) and -variable
(0%;n = 57) Staphylococcus spp., Escherichia coli (4.7%;n = 535), Strep-
tococcus canis (0.4%;n = 243), other Streptococcus spp. (0%;n = 111),
Pasteurella multocida (0%;n = 216), other Pasteurella spp. (0%;n = 32),
Pseudomonas aeruginosa (4.1%;n = 97), other Pseudomonas spp.
(1.4%;n = 74), Proteus mirabilis (3.6%;n = 84), Enterococcus spp.
(5.1%;n = 59), Enterobacter spp. (0%;n = 47), Acinetobacter spp.
(2.5%;n = 40) and Citrobacter spp. (0%;n = 15). MIC50 ranged from
0.016 to 0.125mg/L, except for enterococci, streptococci and P. aerug-
inosa (1mg/L). MIC90 varied from 0.03 to 1mg/L, except for
P. aeruginosa and other Streptococcus (2mg/L). Only in a few cases,
differences among clinical indications and among countries were seen.
Five mecA-positive S. pseudintermedius strains (0.4%) with oxacillin
MICs 0.5 to >128mg/L were seen while oxacillin-resistant S. aureus
was absent.
Conclusions: This survey demonstrates a high susceptibility of major
canine and feline pathogens to enroﬂoxacin. Fluoroquinolone resistance
was absent or low. MRSP (0.4%) and MRSA (0%) were detected rarely
or not at all. Despite the high ﬂuoroquinolone susceptibility, prudent use
of ﬂuoroquinolones as well as resistance monitoring is mandatory.
P1102 Phenotypic and molecular-genetic characterisation of
antimicrobial resistance of Neisseria meningitidis isolates
from Belarus
S. Glazkova*, F. Lebedev, L. Titov (Minsk, BY)
Invasive meningococcal disease (IMD) incidence in Belarus remains quit
high − in 2008 was 1,4/100000, in 2009 − 2,2 per 100000 population.
Mainly three serogroups of meningococci (MC) circulate in Belarus: A,
B and C, the leading serogroup is B. Improving of the diagnostics, as well
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as treatment are crucial for medical science and practice. Antimicrobial
resistance monitoring is an important part of the disease surveillance
system.
Objectives: To characterize antimicrobial resistance of Neisseria
meningitidis isolates from patients and contact persons at the phenotypic
and molecular-genetic levels.
Methods: A total of 19 MC strains were isolated from patients with IMD
and contacts in hospitals of Belarus. All isolates were grown on GC agar
in 5% CO2 at 37ºC. Determination of minimum inhibitory concentrations
(MICs) by agar dilution test was performed. The following antimi-
crobials and range of concentrations were used: ceftriaxone (0.008–
0.0005mg/l), ciproﬂoxacin (0.5–0.06mg/l), ampicillin (0.5–0.015mg/l),
doxycycline (4.0–0.25mg/l), meropenem (0.06–0.004mg/l), levomicetin
(8.0−0.5mg/l) and rifampicin (0.5–0.008mg/l). Ampliﬁcation of penA
and rpoB genes was performed.
Results: All meningococcal strains had reduced susceptibility or/and
resistance to penicillins according to disc diffusion tests performed
directly in the hospitals, where the stains were isolated. No meningo-
coccal strains with high-level resistance to antibiotics were found by
agar dilution method. The following results for MIC 90% obtained:
ceftriaxone − 0.004mg/l, ampicillin − 0.125mg/l, doxycycline −
2.0mg/l, meropenem − 0.003mg/l, levomicetin − 4.0mg/l, rifampicin −
0.03mg/l. Tested strains were susceptible to all used concentrations of
ciproﬂoxacin. PenA and rpoB genes were detected by PCR. Fragments of
these genes were isolated and prepared for further sequencing and point
mutation analysis. The emergence of MC with reduced susceptibility
and/or resistance to pinicillins is of particular concern in regard to the
management of patients with IMD and asymptomatic carriers or contacts.
Conclusions: Resistance of the MC to antimicrobials is a great problem
for public health in the world. According to the data obtained, an increase
of reduced susceptibility and/or resistance level to pinicillins, wide used
in IMD treatment and chemoprophylaxis in Belarus, is observed in recent
years, and should be taken into account.
P1104 Routine susceptibility testing: selection bias, sensitivity,
speciﬁcity, and performance related to MIC
R. Reynolds*, R. Hope, K. Maher on behalf of BSAC Working Party
on Resistance Surveillance
Objective: Routine susceptibility testing inﬂuences treatment choice,
and contributes to large-scale surveillance studies. We compared its
performance with centralised MIC testing, as standard, over a wide range
of organisms and antibiotics tested in the BSAC Resistance Surveillance
Project.
Methods: Laboratories in the UK and Ireland provided varied isolates
from blood (N= 5,628; 28 centres) and respiratory infections (RTI, N=
2,418; 22 centres) in 2008–2009, with their local routine (categorical)
susceptibility results as available. Isolates were tested by the BSAC
agar dilution MIC method at two central laboratories and categorised
by BSAC/EUCAST breakpoints, which did not change for relevant
organism-agent combinations in this period. Analysis covered 94
combinations for blood (46,069 MICs, 15,118 local tests) and 67 for
RTI (19,043 MICs, 10,286 local tests), excluding those with fewer than
25 local results.
Results: Local results were supplied for comparison with 33% of blood
and 54% of RTI MICs. In RTI, centres generally reported on all or none
of the relevant isolates for each organism-agent combination, with partial
reporting (10−90% of isolates) in only 6% of cases. In blood, partial
reporting was widespread at 51%. MICs for locally-reported isolates
were only 0.1 (blood) and 0.05 (RTI) dilutions higher than for all isolates,
giving minimal evidence for selection bias in local reporting. Mean
prevalence of non-susceptibility (NS) across the tested combinations
was 17% for both blood and RTI isolates. Overall test agreement at
the susceptible (S) breakpoint was 94.6 and 93.9% in blood and RTI,
respectively, with 1.8 and 2.8% false NS, and 3.6 and 3.3% false S. For
isolates with MICs equally close to the breakpoint, agreement was much
higher for S than NS isolates, with the lowest agreement (28−50%) for
those with MICs immediately above the breakpoint. Correspondingly,
local tests had quite low sensitivity (to correctly detect NS isolates) at
79.3 and 80.6% overall, with higher speciﬁcity (to correctly detect S) at
97.8 and 96.6% for blood and RTI, respectively.
Conclusion: Agreement between routine and central tests was poorest
for isolates with MICs above but close to the breakpoint, contributing
to low local test sensitivity and approximately 20% probability of
misclassifying a non-susceptible isolate as susceptible. Nonetheless, local
reports may overestimate the prevalence of NS when it is rare, as then
false NS results may outnumber false S.
P1105 Does the long-term use of a triclosan toothpaste lead to
resistant organisms?
M.P. Cullinan*, P.S. Bird, N.C. Heng, G.J. Seymour (Dunedin, NZ;
Brisbane, AU)
Objectives: To determine whether long-term use of a triclosan toothpaste
selects for triclosan-resistant bacteria within the oral bioﬁlm.
Methods: Dental plaque samples were collected from thirty-nine
subjects at the ﬁnal visit of a 5-year longitudinal clinical study examining
the effectiveness of a toothpaste containing triclosan (TCS; 2,4,4′,-
trichloro-2′hydroxydiphenylether) in slowing the progression of chronic
periodontitis in a population with cardiovascular disease. Participants had
been randomly allocated to receive either a triclosan-containing (0.3%
[wt/vol] TCS) or placebo toothpaste. Plaque samples were collected
with sterile curettes, placed in sterile Wilkens Chalgren broth (WCB)
containing 10% glycerol and processed immediately. Plaque samples
(50ul of a 10−1 dilution in WCB) were plated onto Wilkens Chalgren
agar plates supplemented with 5% laked sheep red blood and TCS
(concentration gradient from 25–150mg/ml), and were then incubated
under both aerobic and anaerobic conditions. Plates were examined
for bacterial growth and colony diversity. Isolates were identiﬁed by
partial 16S rDNA sequencing and their MIC (Minimal Inhibitory
Concentration) of triclosan determined.
Results: There were 22 and 17 participants in the TCS and placebo
groups, respectively. No growth, in both aerobic or anaerobic conditions,
was observed in either group with 0.3% TCS. Without 0.3% TCS,
>200 colonies of mixed growth with abundant black-pigmented colonies
occurred in both groups. The lowest level where growth was not inhibited
in both groups was at a TCS concentration of 150mg/ml, however there
was very little growth and very little diversity at this concentration.
The MIC of TCS for isolates growing at 100 mg/ml TCS was similar
in both groups and ranged from 125–1000mg/ml. Species isolated
most frequently were Veillonella parvula (MIC 500–1000mg/ml),
Streptococcus anginosus (MIC 125–250mg/ml), Streptococcus mutans
(MIC 125–250mg/ml) and Campylobacter gracilis (MIC 1000mg/ml).
Conclusion: Continuous use of a 0.3% (wt/vol) triclosan-containing
toothpaste over a 5-year period did not result in the growth of resistant
organisms under either aerobic or anaerobic conditions.
Acknowledgement: Funding for this study was provided by an
unrestricted grant from Colgate Palmolive USA.
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P1106 Antibiotic susceptibility pattern of nosocomial and
community-acquired Clostridium difﬁcile in Hungary
G. Terhes*, J. So´ki, K. Latko´czy, L. Szikra, M. Konkoly-Thege, G. Princz,
T. Nagy, H. Osztie, E. Urba´n (Szeged, Budapest, Sze´kesfehe´rva´r, HU)
Objectives: The rising incidence of C. difﬁcile infection is getting more
and more important, this has been partly attributed to the increased
consumption of broad-spectrum antibiotics among hospitalized patients
and in the community. The increased antibiotic consumption may have
impact on the emergence of multiple resistant C. difﬁcile strains too;
therefore our aims were to continue our previous investigations, in which
changes in the antibiotic susceptibility patterns of toxigenic C. difﬁcile
isolated from human diarrhoeal faeces were determined.
Methods: Up to this time, 171 toxigenic C. difﬁcile strains isolated
between 2008 and 2010 in three Hungarian laboratories represented
West, East and South Hungary from diarrhoeal faecal samples of
both inpatients and outpatients were analyzed. Antibiotic susceptibility
of the isolated toxin-positive strains was determined by MIC Test
Strip (Lioﬁlchem, Italy) for metronidazole, moxiﬂoxacin, clindamycin,
erythromycin and rifampicin. The results were compared with our earlier
ﬁndings given in 2007.
Results and Conclusion: All of the tested isolates were susceptible to
metronidazole during the recent study period. 39 (22.8%) moxiﬂoxacin
resistant isolates were detected between 2008 and 2010. The prevalence
of erythromycin resistant isolates was 28.7%, while 19.9% of tested
strains proved to be resistant to clindamycin. 12.3% of the isolates
were resistant to rifampicin. In comparison of the given results with
our data from a previous study, in Hungary, all of the tested isolates
were sensitive to metronidazole, the prevalence of isolates resistant to
moxiﬂoxacin, or erythromycin, or clindamycin has not been increased,
while the prevalence of rifampicin resistant isolates was higher between
2008 and 2010.
This work was supported by ESCMID/bioMe´rieux grant 2010.
P1107 Antibiotic susceptibility, class I integrons and sporulation
activity of Clostridium difﬁcile strains from antibiotic-
associated diarrhoea patients in two different years in
Estonia and Norway
S. Ko˜ljalg, J. Stsepetova*, I. Smidt, I. Lo¨hr, K. Truusalu, P. Naaber,
E. Sepp (Tartu, EE)
Objectives: To investigate (1) feno- and genotypic characteristics of
antibiotic susceptibility; (2) presence of integrons and (3) sporulation
activity of Clostridium difﬁcile (Cd) strains isolated in patients with
antibiotic associated diarrhea (AAD).
Material and Methods: Altogether 119 Cd isolates − 22 from Estonia
in 1994 (EE1) and 38 in 2008 (EE2) and 59 from Norway in 2008
(NO) from hospitalized patients were included. The values of minimal
inhibitory concentrations (MIC) to metronidazol (MTR), vancomycin
(VAN), erythromycin (ERY), clindamycin (CLI), moxiﬂoxacin (MXF)
and imipenem (IMP) were measured by E-tests. Heteroresistance (HR)
was deﬁned if colonies were growing inside the E-test inhibition zone.
The presence of class I integrons and metallo-b-lactamase (MBL) genes
(IMP, VIM, SPM, GIM, SIM) were studied using PCR. Cd sporulation
level (SL) was tested at room temperature applying serial dilution starting
with the concentration of 8x108 CFU/ml and plating.
Results: All Cd isolates from AAD patients were susceptible to MTR
and VAN. All antibiotic susceptibilities in 1994 and 2008 were similar,
except of median MIC to ERY that had signiﬁcantly decreased. Median
MIC values to MTR, VAN, IMP of EE2 strains were higher whereas
those to ERY, CLI, MXF were lower than in NO strains. 32/56 strains had
HR to IP. Cd isolated before the introduction of carbapenem treatment
(1994) exhibited less frequently IP HR than those isolated after (2008)
(3/21 vs 29/35, respectively; p< 0.001). No MBL genes were detected.
Altogether 29/82 strains possessed class I integrons (200–600 bp) which
were present more often in EE2 than in EE1 or NO strains (27/42
vs 1/21 or 1/17, respectively; p< 0.001). SL varied from 6.1 to 10.7
log10 CFU/ml whereas EE2 strains exhibited higher levels than NO
strains (median 10 vs 8 log10 CFU/ml, respectively; p< 0.001). Integron-
positive strains showed higher SL than integron-negative ones (median
9.7 vs 8.3 log10 CFU/ml, p = 0.02).
Conclusions: In Estonia and Norway MTR and VAN are still equally
effective for the treatment of AAD. Introduction of carbapenems might
be associated with the development of HR in Cd but mechanisms other
than MBL production ought to be suggested.
P1108 Trends in antimicrobial resistance of Pseudomonas
aeruginosa (2001–2010)
J.J. Garcia Irure, C. Ezpeleta Baquedano*, I. Tordoya Titichoca,
C. Fernandez Jauregui, E. Fernandez Vizan, A. Ganuza (Pamplona, ES)
Objectives: The resistance of Pseudomonas aeruginosa to antibiotics
is an increasing problem in hospitalized patients. P aeruginosa is
an opportunistic pathogen characterized by an inherent resistance to
multiple classes of antibiotics. Its ability to acquire resistance via
mutations and its frequent role in serious infections makes especially
difﬁcult the treatment of P aeruginosa infections. The aim of this study
is to analyze the evolution of antimicrobial resistance in P aeruginosa to
imipenem, piperacilline-tazobactam and ceftazidime during the period
from 2001 through 2010 in our hospital.
Methods: All the clinical strains of P aeruginosa obtained from 2001
through 2010 at the Hospital of Navarra (Spain) were characterized
by means of Microscan-walk away (Siemens) non-fermenters Gram-
negative bacilli panels. CLSI (formerly NCCLS) interpretative criteria
were used. Multiple isolates from the same patient and body sites were
excluded. P aeruginosa isolates from 2001 to 2005 were compared with
those recovered from 2006 to 2010. Statistic analysis: c2 was used to
compare the susceptibility patterns of the two time periods.
Results: 4320 isolates of P aeruginosa were obtained and characterized
over the study period: 2006 strains from 2001 through 2005 and 2314
from 2006 through 2010. Globally 89,5% were susceptible to imipenem,
93,22% to ceftazidime and 94,26% to piperacilline tazobactam. As we
compared the susceptibility patterns of 2006 isolates from 2001 through
2005 with those recovered from 2006 through 2010 (2314 strains) we
found that susceptibility to imipenem decreased from 91,63% to 87,65%.
This difference was statistically signiﬁcant (p< 0,001). The susceptibility
to ceftazidime in the two periods was 93,18% and 93,26% and to
piperacilline tazobactam 93,67% and 94,78% respectively. Patients with
an IRPA isolate recovered have higher in-hospital mortality than do
patients with an imipenem-susceptible P aeruginosa isolate.
Conclusions: The resistance of P aeruginosa to ceftazidime and
piperacilline tazobactam remained stable in our hospital during the study
period. Resistance to imipenem increased signiﬁcantly during the last
10 years from 8,37% to 12,35%. The prevalence of IRPA infection
or colonization has increased signiﬁcantly, with implications for both
clinical and economic outcomes. Interventions to improve this increase
are needed.
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P1109 Comprehensive reporting of nosocomial infection incidences
N. Grambauer*, M. Schumacher, M. Dettenkofer, D. Luft,
J. Beyersmann (Freiburg, DE)
Objectives: The incidence of nosocomial infections is often reported by
means of the incidence density (i.e., the number of observed infections
divided by the sample-time at risk) or the incidence proportion (i.e.,
the number of observed infections divided by the disease-free sample
at baseline). However, results based on both quantities do not always
agree. A reason for this is that not all patients experience a nosocomial
infection, but may instead leave the critical phase without infection. We
illustrate the need to report incidence densities for all observed outcomes
besides reporting the incidence proportion. New results will be shown
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from the ongoing German multicenter surveillance project ONKO-KISS
on pneumonia during neutropenia in adult patients who have undergone
blood stem cell transplantation.
Methods: We introduce a new comprehensive multi-state graphic
(see Figure) that clearly displays the complete study situation by
incorporating all relevant incidence densities. In addition, we illustrate
how incidence density and incidence proportion are connected in a
competing risks setting, and how the cumulative incidence function can
be derived.
Results: Allogeneic transplant is seen to have hardly any effect on
the pneumonia incidence density compared to autologous transplant
type, while a doubling of pneumonia incidence proportion is seen for
the former. This seemingly contradictory result can be explained by
considering the competing outcome state of leaving neutropenia without
infection. As seen from the Figure, generally, the incidence density for
leaving neutropenia without getting infected is much more pronounced
than the pneumonia incidence density. However, autologous transplant
even doubles the former compared to allogeneic transplant. Therefore,
more patients that received allogeneic transplants develop pneumonia
during neutropenia.
Conclusion:When reporting infection incidence, all potential competing
events must be considered. This is facilitated by the newly proposed
comprehensive mutli-state graphic. The competing risks perspective also
provides deeper insight with respect to the infection incidence propor-
tion. For clinicians, the graphic provides comprehensive surveillance
data feedback at a glance. This is particularly helpful in situations
with apparently conﬂicting results on incidence densities and incidence
proportions.
P1110 The concordance of European (HELICS/IPSE) and US
(CDC/NHSN) deﬁnitions for healthcare-associated infections
S. Hansen*, D. Sohr, C. Geffers, P. Astagneau, A. Blacky, W. Koller,
I. Morales, M.L. Moro, M. Palomar, E. Szilagyi, C. Suetens,
P. Gastmeier (Berlin, DE; Paris, FR; Vienna, AT; Brussels, BE;
Bologna, IT; Barcelona, ES; Budapest, HU; Stockholm, SE)
Objective: Across Europe comparison of infection rates from surveil-
lance of healthcare-associated infections (HAI) is restricted since
some countries are using Centers for Disease Control and Prevention
(CDC/NHSN) deﬁnitions while others use Hospitals in Europe Link for
Infection Control through Surveillance (HELICS/IPSE) deﬁnitions.
As part of the harmonization process of the European surveillance of
HAI, the European Centre for Disease Prevention and Control (ECDC)
outsourced a study to analyze the concordance between the two deﬁnition
types for HAI.
Methods: A working group with experts from 7 European countries
was set up in order to identify deﬁnitions’ differences and to realize the
surveillance during a 3-months period (1 March until 31 May 2010).
To estimate the agreement between two case deﬁnitions Cohen’s kappa
statistic was chosen.
Results: Differences in HAI deﬁnitions were found for bloodstream
infection (BSI), pneumonia (PN), urinary tract infections (UTI) and the
two key terms “ICU-acquired infection” and “mechanical ventilation”.
Agreement for all of these deﬁnitions except UTI was analyzed. The
study was performed on 47 ICUs and 6506 patients, 180 PN and 123
BSI cases.
Agreement for PN was k= 0.99 (CI95 0.98;1.00) when all cases were
considered. When cases were divided in clinically and microbiologically
deﬁned PN, kappa values were 0.90 (CI95 0.86;0.94) and 0.72 (CI95
0.63;0.82) respectively.
Agreement for BSI was k= 0.73 (CI95 0.66;0.80), but since all BSI cases
secondary to another infection site (42% of all BSI) were missed by the
CDC/NHSN deﬁnitions, BSI concordance was perfect (k= 1.00) when
only primary BSI cases (HELICS/IPSE BSI with origin “catheter” or
“unknown” and CDC/NHSN “Laboratory conﬁrmed BSI” (LCBI)) were
analyzed.
Conclusion: Countries using CDC/NHSN or HELICS/IPSE deﬁnitions
for HAI surveillance can compare PN and primary BSI cases as long
as the following considerations are taken into account: Data on PN
should always be compared in total but not as subcategories. For BSI the
source should always be reported since all “secondary” cases according
to HELICS/IPSE deﬁnitions ought to be excluded in the comparison
with CDC/NHSN deﬁned BSI.
Although other methodological differences exist between HELICS/IPSE
and CDC/NHSN surveillance protocols, HAI case deﬁnitions per se
do not compromise comparability of results between the two protocols
and should therefore not be an obstacle for harmonization of European
surveillance.
P1111 The ECDC Pilot Point-Prevalence Survey of healthcare-
associated infections and antimicrobial use: main results
C. Suetens*, A. Muller, B. Coignard, J. Griskeviciene, S. Hopkins,
K. Weist, M. Goossens, S. Vaerenberg, B. Catry, V. Vankerckhoven,
H. Goossens, P. Zarb on behalf of the ECDC-pPPS Study Group
Objectives: The ECDC pilot Point Prevalence Survey of healthcare-
associated infections (HAI) and antimicrobial use (AU) in European
acute care hospitals (ECDC-pPPS) was coordinated by ECDC and
outsourced to a consortium led by the University of Antwerp (UA) in
collaboration with the French Institute for Public Health Surveillance
(InVS) and the Belgian Scientiﬁc Institute of Public Health (WIV-ISP).
The objectives were to test and ﬁnalize a European protocol allowing
to: estimate the prevalence of HAI and AU in participating hospitals;
stratify estimates by patients’ characteristics and invasive procedures
and; provide a standardized tool for hospitals within Europe to identify
targets for quality improvement.
Methods: All patients on ward by 8:00 am and not discharged at the
time of survey were included. Each ward was surveyed in one day. Two
protocols − a patient-based with risk factors collected for each patient
and a unit-based with aggregated denominator data at ward level −
were tested.
Results: Fifty hospitals using the patient-based protocol and 16 hospitals
using the unit-based protocol contributed a total of 19888 patients from
23 countries from May until October 2010. The overall prevalence of
patients with HAI (n = 1408) was 7.1% [mean of hospitals 7.0%; median
7.6%, IQR 4.2−9.4%] and varied between 0.2% in psychiatric wards to
26.2% in intensive care units. Pneumonia represented 22%, surgical site
infections 19%, urinary tract infections 17% and bloodstream infections
12%. The 3 most frequently reported microorganisms were E. coli (15%),
S. aureus (12%) and Pseudomonas spp. (12%).
The prevalence of AU was 34.6% (n = 6875) [IQR 28.0–44.7%] and
varied between 2.2% in psychiatric wards to 61.3% in intensive care
units. Patients with antimicrobials received on average 1.4 prescriptions.
Combinations of penicillins and b-lactamase inhibitors were the most
frequently prescribed drugs (16%), followed by ﬂuoroquinolones (14%),
second- (9%) and third- (7%) generation cephalosporins. Indication
was treatment intention for 66% (community infection 41%, hospital
infection 24%, other healthcare-associated infection 1%) and prophylaxis
in 31% (surgical 17%; medical 14%).
Conclusions: The successful accomplishment of the pPPS enabled
making adjustments to the ﬁnal ECDC-PPS protocol in view of its
implementation in all EU Member States in 2011–2012. However. the
results of this pilot survey should be interpreted with caution (no
representative sample).
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P1112 Reducing nosocomial infections in neutropenic patients
through participation in the multicentre surveillance project
ONKO-KISS
D. Luft*, F. Schwab, R. Babikir, H. Bertz, W.V. Kern, A.F. Widmer,
M. Dettenkofer and the ONKO-KISS study group
Objectives: Surveillance of nosocomial infections reduces their inci-
dence after initiation of such a program. However, these data were
generated primarily from immunocompetent patients. Only few studies
focused on the effect of surveillance in immunocompromised hosts.
We evaluated the extent of risk reduction achieved by participation
in ONKO-KISS, a German national nosocomial surveillance project
focusing on immunosuppressed patients only. It prospectively collects
data on nosocomial bloodstream infections (BSIs) and pneumonia during
neutropenia in patients undergoing haematopoietic cell transplantation
(HCT).
Methods: Participating centres included adult patients (age 16 years)
undergoing allogenic or autologous HCT during neutropenia. Cases of
BSI were determined using Centers for Disease Control and Prevention
(CDC) deﬁnitions for laboratory conﬁrmed BSI. Cases of pneumonia
were determined using modiﬁed CDC criteria adapted for neutropenic
patients (www.nrz-hygiene.de/surveillance/kiss/onko-kiss).
Data of centres participating for at least 3 consecutive years were
included into the analysis. Relative risks (RR) were calculated (in
univariate analyses) for comparison of incidences and incidence densities
in the ﬁrst year of participation with those in 2nd and 3rd year.
Multivariate analysis was performed using a generalized linear Poisson
regression model including year of participation in ONKO-KISS and
variables related to clinical characteristics and demographic data.
Results: Data from 23 centres were included into the analysis,
representing 8,561 patients, 126,924 neutropenic days, 1,417 cases of
BSI and 724 cases of pneumonia (for details on HCT types see table).
Regression analysis showed a statistically signiﬁcant risk reduction for
BSI in allogenic HCT patients in the third year of participation compared
to the ﬁrst year with an incidence rate ratio (IRR) of 0.62, 95%
conﬁdence interval (CI95): [0.52–0.75], p< 0.001.
For pneumonia in allogenic HCT patients and for BSI and pneumonia
in autologous HCT patients a risk reduction was observed (crude
IRRs [CI95]: 0.80 [0.6–1.06], 0.85 [0.64–1.14] and 0.85 [0.53–1.37],
respectively), but did not reach statistical signiﬁcance.
Conclusion: This study clearly shows that participation in the
active surveillance program ONKO-KISS is associated with signiﬁcant
reduction of BSI rates in neutropenic patients undergoing allogenic
haematopoietic stem cell transplantation.
P1113 Epidemiological trends of emerging organisms and
antimicrobial resistance in Italian ICUs: risk-adjusted rates
from the SPIN-UTI project
A. Agodi*, F. Auxilia, M. Barchitta, S. Brusaferro, D. D’Alessandro,
M.T. Montagna, C. Pasquarella, E. Righi, S. Tardivo, V. Torregrossa,
I. Mura and the GISIO, Italian Study Group of Hospital Hygiene
Objectives: The main aims of our study were to compare risk adjusted
rates from the ﬁrst two editions of the SPIN-UTI, Italian Nosocomial
Infections (NIs) Surveillance in Intensive Care Units (ICUs), project
and to follow up epidemiological time-trends of nosocomial pathogens,
emerging organisms and their antimicrobial resistance patterns.
Methods: The SPIN-UTI methodology is based on the HELICS-ICU
protocol (version 6.1, 2004) (Agodi et al., 2010). Prospective patient-
based surveillance was implemented from October 2006 to March 2007
by 49 ICUs in the ﬁrst edition and from October 2008 to March 2009
in the second one by 28 ICUs.
Results: In the ﬁrst study, the cumulative incidence of ICU-acquired
infections for all sites was 19.8 per 100 patients and the incidence
density 17.1 per 1000 patient-days. The most frequently reported NI
type was pneumonia (PN, 53.6%) followed by bloodstream infections
(BSIs, 23.4%), urinary tract infections (UTIs, 16.7%) and catheter-
related infections (6.3%). In the second study, the cumulative incidence
and the incidence density were 19.9 per 100 patients and 19.0 per 1000
patient-days, respectively. Comparing the proportion of infections by
type, a decrease of PN (from 53.6% to 47.3%) and a signiﬁcant increase
of UTIs (from 16.7% to 22.3%; p< 0.000) were shown. In the ﬁrst
edition, bacterial species most frequently detected were: Pseudomonas
aeruginosa (19.0%), Staphylococcus aureus (9.4%) and Acinetobacter
baumannii (7.5%) (Agodi et al., 2010). In the second, P. aeruginosa
remained the most frequently reported micro-organism (16.9%), while
the proportion of A. baumannii (14.2%) and K. pneumoniae (9.6%)
signiﬁcantly increased. Trend of resistance rates were as follows:
imipenem-resistant A. baumannii revealed no change (76.9% and
77.3%), imipenem-resistant K. pneumoniae increased (from 8.3% to
13.9%), and imipenem-resistant or ciproﬂoxacin-resistant P. aeruginosa
revealed an increase from 40.5% to 48.1% and from 42.7% to 50.6%
respectively.
Conclusion: Our risk estimates of ICU-acquired PN and BSI reﬂect
the European scenario, as reported by the BURDEN project (Lambert
et al., 2010). Furthermore, our study revealed an increasing risk of UTIs
as a target for infection control and highlighted the emerging role of
A. baumannii and K. pneumoniae in Italy as well as an increasing
trend in time of speciﬁc resistance patterns. National and international
cooperative efforts are needed to prevent NIs in ICUs.
Risk factors for nosocomial infections: how
many are modiﬁable?
P1114 Identiﬁcation of widespread seasonal variations in the
occurrence of healthcare-associated infections: role of
climatic and host factors
H. Richet*, D. Raoult (Marseille, FR)
Objective: Seasonal variations have been detected for some health care-
associated infections (HCAI); however, the extent of the phenomenon
is not known. Therefore, we sought to assess the presence of seasonal
variations in the occurrence of HCAI and the role of climatic factors in
those variations.
Methods: Assessment of seasonal variations from 2006 to 2008 in
the incidence rates per 1000 patient-days of various by autocorrelation
analysis, principal component analysis, time series analysis and linear
regression analysis at a teaching tertiary care reference centers in
Marseille, France.
Results: 9,989 HCAI were included. Seasonal variations were detected
for the overall rate of HCAI, bacteremia, deep SWI, methicillin-
susceptible S. aureus, S. epidermidis, K. pneumoniae, and P. aeruginosa.
Time series analysis showed that high temperature was an independent
predictor of seasonal variations for the overall incidence of HCAI,
deep surgical wound infections, third generation cephalosporins-
resistant Enterobacteriaceae, ceftazidime-resistant P. aeruginosa and
K. pneumoniae infections. Seasonal variations were stronger for males
and persons aged 0 to 16 than in the other age groups. No signiﬁcant
seasonal variations of HCAI were observed among ICU patients
hospitalized in units with air conditioning systems and by principal
component analysis no correlation was found between infections and
climatic factors. These ﬁndings were conﬁrmed by a times series
analysis predicting a decrease in the number of HCAI for a decrease
in temperature.
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Conclusions: Seasonal variations are more widespread than expected
and HCAI, as a whole, are subject to seasonal variations. Unexpected,
was the detection of seasonal variations in infections caused by Gram-
positive organisms, in some age groups and male gender. Comparison
between ICU and non-ICU patients conﬁrmed the inﬂuence of climatic
factor in seasonal variations and controlling temperature and humidity
could serve as a prevention method of HCAI.
P1115 Identifying and exploring core group dynamics in
healthcare-associated methicillin-resistant Staphylococcus
aureus transmission
S.R. Deeny*, J.V. Robotham, B. Cookson, D.R. Jenkins, B.S. Cooper
(London, Leicester, UK; Bangkok, TH)
Objectives: Patients admitted to hospital colonized with MRSA have an
increased risk of MRSA infection and are potential sources of onward
transmission. The probability of a patient being colonized on admission
with healthcare-associated MRSA depends on the frequency of previous
hospital admissions and also the duration of MRSA carriage and the
time between admissions. The objectives of this study were to quantify
the impact of a patient’s history of exposure to hospital care on their
potential for MRSA colonization and transmission and to identify the
role of a core group of frequently readmitted patients.
Methods: Data were collected from a 1000 bed teaching hospital during
a 7 year period and parameters calculated governing patient’s length of
stay in hospital, probability of readmission and length of time spent away
from the hospital. These parameters were used to simulate intra-hospital
MRSA transmission with a stochastic individual based model (IBM).
Results: A mean of 58% patient admissions had prior admission in the
previous 7 years. Of these 36% had been discharged from hospital fewer
than 100 days previously. On a patient’s ﬁrst discharge there is a 56%
probability that they will be readmitted; using an estimated mean MRSA
carriage duration of one year (and a negative exponential distribution), a
patient who is MRSA colonized when discharged has a 91% probability
colonization will persist at readmission. Although only 2% of admissions
were admitted at least 10 times within the 7 year period, 93% of
these patients had less than a year between consecutive admissions.
If MRSA colonization prevalence was 5% in patients admitted for the
ﬁrst time, the model showed it would be approximately 10% in patients
admitted for the sixth time, assuming patients differed only in their
frequency of admission. The model indicated that a core group of patients
admitted three times or more account for up to 60% of MRSA colonized
admissions in one year.
Conclusion: Even in the absence of other risk factors for colonization,
those in a core group of frequently readmitted patients have an increased
risk of becoming colonized with MRSA due to frequent exposure to
the hospital environment. If colonized, they are more likely to still
be colonized on subsequent admissions, due to shorter times between
admissions, and may account for up to 60% of MRSA admissions. These
results suggest MRSA control policies could make substantial efﬁciency
savings by targeting this core group.
P1116 Colistin resistance in Gram-negative bacteria during
prophylactic colistin use in intensive care units
E.A. Oostdijk*, M. Leverstein-van Hall, J. Muilwijk, J. Kesecioglu,
M.J. Bonten (Utrecht, NL)
Objectives: Colistin is increasingly used in Intensive Care Units (ICU)
patients as a last resort antibiotic to treat infections caused by multi-
resistant Gram-negative bacteria (GNB). Although reported sparsely,
colistin use may lead to colistin resistance. Selective Digestive Tract
Decontamination (SDD) and Selective Oropharyngeal Decontamination
(SOD) are prophylactic regimens for ICU-patients consisting of topical
application of tobramycin (TOB), colistin (COL) and amphotericin B
applied every 6hr throughout ICU stay. As SDD and SOD are almost
universally used in Dutch ICUs, we quantiﬁed the conversion rate from
COL susceptibility to resistance (S-R conversion) among GNB in a
Dutch tertiary care ICU.
Methods: Using all microbiological data from a tertiary care ICU in the
Netherlands we identiﬁed all S-R conversions of colistin in Escherichia
coli (EC), Klebsiella spp (KS) or Enterobacter spp (EB), occurring
within a single bacterial species, during a single ICU-admission, between
Jan 2008 and Oct 2010. In this ICU, SDD was used from Jan 2008 until
Aug 2009 and SOD from Sep 2009 to Oct 2010. As part of SDD and
SOD rectal and respiratory cultures were obtained at admission and twice
weekly. For each COL S-R conversion, the time between the ﬁrst COL
susceptible and resistant isolate was calculated.
Results: In total 41,597 cultures were obtained in 6049 patients. 2103 of
6049 patients had an ICU stay >48 hours comprising 23,179 patient days.
In 18 ICU-patients (0.86%) COL S-R conversion occurred: 11 (61%) EC,
3 (17%) KP and 4 (22%) EB. 14 Conversions occurred during 20 months
of SDD, and 4 during 9 months of SOD. In 14 episodes COL resistance
was associated with TOB resistance and in 4 of these episodes there
also was a TOB S-R conversion. Median length of ICU stay of COL
S-R converters was 29 days (range 8−96, IQR 29.8) and median time
to conversion was 11 days (range 4−35, IQR 10). Conversion rate was
0.79 per 1,000 ICU-patient days at risk. Two patients had ICU-acquired
bacteremia with the same species after COL S-R conversion, yet the bac-
teremia isolate was COL susceptible. Based on epidemiological linkage
there was no evidence of cross-transmission of colistin resistant GNB.
Conclusion: In an ICU with low endemicity of antibiotic resistance and
continuous exposure to topical COL the COL S-R conversion rate in
GNB was 0.78 per 1,000 patient days at risk.
P1117 Nosocomial infections in critically ill patients: when should
multidrug-resistant Pseudomonas aeruginosa be suspected?
L. Dalﬁno*, A. Mosca, N. Brienza, M. Spada, S. Coppolecchia,
G. Miragliotta, R. Giuliani, F. Bruno (Bari, IT)
Objective: In critically ill patients, multidrug resistant (MDR) Pseudo-
monas aeruginosa (PA) is a leading cause of nosocomial infections,
accounting for a high attributable mortality. Indeed, in this setting
MDRPA represents the main reason of inappropriateness of early
empiric antibiotic therapy. Knowledge of predisposing factors to MDRPA
acquisition could aid to anticipate an effective antimicrobial therapy. The
aim of this study was to identify risk factors for MDRPA in critically ill
patients.
Methods: Patients consecutively admitted to the adult medical-
surgical 16-bed ICU of our University Hospital between 1 October
2007 and 30 September 2009 were enrolled. Patients with either
MDRPA colonization/infection on admission or a ICU stay <72
hours were excluded. A PA isolate was deﬁned as MDRPA when
resistant to at least three of the following antipseudomonal classes of
antimicrobial agents: carbapenems, anti-pseudomonal cephalosporins,
ﬂuoroquinolones, aminoglycosides. Routine tracheal and urinary screen-
ing specimens (on admission and twice weekly), as well as clinical
specimens were analyzed. MDRPA acquisition was deﬁned as a positive
culture after 48 h of ICU stay. Antibiotic exposure was deﬁned by at
least 72 h of treatment in the previous 2 weeks for MDRPA group
and all over the ICU stay for the control group. A binomial analysis,
followed by a stepwise logistic regression procedure, was used to select
the best predictors of MDRPA acquisition. Only those variables with a
p value <0.10 and a number of responses deﬁning the outcome >10 in
the univariate analysis were entered into the logistic model.
Results: Out of 251 eligible patients, 83 patients (33%) acquired
MDRPA. Primary sites of isolation were: lung (79.5%), urine (10.8%),
blood (7.2%), and cerebrospinal ﬂuid (2.5%). Clinical characteristics of
the study population, as well as risk factors for MDRPA acquisition are
illustrated in table 1. In the stepwise analysis, total parenteral nutrition
(p = 0.0001) and previous exposure to glycopeptides (p = 0.008) were the
best independent promoting factors of MDRPA acquisition.
Conclusions: A prolonged ICU lenght of stay, receipt of total parenteral
nutrition, previous exposure to glycopeptides and previous prolonged
exposure to non anti-pseudomonal agents should rise the suspicion
of MDRPA implication, when an empiric antibiotic regimen must be
planned in a critically ill septic patient.
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P1118 Assessing risk factors for acquiring extended-spectrum
b-lactamase-producing Gram-negative infections in
long-term care facilities: a case-control study
E. Tacconelli*, E. Mantengoli, C. Cadeddu, E. Cunietti, F. Luzzaro,
R. Cauda, G.M. Rossolini, M. Tinelli (Rome, Siena, Lodi, Lecco, IT)
Background: Extended-spectrum b-lactamase-producing Gram-negative
(ESBL+Gn) are emerging pathogens among health-care associated
infections. However, to our knowledge, risk factors for ESBL+Gn
infections in long term care facilities (LTCFs) were rarely investigated.
Methods: A prospective case-case-control study. This approach was
chosen because allows to compare the relative contribution of the
ESBL production over and above simply having the Gn infection. To
homogenize the comparisons, urinary tract infection was chosen as
common indicator of infections in LTCFs. ESBL determinants were
characterized by hybridization and conﬁrmed by PCR and sequencing. In
the ﬁrst study, cases were deﬁned as patients harbouring the ESBL+Gn
while controls were those without Gn infections (random sampling). In
the second study, cases were instead deﬁned as those patients harbouring
the ESBL-Gn while controls, similar to the ﬁrst approach, were those
patients without Gn infections.
Results: The study involved 279 patients in a LTCF. Cases (1st
group) developed UTIs due to the following ESBL+Gn: E. coli (71%),
K. pneumoniae (11%), and P. mirabilis (17%). CTX-M-type enzymes
(CTX-M-1 and CTX-M-15) were prevalent (84%). TEM-type were
produced by 10% P. mirabilis (TEM-92). All K. pneumoniae co-produced
CTX-M group 1, SHV and TEM enzymes. Patients with ESBL+Gn
UTIs were more likely to have been hospitalised in the previous year
(p = 0.04), to suffer from cirrhosis (p = 0.04) and to have permanent
urinary catheter (p = 0.02). Compared with controls, these patients had
a longer duration of hospital stay before UTI developed (17 vs. 9
days, OR 1.1 per 1-day longer, p = 0.04) and were more likely to have
had exposure to antibiotics (OR 9, p< 0.01). The risk was higher in
patients with at least 7 days of antibiotic exposure (OR 11). In the
case–case comparison using a multinomial logistic regression model,
after adjusting for demographic and clinical risk factors, we found a
statistically signiﬁcant risk difference for previous use of quinolones
(OR, 11.5, p = 0.01) and 3rd gen. cephalosporins (OR, 3.7, p = 0.02), in
patients with ESBL+Gn infections. For ESBL-Gn infections, no speciﬁc
antibiotic remained a signiﬁcant risk after adjusted analysis.
Conclusions: Exposure to quinolones and 3rd gen cephalosporins
was associated with subsequent UTIs due to ESBL+Gn in a LTCF.
Interventions aimed to the reduction of antimicrobial usage in LTCFs
should be further developed and implemented.
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P1119 Susceptibility proﬁles of most common Polish probiotics to
daptomycin and tigecycline
P. Kochan*, A. Drzewiecki, K. Wajda-Drzewiecka, T. Gosiewski,
K. Pakosz, P. Heczko (Cracow, Katowice, PL)
Objectives: Most probiotics used as dietary supplements and food
products have a long history of safe use and generally recognized as safe
status (GRAS), meaning they are regarded as food-grade microorganisms
with no imposed health risk for consumers or the environment. There
are however documented studies that describe resistance patterns in
these bacteria. The WHO/FAO guidelines were the ﬁrst to draw a
speciﬁc safety list for testing of probiotic microorganisms which included
antimicrobial resistance proﬁle testing. We decided to test selected, most
common probiotic strains used in Poland to daptomycin and tigecycline,
which are considered as salvage therapy in life-threatening infections
due to multiresistant strains.
Methods: Selected probiotic products (n = 6) of different composition
were selected and purchased in the local pharmacies. After initial
quantitative culture on appropriate media, the colonies were identiﬁed by
microscopic observation of stained specimens and by API 50CH. Next
step was setting up Etests for MIC determination for daptomycin and
tigecycline.
Results: We isolated 12 strains including 11 lactobacilli and 1
Biﬁdobacterium strain. MIC values for daptomycin were surprisingly
high, only two strains had MIC values of 1mg/ml and all the other strains
had MIC values above that (up to 48 mg/ml). For tigecycline MIC values
were low, except for 5 strains with MIC values between 1.5−48mg/ml.
The highest MIC values for both daptomycin and tigecycline were shown
for the strains originating from the most popular probiotic in Poland
(used by 66.5–93.7% of persons using probiotics, depending on the
region).
Conclusion: The most popular probiotic products were found to have
very high MIC values to daptomycin and tigecycline. There were reports,
including our previous studies, about infections with strains contained
in probiotic products. The empirical therapy of infections with probiotic
strains in Poland should not include these two novel drugs, especially
daptomycin, owing to high MIC values. Data for other European markets
are not fully described and joint cooperation is necessary in the years
to come. As an additional conclusion, we think it would be wise for
the producers of the oldest probiotic preparation available in Poland
(used from 1960’s) to revise their product formulation or even consider
withdrawing it from the market.
P1120 Trends in antimicrobial susceptibility in European
Gram-positive anaerobes: the Tigecycline European
Surveillance Trial, 2007–2010
M. Hackel, R. Badal, S. Bouchillon, B. Johnson, D. Hoban, S. Hawser*,
M. Dowzicky (Schaumburg, US; Epalinges, CH; Collegeville, US)
Objectives: Antimicrobial resistance in anaerobic isolates is of
increasing concern in clinical settings, with empiric treatment often
employed. The Tigecycline European Surveillance Trial (TEST) has been
monitoring susceptibility of anaerobes in Europe since 2007. This report
compares the trends in susceptibility levels of Gram positive anaerobes
from 2007 to 2010.
Methods: 2,338 Gram-positive anaerobic pathogens, including Anaero-
coccus spp., Clostridium spp., Finegoldia magna, Peptoniphilus spp.,
and Peptostreptococcus spp., were collected and identiﬁed from 44 sites
in 7 countries in Europe, and sent to a central laboratory where MICs
of tigecycline and ﬁve comparators were determined using CLSI agar
dilution. Tigecycline MICs were interpreted using US FDA breakpoints,
while EUCAST guidelines were used for all other drugs.
Results: Overall % susceptibility for Gram-positive anaerobes is shown
below:
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Conclusions: Tigecycline, metronidazole, meropenem and piperacillin
tazobactam showed excellent in vitro activity against Gram-positive
anaerobic bacteria isolated from European hospitals from 2007 to
2010, inhibiting nearly 100% of all isolates. Clindamycin and penicillin
generally inhibited less than 80% of Gram-positive isolates. No
signiﬁcant decreases in susceptibilities were noted over the four years
surveyed.
P1121 Activity of tigecycline and ﬁve comparators against recent
Gram-negative anaerobes in Europe − the Tigecycline
European Surveillance Trial
M. Hackel, S. Bouchillon, B. Johnson*, D. Hoban, M. Renteria,
J. Johnson, R. Badal, S. Hawser, M. Dowzicky (Schaumburg, US;
Epalinges, CH; Collegeville, US)
Objectives: Tigecycline has demonstrated signiﬁcant broad-spectrum
activity against aerobic and anaerobic Gram-positive and Gram-negative
microorganisms. The Tigecycline European Surveillance Trial (TEST)
monitors susceptibility of European anaerobic bacteria to tigecycline,
cefoxitin, clindamycin, meropenem, piperacillin-tazobactam (pip tazo),
and metronidazole. In this study we evaluated tigecycline and the
ﬁve comparator compounds against European Gram-negative anaerobic
isolates from 2007–2010.
Methods: 2,453 Gram-negative anaerobic pathogens were collected and
identiﬁed from 18 sites in 6 countries in Europe. MICs of tigecycline
and ﬁve comparators were determined per EUCAST guidelines using
agar dilution at a central laboratory. Percents susceptible (%S) are based
on EUCAST breakpoints where available (clindamycin, meropenem,
metronidazole, pip tazo), CLSI (cefoxitin) and the FDA (tigecycline).
Results: Results are shown in the table, with MIC values in mg/L.
Conclusions: Tigecycline showed excellent in vitro activity against
Gram-negative anaerobic microorganisms isolated from European
hospitals. MIC50 values for tigecycline against all isolates tested were
0.5mg/L, while MIC90 values were 2mg/L. Metronidazole also
performed well, with MIC50/90 values of 0.5/2 and %S of B. fragilis
group organisms at >99%.
P1122 In vitro activity of tigecycline against clinical isolates from
a large tertiary care institution
L. von Mu¨ller*, M. Herrmann (Homburg/Saar, DE)
Objective: Tigecycline is a novel glycylcycline demonstrating a broad
range activity against numerous Gram-positive, Gram-negative, anaer-
obic and “atypical” bacteria. The worldwide advent of multiresistant
bacteria support its role as an important adjunct in the antimicrobial
armamentarium. The goal of this study was to analyze the activity
of tigecycline against a collection of well-deﬁned clinical pathogenic
isolates of a large tertiary care institution.
Methods: The University of Saarland Hospital is a 1300-bed (150
ICU-beds) tertiary care facility serving all medical specialties including
transplant and oncologic units. From January until June 2009, 751
isolates preferentially recovered from the blood and other primarily
sterile sites were collected. Copy strains were excluded. All isolates
were analyzed according to current CLSI standards for agar dilution
susceptibility testing (AST). Mueller-Hinton Agar plates with serial
dilutions of tigecycline (0.0625 to 8mg/l) were prepared freshly the day
before analysis.
Results: We conﬁrmed that tigecyclin is active against a broad array
of Gram-negative and -positive bacteria. Increased MICs were found
for Morganella, Proteus, Providencia and Serratia spp. Higher MICs
were also found when comparing E. coli with and without ESBL. For
multiresistant Gram-positive bacteria (MRSA and VRE) the MIC was
not increased. Interestingly, MIC50 and MIC90 values were found to be
superior to those previously reported for tigecycline (Table 1), typically
determined using broth microdilution AST. It has been reported that
tigecycline susceptibility testing may be sensitive to the freshness of
the media preparation due to inactivation by oxygen. Accordingly, in
a smaller series of AST, an antioxidant available for human use has
been added to the agar dilution media preparations in order to preserve
tigecycline function. 81/751 clinical isolates have been additionally
tested in parallel in, and in 59/81 isolates, the MIC was found to be
reduced by a factor of 2−16.
Conclusion: Agar dilution techniques may yield elevated MIC values for
tigecycline against a large spectrum of clinical isolates when compared
to broth microdilution assay. The reduction of MIC values as a result
of supplementation with an antioxidant suggests a role of oxidative
inactivation of tigecycline. Whether or not oxidative inactivation is
of relevance in clinical application should be subject of testing in
appropriate models.
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P1123 Tigecycline susceptibility trends in Germany among
Gram-positive and Gram-negative pathogens recovered
from wounds, the peritoneal cavity and blood
M. Kresken*, K. Becker, H. Seifert, B. Ko¨rber-Irrgang, C. von Eiff,
P.-A. Lo¨schmann on behalf of the German Tigecycline Study Group
Objectives: Following regulatory approval for use in complicated skin
and skin structure infections and complicated intraabdominal infections,
tigecycline (TGC) was introduced in Germany in 2006. Data of the
German Tigecycline Evaluation Surveillance Trial (G-TEST) conducted
between 2005 and 2009 were analyzed for the susceptibility of most
important aerobic Gram-pos. and Gram-neg. pathogens to TGC and
comparators.
Methods: The susceptibility of isolates of four Gram-pos. and seven
Gram-neg. species consecutively collected in three surveillance studies
conducted in cooperation with the same 13 laboratories in 2005, 2007,
and 2009 (G-TEST I-III) were tested. Each laboratory collected appr. 250
pathogens from hospitalized patients. MICs were determined in a central
laboratory using the microdilution method according to the standard
ISO 20776−1:2006. EUCAST breakpoints were applied to all antibiotics
for interpretation. ESBL-producing organisms were identiﬁed by CLSI
criteria. E. coli isolates expressing an ESBL phenotype were further
characterized by PCR and sequencing.
Results: A total of 3,248 isolates recovered from wounds (n = 1,573;
48,4%), the peritoneal cavity (n = 567; 17.5%), and blood (n = 1,108;
34.1%) were tested. Based on MIC-50/90 values, TGC demonstrated
unchanged (within +/− one dilution) in vitro activity against all species
tested (see Table). In contrast, a considerable increase of resistance (R)
to b-lactams and ﬂuoroquinolones (FQ) was noted for members of the
Enterobacteriaceae family. Between 2004 and 2009, R to FQ in E. coli,
E. cloacae and K. pneumoniae increased from 20% to 27%, 6% to 11%,
and 7% to 23%, respectively. The increase of R to cefotaxime in E. coli
and K. pneumoniae went along with a rise of ESBL-producing strains,
from 6% to 11% and from 5% to 14%, respectively. In all three studies,
most common ESBLs found in E. coli were CTX-M-1 and CTX-M-15.
R to imipenem in A. baumannii group isolates was not observed in
2005, but was 18% and 8% in 2007 and 2009, respectively. The rate of
vancomycin-resistant strains among Enterococcus faecium isolates varied
between 9% and 19%.
Conclusion: TGC retained its very good in vitro activity against all
Gram-pos. and Gram-neg. organisms tested after the introduction in
Germany. Against a background of pathogens that are frequently resistant
to various antibiotic classes, TGC remains an important treatment option.
P1124 In vitro activity of tigecycline and comparators against
Enterococcus faecalis and Enterococcus faecium isolates
collected in Germany
F.-J. Schmitz* (Minden, DE)
Objectives: Tigecycline is a new broadspectrum antibiotic against Gram-
positive and Gram-negative pathogens including multi-drug-resistant
strains, licenced for complicated intra-abdominal infections (cIAI) and
skin and soft tissue infections (cSSTI) in Germany. Enterococcal
pathogens are one of the most important bacterial species responsible
for cIAI (e.g. peritonitis) and cSSTI (e.g. deep wound infections). Aim
of the present study was to compare the in vitro activities of tigecycline
and comparators.
Methods: In total 600 bacterial strains were tested (200 Enterococcus
faecium and 400 Enterococcus faecalis) mostly collected from patients
with cIAI or cSSTI in the year 2009. MICs were determined by the broth
microdilution according to the guidelines of the CLSI. The accuracy of
susceptibility testing was evaluated by MIC testing of quality control
organisms.
Results: According to MIC ranges as well as to MIC50/90 values,
tigecycline demonstrated excellent in vitro activity against all 600
enterococcal isolates tested. No difference could be observed between
E. faecalis and E. faecium, although E. faecium isolates are very often
multiresistant. In addition, tigecycline was active against vancomycin
resistant E. faecium isolates. None of the isolates tested showed
resistance to tigecycline, although tigecycline has now been used for
a couple of years. In comparison to other compounds with activity
only against Gram-positive isolates (e.g. daptomycin, vancomycin and
linezolid) tigecycline displayed a MIC90 value of 0,125mg/L against
E. faecalis isolates, while the other comparators displayed a value
of 2mg/L. Against E. faecium isolates MIC90 values for tigecycline,
linezolid, daptomycin and vancomycin were 0,125, 2, 4 and 16mg/L,
respectively. Both species (E. faecalis and E. faecium including VRE)
were 100% susceptible to tigecycline and linezolid.
Conclusion: In summary, tigecycline displayed an excellent in vitro
activity against all enterococcal isolates tested and no tigecycline
resistant isolate was found.
P1125 In vitro activity of tigecycline against multidrug-resistant
Klebsiella pneumoniae isolates
V. Papaioannou, S. Tsiplakou, A. Stylianakis, E. Chatziandreou,
K. Ntetsika, N. Zalavras, A. Koutsoukou* (Athens, GR)
Objectives: Tigecycline is a member of the glycylcycline class of
antibiotics highly effective against a wide range of bacteria including
multi-resistant Gram negative and positive pathogens. The aim of this
study was to evaluate the in vitro activity of this agent against multidrug
resistant Klebsiella pneumoniae clinical isolates.
Methods: A total of 684 strains of K. pneumoniae were studied.
Isolates were recovered from blood cultures, body ﬂuids, catheters,
pus, bronchial secretions and urine samples derived from hospitalized
patients (ICU and surgical and medical wards) in a one and a
half year period, from 01/01/09 to 30/06/10. Multidrug resistance
was deﬁned as resistance to more than three of the following
antimicrobials: b-lactams (as for ceftazidime), ﬂuoroquinolones (as for
ciproﬂoxacin) and aminoglycosides (as for amikacin). The identiﬁcation
and susceptibility testing was performed via the Vitek II automated
system (Biomerieux, France), and when necessary susceptibility results
were conﬁrmed with the use of E-test strips (AB Biodisc, Sweden)
according to CLSI guidelines. EUCAST Enterobacteriaceae breakpoints
were used to interpret tigecycline MIC results.
Results: Susceptibility testing revealed 7% resistance to tigecycline for
K. pneumoniae. As for the other agents resistance to amikacin was
at 41%, to aztreonam at 72%, to ceftazidime at 72%, to imipenem
at 61% and to ciproﬂoxacin at 69%. Resistance to colistin (another
agent commonly used against multidrug resistant bacteria) was at 13%.
The majority of isolates resistant to tigecycline were resistant to the
previously mentioned antimicrobial agents as well, except for colistin.
With reference to this agent 23 isolates that were resistant to tigecycline
were found susceptible to colistin, while 14 isolates were resistant to
both agents.
Conclusions: Tigecycline maintains potent in vitro activity against most
isolates of K. pneumoniae and can be used when other agents are
excluded due to multidrug resistance. Nevertheless, due to the possibility
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of losing effectiveness, it is essential for a hospital to remain aware of
the susceptibility patterns of this new agent.
P1126 Comparison of tigecycline activity tested against multidrug-
resistant bacteria isolated from European medical centres
in two time periods: 2003–2005 and 2008–2010
H. Sader*, D. Farrell, P. Rhomberg, R. Jones (North Liberty, US)
Objectives: To compare the activities of tigecycline (TIG) and
comparators tested against bacteria with clinically important resistance
(R) phenotypes isolated in Europe (EU) in 2003–2005 (before TIG
was approved for clinical use) with those isolated in 2008–2010
(contemporary strains).
Methods: 6,345 clinical isolates, including 3,881 oxacillin-R S. aureus
(MRSA), 501 vancomycin (VAN)-R enterococci (VRE), 581 E. coli with
ESBL phenotype (ESBL-EC), 647 K. pneumoniae with ESBL phenotype
(ESBL-KPN), 112 meropenem (MER)-R KPN and 466 imipenem-R
Acinetobacter spp. (IMI-R-ASP), were collected from 48 hospitals in
18 EU countries and Israel. The isolates were tested for susceptibility
(S) by the CLSI microdilution broth method and EUCAST breakpoint
criteria were used for MIC result interpretations.
Results: Overall, 96.6% of strains were TIG-S and TIG MIC
distributions were very similar in the two time periods evaluated.
Two-thirds of TIG non-S strains were IMI-R-ASP with TIG MIC at
>1mg/L (EUCAST breakpoint for enterics). MRSA showed low S
to levoﬂoxacin (LEV; 8.1–11.4%) and clindamycin (50.2–64.7%), and
high S to TIG (>99.9%), VAN (100.0%), daptomycin (DAP; 100.0%),
linezolid (LZD; 99.9–100.0%) and cotrimoxazole (93.4–97.6%) in both
periods. Against VRE, TIG (MIC50/90, 0.06–0.12/0.25mg/L), DAP
(MIC50/90, 2−4/4mg/L) and LZD (MIC50/90, 1/2mg/L) were the most
active compounds (>99% S). 99.5% of ESBL-EC were S (MIC,
1mg/L) to TIG (MIC50/90, 0.25/0.5mg/L). ESBL-EC exhibited low
S to LEV (24.5–31.7%) and gentamicin (GEN; 54.2–59.9%) in both
time periods, but >99% of strains were S to MER. TIG inhibited 89.7–
91.7% of ESBL-KPN and 88.1–88.6% of MER-R-KPN at 1mg/L.
Only 29.6–35.8% of ESBL-KPN was S to GEN, and S to LEV and
MER dropped from 55.2 and 93.9% in 2003–2005 to 26.7 and 86.0% in
2008–2010, respectively. Among MER-R-KPN, S to amikacin and LEV
fell from 59.5 and 42.9% in 2003–2005 to 28.6 and 8.6% in 2008–2010,
respectively. Only 67.1% of MER-R-KPN isolated in 2008–2010 were S
to colistin. TIG (MIC50/90, 1/2mg/L; 66.7–73.1% inhibited at 1mg/L)
and the polymyxins (>99% S) were the most active compounds tested
against IMI-R-ASP.
Conclusion: TIG was very active against this large collection of
multidrug-R organisms and no trend toward decreased TIG activity
overtime was observed for any of the organisms or R subsets. TIG
demonstrated sustained potent in vitro activity and a broad-spectrum
against clinically important R organisms from EU hospitals.
P1127 In vitro activity of tigecycline against non-clonal
Stenotrophomonas maltophilia isolates from serious infection
sites
J. Steinmann*, J. Buer, P.M. Rath (Essen, DE)
Objective: Stenotrophomonas maltophilia is intrinsically resistant to
a plethora of antimicrobial agents that severely limit commonly used
empiric standard antimicrobial therapies. In this study we investigated the
in vitro activity of tigecycline against clinical isolates of S. maltophilia
by comparing Etest to the broth microdilution method (BMD).
Methods: In total, 105 S. maltophilia isolates were obtained from
serious infections sites in a tertiary single center in Germany in 2008
and 2009. Multi-copy strains were excluded from the analysis by
molecular ﬁngerprinting using a repetitive-sequence-based polymerase
chain reaction. Minimal inhibitory concentration values were determined
based on the Clinical Laboratory Standards Institute (CLSI) BMD
method. A tigecycline breakpoint of minor or equal than 2mg/L was
used according to most published studies.
Results: None of the S. maltophilia isolates was tested resistant against
tigecycline. MICs ranged from 0.19 to 2.0mg/L with a MIC50/MIC90 of
1.0/2.0mg/L by BMD. Agreement within one twofold dilution between
the Etest and the BMD method was 85.3%.
Conclusion: In this single center study tigecycline was highly effective
against nonclonal S. maltophilia isolates from serious infections sites.
P1128 Comparative MIC and MPC results for tigecycline
repeatedly tested against American Type Culture Collection
control strains: suggested MPC quality control value ranges
J.M. Blondeau*, C. Hesje, S.D. Borsos, L.D. Blondeau, B.J. Blondeau
(Saskatoon, CA)
Objectives: The minimum inhibitory concentration (MIC) determines
the minimum drug concentration inhibiting 105 cfu/ml of bacteria in
vitro whereas the mutant prevention concentration (MPC) determines
the minimum drug concentration required to block the growth of the
least susceptible cell of a 109 cfu inoculum applied to drug containing
agar plates. While MIC testing is standardized and controlled using
American Type Culture Collection (ATCC) strains, similar standardized
protocols are not yet available for MPC testing. We compared MIC and
MPC results with 2 ATCC strains repeatedly tested against tigecycline
to document MIC and MPC quality control (QC) ranges.
Methods: MIC testing was based on current Clinical and Laboratory
Standards Institute procedures using a 105 cfu/ml inoculum and for
MPC testing 109 CFU were inoculated to drug containing media-
each in 2-fold concentration increments. Optimal media, incubation in
established atmospheres and temperatures were used. For each organism
type, the lowest drug concentration preventing growth was recorded as
either the MIC or MPC. ATCC strains included S. aureus (SA) 29213
and E. coli (EC) 25922 tested against tigecycline.
Results: Following repeat MIC assays, MICs were within acceptable
QC limits: EC 25922 0.016–0.031, SA 29213 0.031–0.063. Following
repeat MPC testing, the following QC organism MPC results (mg/ml)
were noted against ATCC strains SA 29213, EC 25922 respectively: 0.5
and 1; 0.25 and 0.5. MPC values for the QC strains were within one
doubling dilution.
Conclusion: As with MIC testing, MPC testing provides reproducible
QC organism results that are consistent over narrow drug concentration
ranges with MPC values being within one doubling dilution against
the ATCC control strains tested. The MPC drug concentration ranges
presented may serve as a useful guide to insuring MPC assay accuracy
for clinical isolates of EC and SA tested against tigecycline.
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P1129 Dalbavancin surveillance results for European Gram-
positive species in a contemporary (2006–2009) sample of
23,825 strains
R. Jones*, D. Farrell, H. Sader (North Liberty, US)
Objectives: To assess the in vitro activity of dalbavancin (DALB) for
in vitro potency and breadth of spectrum against Gram-positive cocci (3
genera) isolated in European medical centers between 2006 and 2009.
Reference MIC susceptibility (S) testing methods (CLSI, M07-A8, 2009)
and EUCAST breakpoints were applied to comparator antimicrobials.
Methods: A total of 23,825 strains were tested as follows: S. aureus
(SA; 11,658 strains, 27.3% MRSA), coagulase-negative staphylococci
(CoNS; 4,343 strains, 77.5% oxacillin-resistant [R]), Enterococcus spp.
(4,982 strains; 525 strains were vancomycin-non-S, 10.5%), viridans
group streptococci (VGS; 845 strains) and b-haemolytic streptococci
(BHS; 1,995 strains). A total of 5,750 to 6,370 clinical isolates were
sampled each year from 13 nations (30 medical centers), the greatest
numbers from France (19.4%) and Germany (16.1%). Many strains were
from bacteremias (43.2%).
Results: DALB MIC results performed by validated reference methods
(0.002% polysorbate-80 supplement) demonstrated high potency versus
S. aureus (MIC90, 0.06mg/L; all strains inhibited at 0.25mg/L), as
well as CoNS (MIC90, 0.12mg/L), and all streptococci (MIC90, 0.03–
0.06mg/L). Only for VanA phenotype VRE was the DALB MIC at
>0.25mg/L for the majority of strains. In the EU, S. aureus and CoNS
were also highly S to daptomycin (DAP; 100.0%), vancomycin (VAN;
100.0%), linezolid (99.8–99.9%), and quinupristin/dalfopristin (98.2–
99.7%); but less so to teicoplanin (72.0–99.3%).
Conclusions: DALB exhibited stable, potent in vitro activity against an
updated surveillance collection (2006–2009) of Gram-positive pathogens
isolated in EU. The MIC90 results (0.03–0.12mg/L; Table) remain low
and DALB was generally eight- to 16-fold more potent than DAP and
VAN. This long-acting lipoglycopeptide continues to demonstrate high
potencies against EU pathogens through 2009.
P1130 Dalbavancin activity and spectrum evaluated against
a contemporary (2007–2009) worldwide collection of
staphylococci (62,590 strains)
R. Jones*, H. Sader, R. Mendes, D. Farrell (North Liberty, US)
Objectives: To update the in vitro proﬁle of dalbavancin (DALB),
an investigational lipoglycopeptide, for its anti-staphylococcal potency
and spectrum via the testing of a collection of clinical isolates
from 2006–2009. A total of 62,590 staphylococci were evaluated
(14,492−17,604/year) from the Asia-Paciﬁc region (11,692 strains),
Europe (16,001), Latin America (6,711) and North America (28,186).
Methods: All organisms were susceptibility (S) tested by CLSI (M07-
A8, 2009) reference MIC methods in a central laboratory design.
Staphylococcus species from 21 countries (201 medical centers) were
sampled as follows: S. aureus (SA: 50,271 strains; 44.5% MRSA),
and coagulase-negative staphylococci (CoNS; 12,373, 76.4% methicillin-
resistant [R], 23 species). DALB MIC results were determined
in validated panels equivalent to reference polysorbate-80 (0.002%)
containing broth media. All QC results were within published ranges
(CLSI M100-S20-U, 2010). Most isolates came from blood (63.0%),
lower respiratory or acute bacterial skin and skin structure infection
(ABSSSI) sources.
Results: DALB was highly active against SA (MIC50/90, 0.06/0.12
mg/L). Methicillin S or R did not inﬂuence DALB activity (Table)
and DALB potency remained stable across the monitored time interval
(2006–2009). All SA and 99.8% of CoNS were inhibited at 0.5mg/L,
only 30 CoNS had DALB MIC values at 1 or 2mg/L (a number
comparable to daptomycin, data not shown). DALB was 16- and four-
fold more potent than vancomycin and daptomycin, respectively. The sus-
ceptibility rates of comparator agents were not superior to DALB against
staphylococci e.g. daptomycin (99.8–99.9%), vancomycin (>99.9%),
linezolid (99.3–99.9%), teicoplanin (70.8–99.4%) and cotrimoxazole
(61.3–95.4%). No variations in DALB activity by geographic region
were observed.
Conclusions: DALB activity updated with contemporary staphylococcal
strains worldwide through 2009 shows sustained potent inhibition and a
modal MIC value at only 0.06mg/L. This level of potency was many-fold
greater than currently available glycopeptides or lipopeptide-class agents,
thus warranting renewed clinical investigations for several indications
where multidrug-R staphylococci may be prevalent.
P1131 Assessment of oritavancin activity tested against
b-haemolytic streptococci responsible for skin and skin
structure infections in Europe (2008–2010)
R. Mendes*, H. Sader, D. Farrell, R. Jones (North Liberty, US)
Objectives: To evaluate the antimicrobial activity of oritavancin (ORI)
and comparator agents tested against b-haemolytic streptococci (BHS)
responsible for documented skin infections in hospitalized patients from
Europe (EU). ORI is under ﬁnal clinical development for the treatment
of acute bacterial skin and skin structure infections (ABSSSI) in the
United States and EU.
Methods: BHS isolates (457) were consecutively collected from 29
hospitals in 13 EU nations, including Turkey and Israel, as part
of the SENTRY Antimicrobial Surveillance Program. Isolates were
submitted to a central laboratory where bacterial identiﬁcations were
conﬁrmed using standard algorithms and Vitek 2. Isolates were tested for
susceptibility (S) by CLSI methods (M07-A8, 2009). EUCAST (2010)
and CLSI (2010) interpretative criteria were applied. Isolates displaying
resistance to erythromycin (ERY), clindamycin (CLI) and tetracycline
(TET) were considered multidrug-resistant (MDR).
Results: Overall, ORI (MIC90, 0.12mg/L) and penicillin (PEN; MIC90,
0.06mg/L; 100% S) showed similar potency against all BHS. ORI
(MIC90, 0.12mg/L) was two-fold more active than daptomycin (DAP;
MIC90, 0.25mg/L, 100% S) and four- to eight-fold more active than
vancomycin (VAN; MIC90, 0.5mg/L, 100% S), linezolid (LZD; MIC90,
1mg/L, 100% S) and levoﬂoxacin (LEV; MIC90, 1mg/L, 95.0% S
[EUCAST]). CLI (91.4% S) was active against BHS, while ERY (81.2%
S) and TET (51.6% S) showed more limited coverage when EUCAST
criteria were applied. ORI (MIC50/90, 0.06/0.25mg/L) exhibited slightly
higher (two-fold) MIC results against year 2010 isolates compared
to previous years (MIC50/90, 0.03/0.12mg/L). VAN, DAP, LZD, LEV
and PEN remained active (92.9% S) when tested against to MDR
strains. ORI (MIC50/90, 0.06/0.25mg/L) exhibited equivalent MIC90
values compared DAP (MIC50/90, 0.25/0.25mg/L) against MDR BHS;
however, ORI was two- to 16-fold more active than VAN (MIC50/90,
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0.5/0.5mg/L) and LZD (MIC50/90, 1/1mg/L) against MDR strains. ORI
(MIC50/90, 0.03/0.12mg/L) was slightly (two-fold) more active against
Groups A and C BHS when compared with Groups B and G (MIC50/90,
0.06/0.25mg/L).
Conclusions: Based on MIC90 values, ORI showed in vitro activity
equivalent to or greater than those of comparator agents with similar
clinical indications, tested against a contemporary collection of BHS. In
addition, ORI inhibited >99% of all BHS at 0.25mg/L.
P1132 Analysis of oritavancin activity tested against a challenge
set of Staphylococcus aureus from Europe (2008–2010)
R. Mendes*, H. Sader, D. Farrell, R. Jones (North Liberty, US)
Objectives: To assess the activities of oritavancin (ORI) and comparators
tested against S. aureus (SA) from Europe (EU). In addition, this analysis
includes categorization of strains with decreased susceptibility (S) to
vancomycin (VA), teicoplanin (TE) and daptomycin (DA). ORI has
demonstrated potent activity against Gram-positive isolates, including
VA-resistant staphylococcal and enterococcal strains. Moreover, it has
been demonstrated that ORI possesses multiple mechanisms of actions.
Methods: 7,053 consecutive, non-duplicate SA were collected from 29
hospitals in 13 EU countries, including Turkey and Israel, as part of the
SENTRY Antimicrobial Surveillance Program. Isolates were submitted
to a central monitoring laboratory and species identiﬁcation conﬁrmed
by conventional parameters and Vitek 2, as needed. Isolates were S tested
using CLSI methods (M07-A8, 2009). EUCAST interpretive criteria
(2010) were applied, when available. ORI activity was also evaluated
against a challenge set of strains displaying elevated MIC values for VA
(2mg/L), TE (2−8mg/L) and DA (1−2mg/L).
Results: Most isolates were from bacteremia (38.5%) and skin and skin
structure infections (37.8%). ORI (MIC50/90, 0.03/0.06mg/L) was eight-
fold more potent than DA (MIC50/90, 0.25/0.5mg/L) and 16- to 32-fold
more active than VA (MIC50/90, 1/1mg/L) and linezolid (LZ; MIC50/90,
1/2mg/L) when tested against all SA. ORI exhibited similar potency
when tested against methicillin-susceptible SA (MSSA) with decreased S
to VA (MIC50/90, 0.03/0.06mg/L), TE (MIC50/90, 0.03/0.06mg/L) or DA
(MIC50/90, 0.03/0.12mg/L) compared to their respective counterparts
with lower MIC results (all MIC50/90, 0.03/0.06mg/L; Table). When ORI
was tested against a challenge set of methicillin-resistant SA (MRSA),
slightly higher (two- to four-fold) MIC50/90 values were noted for those
strains with elevated MIC results for VA (MIC50/90, 0.03/0.12mg/L),
TE (MIC50/90, 0.03/0.12mg/L) and DA (MIC50/90, 0.06/0.25mg/L).
Conclusions: ORI exhibited overall greater potency (eight-fold) than
four comparators against all SA. When tested against a challenge set
of MSSA clinical isolates, ORI sustained high activity. ORI showed
higher MIC values against MRSA strains with elevated MIC results for
VA, TE and DA, yet inhibiting all SA at 0.25mg/L. The ORI multiple
mechanisms of actions likely provide advantageous in vitro activity even
against isolates with decreased S to same class agents.
P1133 Activity of a novel cyclic lipopeptide, CB-183,315 against
Gram-positive aerobic and anaerobic enteric isolates,
including vancomycin-resistant enterococci and C. difﬁcile
strains with elevated MICs to metronidazole, vancomycin
and ﬂuoroquinolones
D.R. Snydman*, N.V. Jacobus, L.A. McDermott (Massachusetts, US)
Objective: To evaluate in vitro activity of CB-183,315, a novel
cyclic lipopeptide, vs recent clinical aerobic and anaerobic Gram
positive intestinal isolates, including Clostridium difﬁcile, Clostridium
species, Peptostreptococci, Gram-positive-non-spore-forming-anaerobic-
bacilli (GPNSF), enterococci and S aureus.
Methods: The isolates were obtained from patients at Tufts Medical
Center. Resistant strains were included. The MICs vs 199 isolates
were determined by agar dilution following CLSI recommendations.
The activities of CB-183,315 vs the anaerobes were compared to
those of amoxicillin:clavulanate, clindamycin, linezolid, metronidazole,
meropenem, minocycline, vancomycin, moxiﬂoxacin and piperacillin-
tazobactam. Against enterococci, CB-183,315 was compared to dapto-
mycin, ampicillin, levoﬂoxacin, minocycline, erythromycin and linezolid.
For staphylococci, amoxicillin:clavulanate, meropenem, cefuroxime and
trimethoprim:sulfamethoxazole were added. Forty percent of C. difﬁcile,
all from toxin positive stools, were quinolone-resistant, some with MICs
to metronidazole 16 mcg/mL and elevated MICs to vancomycin.
Results: (See table).
Summary: CB-183,315 showed very good activity vs enteric Gram
positive anaerobic and aerobic pathogens. CB-183,315 showed excellent
activity vs 16 quinolone-resistant C. difﬁcile as well as 9 C. difﬁcile
with MICs to metronidazole of 16 mcg/mL and 6 isolates with
vancomycin MICs of 4 mcg/mL. CB-183,315 also showed good activity
against peptostreptococci. CB-183,315 exhibited good activity against
enterococci including 21 vancomycin-resistant strains as well as against
oxacillin-resistant enteric S. aureus pathogens.
Conclusion: Our results showed that CB-183,315 is a potential agent
for the treatment of enteric infections in particular those caused by
antimicrobial resistant strains, including C. difﬁcile.
P1134 Potency of radezolid (RX-1741) and torezolid (DA-7157)
tested against a collection of linezolid-non-susceptible
strains with genetically deﬁned resistance mechanisms
D. Farrell*, R. Mendes, H. Sader, R. Jones (North Liberty, US)
Objectives: To provide a potency evaluation of the investigational
oxazolidinone radezolid (RX-1741), against another investigational
oxazolidinone, torezolid (DA-7157), and linezolid when tested by
reference methods against a collection of linezolid-non-susceptible
(NS) Gram-positive cocci having genetically deﬁned mechanisms of
oxazolidinone resistance.
Methods: A total of 90 linezolid-NS Gram-positive cocci, obtained
through the SENTRY Antimicrobial Surveillance Program, were tested
for susceptibility by CLSI broth microdilution methods (M07-A8 and
M100-S20-U). Linezolid, radezolid and torezolid were manufactured
by Rib-X Pharmaceuticals, Inc. Torezolid could not be tested at
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concentrations greater than 32mg/L due to solubility interference.
Strains were screened for mutations in the 23S rRNA, L3 and L4
encoding genes by PCR and DNA sequencing, and for the presence
of the cfr gene.
Results: From this linezolid-NS strain collection, 40 coagulase-negative
staphylococci (CoNS) isolates were shown to possess a broad variety of
linezolid resistance mechanisms, which included 23S rRNA, L3 and L4
mutations and cfr, alone or in combination. The S. aureus strains tested
were either 23S rRNA G2576T mutants or cfr positive. All E. faecalis
and E. faecium isolates contained G2576T mutations, except for one
strain that exhibited only a L4 F101L alteration. Data describing the
antimicrobial activity of the three oxazolidinone compounds against
these organisms are shown in the table below.
Conclusions: Radezolid and torezolid both demonstrated enhanced ac-
tivity against this collection of 90 linezolid-NS strains. Radezolid showed
at least two-fold greater potency when compared directly to torezolid
against most strains. These investigational oxazolidinones demonstrate
encouraging in vitro activity against contemporary linezolid-NS Gram-
positive pathogens.
P1135 The investigation of antimicrobial activity of 5 heterocyclic
compounds against some clinical isolates of oral streptococci
G. Bancescu*, M. Radu-Popescu, A. Bancescu, A. Neagu, M. Nica,
A. Dascalu, I. Nistor, S-F. Barbuceanu (Bucharest, RO)
Objectives: The aim of this work was to investigate the antimicrobial
activity of newly synthesized heterocyclic compounds of the classes:
1,2,4-triazole, 1,3,4-thiadiazole and 1,3,4-oxadiazole (characterized by
spectral and elemental analysis and recently reported by the last author
of this study) against some oral streptococcal isolates of different species.
Methods: The minimum inhibitory concentrations (MIC) of the fol-
lowing 5 compounds: 4-(4-ﬂuorophenyl)-1-(4-(phenylsulfonyl)benzoyl)-
thiosemicarbazide (C1), 4-(4-ﬂuorophenyl)-5-(4-(phenylsulfonyl)phenyl)
-2H-1,2,4 - triazole -3(4H) - thione (C2), ethyl 2 - (4 - (4 -ﬂuorophenyl) -
5 - (4 - (phenylsulfonyl)phenyl) -4H-1,2,4 - triazol -3 -ylthio)acetate (C3),
N-(4-ﬂuorophenyl) -5- (4- (phenylsulfonyl)phenyl) -1,3,4- thiadiazol -2-
amine (C4), and N-(4-ﬂuorophenyl)-5-(4-(phenylsulfonyl)phenyl)-1,3,4
-oxadiazol-2-amine (C5), were determined by the broth microdilution
method against 64 oral streptococcal strains isolated from paediatric
patients with respiratory infections at 3 hospitals in Bucharest, in 2009.
In addition, the minimum bactericidal concentrations (MBC) of the
5 compounds were determined against the isolates belonging to the
species: S. oralis (33 strains), S. mitis (17 strains), S. sanguinis (9
strains), S. parasanguinis (2 strains), S. constellatus (2 strains) and
S. anginosus (1 strain).
Results: The MIC values ranged between: 32–256mg/l for C1 and C3,
8–256mg/l for C2, 128–256mg/l for C4 and 64–256mg/l for C5. C2
presented the best growth inhibition activity against all isolates except for
the single strain of S. anginosus, when the same MIC value (256mg/l)
was obtained for all tested compounds. The MIC value of C1 and C3
which inhibited 50% of S. oralis, S. mitis and S. sanguinis isolates was
32mg/l, while the MIC50% value of C4 and C5 was 128mg/l. For C2,
the median value of MIC was 16mg/l against S. sanguinis and 32mg/l
against both S. oralis and S. mitis. The MBC/MIC ratios were less or
equal to 4 in all cases.
Conclusion: Acylthiosemicarbazide (C1) and S-alkylated 1,2,4-triazole
derivative (C3) showed a better growth inhibition action compared to
thiadiazole (C4) and oxadiazole (C5) derivatives. The highest degree of
antibacterial activity was found in the case of 1,2,4-triazole-3(4H)-thione
(C2), which might be subjected to other chemical reactions in order to
further improve its antimicrobial action. This work was supported by
CNCSIS − UEFISCSU, project number 1136/12.01.2009 PNII − IDEI
code 2652/2008.
P1136 Antimicrobial activity of solithromycin (CEM-101), a novel
ﬂuoroketolide, tested against isolates collected in Europe
during 2010 surveillance
D. Biedenbach, H. Sader, R. Jones, D. Farrell* (North Liberty, US)
Objective: To evaluate the potency and spectrum of solithromycin
(SOL), a novel ﬂuoroketolide, against a contemporary (2010) collection
of European (EU) pathogens associated with community-acquired
bacterial pneumonia (CABP) and acute bacterial skin and skin structure
infections (ABSSSI), compared to erythromycin (ERY), azithromycin
(AZI), clarithromycin (CLA), clindamycin (CLI) and telithromycin
(TEL).
Methods: 6,378 isolates collected from 41 medical centers (18
EU countries) in 2010 were included. Species/group (number of
isolates) were: Staphylococcus aureus (SA; 2,539), coagulase-negative
staphylococci (CoNS; 610), enterococci (ENT; 934), Streptococcus
pneumoniae (SPN; 764), viridans group streptococci (VGS; 274),
b-haemolytic streptococci (BHS; 762), Haemophilus inﬂuenzae (HI;
326) and Moraxella catarrhalis (MCAT; 169). Consecutive isolates were
susceptibility (S) tested by CLSI broth microdilution methods and results
were interpreted by CLSI and EUCAST breakpoints.
Results: SOL was eight-fold more active (MIC90, 0.25mg/L) against SA
compared toTEL (MIC90, 2mg/L) with off-scale MIC90 values found for
ERY (>4mg/L) and CLI (>2mg/L). SOL (MIC50/90, 0.03/>4mg/L)
had a comparable activity to TEL against CoNS (74.3% S). SOL was
only moderately active against ENT (MIC50/90, 0.5/2mg/L), but was
two-fold more potent than TEL (MIC50/90, 1/4mg/L). SOL demonstrated
greater potency against E. faecalis (EF) (MIC50, 0.06mg/L) compared
to E. faecium (EFM; MIC50, 1mg/L). SOL was very active against SPN
(MIC90, 0.03mg/L), VGS and BHS (MIC90, both 0.03mg/L) with
100.0% of all streptococcal isolates inhibited at 0.5mg/L. The SPN
isolates were only 72.8, 75.1 and 82.5% S to penicillin (PEN), ERY
and CLI, respectively. SOL was very active against MCAT (MIC90,
0.06mg/ml) with lower activity against both b-lactamase-positive and
-negative HI isolates (MIC90, 2mg/ml). SOL activity against HI was four-
fold more active than ERY against MCAT. The EU collection sampled
had 27.1% MRSA, 71.8% MR-CoNS, 1.2% vancomycin-resistant (VR)-
EF, 18.1% VR-EFM, 22.3% PEN non-S VGS and 15.3% of HI were
b-lactamase-positive.
Conclusions: SOL clearly exhibited greater potency than currently
available macrolide agents, CLI and TEL. Against contemporary (2010)
EU pathogens commonly isolated in CABP or ABSSSI. This data
supports clinical trial investigations of SOL for the treatment of these
infections.
P1137 Activity of JNJ-Q2, a new ﬂuoroquinolone, tested against
contemporary (2010) European pathogens isolated from
patients with community-acquired bacterial pneumonia
D. Farrell*, L. Liverman, P. Rhomberg, R. Jones (North Liberty,
Morrisville, US)
Objectives: To determine the activity of JNJ-Q2 tested against contem-
porary (2010) European isolates of the most common bacterial species
isolated from patients with community-acquired bacterial pneumonia
(CABP). JNJ-Q2 is a broad-spectrum bactericidal ﬂuoroquinolone (FQ)
with potent activity against Gram-positive and -negative pathogens,
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including methicillin-resistant Staphylococcus aureus (MRSA), and is in
early clinical development for the treatment of CABP and acute bacterial
skin and skin structure infection.
Methods: A total of 983 respiratory pathogens were collected
from patients with CABP in 22 medical centres in 11 countries
(including Turkey and Israel). Species (number of isolates tested)
were: Streptococcus pneumoniae (SPN, 543), Haemophilus inﬂuenzae
(HI, 308), and Moraxella catarrhalis (MC, 132). Isolates were tested
for susceptibilities by CLSI broth microdilution methods (M07-A8).
Susceptibility rates for comparator agents were determined using
EUCAST breakpoints.
Results: The table shows the cumulative percentage MIC frequency
against each species tested. JNJ-Q2 was highly active against all
three species inhibiting >95% of all 983 isolates at a JNJ-Q2 MIC
of 0.015mg/L. Against SPN, resistances to penicillin, erythromycin,
ciproﬂoxacin (CIP), levoﬂoxacin (LEV) and MOX were 6.1, 27.4, 3.7,
1.1 and 1.1%, respectively, with JNJ-Q2 (MIC50/90, 0.015/0.015mg/L)
demonstrating at least four-fold higher activity compared to MOX
(MIC50/90, 0.12/0.25mg/L) and 32-fold higher activity than LEV
(MIC50/90, 1/1mg/L) and CIP (MIC50/90, 1/2mg/L). 14.9% of HI were
resistant to ampicillin. JNJ-Q2 (MIC50/90, 0.004/0.015mg/L) was at
least four-fold more active than MOX (MIC50/90, 0.015/0.03mg/L)
against HI. JNJ-Q2 (MIC50/90, 0.015/0.015mg/L) was also four-fold
more active than MOX (MIC50/90, 0.06/0.06mg/L) against MC.
Conclusions: JNJ-Q2 demonstrated very potent activity against this
collection of three common respiratory bacterial pathogens isolated from
patients with CABP in European hospitals during 2010, and historically
also covers MRSA. JNJ-Q2 also demonstrated four-fold or greater
activity compared to CIP, LEV and MOX against all three species,
including against strains resistant to these ﬂuoroquinolone antimicrobial
agents. These JNJ-Q2 in vitro results are very promising and support
clinical development of this new FQ for treatment of CABP.
P1138 Activity of JNJ-Q2, a new ﬂuoroquinolone, tested against
contemporary (2010) European pathogens isolated from pa-
tients with acute bacterial skin and skin-structure infections
D. Farrell*, L. Liverman, P. Rhomberg, R. Jones (North Liberty,
Morrisville, US)
Objectives: To determine the activity of JNJ-Q2 tested against
contemporary (2010) European isolates of the most common bacterial
species isolated from patients with acute bacterial skin and skin-structure
infections (ABSSSI). JNJ-Q2 is a broad-spectrum bactericidal ﬂuoro-
quinolone (FQ) with potent activity against Gram-positive and -negative
pathogens, including methicillin-resistant (MR) Staphylococcus aureus
(SA), and is in early clinical development for the treatment of ABSSSI
and community-acquired bacterial pneumonia.
Methods: A total of 750 pathogens were collected from patients with
ABSSSI in 25 medical centres in 12 European countries (including
Turkey and Israel) in 2010. Species/organism group (number of isolates
tested) were: SA (635) and b-hemolytic streptococci (BHS, 115;
33.0% S. pyogenes). Isolates were tested for susceptibility by CLSI
broth microdilution methods (M07-A8 and M100-S20-U). Susceptibility
interpretations for comparator agents were determined using EUCAST
(2010) and CLSI breakpoints.
Results: The table shows the cumulative percentage MIC frequency
against the species/groups tested. Against 635 SA, JNJ-Q2 (MIC50/90,
0.008/0.25mg/L) inhibited all isolates at a MIC 2mg/L. Although
activity was lower against MRSA (MIC50, 0.25mg/L) compared to
methicillin-susceptible (MS) SA (MIC50, 0.008mg/L), 98.1% of MRSA
were inhibited at a JNJ-Q2 MIC value of 0.5mg/L. Against MRSA,
JNJ-Q2 was four- to 16-fold more active than moxiﬂoxacin (MOX;
MIC50/90, 4/8mg/L) and at least 32-fold more active than levoﬂoxacin
(LEV; MIC50/90, 8/8mg/L) and ciproﬂoxacin (CIP; MIC50/90,
8/8mg/L). JNJ-Q2 demonstrated excellent activity (MIC50/90,
0.008/0.015mg/L) against BHS, inhibiting 100.0% of isolates at a
MIC of 0.03mg/L. JNJ-Q2 was 16-fold more active than MOX
(MIC50/90, 0.12/0.25mg/L) and 64-fold more active than CIP (MIC50/90,
0.5/1mg/L) against BHS.
Conclusions: JNJ-Q2 demonstrated very potent activity against this
collection of common bacterial pathogens isolated from patients with
ABSSSI in European medical centers year 2010. JNJ-Q2 also exhibited
four-fold or greater activity compared to CIP, LEV and MOX against
these isolates. The JNJ-Q2 in vitro results were very promising and
support further clinical development of this new FQ for treatment of
ABSSSI, including cases caused by MRSA.
P1139 Activity of ﬁnaﬂoxacin, a ﬂuroquinolone with
enhanced activity at acid pH, against intracellular
Legionella pneumophila: comparison with azithromycin,
clarithromycin, telithromycin, ciproﬂoxacin and moxiﬂoxacin
S. Lemaire*, P. Tulkens, F. Van Bambeke (Brussels, BE)
Background: LP invades macrophages and multiplies in moderately
acidic vacuoles (Sturgill-Koszycki & Swanson, J Exp Med 2000,
192:1261−72). Macrolides and quinolones are commonly recommended
treatment for LP infections. In this context, our aim was to examine
the activity FNX (a novel ﬂuoroquinolone exhibiting increased activity
under acidic conditions [Higgins et al., AAC 2010, 54:1613−5]) against
intracellular LP.
Methods: L. pneumophila ATCC 33153 and THP-1 cells were used.
MICs were measured in a-ketoglutarate buffered yeast extract (pH
6.9). Infection of THP-1 cells was performed as described earlier
(Lemaire et al. AAC 2009, 53:3734–3743). Brieﬂy, cells were allowed
to phagocytize bacteria at a 10:1 bacteria per cell ratio (2 h). Non-
phagocytized bacteria were eliminated by incubation in Phosphate
Buffer Saline (PBS) supplemented with 50mg/L gentamicin (1 h, MIC:
0.25mg/L) and 4 successive washings with PBS. Infected cells were then
transferred in fresh culture medium containing FNX and comparators
covering a wide range of concentrations to obtain full concentration-
dependent effects. After 48 h, cells were harvested, washed with PBS,
lysed and used for enumeration of CFUs and assay of cell protein.
Data were used to determine the apparent static concentration (Cs) of
each antibiotic and its activity (change in log cfu) at a concentration
corresponding to the reported human Cmax.
Results:MICs, Cs and change in log cfu at Cmax are shown in the Table.
Except for AZM, all antibiotics achieved a static effect at concentration
similar to (CIP, MXF) or slightly above their MIC (CLR, TEL and FNX).
At Cmax, AZM was unable to control intracellular bacterial growth,
CLR and TEL were modestly and equally effective, whereas quinolones
showed a clear ranking of efﬁcacy (CIP < MXF < FNX), with FNX
yielding an close to bactericidal effect (deﬁned by a 3 log cfu decrease).
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Conclusions: Compared to macrolides, quinolones appear more effective
against intracellular LP. Amongst them, FNX shows the greatest activity
at clinically-relevant concentrations, perhaps in relation to its improved
activity at acidic pH.
P1140 The activity of ozenoxacin (GF-001001−00) against atypical
bacteria
I. Morrissey, K. Maher*, C. Tarrago´, A. Guglietta (Fordham, UK;
Barcelona, ES)
Objective: To determine the in vitro activity of Ozenoxacin (OZN), a
novel non-ﬂuorinated quinolone with no halogen substituent at 8-position
currently in phase III clinical trials, against atypical bacteria.
Methods:MIC was determined for OZN and levoﬂoxacin (LFX) against
Chlamydophila pneumoniae or Chlamydia trachomatis (McCoy cell
culture line in a supplemented minimal growth medium), Mycoplasma
spp or Ureaplasma urealyticum (broth microdilution in Mycoplasma
Broth Base) and Legionella pneumophila (agar dilution in supplemented
bacteriological agar). OZN and rifampicin (RIF) were tested against
Mycobacterium tuberculosis (CLSI agar dilution).
Results: Summary MIC data are shown in the Table.
Conclusions: OZN was more active than LFX against all atypical
pathogens. OZN and RIF showed similar activity againstM. tuberculosis.
These results support the continued development of OZN as a new
antibacterial agent.
P1141 In vitro activity of omadacycline (PTK796) in broth plus
lung surfactant or human serum
A. Macone, J. Donatelli, M. Draper*, S. Tanaka (Boston, US)
Objective: Determine the effects of lung surfactant and human serum
on the in vitro activity of omadacycline (OMC).
Methods: MICs were performed in three systems. Cation-adjusted
Mueller Hinton broth was used according to standard CLSI microdilution
procedures, in addition to broth enriched with 1% bovine surfactant,
and 25%-50% human serum. The strains included were clinical Gram-
positive, S. aureus, S. pneumoniae, also Gram-negative, E. coli and
H. inﬂuenzae, selected to include a range of susceptibilities, and
appropriate ATCC controls. Doxycycline (DOXY) and daptomycin
(DAPTO) were tested as comparators.
Results: MIC ranges in all three systems are shown in Table 1.
Conclusions: MICs of omadacycline did not increase with the addition
of surfactant or serum for either Gram positive or Gram negative
organisms. The in vitro activity of
DAPTO was markedly affected by surfactant, as well as serum reﬂecting
its high protein binding character. DOXY activity was not affected by
surfactant but exhibited some decreases in activity in the presence of
serum. The inhibition of activity of daptomycin by lung surfactant has
been suggested as the explanation for its lack of efﬁcacy in pneumonia.
(Silverman, JA et al., JID 191:2149–2152. 2005). In contrast, OMC was
not affected by surfactant. This ﬁnding supports the potential use of
OMC in treating pneumonia caused by susceptible bacteria.
P1142 In vitro activity of TP-2758 against panels of recent
bacterial clinical isolates
T. Grossman*, W. O’Brien, C. Fyfe, C. Sun, W. Zhang, J. Sutcliffe
(Watertown, US)
Background: TP-2758 is a novel, fully-synthetic IV/oral antibiotic based
on the proven tetracycline core. TP-2758 was selected from more than
2000 analogs on the basis of its potent antibacterial activity, especially
against multidrug-resistant (MDR) Gram-negative bacteria.
Methods: Using standard CLSI methodology, TP-2758 and clinical
comparators were tested against recent clinical isolates. In vitro
bactericidal activity over 24 hours was determined using standard time-
kill assays and vigorous aeration.
Results: MIC90 results are in Table. TP-2758 was bactericidal against
some, but not all Gram-negative isolates, including Enterobacteriaceae
producing extended-spectrum b-lactamases (ESBL+), Acinetobacter
baumannii, and Proteus mirabilis. TP-2758 also had good antimicrobial
potency against MDR Gram-positive pathogens, with representative
MIC90 values of 0.5, 0.12, 2, 2, and 0.12 mcg/mL for MRSA (n = 105),
MSSA (n = 50), Enterococcus faecalis (n = 59), Enterococcus faecium
(n = 15), and Streptococcus pneumoniae (n = 111).
Conclusion: TP-2758 is 2- to 4-fold more potent than tigecycline
against Gram-negative pathogens and 2- to 32-fold less active against
Gram-positive pathogens. This novel tetracycline strongly targets
MDR Gram-negative bacteria and its potential as a unique IV/oral
therapy for treatment of ESBL-producing and carbapenem-resistant
Enterobacteriaceae is being investigated.
P1143 E-101, a novel ﬁrst-in-class topical anti-infective, has potent
activity against clinical isolates of important pathogens in
Europe collected from 2008–2010
C. Pillar*, G.A. Denys, P. O’Hanley, J.T. Stephens Jr., D.F. Sahm
(Chantilly, Indianapolis, Little Rock, US)
Objectives: E-101 is a novel topical antimicrobial developed in Europe
for the prevention of surgical site infections (SSI). Its unique mechanism
of action utilizes myeloperoxidase (MPO) to produce reactive oxygen
species that kill bacteria locally. As with any new agent, it is important
to understand its current activity proﬁle and to monitor for changes
in that proﬁle that may indicate the emergence of resistance. This
study reports the in vitro activity of E-101 against European isolates
of SSI pathogens alongside key comparators (currently utilized agents
and important phenotypic markers).
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Methods: 260 non-duplicate clinical isolates of S. aureus, coagulase-
negative staphylococci (CoNS), enterococci, enterics (E. coli, K. pneu-
moniae, P. mirabilis, and E. cloacae), and P. aeruginosa collected from
27 sites across 8 countries in Europe were evaluated. E-101 was evaluated
using a modiﬁed broth microdilution method based on CLSI guidelines
(M7) in which MPO was serially diluted and inocula were delivered
in enzyme substrate. E-101 MICs represent mg/L of MPO. Comparator
agents were evaluated in accordance with CLSI M7 and M100.
Results: E-101 had an MIC50 and MIC90 of 0.015mg/L against
S. aureus and CoNS. Among staphylococci, 18% of S. aureus and 77%
of CoNS were methicillin resistant, while 100% were susceptible to
vancomycin, linezolid, and daptomycin. E-101 had an MIC50/MIC90
of 0.06/0.12mg/L against E. faecium (13% vancomycin resistant)
and 0.25/0.25mg/L against E. faecalis (no vancomycin resistance).
Against enterics, E-101 had similar activity by MIC50/MIC90 (mg/L)
across evaluated species (E. coli: 0.06/0.06, K. pneumoniae: 0.12/0.12,
P. mirabilis: 0.03/0.06, E. cloacae: 0.06/0.12). Among enterics, resistance
to imipenem was not observed and resistance to ceftazidime varied
by species (3% for E. coli and P. mirabilis, 14% for K. pneumoniae,
and 20% for E. cloacae). Of the evaluated P. aeruginosa, resistance
to most comparators (gentamicin, imipenem, levoﬂoxacin, piperacillin/
tazobactam) was 10−20%, and E-101 had an MIC50/MIC90 of
0.03/0.06mg/L.
Conclusions: Based on the in vitro activity proﬁle, E-101 has potent
activity against European clinical isolates of both Gram-positive and
Gram-negative pathogens commonly associated with SSI. There is no
apparent impact of current resistance common among these species on
the activity proﬁle of E-101. These data illustrate the potential of E-101
for the prevention of SSI.
P1144 E-101, a novel ﬁrst-in-class topical anti-infective, maintains
a high degree of potency in vitro against problematic
resistant clinical pathogens (ESKAPE pathogens)
C. Pillar*, G.A. Denys, P. O’Hanley, J.T. Stephens Jr., D.F. Sahm
(Chantilly, Indianapolis, Little Rock, US)
Objective: E-101, a topical anti-infective which utilizes myeloperoxidase
(MPO) for the generation of reactive oxygen species to kill bacteria, is
being developed for the prevention of surgical site infections. Infections
caused by antibiotic resistant pathogens have become common and are
increasingly difﬁcult to treat. This study evaluates the activity of E-101
against highly resistant “ESKAPE” pathogens (vancomycin resistant
E. faecium [VRE], methicillin resistant S. aureus [MRSA], extended
spectrum b-lactamase [ESBL]/carbapenemase producing K. pneumoniae,
multi-drug resistant [MDR] A. baumannii and P. aeruginosa, and AmpC
cephalosporinase producing E. cloacae).
Methods: E-101 activity was evaluated using a modiﬁed broth
microdilution method based on CLSI M7. Modiﬁcations included serial
dilution of enzyme (MPO) and inocula delivery in solution containing
enzyme substrate. E-101 MICs represent mg/L of MPO. Comparators
(currently marketed agents and phenotypic markers) were tested in
accordance with CLSI M7 and M100. 115 non-duplicate clinical isolates
were pre-selected based on resistance phenotype for evaluation to include
the “ESKAPE” phenotypes noted above.
Results: Against VRE, E-101 had an MIC50/MIC90 of 0.06/0.12mg/L.
Against S. aureus consisting of linezolid resistant isolates, daptomycin
non-susceptible isolates, hospital and community acquired MRSA,
VISA, and VRSA, E-101 had an MIC50/MIC90 of <0.008/0.015mg/L
with MICs not exceeding 0.06mg/L. E-101 had an MIC50 and
MIC90 0.12mg/L against ESBL E. coli, ESBL K. pneumoniae, and
KPC K. pneumoniae, with an MIC50 and MIC90 of 0.06mg/L
against E. cloacae/C. freundii with derepressed AmpC. Against MDR
P. aeruginosa, E-101 had an MIC50/MIC90 of 0.03/0.06mg/L, with an
MIC50 and MIC90 of 0.03mg/L against MDR A. baumannii. E-101
activity against this subset of purely resistant isolates was equivalent to
that observed for E-101 during recent surveillance where isolates with
these phenotypes were infrequently or not encountered.
Conclusions: E-101 was potent in vitro against ESKAPE pathogens,
which constitute clinically important pathogens with problematic
resistance (multi-drug resistance, emerging resistance to commonly
utilized agents). This attribute highlights the utility of E-101 for the
treatment of surgical site infections where resistant organisms are likely
to be encountered, and potential for the treatment of other superﬁcial
infections caused by resistant organisms.
P1145 Antibacterial activity of nanosized TiO2 against Escherichia
coli
M. Sredkova*, A. Stoyanova, H. Hitkova, R. Iordanova, Y. Dimitriev,
A. Bachvarova-Nedelcheva (Pleven, Soﬁa, BG)
Objectives: The photocatalytic disinfection property of TiO2 has been in
particular interest from the ﬁrst research work of Matsunaga et al., 1985
to nowadays. The bactericidal action of TiO2 photocatalytic reaction
depends on the type and the source of TiO2 and may differ according to
the kind of microorganism. The aim of the present study is to evaluate the
efﬁciency of nanosized TiO2 synthesized by nonhydrolytic route against
Escherichia coli as representative species of bacteria.
Methods: The synthesis of titanium oxide nanoparticles was carried
out following the procedure described by Niederberger et al. (2002)
which is based on the nonhydrolytic sol-gel reaction of benzyl alcohol
and titanium tetrachloride. The reaction was performed at 80ºC under
vigorous stirring. The obtained white suspension was centrifuged and
the collected material was dried and calcinated at 500ºC. The particle
size of thus prepared TiO2 (anatase) was about 10−20 nm and it was
characterized by XRD, IR and SEM.
Antimicrobial activity measurements were performed by E. coli (ATCC
25922). Serial dilution of the E. coli-containing stock solution with PBS
buffer was performed to yield starting concentration of approximately
105 colony forming units (CFU) ml-1.
The bacteria growth was examined by the effect of UV light alone, in
the presence of TiO2 at dark conditions and in the presence of both −
TiO2 and UV radiation. The experiments were continued up to 3 hours
at 25ºC. The dynamics of antimicrobial action was assessed by killing
curves determination.
Results: Our data showed that the antimicrobial activities of TiO2 and
UV light alone were very similar − the number of E. coli cells was
reduced about 50% for 60 min. In contrast, the combination of TiO2
and UV radiation led to complete killing of bacteria in 30 min. It can
be concluded that the removal efﬁciency due to joint action of TiO2 and
UV radiation was markedly increased in comparison to UV radiation or
TiO2 alone.
Conclusion: The synthesized TiO2 (anatase) by nonhydrolytic method
possesses strong bactericidal activity and could be used effectively for
disinfection under UV illumination.
P1146 Activity of the novel sulfactam BAL30072, alone and in
combination with meropenem, against Enterobacteriaceae
harbouring the NDM-1 b-lactamase
T. Walsh*, J. Weeks, M. Toleman, W. Stubbings, M. Page, M. Jones
(Brisbane, AU; Cardiff, UK; Basel, CH)
Objectives: BAL30072 (manufactured by Basilea Pharmaceutica Inter-
national Ltd.) is a new sulfated monocyclic b-lactam not hydrolysed
by metallo b-lactamases (MBLs) and with activity against a broad
spectrum of Gram-negative pathogens, including multidrug resistant
P. aeruginosa and A. baumannii. NDM-1 is a new MBL originating in
India and recently isolated from pathogens infecting patients in Europe.
We investigated the in-vitro activity of BAL30072 alone and in a 1:1
combination with meropenem (MEM) against recent clinical isolates of
carbapenem-resistant Enterobacteriaceae harbouring the NDM-1MBL.
Methods: 78 Enterobacteriaceae comprising: E. coli (n = 33), K. pneu-
moniae (n = 43), K. oxytoca (n = 1) and P. rettgeri (n = 1) were
collected from hospitalized patients in India during 2009. A sample
of strains further characterised contained up to 7 b-lactamases
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including, TEM, OXA, SHV, DHA-1, CTX-M-15, CMY and NDM-1.
MICs of BAL30072, MEM, ceftazidime (CAZ), aztreonam (ATM)
and 1:1 combination of BAL30072:MEM were determined by broth
microdilution according to CLSI standards. All isolates were screened
using PCR for the presence of the NDM-1 gene immediately prior to
MIC testing.
Results: The presence of NDM-1 was conﬁrmed in all isolates.
Susceptibility (presented as % strain inhibited per concentration) of the
78 NDM-1 harbouring isolates to the test drugs is summarised in the
Figure.
Conclusion: BAL30072 alone was active against 60% of the strains at
4mg/L, while ATM, CAZ and MEM covered <10%. Strains harbouring
NDM-1 are known often to express multiple b-lactamases towards some
of which BAL30072 may not be stable.
This data strongly suggests that BAL30072 is stable to hydrolysis
by NDM-1, but that expression of other b-lactamases contributes to
decreased susceptibility to BAL30072 alone. The addition of MEM
protects BAL30072 against hydrolysis by these additional enzymes,
resulting in >90% of isolates being inhibited at 4mg/L.
BAL30072 offers a potential therapeutic beneﬁt for infections caused by
NDM-1-positive Enterobacteriaceae. In addition, the activity BAL30072
is further enhanced in combination with MEM against clinical isolates
carrying NDM-1 and multiple other b-lactamases gene loci.
P1147 Activity of ACHN-490 against MDR clinical isolates of
Klebsiella pneumoniae, Escherichia coli and Enterobacter
spp. from Athens, Greece
I. Galani*, M. Souli, G. Daikos, Z. Chrysouli, G. Poulakou,
M. Psichogiou, T. Panayea, A. Argyropoulou, I. Stefanou, G. Plakias,
H. Giamarellou, G. Petrikkos (Athens, GR)
Objectives: The in vitro activity of ACHN-490, a next-generation
aminoglycoside, was evaluated against a total of 300 multidrug-resistant
(MDR) organisms. Isolates [K. pneumoniae (n = 241), E. coli (n = 33) and
Enterobacter spp (n = 26)] were collected from 4 hospitals in Athens, an
area where carbapenemase-producing organisms are endemic.
Methods: A total of 242 clinical isolates collected between 2008–2010
and 58 fecal carriage isolates were included in the study. Only one isolate
per species per patient was permitted. Clinical isolates were derived
primarily from blood (n = 197), while other sources included pus (n = 16),
bronchial secretions (n = 5) and urine (n = 24). MIC determinations
for most agents were performed with the BD Phoenix automated
system. MICs of ACHN-490, tobramycin and fosfomycin were evaluated
with agar dilution according to CLSI, whereas MICs of doripenem
and tigecycline were determined using E-test, in accordance with the
manufacturer’s instructions. All isolates were screened for MBL and
KPC production with EDTA–imipenem and imipenem–boronic acid disk
synergy tests, respectively. The presence of KPC and VIM genes was
conﬁrmed by PCR. ESBL production was evaluated using the CLSI
conﬁrmatory test with and without carbapenemase inhibitors (EDTA,
Boronic acid).
Results: ACHN-490 MICs were 4mg/L against all 300 MDR isolates
with MIC50 and MIC90 of 1 and 2mg/L, respectively. Most of the
isolates were resistant to the legacy aminoglycosides with the MIC50/
MIC90 to tobramycin, amikacin and gentamicin being 32/>32, 32/>32
and 4/>8mg/L respectively. No differences were observed in the activity
of ACHN-490 against KPC (n = 151), VIM (n = 105), KPC+VIM (n = 15)
or ESBL (n = 29) producing isolates or against K. pneumoniae, E. coli or
Enterobacter spp strains. Colistin was active, with 77.7% of the tested
isolates displaying MICs 2mg/L, while tigecycline’s MIC50 and MIC90
were 2 and 4mg/L, respectively. Finally, fosfomycin demonstrated 84.7%
susceptibility with an MIC50 of 16 and an MIC90 of 128mg/L.
Conclusions: The novel aminoglycoside ACHN-490 retains activity
against all isolates of K. pneumoniae, E. coli and Enterobacter spp tested,
including MDR strains which are carbapenemase producers.
P1148 ACHN-490 as a potential addition to the antimicrobial arma-
mentarium in ICUs with high levels of resistant organisms
T. Kotlovsky*, S. Navon-Venezia, L. Keren, Y. Carmeli (Tel Aviv, IL)
Background: ACHN-490 is a next-generation aminoglycoside that offers
increased spectrum of activity against resistant organisms. Here we
evaluated the in vitro activity of ACHN-490 against clinical isolates from
3 ICUs in Tel Aviv, Israel to explore the potential utility of ACHN-490
in our facilities.
Methods: Data collected from 3 ICUs in Tel Aviv over a 27-month
period (2008–2010) were retrospectively analyzed. All isolates were
identiﬁed and susceptibility testing performed using the Vitek II
system, complemented by disc diffusion and/or E-test as necessary. All
procedures and interpretation were performed according to the CLSI
guidelines. Isolates were classiﬁed as MDR/XDR based on ECDC/CDC
classiﬁcation. 193 randomly selected ICU isolates were tested using agar
dilution method to determine ACHN-490 MICs.
Results: During the study period 4086 pts were admitted to the ICUs
accounting for a total of 23,829 ICU days. 376 (9%) patients had
positive cultures within 72h of hospital admission and 763 (18.6%)
after >72h (nosocomial). Most common pathogens isolated were various
Enterobacteriaceae (1086), P. aeruginosa (502), A. baumannii (447), and
S. aureus (303). Of ICU pathogens isolated within 72h of admission, 160
(43%) were MDR and 44 (12%) XDR. Among nosocomial pathogens
523 (69%) were MDR and 235 (31%) XDR. 57% of S. aureus isolates
were MDR, 48% were MRSA. Resistance rates (calculated as # isolates/
#patients) ×100) among nosocomial Gram negative strains are listed in
table 1.
Activity of ACHN-490 (MIC50, MIC90, upper range) against 202
randomly selected ICU isolates was: S. aureus (n = 44, 22 MRSA)
<0.25, <0.25, <0.25; Enterobacteriaceae excluding Morganella (n = 102
E. coli, K. pneumoniae, Enterobacter, Citrobacter, Serratia, Proteus,
Providencia) 1, 4, 16; Morganella (n = 17) 8, 64, 128; P. aeruginosa
(n = 22) 0.5, 8, >128; A. baumannii (n = 17) 16, >128, >128.
Conclusion: ACHN-490 has potent in vitro activity against most
MDR/XDR S. aureus and Gram negative isolates, including Enter-
obacteriaceae and most P. aeruginosa. ACHN-490 has high MICs
against A. baumannii and Morganella. Addition of ACHN-490 to the
antimicrobial armamentarium could be of great value in ICUs with high
rates of MDR/XDR pathogens.
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P1149 The novel broad-spectrum ﬂuorocycline TP-434 is active
against MDR Gram-negative pathogens
C. Fyfe, T. Grossman*, W. O’Brien, C. Achorn, J. Sutcliffe (Watertown,
US)
Background: TP-434 is a novel broad-spectrum IV/oral ﬂuorocycline
antibiotic being developed by Tetraphase Pharmaceuticals. TP-434
has potent activity against multidrug-resistant (MDR) Gram-negative
pathogens associated with complicated nosocomial and community
infections, including Enterobacteriaceae such as Escherichia coli and
Klebsiella spp. expressing extended-spectrum b-lactamases (ESBL)
and/or carbapenemases, MDR Acinetobacter baumannii, and anaerobic
bacteria such as Bacteroides fragilis.
Methods: Using standard CLSI methodology, TP-434 and clinical
comparators were tested against recent isolates of E. coli (n = 176,
97 were ESBL), K. pneumoniae (n = 226, 90 were ESBL), K. oxytoca
(n = 41, 11 were ESBL), A. baumannii (n = 89) and B. fragilis (n = 30).
The ESBL genotype of select isolates was characterized by PCR. In vitro
bactericidal activity over 24 hours was determined using standard time-
kill assays with vigorous aeration in rich media. In vivo activity was
assessed in a murine septicemia model challenged intraperitoneally with
ESBL (SHV)-producing E. coli strain EC133 and TP-434 administered
intravenously, measuring survival at 48 hours.
Results: TP-434 showed MIC50/MIC90 values (microgram/milliliter)
of 0.25/0.5, 0.5/2, 0.25/1, 0.5/2 and 0.5/1 against multidrug-resistant
panels of E. coli, K. pneumoniae, K. oxytoca, A. baumannii, and
B. fragilis, respectively. The presence of TEM, SHV, CTX-M, OXA,
DHA, FOX, CMY, ACT, KPC ESBL genes had no impact on TP-
434; MIC50/MIC90 values (micrograms/milliliter) for ESBL panels of
E. coli, K. pneumoniae and K. oxytoca were 0.25/0.5, 0.5/2 and 0.5/1,
respectively. Notably, TP-434 showed 2-fold improved potency over
tigecycline, a tetracycline-class clinical comparator, for 28%, 39%, 44%,
76% and 77% of E. coli, K. pneumoniae, K. oxytoca, A. baumannii, and
B. fragilis, respectively. TP-434 was bactericidal in vitro against E. coli
and K. pneumoniae, including ESBL-expressing isolates, showing >3-
log reductions in colony forming units over 24 hours. The IV PD50 of
TP-434 in a mouse septicemia model was 1.3mg/kg versus a 3.5mg/kg
for tigecycline.
Conclusion: TP-434 shows superior activity in vitro versus clinical
comparators against problematic Gram-negative bacteria, supporting
its advancement into a Phase 2 clinical trials for complicated intra-
abdominal infections.
P1150 In vitro bactericidal and anti-bioﬁlm activity of bovine
myeloid antimicrobial peptides against multidrug-resistant
bacteria from patients with cystic ﬁbrosis
G. Di Bonaventura*, A. Pompilio, V. Crocetta, S. Pomponio, V. Di
Vincenzo, M. Scocchi, G. Gherardi, E. Fiscarelli, G. Dicuonzo,
R. Gennaro (Chieti, Trieste, Rome, IT)
Objectives: In cystic ﬁbrosis (CF), pulmonary infections are often
caused by multidrug-resistant (MDR) strains. Efforts to treat these
infections are also hampered by the conditions present in the CF
lung, which could counteract antibiotic therapy, and by formation of
antibiotic-resistant bioﬁlms. It is therefore needed to develop alternative
therapeutic strategies. In this study, the in vitro activity of two bovine
myeloid antimicrobial peptides (BMAPs) against CF bacterial isolates
was assessed for the ﬁrst time in the presence of CF-like physiological
conditions.
Methods: In vitro activity of BMAP-27 and BMAP-28 against 25
P. aeruginosa, 27 S. maltophilia, and 15 S. aureus MDR strains was
evaluated, comparatively to tobramycin, using MIC and killing kinetic
assays. The effects of BMAPs and tobramycin at sub-MICs (1/2x,
1/4x, and 1/8xMIC) against bioﬁlm formation were also assessed by
a colorimetric assay. To simulate CF lung environment, assays were
performed under 5% CO2 atmosphere and by using a deﬁned synthetic
medium that mimics the nutritional composition of CF sputum. The
effects of BMAPs on bacterial morphology were also assessed by
electron and confocal microscopy.
Results: MIC values showed that BMAP-27 and BMAP-28 exhibited
comparable activity against P. aeruginosa (MIC90: 16 and 32 mcg/ml,
respectively) and S. maltophilia (MIC90: 8 and 4 mcg/ml, respectively)
isolates, while BMAP-28 exhibited higher activity than BMAP-27
against S. aureus (MIC90: 32 and >64 mcg/ml, respectively). Tobramycin
resulted to be signiﬁcantly less active than both BMAPs, regardless
of species tested (MIC90: >64 mcg/ml, for all species tested). Time-
killing assays showed that both BMAPs exhibited a rapid (within 30−60
min) bactericidal activity generally leading to the complete eradication
within 120 min. To the contrary, tobramycin showed bacteriostatic effect
allowing some re-growth by 24 h. BMAP-27 and BMAP-28 at sub-MICs
signiﬁcantly reduced the amount of bioﬁlm formed on polystyrene by
CF strains with comparable efﬁcacy, although to a lesser extent than
tobramycin (Figure).
Conclusion: Our results suggested that BMAP-27 and BMAP-28 may
represent a potential therapeutic option for CF lung infections caused by
P. aeruginosa, S. maltophilia, and S. aureus. Further work is warranted
to evaluate their in vivo efﬁcacy using a lung-infected animal model.
(This work was supported by the Italian CF Research Foundation; grant
FFC#12/2009)
P1151 Activity of POL7001 against Pseudomonas aeruginosa
isolates from cystic ﬁbrosis patients
A. Bragonzi*, C. Cigana, F. Bernardini, M. Paroni, S. DeMarco,
P. Misson, N. Schmitt, K. Dembowsky, D. Obrecht (Milan, IT; Allschwil,
CH)
Objectives: POL7001 is a Protein Epitope Mimetic (PEM) antibiotic
with potent antimicrobial activity against Pseudomonas aeruginosa (PA)
(Srinivas et al., Science 2010). Chronic infection with PA is a primary
driver of mortality in cystic ﬁbrosis (CF) patients and resistance to
multiple antibiotics develops over time. We have tested the activity of
POL7001 against PA isolated from time of colonization for up to 16 yrs
or until death/lung transplantation in CF patients, in order to evaluate
CF as potential clinical application of this new class of antibiotics.
Method: Isolates were obtained as described in Bragonzi et al. 2009.
Six patients were included and isolates were taken at ﬁrst positive
culture for PA and during regular visits (at least 4 times per year).
All had conﬁrmed clonal PA infections and harbored different PA
clones. Isolates represent ﬁrst subcultures of the original isolate obtained
from sputum or throat swab. MICs were determined for POL7001,
ciproﬂoxacin (CIP), meropenem (MER), ceftazidime (CAZ), colistin
(COL), gentamicin (GEN), tobramycin (TOB), and imipenem (IMP). The
multi-drug resistant isolate RP73 was used to set up a murine pneumonia
model in order to test the in vivo efﬁcacy of POL7001 in comparison to
ciproﬂoxacin.
Results: MICs for POL7001 ranged between 0.015−0.5mg/mL with a
median of 0.125mg/mL for all isolates. Over time, many of the PA
isolates from patients became resistant to two or more antibiotics while
remaining sensitive to POL7001. One isolate developed resistance to
MER, IMP, COL, CAZ, and GEN 12.6 yrs post-colonization without a
change in sensitivity to POL7001. There was no difference in activity
of POL7001 against mucoid, non-mucoid or hypermutable isolates. The
in vivo efﬁcacy test of POL7001 is on-going.
New non-conventional antimicrobials (no drugs) S307
Conclusions: Multiresistant PA isolated from CF patients shows
sensitivity to the novel antibiotic POL7001. The development of
resistance toward aminoglycoside and cephalosporin correlates with
mortality in CF patients. POL7001 or a related PEM antibiotic may be
a useful therapy for these patients, especially at later stages of disease.
P1152 The biology of environmental bacteriophages lytic to
multidrug-resistant Klebsiella strains
A. Kesik-Szeloch*, Z. Drulis-Kawa, J. Kassner, B. Weber-Dabrowska
(Wroclaw, PL)
Objectives: The purpose of this study was to isolate and characterize
active bacteriophages against Klebsiella pneumoniae ESBL(+) strains
to apply alternative phage therapy in eradication of multidrug resistant
strains.
Methods: The newly isolated phages were characterized by their
morphology, plaque morphology and host range. All these phages
were tested against 168 K. pneumoniae and 54 K. oxytoca multidrug
resistant strains by spot-test method. Plaque morphology was determined
by plaque assay using double-layer agar overlay technique. The
morphological characterization of the bacteriophages was made by
transmission electron microscopy (TEM) observations.
Results: In our research 27 Klebsiella lytic phages were isolated from
environmental water samples and propagated on 10 ESBL-producing
K. pneumoniae strains. Morphologically, they were assigned to three
virus families: Myoviridae, Siphoviridae and Podoviridae. Signiﬁcant
differences in plaque morphology were observed. Results showed that
phages belonging to the Myoviridae family had high efﬁcacy and
relatively broad spectrum of activity within Klebsiella sp. (activity
against 20,2% K. pneumoniae strains and 35,2% K. oxytoca strains).
Conclusions: The isolated bacteriophages demonstrated lytic activity
to multidrug resistant strains of K. pneumoniae and K. oxytoca. The
characterization of this novel phages was helpful to allow the successful
application of phages as therapeutic agents against bacterial infectious
diseases.
New non-conventional antimicrobials
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P1153 In vitro activity of wine compounds (resveratrol, methyl
gallate and other phenolic compounds) against Helicobacter
pylori clinical isolates
T. Alarcon*, S. Rodrigo, A.J. Martinez-Rodriguez, A.V. Carrascosa,
M. Lopez-Brea (Madrid, ES)
Objective: The aim of this study was to determine the in vitro activity
of different phenolic compounds against H. pylori clinical isolates by a
disc diffusion method.
Methods: 28 H. pylori clinical isolates were obtained from gastric
biopsies from patients suffering of gastric symptomatology. Biopsies
were processed following standard methodology for these bacteria.
The in vitro activity of different phenolic compounds was studied by
a disc diffusion method: Epicatechin, gallic acid, resveratrol, coumaric
acid, ferulic acid, methyl gallate, catechin, quercetin, vanillic acid and
kaempferol. Compounds were diluted in ethanol:water (10:90v/v) at
25mM concentration. Ethanol was used in the same conditions to rule
out its activity.
Blank disc were impregnated with 10mcl of each compound and put in
agar Columbia plus 7% sheep blood inoculated with a suspension of a
2 McFarland H. pylori. Plates were incubated for 3 to 5 days at 37ºC in
a 10% CO2 atmosphere. Inhibition zone around disc were measured.
13 strains were susceptible (S) to clarithromycin (CLA) and 15
intermediate or resistant (R). 7 strains were R to metronidazol (MTZ)
and 21 S.
Results: Resveratrol produced inhibition in all the strains tested with
18−45mm inhibition zone. Methyl gallate produced inhibitions in all the
strains with a range of 17 to 35mm. Kaempferol inhibited 10 strains with
10−23mm inhibition zone. Epicatechin inhibited 3 strains with a range
12−25mm, Catechin inhibited 7 strains with inhibition zone 10−20mm.
Quercetin inhibited 7 strains with 10−12mm inhibition zone. Vanillic
acid inhibited one strain with 8mm inhibition zone.
Number of strains inhibited for each compound are included in the
table 1.
Gallic acid, coumaric acid and fereulic acid did not inhibit the strains
tested. Ethanol produced not inhibition in the strains tested.
Some differences were observed according to resistance to CLA or MTZ.
Catechin was more active against CLA-R (6 out of 15, 40%) than
CLA-S strains (1 out of 13, 7.7%) and against MTZ-R (4/7, 57.1%)
than MTZ-S (3/21, 14,3%) strains. Moreover, quercitin was more active
against MTZ-S (6/21, 28.6%) than MTZ-R (1/7, 14.3%) strains and
Kaempferol more active against MTZ-S (9/19, 47.4%) than MTZ-R (1/5,
20%) strains.
Conclusions: Two of the phenolic compounds tested in this study
(Resveratrol and methyl gallate) showed in vitro activity against all
Helicobacter pylori clinical isolates tested by a disc diffusion method.
P1154 Fruit and vegetable extracts as source for anti-adhesion
agents against oral bacteria
M. Stauder, D. Steinberg, M. Daglia, A. Papetti, G. Gazzani, E.I. Weiss,
C. Pruzzo, I. Ofek* (Genoa, IT; Jerusalem, IL; Pavia, IT; Tel Aviv, IL)
Objectives: Anti adhesion-based therapy of bacterial infections have
been recognised as new promising alternative approach as resistance
of bacteria to the commercial available antibiotics is constantly on the
rise. This approach has been studied on oral bacteria using various food
stuff as source to obtain fractions that inhibit bacterial inter-genera or
inter-species interactions, also known as coaggragation, and the adhesion
of oral bacteria to cells and teeth. In this study we tested extracts and
fractions from fruits and vegetables for their ability to inhibit adhesion
and coaggregation of oral bacteria.
Methods: Extracts prepared from frozen mushroom, frozen raspberry
and fresh chicory were fractionated into low and high molecular mass
fractions by ultraﬁltration (mushroom and chicory, less and higher
than 5000 Da) and by dialysis (raspberry, less and higher than 3500
Da). The extracts and fractions were tested for the ability to inhibit
(i) coaggregation between pairs of Fusobacterium nucleatum (Fn)/
Streptococcus mutans (Sm) and Fn/Neisseria subﬂava; (ii) adhesion to
and detachment from hydroxyapatite (HA) beads of Sm, Lactobacillus
casei (Lc) and Streptococcus sanguinis; (iii) adherence of Actinomyces
naeslundii (An) and Prevotella intermedia (Pi) to cultured KB cells;
(iv) bioﬁlm formation by Sm, Lc, An and Pi.
Results: The mushroom extract inhibited the coaggregation of the test
pairs of bacteria from 4+ score in the absence of extract to 0 score
in the presence of 33% (V/V) extract diluted with saline buffer (pH
7.2), whereas the raspberry and chicory extracts were without effect. All
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extracts inhibited bioﬁlm formation, reduced adhesion to HA and caused
detachment from the beads; raspberry and chicory, but not mushroom,
also inhibited adherence to KB cells. The coaggreagation inhibitory
activities were retained in the LMM fraction of the mushroom extract.
Although all fractions displayed some effect in inhibiting adherence
to HA and KB cells and bioﬁlm formation, the LMM fractions were
generally the most effective.
Conclusion: The data taken together suggest that LMM fractions from
the tested extracts may be a useful source to identify speciﬁc anti
adhesion agent(s) to improve oral health care.
This study was supported by the European research project “Nutrident”,
contract No. FOOD - CT-2006–036210.
P1155 Evaluation of the probiotic potential of Weissella confusa
and Lactobacillus paracasei strains isolated from Nigerian
traditional dairy fermented foods and cow’s intestines
F. Ayeni*, B. Sa´nchez, B. Adeniyi, C. de los Reyes-Gavila´na,
A. Margolles, P. Ruas-Madiedo (Bayelsa State, NG; Villaviciosa, ES;
Ibadan, NG)
Objective: Infectious diseases are still major causes of death in
developing countries especially Africa. Current chemotherapy rely
almost exclusively on the use of antibiotics, however this is becoming
ineffective due to global problem of antibiotic resistance. Hence the
need for alternative chemotherapy through the use of viable Lactic Acid
Bacteria (LAB) as probiotics. This study was carried out to characterize
the probiotic potential of selected LAB strains isolated in Nigeria from
traditional fermented dairy foods and cow’s intestines samples in order
to select strains for probiotic use in the gastrointestinal and urogenital
tracts that will lessen possible infections in the tracts.
Method: Antimicrobial potentials of 24 LAB had been previously
reported. Two Lactobacillus paracasei and three Weissella confusa
strains which have been previously selected from the 24 LAB due to their
high antimicrobial activities against uropathogens and enteropathogens
were used in this study. The survival of selected LAB and a probiotic
reference strain (Lactobacillus rhamnosus GG) in chemically simulated
human gastro-intestinal tract conditions, adherence to human intestinal
epithelial cell-lines (Caco-2, HT-29 and HT-29-MTX) and adherence to
epithelial vaginal cell line (HeLa) were all evaluated through counts of
surviving cells.
Result: Resistance of the selected LAB strains to simulated gastroin-
testinal passage was satisfactory and better than that of the reference
L. rhamnosus GG strain. The highest survival after passage through
gastrointestinal conditions was observed withW. confusa UI021 (45.0%).
Lactobacillus paracasei UI014 and W. confusa UI007 strains adhered
better to HT-29-MTX cell line than the reference L. rhamnosus GG strain
while the two L. paracasei strains adhere better to HeLa vagina epithelial
cell line than the reference Lactobacillus rhamnosus GG. strain.
Conclusion: In general, the studied strains showed good survival in the
gastrointestinal transit and acceptable adhesion capability to intestinal
and vaginal epithelia that is comparable and better in some strains to
the tested reference probiotic strain. The strains are good candidates for
further studying of potential beneﬁts that support their use as probiotics
in the gastrointestinal and urogenital tract. This is one of the few studies
reporting the characterization and the probiotic potential of Weissella
species.
P1156 Antimicrobial effect of methanolic extract of ginger on
Helicobacter pylori
N. Rahimifard*, L. Beitolahi, S. Shoeibi, M. Rabiei, F. Bagheri,
H. Hajimehdipoor (Tehran, IR)
Objective: Helicobacter pylori, a Gram negative microaerophilic
bacterium, infection is now recognised as a worldwide problem. The
growing problem of antibiotic resistance by the organism demands the
search for novel herbal compounds.
The present study is designed for evaluating the antimicrobial effect
of methanol extract of this remedy on clinical isolates of H. pylori in
Kashan to identify potential sources of cheap stating materials for the
synthesis of new and more effective drugs.
Method: This study was taken from 20 Helicobacter pylori samples
isolated from patients with gastrointestinal disorders. The samples were
cultured on Columbia agar base plates (Merck) with supplements. Plates
were incubated at 37ºC for 3−5 days in a microaerophilic environment
(using anaerocult C, merck). The isolates that grown on plates were
identiﬁed by bacteriological tests.
The microdilution broth method was used to determine the susceptibility
of methanol extract of ginger on 20 isolates of H. pylori with a serial
dilution of 1000, 500, 250, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78 mg/ml.
Results: The MIC of extract ranged from 3.125−25mg/ml for H. pylori,
the MIC of 12 (60%) isolates were 3.125mg/ml, 4 isolates (20%)
were 12.5mg/ml, 3 isolates (15%) were 6.25mg/ml, 1 isolate (5%) was
25mg/ml.
Conclusions: The methanolic extract of ginger may contain compounds
with therapeutic activity, and the most effective MIC (60%) against
H. pylori were 3.125mg/ml. We also understand that H. pylori has a
high sensivity against ginger.
P1157 Photodynamic inactivation effect of methylene blue on
multidrug-resistant bacteria isolated from chronic diabetic
foot ulcers
N. Kashef, G. Esmaeeli Djavid*, G. Ravaei Sharif-Abadi (Tehran, IR)
Objective: Photodynamic inactivation (PDI) has been investigated
to cope with the increasing incidence of multidrug-resistant (MDR)
pathogens. PDI employs nontoxic photosensitizers (PSs), which localize
in the microbial cells and are activated by a speciﬁc wavelength of visible
light. The excited-state PS reacts with in situ molecular oxygen and
transfers its energy to generate reactive oxygen species (ROS), such as
singlet oxygen and superoxide anion. These ROS can cause damage
to cell walls, proteins, nucleic acids, and membrane lipids, eventually
causing cell death.
Methylene blue (MB) is a widely known histological dye and belongs to
the phenothiazinium class of compounds. The main purpose of this study
was to explore the PDI effect of MB on multidrug-resistant Escherichia
coli and methicillin-resistant Staphylococcus aureus (MRSA) compared
to Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC
25923).
Methods: Effect of MB concentration (12.5, 25, 50 mg/ml) and laser
light dose (54.6, 109.2, 163.8 J/cm2) on lethal photosensitization was
investigated. The conditions tested were: 1) controls which contained
neither MB nor received irradiation, 2) incubation with MB in the dark,
3) irradiation in the absence of MB and 4) the test which was irradiated
in the presence of MB. To enumerate the surviving bacteria, serial 10-
fold dilutions were plated on nutrient agar.
Results: S. aureus (ATCC 25923) and clinical MRSA isolate were
susceptible to killing by photodynamic inactivation. With 50mg/ml MB
at 163.8 J/cm2, 3 log killing was obtained for S. aureus (ATCC 25923)
and 2 log killing was obtained for MRSA (initial concentration 104−105
CFU/ml). Methylene blue (50mg/ml) photosensitization using red laser
light (163.8 J/cm2) was able to achieve reductions of 53.1% and 37.6% in
the viable counts of Escherichia coli (ATCC 25922) and clinical isolate
of multidrug-resistant Escherichia coli (using starting concentrations of
104−105 CFU/ml). The bactericidal effect was not dependent on the
concentration of MB; but it was dependent on the light dose. Under the
same MB concentration and light dose, ATCC reference strains were
consistently killed more when compared with the clinical isolates.
Conclusion: In our study, the selected MDR isolates were more resistant
to PDI-mediated killing than their ATCC reference strains. Therefore,
the PDI efﬁcacy of MB may be affected by the antibiotic resistance
mechanisms that presented in MDR isolates.
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P1158 Sterilisation efﬁcacy of atmospheric plasma sources for
biomedical applications
R. Sadeq*, M. ElShaer, M. Mobasger, R. Sadeek, M. Gohar,
T. Abdel-Fattah (Zagazig, EG)
Objectives: Gaseous non thermal plasma (NTP) has unique characteris-
tics because it contains numerous biochemically active agents like UV
photons, OH radicals, O atoms, etc. A distinguishing property of NTP
is that all the foregoing agents mentioned can be generated in gas or
liquid without heating, close to ambient temperatures.
Aim of work: To evaluate the efﬁcacy of Gaseous non thermal plasma
(NTP) on different microorganisms (vegetative cells, spores, fungi,
bioﬁlms).
Material and Methods: Light microscope (LM) and transmission
electron microscope (TEM) were used to visually inspect the impact
of plasma exposure on E. coli as a Gram-negative bacterium,
Staphylococcus aureus as a Gram positive bacteria, Aspergillus-niger
as a fungus, bacillus stearothermophilus immobilized spores on paper
strip (biological indicator) and bioﬁlm urinary catheter bacteria.
Results: Time dependant study allows us to distinguish between
bacteriostatic and bacteriocidal action of NTP. Visually when the exposed
colonies were used as source of new culture, showed nearly evacuated
Petri dish from colonies. By inverted light microscope treated cells
showed morphologically change in diameter and destruction in relation
to time. Using transmission electron microscope (TEM) in observation
of treated vegetative cells showed that cell wall remains but its central
dissolved and after longer exposure total cell fragmentation and leakage
occurred. As regard immobilized Bacillus stearothermophilus spores
showed erosion of various spore layers. Also NTP were evaluated
quantitatively, number colony forming represented by Log-vertical scale
versus time represented by Log-horizontal scale were plotted in semi-log
scale. This revealed multislope or 3 phases survivor curve for vegetative
cells and spores. Gram negative bacteria showed higher resistance against
plasma treatment in comparison to Gram positive bacteria. Also spores
are more resistant as to reach complete sterility, in which no growth after
7 days incubation needs 10 minutes exposure and addition of oxygen
in plasma forming gas. NTP destroy bioﬁlm by lower exposure time
(hundreds of seconds).
Conclusion: Gaseous non thermal plasma (NTP) can destroy microor-
ganisms but with different time of exposure and addition of oxygen.
P1159 Antimicrobial effect of treated medical textiles
A. Di Nauta*, R. Baldan, C. Romano`, L. Drago, F. Elia, D. Cirillo
(Milan, IT)
Objective: Healthcare-associated infections represent a major challenge
for healthcare systems. Spread of resistant bacteria in hospital settings is
facilitated by the fact that coats and other textiles are easily contaminated
by the nosocomial ﬂora. Recently, antimicrobial textiles have been
developed to prevent bacterial colonization. Aim of the present study
was to assess the antibacterial properties of reusable fabrics, ﬁnished
with a patented antimicrobial product (SANIT® by ALSCO Italia, SpA).
Methods: The in vitro tests were performed according to the EN ISO
20645:2004 (E): textiles specimens (microﬁber polyester and cotton-rich,
treated with 0%,0.5% and 0.9% of antimicrobial product) are placed on
two-layers agar plates. The lower layer consists of culture medium free
from bacteria and upper layer is inoculated with selected bacteria. Fabrics
were tested on both sides against Gram+ and Gram− strains (MSSA,
MRSA, VRE, S. epidermidis, P. aeruginosa, K. pneumoniae), including
both reference and clinical strains with different characteristics and drug
resistances. The absence or presence of bacterial growth in the contact
zone agar-specimen and inhibition zone (IZ) around the specimens were
evaluated.
A double blind randomized study with crossover was then conducted,
involving ten physicians and twenty reusable white coats, ten treated
with the SANIT® and ten untreated. All tested textiles were 60% cotton
and 40% polyester. White coats were randomly given to the physicians
for a total of ten days, for seven hours clinical routine use. Six samples
(contact plates) were taken from the chest area, cuffs and pockets.
Results: Treated fabrics showed a good effect on Gram+ (>1mm IZ,
no growth), although the IZ was reduced in clinical strains compared to
reference ones. No effect was observed on Gram− strains, with absence
of IZ and bacterial growth under the treated specimens.
The in-vivo testing demonstrated that >90% of the retrieved bacteria
were Gram+ strains. The overall bacterial count in the ﬁnished white
coats after ten days of use showed a reduction of more than ﬁve times,
compared to controls (p< 0.02 − Mann–Withney U-test).
Conclusion: The tested antimicrobial ﬁnishing of medical textiles
showed an excellent effect on Gram+ bacteria, that were the prevalent
contaminants of white coats after routine clinical use. Further studies
are under way to assess the efﬁcacy of this technology in the surgical
setting and in intensive care units.
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P1160 Quorum sensing inhibition by triﬂuoromethyl ketones
Z.G. Varga*, E. Szegedi, M. Kawase, N. Motohashi, J. Molnar (Szeged,
Budapest, HU; Ehime, Tokyo, JP)
Objectives: Quorum sensing (QS) is a communication system mediated
by chemical signals which depends on the population density of
microbes. It has great signiﬁcance in the formation of bioﬁlms, the
production of virulence factors, the development of intrinsic antibiotic
resistance, the facilitation of growth in a competitive environment and
the enhancement of motility. Antimicrobial effects of 30 triﬂuoromethyl
ketones (TFs) have already been studied on various bacterial species.
Some of TFs inhibited the growth and the motility of various Gram-
positive and Gram-negative bacteria. Our aim was to study the quorum
sensing inhibitory effect of 12 TF molecules.
Methods: The quorum sensing inhibitor activity of the twelve
Tf compounds were investigated in disc diffusion method with
Chromobacterium violaceum 026 sensor strain. This strain produce a
purple dust pigment only in the presence of N-acyl homoserine lactone
(AHL) signal molecules. We used the EZF 10−17 AHL producer strain
(a grapevine tumor isolate) to prove the signal molecules for the system,
or we added the AHL-s externally. The quorum sensing inhibitor activity
of the TF compounds was evaluated in a bioassay as a reduction of the
diameter and the intensity of pigment production.
Results: The antibacterial effects of twelve TFs (1−12) were investigated
at ﬁrst. It was found that compounds 1, 2, 3 and 9 had remarkable
antibacterial effect on the sensor strain at 20mg/ﬁlter paper discs. Three
TFs 2, 3 and 9 had antibacterial effect on the AHL producer strain. The
QS inhibition was detected in case of six TFs 1, 2, 3, 4, 5 and 9 below
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the growth inhibitory concentrations. The best QS inhibitors were TF 1,
2, 3 and 9.
Conclusion: The chemical-structure dependent activity of TFs on QS
signal cascade and a bacterial motility might open new perspectives
in the synthesis of a new class of proton pump inhibitors to prove
an alternative way to reduce the virulence and bioﬁlm formation of
pathogens.
P1161 Activity of PF-1 and PF-2, novel siderophore conjugated
b-lactams, tested against Enterobacteriaceae strains
carrying emerging resistance mechanisms
M. Castanheira, R. Jones, D. Farrell*, M. Huband, J. Quinn, J. Mueller
(North Liberty, US)
Objectives: To evaluate the activity of two novel conjugated siderophore
b-lactam agents (PF-1 and PF-2) and comparator agents against
Enterobacteriaceae (ENT) producing emerging b-lactamases, including
CTX-M, NDM-1, KPC and OXA-48/-181 or carrying known plasmid-
borne ﬂuoroquinolone resistance (PMQR) genes, qnr and aac(6′)-Ib-cr.
Methods: PF-1 and -2 (with and without the iron chelator 2,2′-
dipyridyl) and comparators were tested for susceptibility using CLSI
broth microdilution methods against 111 clinical strains of ENT (13
species [including 53 K. pneumoniae, 27 E. coli, 10 E. cloacae among
others]) producing CTX-M-14 (12 strains), CTX-M-15 (12), KPC-2 to -4
(24), NDM-1 (12), OXA-48/181 (19), qnr (20), aac(6′)-Ib-cr (3). Isolates
were collected from 2001–2009 from global surveillance programs.
Resistance mechanisms were identiﬁed by PCR and sequencing.
Results: PF-1 and -2 displayed potent activity against all groups tested
(MIC50 results, 0.25mg/L). Overall, in the presence of 2,2’-dipyridyl
(a siderophore chelator; Table) MIC results were either identical or
slightly lower (two- to four-fold) when compared to the compounds
tested alone. PF-1 and -2 were the most active antimicrobial agent
tested against NDM-1-producing strains, which were highly resistant
to nearly all compounds tested except for tigecycline and polymyxin
B (MIC50, 0.5 and 0.5mg/L, respectively). Against KPC-producing
strains, PF-1 and -2 MIC50 results (0.25 and 0.12mg/L) were the lowest
among all agents tested. Enterobacteriaceae strains producing CTX-M
enzymes displayed the lowest MIC50 results for PF-1 and--2 (0.06 to
0.03mg/ml) among all groups. PF-1 and -2 also demonstrated potent
activity against all OXA-48/-181 strains and most PMQR strains tested.
Among all comparator agents, tigecycline was the only antimicrobial
agent demonstrating 100% susceptibility rates against these tested
strains.
Conclusions: Overall, PF-1 and -2 inhibited >90% of all tested strains
at 2mg/L. PF-2 seems to be slightly more active compared to PF-1
against these selected resistant strains. The presence of 2,2’-dipyridyl
did not appreciably impact MIC results. Both PF-1 and -2 retained
activity (MIC50, 0.03 to 0.25mg/L) against strains carrying resistance
mechanisms (including NDM-1) that are rapidly disseminating among
contemporary Gram-negative enteric bacilli.
P1162 Antimicrobial activity of a novel programme of protein
synthesis inhibitors against clinical isolates containing KPC
and NDM-1 carbapenemases
J. DeVito*, J. Remy, A. Bhattacharjee, Z. Kanyo, E.M. Duffy (New
Haven, US)
Objectives:Multidrug-resistant Gram-negative bacteria are an increasing
risk to public health. In these organisms, mobile genetic elements confer
resistance to most antimicrobial agents currently used in the clinic. Of
particular concern are those species of enteric pathogens containing
extended spectrum b-lactamases and carbapenemases such as KPC and
NDM-1. Clinical isolates with such resistance elements have emerged
as a world-wide threat with few therapeutic options remaining for the
infectious disease clinician. We tested representatives from three novel
classes of antibiotics for activity against a number of these highly
resistant Gram-negative organisms. These compounds inhibit protein
synthesis and bind to the 50S ribosomal subunit, a molecular target
not accessed by current drugs used to treat Gram-negative infections.
Methods: Clinical isolates were obtained from various laboratories and
commercial repositories to include the Louis Stokes Cleveland Depart-
ment of Veterans Affairs, Massachusetts General Hospital, Euroﬁns
Medinet Inc., and the American Type Culture Collection. Susceptibility
testing was performed according to CLSI broth microdilution methods
(M07-A8 and M100-S20-U).
Results: Lead molecules from three unique scaffolds in this program
were tested against contemporary clinical isolates of E. coli isolated from
patients with urinary tract and wound infections, many having ESBL,
AmpC, and quinolone resistance mechanisms. The compounds were
highly potent, inhibiting growth of these organisms at concentrations
in the range of 0.25 to 8mg/L. Similar results were obtained against
urine and respiratory isolates of K. pneumoniae with ESBL and KPC
resistance mechanisms, MICs ranging from 0.125−4mg/L. These same
compounds, when tested against NDM-1 strains of K. pneumoniae and
E. cloacae susceptible only to colistin and polymyxin B, gave MIC values
ranging from 2−8mg/L.
Conclusion: These protein synthesis inhibitors represent novel families
of antimicrobial agents with promising in vitro activity against multidrug
resistant Gram-negative pathogens, including isolates expressing the
KPC and metallo-b-lactamases.
P1163 Interactome for essential genes as a prediction of
antibacterial potency
B. Geller, P. Iversen* (Bothell, US)
Phosphorodiamidate morpholino oligomers (PMOs) are short synthetic
DNA mimics that inhibit gene expression by binding speciﬁcally to
mRNA with complementary base sequences. Previously, we synthesized
PMOs targeted to essential genes of bacteria, and found that these PMOs
can be potent bactericidal compounds. However, MIC values for PMOs
can vary from 100 nM to over 256 mM indicating that the process of
selecting the most potent targets from among the hundreds of essential
genes remains empirical.
Objective: Studies were designed to evaluate the role of the interactome
as a theoretical basis for selecting gene targets that would be most
susceptible to inhibition by PMOs. Proteomics and high-throughput
screening methods have shown that proteins tend to associate with
other proteins that function in common pathways. Higher levels of
organization called interactomes are formed when complexes of proteins
link together to form networks that integrate diverse cellular processes.
We hypothesized that the most susceptible targets for PMO antibacterials
would be those whose gene product interacted with a high number of
other proteins.
Methods: To test this hypothesis, we screened an interactome database
(Bacteriome.org, http://www.compsysbio.org/bacteriome/) for all 302
essential genes of Escherichia coli, as deﬁned in “Proﬁling of the
E. coli chromosome” (http://www.shigen.nig.ac.jp/ecoli/pec/index.jsp).
Eighteen essential genes with core interactome scores above 24 were
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selected for targeting, and PMOs were synthesized for each. The minimal
inhibitory concentration (MIC) of each PMO was measured using the
standard clinical method (Clinical Laboratory Standards Institute).
Results: The results show that there was no correlation between core
interactome score and MIC in this study. However, further analyses using
an extended experimental interactome score showed signiﬁcant negative
correlation.
Conclusions: We tested the hypothesis that interfering with protein-
protein interactions, which establish the biological organization of cells
as a network of stable protein-protein interactions, would correlate with
the potency of antibacterial agents. There was a signiﬁcant negative
correlation between increased number of protein-protein interactions and
MIC in this study.
P1164 Inhibiting the activity of the DNA gyrase from E. coli
X. Vila-Farres*, J. Sanchez-Cespedes, E. Giralt, J. Vila (Barcelona, ES)
Objectives: The DNA gyrase is known to be one of the targets for
quinolones. Mutants conferring resistance to quinolones have been
detected, especially, in the QRDR (Quinolone Resistance Determining
Region) region of the enzyme. These mutations in the amino acid codon
ser83 and asp87 are related to the interaction between the enzyme and the
quinolone. The objective of this work was to ﬁnd peptides with inhibitory
activity against DNA gyrase, that could overcome the resistance problem
and provide an alternative to quinolones.
Methods: To ﬁnd peptides with activity against the DNA gyrase four
peptides were synthesized. The sequence of each peptide mimics the
original sequence of the DNA gyrase from the residue 75 to the 130.
Peptide (A) was the original sequence of the enzyme, while in the
other peptides some mutations were introduced in the important residues,
peptide (L) with the mutation S83L, peptide (N) with the mutation D87N
and peptide (M) with both mutations. “In vitro” supercoiling assays were
performed to study the activity of these peptides. This assay consists in
testing the supercoiling of a lineal plasmidic DNA (0.5mg) in presence
of the DNA gyrase (1 unit) and the peptides (250 mg/ml) with or without
ciproﬂoxacin (0.25mg/ml). The reaction was stopped with a stop buffer
and run in a 1.5% agarose gel electrophoresis.
Results: Peptides A and N showed an inhibition of the activity of the
DNA gyrase in the conditions described above, whereas this was not
observed in peptides L and M. In addition, these inhibition was higher
in the presence of ciproﬂoxacin, showing an additive effect between the
speciﬁc peptide and ciproﬂoxacin.
Conclusion: The peptide mimicking the original sequence of the DNA
gyrase and that with the mutation S83L have good inhibitory activity
against the DNA gyrase. Moreover, these results also suggest that
Ser83 plays a more important role than Asp87 in the interaction between
quinolones or peptides and the DNA gyrase.
P1165 Determination of the mechanism of action of three novel
chemical scaffolds with broad-spectrum antibacterial activ-
ity, including multidrug-resistant Gram-negative pathogens
F. Franceschi*, E. Skripkin, A. Bhattacharjee, J. Remy, Z. Kanyo,
E.M. Duffy (New Haven, US)
Objectives: Three completely novel classes of protein synthesis
inhibitors have been designed and prepared as broadest-spectrum
agents, focused on treating multidrug-resistant (MDR) Gram-negative
pathogens. Each class evolved from a unique scaffold designed to target
the large ribosomal subunit. The goal of this study was to demonstrate
that the Gram-negative potency was attributable to protein synthesis
inhibition.
Methods: MIC determinations followed Clinical and Laboratory
Standards Institute (CLSI) guidelines. Compounds were examined at
2× MIC for their inhibitory effects on the synthesis of DNA, RNA, and
protein in Escherichia coli ATCC25922 as the test organism. The assay
exploited the incorporation of an appropriate radiolabeled precursor
into a given macromolecule: [3H]-thymidine for DNA, [3H]-uridine
for RNA and [35S]-methionine for protein. Effect of compounds on in
vivo polysome formation was investigated by treating E. coli cells with
different compound concentrations and analyzing polysome patterns by
sucrose gradient centrifugation.
Results: Exemplar compounds from all three novel scaffolds inhibit
protein synthesis in E. coli cells on a level comparable to chlo-
ramphenicol, a known protein synthesis inhibitor with a different
mechanism of inhibition. However, like chloramphenicol, none of these
novel antibiotics affected appreciably RNA or DNA synthesis, where
the comparators were rifampin and ciproﬂoxacin, respectively. The
mechanism of action was further corroborated in the polysome analysis
experiments. In contrast to controls (with a pattern showing mostly
monosomes and few polysomes), cells treated with exemplars from all
three novel classes show a pattern that is highly enriched in stable
polysomes (di- tri- tetra- and pentasomes). Furthermore, upon longer
exposures the pattern shifts to one enriched in dissociated subunits and
partially assembled ribosomal particles.
Conclusions: The three novel classes presented here clearly exert their
antibacterial activity by interfering with protein synthesis. In addition,
these compounds are also able to “freeze” or stabilize polysomes and
eventually inhibit ribosome maturation, conﬁrming that they have a direct
impact on ribosome function.
P1166 Three completely novel antibiotic scaffolds for treating
multidrug-resistant Gram-negative infections
Z. Kanyo*, A. Bhattacharjee, S. Chen, F. Collin, J. Dalton,
J. DeVito, M. DeVivo, J. Ippolito, R. Lou, H. O’Dowd, J. Martynow,
I.-H. Paik, J. Remy, M. Scheideman, S. Sinishtaj, E. Skripkin, Y. Tang,
B. Wimberly, Y. Wu, E.M. Duffy (New Haven, US)
Objectives: To combat emerging multidrug-resistant (MDR) Gram-
negative pathogens, including the Enterobacteriaceae featuring extended-
spectrum b-lactamases and carbapenemases such as KPC and NDM-1
as well as MDR Pseudomonas aeruginosa and Acinetobacter baumannii
strains, structure-based design was used to discover three chemically-
novel scaffolds with a novel mechanism of inhibition of the large
ribosomal subunit. The primary objectives of this effort were (1)
demonstration that the novel scaffolds inhibited the translation machinery
of the ribosome, (2) conﬁrmation that the novel scaffolds were not
affected by MLSb resistance mechanisms and (3) optimization of
these novel scaffolds along multiple vectors to afford compelling
microbiological activity against a contemporary panel of clinical isolates
of MDR Gram-negatives.
Methods: Translation inhibition in wild-type and MLSb-resistant
Escherichia coli ribosomes served as a surrogate for binding afﬁnity.
MICs against bacterial strains were determined according to CLSI
methods. Clinical isolates were obtained from Euroﬁns Medinet.
Results: Translation IC50s for all three scaffolds were at the lower limit
of detection, 20nM, against both wild-type and resistant E. coli ribo-
somes. Though the initial scaffolds showed little antibacterial activity,
each was evolved to show consistent MICs4mg/L against MDR Gram-
positives (enterococci and staphylococci) and MDR Enterobacteriaceae,
including E. coli and Klebsiella pneumoniae. Several subseries on these
scaffolds showed promising potency against MDR P. aeruginosa and
A. baumannii strains, with MIC ranges of 0.5−16mg/L.
Conclusions: Design of three novel antibiotic scaffolds with a novel
mechanism of inhibition was achieved. The scaffolds were evolved
along several chemical lines to yield multiple series with compelling
activity against MDR Gram-positives and Gram-negatives. Rational
design against a compelling target can pave the way for completely new
antibiotics to stay one step ahead of growing resistance.
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P1167 Antibacterial activity of C10 and C12 fatty acids and their
sucrose esters towards Escherichia coli and Clostridium
perfringens
E. Skrivanova*, M. Marounek, S. Prazakova (Prague, CZ)
Antibacterial activity of C10 and C12 fatty acids and their sucrose
esters against Escherichia coli ATCC 25922 and Clostridium perfringens
CNCTC 5459 was evaluated. In our previous experiments, C2−C18 free
fatty acids were tested for their antibacterial activity against a number
of Gram-negative and Gram-positive bacteria. The most effective ones
(C10 for E. coli and C12 for C. perfringens) were chosen to compare
their effect with the corresponding sucrose monoesters.
Methods: Susceptibility of E. coli and C. perfringens to fatty acids and
their sucrose esters was evaluated using the plating method. Bacterial
cultures were incubated in glucose medium containing C10 or C12 free
fatty acids or their sucrose esters (0.1, 0.2, 0.5, 1, 2, 3 and 5mg/ml).
After the incubation, samples were serially diluted and inoculated on
agar plates (MacConkey or Wilkins-Chalgren). After the incubation,
typical colonies were counted and means and SD of CFU/ml were
calculated. Differences between treated samples and non-treated control
were evaluated using the t-test.
Results: Incubation of E. coli with C10 fatty acid and its ester led to
a signiﬁcant decrease in numbers of viable bacterial cells from 9.76
to 7.91–5.13 log10 CFU/ml. Sucrose ester of C10 showed stronger
antibacterial properties than the free form of acid. Incubation of E. coli
with free C10 fatty acid at the concetration of 5mg/ml led to the
reduction of bacterial cells from 9.76 to 6.84 log10 CFU/ml, whereas
the same concentration of the corresponding ester reduced bacterial cells
from 9.76 to 5.13 log10 CFU/ml. Gram positive C. perfringens was more
sensitive to both forms of C12 fatty acid. Incubation of sucrose ester of
lauric acid led to the reduction of viable cells bellow the detection limit
(2 log10 CFU/ml), free acid showed the same effect at the concentrations
higher than 0.5mg/ml.
Conclusion: Both C10 and C12 fatty acids and their sucrose esters
were shown to be potent antimicrobial agents against E. coli and
C. perfringens. As expected, Gram positive C. perfringens was more
sensitive. Sucrose esters of fatty acids were shown to be more potent
antimicrobials than free acids.
Supported by project MZe 0002701404.
P1168 In vitro activity proﬁle of PMX30063 against recent clinical
isolates of Gram-positive and Gram-negative pathogens
B. Korczak*, R. Scott (Radnor, US)
Objectives: PMX30063 represents the ﬁrst of a new class of antimi-
crobial agents, a non-peptidic compound that mimics the mechanism
of action and function of antimicrobial peptides. PMX30063 is being
developed for the treatment of acute bacterial skin and skin-structure
infections and is currently in phase 2 clinical trial. The full spectrum of
activity of PMX30063 against both target and non-target pathogens was
evaluated in vitro against a diverse array of recent clinical isolates of
Gram-positive and Gram-negative pathogens. In addition, the effect of
human serum on bactericidal activity of PMX30063 was tested against
two MSSA (ATCC 29213 and ATCC 13709) and two MRSA (ATCC
33591 and 102469A) strains.
Methods: Isolates were selected from the Euroﬁns Medinet repository
for MIC broth microdilution testing against PMX30063 and comparator
agents (CLSI M7-A8 method). All isolates selected consisted of
non-consecutive, non-duplicate clinical isolates from the US. Most
recent isolates (2008 to 2009) were preferentially selected and were
predominantly of skin and wound origin.
Results: PMX30063 was potent (MIC90 of 1mg/mL) against staphylo-
cocci and maintained a consistent activity proﬁle against methicillin-
resistant isolates relative to methicillin-susceptible isolates. PMX30063
was more potent against b-hemolytic streptococci (MIC90 of 4−8mg/mL)
than S. pneumoniae and viridans group streptococci (MIC90 of
16mg/mL). PMX-30063 was more active against E. faecium isolates
(MIC90 of 2mg/mL) relative to E. faecalis (MIC90 of 8mg/mL). Among
the evaluated Gram-negative isolates, PMX-30063 was more potent
against E. cloacae and Citrobacter spp. (MIC90 of 4mg/mL) than
P. aeruginosa and Acinetobacter spp. (MIC90 of 16mg/mL). Little
activity was observed against P. mirabilis (MIC90 of 64mg/mL). The
presence of 50% human serum had minimal effects on PMX30063
antimicrobial activity with only a 2−4 fold increase in MIC when
compare to standard.
Conclusions: Overall, PMX30063 was potent against staphylococci
and other Gram-positive cocci including b-hemolytic streptococci and
E. faecium. PMX30063 was comparatively less potent against other
evaluated Gram-positive isolates (S. pneumoniae, VGS, E. faecium)
and Gram-negative isolates (Enterobacteriaceae, P. aeruginosa and
Acinetobacter spp.) though activity is maintained against E. cloacae
and Citrobacter spp. The antimicrobial activity of PMX30063 was only
marginally affected by the presence of human plasma.
Antimicrobial activity of different antibiotics
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P1169 CLSI 2010 recommendations for
cephalosporin/Enterobacteriaceae breakpoints.
What changed?
O¨. Azap*, H. Arslan, F. Timurkaynak, A. Yesilkaya (Ankara, TR)
Clinical and Laboratory Standards Institute (CLSI) has recommended
that most of the members of Enterobacteriaceae should be screened for
extended-spectrum b-lactamase (ESBL) enzyme and reported as resistant
to cephalosporins when found positive since 1999. In January 2010,
the CLSI published new breakpoints for some of the cephalosporins.
The aim of this study is to determine the antimicrobial susceptibility of
ESBL positive Escherichia coli and Klebsiella strains according to the
new CLSI recommendations.
One hundred ESBL producing E. coli strains and 92 ESBL producing
Klebsiella strains isolated from various clinical materials in the year
2010 were included in this study. The antimicrobial susceptibility was
determined via disc diffusion method according to the Clinical and
Laboratory Standards Institute (CLSI) 2010 criteria.
Of 100 ESBL positive E. coli strains 3 (3%) were found to be susceptible
to cefotaxime, 13 (13%) were susceptible to ceftazidime, 16 (16%) were
susceptible to cefepime. None of the E. coli isolates was susceptible to
ceftriaxone, cefuroxime and cefazolin. Seven (7%) of the E. coli isolates
were susceptible to ampicillin-sulbactam, 11 (11%) were susceptible to
amoxicillin-clavulonate and 45 (45%) were suceptible to piperacillin-
tazobactam. Of the 92 Klebsiella spp. strains tested only one (1%)
isolate was found to be susceptible to ceftriaxone, 5 (5.4%) were
susceptible to ceftazidime, 21 (22.8%) were susceptible to cefepime.
None of the Klebsiella isolates was found to be susceptible to cefotaxime,
cefuroxime and cefazolin. Five (5.4%) of the 92 Klebsiella strains
were susceptible to ampicillin-sulbactam, 3 (3.2%) were susceptible to
amoxicillin-clavulonate and 19 (20.6%) were susceptible to piperacillin-
tazobactam.
Antimicrobial treatment of the infections caused by ESBL producing
bacteria has been a matter of debate for a longtime. Data indicating
that all cephalosporins will fail in the treatment of ESBL positive
isolates is not existent. On the other hand, determining the antimicrobial
susceptibility solely by disc difffusion or minimal inhibitory concentra-
tion values, irrespective of the resistance mechanism, may recall false
susceptible results. The results of this study shows that cefepime may
be an alternative in approximately 15−20% of the infections caused by
ESBL positive strains based solely on the inhibition zones. The clinical
impact of these laboratory ﬁndings should be studied meticulously.
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P1170 Susceptibility to expanded-spectrum cephalosporins among
ESBL-producing Klebsiella pneumoniae and Escherichia coli
clinical isolates according to the new CLSI recommendations
I. Kristo, O. Zarkotou, A. Poulou, S. Pournaras*, A. Tsakris (Larissa,
Piraeus, Serres, Athens, GR)
Objectives: Extended-spectrum b-lactamase (ESBL)-producing organ-
isms have rapidly spread worldwide and limit treatment options be-
cause they hydrolyze efﬁciently expanded-spectrum cephalosporins and
monobactams. In 2010 the CLSI has revised susceptibility breakpoints
of these b-lactams eliminating the need for conﬁrmatory phenotypic
tests. We assessed the implications of these new recommendations on
susceptibility reporting of ESBL-producing Klebsiella pneumoniae and
Escherichia coli clinical isolates.
Methods: We studied 141 single-patient isolates of K. pneumoniae and
E. coli that were collected during 2008–2010 and characterized as ESBL
producers based on the CLSI conﬁrmatory phenotypic test and molecular
testing for ESBL genes. PCR and sequencing analysis were performed
for the characterization of ESBL-type. Cefotaxime, ceftazidime and
cefepime MICs were determined by agar dilution method and interpreted
using the 2010 breakpoints issued by CLSI.
Results: 101 isolates (71.6%) were susceptible to at least one of the
tested cephalosporins. Five (3.5%), 49 (34.8%) and 95 (67.4%) isolates
were susceptible to cefotaxime, ceftazidime and cefepime, respectively.
82 of the 113 CTX-M-producing isolates (72.6%) showed susceptibility
to at least one cephalosporin with 49 (43.3%) and 77 (68.1%) of isolates
being susceptible to ceftazidime and cefepime, respectively. Among
the 28 SHV-producing isolates, susceptibility only to cefepime was
expressed in 18 isolates (64.3%). Of the 43 K. pneumoniae isolates,
only one was susceptible to cefotaxime, two to ceftazidime and 25
(58.1%) were susceptible to cefepime, while 47 of 98 (48%) E. coli
were susceptible to ceftazidime and 70 (71.4%) to cefepime.
Conclusion: According to the new CLSI susceptibility breakpoints for
cephalosporins, a considerable percentage of isolates was interpreted as
susceptible, mostly to cefepime and in a lesser extent to ceftazidime.
In contrast, with previous recommendations, these ESBL producers
should be reported as resistant to all cephalosporins irrespective to
their MICs. The currently recommended approach would have important
therapeutic implications. However, more clinical studies are required to
support the use of third-generation cephalosporins against infections by
cephalosporin-susceptible ESBL-producing Enterobacteriaceae.
P1171 The in vitro activity of ceftaroline against isolates from
the 2008 British Society for Antimicrobial Chemotherapy
Bacteraemia Surveillance Programme
D. Biek, K. Krause, I. Critchley* (Oakland, US)
Objective: Ceftaroline (CPT), the active form of CPT fosamil, is a novel
broad-spectrum cephalosporin with activity against MRSA. CPT fosamil
was recently approved in the US for treatment of acute bacterial skin and
skin structure infections and community-acquired bacterial pneumonia.
This study sought to determine the activity of CPT against isolates
collected from patients with signiﬁcant bacteraemia.
Methods: Consecutive isolates were collected from 25 medical centres
in the UK and Ireland. MICs were determined centrally for CPT
and comparators using BSAC methods. A total of 2696 isolates were
collected, including 453 S. aureus, 179 coagulase-negative staphylococci
(CoNS), 201 S. pneumoniae, 201 b-haemolytic streptococci, 144 other
streptococci, 190 enterococci, 467 E. coli, 157 Enterobacter spp., 206
Klebsiella spp., 165 Proteus spp., 119 Serratia spp., 22 M. morganii,
and 190 P. aeruginosa.
Results: CPT exhibited potent activity against staphylococci and
streptococci. MIC90s were 0.5mg/L and 1mg/L for methicillin-
susceptible (MS) and -resistant (MR) S. aureus and 0.25mg/L and
1mg/L for MS and MR CoNS, respectively. The highest observed MIC
against penicillin-susceptible S. pneumoniae was 0.125mg/L (MIC90
= 0.015mg/L). The MIC for 1 penicillin-intermediate isolate was
0.06mg/mL. Against non-pneumococcal streptococci, MIC90s were
0.015mg/L (b-haemolytic) and 0.06mg/L (other). CPT was moderately
active against E. faecalis, with an MIC90 of 8mg/L, and was inactive
against most E. faecium (MIC90 >64mg/L).
CPT MIC90s against a limited number of ceftazidime-susceptible
(CAZ-S) E. coli, E. cloacae, E. aerogenes, and K. pneumoniae
were 0.5mg/L, 2mg/L, 4mg/L, and 1mg/L, respectively. CPT was
generally inactive against CAZ non-susceptible isolates of these species.
The MIC90 against K. oxytoca was >128mg/L because of the
production of ESBLs or K1 b-lactamase. MIC90 values were 0.5mg/L
against P. mirabilis and M. morganii. CPT was less active against
S. marcescens (MIC90 = 32mg/L) where 17.4% of isolates were AmpC
hyperproducers. CPT had little activity against P. aeruginosa, with an
MIC90 of 16mg/L against CAZ-S isolates. MICs were64mg/L against
6 CAZ-R isolates.
Conclusion: CPT exhibited potent activity against Gram-positive
(including MRSA) and CAZ-S Gram-negative isolates collected in 2008
from patients with bacteraemia.
P1172 Expression analysis of DHA-1, AmpR, OmpK35 and
OmpK36 genes in Klebsiella pneumoniae and inoculum
effect determination for selected antibiotics
D. Hepnar, D. Cervena, E. Chudackova, T. Bergerova, V. Studentova,
H. Zemlickova, J. Hrabak* (Pilsen, Prague, CZ)
Objectives: Transferable AmpC-type cephalosporinases have been
increasingly reported in recent years, becoming a signiﬁcant source
of their resistance to newer b-lactams in different geographic areas.
We focused on the determination of AmpC gene (blaDHA-1) and its
regulator (AmpR) together with the main porin genes (OmpK35 and
OmpK35) in different subinhibition doses of cephalosporins.
Methods: Previously well characterized DHA-1-producing strains of
Klebsiella pneumoniae (ST11) with different MIC patterns were used
for the experiments. Two strains with different PFGE patterns and MICs
of cefotaxime and ceftazidime in susceptible/intermediate category and
one strain with a high MICs of 3rd generation cephalosporins (>64mg/l)
were included in the study. Different concentrations of cefotaxime were
added to cultivation media and samples were collected to cover early and
late exponential phase of the bacterial growth. The gene expressions were
determined by RT-PCR. Inoculum effect was determined by a standard
microdilution method.
Results: The expression of AmpR was found to be decreasing
with increasing concentration of antibiotic and the expression of
DHA-1 constantly increased in strains with inducible phenotype. No
changes in porins expression were found, although the expression in
early exponential phase samples was non-detectable. Comparing the
expression of both porins in highly resistant isolate with “susceptible”
ones, no signiﬁcant decreasing production was observed. In the strain
with a high MICs, independent production of DHA-1 on expression of
AmpR was found. In this strain, however, the expression of DHA-1
remained inducible by cefoxitin. After the addition of cefoxitin, the
expression of DHA-1 in all strains signiﬁcantly increased together with
a decreasing of AmpR. Strong inoculum effect was found in all tested
cephalosporins (cefotaxime, ceftazidime, and cefepime) with bacterial
concentrations of 107 and 108 CFU/ml.
Conclusion: The results indicate that the expression of DHA-1 is also
inﬂuenced and slightly inducible with different level of cephalosporins
which are not strong inducers. These results could explain very strong
inoculum effect observed in all tested strains and antibiotics. No
changes of highly resistant strains compared with “susceptible” ones
were observed. These result indicates a presence of another resistance
mechanism in this strain.
This work has been supported by the grants NS9717−4/2008 and MSM
0021620819.
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P1173 Fosfomycin susceptibility testing in Enterobacteriaceae
isolates producing KPC-2, KPC-3, OXA-48 and VIM-1
carbapenemases
M. Kaase*, F. Szabados, A. Anders, S. Gatermann (Bochum, DE)
Objectives: The prevalence of multidrug-resistant gramnegative
pathogens is increasing worldwide. Especially the spread of carbapene-
mase producing Enterobacteriaceae is worrisome since those strains are
usually also resistant to most other antibiotics. No new antibiotics with
activity against gramnegative bacteria will be introduced in the next ﬁve
years. Therefore, testing the activity of older and rarely used antibiotics
is of high clinical impact.
Methods: Enterobacteriaceae with elevated carbapenem MICs were
sent to the National Reference Laboratory for Multidrug-Resistant
Gram-negative Bacteria from several laboratories all over Germany and
investigated for the presence of carbapenemases by the modiﬁed Hodge
test, synergy testing using EDTA and boronic acid, a microbiological
assay using cell-free extracts and PCR followed by sequencing.
Resistance testing of fosfomycin was performed both by Etest as
described by the manufacturer, agar dilution was performed on Glucose-
6-phosphate containing Mueller-Hinton agar as described by CLSI.
Results: K. pneumoniae (n = 16), K. oxytoca (n = 1), E. coli (n = 1),
E. cloacae (n = 1) and S. marcescens (n = 1) isolates were chosen for
this study on the basis of presence of a carbapenemase and diverse
epidemiological background.
KPC-2 was found in two isolates, KPC-3 in six isolates, OXA-48 in
eight isolates and VIM-1 in four isolates.
Using Etest the MIC range was between 1mg/L and >1024mg/L, the
MIC50 was 48mg/L and the MIC90 was >1024mg/L. By agar dilution
a MIC range between 0.25mg/L and >1024mg/L, a MIC50 of 4mg/L
and a MIC90 of 128mg/L was found. Applying EUCAST criteria 65%
of strains would be classiﬁed as resistant using Etest, while only 25%
would be determined as resistant using agar dilution.
Conclusion: Compared to agar dilution, which is considered the
reference method for susceptibility testing of fosfomycin, fosfomycin
MICs determined by Etest tend to be considerably higher. The reason of
this phenomonen remains unclear.
Using EUCAST criteria and agar dilution a diverse collection of
carbapenemase producing Enterobacteriaceae strains showed fosfomycin
susceptibility of 75%.
P1174 Polymyxin heteroresistance in extremely drug-resistant
Acinetobacter baumannii
T. Tan*, C.C. Loh, M.Y. Chin, N. Syahidah, S. Sasikala, T.P. Lim
(Singapore, SG)
Objectives: Polymyxin is an important treatment option for extremely-
drug resistant (XDR) Acinetobacter baumannii, but the phenomenon of
polymyxin hetero-resistance raises some concern about the continued
effectiveness of this antibiotic. This study investigated the prevalence of
polymyxin hetero-resistance in clinical isolates of XDR A. baumannii,
and evaluated the effect of different Etest methods for detection of
polymyxin hetero-resistance.
Methods: Population analysis proﬁles for polymyxin B were performed
for 24 isolates of clonally unrelated, XDR isolates by plating bacterial
suspensions containing 108 cfu/ml on Mueller-Hinton agar plates
containing increasing concentrations of polymyxin B. Polymyxin hetero-
resistance was deﬁned as any isolate with polymyxin B MIC 2mg/L,
in which detectable subpopulations were able to grow in the presence
of >2mg/L. Conﬁrmatory antimicrobial susceptibility testing was
performed on any polymyxin B resistant isolates recovered from PAP
studies. Polymyxin B time-kill testing was performed on a subset of
non-heteroresistant and hetero-resistant strains to compare population
kinetics of different strains to polymyxin B. Finally, the effectiveness of
a hetero-resistant Etest screening protocol was evaluated by performing
polymyxin Etests and varying testing parameters of inoculum density,
media and incubation duration.
Results: Seven of 24 (29%) study isolates demonstrated polymyxin
hetero-resistance, with populations of polymyxin-resistant isolates
detected at concentrations of 101.0–102.2 cfu/ml. These polymyxin-
resistant subpopulations were highly resistant to polymyxin B, but in
contrast to the original isolates, also demonstrated susceptibility to
multiple other antibiotics. Time-kill studies showed no difference in
the activity of polymyxin B against hetero- and non-hetero-resistant
strains. No combination of Etest parameters was effective at screening
for polymyxin hetero-resistant isolates.
Conclusion: Polymyxin hetero-resistance is common in XDR A. bau-
mannii. Polymyxin-resistant subpopulations demonstrated high-level
resistance to polymyxin B, but unlike polymyxin-resistance that develops
in-vivo, these subpopulations also demonstrated reversion of the XDR
phenotype. None of the evaluated Etest parameters were suitable for as
a screening test for detection of the hetero-resistant phenotype. Further
work needs to be performed to determine the clinical relevance of
polymyxin hetero-resistance in A. baumannii.
P1175 Synergy of fosfomycin with carbapenems, colistin, netilmicin,
and tigecycline against MDR Klebsiella pneumoniae, Es-
cherichia coli, and Pseudomonas aeruginosa clinical isolates
G. Samonis*, S. Maraki, D. Karageorgopoulos, E. Vouloumanou,
M. Falagas (Heraklion, Athens, GR)
Objectives: Fosfomycin represents a potential last resort treatment
option for infections caused by certain multidrug resistant (MDR) Gram-
negative pathogens.
Methods: We evaluated double-drug combinations of fosfomycin with
imipenem, meropenem, doripenem, colistin, netilmicin, and tigecycline
for in vitro synergy against 100 MDR Klebsiella pneumoniae,
Escherichia coli, and Pseudomonas aeruginosa clinical isolates, using
the Etest method. Synergy was deﬁned as a fractional inhibitory
concentration index 0.5. The isolates were consecutively collected at
a microbiological laboratory of a university hospital in Greece from
various clinical specimens.
Results: Against 50 serine carbapenemase-producing K. pneumoniae
isolates, synergy of fosfomycin with imipenem, meropenem, doripenem,
colistin, netilmicin, and tigecycline was observed for 74.0%, 70.0%,
74.0%, 36.0%, 42.0%, and 30.0% of the isolates, respectively; against
1 metallo-b-lactamase producing K. pneumoniae isolate fosfomycin
was synergistic only with imipenem. Against 14 extended-spectrum
b-lactamase (ESBL) producing K. pneumoniae isolates, synergy of
fosfomycin with imipenem, meropenem, doripenem, colistin, netilmicin,
and tigecycline was observed for 78.6%, 42.9%, 42.9%, 7.1%, 42.9%,
and 21.4%, respectively; for 20 ESBL-producing E. coli isolates the
corresponding values were 55.0%, 25.0%, 30.0%, 15.0%, 25.0%, and
25.0%; and for 15 MDR P. aeruginosa isolates the corresponding values
were 46.7%, 53.3%, 73.3%, 13.3%, 13.3%, and 13.3%. Antagonism was
not observed for any of the combinations tested.
Conclusion: Fosfomycin was synergistic in combination with a
carbapenem against the majority of the MDR pathogens studied, whereas
synergy with other than carbapenems agents was less common. Further
studies are needed to conﬁrm the clinical relevance of the above ﬁndings.
P1176 Antibiotic combinations for Klebsiella sp. harbouring New
Delhi Metallo-b-lactamase-1 in Singapore
T.P. Lim*, J. Teo, W. Lee, S. Sasikala, D.Q. Chia, T.Y. Tan, L.Y. Hsu,
T.H. Koh, T. Tan, A.L. Kwa (Singapore, SG)
Objectives: Klebsiella sp. (KS) with bla-New Delhi Metallo-
b-lactamase-1 (NDM-1) gene have emerged in Singapore. These easily
transferrable genes pose a huge clinical threat, as they have the potential
to spread rapidly. Effective Antibiotic (Abx) are scarce and we may
have to resort to combination therapy until new antimicrobial agents
are available. We aim to elucidate Abx combinations that may have a
potential for clinical use against NDM-1 KS.
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Methods: 60 KS non-repeat isolates that were ertapenem resistant
were collected from the largest hospital in Singapore in 2010. Clonal
relatedness was determined by multiplex PCR strain typing. They were
then screened for bla-NDM-1-like genes using RT-PCR. MICs of the test
isolates were determined according to the reference CLSI broth-dilution
method. Time-kill studies (TKS) were performed with approximately 5
log CFU/ml at baseline using maximally achievable clinical, unbound
concentration (mg/L) of amikacin (A) (80), levoﬂoxacin (L) (8),
cefepime (C) (200), rifampicin (R) (2), tigecycline (T) (2) and polymyxin
B (P) (2) alone & in combination against the test isolates.
Results: 4 non-clonal isolates harbouring NDM-1 were identiﬁed.
Among the test isolates, they were multidrug-resistant with high
carbapenem MICs (64mg/L). MICs of P ranged from 0.5 to 4mg/L.
In single Abx TKS, most drugs did not exhibit any killing activity in
all 4 strains although P alone exhibited bactericidal activity against all
strains (3 log decrease from baseline inocula) until 8h before regrowth
occurred at 24h. In combination TKS at 24h, P+T was synergistic (>2
log decrease when compared to its most active antibiotic) against strain
1 while A+L, A+R, A+P, A+T, L+T and P+T were bactericidal against
strain 2. Against strain 3, A+L, A+P, A+C, A+T, L+P were bactericidal
while no Abx combinations were even synergistic against strain 4.
Conclusions: Combination therapy may be considered as a therapeutic
option for NDM-1 KS infections. However, there was no antibiotic
combination that reliably demonstrated bactericidal or synergistic activity
against all isolates. The efﬁcacy of combination therapy may be highly
strain speciﬁc. The in-vivo relevance of the results warrants further
investigation.
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P1177 Minimum inhibitory concentrations of meropenem and
doripenem for Pseudomonas aeruginosa from the UK
R. Hope*, A. Chaudhry, R. Adkin, A. Guleri, S. Williams, R. Sharma,
D. Livermore (London, Blackpool, Blackburn, UK)
Objectives: Comparison of the minimum inhibitory concentrations
(MICs) of meropenem and doripenem required for Pseudomonas
aeruginosa from multiple hospitals in the UK.
Methods: Seven-hundred and forty-eight P. aeruginosa were selected
from the British Society for Antimicrobial Chemotherapy (BSAC) bac-
teraemia surveillance programme and supplemented with an additional
216 meropenem- or doripenem-, non-susceptible P. aeruginosa isolates.
MICs were determined using the BSAC agar dilution method.
Results: The table shows doripenem MICs (mg/L) cross tabulated
against those for meropenem for the 964 P. aeruginosa. In 779/964 (80%)
of cases MICs of meropenem were higher than those of doripenem with
30% of isolates 4 foldmore susceptible to doripenem. The degree of
difference between the two carbapenem’s MICs was not uniform across
the MIC distribution. Rather, in general the differences in MICs were
smallest at the extremes of the MIC distribution. Despite the MIC
differential in favour of doripenem only 35 isolates that were non-
susceptible to meropenem were susceptible to doripenem, where as 9
were susceptible to meropenem but not doripenem. This was mostly due
to meropenem’s susceptible breakpoint being 2mg/L vs. 1mg/L for
doripenem, thus off setting the fact that meropenem MICs are higher, in
general, than those of doripenem.
Conclusions: Doripenem MICs for P. aeruginosa were lower than those
of meropenem for 80% of P. aeruginosa isolates. However, due to
doripenem having lower MIC breakpoints, than meropenem this does
not manifest as a large difference in susceptibility. Doripenem’s relative
advantage will only be exploitable if higher dosages can be shown as
effective and safe, justifying a higher breakpoint.
P1178 Activity of doripenem versus imipenem, meropenem and
ceftazidime in clinical isolates of Pseudomonas aeruginosa
and Acinetobacter baumannii in Portugal
L. Sancho*, T. Sardinha, G. Sousa, F. Silva, F. Matos (Amadora, PT)
Objective: The doripenem (DOR) is a new carbapenem with a broad
spectrum of activity against aero and anaerobic bacteria, Gram negative
and Gram positive, with approved indications for nosocomial pneumonia
and complicated intra-abdominal and urinary tract infections.
Studies point to improved activity relative to other carbapenems against
bacteria considered problematic, particularly Pseudomonas aeruginosa,
Acinetobacter baumannii and ESBL-producing Enterobacteriaceae.
The purpose of this study is to compare the activity of this antibiotic with
imipenem, meropenem and ceftazidime in problematic strains isolated
at Hospital Prof. Dr. Fernando Fonseca in Lisbon during 2010, namely
Pseudomonas aeruginosa and Acinetobacter baumannii and to assess the
beneﬁt of introducing this antibiotic in the hospital as a better alternative
to other carbapenems.
Method: Retrospective study of 52 strains of A. baumannii and 60 strains
of P. aeruginosa from clinically signiﬁcant samples of patients from the
hospital.
The identiﬁcations and MIC calculated from the breakpoint of the
susceptibility card, to imipenem, meropenem and ceftazidime of these
strains were obtained from the equipment VITEK2® (Biome´rieux), using
the GN and AST-N093 cards.
The MIC determinations of doripenem were obtained with the Etest
technique (Biomerieux) in Muller-Hinton medium (BioMerieux) with a
suspension of 0.5 McFarland.
Results: Strains of P. aeruginosa revealed for doripenem a sensitivity
of 67% and a resistance of 33%, for meropenem a sensitivity of 77%,
a resistance of 21% and 2% of intermediate results, for imipenem a
sensitivity of 83% and a resistance 17% and for ceftazidime a sensitivity
of 78%, a resistance of 10% and 12% of intermediate results.
Strains of A. baumannii presented for doripenem and meropenem a
sensitivity of 10% and a resistance of 90%, for imipenem a sensitivity
of 8%, a resistance of 90% and 2% of intermediate results and for
ceftazidime a sensitivity of 11%, a resistance of 79% and 10% of
intermediate results.
The MIC50 and MIC90 calculated based on graphs of cumulative
percentages are very close for the several antibiotics and both strains.
Conclusions: The doripenem showed similar results to the other
carbapenems for strains of A. baumannii and slightly lower sensitivity
and greater resistance to P. aeruginosa tested. Doripenem, in a
microbiological level, shows no advantages over other carbapenems and
therefore has no advantages to being available at our hospital.
P1179 Antimicrobial activity and spectrum of doripenem against
contemporary (2010) clinical bacterial pathogens from
Europe
D. Farrell*, G. Moet, H. Sader, R. Jones (North Liberty, US)
Objectives: To evaluate the in vitro antimicrobial activity of doripenem
(DOR) tested against prevalent Gram-negative and -positive pathogens
isolated across Europe (EU) during 2010. DOR is an approved
carbapenem in EU for the treatment of nosocomial pneumonia (NP),
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including ventilator-associated pneumonia (VAP), complicated intra-
abdominal infections (cIAI) and complicated urinary tract infections
(cUTI).
Methods: A total of 9,618 consecutive, non-duplicate isolates from
a wide variety of infections were collected from 39 medical centers
located in Europe, Turkey, and Israel during 2010. Species identiﬁcation
was conﬁrmed by the central monitoring laboratory and all isolates
were susceptibility (S) tested using reference CLSI broth microdilution
methods (M7-A8, 2009) against DOR and numerous comparison agents.
Results: Doripenem was very active against Enterobacteriaceae,
inhibiting 99% of isolates at 0.5mg/L (MIC90, 0.12mg/L). Cumulative
percentage inhibition by DOR MIC for the major organism groups is
shown in the Table. DOR exhibited good activity against P. aeruginosa
(MIC50/90, 0.5/4mg/L) and some Acinetobacter spp., inhibiting 49% of
isolates at 8mg/L. Against Gram-positive pathogens, DOR had very
high activity against methicillin-susceptible S. aureus (MSSA), MS-
coagulase-negative staphylococci (CoNS), b-haemolytic streptococci,
and S. pneumoniae with MIC90 values of 0.06, 0.06, 0.06, and
0.5mg/L, respectively. DOR was less active against MRSA and MR-
CoNS with both having a MIC50 of 2mg/L, as well as E. faecalis
(MIC50, 2mg/L). DOR was not active against the vast majority of
E. faecium (MIC50, >8mg/L, range 2−>8mg/L).
Conclusions: DOR exhibited a wide-spectrum of antimicrobial activity
against 9,618 contemporary EU pathogens and excellent activity against
most Gram-positive pathogens except for MRSA, MR-CoNS and
Enterococci. Against Gram-negative pathogens, DOR showed excellent
activity against Enterobacteriaceae and against many multidrug-resistant
P. aeruginosa and Acinetobacter spp. This data supports the use of DOR
as therapy for hospitalized patients, in whom carbapenem therapy would
be warranted to treat serious and typically difﬁcult-to-treat infections,
such as NP, VAP, cIAI, and cUTI in the European area.
P1180 In vitro activity of doripenem against multidrug-resistant
clinical strains of Acinetobacter baumannii, Pseudomonas
aeruginosa and Klebsiella pneumoniae
N. Skarmoutsou*, M. Kehagia, D. Dimitriadi, K. Stamoulos,
I. Mintziras, M. Martsoukou, E.M. Fakiri (Athens, GR)
Objectives: Doripenem is an injectable carbapenem that gained approval
for treatment of hospital acquired pneumonia, urinary tract infections
and intra-abdominal infections. The objectives of the present study were
to investigate the in vitro activity of doripenem against a range of
multidrug resistant Gram(−) isolates and to compare its activity with
that of meropenem, imipenem and tigecycline.
Methods: A total of 113 different clinical isolates were tested. The
isolates included 30 carbapenem resistant A. baumannii strains (non
MBL or KPC), 30 P. aeruginosa MBL producing strains and 53
K. pneumoniae strains, of which 10 produced ESBL, 6 KPC, 2
MBL, 19 ESBL and KPC, 10 ESBL and MBL, 4 MBL and KPC
and 2 ESBL, MBL and KPC. Susceptibility of the isolates was
initially performed using the Wider system (Soria) and the results
were conﬁrmed using the E-test method following the manufacturer’s
guigelines (bioMerieux, Sweden). Sensitivity and resistance breakpoints
for doripenem, meropenem and imipenem were determined according to
CLSI 2010 new interpretive criteria, while FDA guidelines determined
susceptibility to tigecycline. E. coli ATCC 25922 was used as QC.
The phenotypic detection of the production of extended spectrum
b-lactamases, metallo-b-lactamases MBL and carbapenemases KPC, was
performed by the double disk synergy test, the combined disk test, the
two-sided E-test and the modiﬁed Hodge Test on M. H. agar.
Results: See the table.
Conclusions: The in vitro activity of doripenem, which is considered
superior to meropenem against multidrug resistant A. baumannii, MBL
producing P. aeruginosa and KPC producing K. pneumoniae, does not
seem to support its use as monotherapy in the treatment of infections
caused by those bacteria. On the other hand tigecycline might provide
an alternative therapeutic choice against infections caused by MBL
producing K. pneumoniae strains.
P1181 In vitro antibacterial activity of doripenem against
multidrug-resistant Acinetobacter baumannii isolates from
adult intensive care units
E. Protonotariou, S. Arampatzi*, O. Vasilaki, F. Tsiapara, F. Frantzidou,
E. Diza (Thessaloniki, GR)
Objectives: Acinetobacter baumannii is a frequent cause of serious
hospital infections in intensive care units. Effective treatment options
for these infections are limited. An alternative to current antimicrobial
agents could be doripenem (DOR), a carbapenem with activity against
Gram-negative bacteria, including A. baumannii, approved for the
treatment of adults with complicated intra-abdominal (cIAI) and urinary
tract infections (cUTI) in the United States, and cIAI, cUTI, and
nosocomial pneumonia in Europe. The aim of the present study was
to evaluate the in vitro activity of doripenem against multidrug resistant
(MDR) A. baumannii isolates from hospitalised patients in the adult
intensive care units (ICU) of AHEPA University Hospital.
Material-Methods: Between January and December 2009, 95 MDR
A. baumannii were isolated from cultures of various clinical specimens,
from inpatients of critical care units with a documented infection.
Bacterial identiﬁcation and susceptibility testing was performed using
Vitek2 system (bioMe´rieux, France). Susceptibility testing of doripenem
was performed with E-test strips (AB Biodisc, Sweden). Isolates were
deﬁned as susceptible) (MIC 1mg/ml) or resistant (MIC 4mg/ml)
to doripenem according to the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) guidelines.
Results: 1) Most strains were isolated from cultures of bronchial
secretions (38/95) 2) Overall, 51 (48%) strains were found to be resistant
to >3 antibiotics belonging to different antimicrobial classes. Most
strains were resistant mainly to ceftazidime, ciproﬂoxacin, imipenem
and piperacillin/tazobactam, moderately susceptible to meropenem,
cefepime, and susceptible to gentamicin and tigecycline. 4) All strains
were susceptible to colistin. 4) From 95 strains, only 4/95 (4%) were
susceptible to doripenem, 42/95 (42%) moderately susceptible and 49/95
(54%) resistant. MIC50 of doripenem was 4mg/ml.
Conclusions: A. baumannii strains from adult ICU showed high
resistance rates against doripenem and in our hospital this agent doesn’t
seem an alternative agent against MDR A. baumannii infections.
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P1182 Comparative activity of doripenem, ertapenem and
imipenem against clinical isolates of Klebsiella pneumoniae
producing extended-spectrum b-lactamases, plasmid-
mediated AmpC-type b-lactamases or both, associated or
not with porin deﬁciency
M.C. Conejo, J.M. Rodrı´guez-Martı´nez*, L. Serrano, A´. Pascual
(Seville, ES)
Objective: To evaluate the activity of doripenem (compared to
ertapenem and imipenem) against clinical isolates of Klebsiella pneu-
moniae producing extended spectrum b-lactamases (ESBL), plasmid-
mediated AmpC-type b-lactamases (pACBL) or both, associated or not
with porin (POR) deﬁciency.
Methods: Fifty K. pneumoniae clinical strains were studied, includ-
ing 2 ESBL-/pACBL-/POR-, 10 ESBL+/POR+, 12 ESBL+/pACBL-
/POR-, 18 ESBL-/pACBL+/POR+, 1 ESBL-/pACBL+/POR-, 4
ESBL+/pACBL+/POR+, and 3 ESBL+/pACBL+/POR-. Antimicrobial
susceptibilities to doripenem, ertapenem and imipenem were determined
by broth microdilution (CLSI guidelines) with standard and 10-fold
higher inocula. The inoculum effect was deﬁned as an eight-fold or
greater MIC increase on testing with the highest inoculum. Clinical
categories were assigned applying the new CLSI interpretative criteria
for carbapenems and Enterobacteriaceae (document M100-S20-U; June
2010).
Results: The MIC50 of doripenem, ertapenem and imipenem were
0.125, 0.5 and 0.5mg/L respectively, the MIC90 were 1, 16 and 1mg/L,
respectively. Doripenem and Imipenem displayed an excellent activity
against isolates POR +, irrespective of b-lactamase(s) produced, with
100% of susceptible strains whereas the percentage of susceptibility fell
to 72% in the group of strains POR-. The percentage of susceptibility to
ertapenem among POR+ isolates was 59% and fell to 17% in the group
POR-.
Inoculum effect was observed for all three carbapenems, but almost
always in isolates pACBL+, being more pronounced with doripenem,
but with fewer changes in the clinical category than those observed
in the cases of ertapenem and imipenem. Thereby, at standard inoculum
the percentages of susceptibility to doripenem, ertapenem and imipenem
were 90, 44 and 90%, respectively, whereas at 10-fold-higher inoculum
were 82, 30 and 54%.
Conclusions: Doripenem and imipenem displayed an excellent activity
against clinical isolates of Klebsiella pneumoniae producing ESBL,
pACBL or both and expressing POR. Using the new CLSI interpretative
criteria for carbapenems and Enterobacteriaceae, ertapenem showed the
lowest activity against these strains. Porin deﬁciency decreased the
activity of all three carbapenems. Clinical categories of doripenem, in
contrast to those of imipenem, were rarely affected by high inocula.
P1183 Carbapenems alone or combined with colistin are still
bactericidal against clonal VIM-1 b-lactamase-producing-
Klebsiella pneumoniae epidemic strains
M. Morosini, A. Shan*, M. Garcı´a-Castillo, M. Tato, R. Canto´n
(Madrid, ES)
Objective: Both metallo-b-lactamases (MBL) and Class A carbapene-
mases variably affect in vitro activities of carbapenems and particularly
MBL-producers frequently remain in the clinically susceptible or inter-
mediate category according to new breakpoints (CLSI and EUCAST).
Nevertheless, limited evidence is available supporting the clinical use
of carbapenems either alone or in combination with non-b-lactams in
infections due to MBL-producers. The killing rate of imipenem (IMP),
meropenem (MER) ertapenem (ERT), doripenem (DOR), colistin (COL),
and tigecycline (TIG) and of MER+COL, MER+TIG and COL+TIG
against a clonal VIM-1 producing Klebsiella pneumoniae recovered in
an epidemic at our hospital was assessed.
Methods: Micro and macrodilution tests were performed (CLSI). 24 h-
time-kill studies (KC) with IMP, MER, ERT and DOR were assessed at
1x, 2x and 4xMIC; KC with COL, TIG, either alone or combined with
MER were conducted at 4x MIC each. Bactericidal activity was deﬁned
as a decreased of 3 log CFU/ml of the initial inoculum (ca. 5x10E5
CFU/ml).
Results: The VIM-1-K. pneumoniae strain (representing all the clonal
isolates) was resistant (EUCAST 2010) to all b-lactams including DOR
(MIC 8mg/L), intermediately susceptible to IMI and MER (8mg/L)
and ERT (1mg/L) and susceptible to COL and TIG (MIC, 1mg/L).
MER and ERT exhibited a bactericidal activity even at 1xMIC, IMI was
bactericidal at 2x and 4x MIC, DOR had a more erratic kinetic being
less bactericidal at all concentrations. Bactericidal activity of COL was
almost reached after 4 h but with a sustained regrowth after that time.
TIG was bacteriostatic along the 24 h. MER+COL were bactericidal and
synergistic starting from 4 h and no regrowth was observed. MER+TIG
were bacteriostatic and indifferent despite the bactericidal activity of
MER when tested alone. COL+TIG were bactericidal and synergistic
after 6 h incubation.
Conclusion: IMI, MER and ERT alone were still bactericidal against the
VIM-1-K. pneumoniae strain. Moreover, MER+COL unlike MER+TIG
were bactericidal and suppressed any possible bacterial regrowth after
24 h. These data support the usefulness of certain antibiotic combination
strategies against MBL-producing Enterobacteriaceae.
P1184 In vitro activity of the siderophore sulfactam BAL30072
against meropenem non-susceptible Acinetobacter baumannii
P.G. Higgins*, D. Stefanik, M. Page, M. Hackel, H. Seifert (Cologne,
DE; Basel, CH; Schaumberg, US)
Objectives: Multidrug-resistant Acinetobacter baumannii is a growing
threat leaving few therapeutic options. Recently there has been a dramatic
increase in carbapenem-resistance mediated mainly through the action
of intrinsic and acquired OXA-type enzymes. Metallo-carbapenemases
while rare in this species, are also detected and pose a signiﬁcant
potential threat. Efﬂux does not signiﬁcantly affect carbapenems,
however it plays a role in the intrinsic resistance to ﬂuorquinolones,
tetracyclines, aminoglycosides and macrolides. BAL30072 is a novel
siderophore sulfactam that enters the cells through a non-porin route
and is not affected by efﬂux. The activity of BAL30072 was compared
with anti-Acinetobacter reference drugs against deﬁned A. baumannii
isolates that had either an acquired OXA or up-regulation of the intrinsic
OXA-51-like enzyme.
Methods: Antimicrobial susceptibility testing was investigated by
broth microdilution of 310 non-duplicate, meropenem non-susceptible
A. baumannii isolates to BAL30072, amikacin ampicillin/sulbactam,
aztreonam, cefepime, colistin, imipenem, levoﬂoxacin, meropenem,
rifampicin, tigecycline, and tobramycin.
Results: The MIC range, MIC50 and MIC90 values (mg/ml) of the 310
A. baumannii isolates are summarised in the table. BAL30072 showed
greater activity than the b-lactam comparators, levoﬂoxacin, amikacin,
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tobramycin and rifampicin. MIC50 of BAL30072 was comparable to
tigecycline. Elevated BAL30072 MICs were found, but there was no
correlation with elevated MICs for the other antimicrobials.
Conclusion: BAL30072 is a promising new agent with good activity
against carbapenem-resistant A. baumannii.
Quinolones
P1185 In vitro activity of delaﬂoxacin against European isolates of
Staphylococcus aureus from skin and soft tissue, respiratory,
urine and blood specimens
L. Lawrence*, C. Pillar, D.F. Sahm, E. Burak (New Haven, Chantilly, US)
Objectives: Delaﬂoxacin (DFX) is an investigational ﬂuoroquinolone
with excellent activity against a variety of Gram-positive bacteria,
including quinolone-resistant methicillin-resistant Staphylococcus aureus
(MRSA). We evaluated the in vitro activity of DFX against S. aureus
strains isolated from wound, respiratory, urine, and blood specimens in
Europe. Isolates represented inpatient, outpatient and ICU populations
from 2006 to 2008 from eleven countries.
Methods: Minimum inhibitory concentration (MIC) values were
determined by broth microdilution according to CLSI methodology.
Comparator agents included levoﬂoxacin (LVX), linezolid (LNZ),
daptomycin (DAP), vancomycin (VAN), oxacillin (OXA), clindamycin
(CLI), erythromycin (ERY), and tigecycline (TIG).
Results: Ninety-six percent of strains were found to be methicillin
resistant by susceptibility testing using OXA. DFX MIC values
(mcg/mL) are presented below by country for wound, respiratory and
blood isolates (N = 681). By country MIC90 values for DFX ranged
from 0.12 to 0.5 mcg/mL and MIC50 values ranged from 0.004 to 0.25
mcg/mL. Against all MRSA strains in Europe (n = 676) MIC50/MIC90
values for DFX were 0.12/0.25 mcg/mL. The MIC50/90 values against
MRSA overall for LVX, LNZ, DAP, VAN, OXA, CLI, ERY, TIG were
0.12/>32, 1/2, 1/1, 0.5/1, >8/>8, 0.12/>8, >16/>16, 0.06/0.12 mcg/mL,
respectively. LFX was at least 32-fold less active than DFX against all
geographically grouped strains comparing MIC90s overall or by country.
Conclusions: DFX was more potent than LVX against MRSA, regardless
of geographic region. The activity of DFX was largely consistent across
regions, although isolates with slightly higher DFX MIC values were
more frequently encountered in Germany, Belgium, and Central Europe.
P1186 Antibacterial activity of the investigational ﬂuoroquinolone
ﬁnaﬂoxacin under different pH conditions against
Staphylococcus aureus small-colony variants
E.A. Idelevich, A. Kriegeskorte, W. Stubbings, B. Kahl, G. Peters,
K. Becker* (Mu¨nster, Berlin, DE)
Objectives: Finaﬂoxacin (FIN) is an investigational C-8-cyano-
ﬂuoroquinolone (FC) containing a unique chiral C7 substituent that
exhibits broad-spectrum antibacterial activity. While all other marketed
ﬂuoroquinolones exhibit signiﬁcantly reduced activity at slightly acidic
pH (5.0−6.5), FIN’s activity is enhanced at these conditions typical for
the environment of abscesses. Staphylococcus aureus represents a typical
abscess-forming microorganism and its small colony variant (SCV)
phenotype has been associated with chronic and relapsing infections.
Here, the in vitro activity of FIN against methicillin-susceptible (MSSA)
and methicillin-resistant (MRSA) S. aureus isolates displaying normal
(NP) and SCV phenotypes was compared with those of ciproﬂoxacin
(CIP), levoﬂoxacin (LEV) and moxiﬂoxacin (MOX) at neutral and low
pH conditions.
Methods: In vitro activities of FIN, CIP, LEV and MOX were tested
against 28 MSSA and 3 MRSA clinical strain pairs consisting of
SCVs and their clonally identical S. aureus parental strains displaying
the normal phenotype. Additionally, two S. aureus mutants displaying
the SCV phenotype (hemin-auxotrophic hemB mutant and thymidine-
auxotrophic thyA mutant) and their parental strains were included.
Applying epsilometer test, MIC50, MIC90 and MIC ranges were
calculated at pH 5.8 and pH 7.2.
Results: Against MSSA, FIN demonstrated superior activity under acidic
conditions for both phenotypes (MIC90 of NP/SCV, mg/L: 0.125/0.094
(FIN); 1.5/2 (CIP); 0.75/0.5 (LEV) and 0.25/0.25 (MOX)). At neutral
conditions, the activity against MSSA was as follows: MOX > FIN >
LEV > CIP. In comparison to methicillin-susceptible NP isolates, CIP
was less active against their corresponding SCVs. For other FQs, there
was no marked difference in activity between NPs and SCVs observed.
At pH 5.8, FIN showed highest activity also against the hemB and thyA
mutants and their parental strains as well as against those NP-SCV pairs
tested methicillin-resistant.
Conclusion: Abscesses still represent a therapeutic dilemma because
available antimicrobial agents are often ineffective and their therapy
regularly necessitates surgical intervention. Thus, in particular at acidic
conditions, FIN appears to be a promising antibiotic agent for the
treatment of persistent staphylococcal infections including those caused
by SCVs.
P1188 Comparative in vitro activity of sitaﬂoxacin and other
ﬂuoroquinolones against bacteria isolated from patients with
urinary tract infections and lower respiratory tract infections
V. Thamlikitkul*, S. Tiengrim, D. Phiboonbanakit, S. Thunyaharn,
W. Tantisiriwat, S. Santiwatanakul, W. Susaengrat, N. Srisurat,
A. Malithong, P. Srisangchan (Bangkok, Khon-Kaen, TH)
Background: Sitaﬂoxacin (DU 6859a) is a broad-spectrum oral
ﬂuoroquinolone and it is very active against many bacteria including the
strains resistant to other ﬂuoroquinolones. The objective of the study was
to determine in vitro activity of sitaﬂoxacin and other antibotics against
common causative bacteria isolated from the patients with urinary tract
infections and those with lower respiratory tract infections who attended
ﬁve tertiary care hospitals in Thailand in 2010.
Methods: We studied 1,255 strains of E. coli (N = 140), K. pneumoniae
(N = 196), P. mirabilis (N = 100), P. aeruginosa (N = 216), A. baumannii
(N = 198), Enterococcus spp (N= 100), S. pneumoniae (N = 100),
S. aureus (N = 105), H. inﬂuenzae (N = 50), and M. catarrhalis
(N = 50) isolated from different Thai patients with urinary tract
infection and those with lower respiratory tract infection in 2010. The
minimum inhibitory concentrations (MICs) of sitaﬂoxacin, levoﬂoxacin,
ciproﬂoxacin, moxiﬂoxacin were determined by agar dilution method.
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Results: The MIC50 and MIC90 of tested antibiotics and susceptibility
rate of tested organisms are shown in Table.
Conclusion: Sitaﬂoxacin is much more active than levoﬂoxacin,
moxiﬂoxacin against bacteria including multidrug-resistant strains
isolated from Thai patients with urinary tract infections and lower
respiratory tract infections.
P1189 Bioﬁlm susceptibility of P. aeruginosa isolated from
patients with otitis media to ciprodex, ciproﬂoxacin and
N-acetylcysteine
M. Noble, V. Restelli, B. Westerberg, R. Rennie*, L. Turnbull
(Vancouver, Edmonton, CA)
Objective: P. aeruginosa is a common cause of chronic otitis media in
which bioﬁlm formation favors bacterial resistance. N-Acetylcysteine
(NAC) is a well known mucolytic agent which has limited in vitro
antibacterial activity but synergy with Ciprodex (ciproﬂoxacin 0.3%/
dexamethasone 0.1%). The combination may have promise for the
treatment of chronic otorrhea. Our objective was to demonstrate synergy
between Ciprodex and or ciproﬂoxacin and NAC against bioﬁlm forming
P. aeruginosa strains isolated from otitis cases.
Methods: 15 clinical isolates of P. aeruginosa were tested using
the bioFILM PA ™ antimicrobial susceptibility assay (Innovotech,
Edmonton, AB) to determine antimicrobial susceptibility of both
planktonic and bioﬁlm P. aeruginosa to Ciprodex and ciproﬂoxacin both
alone and in combination with NAC. Isolates were grown on plastic
pegs in a 96 well format to allow identical bioﬁlms to form on all pegs.
The pegs were then placed into 96 well microplates containing Ciprodex
and ciproﬂoxacin both alone or in combination with NAC at various
concentrations. Susceptibility of the planktonic population was measured
by a microreader at 620 nm after overnight incubation. Viability of the
sessile population was assessed after rinsing the pegs and placing them
in recovery medium for 24 hrs.
Results: Of the 15 P. aeruginosa strains, one (7%) showed growth
in all Ciprodex tested concentrations and two strains (13%) showed
growth in two ciproﬂoxacin concentrations in the planktonic state. Higher
resistance to Ciprodex and ciproﬂoxacin was observed in the sessile
population where ﬁve (33%) strains showed growth in one or more
ciprodex or ciproﬂoxacin concentration. NAC, in a ﬁnal concentration of
0.5mg/mL, effectively inhibited both planktonic and sessile populations
when added to any of the Ciprodex or ciproﬂoxacin concentrations. No
growth was observed in any of the wells with added NAC.
Conclusion: Sessile P. aeruginosa were less susceptible than the
planktonic populations to Ciprodex and ciproﬂoxacin when tested alone.
The addition of NAC to Ciprodex or ciproﬂoxacin completely inhibited
the growth of both planktonic and sessile populations. These results
suggest there are differences between bioﬁlm state and planktonic state
in P. aeruginosa strains. Bioﬁlm P. aeruginosa are more resistant to
Ciprodex or ciproﬂoxacin. The combination of these agents with NAC
may increase their clinical utility in the treatment of chromic otitis media.
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P1190 Bacterial co-infections in community-acquired pneumonia
cases of 2009 pandemic inﬂuenza A/H1N1 in Spain
C. Cillo´niz*, R. Menendez, S. Ewig, E. Polverino, A. Gabarrus,
M. Marcos, E. Moreno, J. Mensa, A. Torres (Barcelona, Valencia,
ES; Bochum, DE)
Background: Bacterial co-infection in adult patients with pneumonia has
been scarcely studied and their clinical signiﬁcance remains unknown.
Objectives: To investigate the role and the incidence of bacterial co-
infection in patients with inﬂuenza A (H1N1) pneumonia.
Results: The incidence of H1N1 was 19% at both hospitals. We studied
128 patients: 42 (32.8%) presented with bacterial co-infection. The
most frequently isolated microorganism was Streptococcus pneumoniae
(62%). The factors associated with bacterial co-infection were presence
of COPD (OR 11.79, 95%CI 2.42 to 57.29, p = 0.002), C-reactive protein
(+1mg/dL increase, OR 1.04, 95%CI 1.00 to 1.07, p = 0.070), and
platelets count (per mm3) (+10 units increase, OR 1.06, 95%CI 1.02 to
1.11, p = 0.009). Independent predictors of bacterial co-infection found in
the multivariate analysis were presence of COPD (OR 9.66, 95%CI 1.93
to 48.31, p = 0.002) and platelets count (per mm3) (+10 units increase,
OR 1.05, 95%CI 1.00 to 1.11, p = 0.041).
Twelve patients (9%) died, the mean age of deceased patients was
51 years. Factors associated with mortality were age 65 years (OR
7.57, 95%CI 2.03 to 28.29, p = 0.003), prior inﬂuenza vaccination (OR
4.61, 95%CI 1.12 to 18.93, p = 0.034), serum creatinine (+1mg/dL)
(OR 1.84, 95%CI 1.04 to 3.28, p = 0.038), serum lactate dehydrogenase
(+100U/L) (OR 1.11, 95%CI 1.00 to 1.25, p = 0.060), presence of
chronic cardiovascular disease (OR 15.86, 95%CI 3.70 to 68.01,
p< 0.001), PSI IV–V (OR 6.82, 95%CI 1.85 to 25.14, p = 0.004)
and multilobar inﬁltration (OR 4.74, 95%CI 1.22 to 18.51, p = 0.025).
Factors independently associated with mortality were age 65 years
(OR 5.77, 95%CI, 1.11 to 29.94, p = 0.037), presence of chronic
cardiovascular disease (OR 8.60, 95%CI 1.63 to 45.33, p = 0.011) and
multilobar inﬁltration (OR 5.56, 95%CI 1.12 to 27.68, p = 0.036).
Conclusions: Streptococcus pneumoniae the most common pathogen.
This study conﬁrms that bacterial co-infection was associated with more
severe clinical course among inﬂuenza virus (H1N1) infected patients,
as shown by PSI, rate of ICU admission and MV.
P1191 Comparative analysis of positive and negative H1N1
hospitalised adult patients during the inﬂuenza A pandemic
in Mar del Plata, Argentina
C. Miglioranza*, J. Corral, S. Aquilia, A. Ferro, M. Hualde, G. Corral,
A. Manzo, M. Rosati, L. De labra, G. Loizaga, R. Garcia (Mar del
Plata, AR)
Introduction: Since May 2009 and after the ﬁrst cases of inﬂuenza A
H1N1 detected in Mexico and California, the virus disseminated swiftly
causing a strong impact in the health systems worldwide.
Materials and Methods: A descriptive, observational and multicenter
study was performed including patients >15 years with a severe acute
respiratory infection (SARI) hospitalized in 5 centres of Mar del Plata,
Argentina. Between May to August 2009 a prospective record was kept
of all the patients hospitalized with a diagnosis of SARI.
Patients were divided into 2 groups and a comparison was done between
the conﬁrmed and negative cases using the following deﬁnitions:
Conﬁrmed AH1N1 cases: positive PCR for H1N1 Inﬂuenza found in
nasal pharyngeal swabs.
Negative Cases: negative PCR for H1N1 Inﬂuenza or positive for the
seasonal inﬂuenza strain.
Results: 184 patients were hospitalized with a SARI during the study
period as follows: 100 were conﬁrmed, 84 were negative. Between
conﬁrmed patients the average age was 43, 52% were female and the
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average time between the onset of symptoms and admission was 5 days.
Among the patients deﬁned as negative the mean age was 48, 47% were
female and the average time from onset of symptoms to admission was
7 days.
The main co-morbidities among the conﬁrmed cases were smoking
(37% and 32%); COPD (18% both groups); obesity (16% and 18%).
The clinical presentation was similar in both groups; the majority
reported fever, cough and dyspnoea. No differences were observed in the
laboratory ﬁndings. PaO2 values were 68mmHg in conﬁrmed cases vs.
73mmHg in negative cases. A bilateral interstitial pattern was observed
in 71% of the conﬁrmed cases and in 50% of the negative ones. 99%
and 98% respectively of conﬁrmed and negative cases received treatment
with oseltamivir. Mechanical ventilation was required in both groups at
a equivalent rate (13% and 14% respectively).
No signiﬁcant differences were observed in mortality rates between the
2 groups (13% conﬁrmed and 12% negative). The patients who died
as a result of the H1N1 Inﬂuenza A infection were younger in average
(46 vs. 53 years).
Conclusions: The H1N1 conﬁrmed cases were younger and had a shorter
clinical course. They presented a higher degree of hypoxemia and the
predominant pulmonary radiological pattern observed was bilateral and
interstitial. No differences were found between the groups in terms of
comorbidities, clinical presentation, laboratory ﬁndings and mortality
rates.
P1192 Prospective surveillance of 2009 pandemic inﬂuenza
A/H1N1 at a university hospital: characteristics and factors
associated with severe disease
P. Cassier, N. Voirin, D. Lutringer, C. Payet, M. Gourbil, T. Benet*,
M. Nicolle, V. Escuret, P. Vanhems (Lyon, FR)
Objectives: Inﬂuenza A(H1N1) 2009 can lead to severe disease. The
objective was to assess the characteristics and factors associated with
severe disease in patients with laboratory-conﬁrmed inﬂuenza A(H1N1)
admitted to a University Hospital during the 2009–2010 inﬂuenza
pandemic.
Methods: An analytic study based on a prospective surveillance system
was conducted between September 2009 and January 2010 in the
Edouard Herriot University Hospital (Lyon, France). All patients who
had laboratory-conﬁrmed inﬂuenza A (H1N1) were included. Cases
were identiﬁed through daily monitoring in the Emergency department,
medical consultation dedicated to immunocompromised patients and
from virological laboratory results. We compared patients who had non-
severe disease deﬁned as patients not requiring hospitalisation, who had
mildly severe disease deﬁned as patient hospitalised in short stay units,
and who had severe disease deﬁned as patient requiring hospitalisation in
Intensive Care Units (ICU). Patients with severe disease were compared
1) to patient with non severe disease, and 2) to patients with mildly sever
disease using univariate logistic regression analysis.
Results: Totally, 69 patients were included. Those aged 15−44 years
were most affected (n = 36; 52%), 9 (13%) were older than 65 years;
and 57 (83%) patients had at least one underlying medical condition. A
total of 24 (35%) cases were non severe, 29 (42%) were mildly severe
and 16 (23%) were severe. Among 45 hospitalised patients, 19 (42%)
had complications and 5 (11%) died. The factrors associated with severe
inﬂuenza A(H1N1) were (Table 1): age (45−64 years), cardiovascular
risk factors, heart disease, obesity (body mass index >30), renal disease,
dyspnea and a long delay from onset to diagnostic.
Conclusion: An increase of vaccination coverage among these high risk
patients could improve the management of a future inﬂuenza pandemic.
In this way, the early detection of cases, as conferred by our prospective
surveillance strategy, could be an important tool.
P1193 Immunogenicity and safety of two doses of AS03A-
adjuvanted inﬂuenza A/H1N1 2009 vaccine in cancer
patients on chemotherapy − VACANCE study
P. Loulergue*, B. Rousseau, O. Mir, E. Viel, A. Krivine, F. Goldwasser,
A. de Gramont, O. Launay, C. Tournigand (Paris, FR)
Background: Inﬂuenza vaccination is recommended to cancer patients
on chemotherapy but remains controversial because of vaccine efﬁcacy
concerns. During the 2009 inﬂuenza A H1N1v pandemic, French
recommendations were to vaccinate immunocompromised patients with
two doses of an adjuvanted H1N1v vaccine. The aim of this study was
to evaluate the immunogenicity of the vaccination in cancer patients on
chemotherapy.
Methods: VACANCE is a prospective, multicenter open-labelled study,
evaluating the immunogenicity and safety of two doses of AS03A-
adjuvanted H1N1v vaccine (Pandemrix®) administered on day 1 (D1)
and D21 in cancer patients receiving cytotoxic and/or targeted therapies,
allocated in four groups: cytotoxic drugs each 3 weeks (3W), each 2
weeks (2W), continuously (C), or targeted therapy alone (T). Serum
Hemagglutination-Inhibition Antibody Titers (HI AT) were measured at
D1, D21 and D42.
Results: 64 patients were included: 52% male, mean age 65±10,
74% metastatic 85% on cytotoxic drugs, 53% on targeted therapies.
Treatments were 19% 3W, 56% 2W, 11% C and 14% T.
At baseline, only 3 (5.2%) patients were seroprotected1. Immunogenicity
results after 1st and 2nd doses are presented in Table 1.
Univariate logistic regression revealed positive associations of SC at
D21 with T and C and negative with 3W and 2W (p = 0.03). Adjusted
for age, the associations remained signiﬁcant (p = 0.04). No association
was found at D42.
Conclusions: A single dose of AS03-adjuvanted A/H1N1 vaccine
triggers a low immune response in cancer patients on chemotherapy and
seroconversion seems to be dependent on treatment type and frequency.
Two doses are needed in those patients, achieving satisfying immune
response.
P1194 Knowledge, perception, attitude and behaviour regarding
inﬂuenza immunisation in Lebanon
N. El Chakhtoura*, H. Hassouna, N. Sidani, M. Yasmin, S. Kanj,
Z. Kanafani (Beirut, LB)
Objectives: The objective of the study is to determine the differences
in knowledge, perception, attitude and behaviour relating to inﬂuenza
immunization between healthcare workers (HCWs) and college students.
The aim is to identify factors associated with vaccine use ultimately
helping in the design of vaccination campaigns. This is, to our
knowledge, among the few studies of its kind to be conducted following
the H1N1 pandemic, and the ﬁrst in Lebanon and the region.
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Methods: A self-administered survey was distributed to registered nurses
at the American University of Beirut Medical Centre, a 400 bed tertiary
referral centre, as well as to non-medical students of the university’s
main campus. Data were collected during the 2010 inﬂuenza vaccination
campaign.
Results: The survey was fully completed by 99/100 students and 106/125
HCWs. We found that 7.1% of students and 25.5% of HCWs received
vaccination on a yearly basis (p = 0.002). In addition, 28.3% of students
and 24.5% of HCWs were deemed knowledgeable of inﬂuenza illness
and its vaccination by making no more than one error in answering
the knowledge questions. HCWs were signiﬁcantly more concerned
about side effects from the vaccine than college students. Table 1
shows the differences in the survey responses among students and
HCW. Multivariable analysis revealed that knowledge was the only factor
independently associated with vaccine receipt on a yearly basis among
HCWs (OR=5.8, p = 0.016).
Conclusion: Our ﬁndings suggest that while HCWs have high self-
perceived knowledge, they in fact demonstrate comparable knowledge
to healthy college students. Also, although they recognize the potential
seriousness of the disease, they show substantial scepticism about
the effectiveness and safety of the vaccine. Their main motive for
vaccination is self protection rather than the intended objective of
protecting their patients. Compliance to yearly vaccination is strikingly
low albeit comparable to reported numbers from European countries
but lower than the USA. The only factor which signiﬁcantly affected
compliance to yearly vaccination among HCWs on multivariable analysis
was knowledge. Vaccination campaigns should therefore be directed
towards raising education, keeping in mind the importance of physician’s
recommendations in the clinics, the effect of which was non negligible.
P1195 Individual determinants of seasonal and pandemic A/H1N1
inﬂuenza vaccination among healthcare workers
F. Barbier*, F. Tubach, L. Biard, B. Mourvillier, B. Le Corre,
A. Macrez, C. Zanker, C. Najem, B. Regnier, J. Lucet, M. Wolff,
L. Bouadma for the INFLUENCE-A study group
Objectives: To compare the individual determinants of seasonal (SI)
and pandemic A(H1N1) (PAI) inﬂuenza vaccination among health-care
workers (HCWs) during the 2009–2010 vaccination campaign.
Methods: A one-day questionnaire-based survey was conducted in 5
teaching hospitals of the Paris area between June, 25th and July, 8th,
2010. Anonymous participation was proposed to all HCWs on duty in
emergency departments and wards on study days. Acceptance or refusal
of SI and PAI vaccines were analyzed on the basis of socio-professional
characteristics, history of SI vaccination, previous contacts with inﬂuenza
cases, and 34 propositions elaborated by using the Health Belief Model
(HBM) methodology. Vaccinated and non-vaccinated HCWs’ answers
to HBM items were integrated in a Classiﬁcation And Regression Tree
(CART) algorithm.
Results: A total of 1977 HCWs participated in the study, including
1576 (80%) paramedical (PM) and 401 (20%) medical (M) HCWs.
Vaccination rates of PM-HCWs and M-HCWs were 29% and 58%
for SI, and 20% and 70% for PAI, respectively (P< 0.0001 for both
comparisons). History of SI vaccination was strongly associated with
both SI and PAI vaccines acceptance during the current campaign
(Table 1). HBM analysis showed that, for PM-HCWs, self-protection
and protection of the personal entourage were the only motivations for SI
and PAI vaccines intake, respectively. Willingness to protect the patients
or contribute to limit the spread of inﬂuenza, and fear of side effects
were not discriminatory for PM-HCWs’ decision to accept or decline
either SI or PAI vaccines. For M-HCWs, the leading determinants of
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vaccination were willingness to be a model for other HCW for SI, and
self-protection for PAI. Among HCWs vaccinated against SI, 85% planed
to get vaccinated on subsequent winters. Conversely, among HCWs
vaccinated against PAI, 55% were reluctant or opposed to revaccination
in case of a novel inﬂuenza pandemic.
Conclusion: SI and PAI vaccination rates were very low for PM-HCWs.
Determinants of these 2 vaccinations differed between PM-HCWs and
M-HCWs, suggesting a beneﬁt of separate information campaigns to
improve vaccination rates during subsequent SI epidemics or inﬂuenza
pandemics. However, the association between refusal of SI vaccination
during previous campaigns and refusal of SI and PAI vaccines during the
2009–2010 winter raises concerns about the efﬁcacy of such educational
programs, which may plead for the advent of mandatory vaccination.
P1196 The beneﬁt of early treatment with oseltamivir in
hospitalised patients with documented 2009 inﬂuenza
A/H1N1: retrospective study
V. Hiba* (Tel Aviv, IL)
Objectives: The effects of oseltamivir (Tm) have been documented
among patients with mild inﬂuenza in the community. We sought to
determine its effects on patients with 2009 H1N1 inﬂuenza requiring
hospitalization, by comparing early vs. late initiation of Tm.
Methods: Retrospective cohort study, including all adult patients with
2009 inﬂuenza A(H1N1) documented by RT-PCR of respiratory samples
at the national laboratory, hospitalized in 3 hospitals in Israel after 22
July 2009. During this period the national policy was to hospitalize
only patients with suspected inﬂuenza complications or at risk. Data
were collected through patient chart review by a single investigator.
Early treatment was deﬁned as start of Tm within 48 hrs of symptom
onset, documented prospectively by clinicians. The outcome assessed
was inﬂuenza complications deﬁned as: pneumonia, saturation <90%,
ICU admission, need for hemodynamic support or in-hospital death.
We assessed the effect of early Tm on the outcome adjusting for
other signiﬁcant variables through multivariable logistic regression. In
sensitivity analyses we assessed the effects of Tm administered within
or after 48 hrs of admission on outcomes post-admission (excluding
outcomes present on admission).
Results: Out of 506 patients hospitalized with 2009 inﬂuenza A(H1N1),
449 patients treated with Tm were included. Early Tm was signiﬁcantly
associated with male sex, pregnancy/post-partum, high temperature,
myalgia, lower lymphocyte count, lower LDH and speciﬁc hospital.
Signiﬁcantly more patients receiving Tm>48 hrs after symptom-onset
experienced complications (150/260, 57.7% Tm>48 hrs vs. 67/189,
35.4% Tm<48 hrs), p< 0.001. Similar results were observed when
excluding outcomes present on admission (42/260, 16.2% vs. 15/189,
7.9%, respectively), p = 0.01. In the adjusted analysis, late Tm initiation
remained signiﬁcantly associated with complications, OR 2.25 (95%CI
1.45–3.51). Other risk factors independently associated with the outcome
(p< 0.05) were dyspnea, SOFA score on admission and the speciﬁc
hospital. Rhinorrhea was protective. The model was highly predictive
(ROC area 0.75, 95%CI 0.71–0.80). Initiation of Tm >48 hrs after
admission was signiﬁcantly associated with complications whose onset
was after admission, adjusted OR 4.09 (1.55–10.80), ROC area 0.77
(0.69–0.84).
Conclusions: Within the limitations of an observational study, early
initiation of Tm was associated with fewer severe complications.
P1197 2009 H1N1 inﬂuenza infection in Korean healthcare
personnel
C.S. Lee*, J. Yeom, J.H. Lee, I.G. Bae, W.S. Oh, C. Moon, K.H. Park,
J.H. Lee, E.S. Kim, Y. Kwak, B.N. Kim (JeonJu, Seoul, Jinju,
Chuncheon, Busan, Gwangju, Iksan, Goyang, KR)
Objective: Healthcare personnel (HCP) can acquire inﬂuenza and
transmit it to patients and other hospital staff. The aim of this study
was to evaluate the attack rate of HCP by the 2009 H1N1 inﬂuenza
virus during the 2009 pandemic inﬂuenza season in Korea.
Method: This study was conducted during the 2009 H1N1 inﬂuenza
season from September to December 2009 at nine university afﬁliated
hospitals in Korea. Infection of HCP with H1N1 virus was conﬁrmed
by real-time or multiplex reverse transcriptase polymerase chain reaction
(RT-PCR). The study subjects of HCP were classiﬁed into four groups
based on job type: Group I (physicians), Group II (nurses and
nurse’s aides), Group III (technicians, therapists, et al.), and Group IV
(administrative workers and others employees not directly involved in
patient care but having the potential of being exposed to infectious
agents). HCP infected with H1N1 virus were asked to ﬁll out a
questionnaire, which included job type, method of diagnosis, facility
type, history of contact with patients infected by H1N1 virus, vaccination
status, place of isolation, and use of personal protective.
Results: A total of 328 HCP (31.4% male) was infected with H1N1
virus at the nine study centers. The highest attack rate was in
physicians, followed by nurses and nurses’ aides. Transmission occurred
primarily after contact with outpatients (36.6%), followed by contact
with inpatients (28.9%). The attack rate of infection was highest in
group I (2.87%, 95% conﬁdence interval (CI) 2.29–3.46), followed by
group II (2.80%, 95%CI 2.37–3.23), group III (2.13%, 95%CI 1.40–
2.86), and group IV (1.00%, 95%CI 0.72–1.29). The mean interval
between exposures to a patient with suspected H1N1 and onset of clinical
symptoms was 3.27±2.51 days (group difference p = 0.303 by ANOVA).
The mean interval between initial clinical symptoms and diagnosis was
2.46±3.71 days (p = 0.567). Most (90.7%) of the infected HCP never or
intermittently used an N95 mask during contact with patients. Surgical
masks were used always or usually used by 60.1% of the subjects.
Peak incidence of the H1N1 infection among HCP preceded that among
general population (Figure 1).
Conclusion: Among HCPs, physicians, nurses, and nurses’ aides were at
greatest risk of H1N1 infection. HCP should be more vigilant and protect
themselves with appropriate personal protective equipments during the
inﬂuenza season.
P1198 A comparison of severity scores for identifying adult patients
with severe 2009 pandemic inﬂuenza A/H1N1 pneumonia
S.T. Heo, W.S. Oh*, C.S. Lee, S.W. Park, E.S. Kim, J. Yeom, B.N. Kim,
Y. Kwak, M.D. Oh, J.A. Hur, A.C. Hur, Y.S. Park, I.G. Pai, H.B. Kim,
J.H. Song, K.S. Lee, S.R. Lee, S.J. Lee, J.H. Lee, H.Y. Kim, Y.K. Kim,
N.J. Kim on behalf of the Korean Inﬂuenza Outcome Surveillance
study group
Objective: To assess the performance of severity scores for community-
acquired pneumonia in adult patients with 2009 pandemic in-
ﬂuenza A/H1N1.
Methods: From September 2009 to February 2010, all adult patients
hospitalized with 2009 pandemic inﬂuenza A/H1N1 pneumonia at 17
Korean teaching hospitals were included. Clinical and laboratory ﬁndings
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at initial presentation were used to calculate severity scores using the
pneumonia severity index (PSI), CURB, and CURB-65. The sensitivity,
speciﬁcity, positive predictive value (PPV), negative predictive value
(NPV), and the area under ROC curve (AUC) were compared for ICU
admission or in-hospital death.
Results: A total of 260 patients were diagnosed with 2009 pandemic
inﬂuenza A/H1N1 pneumonia, conﬁrmed by real-time RT-PCR and chest
radiography. Of these, 45 patients (17.3%) were admitted to ICU, and 27
(10.4%) died in hospitals. AUC (0.750 (95% conﬁdence interval (CI),
0.672–0.829)) of PSI classes IV+V was higher for ICU admission or in-
hospital death than those of CURB score of 2 or more (0.688 (95%CI,
0.599–0.777)) or CURB-65 score of 3 or more (0.566 (95%CI, 0.475–
0.657)). The sensitivity, speciﬁcity, PPV, and NPV of PSI classes IV+V
were 68.5% (95%CI, 54.3–80.1), 81.6% (95%CI, 75.4–86.5), 49.3%
(95%CI, 37.7–61.0), and 90.8% (95%CI, 85.4–94.4), respectively.
Conclusion: Although no severity scores showed good performance,
PSI was the better predictor for ICU admission or in-hospital death
than CURB or CURB-65 in adult patients with 2009 pandemic
inﬂuenza A/H1N1 pneumonia.
P1199 Evaluation of different cell lines in the isolation by the
shell vial culture of pandemic inﬂuenza A/H1N1 2009 from
respiratory samples
J. Reina*, C. Marinescu, C. Deniz (Palma de Mallorca, ES)
Objective: To prospective evaluate three different commercial cell lines
in the isolation of pandemic inﬂuenza A/H1N1 (pIA) from respiratory
pediatric samples.
Methods: Over a 3 weeks period we studied the nasophayngeal aspirates
sent to the virology laboratory for the diagnosis of pandemic inﬂuenza.
The samples were screened for IAp by RT-PCR (OneStep Real-Time;
Applied Biosystem, USA). The comparative study was maked with 72
positive samples by RT-PCR. Each sample was homogeneized with 3ml
of PBS. For the shell vial culture 200ml of the sample was inoculated
into a MDCK, Vero and LLC-MK2 vials (Vircell, Granada, Spain).
The vials were then centrifuged at 3500 rpm× 15min. The vials were
incubated for three days at 36ºC and subsequently stained with an
indirect immunoﬂuorescence assay by a monoclonal antibody against
the inﬂuenza A virus (clone IA-52) (Monoﬂuokit Inﬂuenza, BioRad,
Ireland). Two types of positivity were considered: qualitative (presence
of cells with speciﬁc ﬂuorescence) and quantitative (number of infectious
foci, IFs, present in each shell vial). Only one sample per patient was
evaluated.
Results: In 49 (68%) of the samples pIA was isolated simultaneously
in the three cell lines. Only the Vero cell line enabled us to isolste all
the IAp virus (100% sensitivity). In 14 (19.5) of the samples pIA was
isolated in Vero and MDCK cell lines, and in 9 (12.5%) samples IAp was
isolated only in Vero cell line. Compared with the Vero cell line, MDCK
presented a sensitivity of 87.5% (63 positive samples) and LLC-MK2
of 68% (49 positive samples). Statistically signiﬁcant differences were
observed between Vero and LLC-MK2 lines (p< 0.05) and MDCK and
LLC-MK2 lines (p< 0.05). With reference to quantitative sensitivity, the
Vero line was found to be superior to the other two, based on the number
of IFs present in the monolayers. The Vero line’s greatest yield was
obtained in the moderate (11−25 IFs) and low (1−10 IFs) quantiﬁcation
values. In samples with a high viral load (>26 IFs), the three cell lines
displayed the same diagnostic ﬁeld.
Conclusion: The Vero cell line has a greater capacity to MDCK for the
isolation of pIA virus from nasopharyneal pediatric aspirates. This cell
line has been shown to be the most quantitative and qualitative sensitive
(more infectious foci) cell line. The Vero and MDCK cell lines must be
used together in the isolation of pIA from clinical samples.
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P1200 In vitro antimicrobial properties study of a polyurethane
foam that releases silver ions
J.M. Sahuquillo-Arce*, A. Iranzo Tatay, M. Lla´cer Luna, Y. Sanchis
Boix, J. Guita´n Deltell, E.M. Gonza´lez Barbera´, J. Beltra´n Heras,
M. Gobernado Serrano (Valencia, ES)
Objectives: To evaluate the in vitro antimicrobial properties of a
polyurethane foam used for treatment and prevention of wound infections
with a novel release method of silver ions (Ag+).
Methods: V.A.C. GranuFoam Silver® (KCi Spain) was tested on
Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas
maltophilia, Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis,
Staphylococcus aureus, Enterococcus faecium, Streptococcus pyogenes
and Corynebacterium minutissimum.
Time-kill study: Based on the E2149−10 method of the American
Society for Testing and Materials International, 0.10g of silver foam
were introduced in 25ml Phosphate Buffered Saline (PBS) isotonic
medium (chlorine concentration 139 mM/l) with a minimum microbial
concentration of 10-E5 CFU/ml. Then, it was incubated with agitation
at 36ºC and 0.1ml aliquots were drawn and cultured for colony counting
on columbia agar.
Silver release study: The amount of silver ion released was determined
in a PBS sample in contact with the foam at 0 min, 30 min, 1h, 3h, 6h,
12h and 24h by Inductively Coupled Plasma Mass technique.
Results: Ag+ release presented an exponential curve with a sharp
increase and a plateau after 3 hours that was stable up to 24 hours
with Ag+ levels of 0.22 to 0.24mg/l.
After 3h, there was a reduction over 99.9% of the Gram-negative
initial inoculum, except for E. coli which reached 92.5%. Enterobacteria
showed greater initial tolerance than non-fermentative Gram-negative
rods, which had a very sharp decrease in viable cell after contact with
Ag+: 99.9% in two hours, higher in the case of P. aeruginosa: 98.1%
in the ﬁrst hour. However, a very small subpopulation (<1CFU/ml) of
S. maltophilia was able to survive 8 hours.
In the case of the Gram-positive, reduction over 99% was achieved within
2h for both S. pyogenes and C. minutissimum, 6 hour for S. aureus and
14 h for E. faecium, for which a small subpopulation (<1CFU/ml) was
able to survive up to 24 hours. No decrease was observed in the controls.
Conclusions: Our data agree with previous studies that showed a higher
susceptibility to Ag+ in Gram-negative versus Gram-positive. This could
be explained by the thicker layer of peptidoglycan that should confer
Gram-positive some protection against Ag+.
In conclusion, V.A.C. Silver® GranuFoam quickly reached and
maintained levels of Ag+ in ranges that were bactericidal on the
microorganisms tested.
P1201 Optimised antibacterial measures against E. coli O157:H7
and S. aureus
M. Raftari*, F. Azizi jalilian, S. Ghafouryan, F. Abu Bakr (Putra,
MY; Ilam, IR)
Objectives: Decontaminating meat surfaces has been the big concern of
meat industry. Thus, various intervention strategies have been studied to
reduce the level of bacteria on animals’ carcass surfaces. Therefore this
research was an attempt to study the effect of combinations of different
organic acids on Escherichia coli O157:H7 and Staphylococcus aureus
bacteria on meat.
Methods: Varied mixtures of different concentrations 1, 1.5 and 2% of
acetic (AA), lactic (LA), propionic (PA) and formic (FA) acids at 1:1
ratio were spray-washed on inoculated meat to evaluate their efﬁcacy in
reducing loads of Escherichia coli O157:H7 and Staphylococcus aureus
on meat tissue.
Results: It was found that increasing the concentration of the used
organic acids increased the bacterial lethality proportionally. And
signiﬁcant difference (P< 0.05) was observed in the lethal effect of
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different mixtures and concentrations of the used organic acids. As a
novel combination, FA treatments as combinations with AA, LA, and
PA, especially FA with LA, reduced bacterial loads greatly, up to 3 logs
cfu/ml and eradicated inoculated bacteria, E. coli O157:H7 and S. aureus
completely within 3−6 days. This reduction was higher than that incurred
by other combinations. Signiﬁcantly, higher log reductions by the used
organic acids were obtained for S. aureus than for E. coli O157:H7.
Conclusion: It was concluded that the combination of LA and FA
treatment was a highly promising, feasible, and economical method of
decontaminating meat surface from both E. coli O157:H7 and S. aureus
bacteria. Moreover, it is safe if compared with other approaches.
P1202 Multi-resistant bacterial colonisation of reusable hospital
tourniquets
A. Pinto*, T. Phan, G. Sala, E. Cheong, S. Siarakas, T. Gottlieb
(Sydney, AU)
Objective: To determine the prevalence of microbial colonisation of
reusable venesection tourniquets in a Sydney teaching hospital.
Methods: One hundred reusable tourniquets were collected from critical
care areas, general wards, and non-clinical areas. The study was
performed over 11 weeks. Tourniquets were placed in enrichment media
(BHI broth), incubated overnight and subcultured onto general and
selective media. Isolates were divided into commensal, ‘potentially
signiﬁcant’ bacteria and multi-resistant organisms (MROs). MROs were
deﬁned as MRSA, VRE, MBL and ESBL producing enterobacteriaceae.
Van B positive Enterococcus faecium isolates were typed using
DiversiLab rep-PCR system.
Results: The overall bacterial colonisation rate was 78% (78/100).
Seventeen grew commensal bacteria, viz. coagulase negative staphy-
lococci and Bacillus species. Ten grew non multi-resistant Gram-
positive organisms − methicillin sensitive Staphylococcus aureus (1)
and Enterococcus species (9). Non multi-resistant Gram-negatives grew
in 38 specimens, viz: Pseudomonas species (13) and coliforms (26).
MROs were found on 25% of tourniquets, including three from MRO
isolation rooms. An IMP-4 positive Enterobacter cloacae and an ESBL
E. cloacae were isolated from a single tourniquet each. MRSA was
isolated from 14 tourniquets; vanB E. faecium was isolated from18
and vanA E. faecalis from a single specimen. Typing revealed ﬁve
predominant VRE genotypes. MRSA and VRE were isolated together
from nine tourniquets, and 24 tourniquets grew either one of these.
Six of nine tourniquets collected from ICU grew at least one MRO.
MROs were isolated consistently throughout the study period from a
wide variety of hospital locations, including general wards, ICU, burns
unit, operating theatre anaesthetic bay and the blood collection unit.
Conclusion: Reusable tourniquets are frequently colonised with MROs
and may be a potential source of cross-transmission. They are also
a surrogate marker for environmental colonisation and deﬁciencies in
hospital cleaning. Using broth enrichment, 24% harboured either MRSA
or VRE. Continued use of reusable tourniquets may not be justiﬁed in
the current hospital setting.
P1203 Inﬂuence of temperature and chemical decontamination on
the prevalence of Legionella pneumophila in hot water
C. Colombo*, G. Senn, A. Bu¨rgel, C. Ruef (Zurich, CH)
Objectives: To demonstrate the impact of water temperature and
chemical decontamination on prevalence and concentration of Legionella
pneumophila (L.p.) in hot water of high risk medical wards (oncology,
radiation therapy, organ transplantation units and burn ICU).
Methods: Measurement of L. pneumophila concentration and tempera-
ture of hot water of patient care units of the University Hospital of Zurich
monthly during the baseline period (A; 2008/2009), a preparatory period
with reduced water temperature (B; February − June 2010), the phase
prior to chemical decontamination (C; July − September 2010). Chemical
decontamination with copper-silver and chlorine dioxide was started in
separate hospital areas in October 2010 (period C). Concentrations of
chemicals used were measured regularly.
Results: The proportion of positive peripheral sites as well as the
concentration of L.p. increased signiﬁcantly during period B (table),
parallel to a signiﬁcant reduction of the median temperature (p< 0.001).
Serotype 1 was the predominant strain. After raising the temperature
of the outlets to a median of 62 (period C), respectively 60ºC during
period D, the rate of positive samples as well as the concentration
of L.p. dropped signiﬁcantly (p< 0.001). Following the introduction of
chemical decontamination in October 2010, only one sample was positive
for L.p. This sample was found in a unit with copper-silver ionisation.
The median residual concentration on peripheral outlets of silver and
copper (samples n = 54) was 5.5mg/l and 108mg/l respectively. The
median residual concentration on peripheral outlets of chlorine dioxide
(samples n = 29) was 0.02mg/l. Between October and December 2010
we noted a signiﬁcant decrease of mean (7.7 to 2.9mg/l) and median
(7.7 to 2.75mg/l) concentration of silver (p< 0.001), but not of copper
or chlorine dioxide. All measured concentrations were below the upper
threshold concentration required for safety of potable water.
Conclusion: Our data show a strong correlation between low water
temperature and the appearance of L. pneumophila as well as the
positive effect of adequate water temperature (55ºC) and the application
of chemical decontamination on the prevalence and concentration of
L. pneumophila in a hospital hot water system. Chemical decontami-
nation enhances the effect of an increase in water temperature on the
reduction of Legionella concentration. Further follow-up is needed to
determine the long term effect of these measures.
P1204 Impact of a single-room design on the spread of
multidrug-resistant bacteria in an intensive care unit
T. Halaby*, R. de Wit, N. Al Naiemi (Enschede, NL)
Objectives: Cross infection has been shown to occur more frequently in
the intensive care unit (ICU) than in other wards of the hospital. This
may be enhanced by several factors including heavy colonization of
environment and ICU patients, invasive procedures such as mechanical
ventilation and intravascular devices and crowding of both patients and
health care workers (HCW). In such an ICU, high prevalence of multi-
drug resistant (MDR) bacteria was observed despite extensive infection
control measures, which led to the move of the ICU into a new single
room designed facility. The aim of this study is to report the effect of
this move on the prevalence of MDR-bacteria.
Methods: Study period is between January 2001 and November 2010.
The ICU consisted of 18 beds, of which 5 in single ventilated rooms
with ante-room and the remaining 13 in an open bay. Infection
control measures included standard barrier nursing techniques, isolation
of patients when indicated, education and reinforcement of hand
hygiene among HCW, temporary closure of the unit for architectural
modiﬁcations, and the introduction of selective decontamination of
digestive tract (SDD). In April 2009 the whole ICU was converted to a
new unit with the same number of beds but with single ventilated rooms
with an ante-room, in the vicinity of the original unit. Nurse:patient
ratio did not change. No changes were introduced in infection control
protocols. Surveillance cultures have been obtained twice weekly from
all admitted patients, before and after conversion. MDR-bacteria were
deﬁned according to national guidelines.
Results: Despite efforts, high prevalence of MRD bacteria continue to
occur in the original facility. Only after transfer to the new unit could a
sharp decrease in the prevalence be observed (Fig 1).
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Conclusions: Transformation of an ICU with an open bay to a single-
room unit resulted in signiﬁcant decline in the prevalence of MRD-
bacteria. Major factors that may contribute to this effect are inherent
in the design, and enable the block of contact routes of bacterial
transmission between patients. These factors include decreased number
and movements of persons near the patient, the feasibility of and
adherence to adequate barrier patient care techniques before and after
patient contact, and the possibility of adequate separation of medical
waste.
P1205 Objectively improving operating theatre disinfection
cleaning in 12 hospitals
P. Carling*, J. Po, J. Jeffferson, M. Parry for the Healthcare
Environmental Hygiene Study Group
Objective: Environmental bacteria, particularly coagulase negative
staphylococci, are the most common pathogens associated with deep
surgical site infections in all forms of implantation surgery. In light of
this problem and in the context of our evolving understanding of the
healthcare epidemiology of these organisms, optimization of operating
theatre environmental hygiene is imperative. Given our previous studies
demonstrating signiﬁcant opportunities to improve hygienic cleaning
practice in patient rooms, a multi-institutional process improvement
project was implemented to evaluate and enhance compliance with
widely accepted disinfection cleaning standards in the operating theatre.
Methods: An invisible ﬂuorescent targeting method was used to covertly
evaluate the cleaning of twelve standardized high-touch implantation
operating theatre surfaces. Rooms were marked following terminal
cleaning and re-evaluated after several implantation surgeries had taken
place in the room and it had been terminally cleaned on at least two
occasions (after the last case of the day). Following process improvement
interventions which incorporated speciﬁc performance results, the impact
of the interventions was objectively evaluated.
Results: Baseline evaluation of 2,799 surfaces in 205 operating theatres
in 12 highly diverse hospitals found that an average of 23.3% of
recommended surfaces (hospital range 9−53%) had been disinfection
cleaned according to policy. Only three types of objects in two hospitals
were relatively well (>80%) cleaned prior to interventions. Of particular
concern was the fact that only 25% of primary ﬁeld lights and
15.5% of secondary ﬁeld lights were cleaned. Following education and
objective performance feedback to the Environmental Services staff
along with multi-disciplinary collaborative efforts involving Infection
preventionists and administrative champions, overall thoroughness of
cleaning signiﬁcantly improved to 70% (p< 0.0001) (Figure) with 61
types of objects in 10 hospital being cleaned >80% of the time.
Conclusion: The ﬁrst multi-site objective evaluation of the thoroughness
of operating theatre terminal cleaning demonstrated both unanticipated
shortcomings in disinfection cleaning practice as well as the ability
to improve such cleaning using educational interventions along with
ongoing objective feedback to the environmental services staff in all
participating hospitals.
P1206 The in vitro activity of hydrogen peroxide vapour against
spores of epidemic strains of Clostridium difﬁcile strains
F. Barbut, S. Yezli, J.A. Otter* (Paris, FR; Andover, UK)
Objectives: Clostridium difﬁcile spores present a particular challenge to
effective decontamination. They are shed in high numbers by infected
patients and they are resistant to desiccation and some disinfectants.
We explored the in vitro activity of Hydrogen Peroxide Vapour (HPV)
against several strains of C. difﬁcile spores on common hospital
materials.
Methods: The sporicidal capacity of HPV was tested using a spore-
carrier test. The spore carriers used were small (2 cm2) pieces of vinyl
polychloride (PVC) (representative of the room’s ﬂoor) or laminate
(representative of the room’s furniture). Three strains of C. difﬁcile were
tested: a toxinotype 0 reference strain (VPI 10463), a ribotype 027
historical strain (CD 196) and a current ribotype 027 epidemic strain
(1067). For each assay, the 3 strains were tested simultaneously but
separately on the 2 different spore carriers. Each assay was repeated 4
times. C. difﬁcile spores were obtained by using the method described
by Wullt et al. (Infect Control Hosp Epidemiol 2003; 24:765–768). Each
carrier was experimentally contaminated with 100 microlitres of spore
suspension to achieve an inoculum of approximately 106 spores per
carrier. After disinfection, test and control spore carriers were placed
in 3mL of neutralizing solution, vortex mixed and sonicated for 5
minutes. The spores from test and control spore carriers were counted by
serial dilution on selective medium containing taurocholate 0.1%, with a
threshold of sensitivity of 3 spores/spore carrier. The reduction in initial
concentration was calculated as the difference between the number of
spores on control carriers and the number on test carriers after HPV
exposure.
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Results: The concentration of spores on unexposed control carriers
ranged from a mean of 4.7−6.9 log10 spores/carrier for the three strains.
No C. difﬁcile was cultured from carriers exposed to HPV (ﬁgure).
Conclusion: HPV is effective for the inactivation of a range of C. difﬁcile
spores from common hospital materials in vitro. HPV should be
considered for the eradication of C. difﬁcile spores from the hospital
environment.
P1207 Cross-transmission audit of environmental surfaces, clinical
equipment and patient: who touches what?
S.J. Smith, V. Young, S.J. Dancer*, C. Robertson (Glasgow, UK)
Background: Most patients probably acquire pathogens from contam-
inated hands. We conducted an audit of hand-touch events that occur
during patient care throughout the day.
Methods: Cross-transmission pathways were monitored during 40x30
minute covert observation periods (20 summer and 20 winter periods),
beginning with entry of staff into one room on an acute ward. Hand-touch
activities were recorded within the following categories: hand-hygiene
on entry; hand contact with near-patient sites; hand contact with patient;
hand contact with clinical equipment; hand-hygiene on exit; and hand
contact with sites outside the room.
Results: There were 104 entries during the study periods: 77 clinical staff
(59 nurses; 18 doctors), 21 cleaning and catering staff, one pharmacist
and ﬁve relatives. Overall compliance with hand hygiene among clinical
staff before and after entry was 25% (38/154), with markedly higher
compliance during 20 summer (47%: 32/68) as opposed to 20 winter
periods (7%: 6/86). Over half (58%: 45/77) of clinical staff touched the
patient; nearly half (48%: 37/77) handled patient notes; 25% touched the
bed (19/77); and 10% (8/77) touched the patient console. Most frequently
handled equipment inside the room were IV drip (27%: 21/77) and BP
stand (13%: 10/77), and computer (25%: 19/77), notes trolley (23%:
18/77) and telephone (22%: 17/77) outside the room.
Conclusions: Monitoring the sequence of hand-touch events during
patient care has highlighted potential microbial transmission pathways.
Understanding the most frequent interactions between hands and surfaces
could target high risk sites for cleaning, since hand hygiene compliance
remains poor during covert observation.
P1208 Absence of Clostridium difﬁcile stool carriage in
asymptomatic volunteers
M. Hell*, K. Sickau, G. Chmelizek, J.M. Kern, M. Maass, S. Huhulescu,
F. Allerberger (Salzburg, Vienna, AT)
Objectives and Background: Clostridium difﬁcile emerged as important
nosocomial pathogen. It is considered a leading cause of hospital-
acquired diarrhea and can cause a potentially fatal illness.
Up to now there are only case-reports of symptomatic Health-Care-
Workers (HCW) in the literature and only one report demonstrating a
transmission of C. diff from patient to HCW on a molecular basis.
Therefore we initiated a prospective study to evaluate the prevalence of
asymptomatic C. difﬁcile stool carriage among healthcare workers with
direct patient contact at a single university hospital compared to non-
healthcare workers to asses the risk for HCWs acquiring Clostridium
difﬁcile Infection (CDI).
Methods: The study population consisted of 113 healthy HCWs (without
any previous history of diarrhea) of different clinical departments with
a high incidence of CDI in inpatients who were considered to be at high
risk for acquiring C. difﬁcile. The 128 healthy controls were purchased
from the administration department of a big Food Company and from
frozen stool samples.
Both groups were comparable in age- and sex-distribution.
During the time period April − July 2010, in total 241 stool specimens
were collected. Stool samples were tested within 24h hours for toxgenic
culture of C diff using selective culture media (Cycloserine/cefoxitin
agar plates (bioMe´rieux, Vienna, Austria)) and incubated for 48 hours
at 35±2 ºC under anaerobic conditions.
51% of stool samples (58/113) of the study population and all stool
samples of the controls (n = 128) were consecutively sent to the National
Reference Laboratory for C. difﬁcile at the Austrian Agency for Health
and Food Safety (AGES) in Vienna for further conﬁrmation through
cultivation by broth enrichment technique.
Results: Both investigated study-groups (n-total= 241) were negative for
Clostridium difﬁcile by culture techniques (both direct plating and broth
enrichment method).
Conclusion: We conclude therefore that healthy HCWs are probable not
at risk for aquiring C diff spores from CDI-patients contacts and are
themselves no risk for spreading C. diff spores in health-care facilities.
Data about C.diff carriage in the community (up to 3%) possibly reﬂects
an overestimation.
P1209 Do silver-coated needleless intravascular catheter connectors
reduce microbial contamination?
T.J. Karpanen*, A.L. Casey, P. Nightingale, M. Cook, T.S. Elliott
(Birmingham, UK)
Objective: There have been several reports of elevated catheter-related
bloodstream infection (CR-BSI) rates associated with the use of some
needleless intravascular connectors. A connector with a unique silver
coating has been developed. The objective of this trial was to compare
the rate of microbial contamination associated with this antimicrobial
connector to a control non-antimicrobial equivalent.
Methodology: Haemato-oncology patients who required a central
venous catheter (CVC) were recruited into the study and were
randomised to receive either the silver or control connector. Every
4 days the silver or control connectors were removed. To assess
external contamination of the connectors, the silicone compression seals
were imprinted onto an agar plate. The presence of internal microbial
contamination was investigated by sampling in three stages to remove
planktonic, loosely bound bacteria and bacterial bioﬁlms from the
connectors. All patients were monitored for symptoms of CR-BSI.
Results: No episodes of CR-BSI were observed during the study period.
36 of 119 (30.3%) silver connectors were externally contaminated
compared with 41 of 117 (35.0%) controls (OR=0.8, 95%CI=0.47–
1.39, P = 0.49). 31 of 119 (26.1%) silver connectors were internally
contaminated compared with 55 of 117 (47.0%) controls (OR=0.40,
95%CI=0.23–0.69, P = 0.001). There was also a signiﬁcantly lower level
of internal microbial contamination in the silver connectors (P = 0.001).
Some connectors had blood residue in the internal interstitial space
despite optimal ﬂushing. However, this did not have any effect on the
internal contamination rate.
Conclusion: Signiﬁcantly fewer silver connectors were internally
contaminated when compared to controls. This was probably related
to the antimicrobial activity of the silver within the connectors. Such
a difference was not seen on the external compression seal which is
not coated with silver. Blood residue was observed in some connectors
post-ﬂushing but this was not associated with an increased internal
microbial contamination rate. This highlights the advantage of using
transparent connectors which allow internal inspection and facilitates
device change if blood is detected. Although no episodes of CR-BSI were
observed during the study period, the reduction in internal contamination
associated with the silver connectors may lead to a reduced risk of such
infection.
P1210 Disinfection of CVC catheters with ultraviolet-C light
T. Begovic, T. Bjarnsholt, A. Nielsen, J. Bak* (Roskilde, Copenhagen,
DK)
Objectives: To develop a method and a device based on UVC light
emitting diodes (LED’s) that can be used to disinfect the intra-luminal
part of catheters, as a mean to prevent bioﬁlm to establish in central
venous catheters (CVC’s). CVC’s are normally ﬂushed with 0.9% saline
solutions after they have been used for drawing blood or administering
drug and nutrition before anti-coagulating agents are injected. Saline
solutions are transparent for UVC light and the germicidal light can
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then be transmitted from the Luer connector to the distal end of the
catheter tube.
Methods: The device were tested on 20 cm tubes (inner diameter 4mm)
made of ethylene vinyl acetate (EVA) contaminated with 103 CFU/ml
solutions of E. coli, P. aeruginosa and S. aureus. The bacteria in
suspension were inoculated in the tubes for 3 hours prior to UVC
disinfection. The device was connected to the Luer catheter hub and the
UVC light was launched into the connector opening. The UVC ﬂuence
rates at the tube entrances were between 0.41 and 4.11 J/cm2. After
UVC treatment (2−20 min) the number of CFU’s was determined both
in treated and control samples by plating aerobically at 37 C for 24
hours. All tests were done in triplicate. Detection limit was less than 3
CFU/ml.
Results: We found for all three bacterial species that 2 min of UVC
treatment were sufﬁcient 100% disinfection of the tubes. The germicidal
effect of the UVC device is reduced substantially when approaching the
distal end of the tubes. This attenuation of the light is caused primarily
by the absorption of UVC light in the wall of the tube material. We were
able to measure the reduced ﬂuence (dose) delivered to the distal end of
the 20 cm tubes. During the short time of treatment (2 min) a dose (12
mJ/cm2) sufﬁcient to kill all bacteria in the lumen were delivered to the
distal end.
Conclusion: The UVC device presented here has several features that
make it applicable in the clinic. The doses required for 100% kill of
planktonic bacteria can be delivered within a few minutes. We envision
the method to be applied as part of a preventative approach each time the
catheter has been used to avoid bioﬁlm to establish. Flushing with the
UVC transparent 0.9% saline solutions is part of the normal procedure
before lock solution are injected and then no additional preparations
should be done before disinfection can take place.
P1212 Risk of Pneumocystis transmission in an endoscopy
respiratory unit
R. Morilla*, J. Martı´n-Juan, V. Friaza, M. Martinez-Risquez,
E. Campano, B. Romero-Romero, N. Respaldiza, C. De la Horra,
J.M. Varela, E. Caldero´n, F.J. Medrano (Seville, ES)
Objectives: A High prevalence of Pneumocystis (Pc) colonization has
been described in patients with both acute and chronic respiratory
diseases. Several animal and human evidences support the hypothesis of
the active airborne acquisition of the infection, moreover the possibility
of nosocomial transmission has been proposed recently. The aim of
this study was to evaluate the possible presence of Pc infection in
a respiratory endoscopy unit (REU) though as high risk area for Pc
transmission.
Methods: Prospective longitudinal study (February to April of 2010)
carried out in the REU at Virgen del Rocı´o Hospital, Seville, Spain
including the sequential analyses of health-care workers (HCW) and
environmental samples of air at the three different rooms of the unit.
Retrospective evaluation of possible index cases was also included.
Each participant underwent a clinical-epidemiological examination and
oropharygeal wash (OW) samples were collected for analysis. Ambient
samples of air were collected by a spore trap (CIP 10, ARELCO,
Fontanay-Sous-Bois, France). Pc colonization was identiﬁed by nested
PCR at mtLSUrRNA gene using the primers couples pAZ102-E/-H
and pAZ102-X/Y and by touch-down PCR at dihydropteroate synthase
(DHPS) gene using the primers DHPS-3/4. The genotyping was based in
analysis of both genetic loci ampliﬁed: mtLSUrRNA fragment by direct
sequencing showing 4 possible genotypes (1,2,3 and 4) and DHPS locus
by a restriction fragment length polymorphism (RFLP) assay detecting
2 genotypes: wild (w) or mutated (m) associated with sulfa resistance.
Results: During the study period Pc DNA was identiﬁed in 14/24 OW
samples from HCW and in 5/14 air samples. Table shows the results
at the different weeks during the study. Several possible index cases
were identiﬁed: two HIV patients with Pc pneumonia at week 4, two
patients with pneumorenal syndrome at week 4 and one patient with
acute interstitial pneumonitis at week 8.
Conclusions:
1. The study shows for the ﬁrst time a high rate of Pneumocystis
colonisation among health-care workers of a respiratory endoscopy
unit and the presence of DNA of the pathogen in air samples of the
area.
2. These ﬁndings, besides the concordance od genotypes between HCW
and environmental air samples and the possibles index cases identiﬁed
support the possibility of nosocomial transmisison of this infection,
including sulfonamides-resistant strains.
(Support by ERA-NET Pneumocystis-PathoGenoMics and FIS-europeo
03/1743)
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P1213 Reduction of healthcare-associated infections after
implementation of bundle programmes in a tertiary care
teaching hospital in Saudi Arabia
W. Mazi*, D. Abdullah, G. Gasem, N. Helali, A. Senok (Taif, Riyadh, SA)
Objectives: The bundles program introduced in January 2010 at the
King Abdul Aziz Specialist Hospital (KAASH), Taif, Saudi Arabia
aimed to reduce the incidence of Central line-associated bloodstream
infection (CLABSI), Catheter-associated urinary tract infection (CA-
UTI), Ventilator-associated pneumonia (VAP) and cesarean section-
healthcare associated infection (CSEC-HAI). We present data evaluating
the effectiveness of this program in the intensive care unit (ICU) and
surgical-gynecology unit (SGU).
Methods: This prospective study was carried out in the 20-bed medical
and surgical ICU and the 30-bed SGU at KAASH. Laboratory-conﬁrmed
CLABSI, CA-UTI, VAP and CSEC-HAI in 2009 and 2010 (January-
November) were identiﬁed using Centers for Disease Control and
Prevention (CDC) criteria. To enable benchmarking with National
Healthcare Safety Network (NHSN, USA), data collection and analysis
was carried out in accordance with NHSN recommendations.
Results: In 2009 the incidence of CLABSI was 4.79/1000 central line
days with a signiﬁcant decline to 2.45/1000 central line days in 2010
representing a decline from 90th to 50th percentile when benchmarked
with NHSN data. The incidence of CA-UTI was 3.73/1000 catheter
days in 2009 dropping to 2.9/1000 catheter days in 2010. Increased
device utilization ratio was observed for central lines and urinary
catheters. The signiﬁcant decline in VAP incidence from 5.79/1000 to
3.95/1000 ventilator days was not accompanied by increased utilization
of ventilation ratio (Table). In the SGU, 2396 cesarean sections
with 35 HAI events representing CSEC-HAI incidence of 1.46% per
100 cesarean section procedures was recorded for 2009. Post-bundles
implementation HAI events dropped to 21 despite increased cesarean
sections (n = 2616) representing CSEC-HAI incidence of 0.80% per 100
cesarean section procedures. Relative to NHSN data, this represented a
decline from the 75th to 25th percentile. Overall, the implementation
of bundles was accompanied with 51% decline in Methicillin resistance
Staphylococcus aureus (MRSA) HAIs (2009: n = 49 vs. 2010: n = 24).
S328 21st ECCMID/27th ICC, Posters
Conclusion: Reductions in HAIs including MRSA-HAI were observed
in our ICU and SGU following the implementation of bundles. The
trend of increased device utilization ratios for central lines and urinary
catheters in ICU deserves further investigation as well as post-discharge
surveillance for cesarean section surgery is needed.
P1214 Intestinal carriage of colistin resistant Enterobacteriaceae
during selective decontamination of the digestive tract
E.A. Oostdijk*, A.M. De Smet, M. Leverstein-van Hall, M.J. Bonten
(Utrecht, NL)
Objectives: Selective Decontamination of the Digestive Tract (SDD)
has been associated with improved patient outcome in Dutch ICUs. As
part of SDD colistin (COL) − in topical form − is administered four
times daily in the oropharynx and the gut throughout ICU stay. Although
resistance to COL has been reported infrequently, the risks of prolonged
use of SDD (including COL) on resistance development are unknown.
As COL is increasingly important to treat infections with multi-resistant
Gram-negative bacteria, we quantiﬁed the risk of COL resistance in
rectal specimens in SDD-patients participating in a 13-center cluster
randomized study between 2004−6 (NEJM 2009;360:20).
Methods: All SDD-patients with at least 1 rectal sample were included.
Rectal carriage with Escherichia coli (EC), Klebsiella spp (KS) or
Enterobacter spp (EB) was determined at admission and twice weekly
during ICU-stay. Colonization on admission was deﬁned as carriage
demonstrated in the ﬁrst sample and <48 hours after ICU-admission.
Conversion of COL susceptibility to resistance (S-R conversion) was
deﬁned as colonization with COL resistant EC, KS or EB preceded by
colonization with a COL susceptible isolate from the same species. The
COL S-R conversion rate was the number of events per 1,000 patientdays
at risk.
Results: 1917 patients were included and 556 patients (29%) had at
least one sample with EC, KS or EB. In 512 patients 1207 isolates
were tested for COL resistance, which was demonstrated in 73 patients
(14%) and in 13% of isolates (n = 164). COL resistance on admission
was demonstrated in 28 patients (1.5% of 1917; 5.0% of 556). In 19
patients (1.0%) COL S-R conversion occurred; 12 being EC (63%), 6
KS (32%) and 1 EB (5%). Median time to conversion was 5 days (range
2−71; IQR 4). COL S-R conversion rate was 0.73 per 1,000 ICU-patient
days at risk. There was no evidence for clustering.
Conclusion: In patients in 13 Dutch ICUs the admission prevalence of
intestinal carriage with COL resistant EC, KS or EB was 1.5% and COL
S-R conversion occurred in 1% of patients, yielding a C-R conversion
rate of 0.73 per 1,000 ICU patient days at risk.
P1215 Eradication of extended-spectrum b-lactamases during
selective digestive tract decontamination
E.A. Oostdijk*, A.M. De Smet, M.J. Bonten on behalf of the Dutch
SOD-SDD trialists group
Objectives: Selective Digestive Tract Decontamination (SDD) was
beneﬁcial for patient outcome in Dutch ICU patients. SDD consists of
topical antibiotics containing tobramycin, colistin and amphotericin B
to eradicate potential pathogens, such as Enterobacteriaceae, from
the intestinal tract. Although most Extended-Spectrum b-Lactamases
(ESBL)-producing Enterobacteriaceae (ESBL-E) are susceptible to the
SDD-regimen, the effect of SDD on eradication of ESBL-E from the
intestinal tract is unknown. We quantiﬁed eradication rates of non-
ESBL and ESBL-E in SDD-patients participating in a 13-center cluster
randomized study (NEJM 2009;360:20).
Methods: All SDD-patients with culture results from >1 rectal sample
(with the ﬁrst sample obtained <2 days in ICU) were included. Rectal
carriage with Enterobacteriaceae was determined at admission and
twice weekly during ICU-stay. ESBL-E was deﬁned pragmatically as
resistance to either ceftazidime, cefotaxime, ceftriaxone or cefuroxime.
If colonization with Enterobacteriaceae was present at admission, ESBL
status and duration of colonization was determined. Kaplan-Meier
analysis was performed to test for differences in colonization duration.
Patients were censored at ICU-discharge.
Results: 345 (21%) of 1613 patients meeting inclusion criteria were
colonized with Enterobacteriaceae on ICU admission: 111 (32%; 6.9%
of 1613) with ESBL-E. Median lengths of ICU-stay were 8 (range
2–134, IQR 9) and 10 days (range 2−79, IQR 10) for non-ESBL
and ESBL colonized patients, respectively (p = 0.13). Median duration
of colonization was 4.5 days for non-ESBL patients and 5 days for
ESBL patients (p = 0.12, logrank test). The most frequent colonizers
were E. coli (n = 257; 31 ESBL-E (12%)), Enterobacter spp (n = 43; 42
ESBL-E (98%)) and Klebsiella spp (n = 37; 8 ESBL-E (22%)).
Conclusion: SDD was equally effective in eradicating ESBL and non-
ESBL producing Enterobacteriaceae present at ICU admission from the
intestinal tract.
P1216 Screening of gastrointestinal carriage of ESBL-producing
Enterobacteriaceae in neonates
E´. Kenesei*, M. Sze´na´si, M. Szabo´, M. Pataki (Budapest, HU)
Introduction: Whereas human gut is sterile at delivery, bacterial
colonisation occurs during the early postnatal days that presents a
possible source of neonatal systemic infections. Extended-specrum-
b-lactamase (ESBL) producing Enterobacteriaceae are identiﬁed at an
increasing prevalence in Neonatal Intensive Care Units (NICU). The aim
of this surveillance study was to determine the incidence of intestinal
colonisation with ESBL producing Enterobacteriaceae in neonates and
infants treated in our NICU.
Materials and Methods: In 2008 and 2010, 2912 perianal samples
were screened for the presence of ESBL producing bacteria. Samples
were routinely taken from 1093 newborns and infants at the admission
to the NICU and then once a week. Samples were inoculated onto
chromID ESBL and blood agar (BioMerieux). Combination discs, AmpC
and ESBL Detection Set (Mast Diagnostics) were used to identify the
producer present.
Results: 102 of 1093 newborns and infants were colonised with ESBL
producing, and 14 newborns with multidrug resistant enterobacteria.
ESBL producing enterobacterial colonisation was detected in 5, 18, 35
and 44 newborns and infants within the ﬁrst 72 postnatal hour, by the
end of ﬁrst postnatal week, ﬁrst and third postnatal months, respectively.
Major species were Klebsiella pneumoniae, Enterobacter cloacae and
Escherichia coli.
Conclusion: Our results show, that up to 10% of newborns and infants
treated at NICU are colonised with ESBL producing species. These
colonised organisms may serve as a potential source of sepsis and may be
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responsible for nosocomial outbreaks in the NICU. The high prevalence
of colonisation with ESBL points out the importance of a surveillance.
P1217 Risk factors for acquiring extended-spectrum b-lactamase
producing Escherichia coli infection from prior colonisation
T.M. Goulenok*, E. Bille, A. Ferroni, H. Lecuyer, O. Join-Lambert,
A. Kouatchet, X. Nassif, J.-R. Zahar (Paris, FR)
Objectives: Extended-spectrum b-lactamase-producing Escherichia coli
(ESBLEC) is an increasing cause of hospital-acquired infection. Risk
factors for ESBL, faecal carriage and infection, have already been
reported but risk factors for acquiring ESBLEC infection from prior
documented colonization are not well established.
Material and Methods: A retrospective case control study was
performed in the Necker-Enfants Malades hospital, a French tertiary-care
hospital from March 2008 through May 2010. Cases and controls were
deﬁned as ESBLEC colonized (faecal carriage) patients who developed
or not ESBLEC infection respectively. Controls were matched in a 2:1
ratio to case patients according to duration between colonization and
infection. We recorded demographic characteristics, functional status,
underlying diseases, the presence and duration of indwelling devices, any
hospitalization, mechanical ventilation, surgery, endoscopic procedures,
dialysis and antimicrobial use after colonization. Antibiotic exposure
and duration were analyzed separately for each antibiotic. Risk factors
for ESBLEC infection were identiﬁed by univariate and multivariate
analysis.
Results: Forty cases and 78 controls were included. The median
time from colonization to infection was 12.5 days (range 0–522,
mean 45 days). Thirty-two and 26% of patients were admitted in
the nephrology and hematologic ward respectively. ESBLC infections
predominantly included urinary tract infection (85%), bacteraemia
(7.5%) and lower respiratory tract infection (7.5%). Univariate analysis
identiﬁed urinary catheterization (p = 0.0001), use of antibiotic therapy
(p = 0.002) and speciﬁcally b lactamin/b-lactamase inhibitor association
(BLI) (p = 0.017), cephalosporins (p = 0.001), sulfamides (p = 0.025) and
aminoglycosides (p = 0.004) as risk factors of infection. Nevertheless,
only 3 factors were signiﬁcantly associated with infection in multivariate
analysis: duration of urinary catheters (p = 0.01, OR=1.26, 95%CI
1.05−1.5), duration of cephalosporins (p = 0.03, OR=1.15, 95%CI
1.012–1.32) and duration of BLI treatments (p = 0.02, OR=1.15, 95%CI
1.01–1.31).
Conclusion: The identiﬁcation of these risk factors will be helpful to
identify ESBLEC colonized patients who will require broad spectrum
antibiotic therapy in case of nosocomial infection. Restriction/limiting
the use of speciﬁc antibiotics could be new targets for prevention of
ESBLs spread.
P1218 Adequacy of antimicrobial therapy of intra-abdominal
infections: healthcare-associated versus community-acquired
V.M. Meijering, M.B. Ekkelenkamp, D.W. de Lange* (Utrecht, NL)
Background: Intra-abdominal infections (IAIs) represent an important
cause of morbidity and are frequently associated with a poor prognosis.
Mortality has been reported between 20 and 45%, depending on the
population that is studied. Adequate and timely antimicrobial therapy is
essential, but often empirical therapy has to be initiated before culture
results become available. Furthermore, controversy exist about which
cultured micro-organisms (if not all) require treatment.
Methods: 193 patients with peritonitis, with a positive abdominal
microbiological culture, over a six-year interval were retrospectively
included. The cohort was divided into a group with health-care associated
intra-abdominal infection (HA-IAI) and a group with community-
acquired intra-abdominal infection (CA-IAI). In addition, a distinction
was made between complete coverage versus partial coverage of the
antimicrobial treatment of those patients. Patient characteristics and
outcomes of these groups were compared.
Results: One hundred ninety three patients were included, 141 with HA-
IAI and 52 with CA-IAI. Patients with CA-IAI were more severely ill
(APACHE II scores of 21 versus 19 in the HA-IAI), however patients
with HA-IAI had longer lengths of stay and were admitted to the ICU
more often. No difference in mortality between patients with HA-IAI and
CA-IAI was found (24.6% vs 25.2%). 125/157 patients (80%) received
empiric treatment which did not cover all cultured micro-organisms (so-
called partial coverage). Partial coverage of cultured micro-organisms
was associated with a higher mortality, in patients with CA-IAI (OR 9.27;
95%CI 1.095–78.49), but not in patients with HA-IAI (OR 0.89, 95%CI
0.34–2.36). The presence of enterococci and Candida species was not
associated with higher mortality, even when these micro-organisms were
not covered by the empirical antimicrobial therapy.
Conclusion: Although partial coverage of cultured micro-organisms in
CA-IAI was associated with an increased mortality, we could not detect
a relationship with empirical coverage of enterococci and candida in
both CA-IAI and HA-IAI. This contradicts the 2010 IDSA guidelines
that support empirical treatment of entercocci and candida in severely
ill patients with CA-IAI (APACHE II >15) or patients with HA-
IAI. Empirical treatment of IAI, and especially empirical treatment of
enterococci and candida, will remain controversial until a randomized
controlled trial will be performed.
P1219 Disproportionate increase from 2004–2008 in S. aureus
associated US hospitalisation rates in children
R.M. Mera*, J.A. Suaya, H.A. Madsen, F.P. O’Hara, D.F. Sahm,
L.A. Miller, C.A. Rodriguez (Durham, Philadelphia, Upper Providence,
Chantilly, US)
Objectives: To describe recent epidemiological changes in US S. aureus
hospitalization rates in children.
Methods: The study combined discharge data from the Nationwide
Inpatient Sample (NIS), Healthcare Cost and Utilization Project, and
71,272 pediatric inpatient isolates from the TSN electronic surveillance
database (Euroﬁns Medinet) for the years 2004–2008. S. aureus
associated hospitalizations were identiﬁed using ICD-9 codes. Based
on antibiotic susceptibility, isolates were classiﬁed as MRSA and CA-
MRSA, stratiﬁed by age, sex, source of the isolate, and census region.
Blood and bronchial isolates were categorized as invasive disease.
Hospitalization rates, standard errors, proportions and rate ratios (RR)
were obtained using appropriately weighted data that included the
variability of the TSN isolate collection.
Results:While the overall S. aureus hospitalization rate increased by 7%
from 2004 to 2008, among children less than 18 years of age the rate
increased by 49% (p< 0.01), from 14.2 +1.7 to 21.2 +1.8 hospitalizations
per 1,000 discharges. The hospitalization rate increased most among
children in the 1−5 age group (86% rise),followed by those less than
one year old (40%) and those aged 6 to 18 years (33%). There was
no signiﬁcant change in the rate of invasive disease, but there was a
74% (p< 0.001) rise in the rate of skin and soft tissue infection (SSTI)
hospitalizations, from 8.6 +0.97 in 2004 to 14.9 +1.45 in 2008. SSTIs
increased by a factor of 2.2 (p< 0.01) among the 1−5 age group, but
only by a factor of 1.71 and 1.47 among those less than 1 and 6 to 18
years old respectively. MRSA hospitalizations in children increased by
64% (RR 1.6 P< 0.01), from 6.5 +0.78 to 10.7 +0.97 hospitalizations per
1,000 discharges respectively, but this increase was twice as high among
children 1−5 years old (RR 2.2, p< 0.01) during the same period. CA-
MRSA hospitalizations in children increased from 3.8 +0.45 in 2004 to
6.7 +0.62 in 2008, or 80% (RR 1.8, p< 0.001), with a RR of 2.47 for
those between 1 and 5 years of age.
Conclusion: Between 2004 and 2008 US children experienced a nearly
50% increase in hospitalizations associated to S. aureus. The majority
of this increase was due to SSTI hospitalizations. By 2008, 51% of all
S. aureus hospitalizations in children were associated with MRSA, and
32% of them with CA-MRSA. The age group most affected by and
driving this change was children aged 1 to 5 years old.
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P1220 Risk factors for and consequences of nosocomial infections
caused by multidrug-resistant pathogens
E. Hajdu*, Z. Peto, G. Kitti, B. Renata, M. Matuz, R. Benko, Z. Molnar
(Szeged, HU)
Objectives: To identify possible risk factors for nosocomial infections
caused by multiresistant pathogens and to assess the effect of these
infections on treatment parameters and patient outcome.
Methods: Microbiologically conﬁrmed nosocomial infections occurred
at a tertiary care intensive care unit (ICU) between 2004 and 2009 were
retrieved retrospectively and were classiﬁed according to the antibiotic
sensitivity of the pathogen (according to CDC deﬁnitions). The following
patient data were analysed: age, type of admission diagnose, length of
stay, length of antibiotic treatment, number of drains and/or indwelling
catheters, patient severity (SAPS II) score, patient outcome. Statistical
analyses were performed with SPSS and included T- and c2- and
Fischer exact test. P values less than 0.05 were considered as statistically
signiﬁcant.
Results: During the ﬁve years of assessment 4683 cases were treated
on the ICU. The number of microbiologically conﬁrmed nosocomial
infections were 360 of which 240 were caused by antibiotic sensitive
(S group), 120 cases by multidrug resistant pathogen (R group). The
distributions of admission diagnoses differed considerably between the
two groups, multitrauma patients were 23.3% in the S, 39.2% in the R
group. Age and SAPS II score of patients in the two groups did not
differed considerably (S vs. R group: 57. 4±18.7 vs. 51.2±21.6 years)
and (39.2±11.4 vs. 38.6±10.5 points) while the number of catheters/
drains differed signiﬁcantly 4.0±1.3 vs 4.9±1.6. The mean length of
stay were signiﬁcantly longer in the R group (S vs. R group: 9.5±6.3
vs. 16.3±22.5 days) and the length of the antibiotic treatment was two
times longer in the R group (5.5±5.6 vs. 11.5±17.0 days). The mortality
was similar in the two patient group (S vs. R group: 27 vs. 19 cases).
Conclusion: The appearance of multidrug resistant pathogens were irre-
spective of patient’s age and patient’s severity, while the central venous
catheters diagnose and the number of catheters/drains were identiﬁed as
risk factors. Multidrug resistant pathogen caused nosocomial infections
had lead to signiﬁcantly longer antibiotic treatment course and length of
stay but had not resulted in higher mortality.
P1221 Antibiotic drug consumption and the emergence and spread
of antimicrobial-resistant Klebsiella pneumoniae clones in
an intensive care unit
A. Quattrocchi*, M. Barchitta, G. Valenti, L. Giaquinta, M.A. Romeo,
A. Tsakris, A. Agodi (Catania, IT; Greece, GR)
Objectives: Klebsiella pneumoniae has been isolated with an increasing
frequency as reported by the Italian Nosocomial Infections Surveillance
in Intensive Care Units (ICUs) (SPIN-UTI) project. Previous studies
have suggested a causal relationship between antibiotic usage and
antimicrobial resistance. Our study aimed to investigate the relationship
between antibiotic consumption and K. pneumoniae resistance in a
Sicilian ICU.
Methods: The study design integrated the patient-based and the
laboratory-based surveillance approaches (Agodi A, et al., in press J
Hosp Infect 2010, doi:10.1016/j.jhin.2010.10.007). For each antimicro-
bial agent, resistance rates (RR) were calculated as the number of
resistant isolates divided by the total number of the isolates tested.
Monthly data on antibiotic use were obtained from the pharmacy.
The amount of antimicrobial drugs was standardized by conversion to
deﬁned daily doses (DDD, WHO ATC/DDD Index 2008). Antimicrobial
usage density (AD) was calculated as the DDD per 1000 patient
days. Molecular typing of K. pneumoniae isolates was performed by
macrorestriction analysis of the XbaI-digested genomic DNA.
Results: During a seven-month period, 80 patients were enrolled in
the study and a total of 95 isolates were collected from 44 patients.
PFGE analysis of K. pneumoniae isolates led to the identiﬁcation of 4
clones associated to cross-transmission and 22 single patterns associated
with sporadic strains. RRs for K. pneumoniae belonging to epidemic
clones were higher than those for isolates belonging to sporadic strains.
The total AD was 13252. The three most used drug groups were
tetracyclines (AD 4236.5), quinolones (AD 3006.2) and glycopeptides
(AD 1298.5). The single most frequently prescribed antimicrobial agents
were tigecycline (AD 4237), ciproﬂoxacin (AD 2002.5) and levoﬂoxacin
(AD 1003.7). Comparison with international reference AD percentile
distributions revealed high AD values for most of the antimicrobial
groups used. Thus, the high RRs observed in the presence of high ADs
would suggest an overuse of these antimicrobials in the presence of a
relatively high genodiversity.
Conclusion: Increased efforts are required towards controlling antibiotic
use and raising awareness of the need for prudent use of antibiotics.
Surveillance of antibiotic consumption and bacterial resistance is
important to understand the relationship between antibiotic usage and
the emergence of K. pneumoniae resistance.
P1222 Is there a variation in microorganisms causing
healthcare-associated infections in a tertiary care hospital?
Analysis of ﬁve years data
M.A. Yetkin, D. Kanyilmaz, P. Onguru, E. Akinci, S. Eren, N. Avci,
I. Cinarbas, F. Coskun Alaca, N. Aksu, H. Bodur* (Ankara, TR)
Objective: Surveillance of healthcare associated infections and to have a
thorough knowledge of variation of antimicrobial resistance patern of the
isolates are crucial for planning antimicrobial therapy in hospitals. The
aim of this study was to analyze the nosocomial infections surveillance
data collected for ﬁve years and to detect the changes in antimicrobial
susceptibility of the microorganisms.
Methods: Patient-based active nosocomial infections (NI) surveillance
in intensive care units and laboratory-based NI surveillance in selected
clinics has been performed in our hospital between January 2006 and
November 2010. Hospital acquired infections were diagnosed according
to CDC criteria. Conventional methods and automated systems were
used for the identiﬁcation and detection the antimicrobial susceptibility
pattern of the microorganisms.
Results: In the year of 2006 and 2010, 810 and 852 microorganisms were
isolated from the infected patients, respectively. The most frequently
isolated microorganisms in 2006, were Staphylococcus spp (29.8%),
Pseudomonas spp (14.6%), Acinetobacter spp (17.0%), Escherichia coli
(12.6%) and Klebsiella spp (8.0%), whereas in 2010, Acinetobacter
spp (30.3%) was the most frequently isolated microorganism and
E. coli (7.4%) was the least isolated Gram-negative bacteria. There
were a statistically signiﬁcant increment in the isolation frequencies
of Acinetobacter spp, Pseudomonas spp and Klebsiella spp (p< 0.05),
whereas isolation rate of E. coli was decreased (p< 0.001)in 2010. The
isolation rate of Staphylococcus spp. was 10.3%, and the decrease in
the isolation frequency was signiﬁcant (p< 0.05). Methicillin-resistant
S. aureus isolation frequencies in years 2006 and 2010 were 19.1% and
6.7%, respectively (p< 0.001).
Antimicrobial resistance rates of carbapenems were increased in
Acinetobacter spp in 2010 when compared to year 2006 (p< 0.01),
on the other hand there was an increase in antimicrobial susceptibilty
rates of these antibiotics among Pseudomonas spp (p< 0.05). Methicillin
resistance rates in S. aureus were 94.5% and 79.2%, respectively.
Conclusion: Acinetobacter spp especially drug resistant ones have been
isolated more frequently as a cause of NIs whereas isolation rates
of MRSA decreased in recent years. Meticulous infection control are
needed for the control of this resistant Gram-negative microorganism.
P1223 Primary colonisation with coagulase-negative staphylococci
in hospitalised newborns
D. Knaack*, C. Ha¨rtel, J. Knobloch (Lu¨beck, DE)
Objectives: Coagulase negative staphylococci (CNS) are the most often
pathogens causing sepsis in very low birth weight preterm neonates
and are also the most important inhabitant of our skin. Therefore the
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unexplored ﬁeld of the dynamic of the primary colonization with CNS
is an important ﬁeld for the understanding of CNS infections in neonates.
Methods: We investigated the diversity of CNS on the skin of preterm
neonates at the neonatal ICU as well as healthy newborns on the regular
neonatal ward (NW) on day 3 to 5 after birth. For each newborn at least
50 to maximally 240 individual colonies from skin swabs of the ankle
and the elbow were identiﬁed using MALDI-TOF identiﬁcation and 50 to
192 isolates identiﬁed as CNS were phenotypically characterized for their
capacity to form bioﬁlm and the resistance phenotype against Oxacillin.
Results: We identiﬁed 4,549 bacteria of 40 neonates (23 ICU; 17
NW). On the ICU, CNS were predominatly S. epidermidis (78.1%)
and S. haemolyticus (18.4%) and only two other CNS species were
identiﬁed (S. hominis and S. warneri). On the NW, the major species were
S. epidermidis (75.8%) and S. hominis (17.9%), whereas S. haemolyticus
was identiﬁed only in 1.5%. Additionally, 5 more CNS species (S. capitis,
S. cohnii, S. lugdunensis, S. pasteuri, and S. warneri) were identiﬁed
at the NW. A statistically signiﬁcant (p< 0.005) higher prevalence of
Oxacillin resistance was observed for ICU isolates (80.2%) compared to
isolates from the NW (39.1%). The prevalence for the capacity to form
a bioﬁlm was very similar, with 72.1% bioﬁlm forming isolates on the
ICU and 69.3% bioﬁlm-positive isolates identiﬁed at the NW.
Conclusions: Summarizing the epidemiological data it could be
suggested that the residence in the environment of an ICU is a risk
for primary colonization with Oxacillin resistant bacteria. The capacity
to form adherent bioﬁlms is not detrimental in the primary colonization
of sterile skin in contrast to the observation on the skin of healthy adults
(Rogers, AEM, 74:6155). A higher diversity of species in the skin ﬂora
of neonates at the NW could be a fact of a higher frequency with the ﬂora
of persons not associated with the health care system. Further studies
should focus on the question if CNS identiﬁed as primary colonization
are identical with the strains causing neonatal sepsis.
P1224 Retrospective analysis of nosocomial infections in the
intensive care unit of a tertiary hospital in China during
2008 and 2010
Y. Chen*, Z.T. Yang, Z.Q. Che, T.S. Wang, S.Y. Zhao, Y.J. Yang, C. Zhu,
J.W. Shao, W.J. Zhou, H.Q. Sheng, W. Xu, M. Zhong, X.Y. Liu, F. Jing,
E.Z. Chen, Y.M. Lu (Shanghai, CN)
Background: Nosocomial infections such as catheter-associated infec-
tion (CAI) control is of key importance especially in critical patients.
This study was carried out to determine the current status of CAI in a
tertiary hospital in Shanghai.
Methods: A retrospective review of CAIs in the polyvalent ICU
of a tertiary hospital in Shanghai from May 2008 to April 2010
was performed. Nosocomial infections were deﬁned according to the
deﬁnitions of Centers for Disease Control and Prevention. The patients’
data on central line-associated primary bloodstream infections (BSI),
ventilator-associated pneumonias (VAP), and urinary catheter-associated
infections (UTI) was collected. Catheter-associated infection rate (per
1000 device-days) was calculated according to the National Healthcare
Safety Network (NHSN).
Results: A total number of 467 patients, admitted in ICU more than
48h, were enrolled in the study, with 9946 days of total hospitalization.
The rate of utilization of central venous catheter, urinary catheter
and respiratory catheter were 56.32%, 47.97%, 17.13% respectively.
Catheter-associated infection rate (per 1000 device-days) was 3.50 for
central catheter, 10.28 for urinary catheter and 37.80 for respiratory
catheter. Among 80 patients received mechanical ventilator (MV), 49
(61.3%) patients developed at least one episode of VAP. 40 patients
received more than 7 days MV, 31 (77.5%) developed VAP, while 18
patients (45.0%) developed VAP among those with less than 7 days MV.
Total 137 bacteria were isolated from 88 episodes of VAP for 49 patients.
The main pathogens of VAP were Gram negative bacteria, 78.8%
(108/137), followed by Gram positive bacteria, 21.2% (29/108), the latter
was mainly composed of MRSA 69.0% (20/29). Non-fermentation Gram
negative bacilli (NFGNB) were the major component of Gram negative
bacteria 71.3% (77/108), with A. baumannii (29), P. aeruginosa (29),
S. maltophilia (14) and F. meningosepticum (5). There was no signiﬁcant
change in total catheter-associated infections rates during the 2 years, but
there was a decreasing trend in VAP (41.1 vs. 34.9 per 1000 catheter-
day).
Conclusions: There was a higher rate of CAIs in our ICU compared to
their rates of NHSN report in 2006–2007. MRSA and NFGNB were two
major pathogens for VAP. Guidelines for surveillance and prevention of
nosocomial infections must be implemented urgently.
P1225 Clinical ﬁndings and risk factors in children with
imipenem-resistant Acinetobacter infections: single-centre
experience between 2004 and 2009 in Turkey
E.C. Dinleyici*, Z.Y. Yargic, A. Kiremitci, G. Durmaz, N. Tekin,
S. Sahin, F. Aydin, A. Aydin, O. Bor (Eskisehir, TR)
Objective: Acinetobacter species are important opportunistic pathogens
responsible for nosocomial infections especially in intensive care
settings. Management of infections caused by these strains is difﬁcult,
as the strains are often resistant to a wide range of antibiotics,
including broad-spectrum b-lactams, aminoglycosides quinolones and
carbapenems.
Methods: We here, retrospectively evaluated the risk factors and clinical
outcomes of Acinetobacter infections in our pediatric wards including
pediatric intensive care unit, hematological wards and newborn units
between 2004–2009.
Results: According to our results, 137 children (84 boys and
53 girls) have been followed-up in our clinics with diagnosis of
Acinetobacter infections. Median age was 95 days and median hospital
stay was 40 days. 66.4% of these children had a previous history
of hospitalization. 77.4% of these children had chronic underlying
conditions, 8% had neutropenia, 83.2% have required intensive care
unit stay (median 40 days), 52.6% had surgical interventions, 46.7%
had urinary catheterization, 19.7% had central venous line, 78.1% have
required mechanical ventilation and 78.8% have received total parenteral
nutrition. Among these, 62 isolates obtained from tracheal aspirates (all
cases are ventilatory associated pneumonia), 36 obtained from blood,
19 urine samples, 11 cerebrospinal ﬂuid, 6 surgical site samples and 3
peritoneal ﬂuid. 38.2% of these 137 children are died. Among these
137 isolates, 40.1% (n = 55) are imipenem-resistant isolates. Among
138 isolates 89.3% amikacin-resistant, 73% cefepim resistant, 86.9%
ceftazidime resistant, 86.1% ciproﬂoxacin-resistant, 8% resistant to
cefoperazone-sulbactam and 1 isolates resistant to colistin. The presence
of imipenem resitance were not associated with age group, gender,
presence of underlying conditions, presence of surgical interventions,
requiring intensive care unit stay. Presence of imipenem resistance
are 2.2 higher in children requiring mechanical ventilation (OR 2.2;
1.0−4.6;p< 0.05). Mortality rate also 2.7 fold higher in imipenem
resistant group (OR 2.7;1.3−5.4;p< 0.05).
Conclusion: Carbapenem-resistant Acinetobacter infections still remains
major challenge in pediatric age group and are common in children
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stayed in intensive care units with underlying risk factors. Due to
high mortality ratio in these patients with limited therapeutic choices,
prevention measures should carefully be implemented in all hospital
settings.
P1226 Nosocomial infection incidence and risk factors in elderly
patients in intensive care units
K. Ozdemir, M. Dizbay*, A. Dikmen (Ankara, TR)
Objective: Gradually increase in patients over 65 year age accounts a
spesiﬁc population for nosocomial infections. Predisposition to infections
in this age group is a result of impaired host defence such as diminished
cellular immunity. Despite the importance of this fact there is not much
data about the incidence and risk factors of nosocomial infections in
elderly. The purpose of this study is to investigate the risk factors, the
factors effecting mortality and incidence of nosocomial infections in
elderly patients in the medical ICUs of our hospital.
Methods: The patients treated over 48 hours at four ICU’s between
January and December 2008 were enrolled in the study. Data were
collected by active prospective surveillance. Elderly and adult patients
were compared according to the factors effecting the development of
nosocomial infection, causative agents, and mortality rates. Moreover,
elderly patients with/without nosocomial infection were compared for
the risk factors.
Results: A total of 433 patients were included in the study. 288 of
the patients were over 65, and 205 of them were 18−65 age. The
incidence of nosocomial infection was found 51% in the elderly group
and 48.8% in the adult group. There was no difference in the incidence of
nosocomial infection between the elderly and adult groups. The presence
of diabetes, COPD and chronic diseases were statistically higher in the
elderly patients with nosocomial infection. Pneumonia was the most
frequent nosocomial infection in both groups, and mechanical ventilator
utilisation was found to be high in both groups. Mortality rate and
duration of hospitalization were found signiﬁcantly higher in patients
with nosocomial infection than those of without nosocomial infection.
Increased age, lenghtheded duration of hospitalization, deterioration
of conscious, existence of underlying chronic diseases, the presence
nosocomial infection and malignancy as well as the use of MV and
CVC are found to be independent risk factors for mortality.
Conclusion: Nosocomial infection incidence among the elderly patients
in ICUs was high but not statistically different than the adult patients in
our study. However, the mortality was signiﬁcantly higher in elderly
group. We found that use of invasive techniques were related with
increase in the incidence of nosocomial infections. Limited application of
invasive procedures will make a contribution to decrease these infections.
P1227 Staying a step ahead of nosocomial infections: an accurate
predictive model using a novel correlation matrix and
simple linear regression
A. Karunakaran*, A. Arunachalam, K. Sivagnanam, P. Srikanth
(Chennai, IN; Minneapolis, US)
Objectives: To model blood and urinary nosocomial infections in an
ICU and predict the chance of developing an infection and its properties
in a speciﬁed number of days after admission using risk factors.
Methods: A prospective descriptive study on all admissions into a
tertiary care ICU during a 100 day period.
From previous retrospective studies done in the same ICU evaluating risk
factors for infection, a detailed risk-factor pro-forma was generated and
ﬁlled for each patient. Data was collected from review of case records.
Culture reports including susceptibility patterns were assessed.
Variables deﬁned were n as the day of admission, p the day for which
the chance of event is modelled, h the period prior to n from which
predictive data is used, f is the period at the end of which prediction is
required (=p-n). For best predictions, data from an appropriate time prior
to the admission of the patient for whom infection is predicted must be
used (h).
A correlation matrix was generated providing correlations between the
predicted infection rates among people with speciﬁed risk factors and the
actual infection rate. The appropriate regression equation and associated
r2 value for that particular value of h and f was calculated.
Results: 389 and 244 infection events were associated with IV-lines and
urinary catheters respectively. The r2 values of percentage predictive
accuracy were highest for the infection types with the most prevalence.
Urinary infections of any type were more predictable when compared to
blood infections of any type (29±4% and 14±2%).
Predictive accuracy among blood infections was better if predictions
were performed for individual organism groups when compared to the
prediction of any type (r2 of 74% on average compared to 54%). Higher
h values resulted in better prediction (average r2 of 5% in 5 days to 41%
in 45 days).
Range of r2 values was 55% to 95% with an average of 76%. Antibiotics
were better predicted with a range of 64% to 100% with an average of
91%.
Conclusion: The results of the model are encouraging with high
percentage predictive accuracy range for infections. The accuracy of
prediction is proportional to the prevalence of the condition being
modelled, is better for urinary tract infections, individual organism
groups modelled and larger values of h.
Prediction of nosocomial infections and their properties is likely to be
very beneﬁcial improving management and patient outcome.
P1228 Device-associated infection surveillance in intensive care
units of Duzce University Hospital, 2008–2009, Turkey
M. Yildirim*, M.F. Geyik, D. Ozdemir, A. Iskender, M. Erbas, A. Danis
(Du¨zce, TR)
Objectives: Device-associated infections (DAIs), such as catheter-
associated urinary tract infections (CAUTIs), central line-associated
blood stream infections (CABSIs), and ventilator-associated pneumonia
(VAP) pose the greatest threat to patient safety in intensive care units
(ICUs). The purpose of this study was to evaluate the device-associated
infections in Intensive Care Units of Duzce University Hospital, in
Turkey.
Methods: A prospective surveillance was performed to determine DAIs
rates during 2008–2009. Hospital-acquired infections were identiﬁed
according to the deﬁnitions of Centers for Disease Control and
Prevention. DAIs rates were calculated as the number of infections per
1000 device-days.
Results: The hospital-acquired infection incidence was 31.4 per 1000
patient days in 2008, and 28.3 per 1000 patient days in 2009. Ventilator-
associated pneumonia rate was 17.4 and 21.6, CAUTIs rate were 6.3 and
4.8, and CABSIs rate were 8.6 and 6.9 in 2008 and 2009, respectively.
There was not any statistically signiﬁcant difference between DAIs
rates in 2008 and 2009. Pseudomonas spp., Staphylococcus aureus,
Escherichia coli, and Acinetobacter spp. were the most common
causative agents.
Conclusion: In this study, high incidence rates of device-associated
infections were found. Ventilator-associated pneumonia, and high ratios
of Pseudomonas infections were particularly present in our ICUs. To
reduce infection rates and improve quality of care in ICUs in developing
countries such as Turkey, comprehensive infection control programs are
required.
P1229 Increase of patients co-colonised or coifected with
methicillin-resistant Staphylococcus aureus, vancomycin-
resistant Enterococcus faecium or extended spectrum
b-lactamase-producing Enterobacteriaceae
E. Meyer*, R. Ziegler, F. Mattner, F. Schwab, P. Gastmeier, M. Martin
(Berlin, Nuremberg, Cologne, Freiburg, DE)
Objectives: We aimed to determine the incidence of patients with co-
occurrence of MRSA, VRE faecium or ESBL producing enterobacteri-
aceae in four German tertiary care hospitals and to describe the change
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in the incidence of patients with co-occurrence of those pathogens over
the last three years (2007–2009).
Methods: Co-colonization or co-infection was deﬁned as patients
with positive cultures for at least two of the following resistant
pathogens: MRSA, VRE faecium or different species of ESBL-producing
Enterobacteriaceae within one calendar year.
Results: A total of 896,822 patients were analyzed. 10,066 patients har-
boured MRSA, VRE faecium and/or ESBL producing enterobacteriaceae
and 542 patients co-harboured those resistant pathogens. In 2009, 7.6%
of MRSA patients, 13.7% of the VRE faecium patients and even 16.1%
of the ESBL producing enterobacteriaceae patients were co-colonized or
co-infected. The total number of co-infected or co-colonized patients
increased from 157 to 219 over the last three years and accounted
for 6% of all patients with MRSA, VRE faecium or ESBL producing
enterobacteriaceae in 2009. The incidence of patients with co-infection or
co-colonization increased steadily from 5 (2007) to 7 per 10 000 patients
(2009).
Patients harbouring ESBL producing enterobacteriaceae or VRE faecium
had a higher risk to be co-colonized or co-infected than what was to be
extrapolated from their overall incidence. This might be linked to their
gastro-intestinal reservoir and impracticality to decolonize the gut of
resistant.
Conclusion: The burden of patients with co-colonization or co-infection
with MRSA, VRE faecium or ESBL producing enterobacteriaceae
increased from 2007 to 2009 by 40%. This was especially the case
in patients carrying ESBL-producing enterobacteriaceae. Clinicians can
expect to face increasingly patients with co-occurrence of resistant
pathogens. Therefore, three points are paramount: prevention of
transmission, limitation of antibiotic use to curtail the selection and
persistence of predominant clones and, strategies to inﬂuence carriage
especially in the intestinal tract being an important reservoir of antibiotic
resistance genes.
P1230 Frequency of colonisation by multiresistant organisms
among patients hospitalised in a geriatric ward: a one-year
prospective observational study
D. Schoevaerdts*, A. Verroken, M. Frennet, J. Jamart, D. Huang,
P. Bogaerts, C. Swine, Y. Glupczynski (Yvoir, BE)
Objectives: To determine the prevalence, incidence and risk factors
of asymptomatic carriage of extended-spectrum b-lactamase producing
Enterobacteriaceae (ESBL) methicillin-resistant Staphylococcus aureus
(MRSA), and vancomycin-resistant enterococcus (VRE) in elderly
subjects admitted to hospital in a geriatric ward.
Methods: During one year, nasal, oropharyngeal, groin, axilla and
rectal swabs were prospectively collected upon admission and at
discharge for microbiological culture on selective chromogenic agar and
broth enrichment. Identiﬁcation and susceptibility testing of the target
pathogens was performed according to conventional laboratory methods.
Genotypic characterisation of resistance determinants was performed by
multiplex PCR assays.
Results: Out of 445 admitted patients between 12.2009 and 12.2010, 350
were included in the study. The estimated prevalence upon admission
of ESBL, MRSA and VRE carriage was respectively 13% (Conﬁdence
Interval 95% (95%CI):10−17%), 7% (95%CI: 5−11%) and 0.6%
(95%CI: 0.1−2.0%). Escherichia coli (E. coli) was the most frequently
isolated microorganism among ESBL+ isolates (89%). Only 1% of the
patients were co-colonized by ESBL and MRSA on admission. The
incidence density of ESBL and MRSA carriage was respectively of
2.25 and 0.86 new cases for 1000 hospitalization-days. No cases of
VRE acquisition were found. Using a logistic regression model, the
following risk factors for ESBL colonization on admission were: multiple
contacts with hospital within the previous year (Odds Ratio (OR): 3.2;
95%CI: 1.5−6.9; P-value: 0.003), chronic bladder catheter use (OR:
3.4; 95%CI: 1.3−9.1; P-value: 0.01) and a high level of dependency
measured by the 24 items Katz scale (OR: 1.1; 95%CI: 1.0−1.2; P-value:
0.01). For MRSA, the two following risk factors were obtained in the
model: previous known MRSA colonization (OR: 26.8; CI95%: 8.0–
90.0; P-value <0.001) and a high level of dependency measured by the
6 items Katz scale score (OR: 0.7; 95%CI: 0.5−1.0; P-value: 0.08).
Conclusion: This study shows a high prevalence of asymptomatic
colonization by ESBL producing E. coli on admission in an acute
geriatric ward. This rate is almost twice higher than the prevalence
of MRSA carriage. VRE colonization remains low in our setting.
A low functional status is a common risk factor for both ESBL or
MRSA colonization and highlights the need to reinforce infection control
procedures.
P1231 ICU − always the hotbed of resistance?
R. Reynolds*, K. Maher, R. Hope on behalf of BSAC Working Party
on Resistance Surveillance
Objective: Intensive care (ICU) is often considered a hotspot for
development and dissemination of antibiotic resistance. We compared
non-susceptibility (NS) in hospital-acquired infections (patients in
hospital 48 hours) between ICU and other wards, and between blood
and respiratory infections (RTI) monitored in the BSAC Resistance
Surveillance Project.
Methods: Laboratories in the UK and Ireland provided isolates from
blood (28 centres) and RTI (22 centres) in 2008–2009. Isolates were
tested by the BSAC agar dilution MIC method at two central laboratories
and categorised by BSAC/EUCAST breakpoints. Excluding patients in
hospital <48 hours or missing data for speciality left 2622 isolates for
analysis.
Results: In S. aureus, MRSA was much less prevalent in ICU than
other wards (30 vs. 55%) among RTI but not blood (35 vs. 29%),
with corresponding differences in NS to ciproﬂoxacin (CIP, 40 vs.
60%), erythromycin (38 vs. 54%) and penicillin (PEN, 83 vs. 95%).
Within MSSA, blood isolates had less CIP-NS in ICU (0 vs. 13%) and
appeared to have less PEN-NS (77 vs. 84%), but teicoplanin NS was
more common in ICU (7 vs. 0.3%); RTI MSSA similarly appeared to
have lower NS in ICU for CIP (14 vs. 21%) and PEN (75 vs. 89%).
Among MRSA, RTI isolates showed more NS in ICU for gentamicin
(18 vs. 1%) and mupirocin (32 vs. 4%; perhaps also in blood, 18 vs.
5%). For E. coli, CIP-NS was substantially lower in ICU for RTI (18 vs.
29%) and appeared so also in blood (7 vs. 21%), although there was no
difference in ESBL prevalence. Other NS all appeared similar or lower
in ICU than other settings for RTI E. coli, with a more mixed picture for
blood. Klebsiella too tended to have less CIP-NS in ICU (11 vs. 18%,
RTI; 6 vs. 14%, blood) and no clear examples of higher NS in ICU.
Enterobacter had a general but unclear tendency to more NS in ICU.
For Pseudomonas, in both RTI and blood, NS appeared more prevalent
in ICU for all ﬁve agents tested, the difference for imipenem being most
striking (28 vs. 10%, RTI; 22 vs. 5%, blood).
Conclusion: For hospital-acquired infections, non-susceptibility was not
universally more prevalent in ICU than other settings. In some cases
(e.g. methicillin in RTI S. aureus; ciproﬂoxacin in RTI E. coli and blood
MSSA), non-susceptibility was signiﬁcantly less prevalent in ICU than
elsewhere. Relationship of non-susceptibility to ICU varied with site
of infection as well as organism and antibiotic, and was not clearly
explained by patient age.
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Outbreaks
P1232 Molecular typing by pulsed-ﬁeld gel electrophoresis of an
outbreak of multidrug-carbapenem-resistant Acinetobacter
baumannii bacteraemia in a haematology department
E. Us*, A. Azap, H. Aslaner, S. Civriz-Bozdag, A. Tekeli, I. Balik,
H. Akan, G. Gu¨rman (Ankara, TR)
Objective: To characterize multidrug-resistant (MDR)-A. baumannii
strains involved in an outbreak within a 41-bed hematology department
(HD) of an university hospital.
Methods: An increase in the number of cases of A. baumannii
bacteremia was observed among patients of HD. The outbreak lasted
for 12 days, seven patients involved and all of them died due to
A. baumannii sepsis. Outbreak investigation procedures was followed
according to the CDC recommendations on outbreak investigation. Case
control study was designed in order to ﬁnd any association between
MDR-A. baumannii bacteremia and some patients’ characteristics and
variables. Molecular typing by PFGE of the digested genomic DNA
was performed according to WHO protocols with modiﬁcations. In this
method, each isolate was digested with ApaI macrorestriction enzyme
separately. PFGE patterns were analyzed both visually and with computer
assisted analysis with Gene Directory software (Syngene, Cambridge,
UK). A similarity index was determined by using Dice coefﬁcient,
unweighted pair-group method average (UPGMA) method with 1% band
tolerance. Isolates displaying more than three DNA fragment differences
and a similarity of <80% following dendrogram analysis were considered
to represent unrelated PFGE types; isolates with between 1−3 fragment
differences and a similarity of >80% were considered to represent PFGE
subtypes, while isolates showing identical DNA banding patterns were
considered to be clonal.
Results: Three of six MDR-A. baumannii strains from outbreak cases
tested gave an identical banding pattern and were considered to be
clonal, which was designated as clone A. These three isolates also gave
similar antibiotic susceptibility patterns. Remaining three isolates were
unrelated to clone A, two isolates in this group were in clone B, and one
remaining isolate was in clone B1. The isolates from other departments
and environmental isolates tested gave DNA ﬁngerprint patterns distinct
from outbreak isolates tested.
In case control study a statistically non-signiﬁcant association between
MDR-A. baumannii bacteremia and being exposed to heparinized saline
solution (OR:4.6, CI: 0.60–52.94, P = 0.07) was found. The outbreak was
over after prohibiting the common use of heparinized saline solution.
Conclusion: The MDR-A. baumannii outbreak occurred in hematology
department was caused by the spread of two epidemic clones, which was
probably selected because of its resistance to major antimicrobial agents.
P1233 Description of an outbreak of multi-resistant Acinetobacter
baumannii: clinical impact, genotypic analysis and outcome
G. Migliorino*, E. Motta, S. Bramati, G. Foti, M. Rossi, A. Bandera,
E. Vigano`, R. Fumagalli, A. Gori (Monza, IT)
Introduction and aim of the study: A. baumannii (A) is a Gram negative,
non fermenting coccobacillus, widespread in the environment, that
can survive on inanimate surfaces for up to 6−8 weeks. The clinical
relevance of A. is linked to its involvement in nosocomial infections
in critically ill patients and especially its inherent multidrug resistance
(MDR) makes therapy very complex and inﬂuences the outcome. In
the period from February to November 2009 A. was isolated from 20
patients hospitalized in the S. Gerardo Hospital of Monza, Italy. 18/20
strains (90%) were isolated from patients in ICU; 13 developed clinical
infections while 7 cases were considered colonizations.
Material and Methods: Bacterial identiﬁcation and antibiotic sensitivity
were assessed using Vitek system (bioMe´rieux) and conﬁrmed with
MIC by Etest. All MDR strains were resistant to aminoglycosides,
carbapenems, quinolones, and cephalosporins and sensitive to Colistin.
All the isolates responsible for colonization and infection were
genetically related to each other as shown by molecular analysis with
rep-PCR. A space-time analysis of the epidemic spreading was carried
out.
Results: 14/20 patients (70%) had lung as primary location:12 with
clinically manifest infection (60%) and 2 (10%) were considered
colonizations. Multiple sites infections occurred in 35% of the cases.
Pulmonary infections were treated with Colistin 2−3 MU × 3 IV +
Ampicillin/Sulb IV 4 gr × 4 + endobronchial Colistin 1 MU × 3
by aerosol. In two cases was added Tigecycline 50mg ×2 IV. The
crude mortality rate overall was 45% (9/20), but in 8 cases mortality
was attributed to other causes not A.-correlated as shown by negative
cultures for A. to document the effectiveness of antibiotic therapy
instituted. In one case mortality was related to infection: the patient
did not start antibiotic therapy as the identiﬁcation of cultured A. and
communication to the department had taken place just in 24 hours from
the exitus. Therefore, antibiotic therapy was effective, as documented by
microbiological monitoring, in 100% of 12 cases treated.
Conclusion: The attributable mortality by A. Infections observed in our
series is 7,6% (1/13), better than the 10−43% reported in literature in
patients in ICU of which our population represents the vast majority.
The combination of systemic therapy and endobronchial Colistin was
effective against lung infections and there have been no major side
effects.
P1234 Outbreak of methicillin-resistant Staphylococcus aureus in
a neonatal intensive care unit
L. Cariani*, G. Deﬁlippi, R. Colombo, M. Colosimo, L. Pugni,
C. Parlato, P. Cavallerio, F. Mosca, R. Serra, E. Torresani (Milan,
Turin, IT)
Nosocomial outbreaks caused by Methicillin-resistant Staphylococcus
aureus (MRSA) are a major health problem in neonates. Outbreaks
of MRSA colonization and infection in neonatal intensive care units
(NICUs) can lead to signiﬁcant morbidity and mortality.
Objectives: To assess the presence of an epidemic strain of MRSA in a
NICU using genotyping and epidemiological methods, and the probable
relationship between neonates and healthcare workers (HCWs).
Methods: During a period of two months (July-August 2010)
surveillance cultures were obtained from all neonates (150) admitted
and all HCWs (157). A total of 79 MRSA strains were collected from
14 (8,9) HCWs and 65 (43,3%) neonates.
First of all, molecular typing of 52 MRSA isolates was performed
by repetitive extragenic palindromic PCR (rep-PCR) using Diversilab®
system (BioMerieux). Secondly, protein A-encoding gene (spa) of 18
MRSA strain was investigated, to monitoring the clonal distribution of
MRSA strains.
Results: Cluster analysis of rep-PCR ﬁngerprints indicated an hetero-
geneous population of MRSA isolates, especially one major cluster
(similarity >95%) and another distinct group composed only by one
case, isolated in a healthcare worker.
Spa-typing was performed only on 18 MRSA strains from both clusters.
Overall, the largest individual group of spa types (17/18) belonged to
the EMRSA-15 complex, with one spa type, t032, predominating (16/17)
and one spa type t515 that is recently considered to belong to this clonal
group EMRSA-15.
Only one of the 18 MRSA isolates showed the spa type t127 (the
healthcare workers clustered alone) in agreement with the cluster analysis
of rep-PCR.
Conclusion: Automated rep-PCR assays on the DiversiLab system, used
for MRSA, proved as a rapid and reliable method for molecular analysis
of nosocomial outbreaks. In addition, use of spa-typing can give more
information about the current epidemiological distribution of clones.
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P1235 Epidemiological characterisation of epidemic and
non-epidemic clones of Acinetobacter baumannii: is
surveillance of carriage in intensive care units useful?
M. Barchitta*, G. Valenti, A. Quattrocchi, M.A. Romeo, L. Giaquinta,
C. Santangelo, G. Castiglione, A. Agodi (Catania, IT)
Objectives: The emerging role of Acinetobacter baumannii as well as
an increasing trend in time of speciﬁc resistance patterns has been
reported in Italian intensive care units (ICUs) (Agodi et al., 2010).
Active surveillance for A. baumannii acquisition was implemented
simultaneously in multiple ICUs in order to deﬁne the genetic
relationships of isolates, both for local and for global epidemiological
purposes, using Pulsed-Field Gel Electrophoresis (PFGE) and Multilocus
Sequence Typing (MLST) analyses.
Methods: Patterns of A. baumannii acquisition in ICU, during the period
of the study, were carriage, colonization and infection. Identiﬁcation
of A. baumannii was conﬁrmed by Ampliﬁed rDNA Restriction
Analysis (ARDRA), genotyping by PFGE of the ApaI-digested genomic
DNA, and MLST analysis using the Institute Pasteur’s MLST scheme
(Diancourt et al., 2010).
Results: During the six months period, 182 patients were enrolled in
the patient-based surveillance of 3067 patient-days and a total of 149
isolates, all identiﬁed as A. baumannii by ARDRA, were collected from
84 patients. Carriage was associated to 3.3% of isolates; colonization to
25.8%, colonization/infection to 47.5%, and infection to the remaining
23.4% of isolates, using international deﬁnitions. A total of 12 unrelated
pulse-types were identiﬁed. Particularly, two major clones were identiﬁed
involving respectively 42.7% and 34.3% of isolates, showing inter-
hospital spread and intra-ICU spread. All A. baumannii isolates were
multidrug resistant. Most isolates exhibited susceptibility only to colistin
and tigecycline. For each ICU a speciﬁc epidemic curve was plotted and
outlier analysis suggested a carrier patient as the source of the outbreak
at least for one ICU. MLST will further provide characterization of
epidemic and non-epidemic strains as well as carriage or colonization/
infection associated clones.
Conclusions: Our study underlines the importance of early detection of
A. baumannii epidemic clones in the ICU setting, and suggests careful
efﬁcacy evaluation of screening on admission for all patients at high
risk. Therefore, multicentre studies are needed to address the increasing
import of resistant A. baumannii into the ICU and to minimise the risk of
transmission. Furthermore, global epidemiological scenarios are required
in order to deﬁne the efﬁcacy of infection control strategies in ICUs.
P1236 Nosocomial pseudo-outbreak of XDR Pseudomonas
aeruginosa urinary tract infections due to analytical
contamination in the laboratory
M. Hallin*, A. Deplano, S. Roisin, V. Boyart, R. De Ryck, C. Nonhoff,
O. Denis (Brussels, BE)
Background: By the end of may 2010, an increase in the number of
urinocultures positive for extremely drug-resistant (XDR) P. aeruginosa
(deﬁned as resistant to all but one antipseudomonal antibiotics, except
colistin) was observed in our 750-bed university hospital and led to
an infection control alert. No epidemiological link between the patients
and no increase in the frequency of XDR P. aeruginosa in non-urine
samples were observed. Therefore, a pseudo-outbreak due to analytical
contamination in the laboratory was rapidly suspected.
Methods: A retrospective search of cases (deﬁned as patients with an
urinoculture positive for P. aeruginosa non-susceptible to ceftazidime,
imipenem, meropenem and ciproﬂoxacin) was initiated. Sampling of
the automated urinary analysers used in the laboratory was performed.
Antibiotypes of clinical isolates as well as the isolate recovered from
one of the analysers were performed by disk diffusion. Genotypes were
determined by PFGE and the presence of VIM and IMP genes was
searched by PCR.
Results: From February to July 2010, 15 patients, admitted to 11
different departments, four outpatients and one staff member were
included. The mixing device of the cytometric analyser used for
numeration of urinary particles (Sysmex UF1000i) was proved to be
heavily contaminated. Isolates recovered from 12 patients belonged to the
same antibio- and PFGE type as the isolate recovered from the analyser,
all were VIM-positive. Four isolates harboured unrelated PFGE types and
4 isolates were unavailable. Extensive disinfection with a broad spectrum
disinfectant and replacement of the entire tubing was necessary to
achieve complete negativity of culture samples taken from the analyser.
A weekly disinfection procedure followed by sterility control of the
analyser was implemented.
Conclusion: A pseudo-outbreak caused by a VIM positive XDR
P. aeruginosa clone was proved to be due to the contamination of
the cytometric analyser for urinary sediment. Users of such analysers
should be aware that contamination can occur and should perform regular
disinfection and sterility control procedures of their analyser.
P1237 High-throughput molecular screening of methicillin-
resistant Staphylococcus aureus during a major nosocomial
outbreak caused by various genotypes
L. Roorda*, W. Hendriks, A. van der Zee, J. Ossewaarde, J. Buitenwerf
(Rotterdam, NL)
Objective: A major outbreak of methicillin-resistant Staphylococcus
aureus (MRSA) was detected in one of the two locations C and Z of our
hospital. Using genotyping 4 epidemic MRSA clones were identiﬁed
in hospital C that spread to location Z of our hospital and to other
health care related institutions in the region. To efﬁciently handle the
huge numbers of MRSA screening cultures, a molecular approach for
screening was designed and implemented.
Method: A fully automated high-throughput detection system of MRSA
was installed. Screening was carried out by means of chromosome-
SCCmec PCR.
Results: The major epidemic clones of MRSA in the outbreak were
eradicated after implementation of a rapid high throughput molecular
screening system, reducing the time needed to deliver the results, and
reducing the time of containment measures as prescribed by the Dutch
search and destroy policy.
However, not all MRSA were detected and new SCC variants were
identiﬁed. The SCC junctions of the variant types were sequenced and
subsequently included in PCR.
Conclusion: Rapid molecular screening contributed to fast eradication
of epidemic MRSA clones.
Identiﬁcation of several variant SCCmec sequences showed a very
high degree of homology to SCC regions of S. epidermidis and
S. haemolyticus. Thus, SCC sequences showed an unexpected high
degree of variability. As a consequence MRSA may be missed by
commercially available PCR based detection of chromosome-SCC
junctions.
P1238 Outbreak of Pseudomonas (Flavimonas) oryzihabitans
bacteraemia in a neonatal intensive care unit
H. Prifti*, D. Oikonomidou, O. Pappa, K. Tryﬁnopoulou, K. Vatzeli,
K. Karaiskos, E. Kostis, A. Vatopoulos, K. Tzanetou (Athens, GR)
Objective: To report an outbreak of nosocomial bacteremia caused by
P. oryzihabitans in a NICU of a tertiary care hospital.
Patients and Methods: Six premature neonates nursed at the NICU
developed bacteremia at the same day. The mean age, gestational age and
birth weight were 13 days, 30 weeks and 1362g respectively. All neonates
had intravenous catheter (2 of them had also umbilical) and received
total parenteral nutrition. Blood samples were inoculated in PedsPlus
bottles and incubated in BACTEC 9050 system. The API 20NE and
MicroScan were used for bacterial identiﬁcation. Susceptibility testing
was performed by disk diffusion technique and MICs were determined
by MicroScan and Etest. Specimens for culture were taken from the
environment of NICU and milk kitchen, from IV solutions, as well as
from milk preparations in order to identify the source of infection. The
clonal relationship of isolates was investigated by PFGE.
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Results: All blood isolates from the six neonates were identiﬁed as
P. oryzihabitans (a yellow-pigmented, Gram-negative bacillus), and had
an identical susceptibility pattern. All were susceptible to piperacillin,
piperacillin/tazobactam, ticarcillin/clavulanate, carbapenems, aminogly-
cosides ciproﬂoxacin, levoﬂoxacin, and tetracycline and resistant to
aztreonam and trimethoprim-sulfamethoxazole. After removal of IV
catheter and appropriate antibiotic treatment (imipenem combined
with gentamicin) ﬁve neonates recovered, and one developed necrotic
enteritis. Culture results showed contamination of a sponge from
milk kitchen which yielded P. oryzihabitans with a biotype and a
susceptibility proﬁle identical to those of blood isolates. All other
specimens taken from parenteral IV ﬂuids and milk were negative. All
blood isolates showed genetically indistinguishable PFGE patterns; this
ﬁnding combined with the concurrent onset of bacteremia led to the
suspicion of IV ﬂuid contamination, despite the causative agent was not
isolated from the IV ﬂuid preparations. Infection control measures during
preparation and handling of parenteral solutions resulted in elimination
of outbreak.
Conclusions: (a) Although P. oryzihabitans has been rarely reported as
a cause of bacteremia should be considered as a nosocomial pathogen
in neonates with IV ﬂuid administration. (b) Infections are mild and
respond well to treatment. (c) A strict aseptic technique in the preparation
of parenteral ﬂuids may reduce the risk of bacteremia in newborns.
P1239 MALDI-TOF mass spectrometry proteome proﬁling for
identiﬁcation and typing of multidrug-resistant Klebsiella
pneumoniae strains in a paediatric nosocomial outbreak
P. Bernaschi*, L. Putignani, F. Del Chierico, B. Lucignano, S. Ranno,
M. Argentieri, L. Pansani, M. Cioﬁ degli Atti, G. Ciliento, F. Locatelli,
D. Menichella, M. Raponi (Rome, IT)
Objectives: Rapid and reliable description of genetic relatedness of
clinical isolates of Klebsiella pneumoniae is crucial for nosocomial
outbreak investigations. We report an outbreak of severe sepsis in 3
patients hospitalized at the Onco-Haematology Unit of the Paediatric
Hospital “Bambino Gesu`” of Rome, Italy. The patients, who underwent
allogenic haematopoietic steam cell transplant, were infected by
extended-spectrum b-lactamase (ESBL) and carbapenemase (KPC)-
producing K. pneumoniae strains. Proteomic phenotypes from MALDI-
TOF MS were employed as analytical and typing expression proﬁling of
K. pneumoniae. These strains were clustered by using a hierarchical
analysis based on (Unweighted Pair Group Method with Arithmetic
Mean) UPGMA algorithm and Pearson’s coefﬁcient to investigate
correlation similarity.
Methods: Twelve clinical isolates of K. pneumoniae (4 ESBL-KPC-
producing and 8 antibiotic-sensitive controls) were investigated. Bacterial
identiﬁcations (ID) and initial antibiotic susceptibility testing was
performed by using the VITEK II instrument (BioMerie´ux, Marcy
l’Etoile, France) and drug resistance was conﬁrmed by Etest (AB
Biodisk, Solna, Sweden). ID was conﬁrmed by MALDI TOF-MS assay.
Spectra proﬁling from the 12 isolates were converted into virtual gel-like
format and UPGMA analysis was performed to investigate strain typing
correlation. The typing analysis based on repetitive-sequence PCR (rep-
PCR) (DiversiLab, BioMerie´ux) was performed to conﬁrm the results.
Results: Concordant results for K. pneumoniae strain IDs were achieved
with VITEK II and MS methods. The MS typing analysis of ESBL
and KPC-producing isolates proved that three ESBL-KPC isolates had
a similarity of 92% (close-related clustering), one ESBL-KPC belonged
to a different clade (similarity around 60%), while the eight controls
showed a very low similarity value. Rep-PCR corroborated the MS-
based clustering.
Conclusion: In immunocompromised patients the evolution of K. pneu-
moniae colonisation of the upper respiratory tract into episodes of sepsis
is a frequent clinical course. Furthermore, the antibiotic prophylaxis
of patients subjected to allogenic haematopoietic steam cell transplant
represents a strong risk factor for selecting multidrug-resistant (MDR)
Klebsiella strains. Therefore, the MS IDs and typing might provide a new
fast and accurate tool for the implementation of epidemiological controls
aiming to impede the spread of nosocomial pathogen outbreaks.
P1240 Consecutive outbreaks of Serratia marcescens infections in
a neonatal ICU are due to the repeated introduction of new
clones
K. Tryﬁnopoulou*, O. Pappa, M. Polemis, H. Prifti, K. Vatzeli, L. Ftika,
H. Maltezou, K. Tzanetou, A. Vatopoulos (Athens, GR)
Objective: The epidemiological investigation of three consecutive
outbreaks of S. marcescens bloodstream infections in a NICU of a
tertiary hospital in Athens over a 3-year period.
Material and Methods: The outbreaks have occurred from December
2007 to August 2008 (outbreak 1) involving 5 neonates, from September
2009 to February 2010 (outbreak 2) involving 10 neonates and from May
2010 to September 2010 (outbreak 3) involving 5 neonates. During all
three outbreaks extensive screening of patients, health care workers and
inanimate environment was conducted. Typing performed by Pulsed-ﬁeld
gel electrophoresis (PFGE) of Spe-1 digested bacterial DNA.
Results: A total of 58 clinical (20 from neonatal infections and 38 from
patients’ colonization) and 9 environmental S. marcescens isolates were
recovered. PFGE allocated the 58 clinical isolates into 9 PFGE types
(>85% similarity), however 4 types were found to prevail during the
three outbreaks. In outbreak 1 all clinical S. marcescens isolates and one
isolate recovered from a sink drain were genetically indistinguishable
belonging to PFGE type I. In outbreak 2 two PFGE types prevailed,
type III in the ﬁrst part of this outbreak and type VII in the last part of
the outbreak. In outbreak 3 a new PFGE type VIII was recovered from
the vast majority of patients and also from the sink drain in the milk
kitchen. Moreover, 5 other PFGE types were recovered from 5 cases
(IV, V and VI during outbreak 2 and IX and X during outbreak 3). The
rest of the environmental S. marcescens isolates were genetically distinct
belonging to PFGE type II.
Conclusion: Molecular typing elucidate that the three consecutive
outbreaks in the NICU during a 35-months period had been caused
by genetically distinct S. marcescens clones, a fact consistent with the
repeated introduction and spread of new clones in the NICU. The fact
that no S. marcescens PFGE type was found to persist during the
whole period under investigation, indicates good decontamination and
disinfection policies in the ICU. However the entrance and explosive
spread of new clones in the ICU underlines possible gaps in infection
control practices. Thorough review of these practices resulted in the
containment of the epidemic.
P1241 Super spreader and nosocomial outbreaks
L. Danzmann, P. Gastmeier, R.P. Vonberg* (Hannover, Berlin, DE)
Objectives: The role of infected and/or colonized health care workers
(HCWs) as a potential source of a nosocomial outbreak is yet unclear.
The present study summarizes data from such outbreaks in order to
elucidate areas of special interest and to clarify potential reasons for
transmission.
Methods: We conducted a systematic review of the medical lit-
erature based on PubMed, the Outbreak Database (www.outbreak-
database.com), and on a hand search of so retrieved articles. We extracted
data on the setting, type of infection, number of patients, duration of the
epidemic, and infection control measures.
Results: A total of 152 outbreaks and 1,449 patients got included
thereof 51 fatal cases. The main route of transmission was direct or
indirect contact (53% of all outbreaks). Duration of the outbreaks
ranged from 1 to 287 weeks (mean: 28 weeks; median: 10.5 weeks).
The number of affected patients per outbreaks ranged from 1 to 75
(mean: 9.5; median: 7). Surgical (40%) and neonatological departments
(24%) were most often involved in outbreaks primarily caused by staff.
Transmission took frequently place in surgical theaters (40%) and on
peripheral wards (38%). The primary types of infection were surgical
site infections (27%) and hepatitis B (22%). The corresponding causative
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main agents were Staphylococcus aureus (32%), hepatitis B virus (14%),
and Streptococcus pyogenes (12%). Physicians (59 thereof 30 surgeons)
and nurses (56) were the predominant staff spreading the pathogen
to patients. Nine per cent of them were aware of their carrier status.
When checking for the compliance to hand hygiene (HH) of the person
causing the outbreak, we found that HH was considered “adequate”
in 14% of the outbreaks but “poor” in 10.5%. The infection control
measures most often implemented in order to terminate the outbreak
included screening of personnel (90%) and patients (77%), education of
staff and disinfection/sterilization procedures (53% each), application of
antimicrobial substances (47%), improvement in HH (46%), and use of
protective clothing (39%).
Conclusion: Nosocomial outbreaks caused by staff are an important
problem in the ﬁeld of epidemiology and infection control. In the next
step we will check for characteristics of HCWs that may predispose for
an increasedpathogen spread to patients.
P1242 A retrospective review of hospital MRSA outbreaks: does
UK15 cause increased colonisation of healthcare workers?
J. Hart*, R. Lee, K. Christiansen, J.O. Robinson (Perth, AU)
Objectives: In Western Australia (WA) the epidemiology of healthcare-
associated methicillin resistant Staphylococcus aureus (MRSA) strains
has evolved over the last decade, with ST239-MRSA-III (AUS2/3)
decreasing in incidence and a concomitant rise in ST22-MRSA-IV
(UK15). A “Search and destroy” policy that includes screening and
isolating all patients exposed during an outbreak and screening and
decolonising Healthcare workers (HCW) has successfully controlled
nosocomial spread. As result, MRSA is not endemic in WA teaching
hospitals but outbreaks do occur. Assessing factors that contribute to
HCW colonisation will allow better management of outbreaks. It has
been anecdotally noted that the increasing prevalence of UK15 appears
to be associated with increased HCW colonisation during outbreaks;
therefore we aimed at comparing AUS2/3 and UK15 colonisation rates
of patients and HCWs during outbreaks.
Methods: A retrospective review was performed of MRSA outbreaks
occurring between January 2000 and December 2009 at Royal
Perth Hospital. Records were examined and data extracted including
demographic information on colonised patients and HCWs and the
number of patients and HCWs colonised with the outbreak strain of
MRSA.
Results: Six AUS2/3 outbreaks (median duration 49 days [range 20–
392]) were compared with 10 UK15 outbreaks (median duration 52
days [range 22–128], p = 0.69). The number of patients screened during
the outbreaks were similar between AUS2/3 and UK15 (median 124
[range 39–338] and 106 [39–338], p = 0.59). Likewise, the number of
HCWs screened were similar between AUS2/3 and UK15 outbreaks
(median 159 [range 120–288] and 125 [72–330], p = 0.30). The number
of patients colonised were comparable between AUS2/3 and UK15
outbreaks (median 11 [range 5−26] and 7 [3−20], p = 0.07) but the
number of HCWs colonised was signiﬁcantly lower in AUS2/3 (median 2
[range 1−3]) compared to UK15 outbreaks (median 4 [0−12], p = 0.013).
Also, the ratio HCW colonised/screened was lower in AUS2/3 compared
to UK15 outbreaks (median 0.81 [range 0.56–2.17] and 3.36 [0–5.56]
respectively, p = 0.013).
Conclusion: HCWs are more likely to become colonised during
outbreaks of UK15 compared with outbreaks of AUS2/3. Given that
UK15 has largely replaced AUS2/3 as the dominant outbreak strain
in hospitals in Western Australia, and is the dominant strain in many
countries, this highlights the importance of introducing early screening
and decolonising of HCWs to outbreak strategies for swift control.
P1243 A systematic review of nosocomial outbreaks caused by
multidrug-resistant Gram-negative bacteria
E. Zhuchenko, K. Graf*, R.P. Vonberg (Hannover, DE)
Objectives: Multi drug resistant Gram negative bacteria (MRGN)
represent an increasing problem in many health care setting. Until now
there are only few data on sufﬁcient infection control measures that
should be applied in the case of an outbreak.
Methods: We conducted a systematic review of the medical lit-
erature based on PubMed, the Outbreak Database (www.outbreak-
database.com), and on a hand search of so retrieved articles. Pathogens
of interest were Acinetobacter spp. (ACI), Pseudomonas spp. (PAE) and
ESBL-producing Enterobacteriaceae (ESBL). We extracted data on the
setting, type of infection, number of patients, duration of the epidemic,
and infection control measures.
Results: A total of 59 ACI outbreaks, 109 PAE outbreaks, and 57 ESBL
outbreaks were included.
The median duration of the outbreak was 183 days (ACI), 92 days
(PAE), and 210 days (ESBL) respectively. The average number of
affected patients in the three groups was 25 (ACI outbreaks; thereof
infected: 19 patients; thereof died: 4 patients), 23 (PAE; 16; 3),
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and 57 (ESBL; 46; 2). ACI outbreak speciﬁc ﬁndings included an
association to university hospitals, to intensive care units, and to surgery
departments. PAE outbreaks were associated with signiﬁcantly less use
of isolation precautions, less frequently closure of wards, and less use of
protective clothing. ESBL outbreaks took place especially in neonatology
departments and caused signiﬁcantly high numbers of urinary tract
infections. Additional information on the source of pathogen, its route of
transmission, type of infection, age groups of patients, and implemented
infection control measures is provided in the table.
Conclusion: The Outbreak Database served as a valuable tool for
the characterization of nosocomial outbreaks as several signiﬁcant
differences between the three groups of pathogens examined were
detected. Thus, from the ﬁndings of the present study we would
recommend adjusting the infection control measures speciﬁcally on the
type of pathogen. However, from our point of view currently there is no
MRGN bacterium that should be totally disregarded with this respect.
MRSA − colonisation and screening
P1244 Nasopharyngeal colonisation with methicillin-resistant
Staphylococcus aureus among incarcerated population in
Avare´, Brazil
C.L. Witzel* (Botucatu, BR)
Introduction: The emergence of Community-acquired Methicillin-
resistant Staphylococcus aureus (CA-MRSA) in the 1990s posed new
challenges for preventive and therapeutic approaches of staphylococcal
infections. Studies that assess prevalence and characteristics of CA-
MRSA in high risk populations can improve our knowledge of its
epidemiology.
Objective: To identify prevalence, risk factors and molecular character-
istics of nasopharyngeal colonization with CA-MRSA among men in a
correctional facility in the municipality of Avare´, Southeastern Brazil.
Methods: In a cross-sectional survey, nasopharyngeal swabs were
obtained for 302 men from Avare´ Correctional Facility. Resistance
to Methicillin was assessed through disk diffusion (for Oxacillin and
Cefoxitin) and mecA gene identiﬁcation with Polymerase Chain Reaction
(PCR). We also performed PCR to identify genes associated with
Panton-Valentine Leukocidin (lukF-PVe luckS-PV). Risk factors for
carriage of S. aureus (in general), MRSA and Methicillin-susceptible
S. aureus (MSSA) were assessed in univariate and multivariable (logistic
regression) models.
Results: The general prevalence of S. aureus colonization was 16.5%,
while MRSA was found in 5.0% of study subjects. Disk diffusion tests
failed to identify most strains that harboured mecA gene. PVL-related
genes were not found in any of the study isolates. Colonization with
S. aureus was independently associated with “sex with men” (OR=4.37,
95%CI=1.50–12.74) and the presence of pulmonary (OR=12.16,
95%CI=1.99–74.41) or skin (OR=2.44, 95%CI=1.24–4.81) diseases.
Risk factors for MRSA colonization were: “sex with men” (OR=6.07,
95%CI=1.40–26.38) and pulmonary disease (OR=34.4, 95%CI=2.18–
541.47, p = 0.01). On the other hand, MSSA colonization was positively
associated with regular intimal visits (OR=2.79, 95%CI=1.26–5.86)
and use of inalatory illicit drugs (OR=4.20, 95%CI=1.84–9.58), and
negatively associated with the presence of a recent tattoo.
Conclusion: The prevalence of MRSA colonization was high. While
MRSA colonization was related to sex with men (mostly between
inmates from the correctional facility), MSSA was associated with
(mostly heterosexual) intimal visits with partners that came from the
community. Even though there was an association between S. aureus
carriage and skin diseases, no PVL-producing isolates were found.
P1245 ESwab and Xpert MRSA/SA nasal assay optimises collection
to detection of community-acquired MRSA in children
M. Onori*, L. Mancinelli, F. Gesualdo, D. Menichella, C. Russo
(Rome, IT)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is
responsible for localized or systemic infection in hospitalized patients.
MRSA colonized children are at greater risk of developing “difﬁcult
to treat infections” especially because impaired or weakened immune
system.
Sampling collection devices and MRSA detection assays are both critical
steps of the MRSA investigation procedures. Moreover despite the high
incidence of MRSA there is no guidelines to recommend microbiological
workﬂow to detect MRSA carriage.
The objective of this study was to validate the New Copan ESwab
collection devices (consisting of a tube with 1ml of Amies medium and
a ﬂocked swab) and the GenXpert MRSA/SA Nasal Assay (Cepheid),
a multiplex real-time PCR assay that simultaneously detects S. aureus,
mecA gene and staphylococcal cassette chromosome (SCCmec) in less
than in one hour, to optimize MRSA screening “from collection to
detection” in children admitted to the “Bambino Gesu`” Children Hospital
screened for S. aureus colonization.
Methods: Nasal swabs were collected from 853 paediatric patients at
admission and discharge at the Medical Department and tested for both
bacterial culture and molecular assay from the same specimen. One
aliquot of each ESwab sample was cultured in Chapman and MRSA
chromogenic agar. Another aliquot of ESwab was tested directly in the
Xpert MRSA/SA Nasal Assay, to genotypically differentiate MSSA and
MRSA strains.
After 24h growth, S. aureus colonies were identiﬁed by using Maldi-
TOF Mass Spectrometry. Conﬁrmation of Identiﬁcation and oxacillin/
cefoxitin testing was performed by the Vitek2 systems.
Results: In the 1706 nasal swab, S. aureus was found in 356 samples.
The Vitek2 identiﬁed 13 MRSA and 21 MSSA. Instead the genXpert
assay detected all 356 S. aureus positive of which 328 (92.13%) were
MSSA, 13 MRSA (3.65%), 12 empty cassette (SCC positive and mecA
negative) (3.37%) and 4 S. aureus negative and mecA positive (1.12%).
Conclusion: Both cultures and molecular testing results were obtained
from the same ESwab without any interference with the molecular
assay. Availability of a “simple” sample collection swabs able to be
used as well with phenotypical as molecular methods allow to optimize
the MRSA detection strategy. This study demonstrated that the Copan
ESwab sample collection is compatible with the Xpert MRSA/SA Nasal
Assay and, allows MRSA screening “from collection to detection” from
the same clinical sample collection.
P1246 Risk factors for methicillin-resistant Staphylococcus aureus
colonisation on admission to rehabilitation medicine
A. Pan*, F. Antonioli, R. Lazzari, A. Patroni, S. Garilli, F. Bernieri,
P. Mangoni, C. Meinecke (Cremona, Esine, Brescia, IT)
Objective: MRSA may colonize a discrete proportion of patients
transferred to rehabilitation medicine (RM). Deﬁning risk factors
associated with MRSA carriage upon admission could possibly permit
to better allocate resources for microbiologic screening and to identify
patients at higher risk, for preventive isolation.
Methods: All patients admitted to a rehabilitation ward of the hospital
of Cremona, where MRSA nasal screening is routinely performed 48
hours within admission, were investigated for risk factors associated
with MRSA carriage. The clinical chart was analyzed to identify
information regarding: reason of admission, previous diseases, recent
surgery, recent antibiotic therapy, general conditions (Barthel, FIM, CIRS
scales). Univariate and multivariate analysis were performed. A score to
identify patients at higher risk of MRSA carriage was deﬁned.
Results: We evaluated 301 patients, 13 (4,7%) previously unknown
MRSA positive upon admission. Univariate analysis ha identiﬁed 12
risk factors associated with an increased risk of MRSA positivity:
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(1) number of wards where the patient was admitted before transfer
to RM, (2) duration of hospital stay, (3) a program of respiratory
rehabilitation, (4) number of types rehabilitations programmed, (5) 2
or 3 rehabilitations programs as compared to a single one, (6) chronic
renal failure, (7) chronic obstructive pulmonary disease, (8) absence of
any trauma, (9) immunosuppressive therapy, (10) no surgical procedure,
(11) recent treatment with carbapenem antibiotics, (12) non-invasive
ventilation. On multivariate analysis factor associated with an increased
risk of MRSA colonization were: (1) recent treatment with carbapenem
antibiotics (Odds ratio = 17,5; 95% conﬁdence interval − 95% CI − 2,5–
123,8, p = 0,004) and (2) a program of respiratory rehabilitation (OR 7,6;
95%CI 1,8−33; p = 0,007). When 1 point was given for each of these
2 factors, 2 groups were deﬁned: class 1 (1 or 2 points): 10/45 patients
(22%) belonging to this class were MRSA positive on; class 0 (0 points):
4/256 patients of this class (1.6%) were MRSA positive.
Conclusions: A recent treatment with a carbapenem and a program of
respiratory rehabilitation are closely related to MRSA on admission in
our hospital. A scoring system could help in identifying patients for rapid
screening and/or preventive isolation and others who should neither be
screened nor isolated.
P1247 Prevalence and basal characteristics of persistent and inter-
mittent colonisation of methicillin-resistant Staphylococcus
aureus among residents living in long-term care facilities
M.L. Martı´n-Ponce, J. Santos-Morano, J.A. Garcı´a-Garcı´a*, C. Castro,
A. de Miguel-Albarreal, L.M. Martı´n-Rodrı´guez, S. Vergara-Lo´pez,
A. Mateos-Go´mez, E. Bayoll-Serradilla, E. Leo´n-Jime´nez,
J.M. Go´mez-Mateos, J.E. Corzo-Delgado (Seville, Osuna, ES)
Objective: To determine the prevalence and basal characteristics associ-
ated with persistent and intermittent methicillin-resistant Staphylococcus
aureus (MRSA) colonization among subjects living in long-term care
facilities (LTCFs) in southern Spain.
Methods: From April 2009 to November 2009, all subjects living in six
LTCFs of our area were initially included in a prospective longitudinal
study. Subjects were visited by the investigators at baseline and one year
later. Only the residents with two visits were the ﬁnal population of our
study. In each visit, clinical data and cultures of nasal were included.
Subjects were screened using nasal swabs and these were cultured
in a chromogenic media. Individuals were classiﬁed as non-carriers
(both samples were negative), persistent MRSA nasal colonization (both
samples were positive) and intermittent MRSA nasal colonization (at
least one sample was positive). The following data were obtained in
residents to identify risk factors for persistent MRSA carriers: age, sex,
time of living in residence, comorbidities (Charlson index), previous
antibiotic treatment, prior MRSA isolation, presence of decubitus ulcers,
functional status (Barthel index), use of invasive devices and invasive
procedures (surgery, endoscopies) in the last year. Data were analyzed
using SPSS version 14.
Results: A total of 326 subjects were evaluated, of which 258 (79%)
were classiﬁed as no colonizated. Among 68 residents with positive
cultures for MRSA, 54 (79%) were intermittent carriers and 14 (21%)
were persistent carriers. The annual incidence of MRSA adquisition was
10.4%. The only signiﬁcant baseline characteristic related to persistent
MRSA compared with intermittent carrier was an invasive procedure in
the last year [4 (28%) vs. 3 (5%), respectively, p = 0.035)].
Conclusions: A single sample of subjects living in LTCFs could
misclassify the SARM colonization status. It is necessary a major
knowledge about the dynamic of MRSA colonization in residents of
LTCFs. There is a high annual incidence of SARM in these institutions.
An invasive procedure, including surgery in the last year, was the only
factor associated with persistent MRSA carrier.
P1248 Nasal carriage of methicillin-resistant staphylococci among
sick and healthy horses in Portugal
N. Couto*, P. Tilley, J. Simo˜es, J. Sales-Luı´s, C. Pomba (Lisbon, PT)
Objectives: To investigate the frequency of methicillin-resistant
staphyloccoci-MRS carriage in a random sample of equines entering
the Faculty of Veterinary Medicine Teaching Hospital, Lisbon, Portugal.
Methods: From March 2008 to October 2010, nasal swabs were obtained
after admission to the hospital from 71 horses (38 from horses with
Recurrent Airway Obstruction − RAO; 13 from horses with Equine
Gastrointestinal Ulcer Syndrome − EGUS and 20 from healthy horses
that were admitted to either elective surgery (castration) or as part of
a control group for a RAO study). The swabs were enriched in 3ml
of Muller-Hinton broth containing 65 g/l NaCl. Five-hundred ul were
inoculated into 3ml Tryptone Soy Broth with 3,5mg/l cefoxitin and
75mg/l aztreonam. Ten ul were plated onto a chromogenic agar selective
for MRS including Staphylococcus aureus, MRSA-ID − bioMe´rieux.
Antimicrobial susceptibility testing was performed using the microbroth
dilution method (Sensititre CMV1AMAF and BOPO6F microplates,
Trek Diagnostic Systems). MRS isolates were typed with BBLTM
CrystalTM system (BD Diagnostic System, USA) and identiﬁed by PCR
for the mecA gene. MRSA were subjected to spa typing, SCCmec typing,
and ST398 PCR.
Results: From a total of 71 equines 15 MRS were isolated (13 were
methicillin-resistant coagulase-negative staphylococci-MRCoNS and 2
were MRSA). In the RAO group 5 animals carried 5 MRCoNS isolates.
Equines with EGUS carried 1 MRCoNS and 1 MRSA (spa type t062,
SCCmecII, ST5). From healthy horses 7 MRCoNS and 1 MRSA (spa
type t011, SCCmecIV, ST398) were isolated. ST398 MRSA isolate was
co-resistant to tetracycline, gentamicin and spectinomycin. The ST5
MRSA isolate was co-resistant to erythromycin and clindamycin. Among
MRCoNS, 1 Staphylococcus sciuri was co-resistant to gentamicin,
spectinomycin, clindamycin and ﬂuoroquinolones.
Conclusions: Our study detected for the ﬁrst time MRS isolates among
equines in Portugal including MRSA carriage of an associated animal
clone (ST398) and the second human main clone in Portugal (ST5). In
horses it is known that MRS can cause varying types of infection in
both colonized and non-colonized individuals. Resistance to b-lactams,
namely penicillin G and associated resistance among these isolates may
compromise future antimicrobial chemotherapy in equines. The question
of potential interspecies and zoonotic transmission exists and MRS
carriage among equines is a relevant animal and human health issue.
P1249 Methicillin resistance, virulence factors and genetic lineages
of Staphylococcus aureus isolates from nasal samples of
healthy sheep in Tunisia
H. Gharsa*, K. Ben Slama, C. Lozano, E. Go´mez-Sanz, N. Klibi,
A. Jouini, M. Zarazaga, A. Boudabous, C. Torres (Tunis, TN; Logron˜o,
ES)
Objective: To study the carriage rate, resistance mechanisms, virulence
traits and genetic lineages of nasal S. aureus of healthy sheep in Tunisia.
Methods: Nasal swabs of 163 healthy sheeps were obtained in two
farms (n = 59 animals) and in one big abattoir that receives sheeps from
farms of all Tunisia (104 animals, sampled in 6 different days during a
period of two months). Samples were inoculated into Baird Parker and
ORSAB plates for S. aureus and methicillin-resistant S. aureus (MRSA)
recovery, respectively. Isolates were identiﬁed by biochemical methods
and nuc-gene PCR. Antibiotic susceptibility proﬁle was determined by
disk diffusion. The presence of 32 resistance genes, 18 staphylococcal
enterotoxin genes and lukF/lukS (encoding Panton-Valentine leucocidin,
PVL), lukE-lukD, lukM, hla, hlb, hld, hlg, hlgv, eta, etb and tst were
studied by PCR. S. aureus isolates were typed: spa, agr, SCCmec, MLST
and SmaI-PFGE.
Results: 73 of 163 samples contained S. aureus (44.8%) and one isolate
per sample was studied. Five of 73 isolates were MRSA (3% of tested
animals) and the remaining 68 isolates were methicillin-susceptible
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(MSSA). Ten different spa-types were detected among S. aureus isolates
(t044, t223, t267, t967, t1534, t1773, t3576, and t5428) with two new
spa-types (t7579 and t7630). All 5 MRSA isolated from the same farm
showed indistinguishable or closely related PFGE-patterns and presented
the following characteristics: ST153 (single-locus variant of ST80), spa-
type t044, agr-III, contained mecA, tet(K), ant(4′), aph(3′) and ermC
resistance genes, and harbored lukF/lukS, lukED, hla, hld and hlgv genes.
Most of MSSA showed susceptibility to all antibiotics with the following
exceptions: tetracycline (16.4%, with tetK gene), penicillin (4.1%), and
fusidic acid (8.2%). Fifty-three MSSA carried the tst gene but none
of them the gene of PVL. Virulence genes carried by MSSA were: tst
(53 isolates), lukM (61), lukED (67), sec (48), sel (51), ecg cluster-like
(1), hla (68), hlb (67), hld (68), hlg (1) and hlgv (67). The remaining
virulence genes were negative among our isolates.
Conclusions: The nares of healthy sheep could be a reservoir of PVL-
positive community-associated-MRSA and also of genetic lineages of
S. aureus carrying lukED, lukM and tst, sec and sel genes, with
implications in public health.
P1250 Effective screening for methicillin-resistant Staphylococcus
aureus on the basis of hospital-speciﬁc risk factors
A. Bu¨hling*, R. Tech, K. Mydlak, P. Thorausch, F. Schwab, K. Schenke
(Cottbus, Berlin, Luckenwalde, DE)
Objectives: The aim of this study was to determine the MRSA-
prevalence and the risk factors for MRSA-carriage of patients admitted
to a hospital and therefore to ﬁnd the most effective search policy as an
additional part of anti-MRSA-measures.
Methods: A 9 month MRSA-admission screening was performed in a
230-bed hospital. Risk factors to be colonised with MRSA at admission
were determined using a questionnaire based on recommendations of the
Robert Koch-Institute (RKI), the German institution for disease control
and prevention. In addition to these factors we included the age in the
analysis.
All inpatients provided a nasal swab at admission. Patients who were able
to answer the questionnaire were included. Microbiological identiﬁcation
was performed on a MRSA-selective medium and on Columbia blood
agar. Species diagnostic and susceptibility testing were performed by
VITEK2. Meticillin resistance was conﬁrmed by penicillin-binding
protein 2a latex agglutination test.
To determine independent risk factors statistical analysis was done using
univariable and multivariable logistic regression analysis.
Results: From all 7906 admitted patients 6296 (79.6%) provided nasal
swabs. 5244 patients of them (83.3%) had a fully ﬁlled questionnaire
and were included in the further analysis. 47 MRSA-carrier-cases were
detected (prevalence of 0.9 MRSA/100 admissions). Independent risk
factors were previous MRSA-carriage, need for long-term care, receipt
of any antibiotics during the previous six months and age. We found 761
patients with RKI-risk factors (14.5%) and 2653 patients older than 67
years (50.6%). Only 24 (51%) of all MRSA-colonised patients performed
ofﬁcial RKI-risk factors including 11 (23.4%) patients with previous
carriage. Remarkably, 36 (76.6%) of all MRSA-carriers aged >67 years.
Conclusion: The results have shown that for this particular hospital
age >67 years and previous MRSA-carriage are effective and sensitive
indicators for a MRSA colonisation at admission. These independent
and easy to establish risk factors were included in screening policy.
To ﬁnd a search policy for MRSA-carriage on admission for an
individual hospital it can be recommended to perform a short time
screening of all patients with parallel analysis of risk factors.
P1251 Study of Staphylococcus aureus nasal carriage in diabetic
patients and non-diabetic controls: preliminary results
C. Loupa*, A. Karaitianou-Velonaki, C. Chiotis, G. Kouppari,
D. Voyatzoglou, M. Lelekis (Athens, GR)
Objectives: Staphylococcus aureus nasal carriage is an important
predisposing factor for subsequent infection. Aim of the present study
was to estimate the prevalence of S. aureus nasal carriage in diabetic
patients and to compare it with that of nondiabetic controls. We report
our preliminary results.
Methods: 101 consecutive diabetic persons (36 men, 65 women, age
65,2+11,9 years) of Diabetes Outpatient Clinic and 105 nondiabetic
controls of Internal Medicine Outpatient Clinic (30 men, 75 women,
age 67,9+11,3 years) of the same hospital were enrolled in this study.
People with recent antistaphylococcal treatment were excluded. Cotton-
wool swabs and transportation media were used for nasal cultures. We
used SPSS 11.5 for the statistical analysis.
Results: In 27/101 patients (26.7%), cultures were positive for S. aureus
(3 MRSA/24 MSSA isolates). 2 of these patients had a recent history
of both hospitalization and antibiotic treatment, 4 of antibiotic use only
and 4 of hospitalization only. Out of the 14/27 positive patients in whom
culture could be repeated, 10 proved persistent carriers, while in the rest
4 the second culture was negative (2 of these were treated with antibiotics
in the meantime). Regarding nondiabetic controls, 11/105 (10.5%) were
colonized (4 MRSA/7 MSSA isolates). 3/11 reported antibiotic use and
nobody had a recent history of hospitalization. None of the 11 positive
controls had a second nasal culture performed. A statistically signiﬁcant
difference in nasal carriage was found between patients and controls
(p = 0.003, x2, SPSS 11.5).
Conclusions: According to our preliminary results, prevalence of
S. aureus nasal carriage in diabetic patients was high (26.7%, more
than 1 out of 4 patients), and more than 2fold higher than in nondiabetic
people. It is worthnoting that a signiﬁcant proportion of positive cases
were persistent carriers and that among isolates there were methicillin-
resistant strains (MRSA). If our preliminary results are conﬁrmed in
the long term and due to the clinical signiﬁcance of S. aureus carriage,
diabetic patients might have to be checked for S. aureus nasal carriage
during routine visits and carriers have to be treated.
P1252 Staphylococcus aureus colonisation and recurrent
furunculosis in young Greek adults: the role of CA-MRSA
V. Sakka, P. Nikou*, L. Galani, A. Fragou, I. Karaiskos, T. Panagea,
S. Kanellaki, G. Petrikkos, H. Giamarellou (Athens, GR)
Background: The precise role of nasal carriage of Staphylococcus
aureus in recurrent furunculosis remains unclear.
Objectives: To seek correlations between epidemiological characteris-
tics, S. aureus carriage, and clinical manifestations in patients with
community-acquired furuncles.
Methods: Since 2006, we studied clinical data and bacteriological
samples (cultures from lesions and nasal, axillary and inguinal
carriage) prospectively collected from patients presenting with chronic
furunculosis in an Outpatient Infectious Disease Department.
Results: 100 patients, 15−70 years of age (mean: 34.5±11.6years), 40%
men with a history of “heavy” disease (mean of 1.4 preceding years and
3 episodes per year). Diabetes mellitus or impaired glucose tolerance
was recorded in 13/75 (17.3%) patients. Other classical predisposing
factors e.g. chronic renal disease, immunoglobulin deﬁciency, athletes,
recruits and iv drug abusers were not identiﬁed. 43/83 (51.8%) reported
a roommate with some degree of skin infections and 5/80 (6.2%) an
indoor pet. 81 (81.8%) had active furuncles at the initial visit. Thirty six
patients had no S. aureus carriage at any site, where as 50% had nasal,
20.6% axillary and 41% inguinal carriage. S. aureus was conﬁrmed in
74 patients, either from a clinical sample or from carriage. 75.7% were
methicillin (cefoxitin) resistant, whereas the percentage of resistance
for other antibiotics was: erythromycin 14,9%, clindamycin 12.2%,
rifampicin 1.3% and trimethoprim-sulfamethoxazole 5.4%. No strain was
resistant to quinolones, minocyclin, and mupirocin. All patients were
treated with chlorhexidine gluconate for hair and body bathing for a
month, whereas 66% (mostly the nasal carriers) also received intranasal
mupirocin tid for two weeks. 73% of the patients received an antibiotic
regimen for 2 weeks, consisted of a combination of minocyclin 100mg
bid plus rifampicin 600–300mg (54%), cotrimoxazole 960mg bid plus
rifampicin 600–300mg (9%), clindamycin alone or plus rifampicin
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(16%) or other. Ten patients had to discontinue treatment due to minor
or moderate side effects and one patient due to an anaphylactic reaction.
Conclusions: Recurrent furunculosis is a disease of young healthy adults
with staphylococcal colonization as the only risk factor at least in
Greece where community-acquired (CA)- MRSA is the major pathogen
implicated in >75% patients.
P1253 External quality assessment scheme for MRSA screening
E. Fagan*, S. Seaton, C. Walton (London, UK)
Objectives: To evaluate the results from clinical diagnostic microbiology
laboratories taking part in the United Kingdom National External Quality
Assessment Service (UK NEQAS) for Microbiology MRSA screening
scheme between 2009 and 2011.
Methods: Quality assessment of MRSA screening was performed on
twenty simulated nasal swab specimens. Specimens sent included 13
positive and seven negative for MRSA.
Results: Analysis of the results showed that with the exception of
one specimen (specimen 9281) performance by culture was good
with over 93% of participants reporting correctly on the detection
of MRSA. Specimen 9281 contained a methicillin resistant S. aureus
and a coagulase negative staphylococcus; only 84.6% of participants
reported correctly. The overall false positive rate for the MRSA negative
specimens was 1.4% (20/1463). Whilst the overall false negative rate
for the MRSA positive specimens was 2.5% (72/2907). One specimen
contained a ciproﬂoxacin susceptible community MRSA which 12
laboratories incorrectly reported as negative for MRSA. The most
commonly used culture method is Oxoid Brilliance MRSA chromogenic
agar plates.
Overall performance by molecular methods was good with 92.4%
(789/854) of participants reporting correctly on the detection of MRSA.
The most commonly used molecular method is Cepheid Xpert MRSA.
During the 21 months the scheme has been running, the number of
laboratories reporting molecular screening results has risen from 22 to
67, which was an increase of 200%.
Conclusion: The UK NEQAS for Microbiology MRSA screening
scheme has been operating for 21 months and provides participants
with the opportunity to assess the quality of culture and molecular
screening techniques they use to detect MRSA. The results from
participating laboratories demonstrate a good performance. The scheme
has highlighted problems with identifying ciproﬂoxacin susceptible
community MRSA and also that some molecular techniques give false
positive results when confronted with a mecA knockout gene.
P1254 Estimating the effectiveness of isolation and decolonisation
measures in reducing MRSA transmission in hospital
general wards: a model-based analysis
C. Worby*, J.V. Robotham, D. Jeyaratnam, T. Kypraios, P. O’Neill,
D. De Angelis, G. French, B.S. Cooper (London, Nottingham,
Cambridge, UK; Bangkok, TH)
Objectives: Methods used to control the spread of hospital pathogens
such as methicillin-resistant Staphylococcus aureus (MRSA) include
both non-speciﬁc interventions (e.g. hand hygiene) and targeted
interventions (such as screening combined with patient isolation and/or
decolonisation treatment). Such targeted interventions, while widely
used, are controversial due to the lack of robust evidence of their
effectiveness at reducing transmission. In this study we aimed to estimate
the effectiveness of isolation and decolonisation measures in reducing
transmission of MRSA.
Methods: We used prospectively collected MRSA surveillance data
from over 14,000 admissions across ten hospital general wards at
a London teaching hospital between January 2006 and April 2007.
MRSA carriage was assessed with admission and discharge culture
swabs; known MRSA patients were given decolonisation treatment with
chlorhexidine and mupirocin and were isolated using side rooms where
possible, and patient cohorting and contact precautions otherwise. Data
were analysed in a Bayesian framework using a Markov Chain Monte
Carlo (MCMC) algorithm to infer the unobserved colonisation times
from the screening data. We estimated the overall effect of isolation
and decolonisation measures by comparing transmission from isolated
and unisolated individuals separately, and calculating the relative risk of
acquisition.
Results: We estimated that the combined effect of isolation and
decolonisation reduced transmission by 64%: relative risk of acquisition
0.36 (95%CI: 0.21, 0.63). Unisolated patient days were found to be a
determining factor in transmission with background (e.g. environmental)
transmission minimal. Moreover, we estimated that 54% (95%CI: 46%,
60%) of all colonised patient days were spent without any isolation
precautions, mainly due to undetected carriage.
Conclusions: This is the ﬁrst strong evidence that isolation measures
combined with decolonisation treatment are associated with a reduction
in MRSA transmission in general hospital wards. While these ﬁndings
provide support for active methods of MRSA control, further research
is needed to determine the relative importance of isolation and
decolonisation in preventing transmission, and their cost effectiveness.
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P1255 Surveillance of topical antibacterial usage in primary care
in Wales
M. Heginbothom* (Cardiff, UK)
Objectives: Antimicrobial stewardship programs tend to focus on the
appropriate use of systemic antimicrobials. Little data exists regarding
the extent of topical antibacterial use, which also has the potential to
select resistant organisms. The objective of this study was to determine
the extent of topical antibacterial usage across Wales.
Methods: Topical antibacterial dispensing was obtained from the
Prescribing Services Unit (PSU) of Health Solutions Wales. Primary care
dispensing data comprised prescriptions submitted to PSU by dispensing
contractors for re-imbursement purposes.
Results: In 2009, the total number of antibacterial items (oral, parenteral
or topical) dispensed in Wales was 3,016,112, of which 618,519
(20.5%) were topical preparations. Topical antibacterials accounted for
197.8 dispensed items/1000 registered patients per annum (ppa). Skin
preparations were the most commonly dispensed items accounting for
48% of topical antibacterial dispensing across Wales in 2009. Fusidic
acid (FUS) was the most commonly dispensed topical skin preparation,
with an average dispensing of 54.3 items/1000 ppa (See Figure 1).
Eye preparations were the second most commonly dispensed items,
accounting for 31% of topical dispensing across Wales. Chloramphenicol
(CHL) and fusidic acid were the two most commonly dispensed eye
preparation, with an average of 43.5 items/1000 ppa and 15.8 items/1000
ppa respectively.
Ear preparations accounted for 15.1% of topical antibacterial dispensing
across Wales. Aminoglycosides (AMI) were the most commonly
dispensed topical ear preparations, used as both a single antimicrobial
agent and in combination with other antimicrobials: Average dispensing
of 29.8 items/1000 ppa across Wales.
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Conclusions: Topical antibacterials comprised 20.5% of all dispensed
antibacterial prescriptions in Wales, and for some agents such as fusidic
acid and gentamicin, topical agents account for an important proportion
of total use. The role and importance of topical antibacterial agents in
the development and spread of resistance remains unclear, but, given
the volume of use, better data is needed on the effects of this use on
resistance as well as more robust evidence about the effect of topical
antibacterial agents on recovery, which patients are most likely to beneﬁt,
and of the clinical effectiveness of oral versus topical agents.
P1256 More awareness of antibiotic risks and beneﬁts are needed
amongst Polish general public
B. Mazinska*, W. Hryniewicz (Warsaw, PL)
Objectives: Widespread and inappropriate antibiotic use leading to an-
tibiotic resistance directs national and international antibiotic resistance
control strategies to educate not only of health-care professionals but
also of the general public in order to promote prudent antibiotic use.
The aim of the study was to assess the level of knowledge of the Polish
general public regarding antibiotics and whether actions undertaken
during educational campaigns resulted in an increased knowledge of
this subject.
Methods: The survey was conducted in Poland between 2009 and 2010,
in four waves before and after the European Antibiotic Awareness Day
campaign. The survey was based on 14 self-designed questions.
The questionnaire was divided into four sections: previous antibiotic
exposure, patient’s expectation of antibiotic prescription, sources of
information, effectiveness of campaign on prudent antibiotic use.
The survey was carried out by Millward Brown SMG/KRC on
a representative sample of 1000 people, using Computer Assisted
Telephone Interviews (CATI). Statistical analysis was performed by c2-
test.
Results: Overall, the percentage of people using antibiotics was high.
In the fourth wave, 41% of adults had used antibiotics in the last
12 months and 63% in the last 24 months. The majority (91%) had
used antibiotics prescribed by physicians, mostly general practitioners.
Respondents considered that antibiotics were warranted for common
colds (28%), sore throats (27%), the ﬂu (14%) and coughs (18%). The
results of the fourth wave show that the majority of interviewees expected
antibiotics to be prescribed for pneumonia (85%), bronchitis (77%) or
urinary tract infections (59%). More than half of the respondents (63%)
believed that antibiotics kill viruses. The percentage of people who had
encountered any information on the prudent use of antibiotics within
the last year was signiﬁcantly higher in comparison to the third wave
of the survey. The most reliable sources of information on antibiotics
were physicians (92%), hospital staff (77%) and pharmacists (60%).
Almost half (47%) of the respondents who had encountered information/
initiatives within the last year declared a change in their attitude towards
antibiotic use.
Conclusions: Inappropriate antibiotic use is highly prevalent in Poland.
New positive trends sustained by public campaigns have emerged.
Additional didactic and systematic education regarding appropriate
antibiotic use is needed.
P1257 The impact of antibiotic education sessions in primary care
in the Republic of Ireland − a case study
M. Murphy*, S. Byrne, C.B. Bradley (Cork, IE)
Objectives: In 2008, antibiotic use in primary care in the Republic of
Ireland (ROI) declined for the ﬁrst time. The reduction coincided with
European led educational campaigns on prudent antibiotic use for the
public and general practitioners (GPs). The observed rate of antibiotic
use in primary care in Ireland for 2009 was 8.5% lower than the expected
rate as projected by the Health Protection Surveillance Centre in ROI.
Interventions in primary care such as antibiotic workshops have shown to
reduce and rationalise antibiotic prescribing. The objectives of this study
were to observe if antibiotic consumption was reduced where educational
meetings took place in ROI.
Methods: All GP continuing medical education (CME) groups in
ROI were invited to participate. GPs recorded data on all antibiotics
prescribed by them in 100 consecutive patients’ consultations and the
conditions being treated. Educational sessions through CME groups
took place to distribute prescribing feedback and discuss the ﬁndings.
Two Local Health Ofﬁces (LHOs) in nearby locations (A and B) were
chosen to compare the impact of the study. LHO A did not have an
antibiotic CME session for GPs. LHO B had the CME session in
January 2009. Data on systemic antibiotic items were obtained from
the General Medical Services (GMS) database before and after the
antibiotic CME sessions took place. The GMS database contains data
from patients receiving free medical services. Antibiotic prescribing
rates were calculated using the total number of patients who received
a prescription in the time period.
Results: There were 17 GP tutors (43.20%) who ran 65 meetings
nationally. In LHO B, CME sessions on antibiotic use took place in
January 2009. In December 2008, the rate of antibiotic prescriptions was
244 per 1000 patients. There was an immediate reduction in antibiotic
use seen in February 2009 and March 2009 (176, 178/1,000 patients).
The reduction was also sustained 12 months later (December 2009:
162 prescriptions/1,000 patients). There was a smaller reduction seen in
antibiotic use in LHO A (December 2008: 259/1,000 patients, December
2009: 224/1,000 patients).
Conclusion: These results demonstrate that the CME sessions on prudent
antibiotic use played a role in the reductions seen in antibiotic use in ROI
since 2008. This further supports the beneﬁt of educational initiatives
for both the public and health professionals.
P1258 A national study of antimicrobial stewardship structures
and antimicrobial use in Irish long-term care facilities
M.P. Cotter*, S. Donlon, F. Roche, H. Byrne, F. Fitzpatrick (Dublin,
Cork, IE)
Objectives: Essential components of the prevention and control of
healthcare associated infection (HCAI) and antimicrobial resistance
(AMR) in long term care facilities (LTCF) are staff education, the
availability of specialist antimicrobial stewardship advice, and AMR
surveillance. Presently, there is limited information available on this in
Irish LTCFs.
Methods: A point prevalence study was conducted in June 2010 as part
of a European study of HCAI in European LTCFs (HALT). Sixty-nine
Irish LTCFs completed a questionnaire detailing information on LTCF
antibiotics stewardship practices and protocols. Data was collected by
trained local senior clinical staff (nursing or medical) and/or infection
prevention and control nurses. Information was collected on; HCAI risk
factors, signs and symptoms of infection and antimicrobial use from
eligible residents. The aim of this study was to evaluate medical care,
infection control and antibiotic stewardship practices and protocols in
Irish LTCFs.
Results: A total of 4,170 residents in 69 LTCF were surveyed;
1664 (40%) males and 2506 (60%) females. Antimicrobial stewardship
activities included: availability of local antimicrobial guidelines (28%),
antimicrobial consumption surveillance (16%), AMR surveillance (12%)
and prescribers education (7%). The most common HCAIs were urinary
tract (n = 62, 39.7%), respiratory (n = 44, 28.2%) and skin infections
(n = 31, 19.9%). Of the 426 (10.2%) residents on antibiotics, 25
(6%) were prescribed two or more antibiotic types. Antibiotics were
prescribed for treatment (57.8%, n = 262) and prophylaxis (40.2%,
n = 182) of infection. The most common indications for therapy included
respiratory tract (35.1%), urinary tract (32.1%) and skin infections
(21.8%). Prophylactic antibiotics were predominantly prescribed for
prevention of urinary tract infection (35.8% of total prescriptions) with
trimethoprim most frequently prescribed. Seventeen (10.7%) residents
on UTI prophylaxis had a urinary catheter in situ.
Conclusion: This study provides an important baseline on antimicrobial
stewardship activities and antimicrobial consumption in Irish LTCFs
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to inform future HCAI/AMR preventative strategies. The frequency
of prophylactic antimicrobial prescribing underlines the importance of
antimicrobial stewardship in this setting and highlights the need for
national antimicrobial stewardship guidelines speciﬁcally for LTCF.
P1259 Variation in outpatient antibiotic prescribing
J. Zweigner*, F. Schwab, E. Meyer, S. Ebert, P. Gastmeier (Berlin, DE)
Objectives: The overuse and inappropriate prescription of antibiotics
drove bacterial resistance. In Germany ~85% of all antibiotics are
prescribed in ambulatory care but studies about antibiotic prescribing
practice in this setting are rare. Thus, the aim of this study was to
analyse in detail antibiotic prescribing in the outpatient setting.
Methods: We analysed data from the largest regional public-sector
health insurer AOK in the German federal state Brandenburg in respect
to diagnosis and antibiotic prescription in ambulatory care in the 1st
quarter 2009. The AOK provides statutory health insurance to more than
1 million out of ~3 million inhabitants of Brandenburg. We included
data from physicians of all specialisations who treated at least 50 AOK
outpatients per quarter with one or more diagnosis and/or prescription.
Results: A total of 1,983 physicians prescribed 74,529 times antibiotics
for systemic therapy to 685,379 patients. In median, every 10th
patients received an antibiotic. The four top prescribed antibiotics
were ciproﬂoxacin (n = 8283) followed by roxithromycin (n = 6471),
azithromycin (n = 6118) and cefuroxime (n = 5415). The leading infec-
tions made acute upper respiratory tract infections and acute bronchitis
(n = 34,175) followed by urinary tract infections (n = 7,909), acute
tonsillitis (n = 5,453) and viral infections (n = 5,145). Paediatricians and
general practitioner (GP) saw the most patients with infection followed
by urologists and ear, nose and throat (ENT)-specialists. Paediatricians
prescribed in median only 0.4 time an antibiotic per encoded infection.
GPs prescribed an antibiotic 1.1 times, urologists 1.4 times and ENT-
specialists even 3.1 times per infection. The range of the number
of prescription (10th-90th percentile) varied substantially by medical
specialist from 0.7 within the paediatricians to 1.6 within the GPs.
Variation was 8.4 within the ENT doctors and peaked at 8.5 within
the urologists.
Conclusion: Upper respiratory tract and urinary infections were the most
common infections in the outpatient setting and chinolones, macrolides
and cephalosporines the most frequently prescribed antibiotics. Paedia-
tricians were more conservative to prescribe antibiotics in relation to the
numbers and kind of infections. The amount of antibiotics prescribed by
urologists and ENT-specialists varied largely (up to 8.5 times). Analysis
and feedback of outpatient use data are the basis for improving outpatient
antibiotic prescribing.
P1260 How to improve parental knowledge and awareness
about antibiotics? A unique Swedish Strama educational
programme in child health centres
B. Jo¨nsson*, L. Ernstson, M. Erntell (Halmstad, SE)
Objective: The use of antibiotics in Sweden increased during 2004–
2007, particularly in children age 0−4. The overuse of antibiotics
and increasing bacterial resistance is of major concern. The Swedish
governmental initiative on patient safety includes appropriate antibiotic
use. This highlights the needs for educational outreach. We have
developed and implemented a parental educational programme. The aim
was to educate parents about common childhood infections, appropriate
use of antibiotics and resistance. The target audience is parents of young
children in parental groups at Swedish Child Health Centres (CHC). All
children age 0−6 are enrolled in the CHC, which enables a continuing
dialogue. Parental education is an established part of the Swedish CHC
programme.
Method: The educational programme “Children, infections and antibi-
otics” is based on national consensus and guidelines. It consists of a
PowerPoint presentation of 20 slides and a pamphlet, teaching parents
about common childhood infections, antibiotics and bacterial resistance.
Included are interactive case studies. In addition, there is a manual with
facts and pedagogical advices to assist the CHC-nurse as the group
leader. It was introduced to 51 CHC in the county of Halland in 2009.
Each CHC received an USB. The material is also available on the website
of Strama Halland: www.regionhalland.se/strama. The programme was
evaluated to assess the implementation and usefulness by a survey to the
CHC in 2010.
Result: A total of 87% of CHC in Halland had used the programme. The
CHC-nurses found the programme accurate and easy to use, a satisfaction
rate of 99%. Nurses reported that parents gained important information,
awareness and conﬁdence in handling common childhood infections.
They also experienced an interactive and dynamic discussion within the
parental group.
Conclusion: A communication strategy on antibiotic resistance requires
a multidimensional approach. “Children, infections and antibiotics”
targets both parents and health care providers. We have shown it is
a relevant, pedagogical and interactive tool to increase knowledge and
awareness about appropriate antibiotic use. The programme has been
distributed and implemented by CHC in other Swedish counties. The
material is easily updated and can be used in various ways on an
international level.
P1261 Improved compliance to antibiotic guidelines in long-term
care facilities in Region Va¨stra Go¨taland, Sweden
P. Ulleryd*, L. Karlsson, A. Arvidsson, R. Eklund, M. Eriksson,
L. Osbeck, M. Schewenius, T. Wahlberg, S. O¨berg (Region Va¨stra
Go¨taland, Bora˚s, Sko¨vde, Uddevalla, Gothenburg, SE)
Objectives: To evaluate the compliance to regional Strama (Collabora-
tion against antibiotic resistance) guidelines for antibiotic treatment of
elderly in nursing homes in Region Va¨stra Go¨taland, Sweden.
Methods: Point-prevalence studies of all elderly in long-term munici-
pality care in Region Va¨stra Go¨taland, Sweden were performed twice,
the 17 of March 2004 and 2009. The same protocol and methodology
was used. In between, educational programs were launched, focussing
on urinary tract infections.
Results: The study involved 17 477 patients in 2004 and 16 089 in 2009,
which comprise 97% of all long-term municipality care of elderly in the
region. The median age was 87 years and 67% were women. Patients in
short-term care constituted 10%.
A total of 5.3% had antibiotic treatment in 2004 compared to 4.2% in
2009, of which 0.4% was locally administered. Antibiotic use in short-
term municipality care was more common and found in 8%. The decrease
in antibiotic treatment of urinary tract infections was most accentuated,
from 1.9% in 2004 to 1.2% in 2009. Skin and soft tissue infections
(40%) were the major indication for antibiotics followed by urinary tract
infections (29%) and respiratory infections (15%).
The adherence to Strama guidelines for antibiotic treatment was better in
2009 with less ﬂuoroquinolone, tetracycline and cephalosporine use and
increased usage of penicillin and nitrofurantoin, corresponding in 2009
to 8%, 6% and 3% versus 58% and 6% of the total antibiotic treatment,
respectively.
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Hygiene risk factors such as having a wound or an indwelling urinary
catheter were found in 48% and 15% of the patients on antibiotics, in
comparison with 7% and 8% of the patients without antibiotic treatment.
Most of the wounds were located on the lower limb.
Conclusion: We found a decrease in total antibiotic use in long-
term municipality care as well as an improved compliance to regional
antibiotic guidelines in Region Va¨stra Go¨taland, particularly regarding
urinary tract infections. They who were admitted in short-term care and
they with hygiene risk factors such as wounds and indwelling urinary
catheters were more often committed to antibiotic treatment.
Skin and soft tissue infections are now the major indication for antibiotic
treatment, and the predominance of patients with wounds being treated
signal a too liberal prescribing policy for these patients. Educational
packages concerning wound care are launched.
P1262 European Surveillance of Antimicrobial Consumption
(ESAC): disease-speciﬁc quality indicators for outpatient
antibiotic prescribing
N. Adriaenssens, S. Coenen*, S. Tonkin-Crine, T. Verheij, P. Little,
H. Goossens and the ESAC Ambulatory Care subproject
Objectives: To develop a set of evidence-based disease-speciﬁc
outpatient antibiotic prescribing quality indicators in Europe.
Methods: Within the ESAC Ambulatory Care Subproject 2 meetings
were convened in 2008 and 2009 to produce a list of proposed evidence-
based disease-speciﬁc outpatient antibiotic prescribing quality indicators,
building on previous and similar development of drug-speciﬁc quality
indicators, and in close collaboration with CHAMP (www.champ-
antibiotics.org) and HAPPY AUDIT (www.happyaudit.org). 62 experts
from 33 countries were asked to complete 2 scoring rounds of the
proposed indicators on 7 dimensions, i.e. their relevance to 1 reducing
antimicrobial resistance, 2 patient health beneﬁt, 3 cost-effectiveness, 4
policy makers, 5 individual prescribers, 6 their evidence base, and 7 their
range of acceptable use, using a scale ranging from 1 (= completely
disagree) to 9 (= completely agree). According to the UCLA-RAND
appropriateness method, proposed indicators were judged relevant if the
median score was not within the 1−6 interval and if there was consensus,
i.e. the number of scores within the 1−3 interval was less than one third
of the panel.
Results: For each of the 6 mean indications for antibiotic prescribing
(acute otitis media, acute upper respiratory infection, acute/chronic
sinusitis, acute tonsillitis, acute bronchitis/bronchiolitis, cystitis/other
urinary infection) and for pneumonia (labelled by ICPC codes H71,
R74, R75, R76, R78, U71 and R81, respectively), 3 quality indicators
were proposed, i.e. a. the percentage of patients with age and/or gender
limitation prescribed an antibiotic; b. the percentage of patients with
age and/or gender limitation prescribed an antibiotic, receiving the
recommended antibiotic; c. the percentage of patients with age and/or
gender limitation prescribed an antibiotic, receiving quinolones (see
Table). This set was scored by 40 experts from 25 countries. Already
after the ﬁrst scoring round, all indicators were rated as relevant on all
7 dimensions, except 3a. was scored 6 on cost-effectiveness.
Conclusion: All 21 (7x3) proposed disease-speciﬁc evidence based
quality indicators for outpatient antibiotic prescribing have face validity
and are potentially applicable. In line with the main objectives of
antimicrobial use surveillance at the European level, this set could be
used to better describe antibiotic use and assess the quality of antibiotic
prescribing patterns in ambulatory care.
P1263 Antibiotic consumption trends in the adult population in
Emilia-Romagna, Italy, 2003–2009
A. Pan*, R. Buttazzi, M. Marchi, C. Gagliotti, D. Resi, M.L. Moro
for the Antibiotic Use and Resistance Surveillance Study Group of
Regione Emilia-Romagna
Objectives: Antibiotic resistance is closely related to antibiotic use and
Italy is a country with both high levels of antibiotic use and antimicrobial
resistance. We analysed the trend in antibiotic use in the community
among adults (15 years), in the period 2003–2009, in Emilia-Romagna,
Italy, a region with over 4,000,000 inhabitants.
Methods: Data regarding antibiotic use were obtained from the regional
public health system data-bases. Antibiotic consumption was evaluated
using a) deﬁned daily doses (DDD) based on WHO 2010 deﬁnitions, b)
prescription, the number of prescribed antibiotic boxes of a certain drug
reported in the same recipe; 2) treatment: prescriptions t repeated at an
interval of less than 10 days and treaments rates.
Results: Between 2003 and 2009 the antibiotic consumption increased
from 15.4 to 18.7 DDD/1000 inhabitants (+21.4%, p< 0.0001).
Prescriptions and treatments in 2009 were 798 and 696/1000 person-
years, respectively, increasing by 13.8% and 13.2% as compared to
2003. The highest increase in antibiotic use was observed among persons
aged 20−59 (+24.7%). The proportion of subjects receiving at least one
antibiotic treatment was 36.4% in 2003 and 39.7% in 2009, while those
receiving 3 antibiotic treatments were 3.5% and 4.2% respectively.
The analysis as per antibiotic class, showed increases for penicillin +
b-lactamase inhibitor (PBLI) (from 3.6 to 6.3 DDD/1000 person-days),
quinolones (from 2.6 to 3.0) and macrolides (from 3.1 to 3.7), while
cephalosporin use was stable (1.4). Signiﬁcant differences were observed
among the 11 health agencies of the region, both as total antibiotic
consumption, that varied between 15.3 and 18.1 DDD/1000 patient days
in 2003 and between 18.3 and 21 in 2008, (+6.0 to 20.0%), and type of
class prescribed, with PBLI use in 2009 varying in the different local
agencies between 1.95 to 3.28 DDD/1000 patient days, increased 56%
to 106%, as compared with 2003.
Conclusion: A steady increase in antibiotic use in the adult population
has been observed in the Emilia-Romagna between 2003 and 2009, with
a strong increase in the use of PBLI. Signiﬁcant differences both in
terms of total antibiotic consumption and of type of antibiotic class
used. Public health interventions are mandatory to preserve antibiotics
for the future generations.
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P1264 Impact of the H1N1 pandemic on antibiotic consumption
in the adult population in Emilia-Romagna, Italy
A. Pan*, R. Buttazzi, M. Marchi, C. Gagliotti, D. Resi, M.L. Moro
on behalf of the Antibiotic Use and Resistance Surveillance Study
Group of Regione Emilia-Romagna
Objectives: Antibiotic use in Italy increases signiﬁcantly over the winter
period, and the inﬂuenza epidemic is a major cause of an increase
in the inappropriate use of antibiotics. The H1N1 pandemic has been
an relatively mild infection in the elderly, while it has been more
aggressive in the younger class groups. We analysed the antibiotic use
in the community among adults (15 years), in the period 2007–2009,
in Emilia-Romagna, Italy, aiming to identify differences in antibiotic
prescription during the H1N1 pandemic period.
Methods: Data regarding antibiotic use were obtained from the regional
public health system data-bases. Antibiotic consumption was evaluated
using prescriptions, i.e. the number of prescribed antibiotic boxes of a
certain drug reported in the same recipe. Prescriptions were calculate
as per 1000 inhabitant-years and 1000 inhabitant-months. Prescriptions
were calculated for the different age groups among the population aged
15 years: 15−19 years, 20−59, 60−79, and 80.
Results: Yearly prescription rate was 778 prescritpions/1000 inhabitant-
years in 2007, 795 in 2008 and 797 in 2009. The analysis on a monthly
base showed that antibiotic prescriptions peaked in January, with rates
ranging between 71 prescriptions/1000 inhabitant-months in the younger
age groups and 130 in the elderly. The lowest prescription rates were
observed in August, ranging between 36 and 74/1000 inhabitant-months.
Antibiotic prescription rate increased by 41% in the group of patients
aged 15−19 years, in October 2009 and by 90% in November 2009,
during the peak of H1N1 pandemic, as compared with the same months
during 2007 and 2008 (see ﬁgure). A milder increase (37%) was also
observed in the 20−59 years age group between November 2008 and
2009, only. Antibiotic use returned to baseline levels in December 2009.
No other difference in antibiotic consumption was observed for any
month in any other age group.
Conclusion: The H1N1 pandemic did not cause a signiﬁcant increase
in the overall antibiotic consumption on a yearly base in the overall
population. Nonetheless, a striking increase in the group aged 15−19
years and, to a lesser extent 20−59, was observed. It is possible to assume
that a discrete proportion of antibiotics prescribed during the H1N1
peak were used inappropriately in patients with ﬂue-like symptoms.
Campaigns aiming to a better deﬁnition of antibiotic indications,
particularly during the cold season, are needed.
P1265 Identifying determinants of antibiotic use in Europe
P. Beutels*, C. Marais, N. Hens, A. Blommaert, J. Cortinas Abrahantes,
S. Coenen, A. Muller, H. Goossens (Antwerp, Hasselt, BE)
Objectives: To identify determinants contributing the most to observed
differences in outpatient antibiotic use between European countries and
over time.
Methods: Data on outpatient antibiotic use (DDDs and packages)
were collected for 35 European countries from 1999 to 2007 through
the European Surveillance of Antimicrobial Consumption (ESAC)
network. For these country-years, through databases (eg, EUROSTAT)
and surveys, 180 variables were collected in the following categories:
Agriculture (7 variables), Culture (26), Demography (21), Disease
burden (35) Education (6), health care (73) and socioeconomics (12).
Multiple imputation generalized estimation equations with a backward
model selection procedure were applied to select the best ﬁtting model
for the data using outpatient antibiotic use as dependent variable.
Results: The following variables were found to be signiﬁcant in the
overall model: (1) % attaining upper secondary education, (2) population
density, (3) death rate due to chronic liver disease, (4) existence of
restrictions on pharmaceutical companies to pay physicians for attending
conferences, (5) death rate due to respiratory disease, (6) existence of
ﬁnancial incentives for patients to register with one GP, (7) households’
out of pocket payment on health as a % of total health expenditure,
(8) density of GP practices, (9) Corruption Index score, (10) number of
antibiotics available, (11) male life expectancy, (12) extent to which most
people are trusted, (13) death rate due to ischaemic heart disease, (14)
extent to which people respect authority, (15) private health expenditure
as a % of health expenditure. In analyses focused on more developed
countries (human development index >9.3), variables (2), (4), (6), (7),
(12), (15) above were still signiﬁcant, whereas the others above were
not. Instead, the following variables were also signiﬁcant: whether or
not ofﬁcial guidelines for antibiotic prescribing are available for GPs
and pulmonologists, death rate due to AIDS and production of turkey.
Note that some signiﬁcant determinants may act as a surrogate for
combinations of others. In different subgroups of antibiotics similar
results were found.
Conclusion: Our analysis reveals that there are diverse signiﬁcant
determinants and that these vary according to the scope of analysis.
At each level of analysis, some signiﬁcant determinants are inherent
to culture and populations, but others could be changed through
governance.
P1266 Antibiotic prescribing for adults with acute cough/LRTI:
congruence with guidelines
C. Butler*, J. Wood, K. Hood, M.J. Kelly, T. Verheij, P. Little, A. Torres,
F. Blasi, T. Schaberg, H. Goossens, J. Nuttall, S. Coenen (Cardiff, UK;
Utrecht, NL; Southampton, UK; Barcelona, ES; Milan, IT; Rotenburg,
DE; Antwerp, BE)
Objective: European guidelines for treating acute cough/lower res-
piratory tract infection (LRTI) aim to reduce non-evidence based
variation in prescribing, and better target and increase the use of
ﬁrst line antibiotics. However, application in primary care is unknown.
We explored congruence of both antibiotic prescribing and antibiotic
choice with European Respiratory Society-European Society Clinical
Microbiology and Infectious Diseases (ERS-ESCMID) guidelines for
managing LRTI.
Methods: Analysis of prospective observational data from patients
presenting to primary care with acute cough/LRTI. Clinicians recorded
symptoms on presentation, and their examination and management.
Patients were followed up with self-complete diaries.
Results: 1776 (52.7%) patients were prescribed antibiotics. Given
patients’ clinical presentation, clinicians could have justiﬁed an antibiotic
prescription for 1915 (71.2%) patients according to the ERS-ESCMID
guideline. 761 (42.8%) of those who were prescribed antibiotics received
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a ﬁrst choice antibiotic (i.e. tetracycline or amoxicillin). Ciproﬂoxacin
was prescribed for 37 (2.1%) and cephalosporins for 117 (6.6%).
Conclusion: A lack of speciﬁcity in deﬁnitions in the ERS-ESCMID
guidelines could have enabled clinicians to justify a higher rate of
antibiotic prescription. More studies are needed to produce speciﬁc
clinical deﬁnitions and indications for treatment. First choice antibiotics
were prescribed to the minority of patients who received an antibiotic
prescription.
P1267 Severity assessment for lower respiratory tract infections:
potential use and validity of CRB-65 in primary care
N.A. Francis*, J. Cals, C. Butler, K. Hood, T. Verheij, P. Little,
H. Goossens, S. Coenen on behalf of the GRACE Project Group
Objectives: The CRB-65 (Confusion, Respiratory rate, Blood pressure,
and age 65 years) is a useful rule for predicting pneumonia outcome
in hospitals, and has been recommended for use in the community.
We aim explore potential use in primary care by describing the extent to
which components of the CRB-65 rule are routinely assessed in adults
presenting with lower respiratory tract infection (LRTI), and to assess
the validity of CRB-65 for predicting poor prognosis in these patients in
this prospective observational cohort in general practices in 14 research
networks in 13 European countries.
Methods: Clinicians recorded antibiotic treatment and clinical features
for 3,402 adults presenting with LRTI. Patients recorded daily symptoms
for up to 28 days. Multi-level regression models determined the
association between an elevated CRB-65 score and prolonged moderately
severe symptoms, hospitalisation, and time to recovery, controlling for
antibiotic prescribing. Sensitivity analyses used zero imputation.
Results: Respiratory rate and blood pressure were recorded in 22.7%
and 31.9% of patients respectively. 2,690 patients completed symptom
diaries. A CRB-65 could be calculated for 334 (12.4%) of these. A
score of one or more was not signiﬁcantly associated with prolonged
moderately severe symptoms (OR 0.42, 95%CI 0.04 to 4.19) or
hospitalisations (OR 3.12, 95%CI 0.16 to 60.24), but was associated
with prolonged time to self-reported recovery (HR 0.75, 95%CI 0.64 to
0.88).
Conclusions: Respiratory rate and blood pressure are infrequently
measured in adults with LRTI in primary care, suggesting that clinical
practice would have to change if this score were to be used routinely.
CRB-65 score may be useful in predicting time to recovery but not
prolonged moderately severe symptoms. Larger studies are required to
determine the role of CRB-65 in predicting mortality and/or risk of
hospitalisation in this setting.
P1268 Antimicrobial prescribing for urinary tract infections in
European nursing homes
K. Latour*, E. Broex, A. Muller, N. Drapier, V. Vankerckhoven,
R. Stroobants, H. Goossens, B. Jans on behalf of the European
Surveillance of Antimicrobial Consumption (ESAC) Nursing Home
subproject group
Objectives: To explore antimicrobial (AM) prescribing for urinary tract
infections (UTI) in European nursing homes (NH).
Methods: In November 2009 the European Surveillance of Antimicro-
bial Consumption NH subproject organised a second point prevalence
survey (PPS) in order to explore AM prescribing and its indications
by type of treatment and site of infection. A resident questionnaire
was completed for each eligible resident receiving an AM on the PPS
day. All oral, rectal, intramuscular and intravenous treatments with
antibacterials and antimycotics for systemic use and antituberculosis
drugs were included.
Results: Across 21 European countries (including 2 UK administrations)
266 NHs participated. Out of 1435 residents receiving AMs, 702
residents received one or more AM for an indication related to
the urinary tract (81% female; median age=85 year). In total 714
molecules were registered (crude mean prevalence (CMP) of AM use
for UTIs=2.4%; range by country: 0–10.0%) of which 48% served
as uroprophylaxis (CMP=1.5%; range by country: 0−5.0%). Empirical
treatments counted for 32% of all UTI therapies (CMP=0.9%; range
by country: 0−5.3%) and documented treatments for 20% (CMP=0.5%;
range by country: 0−2.0%).
The most frequently prescribed molecules for uroprophylaxis (n = 343)
were nitrofurantoin (29.7%), trimethoprim (19.8%) and nifurtoinol
(16.0%). For empirical treatment (n = 229) of UTI methenamine (14.4%),
ciproﬂoxacin (13.5%) and nitrofurantoin (12.7%) were most commonly
used, while for documented treatment (n = 142) the main molecules were
nitrofurantoin (24.7%), ciproﬂoxacin (16.9%), amoxicillin & enzyme
inhibitor (7.8%) and pivmecillinam (7.8%).
Isolated microorganisms (MO; optional question) were reported in 58.2%
of the cases where a culture sample was taken prior to AM therapy
(n = 304). In total 195 MO were reported. Escherichia coli (n = 98 of
which 6 resistant (R) to 3rd generation cefalosporines), Proteus mirabilis
(n = 13; 1 R to 3rd generation cefalosporines), Pseudomonas aeruginosa
(n = 11; 1 R to carbapenem) and Klebsiella pneumoniae (n = 10; 1 R to
3rd generation cefalosporines) were most frequently documented.
Conclusion: The prevalence of uroprophylaxis is high in European NHs.
Further in-depth research is needed as AM therapy for asymptomatic
bacteriuria has not been shown to be of beneﬁt in elderly living in NHs
and can even be harmful, for instance in light of the development of
AM resistance.
P1269 Repeated point-prevalence surveys on antimicrobial
prescriptions in Finnish nursing homes, 2009−10
M.-L. Rummukainen*, O. Lyytika¨inen, T. Ka¨rki, M. Kanerva,
M. Haapasaari, J. Ollgren, B. Jans, A. Muller, H. Goossens on behalf
of the European Surveillance of Antimicrobial Consumption (ESAC)
Nursing Home Subproject Group
Objectives: Finnish Nursing homes (NH) participated in 3 European
Surveillance of Antimicrobial Consumption (ESAC) Point Prevalence
Surveys (PPS) in April and November 2009 and May 2010 which were
conducted in order to assess the antimicrobial (AB) consumption in
European NHs. We analyzed Finnish ESAC PPS data and compared the
results with those previously published by the ESAC project group.
Methods: All residents present in NH for 24 hours and receiving
systemic ABs on the day of the survey were included. Data on ABs and
their indications were collected from residents’ charts: prophylaxis or
treatment and the type of infection.
Results: In 2009 8 NHs and in 2010 9 NHs participated in the survey.
In total, there were 5791 eligible residents (range by survey, 1706–
2320); 737 (12.7%; range, 9.7–17.2%) of them received at least one AB.
The most common indication was prophylaxis (487/737, 66.0%; range
56.8–73.4%), mainly for urinary tract infection (UTI) (460/737, 62.4%).
Of the residents, 250 (4.3%, range, 3.5−5.2%) were on AB treatment.
UTI (119/250; 47.6%) was the most common indication for treatment.
Methenamine (306/737, 41.5%) was most commonly used AB, followed
by trimethoprim (14.0%) and pivmecilinam (13.2%). The proportion of
residents on methenamine prophylaxis decreased, from 8.3% in April
2009 to 4.0−4.1% in November 2009 and May 2010.
Conclusion: AB consumption in Finnish NHs was high. Most ABs were
used for UTI prophylaxis. Especially the use of methenamine was very
common, even though it reduced by half during the study period. If
methenamine consumption were excluded, the Finnish AB prevalence
would be in line with the ESAC results from spring 2009 (median 5.4%).
Differences in AB consumption between countries may also be related to
differences in NH patient population and patients’ underlying conditions.
Measuring and inﬂuencing community antibiotic use S347
P1270 Antimicrobial consumption and stewardship in nursing
homes in European regions
B. Jans*, K. Latour, E. Broex, A. Muller, N. Drapier, V. Vankerckhoven,
R. Stroobants, H. Goossens on behalf of the European Surveillance
of Antimicrobial Consumption (ESAC) Nursing Home subproject group
Methods: In April 2009 the ESAC point prevalence survey (PPS) on
antimicrobial (AM) use in European nursing homes (NH) was held.
Institutional determinants for AM use and curent AM stewardship
resources were collected through a NH questionnaire. For each resident
with an AM on the PPS day, a questionnaire was completed for
measuring AM use in the NH.
Results: A total of 304 NHs from 20 EU countries participated:
15 in Eastern Europe (E-EU), 86 in Northern EU (N-EU), 43 in
Southern EU (S-EU) and 157 in Western EU (W-EU). In all participating
settings, 5.4% (median) of the residents used an AM on the PPS day
(range by NH: 0−30%). The prevalence of AM use was signiﬁcantly
higher in N-EU NHs (10.4%, range: 0–28.3%) compared to S-EU
(4%, range: 0−30%, p< 0.001), E-EU (5%, range: 0–20.7%, p = 0.002)
and W-EU (4.9%, range: 0−20%, p< 0.001). This variation could not
be explained by differences in care load (incontinence, disorientation,
impaired mobility) nor by the prevalence of wounds in the total NH
populations. In N-EU NHs, urinary catheters were more frequently used
(5.3%) compared to NHs from the other EU regions (2.5%, p = 0.003).
Medical care was only provided by the general practitioner (GP) in 66.2%
of all EU NHs (N-EU: 60.3%, other regions: 68.5%). In 87.2% of all
N-EU NHs only working with GPs, no medical coordinator was present
while in the other regions medical coordination was absent in only 10.5%
of the NHs.
In N-EU NHs, compared to NHs from other regions, some AM
stewardship resources were signiﬁcantly less available such as written
guidelines for prudent AM use (N-EU: 24.6% versus other regions:
59.2%, p< 0.001), a therapeutic formulary (4.3% versus 60.2%,
p< 0.001), annual data on AM consumption (8.7% versus 26.2%,
p = 0.003), a restrictive list of AM to be prescribed (6.% versus 20%,
p = 0.004) and the use of a motivation form for prescription outside
the formulary (0% versus 9.9%, p = 0.007). N-EU NHs were also
more encouraged to take microbiological samples for guidance of AM
prescriptions (92.8% versus 53.4%, p< 0.001). In general, the prevalence
of AM use was signiﬁcantly higher (6.9%) in NHs promoting sampling
prior to prescribing, compared to those who didn’t (4.6%, p = 0.0001).
Conclusions: In EU NHs a lack of medical coordination might
contribute to a more important device use and less AM stewardship.
Promoting microbiological sampling could produce adverse effects when
positive cultures are treated without considering the clinical status of the
residents.
P1271 European Surveillance of Antimicrobial Consumption
(ESAC): outpatient antibiotic use in children and teenagers
in Europe
A. Versporten*, S. Coenen, N. Adriaenssens, H. Goossens on behalf
of the ESAC Ambulatory Care Project Group
Objectives: To provide a detailed description of outpatient systemic
antibiotic use among children and teenagers in Europe, and to assess
differences between two outcome measures in the context of the ﬁrst
European Antibiotic Awareness Day (EAAD) focusing on this target
group.
Methods: Since 2004, the ESAC Ambulatory Care subproject collects
outpatient antibiotic consumption data by age using the Anatomical
Therapeutic Chemical (ATC) Deﬁned Daily Doses (DDD) methodology.
We analysed 2007 and 2008 data on outpatient use of antibacterials
for systemic use (ATC J01) for children and teenagers up to age
20 in countries where use could be expressed in both DDD (WHO
version 2010) and packages per 1000 inhabitants per day (DID and PID,
respectively).
Results: In 2008, outpatient antibiotic use up to the age of 20 (10)
represented 15% (6%) of total antibiotic use in DID compared to 22%
(14%) of total antibiotic use in PID. In DID, use varied with a factor
2.6 between highest (18.7 DID in Luxemburg) and lowest (7.2 DID in
Norway) use. In PID, use among children varied with factor 3.3 between
highest (3.0 PID in Luxembourg) and lowest (0.9 PID in Norway) use.
Between 2007 and 2008 outpatient antibiotic use in Belgium, Denmark,
Luxembourg and Norway decreased both in DID and PID when assessed
by age from the age of 0 until the age of 18 years (see ﬁgure). Use in
DID (age 0−20) decreased with 5% and in PID with 8% as compared
to 2007. Total outpatient antibiotic use (all ages) decreased in PID, not
in DID.
In children, mainly penicillins (J01C) and macrolides (J01FA) are
commonly used, and to a lesser extent second-generation cephalosporins
(J01DC), sulfonamides and trimethoprim (J01EE). Cephalosporin use is
negligible in Norway. Denmark only uses penicillins and macrolides in
children.
Conclusion: Quantities and classes of antibiotic substances used by
children vary substantially between European countries. The proportion
of antibiotic use in children on the total antibiotic use is highly dependent
on the outcome measure. To evaluate the effect of interventions targeting
antibiotic use in children, e.g. the EAAD, antibiotic use data expressed in
DID should best be linked to the patient’s age, and if information on age
is missing, be complemented with used data expressed in PID. Applying
this methodology, the 2008 EAAD appears to have been a success.
P1272 Comparative effects of the extended and the immediate
release formulations of ciproﬂoxacin on normal human
intestinal microﬂora
M. Rashid, A. Weintraub, C.E. Nord* (Stockholm, SE)
Objectives: Ciproﬂoxacin is a well-known ﬂuoroquinolone, active in
vitro against many Gram-negative and Gram-positive bacteria. The
purpose of the present study was to evaluate the ecological effects
of an orally administered extended release ciproﬂoxacin formulation in
comparison with an immediate release ciproﬂoxacin formulation on the
normal human intestinal microﬂora.
Methods: Thirty-six healthy female subjects (18−45 years of age) were
included in the study. The extended release formulation ciproﬂoxacin
Utiminx® 500mg (Rottapharm Madaus SpA, Monza, Italy) was taken
od by 18 volunteers for 3 days and the immediate release formulation
ciproﬂoxacin Ciproxin® 250mg (Bayer HealthCare AG, Leverkusen,
Germany) was taken by 18 volunteers bid for 3 days. Faeces was
collected for determination of ciproﬂoxacin concentrations and analysis
of faecal microﬂora. The faecal specimens were cultured on non-selective
and selective media. Different colony types were counted, isolated
in pure culture, and identiﬁed to genus/species level by biochemical
and molecular tests. All new colonizing bacteria were tested for
susceptibility to ciproﬂoxacin. The faecal concentrations of ciproﬂoxacin
were determined by a microbiological method.
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Results: The volunteers receiving the extended release formulation had
mean concentration of ciproﬂoxacin 453mg/kg at the end of treatment.
In the immediate release formulation group, the mean concentration of
ciproﬂoxacin at the end of treatment was 392mg/kg. No ciproﬂoxacin
was detected in faeces before and after treatment. In volunteers
receiving the extended release formulation, the numbers of E. coli were
signiﬁcantly suppressed while the enterococci decreased moderately.
No signiﬁcant effects were observed on the other Enterobacteriaceae
and B. fragilis. In the volunteers receiving the immediate release
formulation, the numbers of E. coli decreased signiﬁcantly at the end of
treatment while the numbers of other Enterobacteriaceae, enterococci
and B. fragilis were moderately suppressed. In the extended release
group, one volunteer became colonized with resistant E. coli strains
(MIC >1mg/l) and nine volunteers with resistant enterococci. In the
immediate release group, six volunteers were colonized with resistant
enterococci.
Conclusion: No major differences were observed between the two
studied formulations on the normal human intestinal microﬂora.
P1273 Effect of telavancin on the normal human intestinal
microﬂora
M. Rashid, A. Weintraub, C.E. Nord* (Stockholm, SE)
Objectives: Telavancin is a new glycopeptide being developed for
the treatment of complicated skin and skin structure infections and
pneumonia caused by Gram-positive bacteria. Investigating the impact of
antibiotics on the normal microﬂora is important since alteration of the
balance may facilitate colonization by new potentially pathogenic strains
or enable microorganisms in the normal ﬂora to develop resistance.
The purpose of the present study was to investigate the effect of
administration of telavancin on the intestinal microﬂora of healthy
subjects.
Methods: Thirteen healthy subjects (6 males and 7 females) 18−30
years of age received telavancin 10mg/kg over a 60-minute period
by intravenous infusion q 24 h during 7 days. Faeces was collected
for determination of telavancin concentrations and analysis of faecal
microﬂora. Faecal specimens were cultured on non-selective and
selective media. Different colony types were counted, isolated in pure
culture, and identiﬁed to genus level by biochemical and molecular
tests. All new colonizing bacteria were tested for susceptibility to
telavancin. The faecal concentrations of telavancin were determined by
a microbiological method.
Results: No measurable faecal concentrations were found on days 1,
2, 5, 7, 9, 14 and 21. The numbers of staphylococci, enterococci,
lactobacilli and biﬁdobacteria were within the normal variations (1 log
cfu/g faeces). Mean numbers of clostridia decreased by approximately
1.5 log cfu/g faeces from Day 1 to Day 7 with recovery of baseline counts
on Day 21. No Clostridium difﬁcile strains or toxins were detected. No
signiﬁcant effects (>2 log cfu/g faeces) in the number of Escherichia
coli, Enterobacteriaceae species and Bacteroides fragilis group were
observed during or after the administration of telavancin. The number
of Candida albicans in the intestinal microﬂora was not changed within
the observation period. No new colonizing aerobic and anaerobic Gram-
positive bacteria resistant to telavancin (MIC >2mg/l) were found.
Conclusion: Telavancin has a favourable ecological impact on the human
intestinal microﬂora.
Antibiotic use, stewardship and resistance in
the hospital: optimising outcomes
P1274 Results of Irish National point-prevalence studies 2009 and
2010
D. Lambert*, M. Philbin, A. Oza on behalf of the IAPG
Objectives: A one-day point prevalence study of antimicrobial
prescriptions is a methodology used to gather data on the amount and
type of antimicrobials used.
The purpose of this study was to collate and analyse the results of nation-
wide antimicrobial point prevalence studies conducted in Ireland in 2009
and 2010.
These studies were conducted by antimicrobial pharmacists in the
majority of participating hospitals.
Methodology: A point prevalence study of antimicrobial prescribing was
carried out between June & July 2009 by 23 Irish hospitals as part of
the 2009 ESAC PPS. The methodology used was that of the 2009 ESAC
project.
Data collected included: age & sex of patient, details of systemic
antimicrobial therapy, diagnoses and indication, compliance with local
guidelines & documentation of reason for therapy.
The HPSC analysed the data of the Irish participants and participants
were also asked to complete a questionnaire to gather feedback and
suggestions for future studies.
Following on from this work, a national PPS was designed, organised
and carried out in September/October 2010.
The data collection form used in 2010 included additional ﬁelds such
as demographic data on all inpatients (not just those on antimicrobial
therapy) and information on IV/PO switch suitability.
Results: In 2009 5824 patients’ records were examined, of which 2000
received systemic antimicrobial therapy. The median prevalence was
34.3% (range 21.4–55.3%) compared with the European median of 29%.
The average number of antimicrobial drugs per patient was 1.58, the
maximum was 6.
In 2010 28 Irish hospitals participated (6414 patients). Of these a median
of 36.5% were prescribed antimicrobial therapy. Despite this increase,
the average number of antimicrobial drugs per patient was 1.51 (median
1.43), a slight reduction.
Conclusion: This 2009 study allowed comparison between Irish
hospitals and their European counterparts, and the HPSC analysis
facilitated inter-hospital comparison within Ireland.
Positive feedback following participation in the 2009 study prompted
organisation of a national PPS to be conducted again in 2010 with a
slightly modiﬁed methodology.
The results show usage in Irish hospitals to be marginally above the
European average in the 2009 study.
Comparing 2009 and 2010 results a slight increase in the percentage of
all inpatients prescribed antimicrobials was seen.
P1275 The association between “guideline-adherent” empirical
treatment of community-acquired pneumonia and mortality
in the Netherlands
S.M. Huijts*, M.J. Bonten on behalf of the CAP-diagnostics investigators
Objectives: The Dutch guidelines for the empirical antibiotic treatment
of community-acquired pneumonia (CAP) are based on either severity
of disease classiﬁcation by the Pneumonia Severity Index (PSI) or
CURB65-score (categorizing patients in ‘mild’, ‘moderate severe’ or
‘severe’ CAP) or a ‘pragmatic classiﬁcation’ based on the level of care
that is needed (general ward or ICU). Empirical treatment is based
on these different severity classiﬁcations and physicians may choose
which classiﬁcation they prefer. We determined the association between
guideline adherence for empirical antibiotic treatment for each of these
classiﬁcations and in-hospital mortality for hospitalized patients with
CAP in the Netherlands.
Methods: In a prospective, observational study in 23 Dutch hospitals,
patients (18 years) admitted to hospital with a clinically suspected
CAP were included between January 2008 and March 2009. Patients
with missing information on antibiotic use were excluded. Choices of
empirical antibiotic treatment were not dictated by protocol. Changes in
antibiotic treatment after admission were not recorded.
The Dutch guidelines advise treatment with amoxicillin or doxycyclin for
patients with ‘mild’ CAP, b-lactam, macrolide or quinolone monotherapy
for patients with ‘moderate-severe’ CAP depending on the Legionella
antigen test and moxiﬂoxacin monotherapy or a combination of
penicillin, ciproﬂoxacin, macrolide or a cephalosporin for patients
with ‘severe’ CAP. Antibiotic treatment with a narrower spectrum was
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deﬁned as ‘undertreatment’, and treatment with broader antibiotics as
‘overtreatment’. Logistic regression was used to calculate odd ratios for
‘undertreatment’ versus ‘correct or over treatment’ with adjustment for
disease severity based on the PSI score.
Results: 1036 hospitalized patients with conﬁrmed CAP were included,
of whom 69 (6.7%) died in hospital. According to the classiﬁcation
scheme 88, 143 and 31 patients received ‘undertreatment’ for the
PSI, CURB and pragmatic schemes, respectively. The crude OR for
in-hospital mortality for ‘undertreatment’ was 3.75 (2.04–6.90), 2.58
(1.47–4.53) and 2.14 (0.73–6.31) for PSI, CURB or pragmatic severity
classiﬁcations, respectively (table). The adjusted OR were 0.78 (0.37–
1.62), 1.06 (0.57–1.98) and 1.90 (0.59–6.06), respectively.
Conclusion: When adjusted for disease severity, there were no
statistically signiﬁcant associations between ‘undertreatment’ according
to Dutch guidelines and in-hospital mortality.
P1276 Adherence to antibiotic guidelines for empirical treatment
of pneumonia in the Netherlands
S.M. Huijts*, M.J. Bonten on behalf of the CAP-diagnostics investigators
Objectives: The Dutch guidelines for the empirical antibiotic treatment
of CAP are based on either severity of disease classiﬁcation by
the Pneumonia Severity Index (PSI) or CURB65-score (categorizing
patients in ‘mild’, ‘moderate severe’ or ‘severe’ CAP) or a ‘pragmatic
classiﬁcation’ based on the level of care that is needed (general ward
or ICU). Empirical treatment is based on these different severity
classiﬁcations and physicians may choose which classiﬁcation they
prefer. We compared guideline adherence for empirical antibiotic therapy,
according to the 3 classiﬁcation schemes, in hospitalized patients with
CAP in the Netherlands.
Methods: In a prospective, observational study in 23 Dutch hospitals,
patients (18 years) admitted to hospital with a clinically suspected
CAP were included between January 2008 and March 2009. Patients
with missing information on antibiotic use were excluded. Choices of
empirical antibiotic treatment were not dictated by protocol. Changes
in antibiotic treatment after admission were not recorded. Antibiotic
treatment with a narrower spectrum was deﬁned as ‘undertreatment’,
and treatment with broader antibiotics as ‘overtreatment’.
Results: 1758 patients with a clinical suspicion of CAP were included,
of which 552 did not have an inﬁltrate on the chest X-ray <48 hours
after admission, 74 patients did not fulﬁl in-/exclusion criteria, of 33
patients information about antibiotic use was missing and 52 patients
were not admitted, resulting in a study population of 1047 hospitalized
patients with conﬁrmed CAP.
Depending on the different severity classiﬁcations the percentage of
patients correctly treated according to the Dutch guidelines was 43.7%,
31.9% or 63.3% for the PSI, CURB-65 or pragmatic classiﬁcation
respectively (see table).
Conclusion: The three different severity classiﬁcations induce widely
ranging proportions of adherent and non-adherent antibiotic choices.
The pragmatic classiﬁcation has the highest percentage of guideline
adherence.
P1277 Results of a counselling programme in antibiotic treatment
in an Andalusian hospital
A. del Arco Jime´nez*, B. Tortajada Goitia, J. de la Torre, J. Olalla Sierra,
J. Prada Pardal, M. Noureddine Lo´pez, J. Garcı´a Alegrı´a (Marbella, ES)
Objectives: The inappropriate use of antimicrobial agents could
contribute to the development of bacterial resistance to the principal
antimicrobial drugs. We describe the results of a year of a non-
compulsory counselling program in antibiotic treatment in a second level
Andalusian hospital
Methods: A multidisciplinary team composed of pharmacists, Internal
Medicine physician certiﬁed in Infectious Diseases with the support
of Microbiology unit reviewed all the prescriptions of antibiotics for
restricted use approved in committee of infections for a year. Notiﬁcation
of new cases was conducted by e-mail. The infectious diseases physician
interviewed with the medical responsible for the patient and evaluated
the microbiological results.
Result: 281 therapeutic counselling interventions were made in 2009.
The main source of advice was for assessment of empirical therapy in
111 patients (46.25%), evaluation of potential therapeutic de-escalation
82 (34%) and the treatment duration of 32 (13.3%). The recommendation
in 75% of the cases made a modiﬁcation of the treatment. 92%
of the advised recommendations were accepted. 37% of restricted
antibiotics prescribed did not conform to the approved indications.
The drugs tested were imipenem with 78 cases, ertapenem with 44
cases, cefepime 40 cases and linezolid 21. The modiﬁcations were
de-escalation of imipenem or meropenem to ertapenem in infections
with ESBL-producing Enterobacteriaceae, amoxicillin-clavulanate or
ciproﬂoxacin in cases of sensitivity to these antimicrobials, linezolid to
clindamycin, cotrimoxazole or vancomycin (MIC infections <1.5 ug/ml.)
We estimated savings in direct costs for de-escalation exchange (2009
was 33,731 euros). The proﬁle of Pseudomonas aeruginosa sensitive to
imipenem and meropenem improved slightly (imipenem 87% in 2007
compared to 92% in 2009 and meropenem of 94% in 2007 compared to
96% in 2009).
Conclusions: Non-compulsory Counselling programs antibiotics are an
effective tool to prevent antibacterial resistance and increase savings in
addition to providing direct and indirect costs.
P1278 Antimicrobial consumption in VINCat hospitals: stratiﬁed
data by hospital size
S. Grau*, E. Fondevilla, M. Palomar, J. Valles, M. Pujol, F. Gudiol
on behalf of the VINCat Program Group. Department of Health,
Catalonia, Spain
Objectives: VINCat is a nosocomial infection surveillance program in
Catalonia (7.5 million population), Spain. In 2009, a total of 46 acute
care hospitals supplied data on antimicrobial use. Information about
antimicrobial use stratiﬁed by hospital size is scarce. The aim of the
study is to assess the evolution of the antimicrobial consumption in
acute care hospitals stratiﬁed by hospital size.
Methods: A speciﬁc training in data management on antimicrobial con-
sumption was given to all participant hospitals before the implementation
of the program. During the ﬁrst trimester from 2008 to 2010, the VINCat
program requested annual data, from 2007 to 2009, on antimicrobial use
from participant hospitals. Hospitals were stratiﬁed in 3 groups: I (more
than 500 beds), II (200–500 beds) and III (less than 200 beds). Deﬁned
daily doses of 2009 were applied for calculations. Deﬁned daily doses
per 100 occupied bed-days (DDD/100 OBDs) were used to calculate the
average consumption rate among all hospitals. Antifungal consumption
was excluded from the study.
Results: Number of hospitals Group I: 7; Group II: 13; Group III: 19
(2007), 25 (2008); 26 (2009). Mean DDD/100 OBDs Group I: 85.00
S350 21st ECCMID/27th ICC, Posters
(2007), 82.52 (2008), 86.43 (2009); Group II: 69.33 (2007), 70.64
(2008), 72.30 (2009); Group III: 68.55 (2007), 69.79 (2008), 73.32
(2009). Antibiotic with higher DDD/100 OBDs 2007–2009 increase
Group I: carbapenems (4.82–6.44), other antibacterials (7.80–10.26);
Group II: penicillins (30.13–31.26), carbapenems (2.25–3.07); Group III:
quinolones (13.50–15.18), other antibacterials (2.93–3.99), carbapenems
(1.63–2.60). Antibiotic with higher DDD/100 OBDs 2007–2009 decrease
Group I: penicillins (38.81–35.95); Group II: aminoglycosides (3.06–
2.80); Group III: tetracyclines (0.25–0.21).
Conclusion: A higher DDD/100 OBDs consumption was observed in
hospitals with more than 500 beds. However, antimicrobial consumption
was similar between middle and small size acute care hospitals. The
box length gives an indication of a wide variability in the values from
small hospitals. The increase in carbapenem consumption in all hospital
groups is worrying.
P1279 Junior and senior residents’ knowledge and perceptions
about antimicrobial resistance
C. Navarro-San Francisco, J. Rodrı´guez-Ban˜o, J. Cobo, J.H. de
Gea-Garcı´a, S. Van˜o´, F. Moreno-Ramos, M. del Toro, J. Mora´n-Barrios,
J.R. Pan˜o-Pardo* (Madrid, Seville, Murcia, Bilbao, ES)
Objective: To evaluate the knowledge and perceptions about antimicro-
bial resistance (AMR) of junior and senior medical residents in 5 Spanish
hospitals.
Methods: An online survey was conducted between Sept 15th and Nov
15th, 2010. Both junior (postgraduate year [PGY] PGY1) and senior
(PGY4 and PGY5) residents of 5 Spanish academic medical centres were
targeted. The survey explored the perception of doctor residents about
the relevance and scope of the problem of AMR in hospitals. Knowledge
of residents regarding AMR was explored through two questions about
the rate of quinolone-resistant E. coli (QREC) and the rate of MRSA in
each medical center. Residents were also asked to evaluate the relevance
of several factors potentially linked to AMR as suggested by Pulcini
et al. (Clinical Microbiology and Infection. 2010).
Result: 279 responses were received during the study period,
corresponding to 33.05% of all targeted residents. Response rate was
higher among junior doctors (40.71% vs 25.47%). Respondents belonged
mainly to medical specialties (43.4%) while 17.6% and 10.8% of the
responses arose from surgical and critical care residents. Residents of
all hospitals, specialties and seniority mostly considered that AMR was
a signiﬁcant problem. Regarding the extent of the problem, respondents
considered AMR to be a problem at national level (94.3%), at their
institution (91.3%) and for their daily practice (83.8%). The proportion
of residents that correctly identiﬁed the rate QREC and MRSA in their
centres was 40.8% and 25.3%, respectively. There were differences
among hospitals in the proportion of residents identifying the rate of
resistance but no differences were found when different specialties or
seniority was considered. Residents’ perceptions about the relevance of
several factors on the magnitude of the problem of AMR in hospitals
are described in table 1.
Conclusion: The vast majority of residents ﬁnd AMR to be a signiﬁcant
problem but, to some extent, they perceive that it affects others more
(country > hospital > own daily practice). A majority of the residents
cannot accurately identify local rates of resistance involving two major
pathogens, especially MRSA. Spanish residents believe that the main
factor driving AMR in hospitals is an excessive number of antimicrobial
prescriptions. Senior resident doctors perceive that the duration of
therapy is more relevant for AMR than junior resident doctors do.
P1280 Antibiotic management and early discharge from hospital:
an economic analysis
A.M. Gray*, M. Dryden, A. Charos (Oxford, Winchester,
Walton-on-the-Hill, UK)
Objectives: Programmes that shorten or avoid in-patient episodes have
attracted widespread interest, but face many obstacles in practice
including uncertain costs. We report on an Evaluation Tool that uses
bedside review of antibiotic use and infection management in acute
medical and surgical patients, to assess whether patients with infections
could be safely managed out of hospital, and their antibiotic regimen
(IV or oral) changed. Our objective was to assess the potential costs
and savings from implementing the tool in a representative sample of
hospital ward settings.
Methods: The tool was implemented in 30 acute wards in ﬁve hospital
Trusts: Winchester, Glasgow, Imperial, St Thomas’ and Leeds. Data were
collected on demographic variables, diagnosis, social situation, hospital
stay, and all current antibiotic prescribing. A physician and pharmacist
assessed antibiotic therapy and whether discharge was possible with
or without community support. Resource use was measured for each
patient, unit costs attached, and mean and total costs of implementing
recommendations were calculated.
Results: Across the wards 291 patients were on antibiotics: 161 (55%)
on oral antibiotics only and 130 (45%) on IV antibiotics. The assessment
identiﬁed 82 patients (28%) as suitable for discharge: 54 (66%) on oral
antibiotics and 28 (34%) on IV. It showed that 36 of the 54 on oral
antibiotic (67%) could stop current oral antibiotics. From the 28 on IV,
6 (22%) could stop, 18 (64%) could switch to oral and 4 (14%) remain
on IV antibiotic.
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Implementation of these recommendations would reduce total in-patient
days by 494 at a saving of £186,731, and save £1,689 from adjustment of
antibiotic therapy, with additional costs associated with implementation
of the assessment (£2,468) community support costs (£6,227) and OPAT
(£10,758). As a result, net potential savings would be £170,198 or £2,076
(95%CI £1196, £2955) per patient. Excluding eight patients with the
highest (>15 day) potentially avoidable in-patient stays, mean savings
would fall to £1,083 per patient but remain highly signiﬁcant (95%CI
£787, £1378).
Conclusions: Careful assessment of antibiotic use in acute wards has the
potential to reduce use and cost of antibiotics and length of stay. Added
costs of assessment and out of hospital support services would offset
a small proportion of these potential savings. Further observational and
randomised studies are now needed to test these results.
P1281 Consequences of failure of initial antibiotic therapy in
complicated skin and skin structure infections in US
hospitals, 2000–2009
A. Berger, G. Oster, J. Edelsberg, K.T. LaPensee, X. Huang*,
D.J. Weber (Brookline, Jersey City, Chapel Hill, US)
Objective: Initial antibiotic therapy in patients hospitalised for the
treatment of complicated skin and skin structure infections (cSSSI)
is typically empiric, as causative pathogens often are unknown at the
time. While initial treatment is usually successful, many patients fail
to respond to such therapy. The clinical and economic consequences of
failure of initial antibiotic therapy in patients with cSSSI have not been
well described. The objective of this study was to examine this issue.
Methods: Using a US multi-hospital database, we identiﬁed all patients
hospitalised for cSSSI (acute infection [eg, abscess, cellulitis], chronic/
ulcerative infection [eg, decubitus ulcer], surgical site infection) between
1/1/2000 and 6/30/2009 who received parenteral antibiotic therapy for
48 hours (except in event of death) beginning 24 hours of hospital
admission. Initial therapy was deﬁned as all antibiotics received within
the ﬁrst 24 hours. Focusing attention on the 40 most frequently used
regimens, we deﬁned initial antibiotic failure as: (1) receipt >24 hours
of an antibiotic not used in the ﬁrst 24 hours, excluding agents of
similar/narrower spectrum and those begun at hospital discharge; or
(2) drainage, debridement, or amputation after 72 hours. We stratiﬁed
patients according to whether they experienced initial antibiotic failure,
and then compared hospital length of stay, total billed charges, and
mortality between the two groups. Student’s t-tests were used to assess
the statistical signiﬁcance of differences in continuous measures; for
mortality, a c2-test was used.
Results: We identiﬁed 22,382 patients admitted to hospital for the
treatment of cSSSI, of whom 17,543 (78%) received one of the 40 most
frequently used regimens and met all other inclusion criteria. A total
of 3403 patients (19.4%) experienced failure of initial antibiotic therapy.
Patients who experienced failure of initial antibiotic therapy averaged 5.1
additional days in hospital (mean [SD], 9.2 [8.0] days vs 4.1 [3.1] days
for those not experiencing failure) and $14,304 in additional hospital
charges ($25,626 [$43,052] vs $11,322 [$21,632]). Case fatality was
more than 7-fold higher in patients with failed initial therapy (1.5% vs
0.2%, respectively) (p< 0.01 for all comparisons).
Conclusion: Patients hospitalised for cSSSI who experience failure
of initial antibiotic therapy have signiﬁcantly worse clinical outcomes,
longer lengths of stay, and higher costs of care.
P1282 Audits and antibiotic advisors to control antibiotic
consumption and ﬂuoroquinolones use: a ﬁve-year survey
in 74 French hospitals, 2005–2009
C. Dumartin*, A.-M. Rogues, B. Amadeo, M. Pefau, A.-G. Venier,
P. Parneix, C. Maurain (Bordeaux, FR)
Objectives: French hospitals are urged by health authorities to develop
antibiotic stewardship (ABS) programmes in order to improve antibiotic
(AB) use and to decrease their consumption. We performed a ﬁve-year
longitudinal survey to describe ABS measures implementation, AB use
and to study relationships between ABS measures and trends in AB
consumption between 2005 and 2009.
Methods: Annual retrospective surveys were conducted by auto-
questionnaire in voluntary hospitals in Southwestern France from 2005
to 2009. Data on ABS, AB consumption, hospital type and activity were
collected. ABS measures covered organisation, resources, restrictive and
persuasive actions. AB consumption was retrieved from pharmacy record
and expressed in number of Deﬁned Daily Doses (DDD)/1000 patient-
days (PD) according to national and WHO guidelines, using 2009 DDD
values to monitor trends. ABS and AB use were studied according to
hospital type. Relationships between ABS measures and trends in AB
consumption were assessed by multivariate logistic regression.
Results: 74 hospitals (17% of hospital beds in the region) collected data
each year and were involved in the survey. Major progress was achieved
in organisation and human resources for ABS. Least frequent measures
in 2009 were computerised systems for AB prescription management,
ability to quantify time dedicated by the AB advisor, education. AB
consumption remained stable (338 DDD/1000 PD in 2005 and 347 in
2009), with variations according to hospital type and antibiotic classes
(−2% in ﬂuoroquinolones use, +24% in third generation cephalosporins
use). Hospitals with ABS measures in place tended to better control
total AB use and ﬂuoroquinolones use. Fluoroquinolones use remained
stable between 2005 and 2009 (−3.3%) in hospitals having performed
educational activities, whereas it increased (+22%) in others. In the
multivariate analysis, practice audits and time dedicated by the AB
advisor were signiﬁcantly associated with a decrease in total AB use
and in ﬂuoroquinolones use, respectively.
Conclusion: This ﬁrst longitudinal study in 74 hospitals during 5 years
showed that ABS had improved while AB consumption remained stable.
Practice audits and appointment of an AB advisor, with dedicated time
seemed helpful to control total AB and ﬂuoroquinolones consumption.
These ﬁndings could lead to foster these ABS measures, in the context of
a multidisciplinary approach, to reduce AB use and control antimicrobial
resistance.
P1283 Dynamic relationship between ﬂuoroquinolone use and
emergence of E. coli ESBL producers
J.M. Lo´pez-Lozano*, N. Gonzalo Gime´nez, F. Lajara-Marco,
P. Campillos-Alonso (Orihuela, ES)
Introduction and Objectives: During the past decade, Escherichia coli
producing Extended Spectrum b-lactamases (EC-ESBL) has become
a new important threat in our sanitary setting. At the same time,
classical ﬂuoroquinolones were replaced by new ones. We aimed in
this study to investigate the possible relationship between an increase
in the use of newer ﬂuoroquinolones and the emergence of the above
cited bacteria through a time-series analysis as a routinely activity in
ViResiST (www.viresist.org).
Methods: From January 2001 to May 2010 we studied all inpatients
and outpatients with a non duplicate positive culture for E. coli. We
calculated the monthly percentage of EC-ESBL and estimated the use
of ﬂuoroquinolones. Classicals −CF − (ciproﬂoxacin, norﬂoxacin and
oﬂoxacin) and newer − NF − (levoﬂoxacin and moxiﬂoxacin) were
separated. We measured the use as monthly Deﬁned Daily Dose (DDD)
per 1000 inpatients-days (DDD/1000pat-days) and monthly DDD/1000
inhabitants-days, respectively for hospital setting and community. We
identiﬁed and calculated a Transfer Function Model to found a model
for a non contemporaneous relationship between time-series of resistance
and antibiotic use.
Results: During the past decade, the monthly percentage of EC-ESBL,
an unusual phenomenon in our laboratory before the study period, rises
until 14%. The use of CF decreases from 3 to around 1.5 DDD/1000
inhabitants-days and from 100 to 70 DDD/1000pat-days, while NF use
rises from 0.5 to 2 DDD/1000inhab/days and from 0 to 90 DDD/1000pat-
days. We observed that 62% of the variability of EC-ESBL was explained
by the lagged use of NF: 2 months before in hospital setting and 6−12
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months before in community. No relationship was observed with use of
classical ﬂuoroquinolones.
Conclusion: We observed a strong, dynamic and retarded relationship
between the use of newer ﬂuoroquinolones and the emergence of EC-
ESBL, but not so with the classical ones. Reducing the use of these drugs
could help to control this threatening bacteria. We think that ViResiST
approach would potentially improves the knowledge of the relationship
between antibiotic use and resistance due to its ability to handle vast
amounts of data.
P1284 Antibiotic prophylaxis in surgical procedures in the Latium
region, Italy
V. Puro, L.E. Ruscitti*, P. Piselli, L. Martini, F. Ferraro, P. Villari,
D. Orazi, A.L. Scanu, S. Parrocchia, R. Saviano, G. Natalini, A. Silvestri,
G. Pagano, F. Cerquetani, G. Sguazzini, A. Caterini, N. Petrosillo,
G. Ippolito on behalf of Centro Regionale Infezioni Associate Pratiche
Assistenziali − Lazio. Coordinamento: INMI “L.Spallanzani” Roma
Objective: Antibiotic prophylaxis (ABP) is one of the main prevention
measure against Surgical Site infections (SSI) and the adherence to
guidelines (GL) is considered an important indicator. ABP usage in 25
hospital centers in the Latium Region (Central Italy) participating on a
voluntary basis, was studied.
Methods: In 2008 (Apr-Jun), the Regional Center for Health Associated
Infections of the Latium coordinated a SSI surveillance based on the
HELICS project in which 10 different surgical procedures were investi-
gated: appendicectomy, caesarian section, colon-surgery, cholecistectomy
and herniectomy (in laparoscopy or not), arthro- and hip-prosthesis,
cardiovascular surgery, laminectomy and mastectomy. Information on
ABP was collected, and its appropriateness was considered according to
Italian GL adapted from the Scottish Intercollegiate Guidelines Network
(SIGN), and to Surgical Care Improvement Project (SCIP) indicators:
time at starting, drug used, and duration (SCIP1, SCIP2 and SCIP3,
respectively); for each indicators a “best” and “worst” scenario were
deﬁned, considering all cases with missing information adherent or non
adherent to GL, respectively.
Results: A total of 2835 surgical interventions (73% in males; 25% in
emergency; 10% of all analogue procedures performed in the Region
in the same period) was studied. ABP was administered in 2664 (94%)
cases: 2346/2468 (95) pts for whom it was to be provided according
to GL, and in 318/367 (86.6%) even if not indicated. Considering only
the 2346 procedure where ABP was indicated and administered, SCIP1
was in agreement with GL for 1172 pts (50%), and undetermined
in 15.4% cases; SCIP2 for 84.5% pts, while in the remaining cases
second line drugs (66.4% 3rd class cephalosporin, 32.2% penicillin+anti-
b-lactamase) were used; SCIP3 was consistent with GL in 48% of cases,
and undetermined in 7% cases. Considering the “best” scenario, all SCIP
indicators were followed in 37% of cases; two of the three in 18%
cases, only one in 38% cases, and in 7.4% cases all indicators were not
followed; in the “worst” these proportions where respectively 22.7%,
23.1%, 45.6% and 8.6%.
Conclusions: The appropriateness of ABP use appears to be low, mostly
because of prolonged duration and of large use of second line antibiotics.
This suggests the need for further efforts and educational initiatives
aimed to reduce the improper use of antibiotics in the surgical setting.
P1285 Assessing stewardship programmes as a potential
determinant of antibiotic management in European
intensive care units: a survey
G. De Angelis*, M. Cipriani, F. Di Muzio, G. Restuccia, E. Milozzi,
R. Cauda, M. Antonelli, U. Frank, A. Brink-Huis, M. Hulscher,
E. Tacconelli (Rome, IT; Freiburg, DE; Nijmegen, NL)
Objective: Inappropriate antibiotic use is associated with poor patients
outcome, especially in ICUs. Understanding the current antibiotic
practice is extremely important to build effective strategies for improving
antibiotics use. A survey was designed to investigate the self-assessed
rate of compliance with national or international guidelines on antibiotic
usage and diagnostic tests. In addition, as a potential determinant
of antibiotic management, the local implementation of antibiotic
stewardship programmes was assessed.
Methods: A 32-point structured questionnaire was elaborated and sent
to 118 ICUs throughout Europe. ICUs were selected according to
the prevalence of methicillin-resistant Staphylococcus aureus (MRSA)
bacteremia (low, moderate and high MRSA rate).
Results: Completed questionnaires were provided by 35 ICUs (response
rate, 30%). Geographical distribution among Europe was fairly good.
In the majority of cases, ICUs were closed (29, 83%), mixed (18,
51%) and belonged to medium-large size University hospitals (29, 83%).
Ninety one percent of ICUs declared to follow local guidelines for
empirical antibiotic therapy (see Table). The survey documented a high
rate of blood cultures performance (94%) before starting antibiotics,
while cultures from other site was less frequently described (urine and
BAL, 54% and 31%, respectively). Concerning timing, antibiotics were
not started within 4 hours in 4 centers (11%). Infection markers, mainly
serum procalcitonin to start (71%) and to monitor response to antibiotics
(83%), were routinely used in 66% of centers. Interestingly, high
percentage of ICUs declared to regularly apply de-escalation (94%) and
daily reassessment of therapy (77%). Antibiotic stewardship programmes
were not present in 34% of ICUs. High percentages of centers did not
have limitation system for speciﬁc drugs (54%), antibiotic order form
(52%), antibiotic formulary (43%) and automatic stop order (69%). Only
17% of centers used computer decision support system to help antibiotic
choice.
Conclusions: Although the appropriateness of antibiotic use is of
paramount importance in ICU patients, our survey shows that antibiotic
stewardship is far away to be standardized in such setting. Interventions
to improve antibiotic use in ICUs need to be urgently designed on a
European level.
P1286 Comparison of inhaled and intravenous colistin combined
with tigecycline in treatment of multidrug-resistant
Acinetobacter baumannii pneumonia
Y. Tezer Tekc¸e*, A. Erbay, H. Cabadak, S. Sen (Ankara, Yozgat, TR)
Objectives: Increasing antimicrobial resistance in Acinetobacter bau-
mannii lead physicians to search for alternative therapeutic options.
The aim of this study was to investigate the effectiveness of inhaled
and intravenous (i.v.) colistin combined with tigecycline in multidrug-
resistant (MDR) A. baumannii pneumonia.
Methods:Medical records of the patients receiving i.v. or inhaled colistin
combined with tigecycline for at least 72 h for MDR A. baumannii
pneumonia were reviewed retrospectively from 1 October 2009 to 30
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April 2010. Daily dosage of inhaled colistimethate sodium was 2 million
IU divided into 2 doses which was used via ventilator in patients under
mechanical ventilation and via nebulized oxygen ﬂow in spontaneously
breathing patients. Daily dosage of i.v. colistin was 3 million IU divided
into 3 doses. Follow up cultures were evaluated at 7th and 14th days
of treatment. The primary outcome measure was 30 day in hospital
mortality, and secondary outcome was microbiological eradication.
Results: 43 patients with MDR A. baumannii pneumonia were included
in the study. Of these patients, 22 (51.2%) were female and the mean age
for all patients was 64.4±13.6 (range, 22−91) years. Ventilator associated
pneumonia was present in 39 (91%) patients. APACHE II scores were as
follows; <10 (n = 2, 4.7%), 10−20 (n = 14, 32.6%), >20 (n = 27, 62.8%).
Among 43 patients, 42 (97.7%) had a co-morbidity. All patients were
followed up in intensive care units. Duration of ICU stay until pneumonia
was 7.5±7 days. In addition to tigecycline, i.v. colistin was used in
20 (46.5%) and inhaled colistin in 23 (53.5%) patients. Nephrotoxicity
was not observed in both groups, however in one patient bronchospasm
was developed after administration of inhaled colistin. Microbiological
eradication rate was higher in inhaled colistin group than i.v. group both
at day 7th (30% vs 0, p = 0.027) and 14th (53% vs 16%, p= 0.050). In
10 patients microbiological and clinical cure were obtained, in 4 patients
only clinical cure were obtained. In one patient colistin resistance was
developed at the 14th day of inhalation treatment. All cause 30 day
in hospital mortality was 67.4%. There was no signiﬁcant difference
between i.v. and inhaler groups for mortality (70% vs 65.2%, p= 0.738).
Conclusion: Both inhaler and i.v. colistin combined with tigecycline
could be used in treatment of MDR A. baumannii pneumonia. Inhaler
colistin combined with tigecycline provided better microbiological
eradication in this study.
P1287 Audit of antibiotic therapies in 66 cases of endocarditis
E. Demonchy, E. Cua, P. Roger, P. Dellamonica, C. Pulcini* (Nice, FR)
Objectives: We wanted to assess the quality of antibiotic therapies
prescribed for infective endocarditis on our ward. Such audits have rarely
been reported in the literature.
Methods: We conducted a retrospective audit of all adult cases
of endocarditis hospitalised over a 3-year period in the Infectious
Diseases department of Nice University Hospital, France. The quality
of antibiotic therapies was assessed using the 2004 European Society
of Cardiology guidelines as a reference, since no national guidelines
were available in France. The antibiotic therapy was considered as
appropriate only if all the following items were in accordance with the
guidelines: molecule, dose, route and interval of administration, duration
of antibiotic treatment.
Results: Sixty-six patients were included, aged 63 yo on average.
The main characteristics of the cases of endocarditis are presented
in Table 1. One-hundred and ﬁfty-two antibiotics were prescribed,
representing 7 single therapies, 36 combinations of two antibiotics
and 23 combinations of three antibiotics. The molecules that were
the most frequently prescribed were: gentamicin (n = 49), amoxicillin
(n = 29), rifampin (n = 25), vancomycin (n = 17) and oxacillin (n = 14).
The antibiotic therapies were in accordance with the guidelines in 14%
of the cases. The most frequent causes of inappropriate therapies were:
gentamicin prescribed as a single daily dose in 55% of the cases, too
long durations of gentamicin treatments in staphylococcal endocarditis
in 28% of the cases and unnecessary prescriptions of rifampin in 72%
of the cases. An intravenous-oral switch of antibiotic therapies was done
in 29% of the patients (n = 19), 18±9 days after starting therapy on
average, for staphylococcal (n = 12) or streptococcal endocarditis (n = 7);
these endocarditis were mainly left-sided (n = 12) and complicated in
79% of the cases. There was no signiﬁcant association between mortality
and inappropriate antibiotic therapies (14% vs 22%, P = 0.62, N = 66) or
between mortality and oral switch (0% vs 21%, P = 0.052, N = 66).
Conclusion: Infective endocarditis was rarely treated using an antibiotic
regimen in accordance with the 2004 European guidelines, but misuse
did not have a negative impact on mortality. Intravenous-oral switch of
antibiotic therapies was common practice, even in complicated left-sided
endocarditis, and was associated with a favourable outcome in all cases.
P1288 Integrated care pathway for management of infective
endocarditis − an innovative multidisciplinary approach:
clinical outcomes and experience from the Lancashire
cardiac centre, UK
A. Guleri*, R. More, D. Roberts, J. Zacharias, A. Tang, N. Waddington,
M. Przybylo, T. Morris, S. Rogers (Blackpool, UK)
Background: Infective endocarditis [IE]is a complex disease with
poor prognosis and high mortality. The management is complicated
by varied initial clinical manifestation, underlying cardiac disease,
co-morbidities, etiologic agent, complications and delays in optimal
investigations, multidisciplinary input and targeted treatment. A team
of cardiologists, cardiac surgeons, lead physician-medical admissions &
microbiologist from Lancashire cardiac centre collaborated, reviewed
available guidelines to set up a practical IE care bundle [Endocarditis
Pathway − EP]. We present here data and clinical experience from use
of IE integrated care pathway over a 12-months pilot.
Methods: Analysis of database on 32 patients added to the EP. Patients
with suspected IE are e-logged [intranet based registration of patients
on EP] by training doctor/consultant of clinical team and a hardcopy of
pathway form is added to the case notes. Subsequent data is added along
patient journey till discharge from hospital.
Results: Key results from database on 32 patients [24 males:8 females] is
presented. The mean age is 58-years and average duration of hospital stay
5-weeks. 63% (20/32) were diagnosed with left sided IE; 13% (4/32) with
right sided IE and 6% (2/32) had both left and right sided IE. 25% (8/32)
with prosthetic valve IE. 50% had aortic valve followed by 31% mitral
valve involvement. Staphylococcus aureus [MSSA 7/32; MRSA 1/32]
and Streptococcus sp. [8/32] were main identiﬁed pathogens. 58%[19/32]
had surgery while rest had medical management. Antibiotics used for
treatment included ﬂucloxacillin [46%]; daptomycin [35%]; rifampicin
[in combination − 35%]; benzyl penicillin [21%]; vancomycin [18%].
Echocardiogram conﬁrmation of vegetations in 56% [18/32]. 15% [5/32]
had acute renal failure requiring CVVHD. 81% [26/32] were successfully
cured while mortality was 19% (6/32) due to complications of IE or other
diseases.
Conclusions: The EP was piloted at the Lancashire cardiac centre with
plans to extend it for consultation of the regional cardiac network with an
aim to standardise care throughout the region. The multidisciplinary team
input has had an impact in preventing delays with cardiologist/cardiac
surgeon/microbiologist consults and optimal management. Results and
clinical experience from this pilot have been used to inform revised user
friendly version of the EP to be available on the new trust electronic
patient record system. Details to be presented.
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P1289 Results from a non-interventional study: daptomycin as
empiric treatment of Gram-positive infections
K.N. Malizos*, P. Gargalianos-Kakolyris, A. Gonzalez-Ruiz, A. Cogo,
A. Galloway, A. Beiras-Fernandez, M. Heep, Y. Yin, R.L. Chaves
(Larissa, Athens, GR; Kent, UK; Vicenza, IT; Newcastle upon Tyne,
UK; Munich, DE; Basel, CH; East Hanover, US)
Objectives: Inadequate empiric treatment (ET) of S. aureus infections
is frequent and is associated with poor outcome. MRSA coverage is
recommended for ET in regions with high prevalence or for severely ill
patients (pts). Vancomycin is however inferior to penicillin to treat MSSA
infections, a therapeutic dilemma. The objective of this analysis is to
evaluate if treating physicians’ prediction of MRSA or MSSA infection
is accurate and also the role of daptomycin (DAP) in the ET of Gram
positive infections.
Methods: Answers to standardized questions concerning suspected
pathogens in pts receiving DAP as ET were analyzed and compared
to culture results received after treatment initiation in the European
Cubicin® Outcomes Registry and Experience, a retrospective, non-
interventional, multicenter study describing characteristics and outcomes
of pts treated with DAP. Among all 3621 pts enrolled from 2006 to 2010
only those empirically treated were included. Additionally, outcomes
(cured and improved = success, failure, non-evaluable) were assessed
at the end of DAP therapy by the investigators.
Results: A total of 2041 pts were treated empirically. Information on
suspected pathogens was provided in 1841 cases (62% MRSA, 17%
MSSA and 21% other pathogens. Table 1 shows common discrepancies
between the ﬁnal culture results and the suspected pathogens. Overall,
ET with DAP was given to 746 pts (37%) with cSSTI, 330 pts (16%)
with bacteraemia, 317 pts (16%) with uSSTI, 158 pts (8%) with foreign
body/prosthetic, 134 pts (7%) with endocarditis and 105 pts (5%) with
osteomyelitis. Most frequently used DAP doses in ET were 6mg/kg
and 4mg/kg with no clear inﬂuence of the suspected pathogen on dose
choice. Doses higher than 6mg/kg as ET were used in 13% and 10% of
MSSA and MRSA cases, respectively. Clinical success of ET with DAP
in pts with conﬁrmed culture results were: 82% for MSSA, 85% of pts for
MRSA, 78% for coag-neg staphylococci, 72% for E. faecalis and 81%
for E. faecium. Success rate for pts without identiﬁed pathogen was 77%.
Conclusion: This study conﬁrms that in routine practice clinical
suspicion of MRSA or MSSA infections are frequently not conﬁrmed
by laboratory results which commonly leads to inappropriate therapy
(Ammerlaan et al. 2009). The study also expands the results of DAP
pivotal trials, which support DAP as effective empiric treatment of G+
infections, regardless of the presence of MSSA or MRSA.
P1290 Clinical response and nephrotoxicity according to the trough
serum vancomycin concentration among patients with
methicillin-resistant Staphylococcus aureus bacteraemia
W. Choi, J. Noh, J. Huh, Y. Youn, J.Y. Song, J. Sohn, H. Choeng,
W. Kim, M.J. Kim, D.W. Park* (Seoul, KR)
Background: Vancomycin is an important antibiotic for the treatment of
MRSA infection, but has narrow therapeutic window. We conducted the
study to assess the clinical response and nephrotoxicity according to the
trough serum vancomycin concentration among patients with methicillin-
resistant Staphylococcus aureus (MRSA) bacteremia.
Methods: A retrospective cohort study was conducted among patients
who received vancomycin for MRSA bacteremia during the period from
1 April 2002 and 31 March 2010 at Korea University Ansan Hospital.
Patients were included in this study if they (1) were 15 years old, (2)
received vancomycin for more than 48 hours, (3) had 1 vancomycin
trough level collected within 3−7 days from the initiation of vancomycin
therapy, and (4) had serum creatinine level collected within 7−14 days
from the initiation of vancomycin therapy. Patients were excluded if they
(1) had a diagnosis of infective endocarditis, (2) received hemodialysis
or peritoneal dialysis during the vancomycin therapy, or (3) received
vancomycin before the ﬁrst MRSA bacteremia episode. Clinical response
was assessed by the eradication of MRSA bacteremia within 7−14 days
from the initiation of vancomycin therapy or the time required for the
resolution of fever. Nephrotoxicity was deﬁned as an increase in serum
creatinine level of 0.5mg/dL or 50% from baseline. Patients was
classiﬁed according to the trough serum vancomycin level; <15mg/L,
15−20mg/L and >20mg/L.
Results: During the study period, 200 patients had MRSA bacteremia
and 73 patients were included in this study according to the study
protocol. Among 73 patients, 37 (50.7%) had trough serum vancomycin
concentration of <15mg/L, 19 (26.0%) had trough concentration of
15−20mg/L, and 17 (23.3%) had trough concentration of >20mg/L.
MRSA eradication rate was not different between the three groups:
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88.5%, 93.8% and 90.9%. Fever duration was not different between the
three groups: 8.0±6.2 days, 8.32±9.3 days and 6.0±8.1 days. Incidence
of nephrotoxicity was signiﬁcantly higher in the group with trough
concentration of >20mg/L among the three groups: 8.1%, 10.5% and
35.3% (p = 0.015).
Conclusions: The current study revealed that trough serum vancomycin
concentration of 15−20mg/L did not improve clinical response for
MRSA bacteremia. However, the incidence of nephrotoxicity was not
increased compared to the lower trough serum concentration.
P1291 Superinfection during the treatment of nosocomial infection
with tigecycline
M.E. Jime´nez-Mejias, E. Garcı´a-Cabrera, C. Martı´n-Gandul*,
M.J. Go´mez-Go´mez, M. Ruiz-Perez de Piapao´n, M.V. Gil-Navarro,
E.R. Alfaro-Lara on behalf of the Spanish Network for Research in
Infectious Disease
Introduction: Tigecycline is a antibiotic active against Gram positive,
Gram negative included multirestistant drugs agents. Proteae genera
present low sensible and Pseudomonas aeruginosa is inherently resistant.
In large FIII, clinical trials the superinfection rate of tigecycline is 6.7%
but are not speciﬁed focus or aetiology. We observed that superinfection
rates of P. aeruginosa during the treatment with tigecycline is higher
that the previously described (EJCMID 2010 Jul; 29(7): 867−71.).
Objective: The aim of this study was to evaluate the superinfection
rates and colonization including by P. aeruginosa, during tigecycline
treatment, along the time.
Methods: We performed an observational study retrospective (Novem-
ber 1st, 2007 − October 31th, 2008) and prospectively (November 1st
2008 − October 31th 2010) of all adult patients, who received at least 72
hours tigecycline as the treatment for nosocomial infections. All patients
received 100mg of tigecycline as the loading dose, followed by 50mg
every 12 h. The duration of treatments was a decision of the physicians
in charge of the patients and was related to the clinical conditions. In
each patient, we analyzed all cultures made until hospital discharge or
death. Patients without follow up cultures during or after tigecycline
treatment and those with prior or concomitant isolation of P. aeruginosa
at the beginning of the treatment were excluded.
Results: We included 130 patients, 51 (39%) retrospectively and 79
(61%) prospectively. Median of days of treatment with tigecycline was
13 days (9; 20.5) (p25; p75). In the ﬁrst period the time the superinfection
rate 12/51 (23.5%), seven of them (58%) due to P. aeruginosa and the
ﬁve resting were Enterobacter cloacae, Morganella morganii, Proteus
mirabilis, Providencia stuartii and Enterococcus faecalis. In the second
period the superinfection rate was 18/79 (22.7%), nine of them 9 (50%)
due to P. aeruginosa and ﬁve due to Proteus mirabilis, three due to
Morganella morganii, and one due to Enterococcus faecalis.
Conclusion: The superinfection rate during treatment with tigecycline
may be higher than previously reported, and consistent along the time.
Considering the potential risk of infection with P. aeruginosa and other
resistant bacteria, a tight surveillance in the follow up of patients treated
with tigecycline must be performed in order to disregard or conﬁrm this
potential risk.
P1292 Clinical and economic impact of rapid microbiological
information of the samples more frequently processed in
the Department of Clinical Microbiology
A. Galar*, J. Leiva, M. Espinosa, F. Guille´n-Grima, J.R. Yuste
(Pamplona, ES)
Objectives: Up to 50% of the antibiotic prescriptions in hospitals are
considered inappropriate. Antibiotics can represent up to 30% of hospital
pharmacy expenses. The aim of this study was to measure the clinical and
economic impact of rapid microbiological information of the samples
more frequently processed in the Department of Clinical Microbiology.
Methods: 574 hospitalized patients with a bacterial infection conﬁrmed
by culture were assigned to a control group (n = 284; results information
in the following day of their obtaining) or an intervention group (n = 290;
results information in the same day of their obtaining). Vitek® 2 system
(bioMe´rieux) was used for identiﬁcation and susceptibility testing in both
groups. Outcome parameters were length of hospital stay (conventional
hospitalization unit, intensive care unit) and mortality rates (global,
attributable to infection). Treatment recommendations were made by an
infectious diseases physician. Direct ﬁxed costs, direct variable costs
and indirect costs during hospitalization were considered. Costs related
to tests, Laboratory, Microbiology, Pharmacy, hospital stay and “other
costs” (blood bank, anesthesia, clinical assistance, operating room) were
calculated.
Results: The samples more frequently processed were wound and
abscess cultures, blood cultures and genitourinary tract samples cultures.
Baseline characteristics of the patient groups in each study period based
on the McCabe-Jackson criteria (severity of underlying illness) and on
the Charlson score (comorbidity index) were similar. Faster reporting of
identiﬁcation and antimicrobial susceptibility results (p< 0.001) led to
a signiﬁcant reduction in the length of hospitalization for those patients
in which wound and abscess samples (p = 0.014) and genitourinary
tract samples (p = 0.039) were analyzed. Mortality rates did not differ
signiﬁcantly between the two groups. Global costs in the intervention
group were lower than in the control group for those patients in which
wound and abscess samples (p = 0.003) and genitourinary tract samples
(p = 0.038) were analyzed.
Conclusions: Rapid microbiological information was associated with a
signiﬁcant reduction in length of hospital stay and in global costs for
those patients in which wound and abscess samples and genitourinary
tract samples were analyzed. However, identiﬁcation and antimicrobial
susceptibility results of blood culture isolates did not lead to signiﬁcant
clinical and ﬁnancial beneﬁts.
P1293 Forgotten antibiotics: an inventory in Europe, US, Canada
and Australia
C. Pulcini*, K. Bush, W. Craig, N. Frimodt-Mo¨ller, L. Grayson,
J. Mouton, J. Turnidge, S. Harbarth, I. Gyssens on behalf of the
ESCMID Study Group on Antibiotic Policies (ESGAP)
Objectives: In view of the alarming spread of bacterial resistance
in the absence of new antibiotics, this study aimed at collecting
structural, reliable information on the availability of potentially useful
but sometimes old antibiotics.
Methods: A survey on the availability of antibiotics was performed
among hospital pharmacists, microbiologists or infectious diseases
specialists in Europe, the US, Canada and Australia. Systemic
antibacterial drugs (ATC code J01) were selected from the textbook
“Kucers: The use of antibiotics” by an international expert panel. The
experts assessed (potential) activity on resistant microorganisms and/or
narrow spectrum “niche” characteristics for these antibiotics, handling
deﬁned criteria.
Results: The experts identiﬁed 33 valuable antibiotics, 13 because of
their potential activity on resistant Gram negative bacteria and 8 on the
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basis of their narrow spectrum. Availability data were obtained for the
US, Canada, Australia and 27 European countries (Figure 1). The number
of antibiotics available and the way they were available (marketed or via
a special system) differed considerably from one country to another.
Twenty out of the 33 selected antibiotics were available in less than 15
countries. Economic motives are the major cause for (discontinuation
of) marketing of these antibiotics.
Conclusion: Many potentially useful antibiotics, usually low cost and
marketed as generics, are not available in all countries. This is a
worrisome situation, taking into account the current worldwide bacterial
resistance crisis. Measures to improve the availability of these antibiotics
are needed on a global scale.
P1294 Getting acquainted with aztreonam: a six-month audit of
use in a tertiary referral hospital
K. Burns, S. Foley*, F. Fitzpatrick, E. Smyth (Dublin, IE)
Objectives: An outbreak of Clostridium difﬁcile infection occurred in
this hospital during summer 2008. A ﬂuoroquinolone-ban was introduced
as one of the outbreak control measures. The non-availability of
ﬂuoroquinolones led the clinical microbiology team to use alternative
agents, including aztreonam. In Ireland, aztreonam accounted for just
0.1% of total antimicrobial use in 2008 (0.08 deﬁned daily doses/100
bed days used. An audit was carried out to determine the appropriateness
of aztreonam prescription for patients treated between January and
June 2009 and to correlate its use with microbiology results, patient
characteristics and outcomes.
Methods: Following the ﬂuoroquinolone ban, aztreonam was prescribed
on the advice of the clinical microbiology team and a record kept of
patient details; indication for aztreonam prescription; use as monotherapy
or in combination with other therapy; microbiology results and patient
outcomes.
Results: From January to June 2009, aztreonam was administered to 77
patients (40 male). Mean patient age was 64 years (range 14−89 years);
26 patients were admitted to the intensive care unit. Aztreonam was
prescribed for 41 medical and 36 surgical patients for the treatment of:
• Pneumonia (20 patients)
• Wound/soft tissue infection (15 patients)
• Urinary tract infection (15 patients)
• Intra-abdominal infection (12 patients)
• Bacteraemia (10 patients)
• Infection of uncertain source (5 patients)
For 23 patients, aztreonam was used as monotherapy and for the
remaining 54, it was given in combination with other agent(s). Mean
duration of therapy was 8 days (range 1 to 42 days). Positive
microbiology results were recorded for 59 patients. Ninety-six percent
of Gram-negative organisms isolated were susceptible to aztreonam,
44.8% exhibited reduced susceptibility or resistance to piperacillin/
tazobactam and 14% were resistant to ﬂuorquinolones. Extended
spectrum b-lactamase producing Gram-negative organisms were detected
on two occasions necessitating discontinuation of aztreonam. One
patient developed C. difﬁcile infection whilst on combination therapy of
aztreonam and clindamycin. Sixty-two patients recovered from infection,
12 died (7 admitted to ICU) and for 3 patients, the outcome was
unknown. The average length of stay was 51 days.
Conclusion: Aztreonam is a safe and useful alternative to ﬂuoro-
quinolones for the treatment of a variety of infections due to Gram-
negative organisms.
P1295 Drug content, powder characterisation and particulate
matter contamination in imipenem/cilastatin powder for
injections from Asia region
J. Konsil*, S. Supattanapong, O. Apirakkan (Khon Kaen, TH)
Introduction: The report of clinical inferiority of generic imipenem/
cilastatin (IC) injection, compared to the original one, was recently
reported in Thailand. Due to extremely hygroscopic property of cilastatin
sodium and highly agglomerated powder of imipenem monohydrate,
the manufacturing process of these products is usually not simple.
Most of generic IC products in Asia region are provided by the same
manufacturing sources.
Objectives: Samples of IC powder for injection were collected
from China, India, Japan, Taiwan, and Thailand for drug content
analysis, powder characterization and investigation of particulate matter
contamination.
Methods: This was a double blinding study. Powder characterization of
IC was investigated using scanning electron microscope (SEM). Two
laboratory methods were applied to investigate the contamination of
particulate matter after reconstitution, i.e. microscopic and electrical
sensing zone methods. The contents of imipenem and cilastatin were
measured simultaneously using newly developed HPLC technique.
Results: There were eight IC powders for injections, collected during
June 2009 to December 2010. Most of IC products were manufactured
by dry mixing of crystalline imipenem, amorphous cilastatin sodium
and sodium bicarbonate powder. The original imipenem powder was
prepared differently by spray drying process resulting in minimal degree
of agglomeration and more complete reconstitution. The particles burden
found under SEM were undissolved drug/excipient particles as well as
materials from the containers and stoppers. The numbers of particles in
all samples with sizes 25 and 10 micron were within the acceptable
range according to pharmacopoeia standard, with signiﬁcantly lower
numbers of particles found in the original samples. The contents of
imipenem and cilastatin in the original samples were also higher than
those of the others. The difference in drug contents between generic and
original samples was up to 14% for imipenem and 17% for cilastatin,
respectively. The particle burden trapped on the membranes under SEM
also reﬂected the heavy load of contamination in some of generic brands
which also had the low contents of the active drugs.
Conclusion: The commercially available products of IC in Asia region
were different in the contents of active drugs and the contamination of
particulate matter. These differences possibly lead to inferior clinical
safety and efﬁcacy of generic IC, as reported earlier.
P1296 Multiple-dose pharmacokinetics of anidulafungin during
continuous veno-venous haemoﬁltration
J. Leitner* (Vienna, AT)
Objective: Clinical studies support a role of anidulafungin as a ﬁrst-
line treatment of invasive candidiasis in critically ill patients and
postulate no need of dose adjustments in mild to severe renal failure.
Although intensive care patients with organ failure are in particular
at risk of invasive fungal infections, no pharmacokinetic (PK) data
on anidulafungin in continuous renal replacement therapy is available.
Therefore we wanted to study the PK of anidulafungin in critically ill
patients with venovenous haemoﬁltration (CVVHF).
Methods: Ten critically ill patients with CVVHF due to acute renal
failure were included. Anidulafungin was infused on 3 consecutive
days starting with a loading dose of 200mg on day 1, followed by
doses of 100mg on days 2 and 3, respectively. During the 72h study
phase of CVVHF, blood and ultraﬁltrate samples were collected at
corresponding times and anidulafungin concentrations were determined
by high-pressure liquid chromatography (HPLC).
Results: Peak plasma concentrations were reached 3h after the start
of infusion and were 8.5±3.6mg/ml at the pre-ﬁlter port. The mean
arterial area under the curve (AUC) of the study population was 109.9 +
49.82, the total clearance was 1.08±0.41 L/h, the volume of distribution
41.97±22.64L and the elimination half-live 28.78±10.40h. Trough levels
were above previously published minimal inhibitory concentrations
(MIC90) of anidulafungin for relevant pathogens. Anidulafungin was not
ﬁltrated, but CVVHF resulted in a substance loss reﬂected by a difference
between venous and arterial AUC of about 20%, due to adherence to
synthetic surfaces.
Conclusion: Pharmacokinetics of anidulafungin in CVVHF resembled
ﬁndings in healthy adults and adults with fungal infections. Therefore
we recommend a loading dose of 200mg intravenous anidulafungin on
the ﬁrst treatment day and 100mg on consecutive days in anuric patients
during CVVHF.
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P1297 A 3-year survey of antifungal therapy results in febrile
neutropenic patients with haematological malignancies: an
analysis of 335 febrile episodes
F. Aksoy*, I. Koksal, G. Yilmaz, K. Aydin (Trabzon, TR)
Objectives: One of the reasons for the continuing high mortality
rates due to invasive fungal infection is the delay in administering
appropriate therapy in febrile neutropenic patients with hematological
malignancy. Empirical antifungal therapy is the standard form of care
for neutropenic patients with hematologic malignancies who remain
febrile despite broad-spectrum antibacterial treatment. However, targeted
and pre-emptive antifungal therapy is a more effective strategy in the
treatment of fungal infections.
Our aim in this study was to evaluate antifungal treatment in febrile
neutropenic patients with hematological malignancies in our university
hospital.
Methods: 335 febrile neutropenic episodes in 170 patients with
hematological malignancies monitored between October 2005 and
October 2008 at an university hospital in Turkey were included in the
study, which evaluated the antifungal treatments administered.
Results: The average time for the onset of antifungal treatment
for all antifungals was 7.0±4.6 days. Classical amphotericin B
(CAMB) (6.8%), liposomal amphotericin B (LAMB) (9.6%), caspo-
fungin (CASP) (38.2%) and voriconazole (VOR) (17.6%) were used
in antifungal treatment. Mean time to bring fever under control with
antifungal therapy modiﬁcation was 4.4±5.1 days. Duration of antifungal
therapy was 15.2±0.9 days during hospitalization. Nephrotoxicity,
hepatotoxicity, allergic reaction, electrolyte imbalance, polyneuropathy
and hallucination were determined as antifungal treatment-associated
side effects. Side effects were most frequently observed in patients using
CAMB, at a level of 44%. The most common CAMB-associated side
effects were nephrotoxicity and electrolyte imbalance, while polyneu-
ropathy was a signiﬁcant side effect in patients using VOR. Analysis
of antifungal treatments in terms of mortality determined no signiﬁcant
ﬁndings. Analysis of antifungal treatments is shown in the table.
Conclusion: Despite new antifungal treatments, invasive fungal infection
mortality is still high. Deﬁnition of fungal infections and treatment being
directed toward a likely agent/cause or target will enable spending on
antifungal treatment to be used effectively, as well as enhancing treatment
success. Bearing in mind the toxic side effects of other chemotherapeutic
drugs used by patients with malignities, there is a need for antifungal
agents with greater target efﬁcacy in the treatment of fungal infections
and with less toxicity.
P1298 Early antibiotic use during pregnancy changes the vaginal
microﬂora near time of birth
J. Stokholm*, S. Schjørring, L. Pedersen, A.L. Bischoff, N. Følsgaard,
C. Giwercman, B. Chawes, K. Bønnelykke, A. Mølgaard, J.S. Jensen,
K. Krogfelt, H. Bisgaard (Gentofte, Copenhagen, DK)
Objectives: Antibiotics are widely used through pregnancy, mainly to
treat symptoms of urinary tract infections. Symptoms of UTI are very
common among pregnant women, however only a small percentage do
have bacteriuria within the group complaining about typical symptoms of
UTI. Antibiotics are also administered during birth either prophylactic or
because of symptoms. It is known, that antibiotic treatment can eliminate
pathogenic bacteria causing disease, but it does also inﬂuence the normal
colonisation. The aim of this study was to analyse the effect of antibiotic
use during pregnancy on the vaginal colonisation near the time of birth.
Methods: The novel Copenhagen Prospective Study on Asthma in
Childhood (COPSAC2010) prospective unselected birth cohort is an
ongoing study of 700 pregnant women and their children. Vaginal
samples from the pregnant women are characterised by culture at
gestational week 36 and detailed information on antibiotic use during
pregnancy is collected prospectively from participants and double
checked in national registers.
Results: To date 485 vaginal samples have been cultured. 144 of the
485 women included in the study had received antibiotics during their
pregnancy in a total of 255 treatments. Antibiotic treatment at any point
during pregnancy was associated with a decrease in number of different
species colonising the vagina. Antibiotic treatment resulted in detection
of fewer species in the vaginal samples compared to those from women
that did not receive antibiotic treatment.
Conclusion: A change of bacterial diversity was found in the vaginal
microﬂora of the pregnant women, who received antibiotics during
pregnancy. This change is not only observed in the weeks immediately
after antibiotic administration as expected, but remains throughout
pregnancy even though treatment was given as early as the ﬁrst trimester.
Thus, vaginal colonisation seems to be affected more deﬁnitely than
expected, even at early treatments.
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P1299 Nanosensors for antibiotic discovery and therapeutic drug
monitoring in real time
J. Ndieyira*, N. Kappeler, S. Logan, R. McKendry, G. Aeppli (London,
UK)
Today the emergence of new infections and the re-emergence of
old enemies, including methicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant enterococcus (VRE) is a major
global healthcare problem. The frequent use of antimicrobial agents
in developing countries where they are readily available without
prescription and failure to complete treatment courses have escalated
development of resistance to antibiotics. Faced with shortages of new
antibiotics in the drug pipeline, prudent use of current antibiotics is
necessary to curb the incorrect usage of antibiotics which has contributed
to the fuelling of anti-microbial drug resistance. Alternative approach is
to focus on precise dosing by employing novel technologies to optimise
drug therapy for better disease management.
Here we report the development of a new point-of-care (POC)
nanosensor, which in combination with a new model, can be used to
probe in real time, the concentrations of active “free drug” circulating
in serum as well as directly quantify the drug-target interactions at
the receptor site. Using model bacterial cell wall peptides terminating
in Lysine D-Alanine D-Alanine (DAla) on the cantilever surface and
antibiotics incubated with serum, the surface drug-mucopeptide and
solution drug-serum interactions were simultaneously quantiﬁed in near-
physiological conditions. Thereby, the effect of serum binding on the
antibiotic activity is determined, allowing precise tuning by adjusting
the antibiotic doses to optimize antimicrobial activity and monitor
drug resistance. 1 These ﬁndings provide a new paradigm for POC
applications in personalised medicine and drug discovery process.
P1299a Evidence-based recommendations for antibiotic usage in
the intensive care unit: a systematic review
G. De Angelis*, G. Restuccia, F. Di Muzio, M. Cipriani, E. Milozzi,
R. Cauda, M. Antonelli, E. Tacconelli (Rome, IT)
Objective: Inappropriate antibiotic use is associated with increased
patients morbidity and mortality. Building and implementing strategies
to reduce the inappropriate use of antibiotics, especially in ICU patients,
is of crucial importance. A systematic review was performed to identify
evidence based-recommendations and tested tools to drive antibiotic use
in ICU setting.
Methods: We searched MEDLINE and COCHRANE databases up
to July 2010. No restriction of language was applied. National and
international guidelines (GLs), randomised (RCTs) and non randomised
controlled trials (CCTs), systematic reviews (SRs) and controlled before–
after studies (CBAs) were included.
Results: Overall 937 potentially relevant studies identiﬁed, 11 (4 in-
ternational GLs, 1 Spanish GL, 3 RCTs, and 3 SRs) were included.
All GLs were published between 2006 and 2008. All the following
recommendations were classiﬁed as “strong” (see Table): performing cul-
tures (2 blood cultures and 1 from each vascular access) before starting
antibiotics; starting antibiotic as soon as possible (within 1 hour for septic
shock); using empirical antibiotic therapy covering likely pathogen with
good penetration into presumed source; establishing the site of infection
within 6 hours from presentation; evaluating patients for a focus of
infection amenable to source control measures; discontinuing therapy
if diagnostic tests are negative; removing vascular catheter if potential
infected; reassessing therapy daily and performing chest X ray, if patient
is ventilated. Surprisingly, the level of evidence those recommendations
rely on was low or very low (9/12) or moderate (3/12). All RCTs
and SRs focused on the diagnostic power and the efﬁcacy of serum
procalcitonin (PCT) to drive decisions concerning antibiotic therapy.
However, no GL included the use of PCT among their recommendations.
SRs showed that PCT was superior to C reactive protein in testing accu-
racy. RCTs observed a signiﬁcant decrease of the duration of antibiotic
therapy in hospitalised patients after introducing determination of PCT.
Conclusions: Evidence-based recommendations for appropriate anti-
biotic use in ICU patients rely on a very low quality evidence. Public
health ofﬁcers should be aware, when designing intervention strategies,
of the level of the evidence provided by the scientiﬁc literature for
antibiotic usage in the ICU population.
Recommendation Evidence Strength
Perform cultures before starting antibiotics low strong
2 blood cultures, 1 from each vascular access low strong
Starting antibiotics as soon as possible moderate strong
Starting antibiotics within 1 hour for septic shock moderate strong
Initial empirical antibiotic therapy should cover likely pathogen with good penetration into presumed source moderate strong
Anatomic site of infection established as rapidly as possible very low strong
Anatomic site of infection established within 6 h of presentation very low strong
Evaluate patients for a focus of infection amenable to source control measures low strong
Combination empiric therapy in neutropenic patients very low weak
De-escalation therapy as soon as cultures are available very low weak
Discontinuation of therapy if diagnostic tests negative very low strong
Remove vascular catheter if potential infected low strong
Reassess AT daily to reduce toxicity low strong
Chest X ray if patient is ventilated low strong
Use of PCT for diagnosis of infection SRs Not evaluated
Use of PCT to guide duration of antibiotic therapy RCTs Not evaluated
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P1300 Results from the 2010 antimicrobial susceptibility
testing external quality assessment exercise organised for
EARS-Net participants
N. Patel*, C. Walton, A. Laja, C. Gagliotti, O. Heurer, D. Brown,
V. James (London, UK; Bologna, IT; Stockholm, SE; Peterborough, UK)
Objectives: The United Kingdom National External Quality Assessment
Service for Microbiology (NEQAS) provides external quality assessment
for antimicrobial susceptibility testing to the EARS-Net (formerly
EARSS) participants. In 2010 the annual EQA exercise was the
ﬁrst distribution in collaboration with European Centre for Disease
Prevention and Control (ECDC) but the ninth in succession to EARS-Net
laboratories.
Methods: An analysis was carried out on the performance of participants
in the quality assessment exercise. Participation was invited from 872
laboratories in 30 countries and results were returned by 769 laboratories.
The organisms distributed were one each of Klebsiella pneumoniae,
Escherichia coli, Streptococcus pneumoniae, Enterococcus faecium,
Pseudomonas aeruginosa and Staphylococcus aureus. Participants’
results for identiﬁcation and susceptibility testing were assessed.
Results: The level of performance with these quality assessment
specimens was generally high; with concordance with the intended
results over 95% for most organism-antibiotic combinations. For
the K. pneumoniae, (plasmid mediated AmpC) participant reporting
of susceptibility to cephalosporins was more variable (cefotaxime
susceptible (S) 20.1%, intermediate (I) 18.5%, resistant (R) 61.4%;
ceftriaxone S 16.1%, I 24.6%, R 59.3%; ceftazidime S 2.8%, I
22.9%, R 74.3%); the piperacillin-tazobactam discrepancy rate was also
higher. The E. coli was borderline in susceptibility to amikacin (MIC
8−16mg/L) and results were variable (51.4% S, 31.7% I, 16.9% R).
The E. faecium had vanA-mediated low-level teicoplanin resistance
(MIC 8mg/L) and results were more variable among those using CLSI
guidelines than those following EUCAST guidelines. The P. aeruginosa
was borderline in susceptibility to piperacillin-tazobactam and again
more variability in reporting was seen among CLSI users. There were no
signiﬁcant problems with the S. pneumoniae (penicillin S, ciproﬂoxacin
R, erythromycin R) or the S. aureus (ST 239, multi-resistant).
Conclusion: EQA is a valuable tool in the quality assurance of an-
timicrobial susceptibility testing and indicates the validity of comparing
collated data between laboratories in resistance surveillance studies. In
this exercise concordance between participating laboratories was high
except where there was borderline susceptibility or where different
breakpoints in the guidelines were used, resulting in discrepancies in
susceptibility test results.
P1301 Ten years of SARI (Surveillance of Antimicrobial Use and
Antimicrobial Resistance in German Intensive Care Units);
2001–2010
E. Meyer*, F. Schwab, P. Gastmeier (Berlin, DE)
Objectives: To analyse data of SARI (Surveillance of Antimicrobial Use
and Antimicrobial Resistance in Intensive Care Units from 2001–2010
and to look for temporal changes.
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Methods: Prospective unit and laboratory based surveillance in German
ICUs from 2001–2010. The data were calculated on proportions of non-
duplicate resistant isolates (RP), resistance densities (RD; i.e. the number
of resistant isolates of a species per 1000 patient days) of a total 55
ICUs and antimicrobial usage density (AD) expressed as daily deﬁned
doses (DDD) and normalised per 1000 patient-days (pd) of a total of
75 ICUs. Linear trends were calculated using linear regression analysis
with monthly data and c2-trend test for resistance rates with yearly data.
Results: Total mean antibiotic use (without sulbactam) stayed stable over
time. AD was 1180 in 2001 and 1238 in 2010. Carbapenem use more
than doubled to an AD of 176 in 2010. Signiﬁcant increased were also
calculated for quinolones (AD of 169 in 2010 which equals 14% of total
antibiotic use) and 3rd and 4th generation cephalosporin (3 and 4GC)
use (AD of 121 in 2010) and macrolides (AD 105 in 2010). The most
prominent decrease faced aminoglycoside use (AD was 86 in 2001 and
28 in 2010).
RRs were as follows in 2001 and 2010: MRSA 26 and 23%, VRE
faecium 2.3 and 5.1%, 3GC resistant E. coli 1.2, 11.9% and 3GC
resistant K. pneumoniae 3.8 and 18.2%.
The burden of resistance or the RDs did not change for MRSA
but increased signiﬁcantly for VRE and 3GC resistant E. coli and
K. pneumoniae. RD of MRSA was 4.2 in 2010, of VRE faecium 0.26
and of 3GC resistant E. coli 1.64 and K. pneumoniae 1.07 resistant
pathogens/1000 pd.
Conclusion: Total antibiotic use did not change over time with 1.2 DDD
per patient per ICU day. However, there was a signiﬁcant increase in
the use of broad spectrum antibiotics like carbapenems. The burden of
MRSA did not change in contrast to an increase in the burden of 3GCR
E. coli and K. pneumoniae in German ICUs. In the face of resistant
pathogens we prefer to describe and compare the burden of resistance
and the magnitude of the public health problem by resistance densities
besides resistance proportions which are essential for empiric antibiotic
therapy decisions.
P1302 ISIS-AR and ISISweb: a new surveillance system for
antimicrobial resistance surveillance
N. van de Sande-Bruinsma*, M. Leverstein-van Hall, E. Boel, G. Ruijs,
J. Alblas, S. Thijsen on behalf of ISIS-AR participants
Objectives: With the increasing antimicrobial resistance rates, surveil-
lance is an essential tool to monitor trends, rapidly detect and
actively react to new resistance elevations, evaluate policies and
compare laboratory results for quality improvement. For this purpose,
the Dutch Infectious Diseases Surveillance Information System on
Antibiotic Resistance (ISIS-AR) and the interactive database ISISweb
were developed. This paper gives a summary of the achievements and
possibilities of this new surveillance system.
Methods: From 2008 onwards, ISIS-AR has connected 27 medical
microbiology laboratories to a central database, where antimicrobial
susceptibility test (AST) results and epidemiological data from 40
routinely cultured bacterial species are uploaded monthly. Data undergo
thorough quality control and automated feedback reports including an
overview of EUCAST exceptional resistance phenotypes are send to the
laboratories for conﬁrmation. After conﬁrmation, data from ISIS-AR
are freely accessible via a query interface at www.ISIS-web.nl, a joint
venture of the Dutch Society of Medical Microbiology (NVMM) and
the National Institute for Public Health and the Environment (RIVM).
Results: Professionals and policymakers can view the national resistance
trends via ISISweb and data can be used in clinical patient care. For
example the prevalence of ESBL in E. coli blood isolates increased
from 2.3% in 2008 (n = 1943) to 3.6% in 2010 (n = 996, until June,
p< 0.05) and the prevalence of MRSA remained stable around 1%. The
system has also proven successful in the detection of several cases of
carbapenemase producing Enterobacteriaceae (CPE) in the Netherlands.
As a spin-off, national ESBL and concept CPE guidelines have been
developed for laboratory detection and infection control purposes.
On ISISweb, data can also be viewed and compared by institution
type, hospital department and age groups (ao). For example, in 2009
the proportion of ciproﬂoxacin resistance from E. coli urine isolates
collected in hospitals (11.1%, n = 10,834), outpatient departments
(14.9%, n = 10,587) and GPs (8.3% n= 34,660) differed substantially.
Furthermore, participating laboratories can compare their results to those
of their peers on a closed domain.
Conclusions: In the 3 years existence, ISIS-AR has proven very
successful, which was largely due to the joined efforts of RIVM,
NVMM and all participating laboratories. This national framework can
be extended to include other pathogens.
P1303 Antimicrobial resistance surveillance for hospital- and
community-acquired strains from southwestern Romania
M. Licker*, L. Baditoiu, D. Muntean, R. Zugravu, L. Dragomirescu,
F. Horhat, C. Pilut, E. Hogea, P. Deutsch, C. Macarie, M. Radulescu,
R. Moldovan (Timisoara, RO)
Objectives: It is a preliminary study, part of the PNCDII 42121/2008
national research project, aiming the screening of bacterial strains
isolated from intensive care units (ICUs), surgical departments and also
from the community (Timis county, Romania), with the selection and
preservation of multidrug resistant (MDR) strains for future molecular
studies, scheduled in the next stages of the project.
Methods: The participant laboratories (Emergency Clinical County
Hospital Laboratory − P1, Institute of Cardiovascular Diseases
Laboratory − P2 and S.C.Bioclinica S.A. Laboratory − P3), transferred
the MDR selected strains (collected from bronchial aspirates, blood
samples, urines, surgical wound secretions, etc), for conﬁrmation, to the
University Microbiology Department’s Laboratory. These strains have
been reidentiﬁed and phenotyped, with the help of automatic VITEK 2
compact system, using VITEK 2 GP/GN identiﬁcation cards and AST
cards for antimicrobial sensitivity tests. We have also performed Hodge
tests for extended spectrum b-lactamase (ESBL) producing carbapenem
resistant enterobacteria.
Results: From 2437 samples, collected in 2010, we isolated 842
MDR strains (607 from hospitals and 235 from the community). The
percentage of Methicillin-resistant S. aureus strains (MRSA) varied
from 35.44% (P1) to 8% (P2) in hospital environment, being 23.13%
in the community (P3). Regarding hospital acquired ESBL producing
enterobacteria, their prevalence was situated between 37.32% (P1) and
16.67% (P2), with 11.97% for the community (P3). The area of MDR
percentage in the case of carbapenem-resistant non-fermentative strains,
varied from 43.94% (P1) to 11.11% (P2) in hospitals, respectively,
14.70% in the community. All the Hodge tests were negative. Also,
as a part of the project, both ICUs have estimated an average number
of antimicrobial treatment days/MDR infectious episode, which varied
from 9.11days (P1) to 29.57days (P2), with an average hospitalisation
cost of 3657.35 E/patient (P1) and 3780.87 E/patient (P2).
Conclusions: Bacterial MDR it is more frequently described not only
in Romanian hospitals but in our community as well, representing an
alarming phenomenon through the drastically restriction of therapeutic
options. However, in comparison with 2009 (the ﬁrst year of our research
project), we assist to a slow decreasing of MDR prevalence in both
studied hospitals with aproximatively the same prevalence in community.
P1304 Japan Nosocomial Surveillance System (JANIS), a national
surveillance system of antimicrobial resistance and
nosocomial infections in Japan
S. Suzuki*, K. Yamane, A. Tsutsui, T. Yamagishi, Y. Arakawa (Tokyo, JP)
Objectives: A surveillance system for antimicrobial resistance is crucial
to provide information for implementing control measures to limit the
spread of antimicrobial resistant bacteria.
Methods: Japan Nosocomial Infections Surveillance (JANIS) was
launched as a program of Ministry of Health Welfare and Labour of
Japan in 2000 followed by system renewal in 2007 to provide practical
and useful information for infection control practices in hospitals. It
includes hospital with more than 200 beds with voluntary participation. It
consists of ﬁve different divisions and Antimicrobial Resistant Bacterial
S360 21st ECCMID/27th ICC, Posters
Infections (ARBI) division was assigned to monitor all patients with
infections due to ﬁve major types of drug-resistant bacteria, while
Clinical Laboratory (CL) division describes prevalence of major bacterial
species among clinical isolates including antimicrobial susceptibility
data.
Results: Up to January 2011, there are 504 participating hospitals
in ARBI division and 681 in CL division, which covers about 1/4
to 1/3 of target hospitals in Japan. Data submission rate of those
participating hospitals are around 90% and detailed feedback information
for participating hospitals and the summary of JANIS data which is open
to the public are both available thorough website.
Methicillin-resistant Staphylococcus aureus (MRSA) is still the leading
cause of nosocomial infections in Japanese hospitals. In 2009, among
17065 cases reported to JANIS ARBI division, 15093 (88%) were
caused by MRSA and its incidence was 5.3cases/1000 admissions. On
the other hand, infection caused by Vancomycin-resistant enterococci is
still rare as only ﬁve cases were reported in 2009. Most remarkable
change notiﬁed by CL division during the last decade is the increasing
antimicrobial resistance in Escherichia coli. In 2001, only 0.6% of E. coli
isolates were resistant to cefotaxime but it reached up to 10% in 2009.
Fluoroquinolone resistance also increased dramatically as 9% of E. coli
isolates were resistant in 2001 but went up to 27% in 2009. Resistance
in Klebsiella pneumoniae increased gradually but not as signiﬁcant as
E. coli. Unlike European countries and United States, multidrug-resistant
Acinetobacter spp. isolates are quite rare and its prevalence is less than
0.5% among Acinetobacter spp. isolates.
Conclusion: JANIS has been established as a national surveillance sys-
tem and provides useful epidemiological information of antimicrobial-
resistant bacteria in Japan.
P1305 National antimicrobial resistance alerts − an early warning
and quality assurance system
A.T. Eastaway*, J. Wilson, P. Webb, C. Wiuff (Glasgow, UK)
Objectives: To develop and test an alert system at national level for
rare organism/antimicrobial resistance (AMR) combinations ensuring
early identiﬁcation, conﬁrmation and reporting of emerging problems
to enhance the national AMR surveillance programme.
Methods: Laboratories in Scotland use CLSI sensitivity testing and
report results via the Electronic Communication of Surveillance
Scotland (ECOSS) from the Laboratory Information System directly
to Health Protection Scotland (HPS) in line with ECOSS reporting
protocols. Speciﬁc rare organism/antibiotic resistance patterns were
deﬁned. A weekly automated search was run against ECOSS records
which ﬂagged organisms matching these combinations. An alert was
automatically generated for the AMR surveillance team at HPS. Two
alerts were piloted, penicillin resistance in b-haemolytic streptococci
and carbapenem resistance in E. coli and Klebsiella species. The AMR
team followed up all alerts. Where results were conﬁrmed the laboratory
was requested to forward to the appropriate reference laboratory for
further investigations. If not conﬁrmed the ECOSS record was altered
accordingly.
Results: The system has been tested over 9 months. To date there
have been seven reports of b-haemolytic streptococci resistant to
penicillin. None were conﬁrmed on follow up. The HPS database in
ECOSS was amended accordingly. Nine reports of Meropenem resistance
in Klebsiella pneumoniae have been received. Three of these were
conﬁrmed. Two were identiﬁed as possessing a CTX-M and permeability
defect and one was conﬁrmed as a KPC producing strain. Early
awareness at a National level allowed a prompt alert to be sent to
all infection control teams and Microbiologists of possible circulating
strains.
Conclusion: A national surveillance programme can detect uncommon
resistance mechanisms in key organisms using an automated alert
system. This allows timeous follow up ensuring appropriate action by
the referring laboratory where resistance is conﬁrmed, early warnings
to other laboratories and as a quality assurance measure to ensure the
national dataset is as robust as possible.
P1306 Real-time local epidemiological data through the internet
as a management tool for infections in the community
G.S. Simonsen*, T. Chomutare, L. Ilebrekke, P.A. Bakkevoll,
A. Sjøveian, J.G. Bellika (Tromsø, NO)
Objectives: To provide real-time epidemiological data on infectious
diseases through the internet as a management tool for general
practitioners and infection control personnel in the community. Increase
the knowledge of pre-test probability of various infectious agents in order
to optimize diagnostic strategies and treatment.
Methods: The Snow system extracts, classiﬁes and summarizes data
from microbiology production environments. The summarized data are
transferred to a server on the internet every night and communicated to
the users using web based spatiotemporal visualization. Simple heuristics
is used to detect and provide alerts of unusual disease events in the
patient populations.
Results: The Snow system is an open source software tool for
extraction, classiﬁcation, summary and spatiotemporal visualization of
epidemiological data. Privacy issues are handled by a two stepped
approach to production of spatiotemporal disease data as preparation
for visualization. The rule based approach to transformation and
classiﬁcation of the data makes it possible to mask variations in
coding of microbiology analysis and result codes. It also enables input
from a variety of sources, such as labs, GP practices and casualty
clinics. The Snow system currently covers two microbiology laboratories
and the three northernmost counties of Norway with a population of
approximately 470.000.
Conclusion: The Snow system provides real-time epidemiological data
on infectious diseases through the internet as a management tool for
general practitioners and infection control personnel in the community.
The web based spatiotemporal visualization tool enables increased
knowledge of the pre-test probability of various infectious agents and
optimization of diagnostic strategies and treatment.
P1307 Social media and infectious disease surveillance: tweets
indicate norovirus outbreak at a university
E. Velasco, M. Krieck, L. Otrusina, F. Bazoche, J. Linge, T. Eckmanns*,
J. Dreesman for the M-Eco Project
Background: It is not clear whether or not information from social
media can enhance already established indicator-based surveillance of
known infectious diseases. We examined a recent community outbreak
of Norovirus at a university in Lower Saxony, Germany to determine if
news articles and information posted to the websites Facebook, Twitter
and blogs was faster than reporting through established indicator-based
surveillance. This study was part of the Medical Ecosystem (M-Eco)
Surveillance systems S361
project, an EU FP7 funded project, which aims to develop a new platform
for information collection about health events 3.
Methods:We compared information from each day of the outbreak from
local and state health authorities to information from Internet sources.
We obtained news articles from an existing RSS-feed established to
collect news on health and infectious disease in Lower Saxony from
local online news websites. We entered outbreak-related search terms
into Topsy, a search engine to analyse Twitter content, and Google to
search for information from blogs or other Internet forums.
Results: An initial report from the university canteen to the local public
health department occurred a day after ﬁrst signs of infection, and a
timely press report was formulated on August 12, 2010. Activity in all
information sources followed this inquiry closely (Peak 1), and there
was an increase of coverage from social media after ofﬁcial pathogenic
test results from infected individuals were reported on Friday August 13,
2010 (Peak 2). The majority of news media, however, occurred after the
weekend, on Monday August 16, which in turn also spawned more social
media coverage that could be linked to the content in newspaper reports
(Peak 3). A ﬁnal peak occurred in social media a day later (Peak 4)
(Fig. 1).
Conclusion: The ﬁrst notiﬁcation of this case was made by the canteen
to the local health department, a report not required by established laws
for indicator-based surveillance of Norovirus in Germany, and news
and social media followed. Furthermore social media was also used for
information exchange about the event, creating more information and
more noise, and potentially amplifying possible signals for monitoring
purposes. These cases show that individual infections might be caught
when scanning social media and that investigating social media may lead
to potential outbreak indications.
P1308 A validation study of the Korean Nosocomial Infections
Surveillance System
Y.K. Cho*, J.Y. Kim, S.-O. Lee, H.Y. Kim, Y.K. Kim, Y. Kwak,
E.S. Kim, H.B. Kim, M.S. Lee, J.S. Eom, H.Y. Jin, J.Y. Lee, E.S. Park,
S.Y. Jeong, S.R. Kim, H.K. Hong for the Korean Nosocomial Infections
Surveillance System (KONIS)
Objectives: The Korean Nosocomial Infections Surveillance System
(KONIS) was established in 2006 by the Korea Centers for Disease
Control and Prevention (KCDC) and the Korean Society for Nosocomial
Infection Control (KOSNIC). The KONIS conducted prospective surveil-
lance for three major healthcare-associated infections (HAIs): urinary
tract infection (UTI), bloodstream infection (BSI), and pneumonia
with data being collected using an Internet-based data entry interface
(KONIS Web-based Report and Analysis Program, KONIS WRAP,
http://konis.cdc.go.kr). We have performed two investigations to evaluate
the validity of the KONIS intensive care unit data.
Methods: The KONIS Steering Committee reviewed surveillance data
from January through March 2008 and from July through August 2010.
All KONIS hospitals were divided into six groups according to the
healthcare-associated infection rates. Each one hospital was randomly
selected from six groups. The trained members of KONIS Steering
Committee visited each hospital and they reviewed medical records. The
samples included patients with HAIs reported to KONIS and randomly
selected patients without reports of these infections.
Results: We reviewed 195 (11% of total HAIs) reported cases and
age and sex matched 427 patients with no reported infection randomly
selected from 96 ICUs of 56 hospitals in 2008 and 101 ICUs of
57 hospitals in 2010. Sensitivities of UTI, BSI, and pneumonia were
95%, 89%, and 67%, respectively. And speciﬁcities of UTI, BSI, and
pneumonia were 98%, 99%, and 99%, respectively. The overall positive
predictive value for the hospital reports was 93%, and the overall negative
predictive value was 95%. Using KONIS WRAP with standardized
manual, the accuracy of KONIS was similar to that of other countries
such as National Nosocomial Infections Surveillance System (NNIS) in
United States and Krankenhaus Infektions Surveillance System (KISS)
in Germany.
Conclusions: The ﬁndings of this study suggest that there was under-
reporting of healthcare-associated pneumonia to KONIS. Continued
validation and training will be needed in Korea to improve completeness
of reported healthcare-associated infection data and especially to assure
that healthcare-associated pneumonia data are valid.
P1309 The ECDC Pilot Point-Prevalence Survey of healthcare-
associated infections and antimicrobial use: feasibility
analysis
A. Muller*, C. Suetens, B. Coignard, J. Griskeviciene, S. Hopkins,
K. Weist, M. Goossens, S. Vaerenberg, B. Catry, V. Vankerckhoven,
H. Goossens, P. Zarb for the ECDC-PPS Study Group
Objectives: The ECDC pilot Point Prevalence Survey of healthcare-
associated infections (HAI) and antimicrobial use (AU) in European
acute care hospitals was coordinated by ECDC and outsourced to a
consortium led by the University of Antwerp in collaboration with the
French Institute for Public Health Surveillance and the Belgian Scientiﬁc
Institute of Public Health. The objectives of the survey were to test
and ﬁnalize a European protocol allowing to describe and estimate the
prevalence of HAI and AU in hospitals. Two protocols, a patient-based
(PB) with risk factors collected for each patient and a unit-based (UB)
with aggregated denominator data at ward level, were tested. National
questionnaires were sent to collect ﬁgures on hospitals and programmes/
campaigns related to infection control (IC). A feasibility survey was
conducted to assess and compare the burden of each protocol.
Methods: A questionnaire was sent to the 23 participating countries and
to the 66 hospitals. Following items were surveyed: (i) at the national
level: list of hospitals according to a proposed scheme based on hospital
specialties, workload for training and for data collection; (ii) at the
hospital level: workload for data collection and entry, number of health-
care workers (HCW) involved in the survey.
Results: The information needed to classify the hospitals according to
the protocol was not available at the national level in some countries,
requiring a protocol adjustement. At the hospital level, the average time
to fulﬁl the survey was 5 working days (wd; 1wd equals 8 hours) and
4 wd per 100 patients for the PB and UB protocols, respectively. The
difference was mainly due to the data collection time. On average, 6
HCWs were involved in the survey (max: 21) classiﬁable in 4 different
categories (max: 9). The most frequently involved HCWs were IC nurses
and doctors. In 20 hospitals, ward staff were also involved in the survey.
In 11 countries, national coordinating staff participated in the data
collection or data entry processes.
Conclusions: The ECDC-pPPS protocol was well implemented by
national and hospital staff and no major feasibility problems were
encountered. The patient protocol was slightly more labour intensive
than the unit-based version, but brought much more valuable information
and therefore has been chosen as the preferred protocol. The ﬁnal
adjustments to the ECDC-PPS protocol have been done in view of its
implementation in all EU Member States in 2011–2012.
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P1310 The ECDC Pilot Point-Prevalence Survey of
healthcare-associated infections and antimicrobial use:
healthcare-associated infection results
C. Suetens*, A. Muller, B. Coignard, J. Griskeviciene, S. Hopkins,
K. Weist, M. Goossens, B. Catry, S. Vaerenberg, V. Vankerckhoven,
H. Goossens, P. Zarb on behalf of the ECDC-pPPS Study Group
Objectives: The ECDC pilot Point Prevalence Survey of healthcare-
associated infections (HAI) and antimicrobial use (AU) in European
acute care hospitals (ECDC-pPPS) was coordinated by ECDC and
outsourced to a consortium led by the University of Antwerp (UA) in
collaboration with the French Institute for Public Health Surveillance
(InVS) and the Belgian Scientiﬁc Institute of Public Health (WIV-ISP).
The objectives of the ECDC-pPPS were to test and ﬁnalize a European
protocol allowing to: describe and estimate the prevalence of HAI
and AU in participating hospitals; stratify estimates by patients’
characteristics and invasive procedures and; provide a standardized tool
for hospitals within Europe to identify targets for quality improvement.
Methods: All patients on ward by 8:00am and not discharged at the
time of survey were included. Each ward was surveyed in one day. Two
protocols − a patient-based with risk factors collected for each patient
and a unit-based with aggregated denominator data at ward level −
were tested.
Results: The overall prevalence of patients with HAI (n = 1408/19888
patients) was 7.1%. Of 1531 HAI, pneumonia represented 22%,
surgical site infections 19%, urinary tract infections 17%, bloodstream
infections 12% and gastro-intestinal infections 7%. The median length
of stay before onset of HAI acquired during the current hospitalisation
(n = 1378) was 12 days. Of 437 (24%) HAI present at admission, 58%
was associated to a previous stay in the same hospital. Isolated microor-
ganisms are given in the table. Carbapenem resistance was reported
in 3.2% of enterobacteriaceae, 23.4% of P. aeruginosa and 20.4% of
Acinetobacter spp. The percentage MRSA was 34.2%, and resistance to
glycopeptides in Enterococcus spp (VRE) was reported in 5.4%.
In patient-based logistic regression analysis (n = 14329), HAI was
independently associated with length of hospital stay (until infection date
if HAI), number of invasive devices, surgery since admission, McCabe
score, and specialty. Based on this model, expected HAI prevalence at
the hospital level correlated better with observed prevalence than the
expected prevalence based on specialty only (R-squared = 0.69 vs 0.46).
Conclusions: The HAI prevalence in this pilot with 66 European
hospitals was similar to the prevalence of 7.1% found earlier from a
European PPS review [1]. The patient-based protocol was shown to be
superior for risk adjustment than the unit-based protocol.
Reference(s)
[1] ECDC Annual Epidemiological Report 2008.
P1311 Active surveillance for methicillin-resistant Staphylococcus
aureus in intensive care units: incidence density reduced to
that of general wards
B. Ang, A. Earnest, A. Chow, T. See, W. Ng, B. Poh, D. Lye*
(Singapore, SG)
Objective: In 2006, methicillin-resistant Staphylococcus aureus (MRSA)
comprised 45% of all S aureus in our hospital. Hospital-wide MRSA
incidence density (ID) was 2.61/1000 patient-days versus intensive
care units (ICU) of 7.33/1000 patient-days. A MRSA ward started in
September 2007 cohorting <50% of all ward MRSA cases. MRSA
active surveillance (AS) was gradually started in our 4 single-bed ICU’s:
September 2006 in ICU 1, April 2009 in ICU 2, July 2009 in ICU 3
and October 2009 in ICU 4. Chlorhexidine wipes were started in ICU 1
from November 2008 from lack of effect of MRSA AS. Enhanced hand
hygiene campaign was started in January 2009 with stable compliance
rate of ~50%.
Methods:We extracted MRSA ID data from a computerised surveillance
programme of all clinical cultures since 1 January 2006 to compare
MRSA ID in our 4 ICU’s against general wards. We analysed the impact
of AS in each ICU and chlorhexidine wash in ICU 1 by segmented
regression analysis of interrupted time series (ITS) using autoregressive
integrated moving average (ARIMA) model.
Results: Figure shows median quarterly ICU MRSA ID fell in second
quarter of 2009, and remained low for the last six quarters. It
approximated MRSA ID in general wards, regardless of bed numbers,
since January 2009. By segmented regression analysis of ITS using
ARIMA model, MRSA AS was statistically signiﬁcant in lowering
MRSA ID in ICU 3 (P = 0.002) and marginally signiﬁcant in ICU 2
(P = 0.089), and chlorhexidine wipes were effective in loweing MRSA
ID in ICU 1 (P = 0.032). In 2010, MRSA comprised 39% of all S aureus
(from 45% in 2006) and hospital-wide MRSA ID decreased to 1.21/1000
from 2.6/1000 patient-days in 2006.
Conclusion: MRSA AS reduced MRSA ID in 2 ICU’s but chlorhexidine
wipes were needed to reduce MRSA ID in one ICU. Our ICU MRSA
ID is now similar to general wards.
P1312 Korean Nosocomial Infections Surveillance System,
Intensive Care Unit Module Report: data summary from
July 2009 through June 2010 and analysis of 4-year results
Y. Kwak*, Y.K. Cho, J.Y. Kim, H.Y. Kim, Y.K. Kim, E.S. Kim, M.S. Lee,
J.S. Eom, Y.S. Lee, E. Kim (Goyang, Incheon, Wonju, Seoul, KR)
Objectives: In this report, we present the annual data of the
intensive care unit (ICU) module of the Korean Nosocomial Infections
Surveillance System (KONIS) from July 2009 through June 2010 and
analysis of 4-year results since July 2006.
Methods: We performed a prospective surveillance of nosocomial uri-
nary tract infections (UTI), bloodstream infections (BSI), and pneumonia
(PNEU) at 116 ICUs in 63 hospitals using KONIS. Nosocomial infection
(NI) rates were calculated as the numbers of infections per 1,000 patient-
days or device-days. Antimicrobial susceptibilities of major pathogens
isolated from patients with nosocomial infections were also analyzed.
Results: We identiﬁed 3,965 NIs during the study period: 2,156
UTIs (2,119 cases were urinary catheter-associated), 1,110 BSIs (948
were central line-associated), and 699 PNEUs (410 were ventilator-
associated). The rate of urinary catheter-associated UTIs was 4.75 cases
per 1,000 device-days (95% conﬁdence interval, 4.55–4.95) and urinary
catheter utilization ratio was 0.86 (0.859–0.861). Although the urinary
catheter utilization ratios were lower in the hospitals with 400–699 beds
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than in the hospitals with 700–899 beds and more than 900 beds, the
rates of urinary catheter-associated UTIs were higher in the hospitals
with 400–699 beds than in 700–899 beds. The rate of central line-
associated BSIs was 3.28 (3.07–3.49) and the utilization ratio was 0.56
(0.559–0.561). The rate of ventilator-associated PNEUs was 1.95 (1.77–
2.15) and the utilization ratio was 0.41 (0.409–0.411). During the past 4
years, there was no signiﬁcant difference in the rate of urinary catheter-
associated UTIs and central line-associated BSIs. On the other hand, the
rate of ventilator-associated PNEUs was lower in July 2009-June 2010
than in July 2007-June 2008 and July 2006-December 2006. The most
distinctive ﬁnding in the antimicrobial susceptibilities of major pathogens
was that the incidence of carbapenem-resistant Acinetobacter baumannii
increased from 43.6% to 82.5% during the study period.
Conclusion: It appears that the KONIS inﬂuences the reduction in
the rate of device-associated infections, especially ventilator-associated
PNEUs. Carbapenem-resistant A. baumannii was identiﬁed as an
emerging Gram-negative pathogen of nosocomial infections in Korea.
Therefore, ongoing targeted surveillance and infection control strategies
are needed to control device-associated infections and the major
antimicrobial-resistant pathogens.
P1313 Assessment of European practices in infection control. First
results from PROHIBIT
M. Martin*, A. Conrad, W. Zingg, S. Hansen, P. Gastmeier, D. Pittet,
M. Dettenkofer and the PROHIBIT consortium
Objectives: The European Commission (FP-7) funded project “Preven-
tion of Hospital Infections by Intervention and Training” (PROHIBIT
www.prohibit.unige.ch) was established in 2010. PROHIBIT aims to
analyse existing guidelines and practices to prevent healthcare associated
infections (HAI) in Europe, to identify factors that inﬂuence compliance
with best practices and to test the effectiveness of interventions of known
efﬁcacy.
Methods: In August 2010, the European Centre for Disease Prevention
and Control (ECDC) HAI surveillance National Contact Points (NCP)
and HAI experts in 34 countries (27 EU member states [where UK
counts as 4 countries: England, Northern Ireland, Scotland, Wales],
Croatia, Iceland, Norway and Switzerland) were invited to complete an
online questionnaire about (i) existing national guidelines for prevention
of surgical site infection (SSI), ventilator-associated pneumonia (VAP),
urinary tract infection (UTI), catheter-associated blood stream infection
(CA-BSI), C. difﬁcile associated infection (CDI), as well as on
(ii) national HAI surveillance systems and (iii) public reporting policies.
Results: 28 of 34 NCPs (82%) completed the questionnaire. (i) Guide-
lines: 2 countries reported to have no guidelines, 2 to have 1, 3 to
have 2, 2 to have 3 and 6 countries to have 4 guidelines. 13 countries
reported to have guidelines on all 5 topics. Scientiﬁc level of supporting
evidence and strength of recommendation are rated in 46% (12/26) of
the guidelines. (ii) Surveillance: A nationwide HAI-surveillance-system
for public hospitals is established in 86% (24/28) of the countries.
Participation is compulsory in 12 of 24 (50%) countries. Surveillance for
CA-BSI, SSI, VAP, UTI and CDI is implemented in 22, 21, 18, 16 and
15 countries, respectively. 9 countries monitor all 5 topics. (iii) Public
reporting: 7 countries have established public reporting of data on HAI
from individual hospitals.
Conclusions: National HAI surveillance systems are well established
in Europe, especially for SSI and CA-BSI, whereas evidence-based
guidelines for prevention of HAI are still to be developed. Countries
with public reporting do so after HAI-surveillance is established and
declared mandatory. Thus, mandatory surveillance may be considered
a ﬁrst step towards public reporting. Although reasons for this must
be further elucidated, we speculate that once data on HAI are retrieved
systematically, political pressure may be exerted to make the data public.
P1314 A technical committee for epidemiological surveillance
from microbiology laboratories data: an Italian ﬁve-year
period experience in Lombardy region
E. Costa*, A. Pan, M. Arghittu, V. Bettamio, P. Casella, V. Cattolico,
C. Farina, F. Franzetti, M. Moro, G. Ortisi, A. Russo, E.F. Vigano`
on behalf of the Lombardy Group of Technical Assessment (GTA)
for Surveillance from Microbiological Data
Objectives: To establish a permanent epidemiological observatory with
functions of reference and coordination at regional level from data
acquired by microbiology laboratories on a voluntary base.
Observatory objectives are to provide: updated surveillance data,
available in a simple and immediate way; technical support to
microbiology laboratories, particularly for pathogens identiﬁcation and
deﬁnition of antimicrobial resistance.
Methods: Three epidemiological surveillance programs are operative,
namely: a) incidence of Alert microrganisms (Sentilomb, from 2005);
b) Staphylococcus aureus bloodstream infections (Basalomb, 2007);
c) a 3 days/month prevalence of antimicrobial resistance (Resilomb,
2007). Healthcare General Direction of Lombardy Region set up in
January 2010 a Technical Committee of 12 sanitary direction managers,
microbiologists, infectious disease and infection control specialists. In
collaboration with the information technology company, an internet
portal was created in order to record data from the regional laboratories.
Reports related to hospital complexity, ward, type of specimen, species
and antimicrobial resistance (reported as S/I/R and/or MIC) were made
available to all participating centers.
Results: Since January 2005 till June 2010, 122 microbiology
laboratories recorded 87,684 epidemiological case record forms (CRF).
Basalomb: 3,382 S. aureus bloodstream infections (38,1% MRSA), were
identiﬁed among 26 selected hospitals participating throughout all the
study period.
Resilomb: susceptibility data were collected on Escherichia coli (6,108
strains), Serratia marcescens (176, replaced in 2010 with Klebsiella
pneumoniae), Proteus mirabilis (1,119) and Pseudomonas aeruginosa
(1,927).
Sentilomb: 75,845 alerts were recorded, on 24 alert microrganisms (28
since 2010), with the infection rates as per 1,000 admissions and per
10,000 patient days.
Conclusion: The programs produced data both at the regional and single
hospital level, essential to realize active surveillance interventions and
to facilitate the establishment of effective antimicrobial stewardship.
The surveillance program was an effective tool for the diffusion of
technical remarks related to laboratory methods, interpretation criteria
and reporting to clinicians. Reports will be also used to support regional
warnings and guidelines.
Moreover, promoting strains storing, may allow phenotyping and
genotyping from reference laboratory rationalizing the use of resources
and competences.
Infection control
P1315 Prevalence and risk factors for carriage of methicillin-
resistant Staphylococcus aureus in 17 German hospitals:
results of a point-prevalence study in the rural district
Hannover
I.F. Chaberny, H.-B. Behrends, M.-E. Ho¨pken, B. Klingelbiel, U. Mai,
E. Ott* (Hannover, DE)
Background: Methicillin-resistant Staphylococcus aureus (MRSA) as
the predominant multidrug-resistant organism is a well-known causative
agent of healthcare-associated infections in hospitals, but few data about
the prevalence and circulation of MRSA in one geographically deﬁned
area in Germany is available.
Objectives: To determine the prevalence of MRSA and Panton-Valentine
Leukocidin (PVL) among inpatients, to identify patients at risk for
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MRSA carriage and to check infection control measures in inpatients
in the rural district Hannover.
Method: A point-prevalence study was conducted in 17 hospitals from
October 1, 2009 through March 31, 2010. Inpatients were screened by
cultures from nose, throat and broken skin and patient data was recorded.
MRSA isolates were tested for PVL and were analysed by staphylococcal
protein A (spa) typing.
Results: MRSA was isolated from 118 (3.9%) of 3013 consenting
inpatients. The MRSA prevalence ranged from 0.3% to 12.5% in the
respective hospital. The spa typing revealed 26 different types. With
67% was the spa type t032 or so called “Barnimer” strain predominant
followed by t003 (3%), t011 (3%), t020 (3%) and t002 (2%). The PVL
gene was present in two (1.7%) MRSA strains. Factors were found to
be signiﬁcantly associated with MRSA carriage at univariate analysis
were age older than 71 years, prolonged hospital stay (23d vs. 17d),
history of hospitalization (RR, 2.2; CI95, 1.51–3.15) or surgery (RR,
1.5; CI95, 1.01–2.01) or antibiotic therapy (RR, 2.0; CI95, 1.42–2.91),
current antibiotic therapy (RR, 1.4; CI95, 1.01–2.06), dialysis patient
(RR, 2.3; CI95, 1.13–4.87), and presence of open skin lesions (RR, 2.0;
CI95, 1.35–2.90). 42% of all identiﬁed MRSA carriers were detected
on internal medicine wards and 30% on surgery wards. 92 (78%) were
newly identiﬁed MRSA carriers.
Conclusion: The results of our study revealed 78% of all MRSA-
positive inpatients had been missed. Screening for MRSA on admission
is useful to identify the imported cases and should be performed on
wards harboured patients at risk, e.g. internal medicine and surgery.
On the basis of our results, the respective hospital of the rural district
Hannover can optimize its comprehensive infection control strategies
against MRSA.
P1316 Guidelines for infection control staff: goals and reality in
Germany
E.B. Kruse*, H. Gartmann, W. Ga¨rtner, S. Schulz-Stu¨bner (Freiburg, DE)
Objectives: In 2009 the German infection control commission
(KRINKO) at the Robert Koch Institute released guidelines regarding
needs of infection control (IC) personnel in hospitals based on risk
assessment criteria. Our aim was to check the guideline requirements
with reality in German hospitals.
Methods: 70 hospitals visited in 2010 by an external IC physician were
assessed for IC staff working in the hospital, IC training for non-IC staff,
and annual meetings of the IC team with the heads of departments.
The numbers were compared to the numbers recommended by the
KRINKO guidelines, and percentages of adherence to the guidelines
were calculated.
Results: Hospitals were divided into three groups: I: small (<150 beds),
II: medium-sized (151–400 beds) and III: large (>400 beds). In group
I (n = 18), two hospitals (11%) employed the recommended number of
infection control practitioners (ICPs), four (22%) had 75% and 12 (67%)
less than half. IC link nurses were present in four hospitals, IC link
physicians for every specialty in 11 (61%) and one for the whole hospital
in ﬁve (27%). Continuous IC training for non-IC staff was available in 17
institutions (94%), and regular meetings of the IC team with the heads
of department were held in all hospitals.
In group II (n = 36) two hospitals (5%) provided the recommended
number of ICPs, six hospitals (17%) had 75% and 18 (50%) half. IC link
nurses were available in nine hospitals (25%), IC link physicians in 35
(97%), 21 of which had one per specialty. All held regular meetings and
in 34 hospitals (94%) IC training for non-IC staff was offered regularly.
In Group III (n = 16) 11 hospitals (69%) employed less than half the
number of ICPs recommended, four (25%) employed half and one
hospital 75%. All hospitals had IC link physicians, 11 (69%) one per
specialty. Seven hospitals (44%) had IC link nurses as well. IC training
for non-IC staff was offered in 15 hospitals (94%) and all hospitals held
regular IC team meetings.
Conclusion: No hospital in the sample fulﬁlled all recommendations
regarding IC personnel requirements and supporting IC link staff. In most
hospitals, the gap between recommended and actual staff was large, often
more than 50%. Thus infection control in hospitals has to be managed
by non-specialized staff − often as an additional duty. However, there is a
shortage of available IC personnel in Germany, so that increased efforts
will be necessary to ensure training of sufﬁcient numbers of skilled IC
staff.
P1317 Preliminary evaluation of an automated detection tool for
healthcare-associated infections, based on screening natural
language medical reports
Y. Berrouane*, C. Hage`ge, Q. Gicquel, I. Kergoulay, S. Pereira,
D. Proux, S. Darmoni, F. Segond, M.H. Metzger (Nice, Meylan, Lyon,
Rouen, Issy-les-Moulineaux, FR)
Objectives: Surveillance of healthcare associated infections (HAI) is
an important activity in the context of control and prevention. Due
to the limited resources allocated to this activity, developing tools
using hospital information systems for monitoring HAI is required.
An ongoing collaborative project ALADIN is aimed at developing an
automated detection tool of HAI based on natural language processing
of medical documents. The objective of this presentation was to evaluate
the performance of this tool in its current development
Methods: This project is conducted in three steps.
1. First step: development of rules associating expressions, concepts
extracted from multiple medical terminologies and semantic relations
for the detection of HAI. The rules were deﬁned by an interdisci-
plinary work between Infection Control Practitioners (ICPs), semantic
interoperability experts and linguists. For this step, it is planned
to analyze 1200 medical documents, which will be gathered from
four French University hospitals and will focus on surgical activity
(digestive, neurosurgery and orthopaedics) and intensive care units.
2. Second step: development of the detection tool (Xerox Incremental
Parser) based on semantic analysis of natural language
3. Third step: evaluation of the performance of the detection tool in
terms of sensitivity and speciﬁcity (Evaluation of the linguistic rules
is outside the scope of this presentation). For this step, new medical
reports will be analyzed (n = 800). The gold standard will be the
manual analysis of these medical reports by two independent ICPs.
Results: From the 2000 medical documents planned for the project,
635 (31.8%) were already available for this preliminary evaluation.
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From them, 430 were analysed for the rules elaboration (67.7%) and
205 (32.3%) for performance evaluation. Sensitivity and speciﬁcity by
medical specialty are detailed in the table.
Conclusion: The performance of the detection tool was very satisfactory.
The next step will be to integrate the tool in the hospital information
system for screening documents in real time conditions.
P1318 Surgical site infections after cardiac surgery in Oslo, Norway
T. Tollefsen*, B. Andersen, Ø. Vengen (Oslo, NO)
Objectives: To gain insight into the incidence of postoperative infections
after ACB during a follow-up of 30 days.
Surgical Site Infection (SSI) is one of the most common infections
in hospitals and is a serious complication of cardiac surgery. In
2005, incidence registering of coronary artery bypass graft surgeries
(ACB) was introduced at the Department of Thoracic- and Cardiac
surgery, Oslo University Hospital − Ulleva˚l (OUS), according to the
National Nosocomial Infections Surveillance system (NOIS-1). After
postoperative stay of only 3 days (mean), the patient is discharged to
another hospital for further postoperative care.
Methods: A questionary was sent to all operated patients. The infection
status was registered after surgery according to CDC criteria. Patients
were asked to contact primary health care after 30 days for evaluation
of the surgical sites. Any SSI was veriﬁed by a doctor and evaluated by
the head surgeon and infection control personnel.
Results: Included were 1237 ACB-operated patients during the period
2005–2009, who responded to the questionary (ca 80%). SSI was
detected in sternal-, leg- or drain wounds within 30 days after operation
in 14.3% of the cases. The highest incidence of infection was registered
in 2006, and there seemed to be some seasonal variation concerning
SSI. Leg wound infection predominated (7.3%), followed by superﬁcial
sternal wound infection (4.7%) and drain wound infection (1.3%). A few
patients had deep sternal wound infections (1.1%).
Staphylococcus aureus was found in 23.2% of the cases with SSI and
was the most common isolated pathogen. Methicillin resistant S aureus
(MRSA) was detected in a leg wound infection of one patient (0,6%).
Conclusion: SSI is mainly detected after discharge from the hospital.
Infections predominate in the incision site on leg after vein graft
harvesting, and S aureus is the main pathogenic bacteria. Deep sternal
wound infections occur relatively seldom. Incidence registering gives an
important feedback to the surgeons − to evaluate and improve infection
control in cardiac surgery.
P1319 Procedures for isolation and management of patients
with highly infectious diseases in emergency departments:
EuroNHID (European Network for Highly Infectious
Diseases) data from 40 centres in 13 European countries
F.M. Fusco*, G. De Iaco, S. Schilling, H.R. Brodt, P. Brouqui,
H. Maltezou, B. Bannister, G. Thomson, V. Puro, G. Ippolito for the
EuroNHID (European Network for Highly Infectious Diseases) Study
Group
In Health-care settings, isolation of patients with Highly Infectious
Diseases (HIDs, e.g. Viral Hemorrhagic Fevers and SARS) is
fundamental for the prevention of the spreading of these infections.
In particular in the Emergency Departments (EDs), (i) the presence of
infectious patients and many susceptible individuals in the same space;
(ii) the lack of isolation because of mis-diagnosis or unavailability of
adequate areas; (iii) the frequent and close contacts among patients
and HCWs often not protected by PPE, all these are factors increasing
the risk of spreading of transmissible diseases. For HIDs, which may
cause large nosocomial outbreaks, the prompt and effective application
of respiratory hygiene/cough etiquette measures, adequate procedures,
availability of isolation areas, and well-trained personnel, are the most
important measures for reducing the risk of transmission in EDs.
The EuroNHID (European Network for Highly Infectious Diseases)
project collected data about the management of patients with proven
or suspected HIDs from 48 isolation facilities in 16 European countries.
Among these, 40 isolation facilities in 13 countries refer that a ED
is operating in the same centre. We present data, collected with
standardized checklists, about the management of HIDs patients in these
EDs.
Among 40 surveyed EDs, 13 report to have a waiting area large enough
to allow the right distancing among patients, while 19 among remaining
refer to have preparedness plans to enlarge waiting areas if necessary.
Isolation rooms are available in 33 EDs (82.5%): these rooms have an
anteroom in 18, a dedicated entrance in 15, are equipped with negative
pressure in 17, and with HEPA ﬁltration of exhausting air in 12. In 6
EDs only (15%) isolation rooms have all these characteristics. Triage
personnel speciﬁcally trained for the recognition of a suspected HIDs is
available in 23 EDs; management protocols for these patients, including
indications for diagnosis and infection control, are available in 34 EDs.
Surveyed EDs are in the same centre as an isolation facility. These EDs
are the most likely to manage patients with HIDs in their countries.
Despite that, their preparedness level is partially adequate: isolation
rooms are available, but these rooms are mostly not appropriate.
Protocols are present in most EDs, the half only among HCWs has
a speciﬁc training for the recognition and management of these patients.
Targeted interventions including training are needed.
P1320 Does infection control regulation lead to less nosocomial
infections? A comparison of federal states in Germany with
infection control regulations and without
E. Meyer*, F. Schwab, C. Geffers, P. Gastmeier (Berlin, DE)
Objectives: To investigate whether federal states in Germany with
infection control regulations have less nosocomial infections than federal
states without such regulations.
In summer 2010, two hygiene scandals in German hospitals were widely
reported in the media and resulted in a call for tougher laws. The
legislative framework in Germany is as follows: The German Preventing
and Combating of Infectious Diseases in Humans Act (IfSG) took
effect in all federal states already in 2001. However, 5 out the 16
federal states have additional federal regulations for infection control
in hospitals. These federal regulations clarify responsibilities, explain
in detail existing law, constitute structural quality parameters (e.g. the
number of infection control staff) and set rules and authorities (e.g.
to grant inspection of surveillance data). Policy and public opinion
considered these federal regulations necessary for the solution of −
perceived − increasing infection control and resistance problems in
hospitals.
Methods: We analyzed data of 437 intensive care units (ICUs)
taking part in the German hospital surveillance system for nosocomial
infections (KISS) from 2007 to 2008. Nosocomial infections are reported
according to the CDC deﬁnitions and in accordance with the National
Nosocomial Infection Surveillance system (NNIS)/National Healthcare
Safety Network (NHSN) method. Nosocomial infections included blood
stream infections, pneumonia, bronchitis and urinary tract infections and
multidrug resistant pathogens.
Results: The incidence density of all nosocomial infections did not
differ between federal states with or without federal regulations (see
table). Neither were less nosocomial infections observed with multidrug
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resistant pathogens (methicillin resistant S. aureus, vancomycin resistant
enterococci or extended spectrum b-lactamase producing bacteria) in
federal states with regulations.
Conclusion: The call for more or tougher laws was a reﬂex after
hygiene scandals in Germany. However, we could not substantiate the
simple assumption that more regulations are per se associated with
less nosocomial infections or less multidrug resistant pathogens in
nosocomial infections.
P1321 Outbreak investigation because of neonatal listeriosis cases
in a Swiss maternity unit
C. Kahlert*, F. Limacher, W. Girardi, J. Bille, M. Schlegel (St. Gallen,
Grabs, Lausanne, CH)
Objectives: Since 2008, the Federal Ofﬁce of Public Health in
Switzerland has reported no single case of neonatal listeriosis. For this
reason, outbreak investigation was immediately started after occurrence
of severe invasive infection with detection of L. monocytogenes in
two term borne neonates within one week in a Swiss maternity. The
aim was to identify potential sources of this foodborne pathogen and
consecutively being able to prevent further illness.
Methods: Confronted by a foodborne disease outbreak, guidelines for
investigation and control as recommended were applied.
Results: Listeria monocytogenes serotype 4 was cultured in the
cerebrospinal ﬂuid of case 1 as well as 4 days later in the blood
of case 2. Both neonates had pleocytosis and responded to antibiotic
treatment with high dose amoxicillin. Further investigation of listeria
isolates by pulsed ﬁeld gel electrophoresis typing in the national listeria
reference centre identiﬁed both as type 7, a type not detected in the 20
other human isolates that has been tested before. The mother of case 1
showed symptoms of a viral illness 2 weeks before giving birth. Listeria
infection was suspected because of a 4-fold rise in speciﬁc antibody
titers. The mother of case 2 stayed seronegative even 4 weeks post
partum. Neither direct or indirect contacts (separated rooms, different
health care workers), nor common used subjects or food exposure could
be identiﬁed except breast milk of both mothers that has been stored
during one night together in one fridge. After implementation of clearly
spatial separation in clean-contaminated and mother-nurses areas within
the milk kitchen and individually packaged bottles and related accessoirs
no further cases of listeriosis infections occured.
Conclusion: Although transmission by contaminated hands of health
care workers is considered the most frequent reason for nosocomial
infection, this route appears unplausible in this outbreak. In fact, breast
milk was identiﬁed as the most likely source of nosocomial infection. As
a consequence, system changes and structural changes concerning breast
milk administration were implemented. As breast milk administration
errors are not infrequent events, breast milk should be considered in
foodborne outbreak investigations and strict prevention guidelines should
be implemented and controlled in all maternities.
P1322 Epidemiology of Serratia marcescens colonisations and
infections in a neonatal intensive care unit
M. Papadimitriou*, K. Tryﬁnopoulou, D. Kyriakou, A. Doudoulakakis,
O. Pappa, J. Kapetanakis, A. Vatopulos, E. Lebessi (Athens, GR)
Objectives: Serratia marcescens is a well-known causative agent of
nosocomial infections in newborns with severe morbidity and mortality.
The aim of the present work is to elucidate the molecular epidemiology
of S. marcescens colonizations/infections among neonates in a 30-bed,
university-afﬁliated, level III-IV Neonatal Intensive Care Unit (NICU) at
a tertiary pediatric hospital in Athens. The incentive for this study came
from the 4 cases of bacteremia that occurred in the NICU between July
and October 2009.
Methods: All cases of S. marcescens colonization and/or infection in
the NICU between June 2009 and November 2010 were retrospectively
identiﬁed from the laboratory archives and the respective medical
records. Routine surveillance of the patients’ bacterial ﬂora included
cultures of oropharyngeal and rectal swabs upon admission and weekly
thereafter. Culture of samples and identiﬁcation of organisms were made
by standard methods. Susceptibility to antibiotics was performed by disk
diffusion technique according to the CLSI criteria. Genetic relationships
among the isolates were assessed by the Pulsed-Field Gel Electrophoresis
(PFGE) after digestion of genomic DNA with XbaI.
Results: During the study period, 607 neonates were admitted in the
NICU. Eight neonates (1.31%) born in public or private maternity
hospitals in the greater Athens region, parts of southern Greece and many
of the islands, were found colonized with S. marcescens upon admission
(referred cases), whereas ten neonates (1.64%) were colonized during
their NICU stay (NICU-acquired cases). All isolates showed identical
susceptibility pattern (wild type). Bacteraemia occurred in 4 premature
neonates with gestational age <34 wks (27, 29, 32, and 34) and birth
weight <2300 g (880, 1000, 1350, and 2300). Of those neonates, the
most premature died. Three of the bacteremia cases were characterized as
NICU-acquired. Among NICU-acquired cases of colonization 3 occurred
in July 2009, displaying identical PFGE type I, 3 in October 2009 (two of
them displaying identical PFGE type III and 4 between December 2009
and March 2010 displaying identical PFGE type VI). Genetic similarity
among referred cases was no found.
Conclusion: Molecular typing is consistent with possible introduction
and limited spread of various PFGE types in the NICU. Aggressive
infection-control measures in maternity units and NICUs are necessary
to prevent the spread of S. marcescens.
P1323 Infection control in daily practice: improvement in
prevention of catheter-related bloodstream infections with
audit tools
S. Kostourou*, F. Veini, M. Samarkos, K. Papanikolaou,
V. Papastamopoulos, I. Baraboutis, O. Paniara, A. Skoutelis (Athens, GR)
Objective: Catheter Related bloodstream infections (CRBSIs) are
considered adverse events but almost all of them are preventable. These
infections in hematologic patients can be overwhelming and potentially
lethal. Adherence in infection control policies and establishment of safe
practices in the daily care of venous catheters is imperative. Recording
of determinants such as the date of catheterization, the date of dressing
changes, the date of administration sets and stopcocks changes and the
use of the appropriate dressing are crucial in order to avoid these serious
events.
Methods: We conducted a 6-month prospective cohort study in 3
hematologic wards in a 990-bed tertiary hospital. This study used two
interventions to improve the compliance in recording: an educational
intervention and audit tools (ATs) in daily care practices. During the
ﬁrst month we implemented a survey with the use of an audit tool to
identify the care practices and compare them with the standards of care.
The ﬁrst AT was performed to evaluate the baseline characteristics of
daily care practices. After this the educational process was done. The
second (3rd month) and the third (6th month) ATs were performed to
evaluate the improvement of standards of care after education.
Results: The baseline compliance in recording was very low. It was
3.75% in the ﬁrst ward, 14% in the second and 20% in the third ward.
The compliance in the second audit tool increased and was 7% in the
ﬁrst ward, 17.5% in the second and 85% in the third. The compliance
in the third audit tool was 56% in the ﬁrst ward, 51% in the second and
91% in the third ward.
Conclusion: The audit tool seems to be effective in infection control
of CRBSIs. The presence of Infection Control nurses in clinical wards
substantially improves compliance. The results of our study were striking
and suggest that the continuation of the intervention is mandatory.
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P1324 Impact of an intervention based on contact precautions in
hospital-acquired infections in a neonatal unit
I.F. Corrales*, J.A. Cortes, G. Troncoso, M.I. Alvarez, G. Buitrago,
M. Iban˜ez, A.L. Leal (Bogota´, CO)
Objectives: To evaluate the impact of an educative intervention based
on contact isolation precautions and colonization detection in a neonatal
intensive care unit.
Materials and Methods: After a period of observation of 5 months,
an educative intervention about contact isolation precautions based on
skin samples to detect bacterial colonization was done in a reference
neonatal unit. Proportion of hospital-acquired infections (HAI) during
the two periods (before and after the intervention) was evaluated and
an inconditional logistic regression model was used to adjust confusing
variables.
Results: 450 newborns were included in the study, HAI were diagnosed
in 78 patients, 45 (18,2%) in the period before and 33 after the educative
intervention (16,2%). HAI were detected in 17 of 25 patients colonized
(66,7%). 15 of 44 patients without colonization (34%) and just one
case in 134 patients without any skin sample (0,75%; p< 0,01). The
logistic regression model showed an increased risk of infection in the
group without intervention (O.R. 2,99; CI 95%: 1,39−6,46). Other factors
associated with HAI were the use of parenteral nutrition (OR 4,12; CI
95% 1.4−12,3), the presence of congenital cardiopathy (OR 3,1; CI 95%
1.4−6,6) and a longer length of stay in the unit (1,1 per hospital day).
Discussion: An educative intervention about adequate isolation pre-
cautions based on surveillance skin cultures to evaluate bacterial
colonization was associated with a lower rate of nosocomial infection in
the intervention group in a NICU.
P1325 Perioperative antibiotic prophylaxis: results of a second
audit in 7 major hospitals in North Italy
C. Tassan din*, C. Oltolini, P. Scarpellini, G. Vighi, G. Barranco,
V. Conti, G. Genduso (Milan, Lecco, IT)
Objectives: Perioperative antibiotic prophylaxis (PAP) is a cornerstone
of good surgical care and a key-point in surgical site infections
(SSI) prevention. A multicentric protocol providing PAP management
evidence-based recommendations was introduced In 2009 in 7 major
hospitals in North Italy (986 beds each on average). Data regarding
local PAP management before protocol implementation (T0) had been
obtained through a cross-sectional study in 2007. The aim of the
present study was to evaluate the impact on PAP management after the
implementation of the new protocol (T1).
Methods: 2285 clinical charts randomly collected from surgical
activities from June to December 2009 were analyzed. Three indicators
were evaluated: appropriateness (PAP correctly performed + PAP
correctly omitted), adherence to the following criteria a) choice of drug
b) dosage c) time of administration (full adherence: 3 criteria fulﬁlled;
partial adherence: at least 1 criterion fulﬁlled; noncompliance: no one
criterion fulﬁlled) and PAP duration.
Results: PAP was performed in 70% of the procedures. The
appropriateness recorded was of 83% (1457 PAP correctly performed
+ 445 PAP correctly omitted). In 7% of cases PAP was administered
without indication. Full and partial adherence were achieved in 49%
(785/1610) and 43% (690/1610), respectively. Drug choice was correct
in 63%, dosage in 96%, timing in 74%. PAP duration was correct in
55%; remarkably in 64% of PAP with an incorrect duration, supplement
doses exceeding 48 hours after the intervention date were given. Full
adherence and correct PAP duration were fulﬁlled simultaneously in
33% (532/1610); adding these cases to the correctly omitted PAP a
correct protocol application rate of 43% was calculated. No statistically-
signiﬁcant differences between T1 and T0 data were detected.
Conclusion: Our study found a good appropriateness but a scant
adherence rate. Whereas adherence to a single criterion is acceptable,
the different criteria are rarely fulﬁlled concomitantly, likely due to
organization and sanitary-staff interplay difﬁculties. It appears critical
the unjustiﬁed protracted administration of PAP, potentially leading to
antibiotic-resistance selection and costs expansions. T0 and T1 results
are comparable, suggesting a recalcitrance in changing clinical and
organization behaviors; use of incentive patterns and targeted hospital
policies could be useful tools to obtain improvement in this type of
infection control.
P1326 A one-stop shop real-time national decision support system
for infectious disease control in England
C. Kara-Zaitri*, M. Schweiger (Bradford, Leeds, UK)
Objectives: Prior to 2010, various disparate systems have been in use
in England for the control of infectious disease resulting in signiﬁcant
challenges for consistent and timely reporting, surveillance and response.
With the rise of emerging diseases, there is an urgent need for:
1. a single national decision support system to strengthen frontline
infectious disease control;
2. a seemless integration with the laboratories;
3. a real-time overarching view of all infectious disease control at local,
regional and nationals levels.
Methods: The work began with the development of a dynamic risk
assessment model for Infectious disease embedded in a pilot Decision
Support System (DSS) conceived via various regional and national
Delphi workshops. Challenges encountered included standards, changing
notiﬁcation legislation, clinical governance, articulation of national
workﬂows, collection of national reference data sets and integration with
other software suites including the laboratories.
Results: The research has resulted in the design, development and
implementation of the following web-based tools:
1. HPZone: a DSS for the management of Enquiries, Cases and
Outbreaks at 26 Local Units readily providing consistent data.
Basic coincidence and threshold alerts are built in so appropriate
information is automatically brought to the attention of those who
need to know.
2. HPZone-Cosurv interface: A module which automatically harvests
laboratory data from encrypted emails and incorporates them into
HPZone with tight rules for data insertion.
3. Dashboard: a module providing aggregate Case and Outbreak data
collected and presented in different views including geographic,
temporal and disease speciﬁc. Consideration has been given to key
types of data that are informative to those charged with surveillance
and incident management at local, regional and national levels.
Conclusions: The three tools offer immediate beneﬁts in providing key
User deﬁned data, enhanced visibility of real-time critical data for prompt
response, and a ready opportunity for surveillance and epidemiological
research regionally and nationally. The involvement of frontline users
has improved tools’ ownership amongst all users and has paved the way
for more work on data sharing regionally and nationally in time for the
Olympic games in 2012.
P1327 Epidemiology of blood and body ﬂuid exposures among
healthcare workers, in a Greek tertiary hospital
F. Veini, S. Kostourou, M. Samarkos*, E. Dokoutsidou, I. Baraboutis,
V. Papastamopoulos, O. Paniara, A. Skoutelis (Athens, GR)
Objective: A number of Greek hospitals lack an active infection control
team, and the training of HCWs regarding safety issues is not systematic.
Data on the incidence rate of blood and body ﬂuid exposures (BBFE)
from Greece are sparse. The aim of the present study was to describe
the epidemiology of BBFE in a tertiary hospital in Greece.
Methods: This study took place in “Evaggelismos” Hospital, Athens,
Greece, from July 1, 2008 to June 30, 2010. “Evaggelismos” is a 950-
bed public tertiary hospital. It employs 800 physicians and more than
1000 nursing staff. We have used standard deﬁnitions for percutaneous
and mucocutaneous exposures and for risk-posing body ﬂuids. Data
were collected prospectively on a standard form. The management of
the exposure incidents was based on the CDC guidelines.
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Results: We have recorded 406 BBFE. 92.1% involved percutaneous
exposure (PCE) while 7.9% involved mucocutaneous exposure (MCE).
Of the PCEs, 69% involved hollow-bore needles, while 23.1% involved
other sharp devices (non-hollow bore needles, scalpels etc). There were
334 HCW involved in 406 exposures. Of those 34.7% were physicians,
41.2% were nursing staff, 17.0% were students, 5.4% were cleaning staff,
while 1.2% other member of staff.
The total incidence rate of BBFE was 9.1 per 100 FTEs per year, or 25.1
per 100 occupied beds per year. The rates per 100 FTEs per year were
9.2 for physicians, 8.1 for nurses, 29 for students and 4.5 for cleaning
staff.
The most common circumstances associated with a PCE were
inappropriate sharps disposal (18.7%), recapping (17.9%) and use
of non-hollow sharps (17.4%). The incidence rate of BBFEs was
signiﬁcantly higher in medical than in surgical wards (13.1 vs 7.4 per
100 occupied beds per year).
The source patient was known in 93.4% BBFEs. There were 6.0% HbsAg
(+), 12.2% anti-HCV(+), and 1.4% HIV(+) patients. In 9.9% HCWs
vaccination against HBV was initiated or continued. 2/5 HCWs exposed
to HIV(+) source patients refused prophylactic antiretroviral therapy. No
incident associated with transmission of HBV, HCV or HIV has been
documented so far.
Conclusions: BBFE rates in our study are among the highest reported
in the literature. Possible reasons for the high rate of BBFE in our
hospital are the lack of formal training of HCWs on occupational
health and safety issues, limited use of safety or needleless devices and
organizational issues such as high workload and understafﬁng, especially
of registered nurses.
P1328 Transporting patients with highly infectious diseases: a
survey in 14 EU member states
S. Schilling*, H. Maltezou, F.M. Fusco, H.R. Brodt, B. Bannister,
P. Brouqui, V. Puro, R. Gottschalk, G. Ippolito for the European
Network for Highly Infectious Diseases − EuroNHID
Objectives: Highly Infectious Diseases (HIDs) are deﬁned as trans-
missible from person to person, causing life threatening illness and
presenting a serious hazard to the public. A harmonised response to
natural or man-made HIDs plays a vital role in the management of
such emergencies. In most European Union (EU) member states (MS),
specialised hospitals are responsible for the management of such cases.
Ground vehicle transportation capacities for HID patients are often co-
located with such facilities but lack a common design. To date, no data
on technical speciﬁcations and operational procedures of ground vehicles
for HID transport are available in the EU.
Methods: Until 2010, the European Network for HIDs conducted
a cross-sectional analysis of 46 hospitals in 14 MS responsible for
the management of HID patients. The availability of ground vehicle
capacities and management procedures regarding HID patient transport
were assessed. Categories evaluated included (i) legal issues; (ii)
technical and infrastructure issues; (iii) management procedures; and
(iv) promotion and monitoring of procedures.
Results: Only half of all centres evaluated have guidelines for the
transportation of HID patients (n = 23/46), neither national nor local
guidelines are in place in the majority of MS assessed (n = 10/14).
In contrary, the majority of centres evaluated do have access to
ground vehicles (n = 24/42 centres; 8 MS). In MS with speciﬁc
regulations adherence broadly differs: If speciﬁcally designed vehicles
are recommended, 90% of centres (10/11) do adhere to such regulations;
adherence to recommendations without technical speciﬁcations is found
in only 5/14 centres evaluated. Exclusive pathways for the admission of
patients and transport within the facility exist in the majority of centres
(31/43 and 29/24, respectively).
Protocols for the disinfection of ambulances and equipment exist in
33 and 29 centres, respectively; adherence to correct practice while
transporting patents is monitored in 29/42 centres.
Conclusion: Within the EU, quantity and technical speciﬁcation of
ground vehicles broadly differs. Although all centres evaluated are
responsible for the management of HIDs only 50% provide speciﬁc or
reserved ground vehicles. As rapid and short-distance relocation are most
desirable for HID patients, regulations for domestic and cross-border
transportation to the closest HLIU should be harmonised throughout the
EU.
P1329 Implementing peripheral vascular catheter care bundle in
a tertiary care hospital: no room for complacency?
A.F. Talento, M. Morris-Downes, T. Thomas, J. Walsh, E. Smyth,
H. Humphreys, F. Fitzpatrick* (Dublin, IE)
Background: Peripheral vascular catheter (PVC)-related infections are
an important cause of device related blood stream infection and are
potentially preventable. The 2009 Irish guidelines on the prevention of
intravascular catheter-related infection recommend introduction of “care
bundles” as an important component of an intravascular catheter related
infection prevention programme. The PVC care bundle was introduced
in Beaumont Hospital, a 750-bed tertiary referral hospital in Dublin
on April 2010. We assessed compliance with bundle components and
reviewed its impact on the incidence of PVC-related Staphylococcus
aureus blood stream infections (SABSI).
Methods: Compliance with the PVC care bundle was audited by
the Infection Prevention and Control Team in June and November
2010 using the national audit tool. Four components of the PVC
care bundle namely, clinical requirement for a PVC, presence of
extravasation or inﬂammation, status of PVC dressings and duration
of PVC <72 hours were assessed. In addition, documentation in the
daily PVC documentation sheet was assessed. As an outcome measure,
the incidence of PVC-related Staphylococcus aureus bacteraemia (SAB)
was measured.
Results: Overall compliance with the PVC care bundle was 66% and
74% in June and November 2010, respectively. Compliance varied with
ward speciality − In November, compliance was 74% in the medical
wards, 91% in the surgical wards, 74% in the neurosurgical and ENT
wards, 100% in the critical care units and 35% in the renal/transplant
wards. Since April 2010, there have been 10 cases of PVC-related
SABSI, ﬁve of which were in surgical patients.
Conclusion: Overall compliance with the PVC care bundle has improved
since its hospital wide implementation. There has been a slight decrease
in the number of PVC-related SABSI since PVC bundle implementation
when compared to 2009. However, the number of PVC-related SAB
remains high with half in surgical patients despite these wards having
the highest hospital ward compliance. We plan to re-audit these wards
to investigate the reasons for this further. We believe that it is therefore
essential to measure outcome in addition to process measures (such as
care bundles) in order to fully truly reduce PVC-related infection.
P1330 Multidrug-resistant organisms: concurrent burden and
implication on isolation
D. Kee, B. Ang, A. Chow, D. Lye* (Singapore, SG)
Objective: In 2010, at our hospital, 45% of Staphylococcus aureus
were methicillin-resistant (MRSA), 25% Escherichia coli (EC) and 39%
Klebsiella pneumoniae (KP) carried extended-spectrum b-lactamase
(ESBL), and 14% Pseudomonas aeruginosa (CRPA) and 83% of
Acinetobacter baumannii (CRAB) were resistant to carbapenems.
In planning isolation and contact precautions for multidrug-resistant
organisms (MDRO), we wish to know the concurrent prevalence of
different MDRO’s in patients.
Methods: We studied the ﬁrst admission and the ﬁrst isolate for patients
with MDRO’s in 2009 from computerised surveillance of all clinical
cultures since 1 January 2006. We studied the concurrent prevalence of
other MDRO’s for each MDRO, time to ﬁrst positive MDRO culture
from admission, and prevalence and duration of prior MDRO within our
records.
Results: In 2009, there were 860 MRSA, 340 CRAB, 455 ESBL EC,
419 ESBL KP and 111 CRPA fulﬁlling our study criteria.
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Of MRSA, 21% had concurrent CRAB, 6% ESBL EC, 10% ESBL KP
and 18% CRPA. Of CRAB, 8% had MRSA, 4% ESBL EC, 7% ESBL
KP and 16% CRPA. Of ESBL EC and KP, 5% each had MRSA, 8% had
CRAB, 15% and 10% each had CRPA; 9% of ESBL EC had ESBL KP,
and 5% ESBL KP had ESBL EC. Of CRPA, 2% had MRSA, 5% CRAB,
and 3% each had ESBL EC and KP. Patients with 1 MDRO comprised
68%, 2 MDRO’s 22%, 3 MDRO’s 7.6% and 4 MDRO’s 1.4%.
Median time from admission to positive culture for MRSA was 1.5 days
(interquartile range [IQR] 0−13), CRAB 11 days (IQR 5−24), ESBL EC
1 day (IQR 0−11), ESBL KP 5 days (IQR 1−20) and CRPA 10 days
(IQR 1–24.5).
Using only prior clinical cultures, 4% MRSA, 2% CRAB, 6% ESBL EC,
4% ESBL KP and 2% CRPA had the same prior MDRO. For MRSA,
the same MDRO could be traced as far back as 48 months, CRAB
34 months, ESBL EC 46 months, ESBL KP 42 months and CRPA 27
months.
Conclusion: Up to 31% of patients with MDRO had more than 1 MDRO.
Cohorting selected MDRO’s may have additional impact of isolating
other MDRO’s. It is impractical and logistically challenging to isolate
each MDRO separately given the prevalence of concurrent MDRO’s.
Persistence of MDRO is far longer than conventionally accepted 1 year
for MRSA and 3 months for Gram-negative bacteria.
P1331 Development of an epidemiological tool to assess the
potential of spread of organisms in rehabilitation centres
Y. Carmeli*, M. Kazma, E. Mordechai, A. Klein, M. Hochman,
R. Taya, M. Shakler, S. Navon-Venezia, A. Raskin-Segal, G. Rabinowitz,
Y. Lerman, J. Vidal-Samso, A. Salvia, J. Salomon, E. Isakov on behalf
of the MOSAR-WP5
Introduction: MOSAR-WP5 is a study directed at reducing the spread
of antibiotic resistant organisms (MDRO) in rehabilitation centers. Since
isolation of patients is contradictory to many principals of rehabilitation,
we aimed to focus on altering patients activities which are likely to spread
organisms. To estimate the potential of various activities to contribute to
the spread of MDRO, we developed and validated epidemiological tools.
Methods: In a 3-day multidisciplinary workshop of MOSAR-WP5
participants, we described the risk of spread related to activities as
the actual risk per unit of activity multiplied by the frequency of
the activity. Patients’ activities taking place during rehabilitation were
analyzed, and hypothetical risk of transmission deﬁned. By consensus,
universal parameters related to the activities believed to be important
to the risk of spread were agreed upon and graded. Validation of the
parameters was performed using experimental design of contamination.
These parameters were included in the “risk observation score“ (ROS)
measuring the potential risk with a unit of activity. This tool was
validated using environmental sampling with tryptic soy agar and
MacConkey contact plates. Grading activities using the ROS, and
measuring the frequency of each speciﬁc activity resulted in a “risk
assessment score”, which allows determining high risk activities in order
to direct interventions.
Results: The “risk assessment tool” included 5 parameters, 3 of which
were believed to determine potential spread: body area in contact,
duration of contact, and whether body secretions were in contact; and
2 parameters which reduce the potential of spread: protective measures
(such as gowns or gloves) and cleaning.
Preliminary microbiological validation supported the ROS scoring
system. The risk assessment score, was used in 5 rehabilitation centers.
In each center at least 30 types of activities (or object) were examined,
and scored for 30 encounters. Frequency (load) of each activity or object
were samples for a total of 5 hours. The combination of the ROS and
the frequency of use allowed each center to deﬁne the “risk assessment
score”, and identify high risk activities.
Conclusions: The tools developed and methodology used can help direct
infection control measures to combat the spread of MDRO.
P1332 Outbreak of Burkholderia cenocepacia bacteraemia in an
intensive care unit: an epidemiologic and molecular study
M. Katsiari*, Z. Roussou, A. Xydaki, K. Tryﬁnopoulou, A. Vatopoulos,
E. Platsouka, A. Maguina (Athens, GR)
Objectives: Burkholderia cepacia complex is a widespread Gram-
negative environmental bacillus associated with nosocomial infection.
We present epidemiology, diagnosis and surveillance of a 10-month
outbreak of nosocomial Burkholderia cenocepacia bacteremia involving
twenty-one critically ill patients in a 9-bed multidisciplinary Intensive
Care Unit (ICU).
Methods: Medical records of patients infected were reviewed and the
following data were collected: Age, sex, type of admission (medical
or surgical) and APACHE II score, day of bacteremia identiﬁcation
following ICU admission, results of antimicrobial susceptibility tests,
response to therapy, length of ICU stay (LOS) and outcome. PCR
ampliﬁcation of B. cepacia complex recA gene and sequence were
used for molecular identiﬁcation of Burkholderia sp. isolates. Molecular
typing of Burkholderia cenocepacia isolates was performed by Pulsed
Field Gel Electrophoresis (PFGE).
Results: Thirty episodes of B. cepacia bacteremia (3 catheter-related
infections) were diagnosed in 21 patients (15 males), mean age 66±15
years. APACHE II score on admission was 17.8±8.7, 8 cases being
medical and 13 surgical admissions. Median time for a positive
blood culture was 9 days after admission. The pathogen grew in
blood cultures after 3.3±1 days of incubation and was susceptible
in meropenem, piperacillin/tazobactam, ciproﬂoxacin and trimethoprim/
sulphamethoxazole. Surveillance involved environmental and patients-
personnel cultures: chlorhexidine and povidone-iodine disinfectants,
heparin solutions, ventilator tubing condensate, water taps, patients’
skin, personnel hands, blood gas analyser, intravenous lines, saline
and dextrose solutions and bronchial secretions suction equipment.
All samples were negative for B. cepacia. PFGE molecular typing
showed that all isolates were undistinguished. Complete elimination of
the outbreak was achieved only after ICU’s disinfection. All patients
responded to the antimicrobial therapy and had median LOS of 24
days. Among our study population, 6 patients died in septic shock and
multiorgan failure due to other multiresistant Gram negative pathogens.
Conclusions: Although B. cenocepacia outbreaks are quite frequent,
true bacteremias are rare and in our cohort did not affect ICU mortality.
Environmental and epidemiological investigations are necessary to
identify the source of infection. Infection control measures are essential
for hospital outbreaks eradication.
P1333 Infection control and MRSA in nursing homes − the
perspective of nursing home staff
P. McClean*, C. Hughes, M. Tunney, D. Gilpin, C. Parsons, N. Baldwin
(Belfast, UK)
Objectives: In 2008 a cluster randomised controlled trial (cRCT)
involving an infection control education and training intervention in
nursing homes in Northern Ireland found no signiﬁcant difference in
the prevalence of Meticillin resistant Staphylococcus aureus (MRSA) in
homes which received the intervention compared to homes where usual
practice continued. Furthermore, at the end of the study only 37.5%
of intervention homes were deemed compliant when audited against
infection control standards. The purpose of this qualitative study was
to explore the reasons for these results and to determine the feasibility
of carrying out a MRSA decolonisation programme in the nursing home
environment.
Methods: Following ethical approval, staff who were trained in the
intervention nursing homes during the cRCT were invited to participate.
Six one-to-one interviews with nursing home managers and 6 focus
groups each consisting of 4−7 participants i.e. nurses, care assistants
and infection control link workers were conducted between November
2009 and February 2010. Transcripts were reviewed and coded into major
themes using framework analysis.
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Results: Participants identiﬁed that some audit standards could not be
met due to ﬁnancial reasons. Gloves, aprons and hand-gels were readily
available; however, replacing worn furniture and equipment was more
difﬁcult. It was reported that care assistants were poorly paid, which
may explain the high levels of staff turnover and the difﬁculties in
ensuring that all staff are adequately trained in infection control. The
majority of participants stated that they would like nursing homes to be
MRSA free and favoured the concept of decolonisation. However, there
were concerns about carrying out the decolonisation process in frail,
ill and confused residents, about the risk of recolonisation particularly
with frequent hospital transfers, and about the extra workload associated
with decolonisation. It was reported that doctors were not in favour of
prescribing for the decolonisation of MRSA in nursing home residents.
Conclusions: Owners of nursing homes need to review their budgets
to ensure that there are adequate resources to enable infection control
standards to be met. The feasibility of carrying out widespread MRSA
decolonisation in nursing homes may be questionable. Therefore, the
focus must continue to be on good infection control practices.
P1334 Development of a preparedness plan to control the spread
of carbapenemase-producing Gram-negatives in a tertiary
hospital serving a major international airport
S. Thomas*, B. Isalska, C. Thornhill, J. Turner-Gardner, D. Walter
(Manchester, UK)
Objectives: To develop a preparedness plan to prevent the spread of
carbapenem producing Gram negatives (CPGN) focusing on detection,
screening and containment in the setting of a tertiary hospital providing
specialist care for areas such as Burns, Transplant, Cystic Fibrosis and
serving a major international airport.
Methods: Phase 1: Detection. An algorithm for detection of CPGNs was
prepared involving automated sensitivity testing, MIC conﬁrmation, a
Modiﬁed Hodge Test and reference laboratory referral for conﬁrmation
by PCR on any suspicious isolate. Data on all CPGNs was collected
prospectively over a 10 month period, January-October 2010.
Phase 2: Screening. A risk assessment and screening policy was
incorporated into the current A+E Management of Sepsis protocol. “At
risk” was deﬁned as any patient hospitalized abroad, or in a UK hospital
with a known outbreak of CPGN, in the last 6 months. Where a CPGN
was isolated from a ward patient, screening of all patients within the
shared bay was carried out.
Phase 3: Infection Control. An algorithm for isolation and management
of high risk or conﬁrmed cases was rolled out via Infection Prevention.
Early liaison with microbiology was encouraged. A patient information
leaﬂet was designed for any patient undergoing screening. Educational
presentations were given to laboratory, infection control, ICU and A+E
staff.
Results: 13 CPGN isolates have been detected with a variety of
resistance mechanisms. All high risk patients are screened in A+E
and isolated until conﬁrmation of a negative result. Priority is given
over MRSA or C. difﬁcile positive patients. High risk or conﬁrmed
patients receive a ward visit by the Infection Prevention Team.
Strict Infection Control precautions are initiated including side room
isolation with en-suite facilities until discharge. Single use items are
recommended wherever possible; sphygmomanometer, stethoscope, ﬂoor
cloths, medicine pots, host slings and slide sheets. On discharge
a terminal clean with 1,000ppm Chlor-clean is carried out and
environmental screening swabs collected.
Conclusion: The Preparedness Plan has raised awareness of the
emerging public health threat. The laboratory has changed practices
to increase conﬁdence in detection, including isolates with borderline
MICs. Screening has enabled early patient isolation. Infection Control
measures have been strengthened. To date only one conﬁrmed case has
led to cross contamination within the hospital.
P1335 From IPSE to TRICE: evolution in Europe of the state of
the art of infection control
S. Brusaferro*, F. Coiz, B. Cookson, G. Privitera, R. Gallagher,
T. Cooper, J. Fabry, P. Hartemann, S. Kalenic, W. Popp,
K. Mannerquist, P. Viale, C. Ruef, K. Weist, C. Varela Santos,
C. Suetens (Udine, IT; London, UK; Pisa, IT; Lyon, Nancy, FR;
Zagreb, HR; Essen, DE; Stockholm, SE; Bologna, IT; Zurich, CH)
Introduction: Training Infection Control in Europe (TRICE) was
an ECDC funded project aimed to update the information regarding
Infection Control/Hospital Hygiene (IC/HH) training in European
countries.
This paper presents key results related to the evolution in Europe of
infection control resources.
Methods: The project, built on the approach and developed a
questionnaire based on Work Package 1 (2006) EU funded project
“Improving Patient Safety in Europe” (IPSE). IPSE questions considered
still relevant were accepted while new areas of interest were added.
National representatives for the project (NR) were identiﬁed by ECDC’s
national competent bodies for training on ECDC’s request and contacted
to participate in the project between April and August 2010.
Participants in the 2006 IPSE survey were asked to compare situations
between 2006 and 2010. The response rate was 100% amongst the 33
nominated NCPICTs.
Results: Most Countries (81.8% (27/33)) reported the presence of a
deﬁnition of the Infection Control Team within national programmes or
regulations. Six more countries reported it compared to 2006.
87.9% (29/33) of the respondents had recommendations for managing
IC/HH at a national level.
The professionals in charge of IC/HH were mostly associated (78.8%;
[26/33]) with microbiological or infectious diseases departments
followed by global or medical management and management of quality
and safety (each 42.4%[14/33]).
The usual background for IC/HH Nurses was a “graduated/certiﬁed
nurse” (84.4%) followed by Intensive Care Unit and operating theatre
(each 18.2% [6/33]).
Deﬁnitions of a professional proﬁle had increased between 2006
and 2010 (IC/HHDoctors from 58.1% (18/31) to 84.8% (28/33),
IC/HHNurses from 71.0% (22/31) to 81.8% (27/33).
The presence at national or professional levels of a national curriculum
or programme for IC/HH training showed a signiﬁcant increase between
2006 and 2010: doctors from 32.6% (10/31) to 57.6% (19/33) and for
nurses from 54.8% (17/31) to 63.6% (21/33) respectively.
Conclusions: These data show that Europe is moving towards a higher
priority for HAI prevention and control and it is apparent that it is
feasible to deﬁne and attain new targets in the application of EU
Council recommendations provided that all stakeholders (governmental
institutions, universities, health care providers, managers, professionals,
patients and their advocates) are engaged and support and sustain new
initiatives speciﬁcally for professional training.
P1336 Respiratory isolation in HIV patients with suspected
pulmonary tuberculosis: comparison of clinical predictive
models
M. Carugati*, F. Zanini, C. Schiroli, F. Croce, F. Franzetti (Milan, IT)
Objectives: The latest estimates of tuberculosis global burden show that
there are 9.27 million new cases of TB in 2007 including 1.37 million
cases among HIV positive people. Current recommendations to control
TB spread call for immediate isolation of any patient suspected to have
infectious TB. We tested 4 predictive models currently available for early
identiﬁcation of patients at risk for pulmonary TB (Wisnivesky, Rakoczy,
Tattevin and Redd model) in a HIV population in order to identify the
best performing score.
Methods: 119 HIV infected patients admitted to an urban hospital
in Milan from January 2008 to September 2010 with suspicion of
pulmonary TB were retrospectively studied. Cases were those in whom
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active pulmonary TB was diagnosed, while patients placed under
airborne precautions and characterised by sputum cultures negative for
Mycobacterium tuberculosis formed control group. Investigators unaware
of patient status (case or control) analysed data and applied predictive
models. Sensitivity, speciﬁcity, predictive values, diagnostic accuracy,
positive and negative likelihood ratio (LR) and diagnostic odds ratio
(DOR) were assessed for each score. Results were compared to data
obtained in previous studies.
Results: 101 patients tested negative for M. tuberculosis, whereas 18
HIV patients presented pulmonary TB. Rakoczy’s predictive model
showed the highest sensitivity (0.94) and was associated with a notable
negative predictive value (0.98). Sensitivity of Wisnivesky, Redd and
Tattevin score were 0.89, 0.50 and 0.89 respectively. Tattevin’s model
was characterised by the greatest positive predictive value (0.36) and
the highest speciﬁcity (0.71); on the other hand Wisnivesky, Rakoczy
and Redd scores were less speciﬁc (0.29, 0.65 and 0.36 respectively).
When applied to a HIV positive population, as happened in this study,
predictive models were less sensitive than in previous studies applied to
a general population (see Table).
Conclusion: Rakoczy and Tattevin models performed better than
Wisnivesky and Redd scores in HIV setting. Items included in the
former scores were immigration, compatible chronic symptoms and
typical CXR ﬁndings. On the other hand, Rakoczy score considered also
immunosuppression and absence of shortness of breath, whereas Tattevin
score included BCG immunization and homelessness. According to the
great variability of TB clinical presentation in this population, a novel
predictive model should be developed.
P1337 Evaluation of control measurement procedures in the
prevention of carbapenemase-2 (KPC-2)-producing
Klebsiella pneumoniae nosocomial transmission
M. Rossi*, G. Migliorino, E. Motta, S. Foresti, S. Bramati, S. Malandrin,
M. Vanenti, P. Lanfranco, E.F. Vigano`, A. Gori (Monza, IT)
Objective: Antibiotic-resistant pathogens constitute an important and
growing threat to be public health. The aim of the present study was to
evaluate the effectiveness of the implementation of control measures
in the prevention of carbapenemase-2 (KPC-2)-producing Klebsiella
pneumoniae transmission in a university hospital in Italy.
Methods: All isolated of Klebsiella species with reduced susceptibility
to carbapenems and positives by boronic acid and Hodge test were
prospectively collected from December 2009 through December 2010.
One isolate per patient was submitted for further study. MICs of
meropenem, colistin, gentamicin, tigeciclyne and cotrimoxazole were
evaluated by E.test and were classiﬁed according to Clinical and
Laboratory Standards Institute (CLSI) breakpoint. The isolates were
evaluated using rep-PCR (Diversilab bioMerieux) for clonal diffusion.
Contact-isolation precautions for patients colonized or infected with
KPC-2-producing K. pneumoniae were implemented. All patients
with KPC-2-producing K. pneumoniae isolates, if available, were
transferred to Infectious Diseases ward. Other measures were as follow:
improvements in hand hygiene, an educational program for all hospital
department by a protocol, introduction of screening tests of active
sourveillance.
Results: From December 2009 through December 2010, 59 patients
were infected and 2 colonized by KPC-2-producing K. pneumoniae.
Rep-PCR analysis showed a cluster of 57 strains. A single case patient,
infected at a long-term facility, introduced the strain into our hospital, in
Geriatric ward, in December. 15 patients were hospitalized in the ICU
when the KPC-producing isolate was detected, 35 in medical ward and
9 in surgical ward.
Before the introduction of control program 9−11 patients/month were
infected by KPC-2-producing K. pneumoniae. After the application
of the control program a reduction of KPC-2-producing isolates was
observed: in October 10 patients, in November 3 patients, in December
1 patient.
Conclusion: This is one of the largest outbreak of Carbapenemase-2
(KPC-2)-producing K. pneumoniae reported in Europe. The application
of strict combinated control measures was effective in the reduction of
cross-transmission and should be immediately adopted in order to control
the spread of KPC-2-producing K. pneumoniae
P1338 Reducing the spread of Acinetobacter baumannii and
methicillin-resistant Staphylococcus aureus on a burns unit
through the intervention of an infection control bundle
including hydrogen peroxide vapour decontamination
F. Barbut, J. Pham, S. Yezli, M. Mimoun, J.A. Otter* (Paris, FR;
Andover, UK)
Objectives: We investigated the impact of an infection control bundle
on the incidence of nosocomial MRSA and Acinetobacter baumannii on
a burns unit.
Methods: Our 10-bed burns was closed for maintenance in July and
August 2008 and we took the opportunity to decontaminate the entire
unit using a HPV decontamination service (Bioquell) and implement a
bundle of infection control interventions when the unit was reopened in
September 2008, including: regular HPV decontamination of the rooms
following discharge of patients colonized/infected by multidrug-resistant
bacteria, pre-emptive cohort isolation of newly admitted patients before
proven culture negative, cohorting of colonised patients, installation of
two air disinfection systems in the corridors of the unit (Plasmair) and
improvement of material storage. Surfaces were sampled for bacteria
and fungi and air samples were collected for fungi to monitor the
effectiveness of the HPV. The incidence of nosocomial MRSA and
A. baumannii was compared from January 2007-June 2008 (pre-
closure) with September 2008-December 2009 (post-closure). Statistical
comparisons were performed using Fisher’s Exact Test for categorical
variables and the Mann-Whitney U test for continuous variables.
Results: HPV decontamination of the entire unit reduced signiﬁcantly
bacterial surface counts (from mean 4.0 to 0.7 cfu/100cm2, p< 0.02)
and fungal surface (from 3.5 to 0 cfu/100cm2) and air (from 3.7 to 0.5
cfu/m3 air, p< 0.01) counts. However, these samples were collected 3
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days after HPV decontamination was performed so we cannot rule out the
possibility of post-process contamination. Regular HPV decontamination
of patients’ rooms also reduced signiﬁcantly bacterial surface counts
(from mean 2.9 to 0.1 cfu/100cm2, p< 0.001) and fungal surface (from
1.0 to 0 cfu/100cm2) and air (from 5.5 to 0 cfu/m3 air, p = 0.01) counts.
The incidence of nosocomial MRSA fell by 90% from 7.6 to 0.8
cases/1000 patient days (p< 0.001) and the incidence of nosocomial
A. baumannii fell by 89% from 7.3 to 0.8 cases per 1000 patient days
(p< 0.001) (ﬁgure).
Conclusion: A HPV decontamination service is effective for the removal
of environmental contamination on a unit or room scale. A bundle of
infection control interventions resulted in a signiﬁcant reduction in the
incidence of nosocomial MRSA and A. baumannii. However, we were
not able to determine the relative contribution of each of the interventions
to the reduction but it is likely that all were important.
P1339 Effect of multimodal interventions and healthcare-worker
inﬂuenza vaccination on reducing all-cause nosocomial
pneumonia in haematopoietic stem cell transplant recipients
P. Ferguson*, N. Gilroy, T. Sloots, M. Nissen, T. Sorrell (Blacktown,
Sydney, Brisbane, Westmead, AU)
Nosocomial respiratory virus infections (RVI) cause signiﬁcant clinical
disease and poor outcomes in haematopoietic stem cell transplant
(HSCT) recipients, particularly if acquired during the transplant
admission.
Objectives: To improve compliance with recommended methods to
prevent nosocomial RVI in HSCT recipients and evaluate the effect on
all-cause nosocomial pneumonia.
Methods: Multimodal interventions (inﬂuenza vaccination, hand wash-
ing, ward redevelopment, entry restriction, screening patients for RVI,
staff, patient and family education) were instituted in yearly increments
from January 2004. Time to ﬁrst episode of nosocomial pneumonia
was recorded for each HSCT patient admitted to the haematology ward,
Westmead Hospital, Australia, January 2003 to September 2007.
Results: Vaccination of haematology staff against inﬂuenza increased
from 59 to 67% during 2004–2007. Compliance was ﬁve-fold higher
in haematology than intensive care staff (OR 5.3, 95%CI 3.1−9.0,
P< 0.0001).
Nosocomial pneumonia was diagnosed in 182/810 (22.5%) admissions.
Patients admitted for HSCT were most at risk (48.9% and 4.6% in those
with prior HSCT, OR 3.42, 95%CI 2.96–3.96, P< 0.0001). While more
episodes occurred in admissions for allogeneic than autologous HSCT
(25.5% and 16.8% respectively, OR 1.69, 95%CI 1.15–2.49, P = 0.007),
this difference disappeared after adjustment for length of stay (P = 0.8).
RV(s) were identiﬁed in 13.4% of all nosocomial pneumonia episodes.
After adjustment for other variables, nosocomial pneumonia was
associated with admission for HSCT (HR 4.23, 95%CI 2.72–6.58),
female sex (HR 1.49, 95%CI 1.10–2.01), and age >46 years (HR
1.59, 95%CI 1.17–2.16). In patients receiving an allogeneic HSCT, year
of admission, use of stem cells from an unrelated donor (HR 2.03,
95%CI 1.37–8.01, P< 0.0001) and age >46 years (HR 2.15, 95%CI
1.46–3.16, P< 0.0001) were associated with nosocomial pneumonia on
multivariable analysis. The adjusted odds of developing nosocomial
pneumonia in patients admitted in 2005, 2006 and 2007 were 49−55%
less than in those admitted in 2003 (P 0.03).
Conclusion: Over ﬁve years, the incidence of nosocomial pneumonia
in patients receiving allogeneic HSCT at a single centre was halved by
the introduction of multimodal infection control measures. A multicentre
study with randomisation of control and intervention sites is required to
conﬁrm these results.
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P1340 Emergence of novel blaKPC-12 and blaKPC-13 variants
in carbapenem non-susceptible Enterobacter cloacae: a ﬁrst
report of blaKPC gene in Thailand
T. Netikul, P. Kiratisin* (Bangkok, TH)
Objectives: To survey for carbapenem susceptibility and carbapenem-
resistant determinants among Enterobacteriaceae clinical isolates at
a university hospital in Thailand, and characterise blaKPC-carrying
isolates reported for the ﬁrst time in this country.
Methods: All Enterobacteriaceae clinical isolates collected at Siriraj
Hospital, a 2300-bed tertiary care in Bangkok (Thailand), during
2009–2010 were included. Isolates non-susceptible to a carbapenem
(ertapenem, imipenem, meropenem or doripenem) as conﬁrmed by MIC
determination using E-test® method were tested for carbapenemase
production by modiﬁed Hodge test (MHT) and were subject to genotypic
characterisation (PCR sequencing) of various bla genes including
bla(CTX-M, TEM, SHV, VEB, OXA, AmpC, KPC, IMP, VIM and
NDM). Isolates harbouring blaKPC were investigated for their clonality
by pulsed-ﬁeld gel electrophoresis (PFGE).
Results: A total of 172 out of 12,741 Enterobacteriaceae isolates
(1.3%) were non-susceptible to at least a carbapenem. Only 22 isolates
(12.8%) yielded a positive MHT and 45 isolates (26.2%) were resistant
to all four testing carbapenems. Two multidrug-resistant isolates of
Enterobacter cloacae, both from urine specimens, demonstrated positive
PCR for blaKPC, but were negative for MHT. The ﬁrst isolate also
carried bla(TEM-1 and CTX-M-15), and the latter isolate also carried
bla(TEM-1, CTX-M-3, VEB-1 and OXA-10). MICs of ertapenem,
imipenem, meropenem and doripenem, respectively, for the ﬁrst isolate
were 6, 1.5, 0.5 and 0.8, and for the latter isolate were >32, 3, 4 and
4mg/L. blaKPC sequences of the ﬁrst isolate was most closely related to
blaKPC-3 (99.8%) with A272G and C513T mutations, and was named
blaKPC-12. blaKPC sequence of the latter isolate, namely blaKPC-13,
was most closely related to blaKPC-12 (99.7%) with T297C, C487T and
A844G mutations, and carried at least six nucleotide differences from
other previously identiﬁed blaKPC genes. Both isolates were not clonally
related based on PFGE result.
Conclusions: This study identiﬁed the ﬁrst and novel blaKPC genes
in Thailand. blaKPC-12 was less resistant and more related to known
blaKPC genes compared to blaKPC-13. Monitoring of the emergence and
spread of carbapenem non-susceptible Enterobacteriaceae is critical for
infection control. Further characterisation of both novel blaKPC genes
and other carbapenem non-susceptible isolates are warranted for better
understanding of their resistance mechanisms.
P1341 Plasmid-carried blaKPC-2 genes in Enterobacteriaceae in
Brazil
L.N. Andrade, T. Curiao, J.C. Ferreira, J.M. Longo, E.C. Climaco,
R. Martinez, F. Bellissimo-Rodrigues, A. Basile-Filho, M.A. Evaristo,
F. Baquero, R. Canto´n, A.L. Darini*, T.M. Coque (Ribeirao Preto,
BR; Madrid, ES)
Objectives: Globally spread KPC carbapenemases have been sporadi-
cally detected in Brazil and other South American countries. We analyzed
52 carbapenem resistant K. pneumoniae (Kp) (clinical and fecal isolates)
from an university hospital in Brazil (Hospital das Clinicas of Medical
School − University of Sao Paulo) during 2007 to 2009.
Methods: Clonal relatedness was established by PFGE and MLST.
Plasmid characterization (Inc group, RFLP analysis) and identiﬁcation of
the blaKPC genetic environment (Tn4401-PCR mapping) was assessed.
Results were compared with previously available information about KPC
in Brazil.
Results: Kp isolates were grouped in 8 PFGE types and 3 sequence
types: KpA-ST258 (n = 50; 6 subtypes), KpA6-ST11 (n = 1) and KpE-
ST48 (n = 1). All isolates were resistant to ﬂuoroquinolones, susceptible
to polymixin B and tigecycline and variably resistant to amikacin,
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tobramycin and gentamicin. The blaOXA-9 and blaTEM-1 genes were
detected in all strains while blaCTX-M-2 was identiﬁed in the only
KpA-ST48 isolate; never in KpA-ST258 or KpA6-ST11 clones. The
blaKPC-2 gene was located on Tn4401a associated with plasmid of the
incompatibility group FII (130kb-IncFII plasmid).
Conclusions: The study reports an apparent spread of blaKPC-2 in
that hospital in Brazil facilitated by the expansion of globally spread
K. pneumoniae clones of the CC258 complex (ST258 and ST11) and
the spread of an unique plasmid. It also constitutes the ﬁrst description
of ST258 in Brazil, a clone which was able to successfully disseminate
among patients of different hospitals in Sa˜o Paulo State.
This study was funded by research grants from Brazil (CNPq
480848/2008−4, PhD 142736/2008−2, fellowship 201191/2009−1,
FAPESP) and Spain (European Commission: LSHMCT-2008–223031-
CIBERESP Network for Biomedical Research in Epidemiology and
Public Health; Instituto Carlos III, Spanish Ministry of Science and
Innovation − CB06/02/0053 and 201191/2009-1).
P1342 KPC-producing Klebsiella pneumoniae from Rome, Italy
A. Garcı´a-Ferna´ndez*, A. Giordano, L. Villa, C. Venditti, M. Venditti,
C. Mancini, A. Carattoli (Rome, IT)
Nosocomial infections sustained by carbapenem-resistant Klebsiella
pneumoniae (KP) are a global health problem. Active surveillance has
been maintained during the last three years at the Policlinico Umberto
I Hospital, demonstrating that the increasing ertapenem resistance in
KP was mostly associated to the production of Extended-Spectrum
b-Lactamases (ESBLs) in speciﬁc successful clones, showing the
alterations of the major OmpK35, OmpK36 nonspeciﬁc porins. However,
the KP clone ST258 producing KPC was recently introduced in this
hospital and the ﬁrst strain was fully characterized.
Material and Methods: Identiﬁcation and antimicrobial susceptibility
were performed by Vitek 2 with the AST-N089 cards and disk tests with
meropenem and boronic acid and/or EDTA. Strains were analysed by
PFGE, MLST, OmpK-35/36 and ESBL bla gene PCR and sequencing.
Plasmid analysis was done by PBRT and whole plasmid sequencing by
the 454GS-FLX (Roche).
Results: The ﬁrst KPC-3 positive strain was isolated on June 2010 from
an abdominal drainage, belonged to the epidemic clone ST258 and was
resistant to all b-lactam/b-lactamase inhibitor combinations, trimetho-
prim/sulfamethoxazole, ﬂuoroquinolones, tobramicin and amikacin.
Porin analysis demonstrated porin alteration because of the loss of
OmpK35 by a termination of translation, and a novel OmpK36 variant
showing two additional amino acids, located within the internal loop L3,
one of the highly conserved domains of the protein.
The KPC-3 plasmid was fully sequenced revealing high homology with
plasmid pKpQIL identiﬁed in Israel (NC_014016), including the transfer
locus, the replicon (classiﬁed as FIIk), the variable region conferring
multi-drug resistance and the Tn4401 transposon, carrying the blaKPC-3.
This plasmid also showed a second repA3 and a partitioning system of
probable phage origin.
Conclusions: The high and fast spread of blaKPC-3 gene could be
explained by the clonal expansion of the ST258 clone, but also by its
location on the FIIk plasmid. The FIIk family seems very common in KP
of different origin (Villa et al. 2010) but these plasmids were undetected
and ignored since negative for resistance gene markers. As result of
genomic and plasmid high-throughput DNA sequencing, FIIk plasmids
appear as potential virulence plasmids.
In the epidemic clone ST258, a plasmid of this family acquired the
Tn4401 transposon carrying KPC-3 and the clone and the plasmid
successfully spread worldwide.
P1343 Dissemination of DHA-1 and CMY-2 b-lactamases among
Klebsiella spp. and E. coli from Portuguese clinical settings
F. Freitas*, A. Novais, T. Gonc¸alves, S. Amaral, R. Canto´n, T.M. Coque,
E. Machado, L. Peixe on behalf of The Portuguese Resistance Study
Group
Objectives: Acquired AmpC b-lactamases (qAmpC) have increasingly
been recognized as an emerging problem worldwide. We investigate the
occurrence and diversity of genes coding for qAmpC enzymes among
Enterobacteriaceae from Portuguese clinical settings over a 6 year period
(2002−08).
Methods: We analysed 100 presumptive qAmpC producers (34
E. coli, 52 K. pneumoniae, 13 K. oxytoca, and 1 P. mirabilis)
recovered from 3 Portuguese hospitals and 2 ambulatory laboratories
(North and Centre, 2002−08). Antimicrobial susceptibility testing was
performed by standard methods (CLSI). Production of qAmpC and
ESBL enzymes was investigated by the PBA (phenylboronic acid)
and the DDST tests, respectively. Identiﬁcation of genes coding
for qAmpC (blaCMY/MOX/FOX/LAT/ACT/MIR/DHA/MOR/ACC) or
ESBL (blaTEM/SHV/CTX-M) was performed by PCR and sequencing.
Clonal relatedness was established by XbaI-PFGE. E. coli phylogenetic
groups and clonal complexes were identiﬁed by PCR and MLST,
respectively. Transferability of blaqAmpC was tested by conjugation.
Results: qAmpC expression was observed in 59% (59/100) of the
isolates and the enzymes were identiﬁed as DHA-1 and CMY-2.
DHA-1 was the most common variant (80%, 47/59), being found in
K. pneumoniae (n = 41; 12 PFGE-types), K. oxytoca (n = 4; 2 PFGE-
types) and E. coli (n = 2; 2 PFGE-types; B1-ST1196 and B2-fumC24),
throughout the studied period. CMY-2 was only detected among E. coli
(5%, 3/59; 3 B1 PFGE-types; 1 ST101 complex and 1 B1-fumC65)
from one hospital. An epidemic K. pneumoniae clone was identiﬁed in
different hospitals. DHA-1 and CMY-2 producers were mainly recovered
from urine (n = 19, 38%) or respiratory samples (n = 13, 26%). ESBL
co-production (SHV-5, -12, -64, -90, CTX-M-32) was observed in
85% (40/47; 15 PFGE-types; all species) of DHA-1-producing isolates.
Co-resistance to non-b-lactams was frequently observed, mainly to
kanamycin (98%), tobramycin (96%), sulfonamides (96%), streptomycin
(84%), ciproﬂoxacin (82%), and trimethoprim (80%). blaqAmpC were
not transferred by conjugation.
Conclusions: Our study demonstrates the spread of qAmpC (DHA-1,
CMY-2) enzymes in Portuguese clinical settings at least since 2003
within different Enterobacteriaceae species and clones which also
produced ESBL. A shift in ESBL-epidemiology in Portugal might be
anticipated by the dissemination of qAmpC enzymes among particular
ESBL-producing species.
P1344 Emergence of VIM-1-carbapenemase-producing
Enterobacter cloacae isolates in the Tyrol, Austria
I. Heller*, K. Grif, D. Orth-Ho¨ller (Innsbruck, AT)
Objectives: The rapid emergence and dissemination of carbapenemase
producing Enterobacter sp. and other Enterobacteriaceae poses a
considerable threat to clinical patient care and public health. In this
study, Enterobacter isolates demonstrating decreased susceptibility to
carbapenems detected at the Division of Hygiene and Medical Microbi-
ology, Innsbruck Medical University, were evaluated for the production
of metallo-b-lactamases, serine b-lactamases and OXA carbapenemases
using polymerase chain reaction (PCR) tests. Additionally, the isolates
were epidemiologically typed to determine the genetic relatedness.
Methods: From January 2006 to December 2010, isolates of Enter-
obacter sp. with reduced susceptibility to carbapenems were collected
from the University hospital Innsbruck, district hospitals and general
practitioners in the Tyrol. All isolates were tested for bla(VIM-1),
bla(NDM-1), bla(IMP), bla(KPC) and bla(OXA-48, 23, 24, 58) using a
multiplex PCR with published primers. Two typing methods − pulsed
ﬁeld gel electrophoresis (PFGE) and repetitive-sequence-based PCR
(rep-PCR) − were performed to analyse the clonality of the isolates.
S374 21st ECCMID/27th ICC, Posters
Results and Conclusion: In total, 34 isolates (29 Enterobacter cloacae
and 5 Enterobacter aerogenes) were collected during the study period.
From 2006 to 2009, between 2 and 7 isolates were found per year. In
2010, a signiﬁcant increase of carbapenem resistant strains was observed
(n = 12). In 25 isolates of Enterobacter cloacae, the bla(VIM-1) gene was
detected. Typing of Enterobacter cloacae by PFGE and rep-PCR revealed
ﬁve patterns each. Seventeen isolates showed an identical genotype with
both methods. The ﬁve Enterobacter aerogenes isolates were clearly
separated from Enterobacter cloacae and yielded different patterns each.
These ﬁndings demonstrate the emergence of VIM-1-producing Enter-
obacter cloacae in our geographical area (the Tyrol, Western Austria).
The clonal relationship conﬁrms the risk of spread of these organisms
and their possible persistence over the time.
P1345 Microarray analyses of Escherichia coli isolates producing
extended-spectrum b-lactamases from food, farm animals
and humans from the UK, the Netherlands and Germany
G. Wu*, M. Mafura, J. Fenner, M. Woodward, N. Coldham (Addlestone,
UK)
Objectives: Escherichia coli can be harmless commensals or causative
agents of diarrhoea or extraintestinal infections among animals and
humans. The recent rapid increase in the occurrence of extended-
spectrum b-lactamases (ESBL)-producing E. coli that are often resistant
to multiple antimicrobial agents in both animals and humans poses a
serious therapeutic challenge. In order to understand the diversity and
distribution of ESBL-producing E. coli among different host species and
different countries and to gain insight into their transmission, we have
screened ESBL-producing E. coli isolates for their virulence (VIR) and
antimicrobial resistance (AMR) genes.
Method: Approximately 800 E. coli from farm animals (cattle, broilers,
turkeys), animal food products and humans and from different countries
(UK, Netherlands and Germany) shown to produce ESBLs were analysed
for their carriage of 120 VIR and 153 AMR genes using miniaturised
microarrays (IdentiBac). Data were analysed by clustering algorithms,
k-mean partition, and multivariate analysis of variance (MNOVA) whilst
diversities were assessed by Simpson’s diversity index (D).
Results: The majority of isolates were similar to those from the same
host species and different from those from other host species in terms of
their carriage of the VIR and AMR genes (p< 0.001), but other isolates
from different countries and host species were indistinguishable (Fig. 1).
Human isolates from the Netherlands (122 isolates, D= 0.83 and 0.72)
and Germany (14 isolates, D = 0.83 and 0.68) were considerably more
diverse than those from the UK (196 isolates, D = 0.62 and 0.46) based
on the clustering analysis and k-mean partitioning results respectively.
Fig. 1. MNOVA shows the similarities and differences of E. coli strains in regard to
their VIR and AMR genes from different countries and host species. The coloured
circles indicate the approximate areas covered by different host species.
Conclusion: Although some strain types appeared to be mainly
associated with certain host species or country, others were found
in multiple host species or countries suggesting cross-species and
cross-country transmissions. The different levels of diversity observed
among human isolates from different countries indicate that the human
population are receptive to different types of ESBL-producing E. coli
strains. This demonstrates an ongoing requirement to monitor and control
both person-to-person as well as cross-species transmission of ESBL-
producing E. coli.
We thanks FSA for ﬁnancial support and contributions from Federal
Institute for Risk Assessment and Institute of Farm Animal Genetics,
FLI, Germany, Health Protection Agency UK and the Reference
Laboratory on Antimicrobial Resistance in Animals, Netherlands.
P1346 Trends in annual prevalence of Escherichia coli O25b/ST131
(ESBL producer and non-producer), in a 6-year period in
southern Spain
M. Bellido, L. Lo´pez-Cerero*, L. Serrano, D. Navarro,
J. Rodrı´guez-Ban˜o, A. Pascual (Seville, ES)
Objectives: A genetically distinct strain of E. coli sequence type
(ST) 131 harbouring CTX-M-15, as well as producing other ex-
tended spectrum b-lactamases (ESBL) and plasmid-encoded AmpC
b-lactamases (p-AmpC), has emerged worldwide. In our area third-
generation cephalosporins-susceptible isolates belonging to this clone
have been also detected. The annual trend of these bacteria is not known
and longitudinal observations are lacked. The aim of this study was
to assess the prevalence of ST131 isolates in a prospective systematic
collection of E. coli isolates recovered from 2005 to 2010.
Methods: Between 2005 and 2009, the ﬁrst 25 consecutive E. coli
isolates were collected each year during January-February period and
in 2010 all isolates during the same period. One isolate per patient
was selected. The clone was screened by PCR with speciﬁc primers
for O25b serogroup, allele 3 of the pabB gene and a multiplex
PCR assay for B2 phylogroup. The genetic relatedness among E. coli
isolates was determined by XbaI pulsed-ﬁeld gel electrophoresis (PFGE).
Susceptibility pattern was obtained with MicroScan panel. Screening of
ESBL was carried out by using double-disc method on Mueller Hinton
agar and p-AmpC on 200mg/l cloxacillin Mueller Hinton agar. ESBL-
type was determined by PCR assay using speciﬁc primer sets for ESBL
groups.
Results: A total of 506 E. coli isolates were analyzed during the study
period (125 from 2005−09 and 381 from 2010) and 157 O25b/pabB3/B2
positive (13,2%) cases were found. The annual trend of ST131 E. coli
isolates was 3,7% in 2005, 14,8% in 2006, 8.3% in 2007, 12% in
2008, 11.5% in 2009 and 14.5% in 2010. Three (5.5%) O25b/pabB3/B2
positive isolates were CTX-M-1 producers and were recovered in
2010 and the rest were non-ESBL/p-AmpC producers. O25b/pabB3/B2
positive isolates showed 75% similarity by PFGE. Antibiotic resistance
analysis revealed that ST131 isolates were signiﬁcantly more resistant to
gentamycin, tobramycin, and quinolones.
Conclusions: Our ﬁndings suggest that O25b/ST131 emerged in our
area before 2005 and a steady increase was observed, becoming a
prevalent clone in the last three years. Isolates harbouring CTX-M-1
group enzymes were detected only in 2010.
P1347 Multidrug-resistant NDM-1-producing super-bugs in
Bangladesh
M. Islam, P. Talukdar, A. Hoque, M. Huq, A. Nabi, I. Azmi, D. Ahmed,
K. Talukder, J. Hays, A. Cravioto, H. Endtz* (Dhaka, BD; Rotterdam,
NL)
Objective: The main objective was to detect and characterize NDM-1
positive Enterobacteriaceae in Bangladesh.
Methods: A total of 1789 E. coli and 90 Shigella from diarrhoeal
patients and healthy controls in 2009–2010 and 1816 clinical samples
isolated in October 2010 were analysed for imipenem resistance. Gram-
negative strains were isolated from 403/1816 samples. 100 ESBL-
producing E. coli isolated in 2008–2009 were also analysed. Imipenem
susceptibility was determined and the presence of NDM-1 gene was
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assessed by PCR. NDM-1 positive isolates were characterized. Plasmid
proﬁles were analyzed and presence of transmissible R-plasmid was
determined by conjugation and hybridization. All NDM-1 positive
patients were contacted and interviewed using a short standard
questionnaire.
Results: All E. coli and Shigella isolates from diarrhoeal patients and
healthy controls were susceptible to imipenem. Among 403 Gram-
negative clinical isolates, 55/403 (13.6%) were resistant to imipenem
and 14/403 (3.5%) were NDM-1 positive. These 14 isolates were
cultured from 12 patients with the following clinical diagnoses: UTI
(n = 5), RTI (n = 4), wound infections (n = 1), unknown (n = 2). Of
these 12 patients, 10 could be contacted. All 10 patients had received
antibiotics during the last 3 months, 5 were treated with carbapenems.
All patients reported hospitalization in last 3 months. The mean age
of patients was 55 years and the male to female ratio was 1:2
(N= 12). Of the 10 patients, outcome of treatment was not clear for
three, condition improved for three and two patients died. Among 100
ESBL producing E. coli and Klebsiella strains 4 were resistant to
imipenem, of which 3 were NDM-1 positive. Out of 17 NDM-1 positive
strains 10 were Klebsiella pneumoniae, 2 E. coli, 3 Acinetobacter
baumannii, 1 Providencia rettgeri, and 1 Citrobacter freundii. All
NDM-1 positive isolates were resistant to multiple antibiotics, including
aminoglycosides, ﬂuoroquinolones, cephalosporins, and carbapenems.
The only antimicrobials that were effective in vitro were tigecycline and
colistin. ESBL genes were detected, including blaTEM, blaSHV, blaOXA
and blaCTX-M. Many strains contained 2−8 plasmids. Plasmid proﬁles
were diverse. Conjugation and Southern blot hybridization revealed that
the NDM-1 gene was located in a self-transmissible plasmid of ~30 MDa
in size.
Conclusion: This is the ﬁrst systematic study reporting the presence of
NDM-1 gene in Enterobacteriaceae in Bangladesh.
P1348 Surveillance of b-lactamase production in a recent sample
of Klebsiella pneumoniae isolated in Greek hospitals
C.C. Papagiannitsis*, K. Tryﬁnopoulou, P. Giakkoupi, O. Pappa,
M. Polemis, E. Malamou-Lada, M. Orfanidou, S. Tsiplakou,
V. Papaioannou, H. Fakiri, K. Stamoulos, D. Kairis, H. Papoutsidou,
H. Katsifa, F. Kesidou, E. Tsafaraki, A. Tsouri, E. Platsouka,
Z. Roussou, H. Kaitsa-Tsiopoulou, P. Kazila, E. Tzelepi, A. Vatopoulos
(Athens, Thessaloniki, Chania, GR)
Objectives: Since 2002, the proportion of carbapenem-resistant Kleb-
siella pneumoniae has been signiﬁcantly increased due to the circulation
of VIM- and/or KPC-producers in Greek hospitals. Aim of the study was
to determine the frequency and type of b-lactamases in a sentinel sample
of K. pneumoniae strains isolated in Greek hospitals during 2010.
Methods: A total of 256 K. pneumoniae strains were examined. They
were consecutively collected during July 2010 from all clinical samples
in eight hospitals, located in Athens (5), Thessaloniki (2) and Creta (1).
Antibiotic susceptibility was tested by disk diffusion and MICs were
determined by Etest. The b-lactamase content of non-susceptible strains
was examined by isoelectric focusing and the bla genes were identiﬁed by
PCR and sequencing. Thirty-two representative, non-susceptible strains
were genotyped by PFGE after digestion of genomic DNA with XbaI.
Results: One hundred ﬁfty eight strains (62%) exhibited resistance or de-
creased susceptibility to 3rd generation cephalosporins. Carbapenemase
production was conﬁrmed in 83.5% of them and in particular, 103 strains
produced KPC, 22 VIM, and seven strains both carbapenemase types.
All blaKPC amplicons were identical to blaKPC-2. Twenty-three of the
blaVIM amplicons were identical to blaVIM-1 and the remaining six
to blaVIM-19. Imipenem and meropenem MICs for the above strains
ranged from 4−32mg/L and 2−32mg/L, respectively. The remaining
strains (16.5%) produced ESBLs (SHV-12, CTX-M-15, VEB) and/or the
acquired cephalosporinase CMY-4. The majority of the carbapenemase-
producing strains were conﬁrmed to co-produce SHV-12 (69.7%), CTX-
M-15 (3%) and/or CMY-4 (7.6%) enzymes. PFGE analysis of 26 strains
revealed three major puslotypes (A-C) and the remaining six strains
exhibited unique patterns. KPC-2+SHV-12-producers belonged to type
A and VIM-1-producers were clustered in type B whereas type C was
associated to strains producing CMY-4 b-lactamase.
Conclusion: Carbapenemase-producing strains are prevalent in Greek
hospitals. KPC-2-producers, despite their recent emergence (2007),
constitute the majority of multidrug resistant K. pneumoniae, whereas
VIM-producing strains have declined in frequency. In general, KPC
production was accompanied by the presence of multiple other
b-lactamases, which may contribute to the increased resistance levels
in all newer b-lactams.
P1349 High prevalence of clonally related CMY-2-producing
Escherichia coli in poultry from Switzerland
A. Endimiani*, D. Kunz, V. Perreten (Berne, CH)
Objectives: Several reports have clearly indicated that the spread of
extended-spectrum b-lactamases (ESBLs), mainly of CTX-M-type, is
responsible for increasing prevalence of cephalosporins-resistant (CR)
Enterobacteriaceae in poultry. This resistance phenotype could also be
due to the production of plasmid-mediated AmpC (pAmpCs) enzymes.
However, only a few cases of pAmpC-producing Enterobacteriaceae have
been reported in poultry. Furthermore, epidemiological data regarding
this topic in Switzerland are lacking.
Methods: Cloacal swabs from poultry were incubated at 37 C in
MacConkey broth with 5mg/L of ceftazidime overnight. Then, 50mL
were plated on selective chromID ESBL (bioMe´rieux) and re-incubated.
Resistant colonies were identiﬁed at species level using MALDI-TOF
mass spectrometry and antibiotic susceptibility proﬁles were determined
using Vitek 2. PCR and DNA sequencing were performed to characterize
the main blaESBL and blapAmpC genes. Rep-PCR was used to study
the clonality of Escherichia coli strains. Sequence typing analysis was
carried out using the Institute Pasteur MLST methodology. Analytical
isoelectric focusing and plasmid proﬁle analyses were also performed.
Results: Fifty swabs collected during October-December 2010 from
several slaughter houses located in 10 different Swiss cantons were
processed. Fourteen (28%) swabs contained at least one CR E. coli.
More than a half of the isolates were blaCMY-2-positive and were
fully susceptible to aminoglycosides, quinolones, and tetracycline. These
strains shared similar rep-PCR proﬁles and belonged to ST48 or ST37.
The remaining E. coli isolates were usually blaCTX-M-1-like-positive
and showed different rep-PCR and ST patterns. These strains were also
susceptible to aminoglycosides but displayed resistance to quinolones,
tetracycline and trimethoprim/sulfamethoxazole (approximately 80%,
100% and 20%, respectively). The CMY-2-producing E. coli strains were
found in different slaughters located in several cantons.
Conclusion: This is the ﬁrst epidemiological analysis regarding the
spread of CR Enterobacteriaceae in poultry in Switzerland. Our ﬁndings
showed that the diffusion of CTX-M-type ESBLs is likely due to the
spread of common multidrug-resistant plasmids in different clones,
whereas the high prevalence of clonally-related CMY-2-producing E. coli
seems to be associated to a common source.
P1350 High frequency of the ST131-O25b pandemic Escherichia
coli clone among uropathogenic isolates from companion
animals and humans in Portugal
N. Couto, L. Guerreiro, A. Belas, C. Leandro, R. Barbosa,
P. Cavaco-Silva, C. Pomba* (Lisbon, PT)
Objectives: To evaluate the frequency of the Escherichia coli sequence
type 131 (ST131) serotype O25-variant b worldwide pandemic clone
among companion animal and human urinary tract infection (UTI) strains
in Portugal and its association with ﬂuoroquinolone-resistance and ESBL
production.
Methods: The veterinary E. coli isolates (n = 119, 87 from dogs and
32 from cats) were collected from 2004 until 2009 at the Veterinary
Teaching Hospital of the Faculty of Veterinary Medicine and at veterinary
private practices mainly in the Lisbon area. Human strains (n = 138)
were isolated in hospitals and a community Diagnostic Laboratory in
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the Lisbon area, during 2005 and 2006. The clone was screened by
PCR with speciﬁc primers for the O25 serogroup and allele 3 of the
pabB gene. Susceptibility testing was performed by disk diffusion. ESBL
production was screened by double-disk synergy test and characterized
by PCR using speciﬁc primers and full-gene PCR products sequencing.
Results: From a total of 119 animal E. coli isolates, 44 were O25b-
pabB3 positive (37%). Regarding the 138 human isolates, 43 were found
to be O25b-pabB3 positive (31%). Of these, 17 were from hospitalized
patients and 26 from ambulatory patients. Thirteen (30%) ST131 human
isolates were CTX-M-15 b-lactamase producers (7 E. coli isolates from
community-associated UTI and 6 from hospitalized patients). Five (11%)
CTX-M producer E. coli O25b-pabB3 positive strains were isolated from
3 dogs (2 CTX-M-15 and 1 CTX-M-32) and 2 cats respectively (1 CTX-
M-15 and 1 CTX-M-32). All human and animal ESBL-producer strains
were also ciproﬂoxacin-resistant.
Conclusions: Our results suggest that the ST131-O25b pandemic
Escherichia coli clone is a prevalent clone in the Lisbon area in
Portugal and that the majority of these isolates lack ESBL genes.
Nevertheless, the clone has previously been demonstrated as being highly
virulent and, when multiresistant, may have a direct impact in the
management of community-associated UTI in both humans and animals.
Our ﬁndings are of critical relevance, as they show companion animals
as ST131-O25b pandemic Escherichia coli clone reservoirs for human
infections. Furthermore, transfer of resistance markers and resistance
strains between animals and owners/caretakers is a strong possibility
either by infection or direct contact.
P1351 Extended-spectrum cephalosporin resistance and
production of b-lactamases in Salmonella strains of different
serovars in Germany, 2005–2010
Y. Pfeifer*, S. Tru¨pschuch, R. Prager, W. Rabsch, J.-S. Frick, W. Witte
(Wernigerode, Tu¨bingen, DE)
Objectives: The National Reference Centre for Salmonella and other
Enterics in Germany determined serovars, phage types and antimicrobial
susceptibilities of 21.167 human Salmonella isolates from 2005–2010.
Resistance to 3rd gen. cephalosporins ceftazidime or cefotaxime was
detected in 131 Salmonella isolates in this period.
In Salmonella cephalosporin resistance is mainly due to acquisition of
b-lactamase genes. Different extended-spectrum b-lactamases (ESBL)
and AmpC-b-lactamases have been described worldwide in human or
animal isolates of Salmonella. Especially, ESBL-types TEM-52, SHV-
12 and CTX-M-1 and CMY-type enzymes were found frequently. Here
we report the results of molecular analyses of human cephalosporin-
resistant Salmonella isolates from Germany.
Methods:We analysed isolates of Salmonella enterica ser. Typhimurium
(n= 68), Enteritidis (n = 9), Infantis (n = 8), Bareilly (n = 6), Kentucky
(n = 5), Goldcoast (n = 4), Virchow (n = 3) and others (n = 33) from the
strain collection of the German National Reference Centre. b-lactamase
genes were identiﬁed by PCR and sequencing. Conjugation experiments,
plasmid analyses and PFGE-typing were performed.
Results and Conclusion: The majority of isolates (n = 123) showed the
ESBL-phenotype. By PCR and sequencing the ESBL genes blaCTX-
M-1 (n = 72), blaCTX-M-15 (n = 19), blaCTX-M-3 (n = 2), blaCTX-M-9
(n = 10), blaTEM-52, (n = 8) and blaSHV-12 (n = 6) were identiﬁed. Eight
cefoxitin-resistant isolates produced different CMY-type enzymes. XbaI-
macrorestriction analysis revealed that 18 S. enterica ser. Typhimurium
(DT193) isolated from hospitals in ﬁve federal states in 2007 were
identical. By retrospective database analysis we found this strain again
in three fecal samples from pigs isolated in 2006. This S. enterica
ser. Typhimurium (DT193) strain harboured the genes blaTEM-1 and
blaCTX-M-1 that were successfully transferred into E. coli J53. Two
plasmids of ca. 120 kb and 45 kb size and belonging to Inc groups N
and FII were isolated from transconjugants.
ESBL- and AmpC-producing human Salmonella are obviously rare
in Germany. Identical strains occurred in humans and animals
indicating a clonal spread between different sources. Alarming is
the easy transferability of resistance determinants among different
enterobacterial species. Therefore there is an urgent need of surveillance
of cephalosporin-resistant Salmonella in humans, animals and food to
prevent further dissemination of b-lactamase genes.
P1352 Persistence of ciproﬂoxacin- and ceftriaxone-resistant
Salmonella enterica serotype Choleraesuis and emergence
of IncI1 resistance plasmids among ceftriaxone-resistant
nontyphoid Salmonella in Taiwan
L. Su*, T.L. Wu, A.J. Kuo, J.H. Chia, H.-C. Li, C.-L. Chen, C.-H. Chiu
(Taoyuan, TW)
Objectives: The ﬁrst Salmonella enterica serotype Choleraesuis that
demonstrated concomitant resistance to ciproﬂoxacin and ceftriaxone
(CIPr/CROr) was identiﬁed in 2002. Despite a signiﬁcant decline of
S. Choleraesuis infection, clinical isolates of CIPr/CROr S. Cholerae-
suis persist in Taiwan. Furthermore, ceftriaxone resistance increased
signiﬁcantly among nontyphoid Salmonella isolates in 2009. Molecular
investigation was conducted to explore the resistance mechanisms.
Methods: Genetic relatedness of the isolates was investigated by pulsed-
ﬁeld gel electrophoresis (PFGE). Quinolone resistance was examined
by PCR/sequencing of the quinolone resistance-determining regions
of gyrA, gyrB, parC, and parE genes. Ceftriaxone resistance was
investigated by PCR/sequencing of SHV, TEM, CTX-M, and AmpC
genes. Plasmid proﬁling and DNA-DNA hybridisation were performed
to identify the resistance plasmids. Self-transferability and replicon
types of the resistance plasmids were determined by published methods.
Conjugative resistance plasmids were further characterised by a recently
described plasmid multilocus sequence typing (pMLST) method.
Results: Ten cases of CIPr/CROr S. Choleraesuis infection were
identiﬁed during 2003–2009; only 7 blood isolates were available for
study. One 2008 isolate demonstrated a different PFGE pattern from the
others. Quinolone resistance was associated with amino acid changes
at codon 83 (serine to phenylalanine) and codon 87 (aspartic acid
to asparagine) of gyrA and codon 80 (serine to isoleucine) of parC.
Ceftriaxone resistance was due to the presence of a plasmid-mediated
CMY-2 gene located on the transposon Tn6092. The Tn6092-containing
plasmids were non-conjugative in early CIPr/CROr S. Choleraesuis
isolates. In the two isolates collected after 2007, the resistance plasmid
became self-transferable due to the recombination with a conjugative
IncI1 plasmid. The Tn6092-harboring conjugative IncI1 plasmid was
also found in all the 6 ceftriaxone-resistant isolates of Salmonella
enterica serotypes Typhimurium, Agona, and Enteritidis recovered in
2010. Although 6 new sequence types were revealed among the 8
IncI1 plasmids identiﬁed, they formed a separate group from the two
clonal complexes, CC-2 and CC-12, commonly found among the
IncI1 plasmids in Europe and North America.
Conclusion: Spread of the IncI1 resistance plasmid among nontyphoid
Salmonella represents a threat to the public health and should be closely
monitored.
P1353 Turkey meat as a source of determinants conferring
plasmid-mediated quinolone resistance in Salmonella
B. Guerra*, K. Thomas, J. Beutlich, L. Cavaco, K. Veldman,
R. Helmuth, A. Schroeter (Berlin, DE)
Objective: Molecular characterization of antimicrobial resistance (R) in
Salmonella (S.) isolates, mainly originating from turkey meat, showing
a PMQR-phenotype, in Germany.
Methods: Among the S. enterica isolates from animal and food
origin (2000–2008) obtained in the National Reference Laboratory
for Salmonella (NRL-Salm) strain collection, isolates showing a MIC
for nalidixic acid = 8−32mg/L and for ciproﬂoxacin 0.125−1mg/L,
were selected for further studies. Sixteen of these isolates (avoiding
siblings) originated from turkey meat (eleven), turkey (one), a not
determined (ND) meat source (three) or poultry (one). The isolates
were characterized by PCR ampliﬁcations/sequencing, PFGE with XbaI,
plasmid proﬁle analysis and Southern-blot hybridization to determine the
resistance determinants and epidemiological relationship of the isolates.
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Results: These isolates were positive for PMQR-genes. The qnrB19
gene was present in nine strains isolated in different years in different
German regions: eight S. Hadar (six isolated from turkey meat, one from
poultry and once from ND meat), and one S. Uganda (ND meat). All
S. Hadar showed an identical XbaI-PFGE pattern, and all except one
carried three small plasmids (<4 kb) suggesting the clonal spread of a
qnrB19-positive strain. The qnrS1 gene was found in ﬁve S. Saintpaul
(four of them from turkey meat, one of them from ND minced meat,
different years and different regions). These isolates showed two similar
PFGE-patterns (differing in only band in one isolate), and three different
plasmid proﬁles, all of them carrying a small plasmid of about <10
kb. Finally, the qnrA gene was present in a S. Typhimurium isolate
from turkey, and qnrB2 in a S. Uganda isolate from ND meat. Plasmid
location of these genes was conﬁrmed. No qnrC, qnrD or qepA genes
were detected among the isolates.
Conclusions: Our results show that various determinants conferring
PMQR are present in Salmonella isolates originating from turkey/turkey
meat. This kind of food can contribute to the further spread of these
determinants, and this fact needs to be further investigated.
P1354 Multidrug-resistant Salmonella clones in slaughtered swine
E. Gomes Neves*, P. Antunes, A. Tavares, P. Themudo, J.M. Correia
da Costa, L. Peixe (Porto, Vaira˜o, Lisbon, PT)
Objectives: Particular multidrug-resistant (MDR) Salmonella clones
mainly attributed to pork products have been increasingly involved in
human infections, as Salmonella S.4,5,12:i:-, Typhimurium DT104 or
S. Rissen. Occurrence and characterization of these clones at slaughtered
swine is scarce. In this study we characterize clonal relationships,
antibiotic resistance proﬁles and associated genetic determinants of
isolates obtained from slaughtered swine and meat handlers in Portugal.
Methods: Sixty Salmonella isolates, from swine (ileoceacal lymph
nodes, carcass surface and meat) and meat handlers collected in 8
abattoirs (July 2007-August 2008) were included: 26 S.Typhimurium,
10 S.4,5,12:i:-, 10 S.Derby, 4 S.Rissen, 3 S.Mbandaka, 3 S.London, 2
S.Give, 1 S.Enteritidis, and 1 S. Sandiego. Antimicrobial susceptibility
was determined by the disc diffusion method according to CLSI
standards. PCR and sequencing were used identify antimicrobial
resistance genes and class 1 integrons. Genetic relatedness was analyzed
by PFGE.
Results: Resistance was found in 75% of Salmonella isolates, being
68% MDR, dispersed in the different abattoirs and samples. The
most common resistance phenotypes were to tetracycline (Tet) (65%,
tet(A), tet(B) tet(G), sulfamethoxazole (Sul) (63%, sul1, sul2, sul3),
streptomycin (S) (62%, aadA), ampicillin (A) (57%, blaPSE-type,
blaTEM-type) and chloramphenicol (C) (15%, ﬂoR, cmlA). Thirty-seven
percent were positive for class 1 integrons, with a variable region between
400–2000 bp. The isolates studied (9 serotypes) corresponded to 17
PFGE types. S. Typhimurium (12 PFGE types) was observed in swine
samples and in meat handlers of 6 and 2 abattoirs, respectively. Mostly
of them revealed features of the main human clones spread in Portugal
(DT104 and sul3). S.4,5,12:i:- recovered from swine in 3 abattoirs
clustered with some S. Typhimurium isolates in two PFGE types and
were mostly associated to ASSuT type (blaTEM, strA-strB, sul2 and
tetB). Isolates belonging to the emerging S. Rissen (1 PFGE type),
recovered in swine and meat handlers of 3 and 1 abattoir, respectively,
differed in the resistance proﬁle (Tet; ASTet; ASSulTetT; ACSSulTetT)
being Tet resistance associated to tet(A), A to blaTEM-1, Sul to sul1
and/or sul3.
Conclusions: Swine and abattoir environment seems to contribute to the
load of MDR Salmonella isolates and to the emergence of monophasic
variant S.4,5,12:i:- in humans.
P1355 High prevalence of plasmid-mediated quinolone resistance
among nalidixic acid resistant, ciproﬂoxacin susceptible
Enterobacteriaceae isolated in a Greek university hospital
A. Margaritis*, I. Galani, T. Panayea, G. Petrikkos, M. Souli (Athens,
GR)
Objectives: To determine the prevalence of plasmid-mediated quinolone
resistance (qnr) genes in nalidixic acid resistant (NR), ciproﬂoxacin
susceptible (CS) E. coli and K. pneumoniae recovered from clinical
specimens in “Attikon” University Hospital, Athens, Greece.
Methods: During an 18-month period (July 2008 to December 2009)
30 E. coli and 13 K. pneumoniae isolates resistant to nalidixic acid but
susceptible or intermediate to ciproﬂoxacin were collected from separate
inpatients and outpatients. Isolates were screened for the presence of
genes qnrA, qnrB and qnrS by multiplex PCR, using universal primers
for each gene amplifying all related alleles. The respective genes
were conﬁrmed by genomic sequencing. The qnr positive isolates were
additionally tested for extended-spectrum b-lactamases (ESBL), metallo-
b-lactamases (MBL) and Klebsiella pneumoniae carbapenemase (KPC).
Clonal relatedness of qnr-positive strains was determined by REP-PCR.
Results: Five E. coli (5/30, 16.7%) and 12 K. pneumoniae (12/13,
92.3%) were positive for qnr determinants (E. coli: 4 qnrB, 1 qnrS;
K. pneumoniae: 1 qnrB and 11 qnrS). Ciproﬂoxacin and nalidixic
acid MIC values ranged from 0.125 to 3 and 2 to >256mg/L,
respectively. Only one qnrB positive E. coli isolate was an ESBL
producer resistant also to trimethoprim/sulfamethoxazole (SXT), while
the rest were susceptible to 2nd, 3rd and 4th generation cephalosporins,
aminoglycosides and 50% susceptible to SXT. Among K. pneumoniae
two of the qnrS positive isolates were ESBL and MBL or KPC producers,
while the rest were susceptible to 3rd and 4th generation cephalosporins,
aminoglycosides and 91% susceptible to SXT. REP-PCR revealed that
all qnr-positive isolates were distinct clones.
Conclusions: The high prevalence of qnr − determinants among NR
and CS E. coli and K. pneumoniae strains isolated in our hospital
is probably suggestive of a high prevalence of these genes in Greek
hospitals. Multicenter surveillance studies are warranted.
P1356 Distribution of virulence determinants and serotypes in
relation to ﬂuoroquinolone resistance and the presence of
blaCTX-M among Klebsiella pneumoniae isolates
J. Chang*, S.B. Han, J.K. Yu, H. Chae, K. Park, Y.J. Park (Seoul, KR)
Introduction: Klebsiella pneumoniae is a common cause of nosocomial
infections that range from mild urinary tract infection to severe bac-
teremia. Several serotypes and virulence determinats (wcaG, rmpA, allS,
aerobactin, kfu) are important for virulence. In this study, we investigated
the prevalence of virulence determinants and serotypes according
to the ciproﬂoxacin resistance and presence of blaCTX-M. among
K. pneumoniae isolates from various specimens.
Materials and Methods: A total of 310 consecutive, non-duplicate
isolates were collected from clinical specimens at 16 clinical laboratories
in Korea in 2010. The MICs of ciproﬂoxacin were determined by an agar
dilution method according to the CLSI guideline. Of them, 156 isolates
(6 isolates from abscess specimens, 35 from blood, 58 from sputum, and
57 from urine specimens) were selected. As there was no difference in the
ciproﬂoxacin susceptibility in the whole 310 isolates, the ciproﬂoxacin
susceptibility rate was kept similar regardless of specimen types.
The determination of serotypes (K1, K2, K5, K54, K57 and K20)
and detection of virulence factors and blaCTX-M were determined by
multiplex PCR.
The X2 test was used for statistical evaluation. A P value of <0.05 was
considered to be statistically signiﬁcant.
Results: Among the 156 isolates, 103 and 53 isolates were susceptible
and resistant to ciproﬂoxacin, respectively. The general prevalence
of capsule K genotypes were K1 (n = 22), K2 (n = 10), K5 (n = 1),
K20 (n = 2), K54 (n = 5), K57 (n = 4), and non-typeable (n = 112). The
prevalence of the ﬁve virulence factors serotypes according to the
S378 21st ECCMID/27th ICC, Posters
ciproﬂoxacin susceptibility and the presence of blaCTX-M are described
in Table1. According to the serotypes, almost all of the K1 serotype
isolates harbored ﬁve virulence genes. In K2 isolates, the prevalence
of only rmpA and aerobactin was high. In K54 isolates, all of the ﬁve
isolates had wcaG but the prevalence of other virulence genes were low
(20−40%). For K57 isolates, all harbored rmpA and aerobactin, but none
harbored other virulence genes. There was no difference in distribution of
virulence genes (except rmpA) or serotypes according to the specimens.
Conclusion: The prevalence of virulence determinants was signiﬁcantly
higher in ciproﬂoxacin-susceptible isolates and it was different according
to the serotypes. The K1 and K54 serotype was more frequent
in ciproﬂoxacin-susceptible isolates and blaCTX-M-positive isolates,
respectively.
P1357 Escherichia coli from human and avian origin: detection
of ﬂuoroquinolones-resistance associated clonal groups
M. Giufre`, M. Accogli, C. Graziani, I. Luzzi, M. Argentieri,
A. Giammanco, A. Lettini, P. Pecile, A. Raglio, M. Staffolani, G. Tosi,
M. Cerquetti* (Rome, Palermo, Legnaro, Padua, Florence, Bergamo,
Macerata, Forlı`, IT)
Objectives: Previous studies have suggested chicken as reservoirs
for ﬂuoroquinolones (FQ)-resistant extraintestinal pathogenic E. coli
(ExPEC) strains isolated from humans. Our aim was to identify clones
associated with FQ-resistance among human ExPEC strains and to
investigate the possible source of these clones.
Methods: A total of 378 E. coli strains (277 from humans and 101 from
avian species) were analyzed. Human ExPEC strains (142 FQ-susceptible
and 135 resistant) were isolated from cases of urinary tract infections
and sepsis. E. coli strains from avian source (68 FQ-susceptible
and 33 resistant) were collected during routine control activities.
Antimicrobial susceptibility was assessed by E-test. Phylogenetic groups
were determined by PCR. MLST analysis was performed on a sample
of E. coli strains from both human and avian sources. All phylogenetic
group B2 strains were screened for the ST131 clone by PCR and then
conﬁrmed by MLST.
Results: Most FQ-resistant strains exhibited a multi-drug resistant
(MDR) phenotype. Triple resistance to FQ, ampicillin and trimethoprim/
sulfamethoxazole was the most frequent in both human and avian strains
(30.5% and 60.6%, respectively). Overall, human ExPEC strains mostly
fell into the phylogenetic group B2 (56.7%), followed by group D
(17.7%). Avian strains mainly belonged to group A (34.6%) and group
B1 (29.7%). A shift in phylogenetic distribution from group B2 to
group A was observed associated to FQ-resistance in human strains.
No shift associated with resistance was detected in avian strains. By
MLST, human strains were distributed into 37 different sequence types
(STs). Among FQ-resistant strains with a MDR phenotype, ST131
predominated (40%) followed by ST23 and ST10 complexes both
belonging to the phylogenetic group A. FQ-susceptible strains from
humans were widely dispersed among several STs and ST131 was found
at low percentage (3.5%). Among avian E. coli strains, 27 different
STs were identiﬁed. The clonal complexes ST 23, ST10 and ST156
were more common, each including FQ-resistant strains with a MDR
phenotype. One ST131 FQ-susceptible strain was detected.
Conclusions: The major human and avian E. coli ST clones associated
with FQ-resistance and MDR phenotype were identiﬁed. Although our
results do not support the hypothesis of the possible avian origin of the
major ST131 clone affecting humans, the sharing of the ST23 and ST10
clones across strains from human and avian sources poses a zoonotic
risk.
P1358 Spread of plasmid-mediated quinolone resistance and
pathogenic islands in Escherichia coli isolated from water
N. Mendonc¸a*, J. Ramalho, P. Vieira, A. Tavares, P. Pereira, G. Da
Silva (Coimbra, Aveiro, Leiria, PT)
Objectives: We report the search for plasmid-mediated quinolone
resistance (PMQR) genes and virulence factors encoded in pathogenic
islands (PAIs) among Escherichia coli strains isolated from waters of
different origins.
Methods: Between May 2009 and February 2010, 37 isolates were
recovered from drinking, recreational, waste, surface and ground waters.
The antimicrobial susceptibilities were determined by the disc diffusion
method by using CLSI guidelines. PMQR (qnr, aac(6′)-Ib-variant
and qepA) determinants and PAIs markers were screened by PCR.
Determination of the E. coli phylogenetic group was also performed
by PCR.
Results: Mostly strains were isolated from surface waters (49%), and
during the Summer 2009 (49%); 19% of the strains were resistant to
nalidixic acid, 11% to ciproﬂoxacin and 5% to gentamicin. Molecular
methods detected one type of PMQR: qnrA was detected among 16%
of strains, all of which susceptible to quinolones. Pathogenicity islands
(PAIs) IV536 was detected among surface (8%), drinking (5%) and
ground waters (3%), while PAI IICFT073 was detected among drinking
water (3%). According to the phylogenetic groups, we detected 41% and
27% of strains belonging to the less-virulent groups A and B1, while
30% and 3% were from groups D and B2, respectively. Our results
showed 45% of strains from group D with the PAI IV536, a phylogenetic
group also considered virulent. The PAI IV536 was also found in an
isolate belonging to group B1 carrying a qnrA gene. All the qnrA genes
were detected in group B1 strains collected in waters of different origin,
geographical location and season.
Conclusions: The results showed the presence of potential pathogenic
strains encoding resistance determinants and/or pathogenic islands
among surface, ground and drinking waters. These strains can represent
an increased risk for public health, as they were isolated from samples
collected from waters with potential contact with humans and animals.
Thus, it’s of crucial importance a periodic monitoring of the water
quality, not only for the presence of microorganisms, but also for
screening antibiotic resistance and virulence factors.
P1359 Occurrence of plasmid-mediated quinolone resistance
among bacteria isolated in animals in Portugal
E. Ferreira, L. Clemente, D. Jones-Dias, A.P. Francisco, V. Manageiro,
P. Themudo, T. Albuquerque, A. Amado, M. Canic¸a* (Lisbon, PT)
Background: Plasmid-mediated quinolone resistance (PMQR) is in-
creasingly identiﬁed worldwide in Enterobacteriaceae. The aim of this
study was to evaluate the extension of PMQR in isolates from animals
in Portugal.
Methods: We screened 186 Enterobacteriaceae isolates for the presence
of PMQR determinants, identiﬁed at National Laboratory of Veterinary
Research (2008–2009). A total of 92 Salmonella isolates were isolated
from broilers, layers and pigs, and 94 Escherichia coli were from
farm animals, birds and mammals. Susceptibility testing of all isolates
was performed by disk diffusion method, and MICs against nalidixic
acid, ciproﬂoxacin, gatiﬂoxacin, levoﬂoxacin, oﬂoxacin, enroﬂoxacin,
morbiﬂoxacin and norﬂoxacin were determined by E-test for PMQR-
positive isolates. PCR and nucleotide sequencing, by using speciﬁc
primers, were used to screen for the presence of PMQR-encoding genes.
The genetic context of PMQR genes was evaluated by using different
molecular methods.
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Results: We identiﬁed 5 qnrC-positive isolates: 2 Salmonella enteritidis
collected in 2 layer chicken and in 3 E. coli from 2 broilers and one
pig; 3 qnrS1 genes were detected in E. coli isolates from a broiler (co-
expressing a qnr-C gene), a dog and a turtle-dove. The aac-(6′)-Ib-cr
gene was detected in an E. coli isolated from a mammalian. Seven
PMQR-positive isolates showed diminished susceptibility to at least one
quinolone, and one was detected in the range of susceptibility against the
seven (ﬂuoro)quinolones tested. Three E. coli and one S. enteritidis were
PMQR- and TEM-1 and/or CTX-M-15-producing isolates. An E. coli
with qnrC, qnrS1, and blaTEM-1 genes and an E. coli with qnrC gene
were positive for genes coding to class 1 integrons.
Conclusions: This survey showed that PMQR determinants are present
in animals from different environments in Portugal, including food-
producing animals, with a high frequency (3%) of QnrC-producing
isolates. Susceptibility results demonstrate the difﬁculty to predict the
PMQR mechanisms by phenotypic methods. Overall, the study suggests
that PMQR genes are undergoing a dissemination process, which needs
surveillance.
P1360 Aminoglycoside resistance in Escherichia coli in western
Norway
P.C. Lindemann*, K. Risberg, H. Mylvaganam (Bergen, NO)
Objective: There had been a steady increase in gentamicin resistance,
from 1.2% in 2000 to 4% in 2009, in E. coli isolated from blood cultures
in Norway. Aminoglycoside modifying enzymes (AME) are important
in resistance development and are acquired by horizontal transfer of
the respective genes located on plasmids. In E. coli the most prevalent
AMEs are AAC(6′)-Ib and AAC(3)-II. Our objective was to ﬁnd the
prevalence of the genes encoding these AMEs among Norwegian E. coli
isolates that were resistant to aminoglycosides (AGs) and to use their
resistance proﬁles for different AGs to consider their value in predicting
the responsible AME.
Methods: A total of 108 clinical isolates of E. coli from Western
Norway were included, consisting of 42 from blood culture isolates
that had reduced susceptibility to gentamicin/netilmicin, and 65
isolates from other sites that were non-susceptible to gentamicin/
tobramycin, and also produced extended b-lactamases (ESBL). Minimum
inhibitory concentrations (MIC) were determined by E-test/MIC test
strips for gentamicin, netilmicin, tobramycin, kanamycin, amikacin and
streptomycin. The isolates were screened by PCR for aac(6′)-Ib and
aac(3)-IIa/c. aac(6′)-Ib was sequenced to identify its variant aac(6′)-Ib-
cr, which confers resistance also to ﬂuoroquinolones.
Results: The prevalence of aac(3)-IIa or -IIc was 79.6% (86/108) with
no differences seen in the two groups. Resistance to gentamicin was seen
in all isolates that had aac(3)-II, however 1−2 isolates were susceptible
to netilmicin/tobramycin. aac(6′)-Ib was found in 35.2% of the isolates
(38/108), of which 37 were identiﬁed as aac(6′)-Ib-cr, with a higher
prevalence in ESBL isolates. The substrate speciﬁcity was as expected
for kanamycin, netilmycin, tobramycin, but amikacin resistance was not
found, although the MICs were marginally elevated in 9 of the 38
isolates. Isolates with aac(3)-II had higher MIC values for netilmicin than
isolates with aac(6′)-Ib, and aac(6′)-Ib was associated with higher MICs
for tobramycin. The prevalence (91.7%) and the degree of quinolone
resistance could not be attributed solely to the presence of aac(6′)-Ib-cr.
Conclusion: aac(3)-II and aac(6′)-Ib-cr possibly contributed to the recent
increase in gentamicin resistance. The resistance proﬁle, MIC values for
netilmicin and tobramycin and association with ESBL might be useful
in predicting the AME.
P1361 Phenotypic and genotypic characterisation of
aminoglycoside resistance in Norwegian clinical isolates of
Escherichia coli and Klebsiella spp.
B. Haldorsen*, K. Hegstad, G.S. Simonsen, A. Sundsfjord, Ø. Samuelsen
on behalf of the Norwegian Study Group on Aminoglycoside Resistance
Objectives: Resistance to gentamicin among both Escherichia coli and
Klebsiella spp. in Norway have increased over the last 5 years. The
aim of this study was to investigate the susceptibility to different
aminoglycosides and the prevalence of aminoglycoside modifying
enzymes (AME) among clinical isolates of Escherichia coli and
Klebsiella spp. collected through the Norwegian Surveillance Program
for Antimicrobial Resistance (NORM).
Materials and Methods: Collection I included 137 isolates of E. coli
(blood n = 61, urine n = 44) and Klebsiella spp. (blood n = 17, urine
n = 15) with reduced susceptibility to gentamicin and/or tobramycin
selected from NORM 2009. NORM 2009 included a total of 2,510 E. coli
isolates (blood n = 1,381, urine n = 1,129) and 1,578 Klebsiella spp.
isolates (blood n = 571, urine n = 1,007). In addition, 68 ESBL-positive
E. coli (CTX-M n= 56, SHV n= 4) and Klebsiella spp. (CTX-M n= 3,
SHV n= 5) isolates from NORM 2007−08 was included as collection
II. The susceptibility patterns for gentamicin, tobramycin and amikacin
were investigated using Etest. PCR was used for the detection of the
following AMEs: aac(6′)-Ib, aac(3)-Ia, aac(3)-II, ant(2′′)-Ia and ant(4′)-
IIb.
Results: The prevalence’s of resistance among E. coli isolates in
collection I (NORM 2009) were 3,2%, 3,4%, and 0,4% to gentamicin,
tobramycin and amikacin, respectively. Among Klebsiella spp., 1%,
1,3%, and 0,3% were resistant to gentamicin, tobramycin and amikacin,
respectively. In collection II; 45%, 57%, and 0,2% of the ESBL-positive
E. coli and 38%, 50% and 0% of the ESBL-positive Klebsiella spp. were
resistant to gentamicin, tobramycin and amikacin, respectively.
aac(3)-II was the most prevalent AME detected in 123 isolates (collection
I n = 84, collection II n = 39), followed by aac(6′)-Ib where 53 isolates
were positive (collection I n = 30, collection II n = 23). ant(2′′)-1a was
detected in 3 isolates from collection I. aac(3)-Ia and ant(4′)-IIb were
not detected.
Conclusion: The prevalence of aminoglycoside resistance is still low
among Norwegian E. coli and Klebsiella spp. isolates. In contrast, ESBL-
positive isolates showed a high prevalence of resistance to gentamicin
and tobramycin. Amikacin resistance was low and comparable in both
collections. aac(3)-II, which confers resistance to both gentamicin and
tobramycin, was the predominant AME in both collections.
P1362 Carbapenemase-producing Acinetobacter spp. in
Kyoto University Hospital, Japan: the occurrence of
metallo-b-lactamases
M. Yamamoto*, K. Yasuma, Y. Matsumura, A. Matsushima, M. Nagao,
Y. Ito, S. Takakura, S. Ichiyama (Kyoto, JP)
Objectives: In recent years, carbapenemase-producing Acinetobac-
ter spp. has increased substantially. The carbapenem-hydrolyzing
b-lactamases in Acinetobacter spp. are either metallo-b-lactamases
(MBLs) or oxacillinases (carbapenem-hydrolyzing class D b-lactamases
[CHDLs]). Although CHDLs were reported as more major carbapen-
emase than MBLs, blaIMP-2 detection in Acinetobacter spp. was
previously reported in Japan. The aim of this study was to evaluate the
occurrence of CHDL- and MBL-encoding genes among Acinetobacter
spp. isolates recovered from Kyoto University Hospital, Japan.
Methods: During 2004–2009, 435 Acinetobacter spp. were recovered
and 28 (6.4%) isolates were carbapenem-non-susceptible. Only the ﬁrst
isolate was included in this study. 16 of 28 carbapenem-non-susceptible
Acinetobacter spp. isolates were preserved in our hospital. Carbapenem-
non-susceptibility, MIC >4mcg/ml for imipenem or meropenem was
determined by the broth microdilution method according to CLSI M100-
S20 guideline. These isolates were all screened for CHDL-encoding
genes (OXA-23, OXA-24, OXA-51, OXA-58) and MBL-encoding genes
(IMP1/2,VIM1/2, SPM-1, SIM-1, GIM-1), and conﬁrmed by sequencing.
Clonality of A. calcoaceticus-A. baumannii complex was analyzed by
MLST.
Results: 16 carbapenem-non-susceptible Acinetobacter spp. included 8
A. genomic sp.3, followed by 2 A. baumannii, 2 A. lwofﬁi, and 4 other
Acinetobacter spp. CLDL- or MBL-encoding genes were detected in
14 (87.5%) isolates. All 8 of carbapenem-non-susceptible A. gen. sp. 3
harboured MBL-encoding gene (1 IMP-1 and 7 IMP-2), and 1 isolate
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with blaIMP-1 harboured blaOXA-58 together. 1 of carbapenem-non-
susceptible A. baumannii harboured MBL-encoding gene (IMP-2). 1 of
A. lwofﬁi and 3 of other Acinetobacter spp. had blaIMP-2 (TABLE). 8
isolates of A. gen. sp. 3 were differentiated into 4 genotypes by MLST.
A. baumannii had no relation to pan-European outbreak clones.
Conclusion: Although widespread dissemination of CHDLs among
Acinetobacter spp. was reported worldwide, MBL (IMP-2) producing
A. gen. sp. 3 was the leading cause of carbapenem-non-susceptibility in
our hospital. MBL-encoding gene (IMP-2) can be disseminated among
Acinetobacter spp.
P1363 Evolution of Acinetobacter baumannii clonal lineages in
Greek hospitals over the last 15 years
V. Gogou*, M. Giannouli, E. Voulgari, R. Zarrilli, A. Tsakris,
S. Pournaras (Larissa, GR; Naples, IT; Athens, GR)
Objectives: Acinetobacter baumannii is a multidrug-resistant (MDR)
pathogen increasingly affecting severely ill patients. The aim of the
study was to analyze the genetic relatedness and the evolution of clonal
lineages in A. baumannii isolates recovered from Greek hospitalized
patients during a long-term period.
Methods: The study included 97 A. baumannii isolates randomly
selected among those recovered during 1994–2008 in seven institutions,
located in four different Greek regions. Carbapenem MICs were
determined by Etest and broth microdilution. PCR and sequencing
analysis were used for testing the presence of class D OXA-type
carbapenemase genes (blaOXA-23, blaOXA-24 and blaOXA-58). The
isolates were typed by PFGE, the trilocus ST protocol developed by
the UK HPA and the MLST scheme developed by the Pasteur Institute
followed be e-Burst analysis of MLST types.
Results: blaOXA-58 was the only identiﬁed carbapenemase gene,
detected in 51/54 imipenem-non-susceptible and 15/43 imipenem-
susceptible A. baumannii isolates. Nine PFGE types (I-IX) and seven
PFGE subtypes were identiﬁed. Molecular typing of A. baumannii
isolates showed already identiﬁed ST groups (1, 2, 4 and 5) and MLST
types (1, 2, 15, 45 and 54), but also the novel MLST types 85 and 86.
Sequencing of the ampliﬁed 3ST typing alleles identiﬁed eight novel
alleles for blaOXA-51-like, csuE and ompA genes; alleles 2−1, 10, 11
and 12 were identiﬁed for blaOXA-51 like, alleles 11 and 12 for csuE
and alleles 8 and 9 for ompA. The majority of strains (52) were assigned
to ST group 1 and clonal complex 1 that includes MLST type 2 and its
single locus variant MLST type 45 corresponding to international clone
II. Thirty-one strains were assigned to ST group 2 and MLST type 1
corresponding to international clone I. The new MLST type 85 was
present in distant geographical regions in Greece throughout the whole
period of the study.
Conclusion: These results indicate that some of the worldwide
disseminated clonal lineages have also accounted for the emergence of
MDR A. baumannii in Greece all over the last 15 years. Of note is
also the spread of novel ST alleles and MLST types, underlining some
evolutionary divergence in Greek MDR A. baumannii clonal lineages.
blaOXA-58 was found to be the only carbapenemase gene harbored by
A. baumannii strains in Greece, in difference with other Mediterranean
countries, where in the same clonal lineages, blaOXA-23 and blaOXA-24
genes are also prevailing.
P1364 Spread of imipenem-resistant Acinetobacter baumannii of
European clone II in western China
C. He*, Y. Xie, H. Fan, M. Kang, C. Tao, R. Zhang, Y. Hu, Z. Chen,
L. Wang (Chengdu, Hangzhou, Beijing, CN)
Objectives: To investigate the distribution of resistance genes and clonal
relationship in the imipenem-resistant Acinetobacter baumannii isolates
from ten hospitals in western China, and compare the epidemiologic data
with those of the isolates from two hospitals in Hangzhou and Beijing.
Methods: The genes encoding OXA carbapenemases, metallo-
b-lactamases (MBLs), AmpC cephalosporinase, and Carbapenem
Resistance-Associated Outer Membrane Protein (CarO) were screened
by PCR and sequencing. PCR mapping were performed to determine
whether ISAba1 elements preceded OXA carbapenemases and AmpC
cephalosporinase respectively. International clonal lineages were iden-
tiﬁed by sequence-type multiplex PCR and sequencing recA gene.
Multilocus sequence typing (MLST) was performed to determine the
sequence types (STs), and then eBURST algorithm was applied to assign
clonal complexes (CCs).
Results: In this study, acquired ISAba1 preceding blaOXA-23-like was
the predominant blaoxa-type gene among the 272 isolates studied. Genes
encoding MBLs were not identiﬁed. Though blaAmpC was found in all
the isolates, its association with ISAba1 was not found among some
isolates. Eight isolates harbored the disrupted carO gene or lacked
this kind of gene. In 36 representative A. baumannii isolates, except
that 2 isolates from Hangzhou did not belong to European clone I; or
II, European clone II; was identiﬁed for the other isolates. Ten STs,
including 3 novel types, were identiﬁed and clustered into clonal complex
92 (CC92) and two distinct singletons.
Conclusion: Our observations suggest that imipenem-resistant A. bau-
mannii of European clone II, which carried acquired ISAba1 preceding
blaOXA-23-like gene and belonged to CC92, could spread widely in
western China.
P1365 Retrospective analysis of carbapenem-resistant
Acinetobacter baumannii strains in a tertiary hospital
M. Pirs*, T. Cerar, R. Kofol, M. Mueller Premru, V. Krizan Hergouth,
J. Ambrozic Avgustin, K. Seme (Ljubljana, SI)
Objective: Carbapenem-resistant Acinetobacter baumannii (CR-AB)
isolates have been isolated with increased frequency in our tertiary
hospital; mostly in the surgical ICUs. The aim of the present study was
to analyze antimicrobial susceptibility of A. baumannii and to detect the
presence of carbapenemase genes using molecular methods.
Methods: Laboratory records of patients with A. baumannii isolates
were analyzed from 2005 to 2010. CR-AB was isolated in 109
patients and 14 non-repetitive isolates of CR-AB were analyzed.
Characterization of blaKPC, blaVIM, blaIMP was performed using
Hyplex KPC/MBL kit (Amplex BioSystem GmBH, Germany), detection
of blaNDM-1 was performed using PCR as described previously. Class
D carbapenemase detection was performed using Hyplex CarbOXA
kit (Amplex BioSystem GmBH, Germany) which detects blaOXA-58,
blaOXA-40 and blaOXA-24 genes.
Results: CR-AB has been sporadically isolated from 2005 to 2007;
resistance to imipenem in A. baumannii primoisolates was below 1%.
The resistance to imipenem has increased to 5.3% in 2008 and to 15.5%
in 2009. In the 2010 there has been a decrease of resistance to imipenem
to 8.5%. Before 2008, there were 3 to 6 patients with CR-AB per year.
In 2008 CR-AB was isolated from 23 patients, in 2009 there was a sharp
increase in the number of patients (58 patients) with a decrease in the
year 2010 (21 patients). Majority of patients (75%) were hospitalized in
surgical wards, mostly in ICUs. Half of the CR-AB were isolated from
the respiratory tract, 19.8% from wounds and 5% from blood cultures and
urine. 60.2% of the carbapenem-resistant primoisolates were susceptible
to ampicillin/sulbactam, 30.6% to ceftazidime, 21.3% to amikacin
with less than 2% isolates susceptible to piperacillin/tazobactam or
ciproﬂoxacin. The presence of carbapenemases was conﬁrmed in 13
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out of 14 isolates using molecular testing. One isolate was positive for
NDM-1 carbapenemase (2008), 7 isolates were positive for OXA-58 and
5 for OXA-40 carbapenemases (2008–2010). Molecular mechanism of
carbapenem resistance for the remaining isolate has not been determined
yet.
Conclusions: Our retrospective analysis has indicated a possibility of
a silent outbreak of CR-AB in our tertiary hospital which began in
2008 and has peaked in 2009. Carbapenemase characterization of CR-
AB in our study has shown the predominance of OXA-58 and OXA-
40 carbapenemases and a surprising sporadic occurence of NDM-1
carbapenemase in 2008.
P1366 Phenotypic and molecular characterisation of carbapenem-
hydrolysing class D b-lactamase-producing Acinetobacter
baumannii isolated in Portugal
V. Manageiro*, D. Jones-Dias, E. Ferreira, D. Louro, M. Canic¸a on
behalf of the Antibiotic Resistance Surveillance Program in Portugal
(ARSIP)
Objectives: Acinetobacter baumannii is a ubiquitous pathogen able
to cause colonization and both community and healthcare-associated
infections. Our purpose was to evaluate the genetic relatedness of
carbapenem-hydrolyzing class D b-lactamase (CHDL) producing MDR-
Ab from different geographic regions of Portugal. The correlation with
carbapenem resistance was also analysed.
Methods: The study included 127 clinical A. baumannii isolates
recovered in Portuguese hospitals (116 from Apr2009-Apr2010); 11
from 2005–2008 were included for genetic evolution comparison. The
identiﬁcation of strains was conﬁrmed by PCR (based on the presence
or absence of OXA-51-like genes) and antimicrobial susceptibility was
screened by TSA and E-test. PCR and sequencing were applied to
detect and identify genes encoding CHDLs, class B metallo-b-lactamases
(MBL) (blaIMP and blaVIM), and class A b-lactamases (blaTEM,
blaSHV and blaCTX-M). Genetic relatedness of MDR-Ab was examined
by PFGE and MLST (typing of 25 isolates representative of different
PFGE-clusters).
Results: All isolates were MDR but susceptible to colistin. However, the
MICs of colistin conﬁrmed one isolate as nonsusceptible. Overall, 77%
of the isolates carried blaOXA-23, 18% blaOXA-24, 28% blaTEM-1, 2%
blaCTX-M-15-type and 1% blaTEM-110 genes. None of the isolates
carried OXA-58 or MBL-encoding genes. All isolates carried the
blaOXA-51-type gene, and expressed OXA-66 (98%), OXA-71 (1%)
or OXA-104 (1%) CHDL. The blaOXA-104-CHDL gene carries 182
synonymous mutations comparing with the ﬁrst-described b-lactamase.
PFGE analysis revealed that 81 isolates clustered into six clones and
2 presented unique proﬁles. PFGE proﬁles were associated with ﬁve
distinct STs, being ST118 the most frequently encountered, which was
found in all 9 hospitals since 2009; this ST was followed by ST92, a
single-locus variant (SLV) of ST118, which includes all but one isolate
from 2009 and 2010. ST98, also a SLV of ST118, appeared since 2005.
The ST187 appeared in 2006 and the novel ST188, appeared in 2009.
Conclusion: This study provides updated data regarding the molecular
epidemiology of MDR-Ab in Portugal. Here, we report the ﬁrst
appearance of two epidemic ST OXA-23-producers in the country,
ST92 and ST118, suggesting clonal importation; during the study, both
STs have successfully spread among all hospitals, suggesting clonal
expansion. Indeed, they seem to be replacing the only ST described
so far as endemic in Portugal (ST98).
P1367 Linezolid susceptibility in Europe for 2010: ZAAPS
Program (5,532 strains)
R. Jones*, J. Ross, H. Sader, D. Farrell, R. Mendes (North Liberty, US)
Objectives: To report the most recent full-year of linezolid (LZD)
resistance surveillance (ZAAPS Program) monitoring European (EU)
medical centers for 2010. A total of 5,532 Gram-positive organisms
were consecutively collected (prevalence design) from 39 hospitals in 17
countries. Results represent the ninth yearly EU sample for this central
laboratory-based study.
Methods: All susceptibility (S) tests were performed applying reference
CLSI broth microdilution methods, using validated panels (TREK Di-
agnostics). Sampled strains came from bacteremias (52.4%), respiratory
tract (25.5%) and skin infections (22.1%) sources; one organism per
patient episode. The number of strains tested were: S. aureus (SA; 2,552,
27.0% MRSA), coagulase-negative staphylococcal species (CoNS; 593,
71.7% methicillin-resistant [R]), Enterococcus spp. (ENT; 864 with 542
E. faecalis [EF] and 288 E. faecium [EFM]), S. pneumoniae (SPN, 747),
viridans gr. (VGS, 250) and b-haemolytic (BHS, 625). Streptococcal
strains R to LZD (MIC, 8mg/L) were tested by molecular methods
(PCR/sequencing, PFGE) to determine R mechanism (23S target, L3,
L4 mutations and cfr).
Results: LZD potency for indicated species in the ZAAPS Program
remained stable (MIC90 for all species at 1mg/L), see Table. Nearly all
MIC values for LZD were 0.5, 1 or 2mg/L. No LZD-R isolates were
detected among SA and the three streptococcal pathogens monitored.
LZD-R strains were EFM (1 strain with G2576T mutation) and 2
S. epidermidis strains (both with G2576T mutations) and no other
mechanisms were detected. Three countries had LZD-R strains: Germany
(Frankfurt), Italy (Genoa) and Spain (Madrid) with LZD-R MIC values
at 8−64mg/L. Other agents with >90% S rates versus SA were: fusidic
acid (92.9%), daptomycin (99.9%), doxycycline (94.0%), gentamicin
(91.4%), mupirocin (98.1%), quinupristin/dalfopristin (99.8%), tigecy-
cline (100.0%), and vancomycin (100.0%).
Conclusions: LZD-R rate for the worldwide 2009 ZAAPS Program was
only 0.14% and these 2010 EU ZAAPS results showed no escalation
of R (0.05%; 3/5,532) with no evidence of clonality. CoNS and ENT
species have the highest LZD-R occurrences and no mobile cfr genes
were identiﬁed among 3,045 staphylococci screened in EU.
P1368 Erythromycin resistance of clinical isolates of Streptococcus
pneumoniae isolated over a thirty-year period in Barcelona,
Spain (1979–2008)
L. Calatayud, C. Ardanuy, F. Tubau, M.A. Dominguez, I. Grau,
R. Pallare´s, R. Martı´n, J. Lin˜ares* (Hospitalet de Llobregat, ES)
Objectives: The aims of this study were to analyze trends of
Erythromycin resistance (EryR) in S. pneumoniae (Spn) over thirty
years period in a hospital in Barcelona. The distribution of serotypes,
genotypes and macrolide resistance genes were analyzed.
Methods: Among 8620 pneumococci collected from 7585 adult patients
in 1979–2008 period, 2030 (23.5%) were EryR. Of them, 1686 (83%)
were serotyped by Quellung reaction or PCR, 1082 (53%) were
genotyped by PFGE/MLST and the erm(B) and mef(A) genes were
detected by PCR in 1098 (54%) of the strains.
Results: The overall EryR rate was 23.5% (2030/8620). EryR rates
progressively increased from 0% in 1979 to 35.3% in 2001, thereafter
EryR rates ranged from 25 to 30%. EryR rates were higher among non-
invasive 26.9% (1638/6099) than invasive isolates 15.5% (392/2521),
p< 0.001. The 94.2% of EryR-Spn strains had MLSB phenotype. The
most frequent serotypes were: 19F, 6B, 23F, 14, 19A, 15A, 23A, and 6A.
Among 1013 MLSB phenotype strains 956 (94.4%) had erm(B) gene, 22
(2.2%) had both erm(B) and mef(A/E) genes and 35 (3.5%) had neither
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genes. All 85 M phenotype isolates had mef(A/E) genes (92% mefE
and 8% mefA). Among MLSB strains, eleven clones (Spain23F-ST81,
Spain6B-ST90, Sweden15A-ST63, ST4223A, ST8819F, Denmark14-
ST230, Spain14-ST18, ST3016F, Poland6B-ST315, Spain9V-ST156 and
ST71733F) accounted for the 62% of the strains. The predominant
clones among M phenotype strains were Spain9V-ST156, England14-
ST9 and ST6211. Three clones related to PCV7 serotypes decreased:
Spain14-ST18, Spain23F-ST81 and Spain6B-ST90 (p< 0.05), whereas
Denmark14-ST230, ST3016F, ST42 and ST717 increased (p< 0.05).
Conclusions: EryR rates progressively increased in Spain in the late 80s
coinciding with the introduction of long-acting macrolides in the clinical
practice, and were associated to the spread of few multidrug-resistant
clones that decreased after PCV7 introduction. However, EryR rates did
not decrease due to both spread of minor macrolide resistant clones and
the emergence of new resistant clones such as Denmark14-ST230.
P1369 Serotype distribution of nasopharyngeal pneumococci
among children having acute otitis media before the
introduction of a pneumococcal conjugate vaccination
programme
K. Vuorenoja*, L. Siira, A. Virolainen, J. Jalava, P. Huovinen,
P.A. Ta¨htinen, M.K. Laine, A. Ruohola (Turku, Helsinki, FI)
Objectives: Streptococcus pneumoniae is the main pathogen in acute
otitis media (AOM). Pneumococcal serotypes are determined according
to the composition of capsular polysaccharides. More than 90 different
serotypes known to date differ in their ability to cause diseases.
In Finland, the 10-valent pneumococcal conjugate vaccine containing
serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F, has been included
into the national vaccine program in autumn 2010.
The aim of this study was to investigate the serotype distribution
of pneumococcal isolates from nasopharyngeal samples of children
having AOM, during the years 2006–2008, before the era of nationwide
pneumococcal vaccination.
Methods: Nasopharyngeal samples were taken from children (6−35 mo)
at entry visit of an AOM treatment trial. Thus far, 96 pneumococcal
isolates from nasopharyngeal samples have been serotyped in the
Bacteriology Unit of the National Institute for Health and Welfare.
Results: The most common pneumococcal serotypes were 6B, 19F, 14,
23F and 6A, in decreasing order of incidence. These serotypes covered
nearly 90% of all studied isolates. Four of these serotypes: 6B, 19F, 14,
and 23F are included in the 10-valent pneumococcal conjugate vaccine,
which cover altogether 82% of pneumococcal serotypes detected in the
nasopharyngeal specimens. Pneumococcal serotype 6A, which is not
covered by this vaccine, was detected in 8% of the nasopharyngeal
isolates. Other pneumococcal serotypes detected were 37, 10A, 15B,
15C, 18C, 35B, 6C and 9A.
Conclusion: Our results conﬁrm that the most common serotypes of
pneumococci isolated from the nasopharyngeal samples of children with
AOM are covered by the 10 valent pneumococcal conjugate vaccine
currently in nationwide use in Finland. This indicates that the vaccine
program might decrease the number of pneumococcal AOM cases.
However, the possible increase by non-vaccine serotypes like 6A already
present in the nasopharynges of children calls for careful monitoring of
the serotype distribution during the coming years.
P1370 Prior use of ﬂuoroquinolones, ﬂuoroquinolone resistance
and gyrA/parC mutations in Streptococcus pneumoniae in
Ontario
A. McGeer*, R. Melano, S. Patel, S. Drews, K. Green, D.E. Low
on behalf of the Canadian Bacterial Surveillance Network
Objectives: Use of FQ is known to be associated with selection for FQ
resistance (FQR) in SPN. We assessed the extent to which prior FQ use
was associated not only with increases in FQR but also with increases
in parC and gyrA mutations in FQ susceptible SPN.
Methods: TIBDN performs population-based surveillance for invasive
pneumococcal disease (IPD) in Toronto/Peel (pop. 4M); respiratory
isolates are also collected. Prior antibiotic use is collected via chart
review and patient/physician interview. Broth microdilution susceptibility
testing to CLSI standards is performed. QRDR were sequenced for
all FQR isolates (Cip mic >2mg/ml or Lev R or Moxi R), all SPN
isolates from patients (PTs) with FQ exposure (FQEXP=any FQ in prior
3 months), and a sample of other isolates from 2000 to 2007. Population
FQ use was obtained from IMS Health.
Results: From 2000–2009, FQ use increased from 68−97 scripts/
1000pop/yr; Levo from 0−9.3 scripts/1000pop/yr, Moxi from 0−18
scripts/1000pop/year. 4071 respiratory isolates and 4657 IPD cases were
identiﬁed. FQR decreased signiﬁcantly from 2002 to 2007, then remained
stable: Levo R for IPD was 1.1% (2002), 0.46% (2007), 0.78% (2009)
and for respiratory isolates was 5.9% (2002), 1.9% (2007), 1.6% (2009).
Overall, Moxi R was 0.49% (2002), 0.46% (2007), 0.60% (2009). Of
97 Levo R isolates with QRDR sequencing, 89 had mutations in gyrA
and parC, 6 in gyrA only, and 2 in parC only. Of 3098 lev S/I isolates
sequenced, 2 had both parC and gyrA mutations, 48 parC mutations
only, 2 a gyrA mutation only, and 3046 had no mutations. Complete
data on prior FQ use was available for 70% of cases. 957/7517 (13%)
PTs reported FQEXP. Of the 106 Levo R isolates, 63 (59%) occurred
in PTs with FQEXP; while 43 (41%) occurred PTs without FQEXP.
Of the 52 lev S/I isolates with QRDR mutations, 22 (51%) occurred
in 417 isolates from PTs with FQEXP; and 21 (49%) in 2018 others
(P< 0.001). Moxi represented none of FQEXP before 2002, and 42% in
2007/8. Among Lev S isolates, at least one mutation in QRDR was found
in 10/153 (6.5%) from PTs with Cipro EXP, compared to mutations being
identiﬁed in 2/139 (1.4%) isolates from PTs reporting Levo EXP and
1/51 (2.0%) isolates from PTS reporting Moxi EXP (P = 0.056).
Conclusions: Despite increased use of FQs, FQR decreased. Most FQS
isolates with QRDR mutations are found in PTs with recent FQEXP.
Exposure to more active FQ may be associated with reduced risk of
development of QRDR mutations.
P1371 Invasive pneumococci in Italy: serotype changes and
antibiotic resistance after pneumococcal conjugate vaccine
implementation
M. Del Grosso*, R. Camilli, F. D’Ambrosio, M. Monaco, F. D’Ancona,
G. Gherardi, A. Pantosti (Rome, IT)
Objectives: In Italy, pneumococcal conjugate vaccine (PCV7) was
licensed in 2001 and slowly implemented in the Regional strategies for
vaccination. Aim of this study was to analyze changes in serotypes and
antibiotic susceptibility of Streptococcus pneumoniae in three periods,
in relation to PCV7 introduction.
Methods: In a nationwide surveillance a total of 1250 invasive
S. pneumoniae isolates from children and adults were voluntarily sent
and examined in Istituto Superiore di Sanita`: 428 isolates were obtained
from 2001 to 2003, 439 from 2005 to 2007, and 383 from 2008 to 2010.
Serotyping and susceptibility to antibiotics, including penicillin (PEN)
and erythromycin (ERY), were performed. ERY-resistance genes were
detected by PCR.
Results: Of the 428 S. pneumoniae isolates collected during 2001–2003,
227 (53%) belonged to vaccine serotypes (VS), and 201 (47%) to non-
vaccine serotypes (NVS); of the 439 isolates recovered during 2005–
2007, 148 (33.7%) belonged to VS and 291 (66.3%) to NVS: of the 383
isolates recovered during 2008–2010, 91 (23.8%) belonged to VS and
292 (76.2%) to NVS. The increasing trend observed among NVS was
mainly due to increase in serotypes 1 (from 3.7% in 2001–2003 to 11.7%
in 2008–2010), 6C (from 0.5% to 1.8%), 7F (from 5.6% to 9.7%), 19A
(from 4% to 15.1%), and 24F (from 0.2% to 2.9%). An increase in PEN
non-susceptible S. pneumoniae (PNSSP) was observed both among VS
(from 18.1% to 36.3%) and NVS (from 1.5% to 9.6%). An overall stable
rate of ERY-resistant (R) pneumococci was observed during the three
periods but the higher proportion of ERY-R VS with respect to ERY-R
NVS, that was observed in 2001–2003, was reversed in 2008–2010 due
to a sharp increase in ERY-R NVS (from 18.4% to 30.8%). Most of
serotypes 19A and 24F isolates were ERY-R and a portion was also
PNSSP. Almost all of serotypes 1, 6C, and 7F isolates were susceptible
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to both PEN and ERY. In NVS, ERY resistance was mainly conferred by
erm(B) but isolates carrying both erm(B) and mef(E) increased in the
last two periods.
Conclusion: In the PCV7 era and before the implementation of PCV13
in Italy, the increase of NVS pneumococci mainly involved both
serotypes 19A and 24F resistant isolates, and serotypes 1, 6C, and 7F
susceptible isolates. These data emphasize the importance of continuous
surveillance with the introduction of PCV13 vaccine.
P1372 Prevalence and characteristics of pneumococci colonising
adults older than 60 years in Portugal: the PneumoEL
project
S. Nunes*, S. Almeida, I. Valadares, S. Martins, F. Breia, A. Brito-Avoˆ,
A. Morais, H. de Lencastre, R. Sa´-Lea˜o (Oeiras, Montemor-o-Novo,
PT; New York, US)
Objectives: The PneumoEL project was launched in 2010 in two areas
of Portugal, and aims to gain insights on pneumococcal carriage patterns
among the elderly.
Methods: Between April and November of 2010, adults (aged >60 years)
were enrolled. The participants lived either in the urban area of Oeiras
(n = 650), or in the rural area of Montemor-o-Novo (n = 650). Swabs of
the nasopharynx (NP) and oropharynx (OP) were obtained. Identiﬁcation
of pneumococci was done by optochin susceptibility, solubility in
bile salts, and detection of lytA (major pneumococcal autolysin) and
cpsA (conserved capsular gene) genes. Isolates were tested by disk
diffusion for susceptibility to erythromycin (Ery), clindamycin (Cc),
chloramphenicol (Chl), tetracycline (Tet), and co-trimoxazole (SXT), and
by E-test to ciproﬂoxacin (CIP) and penicillin (PG). Serotyping was done
by multiplex PCR and/or the Quellung reaction.
Results: Sixty-three (4.8%) adults were pneumococcal carriers. Carriage
rates were 4.0% and 1.5% in the NP and in the OP, respectively.
Pneumococci were isolated from both sites in seven adults (0.5%).
Additionally from one NP sample, two types of colonies were detected.
A total of 71 isolates were obtained. Serotyping and antibiotyping
revealed that six of the seven adults that carried pneumococci in both
sampling sites carried a single strain. Co-colonization was detected in
two adults only. The 65 strains were of types 11A (n = 4), 22F, 23B,
and 37 (3 each), 19A, 6A, 35F, 39 and 3 (2 each), 5, 16A, 23A,
18A, 15B, 15A, 36, 31, 9L, and 21 (1 each); 32 isolates were non-
typeable (NT). Six isolates (9.2%) had decreased susceptibility to PG
(0,19mg/LMIC 1mg/L); seven (10.8%) had a CIP MIC 2mg/L.
Rates of resistance to Ery, Cc, Tet, SXT, and Chl, were 15.4%, 4.6%,
10.8%, 9.2%, and 0%, respectively. Multidrug resistance was found in
ﬁve isolates associated with NT (n = 3), 15B, and 19A. The potential
coverages by the 23-valent pneumococcal polysaccharide vaccine and by
the 13-valent pneumococcal conjugate vaccine among capsulated isolates
were 36.4% and 21.2%, respectively.
Conclusion: This is the ﬁrst data from Portugal on pneumococcal
colonization among the elderly. Carriage rates in this age group are
low. There is a great variability of serotypes. Moderately high rates of
resistance to antimicrobial agents were found. Our results provide an
important baseline to monitor the impact of upcoming pneumococcal
vaccines in patterns of colonization among the elderly.
P1373 Penicillin non-susceptible pneumococcal invasive clones
circulating in Italy in the vaccine era (2006–2010)
G. Gherardi*, F. D’Ambrosio, M. Del Grosso, R. Camilli, D. Visaggio,
G. Dicuonzo, A. Pantosti (Rome, IT)
Objectives: The aim of this study was to assess the impact of the 7-valent
conjugate vaccine (PCV7) on the serotypes and the population structure
of penicillin-non susceptible pneumococci (PNSSP) in Italy.
Methods: All pneumococcal invasive isolates recovered in an Italian
nation-wide surveillance in 2006–2010 were studied. All isolates were
serotyped and examined for susceptibility to penicillin, cefotaxime,
erythromycin, clindamycin, tetracycline and chloramphenicol following
the CLSI procedures. Clonal groups were deﬁned on the basis of
both Pulsed-Field Gel Electrophoresis and Multilocus Sequence Typing
(MLST). Isolates were also genotyped by restriction analysis of pbp2b
and pbp2x genes.
Results: Among 778 invasive isolates, from both adults and children,
a total of 118 PNSSP isolates were found, with 67 and 51 isolates
being vaccine serotypes (VS) and non-vaccine serotypes (NVS),
respectively. Differences were observed about the relative frequencies
of VS, NVS, and clones between vaccine and pre-vaccine (1999–
2003) eras. Among PNSSP VS, serotype 14 increased in the vaccine
era, while serotypes 9V, 19F and 6B signiﬁcantly decreased. Within
NVS, a large increment in the rates of serotypes 19A, 24F, 15A, and
6A was noted. Conversely, serotype 35F, that was quite represented
in the pre-vaccine era, completely disappeared. Among 92 PNSSP
available for genotyping, 15 different CC/PFGE combinations were
found. Sweden15A-25/CC63/PFGE 2 (23 isolates, 25%), Spain9V-
3/CC156/PFGE 1 (22 isolates, 23.9%), Denmark14−32/CC230/PFGE 3
(15 isolates, 16.3%), and Spain23F-1/CC81/PFGE 34 (7 isolates, 7.6%)
accounted for 85.9% of the genotyped PNSSP. Clones Sweden15A-
25/CC63/PFGE 2 and Denmark14−32/CC230/PFGE 3 largely increased
in the vaccine era. Other clones, previously encountered, completely
disappeared in the vaccine period (i.e., ST676/PFGE 5). New CC/PFGE
combinations were also observed, as in the case of Taiwan19F-
14/CC271/PFGE 85. A high correspondence between pbp2b/2x proﬁles
and speciﬁc clones was found. New associations of serotypes with
speciﬁc clones were also observed, compared to those found in pre-
vaccine period.
Conclusion: Differences in the prevalence of serotypes and clones
among PNSSP have been observed if compared to those found in the
pre-vaccine era. Not all the differences can be directly attributed to the
vaccine impact, but rather reﬂect the continuous antibiotic pressure.
P1374 Emergence of a macrolide-resistant lineage among invasive
serotype 6C pneumococci in Spain
D. Rolo, A. Fenoll, C. Ardanuy, L. Calatayud, M. Cubero, J. Lin˜ares*
(Barcelona, Madrid, ES)
Objectives: Little is known about macrolide-resistance of the recently
described serotype 6C among invasive pneumococci. This study
analyzes the epidemiology of invasive macrolide-resistant serotype 6C
pneumococci (MRSer6C) isolated from children and adults in Spain
(1997–2009).
Methods: The MRSer6C pneumococci were screened for mechanisms
of resistance, macrolide- and tetracycline- resistance determinants
(detection by PCR of ermB, mefA/E, tetM, tnpA, tnpR, xis, int and
aph3’ genes). Strains were genotyped by PFGE and MLST.
Results: Of 213 serotype 6C pneumococci isolated from 1997 to 2009,
33 (15.5%) were macrolide-resistant, being 32 isolated from adults. Out
of 33 MRSer6C isolates, 31 (93.9%) were collected in the 2006–2009
period. The majority (81.8%, 27/33) of the MRSer6C isolates had a
cMLSB phenotype. Among 27 cMLSB phenotype isolates, 20 harboured
the Tn6002 transposon and were related to the ST386/ST4310/ST4825
lineage. The remaining seven isolates were mainly associated with the
acquisition of different transposons (Tn1545/Tn6003, Tn2010, Tn2009)
by the major serotype 6 lineage ST224/ST1150. Six (18.2%) of the
MRSer6C isolates were of M phenotype and had the mefE gene
(related to MEGA element). Of them, four were associated with the
ST473/ST1616/ST3620 lineage (all with different PFGE proﬁles).
Conclusion: The increase of macrolide-resistance among invasive
serotype 6C isolates in Spain was associated with the emergence of
the ST386/ST4310/ST4825 lineage which carried a Tn6002 transposon.
However, dissemination of macrolide resistance determinants among
previously susceptible clones was also documented.
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P1375 Phenomenal increase in ﬂuoroquinolone-non-susceptibility
among clinical group A streptococci in Belgium during
2007–2010
L. Van Heirstraeten*, G. Leten, C. Lammens, S. Malhotra-Kumar,
H. Goossens on behalf of the Belgian reference centre for Group
A Streptococcus
Objectives: Fluoroquinolones (FQs) are not recommended for Group A
Streptococcus (GAS) infections, however resistance to FQs is frequently
reported in GAS. We evaluated the impact of a reportedly high FQ use
in Belgium on the evolution of FQ non-susceptibility (FQ-NS) in GAS
during 2007–2010.
Methods: A total of 4495 conﬁrmed GAS isolates recovered from
patients suffering from pharyngitis or invasive infections during 2007–
2010 in Belgium were screened for ciproﬂoxacin susceptibility on disc
diffusion. MICs to ciproﬂoxacin were determined for GAS with a zone
diameter <20mm. FQ-NS strains (MIC ciproﬂoxacin 2mg/ml) were
further screened for norﬂoxacin MICs and reserpine-sensitive efﬂux
by agar dilution. Emm typing of FQ-NS GAS was done using PCR
and sequencing. Quinolone resistance determining regions (QRDR) of
topoisomerase genes, parC and gyrA, were screened for mutations in
selected FQ-NS GAS (n = 44). Pearson’s Chi square test was used for
statistical analysis.
Results: A total of 499 (11.1%) of the 4495 GAS collected during 2007–
2010 were FQ-NS. Prevalence of FQ-NS GAS increased signiﬁcantly
from 4.4% to 10.9% between 2008 and 2009, and more than doubled
to 22.1% in 2010 (P< 0.01 for both) (Table). During 2008–2010,
nonsusceptible GAS recovered from both children and adults showed
a signiﬁcant increase (P< 0.01). Majority of FQ-NS GAS belonged to
emm6 (n = 329, 65.9%) and emm75 (n = 87, 17.4%), and proportion
of emm6 strains increased signiﬁcantly during 2008–2010 (P< 0.01).
Ciproﬂoxacin MICs for 497 FQ-NS GAS ranged from 2−8mg/mL and
2 strains (emm89 and emm11) exhibited high-level resistance with
MICs of 32mg/ml. Ciproﬂoxacin MICs of 2−8mg/ml correlated to ParC
substitutions at the Ser79 hotspot (substituted by Ala, Phe, or Tyr). Other
changes in ParC were noted at Asp83 (to Asn, Gly), Asp91 (to Asn),
and Ser140 (to Pro). Interestingly, the 2 FQ-NS GAS with ciproﬂoxacin
MICs 32mg/ml also showed second-step substitutions in GyrA at Ser81
(to Tyr in emm89, and Phe in emm11). Reserpine-sensitive efﬂux was
not observed.
Conclusions: We recorded a phenomenal increase in FQ-NS among
GAS that has not been reported before and is of concern. Reassuringly,
FQ-NS is still primarily conﬁned to emm6 GAS that have consistently
exhibited low-level FQ resistance linked to ﬁrst-step ParC substitutions.
P1376 Unexpectedly high prevalence of spa type t008, SCCmec
type IV MRSA clone in Russian paediatric hospitals
A. Romanov*, A. Dekhnich, M. Edelstein, L. Kozlova, R. Kozlov
(Smolensk, RU)
Methicillin-resistant Staphylococcus aureus (MRSA) is shown to
have a clonal population structure, and is characterized by limited
number of clonal groups distributed worldwide and having different
pathogenicity and antimicrobial resistance patterns. The data about
molecular epidemiology of MRSA in Russian paediatric hospitals are
sparse.
Objective: To determine molecular types of S. aureus strains causing
nosocomial infections in children in different regions of Russia.
Materials and Methods: A total of 112 isolates (67 MSSA and 45
MRSA) collected from 28 hospitals of 23 geographycally distinct cities
of Russia in 2002–2008 were studied. The isolates were selected to
represent unique resistance patterns within one ward of a given hospital
and were typed by: (i) automated ﬂuorescent multilocus VNTR analysis
(MLVA) of 6 loci (SIRU01, -05, -07, -13, -15, -21) described by Ikawaty
et al. (2008); (ii) spa sequence typing; and (iii) multiplex PCR SCCmec
typing. Assignment and cluster analysis of spa types as well as clustering
of MLVA proﬁles were performed using BioNumerics software, v6.1
(Applied Maths).
Results: Based on results of MLVA typing, MSSA isolates were
clustered into 28 distinct groups encompassing 58 types while all but
two MRSA isolates were distributed into 17 related types differing at
no more than 2 VNTR loci. Spa sequence typing further divided MRSA
isolates from major MLVA cluster into two groups: one including t008
(n = 20) and highly related t024 (n = 1) types, and the other including
t037 (n = 7), t030 (n = 5) and 6 related (n = 10) types. SCCmec III and
SCCmec IV were harbored by 21 and 24 isolates, respectively. All MRSA
of spa type t008 had SCCmec IV. Interestingly, this major group of
MRSA included isolates originating from 7 different cities and exhibiting
variable susceptibilities to ciproﬂoxacin, gentamicin, erythromycin and
clindamycin.
Conclusions: Epidemic spread of MRSA isolates causing nosocomial
infections in children in Russia involves a limited number of genetic
groups. Of notice, spa type t008, SCCmec type IV reported in the late
1990’s as community acquired MRSA was shown in our study to be
predominant among nosocomial pediatric isolates in Russia.
P1377 Clonal dissemination with particular phenotypes of
methicillin-resistant Staphylococcus aureus isolates from
patients diagnosed with mastitis in Central Taiwan
W.Y. Wang*, T.S. Chiueh, J.R. Sun, J.J. Lu (Taichung, Taipei, TW)
Background: Mastitis, frequently seen in puerperal and breast-feeding
women, is often caused by Staphylococcus aureus. Methicillin-resistant
S. aureus (MRSA) accounts for 70% to 80% of S. aureus isolates in
Taiwan.
Objectives: The goals were to delineate the clinical aspects and
molecular and phenotypic characters of MRSA isolates that caused
mastitis.
Materials and Methods: Demographic data of patients diagnosed
of mastitis (ICD:611) from Jan 1st, 2008 to Jun 30th, 2010 were
analyzed. S. aureus isolates from mastitis patients and environmental
sampling were collected from Oct 1st, 2009 to Jun 30th, 2010.
Molecular types were assigned with PFGE, SCCmec, MLST, spa, agr,
and dru. Phenotypes were assigned with disc diffusion method, MIC to
vancomycin (VA) by agar dilution, pvl, and superantigenic toxin proﬁles
by multiplex PCR. M-W-U and c2-tests were used accordingly.
Results: The episodes of total and breast-feeding related mastitis in
30-month period were 240 and 220, respectively. The prevalence of
total and MRSA mastitis increased signiﬁcantly after Sep 2009 (0.95
vs. 1.42 and 0.05 vs. 0.40/1,000 patient-day, respectively, p< 0.05; 6.42
vs. 13.01 and 0.32 vs. 3.70/100 delivery, respectively, p< 0.01). All
patients were females; with mean age of 30.4; and 98 (40%) with right,
84 (35%) with left, and 18 (8%) with both sides; the mean duration
from delivery and onset of symptoms was 25.3 days. Totally 26 isolates
(MRSA:25, MSSA:1) from mastitis patient and 15 isolates (MRSA:10,
MSSA:5) from sampling of healthcare-givers were collected. All 25
clinical MRSA were typed as SCCmecVT-ST59-spa t437-agrI-dru 6, 7,
8. Genetic variation was seen in 10 MRSA colonized isolates (each 3 of
6 for SCCmecVT-ST59-spa t437 and spa t529, respectively; 4 isolates for
SCCmecIV-ST59-spa t437). All except 2 clinical MRSA were resistant
to 3 antibiotics (erythromycin, clindamycin, and tetracycline); all with
pvl (+) and VA MIC of 1mg/L except 1 (MIC:1.5); and all but one
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with seb-selk-selr. Thirteen pulsotypes were assigned, which 5 major
types including pulsotype A (15 isolates) belonged to clinical isolates
and pulsotype B (2 clinical and 3 screening isolates) were characterized.
Conclusions: A particular MRSA clone with unique molecular and
phenotypic characteristics was identiﬁed in mastitis patients in central
Taiwan. Horizontal transmission of MRSA between patients and hands
of healthcare givers was demonstrated and further control maneuvers
should be implemented.
P1378 Report from the National Surveillance Program (2000–2009)
of Enterococcus in Cuba: phenotype and genotype studies
D. Quin˜ones Pe´rez*, D. Marrero, M. Abreu, A. Llop, R. del Campo,
R. Go´mez Luz, C. Rubio, P. Gon˜i, N. Kobayashi (Havana City,
Holguı´n, CU; Madrid, Zaragoza, ES; Sapporo, JP)
Objective: Enterococci have emerged as important nosocomial
pathogens worldwide. This work presents the report of national
surveillance of enterococci in Cuba during 2000–2009. This study
included prevalence of species, phenotype and genotype resistance
patterns, virulence determinants, and genetic diversity among selected
enterococcal isolates.
Methods: A total of 687 Enterococcus recovered from 30 hospitals of
Cuba during a period between 2000 and 2009 were studied. The min-
imum inhibitory concentration was determined to seventeen antibiotics
and resistance genes to aminoglycosides, glycopeptides, macrolides and
tetracyclines were examined by PCR. Clonal relationships were studied
by pulsed-ﬁeld gel electrophoresis.
Results: Eight enterococcus species were detected. Enterococcus
faecalis was the most prevalent (83%), followed by Enterococcus
faecium (12.2%), Enterococcus avium (1.3%), Enterococcus gallinarum
(1.4%), Enterococcus durans (0.4%), Enterococcus hirae (0.6%),
Enterococcus rafﬁnosus (0.4%) and Enterococcus casseliﬂavus (0.7%).
High level resistance to gentamicin, streptomycin and amikacin was
detected in 31%, 29% and 29% of the isolates, respectively. Six
percent of Enterococcus was resistant to ampicillin. The resistance to
glycopeptides was rare (vancomycin, 0.7% and teicoplanin, 0.4%) and
it was mediated by Van A and Van B genes. Not resistant isolates
to linezolid was detected. Resistance to other drugs, including the
ﬂuoroquinolones, was present. High level resistance to aminoglycoside
was mediated by the genes aac(6′)-Ie-aph(2′′)-Ia, aph(3′)-IIIa, ant(6), and
ant(3′′)(9). The erm(B) gene was found in 74% of the erythromycin-
resistant strains. The resistance to tetracycline (56%) was mediated
by tet(L) (7%) and tet(M) (75%) genes. Dissemination of intra- and
inter-hospital of clones of Enterococcus spp. was evident in Cuba.
The resistance to different antimicrobianos was inﬂuenced by the
dissemination of resistant clones and/or the transfer of genetic elements.
Conclusions: Vancomycin resistant enterococcus is infrequent in Cuba.
In contrast, high-level aminoglycoside resistance is highly prevalent,
suggesting a problem of its expansion through selective pressure to
antibiotics and dissemination in hospital environment. The dissemination
of resistant clones within the hospitals indicated the signiﬁcance of
infection control and monitoring of antibiotic susceptibility to prevent
selection of resistant enterococci in the hospital.
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P1379 “Hand-hygiene champion junior doctor picks up the
gauntlet”: The hand hygiene re-audit conducted by junior
doctors in a large district hospital of northwest England
M. Przybylo*, L. Moorhouse, A. Guleri (Blackpool, UK)
Background: Several Department of Health high proﬁle hand hy-
giene (HH) campaigns have made HH compliance results a required
item of trust board, divisional, hospital infection control meetings, and
trust induction day. HH audits are conventionally conducted monthly by
infection control/link nurses. The results are fed back to the board for
discussion of intervention effectiveness and action plans. Historically,
compliance rates of above 90% have led to a culture of ignorance.
We present an innovative reaudit by junior doctors (JD). The initial
2009 audit reported a 37% (667/1787) compliance in HH throughout
the trust. The aim of the reaudit was to assess the effectiveness of
the intervention proposed by the divisions, and to provide prospective,
unbiased, sizable data on HH compliance in 2010. Secondary outcome
was to raise awareness and engage JDs in the hospital hand hygiene
program (HHP).
Methods: Data from 1840 minutes (92×20-min observational (HHA))
performed by randomly selected 6 JDs across 19 wards. Standard
HHA tool (as used by nurses for monthly HHA) was used. Each
JD had an audit induction explaining the procedure. The observer
selected any clinical areas and observed each area at least 3 times at
different times and different days (to eliminate ’bad-day’ effect).’Fly-
on-the-wall’ [un-noticed] technique was used during observations
(to eliminate observation related change in behavior). Deﬁnitions:
Opportunity (O) for HH − touching patient or immediate surrounding
(bed frame, med equipment, curtains, notes/trolley on bedside, etc). Hand
hygiene (H) with alcohol gel or washing-soap & water. HH compliance =
(total H÷ total O)× 100.
Results: Overall HH during the 2010 study period was 35% (353/1015).
There was no statistical difference between total HH compliance during
2009 and 2010 (p 0.05).
Conclusions: Poor hand hygiene compliance can potentially undermine
the hospital HCAI program. This study has revealed a detailed picture
regarding hand hygiene compliance. Poor past performance coupled
with lack of initiative results in no signiﬁcant change in HH culture.
Recommendations from this audit will be to completely abandon the
HH audit and focus on infection intervention and nosocomial hospital
infection rates. It is stipulated that outcomes of nosocomial infections
rather than audit results will encourage greater compliance rates to HH
and other infection interventions measures leading to an environment of
accountability and ownership.
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P1380 Reliability testing of the WHO Hand Hygiene
Self-Assessment Framework
A. Stewardson*, B. Allegranzi, H. Attar, T. Perneger, D. Pittet (Geneva,
CH)
Objectives: The Hand Hygiene Self-Assessment Framework (HHSF)
was developed by the WHO 1st Global Patient Safety Challenge as a
systematic self-assessment tool to provide a situation analysis of hand
hygiene (HH) resources, promotion, and practices within healthcare
facilities. It is comprised of a questionnaire with 27 indicators arranged
in 5 components. Our aim was to assess the inter-rater reliability of this
tool, i.e. the degree to which independent testers within a single facility
give consistent answers.
Methods: National or sub-national HH campaign coordinators in 13
countries were each asked to nominate 10 appropriate facilities. In
addition, facilities participating in earlier stages of testing of the HHSF
were invited. Inclusion criteria were: 1) implementation of a local HH
promotional strategy, and 2) the availability of two individuals with good
knowledge of the local HH promotional activities and resources. The two
testers in each facility were instructed to independently complete the
HHSF and to provide basic demographic details. Using the variance
components model (with raters nested within hospitals), reliability
was estimated by the ratio of (true) between-hospital variance over
total variance in ratings. This was performed for each indicator, each
component sub-total and the overall score of the HHSF. By convention,
results with a reliability <0.4 were considered as having poor reliability
and examined individually with regard to the need for modiﬁcation.
Results: Complete responses were received from 41 facilities in 16
countries, representing all 6 WHO regions. The reliability results for the
total score for the HHSF and the subtotal of each of the ﬁve components
ranged from 0.54 to 0.86. Seven of the 27 indicators had poor reliability,
with a percentage true variance <0.4 for either the entire indicator or
a part thereof. These indicators were examined by experts for potential
sources of unreliability and modiﬁed accordingly.
Conclusion: The reliability testing demonstrated that this tool can
be conﬁdently used by different infection control professionals within
an institution and also drew attention to several indicators with poor
reliability that were examined for appropriate modiﬁcations. These
results support the repeated use of the HHSF to document progress in
HH promotion within a facility.
P1381 The Feedback Intervention Trial: a randomised controlled
trial to improve hand-hygiene compliance in ITUs and
acute elderly wards in 16 hospitals
S. Stone*, C. Fuller, J. Savage, S. Besser, S. Michie, J. MacAteer,
A. Hayward, A. Charlett, B. Cookson, M. Murray, G. Duckworth,
J. Roberts, L. Teare, A. Jeanes (London, Chelmsford, UK)
Objectives: Although randomised controlled trials (RCT) show feedback
improves healthcare workers’ (HCWs) implementation of best practice,
effects are modest & most trials don’t use psychological theory to design
interventions. Systematic review suggests feedback may improve hand
hygiene compliance but needs regular repetition with studies being small,
short term & poorly designed. We therefore performed a national 3 year
RCT of the effect of a psychological-theory based feedback intervention
on hand hygiene compliance.
Methods: Stepped Wedge cluster RCT in 60 wards (16 ITUs & 44
acute care of the elderly [ACE] wards in 16 English/Welsh hospitals
(Oct 2006-Dec 2009) NRR Web site N0256159318
The intervention was based on Goal-setting & Control theories &
comprised a repeating 4 week cycle (20−30 mins/week) of observation,
feedback & action planning, with HCWs & groups, recorded on forms.
Randomisation − computer generated step wise entry of hospitals.
Primary outcome − observed hand hygiene compliance (%) with blinded
observers. Secondary outcome –soap & alcohol hand rub (AHR)
procurement (mls/bed day).
Fidelity to intervention (forms used/month) & Confounders (stafﬁng
levels, skills mix, agency rates) measured.
Mixed effects regression analysis, accounting for confounders &
temporal trends.
Results: All 60 wards randomised & analysed; 8 closed during study.
33 wards implemented intervention (11 ITU, 22 ACE).
Intention to treat analysi (ITT)s: estimated odds ratio (OR) for
compliance rose post-randomisation (1.44; 95%CI 1.18–1.76; p< 0.001)
in ITUs but not ACE.
Per protocol analysis (implementing ward): OR for compliance rose for
both ACE wards (1.67 [1.28–2.22]; p< 0.001) & ITUs (2.09 [1.55–
2.81] p< 0.001), equating to a 10%-13% & a 13%-18% absolute rise
in compliance in ITU & ACE wards respectively (Figure). OR for non-
implementing wards fell (ACE) or was unchanged (ITU). Fidelity to
intervention closely related to compliance on ITUs. OR for compliance
1.12 [1.04, 1.20] p = 0.003 per completed form).
Conclusions: Despite difﬁculties in implementation, ITT & per protocol
analyses showed a feedback intervention based on behavioural theory
signiﬁcantly improved hand hygiene compliance. The effect increased
with ﬁdelity to intervention. In any one month, the greater adherence the
higher the compliance. The effect was greater on ITU than ACE wards.
A study of the barriers & facilitators of implementation is needed to
improve this & maximise the intervention’s effect in different settings.
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P1382 Linear correlation between the compliance with hand
hygiene and glove using without indication
M. Eveillard*, V. Guilloteau, B. Lefrancq, A. Rabjeau, M. Pradelle,
V. Bre´jon, F. Raymond, M. Joly-Guillou, P. Brunel (Angers, Nantes, FR)
Objectives: Although hand hygiene is usually considered as the
cornerstone of the prevention of micro-organism transmission, the overall
compliance for this practice is often low. According to certain studies,
failure to change or remove contaminated gloves could represent an
important component in this poor compliance. Therefore, a growing
number of experts consider that non-sterile glove usage should be
restricted to limited indications. Our objective was to study the
correlation between the compliance with hand hygiene and glove using
without indication.
Methods: The study was conducted in 11 healthcare settings including
rehabilitation units, acute geriatric wards, and nursing homes. The
compliance with hand hygiene and gloving practices were recorded
by observers speciﬁcally trained for the study. The observations were
performed between the 15th and the 30th October 2010. The compliance
for hand hygiene was recorded before and after a unique contact with
a patient or its environment, before and after a sequence of successive
contacts in the same room, and lastly between contacts in the same
sequence. Glove usage was deﬁned as indicated if the healthcare workers
had contacts presenting a risk of exposure to body ﬂuids. Otherwise,
glove usage was considered as not indicated. The proportion of glove
usage without indication was deﬁned as the ratio “number of contacts
in which gloves were used without indication/total number of contacts
with gloves” (N1/N2). The linear correlation between hand hygiene
compliance and N1/N2 was studied with the Pearson’s coefﬁcient (r).
Results: During the study, 848 contacts representing 1252 opportunities
of hand hygiene were observed. Gloves were used for 344 (39.2%)
contacts. The compliance with hand hygiene varied from 36.5% to 84.7%
according to the healthcare settings. The ratio N1/N2 varied from 7.7%
to 52.8% according to the healthcare settings. There was a signiﬁcant
linear correlation between the compliance with hand hygiene and the
ratio N1/N2 (r = −0.74, P< 0.01), showing a decrease of compliance
with increasing N1/N2.
Conclusion: This study conﬁrms the deleterious effects of the glove mis-
use on the compliance with hand hygiene. Interventions for improvement
of glove usage including education, evaluation and feedback should be
included in programs of infection control, particularly when they concern
hand hygiene.
P1383 Sustaining hand-hygiene compliance following implemen-
tation of the World Health Organization Hand Hygiene
Improvement Strategy in a tertiary hospital in Saudi Arabia
W. Mazi*, A. Senok, D. Abdullah, S. Al Khaldy (Taif, Riyadh, SA)
Objective: King Abdul Aziz Specialist Hospital (KAASH), Taif, Saudi
Arabia is a participating hospital in World Health Organization (WHO)
SAVE LIVES: Clean Your Hands Initiative. This study aimed to
assess hand hygiene compliance in KAASH and determine appropriate
strategies for improvement.
Methods: Hand hygiene compliance using the WHO Hand Hygiene
Observation Form was assessed in the Intensive Care Unit (ICU),
Neonatal ICU (NICU), Kidney Center (KC) and Burns Unit (BU) in
KAASH over three study periods in 2010. A hand hygiene intervention
campaign was a symposium/workshop which took place on 8th May.
Data was collected during the pre-intervention phase (April 24-May
06) and post-intervention phase (May 29-June 09). During the post-
intervention period, ongoing intervention measures including feedback,
reminders and direct observation were in place. The third period from
01−15 October 2010 was a follow-up phase with no intervention
measures.
Results: A total of 1425 hand hygiene observations were carried out
and compliance increased from 67.5% pre-intervention to 80.5.6% post-
intervention but was only 59.5% in the follow-up phase. The highest
compliance rate was in NICU (from 87.6% to 90.4%) followed by BU
(from 70% to 78%) and ICU (from 38.85% to 56.8%) pre to follow-
up phase respectively. In the post-intervention period, the improved
compliance rate in KC was statistically signiﬁcant (pre:43.37%; post:
70.8%, p= 0.0001). Nurses showed the highest compliance rate (63%
and 73.5%) followed by physicians (56.5% and 67.9%) in pre and post
intervention phases respectively. Five months after the intervention, hand
hygiene compliance rate remained sustained in the NICU (90.4%) but
declined in other units (ICU 53%; BU 78%; KC 36%). The main sources
of missed action were before patient contact with/without donning
gloves, after touching patient surrounding and before aseptic techniques
when they don gloves directly without hand hygiene.
Conclusion: Our preliminary data indicates improved hand hygiene
compliance after a using a combination of direct supervision and
feedback. To sustain high rates of hand hygiene compliance, ongoing
hand hygiene observations with continuous feedback are needed.
P1384 The short-term and long-term effectiveness of a
multidisciplinary hand hygiene improvement programme
M. Tromp*, A. Brink-Huis, I. de Guchteneire, J. van der Meer, T. van
Achterberg, M. Hulscher, C. Bleeker-Rovers (Nijmegen, NL)
Objectives: To test the effects of multidisciplinary hand hygiene (HH)
improvement programme.
Methods: We performed an observational study in the department of
internal medicine of a 953-bed university hospital in the Netherlands. A
multiple strategy programme including education, feedback, reminders,
and social inﬂuence was developed. In addition, HH facilities were
improved. All strategies were aimed at the nurses as well as the
physicians. During a 5 month period, a registered nurse and an
experienced infectious disease staff physician were appointed as role
models. They were trained in teaching and motivating their colleagues
in using the HH guidelines. Five group meetings were conducted.
Goals of these meetings were setting norms and targets within the
team, identiﬁcation of obstacles, improvement activities at team level,
and activities to achieve sustainability. The nursing staff and medical
staff prioritized good HH behaviour as speciﬁc team goal, provided
facilities, and supported all HH improvement activities. We measured
HH knowledge and HH compliance before (baseline), directly after (post
strategy), and 6 months after the performance of the HH team strategies
(follow up).
Results: Ninety-two nurses and physicians were included in the study.
Compared to baseline, there was a signiﬁcant improvement in the overall
mean HH knowledge score (0−10 scale) at post strategy (from 7.4
to 8.4) and follow up (from 7.4 to 8.3). The overall HH compliance
was 27% at baseline, 83% at post strategy, and 75% at follow up. In
the subgroup of nurses, the HH compliance was 17% at baseline and
signiﬁcantly improved to 83% at post strategy, and to 63% at follow up.
The HH compliance by physicians was 43% at baseline and signiﬁcantly
improved to 83% at post strategy, and to 91% at follow up.
Conclusion: Our multifaceted HH improvement programme was
successful and resulted in a sustained improvement of HH knowledge
and HH compliance in nurses as well as physicians. Appointing role
models, setting norms and targets within the team, identiﬁcation of
obstacles, improvement activities at team level, and activities to achieve
sustainability can result in improved HH knowledge and HH compliance.
Our results emphasize that quality of care can be improved if social
inﬂuence activities are used more frequently.
P1385 Hospital-wide evaluation of hand disinfectant tolerability:
is sufﬁcient good enough?
B. Bertisch*, B. Scho¨bi, T. Lehmann, M. Schlegel (St. Gallen, CH)
Objectives: Adherence to hand disinfection is the single most important
intervention to prevent healthcare associated infections. Therefore, hand
disinfectants should be both microbiologically effective and tolerable.
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After a modiﬁcation of the currently used alcohol formulation,
tolerability and acceptance decreased inacceptably at our tertiary care
hospital with 700 beds. The aim of this study was to evaluate different
hand disinfectants in the hospital daily routine.
Methods: Selection of hand disinfectants: The following preconditions
for testing had to be fulﬁlled: Ofﬁcial approval for hand disinfection,
effectiveness against norovirus, no colorants or perfume additives.
Disinfectants without activity tests against norovirus had to have at
least identical concentration of the disinfectant ingredient. After internal
evaluation, 4 products (one gel formulation) were selected (Products
A-D, concentration of alcohols see table).
Hospital-wide testing: 18 of the 34 wards from medicine, surgical and
obstetric departments including intensive care units were chosen to
participate. Health care providers were informed in written and oral
form. Participation was voluntary.
All 4 selected products were tested non-blinded sequentially for 3 weeks
each from July to September 2010. All the dispensers and personally-
used hand disinfectant bottles were equipped with the test product.
After every test phase, an electronically generated questionnaire had
to be completed by the test persons. Questions included tolerability,
appearance of redness, dryness, effect on skin care and breakoff for any
reason.
Results: Response rates per disinfectant varied from 225 to 290
providers. No product showed eminent tolerance results, but two products
rated clearly better than the others (see table). Among these, product A
was equal or slightly superior to product C for all evaluated factors.
Product D, a gel formulation, was not accepted with a high break off
rate.
Conclusion: Even the best-rated product only showed “sufﬁcient”
tolerability expressed by dryness, redness, skin care effect and general
impression. Tested products showed congruent results for the different
evaluated factors.
The hospital-wide aim of a norovirus-effective hand disinfectant is
probably associated with reduced tolerability. Therefore, it is important to
make available alternative disinfectants in personally used pocket-sized
bottles for providers intolerant to the used disinfectant.
P1386 Increase of alcoholic hand disinfection performance due to
new touchless dispensers
S. Scheithauer*, H. Haefner, A. Koch, S. Lemmen (Aachen, DE)
Background: Hand hygiene is considered to be the single most
effective tool to prevent healthcare associated infections. Despite several
recommendations and efforts undertaken, compliance still remains low.
In order to evaluate a new touchless dispenser for hand disinfection (HD)
with an alcoholic solution, we conducted an observational study at the
University Hospital Aachen, Germany.
Methods: Baseline usage of mechanical dispensers with counters were
documented on an medical ICU over a 8 weeks time period from June
to July, 2010 and compared to data with a new touchless dispenser over
a 12 weeks time period from August to October, 2010. In total the
ICU was equipped with 28 dispensers in each period. During the study
the personnel/patient ratio and the number of patient days (PD) were
comparable.
Results: The performance with the hygienic HD increased on average
by 53% from 34 to 52 HD/PD (see Figure 1). It is of note that the
operations next to the patients beds increased from 42 to 82 and on the
corridors from 22 to 40 HD/PD, respectively. During the time period the
touchless dispensers were used a steady increase of mean HD/PD could
be observed.
Conclusion: Utilization of a dispenser with a new touchless mechanism
for hygienic HD with an alcoholic solution resulted in an increase of 53%
from 34 HD/PD to 52 HD/PD) on average. This observation showed at
least a sustained effect, since the mean values for HD/PD increased
steadily during the 12 weeks study period with the touchless dispenser.
In conclusion, the use of a touchless dispenser might contribute to
increase the compliance with hygienic hand disinfection in the setting
of an ICU.
Author Disclosure Information: This study was sponsored in part by
Ophardt Hygiene-Technik GmbH+Co KG, Germany.
P1387 Beyond compliance with hand hygiene: watch out for the
WHO hand hygiene technique!
A.F. Widmer*, N. Frey, M. Dangel, M. Battegay, S. Tschudin Sutter
(Basel, CH)
Objectives: Hand hygiene belongs to the basic components of any
infection control program. The WHO initiative primarily focused on
the introduction of the alcoholic hand rub and the improvement of
compliance, a most successful program of the patient safety initiative.
Proper technique of hand hygiene signiﬁcantly improves bacterial killing,
but compliance with this technique has not been studied in large trials.
Methods: The university of Basel hospitals is a 900 bed tertiary care
center with 5 Intensive CUs and kidney and bone marrow transplant
program. After introduction of the alcoholic hand rub in 1970, hand
washing has been replaced with the alcoholic hand rub in >90%. A
trained investigator observed health care workers during their daily work,
regarding their compliance with the hand hygiene technique using an
alcoholic hand rub during a 3 months period using a standardized case
report form.
Results: 1030 observations were made in different wards, emergency
rooms, ICUs and transplant units. Overall compliance with all 6
steps was 13.4%. The steps focusing on the ﬁngertips and the thumb
were frequently missed, namely 83−90% for nurses and 95−97% for
physicians (p< 0.05).
Conclusions: The compliance with hand hygiene technique requires
more focus and training: the thumb and the ﬁngertips are frequently
not adequately in contact with alcohol. Several techniques have been
proposed, but basic training should ensure that the ﬁngertips and the
thumb are not missed during the alcoholic rub-in.
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P1388 Healthcare workers’ perceptions of a programme inviting
patients to report staff hand-hygiene compliance
N. Farquet*, Y. Longtin, A. Gayet-Ageron, H. Sax, T. Perneger,
D. Pittet (Geneva, CH)
Objectives: Patient involvement in hand hygiene (HH) promotion is a
novel strategy to prevent healthcare-associated infections. Patients could
play a role in improving healthcare workers’ (HCWs) HH practices in
two different ways: 1. by participating actively in reminding HCWs to
cleanse their hands (Patient participation [PP]); 2. by observing and
assessing HCWs’ HH practices (Patient observer [PO]).
Some experts suggest that patients could be invited to prospectively
evaluate HCWs’ hand hygiene compliance. However, little is known
about HCWs’ views of such strategy.
Methods: Cross-sectional study in 700 randomly selected registered
nurses and physicians actively engaged in direct patient care at a public
teaching hospital. Respondents were asked about their knowledge and
perception on HH and PO. Independent predictors of acceptance and
rejection of PO were assessed by multivariate logistic regression.
Results: Response rate was 40.5% (284 respondents: 64%, female;
56.5%, nurses). Overall, 108 respondents (39%) had a favourable opinion
of such PO program while 90 (32%) did not, others being neutral. 165
(58.5%) believed that it would help them improve their HH compliance.
93 (33%) feared that, if a patient noticed that they forgot to cleanse their
hands, it could interfere in their relationship; moreover 78 (28%) would
feel uncomfortable knowing that patients could potentially assess them.
Independent factors associated with the acceptance or rejection of PO,
adjusted for sex, age, profession, years of work experience and work
experience at HUG, are presented in Table.
Conclusion: Although the concept of PO is less appealing to HCWs that
PP, more than a third of HCWs are favorable, which is not negligible.
This study identiﬁes several potential barriers to the implementation of
a PO program that could guide the development of future strategies and
highlights the importance of reassuring HCWs upon the implementation
of such strategy.
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P1389 Extended-spectrum b-lactamase producing urinary tract
infection isolates
V. Skandami-Epitropaki*, M. Papadaki, A. Xanthaki, A. Karaferi,
E. Zampeta, A. Tsiringa, M. Toutouza-Giotsa (Athens, GR)
Objectives: This study was performed to ﬁnd out the frequency
and antimicrobial susceptibility of extended-spectrum b-lactamase
(ESBL) producing Enterobacteriaceae strains isolated from urinary tract
infections.
Methods: During the study period (November 2009 − November 2010)
540 strains of Escherichia coli and 129 strains of Klebsiella pneumoniae
were isolated from midstream urine samples in our microbiology
laboratory. The identiﬁcation to the species level was performed with the
VITEK TWO system (Bio-Merieux) and susceptibility to antimicrobial
agents was tested by the disk diffusion method according to CLSI
recommendations. Detection of ESBL expression was performed by
the double-disk synergy (DDS) test and with the VITEK TWO card
MIC/AST for ESBL.
Results: ESBL production was determined in 52 out of 669 strains of
Enterobacteriaceae (7,7%). The ESBL phenotype was detected in 7,7%
(42 out of 540) strains of E. coli and 7,7% (10 out of 129 strains) of
K. pneumoniae urine isolates. For E. coli, ESBL production was detected
in 36 out of 325 strains isolated from hospitalized patients (11%) and 6
out of 215 patients of the community (2,7%). For K. pneumoniae only
one ESBL producing strain was isolated from the 33 community patients
(3%). The antibiotic susceptibility rates for the ESBL producing strains
were for E. coli and K. pneumoniae respectively: Imipenem 100%-100%,
gentamicin 66,6%-50%, amikacin 71,4%-37,5%, netilmicin 66,6%-
25%, tobramycin 26,1%-6,2%, ciproﬂoxacin 14,2%-6,2%, norﬂoxacin
9,5%-6,2%, nitrofurantoin 66,6%-6,25%, tetracycline 14,2%-18,7%,
trimethoprime/sulfamethoxazole 21,4%-0%.
Conclusions: Our ﬁndings demonstrate an increasing incidence of
urinary tract infections with ESBL producing bacteria not only in
hospitalized but also in community patients. Most of ESBL producing
isolates were multidrug resistant. High resistance rates to quinolones
were observed among these strains, but carbapenems had a good activity.
Monitoring of ESBL production and antimicrobial susceptibility testing
are necessary to avoid treatment failure in patients with urinary tract
infections.
P1390 Trends in antimicrobial susceptibility among bacterial
isolates from UTI of Japanese hospitals participating in the
Levoﬂoxacin Surveillance Group during 1994–2010
Y. Ishii*, A. Ohno, K. Tateda, K. Yamaguchi (Tokyo, JP)
Objectives: Multidrug resistance Gram-negative pathogens are serious
problem worldwide. In Japan, the prevalence of FQ resistant Escherichia
coli and Proteus mirabilis increased annually from 1994 to 2007 however
FQs retained activity for Klebsiella pneumoniae, Serratia marcescens
and Acinetobacter species during this period. We present here the
nationwide surveillance data from 1994 to 2010 for the above ﬁve
causative pathogens of UTI.
Methods: A total of 17,086 isolates belonging to 5 species were
collected from 92 centers participating in the Levoﬂoxacin Surveillance
group in Japan from 1994 to 2010. Antimicrobial susceptibility testing
by broth microdilution methods followed the Clinical and Laboratory
Standards Institute (CLSI) guidelines. ESBL phenotypic conﬁrmatory
testing for E. coli, K. pneumoniae and P. mirabilis was performed by the
disk diffusion method following the CLSI document. ESBL typing was
performed by PCR analysis.
Results: In E. coli, the percentage of levoﬂoxacin susceptible isolates
decreased from 97.9% (1994) to 71.5 (2010). The susceptibility of
P. mirabilis isolates also decreased from 97.9% (1994) to 78.6% (2010).
On the other hand, levoﬂoxacin susceptible K. pneumoniae slightly
increased from 99.7% (1994) to 98.2% (2010). Acinetobacter spp.
susceptibility also slightly decreased from 90.4% (1996) to 86.2%
(2010). Interestingly, the percentage of susceptibility to levoﬂoxacin in
S. marcescens increased dramatically 86.5% (1994) to 96.9% (2010).
In 2004, 3.3% of E. coli isolates produced ESBL however 8.6% of
E. coli produced ESBL in 2007. The frequencies of CTX-M-1 group,
CTX-M-2 group and CTX-M-9 in E. coli were 25% (16 isolates), 3.1%
(2 isolates) and 64.1% (41 isolates), respectively. Interestingly, 73.4% of
ESBL producing isolates show resistance to levoﬂoxacin. The percentage
of levoﬂoxacin resistance in ESBL producing E. coli was higher than
non ESBL producing E. coli (18.7%). In 2002, levoﬂoxacin resistance
percentages in ESBL producing and non ESBL producing E. coli were
15.4% and 8.5%, respectively.
Conclusions: The percent susceptibility of levoﬂoxacin against Gram-
negative organisms from UTI was maintained at 70% to 97%.
Levoﬂoxacin still retains activity for K. pneumoniae, S. marcescens and
Acinetobacter spp. On the other hand, the isolation frequency of ESBL
producing E. coli is increasing in Japan and the predominant type of
ESBL was CTX-M-type including the CTX-M-9 and CTX-M-1 groups.
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P1391 Clinical impact of ﬂuoroquinolone resistance in acute
pyelonephritis caused by Escherichia coli
S.J. Kang*, D.R. Chung, S.Y. Park, Y.E. Ha, E.J. Joo, M.K. Joung,
C.I. Kang, K.R. Peck, J.H. Song (Seoul, KR)
Objectives: Escherichia coli is the most common etiology of uncompli-
cated urinary tract infection. As ﬂuoroquinolone (FQ) resistance rate of
E. coli has been increasing, concern about possible poor outcome due
to inappropriate empirical therapy has been arisen. We determined the
impact of FQ resistance on the treatment outcome of acute pyelonephritis
by E. coli initially treated with FQ.
Methods: From the databases of Korean multicenter surveillance studies
for bacteremia and urinary tract infection from 2006 to 2009, a post-hoc
analysis was conducted. Cases of community-onset acute pyelonephritis
caused by E. coli, initially treated with FQ, were included. Primary
outcome was defervescence within 3 days and length of hospital stay of
7 days or less.
Results: A total of 191 cases were included. FQ resistance rate
was 21.5%. The mean age (63.0±12.5 vs. 56.8±17.0, P = 0.030) and
the proportion of healthcare-associated infection (39.0% vs. 17.3%,
P = 0.003) was signiﬁcantly higher in FQ resistance group. In univariate
analysis, the rates of patients achieved defervescence within 3 days did
not differ between two groups (80.4% vs. 78.9%, P =0.839). More
patients stayed longer than 7days in hospital in FQ resistance group
(25.3% vs. 43.9%, P =0.021). In-hospital mortality was observed in only
3 cases, all of which were FQ susceptible. In multivariate analysis, FQ
resistance was not associated with fever beyond 3 days or hospital stay
longer than 7 days (OR 0.774, 95%CI 0.257–2.328; OR 1.580, 95%CI
0.579–4.315). Severe sepsis was only signiﬁcant risk factor for longer
hospital stay (OR 5.828, 95%CI 1.367–24.860).
Conclusion: Fluoroquinolone resistance did not show any association
with fever beyond 3 days or hospital stays longer than 7 days in acute
pyelonephritis by E. coli, initially treated with FQ. Severe sepsis was a
risk factor for hospital stay longer than 7 days.
P1392 Clinical predictors for the acquisition of ﬂuoroquinolone-
resistant uropathogens among patients with
community-onset complicated acute pyelonephritis
Y.K. Cho*, H. Pai, J. Kim, S. Wie, S. Lim, S.Y. Shin, J.S. Yum,
J.S. Lee, K.T. Kweon, H. Lee, H.J. Cheong, S.H. Park, D.W. Park,
S. Ryu, M. Chung (Incheon, Seoul, Suwon, Jeju, Daegu, Busan, KR)
Objectives: The emergence and spread of ﬂuoroquinolone-resistant
Gram-negative uropathogens (FQR-GNUP) is already a serious problem
in the community of Korea. The aim of this study is to ﬁnd out clinical
predictors for acquiring FQR-GNUP among patients with community
onset complicated acute pyelonephritis (CAPN) in Korea.
Methods: Clinical data of all APN patients who visited 14 hospitals
during 2008 were collected retrospectively. Among them, cases having
underlying systemic diseases or urinary conditions were included as
CAPN cases. The information on fever duration before visit and
histories of previous antibiotics, urinary tract infections (UTIs), and
hospitalization was also inputted. Covariates found to be associated with
FQR-GNUP on univariate analysis at a level of signiﬁcance p< 0.2 were
eligible for inclusion in a multivariate logistic regression model using a
backward selection procedure.
Results: Total 890 cases of CAPN were included for analysis. Gram-
negative uropathogens were identiﬁed in 573 cases (64%). The median
age was 66 years (interquartile range 53−73 years) and 68 (12%)
were male. The frequent comorbid conditions were diabetes mellitus
(280, 49%), cerebrovacular accident (100, 18%), and malignancy (80,
14%) and commonly combined urinary abnormalities were urinary
stone (42, 7%), hydronephrosis (37, 7%), and indwelling catheter
(30, 5%). Escherichia coli was the most common pathogen (491,
85.7%), Klebsiella species (36, 6.3%), Pseudomonas species (15, 2.6%),
Enterobacter species (9, 1.6%), and Proteus species (8, 1.4%) were
also identiﬁed. Ciproﬂoxacin-resistance rate of GNUP was 27.2%. The
independent clinical predictors for acquiring FQR-GNUP identiﬁed were
male sex (hazard ratio [95% conﬁdence interval], 2.14 [1.26–3.64]),
intermittent catheterization (3.26 [1.06–10.02]), previous UTIs more than
once within 1 year (1.57 [1.03–2.39]).
Conclusion: Male, intermittent catheterization, and UTIs within 1 year
were signiﬁcant clinical predictors for acquiring FQR-GNUP in patients
with community-onset CAPN in the country with high rate of antibiotic
resistance.
P1393 Fluoroquinolone resistance in community-acquired urinary
tract infections
V. Skandami-Epitropaki*, E. Zampeta, A. Tsiringa, A. Karaferi,
M. Papadaki, A. Xanthaki, M. Toutouza-Giotsa (Athens, GR)
Objectives: To study the frequency and antibiotic susceptibility
of quinolone resistant bacterial stains isolated from patients with
community-acquired bacteriuria and compare it with urinary pathogens
from hospitalized patients.
Methods: During a 12-month period (November 2009 − November
2010) a total of 764 bacterial strains were isolated out of 6826 urine
samples submitted for culture in our hospital laboratory from the
community and from hospitalized patients with urinary tract infection
symptoms. Cultures and bacterial identiﬁcation were obtained by
conventional methods. Antibiotic susceptibility testing was done by
Kirby-Bauer disk diffusion method according CLSI criteria.
Results: Of the 764 bacterial strains studied (Escherichia coli 540,
Klebsiella pneumoniae 149, Proteus mirabilis 75), 25,6% of them
were found to be quinolone resistant. The percentage of quinolone
resistance was 31,1% for hospitalized patients (HP) and 15% for
community patients (CP). The quinolone resistance for E. coli was
39,3% for HP and 14,6% for CP, for K. pneumoniae 44,9% for HP
and 18,2% for CP and for P. mirabilis 23,6% for HP, 15% for CP.
Susceptibility pattern of the 196 quinolone resistant isolates to other an-
timicrobial agents was for hospitalized patients and community patients
respectively as following: For E. coli ampicillin 8,6−6,6%, amoxicillin-
clavulanate 52,2%-63,1%, piperacillin-tazobactam 56,6%-76,3%, ce-
furoxime 56,5%-80,3%, sulfamethoxazole-trimethoprime 19,6%-23,3%,
cefepime 63,7%-83,3%, gentamicin 71,7%-73,2%. For K. pneumoniae,
ampicillin 1,9%-0%, amoxicillin-clavulanate 15,4%-57,1%, piperacillin-
tazobactam 17,3%-57,1%, cefuroxime 17,3%-57,1%, sulfamethoxazole-
trimethoprime 3,8%-28,6%, cefepime 17,3%-57,1%, gentamicin 67,3%-
100%. For P. mirabilis, ampicillin 15,4%-0%, amoxicillin-clavulanate
46,2%-100%, piperacillin-tazobactam 84,6%-100%, cefuroxime 46,1%-
66,6%, sulfamethoxazole-trimethoprime 7,6%-0%, cefepime 100%-
100%, gentamicin 53,8%-100%. Ten strains of K. pneumoniae (17,2%)
were carbapenem resistant metallo-b-lactamase producing and quinolone
resitant strains.
Conclusions: High resistance rates to ﬂuoroquinolones were observed in
uropathogen bacteria isolated not only from hospitalized patients but also
in bacteria associated with community-acquired urinary tract infections
in Greece. Increasing resistance rates to the rest antibiotic agents make
the treatment of urinary tract infections a very difﬁcult problem.
P1394 Nationwide survey of community-acquired lower urinary
tract infections in primary care
D. Arman*, C. Agalar, M. Dizbay, O. Tunccan, D.T. Keten, G. Aygun,
O. Tunger, N. Demirturk, D. Inan, C. Ozakin, Y. Bayindir, A. Akbulut,
M. Bakir, I. Koksal, M.A. Ozinel, N. Oztoprak, E. Aktas, Y. Alpay
on behalf of the Turkish urinary infection study group
Objectives: The aim of the study was to determine the in vitro resistance
of nationwide urinary E. coli isolates to oral antibiotics and to evaluate
the treatment choices of primary care physicians.
Methods: The study was performed in 55 primary care center in 13
cities of Turkey, between May to July 2009. Adult patients with at least
two of dysuria, pollakuria, nocturia, suprapubic tenderness or blurred
urine symptoms, but not fever were included. Urinary samples were
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obtained and the patient data was ﬁlled at the primary care centers.
After incubation and isolation procedure in a research laboratory in the
same city, microbiological procedures were done in the central research
laboratory.
Results: Totally 400 patients were enrolled. In 43.8% patients, urine
cultures yielded a urinary pathogen. The most encountered pathogen
was E. coli (62,8%). Other enteric Gram negatives (5%), CNS
(24,5%), other Gram positives (5,7%) and Candida spp. (1,7%) were
isolated microorganisms. The lowest resistance rates were detected for
nitrofurantoin (0,9%) and fosfomycin (3,6%) among E. coli isolates.
Resistance rates to 3rd generation cephalosporin (3GC) was 31%. It
was >20% to both TMP-SMX and quinolones and were signiﬁcantly
higher in 3GC resistant isolates (P = 0,04 and p< 0.001). The MIC levels
for ciproﬂoxacin and levoﬂoxacin were shown in Table 1. When MIC
levels were evaluated with respect to the previously detected urinary
concentrations of ciproﬂoxacin and levoﬂoxacin, therapeutic MIC levels
were provided in 83.6% and 98.2% of the strains, respectively. Although
quinolone resistance was higher in patients with history of antibiotic
treatment during last 3months (p< 0.001); resistance rates did not differ
in complicated and uncomplicated cases.
Primary care physicians prescribed empiric antimicrobial treatment in
49,5% patients. Levoﬂoxacin (62,6%) or ciproﬂoxacin (17%) were most
frequently chosen antibiotics.
Conclusions: Preliminary in vitro data shows that nitrofurantoin or
fosfomycin are appropriate choices for community acquired lower
urinary tract infections, especially in patients with a history of
antimicrobial treatment in the last 3 months. Quinolones especially
levoﬂoxacin may be efﬁcious, because of pharmacokinetic properties,
but needs further evaluation on clinical basis. For rational use of
antimicrobials in the primary care setting, postgraduate education on
diagnosis, resistance and treatment of urinary tract infections is needed
in Turkey.
P1395 The emergence of antimicrobial resistance in various
urinary pathogens in Japan
K. Ishikawa* on behalf of the JSC Surveillance Committee
Educational Workshops: Optimal management of urinary tract infection
and prostatitis.
Objectives: An alarming trend of resistance development among
common pathogen caused urinary tract infection (UTI) has been
observed worldwide. In order to investigate the emergence of antimi-
crobial resistance in various urinary pathogens, the Japanese Society
of Chemotherapy (JSC) established the ﬁrst nationwide surveillance
network in 2008. I demonstrate other data from some international
surveillance.
Methods: The ﬁrst survey was conducted during the period from
January to June 2008. With the cooperation of 28 medical institutions
throughout Japan, a total of 688 strains belonging to six clinically
relevant bacterial species were collected from adult patients with well-
diagnosed complicated UTIs. The minimum inhibitory concentrations
of 39 antibacterial agents were determined according to the Clinical and
Laboratory Standards Institute manual.
Results: All E. faecalis strains were susceptible to ampicillin and
vancomycin. Although a majority of them were susceptible to linezolid,
11 strains (7.8%) were found to be intermediately resistant. The
proportions of ﬂuoroquinolone-resistant E. faecalis, E. coli, P. mirabilis,
and S. marcescens strains were 35.7%, 29.3%, 18.3%, and 15.2%,
respectively. The proportions of E. coli, P. mirabilis, K. pneumoniae,
and S. marcescens strains producing extended-spectrum b-lactamase
were 5.1%, 11.9%, 0%, and 0%, respectively. The proportions of
P. aeruginosa strains resistant to carbapenems, aminoglycosides, and
ﬂuoroquinolones were 9.2%, 4.4%, and 34.8%, respectively and 2 strains
(1.8%) were found to be multidrug resistant. By other three studies, it
has been reported that ﬂuoroquinolone-resistant E. coli accounted 8%
of isolates from patients with uncomplicated UTI in Japan. However,
in South Korea, it has been shown that the resistance rate of E. coli
isolated from acute uncomplicated UTI to ciproﬂoxacin increased from
15.2% in 2002 to 24.8% in 2009. From European reports, E. coli
caused uncomplicated UTI showed the highest rate of susceptibility
to fosfomycin (98.1%) followed by mecillinam (95.8%), nitrofurantoin
(95.2%), and ciproﬂoxacin (91.8%).
Conclusions: Surveillance data of the current antimicrobial agents are
essential for the optimal management of patients with UTI. These data
will be a useful reference for future periodic surveillance studies, as well
as for investigations to control antimicrobial-resistant pathogens.
P1396 Urinary pathogens in Greek children: prevalence and
antibiotic resistance trends over a 5-year period (2005–2009)
D. Hatzaki*, E. Vetouli, G. Kalogeras, N. Palaiologou, G. Antonaki,
M. Matsas, E. Lebessi (Athens, GR)
Objectives: Urinary Tract Infections (UTIs) are a serious cause of
morbidity for infants and young children. The aim of this study was
to evaluate the isolation rates and trends in antimicrobial resistance for
pathogens associated with UTI in Greek children over a 5-year period
(2005–2009).
Methods: All urine cultures obtained from children referred to the
outpatient clinics or hospitalized in the pediatric wards, were reviewed
by using WHONET system. Patients hospitalized in surgical wards,
oncology and nephrology department, PICU and NICU were excluded
from the study. WHONET data were analyzed, considering only the
ﬁrst isolate per patient. Identiﬁcation of the isolates was performed by
classical methods and susceptibility to antimicrobials was tested by the
disk diffusion agar method according to the CLSI guidelines. Resistance
mechanisms were researched by phenotypic methods.
Results: A total of 4,008 isolates associated with UTI were recovered.
The isolation rates were as follows: Escherichia coli 65.42%, Proteus spp
12.05%, Klebsiella spp 6.46%, Enterococcus spp 4.64%, Pseudomonas
aeruginosa 3.94%, Enterobacter spp 1.97%, Staphylococcus spp 1.67%,
Citrobacter spp 0.70%,Serratia spp 0.57%,Candida spp 0.43% and
other bacteria 2.15%. During the study period (2005 through 2009)
antimicrobial resistance rates for E. coli isolates showed a signiﬁcant
increase to ampicillin (41.4% to 58.6%), 3rd generation cephalosporins
(2.7% to 8.6%), cotrimoxazole (25.3% to 37.9%), nalidixic acid
(4.2% to 10.9%), ciproﬂoxacin (1.7% to 5.1%) and aminoglycosides
(0.8−2.9% to 2.5−8.4%). Similar trends in resistance were observed
for Proteus mirabilis to cotrimoxazole (11.2% to 18.4%), nalidixic
acid (1% to 6.1%), and less to ampicillin (26.9% to 28.6%).
Concerning Klebsiella spp isolates, a random annual variation for
ESBL produsers was noted (18.6%, 5.7%, 17.8%, 7.0%, 22.2%), with
similar resistance rates to aminoglycosides. P. aeruginosa strains were
found susceptible to antibiotics, except to aminoglycosides (0−2.3%
to 0−8.8%). Carbapenemases were not detected among Gram negative
isolates. All E. faecalis isolates were susceptible to ampicillin and
nitrofurantoin. VRE strains were not isolated.
Conclusion: E. coli was the most frequently isolated pathogen, as
expected. The trend of resistance rates for E. coli isolates to most
antibiotics is upwards. This phenomenon reﬂects the worrisome increase
of resistance rates to commonly used antibiotics in the community.
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P1397 The changing pattern of antimicrobial resistance within
42033 Escherichia coli isolates from nosocomial, community,
and urology patient-speciﬁc urinary tract infections, Dublin,
1999–2009
I.M. Cullen*, R.P. Manecksha, E. McCullogh, S. Ahmad, R. Grainger,
R. Flynn, T. McDermott, J.A. Thornhill, J. Fennell, P. Murphy (Dublin, IE)
Background: Escherichia coli (E.Coli) is the most common uropathogen
in community and nosocomial urinary tract infection (UTI). Knowledge
of local antimicrobial resistance patterns is essential for evidence based
empirical antibiotic prescribing. A cut off point of 20% has been
suggested as the level of resistance at which an agent should no longer be
used empirically. Antibiotic resistance rates vary depending on whether
the sample represents a nosocomial, community acquired or urology
patient speciﬁc UTI.
Methods: A retrospective analysis of the 42033 E.Coli urine isolates
from the eleven-year period 1999 to 2009 in a single Dublin teaching
hospital was performed. WHONET software was used to analyse the
changing pattern of sensitivity and resistance of E.Coli to commonly
used antibiotics over the study period. The origins of the urine samples
were stratiﬁed into three groups − inpatients with nosocomial UTIs,
urines originating from the emergency department and general practice
(community UTIs), and UTIs in urology patients.
Results: Ampicillin and trimethoprim were the least active agents against
E.Coli with total eleven-year resistance rates of 58.3% and 33.8%
respectively. The overall gentamicin resistance rate was 3.4% and is
climbing at a rate of 0.7% per year (p< 0.0001). Within the urology
sample population the rate of resistance was 6.4%.
Signiﬁcant trends of increasing resistance over the eleven-year
period were identiﬁed for ampicillin, trimethoprim, gentamicin
and ciproﬂoxacin. Signiﬁcant differences were demonstrated in co-
amoxyclav, gentamicin, nitrofurantion and ciproﬂoxacin resistance rates
depending on the sample origin. Ciproﬂoxacin resistance approaches
20% in the nosocomial UTI population and approaches 30% in the
urology population. It remains reasonable empirical antibiotic choice
in this community with eleven-year resistance of 10.6%. UTIs in the
urology patient population demonstrate higher antibiotic resistance rates
than nosocomial or community UTIs.
Conclusion: E. coli remains the commonest uropathogen in the
community and hospital setting with its incidence climbing from 50% to
60% of UTIs over the eleven-year period. Penicillins and trimethoprim
no longer represent suitable empirical agents for UTI. Ciproﬂoxacin
resistance in this Dublin based study render it unsuitable empirical
therapy for nosocomial UTI and UTI in the urology population.
The dramatic eleven-year rate increase in gentamicin resistance is of
paramount concern.
P1398 Aetiology and antibiotic susceptibility of urinary tract
infections in the elderly: a cohort study
E. De Vecchi*, S. Sitia, R. Mattina, T. Luraschi, S. Santinato, L. Drago
(Milan, IT)
Objectives: Urinary tract infections (UTIs) are the most common
infections in elderly (age >65 years), whether they are community
dwelling, live in long term care facilities or are hospitalized.
While etiology of UTIs in young and adult population is well known,
less data are available on pathogens responsible of UTIs in the elderly.
Methods: Samples were obtained from a cohort of residents in 12
nursing homes in Milan and its province in the 2009. Only a single
positive culture per patient was considered in the analysis, unless new
pathogens from the same patient were isolated.
Pathogens were identiﬁed by Gram stain and standard biochemical
procedures. Antimicrobial susceptibility testing was carried out by using
the disk diffusion method as described by the Clinical Laboratory
Standard Institute.
Results: Mean age of patients with diagnosed UTIs was 86±8 years
(median 86 years): 71.5% were females and 28.5% males. Of 472
samples 328 resulted positive. Polymicrobial infection was diagnosed
in 20.1% of samples. A total of 392 microorganisms were isolated:
Escherichia coli was the most prevalent (45.1%), followed by Proteus
mirabilis (20.7%), Providencia spp. (9.18%), Klebsiella spp. (6.38%),
and Pseudomonas aeruginosa (4.34%). Enterococci were the most fre-
quently isolated Gram positives (7.14%) while staphylococci accounted
for 2.8% of cases. Almost all Enterobacteriaceae were susceptible to
nitrofurantoin (97.6%), carbapenems (97.2%) and amikacin (93.3%).
Limited activity was observed for ﬂuoroquinolones (41.3%), tetracycline
(34.5%) and ampicillin (16.5%). ESBL were detected in 42.1% of
isolates. The most active antibiotics against P. aeruginosa were colistin
(100% susceptibility), amikacin and piperacillin/tazobactam (83.3%).
Fluoroquinolones resulted active against 66.7% of P. aeruginosa. All
Gram positives were susceptible to glycopeptides and linezolid, 90%
of them were susceptible to nitrofurantoin, while only 35% of isolates
was susceptible to levoﬂoxacin. b-lactamases production and methicillin
resistance occurred in 60% and 41.7% of staphylococci, respectively.
Conclusion: E. coli remains the major responsible of UTIs in older
people, although at a lesser extent than in younger population.
Polymicrobial infections were less frequent than reported in similar
studies (about 30%). Antimicrobial resistance was quite spread, thus
reducing therapeutic options. A careful use of antibiotics is advisable to
limit further development of resistance.
P1399 The inﬂuence of menopause on the species and distribution
of causative bacteria isolated from patients with acute
uncomplicated cystitis and on the sensitivity to antibacterial
agents
T. Matsumoto*, R. Hamasuna, K. Ishikawa, S. Takahashi, M. Yasuda,
H. Hayami, K. Tanaka, H. Kiyota, T. Muratani, K. Monden,
S. Arakawa, S. Yamamoto (Fukuoka, Toyoake, Sapporo, Gifu,
Kagoshima, Kobe, Jikei, Kyurin, Okayama, Hyogo, JP)
Objectives: The inﬂuence of menopause on the species and distribution
of causative bacteria isolated from patients with acute uncomplicated
cystitis and on the sensitivity to antibacterial agents were studied. Risk
factors for the detection of quinolone-resistant Escherichia coli were also
investigated, because its frequency has increased and it is now a clinical
problem in Japan.
Methods: The subjects were patients with acute uncomplicated cystitis
who presented with urinary tract symptoms from 294 institutions in
Japan between January and December 2008. At admission, patient
characteristics (age, frequency of cystitis, history of antibacterial
medication, etc.) were investigated and bacterial cultures were performed
using urine samples by the dip slide method. Also, the MIC values
of levoﬂoxacin (LVFX), sitaﬂoxacin (STFX), ciproﬂoxacin (CPFX),
tosuﬂoxacin (TFLX), cefcapenepivoxil (CFPN) and cefdinir (CFDN)
were measured. The sensitibity to each antibacterial agents was
calculated using the breakpoints speciﬁed by CLSI.
Results: 990 patients with acute uncomplicated cystitis were entered
in this study. They included 489 premenopausal patients (mean age: 32
years) and 501 postmenopausal patients (mean age: 69 years). The major
causative bacteria were E. coli, Enterococcus faecalis, and Streptococcus
agalactiae, and the detection rates in premenopausal patients were
65.0%, 12.0% and 5.5%, respectively, while the detection rates in
postmenopausal patients were 61.5%; 13.7% and 4.0%, respectively.
Species and the distribution were the same regardless of the presence of
menopause. MIC50, MIC90 and sensitivity to six antibacterial agents are
shown in Table 1. Sensitivities to quinolones were signiﬁcantly decreased
in postmenopausal patients. As risk factors for detecting quinolone-
resisitant E. coli (MIC of LVFX 4mg/mL), signiﬁcant differences were
observed in patients with more than two episodes of cystitis within a
year in whom quinolones were ineffective against cystitis, and who had
a history of quinolones administration within 1 month.
Conclusions: Although species and distribution of causative bacteria of
acute uncomplicated cystitis were the same regardless of the presence
of menopause, sensitivities to quinolones against E. coli detected in
postmenopausal patients were signiﬁcantly decreased. The major factors
Urinary tract infections S393
were a history of quinolone administration and morbidity of cystitis
rather than menopause.
P1400 Antimicrobial resistance of Escherichia coli isolates
collected from eight urology services in the EU region
Meuse-Rhine, 2009–2010
C. van der Donk*, T. Trienekens, E. De Brauwer, S. Nys, I. Thoelen,
W. Kalka-Moll, E. Stobberingh (Maastricht, Venlo, Heerlen, NL;
Hasselt, Tongeren, BE; Mo¨nchengladbach, DE)
Objectives: In this study the regional differences in antibiotic resistance
of Escherichia coli isolated from eight urology services in the euregion
Meuse-Rhine were assessed. This region covers parts of three countries
i.e. Limburg province in Belgium and the Netherlands, and Aachen
region in Germany. Differences in resistance pose a risk to cross-border
patient mobility and safety. Therefore, a current overview of resistance
is needed, which may enable adaptation of treatment protocols.
Methods: E. coli isolates were collected from urology services in
hospitals in the euregion; two in Belgium and three in both, Germany and
the Netherlands. Quantitative susceptibility testing was performed with
the micro-broth dilution method. Susceptibility breakpoints were deﬁned
by the European Committee on Antimicrobial Susceptibility Testing.
Putative extended b-lactamase (ESBL) producing isolates (minimal
inhibitory concentration for ceftazidime or cefotaxime >1mg/L) were
tested with a combination disk diffusion test to conﬁrm ESBL
production. Multidrug resistance was deﬁned as resistance to three or
more classes of antibiotics.
Results: A total of 360 isolates were collected: 65, 119 and 176 from the
Belgian, German and Dutch urology services, respectively. Resistance
to trimethoprim-sulfamethoxazole, amoxicillin-clavulanate, cefuroxime,
ceftazidime and norﬂoxacin are shown in Figure 1. Resistance to
piperacillin-tazobactam varied from 1% in Germany to 3% in the
Netherlands and 6% in Belgium (p = 0.03). In contrast with resistance
to ceftazidime, the prevalence of ESBLs was highest in Germany
(8%) compared with 2% in the Netherlands (p = 0.01) and 5% in
Belgium. Resistance to carbapenems was not detected. Multidrug-
resistance ranged from 11% in the Netherlands to 17% in Germany
and 23% in Belgium (p = 0.02).
Conclusions: In the euregion Meuse-Rhine, there are regional differ-
ences in resistance for E. coli. Resistance was highest for most antibiotics
in the Belgian part of the euregion. This may be caused by higher use
of antibiotics in Belgium, which would be in line with the generally
accepted believe, that high use is a risk factor for the emergence of
resistance. On the other hand, the prevalence of ESBLs was highest in
the German part. Carbapenemases were not demonstrated.
Figure 1: Antimicrobial resistance. *signiﬁcant difference. SXT = trimethoprim-
sulfamethoxazole, AMC = amoxicillin-clavulanate, CXM = cefuroxime, CAZ =
ceftazidime, NOR = norﬂoxacin.
P1401 How do we manage pre-operative quantiﬁed bacteriuria by
antimicrobial administration?
J. Hashimoto*, S. Takahashi, T. Uehara, Y. Kurimura, T. Tsukamoto
(Sapporo, JP)
Objective: Bacteriuria is common in patients with complicated urinary
tract condition. If such patients undergo operation without any
preoperative antimicrobial chemotherapy, postsurgical infection can
occur due to dissemination of bacteria. We retrospectively examined the
association between preoperative bacteriuria and postsurgical infection
in patients with urological surgery.
Methods: Medical charts were reviewed from April 2007 to December
2009, and 413 patients who underwent urological clean-contaminated
surgery and were followed for at least one month were enrolled in
this study. The protocol for surgical antimicrobial prophylaxis in our
department is follows: a single antimicrobial agent is administered
just before the start of transurethral surgery, and from just before
surgery up to 48 hours after open surgery. The decision for preoperative
antimicrobial administration for patients with bacteriuria depends on the
results of culture and antimicrobial sensitivity tests.
Results: Of 413 patients, transurethral surgery was performed in
211 and open and laparoscopic surgeries in 204. Thirty-eight of the
413 patients developed infections within one month after surgery.
There was no signiﬁcant difference in the frequency of postoperative
infectious disease between patients with preoperative bacteriuria of
104 colony-forming units per milliliter (CFU/ml) and those without
preoperative bacteriuria (p = 0.924). In the patients with preoperative
bacteriuria of 103 CFU/ml, there was no signiﬁcant difference in
the frequency of postsurgical infection whether or not there was
preoperative antimicrobial chemotherapy (p = 0.563). On multivariate
analysis, preoperative antimicrobial administration and the existence
of preoperative pyuria were not associated with the development of
postsurgical infection in the patients with 103 CFU/ml (p = 0.958).
Conclusions: In this study, the frequency of postoperative infectious
disease was almost the same in the antimicrobial-treated patients with
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signiﬁcant preoperative bacteriuria (104 CFU/ml) and those without
preoperative bacteriuria. If the patients with signiﬁcant preoperative
bacteriuria undergo a clean-contaminated operation, preoperative an-
timicrobial chemotherapy contributes to control post-surgical infection.
When the patients with preoperative urine 103 CFU/ml undergo
operation, preoperative antimicrobial chemotherapy is not necessary for
prevention of postsurgical infection.
P1402 A randomised clinical trial to evaluate the preventive effect
of cranberry juice (UR65) for patients with recurrent
urinary tract infection
S. Takahashi*, R. Hamasuna, M. Yasuda, S. Arakawa, K. Tanaka,
K. Ishikawa, H. Kiyota, H. Hayami, T. Matsumoto on behalf of the
Japanese UTI Research Group
Objectives: The purpose of this trial was to examine the relapse rate
of urinary tract infection (UTI) in the patients who suffered recurrent
cystitis when cranberry juice (UR65) or placebo beverage was taken
continuously for maximum 24 weeks.
Methods: The study design was a randomized, placebo-controlled,
double-blind clinical trial. Outpatients aged 20 to 79 year-old with
aggravation of acute uncomplicated cystitis or chronic complicated
cystitis (including self-catheterization) who have a past history of
recurrent cystitis and been conﬁrmed the healing by antimicrobial
chemotherapy were included in this study. We deﬁned the group that
women aged 25 to 29 or 55 to 69 year-old who suffered relapses and
healed after medical treatment before the registration of the study as the
ideal target population (ITP). The participants were randomly assigned
to cranberry juice (UR65) group (CBJ group) or placebo beverage group
(PB group). They took in one bottle of 125ml cranberry juice (UR65)
in CBJ group and 125ml placebo beverage adjusted color and taste
to cranberry juice in PB group. They commonly drink it once daily
before sleep for maximum 24weeks. The relapse of cystitis was the
primary analysis target for this study. Therefore, the study in each
participant discontinued when the ﬁndings of cystitis were obtained
microbiologically and antimicrobial agents were administered. This trial
was approved by IRB and written informed consent was obtained from
the participants.
Results: The duration of this study was from October 2007 to December
2009. Two hundred and thirty seven participants were registered in
this trial and 227 could be analyzed as intention-to-treat ﬁnally. The
overall ITT analysis on relapse of cystitis was not signiﬁcantly difference
between those 2 groups (p = 0.430, Log-Rank test). In the subset analysis
of ITP group with continuous intake of more than 8weeks, there was
signiﬁcant difference between those 2 groups (p = 0.030, Log-Rank test)
and the relapse rate of cystitis in CBJ group was lower than that in PB
group.
Conclusion: The results of this study clearly showed that cranberry juice
could prevent recurrent cystitis signiﬁcantly in ITP if intake of cranberry
juice could be tolerable more than 8weeks. The prevention of recurrent
cystitis without using additional antimicrobial agents contributes to
not only the patients distressed by recurrent cystitis but also avoiding
unnecessary antimicrobial chemotherapy.
P1403 Clinical and microbiological survey of indwelling catheter
M. Tinelli*, A. Piatti, L. Pagani, F. Luzzaro, R. D’Angelo, L. Trezzi,
M. Di Stefano, R. Caprioli, M. Gramegna, L. Zerbi (Sant’Angelo
Lodigiano, Milan, Pavia, Lecco, Bergamo, IT)
Objectives: This report describes a clinical and microbiological survey
of indwelling catheter urinary tract infections (CAUTI) occurred in
Rehabilitations Units (RUs) of the Lombardy Region during the ﬁrst
three months of the years 2009 and 2010.
Methods: This retrospective observational cohort study was set up
basing on previous observations, performed during the years 2005
and 2006, about the risk factors for infection in these RUs where at
least one infection occurred during 14.9% of admissions, with 65% of
infections being urinary, 8.0% respiratory, and 5% skin and soft tissue.
From January 2010 a new protocol to manage patients with indwelling
catheter have been applied in all the 28 RUs participating to the study:
294 patients hospitalized in 28/131 RUs of the region were enrolled
between the ﬁrst three months of the years 2009 and 2010. CAUTI was
ascertained in 114 (control group) and 180 patients (intervention group)
in the years 2009 and 2010 respectively by patient’s chart review and
conﬁrmed by microbiological data recorded in the laboratory data base.
A multivariate regression analysis was performed.
Results: CAUTI rate was not signiﬁcantly different between control
group (2009) compared to intervention group (2010) for considered
variables. Antibiotic sensitivity tests for determining resistance of
bacteria was performed with an automatic system (Vitek 2 or Phoenix).
Enterobacteriaceae resulted the most frequent isolated microrganisms.
The distribution of isolated microrganisms showed respectively E. coli:
48.52%, K. pneumoniae: 8.88%, P. mirabilis: 10.66% (31% during
2009 and 38% during 2010 were identiﬁed as ESBL positive strains),
P. aeruginosa 7,10%, E. faecalis 9,47%. Ciproﬂoxacin showed an
increased pattern of resistance from 30% to 35% in 2009 and 2010
respectively.
Conclusion: The frequency of CAUTI was not modiﬁed after the usage
in all RUs participating to the survey of new protocol to manage patients
with indwelling catheter. Enterobacteriaceae uropathogens are prevalent
in these settings. The progressive increase of ESBL and quinolone-
resistant strains should lead health authorities to re-evaluate the antibiotic
stewardship in order to review the ﬁrst and second line therapies for the
treatment of UTI adapting to the local epidemiology. Further efforts in
teaching the caregiver and patient about the catheter management can
lead to reduce CAUTI and better acceptance of the device.
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P1404 Comparison of three treponemal assays for anti-Treponema
pallidum antibodies detection
N. Calvo Sanchez, M.L. Ferna´ndez Rueda, M.N. Gutie´rrez Zuﬁaurre,
A.M. Bla´zquez de Castro, S. Mun˜oz Criado, J.L. Mun˜oz Bellido*
(Salamanca, ES)
Introduction: The diagnosis for T. pallidum infections is based
on treponemal and non-treponemal serologic tests. Nontreponemal
tests are inexpensive and easy to perform, and allow evaluating
treatment response. False-positive results can be found in some
situations (pregancy, autoimmune diseases), thus treponemal-based
conﬁrmation is required. Recently, newer treponemal-based EIAs and
chemoluminiscence immunoassays (CIA) have been released. These tests
can be automated, and have been reported to be highly sensitive and
speciﬁc. Nevertheless, the interpretation of low positive CIA results,
with non-treponemal test negative, may be doubtful. The aim of this
study was to compare the results obtained with one of these CIAs with
FTA-ABS and a line immunoassay (LIA). RPR was also determined for
all the samples studied.
Methods: We studied serum samples from 36 patients positive in
CIA (Syphilis TP, Abbott, Diagnostic Division) (CIA). These serum
samples were therefore studied by RPR (bioMerie´ux, France), by a
classical treponemal test (FTA abs) (Trepo-Spot IF, Biomerieux), and
a LIA (INNO-LIATM Syphilis Score, Innogenetics, Belgium) (LIA).
Both the CIA and the LIA detect antibodies against the same three
immunodominant bacterial proteins (TpN15, TpN17, TpN47). The LIA
also detect antibodies against one synthetic peptide (TmpA) derived
from transmembrane protein A. CIA and LIA positivity was considered
according manufacturers instructions. FTA-Abs positivity was scored as
+, ++ or +++ according ﬂuorescence intensity.
Results: The 36 samples positive in the CIA had been obtained from
19 men, 16 women (10 of them pregnant), and one sample was fetal
blood from a fetus whose mother had been positive. Results obtained
appear in Table 1. Among the 10 samples belonging to pregnant women
and positive in CIA, six were positive in LIA and FTA-Abs, 2 were
indeterminate in LIA and negative in FTA-Abs and 2 were negative
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both in LIA and FTA. Eight samples were positive in RPR. Seven were
positive in the three treponemal tests. One sample, positive in RPR only
in undiluted serum, was positive in CIA, but negative in LIA and FTA-
Abs.
Conclusions: CIA are excellent alternative to non-treponemal assays as
screening tests, but are less speciﬁc than other treponemal tests. FTA-
Abs or LIA tests may be recommendable for CIA positive conﬁrmation,
especially in some patients groups, such as pregnant women, in which
CIA false positive results seem to be more frequent.
P1405 Bioplex 2200, a new treponemic assay to diagnose syphilis
J. Acosta*, L. Barrado, E. Viedma, A. Fuertes (Madrid, ES)
Objectives: The diagnosis algorithm of syphilis has been changed
recently due to the increasing number of samples. The samples are
ﬁrst tested by a speciﬁc treponemal assay and the positive samples
are tested further by RPR or V.D.R.L. test, to establish the stage of
disease. Recently a new multiplex ﬂow immunoassay (MFI) has been
evaluated for the diagnosis of syphilis, including IgG and IgM. We assess
the performance of BioPlex 2200 Syphilis multiplex assay (Bio-Rad
Laboratories, Hercules, California, EEUU) compared with a treponemic
assay.
Methods: We recovered 153 serum samples belonged to 105 patients,
112 positive by a ELISA treponemic assay test (Etimak Treponemic
assay − DiaSorin, Italy) and 41 negative samples as control. All
the samples had non-treponemic assay (RPR) performed. During the
study all the samples were tested by the BioPlex 2200 Syphilis IgM
and IgG assays. Kits uses different population of microspheres coated
with recombinant proteins from T. pallidum Nichols strain (ﬂagellar
polypeptides TpN15, TpN17 and TpN47 for IgG and TpN17 and TpN47
for IgM).
Results: We grouped the samples according to the previous results in
3 groups: Group 1 − 41 samples with negative treponemic and RPR
assay; Group 2 − 105 samples whit positive treponemic and RPR assay
and Group 3 − 7 samples with positive treponemic assay and negative
RPR assay (with uncertain interpretation).
For the IgG assay the BioPlex MFI show a sensibility (S) and speciﬁcity
(SP) of 100%. We could not determined the S and SP for IgM because
the lack of ELISA comparative assay and lack of clinical data (Table 1).
Conclusion: BioPlex IgG MFI is a rapid and sensitive and speciﬁc
assay to diagnosis of Syphilis compared with a reference technique. It
provides additional information through the capability to analyze speciﬁc
polypeptides that could be a tool to evaluate evolution of the disease.
TpN 17 is responsible of the speciﬁcity of IgG assay and TpN 47 of the
IgM assay.
P1406 Evaluation of the Liaison® Treponema screen assay
compared to ELISA and CLIA assays
D. Itzhaky*, H. Poran, O. Rozenberg, M. Barak, G. Blumstein,
O. Cooper (Kfar-Saba, Nesher, Haifa, Abu Kabir, IL)
Objectives: Syphilis is usually transmitted by sexual contact and rarely
by congenital transmission or blood transfusion, and is caused by
systemic infection with the bacterium Treponema pallidum. Syphilis can
be diagnosed by different serological laboratory tests, which are also
useful in establishing the disease stage, in conjunction with other clinical
tests. Serological diagnosis is generally established using a standard
non-treponemal antibody screening test, the Venereal Disease Research
Laboratory test (VDRL) or the Rapid Plasma Reagin test (RPR) are most
commonly used, in combination with a speciﬁc treponemal antibody
test such as the Treponema pallidum haemagglutination test (TPHA) for
conﬁrmation. The aim of the study was to evaluate the performance of
the LIAISON® Treponema screen assay on an automated random access
platform.
Methods: 249 sera samples previously collected from ﬁve hospital and
community labs were used. Three assays were compared for treponema
total antibody detection. ELISA (Trinity, biotech) was tested on the ETI-
Max 3000 analyzer. CLIA (chemiluminescent immunoassay) was tested
on the Architect (Abbott) and on the LIAISON® (DiaSorin). Positive
and discrepant results were conﬁrmed at the National Reference Center
for Syphilis, Ministry of Health Public Health Laboratory. Conﬁrmation
was triple checked with TPHA (Axis-Shield), ﬂuorescence treponemal
antibody absorption test (FTA-Abs, Biome´rieux) and VDRL test (BBL).
Results: 150 samples were positive with all three assays and 94 were
consensus negative for treponema antibodies. Two discrepant samples
were positive by the Reference Center TPHA only, rendering a false
positive result for 2 assays. One discrepant sample was negative by all
reference methods, rendering a false positive result for 1 assay. Two more
samples had discrepant results by all comparison and reference methods.
Total agreement between the 2 CLIA was 99.2%, positive agreement
99.3% and negative agreement 98.9%. Total agreement between the
LIAISON® CLIA and ELISA was 99.6%, positive agreement 99.4%
and negative agreement 100%.
Conclusion: The DiaSorin Liaison® Treponema screen assay exhibited
very good performance and was found to be suitable for random access,
relatively rapid detection of antibodies to Treponema pallidum.
P1407 Evaluation of two automated chemiluminescence
immunoassays, the Liaison Treponema screen and the
Architect Syphilis TP, as screening tests for syphilis
N. Wellinghausen* (Ravensburg, DE)
Objectives: The aim of this study was to evaluate two automated
chemiluminescence immunoassays (CLIA), the LIAISON Treponema
Screen (LIA) and the ARCHITECT Syphilis TP (ARCH), as a screening
test for the diagnosis of syphilis.
Methods: In a prospective study 577 unselected sera submitted to
our laboratory for syphilis screening, including 318 samples from
pregnant women, were investigated by LIA (n = 577) and ARCH
(n = 571) in comparison to a Treponema pallidum particle agglutination
(TPPA) screen algorithm. A serum was deﬁned as true antitreponemal
antibody positive by a TPPA titer of 1:80 conﬁrmed by ﬂuorescent
treponemal antibody absorption test (FTA-ABS), and/or recombinant
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immunoglobulin G (IgG) immunoblot. In addition, 42 stored sera
from 32 patients with clinically and serologically characterized syphilis
infection were investigated.
Results: Out of the 577 serum samples, 18 samples were true
antitreponemal antibody positive. LIA was positive in 18/18 and ARCH
in 17/17 samples (sensitivity 100%). Out of the TPPA-negative sera
(n = 557) and TPPA-positive sera which were not conﬁrmed by other
treponemal tests (n = 2), LIA was negative in 558/559 (speciﬁcity 99.8%)
and ARCH in 552/554 (speciﬁcity 99.6%). LIA and ARCH both detected
antitreponemal antibodies in a 7 month-old infant born from a mother
with syphilis infection in pregnancy. In addition, LIA and ARCH were
positive in all investigated sera from known syphilis patients.
Conclusion: Both automated CLIA demonstrated excellent diagnostic
sensitivity and speciﬁcity when evaluated as a screening test for syphilis
under routine conditions of a diagnostic laboratory and may, thus,
independently be used as an alternative to manual TPPA screen.
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P1408 IgG avidity maturation with Liaison® IgG avidity II assay
for the diagnosis of toxoplasmosis in pregnant women
F. Peyron*, J. Chevallier, C. Goy, C. Garrigou, M. Wallon (Lyon, FR)
Objectives: The aim of the study was to evaluate the performance
of LIAISON® Toxo IgG AvidityII kit immunoglobulin G avidity for
estimating the date of toxoplasmic infection in pregnancy.
Method: LIAISON® Toxo IgG Avidity II is a chemiluminescent
immunoassay for the detection of antigen-binding avidity of IgG
antibodies to T. gondii antigens.
Subjects were divided in 3 groups according to their clinical settings.
Group 1: Twenty pregnant women with acute infection (74 samples)
treated and followed in our clinic.
Group 2: Fifty four pregnant women with infection more than 4 months
determined either on the basis of kinetic of antibodies or history of
positive anteriority.
Group 3: Sixty ﬁve pregnant women with a history of positive serology
more than 1 year before sampling.
Results: Group 1: Eighteen samples were excluded because of negative
or low IgG titers. Among the 56 tested sera, high avidity was observed
only in 2 cases, 32 weeks after estimated date of infection. Five and
2 samples withdrawn more than 32 weeks after infections displayed
respectively low and intermediate index.
Group 2: Thirty nine sera (66%) displayed high avidity. Eight and 7
having respectively intermediate or low avidity index.
Group3: Avidity was performed on 55 sera. Two had an intermediate
index despite a positive serum respectively 3 and 8 years before
sampling.
Conclusion: In treated pregnant women avidity maturation is often
delayed. Low avidity index can persist at least 32 weeks post infection. In
untreated women, low avidity can be observed event more 4 months after
infection and more than 1 year after infection in some rare cases. Only
high avidity index can rule out a recent toxoplasmic infection. Although
useful for estimating the date of maternal infection and estimating the
risk of foetal contamination, avidity interpretation is limited by slow
maturation even in non treated pregnant women. Additionally, even in
chronic infection, low IgG titres should be interpreted carefully.
P1409 Performance of two rapid tests for the diagnosis of malaria
imported in travellers: inﬂuence of anti-malarial prophylaxis
N. Iglesias*, A. Palmeiro, P. Trevisi, A. Olaiz, C. Toro, M. Subirats,
M. Baquero (Madrid, ES)
Objectives: Rapid tests are a rapid and accuracy tool for the diagnosis
of malaria. However, factors as low parasitemia presented in subject who
had followed anti-malaria prophylaxis may compromise its performance.
Our study aims to evaluate the effectiveness of two rapid diagnostic tests
(SD BIOLINE Malaria Antigen P.f./P.v. and BinaxNOW® Malaria) in this
clinical setting.
Methods: From July to November 2010, blood samples from patients
with clinical suspicion of malaria remitted from the emergency
department of our Hospital were studied. Samples were tested by thin
and thick smear and in-house real-time PCR. In addition, SD BIOLINE
Malaria Antigen P.f./P.v., a rapid test for the detection of a speciﬁc
protein to Plasmodium falciparum and a speciﬁc protein to P. vivax;
and BinaxNOW® Malaria, a rapid test for the detection of a speciﬁc
protein to P. falciparum and a pan-speciﬁc protein were performed. Real-
time PCR was considered as the gold standard. Data from anti-malarial
prophylaxis was recorded.
Results: A total of 52 blood samples corresponding to 52 patients were
included. Thirty-three patients were positive for P. falciparum. Seventeen
of these subjects had taken anti-malarial prophylaxis and the remaining
had not followed prophylaxis. The overall sensitivity and speciﬁcity of
both rapid tests were 100% to diagnose P. falciparum. In contrast, overall
sensitivity of blood ﬁlms was 60.6% and speciﬁcity of 94.7%. According
to prophylaxis, sensitivity of blood ﬁlms was 35.3% in subjects who
underwent prophylaxis and 87.5% in subjects with no anti-malarial
prophylaxis.
Conclusion: The two rapid tests showed a high sensitivity and speciﬁcity
for diagnosis of malaria. In contrast, accuracy of smear blood ﬁlms
may be compromised in travellers who underwent prophylaxis due to
low parasitemia and distorted parasites. Because PCR is not a simple
procedure, rapid test can be useful in diagnosis malaria, notably in
travellers with no underwent correct prophylaxis.
P1410 Rapid diagnosing test in malaria screening
P. Davoodian*, A. Daryanavard, R. Safari, T. Eqbal Eftekhaari,
M. Khalilzadeh, S. Fekri, M. Mehranzadeh (Bandar-Abbas, IR)
Background: Diagnosis of malaria presents a clinical challenge in
most tropical countries. The gold standard for diagnosing malaria
infections in clinical practice and research is microscopic method,
however, microscope diagnosis is labour intensive, requires signiﬁcant
skills and time, which causes therapeutic delays. Because of delayed
diagnosis with microscope and necessity to start treatment as soon as
possible, over diagnosis of malaria contributes to improper treatment,
wastage of drugs and resistance to the few available drugs so accurate
microscopic diagnosis is compulsory. Several rapid diagnostic tests
(RDTs) are available, which are fast, reliable and simple to use and can
detect Plasmodium falciparum and non-falciparum infections or both.
Sensitivity and speciﬁcity of RDTs have been reported to be variable in
several studies.
Methods: A cross-sectional study was designed in Bandar abbas and
Jask in Hormozgan province of Iran where malaria is highly prevalent.
Blood samples were taken from patients suspected of malaria from Jun
2010 till Dec 2010. RDt was performed with the First Response® Combo
Malaria Ag (pLDH/HRP2) card test and after performing RDT, blood
ﬁlms were sent to Malaria reference lab for microscopic diagnosis.
Results: In this 6 months a total of 421 cases were collected. Rdt was
positive in (82)19.5%, blood ﬁlms were positive in (84)20% of cases.
64.4% of cases were from Bandar abbas and the rest were from jask.
16.66% of positive cases were diagnosed as P. falciparum and 83.33%
were diagnosed as P. vivax. Positive predictive value of RDT was 100%
and negative predictive value was 99.4%. Sensitivity of RDT was 94.20
and speciﬁcity was 100.
Conclusion: It is concluded that RDT is easy to use, reliable and simple
to interpret, and is more suited for situations where health services are
deﬁcient or absent. This test can be used as epidemiological tool for
rapid screening of malaria.
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P1411 Detection of malaria infection in blood transfusion: a
comparative study among real-time PCR, rapid diagnostic
test and microscopy
G.R. Hassanpour*, H. Keshavarz, M. Mohebali, H. Zeraati, E. Azizi,
A. Raiisi (Tehran, IR)
The transmission of malaria by blood transfusion was one of the ﬁrst
transfusion-transmitted infection recorded in the world. Transfusion-
transmitted malaria may lead to serious problems because infection with
Plasmodium falciparum may cause rapidly fatal death. This study aimed
to compare real-time PCR with Rapid Diagnostic Test (RDT) and light
microscopy for the detection of Plasmodium spp in blood transfusion,
both in endemic and non-endemic areas of malaria disease in Iran.
Two sets of 50 blood samples were randomly collected. One set was
taken from blood samples donated in blood bank of Bandar Abbas, a
city located ina malarious endemic area, and the other set from Tehran,
a non-endemic one. Light microscopic examination on both thin and
thick smears, RDTs, and real-time PCR were performed on the blood
samples and the results were compared. Thin and thick light microscopic
examinations of all samples as well as RDT results were negative for
Plasmodium spp. Two blood samples from endemic area were positive
only with real-time PCR. It seems that real-time PCR as a highly
sensitive method can be helpful for the conﬁrmation of malaria infection
in different units of blood transfusion organization especially in malaria
endemic areas where the majority of donors may be potentially infected
with malaria parasites.
P1412 Feconomics®: a simple, novel and fast technique for stool
concentration in the parasitology laboratory
O¨. Kurt*, I. Akyar, S. Go¨rgu¨n, T. Kocago¨z, A. O¨zbilgin (Manisa,
Istanbul, TR)
Objectives: We have developed a simple technique and turned it into
a ready-to-use kit named as “Feconomics®*” for fecal concentration.
Feconomics® eliminates the need for centrifugation and ﬂoation by
using absorbent beads that help homogenization and concentration of
the sample. These beads have pores smaller than parasite eggs and
trophozoites; while the liquid is absorbed, the parasites are concentrated
in a smaller volume. For application, 1−2cm3 of stool samples are put
into the sample cup of Feconomics® that contain sodium acetate, acetic
acid and formaldehyde (SAF) solution. The absorbent beads are then
poured into the cup and shaken with the sample to homogenize. The
procedure takes ﬁve minutes including staining the sample with iodine.
Methods: To assess the efﬁcacy of Feconomics® in the diagnosis of
intestinal parasites, a comparative, double-blind study was conducted in
the Parasitology Laboratory of Celal Bayar University Medical Faculty
in Manisa, Turkey. Stool samples of individuals (Group I, n = 251)
submitted for routine ova and parasite examination were concentrated
both with routine formalin ethyl acetate concentration technique (FEAC)
and Feconomics®. Intestinal parasites obtained from animal models in
the laboratory (such as Trichostrongylus sp., Hymenolepis nana) as well
as pre-diagnosed parasite-positive samples (Group II, n = 11) were also
used. The iodine-stained samples were read by different microscopists
and some positive samples were stained with Gomori’s trichrome and
Kinyoun’s acid fast.
Results: In Group I, 103 of 251 samples were positive for intestinal
parasites; seventy six (74%) and 97 (94%) samples were positive with
FEAC and Feconomics®, respectively. While 6 FEAC-positive samples
were negative with Feconomics®, 27 Feconomics®-positive samples were
negative with FEAC. In Group II, the microscopic examination revealed
the same results for both techniques. There was no difference between
the techniques for the morphological integrity and visual appearances of
the parasites. Indeed, trophozoites of Giardia lamblia and Dientamoeba
fragilis were only identiﬁed with Feconomics® after staining with
Gomori’s trichrome.
Conclusion: As more parasites were identiﬁed in Group I and
morphological integrity of the parasites were well-protected with
Feconomics®, it may be suggested as a fast and effective fecal
concentration method for routine laboratories.
*Feconomics is a patent pending product: Patent application number:
2010/07549
P1413 Reliability of immunodiagnostic tests for diagnosis of
alveolar echinococcosis
Y.A. O¨ner*, G. Adas, H. Uysal, I. O¨zden, S. Bayirlioglu (Istanbul, TR)
Objectives: Diagnosis of alveolar echinococcosis (AE) is primarily
based on imaging techniques in addition to clinical criteria. These
imaging techniques are useful and reasonably accurate but have
sometimes limitations in the small size of visualized lesions or atypical
images. Moreover, these techniques are too expensive and inaccessible
in most areas where AE is endemic. Therefore the development of
immunodiagnostic tests that detect species-speciﬁc antibodies or antigens
in patient specimens is urgently required because of its simplicity and
reliance. Our aim is to investigate the accuracy of diagnosis of AE using
different serologic tests, and to use in the follow up of patients who have
RO resection.
Method: We investigated 39 patients who diagnosed AE. The diagnosis
of AE was based on history, imaging techniques and conﬁrmed by
histopathological examination. Patients were divided into three groups.
Group 1 (n = 16) inoperable patients,
Group 2 (n = 11) performed R0 resection,
Group3 (n = 12) performed R1 resection
From all of the patients venous blood samples were taken for serologic
diagnosis of AE. The serum samples used for assessing diagnostic
sensitivities of ELISA and western blot methods. We used two different
commercially tests for the serodiagnosis of AE in humans (Em2plus
Elisa; Bordier Afﬁnity Products, Switzerland) and echinococcus western
blot IgG (LDBIO Diagnostics, France). We investigated three different
markers including Em2plus, Em16−18 and Em12.
Results: We found that sensitivity for serologic diagnosis of AE
was 88% (Em2plus), 94% (Em16−18), and 69% (Em12) in group 1,
55% (Em2plus), 27% (Em16−18) and 18% (Em12) in group 2, 75%
(Em2plus), 100% (Em16−18), 75% (Em12) in group 3 respectively. The
serologic test of Em16−18 was found most sensitive test in group 1 and
group 3.
Conclusion: In conclusion, the serologic diagnostic tests are easily
performed, and cheap diagnostic tools are use in the diagnosis of the
AE. In our study 16−18 bands shown using western blot method, are
determined to be the most reliable test in the diagnosis of AE for groups
1 and 3. According to our results in group 2, these tests can be used as
a marker in the following criteria.
P1414 Comparison of two methods for detection and quantiﬁcation
of leptospires in tissue samples: immunoﬂuorescence-based
leptospiral detection in imprint samples versus real-time
PCR
A.D. Chagas Jr*, C.L. da Silva, D. Athanazio, C.S. Santos, C.D. Matos
Silva, M.G. Reis, F.W. McBride, A.J. McBride (Salvador, BR)
Objectives: To compare two methods for detection and quantiﬁcation of
leptospires in tissue samples.
Methods:We compared immunoﬂuorescence-based leptospiral detection
in imprint samples (ILDIS), as previously described by our group, with
the now widely used real time PCR (qPCR) targeting the LipL32 gene,
which is highly conserved among pathogenic leptospires. The units
are expressed as leptospires counted in ten high power ﬁelds (400x)
for ILDIS and gene copies per gram for qPCR. Eleven hamsters and
ﬁfteen mice (strain A) were experimentally infected by an intraperitoneal
inoculum of 500, 106 or 108 leptospires. The strain used in all assays
was Leptospira interrogans serogroup Icterohaemorrhagiae Cop strain.
Hamsters were necropsied eight days after infection (mirroring acute
phase disease) and mice were necropsied at day 28 (mirroring the chronic
carrier state). Kidneys samples were obtained for the comparison of the
two methods.
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Results: All hamsters and mice gave positive ILDIS and qPCR results.
For hamsters, the mean values of quantiﬁcation (standard deviation in
parenthesis) were 152 (92) leptospires by ILDIS and 21,699 (15,867)
copies per gram by qPCR (spearman’s correlation, rs = 0.65, p< 0.02).
For mice, the mean values of quantiﬁcation were 228 (253) leptospires
by ILDIS and 67,123 (167,047) copies per gram by qPCR (rs = 0.54,
p< 0.03).
Conclusions: In both cases of acute and chronic infection, the correlation
between both methods was strong. ILDIS is a method of detection which
is cheaper, easier to put into practice in the laboratory, and that allows the
morphological identiﬁcation of leptospires, thus implying their viability.
ILDIS should be regarded as an option for detection and quantiﬁcation of
leptospires particularly when the use of molecular biology is not feasible.
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P1415 Performance of new ELISA IgG anti-Aspergillus (Platelia
Bio-rad) using recombinant proteins
M. Dautigny*, S. Le Cam, O. Cornet, T.D. Ly (Ivry-sur-Seine, Lyon, FR)
Introduction: Aspergillus can cause several types of disease, which
depends, in large part, on the underlying immune function of the
host. Aspergillus fumigatus is the most commonly isolated. In the
immunocompetent host, the diagnostic of aspergillosis is based on the
presence of speciﬁc anti-Aspergillus antibodies (mostly par ELISA test).
The detection of precipitins is conﬁrmed by immunoelectrophoresis
(IEP) or other immunodiffusion tests (ID).
Objectives: In this study, the performance of the new ELISA
PLATELIA Aspergillus IgG (Bio-Rad, Marnes la Coquete, France),
using recombinant proteins, was compared to that of 2 other ELISA:
Aspergillus fumigatus IgG (IBL, Hamburg, Germany) and Aspergillus
fumigatus IgG (Virion, Wu¨rburg, Germany) and referred to IEP.
Methods: 306 unselected sera and 108 sera with different IE results
were tested with the 3 ELISA tests on ETIMAX (Diasorin).
IEP was performed on all samples using aspergillus fumigatus antigen
(somatic and metabolic) and catalasic activity was measured. The
presence of 3 or more precipitins indicates an evolutive aspergillosis.
Results: The IBL, PLATELIA and VIRION have an overall agreement
of 67%, 94% and 86% respectively versus IEP (equivocal results are
excluded). The sensitivity of the IBL, PLATELIA and VIRION is
respectively 80%, 92,7% and 78%. And the speciﬁcity is 63%, 93,8%
and 88% for IBL, PLATELIA and VIRION respectively. In addition, the
PLATELIA index versus numbers of precipitins (IEP) showed a poor
correlation coefﬁcient <50%.
Conclusion: The ELISA PLATELIA Aspergillus IgG is the ﬁrst test
using recombinant proteins. According to IEP results, it is the most
sensitive (92.7%) and speciﬁc (93.8).
As the ELISA is a semi quantitative essay, it was not possible to establish
a link between the ELISA ratio and the number of precipitins in IEP.
The PLATELIA Aspergillus is an excellent test for detection of
antibodies to aspergillus, but does not take the place of IEP test for
the evaluation of the extension of aspergillosis.
P1416 Evaluation of a new immunochromatographic assay for the
detection of antibodies against Francisella tularensis
A. Cubero-Ribas, T. Pardo, F. Menegotto, S. Gonza´lez-Cabrero,
P. Gutie´rrez, M.A. Bratos-Pe´rez, J.M. Delgado, A. Ordun˜a* (Valladolid,
Santa Fe, ES)
Objectives: To evaluate a new immunochromatographic test for the
qualitative detection of total antibodies against Francisella tularensis
in both serum and plasma samples.
Methods: A new immunochromatographic test (ICA), VIRapid Tu-
laremia, has been designed for the qualitative detection of anti-
Francisella tularensis antibodies in both serum and plasma samples. This
test is based on lipopolysccharide (LPS), obtained from F. tularensis
(NCTC10857 strain) grown in Mu¨eller Hinton liquid medium and
extracted by the hot phenol-water method. LPS was both adsorbed on
the conjugate and test line to generate a lateral ﬂow ICA. A control line
was also included to check the correct performance of the test. Results
were read out after incubation for 15 minutes at room temperature (see
attached ﬁgure). The assay performance was evaluated with 247 human
serum samples; 134 negative (donors from Almeria and Valladolid,
Spain), 102 positive (patients from Valladolid, Spain) and 11 sera from
brucellosis patients (with brucella-agglutination titers above 1/320). The
microagglutination test (MAT) was used as reference method. This assay
was carried out with a suspension of safranin stained F. tularensis in an
U-bottom microtiter plate.
Results: 101 out of 102 sera showed a distinct red test line in the ICA.
132 out of 134 negative sera showed no reactivity on the test line in
the ICA. Calculated sensitivity and speciﬁcity were 99.0% and 98.5%
respectively. None of the 11 brucellosis sera reacted in the test.
Conclusions: The new test has proved to be able to detect anti-
Francisella antibodies in human serum samples with good sensitivity
and speciﬁcity values. Since MAT is the most frequently used technique
for the serological diagnosis of tularemia, this test offers a new diagnostic
tool that brings together good performance characteristics with the
advantages of rapid tests (easy to run, easy to interpret and easy to
store). It suits the demand of a test easy to implement that gives results
in a few minutes for a disease with low prevalence such as tularemia.
P1417 Neuroborreliosis: detection of intrathecally produced
antibodies against Borrelia in cerebrospinal ﬂuid using the
line blot immunoassay Anti-Borrelia Euroline-RN-AT
W. Meyer*, T. Scheper, A. Ott, B. Kuehn, S. Falke, L. Persson Rova,
K. Steinhagen, D. Eichhorst, W. Schlumberger, W. Stoecker (Lu¨beck,
DE; Karlskrona, SE)
Objectives: The line blot immunoassay “Anti-Borrelia EUROLINE-
RN-AT (IgG)” is validated for the determination of Borrelia-speciﬁc
antibodies of class IgG in serum and cerebrospinal ﬂuid (CSF). An
intrathecal antibody production is assumed if the number of speciﬁc
bands in CSF is larger than in serum or at least one speciﬁc band in
CSF shows a 1.5 fold relative intensity compared to the corresponding
band in serum.
Methods: 50 CSF/serum pairs from patients with suspected neu-
roborreliosis and different neurological symptoms were incubated in
a modiﬁed procedure using the “Anti-Borrelia EUROLINE-RN-AT
(IgG)” test system (EUROIMMUN AG). Furthermore total IgG and
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albumin concentration were determined and the “Anti-Borrelia plus CSF
ELISA (IgG)” test system (EUROIMMUN AG) was performed. For
comparability, the IgG concentration in serum was equalized to the 1:4
diluted CSF. In case of an additional IgG synthesis in the CNS, the
limiting quotient CSQ lim IgG, based upon CSQ alb, was calculated
and considered.
The number of bands and the band intensities were automatically
evaluated using a commercial computer programme (EUROLineScan
from EUROIMMUN AG).
Results: 22% (11/50) of the patients with suspected neuroborreliosis
showed indications of Borrelia-speciﬁc intrathecal antibody production.
54.5% (6/11) of them demonstrated more bands in CSF than in serum
and 45.5% (5/11) displayed higher band intensities in CSF than in serum.
There was a 98% agreement between the results of the “Anti-Borrelia
EUROLINE-RN-AT (IgG)” and the CE-labelled “Anti-Borrelia plus CSF
ELISA (IgG)”.
Conclusion: The line blot immunoassay “Anti-Borrelia EUROLINE-
RN-AT (IgG)” is valuable to conﬁrm the presence of intrathecally
produced Borrelia-speciﬁc antibodies in neuroborreliosis. The analysis
of CSF/serum pairs using a line blot immunoassay also allows qualitative
characterisation of intrathecally produced pathogen-speciﬁc antibody
patterns in addition to quantitative determination of relative CSQ values
using ELISA.
P1418 Evaluation of serological tests and clinical features in
patients with culture-positive brucellosis
A. Al Aska*, I. Al Orainey, A. Kambal, M. Gad El Rab, M. Al
Hedaithy, A. Al Anazi, S. Al Sobaie, K. Halim, F. Buba, U. Yusuf,
N. Al Anazi (Riyadh, SA)
Objective:
1. To evaluate the sensitivity and speciﬁcity of different serological test
in patient with culture positive Brucellosis.
2. To evaluate the clinical features encountered in this group of patients.
Methodology: Sera of patients with culture positive brucellosis
were tested for the presence of antibodies by the following tests:
(1) Microplate Agglutination test (in this method the antigens were
prepared by dilution in normal saline solution (0.9%) to give a 1:20
dilution, 1% buffer solution was prepared by adding 1.05ml of normal
saline solution to 5ml (22%) bovine albumin, (2) Standard tube
Agglutination test, (3) 2-Mercaptoethanol Agglutination test, (4) Coombs
test, (5) ELISA test.
Laboratory data and clinical information obtained from theses patients
were ﬁnally analyzed.
Results: The microplate agglutination test was found to be the most
sensitive detecting antibodies in 91.7% of the sera where the titre range
between 1/20−1/20480. The standard tube agglutination test showed
positivity in 87.8% of samples with a titre range of 1/20−1/10240.
The 2-Mercaptoethanol agglutination test detected antibodies in 53.2%
samples with a titre range of 1/20−1/2580. The Coombs Anti-human
Globulin test was positive in 62.5% of the sera at a maximum titer
of 1/160. The ELISA test was signiﬁcantly positive for IgG and IgM
antibody in 43.6% and 89.5% of sera respectively. The most encountered
symptoms were fever, sweating, weight loss, abdominal pain, joint pains
and body aches. The most important physical signs were hepatomegaly
in 42.8% splenomegaly in 32% and iliosacral tenderness in 27% of
patients.
Conclusion: We conclude that the most sensitive serological test for
the serological diagnosis of Brucellosis is the Microplate Agglutination
test followed by the ELISA IgM test. However, in clinical practice, the
signiﬁcant cut off point of Microplate Agglutination test and the ideal
cut off value of ELISA test for the diagnosis of active Brucellosis should
be established.
P1419 Dimeric OspCadv − advanced recombinant OspC antigens
for the sensitive and speciﬁc detection of class IgM
antibodies in early stages of Borrelia infections
A. Ott*, L. Komorowski, C. Probst, W. Schlumberger, W. Stoecker,
T. Scheper, W. Meyer (Lu¨beck, DE)
Objectives: In the early phase of borreliosis, antibodies of class IgM
against OspC are generally the most important serological markers. In
contrast to native OspC antigens, the diagnostic value of recombinant
OspC used as antigenic target has been limited until now due to
unspeciﬁc reactivity with sera from healthy individuals. Here we present
data from three human pathogenic Borrelia genospecies, showing that
recombinant homodimeric OspCadv achieves an equivalent speciﬁcity
and increased sensitivity compared to native OspC antigens puriﬁed from
Borrelia membranes.
Methods: A line blot immunoassay was developed containing recom-
binant dimeric OspCadv antigens from pathogenic Borrelia afzelii,
Borrelia burgdorferi and Borrelia garinii, expressed in E. coli and
puriﬁed by afﬁnity chromatography. This assay and a commercially
available line blot immunoassay (“EUROLINE Borrelia RN-AT”,
EUROIMMUN AG) comprising puriﬁed, isolated native OspC antigens
from the same Borrelia genospecies were used to screen for antibodies
of class IgM in 150 sera from patients with borreliosis and 126 control
sera (16 from patients with past infection and persisting IgM, 10 from
patients with acute EBV infection, 50 from pregnant women and 50 from
blood donors). Prevalence and intensity of the bands were automatically
evaluated using a commercial computer programme (EUROLineScan
from EUROIMMUN AG).
Results: In 95.7% (264/276) of the sera tested, the antibody reactivity
to dimeric OspCadv and native OspC antigens was concordant. 3.3%
(9/276) of the sera, 88.9% (8/9) of which were from the borreliosis
cohort, exclusively contained antibodies against OspCadv antigens. The
OspCadv antigens showed a speciﬁcity of 99%.
Conclusion: With dimeric OspCadv antigens, the assay sensitivity in
borreliosis patients was increased without loss of speciﬁcity, compared
to monomeric recombinant OspC. We conclude that unspeciﬁc reactions
have been prevented by optimal antigen design: the immunodominant
epitopes of the OspCadv antigens agree exactly with the structures of the
epitopes of native OspC antigens, thus providing an excellent sensitivity
and speciﬁcity.
P1420 New liaison® automated immunoassays for the detection of
Mycoplasma pneumoniae IgG and IgM antibodies in human
serum/plasma specimens
F. Capuano*, B. Grassi, L. Pallavicini, Z. Greenberg, M. Lipson
(Saluggia, IT; Ashdod, IL)
Objective: To evaluate the diagnostic performance of two recently
developed automated immunoassays for determination of IgG and IgM
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antibodies to Mycoplasma pneumoniae in human serum/plasma. Auto-
mated LIAISON® Mycoplasma pneumoniae IgG and IgM assays were
developed in cooperation between DiaSorin and Savyon Diagnostics.
Methods: Semi-quantitative determination of speciﬁc IgG to My-
coplasma pneumoniae is an indirect, two steps, chemiluminescence
immunoassay (CLIA). P1 recombinant antigen (in E. coli) is coated
onto magnetic particles. A monoclonal Ab to human IgG, linked to
an isoluminol derivative (isoluminol-antibody conjugate), is used to
detect speciﬁc IgG antibodies present in calibrator, samples or controls.
IgM to Mycoplasma pneumoniae are detected by a qualitative, two
steps, CLIA assay. Mycoplasmal lysate enriched with P1 recombinant
antigen is coated onto magnetic particles. Speciﬁc IgM antibodies are
detected by a monoclonal Ab to human IgM, linked to an isoluminol
derivative. Study population included 465 samples from patients with
symptoms of atypical pneumonia, 49 paired samples from patients with
recent M. pneumoniae. infection and samples from subjects positive for
antibodies to other microrganisms that may cause symptoms similar to
M. pneumoniae infection (e.g. inﬂuenza virus, adenovirus), or other
infectious diseases. Both assays were designed to be used on the
LIAISON® instrument.
Results: Specimens were tested using the LIAISON® Mycoplasma
pneumoniae assays and reference ELISA tests. Overall agreement was
90.1% for IgG and 91.9% for IgM detection. Consensus with additional
serological data was then applied on discrepant specimens. Diagnostic
sensitivity and speciﬁcity were respectively 94.2% and 98.8% for IgG,
97.8% and 99.1% for IgM. Signiﬁcantly increased (i.e. of the order of
three fold or greater) M. pneumoniae IgG concentration between two
consecutive bleeds is considered suggestive of acute infection or re-
infection, even in the absence of IgM. Diagnostic concordance on the
assessed paired samples was 100% on determination of acute infections,
using LIAISON® Mycoplasma pneumoniae assays and Savyon SeroMP
recombinant IgG/IgM assays.
Conclusions: These assays shows high analytical performance in the
determination of speciﬁc antibodies to Mycoplasma pneumoniae in
human serum or plasma samples. Results obtained with paired sequential
samples allow to correctly diagnose acute infections.
P1421 PCR versus serology for diagnosing mycoplasma
pneumoniae infection: a systematic review and meta-analysis
L. Zhang, X.-J. Lv* (Chengdu City, CN)
Background and Objectives: Diagnosis for Mycoplasma pneumoniae
usually relied on serological tests. PCR technology has some advantages
but still with limitations. The optimal selection for these tests still needs
to be discussed. This review studies the overall diagnostic accuracy of
PCR versus serological assays for diagnosis ofM. pneumoniae infections
and to identify factors associated with heterogeneity of results.
Methods: MEDLINE etc. databases were searched. Articles meet the
selection criteria were retrieved for data collection and analysis. Studies
were assessed for methodological quality using QUADAS. HSROC
model was used to estimate summary ROC curve.
Results: Initial meta-analysis showed a summary estimate of sensitivity
(SEN) 0.62 (95%CI, 0.45–0.76), speciﬁcity (SPE) 0.96 (95%CI, 0.93–
0.98). Subgroup analyses were performed to identify some factors
associated with heterogeneity. For different gene targets, reference
standards, subjects (children or adults) and different PCR types, these
aspects all can generate results of heterogeneity. The 16s rDNA target
and adult subjects and real-time PCR may have better test results for
PCR. Interpretation and conclusions Commercial PCR tests generated
consistent results with high speciﬁcity but a lower and more variable
sensitivity. This review suggest commercial PCR tests have superiorities
in diagnosingM. pneumoniae infections but still can not replace serology
as the perfect method. PCR plus serology could be good screening tests
at ﬁrst, a combination of serology and PCR was still recommended.
P1422 Clinical potential of diagnostic methods for the rapid
diagnosis of Mycoplasma pneumoniae pneumonia in adults
N. Miyashita*, Y. Kawai, K. Ouchi (Kurashiki City, JP)
Objectives: Results from rapid diagnostic tests can be used to initiate
appropriate antibiotic treatment and prevent antimicrobial resistance
through the use of narrow-spectrum antibiotics. The purpose of the
present study was to evaluate the accuracy and usefulness of three rapid
diagnostic methods: ImmunoCard Mycoplasma kit, chest high-resolution
computed tomography (HRCT) ﬁndings, and the Japanese Respiratory
Society (JRS) scoring system, for the early presumptive diagnosis of
Mycoplasma pneumoniae pneumonia.
Methods:We performed three rapid diagnostic methods at the same time
in four pneumonia groups: 68 cases with M. pneumoniae pneumonia,
133 cases with Streptococcus pneumoniae pneumonia, 30 cases with
Haemophilus inﬂuenzae pneumonia, and 20 cases with Legionella
pneumonia.
Results: The sensitivity and speciﬁcity were 35% and 68% for
ImmunoCard, 73% and 85% with HRCT, and 83% and 90% with the JRS
scoring system, respectively. Among the 57 positive cases with the JRS
scoring system, ImmunoCard and HRCT were positive in all 57 patients
and in 39 patients, respectively. To conﬁrm the positive reactivity of
ImmunoCard, we tested the sera from 200 adult healthy volunteers, and
IgM-positive cases were observed in 61 (30%) subjects. IgM antibodies
of M. pneumoniae pneumonia persist for several weeks and months and
the longest positive period was 512 days.
Conclusion: Among the three rapid diagnostic methods, the JRS scoring
system was the most useful tool for initiating the administration of
adequate antibiotic therapy for probable M. pneumoniae pneumonia. We
suggest that M. pneumoniae pneumonia should be suspected when there
is a correlation of more than ﬁve parameters in the JRS scoring system
(99% speciﬁcity). If there is a correlation of three or four parameters in
the JRS scoring system, chest CT ﬁndings are helpful for the presumptive
diagnosis of M. pneumoniae pneumonia.
P1423 Cloning and expression of Helicobacter pylori cagA
C-domain for screening high-risk populations through a
Western blotting assay
M. Esmaili, F. Ebrahimzadeh*, Y. Talebkhan, S. Saberi Kashani,
Z. Karimi, S. Jahangiri, P. Hassanpour, A. Oghalaie, A. Nahvijoo,
M. Mohagheghi, M. Eshagh Hosseini, M. Mohammadi (Tehran, IR)
Objective: H. pylori is a microaerophil, spiral-shaped and Gram-negative
bacterium which causes gastric diseases ranging from chronic active
gastritis to gastric cancer. Cytotoxin associated gene A (cagA) encodes
CagA protein which is associated with severe gastric clinical outcomes.
The number of EPIYA motifs is a critical factor in pathogenesis of CagA
related cytoskeletal change in gastric mucosa. It has also been repeatedly
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reported that host antibodies against this protein can be applied in
serological screening approaches.
Aim: The aim of this study was to produce CagA C domain in a
recombinant format for incorporation into a serological kit for screening
of HP infected patients.
Methods: Genomic DNA was extracted from Iranian Hp strains with
the 3′ ABCCC motif. Designed speciﬁc primers were used for PCR
ampliﬁcation of the 3′ cagA region corresponding to the triple EPIYA C
domain. The ampliﬁed (400bp) fragment was cloned into pET23a, an
E. coli expression vector. Expression of r-protein was induced by 0.5mM
IPTG. The identity of the expressed (18kDa) protein was conﬁrmed
through immunoblotting with anti His6 antibodies as well as pooled
Hp negative and positive sera. The recombinant protein was used
for screening patients’ sera in comparison with the obtained cagA 3′
genotyping data. The following groups of subjects were screened:
(1) Hp negative subjects, or those infected with Hp strains with missing
or incomplete cagA gene (lacking one of 5′ or 3′ region) or AB type
cagA gene (n = 109), (2) Patients infected with Hp strains with complete
cagA gene with one or more EPIYA C domains (n = 223).
Results: Presence of antibodies against rCagA C3 domain could
signiﬁcantly reﬂects patients infected with Hp strains with complete
cagA gene with one or more EPIYA C domains as compared to the
ﬁrst group which were either HP negative or harbored Hp strains
with incomplete cagA gene or cagA gene without EPIYA C domain
(P< 0.001).
Conclusion: Serologic screening of populations against the recombinant
CagA triple C fragment presents a non-invasive method in identiﬁcation
of subjects infected with the more virulent subtypes of Hp (EPIYA C
positive strains).
P1424 Helicobacter pylori CagA sero-reactivity and serum
pepsinogen levels in developing gastric cancer screening
approaches in Iranian high-risk populations
Y. Talebkhan*, F. Ebrahimzadeh, M. Bababeik, A. Farjaddoost,
F. Fereidouni, A. Morakabati, M. Eshagh Hosseini, M. Mohagheghi,
M. Mohammadi (Tehran, Qom, IR)
Objectives: Several studies have shown that beside Helicobacter pylori
(Hp) and its virulence factors, host genetic and protein content as well as
environmental factors are involved in gastric carcinogenesis. In this study
we aimed to estimate the risk of gastric cancer development associated
with serum anti-Hp and its cytotoxin associated gene A product (CagA)
as well as serum pepsinogen as non-invasive screening markers.
Methods: 382 gastric cancer cases, 626 non ulcer dyspeptic patients and
179 asymptomatic blood donors were enrolled in the study. Fasting blood
samples were obtained for measurement of serum pepsinogen as well as
anti Hp IgG and anti recombinant CagA IgG antibodies using home made
ELISA and Western blotting assays. PMN/neutrophil inﬁltrations, gastric
atrophic and intestinal metaplastic changes were also graded according
to OLGA staging system. Asymptomatic subjects and dyspeptic patients
with low grades of atrophic changes were categorized as “none to mild”
patient group whereas dyspeptic patients with high grades of atrophy and
gastric cancer patients were merged as the “moderate to severe” patient
group.
Results: Multiple logistic regression analysis adjusting for age, gender
and ethnicity of subjects demonstrated that the presence of serum
antibodies against CagA increased the risk of subject placement in the
high risk group by 1.5 folds which did not reach statistical signiﬁcance.
On the other hand, serum pepsinogen levels below 25 mg/L represented
a signiﬁcantly increased risk of “moderate to severe” gastric diseases
(OR=4.54; 95%CI=2.5−8.2, P< 0.001). The joint effect of these two
screening factors however represented an even higher increased risk for
development of moderate to severe gastric premalignant and malignant
disorders (OR=6.8; 95%CI=1.33–35.2, P< 0.05).
Conclusions: Our data recommends the assessment of serum anti-CagA
antibodies in addition to pepsinogen levels for population screening and
identiﬁcation of high risk subjects whom should then be referred for
routine follow-up endoscopy and detection of premalignant lesions and
intervention treatments.
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P1425 Time-dependent effect of MBL, TLR2, TLR4,
FcgammaRIIA genes polymorphisms, treatment and sepsis
in invasive pneumococcal disease mortality
E. Garcı´a Cabrera, A. Dı´az-Martin, J. Garnacho-Montero*,
R. Jime´nez-A´lvarez, C. Garnacho-Montero, J. Revuelto-Rey, J. Aznar
for the Spanish Network for the Research in Infectious Disease
Objectives: Our aim was to assess the impact on mortality of different
genotypic variants of the innate immunity in patients admitted to the
hospital with invasive pneumococcal disease (IPD).
Methods: All Caucasian adults admitted to the hospital with diagnosis
of IPD were enrolled in this prospective study and SNPs in MBL, TLR2,
TLR4 and Fcgamma-RIIa genes were genotyped. Underlying diseases,
severity of illness, antibiotic management and other variables related to
outcome were also recorded. To determine the independent effect of the
variables on outcome, we calculated multivariate-adjusted hazard ratio
of death using the Cox proportional hazard regression analysis.
Results: We included 117 patients with IPD: 98 episodes (83.6%) of
pneumonia, 17 (14.5%) meningitis, and 2 patients (1.9%) with primary
pneumococcal bacteremia. Polymorphisms of MBL A0/00 were present
in 37 patients (32%) (individuals heterozygous or homozygous for
one of the allelic variant B, C or D), TLR4 T399I in 19 (16.2%),
TLR4 D299G/T399I in 11 (9.4%), TLR2 R753Q in 3 (2.56%), and
FcgRIIa-H/H131 in 26 patients (23%). All genotype frequencies were
in Hardy-Weinberg equilibrium. Forty patients (34%) developed septic
shock secondary to IPD. We did not ﬁnd difference between genotype
frequencies on the occurrence of septic shock. The bivariate analysis
identiﬁed that median Charlson Index (IQR) 4 (4) vs 6 (3) (p = 0.04),
presence of septic shock 21 (22) vs 19 (86) (p< 0.001)and ﬁrst
adequate antibiotic within the ﬁrst 4 hours after admission 66 (69) vs
8 (36) (p = 0.04) were signiﬁcantly different between survivors and non-
survivors. Factors associated independently with mortality were SNP
MBL A0/00 [Adjusted hazard ratios (aHR) 3.06 conﬁdence interval
(CI) 95% 1.01–9.31] and septic shock [aHR 10.73 (CI 95% 3.14–36.70]
whereas ﬁrst adequate antibiotic dose 4h was a protective factor [aHR
0.24 CI 95% 0.08–0.74].
Conclusions: After controlling for confounding variables, variant alleles
in the MBL2 gene are independently associated with mortality in patients
admitted to the hospital with IPD.
P1426 Mannose-binding lectin inhibits cytomegalovirus capture
and transmission by human primary monocyte-derived
dendritic cells
S.Q. Shang*, Y.H. Chen, R. Tao, H.J. Qiao, W. Wu (Hangzhou, CN)
Objectives: Human cytomegalovirus (HCMV) infection is common,
and can’t completely get rid of from the host with present anti-
cytomegalovirus therapy. The research was a study on human mannose-
binding lectin (hMBL)/recombinant human wild-type MBL (rhMBL)
inhibiting monocyte-derived DC (MD-DC) capturing HCMV and
preventing transmission to T cells, and exploring its mechanism.
Methods: All methods included the establishment of the Chinese
hamster ovary (CHO) cell line secreting rhMBL; the preparation,
puriﬁcation, identiﬁcation and quantiﬁcation of hMBL and rhMBL;
the preparation of MD-DC; testing the inhibitory of MBL on the
ability of MD-DC to capture and transmit HCMV particles by RT-PCR,
immunoﬂuorescence confocal microscopy and ﬂow cytometry.
Results: Establishing a stable cell line that human wild-type MBL gene
expression is 103 times more than that in the empty vector, preparing
high purity hMBL, rhMBL, MD-DC (expression of CD209 was higher
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than 85%) and activated T cells; 10mg/ml hMBL or rhMBL efﬁciently
blocked the capture of MCV by DC-cells under immunoﬂuorescence
confocal microscopy; the IC50 of hMBL and rhMBL inhibiting capture
of HCMV by MD-DC was 4.5mg/ml and 7.4mg/ml respectively in
dose-dependent manner. The IC50 of hMBL and rhMBL inhibiting the
transmission of HCMV was 4.7mg/ml and 3.1mg/ml respective on day
3 of coculture MD-DC and T cells; and the IC50 of hMBL and rhMBL
was 4.6mg/ml and 2.1mg/ml respectively on day 4 of coculture. The DC-
SIGN antibody proved able to prevent HCMV transmission to activated
T cell at day 3 and day 4 (P = 0.001, 95%CI: 5.6740–16.9660; P = 0.001,
95%CI: 13.0888–38.0132), while MMR antibody didn’t prevent these
events (P = 0.91, 95%CI: -5.3460–5.9460; P = 0.707, 95%CI: 14.6712–
10.2712). Thus, the ability of anti-DC-SIGN antibody inhibit HCMV
transmission to T cells supports the idea that the interaction of HCMV
with MD-DC is predominantly DC-SIGN-mediated.
Conclusion: HMBL and rhMBL efﬁciently inhibit the capture and
transmission of HCMV by MD-DC with DC-SIGN-mediated.
P1427 Mannose-binding lectin inhibits human cytomegalovirus
infection in human embryonic pulmonary ﬁbroblasts
W. Wu*, S.Q. Shang, R. Tao, Y.H. Chen, H.J. Qiao (Hangzhou, CN)
Objectives: A limited number of drugs have been used for treatment
of Human cytomegalovirus (HCMV), all sharing the similar antiviral
mechanism of inhibiting virus replication. This study is to study the
anti-HCMV activities of Mannose-binding lectin (MBL) from blocking
virus entry.
Methods: Recombinant human MBL (rMBL) was produced in CHO
cells using a PIRES2-AcGFP expression vector system. Native human
MBL (hMBL) was isolated from human serum. The concentration of
puriﬁed MBL was determined by ELISA. HCMV neutralization test
was carried out by treating HCMV with each diluted MBL solution
and then treated HCMV being inoculated onto the human embryonic
pulmonary ﬁbroblasts (MRC-5 cell). The cells were then washed and
the HCMV-DNA in cells was quantiﬁed by real-time quantitative PCR
(Q-PCR). To get confocal pictures, in some experiments, the HCMV
were stained by PKH-26 before treated with MBL and the cells were
applied with anti-vimentin. A HCMV growth inhibition test were also
done in HCMV infected cells. After the invasion of HCMV, the cells were
incubated with MBL, every 24 hour, the supernatant of cell culture was
tested for HCMV-DNA by Q-PCR. At 72 hour, cytopathic effect (CPE)
was observed by the inverted microscope and cells were collected for
HCMV-DNA examination.
Results: HCMV neutralization test revealed 10mg/ml MBL signiﬁcantly
decreased the HCMV invasion in MRC-5 cell. However, the activity
can be blocked by incubating together with 20mg/ml mannan. The
neutralizing activity of hMBL was higher than rMBL. Confocal pictures
conﬁrmed less HCMV invasion after MBL treatment. HCMV growth
inhibition test indicated at 24th hour and 48th hour after HCMV
invasion, there was no difference of the HCMV-DNA levels between
MBL incubated cells supernatant and control supernatant. At 72nd hour,
the HCMV-DNA levels in both culture supernatant and cells incubated
with MBL were lower than the control.
Conclusion: MBL can inhibit invasion of HCMV to MRC-5 cells and
prevent viral spreading to contiguous cells. The anti-HCMV activities of
MBL were blocked by mannan, suggesting binding of MBL to HCMV
is through the interaction of the MBL with the glucoprotein of HCMV.
P1428 Association of Toll-like receptor 4 (A896G, C1196T
and G1199A) and CD14 (C-159T) polymorphisms with
susceptibility to brucellosis
M. Rasouli*, M. Kalani, S. Kiany, S. Asaei, A. Moravej (Shiraz, IR)
Objectives: Toll-like receptor 4 and CD14 are macrophage surface
proteins that contribute to the control of Brucella and help macrophages
to kill the bacteria more efﬁcient. Indeed, signaling through TLR4 and
CD14 has been associated with the induction of Th1 responses and a lack
of signaling has been associated with the induction of Th2 responses.
Since the expression of TLR4 and CD14 can be affected by functional
polymorphisms within their genes, we tried to ﬁnd any probable relation
between Toll-Like Receptor 4 (A896G, C1196T and G1199A) and CD14
(C-159T) polymorphisms with susceptibility to brucellosis.
Methods: One hundred and seventy-ﬁve patients with brucellosis
and 77 healthy animal husbandmen, who had infected animals and
consumed their dairy products, joined this study. DNAs extracted from
samples were genotyped for Toll-Like Receptor 4 (A896G, C1196T
and G1199A) and CD14 (C-159T) using polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP).
Results: There was not any statistical signiﬁcant difference in the
frequencies of Toll-Like Receptor 4 (positions 1196 and 1199) and
CD14 (position −159) genotypes and alleles between patients and control
group. Whereas the frequencies of the AG genotype and G allele at
position 896 of TLR4 were signiﬁcantly higher in controls compare to
patients (P = 0.00014 and P = 0.00003, respectively).
Conclusion: Based on the results, the AG genotype and G allele at
position 896 of TLR4, which is a functional polymorphism, can be
considered as resistance factor against brucellosis. Then it seems that
individuals who inherited the genotypes that cause glycin in the position
299 instead of arginin may resist more against Brucella infection.
P1429 IL-15 gene polymorphisms are associated with resistance
to visceral leishmaniasis
M. Rasouli*, S. Asaei, M. Choopanizadeh, A. Moravej, M. Kalani,
S. Kiany (Shiraz, IR)
Objectives: Protozoan parasites of the genus Leishmania infect millions
of people worldwide causing a wide spectrum of diseases collectively
termed leishmaniasis that vary in their clinical manifestations. There
are several reports on the importance of IL-15 in the immunity against
leishmaniasis. Since the production of IL-15, like other cytokines, is
under control of its gene, we tried to ﬁnd any relationship between
visceral leishmaniasis (kala azar) and IL-15 genetic polymorphisms.
Methods: One hundred and seventeen patients with kala-azar and 146
individuals who lived in the same area as patients and didn’t have
any history of leishmaniasis, joined this study. DNAs extracted from
samples were genotyped for IL-15 (267C/T, 367G/A, 13687C/A, and
14035A/T) polymorphisms using polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) method.
Results: IL-15 (267) TT and T genotype and allele were signiﬁcantly
higher in the patients than the controls (P< 0.001 and P< 0.003,
respectively). Also IL-15 (13687) CC and C genotype and allele
were less frequent in the controls than the patients (P< 0.015 and
P< 0.031, respectively). Haplotype analysis showed a higher frequency
of 13687C/267T/367G/14035A in the patients than the controls
(P< 0.000001).
Conclusion: As data shown IL-15 267T allele could be considered as
a susceptibility factor for kala azar. Vice versa, IL-15 13687C allele
might be one of the genetic resistance factors against kala azar. In
addition, we can consider the haplotype 13687C/267T/367G/14035A as
a susceptibility factor for kala azar. Evaluation of IL-15 level beside
genetic polymorphisms is recommended.
P1430 The effects of Candida albicans cell wall protein fractions
on dendritic cell maturation and cytokine secretion proﬁle
by Th1 and Th2 in mice
M. Roudbary*, S. Roudbarmohammadi, M. Bozorgmehr, S. Moazzeni
(Tehran, IR)
Objective: Candida albicans is an opportunistic fungal pathogen that
causes oral and vaginal mucosal infections as well as systemic disease.
C. albicans cell wall is composed of several protein and carbohydrate
components that have been shown to play a critical role in interaction
with the host immune system. This major components of C. albicans cell
wall can partially modulate the host immune responses. Dendritic cells
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(DC), as the most important antigen-presenting cells of the immune
system, play a critical role in inducing immune responses such as
initiation and activation of T lymphocytes as mainly cellular immunity
for elimination of different pathogens. We evaluated the effect of the
cell wall protein fraction (CPF) of C. albicans on DC maturation and
Th1/Th2 cytokine secretion pattern by T lymphocytes.
Methods: The CPF of C. albicans cells was extracted by a lysis buffer
containing sodium dodecyl sulphate, 2-mercaptoethanol and phosphate-
buffered saline. The extract was dialyzed and its protein pattern was
evaluated by electrophoresis. Dendritic cells were puriﬁed from Balb/c
mice spleens through a three-step method including mononuclear cell
separation, as well as 2-h and overnight cultures. different concentrations
of puriﬁed CPF( 5, 10, 15mg/ml) was added to DC. The purity and
maturation status of DC were determined by ﬂow cytometry using
monoclonal antibodies against CD11c, MHC-II, CD40 and CD86.
T lymphocytes were puriﬁed from lymph node of C57BL/6 mice
by nylone wool method and theirs purity were determined by ﬂow
cytometry. T cells were cocultured with DCs that was pulsed with CPF.
Supernatants of culture were collected for determination of cytokine
secretion (IFNg, IL4) by ELIZA method.
Results: Treatment of DC with 10 microg/ml of CPF signiﬁcantly
(P value <0.05) increased both the expression of maturation markers
including MHC-II, CD86 and CD40 on DC and production of IFN g
cytokine byT cells compared to the control group.
Conclusion: In this study we used C. albicans CPF with the molecular
weight of 40−45 kDa for pulsing and maturation of dendritic cells and
cytokine pattern secretion pattern in T lymphocytes. Since according
to our results CPF signiﬁcantly increased the expression of maturation
markers on DC and Th1 cytokine secretion, we investigated that CPF
may act as an efﬁcient immunomodulator, or may be used as a
potential adjuvant to boost the host immune system against infections
for immunotherapy in clinical trials.
P1431 IgG2 and IgG3 subclass response to merozoite surface
protein-2 and malaria status
A. Khosravi*, E. Asadollahy (Ilam, IR)
Background: The role of naturally acquired human IgG antibodies in
immunity against the asexual blood stages of Plasmodium falciparum has
been the focus of interest of many studies. It has been suggested that
total IgG may not be the most suitable measurement for the antibody
responses against malaria. The current study was designed to evaluate the
various IgG subclass responses over time in an age cohort and to examine
the correlation with two markers of malaria morbidity, parasitaemia and
haemoglobin levels.
Methods: The IgG2 and IgG3 responses of 178 individuals from
a malaria endemic area of The Gambia have been analysed, at a
20-year longitudinal study, by ELISA against different recombinant
domains of the merozoite surface protein-2 (MSP-2) and a crude
schizont extract. The Kolmogorov–Smirnov method was used to check
the normal distribution of absorbance, haemoglobin and parasitaemia,
and a Spearman Correlation was applied to analyse the data.
Results: The results of the present study showed that the speciﬁc IgG2
and IgG3 levels, as well as the IgG3/IgG2 ratio against different domains
of MSP-2 were increased with the age of subjects, along with the
increasing of the haemoglobin and decreasing of the parasitemia levels.
Similar pattern was observed for the crude schizont extract.
Conclusion: Both the frequency and concentrations of IgG2 and IgG3
either against domains 2 and 3 of MSP-2 or crude schizont extract were
increased with increasing the age. At the same time the Pearson analyses
showed that, at the end of the follow up, high levels of IgG2 and IgG3 to
MSP2 epitopes were associated with low levels of parasitemia and high
levels of hemoglobin. In conclusion, bringing together, these results favor
a protective role of IgG3 and IgG2 against domains 2 and 3 of MSP-2.
P1432 Interleukin-33 induction is correlated with an efﬁcient
hepatic granulomatous response during experimental
Leishmania donovani visceral leishmaniasis
F. Robert-Gangneux*, O. Rostan, M. Rauch, M. Samson, J.-P. Gangneux
(Rennes, FR)
Objectives: During Leishmania donovani infection, spleen and bone
marrow are not able to control the infection, whereas the liver
displays a speciﬁc microenvironment allowing the development of
mature inﬂammatory granulomas, warranting clearance of parasites.
Macrophages and T lymphocytes as well as cytokines (IFN-g, TNF-a
or IL-12) contribute to the granuloma development and maturation, and
thus to the control of hepatic infection. However, regulation of these
cellular and soluble mediators is complex. Here, we studied the potential
implication of a recently described cytokine, IL-33.
IL-33 is mainly localized in the nucleus and released by epithelial and
endothelial cells in a damage context to early induce an adapted response.
It is recognized by its receptor ST2 which recruits the IL-1 accessory
receptor on target cells leading to pro-inﬂammatory gene expression.
IL-33 is also induced by various cell types in a chronic pathological
context such as viral or toxic chronic ﬁbrosis. An ST2 implication has
been studied during cutaneous leishmaniasis due to Leishmania major.
Methods: In this work, we studied the hepatic IL-33 and ST2 expression
in vivo during visceral leishmaniasis in C57BL/6 mice infected with
L. donovani and sacriﬁced after 15, 30 or 60 days. Granuloma foci were
counted on HES stained liver sections. Parasitic loads were evaluated by
microscopic examination of Giemsa stained smears. mRNA induction of
IL-33, ST2, IFN-g, TNF-a, IL-12 and IL-4 were analyzed by quantitative
PCR after RNA extraction of liver samples and reverse transcription.
Immuno-ﬂuorescence staining was also performed on liver thin sections
in order to localize IL-33 producing cells.
Results: Histochemical and immunoﬂuorescent staining revealed IL-33
positive cells, mainly localized in granulomas, with an increasing number
of producing cells from day 15 to day 60 post-infection. In addition, a
qPCR analysis showed a signiﬁcant IL-33 and ST2 mRNA induction
at day 60 post-infection. This concomitant induction of IL-33 and its
receptor was correlated to the induction of other cytokines: IFN-g,
TNF-a, IL-12 and IL-4. IL-33 induction in the liver of infected mice
was correlated to the growing granuloma number and size during the
course of the disease and to the parasitic clearance.
Conclusion: We showed that the IL-33 expression is highly associated
with the efﬁcient granulomatous response in C57BL/6 mice infected
with L. donovani.
P1433 Oral intake of heat-killed Lactobacillus pentosus strain
b240 reduces incidence of acute upper respiratory tract
infection in the elderly: a randomised, double-blind,
placebo-controlled trial
M. Toba*, S. Shinkai, T. Saito, I. Sato, M. Tsubouchi, K. Taira,
T. Inamatsu, H. Yoshida, H. Amano, Y. Fujiwara, N. Kohda (Otsu,
Tokyo, JP)
Objectives: Mucosal immunoglobulin A (IgA) secretion decreases with
age, stress and intense exercise. The decline of the salivary IgA secretion
could be correlated with the raising the risk of acute upper respiratory
tract infections (URTI). We have conﬁrmed that intake of heat-killed
Lactobacillus pentosus ONRICb0240 (b240) for 12 weeks signiﬁcantly
increased salivary IgA secretion in healthy elderly. The object of this
study was to demonstrate the reduction of incidence of acute URTI in
the elderly by oral intake of b240.
Methods: A total of 294 healthy elderly individuals were randomly
allocated to 3 groups as follows. 1) Placebo group, 2) Low dose group
(heat-killed b240: 4×109 cells), 3) High dose group (heat-killed b240:
4×1010 cells). Those groups received their respective test food once
daily for 20 weeks. Questionnaire survey was performed concerning the
occurrence of the URTI and the specialist for Infectious diseases judged
the episodes in consideration of all information. Saliva was collected
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at 0, 2, 4, 8, 12 and 20 weeks and salivary IgA were measured. QOL
survey was performed.
Results: The incidence of URTI was signiﬁcantly decreased in healthy
elderly by taking high dosage for 20 weeks, and the protective effect
of taking b240 on the URTI was dose dependently. In high dose group,
salivary IgA secretion was signiﬁcantly increased. In addition, it was
suggested that the salivary IgA secretion is related to the reduction of
URTI incidence. QOL was signiﬁcantly increased in high dose group.
No problematic adverse event was reported by taking b240 for 20 weeks.
Conclusion: Oral intake of Lactobacillus pentosus ONRICb0240 for 20
weeks reduces incidence of acute URTI in the elderly. From these results,
b240 is thought to enhance the ability to protect against infection in the
elderly.
P1434 Cellular immune responses in the ferret (Mustela putorius
furo): tools for understanding the correlates of protection
and pathogenesis for pandemic inﬂuenza and Dengue fever
G. Manukian*, S. Naveen, M. Chen, R. Cross, C. Garry, B. Kaplan,
G. Nichols, T. Voss (New Orleans, US)
Objectives: Our laboratory utilizes the ferret (Mustela putorius furo)
as a model of acute respiratory (inﬂuenza and coronavirus) infection
and is actively developing the ferret as a model of Dengue fever,
Dengue hemorrhagic fever, and Dengue shock syndrome. While the
ferret has been demonstrated as a useful model of virus replication
and pathogenesis for multiple viral pathogens of humans and animals,
a paucity of ferret speciﬁc reagents has hindered detailed analysis of
immune responses to infection, particularly with regard to innate and
cellular effectors. We are focused on the development and utilization
of reagents in understanding the potential role of innate and adaptive
effector cells in the context of inﬂuenza, SARS-CoV, and Dengue
infections in ferrets. Advancements in the ﬁeld of immunology have
led to the identiﬁcation of various helper T cell subsets, such as
CD4+CD25+ FoxP3+ regulatory T cells, that have proven to be critical in
the development of a robust immune response. The role of these cells in
the pathogenesis of viral infections in the ferret is a primary focus of our
lab. In order to design more effective vaccines and treatments as well as
to better understand disease pathophysiology in the ferret animal model,
it is critical to develop reagents to study the interactions between these
cells. Consequently, we have focused our efforts on cloning ferret genes
speciﬁc for identifying these subsets, such as FoxP3, and identifying
commercially available antibody clones that are cross-reactive with ferret
antigens.
Methods: Primers for ferret FoxP3 (F-FoxP3) were generated from
highly conserved sequences from different species. F-FoxP3 was cloned
from mRNA isolated from ferret PBMCs and splenocytes. Cross-reactive
antibodies were tested in ﬂow cytometry based on the manufacturer’s
protocols in both fresh and frozen PBMCs and splenocytes.
Results: We have successfully cloned F-FoxP3 (unpublished) and
sequencing data revealed a 94% homology between conserved sequences
from various species.
Conclusions: Using the techniques described, we have for the ﬁrst time
cloned FoxP3 in the ferret. We have also identiﬁed several commercially
available antibody clones used in ﬂow cytometry that cross-react with
ferret antigens. With these reagents at our disposal we will be able to
characterize the ferret immune response in various infection and vaccine
models.
P1435 Increased activated and proliferating T-cells in acute
respiratory distress syndrome with altered CD28 and
CTLA-4 expression in humans
G. Kumar*, K. Risso, C. Marquette, C. Sanﬁorenzo, P. Dellamonica,
P.M. Roger, A. Bernard (Nice, FR)
Objectives: Acute Respiratory Distress Syndrome (ARDS) is a common,
devastating clinical syndrome of acute lung injury but most often those
with sepsis. The pathophysiolgy of this disease is still unknown. Studies
have shown that lymphocytes, in addition to neutrophils, inﬁltrate the
lung in ARDS and regulatory T cell subset contribute to its resolution.
Therefore our present study aims to determine the T cell and its subset
distibution as well as the expression of the costimulatory markers in
ARDS and compare it with those of the normal.
Methods: Bronchoalveolar Lavage (BAL) from patients with ARDS
due to infection, and that of normal group was taken during the
standard sterile pulmonary bronchoscopic procedures from Pulmonology
Department. BAL from each patient was taken during the initial phase of
infection or at the starting phase of ARDS. Cell suspension was made
from BAL, red blood cells were lysed, labelled and analysed in ﬂow
cytometer. Lymphocytes were detected by CD3+CD45+ double positive
cells. Activated T-cells for both CD4 and CD8 were detected by HLA-
DR+, T-regulatory cells by CD25+FoxP3+. Proliferation were screened
using Ki67 staining for both subsets. Costimulatory molecules CD28
and CD152(CTLA-4) along with CD80 and CD86 were also analyzed
on both T-cell subsets.
Results: The data of 10 BAL from ARDS patients and 10 normals are
presented in the following table. The values represent the median value
in percentage. The values in the bracket represents the range. p value
represents non-parametric Mann-Whitney’s U test p value.
Conclusion: From the data it is clear that in ARDS their is increase in
both the actiavted and proliferating T cells in comparison to normal in
both CD4 and CD8 T cell subsets. In case of lung infection, in both the
T cell subset population, there is decrease in expression of costimulatory
marker such as CD28 and CD80 with a signiﬁcant increase in CTLA-
4/CD152 and CD86+ T cells. There is also a slight increase in the
population of T-regulatory cells in case of ARDS.
P1437 Production of human b-defensin-1 in the urinary tract and
its correlation to uncomplicated urinary tract infection in
women
K.L. Nielsen*, P.S. Andersen, N. Frimodt-Møller (Copenhagen, DK)
Objectives: Human b-defensin 1 (HBD-1) is excreted in the kidneys and
thought important for keeping the urinary tract sterile. The production of
HBD-1 is up-regulated during pyelonephritis, indicating its importance
for protection of the urinary tract. Furthermore, knockout defb-1 mice,
the mouse ortholog of HBD-1, have 30% more bacteria in their urine
than WT mice. In this study we asked, whether women who have had
urinary tract infection (UTI) 1 times produce the same amount of
HBD-1 as control subjects.
Methods: Included were 29 UTI patients (E. coli infection of 104
CFU/mL and leucocyturia) and 48 control subjects (who had never had
UTI, presenting urine sample without bacteria and leucocyturia). All
were women between 18 and menopause, and generally healthy. Patient
samples were collected at presentation of UTI and 1−3 weeks after
completion of antibiotic course. Clinical data regarding history of UTI
were provided for both cases and controls.
HBD-1 was measured in urine by ELISA. The amount of HBD-1 was
normalized to creatinine levels (measured by an enzyme immunoassay)
in the urine sample, i.e. expressed as ng HBD1/mg creatinine.
Results: The median HBD-1 levels for patients during and after
infection, as well as for controls, were 83ng/mg, 88 ng/mg and 78ng/mg,
respectively. Patient levels did not differ signiﬁcantly from control levels
(P = 0.64 and P = 0.86, respectively). Compared to infection levels, 10
patients had lower HBD-1 level after infection, 6 had similar level,
whereas 13 patients had higher HBD-1 contents in urine.
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There was a signiﬁcant positive correlation between level of CFU/mL in
urine samples of patients during infection and their level of HBD-1 after
infection (P = 0.01). There was no correlation between level of HBD-1
in patients during nor after treatment and UTI history.
Conclusion: These results indicate that (1) Urinary levels of HBD-1
are not elevated signiﬁcantly during uncomplicated UTI nor signiﬁcantly
different from HBD-1 levels of controls, however (2) the level of HBD-1
was positively and signiﬁcantly correlated to level of infection in terms
of increasing CFU/mL in urine. This indicates, that the ability of patients
to produce HBD-1 in the urinary tract is not affected compared to
controls, and that the concentration of HBD-1 increases with increasing
inﬂammation, as evidenced by increasing CFU/ml.
P1438 AZD9773 is a novel selective anti-TNF-a ovine polyclonal
immune Fab
P. Newham*, A. Heier, F. Brennan, P. Ceuppens, J. Growcott
(Macclesﬁeld, UK)
Objectives: TNF-a is thought to play a central role in the pathogenesis
of sepsis and septic shock. AZD9773 is an ovine polyclonal anti-human
TNF-a (rhTNF-a) immune Fab and comprises both TNF-a-directed
and non-speciﬁc Fab populations. Here we describe the binding and
functional potency of AZD9773 against rhTNF-a and TNF-a orthologues
from a number of species and characterise the speciﬁcity of AZD9773
against a panel of human frozen tissues.
Methods: AZD9773 binding and functional potency (IC50) versus
rhTNF-a and TNF-a orthologues was assessed using surface plasmon
resonance (SPR) technology and TNF-a-mediated cytotoxicity in L929
and PK(15) cell lines, respectively. AZD9773 binding to a variety of
fresh frozen tissues from three unrelated human donors was determined
via detection of ﬂuorescein isothiocyanate-(FITC-)conjugated AZD9773
by immunohistochemical (IHC) staining. FITC sheep anti-digoxigenin
Fab was used as a control.
Results: SPR revealed that AZD9773 total Fabs binding to other species
TNF-a was less than that obtained with rhTNF-a. AZD9773:TNF-a
orthologue binding relative to AZD9773:rhTNF-a binding was ap-
proximately 50−60% for canine, equine, feline and primate TNF-a,
approximately 20% for porcine TNF-a and <20% for bovine, murine,
cotton rat and rat TNF-a. In cytotoxicity assays, AZD9773 potently
inhibited the bioactivity of human and primate TNF-a with limited or
no inhibition of canine, porcine, mouse and rat TNF-a. IHC analysis
revealed speciﬁc AZD9773 staining of occasional cells in the lung,
thymus and lamina propria of the ileum, and in cells within the red
and white pulp of the spleen.
Conclusion: AZD9773 has limited capacity to bind and neutralise
common TNF-a orthologues; consistent with the conservation of key
TNF-a receptor-binding epitopes and overall sequence-identity between
species. Speciﬁc binding of AZD9773 to human tissues was consistent
with the theoretical distribution of TNF-a producing cells, reﬂecting
the intended pharmacological binding. The non-TNF-a-direct Fab
populations of AZD9773 do not appear to bind human antigens. Thus,
AZD9773 is a potent and selective human TNF-a-neutralising ovine
immune Fab. #FB Currently at Novartis, Basel, Switzerland.
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P1439 Safety of hepatitis B, pneumococcal, and meningococcal
vaccines in pregnancy: evaluation of the published evidence
M. Makris, K. Polyzos, M. Mavros, S. Athanasiou, P. Rafailidis*,
M. Falagas (Athens, GR)
Objectives: Immunization during pregnancy has the potential to protect
the mother and the newborn from preventable diseases. Current
recommendations suggest that inactivated vaccines might be considered
during pregnancy when the beneﬁts outweigh the risks, although the
evidence supporting this statement has been questioned. We aimed
to evaluate the safety of hepatitis B (HB), pneumococcal (PPV), and
meningococcal vaccine (MPV) during pregnancy.
Methods: We performed a review of the available published studies.
Results: A total of 15 studies were eligible for inclusion in our review.
Four studies reported data on HB vaccine, 5 on the PPV, and 3 on
the MPV, while 3 additional studies compared MPV with PPV. Minor
local reactions, including tenderness and swelling, were common. No
serious adverse reactions or life-threatening conditions were reported
among vaccinated pregnant women, and maternal immunization was not
associated with a teratogenic effect on the fetus. Stillbirths, delivery
complications and infant mortality were generally within expected
ranges.
Conclusion: Although the published evidence regarding safety of the
hepatitis B, pneumococcal, and meningococcal vaccine during pregnancy
is limited, the available relevant data seems reassuring. Large, well-
organized RCTs may further clarify the issue and thus aid in the
implementation of a strategy to decrease the incidence of preventable
diseases in the mothers and newborns.
P1440 Process development of an affordable bivalent conjugate
vaccine against the two major causes of enteric fever,
Salmonella typhi and Salmonella paratyphi A
S. Kothari*, J.A. Kim, N. Kothari, R. Carbis (Seoul, KR)
Background: A recent IVI study found that in Kolkata, India, 24% of
enteric fever episodes were due to S. paratyphi A. Vi based vaccines only
protect against typhoid fever and thus would have no impact on enteric
fever episodes caused by S. paratyphi A. A bivalent vaccine offer broader
protection against the two major causes of enteric fever, without the need
to implement additional immunization programs. Published estimates
indicate that the incidence of enteric fever, in India, due to S. paratyphi
A is 2.2 million cases per annum.
Methods: We developed a high yielding production and puriﬁcation
process for Vi capsular polysaccharide (Vi). A Vi conjugate vaccine
using Diphtheria Toxoid (DT) as the carrier protein has also been
developed. IVI’s technologies were transferred to Shantha Biotechnics
(India) in 2009.
A high yielding fed batch fermentation system for Salmonella paratyphi
A was ﬁrst developed. The Lipopolysaccharide was separated from the
cells using micro and ultraﬁltration then detoxiﬁed by acid hydrolysis
to release O speciﬁc polysaccharide (OSP) from the Lipid A.The OSP
was further puriﬁed by precipitation of contaminating Lipid A, proteins
and nucleic acid, concentrated by ultraﬁltration then sterilized by 0.2mm
ﬁltration. The process developed uses equipment that is scalable and
cGMP compliant thus it is anticipated that the technology transfer and
scale up to a manufacturer will not be overly complicated.
Usually separation of precipitate from soluble components involves
centrifugation, ultracentrifugation; the noble method developed at IVI
utilizes microﬁlters resulting in a highly puriﬁed sterile product. This
method has the added of being a completely closed system thus
complying with cGMP principles.
Results: OSP from S. paratyphi A has been successfully puriﬁed and
the ﬁnal bulk contains less than 1% of contaminating nucleic acid and
protein, and very low endotoxin (by LAL) values. The puriﬁed OSP
has been used to prepare a series of conjugates using Diphtheria Toxoid
(DT) as the carrier protein. The conjugates are currently undergoing
preclinical evaluation.
Conclusion: We have developed a high yielding and efﬁcient
technologies for Vi and OSP production and for conjugation to these
polysaccharides to DT. Our aim is to develop a cost effective bivalent
conjugate vaccine for developing countries.
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P1441 Development of chimeric peptides based on group B strep-
tococcal surface proteins as potential vaccine components
A. Lanskova, M. Samoilovich, I. Krutetskaya, T. Gupalova,
K. Grabovskaya, A. Suvorov* (Saint-Petersburg, RU)
Objectives: Group B strepotcocci (GBS) causes severe neonate’s
diseases. The most cost effective and less labor-intensive approach for
preventing of GBS infection is the development of vaccines which use
not single proteins as components but consisting of epitopes which
correspond to several surface GBS antigens. The chimeric structure was
created on the basis of two GBS surface proteins − SspB1 adhesin and
Bac protein accordingly. Other objectives of the study were to examine
the immunogenic activity of the components of the chimera − fragments
of SspB1 (rSspB) and Bac (P7) employing monoclonal antibodies (Mab)
and protection studies on laboratory animals.
Methods: All the constructs have been cloned in pQE32 vector (Qiagen)
and resultant recombinant proteins rSspB, P7, and chimera SspBBac
were expressed in E. coli after induction with IPTG. Protein puriﬁcation
was made on Ni-sepharose columns.
Mab were obtained according to the standard protocol. Cells of
myelogenic strain 653 A were conjugated with spleen cells of mice,
immunized with P7 or rSspB. Female mice of inbreeding lines
F1(SjL/j*Balb/c), F1(DBA/2*Balb/c) were used. These mice, immunized
with P7 or rSspB for three times (with complete, incomplete Freund’s
adjuvant and without adjuvant). In vivo protection has been done after
infection of mice with virulent GBS strains (O9OR, H36) after 15
months since ﬁrst immunization. Detection of a chimera with Mab was
made by ELISA or Western-blot.
Results: A chimera SspBBac with molecular weight of 79.3 kDa
was created. It included a-helical region of SspB1 and Bac protein
immunogenic region without IgA binding both fused in one molecule.
Mab panels to various P7 and rSspB epitopes were obtained. The ability
of long-term immune response (about 11.5 months) was noted.
Immunization of mice with P7 and rSspB polypeptide resulted in their
protection from systemic GBS infection.
It was shown that Mab to P7 and rSspB can detect a chimera, allowing
to assume that immunogenic epitopes of Bac and SspB1 were also
expressed in SspBBac.
Conclusion: Antibodies to Bac and SspB1 were protective against GBS
infection. Mab to GBS recombinant proteins P7 and rSspB were also
able to detect a SspBBac. It allows assuming that a chimera, made on
the basis of P7 and rSspB, has the ability to cause synthesis of speciﬁc
antibodies to both Bac and SspB1 epitopes. The potential of chimeric
proteins as vaccine candidates is discussed. The work was supported
with RFBR grant 10−04–00750a.
P1442 Effectiveness versus efﬁcacy of conjugated pneumococcal
vaccine: a systematic review of randomised, controlled
trials with meta-analysis examining absolute risk reduction
and relative risk
J. Puliyel*, J. Mathew, N. Vashisht, V. Sreenivas (Delhi, Chandigarh, IN)
Objectives: Use of the 7-valent pneumococcal conjugate vaccine (PCV7)
resulted in reduction in vaccine serotypes invasive pneumococcal disease
(IPD). However, IPD due to serotypes not included in the PCV7
increased in frequency. This prompted the introduction of a 13 valent
vaccine. Previous systematic reviews have examined vaccine efﬁcacy
(odds ratio and relative risk). However, effectiveness of PCV in reducing
childhood morbidity and mortality (in terms of absolute risk reduction
(ARR) and numbers needed to treat (NNT)) has not been published. At
the threshold of introducing the PCV13, such an assessment of the old
vaccine is useful for comparison. The objective here was to evaluate the
effectiveness of PCV through a systematic review of literature.
Methods: Systematic literature search for randomized controlled trials
reporting on measures of vaccine effectiveness (invasive Pneumococcal
disease, pneumonia, meningitis, all-cause mortality, Pneumococcal
disease speciﬁc mortality, and systemic adverse events/effects) was
undertaken and data extracted based on a priori criteria. Data were
analysed to calculate odds ratio, relative risk and absolute risk reduction
(ARR); and pooled through meta-analysis. Number needed to treat
(vaccinate) was calculated for effectiveness.
Results: There were ﬁve methodologically good trials presenting data
through 11 publications. There was a small but statistically signiﬁcant
beneﬁt of vaccination on clinical pneumonia (OR=0.927, 95%CI 0.885–
0.971, NNT=200), radiological pneumonia (OR=0.749; 95%CI 0.682–
0.822, NNT=143) and invasive disease caused by vaccine serotypes
(OR=0.215, 95%CI 0.149–0.311, NNV=500). The effect on all-cause
mortality was OR and RR=0.88, 95%CI 0.78 to 0.99, and RD 0.00,
95%CI −0.01 to 0.00 (NNT cannot be calculated). There was no
difference in invasive Pneumococcal disease caused by vaccine-related
and vaccine-unrelated serotypes. There was no data on meningitis
and Pneumococcal disease-speciﬁc mortality. Examination of multiple
adverse events did not show a difference in risk compared to control,
except for a small but statistically signiﬁcant increase in risk of asthma.
Conclusion: PCV7 appears to have limited effectiveness against
pneumonia; but does not reduce all-cause mortality. There is signiﬁcant
reduction in vaccine serotype IPD. There is no data to draw conclusions
for other clinical problems of public health signiﬁcance such as
meningitis, and Pneumococcal disease-speciﬁc mortality.
Table: Meta-analysis showing efﬁcacy and safety data of Pneumococcal
conjugate vaccine
Outcome RCT Vaccinated
(n)
Control
(n)
OR (95% CI),
I2
RR (95% CI),
I2
RD (95% CI), I2 NNT (95%
CI)
Clinical Pneumonia 3 43335 43284 0.927
(0.885, 0.971),
0%
0.940
(0.905, 0.977),
0%
−0.005
(−0.010, 0.001),
41.1%
200
(100, 1000)
Radiological
Pneumonia
3 43335 43284 0.749
(0.682, 0.822),
64.7%
0.744
(0.636, 0.870),
64.4%
−0.007
(−0.012, 0.002),
84.9%
143
(83, 500)
IPD (vaccine
serotypes)
5 46998 45886 0.215
(0.149, 0.311),
0%
0.158
(0.075, 0.333),
24.0%
−0.002
(−0.004, −0.000),
90.6%
500 (250, ~)
IPD (all serotypes) 5 46998 45886 0.395
(0.297, 0.526),
57.7%
0.341
(0.180, 0.645),
62.2%
−0.002
(−0.004, −0.000),
85.7%
500 (250, ~)
IPD (Vaccine
related serotype)
4 45407 45092 0.838
(0.376, 1.866),
35.8%
0.931
(0.286, 3.027),
25.8%
−0.000
(−0.001, 0.001),
59.1%
**
IPD (Vaccine
unrelated serotype)
5 46998 45886 1.199
(0.667, 2.155),
10.3%
1.151
(0.599, 2.210),
5.2%
0.000
(−0.000, +0.000),
100.0%
**
Meningitis 0
All cause mortality 3 27411 28065 0.88
(0.78, 0.99),
0%
0.88
(0.78, 0.99), 0%
0.00
(−0.00, 0.00)
**
Pneumococcal
disease speciﬁc
mortality
0
Adverse Events
Mortality 4 28753 27618 1.02
(0.53, 1.96),
28.5%
1.02
(0.53, 1.96),
28.4%
0.00
(−0.002, 0.002),
14.8%
Hospitalization 3 27162 26824 0.910
(0.857, 0.965),
72.3%
0.925
(0.831, 1.031),
77.8%
−0.008
(−0.020, 0.005),
76.2%
125
(50, 200)
Serious adverse
events as deﬁned by
authors
4 31745 30632 0.987
(0.785, 1.242),
69.9%
1.500
(0.748, 3.006),
67.8%
0.000
(−0.002, 0.003),
73.6%
***
Seizures 2 33810 33804 1.095
(0.721, 1.664),
88.7%
0.957
(90.255, 3.598),
88.2%
0.000
(−0.002, 0.002),
89.2%
***
** NNT cannot be calculated; ***NNT result suggests that vaccination could beneﬁt as well as harm.
P1443 HPV vaccine awareness and willingness of ﬁrst-year
students entering university in western Turkey
R. Durusoy*, M. Yamazhan, M. Tasbakan, I. Ergin, M. Aysin,
H. Pullukc¸u, T. Yamazhan (Izmir, TR)
Objectives: This study were to assess the level of knowledge on HPV
and HPV vaccination, and to determine vaccination attitude among
university students in Izmir, Turkey.
Methods: A cross-sectional survey was conducted among students
of Ege University enrolled in ﬁrst-year English preparatory class. A
systematic cluster sampling was applied and 717 (72.6%) of students
registered to the 54 classes selected were contacted. Students were from
17 different faculties/schools. Data were collected between April 30
and May 18, 2010, through a self-reported questionnaire including 40
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questions. A knowledge score was calculated by summing up the number
of correct answers given to the 12 knowledge questions. Analyses were
done using t-test, chi-square test, univariate and multivariate logistic
regression.
Results: The mean age of participants was 19.7±1.5 and 445 (62.1)
were female. Overall, 132 (18.9%) had sexual intercourse, and only 7
of them female. Among participants, 24.1% had heard of HPV and
25.1% about HPV vaccine. The knowledge item with the highest correct
answer rate (32.3%) was that HPV caused cervical cancer. The mean
total knowledge score was remarkably poor (1.8±2.6 over 12 items), with
59.6% of respondents having zero as their score. There was no difference
in mean knowledge scores between males and females. Higher income,
history of sexual intercourse and higher knowledge score were signiﬁcant
factors increasing HPV and vaccine awareness for the whole group,
adjusted for gender. Genital cancer history in the family signiﬁcantly
increased awareness, but only among girls. Only three students (0.4%)
had already been vaccinated, all being female. Among females, 11.6%
intended to be vaccinated vs. 10.1% for males, without a signiﬁcant
difference. Visiting a gynaecologist/urologist in the last three years, a
history of genital cancer in the family, vaccine awareness, a higher total
knowledge score, and being from the East of Turkey were signiﬁcant
predictors of a positive vaccination attitude.
Conclusion: HPV and vaccination still remain as a ‘hot medical topic’
in Turkey, since it hasn’t yet become a popular health issue. Based on
their age of ﬁrst intercourse, ﬁrst year at the university seems to be
appropriate timing to inform Turkish girls, whereas it is a bit late for
boys. Thus, the integration of HPV education to secondary/high schools
could be considered.
P1444 Vaccine status of Streptococcus pneumoniae evaluated with
a 12 plex luminex based method: comparison of data from
a 6 plex ELISA versus a 12 plex luminex method
B. Kantsø*, K. Krogfelt, C. Jørgensen (Copenhagen, DK)
Objectives: The level of antibodies against Streptococcus (S) pneumo-
niae is used as a predictor of protection against invasive pneumococcal
diseases. Since 1995 an ELISA measuring total Ig for 6 serotypes has
been used to determine the immune status. This is changed from the
beginning of 2011 to a multiplexed Luminex assay measuring IgG for
12 serotypes. The protective level of antibodies directed against the
serotypes in the polysaccharide vaccine has to our knowledge never been
established, though a protective level of 1mg/ml has been suggested. For
the conjugated vaccine a protective levels of 0.35mg/ml has been found.
Therefore the objective of this study is to compare the protective level
of antibodies obtained by the ELISA method against the data obtained
with the new Luminex method for the polysaccharide vaccine.
Methods: The ELISA measures total Ig antibodies against serotypes 1,
4, 7F, 14, 18C, and 19F, whereas the 12 plex Luminex assay measures
IgG antibodies against serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A,
19F and 23F.
Samples sent to our laboratory for routine analysis of antibody levels
against S. pneumoniae were analyzed with the new 12 plex Luminex
assay, and data compared with the results from the ELISA. For this
study, the ELISA results (protected or unprotected) are used as the “gold
standard”.
Results: The outcome of the ELISA is compared with the levels of
antibodies found using the Luminex assay.
As expected, the results from the comparison of the putative protective
levels of antibodies shows that 72% of the samples from unprotected
patients have GM above the protective level used for the conjugated
vaccine (0.35mg/ml) and therefore this level cannot be applied to the
polysaccharide vaccine.
A protective level of 1 mg/ml is suggested, since this corresponds better
with the ELISA. When applying this level, 68% of the unprotected
patients is below and 72% of the protected patients is above this cut
off.
Conclusion: The protective level from the conjugated vaccine cannot be
applied to the polysaccharide vaccine due to a higher antibody level from
the polysaccharide vaccine. We suggest a protective level of 1mg/ml for
the polysaccharide vaccine.
P1445 Safety and immunogenicity of an inactivated pandemic
H1N1 vaccine provided by the Thai Ministry of Public
Health as a routine public health service
O. Kankawinpong, C. Sangsajja, A. Chonlapan, W. Manosuthi*,
V. Thientong, P. Noitung, P. Puthavathana (Nonthaburi, Bangkok, TH)
Background: The national vaccination program against the 2009 H1N1
virus was implemented in high risk populations in Thailand, including
frontline medical personnel. Therefore, the safety and immunogenicity
were studied.
Methods: Following immunization with 15 microgram of unadjuvanted
inactivated H1N1 inﬂuenza vaccine in the ﬁrst 252 participants,
assessment of adverse events (AEs) by interviewing was performed
at Day 2, Day 7 and Day 21 postvaccination. Immunogenicity testing,
measured by hemagglutination inhibition (HAI) assay, was obtained on
Days 0 and 21.
Results: Of 252 participants, mean±SD age was 45±11years, body
weight was 62±13 kilograms and 65% were female. Seventy percent
were healthy personnel, 28% were patients with chronic illnesses, and 2%
were pregnant women. Median (IQR) hemoglobin was 13.0 (12.3–13.9)
mg/dL, aspatate aminotransferase was 18 (13−22) U/L and creatinine
was 0.7 (0.6−0.9) mg/dL. No serious systemic AEs were reported after
vaccination. Mild erythema and local reaction at Day 2 were reported
in 9% (23 of 252). The HAI geometric mean titers (GMTs) was 6.9 at
Day 0 and 33.4 at Day 21 (4.8 times compared to Day 0; P< 0.001, by
repeated measurement analysis). At Day 0 and Day 21, proportion of
subjects with HAI titers 40 was 7.5% (19 of 252) and 51.2% (129 of
252), respectively. Of all, four-fold rising of HAI titers was 56% (142 of
252). Of 19 subjects with Day 0 HAI titers >40, 10 (53%) had four-fold
rising of HAI titers after vaccination. By multivariate analysis, a factor
‘older age’ was associated with lower Day 21 log10HAI titer (P = 0.001,
b =−0.016, 95%CI of b: −0.026 to −0.007). The age ranged ‘20−34’,
‘35−49’ and ‘50−65’ years had percentage of participants with HAI
titers >40 at Day 0 vs. Day 21 HAI titers of 1.8% vs. 68.8% (P = 0.041),
7.0% vs. 50.0% (P = 0.006), and 2.2% vs. 36.7% (P = 0.132), respectively.
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Conclusions: Monovalent H1N1 vaccination was found to be safe and
well tolerated without serious AEs. Over all antibody response rate after
one dose of vaccination in this study is relatively low, especially in the
old age group. Thus, a booster H1N1 vaccination is needed.
P1446 Preclinical development of a bio-conjugate vaccine against
Staphylococcus aureus disease
V. Gambillara*, J. Lee, K.A. Kelley, K. Shields, M. Shields, C. Alaimo,
D. Desgrandchamps, G. Lipowsky, M. Kowarik, M. Wacker (Schlieren,
CH; Boston, US)
Objectives: S. aureus is a leading cause of serious infections. Antibiotic
therapy is compromised by the frequent and rapid appearance of
resistance. Control of S. aureus relies on hygienic measures and
screening. Prevention by vaccination would substantially reduce the
medical and economic impact of these infections.
Methods: GlycoVaxyn has developed a proprietary technology that
enables the manufacture of immunogenic glycoprotein bioconjugate
vaccines in bacterial cells. In an in vivo protein glycosylation system
polysaccharides are enzymatically transferred to a protein of choice. A
bioconjugate containing S. aureus capsular polysaccharide CP5 and the
carrier protein rEPA (nontoxic recombinant P. aeruginosa exotoxin A)
was produced. The vaccine was puriﬁed, characterized, and injected into
mice, rabbits and rats to demonstrate immunogenicity. Vaccine efﬁcacy
was demonstrated in in vivo mice models and in vitro opsonophagocytic
assays.
Results: Immunogenicity of the CP5-EPA conjugate was observed in
mice and rats with different doses of CP5. The immune response was
signiﬁcantly higher in rats injected with the 0.2 mcg dose compared to
2.5 mcg. An increase in the CP5-speciﬁc immune response was seen in
all groups after the second injection of CP5 conjugate. Animals tested
for antibodies against the protein carrier rEPA showed also a positive
response.
High-titer rabbit antibodies to CP5-EPA promoted opsonophagocytic
killing of all ﬁve S. aureus strains tested in an in vitro assay with human
neutrophils. Passive immunization with CP5-EPA antibodies protected
mice against bacteremia. Likewise, active vaccination of mice provided
protection from S. aureus bacteremia, weight loss, and renal abscess
formation. A signiﬁcant reduction in the bacteremia level between the
mice immunized with 0.2−1mcg CP5 and the control group was observed
for most of the tested S. aureus strains. Similar bacteremia levels were
observed for all the vaccinated groups (0.2 and 1 mcg of CP5), and a
correlation between CP5-antibodiy titer and protection was found.
Conclusion: An in vivo synthesized, bioconjugate vaccine containing
S. aureus polysaccharides and rEPA proved to be immunogenic and
protective in pre-clinical studies. The S. aureus bioconjugate will now
be evaluated in clinical trials and further developed with the ultimate
goal of a vaccine containing both polysaccharide and protein antigens
from S. aureus.
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P1447 Chelation of nickel cations by the urinary antimicrobial ni-
troxoline (5-nitro-8-hydroxyquinoline) inhibits urease activ-
ity and stone formation in clinical isolates of Proteus mirabilis
A. Sobke*, S. Sachse, C. Ba¨r, C. Ranke, E. Straube, W. Pﬁster (Jena, DE)
Objectives: Urease synthesis during UTI with P. mirabilis constitutes an
important virulence factor, as the generation of NH4+ and CO2 will
cause an increase in pH with subsequent precipitation of phosphate
salts and formation of septic kidney and bladder stones. Infections
are therefore often found in patients with catheters, stents or other
urinary ﬂow disturbances and are extremely difﬁcult to clear. Apart from
lithotripsy and surgical intervention, antibiotics and acetohydroxamic
acid (AHA) are currently the only therapeutic options. AHA functions
as an urease inhibitor by binding to the Ni2+ containing active centre
of the enzyme. However, AHA is only effective when combined with
antibiotic treatment and has severe side effects. In contrast, nitroxoline
(NIT) is an antibiotic that functions by chelation of di- and trivalent
cations, has no reported serious side effects and has been licensed for
the treatment and prophylaxis of complicated UTI. We thus examined
the potential of NIT as a possible alternative.
Methods: P. mirabilis UT isolates were collected during routine
diagnostic procedures and MIC determined in MH or in artiﬁcial urine
with 2% TSB by the broth microdilution method. Bacteria were grown
in MH broth containing 12 g/L urea and late logarithmic growth cultures
harvested by centrifugation. Pellets were resuspended in artiﬁcial urine
with or without NIT and supplemented with or without Fe2+ or Ni2+.
At regular intervals, precipitates and supernatants were collected by
centrifugation and the pH measured. NH4+ in the supernatant was
determined by the indophenol method and carbonate in the sediment
by staining with alizarin red S.
Results: All P. mirabilis isolates tested were found NIT susceptible by
agar diffusion testing (breakpoint 18mm) and MIC values lay between
2−16mg/mL. In comparison, MIC in artiﬁcial urine were typically
1−2 titers lower. The maximal pH increase was observed after 50−55
minutes reaching a plateau at about pH 9. This was accompanied by
a corresponding increase in NH4+ and the formation of a calcium
containing precipitate. Inclusion of 200mg/mL NIT (1.05 mM) resulted
in the complete inhibition of all these effects. In the presence of 100mM
Ni2+ this blockage was partially resolved, whereas Fe2+ was without
any effect.
Conclusion: NIT completely inhibits the urease activity of P. mirabilis
at concentrations found in urine by chelation of Ni2+. Further studies
will be warranted to conﬁrm its activity in vivo.
P1448 Uncovering the mechanism of action of the phenothiazine,
thioridazine, using Salmonella typhimurium as a model
bacterium
M.P. McCusker*, M.S. Martins, M. Viveiros, L. Amaral, S. Fanning
(Dublin, IE; Lisbon, PT)
Objectives: To study the mechanism of action of Thioridazine (TZ),
using Salmonella enterica serovar Typhimurium as a model bacterium.
Methods: The MIC of thioridazine (TZ) was determined using
the microbroth dilution method. Analysis of growth kinetics of
S. Typhimurium SL1344 in the presence of 0, 50, 100, 150 and
200mg/L of TZ were assessed at 370C with shaking (200 rpm). The
effect of exposure of S. Typhimurium to sub-MIC concentrations of
TZ was assessed using Transmission Electron Microscopy (TEM) and
standard protocols. Membrane permeability on exposure to sub-MIC
concentrations of TZ was measured using the H33342 bisbenzimide
accumulation assay (Piddock et al., 2010). Gene expression analysis
was determined using microarray and RT-qPCR analysis. Generation
of S. Typhimurium mutants was carried out using the lambda Red
recombination method (Datsenko and Wanner, 2000).
Results: The MIC of TZ for all Salmonella serovars tested was
200mg/L. S. Typhimurium treated with 200mg/L of TZ exhibited
discernable changes in the morphology of the cell but in particular
in the cell-envelope, while untreated cells showed normal envelope
morphology. Changes to the cell-envelope were observed after only 5
min exposure. These changes to the cell-envelope increased as a function
of time and showed an apparent loss of cell integrity after only 30
minutes. In the absence of TZ there is little accumulation of H33342,
while a concentration of 50mg/L of TZ rapidly promoted accumulation,
indicating an increase in membrane permeability. Microarray analysis
identiﬁed a number of genes involved in drug resistance and envelope
stress that were upregulated in the presence of TZ. These included marA,
ramA, soxRS, acrB, tolC, the cpx operon as well as a number of sigma
factors. Deletion of ramA, acrB or tolC resulted in a >2-fold increase
in the MIC for ramA and a >8-fold increase for both acrB and tolC.
Conclusion: The results obtained in this study suggest that TZ acts by
targeting the cell-envelope. When exposed to TZ cellular permeability
increases, resulting ultimately in the loss of cell integrity. Findings that
S. Typhimurium responds to the in vitro presence of TZ by activating
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genes involved in drug resistance and envelope stress responses support
this hypothesis.
P1449 Fluoroquinolones induce the expression of smaqnr, a
chromosome-encoded quinolone resistant determinant, in
Serratia marcescens
A. Briales, J.M. Rodrı´guez-Martı´nez*, C. Velasco, A´. Pascual (Seville,
ES)
Objectives: A new pentapeptide repeat protein, named SmaQnr, has
been recently reported from the chromosomal of Serratia marcescens.
This protein confers low level quinolone resistance when expressed in
Escherichia coli. The up-stream sequence of this gene contains putative
LexA box, similar to that found in qnrB1 whose expression is regulated
by SOS system. The aim of this study was to evaluate if smaqnr gene is
induced by SOS activators such quinolones.
Methods: Three clinical strains of S. marcescens, S. marcescens 257
reference strain (Institute Pasteur collection) and Escherichia coli J53
carrying a natural plasmid that harboured qnrB1 as control were used in
this study. Expression of smaqnr gene was analyzed by real time RT-PCR
and quantiﬁed in relation to that of rpoB gene for S. marcescens and
mdH gene for E. coli. The ﬂuoroquinolones (FQ) ciproﬂoxacin (CPX),
moxiﬂoxacin (MXF) and levoﬂoxacin (LVX) were tested as possible
inducers of the expression of smaqnr gene. Strains were grown at 37ºC
to exponential phase (DO620nm=0.3−0.4) and then the FQ inducers
were added in function of MIC (1/2, 1/4, and 1/8 of MIC values of each
one) during 45 minutes, leaving one culture as control. RNA extraction
was performed using RNeasy Mini kit (Qiagen). Normalized expression
levels of the target gene transcripts were calculated relative to rpoB
(mdH in E. coli) using the 2-DDCT method.
Results: All S. marcescens strains were susceptible to FQ and a LexA
box (CTGTATAAATAAACAGG) was present up-stream of smaqnr
genes. Induction was observed in two clinical isolates (Sm5 and Sm8)
and S. marcescens 257 strain. CPX induced the expression 2- to 8-folds
compared to the controls depending of induction conditions. MFX
induced the expression 2- to 4-folds and LVX induced the expression
4- to 20-folds compared to the controls. For LVX the highest value was
reached by Sm8 clinical isolate (up to 18-folds) while for CPX and MXF
the highest level of induction was found in Sm5 clinical isolate (up to
8-folds). The control E. coli harbouring a natural qnrB1-plasmid show
an induction of qnr gene expression quinolone concentration dependent
as expected.
Conclusions: CPX, MXF and LVX induce smaqnr expression in Serratia
marcescens and could participate in emergency response against these
antimicrobial agents. Whether this phenomenon occurs in other species
harbouring chromosomal pentapeptide repeat protein is unknown.
P1450 The biological ﬁtness cost and mutation frequency associated
with MDR development in Acinetobacter baumannii
P. Komp Lindgren*, O. Klockars, H. Seifert, O. Cars (Uppsala, SE;
Cologne, DE)
Objectives: To study the biological ﬁtness cost (BFC) and mutation
frequency (MF) associated with stepwise in vitro selection of MDR in
A. baumannii (AB).
Methods: The ATCC 19609 strain (WT) was used to select single,
double and triple MDR mutants. To determine the MF of antibiotic
resistance development, ten ON cultures (WT or mutant) were plated
onto antibiotic containing MH-agar plates (rifampicin (RIF, 5mg/mL),
tigecycline (TGC, 5mgmL) or colistin (COL, 100 mgmL). After 24−48 h
MF was determined for each selection step and drug combination.
Mutants were collected and MICs for each mutant was veriﬁed by
E-test. To assess changes in BFC the growth rate for all mutants was
measured. Four independent cultures/mutant, were used to determine the
doubling time in Mueller Hinton broth. Doubling time for each mutant
was compared with WT and related antibiotic resistance mutants.
Results: MF and BFC values are summarised in the table. No 3rd
step mutants were obtained even when 1010 cells were plated. MICs
for RIF, TGC and COL mutants were >32mgmL, 1.5−24mgmL and
0.25–192mgmL, respectively. However for some 2nd step RIF and TGC
mutants (selected from a COL-R background) colistin resistance was
lost. The doubling time (DT) for WT was ~25 min and was set as 100%
ﬁt. DT of resistant mutants was related to WT DT and presented as
% change in BFC compared to WT. RIF-COL and TGC-RIF mutants
suffered most loss of ﬁtness.
Conclusion: In AB, MDR development is of huge concern and to
date little is known about MFs and BFCs impact on drug resistance
development. With the in vitro selection of MDR, the MF decreased
with each selection step. This is probably due to the increased cost in
bacterial ﬁtness for each mutational event, which is reﬂected by the
drop in DT in resistant mutants. BFC is frequently connected with drug
resistant development and are often compensated by intra and extragenic
mutations. This is thought to be one way of evolution to sustain MDR
resistance. This study invites studies to prove that the use of combination
treatment could prevent MDR development, by lowering the probability
of selecting antibiotic resistant mutants that can be enriched during
treatment.
P1451 Effect of colistin exposure and growth phase on the surface
properties of live Acinetobacter baumannii cells examined
by atomic force microscopy
R. Soon, R. Nation, M. Harper, B. Adler, J. Boyce, R. Tan, J. Li*,
I. Larson (Melbourne, AU)
Objectives: The dry antibiotic discovery pipeline has forced the revival
of Col as a last line of defence for Gram-negative ‘superbugs,’ such
as Acinetobacter baumannii. The complete loss of lipopolysaccharide
(LPS) arising from mutations in lipid A biosynthesis genes, mediates
Col resistance in some A. baumannii strains; however, characterisation
of Col resistance in A. baumannii warrants greater attention.
Methods: Two Col-heteroresistant A. baumannii strains ATCC 19606
and a clinical isolate (Col MICs 1mg/L), and their paired Col-resistant
strains were employed. Bacterial cells were immobilised on clean glass
slides coated with gelatin. Live/Dead BacLight™ and confocal laser
scanning microscopy were employed to determine the viability of cells
which were untreated and treated with Col before immobilisation. AFM
examination was conducted for the morphology and surface properties
of hydrated Col-susceptible and resistant A. baumannii at mid-log and
stationary growth phase, and in response to Col treatment at 1 and
32mg/L for 20 min at 37ºC. The contribution of LPS to surface
properties was investigated using A. baumannii strains constructed with
and without the lpxA gene.
Results: Superior immobilisation was achieved for Col-susceptible
cells in comparison to resistant cells; the latter required a longer
duration (at least 1 h) to adhere securely to the gelatin surface. Rod-
like Col-susceptible cells (length 2.62±0.40mm) were distinguished
from spherical Col-resistant cells (diameter 1.72±0.25mm); the latter
aggregated in small clusters or chains. The cell membranes of
strains of either phenotype remained intact following Col treatment,
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and comparative measurements of surface roughness did not reveal
differences between samples. Bacterial spring constant measurements
revealed that Col-susceptible cells were signiﬁcantly stiffer than resistant
cells at both growth phases (p< 0.01), while Col treatment at 32mg/L
resulted in more rigid surfaces for both phenotypes. Multiple, large
adhesive peaks frequently noted from force curves captured on Col-
susceptible cell, were not evident for Col-resistant cells. Adhesion events
were markedly reduced following Col exposure.
Conclusions: This study is the ﬁrst to employ AFM to examine the
morphological and surface properties of hydrated Col-susceptible and
resistant A. baumannii cells, and provides important insights into the
understanding of Col action in this problematic pathogen.
P1452 Ribosomal mutations associated with ketolide resistance
in Haemophilus inﬂuenzae found in the SENTRY
Antimicrobial Surveillance Program
D. Farrell*, L. Deshpande, R. Mendes, R. Jones (North Liberty, US)
Objectives: To determine the mechanisms of ketolide resistance in
H. inﬂuenzae. Ketolide resistance is very rare in H. inﬂuenzae and
is usually associated with a variety of ribosomal mutations. We
report on the ribosomal mutations detected in 9 telithromycin (TELI)-
resistant H. inﬂuenzae found in the SENTRY Program (2009) and
assess the activity of solithromycin (SOLI, formerly CEM-101), a new
ﬂuoroketolide in clinical development.
Methods: 1,198 H. inﬂuenzae isolates obtained from patients with
community-acquired bacterial pneumonia in 24 countries were tested for
susceptibility to TELI by CLSI methods (M07-A8 and M100-S20-U) as
part of the SENTRY Program during 2009. Only nine (0.8%) isolates
were found to be TELI-resistant (MIC, 16mg/L). Extended MICs were
performed by Etest and strains were screened for mutations in the 23S
rRNA, L22 and L4 proteins by PCR and DNA sequencing.
Results: Seven different mutation patterns were observed in 8 of the 9
strains. No mutations were detected in the genes sequenced for one strain
(Isolate 3042). The highest TELI MIC values (>256mg/L) were found in
two geographically diverse (Sweden and USA) strains with a 23S rRNA
A2059G mutation. H. inﬂuenzae with L4 and L22 riboprotein mutations
showed TELI MIC values from 32 to 256mg/L. TELI was 1.5- to at least
4-fold more active than azithromycin (AZI); and SOLI was 2- to at least
4-fold more active than TELI. Against all 1,198 H. inﬂuenzae isolates,
the MIC50/90 for TELI and SOLI were 1/4 and 1/2mg/L, respectively.
Conclusions: Ketolide resistance in H. inﬂuenzae continues to be
rare (<1%) globally. Resistance was found to be associated with a
variety of ribosomal mutations and was widely distributed geographically
thus suggesting a lack of both local and global spread. Although
solithromycin MIC results were 2- to at least 4-fold lower than
telithromycin against these strains, cross-resistance to solithromycin was
conﬁrmed. The mechanism of ketolide resistance in one UK strain is
under further investigation.
P1453 Effect of E-101 solution and its oxidative products
on microbial ultrastructure changes associated with
microbicidal action
G.A. Denys*, M.P. Goheen, R.C. Allen, P. O’Hanley, J.T. Stephens
Jr. (Indianapolis, Omaha, Little Rock, US)
Objective: E-101 Solution (E-101) is a novel cell free myeloperoxidase-
mediated antimicrobial developed for topical application directly into
surgical wounds. It is composed of 1) porcine myeloperoxidase (pMPO)
and glucose oxidase (GO), 2) glucose, 3) sodium chloride, and 4) speciﬁc
amino acids. Once activated, hydrogen peroxide (H2O2) is produced
in situ by GO dehydrogenation of glucose and reduction of oxygen.
The MPO-catalysed oxidation of chloride ion by H2O2 generates
hypochlorous acid (HOCl). Once generated, HOCl reacts in a diffusion-
controlled reaction with a second H2O2 molecule to yield singlet oxygen.
We evaluated the treatment effects of E-101 and its oxidative products
on ultrastucture changes and microbicidal activity against methicillin-
resistant Staphylococcus aureus (MRSA) and Escherichia coli.
Methods: Time kill and transmission electron microscopy (TEM) studies
were performed on MRSA ATCC 43300 and E. coli ATCC 25922
using proposed therapeutic doses of E-101 (150 and 300 GU/mL) and
formulations with pMPO or GO omitted. For TEM, early exponential
phase growth were exposed to each formulation and sampled at 0, 30,
60, and 120 min. Bacteria were ﬁxed in 3.0% glutaraldehyde, embedded
and thin sectioned for analysis.
Results: E-101 demonstrated rapid bactericidal activity and dramatic
effects on S. aureus and E. coli morphology characterized as
septal deformation. Both formulations of E-101 induced cytoplasmic
membrane inclusions (mesosomes) in S. aureus indicating a membrane
effect. Increase vacuolation of the cytoplasm and cell ghosts were also
observed. E. coli appeared elongated with no visible septa, highly
vacuolated cytoplasm with pleated cell walls compared to controls.
When GO was omitted from the formulation no antimicrobial activity
or cellular damage was observed. When pMPO was omitted from the
formulation, only increased vacuolation due to H2O2 was observed at
the longer exposure times. High levels of H2O2 generated from GO
and glucose demonstrated microbicidal activity with minimal cellular
damage.
Conclusions: E-101 is a potent myeloperoxidase enzyme system
with multiple oxidative mechanisms of action. Ultrastuctural analysis
following E-101 treatment showed targeted septum formation in both
S. aureus and E. coli. Induction of mesosomes in S. aureus by E-101 is
indicative of an effect on the cytoplasmic membrane.
P1454 Antibacterial mode of action and resistance studies with
the silver cation (Ag+) in Staphylococcus aureus
C. Randall*, L. Oyama, J. Bostock, I. Chopra, A.J. O’Neill (Leeds, UK)
Objectives: Compounds containing Ag+ are commonly used to treat
and prevent bacterial infection in burns and chronic wounds. However,
the antibacterial mode of action of Ag+ remains poorly characterised.
Furthermore, the current susceptibility levels of clinical isolates towards
Ag+ and the propensity for bacteria to develop Ag+ resistance have not
been established. Here we present a series of studies to investigate these
aspects in Staphylococcus aureus.
Methods: Membrane integrity of S. aureus SH1000 exposed to Ag+ (in
the form of silver nitrate) at 4x the minimum inhibitory concentration
(MIC) was examined using the BacLight® assay, and by measurement
of potassium ion (K+) leakage from cells using atomic absorption
spectroscopy. Bacteria were examined for morphological changes using
scanning electron microscopy (SEM) after exposure to Ag+ at 4x MIC
for 5 and 120 min. Silver nitrate MICs were determined by agar
dilution for a collection of S. aureus isolates (n = 833) collected from
hospitals across Europe between 1997 and 2010. To examine the in vitro
development of staphylococcal resistance to Ag+, S. aureus SH1000
was subjected to continuous subculture in the presence of sub-MIC
concentrations of Ag+ for up to 42 days.
Results: Membrane integrity decreased by 97% after 10 min exposure
to Ag+ as determined by the BacLight® assay, coinciding with 96%
loss of intracellular K+. SEM revealed no morphological changes in
bacteria exposed to Ag+. All clinical S. aureus isolates were susceptible
to 8−16mg/L silver nitrate. Reduced susceptibility to Ag+ was not
observed in S. aureus SH1000 following 42 days continuous challenge
with sub-MIC concentrations of Ag+.
Conclusions: Although no overt cell lysis occurred in cells following
challenge with Ag+, the rapid and extensive loss of membrane
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integrity observed strongly suggests that the antibacterial activity of
Ag+ results directly from damage to the bacterial membrane. The
universal susceptibility of staphylococcal isolates to Ag+, coupled with
the inability to select endogenous resistance upon extended exposure
to Ag+, conﬁrm that silver compounds remain a viable alternative to
antibiotics for the treatment of topical staphylococcal infections.
P1455 Detection of lymphogranuloma venereum based on the
deletion in pmpH gene may underestimate the extension of
the European outbreak
M. Rodriguez-Dominguez*, T. Puerta, J.M. Gonzalez-Alba, B. Mene´ndez,
F.J. Gonzalez-Sainz, R. Canton, J. del Romero, J.C. Gala´n (Madrid, ES)
Objective: During the last decade, an increase number of linfogranoloma
venereum (LGV) L2b-serovar has been described in Europe. According
to a low number of known sequences, different multiplex real-time PCR
assays were adapted to detect simultaneously Chlamydia trachomatis
and LGV. They were based on the detection of ompA gene or multicopy
criptic plasmid and an internal deletion in pmpH gene, respectively. In
this study we evaluate the usefulness of this deletion to detect LGV
clinical strains.
Methods: C. trachomatis was detected in 130 rectal samples from men
who have sex with men (MSM) with proctitis using BD ProbeTec-ET
system and Abbott RealTime CT/NG. In order to speciﬁcally detect
L-serovars, a second real-time PCR was performed based on the deletion
in pmpH described in all known sequences of LGV, according to the
literature. Independently of the real-time PCR result, the complete
ompA gene and a fragment of pmpH gene (400bp) were sequenced.
Phylogenetic analyses with clinical and reference sequences of ompA
and pmpH were constructed using PhyML method.
Results: 32/130 (24.6%) were positive for LGV by real-time PCR based
on internal deletion of pmpH gene. Sequencing of ompA gene conﬁrmed
that they are highly associated with L2b-serovar. Phylogenetic analysis
with ompA sequences from clinical and reference strains revealed the
differentiation of three seroclass clusters, which do not correlate with
disease phenotype, being all LGV-PCR positive samples included in
B-class (next to D, B, E, L1 and L2/L2b). Interestingly 22 sequences
initially LGV-negative (22.4%, 22/98), were also clustered with B-class.
Phylogenetic tree of pmpH gene from clinical and reference sequences
showed three pathobiotypes (ocular, urogenital and LGV) with bootstrap
value >95%. The LGV cluster included those 32 LGV-positive based on
real-time PCR but also those 22 LGV-negative. The 22 LGV-negative
did not carry the deletion in pmpH widely used in diagnosis.
Conclusion: A high proportion of clinical strains of LGV were found
without the deletion in pmpH gene widely used in the diagnosis of
LGV. This result revels that this new variant will be not detected in the
clinical setting which may underestimate their detection in the L2b-
serovar European outbreak. This ﬁnding has important public health
consequences for the management and control of this epidemic.
P1456 Pharmacoeconomic analysis of perioperative antibiotic
prophylaxis application in Lombardy, Italy
P. Scarpellini*, G. Vighi, E. Spreaﬁco, G. Barranco, V. Conti, C. Tassan
Din, G. Genduso on behalf of the PAC Project Regional Group
Objectives: This study analyzes the actual cost of perioperative antibiotic
prophylaxis (PAP) in our region and compares it with the ideal cost of
an appropriate antibiotic prophylaxis according to an evidence-based
protocol.
Methods: We performed a cross-sectional analysis of PAP in 7 major
general hospitals (986 beds each on average) in Lombardy. We evaluated
the appropriateness of: the PAP prescription, the choice of drug and the
PAP duration. The analysis included 2.0% of all surgical procedures
performed in these hospitals in two different semesters (2007-T0 and
2009-T1). Sample selection occurred as follows: 1) each hospital
analyzed the clinical records of 2.0% of surgical activity performed in
periods listed above; 2) the analysis comprised 2.0% of every type of
operation (according to ICD9 CM codes). The cost of each antibiotic
was assumed to be half of the list price, that is the hospital price in Italy.
Data regarding T1 are shown here.
Results: We analyzed 2285 records and identiﬁed 6 sample groups:
1. PAP not performed and not expected, 445 pts; 2. PAP correctly
performed and expected, 485 pts; 3. PAP not performed, but expected,
228 pts; 4. PAP performed, but not expected, 153; 5. PAP expected
but performed with an incorrect drug, 517 pts; 6. PAP expected but
inappropriate prolongation of antibiotic course, 457 pts. The theoretical
cost of PAP in our sample should have been €4,915.95 (mean cost
per pt €2.15, 95%CI 2.08–2.23), while the actual cost of PAP plus
unnecessary prolonged antibiotic courses was €22,036 (mean cost per pt
€9,66, 95%CI 8.88–10.44). In 2009, the surgical interventions performed
were 111,917 in the 7 hospitals under study, and 846,372 in Lombardy.
According to our data we can estimate that the mean difference
between real and theoretical cost per pt is €7.51 (95%CI 6.74–8.28):
€5.32 (95%CI 4.66–5.96) for unnecessary antibiotic therapy, and €2.19
(95%CI 1.82–2.54) for the increasing cost of inappropriate PAP. Hence,
applying an appropriate PAP, we could save each year €840,440 (95%CI
753,937–926,943) in our 7 hospitals (€595.905 for unnecessary antibiotic
therapy and €244,167 for inappropriate PAP) and €6,355,826 (95%CI
5,701,645−7,010,008) in Lombardy.
Conclusion: PAP is often inappropriate in our hospitals in Lombardy
and the implementation of a common, evidence-based protocol could
signiﬁcantly reduce PAP cost, as well as unnecessary antibiotic
administration and therefore antibiotic resistance.
P1457 Granulomatous diseases following treatment with anti-TNF
therapies
D. Ersozlu Bozkirli, T. Turunc*, A. Gorek Dilektasli, E. Yucel (Adana,
Ankara, TR)
Objective: In this study, we have aimed to determine the prevalence of
granulomatous diseases following anti TNF therapy.
Methods: We retrospectively analysed the clinical data of 142 patients
who were treated by anti-TNF therapies between April, 2005 and
December, 2010 in Department of Rheumatology. All of the patients
underwent routine Tuberculin Skin Test (TST) before starting anti-TNF
therapy. Patients with an induration of 5mm received a nine months
preventive therapy with isoniazid. In these patients with positive TST
results the anti-TNF thearpy was started at least three weeks after starting
preventive chemotherapy with isoniazid. A second TST was performed
two weeks later if the initial TST was negative.
Results: Baseline characteristics, TST results, type of the anti-TNF
therapy, and the preventive therapy status of the subjects are shown in
Table-1. Granulomatous infections were diagnosed in two of 142 patients
and both of them recieved preventive chemotherapy with isoniazid for
nine months. One patient with ankylosing spondyilitis with 13mm
induration of TST and with known previous TB contact an active TB
patient received subcutaneous Etanercept therapy for six months. After
starting Inﬂiximab for recurrence of disease, TB lymphadenitis was
diagnosed at the 4th month of inﬂiximab therapy. Second patient with
rheumatoid arthritis received subcutaneous Etanercept therapy for 12
months. After starting subcutenous Adalimumab therapy for recurrence
of the disease, cutaneous leishmaniasis was diagnosed at the 10th month
of this therapy.
We did not observe development of TB in the subgroup that was treated
by Etanercept (60% of the study patients). Additionally, we did not
observe TB reactivation in two patients with rheumatoid arthritis who had
been treated for previous pulmonary TB during in last 2 years before
Etanercept therapy. These patients with rheumatoid arthritis has been
threated with etanercept for 30 and 42 months.
Conclusion: Undetection of TB reactivation after Etanercept therapy in
two RA patients who were treated for pulmonary TB was evaluated as
a meaningful data the drug reliability.
In our both patients, the granulomatous infection occured after the switch
of anti-TNF agent. Interestingly these patients were receiving Etanercept
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therapy before switchthing and did not develop TB. This data is a new
ﬁnding of our series.
As our study group is relatively small, furter studies are warranted in
larger series.
P1458 Campylobacter bacteraemia: a 10-year experience in a
single centre
K. Hussein*, Y. Shachor Meyouhas, A. Raz-Pasteur, I. Oren,
R. Finkelstein, I. Kassis (Haifa, IL)
Objectives: Campylobacter bacteremia (CB) is uncommon and occurs
particularly among patients with HIV, hypogammaglobulinemia and
in extreme ages. This study was designed to evaluate the clinical
characteristics and risk factors for CB in a tertiary referral center, serving
over a million citizens in northern Israel and over 40,000 blood cultures
taken a year.
Methods: Retrospective computerised data was retrieved from January
2000 to October 2010.
Results: There were 36 patients with CB including 10 patients less than
18 years of age including only 3 neonates and 7 patients were older than
65 years (mean age was 42 years, range 1 month-91 years). Common
underlying conditions were: hematological malignancy (16), solid tumor
(2), organ transplantation (2), chronic liver disease (3), and diabetes
mellitus (2). Three patients had underlying disease. Of notice, 23 (64%)
patients were on immunosuppressive therapy at the time of bacteremia.
The most common symptom among these patients was fever followed
by abdominal pain, diarrhea and vomiting. CB was asymptomatic in 3
cases. Three patients had a concomitant positive stool culture.
Campylobacter jejuni was the most common isolated species (15
isolates, 41.6%), followed by C. coli (4 isolates, 11%), C. fetus
(2isolates, 5.5%). Species were not identiﬁed in 15cases (41.6%).
Most isolates were susceptible to macrolide drugs (29/31 tested, 94%),
Aminoglycosides (23/24 tested, 96%) and clindamycin (18/20 tested,
90%). But 14/30 tested (53%) were resistant t ﬂuroquinolones. Antibiotic
treatment was given to 31 patients but it was adequate (according
to in vitro susceptibility) in only 18 patients (58%). The different
regimens included: quinolones, macrolides, penicillins, aminoglycosides,
combination of aminoglycosides and b-lactam drugs. Relapse occurred
in 3 patients. The thirty day mortality rate was 8.3% (3 patients); in only
one case mortality was due to CB.
Conclusion: In this study most episodes of CB occurred among severely
immunocompromised patients and were caused by C. jejuni. Mortality
rate was low despite the discrepancy between antibiotic regimens and in
vitro susceptibility results.
P1459 Therapeutical approach and prognostic factors in Listeria
monocytogenes meningitis
I. Pelegrin*, A. Ribera, C. Suarez, M. Moragas, R. Verdaguer,
S. Martı´nez-Yelamos, F. Gudiol, P.F. Viladrich, C. Cabellos
(L’Hospitalet de Llobregat, ES)
Background: LMM in adults is a severe infection whose best mode of
therapy (Tx) is not well established. We have analyzed prognostic factors
and Tx in all LMM cases treated in our hospital.
Methods: All cases of CNS infection are prospective and routinely
recorded. Diagnosis was made by compatible clinical features and
cytochemical CSF ﬁndings with positive CSF or blood culture.
Results: 59 pts (41 (69%) men), mean age 63±13 (range 29−94) have
been treated in 3 periods: 1977–1987 (16 pts), 1988–1998 (15 pts)
and 1999–2009 (28 pts, 21 in 2004–2009). 47 pts (80%) presented
underlying conditions: 14 (24%) diabetes, 14 (24%), steroidal therapy,
6 (10%) cirrhosis, 4 (7%) solid cancer, 3 (5%) hematological cancer, 1
(2%) other immunosuppressor (IS) Tx and 5 (8%) other IS diseases.
On admission 54 (91%) showed fever, 46 (78%) neck stiffness, 43
(73%) altered sensorium, 42 (71%) headache and 7 (12%) seizures.
Mean CSF WBC was 629±762 (51% lymphocytes). 48 pts (81%) had
positive CSF culture and 34 (58%) blood culture. 3 (5%) had positive
CSF Gram stain. Empirical antibiotic Tx was appropriate in 49 pts.
Final Tx consisted on 15 (25%) pts ampicillin (Amp), 12 (20%) Amp
+ aminoglycoside (AG) < than 1 week, 27 (46%) Amp + AG > than
1 week and 3 (5%) other therapies. AG was administered once a day
in 31/39 pts who received AG. Dexamethasone (DEX) as adjunctive Tx
the ﬁrst 48 h was used in 30 (51%) pts. Mean duration of Tx was 21
d. Hydrocephalus was present in 8 (14%) pts. Overall mortality was 14
(23.7%). Mode of Amp±AG Tx did not inﬂuence mortality. Use of DEX
was not related with a worse prognosis. Development of hydrocephalus,
age and presence of underlying disease were the independent mortality-
related factors (p< 0.05).
Conclusions: LMM is increasing their frequency in adults. Presence
of hydrocephalus, age and underlying disease are mortality prognostic
factors. Short course AG, AG administration once a day and early use
of DEX seem to be safe procedures in LMM.
P1460 Distinctive characteristics of pneumococcal meningitis in
cirrhotic patients
P. Pagliano*, V. Attanasio, M. Rossi, F. Fraganza, N. Carannante,
A. Pomicino, R. Di Sarno, M. Conte, F. Faella (Naples, IT)
Although susceptibility of cirrhotics to pneumococcal meningitis may be
postulated on epidemiologic and immunologic considerations, only few
data are available on this argument. Aim of the study was to determinate
the ﬁndings of pneumococcal meningitis in cirrhotics in respect to those
retrieved in non-cirrhotics.
Methods: This was a prospective study including adult patients observed
during a 13-year period who had pneumococcal meningitis conﬁrmed
by culture of blood or cerebrospinal ﬂuid (CSF) and characteristic
clinical ﬁndings. Clinical and laboratory data were collected for each
case, underlying diseases were evaluated and diagnosis of cirrhosis
was conﬁrmed by unequivocal clinical, laboratory and ultasonographic
ﬁndings. Statistical analysis was performed by two-tailed c2 test, Fisher’s
exact test, Spearman’s correlation, and by Mann-Whitney U-test.
Results: Two-hundred-two cases of pneumococcal meningitis were
included [median age 57 years (IQR 38−65), males 58%]. Cirrhosis was
diagnosed in 21 (10%) cases [median age 61 (IQR 53−68), males 67%].
Fourteen (67%) cases with cirrhosis reported extrameningeal infective
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foci. A higher proportion of patients with cirrhosis presented without
nuchal rigidity (10/21 Vs 43/181; c2 = 5.54, p = 0.018, 95% C.I. 1.2−3.4).
WBCs, neutrophils, platelets, and erytrocyte sedimentation rates were
lower in cirrhotics (Table). Streptococcus pneumoniae with reduced
susceptibility to penicillin was cultured more frequently among patients
with cirrhosis (10/21 Vs 48/181; c2 = 4.1, p = 0.04, 95% C.I. 1.1−3.0).
A comparable proportion (cirrhotics 52%, non-cirrhotics 49%) of cases
needed mechanical ventilation within 48 hours from admission. Overall
mortality rate was 28.2%. There was a correlation through mortality and
values of Child (rho 0.59, p = 0.003) and MELD (rho 0.68, p = 0.001)
scores.
Conclusion: Pneumococcal meningitis diagnosis may be troublesome
in cirrhotics, since we demonstrate that WBCs are frequently close to
the higher range of normality and half of the cases presents without
signs highly suggestive of bacterial meningitis such as nuchal rigidity.
When some diagnostic doubt exists, the evidence of extrameningeal
infective foci or rapidly worsening clinical conditions warrant CSF
analysis to establish the deﬁnite diagnosis. The frequent exposure to
antibiotics of cirrhotics justiﬁes the prevalence of S. pneumoniae strains
non-susceptible to penicillin reported. Mortality rate is related to liver
function.
P1461 Infections by Corynebacterium species in immunocompro-
mised and non-immunocompromised patients
I. Ferna´ndez-Natal*, J.A. Sa´ez-Nieto, S. Valdezate-Ramos,
R.H. Rodrı´guez-Polla´n, S. Lapen˜a, J.M. Guerra-Laso, F. Soriano
Garcı´a (Leo´n, Madrid, ES)
Objectives: Firstly, to evaluate the clinical signiﬁcance of Corynebac-
terium isolation from clinical samples taken to immunocompromised
(IC) and non-immunocompromised (non-IC) patients. Secondly, to
determine possible clinical differences among infected patients of both
groups (IC and non-IC).
Methods: During a 5 years period (2000–2004) all Corynebacterium
species isolated from 136 selected clinical specimens (94 blood cultures,
24 intravascular catheters, 5 vascular ulcer exudates, 1 deep bruise, 5
urines, 2 epidural catheters, 2 peritoneal ﬂuids, 1 joint ﬂuid, 1 pacemarker
and 1 sputum) were identiﬁed at species level by using API Coryne™,
V2.0, Biolog™ GP2, and 16S rDNA and rpoB.
The clinical signiﬁcance of each isolate was categorized by means of
clinical and epidemiological data as deﬁnitive or probable. All charts
were examined, and the main data noted. Patients were classiﬁed as IC
or non-IC, and differences between both groups were compared by the
EPIDAT program.
Results: A total of 108 patients were diagnosed of signiﬁcant clinical
infection by Corynebacterium spp.: 81 in IC (68 deﬁnitive, 13 probable)
and 27 in non-IC (26 deﬁnitive, 1 probable) patients.
The most frequent species identiﬁed in IC/non-IC patients were
C. amycolatum (23/4), C. jeikeium (12/4), C. striatum (10/5),
C. afermentans spp. afermentans (8/1), C. coyleae (7/2), C. urealyticum
(3/3), C. ureicelerivorans (2/3), C. imitans (1/2), C. mucifaciens (1/1),
C. simulans (1/1), C. xerosis (1/1). Twelve patients, all IC, had infections
by rare or non-identiﬁed species: C. appendicis (2), C. aurimucosum
(2), C. propinquum (1), C. pseudodiphtheriticum (2), C. riegelii (1), and
Corynebacterium spp. (4.
Table shows clinical data of 108 patients (81 IC and 27 non-IC) with
infections by Corynebacterium species.
Conclusions:
1. Infections were more common in males (IC: 66.6%/non-IC: 63.0%)
than in females.
2. Most patients had suffered recent invasive procedures (88.0%) and
were IC (90.1%).
3. Most patients were treated with glycopeptides, aminoglycosides and
penicillins
4. The outcome was mostly favorable (IC: 77.8%/non-IC: 74.1%).
5. The highest rate of history of recent invasive procedure (p = 0.041)
and increased use of glycopeptides (p = 0.026) in IC patients than in
non-IC, was probably due to the nature of the process and empirical
treatment with glycopeptides (and later maintained them) in IC
patients.
P1462 Viral infections and analysis of circulating immune
complexes in patients with Nijmegen breakage syndrome,
a cancer-prone disease with profound immunodeﬁciency
H. Gregorek, A. Zapasnik*, K.H. Chrzanowska, B. Kasztelewicz,
B. Pietrucha, E. Heropolitanska-Pliszka, K. Dzierzanowska-Fangrat
(Warsaw, PL)
Objectives: Nijmegen breakage syndrome (NBS) is an autosomal re-
cessive chromosomal instability disorder characterized by microcephaly,
growth retardation, radiosensitivity, combined immunodeﬁciency, in-
creased susceptibility to infection, and a high predisposition for the
development of lymphoid malignancy. Previously we reported on a high
prevalence of viral infections among NBS patients caused by viruses
known to be associated with lymphomas, with a high frequency of EBV
followed by HBV. Although in about 35% patients these viruses were
not detected or were only transiently present, formation of circulating
immune complexes (CIC) or non-speciﬁc aggregates could not be ruled
out.
The aim of the study was to assess whether the absence of detectable
genetic material of selected viruses in peripheral blood of patients with
NBS may be caused by their protection within a thick layer of serum
proteins or masked in the form of CIC.
Methods: A total of 52 patients from Polish registry in whom
detailed investigations conﬁrmed the diagnosis of NBS were periodically
monitored for humoral and cellular immune parameters, C3 and C4
complement components, and for selected viral infections by PCR
analysis. In patients with abnormally high activity or progressive
disruption of complement, immune complexes were isolated and viral
genetic material was analysed at the molecular level.
Results: Viral infections (EBV, HBV, HCV and/or CMV) were found in
65.2% patients. All of them were EBV DNA positive; persistent HBV
DNA was present in 9.6% patients, HCV RNA in 3.8% and CMV DNA
in 5.8%. “Transient” EBV DNA was observed in 3 patients and HBV
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DNA in 2. During follow-up severe decrease of C4 component was found
in 11 (21.2%) patients accompanied by deﬁcit of C3 component in 4 of
them. Two patients with negative and one with transiently detected HBV
DNA in whole serum have had detectable HBV DNA in CIC, while
EBV DNA was found in CIC from one patient.
Conclusion: Our results show that in patients with NBS viruses may
be hidden in CIC. Progressive hypocomplementemia may result from
increased consumption secondary to persistent CIC. This, in turn, may
be responsible for increased susceptibility to recurrent infections and
should be warning for clinicians.
The study was supported by grant No. NN407 1714 34 from the Polish
Ministry of Science and Higher Education
P1463 Studies on sepsis in haemodialysis patients
H. Iwabuchi*, T. Nakahara, M. Okamoto, M. Asano, K. Oguchi,
K. Tateda, K. Yamguchi (Tokyo, JP)
Objectives: According to the annual statistical survey conducted by the
Japanese Society for Dialysis Therapy, the most common cause of death
in total dialysis patients in 2008 was heart failure (23.7%), followed by
infections (19.9%). Especially, sepsis is noted as requiring the utmost
caution among other infections because of the high case fatality rate
as well as the high chance of infection. The aim of this study is to
summarize sepsis cases that occurred in hemodialysis patients at our
institution and to investigate relevant bacteriologic background and risk
factors.
Methods: In the 9-year period from 2001 to 2009 at our hospital, 205
patients receiving prolonged dialysis presented with fever and had blood
culture tests due to suspected sepsis. The factors considered were the
associated prognostic factors of age, gender, dialysis history, presence
of diabetes, catheter placement, body temperature, and blood culture
test results such as C-reactive protein (CRP), white blood cell count,
hemoglobin, platelet count, serum albumin, presence of methicillin-
resistant bacteria, and presence of Gram-negative bacilli.
Results: In total, 465 blood cultures from 205 cases of patients were
performed, yielding a positive rate of 23.7%. Gram-positive cocci, Gram-
positive bacilli, and Gram-negative bacilli accounted for 78.4%, 5.2%,
and 16.4% of the isolates, respectively. Among the Gram-positive cocci,
staphylococci were the most common species with a rate of 83.5%.
Among the staphylococci, methicillin-resistant Staphylococcus aureus
was the most frequent with a rate of 42.1%. As a result, 73 patients
were clinically diagnosed with sepsis. Regarding outcome, there were
38 deaths during the course of treatment; methicillin-resistant bacteria
were detected in 24 of these cases, reconﬁrming the poor prognosis.
Furthermore, multiple logistic regression disclosed that both CRP and
thrombocytopenia had a signiﬁcant effect on mortality rate.
Conclusion: Hemodialysis patients are exposed to increased opportu-
nities for infection from various reasons, including vascular access and
frequent hemodialysis procedure in addition to the lowered cellular and
humoral immunity. Our results indicate a poor prognosis for elevated
CRP and reduced platelet count. When administering antibiotic agent,
selection of vancomycin should be considered as an initial treatment by
assuming infection of methicillin-resistant bacterium from the beginning.
P1464 Fluorine-18 ﬂuoro-2-deoxy-D-glucose positron emission
tomography/computed tomography (PET/CT) contributes
to the diagnosis and management of patients with brucellar
spondylodiscitis
S. Ioannou*, S. Chatziioannou, S. Pneumatikos, N. Sipsas (Athens, GR)
Objectives: Limited data suggest that ﬂuorine-18 ﬂuoro-2-deoxy-D-
glucose (F-18 FDG) positron emission tomography combined with
computed tomography (PET/CT) may be useful for diagnosing infections
of the spine. Brucellar spondylodiskitis might be devastating and current
imaging techniques lack sensitivity and speciﬁcity. The aim of this
prospective study was to determine the role of F-18 FDG PET/CT in the
diagnosis of brucellar spondylodiskitis and in monitoring the efﬁcacy of
treatment.
Methods: Ten consecutive patients with brucellar spondylitis were
prospectively evaluated with PET/CT. Baseline evaluation included also
magnetic resonance imaging (MRI) of the affected spine, indices of
inﬂammation, the slide agglutination test (SAT), and the standard
hematology and biochemistry. All patients were treated with suitable
antibiotics until resolution or signiﬁcant improvement of clinical and
radiological (MRI) ﬁndings. Upon completion of treatment, all patients
were re-evaluated with follow-up PET/CT scanning. The maximum
standardized uptake values (SUV) were measured and compared with
indices of inﬂammation.
Results: F-18 FDG PET/CT provided additional information, compared
to MRI, in 4 (40%) patients. More speciﬁcally it revealed other
spine lesions not detected by MRI, mediastinal lymphadenitis, arthritis,
organomegaly, as well as new paravertebral soft tissue involvement and
epidural masses. This additional information had an impact on the
duration of treatment in these patients. The median SUV in all cases
of spondylitis was 5.5 (range 1.8−9.4). The follow-up PET/CT after
treatment revealed a decreased FDG uptake (median 2.6, range 0−4.4)
corresponding to clinical and radiological improvement. No signiﬁcant
association was observed between the SUV and indices of inﬂammation
or SAT.
Conclusion: Our study suggests that the F-18 FDG PET/CT is a useful
tool for the diagnosis of brucellar spondylodiskitis, for deﬁning the
extend of the disease and for monitoring the efﬁcacy of treatment.
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P1465 A randomised controlled trial on the clinical signiﬁcance
of use of PCR for 16S ribosomal DNA and sequencing in
patients with bacteraemia
C. Moser*, M. Bjørnsdottir, P. Rammer, J. Lorenzen, T. Thomsen,
P. Nielsen, N. Høiby, T. Bjarnsholt (Copenhagen, Aarhus, Aalborg, DK)
Objectives: Early and sufﬁcient antibiotic treatment of patients with
signs of sepsis is mandatory for better outcome. Rapid and precise
microbiological diagnosis is believed to be of pivotal signiﬁcance in
this respect.
Methods: A RCT was performed where the results of Gram-stained
smears of the blood and subsequent traditional phenotypic identiﬁcation
(Vitec®, Api®) was augmented with direct 16S rDNA PCR and
sequencing (16S) of the ampliﬁed product on all blood culture ﬂasks
(BACTEC, B&D) which were reported positive during a 3.5 month
period in 2010 in a tertiary hospital.
For all pts with bacteremia, the initial advise about the appropiate
antibiotic therapy from the clinical microbiologist to the clinicians
responsible for the pts were based on the results of the Gram-stains.
Later the same day, the 16S results from 50% of the pts were reported
to the clinical microbiologists who could adjust the advise.
Results: The results from 293 positive culture ﬂasks were evaluated.
The 16S diagnosis was found acceptable in 217 (74%), unacceptable
in 44 and failed analysis in 32 cases. Identical results between 16S
and traditional phenotypic identiﬁcation was obtained in 185/293 (63%),
species differences in 30 and genus differences in 15 ﬂasks. Cultures
were polymicrobial in 30 and yeast was cultured in 9 ﬂasks. Either the
16S or traditional identiﬁcation was negative in 24 ﬂasks (10 double
negative).
Median time to ﬁnal identiﬁcation was 6h for 16S as compared to 50 h
(4–484h) for phenotypic methods (p< 0.0001). For evaluation of the
impact on the course of the infection we compared the cases for 140
pts (80 pts +16S and 60 pts −16S) where a microbiological difference
in identiﬁcation did not exceed the species level. Empiric treatment
(initiated in 129 pts) or treatment after ﬁrst contact with a clinical
microbiologist was adequate in 119 pts (92.2%). We did not ﬁnd any
signiﬁcant differences in median time to deﬁnitive treatment, to step-
down to oral treatment, to end of treatment, to discharge from the ICU
or the hospital, of number of antibiotics given or of mortality between
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the two groups (7 dead/80 pts (8.8%) in the 16S group vs 4 dead/60 pts
(6.7%) in the control group).
Conclusion: The faster identiﬁcation provided by PCR for 16S
ribosomal DNA and sequencing did not result in signiﬁcantly changed
course of infections probably because of the adequate coverage of the
emperic antibiotic therapy, reﬂected by the low mortality.
P1466 A single-centre epidemiological study of E. coli bacteraemia,
antibiotic resistance, and association with hospital exposure
C. Jeppesen*, A. Claxton, B. Muller-Pebody, K. Henderson,
E. Sheridan (London, UK)
Objectives: E. coli bacteraemia has increased in incidence in the UK
over the past 5 years by 37%. We describe the epidemiology of this
infection in a London hospital to assess its association with hospital
exposure and inform the design of a potential national surveillance
programme.
Methods: Available data on all cases of E. coli bacteraemia was collected
retrospectively from computerised records at the Homerton Hospital,
London, for the period April 2005–2010.
Results: 476 episodes occurred, accounting for 10−11% of all positive
blood cultures annually. Aetiology could be determined for 338 cases;
of these 73% (247 cases) were of urinary tract origin. The proportion of
episodes caused by probable ESBL producers was 9.6% (44 episodes)
overall, ranging from 4% in community-onset urinary-origin episodes in
adults aged 16−64, to 38% in non-urinary, hospital-onset infections in
the same age group.
Of the 436 episodes which occurred in those aged >16years, 330
(76%) were community onset. 131 (40%) of adult community-onset
cases had been admitted within the past year. When cases with hospital
admission within the preceding 14 days, 30 days, 3 months or 12
months were compared a gradual decline in antibiotic resistance was
seen. The proportion due to biliary aetiology was 11% in community-
onset episodes with prior hospital contact compared with 5% in both
hospital-onset and hospital-naive cases, but no stepwise change in the
characteristics of these groups was observed as time since last admission
increased.
Conclusions: The majority of cases of E coli bacteraemia are
community-onset and urinary origin. For surveillance to be useful in
clarifying the role of healthcare in the observed rise in incidence of E
coli bacteraemia, detailed information about procedures in hospital and
the community would need to be collected, as deﬁnitions of healthcare
association based on temporal cut-offs appear to have limited utility with
this pathogen.
P1467 Predictors of bloodstream infection in 673 episodes of
bacteraemia with coagulase-negative staphylococci
L. Elzi*, N. Vo¨geli, M. Dangel, M. Battegay, R. Frei, A.F. Widmer
(Basel, CH)
Background: Coagulase-negative staphylococci (CNS) are frequent
contaminants of blood cultures. We investigated predictors of blood
stream infection (BSI) in patients with CNS bacteraemia, and the
usefulness of the Systemic Inﬂammatory Response Syndrome (SIRS)
criteria.
Methods: Prospective collection of clinical and laboratory parameters
in adults with 1 positive blood culture in a tertiary hospital between
2003 and 2007. One episode of CNS bacteraemia was deﬁned as growth
of CNS only in 1 blood culture taken within 1 week. Diagnosis of
BSI versus contamination was assessed by a trained investigator and
conﬁrmed by an infectious disease specialist. Logistic regression was
used to estimate the odds ratios (OR) of BSI in patients with CNS
bacteraemia.
Results: Of 3,060 positive blood cultures, 673 episodes of CNS
bacteraemia were identiﬁed. Of these, 243 (36.1%) were considered as
BSI and 430 (63.9%) as contamination. The median number of positive
blood cultures was 1 (IQR 1−1) for contamination and 2 (IQR 1−4)
for BSI. There was no difference in age, sex, comorbidities (diabetes,
alcohol, intravenous drug use, HIV, immunodeﬁciency) between patients
with BSI and those with contamination. BSI was associated with surgery
during hospitalization (37.9% versus 22.8%, p< 0.001), central venous
catheter (67.9% versus 28.8%, p< 0.001) and intensive care unit (49.0%
versus 34.2%, p< 0.001). Overall, 232 patients (95.5%) with BSI and
307 (71.4%) with contamination (p< 0.001) had 1 SIRS criterion.
Leukocytes >12 or <4 G/L was the most frequent SIRS criterion
associated with BSI, followed by fever or hypothermia, tachycardia and
tachypnea. The probability of BSI increased with additional SIRS criteria
(test for trend p< 0.001), ranging from 19.8% in patients with only 1
criterion to 49.3% for 2, 66.4% for 3, and 80.8% for 4 SIRS criteria.
Among patients with 2 SIRS criteria, probability of BSI increased to
67.0% if there was a central venous catheter.
In multivariate analysis, independent predictors of BSI were leukocytosis
or leukopenia (OR 3.35, 95%CI 2.68–4.95, p< 0.001), fever or
hypothermia (OR 2.82, 95%CI 1.90–4.19, p< 0.001), tachycardia (OR
2.48, 95%CI 1.68–3.67, p< 0.001), tachypnea (OR 2.37, 95%CI 1.34–
4.19, p = 0.003), and the presence of a central venous catheter (OR 5.92,
95%CI 3.64–9.63, p< 0.001).
Conclusion: A positive blood culture for CNS likely represents BSI if
the patient has 3 SIRS criteria or 2 SIRS criteria and a central venous
catheter.
P1468 Bloodstream infection in patients with kidney disease. Risk
factors for poor outcome and mortality
L. Rojas, P. Mun˜oz*, M. Kestler, D. Arroyo, M. Rodrı´guez-Cre´ixems,
E. Verde, E. Bouza (Madrid, ES)
Patients with kidney disease are especially susceptible to severe
infections, including bacteremia (bloodstream infection [BSI]). Therapy
in these patients is particularly challenging. Data on BSI in this
population are scarce and mainly derived from selected groups of
patients.
Objectives: To assess the characteristics of BSI in a non-selected
population of patients with kidney disease, including renal transplant
recipients and patients with chronic kidney failure receiving or not
receiving dialysis.
Methods: Retrospective cohort study (January 2007 to June 2010) of
all patients who presented signiﬁcant bacteremia while hospitalized in
the Nephrology Unit of a large teaching hospital. Clinical records were
reviewed according to a pre-established protocol and standard deﬁnitions
were used.
Results: There were 155 episodes of BSI in 108 patients. The incidence
of BSI was 77 episodes per 1000 admissions (2.5-fold higher than in
the general population), and 5.7 episodes per 100 patients followed
per year. Hemodialysis patients had the highest incidence of BSI (8.8
per 100 patients followed per year). Gram-negative microorganisms
predominated (52.3%), followed by Gram-positive ones (46.5%), and
fungi (1.2%). E. coli was the most common microorganism (27%). Of all
the Gram-negative microorganisms, 8.6% were producers of extended-
spectrum b-lactamases.
BSI was due to primary bacteremia (29.7%), urinary tract infection
(23.2%), vascular access infection (17.4), and other infections (29.7%).
Urinary tract infection predominated in kidney recipients and in
patients with chronic renal failure not on hemodialysis, while patients
on hemodialysis had mainly catheter-related bacteremia. Eighteen
patients (11.6%) developed septic shock or multi-organ failure, and
the same proportion had persistent bacteremia. Twenty-one (13.5%)
patients had other focal infections (endocarditis, abscesses, and bone-
joint involvement). The global mortality rate was 14.6% and related
mortality was 11.6%. Mortality risk factors were a high Charlson index,
methicillin-resistant S. aureus BSI, catheter-related BSI, absence of
fever, persistent bacteremia, and metastatic infection.
Conclusions: The different populations attended by the Nephrology
Unit share a high incidence of BSI and high BSI-related morbidity and
mortality. Our results may help to design interventions tailored to speciﬁc
groups of patients with kidney disease.
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P1469 Capsular types and genetic relatedness of Klebsiella
pneumoniae isolates causing recurrent bloodstream infection
C.Y. Liu*, P.R. Hsueh, C. Liao, J. Wang, Y. Huang (Taipei, TW)
Background: Capsular types and genetic relatedness of Klebsiella
pneumoniae (KP) causing recurrent bloodstream infections (RBSI) have
rarely been previously described.
Methods: We enrolled all patients with positive KP bacteremia from
January 2000 to December 2008 in a tertiary hospital for further analysis.
RBSI was deﬁned as 2 or more episodes of KP bacteremia occurred
more than 30 days apart. All RBSI isolates were retrieved for capsular
cps genotyping for seven clinical signiﬁcant capsular types (K1, K2, K5,
K20, K54, K57 and a new capsular type [N1]) as previously described.
Isolates with the same capsular type from the same patients were further
evaluated by pulsed-ﬁeld gel electrophoresis for their genetic relatedness.
Results: There were 3067 patients with KP bacteremia during the study
period and 129 patients (4.2%) with 301 episodes of bacteremia were
considered as RBSI during the 9 year period. Capsular types were
determined in 127 isolates (42.2%) from 73 patients by cps genotyping.
Capsular type K2 was the most commonly encountered (N= 52, 17.3%)
followed by K1 (N= 27, 9.0%), K54 (N= 18, 6.0%), K20 (N= 11, 3.7%),
K57 (N= 11, 3.7%), K5 (N= 6, 2%) and N1 (n = 2, 0.6%). There were
27 male and 7 female patients (46.6%) infected by the same capsular
type in their each episode. The median age was 55 year-old (range:
27−86). Time between each bacteremia episode ranged from 35 days to
2806 days (median: 195 days). Underlying conditions include diabetes
mellitus (50%), malignancies (38.2%) and liver cirrhosis (26.5%). The
origin of bacteremia included biliary tract infection (N= 9, 26.5%), liver
abscess (N = 8, 23.5%), pneumonia (N= 8, 23.5%), primary bacteremia
(N= 7, 20.6%), urinary tract infection (N= 4, 11.8%). The PFGE results
were indistinguishable for 30 patients of their isolates (N = 58). Four
patients were infected by the different pulsotypes of KP with the same
capsular types (one K1 and 3 K2 capsular types).
Conclusions: RBSI cause by K. pneumoniae is not uncommon and
infection by the same capsular strain could be found in certain patients.
Further study is mandated to identify risk factors of KP related RBSI.
P1470 A 5-year retrospective review of BSI in a national bone
marrow transplantation unit
M. Fraher*, M. Kelleher, E. Conneally, B. O’Connell (Dublin, IE)
Objectives: Blood-stream infection (bsi) is an important cause of
morbidity and mortality among patients with haematological malignancy
and those undergoing bone marrow transplantation. The spectrum
of infections and susceptibility patterns are extremely important in
determining the empiric antimicrobial choice for febrile neutropenia.
We performed at 5-year retrospective review of bsi among haematology
patients in order to review causative organisms and their susceptibility
patterns and compare to National and European data.
Methods: St. James Hospital is a 1,000 bed tertiary referral university
hospital with a 21 bed HEPA-ﬁltered, positive pressure, purpose
built Haematology ward that includes the National Bone Marrow
transplantation unit.
A retrospective ﬁve-year review of all episodes of bsi between 2005
and 2009 was undertaken. An episode of bsi was deﬁned as isolation
of a micro-organism from blood cultures. All isolates recovered from
a patient within 14 days of a positive blood culture were counted as
a single episode. Two isolates of coagulase negative staphylococci or
corynebacteria from one blood culture set were required to be considered
signiﬁcant.
Results: There were 623 episodes of bsi; 50% were caused by Gram-
negative organisms (GNO) and 47% by Gram-positive organisms (GPO)
(Table 1).
Coagulase negative staphylococci were the predominant cause of bsi
(27%), followed by E. coli (19%) and Klebsiella species (10%). 14 of 39
(36%) of Staphylococcus aureus bsi were caused by Meticillin Resistant
Staphylococcus aureus. 29 of 45 (64%) of Enterococcus faecium bsi
were vancomycin resistant.
Ciproﬂoxacin resistance among GNO rose from 8% in 2005 to 33% in
2007 and decreased to 8% in 2009 with a similar trend in gentamicin
resistance. Ciproﬂoxacin resistance rates reﬂected ciproﬂoxacin usage.
Less than 1% of GNO displayed extended spectrum b-lactamase
production.
Conclusion: Our study demonstrates that GNO account for slightly
more bsi’s than GPO which is consistent with more recent studies.
Resistance to methicillin among MRSA are similar to national data,
but vancomycin resistance among enterococci is higher. It is likely that
quinolone resistance among GNOs reﬂects quinolone usage and has a
similar effect on gentamicin resistance.
Table 1: Distribution of organisms 2005–2009
n (%) 2005 2006 2007 2008 2009 Total
GP bacteria 47 (48.4) 37 (38.5%) 73 (50%) 69 (51%) 80 (45%) 306(47)
GN bacteria 48 (49.4) 56 (58.3%) 70 (49%) 60 (44%) 94 (54%) 328(50.4)
Anaerobes 0 0 1 0 0 1(0.1)
Fungi 2 2 1 5 3 13(2)
Mycobacteria 0 1 0 1 0 2(0.3)
Total 97 96 145 135 177 650
n = number; GP: Gram positive, GN: Gram negative.
P1471 Candidaemia in an intensive care unit: epidemiology and
predisponent risk-factors
C. Ruiz de Alegrı´a Puig*, M.A. Ballesteros Sanz, J.L. Teja Barbero,
C. Ferna´ndez-Mazarrasa, M. Gutie´rrez Cuadra, L. Martı´nez-Martı´nez
(Santander, ES)
Objective: To study the etiology, epidemiology, risk and prognostic
factors associated with candidemia in Intensive Care Units (ICU).
Methods: A retrospective cohort study of candidemia episodes in
patients admitted to Intensive Care Units of a third welfare level hospital
with 800 beds (44 ICU’s beds) was carried out. Demographic and clinical
information were collected from 2005 to 2009. The mortality associated
with the candidemia was the independent variable. The relative risk (RR)
was calculated in case of categorical variables. A logistic regression
model was used to evaluate the factors related with mortality. The results
appear as proportion or average and standard desviation (SD).
Results: 70 patients were included with 71 episodes of candidemia.
Males were more prevalent that women (67.6% vs 32.4%). Average age
was 61.8 (SD:15.7) years. The nosocomial acquisition rate was 94.4%.
64% of the patients were in a hospitalization ward before the admission
in UCI. C. albicans was isolated in 31% of the episodes. C. parapsilosis
(38%) and C. tropicalis (12.7%) were the most frequent in the group of
non-albicans Candida. 52.8% of the patients were receiving parenteral
nutrition, 20.4% suffered a neoplasic process, 98,1% had previously
received antibiotic treatment, 16,7% were transplanted patients, 100%
had central venous access and 37% had received antifungal prevention.
The source of the candidemia was considered unknown in 47.2% of
cases, whereas in 26% of them it was associated to i.v. catheters. Patients
developed sepsis, septic shock and multiorganic dysfunction in 33.3%
50% and 34.6% of cases, respectively. The mortality rate was 59.3%.
Previous administration of antibiotics was associated to the presence of
candidemia (RR 1.7; IC 95%: 1.3−2.1). The etiology of C. albicans
(OR: 1.9; IC 95%: 0.5−8.2), immunosuppression (OR: 3; IC 95%: 0.3–
32.3) and the absence of empirical antifungal therapy (OR: 1.9; IC 95%:
0.3–10.3) were independent factors from mortality in the multivariable
analysis.
Conclusions: Non-albicans species of Candida has been the most
common etiology of candidemia in our series. C. albicans etiology,
immunosuppression and the absence of empirical antifungal therapy were
the factors associated with mortality.
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P1472 Can syndromic surveillance based on crude mortality serve
as a tool for monitoring healthcare-associated bloodstream
infection?
H. Richet*, V. Loffeier, N. Cassir, D. Raoult (Marseille, FR)
Objective: French hospitals must report all deaths attributable to health
care associated infections (HCAI); however, in 2006, only 300 deaths
were reported. This study was performed at a 2,789 tertiary-care referral
teaching center admitting yearly >120,000 patients in Marseille (France)
to evaluate if syndromic surveillance of HCAI bloodstream infections
(HCA-BSI)-associated deaths could be substituted to mandatory
reporting.
Methods: Attributable mortality was calculated for HCA-BSI patients
and a cohort study was performed to compare patients whose deaths
were reported to patients whose deaths were not.
Results: In 2008, 1,033 HCA-BSI were included, 115 patients died
within 15 days after the onset of BSI while 10 deaths were reported.
Attributable mortality was 11.89% representing an excess of 100 deaths.
The cohort study showed no difference between both groups regarding
age, gender, severity of illness, underlying disease, organ dysfunction,
surgical intervention, time between admission and BSI onset, primary
or secondary BSI, duration of bacteremia, ICU transfer, or treatment
limitation. One signiﬁcant difference was found: admission at hospital S
following the arrival of a young hospital epidemiologist. Extrapolation
of our data to the national level suggests that 12,400 patients could have
died of HCA-BSI constituting the 6th leading cause of death in France.
Conclusion: Report of HCA-BSI-related deaths is more linked to
subjectivity than to rigorous analysis with a number of HCA-BSI
related deaths >10 times higher than the reported one. These results
underline the necessity to switch from mandatory reporting to systematic
surveillance of laboratory results of HCA-BSI-related deaths to obtain
reproducible results.
P1473 Bacterial bloodstream infections in a newly constructed
medical centre in Saint Petersburg, Russia
E.P. Barantsevich*, N.E. Barantsevich, N.E. Pestova, N.S. Rybkova
(St. Petersburg, RU)
Objectives: The aim of the present study was to reveal the spectrum of
bacteria, causing bloodstream infections, in the multidisciplinary medical
center, that accumulates patients from all regions of Russia, during the
ﬁrst year from it’s foundation, with low possibility of local nosocomial
strains’ formation.
Methods: The cultures were isolated from blood with BactAlert
(BioMerieux, France). The identiﬁcation was performed by routine
methods and sequencing (ABI Prism 3130, MicroSeq ID v2.0 Software,
MicroSeq ID 16s rDNA500 Library v2.0). Resistance to routinely used
antibiotics was studied by dilution techniques on Muller-Hinton agar
(Oxoid, GB).
Results: Bacterial bloodstream infections were revealed in 101 cases:
Staphylococcus spp. were responsible for 47 (46.6%) ones. S. aureus
was the causative agent in 18 (17.8%), coagulase-negative staphylococci
(S. epidermidis, S. capitis, S. haemolyticus, S. hominis) − in 29 (28.7%)
infections. Other Gram-positive cocci were Enterococcus faecalis in
7 (6.9%), E. faecium in 4 (3.9%) and Streptococcus spp. (S. constellatus,
S. mitis, S. sanguinis) in 3 (2.9%) cases. Acinetobacter baumannii was
revealed in 12 (11.8%), Klebsiella spp. (K. pneumoniae, K. oxytoca)
in 10 (9.9%), E. coli in 8 (7.9%), Enterobacter spp. (E. cloacae,
E. aerogenes, E. hormaechei) in 3 (2.9%) patients with sepsis. Rarely
isolated bacteria comprised Bacillus thuringiensis in 1, B. cereus
in 1, Stenotrophomonas maltophilia in 1, Pantoea agglomerans in 1,
Corynebacterium mucifaciens in 1, Paenibacillus spp. in 1 and non-
identiﬁed bacterium in 1 case.
Resistance to antibiotics was observed in 96 (95.1%) of bacterial isolates,
multi-drug-resistant (MDR) were 34 (33.7%) strains. All E. faecium and
7 (58.3%) strains of A. baumannii were resistant to 7 or more antibiotics.
Multi-drug resistant E. faecium strains were susceptible to linezolide,
A. baumannii − to tigecycline.
Meticillin resistant were 2 (11.1%) strains of S. aureus and 17 (58.4%)
strains of coagulase-negative staphylococci. Vancomycin-resistant were
3 strains of E. faecium.
Conclusions:
1. Gram-positive bacteria were the leading causative agents of
bloodstream infections in the newly-constructed hospital in Saint-
Petersburg in 2010.
2. Meticillin-resistance was observed predominantly in coagulase-
negative staphylococci, vancomycin-resistance − in E. faecium.
3. The most widespread Gram-negative agent of bloodstream infections
was A. baumannii. All MDR A. baumannii strains were susceptible
to tigecycline.
P1474 Coagulase-negative Staphylococcus bacteraemia: a
prospective study of clinical and microbiological predictors
of true bacteraemia
A. Ferna´ndez-Rufete*, E. Garcı´a-Vazquez, J. Ruiz, A. Herna´ndez-Torres,
E. Moral-Escudero, H. Albendin, J.A. Herrero, J. Go´mez-Go´mez,
L. Martinez-Lage, T. Garcı´a-Lucas (Murcia, ES)
Background: Coagulase-negative staphylococci (CNS) are both an
important cause of nosocomial blood-stream infections and the most
common contaminants of blood cultures (BC); judging the clinical
signiﬁcance of CNS is vital but often difﬁcult. A prospective cohort
study of patients with at least one BC positive for CNS was performed
in order to explore the clinical and microbiological predictors of true
bacteraemia (TB) caused CNS.
Patients and Methods: A single reviewer examined the medical records
of consecutive patients (with at least 2 consecutive samples for BC)
with CNS positive BC in a tertiary-care referral teaching hospital (from
January through June 2010). A determination of clinical signiﬁcance
was made and the result was considered as a TB (according to CDC
criteria) or contaminant. Data collection from clinical records has been
done according to a standard protocol. We analysed epidemiological,
clinical, microbiological and laboratory variables to identify clinical and
microbiological predictors of CNS TB.
Results: A total of 269 cases were included, 61% of which were
men; mean age was 61 year-old; 97 (36%) were considered as TB.
Predictors of TB in the bivariate analysis were: BC obtained in already
admitted patients (versus those obtained at the Emergency Department −
AP vs ED), having >2 positive blood cultures, time to positivity
<16 hours, identiﬁcation of Staphylococcus epidermidis, nosocomial
bacteraemia, hospital admission within the previous month, renal failure,
alcoholism, severe liver failure, chemotherapy, immunesuppressive
therapy, Charlson score >3, acute severity of illness at onset according
to Winston criteria (I, II and III) and PITT score >1, previous surgery,
previous invasive procedures, ICU admission, phlebitis, total parenteral
nutrition and having a central venous catheter. In multivariate analysis
predictors of true CNS bacteraemia were: time to positivity <16 hours
(OR 5.688; 95%CI 2.030–15.933), identiﬁcation of S. epidermidis (OR
1.927; CI 95% 1.357–19.199), having >2 CNS positive BC (OR 1.927;
CI 95% 1.357–19.199), central venous catheter (OR 2.810; 95%CI
1.332–5.930) and APvsED (OR 8.139; 95%CI 3.450–19.199).
Conclusions: The analysis of a cohort of patients with CNS bacteraemia
identiﬁed as predictors of TB microbiological features (time to positivity
<16 hours and identiﬁcation of S. epidermidis and >2 CNS positive
blood cultures) and clinical aspects (having a central venous catheter
and APvsED).
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P1475 Comprehensive analysis of the impact of empirical therapy
in the mortality of bloodstream infections
P. Retamar*, M. Lo´pez-Prieto, M. Portillo, C. Natera, E. Nun˜o,
M. Herrero, A. Arco, A. Mun˜oz, F. Te´llez, M. Torres, A. Martin,
S. Pe´rez-Cortes, R. Moya, J.E. Corzo-Delgado, L. Leo´nn,
M.A. Martinez, J. Rodriguez-Ban˜o on behalf of SAEI-SAMPAC
Objectives: The epidemiology of bacteraemia has changed during last
years. We aimed at identifying independent predictors of mortality in
patients with bloodstream infections (BSI) and speciﬁcally, to estimate
the impact of innapropriate empiric treatment (IET) in mortality after
controlling for confounding factors.
Methods: A multicenter, prospective cohort study of BSI which occurred
in adult patients in 15 Spanish hospitals from November 2005 throughout
March 2006 was performed. BSI were classiﬁed as nosocomial (NOS),
healthcare-associated (HCA) or community-acquired (CA) according to
Friedman’s criteria. The outcome variables were mortality at days 14 and
30. Multivariate analysis were performed by logistic regression.
Results: 822 episodes of BSI were included; 476 (58%) were NOS,
227 (28%) HCA, and 119 (14%) CA. Mean age was 66 years. Crude
mortality at day 14 and 30 were 19% (155) and 23% (190), respectively.
S. aureus, S. pneumoniae, Enterococcus sp., P. aeruginosa, A. baumannii,
and Enterobacter sp. were considered as high risk microorganims
because were associated with higher mortality than other microorganisms
(26% vs 14%; p< 0.001). Also mortality was lower when the source of
BSI was the urinary tract, the catheter or the biliary tract (14% vs 28%;
p< 0.001); the rest of sources were considered “high risk source”. In
the multivariate analysis, variables independently associated with higher
mortality at days 14 and 30 were: age (OR=1.2 and 1.5, respectively),
ICU admission (OR=2.0 and 1.9), Charlson score >2 (OR=2.1 and 2.1),
high risk microorganisms (OR=1.6 and 1.7), high risk source (OR=1.6
and 2.2), presentation with severe sepsis or shock (OR=3.4 and 3), and
Pitt score >2 (OR=1.5 and 1.6). IET therapy was only associated with
increased risk of mortality at day 14 (OR= 1.7). The type of acquisition
was not associated with mortality. When speciﬁcally investigating the
impact of IET therapy in the 14-day mortality, Charlson score, ICU stay,
presentation with severe sepsis or shock, and high risk microorganisms
were found to be confounders; after controlling for these confounders
using a forward multivariate analysis, the adjusted OR for IET was 1.8
(95%CI:1.1−3.0).
Conclusion: We identiﬁed predictors of mortality in patients with BSI.
After carefully controlling for confounders, IET is associated with an
increased risk of early death at day 14, but we were unable to demonstrate
an impact at day 30, when the impact of other baseline features was
higher.
P1476 Clinical features and prognosis of bacteraemia caused by
Acinetobacter lwofﬁi
H. Tsai*, Y. Huang, C. Liao, P.R. Hsueh (Taipei, TW)
Background: Acinetobacter lwofﬁi is an environmental commensal
causing catheter related infections in immunocompromised patients.
Data about clinical presentations of A. lwofﬁi bacteremia (ALB) and
its antimicrobial susceptibilities remained scarce.
Methods: We conducted a retrospective study to analyze the demo-
graphics, clinical information and microbiological data of ALB patients
in a tertiary center in north Taiwan from January 2000 to June 2010.
Identiﬁcation of A. lwofﬁi was performed by conventional methods
using API 20NE system (bioMe´rieux, Marcy l’Etoile, France) and
after 2007 by Phoenix Automated System (Becton Dickinson, Sparks,
MD). Antimicrobial susceptibilities were determined by disc diffusion
methods according to Clinical and Laboratory Standards Institute (CLSI)
recommendations for all isolates. A case of catheter related bloodstream
infection was deﬁned as either 1) a bloodstream infection due to same
organism isolated from the removed central venous catheter or 2) clinical
judgments by the physicians in charge.
Results: There were 251 ALB patients enrolled for analysis. The mean
age was 56 years (56.41±20.8 years) and 123 patients (49%) were male.
Most of the cases were hospital acquired (N= 197, 78.5%) or health-
care facility related infection (N= 32, 12.7%) and the mean time from
hospitalization to bacteremia onset was 22.2 days (range 2–358 days;
S.D: 32.62). Eleven patients (4.3%) had Pitts bacteremia score more than
3. Fever was noted in 87.3% patients and 49 patients (19.5%) developed
shock and 20 patients (8%) required inotropic agents. The central venous
devices implantation was noted in 63% of patients (N = 160) and Port-A
CATH was the most commonly used (N= 80 patients, 50%) followed
by central venous catheter usage (N= 73; 45.6%) and hemodialysis-
catheter (N = 13; 8.1%). Catheter related bloodstream infection was
diagnosed in 49 cases (30.6%). In-hospital mortality rate was 12% and
had higher charlson cormobidity index (mortality: 4.533±1.852 vs non-
mortality: 2.755±2.247, p< 0.01). The non-susceptible rate was highest
for aztreonam (84.6%) followed by ceftazidime (43.5%), ciproﬂoxacin
(16.0%), amikacin (14.3%) and carbapenems (10.4%).
Conclusions: Patients with A. lwofﬁi bacteremia have low mortality
rate and may be associated with underlying disease. Mechanisms of the
high non-susceptible rate of A. lwofﬁi against certain antibiotics should
be further investigated since these isolates could be reservoirs of drug
resistant genes.
P1477 Bloodstream infections due to ESBL-producing Escherichia
coli can be safely treated with active b-lactam/b-lactam
inhibitors
J. Rodrı´guez-Ban˜o*, M. Navarro, P. Retamar, E. Pico´n,
L. Lo´pez-Cerero, A. Pascual (Seville, ES)
Objectives: Carbapenems (CAR) are considered the drugs of choice
for the treatment of invasive infections caused by extended-spectrum
b-lactamase (ESBL) producing enterobacteria. The clinical efﬁcacy of
b-lactam/b-lactam inhibitors (BLBLI) is controversial. We compared the
prognosis or patients with bloodstream infection (BSI) due to ESBL-
producing Escherichia coli (ESBLEC) treated with BLBLI or CAR.
Methods: A pos-hoc analysis of all episodes of BSI due to ESBLEC
treated with BLBLI or CAR in monotherapy included in previously
published prospective cohorts developed by our group between 2001 and
2006 were included. Episodes were excluded if the isolate was resistant
to the antimicrobial used. All cohorts used similar questionnaires and
the same microbiologic methods; ESBL detection and antimicrobial
susceptibility were performed following the CLSI recommendations. We
compared mortality at days 7, 14 and 30 by chi squared or Fisher tests,
and by log rank test for Kaplan-Meier curves. Multivariate analysis using
Cox regression were performed.
Results: Among the 72 patients empirically treated with BLBLI (37
amoxicillin-clavulanate [AMC] and 35 piperacillin-tazobactam [PTZ])
and the 31 with CAR (22 imipenem [IMP], 8 meropenem [MER] and
1 ertapenem [ERT]), mortality was: 2.8% vs 9.7% (day 7); 9.7% vs
16.1% (day 14); and 9.7% vs 19.4% (day 28), respectively (p> 0.1 for all
comparisons; log rank test, p = 0.2). In Cox regression analysis, therapy
with BLBLI or CAR was not associated with mortality. The variables
associated were (HR and IC 95%): Pitt score >2 (3.4; 1.1–10.4), severe
sepsis or shock (3.7; 1.1–11.8), and source other than urinary or biliary
tracts (5.0; 1.5–17.2). Among the 54 patients who received deﬁnite
therapy with BLBLI (34 AMC, 18 PTZ, and 2 ampicillin-sulbactam)
and the 120 with CAR (84 IMP, 16 MER, 20 ERT), mortality was:
1.9% vs 4.2% (day 7); 5.6% vs 11.7% (day 14); and 9.3% vs 16.7%
(day 30) (p> 0.2 for all comparisons; log rank test, p = 0.4). In Cox
regression analysis, therapy with BLBLI or CAR was not associated
with mortality. The variables associated were: severe sepsis or shock
(3.7; 1.6−8.1) and source other than the urinary or biliary tracts (2.0;
0.9−4.5). No differences were found for individual drugs.
Conclusion: Until more data are available, we advocate the use of
BLBLI as an alternative to CAR in the treatment of BSI due to
susceptible ESBLEC. BLBLI are particularly useful as deﬁnite therapy
to avoid the overuse of CAR.
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P1478 Trends of nosocomial bloodstream infection incidence in a
haematology department, Edouard Herriot hospital, Lyon
(France), 2004–2009: a surveillance-based study
C. Dell’Agostino, T. Be´net, D. Lutringer, M. Michallet, M. Nicolle,
P. Cassier, P. Vanhems* (Lyon, FR)
Objectives: To report the trends of nosocomial blood infection (NBI)
incidence in a French hospital hematology department.
Methods: A prospective surveillance was performed in 3 hematology
units of the Edouard Herriot university Hospital, Lyon (France) between
01/01/2004 and 12/31/2009. All patients hospitalized 48 hours were
included, only the ﬁrst NBI was accounted if it occurred 48 hours
after patient entry in the department and before the end of hospital stay.
The case deﬁnitions of NBI infection were #1) at least one positive
blood culture with clinical signs for non-commensal microorganisms
or #2) at least two positive blood cultures in case of microorganism
such as: coagulase-negative staphylococci, Bacillus sp. (except Bacillus
anthracis), Corynebacterium spp., Propionibacterium spp., Micrococcus
spp. or another commensal microorganism with similar pathogenic
impact. Incidence was the number of NBI per 1 000 patient-days at risk.
Poisson regression with year as explanatory variable was used for trend
analysis.
Results: Totally, 3 001 patients counting for 77 380 patient-days at risk
were included. Overall, 652 (20.2%) patients had NBI, the incidence
was 11.25 per 1 000 patient-days. Demographic characteristics and trends
of NBI incidence are reported in Table 1. An increased proportion of
patients with aplasia (P< 0.001) and with central venous catheter was
observed (P< 0.001). The NBI incidence increase was 8% per year (95%
conﬁdence interval 3%-14%, P< 0.001).
Conclusion: An increase of the NBI incidence was observed. The recent
increased proportion of patient with aplasia since 2006 and the increase
proportion of patients with central venous catheter for perfusion of more
aggressive chemotherapy could explained these results.
P1479 Pathogenic proﬁles of bloodstream infections in a West
China hospital
C. He*, Y. Xie, M. Kang, C. Tao, B. Xie, H. Fan, L. Wang (Chengdu, CN)
Objectives: To investigate the pathogenic characteristics in bloodstream
infections (BSIs) in west china hospital.
Methods: A retrospective analysis of the microbiological results of
blood culture and clinical data of BSIs from Jan 2009 to Mar 2010
was conducted at west china hospital.
Results: A total of 834 organisms were identiﬁed from the 826 episodes
of the bloodstream infections during the study period. The organisms
were most frequently (28.2%) recovered from the blood culture of the
patients admitted to the intensive care unit (ICU). Gram-negative organ-
isms, Gram-positive organisms and fungi constituted 434 (52.0%), 342
(41.0%) and 58 (7.0%) of the pathogens, respectively. Escherichia coli
(42.2%), Klebsiella pneumoniae (15.4%), Acinetobacter spp. (11.5%)
were the frequently isolated Gram-negative bacteria, moreover 60.7% of
E. coli isolates and 37.3% of K. pneumoniae isolates produced Extended
Spectrum b-lactamase and were multiresistant. Multidrug resistance
was observed in 77.0% of all Acinetobacter spp. isolates. Coagulase-
negative staphylococci (CoNS) (40.9%), Staphylococcus aureus (17.5%)
and Enterococcus spp. (17.5%), were the most prevalent Gram-positive
bacteria. The percentages of oxacillin resistant CoNS isolates and
methicillin-resistant Staphylococcus aureus isolates were 84.2% and
30.0%, respectively. Only one Vancomycin resistant Enterococci was
found. Candida spp. accounted for 82.8% of the fungi identiﬁed and
non-albicans Candida spp. was predominant (77.1%). Of non-albicans
Candida spp., C. parapsilosis was the leading species (27.1%), followed
by C. tropicalis (22.9%), and C. glabrata (18.8%).
Conclusion: Gram-negative bacteria were the predominant pathogens
for BSIs in west china hospital from Jan 2009 to Mar 2010. Multidrug
resistant bacteria and non-albicans Candida species should be paid
more attention to during the infection control, especially for the patients
admitted to ICU.
P1480 Few blood cultures − few infections?
P. Gastmeier*, F. Schwab, M. Behnke, C. Geffers (Berlin, DE)
Objectives: The frequency of central venous catheter associated
bloodstream infections (CVC BSI) is an important quality indicator in
many European countries. However, according to CDC deﬁnitions CVC
BSI can only be diagnosed when a positive blood culture (BC) report is
available. The objective of this study was to investigate the association
of BC frequencies and CVC BSI rates in intensive care units (ICUs).
Methods: The data of the German national nosocomial infection
surveillance system (KISS) for ICUs were used to investigate this
association. A questionnaire asking for the frequency of BC taken was
send to all ICUs participating in KISS. The ICUs were stratiﬁed in
four groups by their BC frequency and BC rates were associated with
CVC BSI rates using a univariable and multivariable approach. The
following parameters were used for adjustment: Type of ICU and type
of hospital, afﬁliation of the microbiology laboratory, duration of stay,
device utilization rates (CVC and ventilation).
Results: 223 ICUs provided their data. The median number of BC pairs
taken was 60 with a huge variety from 3.2 to 680 per 1000 patient
days. The median CVC BSI rate was 0.75 per 1000 CVC days. An
increase of the BC frequency of 100 BC per 1000 patient days lead to
a 1.27 fold higher incidence density of CVC BSI (CI95 1.01–1.26). A
further signiﬁcant risk factor for CVC BSI were length of stay in the
ICU (adjusted Incidence rate ratio (IRR) 1.25 (CI95 1.15–1.35). To have
the status of an interdisciplinary ICU was a signiﬁcant protective factor
(IRR 0.64 (CI95 0.45–0.92). The same predictors were identiﬁed when
only CVC BSI due to Coagulase negative staphylococci was used as
endpoint of analysis.
Conclusions: We were astonished about the very low BC frequencies
in many German ICUs which may lead to inadequate antimicrobial
therapy. The interpretation of CVC BSI rates in German ICUs in the
context of quality management is only possible if BC frequencies are
also considered. If an external benchmarking of ICUs according to their
CVC BSI rates is intended an adjustment according to the BC frequency
is necessary.
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P1481 Inﬂuence of the timing of therapeutic interventions on
the outcome of catheter-associated Staphylococcus aureus
bacteraemia: is there a need for speed?
S.C. de Ruiter, P.M. Ellerbroek, D.J. Hetem, A.G. Buiting, J. Kluytmans,
S. Thijsen, B.J. Vlaminckx, R.G. Wintermans, M.J. Bonten,
M.B. Ekkelenkamp* (Utrecht, Tilburg, Breda, Nieuwegein, Roosendaal,
NL)
Objectives: The objective of this study was to evaluate the effect on
attributable mortality due to catheter-associated Staphylococcus aureus
bacteremia (CA-SAB) of its two main therapeutic measures: the rapidity
with which adequate antibiotic therapy is initiated and time taken to
remove the intravenous catheter.
Methods: Adult patients from eight Dutch hospitals with a ﬁrst episode
of CA-SAB were included in this study. Inclusion was retrospective
and began between July 1st 2003 and January 1st 2005, depending on
the hospital; inclusion ended on December 31st 2008. Risk factors and
outcome were retrieved from the patient charts. Primary risk factors
were: failure to remove the intravascular catheter within 24 hours
and failure to initiate antibiotic therapy within 24 hours. The primary
outcome was attributable 3-month mortality. Secondary outcomes were:
all cause 3-month mortality, hematogenous complications at 3 months,
and all cause 12-month mortality.
Results: A total of 268 patients were included. Median age was
60 years. Co-morbidity included cardiovascular disease (44%), heart
failure (15%) diabetes mellitus (23%), malignancy (28%), hematological
malignancy (5.9%), and chronic obstructive pulmonary disease (9.3%).
34% of patients had tunneled catheters. The catheter was used for
chemotherapy in 11% of the patients, total parenteral nutrition in 21%,
and hemodialysis in 37%. Attributable 3-month mortality was 9.0%, all
cause 3-month mortality 18%, and all cause 12-month mortality 30%.
27 patients (10%) suffered hematogenous complications. The catheter
was removed within 24 hours in 62% of the patients, antibiotic therapy
was initiated within 24 hours in 87%.
Attributable mortality was signiﬁcantly associated with failure to initiate
antibiotic therapy withing 24 hrs and with age, but not with failure
to remove the intravascular catheters within 24 hrs. The use of a
tunneled intravenous catheter was associated both with a delay in catheter
extraction and with a rapid initiation of antibiotic therapy. Changes in
the assessment of outcome (all cause mortality, attributable mortality or
hematogenous complications) determined which risk factors were found
signiﬁcant.
Conclusion: In this study, immediate initiation of antibiotic therapy was
signiﬁcantly associated with a lower incidence of attributable 3-month
mortality, but not with less all cause 3-month mortality. However, studies
into this subject are severely hampered by selection bias.
P1482 Healthcare-associated versus hospital-acquired
Staphylococcus aureus bacteraemia
H. Shaked*, M. Paul, J. Bishara (Petah Tikva, IL)
Objective: Staphylococcus aureus bacteremia is acquired mainly in the
hospital or in other healthcare settings. Data indicate that patients with
health-care-associated (HCA) infections have a unique epidemiology and
that the causative pathogens and the outcomes related to these infections
more closely resemble those seen with infections acquired in the hospital.
The objectives of this study were to characterize demographic, clinical
features, and outcomes of patients with HCA and HA Staphylococcus
aureus bloodstream infections.
Methods: Retrospective cohort study conducted in a single center
between 1988–2007. Patients with clinically-signiﬁcant S. aureus
bacteremia were included and classiﬁed by place of acquisition. We
compared between patients with hospital-acquired (HA) and healthcare-
associated (HCA) bacteremia. Risk factors for 30-day all-cause mortality
were assessed using multivariable logistic regression analysis. We
documented microbiological failure (deﬁned as persistence or relapse),
1-year mortality and 5-year survival. Cox regression analysis was used to
estimate the hazard ratio (HR) for 5-year mortality with 95% conﬁdence
intervals (CI).
Results: Out of 1,347 episodes of S. aureus bacteremia, 86 were
community-acquired and 1,261 episodes acquired in hospital or health-
care setting constituted the study population. The proportion of MRSA
was 48.2% (354/735) in HA vs. 42.2% (222/526) among HCA
bacteremias, p = 0.04 overall and similar in the last 3 study years
(122/244, 50% vs. 71/147, 48.3%, respectively, p = 0.74). The proportion
HCA S. aureus bacteremias or MRSA bacteremias did not change
throughout the study period. Mortality at 30 days and 1 year was
40.2% (507/1261) and 63.4% (800/1261) and similar for HA and HCA
bacteremias. Five-year survival curves in both settings followed very
similar patterns (HR 1.01, 95%CI 0.89–1.15). Risk factors for 30-day
mortality were similar except for primary bacteremia, female sex and
heart valve disease in the HA bacteremia group, and poor functional
capacity in the HCA group.
Conclusion: HCA S. aureus bacteremia shares many similarities with
HA bacteremia, especially with respect to the prevalence of MRSA
strains and mortality rates and should be managed similarly.
P1483 Impact of infectious diseases consultation on outcome of
methicillin-resistant Staphylococcus aureus bacteraemia in
a tertiary care centre: a ten-year experience
F. Tissot*, T. Calandra, G. Prod’hom, D.S. Blanc, G. Zanetti, G. Greub,
L. Senn (Lausanne, CH)
Objectives: To assess the impact of infectious diseases (ID) consultation
on the management and outcome of methicillin-resistant Staphylococcus
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aureus (MRSA) bacteremia in a tertiary care center over the last ten
years.
Methods: Medical records of all patients with MRSA bacteremia
from 2001 to 2010 were retrospectively reviewed. Data regarding
demographics, clinical and microbiological characteristics of MRSA
infections, ID consultation, antibacterial treatment, vancomycin blood
levels and outcome were collected.
Results: From January 2001 to July 2010,160 MRSA bacteremia
episodes occurred in 143 patients. One hundred nineteen episodes (74%)
were hospital-onset infections. Seventy-two percent of patients were
male. Median age was 71 (range 1−97). Fifty-three percent were known
to be colonized with MRSA before the ﬁrst episode of bacteremia. The
most frequent sites of primary infection were central venous catheter
(29%), skin (23%), lung (14%) and urinary tract (12%). An MRSA-
active antibiotic was prescribed in 147 episodes (92%). Vancomycin
was the ﬁrst-line treatment in 138. Vancomycin blood level was done in
130 and ﬁrst through level was <15mg/l in 74%. Overall mortality was
41% and attributable mortality 21%. ID consultation was performed for
107 (67%) episodes of bacteremia, rising from 44% in 2001 to 73% in
2010. ID consultation was signiﬁcantly associated with a more frequent
use of MRSA-active treatment (98% vs 81%, p< 0.001), more frequent
vancomycin blood level measurements (98% vs 77%, p< 0.001), more
frequent bacteremia >7 days (12% vs 0%, p = 0.02) and lower overall
mortality (34% vs 56%, p = 0.011). First vancomycin through level
<15mg/l was less frequent in ID consultation group (70% vs 84%,
p = 0.16) and repeat blood culture more frequent (63 vs 46%, p = 0.08),
although not signiﬁcantly. Attributable mortality was also decreased
(17% vs 31%, p = 0.06).
Conclusion: ID consultation was associated with a higher rate of
appropriate antimicrobial therapy and a reduced overall and attributable
mortality in patients with MRSA bacteremia. ID consultation should be
obtained in all MRSA bacteremia.
P1484 Clinical and molecular characterisation of Staphylococcus
aureus bloodstream infections in a university hospital, Italy
F. Tordato*, E. Borghi, M. Cainarca, F. Crippa, G. Morace,
A. d’Arminio Monforte (Milan, IT)
Objectives: Staphylococcus aureus (SA) is one major cause of
bloodstream infection (BSI) and is associated with signiﬁcant morbidity
and mortality. As the outcome of these infections is usually determined
by virulence factors and host response, we focused on clinical and
molecular characterization of all consecutive SA BSI observed in our
hospital during a 2-year-surveillance.
Methods: Observational, prospective study. We included all the
inpatients consecutively observed between 01/01/2008 and 31/12/2009
with 1 positive blood culture for SA in the presence of clinical signs
of infection (SA-BSI). Clinical and demographic parameters of patients
enrolled in the study were compared using the chi-square and t test. In
MRSA strains, the SCCmec type was determined.
Results: We observed 81 SA-BSI in 72 patients. 32% (25/72) of BSI
were caused by MRSA (MRSA BSI). In MRSA strains, SCCmec type
I was found in 45% and type IV in 55% of cases. Both microbiology
and clinical data are available for 51 out of 72 patients. Median age was
68 years (range 2−99); diabetes (36%) was the most frequent underlying
disease, followed by haemodialysis (21%) and cancer (18%). 37% of
cases were CVC related. Overall crude mortality was 30%; MRSA BSI
were associated with higher prevalence of mortality (57% vs 6% MSSA
BSI, p 0.0001). Patients with MRSA BSI were older than those with
MSSA BSI (75 vs 63 years; p = 0.04) whereas the two groups were
comparable for underlying diseases. As compared with MSSA BSI,
MRSA BSI were more frequently related to presence of CVC (64%
vs 28% MSSAB; p = 0.01) and to surgical procedures (42% vs 16%;
p = 0.04).
Conclusion: Our ﬁndings conﬁrm a high prevalence of mortality
associated with SA BSI, mainly in MRSA BSI. Patients carrying
indwelling devices, with history of surgery and older age are prevalent
in MRSA BSI. Type IV represents the most common SCCmec type in
our hospital.
P1485 Intensive care unit candidaemia: a 2-year retrospective
analysis in a Greek tertiary-care hospital
V. Mamali*, G. Vrioni, M. Drogari-Apiranthitou, A. Prekates, K. Themeli-
Digalaki, A. Mitroussia-Ziouva, A. Tsakris (Piraeus, Athens, GR)
Objectives: Candidaemia represents an important cause of morbidity
and mortality in critically ill patients. We investigated the species
distribution among Candida isolates from blood cultures and their
antifungal susceptibility patterns during a 2-year period in the intensive
care unit (ICU) of a tertiary care hospital.
Methods: A retrospective analysis was conducted from Jan 2009 to
Dec 2010 in the 13-bed ICU of Tzaneion General Hospital, Greece.
Candida isolates were identiﬁed using API AUX and Vitek2 automated
system (BioMerieux). Antifungal susceptibility was investigated using
the Vitek2 system complemented with Etesting (AB Biodisk) and
broth microdilution method (Yeast One 10, Oxoid, UK). MICs were
evaluated according to CLSI criteria for anidulafungin, amphotericin B,
ﬂuconazole, voriconazole and 5-ﬂucytosine.
Results: During the study 41 episodes of candidaemia were identiﬁed in
38 patients. Three patients developed a second episode of candidaemia
within four to eight weeks, caused by different Candida species.
C. parapsilosis was the prevailing species representing 51.2% of all
isolates (21/41), followed by C. albicans (24.4%, 10/41), C. glabrata
(12.2%, 5/41), C. tropicalis (9.8%, 4/41) and C. dubliniensis (2.4%,
1/41). In terms of in vitro susceptibility, all Candida isolates were
susceptible to amphotericin B and voriconazole. Only one C. glabrata
isolate was found highly resistant to 5-ﬂucytosine (MIC >64). Two
C. parapsilosis strains showed resistance to ﬂuconazole (MIC >64).
The majority (61.9%) of C. parapsilosis exhibited resistance to
anindulafungin (MIC 8).
Conclusions: In our hospital setting, C. parapsilosis outranked
C. albicans as the dominant species causing candidaemia among ICU
patients. The emergence of C. parapsilosis strains with in vitro resistance
to echinocandins poses a challenge for the empirical treatment of
candidiasis in ICU patients.
P1486 Epidemiology of candidaemia in an Italian tertiary hospital
during a 7-year period: January 2004-November 2010
A.M. Azzini, M. Cordioli*, G. Lo Cascio, P. Sette, E. Concia (Verona,
San Bonifacio, IT)
Objective: To evaluate trends in candidaemia (CA) between 2004 and
2010.
Methods: From Jan 2004 to Dec 2008 (period A) all CA episodes
were retrospectively identiﬁed and demographic/clinical characteristics,
data about antifungal drugs and other predisposing factors within the 2
weeks before its onset were collected, including CVC-related CA The
antifungal susceptibility patterns of species were collected. Same data
were perspectively collected from Jan 2009 to Nov 2010 (period B).
Results: We identiﬁed 226 CAs (170 period A, 56 period B). The
incidence was 1.71/10000 patient-days in 2004 and 2.09 in 2009, with
a peak of 2.53 in 2005; 92% was hospital acquired.
During A 29.4% of CA occurred in ICU, followed by surgical and
medical wards (both 28.2%) and neonatal intensive care unit (NICU)
(14.1%); during B 48.2% of CA occurred in medical wards, followed
by surgical ones (30.4%), ICU (16.1%) and NICU (5.4%).
Table 1 shows Candida isolates and their ﬂuco-susceptibility.
During A and B the most frequently isolated species in medical wards
was C. albicans (50% and 37%). Inside ICU, NICU and surgical wards
it was the ﬁrst species during B (67%, 67% and 59%) but during A
C. parapsilosis was more frequent (37.5%, 45.8% and 44%).
CVC-related CA increased (31.2% in A,51.5% in B), in both periods
2/3 of CVC were removed but later than 48 hours from the diagnosis in
26.2% and 25.6% respectively.
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84.4% of patients received antifungals in period A and 83.9% in period
B, therapy started within 48 hours from the diagnosis in 59.2% of CA
during A and 61.7% during B. It was adequate for the antimycogram in
56.6% and 89.4% of cases respectively, and for duration in 62.5% and
42.6%. During A and B ﬂuconazole was the ﬁrst employed drug (67.8%
and 51.4%), followed by any amphotericin B lipid-formulations during
A (44.8%) and caspofungin during B (22.9%).
Conclusions: CA annual incidence was high. There was a shift of CA
from ICU toward surgical and medical areas, maybe for the greater
number of abdominal-pancreatic surgical patients and, in general, for
the increasing number of more serious patients bedridden outside the
ICU. The increased frequency of CVC-related CA in part is due to
the perspective way to collect data and reﬂects the larger use of the
device (CVC presence 81.2% during A and 92.9% during B). Treatment
adequacy remains a challenge in terms of starting delay (median 4 days
in period A and 4.5 days in period B) and duration (median 8 days in
period A and 9 days in period B).
P1487 Pre-exposure to antifungals as a risk factor for
ﬂuconazole-non-susceptible Candida species in hospitalised
patients with candidaemia
D. Shah*, R. Yau, J. Weston, T. Lasco, M. Salazar, H. Palmer, K. Garey
(Houston, San Antonio, US)
Objective: Pre-exposure to azole antifungals has been identiﬁed as a
risk factor for ﬂuconazole-non-susceptible (FLU-NS) Candida species in
hospitalized patients with candidemia. However, whether pre-exposure
to other antifungals increase the risk of FLU-NS Candida species is
unknown. The purpose of this study was to evaluate antifungals as a
risk factor for ﬁrst occurrence of candidemia with FLU-NS Candida
species.
Methods: Retrospective cohort study of hospitalized patients with
ﬁrst occurrence of candidemia from 2006−09. Susceptibility of
Candida species was determined using automated susceptibility testing
(ﬂuconazole) or E-test (caspofungin). The CLSI MIC breakpoint of
8mg/ml of ﬂuconazole was used to deﬁne susceptible Candida species
and MIC of 16mg/ml deﬁned was used to deﬁned FLU-NS. Relative
risk (RR) and 95% conﬁdence intervals (CI) were calculated for variables
with signiﬁcant difference between patients with ﬂuconazole susceptible
(FLU-S) vs. FLU-NS Candida species candidemia (p< 0.05 considered
signiﬁcant).
Results: One hundred seventy-seven patients aged 59±16 years (male:
55%, Caucasian: 53%, Apache II15: 47%) were identiﬁed o f whom 34
(19%) had FLU-NS Candida species. One isolate was non-susceptible
to caspofungin (MIC=16mg/ml). Candida species includedC. albicans
(49%), C. glabrata (20%), C. parapsilosis (13%), and C. tropicalis
(13%). Thirteen of 143 (9%) patients with FLU-S species and 8 of
34 (24%) patients with FLU-NS species had prior azole exposure (RR:
2.29, 95%CI: 1.20–4.37, p = 0.02). Ten of 143 (7%) patients with FLU-S
species and 5 of 34 (15%)patients with FLU-NS species had prior
echinocandin exposure (RR: 1.86, 95%CI: 0.85–4.09, p = 0.15). The
other identiﬁed risk factor for FLU-NS species was total parenteral
nutrition (TPN) administered to 56 of 143 (39%) patients with FLU-S
candidemia and 20 of 34 (59%) patients with FLU-NS candidemia (RR:
1.90,95%CI: 1.03–3.51, p = 0.04).
Conclusion: Prior azole exposure and administration of TPN were
identiﬁed as risk factors for ﬁrst occurrence of candidemia with FLU-NS
Candida species. Echinocandins were not identiﬁed as a risk factor for
isolation of FLU-NS Candida species.
P1488 Sepsis in critically ill patients in Swedish intensive care units
G. Fransson, L. Nilsson, A. Petropoulos, S. Walther, H. Hanberger*
on behalf of the ICU-Strama and Swedish Intensive Care Registry
Objectives: Almost all Swedish ICUs report patient data to the Swedish
Intensive Care Registry (SIR), which is linked to the national mortality
registry, but data from the microbiology laboratories have been missing
in SIR. The purpose of this work was to develop and test the feasibility
of a web service system for continuous collection of results from
microbiological cultures in critical ill patients and to measure the
mortality in culture veriﬁed sepsis in critical ill patients.
Methods: 1073 patients admitted to ICUs in the county of O¨stergo¨tland,
from 2005 to 2010, with sepsis as the main diagnosis and positive blood
cultures, were included. A web service was developed for individual
collection of results from microbiological cultures taken 2 weeks before,
during and 2 weeks after each admission to the ICU. Data on gender, age,
co-morbidity were collected from SIR and correlated to microbiological
ﬁndings and 30-day mortality.
Results: The most common pathogens found in blood cultures
were Coagulase Negative Staphylococci (CoNS), (38.9%) followed
by S. aureus (22%), Enterobacteriaceae (21.6%): E. coli (8.8%),
Klebsiella spp (5.7%), Candida spp (5.7%) and Streptococcus spp
(4.5%). Frequencies of decreased susceptibility among E. coli were for
cefotaxime (1.9%), imipenem (0%), piperacillin-tazobactam (5.2%) and
tobramycin (1.7%). Corresponding ﬁgures for Klebsiella spp were for
cefotaxime (3.8%), imipenem (0%), pip-tazo (6.7%) and tobramycin
(1.8%). The frequencies of methicillin and klindamycin resistance among
S. aureus were (4.8%) and (5.0%) respectively. The 30 day mortality in
patients with sepsis/fungemia caused by the following pathogens were:
Candida spp 24.1%, CoNS 7.8%, E. coli 14%, Klebsiella spp 18% and
S. aureus 39%.
Conclusion: S. aureus, the second most prevalent pathogen found in
blood cultures, was associated with the highest 30 day mortality. CoNS,
which is less virulent, was the most frequently found pathogen in
blood cultures and associated with the lowest mortality. The ﬁnding
of CoNS in blood cultures should always be interpreted with caution
and further validated since CoNS often contaminates blood cultures.
E. coli and Klebsiella spp were associated with intermediate 30 day
mortality. Antibiotic resistance was in general low but increasing. The
new microbiological web service may be a useful tool for future studies
of burden of antibiotic resistance in the critically ill.
P1489 Risk factors of nosocomial bacteraemia in intensive care
units vary between causative agents: results of a prospective
surveillance data from 2003 to 2006
N. Khanafer*, P. Vanhems (Lyon, FR)
Objectives: Risk factors of nosocomial bloodstream infections (NBSI)
are rarely compared by bacteria. The objectives were to describe NBSI
in intensive care unit (ICU), to identify their associated risk factors and,
to compare the risk factors of Staphylococcus aureus- and Pseudomonas
aeruginosa-related NBSI.
Methods: A nested case-control study, based on surveillance data in
ICU of Lyon University hospitals, was conducted between 2003 and
2006. 8,755 adult patients and admitted in ICU for more than 48 hours
were included.
Results: A total of 389 (4.4%) patients had NBSI. The most frequently-
isolated micro-organisms were S. aureus (17.0%) and P. aeruginosa
(11.8%). Previous ICU hospitalization (OR: 2.02), urgent surgery (OR:
1.32), elective surgery (OR: 1.62), Simpliﬁed Acute Physiology Score
II (SAPS II) >30 (OR: 1.66), exposure to invasive devices (OR: 26.10),
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length of stay (LOS) >1 week (OR: 3.72) and period of stay (OR: 1.50)
were independent risk factors for NBSI.
Age 40 to 50 years (OR: 4.38) and LOS >7 days (OR: 4.42) were
linked with S. aureus NBSI. Admission from long-term care facilities
(OR: 4.88) or previous ICU hospitalization (OR: 3.40), LOS >7 days
(OR: 8.26), elective surgery (OR: 2.23), increasing SAPS II score (OR:
3.06) and year 2005 (OR: 4.32) were risk factors of P. aeruginosa NBSI.
Previous hospital stay (long-term care OR: 20.47; acute care OR: 2.72;
and ICU OR: 7.42), elective surgery (OR: 7.38) and year 2005 (OR:
10.04) were associated with P. aeruginosa NBSI rather than S. aureus
NBSI.
Conclusion: Identifying risk factors of ICU-acquired BSI may help to
optimize appropriate preventive procedures and some measures might
have different impact regarding the causal bacteria.
P1490 Antimicrobial resistance in ICU-acquired bacteraemias in
13 European intensive care units
L.P. Derde, M.J. Dautzenberg, P.J. van Duijn*, C. Brun-Buisson,
M.J. Bonten on behalf of the MOSAR research consortium
Objective: To quantify incidences of ICU-acquired bactaeremia caused
by Antimicrobial Resistant bacteria (AMRB) in 13 European ICUs
participating In the MOSAR ICU trial.
Methods: As part of a European cluster-randomized trial, a 6 month
observational study was performed between May 2008 and Oct 2009.
The 13 participating ICUs were in France, Greece, Italy, Latvia,
Luxemburg, Portugal, Slovenia and Spain. ICU-acquired bactaeremia
(MRSA, VRE and Gram-negative) was deﬁned as occurring >2 days
after ICU-admission.
Results: During the study 2854 patients were included comprising
30400 admission days. Patients had an average age of 64 years and
median APACHE-II and SAPS-II scores of 15 and 57, respectively. There
were 74 episodes of AMRB bacteraemia in 50 patients (3 (6%) were
polymicrobial) caused by MRSA (n = 6), VRE (n = 4), Enterobacteriaceae
(n = 32), Acinetobacter (n = 11), P. aeruginosa (n = 18) and “Other”
(n = 3). Of non-bacteraemia patients 19% deceased in the ICU, versus
52% of bacteraemia patients. Patients acquiring a ICU-bacteraemia had
a median LOS of 36 days. Patients were admitted a median of 21
days (range 3–154) before acquiring a bacteraemia. For all pathogens,
the incidence rate was 25 per 10,000 days at risk with a range of 0
to 142 episodes per 10,000 patient days at risk. The incidence was
21 (range 0–143) and 3 (range 0−14) per 10,000 patient days at risk
for Gram-negative and Gram-positive (MRSA and VRE), respectively.
ICU-acquired bacteraemia caused by Enterobacteriaceae occurred most
frequently (16 per 10,000 patient days at risk; range 0−72), followed by
P. aeruginosa (6,3; range 0−25), Acinetobacter species (5; range 0−28)
and MRSA (4,6; range 0−21,9).
Conclusion: In these 13 ICUs across Europe the average incidence
of ICU-acquired bacteraemia was 25 per 10,000 patient days at risk,
with marked geographical variance in incidence rates. Most episodes
were caused by Gram-negative bacteria. This 6-month baseline period,
will be followed by implementation of hand hygiene improvement
and chlorhexidine body washings (period 2, 6 months) and additional
rapid diagnostic testing to detect carriage with ARB at ICU-admission
followed by isolation of carriers (period 3, 12 months).
P1491 Bacteraemia and antibiotic resistance of its pathogens
reported in Greece between 2000 and 2009: trend analysis
M. Polemis*, K. Triﬁnopoulou, S. Chrisochoidou, M. Panopoulou,
E. Platsouka, K. Tzanetou, V. Galanopoulou, E. Skouteli,
C. Koutsia-Carouzou, K. Poulopoulos, M. Anagnostopoulou,
M. Toutouza, K. Aveliodi, A. Pasxali, K. Dimarogona, P. Karampogia,
A. Petridis, A. Mavridis, E. Tsorlini, E.M. Fakiri, S. Nikolaou,
E. Kaitsa-Tsiopoulou, G. Stamatopoulou, A. Vatopoulos (Vari,
Thessaloniki, Alexandroupolis, Athens, Corfu, Ioannina, Xanthi, GR)
Objectives: Since 1996, the surveillance network for antimicrobial
resistance in Greece (WhoNet Greece) has been collecting and analyzing
routine antimicrobial susceptibility test results of all the microorganisms
isolated in Greek hospitals. Aim of the study was to explore the
existence of temporal trends in both the frequency of isolation and the
susceptibility variation of prevalent pathogens, causes of bacteraemia in
the last 10 years.
Methods: Data from 21 hospitals with consistent participation in the
WhoNet Greece network was used. The existence of temporal trends was
conﬁrmed using the statistical method of trend analysis for proportions
(Stata) with a signiﬁcance threshold of p-value 0.05.
Results: We found a statistically signiﬁcant increase in the isolation
frequency of Klebsiella pneumoniae, Acinetobacter baumannii and
Enterococcus sp strains and a decreasing trend in the isolation frequency
of Enterobacter sp, Escherichia coli and Staphylococcus aureus strains
in blood cultures from both intensive care units and medical/surgical
wards. The isolation frequency of Pseudomonas aeruginosa was stable
over time. A temporal increase was observed in the resistance of
K. pneumoniae, A. baumannii and P. aeruginosa strains to both third-
generation cephalosporins and carbapenems. As far as Gram-positive
cocci are concerned, the existence of an increasing resistance trend of
Enterococcus faecium to vancomycin was noted, while the resistance
levels of S. aureus to methicillin were stable over time.
Conclusion: The increasing isolation trends for multiresistant Gram-
negative bacteria and more speciﬁcally for K. pneumoniae and
A. baumannii, indicate an alteration in the epidemiology of infections in
Greek hospitals and should be regarded in connection to the observed
increased resistance levels in carbapenems.
P1492 Resistance evolution in antibiotics of the most prevalent
Gram-negative bacteria isolated from blood cultures in ICU
patients during eight years (2002–2009)
M. Orfanidou, M. Kamperogianni, E. Vagiakou*, G. Ganteris,
P. Afentoglou, A. Karabinis, E. Malamou-Lada (Athens, GR)
Objectives: To study the resistance evolution in antibiotics of the most
frequent Gram negative bacteria, which have been isolated from blood
cultures in ICU patients, during eight years, in a tertiary hospital of
Greece.
Methods: A total of 2474 strains were isolated from blood cultures of
ICU patients using BacT-ALERT bottles (bioMerieux). The identiﬁcation
was performed by VITEK II (bioMerieux) and susceptibility testing by
Kirby-Bauer method. MICs were determined by VITEK II and E-test
method, according to CLSI instructions.
Results: The number of Gram negative isolated bacteria was 1343
and the most prevalent were: Acinetobacter baumannii (Ab) (539/1343,
41%), Klebsiella pneumoniae ssp pneumoniae (Kp) (343/1343, 25%)
and Pseudomonas aeruginosa (Pa) (304/1343, 23%).
Ab revealed increased resistance to ampicillin/sulbactam from 16%, ini-
tially, to ~70% in the last three years. The resistance to aminoglycosides
started from ~90%, the ﬁrst two years, to decrease, in the next years, to
45−75%. Carbapenem resistance was 60−80% the ﬁrst three years and
>90% the rest ﬁve years. Resistance 3% in colistin was ﬁrst notiﬁed in
2009.
Kp revealed resistance in cephalosporines >80%. In aminoglycosides,
from <20% reached ~60% in 2008; but in 2009 a decrease of gentamicin
(GN) resistance (14%) was observed, while it remained high in amikacin
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(AM) (73%). Carbapenem resistance started from ~30% and remained
<60% until 2005, to reach 85% in 2009. In 2006, rises resistance 7% to
colistin and remained to 3−6%.
Pa revealed resistance in ceftazidime 60−85% and in both carbapenemes
50−80%, during the study period. In AM and GN, a decrease of
resistance was observed from 80% and 94%, initially, to 40% and 45%
in 2009, respectively. No resistance was recorded for colistin.
Conclusions: The most frequently isolated Gram negative bacteria
from blood cultures of ICU patients were Ab, Kp and Pa. All strains
revealed high level resistance in cephalosporines, carbapenemes and
aminoglycosides. Last choice for the confrontation of the ICU infections,
remains colistin, although there is a rising resistance to colistin in
Ab and Kp. So, antibiotic policy along with the implementation of
infection control measures are warranted for the prevention of infection
dissemination.
P1493 Burden of resistance: mortality and hospital stay
attributable to antibiotic-resistant Staphylococcus aureus
and Escherichia coli bacteraemias in Europe
M.E.A. de Kraker*, P.G. Davey, H. Grundmann (Bilthoven, NL;
Dundee, UK)
Objectives: The relative importance of human diseases is conven-
tionally assessed by cause-speciﬁc mortality, morbidity and economic
impact. Current estimates for infections caused by antibiotic-resistant
bacteria are not sufﬁciently supported by quantitative empirical data.
This study determined the incident and expected excess number
of deaths, bed-days and hospital costs attributable to bacteraemias
caused by methicillin-resistant Staphylococcus aureus (MRSA) and
third-generation cephalosporin-resistant E. coli (G3CREC) in 31
countries which participated in the European Antimicrobial Resistance
Surveillance System (EARSS).
Methods: The incidence of MRSA and G3CREC bacteraemia per
100,000 population was extracted from EARSS prevalence data and
national health care statistics. Prospective cohort studies, carried out in
hospitals participating in EARSS in 2007, provided the parameters for
estimating the 30-day excess mortality and extra hospital stay attributable
to MRSA and G3CREC bacteraemias between 2007 and 2015. Hospital
expenditure was derived from a publicly available cost model.
Results: In 2007, 4.8 (CI95 4.5−5.0) episodes of MRSA bacteraemias
per 100,000 population caused 5503 (CI95 3136–8276) excess deaths
and 255,683 (CI95 142,934–375,880) extra hospital days in 31 countries
in the European region, whereas 2.6 (CI95 2.4−2.8) episodes of G3CREC
bacteraemias per 100,000 population led to 2712 (CI95 595–5780)
excess deaths and 120,065 (CI95 52,272–198,338) extra hospital days.
The total cost attributable to extra hospital stay was 44.0 and 18.1
million euro, equivalent to 63.1 and 29.7 million international dollars,
respectively. Based on prevailing trends, the number of excess deaths
attributable to MRSA bacteraemias is estimated to decrease to 2075
(CI95 1106–3293), but deaths attributable to G3CREC are predicted to
increase to 15,297 (CI95 3435−32,408) in 2015.
Conclusion:Mortality attributable to MRSA and G3CREC bacteraemias
is signiﬁcant, and the attributable bed-days impose a considerable
burden on health care systems. A foreseeable shift in the burden of
antibiotic resistance from Gram-positive to Gram-negative infections will
exacerbate this situation and is reason for concern.
P1494 Empiric antibiotic therapy and multidrug-resistant Gram-
negative bloodstream infections in critically ill patients: does
colonisation status make a difference? A preliminary study
A. Mosca*, L. Dalﬁno, G. Tzakis, M. Spada, S. Coppolecchia,
F. Bruno, G. Miragliotta (Bari, IT)
Objective: Timely adequate empirical antimicrobial therapy signiﬁcantly
affects the outcome of critically ill patients with multi-drug resistant
(MDR) Gram negative bacteria (GNB) severe infections. The aim of the
study was to evaluate whether colonization status may predict etiology of
subsequent infection, improving adequacy of early empiric antimicrobial
treatment in ICU patients with MDR-GNB nosocomial bloodstream
infections (BSI).
Methods: A retrospective cohort study on nosocomial episodes of
MDR-GNB BSI in an adult population of critically ill patients was
carried out (1 August-30 November 2010). BSI was deﬁned as a
positive blood culture result on a sample obtained at the onset of
an infectious episode occurring after 48 hours of ICU stay. MDR
Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella
pneumoniae bacteraemic episodes were considered. For each patient,
only the ﬁrst episode was considered. Colonization status was detected by
active surveillance on rectal swabs (once weekly), tracheal aspirates and
urines (on admission and twice weekly). The isolation of microorganisms
with identical antibiotic susceptibility proﬁle from both prior (i.e. 7
preceeding days) surveillance specimen and bloodstream was deﬁned as
colonization concordance. The administration of at least one effective
in vitro antibiotic against the isolated pathogen, during the ﬁrst 24
hours from the onset of the infectious episode was deﬁned as the early
appropriate empiric antibiotic therapy.
Results: Out of 53 eligible patients, 25 BSI episodes were identiﬁed in 13
patients (Table 1). The lag time between colonization and bacteraemia
was 4.7 (±2) days. Colonization concordance was 68%: in particular,
prior colonization accurately predicted the implicated pathogens in 17
BSI episodes. In 15/17 (88.3%) episodes the detection of previous
colonization status made adequate the early empiric treatment, whereas
only in 3/8 (37.5%) episodes without pathogen prediction by surveillance
specimens the treatment resulted adequate (p = 0.007).
Conclusions: In critically ill patients, the knowledge of colonization
status by MDR-GNB might act as an useful guide for empiric antibiotic
selection, leading to higher rates of appropriate empiric therapy within
the ﬁrst 24 hours of infection. Cost-effectiveness of this strategy requires
further clariﬁcation on a larger basis.
P1495 Gram-negative bacterial bloodstream infections: resistance
patterns and risk factors
A. Hristea, I. Olaru*, O. Dorobat, M. Nica, M. Ion, V. Petcu, C. Tenea,
I. Badicut, R. Moroti, V. Arama, C. Popescu, A. Raﬁla, E. Ceausu
(Bucharest, RO)
Objectives: (1) To describe the resistance patterns of Gram negative
bacilli (GNB) isolated from blood cultures and (2) identify the
epidemiological characteristics associated with multi-drug resistance
(MDR).
Materials and Methods: Retrospective study of the susceptibility proﬁle
of GNB strains isolated from blood stream infections (BSI) from patients
admitted to two tertiary infectious diseases facilities between Jan 2009-
Dec 2010. Bacteria were isolated in BacT/ALERT and identiﬁed by
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classic techniques or automated methods: miniAPI, VITEK2C. The
susceptibility test was done by disk-diffusion and automated methods
(CMI-ATB Expression/BioMerieux, VITEC2C, E-test) according to
CLSI guidelines. Clavulanic acid synergy test was done to identify
extended spectrum b-lactamase (ESBL) production. MDR was deﬁned
as resistance to 3 or more classes of antimicrobial agents.
Results: From 214 patiens, 219 non-duplicate isolates were identiﬁed.
The strains included: E coli (54%), Klebsiella spp (17%), Salmonella spp
(5%), P aeruginosa (7%), Acinetobacter spp (5%), other Enterobacteri-
aceae (9%) and other non-fermenters (3%). The prevalence of resistance
to at least one, two, and three classes of drugs were 69%, 52% and
33%, respectively. ESBL production was detected in 13% of E. coli
and 38% of Klebsiella spp. Carbapenem resistance was identiﬁed in 8
of 11 Acinetobacter spp and 9 of 15 P aeruginosa isolates as compared
with 2.2% in Enterobacteriaceae. Clinical and epidemiological data were
available for 140 (65%) patients. The primary source of bacteremia
were suspected to include: urinary tract (44%), gastrointestinal (18%),
pulmonary (12%), others (6%), and unknown sites (20%). Nosocomial
infections occurred in 51%. Combined resistance to third generation
cephalosporins (C3G), aminoglycosides (AG) and quinolones (Q) was
observed in 22% of nosocomial infections and 8,8% community
infections. Prior hospitalization, recent urinary tract infection, antibiotic
use and recent surgery were each associated with MDR BSI. In
multivariate analysis, only prior antibiotic use was associated with MDR
BSI (p = 0.02, 95%CI).
Conclusions: High MDR prevalence (33%) was observed in patients
with BSI in our study. Combined resistance to C3G, AG and Q was
considerably higher than that reported for other European countries,
especially in patients with nosocomial infections. Antibiotic use within
the past 3 months was associated with MDR BSI in our patient
population.
This paper is partially supported by the Sectoral Operational Programme
Human Resources Development, ﬁnanced from the European Social
Fund and by the Romanian Government under the contract number
POSDRU/89/1.5/S/64109
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P1496 Factors associated with death or ICU admission due to
pandemic 2009 inﬂuenza A/H1N1 infection
A. Moradi*, P. Tabarsi, S.A. Nadji, M. Marjani, P. Baghaei,
D. Mansouri (Tehran, IR)
Objective: Because, identifying factors associated with death or ICU
admission of patients who were hospitalized with 2009 H1N1 inﬂuenza
is important in preparation for potential upcoming waves of pandemic
H1N1 inﬂuenza, the study was designed to describe the clinical and
epidemiological features associated with ICU admission or death of
patients who were hospitalized with 2009 H1N1 inﬂuenza infection.
Methods: A retrospective cross-sectional study was conducted among
patients who were hospitalized with conﬁrmed 2009 H1N1 virus
infection. Their demographic, clinical, laboratory, radiological ﬁndings
and epidemiologic data were abstracted from medical records, using a
standardized report case-history form.
Results: From June through December 2009, 20 out of 46 conﬁrmed
hospitalized cases of 2009 H1N1 virus infections were admitted to an
intensive care unit (ICU) and 7 (15%) died. Among various variables,
opium inhalation (P-value: 0.01), having productive cough, hemoptysis,
chest pain, confusion and loss of consciousness were signiﬁcantly related
to ICU admission (p-value <0.05). Pleural effusion (P-value=0.006),
elevated liver enzymes, CPK and LDH level were signiﬁcantly relevant
to ICU admission. (P-value <0.05) Delayed antiviral treatment was more
common among patients who died and they were aged.
Conclusion: Severe pandemic H1N1 inﬂuenza necessitating admission
to the ICU was associated with delayed initiation of antiviral therapy,
history of opium inhalation and some symptoms including; productive
cough, hemoptysis, chest pain, confusion and loss of consciousness.
Mortality rate in the population study was high but compares favorably
with other studies have been published yet.
Table: Co-existing conditions, para clinical data and treatment regimen of
hospitalized patients with laboratory-conﬁrmed 2009 pandemic (H1N1)
inﬂuenza
Characteristic Total
(n = 46)
ICU (n = 20) Hospital
(other
than ICU)
(n = 26)
p value*
Lab Data, %
Leukocytosis 25.6 25 26.1 0.9†
Leukocytopenia 11.6 20 4.3 0.1‡
Thrombocytopenia 41.9 55 30.4 0.1†
Anemia 34.9 35 34.8 0.9†
Elevated LFT 65.2 85 54.2 0.05‡
CPK 440±567 639±696 259 ±342 0.02‖
LDH 825±609 115 ±727 550 ±286 0.001‖
ESR 45.9±35.2 47.5±36.4 44.3±35 0.7‖
O2 saturation 79.3±12.9 70±12.2 87.3±6.8 0.000‖
Cr 1.1±1.1 1.4±1.57 0.9±0.2 0.16‖
Positive Sputum Culture for
bacteria, %
19.6 30 11.5 0.1‡
Acinetobacter 8.7
Pseudomonas 6.5
Coagulase negative staphylococci 4.3
Positive Blood Culture, % 10.9 15 7.7 0.6‡
E-coli 4.3
Pseudomonas 4.3
Acinetobacter 2.3
Abnormal Chest X-Ray ﬁndings, % 73.9 95 57.7 0.006‡
Bilateral 80 90 66.7 0.1†
Ground glass 42.9 50 33.3
patchy 32.6 30 33.3
consolidation 25.7 20 33.3
Pleural effusion 8.7 20 0 0.03‡
Pneumothorax 4.3 10 0 0.2‡
Coexisting conditions, %§
Any 45.7 45 46 0.5†
Asthma 17.4 20 15 0.7‡
Malignancy¶ 8.7 5 11 0.4‡
Hypertension 8.7 5 11 0.4‡
Transplantation†† 4.3 0 8 0.3‡
COPD 4.3 5 3.8 0.6‡
HIV 2.3 5 0 0.4‡
Diabetes 2.3 0 3.8 0.5‡
Chronic renal failure 2.3 5 0 0.4‡
Primary Immune deﬁciency§§ 2.3 5 0 0.4‡
Treatment Regimen
Oseltamivir 100 100 100
Antibiotic 97.8 100 97.8 0.5‡
Ceftriaxone 93.5 100 88.5 0.2‡
Azithromycin 95.7 100 92.3 0.4‡
Vancomycin 52.2 90 23.1 0.000‡
Corticosteroids 73.9 95 57.7 0.006‡
Intravenous immunoglobulin 4.3 10 0 0.1‡
*P values are for the comparison of patients admitted to ICU and regular ward; missing data were excluded.
†The P value was calculated with the use of a two-sided chi-square test.
‡The P value was calculated with the use of a two-sided Fisher’s exact test because of the small number of patients
(in one or both groups).
‖The P value was calculated with the use of t-test.
§Patients could have more than one symptom coexisting illness.
¶ including lymphoma (1), multiple myeloma (1), sarcoma (1), Hodgkin’s lymphoma (1).
†† one cardiac transplantation and one lung transplantation.
§§ including common variable immunodeﬁciency (CVID).
P1497 Two-site intradermal inﬂuenza vaccination in elderly
S. Sibunruang* (Bangkok, TH)
Objectives: While elderly possess one of the highest risk group
for serious inﬂuenza related complications but the immunosenescence
results in suboptimal response to preventive vaccination. Intrader-
mal (ID) approach had shown satisfactory outcomes both economics and
immunogenicity in young adults. We try to optimize the advantages of
ID vaccination to the aged by evaluating and comparing immunogenicity
and safety of the reduced-dose two-site intradermal (ID) inﬂuenza
vaccination containing all 6 and 12 micrograms of hemagglutinin antigen
(HA) per strain with standard intramuscular (IM) immunization in
elderly.
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Methods: We performed a randomized, open-label study in 180 healthy
community-dwelling adults age over 60 years. Subjects were randomly
assigned to receive two-site intradermal 2010 Southern hemisphere
trivalent inactivated split-virion inﬂuenza vaccine containing 3 or 6
micrograms of HA per strain per site into both deltoid each or
standard intramuscular injection containing 15 micrograms of HA per
strain (The vaccine was manufactured by Sanoﬁ Pasteur S.A. and
provided by Government Pharmaceutical Organization). Pre- and
Postvaccination measurements in the strain-speciﬁc hemagglutination
inhibition titers were analyzed by comparing geometric mean titers
(GMTs), seroconversion factor, seroconversion rates and seroprotection
rates. Local and systemic reactogenicity were assessed.
Results: Total 180 subjects aged 60−90 years (median 67±6 yrs, female:
male 4:1), of which Pre-vaccination HAI titers 1:40 were observed
for 5 (2.8%), 11 (6.1%), 11 (6.1%) of subjects to inﬂuenza A/H1N1,
A/H3N2 and B respectively. Four weeks after vaccination, GMTs,
seroconversion factor, seroconversion rates and seroprotection rates in
both ID groups were signiﬁcantly less than those of the IM group as
shown in table 1. However, the immune responses elicited by two-
site ID vaccinations were still sufﬁciently met the Committee for
Proprietary Medicinal Products (CPMP) criteria. Subanalysis among
subset of previous inﬂuenza vaccination recipients (n = 46) demonstrated
antibody responses achieved by all injection methods were comparable.
Local reactions at injection sites were signiﬁcantly higher among ID
groups but tolerable and transient.
Conclusion: In this study of vulnerable population, two-site ID
vaccination could be alternative dose-sparing strategies to expand annual
inﬂuenza vaccine supplies as well as prepare for waves of pandemic.
P1498 Immunogenicity of whole virion pandemic inﬂuenza H1N1
vaccine in HIV-infected patients
H. Lagler*, K. Grabmeier-Pﬁstershammer, V. Touzeau-Ro¨mer,
S. Tobudic, J. Leitner, G. Gualdoni, M. Redelberger-Fritz, S. Neumu¨ller-
Guber, T. Popow-Kraupp, A. Rieger, H. Burgmann (Vienna, AT)
Background: During the pandemic 2009 a whole virion, verocell
derived, inactivated, pandemic inﬂuenza H1N1 vaccine has been used
on a large scale in Austria (11/2009 to 3/2010). The objective of this
study was to determine the immunogenicity of the H1N1 vaccine in HIV
positive patients. No such analysis exists for this H1N1 vaccine, the only
unadjuvanted H1N1 vaccine at that time in Europe.
Methods: HIV-infected adults were recruited from the HIV department
at the Medical University of Vienna (Austria). The vaccination schedule
consisted of 2 intramuscular injections of the H1N1 vaccine (Celvapan®,
Baxter) with a 3 weeks interval. Efﬁcacy of the vaccination was assessed
by using a standard haemagglutination inhibition assay (HAI) before and
after each vaccination. The primary immunological end point was the
seroconversion rate, which was deﬁned as the proportion of subjects
with a 4-fold increase in HAI titer and a post-vaccination HAI titer
of 1:40. H1N1-speciﬁc IgG was determined by ELISA. Seropositivity
was deﬁned as IgG levels above 11 Virotech Units (VE).
Results: A total of 79 patients were enrolled (76% men, median age
of 40 years) and samples were taken for serological analysis. In 72
patients the full scheduled course of 2 vaccinations took place, 7 were
vaccinated only once. 59% of the patients received HAART therapy with
a VL below the limit of quantiﬁcation (BLQ), 51% had a VL BLQ since
more than 12 months and the median CD4 cell count was 505 cells/mm3.
Before vaccination the median HAI titer was 1:40 and increased to 1:80
after two vaccinations. 70% of serum samples at baseline had HAI titer
1:40, and 30% >1:40. After the 1st vaccination 29% demonstrated
seroconversion in the HAI and 24% were seropositive for IgG. After
the 2nd vaccination 41% showed seroconversion in the HAI, and 37%
were seropositive for IgG. Among the 21 (30%) participants with HAI
titers <1:40 before vaccination, at least 63% developed protective HAI
titers, but only 20% of these had also an IgG titer >11 VE after 2nd
vaccination (Figure 1). Young age was associated with seroconversion,
whereas none of the 7 patients >60 years seroconverted.
Conclusion: Our results show that the unadjuvanted pandemic H1N1-
Inﬂuenza vaccine induced limited but useful protective immune
responses in HIV-infected individuals.
P1499 Pandemic inﬂuenza on a military ship: retrospective
investigation of an inﬂuenza A/H1N1pdm outbreak on an
Italian military ship cruising in the Mediterranean Sea,
May-September 2009
D. Lapa*, C. Castilletti, M. Tarabbo, P. Tommaselli, R. Guarducci,
G. Luca`, A. Emanuele, O. Zaccaria, V. La Gioia, E. Girardi,
M.R. Capobianchi, G. Ippolito (Rome, Taranto, IT)
Background: Clinical surveillance may have underestimated the real
extent of the spread of the new strain of inﬂuenza A/H1N1, which
surfaced in April 2009 originating the ﬁrst inﬂuenza pandemic of the
21st century. Here we report a serological investigation on an inﬂuenza
A/H1N1pdm outbreak in an Italian military ship while cruising in the
Mediterranean Sea (May 24-September 6, 2009).
Methods: The contemporary presence of HAI and CF antibodies was
used to retrospectively estimate the extent of inﬂuenza A/H1N1pdm
spread across the crew members (median age: 29 years).
Findings: During the cruise, 2 crew members fulﬁlled the surveillance
case deﬁnition for inﬂuenza, but only one was laboratory conﬁrmed by
inﬂuenza A/H1N1pdm-speciﬁc RT-PCR; 52 reported acute respiratory
illness (ARI) episodes, and 183 reported no ARI episodes. Overall,
among the 211 crew member for whom a valid serological result
was available, 39.3% tested seropositive for inﬂuenza A/H1N1pdm.
The proportion of seropositives was signiﬁcantly associated with more
crowded living quarters and tended to be higher in those aged <40 and
in those reporting ARI or suspected/conﬁrmed inﬂuenza A/H1N1pdm
compared to the asymptomatic individuals. No association was found
with previous seasonal inﬂuenza vaccination.
Conclusions: These ﬁndings underline the risk for rapid spread of
novel strains of inﬂuenza A in conﬁned environment, such as military
ships, where crowding, rigorous working environment, physiologic stress
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occur. The high proportion of asymptomatic infections in this ship-
borne outbreak supports the concept that serological surveillance in
such semi-closed communities is essential to appreciate the real extent
of inﬂuenza A/H1N1pdm spread and can constitute, since the early
stage of a pandemic, an useful model to predict the public health
impact of pandemic inﬂuenza and to establish proportionate and effective
countermeasures.
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P1500 Diffusion of oﬂoxacin in the endocarditis vegetation
assessed with synchrotron radiation UV ﬂuorescence
microspectroscopy
E. Batard*, F. Jamme, S. Villette, E. Montassier, G. Potel,
M. Re´fre´giers (Nantes, Gif-sur-Yvette, Orle´ans, FR)
Objectives: Although the diffusion of antibiotics in vegetation bacterial
masses may inﬂuence their efﬁcacy in endocarditis, it has never been
studied. Synchrotron radiation UV ﬂuorescence microspectroscopy is
a new imaging tool which detects autoﬂuorescent molecules in cells
and tissues with a 1-mm spatial resolution. Oﬂoxacin has interesting
autoﬂuorescence properties: it emits ﬂuorescence between 390 and
550 nm (peak at 460 nm) after excitation at 275 nm. Here, we used
synchrotron UV ﬂuorescence microspectroscopy to study the diffusion
of oﬂoxacin in endocarditis vegetation bacterial masses.
Methods: Streptococcal aortic endocarditis was induced in 5 rabbits.
Three animals received an unique 1-hour IV injection of oﬂoxacin, and
were euthanized 30 minutes after the end of perfusion. Two controls
were left untreated. Vegetation cryo-sections were deposited on UV
transparent slides and contiguous slices were stained with Hematoxylin
and Eosin to localize bacterial masses within the vegetation. Two
ﬂuorescence microscopes were coupled to a synchrotron beam for
excitation at 275 nm (Synchrotron Soleil, France). A spectral microscope
collected ﬂuorescence spectra between 285 and 550 nm. A second, full
ﬁeld microscope collected ﬂuorescence light between 510 and 560 nm.
Results: Fluorescence emission spectra of oﬂoxacin-treated vegetations
showed higher intensities than control between 390 and 540 nm.
Furthermore, images obtained with the full-ﬁeld microscope showed
that oﬂoxacin increased ﬂuorescence between 510 and 560 nm in
comparison with control tissues. Oﬂoxacin ﬂuorescence was detected
as well in bacterial masses as in surrounding tissue. However, oﬂoxacin
ﬂuorescence maximal values located in the immediate neighborhood of
bacterial masses. There was no ﬂuorescence gradient between peripheral
and central areas of bacterial masses. Finally, ﬂuorescence images of
bacterial masses located in various parts of vegetation suggested than
oﬂoxacin ﬂuorescence was lower in vegetation central area than in its
periphery.
Conclusion: Oﬂoxacin diffuses into vegetation bacterial masses, but it
accumulates in their immediate neighborhood. There may be an oﬂoxacin
concentration gradient between vegetation peripheral and central areas.
Synchrotron radiation UV ﬂuorescence microscopy is a promising tool
for assessment of antibiotic diffusion in the endocarditis vegetation
bacterial masses.
P1501 Bone tissue distribution of gentamycin and vancomycin
from polymethylmethacrylate intramedullary nails in
experimental osteomyelitis model (MRSA infection)
E. Bertazzoni Minelli*, A. Benini, T. Della Bora, M. Fini, G. Giavaresi,
R. Giardino (Verona, Bologna, IT)
Objectives: Polymethylmethacrylate (PMMA) bone cements are used
for the ﬁxation of joint prostheses and for the production of spacers
as well as carrier to deliver antibiotics into infection site. We studied
the local release of antibiotics from PMMA bone cement nails loaded
with a combination of Gentamicin (G) and Vancomycin (V) in an
experimental model of osteomyelitis (Methicillin-Resistant S. aureus-
MRSA in rabbits) and the correlation with the effect of treatment.
Materials and Methods: Experimental osteomyelitis was induced by
MRSA inoculum in rabbits femurs. PMMA intramedullary nails loaded
with G (1.9%) and V (1.9%) were inserted for 3 weeks then explanted.
Eight New Zealand rabbits (weight 3.0±0.2 kg) were assigned to the
following treatments:
group 1 (n = 3): 4 weeks after infection nails were inserted in both
femurs;
group 2 (n = 2): no infection but nails were inserted in both femurs;
group 3 (n = 3): 4 weeks after infection, Teicoplanin was given
parenterally (T, 20mg/kg, i.m., b.i.d) for 6 days. Femurs were taken 2
weeks after the end of T administration.
Five different samples from condyle and diaphysis of each femur
(trabecular bone and bone marrow) and serum were obtained. Bone
samples were pulverized by Mikro-dismembrator and antibiotics
extracted in appropriate buffers. G and V concentrations were determined
by FPIA and T by microbiological method (B. subtilis in Isosensitest
agar).
Results: High concentrations of G and V diffused in different
bone fractions from PMMA intramedullary nails. In all samples the
concentrations of V were higher than those of G (495.6mg/kg and
194.7mg/kg, respectively, group1). The distribution of V and G was
irregular, being the concentrations in condyle higher (342.8mg/kg and
148.4mg/kg, respectively, group1) than those found in the diaphyseal
fractions (152.9mg/kg and 46.2mg/kg, respectively). The greatest
antibiotics concentrations were found in the condyle trabecular bone
fraction. The levels of G and V in infected bone tissue were
lower than those in uninfected tissues (group 2). Serum levels of
both antibiotics were always below sensitivity limits (traces). Local
concentrations of combined G and V eradicate the infection, while
systemic administration of T showed partial efﬁcacy. These data are
in accord with microbiological and histological results.
Conclusions: PMMA bone cement loaded with G and V can be
considered an effective system for the local delivery of antibiotics to
the infected bone tissue.
P1502 In vivo efﬁcacy of ceftaroline in a methicillin-resistant and
PVL-producing Staphylococcus aureus pneumonia rabbit
model
D. Croisier-Bertin*, D. Biek, D. Hayez, S. Rousseau, D. Labrousse,
C. Badiou, M. Dumitrescu, F. Vandenesch, G. Lina, J. Etienne,
L. Piroth, P. Chavanet (Dijon, FR; Oakland, US; Lyon, FR)
Objectives: Many strains of community-acquired (CA) Staphylococ-
cus aureus harbour the Panton-Valentine Leukocidin (PVL) phage,
which may contribute to severe necrotizing pneumonia in young
immunocompetent patients. In vitro studies demonstrate that some anti-
staphylococcal drugs induce or inhibit PVL production. Animal models
are needed to evaluate new therapeutic strategies in such infections. We
compared the efﬁcacy of ceftaroline, the active component of the prodrug
cephalosporin ceftaroline fosamil, to 3 other antibiotics in a severe model
of PVL CA-MRSA pneumonia in rabbits.
Methods: The well-described USA300 PVL+ clone was used to induce
pneumonia in immunocompetent New Zealand rabbits (inoculum = 9.5
log10 CFU/mL). Animals were administered a human equivalent dosage
of either ceftaroline (CPT 600mg/12h), clindamycin (CLI 600mg/8h),
linezolid (LZO 600mg/12h), or vancomycin (VAN continuous perfusion
30mg/kg) intravenously over 48 h. Infected animals that did not receive
any antibiotic treatment were used as controls. Serum drug levels were
measured by microbiological assay, HPLC, or Fluorescence Polarization,
and pharmacokinetic data were determined. Overall efﬁcacy of the
antibiotic treatments was assessed according to bacterial counts in lungs
and spleen, and residual quantity of PVL was determined by a speciﬁc
Elisa method.
Results: They are expressed as m±SD. Quantitative variables were com-
pared with an ANOVA completed by a post-hoc analysis (Bonferroni).
Early mortality: While not signiﬁcantly affected by VAN, the mortality
rate was greatly reduced by LZO, CPT, and CLI.
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Bacterial reduction: No signiﬁcant antibacterial efﬁcacy was obtained
with VAN in lungs or spleen. In contrast, LZO reduced the pulmonary
bacterial content by 3 log10 CFU/g. CLI and CPT were also
highly effective, reducing pulmonary counts by 5 to 6 log10 CFU/g,
respectively, with counts near the limit of detection in spleen.
PVL assessment: The amount of total PVL in lungs was signiﬁcantly
decreased following treatment with LZO, CLI, and CPT, but was only
moderately decreased relative to controls following treatment with VAN.
Conclusion: In this model of CA-MRSA PVL+ severe pneumonia, CLI
and CPT (and to a lesser extent LZO) achieved bacteriological reduction
and an anti-toxic effect (reduction of the macroscopic score and PVL
production vs controls). The efﬁcacy of ceftaroline in this in vivo model
provides support for additional studies of CPT in treatment of CA-MRSA
pneumonia.
P1503 Experimental infections caused by oxacillin-susceptible
mecA-positive Staphylococcus aureus clinical isolates treated
by oxacillin versus vancomycin
G. Michail, M. Labrou*, C. Stathopoulos, A. Tsakris, S. Pournaras
(Larissa, Athens, GR)
Objectives: We previously characterized four mecA-positive oxacillin-
susceptible Staphylococcus aureus strains (OS-MRSA) that were
partially responsive to oxacillin in animal infections. Vancomycin is
mainly used against MRSA infections however its bactericidal activity
is usually suboptimal. We report in vivo results of oxacillin activity
compared with that of vancomycin in a larger collection of OS-MRSA
isolates.
Methods: Fifteen oxacillin- and vancomycin-susceptible MRSA clinical
isolates (oxacillin agar dilution MICs 0.25−1mg/L, vancomycin MICs
0.5−2mg/L) were studied. Experimental murine thigh infections were
performed and treated with dicloxacillin versus vancomycin. For these
infections, 6-week-old, speciﬁc pathogen-free, female BALB/c mice
were used in each test group, after being rendered neutropenic by
cyclophosphamide. Thighs were infected by 7log10 CFU of each
strain and treated with dicloxacillin 500mg/kg/12h intraperitoneally,
vancomycin 180mg/kg/12h subcutaneously or left untreated over a
24-h period, when animals were euthanized. Thigh muscles were
homogenized, serially diluted and CFU enumerated. The mecA-
negative ATCC29213 strain, a low- (MIC 16mg/L) and a high-level
(MIC >256mg/L) oxacillin-resistant mecA-positive strain were used as
controls.
Results: The thigh infections in murine revealed that in 10 isolates
colonies grown from infected thighs of murine treated with dicloxacillin
were signiﬁcantly reduced (P< 0.05) compared with those of untreated
controls, while in ﬁve isolates dicloxacillin caused a non-signiﬁcant
reduction of colonies (P> 0.05). Dicloxacillin was also effective against
the low-level MRSA and ineffective against the high-level MRSA control
infections. Vancomycin treatment caused in all isolates a signiﬁcant
reduction in colonies grown from infected thighs (P< 0.05). In eight
study isolates, the reduction in colonies grown from murine treated
with dicloxacillin did not differ signiﬁcantly from that of vancomycin
(P> 0.05), while in seven isolates, vancomycin had signiﬁcantly higher
efﬁciency compared with dicloxacillin (P< 0.05).
Conclusion: The results of the present study suggest that a considerable
proportion of OS-MRSA isolates may be responsive to oxacillin in vivo
in a manner similar to that of vancomycin. This could have signiﬁcant
implications for the treatment of MRSA infections.
P1504 Assessment of linezolid, vancomycin, and rifampicin
as monotherapy in comparison with combination of
linezolid/rifampicin and vancomycin/rifampicin in the
treatment of methicillin-resistant Staphylococcus aureus
acute osteomyelitis
C. Jacqueline*, G. Amador, C. Desessard, V. Le Mabecque,
A.F. Miegeville, J. Caillon, G. Potel (Nantes, FR)
Objectives: RA displays excellent bactericidal activity against MRSA,
but should be used in combination with other drugs because of the
emergence of resistance. We assessed the activity of LZO, VAN, and RA
alone in comparison with LZO and VA in combination with RA using an
acute model of osteomyelitis. The emergence of resistant variants during
therapy was assessed.
Methods: Femoral trepanation of rabbits was performed, followed
by injection of 109 CFU MRSA suspension into the knee cavity.
A surgical debridment of the infected tissues was performed 3 days
later and animals were randomly assigned to: no treatment (controls),
LZO (simulating a human-equivalent (HE) dose of 10mg/kg/12h),
VAN (constant IV infusion to reach a 20xMIC serum steady-state
concentration), RA (intramuscular injection of 20mg/kg every 12 h),
LZO plus RA, and VAN plus RA. Surviving bacteria were counted in
infected joint ﬂuid (JF), bone marrow (BM) and bone (BO) at day 3 and
at the end of 4-days treatment (day 7).
Results: In vivo results are shown in Table.
Conclusion: 1/. LZO and RA as monotherapy showed signiﬁcant in
vivo activity after a 4-day treatment in BM and BO, while VAN was
ineffective in this model of acute osteomyelitis. 2/. Despite excellent
activity in bone, RA-resistant mutants were isolated in 4/6 animals
with RA MICs >32mg/L. 3/. The addition of RA to LZO and VAN
signiﬁcantly improved in vivo activity against MRSA. 4/. By increasing
both the antibacterial activity and the sterilization of infected bone
tissues, and avoiding the emergence of resistance, LZO plus RA
demonstrated a very powerful activity in this experimental model of
acute osteomyelitis.
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P1505 Efﬁcacy of human simulated ceftaroline exposures against
phenotypically diverse Staphylococcus aureus in a mouse
thigh model
R. Keel*, J. Crandon, D. Nicolau (Hartford, US)
Objectives: Ceftaroline (CPT), the active component of the prodrug cef-
taroline fosamil, is a new broad-spectrum cephalosporin exhibiting bac-
tericidal activity against Gram-positive pathogens, including methicillin-
susceptible (MSSA) and -resistant Staphylococcus aureus (MRSA), as
well as common Gram-negative pathogens. This study evaluated the
efﬁcacy of human-simulated exposures of CPT against Staphylococcus
aureus in both the neutropenic (I-) and immunocompetent (I+) mouse
thigh infection models.
Methods: 26 Staphylococcus aureus (4 MSSA, 22 MRSA) isolates with
CPT MICs ranging from 0.125−4mg/L were tested in the I− model. 13
of these MRSA isolates were also tested in I+ animals. Two hours after
inoculation, CPT was administered SQ using a regimen that simulated
free-drug steady state exposures of CPT 600mg q12h infused over 1
hour in patients by mimicking the percentage of the dosing interval that
the free drug concentration remained above the MIC of the infecting
organism (fT>MIC). The change in log CFU after 24 hours of treatment
was analyzed relative to the 0 and 24 hour controls for I− and I+,
respectively.
Results: Human-simulated exposures resulted in efﬁcacy against all
isolates tested in both mouse models. In the I− model, a greater than 1
log CFU reduction was observed when compared to the 0 hour control
against 25 of the 26 isolates (change in log CFU range: −0.95 to
−3.28); whereas, for the I+ model, all isolates obtained a greater than
1 log CFU reduction (change in log CFU range: −1.06 to −2.43) in
bacterial density. An additive effect due to the immune system was not
observed presumably because the human-simulated regimen had already
achieved maximal kill in I− animals. Irrespective of immune competency,
a reduction in bacterial density was observed at the highest MIC of
4mg/L equivalent to a fT>MIC exposure of 27.5%.
Conclusion: Patient derived human-simulated ceftaroline 600mg q12h
exposures provided predictable efﬁcacy against all tested Staphylococcus
aureus isolates in the mouse thigh model independent of immune status.
These data support the durability and clinical utility of ceftaroline against
Staphylococcus aureus, including MRSA with MICs up to 4mg/L.
P1506 Treatment of renal abscesses caused by Staphylococcus
aureus MW2, using delaﬂoxacin and moxiﬂoxacin
Y. Ding*, R. Villet, J. Lee, D. Hooper (Boston, US)
Objectives: Antibiotics are in general poorly effective in treatment of
abscesses, which are a common type of infection that often involves
methicillin-resistant Staphylococcus aureus. We tested the activity of
delaﬂoxacin (DFX), a new quinolone under development, in comparison
to that of moxiﬂoxacin (MFX) against renal abscesses formed by
S. aureus MW2 in a murine model of systemic infection.
Methods: On day 0, 7-to-8-week old male Swiss-Webster mice were
injected intravenously with S. aureus MW2. On days 4, 5, and 6,
by which time renal abscesses had developed, twice daily treatment
with DFX, MFX (10 and 30mg/kg), or vehicle was administrated
subcutaneously. On day 7, kidneys were harvested, homogenized, and
plated quantitatively. In addition, a 2-day early-treatment regimen was
begun 24 h after injection and renal CFU was measured in a similar
manner.
Results: Renal abscesses formed reliably by 4 days after injection
with S. aureus inocula in the range of 3−8×106 CFU. Both DFX
and MFX at 10mg/kg signiﬁcantly reduced CFU (1.7 and 8.1×106
CFU/g kidney, p = 0.0003 and 0.0009, respectively) compared to controls
(9.77×107 CFU/g kidney), and the reduction of bacterial load by DFX
was signiﬁcantly greater than that by MXF (p = 0.0121). The bacterial
load in mice given 30mg/kg DFX was reduced signiﬁcantly relative
to controls (from 2.0×107 to 4.96×105 CFU/g kidney, p = 0.0205).
MXF at this dose also reduced the CFU, but the effect did not reach
statistical signiﬁcance (2.0×106 cfu/g kidney, p = 0.0541). In the early
treatment regimen, both DFX and MXF (10mg/kg) showed a signiﬁcant
reduction in bacterial load (1.14 and 5.00×105 CFU/g kidney, p = 0.0019
and 0.007, respectively), compared to that in controls (2.3×108 CFU/g
kidney).
Conclusion: S. aureus MW2 reliably produced renal abscesses in mice
when injected intravenously. Both DFX and MFX were effective in
reducing the bacterial load in established renal abscesses, but DFX was
superior to MXF. DFX and MXF showed similar efﬁcacy in an early
treatment regimen whereby mice were treated prior to the formation of
mature renal abscesses.
P1507 Antisense phosphorodiamidate morpholino oligomers
inhibition of Burkholderia cepacia complex
D. Greenberg, K. Marshall-Batty, P. Iversen*, B. Geller (Dallas,
Bothell, US)
Objectives: The Burkholderia cepacia complex (Bcc) comprise 17
phenotypically similar but genetically distinct species. The Bcc cause
signiﬁcant infections in patients with chronic granulomatous disease
(CGD) and cystic ﬁbrosis (CF). In CF, Bcc are frequently antibiotic
resistant making treatment difﬁcult. We aim to develop novel therapeutic
approaches for Bcc by developing gene speciﬁc therapies using
antisense technologies. Speciﬁcally, we utilized peptide-conjugated
phosphorodiamidate morpholino oligomers (PPMOs) to inhibit bacterial
growth.
Methods: PPMOs were designed against gene targets in Bcc that are
known or suspected to be essential for organism growth. Overnight
cultures of different Bcc strains were incubated alone or in the presence
of a target PPMO or placebo. Minimum inhibitory concentrations (MICs)
were determined and promising compounds were moved into a mouse
model of Bcc infection utilizing the CGD mouse.
Results: Targeting of an essential gene that encodes an acyl carrier
protein (acpP) showed good MIC values across numerous strains of
Bcc (2.5−10mM) and showed >4-log reduction in growth in overnight
inhibition assays. CGD mice were infected intranasally (IN) with 6x105
colony forming units (cfu) of Burkholderia multivorans. Mice were
treated with 200mg of AcpP PPMO or placebo PPMO at 6, 30 and 44
hours. All mice were euthanized at 72-hours post-infection. AcpP PPMO
reduced cfu/g lung tissue by >2.5 logs (3.7x105 cfu/ml vs 2.56x108
cfu/ml;p = 0.01).
Conclusion: Targeting the essential Bcc gene, acpP, with PPMOs shows
potency in in vitro and in vivo models of infection. PPMOs have potential
therapeutic uses for pulmonary infections caused by bacterial pathogens
such as the Bcc.
P1508 Efﬁcacy of a LRS inhibitor GSK2251052 against
Enterobacteriaceae isolates using a computer-controlled
infusion system to recreate human PK proﬁles in rats
C. Singley*, R. Page, J. Hoover, P. Elefante, P. DeMarsh (Collegeville,
US)
Objective: GSK2251052 (GSK052) is the ﬁrst in a new oxaborole
class of antibiotics with robust Gram-negative coverage against drug-
resistant Enterobacteriaceae and Pseudomonas aeruginosa. GSK052
inhibits leucyl tRNA synthetase (LRS), an essential enzyme required
for bacterial growth, by forming an adduct with the tRNALEU in the
editing active site, essentially locking tRNALEU in an unproductive
state. GSK052 is presently in clinical development for serious Gram-
negative infections. Efﬁcacy of GSK052 was evaluated against three
strains of Klebsiella pneumoniae (K. pneum) in a respiratory tract
infection and two strains of Escherichia coli in a thigh suture infection in
rats using a controlled infusion system that recreated the human exposure
proﬁle in the animal.
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Methods: Adult male cannulated rats were anesthetized and infected
either in the lungs by instilling 200 ul of a bacterial suspension of
K. pneum or in the thigh by placing an infected E. coli suture. Therapy
was administered starting 1 hr post infection by recreating in the rats the
human concentration time proﬁles for the following antibiotics: GSK052
repeat dose of 500mg i.v. (b.i.d), levoﬂoxacin (LEV) 500mg p.o. (o.d.)
and ceftazidime (CEF) 1 gm i.v. (t.i.d.). Therapy continued for 4 days.
At 96 hr post infection, rats were euthanized and the infected tissue (lung
or thigh) was excised to assess viable bacterial numbers.
Results: See the table.
Conclusion: The human exposure proﬁle of GSK052 was highly
efﬁcacious against the three K. pneum and two E. coli strains tested.
These studies indicate the potential beneﬁt of GSK052 in the treatment
of serious Gram-negative infections.
P1509 Broad-spectrum ﬂuorocycline TP-434 has oral
bioavailability in humans
A. Leighton*, I. Zupanets, N. Bezugla, L. Plamondon, G. Macdonald,
J. Sutcliffe (San Francisco, US; Kharkov, UA; Watertown, US)
Background: TP-434 is a novel broad-spectrum ﬂuorocycline antibiotic
with potent activity and efﬁcacy against multidrug-resistant (MDR)
Gram-negative and Gram-positive aerobic and anaerobic pathogens, in-
cluding Enterobacteriaceae expressing extended-spectrum b-lactamases
(ESBL) and/or carbapenemases, MRSA, and VRE; it has limited activity
against Pseudomonas spp. The IV formulation of TP-434 is currently in
Phase 2 clinical development. TP-434 had 29% oral bioavailability in
chimpanzee.
Methods: A single-center, double-blinded, placebo-controlled single-
ascending dose study with an oral solution of TP-434 was done in
healthy men and women aged 18−50 years. Escalation of 50, 100, 200,
and 300mg doses was performed sequentially in Dose Groups (DG) of
8 subjects (6 TP-434 and 2 placebo). Safety panels included hematology,
biochemistry, urinalysis, and for women, a pregnancy test, at screening,
check-in, after dose administration and each of the 5 days the subjects
were in the study unit as well as a follow-up assessment on Day 9.
Electrocardiograms were collected in triplicate pre- and post-dosing and
physical examinations were performed at screening, check-in, and at
study exit (or early termination). Plasma concentration data from a total
of 24 subjects who received study drug were included in the statistical
analysis.
Results: No serious adverse events were reported over the course of this
study. In general, doses up to 200mg of TP-434 were well tolerated;
1 subject each receiving 200mg reported dizziness or nausea. At a
dose of 300mg, increases in partial thromboplastin time were noted
(<1.5 upper limit of normal), and 1 subject each had increased alanine
aminotransferase (<1.2xULN) and unconjugated bilirubin (<1.2xULN)
or nausea and transient vomiting of mild severity. All AEs resolved
spontaneously. Tmax was reached at approximately 2 hours for all
DGs studied. The overall systemic exposure of TP-434 was dose-
proportional and linear as doses increased from 50mg to 300mg.
Exposures consistent with therapeutic efﬁcacy were reached. Average
oral bioavailability across DGs was 28%.
Conclusion: The feasibility of development of an oral formulation was
conﬁrmed. TP-434 showed promising oral bioavailability in humans,
reaching exposures predicted to be therapeutically efﬁcacious. The
availability of an oral step-down option with a novel broad-spectrum
antibiotic would fulﬁll an increasing medical need.
P1510 MUT056399: a single intravenous ascending dose study in
healthy human volunteers
C. Soulama-Mouze´*, A. Bryskier, D. Chassard, S. Fischer (Paris,
Rennes, FR)
Objectives: MUT056399 was designed to overcome staphylococcal
infections. MUT056399 inhibits the fatty acid biosynthesis pathway by
acting on an unexploited target FabI, a speciﬁc and lethal bacterial
enzyme. Mode MICs are 0.03mg/L whatever the resistance phenotype
of staphylococci.
A phase I study was conducted to investigate safety, tolerability and
pharmacokinetic proﬁle after single intravenous and escalating doses of
MUT056399.
Methods: 72 male healthy volunteers (18 to 40 years old) were
enrolled into ten cohorts. MUT056399 was intravenously administered in
escalating doses from 10mg to 7200mg. Two regimens of administration
were tested: a short infusion, 1mL/minute, of MUT056399 at 10mg/mL
in cohorts 1 to 7 and a 24-hours continuous infusion, with a lower ﬂow
rate of infusion of 0.66mL/minute, of MUT056399 diluted in 0.9% NaCl
in cohorts 8 to 10.
Results: Following single ascending intravenous doses, MUT056399 was
well tolerated up to 4800mg. No severe adverse events were reported.
No clinically relevant changes were observed in ECG time intervals.
The mean plasma PK parameters are summarized in table 1.
The mean plasma terminal elimination half lives were around one hour.
MUT056399 was recovered in small amounts in the urines.
Conclusion: In the two above mentioned regimens of single intravenous
administration, MUT056399 was well tolerated and safe up to 4800mg.
The plasma t1/2 was around one hour, the Clp was around 50 L/h, the Vd
ranged from 30.7 L to 101.5 L and the AUC0-t ranged from 157 ng.h/mL
to 127721 ng.h/mL.
P1511 Phosphorodiamidate morpholino oligomer RNA therapeutics
cross the blood-brain barrier of healthy volunteers
S. Shrewsbury*, P. Iversen (Bothell, US)
Objectives: The phosporodiamidate morpholiono oligomers (PMO) can
be designed to inhibit gene expression by binding speciﬁcally to RNA
with complementary base sequences. We have investigated the utility
of these PMOs extensively as antiviral and antibacterial agents with
numerous successes. We reported that AVI-4020 can cross the blood
brain barrier (BBB) of individuals with neuroinvasive West Nile Virus.
The goal of these studies was to evaluate the potential for PMOs
with different sequence composition to cross the BBB and enter the
cerebrospinal ﬂuid (CSF) of healthy volunteers.
Methods: Three different PMOs, AVI-4020 designed to inhibit West Nile
Virus (WNV), AVI-4126 designed to inhibit expression of c-myc, and
AVI-4065 designed to inhibit hepatitis C virus (HCV), were administered
to healthy volunteers as a single bolus i.v. 100mg dose. Blood plasma
and CSF samples were collected for quantitative determination of
oligomer concentrations at 6, 12 and 18 hours post administration (4
subjects per time interval).
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Results: CSF concentrations for AVI-4020 were detectable in all subjects
ranging from 19.6 to 44.5 ng/mL at 6 hours post-dose (4 subjects), 13.3
to 16.3 ng/mL at 18 hours post dose (4 subjects), and 22.1 to 24 ng/mL at
112 hours post-dose (3 subjects). CSF concentrations for AVI-4126 were
below the limit of quantitation in subjects 6 hours post-dose (4 subjects),
at 12 hours post-dose AVI-4126 was detected in 2 of 4 subjects ranging
from 12 to 13 ng/mL, and at 18 hours the range was from 10 to 14 ng/mL
for the 3 of 4 subjects with detectable AVI-4126. Finally, CSF levels of
AVI-4065 were detected in all subjects ranging from 31 to 33 ng/mL at
6 hours post-dose (4 subjects), 32 to 36 ng/mL at 12 hours post-dose
and 32 to 41 ng/mL at 18 hours post-dose.
Conclusions: These studies indicate phosphorodiamidate morphlino
oligomers (PMOs) cross the BBB of normal healthy human volunteers.
The observations suggest that the sequence composition may inﬂuence
the rate and quantity of oligomer that will enter the CSF.
P1512 The effect of H2 blockade and food on the pharmacokinetics
of GSK1322322 in healthy subjects
O.J. Naderer*, L.S. Jones, J.Z. Zhu, M. Kurtinecz, E.F. Dumont
(Research Triangle Park, Upper Merrion, Upper Providence, US)
Objectives: GSK1322322 (GSK322) is an antibacterial agent currently
in development that inhibits bacterial peptide deformylase (PDF)
function, a clinically unexploited target. GSK322 demonstrates targeted
antibacterial activity against multi-drug resistant respiratory and skin
pathogens, including methicillin-resistant Staphylococcus aureus, and
represents a new antibiotic class with a novel mode of action. Because
GSK322 has pH dependent solubility, the study was designed to assess
the PK effect on GSK322 when coadministered with food alone, an H2
blocker alone, or an H2 blocker given in combination with ascorbic acid
(Vitamin C).
Methods: This study was an open-label, randomized, balanced, crossover
study. Each subject received a total of 3 single doses of GSK322
(1000MG) with food alone, or an H2 blocker alone or in combination
with ascorbic acid (Vitamin C tablet) with a washout period of at least
3 days between doses. Serial PK samples were collected for up to 48
hours following each dose of study drug.
Results: Twenty healthy males were enrolled into the study. GSK322 was
well-tolerated when co-administered with high fat meal, an H2 blocker
(ranitidine) alone, and the combination of an H2 blocker with ascorbic
acid. There were few AEs or drug-related AEs during the study and there
were no clinically signiﬁcant vital signs, ECGs, or clinical laboratory
abnormalities. A summary of the PK parameters are listed below.
Conclusion: Food lowered the rate of absorption, but did not substan-
tially affect the extent of absorption for GSK322. Coadministration of
GSK322 with an H2 blocker resulted in a slight delay in absorption and
58% and 38% decreases in Cmax and AUC(0−inf) values, respectively.
Coadministration of GSK322 and H2 blocker in combination with Vit C
showed that Vit C can somewhat overcome the reduced bioavailability
of GSK322 observed with administration of the H2 blocker alone.
P1513 Phase I study with the novel Pseudomonas aeruginosa
antibiotic POL7080 in healthy volunteers
D. Wilbraham, S. DeMarco, A. Ograbek, J. Agren, A. Wach, D. Obrecht,
K. Dembowsky* (London, UK; Allschwil, CH; Uppsala, SE)
Objectives: POL7080 is a novel PEM (Protein Epitope Mimetic)
antibiotic selectively targeting Pseudomonas species with demonstrated
potent in vitro activity and in vivo efﬁcacy in murine infection models.
A single ascending dose (SAD) study was conducted to evaluate safety,
tolerability, plasma pharmacokinetics (PK) and urinary excretion.
Methods: Forty-eight healthy male subjects, aged 18−40, were
randomised and participated in a double blind, placebo-controlled study
with single ascending doses. Each of the 8 dose groups consisted of
4 subjects randomised to receive POL7080 and 2 to receive placebo.
All doses were given as three hour infusions. Plasma concentrations of
the drug were determined by LC-MS/MS analysis and interim (using
nominal time) PK parameters were calculated using WinNonlin®.
Results: POL7080 was detected in plasma of all dose groups with
Cmax at the end of infusion. PK was dose proportional and plasma
exposure increased linearly with respect to AUC0 inﬁnity and Cmax.
Inter-subject variability was generally less than 20% for both parameters.
Dose normalized AUC and Cmax averaged for all groups were
9.2±2.0mg*h*kg/mL/mg and 1.9±0.4mg*kg/mL/mg, respectively. The
mean half-life (t1/2) ranged from 2.6−5.5 hours (study grand mean±SD =
4.6±1.2 h). No serious adverse events (SAEs) were reported for any dose
group and all AEs were mild and not prohibitive to dose increases. Blood
chemistry and clinical laboratory results were normal during dosing and
at follow up, indicating that POL7080 was well tolerated in all dose
groups.
Conclusions: Single doses of POL7080 were well tolerated at plasma
concentrations expected to meet or exceed efﬁcacious levels and no
serious adverse event was reported. A multiple ascending dose study
has been initiated to assess safety and tolerability of repeated dosing
over 5−7 days.
P1514 PMX30063 − understanding neuronal effects in multi
dose-phase 1 clinical study
B. Korczak*, R. Echols, E. Walters (Radnor, Easton, US)
Objective: PMX30063 is the ﬁrst of a novel class of antibiotics, a
non-peptidic amphiphilic compound that mimics the properties and
mechanism of action of the host defense proteins. Two phase 1
clinical studies were conducted in healthy males (77 subjects). The
primary adverse event was described as a transient, self-limiting,
sensory syndrome that was characterized by peripheral sensations of
numbness and tingling. The syndrome, deﬁned as a paraesthesia, was
fully reversible within minutes to days following discontinuation of the
treatment. A neurological assessment scale was recommended by a Board
Certiﬁed neurologist, and implemented in the clinical trial PMX63–
103: Randomized, Double-Blind, Placebo Controlled Study to Evaluate
the Safety and Pharmacokinetics of Intravenous PMX30063 in Healthy
Adult Subjects.
Method: Ten male subjects (8 active/2 placebo) and 10 female
subjects (8 active/2 placebo) were enrolled in a randomized, double-
blinded, multiple-dose, safety, tolerability and pharmacokinetic study
of PMX30063. Subjects randomized to PMX30063 received a loading
dose on day 1 of 1.0mg/kg administered intravenously over 60
minutes followed by 0.35mg/kg doses on days 2−14. In addition
to pharmacokinetic, adverse events, safety chemistry, hematology,
urinalysis and ECGs, speciﬁc assessments of neurological symptoms
and objective neurological exams were performed. The symptoms-
based neurological assessment captured severity, symmetry, region and
intermittency of reported sensations of tingling, burning, numbness or
pain. The objective neurological assessments conducted by a neurologist
consisted of 11 tests (deep tendon reﬂexes, pinprick pain sensation,
light touch, vibration, joint position, ﬁnger-nose test, index ﬁnger
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approximation, Romberg test, gait, ankle dorsiﬂexion strength and ankle
planar ﬂexion strength).
Conclusion: Preliminary results indicate that the most common
neurological symptoms were tingling and numbness in lips, face and
ﬁngers. Most neurological tests conducted by neurologist were normal
with few abnormalities noted in tendon reﬂexes, pinprick and light touch
tests.
P1515 A phase 1 trial to evaluate the tolerability, safety and
pharmacokinetics of multi-dose intravenous regiments of
PMX30063
B. Korczak*, E. McAllister (Radnor, US)
Objectives: There is a major need for the development of novel
antimicrobial agents that attack new targets to evade resistance issues
which limit the usefulness of many antibiotics. PMX30063, a non-
peptidic compound that mimics the properties and mechanism of action
of the host defense proteins and has not demonstrated resistance
development in vitro, is currently in phase 2 clinical study. We have
studied safety, pharmacokinetics and pharmacodynamics of multiple
doses of this novel antibiotic in healthy male volunteers.
Methods: Seventy seven subjects (55 PMX30063, 22 placebos) were
enrolled in up to 12 cohorts and randomized to either PMX30063
or placebo in a 5:2 ratio. All infusions were 1 hour in duration,
administered via a peripheral vein. Cohorts 1 and 2 received 0.1mg/kg
and 0.2mg/kg, respectively every 48 hours for total of 5 doses each.
Cohorts 3−8 received once-daily (Q24H) infusions to a total of 5
infusions starting at 0.1mg/kg and proceeding to 0.2, 0.3, 0.4, 0.5
and 0.6mg/kg. Cohorts 10−12 received twice-daily (Q12H) infusions
of 0.08, 0.16 and 0.30mg/kg to a total of 10 infusions and doses
were chosen to enable comparison with once-daily infusions of 0.1, 0.2
and 0.3mg/kg. Assessments included adverse events, laboratory, ECG,
plasma pharmacokinetics and ex-vivo antimicrobial activity.
Results: There were no serious adverse events, laboratory or ECG
ﬁndings of clinical concern. The most common adverse events were
paraesthesia and increase in blood pressure and heart rate, all of which
were transient and required no treatment. No gastrointestinal or renal
effects were observed. Key pharmacokinetic parameters were determined
and the terminal elimination half life varied between 16.6 and 23 hours.
Bactericidal activity of PMX30063 in subjects’ serum against MSSA
and MRSA strains was observed at a single dose of 0.1−0.3mg/kg.
Conclusions: Plasma concentration of PMX30063 shows uncomplicated
pharmacokinetics and dose-dependent pharmacokinetic parameters for
all 3 dosing regimens. Serum antimicrobial activities showed that
bactericidal concentrations can be achieved at a single and initial
dose as low as 0.1−0.3mg/kg. Overall, PMX30063 appears to show
unremarkable safety proﬁle between 0.1 and 0.3mg/kg Q24H dosing.
Increasing the frequency of administration from Q24H to Q12H did not
seem to improve the safety proﬁle of PMX30063 at comparable doses.
P1516 Assessment of the venous tolerability of torezolid phosphate
infused via a peripheral catheter: a novel approach
K.A. Mun˜oz, P. Bien, P. Prokocimer* (San Diego, US)
Objectives: Torezolid phosphate (TR-701) is an investigational oxa-
zolidinone antibiotic currently in Phase 3 testing for the treatment of
Acute Bacterial Skin and Skin Structure Infections (ABSSSI). In one
of the two Phase 3 trials an initial 200mg dose of TR-701 will be
administered intravenously through a peripheral vein followed by step-
down to subsequent oral doses of TR-701 therapy. Prior to initiating the
Phase 3 IV trial, Trius investigated the venous tolerability of IV TR-
701 using a method allowing for a rigorous comparison vs. IV placebo
administration.
Methods: The venous tolerability of an IV dose of 200mg TR-701 was
examined in a randomized, double-blind, placebo-controlled, crossover
study in healthy subjects (n = 10). Subjects received either TR-701 or
placebo infused over 60 minutes in 250mL saline via a 22 gauge catheter
once daily for 3 consecutive days. Each subject served as their own
control and received either TR-701 or placebo for 3 days in the right
arm followed by 3 days of the alternate regimen in the left arm. Venous
access was evaluated for evidence of early signs of phlebitis before the
start, during, at the end, and 6 hours after the end of infusion. The
primary endpoint was the occurrence of early signs of phlebitis deﬁned
as a score of 2 or higher using a modiﬁed Visual Infusion Phlebitis (VIP)
scale. The time to a score difference of 2 or higher was determined using
all matched time points at which the modiﬁed VIP score was measured.
Results: See the Table.
The difference (VIP score on TR-701 minus the score on placebo) was
categorized as 3, 2, 1, 0, and 1. Thus, a negative VIP score difference
indicates that phlebitis was more severe when the subject was on placebo.
Conclusions: The VIP score results demonstrate that over 3 days, a
200mg TR-701 IV infusion does not produce signs of phlebitis (score
of 2) earlier or more often than placebo infusions. These data show that
200mg of IV TR-701 can be administered safely through a peripheral
vein.
P1517 The effect of food on the oral bioavailability of AFN-1252
in healthy human subjects
N. Kaplan*, B. Hafkin (Toronto, CA; Austin, US)
Objectives: AFN-1252, a new molecular entity with a novel mechanism
of action, is a potent inhibitor of staphylococcal FabI, an essential
enzyme in bacterial fatty acid synthesis and is in development as an
oral, speciﬁc-spectrum, anti-staphylococcal antibiotic. A novel tablet
formulation of AFN-1252 is currently in Phase 1 studies. Early
development of the formulation was guided by studies in Beagle dogs.
Bioavailability of AFN-1252 was better in the fasted state than in the fed
state in Beagles. To study the effect of food on the oral bioavailability
of the new AFN-1252 formulation in normal healthy human subjects, a
traditional fast/fed study was conducted.
Methods: For the Beagle study, a cross over design with a cohort
of 8 dogs was used. A single 200mg dose of AFN-1252, as an oral
suspension, was administered with fasting for 3 hours both before and
after dosing. After a 1 week washout period dosing was repeated in the
dogs with free access to food before and after dosing. AFN-1252 plasma
levels were determined for 24 hours following each dose. For the human
study, a double blind, cross over design was used. A cohort of 8 healthy
volunteers was randomized to receive a single dose of two 100mg tablets
(200mg dose) of AFN-1252 either after an overnight fast or after a
high fat meal. After a 1 week washout period the subjects were dosed
again in the alternate fed/fasted state. AFN-1252 plasma concentrations
were determined for 72 hours following each dose. Pharmacokinetic
(PK) parameters were estimated with WinNonLin v.6.1 using a non-
compartmental model.
Results: In the dog study, reduced bioavailability was seen after non-
fasting compared to fasting conditions. The mean Cmax and AUC values
decreased by 45% and 40%, respectively, and no effects on Tmax and
half-lives were observed. In the human study, all subjects showed reduced
bioavailability when AFN-1252 was given after a fatty meal compared
to after fasting. The mean Tmax increased from 3 to about 7 hours, and
mean Cmax and AUC values decreased by 50% and 40%, respectively.
No effect on terminal half-lives was observed.
Conclusions: The presence of food in the GI tract had a signiﬁcant effect
on the oral bioavailability of AFN-1252 in healthy human subjects, with
a mean relative bioavailability of 60% compared to the fasted state. The
Beagle dog model was a valuable predictor of human PK underscoring
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the merit of using an animal model in the early development of novel
oral formulations.
P1518 Pharmacokinetic and pharmacodynamic modelling of the
anti-staphylococcal activity of AFN-1252 in humans
N. Kaplan*, J.R. Koup, B. Hafkin (Toronto, CA; Ann Arbor, Austin, US)
Objectives: AFN-1252, a new molecular entity with a novel mechanism
of action, is a potent inhibitor of staphylococcal FabI, an essential
enzyme in bacterial fatty acid synthesis. AFN-1252 is currently in Phase
1 studies as an oral, speciﬁc-spectrum anti-staphylococcal antibiotic.
To predict the anti-staphylococcal pharmacodynamic (PD) effects of
AFN-1252 in humans, pharmacokinetic (PK) and PD data from two
neutopenic mouse thigh abscess infection models were used to develop
a bacterial net growth PK/PD model. The primary variable between the
two mouse models was drug half-life due to different oral formulations.
A population PK model was constructed with AFN-1252 oral Phase 1
PK data that was then applied to the net growth PK/PD model to predict
the AFN-1252 PD effects in humans.
Methods: Staphylococcus aureus 29213 was the test organism in both
mouse thigh abscess models. Bacterial growth parameters and AFN-1252
PD effects were estimated with the bacterial net growth PK/PD model
using a modiﬁcation of Campion et al. (Antimicrob. Agents Chemother.
49: 209–219, 2005). Population human plasma concentrations were
modelled from oral Phase 1 single ascending dose cohorts of 100 to
400mg AFN-1252 (6 healthy subjects per cohort), and then expanded
to predict multiple dose PK for 4 days (at steady-state). NONMEM
version 6.1 was used employing a linear one-compartment disposition
model with ﬁrst order absorption.
Results: The S. aureus net growth model successfully integrated the
results from the two mouse thigh abscess experiments and showed an
excellent correlation (r2 = 0.889) between observed and predicted log-
CFU/thigh values. Simulation of the AFN-1252 antibacterial response in
humans using modelled 4 days of QD dosing showed that for S. aureus
at the MIC90 (0.016mgml) all subjects showed ranges of log CFU/g
reduction (compared to time 0) of +2.5 to −3.5, −1.5 to −4.2, −2.2 to −5.1
and −3.5 to −5.5 for the 100, 200, 300 and 400mg doses, respectively.
Conclusions: Combination of bacterial growth/kill PK/PD parameters
with predicted individual plasma concentration values allowed for
simulation of log-CFU/g values vs. time following single and multiple (4
day) AFN-1252 oral dose administration in humans. These simulations
predicted signiﬁcant antibacterial response at AFN-1252 QD doses
200mg for S. aureus strains with an MIC of 0.016 mg g/ml (MIC90).
P1519 Pharmacokinetics of CXA-101/tazobactam in subjects with
mild or moderate renal impairment
E. Hershberger*, D. Benziger, L. Pheng, M. Trinh, J. Marier,
I. Friedland (Lexington, US; Montreal, CA)
Objectives: To evaluate the PK of a single IV administration of
CXA/TAZ in subjects with normal renal function (NRF) or mild or
moderate renal impairment (RI).
Methods: Using the Cockcroft-Gault formula to estimate creatinine
clearance (CrCl), 24 subjects with mild (CrCl 60−89mL/min) or
moderate (CrCl 30−59mL/min) RI and matched subjects with NRF
(CrCl 90mL/min) received a single 60-minute IV infusion of CXA-
101/tazobactam (1000mg/500mg). Blood and urine samples for PK
analyses were obtained prior to and at various time points up to 35
hours following the completion of drug administration.
Results: Negligible differences were observed in the PK of CXA-
101, TAZ and metabolite M-1 in subjects with mild RI as compared
to subjects with NRF. In subjects with moderate RI, AUC0-inﬁnity
and t1/2 were increased for CXA-101 (2.6 and 2.1-fold, respectively)
and TAZ (2.0 and 1.6-fold, respectively). The parent-to-metabolite ratio
(AUCTAZ/AUCM-1) in the moderate RI group was 2.6-fold higher than
the NRF group. These were related to a decrease in renal clearance (CLr)
of TAZ in this group. The linear equation describing the relationship
between CrCl and CXA-101 PK suggested that a decrease in CrCL
from 90 to 50mL/min would decrease its plasma and renal CL by 36 and
29%, respectively, resulting in an increase of 53% in AUC0-inﬁnity, with
no change in Cmax. The linear relationship between CrCl and TAZ PK
suggested that a similar decrease in CrCL would decrease its plasma and
renal CL by 31% and 29%, respectively, resulting in an increase of 44%
and 20% in AUC0-ininity and Cmax, respectively. These results suggest
that a 50% reduction in CXA-101/TAZ doses in subjects with moderate
RI would achieve plasma concentrations comparable to those observed
in subjects with NRF. Additional Monte Carlo simulations showed that
the proposed 50% dose reduction would achieve the desired target of
40−50% time above MIC in 100% of the subjects (MICs 8mg/mL).
Conclusion: No clinically meaningful differences were observed in
the plasma PK of CXA-101, TAZ, or M-1 in subjects with mild RI
indicating that dosage adjustment is not required. However, based on
increases observed in systemic exposure of CXA-101, TAZ, and M-1 in
subjects with moderate RI, a 50% reduction in CXA-101/TAZ doses is
predicted to achieve plasma concentrations comparable to those observed
in subjects with NRF.
P1520 CXA-101/tazobactam probability of target attainment using
population pharmacokinetic analysis
E. Hershberger*, M. Mouksassi, J. Steenbergen, D. Benziger,
F. Fenneteau, J. Marier, I. Friedland (Lexington, US; Montreal, CA)
Objectives: To evaluate PK-PD target attainment (TA) using different
dosing strategies for CXA/TAZ against difﬁcult to treat Gram-negative
pathogens.
Methods: Population PK analysis of CXA/TAZ was performed using
2-compartment models with linear elimination. Monte Carlo (MC)
simulations were conducted taking into account between subject
variability, residual variability and the covariate distribution in the
population. PK-PD TA probabilities by MIC and by various treatment
regimens were generated for CXA/TAZ. Furthermore, %T>MIC targets
for efﬁcacy (35% shown in animal models to achieve bacteriostasis and
40−50% to achieve 1−2 log kill) were determined for each pathogen of
interest using its speciﬁc observed MIC distribution.
Results: PK-PD TA probabilities for 3 different CXA/TAZ dosing
regimens are presented in the table below. The MC-simulated PK-PD TA
show that a 50% T>MIC of 8mg/mL was achieved in 90% of subjects
using a dose of 1500mg (1000mg CXA/500mg TAZ) q8 infused over 60
min. Using 2008 CXA/TAZ surveillance data there is a high probability
of TA for the majority of the organisms tested: E. coli (N = 721, MIC90
= 0.25), K. pneumoniae (N = 798, MIC90 = 2), E. cloacae (N = 266,
MIC90 = 16), P. aeruginosa (N = 914, MIC90 = 2) and Acinetobacter
spp. (N = 238, MIC90 >32). Based on the observed MIC distribution for
P. aeruginosa and Acinetobacter spp, 50% T>MIC was achieved in 99%
and 61.3% of the subjects, respectively. Over 95% of subjects achieved
a 35% T>MIC for a 16mg/mL target at 1500mg dose infused over 3 hrs
or 3000mg (2000mg CXA/1000mg TAZ) infused over 60 min.
Conclusion: Based on recent surveillance data, CXA/TAZ 1500mg q8
infused over 60 min is predicted to achieve excellent TA for species such
as Enterobacteriaceae and P. aeruginosa. Using 40−50% T>MIC as a
target, CXA/TAZ is expected to display excellent target attainments up
to a MIC of 8 mg/mL.
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P1521 Safety, tolerability, and pharmacokinetics of a novel Gram-
negative antimicrobial, GSK2251052, in healthy subjects
L.T. Zane*, S. Shakib, R. Milne, L. Liu, S. Baker, F.A. Heerinckx
(Palo Alto, US; Adelaide, AU)
Background: GSK2251052 (GSK ’052) is a novel boron-based
antimicrobial which speciﬁcally targets bacterial leucyl-tRNA synthetase,
an essential enzyme in protein synthesis.
Objectives: Phase I, single-centre, randomised, placebo-controlled,
double-blind, ﬁrst-time-in-human study conducted to determine the
safety, tolerability, and pharmacokinetic (PK) proﬁle of GSK ’052
(formerly AN3365) in single and multiple intravenous (IV) doses.
Methods: Two-stage (single and multiple ascending dosing; SAD and
MAD) fusion protocol using adaptive design. Each cohort had 8 young
healthy men randomised to either GSK ’052 or placebo (normal saline)
by 1 h infusion in a ratio of 6:2. See Table 1 for cohort dosing
characteristics.
Results: PK results demonstrated dose proportionality of AUC and
Cmax across a wide dose range (Table 1). Maximum doses of 3000mg
(SAD) and 2000mg (MAD) of GSK ’052 were well-tolerated. There
were no deaths, SAEs or any AEs leading to withdrawal from the study.
The 3 most common AEs reported in the trial, irrespective of stage, were
headache (HA, 20% of subjects), orthostatic hypotension (OH, 18%),
and cannulation site injury (CSI, 22%). There was no apparent dose
response to these AEs and all were also observed in subjects receiving
placebo. There were no clinically signiﬁcant laboratory values or ECG
ﬁndings that were considered AEs. Most notable laboratory abnormality
was a reversible decrease in reticulocyte (Rc) counts to approx. 20−50%
of baseline values after approx. 4−8 d of repeat dosing and a return to
normal levels within 6 d after end of dosing. No scheduled doses were
held due to low Rc or red blood cell (RBC) count. No AEs were causally
attributed to low Rc or RBC count.
Conclusion: GSK ’052, a novel Gram-negative antimicrobial, demon-
strates dose proportionality in plasma AUC and Cmax across a wide
dose range without SAEs or dose-limiting AEs. A consistent clinical
AE proﬁle was demonstrated with the most common AEs being HA,
OH, and CSI, none of which was found exclusively in subjects receiving
GSK ’052. No clinically signiﬁcant laboratory values or ECG ﬁndings
were considered AEs, though a reversible decrease in Rc count was
observed.
P1522 Antifungal activity of the Neosartorya ﬁscheri antifungal pro-
tein against ﬁlamentous fungal isolates from clinical sources
L. Kova´cs*, M. Vira´gh, M. Tako´, T. Papp, C. Va´gvo¨lgyi, L. Galgo´czy
(Szeged, HU)
Objectives: The incidence of fungal infections has increased over
the past years due to the increasing number of immunocompromised
hosts and the emergence of antibiotic-resistant strains. Some of the
antifungal drugs are quite toxic and have serious side effects. Thus,
there is a considerable demand for new compounds with antimicrobial
activity. The extracellular defensin-like antifungal peptides secreted by
ﬁlamentous fungi are interesting in this respect, because they have
effective inhibitory potential against other fungi. In silico analysis
revealed a putative defensin-like antifungal protein encoding gene in
the Neosartorya ﬁscheri genome (N. ﬁscheri antifungal protein, NFAP).
Experiments have been carried out for the isolation of NFAP and for the
investigation of its antifungal activity against ﬁlamentous fungi.
Methods: N. ﬁscheri was cultivated in antifungal peptide induction
medium and the extracellular NFAP was puriﬁed from the ferment
broth. The in vitro antifungal effect of NFAP on 20 fungal isolates (15
asco- and 5 zygomyceteous fungi) from clinical sources representing
6 different genera and 17 species has been investigated in 96-well
microtitre plate bioassay based on the recommendation of the standard
Clinical and Laboratory Standards Institute (CLSI) M38-A2 microbroth
dilution method.
Results: The puriﬁed ~6.6 kDa molecular weight NFAP exerted
remarkable antifungal activity above its concentration of 12,5mg/ml
against 9 ascomycetous fungal isolates belonging to the genera
of Aspergillus and Fusarium. On the other hand, all investigated
zygomyceteous fungal isolates were completely insensitive to NFAP.
Microscopic observation revealed that germination tubes and forming
hyphae from conidiospores of Aspergillus species exhibited substantial
deviation from normal morphology when cultivated in presence of
100mg/ml NFAP. They displayed abnormal and delayed germination
compared to the untreated control. Treated conidiospores formed very
short, swelled, curved hyphae with multiple branches and fragmented
cytoplasm.
Conclusions: Based on the observed characteristics, NFAP would be a
promising antifungal compounds in the near future against ascomycetous
fungal species after further in vitro and in vivo investigations.
L. G. holds a postdoctoral fellowship from the Hungarian Scientiﬁc
Research Fund (OTKA; grant reference number PD 83355).
P1523 In vitro susceptibility of Cryptococcus neoformans
preincubated with anti-Hsp90 to many antifungal agents
R. Alakeel* (Riyadh, SA)
Objectives: The present examines the effect of many antifungal agents
against C. neoformans isolates pre-incubated with anti-Hsp90.
Methods: The antifungal activity of AMB in combination with FCZ or
5-FC against eight C. neoformans isolates pre-incubated with anti-Hsp90
was evaluated using the microdilution checkerboard technique.
Results: Depending on the deﬁnition of the FIC used (FIC-0), a
synergistic, additive interaction was found with a signiﬁcant portion
of the isolates. In vitro susceptibility testing of 5FC in combination
with anti-Hsp90 against C. neoformans isolates was determined using
a checkerboard assay. Synergism, indifferent and additive interactions
were observed in 37.5%, 12.5% and in 50% of isolates, respectively.
Conclusion: Cryptococcus neoformans cells became considerably more
sensitive to the action of standard antifungal agents when grown in
media supplemented with anti-Hsp90. Anti-Hsp90 at concentrations of
4−32mg/ml signiﬁcantly decreased the MIC-0 of amphotericin B, the
MIC-2s of ﬂuconazole and the MIC-2s of 5-ﬂucytosine. Preincubation
of the C. neoformans cells with Anti-Hsp90 signiﬁcantly enhanced
the antifungal activity of amphotericin B in combination with either
ﬂuconazole or 5-ﬂucytosine. The interaction between 5-ﬂucytosine and
anti-hsp90 was synergistic, additive or indifferent. Flucytosine alone
was inactive and upon combination with anti-Hsp90, the interaction was
synergetic in three isolates, additive in four isolates and indifferent in
one isolate.
P1524 BC-3781: evaluation of the CYP3A interaction potential
U. Schmidt, W.W. Wicha, F. Obermayr*, R. Novak, W. Prince (Vienna, AT)
Objective: In vitro and in vivo assessment of the interaction potential
of BC-3781, an investigational pleuromutilin, with CYP450 enzymes.
Methods: Interaction of BC-3781 with CYP450 enzymes was inves-
tigated by reaction phenotyping using human recombinant CYP450
enzymes. Inhibition and induction was investigated in vitro using
microsomes and human hepatocytes. The in vivo interaction of BC-
3781 on the pharmacokinetics (PK) of midazolam and the interaction of
ketoconazole on the PK of BC-781 were investigated in two cross over
phase I studies in healthy subjects.
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Results: Reaction phenotyping using CYP1A2, 2B6, 2C8, 2C9, 2C19,
2D6 and 3A4 demonstrated exclusive metabolism of BC-3781 by
CYP3A4 in this setting. Microsomal inhibition experiments identiﬁed
CYP3A as primary target of BC-3781. While CYP3A mediated
testosterone hydroxylation was very weakly affected by BC-3781 (IC50
>300 microM) midazolam hydroxylation was inhibited with an IC50
value of 5.5 microM. Induction experiments with human hepatocytes
from three single donors did not reveal any induction of CYP1A2 or
3A4 by BC-3781.
A clinical study investigating the effect of BC-3781 on midazolam PK
identiﬁed BC-3781 as a very weak inhibitor of CYP3A. The AUC
of midazolam increased by 1.17 (CI90 0.82–1.67) while Cmax was
increased by a factor of 1.04 (CI90 0.82–1.30) in the presence of BC-
3781. Inhibition of CYP3A with ketoconazole identiﬁed BC-3781 as a
weak CYP3A substrate in vivo with geometric mean AUC ratio estimates
of 1.29 (CI90 1.20–1.40). A Cmax increase of 1.06 (CI90 0.98–1.14)
was below the weak CYP3A interaction threshold of 1.25 and within the
no-effect boundaries.
Conclusions: While BC-3781 did not induce CYP1A2 and 3A4 it
could be demonstrated that BC-3781 serves as a CYP3A4 substrate and
inhibitor in vitro.
Two clinical drug interaction studies with BC-3781 showed that the PK
of BC-3781 is only marginally affected in the presence of ketoconazole
and only a weak inhibition of CYP3A could be suggested from the study
where midazolam was co-administered. The data obtained in both studies
suggest that BC-3781 can be classiﬁed as having only a weak interaction
with either CYP3A4 substrates or inhibitors in a clinical setting.
Taken together, these results suggest that no major CYP450 mediated
drug-drug interactions are expected with BC-3781.
P1525 Antimicrobial peptides with antiviral activity against a
novel bunyavirus
Q. Bian*, Y. Chi, Y. Li, X. Guo, Z. Shi, H. Wang (Nanjing, CN)
Objectives: To explore if any antimicrobial peptide (AMP) could
effectively inhibit the novel bunyavirus and its possible mechanism.
Methods: A novel bunyavirus associated with this life-threatening
infectious disease was isolated from one patient’s blood sample from
eastern China by staffs from Jiangsu CDC on Oct 2010. The novel
bunyavirus was discovered by China CDC in 2009. In this study, the
blood sample from a single patient was inoculated into VERO cell
culture to isolate the pathogen. The pathogen was indentiﬁed by electron
microscopy and DNA sequencing. AMP was a gift from Dr. Yong YANG
which had been observed to inhibit both bacteria and cancer (results
unpublished). In this study, the antiviral activity of the AMP against the
novel bunyavirus was tested in the VERO cell line by antiviral activity
assay.
Results: The maximal non-cytotoxic concentration of AMP in VERO
cell was determined to be 16 ug ml-1. The effects of antiviral activity
of 24-h pretreated and non-pretreated AMP were examined respectively
and the pretreated cells showed distinct antiviral activity against the
novel bunyavirus. Further more, AMP inhibited bunyavirus infection in
a dose-dependent manner.
Conclusion: This study revealed the AMP with antiviral activity on the
novel bunyavirus and shed light on the future application in antivirual
therapy.
Fig. 1. The antiviral effects of AMP on VERO cell with or without novel bunyavirus
infection were observed by microscope (×40). A. the normal cells. B. the cells
with AMP pretreated for 24h. C. the normal cells infected by novel bunyavirus
for 5d. The majority of the cells were ﬂoated and shrunk. D. the AMP pretreated
cells infected by novel bunyavirus for 5d. The cell number was reduced but the
morphologic character was same with the normal cells.
Fig. 2. The antiviral activity of AMP against novel bunyavirus was dose-dependent.
Bunyavirus was respectively treated with 250, 500 and 1000 ug ml-1 of AMP for
24h, and then titrated on VERO cells. LogNI values were determined 6 dpi. Each
value is the mean±SD of three independent experiments conducted in triplicaes.
P1526 Phosphorodiamidate morpholino oligomer RNA
therapeutics for neuroinvasive infectous disease
S. Shewsbury*, P. Iversen (Bothell, US)
Objectives: The phosporodiamidate morpholiono oligomers (PMO) can
be designed to inhibit gene expression by binding speciﬁcally to RNA
with complementary base sequences. We have investigated the utility
of these PMOs extensively as antiviral and antibacterial agents with
numerous successes. However, numerous infectious diseases present
therapeutic target challenges due to the neuroinvasive character of
the infectious agent. The goal of these studies was to evaluate the
potential for PMOs to cross the blood brain barrier (BBB) and enter
the cerebrospinal ﬂuid (CSF).
Methods: AVI-4020 is a PMO with sequence 5’-CTT AGA CAT CGA
GAT CTT CGT G-3’ was designed to inhibit West Nile Virus (WNV).
Non-clinical studies involved a bolus i.v. injection of 50mg/kg into adult
male Sprague-Dawley rats. CSF was collected at 8 and 24 hours post
injection for quantitative determination of AVI-4020 with 4 rats per
group. A multicenter, placebo-controlled single-blinded, clinical study
was conducted in patients with neuroinvasive disease suspected to be
the result of WNV. A total of 10 subjects were enrolled in the study, 9
received 15mg of AVI-4020 i.v. every 12 hours for 5 days and 1 subject
received placebo. Blood plasma and CSF samples were collected for
quantitative determination of AVI-4020.
Results: In rats, the CSF concentrations were 204±43 ng/mL (26.8±5.6
nM), 8 hours post injection and below the limit of quantitation 24 hours
post injection. Plasma concentrations in the rats was below the limit
of detection at 8 hours. In humans, CSF samples from 7 subjects were
obtained 18.8 hours (range 11.3 to 35.2 hours) after the ﬁnal administered
dose. Each subject had detectable AVI-4020 at a mean concentration of
8.1 ng/mL (range 5.4 to 22.0). Interestingly, AVI-4020 crossed the BBB
regardless of clinical disease status classiﬁcation or if the meninges were
inﬂamed or not based on CSF cytology ﬁndings.
Conclusions: These studies in both rat and human provide evidence that
a PMO with molecular weight of 7624 daltons can cross the BBB. The
PMO is detected in CSF as early as 8 hours post a single injection in rat,
and up to 35 hours post repeated injections in the human. In the human,
AVI-4020 crossed the BBB regardless of disease status or meningial
inﬂammation.
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P1527 AVI-6006 for the treatment of Dengue viral infections
P. Iversen*, S. Crumley, D. Mourich, S. Perry, S. Shresta, T. Voss
(Bothell, LaJolla, New Orleans, US)
Objective: Dengue virus infections result in a spectrum of disease,
ranging from Dengue fever (DF), to Dengue hemorrhagic fever
(DHF) and Dengue shock syndrome (DSS). Earlier studies utilized a
phosphorodiamidate morpholino oligomer (PMO) or peptide conjugated
PMO to identify the 5′-stem loop (5′-SL) and the 3′-cyclization sequence
(3′-CS) as highly conserved viral targets. The purpose of these studies
was to evaluate new positively charged PMO oligomers (PMOplusTM)
for potentially enhanced efﬁcacy in both mouse and ferret Dengue type
2 (DV2) challenge models.
Methods: In vivo efﬁcacy studies were conducted with AVI-6006, a
combination of the two 5′-SL and 3′-CS PMOplusTM oligomers, in
AG129 mice inoculated intravenously with the DEN2 S221 viral strain
which causes early lethal disease in mice. In addition, efﬁcacy studies
were conducted in ferrets inoculated i.p. with DV2. The endpoints of the
studies included median survival time (MST), long term survival, body
weight changes, necropsy and tissue evaluation of selected organs and
blood and tissue virus load.
Results: In the mouse a 3.0mg dose of AVI-6006 administered by the
intraperitoneal route on days 0, 1, 2, 4, 6 and 8 post infection provided
for a MST of 14 days and 20 percent long term survival versus MST of
4 days and no long term survival in the saline control and the scramble
PMOplusTM control sequence (p< 0.05). Viral load in kidney, liver,
serum and small intestine was reduced in a dose dependent manner.
In the ferret, a dose of 150mg/kg (75mg/kg each of 5′-SL and 3′-
CS oligomers) was well tolerated and reduced body weight loss. Viral
load was reduced to undetectable levels in the liver and small intestine.
Finally, histological evaluation of liver and lung indicate AVI-6006 has
a protective antiviral effect on those tissues.
Conclusions: AVI-6006 PMOplusTM oligomers targeting the 5′-SL
and the 3′-CS are effective against Dengue 2 in both the mouse
lethal challenge and ferret challenge models providing survival beneﬁt,
reduction in viral titer and prevention of body weight loss. The 5′-SL
and 3′-CS combination provides a broad therapeutic index.
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P1528 In a phase 2 complicated skin and soft tissue infections trial,
outcomes assessed early in the course of therapy were con-
sistent with outcomes 10−17 days after completing therapy
with either omadacycline (OMC; PTK796) or linezolid
H. Hait, R. Arbeit, D. Molnar, G.J. Noel*, S.K. Tanaka (Boston, US)
Background: A successful phase 2 program studying OMC has been
completed that suggested efﬁcacy comparable to linezolid and thus
supported progression to a phase 3 program in patients with serious
skin infections. Because of an evolving concern that assessing outcome
10−17 days after completing therapy for complicated skin and soft tissue
infections (cSSTI) may poorly correlate with historical trial data used
to establish treatment effect of antibacterials in this disease, the early
responses in patients with cSSTI randomized to either OMC or linezolid
were further assessed.
Methods: A post-hoc analysis was conducted that was aimed at deﬁning:
1) incidence of cessation of spread of infection (no increase in either
maximum length or width of infection site inﬂammation) and absence
of fever (core body temp <38.2 C) 1−3 days after starting therapy and
2) reduction of lesion size during the treatment course.
Results: In OMC and linezolid-treated patients respectively, the clinical
response rates 10−17 days after completing therapy were 88.3% (98/111)
and 75.9% (82/108) [95%CI for the difference: 1.9, 22.9] in the
ITT population, 98.0% (98/100) and 93.2% (82/88) [95%CI for the
difference: −1.7, 11.3] in the CE population. The incidence of cessation
of lesion size increase and absence of fever at day 1−3 in OMC and
linezolid-treated patients respectively were 96.8% and 94.4% in the
ITT and 96.4% and 93.8% in the CE population. In ITT patients in
whom complete data were collected on lesion size, mean reduction of
maximal lesion dimension was greater for patients treated with OMC
than those treated with linezolid evaluated within 1−3 days of starting
(31.8%; SE 4.6% for OMC and 6.7%; SE 15.1% for linezolid) and upon
completion of therapy (81.1; SE 3.4% for OMC and 63.2%; SE 5.8%
for linezolid). Among the ITT subjects who received systemic antibiotics
prior to enrolment, mean reductions were 28.3% (SE 5.1%) for OMC
treated and −6.7% (SE 25.4%) for linezolid treated patients at 1−3 days
of starting therapy. At completion of therapy mean reduction of lesion
size in these patients was 82.7% (SE 4.3%) for OMC treated and 63.0
(SE 8.0%) for linezolid treated patients.
Conclusions: Consistent with outcomes assessed 10−17 days after
completing therapy, outcome assessed early in the course of therapy with
OMC compared favorably to that of linezolid. This phase 2 experience
strongly supports continued development of OMC as a treatment of
patients with serious skin infections.
P1529 Characteristics of bacterial isolates from a phase 2 study of
oritavancin for treatment of acute bacterial skin and skin
structure infections
F.F. Arhin*, I. Sarmiento, G. Moeck (Ville Saint Laurent, CA)
Objective: Oritavancin is an investigational lipoglycopeptide under study
for treatment of acute bacterial skin and skin structure infections
(ABSSSI) caused by Gram-positive pathogens. Its spectrum of activ-
ity includes methicillin-resistant (MRSA) and methicillin-susceptible
(MSSA) S. aureus as well as streptococci and enterococci. We describe
here the distribution of bacterial isolates from a phase 2 study comparing
single vs. infrequent vs. daily oritavancin dosing and their susceptibilities
to oritavancin.
Methods: Bacterial isolates from patients enrolled in the SIM-
PLIFI study (conducted in 2007–2008; ClinicalTrials.gov identiﬁer
NCT00514527) were obtained from skin aspirate, biopsy, purulent
drainage swab, or blood cultures at baseline and if clinically indicated,
at end of therapy, test-of-cure, and late follow-up visits (Day 4−7, Day
21−29 and Day 30−42, respectively). Isolates were identiﬁed at local
sites and identities were conﬁrmed at a central laboratory. Susceptibility
to oritavancin was also determined at the central laboratory by broth
microdilution following CLSI M7-A8 guidelines.
Results: At least one Gram-positive pathogen was isolated from 69.2%
(209/302) intent-to-treat patients; a total of 233 isolates were isolated
at baseline. S. aureus (isolated from 87.6% [183/209] of patients) was
the major pathogen at baseline; prevalence of all other pathogens was
<7%. Fully 56.3% (103/183) of baseline S. aureus isolates were MRSA.
Oritavancin MIC range for all isolates was 0.002−0.5mg/L. Oritavancin
MIC90 values for MSSA and MRSA were identical (0.12mg/L).
Oritavancin MICs of all post-baseline isolates including isolates collected
at late follow up visits (up to Day 42) were identical to those
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obtained at baseline; this includes isolates obtained from 38 of the 161
microbiologically-evaluable patients who failed oritavancin therapy.
Conclusions: S. aureus was the major baseline pathogen in this recent
phase 2 ABSSSI study. The high incidence of MRSA (56.3% of all
S. aureus strains) is consistent with contemporary clinical studies in
ABSSSI. All organisms isolated in the study exhibited oritavancin
MICs 0.5mg/L. Oritavancin susceptibility of baseline Gram-positive
pathogens was unchanged by oritavancin treatment, suggesting that
clinical failure (23.6% of microbiologically-evaluable patients) was not
a result of resistance development.
P1530 Dalbavancin versus linezolid for acute bacterial infections
of the skin: a comparison of early and standard outcome
measures in study VER001–009
M. Dunne*, G. Talbot, A. Das (Morristown, Philadelphia, San
Francisco, US)
Objectives: FDA Draft Guidance for treatment of skin infections has
recommended the implementation of an outcome assessment at 48−72
hours post baseline of the cessation of spread plus resolution of elevated
temperatures as the primary point for comparisons in non-inferiority
studies, rather than the test of cure historically measured post therapy. We
performed a retrospective analysis of this new endpoint in a previously
completed registrational trial and compared the outcome to the protocol
prespeciﬁed primary endpoint of clinical response at Day 28.
Methods: The primary endpoint at Day 28 was originally deﬁned in
the clinically evaluable population which was then further analyzed in
subgroups of patients meeting the newly deﬁned FDA inclusion criteria
(surface area of lesion >75cm2; one sign of either fever, elevated white
blood cell count or bandemia) as well as the early response endpoint
at Day 3/4 (lesion size the same or smaller relative to baseline and
temperature <37.6ºC).
Results: See table.
Conclusion: Dalbavancin non-inferiority relative to linezolid as assessed
by the prespeciﬁed primary analysis is reinforced with an early responder
analysis performed at Day 3/4, with very similar differences in the point
estimate regardless of outcome measure.
P1531 Integrated safety analysis of CANVAS and FOCUS studies:
randomised, double-blinded, phase 3 studies of ceftaroline
versus comparators in complicated skin and skin structure
infection and community-acquired bacterial pneumonia
D. Rank*, T. Baculik, P.B. Eckburg, A. Smith, J. Laudano,
H.D. Friedland (Oakland, US)
Objectives: Ceftaroline (CPT), a novel parenteral cephalosporin
approved by the United States Food and Drug Administration in October,
2010, for treatment of acute bacterial skin and skin structure infection
and Community-Acquired Bacterial Pneumonia (CABP), has activity
against a broad range of Gram positive and negative pathogens, including
methicillin resistant Staphylococcus aureus. In each clinical trial, CPT
had a safety proﬁle reﬂective of the cephalosporin class. To assess
overall safety, including incidences of adverse events (AEs), safety
data from 4 randomized (1:1) and double blinded phase 3 trials, 2
CANVAS (CeftAroliNe Versus [vs] vAncomycin in Skin and skin
structure infection) and 2 FOCUS (ceFtarOline Community-acquired
pneUmonia trial vS ceftriaxone) trials, were integrated and are presented.
Methods: In the CANVAS trials, adults requiring therapy intravenously
(IV) for cSSSI received CPT (600mg) or vancomycin (1 g) plus
aztreonam (1 g) IV every 12 hours (q12h) for 5 to 14 days; in the
FOCUS trials, adults requiring hospitalization and therapy IV for CABP
received CPT (600mg) q12h or ceftriaxone (1 g) every 24 hours IV for
5 to 7 days.
Results: 1305 patients received CPT, and 1301, comparators. In the CPT
and comparator groups, baseline characteristics were comparable, and
rates of AEs (45.7% vs 46.7%), serious adverse events (7.6% vs 7.7%),
deaths (1.4% vs 0.9%), and discontinuations due to AEs (3.7% vs 4.5%)
were similar. No individual AEs occurred in 5% of patients. The most
common AEs in the CPT group were diarrhoea, headache, and nausea;
those in the comparator group were pruritus, nausea, and diarrhoea. In
the 2 groups, AE severity was similar (most AEs were mild or moderate),
and incidences of drug related AEs were approximately 20%. The most
common drug related AE in the CPT group was diarrhoea, and that in
the comparator group was pruritus. The direct Coombs seroconversion
rate was higher in the CPT group than in the comparator group (10.7%
vs 4.4%); however, there was no evidence of haemolytic anaemia. In the
CPT and comparator groups, incidences of potential allergic reactions
were similar (5.4% vs 8.5%), and AEs conﬁrmed due to Clostridium
difﬁcile, rare (0.2% vs <0.1%). Differences between groups in other
safety ﬁndings were not clinically meaningful.
Conclusion: Based on safety data from 1305 patients treated with CPT
in the CANVAS and FOCUS trials, CPT was well tolerated with no
unexpected safety concerns and had a safety proﬁle reﬂective of the
cephalosporin class.
P1532 Efﬁcacy and safety of ceftazidime/NXL104 plus
metronidazole vs. meropenem in the treatment of
complicated intra-abdominal infections in hospitalised adults
C. Lucasti*, I. Popescu, M. Ramesh, J. Lipka, C. Sable (Somers Point,
US; Bucharest, RO; Bangalore, IN; Wilmington, US)
Objectives: This phase II study evaluated the efﬁcacy and safety
of ceftazidime/NXL104 (CAZ104) plus metronidazole (MTZ) vs.
meropenem in the treatment of hospitalised adults with complicated
intra-abdominal infections (cIAIs).
Methods: This was a prospective, multicentre, double-blind, randomised,
comparative study (ClinicalTrials.gov Identiﬁer: NCT00752219). cIAIs
were deﬁned as those extending into the peritoneal space and which
required surgical intervention. Eligible patients (pts) from 33 sites in 8
countries worldwide were stratiﬁed according to APACHE II score and
randomised (1:1) to receive either CAZ104 (2000/500mg) plus MTZ
(500mg) or meropenem (1000mg) IV every 8 h. Pts were treated for
a minimum of 5 and maximum of 14 days. A test of cure (TOC) visit
occurred 2 weeks after last treatment. A ﬁnal visit took place 4−6 weeks
after last treatment. The primary endpoint was clinical response at the
TOC visit in microbiologically evaluable (ME) pts. Clinical response was
complete resolution or signiﬁcant improvement of signs and symptoms
of infection, with no additional antibiotics or surgery required.
Results: 203 pts aged 18−90 years were randomised and clinical
characteristics were comparable between groups. Overall, 47.3%
presented with appendicitis. The ME population comprised 144 pts
(CAZ104+MTZ, n = 68; meropenem, n = 76). Most infections were
polymicrobial and due to Escherichia coli (CAZ104+MTZ, n = 52;
meropenem, n = 53) and Klebsiella pneumoniae (CAZ104+MTZ, n = 6;
meropenem, n = 11). The mean duration of therapy was ~7 days. At
TOC in the ME population, 91.2% of pts treated with CAZ104+MTZ
(62/68) achieved a favourable clinical response compared with 93.4% of
meropenem-treated pts (71/76; difference: −2.2%; 95%CI: −20.4, 12.2;
p = 0.6). Among patients with Gram-negative CAZ-resistant infection,
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favourable microbiological responses were demonstrated in 25/26 pts
overall in the CAZ104+MTZ group (E. coli, 19/20; K. pneumoniae,
3/3) and 17/18 pts overall in the meropenem group (E. coli, 13/14;
K. pneumoniae, 3/3). The most common adverse events overall for
CAZ104+MTZ were nausea (10%) and vomiting (14%). The incidence
of drug-related adverse events was similar for CAZ104+MTZ (15%) and
meropenem (17%).
Conclusion: In this study, CAZ104+MTZ was generally well tolerated
and demonstrated efﬁcacy in the treatment of hospitalised adults with
cIAIs, with similar efﬁcacy to that of meropenem.
Supported by AstraZeneca, Macclesﬁeld, UK.
P1533 Efﬁcacy, safety and tolerability of ceftazidime/NXL104 vs.
imipenem cilastatin in the treatment of complicated urinary
tract infections in hospitalised adults
J. Vazquez*, L.D. Gonzalez Patzan, J. Lipka, C. Sable (Detroit, US;
Guatemala City, GT; Wilmington, US)
Objectives: Phase II study evaluating the efﬁcacy and safety of a
combination of ceftazidime plus a novel non-b-lactam b-lactamase
inhibitor, NXL104 (CAZ104) vs. imipenem cilastatin in the treatment
of hospitalised adults with complicated urinary tract infections (cUTIs)
due to Gram-negative pathogens.
Methods: Prospective, multicentre, investigator-blinded, randomised,
comparative study (ClinicalTrials.gov Identiﬁer: NCT00690378) eval-
uating the treatment of cUTIs, including acute pyelonephritis, UTI in
men, or UTI associated with obstruction, foreign bodies or urological
abnormalities. 135 patients (pts) were enrolled from 5 countries and
stratiﬁed based on type of infection (pyelonephritis or other cUTI).
Pts were randomised (1:1) to receive CAZ104 (500/125mg) IV every
8 h or imipenem cilastatin (500mg) IV every 6 h. Pts were treated
for a minimum of 7 and a maximum of 14 days. Pts who met pre-
speciﬁed criteria for clinical improvement after day 4 and had susceptible
pathogens were switched to oral ciproﬂoxacin (500mg) monotherapy
every 12 h for the remaining treatment course. Efﬁcacy was assessed at
the end of IV therapy, at the test of cure (TOC) visit 5−9 days after last
treatment, and during a late follow-up, 4−6 weeks after end of therapy.
The primary efﬁcacy end point was microbiological response at the TOC
visit in microbiologically evaluable (ME) pts. Favourable microbiological
response in a pt was deﬁned as eradication of all infecting pathogens;
eradication of a pathogen was deﬁned as reduction of baseline urine
pathogen level from 105 CFU/mL to <104 CFU/mL within 5−9 days
of last treatment (TOC), without evidence of the pathogen in the blood.
Results: The microbiological response of CAZ104 vs. imipenem
cilastatin at the TOC visit, in the ME population will be presented,
along with the safety and tolerability of CAZ104.
Conclusion: This study will report the efﬁcacy and safety of CAZ104
relative to imipenem cilastatin in the treatment of hospitalised adults
with cUTIs.
Supported by AstraZeneca, Macclesﬁeld, UK.
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P1534 Linezolid and vancomycin in the treatment of lower
extremity complicated skin and skin structure infections
caused by methicillin-resistant Staphylococcus aureus by
vascular disease status
T. Duane*, C. Thompson, L. Puzniak, D. Huang, A. Reisman, J. Weigelt
(Richmond, Collegeville, Milwaukee, US)
Objectives: Physiologic differences exist in patients with vascular
disease (PVOD) that may impact drug delivery and subsequent outcomes
when treating PVOD patients with lower extremity (LE)complicated
skin and skin structure infections (cSSSI) caused by methicillin-resistant
Staphylococcus aureus (MRSA). We sought to evaluate the outcomes
between patients with and without PVOD who were treated for a LE
cSSSI caused by MRSA.
Methods: Data from two prospective randomized, clinical trials
evaluating the safety and efﬁcacy of linezolid (LZD) and vancomycin
(VAN) for the treatment of MRSA cSSSI were pooled to evaluate
outcomes by vascular disease status. In each trial, eligible adults were
randomized in a 1:1 ratio to receive LZD 600mg IV or orally every 12 h
or VAN 15mg/kg or 1 g IV every 12 h (adjusted for creatinine clearance)
for 7−28 d. Patients with PVOD were identiﬁed by the investigator. Only
patients with a LE cSSSI caused by culture proven MRSA were included
in this analysis. Clinical success rates among patients with and without
PVOD receiving LZD and VAN were compared at end of treatment
(EOT) and at end of study (EOS; 6−28d after EOT).
Results: There were 477 patients with LE cSSSI caused by MRSA
(230 LZD and 247 VAN). Treatment groups were comparable for
demographics and clinical characteristics for subjects with (139 LZD,
135 VAN) or without PVOD (91 LZD, 112 VAN). For those with
PVOD, treatment duration was 12.7 and 11.7d for the LZD and VAN
groups (p = 0.07), respectively, and for those without PVOD, 11.5d and
9.5d (p = 0.002), respectively. Clinical outcomes are shown in the table
below. The number of subjects with treatment-related AEs (LZD=58
vs VAN=53), serious AEs (LZD=13 vs VAN=11), and study drug
discontinuations (LZD=7 vs VAN=6) were comparable between LZD
and VAN treated patients. Thrombocytopenia was identiﬁed in 4.3% and
0.7% of patients treated with LZD and VAN, respectively, and anemia
in 7.2% and 1.5% of patients treated with LZD and VAN, respectively.
Conclusions: Clinical success rates at EOT and EOS were statistically
signiﬁcantly higher with LZD compared to VAN in patients with PVOD
and LE cSSSI caused by MRSA. Thrombocytopenia and anemia were
identiﬁed more frequently among LZD treated compared to VAN treated
patients and AE proﬁles were consistent with known safety proﬁles.
P1535 The impact of linezolid versus vancomycin treatment on
the resolution of local signs of inﬂammation of complicated
skin and skin structure infections caused by culture proven
methicillin-resistant Staphylococcus aureus
A. Tice*, O. Equils, D. Huang, D. Stevens (Honolulu, Collegeville,
Boise, US)
Objectives: A recent clinical trial demonstrated linezolid (LZD) to be
comparable to vancomycin (VAN) in clinical outcomes (LZD 84% vs.
VAN 80%; p = 0.25) among patients with culture proven methicillin-
resistant Staphylococcus aureus (MRSA) complicated skin and skin
structure infections (cSSSI). However, the impact of treatment on
resolution of local signs of inﬂammation have not been analyzed. We
assessed the effect of LZD and VAN treatment on the resolution of local
signs and symptoms of inﬂammation among adult patients with cSSSI
due to culture proven MRSA.
Methods: We conducted post hoc analyses on data obtained from a
recent phase 4, multicenter, open-label, 1:1 randomized, comparator
controlled study conducted in adults with cSSSI due to culture proven
MRSA. Adult patients were treated with linezolid 600mg IV or orally
twice a day, or VAN 15mg/kg every 12 h adjusted for creatinine
clearance. Study treatment was to be administered for a duration of 7 to
14 days. The presence or absence of purulent discharge and inﬂammation
(tenderness, induration, local warmth, erythema, or ﬂuctuance) was
assessed and recorded by the site investigator at baseline, day 7±1, at
the end of treatment (EOT; within 72hr after discontinuation of study
medication), and at the end of study (EOS) visit, which occurred 6 to
28 days after treatment completion.
Results: Out of 654 patients who received at least one dose of
study drug and had a baseline MRSA culture, 329 were treated with
LZD and 325 were treated with VAN. The groups were comparable
with respect to baseline demographics, clinical presentation, comorbid
diseases, microbiology, frequency of incision and drainage. At Day 7,
fewer patients in the LZD group had swelling (49% vs. 59%; p = 0.03)
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and tenderness (52% vs. 62%; p = 0.02) and, at EOT, fewer patients
in the LZD group, compared to the VAN group, had erythema (28%
vs. 35%; p = 0.07), discharge (27% vs. 34%; p = 0.05), tenderness (30%
vs. 38%; p = 0.04), pain (23% vs. 32%; p = 0.009), swelling (22% vs.
32%; p = 0.008), and warmth (8% vs. 15%; p = 0.001). At the EOS
fewer patients in the LZD group had warmth (7% vs. 12%; p = 0.03)
and purulent discharge (7% vs. 14%; p = 0.006).
Conclusion: We observed more rapid and greater resolution of many
clinical ﬁndings of inﬂammation in adult subjects receiving LZD for
MRSA cSSSI compared with subjects receiving weight based VAN
(15mg/kg every 12 h).
P1536 Linezolid versus vancomycin in the treatment of
healthcare-associated pneumonia caused by culture-proven
methicillin-resistant Staphylococcus aureus
M. Bassetti*, D. Kett, S. Puttagunta, E. Scerpella, P. Biswas, D. Huang
(Genoa, IT; Miami, Collegeville, US)
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) is a
major cause of health care-associated pneumonia (HCAP). We describe
outcomes of the HCAP subgroup from a double-blind randomized
controlled trial (DBRCT) comparing linezolid (LZD) to vancomycin
(VAN) in adults with nosocomial pneumonia (NP), including HCAP,
caused by culture-proven MRSA.
Methods: We identiﬁed all patients with HCAP enrolled in an
international DBRCT of LZD (600mg IV twice daily) compared to
VAN (15mg/kg IV twice daily) for NP, including HCAP, caused by
MRSA. HCAP was deﬁned as pneumonia acquired in a long-term care
or sub-acute/intermediate health care facility; or following a recent
hospitalization (hospitalized for 48h and discharged within 90 days
of current admission); or in a subject who received chronic dialysis
care within the 30 days prior to study enrollment. In this population, we
examined clinical and microbiologic success at end of study (EOS, 7−30
days after the end of therapy). We also recorded rates of treatment-related
adverse events (TRAEs), serious adverse events (SAEs), AEs that led to
study drug discontinuation, and 28-day all-cause mortality rates.
Results: Among the 78 subjects with MRSA HCAP, patients randomized
to LZD (n = 38) were similar to those treated with VAN (n = 40) with
respect to demographics, co-morbidities (with the exception of chronic
obstructive pulmonary disease 95% LZD, 77% VAN), and APACHE II
score (mean LZD 17.3 and VAN 17.9). At EOS the clinical success rates
were 57% with LZD compared to 44% with VAN (OR=1.7; 95%CI,
0.6−4.6) and the microbiological success rates were 66% with LZD
compared to 38% with VAN (OR=3.1; 95%CI, 1.1−8.6). All-cause
mortality within 28 days after randomization (LZD=8 vs. VAN=11)
were comparable between LZD and VAN treated patients. The number
of subjects with treatment-related AEs (LZD=9 vs. VAN=11) and
study drug discontinuations (LZD=0 vs. VAN=2) were comparable. No
treatment-related serious AEs were observed, and AE distribution was
similar for both groups.
Conclusions: At EOS, LZD resulted in numerically higher rates of
clinical success (although not statistically signiﬁcantly different), and
statistically signiﬁcantly higher microbiological success in MRSA HCAP
than weight-based VAN dosing (15mg/kg IV q12h). Both LZD and VAN
had comparable 28-day all-cause mortality and frequencies of TRAEs,
SAEs, and study drug discontinuations.
P1538 Evaluation of safety and tolerability of daptomycin
doses 8mg/kg/day: results from 270 patients in the
European Cubicin® Outcomes Registry and Experience
(EU-COREsm)
R. Utili*, P. Dohmen, Z. Dailiana, F. Nacinovich, B. Almirante,
A. Galloway, M. Heep, U. Trostmann, Y. Yin, R.L. Chaves (Naples, IT;
Berlin, DE; Larissa, GR; Buenos Aires, AR; Barcelona, ES; Newcastle
upon Tyne, UK; Basel, CH; East Hanover, US)
Objectives: Daptomycin (DAP) has concentration-dependent bacterici-
dal activity. In vitro/in vivo studies and increasing clinical experience
support doses up to 12mg/kg once daily especially in difﬁcult-to-treat
infections. The objective of this study was to assess the safety and
efﬁcacy of DAP doses 8mg/kg/day.
Methods: All pts receiving doses 8mg/kg/day in this multicentre,
retrospective, noninterventional registry were included in this analysis.
Outcomes of efﬁcacy (cured and improved = success, failure, non-
evaluable) at the end of DAP therapy and safety up to 30 days after
DAP were assessed by the investigators.
Results: In the reported treatment period (Jan 2006-Jun 2010), 270 pts
received DAP 8mg/kg (H8), while 3351 pts received doses <8mg/kg,
including 2731 pts who received the approved doses, 4 and 6mg/kg.
The frequency of H8 use increased over the 3 reporting periods (3%,
8%, and 12%, respectively); 63% of pts were male with a median
age of 63y (range: 6−94). At baseline H8 pts had more frequently
valve heart disease, sepsis and infections caused by MSSA than pts
treated with lower doses. The most common infections in H8 pts were
endocarditis, bacteraemia, SSTI and osteomyelitis/orthopedic devices.
Empiric treatment was used in 42% of pts. The most common pathogens
isolated in H8 pts were S. aureus (33%), coag-neg staphylococci (27%)
and enterococci (11%, most E. faecalis). The mean DAP dose of
10mg/kg was given for a median duration of 14 d. Longest treatment
was 110 d for in-pts and 60 d for out-pts. 8% of H8 pts were on dialysis
(dosing Q 48h) and 17% received statins during DAP therapy. The safety
proﬁle of H8 was good, no clinically relevant differences were detected
vs lower doses. Adverse events (AEs), regardless of relation to DAP,
were reported in 14% of H8 pts, incl. 2.6% with CPK elevations and
0.4% with musculoskeletal AEs. The most common AEs leading to DAP
discontinuation in H8 pts were infections (1.5%). The overall clinical
success rate with H8 DAP was 76% (Figure). Lower treatment failure
rates in left-sided endocarditis were observed in H8 pts vs lower doses.
Conclusion: The use of high dose DAP, including long duration therapy
for >100 days, has increased since 2006. Doses 8mg/kg for a median
duration of 14 days were safe and well tolerated in pts with diverse G+
infections. The role of high dose DAP seems to be promising in pts with
difﬁcult-to-treat infections and deserves further studies.
P1539 Results from an observational study: daptomycin is safe
and well tolerated in patients receiving haemodialysis
P. Nikolaidis*, A. Simon, S. Suefke, I. Lampreabe Gaztelu, P. Dohmen,
G. Petrikkos, A. Manzano Ramı´rez, W. Jabs, A. Beiras-Fernandez,
M. Scialabba, M. Heep, Y. Yin, R.L. Chaves (Thessaloniki, GR;
Hannover, Lu¨beck, DE; Bizcaia, ES; Berlin, DE; Athens, GR; Vitoria-
Gasteiz, ES; Munich, DE; Cefalu`, IT; Basel, CH; East Hanover, US)
Objectives: Infections are the 2nd most common cause of death in
end stage renal disease and account for ~14% of deaths in this
population. Dialysis patients (pts) are at 100-fold higher risk for invasive
MRSA infection and new therapeutic options are needed. In 2010
daptomycin (DAP) was approved in Europe to treat HD pts with S. aureus
bacteraemia (BAC) at 6mg/kg Q48h. As DAP levels are higher in this
population, this study aimed at evaluating the outcomes of HD pts treated
with DAP with focus on the drug safety proﬁle.
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Methods: All pts enrolled from Jan 06 to Jun 10 in EU-CORE, European
CUBICIN® Outcomes Registry and Experience − a retrospective, non-
interventional, multicenter study describing characteristics and outcomes
of pts treated with DAP − could be included. According to investigator’s
judgment outcomes are success (cure or improvement), failure and
not evaluable. All pts who underwent HD during DAP treatment were
selected for this analysis.
Results: Of 3621 pts enrolled, 207 underwent HD (64% male). Most
pts had signiﬁcant underlying disease including chronic renal failure,
hypertension and diabetes mellitus. The primary infections included
86 cases of BAC (42%), 58 SSTI (28%), 21 endocarditis (10%) and
17 foreign body/prosthetic infections (8%). S. aureus was identiﬁed in
61 cases (MRSA rate = 51%). Coagulase-negative staphylococci were
isolated in 32 cases and enterococci in 23, including 3 VRE. Prior to DAP
68% of pts received other antibiotics, most commonly a glycopeptide
or a penicillin, and the most frequent reason for its discontinuation
was treatment failure. The most frequent dosing interval for DAP in
HD was Q48h. Overall, therapy duration ranged from 1 to up to 85
days. Overall clinical outcomes were 71% success, 15% failure, and
14% non-evaluable (Figure 1). Highest success rates were achieved in
osteomyelitis and bacteraemia, 88 and 79%, respectively. Serum CPK
values were elevated at baseline in 23% of cases. Among pts with CPK
measurements during therapy normal levels were detected in 63%. There
was no DAP discontinuation due to CPK elevation. Serious AEs occurred
in 12.6% of pts most commonly infections − no musculoskeletal SAE
was reported.
Conclusion: DAP was safe and well tolerated in HD pts with a variety
of infections. The high success rates and favourable safety proﬁle
were comparable to those observed in pts with normal renal function.
Further clinical studies on speciﬁc subsets of infections in HD might be
warranted.
P1540 Treatment of multi-resistant typhoid fever with tigecycline:
the ﬁrst 10 cases
H. Laferl, P. Pongratz, G. Tucek, J. Leitner, C. Wenisch* (Vienna, AT)
Typhoid fever has become more refractory to standard therapy
due to increased resistance to numerous antibiotics. In addition,
relapsing disease and/or chronic carriage are pivotal public health
issues. Tigecycline has a favourable kinetic proﬁle (high intracellular
concentration, excellent tissue penetration) and MICs of Salmonella
typhi/paratyphi isolates range 0.12−2mg/L (data from India and Taiwan).
We describe 10 Austrian tourists returning from Asia with refractory
(n = 1) relapsing (n = 4), or resistant infection (n = 5), who where treated
with tigecycline 150mg once daily for 7−21days. In 8 patients (m/f = 3/7,
age=median 24 (16−47)) therapy was successful with a median fever
clearance time of 66 (24–168) hours and no relapse in a follow up
period of 90 days (no symptoms and repetitive negative blood cultures);
in 2 patients tigecycline was stopped due to nausea/vomiting after 3
days, all other patients had no side effects. This outcome suggests that
tigecycline might be a useful alternative for treating refractory, relapsing
or drug resistant typhoid fever.
P1541 Tigecycline as a therapeutic option in Stenotrophomonas
maltophilia infections
Y. Tezer Tekc¸e*, A. Erbay, H. C¸abadak, S. Sen (Ankara, Yozgat, TR)
Objectives: To compare the efﬁcacy of tigecycline (TGC) treatment
with trimethoprim-sulfamethoxazole (TMP-SXT) in Stenotrophomonas
maltophilia infections.
Methods: A retrospective cohort study was performed in a 432-bed
tertiary care hospital. Adult patients who had received more than 3
days of SXT or TGC for S. maltophilia infection were included in
the study during 3-y period (2008–2010). Patient characteristics and
laboratory test results were obtained for each patient from the medical
records and a computer database. The primary outcome measure was
30 day in hospital mortality, and secondary outcome measures were
microbiological eradication and clinical improvement.
Results: Among the 54 cases (mean age, 64.1±13.6 years (range,
26−88); M:F, 30:24) of S. maltophilia infection included in the study,
23 (42.6%) had pneumonia, 13 (24.1%) had surgical wound infection,
9 (16.7%) had primary bacteremia, 5 (9.3%) had secondary bacteremia
due to pneumonia and 4 (7.4%) had both pneumonia and surgical wound
infection. S. maltophilia infections occurred a mean of 28.6±13.2 days
after hospital admission. APACHE II scores were as follows; <10 (n = 6,
11.1%), 10−19 (n = 19, 35.2%), >20 (n = 29, 53.7%). Comorbidities
were present in 52 (96.3%) patients. 43 (79.6%) patients were followed
up in ICUs. Additional infections were found in 31 (57.4%) patients.
Among all isolates, the rates of susceptibility to TMP-SXT and TGC
were 98.2% and 100%, respectively. For the treatment of S. maltophilia
infection, 35 (64.8%) patients received TMP-SXT and 19 (35.2%)
patients received TGC. There were no statistically signiﬁcant differences
in patient characteristics between two groups, except the treatment of
patients with primary bacteremia, whom all had been received TMP-
SXT. Culture positivity rate was 93.6% in TMP-SXT group and 70.6%
in TGC group at 7th day (p = 0.031), whereas 24% versus 18.8% at 14th
day (p = 0.692). Clinical improvement was observed 71.4% in TMP-SXT
group and 68.4% in TGC group at 14th day (p = 0.817). Mortality rates
at 30 days after the infection were respectively, 28.6% and 21.1% in
TMP-SXT and TGC groups (p = 0.747).
Conclusion: There were no signiﬁcant differences in mortality and
clinical response rates between TMP-SXT and TGC treatment in
S. maltophilia infections. TGC had better microbiological eradication
rate at day 7. Tigecycline may be considered as alternative option beyond
TMP-SXT in treatment of S. maltophilia infections.
P1542 Effectiveness and safety of colistin therapy: a study in a
tertiary hospital in Korea
E.J. Choo*, M.H. Jeon, E.J. Lee, Y. Kwak (Bucheon, Goyang, KR)
Objective: Colistin has re-entered clinical use by necessity. We
investigated clinical features of patients who administrated with colistin,
aimed to assess its effectiveness and satety.
Methods: This study was conducted at a 980-bed tertiary care university
hospital in Korea. We retrospectively collected the data of the patients
who were admitted to hospital between January 2005 and July 2010.
Nephrotoxicity was deﬁned as an increase of creatinine more than 150%
from the baseline creatinine during colistin use. The primary outcome
was 30 day mortality and nephrotoxicity.
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Results: One hundred patients who had received intravenous colistin for
at least 48 hours for microbiologically documented multidrug-resistant
Gram negative bacterial infections were included. The patients’ age was
61.7±15.3 years. Almost of them (98%) had underlying diseases, such as
malignancy, neurologic disease, trauma, COPD, ESRD and heart failure.
Among these, 86 patients (86%) were hospitalized in ICU. Half of them
(48%) underwent operations. The mean duration of hospital stay until
the start of colistin administration was 44.3±57.3 days. The patients
were treated with colistin for pneumonia (58%), urinary tract infection
(20%), bacteremia (11%), abdominal infection (9%) and meningitis
(2%). The causative microorganisms were Pseudomonas aeruginosa
(56%) and Acinetobacter baumannii (44%). The duration of colistin
use was 9.0±5.2days. The 30 day mortality was 39% (39/100) and all-
cause in-hospital mortality was 52%. Nephrotoxicity occurred in 48 of
100 patients (48%) and 19 of them were recovered. In the multivariate
analysis, no independent predictors of nephrotoxicity were observed.
Conclusions: Our study showed that incidence of nephrotoxicity was
high after colistin use. They had severe underlying diseases and in-
hospital mortality of them was high.
P1543 An observational, follow-up study in a clinical cohort of
Clostridium difﬁcile infection patients comparing three
initial treatment regimes
J. Leitner*, D. Schmid, H. Kuo, V. Michl, F. Allerberger, C. Wenisch
(Vienna, AT)
Increase in the incidence as well as a high relapse and treatment failure
rate complicate current management of C. difﬁcile infection (CDI).
A prospective, observational follow-up study of a clinical cohort of
patients with Clostridium difﬁcile infection following case deﬁnition
of the European CDI Working Group comparing three initial therapy
regimens (121 patients were treated with metronidazole 3×500mg/d p.o.
for 5−14 days (group I); 42 patients were treated with metronidazole
3×500mg/d i.v. for 5−14 days (group II) and 42 patients were treated
with vancomycin 4×125–500mg/d p.o. for 5−14 days (group III).
Risk ratios provided with 95% conﬁdence intervals were calculated as
measures of the effect of the three therapy regimes on the endpoints
comparing Group I with Group II used as reference, Group III with
Group II used as reference and Group III with Group I used as reference
by applying c2 or Fisher’s exact tests. A Poisson regression model was
performed in order to control for possible confounding effects of co-
morbidity, age and sex.
Between the 3 groups there was no demographic differences (sex, age,
fever, or co-morbidity measured by Charlson’s index). 100 (82.6%) were
cured in group1, 22 (52.4%) in group2, and 34 (81%) were cured in
group 3 (p< 0.001). Persistent diarrhoea was present in 12 (9.9%), 4
(9.5%), 4 (9.5%) (p = 0.99). Death occurred in 9 (7.4%), 16 (38.1%),
and 4 (9.5%) patients (p< 0.001). The results of the comparative analysis
are depicted in the table. The protective effect of the therapy regimes
metronidazole p.o. and vancomycin po on the risk of death as compared
with the therapy regime metronidazole i.v. was controlled for possible
confounding effects of sex, age (>65 years) and co-morbidity. We
conclude that iv metronidazole should be avoided in the therapy of
C. difﬁcile infection.
P1544 A randomised, double-blind, placebo-controlled pilot study
to assess the effect of rifaximin “chaser” to prevent recurrent
diarrhoea in patients with Clostridium difﬁcile infection
K. Garey*, S. Ghantoji, D. Shah, M. Habib, V. Arora, Z.D. Jiang,
H. DuPont (Houston, US)
Objectives: Uncontrolled case series have demonstrated decreased
diarrhea recurrence in patients with Clostridium difﬁcile infection (CDI)
given rifaximin after conventional therapy. However, whether rifaximin
decreases recurrent diarrhea in patients with CDI is unknown. The
purpose of this study was to assess rates of recurrent diarrhea in patients
with CDI given rifaximin vs. placebo immediately after conventional
therapy.
Methods: This was a randomized, double-blind, placebo controlled pilot
study. Patients with CDI and a Horn’s index >2 were randomized to
receive rifaximin 400mg three times daily or placebo for 20 days given
immediately after ﬁnishing conventional anti-CDI antibiotics. Patients
were followed for three months and assessed for a composite endpoint
of recurrent diarrhea that included CDI recurrence (return of diarrhea
with a positive toxin test) and patient self-reported return of non-CDI
diarrhea after a period of wellness.
Results: Sixty-eight patients aged 61±18 years (50% male) were given
rifaximin (n = 33) or placebo (n = 35). Twenty four of 68 (35%) patients
had recurrent diarrhea either due to recurrent CDI (23.5%) or self-
reported diarrhea (11.5%). Recurrent diarrhea occurred in 17 of 35
(49%) patients given placebo and 7 of 33 (21%) given rifaximin
(p = 0.010). CDI recurrence occurred in 11 of 35 (31%) patients given
placebo and 5 of 33 (15%) patients given rifaximin (p = 0.087). Self-
reported diarrhea occurred in 6 of 35 (17%) of patients given placebo
and 2 of 33 (6%) given rifaximin (p = 0.17).
Conclusion: A rifaximin chaser regimen decreased the incidence of a
recurrent diarrhea in patients with CDI.
P1545 Comparison of doxycycline-streptomycin, doxycycline-
rifampin and oﬂoxacin-rifampin in the treatment of human
brucellosis
S. Hashemi*, L. Gachkar, F. Keramat, M. Mamani, M. Hajilooi,
A. Janbakhsh, M. Majzoobi, H. Mahjub (Hamedan, Tehran,
Kermanshah, IR)
Objectives: Traditional regimens for the treatment of brucellosis are
associated with signiﬁcant rates of relapses. A few clinical studies with
quinolone containing regimens have shown conﬂicting results. The aim
of this study was to compare the efﬁcacy of oﬂoxacin plus rifampin
(OR) versus doxycycline plus streptomycin (DS) and doxycycline plus
rifampin (DR) regimens in the treatment of brucellosis.
Methods: In a randomized clinical trial, 191 patients with brucellosis
were enrolled in the study. One of the three therapeutic regimens
including DS, DR, and OR was selected for each patient randomly.
All patients were assessed during the period of therapy in the second,
fourth and sixth weeks of therapy by clinical course. They also were
followed-up clinically and serologically for six months after the cessation
of therapy.
Results: Out of 191 patients with brucellosis 64, 62, and 65 patients
received OR, DR, and DS regimens respectively. After four weeks of
therapy, the highest clinical response was observed in the DS group.
Therapeutic failure was observed in 9% of all patients. The DR group
showed the highest rate of failure (16.9%) and the least rate was observed
in DS group (4.6%). Adverse reactions were seen in 16.8% of patients,
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but there was no signiﬁcant difference among three groups. The lowest
relapse rate (4.6%) was observed in the DS group.
Conclusion: The DS combination is still the ﬁrst line regimen for the
treatment of brucellosis in our region; we recommend the DR and OR
combinations as the second-line regimens.
P1546 Single-dose doxycycline for the treatment of Mediterranean
spotted fever
A. Toumi*, A. Aouam, F. Ben Romdhane, H. Ben Brahim, C. Loussaief,
M. Chakroun (Monastir, TN)
Introduction: Mediterranean spotted fever (MSF) due to Rickettsia
conorii is the most important tick-borne disease occurring in North
Africa. Tetracycline constitutes the conventional therapy for treatment
of MSF. Doxycycline has been reported as an effective alternative. We
therefore did a prospective study to compare doxycycline short-course
treatment with standard tetracycline therapy for patients with MSF.
Patient and Methods: A prospective and randomized study of 132
patients hospitalized for MSF in the department of infectious diseases,
university hospital Monastir, Tunisia, during the period 1987–2006. All
patients fulﬁlled Raoult criteria and had a positive serology of Rickettsia
conorii (a four-fold rise in antibody titer, a single high titer 64 or
seroconversion to speciﬁc antigen by indirect ﬂuorescent assay (IFA)).
We divided the patients into a tetracycline antibiotics-treated group
(group A) and doxycycline-treated group (group B). The patients were
initially randomly assigned 1 week of daily oral treatment with 2g
tetracycline (A) or a single dose of doxycycline (B).
Results: The mean age of the 132 patients was 39 years (range,
14−80 years). Eigthy-four of the 132 patients were males (63.6%).
Group A included 96 patients and group B 36 patients. There was
no statistically signiﬁcant epidemiological difference between the two
groups, particularly the age (39.5 versus 40.2 years, p = 0.81) and the
sex ratio (1.52 versus 2.59, p = 0.2). All patients had fever; a generalized
maculopapular rash was seen in 94 patients (98%) of group A and in
all patients of group B (p = 0.38). The presence of an inoculation eschar
was observed in 59 patients of group A (61.4%) and 25 patients of
group B (69.4%). In group B, the average time for apyrexia was shorter
(2.91±1.1 days versus 3.39±1.1 days, p = 0.03). The average time of
disappearance of myalgia was also shorter in group B (3.4±1.2 days
versus 4.11±1.3 days, p = 0.018). The rash disappeared after a mean of
3.68±1.45 days in the group B and 4.62±59 days in group A (P = 0.003).
The duration of hospitalization was longer in the tetracycline-treated
group compared with the doxycycline-treated group (6.45±2.73 versus
5.05±1.72, p = 0.005). We did not ﬁnd any side effects in the 2 groups.
Conclusion: A single dose of doxycycline may be an interesting
alternative to tetracycline antibiotics to treat MSF, because of its
effectiveness and safety compared to tetracycline.
P1547 A randomised, placebo-controlled trial of trimethoprim-
sulfamethoxazole plus doxycycline versus trimethoprim-
sulfamethoxazole alone for eradication phase treatment of
melioidosis
P. Chetchotisakd*, W. Chierakul, V. Chaowagul, W. Susaenrat,
S. Piphitaporn, J. Pilaikul, P. Mootsikapun, S. Anunnatsiri,
D. Limmathurotsakul, B. Thinkhamrop, N. Day, S. Peacock (Khon
Kaen, Bangkok, Ubon Ratchathani, Udon Thani, Mahasarakam, TH)
Background: Recurrence infection of melioidosis occurs around 5 to
25% of patients who survive the acute phase. After recover from the
acute phase with intravenous antibiotics administration, an eradication
treatment with oral antibiotics is required for at least another 20
weeks. The current recommended oral eradication regimen in Thailand
is combination of trimethoprim/sulfamethoxazole (TMP/SMX) and
doxycycline whereas in Australia only TMP/SMX is used.
Objectives: Primary outcome was to compare the efﬁcacy (overall
relapse and microbiological documented relapse) of TMP/SMX and
doxycycline with TMP/SMX alone for the eradication phase treatment of
melioidosis. The secondary outcomes were mortality, switched therapy
and adverse drug reaction (ADR).
Methods: A randomized, placebo-controlled trial was conducted in 5
hospitals in Thailand during October 2005-October 2010. The dose of
TMP/SMX used in the study was calculated based on patient weight
(TMP/SMX 10/50mg/kg/d). Patients received 20 weeks of treatment
and then followed for another 48 weeks.
Results: There were 611 patients which survived from the acute phase of
culture-proven melioidosis recruited. Among these, 306 cases received
combination treatment and 305 cases received TMP/SMX alone. Their
baseline characteristics were comparable between 2 groups. There were
20 (6.5%) of 306 cases in combination group and 16 (5.2%) of 305 cases
in TMP/SMX alone relapsed (difference 1.3%, 95%CI −2.4 to 5.0).
The culture proven relapse occurred in 11/306 (3.6%) in combination
and 9/305 (2.9%) in TMP/SMX alone group (difference 0.6%, 95%CI
−2.1 to 3.4). There was no signiﬁcant difference in mortality between
the 2 groups (3.6% vs. 3.9%, p = 0.825). Patients received combination
therapy switched their regimen more common that TMP/SMX alone
group (21.2% vs 14.4%, p= 0.028). More patient in combination group
experienced treatment related GI side effects (20.9 vs. 11.1%, p = 0.001),
allergic reactions (17.3% vs. 11.5%, p = 0.04), photosensitivity (8.8%
vs. 1.6%, p< 0.001), any ADR (7.2% vs. 2%, p = 0.002) than in the
TMP/SMX alone group.
Conclusion: Cotrimoxazole alone with weight-adjusted dosing should
be use as maintenance therapy for melioidosis.
P1548 Moxiﬂoxacin versus ceftriaxone in the treatment of
primary pyogenic liver abscess: a prospective, randomized,
open-labelled, active-controlled trial
S.S.J. Lee*, K. Wu, Y. Ni, C. Sy, C. Kao, J. Chen, Y. Wang, H. Tsai,
S. Wann, Y.S. Chen (Kaohsiung, TW)
Background: Primary pyogenic liver abscess (PPLA) is a distinct
disease entity primarily caused by Klebsiella pneumoniae. This trial aims
to determine whether the use of moxiﬂoxacin can effectively treat PPLA
and shorten hospitalization, compared to ceftriaxone. Development of
antibiotic resistance to colonized bacteria in the gastrointestinal tract
was evaluated.
Methods: Adults with clinical diagnosis of liver abscess, supported by
symptoms and radiological imaging were eligible for enrollment. Patients
with biliary tract stones, malignancy, septic metastatic infections to the
central nervous system and the eye, APACHE II score >20, rupture
of liver abscess, and resistant micro-organisms were excluded. Stool
cultures were collected at entry and 3 months.
Treatment arms: Moxiﬂoxacin 400mg IV qd for 2 weeks, then 400mg
PO qd for 7 days. Ceftriaxone 2gm IV q12h for 2weeks, then cephalexin
1gm PO q6h for 7 days (ClinicalTrials.gov identiﬁer: NCT00895089).
Results: Thirty-nine of 63 screened patients were excluded. Twenty-
four patients (moxiﬂoxacin 13, ceftriaxone 11) were enrolled, with no
difference in age (56.0 vs 63.4 years, p = 0.32) sex (8 vs 9 male, p = 1.00),
median APACHE II score (8 vs 9, p = 0.43), diabetes (63.6 vs 61.5%,
p = 1.00), and clinical symptoms, except for a longer duration of fever in
days (3.7 vs 1.2, p = 0.03). Abscesses were larger in the ceftriaxone group
(median 5.8 vs 2.8 cm, p = 0.01). Bacteremia occurred in the majority
(81.8 vs 69.2%, p = 0.65), all K. pneumoniae except for one case with
E. coli. Percutaneous aspiration/drainage was done whenever possible
(81.8 vs 51.5%, p = 0.39). Cure was achieved in the majority (81.8 vs
76.9%, p = 1.00 on intent-to treat, and 90.0% versus 100.0% on per
protocol analysis). Only one treatment failure occurred in the ceftriaxone
group. All K. pneumoniae isolated from the stool at 2−3months remained
susceptible to most antibiotics.
Conclusion: Treatment with moxiﬂoxacin is comparable with ceftriax-
one in the treatment of PPLA, and hospitalization can be shortened to 2
weeks without affecting outcome.
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P1549 Outcome of initial ciproﬂoxacin treatment for bloodstream
infections caused by extended-spectrum b-lactamase
producing E. coli and K. pneumoniae
J. Son*, J.H. Song, C.I. Kang, D.R. Chung, K.R. Peck, K. Ko, J. Yeom,
H. Ki, S.W. Kim, H.H. Chang, S. Ryu, Y.S. Kim, S. Jung, S.S. Lee,
K.T. Kwon, H. Lee, C. Moon on behalf of the Korean Network for
Study of Infectious Diseases (KONSID)
Objectives: The Purpose of the study was to evaluate the treatment
outcome of initial ciproﬂoxacin for patients with bacteraemia caused by
ESBL-producing E. coli and K. pneumoniae.
Methods: From the database of a nationwide surveillance program
(from October 2006 to April 2009) for bacteraemia, we analyzed
the clinical data of 1,647 patients with bacteraemia due to E. coli
and K. pneumoniae. Patients with initial ciproﬂoxacin treatment for
bacteraemia due to ESBL-producing E. coli and K. pneumoniae were
compared with those with non-ESBL-producing bacteraemia.
Results: Of total 1647 patients with bacteraemia, 238 (14.5%) were
ESBL-producing group (153 in E. coli, and 85 in K. pneumoniae),
and 1409 (85.5%) were non-ESBL-producing group (968 in E. coli,
and 441 in K. pneumoniae). And of all, 10.7% (177/1647) patients
were given initial ciproﬂoxacin without combination (5.5% [13/238] in
ESBL-producing group, and 11.6% [164/1409] in non-ESBL-producing
group). Ciproﬂoxacin was susceptible in 20.2% (48/238) of ESBL-
producing group (21.6% [33/153] in E. coli, and 17.6% [15/85]
in K. pneumoniae), whereas 60.0% (846/1409%) was susceptible in
non-ESBL-producing group (58.3% [564/968] in E. coli, and 63.9%
[282/441] in K. pneumoniae).
30-days mortality rate of patients with initial ciproﬂoxacin treatment
was signiﬁcantly lower in non-ESBL-producing group (9.1% [129/1409])
than in ESBL-producing group (15.1% [36/238]) (P< 0.001). By
univariate analysis, male gender, presence of hematologic disease,
presence of renal disease, primary bacteraemia, higher PITT score (>4),
and severe sepsis (P< 0.05 for all) were the risk factors for 30-
day mortality in initial ciproﬂoxacin treatment group for bloodstream
infections caused by E. coli and K. pneumoniae. By multivariate analysis,
only higher PITT score (>4), and severe sepsis (P< 0.05 for all) were
the common independent risk factors for mortality.
Whereas ESBL production was a risk factor in all patients with
bloodstream infection caused by E. coli and K. pneumoniae (P = 0.005),
it was not found to be an independent factor for mortality in initial
ciproﬂoxacin treatment group (P = 0.569).
Conclusion: In bloodstream infection caused by ESBL-producing E. coli
and K. pneumoniae, initial ciproﬂoxacin treatment was associated with
higher mortality. However other factor such as severe sepsis rather than
initial ciproﬂoxacin use should be considered as an important prognostic
factor.
P1550 Efﬁcacy and safety of 5-day therapy with ceﬁxime versus
ciproﬂoxacin for uncomplicated urinary tract infections in
women: randomised, controlled study
E. Dovgan*, V. Rafalskiy, V. Galkin, I. Malev (Smolensk, RU)
Objectives: To evaluate efﬁcacy and safety of short course of ceﬁxime
and ciproﬂoxacin in women with acute uncomplicated urinary tract
infections (uUTI).
Methods: A multicenter prospective randomized controlled trial was
performed in 3 centres in Russia. Female patients 18 years or older with
symptoms of uUTI and bacteriuria (103 CFU/ml) were included in
the study after giving informed consent. Patients with anatomical or
functional abnormalities of the urinary tract and signs or symptoms
of upper UTI were excluded. The study protocol was approved by
independent ethic committee. Patients were randomized in 1:1 ratio to
two study group − group 1 − treatment with ceﬁxime (Suprax®, Gedeon
Richter) 400mg OD for 5 days or group 2 − ciproﬂoxacin (Ciprolet®,
Dr. Reddy’s) 250mg (before interim statistical analysis[ISA]) or 500mg
twice daily for 5 days (after ISA). Patients were evaluated on days 3−5
(visit 2) and 28 (visit 3) after end of treatment.
Results: A total of 104 patients were included in the study − 49 in group
1, 55 − in group 2. ISA was carried out when 42 patients had been
included into the study. At visit 2 bacteriuria had been detected in 0%
(0/24) and 44.4% (8/18) among patients from group 1 and 2, respectively,
p = 0.0003. After ISA the dose of ciproﬂoxacin was increased from 250
to 500mg twice a day. Final statistical analysis showed that clinical
efﬁcacy in group 1 was 75.5% (37/49) and in group 2 − 58.1% (31/53),
p = 0.96. Eradication at visit 2 were 95.9% (47/49) in group 1 and 66%
(35/53) in group 2, p = 0.0002. An adverse events during therapy had
2 patients (4.1%) in the group 1 (bacterial vaginosis) and 11 (20%) in
the group 2 (7 − diarrhea, 2 − bacterial vaginosis, 1 − urticaria and 1 −
pyelonephritis).
Conclusion: Ceﬁxime (400mg twice a day) is a more effective and safe
than ciproﬂoxacin (250–500mg twice a day) in the treatment of uUTI
in women.
P1551 Pivmecillinam in the treatment of ESBL-producing
Escherichia coli
G. Scho¨n*, K. Hedin, M. Sundqvist (Va¨xjo¨, SE)
Objectives: Pivmecillinam (MEC) is a b-lactam for the treatment of
uncomplicated urinary tract infection. In vitro MEC is stable against
most extended spectrum b-lactamases (ESBL) but so far there are no
clinical data supporting its use. We here present a retrospective cohort
study on the efﬁcacy of MEC in patients with ESBL-producing E. coli
in urinary samples.
Methods: All patients above 12 years of age with urinary samples
positive for an ESBL-producing E. coli in Kronoberg County, Sweden,
during 2009 were identiﬁed in the database of the Dept of Clin
Microbiology, Va¨xjo¨, Sweden (n = 52, 38 women and 14 men). The
EUCAST method was used for susceptibility testing. A retrospective
chart review was performed and the age, sex, underlying medical
conditions and treatment given at the time of culture was recorded.
Outcome measures were change of therapy due to culture results and
recurrent UTI after 1 and 3 months after the ﬁrst culture.
Results: Mecillinam resistance was 6% while corresponding rates for
trimethoprim (TMP) and ciproﬂoxacin (CIP) were 73% and 77%. In
16/52 patients no empirical antibiotic treatment was administered. Four
of these were treated with MEC and one with ertapenem after culture
results were available. In total 17 of the 52 patients were treated with
MEC (in 14 patients administered 200mg TID for 5 days). Two had
an underlying urinary tract malignancy and seven had a history of
recurrent UTI. The documented diagnosis was cystitis in 12 patients.
Within one month 5/17 patients treated with MEC experienced recurrent
infection, compared to 13/35 patients receiving other antibiotics or no
treatment. After three months additionally 3 and 8 patients, respectively,
had experienced a new UTI. No empirical MEC treatment was changed
due to resistance, the ESBL-production resulted in a changed therapy in
4 patients and the corresponding ﬁgure for TMP and/or CIP resistance
was 8.
Conclusion: This study, although small, is the ﬁrst to report MEC
as effective treatment as other antibiotics against ESBL-producing
E. coli if the isolate is reported susceptible using EUCAST breakpoints.
Resistance to TMP and or CIP caused twice as many shifts in therapy
as did the ESBL-production indicating the importance of the associated
resistance to other antibiotics rather than the ESBL-production itself for
treatment decisions in UTI. Pivmecillinam seems as a safe treatment in
uncomplicated UTI caused by ESBL-producing E. coli
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P1552 Comparative effectiveness of 1 dose versus 3 weekly doses
of benzathine penicillin in treatment of early syphilis in
HIV-infected patients
H. Wu*, C. Yang, Y. Lin, H.C. Lee, N. Lee, W. Ko, W. Liu, C. Hung,
S.C. Chang (Taipei County, Taichung, Tainan, Taipei, TW)
Objective: Serologic responses of early syphilis, which includes primary,
secondary, and early latent syphilis, to a single-dose benzathine penicillin
G or three weekly doses of benzathine penicillin among HIV-infected
patients have rarely been evaluated before, though three weekly doses of
benzathine penicillin has been recommended in the US CDC guidelines
for treatment of syphilis in HIV-infected patients. We aimed to compare
the effectiveness of 1 dose versus 3 doses of benzathine penicillin in
treatment of early syphilis in HIV-infected patients.
Methods: From January 1, 2007 to November 30, 2009, 146 HIV-
infected patients with early syphilis who were treated with benzathine
penicillin at 4 referral hospitals for HIV care were enrolled in
a prospective observational study for occurrence Jarisch-Herxheimer
reaction. Decision of giving a single-dose or three weekly doses of
benzathine penicillin for these patients with early syphilis was made at
the discretion of treating physicians. Follow-up of rapid plasma reagin
(RPR) or Venereal Disease Research Laboratory (VDRL) titers was
performed every 3 to 6 months. Serologic responses were deﬁned as
4-fold or greater decrease in RPR/VDRL titers 12 months following
penicillin therapy. For those patients with missing data during the 12-
month follow-up period, the principle of last-observation-carried-forward
was applied.
Results: During the 35-month study period, 146 HIV-infected patients
with early syphilis were enrolled; 80 received 1 dose and 66 received
3 doses of benzathine penicillin. Serologic failure and/or reinfection
occurred in 48 patients (32.9%). There was no statistically signiﬁcant
difference of serologic failure and/or reinfection rate between HIV-
infected patients receiving one-dose penicillin and those receiving 3
weekly doses (35.0% [28/80] vs 30.3% [20/66], P = 0.60). The serologic
response was not associated with low CD4 cell count, detectable plasma
HIV RNA load or use of highly active anti-retroviral therapy when
penicillin was administered.
Conclusion: In this multi-center prospective observational study, the
difference of serologic response rate between one-dose and 3 weekly
doses of benzathine penicillin could not be demonstrated in treatment of
HIV-infected patients with early syphilis.
Paediatric infections: preclinical and clinical
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P1553 The impact of HIV-1 infection on B-cell subpopulations in
children
C. Bertaina*, F. Mignone, S. Garazzino, D. Montin, F. Licciardi,
E. Ricotti, C. Calitri, C. Gabiano, P.A. Tovo (Turin, IT)
Objectives: B cell count and subpopulations have recently been
identiﬁed as a possible diagnostic tool to monitor the progression of
HIV-infection and response to antiretroviral therapy in adults. To date,
few studies have focused on B cells in HIV-infected paediatric patients.
We analyzed the distribution of B cell subsets in HIV-1 infected children
followed at Regina Margherita Children’s Hospital, Turin, Italy.
Methods: Vertically-infected children on current highly active an-
tiretroviral therapy since at least 3 months were studied. 11 healthy
children were used as controls. B cell immunophenotype (including
naı¨ve, transitional, switched memory, CD21-low and marginal zone cells)
were measured by ﬂow cytometry. In infected patients, HIV viral load
(VL) and CD4+ T-cells were evaluated. According to VL, we identiﬁed
viremic and non viremic (VL <50 copies/ml) patients. Statistical analysis
was performed using PASW Statistics software; Student t-test was used
to compare groups and signiﬁcance was set at p< 0.05.
Results: Thirty-three patients (18 males and 15 females, mean age 11.4
years, range 1.7–18.0) were studied. 11 children were viremic (mean VL
582 copies/ml, SD 675; mean CD4+ % 34.8, SD 6.5) and 22 were non
viremic (mean CD4+ % 32.6, SD 6.6).
In HIV-infected children (regardless of VL) a signiﬁcant reduction
in marginal zone cells was observed, compared to healthy controls,
while naı¨ve cells were increased (although in viremic patients the
difference didn’t reach statistical signiﬁcance). Switched memory cells
were reduced in non-viremic children, compared to controls. CD21-low
cells were increased in viremic more than in non viremic patients, though
without statistical signiﬁcance (p = 0.054). No difference between the
three groups was observed in transitional cell count.
Conclusions: Our data conﬁrm that in children, as well as in adults, HIV
infection may result in a loss of switched and un-switched memory B
cells and in an increase of naı¨ve B cell count, as a possible consequence
of alteration in B cells differentiation. Secondly, persistent HIV-viremia is
associated with the expansion of CD21-low activated B cells, according
to the fact that the loss of CD21 expression may be a marker of ongoing
HIV replication.
The low prevalence of CD4+ depletion in our patients may explain the
absence of T-lymphopenia-related transitional cells expansion. Further
studies are needed to better clarify the role of B cell subpopulations in
HIV-infected children.
P1554 Detection of both known and newly identiﬁed viruses in
children hospitalised for acute respiratory infections
A. Zappa, M. Martinelli*, D. Dilillo, E. Galli, F. Salvini, M. Giovannini,
E. Riva, A. Amendola, G. Zuccotti (Milan, IT)
Objectives: The aim of this study was to carry out a surveillance of
respiratory infections sustained by both known (seasonal inﬂuenza A/H1,
A/H3 and B, RSV-A and -B) and newly identify (pandemic inﬂuenza
A/H1N1v, hBoV and hMPV) viruses in hospitalized children.
Methods: The study involved 342 patients (199 male, 143 female,
median age: 9 months) hospitalized with ARI in Milan (Italy), between
December 2008 and December 2009. Oro-pharyngeal swabs were
collected and a datasheet containing epidemiological and clinical data
was completed for each participant. The samples were subjected to PCR
assays for the detection of viral gene sequences.
Results: Viral gene sequences were found in 46.7% (160/342) of
samples: 73.1% resulted positive for RSV (RSV-A vs. RSV-B: 65.8%
vs. 34.2%, P< 0.05), 14.4% for hBoV, 10.6% for hMPV and seasonal
inﬂuenza A (A/H3 vs. A/H1: 88.2% vs. 11.8%, P< 0.05). The analysis
of RSV temporary distribution showed two epidemic peaks, in January
2009 and in December 2009, respectively. Inﬂuenza viruses circulated at
higher frequency in December 2008. HBoV was found mostly between
December 2008 and February 2009 and hMPV in April 2009. Children
with inﬂuenza virus infection had a signiﬁcantly higher mean age
(21.5 months, P< 0.05) than patients with either RSV-, or hMPV- or
hBoV-infection. The 42.5% of infected patients had bronchiolitis, 23.8%
pneumonia, 10.6% bronchitis, 5.6% asthmatic bronchitis and 17.5%
upper respiratory infections.
All viruses were involved with similar frequencies in upper respiratory
infections (% range: 17−35%), whereas in the onset of lower respiratory
infections RSV was the main agent implicated (% range: 92.6–55.6%).
From April 2009, PCR for A/H1N1v virus detection was carry out.
The 11.3% of patients was A/H1N1v-positive and showed, as the main
clinical manifestation, upper respiratory infections. Most frequently
observed risk factors for infection/disease were: the presence of at least
one sibling (58.1%), attendance of a community (28.1%) and exposure
to environmental tobacco smoke (25%).
Conclusions: The study showed the clinical relevance of RSV in
lower respiratory infections and a similar contribution of both seasonal
inﬂuenza and newly identiﬁed viruses in children hospitalization for
ARI. The respiratory virology needs a constant update of diagnostic
procedures and surveillance, essential support in the study of ARI.
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P1555 Transmission of pertussis to 2 young infants: identiﬁcation
of their mothers as the potential source of infection
A. Zouari*, H. Smaoui, S. Bousnina, A. Kechrid (Tunis, TN)
Objective: To identify the source of pertussis transmission to two young
infants.
Methods: In July 2009, two young baby girls aged 2 months old were
separately admitted to the Department of Pediatrics B at the Children’s
Hospital of Tunis for difﬁculty breathing and pertussoid cough. A
nasopharyngeal aspirate was collected from each infant and was sent
to the Laboratory of Microbiology at the same hospital for pertussis
investigation. The diagnosis was based on real-time PCR (RT-PCR)
targeting the IS481, the IS1001 and the pertussis toxin promoter gene
speciﬁc of Bordetella pertussis. Afterward, the investigation revealed
that the babies’ mothers had a 3-week history of upper respiratory tract
infection and cough. Each mother administered a nasopharyngeal sample
for pertussis testing.
Results: The RT-PCR turned out to be positive for Bordetella pertussis
for both the infants and their mothers. Precisely, the Ct (threshold cycle)
values for the ﬁrst couple “baby-mother” were respectively 24.18 and
33.76, and for the second couple, the values scored at 14.50 and 31.17,
respectively. The Ct values were higher for the mothers than for their
babies pointing out hence a relatively old Bordetella pertussis infection
for the formers. These assumption advance enough proofs to consider
the mothers as the source of infection.
Conclusion: Understanding the source of pertussis transmission to
infants may provide new approaches to prevent pertussis in the
most vulnerable infants, particularly those who are too young to
be immunized. Public health measures to prevent the disease could
be strengthened and booster vaccinations for adults against pertussis
considered.
P1556 Pertussis cases in the paediatric department of a university
hospital
L. Oksuz*, N. Gurler, S. Hancerli Torun, A. Somer, N. Salman
(Istanbul, TR)
Whooping cough (pertussis) is a highly contagious, acute respiratory
illness of humans that is caused by the Gram-negative bacterial pathogen
Bordetella pertussis. Vaccination plays an important role in protection
against pertussis. Due to routine vaccination programmes, the incidence
and mortality rates of the disease have decreased signiﬁcantly. However,
an increase in the number of cases has recently been reported, most of
which were in the population aged >4 years.
158 paediatric patients, aged 0−18 years with paroxysmal cough or
prolonged cough who admitted to the Department of Pediatric at
the Istanbul Medical Faculty between February-December 2010 were
studied. A pertussis-spesiﬁc transport medium was used for tansporting
of nasopharyngeal aspirates to the laboratory. The cultures were
made on Bordet-Gengau medium. The molecular genetic detection of
Bordetella pertussis/parapertussis was directly made from the swabs
by using the fast identiﬁcation kit, GenoQuick® Bordetella Ver 1.0
(HAIN Lifescience, Germany). As brieﬂy, the single stranded amplicons
hybridize with speciﬁc probes included in the Primer Nucleotid Mix.
These complexes selectively bind to the test band on the dipstick and
are visualized by a gold labeling. It has been reported that sensitivity is
100%, the speciﬁcity is 98% for GenoQuick® Bordetella test.
Bordetella spp. was detected positive in only three (2%) cultures versus
62 (39%) with Bordetella-PCR out of 158 samples. Positivity rate for
Bordetella-PCR was 44% in the 7−12 years (n = 27) group, 41% in the
0−12 months (n = 68) group, 40% in the 13−18 years (n = 10) group
and 34% in the >1−6 years (n = 53) group. Furthermore, three of ﬁve
adults, who were directly contact with patients, were also found to be
Bordetella-PCR positive.
According to the results of our study, the high positivity rate (34%-
44%) for Bordetella-PCR was detected at all age groups, especially,
those whom ages varied between 7−12 years and 0−12 months groups.
A remarkable high positivity rate (41%) was detected in 0−3 months-
aged children with incomplete-vaccination.
In conclusion, pertussis vaccination schedule is needed to be review to
include both children and adults.
P1557 Serotype distribution of Streptococcus pneumoniae isolated
from Argentinian paediatric patients
V. Reijtman, S. Fossati, C. He´rnandez, P. Sommerﬂeck, P. Bernaldez,
M. Litterio, J. Pinheiro, H. Lopardo* (Buenos Aires, AR)
Introduction: Streptococcus pneumoniae (Spn) is a major cause of acute
otitis media (AOM) and invasive infections (INV) such as pneumonia,
blood-stream infections and meningitis. Identiﬁcation of serotypes
involved in different pathologies may help in deciding formulations
of new anti-pneumococcal vaccines and is directly related to levels of
resistance to penicillin.
Objectives: To record the serotype distribution in AOM and INV in
pediatric patients. To evaluate the coverage of 7-valent (PCV7), 10-
valent (PCV10) and 13-valent (PCV13) pneumococcal protein conjugate
vaccines. To evaluate the relationship between serotypes and resistance
to penicillin.
Materials and Methods: Between May 2009 − August 2010 we
studied 127 Spn isolated from middle ears of <10 y-o patients by
tympanocentesis and 89 Spn isolated from normally sterile ﬂuids
in <19 y-o patients with INV. They were identiﬁed by optochin
susceptibility and bile solubility. Penicillin MICs were determined by
the Etest and were interpreted using CLSI guidelines. Serotyping was
performed by the quellung reaction.
Results: Thirty serotypes were identiﬁed. The twelve most frequently
isolated serotypes were, in decreasing order, 14 (14.2%); 19A (11.8%);
9V (8.7%); 3 and 19F (7.1%); 6A (6.3%); 18C (4.7%); 23F (3.1%); 5,
6B, 7F and 33F (2.4%) in AOM, and 14 (28.1%); 1 (6.7%); 5, 12F and
19A (5.6%); 6B and 18C (4.5%); 3, 6A, 7F, 15A and 19F (3.4%) in INV.
Serotypes related to penicillin resistance were: 14; 19A; 6A y 9V. The
coverage of different vaccines was 41.7% and 44.9% by PCV7, 48.1%
and 60.6% by PCV10, and 73.3% and 73.0% by PCV13; for AOM and
INV respectively.
Conclusion: The most frequently isolated serotype was 14 in both cases.
Serotypes: 19A, 9V, 19F y 3 were isolated most frequently in AOM that
in INV (p> 0.05). The highest potential coverage would be obtained
with PCV13 (>70%). Non-signiﬁcant differences between coverage of
Spn in OMA and INV were observed with all vaccines.
P1558 The dynamics of Streptococcus pneumoniae nasopharyngeal
carriage in mothers and children of the Warao Amerindians
from Venezuela
M.C. Sisco*, I.A. Rivera-Olivero, B. Del Nogal, P. Hermans, J. De
Waard (Caracas, VE; Nijmegen, NL)
Objectives: To describe the dynamics of pneumococcal transmission in
Warao Amerindian communities from Venezuela with emphasis for the
role of the mother as carrier and source of introduction of new serotypes
into the family.
Methods: Nasopharyngeal samples were obtained from 157 families,
including 336 children between 2 months and 10 years old and 152
mothers. S. pneumoniae was isolated and identiﬁed according to standard
microbiological procedures and serotyped with a multiplex PCR for 35
serotypes. Pneumococcal isolates of 10 families in which the mother
and at least one of her children shared a pneumococcal serotype were
selected for MLST analysis.
Results: The overall pneumococcal nasopharyngeal carriage rate in our
study population was 60.2% (n = 294) with 239 children (n = 71.1%)
and 55 mothers (n = 36.2%) colonized. The most important capsular
serotypes/serogroups found were 6 (24.5%, n = 95), 19A (12.4%, n = 48),
23F (11.1%, n = 43), 4 (4.9%, n = 19), 23A (4.4%, n = 17) y 11A (3.9%,
n = 15), indicating a theoretical coverage for the 13 valent conjugate
vaccine of 59%. In 92 families at least two members were colonized,
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with 53 of these families sharing the same serotype. 27 mothers were
colonized with a serotype different of those isolated from their children.
In 23 families the serotype was shared between the mother and at least
one of her children and the isolates of 10 of these families were selected
for MLST analysis. We detected 13 clones of which 4 never have been
described. In 7 families the mother and the children were colonized with
a strain of the same serotype and genotype. In 3 families mothers and
children were colonized with the same serotype but a different genotype.
Conclusions: The high pneumococcal colonization rate found in the
Warao children justiﬁes the introduction of a conjugate vaccine in
this population. Our study demonstrates that the Warao mother is an
important pneumococcal reservoir sharing serotypes and genotypes with
their children but also carrying serotypes or genotypes not (yet) found
in the family, pointing toward a possible role of her in the transmission
of the bacteria and in the introduction of new serotypes into the family.
The proposed introduction of the 13-valent conjugate vaccine in this
population in the beginning of the year 2011 should be used to follow
up on pneumococcal carriage of the Warao mothers to study the herd
effect of this vaccine.
P1559 Nasopharyngeal carriage of Streptococcus pneumoniae in
healthy Czech children: implications for clinical practice
M. Trojanek, Z. Vancikova, M. Fridrichova, H. Zemlickova*, J. Motlova,
Z. Blechova, J. Matejkova, N. Kocnarova, V. Maresova (Prague, CZ)
Objectives: The aim of this study was to assess the prevalence of
pneumococcal serotypes in nasopharynx of healthy children attending
day-care centres, determine their antimicrobial susceptibility and
compare the ﬁndings in vaccinated and non-vaccinated children.
Methods: Nasopharyngeal samples were collected in January-March
2010 from children attending 9 day-care centres in Prague. The spec-
imens were selectively cultivated for pneumococci. The susceptibility
testing was performed by disk diffusion method and by determination of
MIC according to current CLSI standards. The serotype was identiﬁed
by latex-agglutination (SSI, Copenhagen).
Results: The nasopharyngeal swab specimens were obtained from 230
children. Streptococcus pneumoniae was cultivated in 119 of them
(51.7%). The age median of the study group was 57.97 months
(IQR 45.82–67.32). 40 children (19.0%) were vaccinated with the
recommended vaccination schedule (PCV7). The highest number of
carriers was in the cohort of 48−59 months old children (colonization
rate (60.1%). The nasopharyngeal carriage in children 60−71 and 72−83
months old remained relatively high, 54.8% and 50% respectively. In
vaccinated children was the colonization rate 22/40 (55.0%), in non-
vaccinated 103/190 (54.2%), p = 1.00. The most frequently isolated
serotypes were: 19F (16×), 23F (13×), 3 (12×), 6B (11×) and 19A
(10×). Serotypes 19A and 19F were the most frequent in vaccinated
children, both were cultivated in 4/22 (18.2%). The susceptibility of
isolated strains to b-lactams was high (108/115, 93.9%), 6 strains were
intermediate resistant (5.2%) and only 1/115 (0.9%) resistant; 2 strains
(1.7%) were resistant to erythromycin and 1 (0.9%) to clindamycin.
Conclusion: Relatively high colonization rate supports the importance of
Streptococcus pneumoniae as a signiﬁcant cause of community-acquired
infections in children. High susceptibility of the isolates to b-lactams
ampliﬁes the importance of this antibiotic class in prescription practice
in paediatric community-acquired respiratory tract infections. Vaccine
and antimicrobial selective pressure represents a risk of replacement
with different serotypes and bacteria and enhances the necessity of good
surveillance programs.
Acknowledgement: This study was supported by a research grant from
the Internal Grant Agency, Ministry of Health (CZ), IGA 9643−4.
P1560 Invasive pneumococcal disease in Austrian children <5
years of age (2007 to 2009)
M. Paulke-Korinek*, B. Schmidle-Loss, C. Seidl-Friedrich, A. Postl,
B. Laaber, H. Burgmann, P. Rendi-Wagner, H. Kollaritsch (Vienna,
AT; Tel Aviv, IL)
Objective: Since 2004 vaccinations against invasive pneumococcal
disease (IPD) have been subsidized for children at special risk of
infection with S. pneumoniae in Austria. The aim of the study was to
show the burden of disease in Austrian children below 5 years of age.
Methods: In a nationwide study including all Austrian pediatric hospital
wards cases of IPD in children below 60 months of age were collected.
Isolates of S. pneumoniae were serotyped and tested for antimicrobial
resistance.
Results: Between 1.1.2007 and 31.12.2009 95 cases of IPD were
reported. Among them there were 26 cases of meningitis and 4 deaths,
giving a case fatality rate of 15.4% for pneumococcal meningitis. The
average annual incidence rate for children <60 months of age was 8.0
per 100.000 for IPD and 2.2 per 100.000 for meningitis. Incidence rates
for children <24 months of age were 11.8 per 100.000 for IPD and 4.5
per 100.000 for meningitis, respectively.
Risk factors for IPD were present in 16.8% of the affected children;
vaccine-serotypes (contained in PCV13) were identiﬁed in 57.1% of the
isolates from risk-children. 18 children attended community institutions
prior to the IPD.
Antimicrobial resistance was tested in 49 isolates. No resistance
was detected to amoxicillin, amoxicillin-clavulanate or ceftriaxone.
Resistance to macrolides (erythromycin and/or clarithromycin) was
present in 9 isolates (6 isolates 14, 15C, 19F, 23F), 2 isolates (14 and
19A) were resistant to 3rd generation cephalosporin (cefpodoxime and/or
ceﬁxime) and one strain (serotype 3) showed resistance to lincosamide
(clindamycin). Multiresistance, deﬁned as resistance to two antibiotic
classes or more, was present in 6 isolates. The multiresistant isolates
were serotypes 1, 14 (3 isolates), 15A and 24F.
The serotype was detected in 71.6% of all IPD (68 cases). The
hypothetical vaccination coverage rate for the ten-valent pneumococcal
conjugated vaccine was 61.8% and for the thirteen-valent vaccine it was
76.5%.
Conclusion: IPD is a rare, but severe disease in Austrian children and
especially meningitis has a high fatality rate. The bigger part of the
circulating serotypes, in particular isolates with resistance to antibiotics,
were covered by PCV10 and PCV13 justifying not only a risk-group
vaccination program, but general vaccination of all children.
P1561 Determination of immunoglobulin E and eosinophil cationic
protein in children with Mycoplasma pneumoniae infection
G. Antonaki, M. Matsas*, K. Giannakopoulou, E. Lebessi, I. Paraskakis
(Athens, GR)
Objectives: Mycoplasma pneumoniae has worldwide distribution and
may cause severe respiratory infections in children. M. pneumoniae
stimulates production of immunoglobulin E (IgE). Eosinophil cationic
protein (ECP) derived from activated eosinophils in these patients may
play a role in the pathogenesis of the inﬂammatory process. In this study
we evaluated the clinical signiﬁcance of IgE and ECP levels in serum
of children with M. pneumoniae infection.
Methods: A total of 230 pediatric patients aged 1,5 to 14 years old
were divided into three groups. Group 1 comprised of 150 patients
with M. pneumoniae infection indicated by the presence of speciﬁc IgM
antibodies and the absence of speciﬁc IgG antibodies. Group 2 comprised
of 50 children suffered from pneumonia other than mycoplasma etiology.
Group 3 consisted of 30 healthy children with negative serology against
M. pneumoniae and was designated as control group. IgM and IgG
antibodies against M. pneumoniae were determined by EIA (Platelia −
Biorad). Total IgE and ECP levels in serum were measured using a
FEIA method (Immunocap 250 − Pharmacia). Statistical analysis was
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performed using the chi-square test for IgE abnormal levels and the
Wilcoxon signed-rank test for levels of ECP.
Results: Abnormal IgE levels were found in 50% (75/150) of group 1
children, in 60% (30/50) in group 2 and in 33,3% (10/30) in control
group. Statistically signiﬁcant difference was found between children
with mycoplasma infection and control group, and also between children
with, other than mycoplasma, pneumonia and control group. Conversely,
no signiﬁcant difference was noted between subjects including in group
1 and 2. Further, mean levels of ECP serum in children including in the
ﬁrst group (13.04) were statistically signiﬁcant higher (p< 0,001)than
those observed in both other groups; 9.11 in group 2 vs 8.33 in group
3.
Conclusions: Pneumonia in pediatric patients regardless the causing
agent is associated with high levels of serum total IgE, suggesting
that respiratory tract infection may be implicated in the initiation of
asthma. The elevated ECP levels found in the serum of children with
mycoplasmal pneumonia may be associated with the damage to the
respiratory epithelium. Potentially serum ECP levels may be a useful
marker for identifying disease activity.
P1562 Norovirus prevalence in “pathogen negative” gastroenteritis
in Peruvian children
F. Rivera, T. Ochoa, J. Ruiz*, A. Medina, L. Ecker, A. Gil, L. Huicho,
C. Lanata (Lima, PE; Barcelona, ES)
Objective: The aim of this study was to determine the prevalence of
norovirus in children with gastroenteritis in whom all common pathogens
had been excluded (“pathogen negative”).
Methods: Specimens analyzed in this study were obtained as part of
a prospective, passive surveillance cohort diarrhoea study in children
2−24 months of age in periurban communities of Lima, Peru. The
study was conducted between September 2006 to December 2007 (1034
children) and from January to July 2008 (529 children). We used
a modiﬁed Vesikari score to determine the severity of a norovirus-
associated diarrhoea episode and to compare it with the clinical
characteristics of rotavirus diarrhoea from infants of the same cohort
study. We obtained 1,102 diarrhoea stool samples in the cohort study;
739 (67%) were negative for all common pathogens (Salmonella,
Shigella, Campylobacter, Vibrio, diarrhoeagenic E. coli, rotavirus and
parasites), and were considered “pathogen negative”. From these, 224
(30%) samples were available for the current study. Viral RNA was
extracted from 10% fecal suspension by a spin column technique, and
was reverse transcribed using a commercial kit. Two sets of primers were
used to amplify capsid region of norovirus as previously described.
Results: Norovirus was detected in 17.4% of 224 “pathogen negative”
diarrhoeal samples. Norovirus prevalence in each age group was 8%
in children 2−5 months of age (n = 64 samples), 9% in children 6−11
months of age (n = 80 samples), 33% in children 12−17 months of age
(n = 36 samples); and 34% in children 18−24 months of age (n = 44
samples). Norovirus was identiﬁed more frequently in samples from
children older than 12 months of age than in younger children (34% vs.
8%, p< 0.001). Among norovirus-positive samples, norovirus genogroup
II was identiﬁed more frequently (92%) than norovirus genogroup I (8%).
Norovirus GII was the most frequent genogroup in each age group. All
episodes associated with norovirus were acute. When comparing the
clinical characteristics of norovirus with those of rotavirus, the former
was more common in older children, while rotavirus was more common
in younger children (mean 14.1 vs. 8.3 months, p< 0.001). Norovirus
episodes tended to be of shorter duration and less severe than rotavirus
episodes.
Conclusion: The role of norovirus as a cause of diarrhoea and the
ascertainment of its severity in developing countries needs further
conﬁrmation by future epidemiological studies.
P1563 Molecular versus traditional methods for the detection of
gastrointestinal pathogens in children
M. Onori*, A. Grandin, L. Coltella, D. Valentini, M. Argentieri,
A. Villani, C. Russo (Rome, IT)
Objectives: Diarrhoea is a common cause of infectious disease among
children in the paediatric age. A quick and accurate diagnosis is
important for timely and appropriate patient management. About 40% of
infections in children under 5 years of age are caused by viruses (mainly
Rotaviruses), while about 20% are referred to a bacterial pathogen.
Purpose of this study was to investigate the aetiology of diarrhoea in
children admitted in a reference Italian children hospital and to evaluate
a new multiplex PCR assay able to detect simultaneously gastrointestinal
bacteria and viruses.
Methods: We evaluated 159 paediatric patients (2m-18y) suspected of
infectious gastroenteritis, admitted at the medical Department of the
“Bambino Gesu`” children hospital.
Stool samples were tested for a large panel of pathogens by using both
phenotypic and molecular assays.
We investigated 5 viruses (Adenovirus, Group A Rotavirus, Norovirus GI
and GII, Astrovirus) and 10 bacterial species (Salmonella spp., Shigella
spp., Vibrio spp., Clostridium difﬁcile toxin B, Campylobacter spp.,
Clostridium perfringens toxins, Yersinia enterocolitica, Aeromonas spp.,
Escherichia coli O157:H7, verocytotoxin-producing Escherichia coli).
Results: 33 stool samples resulted negative by both methods. According
to phenotypical method we isolated 59 bacterial pathogens (37.1%) and
76 enteric viruses (47.7%); while with the molecular assay we obtained
78 bacteria (49%) and 79 viruses (49.6%).
Conclusion: These results are preliminary but already it is clear that the
multiplex PCR assay is highly speciﬁc for detection of target viruses.
By the contrary, this assay must be optimized to detect bacteria. The
combined investigation of bacteria and viruses allows an evaluation of
circulation and prevalence of gastrointestinal pathogens in children.
P1564 Prevalence of O122 genes in enteropathogenic Escherichia
coli strains isolated from Peruvian children
N. Piscoche*, C. Contreras, D. Durand, J. Ruiz, T. Cleary, T. Ochoa
(Lima, PE; Barcelona, ES; Houston, US)
Objectives: To determine the prevalence of virulence genes of the O122
pathogenicity island (PAI O122) in EPEC strains and to determine its
association with clinical characteristics of diarrhea episodes.
Methods: We analyzed 174 EPEC strains isolated from a cohort study
of 450 children less than 2 years old, collected from April-2008 to
December-2009 in Lima. 59 samples were from children with diarrhea
and 115 were from children without diarrhea (control). The strains were
analyzed by PCR to identify the presence of genes belonging to the
pathogenicity island O122 (efa1/lifA, senA, nleB, nleE, and pagC). The
bfpA gene was used to differentiate between typical EPEC (tEPEC,
bfpA+) and atypical EPEC (aEPEC, bfpA−) strains.
Results: aEPEC were the most common pathotype present in 83%
(49/59) of diarrhea and 88% (101/115) controls. The O122 genes
frequency was: nleB and nleE 42%, senA 36%, efa1/lifA 16% and pagC
13%. Overall, the 5 genes were found more frequently in cases than
controls, nleE 46% (27/59) vs. 40% (46/115), nleB 44% (26/59) vs. 41%
(47/115), senA 42% (25/59) vs. 32% (37/115), efa1/lifA 20% (12/59)
vs. 13% (15/115) and pagC 19% (11/59) vs. 10% (12/115), respectively.
Regarding its distribution among tEPEC and aEPEC strains, there was
a higher frequency of nleB 54% (13/24) vs. 40% (60/150), nleE 50%
(12/24) vs. 41% (61/150) and senA 50% (12/24) vs. 33% (50/150) in
tEPEC than aEPEC, respectively; whereas efa1/lifA was more common
in aEPEC [16% (24/150)] than tEPEC [13% (3/24)]. The frequency
of pagC was similar between tEPEC [13% (3/24)] and aEPEC [13%
(20/150)]. The distribution of the strains with the 5 genes tended to be
more related to diarrhea cases than controls (6/59, 10% vs. 3/115, 3%;
p = 0.07). There were not differences between the distributions of these
genes in strains isolated from persistent (diarrhea 7 days) versus not
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persistent diarrhea episodes. The frequency of the all genes was similar
between severe and moderate episodes (Vesikari score), except pagC
which was more common in severe cases (p< 0.05).
Conclusion: Our ﬁndings indicate that in EPEC strains isolated from
Peruvian children O122 genes are frequently present. Of these studied
genes, efa1/lifA was more frequent in diarrhea caused by aEPEC strains.
Additionally the EPEC strains founded in diarrhea cases tended to have
all 5 genes of the PAI O122. Further studies are needed to evaluate
additional EPEC strains to determine the importance of these genes in
the disease.
P1565 Community-acquired respiratory tract infections during
childhood
T. Guahardo, I. Grafakos, A. Kyratsa, H. Iliadou, P. Giannopoulou,
F. Lykou, P. Saﬁoleas, E. Trikka*, A. Voyatzi (Athens, GR)
During childhood there is a high incidence of bronchiolitis and
community acquired pneumonia due to viruses (Respiratory Syncytial
Virus-RSV) and atypical bacteria (Mycoplasma pneumoniae), leading
to an increased admission to paediatric hospitals requiring appropriate
therapy.
Objectives: To ascess the incidence of respiratory infections due to
RSV and M. pneumoniae in children in various ages with respiratory
symptoms (fever, cough) and X-ray ﬁndings (pulmonary consolidation),
in order to provide appropriate antibiotic treatment.
Methods: A total of 1074 bronchoalveolar lavage specimens for RSV
and 1149 blood samples for M. pneumoniae from children aged 1
month to 14 years (boys/girls:2/1). Detection of RSV was performed
with rapid immunochromatography (Meridian, Bioscience). Detection
of IgM antibodies against M. pneumoniae, was performed with rapid
immunoassay, as well as with ELISA for both IgM and IgG antibodies
(Vircell Microbiologists). Positive results were conﬁrmed with indirect
immunoﬂuorescence (Bios, Germany).
Results: From a total of 1074 respiratory specimens, 27,1% were
positive for RSV, while IgM and IgG antibodies were positive in a
percentage of 24.5% and 43% respectively. RSV was the predominant
pathogen causing bronchiolitis in children between 2 months and 1 year
old, whileM. pneumoniae in children aged above 4−6 years with atypical
pneumonia. Morbidity was higher during winter and spring months.
Conclusions: RSV is the predominant pathogen in children less than
1 year causing bronchiolitis. Rapid detection of IgM antibodies against
M. pneumoniae is a reliable diagnostic procedure during the acute phase
of community acquired pneumonia in childhood.
P1566 Neonatal bacteraemia due to Pasteurella bettyae
L. Moreno Parrado, J.J. Palomar Pe´rez, L. Robles Fonseca, J. Lozano
Serra*, M.R. Vicente Romero, E. Riquelme Bravo, M. Martı´nez
Serrano, M.D. Crespo Sa´nchez (Albacete, ES)
Objectives: To describe a case of mother-to-child transmission of
Pasteurella bettyae through the birth canal, with occurrence of
bacteraemia in the neonate. Cases of bacteraemia are rare, and neonatal
bacteraemia due to vertical transmission, which may have severe effects,
is infrequent.
Methods: Study of a case of neonatal bacteraemia by referencing the
medical record and reviewing the literature published so far.
Results: The child was born by vaginal delivery induced at 39 weeks,
with Apgar score of 7−9, head circumference of 36 cm and weight of
3,150 g (p 50−75). After delivery, he suffered from respiratory distress
and was admitted after leaving the delivery room. The hemogram showed
45,490 leukocytes (77%N), the remaining parameters being normal.
An empiric treatment with ampicillin and gentamicin was applied.
24 hours after admittance, Gram-negative cocobacilli were reported to
have grown in hemocultures (BacT/ALERT, bioMe´rieux, Marcy l’Etoile,
France) − suprapubic and lumbar punctures were made, without any
relevant ﬁndings, and cefotaxime was added to the treatment. The
bacterium was biochemically identiﬁed as P. multocida (Api 20 NE,
bioMe´rieux, Marcy l’Etoile, France) and showed sensitivity to ampicillin,
penicillin, gentamicin, cefuroxime and amoxicillin/clavulanic acid. The
child completed the treatment and his progress was satisfactory. It was
decided to study urine and cervical-vaginal samples from the mother,
in the latter of which P. multocida was isolated. The mother did
not show any symptoms and reported not to have had contact with
pets. In the national reference laboratory, identiﬁcation and molecular
characterization revealed that the same strain was involved in both cases,
but also that it was P. bettyae.
Conclusion: Even though P. multocida is the species of Pasteurella
spp. which more frequently leads to infections, sometimes different
species are identiﬁed, such as P. bettyae, whose only reservoir known
so far is human being. Species of non-multocida Pasteurella should be
identiﬁed by molecular methods in reference centres, as conventional
methods might produce wrong results. In general, this microorganism
is sensitive to b-lactam antibiotics, which are the treatment of
choice. b-lactam production is rare but should be considered − in
such cases, amoxicillin/clavulanic acid, 3rd generation cephalosporins,
ﬂuoroquinolones, doxiciclin or cotrimoxazole may be used.
P1567 Complications of bacterial meningitis in children
T. Habanec*, L. Homola, P. Mikolasek, J. Pavelka, J. Helesic (Brno, CZ)
Festering inﬂammations of CNS still remain one of the last infectious
diseases with considerably high mortality and morbidity accompanied
by numerous complications and consequences even in the developed
countries.
Out of a group consisting of 137 children admitted to a hospital with
proven purulent meningitis in the Paediatric Infectious Diseases Clinic
(PIDC) in the Brno Faculty Hospital, in the years 2001 to 2008, 96
patients have fulﬁlled the evaluation criteria of the study.
The study carried out in the PIDC has proven that the incidence of
festering affections of the CNS does not depend on the sex of the
patients, and at the same time there is no difference in the frequency of
complications and consequences in terms of male and female population.
We have not proven the evidence of a seasonal increase or decrease
of patients with purulent affections of the CNS. After the admission
to the hospital 34 of paediatric patients had average up to severe
consciousness disorders (GCS around 10), however only 12% of them
required intubation. Almost half of the patients were of pre-school age
(0−6 years). The initial phase of the disease is accompanied by vomiting
in 70%, and by spasms in 23%. Bleeding symptoms into hypodermis
and mucosa appeared in 34% of the patients, which correlates with
the frequency of meningococcal infections (37%). In the childhood the
primary forms of purulent meningitis (66%) prevail. Among very rare
childhood complications we can rank the incidence of: hydrocephalus
(2%), brain abscess (1%), thrombosis of cerebral sinus (3%), necrosis-
gangrenes of acral parts of extremities (3%).
On the contrary, as a frequent necessary measure in case of festering
affections of the CNS there seems to be a need of indication of the
imaging methods (CT, MRI of brain − up to 47% of the patients have
serious positive ﬁnding). In addition, there is a necessity to provide
for interdisciplinary cooperation (indication of surgical intervention −
up to 17% of patients require invasive intervention). In addition the
execution of the EEG study (up to 17% of patients for the pathologic
ﬁnding from EEG require a temporary medication and neurologist’s
monitoring. Hearing impairment (up to 29%),visual impairment (8%),
CNS impairment (up to 27% of the patients − subdural effuse, dilatation
of chamber system, epilepsy etc.), and also incidence of profound
psychomotor retardation (up to 40% of the patients) rank among the
serious and frequent consequences.
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P1568 Risk factors associated with mucosal colonisation by
common Gram-negative species and yeasts in the neonatal
intensive care unit
U¨. Parm*, T. Metsvaht, E. Sepp, M. Ilmoja, H. Pisarev, M. Pauskar,
I. Lutsar (Tartu, EE)
Objective: To characterize the dynamics of mucosal colonization
of neonates by common aerobic Gram negative microorganisms and
Candida spp. and to identify independent perinatal, neonatal, and
environmental risk factors inﬂuencing the colonization process in
neonatal intensive care unit (NICU).
Methods: The nasopharyngeal (NP) and rectal swabs were collected on
admission and thereafter twice weekly in all newborns (n = 276) admitted
within the ﬁrst 72h of life with risk factors of early onset sepsis. The
association between colonization by different microbes and a total of
22 predeﬁned risk factors was determined by univariate and multiple
logistic regression analyses.
Results: A total of 1242 rectal and 1145 NP swabs with a per patients
median of 3 (rectal and NP IQR 2/6 and 2/5, respectively) for both sites
were collected. During the study about half of the patients had rectal
(55.8%) or NP (42.8%) colonization with Gram-negative microorganisms
and 38.8% had colonization of both sites. Colonization dynamics and
interfering risk factors were similar for a given bacterial species in both
mucosal sites, except that nonfermentative microbes more commonly
harbored NP and Enterobacteriaceae in rectal swabs. The duration of
NICU stay (median 6.7 days; IQR 3.75/17) as the factor most inﬂuencing
mucosal colonization was associated with rectal and NP colonization of
Acinetobacter spp. and all Enterobacteriaceae except E. coli, and rectal
colonization by Candida spp. Depending on the species each day in
NICU increased colonization risk by 5% to 8%. Factors interfering with
the mucosal colonization were species speciﬁc depending on the origin
of the particular species. While colonization by E. coli, K. oxytoca and
C. albicans was most likely of maternal origin being associated with
early perinatal factors like prolonged rupture of membranes, vaginal
delivery and breast milk feeding, colonization by K. pneumoniae,
E. cloacae, Acinetobacter spp. and non-albicans Candida spp. likely
originated from hospital environment being inﬂuenced by treatment unit
and period, duration of hospital stay and invasive interventions. The latter
four organisms were also affected by low gestational age.
Conclusions: Risk patterns of Gram-negative colonization in NICU are
bacterial species speciﬁc. The knowledge of risk factor proﬁles allows the
development of strategies to prevent heavy colonization and subsequent
invasive disease in high risk neonates.
P1569 Reduced vancomycin susceptibility in Staphylococcus capitis
strains causing late-onset sepsis in intensive care neonates
J.P. Rasigade*, C. Tellini, O. Raulin, M. Ben Saı¨d, J.-C. Picaud,
O. Claris, J. Etienne, F. Vandenesch, S. Tigaud, F. Laurent (Lyon, FR)
Objectives: Coagulase-negative staphylococci (CoNS) are the leading
cause of late-onset sepsis (LOS) in the neonatal intensive care unit
(NICU) setting, in which the high prevalence of methicillin resistance
leads to the massive use of vancomycin. In the NICUs of Lyon, France,
the majority of CoNS belong to a single pulsotype of Staphylococcus
capitis (pulsotype A), also found in other French NICUs but distinct
from pulsotypes isolated from adult patients. We determined the rates of
resistance and heteroresistance to vancomycin (VRSCap and hVRSCap,
respectively) among pulsotype A isolates, and searched for an association
of S. capitis with persistent or recurrent bacteremia in NICU infants.
Methods: Vancomycin resistance. Vancomycin MIC was measured using
E-test method in 53 S. capitis isolates (pulsotype A, n = 40, and other
pulsotypes isolated from adult patients, n = 13). An isolate was VRSCap
if its vancomycin MIC was >2mg/l (EUCAST 2010 breakpoint), or
was hVRSCap if initial MIC was 2mg/l and if a stable resistant
subpopulation was recovered after a selection step on agar containing
4mg/l vancomycin. Persistent bacteremia. Microbiological records of
neonates admitted to 2 NICUs of Lyon from 2004 to 2009, with LOS
caused by either S. capitis (n = 234) or S. epidermidis (comparator,
n = 176), were reviewed. Persistent or recurrent bacteremia was deﬁned
by 3 distinct positive blood cultures with the same species over a
period 72h.
Results: Vancomycin resistance. Among pulsotype A isolates, the
proportion of VRSCap (n = 15; 37.5%) and hVRSCap (n = 14; 35.0%;
total, n = 29; 72.5%) was signiﬁcantly higher than in other pulsotypes
(total 23.1%) (p< 0,01, Z-test). Persistent bacteremia. Persistent or
recurrent bacteremia were signiﬁcantly more frequent during LOS caused
by S. capitis (21.4%) than by S. epidermidis (9.1%) (OR=2.72 [1.49–
4.96]).
Conclusion: S. capitis pulsotype A strains, which are currently endemic
in several French NICUs, exhibit worrisome rates of vancomycin
resistance and heteroresistance, and are associated with persistent or
recurrent bacteremia in NICU infants.
P1570 Fungaemia in paediatrics patients − population
characteristic, trends in infection frequency, aetiological
factors and strain susceptibility. Epidemiological study
2000–2009, Poland
E. Romanowska, P. Nadkowska, K. Dzierzanowska-Fangrat*,
D. Dzierzanowska, M. Migdal, D. Perek, O. Gryniewicz, J. Ksiazyk,
J. Teisseyre (Warsaw, PL)
Objectives: The aim of the study was to determine aetiological factors,
frequency and antifungal susceptibility of clinical yeast strains isolated
from blood samples of paediatric patients hospitalised in The Children’s
Memorial Health Institute. We also characterised the patients population
according to medical records describing their age, sex, hospital ward
at the time of infection diagnosis, underlying disease, agents used for
prophylaxis, risk factors as well as the length of stay at the hospital and
the outcome.
Methods: The clinical material was peripheral blood incubated directly
in automated Bact/Alert system (bioMerieux). After receiving positive
blood cultures, fungal isolates were identiﬁed by their morphological
and biochemical features using ID 32C test (bioMerieux). Antifungal
susceptibility was assessed using ATB Fungus tests (bioMerieux).
Results: During the 10-year period of time (from 2000 to 2009),
mycological assays conﬁrmed 118 cases of fungaemia in 107 patients.
The highest number of infections occurred at the oncology ward (27,2%),
nutrition and paediatrics ward (19,5%), intensive care ward (18,3%),
transplantology and surgery ward (9,4% and 8,2%, respectively). The
main aetiological factor was Candida parapsilosis (39,0%) followed by
C. albicans (35,6%), C. tropicalis (5,1%), C. glabrata (5,1%) Candida
lusitaniae (3,4%), C. krusei (0,8%) and Saccharomyces cerevisiae
(3,8%). Underlying conditions in patient population were characterized
as cancer in 30 cases (28%), gastrointestinal disorders in 29 cases (27%),
congenital heart disease in 13 cases (12,2%), respiratory failure in 11
cases (10,3%), preterm birth (6,5%), immunological disorders (3,7%),
cardiovascular disorders (2,8%), organ transplant (1,9%), cerebral palsy
(1,9%), other (14%). The main risk factor appeared to be central venous
catheterisation (72,9%), parenteral nutrition (51,4%), immunosuppres-
sive treatment (19,6%), broad-spectrum antibiotic therapy (60,7%), and
antifungal prophylaxis with ﬂuconazole alone or in combination with
other antifungal agents (28%).
Conclusion:
1. Until 2005 C. albicans was the predominant aetiological factor of
fungemia. Since then a prevalence of non albicans candidaemias with
a beneﬁt towards C. parapsilosis is observed.
2. Increasing occurrence of Candida species with intrinsic resistance to
ﬂuconazole (C. dubliniensis) and amphotericin B (C. lusitaniae) and
appearance of other fungal genus, such as Saccharomyces.
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P1571 Mycoplasma pneumoniae is not an important cause of lower
respiratory tract infections in the European GRACE study:
a combination of methods is necessary for early detection
of cases
M. Ieven*, C. Lammens, K. Loens, A. Vanderstraeten, D. Ursi,
S. Dettlaff, H. Goossens on behalf of the GRACE study group
Objectives: Diagnosis of atypical bacteria such as M. pneumoniae (MP)
is often based on serology, which may require up to 3 weeks for a
deﬁnite result. PCR based assays offer earlier diagnosis; however often
respiratory specimens are not available from patients in a primary care
setting. The aim of this study was to evaluate the prevalence of MP
infection and compare serology and real-time PCR on both sputum and
nasopharyngeal ﬂocked swabs (NPFS) for diagnosis of MP.
Methods: From 10/2007 through 04/2010, a total of 3102 adult patients
with lower respiratory tract infections (LRTI) in the community and 2984
controls were enrolled in a 3 year prospective study in 16 primary care
networks PCNs in 11 European countries. NPFS, sputa, and paired sera
were collected and sent to the local laboratory to be frozen until transport
to the central lab in Antwerp. On a subset of 374 patients from whom
sputa were available in the ﬁrst winter period, in-house real-time PCR
for MP was performed both on the sputum and NPFS. Sputa were scored
according to the number of leucocytes (WBC) and squamous epithelial
cells: specimens with ratios of WBC/epithelial cells 1 were deﬁned as
good quality sputa, ratios <1 were considered low quality sputa. IgG and
IgM serology was performed using Mycoplasma pneumonia-IgG/IgM-
ELISA (Medac GmbH, Wedel, Germany) for detection of IgM or a IgG
seroconversion or signiﬁcant rise in anti MP IgG in sera collected 3−4
weeks apart; paired sera were available from 313 patients.
Results: MP was detected in 2.9% (9/313) of the studied adults with
CA-LRTI by a IgG seroconversion or signiﬁcant rise in IgG, only 3
(33%) tested IgM positive.
In 4/374 (1.1%) of the sputa MP was detected by PCR, with a mean
Ct value of 19.62: only 1/374 (0.3%) was also positive in the NPFS
with a Ct value of 34.27. PCR positivity in sputum was not related to
sputum quality. All patients positive by PCR were also positive by IgG
seroconversion; 6/9 IgG positive patients were positive in the acute phase
by either IgM or PCR.
Conclusion: This is the largest etiologic study on LRTI in primary care
ever done. Prevalence of MP infection in the ﬁrst winter period was
low. Detection of MP IgM antibodies in the early phase of LRTI is
too insensitive. A combination of IgM and PCR on sputum is the most
sensitive method for early detection of a MP infection. Bacterial loads
are higher in sputum samples; these are therefore superior to NPFS for
PCR detection.
P1572 Review of positive Chlamydia pneumoniae PCR in a tertiary
care centre over a ten-year period (2001–2010)
L. Senn*, K. Jaton, J.W. Fitting, G. Greub (Lausanne, CH)
Objective: In recent studies, the prevalence of respiratory infection due
to Chlamydia pneumoniae was reported to be lower than previously
published. Our objective was to review the prevalence of positive
C. pneumoniae PCR results in a tertiary care center over a ten-year
period (2001–2010).
Methods: A duplex real-time PCR for the detection of Chlamydia
pneumoniae and Mycoplasma pneumoniae has been developed (Welti
et al. 2003) and applied in our routine diagnostic laboratory since
October 2001. We reviewed all duplex C. pneumoniae + M. pneumoniae
PCR analyses performed from October 2001 to June 2010.
Results: During the study period, 2244 respiratory specimens retrieved
from 1583 patients were sent to the diagnostic laboratory for
C. pneumoniae and/or M. pneumoniae PCR: 884 bronchoalveolar
lavages, 843 nasopharyngeal swabs, 354 bronchial aspirates, 111 sputa
and 52 other samples. Only four (0.2%) PCR in 2 patients were positive
for C. pneumoniae, whereas 76 (3.4%) were positive for M. pneumoniae
in 65 patients. The ﬁrst patient with a positive C. pneumoniae PCR was a
48-year old man receiving immunosuppressive therapy for inﬂammatory
bowel disease. He presented with a chronic cough initially suspected to
be asthma and a febrile exacerbation. The second patient was a healthy
13-year old girl presenting with a third episode of pneumonia over a
5-month period. In both cases, the diagnosis of C. pneumoniae infection
was not suspected by the clinician and the test was done thanks to the
duplex format of our molecular test.
Conclusion: This study conﬁrms that C. pneumoniae is rarely detected,
at least in our setting. This may reﬂect a low prevalence of the disease
and/or suggests that clinicians do not target the right population.
P1573 Hospitalised community-acquired pneumonia: role of
atypical organisms
I. Edelstein*, A. Punin, O. Shelyakina, A. Chagarjan, R. Kozlov
(Smolensk, RU)
Objectives: Atypical respiratory pathogens such as Mycoplasma pneu-
moniae (MP), Legionella pneumophila, and Chlamydophila pneumoniae
(CP) are isolated with increasing frequency from community-acquired
pneumonia (CAP). Local epidemiologic data on the etiologies of
hospitalized patients aids in developing guidelines for clinical practice.
This study elaborates the role of such “atypical pathogens” (AP) among
adult hospitalized patients from Smolensk with CAP.
Methods: A prospective, observational study of consecutive adult
CAP patients hospitalized during December 2009-November 2010
in Municipal Clinical Hospital was conducted. All adult patients
(18 yr) had clinical features and radiological ﬁndings compatible
to CAP. Inclusion criteria were new inﬁltrates on chest radiography
or consolidation that could not be attributed to some other etiology
and 3 or more of the following signs and symptoms: cough, acute
changes in the quality of sputum (<10 epithelial cells and >25
polymorphonuclear leukocytes per low-power ﬁeld in microscopy),
documented fever (>38ºC) or hypothermia (<36.1ºC) within the
preceding 24 hr, rales, leukocytosis (>1E10/L or >15% bands), malaise,
myalgia or gastrointestinal symptoms. All patients were enrolled in this
study before antibiotic treatment. Nasopharyngeal swabs were obtained
for detection of MP, Legionella pneumophila, and CP by species-
speciﬁc real-time polymerase chain reaction (AmpliSens, Interlabservice,
Russia).
Results: A total of 74 patients (36 males, 38 females), averaging
44.7 yr (SD±15.8) were included in this study. Atypical pathogens were
identiﬁed in 18 patients (24.3%), 15 of which were 40 yr (83.3%),
and 3 (16.7%) more than 40 yr. The most common pathogen was CP −
10 (14%), followed by MP − 8 (11%). No cases of L. pneumophila
or mixed infections were observed. A retrospective analysis of these
patients revealed an association of CAP with frequent respiratory viral
infections, especially in patients working in service sectors.
Conclusion: Our data reﬂects an overall low prevalence of these atypical
pathogens among Smolensk patients with CAP. Local microbiological
data could be helpful in outlining therapeutic guidelines and diagnostic
approaches for MP and CP species. A higher prevalence of AP in CAP
is evident in young patients.
P1574 Doxycycline versus macrolides in combination therapy for
treatment of atypical community-acquired pneumonia:
outcomes from ACAPS
B. Teh*, L. Grayson, P.D. Johnson, P. Charles (Melbourne, AU)
Objectives: Atypical pathogens (Legionella, Chlamydophila and My-
coplasma species) make up approximately 15% of the aetiology of
community-acquired pneumonia (CAP) with many international and
Australian guidelines recommending the use of empiric therapy with a
b-lactam combined with a macrolide or doxycycline. We have attempted
to determine whether there is any difference in patient outcomes when
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doxycycline or a macrolide is used in combination with b-lactams
for empiric CAP treatment as little data is available comparing these
combinations.
Methods: The Australian CAP Study (ACAPS) was a prospective,
multicentre study of 885 episodes of CAP. Analysis of the recorded
initial choice of antibiotic agents, in particular the choice of doxycycline
or macrolide in combination therapy with a b-lactam antibiotic and the
relevant clinical outcomes, including time to stability and length of stay
(LOS), was performed. Possible confounding factors of age and severity
of the presenting illness as measured by the Pneumonia Severity Index
and SMART-COP scores were accounted for by the performance of
multivariate regressions on the two patient groups (doxycycline versus
macrolide-treated).
Results: For patient episodes due to atypical pathogens, patients treated
with combination therapy containing doxycycline had a shorter median
time to clinical stability (median 2.0 days vs. 2.0 days, Hazard ratio =
0.5 (0.31–0.82), p = 0.006) and LOS (3.0 vs. 6.0 days, HR= 0.32 (0.19–
0.53), p< 0.001) compared to those who received macrolide containing
combinations. A subgroup analysis looking at Legionella species alone
still showed a trend favouring the doxycycline treatment group with a
median time (interquartile range) to stability of 2.5 (2−3) days and LOS
of 6 (4−6) days in comparison to 4 (2−6) days and 6.5 (4.5−13) days
for the macrolide-treated group with a hazard ratio of 0.36 (p = 0.09)
and 0.27 (p = 0.06) respectively. A similar trend was noted in other
aetiological categories including those unknown, and without an atypical
aetiology.
Conclusion: The use of doxycycline in combination with b-lactams for
the treatment of CAP resulted in outcomes for time to clinical stability,
LOS and, need for mechanical ventilation or vasopressor support
that were at least as good as those in patients receiving macrolides.
Doxycycline in combination with a b-lactam is suitable as ﬁrst line
therapy for the empiric treatment of CAP.
P1575 The impact of Q fever on community-acquired pneumonia
in Germany
K. Boden*, M. Schack, S. Sachse, M. Baier, E. Straube (Jena, DE)
Objectives: The aim of our study was to determine the relevance of
Coxiella burnetii-infection (Q fever) as community acquired pneumonia.
Methods: In the German wide CAPNETZ study started 2001 by the
German competence network for community acquired pneumonia (CAP)
data and specimens from in- and outpatients with community acquired
pneumonia were collected. In our study we enrolled all cases of this
database with a remaining serum and corresponding respiratory sample
collected during May and September 2005. As diagnosis of acute Q fever
is nowadays based on antibody detection as well as PCR we applied both
[1−3]. The screening was done by an enzyme-linked immunosorbent
assay (ELISA, Virion/Serion) for IgG as well as IgM and a nested PCR
[1] targeting the IS1111 element of C. burnetii in serum and respiratory
material. All ELISA positive results were veriﬁed by immunoﬂuorescent
antibody test (IFAT, BIOS/Focus). In all specimens with a positive
nested PCR result a real time PCR (Adiagene AES) were performed
as conﬁrmation test.
Results: 255 cases could be included in our study with a male female
ratio of 131 to 124. In nine cases (3.5%) a Coxiella burnetii-infection
could be identiﬁed. In one case a combination of a positive PCR result
in the serum and antibody detection by IFAT could be found. In six cases
a single positive PCR result in a respiratory sample and in two cases
IgM− and IgG− antibodies were detected.
Conclusion: In spite of the signiﬁcant relevance of Coxiella burnetii as
causative agent of big outbreaks even in Germany [4, 5], our data indicate
a low impact of it as pathogen of community acquired pneumonia
in Germany in general. Respiratory samples seem to be promising
for Coxiella burnetii PCR protocols. The results also demonstrate the
necessity of a sophisticated microbiological approach to diagnose acute
Q fever.
This publication was supported by Grant 01 KI 0730 from the Federal
Ministry of Education and Research Germany.
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P1576 Spectrum of causative agents of community-acquired
pneumonia in hospitalised adults and their susceptibility
to antimicrobials
S. Rachina*, E. Shal, R. Kozlov, N. Ivanchik, O. Kretchikova
(Smolensk, RU)
Objectives: Local surveillance of community-acquired pneumonia
(CAP) etiology and resistance patterns remain a cornerstone in
adjustment of empirical antimicrobial (AM) therapy. Our study aimed
to determine the spectrum of bacterial agents causing CAP among
hospitalized adults and assess their susceptibility to commonly used AM.
Methods: Adults admitted to ﬁve different city hospitals of Smolensk
region in 2007 with CAP were eligible for the study. Sputum, blood
samples (if clinically indicated) were collected within 24 hours upon
admission for routine culture and susceptibility testing. In fatal cases
of CAP lung biopsy samples were also processed. Susceptibility of
H. inﬂuenzae (Hi)and S. pneumoniae (Sp) to AM was determined by
broth dilution technique, other causative agents − by disk-diffusion
method. Interpretation was performed using CLSI (2009) criteria.
Results: A total of 326 patients aged from 18 to 87 years (mean
age 43.0±19.9), 263 (81%) males, 63 (19%) − with severe CAP
were enrolled. Bacterial pathogens were identiﬁed in 119 samples from
90/326 (27.6%) patients; they were isolated from sputum, blood and
lung biopsy samples in 104/119 (87.4%), 9/119 (7.6%) and 6/119
(5%) of cases, respectively. Hi (49/119) and Sp (41/119) were the
most common pathogens, followed by K. pneumoniae (14/119), E. coli
(6/119), E. cloacae (3/119), S. aureus (3/119), Enterococcus spp.
(1/119), P. mirabilis (1/119) P. aeruginosa (1/119). All Hi isolates
were susceptible to amoxicillin/clavulanate (amc), cefotaxime (ctx),
moxiﬂoxacin (mxf), susceptibility to amoxicillin (amox), tetracycline
(tet) and trimethoprim/sulfamethoxazole (cot) was 86%, 93% and 74%,
respectively. Sp was susceptible to penicillin, amox, ctx, clindamycin,
mxf in 100% of cases, to erythromycin, tet and cot in 98%, 90%
and 68% of cases, respectively. Only imipenem retained 100% activity
against Enterobacteriaceae, susceptibility to amikacin, amc, cefepime,
ctx, ceftazidime and ciproﬂoxacin was 86%, 68%, 86%, 86%, 86% and
86%, respectively.
Conclusions: Hi and Sp remain the most common causative agents of
CAP in hospitalized adults in Smolensk region with high susceptibility
to commonly used AM. High prevalence of Enterobacteriaceae causes
grave concern and needs further investigations.
P1577 Statin use and hospitalisation with pneumonia:
population-based observational study of risk and prognosis
among 70,914 hospitalised pneumonia patients in Northern
Denmark
A.G. Nielsen*, R.B. Nielsen, A.H. Riis, H.T. Sørensen, R.W. Thomsen
(Aarhus, DK)
Objectives: Evidence regarding the impact of statin use on pneumonia
risk and outcome is conﬂicting. We examined the association between
statin use and risk of being hospitalized with pneumonia in a population-
based case-control study. We also performed a 5-year update of previous
mortality analyses among statin users and nonusers with pneumonia.
Methods: We identiﬁed 70,914 adults with a ﬁrst-time hospitalization
with pneumonia between 1997 and 2009 in Northern Denmark
(population = 1.8 million). Ten controls, matched by age and sex,
were selected for each pneumonia patient. To control for potential
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confounders, we retrieved individual-level data on use of statins, other
medications, comorbidities, and socioeconomic markers from medical
databases. For the cohort outcome analysis we followed pneumonia
patients for 30 days after hospital admission.
Results: Among the 70,914 patients hospitalized with pneumonia, 10.2%
(7,223) were current statin users compared with 9.1% (64,523) among
709,140 population controls, corresponding to a crude pneumonia OR of
1.17 (95%CI: 1.14–1.21). However, current statin users had considerably
more comorbidity and medication use than non-users. After adjusting
for these and other confounders using conditional logistic regression
analysis, the adjusted OR for a pneumonia-related hospitalization
associated with current statin use was 0.80 (95%CI: 0.78–0.83). In
contrast, we found no decreased pneumonia risk in former statin users
(adj. OR= 0.98, 95%CI: 0.92–1.04). The prevalence of current statin use
among our Danish pneumonia patients more than doubled from 4.6% in
1997–2004 (Thomsen et al., Arch Intern Med 2008) to 10.2% in the
updated study period 1997–2009. Updated outcome analyses showed a
30-day mortality following pneumonia hospitalization of 11.3% among
statin users vs. 15.1% among nonusers. Cox’s regression analyses showed
a 31% decrease in pneumonia mortality with current statin use (adjusted
hazard ratio = 0.69, 95%CI: 0.64–0.74), similar to our earlier ﬁndings.
Conclusion: Statin use appears to be associated with a decreased
risk of hospitalization for pneumonia in Denmark. Moreover, with the
dramatic increase in the prevalence of statin use in Denmark’s population,
the apparent pneumonia mortality reduction associated with statin use
remains unchanged. Large randomized trials are needed to prove or
disprove the effect of statin therapy in preventing severe pneumonia
and improving prognosis.
P1578 Management of community-acquired pneumonia and
capping Clostridium difﬁcile infections: are we falling at the
CURB?
M. Paracha, M. Przybylo*, K. Polster, T. Adizie, S. Staff, A. Guleri
(Blackpool, UK)
Background: Community Acquired Pneumonia (CAP), a common lower
respiratory tract infection, accounts for 83000 annual hospitalizations in
UK. BTS guidelines for management of CAP include severity assessment
by calculation of CURB-65 to help guide choice, route and duration of
antibiotics, investigations and discharge of low risk patients. Blackpool
Victoria Hospital operates a successful Clostridium difﬁcile infections
(CDI) programme with high emphasis on antibiotic stewardship and
root cause analysis (RCA) of CDI cases. We present results of audit
on management of CAP and its association with ﬁndings of CDI-RCAs.
These were used to inform remedial steps in the trust CDI programme.
Methods: Retrospective notes review of 50 randomly selected patients
admitted with CAP between January and September 2009. Review of
joint infection control-Microbiologist CDI-RCA database.
Results: CAP AUDIT: M:F ratio[1: 1.7] with 68% [34/50] patients
over 70-years & 16% over 90y. CURB65 score was documented in
32%[16/50] patients; 44% (7/16)was incorrect. 15/16 patients had a
CURB 65 score 0−1. Poor documentation limited analysis of reason for
admission. 68% (34/50) of patients received antibiotics within 6 hours.
Inappropriate antibiotics were prescribed in 42% (21/50) & improper
route in 32% (16/50). IV to oral switch was delayed in 20% (10/50).
Duration was appropriate in 90% (45/50). Mean length of stay was 13.7
days while in-patient mortality was 26% (13/50).
CDI-Root cause analysis: RCA data on 113 cases revealed: avoidable
cases 57% [64/113]; key associations:78%[50/64] − non-compliance to
antibiotic formulary & co-amoxiclav use each. Co-amoxiclav followed
by quinolones and cephalosporin use; delay in sample testing; repeated
and prolonged courses of high risk antibiotics not supported by
documentation, radiology/microbiology investigations.
Conclusions: Despite availability of updated guidelines, management
of patients with CAP remains suboptimal. In a large number of
patients CURB-65 is not calculated and this may lead to inappropriate
management including inappropriate choice, route, duration of antibiotic
use. Most of patients are elderly. Risk of CDI, complications and
mortality is higher than previously reported. Findings from CDI-RCAs
and this audit are associated and have been used to raise emphasis
on intensive education of junior doctors, dissemination of guidelines,
joint ward rounds with microbiologists, antibiotic prescribing audits &
feedback. This is being done in our trust as a part of advancing quality
program.
P1579 Epidemiology, clinical features, and outcomes of community-
acquired pneumonia in patients with diabetes mellitus
S. Di Yacovo*, C. Garcia-Vidal, I. Oriol, F. Gili, J. Adamuz, D. Viasus,
R. Verdaguer, F. Gudiol, J. Carratala` (Barcelona, ES)
Objectives: Although DM is associated with many alterations of
the immune system that predispose to infection, current information
regarding CAP in this population is scarce. We aimed to ascertain
epidemiology, clinical features, and outcomes of CAP in pts with DM.
The risk factors for mortality and the impact of immunomodulatory
drugs on outcomes were also analyzed.
Methods: Observational analysis of a prospective cohort of nonseverely
immunosuppressed hospitalized adults with CAP (1995–2008). A
diagnosis of DM was based on a previous clinical and/or biochemical
diagnosis of DM and/or treatment with oral antidiabetic agents or insulin.
Results: We documented 2407 CAP episodes, of which 516 (21.4%)
cases occurred in pts with DM; 483 (97%) pts had DM tipus II,
and 197 (40%) were on insulin treatment. The median value of
HbA1c was 6.85mmol/l. A total of 119 (23.9%) pts had DM-related
complications. Compared with the remaining pts, those with DM were
older (76.6% vs 31.6% p 0.001), more often had been vaccinated
against pneumococcus (67.9% vs 48.2%; p 0.001) and inﬂuenza
(30.3% vs 21.4%; p 0.001), and had more comorbid conditions (70.7%
vs 58.4%; p 0.001). Conversely, they were less frequently current
smokers (15.2% vs 28.3% p 0.001) and heavy drinkers (12.5% vs
18.3% p 0.002). Pts with DM had more commonly altered mental
status at admission (19.4% vs 14.5%; p = 0.007) and were more often
classiﬁed into high-risk PSI classes (groups IV-V) (77.5% vs 56%;
p 0.001). In contrast, cough (79.6% vs 84.2%; p = 0.01), pleural chest
pain (29.1% vs 43.5%; p 0.001), multilobar pneumonia (28.4% vs
33.2%; p = 0.043) and pleural effusion (12.8% vs 18.6%; p = 0.002) were
less frequent. No differences in causative agents were found between
groups. The frequency of bacteremia was similar in both groups (11%
vs 12.7%). No differences in main outcomes were found. Independent
risk factors associated with mortality in pts with DM were advanced age
(OR 5.29; CI 95% 1.17–23.89), DM-related nephropathy (2.50;1.07–
5.84), multilobar pneumonia (2.46;1.11–5.43), shock at admission
(5.05;2.05–12.45), and chronic heart disease (2.31;1.06–5.04). The use
of immunomodulatory drugs (statins, ACEI, ASA, and b-blockers) was
not associated with better outcomes.
Conclusions: CAP in pts with DM is quite similar than in pts without
this condition. In our study, the use of immunomodulatory drugs has not
a beneﬁcial effect on the outcomes of CAP in pts with DM.
P1580 Clinical impact of combined viral and bacterial infection
in patients with community-acquired pneumonia
N. Johansson*, M. Kalin, J. Hedlund (Stockholm, SE)
Objectives: To compare hospitalised patients with community-acquired
pneumonia (CAP) and a pure bacterial aetiology with those with CAP
and ﬁndings of both bacteria and virus regarding severity of illness and
length of hospital stay.
Methods: Adults with CAP admitted to Karolinska University Hospital
were studied prospectively (n = 184). Microbiological methods included
cultures from blood, sputum and nasopharyngeal secretions, sputum
samples analysed with real-time quantitative PCR for Streptococcus
pneumoniae, Haemophilus inﬂuenzae, Moraxella catarrhalis, nasopha-
ryngeal specimens analysed with PCR and serology for Mycoplasma
pneumoniae, Chlamydophila pneumoniae and virus common in the
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respiratory tract, and urine antigen assays for detecting pneumococcal
and Legionella pneumophila antigens.
The pneumonia severity index (PSI) was used for assessing the severity
of illness.
Results: The risk to develop severe pneumonia, deﬁned as PSI classes
IV or V, was at least twice as high among the patients with both a
bacterial and viral aetiology as compared to the patients with ﬁndings
of only a bacterial pathogen (22/35, 63% vs. 18/71, 25%, P< 0.001).
The likelihood of getting a score corresponding to PSI classes IV or V
was higher in patients with ﬁndings of both bacteria and virus than in
those with a bacterial pathogen alone (OR, 4.98; 95% Cl 2.09–11.89;
P< 0.001). The median length of hospital stay was seven days among
the patients with mixed infections and four days among those with a
bacterial aetiology alone (P = 0.02).
Conclusions: Patients infected with a virus and a bacterial pathogen
more often develop severe CAP, with longer hospitalisation, than those
with bacterial aetiology alone.
P1581 The relative importance of respiratory viruses in lower
respiratory tract infections in primary care
F. Coenjaerts*, C. Lammens, M. Viveen, L. Tan, K. Loens, H. Goossens,
M. Ieven, A. van Loon, E. Claas on behalf of the GRACE study group
Objectives: The role of viruses in adult lower respiratory tract infections
(LRTI) in the community is not well known. We therefore investigated
the viral aetiology in LRTI at the GPs ofﬁce in the European GRACE
primary care network using sensitive real-time PCR.
Materials and Methods: From October 2007 through April 2010,
a total of 3102 adults with LRTI in the community were enrolled
(P1) in a prospective study in 11 European countries. For these
patients, matched controls (1198; Con.) and follow-up samples (1987;
P2) were collected. Nasopharyngeal swabs were analyzed for the
presence of inﬂuenzavirus (INF) A/B, parainﬂuenzavirus (PIV)1−4,
rhinoviruses, human metapneumovirus, respiratory syncytial virus,
adenovirus (HAdV), bocavirus (BOCA), coronaviruses (HCoV) OC43,
NL-63, 229E, as well as the novel polyomaviruses KI and WU. Primary
etiological data will be presented in an abstract by Ieven et al. Here, we
investigated i. the relative importance of quantitative measurements (Ct
values); ii. the aetiology of double infections and iii. the results of Con.
and P2 samples.
Results:
i. DNA viruses were found at signiﬁcantly lower loads (average Ct 37)
than RNA viruses (average Ct 29.8). RSV and PIV3 were the only
viruses for which Ct values differed signiﬁcantly between P1 samples
(−4 Ct) compared to Con. and P2.
ii. WU (26.7%) and KI (21.8%) were most frequently found in double
infections. Of all positive V1 patients 7.1% was double-infected, in
Con. 7.9% and P2 7.0%, despite lower infection rates.
iii. PIV positive patients (P1) were most prone to a positive follow up
(12.7% positive P2; any other virus), for PIV3 this ﬁgure increased
to 27.3%. HAdV, WU and KI are prominent secondary pathogens
(48%, 40% and 42% of all positive samples, resp., are in P2). 96.6%
of INF positive samples were in P1, for INF B this ﬁgure was
100%. Despite the fact that DNA viruses are detected substantially
(0.5%, 1%, 1.4% and 1.5% for BOCA, KI, HAdV and WU, resp.)
in respiratory specimen, their overall impact is overestimated since
these viruses are largely present in Con., P1-double infections, or P2
(70%, 82%, 72% and 83%, resp.). On the other side of the spectrum,
90% of INF infections were detected in P1 as mono-infection (99.6%
for INF B).
Conclusions:
• Quantitative viral load data will contribute little to individual patient
management.
• Double infections do not affect presentation rates.
• The relative importance of DNA viruses as respiratory pathogens is
low.
P1582 Value of prognostic scores in predicting mortality from
community-acquired pneumonia. A prospective comparison
in emergency departments
F. Tumietto, L. Scudeller, S. Tedeschi, R. Ferrari, P. Viale* (Bologna,
Pavia, IT)
Objectives: The routinely use of prognostic scores provide pivotal
information for the management of infectious diseases, helping
decisions about diagnostic and therapeutic strategies. Community-
acquired pneumonia (CAP) represents the ﬁeld where the clinical value
of prognostic scores was better developed. Existing rules have different
strengths and weaknesses, and have rarely been validated in populations
different from the original cohorts. The objective of this analysis is
to compare performances and concordance of two of the most used
scores (CURB-65 and SCAP) and the sepsis grading, in terms of 30-day
mortality, in totally different population.
Methods: Prospective enrolment and follow up of a population-based
cohort of adults with pneumonia diagnosed in Emergency Departments
(ED) is planned from the summer 2009 to the end of 2011. In this
interim analysis, relation between prediction scores and 30-day mortality
were examined using ROC curves analysis. Kappa coefﬁcient was also
calculated.
Results: Enrolled patients were 442, females were 40%, mean age (sd)
was 60.6 (21.1) years (min max 17−99); comorbidities were present in
66.4%. Deaths at 30 days were 22 (5%). 64.6% of patients were in
CURB65 low risk class, 68.9% in SCAP low risk, 69% in no sepsis or
sepsis class. ROC curve analysis is reported in the graph. No statistically
signiﬁcant differences between ROC AUC were found (p = 0.21).
Kappa statistic was 0.54 between CURB65 and SCAP, 0.17 between
CURB65 and sepsis, 0.21 between SCAP and sepsis.
Conclusion: The SCAP score performs better than others in predicting
30-days mortality. Of particular concern are the low level of sensitivity
of sepsis score and the minimal concordance with the speciﬁc scores for
pneumonia in the identiﬁcation of severe disease.
P1583 The use of procalcitonin to guide antimicrobial use for
respiratory tract infections in a district general hospital:
a feasibility study
R. Scott, B. Sage, K. Cheah, R. Vancheeswaran, D.J. Mack* (London, UK)
Objectives: Our Trust, consisting of two large district general hospitals,
admits 1700 patients with lower respiratory tract infections (LRTI)
per year. A recent national audit of patients with chronic obstructive
pulmonary disease (COPD) revealed our patients had a higher than
average rate of antimicrobial use, including intravenous (IV) antibiotics.
LRTI patients also had a longer than average length of stay. Our aim was
to investigate the feasibility of using procalcitonin (PCT) in our setting
to guide the use of antimicrobials in patients admitted with LRTI.
Methods: We conducted a retrospective observational study. Patients
admitted to medical wards with a diagnosis of LRTI were identiﬁed
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from daily medical handover sheets and a review of the clinical notes.
Serum from routine biochemistry samples from the day of admission
(Day 0) and the second day of admission (Day 2) was saved. The
serum samples were frozen and later tested for PCT, and clinical
treatment and outcome data collected from the patient notes. Low PCT
levels (<0.25 micrograms/L) were interpreted to mean antimicrobial use
could safely be discouraged. The costs of the antimicrobials used were
calculated according to prices in the British National Formulary (BNF
60, September 2010).
Results: Ninety-nine patients admitted with LRTI were identiﬁed over
a 2 month period, of whom Day 0 and Day 2 PCT levels were available
for 62 patients. In four patients, PCT levels changed from low (<0.25
micrograms/L) on Day 0 to high (>0.5 micrograms/l) on Day 2: in these
cases clinical details were consistent with the development of bacterial
infections post-admission. Twenty-three (45%) patients had low PCT on
Day 0 and Day 2, suggesting antimicrobials could be withheld. All 23
received antimicrobials. Fourteen (60%) of these patients received IV
antibiotics, one patient was excluded due to ITU admission (Figure 1).
The antimicrobial costs for these 22 patients totalled £2360 of potential
savings. Averaged across the group of 62, the potential saving in
antibiotic costs per patient tested for PCT was £38, compared to costs
of approximately £15 per PCT test.
Conclusion: Our results showed 45% of patients admitted to medical
wards with a diagnosis of LRTI had low PCT levels. Antibiotic use could
be discouraged in these patients using a single PCT measurement on
admission. Repeat PCT testing should be allowed if clinically indicated.
Using PCT could reduce antimicrobial costs.
P1584 Practical use of urine antigens and implementation of na-
tional recommendations for the management of community-
acquired pneumonia (CAP): results from a retrospective
study on 214 CAP hospitalised by the emergency department
C. Bastide, F. Borlot, G. Le Falher, J. Reny, A. Dao, E. Mennesson,
B. Simorre, E. Oziol* (Be´ziers, FR)
Objectives: To evaluate the use of the urine antigens for Legionella
pneumophila (Lp) and Streptococcus pneumoniae (Sp) in the manage-
ment of CAP and the agreement of ﬁrst empirical antibiotherapy with
the French NR.
Methods: This is a retrospective study on consecutive patients with CAP
hospitalised by the emergency department in a general hospital between
November 1st 2006 and October 31st 2007 (corresponding to two full
resident periods). We excluded lung abscess and aspiration or nosocomial
pneumonia. Diagnosis with the subsequently Fine scoring and antibiotic
strategy were compared to the march 2006 French NR and to a more
simple clinical algorithm intended for general practitioners and based on
early clinical severity and comorbidities and/or age >70 year.
Results: 214 patients fulﬁlled the inclusion criteria. Median age was 79
years with 53% of male. 72% had at least one comorbidity and 21%
were living in an institution. In-hospital mortality rate was 14%. There
was only 36% of bacterial documentation among which 25 Sp and 8
Lp. Use of both urine antigens, 60% and 70% for Sp and Lp done
respectively, were not performed in accordance with the NR and had
no impact on the antibiotherapy for Sp. It remained the only test for an
early diagnosis and treatment for Lp. The Fine score was never reported
in practice. Using an a posteriori computed Fine score, based on chart
records, the initial therapy would have agreed with the recommendations
in only 20% (in 12% larger spectrum and in 61% antibiotics not agreed
with suspected bacteria were used). The concordance between the NR
algorithm based on the Fine score and the algorithm based on clinical
signs, was good (kappa 0.80 to 0.61) except for 6 very old patients for
whom broader spectrum antibiotics should have been given with the Fine
score algorithm, but without any difference in outcome. This suggests
that comorbidities are more relevant than the weighting by age beyond
the 70 years old cut-off for the prognosis and ﬁrst empiric therapy.
Conclusion: The Fine score is not used in real life emergency practice
and may not be relevant for our emergency practitioners. We think
that simpler clinical algorithm could be an alternative and should be
prospectively evaluated.
P1585 Pneumonia treated in the internal medicine department:
a nationwide study in Spain
M. Giannella*, E. Bunsow, B. Pinilla, J.A. Capdevila, J. Martinez
Alarcon, P. Mun˜oz, E. Bouza on behalf of the ENEMI Study Group
Objectives: To assess the incidence, epidemiology, use of microbiolog-
ical resources, management, and outcome of pneumonia treated in the
internal medicine department (IMD) in Spain.
Methods: IMD reported all patients with pneumonia attended in their
department during 1 week in January 2010 and 1 week in June 2010.
Results: Seventy-two IMDs from 66 hospitals submitted 1,031 patient
records, of which 1,002 fulﬁlled the criteria for pneumonia. Patients
were classiﬁed as having community-acquired pneumonia (CAP) in 60%
of cases, healthcare-acquired pneumonia (HCAP) in 30%, and hospital
acquired pneumonia (HAP) in 10% of cases. The incidence of pneumonia
was 141 episodes/1,000 IMD admissions in January and 75.3/1,000 IMD
admissions in June. According to the pneumonia severity index (PSI)
score, 24% of CAP and HCAP patients were classiﬁed as having a low
risk of death (classes I, II and III) and 76% a high risk (classes IV or
V). According to CURB-65, 31% of patients were low-risk (<2 points)
and 69% were moderate to very high risk (2 points). Thus, according
to the PSI and CURB-65 scores, 24% to 31% of admissions were not
strictly necessary. A request for microbiological diagnosis (1 sample
sent to microbiology departments) was made in 87%, 78%, and 71%
of CAP, HCAP, and HAP patients (p< 0.001), with an overall positivity
of 29%. S. pneumoniae was the main pathogen of CAP and HCAP,
while P. aeruginosa was the main pathogen of HAP. Overall, 30% of
patients did not receive any antibiotic within 6 hours of evaluation.
Adherence to IDSA guidelines in CAP was 70%; adherence to ATS
guidelines in HCAP and HAP was 23% and 56% (p< 0.001). In patients
with an etiological diagnosis, empirical antibiotic treatment was active
against 73% of isolates. For CAP, HCAP, and HAP, the median length of
hospital stay was 8, 9, and 11 days (0.002), and in-hospital mortality
8%, 19%, and 27% (p< 0.001). Therapy was switched in 60% of
patients and discharge delayed a median of 5 days after the patient was
considered clinically stable. Only 2% of patients were vaccinated against
S. pneumoniae during their hospital stay.
Conclusions: Pneumonia affects 7% to 14% of patients hospitalized in
the IMD in Spain. Admission policy, use of microbiological resources,
therapeutic management, discharge criteria, and prevention of future
episodes are amenable to intervention.
P1586 Incidence, length of stay, and prognosis among patients
hospitalised with thoracic empyema: a Danish nationwide
study, 1995–2009
R.W. Thomsen*, J.B. Kornum, R.B. Nielsen, M. Søgaard,
H. Schønheyder, H.T. Sørensen (Aalborg, DK)
Objectives: Concerns have been raised about trends towards increasing
diagnoses of empyema in the adult population, but updated data on
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incidence and mortality are sparse. We examined temporal changes in
the incidence, length of hospital stay, and patient mortality associated
with empyema-related hospitalizations.
Methods: Using nationwide health registries covering all Danish
hospitals, we identiﬁed all adults with a ﬁrst-time hospital diagnosis
of empyema between 1995 and 2009, and ascertained their comorbidity,
length of hospital stay, and dates of death (if any). We computed age-
standardized incidence rates and adjusted mortality rates by calendar
year.
Results:We identiﬁed 6,549 patients with empyema, of whom 67% were
men. The incidence rate increased from 8.7 per 100,000 person-years in
1995 to 13.3 per 100,000 person-years in 2009, representing a relative
increase of 53.5%. During the same period, the median length of hospital
stay for empyema decreased slightly, from 17 days (interquartile range
(IQR): 9−31 days) to 14 days (IQR: 7−22). Mortality among patients
diagnosed during the most recent 5-year calendar period (2005–2009)
was only slightly lower than among patients diagnosed during the earliest
period under study (1995–1999): 9.0% vs. 9.6% after 30 days. This
corresponds to an adjusted 30-day mortality rate ratio of 0.76 (95%CI:
0.62–0.93) after controlling for changing age and comorbidity over time.
Advanced age and high comorbidity level were poor prognostic factors.
Conclusion: Similar to previous ﬁndings for pneumonia, the incidence
of empyema-related hospitalizations among adults in Denmark has
increased substantially during the last 15 years. In the same time interval
prognosis has improved modestly.
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P1587 Trends in the incidence of bloodstream infections and sepsis
management organisation in Emilia-Romagna, Italy
A. Pan*, R. Buttazzi, C. Gagliotti, C. Capatti, S. Giordani, M. Parenti,
F. Pedna, D. Resi, M. Sarti, C. Venturelli, M.L. Moro on behalf of
the Antibiotic Use and Resistance Surveillance Study Group of Regione
Emilia-Romagna and LaSER Study Group
Objectives: Blood stream infections are frequent and severe infections,
with an incidence on the rise. To face this problem, as regional campaign
to ﬁght sepsis (LaSER − Lotta alla Sepsi in Emilia-Romagna) was
launched in 2007. We report the trend in blood-stream infections (BSI)
in the period 2005–2009, and an analysis of the organization of sepsis
mangement in Emilia-Romagna, Italy.
Methods: Data regarding BSI and antibiotic resistance were obtained
from the regional public health system data-bases, merging data
from 50/60 regional hospitals. BSI rates were calculated on the
regional population. Coagulase-negative staphylococci and other possible
skin contaminants isolate form blood-cultures were excluded, due to
limitation in the interpretation of these blood cultures results of the
system. Data regarding sepsis management were obtained from the
LaSER project data.
Results: Between 2005 and 2009 the incidence of BSI increased from 78
to 120 cases/100,000 inhabitants (+55%, p< 0.0001), with Escherichia
coli and Staphylococcus aureus being the most common germs isolated:
51.8 and 25.1 cases/100,000 inhabitants-year in 2009, respectively.
Striking increases were observed for Klebsiella pneumoniae (from 5.2
to 10.2 cases/100,000 inhabitants, + 97%), E. coli (from 28.2 to 51.8,
+84%), Enterococcus faecium (from 3.4 to 5.8, +71%, and Enterococcus
faecalis (from 7.4 to 11.5, +55%) (see table). Antibiotic resistance
increased signiﬁcantly both for E. coli and K. pneumoniae. Antimicrobial
resistance increased strikingly among Enterobacteriaceae (see table), and
it remained stable among Gram-positive cocci and non-fermenting Gram-
negative rods. The LaSER project educated 5,800 health-care workers on
sepsis diagnosis and management, made drawing blood-cultures possible
in the casualty ward in 13/18 trusts, made urgent lactate dosage available
in 16/18 trusts and a sepsis team has been organized in 13 trusts.
Conclusion: A steady increase in BSI was observed between 2005 and
2009, slightly more evident from 2008 after the implementation of the
LaSER project. The increase observed among Enterobacteriaceae was
mostly due to the emergence of antimicrobial resistant isolates. The
LaSER project favored improvement in the organization regarding sepsis
management, of primary importance in this epidemiological setting.
Evaluation of efﬁcacy need to be performed in order to permit more
appropriate analysis of the impact of the project.
P1588 The impact of diabetes and poor glycaemic control on risk of
bacteraemia with haemolytic streptococci groups A, B and
G in adults: a 15-year population-based case-control study
R.W. Thomsen*, A.H. Riis, S. Kjeldsen, H.T. Sørensen, H. Schønheyder
(Aarhus, Aalborg, DK)
Objectives: Diabetes has been associated with bacteraemia due to
haemolytic streptococci (HS) but epidemiological evidence is limited.
Methods: We conducted a population-based case-control study of all
adults with a ﬁrst-time diagnosis of bacteraemia with HS groups A, B,
and G and matched population controls. The study setting was Northern
Denmark between 1992 and 2006. We computed odds ratios (ORs) for
streptococcal bacteraemia according to diabetes and glycaemic control,
using regression analysis for confounder adjustment.
Results: We identiﬁed 397 adult patients with HS bacteraemia (median
age = 67 years, 51% women), of which 63 (17%) had diabetes. Persons
with diabetes had a 2.1-fold increased risk of streptococcal bacteraemia
compared with population controls (adjusted odds ratio (OR) = 2.1;
95% conﬁdence interval (CI): 1.5−2.9). For persons with type 1
diabetes, the adjusted OR was 14.8 (95%CI: 2.4–91.2). Longer diabetes
duration and poor glycaemic control conferred higher risk estimates:
adjusted OR= 1.5 (95%CI: 0.8−3.0) for HbA1c level <7%, and OR= 3.6
(95%CI: 1.6−8.1) for HbA1c level 9%. The association between
diabetes and HS bacteraemia was independent of the underlying foci
of infection and was strongest for HS group B bacteraemia (OR= 3.5;
95%CI: 1.8−7.0) and for HS group G bacteraemia (OR= 2.6; 95%CI:
1.6−4.4). There was no clear increase in risk for HS group A bacteraemia
(OR= 1.2; 95%CI: 0.7−2.2).
Conclusions: Diabetes is a strong risk factor for group B and group
G, but not group A, HS bacteraemia. The risk increase is particularly
high for type 1 diabetes, long diabetes duration, and poor long-term
glycaemic control.
P1589 Delayed appropriate therapy in Staphylococcus aureus
bloodstream infection does not inﬂuence outcome
A.J. Kaasch*, S. Rieg, J. Ku¨tscher, T. Widmann, C. Meyer, P. Kern,
U. Haars, I. Hu¨bner, B. Sinha, F. Brunkhorst, W.V. Kern, H. Seifert
on behalf of the preSABATO study group
Objectives: Delayed treatment with appropriate antimicrobials has been
shown to augment mortality in patients with septic shock. Therefore
early, aggressive treatment has been advocated for all bloodstream
infections. However, clinical experience suggests that a delay of therapy
is not as critical in patients with Staphylococcus aureus bloodstream
infections (SAB). Therefore, we conducted a prospective epidemiological
study to test whether treatment delay inﬂuences outcome parameters in
patients with SAB.
Methods: 258 patients with SAB from 10 study centers were enrolled
in the prospective preSABATO study. All patients were followed
for 3 months and predisposing factors, clinical features, diagnostic
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measures, antimicrobial therapy, and outcome were recorded. Therapy
was considered delayed when appropriate therapy was initiated 48h
after the initial positive blood culture; antimicrobial therapy was
considered appropriate when in-vitro activity against S. aureus was
demonstrated and the correct dosage was given.
Results: In 48 (18.6%) patients SAB was classiﬁed as community-
acquired not healthcare-associated, in 70 (27.1%) patients as community-
acquired healthcare-associated, and in 140 (54.3%) patients as noso-
comial infection. The most prevalent portals of entry were catheter-
related infections (78, 30.2%), skin and soft-tissue infections (25, 9.7%),
pneumonia (23, 8.9%), and endocarditis (21, 8.2%). In 48 (18.6%) cases
the infection was caused by a methicillin-resistant strain. Antimicrobial
therapy was administered delayed in 73 (28.3%) patients. Between
patients with timely vs. delayed therapy, no signiﬁcant difference in crude
mortality (in-hospital, 30-day, 90-day mortality) and late complications
was noted (Table).
Conclusion: In our study, delayed appropriate antimicrobial treatment
did not adversely affect crude mortality in SAB.
P1590 Clinical signiﬁcance of Staphylococcus aureus bacteriuria
in patients with S. aureus bacteraemia
H. Asgeirsson*, M. Kristjansson, K. Kristinsson, O. Gudlaugsson
(Huddinge, SE; Reykjavik, IS)
Objectives: S. aureus bacteriuria (SABU) in association with S. aureus
bacteraemia (SAB) is well documented while its clinical signiﬁcance is
not well understood. The study objective was to evaluate the relationship
between SAB and concomitant SABU and assess its clinical signiﬁcance.
Methods: This population based retrospective cohort study included all
individuals 18 years old being diagnosed with SAB in Iceland between
December 1st 2003 and November 30th 2008. Concomitant SABU was
deﬁned as growth of S. aureus in urine sample taken within 24 hours
of the index blood culture. SAB was deﬁned as being of urinary tract
origin if there was clinical suspicion of genitourinary tract infection with
known structural abnormality or recent instrumentation, and no other
identiﬁed source for the SAB. Complicated SAB was deﬁned as one
with secondary haematogenous or unknown focus; three day persistence
on active treatment; or signs of metastatic infection remote from initial
focus.
Results: Concurrent urine culture was done in 199 of 300 SAB cases
(66%), but in 33 a negative result was unreliable as antibiotics had
already been administered. SABU was seen in 27 of 166 episodes
(16.3%) of whom 11 were of urinary tract origin. Concomitant SABU
was thus seen in 16 of 152 cases (10.5%) of non-urinary tract origin.
In this group it was correlated to community acquisition (68.8% vs.
33.8%, p = 0.006), having complicated bacteraemia (87.5% vs. 53.3%,
p = 0.009) and endocarditis (18.8% vs. 3.7%, p = 0.01), while a trend was
seen with being admitted to intensive care unit (ICU) (37.5% vs. 17.6%,
p = 0.06). By using logistic regression analysis concomitant SABU was
shown to be independently associated with having endocarditis [risk
ratio (RR) 6.68; 95% conﬁdence interval (CI) 1.53–17.3; p = 0.01] and
ICU-admissions [RR 2.84; 95%CI 1.25–4.44; p = 0.02], with a trend for
having complicated SAB [RR 1.56; 95%CI 0.96–1.80; p = 0.06]. These
associations were however not observed when SAB cases of urinary tract
origin were included in the analysis. There was no correlation to 30-day
mortality (6.3% vs. 16.9%, p = 0.27) or relapse rates (12.5% vs. 6.6%,
p = 0.39).
Conclusion: Concomitant SABU appears to be secondary to SAB in
some patients while primary urinary tract infection causes the SAB in
others. In patients with SAB of non-urinary tract origin, concomitant
SABU should probably be regarded as distant haematogenous seeding
and the bacteraemia therefore regarded as complicated one.
P1591 Community-onset ESBL E. coli bacteraemias: prevalence,
risk factors and outcomes in a London tertiary hospital
S. Reddy*, L. Phee, A. Sivaramakrishnan, E. Hennessey, M. Millar
(London, UK)
Objectives: Community onset infections caused by extended spectrum
b-lactamase (ESBL) producing E. coli is a growing problem. The
primary aim of this study was to determine prevalence and risk factors
for community onset bacteraemia due to ESBL producing E. coli (ESBL-
EC).
Methods: We conducted a retrospective study of patients who presented
to Accident and emergency department at Royal London Hospital with
laboratory conﬁrmed E. coli bacteraemia between 1 February 2005 and
31 December 2007. Demographic, clinical, laboratory data, length of
stay and 14-day mortality data were collected from medical records.
Results: Of the 162 patients admitted with community onset E. coli
bacteraemia, 21 of 162 (13%, 95%CI: 8.2 to 19.1%)) E. coli isolates
were ESBL producing. Those with ESBL producing isolates were on
average 9 years older (p = 0.077), more likely to have been hospitalized
in the previous 3 months (OR 4.9; 95%CI, 1.9 to 12.8; p = 0.001). They
were also marginally more likely to die within 14 days, 19.1% and 6.4%
respectively (OR= 3.9; 95%CI, 1.1 to 14; p = 0.052). Among patients
with accessible medical records (95), those with ESBL-EC bacteraemia
were more likely to present with hypotension (OR 2.7; 95%CI, 0.85 to
8.6; p = 0.092). Patients with ESBL producing isolates were less likely
to be treated initially with an appropriate empirical antibiotic 11% vs
95% (p< 0.001).
Conclusions: Community onset ESBL-EC bacteraemia is a signiﬁcant
problem in tertiary care hospitals and current empirical b-lactam based
antibiotic regimens may be inadequate to treat suspected Gram negative
sepsis. There is an urgent need to establish antibiotic resistance threshold
at which empirical antibiotics should be changed.
P1592 Laboratory predictors of mortality in community-acquired
Escherichia coli bloodstream infection
C.J. Collins*, M. Kelleher, T.R. Rogers (Dublin, IE)
Objectives: As laboratory clinicians with the telephone as a key means
of initial clinical liaison, it may be difﬁcult for the Clinical Microbiology
(CM) team to help identify for physicians those at most risk of death from
an infection or to prioritise those for a CM bed-side review. Laboratory
data on the Laboratory and Hospital Information Systems (LIS & HIS)
provide objective readily available information for the CM team. The
aim of this study was to determine laboratory predictors of 7-day in-
hospital mortality in community-acquired Escherichia coli bloodstream
infection (CA-E. coli BSI).
Methods: A retrospective analysis of CA-E. coli BSIs in St. James’s
Hospital, Dublin (SJH) from March 2004-December 2009 was performed
using the CM laboratory BSI database, the LIS, and the HIS. CA-
E. coli BSI was deﬁned as infection where E. coli was cultured from
a blood culture taken within 48 hours of presentation and the patient
was not an in-patient in SJH for the preceding 3 months, had not
attended SJH out-patients or Emergency Department within the previous
month, and had not been admitted from another healthcare facility.
For each haematological and biochemical parameter analysed, the ﬁrst
available result within 48 hours of presentation was recorded. Laboratory
parameters were analysed for an association with in-hospital mortality
within 7 days of presentation. Only those parameters for which results
were available in 90% of cases were included.
Results: There were 172 CA-E. coli BSIs during the time period. In
11 (6.4%) of these, death occurred within 7 days of presentation. ESR,
CRP, coagulation proﬁles and glucose data were not available in 90%
of cases and were excluded. The following were signiﬁcantly associated
with 7-day in-hospital mortality: white cell count <4x109 cells/L, urea
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>20mmol/L, creatinine >150mmol/L, bicarbonate <21mmol/L, bilirubin
>60mmol/L, LDH >600IU/L, AST >400IU/L, albumin <35g/L, time to
detection of blood culture isolate <10.5 hours, the presence of another
signiﬁcant isolate in the blood culture, ciproﬂoxacin resistance, and
gentamicin resistance.
Conclusion: Laboratory parameters provide objective data to identify
those at risk of in-hospital death within 7 days of presentation with a
CA-E. coli BSI. These data may help prioritise those in need of an urgent
CM bed-side review. Further studies are needed to determine if such CM
bed-side reviews for these selected high-risk patients have any impact
on mortality.
P1593 Clinical characteristics and outcome of Haemophilus
bacteraemia in the post-vaccination era
S. Thønnings, C. Østergaard* (Herlev, Hvidovre, DK)
Objective: Despite the epidemiology has been extensively studied,
little information is still available about clinical characteristics of
Haemophilus bacteremia in the post-vaccination era.
Methods: All episodes of positive blood cultures with Haemophilus
species identiﬁed at the Department of Clinical Microbiology, Herlev
Hospital during the time period 2000–2009 were included in the study.
Clinical and laboratory information were collected retrospectively from
medical records.
Results: 105 consecutive episodes (median age: 69 years) with only 4
children <16 years were identiﬁed (see Figure). 72% of the Haemophilus
bacteremic episodes were due to non-typeable H. inﬂuenzae (NTHi),
16% to typeable H. inﬂuenzae type b (serotype b and f) and 11% to
other Haemophilus species. 58% of episodes were community-acquired,
30% healthcare-related, and 22% hospital-acquired. Healthcare-related
infections were predominantly caused by NTHi (87%), and 82% of
episodes due to typeable H. inﬂuenzae were community-acquired.
Pneumonia was the most common primary focus (in 48%), and these
episodes were mainly caused by NTHi (94%). Contrary, foci in the upper
respiratory tract (83%) and meningitis (75%) were predominantly due to
typeable H. inﬂuenzae, whereas all 3 episodes of endocarditis were due
to H. parainﬂuenzae.
58% of the patients in the study population scored “medium” or “high”
in the Charlson comorbidity index, 48% were smokers, 21% were
immunosuppressed, and 23% had an alcohol abuse. The 30-days CFR
was 22% (24% female, 20% male), highest for NTHi (25%) and lowest
for typeable H. inﬂuenzae (12%).
Risk factors for death in the unadjusted analysis were hospital-acquired
bacteremia, alcohol abuse, altered mental status, development of septic
shock, need for assisted ventilation, temperature <38 degrees, low
P-sodium, and therapy with benzylpenicillin (P< 0.05), whereas altered
mental status was the only signiﬁcant risk factor in the multivariate
analysis (P = 0.01).
Conclusion: Haemophilus bacteremia still carries a high mortality and
is predominantly caused by NTHi among elderly having comorbidity and
with a primary lung focus. Benzylpenicillin should not be considered as
therapy for Haemophilus bacteremia.
P1594 Five cases of Campylobacter fetus infection detected at a
university hospital in Japan
A. Uehara*, M. Nakashima, M. Kadowaki, Y. Uchida, N. Shimono,
K. Akashi (Fukuoka, JP)
Objectives: Campylobacter fetus is a rare pathogen causes bloodstream
infection presenting variety of clinical features. We investigated clinical
and bacteriological characteristic of the recent ﬁve cases at Kyushu
University Hospital and summarize regional overview of this infection
in characteristics.
Methods: We reviewed medical records of the ﬁve cases admitted to
Kyushu University Hospital from January 2005 to December 2010.
C. fetus isolated from blood, drained liquid from abscess or subcutaneous
puncture, and bone marrow were analyzed by clinical microbiological
methods and pulse ﬁeld gel electrophoresis.
Results: Three of the ﬁve patients were male and their age ranged from
35 to 69 years old. The C. fetus infections of all cases were community
acquired. Except for a one previously healthy male aged 32, the patients
had underlying diseases causing signiﬁcant immunocompromised
condition, such as diabetes mellitus, post hematopoietic stem cell
transplantation, and cardiovascular disease. Major symptom was fever
and clinical presentations of the infection were bacteremia, cellulites,
osteomyelitis and arthritis. All C. fetus strains isolated were sensitive
to antimicrobials generally recommended for treatment. Patients were
treated by ampicillin, carbapenems, ﬂuoloquinolones, or cefetriaxone
with or without gentamicin or clindamycin. The duration of treatment
for bacterial infection and underlying condition ranged from 21 days for
the case with cellulites and 3 months for the case with osteomyelitis.
Conclusion: C. fetus infection occurs mainly among immunocompro-
mised patients. We experiences ﬁve cases in 13 year including one
previously healthy patient. Choosing antimicrobial drugs guided by
sensitivity analysis of the isolated strain is a key to effective treatment.
P1595 Abiotrophia endocarditis and bacteraemia − an 8-year
experience in a tertiary care centre
Y. Maor*, N. Belausov, D. Ben-David, G. Smollan, N. Keller, G. Rahav
(Ramat Gan, IL)
Background: Abiotrophia defectiva and A. adiacens are rare causes
of endocarditis (IE). Previous publications suggest that morbidity and
mortality exceed those of other forms of viridans streptococci IE with
bacteriological failure in 41% of patients. More than 30% of strains of
Abiotrophia sp. were found to be resistant to penicillin. We report our 8
year experience with Abiotrophia endocarditis and bacteremia.
Methods: All cases (n = 36) of Abiotrophia bacteremia diagnosed at
our institution from 2002–2010 were included in the study. Medical
records of all patients were reviewed. IE was diagnosed according to
the modiﬁed Duke criteria. Frozen bacterial isolates were available in
25 (69%) cases. Isolates were thawed and bacterial identiﬁcation was
repeated using API and classical methods. Antibiotics susceptibility was
assessed using Etest. Fisher exact tests were used when appropriate.
Results: IE, was diagnosed in 13/36 (36%) patients (9 deﬁnite and
4 possible). Most cases involved the mitral valve (n = 7). Primary
bacteremia was diagnosed in 23 (64%) patients. A. adiacens was more
common than A. defectiva in both groups (7 and 4 in IE patients and
13 and one in bacteremia patients, respectively). The median age was
57 years in IE patients and 48 years in bacteremia patients. Underlying
heart disease was found among 9/13 (69%) patients with IE and none of
those with bacteremia (p< 0.0001). 9/23 (39%) patients with bacteremia
were immunocompromised in contrast to none among those with IE
(p = 0.014). Hemiparesis or other neurological signs were the presenting
symptom in 4/13 (31%) IE cases. The mortality rates among patients
with IE and bacteremia were 3/13 (23%) and 7/23 (30%), respectively.
In bacteremic patients there was a trend towards increased mortality
in immunocompromised patients (p = 0.06). Nine (36%) isolates were
resistant to penicillin (MIC range 0.006−1.0mg/l), three (12%) were
resistant to ceftriaxone (MIC range 0.016−4.0mg/l), and two (8%) were
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resistant to clindamycin (MIC range 0.064−>256mg/l), All isolates were
sensitive to vancomycin (MIC range 0.25−0.5mg/l), and linezolid (MIC
range 0.25−1.0mg/l).
Conclusions: Abiotrophia is an important pathogen not only in the
context of IE but also among patients with bacteremia. The mortality
rate is high particularly among immunocompromised patients and
bacteremia. Patients with IE frequently present with central nervous
system involvement.
P1596 Signiﬁcance of troponin-I value in infective endocarditis
N. Mewada*, A. Mewada, D. Levine (Detroit, Michigan, US)
Objectives: To assess signiﬁcance of Troponin-I values in Infective En-
docarditis for its association with different variables and complications.
Method: We analyzed data of 78 patients from the hospital registry.
There were 46 Males & 32 Females. Mean age was 52.5 + 3.1 years,
Mean BMI was 28.3 + 3.4. Our study population included a diverse
population with 77.6% African Americans, 18.4% Caucasians, and
2.6% Hispanics. Since some patients had ultra-sensitive Troponin-I
value and the rest had conventional Troponin-I value, we considered
the percentage rise of the Troponin-I values from the reference high
values. 33 patients had increased Troponin-I levels values (Mean %
form reference high 1417.99 + 598.52) and 45 patients had normal
Troponin-I values (Mean % to reference High 41.39 + 7.74). We analyzed
the Troponin-I values for association with incidence of death, embolic
event, intracranial hemorrhage, intracardiac abscess, rise in creatinine
value, ICU admission, left-sided endocarditis, congestive heart failure,
pulmonary embolism, IV risk factor (IV drug abuse or permanent IV
line placement), history of prosthetic valve, prior endocarditis, prior
hospitalization in 1 year and need for cardiovascular surgical intervention
for treatment.
Results: Increased Troponin-I values were signiﬁcantly associated
with death (p< 0.001, HR 22.84, 95%CI 4.7–110.2), embolic event
(p = 0.003, HR 5.86, 95%CI 1.7–20.4), intracranial hemorrhage
(p = 0.003, 95%CI 1.04–1.44), intracardiac abscess (p = 0.048, HR 4.78,
95%CI 0.9–25.4), rise in creatinine value (p< 0.001, HR 7.66, 95%CI
2.5–23.5), ICU admission (p = 0.004, HR 4.0, 95%CI 1.5–10.3), left-
sided heart disease (p< 0.001, HR 16.1, 95%CI 3.0–84.3). No signiﬁcant
association was found between Troponin-I and congestive heart failure
(p = 0.066, HR 2.7, 95%CI 0.9−8.0), pulmonary embolism (p = 0.072,
HR 0.17, 95%CI 0.2−1.5) IV risk factor, history of prosthetic valve, prior
endocarditis, prior hospitalization in 1 year and need for cardiovascular
surgical intervention for treatment.
Conclusion: Increase in Troponin-I serum level can serve as a sensitive
prognostic tool for patients with infective endocarditis.
P1597 The broadening spectrum of septic pulmonary embolism:
a retrospective review
D.N. Williams*, U. Goswami, J. Brenes (Minneapolis, US)
Objectives: Septic pulmonary embolism (SPE) is a rare manifestation of
systemic infections most commonly associated with right sided infective
endocarditis (RIE) in intravenous drug users (IVDU). Prompted by recent
clinical experiences, we undertook a review of the epidemiology of
presumptive cases of SPE seen at our hospital.
Methods: Cases of SPE were identiﬁed by a retrospective computer
assisted search of the chest CT scan reports at our hospital between
January, 2000 and June, 2010. Electronic charts of patients were studied
to establish the diagnosis and to follow their course of illness and
treatment. A “deﬁnite” case of SPE was deﬁned as having chest
CT ﬁndings of focal or multifocal lung inﬁltrates; an extrapulmonary
infectious source for emboli; exclusion of other explanations for the
lung inﬁltrates; and resolution of the inﬁltrates with antibiotic therapy.
A “probable” case had typical CT ﬁndings but lacked one or more of
the other features.
Results: 34 patients (25 deﬁnite and 9 probable), 24 male and 10
female with ages ranging from 1 to 71 years (median − 45 years)
were identiﬁed. The most common presenting complaint was fever
in 31 patients while 3 patients presented with dyspnoea and cough.
Sources of infectious emboli were identiﬁed in all but 6 cases. These
included − 12 peripheral (skin; soft tissue deep venous plexus); 7 cardiac
(4 RIE); 7 long term intravascular devices; and 2 dental/throat foci.
26 patients were bacteremic and 8 had pathogenic bacteria isolated
from other sites. Staphylococcus aureus (MSSA in 20 and MRSA in
5) was the predominant pathogen. 24 (70%) had echocardiograms and
valvular vegetations were identiﬁed in 6 patients. All received antibiotic
therapy for 2 to 8 weeks (mean duration 27 days). The most common
associated comorbidities included IVDU in 8, end stage renal disease (on
hemodialysis or with transplant) in 7 and diabetes mellitus in 6 patients.
Follow up imaging was performed on 16 patients. 5 patients died and 4
were lost to follow up.
Conclusions: The epidemiology of SPE has broadened over the past
decades with an increase in identiﬁed non cardiac sources related to
contiguous infections. Radiologic studies can identify possible venous
embolic sources. Prolonged antibiotic therapy is required. A clearer
understanding of the etiologies of SPE will help facilitate the diagnosis
and management of this potentially fatal condition.
P1598 Outcome and prognostic factors in patients with community-
acquired bacteraemic severe sepsis or septic shock
Y.K. Yoon*, D.W. Park, S. Kwon, B. Chun, J. Sohn, H.J. Cheong,
J.Y. Choi, H.J. Choi, Y.H. Choi, H.Y. Kim, J.S. Eom, S.I. Kim,
Y.G. Song, K.R. Peck, Y.S. Kim, J.M. Kim, M.J. Kim on behalf of
the Korean Sepsis Working Group
Objectives: The objective of this study is to describe epidemiology
and to determine prognostic factors related to outcome in patients
with community-acquired severe sepsis or septic shock accompanied
by bacteremia.
Methods: Study subjects included patients with the identiﬁcation of a
pathogen in a blood culture from database of the Korean Sepsis Registry
System (KSRS), prospectively registered at the 12 teaching hospitals in
Korea from May 2005 to December 2008 Clinical data from KSRS were
collected and analyzed, including demographic characteristics, comorbid
illness, source of infection, severity of sepsis, 7-day, 28-day and in-
hospital mortality, causative microorganisms and the appropriateness of
empirical antimicrobial therapy.
Results: Of 1,152 patients with community-acquired severe sepsis,
422 (36.7%) patients showed bacteremia with the identiﬁcation of
pathogens. Of them, 253 (60.0%) patients presented as septic shock.
In-hospital and 7-day mortality were 28.7% and 14.9% respectively.
Primary bloodstream infection accounted for 47 (11.1%) patients. Sec-
ondary bloodstream infections originated from intraabdominal infections
(34.4%), urinary tract infections (28.4%) and respiratory tract infections
(10.9%) in decreasing order. The most predominant pathogens were
E. coli (37.7%), followed by Klebsiella spp. (22.2%), Staphylococcus
spp. (11.8%) and Streptococcus spp. (10.2%). The proportion of
patients receiving inappropriate initial empirical antimicrobial therapy
was 15.4%. In a multivariate logistic regression analysis, respiratory
tract infections [odds ratio (OR), 2.60; 95% Conﬁdence interval (CI),
1.11–6.09], number of organ dysfunction [OR, 1.39; CI, 1.13–1.71],
Acute Physiology and Chronic Health Evaluation (APACHE) II score
(per 1-point increment) [OR, 1.08; CI, 1.03–1.13] and E. coli as a
causative pathogen [OR, 0.31; CI, 0.16–0.64] were independent risk
factors associated with in-hospital mortality.
Conclusions: The severity of illness on admission as well as respiratory
infections might be the most important prognostic factors in patients
with community-acquired bacteremic severe sepsis or septic shock.
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P1599 The role of imaging of the urinary tract in patients with
urosepsis
S.M. Sørensen*, H. Schønheyder, H. Nielsen (Aalborg, DK)
Objectives: The study aim was to provide recommendations for imaging
of patients with urosepsis in order to detect urological complications that
need intervention as well as conditions that predispose to renal infection.
Methods: We conducted a retrospective, observational study of adults
admitted to medical wards at a Danish university hospital. Eligible
patients had community-acquired bacteraemia with a urinary tract focus
in 2005 through 2009. Electronic admission ﬁles, laboratory data and
radiological data were reviewed. Outcomes of ultrasonography and/or
x-ray computed tomography were classiﬁed as ”major abnormalities”,
”minor abnormalities” and ”normal”. A major abnormality was deﬁned
as a ﬁnding that should inﬂuence subsequent treatment. Data were
analysed with c2 or Fisher’s exact test or Wilcoxon, as appropriate.
Results: A total of 225 patients were included in the study. Radiological
imaging had been performed in 116 patients (52%), 74 females
and 41 males. Major abnormalities were found in 50 of the 116
(43%) patients. The three most common major abnormalities were
signs of acute pyelonephritis (n = 21, 18%), hydronephrosis (n = 20,
17%) and urolithiasis (n = 9, 8%). The following biochemical and
clinical parameters were statistically signiﬁcant predictors of a major
abnormality: C-reactive protein (P = 0.002), p-creatinine (P = 0.002),
diabetes with complications (P = 0.04), known kidney disease (P = 0.03)
or alternatively, a history of kidney disease, urolithiasis, congenital or
acquired structural abnormality (combined, P = 0.005). Other clinical
parameters such as gender, age, blood pressure, fever, malignant disease,
liver disease, neurological disease, prostatic disease, chronic indwelling
urinary catheter, white blood cell count and neutrophils, did not
show a statistically signiﬁcant association with the ﬁnding of major
abnormalities.
Conclusion: A large fraction (0.43) of the subset of patients scanned in
this study had a clinically important ﬁnding as a result of the radiological
evaluation. It indicates that a visible renal infection or an abnormality of
the kidney or the urinary tract that might predispose to renal infection
is common in medical patients with urosepticaemia.
Elevated C-reactive protein, p-creatinine and a positive history of
diabetes with complications, kidney disease, urolithiasis or structural
abnormality may be particularly helpful in clinical decision making in
this group of patients.
P1600 Evaluating the importance of deﬁning healthcare-associated
bloodstream infections
R. Lenz*, J.R. Leal, D.L. Church, D.B. Gregson, T. Ross, K. Laupland
(Calgary, CA)
Background: Bloodstream infections have been traditionally classiﬁed
as either community or nosocomial in origin. However, more recently
the category of healthcare-associated community onset disease has been
recognized. The objective of this study was to evaluate characteristics of
adults with bloodstream infection according to acquisition setting.
Methods: All ﬁrst episodes of incident bloodstream infections (BSI)
occurring among adults admitted to hospitals in a large health region
in Canada during 2000–2007 were included. BSI cases were classiﬁed
as either nosocomial (NA), community acquired (CA), or community
onset healthcare associated (HCA) infections. NA BSI was deﬁned as
ﬁrst culture positivity 48 h following hospital admission or within 48 h
of discharge. HCA BSI was deﬁned as (i) discharge from an home
parenteral therapy clinic within 2−30 days before BSI (ii) attendance at
a hospital clinic or emergency room within 2−30 days before BSI; (iii)
hospital admission for two or more days within 90 days before BSI; (iv)
sample sent from a nursing home or a long-term-care facility resident;
and (v) outpatient haemodialysis. CA BSI were deﬁned as those with
ﬁrst culture-positivity within <48 h of admission or >48 h after discharge
from hospital, provided no HCA criteria was met.
Results: A total of 7,712 patients were included; 2,132 (28%) NA, 2,492
(32%) HCA, and 3,088 (40%) community-acquired infection. Patients
with CA BSI were signiﬁcantly younger and less likely to have co-morbid
medical illnesses than patients with HCA or NA disease (p< 0.001).
The proportion of cases in males was higher for NA (60%; p< 0.001
vs. others) as compared to HCA or CA (52% and 54%; p = 0.13). The
proportion of cases that had a poly-microbial etiology was signiﬁcantly
lower for CA (5.5%; p< 0.001) compared to both NA and HCA (8.6
vs. 8.3%). The microbiology of infections differed between acquisition
setting, with the distribution of organisms causing HCA intermediate
in the spectrum between NA and CA. The median length of stay was
29.9 days for NA, 9.1 days for HCA, and 7.5 days for CA (p< 0.001).
Thirty-day all cause case-fatality rates were 26%, 19%, and 10% for
NA, HCA, and CA disease, respectively (p< 0.001).
Conclusion: Healthcare-associated infections are distinctly different
from CA and NA infections. These data support the classiﬁcation of
community-onset disease into separate CA and HCA categories.
P1601 Risk factors of septic shock in patients with bacteraemic
acute pyelonephritis visiting emergency room
J. Lee*, J. Cho, S. Shin (Iksan, KR)
Objectives: The aim of this study was to identify factors associated to
septic shock from bacteremic acute pyelonephritis.
Methods: Among the patients visiting to ER between January 2000
and December 209, we evaluated the risk factors of septic shock in
patients with bacteremic acute pyelonephritis, using the review the
clinical records.
Results: During the study period, the number of 205 patients was
included. The median age of these patients was 65.9±15.2 years
and 81% were females. Of these, 51 patients (24.9%) had occurred
septic shock and were classiﬁed as the shock case. The rest, 154
patients, were used as the non-shock case. A total 16 patients died, and
septic shock occurred in all of them. Among the patient’s underlying
conditions, liver cirrhosis was more common in the shock case (17.6%
vs 5.2%, p = 0.005). The rate of healthcare associated infection was
signiﬁcantly higher in the shock case (29.4% vs 13.6%, p = 0.010).
Acute renal failure was presented more frequently in the shock case
(29.4% vs 13.0%, p = 0.007). Among initial laboratory ﬁndings, there
were signiﬁcant differences in the platelet count, serum albumin levels,
and serum urea nitrogen (BUN) levels between two groups. Multivariate
analysis demonstrated that urinary tract obstruction (OR, 9.154; 95%CI,
2.896–28.932, p< 0.0001), renal abscess (OR, 5.381; 95%CI, 1.026–
28.209, p = 0.047), and liver cirrhosis (OR, 5.015; 95%CI, 1.423–17.671,
p = 0.012) were signiﬁcantly associated with septic shock in bacteremic
acute pyelonephritis.
Conclusions: Septic shock in patients with bacteremic acute
pyelonephritis showed high mortality rate (31.4%). Physicians should be
aware that liver cirrhosis be an independent risk factor of septic shock in
patients with bacteremic acute pyelonephritis. And, urologic evaluation
should be promptly performed for the septic shock patients.
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P1602 In vitro activity of antimicrobial agents against Streptococcus
pyogenes obtained in four different regions of Turkey
H. Erdogan*, F. Can, M. Demirbilek, S. Colakoglu, H. Turan, O. Azap,
H. Arslan (Antalya, Istanbul, Ankara, Adana, Konya, TR)
Objectives: Although penicillin-resistant isolates of Streptococcus
pyogenes have not been established to date, non-b-lactams such as
macrolide and quinolone resistance among S. pyogenes have emerged in
recent years. Surveillance studies are important to identify any changes
in antimicrobial susceptibility rate.
Material and Methods: From January 2007 and May 2009, 395
consecutive clinical isolates of S pyogenes obtained from 4 different
regions of Turkey were tested. Isolate identiﬁcation was conﬁrmed
using standart methods, PYR test and/or by a latex agglutination
assay. The isolates were stored at −80ºC and sent to a central
laboratory for MIC testing. The susceptibility to penicillin, ceftriaxone,
vancomycin, erythromycin, azithromycin, clindamycin and levoﬂoxacin
were determined by the agar dilution method according to Clinical and
Laboratory Standards Institute.
Results: The MIC50 for penicillin, ceftriaxone, vancomycin, ery-
thromycin, azithromycin, clindamycin and levoﬂoxacin were 0.007,
0.06, 0.5, 0.125, 0.125, 0.125, and 0.5mg/L, respectively. The MIC90
for penicillin, ceftriaxone, vancomycin, erythromycin, azithromycin,
clindamycin and levoﬂoxacin were 0.03, 0.25, 0.5, 0.25, 0.5, 0.25, and
2mg/L, respectively. All isolates of S. pyogenes tested were susceptible
to penicillin, ceftriaxone, and vancomycin. Erythromycin, azithromycin,
clindamycin and levoﬂoxacin resistance were 6.4%, 3.1%, 5.6% and
5.1%, respectively.
Conclusions:
These results show that antimicrobial resistance against S. pyogenes is
not yet a problem in Turkey but epidemiological studies for antimicrobial
resistance proﬁles of S. pyogenes must be go on periodically.
P1603 Susceptibility of respiratory pathogens to less common
agents
V. Daniels*, M. Wootton, L. Davis, R. Howe (Cardiff, UK)
Objectives: Over the past two years, swine ﬂu incidences have increased
in the UK. There is concern that supplies of the most common antibiotics
to treat secondary bacterial infections may become low, especially after
stockpiling in 2009. We studied the susceptibility of likely secondary
bacterial pathogens to less common agents to establish additional
potential empiric therapies.
Methods: Over a 3 month period laboratories across Wales were
asked to submit 10 isolates each of Haemophilus inﬂuenzae (HFLU),
Streptococcus pneumoniae (SPN), and meticillin-sensitive Staphylococ-
cus aureus (MSSA) from community sputa, and meticillin-resistant
S. aureus (MRSA), and Group A streptococci (GAS) from any
community specimens. Agar dilution MICs were performed by BSAC
methods for ﬂucloxacillin (FLU), co-amoxiclav (COA), cefuroxime
(CXM), erythromycin (ERY), clarithromycin (CLM), clindamycin
(CLD), tetracycline (TET), chlortetracycline (CTE), oxytetracycline
(OXY), lymecycline (LYM), doxycycline (DOX), chloramphenicol
(CHL). D-tests were performed on staphylococci resistant to ERY but
sensitive to CLD.
Results: 252 isolates from 10 laboratories were tested. Geometric mean
MIC (mg/L) and % sensitivity (using BSAC/EUCAST breakpoints) are
shown in the table. Tetracyclines had good activity against all pathogens,
although DOX was less active against H. inﬂuenzae. CLD showed poor
activity against H. inﬂuenzae and S. pneumoniae and FLU had potentially
useful activity against some H. inﬂuenzae (62.8% had MIC 2mg/L).
Conclusions: Some agents not usually used for respiratory infections
may have useful activity against respiratory pathogens. In the event of
a shortage of the most commonly used antibiotics during ’ﬂu outbreaks
their potential use should be evaluated.
P1604 Nationwide surveillance of bacterial pathogens isolated from
patients with lower respiratory infections in 2010 in Japan
A. Watanabe*, T. Matsumoto, A. Iwamoto, K. Totsuka, N. Aoki,
K. Yanagihara, T. Matsumoto, M. Yagisawa, J. Sato, K. Sunakawa,
H. Hanaki (Tokyo, JP)
Objectives: The surveillance committee has been operating a nationwide
surveillance study of the major bacterial pathogens of lower respiratory
infections in Japan since 2006. We report here the results of our
etiological and antibiotic susceptibility studies conducted in 2010.
Methods: Bacterial strains reported here were S. aureus, S. pneumoniae,
H. inﬂuenzae, K. pneumoniae and P. aeruginosa and they were isolated
from patients who were ﬁrmly diagnosed as respiratory infection. A
total of 1002 clinical isolates were obtained from April through Sep.
2010 from 33 hospitals throughout Japan. The antibiotic susceptibility
of was tested by the broth-microdilution method.
Results: Among 201 strains of S. aureus, 170 and 31 were isolated
from in-patients (IP) and out-patients (OP), respectively, and of 57.6 and
25.8%, respectively, were classiﬁed to the methicillin-resistant S. aureus
(MRSA). The MIC of vancomycin, teicoplanin and linezolid in the
MRSA strains tested were within the susceptible range by the CLSI
criteria without exception and their MIC90 were 1, 2 and 2mg/L,
respectively. The penicillin resistant S. pneumoniae was 63.9% in the
strains from IP and that in OP was 58.2% as judged by the CLSI
criteria 2007. The penicillin resistant S. pneumoniae in 2006 through
2009 was in the range of 35−47% and that in 2010 was 60.9%.
Among 169 H. inﬂuenzae strains the ampicillin resistant strains was
67.8% in the strains from IP and that in OP was 60.8%. The penicillin
G resistant S. pneumoniae and the ampicillin resistant H. inﬂuenzae
showed high susceptibility to meropenem, garenoxacin, and sitaﬂoxacin
(MIC90, less than 0.5mg/L). Among 139 strains of K. pneumoniae, three
were found to be the extended spectrum b-lactamase (ESBL)-producing
strains. Among 156 strains of P. aeruginosa, we found only one metallo-
b-lactamase (MBL)-producing multi-drug resistant strain. The fact that
only a few ESBL- and MBL-producing strains were isolated was a relief
to the surveillance committee.
Conclusion: This study revealed the followings. (i) The frequency of
MRSA from IP was considerably high compared with that from OP.
However, the ratio of penicillin resistant S. pneumoniae was comparable
between IP and OP and this tendency was also found in the ampicillin
resistant H. inﬂuenzae. (ii) The MBL-producing P. aeruginosa and
ESBL-producing K. pneumoniae were very few.
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P1605 Antimicrobial resistance of respiratory pathogens in
Finland, 2005–2009
M. Bergman*, P. Huovinen, A. Hakanen and the Finnish Study Group
for Antimicrobial Resistance (FiRe Network)
Objectives: Respiratory tract infections are the most common indication
for antimicrobial treatment. The most important respiratory bacterial
pathogens are Streptococcus pneumoniae, Streptococcus pyogenes,
Haemophilus inﬂuenzae, and Moraxella catarrhalis. In this study, we
present the latest resistance results of these pathogens in Finland.
Methods: The resistance data was collected by the Finnish Study Group
for Antimicrobial Resistance. It is a national network of 24 laboratories
which collects resistance data from all central hospital districts in
Finland. The resistance data was collected during the years 2005–2009.
The number of studied strains per bacterial species per year varied from
~700 to ~18000. Only one strain per patient per year was included. A
harmonised FiRe standard (based on the CLSI standard) was used in the
susceptibility testing.
Results: Macrolide resistance in invasive S. pneumoniae isolates
increased during the study period from 19.0 to 27.1% (Table 1).
Ampicillin resistance in H. inﬂuenzae increased from 13.4 to 25.6%.
Sulfatrimethoprim resistance in M. catarrhalis increased from 2.1 to
4.4%. Macrolide resistance in S. pyogenes throat isolates decreased from
4.9 to 2.2%.
Conclusion: Macrolide resistance in S. pneumoniae in Finland is at a
high level and is increasing while in other European countries the trend
seems to be decreasing. Also penicillin non-susceptible pneumococci
are prevalent. This development has major clinical consequences for the
treatment of respiratory tract infections. Pediatric pneumococcal vaccine
was introduced in Finland in 2010, and hopefully it has an effect on
the resistance trends. Macrolide resistance of S. pyogenes is at a low
level and has not changed markedly during the study period. Ampicillin
resistance in H. inﬂuenzae will be carefully monitored, because of the
increasing trend.
P1606 Risk factors for ﬂuoroquinolone-resistant Streptococcus
pneumoniae bacteraemia
M.C. Isea Pen˜a*, J. Esteban, R. Ferna´ndez Roblas, J. Sanz, B. Ramos,
M. Ferna´ndez Guerrero (Madrid, ES)
Objectives: Resistance of Streptococcus pneumoniae to ﬂuoro-
quinolones is rare but it is increasing. The aim of this study is
to determinate risk factors associated with development of resistance
against ﬂuoroquinolones among S. pneumoniae isolated from blood
cultures.
Methods: Review of cases of bacteremia caused by FQRSP from
January 2007 to April 2010 according to a previously designed protocol.
Susceptibility was studied following the CLSI standards. A randomly
selected group of patients with bacteremia caused by ﬂuoroquinolone-
susceptible S. pneumoniae (FQSSP) was reviewed with the same protocol
for comparative purposes as control. Fisher’s exact test and logistic
regression were used for statistical analysis.
Results: 17 cases of FQRSP bacteremia were found. An increasing
number of cases was observed during the study period. No differences
were found regarding age, sex or presence of chronic cardiac and
respiratory diseases. FQRSP isolates were commonly resistant against
other antimicrobials (macrolides, tetracyclines, chloramphenicol and
cotrimoxazole). Most isolates belonged to serogroup 8. Statistically
signiﬁcant risk factors for FQRSP were: previous admission to hospital
(RR 3,66; IC95 1,06−12,62; p = 0,036); reside in homeless shelters
(RR 4; IC95 1,40−11,42; p = 0,0080893321); previous treatment with
ﬂuoroquinolones (RR 7,23; IC95 1,57−33,37; p = 0,01) HIV infection
(RR 6,67; IC95 1,62−27,38; p = 0,012); chronic B or C hepatitis infection
(RR 5,51; IC95 1,54−19,71; p = 0,006) and alcohol intake (RR 4,34;
IC95 1,23−15;36; p = 0,019). No differences in mortality between both
groups of patients were detected.
Conclusions: Resistance of S. pneumoniae to ﬂuoroquinolones is an
emerging problem. Previous admission to hospital, ﬂuoroquinolone
treatment, reside in homeless shelters, HIV and Hepatitis B or C
infections and alcohol intake may be risk factors for FQRSP bacteremia.
P1607 Activity of ceftaroline and comparator agents tested against
organisms responsible for community-acquired respiratory
tract infections in Europe (2009)
M. Castanheira*, P. Rhomberg, R. Jones, H. Sader (North Liberty, US)
Objective: To evaluate the activity of ceftaroline (CPT) and comparators
against isolates from patients with community-acquired respiratory tract
infections (CARTI) in European (EU) medical centres. CPT, the active
component of the prodrug CPT fosamil, exhibits broad-spectrum activity
against Gram-positive organisms, including resistant (R) subsets of
methicillin-R S. aureus (MRSA) and penicillin (PEN)-R S. pneumoniae
(SPN).
Methods: 1085 consecutive, non-duplicate isolates from RTI (n = 942)
and blood cultures (n = 143, including; SPN and H. inﬂuenzae [HI]) were
collected in 2009 from 25 hospitals located in 13 EU countries. Isolates
included: SPN (n = 581; 16.4% PEN-R [MIC, 2mg/L]), HI (n = 292;
16.1% b-lactamase [BL] producers),M. catarrhalis (MCAT; n = 134) and
S. aureus (n = 78 [44.9% MRSA]). All isolates were susceptibility (S)
tested using reference CLSI broth microdilution methods against CPT
and comparators for RTI treatment.
Results: CPT inhibited all SPN, MCAT and HI isolates at 0.25, 0.25
and 0.03mg/L, respectively (Table). CPT was the most active b-lactam
tested against SPN (MIC50/90, 0.008/0.12mg/L), exhibiting 8-, 16- and
64-fold lower MICs than ceftriaxone (CRO; MIC50/90, 0.25/1mg/mL),
amoxicillin/clavulanate (A/C; MIC50/90, 1/2mg/mL) and cefuroxime
(MIC50/90, 1/8mg/mL), respectively. Against PEN-R SPN (n = 95),
CPT (MIC50/90, 0.25/0.25mg/L) was at least 4- and 8-fold more
potent than CRO (MIC50/90, 1/2mg/L) and A/C (MIC50/90, 2/8mg/L),
respectively. CPT was very active against HI (MIC90, 0.015mg/L)
regardless of BL production. BL-producing HI isolates showed CPT MIC
values slightly higher (MIC50/90, 0.015/0.03mg/L) than those of non-BL-
producers (MIC50/90, 0.008/0.015mg/L). CPT was very active against
MCAT isolates (MIC50/90, 0.03/0.12mg/L), most (>90%) BL-positive.
All methicillin-S S. aureus (MSSA) were inhibited by CPT at 0.5mg/L
and the highest CPT MIC among MRSA was only 2mg/L (MIC50/90,
1/2mg/L). Against MSSA, CPT (MIC50/90, 0.25/0.5mg/L) was 8- to 16-
fold more potent than CRO (MIC50/90, 4/8mg/L) and cefepime (CPM;
MIC50/90, 2/4mg/L), respectively.
Conclusion: CPT was the most active b-lactam agent tested and
demonstrated good coverage against contemporary (2009) CARTI
organisms recovered from EU hospitals. CPT showed excellent in vitro
activity against all PEN-R SPN, BL-producing HI and MCAT, MSSA
and MRSA isolates tested.
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P1608 Macrolide resistance in European isolates of Streptococcus
pneumoniae, 2009–2010
D. Hoban, M. Hackel, S. Bouchillon, J. Johnson*, R. Badal, S. Hawser,
M. Dowzicky (Schaumburg, US; Epalinges, CH; Collegeville, US)
Background: S. pneumoniae continues to be an important cause of
community acquired pneumonia and bacteremia globally. Macrolides
constitute an important ﬁrst or second line antibiotic choice for
community acquired SPN infections. This study describes the prevalence
of macrolide resistance in European SPN 2009/2010 and the activity
of relevant comparator antibiotics against Streptococcus pneumoniae of
various phenotypes.
Methods: 1086 clinical isolates of SPN were collected from European
countries between 2009 and 2010 from a variety of clinical sources
including blood and the lower respiratory tract. MICs were determined
and interpreted by broth microdilution according to EUCAST guidelines.
Results: The following table reports the percent susceptible and MIC90
(mg/L) of SPN including resistant phenotypes.
Conclusions: Linezolid, meropenem, tigecycline and levoﬂoxacin were
the most active agents against SPN including both penicillin and
macrolide resistant phenotypes with % susceptible >98%. In Europe in
2009–2010 28.8% of SPN were resistant to the macrolides azithromycin
or clarithromycin.
P1609 Trend of antimicrobial susceptibility among bacterial
isolates from RTI of Japanese hospital participating in the
levoﬂoxacin surveillance group during 1994–2010
Y. Keizo*, O. Akira, I. Yoshikazu, T. Kazuhiro for the Levoﬂoxacin
Surveillance group
Objectives: Fluoroquinolones (FQs) are widely used as antimicrobial
agents to treat respiratory tract infections (RTI). FQs resistance is
still very rare in Streptococcus pneumoniae, Streptococcus pyogenes,
Moraxella catarrhalis and Haemophilus inﬂuenzae. In the past several
years, however, FQs resistance in these organisms has been sporadically-
reported. We have already been taken nationwide surveillance for FQs
and other antimicrobial resistance against many bacterial clinical isolates
in Japan since 1994. In this study, we report surveillance data between
1994–2010 for the above four causative pathogens of RTI.
Methods: A total of 12,269 clinical isolates in 4 species were collected
from 92 centers participating in the Levoﬂoxacin Surveillance group
during 1994–2010 in Japan. Antimicrobial susceptibility testing by broth
microdilution methods was based on CLSI guidelines that were updated
annually as revised documents were published.
Results:
1. S. pneumoniae; The increase of resistance rate for levoﬂoxacin
was not recognized and ﬂuctuated at a low level of 1.03±1.34%.
Interestingly, MIC mode of ‘levoﬂoxacin-susceptible’ isolates was
0.5mg/mL until 2004 but was 1.0mg/mL since 2007. However, the
rate of isolates with one mutation in QRDRs did not differ between
isolates with MIC of 1.0mg/mL in 2004 and 2007. The rate of
‘Susceptible’ isolates for maclorides has rapidly decreased since 2002.
2. S. pyogenes; A high susceptible level to levoﬂoxacin, sitaﬂoxacin,
penicillin and cefdinir has been maintained during 1994–2010, in
contrast the susceptibility to macrolides has rapidly decreased since
2002.
3. M. catarrhalis; ‘Susceptible’ rate of almost 100% was maintained to
levoﬂoxacin, the advanced-generation cephalosporines, carbapenems
and maclorides during 1994–2010.
4. H. inﬂuenzae; Resistant isolate for levoﬂoxacin was not found or very
few if any. Macrolide resistance was slightly-increased since 2007.
The rate of BLNAR has rapidly increased from 20% in 2002 to 50%
in 2010.
Conclusions: Levoﬂoxacin continued to have still a high level activities
against S. pneumoniae, S. pyogenes, M. catarrhalis and H. inﬂuenzae,
and maintained one’s position of useful therapeutic medicine in RTI. It is
deeply concerned that the resistant rate of S. pneumoniae and S. pyogenes
for macrolides is rapidly increasing, because ﬂuoroquinolones and
b-lactams are not available for child and for patients with penicillin-
allergy, respectively.
P1610 Serotype distribution and antimicrobial susceptibility of
IPD-causing Streptococcus pneumoniae in the Comunidad
Valenciana, Spain during the winter of 2009–2010
C.M. Gant*, A.W. Rosingh, M. van der Heijden, E. Canton,
M. Gobernado, F. Gonza´lez-Mora´n, J.J. Bijlsma for the RedMiva
(Red Microbiologı´a Valencia)
Objectives: Streptococcus pneumoniae is a bacterium that can cause
serious invasive pneumococcal disease (IPD) such as meningitis and
pneumoniae and is cause of morbidity and mortality worldwide.
The bacterium produces a capsule, of which 90 serotypes exist.
After the introduction of the vaccine PCV7 that protects against 7
serotypes, a shift in IPD-causing serotypes has been observed worldwide
towards serotypes not included in the conjugate vaccine. Furthermore,
penicillin intermediate resistance increased in the years following PCV7
introduction, especially in these non-PCV7 serotypes. The ﬁrst objective
of this study was to determine the serotype distribution of IPD-causing
S. pneumoniae in Valencia, Spain, and thus determining the coverage
rates of the two new vaccines PCV10 and PCV13. The second objective
was to measure the antimicrobial resistance of these strains.
Materials and Methods: During September 2009 until March 2010, 285
S. pneumoniae IPD strains were collected in the 22 participating hospitals
in the Comunidad Valenciana and sent to the University hospital La Fe.
Serotyping was performed by serum slide agglutination (Denka Seiken,
Tokyo, Japan). Antimicrobial resistance proﬁles were determined using
E-tests.
Results: The serotype of 273 IPD strains of S. pneumoniae was
determined; 12 strains were not typable. The most common serotypes in
order of prevalence were: 19A (17,9%), 7F (13%), 1 (12,3%), 3 (9,1%)
and 22F (5,3%). The antimicrobial resistance proﬁle was determined of
203 strains. The majority of the strains (70,4%) was penicillin sensitive,
24,1% was intermediate resistant, and 5,4% was resistant. Seventy ﬁve
percent of the strains was erythromycin sensitive, and 10,8% of the
strains was resistant to levoﬂoxacin. None of the strains was resistant
to vancomycin, teicoplanin or linezolid. Compared to 2008, the number
of multi resistant strains has risen. Currently the genetic determinants
and molecular mechanisms underlying the antimicrobial resistance are
determined.
Conclusions: The serotype coverage of the newly developed vaccines in
Valencia (Spain) are: PCV7 9,9%, PCV10 35,9% and PCV13 71,8%. The
majority of the antibiotic resistant strains belongs to serotypes, which are
included in PCV13. The increase in multi resistant strains might indicate
possible increasing therapeutic difﬁculties These data implicate that
PCV13 might be a good option to include in the vaccination calendars
in the Comunidad Valenciana.
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P1611 Measurement of C-reactive protein velocity in febrile
bacterial infections and non-bacterial febrile illnesses
D. Koutete*, E. Koukou, I. Pilios, C. Karagiannis, S. Velakoulis,
P. Tsiodra, S. Pagoni (Xolargos, GR)
Objectives: C-reactive protein (CRP) is one of plasma proteins known
as acute-phase proteins (proteins whose concentrations increase during
inﬂammatory disorders). We hypothesized that measuring the velocity of
this biomarker instead of its absolute serum concentration could enhance
its ability to distinguish febrile bacterial infections from non-bacterial
febrile illnesses.
Methods: We prospectively studied 357 adult patients who presented to
the emergency department with fever. CRP velocity (CRPv) was deﬁned
as the ratio between CRP on admission and the number of hours since
the onset of fever. Patients were diagnosed by clinical symptoms, blood
cultures and imaging studies.
Results: A total of 357 patients met the inclusion criteria for the current
study, 236 (66%) of which were classiﬁed as having bacterial infection
and 121 (34%) as having a non-bacterial febrile illness. The mean age
of patients with bacteria infection was higher relative to patients with
non-bacterial febrile illness (62,6±18,4 vs 32,2±14,1 years, p< 0,001)
and 61% were women. Patients with bacterial infection had signiﬁcantly
higher CRP levels than those with non-bacterial infection (72,6mgr/dl vs
25,3mgr/dl, respectively p< 0,001). The febrile illness CRPv was also
signiﬁcantly higher in the bacterial group compared to the non-bacterial
(4,32mgr/dl/hour vs 0,56mgr/dl/h, respectively p,0,001).
Conclusion: CRPv is possible to improve the differentiation between
acute bacterial infections and non-bacterial febrile illnesses.
P1612 CSF LDH estimation to differentiate pyogenic and viral
meningitis and its role in tuberculous meningitis
T. John*, C. Ittycheria, J. George, C. Jacob, A. Jacob, A. George
(Kottayam, IN)
Background and Objectives: Acute infections of the central nervous
system are among the most important problems in medicine because
early recognition, efﬁcient decision making, identifying the responsible
pathogen and rapid institution of therapy can be life saving.
Aim was to ﬁnd out the role of CSF LDH in differentiating viral and
purulent meningitis and its role in TB meningitis.
Materials and Methods: CSF and serum LDH was estimated for
all patients admitted with a clinical triad of fever, headache and neck
stiffness with biochemical evidence of meningitis from 1/10/2008 to
1/09/2009.150 patients were included of which 50 had viral, 50 had
bacterial, 7 had tuberulous and 43 had partially treated meningitis.
Repeat CSF LDH estimation was done to assess the prognosis. Patients
with AIDP, ADEM, Carcinomatous meningitis, hemorrhagic lumbar
puncture, other organ dysfunction like hepatitis, hemolysis and renal
failure (which can cause a false elevation in serum LDH) were excluded
from the study.
Results: In bacterial meningitis, mean CSF LDH was 96.5 IU/L (normal
value was 20−30IU/L) and corresponding serum LDH was normal. In
viral meningitis the mean CSF LDH was 31.5 IU/L and when compared
to bacterial meningitis the mean value showed a standard deviation of
65.7 IU/L and this was statistically signiﬁcant. In tuberculous meningitis,
mean CSF LDH was 110 IU/L. This high value in TBM was statistically
signiﬁcant when compared to the viral meningitis and not statistically
signiﬁcant when compared to bacterial meningitis. The mean CSF LDH
in partially treated meningitis was28.9 IU/L. A reduction CSF LDH of
24.8 IU/L from the mean value was seen after treatment for 3 days and
this change was statistically signiﬁcant.
Conclusion: CSF LDH >35 IU/L has a high negative predictive value
to exclude the diagnosis of aseptic meningitis and even in aseptic
meningitis, a value above 35 IU/L has a positive predictive value of
75% to predict the chance of encephalitis. CSF LDH alone cannot
differentiate pyogenic and tuberculous meningitis. Reduction in CSF
LDH after treatment can be used as a prognostic marker, along with
CSF glucose.
P1613 Establishing the optimal breakpoints in cerebrospinal ﬂuid
cell counts for the diagnosis of secondary meningitis
B. Hilvering, A. Huisman, P.A. Woerdeman, M.J. Bonten,
M.B. Ekkelenkamp* (Utrecht, NL)
Background: Secondary meningitis is a frequent complication of
neurosurgical procedures. The diagnosis relies on clinical symptoms,
cerebrospinal ﬂuid (CSF) cell counts and biochemistry and CSF culture
results, all of which have limitations. In practice, the diagnosis is
established based primarily on CSF culture results and white blood cell
(WBC) counts, but no consensus exists on the adequate cut-off point
for the latter. This study intended (1) to establish an evidence based
WBC cut-off point for the diagnosis of secondary meningitis, and (2) to
determine the optimal CSF WBC correction factor for red blood cells
(RBCs) in the CSF.
Methods: Cases were patients with positive CSF cultures and a diagnosis
of secondary meningitis, controls were patients with >4 negative CSF
cultures, no positive CSF cultures at any time and no suspicion of
secondary meningitis. Receiver operating characteristic (ROC) curves
were constructed to determine the optimal WBC cut-off point to diagnose
secondary meningitis. The correction factor for RBCs was determined
from CSF samples with >1000 RBCs/mm3, drawn from patients who
did not suffer meningitis. Data were extracted from the microbiology
laboratory management and information system, from the Utrecht Patient
Oriented Database (UPOD), and from the patient charts.
Results: 134 cases and 34 controls (with 227 control CSF samples)
were included in the study. Median CSF WBC count was 380 in cases
with secondary meningitis, and 10 in controls. The WBC count was
signiﬁcantly higher in cases where secondary meningitis was caused
by Gram-negative micro-organisms. A sensitivity of 70% for secondary
meningitis could be achieved with a speciﬁcity of approximately 80%
applying a cut-off for CSF WBC counts of 90–100 WBCs/mm3. A
median of 1 WBC/443 RBCs was found in patients with an initial
CSF sample with >1000 RBCs/mm3; this ratio, however, declined in
subsequent CSF samples. Correction of the WBC count based on the
RBC count changed the cut-off points, but did not improve the test
characteristics.
Conclusion:WBC counts are useful in diagnosing secondary meningitis,
but understanding of the predictive value of different cut-off points is
necessary for adequate evaluation of patients.
P1614 CSF lactate level in diagnosis of bacterial meningitis
following neurosurgical intervention
A. Deveci, O. Acicbe, B. Avci, A. Ulus, F. Celik, N. Tulek* (Samsun,
Ankara, TR)
Objectives: Post-neurosurgical bacterial meningitis (BM) causes a high
mortality and morbidity rate. Diagnosis of bacterial meningitis is
complicated by several factor related to neurosurgical intervention. The
aim of this observational study is to investigate the value of cerebrospinal
ﬂuid (CSF) lactate level for the diagnosis of post-neurosurgical BM.
Methods: Fifty of CSF samples were collected from 23 patients with
clinical suspicion of post-neurusurgical bacterial meningitis for bacterial
culture, leukocyte count, glucose, protein and lactate level. Simultaneous
serum glucose concentration was also measured for determination of
CSF/serum glucose ratio. All patients were evaluated by Infectious
Diseases (ID) physicians for bacterial meningitis. Eleven of 23 patients
were diagnosed with BM and received anti-bacterial treatment. In the
study, we used a cutoff of >4mmol/L for the lactate level and <0.5 for
CSF/serum glucose ratio. BM was identiﬁed as pleocytosis and <0.5 of
CSF/serum glucose ratio in patients diagnosed with BM by ID physician
in the study.
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Results: Mean lactate levels were 4.28±2.08 and 2.94±1.00mmol/L
among patients with BM diagnosis and no BM diagnosis, respectively.
The difference of CSF lactate level between BM diagnosed and no BM
diagnosed patients was statistically signiﬁcant (p:0.008). CSF lactate
level had 88% sensitivity and 81% speciﬁcity in the diagnosis of post-
neurosurgical BM. Positive predictive value was 50% and negative
predictive value was %97. In addition, CSF lactate level had positive
correlation with leukocyte count in CSF (r:1.00) and negative correlation
with CSF/serum glucose ratio (r:-0.527).
Conclusion: Determination of lactate level in CSF is a sensitive, speciﬁc
test in diagnosis of post-neurosurgical BM.
P1615 Prospective study of diagnostic and prognostic signiﬁcance
of C-reactive protein in cerebrospinal ﬂuid in critically ill
patients in the intensive care unit
J. Nikolic*, A. Urosevic, A. Mitrovic, B. Milosevic, O. Dulovic
(Belgrade, RS)
C-reactive protein is one of the most frequently used acute-phase proteins
in clinical practice for patients with acute neuroinfections in emergency
departments. This marker facilitates initial diagnosis and enables prompt
presumptive treatment, since there are often no reliable clinical and
biochemical parameters.
The objective of this prospective study was to evaluate the role
of cerebrospinal ﬂuid (CSF) levels of C-reactive protein (CRP)
in differential diagnosis and management in patients with acute
neuroinfections. The study group included a total of 176 consecutively
admitted patients, treated at the intensive care unit of Clinic for Infectious
Diseases, Clinical Centre Serbia, from January 2009. to October 2010.
This population included 72 female (40.9%) and 104 (59.1%) male, with
average age of 52.4±19.8 years, who were classiﬁed in three subgroups
depending on the etiology of neuroinfections.
Levels of CSF were signiﬁcantly higher (3.9±3.2mg/l) in pa-
tients with bacterial neuroinfections, compared with viral neuroin-
fections (0.5±0.4mg/l) and culture-negative and viral-negative CSF
(1.8±1.07mg/l) (p< 0.05). There was a signiﬁcant positive correlation
between CSF levels of CRP and serum levels of CRP, ﬁbrinogen and
procalcitonin (p< 0.05). Cytological CSF ﬁndings, proteinorachia and
levels of CSF lactates were also higher in patients with elevated CSF
CRP. Although there was no signiﬁcant difference in recovery duration,
relative risk for mortality was higher in patients with elevated CSF CRP
(p< 0.05), especially in the subgroup of bacterial neuroinfections.
Routine detection of CRP in CSF in patients with bacterial and
aseptic neuroinfections is an inexpensive and useful tool for quick
orientation and decision upon empyrical treatment, which has proven to
be associated with other inﬂammatory markers and the clinical outcome.
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P1616 Predictive value of soluble urokinase plasminogen activator
factor in ventilator-associated pneumonia and sepsis
A. Savva, C. Routsi, G. Dimopoulos, A. Antonopoulou, M. Georgitsi,
E.J. Giamarellos-Bourboulis* (Athens, GR)
Objectives: Urokinase plasminogen activator (uPAR) is a receptor
expressed on neutrophils and NK cells. The role of its soluble form,
namely suPAR, as a predictor of sepsis outcome was investigated.
Methods: Blood samples were collected from 180 patients with
ventilator-associated pneumonia (VAP) and sepsis for seven consecutive
days; 47 with sepsis; 49 with severe sepsis; and 84 with septic shock.
suPAR was measured in serum by an enzyme immunoassay and PCT by
an immuno-time-resolved ampliﬁed cryptate assay.
Results: ROC analysis of day 1 measurements for prediction of death
is shown in the Figure. Mean suPAR of days 1, 2, 3, 4, 5, 6 and 7
among survivors was 9.1, 10.5, 10.7, 10.6, 10.5, 11.2 and 10.9 ng/ml
respectively; respective values among non-survivors were 14.1, 14.7,
15.1, 16.1, 18.1, 19.3 and 19.3 ng/ml.
Conclusion: suPAR is a strong predictor of unfavorable outcome in VAP
and sepsis probably superior than PCT. Serum concentrations remain
constantly elevated among non-survivors.
P1617 Panel or serial analyses of inﬂammatory markers do not
improve the prediction of bacteraemia compared with a
single determination of procalcitonin
M. Tromp*, B. Lansdorp, C. Bleeker-Rovers, J. KleinGunnewiek,
B. Kullberg, P. Pickkers (Nijmegen, NL)
Objectives: To evaluate the predictive value of single biomarkers,
biomarker panels, biomarkers plus clinical signs, and serial determi-
nations of biomarkers in the prediction of bacteraemia in emergency
department (ED) patients suspected of sepsis.
Methods: We performed a prospective, descriptive, single centre study
at the ED of a 953-bed university hospital in the Netherlands. Patients
(16 years old) visiting the ED because of a suspected infection with
two or more extended SIRS criteria were included.
Procalcitonin (PCT), interleukin-6 (IL-6), lipopolysaccharide-binding
protein (LBP), C-reactive protein (CRP), and two blood cultures
were taken in the ED. The analyses was divided into three steps:
(1) Determination of the best performing biomarker and the predictive
value of this biomarker in combination with the other biomarkers;
(2) Analysis of the best biomarker data plus clinical signs of sepsis;
(3) Analysis of serial data (3 days) of the best biomarker.
Single parameter analysis, multivariate logistic regression analysis,
and threshold analysis were performed. Receiver-operator characteristic
(ROC) curves were constructed, and the area under the curve (AUC),
sensitivity, and speciﬁcity were calculated. All values were reported with
the 95% conﬁdence interval (95%CI).
Results: A total of 342 patients were included in the study. Fifty-
ﬁve patients (16%) had bacteraemia. The most common causative
agents were E. coli (29%) and Streptococcus pneumoniae (23%).
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Biomarker levels were signiﬁcantly higher in bacteraemic patients
compared with those in non-bacteraemic patients (p< 0.001). PCT
had the best predictive value for bacteraemia with an AUC of 0.80
(95%CI: 0.75–0.84), sensitivity 89% (95%CI: 78−96%), speciﬁcity 58%
(95%CI: 52−64%), and an optimal PCT cut-off value of 0.253 ng/ml
(Figure 1). The predictive value of a combination of PCT plus a panel
of the other biomarkers (sensitivity 91%, speciﬁcity 63%), or clinical
signs (sensitivity 91%, speciﬁcity 57%), or analysis of serial PCT
levels (sensitivity 64%, speciﬁcity 73%) did not lead to a signiﬁcant
improvement of the predictive value of PCT alone.
Conclusion: The value of PCT to predict bacteraemia in patients with
sepsis does not further improve when combined with other biomarkers,
clinical signs, or serial measurements.
P1618 Evaluation of procalcitonin and sTREM-1 levels in early
diagnosis and monitoring of sepsis
H. Bayram, O. Tunger, M. Sakarya, H. Yuceyar, C. Ulman, G. Dinc,
C.B. Cetin* (Manisa, TR)
Objectives: Sepsis is still one of the major causes of morbidity
and mortality despite the improvements of diagnosis and treatment in
the modern medicine nowadays. Therefore, correct and rapid resulted
laboratory examinations are needed to support the diagnosis. This
study was planned to investigate the value of procalcitonin and soluble
triggering receptor expressed on myeloid cells-1 (sTREM-1) in the
differential diagnosis of patients with sepsis and SIRS and to measure
the importance of them in determining the prognosis of patients with
sepsis.
Methods: This prospectively planned study included total 74 patients,
41 patients with at least two SIRS criteria and 33 sepsis patients, ages
between 18 and 80 and hospitalized in Celal Bayar University hospital
in Manisa, Turkey between June 2008 and August 2009. Blood samples
were taken from SIRS patients at the 0 and 3rd day and from sepsis
patients at the 0, 3rd, 4th, 7th, 14th, 20th days and their clinical status
were made according to the SOFA scoring system.
Results: In the statistical evaluation of the results, both the SOFA
scoring system, and procalcitonin and sTREM-1 levels were observed
to be signiﬁcant in the differential diagnosis of sepsis and SIRS patients
(p< 0.05). When the predictive values for procalcitonin and sTREM-1
were considered respectively, 1,63 ng/ml and 199,72 pg/ml, sensitivity
and speciﬁcity were determined as 81,8% and 73,2% for both markers.
When the value of clinical and laboratory markers were statistically
evaluated in determining the prognosis of patients with sepsis, the SOFA
scoring system had been identiﬁed as the most signiﬁcant indicator.
Procalcitonin levels showed ﬂuctuations in patients with poor prognosis,
while sTREM-1 levels had a progressive increase. Sensitivity and
speciﬁcity rates of indicators were shown to be increased with longer
follow-up period.
Conclusion: As a result, in differentiation of sepsis and SIRS, as well
as evaluating the prognosis of patients with sepsis, procalcitonin and
sTREM-1 are signiﬁcant indicators.
P1619 Increasing yield and reducing contamination rates of blood
cultures: an audit at James Paget University Hospital,
January 2006 to December 2007
T. Chinniah*, T. Elumogo (Colombo, LK; Great Yarmouth, UK)
Objective: To assess the yield and contamination rate of blood cultures at
James Paget hospital between January 2006 to December 2007. Also to
compare yield, contamination rates and patient to blood set ratio before
and after intervention.
Methods: All blood cultures submitted were included in this study and
were incubated in a continuous monitoring system for 7 days before
discarding negative. On signaled positive, organism was identiﬁed by
conventional methods and grouped into potential contaminants, possible
contaminants and probable pathogens according to Weinstein et al. This
interventional audit was done in two phases.
Pre-interventional phase from January 2006 to October 2006 consisted
of 3572 adult and 823 paediatric sets. Interventions were introduced
from 1st of November 2006. Disinfectant swipes, blood culture bottles
and 20ml syringe were distributed as a pack with an instruction leaﬂet
on proper blood culture collection techniques. Junior doctors, nurses
and phlebotomists were actively and individually informed of their short
comings with feedback sent to each unit. Post interventional phase from
November 2006 to December 2007, consisted of 4724 adult and 977
paediatric sets.
Results: Though an increase from 21% to 24% among positive yield
was observed before and after intervention this was not statistically
signiﬁcant However, a reduction of potential contaminants (62% vs 56%,
p< 0.05) and an increase in yield of probable pathogens (27% vs 33%,
p< 0.05) for the adult sets were observed and shown to be statistically
signiﬁcant. The monthly average of adult blood culture bottles submitted
was reduced from 357 to 337 and the paediatric samples from 82 to
70 post intervention. These indicates better patient selection according
to the provided guidelines. The drop in numbers of paediatric samples
(31% vs. 9.5%, p< 0.001) may be explained by more accurate sample
collection post intervention by avoiding contamination.
Conclusion: The intervention adopted by James Paget hospital
demonstrates that inexpensive interventional methods will be adequate
to increase the yield of blood cultures and reduce the contamination by
normal skin ﬂora. It also shows that in adults where sample collection is
relatively easy, improving standards will increase the pathogen isolation.
The ﬁndings to contrary in paediatric group suggest that more difﬁcult
sample collection may overestimate the pathogen positivity due to
contamination.
P1620 Transport time for blood culture bottles: underlying factors
and their consequences
V. O¨zenci*, M. Mildh, M. Ullberg (Stockholm, SE)
Objectives: To measure and analyze transport times for blood cultures,
identify the factors for long transport time, and study which possible
consequences the transport time may have on detection of the sepsis
pathogens.
Methods: A total of 909 blood cultures from 10 clinics from 3 hospitals
were included in the study. Only one blood culture per patient was
included. Transport time was deﬁned as the time between the sampling
and the insertion of the bottle into the blood culture system. The impact
of the following factors on transport time were analysed: i) time and
day of sampling ii) clinic and hospital iii) the number of transports per
day and iv) laboratory working hours. Further analysis of effects of long
transport time on time to detection (from incubation to positivity in
the system) and on total time to detection (from inoculation at RT to
positivity in the system) were done by performing in vitro experiments
using standard inocula and 5ml human blood. Fifteen clinical isolates
were inoculated in BacT/ALERT system after various holding times of
2 h, 9,5 h, 19 h at room temperature (RT).
Results: The average transport time for blood cultures was 9,37 h (1,48 h,
10%tile and 18,35 h, 90%tile). The hospital where the microbiology
laboratory is located had the shortest transport time compared to others
(p< 0,0007). There was no difference in transport time between the
clinics in the same hospital. Similarly no difference was observed
between the days of the week. There was signiﬁcant difference depending
on sampling time on the same day. Samples taken between 16:00−24:00
had 6−9h longer transport time compared to samples taken between
8:00−16:00 or 24:00−08:00. Both the numbers of transports per day and
laboratory working hours were signiﬁcantly related to transport time. In
vitro experiments showed that the average time to detection is shorter for
the samples that were preincubated at RT for 19 h compared to the ones
preincubated for 2h or 9,5h (7,6 h vs. 16,7 h and 15,6 h respectively). In
contrast total time to detection was signiﬁcantly longer for the samples
that were preincubated at RT for 19 h compared to the ones preincubated
for 2h or 9,5h (27,9 h vs. 18,8 h and 25,0 h respectively).
Conclusion: Off-site location, time of sampling, numbers of transports
per day and laboratory working hours were signiﬁcantly related to
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transport time. The in vitro data shows that the growth of bacteria at
RT does not compensate the long transport time.
P1621 Differential time-to-positivity for the diagnosis of
catheter-related bloodstream infection: do we need to
obtain one or more peripheral vein blood cultures?
M. Guembe*, M. Rodrı´guez-Cre´ixems, C. Sa´nchez, P. Martı´n-Rabada´n,
E. Bouza (Madrid, ES)
Differential time to positivity (DTTP) for the diagnosis of catheter-
related bloodstream infection (CRBSI) requires blood cultures taken
from each catheter lumen to be compared with a blood culture obtained
by direct puncture of a peripheral vein.
Objectives: Our objective was to determine whether it is necessary to
obtain more than 1 peripheral blood culture in order not to miss CRBSI
episodes.
Methods: We performed a retrospective study in patients with
microbiologically proven CRBSI in whom catheter lumen cultures and
2 or more peripheral blood cultures were performed simultaneously. We
calculated the number of episodes that would have been recovered if the
culture of 1 or more peripheral blood samples had been eliminated.
Results: We collected 60 episodes of proven CRBSI from 58 patients
(Jan 1, 2006 to Jul 31, 2010). If 1 peripheral vein culture had been
eliminated in the patients with 2 or 3 peripheral blood cultures, we
would have recovered 91.8% (p = 0.362) and 96.9% (p> 0.999) episodes
of CRBSI, respectively. If we had eliminated 2 peripheral blood cultures
in patients with 3 peripheral blood cultures, we would have recovered
90.8% (p> 0.999) of episodes.
Conclusions: When performing DTTP to conﬁrm CRBSI, a single
paired blood culture obtained through a peripheral vein was has not
associated with a signiﬁcant number of missed CRBSI episodes.
P1622 Bloodstream infections related to Gram-negative rods. Use-
fulness of the Vitek2C System for direct identiﬁcation and
susceptibility testing from positive Bact-Alert blood cultures
R. Soloaga*, J. Pidone, M. Mendez Aranibia, M. Giovanakis,
A. Sujemecki, C. Bondulich, L. Guelfand, A. Margari, N. Carrion
(Buenos Aires, AR)
Objectives: To compare the result of identiﬁcation and antimicrobial
susceptibility testing obtained directly from the positive bottle of
the blood culture with those performed according to manufacturer
indications from isolated colonies and to determine the usefulness of
these results on the antibiotic initial election.
Methods: A prospective observational study was conducted in two
hospitals of Buenos Aires city (Argentina); 191 clinically signiﬁcant
monomicrobial Gram-negative bloodstream infections were included,
corresponding to 189 patients. The median patient age was 72.5 years
(range 1−94), 51% were males and 49% females.
Organism identiﬁcation and susceptibility results directly from the bottle
using serum separator tube (Becton Dickinson) to prepare the inoculum
were compared with those obtained from cards inoculated with a
standardized bacterial suspension obtained following subculture to agar.
Species identiﬁcation was carried out with the GNI card. Antibiotic
susceptibility testing was determined by the AST-82 card of the Vitek
2C System (Biomerieux, Marcy, France).
During the study period, a total of 191 clinically signiﬁcant isolates
of Gram negative-rods including 157 Enterobacteriaceae and 34
non.fermenting rods were tested.
Results: The blood culture positivization median time was 14.1 h (range:
2−71 h) and the median time to obtain the ﬁnal result of identiﬁcation and
susceptibility testing directly from the blood culture bottle by Vitek 2C
was 8.2 h (range: 3.75−18 h); by using the identiﬁes obtained from pure
cultures with the Vitek 2C System as reference method, the agreement
between the reference method and the Vitek 2C system tested directly
by using cultures of blood from patients was 99%. By antimicrobial
susceptibility test the overall categorical accuracy was 99%, with 0.21%
very major errors, 0.17% major errors and 0.61% of minor errors.
The overall 14-day mortality rate for all patients was 24.3%. Of the 189
bloodstream infections episodes, 108 (57%) received appropriate initial
empirical antibiotics.
After the results obtained directly from the bottle were reported,
antimicrobial therapy was changed in 116 (60.7%) of the bloodstream
infections episodes.
Conclusion: The identiﬁcation and antimicrobial susceptibility testing
results obtained directly from the blood culture bottles were reliable
and had an important impact in the election of the initial antimicrobial
treatment.
P1623 Comparison of three blood culture systems (Bactec
9240, Bact/ALERT 3D, and Versatrek) for blood cultures
involving delayed vial entry
S.Y. Ng*, S. Teh, T. Tan (Singapore, SG)
Objective: Accurate and timely detection of bacteraemia is important
in determining appropriate treatment of systemic sepsis. The use
of automated continuous monitoring equipment for blood cultures is
the current gold standard. This study simultaneously evaluated the
performance of three blood culture systems.
Methods: The equipment and blood culture media were provided
by representing vendors, and consisted of Bactec™ 9240 (Becton
Dickinson), BacT/ALERT 3D (bioMe´rieux) and Versatrek (Trek
Diagnostic). Multiple vials from each system were inoculated with
standard dilutions containing ATCC strains of Escherichia coli,
Staphylococcus aureus and Streptococcus pneumoniae, and wild-type
strains of Klebsiella pneumoniae, Streptococcus intermedius, methicillin-
resistant Staphylococcus aureus, Bacteroides fragilis, Candida glabrata,
and Candida albicans,. The performance of each system was evaluated
for multiple variables: 2ml inocula, 0.5ml inocula, delayed entry of
vials following retention of inoculated vials at 4ºC, 25ºC, and 35ºC for
14 hours. The time-to-detection (TTD) was monitored for all inoculated
vials.
Results: Some inoculated vials failed to ﬂag positive after incubation for
5 days (Bactec 2%, BacT/ALERT 3%, Versatrek 3%). For vials that were
incubated immediately following incubation, average TTD was lowest for
the Versatrek system (9.2 hours for Gram-negative bacilli, 12.6 hours
for Gram-positive bacteria, 18.0 hours for Candida spp. and 38.6 hours
for Bacteroides spp.). The Bactec system signiﬁcantly outperformed the
BacT/ALERT system for detection of Candida spp. (TTD 36.1 hours
compared with 68.7 hours), but performed worse for Bacteroides spp.
(TTD 95.7 hours compared with 43.3 hours). For vials with delayed
entry, the Versatrek maintained a lower TTD for all tested organisms.
Vial management and workﬂow was easiest for BacT/ALERT, followed
by the Bactec system.
Conclusion: The Versatrek system had the lowest TTD for all test
organisms in this evaluation for both immediate and delayed vial entry.
P1624 Performance analysis of blood culture and frequency of med-
ically important bacteria in 9 university hospitals in Korea
S. Kim*, J. Shin, N.Y. Lee, E. Kim, M.N. Kim (Jinju, Busan, Seoul, KR)
Background: Optimal blood culture performance is critical for
successful diagnosis and treatment of sepsis. To understand the status of
blood culture, we investigated several issues regarding the procedure at
nine university hospitals.
Methods: Ordering blood culture sets and sampling volume for adults
and children were investigated in Jan. through Apr. 2010, while positive
rate and growth of skin contaminants were compared in 2009. Microbial
growth in aerobic and anaerobic bottle was investigated prospectively.
The frequency of common pathogens was analyzed.
Results: Most of the hospitals used two sets of bottles in adults and one
bottle in children. The average blood volume of each set was 7.7mL
in adults and 2.1mL in children. The positive rate of microorganisms
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was 8.0%. The isolation rate of skin normal ﬂora was 2.1%. Bacterial
growth rates only in aerobic and in anaerobic bottles were 31.8% and
24.5% respectively.
Among about 40,000 microorganisms grown in 2009, the frequency of
S. aureus, E. faecium and CNS among G(+) cocci were 11.7%, 3.4%,
and 23.6% respectively. Among G(−) bacilli, E. coli, K. pneumoniae,
P. aeruginosa, and A. baumannii were isolated in 13.5%, 6.5%, 2.6%, and
2.6% respectively. The isolation rate of C. albicans was 2.3%, followed
by C. parapsilosis (1.7%), and C. tropicalis (1.3%).
Conclusion: Ordering of blood culture sets and sampling volume did
not comply with the Clinical Laboratory Standards Institute (CLSI)
guidelines. However, the rate of positive cultures and skin contamination
rate were acceptable. The anaerobic bottle was useful to enhance the
yield of microorganisms.
P1625 Nationwide survey of blood culture performance in Korea,
2010
S. Kim*, J. Shin, M.N. Kim, N.Y. Lee (Jinju, Busan, Ulsan, Seoul, KR)
Objectives: Blood culture is essential in the diagnosis of sepsis.
Although many laboratories have instituted the use of automated blood
culture systems, adequate skin disinfection and optimal volume of
sampling are major factors for successful blood cultures. Information
on positive rates and skin contamination rates, as well as knowledge of
optimal procedures, are requirements for the medical personnel.
Methods: The questionnaires included details on disinfection materials,
sampling intervals, and recommended blood volumes. Laboratory
personnel were asked about the equipment used and the storage place of
the sample before installation. For the quality control, the positive rates
and skin contamination rates were recorded.
Results: Answers to the survey were collected from 74 hospitals across
the country. Povidone iodine with either isopropyl alcohol (31.1–44.6%)
or ethanol (14.9–20.3%) was the most widely used skin disinfectant.
Sampling of the 2nd specimen was performed simultaneously in 38%,
within 30 min in 50%, and within 1 hr in 5%. The recommended blood
volume was predominantly 10mL (69%), whereas 24% of hospitals use
20mL. bioMerieux 3D was used at 54.1%, Becton Dickinson 9240 at
23.0%, and both at 10.8%. The bottles were stored at 37ºC in 23%
hospitals and at room temperature in 16% before installation, whereas
57% practice direct installation into the equipment. Positive rates were
8−10% at 32%, 5−8% at 23%, and <5% at 12%. Skin contamination
rates were 2−3% at 32%, 1−2% at 27%, and >3% at 13%.
Conclusion: Skin decontamination, including the type of disinfectant
used and the waiting time, varies among the hospitals. Sampling intervals
and volumes should be standardized. Positive growth rates and skin
contamination rates were acceptable.
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P1626 C-reactive protein is not a clinically useful predictor of
outcome in prosthetic joint infection
N. Gordon*, A. Berendt, I. Byren, B.L. Atkins, P. Bejon (Oxford, UK)
Objectives: Prosthetic joint infection (PJI) complicates up to 2.5%
of arthroplasties. Management is usually with surgical removal or
debridement followed by antibiotics. Measurement of C-reactive protein
(CRP) is often used to monitor response to treatment. However, there are
no data on its use in this context. In this study, we analysed CRP data
from patients treated by debridement, antibiotics and implant retention
(DAIR) or by two-stage revision for PJI, to determine its usefulness in
predicting treatment failure.
Methods: Retrospective data were collected for patients with PJI
managed either by DAIR (n = 109) or by two-stage revision (n = 151).
CRP data were analysed in four datasets: (1) DAIR patients during the
ﬁrst 180 days; (2) DAIR following the ﬁrst 180 days, using time to
treatment failure or to the end of follow up; (3) two-stage revision
patients during the ﬁrst 120 days after the 1st stage and (4) two-
stage revisions after re-implantation, excluding the ﬁrst 28 days post
re-implantation.
Results: During the ﬁrst 180 days after DAIR, CRP readings were 57%
higher (95%CI 7% to 200%, p = 0.02) in the group who ultimately
experienced treatment failure. There was no signiﬁcant change in CRP
over time in patients without failure, but a signiﬁcant increase over time
in subjects who did experience failure (15% per month, 95%CI 6% to
25%, p = 0.006).
During two-stage revision, the CRP between 1st stage excision and re-
implantation was not signiﬁcantly different between patient groups, but
there was a 2% increase per month following re-implantation (95%CI
−3% to +7%) in patients with treatment failure. However, there was wide
scatter of CRP results within all datasets, and hence CRP was poorly
predictive of outcome despite the association observed (areas under the
receiver operator curve (AUROC) were 0.6, 0.65 and 0.55 for the ﬁrst
180 days of DAIR, DAIR after 180 days and two-stage revision after
re-implantation respectively).
Discussion: CRP weakly predicted eventual treatment failure of DAIR
but not two-stage revision in the immediate post-operative period.
However, the sensitivity and speciﬁcity reﬂected by AUROC analysis
suggest that the overall association with outcome is weak. Caution should
be exercised when interpreting results: a high CRP in the absence of
other clinical signs is not an important measure of treatment failure and
conversely, clinicians should not be falsely reassured by a falling CRP
when other features suggest complications.
P1627 Is prosthetic joint vortexing/sonication effective in aseptic
failure?
M. Fernandez-Sampedro*, C. Salas-Venero, C. Farin˜as-Alvarez,
S. Plaza Garcia, M.A. Alonso-Aguirre, M.B. Busta-Vallina, F. Figols,
J. Gomez-Roman, L. Martinez-Martinez, M.C. Farin˜as (Santander, ES)
Background: It has been shown that sonication of prosthetic joints
is more sensitive than peri-implant tissue culture for diagnosis of
prosthetic joint infection (PJI). Herein, we study whether sonication
improves the microbiological diagnosis in implants removed due to
aseptic failure (AF). We also evaluated the relative frequencies of
deﬁnitive diagnosis of PJI in the postoperative period among patients
with pre-and intraoperative diagnosis of AF.
Methods: From February 2009 to November 2010 all consecutive
patients undergoing partial or total removal of hip or knee implants
due to AF were included. Pre-operative AF was deﬁned when the
patient had radiological signs of loosening without symptoms or signs
of infection; intraoperative diagnosis was conﬁrmed in the absence of
purulence or sinus tract. Deﬁnitive PJI was based on histopathological
criteria. The retrieved implants were vortexed, sonicated (40 kHz, 5
minutes) in 400ml Ringer solution and concentrated. Microorganisms
were deﬁned as causative if 2 peri-implant tissues were positive for
the same organism and sonicate ﬂuid culture 100 cfu on either plate.
Results: A total of 139 patients were studied; 20 had PJI (Hip 18, Knee
2) and 119 AF (Hip 73, Knee 46). All pre-and intraoperative AF patients
with deﬁnitive PJI had 10 cells per high power ﬁeld in frozen sections.
75% (15/20) of PJI and 55% (66/119) of AF were partial removal (p=
0.1). The median age was 69 years. Sensitivities of peri-implant tissue
and sonicate ﬂuid cultures were 40% and 75% (p= 0.025), respectively,
and the speciﬁcities were 98% and 97%, respectively. Coagulase negative
staphylococci was the most frequent microorganism detected by both
peri-implant tissue 62.5% (n = 5) and sonicate ﬂuid 73% (n = 11) cultures.
Conclusion: Fourteen percent of the patients with pre- and intraoperative
suspicion of AF had a deﬁnitive diagnosis of PJI. Patients undergoing
partial removal due to AF were more likely to have deﬁnitive PJI. Implant
sonication followed by culture was more sensitive than peri-implant
tissue culture for the microbiologic diagnosis of PJI.
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P1628 Improving the diagnosis of prosthetic joint infection by
prolonged culture of periprosthetic tissues
A.L. Skovby*, N. Bjørslev, M. Andersen, J.J. Hvolris, A. Friis-Møller
(Hvidovre, Bispebjerg, DK)
Objective: To clarify if prolonged bacterial culture from 5 to 12 days of
periprosthetic tissue samples from prosthetic joint revision surgery would
result in a better bacteriological diagnosis of prosthetic joint infection
(PJI).
Methods: All patients from the departments of Orthopedic Surgery at
Bispebjerg and Hvidovre Hospitals, Copenhagen DK, from the period
June 2008 to July 2010 with positive periprosthetic tissue samples were
included in the study. The patients had undergone revisions of hip or knee
arthroplasty and 5 sterile tissue samples were taken during operation.
Tissue samples were immediately transported to the Department of
Clinical Microbiology, Hvidovre Hospital, servicing both orthopedic
departments, and processed: Gram stain, aerobic and anaerobic cultures
on 5% horse blood agar, anaerobic agar and in semi-solid thioglycolate,
which were inspected daily for ﬁve days or until growth whereupon
classic microbiological diagnosis and sensitivity testing were made.
Positive results were immediately reported to the clinicians. Negative
ﬁnal results were reported on day 5 and the samples from the semi-solid
thioglycolates were subcultered onto 5% horse blood agar and anaerobic
agar for further 7 days. The plates were evaluated on day 12 and only
positive growth results were reported to the clinicians. Two or more
samples with growth of identical isolates were used as a deﬁnition of
infection.
Results: During the two year period the two orthopedic departments did
371 revisions of hip and knee arthroplasty suspected for PJI.
A total of 317 revisions (279 patients) were positive with growth of one
to ﬁve tissue samples.
237 revisions of hip arthroplasty were positive and of these 153 in two
or more samples: 136 (89%) were positive on day 5 and 17 (11%) on
day 12.
Of 80 revisions with positive samples after revions of knee arthroplasty
60 had growth of two or more samples: 55 (92%) on day 5 and 5 (8%)
on day 12.
The most often isolated bacteria after 12 days were slow growing and low
pathogenic bacteria as coagulase-negative staphylococci, enterococci,
Corynebacterium species and anaerobes but also S. aureus and
Streptococcus species.
Conclusions: The prolonged culturing of periprosthetic tissue samples
from revision of hip and knee arthroplasty increased the number of
patients with a conﬁrmed bacteriological diagnose with approx. 9%. The
strategy is easy to implement, it improves the diagnosis of PJI and makes
the choice of antimicrobial treatment more relevant.
P1629 Three different ways of processing samples from sonication.
Which is the best to improve diagnosis of infected
orthopaedic devices?
E. Cuchi*, A. Matamala, D. Haro, L. Go´mez, G. Mun˜oz, S. Quintana,
J. Perez, F. Angle´s (Terrassa, ES)
Background: Diagnosis of infection in orthopedic implants remains
difﬁcult. Sonication of orthopedic devices (OD) seems to improve the
isolation of bacteria causing infection.
Objective: To evaluate 3 different methods of processing samples
obtained from sonication compared to standard cultures of tissue
samples (TS).
Methods: All patients who had orthopedic sugery for removal of an
OD were included (Oct 2009-July 2010). None of the patients received
antibiotics in the previous 14 days. Standard samples from bone, synovial
ﬂuid, synovial membrane, bone interface and cement were collected
in the surgical procedure, as well as OD (prosthesis, spacers, internal
ﬁxation devices) and they were sent for sonication and for conventional
cultures. Standard TS were inoculated in solid aerobic and anaerobic
media and thioglicolate broth was incubated for 5 days in standard
conditions; systhematic subculture of thioglicolate broth in solid media
was done for another 5 days.
Sonication: OD were sent in sterile containers to the lab, where 500 cc
of Ringer lactate solution was added; samples were vortexed for 30′′,
then sonicated at 50 kHz for 5′ and vortexed for 30′′. The solution
obtained after sonication was processed in 3 different ways: A, 10mL
were centrifuged at 2500 rpm for 5′ and the culot was cultured in the
same way as standard TS; B, 10ml were incubated for 24 h at 37ºC and
were processed as A, and C,10ml were incubated in a blood culture
bottle (Bactalert®) for 5 days.
Diagnosis of infection was based on clinical data and 2 standard positive
intraoperative cultures for the same bacteria; results of sonication were
not known by the orthopedic surgeon.
Sensitivity, speciﬁcity, positive predictive value and negative predictive
value were calculated.
Results: 34 surgical procedures in 29 patients were analysed [17 knee
prosthesis, 5 hip prosthesis, 6 cement spacers and 6 internal ﬁxation
devices]. 224 surgical TS were processed (median 7.7 samples/surgery),
and 46 were from sonicated devices. 12/34 (35%) episodes had diagnosis
of infection (9 knee arthroplasty, 3 hip arthroplasty) with a median
number of positive cultures of 4.9. 22/34 (65%) of episodes had
no infection (median number of positive cultures 0.8). Results are
summarized in the table.
Conclusions: (1) NPV of direct sonicated samples are higher than
standard culture TS. (2) Additional methods of processing sonicated
samples do not contribute to improve the diagnosis of infected OD.
P1630 Predictive value of surface cultures in tunnelled
haemodialysis catheter-related bloodstream infections.
Do they select a low-risk population?
E. Bouza*, L. Rojas, M. Guembe, M. Marı´n, F. Anaya, J. Lun˜o,
J. Lo´pez, P. Mun˜oz on behalf of the Colonized Catheter in Hemodialysis
(COCADI) Study Group
Hemodialysis catheter-related bloodstream infection (H-CRBSI) is one
of the most frequent causes of sepsis in hemodialysis patients and is
associated with high morbidity, mortality, and cost.
Objectives: To evaluate the positive predictive value (PPV) and negative
predictive value (NPV) of surface (skin and hub) Gram stain and culture
to anticipate dialysis catheter exit-site infection (ESI) and H-CRBSI and
to assess risk factors of catheter infection.
Methods: We performed an observational, prospective cohort study over
a 9-month period (March 1 to October 30, 2010). We studied 115
catheters from 95 patients with chronic kidney failure on hemodialysis
and 3 patients on apheresis with tunneled catheters. We performed
surveillance surface cultures (semiquantitative cultures of swabs taken of
the skin around the catheter exit site and of the catheter hubs) every 15
days for 6 months. Patients with 15 cfu/ml in any of the cultures were
considered colonized. Patients were followed for 9 months. The primary
endpoint was development of catheter infection (ESI and/or H-CRBSI).
Results: During the study period, 1845 surface cultures (615 cultures of
skin and each hub) were performed. Colonization was detected in 267
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(42.2%) skin samples, 14 (2.28%) venous hubs, and 7 (1.14%) arterial
hubs. Gram-positive microorganisms predominated (76.4%), especially
coagulase-negative staphylococci. There were 17 episodes of ESI and 6
of H-CRBSI, with an incidence density of 1 and 0.35 episodes per 1000
catheter-days, respectively. H-CRBSI mortality was 16.7%.
The efﬁcacy of Gram stain for anticipating ESI/H-CRBSI was as
follows: sensitivity (S), 94.1%/66.7%; speciﬁcity (SP), 33.3%/28.3%;
PPV, 22.9%/5.7; NPV, 96.4%/92.9%; positive likelihood ratio (PLR),
1.4/0.9; negative LR, 0.2/1.2; and accuracy, 43.9/30.6. The efﬁcacy
of surface cultures for anticipating ESI/H-CRBSI was as follows: S,
100%/100%; SP, 43.2%/38%; PPV, 27%/9.5%; NPV, 100%/100%; PLR,
1.8/1.6; NLR, 0/0; and accuracy, 53.1/41.8. Among the 63 colonized
patients, the risk factors associated with ESI or H-CRBSI were coronary
disease, a high number of positive surface cultures, a high number of
catheters replaced, and skin site injury.
Conclusions: Periodic surveillance cultures of the skin and hubs of
patients with hemodialysis catheters can identify a population at higher
risk of infection amenable to preventive or anticipative therapeutic
measures.
P1631 The role of Gram staining in the rapid diagnosis of
tunneled central venous catheter colonisation
M. Guembe*, P. Martı´n-Rabada´n, A. Echenagusia, F. Camu´n˜ez,
G. Rodrı´guez Rosales, G. Simo´, M. Echenagusia, E. Bouza (Madrid, ES)
Gram staining of catheter tips from withdrawn non-tunneled central
venous catheters (CVCs) is very useful for anticipating catheter
colonization or central line-associated bloodstream infection (CLABSI)
(Bouza et al., DMID, 2006, 56 [255–256]). No similar data are available
for tunneled catheters.
Objectives: Our objective was to deﬁne the validity values of Gram
staining for the prediction of colonization and CLABSI in patients with
tunneled CVCs.
Methods: All tunneled catheters removed in our institution were
prospectively and routinely sent to the microbiology laboratory for Gram
staining (ﬁrst) and tip culture (Maki and sonication in a random order).
Breakpoints for positive culture were as follows: roll-plate technique
(Maki), 15 cfu/plate; tip sonication 100 cfu/plate. CLABSI was
deﬁned as isolation of the same microorganism in both peripheral blood
culture and catheter tip culture.
Results: We received 111 tunneled catheters of which 25.2% were
colonized. The microorganisms isolated in the colonized catheters were
Gram-positive (66.7%), Gram-negative (24.2%), and fungal (9.1%).
Of all withdrawn catheters, 8 (7.2%) were from bacteremic patients.
The validity values of Gram staining for detecting colonization and
CLABSI were as follows: sensitivity, 32.1% and 50.0%; speciﬁcity,
100% and 95.1%; positive predictive value, 100% and 44.4%; and
negative predictive value, 81.4% and 96.1%.
Conclusion: Gram staining of catheter tips from withdrawn tunneled
CVCs is highly predictable of colonization. Negative results rule out
CLABSI.
P1632 Is it possible to know whether candidaemia is caused by
catheter-related infection without having to remove the
catheter?
M. Rodrı´guez-Cre´ixems*, L. Alcala´, P. Mun˜oz, P. Martı´n-Rabada´n,
M. Guembe, E. Bouza (Madrid, ES)
CDC guidelines recommend withdrawing the catheter in patients with
candidemia when there is evidence that the catheter is the source of
infection. However, data regarding minimal time to positivity (MTTP),
proportion of positive blood cultures (BC) (in patients with two or three
BC drawn), and differential time to positivity (DTTP) from BCs obtained
from the catheter and peripheral veins have not been properly assessed
in patients with candidemia.
Objectives: Our objective was to compare MTTP, the proportion of
positive BCs, and DTTP in patients with well-demonstrated catheter-
related candidemia (C-RC) and non-catheter-related candidemia (NC-
RC).
Methods: We included patients with a catheter tip culture performed
within 7 days after the episode of candidemia (July 2005 to August
2010). An episode was considered C-RC only when there was a positive
catheter tip culture (15 cfu/plate) with the same Candida species. An
episode was considered NC-RC when there was no evidence of Candida
species in catheter tip culture. For each variable evaluated, a ROC curve
was created to determine the best cut-off for predicting C-RC.
Results: We retrospectively collected a total of 108 episodes of
candidemia (84 in adults and 24 in children; 67 C-RC and 41 NC-
RC) fulﬁlling our enrolment criteria and caused mainly by C. albicans
(49.1%) and C. parapsilosis (30.6%). Values for the different tests are
shown in the table.
Conclusions: None of the tests evaluated allows for a clear-cut
prediction of C-RC, and criteria accepted for bacteremia should not be
automatically extrapolated to candidemia. In our study, a low proportion
of positive blood cultures with Candida had a high negative predictive
value for a catheter origin.
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P1633 Nosocomial infections, emerging MDR pathogens and
antibiotic prophylaxis in cardiothoracic surgery: clinical
surveillance study at Lancashire cardiac centre, UK
K. Al-hadid*, L. Moorhouse, A. Guleri (Blackpool, UK)
Background: Guidelines recommend use of prophylactic antibiotics to
decrease the risk of post operative infections. Lancashire cardiac unit
is a tertiary centre located in Blackpool. We present ﬁndings from
a comprehensive retrospective surveillance study over 12-months to
examine the association between emergence of multi-drug pathogens,
apparent rise in post operative infections, C. difﬁcile infections
and variations in practices of antibiotic prophylaxis between cardiac
surgeons.
Methods: Retrospective review [April 2009 − March 2010] of
cardiac surgery and pathology database to establish patients with
clinically signiﬁcant post operative infections;Further case notes review
of randomly identiﬁed 50 patients with prolonged infections, re-do
operations due deep infection, and death with infection.
Results: 1096 patients underwent elective/urgent cardiac surgery during
Apr09-Mar10. 280 patients [electives − 160; urgent − 120] had 503
specimens cultured for suspected infection. 58%[294/503] samples had
signiﬁcant pathogen. Mortality was 5%[14/280]. 8 cases of CDI and
nil MRSA bacteraemia. Details of infections [UTI, sternal/soft tissue
infections, line infections, pneumonia, bacteraemia & others] with
etiological agents to be presented. Multidrug resistant Pseudomonas
aeruginosa, Serratia marcescens and Stenotrophomonas maltophilia
isolated from cases with pneumonia and empyema.
Antibiotic prophylaxis: The eight surgeons vary in the choice, single/
combination and duration of prophylactic antibiotic. Cefuroxime at
1.5g/0.75g at induction followed by IV 0.75g ×3-doses to removal of
central line/d3. Teicoplanin [800mg q24h ×3 doses till d3] used in
combination by one surgeon.
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Conclusions: Most guidelines on antibiotic prophylaxis in surgery
recommend single or 24h use of antibiotic. The choice is based on type
of surgery, likely pathogens, and local resistance.
A recent audit on antibiotic prophylaxis in cardiac surgery across cardiac
units in UK revealed a shift away from use of cephalosporins to a
single dose or 24hr use of Flucloxacillin±gentamicin in most centres.
This change in practice may be secondary to increased concern about
emerging multi-resistant pathogens, CDI rates, antibiotic stewardship and
surgical site infections linked to surgeon performance indicator. The
ﬁndings from this study have been used to inform an action plan &
strategy including revision of antibiotic prophylaxis guide, skin prep
audit, microbiologist ward rounds, etc.
P1634 Perioperative statin for the prevention of infectious
complications in patients who undergo neurosurgery
S. Shokouhi*, G. Shariﬁ, L. Gachkar, A. Amirsardari, M. Samadian,
A. Aliasgari (Tehran, IR)
Objectives: Controversies exist in the results of studies on the effect of
statins (as an immunomodulator) for the prophylaxis of postoperative
infections. The aim of this study was to determine the efﬁcacy of
preoperative treatment with lovastatin in the prevention of neurosurgical
infections.
Methods: A randomized controlled trial was conducted at Loghman
Hakim hospital of Shahid Beheshti University of medical sciences,
Tehran-Iran. Patients with indication of elective neurosurgeries (we
excluded emergency surgeries & surgeries because of infectious causes)
were randomized to receive lovastatin 20mg for 4 days (1 day prior
to surgery & 3 days after that) or placebo. The primary outcome
measure was the occurrence of a postoperative infectious complication,
including: surgical site infections, Different kinds of central nervous
system infection, nosocomial infections & bacteremia. All the patients
has been followed up and seen by a doctor, everyday in the admission
period & days 10, 30, 60, 90, 180 after surgery.
Results: A total of 224 patients (110 male, 114 female; mean
age 42.1±16.7 years) were enrolled. None of the patients in the
lovastatin group developed a postoperative infection, while 9 infectious
complications (7.0%) (3 pneumonias & 6 meningitis) were found in the
control group which is statistically signiﬁcant (p = 0.011).
Conclusions: The use of lovastatin was associated with a decrease in
infections complicating neurosurgeries. Larger trials are warranted to
conﬁrm these results.
P1635 Risk factors affecting the incidence of infection after
orthopaedic surgery: the role of chemoprophylaxis
A. Masgala*, E. Chronopoulos, G. Nikolopoulos, J. Sourlas, E. Brilakis,
S. Lallos, J. Lazarettos, S. Soultanis, N. Efstathopoulos (Athens, GR)
Objectives: The incidence of surgical site infection (SSI), and urinary
tract infection (UTI) following orthopaedic procedures, has extremely
diminished during recent decades due to modern antibiotic prophylaxis.
Risk factors associated with SSI include obesity, diabetes mellitus,
rheumatoid arthritis, increased American Society of Anesthesiologists
(ASA) risk index score (3), whereas female sex, number of days of
urinary catheterization and inappropriate catheter management seem to
affect the risk of UTI (2).
Methods: We conducted a case-control study (100 cases, 100 controls)
in order to evaluate the risk factors associated with infection after
orthopaedic procedures. As risk factors were deﬁned: gender, age,
comorbidities [rheumatoid arthritis, diabetes mellitus, obesity (>30
kg/m2), peripheral vessel disease], pre- and post-operative glucose levels,
the pre-operative and the post-operative length of stay (days), the
duration (days) of urinary catheterization, the type of parenteral antibiotic
prophylaxis (cefotaxime or vancomycin), the time of surgery (elective
or scheduled), the ASA score (0−3), the type of surgery (fracture
osteosynthesis, joint replacement, spinal surgery, other), and the type
of anesthesia administered (general, epidural, spinal).
Results: Among cases, 71 had an UTI, 15 had a SSI, 10 developed
pneumonia, 1 patient had a SSI plus UTI, while the remaining 3 cases
experienced other kind of infection.
The univariable logistic regression model revealed the following
signiﬁcant predictors (p< 0.10) of post-operative infection: age, obesity,
ASA score, the duration of urinary catheterization, the anatomical
location of the surgical procedure, the type of anesthesia and the kind
of the chemoprophylactic regimen. However, in multivariable modeling,
only the type of chemoprophylaxis retained the statistical signiﬁcance.
More speciﬁcally, cases were almost 60% less likely (OR: 0.41; 95%CI:
0.19–0.89) to have received vancomycin as prophylaxis rather than
cephalosporin compared with the control population.
Conclusion: UTI was the most frequent infection after orthopaedic
procedure in our study following by SSI. Although many factors
were signiﬁcantly associated with post-operative infection in univariate
analysis, only the kind of chemoprophylaxis remained a statistically
signiﬁcant predictor in multivariable modeling. More speciﬁcally, the
use of vancomycin, instead of cephalosporin, is associated with a lower
risk of infection.
P1636 Associations between operative site microbial counts and
procedure classiﬁcation in neurosurgery
I. Kourbeti*, S. Tsiodras, S. Maraki, D. Karabetsos, C. Neophytou,
M. Filippou, A. Ioannou, A. Vakis (Chalkida, Athens, Heraklion, GR)
Objective: Correlation between operative site skin bacterial counts in
neurosurgical procedures and the development of surgical site infections
(SSI) has not been proven. We evaluated the association of bacterial
Colony Forming Units (CFU), type of procedure and development of
SSI in a prospective pilot study.
Methods: Skin swab cultures were obtained within 1 cm from the
incision;pre-,post-preparation and preclosure samples were obtained.
Bacterial counts were enumerated and the most prevalent organisms were
recorded. Procedures were classiﬁed as clean, clean with a foreign body,
clean contaminated, contaminated and dirty.
Results: 157 procedures (43.9% clean, 19.1% clean-contaminated,
26.1% clean with foreign body, 7.6% contaminated and 3.2% dirty) in
118 patients (62.4% male) were evaluated prospectively. 38.9%patients
were hospitalized in the ICU. Oncology and trauma were the most
common reasons for surgery (28% and 26.8% respectively). 157 sample
sets were cultured. 85.4% pre-prep,27% post-prep and 43.9% of
the preclosure samples tested positive. Coagulase-negativestaphylococci
(CoNS) were the most frequently isolated organisms irrespectively
of sampling time (65%, 17.8% and 27.4% for samples 1, 2 and 3
respectively) and independently of procedure classiﬁcation followed by
P. acnes. The median cfu count log for CoNS were 2.97log (IQR 2.47–
3.73), 2.48 (range 2–2.76) and 2.47 (IQR 2–2.69) respectively for each
sampling.P. acnes was the second most frequentpathogen isolated. The
median cfu count log for P. acnes were 4.25log (IQR 3–4.58), 2.87
(IQR 2.48–3.43) and 4.3 (IQR 3.35–4.69)respectively for each sampling.
There was a signiﬁcant difference in rates of pathogens in preprep
samples for the head compared to other sites (OR 2.9,p= 0.028). The
same was true for the P. acnes isolated from head versus other sites for
preprep and postprep samples (OR 5.2, p = 0.01 and OR 1.16, p = 0.024
repectively). Procedure classiﬁcation or prolonged surgery duration were
not associated with microbial counts irrespectively of sampling time. SSI
development was not associated with bacterial CFU at any sampling but
with ICU stay (p< 0.001).
Conclusion: CoNS and P. acnes were the most frequent bacterial
pathogen cultured irrespectively of sampling. The pathogen cfu log did
not signiﬁcantly differ among the samples. P. acnes isolation correlated
with head specimens. Procedure classiﬁcation was not associated with
microbial skin counts at any sampling. SSI was associated with ICU stay.
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P1637 Gram-negative bacillary meningitis in post-neurosurgical
patient associated with high mortality
C. Moon*, J. Lee, J. Shin, M. Kim (Busan, KR)
Objectives: Widespread use of antibiotics and the increasing frequency
of neurosurgical procedures have altered the epidemiology of post-
neurosurgical meningitis in recent years. Gram-negative bacillary
meningitis (GNBM) has become increasingly common. We investigated
the changing etiology and outcome of GNBM in post-neurosurgical
patients at our center.
Methods: All patients with culture-proven post-neurosurgical meningitis
diagnosed between January 2006 and November 2010 were retrospec-
tively reviewed.
Results: Fifty-four episodes of culture-proven meningitis were reviewed.
A total of 66 isolates were identiﬁed from cerebrospinal ﬂuid.
Gram-negative bacilli (41 isolates) were Acinetobacter baumannii (16,
39.0%), Pseudomonas aeruginosa (8, 19.5%), Stenotrophomonas spp.
(4, 9.8%) and Klebsiella pneumoniae (3, 7.3%). Glucose non-fermenting
organisms accounted for 78.0% of the total Gram-negative bacilli. Gram-
positive cocci (25 isolates) were coagulase-negative staphylococci (10,
40%) and Staphylococcus aureus (9, 36.0%). The resistance rate of
Gram-negative bacilli to ceftazidime, cefepime and meropenem were
70.7%, 48.8% and 41.5%. Compared to the patients with meningitis
caused by Gram-positive cocci, those with GNBM had a higher incidence
of neurologic complication (74.2 vs. 30.4%, p = 0.001) and in-hospital
mortality (54.8 vs. 30.4%, p = 0.065). The mortality from GNBM was
signiﬁcantly associated to the carbapenem resistance (p = 0.044) and
inappropriate antimicrobial therapy (p = 0.042).
Conclusion: GNBM in post-neurosurgical patient showed a higher
mortality than previous studies. Carbapenem resistance of GNBM is
signiﬁcantly increasing during relatively short period. Adequate use of
antibiotics and effective infection control program is needed in post-
neurosurgical patients.
P1638 Risk factors for mesh-related infections after hernia repair
surgery: a meta-analysis of cohort studies
M. Mavros*, S. Athanasiou, V. Alexiou, P. Mitsikostas, G. Peppas,
M. Falagas (Athens, GR)
Objective: Mesh infection, although infrequent, is a devastating
complication of mesh hernioplasties. We aimed to systematically review
and synthesize the available evidence on risk factors for synthetic mesh
infection post-hernioplasty.
Methods: A systematic search was performed in PubMed and Scopus
databases. The extracted data were synthesized with the methodology of
meta-analysis.
Results: We identiﬁed 6 eligible studies, reporting on 2418 mesh
hernioplasties. The crude mesh infection rate was 5%. Statistically
signiﬁcant risk factors were smoking (risk ratio [RR]=1.36 [95%
conﬁdence intervals: 1.07, 1.73]), American society of anesthesiologists
(ASA) score 3 (RR=1.40 [1.15, 1.70]), and emergency operation
(RR=2.46 [1.56, 3.91]). A trend towards higher mesh infection rates
was observed in obese patients (RR=1.56 [0.96, 2.55]) and in patients
operated by a resident (in contrast to a consultant; RR=1.18 [0.99, 1.40]).
Moreover, mesh infections were signiﬁcantly correlated to patients’ age
(weighted mean difference [WMD]=3.29 [0.59, 5.98]) and ASA score
(WMD=0.23 [0.08, 0.38]), as well as the duration of the hernioplasty
(WMD=50.20 [28.64, 71.76]).
Conclusion: Patient’s age, ASA score, and smoking, as well as
the duration and emergency setting of the operation were found
to be associated with the development of synthetic mesh infection.
The heterogeneity of the available evidence should be taken under
consideration. Prospective studies are warranted to further investigate
mesh-related infections.
P1639 External ventricular drain-related ventriculomeningitis −
a ﬁve-year, single-centre survey
M. Hell*, M. Lunzer, C. Unterkoeﬂer, G. Forsthuber, M. Dollenz,
M. Maass, B. Richling (Salzburg, AT)
Objectives and Background: External ventricular drainage (EVD) is
frequently used in neurosurgical and neurological intensive care. Central
Nervous System (CNS) infections related to EVD, namely ventriculitis
and meningitis, have been well described and pose a dangerous threat
to critical care patients. In this report data from one single institution
collected prospectively from 2005 to 2009 is presented, giving detailed
information on the incidence of infection and pathogens involved.
Methods: Description of prospectively collected data, inlcuding 371
patients with a total of 481 EVD betweeen 2005 and 2009. Detailed
information on every patient receiving EVD is collected in a database
as part of an active infection surveillance program and evaluated
continuously in the KISS-infection surveillance system. Handling of
EVD is standardized, and ICU personnel is well trained. Cerebro-
Spinal Fluid (CSF) diagnosis including cell count, protein-, glucose-
and lactate concentration, as well as Gram stain is performed routinely
on a daily basis. CSF microbiological cultures are sent to the laboratory
twice weekly as routine, or immediately anytime if infection is likely.
All relevant laboratory tests and microbiological ﬁndings are recorded.
Weekly conferences have been established, with close and prompt
information exchange on any change of status of patients under
surveillance.
Results:
57 infections meeting the KISS criteria of ventriculomeningitis were
diagnosed. In 51 cases infectious microorganisms could be cultured
from CSF.
The overall device-related infection rate was 11.63 per 1000 EVD-days
(57/4901).
There was a signiﬁcant decrease from 2005 (18.23) compared to 2009
(10.59).
The spectrum of microorganisms causing infections in our patients
covered mainly Gram-positive cocci, but also some Gram-negative
strains, namely Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella
pneumoniae, Citrobacter koseri, Enterobacter cloacae and in some cases
also yeasts (Candida albicans and Candida parapsilosis).
Conclusion: This survey demonstrates the value of an active surveillance
program for reducing device-related ventriculomeningitis in neurosurgi-
cal critically ill patients and gives insight in the changing epidemiology
of microorganisms associated with EVD-related infections.
P1641 Hardware-related infections in patients subjected to
deep-brain stimulation
K. Chang*, A. San Gil, M. Varela, E. Calbo, M. Garcı´a-Bach,
V. Pascual, J. Garau (Terrassa, Barcelona, ES)
Background: Deep brain stimulation (DBS) is a commonly performed
procedure for intractable movement, psychiatric disorders and pain. As
with any implanted device, hardware for DBS (H-DBS) constitutes a
new risk of infection.
The aim of our study is to describe 3 cases of H-DBS infection from a
single center and another 178 cases found in the review of the literature.
Methods: From 2004–2010, 3 cases of infection related to DBS
(performed by a single surgeon team and one centre) were included.
An exhaustive literature review was conducted to identify any possible
reported cases. Data on incidence, DBS indication, time to initiation
of symptoms, diagnoses, site of infection, clinical features, causative
microorganism, antimicrobial therapy and surgical management were
recorded.
Results: Between 2004 and 2010, 102 H-DBS were implanted. Hardware
related infection was diagnosed in 3 patients. 178 other cases were found
in the literature review. Incidence of infection ranged from 0.62% to 15%
for patients or 1% to 9% for electrodes. In only 92 cases a microorganism
was reported. The most common isolated microorganism was S aureus
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(45,6%) followed by coagulase negative staphylococci (11,9%) and Gram
negative bacilli (5,4%);34/92 (37%) were diagnosed within one month,
and 54/92 (59%) within three months after implantation, respectively.
Only two patients presented with intracranial abscess (1.1%). Total
removal was initially required in 22 patients (17%). Partial removal
(either electrodes or generator) was applied in 60/181 (33.1%) patients,
but of those, 27 (45%) ﬁnally required total removal. In 12.1% (22/181)
of patients the device was left in place and cure was achieved with
medical therapy alone.
Conclusions: H-DBS infection is an uncommon event and it occurs
early after implantation mainly due to patient’s skin ﬂora. It is rarely
accompanied by intracranial abscess. Complete hardware removal is
frequently required to cure the infection.
P1642 Surgical wound infections after median sternotomy: clinical
and microbiologic preliminary results of a large multicentre
study in Italy
L. Scudeller, L. Soavi, E. Pistella, C. Santini* on behalf of the
GIS-INCARD
Objectives: Sternal wound infection (SWI) after cardiac surgery is a
rare complication associated to high mortality and costs. Few SWIs
are treated in every single center and the approach is often empiric.
Multicentric studies are needed to evaluate the optimal management.
Methods: Twenty divisions of Cardiac Surgery spread all over Italy
participated in this observational study. All patients developing SWI
in two periods (from Oct. 2005 to July 2006 and from March to
Sept. 2008) were included. SWI was deﬁned according to the CDC
diagnostic criteria. Patients characteristics, comorbidities, ASA score,
pre-operative risk factors, S. aureus nasal colonization, modality of
depilation, perioperative prophylaxis, clinical manifestations of SWI,
microbiological results, therapeutic approaches and outcome were
recorded, inserted in a data base and analysed by a central supervisor.
Results: Out of 4711 pts undergoing cardiac surgery, 131 (2.7%)
developed SWI and were included. The mean age was 68.3 years.
The mean time of pre-operative hospital stay was 5.3 days. Eighty-one
percent of pts had ASA score >2. The most frequent pre-operative risk
factors were: obesity (32.0%), hyperglycemia (31.3%), COPD (24.4%)
and cigarette smoking (19.8%). Out of 69 pts investigated for S. aureus
nasal colonization (17.3%) were positive. Shave of the operative site
was performed in 88.5%. Ninety-one SWIs (69.4%) were incisional, 33
(25.1%) organ/space involving and 7 (5.3%) not classiﬁed. Dehiscence
was present in 87.7%, sternal instability in 33.5%, fever in 35.8%.
Cultures from SWI were obtained in 114 pts (82%). Blood cultures were
performed in 86 pts (61.8%) and were positive in 29 (32.5%). Pathogens
were identiﬁed in 96 pts (73.2%): CNS (n. 36) and S. aureus (n. 26)
were the microrganisms more frequently isolated. Systemic antibiotics
(64.8%), vacuum aspiration (33.5%) and mediastinal irrigation (32%)
were the most frequent therapeutic approaches.
Surgical revision was performed in 93.9% of pts with grade 3 or 4
infection, followed by vacuum aspiration in 45.4%. Median hospital
stay was 45.5 days for deep SWIs and 18.5 days for superﬁcial SWIs.
Mortality in organ/space SWIs was 18.1% and 13.7% of pts developed
chronic infection and needed additional treatment.
Conclusions: SWI are rare, but require prolonged hospital stay. If
deep tissue are involved, surgical revision often associated to vacuum
aspiration is needed. Despite the aggressive approach, mortality and
morbility are high.
P1643 Procedure speciﬁc surgical site infection rates in a tertiary
care hospital in Turkey
R. Guner, I. Hasanoglu*, S. Ascioglu, A. Kaya Kalem, S. Keske,
M.A. Tasyaran (Ankara, TR)
Objectives: To describe the incidence of procedure speciﬁc surgical site
infections (SSI) in a tertiary care hospital in Turkey and compare it with
National Nosocomial Infections Surveillance (NNIS) system rates.
Methods: We conducted a prospective surveillance study among 8204
patients who underwent surgery during a period of 42 months. SSI rates
were calculated using US Centers for Disease Control and Prevention
and NNIS deﬁnitions. The SSI rates were computed and benchmarked
with the US rates by using standardized infection ratio (SIR).
Results: We observed 8204 operations and 309 SSIs. Overall crude
SSI rate was 3.76%. Most SSIs were classiﬁed as deep incisional
SSI 55.6%, followed by organ/space SSI 25.9% and superﬁcial SSI
18.5%. Table 1 shows the crude infection rates (CIR) and SIR for each
procedure and risk category. The most commonly isolated pathogens
were E. coli (34%), A. baumannii (12%), K. pneumoniae (8%) and
Gram-positive microorganisms (21%). The most common frequently
performed operative procedures were appendectomy, herniorrhaphy and
knee prosthesis.
Conclusion: We found SSI rates higher in our hospital than those
reported by the NNIS system. Benchmarking infection rates with NNIS
datas can be misleading where the number of operative procedure is
limited. Comparing infection rates with SIR may offer a resolution to
this issue. To reduce the rate of infection, it must be kept in mind that
the most important aspect of this effort is to comply with strict infection
control practices.
P1644 Impact of post-discharge surveillance on the incidence of
surgical site infections in cardiac surgery in a Swiss tertiary
care hospital
D.L. Braun*, R. Gaudenz, C. Ruef (Zurich, CH)
Objectives: To demonstrate the impact of formal post-discharge
surveillance (PDS) on the incidence of surgical site infections (SSIs)
in cardiac surgery.
Methods: We performed a prospective surveillance of cardiac-surgery
patients (316 valve replacements, 221 aorto-coronary bypass procedures,
96 combined interventions) from June 1, 2009 to May 31, 2010 regarding
the incidence of SSIs. CDC-Deﬁnitions were used to diagnose and
classify SSIs in superﬁcial, deep and organ-space infections. PDS was
performed by standardized telephone-interview of patients, 1 and 12
months (in case of implantation of prosthetic material) after intervention.
Results: Among a total of 633 patients (69% male, mean age 66 years)
49 developed a SSI within 12 months of surgery at the chest site (7.7%).
To distinguish the impact of PDS on SSI-incidence, we compared the
in-hospital infection rate with the infection rates 1 and 12 months after
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intervention, respectively (Table 1). The in-hospital SSI-incidence was
0.8% (5 SSIs, 10% of all SSIs). The SSI-incidence increased signiﬁcantly
to 5.8% (37 SSIs, 65% of all SSIs; p< 0.001) at 1 month follow-up
and even to 7.7% (49 SSIs, 90% of all SSIs; p< 0.001) at 12 months
follow-up, respectively. The incidence of deep sternal wound infections
(DSWI) during the initial hospital stay was 0.5% (3 SSIs, 18% of all
DSWI), increased to 1.9% (12 SSIs, 53% of all SSIs; p> 0.05) at 1
month follow-up and 2.7% (17 SSIs, 82% of all DSWI; p> 0.05) at
12 months follow-up, respectively. All patients with a DSWI had to be
rehospitalized during the PDS period, whereas only 47% of all patients
with superﬁcial SSI required rehospitalisation (p< 0.001). While all
patients with DSWI returned because of infection, only 18% of all DSWI
were diagnosed during the initial hospitalisation. Overall, 63% of all SSIs
would have been detected during the primary hospitalisation or during
rehospitalisation, but 37% would have been missed without formal PDS.
Conclusion: Our results demonstrate the impact of formal post-discharge
surveillance (PDS) on the detection of SSIs. Formal PDS increases
sensitivity for superﬁcial SSI but has a lesser impact on DSWI detection.
The data suggest that PDS is not essential for the detection of DSWI.
The fact that most SSIs are diagnosed after discharge illustrates that
a comprehensive comparison of incidence data between countries and
institutions requires standardized surveillance programs including a 12
months follow-up period.
P1645 Incidence and risk factors for surgical site infection in
Latium, Italy
V. Puro*, F. Ferraro, L.E. Ruscitti, P. Piselli, L. Martini, N. Petrosillo,
G. Ippolito on behalf of “Centro Regionale Infezioni nella Pratica
Assistenziale” (CRIPA)
Background: Surgical site infections (SSI) represent a signiﬁcant
problem in terms of morbidity, mortality, and costs. Aim of this regional
prospective multicenter study was to assess the incidence of in-hospital
and post-discharge SSI and associated risk factors.
Methods: In April-June 2008 a SSI surveillance was conducted
in 28 centers in Latium Region, Centre-Italy. SSI were assessed
according to the CDC deﬁnition and NNIS system. Ten different
interventions were monitored and information (such as diagnosis, wound
class, type, duration, ASA score, SSI diagnosis and localization) on
intervention, patients and eventual SSI were collected using the HELICS
project protocol. Surveillance was conducted up to 30 days post-
intervention (either during in-hospital permanence than after discharge)
and individual contribution (person-days at risk, PD) was calculated.
Association of SSI with selected characteristics was assessed through
univariate logistic regression odds-ratio (OR) and through multivariable
regression OR (MLR-OR) after adjustment for those variables found to
be signiﬁcative (p< 0.10) at univariate analysis.
Results: A total of 3193 interventions was surveilled (72.2% females,
median age 43: interquartile range: 33−65 years) adding to a total follow-
up of 91,664 PDs (of which 19,593 PDs in hospital). Eighty-seven SSI
were observed (2.7% cumulative incidence), mostly superﬁcial (73.6%).
Fifty-ﬁve (63.2%) SSI occurred post-discharge. Higher incidence was
observed in colon-surgery (8.6%) and appendicectomy (3.9%).
Overall, risk factors found to be signiﬁcantly associated with SSI were
age (OR=1.2 for each 10yrs increase), NNIS score >2 (OR=3.0) and
non elective admission (OR=2.0). These ﬁndings did not substantially
change when only in-hospital SSI were considered.
Conclusions: The study is consistent with national data and stresses
the relevance of the 30-day post-intervention SSI survey. Future surveys
should auditing the application of preventive bundle for SSI, in order to
verify the observed associations adjusted for this important variable.
P1646 Postoperative bacterial meningitis after trans-sphenoidal
surgery: a retrospective study of 99 interventions over a
10-year period
S. Giulieri*, D. Bervini, K. Darling, A. Trampuz, R. Daniel (Lausanne,
CH)
Objectives: Bacterial meningitis is a rare but severe complication
of trans-sphenoidal surgery, associated with high morbidity and
mortality. The optimal type and duration of perioperative antibiotic
prophylaxis respective preemptive treatment has not yet been deﬁned.
Recommendations vary from a single-dose antibiotic prophylaxis to a
one-week treatment. We evaluated the incidence and risk factors for early
bacterial meningitis after trans-sphenoidal surgeries at our institution.
Methods: We reviewed all trans-sphenoidal surgeries performed at our
institution over a 10-year period (2001–2010). Cases with early bacterial
meningitis (within 30 days of surgery) were compared to controls
without early postoperative meningitis. Bacterial meningitis was deﬁned
according to the CDC deﬁnition of nosocomial meningitis.
Results: Among 99 trans-sphenoidal surgeries performed during the 10-
year study period, 3 cases of early bacterial meningitis occurred in 3
women aged 29, 59 and 79 years. The meningitis was diagnosed 1,
8 and 10 days after surgery. The following pathogens were identiﬁed
in the cerebrospinal ﬂuid (CSF): Streptococcus pneumoniae in 2 cases
and Proteus vulgaris in 1 case. One patient died, while the other two
patients recovered without sequelae. All 3 cases of bacterial meningitis
occurred as a cluster during early 2010, resulting in this investigation.
The following risk factors were identiﬁed: visible CSF leakage during
surgery, which was immediately closed (present among all 3 cases
compared to 23% in controls), trans-nasal endoscopic approach (used
in all 3 patients compared to 23% in controls) and a short (single
dosis) prophylaxis compared to a prolonged prophylaxis in controls
(mean, 5.5 days, range 1−15 days). Cases received cefazolin (n = 2)
or amoxicilline/clavulante (n = 1), whereas controls received mainly
amoxicilline or amoxicilline/clavulanate (78%). The identiﬁed pathogens
were susceptible to the antibiotic they received as prophylaxis in 2 cases
and intermediate resistant in 1 case.
Conclusions: We describe a cluster of 3 cases with early bacterial
meningitis after trans-sphenoidal surgery, which occurred in 2010.
The following risk factors were identiﬁed: visible CSF leakage during
surgery, trans-nasal endoscopic approach and short antibiotic prophylaxis
(single dose). Further studies are needed to evaluate if longer prophylaxis
for patients with intraoperative CSF leakage may prevent meningitis.
P1647 Surgical site infections after elective craniotomy: a review of
362 procedures performed in a four-year period (2006–2010)
I. Rodrı´guez-Pinto´*, L. Sorli, G. Villalba, H. Knobel, R. Gu¨erri,
M. Montero, E. Torres, E. Molas, G. Conesa, J.P. Horcajada
(Barcelona, ES)
Objectives: Nosocomial infections of the central nervous system are a
serious complication contributing to morbidity, prolonged length of stay
in the ICU and/or hospital, and mortality of neurosurgical patients. The
aim of this study was to provide an overview of surgical site infections
after elective craniotomies in a tertiary hospital.
Methods: Retrospective study of adult patients who had surgical site
infection after elective craniotomy. The study was performed at Hospital
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del Mar, Barcelona, between July 2006 and June 2010. Collected data:
demographic characteristics, Charlson score, operation type, type of
infectious cranial complication, bacterial ﬁndings and ﬁnal outcome.
All patients had a minimum follow up of 1 year. In 2009 a bundle
of preventive measures was implemented.
Results: During the period of study 362 craniotomies were performed,
38 of which presented an infectious intracranial complication (10,5%):
13 out of 112 in 2007 (11,6%), 10 out of 82 in 2008 (12,2%), and 5 out of
88 in 2009 (5,7%). Among the infectious intracranial complications, 14
(36,8%) had meningitis, 11 (28,9%) surgical wound infection, 8 (21,1%)
subdural empyema, 3 (7,9%) epidural empyema and 2 (5,3%) presented
cerebral abscess. In patients with meningitis, the most common identiﬁed
microorganisms were: S. aureus (28.6%), P. aeruginosa (14.3%) and
Enterococcus spp. (14.3%). In patients with surgical wound infection,
S. aureus (45,5%) was also the most frequently isolated microorganism.
All S. aureus isolated were methicillin susceptible. The crude mortality
in our study was 5,2%, but the related mortality was 0%.
Conclusions:
1. A high incidence of infectious intracranial complications after elective
craniotomies was found in our center. This incidence decreased over
this 3-year period due to the implementation of a bundle of preventive
measures.
2. Our microbiological data are different from those reported by other
studies because we had fewer infections due to S. aureus and P. acnes
but we found more infections due to P. aeruginosa, Enterococcus spp.
and Enterobacter spp.
3. In our series there were not postoperative infections due to MRSA.
This could suggest that the protocol of empirical antibiotic in our
institution, which includes MRSA coverage, could be reviewed.
P1648 Analysis of risk factors for surgical site infections after
gastric surgery in the Korean Nosocomial Infections
Surveillance System (KONIS)
E.S. Kim*, H.B. Kim, H.J. Choi, H.Y. Kim, Y.K. Cho on behalf of KONIS
Background: A nationwide prospective multicenter study using web-
based report system was performed to evaluate the risk factors for
surgical site infections (SSIs) after gastric surgery in Korea.
Methods: SSI was assessed according to the methods of National
Nosocomial Infection Surveillance (NNIS) system. Demographic data,
host factors, and perioperative risk factors were collected in 21 hospitals
during 2007.7–2009.12. Statistical analyses were conducted to identify
variables related to SSIs using MedCalc Ver 11.2.
Results: Among a total of 4,240 cases monitored, 1,486 (35%) were
females and median age was 60 years (range 0−96). The 75th percentile
(T75) of durations of the operations was 260 minutes. The SSI
rates based on NNIS risk index scores were as followings: 2.11%
(19/900) in score 0 (laparoscopic surgery), 3.26% (70/2,149) in score 0
(laparotomy), 6.45% (71/1,100) in score 1, and 10.99% (10/91) in score
2 or 3. The univariate analysis showed that longer operative duration
(>T75), diabetes mellitus (DM), emergent operation, higher classes of
wound, multiple procedures in the same operation, combined infections,
perioperative transfusion, reoperation, smoking, recent steroid use, and
male gender were signiﬁcant risk factors for SSIs after gastric surgery.
The multivariate analysis revealed that signiﬁcant risk factors were
reoperations, longer operative duration, male gender, DM, and multiple
procedures.
Conclusions: Host factors (male gender and DM) and operation-
related factors (longer duration of operation, reoperation, and multiple
procedures) were signiﬁcantly associated with SSIs after gastric surgery
in Korea.
P1649 Using a data warehouse to predict rates of external
ventricular and lumbar drain-related meningitis
M.S. van Mourik*, R.H. Groenwold, A. Troelstra, M.J. Bonten (Utrecht,
NL)
Objective: Use of external ventricular (EVD) and lumbar (ELD) drains
is frequently complicated by the development of drain-related meningitis
(DRM). Monitoring of DRM rates is important for infection control,
but manual surveillance is time-consuming and susceptible to error. We
aimed to develop a prediction model to retrospectively detect DRM using
data stored in a clinical data warehouse.
Methods: As part of the hospital infection control programme all
patients receiving an EVD or ELD (2004 to 2009; n = 742) had
been evaluated for the development of DRM. Two infection control
professionals performed manual chart review, with adjudication through
review in case of disagreement. This categorization was used as reference
standard. Children, patients dying <24 hours after drain insertion or
with <1 day follow up and patients with infection at the time of
insertion or multiple simultaneous drains were excluded. All data
on demographics, microbiology reports, clinical chemistry results of
blood and cerebrospinal ﬂuid (CSF) and antibiotic use present in the
clinical data warehouse were used to develop a model predicting DRM
(logistic regression, stepwise backward selection). Missing data were
imputed using single imputation. Shrinkage was applied to increase
generalizability.
Results: 82 out of 537 included patients developed DRM (13.5/1000
days at risk). The ﬁnal model used the number of drains placed during
admission, drain type (EVD or ELD), blood leukocyte count, C-reactive
protein, CSF leukocyte count and culture result, number of antibiotics
started during admission and empiric antibiotic therapy. Discriminatory
power of the model was excellent (area under the ROC curve 0.97,
95%CI 0.95–0.99). A predicted probability cut-off of 0.10 achieved
sensitivity and speciﬁcity of 98.8% and 87.5% respectively. Positive
and negative predictive values were 58.7% and 99.7% respectively.
Overall, predicted yearly infection rates (summed predicted probabilities)
concurred with observed infection rates without the need for manual
conﬁrmation.
Conclusion: A prediction model based on multi-source data stored in a
clinical data warehouse can identify the occurrence of DRM in patients
with an EVD or ELD and can accurately quantify incidence rates. This
method allows reliable DRM surveillance at the patient level with a 75%
workload reduction when limiting manual review to patients identiﬁed
by the model.
P1650 The surgeon as an independent risk factor for surgical site
infection
M. Hu¨bner, M. Diana*, G. Zanetti, M.C. Eisenring, N. Demartines,
N. Troillet (Lausanne, Sion, CH)
Objective: To determine the role of the surgeon in the occurrence of
surgical site infection (SSI) following colon surgery, with respect to his
adherence to guidelines and his experience.
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Methods: Prospective cohort study of 2393 patients who underwent
colon surgeries performed by 31 surgeons in 9 secondary and tertiary-
care public Swiss hospitals, recruited from a surveillance program for
SSI between March 1998 and December 2008 and followed-up for
one month after their operation. Risk factors for surgical site infection
were identiﬁed in univariate and multivariate analyses that included the
patients’ and procedures’ characteristics, the hospitals, and the surgeons
as candidate covariates. Correlations were sought between surgeons’
individual adjusted risks, their self-reported adherence to guidelines, and
the delay since their board certiﬁcation.
Results: 428 surgical site infections were identiﬁed (17.9%) with
hospital rates varying from 4% (95%CI: 0 to 8) to 25% (21 to 29)
and individual surgeon rates varying from 4% (0 to 8) to 36% (27
to 46). Features of the patients and procedures associated with SSI in
univariate analyses were: male gender, older age, higher ASA score
and contamination class, longer operation duration, and emergency
procedure. Correctly timed antibiotic prophylaxis (within 1 hour) and
laparoscopic approach were protective. Multivariate analyses adjusting
for these features and for the hospitals found 4 surgeons with higher
risks of SSI (OR, 95%CI: 2.37, 1.51 to 3.70; 2.19, 1.41 to 3.39; 2.15,
1.02 to 4.53; and 1.97, 1.18 to 3.30), and 2 surgeons with lower risks
of SSI (OR, 95%CI: 0.43, 0.19 to 0.94; and 0.19, 0.04 to 0.81). No
correlation was found between surgeons’ individual adjusted risks and
their adherence to guidelines or their experience (Spearman coefﬁcients:
−0.16, P = 0.39 and −0.20, P = 0.30).
Conclusion: For reasons beyond his adherence to guidelines or his
experience, the surgeon may constitute an independent risk factor for
SSI after colon surgery. Reliable assessment methods of surgical skills
are needed.
P1651 Persistently bacteraemic infective endocarditis
V. Krcmery*, P. Kisac (Bratislava, SK)
Objectives: Persistent bacteremic infective endocarditis (PBIE) is
deﬁned as persistence of positive blood cultures for 3 or more days
despite antibiotic therapy. The reason for persistent bacteremia is
deﬁcient or inappropriate selection of antimicrobials, resistant organism,
foreign body or prosthetic endocarditis.
Methods: Within 606 cases of infective endocarditis within last 25 years
in Slovakia, 85 (14%) of infective endocarditis fulﬁlled this deﬁnition
and had positive blood culture for 3 and more days (3 to 7 positive
blood cultures). We have compared 85 cases of PBIE to 606 cases of all
infective endocarditis from the database of the national survey.
Results: Several risk factors were more frequently observed among
persistent infective endocarditis: elderly age (60% vs. 33%; p< 0.01),
diabetes mellitus (26.9% vs. 11.4%; p< 0.01), prior cardiac surgery
(20% vs. 9.9%; p< 0.05), prior surgery (19.4% vs. 42.7%; p< 0.001),
right side (17.6% vs. 11.4%; p< 0.001) and prosthetic valve (32.9% vs.
2.4%, p< 0.001).
Localisation etiology was different in persistent infective endocarditis in
comparison to all infective endocarditis.
Viridans streptococci (37.5% vs. 15.2%; p< 0.001), coagulase negative
staphylococci (51.8% vs. 21.9%; p< 0.001) and enterococci (23.5%
vs. 7.6%; p< 0.001) were more frequently observed among persistent
infective endocarditis and vice versa, embolisation (7.1% vs. 35.5%;
p< 0.001) rheumatic fever (9% vs. 22.3%; p< 0.05) were less frequent.
However, mortality and type of intervention (surgery, antimicrobials
only) were similar in both groups. This surprising ﬁnding is difﬁcult to
explain, because persistent bacteremia in infective endocarditis should
be logically related with increased death rate.
Conclusions: In conclusion, diabetics or elderly patients after prior
surgery as well as those with prosthetic or right sided infective
endocarditis may suffer on PBIE with multiple positive blood cultures.
However, risk of embolisation as well as mortality was surprisingly lower
among persistent infective endocarditis.
P1652 Drainage days − an independent risk factor for serious
sternal wound infections after cardiac surgery
S. Tschudin Sutter*, R. Meinke, H. Schuhmacher, M. Dangel,
O. Reuthebuch, F.S. Eckstein, A.F. Widmer (Basel, CH)
Objectives: Postoperative organ/space surgical site infections (SSIs) are
a potentially devastating, complication following cardiac surgery. Sternal
wound infections lead to increased morbidity and mortality. The aim of
this study was therefore to determine risk factors associated with the
patient’s baseline characteristics, the peri- and postoperative management
for the development of SSIs after cardiac surgery involving sternotomy.
Methods: Since 2009, the University Hospital of Basel participates in
the national SSI surveillance program with post discharge surveillance,
using the Centers for Disease Control and Prevention (CDC) deﬁnitions
of SSIs. To determine risk factors for SSIs, we conducted a case control
study. 30 consecutive patients were included as cases after development
of an organ/space SSI after cardiac surgery from January, 2009 to May
2010 involving sternotomy. Control patients after heart surgery involving
sternotomy without development of a SSI were matched to cases in
2:1 ratio, according to age, gender, identical kind of heart-surgery, and
preoperative length of hospital stay, adjusting for time at risk before
surgery. The groups were compared by univariate and multivariable
logistic regression analysis.
Results: There were no signiﬁcant differences between the 30 cases and
60 matched controls regarding age and underlying diseases. Univariate
analyses revealed receipt of antibiotics prior to operation and elevated
levels C-reactive protein (CRP) on admission as signiﬁcant patient-
associated risk factors (p = 0.032 and 0.018, respectively). The number
of drainages inserted at the operation site, and the duration of their
retention, as well as central, peripheral and urinary catheter days,
ventilation days, days to the ﬁrst change of dressings, days on the
intensive care unit, and resuscitation during hospital stay, were all
signiﬁcantly associated with SSIs. Drainage days (3.7 versus 2.08)
remained highly signiﬁcant in multivariable logistic regression analysis
(p = 0.001).
Conclusion: Receipt of antibiotics prior to cardiac surgery and elevated
CRP levels on admission, predispose for the development of a SSI.
The duration of retention of drainages (>2 days) at the operative site
is an independent risk factor for organ/space SSI after cardiac surgery,
involving sternotomy.
P1653 Shifting sands: a multicentre survey of changes in practices
of antibiotic prophylaxis in cardiac surgery across cardiac
centres in United Kingdom
S. Hosmane*, R. Williams, L. Moorhouse, J. Moon, M. Przybylo,
A. Guleri (Plymouth, Blackpool, UK)
Background: The use of prophylactic antibiotics has been shown
to decrease the incidence of surgical site infection in several
previous studies. However, the lack of national guidelines for cardiac
surgery has resulted in marked variance in the choice of agent/s
and duration of antibiotic usage across cardiac centres in United
Kingdom. Antibiotic stewardship programmes in institutions for reducing
healthcare associated infections including MRSA, Clostridium difﬁcile
and multiresistant organisms have dictated prudent antibiotic use. This
survey [joint initiative Cardiac centres Plymouth & Blackpool] included
cardiac centres in UK to assess changes in practice of prophylactic
antibiotics compared to the previous audit two years ago. Also assess
C. difﬁcile and MRSA rates and quality of data collection for cardiac
centres.
Method: A telephone survey across 36 cardiac surgical units in the UK
was conducted. The information regarding the choice, duration and dose
of prophylactic antibiotic used for cardiac surgery; MRSA and C. difﬁcile
infection rates were obtained either from microbiologist or the cardiac
surgeon. This was compared to information carried in 2008.
Results: Data from 36 centres is presented. 32 (88.88%) hospitals had
unit protocols for antibiotic prophylaxis in cardiac surgery; 12 (37.5%)
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units use single agent and the rest 20 (62.5%) use dual antibiotics.
The different antimicrobial agents used in varying combinations include
ﬂucloxacillin (56.25%), cefuroxime (34.37%), gentamicin (59.37%), co-
amoxiclav (9.37%) and teicoplanin (3.12%). The prophylactic antibiotic
is administered at induction in 84.37% units and within 1hr before skin
incision in the rest (15.63%). The duration of antibiotic usage was
48hrs (3.12%), 24hrs (75%), 12hrs (6.25%), single dose (9.37%) and
during surgery (6.25%) {3 doses given at induction, during bypass and
post bypass}. The comparison of antimicrobial use between 2008 and
2010 is shown in the graph below. During 2009−10 the cardiac centres
had between 0−2 MRSA bacteraemias and 0−21ºC. difﬁcile infections.
Details to be presented.
Conclusions: There is some evidence of streamlining in the choice of
prophylactic antibiotic/s in cardiac surgery with a shift away from broad
spectrum cephalosporins. This may be attributed to the concerns and
efforts in reducing cephalosporin use across healthcare institutions to
contain MRSA and C. difﬁcile infections rates. A marked variation in
data collection for cardiac centres was evident.
Prosthetic joint infections
P1654 Epidemiology and outcome after treatment of prosthetic
joint infections. Observational study
T. Ascione*, M.D. Iannece, P. Rosario, P. Pagliano, M. Conte,
R. Rotondo, M. Mariconda, C. Pempinello, S. Lepore, R. Pempinello
(Naples, IT)
Prosthetic joint infections (PJI) are the most devastating complication of
joint replacement surgery and report a considerable disability and cost.
Aim of this study was to evaluate the characteristics of patients with
prosthetic joint infection and their outcome after treatment.
Methods: In an observational study we included the cases of prosthetic
joint infection referred to our division during the last 5 years. PJI was
deﬁned by local pain, erythema or tenderness, by radiologic ﬁndings,
and by positive cultures obtained from a sinus tract or from pus
collected from the periprosthetic tissue. Epidemiological, laboratory and
microbiologic ﬁndings were considered. Cure was deﬁned by clinical
and microbiologic evidences, coupled with a negative imaging study or
with the absence of captation by scintigraphic examination, as assessed
6 months after the end of therapy.
Results: Seventy-three cases (median age 64 years, range 48−82, males
45%) were observed (hip replacement 33 cases, knee replacement
40 cases). Co-morbidity were reported in 38 (52%) patients, diabetes
mellitus, cardiovascular co-morbidities, and chronic liver disease were
retrieved more frequently. Twenty-ﬁve cases were observed within 3
months from surgical procedure (early infection), and 48 cases were
observed after >3 months (late infections). Staphylococcus aureus was
identiﬁed in 26 (36%) cases (18 strains were methicillin resistant), 16
(22%) cases were sustained by coagulase negative Staphylococci, 6 (8%)
by Enterococcus spp, 4 (5%) by Pseudomonas aeruginosa, and 11 (15%)
by other bacteria. Polymicrobial infections were reported in 2 (3%) cases.
No microbiologic evidence was reported in 8 (11%) cases. All early
infections received debridement followed by antibiotic therapy (success
rate 96%). Late infections were treated with a two-stage exchange in
14 cases (success rate 86%). The remaining cases received long-term
suppressive antibiotic treatment without prosthetic joint replacement,
because of refusal of further surgical procedure (12 cases), or because of
co-morbidity (22 cases). On treatment infection suppression was reported
in 23 (68%) cases.
Conclusion: Prosthetic joint infections are frequently sustained by multi-
drug resistant bacteria. Debridement followed by antibiotic treatment is
a successful procedure for early infection. Patients with late infections
have to be evaluated on the basis of underlying conditions to establish
the surgical and antimicrobial approaches.
P1655 Outcome of periprosthetic joint infection caused by
rifampin-resistant staphylococci
K. Eigenmann*, Y. Achermann, M. Clauss, P. Rafeiner, L. Derksen,
R. Nueesch, C. Zellweger, M. Vogt, W. Zimmerli, A. Trampuz (Zurich,
Liestal, St. Gallen, Lucerne, Berne, Baar, Lausanne, CH)
Objectives: Periprosthetic joint infection (PJI) caused by rifampin-
resistant staphylococci are considered difﬁcult to treat. Their optimal
treatment approach is not universally accepted, but most experts
recommend a 2-stage exchange of the prosthesis with a long interval (6
weeks) and without the use of spacer. We investigated the characteristics
and outcome of PJI caused by rifampin-resistant staphylococci.
Methods: In a multicentre study (01/2000−12/2010), PJI caused
by rifampin-resistant Staphylococcus aureus or coagulase-negative
staphylococci (CNS) were retrospectively included. PJI was deﬁned as
previously published by Zimmerli et al. (NEJM 2004). Patients were
regularly followed at the outpatient orthopedic clinic or were contacted
by phone. A relapse was deﬁned as recurrence of PJI with the same
organism. A Kaplan-Meier survival and Cox proportional regression
analysis were performed.
Results: We included 47 patients (17 females; median age 67 y; range
39−88 y) with PJI involving the following joints: hip in 28 (60%), knee in
13 (28%), elbow in 4 (9%), shoulder and ankle each in one patient (2%).
S. aureus was isolated in 9 (19%), CNS in 38 (81%) cases. Debridement
and device retention was performed in 13 cases, 1-stage exchange in
9 cases, 2-stage exchange with short interval (<6 weeks) in 4 cases,
2-stage exchange with long interval (6 weeks) in 16 cases, a resection
arthroplasty in 4 cases and no surgical intervention in 1 case. The median
duration of intravenous antibiotic therapy was 27 days (range 0–102
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days), whereas the median complete duration was 3 months (range 0.5–
101 months). The median follow-up was 21.9 months (range 6.7–89.1
months). The relapse-free survival (95% conﬁdence interval)after 1, 2
and 3 years was 75% (59−85%), 60% (41−75%) and 55% (35−71%),
respectively. The relapse-free survival after 3 years was better when a
2-stage exchange with long interval and no spacer was used (11 of 16
cases, 70%) compared to the debridement and device-retention procedure
(2 of 13 cases, 18%) with a hazard ratio of 0.39 (Figure).
Conclusion: PJI caused by rifampin-resistant staphylococci are difﬁcult
to treat and should be managed by a 2-stage prosthesis exchange with a
long interval (6 weeks) and without spacer.
P1656 Multicentre review of prosthetic joint infections treatment
and outcomes
T. Peel*, K. Buising, A. Cheng, P. Choong (Melbourne, AU)
Objectives: Prosthetic joint infection (PJI) remains a devastating
complication of arthroplasty. There is signiﬁcant heterogeneity in
treatment approaches to these infections and information on their efﬁcacy
relies on single-centre studies. This multi-centre study examines current
treatment approaches and outcomes of patients with PJI.
Methods: A retrospective cohort study was conducted over a 3-year
period (January 2006–December 2008) involving 10 hospitals in
Victoria, Australia. Cases of prosthetic joint infections of hips and
knees were identiﬁed using an established statewide nosocomial infection
surveillance network. Individual medical records were accessed to
describe the management and record the outcomes of these patients.
Results: Initial analysis from ﬁve hospitals revealed 100 patients with
PJI.
Polymicrobial infections occurred in 44% of cases. Staphylococci species
was the most common pathogen in monomicrobial infections accounting
for two thirds of these infections. Debridement and retention (DR)
was the most common treatment modality (73%), followed by resection
arthroplasty without reimplantation (12%), superﬁcial debridement and
antibiotics (8%), two-stage exchange (4%) and one-stage exchange
arthroplasty (3%). The timing and number of surgical interventions was
however highly variable. Of the patients with staphylococcal infections,
two-thirds received a rifampicin-containing regimen. Overall 72% of
patients remained infection-free after median follow-up of 12 months,
however this differed signiﬁcantly between hospitals with success
ranging from 50%-95%. Overall in patients undergoing DR, 76% of
patients were successfully treated. There was no signiﬁcant difference in
survival according to treatment modality.
Conclusions: This multi-centre study demonstrates that DR is the
favoured treatment modality in Australia with reasonable success. Of
note, the management and outcomes of patients markedly differed
between hospitals. This study reports real-life management and outcomes
from patients at several centres, including many that do not have
dedicated research interest in PJI.
P1657 Gram-negative prosthetic joint infection
G. Mun˜oz-Gamito*, L. Go´mez, A. Matamala, D. Haro, E. Cuchı´
(Terrassa, ES)
Objectives: To describe the characteristcs of Gram negative prosthetic
joint infections (GN PJI).
Methods: All patients with documented GN PJI were analysed from
2003 to 2009. PJI was diagnosed if the same microorganism was
recovered from at least 2 joint aspirate or intraoperative tissue cultures
or if one intraoperative culture was positive plus clinical evidence of
infection. Acute PJI (APJI) was considered if it was diagnosed before 1
month from surgery. The rest were chronic (CPJI). Demographic data,
comorbidities, local complications of wound, clinical symptoms, ﬁsical
exam, lab and radiologic ﬁndings and treatment were collected. An
accurate follow up was performed to evaluate the outcome.
Results: 145 episodes of PJI were reviewed. 17 were GN PJI (11.7%).
10 were APJI (6 knee prosthesis and 4 hips) and 7 were CPJI (6
knee and 4 hips). Median age was 71.2 vs 66.8 years. Charlson
index of comorbidity was 1.4 in APJI vs 1.5 in CPJI. There were no
patients with rheumatoid arthritis nor taking immunossupresive therapy.
Complications of the wound were present in 80% of APJI vs 28% CPJI.
Pain was present in 1% APJI vs 71.4%. In CPJI, pain was the main
reason for revising the joint. Abnormal radiological ﬁndings were seen
in 1 patient of each group. Infection was polimicrobian in 40% APJI vs
57% CPJI. Most frequent microorganisms were Enterobacter spp (60%
APJI vs 40% CPJI), E. coli (20% AJPI vs 14% CPJI),Klebsiella spp
(20% APJI vs 28% CPJI) and Pseudomonas spp (10% APJI vs 28%
CPJI). None of them were resistant to quinolones. Quinolones were the
most used antibiotic in the two groups with a median length of treatment
of 5.5 months. 40% AJPI need 2-stage replacement vs 57% CPJI. The
median of follow up was 2.5 years in the two groups. Only one patient
with CPJI was considered as a failure after a 2-stage replacemet and a
Girldestone was performed. None of the APJI had pain in the follow
up vs 70% CPJI. Joint function was normal in both groups. One aseptic
loosening was detected in the follow up with scintigraphy in one CPJI
patient. No altered lab parameters were detected in the time of follow
up after stopping antibiotic.
Conclusions: In GN APJI the ﬁrst alert symptoms are local
complications of the wound. APJI have a good functional outcome in
all cases, and in almost 2/3 of patients the prosthesis can be retained.
First alarm symptom in CPJI is pain but it doesn’t dissapear when the
infection does. More studies are needed to understand GN PJI.
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P1658 Healthcare-associated pneumonia: an attempt to reﬁne the
concept
M. Salvado´*, V. Pascual, E. Calbo, N. Freixas, M. Riera, M. Xercavins,
J. Garau (Martorell, Terrassa, ES)
Background: A reassignment of the criteria for health care associated
pneumonia (HCAP) has been proposed recently in order to reconstruct
the classical triad of community acquired pneumonia (CAP), hospital
acquired pneumonia (HAP) and pneumonia in immunosupressed patients
(PISP). (Ewig S et al. Rethinking the concepts of community-acquired
and health-care-associated pneumonia. Lancet Infect Dis 2010). The aim
of our study was to revise the new criteria in a cohort of patients with
bacteraemic pneumonia (BP).
Methods: From Jan 2004 to Feb 2010 consecutive adult patients with
BP were identiﬁed in a 500-bed acute care-teaching hospital. Patients
who resided in a nursing home and those receiving any sort of home
care were included in the group of CAP. Any patient with a previous
hospitalization was considered as HAP, except for immunosupressed
patients that were always categorized in the PISP group. PISP
included patients on haemodialysis, with chemotherapy, neutropenia,
stem-cell transplantation, HIV/AIDS or iatrogenic immunosupression.
Data obtained included demographics, co-morbidities (Charlson score),
aetiology, severity of disease (Pitt score) and in-hospital mortality.
Results: 306 episodes of BP were identiﬁed. CAP was diagnosed in 195
(63.3%) patients, PISP in 84 (27.3%) and HAP in 27 (8.8%). Mean age
was 62 in CAP, 64 in PISP and 71 years in HAP (NS). Charlson score
was 1.66 in CAP vs. 2.7 in PISP (p< 0.001) and 2 in HAP (PISP vs.
HAP, NS). Pitt score was 1.22 in CAP vs. 1.3 in PISP (NS) and 1.83 in
HAP (NS). S. pneumoniae was isolated in 91%, 62% and 48%, S. aureus
in 1%, 5% and 15%, P. aeruginosa in 1%, 20% and 18.5% in CAP, PISP
and HAP, respectively. The in-hospital mortality rate was 16.5% in CAP
vs. 28% in PISP (p = 0.03) and 22.2% in HAP (NS).
Conclusions: PISP is similar to HAP in terms of presence of co
morbidities, pathogens and in-hospital mortality.
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P1659 Ventilator-associated pneumonia rates in three different
intensive care units in a tertiary care hospital
M.A. Yetkin, D. Kanyilmaz, P. Onguru, E. Akinci, A. But, F. Alaca
Coskun, N. Aksu, H. Bodur* (Ankara, TR)
Objective: Ventilator associated pneumonia (VAP) is the most frequent
healthcare associated infection in intensive care units. The aim of this
study to assess the ventilator associated pneumonia (VAP) rates and
frequency of nosocomial pathogens in our intensive care units.
Methods: Patient-based active nosocomial infections surveillance in
medical intensive care unit (M-ICU), surgical intensive care unit (S-
ICU) and medical/surgical intensive care unit (M/S-ICU) has been
performed in our hospital since January 2007. Hospital acquired
infections were diagnosed according to CDC criteria. Conventional
methods and automated systems were used for the identiﬁcation and
detection the antimicrobial susceptibility pattern of the microorganisms.
Results: In 2007 a total number of 517 patients with a 2164 patient
days were hospitalized in M-ICU. Detected VAP rate was 18.22/1000
ventilator days and ventilator utilization rate was 0.4 in this year.
Ventilator utilization rates increased and VAP rates decreased in this
ICU in the following years and in 2010 the same ratios were 14.87/1000
ventilator days and, 0.51 respectively. During the study period in M/S-
ICU, the highest VAP rate (26.70/1000 ventilator days) was detected
in the year 2007 whereas the same ratio was decreased to 19.69/1000
ventilator days with approximately the same ventilator utilization ratios.
Same as the other ICUs, the highest VAP rate (24.87/1000 ventilator
days) was detected in year of 2007 and VAP rates decreased in the
following years in S-ICU also.
The most frequently isolated pathogens were Staphylococcus spp,
Pseudomonas species and Acinetobacter spp. among patients with
VAP all through four years, but signiﬁcant changes had been detected
among the frequencies of the microorganisms. There were a statistically
signiﬁcant increment in the isolation frequencies of Acinetobacter spp,
(p< 0.001), whereas isolation rate of Staphylococcus spp. was decreased
(p< 0.001) in 2010 when compared to isolation rates of the same
microorganisms in 2007. Isolation frequencies of Pseudomonas spp. did
not change through the years.
Conclusion: Although there seems to be a decrease in VAP rates
during the following years in all three ICUs, these rates are still higher
than NHSN rates. Effective strategies such as continuing educational
programs and applying strict infection control practices should be
developed to reduce the rate of infection.
P1660 Candida sp. colonisation could promote antibiotic-resistant
bacteria selection within the airways of the patients with
clinically suspected ventilator-associated pneumonia
M. Hamet*, A. Pavon, S.D. Barbar, S. Prin, J.P. Quenot, F. Dalle,
P.E. Charles (Dijon, FR)
Objectives: Candida sp. airways colonization has been shown to pro-
mote the development of VAP especially those caused by Pseudomonas
aeruginosa, a bacteria prone to become resistant to antibiotics. We
address therefore the question of the risk of selecting bacterial resistance
within the airways of the patients undergoing mechanical ventilation
whether Candida sp. was present or not.
Methods: A prospective one-center observational study including all
the patients with clinically suspected VAP over a 5-year period. Every
episode was assessed according to the Clinical Pulmonary Infection
Score (CPIS). Airways’ specimen were systematically collected for
culture on speciﬁc medium for yeast isolation.
Results: 323 clinically suspected VAP were recorded. Among these
patients, 192 (59.4%) were simultaneously colonized by Candida sp.
No difference was found between colonized and not colonized patients
regarding baseline characteristics including severity score and prior
exposure to antibiotics. The VAP current episode was also found to be
similar with regard to clinical data. However, in proportion, P. aeruginosa
was more frequently encountered in the colonized patients than in the
not colonized ones (67% vs. 33%, respectively; p< 0.05). In addition,
regardless of the bacterial species, antibiotic-resistant strains were more
likely to be recovered from the airways of the patients with Candida sp.
colonization than in those without (76% vs. 24%, respectively; p< 0.05).
This could account for the increased mortality rate met in this subset of
patients.
Conclusions: In our cohort of patients with clinically suspected VAP,
airways colonization with Candida sp. is associated with an increased
risk of P. aeruginosa as well as other antibiotic-resistant bacterial strains
isolation, which could participate to worsen the outcome.
P1661 Hospital-acquired bacteraemic pneumonia in non-ventilated
patients
E. Espejo*, M. Andre´s, J. Torviso, M.A. Morera, R.M. Borrallo,
J. Pe´rez, F. Bella (Terrassa, ES)
Objectives: To evaluate the characteristics, factors related to etiology and
prognostic factors of hospital-acquired bacteremic pneumonia (HABP)
in non-ventilated patients.
Methods: Prospective study of 90 consecutive cases of HABP outside
the Intensive Care Unit, from 1984 to 2009, in a 350-bed teaching
hospital.
Results: Of the 90 patients with HABP, there were 68 males (75%)
and 22 females (25%), aged 68±13 yr. The mean length of hospital stay
(LOS) until the occurrence of pneumonia was 16±11 days. Chronic
obstructive pulmonary disease (43%), malignancy (39%), diabetes
mellitus (16%), chronic renal failure (14%) heart failure (13%), and
HIV infection (11%) were the main underlying conditions. These were
ultimately fatal in 42 cases (47%) and rapidly fatal in 11 cases (12%).
The main causative microorganisms were Pseudomonas aeruginosa
(39 cases) and Streptococcus pneumoniae (24), followed by Klebsiella
pneumoniae (6), Escherichia coli (6), Staphylococcus aureus (5), and
Haemophilus inﬂuenzae (4). The LOS until the pneumonia was similar in
cases caused by P. aeruginosa (19±10 days) and S. pneumoniae (16±10
days). P. aeruginosa infection was associated with previous antibiotic
treatment, COPD, and neutropenia (P< 0.001). The empiric antibiotic
treatment was appropriate in 75 cases (83.3%). The crude mortality
was 48.8%. The factors signiﬁcantly associated with a worse prognosis
were the presence of shock (OR 2.3; 95%CI 1.5−3.3), disseminated
intravascular coagulation (OR 1.9; 95%CI: 1.4−2.8) and inappropriate
antibiotic treatment (OR 1.7; 95%CI: 1.1−2.5).
Conclusions: Most cases of HABP in non-ventilated patients are due
to P. aeruginosa or S. pneumoniae, irrespective of the LOS. Previous
antibiotic treatment, COPD and neutropenia are signiﬁcantly associated
with P. aeruginosa pneumonia. Mortality is high. Shock, disseminated
intravascular coagulation and inappropriate antibiotic treatment are
adverse prognostic factors.
P1662 A study on aetiology and drug resistance pattern of
ventilator-associated pneumonia in an Iranian 1.000-beds
tertiary care hospital
M. Rahbar*, H. Bahrami (Tehran, IR)
Objectives: Ventilator associated pneumonia (VAP) is the most common
nososcomial infection in ICUs and making up one-third of the total
nosocomial infections. The aim of this study was to determine etiology
and drug resistance pattern of most frequency isolates in an Iranian
1000-bed tertiary are hospital in Tehran.
Methods: VAP was deﬁned as any lower respiratory tract infection
that developed 48 hour after mechanical ventilation. The criteria for
clinical suspicion of pneumonia were as follows: presence of a new
or persistent lung opacity on chest radiographic plus two of the
following items: fever >37ºC, WBC count >10,000mmma and Purulent
tracheal aspirate. Tracheal Specimens were collected and processed
according standard microbiological methods. Bacterial identiﬁcation
and susceptibility testing were performed using standard methods.
Demographic date of patients abstracted from their ﬁles.
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Results: One hindered and one patients developed at least one episode
of nosocomial pneumonia. Of 101 patients 61 patients were male and
40 patients female. The mean time for hospitalization in ICUs and
ventilation were days were 16 and 9, 5 days respectively.
Old age, History of previous use of antibiotics and duration of ventilation
times were the most important risk factors for VAP. In total 126
microorganisms were isolated from VAP cases. Acinetobacter baumannii
with 46 (36.5%) isolates was the predominant organism followed by
Staphylococcus aureus with 31 (24.6%). Pseudomonas aeruginosa were
accounted 19 (15%) isolates. Other isolated organisms were Klebsiella
pneumoniae and E,coli. The majority isolated organism including
Acinetobacter baumannii and Pseudomonas aeruginosa were resistant
to many antibiotics including third generation of cephalosporins and
nearly 50% isolates were resistant to Amikacin. Colistin was the most
effective antibiotic against multidrug resistant (MDR) isolates. We found
a high rate of resistance among isolates of S. aureus (93.54, %) isolates
were MRSA. All isolates of S. aureus were susceptible to vancomycin.
Conclusion: Our study revealed that A. baumannii, S. aureus and
P. aeruginosa were the major etiological agents of VAP in our
hospital. The majority isolates were resistant to routinely used antibiotics
including third generation of cephalosporins. We also observed a high
rate of MRSA among our isolates.
P1663 Hospital-acquired Klebsiella pneumoniae bacteraemia:
risk factors for carbapenem-resistance and predictor for
mortality
K. Hussein*, A. Raz-Pasteur, A. Neuberger, Y. Shachor Meyouhas,
I. Oren, R. Finkelstein, I. Kassis (Haifa, IL)
Objective: To identify risk factors for carbapenem-resistance and
predictors of mortality among adult patients with hospital-acquired
bacteremia due to Klebsiella pneumoniae.
Methods: Retrospective cohort study.
Results: Between January 1, 2006 and December 31, 2008 there
were 510 patients with K. pneumoniae bacteremia in our hospital. Of
this, 317 patients, including 103 patients with carbapenem-resistant
K. pneumoniae (CRKP), fulﬁlled our inclusion criteria and were
evaluated. As compared with 214 patients with carbapenem-susceptible
K. pneumoniae (CSKP), several characteristics (hematological ma-
lignancy, renal failure, chronic liver disease, previous bone marrow
transplantation, mechanical ventilation, central vein catheterization,
urinary catheterization, hemodialysis, stay in the ICU or in the
hematology department and prior antibiotic use) were signiﬁcantly
more common among CRKP. On multivariable analysis, prior use of
macrolides (OR 3.3, 95%CI 1.295–8.45; P = 0.012) and any antibiotic
exposure for 14 days (OR 17.3, 95%CI 4.568–65.5; P< 0.001)
remained independent factors associated with CRKP. Mortality rate
among patients with CRKP was signiﬁcantly higher than that found
for patients with CSKP (45 of 103 patients, 43.7% vs. 62 of 214
patients, 29% respectively, P< 0.001). On multivariable analyses, bed
ridden status (OR 2, 95%CI 1−3.8; P = 0.044), chronic liver disease
(OR 4.8, 95%CI 1.8–12.8; P = 0.002), Charlson Comorbidity Index >5
(OR 6.7, 95%CI 2.4–18.9; P< 0.001), mechanical ventilation (OR 4,
95%CI 2.2−7.2; P< 0.001), and hemodialysis (OR 2.7, 95%CI 1.2−6.2;
P = 0.019) remained independently associated with mortality among
patients with K. pneumoniae bacteremia.
Conclusion: This study conﬁrms that previous antibiotic exposure is a
risk factor for severe infections due to CRKP. Mortality among patients
with K. pneumoniae bacteremia is associated with severity of illness and
many other well known serious co-morbidities, but not with carbapenem-
resistance.
P1664 Ventilator-associated pneumonia due to methicillin-resistant
Staphylococcus aureus: risk factors and outcome in a large
general hospital
E. Bouza, M. Giannella*, E. Bunsow, M. Torres, P. Martin-Rabadan,
P. Mun˜oz on behalf of the Gregorio Maran˜o´n Task Force for Pneumonia
Objectives: To assess the frequency, risk factors, and outcome of
ventilator-associated pneumonia (VAP) due to methicillin-resistant
S. aureus (MRSA) in adult intensive care units (ICUs) in a large teaching
institution.
Methods: Comparative study carried out over 4 years in 3 adult ICUs
at our hospital. All mechanically ventilated patients with suspicion of
VAP were prospectively followed. Clinical and microbiological data
were recorded. Patients with conﬁrmed MRSA-VAP were compared with
those with bacterial VAP caused by other microorganisms.
Results: Overall, 474 episodes of conﬁrmed bacterial VAP were
collected during the study period. The frequencies of pathogens were
as follows: P. aeruginosa, 29%; MRSA, 23%; Enterobacteriaceae,
23%; MSSA, 10.5%; Haemophilus spp., 6%; A. baumannii, 4%;
S. pneumoniae, 2.5%; and S. maltophilia, 2%. Overall, 32% of VAP were
polymicrobial. Differences between MRSA-VAP patients (111) and those
with VAP due to other microorganisms (363) were found for median age
(68 vs. 62 y, p = 0.003), median Apache II score (12 vs. 11, p = 0.006),
previous abdominal surgery at the present admission (35% vs. 19%,
p = 0.001), receiving any antibiotic treatment at the present admission
before VAP (82.9% vs. 64.5%, p< 0.001), receiving imipenem (24%
vs. 11%, p = 0.001), and evidence of pleural effusion on x-ray (12% vs.
5%, p = 0.01). A multivariate analysis of risk factors for MRSA adjusted
for age, McCabe/Jackson, Charlson comorbidity, number of antibiotics
before VAP, Apache II score, and days from hospital admission to VAP
diagnosis showed that emergency surgery during the present admission,
prior treatment with imipenem, high Apache II score, and pleural
effusion were independently associated with MRSA. As for treatment
and outcome, the differences between MRSA-VAP and other VAP were
empiric treatment that was not effective against the causative agent of
VAP (70% vs. 53%, p = 0.001), severe sepsis (43% vs. 31%, p = 0.04),
median cost of antibiotic treatment per episode (€974 vs. €726, p = 0.05),
and in-hospital mortality (60% vs. 47%, p = 0.02). In the multivariate
analysis, however, MRSA was not found to be an independent risk factor
for mortality.
Conclusions: MRSA is the second most common cause of VAP in our
hospital. High Apache II score, prior emergency surgery, and antibiotic
treatment, especially with imipenem, are predisposing factors. The high
mortality of MRSA-VAP was not attributed to the microorganism itself
but to underlying conditions.
P1665 Low incidence of multidrug-resistant organisms in
healthcare-associated pneumonia requiring hospitalisation
C. Garcia-Vidal*, D. Viasus, J. Adamuz, A. Roset, R. Verdaguer,
J. Dorca, F. Gudiol, J. Carratala` (Barcelona, ES)
Objectives: Healthcare-associated pneumonia (HCAP) includes a broad
spectrum of patients who acquire pneumonia through outpatient contact
with the health system. Although limited prospective data exist, it
has been suggested that all patients with HCAP should receive
empiric therapy with a multidrug regimen directed against drug-resistant
organisms. We aimed to determine the differences in etiology and
outcomes between HCAP groups and community-acquired pneumonia
(CAP), and to assess the presence of antibiotic-resistant bacteria.
Methods: All consecutive nonimmunocompromised adults hospitalized
with pneumonia were prospectively included from 2001 to 2009. Patients
who had recent contact with the health system through nursing homes,
home health care programs, hemodialysis clinics, or prior hospitalization
were considered to have HCAP.
Results: A total of 2245 patients with pneumonia were hospitalized
through the emergency room, of whom 577 (25.7%) had HCAP.
Signiﬁcant differences in causative pathogens were found between
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groups (table). The presence of antibiotic-resistant organisms, including
methicillin-resistant Staphylococcus aureus, resistant strains of Pseudo-
monas aeruginosa, and extended-spectrum b-lactamase producing
Enterobacteriaceae, was scarce in all groups. In contrast, aspiration
pneumonia was particularly frequent. No differences were found
regarding inappropriate initial empirical antibiotic therapy between
groups. Overall mortality was higher in patients who attended a hospital
or hemodialysis clinic or received intravenous chemotherapy in the 30
days before pneumonia and among patients who resided in a nursing
home or long-term care facility.
Conclusions: According to our study, most HCAP patients could be
treated in the same way as patients with CAP, after carefully ruling out
the presence of aspiration pneumonia.
Gram-negative bacteria: molecular detection
of antibiotic resistance
P1666 Real-time PCR for detection of NDM-1-carbapenemase
genes from stools
T. Naas*, A. Ergani, A. Carrer, P. Nordmann (Le Kremlin-Biceˆtre, FR)
Objectives: Several carbapenemases, such as the Ambler class A KPC,
the class D OXA-48, or the metallo-enzymes (IMP, VIM or NDM-1) have
now widely emerged. The latest, NDM-1 is probably the most worrisome,
in part due to its gene that is largely encountered in E. coli and in the
community. In order to control the spread of carbapenemase producers in
hospitalized patients, effective infection control measures and controlled
antibiotic usage must be complemented by the utilization of rapid and
sensitive molecular diagnostic assays, as suggested for KPC control. An
in house Real time PCR (qPCR) assay using TaqMan chemistry has been
developed to detect NDM-1 carbapenemase genes in pure culture and
directly from stool samples.
Methods: The assay was validated by comparing q-PCR with bacterial
culturing on ChromID ESBL™ and CHROMagar KPC media of diluted
bacterial suspensions or of spiked stool samples with several species of
NDM-1-producing bacteria.
Results: The q-PCR ampliﬁcation of blaNDM-1 DNA was linear
over 10 log dilutions (r2 = 0.99), and the ampliﬁcation efﬁciency
was 1.27. The q-PCR detection limit was reproducibly 1 CFU, or
10 plasmid molecules, and there was no cross-reaction with DNA
extracted from several multidrug-resistant bacteria harboring other
b-lactam resistance genes. Feces spiked with decreasing amounts of
enterobacterial isolates producing NDM-1, were spread on ChromID
ESBL™ and on CHROMagar KPC media and were subjected to the
qPCR. The limits of carbapenem-resistant bacterial detection from stools
was reproducibly 1−3×101 CFU/100mg feces with ChromID ESBL™.
The CHROMagar KPC culture medium had higher limits of detection
(1×101 to 4×103 CFU/mL) especially with bacterial isolates having low
carbapenem MICs. The limits of detection with the qPCR assay was
reproducibly below 10 CFU/100mg of feces by qPCR assay. Samples
spiked with NDM-1-negative bacteria were negative by q-PCR. The
sensitivity and speciﬁcity of the blaNDM-1 q-PCR assay was 100%
in both cases. Using an automated DNA extraction system (Qiacube
system), the qPCR assay was reproducible.
Conclusion: The utilization of q-PCR shortens the time for blaNDM-1
detection from 48 h to 4 h and will be a valuable tool for rapidly isolating
colonized or infected patients and assigning them to cohorts.
P1667 The complete sequence of the F group Plasmid p3452 from
E. coli 345−2 carrying silent antibiotic resistance genes
B. Humphrey, D. Walker, N.R. Thomson, V.I. Enne* (London,
Cambridge, UK)
Objectives: We have previously reported the naturally occurring
silencing of antibiotic resistance genes encoded on the IncN plasmid
pVE46 in Escherichia coli 345−2, a wild-type strain of porcine origin. In
affected isolates transcription of aadA1, blaOXA-2, sul1 and tet(A) was
absent but the wild-type genes were retained, following passage through
the pig gut. The mechanism by which silencing occurs is unknown.
E. coli 345−2 also carries a large cryptic plasmid, named p3452. The aim
of this study was to obtain the DNA sequence of p3452, and investigate
its possible association with the observed silencing phenomenon.
Methods: The complete DNA sequence of plasmid p3452 was obtained
from small insert libraries using dye terminator chemistry on ABI3700
automated sequencers and analysed using Artemis and BLAST. The
mobility of p3452 was investigated by conjugation using the agar mating
method following insertion of a kanamycin resistance marker onto the
plasmid using the Tn5 transposon. The presence of p3452 in different
variants of E. coli 345−2 was investigated by PCR.
Results: DNA sequencing revealed that p3452 is 87.6 kb in size
and encodes 84 putative open reading frames. The core replication,
transfer and stability functions of the plasmid are encoded in a region
approximately 50kb in size with more than 90% nucleotide identity with
the archetypal F plasmid, indicating p3452 is a member of the IncF
group. The remainder of the plasmid encodes a putative novel type IV
secretion system, which appears to have been mobilised onto p3452 via a
composite IS91 transposon. There are also putative novel ﬁmbrial genes,
located between identical IS1 elements, implicating involvement of IS1
in their acquisition. The presence of putative ﬁmbriae indicates a possible
role for p3452 in virulence. p3452 could be transferred by conjugation
into E. coli DH5a, demonstrating its transfer system is functional.
PCR showed a loss of the plasmid in variants of 345−2 carrying both
expressed and silent versions of the antibiotic resistance plasmid pVE46
indicating that p3452 had become unstable. Simultaneous instability and
silencing of unrelated, normally stable plasmids in the same strains
suggests the two phenomena may be linked.
Conclusion: The cryptic plasmid p3452 from E. coli 345−2 is an F-like
plasmid encoding putative virulence functions. It may be linked to the
phenomenon of antibiotic resistance gene silencing observed in the
strain.
P1668 Evaluation of an ESBL microarray as a conﬁrmation test
for the presence of extended-spectrum b-lactamases in the
routine clinical setting
T.N. Platteel*, J.W. Cohen Stuart, G.M. Voets, J. Scharringa, N. van
de Sande, A.C. Fluit, M. Leverstein-van Hall on behalf of the ESBL
working group
Objectives: For rapid detection of ESBL of the CTX-M, TEM and SHV
families we have co-developed an ESBL microarray. The diagnostic
characteristics of this microarray have not been determined as a
conﬁrmation test for the routine clinical setting. The aim of this study
was to determine the accuracy of the ESBL microarray as a conﬁrmation
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test of ESBLs in the routine laboratory setting, i.e. on randomly selected
clinical isolates with a positive ESBL screen test.
Methods: The microarray (Check-KPC, Check-Points, Wageningen) was
evaluated on a random selection of 344 clinical isolates with a positive
ESBL screen test (MIC >1mg/L for cefotaxime or ceftazidime or an
ESBL alarm from the Phoenix or Vitek-2 expert system) collected from
31 clinical microbiology laboratories in The Netherlands in 2009, using
sequencing as the reference method.
Results: Of the 344 isolates, 75% were E. coli (n = 257), 10%
K. pneumoniae (n = 35), 10% E. cloacae (n = 33), 3% P. mirabilis (n = 10)
and 3% K. oxytoca (n = 9). Based on PCR and sequencing, 245 isolates
were ESBL positive and 99 ESBL negative. Among the 245 ESBL-
positive isolates in total 251 ESBL genes were identiﬁed: 208 CTX-M,
25 SHV, 16 TEM, 1 GES and 1 PER. The sensitivity of the microarray
was 97% (237/245), the speciﬁcity 98% (97/99), the positive predictive
value 99% (237/239) and the negative predictive value 92% (97/105).
In 6 isolates, a CTX-M-1 group ESBL gene was not detected even after
repeating the test and 2 isolates contained an ESBL gene not included
in the design of the array (PER and GES). A false-positive result was
obtained in 2 isolates containing a TEM-1 gene. However, a TEM-17
and a TEM-19 group ESBL gene were identiﬁed by the array and both
isolates had an ESBL-positive phenotype as determined by Etest ESBL.
These false-positive results may be explained by the limitation of using
an unselective PCR and sequencing as the reference test, which may fail
to detect TEM ESBL genes in the presence of non-ESBL TEM genes,
whereas the microarray system uses a selective ampliﬁcation approach
that detects these TEM-ESBL genes accurately.
Conclusion: This study shows that the ESBL microarray is an accurate
conﬁrmation test for the presence of ESBL genes in the routine clinical
setting.
P1669 Multicentre evaluation of a new DNA microarray for
the detection of plasmidic AmpC and NDM-1 genes in
Enterobacteriaceae
P. Bogaerts*, A.M. Hujer, T. Naas, R. Rezende, A. Endimiani,
P. Nordmann, R.A. Bonomo, Y. Glupczynski (Yvoir, BE; Cleveland,
US; Paris, FR)
Objectives: To evaluate the performance of a new commercial
ESBL/plasmidic AmpC (pAmpC)/KPC/NDM DNA low density microar-
ray (Check-Points, Wageningen, The Netherlands) against a large set of
Enterobacteriaceae isolates with characterized mechanisms of resistance
to b-lactams.
Methods: 207 characterized (including bla gene sequencing) Enterobac-
teriaceae isolates (89 E. coli, 67 K. pneumoniae, 10 C. freundii, 8
P. mirabilis, 7 E. aerogenes, 5 E. cloacae, 21 others) were selected
according to their known resistance genes (86 pAmpCs, 91 non AmpC
and non NDM (various ESBLs and KPCs), 15 NDM-1 (including
10 concomitantly NDM-1 and pAmpC-positive isolates), 25 pAmpC
progenitors (strains harbouring natural chromosomal AmpC sharing very
similar DNA sequences with plasmidic AmpCs). Samples were blindly
processed and analyzed for the presence of pAmpC (CMY-2 like, DHA,
FOX, ACC, ACT/MIR, CMY-1 like), NDM and also for TEM, SHV,
CTX-M groups and KPC which were validated previously. Results were
interpreted according to the manufacturer’s instructions and they were
compared with those obtained by PCR and sequencing.
Results: All of the 86 pAmpC-positive isolates (64 CMY-2-like, 3 CMY-
1-like, 9 DHA, 7 FOX, 3 ACT/MIR), and the 15 NDM-1 (10 of these
co-expressing CMY-2 like) were correctly identiﬁed by the array (100%
sensitivity). Regarding speciﬁcity, all 91 strains harbouring resistance
mechanisms other than, and not including, pAmpC or NDM-1 (55 TEM;
37 SHV, 19 CTX-M, 3 LEN; 16 KPC), did not yield any positive signal
neither for pAmpCs nor for NDM-1 (100% speciﬁcity). Cross-reactivity
was nevertheless observed with chromosomal AmpCs harbouring species
known to be progenitors of the AmpCs by escaping the chromosome
(cross reactivity for 4/10 C. freundii (CMY-2), 4/4 M. morganii (DHA),
5/6 E. cloacae/asburiae (MIR/ACT), 1/1 chromosomal AmpC gene from
E. cloacae cloned in E. coli and 1/2 H. alvei (ACC), 0/2 A. hydrophila
(CMY-1)).
Conclusion: The Check-Points array appears as a robust tool for the
detection of pAmpCs and of NDM-1 in addition to other ESBL and KPC
encoding genes in Enterobacteriaceae. Detecting these novel resistance
determinants in addition to other ESBL encoding genes in complex
genetic backgrounds (large number of different b-lactamase genes)
provides signiﬁcant versatility to this system. Cross-reactivity is observed
with natural chromosomal AmpC genes of species known as pAmpCs
progenitors.
P1670 Evaluation of a DNA microarray for the rapid detection of
extended-spectrum b-lactamases (TEM, SHV and CTX-M),
and carbapenemases KPC, OXA-48, VIM, IMP, and NDM
T. Naas*, G. Cuzon, P. Bogaerts, Y. Glupczynski, P. Nordmann (Le
Kremlin-Biceˆtre, FR; Mont-Godinne, BE)
Objectives: Extended-spectrum b-lactamases (ESBLs) and carbapen-
emases (CARBA) are reported increasingly in Gram-negative bacilli
(GNB) and represent an emerging public-health concern. Laboratory
detection of ESBL- and CARBA-producers remains a challenge for the
microbiology laboratory and is important to avoid clinical failure due to
inappropriate antimicrobial therapy and to prevent nosocomial outbreaks.
We evaluated a new molecular diagnostic test for speciﬁc identiﬁcation
of TEM-, SHV- and CTX-M-type ESBLs, and of NDM, KPC, OXA-48,
VIM and IMP carbapenemase producers.
Methods: We evaluated the “Check-Points ESBL/CARBA array” test
(Check-Points, Wageningen, Netherlands) that employs highly speciﬁc
DNA markers to identify the b-lactamase genes of TEM, SHV, CTX-M,
NDM, KPC, OXA-48, VIM and IMP, and discriminates between ESBL
and non-ESBL TEM and SHV variants. 144 well-characterized Gram-
negative rods (Enterobacteriaceae, Pseudomonas sp., Acinetobacter sp.)
isolates possessing different bla genes were tested. Several wild-type
isolates or isolates harbouring other b-lactamase genes were used as
controls. Total DNAs were extracted using Qiagen DNA mini kit.
Results: The “Check-Points ESBL/CARBA array” system identiﬁed
correctly representatives of the three ESBL gene families tested,
including differentiation between non-ESBL and ESBL TEM and SHV
variants. In addition, the clinically relevant carbapenemases were also
reliably detected. Speciﬁcities and sensitivities of 100% were recorded
for the blaKPC, blaVIM, blaIMP, blaNDM, and blaOXA-48 genes,
whereas the sensitivities for blaKPC genes was 98%, likely as a result
of plasmid instability.
Conclusion: The “Check-Points ESBL/CARBA array” is a pow-
erful high-throughput tool for rapid identiﬁcation of ESBLs and
carbapenemase-producers such NDM in cultures. Due its rapid
performance, this platform could be used in epidemiological or infection
control studies in which large collections of isolates need to be
characterized.
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P1671 Bacteriophage and Helicobacter pylori: an underestimated
phenomenon
F. Vale, J. Guegueniat, S. Lacomme, E. Gontier, A. Alves Matos,
L. Engstrand, F. Me´graud, P. Lehours* (Lisbon, PT; Bordeaux, FR;
Stockholm, SE)
Introduction: The recently sequenced strain B45 isolated from a gastric
MALT lymphoma patient has a prophage sequence in its genome with
26.6 kb, highly similar to Helicobacter acinonychis prophage II. Until
now Helicobacter pylori has been described has a species without
prophage with the exception of the strain B38 (Thiberge JM et al., BMC
Genomics 2010) which contains some prophage remnant sequences.
Moreover, the number of reports of H. pylori phages is sparse in the
literature.
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Methods: The aim of our study was (1) to test the inducibility of the B45
prophage and using mitomycin C or UV, (2) to investigate the prevalence
of H. pylori-prophage carrying isolates. The reference strain H. pylori
26695 was used a negative control, and the JP1 strain which contains an
inducible ﬁlamenteous phage, as positive control (Vale FF et al., Microsc
Microanal 2008).
Results: On agar plates, no signiﬁcant lysis plaque was observed
after mitomycin or UV induction. On liquid media, mitomycin has a
toxic effect on bacterial cells even at low concentration (0.1mg/mL).
Finally, good results were obtained after UV irradiation of a 24h
inoculated broth followed by 24h more incubation. Phages particles were
obtained after polyethylene glycol precipitation followed by transmission
electron microscopy using negative staining or ﬁxation embedding and
sectionning. Phage particles having a structure compatible with the
Siphoviridae phage family were observed. Circular phage DNA was
recovered after alkalin extraction and detected by PCR. Using a PCR
strategy, based on degenerated primers designed on the B38, B45 and
H. acinonychis prophage II aligned bacteriophage integrase genes, we
have screened until now 340 H. pylori strains isolated from different
geographic regions (Europe, Africa, and Asia) and representative of
the H. pylori associated gastroduodenal pathologies (gastritis, ulcer,
cancer and MALT). The prevalence of the integrase sequence was
20.9%, suggesting that this is a much frequent phenomena that initially
estimated. Phylogeny analysis showed a trend for a geographical
distribution and especially well deﬁned European, and Asian clusters.
Conclusion: The B45 strains harbours a temperate phage. This study
shows for the ﬁrst time that bacteriophage can play a signiﬁcant role
in H. pylori genetic diversity. It also opens new exciting ways in
the comprehension of the interaction between the bacteria within its
environment.
P1672 IS-pro: fully automated molecular analysis of the human
intestinal microbiota
A.E. Budding*, M.E. Grasman, A.A. van Bodegraven, P.H. Savelkoul
(Amsterdam, NL)
The human large intestine is one of the most densely populated
microbial ecosystems on earth, with bacterial cell counts of up to
1011/g luminal content. An especially intriguing feature of this ecosystem
is its commensalism with the human host. It has been shown that
the intestinal microbiota is strictly species speciﬁc, implying that host
and microbiota have co-evolved for a long time. The relatively recent
adoption of a modern ‘westernized’ lifestyle, coincides with a dramatic
increase in a number of previously rare diseases, including inﬂammatory
bowel disease, asthma, diabetes mellitus, rheumatoid arthritis, multiple
sclerosis and others. Many of these diseases have now been shown to be
characterized by an altered intestinal microbiota.
Analysis of the exact nature of the often complex changes in the intestinal
microbiota may greatly enhance our understanding of the etiology of
these diseases. Moreover, as these changes are often disease speciﬁc,
analysis of fecal microbiota may be used as a non-invasive diagnostic
tool. Currently however, the techniques employed for these analyses are
typically expensive, laborious or both. This has restricted research in
this ﬁeld to small patient numbers and has prohibited implementation of
microbiota analysis in clinical diagnostics.
We developed IS-pro: an inexpensive and fast method for high-
throughput analysis of the human intestinal microbiota which has been
fully validated in silico, in vitro and in vivo in human samples. The
method combines species identiﬁcation by 16S-23S interspace (IS)
length with phylum identiﬁcation by colour labelling of primers. The
entire process of IS-pro consists of a single PCR followed by fragment
analysis by capillary gel electrophoresis and automated analysis of digital
proﬁles. For the automated analysis we developed a web-based software
tool that ﬁrst calibrates proﬁles and identiﬁes peaks and then translates
proﬁles into a list of bacterial species by means of a large library of IS
sequence data that we built. An internal ampliﬁcation control consisting
of multiple DNA fragments of varying lengths is used for quality control
of the PCR process over the entire range of fragment lengths. IS-pro is
currently optimized for the human intestinal microbiota, but may easily
be adapted for use in other microbial communities.
P1673 Evolution of a high-prevalent clone of Pseudomonas aerug-
inosa in a cystic ﬁbrosis patient during chronic infection
R. van Mansfeld*, M.J. Bonten, R.J. Willems (Utrecht, NL)
Objectives: Adaptation of Pseudomonas aeruginosa (PA) during chronic
lung infection in cystic ﬁbrosis (CF) patients includes conversion to a
mucoid phenotype, increased antibiotic resistance and reduced virulence
(ref 1). We reported previously on the existence of a high prevalent PA
clone, ST406, among Dutch CF patients (ref 2). To investigate adaptation
of this clone to the CF lung during chronic infection two ST406 isolates,
recovered from the same patient three years apart, were analysed.
Methods: The ﬁrst ST406 strain was obtained one month after ﬁrst
PA colonization (2004) and the second isolate three years later. Both
had identical MLST, MLVA and SNP typing (AT biochip) and were
sequenced using 454 pyrosequencing, and annotated using RAST. Gene
content differences were conﬁrmed by PCR and evaluated in a set of 30
different ST406 isolates and 30 non-ST406 isolates. Differences in gene
expression were assessed using a PA Affymetrix microarray.
Results: Whole genome sequencing revealed a highly conserved gene
content in both isolates. The only observed difference was the insert of
a gene cluster of ﬁve genes in the late isolate next to a tRNA gene. The
genes putatively encode a bacteriophage protein, an intergrase and three
hypothetical proteins. This gene cluster was found in 12 of 30 ST406
isolates and in none of 30 non-ST406 isolates.
Transcriptomics revealed that in the late isolate 76 genes were at least
2-fold up-regulated and 34 genes 2-fold down-regulated compared to
the early isolate. The down-regulated genes include known virulence
genes like those encoding the type III secretion apparatus, exoS and
iron transport proteins.
Conclusion: Whole genome sequencing revealed high conservation of
the gene content in an early and late isolate recovered from a CF patient,
after one month and three years of colonization, respectively. Yet, it is
not clear if or how the acquired gene cluster facilitates adaptation during
chronic infection. Several of previously described virulence factors were
down-regulated in the late isolate corroborating previous ﬁndings of
reduced virulence of chronically infecting PA strains.
Reference(s)
[1] Holm Rau et al., Environ Microbiol. 2010 Jun; 12(6): 1643−58.
[2] Mansfeld et al., J Clin Microbiol. 2009 Dec; 47(12): 4096–101.
P1674 Identiﬁcation of a novel Brachyspira species in human
intestinal spirochaetosis
L.J. Westerman, H.V. Stel, M.E. Schipper, L.J. Bakker, E. Boel*,
J.H. van den Brande, P.D. Siersema, J.G. Kusters (Utrecht,
Blaricum/Hilversum, NL)
Objective: Infections by the spirochaete Brachyspira are a common
cause of intestinal disorders in animals and consequently have been
studied extensively in veterinary science. Knowledge of human intestinal
spirochaetosis is scarce. It is thought to be caused by two Brachyspira
species: Brachyspira aalborgi and Brachyspira pilosicoli. Prevalence
rates are estimated between 1−32% in the general population and up
to 63% homosexuals. Diagnosis of intestinal spirochaetosis is based
on histopathology of colon-biopsies and does not allow for species
identiﬁcation. The aim of this study was to use molecular techniques
to identify the infecting Brachyspira species in human intestinal
spirochaetosis.
Methods: A speciﬁc primerset was designed against a region of the
16S rRNA gene that was both speciﬁc for, and conserved within
all Brachyspira species. Formalin ﬁxed colon biopsies were included
from histopathology spirochaete positive patients (n = 25 patients, n = 50
biopsies) and spirochaete negative patients (n = 19 patients, n = 23
biopsies). All samples were revised by a gastrointestinal pathologist to
conﬁrm the diagnosis. DNA was isolated from the biopsy samples with
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a Roche MP96 and real-time PCR and SYBR-green melt-curve analysis
of the PCR products was performed on a Roche LC480. Speciﬁcity of
the ampliﬁcation was conﬁrmed by DNA sequence analysis of the PCR
fragments.
Results: All colon samples from histopathology positive patients showed
ampliﬁcation of the predicted 136 bp 16S rRNA amplicon, whereas
all negative controls did not generate a PCR product. SYBR-green
based melt-curves indicated that next to the two Brachyspira species
known to infect humans, a third Brachyspira species was occasionally
present. Sequence analysis conﬁrmed the presence of single infections
with B. aalborgi (12/25), B. pilosicoli (3/25), and a thus far unreported
Brachyspira species (3/25). In addition, there were seven double
infections: 3/25 B. aalborgi together with the novel Brachyspira species,
2/25 B. pilosicoli with the novel Brachyspira species and 2/25 B. aalborgi
with B. pilosicoli.
Conclusions: To our knowledge this is the ﬁrst real-time PCR that allows
for immediate detection and species discrimination of Brachyspira on
routine biopsy materials. The PCR revealed that in human spirochaetosis
a surprisingly high number of double infections is present, and a thus
far unreported Brachyspira species is involved.
P1675 Genotypic detection of rifampicin- and isoniazid-resistant
Mycobacterium tuberculosis strains by the pyrosequencing
method
I. Herna´ndez-Ca´ceres*, O´. Dı´ez-Gil, J. Alcoba-Flo´rez (Santa Cruz
de Tenerife, ES)
Objectives: Tuberculosis (TB) is a major global health problem,
worsened by the emergence of isoniazid (INH) and rifampin (RIF)
resistant strains (multi-drug resistant, MDR). The objective of our study
was to evaluate a method for molecular monitoring of the most common
mutations conferring resistance to INH and RIF in clinical isolates of
Mycobacterium tuberculosis, based on pyrosequencing techniques.
Methods: 72 M. tuberculosis (MTC) strains isolated from clinical
samples of different patients were selected. The source of the bacteria
was either a colony grown on Lo¨wenstein-Jensen or from pelleted
MB/BacT® (Biome´rieux) broth cultures. DNA was extracted using a
Capture Column DNA extraction kit (QIAGEN) and the NucliSens®
easyMAG® system (BioMe´rieux).
For the detection of INH and RIF resistance, we studied mutations in
different genes (katG, inhA ahpC and rpoB) by pyrosequencing and the
MTBDR Assay (Hain Lifescience GmbH, Germany).
Pyrosequencing was performed in the automated PSQ 96MA 96-
well pyrosequencer (Biotage). Preparation of templates and sequencing
reactions was performed according to the manufacturer. A cyclic
nucleotide dispensation strategy and a sequence analysis (SQA) software
were used. The sequences deemed acceptable by the software were
submitted as BLAST queries through NCBI.
Results: The concordance between the MTBDR assay and the
pyrosequnecing results was 100%. All susceptible strains showed a wild-
type MTBDR hybridization pattern and no mutations were found at the
codons studied by pyrosequencing. Three isolates were resistant to RIF
and INH (MDR-TB), 2 were high-level INH mono-resistant and 6 were
low-level INH mono-resistant. 64 were susceptible to both drugs.
For the three isolates resistant to RIF, the rpoB gene mutations found
were Ser531Leu, His526Tyr and Asp516Val.
A Ser315Thr mutation in katG was identiﬁed in 4 of the 8 isoniazid-
resistant isolates. Two of these isolates presented mutations in both katG
and inhA. The other 6 isolates presented a mutation only in the inhA
gene. The inhA promoter gene was the most frequently mutated gene.
No mutations in the ahpC gene were detected.
Conclusion: Pyrosequencing is a real-time sequencing technique that is
fast, reliable and cost-effective for the detection of resistance to RMP
and INH in clinical M. tuberculosis isolates.
Both the MTBDR Assay and pyrosequencing are useful tools for the
diagnosis of MDR-TB, but pyrosequencing is more versatile and allows
the detection of new mutations.
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P1676 Detection of epidemiologically signiﬁcant organisms (ESO)
from surveillance specimens using pooled ESwabs compared
to swabs in Amies transport medium
B.M. Willey*, P. Gnanasuntharam, G. Nguyen, B. Borgundvaag,
W. Leung, M. Loftus, R. Thanabalan, V. Porter, G. Small, I. Edwards,
P. Lo, K. Wong, Y. Wei, G. Mahli, A. McGeer, S.M. Poutanen (Toronto,
CA)
Objectives: A pilot study comparing 254 single eSwabs to mattress
swabs in ATM for detection of methicillin-resistant and -susceptible
S. aureus (MRSA, MSSA) from nares and axilla indicated that yield
from eSwabs fell in between ATM with direct plating and ATM broth
enrichment culture. This study compared the yield from pooled nasal
(NAS) and rectal (REC) eSwabs (PeS) to individual swabs in ATM.
Methods: From Aug-Dec 2010, with ethics approval and informed
consent, single NAS and REC swabs in ATM were collected in
parallel to PeS from Emergency Room and Inﬂammatory Bowel
Disease Clinic patients. The ATM swabs were plated manually as
per laboratory protocol to selective agars for MRSA, MSSA, resistant
(R) Gram-negative bacilli (R-GNB; deﬁned as acquired 3rd generation
cephalosporin-R plus R to ﬂuoroquinolones and/or aminoglycosides)
and vancomycin-resistant enterococci (VRE). The automated WASP
instrument (Copan) plated 30uL of liquid from each PeS to the same
media. Incubation and identiﬁcation methods were standardized.
Results: In total, 475 patients consented to parallel specimens. MRSA
was identiﬁed from 7 patients, of which 5 (1.1%) were detected from
NAS-ATM, 4 (0.8%) from REC-ATM and 6 (1.3%) from PeS. Due to
the low MRSA prevalence among this population, comparison of swab
types was performed using MSSA detection as a proxy. As such, MSSA
was identiﬁed from 102 (21.5%) NAS-ATM, 37 (7.9%) REC-ATM (112
patients with the NAS-ATM and REC-ATM swab sets combined), while
107 (22.5%) were detected by the PeS, from a total 118 MSSA cases.
The difference in overall number of MSSA patients detected between
the combined ATM and the PeS was not statistically signiﬁcant (107
PeS MSSA+ versus 112 ATM MSSA+: Fisher’s exact test/two tailed P
value = 0.7079). Similarly, there was no statistical difference between
detection for R-GNB by the 2 swab systems: REC-ATM and PeS both
detected 49 R-GNB, respectively, from 51 positive patients. Of the 51
patients with R-GNB (1 C. freundii, 42 E. coli, 4 K. pneumoniae, 4
P. mirabilis), 47 were identiﬁed from both REC-ATM and PeS, while
E. coli from 4 remaining patients were identiﬁed from REC-ATM (2
isolates) or PeS (2 isolates) only. No VRE were identiﬁed from any
swab.
Conclusions: This study found the WASP planted PeS (nasal plus rectal)
to have an equivalent yield of ESO compared to NAS-ATM and REC-
ATM planted separately.
P1677 Stability of Bordetella pertussis and Bordetella parapertussis
in the ESwab transport system for culture and PCR
K. Van Horn*, C. Audette (Cypress, US)
Objectives: Pertussis (whooping cough) is caused by Bordetella
pertussis and Bordetella parapertussis, with several states in the USA
reporting an increased incidence. Laboratory detection methods include
culture, direct ﬂuorescence assay, and PCR methods; Successful culture
and PCR detection requires proper specimen collection and transport.
This study examined the effectiveness of the ESwab system (consisting
of liquid Amies transport medium and a ﬂocked nasopharyngeal swab,
Copan Diagnostics, Inc.) for maintenance of viability of B. pertussis
and B. parapertussis for culture and preservation of nuclear material for
detection by PCR.
Methods: Seven Bordetella isolates were tested: including 4 B. pertussis
isolates (ATCC 9340 strain and 3 recent clinical isolates of B. pertussis)
and 3 B. parapertussis isolates (ATCC 15237 strain and 2 recent
clinical isolates). Test methods were based on CLSI M40 guidelines.
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Three Bordetella saline suspensions (108, 106, and 104 CFU/mL) were
prepared. Each suspension was used to inoculate ESwabs in triplicate.
The inoculated ESwabs were stored refrigerated (2−8ºC) for up to 96
hours prior to plating. Bacteria from the ESwabs were cultured on Regan
Lowe agar plates at 0, 24, 48, and 96 hours of refrigerated storage
post-inoculation; plates were then incubated at 37ºC in ambient air for
a minimum of 4 days. The numbers of colonies at 24, 48, and 96
hours were compared to the 0 hour count to determine percent recovery
(viability). Real-time PCR, using primers targeting the IS481 gene of
B. pertussis and the IS1001 gene of B. parapertussis, was performed on
24-hour and 96-hour inoculum in the ESwab.
Results: Bordetella was isolate from all of the ESwabs after 96 hours
of refrigerated storage. Percent recovery ranged from 36.6% to 96.3%
for B. pertussis, and from 32.7% to 74.5% for B. parapertussis, and was
similar across the three inoculum densities for all isolates tested. PCR
detected B. pertussis and B. parapertussis in all of the 24- and 96-hour
ESwabs, regardless of initial inoculum concentration (104 or 106).
Conclusion: The ESwab maintains sufﬁcient viability of B. pertussis and
B. parapertussis to permit detection in bacteria cultures and preserves
DNA integrity for PCR detection, even after 96 hours of refrigerated
storage.
P1678 Preliminary evaluation of a Copan ESwab system for lower
respiratory tract samples for microbiological culture
M. Avolio*, R. De Rosa, P. Stano, M. Modolo, A. Camporese
(Pordenone, IT)
Objectives: To evaluate the ability of a preservative impregnated sponge
to preserve the quality of lower respiratory tract samples for accurate
quantiﬁcation and species identiﬁcation in the microbiology laboratory.
Methods: 78 samples (67 bronchial aspirate and 10 bronchoalveolar
lavage) were evaluated. Specimens collected into screw cup containers
were inoculated over the routine culture solid medium according to
laboratory-deﬁned standard procedures. The preservative sponge (Copan
Liquid Amies Elution Swab Collection and Transport System, Brescia,
Italy) was dipped into the remaining sample to adsorb it, and then the
swab applicator was inoculated into Copan liquid amies, mixed using a
vortex for 5 seconds and then 10 l of this suspension were inoculated
over the routine culture solid medium.
Results: Signiﬁcant growth of pathogens bacteria (104−1 and 105
colony-forming units/mL for bronchoalveolar lavage and bronchial
aspirate respectively) were evaluated.
77 of the cultures (98,7%) showed equivalent results for both methods.
Among the 14 positive case, 92, 8% showed concordance in terms
of signiﬁcant growth and species identiﬁcation. Only 1 case was not
detected in signiﬁcant growth by Copan ESwab system thus generating
a major error in the ﬁnal result.
Conclusion: In this study for detection of patients with potentially
signiﬁcant lower respiratory tract infections, the two system showed a
concordance of 92, 8%. Differences in volume inoculated or sampling
error might account for the quantitative variation observed in 1 positive
culture.
The preservative impregnated sponge may offer a simple alternative
method for the transport of lower respiratory tract samples for
microbiological culture. Nevertheless several studies are needed to
address this issue.
P1679 Comparison of the Copan fecal swab to dry containers for
collection and transportation of stool samples for detection
of bacteria causing gastrointestinal infections
A. Altieri, M.C. Bossa*, F. Capalbo, L. Di Traglia, C. Fontana (Rome, IT)
Objectives: Collection, preservation and transportation of stool speci-
mens is important for the diagnosis of microbes causing gastrointestinal
infections. Liquid Base Microbiology (LBM) is a new concept of liquid
specimens transport used with the Walk Away Specimens Processor
(WASP). The Fecal Swab (a tube with 2ml of Cary Blair medium and a
ﬂocked Swab) and 2 enrichment broth, a Selenite (SE) and a Rappaport
Vassiliadis (RVS) broth, both available in 2ml tube, are part of the LBM
media. The objective of this study was to compare the Copan Fecal
Swab (FS) device to dry containers (DC) for the collection, storage and
transportation of stools (S) specimens for detection of bacteria, toxins
and nucleic acids of gastrointestinal bacteria. To compare the Copan SE
and RVS broth to SE broth currently used.
Methods: Stool samples (N = 125), collected in FS and in DC, were
analyzed as per current laboratory procedures. For the DC 4−5mg of
sample were transferred in SE broth and processed on the ROBOBACT
(Diesse) for the detection of Salmonella (SA) and Shigella (SH). For FS
samples, after vortexing, 300 ul of each sample was inoculated into each
of 2ml tube of Copan SE and RVS broths and incubated at 37ºC for
18−24h. Both broths for SA/SH culture were loaded on the WASP and
inoculated with the 10ul loop on SS, McConkey and SM2 chromogenic
Salmonella agar plates. Both DC and FS samples for Campylobacter,
were passed through a Campylosel microﬁlter on Skirrow agar. Detection
of Clostridium difﬁcile (CD) toxin A/B was tested with the Xpect CD
Toxin A/B test (Remel) as per kit procedure. For C. difﬁcile culture,
samples were shock treated with ethanol and seeded on CLO selective
agar. CD toxin was also tested with the Xpert CD (Cepheid) assay as
per kit method.
Results: Of the 125 S samples, 72 were negative, 35 were positive for SA
group, 7 positive for C. jejuni, and 11 positive for CD toxin (11 cultures
positive) for the DC samples. For the FS samples, 64 were negative, 40
were positive for SA group, 10 positive for C. jejuni, 10 positive for
CD toxin (10 cultures positive). Concordant results were found in the
detection of SA with the Copan SE and RVS broths.
Conclusions: More positive were detected by all testing methods in S
samples collected with the Copan FS and shown to be a better device
for transporting and storing gastrointestinal tract pathogens. RVS can be
used instead of SE, eliminating the problem of SE disposal problems for
the laboratory.
P1680 SL-Solution for pre-treatment of mucus-rich respiratory
specimens for culture and molecular assays
M. Favaro, M. Pellicioni, C. Fontana* (Rome, IT)
Objectives: Respiratory samples represent a signiﬁcant proportion
of routine microbiological specimens and are very important for
management of critically ill patients. Copan has developed the SL-
Solution (SL); a ready to use mucus dissolving solution that comes
in tubes with 1.0ml. The objective of this study was to compare the
performance of Copan SL-Solution to Sputasol (SPU; Oxoid) with
microscopical, culture and molecular assays.
Methods: In this study were compared 100 specimens, 81
bronchoalveolar-lavages (BAL), 3 bronchial-aspirates (BA) and 16
sputum (SP) for microscopy, UFC and culture inoculation with the Walk
Away Specimens Processor (WASP). Forty-ﬁve (15 BAL, 15 BA and 15
SP) were also tested for: b-actin gene and 16S rDNA by real time PCR;
C. pneumoniae,M. pneumoniae, L. pneumophila with the Duplicate Real
Time CP, MP, LP on the Smart Cycler, (Euroclone); M. tuberculosis
complex with the MTB GeneXpert (Cepheid); MOTT (Mycobacteria
other than tuberculosis) with the Genotype Mycobacteria Direct (Hain
Life Science) Each sample was treated in duplicate, one with SPU after
30 minutes incubation at 350C, the other with SL, 1ml specimen was
added to a SL tube to obtain a 1:1 ratio (sample/SL, with the exception
of samples tested on GeneXpert for which a ratio 2:1 is recommended by
the manufacturer), vortexed and used immediately. Smears of SL treated
samples were prepared immediately (time 0) and after 15 minutes, to
evaluate if time could affect the microscopic results. Nucleic acid was
extract from all samples with the easyMag (Biomerieux) and the EZ1
Robot (Qiagen). Nucleic acid obtained from all samples was tested for
b-actin gene, a portion of the 16S rDNA and for the agents listed in the
above assays.
Results: SL-samples showed 100% concordance with culture results
on the WASP as SPU-samples. 34 samples were positive with
signiﬁcant pathogens and 66 negative. SL microscopy results had 100%
Molecular diagnosis of urogenital infections S485
concordance at time 0, but 30% discrepancies in smears prepared after
15 minutes. The UFC results, had 7 discrepant, 6 SL-samples had lower
UFCs than same SPU-samples, one had greater UFCs with SL. The
molecular results had 100% agreement and no inhibition was present in
both samples pre-treatments.
Conclusion: The SL is excellent for recovering microorganisms by
culture on the WASP and with molecular assays. Its user friendly, enables
rapid and uniform ﬂuidization without pre-incubation, but smear must
be prepared immediately.
P1681 Cryopreservation of Blastocystis: signiﬁcance of foetal calf
serum
A. O¨zbilgin*, O¨. Kurt, T. Oyur, V.O¨. Ermis, T. Tabak, E. Kal
Cakmakliogullari, C. Stensvold (Manisa, TR; Copenhagen, DK)
Objectives: Cryopreservation is deﬁned as keeping living cells frozen
with the chance of regaining cellular viability, functions and antigenic
structures whenever required, after heating. Blastocystis is a common
intestinal protozoon infecting people worldwide with a high prevalence
especially among patients with irritable bowel syndrome. Owing to its
easy cultivation in vitro, Blastocystis is both an in vitro and in vivo
model for intestinal protozoa in laboratory studies. Our aim is to conduct
cryopreservation of Blastocystis with different solutions to identify the
most appropriate option for the procedure.
Methods: Blastocystis-positive stool samples of six patients were
cultivated in Jones medium at 37ºC for 48 hours, followed by successive
passages every 48 hours. The growth rates and viabilities of Blastocystis
were determined by counting on hemocytometer and staining with
eosine, respectively. Positive cultures were then centrifuged at 1000
RPM for 10 minutes, and the pellets containing 2×109 parasites/ml were
suspended in equal volumes of dimethyl sulphoxide (DMSO) and Jones
medium, or glycerine and Jones medium (50%/50%), or DMSO and
fetal calf serum (FCS) (10%/90%), or glycerine and FCS (10%/90%).
All tubes were kept for 1 hour at +4ºC, 2 hours at −20ºC, overnight
at −86ºC and then taken to liquid nitrogen tank for cryopreservation.
Control examination was done after 3 months; the ingredients were
thawed at 37ºC, inoculated in tubes containing fresh Jones medium and
their growth rates and viabilities were checked every 48 hours.
Results: A total of 5×107 viable Blastocystis were counted both in
DMSO/FCS (10%/90%) and glycerine/FCS (10%/90%). It was also
detected that Blastocystis isolates maintained their viabilities even in
subcultures.
Conclusion: Cryopreservation with DMSO/FCS (10%/90%) or glycer-
ine/FCS (10%/90%) seems to be an optimal protocol for Blastocystis.
P1682 Preliminary evaluation of the HB&L system for the
microbiological screening of storage liquids of preserved
corneas at 31ºC
D. Camposampiero*, S. Grandesso, E. Zanetti, S. Mazzucato,
M. Solinas, R. Bussolotto, M. Gion, D. Ponzin (Venice, IT)
Objectives: Aim of this study is to compare the performances of
the HB&L with the Bactec system, validated and used in the Veneto
Eye Bank Foundation to identify microorganisms contaminating storage
liquids of human corneas preserved at 31ºC for transplantation.
Methods: Corneas collected within 24 hours from the death after
disinfection of the ocular surface are stored at 31ºC in preserving liquid.
Suitable tissues are transferred into a deturgescent liquid to restore
physiological thickness. The microbiological tests by inoculing a sample
of liquid in Bactec Peds Plus and Bactec Plus Anaerobic bottles are
performed after six days of storage, at the end of storage and after
24 hours of permanence of the cornea in deturgescent liquid. For this
preliminary study 1476 samples of preserving and deturgescent liquids
were subjected to microbiological control in parallel using the Bactec
and the HB&L system. Samples were incubated for 24 hours in HB&L
and for 6 days in Bactec. The positive results were subjected to standard
identiﬁcation procedures.
Results: 23 positive samples (1.6%) and 1453 negatives (98.4%)
were detected. Among the positive samples, 7 samples were positive
for HB&L+/BACTEC+, 14 samples HB&L+/BACTEC−, 2 samples
HB&L−/BACTEC+.
Samples HB&L+/BACTEC+ are represented by streptococci (3),
Candida sp. (2), enterococci (1) and Kocuria sp. (1), in samples
HB&L+/BACTEC− have been identiﬁed staphylococci (13) and Candida
sp. (1) and then the samples HB&L−/BACTEC + showed the presence
of Fusarium (1) and Bacteroides (1).
Conclusion: HB&L+/BACTEC+ samples should be considered bacteria
present in the cornea, because the organisms isolated were the same
in the two diagnostic systems. Samples HB&L+/BACTEC− should
be considered as contamination of the sample inoculum, whereas
staphylococci were not found in the preserving liquid analyzed with
traditional culture. The only exception is the detection of Candida found
in HB&L and the preserving ﬂuid, but not in Bactec bottles. The 2
samples resulted BACTEC+/HB&L− were a ﬁlamentous fungus and an
anaerobic bacterium; this was a supposed limit of the HB&L system
because the broth is suitable for aerobic bacteria. Further investigation
will be done with new broths that are under development especially
formulated for anaerobic bacteria and fungi. The HB&L system could be
proposed as a fast test for the detection of the absence of microorganisms
in liquid storage of corneas as supporting the existing method.
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P1683 Diversity of human vaginal bacterial communities in
healthy women and bacterial vaginosis
K. Wang, Z. Lv, J. Su* (Beijing, CN)
Background: Balance of microbial ﬂora in the vagina plays an important
role in preventing genital tract infections in women, thus an accurate
understanding of the composition and ecology of the ecosystem is
essential for understanding the aetiology of related diseases. Traditional
cultivation technologies are limitative for most of the microbial species
that reside in the vagina, while the method of construction 16S rRNA
library is credible for illuminate the diversity of human vaginal bacterial
communities.
Methods: Broad-range polymerase-chain-reaction (PCR) ampliﬁcation
of 16S rRNA and construction of 16S rRNA library were used to
analysed the vaginal ﬂora diversity of 20 healthy women and 20 bacterial
vaginosis (BV), and Fluorescence in situ hybridization (FISH) performed
directly on the vaginal ﬂuid to illuminate the relationship between
bacteria and epithelial cells. Clinical manifestation, Amsel criteria and
Nugent score were used to strictly distinguished the healthy and BV
positive women.
Results: The diversity and kinds of organisms that comprise the
vaginal microbial community varied among women. Women without
bacterial vaginosis had 1 to 5 vaginal bacterial species (phylotypes)
in each sample, as detected by broad-range PCR of 16S rDNA,
and lactobacillus species were the predominant bacteria. Women with
bacterial vaginosis had greater bacterial diversity, where Gardnerella,
Atopobium, Prevotella, Leptotrichia/Sneathia were strongly associated
with BV. FISH conﬁrmed that BV associated bacteria detected by PCR
corresponded to speciﬁc bacterial morphotypes visible in vaginal ﬂuid.
Discussion: Culture-independent methods can provide new insights into
the diversity of bacterial species found in the human vagina, and this
information could prove to be pivotal in understanding the etiology of
BV.
P1684 Diagnostic accuracy of molecular biology in the diagnosis
of syphilis: a meta-analysis
A. Gayet-Ageron*, S. Lautenschlager, B. Ninet, T. Perneger,
C. Combescure (Geneva, Zurich, CH)
Objectives: Syphilis remains an important sexually transmitted infection
(STI) worldwide. However, the diagnosis of syphilis is based on
S486 21st ECCMID/27th ICC, Posters
imperfect serological tests and/or darkﬁeld microscopy which requires
skilled personnel. Treponema pallidum gene ampliﬁcation by Polymerase
Chain reaction (TpPCR) is viewed as an interesting alternative. We
conducted a systematic review of published studies assessing the
diagnostic performance of TpPCR.
Methods: We searched bibliographic databases (Medline, Embase, ISI
Web) and abstracts from the main infectious diseases and STI congresses
between 1999 and 2009 (ICAAC, ECCMID, ICID, IUSTI). We included
all cross sectional and diagnostic accuracy studies with data on the
diagnostic performance of TpPCR compared to traditional syphilis tests.
Pooled sensitivities and speciﬁcities were assessed by syphilis stage
and biological specimen using systematically random effects models.
Heterogeneity was explored.
Results: We identiﬁed 55 studies of primary syphilis (1379 cases,
2676 controls), secondary syphilis (411 cases, 296 controls), early
syphilis (including primary, secondary and early latent) (670 cases, 1737
controls), neurosyphilis (106 cases, 24 controls), latent syphilis (292
cases, 40 controls) and congenital syphilis (89 cases, 99 controls). Most
studies used the 47kDa membrane lipoprotein gene as target (69%) or
the polA gene (18%). Patients were more often male (69%) with a
median age of 31.5 years, and the prevalence of HIV, when tested, was
38.0%. In a majority of specimens tested by syphilis stage, the pooled
sensitivity was below 50% (Table). A high degree of heterogeneity
was detected. Pooled sensitivities were signiﬁcantly lower in studies
from African countries compared to those conducted in North America.
Pooled sensitivities from West European countries were systematically
the highest. Pooled speciﬁcities ranged from 89.8% (95%CI: 52.7–98.6,
n = 3) in CSF of latent syphilis to 97.9% (95%CI: 93.0–99.4, n = 4) in
ulcers of secondary syphilis. Overall heterogeneity was not detected in
speciﬁcities.
Conclusion: The results of the meta-analysis suggest that TpPCR cannot
be proposed as an alternative reliable diagnostic tool, even in genital
ulcers, nor can it replace the traditional serological tests.
P1685 Evaluation of the Bio-rad Dx CT/NG/MG assay, a
new real-time PCR test for the simultaneous detection
of Chlamydia trachomatis, Neisseria gonorrhoeae and
Mycoplasma genitalium
P. Sednaoui*, N. Nassar, G. Allemelou, F. Castano, L. Monfort (Paris,
FR)
Objectives: The Bio-Rad Dx CT/NG/MG Assay is a new real-time PCR
test for the direct and simultaneous detection of Chlamydia trachomatis
(CT), Neisseria gonorrhoeae (NG) and Mycoplasma genitalium (MG)
in urogenital and anorectal samples.
This study was conducted in order to evaluate the clinical performance
of the Bio-Rad Dx CT/NG/MG Assay versus Roche Cobas TaqMan CT,
Gen-Probe AC2 CT/NG and culture for NG. For M. genitalium, positive
samples were sent to the Bacteriology lab of V. Segalen University
(Bordeaux) for conﬁrmatory testing.
Methods: For this prospective study, urogenital and anorectal samples
were obtained from symptomatic and asymptomatic patients attending
the Alfred Fournier Institute for a STI screening, a medical consultation
or a biological check-up, from December 2009 to April 2010. For
clinician-collected genital (urethral, endocervical, vaginal) and ano-rectal
samples, a Bio-Rad ﬂocked swab was collected in addition to the routine
technique’s swab. Urine samples from each patient were dispatched
between the different techniques. For each molecular test, DNA was
extracted by manual extraction method then ampliﬁed according to each
manufacturer’s instructions.
Results: A total of 1697 specimens from 955 patients (327 men and
628 women) were analyzed. The prevalence of CT, NG and MG was
respectively 6,2%, 0% and 1,4% in women, and 11,6%, 10,1% and 3,4%
in men. For CT, the relative sensitivity of the Dx CT/NG/MG Assay
was 98% (50/51) versus Roche and 92,7% (51/55) versus Gen-Probe;
the relative speciﬁcity was 100% (649/649) versus Roche and 99,9%
(953/954) versus Gen-Probe. For NG, the relative sensitivity of the Dx
CT/NG/MG Assay was 100% (30/30) versus culture and 90,9% (10/11)
versus Gen-Probe; the relative speciﬁcity was 99,7% (675/677) versus
culture and 100% (998/998) versus Gen-Probe. For MG, all positive
samples obtained with the Dx CT/NG/MG Assay were sent to Bordeaux
to be tested with an inhouse real-time PCR test: a concordance of 95,8%
(23/24) was found.
Conclusion: The new Bio-Rad Dx CT/NG/MG Assay has been found
to be highly performant and very easy to use. We also appreciated the
quality of its associated sample collection systems and the compacity and
simplicity of the Dx Real-Time System instrument and software. This
kit is well suited for the routine simultaneous detection of Chlamydia
trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium in
urogenital specimens from asymptomatic and symptomatic patients.
P1686 Duplex PCR for systematic simultaneous detection of
Chlamydia trachomatis and Neisseria gonorrhoeae in clinical
specimens: the added value of a dual approach
K. Jaton*, R. Brouillet, G. Greub (Lausanne, CH)
Objective: To reduce costs and increase throughput, we developed
a quantitative real-time duplex PCR (q-PCR) for the simultaneous
diagnosis of Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae
(Ng). The costs being reduced by duplexing, we tested clinical samples
for both pathogens in all samples whenever either Ct or Ng was requested
by clinicians to measure the added value of such a systematic dual
approach.
Methods: The porA region for Ng and the cryptic plasmid for Ct were
targeted (Jaton et al., JCM, 2006). The duplex PCR was run on an
automated platform (MagnaPure LC (Roche) for the extraction, Tecan
liquid handling system for the 384 plate assembly, ABI 7900 (Applied
Biosystems) for the TaqMan assay on 11470 clinical samples received
in our laboratory (2006–2010). Among these specimens 78% were from
women and 22% from men.
Results: For 65% of specimens (7408/11470), testing for both Ct and
Ng were requested by the clinicians, whereas for 34% (3918/11470)
and for 1% (144/11470) only Ct or Ng was requested, respectively. The
rate of positivity was 5.8% (661/11470) for Ct and 1.1% (130/11470) for
Ng. Twenty-two specimens were Ct+/Ng+ (18% women corresponding to
n = 4), 639 Ct+/Ng− (70% women, n = 428), 108 Ct−/Ng+ (25% women,
n = 27), 10701 Ct−/Ng− (79% women, n = 8499). The added value of the
dual approach, i.e. a result positive when Ct or Ng was not requested by
the clinician was 0.8% (5/661) of positive cases for Ct (3 women) and
9.2% (12/130) of positive cases for Ng (10 women). Thus, among the
144 samples for which Ct was tested but not requested, 3.4% (5/144)
were positive whereas among the 3918 samples for which Ng was tested
but not requested, 0.3% (12/3918) were positive. Interestingly, among the
31 samples positive for Ng from women, 10 (32%) were not requested
by clinicians.
Conclusion: This dual PCR allows high throughput real-time PCR
and might be a very useful tool in large epidemiological studies of
sexually transmitted infections. Moreover, given the nearly absence of
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speciﬁc signs and the similar sexual transmission of both agents, it is
very difﬁcult to argue to test only one of those pathogens, especially
for C. trachomatis infection which is commonly asymptomatic and for
women regarding N. gonorrhoeae.
P1687 Fully automated microﬂuidic PCR for the detection of
Chlamydia trachomatis with the BD MAX™ instrument
L. Berlinger*, E. Sutter-Minder, K. Egli, M. Altwegg (Lucerne, CH)
Objectives: To transfer our routinely used Chlamydia trachomatis (CT)
assay to the BD MAX™ instrument (Becton Dickinson) and to validate it
for various commonly used transport media and urine. The BD MAXTM
is a fully integrated and automated device for the extraction and detection
of nucleic acids from up to 24 specimens within about 2.5 hours. It
supports ﬂuorescence detection at 2 wavelengths, Cal Red for the process
control and FAM for the target sequence. Specimens undergo extraction,
puriﬁcation, ampliﬁcation and detection using the respective extraction
strips and microﬂuidic cartridges with only two manual pipeting steps
(adding specimen to sample prep tube and primer/probe solution to the
T1 tube).
Methods: Microﬂuidic PCR in a ﬁnal volume of 4ul was optimized
(primer, probe and MgCl2 concentrations, annealing/extension temper-
ature and time). After LOD determination, the optimized assay was
challenged with urogenital specimens (186 Amplicor standard transport
medium, STM, Roche; 122 e-Swabs, Copan; 122 native urines) which
had previously been analyzed using our home-brew real-time PCR after
easyMAG extraction. Total assay and hands-on times were compared
for the two procedures. In addition, specimens from two different
commercial systems (72 Viper and 50 ProbeTec, both Becton Dickinson)
in their respective transport systems were analyzed.
Results: The assay had an analytical sensitivity of 1 to 10 organisms per
PCR and thus was about as sensitive as our routinely used procedure.
Only 4/552 (0.7%) clinical specimens were inhibited, i.e. were negative
for CT and had a cycle threshold (Ct) of the process control >36.
After discrepant analysis, overall sensitivity and speciﬁcity were 93.7
and 99.7% with 94.7 and 100% for STM, 100 and 100% for e-swabs,
91.4 and 100% for urines, 100 and 100% for Viper, and 88 and 96% for
ProbeTec. False negativity correlated with high Ct values in the reference
assays and may have been inﬂuenced by the smaller sample volumes
tested (100 versus 400ul for transport media and 500 versus 1000ul for
urine). As compared to our routine test format, the BD MAXTM had a
slightly longer total assay time but a considerably shorter hands-on time.
Conclusion: BD MAX™ is an easy to use and fully automated platform
for the sensitive and speciﬁc detection of CT in various commercial
transport media and urine. It can be used as a primary diagnostic tool
or as a conﬁrmation test.
P1688 Vaginal swabs are the optimal sample for screening women
for chlamydial and gonorrheal infection using the Roche
Cobas® 4800 system
B. Van Der Pol*, B. Body, M. Nye, C. Eisenhut, S. Taylor, O. Liesenfeld
(Bloomington, Burlington, Indianapolis, New Orleans, Pleasanton, US)
Objective: To evaluate the performance of self-obtained and clinical
collected vaginal swabs for use with the cobas® 4800 CT/NG assay.
Methods: The cobas® 4800 CT/NG assay is a DNA-based ampliﬁcation
assay for C. trachomatis (CT) and N. gonorrhoeae (NG) performed
on a fully automated platform. The assay detects both the wild-type
and Swedish-variant forms of CT and has dual NG targets. In a
study evaluating the performance characteristics of this assay, women
attending STD, family planning, and gynecology/obstetrics clinics, who
had provided urine and endocervical swabs were randomized to either
self-collection (SC) or clinician collection (CC) of vaginal samples. The
infection status of the participant was determined using results of urine
and endocervical samples tested with other nucleic-acid based tests (Gen-
Probe AC2 and BD ProbeTec). A positive result was required from each
of the comparator assays to classify a participant as infected.
Results: The overall sensitivity of vaginal swab specimens from 1,722
women was equivalent to other sample types with sensitivity of 94.3%
and 100% for CT and NG, respectively. For comparison, the CT
sensitivity for endocervical and urine samples was 88.7% and 90.0%,
respectively. Interestingly, the sensitivity of SC was higher than that of
CC for CT: 98.1% and 90.4%, respectively. For NG, the sensitivity was
100% for both methods of collection. The lowest sensitivity of vaginal
swabs (86.4%, n = 22) was seen in clinician-obtained samples collected
at Family Planning clinics. In these same clinics, SC swabs had CT
sensitivity of 100% (n = 31). The overall speciﬁcity was 99.8% and 100%
for CT and NG, respectively. The speciﬁcity for SC and OC was 99.7%
and 99.9%, respectively.
Conclusions: Vaginal swabs using the cobas® 4800 CT/NG assay
performed as well, or better than, endocervical and urine samples for
women. These specimens are simple to collect and transport and may
improve clinic ﬂow by reducing the need for speculum-aided pelvic
exams in asymptomatic women being screening for these infections.
Women may self-sample more vigorously than clinicians resulting in
higher sensitivity, thus self-collection of this sample type should be
encouraged.
P1689 Evaluation of Seeplex STD6 ACE detection kit for the
diagnosis of six sexually transmitted pathogens
S.J. Lee*, C.H. Han (Suwon, Uijeongbu, KR)
Objectives: Traditionally, the diagnosis of bacterial sexually transmitted
disease (STD) has been dependent on the isolation of the causative
pathogens by culturing endocervical or urethral swab specimens on
selective media. While such procedures typically provide excellent
diagnostic accuracy, they often are time consuming and expensive. A
multiplex polymerase chain reaction (PCR) assay was evaluated for
detection of six STD causative pathogens based on the Seeplex STD
detection system.
Methods: The Seeplex STD6 ACE Detection (Seegene Inc.) assay
employed six pairs of DPO primers speciﬁcally targeted to unique genes
of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genital-
ium, Ureaplasma urealyticum, Mycoplasma hominis, and Trichomonas
vaginalis. A total of 347 specimens (155 of cervical swab and 192 of
urine) collected for 2 months were tested, and results were compared to
those obtained with a combined monoplex PCR.
Results: The accuracy was 100% between Multiplex PCR and monoplex
PCR assay for both sensitivity and speciﬁcity. Furthermore, the presence
of two pathogenic bacteria (C. trachomatis, and N. gonorrhoeae) was
tested in 347 clinical samples by Seeplex STD6 ACE Detection and
the ProbeTec ET CT/GC test (BD Inc.). The results of these two tests
were 99.71% concordant for C. trachomatis and 100% concordant for
N. gonorrhoeae.
Conclusion: Multiplex PCR assay using Seeplex STD6 ACE Detection
proves to be a novel cost-effective and fast diagnostic tool with high
sensitivity and speciﬁcity for the simultaneous detection of six STD
pathogens.
P1690 Usefulness of Neisseria gonorrhoeae systematic PCR
detection on urogenital specimens with the Abbott real-time
Chlamydia trachomatis/Neisseria gonorrhoeae assay
J.M. Rousee*, C. Rieder-Monsch, T. Gueudet (Strasbourg, FR)
Objectives: To evaluate the usefulness of Neisseria gonorrhoeae (NG)
systematic PCR detection on all urogenital samples sent to diagnose
a sexually transmitted infection (STI) including Chlamydia trachomatis
(CT) screening.
Methods: From January 1, 2010 to December 16, 2010 an Abbott
RealTime CT/NG assay was systematically performed on all urogenital
specimens sent to diagnose a STI. Molecular detection of NG was
compared with the results of Gram-stained smear and culture.
Results: 3989 CT/NG PCR were performed during this period (3311
women and 678 men). 137 specimens were positive for CT (93 women
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and 45 men) and 44 for gonorrhea (10 women and 34 men). Four
specimens (3 urethritis and 1 salpingitis) were positive for both.
In men with symptomatic urethritis (29 cases), Gram-stained smears,
culture and PCR were positive in all cases.
Eight gonorrhea were diagnosed from urine by PCR. Only 2 cultures
were positive after 5 days incubation. Microscopic examinations were
positive, equivocal and not performed, respectively, in 4, 2, 3 cases.
Four anorectal infections in men were diagnosed by PCR.
Nine women’s specimens (pelvic inﬂammatory disease or cervical
infection) were positive by PCR. Seven cultures were weakly positive and
Gram-stained smears were often doubtful or negative due to association
with polymicrobial ﬂora.
Every diagnosis obtained by Gram-stained smear and/or culture was
conﬁrmed by PCR (no false-negative case). Nine diagnosis of gonorrhea
were only achieved by PCR. No false-positive case was observed by
PCR.
Conclusion: Forty-four gonococcal infections were diagnosed by PCR.
The deﬁnitive diagnosis was obtained by PCR in 15 cases (doubtfuf result
of Gram-strain smears or delayed isolation on culture). In acute urethritis,
Gram-stain examination remained very effective, cheaper and faster than
PCR. In other cases, especially with urine or specimens associated with
polymicrobial ﬂora or with prior antibiotic administration, NG detection
by PCR was particularly useful in conﬁrmation of the diagnosis of
gonorrhea.
P1691 Comparison of three commercial molecular assays for de-
tection of Chlamydia trachomatis and Neisseria gonorrhoeae
J. van de Bovenkamp*, J.W. Rossen, C.M. van Herk, L.M. Raaijmakers,
R. Roymans, J.M. Verbakel, A.J. van den Brule (Veldhoven, Tilburg,
Eindhoven, NL)
Objectives: Several automated systems to detect Chlamydia trachomatis
(CT) and Neisseria gonorrhoeae (NG) are currently available. Here
we determined and compared the performance of the Roche COBAS®
AMPLICOR CT/NG Test (CA), the Siemens VERSANT® CT/GC DNA
1.0 (kPCR) assay and the Abbott RealTime CT/NG assay (M2000).
Methods: Five hundred and three samples (143 urines and 364 swabs)
were prospectively collected, and divided into three aliquots that were
subsequently used in one of the three assays. Samples positive for
Neisseria gonorrhoeae (NG) in the Roche CA assay were conﬁrmed
by a cppB/16S real-time PCR as this system is known to report NG
false-positives. In case of discrepancies the result found by two of the
three assays was taken as the ﬁnal outcome.
Results: 503 samples were tested for CT in the CA, kPCR and M2000
resulting in 43 positive, 456 negative and 4 discrepant outcomes.
Discrepancies observed included 1 sample negative in the CA- but
positive in the kPCR and M2000-assay. In addition, three samples were
negative in both the CA and M2000-assay but positive in the kPCR-
assay. The Ct values of these latter 3 samples reported by the kPCR
were above 35 and became negative after retesting.
In addition, 438 samples were tested for the presence of NG with all three
assays, resulting in 6 positive and 431 negative outcomes. Furthermore,
1 discrepant result was observed (negative in the CA and M2000 assay
but positive in the kPCR assay). However, after analysing the kPCR
ampliﬁcation plot this sample was interpreted as negative.
Conclusion: The three commercial assays have identical performance.
However, positive Neisseria gonorrhoeae in the Roche COBAS®
AMPLICOR CT/NG Test must be conﬁrmed as this system reports NG
false-positives. The VERSANT® CT/GC DNA 1.0 (kPCR) assay has
the lowest hands-on time compared to the other two automated systems,
therefore the kPCR system is very useful for high throughput molecular
diagnostic testing.
P1692 Performance of the Bio-Rad Dx CT/NG/MG assay for simul-
taneous detection of Chlamydia trachomatis, Neisseria gon-
orrhoeae and Mycoplasma genitalium in urogenital samples
C. Le Roy, I. Le Hen, M. Clerc, V. Arfel, F. Normandin, C. Be´be´ar*,
B. de Barbeyrac (Bordeaux, FR)
Objectives: To investigate the performance of the Bio-Rad Dx
CT/NG/MG Assay with an internal control for the detection of
Chlamydia trachomatis (CT) and Mycoplasma genitalium (MG) in
urogenital samples in comparison with the Roche Cobas TaqMan CT test
and an in-house TaqMan PCR test for MG. For Neisseria gonorrhoeae
(NG), only positive PCR results were controlled by culture.
Methods: In this prospective study, urogenital samples were obtained
from symptomatic and asymptomatic patients attending the STI center of
Bordeaux, France, from January to April 2010. For symptomatic women
and men, two endocervical swabs and two urethral swabs were collected,
respectively. All patients and women collected ﬁrst-catch urines and two
vaginal swabs, respectively. Two swabs per site were used, a ﬂocked
swab in the universal transport medium and the Bio-Rad ﬂocked swab
in its transport medium. For the Bio-Rad CT/NG/MG assay, the DNA
was manually extracted and ampliﬁed according to the manufacturer’s
instructions. For the comparator PCR tests, DNA was extracted using
the MagNa Pure LC instrument (Roche Diagnostics) and ampliﬁed with
the Cobas TaqMan CT 48 assay (Roche Diagnostics) and with a MgPa-
targeted PCR assay on an ABI Prism 7000 (Applied Biosystems) for
MG. The patient was considered as infected if at least two of the 4 or
6 PCR tests performed according to the gender and characteristics of
patients, were positive. For asymptomatic men, in case of discrepancy,
the urine sample was retested by both methods and the patient was
considered infected if at least two of the four PCR results were positive
for the considered microorganism.
Results: A total of 658 clinical specimens (259 male and 180 female
urines, 191 vaginal, 21 cervix and 7 urethral swabs) from 453 patients
were analyzed. The prevalence of CT and MG infections was 7.7%
(20/260) and 1.9% (5/260) in men and 10.3% (20/193) and 2% (4/193)
in women, respectively. The Bio-Rad Dx CT/NG/MG test sensitivity was
100% for CT and MG in men and women. In male urines, the speciﬁcity
was 99.6% for CT and 100% for MG. In women, the speciﬁcity was
99.5% for swabs and 100% for urines for CT and MG. All 7 NG-PCR
positive samples were positive by culture. Patients were co-infected in
5/56 (9%) with CT/MG in 3 cases and CT/NG in 2 cases.
Conclusion: The Bio-Rad Dx CT/NG/MG Assay was found to be very
effective for the simultaneous detection of CT, MG, and NG infections
in urogenital specimens.
P1693 Evaluation of the platform cobas® 4800 CT/NG test for
detecting Chlamydia trachomatis in urogenital samples
B. de Barbeyrac*, V. Mehats, M. Clerc, C. Le Roy, C. Be´be´ar
(Bordeaux, FR)
Objectives: To assess the performance of the Roche fully automated
cobas® 4800 CT/NG test for the detection of C. trachomatis (CT)
infection in clinical specimens compared to the current routine practice.
Methods: Consecutive clinical specimens sent to the Bacteriology
department of the Bordeaux University Hospital, Bordeaux, between July
and September 2010 were included. Results of the cobas® 4800 CT/NG
test were compared with those obtained with the cobas® TaqMan CT
48 assay (Roche). For the latter, DNA from 200 ml of urine or swab
resuspended in transport medium, (2SP or universal transport medium)
was extracted on the MagNA Pure using the DNA I isolation kit (Roche)
and ampliﬁed on the TaqMan 48 automates. The cobas® 4800 CT/NG
performed DNA extraction from urine specimens prepared by adding
4.5mL to 4.5mL of cobas® PCR media, and from swabs discharged in
1.0mL of the same media. The cobas® 4800 system loaded extracted
DNA, controls and ampliﬁcation reagents into 96-well ampliﬁcation
plates. Plates were then covered and placed into the cobas® z480 real-
time PCR instrument. Retesting in both cobas® 4800 and TaqMan
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48 assays was performed to further investigate specimens providing
discrepant results.
Results: A total of 708 clinical specimens (293 male urines and 415
swab specimens, of which 356 self-collected vaginal swabs, 45 swabs
from cervix and 14 swabs from male urethra) were analyzed. The results
were concordant in 98.5% of cases (697/708). Out of 708 samples, 50
provided positive results (17 men, 33 women). Three urine specimens
and 8 vaginal swabs provided discrepant results. Out of 5 specimens
providing positive results in the reference CT assay, 4 were false-negative
in the cobas® 4800 CT test. Out of 6 positive results by the cobas® 4800
assay, ﬁve were false-positive. After discrepancy analysis, the prevalence
of the CT infection was 7.7% (55/708). The sensitivity and speciﬁcity
of the cobas® 4800 CT/NG test were 92.7% (urine specimens 94.1%,
swab specimens 92.1%) and 99.2%, respectively. The 3 false-negative
results in swabs could be explained by the procedure not consistent with
the manufacturer’s instructions. Indeed, swabs were not inserted directly
into the cobas® media vials.
Conclusion: The cobas® 4800 CT/NG test is suitable for high through-
put identiﬁcation of the C. trachomatis infection.
P1694 Evaluation of Versant® CT/GC DNA 1.0 assay for
the detection of Chlamydia trachomatis and Neisseria
gonorrhoeae in urine specimens in selected STD patients
A. Marangoni*, C. Foschi, P. Nardini, A. D’antuono, N. Banzola,
A. Di Francesco, R. Cevenini (Bologna, IT)
Objectives: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae
(GC) are the two most common sexually transmitted bacterial infections
in the developed countries. Since the introduction of nucleic acid
ampliﬁcation tests (NAATs) for CT/GC detection in genital tract
specimens, this approach has become the most used diagnostic method.
Moreover, urine has also been validated as an adequate specimen for
diagnostic testing in many studies.
Here we report on the evaluation of a new fully automated system for
CT/GC detection in urine specimens.
Methods: A total of 700 ﬁrst void urine specimens were obtained from
patients (330 males and 370 females) attending the STD Outpatients
Clinic of the St. Orsola University Hospital in Bologna, Italy. Samples
were tested by VERSANT® CT/GC DNA 1.0 Assay (Siemens Healthcare
Diagnostics Inc., Tarrytown, USA), a multiplex Real-Time PCR assay for
simultaneous CT/GC detection. A total of three specimens were collected
from each patient, respectively: one urine sample for VERSANT®
testing and two urethral or endocervical swabs for the detection of
C. trachomatis and N. gonorrhoeae by culture.
Results: Out of the 700 specimens, 83 (11.9%) and 41 (5.9%)
were found positive by VERSANT® for CT and GC, respectively.
C. trachomatis and N. gonorrhoeae were isolated from 55 (7.9%) and
33 patients (4.7%), respectively. Sensitivity of VERSANT® compared
to culture was 100.0%, since no patient was scored positive by culture
and negative by VERSANT®.
When a urine sample was scored positive by VERSANT®, but the
corresponding swab for C. trachomatis culture was negative, an “in
house” omp1 Nested PCR assay was performed on remnant VERSANT®
extracted DNA. 23/28 samples with discordant results were conﬁrmed
positive by Nested PCR.
VERSANT® speciﬁcity compared to N. gonorrhoeae culture was 98.8%,
whereas its speciﬁcity compared to C. trachomatis culture was 95.7%.
Speciﬁcity for CT rose to 99.2% when results obtained by Nested PCR
on discordant specimens were considered.
The overall CT prevalence in male patients with symptoms of urethritis
was 37.7%, whereas GC prevalence was 29.9%. In this group of patients,
5.2% of the subjects presented CT/GC co-infection. Regarding female
patients presenting discharge or dysuria, we noticed a CT prevalence of
27.8% and no GC cases.
Conclusion: VERSANT® CT/GC DNA 1.0 Assay demonstrated to be
a highly sensitive and speciﬁc technique for CT/GC detection in several
groups of patients attending a STD Clinic.
P1695 Molecular detection of Chlamydia trachomatis and Neisseria
gonorrhoeae in (self)collected vaginal swabs and rectal
swabs with the Cobas 4800 system
P.H. Savelkoul*, L. Poort, S. Morre´, W. Ritmeester, H. van Krugten,
M.M. van de Pas, A. Beerens, J.W. Rossen (Amsterdam, Tilburg,
Groningen, NL)
Objectives: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae
(NG) are the most prevalent sexual transmitted diseases worldwide. In
recent years molecular diagnostics for the standard sample types like
cervical swabs and urines has been highly adapted in most laboratories.
Currently more difﬁcult samples types, with regard to inhibition,
sensitivity and speciﬁcity, like rectal swabs and (self collected) vaginal
swabs are received more often in the laboratories. This study describes
the performance of the new Cobas 4800 for the detection of CT and NG
in these difﬁcult sample types.
Methods: A total of 1100 co-collected swabs were tested (900 vaginal;
200 rectal). Informed consent for co-collection was obtained from all
patients. All swabs were tested routinely with the M2000 system (Abbott)
and the co-collected samples were tested in the Cobas 4800 system
(Roche) according to the manufacturers and tested blinded. Discrepant
results were retested with an independent real time PCR method.
Results: From 900 vaginal swabs 10% (n = 90) were positive for CT and
0.5% (n = 4) for NG and in 200 rectal swabs 12% CT positives (n = 24)
and 6% NG positives (n = 12) were identiﬁed. In the vaginal samples
9 discrepant results between the Cobas 4800 and M2000 system were
identiﬁed. Five with borderline values and 4 with clear different results
(1 NG, 3CT). Two M2000 positive results (Ct 35.7; 32.3) were available
for home brew analysis and could not be conﬁrmed. In the rectal samples
8 discrepant results were found including 3 clear differences (2 NG; 1
CT). The CT discrepant sample was positive in the Cobas 4800 system
(Cp 33.1) and negative in the M2000 system. For NG 2 samples were
negative in the Cobas 4800 system but positive (Ct 23.8; 32.0) in the
M2000 system. All 3 clear discrepant results were available for home
brew analysis and conﬁrmed the Cobas 4800 results.
Conclusion: Both samples types showed a high concordance between
the two systems (kappa 0.95 for CT; kappa 0.93 for NG). For detection
of vaginal swabs only small differences were found both for CT and
NG but these were equally spread between the two systems. There is no
difference between self collected and clinician taken vaginal swabs. All
clear rectal swabs discrepancies conﬁrmed the Cobas 4800 results. This
remarkable difference will be further studied. In general, (self collected)
vaginal swabs and rectal swabs show reliable results for routine detection
of CT and NG.
P1696 Evaluation of the Cobas® 4800 CT/NG test using clinician
and self-collected vaginal swabs, cervical specimens in
PreservCyt Solution, and pharyngeal throat wash specimens
D. Hardy, J. Pane, A. Sunhachawee, E. Cervantes, R. Kotadia,
S. Joshi, R. Puckett, M. Watson, J. Cheung, O. Liesenfeld*, M. Krevolin
(Pleasanton, US)
Objective: To evaluate the limit of detection (LOD), inclusivity,
exclusivity, and interfering substances of the cobas® 4800 CT/NG Test
using vaginal, PreservCyt, and pharyngeal specimens.
Methods: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG)
cultures were diluted into pools of negative patient specimens at six
concentrations to determine the LOD (lowest concentration giving a
95% hit rate). A panel of 15 serovars of CT, plus the Swedish variant
(nvCT), and 45 strains of NG was diluted into each sample matrix to
determine inclusivity. To ensure speciﬁcity, a panel of 184 non-CT and
non-NG organisms that may be found in the oral or urogenital region
was tested at 105 CFU or copies/mL. The organisms were diluted into
CT/NG positive and negative samples. 10 CT/NG positive and negative
samples were spiked with blood (up to 5%), leukocytes (up to 107
cells/mL), cervical mucus, and saliva at concentrations up to 10% to
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check for interference. 10 (for pharyngeal) and 18 (for urogenital) over-
the-counter products, e.g. mouth wash, vaginal creams and gels, were
also tested.
Results: LODs were as follows: Vaginal CT 10 IFU/mL, NG 100
CFU/mL; PreservCyt CT 0.6 IFU/mL, NG 3.5 CFU/mL, Pharyngeal
CT 0.5 IFU/mL, NG 2.25 CFU/mL. All 15 serovars of CT, plus the
Swedish variant (nvCT), and 45 strains of NG were detected at, or
near the LOD. No cross reactivity was noted with 184 non-CT and
non-NG organisms in any specimen type. Vaginal but not PreservCyt
samples showed interference from leukocytes at >106 cells/mL. This
interference was noted as clot detections and samples were not processed.
Pharyngeal samples showed false negative results in the presence of
blood at >0.25%, and saliva at >2.5%. No interference was noted with
any over-the-counter products in any specimen type.
Conclusions: Vaginal, PreservCyt, and pharyngeal specimens are
suitable sample types for the cobas® 4800 CT/NG Test.
P1697 Comparison of the VERSANT® CT/GC DNA assay and the
APTIMA Combo 2® rRNA assay for detection of Chlamydia
trachomatis and Neisseria gonorrhoeae in male urine
J.K. Møller* (Vejle, DK)
Objectives: To evaluate the Siemens VERSANT® CT/GC DNA 1.0
Assay (kPCR) for simultaneously detection of Chlamydia trachomatis
(CT) and Neisseria gonorrhoeae (GC) in urine samples and to compare
it to the Gen-Probe APTIMA COMBO 2® assay (AC2).
Methods: Aliquots of randomly selected fresh urine specimens
submitted for routine testing of C. trachomatis were transferred into
the Siemens VERSANT® Urine Transport Kit and the Gen-Probe
APTIMA® Urine Specimen Collection Kit for Male and Female Urine
Specimens. Samples were tested on the VERSANT® kPCR Molecular
System with the kPCR assay and the TIGRIS® DTS® Automated
Analyzer with the AC2 assay, respectively. Samples with discrepant
results were subjected to repeat testing by both methods. Supplemental
testing by use of the Gen-Probe single analyte APTIMA assays for
individual testing for CT (APTIMA® CT Assay) and GC (APTIMA®
GC Assay, AGC) on the TIGRIS were furthermore performed to resolve
discrepant results. Specimens conﬁrmed positive by both methods or
with discrepant results resolved by the supplemental testing with a single
analyte APTIMA assay were deﬁned as true positives.
Results: A total of 784 male urine specimens was examined of which
131 (16.7%) were C. trachomatis positive. Both methods agreed on
762 samples (122 positive and 640 negative). Among the remaining 22
samples with discrepant results, 12 kPCR tests were ‘invalid’, 3 samples
positive in kPCR only. Twelve of 22 samples were positive in AC2 only.
Ten of 12 ‘invalid’ kPCR tests were repeatedly ‘invalid’, two repeat
tests became positive. Nine of the 12 AC2 discrepant positives were
conﬁrmed positive by the repeat test with AC2 and the APTIMA® CT
Assay (ACT). None of the 3 kPCR discrepant positives were conﬁrmed
by ACT. Thus, the sensitivity of the kPCR assay was 94.7% (124/131)
compared to 100% (131/131) of the AC2 assay. The difference was
statistically signiﬁcant (c2 = 5.28, 0.05> p> 0.01). The speciﬁcity of the
two assays was 99.5% (650/653) for kPCR and 99.5% (650/653) for
AC2. Four male urine specimens contained N. gonorrhoeae (0.5%) of
which one specimen additionally contained C. trachomatis. The latter
was detected by both kPCR and AC2. One of the GC-positive samples
was ‘invalid’ in the kPCR assay but conﬁrmed positive by the AGC
assay.
Conclusion: Both methods had a high speciﬁcity, but the APTIMA
Combo 2 assay had a signiﬁcantly higher sensitivity than the VERSANT
assay in detecting C. trachomatis in male urine.
P1698 Evaluation of the Siemens Versant® CT/GC DNA 1.0
(kPCR) assay for detection of Chlamydia trachomatis and
Neisseria gonorrhoeae
M. Bongaerts*, J. van de Bovenkamp, S. Morre´, M. Manders,
E. Heddema (Sittard-Geleen, Veldhoven, Amsterdam, NL)
Objectives: The Siemens VERSANT kPCR system is an automated
system which combines extraction of nucleic acids from 96 samples with
subsequent real time PCR. The VERSANT CT/GC DNA 1.0 (kPCR)
assay detects Chlamydia trachomatis (CT) and Neisseria gonorrhoeae
(GC) in a multiplex real time PCR on this system. We compared this
assay with the BD ProbeTec™ ET System (PT). In addition we blindly
tested approximately 300 urine samples obtained at a different lab.
Methods: Three different sets of samples were tested in the kPCR:
(1) PT pretreated samples (for each CT or GC positive sample a negative
sample of the same run was also collected) (2) prospectively collected
urine samples during routine CT/GC testing and (3) urine samples
obtained in a blinded fashion by an external lab facility.
The ﬁrst and second set were tested by kPCR and PT and were used
to reﬁne the interpretation of the kPCR. GC positive PT samples were
conﬁrmed by real-time PCR targeting the Opa gene.
The third set was tested by kPCR and Roche Cobas Amplicor (CA) with
GC conﬁrmation by Opa-PCR. Samples were judged with the newly
derived rules of interpretations.
Results: Set (1): 308 PT samples were tested in kPCR for CT and
GC. 130 were CT positive and 22 were GC positive in both tests. 1
descrepancy in CT (positive in PT and negative in kPCR). 1 descrepancy
in GC, but after conﬁrmation in agreement with kPCR.
Set (2): 243 urine samples tested in PT and kPCR with 16 CT positives
and 5 GC positives in both tests. In this set two samples were repeated
in kPCR as the Ct value was above 35 cycles. Both samples became
negative after retesting. With this interpretation rule PT and kPCR were
in complete agreement.
Set (3): 292 CT samples were tested in CA and kPCR. 27 positives,
260 negatives and surprisingly 5 discrepant results were obtained. After
testing these 5 samples by the Dutch CT reference centre all 5 samples
were in agreement with kPCR.
267 GC samples were tested in CA with GC conﬁrmation and kPCR. 2
positive and 265 negative results were obtained in both tests.
Conclusion: If the above mentioned rules of interpretation were used the
VERSANT CT/GC DNA 1.0 (kPCR) assay demonstrated to be a robust
diagnostic tool which is easy to use. In addition no GC conﬁrmation is
required.
P1699 Evaluation of the new Versant® kPCR CT/GC DNA 1.0
assay for detecting Chlamydia trachomatis compared to the
Aptima Combo 2 assay
M. Dautigny*, S. Merlin, C. Ronsin (Ivry-sur-Seine, FR)
Objectives: The VERSANT® kPCR CT/GC DNA 1.0 assay is a
automated qualitative multiplex assay for the detection of Chlamydia
trachomatis (CT) and Neisseria gonorrhoeae (GC) on swab and urine
specimens. The purpose of this study was to investigate the analytical
and performance characteristics of the fully automated VERSANT®
kPCR CT/NG DNA 1.0 assay for detection of Chlamydia trachomatis in
comparison with that of the commercially available Gen Probe APTIMA
Combo2 assay.
Methods: The routine laboratory performances of the assay were
evaluated on a total of 470 clinical specimens. 188 specimens were
randomly selected. Then 188 positive specimens: 94 from male and 94
from women (47 urine samples and 47 uretral swabs for each group)
were selected on the CT results obtained with the Roche COBAS®
AMPLICOR CT/NG assay. These samples were simultaneously tested
with VERSANT® kPCR CT/NG DNA 1.0 assay and the Gen-Probe
APTIMA COMBO 2 Assay performed on the Tigris DTS system. At last,
to evaluate a potential cross-contamination during specimen processing,
94 positive and negative specimens (results obtained with the Roche
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COBAS® AMPLICOR CT/NG assay) were analyzed in the VERSANT®
kPCR instrument in an alternating order.
To evaluate the limit of detection (LoD) the QCMD 2009 09B was used
and serial dilutions were performed (concentration range between 0.44
and 3560 copies/ml for urine matrix, and 0.47 to 1900 copies/ml for
swab matrix). Each concentration was tested twenty times and the LoD
was determined by the logistical regression.
Results: Concerning random samples, the concordances between the 2
assays were 99.1% and 97.3% respectively for swab and urine specimens.
With the positive women samples, concordances were 100%, and with
the positive men samples, concordances were 97.9 and 100% respectively
for swab and urine. No cross contamination was detected on the
VERSANT® kPCR platform. The limit of detection was determined to
be 39.3 copies/ml and 69.5 copies/ml respectively for urine and swabs.
Conclusion: The results obtained from this prospective and retrospective
study with either the VERSANT® kPCR CT/GC DNA 1.0 assay and the
APTIMA COMBO 2 Assay were comparable. The VERSANT® kPCR
represents a convenient high-throughput and sensitive system for the
routine clinical diagnosis of Chlamydia trachomatis infection.
However, we propose to improve the assay by enlarging the grey zone
in order to increase the speciﬁcity of Versant kPCR CT/GC DNA 1.0
assay.
P1700 Chlamydia trachomatis and other bacteria as aetiological
agents to pelvic inﬂammatory disease by 16S rRNA gene
sequencing
B. Hammas*, C. Bjartling, K. Persson, H. Janson (Malmo¨, SE)
Objectives: The most common causes of pelvic inﬂammatory disease
(PID) are Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (Ng)
in which both are easily detected by culture or PCR of genital samples.
For other bacterial species it may be more difﬁcult to use cultivation or
PCR of genital samples to get a causative agent for PID. In Sweden,
laparoscopy is considered as a gold standard for PID-diagnosis. In this
study, we have used 16S rRNA gene sequencing from abdominal ﬂuid
to identify bacteria that could be associated with PID.
Methods: Women undergoing diagnostic laparoscopy due to abdominal
pain at Ska˚ne University Hospital in southern Sweden were included
in the study. Abdominal ﬂuid from 73 women aged 15−54 years
was collected. Of these, 33 patients that were diagnosed as non-PID
(endometriosis etc) served as a control group to the remaining 40 PID
patients. Samples were DNA-extracted by MagNA Pure LC (Roche
Diagnostics) and ampliﬁed with conserved primers covering the ﬁrst
550 bp of the 16S rRNA gene. The nucleotide sequence of PCR-positive
samples were compared to available public 16S rRNA gene sequences by
using the BLAST algorithm. The Ripseq software (Isentio AS, Norway)
was used on mixed sequences.
Results: Among 40 women diagnosed as acute PID, bacterial DNA could
be identiﬁed in 25 cases (62.5%) compared to 24.2% in the control group
(n = 33). The most common ﬁnding in PID-cases was Ct (n = 8) followed
by Fusobacteria spp (n = 4), Streptococcus anginosus group (n = 4) and
Escherichia coli (n = 3). All samples were subjected to species-speciﬁc
PCR for M. genitalium and Ct. In addition to ﬁnding all 8 Ct-positive
samples, two additional samples were positive for Ct and one sample
was positive for M. genitalium. Three cases of mixed infections could
be resolved with Ripseq. In all of these cases DNA from the S. anginosus
group was detected.
Conclusion: Ct was the most common individual pathogen among PID-
cases but more than half of the cases were possibly caused by other less
established pathogens. No cases of Ng were detected which reﬂects the
low incidence of gonorrhoea in Sweden. As 16S rRNA gene sequencing
predominantly found relevant pathogens in PID-cases compared to DNA
from normal skin ﬂora of non-PID cases, it is concluded that it may be a
complementary diagnostic tool. In cases of mixed infections, Ripseq is a
valuable tool to separate sequences and determine the bacterial species.
P1701 Evaluation of the new Cobas 4800 CT/NG test for detecting
Chlamydia trachomatis and Neisseria gonorrhoeae in
urogenital swabs and urine specimens
M. Parra, S. Bernal, N. Sivianes, L. Pe´rez, I. Pueyo,
E. Martı´n-Mazuelos, J.C. Palomares* (Seville, ES)
Objectives: To evaluate the new automatic system cobas 4800 in
comparison with COBAS AMPLICOR for detecting C. trachomatis (CT)
and N. gonorrhoeae (NG) in urogenital swabs and urine specimens in
both women and men. Our aim was to compare that urine specimen
results to those obtained by urogenital swabs.
Methods: A total of 696 clinical specimens for CT and NG testing
from both symtomatic and asymtomatic patients were used in this
study. These samples comprised 488 urogenital swab specimens (276
endocervical and 212 urethral) and their corresponding self-collected
urine specimens (a total of 208 urines: 156 women and 52 men)
submitted from the Center of Sexually Transmitted Infections located
in Seville, Spain. First, we compared the results of urogenital swabs
processed with cobas 4800 CT/NG test (c4800) (Roche Diagnostics)
versus those processed with Cobas AMPLICOR CT/NG test (CAM)
(Roche Diagnostics). Second, we analised the results obtained with
208 urogenital swabs specimens with their corresponding self-collected
urine samples in c4800. Discordant results were analysed with MultiNA
system (Shimadzu Biotech).
SPSS Statistic program v18 (IBM Ibe´rica) were used for the statistical
analysis.
Results: Data are shown in Table 1. Statistical data for sensitivity (%),
specyﬁty (%), positive predictive value (%), negative predictive value (%)
and kappa value, respectively, were:
1. CAM vs c4800 for CT detection: 77.9, 100, 100, 96 and 0.86.
2. CAM vs c4800 for NG detection: 68.3, 100, 100, 97.2 and 0,8.
3. c4800 swab specimens vs urine specimens for CT detection: 92.9,
100, 100, 98.9 and 0.96.
4. c4800 swab specimens vs urine specimens for NG detection: 100,
100, 100, 100 and 1.
Discordant results were analysed with MultiNA system and all of them
were negatives. These data suggest that results obtained by CAM were
false-positive results. Besides, we studied that clinical data backed up the
MultiNA and cobas 4800 results. For NG, it is known that false-positive
results for other non pathogenic Neisserias are possible with CAM.
Conclusions:
1. We had an excellent agreement between CAM and c4800; so, we
could use either in routine workﬂow.
2. Self-collected urine specimens are as well as urogenital swabs for
diagnosing and screening for C. trachomatis and N. gonorrhoeae
infections.
3. In this study, no positive cervical specimens for NG were found, but
the results obtained for men would allow the same conclusion.
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P1702 Demonstrating the performance of a fully integrated,
low-cost, ultra-rapid PCR device with true point-of-care
applications
M. Green*, A. Larry, D. Shenton, D. Pearce (Trowbridge, UK)
Objectives: To develop a highly sensitive, ultra-rapid, multiplex
PCR method with fully integrated DNA preparation and ambient-
stable reagent presentation. To be used in conjunction with a novel
electrochemical detection method to demonstrate low copy number
ampliﬁcation and detection in under 20 minutes, for a point-of-care
(POC) diagnostic test for Chlamydia trachomatis (CT).
Methods: The method employs a custom developed microﬂuidic PCR
card, utilising a thin-ﬁlm laminate construction, to achieve rapid heat
transfer, in conjunction with an ultra-rapid thermocycler. All reagents
necessary to perform the extraction, ampliﬁcation and detection are
deposited into the card and air dried, at the point of manufacture. Novel,
ambient-stable reagent formulations with an 18 month shelf-life have
been developed. A sample is added to the card and DNA extracted from
the sample. The resulting eluate reconstitutes the dried PCR reagents and
a 40-cycle multiplex PCR is performed using rapid thermocycling in 17
minutes. Ampliﬁed target is detected using electrochemically labelled
target speciﬁc probes and a double-stranded DNA speciﬁc exonuclease
to release the electrochemical label. Released label is read by applying
a voltage to a screen printed carbon electrode, and at a known oxidation
potential the label is oxidised producing a measurable current. The
unique rapid performance of this device has been demonstrated in terms
of analytical sensitivity and reagent stability under ambient storage
conditions. Multiplex capability is demonstrated in this test with the
presence of the control DNA.
Results: Analytical sensitivity of the device was evaluated by testing
dilutions of CT DNA in the presence of the control DNA. The results
show detection of CT down to 50 copies when co-extracted, ampliﬁed in
duplex and detected electrochemically, with the control DNA (see graph).
Stability tests on the reagents, dried into the device, showed stability
for 18 months, stored at ambient temperature (20−25ºC). Reagent
performance after 18 months storage was shown to be equivalent to
performance at time 0.
Conclusion: The results show that this device can be used to perform
ultra-rapid multiplex PCR with no user intervention after sample
addition, allowing minimally trained staff to carry out the assay in
under 20 minutes, meeting the needs for a ‘true’ POC device. Ambient
stability of the reagents negates the requirement for any specialised
storage conditions.
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P1703 Spa typing and multilocus variable-number tandem-repeat
analysis of methicillin-resistant S. aureus in The Netherlands
G.N. Pluister, M. van Luit, T. Bosch, M.E. Heck* (Bilthoven, NL)
Objective: To elucidate the spread and transmission routes of MRSA an
epidemiological typing method is indispensable.
Currently Spa typing is one of the methods most frequently applied
and has been used successfully in the Netherlands. It is a standard
international method.
Multilocus Variable-Number Tandem-Repeats Analysis (MLVA) as
described by Schouls et al. is a PCR method based on fragment analysis
of eight repeat loci. In this study we compare the results of both methods
and their signiﬁcance in epidemiological typing.
Methods: For this study we typed 8912 MRSA isolates sent to our lab
for typing. All strains were typed by spa- and MLVA typing.
An overall comparison was made between these two typing methods. The
most frequent Spa types and MLVA types were investigated in depth i.e.
related to their geographical dispersion with help of the geographical
tool on the Dutch MRSA website: http://mrsa.rivm.nl
Results: Among the 8912 MRSA strains we found 584 spa types and
1047 MLVA types.
Spa type t011 and t108, animal related types, were among the most
prevalent strains in our assessment. Other common types were: t002,
t008 t032 and t064.
Of 584 spa types 174 (30%) types could be subdivided into at least 2
MLVA types and 55 (9%) could be subdivided in 5 or more MLVA types.
Among the common types we found that both t011 and t108 were
dominated by one MLVA type. Spa types t008 and t064 were represented
by 3 respectively 2 main MLVA types. Spa type t032 had 3 main MLVA
types whereas spa type t002 had an even distribution of MLVA types.
Overall, we found that common spa types could be sub-divided by
MLVA.
Conclusions and Comments:MLVA typing can sub-divide common spa
types signiﬁcantly and consequently provide a signiﬁcant understanding
of the spread strains. However, MLVA typing did not breakdown the
animal related spa types t011 and t108.
As with spa-typing, MLVA by means of its simplicity is suitable for
web based tools to submit data into data bases and to make queries.
Subsequently we should aim to build national and international networks
using MLVA typing method to elucidate the transmission of MRSA.
P1704 Entamoeba dispar: genetic diversity of clinical isolates-based
on four tRNA gene-linked short repeat loci
E. Nazemalhosseini-Mojarad*, A. Haghighi, M. Alebouyeh, M. Zali
(Tehran, IR)
Objectives: E. dispar is, to some extent, capable of producing variable
focal intestinal lesions in animals and of destroying epithelial cell
monolayers in vitro as well as producing amoebic liver abscess in
hamsters. However evidence is still insufﬁcient to link E. dispar with
human diseases. A recent search for new polymorphic sequences in
E. histolytica unearthed a number of loci suitable for strain typing, and
revealed a unique gene organization at the same time. These loci are
all characterized by the presence of A + T-rich STRs that vary in both
number and sequence between strains.
In this study, genetic polymorphism of four tRNA-liked STR-containing
loci including S-Q, D-A, A-L and R-R were analyzed in order to clarify
further the genotypic differences among E. dispar isolates.
Methods: A total of 28 E. dispar from gastrointestinal disorder patients
were characterized using PCR and sequences methods.
Results: Sequence analysis showed 9, 12, 7 and 8 different patterns
based on variation of units in this repeat-containing region of R-R, D-A,
A-L and S-Q loci, respectively.
Conclusion: The results demonstrate an extensive genetic variability
among E. dispar clinical isolates. The repeat-containing regions of R-R,
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D-A, A-L and S-Q loci were found extensively polymorphic in size,
number and also in order of repeat units. The genetic diversity of
tRNA Gene-Linked short Repeat loci shows them to be suitable for
epidemiological studies such as the characterization of the routes of
transmission of these parasites in Iran.
P1705 Molecular characterisation of high-pathogenicity Yersinia
enterocolitica bioserotype 1B/O8 clinical isolates collected
in Poland, 2009
K. Zacharczuk*, R. Gierczynski, J. Szych, N. Rokosz, W. Rastawicki
(Warsaw, PL)
Objectives: Yersinia enterocolitica, is one of the major foodborne
pathogen that can cause yersiniosis in human. Infections with Y. en-
terocolitica can cause illness ranging from self-limited gastroenteritis,
mesenteric lymphadenitis to postinfectious complications such as
arthritis and erythema nodosum. Among pathogenic Y. enterocolitica
predominating types of isolates in Europe belonging to bioserotype
4/O3. However, in 2003, the ﬁrst cases of infections caused by high-
pathogenicity Y. enterocolitica bioserotype 1B/O8, were reported in
Germany and in Poland. In the following years we observed continuous
increase of Y. enterocolitica 1B/O8 isolations from human in Poland. The
highest number of the isolations was in 2009, when 64 clinical isolates
of this high-pathogenicity bioserotype were collected in our country. We
investigated genetic similarity of these isolates and the presence of the
major virulence markers including high-pathogenicity islands YSA and
HPI.
Methods: All tested isolates (n = 64) were assigned to biotype according
to the scheme of Wauters. The serotype was determined by a latex
agglutination. Genetic relatedness of the isolates was assessed by pulsed-
ﬁeld gel electrophoresis (PFGE) with XbaI and NotI enzymes, that is
the current gold standard for Y. enterocolitica genotyping. The presence
of virulence genes (ail, ystA, irp1, yst1M, ysrS) was examined by PCR.
Results: All the investigated isolates of Y. enterocolitica belonged
to bioserotype 1B/O8, and yielded PCR amplicons for virulence
determinants: ail, ystA, and for signature genes: irp1, yst1M, ysrS which
are associated with the major genomic-islands of the high-pathogenicity
Y. enterocolitica biotype 1B. The PFGE proﬁles were endonuclease
speciﬁc and homogeneous for the all 64 clinical isolates.
Conclusion: The bioserotype 1B/O8 isolates of Y. enterocolitica
collected in 2009 in Poland were found to belong to the high-
pathogenicity lineage. PFGE analysis revealed that these isolates are
highly related and together constitute a single strain sensu stricto. Our
results strongly suggest a common source of the isolates.
P1706 Interlaboratory comparison of DiversiLab® rep-PCR clus-
tering against characterised Acinetobacter baumannii isolates
P.G. Higgins*, A.M. Hujer, K.M. Hujer, R.A. Bonomo, H. Seifert
(Cologne, DE; Cleveland, US)
Objectives: DiversiLab® is a powerful epidemiological typing tool
that uses micro-ﬂuidic chips to provide standardized, semi-automated
rep-PCR ﬁngerprints, potentially allowing users to archive, compare
and share ﬁngerprints. We sought to investigate the reproducibility of
DiversiLab® rep-PCR ﬁngerprints between two laboratories with the aim
to determine if the ﬁngerprints and clustering are laboratory-speciﬁc or
portable.
Methods: 100 non-duplicate A. baumannii isolates were used in this
study including representative isolates belonging to A. baumannii
worldwide clonal lineages 1−8 previously identiﬁed using DiversiLab®.
A cluster was deﬁned as isolates sharing >95% similarity. DNA isolation
and rep-PCR was performed separately in the two laboratories. PCR
products were run on micro-ﬂuidic chips and analysed in the Agilent
2100 Bioanalyzer. Rep-PCR patterns generated in laboratory A were
compared to those from laboratory B. Samples were tested blind. We
compared both strain vs. strain and cluster vs. cluster. The Pearson
Correlation (PC) and Kullback-Leibler (KL) statistical methods were
employed in the analysis.
Results: 100 repPCR patterns from laboratory A were compared to
100 patterns from laboratory B. The PC statistical method gave greater
similarity than KL and was used for all further analysis. 12 isolates from
laboratory A showed 98% similarity with the corresponding 12 from
laboratory B and were considered identical. 64 isolates showed 95–97.9%
similarity with their corresponding isolates. 23 isolates showed 90−94%
similarity with the corresponding isolates, while 1 isolate showed 87.4%
similarity and therefore appeared unrelated. In the majority of cases,
differences between ﬁngerprints were related to band intensity and not
absence of bands. However, intra-laboratory clustering was conserved;
isolates that clustered in laboratory A, also clustered in laboratory
B. Therefore, clustering was conserved, but ﬁngerprints showed more
variability.
Conclusion: Our data suggest that individual rep-PCR libraries should
be generated in different laboratories to serve as reference standards for
regional analysis of outbreaks. Clustering of isolates was reproducible,
demonstrating the robustness of rep-PCR. This comparison allows
conclusions regarding clonality to be reached independent of the
laboratory where the analysis is performed.
P1707 MLST types of vancomycin-resistant Enterococcus faecium
isolated from blood samples in a university hospital in
Konya, Turkey
U. Arslan*, E. Demir, E. Oryasin, I. Tuncer, D. Findik, B. Bozdogan
(Konya, Aydin, TR)
Objective: Longtime considered as commensal organisms, Enterococci
have become an important nosocomial pathogen since a couple of
decades. However infections and outbreaks with vancomycin-resistant
Enterococci appear relatively rare in Turkey. We aimed to determine the
glycopeptide resistance mechanism and the genetic relatedness among
vancomycin resistant Enterococci isolated from blood culture in a
university hospital in Turkey.
Materials and Methods: Vancomycin resistant Enterococci (VRE) were
isolated from blood culture since 2005 in a University Hospital. A total
of 37 strains were studied and all isolates were identiﬁed by 16S rRNA
sequencing. These isolates were further studied for their vancomycin
resistance mechanism and their clonality. Presence of resistance genes
was detected by PCR. Clonality among vancomycin resistance strains
was studied by PFGE and MLST were done for one of each pulsotype.
Results: All isolates were from blood. A total 37 vancomycin-resistant
strains were further studied and all were identiﬁed as Enterococcus
faecium by 16S rRNA sequencing. PCR were positive for 37 VRE with
speciﬁc primers for vanA gene. A total of 4 pulse-types A(32), B(3),
C(2), D(2) and their varieties observed by PFGE. Samples were choosen
from varieties of pulse-types and showed that ST117 (pulsotype A), ST18
(pulsotype C), ST280 (pulsotype B) and ST17 (Pulsotype D) by MLST.
Conclusions: Isolation of vancomycin resistant Enterococci rates
remains relatively low in Turkey. Among 37 E. faecium with vanA gene
from blood cultures, one clone with pulsotype A and ST117, was the
most common although other clones were observed. Presence of variants
of the common clone named as Konya clone (Pulsotype A, ST117)
may be explained by establishment of this clone since long time in our
hospital.
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P1708 Multilocus sequence typing used as a tool to conﬁrm the
ability of susceptible Helicobacter pylori strains to gain
resistance to clarithromycin during eradication therapy
S. Jeverica*, A. Ihan, B. Tepesˇ (Ljubljana, Rogasˇka Slatina, SI)
Primary resistance of H. pylori to clarithromycin and metronidazole
is the most common reason for eradication failure, followed by poor
compliance to therapy and mixed susceptible and resistant H. pylori
strain infection. To distinguish between mixed infections and H. pylori
switch to resistance phenotype during eradication therapy, we proceeded
with multi locus sequence typing (MLST) of H. pylori strains isolated
from stomachs of patients before and after eradication therapy.
The study took place from November 2008 to December 2009. We
collected H. pylori isolates from gastric biopsies from 133 patients
who were never treated for H. pylori before or after antibiotic therapy.
Five patients had eradication failure with the ﬁrst isolate susceptible and
second isolate resistant to clarithromycin. To analyse genotypes of ﬁrst
and second H. pylori isolates, we compared H. pylori strain sequences
of 7 housekeeping genes with MLST.
Five patients had clarithromycin-sensitive H. pylori before eradication
therapy and were H. pylori-resistant to clarithromycin after erradication
therapy. The sensitive and resistant colonies of each of the H. pylori
populations, taken from patients before/after antibiotic therapy, had
identical sequence types (ST) obtained with MLST.
None of the patients became resistant to clarithromycin during the
therapy due to mixed infection with H. pylori. All 5 patients with
eradication failure were colonised with the same H. pylori strain before
and after therapy. The factors favouring H. pylori survival and switch
to antibiotic-resistance during eradication therapy must probably enable
milder environmental conditions for H. pylori survival during the therapy.
One of such factors is the ineffective destruction of mucosa-adhered
H. pylori by immune cells during therapy which may be due to immune
deﬁcit like interferon-g deﬁciency or locally induced immune deﬁcit
by biologically active H. pylori molecules like strain speciﬁc H. pylori
lipopolysaccharides.
P1709 Evaluation of the performance of the Chlamydia trachomatis
detection kit and Ct Genotyping RHA kit compared to
the Cobas Amplicor CT/NG in SVS from females visiting
a STI clinic
L. van Dommelen*, A.A. Brink, F.H. van Tiel, W.G. Quint, S. Morre´,
P. Wolffs, C.J. Hoebe (Maastricht, Voorburg, Amsterdam, Geleen, NL)
Introduction: Improving diagnostic methods for the detection of
Chlamydia trachomatis (CT), including genotyping, can contribute to
control of CT by acquiring knowledge on epidemiology, transmission,
sexual networks and pathogenicity. In the present study, we have
compared the performance of the Chlamydia trachomatis detection and
genotyping (Ct-DT) kit (Labo Bio-medical Products BV, Rijswijk, The
Netherlands) with the COBAS Amplicor CT/NG (Roche Diagnostics
Systems, Basel, Switzerland) in a well described female population
consulting a sexually transmitted infection (STI) clinic.
Methods: Self obtained vaginal swabs (SVS) were collected from
females visiting a STI clinic. The presence of Chlamydia trachomatis
DNA was determined by the COBAS Amplicor CT/NG. In agreement
with the manufacturer, 200ml of processed COBAS Amplicor CT/NG
medium was used for DNA isolation using the Qiagen DNA mini kit
(Qiagen GmbH, Hilden, Germany). For the Ct-DT kit, 10mL DNA was
used. All CT positive samples were used for serovar typing. Discrepant
samples were retested using COBAS TaqMan CT Test v2.0 (Roche
Diagnostics Systems, Basel, Switzerland). A sample was considered CT
positive (comparison standard) if both NAAT were positive or if one
these NAAT and the retest was positive.
Results: In all, 772 clients were included in the original study. COBAS
medium was available from 71 CT positive clients and 179 CT negative
samples were randomly selected. With the Ct-DT kit, 68 out of 71
CT positive samples (97%) tested positive and 1 borderline, leaving 2
discrepant results. Retesting of the latter two samples using the COBAS
TaqMan assay resulted in two positive tests. All COBAS Amplicor CT
negative samples were also negative with the Ct-DT kit. The sensitivity,
speciﬁcity, positive and negative predictive value of the Ct-DT kit were
97%, 100%, 100% and 99%, respectively, if the borderline result is
included in the positive results. Genotyping results are presented in
Table 1. Serovars D/Da, E and F were most prevalent. The serovar
distribution is comparable to previously published Dutch data.
Conclusion: Compared with COBAS Amplicor CT/NG, the Chlamydia
trachomatis detection and Ct Genotyping RHA Kit combination is a
sensitive and highly speciﬁc assay to detect Chlamydia trachomatis.
Moreover, it is a more rapid and easy to perform method to detect the
most commonly detected serotypes compared to PCR-RFLP typing.
P1710 Extended multilocus variable-number tandem-repeat
analysis of Clostridium difﬁcile
S. Manzoor*, H.E. Tanner, C. Marriott, J.S. Brazier, K. Hardy,
S. Platt, P. Hawkey (Birmingham, Cardiff, London, UK)
Objectives: PCR Ribotyping is currently used in the UK for epi-
demiological investigations to track transmission and identify emerging
variants of Clostridium difﬁcile. Although PCR Ribotyping differentiates
over 300 types, it is not always sufﬁciently discriminatory for
epidemiological investigations. MLVA is a more highly discriminatory
molecular subtyping method which can identify/conﬁrm transmission
events. The aim of this study was to identify further novel VNTR loci and
evaluate their discriminatory power for prevalent C. difﬁcile ribotypes.
Methods: Eight novel loci were identiﬁed, using Tandem Repeats
Finder software on the genomes of C. difﬁcile strains 630 and QCD-
32g58, and evaluated alongside seven published loci against a panel of
C. difﬁcile. Isolates were selected from a collection of epidemiologically
clustered and diverse C. difﬁcile isolates from 10 different PCR ribotypes
(001, 002, 012, 014, 015, 017, 020, 027, 078 and 106). The 15
loci were ampliﬁed by PCR using ﬂuorescently labelled primers. Four
PCR products, each labelled with a different ﬂuorophore, were mixed
together with HiDi formamide and LIZ600 size standard (Applied
Biosystems). PCR product size was determined by multicoloured
capillary electrophoresis using the 3130xl Genetic Analyzer (Applied
Biosystems).
Results: When all 299 isolates were analysed using the eight novel
Birmingham VNTR loci, each novel locus showed tandem repeat number
variability between ribotypes. Isolates were grouped into tight ribotype
clusters, with the exception of isolates from two ribotypes, 014 and 020,
which clustered together in one group. Using extended MLVA (eMLVA)
all isolates clustered in concordance with ribotyping data but were also
differentiated within ribotypes.
Conclusion: This study demonstrates that by extending MLVA for
C. difﬁcile to the 15 VNTR loci, common ribotypes can be distinguished
in a way that mirrors the true phylogenetic structure of C. difﬁcile
providing an insight into genetic diversity of the C. difﬁcile population.
Clinical isolates also can be meaningfully sub-typed giving results
relevant for outbreak investigation and infection control.
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P1711 Allele-speciﬁc real-time PCR for cost-effective canonical
SNP genotyping of Bacillus anthracis
I. Ivanov*, K. Marinov, E. Tsvetkova, R. Nenova,
R. Vatcheva-Dobrevska, E. Dobreva, T. Kantardjiev (Soﬁa, BG)
Objectives: We have previously shown the emergence of unique
Bacillus anthracis MLVA genotypes in Bulgaria. To further characterize
these strains, an Allele-speciﬁc Real-time PCR assay (ASRT-PCR) was
developed and validated based on 12 standardized canonical SNPs (Van
Ert 2007). According to these canSNPs all B. anthracis isolates are
grouped into twelve global sub-lineages correlating with geographical
and historical distribution of this agent.
Methods: Two forward allele speciﬁc primers with 3‘ terminal SNP and
a common reverse primer were designed for analysis of each canSNP.
The allele-discriminating primes incorporated an additional destabilizing
mismatch at the SNP penultimate site which has been reported to result
in greater speciﬁcity (Wangkumhang 2007). The type of mismatch was
adjusted according to the principle of Little et al. 2001. Primers were
tested against available B. anthracis genomes in GenBank as well as
with reference strains of various canSNP sub-lineages representative of
all possible alleles. The assay was optimized in a closed-tube format as
EVA Green Real-time PCR followed by melting curve analysis. ASRT-
PCR was applied for genotyping of 51 isolates originating from different
regions in Bulgaria previously characterized by MLVA8. Phylogenetic
analysis was performed with MEGA4 software.
Results: ASRT-PCR resulted in an unambiguous allele discrimination
in each of the twelve target canSNP and all of the tested reference
strains were correctly classiﬁed into their respective sub-lineages. By
applying a touch-down PCR protocol it was found that not only
extensive optimization proved unnecessary but all SNPs could be
analyzed with identical PCR conditions. Most of the Bulgarian isolates
(50/51) including those represented by unusual MLVA8 genotypes, were
classiﬁed in the A.Br.008/009 sub-lineage which is predominant in
Europe, Middle East and Asia. Interestingly a single isolate was referred
to the A.Br.001/002 sub-lineage which is rare and appears to have either
originated and/or expanded signiﬁcantly in China (Simonson et al. 2009).
Conclusions: The ASRT-PCR developed and validated in this study
is a robust and cost-effective alternative to the TaqMan® MGB
or hybridization probes for canSNP typing of B. anthracis. The
A.Br.008/009 sub-lineage is predominant in Bulgaria but testing more
isolates from the Balkan Peninsula where B. anthracis is endemic is
necessary to establish the regional population structure.
P1712 New approaches to genotyping of clinically relevant
bacteria: typing of Escherichia coli by single nucleotide
polymorphism pyrosequencing
N. Ferna´ndez-Romero*, M.P. Romero-Go´mez, M.R. Go´mez-Gil,
J. Mingorance (Madrid, ES)
We have developed a single nucleotide polymorphism (SNP) scheme
based on multilocus sequence typing (MLST) for typing of E. coli
clinical isolates. The SNPs are read by pyrosequencing and the sequences
are converted into allelic patterns that can be analyzed using the same
tools used for MLST studies. With this approach we have studied
two collections of clinical isolates of E. coli obtained blood and urine
cultures. The two collections show an epidemic structure, with four major
complexes (including the international ST131 complex) accounting for
nearly forty percent of the isolates. One of the major clones, related to the
known CFT073 uropathogenic strain, was signiﬁcantly more abundant
among urine isolates. The method is easy to perform, is cheaper than
other methods currently in use, it provides an output that is easy to read
and interpret, and most important it is a high throughput approach that
will be useful for typing of large collections of clinical isolates.
P1713 Genetic diversity of invasive strains of Neisseria meningitidis
serogroup B before the introduction of the new menB
vaccine in Italy
C. Fazio*, A. Carannante, T. Soﬁa, A. Neri, P. Mastrantonio,
P. Stefanelli (Rome, IT)
Objectives: Invasive Meningococcal Disease (IMD) caused by serogroup
B Neisseria meningitidis is of particular interest due to the challenge
it presents concerning vaccine development. To assess the pattern
of IMD in Italy due to serogroup B before the introduction of an
anti-meningococcus B vaccine, analyses of phenotypic and genetic
characteristics of serogroup B meningococci have been carried out.
Methods: 1156 IMD cases from 2005 through 2010 have been reported
to the National Meningococcal Surveillance System. Serogrouping and
antibiotic susceptibility against penicillin, ciproﬂoxacin, ceftriaxone
and rifampin were determined for 653 meningococci received at the
National Reference Laboratory (NRL) of the Istituto Superiore di Sanita`.
MultiLocus Sequence Typing (MLST), porA VRs and FetA typing were
performed on a subsample of serogroup B strains (N = 340).
Results: During the study period the percentages of meningitis and
septicaemia due to serogroup B meningococci remained quite stable,
52% and 25%, respectively. Since 2005 an increase in the proportion of
serogroup B strains (more than 50%) has been observed paralleled by a
signiﬁcant decrease of serogroup C strains (from 54% in 2005 to 21%
in 2010). All the meningococci were fully susceptible to the antibiotic
tested, except for one serogroup B strain, ciproﬂoxacin resistant (MIC =
0.19mg/L). Preliminary analysis of MLST data showed an heterogeneity
among the isolates analysed so far, comprising 13 clonal complexes.
However, 76% belonged to four Clonal Complexes, ST-41/44 (54.8%),
ST-32 (13%), ST-269 (4.8%), ST-461 (3.4%). Eleven percent of strains
was not assignable to a known Clonal Complex on the neisseria website.
The PorA VR1, VR2 and FetA variants more frequently detected were
7−2, 4 and F1−5 for the ST41/44; 19, 15 and F3−3 for the ST-32; 19−1,
15−11 and F1−7 for the ST-269; 19−2, 13 and F5−5 for the ST-461.
Conclusion: Serogroup B meningococci have been predominant in Italy
during the last ﬁve years. Moreover, they are characterized by few Clonal
Complexes, porA VRs and FetA variants.
Although the correlations between MenB vaccine antigenic variants
and MLST results are not sufﬁcient to predict vaccine coverage, the
molecular characterization of serogroup B meningococci is essential for
both epidemiological and vaccine development purposes.
P1714 Using the Argus™ optical mapping system to investigate
a Salmonella enterica serovar Saintpaul outbreak occurring
in alfalfa sprouts
E. Zentz*, A. Briska, S. Hinrichs, P. Iwen, J. Henkhaus (Gaithersburg,
Lincoln, US)
Objectives: Pulsed ﬁeld gel electrophoresis (PFGE) serves as the gold
standard for outbreak investigations but lacks sufﬁcient resolution to
locate key differences between isolates. Optical Mapping (OM) creates
ordered, restriction maps for whole genome comparative analysis. With
hundreds of markers across the genome, Optical Maps differentiate
strains and precisely describe genomic variation. We applied OM to
a 2009 Salmonella enterica outbreak to assess OMs utility in outbreak
situations. Speciﬁcally, we examined OMs ability to distinguish common
serovars of Salmonella enterica, to differentiate outbreak from non-
outbreak, and describe the genomic variation within the outbreak.
Methods: 50 Salmonella enterica isolates were analyzed by Optical
Mapping. The sample set included a mixture of outbreak and non-
outbreak associated Saintpaul serovar isolates as well as isolates from
non-Saintpaul serovars. Genomic DNA was extracted and Optical Maps
were prepared using the Argus Optical Mapping System (OpGen, Inc.).
Optical Maps were compared to each other and to a reference dataset
consisting of 15 maps spanning 11 serovars. Whole genome clustering
was performed on the entire dataset to segregate the maps according to
genome similarity − MapTypes (MapSolver™ software OpGen, Inc.).
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Likewise, pairwise alignment analysis was performed between closely
related isolates to identify genomic differences.
Results: Whole genome clustering segregated the 50 isolates and
reference strains into 8 different MapTypes, each corresponding to a
different serovar. Of the 34 Saintpaul isolates: 25 were outbreak and
9 non-outbreak. This was highly consistent with PFGE data with one
exception, where Optical Mapping grouped a putative non-outbreak
isolate with outbreaks. The outbreak isolates were highly similar to each
other (<0.2% difference). The outbreaks as a group were 1.2% different
from the non-outbreak isolates. Indels represented the major variation
between outbreak and non-outbreak.
Conclusions: Optical Mapping segregated the isolates into their
respective MapTypes, each corresponding to a different serotype.
Outbreak and non-outbreak isolates were also differentiated. No
signiﬁcant differences were identiﬁed among the outbreaks, whereas
numerous differences were observed between outbreak and non-outbreak
as well. These differences could not be discerned with PFGE. The clonal
nature of the outbreak isolates suggests a single event or common source
for the outbreak.
P1715 Multilocus sequence typing characterisation of Streptococcus
dysgalactiae subsp. equisimilis isolates from Portugal
M. Pinho*, M. Ramirez, J. Melo-Cristino on behalf of the Portuguese
group for the study of streptococcal infections
Objectives: Streptococcus dysgalactiae subsp. equisimilis is the
b-haemolytic Lanceﬁeld group C or G streptococcal species most
commonly reported worldwide and is increasingly recognized as an
important human pathogen. To gain further insights into the clonal
structure of the S. dysgalactiae subsp. equisimilis population, a recently
described multilocus sequence typing (MLST) scheme was used. The
current study also aimed to evaluate the congruency of the MLST results
with those obtained by other typing methods used in S. dysgalactiae
subsp. equisimilis epidemiology.
Methods: Thirty-six isolates (28 Lanceﬁeld group G and 8 group C)
obtained from invasive and non invasive infections were selected for
analysis by MLST. These isolates belonged to a collection of 314
S. dysgalactiae subsp. equisimilis strains associated with human infection
in Portugal previously characterized by pulsed-ﬁeld gel electrophoresis
(PFGE) and emm typing. The relationships between the sequence
types (STs) as determined by MLST were determined with goeBURST
(http://goeburst.phyloviz.net/). Clonal complexes were deﬁned as STs
that were linked through single locus variants.
Results: A total of 22 STs were found among the 36 isolates
analyzed by MLST. They were grouped into 5 clonal complexes and
11 were singletons. The diversity of STs observed was in line with the
heterogeneity of PFGE clones (n = 11) and emm types (n = 17) presented
by the isolates analyzed. Invasive and non-invasive isolates were not
completely separated by any of these techniques. Several emm types
were found associated with more than one ST and three STs harboured
more than one emm type. The heterogeneous distribution of emm types
across the STs was also evident for PFGE clones indicating a low level
of correspondence between the three typing methods. In contrast to the
situation observed with PFGE and emm, goeBURST analysis showed
that distinct STs and clonal complexes were associated with either the
Lanceﬁeld group C or group G carbohydrates.
Conclusion: The MLST analysis of S. dysgalactiae subsp. equisimilis
isolates supports the existence of several genetic lineages responsible for
human infections in Portugal, in agreement with PFGE and emm typing
results. The variability of the MLST groups in terms of PFGE, emm type
and group carbohydrates also points to the genetically heterogeneous
nature of this streptococcal species.
P1716 Genetic lineages and plasmid proﬁle of extended-spectrum
b-lactamase producing Escherichia coli isolates of food and
animal origin
S. Somalo*, Y. Sa´enz, V. Estepa, S. Martı´nez, L. Vinue´, C. Torres
(Logron˜o, ES)
Objectives: To determine the genetic lineages and the plasmid content
in a collection of Extended-Spectrum-b-Lactamase (ESBL)-producing
E. coli isolates recovered in previous studies from food and healthy dog
faecal samples.
Methods: Fifty isolates were included, 30 of food origin and 20 of faecal
samples of healthy dogs. They produced the following ESBLs (number of
isolates food/animals): CTX-M-14a (13/5), CTX-M-14b (3/2), CTX-M-9
(4/0), CTX-M-1 (0/3), CTX-M-32 (1/2), and SHV-12 (9/8). Multilocus
sequence typing was carried out by PCR and sequencing and plasmid
proﬁle was determined by PCR based replicon typing. Phylogenetic
groups of isolates were determined by PCR.
Results: A high diversity of sequence types (ST) was identiﬁed among
the food (20 different ST) and animal isolates (13 different ST). Six
of them were new (ST1911, ST1912, ST1913, ST1914, ST1968, and
ST2027). Ten ST were detected in more than one isolate (ST665, ST359,
ST224, ST155, ST117, ST10, ST57, ST23, ST1914, and ST1615). The
ST665 and ST224 were identiﬁed among isolates of both food and
animal origins. The ST10 complex (ST10Cplx) (including ST10, ST43,
ST176, ST617) was detected in 6 isolates of food and animal origin.
The ST23Cplx and ST350Cplx were identiﬁed in 4 isolates of animal
origin and the ST155Cplx in 2 isolates of food origin. Phylogroups
detected among ESBL-positive isolates were (number of isolates food/
animal): A (8/8), B1 (13/5), B2 (1/1), D (4/4), and U (4/2). All isolates
of the ST10Cplx were ascribed to the phylogroup A. The two isolates
typed as ST23 were of phylogroup A and harboured SHV-12. The two
isolates of phylogroup B2 produced CTX-M-9 and CTX-M-14b, and
were typed as ST770 and ST372, respectively. The plasmid proﬁle of
isolates in relation to the ESBL were as follows (replicon type/number
isolates): CTX-M-14a (FIB-FII/13; FII/2; I1/6; N/5; FIC/2; B/O/10; K/6;
Y/1; X/1; P/1); CTX-M-14b (I1/3; FIB-FII/1; B/O/4; FII/2; Y/1; HI2/1),
CTX-M-9 (FIB-FII/2; HI2/2; I1/2; FII/2; FIC/2; K/2; A/C/1; B/O/1);
SHV-12 (I1/17; FIB-FII/14; FII/1; K/11; B/O/2; P/2; FIC/2; N/1; Y/1;
T/1), CTX-M-1 (I1/3; FIB-FII/3; P/1; K/1) and CTX-M-32 (HI1/1; X/2;
FIB-FII/2; P/2; K/2).
Conclusion: A high diversity of sequence types was detected among
ESBL-producing isolates of food and animal origin, being those of
ST10Cplx the most frequently detected in both origins. Phylogroups
A and B1, and FIB+FII and I1 replicon types are mostly found among
these isolates.
P1717 Usefulness of SpectraCell RA Ramen spectroscopy in
tracking epidemic methicillin-resistant Staphylococcus
aureus in Scotland
R.V. Goering*, M.R. Donnellan, E.K. Girvan, A. Holmes,
K.E. Templeton, G. Edwards (Omaha, US; Glasgow, Edinburgh, UK)
Objectives: Two epidemic methicillin-resistant Staphylococcus aureus
strains, EMRSA-15 and EMRSA-16, account for the overwhelming
majority of all Scottish MRSA. PFGE has long been considered the
gold standard for the molecular typing of problem bacterial pathogens
including MRSA. However, issues of expertise, throughput, cost, and
interpretation have spurred the quest for newer more molecularly based
approaches. In addition, a signiﬁcant number of Scottish EMRSA15
and EMRSA16 isolates are indistinguishable by PFGE typing thus
complicating epidemiological monitoring. The SpectraCell RA system
(River Diagnostics, BV, Rotterdam, The Netherlands) is an optical typing
method based on Raman spectroscopy. We evaluated the SpectraCell for
its ability to identify Scottish EMRSA-15 and EMRSA-16, the former
including two isolate clusters of known epidemiological linkage.
Methods: A total of 430 MRSA including 57 and 41 Scottish
EMRSA-15 and EMRSA-16 isolates, respectively, were analyzed. The
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former included 25 isolates from two epidemiologically linked clusters
partially subtyped by PFGE using ApaI but differentiated by recently
published variable-number tandem-repeat ﬁngerprinting (MLVF) and
multilocus variable-number tandem-repeat analysis (MLVA) protocols (J.
Clin. Microbiol. 2010. 48:3600–3607). Bacterial cultures were prepared
according to a standardized protocol with overnight growth on Trypticase
Soy Agar (BD, Franklin Lakes, NJ). Aliquots of washed diluted cultures
were dried on fused silica slides and Raman spectra were generated
(ca. 2 hrs/24 samples). Using on-board analysis software, similarity
dendrograms were produced using a squared Pearson correlation
coefﬁcient of 99.98 as the cut-off point.
Results: The SpectraCell system identiﬁed the EMRSA-15 and EMRSA-
16 strain types although in rare instances isolates were grouped outside
their respective major strain clusters. The two epidemiologically distinct
EMRSA-15 groups were also identiﬁed with greater sensitivity and
speciﬁcity than PFGE but comparable to MLVA and MLVF.
Conclusions: SpectraCell high throughput recognition of MRSA strain
types was quick and straightforward, making it an attractive alternative
to current approaches. However, questions regarding epidemiological
clustering suggest the need for additional investigation and optimization.
P1718 Molecular characterisation of Clostridium difﬁcile clinical
strains from Bulgarian hospitals
E. Dobreva*, I. Ivanov, R. Vatcheva-Dobrevska, K. Ivanova,
M. Marina, T. Kantardjiev, E. Kuijper (Soﬁa, BG; Leiden, NL)
Objectives: Characterization of C. difﬁcile isolates by PCR-ribotyping
and evaluation of the most frequent ribotypes in our country as well as
detection of toxin genes by Real-time PCR.
Methods: During the period of November 2008 to March 2010, 65 stool
samples were analyzed from patients with mild to severe enterocolitis
and history of previous antibiotic therapy. The cases were registered
from nine hospitals in Soﬁa and Plovdiv. Isolation and identiﬁcation of
C. difﬁcile was performed by standard microbiological techniques and
latex-co-agglutination test. Production of toxins A and B was analyzed
by enzyme-immunoassay (EIA). Detection of toxin genes tcdA, tcdB,
cdtA and cdtB (binary toxin) was performed by Eva Green Real-time
PCR. PCR-ribotyping coupled with fragment analysis on capillary gel
electrophoresis was applied as a typing method.
Results: The overall C. difﬁcile isolation rate was 23% (15/65).
Production of Toxin A and B was detected in 21, 5% stool samples by
EIA. Three toxigenic types have been distinguished by Eva Green Real
time PCR: 53,3% (8/15) toxin A+B+; 20% A−B+ and 26,7% A−B−.
The binary-toxin genes cdtA/B was detected by PCR in one of the
tested A+B+ strains. Six ribotypes were distinguished among the 15
clinical strains. The most prevalent ribotypes were: 017 − 40% (6/15);
002 − 13%; 014/020 −13% and 012, 046, 078 were represented by 7%
each. Four of the ribotype 017 isolates originated from a single hospital
A. Patterns were compared to reference ECDC C. difﬁcile collection.
Thirteen percent of C. difﬁcile strains were corresponded to unknown
PCR-ribotypes.
Conclusion: Infections of C. difﬁcile are an emerging problem in
Bulgaria. The incidence of C. difﬁcile infections increased in the recent
years and at least 5 cases led to serious outcome and death. The
signiﬁcant number of cases C. difﬁcile diagnosed with outbreak ribotypes
might represent a signiﬁcant problem in the future. The results of the
current study would improve the diagnostic and therapeutic preparedness
of the Bulgarian hospitals when dealing with C. difﬁcile infections.
P1719 Blastocystis sp. subtype 4 is common in Blastocystis-positive
patients presenting with acute diarrhoea
C. Stensvold*, D.B. Christiansen, K.E. Olsen, H.V. Nielsen
(Copenhagen, DK)
Objective: Blastocystis is possibly the most common non-fungal
eukaryotic organism found in the human intestinal tract. Extensive
genetic diversity within the genus has been demonstrated, and the genus
comprises at least 13 subtypes (STs), 9 of which have been found
in humans. It is hypothesised that differences in clinical outcome of
Blastocystis carriage is linked to differences in genetic make-up. The aim
of study was to identify the prevalence of Blastocystis and distribution
of Blastocystis subtypes in patients presenting with acute diarrhoea.
Methods: Faecal samples from 444 Danish patients presenting with
acute diarrhoea were submitted to standard panels of microbiological
analyses and moreover tested for Blastocystis by culture. Positive samples
were subtyped by PCR and sequencing. Acute diarrhoea was deﬁned as
three or more loose or watery stools per day for less than two weeks.
Analysis of subtype frequency distribution was performed using the one-
way Chi-Square goodness of ﬁt test and analysis of categorical data was
performed using Fisher’s exact test (two-tailed).
Results: A total of 25 patients (5.6%) were positive for Blastocystis by
culture and PCR, 19 (76%) of whom were positive for Blastocystis sp.
ST4 (P< 0.001). ST2 was seen in 4 patients (16%); ST3 and ST1 were
each seen in one patient. Although 66% of the patients aged 11 y or
more were females, a positive test was signiﬁcantly associated with the
female gender (P< 0.01); only one male in the group of patients aged
11 or more was positive for Blastocystis. A total of seven Blastocystis-
positive patients were positive for pathogenic bacteria or virus, four of
whom were positive for ST4.
Conclusion: Comparing the study population with patients suffering
from chronic, HIV-related or travel-related diarrhoea, the overall
prevalence of Blastocystis in patients with acute diarrhoea was relatively
low, whereas the relative prevalence of ST4 was remarkably high. Hence,
since the relative prevalence of ST4 in patients presenting with other
types of diarrhoea in Denmark is low, the role of Blastocystis sp. ST4
in the etiology of acute diarrhoea should be investigated further.
P1720 Application of three different variable number tandem
repeat typing schemes on Staphylococcus aureus within the
east and west Midlands
M. Lewis, K. Hardy, S. Shabir*, C. McMurray, P. Hawkey
(Birmingham, UK)
Objectives: Variable number tandem repeat (VNTR) typing can be
performed on several loci to provide a strain speciﬁc numerical identiﬁer
useful in epidemiological studies such as monitoring transmission within
a clinical setting. Currently in Staphylococcus aureus three key schemes
have been investigated with varying levels of discrimination shown by
each loci. The objectives of this study are to compare these schemes on
clinical isolates from the East and West Midlands (UK) and identify the
most discriminatory loci.
Methods: A collection of methicillin resistant S. aureus (MRSA) and
methicillin sensitive S. aureus (MSSA) were obtained from clinical
studies previously performed within the East and West Midlands.
Isolates were selected on the basis of distinct PFGE and Staphylococcal
Interspersed Repeating Unit (SIRU) proﬁles. Prior to VNTR typing the
restriction modiﬁcation (RM) test was performed on the isolates to
determine the clonal complex (CC). Isolates were selected based on CC
to be typed by VNTR using the 21 loci from three published schemes.
PCR amplicons of the VNTR loci were subsequent analysed by capillary
gel electrophoresis using QIAxcel to determine repeat number.
Results: CC22 (EMRSA-15) is the most frequently observed healthcare
associated strain within the Midlands region. From an initial screen
of 80 MRSA and 66 MSSA isolates, 28 and 4 isolates respectively
were determined to be CC22. The other epidemic strain seen within the
Midlands is CC30 (EMRSA-16)and 4 of the MRSA plus 6 of the MSSA
isolates were deﬁned as CC30 For development of a calibration panel
to compare the VNTR typing schemes only CC22 and CC30 isolates
were included from the MRSAs. Due to the higher level of variability in
SIRU proﬁles observed within the MSSAs, isolates from CC1 (6) CC8
(2) and CC45 (4) were also included. The number of repeating units at
each locus was determined on this panel of isolates.
Conclusion: Initial work demonstrates that all three VNTR typing
schemes can be used to produce strain speciﬁc identiﬁers important in
epidemiological studies and inﬂuencing infection control in outbreaks.
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The discriminatory power of each locus varies and will be investigated
in greater depth in further work. The most discriminatory loci will be
selected to be used in a robust typing assay examining the epidemiology
of hospital associated S. aureus within the East and West Midlands.
P1721 Evaluation of DiversiLab system performance for typing
of multi-resistant bacterial pathogens
A. Deplano*, M. Hallin, R. De Ryck, H. Rodriguez-Villalobos,
M. Struelens, O. Denis (Brussels, BE)
Objective: To evaluate the typing performance of rep-PCR using the
semi-automated DiversiLab (DL) system for typing a range of multi-
drug resistant (MDR) pathogens commonly recovered in nosocomial
infections.
Methods: Performances of DL − including reproducibility, typeability,
discriminatory power, concordance with pulsed ﬁeld gel electrophoresis
(PFGE) and multilocus sequence typing (MLST) − as well as its
epidemiological concordance were evaluated using collection of 160
well-characterised MDR strains of vanA E. faecium (VREF) (n = 12),
K. pneumoniae (n = 34), A. baumannii (n = 33), P. aeruginosa (n = 41)
and E. coli (n = 40).
Results: DL showed excellent performances for typing VREF and
K. pneumoniae collections, displaying 100% typeability and repro-
ducibility, a discrimination index (DI) >95% and >99% concordance
with PFGE and MLST. Good performance values were also observed for
other species except that (i) DL presented DI< 95% for A. baumannii
and E. coli collections (93.9% and 92.6%, respectively) mainly due to
clustering of isolates belonging to distinct PFGE/MLST types into the
same DL type and (ii) DL showed poor concordance with PFGE (87.9%)
and MLST (78.6%) regarding P. aeruginosa because isolates belonging
to clone ST235 were classiﬁed into distinct DL types. Excellent (100%)
epidemiological concordance was observed, as all outbreak-associated
isolates clustered in identical DL types, distinct from unrelated isolates
of the same species.
Conclusions: DL revealed to be a reliable typing tool for outbreak
investigation but was generally less discriminant than PFGE analysis.
Due to problems of concordance between the two methods, MLST type
should not be infer from DL type for P. aeruginosa.
P1722 Molecular epidemiology of human listeriosis in Andalucı´a,
Spain
M.J. Torres, J.A. Lepe, J. Liro´, J. Aznar* (Seville, ES)
Objectives: The aim of this study was to perform a retrospective study
genotyping 154 isolates from human listeriosis cases occurred in the
region of Andalusia (southern Spain) in the period 2005–2009.
Methods: Serotyping was performed for 1 and 4 somatic antigens
using commercial Listeria antisera, and by multiplex-PCR serogrouping
according to the method described by Doumith et al. (2004).
PFGE was performed according to the PulseNet protocol with the
ApaI enzyme. The similarity of PFGE proﬁles was evaluated using the
Bionumerics software.
The multiplex PCR protocol described by Chen and Knabel (2007) was
used for the identiﬁcation of isolates belonging to L. monocytogenes
ECI, ECII, and ECIII epidemic clones.
Results: The 154 isolates were grouped into four serotypes: 4b [94
(61%)] strains, 1/2b [30 (19%)] strains, 1/2a [27 (18%)] strains and 1/2c
[3 (2%)] strains.
Sixty-two ApaI distinct pulsotypes were recognized among the 154
human isolates. Thirty-seven isolates (24%) showed unique ApaI
pulsotypes, and the remaining 117 strains (76%) were assigned to 25
ApaI clusters, 60% in clusters of more than two isolates. Sixty-nine
(45%) of the strains are included in six PFGE types.
Regarding the unique pulsotypes, they accounted for 24% of the strains
and 60% of thepulsotypes: 49% of serogroup 4b, 27% of serogroup 1/2b
and 24% of serogroup 1/2a.
The EC markers were found in 62 (40.3%) L. monocytogenes isolates
tested. The ECI marker was present in 43 (46.2%) 4b serotype isolates,
ECII in 10 (10.7%) 4b serotype isolates, and ECIII in 9 (33,3%) 1/2a
serotype isolates.
Conclusions: A large proportion of the human listeriosis cases under
investigation could be grouped into molecular subtype clusters, and
our cases may there be related to international food borne outbreaks,
involving both the United States and European countries. In conclusion,
this is the ﬁrst large Spanish molecular epidemiology study of human
listeriosis and the results obtained could be helpful in reinterpreting the
epidemiology of L. monocytogenes in southern Spain.
P1723 Comparison between automated rep-PCR and MALDI-TOF
for molecular typing of AmpC-producing Proteus mirabilis
M. Trevino*, D. Navarro, G. Barbeito, C. Garcı´a-Riestra,
M.D. Pen˜alver, F. Pardo, M. Herna´ndez, M.T. Garea, B.J. Regueiro
(Santiago de Compostela, ES)
Objectives: The clinical relevance of Proteus mirabilis infection
is increasing as well as the resistance of this bacterium against
antimicrobial treatments. We studied the clonal relationship among
AmpC-producing P. mirabilis from nosocomial and community source
in the Health Area of University Hospital Complex of Santiago de
Compostela (Spain). Results obtained by automated rep-PCR and
whole-cell matrix-assisted laser desortion ionization-time of ﬂight mass
spectrometry (MALDI-TOF MS) are compared.
Methods: Isolates were obtained from routine cultures at the University
Hospital Complex of Santiago de Compostela from 2006 to 2009.
Only one isolate per patient was considered for analysis. Species
identiﬁcation was performed by both, Vitek 2 System and MALDI-
TOF MS. Antimicrobial susceptibility testing of isolated bacteria was
assayed using Vitek 2 System. Isolates showing intermediate or total
resistance to amoxicillin-clavulanic, cefotaxime or ceftazidime according
to CLSI breakpoints were selected for screening of AmpC production by
the double-disk synergy test with phenyl boronic acid, third generation
cephalosporins and cloxacillin. Multiplex PCR for identifying family-
speciﬁc AmpC b-lactamase genes were used.
Molecular-epidemiological analysis of the strains was performed by both,
automated rep-PCR and MALDI-TOF MS AXIMA (SARAMIS).
Results: DiversiLab analysis results detected great variability among
bacterial isolates. The AmpC-producing P. mirabilis isolates (35 in
total) showed 29 different banding patterns. Isolates from community
source clustered near in the dendrogram. The strains with lower
similarity coefﬁcient (<70%) were from community home patients.
The comparison among spectra obtained by MALDI-TOF analysis also
showed the proximity of the community strains in the dendrogram
(similarity coefﬁcient >70%). The indistinguishable/similar isolates
according to DiversiLab criteria also were located nearby in the
dendrogram constructed by SARAMIS software. However, the more
divergent strains mismatch between both methods.
Conclusions: MALDI-TOF MS for species identiﬁcation and automated
rep-PCR (DiversiLab System) for clonal strain typing are sensitive and
reproducible techniques which combined use may be a useful tool for fast
and accurate molecular-epidemilogical analysis of bacterial outbreaks.
However, further studies should be designed to establish the correlation
between genomic and proteomic methods.
P1724 Epidemiological typing of Clostridium difﬁcile isolates from
China
C. Marriott, S. Manzoor*, K. Hardy, L. Xu, W.E. Liu, Z.J. Jian,
Q. Gao, P. Hawkey (Birmingham, UK; Changsha, CN)
Objectives: Whilst Clostridium difﬁcile infection (CDI) is well
recognised in Europe and North America there are few reports from Asia,
mainly from Korea. In China CDI has been reported only from Shanghai.
We have surveyed a large teaching hospital in Changsha, Hunan, 550
miles from Shanghai for CDI and collected clinical/epidemiological data
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and applied PCR ribotyping and multilocus variable-number tandem-
repeat analysis (MLVA) subtyping.
Methods: Twenty one isolates from April 2009 to February 2010 were
obtained from 70 patients at Xiangya Hospital with symptoms of CDI
and typed using PCR ribotyping. MLVA was applied to the three most
common PCR ribotypes to further subtype the isolates into distinct
MLVA types. Presence of tcdA and tcdB was tested for in PCR ribotype
017 isolates.
Results: Seven different PCR ribotypes were identiﬁed, the dominant
PCR ribotype was 017 (48%) followed by 046 (14%) and 012 (14%).
The PCR ribotypes were randomly spread over the time period and
did not cluster. The hypervirulent strain 027 was not observed. Within
the ten PCR ribotype 017 isolates, four separate MLVA types were
identiﬁed. Two clusters were found, each containing 4 isolates. All 3
PCR ribotype 012 isolates were distinct MLVA types as were the 3
PCR ribotype 046 isolates. Toxin testing conﬁrmed all PCR ribotype
017 isolates to be toxin A negative, toxin B positive (A−B+). All
patients received at least one antibiotic prior to onset of diarrhoea with
a mean of 2.7 antibiotics administered per patient; the most common
antibiotics were cephalosporins and ﬂuroquinolones, both used in 81%
of cases. Two patients were admitted to the intensive care unit due to
C. difﬁcile infection however there were no cases of toxic megacolon,
pseudomembranous colitis or patient deaths.
Conclusion: We have conﬁrmed the presence of CDI in another major
Chinese city with evidence of probable nosocomial transmission of the
dominant PCR ribotype 017. CDI is an under recognised infection in
China and a distinct distribution of PCR ribotypes compared to Europe
is seen.
P1725 Re-identiﬁcation according to the new taxonomy and
genetic diversity of Streptococcus bovis causing bacteraemia
in the last 8 years
B. Romero*, M. Morosini, E. Loza, M. Rodriguez-Ban˜os, R. Canton,
R. del Campo (Madrid, ES)
Objective: To re-identify clinical S. bovis blood culture isolates
recovered from Jan-2003 to Jan-2010 by implementation of new
taxonomic criteria based upon their genetic diversity.
Methods: All isolates causing bacteraemia and identiﬁed as S. bovis
(n = 50) were included. Initial identiﬁcation was performed by the
semiautomatic WIDER System (Fco. Soria-Melguizo, Spain) and the
API 20-Strep (BioMe´rieux, France). Antibiotic susceptibility testing
was performed by microdilution using the WIDER system. All
isolates were re-identiﬁed by the following methods: PCR ampliﬁcation
and sequencing of both 16S rDNA and sodA genes and by Mass
Spectrometry using MALDI-TOF MS (Bruker, Germany). Genetic
diversity was determined by PFGE-SmaI and a dendrogram was
constructed using the Phoretix 5.0 software based on the Dice’s
coefﬁcient.
Results: 14 S. gallolyticus subsp. gallolyticus, 26 S. gallolyticus subsp.
pasteurianus, 7 Streptococcus spp. and 3 Lactococcus lactis were
identiﬁed by 16S rDNA PCR ampliﬁcation and sequencing. When using
the sodA gene sequence as a genetic marker, 14 S. gallolyticus subsp.
gallolyticus, 26 S. gallolyticus subsp. pasteurianus, 2 S. infantarius
subsp. infantarius, 2 S. infantarius subsp. coli, 3 S. lutetiensis, and
3 L. lactis were recognized. Finally, the analysis conducted using the
MALDI TOF system identiﬁed 28 S. gallolyticus without no possible sub
speciation, 3 L. lactis, 6 S. lutetiensis and 13 isolates rendered a “non
reliable identiﬁcation” result. PFGE grouped all S. gallolyticus subsp.
pasteurianus into 6 different clusters clearly different from those of the
subsp. gallolyticus which, in turn, exhibited no PFGE related patterns
between them. As expected, all streptococcal isolates (n = 47) showed
low level resistance to aminoglycosides with 10 of them exhibiting high
level resistance to streptomycin (>1,000mg/l) while another 1 isolate
demonstrated high level resistance to gentamicin (>500mg/l). Resistance
percentages for other antimicrobial tested were: 38% erythromycin, 23%
fosfomycin, 10% levoﬂoxacin, 6% tetracycline, and 4% cotrimoxazole.
Conclusion: The most discriminatory method to identify the strepto-
coccal species and subspecies previously characterized as S. bovis by
conventional biochemical tests was the sodA gene nucleotide sequencing.
In epidemiological terms, S. gallolyticus subsp. pasteurianus isolates
appear to have a higher genetic relatedness than S. gallolyticus subsp.
gallolyticus.
P1726 Speciation of Brachyspira, Brucella and Mycoplasma species
by MALDI-TOF
L.P. Randall*, L. Mappley, F. Lemma, C. Churchward, R. Ayling,
M. Fielder, A. Whatmore, N. Coldham (New Haw, Kingston Upon
Thames, UK)
Objectives: MALDI-ToF is fast becoming a mainstream method for
identiﬁcation of micro-organism and commercial databases of bacterial
spectra are increasingly available for identiﬁcation of a wide range
of organisms. However, some bacteria, such as Brachyspira, Brucella
and Mycoplasma species, are poorly represented by some commercial
databases but are important human and animal pathogens. The aim of
this study therefore was to determine if MALDI-ToF was a useful tool in
the identiﬁcation of Brachyspira, Brucella and Mycoplasma to the genus
and species level.
Methods: Isolates were obtained from collections held at the Veterinary
Laboratories Agency (VLA), Weybridge, UK and at Kingston University,
Kingston-upon-Thames, UK. Standard Bruker protocols were used for
analysis of bacteria spotted directly to the target plate and also for
ethanol/formic acid extracts. Samples were analysed using a Bruker
Autoﬂex 2 MALDI-ToF machine. MSP (main spectral projection)
reference spectra and dendrograms were created using MALDI Biotyper
software (Bruker Daltonics). The MSP reference spectra were then added
to the Bruker standard database and used to identify known and unknown
strains.
Results: The same Brachyspira and Mycoplasma (Figure 1) species
clustered together, but were also suitably distinct other species to make
identiﬁcation to the species level possible for these two genera of bacteria
using MALDI Biotyper software. Different Brucella species were not
in distinct clusters and it was not possible to reliably identify species
from each other by the standard algorithm. However, it was possible
to distinguish them from other bacteria, based on the scoring given by
the MALDI Biotyper software. In particular, some species of Brucella
may be difﬁcult to distinguish from Ochrobactrum species by standard
methods, but the MALDI-Biotyper scores showed the Brucella species
to be very distinct from species of this genus.
Conclusions: The results demonstrate that MALDI-ToF is able
to speciate important Brachyspira and both human and veterinary
Mycoplasma species and differentiate them from other bacteria. It was
also be able to distinguish the important zoonotic pathogen Brucella
species from closely related organisms. MSP spectra for these organisms
are now being further validated and will possibly added to the main
commercial Bruker database to facilitate speciation of these organisms.
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P1727 Molecular characterisation of methicillin-resistant Staphylo-
coccus pseudintermedius of canine origin from central Italy
J. Kandhavelu, S. Preziuso, A.R. Attili, J.S. Weese, V. Cuteri* (Matelica,
IT; Guelph, CA)
Objective: In veterinary medicine, methicillin resistant Staphylococci
have emerged as a clinical challenge in the last few decades. From a
clinical point of view, S. pseudintermedius(Sp) is probably the most
signiﬁcant species of the Staphylococcus Intermedius Group (SIG),
being an important canine opportunistic pathogen, often isolated from
dermatitis, otitis and other secondary infections in dogs. The aim
of this study was to unraveled the genetic relatedness of Methicillin
Resistant Staphylococcus pseudintermedius(MRSP) strains from Italy
by using some molecular typing method like Staphylococcal Cassette
Chromosome (SCC)mec typing, dru typing and detection of leukocidin
toxin (lukS).
Methods: A total of 30 MRSP isolates were identiﬁed by PCR using
pse primer from dogs with different clinical symptoms in central Italy.
SCCmec elements were characterized by multiplex PCR and lukS gene
were detected by PCR. Genetic diversity was accessed by dru typing.
Results: All the strains identiﬁed previously as methicillin resistant SIG
were reconﬁrmed as Sp by species speciﬁc PCR. 19 out of 30 MRSP
showed dru type dt9a (63.3%), 8 samples were dt11a (26.6%) and 3
samples were dt10h (10%) type. SCCmec typing revealed the presence
of four types (II-III, III, IV, and V). SCCmec II-III was most frequently
seen (16/30, 53.3%). SCCmec III was detected in 3 isolates (10%) and
other 3 isolates showed SCCmec IV (10%). Five isolates were SCCmec
type V (16.6%). Three were non type able by SCCmec typing. Overall,
isolates with dt9a and SCCmec II-III were predominating. All the isolates
were positive to lukS gene and the sequencing of one ampliﬁed lukS gene
PCR product revealed the homology with deposited sequence of lukS of
MRSP in NCBI.
Conclusion: Overall, the results of the present study allowed us to
conclude that associations exist between dru type dt9a and SCCmec
II−III/III, dt11a and SCCmec V, dt10h and SCCmec IV in contemporary
clinical isolates of Sp from dogs in central Italy. The lukS gene
expression seems to belong to all MRSP investigated here, not showing
any speciﬁc relation to dru type, SCCmec type or site of infection. The
SCCmec V was most predominant in US and Canada, but in this study
this type is identiﬁed as close to European predominant type SCCmec II-
III. In conclusion, the emergence of health associated strains like MRSP
with SCCmec IV and V in dogs should be seriously considered to avoid
the MRSP transmission from animal to humans and vice versa.
P1728 Horizontal spread of highly resistant Gram-negative rods −
evaluation of the Diversilab® typing method
I. Overdevest*, I. Willemsen, S. Elberts, C. Verhulst, J. Kluytmans
(Tilburg, Breda, NL)
Objectives: The worldwide prevalence of highly resistant Gram-negative
rods (HR-GNR) is increasing. Typing methods are needed in case of
an outbreak or to monitor the endemic situation. In this study we
investigated the performance of the DiversiLab® typing method in
comparison with the AFLP typing method.
Methods: A collection consisting of 653 HR-GNR, that were obtained
during a 6 months prospective survey in 18 Dutch hospitals, was typed
by AFLP and DiversiLab®. Results were compared directly to each
other. Subsequently, the sensitivity and speciﬁcity of DiversiLab® were
calculated, using AFLP as the reference method. Furthermore, results
were compared by means of epidemiological linkage and Cohen’s kappa
for agreement was calculated.
Results: DiversiLab® considered signiﬁcantly more isolates (275) to
belong to a cluster than AFLP (198). The sensitivity was 83.8%, and the
speciﬁcity was 78.6%. When epidemiological linkage was included in
the analysis, DiversiLab® considered 9 isolates as secondary cases which
were considered unique in AFLP. Only 2 secondary cases according
to AFLP were missed by DiversiLab®. This results in a Kappa for
agreement of 0.983.
Conclusion: In daily practice a typing method has to be used in
combination with epidemiological information. When this was done,
DiversiLab® showed to be a highly reliable method for the typing of
HR-GNR. This in combination with the ease of use and the speed,
makes DiversiLab® an appropriate screening in routine clinical practice.
When a cluster is suspected and the consequences of these ﬁndings are
substantial, a conﬁrmatory analysis should be performed.
P1729 Rapid typing of Listeria monocytogenes by high-resolution
melting curve analysis of inlB
A. Pietzka*, A. Sto¨ger, S. Huhulescu, F. Allerberger, W. Ruppitsch
(Vienna, AT)
Objectives: In listeriosis outbreaks and for epidemiological investi-
gations a fast and accurate protocol to subtype L. monocytogenes is
essential for control and prevention of listeriosis. In outbreak situations
the L. monocytogenes serotyping scheme, based on somatic (O) and
ﬂagellar (H) antigens, has limited value for tracking isolates. For
rapid identiﬁcation and typing of isolates in routine diagnostics, a
PCR-based typing method targeting a single genetic region would be
preferential in terms of cost, simplicity, turnaround time, and potential
for standardization, since PFGE, MLST and MVLST still represent time-
consuming and cost intensive approaches. The aim of the study was the
evaluation of a rapid typing method based on polymorphisms of the
internalin B gene.
Methods: One hundred seventy two clinical and 267 food derived
L. monocytogenes isolates and 20 isolates from culture collections were
typed by high resolution melting curve analysis of a speciﬁc locus of
the internalin B (inlB) gene. All obtained melting curve proﬁles were
veriﬁed by sequence analysis.
Results: All tested L. monocytogenes isolates yielded 15 speciﬁc melting
curve proﬁles (ﬁgure). Sequence analysis revealed that these 15 melting
curve proﬁles corresponded to 18 distinct inlB sequence types. All
clinical isolates were assignable to all deﬁned 18 STs, whereas two STs
were absent in food isolates. The most frequent STs were ST-2, ST-9 and
ST-1 among the clinical isolates and ST-7 and ST-9 and ST-1 among
the food isolates. The high resolution melting curve proﬁles obtained
correlated to the ﬁve phylogenetic groups I.1, I.2, II.1, II.2, and III
(ﬁgure).
Conclusion: High resolution melting curve analysis constitutes an
inexpensive assay, which represents an improvement in typing compared
to classical serotyping or multiplex PCR typing protocols. This new
method is a rapid and powerful screening tool for simultaneous
preliminary typing of up to 384 samples in about two hours in advance
to more demanding methods such as PFGE or MLST.
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P1730 Evaluation of a novel ﬂuorescent ampliﬁed fragment length
polymorphism assay and optical mapping to probe the
genetic diversity of Staphylococcus aureus
D. Desai*, M.J. Ellington, C. Arnold, M. Desai (London, Cambridge,
UK)
Objectives: To evaluate and compare non-biased genome sampling
approaches for probing genetic diversity within Staphylococcus aureus
and implementation as tools for dissecting major methicillin resistant
clones.
Methods: Fluorescent ampliﬁed fragment length polymorphism
(FAFLP) is an analytical methodology that allows random sampling of
chromosomal DNA through double endonuclease digestion and selective
ampliﬁcation using restriction-site speciﬁc primers. Optical mapping, on
the other hand, utilises a single endonuclease for digestion of individual
chromosomal DNA molecules as a gross alignment and orientation
method. S. aureus isolates from six major multilocus sequence types
(MLST) were sampled using both approaches in parallel. Genomic DNA
was restricted using the endonuclease combination Csp6I and BglII for
FAFLP and NocI for optical mapping. FAFLP products were analysed on
an automated sequencer using GeneMapper and Bionumerics software.
Optical maps were analysed against entire genome sequences using
MapSolver. Derived FAFLP proﬁles and optical maps were analysed in
conjunction with staphylococcal cassette chromosome mec (SCCmec)
and MLST data.
Results: FAFLP extracted ~0.65% of the genome and generated a
proﬁle consisting of 50−85 fragments of 50–585bp. Optical mapping
encompassed the whole genome, generating 200–230 fragments between
1100 and 94000bp. Unique sequences speciﬁc to isolates and clusters
were identiﬁed from optical maps. At 95% similarity target, 13 and eight
unique proﬁles were exhibited with FAFLP and optical maps respectively.
Four highly similar clusters exhibiting differences of up to 14% with
optical mapping and 51% with FAFLP were identiﬁed. Interestingly,
genome topology supported MLST micro-evolution but no concordance
was observed with the SCCmec type.
Conclusions: FAFLP identiﬁed genetic micro-heterogeneity between and
within clusters as it sampled more loci relative to the genome area.
Differential fragments identiﬁed between MRSA lineages by FAFLP can
be used in diagnostic assay development. Optical mapping identiﬁed
macro-variation within the whole genome and indicated genetic transfer
events possibly caused by recombination or transposition. Sequenced
genome analysis generated in-silico maps aiding genome comparisons
and synteny assessment. Understanding and mapping the evolution of
MRSA lineages requires such methods to probe the genetic variation on
a micro and macro scale.
P1731 Correlation between blaOXA-51 variant and DiversiLab®
worldwide clonal lineages in Acinetobacter baumannii
E. Zander*, P.G. Higgins, H. Seifert (Cologne, DE)
Objectives: All Acinetobacter baumannii studied to date are in pos-
session of the intrinsic oxacillinase blaOXA-51. There are currently 61
published variants of OXA-51 and it has been suggested that sequence-
based typing of OXA-51-like can be used as an epidemiological
tool. Indeed, OXA-69, OXA-66 and OXA-71 are associated with
A. baumannii European clonal clusters 1, 2 and 3, respectively. We have
previously identiﬁed using the DiversiLab® rep-PCR typing system 8
carbapenem-resistant A. baumannii worldwide clonal lineages (WW1-
WW8). In this study we have investigated the correlation between
worldwide clonal lineages and OXA-51-like oxacillinases.
Methods: blaOXA-51-like genes from 48 non-duplicate carbapenem-
resistant isolates were ampliﬁed by PCR and sequenced. Isolates
originated from multiple countries and represented at least 5 isolates
from each worldwide clonal lineage. OXA-51-like gene sequences
were translated and identiﬁed by BLAST query. Novel sequences were
submitted to the b-lactamase database and assigned a new number
(http://www.lahey.org/Studies/).
Results: Results are summarised in the table. Three novel OXA-51-like
were identiﬁed; OXA-200, OXA-201 and OXA-202. Isolates within a
cluster had the same OXA-51-like enzyme or an amino acid variant. For
example, OXA-69 and OXA-92 (WW1 cluster) differ by a single amino
acid and OXA-172, OXA-201 and OXA-202 differ by one amino acid
from OXA-66 (WW2 cluster).
Conclusion: There was good correlation between OXA-51-like and
rep-PCR deﬁned clonal lineages. Isolates with identical OXA-51-like
originated from multiple countries, demonstrating the relative stability
of the enzyme. Sequence-based typing of OXA-51-like can be employed
to identify not only European clonal cluster 1−3 but also A. baumannii
isolates belonging to worldwide clonal lineages 1−8.
P1732 Multilocus sequence typing of Propionibacterium acnes with
diverse origin
S. Davidsson*, B. So¨derquist, F. Elgh, O. Andre´n, M. Unemo,
P. Mo¨lling (O¨rebro, Umea˚, SE)
Objectives: Propionibacterium acnes is a Gram-positive, slow growing,
aerotolerant anaerobic bacillus, predominantly found on the skin of
adults. It is, however, considered an opportunistic pathogen and is mostly
associated with acne vulgaris and rarely also with severe infections such
as infective endocarditis, prosthetic joint infections and deep sternal
wound infections following cardiothoracic surgery. It is however, not
known if speciﬁc subtypes are more prone to cause invasive infection
compared with commensals. In order to characterize P. acnes isolates,
phylogenetic analysis has been performed based on sequencing of
the housekeeping gene recA, a putative hemolysin gene (tly) and the
transcarboxylase 12S gene (Tc12S). So far, based on those genes, four
major groups are known.
The aim of the present study was to obtain a well-deﬁned multilocus
sequence typing (MLST) protocol for P. acnes, in order to investigate
the genetic heterogeneity of P. acnes isolates with diverse origin.
Methods: The MLST was based on internal fragments of nine
housekeeping genes, lac, oxc, fba, coa, zno, gms, pak, cob and cel. All
the MLST genes as well as recA, tly and Tc12S were PCR ampliﬁed
and sequenced in 29 different P. acnes isolates with diverse origin
including all known subtypes, i. e. IA, IB, II and III. Allelic proﬁles
based on concatenated sequences from each MLST gene were performed,
where the most common sequence type (ST) was graded with the lowest
ﬁgure. To identify different sequence variants phylogenetic analysis was
subsequently performed.
Results: The MLST analysis identiﬁed 23 STs within the collection.
Furthermore, the phylogenetic trees showed a superior capability to
discriminate P. acnes isolates when based on the concatenated sequences
compared with analysis based on the sequence of each gene individually
and also compared with only using recA, tly and Tc12S.
Conclusion: The results support the hypothesis that P. acnes is more
diversiﬁed than the four major groups known up till now. Our data
suggest that presented MLST protocol is superior when investigating
the heterogeneity of P. acnes isolates with diverse origin compared with
using recA, tly and Tc12S.
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P1733 Changes in Clostridium difﬁcile type distribution: a national
reference laboratory perspective
S. Mentula*, S. Kotila, S. Ibrahem, O. Lyytika¨inen, J. Jalava,
A. Virolainen (Helsinki, Turku, FI)
Objectives: The aim of our national reference laboratory at THL is to
support regional and local infection control teams to identify Clostridium
difﬁcile (CD) epidemics and monitor the effects of prevention and control
measures. When the national surveillance and ribotyping service began
in 2008, the emphasis and concern was around identifying ribotype
027. As diagnostic methodology and awareness has improved along with
new commercial applications, several hospitals are now able to identify
type 027 directly from clinical samples. The objective of this study is
to analyse the type distribution of CD isolates sent for genotyping in
Finland in 2008–2010.
Methods: All clinical laboratories have reported all CD ﬁndings (posi-
tive culture and/or toxin production) from stools to the National Infec-
tious Disease Register since 2008. The laboratories have also been asked
to send CD isolates from severe cases and persistent outbreaks to the
reference laboratory at THL for genotyping. All sent toxinogenic isolates
have been ribotyped, and PFGE has been performed when necessary.
Results: In 2008–2010 only 13/20 hospital districts sent isolates for
ribotyping. The number of isolates sent varied between 1−72/district/
year. The total number of isolates sent for typing has decreased every
year since 2008 covering now 5.5% of all reported CD ﬁndings. Also
the incidence of CD associated infections in Finland has decreased since
2008. More sporadic ribotypes are identiﬁed. In 2008, 36% of the strains
analyzed were of type 027, in 2009, 26%, and in 2010, 12%. The
distribution of other ribotypes has been rather stable, type 001 being the
most common followed by ribotypes 014, 020, 005, 011, 002, 023, 018,
003, 078, 056, and about 30 ribotypes that are identiﬁed sporadically.
Conclusion: Since we respond to the needs of regional infection control
teams, our typing data represents persistent and virulent strains rather
than the wholesome distribution of ribotypes in Finland. Utilization
of the typing service, local activities and available methodology vary
considerably between different regions. Special care must be taken when
analyzing data received by new commercial applications with some
limitations. Isolation of CD enabling more complete clonal, virulence
and susceptibility analysis is still essential to monitor the evolutionary
changes among the CD population behind the disease.
P1734 A population study on Chlamydia trachomatis in adolescents
in a high-incidence area in north Norway reveals multiple
new MLST genotypes and the new Swedish mutant (nvCT)
K. Gravningen*, L. Christerson, A. Sta˚hlsten, G.S. Simonsen,
K. O¨dman, A.-S. Furberg, B. Herrmann (Tromsø, NO; Uppsala, SE)
Objectives: Our study aimed to; (1) assess the prevalence of
C. trachomatis (CT) among adolescents in Finnmark county, (2) map
CT genotypes in Finnmark and compare with variants in Tromsø and
Trondheim, (3) investigate possible spread of the nvCT, and (4) examine
associations between speciﬁc genotypes and clinical symptoms.
Methods: Finnmark borders Northwest Russia and Finland and is an
extended county with sparse population in minor municipalities. This
population based cross-sectional study inviting all high school students
in ﬁve Finnmark towns included a web based questionnaire and urine
samples (participation rate: 77.4%; n = 1476; females 725/males 751;
mean age: 17.2 years). Parallel to this cohort providing 60 CT positive
samples, positive clinical CT samples were collected from the routine
laboratories in Tromsø (n = 80), Trondheim (n = 88), and Finnmark
(n = 20) giving a total of 248 samples. High resolution multilocus
sequence typing (MLST) targeting ﬁve genetic regions and ompA
sequencing were used to characterize CT in the PCR positive urine
samples. nvCT was veriﬁed using a PCR detecting the plasmid mutation.
Results: CT prevalence in the Finnmark study was 5.6% among the
sexually active (females: 7.1%, males: 3.9%). Complete MLST proﬁles
were obtained for all samples with detection of 50 sequence types (ST),
of which 62% (31/50) were novel. 12 new alleles in the MLST scheme
were detected. Sequencing of ompA identiﬁed 11 unique genotypes.
By combining MLST and ompA, 54 genotypes were identiﬁed. 57.3%
(142/248) of the isolates had STs that were present in Finnmark,
Tromsø, and Trondheim. But different STs predominated at different
sites. New STs were present in all three areas. nvCT was present in
1.6% (4/248) of the samples. The common genovar E predominated
in Tromsø and Trondheim (56%) whereas genovar G (36.2%) was
most frequent in Finnmark. CT infected females with rare STs reported
urogenital symptoms more frequently (72.2%) than those with common
STs (52.1%). Due to small number of specimen (n = 41), the difference
was not statistically signiﬁcant.
Conclusion: A CT prevalence of 5.6% was as expected according to
surveillance data with Finnmark reporting incidence rates twice the
national average. 31 new STs and 12 new alleles in the MLST scheme
were detected. The MLST system had a 4.5 higher discriminatory power
compared to conventional ompA genotyping. Only four cases of nvCT
indicated a limited spread in North and Middle Norway.
Molecular tools for the diagnosis of
culture-negative infections
P1735 Molecular pathogen detection (16S rDNA-PCR/sequencing)
in culture-negative infections
O. Nolte*, F. Locher, H. Haag (Constance, DE)
Objective: Universal pathogen PCR by use of broad range 16S primers
(16S-PCR), followed by sequencing, is a highly speciﬁc, technically
demanding diagnostic tool in the routine laboratory. Although still
being a niche indication, reserved mainly for severe or life threatening
infections, acceptance of this method by clinicians is increasing.
Despite uncertainties in interpretation of culture negative/PCR positive
cases, 16S-PCR might provide the life threatening clue. However,
contamination, either during pre-analytics or in the molecular laboratory,
poses the risk of pointing in the wrong direction. By discussing well
documented clinical cases both, the power and the limitations of 16S-
PCR in daily routine work will be discussed.
Methods: 16S-PCR followed by cycle sequencing was done using
the SepsiTest kit (MolZym, Germany) according to the manufacturer’s
instructions. Amplicons were sequenced commercially (gatc, Germany)
and sequences were analysed using at least two different algorithms
(NCBI BLAST, leBIBI or SepsiTest-Blast). Mixed sequences were
analysed using a speciﬁc programme (RipSeq by iSentio, Norway). The
most common specimen was blood (n = 23), followed by aortic or mitral
valve tissue (18) and synovia/synovial ﬂuid (n = 10). All specimens were
obtained and analysed as part of routine diagnostic procedures.
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Results: Sixty-ﬁve samples were processed in 2010. Out of 41
positive PCR reactions, 35 could be successfully sequenced, representing
21 different taxa. Six sequences were mixed sequences. The most
common sequence was of Staphylococcus aureus. Conﬁrmation by
concomitant culture was possible in 13 cases, the remainder being
negative in (repeated) culture. While in some cases the result of
molecular identiﬁcation was regarded as etiologic signiﬁcant, in other
cases interpretation was equivocal (i.e. etiologic relevant pathogen vs.
contaminant).
Conclusion: 16S-PCR followed by sequencing is a powerful method if
culture stays negative. Technical challenges are weak positive samples
and mixed sequences. Highly trained personnel, great experience
and strict rules during pre-analytics are obligate prerequisites. A
main problem is interpretation of the ﬁnding. While in some cases
contamination might pose uncertainties, the result of molecular
identiﬁcation often provides the lifesaving clue.
P1736 Evaluation of real-time 16S rDNA PCR and pyrosequencing
for routine diagnostic practice
N.J. Gadsby*, A. Onen, S.-A. Phillips, L. Tysall, S. Breusch,
H. Simpson, J. Dave, E. Czarniak, K.E. Templeton (Edinburgh, UK)
Objectives: Detection and sequencing of the bacterial 16S rRNA
gene has the potential to be a rapid and sensitive diagnostic tool
for specimens from sterile sites. However, 16S rDNA real-time PCR
and pyrosequencing have had limited evaluation for use in day-to-day
diagnostic practice. The study objective was to assess the value of using
such an approach in our routine microbiology laboratory.
Methods: Joint ﬂuid and tissue specimens from 100 orthopaedic patients
were submitted for routine microbiological culture (37ºC 48 hour
incubation of blood agar, chocolate blood agar and anaerobic blood agar
plates and sub-culture from broth media) between February and May
2010. One hundred and ﬁfty-two of these specimens were retrospectively
tested using a published 16S rDNA real-time PCR assay, followed by
standard Sanger sequencing and pyrosequencing of positives. Clinical
information, including details of antibiotic treatment, was available for
87 of the patients.
Results: 15/152 specimens (9.9%) were positive by bacterial culture
and 15/152 specimens (9.9%) were positive by 16S rDNA assay. Three
culture-positive specimens were found to be negative by 16S rDNA
assay; the PCR was inhibited in 2 cases and a low bacterial load of
doubtful clinical signiﬁcance was found in the remaining case. Three
culture-negative specimens were positive by 16S rDNA assay and at least
2 were clinically signiﬁcant. Overall in this study, 18/152 specimens were
positive for bacterial infection and an analysis of clinical information
noted a clinical suspicion of infection in only 56% of patients.
Conclusion: The use of a 16S rDNA assay allowed us to detect additional
positive results which were clinically signiﬁcant. However, such an
approach would be better targeted to those specimens accompanied by
clinical information detailing a suspicion of infection, and would not be
suitable for the general testing of all orthopaedic specimens received by
the routine laboratory.
P1737 A novel FISH test for rapid pathogen identiﬁcation in
positive blood cultures
A. Makristathis*, S. Riss, M. Hirschl (Vienna, AT)
Objectives: Conventional blood culture is regarded the gold standard for
the detection of blood stream pathogens. In the present study, a novel
commercially available ﬂuorescence in situ hybridization (FISH) test has
been validated allowing for rapid bacterial pathogen identiﬁcation in
positive blood cultures.
Material and Methods: FISH (Lucesco, Miacom) analysis was
conducted always using the bottle which became positive ﬁrst by
the BacT ALERT® 3D system (Bio Merieux) of 152 positive blood
cultures from different patients. Dependent on the Gram stain either a
Gram negative (Bac I) or a Gram positive panel (Bac II) were used.
Pathogens included in both panels are regarded as being responsible for
approximately 90% of blood stream infections. The time to result was
30 min and the hands-on time only 10 min.
Results: Fifty eight Gram negatives and 94 Gram positives were
identiﬁed by conventional methods. In comparison to the latter, the test
agreement was 84.9% (129/152). In 14 out of 152 cases (9.2%) the
microorganism identiﬁed by the reference method was not included in
the respective panel by FISH. Of the remaining 138 cases, in 8 (5.8%, 5
of a Gram negative and 3 of a Gram positive pathogen) the result of the
FISH test differed from that of the reference method being either false
positive or false negative.
Conclusion: These data suggest that this novel FISH test accurately
identiﬁes blood stream pathogens in positive blood cultures and may
considerably reduce the time to result.
P1738 Detection of bacterial endocarditis by using culture and
culture-independent analysis of cardiac biopsies
L. von Mu¨ller*, O. Wick, H.-J. Scha¨fers, M. Herrmann (Homburg, DE)
Objective: Endocarditis is a severe disease affecting cardiac valve
functions. As a consequence many patients require cardiac surgery.
In many cases the etiologic bacteria can be isolated by blood culture
in the acute phase of infection; however, following initial antibiotic
treatment identiﬁcation of causing pathogens are generally no more
possible. Additionally endocarditis can be also caused by fastidious or
non-cultivable bacteria without positive blood cultures.
Methods: The Cardiac surgery department at the University of Saarland
Hospital, a 1300-bed tertiary care facility, is highly experienced in
cardiac valve replacement and reconstruction. Since August 2008 regular
intra-operative cardiac valve biopsies are routinely analyzed also by
culture-independent 16S RNA pan-bacterial PCR following sequence
typing in addition to the classical culture-based analysis. Culture-
dependent and culture-independent results were compared in the present
retrospective single centre study.
Results: A total number of 78 patients with endocarditis were
diagnoses by culture-independent detection of bacterial 16S RNA
gene in cardiac valve biopsies. Sequence typing could identify typical
pathogens for bacterial endocarditis in most cases as e.g. viridans
streptococci, staphylococcus aureus and enterococci. A number of
infections with fastidious growing (e.g. haemophilus, abiotrophia) or
anaerobic bacteria were found (granulicatella) but also two patients
with un-cultivable disease due to Tropheryma whipplei. Parallel cultures
remained sterile in 57.7% of PCR-positive samples, 34.6% were
independently conﬁrmed by culturing whereas discrepant culture results
were found in 7.7% of samples. Discrepant results were all caused by
isolation of potential contaminating bacteria as e.g. corynebacteria and
coagulase-negative staphylococci using enrichment cultures. We suggest
that culture-independent detection of corynebacteria and coagulase-
negative staphylococci in cardiac valve biopsies is associated with
endocarditis and not with contamination.
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Conclusion: Culture-independent analysis of bacteria by 16S RNA PCR
and sequence typing in cardiac biopsies is an important diagnostic tool
to identify etiology of endocarditis even years after antibiotic treatment.
Thereby, DNA of viable and also of dead bacteria can be detected
in a very sensitive way at the site of infection. Culture-independent
analysis may also help to discriminate bacterial contaminations from
true infections.
P1739 16S ribosomal RNA gene sequences from cardiac valve tissue
biopsies convey the diagnosis of culture-negative endocarditis
M. Bjørnstad, F. Mu¨ller, I. Nordøy, A. Fiane, O. Geiran, J. Svennevig,
T. Tønjum* (Oslo, NO)
Objectives: Culture-negative endocarditis accounts for nearly half of all
cases of infectious endocarditis. Prior or concurrent antibiotic treatment
at the time of blood cultures taken accounts for 45−60% cases of
this situation; the remainder are caused by slow-growing and fastidious
organisms. We hypothesized that detection of the bacterial 16S ribosomal
rRNA gene from peroperative cardiac valve tissue and subsequent
sequencing and species identiﬁcation was more sensitive than culture
for the identiﬁcation of the cause of endocarditis.
Methods: Infecting strain identity was achieved by culture and by
using polymerase chain reaction (PCR) that targeted highly conserved
regions of the 16S rRNA gene to diagnose the cause of endocarditis in
peroperative cardiac valve tissue biopsies from 179 patients in Norway.
The identity of cultivated organisms were identiﬁed by conventional
techniques and mass spectrometry, while the identity of noncultivated
infecting agents was determined by sequencing 16S rRNA gene-speciﬁc
PCR products and comparing them with known 16S rRNA gene
sequences from a wide range of bacteria. Thereby, the sensitivity and
performance of 16S rRNA gene-based identiﬁcation and culture in
detecting the cause of endocarditis was compared.
Results: The 16S rRNA gene PCR sequencing was by far more sensitive
than culture and yielded a broad range of Gram-positive and Gram-
negative species that were the likely cause of endocarditis. Interestingly,
one case each of Tropheryma whipplei, Bartonella quintana, and
Bartonella henselae were among the species identiﬁed. Thereby, the
approach served to broaden the etiologic diagnosis of culture-negative
endocarditis.
Conclusion: PCR that targets highly conserved regions of the 16S rRNA
gene and subsequent sequence comparison enabled the identiﬁcation
of cultivated and noncultivated endocarditis agents from peroperative
cardiac valve tissue biopsies. Direct detection of microbial agents by
PCR has clearly served to broaden the etiologic diagnosis of endocarditis.
Thereby, the diagnosis of the cause of endocarditis can be secured and
also be a guide for optimal antibiotic therapy to be implemented.
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P1740 Immunomodulatory effects of voriconazole and caspofungin
on human peripheral blood mononuclear cells stimulated
with Candida albicans and Candida krusei
I. Fidan*, E. Yesilyurt, A. Kalkanci, S. Ozyegen Aslan, N. Sahin,
M.C. Ogan, M. Dizbay (Ankara, TR)
Objectives: Candida infections are frequently associated with high
morbidity and mortality in immunosupressive patients. Although
Candida albicans is the most frequently isolated species of candidemic
patients, the occurence of infections caused by other Candida species
is increasing. Cell-mediated immunity and humoral immunity are
the principle protective immune response against fungal infections.
Phagocytic cells are known to be important in clearing fungal infections.
Antifungal agents such as voriconazole and caspofungin enter phagocytic
cells and cause intarcellular activities. The purpose of this study was to
evaluate the immunomodulatory effects of voriconazole and caspofungin
on human peripheral blood mononuclear cells (PBMC) stimulated with
C. albicans and C. krusei.
Methods: Human PBMC isolation was done by Ficoll-hypaque
density gradient centrifugation method. Cell proliferation was assayed
by colorimetric method using MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide). The cytokine levels in the human PBMC
culture supernatants stimulated with C. albicans and C. krusei were
determined by ELISA.
Results: The addition of voriconazole and caspofungin lead to
proliferation of PBMC. In the presence of voriconazole and caspofungin,
the levels of IL-2, IFN-g, and IL-6 increased remarkably in PBMC
stimulated by C. albicans and C. krusei. Otherwise, the combination of
antifungal drugs and PBMC stimulated by Candida spp. did not increase
the levels of TGF-b and IL-10.
Conclusion: Our results suggest that voriconazole and caspofungin have
immunomodulatory effects on human PBMC stimulated with Candida
spp. The interaction between antifungal drugs and PBMC stimulates Th1
type cytokine secretion. Cytokine stimulation from immune cells can
assist in the elimination of fungal pathogens. So, immune modulators
such as cytokines may be useful as therapeutic adjuvants to antifungal
drugs for treatment of infections caused by Candida spp.
P1741 Lipopolysaccharides O1 antigen and outer membrane
proteins contribute to virulence and protective efﬁcacy of
O1 antisera in Klebsiella pneumoniae
P.F. Hsieh, T.L. Lin, J. Wang* (Taipei, TW)
Background: To explore the mechanisms enabling Klebsiella pneumo-
niae to disseminate through the bloodstream, we characterized the roles
of lipopolysaccharides (LPS) O antigens and outer-membrane proteins
(OMPs) in the pathogenesis of K. pneumoniae causing community-
acquired pyogenic liver abscess (PLA).
Methods: The O1-antigen seroepidemiology of K. pneumoniae clinical
isolates was analyzed by magA-mutant hyperimmune mouse serum. The
virulence of deletion mutants was compared with that of the wild-
type strain by intraperitoneal and intragastric infections in mice. The
in vivo protective capacity of O1 antiserum was tested by experimental
K. pneumoniae infection.
Results: The O1 serotype was more prevalent in PLA strains,
and the O1 serotype isolates had a higher frequency of serum
resistance. Mutation of the O1 antigen changed serum resistance in
K. pneumoniae. Peptidoglycan-associated lipoprotein (Pal) and murein
lipoprotein (LppA) were essential for K. pneumoniae to proliferate
and survive in blood. Immunization of mice against LPS O1 provided
protection against infection with capsular type K2 strain, but not capsular
type K1 strain.
Conclusions: Our ﬁndings indicate that LPS O1 antigen and LPS-
associated OMPs are important virulence factors for PLA caused by
K. pneumoniae. LPS O1 antigen could be a useful vaccine candidate
against infections by K. pneumoniae with loose capsule structures.
P1742 Isolation of genetic loci associated with phagocytosis and vir-
ulence in Klebsiella pneumoniae using a Dictyostelium model
Y.J. Pan, T.L. Lin, C.R. Hsu, J. Wang* (Taipei, TW)
Phagocytosis resistance is an important virulence factor in Klebsiella
pneumoniae. Dictyostelium has been used to study the interaction
between phagocytes and bacteria because of its similarity to mammalian
macrophages. In this study, we used a Dictyostelium model to investigate
genes for resistance to phagocytosis in NTUH-K2044, a strain of
K. pneumoniae causing pyogenic liver abscess that is highly resistant
to phagocytosis. A total of 2500 transposon mutants were screened by
plaque assay, and 29 of them permitted phagocytosis by Dictyostelium.
In the 29 mutants, 6 loci were identiﬁed; three were capsular
synthesis genes. Among the other three, one was related to carnitine
metabolism, one encoded a subunit of protease (clpX), and the other
encoded a lipopolysaccharide O-antigen transporter (wzm). Deletion and
complementation of these genes showed that only DclpX and Dwzm
mutants became susceptible to Dictyostelium phagocytosis, and their
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complementation restored the phagocytosis resistance phenotype. These
two mutants were also susceptible to phagocytosis by human neutrophils
and revealed attenuated virulence in a mouse model, implying that they
play important roles in the pathogenesis of K. pneumoniae. Furthermore,
we demonstrated that clpP, which exists in an operon with clpX, was
also involved in resistance to phagocytosis. The transcriptional proﬁle
of DclpX was examined by microarray and revealed a 3-fold lower level
of expression of capsular synthesis genes. Therefore, we have identiﬁed
genes involved in resistance to phagocytosis in K. pneumoniae using
Dictyostelium, and this model is useful to explore genes associated with
resistance to phagocytosis in heavily-encapsulated bacteria.
P1743 Effect of endoplasmic reticulum stress pathway on
mycobacteria-induced cell death
Y. Lim, H.H. Choi, J.A. Choi, H.J. Kim, E. Jo, J. Park, C. Song*
(Daejeon, KR)
Objectives: To investigate the role of endoplasmic reticulum stress
pathway in mycobacteria infected cells and to determine its role
intracellular survival in host cells.
Methods: A549 cells and Raw 264.7 cells were cultured in MEM
supplemented with 10% FBS and antibiotics. The cells were stimulated
with mycobacterial antigen ESAT-6 and were infected with M. tuber-
culosis H37Rv (Mtb). Macrophages infected with mycobacteria were
lysed for intracellular survival CFU counting. Quantitative RT-PCR and
western blot analysis were used for determination of mRNA expression
or protein induction after antigen stimulation or mycobacterial infection.
Cell viability was assessed with a Cell Counting Kit-8 or FACS ﬂow
cytometry. Reactive oxygen species (ROS) production was measured by
laser-scanning microscopy using DHE staining.
Results: Mycobacterial secreted antigen ESAT-6 stimulation induced
apoptosis with ER stress response. We found XBP-1 mRNA splicing,
GRP78, ATF4 and CHOP mRNA induction was increased by
ESAT-6 antigen stimulation. Similar results were observed with Mtb
infected macrophages. ER stress-mediated host cell response during
mycobacterial infection was induced XBP-1 mRNA splicing, GRP78
and CHOP expression. Caspase-12 and caspase-3 were activated by
ESAT-6 or Mtb infection in macrophages. We also found ASK1/JNK
signaling pathway was involved in ESAT-6 mediated ER stress apoptosis.
Cytosolic calcium released by ER stress response was increased by
ESAT-6 stimulation. It was conﬁrmed by confocal microscopy after
pretreatment of calpain inhibitor PD150606. Interestingly, we found
induced phosphorylated a-subunit of eukaryotic initiation factor 2 was
related to CHOP expression during Mtb infection. Furthermore, we
found the results of CHOP expression were important for Mtb survival
in macrophages. The increased CHOP expression was not observed in
heat-killed bacteria but in live Mtb.
Conclusion: These results demonstrate a stronger induction of ER stress
response chaperones by not only mycobacterial secreted antigen ESAT-6
but Mtb infection. Mycobacterial antigen induced intracellular calcium
concentration, which resulted in ROS accumulation, and therefore
induces the onset of ER stress-induced apoptosis. Live Mtb could control
ER stress pathway to survive in macrophages. These observations lend
support to the hypothesis that ER stress mediated apoptosis may play an
important role in the pathogenesis of tuberculosis.
P1744 The role of aberrant tcdC sequences in toxin production
by Clostridium difﬁcile
S.T. Cartman*, M.L. Kelly, S.A. Kuehne, J.T. Heap, N.P. Minton
(Nottingham, UK)
Objective: In the current model of Clostridium difﬁcile toxin regulation,
TcdC is a negative regulator/repressor of toxin production. Epidemic
strains of C. difﬁcile frequently carry an aberrant tcdC gene,
characterised by a frame-shift mutation. We tested the popular hypothesis
that this is the reason for the hyper-toxin-production phenotype reported
for epidemic strains.
Methods: We developed a new method for precise manipulation of
the C. difﬁcile chromosome; a major breakthrough for this genetically
intractable organism. This enabled us to correct the tcdC frame-shift
mutation in the epidemic C. difﬁcile strain, R20291 (the notorious Stoke
Mandeville, UK outbreak strain), as well as substitute the native tcdC
gene for that of the non-epidemic strain, 630.
Results: Production of toxin A and toxin B by C. difﬁcile R20291
remained unchanged, regardless of the tcdC allele present in the
chromosome.
Conclusion: This work demonstrates that an aberrant tcdC sequence
alone does not explain the hyper-toxin-production phenotype reported
for epidemic strains of C. difﬁcile. Furthermore, it indicates that our
current model of C. difﬁcile toxin regulation needs revision.
P1745 Analysis of cellular senescence induced by
lipopolysaccharide in pulmonary alveolar epithelial cells
C. Kim*, S. Han, N. Ku, B. Chin, S. Jin, S. Jeong, Y.G. Song, Y.K. Kim
(Seoul, KR)
Objectives: There have been few studies on the relationship between
senescence and acute infection, although immunosenescence has been
recently introduced. In this work, it was examined the possibility of
lipopolysaccharide (LPS) causing cellular senescence in lung alveolar
epithelial cells. The morphologic and biochemical characteristics of
senescence induced by LPS were analyzed. Then, it was clarifed how
this cellular senescence phenomenon is associated with oxidative stress
effect induced by LPS and whether antioxidants could inhibit reduced
cellular viability by oxidant stress effect of LPS.
Methods: Human-like type II lung epithelial cell (A549) is obtained
from cell-bank. Cell viability was checked using cell counting kit-8.
Cell morphology was examined for morphological changed at 2, 5
and 7 days post-LPS treatment by phase-contrast microscopy. The
presence of apoptotic cells was assessed by determining caspase
activation using a Caspase-Glo 3/7 luminescence assay kit. Detection
of cellular lysosomal content was determined by staining with acridine
orange. The biochemical senescence was checked by the presence of
senescence-associated b-galactosidase (SA b-gal) activity. We evaluated
the determination of LPS-generated hydrogen peroxide and the effect of
the antioxidant GSH.
Results: A549 cells exposed to LPS were showed decreased viability
and growth arrest in concentration-dependent manner. The pre-apoptotic
concentration of LPS developed morphological senescence changes
and elevated SA b-gal activity. Also, senescence asssociated lysosomal
content was increased in pre-apoptotic LPS. Exposure of A549 cells to
LPS resulted in the formation of hydrogen peroxide in proprotion to
concentration. The ability of LPS to induce cellular viability inhibition
was prevented by the presence of adequate levels of GSH.
Conclusion: This study revealed that LPS could induce cellular
senescence in lung alveloar epithelial cells, and these phenomena were
closely associated with hydrogen peroxide production by LPS. Taken
together, it is suggested that LPS-induced cellular senescence may play
an important role in limiting the tissue repair response after sepsis.
P1746 Virulence genes focG and agn43aCFT073 are related to
mortality in Escherichia coli bacteraemia
L. Skjøt-Rasmussen*, K. Ejrnæs, B. Lundgren, A.M. Hammerum,
N. Frimodt-Møller (Copenhagen, DK)
Objectives: E. coli is a leading cause of bloodstream infections. More
than 30% of bacteraemia cases in community- and hospital-acquired
infections are due to E. coli, and it is the major cause of mortality from
these infections. The pathogenesis of E. coli bloodstream infections is
largely unknown, why preventive measures are lacking. We studied 198
E. coli strains causing bacteraemia according to virulence factor (VF)
genes and the relation of these to mortality.
Methods: January 2003–May 2005, 198 E. coli blood isolates were
collected at Hvidovre Hospital from 197 bacteraemic patients with E. coli
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in both blood and urine cultures. The patients (134 women, 63 men) were
aged 0–102 years (median age, 79 years). Deﬁned as a positive culture
obtained >48 h after admission to hospital, 21 episodes (11%) were
considered hospital acquired (HA) and 176 episodes (89%) community-
acquired (CA), respectively. The isolates were screened for the presence
of 29 VF genes representing six functional groups: Adhesins, bioﬁlm
related, iron uptake, protectins, toxins and miscellaneous (Table 1). The
genes were detected by using a multiplex PCR protocol.
Results: The occurrence of VFs among the E. coli isolates ranged from
<1% (kpsMT III) to 98% (ﬁmH) (Table 1). The median of the aggregate
virulence scores was 14 (range 1−22). Total 30-day mortality was 11%,
24% among HA episodes and 10% among CA episodes. Among the
29 VF genes, only two were signiﬁcantly related to mortality, i.e. focG
(F1C ﬁmbria) and agn43aCFT073 (bioﬁlm related antigen 43, allele a
CFT073). focG was present in isolates from 39% (9/23) of patients
dying within 30 days of culture, as compared to 20% (35/175) of isolates
from patients not dying (p = 0.0380). agn43aCFT073 was present in 61%
(14/23) of isolates from patients dying within 30 days, as compared to
31% (55/175) of isolates from patients not dying (p = 0.0053).
Conclusion: Overall mortality of E. coli bacteraemia cases was low
(11%), however the two VF genes focG and agn43aCFT073 were
signiﬁcantly related to mortality. Thus, F1C ﬁmbriae and bioﬁlm
formation capacity appear to play a signiﬁcant role in the pathogenesis
of serious E. coli infections. More studies on selected strains harbouring
focG and agn43aCFT073 are needed in order to examine the virulence
potential of such strains in further detail and whether prospective
detection of these genes in blood culture E. coli isolates could inﬂuence
treatment of bacteraemia.
P1747 Stenotrophomonas maltophilia phenotypic properties of
clinical relevance
M. Adamek* (Karlsruhe, DE)
Stenotrophomonas maltophilia, belonging to the g-b subclass of
proteobacteria, is found ubiquitously distributed in the environment and
is gaining importance as a nosocomial pathogen.
In our previous work we analyzed genetic diversity of S. maltophilia
by rep (repetitive extragenic palindromic)-PCR ﬁngerprinting and gyrB
gene sequencing, for a collection of 171 environmental and clinical
strains. This revealed 11 genetic subgroups for S. maltophilia. A
subset of 50 representative isolates for these groups was then used
for further investigation of phenotypic properties. With respect to
its role as opportunistic pathogen, potential virulence traits, as the
production of extracellular proteases, haemolysins and siderophores
were investigated. Furthermore, factors supporting colonization of a
human host were examined by swimming and twitching motility and
bioﬁlm assays. Virulence was tested by co-culturing the bacteria with
the amoebae Dictyostelium discoideum and Acanthamoeba castellanii
as model organisms. After testing twenty different antibiotics on a small
subset of strains, gentamicin, vancomycin, norﬂoxacin, tetracycline and
co-trimoxazole, were chosen to determine MICs for the 50 S. maltophilia
isolates.
Nearly all investigated isolates produced proteases and haemolysins and
all of them produced siderophores. Motility assays revealed differences
in swimming and twitching motility. Bioﬁlm formation generally
differed, but did not correspond to their genetic subgroups of the
isolates. An exception is that all isolates from environmental group
E2 showed only slight potential for bioﬁlm formation. Virulence for
amoebae was shown for about one third of the tested isolates and was
in no relationship to clinical or environmental origin. All isolates were
resistant to vancomycin and most to gentamicin. Most of them showed
intermediate MICs for norﬂoxacin and tetracycline, and all isolates were
susceptible to co-trimoxazole.
For motility assays, bioﬁlm formation, virulence and antibiotic resistance
generally no correlation to the previously deﬁned genetic groups was
found. In this context it was expected that housekeeping genes and
rep-PCR ﬁngerprints are not suitable markers to determine phenotypic
properties of S. maltophilia.
P1748 Expression of virulence factors in Pseudomonas aeruginosa
strains from nosocomial pneumonia and from non-infectious
respiratory colonisation processes
H. Sahly*, R. Podschun (Hamburg, Kiel, DE)
Objectives: Pseudomonas aeruginosa is a frequent agent of nosocomial
pneumonia but is also found as colonizer of asymptomatic patients.
Recently, strains from patients with pneumonia were shown to
posess higher “serum-resistance” ability as compared to strains from
asymptomatically colonized ICU patients. In this study we investigated
P. aeruginosa strains collected from patients with pneumonia and from
asymptomatic patients with regard to their lipolytic, haemolytic and
elastolytic activity, all properties that are suggested to be virulence
factors.
Bacteria and Methods: Bacteria: 171 P. aeruginosa strains were
consecutively isolated from bronchoalveolar lavage ﬂuids or transtracheal
aspirates of ICU patients with monobacterial nosocomial pneumonia, and
49 strains were isolated from the respiratory tract of ICU patients without
respiratory tract infections.
O-serotyping: All strains were serogrouped using O-antigen-speciﬁc sera
for the 14 P. aeruginosa O serogroups.
The haemolytic activity of the strains was tested on Columbia agar
containing 5% sheep blood incubated over 72 h.
Elastase and lipases: Lipolytic activity was tested on Tryptic-Soy-Agar
supplementd with various fatty acid ester (1% Tween20−85); the expres-
sion of elastase was determined on 0,25% Elastin-Trishydrochloride agar.
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The bacteria were cultivated on the various media for 3 days (lipase) or
7 days (elastase) at 37ºC.
Results: Higher frequency of the serogroups A (11.9% and 16.3%,
respectively), B (14.3% and 21%), E (26.5% and 24.6%), and I (28.6%
and 28%) was detected in both strain collections. Both strain collections
did not differ signiﬁcantly in their haemolytic elastolytic lipolytic, and
activity (p> 0.05).
Conclusions: The haemolytic, lipolytic and elastolytic activities are
less likely to contribute to the putative higher pathogenic potential of
P. aeruginosa pneumonia strains.
P1749 Alginate exopolysaccharide acts as a ligand for P. aeruginosa
invasion of lung epithelial cells through its interaction with
p63
M. Barbier*, I. Martı´nez-Ramos, S. Alberti (Palma de Mallorca, ES)
Background: The interplay of P. aeruginosa with the airway epithelial
cells is a crucial step in the pathogenesis of the respiratory infections
caused by this microorganism. Both, bacterial and host factors modulate
this interaction. In this work, we investigated the role of the alginate
exopolysaccharide, a key virulence factor associated to severe respiratory
infections, and the surfactant protein A (SP-A), a broad spectrum opsonin
with membrane permeabilisation properties in this interaction.
Methods: Bacterial invasion capacity of human bronchoepithelial cells
(16HBEo-) and human type II pneumocytes (A549) monolayers was
determined by standard invasion assays in presence of SP-A with
the type strain PAO1, an isogenic alginate hyperproducing mucA
mutant (PAOMA), an isogenic alginate deﬁcient algD mutant and 2
clinical isolates (PAA2 and PAC20). The role of p63 in P. aeruginosa
internalization by respiratory epithelial cells was studied using standard
invasion assays in presence of a p63 blocking antibody or using p63
silenced cells by siRNA. Alginate binding assays were performed
measuring puriﬁed P. aeruginosa FITC-labelled alginate union to A549
monolayers by ﬂuorescence spectroscopy.
Results: Opsonisation of P. aeruginosa with SP-A did not affect the
invasion of the airway epithelial cells by the microorganism. However,
SP-A inhibited P. aeruginosa internalization by airway epithelial cells
through direct interaction of the protein with the cells, suggesting that
the microorganism attached to the cells through a speciﬁc receptor for
SP-A such as p63. Speciﬁc anti p63 antibodies blocked the invasion of
epithelial cells by alginate-producing P. aeruginosa strains. Furthermore,
the invasive capacity of these strains was reduced in p63 silenced cells.
Finally, the binding of puriﬁed alginate to p63 silenced cells or cells
pretreated with p63 blocking antibodies was signiﬁcantly reduced.
Conclusions: Altogether these results indicate that P. aeruginosa and
SP-A share a common receptor, p63, on the surface of respiratory
epithelial cells. Alginate exopolysaccharide appears to be involved in
the interaction of the bacterium with this receptor and could play an
important role during the process of infection by promoting bacterial
internalization.
P1750 In vivo gene expression and growth conditions of
Pseudomonas aeruginosa in cystic ﬁbrosis lungs
M. Macedo-Vinas, T. Ko¨hler, D. Hocquet, C. Amstutz, J. Dalphin,
P. Pleasiat, C. van Delden* (Geneva, CH; Besanc¸on, FR)
Background: P. aeruginosa is the main pathogen responsible for
progressive lung destruction in cystic ﬁbrosis (CF) patients, in whom
they persists despite aggressive antibiotic treatments. Bioﬁlm and
anaerobic growth conditions might be responsible for these treatment
failures. We investigated by in vivo gene expression analysis whether
P. aeruginosa grows anaerobically within the CF-lung.
Methods: We collected sequential sputa obtained after respiratory
physiotherapy from 26 CF-patients over a 17 months period at the
University Hospital Besanc¸on. From each sputum we isolated one or
two P. aeruginosa strains and extracted total DNA and RNA. Bacterial
load and in vivo gene expression were determined by qRT-PCR on DNA
and RNA preparations, respectively. In vitro anaerobic conditions were
created with the Gene Bag system in an anaerobic jar. Genotypes of
isolates were compared by RAPD.
Results: Sixty sputum samples and 68 isolates from 10 of the 26 patients
were retained for ﬁnal analysis. Each of the 10 patients carried one
genotype. In vivo expression of nirS and norB, two anaerobically induced
genes, was compared to their in vitro expression by the corresponding
isolate under aerobic and anaerobic growth conditions. We found that in
9/10 patients nirS and norB expression was indicative of aerobic growth,
whereas in one patient expression of these genes suggested anaerobic
growth. In vivo expression of nirS and norB did not correlate with the
patient’s clinical stage (exacerbations vs chronic phase).
Conclusion: In sputum P. aeruginosa grows aerobically in 90% of
CF patients. These isolates should therefore be susceptible in vivo
to antimicrobials. This might explain the clinical improvement after
antimicrobial treatments, however anaerobic growth conditions might
prevail deeper in the lung.
P1751 Comparative evaluation of enterotoxin 2 encoding gene
expression levels in Shigella spp. and EIEC strains grown in
the presence of eukaryotic HeLa cells and artiﬁcial culture
media
V. Lazar*, M.C. Chiﬁriuc, S. Dinu, C. Szmal, D. Cristea, I. Aldea,
L. Dascalu, A.I. Cotar, M. Popa, A. Holban, C. Bleotu (Bucharest, RO)
Objectives: Pathogenesis of Shigella spp. and enteroinvasive E. coli
(EIEC) strains is dependent on their ability to express the invasive
phenotype in the presence of different populations of eukariotic cells,
process involving complex interactions, whose results are leading
to disruption, invasion and destruction of the intestinal barrier. The
enterotoxin-2 (ShET-2) encoding gene (sen) is located on a invasion
associated 140 Mda plasmid.
Purpose: To study the sen gene expression in 16 Shigella spp. and EIEC
strains, in the presence of artiﬁcial culture media and respectively, in the
presence of eukariotic HeLa cells, in order to investigate the utility of
this method for the further development of an alternative assay of the
invasive potential to replace the in vivo guinea pig Sereny test.
Methods: 13 Shigella spp. strains and 3 EIEC strains isolated in
Romania from children with dysenteria and aqueous diarrhea during
2005–2007 and positive for Sereny test were analyzed. The expression
levels of sen gene in bacterial cells cultivated in the presence of
eukaryotic HeLa cells were determined by SYBR Green Real-Time
PCR. As control for relative quantiﬁcation were used standard microbial
culture obtained in liquid broth.
Results: sen gene was present in all selected strains. Cultivation on
artiﬁcial media resulted in sen gene expression in only one strain,
conﬁrming that Shigella spp. and EIEC strains lose their invasion ability
by conservation and passages on artiﬁcial culture media. In contrast,
sen gene expression is induced in the presence of eukariotic HeLa cell
substrate in 15 of the 16 tested strains, the expression level being strain
dependent.
Conclusions: These results demonstrate the potential utility of cell lines
for the study of invasive potential of Shigella spp. and EIEC strains
by the expression level analysis of bacterial genes involved in invasion,
after the bacterial cultivation in cell cultures and the opportunity for
standardization and optimization of an in vitro model for assessing the
invasive potential.
P1752 Virulence patterns of Pseudomonas aeruginosa nosocomial
strains associated with different clinical infections
A.I. Cotar*, M.C. Chiﬁriuc, A. Holban, M. Popa, O. Banu, V. Lazar
(Bucharest, RO)
Objectives: Te purpose of this study was to perform the phenotypic and
molecular characterization of the most important virulence factors in
P. aeruginosa strains isolated from different clinical specimens, in order
to establish an association between certain virulence patterns and the
type of nosocomial P. aeruginosa infection.
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Methods: The study was performed on 50 P. aeruginosa strains
isolated from: respiratory samples (tracheal and bronchial secretions),
dermal samples (wound secretions) and blood cultures. Six enzymatic
virulence factors (lechitinase, lipase, gelatinase, amylase, caseinase,
DN-ase, and hemolysins) were investigated by phenotypic assays
based on cultivation of bacterial strains on culture media containing
speciﬁc substrate, while eleven (elastase, alkaline protease, protease IV,
rhamnolipid, haemolytic phospholipase C, non haemolytic phospholipase
C, exotoxin A, exoenzyme S, exoenzyme T, exoenzyme U and
pyoverdine A) by PCR detection of the respective encoding genes.
Results: The results of phenotypic characterization of the analyzed
P. aeruginosa strains showed that the patterns of soluble virulence factors
varied among the strains isolated from different specimens, as well as in
those with the same clinical origin. However, the strains isolated from
wound secretions preferentially expressed DNase and hemolysins, but
do not express gelatinase, whereas the strains isolated from tracheal
secretions expressed the majority of soluble virulence factors tested by
phenotypic methods, excepting gelatinase and hemolysins. The results
of PCR assays showed that all P. aeruginosa strains isolated from all
types of clinical specimens do possess genes encoding elastase, alkaline
protease, rhamnolipid, exotoxin A and non haemolytic phospholipase
C. Exoenzyme S was present in strains isolated from wound secretions
and bronchial secretions, but was absent in those from tracheal
secretions, while the gene encoding protease IV was present in a small
number of strains isolated from wound secretions and tracheal secretions,
and absent from those isolated from bronchial secretions.
Conclusion: The presence of genes encoding for haemolytic phospho-
lipase C, pyoverdine A and exoenzymes S, T and U was associated
with the clinical origin of the tested strains, proving that these virulence
genes could represent useful diagnosis markers of different P. aeruginosa
strains, that could improve the therapeutic approach of different types of
clinical infections.
P1753 Interaction between oral streptococci and two Prevotella
species: an in vitro study
C.S. Stingu*, A.C. Rodloff (Leipzig, DE)
Objectives: Earlier studies have shown that periodontitis is associated
with a loss of colonization of S. sanguinis and an increased colonization
of P. intermedia and P. nigrescens. Our goal was to describe the behaviour
of these two Prevotella species in the presence of two oral streptococci.
Methods: The effect of clinical strains of S. sanguinis, S. anginosus
was evaluated against reference strains of P. intermedia (DSM 20706)
and P. nigrescens (DSM 13386) as well as clinical strains (one each).
All clinical strains were identiﬁed using MALDI-TOF-MS. Suspensions
of 0.5 McFarland from streptococci and Prevotella species (one strain
each) were co-cultured in multi-well dishes (6 wells) (NUNC, Thermo
Fisher Scientiﬁc, Denmark) as follows: streptococci on the apical side
of the Anopore membrane (0,2mm pore size; NUNC) and Prevotella on
the underside of the membrane. The plates were incubated at 37ºC in
anaerobic conditions. Aliquots were taken at 6, 24, 48, 72, 96 hours of
incubation and colony counting was performed. The number of viable
CFU was determined by 10 fold serial dilutions and plating 100ml of
each on Columbia blood agar (Oxoid, Basingstoke. UK) supplemented
with 5% sheep blood, haemin (5mg/L) (Sigma, Taufkirchen, Germany)
and vit. K1 (Sigma). Colonies were counted after 5 days of anaerobic
incubation. Each Streptococcus/Prevotella combination was repeated 5
times in parallel with a negative control (sterile broth above Prevotella).
Results: After 24 h of incubation a bactericidal effect of S. sanguinis
(at least 3-log reduction of initial inoculum) was observed against both
strains of P. intermedia while S. anginosus inhibited the P. intermedia
DSM strain only. The same bactericidal effect but after 48 h was observed
with S. anginosus against P. intermedia. No bactericidal effect was
observed against P. nigrescens. The growth of P. nigrescens in the
presence of the streptococcal strains remains either unchanged or slightly
decreased.
Conclusions: Both S. sanguinis and S. anginosus have a signiﬁcant
bactericidal effect against P. intermedia. On the other hand, P. nigrescens
seams not to be inﬂuenced or even to grow better in the presence of
the two streptococcal strains. Loss of streptococci seems to offer an
advantage for the pathogenic Prevotella intermedia.
P1754 Prevalence of cytolethal distending toxin (cdtABC) virulence
gen in Campylobacter spp. isolated from diarrhoeal and
control cases in Peruvian children under 2 years of age
A. Lluque, J. Ruiz*, A. Prada, T. Ochoa (Lima, PE; Barcelona, ES)
Objective: The aim of this study was to describe the prevalence of
cdtABC genes; associated with virulence of Campylobacter species by
producing cytotoxin lethal for host enterocytes, in isolates from Peruvian
children under 2 years of age, with and without diarrhoea.
Methods: Fifty-three Campylobacter strains isolated from a cohort study
in Lima, Peru were analyzed. Campylobacter species were identiﬁed by
colony morphology, Gram’s staining and biochemical reactions. Species
identiﬁcation and the presence of cdtABC gene was performed by PCR
with speciﬁc primers as described previously. A multiplex PCR using
primers previously described was performed to differentiate between
C. jejuni and C. coli
Results: 27 (51%) strains were C, jejuni, and 26 (49%) C. coli. 29 (55%)
were from diarrhroea cases, and 24 (45%) were from healthy control.
The cdtABC gene was most frequently found in C. jejuni isolates 96%
(26/27) (p< 0.001), the one that did not present this gen was from a
control case. Only 8% (2/26) of C. coli presented this gene, the two
strains belonged to diarrhoea case. 59% (17/29) strains that presented
cdtABC gen were from diarrhea cases and 46% (11/24) were from
control cases.
Conclusions: Campylobacter strains, specially C. jejuni carrying
important toxin production and invasiveness genes are circulating in
the population studied. This virulence factor was found not only in
diarrhoea cases but also in clinical control cases of C. jejuni, for this
reason a surveillance of this bacteria is necessary in both symptomatic
and asymptomatic cases. Further studies are necessary in order to look
for association among the presence of this gene and clinical features.
P1755 Stool culture proﬁle and long-term follow-up of antibiotic
associated haemorrhagic colitis
M. Yilmaz*, Y.A. Bilir, Y. Erzin, R. Ozturk, A.F. Celik (Istanbul, TR)
Antibiotic-associated hemorrhagic colitis (AAHC) is a distinct form
of antibiotic-associated colitis and can be a signiﬁcant source of
morbidity. Although the cause is not exactly known, reports suggesting
the role of Klebsiella oxytoca and/or Clostridium difﬁcile have been
published. In this study we prospectively assessed and reviewed the
K. oxytoca/C. difﬁcile proﬁle and long term follow up of patients with
AAHC.
Methods: Between 2001–2006, we studied 21 consecutive patients who
had AAHC. Stool samples of all patients were cultured for K. oxytoca,
and tested for C. difﬁcile toxin A+B in less than 24 hours of their
initial application. While 6 patients underwent colonoscopy with biopsy
within 24 hours, the rest did not accept the procedure mainly because
of rapid dissappearance of their symptoms within hours. The patients
were followed prospectively until December 2010 for recurrence of
hemorrhagic colitis.
Results: The occurence of the symptoms ranged (6 hrs-14 days)
following ﬁrst dose of the responsible antibiotic, and the duration
of AAHC ranged (6 hrs-21 days). The offending antibiotic was oral
ampicillin/sulbactam in 18 (85%) of cases, oral amoxicillin/clavulanate
in 2 (10%) and other agents in the remaining 1 (5%) patient. C. difﬁcile
toxin A+B production was positive in 24%, negative in 76%. Eleven
(52%) out of 21 patients had positive cultures for K. oxytoca. Long
term follow-up (4−9 yrs) of patients revealed that none of the patients
ever used the offending antibiotic again but only one of the patients
had episodes of hemorrhagic colitis. Past medical history of that patient
was also remarkable in that she had had a self limited hemorhagic
colitis following oral sulbactam/ampicilin use one year prior to her initial
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admission to this study. She was diagnosed with ulcerative colitis during
follow-up period and cured with colectomy. Histology in limited cases
did revealed no more than nonspeciﬁc acute colitis.
Conclusions: Although this study conﬁrms that AAHC may have some
relation either with K. oxytoca or C. difﬁcile, unrecognised organisms or
any other reason may be considered in patients who remain negative for
both pathogens. Not seeing any ﬂares in disease during the long term
antibiotic free follow up in nearly all of the patients indicates that AAHC
is a distinctive entity. However, long term follow up may be necessary to
discriminate antibiotic triggered background silent inﬂammatory bowel
disease.
P1756 Mechanical ventilation up regulates Toll-like receptor 2 and
activation of the lung by bacterial lipopeptide
S.D. Barbar*, P.E. Charles, P. Tissie`res, D. Croisier, J. Dufour,
P. Chavanet, J. Pugin (Dijon, FR; Geneva, CH)
Objectives: To assess the impact of mechanical ventilation (MV) on the
expression of Toll-like receptor 2 (TLR2) and responsiveness to Gram
positive bacterial lipopeptide (BLP), in pulmonary epithelial cells and in
ventilated rabbits.
Methods: In vitro experimental study and prospective, randomized
animal study. Experiments were performed in two research laboratories
from two distinct universities in France and Switzerland.
Subjects: male adult rabbits.
Results: Cyclic stretch of human pulmonary epithelial cells lines
increased both TLR2 mRNA and protein expression. Cells submitted
to cyclic stretch also increased interleukin (IL)-6 and IL-8 secretion
in response to the bacterial lipopeptide PAM3CSK4, a classical TLR2
ligand. A mild mechanical ventilation protocol induced a 60-fold
increase TLR2 mRNA expression in lung tissue when compared with
unventilated controls. The combination of mechanical ventilation and
airway exposure to PAM3CSK4 acted synergistically in causing lung
inﬂammation and injury. In addition, bacterial growth and pulmonary-
to-systemic translocation were increased in rabbits subjected to MV
as compared to spontaneously breathing animals in a model of
Staphylococcus aureus pneumonia.
Conclusions: Mechanical ventilation increases lung expression of TLR2
and sensitizes the lung to bacterial TLR2 ligands. This may account for
the propensity of mechanically ventilated patients to develop acute lung
injury in the context of airway bacterial colonization/infection.
P1757 Virulence of Salmonella enterica serovar Agona Pulse
Field Type SAGOXB.0066, cause of the 2008 European
outbreak − ex vivo studies
M.S. Martins*, M.P. McCusker, S. Fanning (Dublin, IE)
Objectives: To study the virulence of a Salmonella enterica serovar
Agona PFGE-type SAGOXB.0066 strain, directly linked to a pan
European outbreak in 2008.
Methods: Ex vivo studies were conducted with Caco-2 cells and human
THP-1 macrophages. Salmonella Typhimurium SL1344 was used as a
reference. The invasiveness and intracellular growth in Caco-2 cells
was assessed using standard protocols. Survival assays were conducted
in human macrophages for up to 7 days. Microscopy studies were
performed on the macrophages. The supernatants of the cultures were
recovered and kept for further analysis. The activation of macrophages
was evaluated by the Griess test. An array of cytokines was used to
characterize the immunological responses induced by this strain.
Results: Salmonella Agona SAGOXB.0066 showed an increased ability
to adhere and invade Caco-2 cells when compared with Salmonella
Typhimurium SL1344. This strain showed a 10-fold difference in
adherence and a 20-fold difference in invasion. In the macrophage
survival assays S. Agona showed a 10-fold increase. By extending
the assay to 7 days S. Agona exhibited an ability to survive and
replicate inside the macrophages, while the S. Typhimurium SL1344
infection was cleared. Microscopy studies showed distinct differences in
cell differentiation induced by the strains. Macrophages infected with
S. Agona showed a signiﬁcant increase in the number and size of
vesicles. Cell culture supernatants were tested for macrophage activation
and cytokine production and showed signiﬁcant differences in the
responses induced between the two strains.
Conclusion: In this study, we tested the virulence of Salmonella Agona
PFGE-type SAGOXB.0066. This strain exhibited enhanced attachment
and invasion of Caco-2 cells. S. Agona showed enhanced survival in
the THP-1 macrophages in comparison with SL1344. S. Agona was
able to manipulate the macrophage apparatus, avoiding killing to survive
even after 7 days post-infection. These ﬁndings may explain why this
particular S. Agona pulse-ﬁeld type has caused numerous outbreaks
including the pan European outbreak that took place in 2008.
P1758 Bacterial lipoprotein acylation is dispensable for the patho-
physiology of experimental group B streptococcal meningitis
D. Grandgirard*, P. Henneke, P. Trieu-Cuot, S. Leib (Berne, CH;
Freiburg, DE; Paris, FR)
Objectives: Group B streptococcal (GBS) meningitis is particularly
frequent in newborns. GBS bacterial lipoproteins (BLPs) are recognized
by Toll-like receptor 2. The resulting inﬂammation initiates the
pathophysiology of neuronal damage. We investigated the impact of
BLPs acylation on inﬂammation and brain injury during experimental
GBS meningitis.
Methods: GBS strains NEM316 and COH1 and their mutants defective
in prolipoprotein diacylglyceryl transferase (delta-lgt) were used either
live or ethanol-ﬁxed to induce inﬂammatory reaction and brain damage.
Ethanol-ﬁxed bacteria were injected intracisternally at 4×107 CFU
in eleven day old rats. Live bacteria were injected at 2×103 CFU
(COH1) or 1×105 CFU (NEM316) and animals were treated 16 h later
with ceftriaxone (100mg/kg, s.c., bid). Cerebrospinal ﬂuid (CSF) was
sampled at 2, 4, 8, 12, 16 and 24 h after injection and analysed for
myeloperoxidase (MPO), matrix metalloproteinase-9 (MMP-9) and cyto/
chemokines. Brain damage in the cortex and the hippocampus was
analysed by histomorphometry.
Results: (A) Ethanol-ﬁxed bacteria: No differences could be found for
MPO and MMP-9 between wild type and corresponding isogenic mutant
strains, while signiﬁcant differences were observed for IL-1b, IL-10 and
IFN-g. Comparison between NEM316 and COH1 revealed that MMP-9
and all cyto-/chemokines except IL-10 were signiﬁcantly higher in the
COH1 group. Meningitis by ethanol-ﬁxed GBS was characterized by low
apoptosis in the hippocampus and no cortical damage. (B) Live bacteria:
Productive infection was observed for COH1, while infection with 100x
more NEM316 bacteria did not result in consistent bacterial growth.
COH1 and its mutant revealed similar bacterial growth in the CSF,
similar mortality curves and no differences in cyto/chemokine levels.
Similar levels of hippocampal apoptosis and cortical damage were found
in animals infected with COH1 or its mutant.
Conclusions: Differences in the initiation of inﬂammatory processes
could be observed between strains when used after ethanol ﬁxation.
However, they did not translate into signiﬁcant changes in the
pathophysiology of meningitis by live GBS. This argues for LBPs
acylation being dispensable for immune recognition during GBS
meningitis. Hypervirulence of COH1 compared to NEM316 was
conﬁrmed in the present study by a stronger inﬂammatory CSF reaction
and a increased ability to cause productive CSF infection in infant rats.
P1759 Characterisation of virulence factors and antimicrobial
resistance in Escherichia coli strains causing pyelonephritis
in children
J. Koren, K. Curova, M. Kmetova, L. Siegfried*, L. Kovacs, H. Hupkova
(Bratislava, Kosice, SK)
Objectives: Urovirulence factors of E. coli play important role in
urinary tract infections. This study was performed to investigate the
following urovirulence factors in clinical isolates of E. coli causing
S510 21st ECCMID/27th ICC, Posters
pyelonephritis in children: alfa-haemolysin (alfa-hly), aﬁmbrial adhesin
(afa), aerobactin (aer), cytotoxic necrotising factor 1 (cnf1), s ﬁmbriae
(sfa) and p ﬁmbriae (pap). Resistance to selected antiinfectious agents
was determined as well.
Methods: Two hundred and ten urine samples from 0- to 19-years old
children, hospitalized in the Second Pediatric Clinic of the Children’s
University Hospital in Bratislava with pyelonephritis were investigated
in the period of time from March 2007 to December 2009.
The minimal inhibitory concentration of the tested drugs was detected
according to the CLSI recommendations. The virulence factors (VFs)
genetic determinants were detected by a multiplex PCR.
Results: Out of 210 tested samples, 140 (66.7%) were found to be
positive for E. coli. Five patients had 2 different E. coli strains. The
tested VFs were found with the following frequency: aer in 105 strains
(72.4%), pap in 99 (68.3%), sfa in 78 (53.8%), alfa-hly in 60 (41.4%),
cnf1 in 55 (37.9%), and afa in 4 (2.7%) strains. Eight strains (5.5%) had
no VF detected, 32 (22.1%) had one, 40 (27.6%) had two, 23 (15.8%)
had three, 22 (15.2%) had four and 28 (19.3%) strains had ﬁve VFs.
Sixty three (43.4%) isolates of E. coli strains were resistant to
ampicillin and 16 (11,0%) isolates were not susceptible to trimethoprim/
sulphamethoxasole; only 6 (4.1%) strains were resistant to ampicillin/
sulbactam, 4 strains (2.7%) to cefuroxime, 3 isolates (2.1%) to
ciproﬂoxacin and 1 isolate (0.7%) to gentamicine.
Conclusion: The results showed that E. coli is important etiological
agent of pyelonephritis in children, with aerobactin as the most frequently
detected VF.
Although 43.4% of strains were resistant to ampicillin and 11, 0%
to trimethoprim/sulphamethoxasole; ampicillin/sulbactam, cefuroxime,
ciproﬂoxacin and gentamicin might still be used in the therapy.
Acknowledgment: This study was supported by project VEGA 1/0857/10
Ministry of Education of the Slovak Republic.
P1760 Pathogenic elements among staphylococci isolated from
bloodstream and prosthetic devices-associated infections
N. Giormezis*, F. Kolonitsiou, A. Foka, E. Drougka, G. Dimitriou,
A. Spiliopoulou, E.D. Anastassiou, I. Spiliopoulou (Patras, GR)
Objective: Coagulase-negative staphylococci (CNS), especially Staphy-
lococcus epidermidis and S. haemolyticus, are the leading causative
agents of neonatal nosocomial sepsis. CNS are also a major cause
of bioﬁlm-mediated device-associated infections among hospitalized
patients. The ﬁrst step of staphylococcal infection is attachment to var-
ious surfaces followed by production of an extracellular polysaccharide
intercellular adhesin (PIA), encoded by the ica operon, and ultimately,
bioﬁlm formation. Of clinical importance is also the possible production
of TSST-1 and enterotoxins, acting as superantigens, by CNS. In this
study, CNS isolated from bacteraemias and device-associated infections
in terms of methicillin resistance, bioﬁlm formation, ica and toxin gene
carriage, were compared.
Methods: A total of 348 CNS (163 from 69 bacteraemic infants and
185 from intravenous catheters, tracheal aspirations and other device-
associated infections) were identiﬁed at species level by the API Staph
System and Vitek 2 Advanced Expert System (bioMerieux, France).
Susceptibility tests were performed by the disk diffusion method and
Etest to antistaphylococcal agents. PBP2a production was tested by
an agglutination test (bioMerieux). Bioﬁlm formation was tested by
Christensen’s method. Clonality was identiﬁed by PFGE analysis of SmaI
chromosomal DNA digests. The presence of mecA gene, icaA and icaD
(ica operon), tst (TSST-1) and the enterotoxins’ genes sea, seb, sec and
sed was tested by PCRs. Data were statistically analysed using SPSS.
Results: In total, 161/163 CNS from blood cultures and 160/185 CNS
from various devices were mecA-positive (MR-CNS), whereas, 84 CNS
from bacteraemias and 81 from devices, formed bioﬁlm. There was
a signiﬁcant difference in PBP2a production and mecA, icaA, icaD
and sea gene carriage, in favour of bacteraemic CNS. Staphylococci
from both groups were multi-resistant, with two dominant clones among
S. epidermidis and one in S. haemolyticus. No signiﬁcant difference was
found in regards of tst, seb, sec and sed gene carriage.
Conclusions: Multi-resistant MR-CNS clones, mainly S. epidermidis
and S. haemolyticus, are a major cause of bacteraemia and bioﬁlm-
mediated device-associated infections among hospitalized patients.
Among tested CNS, those causing blood infections carried a higher
number of pathogenic elements, as far as methicillin resistance, bioﬁlm-
associated genes and toxin genes.
P1761 The role of monocyte derived VEGF in hantavirus induced
vascular leak
R. Cross*, T. Voss (New Orleans, US)
Objectives: Vascular leak is one of the hallmarks of hantavirus
pathogenesis. Recent evidence suggests that vascular endothelial growth
factor (VEGF) is up-regulated in endothelial cells after infection with
select species of hantavirus. There is, however, no such data describing
the role of immune effector cells found in association with tissues from
infected humans. These data provide evidence for the contribution of
VEGF produced by infected monocytes to the vascular leak syndrome
associated with hantavirus infection in humans.
Methods: VEGF receptor and VEGF protein and mRNA expression
were measured from Andes, Sin Nombre, or Seoul virus infected cultures
of human peripheral blood mononuclear cells (PBMC), THP1, and
human pulmonary (HPMECST1.6) and dermal (HMEC-1) cells. We also
documented changes in monocyte chemokine production by infected
endothelial cell lines. Trans-endothelial electrical resistance assay was
used to model vascular leak induction using co-cultures of infected
monocytes and endothelial cells. Finally, we analyzed cellular junction
protein expression proﬁle changes that occurred as a result of this co-
culture system.
Results: In support of previous ﬁndings, we report an induction of
VEGF in both endothelial cell lines tested. We also provide evidence
for increased expression of monocyte speciﬁc chemokines by infected
endothelial cells. Furthermore, we report that cells from monocyte
lineages up regulate VEGF after infection with hantaviruses and
demonstrate co-culture of infected cell lines results in a synergistic
lowering of TEER and alteration in expression of paracellular junction
protein proﬁles.
Conclusions: The pathological mechanism responsible for inducing
vascular leak in hantavirus infection remains poorly deﬁned. Data from
this work provide additional evidence to this disease have considerable
contributions stemming from a deregulated immune response. Here we
provide the ﬁrst evidence of a direct interaction between immune effector
cells with the infected endothelium that result in changes in vascular
permeability during hantavirus infection.
P1762 A role of triggering receptors expressed on myeloid cells
and the myeloid differentiation factor 88 in Helicobacter
pylori infection in children
J. Michalkiewicz, A. Szaﬂarska, A. Helmin-Basa, A. Marszalek,
B. Kasztelewicz, K. Dzierzanowska-Fangrat* (Warsaw, Torun, PL)
Objectives: The host response to bacterial antigens is a key component
of the pathogenesis of Helicobacter pylori-related diseases. Triggering
receptors expressed on myeloid cells-1 (TREM-1) and TREM-2 are
involved in the regulation of the immune response to lipopolysaccharide,
and the myeloid differentiation factor 88 (Myd88) mediates Toll-like
receptor signaling. The aim of this study was to investigate an association
between TREM-1, TREM-2 and Myd88 expression and inﬂammatory
response in the gastric mucosa in H. pylori-infected children.
Methods: Children referred for endoscopy with clinical symptoms
indicating a pathology in the upper gastrointestinal tract were eligible
for inclusion. H. pylori infection was conﬁrmed by UBT and PCR
of gastric biopsies. The expression of TREM-1, TREM-2 and MyD88
in the gastric mucosa was examined by Real-time PCR (mRNA) and
immunohistochemistry (proteins), both in the gastric epithelium and the
lamina propria.
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Results: A total of 78 children were included in the study (40 H. pylori-
infected and 38 − uninfected). Expression levels of TREM-1, TREM-2
and MyD88 were similar between H. pylori-positive and -negative groups
both in the gastric epithelium and the lamina propria. Similarly, no
differences were seen regarding TREM-1, TREM-2 and MyD88 levels
and the cagA status or severity of gastric inﬂammation.
Conclusion: These results indicate, that in contrast to adults, TREM-1,
TREM-2 and MyD88 do not play an important role in a local response
to H. pylori in children.
Acknowledgments: This work was supported by grant no 1321/P01/
2006/30 from the Polish Committee for Scientiﬁc Research.
P1763 Antibodies against a 20-kDa polysaccharide of
Staphylococcus epidermidis inhibit adhesion and facilitate
endocytosis to human macrophages
A. Spiliopoulou, F. Kolonitsiou, I. Spiliopoulou, N.K. Karamanos,
D. Mack, E.D. Anastassiou* (Patras, GR; Swansea, UK)
Objectives: S. epidermidis is a leading cause of hospital-acquired and
biomaterial-associated infection. 20-kDa PS is an extracellular polysac-
charide of S. epidermidis, distinct from Polysaccharide Intercellular
Adhesin (PIA). Immunization of rabbits with puriﬁed 20-kDa PS elicits
production of antibodies that react speciﬁcally with 20-kDa PS and 20-
kDa PS-producing S. epidermidis strains. Involvement of anti-20-kDa
PS antibodies in bacterial adhesion to macrophages and endocytosis was
studied.
Methods: S. epidermidis ATCC35983 (20-kDa PS (+), PIA (+), bioﬁlm
producing, icaADBC (+)) and clinical strain 1505 (20-kDa PS (−),
PIA (−), bioﬁlm negative, icaADBC (−)) and speciﬁc anti-20-kDa PS
antiserum raised in rabbits against puriﬁed polysaccharide were used in
the present study. Human monocytes collected from healthy volunteers
were differentiated to macrophages. Bacteria were pre-incubated with
PBS, pre-immune rabbit serum, and speciﬁc anti-20-kDa PS antiserum.
Biotinylated bacteria were allowed to adhere to macrophages for 1 h
and attached bacteria remaining after washing were detected by a
NeutraAvidin-HRP TMB substrate commercial kit. Macrophages were
incubated with bacteria for 1 h, extracellular bacteria were lysed with
lysostaphin, cells were lysed with Triton and intracellular bacteria were
counted by plating serial dilutions of lysates on agar plates.
Results: S. epidermidis ATCC35983 exhibits higher attachment as
compared to the clinical strain. Preincubation of ATCC35983 with
pre-immune serum does not alter adherence potential, whereas,
incubation with anti-20-kDa PS serum diminishes attachment up to
89%. Preincubation of clinical strain with pre-immune serum and
anti-20-kDa PS serum minimally inhibit adhesion to macrophages. In
terms of anti-20-kDa PS involvement to endocytosis, preincubation
of ATCC35983 with pre-immune serum does not alter endocytosis,
whereas, preincubation with immune serum increases endocytosis by 10-
fold. Preincubation of clinical strain with pre-immune or anti-20-kDa PS
serum minimally enhances endocytosis (1.5-fold).
Conclusion: 20-kDa PS mediates attachment to human macrophages
as speciﬁc anti-20-kDa PS antiserum inhibits adherence. Anti-20-kDa
PS antiserum seems to exhibit opsonic properties as preincubation of
ATCC35983 promotes endocytosis of bacteria in macrophages. 20-kDa
PS could serve as target for opsonic antibody development.
P1764 A new model to study microRNA modulation in response
to Mycobacterium tuberculosis infection
E. Schena*, B. Gentner, P. Miotto, L. Sergi Sergi, D. Cirillo, L. Furci
(Milan, IT)
Objectives: MicroRNAs are critical regulators of the mammalian im-
mune system through the ﬁne-tuning of gene expression. M. tuberculosis
(Mtb) can persist alive and replicate into the host due to its ability to
interfere with macrophages antimicrobial mechanisms. Up to date little
is known on miRNAs role in tuberculosis pathogenesis. Aim of this
study is to develop a cellular model to monitor the dynamic regulation
of endogenous miRNAs in living cells during Mtb infection.
Methods: Human macrophage cells (THP1) were transduced with a
lentiviral vector, which expresses two transgenes, green ﬂuorescent
protein and low-afﬁnity nerve growth factor receptor (NGFR). By
inserting a speciﬁc miRNA target sequence (miRT) into the 3-prime UTR
of the GFP transcript, GFP expression is subject to miRNA-mediated
regulation. NGFR is unaffected by miRNA activity and serves as a
control. Transduced THP1 were infected with virulent Mtb (H37Rv)
or attenuated strains, M. bovis and BCG. At selected time points, GFP
and NGFR expression was quantiﬁed by FACS analysis or by qRT-PCR.
Prototypical studies were done with miR-155 and miR-146, reported
to be key regulators of immune response in macrophages. MiR-223
a hematopoietic stem cell-speciﬁc micro-RNA was used as internal
reference.
Results: (a) THP1 cells were efﬁciently transduced at MOI 1 with no
toxic side effects. (b) Consistently with ﬁndings in other experimental
models, 100nM LPS caused speciﬁc raise in miR-146 and -155 levels,
thus validating our system. (c) Infection with H37Rv and BCG resulted
in a time dependent increase of miR-146 levels, as indicated by
progressive decrease in GFP ﬂuorescence. Unexpectedly the levels of
miR-155 did not change. MiR-223, which is involved only in cell
differentiation, did not respond to infection. (d) Incubation of transduced
THP1 with Mtb cell lysates resulted in a strong time-dependent increase
of miR-146 expression. This is consistent with previous studies reporting
that lipoarabinomannan (LAM) cause miR-146 increase upon binding
of TLR2.
Conclusion: Here, we developed a novel and useful tool for real-time
and ﬂuorescence monitoring of miRNAs of interest in living cells. This
model could represent a fast screening method to identify miRNAs that
are differentially modulated by different Mtb strains. This could be a
fundamental step towards the comprehension of the pathogenesis of
tuberculosis and the design of new drugs and vaccine strategy.
P1765 Early correlates between viral load and host immune
response in critical pandemic inﬂuenza disease at ICU
admission
R. Almansa, A. Anto´n, T. Pumarola, J. Bermejo-Martin, P. Ramirez,
D. Andaluz, I. Martin-Loeches, P. Merino, L. Xu, L. Ran, D. Banner,
J. Eiros, L. Socias, A. Loza, E. Maravi, M. Marcos, D. Kelvin, R. Ortiz
de Lejarazu* (Valladolid, Barcelona, Valencia, Tarragona, ES; Toronto,
CA; Palma de Mallorca, Seville, Pamplona, ES)
Objectives:
– Evaluate the burden of virus secreted by the respiratory tract in the
infected patients.
– Identify early host response signatures characterizing those patients
admitted to the ICU with the most severe form of the disease.
Methods: We recruited 23 patients attending the participants’ ICUs with
primary viral pneumonia with negative respiratory and blood bacterial
cultures at admission and 15 controls. Patients were divided into two
groups, the MV group needed of invasive mechanical ventilation (n = 15)
and the NMV group composed of patients not needing of mechanical
ventilation at any moment during hospitalization (n = 8).
Viral diagnosis and viral load was performed on RNA from pharyngeal
swabs by RT-PCR. Oseltamivir resistance was directly detected in the
initial positive pharyngeal swab by RT-PCR and sequencing. Immune
mediator levels in plasma were measured by using the multiplex Bio-
Rad 27-plex assay and ELISAs. For gene expression proﬁling, RNA was
stabilized, puriﬁed, ampliﬁed, labelled, hybridized to Sentrix Human-6
v2 Expression BeadChip (Illumina) and scanned on Illumina BeadStation
500GX. Data was analyzed by Ingenuity Pathway Analysis 8.5 software.
Results: Viral load in pharyngeal swabs was 300 fold higher in the
group of patients with the worst clinical condition at admission to the
ICU. Comparison of cytokine proﬁles evidenced signiﬁcant higher levels
IL-8, MCP-1, MIP-1, IL-12p70, IFN-g, IL-6, VEGF, GM-CSF, IL-1ra
and IL-10 in the MV group. Correlation analysis demostrated a positive
associations between these mediators and viral load. Comparison of
gene expression proﬁles between MV and NMV patients revealed 2449
genes differentially expressed between them (P< 0.05, FDR< 0.1). IPA
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revealed that these genes participate in different host response-related
signaling pathways.
Conclusion: At admission to the ICU, severe respiratory disease
following pandemic inﬂuenza infection is characterized by an exhuberant
innate immunity programm which correlates with uncontroled viral
replication in these patients. Understanding the role of this initial
response to the virus in the genesys of the severe respiratory compromise
observed in these patients could help to design better treatment strategies
for this disease.
P1766 Bacterial inoculum impact on the prognosis of patients
with Escherichia coli bacteraemia
L. Vin˜as Castillo* (Seville, ES)
Objectives: 1. To conﬁrm the association between the severe prognosis
and the time to detection of growth (TDG) in E. coli bacteraemia.
2. To evaluate the inﬂuence of TDG by extended spectrum b-lactamases
(ESBL) production.
Methods: Retrospective observational study. All patients with E. coli
bacteraemia from 1 January to 31 December 2009 were identiﬁed.
Data collected included prognosis factors known for E. coli bacteraemia
(co-morbidities using the Charlson co-morbidity score, the presence of
sepsis, severe sepsis and septic shock, and the Pitt score when the
blood culture was obtained, supportive treatment and adequate empirical
antimicrobial treatment), the TDG as an indirect measure of the bacterial
inoculum, fatal clinical outcome (mortality in 48 hours and in 30 days)
and other clinical and microbiological variables (source of infection,
place of acquisition, ESBL production and the presence of polymicrobial
bacteraemia). In a multivariate analysis were included the Charlson and
Pitt score and the TDG as variables related to the global and early
mortality.
Results: During the study period, 226 episodes in 212 patients
with E. coli bacteraemia were analysed, of which twenty (9%) were
polymicrobial bacteraemia. The median age was 63,3 years (range,
18,8−89,8). Median Charlson score was 2 (range, 0−10) and median
Pitt score was 1 (range, 0−14). Thirty-one (14%) patients had severe
sepsis and twenty-nine (13%) septic shock at presentation. The empirical
antimicrobial therapy was adequated in 76% cases and its median delay
was zero hours (range, 0−70). The most frequent source of infection was
urinary (31%), followed by biliary (26%) and unknown (22%) infections.
One hundred sixty-seven (74%) infections were nosocomial and health-
care related infections. Thirty-nine (17%) patients died in 30 days and
seventeen (7.5%) in 48 hours. The median TDG was 8.3 hours (range,
0.42–76.5). Thirty-one (15%) E. coli strains were ESBL producers. In
a bivariate analysis, variables associated with a 8h TDG were the
presence of septic shock (p 0.001) and the global mortality (p 0.05) but
not a ESBL production (p 0.34). A multivariate analysis, showed that a
8h TDG was related to global mortality (OR 2.69; 95%CI 1.09–6.62;
p 0.03).
Conclusions: 1. The time to detection of growth equal or less than 8
hours is an independent predictor fatal outcome in episodes of E. coli
bacteraemia. 2. The TDG in E. coli bacteraemia is not modiﬁed by ESBL
production.
P1767 Role of surface structures of an atypical enteropathogenic
Escherichia coli in attachment and induction of IL-8
production at early stages of intestinal cells infection in vitro
S. Sampaio*, T.A. Gomes (Sa˜o Paulo, BR)
Atypical Enteropathogenic Escherichia coli (aEPEC) promote attaching
and effacing (A/E) lesions in the intestinal epithelium, with intimate
bacterial attachment to host cells mediated by intimin, an outer
membrane adhesin. A/E lesions formation is dependent on the injection
of effector proteins by a type 3 secretion system (T3SS). Recent studies
have shown an important role of ﬂagellar proteins in adherence and gut
colonization in different bacterial pathogens.
Objectives: To evaluate the role of three surface structures of aEPEC
strain 1711−4 (serotype O51:H40): ﬂagellum, intimin and the T3SS in
the adhesion and induction of IL-8 production at early stages of intestinal
cells infection in vitro.
Methods: Mutants deﬁcient in FliC, the main ﬂagellum protein (strain
17ﬂiC-), EscN (the ATPase component of the T3SS) (strain 17escN-)
and intimin (strain 17eae-) were constructed by insertion mutagenesis.
Polarized monolayers of Caco-2 or T84 cells were infected separately
with approximately 1.5×107 colony forming units (CFU)/well of aEPEC
1711−4 or each isogenic mutant. Strains E. coli DH5a (non-pathogenic)
and Salmonella Typhimurium (IL-8 inducer) were used as controls.
Cell culture supernatants were collected two hours after infection and
concentrations of IL-8 were measured by ELISA. Cells were lysed and
the number of bacteria was determined.
Results: Two hours after infection of Caco-2 and T84 cells, the mean
CFU/well of cell-associated aEPEC 1711−4 was at least 100 and 600 fold
that of isogenic mutants (P< 0.001), respectively. In Caco-2 cells, only
the 17ﬂiC- mutant showed a signiﬁcant reduction in the ability to induce
IL-8 production, i.e., ~20 fold less than aEPEC 1711−4 (45 pg/ml) or the
17escN- and 17eae- mutants (53 and 38 pg/ml respectively). Likewise,
in T84 cells, only the 17ﬂiC- mutant showed a signiﬁcant reduction of
IL-8 production (10 pg/ml) as compared to aEPEC 1711−4 (37 pg/ml)
(P< 0.001). After 24 h of infection, there was no difference between IL-8
levels induced by aEPEC 1711−4 and its isogenic mutants in Caco-2
cells, whereas in T84 cells there was a twofold difference between IL-8
levels induced by aEPEC 1711−4 (240 pg/ml) and the 17ﬂiC- mutant
(150 pg/ml), in the same period.
Conclusion: Our data suggest that ﬂagella, intimin, and the T3SS are
necessary for efﬁcient adhesion of aEPEC 1711−4 and FliC is the main
IL-8 inducer at early stages after enterocytes infection in vitro.
P1768 Association of in vitro growth parameters with in vivo
virulence of Aspergillus fumigatus based on a novel
virulence index
E. Mavridou*, J. Meletiadis, P. Jancura, S. Abbas, M. Cavling
Arendrup, W. Melchers, J. Mouton, P. Verweij (Nijmegen, NL; Athens,
GR; Copenhagen, DK)
Background: The relationship between virulence and growth of
A. fumigatus (Af) is unclear. Currently, there is no consensus on how
to identify or measure virulence. Reliable and robust in vivo virulence
markers are lacking whereas in vitro growth characteristics are limited
to growth rate. We therefore determined virulence markers of clinical
A. fumigatus isolates in a murine model of disseminated aspergillosis
and we associated them with in vitro growth properties.
Methods: CD-1 mice were challenged i.v. with 4 different inocula of
14 A. fumigatus isolates. The extent and rate of killing were assessed
by percentage survival (%SUR) and median survival time (MST),
respectively for each isolate. A function combining SUR and MST
(SURxMST) was generated in order to deﬁne a virulence index (VI).
High VI values correspond to low virulence and low VI to high virulence.
In vitro growth curves of the 14 isolates were determined with an in vitro
kinetic system previously described (Meletiadis et al. J Clin Microbiol
2001). A modiﬁed logistic growth function was used to describe the
natural growth of Af and to determine the growth function parameters:
lag phase duration (X0), maximum growth/biomass capacity (Ymax) at
80h, the growth rate (K) and the initial inoculum (Y0). The relationship
between the in vivo parameters SUR, MST and VI and the in vitro
growth parameters was investigated with Spearman correlation analysis
and nonlinear regression analysis based on Emax model.
Results: Among all correlations, Spearman correlation analysis showed a
strong correlation between X0 and MST (r = 0.67, p = 0.008) and between
Ymax and SUR (r = −0.76, p = 0.0007). Regression analysis showed that
the X0-MST and Ymax-SUR followed a sigmoidal pattern (R2 0.56 and
0.88, respectively). A signiﬁcant better sigmoidal ﬁt was found when
the combined X0/Ymax ratio was plotted against MST (R2 = 0.80) and
SUR (R2 = 0.83) which was further improved when plotted against the
VI (R2 = 0.94).
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Discussion: The duration of the lag phase was associated with median
survival time whereas the maximal fungal biomass was related with
survival. The combination of in vitro growth indices like the X0/Ymax
ratio and in vivo virulence indices like SURxMST may be a useful tool
for predicting virulence in Af.
P1769 May the brain parenchyma be inﬂuenced in cutaneous
anthrax patients without central nervous system disorder?
A magnetic resonance spectroscopy study
Y. Bayindir*, A.K. Firat, U. Kayabas, A. Alkan, F. Yetkin, H.M. Karakas
(Malatya, TR)
Objectives: Cutaneous anthrax, caused by Bacillus anthracis, is the
most common form of human anthrax. After gaining access of spores
to tissues, the spores germinate into vegetative forms. The symptoms
appear after producing of toxins by vegetative bacteria. The roles of
anthrax toxins in the cellular pathology of infected hosts are mostly
unknown. We aimed to evaluate whether the subtle metabolic cerebral
changes are present in normal-appearing white matter on conventional
magnetic resonance (MR) imaging, in patients with cutaneous anthrax,
by using MR spectroscopy (MRS).
Methods: The group of patients with cutaneous anthrax had consisted of
5 males and 5 females not having systemic or neurological diseases, with
ages between 16 and 63 (36.3±17.0) years. Thirteen healthy subjects
with ages between 26 and 43 (34.1±5.2) years constituted the control
group.
Brain magnetic resonance imagimg (MRI) examination consisted of
conventional imaging and single-voxel MRS. Magnetic resonance
spectroscopy was performed by using a point-resolved spectroscopy
sequence (PRESS; TR/TE: 2000/136, 128 averages). 20mm× 20mm×
20mm voxels were placed in normal-appearing parietal white matter
(NAPWM).
Conventional MRI and MRS ﬁndings were evaluated by three
neuroradiologists, independently.
Results: Ten patients with cutaneous anthrax and 13 healthy control
subjects, had no signs and symptoms in terms of involvement or diseases
of central nervous system, were investigated with conventional MR
imaging and single-voxel MRS. N-Acetyl aspartate (NAA)/creatine (Cr)
and choline (Cho)/Cr ratios were calculated. There were no statistically
signiﬁcant differences between patients and controls in NAA/Cr ratios
on the MRS ﬁndings (2.11±0.35 and 2.10±0.12, respectively, p = 0.90).
However, Cho/Cr ratios were signiﬁcantly increased in the patients
compared to controls (1.18±0.12 and 0.99±0.11, respectively, p = 0.001)
(Figure).
Conclusion: MRS revealed metabolic changes in normal-appearing
white matter of patients with cutaneous anthrax. Anthrax may cause
subtle cerebral alterations, which may only be discernible with
MRS. Increased Cho/Cr ratio possibly represents an initial phase of
inﬂammation due to anthrax toxins in the central nervous system.
Metabolic changes of cerebral parenchyma without neurological ﬁndings
were showed in cutaneous anthrax. These changes may be related to
systemic effects of anthrax toxins.
P1770 The cutaneous interface as a key event in Lyme borreliosis:
study of different human pathotypes in a murine model
A. Kern, E. Collin, C. Barthel, S.J. De Martino, B. Jaulhac*,
N. Boulanger (Strasbourg, FR)
Lyme disease, is an infectious disorder caused by a tick-transmitted
bacteria: Borrelia burgdorferi. The skin constitutes an essential interface
in this arthropod borne disease. Indeed, the primary manifestation is
a cutaneous inﬂammation, the erythema migrans. Dissemination of
spirochetes from the site of inoculation can lead to other manifestations
typically involving the skin, heart, joints or central nervous system.
Mechanisms responsible of this speciﬁc dissemination are not known.
In this study we postulate that a speciﬁc cutaneous innate immune
response could be involved in the bacterial organotropism. Part of skin
innate immunity is constituted by the secretion of antimicrobial peptides
(AMPs). Two families of AMPs are well-represented in the skin: the
cathelicidin (CRAMP) and the defensin (mBD3 and mBD14). The role
of these AMPs, of the TNF-a and of the chemokine MCP-1 has been
assessed. We studied their potential role in the skin interface during the
early development of Lyme borreliosis.
We challenged C3H/HeN mice with spirochetes from B. burgdorferi
sensu stricto strains initially isolated from human single skin lesions
(EM), from disseminated skin lesions (multiple EM), from cerebrospinal
ﬂuid of a patient with neuroborreliosis. The Borrelia strain N40 isolated
from an Ixodes tick was also tested as a reference strain. Mice
were syringe inoculated and the skin innate immunity at the site of
inoculation was studied for each strain. Gene expression was analyzed by
quantitative RT-PCR. The different Borrelia pathotypes induce different
gene expression proﬁles: N40 induces a high expression of cathelicidin,
MR726 induces mBD-3 defensin. At 5 or 7 days post-infection, a
strong induction of TNF-a and MCP-1 was noticed for all strains
tested. MCP-1 is known to increase endothelial permeability, that could
facilitate Borrelia dissemination. This study underlines the importance
of the Borrelia strain choice, in the study of Borrelia pathogenesis.
P1771 Pseudomonas aeruginosa virulence potential: comparison
between clinical isolates and pristine water isolates obtained
from a hydrotherapy facility
S.G. Pereira*, R. Leita˜o, O. Cardoso (Coimbra, PT)
Objectives: Pseudomonas aeruginosa (PA) is a ubiquitous environmen-
tal bacterium capable of causing a variety of human infections. Several
virulence factors (VF) have been detected in clinical PA, and these traits
are also important for environmental bacteria, as previously reported.
Thermae is a health care unit that uses natural mineral water (NMW) to
treat several health conditions by inhalation and irrigation of different
mucosal tissues. Thermae NMW cannot be disinfected and if PA appears
in NMW it can spread through the water distribution system and arrive
at the treatment equipments, contacting with the thermae users. The aim
of this study was to understand the prevalence of VF in NMW PA and
to compare them with PA clinical isolates.
Methods: PA collection was composed of 49 isolates obtained from a
central hospital, 32 resistant to several antimicrobials and 16 susceptible,
and 77 isolates obtained from a hydrotherapy facility, susceptible, in
general, to antimicrobials. PCR of 7 different VF encoding genes was
performed: 3 secreted VF genes (phenazineI, apr, lasB); 2 type III efector
system genes (exoS, exoY) and genomic islands PAGI-1 and PAGI-2
genes (orf3 and c105, respectively).
Results: VF genes were more frequent in PA environmental isolates
except for exoY and c105, present in a higher rate in clinical isolates. All
VF genes were present in more than 60% of all environmental isolates,
except for PAGI-2 gene (24%). Curiously, PAGI-1 gene was the more
prevalent VF gene in the environmental collection, present in more than
90% of all these isolates. Regarding clinical isolates, VF genes were
present in a lower rate, with 3 VF genes present in less than 50% isolates.
ExoY was the more prevalent VF gene in clinical isolates (90%) and
lasB the less frequent (41%). Comparing antimicrobial resistant clinical
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isolates to susceptible ones, all VF genes were detected in a higher rate
in the former, except for apr. ExoY was present in all resistant isolates.
Conclusion: Environmental PA was obtained from a thermae facility,
where patients contact with pristine NMW to improve their health.
Clinical PA isolates, obtained from human infections, presented lower
rates of VF genes when compared to environmental ones. Although
we cannot predict if the detected genes are functional, the remarkable
conservation of genes encoding VF indicates that most isolates,
regardless of source, possess the basic pathogenic mechanisms necessary
to cause human infections.
P1772 Chemokine secretion after stimulation with Staphylococcus
aureus is increased in human neutrophil granulocytes from
female donors compared to male controls
F. Hitzenbichler*, W. Falk, P. Groß, B. Salzberger, F. Hanses
(Regensburg, DE)
Objectives: Male patients have a higher incidence of invasive infections
with Staphylococcus aureus (S. aureus). The reason for this gender-
speciﬁc difference, however, is unknown. The goal of our study
was to investigate the role of chemo- and cytokines secreted by
neutrophil granulocytes (polymorphonuclear leucocytes, PMN) − the
most important cells in the ﬁrst line of defence against bacterial
pathogens − in this setting.
Methods: We isolated PMNs from peripheral blood of age-matched
healthy female and male human donors. After stimulation with opsonised
S. aureus or lipopolysaccharide (LPS) the production of IL-8, MIP-1a,
MIP-1b, IL-1ra, and TNF was measured using ELISA and Luminex®
technology.
Results: PMNs of female donors incubated with S. aureus produced
signiﬁcantly more chemokines IL-8 and MIP-1b than male controls,
whereas stimulation with LPS alone did not lead to signiﬁcant
differences. No signiﬁcant differences in the production of TNF, IL-1ra,
and MIP-1a were observed after stimulation with either S. aureus or
LPS.
Conclusions: IL-8 and MIP-1b play an important role in activation and
recruitment of PMNs. An increased production of these chemokines in
the early stages of bacterial infections might contribute to the lower
incidence of invasive bacterial infections in female patients.
P1774 Dexamethasone reduces Staphylococcus aureus-induced
production of inﬂammatory cytokines and matrix
metalloproteases in primary human chondrocytes and
synovial ﬁbroblasts
F. Hanses*, I. Fink, S. Graessel, B. Salzberger, M. Fleck (Regensburg,
DE)
Objectives: Staphylococcus aureus (S. aureus) is the most frequent
pathogen involved in acute bacterial arthritis. Joint infections due to
S. aureus are associated with a high rate of sequelae and poor functional
outcome. We hypothesize that concomitant glucocorticoid therapy may
reduce joint destruction during staphylococcal arthritis.
Methods: Primary human chondrocytes, synovial ﬁbroblasts and
osteoblasts were infected with viable S. aureus. The production of the
inﬂammatory cytokines IL-6 and IL-8 (CXCL8), the secretion of matrix
metalloproteases (MMP-1, MMP-13), cell viability and intracellular
bacteria with or without coincubation with dexamethasone were studied
for 5 days.
Results: Primary human chondrocytes produced signiﬁcantly more
IL-6 and IL-8 than ﬁbroblasts and osteoblasts and high levels of
matrix metalloproteases in response to S. aureus. Coincubation with
dexamethasone led to a signiﬁcant decrease in IL-6 and IL-8 production
in all cell types. Additionally, dexamethasone led to a signiﬁcant
reduction in the S. aureus induced production of matrix metalloproteases
by primary chondrocytes. No differences in cell viability and intracellular
CFU were found between cells incubated with dexamethasone and
controls.
Conclusion: The host immune system and tissue destructive substances
contribute to permanent joint damage in S. aureus arthritis. The use of
dexamethsone may modulate inﬂammation and tissue destruction and
may eventually contribute to a better functional outcome after S. aureus
arthritis.
P1775 Relationship between Bordetella pertussis and chronic
obstructive pulmonary disease
S. Hashemi*, E. Nadi, M. Hajilooi, M. Seif-Rebiei, A. Samaei
(Hamedan, IR)
Objectives: There is some evidence indicating the role of Bordetella
pertussis as a trigger for pulmonary diseases. The aim of this study was
to investigate the association of B. pertussis with chronic obstructive
pulmonary disease (COPD).
Methods: In a case-control study, two groups including patients
with COPD and age- and sex-matched control group were included.
Serum samples were tested for Bordetella IgG and IgA by Enzyme
Linked Immunosorbant Assay. A questioneir including demogrophic
characteristics, habitual history, and spirometry ﬁndings was completed
for each patient. Data were analyzed using SPSS.
Results: Ninety patients with COPD and 90 subjects in the control
group enrolled in the study. Bordetella IgG seropositivity was detected in
83 (92.2%) COPD patients and 46 (51.1%) controls (P< 0.001). There
was no signiﬁcant association between Bordetella IgA seropositivity and
COPD. Of 90 patients with COPD 66 (51%) had mild, 31 (34.4%)
moderate, and 13 (14.4%) sever disease. No signiﬁcant association was
found between the severity of COPD and the frequency of Bordetella
IgG and IgA seropositivity.
Conclusion: The results suggest that there is an association between
B. pertussis infection and COPD. Further studies should be planned
to understand the potential pathogenic mechanisms that might underlie
these associations.
P1776 Altered protein secretion of Chlamydia trachomatis in
persistently infected human endocervical epithelial cells
J. Wang*, A.J. Quayle, L. Buckner, K. Frohich, L. Shen (Beijing, CN;
New Orleans, US)
Objectives: To observe altered protein secretion of Chlamydia
trachomatis in persistently infected human endocervical epithelial cells.
Methods: We demonstrate that ampicillin exposure resulted in altered
C. trachomatis secretory activity that is coupled with its adaptation to
a persistent mode of growth using both primary human endocervical
epithelial and HeLa cell infection models.
Results: We observed a decrease in secretable CPAF in the cytosol
of epithelial cells with no evident reduction of CPAF product by
C. trachomatis. In contrast, the expression of CopN and Tarp were down-
regulated, suggesting C. trachomatis responds to ampicillin exposure
by selectively altering the expression of secretable proteins. We also
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demonstrated that ampicillin exposure resulted in alterations to the outer
membrane of C. trachomatis.
Conclusion: Together these results suggest that the regulation of
both gene expression and the sub-cellular localization of secretable
virulence proteins of C. trachomatis are involved in the adaptation of
C. trachomatis to a persistent infection state in human genital epithelial
cells.
P1777 Screening of nuclear targeting proteins in Acinetobacter
baumannii and their pathologic effects on host cells
J.C. Lee*, D.C. Moon, M. Gurung, J.H. Lee, S. Jun, J.S. Jin, B. Kim
(Daegu, KR)
Acinetobacter baumannii is an important nosocomial pathogen that
causes a variety of human infections, but pathogenic mechanisms of this
microorganism are not fully understood. To investigate A. baumannii
pathogenesis regarding the nuclear targeting of A. baumannii proteins
and subsequent host cell pathology, we screened nuclear targeting
proteins in A. baumannii and determined their cytotoxic activity in host
cells. Thirty-seven functional or hypothetical proteins were predicted to
carry the putative nuclear localization signal (NLS) sequences among
3,367 open reading frames of A. baumannii ATCC 17978. Of the 31
clones generated by the Gateway® recombinational cloning system, 14
A. baumannii proteins tagged with green ﬂuorescent protein (GFP)
targeted to the nuclei of host cells, whereas 17 GFP-tagged proteins
localized in the cytoplasm. Among the 14 nuclear targeting proteins,
S21, L20 and L32 ribosomal proteins and transposase were predicted
to carry nuclear export signal (NES) sequences, but only transposase
harbored the functional NES. After translocation to the nuclei of host
cells, seven A. baumannii proteins induced host cell death. Five nuclear
targeting proteins were found in A. baumannii-derived outer membrane
vesicles (OMVs), suggesting that OMVs may deliver these proteins
to host cells. Our data provide a novel insight into A. baumannii
pathogenesis regarding nuclear targeting of bacterial proteins and extend
our knowledge of bacterial pathogenesis.
P1778 Effect of avian inﬂuenza A/H5N1 infection on human
cellular microRNA proﬁle − identiﬁcation of gene regulatory
pathways leading to adverse clinical outcome
P. Chan*, W. Lam, K. To (Shatin, HK)
Background: Avian inﬂuenza remains as a serious threat to poultry
and human health. Recently, a novel system of gene regulation
in plant and mammalian cells has been revealed. This system is
orchestrated by short RNA molecules (microRNAs) that are differentially
expressed according to the physiological and pathological status of the
cells concerned. Viruses can interact with the miRNA-mediated gene
regulatory pathways. Therefore, the proﬁle of host cell miRNAs may
change as a consequence of avian inﬂuenza viral infection.
Aims and Objectives: This study aims at elucidating how avian
inﬂuenza infection perturbs the human gene regulatory pathways leading
to adverse pathological events, e.g. cytokine storm. The ultimate goal is
to generate essential information for further studies to identify novel
intervention targets to ameliorate the outcome of infection.
Study design and Methods: The human lung cell-derived H292 cell line
were used to establish an in-vitro system for inﬂuenza infection. H5N1-
infected cells were screened for the expression proﬁle of miRNAs using
a highly sensitivity, broad-catching approach, i.e. microarray. Similar
data were obtained from H1N1-infected cells for comparative analysis
to identify miRNAs that were differentially up/down-regulated following
H5N1 infection.
Results and Conclusions: Based on the broad-catching miRNA
microarray results, we found that dysregulation of miRNA expression
were mainly observed in highly pathogenic avian inﬂuenza infection.
A list of differentially expressed miRNAs was identiﬁed for subtypes
H1N1 and H5N1, and the temporal pattern of expression was delineated.
Among the differentially regulated miRNA, it was found that hsa-miR-
1246, hsa-miR663 and hsa-miR-574−3p were highly up-regulated (>3-
fold) in H5 infection compared to H1. Also, hsa-miR-100*, hsa-miR-
21*, hsa-miR-141, hsa-miR-1274a and hsa-miR1274b were found to be
highly down-regulated (>3-fold) in H5 infection, particularly during the
late post-infection phase compared to H1. It is worthwhile to further
predict and characterize the function of these miRNAs by in-vitro and
in-silico approaches.
P1779 Dependence of group B streptococci adherence on serotypes
and a-like protein genes
M. Bodaszewska-Lubas*, M. Brzychczy-Wloch, T. Gosiewski,
P. Adamski, M. Strus, P. Heczko (Cracow, PL)
Objectives: Adherence of Group B streptococci (GBS) to epithelial cells
has been shown to be an important factor in the colonization of mucus
membranes of human rectum and vagina. Therefore, the aim of the study
was an assessment of the adhesion of chosen GBS strains to the human
colon adenocarcinoma cell line (HT29) and human epidermoid vulvo-
vaginal cells (A431) in relation to capsular polysaccharides of GBS and
a-like protein genes.
Methods: The adherence of GBS to HT29 and A431 cell lines was
tested. 26 strains of GBS from human sources belonging to Ia, Ib,
II, III or V serotypes possessing different a-like protein genes such as
alp2, alp3, bca, e or rib and GBS standard strains in the conventional
adherence assay were used. GBS strains were inoculated at 1×108
CFU/ml/well (OD600 of 0.6−0.7) onto HT29 monolayers and A431
cells for 30 minutes. The infected cells were washed 3 times in PBS,
ﬁxed in formaldehyde and Gram-stained. The results were obtained
semiquantitatively by counting bacterial cells in randomly chosen 20
ﬁelds. Each test was done in duplicate. This study was supported by
grants no. NN401 042337 and NN401 042938.
Results:
1. Adherence of GBS strains to HT29 cell line was signiﬁcantly higher
than to A431 cell line.
2. For GBS serotype III and II a signiﬁcant difference between adhesion
to HT29 and A431 cell lines was shown.
3. Adhesion of GBS strains to HT29 was not dependent on serotype
but on a-like protein genes. The most adhesive were the GBS strains
containing rib and alp2 genes.
4. Adherence of GBS strains to A431 depended on both their serotype
and a-like protein genes. Serotype III adhered to A431cells the
strongest, especially strains containing rib and alp2 genes.
5. GBS strains containing the rib gene adhered to HT29 and A431 cell
lines more strongly than GBS strains possessing other a-like protein
genes.
Conclusions: Adherence of GBS is not a species attribute, so it changes
among strains and depends on GBS serotype and a-like surface proteins.
Our results showed signiﬁcantly higher adherence to HT29 cell line than
to A431 and it is a conﬁrmation that GBS is primarily a constituent
the gastrointestinal tract and only secondarily colonises the vagina.
Moreover, GBS adherence to vulvo-vaginal cells was closely related
to serotypes and a-like protein genes in opposition to the adherence to
HT-29 which showed a the relation only to rib and alp2 genes.
P1780 The Sov protein of the Porphyromonas gingivalis secretion
system functions as an independent virulence factor
S. Shashkova*, J. Koziel, K. Maresz, I. Thogersen, J. Enghild, Y. Guo,
J. Potempa (Cracow, PL; Aarhus, DK; Louisville, US)
Objectives: Porphyromonas gingivalis, an asaccharolytic, Gram-negative
anaerobic bacterium is recognized as an important pathogen of
periodontitis. The bacterium secretes large amounts of cysteine proteases,
gingipains, which are essential virulence factors. The mechanism of
gingipain secretion is a subject of intense investigation and up to
date several proteins have been identiﬁed as components of the outer
membrane (OM) translocation machinery. Apart from functioning in the
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gingipain secretion some proteins of the secretion apparatus may work
as independent virulence factors. To verify this assumption we have
compared ability of mutants deﬁcient in individual proteins involved in
secretion to form bioﬁlm and adhere to professional phagocytes in the
context of the outer membrane proteome.
Materials and Methods: Wild-type P. gingivalis W83 and isogenic
mutants deﬁcient of sov, porT, PG0022, PG0266, PG0543, and PG1403
genes essential for gingipains secretion were grown to an early stationary
phase. Bacterial bioﬁlm formation and adherence to the RAW 264.7
macrophages were estimated by crystal violet staining and FACS
analysis, respectively. Gingipain activity was assayed in full culture
and bacterial cell homogenates. The outer membrane fraction was
separated, resolved by SDS-PAGE and subjected to peptide ﬁngerprinting
to identify proteins in the OM.
Results: In contrast to the parental strain, secretion system mutants show
no gingipain activity in full cultures and in cell homogenates. All mutants
adhered to the plastic surface far more efﬁciently than the wild type
strain W83. Most interestingly, however, only the sov mutant vividly
adhered to macrophages. To explain the mechanism of adherence, the
proteome of the OM derived from wild-type, delta-sov and delta-PG0266
strains was compared. The proteome of both strains was found identical
but different than that of the parental strain.
Conclusion: The lack of gingipain secretion strongly enhances the
P. gingivalis binding to plastic surface. Conversely, gingipains are
apparently dispensable for protecting the bacterium from adherence
to macrophages. From the comparative analysis of mutant strains
phenotype and the OM proteome, the Sov protein was identiﬁed as the
virulence factor which prevents the direct contact between P. gingivalis
and phagocytes. This may protect the bacterium from phagocytosis
and destruction. In this way Sov may signiﬁcantly contribute to the
P. gingivalis pathogenicity.
P1781 Impact of different peritoneal dialysis ﬂuids on bacterial
and yeast growth of common pathogens
S. Tobudic*, C. Kratzer, H. Schranz, W. Poeppl, H. Burgmann (Vienna,
AT)
Objectives: Peritoneal dialysis (PD) used in the treatment of patients
with end-stage renal failure is often complicated by peritonitis. The
major pathogens of PD associated peritonitis are staphylococci, followed
by P. aeruginosa, E. faecalis, and yeast. The aim of this study
was to evaluate the growth of the most common pathogens of PD
associated peritonitis in PD ﬂuids (PDFs) containing different glucose
concentrations, icodextrin or amino acid.
Material and Methods: Growth kinetics of microorganisms were
performed in the PDFs: Dianeal PD4® (glucose 1.36%, 2.27%, 3.86%),
Physioneal 40® (glucose 1.36%, 2.27%, 3.86%), Extraneal® (7.5%
icodextrin), and Nutrineal PD4® (1.1% amino acid). The bacterial test
isolates comprise S. aureus ATCC 25923, S. epidermidis ATCC 35983,
E. faecalis ATCC 29212, P. aeruginosa ATCC 27583, and C. albicans
ATCC 90029. Sabouraud buillon (SAB) and Mueller-Hinton Broth
(CAMHB) were used as control broths. Ten milliliters of each PDF and
of control broths containing an inoculum of approximately 106 CFU/ml
were incubated for 24 h at 37 ºC, and for 24ºC for yeasts. Samples were
taken at 0, 2, 4, 6, 8 and 24 h the number of CFU/ml was determined.
Results: Inﬂuence on bacterial and yeast growth in terms of less
pronounced growth was demonstrated for all eight PDFs when compared
to the control broths. After 24 hours incubation a signiﬁcant reduction
in the number of viable bacteria (p< 0.05) was detected for each
PDF compared to the initial inoculums. However, glucose-based
PDFs supported less bacterial growth than non-glucose-based PDFS,
particularly in staphylococci. After 4 hours, a signiﬁcant reduction of the
viable bacterial count of S. aureus and S. epidermidis (mean 0.82–1.44
log10 CFU/ml, p< 0.05) was detected in all glucose-containing PDFs
regardless of the tested glucose concentration. When comparing the two
different types of glucose-containing PDFS, growth of S. aureus was
higher suppressed in Physioneal 40® within four hours than in Dianeal
PD4® (p< 0.05), whereas no difference in growth of S. epidermidis was
detected. In C. albicans, suppressive effect on the fungal growth was
detected after 24 hours in all PDFs.
Conclusion: Our in vitro study show that all tested PDFs attained
inhibitory effect on the microorganism. This in vitro observation could
be beneﬁcial for prophylaxis and treatment of patients with recurrent
PD-associated infections.
Pathophysiology of infectious diseases, in
vivo
P1782 Can Salmonella cure cancer? Insights on a novel
antitumoural mutant
I.A. Campos Damiani*, M.H. de Moraes, A. dos Santos Moraes,
A. Farias, L.M. Santos, M. Brocchi (Campinas, BR)
Objectives: Salmonella enterica serovar Typhimurium attenuated mu-
tants have been tested in experimental treatments against different cancer
lineages. It has been demonstrated by different groups that those mutants
present a strong tropism for necrotic/hypoxic regions, colonizing areas
that are inaccessible to conventional chemotherapic drugs. Our goal is
to discuss the efﬁcacy of a novel Salmonella Typhimurium attenuated
mutant (under patent requirement) in the treatment of murine 3LL
carcinoma and B16F10 melanoma.
Methods: The S. enterica Typhimurium mutant was constructed using
the lambda red system.
B16F10 melanoma and 3LL carcinoma cells were cultured in vitro and
injected subcutaneously in the back of C57/BL6 female mice. Intratu-
moural injections of the mutant strain in different c.f.u. concentrations
were administered when tumour volume reached approximately 50mm3.
Results: When mice were administered with S. enterica titles equal
or higher than 107 c.f.u. B16F10 tumour disappeared completely
within 24 hours (3LL tumour became smaller and presented a necrotic
aspect), but mice mortality was high probably due to a strong
immunological response or tumour lysis syndrome, since oral and
intravenous administration of the mutant strain in health mice did not
cause any collateral effect. Administration of lower doses decreased
tumour volume but did not eliminate the total tumour mass. Instead,
within 4 days, part of the 3LL and B16F10 tumour masses sear and
80% of mice survive longer than the control group administered with
PBS. Histological analyses of treated 3LL show hemorrhagic sites,
polymorphonuclear cells inﬁltration and areas of cell death.
Conclusions: Our novel S. enterica mutant has potential antitumour
efﬁcacy but new treatment improvements must be done in order to obtain
optimal results.
P1783 Induction of streptococcal experimental endocarditis by
cumulative low-grade bacteraemia mimicking spontaneous
bacteraemia in humans
T.R. Veloso, M. Amiguet, M. Giddey, J. Vouillamoz, V. Rousson,
P. Moreillon, J.M. Entenza* (Lausanne, CH)
Objectives: Medico-surgical procedures in the oral cavity can provoke
transient, high-grade bacteremia. This is a risk factor for infective endo-
carditis, as supported by clinical studies and experimental endocarditis
in animals. Yet, case control studies suggest that cumulative exposures to
low-grade bacteremia occurring during daily-life activities, such as tooth
brushing, can also provoke IE. However, no experimental demonstration
of this later possibility exists. Here we investigated the capacity of oral
streptococci − one of the primary causes of infective endocarditis −
to induce valve infection in a new model of experimental endocarditis
induced by persistent, low-level bacteremia.
Methods: Rats with sterile aortic vegetations were inoculated with 10e5
or 10e6 CFU of strains Streptococcus intermedius or Streptococcus
gordonii. Identical inoculum sizes were administered either by intra-
venous bolus (1ml in 1 min) or by continuous intravenous infusion
(0.0017ml/min over 10 h). Bacteremia levels were determined 1 min
(bolus) or 2 h (continuous infusion) after inoculation [expressed as
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median (range) CFU/ml of blood]. Vegetation infection was assessed
24 h later.
Results: Bacteremia levels and rates of vegetation infection are shown
in the table.
Conclusion: Persistent, low-grade streptococcal bacteremia represents a
non-negligible, sometimes even similar risk of experimental endocarditis
than transient high-level bacteremia. These experimental results support
the hypothesis that streptococcal infective endocarditis can result from
cumulating bouts of low-grade bacteremia provoked by daily-life events,
rather than only after procedure-induced high-level bacteremia.
P1785 Role of Candida albicans and Pseudomonas aeruginosa
direct interaction in the protective effect of C. albicans
colonisation on P. aeruginosa-induced lung injury
J.B. Mear*, E. Kipnis, H. Tiesset, S. Jawahara, C. Rouyer, F. Vuotto,
D. Poulain, K. Faure, B. Guery (Lille, FR)
Objectives: Pseudomonas aeruginosa, frequently responsible for ven-
tilator associated pneumonia, can often be isolated in association
with Candida albicans, mostly considered a colonizing agent in the
respiratory tract. These pathogens can interact through their Quorum
Sensing (QS) or adhesion molecules which may modulate each other’s
virulence. In a mouse model, prior airway colonization with C. albicans
attenuated P. aeruginosa-induced lung injury. Our aim was to determine
whether C. albicans was responsible for this protective effect through
direct interactions, either by modulation of QS-dependant P. aeruginosa
virulence or as a decoy target for P. aeruginosa.
Methods: Reference strains were C. albicans Ca SC 5314 (Ca)
and P. aeruginosa PaO1. Ca ATCC 10231 (CaD) was used as a
strain naturally deﬁcient in the C. albicans QS molecule, farnesol.
Germ-tube formation inhibition assay was used to conﬁrm farnesol
deﬁciency. In vitro effect of farnesol (1microM) on PaO1 QS-dependent
virulence factors (pyocyanin, rhamnolipid, and elastase) were assessed
by colorimetric assays. Ca EFG1−/− (CaDEfg1) was used as a non-
ﬁlamentous strain. C. albicans was assessed as a target for P. aeruginosa
by an in vitro co-culture killing assay. The in vivo effects of prior
colonization by C. albicans, either farnesol-deﬁcient or nonﬁlamentous,
were evaluated at 48h on P. aeruginosa-induced lung injury as assessed
by alveolo-capillar permeability to FITC-Albumin and on bacterial
clearance assessed by P. aeruginosa burden.
Results: CaD strain was conﬁrmed as farnesol-deﬁcient since its
supernatant did not prevent germ-tube formation (p< 0,001 vs. Ca).
Farnesol in vitro signiﬁcantly lowered P. aeruginosa QS-dependant
virulence factor secretion (p = 0.0016 for pyocyanin, p = 0.0061 for
rhamnolipid and p = 0.0043 for elastase). Ca ﬁlaments were conﬁrmed as
a target for P. aeruginosa, killed in an in vitro co-culture assay (p< 0,05
vs. nonﬁlamentous strain), whereas CaDEfg1 survived. However, in
vivo, prior airway colonization with either farnesol-deﬁcient (CaD) or
nonﬁlamentous (CaDEfg1) strains did not decrease the protective effect
of Candida on P. aeruginosa-induced lung injury (p< 0,0001 for Ca and
CaD, p< 0,05 for CaDEfg1) and bacterial clearance (p< 0,0001 for Ca
and p< 0,05 for CaD and CaDEfg1).
Conclusion: Decreased severity of P. aeruginosa-induced lung injury
occurring after C. albicans airway colonization is not due to farnesol
nor to C. albicans as a decoy target.
P1786 Evaluation of bacterial colonisation of biomaterials and its
effect on TNF-A,-B defensin-2 and Il-10 expression in tissues,
in vivo study, after 2- and 4-week exposure in rabbit tissues
A. Reinis*, M. Pilmane, J. Kroica, J. Vetra, A. Stunda,
L. Berzina-Cimdina, V. Kuznecova, D. Rostoka (Riga, LV)
Objectives: The aim of the study is to explore 3 originally synthesised
biomaterials and bacterial colonisation risk and their impact on the
surrounding tissue: material A − raw materials and products are
crystalline, B − the substance is an amorphous, crystalline product;
B+ − B etched in order to reduce the amorphous phase.
Methods: Ps.aeruginosa, S. epidermidis were used for the preparation
of suspensions in concentration of 100 and 1000 CFU/ml. Biomaterial
samples were cultivated at 37 C for 2h to promote adhesion and then
were implanted in interscapular area of rabbits (for 2 and 4 weeks).
The biomaterial was removed and, using plate count and soniﬁcation
method the bacterial colonisation on the surface of the biomaterial was
determined, however, we prepared preparations from the surrounding
tissues, staining in haematoxylin-eosin and using immunohistochemistry
methods thus determining TNF-A,-B defensin-2 and Il-10.
Results: Biomaterial samples contaminated with S. epidermidis showed
a low degree of colonisation. Two samples (A and B) after 2 weeks
of exposure were sterile. Ps.aeruginosa showed a higher degree of
colonisation with intensity from 0.21 CFU/ml (B biomaterial) up to 8.7
CFU/ml (B+ biomaterial).
The most intense inﬂammatory reaction was observed around the
Ps.aeruginosa contaminated biomaterials. Many TNF-A and Il-10-
containing inﬂammatory cells inﬁltrated tissues surrounding the afore-
mentioned materials. Indicators of inﬂammation practically did not differ
for the 2 and 4 week implants of biomaterials.
We observed some defensin-containing cells in tissue surrounding
biomaterials after Ps.aeruginosa infection, while in other biomaterial
contamination cases such cell amount were much more moderate.
Conclusions: The study showed that Ps.aeruginosa compared with
S. epidermidis more intensively colonised biomaterials in the in vivo
study. Ps.aeruginosa infection tends to cause depletion of B-defensin
2 production in tissues, and therefore may lower the host non-speciﬁc
resistance. TNF-A and Il-10 production expression is not affected
by such a short (2 and 4 weeks) biomaterial implantation. Cytokine
expression is characterised by pronounced tissue around biomaterials,
which are contaminated with Ps.aeruginosa.
Acknowledgements: This work has been partly supported by the
European Social Fund within the project “Multidisciplinary Re-
search in Biomaterials Technology of New Scientist Group”, No.
2009/0199/1DP/1.1.1.2.0/09/APIA/VIAA/090, (PVS ID 1380).
Molecular point-of-care tests
P1787 Clinical and economic impact of GBS intrapartum
screening using molecular diagnosis
N. El Helali*, Y. Giovangrandi, M.D. Kitzis, M. Bobin, J. Fresson
(Paris, Nancy, FR)
Objective: Since January 2010, in our institution, the prevention of
neonatal EOGBS infections is based on intrapartum screening using real
time PCR. The objective of this study is to assess the cost of this strategy
from the perspective of the French Health Insurance (Assurance Maladie)
as well as the consequences in terms of number of infections, compared
with prevention based on antenatal screening as used previously (2009).
Materials and Methods: An exhaustive data collection on EOGBS
infections was performed. French Healthcare Reimbursement rates from
2009 were applied to data recorded in 2009 and data for the ﬁrst 9
months of 2010. The cost of intrapartum screening by PCR could not be
coded, and was evaluated on the basis of “Nomenclature Montpellier”
reimbursement scheme.
Results: The incidence of EOGBS infections was 9.06‰ in 2009
(prevention based on antenatal screening by culture) and was 4.23‰
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in 2010 (prevention based on intrapartum PCR screening) (p = 0.04).
Calculated on the basis of the 2009 activity, in 2010, if prevention had
been based in its totality on antenatal screening, we would have expected
19 GBS infections with subsequent 90 neonatology hospitalization days
and 33 days on ICU. In applying the 2009 rates, the cost for the
health insurer would have been €90 311 in neonatology and €29 662
for antenatal screening by culture: a total cost of €119 973 (= cost A).
In reality only 9 GBS infections were observed with 68 days of
hospitalization in neonatology and 4 days in ICU. The actual cost of
care for the French healthcare system was only €35 805 for neonatology
hospitalization days. The cost for intrapartum screening by PCR would
have been €113 705 if codiﬁed: the sum being €149 510 (= cost B) as
total cost.
For the total of 2070 term deliveries and the 2130 live term births during
the study period, there was a decrease in the number of hospitalization
days of 24.44% in neonatalology and 87.9% in ICU with an overall
cost supplement estimated at €29 537 (= cost B minus cost A) if
reimbursement codes were applied.
Conclusion: This study showed that intrapartum GBS screening by real-
time PCR (GeneXpert Xpert GBS) resulted into a signiﬁcant decrease
in GBS infections and in the number of hospital days. The additional
cost would theoretically be only €14.27 per delivery in order to avoid
at least 10 infections annually in our institution. Additional multicenter
studies should be performed to validate these preliminary results.
P1788 Quick and accurate diagnosis of toxinogenic C. difﬁcile
combining Techlab C. diff Quik Chek Complete and
GeneXpert C. difﬁcile RT-PCR
P. Vandecandelaere*, R. Joseph, C. De Ridder (Ypres, BE)
Objective: We evaluated if selective addition of GeneXpert C. difﬁcile
PCR to the routine C.diff. test algorithm could ameliorate the turnaround
time for complete and correct results.
Methods: As standard procedure we perform a Techlab C.diff Quik Chek
Complete assay (Techlab Cdiff) and a toxinogenic culture (CDTC) for
all diarrheal stool samples.
Techlab Cdiff detects both glutamate dehydrogenase (GDH) and
Clostridium difﬁcile toxin A and B (ToxAB). CDTC consist of a culture
on Cdiff agar (BioMerieux) and a second toxine A/B test (Immunocard
Toxins A&B − Meridian) on colonies grown of stool samples that were
toxin A/B negative directly on stool.
GeneXpert Xpert C. difﬁcile RT-PCR (Cepheid) (Cdiff PCR) detects
toxin B gene, the gene for binary toxin and the tcdC deletion.
In the new test algorithm we perform a Cdiff PCR on stool samples
with GDH pos and tox AB neg result (n = 76) and on stool samples with
GDH neg and ToxAB pos result (n = 6). For GDH and ToxAB positive
stools that were CDTC negative we also performed a Cdiff PCR on the
stool (n = 2).
Results: During the evaluation period 1136 stools could be included for
evaluation and 84 PCR tests had to be performed. (7.4%).
Overall 83 stools tested positive for toxin producing C. difﬁcile (7.3%)
and the results of 4 stools were inconclusive (Techlab Cdiff GDH pos
and toxAB neg, Cdiff. PCR pos and CDTC neg).
With the CDIF QUIK CHEK 35 positive stools had a correct answer on
day 1 (42.2% of the positive samples) and 82/1136 samples (7.2%) had
a nonclusive result (only GDH or toxAB test positive). By adding PCR
we could give a conclusive result for those patients: 45/82 (54.9%) are
PCR positive (41 results conﬁrmed by CDTC). These patients could be
timely isolated to prevent nosocomial infections and the others were not
unnecessarily isolated.
With the new test algorithm we can give a correct same-day result
(positive and negative) for 99.3% of all stools (1128/1136) and for 96.4%
of positive stools (80/83).
Conclusions: Selective addition of GeneXpert Cdiff PCR to Techlab
C.diff Quik Chek Complete assay for diagnosis of CDAD allows us to
give a same-day correct answer for C. difﬁcile diagnosis for 99.3% of all
stools and for 96.4% of the positive stools. GeneXpert Cdiff. RT PCR
has only to be performed on a minority of the stools (7.4%).
P1789 Evaluation of the Xpert MRSA/SA® SSTI RT-PCR assay for
rapid detection of staphylococcal osteoarticular infections
F. Laurent, V. Blanc-Pattin, J.M. Gandois, A.M. Freydiere, N. Mehdi,
S. Boisset, R. Guinand, E. Chanard, A. de Ladoucette, D. Benzaquen,
A. Dubouix-Bourandy* (Lyon, L’Union, FR)
Staphylococcus aureus (SA) and coagulase negative Staphylococcus
(CNS) are the most prominent pathogens isolated from osteoarticular
infections. Methicillin resistance (MR) occurs frequently. Rapid and
accurate diagnosis is a real concern as efﬁcient antimicrobial therapy
has to be initiated as early as possible.
Objectives: The aim of our study was to evaluate Xpert MRSA/SA®
SSTI RT-PCR assay (Cepheid®) directly on perioperative osteoarticular
samples. The random access GeneXpert® performs extraction, ampliﬁ-
cation and detection of three targets (spa, SCCmec and mecA genes) in
a single use cartridge so that results are available in 56 minutes.
Methods: A retrospective analysis was ﬁrst performed on 91 selected
samples (MSSA, n = 63; MRSA, n = 9; negative, n = 19) in order to
validate the use of the assay (synovial ﬂuids, n = 24; bone biopsies,
n = 42; tissue biopsies n = 25). Then, 135 samples from 105 patients (45
prosthetic joint infections, 3 spondylodiscitis, 14 acute septic arthritis,
and 33 non infected controls) were tested prospectively. In all cases,
molecular results were compared to microbial cultures.
Results: Retrospective study: Sensitivity and Speciﬁcity for the detection
of SA, were 94.4% and 100%, respectively. All MRSA positive samples
were detected.
Prospective study: Sensitivity, Speciﬁcity, Positive Predictive Value
and Negative Predictive Value for the detection of MSSA, MRSA
and MRCNS in clinical specimens were 100%, 97%, 96% and 100%,
respectively. The median of hands-on time for standard culture and Xpert
MRSA/SA SSTI® assay were respectively 25 minutes vs 2 minutes,
while the median turnaround-time from admission to notiﬁcation
of results were respectively 72 hours vs 72 minutes. Detection of
methicillin resistance improved the antimicrobial therapy management
as vancomycin could be avoided in many cases.
Conclusion: Xpert MRSA/SA SSTI assay is a rapid and accurate method
for the detection MRSA, MSSA and MRCNS in perioperative specimens.
It can dramatically improve the clinical management of patients suffering
from osteoarticular infections. Further studies must be conducted in order
to evaluate the clinical and economical impact of such an assay.
P1790 Detection of MRSA by GeneXpert: poor sensitivity of
throat specimens compared to nose and groin specimens
D.S. Blanc*, L. Senn, G. Zanetti (Lausanne, CH)
Background: New rapid PCR-based techniques are now commercially
available for the detection of methicillin-resistant Staphylococcus aureus.
Most of them were evaluated for nose specimens. However, it was well
Lab automation S519
demonstrated with culture that the addition of throat and groin specimens
increased the sensitivity of detection. The high price of rapid tests incites
to pool the three specimens into one analysis. Preliminary data suggested
that the sensitivity of PCR on throat specimen is lower than on the
others. Pooling this specimen with others might inﬂuence the overall
performance of the assay.
Objective: To compare performances of GeneXpert MRSA on throat
specimens with those of nose & groin specimens.
Methods: Specimens were obtained using the eSwabs collection devices
(Copan) from patients eligible for screening according to the hospital
policy. Nose and groin samples were pooled in the same eSwab device
(two nylon ﬂocked swabs in one tube), whereas throat specimens were
collected separately (one nylon ﬂocked swab in one tube). Samples were
eluted into 1mL of liquid Amies medium. 150 microL were used to
perform the analysis with GenXpert MRSA, and the remaining was used
for culture (enrichment broth followed by inoculation onto chromogenic
M-select agar plates [Biorad]).
Results From September 2010 to November 2010, 441 screening were
performed and analyzed both by GenXpert MRSA and by culture.
Among these, 377 (84%) were negative by both methods in both samples.
Considering the results from culture as the gold standard, the sensitivity
of GeneXpert MRSA was lower for the throat: 0.56 (95%CI, 0.40–
0.72) than for the nose&groin: 0.84 (95%CI, 0.71–0.93); whereas the
other performances (speciﬁcity, positive predictive value, and negative
predictive value) were similar.
56 screenings were positive by GeneXpert MRSA (48 in nose&groin
samples and 25 in throat samples). Among these, 8 (14%) were positive
only in the throat.
Conclusions: Sampling of the throat contributed to a non negligible
number of positive screenings (14%). However, the sensitivity of throat
swabs was nearly signiﬁcantly lower than the pooled nose and groin
swabs. Although the reason for this ﬁnding is still unclear, we advise
not to pool the three specimens since it could lower the sensitivity of
MRSA detection with the GeneXpert assay.
P1791 Is VRE screening by Xpert™ vanA/vanB PCR superior to
selective culture on chromID™ VRE indicator agar?
H. Peltroche-Llacsahuanga*, G. Haase (Aachen, DE)
Prevalence rates of VRE increased worldwide over the past 15yrs. Active
control measures are being implemented in some hospitals e.g. detection
of non-infected but gut-colonized patients that might serve as a source
of the spread of VRE.
In this VRE surveillance study 270 rectal double swab samples
recovered from patients at admission to the university hospital were
tested by using the recently released Xpert™ vanA/vanB PCR assay
(Cepheid, USA) in parallel to enriched culture on chromID™ VRE
medium (C-ID; bioMe´rieux, FRG). Overnight enrichment in BHI
with 3 g/L vancomycin preceded inoculation of the chromogenic
agar, as described recently (Peltroche-Ll. et al.; 2009). Final species
identiﬁcation of microorganisms recovered from C-ID was achieved by
mass spectrometry ﬁnger printing using Maldi-TOF (Microﬂex; Bruker
Daltonics, FRG). Presumed VRE were conﬁrmed by vancomycin Etest.
The study revealed highly disparate results for PCR and culture (Tab.
1a, b). The detected VRE rate was 21% comprising 54 vanA E. faecium,
4 vanA E. faecalis, 4 vanB E. faecium, and 2 vanB E. faecalis.
Considering that the PCR assay is detecting genes that are not unique
for enterococci, the highly disparate results become comprehensible.
Particularly the vanB operon is naturally occurring in obligate anaerobes,
e.g. Clostridium spp. (Ballard et al.; 2005). Consequently, the positive
agreement of vanB PCR with culture of VRE is only 5%, whereas the
vanA PCR revealed 70%. Of note, in case of 10 positive vanA PCRs,
only Lactobacillus spp., that are potentially able to acquire vancomycin
resistance (Mater et al.; 2005), were cultured on C-ID.
Since Xpert PCR assays can be processed in less than 1h with
minimal hands-on time, results can be provided instantaneously enabling
immediate respective patient management. Unfortunately, the costs for
this PCR are about 6fold higher than for culture on C-ID agar. On the
other hand culture needs at least 48h to reveal results.
However, as long as vanA/vanB PCR performed with specimens
comprising complex intestinal microbiota is in such an extent unspeciﬁc
for presence of VRE, the beneﬁt for patient management is most
questionable. Although rapid detection of VRE can be of help
under certain circumstances, culture revealing the identiﬁcation of the
speciﬁc microorganism is still of advantage, particularly in case of
VRE screening with potentially transferable resistance genes such as
vanA/vanB.
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P1792 Automating the bacteriology laboratory
N. Bentley* (Cambridge, UK)
Objectives: Bacteriology laboratories historically have seen limited
automation with much restricted to separate modules (e.g. blood cultures,
urine microscopy) with scientiﬁc staff performing tasks associated with
manual operations, e.g ﬁnding and carrying culture plates and loading
incubators. Our laboratory has implemented total system automation
using of Kiestra Lab Automation®. This has facilitated a paradigm
shift in working practice enabling a focus on the patient rather than
the process. The system has been in place for over a year and beneﬁts
are described.
Methods: The system covers 210 m2 and comprises automatic plate
selection, bar-coding, incubation and digital imaging, 8 bench work-
stations, a plate transport track, and management software. Plates are
read as images on high resolution screens, individual colonies are
digitally marked to direct future work by lower-grade staff. Incubation
times are standardised, and quality management is facilitated by bar-
coding, automated batch recording, and image storage. Working practices
have been modernised to enable effective use of the system.
Results: Installation took 14 days with the extensive vocational training.
Minor discrepancies observed during comparison of traditional and
automated systems were resolved by image adjustments and increased
staff experience. All sample types except urine utilise the system. After
installation mean turn-around-times for MRSA screens fell from 30 to
22h, with daily analysis (mean 300 samples) reducing to 0.5h compared
with 1.5h previously. A year on, the system enables further reduction in
bench reading times, allows quick negative authorisations and automatic
zone reading for antibiotic susceptibility. Assessments in the 3rd and
52nd weeks of operation show 7535 and 9848 plates were used for 3782
and 5186 samples, respectively; the mean time between failures rose
from 6.2h to 7.5h.
Conclusion: A linked modular automation system allows experienced
staff to focus on productive tasks and move away from traditional
working practice. Allowing the laboratory to move away from “batch
analysis” to patient centred bacteriology, facilitates 24/7 working, enables
predictable turn-around-times and provides extensive quality metrics.
Automation has enabled the laboratory to re-skill the workforce and
reduce the headcount by 5 scientists while workload has increased by 4%.
Furthermore, Kiestra will enable planned future laboratory consolidation
to one site.
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P1793 Experience with KIESTRA’s Total Lab Automation solution
to meet the challenge of universal MRSA screening for
Lister Hospital, a large UK district general hospital
G. Humphrey, C. Malone, H. Gough, F.M. Awadel-Kariem* (Stevenage,
UK)
Objectives: The Microbiology Department at the Lister Hospital
introduced KIESTRA’s Total Lab Automation solution “It’s The Sample
That Moves!”. This study was designed to assess the impact on
productivity. Furthermore, the UK Department of Health has set all UK
hospitals a target to screen all elective admission patients for MRSA
carriage by March 2009, and all patients by March 2012. To meet these
targets there is a need to increase capacity and to provide a rapid,
cost effective screening method. The second objective of this study
was to look at KIESTRA’s role, and the role of the Vision Toolbox
in conjunction with KIESTRA, to address this need.
Methods: The Laboratory productivity index (LPI) was used to assess
productivity before and after the implementation of KIESTRA in June
2008. To enable a major change in working practice, the ﬁrst step was
to ask the consultant staff to agree on a set of base line algorithms,
thus deﬁning what the departments product is. It also meant that the
scientist could concentrate their professionalism on the small number
of isolates that fell outside the predicted algorithms. In June 2009, the
use of Vision Toolbox in conjunction with KIESTRA was examined to
address the second objective.
Results: The Laboratory productivity index (LPI) has improved from
24.7 to 63.9, an increase by a factor of 2.6. This has been achieved by
altering working practices so as to enable the automation to work at its
most efﬁcient level. This improvement was achieved by: a) halving the
time taken to culture plates; b) developing a productive process where a
team reads, picks, tests and carries out susceptibility tests in a seamless
process; c) since 2006, absorbing 70% more work into the work stream
with 21% less staff; d.) implementing novel time-management processes
to maximise productivity.
For the second objective, a validation trial of the Vision Toolbox against
324 positive samples and 240 negative ones resulted in accurate results
with high sensitivity and speciﬁcity. It obviated the need for manual
reading with added savings in speed and productivity.
Conclusions: The implementation of KIESTRA has resulted in measur-
able productivity improvements. Using Vision Toolbox in conjunction
with KIESTRA has demonstrated signiﬁcant promise in meeting the
imminent challenge of universal MRSA screening.
P1794 Design of a new microbiology laboratory based on Lean Six
Sigma principles
J.P. Brochet*, J.M. Cassorla, H. Palumbo (Le Haillan, Lyon, FR)
Objectives: In an already weakened economy, microbiology laboratories
are under increased pressure to provide the highest quality patient test
results.
In this context, our laboratory had to consolidate the activity of 22
peripheral labs into one single platform. This challenge meant a new
structure, had to be built its architecture and ensure integrated current
and new automated solutions. In this competitive landscape, decreasing
turn around time to deliver results to physicians is also a critical success
factor to ensure better patient management. This is why we set up a
project to apply Lean/Sigma principles to our microbiology lab.
Methods: Lean and Six Sigma are the two most powerful strategies for
achieving operational and service excellence in any organization today.
The project started by observing the laboratory in its current state −
the physical layout and how samples were processed. The roadmap
obtained outlined how the lab could improve processes to reduce waste
and enhance efﬁciency, while simultaneously increasing results quality
and reducing errors.
The Lean Lab assessment was been managed by a Lean Engineer and
a Microbiology Application Specialist in two main phases. The ﬁrst
phase was performed in March 2008 to provide recommendations and
the second in November 2010 to assess how the lab was successful in
implementing them.
Results: The new microbiology laboratory was built with a surface of
177m2 (former lab 60m2). The improvements enabled the management
of 1385 specimen (an increase of +185% in terms of activity.
Productivity was increased by 138% with 6.6 patients managed per
working hour (productivity was previously 2.77 patients).
The time dedicated to quality management has been increased by more
than eight times between March 2008 and November 2010 (1.5h to
12.5h). This enabled staff to focus on lab accreditation. Turn around
time for urine specimens, which represents 67% of the total number of
specimens, was decreased by 21% (providing a +2% increase of positive
samples).
These ﬁgures were achieved by integrating UF 1000i, PREVI™ Color
Gram, PREVI™ Isola, VITEK 2 and automatic patient data capture.
Conclusion: The workﬂow of the entire Microbiology lab has
been greatly improved through the newly optimized organization by
matching workload/capacity (specimen processed/resources required).
These improvements enabled the lab to prepare for the accreditation
process and be able to handle an increased workload in the near future.
P1795 Efﬁciency of an automated streaking system for
bacteriological diagnostics
J. Knobloch* (Lu¨beck, DE)
Objectives: The increasing economic pressure in microbiologic labora-
tories results in the need for increased automation. The automation of
microbiological techniques can help to focus the personnel capacities
on core duties. Therefore, the PREVI™ Isola automated plate streaking
system was evaluated for its efﬁciency and quality in the processing of
urine and stool specimen.
Methods: Manual streaking was compared to streaking using the
PREVI™ Isola system for 500 urine and 250 stool specimen. 10 ml of
the urine sample as well as 10ml of a 1:100 diluted urine was manually
streaked on agar plates. For PREVI™ Isola streaking the original urine
containers were placed in the system. For stool specimen the volume of
suspension media (NaCl solution) was adapted to 1.5mL to avoid strong
dilution effects for watery stool specimen and about 0.2 g or 200mL
were resuspended and placed in the automated system. Agar plates
were incubated for 18 to 24 h and the streaking results were compared.
Additionally, the time needed for manual and automated streaking was
measured for representative batches of the respective specimen.
Results: The quality of automated streaking was highly reproducible
with a good separation of single standing colonies in a range of 102 to
107 cfu per mL. Streaking quality was equal in 78.0% for urine specimen
and 75.6% for stool specimen. A superior result using the automated
streaking procedure was observed in 16.0% for urines and 5.2% for stool
specimen. Superior results for manual streaking were observed for 6.0%
of urines and 19.2% of stool specimen. Superior results of the manual
method were observed in stool specimen with a tenacious consistency.
In watery stool specimen the sensitivity was reduced due to the dilution
for few probes. The average hand-on-time was reduced from 84 s to 21
s per probe for urine specimen and from 91 s to 61 s for stool specimen,
respectively.
Conclusions: Automated streaking decreased hand-on-times signiﬁ-
cantly for both urine and stool specimen. Standardization of the streaking
procedure resulted in a higher streaking quality for urine specimen and
an almost comparable streaking quality for stool specimen, indicating
that automated streaking is able to reduce personnel cost together with
an increased or at least equal quality. For stool specimen with tenacious
consistency the manual streaking procedure should be used to avoid
minor streaking quality.
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P1796 Lean Six Sigma methods as a core asset of the microbiology
lab
J.M. Rousee*, T. Gueudet, C. Rieder-Monsch, J.M. Cassorla,
H. Palumbo (Strasbourg, Montoison, Marcy-L’Etoile, FR)
Objectives: In an already weakened economy, clinical microbiology
laboratories need to reduce cost, to improve productivity, to respond
to accreditation requirement and to provide high-quality results.
In this competitive landscape, decreasing turn around time to deliver
results to physicians is also a critical success factor to ensure better
patient management.
This is why we set up a project to apply Lean/Sigma principles to our
microbiology lab.
Methods: Lean and Six Sigma are the two most powerful strategies for
achieving operational and service excellence in any organization today.
The project started by observing the laboratory in its current state − the
physical layout and how the samples were processed. The roadmap we
obtained outlined how the lab could improve processes to reduce waste
and enhance efﬁciency, while simultaneously increasing quality result
and reducing errors.
The Lean Lab assessment was been managed by a Lean Engineer and
a Microbiology Application Specialist in two main phases. The ﬁrst
phase was performed in November 2008 to provide recommendations
and the second in June 2010 to assess how the lab was successful in
implementing them.
Results: The identiﬁed improvements enabled the management of 1540
specimen by week (+24% of increase in terms of activity). Productivity
was increased by 37% with 3.89 patients managed per working hour
(former productivity was 2.84 patients).
The time dedicated to quality management has been increased per three
fold between the two steps (5h to 15h).
Turn around time for urine and genital specimens, representing 63% of
the total number of specimens, was decreased by 10−11% (providing a
8% increase of positive samples for urine and 5% for genital swabs).
These ﬁgures were achieved by integrating UF 1000i urine cell
analyzer and PREVI™ Isola automated plate streaker in our lab. The
challenge was to manage an increased workload (+24%) inside the same
Microbiology laboratory that had only been extended by few square
meters (30m2).
Conclusion: The workﬂow of our Microbiology lab has been greatly
improved, 90% of the daily issues have been solved. Processes
standardization and training program for skilled technicians were also
two main outcomes. Being more focused on microbiology expertise
helped to manage more analyses with added value and to save time.
P1797 Is liquid microbiology by the WASP® reliable?
M.E. Bierma*, J.M. van Bree, M.J. van de Ven, T.C. Liebregts,
N.L. Arents (Veldhoven, NL)
Objectives: The ESwab® and UriSwab® have been proven to be reliable
specimen collection systems. Liquid specimen collection systems give
the opportunity for automation in medical microbiology. In this study
we evaluated the reliability of the Walk Away Specimen Processor
(WASP)® (COPAN, Italia) by studying the endpoint: amount of growth
and different species detected.
Methods: Randomly selected urine samples and ESwab samples
received by our laboratory from clinical patients were processed
manually and by the WASP. From urine samples 10 mcl was
inoculated on a bloodagar plate containing colistin and aztreonam
and a chromogenic medium (CPS3 agar; bioMerieux; France) by both
methods. After inoculation streaking was done using the the same
streakingpattern. The swabs of the ESwabs were manually plated on a
subset of culturemedia and streaked in 4 quadrants. The WASP used 30
mcl liquid medium of the ESwab to inoculate the plates and also streaked
this in 4 quadrants. The subset of culture for the ESwabs depended on
the origin of the specimen but was always the same for both the manual
and the WASP method. After overnight incubation grown colonies were
counted and identiﬁed according to conventional methods.
Results: In total 218 urine samples and 79 ESwab samples (19 vaginal
swabs; 17 throat swabs; 14 wound swabs; 14 rectal swabs; 5 ear swabs;
4 fecal swabs; 2 cervical swabs; 2 nose swabs; 2 abscess swabs) were
included in the study. Table 1 shows the methods compared to each
other in terms of species grown and their amount of growth. Most
discrepancies [33/47 (70%)] were encountered in urine samples.
Conclusion: The WASP is capable of fully automatically inoculating
liquid specimen and produces more frequently a higher amount and/or
additional species as compared to standard manual procedures.
P1798 Automation in routine bacteriology − experience with the
WASP inoculation robot
O. Nolte*, H. Haag, M. Kommerell, S. Brunner-Zillikens (Constance,
DE)
Objective: Our laboratory is a privately owned laboratory with an
average of ~100 specimens for bacteriologic examinations, daily.
Workﬂow, cost effectiveness and daily sample size are highly different
from academic or tertiary hospital centres. To optimize workﬂow and
save hands-on-time, we introduced an automated inoculation device.
Being the ﬁrst laboratory in Germany, we got the WASP (Walk Away
Specimen Processor, Copan, Italy) installed in Sept. 2010. After three
month of operation we were able to rate the beneﬁt of automation in our
laboratory.
Methods: Using the WASP, urines (in Sarstedt Monovettes), stool and
swabs were inoculated and streaked automatically. The majority of
specimens, however, are not yet delivered as eSwabs but as conventional
swabs or specimen containers. These were transferred to empty tubes,
preﬁlled with physiologic saline, upon reception. All materials were
streaked by WASP according to speciﬁed protocols already established
in our routine diagnostics.
Results: LIS-connected WASP was ready for accepting routine samples
for method veriﬁcation immediately after installation. Transfer of our
speciﬁc streaking protocols to the WASP was laborious (manual typing)
but easy. Although eSwabs have been proven to be better than standard
swabs in a couple of independent studies, senders are not fully organised
yet to use eSwabs. Therefore, still more than 85% of specimens (with
the exception of urines) have to be transferred to pre-ﬁlled tubes prior to
inoculation by WASP. All specimen-types were accepted and automated
streaking was in general much better than manual streaking (i.e. clearly
distinguishable single colonies [4 quadrant streaking pattern] even from
stool, virtually no need for repeated inoculation). Following method
veriﬁcation, WASP optimized workﬂow in the order of 1 FTE.
Conclusion: Although our laboratory is comparatively small in terms of
daily sample size, WASP reduced manual workﬂow in the expected order
(time savings due to automated streaking, easier processing of colonies,
elimination of repeated streaking) and eliminated potential sources of
error (printed vs. manual label on each plate). Our example shows that
even smaller sized laboratories may effectively use and beneﬁt from
automation in the bacteriology lab. For optimal use of instruments like
WASP, liquid-based microbiology needs to be more widely implemented.
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P1799 Use of a sputum dipper and sputum liquifying solution
to process sputum specimens prior to inoculation with the
Copan WASP instrument
P. Bourbeau*, F. Tomashefski, M. Tomcavage, R. Wywadis (Danville, US)
Objectives: Sputum and trach aspirate (SP/TA) specimens are not very
amenable to automated planting instruments due to the viscous nature
of the specimens, which can also make it difﬁcult to obtain reproducible
results with manual planting methods. We have previously shown
that, using a new pre-packaged mucolytic agent, Sputum Liquifying
Solution (SLS) (Copan), SP/TA specimens can be prepared (liquiﬁed)
for processing on the Copan WASP instrument. When 1ml of SP/TA
specimen was combined with 1ml of SLS and plated with a 30 ul loop
on the WASP, culture results were comparable to manually plated SP/TA
specimens. To better facilitate the transfer of SP/TA specimens to tubes
of SLS solution, Copan has developed a corkscrew shaped disposable
Sputum Dipper (SD). This study evaluated the utility of the SD for use
with SLS.
Methods: In a pilot study, we determined that the SD picks up about
400 ul of SP/TA specimens, suggesting that using the SD with 0.5ml
of SLS should produce comparable cultures results to what we obtained
using 1ml of SP/TA specimen combined with 1ml of SLS (maintaining
~1:1 ratio of specimen to SLS). In this study we compared the results of
SP/TA specimens processed in 2 different ways with all specimens plated
with the WASP to BAP, Choc, and Mac plates. One set of plates was
inoculated from a 1-ml SLS tube to which 1-ml of purulent specimen was
added using a 1-ml syringe. The second set of plates was inoculated from
a 0.5-ml SLS tube to which SP/TA was added with an SD. The WASP
utilized a 30ul loop with the same streaking pattern for all specimens.
Results: Results were sorted into 4 groups: no growth (NG), pharyngeal
ﬂora (PF), yeast, and potential pathogens (PP). Each result was semi-
quantitated as no growth, few, moderate or many colonies. From a total
of 168 specimens tested, there were 218 results. The same qualitative
result was obtained for 216/218 results (11 NG; 118 PF; 16 yeast;
and 71 PP). Of the 216 results in qualitative agreement, 202 had the
same quantitation. 2 results from 2 specimens had moderate B strep x.
group A on the specimen processed with the syringe and no growth on
the specimen processed with the SD.
Conclusions: The Copan Sputum Dipper is a very effective transfer
device which, when used with SLS, facilitates processing of SP/TA
specimens on the WASP, producing accurate, reproducible test results.
SD/SLS processing is an acceptable alternative to manual planting and
offers the beneﬁts of automation.
P1800 WASP, a Walk Away Specimen Processor enables accuracy
and cost beneﬁts managing multiple specimens on a single
culture plate
G. Catalano*, M. Savarese, R. Botrugno, S. Castriciano (Brescia, IT)
Objectives:Microbiology laboratories are burden with high costs to pro-
cess numerous samples for the identiﬁcation of colonized patients with
methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-
resistant enterococci (VRE) and extended spectrum b lactamase bacteria
(ESBL) to prevent nosocomial infections. Automation in microbiology is
essential for handling the many samples and new strategies are necessary
for reducing chomogenic plates and staff time costs. Copan, in the last
2 years, introduced a fully automated Walk Away Specimen Processor
(WASP) for bacteriology analysis. The objectives of this study are
to validate the unique WASP feature to inoculate, streak and label 2
different samples on the same agar plate 1) without cross-contamination
2) without labeling or specimen transposition errors and to 3) calculate
the cost saving.
Study method: Simulated 1.0 McF ESwab positive (ESP) samples
prepared with E. coli, H. inﬂuenzae MRSA, MSSA and VRE and ESwab
negative (ESN) samples were used. A 10ul inoculation loop and inverted
“Christmas tree” streaking pattern were used in the WASP protocol. First,
500 of each sample type were loaded on the WASP to have an ESP
and an ESN on the same plate. After, all ESN and ESP samples were
randomly loaded to simulate real life processing conditions and the Two
Specimens per Plate Protocol was selected. All plates were incubated at
35C for 24 hrs; labeling errors and cross-contamination were monitored.
Materials cost saving was calculated.
Results: In the ﬁrst 500 plates inoculated with ESN and ESP samples
all labels were placed on the correct side of the plate and all the positive
cultures corresponded to the ESP sample label and all negative cultures
corresponded to the ESN sample label on the plate.
No cross-contamination was found in all the 500 12 plates inoculated
with ESN and in the 12 plate inoculated with ESP samples; no cross-
contamination was found in the 500 randomized samples inoculated on
the same plate. 1000 plates were used to culture 2000 samples, at a cost
of 1.5€ per plate resulting in 1500€ savings in plates only, the actual
staff savings depends on each institution.
Conclusions: It was demonstrated that the WASP can reliably and
accurately inoculate 2 samples on the same plate without errors and
provide a 50% cost saving for materials as well as reduced staff time. The
ability of inoculating 2 samples on the same plate can be implemented
for screening MRSA, VRE or ESBL colonized patients.
P1801 Reproducibility and quality of the InoqulA
M. Kleefstra*, C. Visser, M. van der Kaap (Drachten, Amsterdam, NL)
Objectives: Quantiﬁcation of bacterial cultures is necessary to be able
to interpret culture results. Clinical relevance of these cultures is often
based on the amount of growth. Therefore, ﬁrst inoculation of clinical
samples needs to be standardized and reproducible. Furthermore, the
yield of single colonies in mixed cultures is essential to perform further
testing for identiﬁcation and AST. A novel inoculation method was
introduced by Kiestra Lab Automation (the Netherlands). Inoculation
with the automated InoqulA is based on bacterial spreading through a
magnetic bead instead of an inoculation loop or similar device. The
objective of this study was to determine the reproducibility and quality
of this novel principle.
Methods: Three known bacterial species (E. coli, Klebsiella pneumoniae
and Staphylococcus aureus) were used in different combinations and
different dilutions (table 1). These 9 samples were inoculated in 15
fold on CPS3 chromogenic agars (bioMerieux) with the InoqulA (10
microl/plate). Subsequently, the 9 different samples were inoculated in
6 fold on CPS3 chromogenic agars with the InoqulA and manually. By
using Vision Technology Software the percentage of growth on an agar
plate was determined. The bacterial species which were used all have a
distinctive appearance on the CPS3 agar (E. coli is pink, K. pneumoniae
is green and S. aureus is whitish). Because of this it is easy to determine
whether single colonies are present.
Results: The ﬁrst 3 (1−3) samples (0.5 McFarland) all showed 95%
conﬂuent growth and single colonies (sc) after 25mm of spreading,
the second 3 (4−6) samples showed 75% conﬂuent growth and sc after
15.8mm and the last 3 (7−9) samples showed 50% conﬂuent growth
and sc after 18.6mm. The range of distribution (RD) was less than 10%
in the InoqulA, whereas the RD in the manually inoculated samples
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was 50%. Distinct single colonies were observed less in the manually
inoculated samples compared to the automated inoculated samples.
Conclusion: The InoqulA is able to perform reproducible, high quality
ﬁrst inoculation results compared to manually inoculation. Multiple
inoculations with the InoqulA of the same samples showed less than
10% variation. Sc were observed in all samples, but less in the manually
inoculated samples. Based on the percentage of conﬂuent growth and the
distance to the appearance of sc the amount of growth can be deduced.
P1802 Evaluation of the UriSwab® as a tool to diagnose urinary
tract infections
N.L. Arents*, U. Bayir, M. Fo¨rster, A.R. Jansz (Veldhoven, NL)
Objectives: Getting patients to collect a reliable urine specimen is a
challenge. Filling the test tube without contaminating the inside with
bacteria or the outside with urine is a well known problem. Recently the
UriSwab® (COPAN, Italia;US) became available and is claimed to be
more practical to use and thus may increase the reliability of the sample.
While urinating, two sponges on an applicator are inserted in the stream
and absorb exactly 1200 mcl of urine. The sponges retain the ﬂuid during
transport preventing the sample from leakage and bacterial overgrowth.
In this study we investigated the reliability of the US considering the
species grown, their amount of growth and the presence of squamous
and bladder cells.
Methods: In the ﬁrst part of the study urine samples were collected by
US and sterile container from clinical patients during a single miction
episode. The container and the US (after centrifugation) were both
processed immidiately by inoculating a tri-plate containing bloodagar,
McConkey agar and Streptococci selective agar with 10 mcl of urine.
After 24 hours storage at roomtemperature (representing transport time)
both collection systems were again processed in the aforementioned way.
Grown colonies were identiﬁed by standard methods. In the second part
of the study, employees of our laboratory were asked to collect a urine
sample by US and sterile container directly at awakening before they
washed themselves. Both samples were processed by Gram staining and
the presence of squamous and bladder cells was scored by standardized
methods (ranging from absent to 4+). A difference of at least 2+ was
considered relevant.
Results: Table 1 shows the result for the ﬁrst study. The second study
showed the absence of squamous cells in both samples in 59 cases,
identical presence of squamous cells in 38 cases, at least 2+ or more
squamous cells in the container sample in 3 cases and at least 2+ or
more squamous cells in the UriSwab sample in 0 cases. Bladder cells
were not observed in any sample.
Conclusion: The number of species, their amount of growth and the
presence of squamous cells did not differ signiﬁcantly between the
UriSwab and container method independent of the time of processing
indicating that the UriSwab may be used as a reliable alternative.
P1803 The utilisation of the bacterial mode on UF 1000i for the
screening of urine samples submitted to a microbiology
laboratory for culture
J. Jurankova*, J. Protivinsky (Brno, CZ)
Objectives: The UF1000i urine analyser (Sysmex) is routinely
utilized for microscopic examination of the urine sediment in clinical
biochemistry laboratories. Our aim was to evaluate a suitability of UF
1000i bacterial mode for a pre-culture urine screening in a clinical
microbiology practice and to assess the system reliability during a fast
diagnostics of urine track infection (UTI).
Methods: In our study, 1162 fresh urine samples were collected. These
samples were simultaneously run on the UF 1000i and inoculated onto
blood agar and MacConkey agar plates and incubated at 37ºC from
18 to 24 hours. Results were then compared with respect to the UTI
ﬂag presence generated by the analyzer. To more precisely interpret
the results, diagnosis, clinical ﬁndings of UTI, antibiotic administration,
changes in blood count, concentration of C-reactive protein (CRP), and
the presence of the other originator of the UTI such as Ureaplasma
urealyticum, Mycoplasma hominis were considered.
Results: Of all samples, with the cut-off values of UTI set to 10 white
blood cells/ml and 100 bacteria/ml, 91.3% were correctly evaluated by the
UF 1000i, falsely positive samples were found in 8.2% while the total
percentage of falsely negative samples was 0.5%. After implementation
of the UF 1000i into our workﬂow, the number of true positive samples
increased by 10% as compared to the simple culture results. It was
found that as many as 53% of all samples submitted to the microbiology
laboratory were unnecessarily examined since UTI was ruled out by
using the UF 1000i. The system sensitivity and speciﬁcity were 97%
and 95% respectively. The UF 1000i positive predictive value of the
UTI was 82.6% while negative predictive value was 99%.
Conclusion: The UF 1000i has proved to be a suitable tool for pre-
culture urine screening in a clinical microbiology laboratory practise.
All results, gained by the UF 1000i, possess a high negative predictive
value whereby a presence of UTI can be easily excluded and thus, a
reduction in hospitalization of patients, rational antibiotic administration
can be applied leading to the faster diagnostics and a ﬁnancial beneﬁt
for health care providers.
P1804 Automated microscope and ﬂow cytometer to screen
bacteriuria: a comparison
M. Trevino*, P. Areses-Elizalde, D. Navarro, D. Pen˜alver-Barral,
A. Garcı´a-Zabarte, C. Garcı´a-Riestra (Santiago de Compostela, ES)
Objectives: There is strong recommendation to use automated methods
as a screening tool for detect negative urine samples of patients, except
children, pregnant woman and immune-compromised. We evaluated two
automated screening test for urinary tract infections (UTI).
Material and methods. A total of 500 urine specimens from outpatients
were selected for the study. All urine samples were analyzed, in
parallel, with the Sysmex UF1000i (BioMe´rieux), Iris Diagnostics
iQ200 (Izasa) and bacterial culture, the latter considered the gold
standard. Before testing urine samples each day, positive and negative
controls were running in the automated systems according to the
manufacturer’s instruction. The cut-off values used were 140 bacteria/
microliter (UF1000i) and 2,800 small particles/microliter (iQ200).
Results: Sensitivity (S), speciﬁcity (Sp), positive predictive value (PPV)
and negative predictive value (NPV) found are listed in the table. We
found major discrepancies (positive samples detect as negative) in 14
cases with iQ200 and 6 cases with UF 1000i.
Conclusions: The two methods were acceptable to use as screening test.
We found a higher S and NPV with UF1000i. Although labour and
S524 21st ECCMID/27th ICC, Posters
time are saved with the screening methods, like iQ200 and UF1000i, we
need clinical judgment (to combine different indicators of infection) and
interpretation. National and European guidelines are needed.
P1805 Comparison between UF-1000i (Sysmex) ﬂow cytometer and
bacterial culture in rapid diagnosis of urinary tract infection
I. Caola*, P. Lanzafame, R. Predazzer, A. Amari, A. Rigoni (Trento, IT)
Objectives: In order to assess the analytical performances of UF-1000i
cytometer (Sysmex) in rapid diagnosis of urinary tract infections (UTIs),
we conducted a study to select a suitable cut-off value for bacteria and
leukocytes.
Methods: A total of 948 consecutive urine samples were tested in
parallel by UF-1000i and routine culture (gold standard for the diagnosis
of UTIs). Urine samples were from hospital and general practice patients
and were representative of all age groups. CFU quantiﬁcation was
performed on TSA+5%SB using standard 1 mL loops and incubating
plates overnight at 37ºC in air. In UF1000i system, cells in the urine were
stained with ﬂuorescent dyes for membranes and/or DNA. The combined
analysis of scattered light and ﬂuorescence allowed the identiﬁcation and
quantiﬁcation of particles as leukocytes, bacteria and yeast-like cells.
Results: Cultures were considered positive with 103CFU/mL. UF-
1000i results were considered positive at cut-off values of 70BACT/mL
and of 100WBC/mL. On this basis of the 948 urine samples, 38% of
the cytometer results were true positive, 47,5% true negative, 12.0%
false positive and 2,95% false negative. 12 false negative results were
from potentially neutropenic patients (from haematology/oncology, renal
transplant wards). Excluding this group of patients, whose urine samples
are routinely cultured, cytometer false negative results lowered to1,8%.
The system performed with a sensitivity of 95,5%, a speciﬁcity of 79,9%,
a NPV of 96,4%, a PPV of 75,9%.
Conclusions: UF-1000i (Sysmex) was useful in ruling out UTIs, with
an acceptable amount of false negative results when cut-off values for
WBC and bacteria are properly settled. False positive results depend
on cytometric detection of viable and dead bacteria. Rapid counting of
leukocytes and bacteria improved turnaround time of negative results
and laboratory workload.
P1806 Screening for urinary tract infection in children: evaluation
of diagnostic performance and optimal cut-off for Sysmex
UF1000i ﬂow cytometer
R. De Rosa*, S. Grosso, M. Avolio, M. Modolo, P. Stano, A. Camporese
(Pordenone, IT)
Objectives: The diagnosis of urinary tract infection (UTI) in pediatric
patients is challenging because the clinical presentation is often not
speciﬁc and the gold standard test, urine culture, does not supplie
same-day results. A lot of studies in adult population evaluated the
performance of ﬂow cytometer for detection of bacteriuria and now this
instrumentation is admitted in the routine of many laboratories, providing
results in a few minutes. We aimed to evaluate analytical performance
and optimal cut off value of Sysmex UF 1000i for bacteria counting by
comparing culture, to guide early diagnosis and treatment of UTI in a
pediatric population.
Methods: Sysmex UF1000i (Sysmex Co. Japan), a ﬂuorescence ﬂow
cytometer intended for urinalysis purpose, has a speciﬁc analitical
channel for bacteria counting. 350 samples were obtained from children
up of 10 years (212 female, 138 male; 124 in- and 226 out-patients)
from clean catch midstream urine or, from 94 infant younger than one
year, by a sterile collection bag or urethral catheterization. Samples
were examined by Sysmex UF1000i and cultured onto CLED and
CNA agar plates (Kima, Padua, Italy) by means of 10 uL loop. The
results of UF1000i analysis for each sample were compared with urine
culture results, considered positive as106 CFB/L (corresponding to 103
CFU/mL), and the instrumental performance evaluated using receiver
operating characteristic (ROC) analysis.
Results: 202 samples were negative at bacterial culture (57,7%) and 148
were positive (42,3%). Different cut off values for instrumental bacteria
count were considered. At a bacteria count >10/uL UF1000i results were:
true positives 146 (41,7%); true negatives 104 (29,7%); false negatives 2
(1,3% of all positive samples); false positives 97 (27,7%). In this setting
we obtained a sensitivity of 98.6%, a speciﬁcity of 51,7%, with a area
under the curve = 0,956, a negative predictive value of 98,1% and a
positive predictive value of 60%.
Conclusion: The obtained results indicate that Sysmex UF1000i is a
valid method for ruling out samples do not need to be cultured. In our
experience cut off points for bacteria count in children up to 10 years
differed remarkably from those of adult population, so that the threshold
for signiﬁcant counts should be selected on age basis. Moreover at the
above mentioned point of bact count, leucocytes count didn’t improve
the screening of culture positive samples.
P1807 Evaluation of automated microbiology identiﬁcation
systems: comparison of the Sensititre Aris® and Vitek® 2
when testing Gram-positive and -negative pathogens
S. Swoboda, B. Olson, T. Novicki, S. Shukla, J. Meece, T. Fritsche*
(Marshﬁeld, US)
Objectives: To evaluate the accuracy of Gram-positive and −negative
bacterial identiﬁcations using commercial automated systems includ-
ing the Sensititre ARIS® (Trek Diagnostic Systems) and Vitek®
2 (bioMerieux) compared with existing identiﬁcation algorithms.
Automated systems have been shown to have variable failure rates
requiring periodic re-evaluation of contemporary isolates to assure
continued performance. Correct pathogen identiﬁcations are mandatory
for diagnostic, prognostic and therapeutic purposes.
Methods: Clinically signiﬁcant challenge pathogens (404 total) from
patients attending a large regional medical centre were collected
prospectively in 2010 and included staphylococci (108), enterococci (40),
streptococci (13), Enterobacteriaceae (136), Pseudomonas aeruginosa
(59) and other non-fermentative bacilli (48). Isolates were tested
according to the manufacturers’ recommendations using Sensititre®
GPID and GNID, and Vitek® 2 GP and GN identiﬁcation panels;
results were compared with existing laboratory biochemical algorithms,
including use of the Phoenix® PID and NID panels. Consensus was
deﬁned as all 3 systems providing matching results. Any system result
discrepant from the other 2 were considered erroneous, and alternative
testing methods were used for adjudication.
Results: This evaluation generated a total of 1,212 identiﬁcations
between the current laboratory testing algorithm and the automated
systems. Overall, 95.3% and 88.9% of Vitek 2 identiﬁcations were
correct at genus and species levels, respectively, for this challenge
set compared with 91.3% and 81.4% for Sensititre. Both systems
provided acceptable (90%) species-level identiﬁcations for E. coli,
Klebsiella, group B streptococci and Enterococcus spp. but performed
less well for other Enterobacteriaceae, other non-fermentative bacilli
and other staphylococcal species. Sensititre was inferior in identifying
P. aeruginosa (79.7% at the species level) compared with Vitek 2 (100%).
Results for the two assay systems are in the Table.
Conclusions: Both the Sensititre® and Vitek® 2 systems produced a
high level of accurate identiﬁcation at the genus level (91.3% and
95.3%, respectively) but less well at the species level (81.4% and
88.9%). In particular certain Enterobacteriaceae, non-fermentative bacilli
and staphylococci other than S. aureus were found to be problematic.
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Limitations with each system were apparent and require consideration
with implementation.
P1808 Efﬁciency of an automated Gram-staining system for
bacteriological diagnostics
J. Knobloch* (Lu¨beck, DE)
Objectives: Automation of time consuming manual procedures in
bacteriological laboratories can help to focus the personnel capacities
on core duties. Therefore, the PREVI™ Color automated Gram-staining
system was evaluated for its efﬁciency and quality in processing of slides
inoculated with a wide variety of clinical specimen as well as pure
bacterial cultures.
Methods: Manual Gram-staining was compared to automated staining
using the PREVI™ Color system for 700 slides from different specimen
(BAL n= 50, genital swabs n = 98, sputum n= 100, Stool n = 100, urine
n = 151, wound swabs n = 151, and pure bacterial cultures n = 50). For
the manual staining slides were heat ﬁxated and stained by the classical
Gram-staining procedure. For automated staining ﬁxation of the slides as
well as staining was performed within the PREVI™ Color system. The
staining method was blinded prior microscopy. Additionally, the hand-
on-time needed for manual and automated staining was measured for
representative batches of slides.
Results: The quality of automated Gram-staining was interpreted by
microscopy of slides blinded for the staining method. The overall staining
quality was equal in 71.3%. A superior result using the automated system
was observed in 21.1% and for manual staining 7.6%. For complex
specimen (genital swabs, sputum, stool, and wound swabs) signiﬁcant
differences were observed with only 59.2% equal results and superior
results in 29,8% for automated staining and 11.0% for manual staining.
Minor differences were observed in specimen with low complexity
(BAL, urines, and pure bacterial cultures) with 87.4% equal results and
superior results in 9,6% and 3.0% for automated and manual staining,
respectively. The average hand-on-time was reduced by 34%.
Conclusions: Automated Gram-staining decreased hand-on-times sig-
niﬁcantly. Standardization of the staining procedure resulted mainly in
higher or equal staining quality for all specimen, indicating that the
introduction of automated Gram-staining is able to reduce personnel cost
together with an increased or at least equal quality of staining results.
P1809 Evaluation of the Vitek2 ANC card for the identiﬁcation
of clinical isolates of anaerobic bacteria
E.H. Lee*, J. Degener, G.W. Welling, A. Veloo (Groningen, NL)
Objectives: The aim of this study is to compare the accuracy of the
VITEK 2 ANC card (bioMe´rieux, Marcy l’Etoile, France) with 16S
rRNA gene sequencing for identiﬁcation of anaerobic species.
Methods: An evaluation of the VITEK 2 ANC card was performed with
301 anaerobic isolates, including 100 species that were not contained in
the database. Each strain was identiﬁed by 16S rRNA gene sequencing,
which was considered to be the reference method. Inocula were made
from subcultures grown for 24 to 48h on BBA agar. Cells were suspended
in 0.45% NaCl, pH 5.7, and adjusted to a McFarland number 2.7 to 3.3
using a calibrated VITEK® 2 DENSICHEK (bioMe´rieux, Marcy l’Etoile,
France).
Results: Of the 301 isolates, 79.4% (239/301) and 60.1% (181/301)
were correctly identiﬁed to the genus and species level respectively.
Of the 201 isolates species which are included in the database, correct
genus and species identiﬁcation were obtained for 95.6% (192/201) and
90.0% (181/201). For the 100 isolates unclaimed at the species level,
47.0% (47/100) gave correct identiﬁcation to the genus level and 16.0%
(16/100) were accurately designated as not identiﬁed. Strains which were
difﬁcult to characterize to the species level using current phenotypic
methods, were misidentiﬁed by VITEK 2 ANC card. For example,
Peptoniphilus harei and Peptoniphilus asaccharolyticus, Fusobacterium
nucleatum and Fusobacterium naviforme, Prevotella nigrescens and
Prevotella intermedia cannot be easily distinguished from each other.
Conclusions: The VITEK 2 ANC card allows rapid identiﬁcation of
anaerobic bacteria within 6h. This system is an acceptable method for
identiﬁcation of those species which are included in the database.
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P1810 The small resistance plasmid p9123 is widespread among
enteric pathogens and enhances their ﬁtness
C.S. Wong, L.M. Hall, V.I. Enne* (Bristol, London, UK)
Objectives: We previously demonstrated the small sulphonamide
and streptomycin resistance plasmid p9123 enhances the ﬁtness of
Escherichia coli K12 JM109 by approximately 5% per generation, even
in the absence of an evolutionary history. Here, we investigated the
ﬁtness impact of the plasmid on other strains of enterobacteriaecae, with
particular emphasis on enteric pathogens.
Methods: BLAST searches were used to identify homologues of p123
to establish the distribution of the plasmid. p9123 was introduced
into selected enteropathogenic bacterial strains by electroporation.
Sulphonamide and streptomycin susceptibility was determined by Etest.
Fitness was estimated by determining the growth rates of strains with
and without p123 in nutrient broth. Statistical analysis was carried out
with the student’s t-test.
Results: An interrogation of Genbank revealed 12 occurrences of p9123
or closely related plasmids. Of these, nine were among isolates of enteric
pathogens such as Shigella spp., Salmonella enterica sv. Choleraesuis
and enterotoxigenic E. coli (ETEC). Some variants encode additional
resistance determinants such as tet(A) or ampC. Acquisition of p9123
by the bacterial strains studied elevated their sulphonamide MICs from
4−48mg/L to >1024mg/L whereas their streptomycin MICS increased
from 3−12mg/L to 32–128mg/L except in the case of Shigella ﬂexneri
M90T which is intrinsically highly resistant to streptomycin due to rpsL
mutation. Fitness results are shown in the table.
Acquisition of p9123 signiﬁcantly improved the ﬁtness of S. ﬂexneri
M90T, whereas in EPEC E2343/69 and S. Typhimurium LT2 the plasmid
had a neutral effect on ﬁtness.
Conclusion: The resistance plasmid p9123 has no detrimental effect
on the ﬁtness of a variety of pathogenic enterobacteriaceae and
confers a ﬁtness beneﬁt in S. ﬂexneri as previously observed in non-
pathogenic E. coli. The widespread distribution of the plasmid among
enterobacteriaceae may hence be due to its ﬁtness neutral and/or
enhancing properties. The spread of a beneﬁcial plasmid s among
pathogens is of concern as it may potentially enhance the spread of
the pathogenic strains themselves.
P1811 Complete sequences of two ’untypable’ plasmids carrying
blaCTX-M-1 group genes
S. Partridge*, J. Ellem, Z. Zong, S. Tetu, I. Paulsen, J. Iredell (Sydney,
AU; Chengdu, CN)
Objectives: A local survey of genes conferring resistance to extended-
spectrum b-lactamases identiﬁed conjugative plasmids that could not
be typed by the commonly-used PCR-based replicon typing scheme
carrying blaCTX-M-15 (pJIE143; from Escherichia coli) or blaCTX-
M-62 (pJIE137; from Klebsiella pneumoniae). blaCTX-M-15 appeared
to be associated with ISEcp1 alone in pJIE143. pJIE137 was found to
carry a class 1 integron with several insertions separated from ISEcp1-
blaCTX-M-62 by a segment that is not closely related to known plasmids.
The aim of this study was to completely sequence pJIE143 and pJIE137.
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Methods: Transconjugants carrying pJIE143 or pJIE137 were subjected
to S1 nuclease/pulse-ﬁeld gel electrophoresis to conﬁrm that only one
plasmid species was present and for size estimation. Plasmid DNA was
extracted from transconjugants, treated with Plasmid Safe DNAse to
remove chromosomal contamination and ampliﬁed using Genomiphi.
Puriﬁed DNA was tagged with molecular barcodes and pooled with other
plasmids for emulsion PCR and Roche 454 Titanium pyrosequencing.
Data for each plasmid were separated bioinformatically, sequences were
partially assembled using the Newbler software provided and PCR was
used to complete assembly.
Results: pJIE143 produced a single >34 kb contig with 180x coverage
that could be assembled as a circular molecule with the usual 3
kb ISEcp1-blaCTX-M-15 transposition unit inserted in the plasmid
backbone, ﬂanked by direct repeats. The whole backbone sequence is
~99% identical to pBS512_33 from Shigella boydii, which carries no
known resistance genes and has a pir-type replicon, and also to pCROD2
from Citrobacter rodentium. pJIE137 produced a 37 kb contig (128x
coverage) that corresponded to most of the plasmid backbone and six
shorter contigs (0.5−9 kb, >50x coverage) that corresponded to parts of
the previously mapped resistance regions containing several repeats. All
seven contigs were assembled into a single 58 kb circular molecule and
parts of the pJIE137 backbone were found to be related (~70% identical)
to IncN plasmids.
Conclusions: pJIE143 illustrates that ISEcp1-blaCTX-M-15 is not
always associated with Tn2 and may be found on plasmids that are
quite different from the IncF and IncI groups commonly carrying with
this gene. pJIE137 also represents a novel plasmid type with independent
insertions of two resistance regions.
P1812 Plasmid-mediated antimicrobial resistance: characterising
extended-spectrum b-lactamases in Escherichia coli isolated
from cattle
C. Boinett*, M. Anjum, L. Villa, A. van Essen, M. Woodward (Surrey,
UK; Rome, IT; Lelystad, NL)
Objectives: The aim of this study was to characterize the clonality of
blaCTX-M bearing Escherichia coli strains from the United Kingdom,
harbouring blaCTX-M and other antimicrobial resistance genes with
respect to their relative plasticity and ease of dissemination.
Methods: Bovine E. coli isolates (n = 52) collected between the period
of March and October 2007, found to posses the blaCTX-M gene were
examined. Resistance phenotypes were determined using disk diffusion
assay. Isolates were also analysed by pulse ﬁeld gel electrophoresis,
conjugation, plasmid proﬁling, miniaturized DNA microarray analysis
and PCR based replicon typing (PBRT) and IncI1 plasmid MLST
(pMLST).
Results: All strains were found to be resistant to cefotaxime (CTX)
and harboured large plasmids (50–100 kb) of varying macro-restriction
proﬁles (25–100% similarity) and PFGE patterns. The isolates encoded
either CTX-M group 1 (blaCTX-M-1, -15 and -32) or CTX-M group 9
(blaCTX-M-14 and -14b) gene, with three isolates encoding both. The
isolates harboured multiple plasmids of varying incompatibility (Inc)
groups including; IncB/O, IncF, IncFIB and IncI. Forty-seven of the
ﬁfty-two strains transferred plasmids conferring cefotaxime resistance to
recipient E. coli K12 strains with relative frequency of transfer between
1.25×10−3 and 9.23×10−9. Thirty-nine of the resultant transconjugants
harboured a single IncF, IncN or IncI1 plasmid. These plasmids were
found to be resistant to multiple antimicrobial agents. IncI1 strains were
further characterised using pMLST and found to be the same as types
from human isolates of E. coli and Shigella sonnei.
Conclusion: These data conﬁrm the variable nature of bovine CTX-M
ESBL E. coli based on PFGE proﬁles, although only a limited number of
CTX-M sequence types were seen. Interestingly, 20 isolates encoded the
blaCTX-M-15 gene, the most prevalent b-lactamase worldwide, although
none of these were the ST131 clone. CTX-M encoding plasmids were
found to be largely on IncF and IncN plasmid groups with the ability
to transfer to a recipient E. coli strain. The presence of these genes
on transferable plasmids expands its available niche and increases the
probability of transfer of multi-resistant plasmids harbouring blaCTX-M
genes, between bacteria, including zoonotic, commensal and pathogenic
bacteria, with potential consequences for both public and animal health.
P1813 Genetic environments of aac(6′)-Ib-cr and qnrs1 genes and
plasmid content in Enterobacteriaceae
E. Ruiz*, R. Rocha, M. Zarazaga, C. Torres, G. Arlet (La Rioja, ES;
Puebla, MX; Paris, FR)
Objective: To characterize the genetic environment of aac(6′)-Ib-cr and
qnrS1 genes and the plasmid content in Enterobacteriaceae strains, most
of the them harbouring blaCTX-M-15.
Methods: Ten Escherichia coli, ﬁve Klebsiella pneumoniae, and
two Enterobacter aerogenes isolates were recovered from clinical
and environmental samples. Antibiotic susceptibility patterns were
determined using agar dilution methods. Several resistance genes were
analyzed by PCR and sequencing: 1) blaTEM, blaCTX-M, blaOXA,
blaSHV, qnrA, qnrB, qnrS, qepA, aac(6′)-Ib-cr and oqxAB; 2) presence
of type 1 and 2 integrons; and 3) mutations in gyrA and parC genes.
Molecular typing and phylogenetic group were determined by MLST
and PCR or PCR-RFLP. Number and plasmid type were analyzed by
PFGE-S1 and PCR-based replicon-typing (PBRT). Characterization of
addiction systems were carried out by PCR. The genetic environment
of quinolone resistance genes were studied by PCR-mapping or cloning
and subsequent sequencing.
Results: The aac(6′)-Ib-cr gene was detected in all tested isolates
and blaCTX-M-15 gene in all but one E. coli. Three K. pneumoniae
isolates presented as well qnrS1 and one E. coli and all K. pneumoniae
strains harboured oqxAB gene. Most of the isolates showed high level
quinolone resistance due to mutations in gyrA and parC genes. All
K. pneumoniae isolates belonged to the KpI phylogenetic group and to
sequence-types ST341 and ST433. E. coli isolates belonged to B1, B2
and D phylogenetic groups and to the sequence-types ST224, ST648
and ST131. All E. coli and E. aerogenes and one K. pneumoniae
strain presented type 1 or 2 integrons. Several plasmid types were
detected: IncF, IncFIA, IncFIB, IncN, IncR and colE. The following
addiction systems were identiﬁed: pemK/I, hok-sok, ccdAB, srnBC
and vagC/D. Different genetic environments of aac(6′)-Ib-cr gene were
detected among studied isolates: 1) located in the variable region of a
type 1 integron; 2) located in a Tn1721 transposon; 3) related to aac(3)-
II gene; and 4) related to mrx gene. The genetic environment of qnrS1
gene was the same in all the positive strains, presenting an IS26 and a
truncated ISEcl2 upstream of the gene and an hypotetical protein and a
resolvase downstream.
Conclusions: The aac(6′)-Ib-cr gene can be located in different genetic
environments, associated or not with integrons and the bacteria that carry
this gene contain four different plasmid types and a high diversity of
addiction systems.
P1814 Novel gene cassettes and integrons in environmental
antibiotic-resistant bacteria
A. Moura*, C. Pereira, I. Henriques, A. Correia (Aveiro, PT)
Objectives: To evaluate the occurrence of integrons and diversity of
gene cassettes arrays among Enterobacteriaceae and Aeromonadaceae
isolated from urban wastewaters.
Methods: Screening of integrase genes was performed in 697 isolates
by dot blot hybridization; integrase-positive strains were further
characterized in terms of phylogenetic afﬁliation to species level and
antimicrobial resistance proﬁle. The genetic location of integrons was
determined and strains containing plasmid-borne integrons were selected
for mating experiments. Integron’s variable regions were characterized
by sequencing analysis.
Results: The prevalence of intI genes was 3.73%. One third of intI
genes were located in plasmids and could be transferred at frequencies of
10−5 and 10−6 transconjugants/recipient cell. Twelve different integrons
(4 representing novel arrays) were detected and included 3 new gene
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cassettes: a novel aadA variant (aadA17), a gene putatively involved
in cell signalling and bioﬁlm formation (dcyA) and an open reading
frame encoding a putative protein of unknown function (orfER.1.20). In
addition, a novel insertion sequence (ISAs12) was found. Approximately
80% of strains, most of them belonging to Aeromonas, were resistant to
at least 3 antibiotics of different classes.
Conclusions: The high prevalence of multiresistant isolates highlights
the urgent need to employ effective means of efﬂuent disinfection
to avoid the dissemination of antibiotic-resistant bacteria. Moreover,
the presence of novel integron structures in treated efﬂuents suggests
that domestic wastewater environments may favour the formation of
novel combinations of gene cassettes. Results obtained also emphasize
the importance of Aeromonas as potential vectors of dissemination of
integrons and antibiotic resistance genes.
P1815 Presence of mobile genetic elements carrying virulence and
antibiotic resistance genes in non-pathogenic Vibrio strains
M. Gennari*, V. Ghidini, M. Taﬁ, M. Lleo` (Verona, IT)
Objectives: Non pathogenic Vibrio species can be occasionally
responsible for infectious diseases in humans.
Horizontal gene transfer and the acquisition of foreign DNA is a
fundamental process in the evolution of most bacterial species. Many
genes can be mobilized in extra-chromosomal elements thus having the
possibility of mix or recombine in the aquatic environment.
In this study we have screened a collection of North Adriatic marine
Vibrio strains for the detection and analysis of mobile genetic elements
such as the V. cholerae pathogenicity island (VPI-2) and class 1 integrons.
Methods: A total of 152 Vibrio spp. strains were isolated from water,
plankton, sediment and ﬁsh samples obtained in the area of the northern
Adriatic sea during the period 2006–2009. The identiﬁcation of the
environmental strains at the species level was performed by standard
biochemical methods. DNA extracted from vibrios with a standard
protocol was subjected to PCR. The obtained PCR products were
analyzed by sequencing.
Results: In order to investigate the transfer of VPI-2 from V. cholerae to
non-pathogenic Vibrio species we have screened the environmental strain
collection with different pair of primers designed on some pathogenicity
island gene clusters (5’,3’,TMRF,nagC,nanH,FAGHE).
A total of 18 strains carried at least one of the genes. Four strains
(NPV3,NPV6,NPV7,NPV18) presented both the 5′ and 3′ insertion sites
of the pathogenicity island VPI-2 into the chromosome and the nanH
gene. The strain NPV18 also carried the nagC gene. The TRMF and
FAGHE clusters have not been detected in any of the four strains.
Moreover, we found some other strains carrying only partial fragments
of the island.
A total of 13 environmental non-pathogenic Vibrio strains, all isolated
from ﬁsh farms, show the presence of the integrase gene from class1
integrons. Strains were screened for entire class1 integron using primers
designed in the 5′ and 3′ conserved segments (in-F/in-B): eight strains
carried the entire class1 integron while 5 strains seem to have only the
integrase site.
Conclusions: This study shown possibility for a non pathogenic Vibrio
strain of acquiring integrons containing AR cassettes and an entire or
partial pathogenicity island containing virulence factors. We suggest that
non pathogenic vibrios might represent a marine reservoir of virulence
and AR genes and of genetic elements of medical interest and for this
reason could constitute a risk for human health.
P1816 The Repository of Antibiotic-resistance Cassettes − an
online database of gene cassettes found in mobile resistance
integrons and a web-based application for annotation of
DNA sequences containing these cassettes
S. Partridge*, G. Tsafnat (Sydney, AU)
Objectives: Gene cassettes carried by mobile resistance integrons (MRI;
generally classes 1−3) frequently contribute to transmissible antibiotic
resistance (including multi-resistance) in Gram-negative bacteria. Gene
cassette nomenclature is complicated and currently largely unregulated,
so that many cassettes are incorrectly named in publications and
incorrectly or incompletely annotated in sequences in GenBank. We
previously used an automated annotation system (called Attacca) to
identify over 130 different (<98% identical) cassettes carrying antibiotic
resistance genes in sequences of MRI in GenBank. Our aim was to make
a database containing these cassettes and our cassette annotation system
available to the research community as a web-based application.
Methods: Our previously published method uses a database of
known gene cassettes, automated BLASTn searches and computational
grammars to identify gene cassettes in arrays in MRI in all sequences
in GenBank. We have made our cassette database accessible online and
the Attacca system has been adapted to a web-based application that
allows annotation of individual sequences submitted by researchers. The
annotation system was also modiﬁed to use amino acid sequences to
distinguish between different b-lactamase variants encoded by closely
related cassettes.
Results: The Repository of Antibiotic-resistance Cassettes (RAC)
website (http://www2.chi.unsw.edu.au/rac/) is offered as a free service
that allows researchers to browse our database of known gene cassettes,
which includes notes about different cassettes and links to exemplar
sequences. After registration, requiring only an e-mail address, users can
submit DNA sequences (e.g. obtained by PCR ampliﬁcation of cassette
arrays or from sequencing of complete plasmids) for accurate annotation
of gene cassettes. Gaps in annotations are ﬂagged for manual review
and any novel cassettes identiﬁed will be assigned appropriate names.
Initially the details and sequences of these cassettes will be available to
the submitter only. Following publication elsewhere, or given permission
from the submitter, they will be added to the public database and may
then appear in annotations of sequences submitted by all users.
Conclusions: RAC is an on-line application that allows browsing of a
comprehensive database of antibiotic resistance gene cassettes, accurate
annotation of gene cassettes in DNA sequences and appropriate naming
and incorporation of new cassettes.
P1817 Mobile genetic elements: a comparative study of their
presence in bacteria from inanimate surfaces in Hospital
Infante D. Pedro, Aveiro, central Portugal, in 2005 and 2008
C. Santos*, R. Diaz, E. Ramalheira, T. Caetano, S. Mendo (Aveiro, PT)
Objective: Due to the high antibiotic pressure, multidrug resistant
bacteria are abundant within the hospital environment. This study
aimed to compare the presence of mobile genetic elements in Gram-
negative bacteria collected from inanimate surfaces within Hospital
Infante D. Pedro, Aveiro, in 2005 and 2008.
Methods: Samples from different inanimate surfaces were collected,
during one month period in 2005 and the same period in 2008. Sterile
swabs were rubbed in the surfaces and then placed in rich medium
(TSB), and incubated overnight at 37ºC. Serial dilutions were plated
in MacConkey agar. Phenotypical different colonies were selected and
their clonal relationship was evaluated by rep-PCR. Identiﬁcation to the
species level was determined by 16S ampliﬁcation. Screening for class
1 integrons, insertion sequence common regions (ISCR1) and sul3 gene
was performed by PCR, using appropriate primers.
Results: In 2005, 85 phenotypically different bacteria were isolated,
from which 45 did not show clonality and were further studied; from
these, 33% isolates were positive to intI1 gene. ISCR1 was detected
in 31% of the integron positive isolates. In 2008, 227 phenotypically
different bacteria were isolated; 153 did not show clonality and were
further studied; from these 46% possess class 1 integron, 60% of which
possess ISCR1. In some isolates of 2008 the variable region could not
be ampliﬁed although the intI1 gene was present. In these cases the
presence of sul3 gene was investigated, revealing its presence in 60%
of the isolates. Escherichia coli, Klebsiella spp., Pseudomonas spp. and
Proteus mirabilis were the most frequently found microorganisms.
Conclusion: This study reveals a high prevalence of mobile genetic
elements, namely in intI1 and sul3 genes, and ISCR1 element in bacteria
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from inanimate surfaces. These elements are responsible by horizontal
gene transfer among bacteria and may therefore be implicated in the
multidrug resistance proﬁle observed in bacterial species. It is likely that
these bacteria can ﬁnd their way into debilitated hospitalized patients.
New species and unusual pathogens:
usefulness of molecular tools for bacterial
identiﬁcation
P1818 A quantitative assessment of Borrelia and Bartonella DNA
and tick-borne encephalitis virus RNA in Ixodes persulcatus
Schulze ticks collected in Chelyabinsk region of Russia
A. Grishechkin*, A. Kon’kova-Reidman, O. Morozova (Moscow,
Chelyabinsk, RU)
Borrelia and Bartonella DNA and tick-borne encephalitis virus (TBEV)
RNA were detected in Ixodes persulcatus Schulze ticks collected in
May 2009 in Chelyabinsk region, Ural, Russia by means of PCR
with subsequent electrophoresis or real-time PCR with ﬂuorescent
TaqMan probes. Borrelia burgdorferi sensu lato DNA was found in
36.6±5.0% ticks analyzed. Phylogenetic analysis of the PCR product
nucleotide sequences showed 2 species Borrelia afzelii and Borrelia
garinii. Threshold cycles Ct = 23,4−46,3 corresponded to approximately
1–105 genome-equivalents in reaction mixtures or nearly 101–106 DNA
copies per an infected tick. Among 76.5% of studied ticks low bacterial
loads with Ct> 35 were obsereved. Bartonella DNA was revealed in
38.9±5.2% I. persulcatus. Based on phylogenetic analysis of nucleotide
sequences of the Bartonella-speciﬁc PCR-products Bartonella quintana
and Bartonella henselae were found. Threshold cycles varied from
Ct = 25.7 till 39.5 with evident prevalence of samples with Ct< 30.
It might suggest higher amounts of Bartonella DNA in taiga ticks
compared to Borrelia DNA. The tick-borne encephalitis virus RNA of
Siberian genetic subtype was detected in 16.9±4.3% of I. persulcatus
using reverse transcription with subsequent real time PCR with TaqMan
probe. Based on threshold cycles Ct = 21,3−48,1 and taking into account
RNA isolation and reverse transcription efﬁciency the viral loads could
be estimated as 104–107 genome-equivalents per a tick. The TBEV
quantities exceeded the tick-borne bacteria amounts. Experimentally
observed frequencies of mixed infections with Borrelia and Bartonella in
13.0% of ticks ﬁtted well to theoretical estimations based on independent
distribution of the tick-borne bacteria among vectors. Bacterial loads for
individual and mixed infections have similar spans but Ct> 39 were more
typical for mixed infections.
P1819 Application of DNA sequence analysis of 16S-23S intergenic
spacer region for species identiﬁcation of strains belonging
to the genera Abiotrophia, Aerococcus, Facklamia, Gemella,
Globicatella, Granulicatella, Leuconostoc, and Rothia
X.C. Nielsen*, R. Dargis, M. Hammer, A. Hesselbjerg, L. Hannecke,
U.S. Justesen, M. Kemp, J.J. Christensen (Slagelse, Copenhagen,
Næstved, Odense, DK)
Objectives: The 16S-23S Intergenic Spacer (ITS) region has been
found useful in separating most of the clinically relevant non-haemolytic
streptococci (NHS). The group of catalase-negative Gram-positive cocci
not belonging to the Streptococcus genus is also difﬁcult to identify
with conventional methods. In this study we have included 39 species
belonging to the genera of Abiotrophia (1), Aerococcus (7), Facklamia
(6), Gemella (6), Globicatella (2), Granulicatella (3), Leuconostoc
(4), and Rothia (6). The purpose of this study was to investigate the
possibility of using the ITS sequence analysis for species identiﬁcation
of the strains belonging to these genera.
Methods: There are only a few published ITS sequences of the included
species. It was therefore investigated whether ITS is a good target for
this group of bacteria. 39 type strains were purchased from CCUG. Six
pairs of primers were designed based on the available 16S and 23S
sequences from these species from GenBank. PCR was performed with
the most optimal primer pair for all species. PCR products were analysed
by Qiaxel (Qiagen). DNA sequencing was performed for those strains
that generated one product. The achieved ITS sequences were edited and
aligned using the Mega4 program.
Results: The species belonging to the genera Aerococcus and
Globicatella generated two or more products after PCR, indicating that
there could be two or more different ITS regions in these species. The
species belonging to the genera of Abiotrophia, Granulicatella, Gemella,
Facklamia, Leuconostoc, and Rothia generated only one PCR product.
Sequencing results showed that there was great interspecies variation
among the different species belonging to the same genus (>5%).
Conclusions: ITS gene sequence analysis seems to be a good candidate
for species identiﬁcation of strains belonging to the genera Abiotrophia,
Granulicatella, Gemella, Facklamia, Leuconostoc, and Rothia. Also, the
potential usefulness of ITS for identiﬁcation of the genera Aerococcus
and Globicatella has to be explored further as, if possible, ITS can be
used as the initial step in identifying this large group of genera, including
NHS.
P1821 Combined DVC-FISH method for in situ detection of viable
Arcobacter butzleri cells
M.A. Artigot, A. Gonza´lez*, Y. Moreno, M.A. Ferru´s (Valencia, ES)
Objectives: Arcobacters can enter into a viable but non-culturable
(VBNC) state, which is a problem for the detection by tradicional cultural
methods of this emerging human pathogen. Moreover a standardized
reference method of detection has not so far been proposed. In this study
we have developed a technique for the speciﬁc enumeration and rapid
discrimination of viable and non viable cells, combining direct viable
count (DVC) procedure with ﬂuorescent in situ hybridization (FISH)
method.
Methods: The reference strain Arcobacter butzleri DSM 8739 was used
to develop and set up the technique. DVC method was modiﬁed and
adapted to A. butzleri analysis by testing different times of incubation
and concentrations of DNA-gyrase inhibitors. The tested antibiotics were
ciproﬂoxacin, novobiocin and nalidixic acid. We combined incubation
times of 3, 6, 7, 8, 9 and 24 hours with concentrations of 0.3, 0.4, 0.5, 0.6
and 0.8mg/mL. FISH was performed by using the probe ARC94, with the
sequence 5′TGCGCCACTTAGCTGACA3′, targeting 16S rRNA. The
detected bacteria were counted by direct plate counting, ﬂuorescence
microscopy and by the viability kit LIVE/DEAD® BacLight. These data
let us select the best time of incubation and antibiotic concentracion
without compromising the cell viability. Furthermore, the theoretical
detection level of the method was tested in phosphate-buffered saline
1x.
Results: The optimal conditions for the DVC-FISH method were the
incubation with 0.3mg/mL of ciproﬂoxacin during 6−7 hours. We
observed cell degradation or decreasement of the number of bacterial
cells with times of incubation higher than 9 hours and/or concentrations
higher than 0.5mg/mL. With this DVC-FISH combination we obtained
more than 2 times the original size of A. butzleri allowing the detection
of elongated viable cells. The sensitivity established for the DVC-FISH
method in phosphate-buffered saline was 103 ufc/ml.
Conclusion: Our results show that the DVC-FISH combination is an
effective, rapid and culture-independent useful method to detect and
identify viable and non viable Arcobacter cells. Therefore, DVC-FISH
method could be applied for detection of these bacteria in different
clinical samples as well as for the analysis of possible sources of
transmission.
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P1822 Faster microbial identiﬁcation with MALDI-TOF mass
spectrometry and digital imaging: a pilot study
N. Mutters, C. Hodiamont*, C. Visser (Heidelberg, DE; Amsterdam, NL)
Objectives: In this pilot study, we assessed the potential acceleration
of identiﬁcation with Matrix-assisted laser desorption ionization time-
of-ﬂight mass spectrometry (MALDI-TOF MS) as compared to
conventional methods (CM) and investigated whether identiﬁcation time
can be further minimized by combining MALDI-TOF MS with the
“It’s The Sample That Moves!®” system (ITSTM®, KIESTRA Lab
Automation, The Netherlands), a fully automated incubation system
which produces digital images of agar plates using different photographic
settings to detect early growth. Finally, to assess the potential clinical
impact of accelerating identiﬁcation but not susceptibility testing, we
evaluated how availability of microbial identiﬁcation results could
inﬂuence prescribed antibiotic treatment.
Methods: Prospectively, identiﬁcation time and results by CM of 219
consecutive positive blood culture isolates was assessed. Retrospectively,
MALDI-TOF MS identiﬁcation was performed using a Microﬂex mass
spectrometer (Bruker Daltonik, Bremen, Germany) and the Bruker
Biotyper database 3.0. Identiﬁcation time and accuracy was measured.
Discrepancies were resolved by 16S rRNA sequencing. Minimal
incubation time to detect growth with digital imaging by ITSTM® and
subsequently perform MALDI-TOF MS identiﬁcation was determined
for different microbial species. Adjustments in antibiotic treatment
regimen, based on availability of pathogen analysis results, were
appraised retrospectively from the Electronic Patient Record system.
Results: Pathogen identiﬁcation by MALDI-TOF MS succeeded in
95.7% of all isolates. MALDI-TOF MS and CM were concordant in
94.1% of all isolates. The combination with ITSTM® resulted in a mean
time gain of 30.6 hrs compared to CM. The incubation time in ITSTM®,
needed for detection of microbial growth and successful subsequent
MALDI-TOF MS analysis, was lowest in Gram negative rods and highest
in yeasts. All microbial groups showed signiﬁcantly longer incubation
times in lower concentration (1×104 CFU/ml, 1×102 CFU/ml). Early
microbial identiﬁcation without susceptibility results led to an adjustment
of the antibiotic regimen in 12% of all patients.
Conclusion: With the combination of ITSTM® and MALDI-TOF MS,
microbial identiﬁcation could be signiﬁcantly accelerated as compared to
CM. Workﬂow could be optimized, costs reduced, pathogen identiﬁcation
accelerated and potentially lifesaving switches in antibiotic regimen
could occur earlier.
P1823 Tapping the potential of intact cell mass spectrometry with
a combined data analytical approach
M. Wittwer*, J. Heim, M. Schaer, N. Schuerch (Spiez, CH)
Objectives: Identiﬁcation of microorganisms with matrix assisted laser
desorption ionization time of ﬂight (MALDI-TOF) intact-cell mass
spectrometry (ICMS) has proven to be a valuable alternative to time
consuming biochemical identiﬁcation approaches. However, due to
the complexity and noisiness of MALDI-TOF spectra, the taxonomic
resolution of the method is often not fully exploited by commercial
tools, which often rely on a single data analytical approach.
Methods: In the present work, we propose a workﬂow which uses the
spectral diversity of a commercial database (SARAMIS) to narrow down
the search ﬁeld at a certain taxonomic level, followed by a reﬁned
classiﬁcation by supervised modeling. As supervised learning algorithm,
we have chosen a shrinkage discriminant analysis approach, which takes
colinearity of the data into account and provides a scoring system for
biomarker ranking. This ranking can be used to tailor speciﬁc biomarker
subsets, which optimize discrimination between subgroups, allowing
a weighting of misclassiﬁcation. The suitability of the approach was
veriﬁed based on a dataset containing the mass spectra of three Yersinia
species Y. enterocolitica, Y. pseudotuberculosis and Y. pestis. Thereby,
we laid the emphasis on the discrimination between the highly related
species Yersinia pseudotuberculosis and Yersinia pestis.
Results: All three species were correctly identiﬁed at the genus level
by the commercial database. Whereas Y. enterocolitica was correctly
identiﬁed at the species level, discrimination between the highly related
Y. pseudotuberculosis and Y. pestis strains was ambiguous. With the
use of the supervised modeling approach, we were able to accurately
discriminate all the species even when grown under different culture
conditions.
Conclusion: The proposed workﬂow, which combines the diversity of a
commercial database with the discriminative power and feature selection
capabilities of supervised classiﬁcation has the potential to ameliorate
the taxonomic resolution of intact-cell mass spectrometry.
P1824 Methods for the immediate identiﬁcation of bacteria in
charcoal-containing BacT/ALERT® blood cultures by
MALDI-TOF mass spectrometry
J.D. Walsh*, J.M. Hyman (Durham, US)
Objectives: Direct analysis of positive blood culture broth using
MALDI-TOF can potentially identify the organism within one hour of
the bottle ﬂagging positive. However, isolating microorganisms from
charcoal-containing blood culture broth in sufﬁcient purity for MALDI-
TOF analysis is challenging using known methods, due to the size
distribution of charcoal particles and the selective adherence of certain
species. This study was designed to evaluate the performance of two
new methods developed for processing positive charcoal-containing
BacT/ALERT® blood culture broth for immediate identiﬁcation by
MALDI-TOF MS.
Methods: BacT/ALERT® FA bottles were inoculated with 40–400
CFU and 10mL human blood, and incubated in a BacT/ALERT® 3D
Microbial Detection System. Samples of positive broth were treated by
one of two methods depending on their Gram morphology. For broth
containing Gram-positive cocci in clusters, a sample was sonicated to
detach adsorbed bacteria, treated with a proprietary ﬂocculating agent
and puriﬁed over a density cushion. For non-staphylococci, a sample
of broth was subjected to differential centrifugation and puriﬁed over a
density cushion. Bacteria enriched by these methods were treated with
formic acid-acetonitrile and the extracts applied to a MALDI target plate.
Samples were then overlaid with HCCA matrix and analyzed with an
Aximaa¨ Assurance system (Shimadzu Corp.) and SARAMIS™ database
(bioMe´rieux).
Results: Staphylococci processing method: 17 of 18 FA broth samples
containing individual strains of staphylococci gave correct ID by
MALDI-TOF (8/8 Staphylococcus aureus and 9/10 Staphylococcus
epidermidis).
Non-Staphylococci processing method: 19 of 20 FA broth samples
containing individual strains gave correct ID by MALDI-TOF (4/4
Escherichia coli, 2/2 Klebsiella pneumoniae, 2/2 Enterobacter aero-
genes, 2/2 Pseudomonas aeruginosa, 2/2 Enterococcus faecalis, 2/2
Enterococcus faecium, 3/4 Streptococcus pneumoniae/mitis and 2/2
Streptococcus pyogenes).
Conclusion: Both new methods provided acceptable performance
(94.7% correct) for the identiﬁcation of bacteria directly from charcoal-
containing blood culture broth using MALDI-TOF mass spectrometry.
P1825 Improved method for the immediate identiﬁcation of
pathogens in BacT/ALERT® standard aerobic blood
cultures by MALDI-TOF mass spectrometry
J.M. Hyman, J.D. Walsh* (Durham, US)
Objectives: The ability to characterize bloodstream infections within
the ﬁrst hour after a positive blood culture result would boost the
clinical relevance of the diagnostic information provided. MALDI-TOF
mass spectrometry (MS) has emerged in recent years as a fast and
reliable method for the identiﬁcation of microorganisms. This study was
designed to evaluate the performance of a novel method for processing
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positive BacT/ALERT® Standard Aerobic (SA) blood culture broth for
immediate identiﬁcation by MALDI-TOF MS.
Methods: BacT/ALERT® SA bottles were inoculated with 40–400
CFU and 10mL human blood, then incubated in a BacT/ALERT®
3D Microbial Detection System. A sample of positive broth was
brieﬂy treated with proprietary lysis buffer and passed through a 0.45
micron membrane ﬁlter. Following several washes, microorganisms
were recovered by scraping the ﬁlter surface and smearing the cells
directly onto a MALDI target plate. Samples were analyzed with an
Aximaa¨ Assurance system (Shimadzu Corp.) and SARAMIS™ database
(bioMe´rieux).
Results: A total of 46 samples of positive BacT/ALERT® SA broth were
tested, each containing a separate strain, representing eleven species
commonly associated with positive blood cultures (Staphylococcus
aureus, Staphylococcus epidermidis, Candida albicans, Escherichia
coli, Klebsiella pneumoniae, Enterobacter aerogenes, Pseudomonas
aeruginosa, Enterococcus faecalis, Enterococcus faecium, Streptococcus
pyogenes and Streptococcus pneumoniae/mitis group). The overall
accuracy of this rapid method was 97.8% to the species level (45/46
strains). One of eight S. epidermidis strains tested was not identiﬁed.
Conclusion: This study demonstrates the effectiveness of a novel lysis-
ﬁltration (LF) method to process positive blood culture broth for analysis
by MALDI-TOF. The patent-pending selective lysis buffer used in this
method quickly and effectively dissolves blood cells while leaving
microorganisms intact. The LF method has the advantage of requiring
less manual manipulation and no centrifugal processing, and produces
a clean concentrated paste of microorganisms in 10−12 minutes that is
optimal for MS analysis.
P1826 Use of MALDI-TOF technology for the rapid
microbiological diagnosis from blood samples
A. Pen˜a*, R. Camacho, V. Guillot, J.A. Perez-Lopez, M. Alvarez,
F. Garcia Garcia, J. Roman, T. Escobar, F. Garcia (Granada, ES)
Objective: To evaluate how MALDI-TOF technology impacts the time
to microbiological diagnosis from blood samples and the concordance
with standard identiﬁcation methodology.
Methods: 155 positive blood cultures have been analysed in parallel
using MS MALDI-TOF Autoﬂex III (Bruker) and a variety of standard
procedures (Wider, Vitek II, Api, or manual identiﬁcation). Time to
identiﬁcation and concordance with standard methods was investigated.
Kappa correlation coefﬁcient was estimated to evaluate the correlation
between both diagnostic approaches.
Results: Use of MALDI-TOF reduced a median of 14 hours (range
12−18 horas) time to species identiﬁcation from positive blood samples.
Identiﬁed microorganisms comprised 27.1% Gram negative [E. coli (23),
P. aeruginosa (9), A. lwofﬁi (1), E. aerogenes (1), K. pneumoniae (2),
K. oxytoca (2), A. hydrophila (1), B. fragilis (1), E. cloacae (1) and
A. baumannii (1)] and 72.9% Gram positive microorganisms [S. aureus
(13), S. epidermidis (35), S. hominis (25), S. capitis (2), S. warneri
(2), S. haemolyticus (9), S. simulans (3), S. viridans (5), S. pneumoniae
(1), E. faecalis (6), E. faecium (1), P. acnes (1), L. monocytogenes (1),
M. luteus (4), Bacillus circulans (2), Clostridium perfringens (2), and
Corynebacterium sp (1)]. Globally, concordance was 95.8% (k = 0.928)
for species identiﬁcation, and 98.7% for genus identiﬁcation (k = 0.977).
For Gram negative rods, concordance was 95.2% (species, k = 0.946),
and 100% (genus), while for Gram positive microorganisms concordance
was 82.3% (k = 0.627), and 98.2% (k = 0.931) for species and genus
identiﬁcation, respectively. Gram positive discordant identiﬁcations
[Maldi/standard ID] were as follows: [St. viridans (6)/St. oralis (1),
St. salivarium (1), St. australis (1), St. canis (1), St. pneumoniae];
[Corynebacterium spp/S. pettenkoferi]; [S. epidermidis/R. mucilaginosa];
[S. haemolyticus (1)/S. hominis (1)]; [S. hominis (11)/S. epidermidis (9)
S. warneri (1) S. simulans (1)]. Gram negative discordant results [Maldi/
standard ID] were infrequent: [P. aeruginosa/P. stutzeri]; [Aeromonas
hydrophila/A. veronii].
Conclusion: The use of MALDI-TOF for the identiﬁcation of
microorganisms from positive blood cultures reduces considerably the
time to results. MALDI-TOF identiﬁcation has shown an excellent
correlation with standard identiﬁcation procedures for Gram negative
(genus and species level) and Gram positive microorganisms (genus
level).
P1827 Comparison of two MALDI-TOF mass spectrometry
instruments in a routine microbiological laboratory
E. Leitner*, M. Keimel, B. Heiling, S. Grabner, G. Feierl, W. Buzina,
A.J. Grisold, L. Masoud, U. Wagner-Eibel, M. Gehrer, E. Marth (Graz,
AT)
Objectives: Matrix assisted laser desorption ionization time-of-ﬂight
mass spectrometry (MALDI-TOF MS) is a new approach for rapid
identiﬁcation of microorganisms. It is well recommended as a tool having
the ability to replace or support conventional methods in the routine
settings. Aim of this study was to compare two commercially available
MALDI-TOF MS instruments in the routine diagnostic laboratory at
the Institute of Hygiene, Microbiology and Environmental Medicine,
Medical University of Graz.
Materials: In 2010, 1016 microorganisms, 911 bacteria and 105
yeasts were tested in parallel with two different MALDI-TOF MS
Systems. The MALDI target plates of both MALDI-TOF MS instruments
provided from Bruker Daltonics and Shimadzu Corporation were
inoculated with the smear method using HCCA Matrix according to
manufacturer’s recommendations. The generated mass spectra were
analysed automatically from the company’s databases Bruker Daltonics
and AnagnosTec GmbH, respectively. Using the given scores the results
were sectioned at species, genus or family level. For Identiﬁcation
of isolates without a result or no concordant results 16S rRNA gene
sequencing for bacteria or ITS sequencing for yeasts were applied.
Results: Of the 1016 isolates on species level the Shimadzu instrument
identiﬁed 78.7%, the Bruker instrument 77.3%. The genus level was
identiﬁed in 6.2% on the Shimadzu instrument and 16.5% on the
Bruker instrument, respectively. No identiﬁcation was found in 14%
from the Shimadzu instrument and 6.2% from the Bruker instrument.
The overall agreement of the instruments was 61.3% on species level
and 20.3% on genus level. On species level the 911 bacterial isolates
were slightly better identiﬁed with the Bruker instrument (82%) than
with the Shimadzu instrument (77.1%), whereas the 105 yeasts were
better identiﬁed from the Shimadzu instrument (93.3%) than from the
Bruker instrument (36.2%).
Conclusion: In summary, both instruments, from Bruker and Shimadzu
were able to provide rapid and accurate results and are easily to
implement in a routine diagnostic laboratory.
P1828 MALDI-TOF in diagnosis of fungal infections
A. Iranzo Tatay*, J. Frasquet Arte´s, G. Fagundez Machiain,
M. Gobernado Serrano (Valencia, ES)
Objectives: Assay mass spectrometry for identiﬁcation of various
ﬁlamentous fungi isolated and identiﬁed in samples from two groups
of patients, one with fungi skin diseases and the other with hematology
and oncology underlying diseases.
Methods: Samples were grown in fungi culture usual mediums. Fungi
were identiﬁed using our routine techniques of the laboratory, which
consist in the observation of their differential macroscopic growth,
and microscopic differences in their structures such as conidia and
hyphae among others. These isolates subsequently were analyzed by
mass spectrometry. For that purpose a previous extraction protocol, using
formic acid and acetonitrile, was made. The extract was analyzed in the
microﬂex mass spectrometer (Bruker Daltonik GmbH, Bremen). Spectra
obtained were compared with the program MALDI biotyper 2.0 43.8.
Results: Mass spectrometry achieved correct identiﬁcation of the
following ﬁlamentous fungi:
Fungi of patients with hematology and oncology underlying diseases:
Hypomicetum: Aspergillus fumigatus (1), A. ﬂavus (1), A. terreus (1),
A. thermomutatus (1). Dematiaceous: Alternaria alternata (3).
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Fungi of patients with fungi skin diseases: Dermatophyton: Trichophyton
tonsurans (1), T. rubrum (1), Scopulariopsis brevicaulis* (1), Microspo-
rum gypseum (1).
There was no reliable identiﬁcation in the case of: Scedosporium
apiospermum (1), S. proliﬁcans (1), Trichophyton interdigitale (1),
T. verrucosum (1).
In these cases we had score values below 1,7 and the organisms were
proposed by MALDI biotyper were bacterium.
Of the 15 ﬁlamentous fungi tested were correctly identiﬁed 11 (73.3%).
The range of score we obtain for correct identiﬁcations was between
1,465 for A. terreus and 2,005 for A. thermomutatus.
Conclusion: Mass spectrometry should improve to be a fungal
identiﬁcation reference method. In the list of 10 micro-organism
proposals, following the correct one there was no same or similar
genus fungi which could cause confusion or doubt in the identiﬁcation.
In some cases we observe what we have called “score jump”, that
is a great difference of score between the true identiﬁcation and the
following failed identiﬁcation in the ranking, and also not being related
taxonomically (fungi-bacteria). We believe score jump gives greater
value to the result, because is not just about the organism most similar
to, but it also sets a big distance with the following, which means there
are not more possible similarities than the real.
P1829 Replacement of classical non-automated methods by
MALDI-TOF mass spectrometry for routine identiﬁcation
of bacteria and yeasts
G. Coppens*, K. Martens, G. De Sutter, J. Heyligen, E. Oris (Genk, BE)
Objectives: To evaluate replacement of classical non-automated methods
by MALDI-TOF MS (MDT) for identiﬁcation of Bacteria and Yeasts
from clinical samples in our routine laboratory. Components of this
evaluation are accuracy, reproducibility, turnaround time (TAT) and cost.
Methods: Accuracy: 850 clinical isolates collected during a 1 12 month
period are identiﬁed by MDT in parallel with the routine classical
identiﬁcation (CI). In brief CI consists of Gram staining, growth
and susceptibility features, coagulase, dnase, oxidase, mobility, non-
automated biochemical and agglutination tests, and/or API® bioMe´rieux.
MDT is performed by a Microﬂex® LT Bruker spectrometer with
FlexControl v 3.0 and MALDI Biotyper v 2.0 software with Reference
Library 3.0. In addition 50 ATCC reference strains are identiﬁed by
MDT.
Reproducibility of MDT is assessed with 4 ATCC strains in 10 inter-run
and 4 intra-run identiﬁcations for each strain.
Acceptance criteria for MDT are a score value of 1.9 for species and
1.7−1.9 for genus identiﬁcation.
Measurement of TAT is done from specimen delivery to identiﬁcation
result reporting.
In order to establish the price for both methods, costs of reagents, labor,
equipment purchase and lease are calculated.
Results: Of the 900 identiﬁed strains with MDT, 96% are concordant
with CI (table 1), by which Cumitech 31A criteria are met to accept the
new identiﬁcation method.
Intra-run and inter-run reproducibility of MDT assessed with 4
ATCC strains is 100% (qualitative). Reproducibility of score values
(quantitative) is comparable for all strains: E. faecalis 29212 (mean:
2.390; range: 2.236–2.501; SD: 0.060); E. coli 5922 (mean: 2.395; range:
2.304–2.494; SD: 0.047); S. aureus 25923 (mean 2.359; range 2.188–
2.450; SD: 0.057); P. aeruginosa 27853 (mean 2.369; range: 2.260–
2.485; SD: 0.052).
Mean TAT for MDT identiﬁcation is 24 hour, which means a gain of 24
hours in comparison to CI.
The mean cost of one routine CI (without API®) in our laboratory setting
is 2.93 euro; the mean cost of one MDT identiﬁcation is 3.16 euro.
Conclusion: For routine identiﬁcation of Bacteria and Yeast in our
laboratory, CI can be replaced by MDT with at least a comparable test
performance and an improvement in TAT of 24 hours at a similar cost.
P1830 Improvement of identiﬁcation of anaerobes by MALDI-TOF
mass spectrometry analysis
M. Marschal*, U. Schumacher, I. Autenrieth (Tu¨bingen, DE)
Matrix Assisted Laser Desorption/Ionisation (MALDI-TOF-MS) is
increasingly used for identiﬁcation of bacterial isolates. MALDI-TOF-
MS identiﬁcation is based on the comparison of a spectrum of mass
signals of an isolate with a variety of spectra stored in a database.
In contrast to other identiﬁcation systems, the MALDI-TOF-MS
database allows amendments of additional species regarding to individual
requirements. Here we describe the implementation of MALDI-TOF-MS
analyses (MTA) for identiﬁcation of anaerobic species.
In July 2009 MTA was established as the ﬁrst line identiﬁcation method
for anaerobic bacteria. Validation of the MTA-results was performed by
the following protocol: each anaerobic isolate was analyzed by MTA
in parallel to standard identiﬁcation procedures. In case of discrepant
results or if no identiﬁcation could be obtained with MTA, additional
identiﬁcation assays and gene sequence analysis have been performed.
When 15 of 15 strains of a given species had been identiﬁed correctly
by MTA, the MTA-result of this species was accepted as validated and
standard identiﬁcation was aborted. Spectra of sequenced species, not
represented in the database were added leading to continuous expansion
of the database. Until today we successfully validated MTA based
identiﬁcations of 27 anaerobic species, representing 80% of the anaerobic
clinical isolates.
One of the main advantages of the MTA is that spectra of new species
result in “No Identiﬁcation” but not to misidentiﬁcation, triggering
attention to unusual strains. Using this protocol we were able to isolate
surprisingly often rare identiﬁed species including Bacteroides dorei,
Bacteroides xylanisolvens, Porphyromonas somerae, Porphyromonas
timonensis, Eggerthella lenta, Robinsoniella peoriensis, and Synergistes
species. Due to the short time needed for MTA of anaerobe cultures
especially the identiﬁcation of delicate species (eg Porphyromonas
species, Peptostreptococcus anaerobius) has increased signiﬁcantly up
to 200%.
MALDI-TOF-MS is a promising new tool for a rapid, accurate and cost-
effective identiﬁcation of anaerobic species.
P1831 Identiﬁcation of clinically relevant anaerobic bacteria using
two different MALDI-TOF mass spectrometry methods
M. Knoester*, A. Veloo, J. Degener, E. Kuijper (Leiden, Groningen, NL)
Objectives: Identiﬁcation of anaerobic bacteria in routine diagnostics is
difﬁcult and time consuming. Recently, matrix-assisted laser desorption
and ionisation-time-of-ﬂight mass spectrometry (MALDI-TOF MS) has
been introduced as a rapid and reliable identiﬁcation method for routine
application in diagnostic laboratories. The objective of this study was
to compare two commercially available MALDI-TOF MS systems for
identiﬁcation of clinically relevant anaerobic bacteria with 16S rRNA
gene sequencing as gold standard.
Methods: A selection of 79 clinical isolates, representing 19 different
genera, were tested and compared with identiﬁcation obtained by
16S rRNA gene sequencing. The strains were tested in the Bruker
system with a Microﬂex mass spectrometer (Bruker Daltonik, Bremen,
Germany) using FlexControl software (version 3.0). The Biotyper
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database contained 3476 spectra and was updated until February 17th,
2010. MALDI-TOF MS measurements by Shimadzu were performed
on an AXIMA conﬁdence (Shimadzu); data were analyzed with the
SARAMIS software package (AnagnosTec, Golm, Germany). The
database, which was updated until February 4th, 2010 contained 2875
super spectra and 37804 reference spectra of 701 and 1439 taxonomic
units, respectively.
Results: Correct genus identiﬁcation was achieved for 71% of isolates
by Shimadzu MS and for 61% by Bruker MS. Correct identiﬁcation at
the species level occurred in 61% and 51% respectively (p = 0.139). The
number of strains that could not be identiﬁed because of absence of
reference strains in the database was signiﬁcantly larger for the Bruker
system than the Shimadzu system (19% versus 6%, p = 0.017). Shimadzu
showed pronouncedly better results for identiﬁcation of Gram-positive
anaerobic cocci. In contrast, the Bruker system performed better than
Shimadzu for the Bacteroides fragilis group. When strains not present
in the database were excluded from the analyses for each database,
both systems performed equally well, with 77% and 75% correct
genus identiﬁcation for Shimadzu and Bruker, respectively (p = 0.386).
Similarly, when the most recently updated Bruker database was applied,
no difference was observed (Shimadzu 71%, Bruker 72% correct genus
identiﬁcation, p = 0.372).
Conclusion: The databases currently available for MALDI-TOF MS
need to be optimised before MS can be implemented for routine
identiﬁcation of anaerobic bacteria.
P1832 Excellent identiﬁcation of coagulase-negative staphylococci
using MALDI-TOF despite a rough procedure
J. A˚hman, A.-K. Gustafsson, M. Bergman Jungstro¨m, L. Serrander,
M. Sundqvist* (Va¨xjo¨, Karlskrona, Linko¨ping, SE)
Objectives: The identiﬁcation of coagulase-negative staphylococci
(CoNS) to species level is traditionally labour intensive and sometimes
expensive. Previous studies using MALDI-TOF (MS) have shown
promising results using optimised conditions. We tested the performance
of the Bruker Microﬂex system to identify CoNS without an extraction
procedure and with 20h transportation of the matrix overlaid sample
between two laboratories.
Methods: A total of 176 CoNS were collected from several laboratories
in Europe and the USA. They were previously species identiﬁed with
various phenotypic and genotypic methods to S. epidermidis (68),
S. capitis (40), S. hominis (28), S. haemolyticus (16), S. cohnii (8),
S. warneri (7) S. lugdunensis (6) and S. simulans (3). All isolates were
cultured on blood agar over night, put on the target plate and overlaid
with matrix. The target plate was stored in a dark environment in room
temperature and transported to another laboratory resulting in a delay of
20 hours from application of the sample to analysis. The identiﬁcation of
isolates was performed on a Microﬂex LT instrument (Bruker Daltonics,
Germany) and masspectra were automatically analysed in the MALDI
Biotyper 2.0 Software (Bruker Daltonics, Germany). Discrepant results
were further analysed with 16SrRNA sequencing.
Results: A score value of >2.000 was at ﬁrst run reported for 77% of
the isolates. After retesting the isolates with ﬁrst score value <2.000 the
ﬁnal median score value was 2.085 (range 1,705–2.376). The MS ID
was in concordance with the previous species ID in 155/176 isolates.
The 21 isolates showing different ID were analysed using 16SrRNA
sequencing, conﬁrming the species suggested by MS in 20/21 isolates.
In one S. hominis isolate (veriﬁed by 16SrRNA) the 1st MS report was
S. epidermidis (score 1.938) and when retested S. hominis (score 1.705).
Two isolates previously reported as S. cohnii and S. epidermidis were
identiﬁed by MS as S. aureus, which was also veriﬁed by 16SrRNA
analysis.
Conclusion: We conﬁrmed previous ﬁndings that the Microﬂex LT with
the Biotyper software 2.0 is accurate in the identiﬁcation of clinical
isolates of CoNS. We show that the performance was very good despite
a rough handling of the sample, ie. without an extraction procedure
together with a 20h delay of analysis from sample preparation.
P1833 Evaluation of MALDI-TOF mass spectrometry to identify
Corynebacterium spp.
P.M. Juiz*, C. Salas, C. Garcı´a de la Fuente, J. Agu¨ero, C. Pitart,
F. Marco, M. Almela, L. Martı´nez-Martı´nez, J. Vila (Barcelona,
Santander, ES)
Objectives: The objective is to compare traditional biochemical
identiﬁcation of different Corynebacterium species with MALDI-TOF
technology (matrix-assisted laser desorption/ionization time-of-ﬂight,
Bruker), analyzing which of these two methods is more accurate,
measuring also time costs derived from both methods.
Methods: Eighty-eight different strains of Corynebacterium spp. were
analyzed by two different methods. First were identiﬁed by conventional
biochemical testing (APICoryne, BioMerieux) from 24h growth agar
plate colonies. Afterwards, one colony of each strain was deposited
directly on the MALDI-TOF plate, covered with 1 mcL of matrix
and analyzed using an Autoﬂex II Bruker Daltonik mass spectrometer.
Discrepancies were resolved by 16S rRNA sequence-based molecular
identiﬁcation.
Results: Strains were separated in eight species by biochemical identi-
ﬁcation: 18 C. jeikeium (CJEI), 18 C. pseudodiphtheriticum (CPSE), 8
C. minutissimum (CMIN), 4 C. xerosis (CXER), 3 C. glucuronolyticum
(CGLU), 12 C. amycolatum (CAMY), 10 C. urealyticum (CURE) and
15 C. striatum (CSTR). MALDI-TOF identiﬁcation showed only one
discrepancy in CJEI group (identiﬁed through m.s. as CAMY), 7 in
CPSE group (identiﬁed through m.s. as C. propinquum (CPRO)), 5 in
CMIN group (3 identiﬁed through m.s. as C. aurimucosum (CAUR), one
as C. liquefaciens, an one as CAMY), 4 in CXER group (all of them
identiﬁed through m.s. as CAMY), 1 discrepancy in the CURE group
(identiﬁed through m.s. as CJEI), and no one in the CGLU, CAMY and
CSTR groups.
After 16S rRNA identiﬁcation, CJEI identiﬁed through mass spectrom-
etry (m.s.) as CAMY was conﬁrmed as amycolatum by molecular
identiﬁcation. Seven CPSE identiﬁed through m.s. as CPRO were
conﬁrmed as propinquum. Three CMIN identiﬁed through m.s. as
CAUR and CMIN identiﬁed through m.s. as CAMY were conﬁrmed
as aurimucosum and amicolatum respectively, though CMIN identiﬁed
through m.s. as C. liquefaciens was ﬁnally identiﬁed through 16S
sequencing as CAUR. Four CXER identiﬁed through m.s. as CAMY
were conﬁrmed as amycolatum by molecular identiﬁcation.
Conclusions: MALDI-TOF is more accurate and less time-consuming
for identiﬁcation of different Corynebacterium species comparing to
biochemical testing, due to poor biochemical differenciation between
certain species, and to the incubation time needed for biochemical
commercial galleries, often nearly 24h compared to 10 minutes spent
processing one colony through MALDI-TOF.
P1834 MALDI-TOF mass spectrometry-based analysis for
identiﬁcation of CF Burkholderia strains and validation of
phylogenetic tree by triple-locus sequence typing
C. Vogne*, G. Prod’Hom, K. Jaton, G. Greub (Lausanne, CH)
Objectives: Patients with cystic ﬁbrosis (CF) are susceptible to chronic
respiratory infections with a number of bacterial pathogens including
Burkholderia cepacia complex (Bcc). Identiﬁcation of these species is
important because of their innate resistance to various antimicrobial
agents and to the difﬁculty to eradicate them from the lungs of CF
patients. In addition, the ability to spread between CF individuals and
their incidence of nosocomial acquired infection make their detection
warranted. However, identiﬁcation is difﬁcult and challenging.
Methods: Since even 16S rDNA sequencing do not allow identiﬁcation
at species level, the usefulness of MALDI-TOF-mass spectrometry (MS)
(Bruker Daltonics, Leipzig, Germany) for the identiﬁcation and typing
of Burkholderia spp. strain was investigated on 40 strains isolated from
respiratory tract taken from 4 different CF patients in our hospital
between 2003 et 2008.
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Results: Among these 40 CF Burkholderia strains, 20 of them isolated
from one CF patient were identiﬁed as Burkholderia gladioli by MALDI-
TOF MS analysis and the 20 other as Burkholderia multivorans isolated
on three different CF patients. Analysis of each raw spectras obtained
by the BioTyper software (Bruker Daltonics) allows us to create a
phylogenetic tree between the different strains and to highlight epidemic
spread within CF populations and colonization of a patient by different
Burkholderia strains.
Conclusion: In conclusion, MALDI-TOF proves very useful to type
the Bcc complex. In order to validate results obtained by MALDI-TOF
spectra analysis, triple-locus sequence typing (recA, gltB, gyrB) will be
used and should allow tracing the global spread of Bcc bacteria.
P1835 Candida identiﬁcation with direct smear and ethanol-formic
acid extraction methods of MALDI-TOF: comparison with
Vitek2
E. Kalogeropoulou*, G. Vrioni, W. Solbach, A. Tsakris, J. Knobloch
(Chaidari, Athens, GR; Lu¨beck, DE)
Objective: MALDI-TOF mass spectrometry (MS), a new simple and
fast diagnostic method that provides rapid and accurate identiﬁcation of
bacteria (MALDI-TOF), can be applied for the identiﬁcation of Candida
species.
Methods: 155 clinical important strains of Candida species (61%
C. albicans, 15% C. parapsilosis, 10% C. tropicalis, 9% C. glabrata, 5%
C. krusei, 1% C. lusitaniae) identiﬁed by Vitek2 automated system were
tested by MALDI-TOF MS using two different procedures for sample
preparation (Direct Smear-DS and Ethanol-Formic Acid Extraction-
EFAE). Each strain was tested 4-fold with each method and processing
was performed with the BioTyper™ software system. The results of MS
identiﬁcation were classiﬁed as “probable species identiﬁcation” (A),
“probable genus identiﬁcation” (B) or “no reliable identiﬁcation” (C)
as given by the automated BioTyper™ identiﬁcation system and were
compared with the results of Vitek2.
Results: Only 3 isolates (2%) displayed discrepancy regarding the results
of MALDI-TOF vs Vitek2 (PCR/Sequencing will be performed for these
3 isolates). Comparison between the two different MALDI-TOF methods
regarding the quality of results, displayed no discrepancy. Regarding
the remaining 152 isolates, 608 tests were done in total by applying
each MALDI-TOF method. Classiﬁcation of these tests in A/B/C
groups was 63.5%/32.4%/13.1% for DS method and 70.4%/2.1%/27.5%
for EFAE method, respectively. Species identiﬁcation was succeeded
in 64.5%/79%/84%/88.2% of isolates by applying the 1st/2nd/3rd/4th
DS test for each strain and in 77%/81%/89%/89% by applying the
1st/2nd/3rd/4th EFAE test respectively. Despite the classiﬁcation by the
system, all results classiﬁed in B displayed the correct species and not
only the genus.
Conclusions: Discrepancy of Candida identiﬁcation between Vitek2 and
MALDI-TOF is rare (2%). No discrepancy was observed comparing
the results of the two preparation methods (DS and EFAE) prior
MALDI-TOF identiﬁcation. The incidence of no reliable identiﬁcation
by applying 4-fold DS and EFAE tests for each isolate was 11.8%
and 11% respectively. However, only 2% of Candida remained without
identiﬁcation by applying both DS and EFAE. MALDI-TOF is a simple,
fast, and cost effective diagnostic method. Multiple tests for each isolate,
combination of DS and EFAE methods and future modiﬁcation of the
software can further improve the species identiﬁcation for Candida
species by MALDI-TOF.
P1836 Prediction of carbapenem resistance in Bacteroides fragilis
by MALDI-TOF mass spectrometry analysis
I. Wybo, A. De Bel, O. Soetens, F. Echahidi, K. Vandoorslaer, M. Van
Cauwenbergh, D. Pierard* (Brussels, BE)
Objectives: To examine the discrimatory power of MALDI-TOF MS to
differentiate between cﬁA-negative and cﬁA-positive Bacteroides fragilis
in order to predict carbapenem susceptibility.
Methods: Ten cﬁA-positive B. fragilis isolates from a previous study
as well as 13 cﬁA-positive meropenem non-susceptible isolates from
routine cultures were compared to 125 cﬁA-negative isolates of the
same survey. cﬁA gene detection was performed by PCR with speciﬁc
primers. Strains were cultured anaerobically on Fastidious Anaerobic
Agar® (LABM, Bury, UK) with 5% horse blood at 35ºC. 4 cﬁA− (1−4)
and 4 cﬁA+ (5−8) isolates were spotted on the target plate after ethanol/
formic acid extraction. One colony was smeared directly on the target
plate. The spots were overlaid by alfa-cyano-4-hydroxycinnamic acid
matrix. Spectra were obtained with Microﬂex LT mass spectrometer and
analyzed with Biotyper 2.0 software (Bruker Daltonics GmbH, Bremen).
The relatedness between spectra was determined using the composite
correlation index (CCI) tool of Bruker Biotyper. CCI values around 1
represent a high relationship between spectra.
Results: Visual inspection of the mass spectra revealed several peak
differences between both groups. A CCI matrix was created using 48
raw spectra of isolates 1−8 after extraction. Mean of CCI values between
respectively cﬁA+ (1−4) and cﬁA− (5−8) isolates were 0.98 and 0.93
and was higher than the mean (0.63) of CCI values (t-test; p< 0.001)
if CﬁA+ isolates were compared with cﬁA− isolates. Spectra obtained
after direct transfer were matched into the CCI matrix. The CCI matching
results classiﬁed unequivocally all strains in the expected group. In the
dendrogram the spectra were clustered in a cﬁA+ and a cﬁA− group
without overlap.
Conclusion: Our data suggest it is possible to differentiate cﬁA-positive
from cﬁA-negative isolates and so predict carbapenem resistance in
B. fragilis strains with MALDI-TOF MS. This discrimination is not
based on the absence or occurrence of speciﬁc peaks. The protein
proﬁles of these two genotypically distinct groups differ at a decade
of m/z values. Since the occurrence of two separate genetic divisions
of B. fragilis is not clustered geographically, the rapid detection of
carbapenem resistance can probably be applied universally. It would be
interesting to add and mark cﬁA positive isolates to the MALDI-TOF
MS databases used for bacterial identiﬁcation, as a surrogate marker for
detection of carbapenem resistance.
P1837 Comparison of Vitek2, Phoenix, and MALDI-TOF for the
identiﬁcation of Acinetobacter species
N. Karah, R. Smyth, B. Haldorsen, A. Sundsfjord, Ø. Samuelsen*
(Tromsø, NO; Va¨xjo¨, SE)
Objectives: Acinetobacter spp is a heterogeneous group of bacteria. At
present, 33 genomic species (gen. sp.) of Acinetobacter are recognised.
The aim of this project was to compare automated phenotypic
identiﬁcation systems (VITEK2 and Phoenix) and MALDI-TOF for the
correct species identiﬁcation of Acinetobacter.
Materials and Methods: The study included 110 Acinetobacter blood
culture isolates collected in Norway between 2005–2007 and typed to the
species level using partial sequencing of rpoB (zone 1). The collection
included Acinetobacter gen. sp. 13TU (n = 53), Acinetobacter gen. sp. 3
(n = 22), A. baumannii (n = 10), A. lwofﬁi/Acinetobacter gen. sp. 9 (n = 8),
A. ursingii (n = 3), A. radioresistens (n = 3), Acinetobacter gen. sp. “close
to 13TU” (n = 3), Acinetobacter gen. sp. “close to towneri” (n = 2), A. soli
(n = 2), Acinetobacter gen. sp. “between 1 and 3” (n = 1), A. guillouiae
(n = 1), Acinetobacter gen. sp. 14BJ (n = 1), and A. calcoaceticus (n = 1).
Identiﬁcations using VITEK2 (bioMe´rieux), Phoenix (Becton Dickinson)
and MALDI-TOF (Bruker Daltonics) were performed according to the
manufacturer’s instructions.
Results: VITEK2 correctly identiﬁed only 12/110 isolates (A. bauman-
nii, n = 9 and A. lwofﬁi, n = 3). 86/110 isolates were incorrectly identiﬁed,
predominantly as A. baumannii. VITEK2 reported a combination
of species and “Low discrimination” or “Inconclusive” for 7/110
isolates. 5/110 isolates were identiﬁed as non-Acinetobacter with
“Excellent identiﬁcation”. Phoenix reported 89 isolates as A. baumannii
(n = 47) or A. baumannii-A. calcoaceticus complex (n = 42), correctly
assigning 80/110 isolates using this broad deﬁnition. 9/110 isolates were
reported as a combination of species of which 5 included the correct
species. Eleven isolates were reported as non-Acinetobacter species or
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unidentiﬁed. MALDI-TOF correctly identiﬁed 49/110 isolates to the
species level. However, 6 of these isolates were reported with a MALDI
score representing “Probable genus identiﬁcation”. 56/110 isolates were
misidentiﬁed by MALDI-TOF mainly because all Acinetobacter 13TU
(n = 53) strains were misidentiﬁed due to the lack of this species in the
database. 5/110 isolates were unidentiﬁed by MALDI-TOF.
Conclusion: VITEK2 and Phoenix showed low resolution and discrim-
inatory power in identiﬁcation to the species level. In contrast MALDI-
TOF was able to distinguish between different species, with the exception
of Acinetobacter gen. sp. 13TU.
P1838 Identiﬁcation of Acinetobacter calcoaceticus–Acinetobacter
baumannii complex strains by MALDI-TOF mass
spectrometry
P. Espinal*, I. Roca, J. Vila (Barcelona, ES)
Objective: Members of the Acinetobacter calcoaceticus–Acinetobacter
baumannii (ACB) complex (A. calcoaceticus, A. baumannii, A. genomo-
species 3 and 13 TU) are phenotypically closely related making their
identiﬁcation very difﬁcult for routine diagnostic laboratories. Although
ARDRA (ampliﬁed rDNA restriction analysis) and PCR-based methods
have shown good correlation with DNA-DNA hybridization results, they
are both laborious and time consuming. The aim of this study was
to identify members of the ABC complex using matrix-assisted laser
desorption/ionization time of ﬂight (MALDI-TOF MS).
Methods: The study included a set of external reference strains of
described genomic species and a set of known clinical genomospecies
from our collection: 1 each of A. junii, A. haemolyticus, A. lwofﬁi,
A. radioresistens, A. calcoaceticus; 20 A. baumannii; 19 genomospecies
3; and 20 genomospecies 13TU. All strains were veriﬁed by ARDRA,
16S-23S rRNA intergenic spacer (ITS), recA typing, presence/absence
of blaOXA-51, and MALDI-TOF MS. Bioinformatic tools were applied
for sequence analysis and MALDI-TOF spectra from were processed
using the BioTyper Software (Bruker Daltonik).
Results: Overall, both reference and clinical strains were correctly
identiﬁed by ARDRA, ITS and recA sequencing. The blaOXA-51 gene
was only found in A. baumannii strains. MALDI-TOF MS correctly
identiﬁed all the genomic strains except A. genomospecies 13TU, since
there is no reference strain within the Bruker database and, therefore,
they were assigned as A. baumannii with a low score. However, MALDI
analysis provided speciﬁc spectra of peaks for all representatives of every
given genomospecies, allowing direct identiﬁcation of ACB complex
strains when speciﬁc proﬁles were compared.
Conclusion: We have shown that each genomic species has a unique
MALDI-TOF MS pattern that can be used as a fast, simple and reliable
alternative to identify members of the ABC complex. However, current
databases need to be expanded to allow for the automated identiﬁcation
of A. genomospecies 13TU. The rapid and accurate identiﬁcation of
clinically signiﬁcant strains will provide better therapeutic alternatives
against nosocomial/community-acquired resistant ABC complex strains.
P1839 Identiﬁcation of non-tuberculous mycobacteria by
MALDI-TOF mass spectrometry ﬁngerprinting
A.J. Buss*, M. Timke, M. Kostrzewa (Groningen, NL; Bremen, DE)
Objectives: Next to the clinical important Mycobacterium tuberculosis
complex (MTC) Nontuberculosis mycobacteria (NTM) are pathogens
especially in immunocompromised and senior people. Identiﬁcation of
NTM species is important for diagnosis and optimal treatment. The
aim of this study is a comparison of genus probe and MALDI based
identiﬁcation results and to investigate the discriminatory power of
MALDI-TOF molecular proﬁling, even for long-time stored samples.
Methods: 19 Mycobacterium species from a laboratory collection were
characterized conventionally using PCR followed by reverse line blot
hybridization of the ampliﬁed products to an in-house or commercial
(Innolipa, Innogenetics) DNA probe assay. Biomass was harvested and
analyzed using the MALDI Biotyper. Mycobacterium samples were
heated at 95ºC for 30 min, washed twice with 500ml of water. The
pellet was extracted with 70% formic acid and pure acetonitrile in
equal amounts. The supernatant was measured in a Microﬂex™ (Bruker
Daltonics, Germany) mass spectrometer and spectra analyzed using
MALDI Biotyper 2.0 software. Furthermore, identiﬁcation results of
Mycobacterium spp. biomass stored for 3 up to 4 years on pyruvate-
enriched Loewenstein-Jensen medium at 4ºC and of freshly cultured ones
were compared for 11 samples. Samples with divergent identiﬁcation
results between reverse line blot hybridization and MALDI-TOF and “no
reliable identiﬁcation“ MALDI Biotyper samples were sequenced and
will be used for database complementation after ﬁnalization of analysis.
Results: Mycobacterium strains were identiﬁed as M. avium, M. fortu-
itum, M. gordonae, M. kansasii, M. malmoense and M. terrae. Some
strains were assigned to different species by MALDI Biotyper than by
the conventional identiﬁcation methods, some as a different species and
few mycobacteria were not identiﬁed using the MALDI Biotyper. Adding
new species to the database enable their secure identiﬁcation in future
times. Dendrograms were calculated with acquired and database spectra.
Diverging identiﬁcation results were examined by additional methods
and discussed.
None of the identiﬁcation results of the 3 to 4 years old biomass differed
from the results of fresh cultivated samples. Therefore, it is suitable to
analyze even long-time stored samples by MALDI-TOF MS.
Conclusions: It has been demonstrated that MALDI-TOF MS is a
rapid and reliable method for discrimination and identiﬁcation of NTM
species.
P1840 Challenges when applying MALDI-TOF mass spectrometry
as a diagnostic tool for the identiﬁcation of dermatophytes
R. Jensen*, D. Nielsen, M. Cavling Arendrup (Copenhagen, DK)
Objectives: Matrix-assisted laser desorption/ionisation time-of-ﬂight
mass spectrometry (MALDI-TOF MS) has proven a valuable tool for
identiﬁcation of microorganisms and we thus investigated the applica-
bility of MALDI-TOF MS for routine identiﬁcation of dermatophytes.
Methods: Forty-six clinical dermatophyte isolates and 20 reference
strains representing 17 of the most clinically relevant dermatophytes were
included (Table). Species identiﬁcation was conﬁrmed by sequencing
of the ITS1 and ITS2 regions. Sample preparation for MALDI-TOF
MS were evaluated and optimised by adjusting volume of formic
acid, incubation time and extraction technique with/without preliminary
ethanol ﬁxation (Erhard, M. Experimental Dermatology 2007) and mass
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spectra were measured for the clinical isolates whereas multiple spectra
were obtained from the reference strains and added to the original
spectrum database. The Bruker pre-deﬁned score intervals was applied,
requiring a log-score 2.0 for a reliable identiﬁcation to species level
and 1.7 to the genus level.
Results: MALDI-TOF mass spectra were successfully obtained from
35/46 clinical isolates and 17/20 reference strains. Spectra from clinical
isolates were evaluated against the modiﬁed spectrum database yielding
31/35 with correct best match (81.6%) based on molecular identiﬁcation.
In 18 cases (51.4%) the log-score value was 2.0 indicating reliable
species identiﬁcation. In ﬁve cases, all with a log-score below 1.7
an incorrect best match was suggested three of which was incorrect
at the genus level. Overall, the MALDI-TOF identiﬁcation performed
best for T. interdigitale, A. benhamiae, T. erinacei, T. tonsurans, and
T. schoenleinii (15/19 correct with log-score2), while only 2/10 clinical
Microsporum isolates and 0/3 E. ﬂoccosum isolates yielded high quality
spectra and correct identiﬁcation.
Conclusion: Successful protein extraction is a signiﬁcant criterion
for successful MALDI-TOF MS analyses, and despite optimisation
of sample preparation and supplementation of the database with 20
reference isolates several clinical isolates failed to yield high quality
spectra. This may be related to the multifaceted structure and robust
nature of dermatophytes rather than a general complication when
analysing fungi with MALDI-TOF MS.
P1841 Rapid identiﬁcation of bacteria and fungi from positive
blood cultures by MALDI-TOF proteome proﬁling
F. Del Chierico, S. Ranno, B. Lucignano, M. D’Urbano, S. Tredici,
P. Bernaschi, L. Putignani*, D. Menichella (Rome, IT)
Objective: A rapid and reliable identiﬁcation (ID)of pathogens
responsible of blood stream infection is very important to applied
a targeted therapy with a positive outcome of paediatric patients.
Blood culture is actually considered the gold standard technique in
microbiological routine, because allows pathogens ID and antibiotic
susceptibility. However this technique is time consuming, then the use of
MALDI TOF MS ID assay can give a potential improvement in clinical
management. In our experience we have analyzed positive blood cultures
with both traditional and proteomic approach to compare the efﬁcacy of
two methods in a paediatric reality.
Methods: 200 blood cultures resulted positive to BACTEC System (BD
diagnostics) were Gram stained and cultured on solid media for microbe
ID and antibiotic susceptibility by VITEK 2 (Biomerieux) or Phoenix
(BD diagnostics). For MALDI TOF MS ID 6mL from each bottle
was centrifuged in gel Vacutainer tubes (BD diagnostics), to separate
microorganism. The peptides were extracted by the standard ethanol/
formic acid protocol and analysed by Microﬂex mass spectrometer
(Bruker Daltonics). Spectra generated were processed by Biotyper
software with scores associated with the correct ID probability. Results
were compared to the reference biochemical systems and, when
discordant, veriﬁed by MALDI-TOF MS on colonies isolated.
Results: 13 samples were false positive on BACTEC system, results
shown by negative Gram stain, no microbial growth, and no MALDI
MS ID. Of 200 strains, 109 were correctly identiﬁed by both methods,
19 were discordant and 45 were identiﬁed only by traditional technique.
Of interest, the scores were reliable at genera and species level in 58/109
samples, at genera level in 28/109, and in 23/109 were correspondent to
a not reliable ID.
14 blood culture had polimicrobial growth, in 11 MALDI TOF assay
provided a correct ID of only one microbe. 21/200 isolates were
identiﬁed as yeast by vitek-2, but only 3 were identiﬁed by MALDI
TOF MS.
Conclusions: MALDI TOF MS is a useful method to support routine
ID of bacterial isolates in blood culture, because of its rapidity (around
45 minutes), with a sensitivity of 65% and a speciﬁcity of 72%.
However this method shows few limits: i) the algorithm of scores is not
representative of the true ID; ii) failure of yeast ID; iii) in polimicrobial
samples microbe discrimination is not achieved; iv) the sensitivity (65%)
is affected by single spot loading capacity.
P1842 Direct identiﬁcation of microorganisms from the bioMe´rieux
BacT/Alert blood culture system by MALDI-TOF is possible
J.D. Haigh*, D. Ball, M. Eydmann, M. Millar, M. Wilks (London, UK)
Objectives: Several studies have reported poor results when trying to
identify microorganisms directly from the bioMe´rieux BacT/ALERT
blood culture system using MALDI-TOF. The aim of this study was
to evaluate two new methods for direct identiﬁcation of microorganisms
from this system.
Methods: Aliquots were removed from any positive bottle and processed
by two different methods. 1. Enrichment by centrifugation over a density
cushion, and 2. Bruker MALDI Sepsityper™ method. In both cases, the
resultant pellets were extracted with formic acid and acetonitrile, applied
onto a steel MALDI target and overlaid with a-cyano-4-hydroxycinnamic
acid matrix. Analysis was performed with the Bruker Microﬂex LT
MS running Bruker MALDI Biotyper software (V2.0). Results were
compared to the identiﬁcation results obtained after subculture in the
conventional manner.
Results: Thus far, 181 positive blood cultures have been processed by
both methods (see table). Overall the two methods gave similar results
with 74% correct identiﬁcations obtained with the Bruker Sepsityper™
method and 75% for the enrichment method. Gram negative bacilli
(GNB) were correctly identiﬁed in 90% and 91% of cases respectively.
Gram positive bacilli (GPB) proved to be the most difﬁcult organisms to
identify with only 2/13 (15%) correctly identiﬁed by the enrichment
method compared to 5/13 (38%) with the Sepsityper™ system. No
signiﬁcant difference between the two methods. The presence of charcoal
in the blood culture medium had an impact on the ability of both methods
to give a good identiﬁcation in some cases. Thus, although 90% of
GNB could be identiﬁed directly, 5/6 (83%) of GNB which could not be
identiﬁed by the enrichment method and 7/7 (100%) of those which could
not be identiﬁed by the Sepsityper™ method, were derived from charcoal
containing bottles. There were 10 mixed cultures which, neither method
was able to identify successfully, these were excluded from the analysis.
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Conclusion: These results show that contrary to previous reports it is
possible to identify bacteria directly from bioMe´rieux blood cultures in
about three quarters of cases where there is only one organism present.
Further modiﬁcation of the methods described above are currently being
evaluated.
P1843 Streptococcus identiﬁcation using proteomic, metabolic and
molecular biologic approaches
M. Risch, T. Leibundgut, U. Nydegger*, D. Radjenovic, L. Risch
(Liebefeld, CH)
Objectives: The taxonomy of Streptococci currently comprises 17
genera of catalase-negative Gram-positive cocci split off the genus
Streptococcus since 16S rRNA gene sequencing patterns deviated
from identiﬁcations based solely on haemolysis reaction, colony size,
biochemical properties and presence of Lanceﬁeld antigens. 16S rRNA
assays are considered as ‘gold standard’ but they suffer from non-
applicability in daily routine. MALDI TOF fails in producing signiﬁcant
matches of S. pneumoniae with genome databases.
Methods and Results: We here collect 75 clinical routine samples
revealing the agar plate identity of S. viridans and further delineate
their speciﬁcity using MALDI TOF (Bruker) and Vitek (BioMe´rieux),
completed by 16S rRNA (800 bp) in selected disparate results.
Complete genus and species agreement: 25 (33%); disagreement: 50
(66%), of which 14 cases (28% of disagreeing cases) concerned
genus disagreement, the remainder only species disagreement. Species
identiﬁcation prior to release of the results was made in 13 instances
using conventional optochin test, colony appearance, Gram staining
and latex-enhanced agglutination assays Pastorex (Bio-Rad, Marnes,
France). In 8/15 cases MALDI erroneously revealed S. pneumoniae with
samples clearly being of another species, the most frequent disagreement
being S. pneumoniae/S. mitis/S. oralis. With two samples, further
distinction potential was brought by 16S rRNA-Gene PCR − in one
case: S. anginosus (MALDI was right, Vitek result: S. sanguinis) and
in the other: S. pneumoniae (MALDI was right, Vitek was loaded with
metabolically weak sample − artefact).
Conclusion: Our results indicate that MALDI TOF has a reduced
speciﬁcity in correctly identifying Streptococci. Often, isolates remain
misidentiﬁed as S. pneumoniae, most belonging to S. mitis.
P1844 Discrepancies in Gram-positive cocci identiﬁcation when
comparing conventional tests and mass spectrometry
A. Iranzo Tatay*, J.L. Lopez Hontangas, M. Gobernado Serrano
(Valencia, ES)
Objectives: Study if there are discrepancies in the results of
identiﬁcation of Gram-positive cocci using our usual techniques of
identiﬁcation, with the results obtained using mass spectrometry Maldi-
Tof as a new method for identiﬁcation.
Methods: 80 Gram-positive cocci (see table) isolated from different
types of patient samples were identiﬁed in our laboratory by our usual
techniques of identiﬁcation VITEK2 (bioMe´rieux, Marcy l’Etoile, FR)
API rapid ID 32 Strep (bioMe´rieux) and other conventional routine
identiﬁcation tests as Dnase, manitol, esculin hydrolysis among others.
Then isolated strains were analysed by mass spectrometry using the
Maldi-Tof microﬂex (Bruker Daltonik, Bremen, DE). Spectra were
compared using maldiBiotyper 2.0 18.0 software (Bruker Daltonik). In
some cases a pre-extraction with formic acid and acetonitrile according
to protocol was made.
Results: Matching identiﬁcation was obtained in the 93,7% of cases,
97,4% to Staphylococcus (100% S. aureus), Enterococcus 100%,
Streptococcus 87,5%.
Discrepancies we found:
Staphylococcus epidermidis by VITEK2 was identiﬁed as Staphylococ-
cus hominis by MS. Colimycine resistance and anaerobic growth
indicate that should really be a S. epidermidis*.
Streptococcus (3) optochin resistant and bile insoluble identiﬁed by
API rapid ID 32 as Strep. mitis/oralis, were wrongly identiﬁed as
Streptococcus pneumoniae by MS with score values higher than 2 in
all cases.
Gemella bergeri* identiﬁed by VITEK2 (97% probability) there was
no reliable identiﬁcation (score below 1,700) by MS neither by
direct transfer or pre-extraction. Results were Staphylococcus equorum
(score: 1,246) and Gemella morbillorum (score: 1,525) respectively.
*Pending sequencing.
Conclusion: Mass spectrometry is a rapid and reliable method for
identiﬁcation of Gram-positive cocci, especially Enterococcus, and
Staphylococcus with rare exception.
Currently is not a suitable method for identiﬁcation of Streptococcus
pneumoniae. False positive ID for this pathogen was already described
in literature and we have conﬁrmed in our lab that MS is not able to
differentiate between S. mitis/oralis and Streptococcus pneumoniae.
MS was not able to generate any reliable identiﬁcation for a Gram
positive cocci identiﬁed as Gemella bergeri by VITEK2 with 97%
probability. We belive this is because Maldibiotyper database is not yet
sufﬁciently developed.
Bioﬁlm: diagnostic approaches to therapeutic
measures
P1845 Evaluation of colonisation of pacemakers and deﬁbrillators
from strains that produce bioﬁlm and their study with
atomic force microscopy
S. Arampatzi*, G. Giannoglou, E. Protonotariou, S. Logothetidis,
S. Paraskevaidis, V. Vasilikos, I. Styliadis, E. Diza (Thessaloniki, GR)
Objectives: Part of the pathogenesis of infections in patients with cardiac
implants is the ability of microorganisms to create bioﬁlms, which are
resistant to the immune responses and antimicrobial agents. Recently,
Atomic Force Microscopy (AFM) is being used for studing phenomena
such as the irreversible cell adhesion and bioﬁlm formation. The aim of
this study was the investigation of colonization of implantable cardiac
pacemakers and deﬁbrillators in hospitalised patients, the detection of
possible bioﬁlm creation by these strains, and their study with AFM.
Methods: The study included 26 patients that were hospitalized
in Cardiologic Clinic from which, 25 brought pacemaker and one
deﬁbrillator. Reason for admission was replacement of the pacemaker
system. Tissue specimen from the ﬁbrous capsule surrounding the
pacemaker and swab from coating of ﬁbrous capsule was obtained
from each patient. Specimens were cultured following routine methods.
Bacterial identiﬁcation and antimicrobial susceptibility was performed
with VITEK2-automated system (bioMerieux, France). The Tube method
was used for the detection of slime-producing ability and in vitro bioﬁlm
formation was quantiﬁed by the polystyrene adherence assay. All isolates
with high and moderate slime production were studied with AFM tapping
mode technique on a surface of Highly Oriented Pyrolytic Graphite
(HOPG). The surface roughness was estimaded by the measurement
of root-mean-square roughness (Rrms) and peak-to-peak distance (P2P)
parameters.
Results: (1) Pacemakers and deﬁbrillators showed high rates of colo-
nization (74%), mainly by Staphylococcus hominis and Staphylococcus
epidermidis. (2) 50% of the strains isolated (mainly S. hominis,
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S. epidermidis) were positive for slime production with the tube method,
while the quantitative method showed that 15% of the strains were
high-slime producers (S. hominis, Rhizobium radiobacter) and 7% were
moderate producers (S. hominis, Leuconostoc spp). (3) The study of
surface roughness on HOPG with AFM showed that high and moderate
slime producers presented different roughness (Rrms and P2P) compared
with slime non producers.
Conclusions: (1) Implantable cardiac pacemaker systems are highly
colonized by strains of normal skin microﬂora 50% of which may
produce slime. (2) AFM is a powerful technique that can be used for
studying the matrix of microorganisms that create bioﬁlm.
P1846 Evaluation of bioﬁlm formation on coronary angiography
catheters and their study with atomic force microscopy
S. Arampatzi*, G. Giannoglou, E. Protonotariou, S. Logothetidis,
Y. Chatzizisis, S. Hatzimiltiadis, I. Styliadis, E. Diza (Thessaloniki, GR)
Objectives: Catheter related infections (CRI) are a signiﬁcant cause
of morbidity and mortality in hospitalised patients. The pathogenesis
of most CRI is complex and multifactorial and has been linked with
the capacity of microorganisms to form sessile communities, known
as bioﬁlm. AFM can be used for imaging biological samples and in
the investigation of phenomena such as the irreversible cell adhesion
which is the initial stage of bioﬁlm formation. Aim of this study was
the investigation of colonization of coronary angiography catheters by
different strains, in patients hospitalised in a Cardiologic Clinic, the
detection of possible creation of bioﬁlms by these strains and their study
with AFM.
Methods: From a total of 26 hospitalised patients in a Cardiologic Clinic
for coronary angiography, a catheter section about 20 cm was taken
after its removal. Duration of catheter retention time was 8,8±3,4 hours.
No patient showed local or generalized infection during hospitalization.
Specimens were cultured following routine methods. Detection of
potential colonization was done following the semi quantitative technique
Maki et al. and bacterial identiﬁcation was performed with VITEK2-
system (bioMerieux, France). The Tube method was used for phenotypic
detection of slime producing ability and in vitro bioﬁlm formation was
quantiﬁed by the polystyrene adherence assay. Isolates were studied
with AFM tapping mode technique on a surface of Highly Oriented
Pyrolytic Graphite (HOPG). The surface roughness was estimated by the
measurement of root-mean-square roughness (Rrms) and peak-to-peak
distance (P2P) parameters.
Results: (1) Coronary angiography catheters showed high rates
of colonization (73%), mainly by Staphylococcus epidermidis and
Staphylococcus hominis. (2) 33% of the strains isolated (mainly
S. hominis, S. epidermidis), were positive for slime production while the
quantitative method didn’t show strains that were high-slime producers
and only 20% were moderate producers (S. hominis, S. epidermidis)
(3) Images were taken of all strains with moderate slime production
studied with AFM. Rrms and P2P parametres showed that surface
roughness increased compared to bioﬁlm non-producers control strains.
Conclusions: (1) Coronary angiography catheters are highly colonized
by strains of normal skin microﬂora, 33% of which may produce slime.
(2) AFM is a technique that can be used for the detection of bioﬁlm
matrix.
P1847 Visualisation of microbial bioﬁlm on explanted central
venous catheters by two-photon laser scanning microscopy
F. Tessarolo*, I. Caola, M. Lorenzato, F. Piccoli, G. Nollo, P. Caciagli
(Trento, IT)
Objectives: To visualize microbial bioﬁlm by two-photon laser scanning
microscopy (TPLSM) on central venous catheters (CVC) removed from
patients.
Methods: In TPLSM an infrared laser is used to deliver two infrared
photons to excite visible ﬂuorescence from a ﬂuorochrome. Because
infrared photons are typically absorbed by biological systems less
than visible light, this technique allows deeper penetration and optical
sectioning, reducing cell phototoxicity and dye photobleaching.
We used a two-photon laser scanning system mounted on an upright
microscope. The light source was a Ti:Sa fs-laser tunable in the 690–
1040nm range.
Four ﬂuorochromes were preliminarily tested on microbial bioﬁlm grown
in vitro: Fluorescein-5(6)-isothiocyanate (FITC), 5-Carboxyﬂuorescein
(FCARB), Fluorescein Acid Yellow (FLAY), Rhodamine 6G (RH6G).
Glass cover slips were introduced in a screw-cap tube with 3ml
of bacterial suspension and incubated in a oscillating waterbath at
37ºC. After 3 days, colonized cover slips were extracted, washed in
HEPES, ﬁxed in 2.5% glutaraldehyde in HEPES, and stained with a
ﬂuorescent dye (1 mM in water). Two-photon excitation was carried out
at wavelengths from 800 to 1000 nm in 20 nm steps and ﬂuorescence
intensity was obtained by image analysis. Two photon auto-ﬂuorescence
of non-stained polyurethane CVC was similarly quantiﬁed.
CVC removed from patients and positive to quantitative cultures were
immediately ﬁxed for 24 h in 2.5% glutaraldehyde in HEPES. Catheter
tips (1 cm segment) were glued to a glass slide and stained with a
ﬂuorescent dye. Optical sections of the biological layer were obtained
adjusting the excitation wavelength in order to obtain dye ﬂuorescence
and to limit catheter auto-ﬂuorescence.
Results: FITC, FCARB, FLAY, RH6G showed a decrease of relative
ﬂuorescence intensity to less than 50% for excitation wavelength
respectively higher than 960, 940, 960 and 840 nm. CVC auto-
ﬂuorescence was reduced after 860 nm.
TPLSM on catheters removed from patients allowed optical sectioning
of blood coagulum and microbial bioﬁlm showing embedded bacterial
colonies (Fig. 1). Signal to noise ratio was high with FLAY excited at
940 nm.
Conclusion: TPLSM allowed high magniﬁcation of bacterial bioﬁlm
on CVC removed from patients. Optical sectioning of thick (20−30
micrometers) biological residuals and the detection of bacteria close to
the catheter surface was obtained.
P1848 The effects of ferulic and gallic acids on motility and
bioﬁlm control of pathogenic bacteria
A. Borges*, M.J. Saavedra, M. Simo˜es (Vila Real, Porto, PT)
Introduction: Bioﬁlms are multicellular communities and represent the
prevalent mode of microbial life in nature, industrial processes, and
health. It is estimated that bioﬁlms contribute to more than 80% of
all infections in humans. A particular characteristic is their extreme
resistance to antimicrobial treatments. Moreover, the emergence of
resistant bacteria to conventional antimicrobials clearly shows that
new bioﬁlm control strategies are required. Most of the antibiotics
available today come from natural origin, especially from microbial
sources. Recent ﬁndings indicate that some natural phenolic compounds
commonly found in plants have anti-biofouling potential.
Objectives: The aim of this study was to evaluate the activity of two
phenolic acids [gallic acid (GA) and ferulic acid (FA)] against bacterial
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motility and bioﬁlm formation by Escherichia coli, Pseudomonas
aeruginosa, Staphylococcus aureus and Listeria monocytogenes.
Methods: The anti-biofouling activities of GA and FA were tested
against the bacteria using a microtiter-plate assay for bioﬁlm mass
quantiﬁcation (crystal violet staining) and viability activity assessment
(alamar blue staining). The effects of the phenolics were also tested on
bacterial swimming, swarming and twitching motilities.
Results: The phenolics tested showed a higher potential to reduce the
mass of bioﬁlms formed by the Gram-negative bacteria comparatively
to those Gram-positive. In terms of viability, FA and GA promoted
reductions higher than 70% for all the bioﬁlms tested. The application
of FA and GA promoted a signiﬁcant decrease in swimming, swarming
and twitching motilities. GA caused total inhibition of swimming
(L. monocytogenes), swarming (L. monocytogenes, E. coli and S. aureus)
and twitching (L. monocytogenes, E. coli and S. aureus) motility. FA
caused total inhibition of swimming (L. monocytogenes and S. aureus),
swarming (L. monocytogenes, E. coli and S. aureus) and twitching
(L. monocytogenes, E. coli and S. aureus) motility. These results are
important because motility inhibition can account for bioﬁlm control.
Conclusion: FA and GA demonstrated potential to inhibit bacterial
motility and to control bioﬁlms of pathogenic bacteria. Further studies
will be developed in order to assess the effects of their combination in
bioﬁlm control.
P1849 Characterisation of bacterial cells recovered from bioﬁlms
formed on orthopaedic metal components used in surgical
implants
E.L. Pizzolitto*, C.A.L. Santos, F.F. Campos Junior, A.C. Bernardi,
T.P. Leivas, K.E. Kojima, A.C. Pizzolitto (Araraquara, Sao Paulo, BR)
Objectives: The aim of this study was to isolate and identify
microorganisms growing in bioﬁlms on orthopaedic metal implants as
plates/screws and bone screws used in the alignment and ﬁxation of
fractures at skeletal system until healing to occur.
Methods: We studied a set of screw-plate and screws of austenitic
stainless steel ASTM F138/F139 and NBR ISO 5832−1/9 after surgical
removal, which were transported to a Clinical Microbiology Laboratory
in a sterile polyethylene bag in Ringer’s solution. They were then rinsed
with phosphate buffered saline (PBS) solution and, also, submitted
to ultrasonic bath at a frequency of 40 kHz±2 per 5 minutes for
recovery of microorganisms attached to the implant. After sonication
and vortexing the PBS aliquot was cultured aerobically by using standard
clinical methodology. All of the bacterial isolates obtained from these
samples were characterized and identiﬁed using accepted microbiological
techniques. Gram-positive, catalase-positive, coagulase-negative cocci
and, Gram-negative bacteria were identiﬁed by using the BD BBL
Crystal™ Identiﬁcation Systems − Gram-Positive/Enteric/Nonfermenter.
The Christensen assay was used to assess slime production for all
staphylococci isolated. The antibacterial susceptibility was determined
by using the disk-diffusion Kirby-Bauer method.
Results: The organisms isolated from sets of plate-screw and screw were:
Staphylococcus epidermidis (S. epidermidis), S. schleiferi, S. simulans,
Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacter
cloacae. The coagulase-negative cocci are slime producers and, shown
resistance to erythromycin, clindamycin and oxacillin; Pseudomonas
aeruginosa: trimethoprim/sulfamethoxazole, ticarcillin/clavulanic acid
and ampicillin; Acinetobacter baumannii: ceftazidime and Enter-
obacter cloacae: amoxicillin/clavulanic acid, ampicillin, cephalothin,
cefoxitin, cefazolin, ciproﬂoxacin, trimethoprim/sulfamethoxazole and
levoﬂoxacin.
Conclusion: The results showed that Gram-negative bacilli, Gram-
positive, catalase-positive cocci can colonize internal ﬁxation devices
and can be multidrug resistants to antimicrobial agents.
P1850 Isolation of genes involved in bioﬁlm formation of a
Klebsiella pneumoniae strain causing pyogenic liver abscess
M.C. Wu*, T.L. Lin, P.F. Hsieh, H.C. Yang (Taipei, TW)
Community-acquired pyogenic liver abscess (PLA) complicated with
meningitis and endophthalmitis caused by Klebsiella pneumoniae is an
emerging infectious disease. To investigate the mechanisms and effects
of bioﬁlm formation in virulence of K. pneumoniae causing PLA, we
used microtiter plate assay to determine the levels of bioﬁlm formed
by K. pneumoniae mutants from a transposon mutant library of a
K. pneumoniae PLA-associated strain. A total of 4 bioﬁlm-increased
mutants and 23 bioﬁlm-decreased mutants were identiﬁed. One of
the 4 bioﬁlm-increased mutants was sugE insertion mutant. Further
characterization showed that mucoviscosity, expression of capsular
polysaccharide (cps) genes, and production of CPS raised in sugE
mutant strain. One of the 23 bioﬁlm-decreased mutants was treC
insertion mutant. Deletion of treC not only impaired bioﬁlm formation
from early stage but also reduced the production of CPS. In addition,
bioﬁlm cells had higher expression levels of treC. In vitro and in vivo
competition assays revealed that the treC mutant strain was attenuated in
competitiveness with regard to bioﬁlm formation and colonization during
infection in mice. treC affects K. pneumoniae colonization through
bioﬁlm regulation. Bioﬁlm formation may play a role in K. pneumoniae
PLA pathogenesis.
P1851 Molecular genotyping, adhesion and bioﬁlm formation in
methicillin-resistant Staphylococcus aureus clinical strains
G. Gherardi, S. Pomponio, D. Visaggio, A. Pompilio, G. Dicuonzo,
S. Angeletti*, R. Creti, L. Baldassarri, G. Di Bonaventura (Rome,
Chieti, IT)
Objectives: In the present study we evaluated the correlation between
methicillin resistance and bioﬁlm formation in S. aureus clinical isolates.
Methods: A total of 36 methicillin-resistant (MRSA) and 73 methicillin-
susceptible (MSSA) S. aureus clinical strains from different source of
isolation were genotyped by Pulsed-Field Gel Electrophoresis (PFGE).
Resistance to methicillin was conﬁrmed by the detection of the mecA
gene. Adhesion to and bioﬁlm formation on polystyrene were evaluated
by the microtiter plate assay in aerobic, microaerophilic (5% CO2), and
anaerobic atmospheres.
Results: Twenty-one different PFGE types were identiﬁed. A total of 8
and 16 PFGE types were found among MRSA and MSSA, respectively,
while 3 were shared by both groups. Among PFGE types shared by more
than 5 isolates, PFGE types 1 and 15 were identiﬁed only in MRSA,
while PFGE types 2, 3, 7, 10 and 14 consisted only of MSSA. Among
PFGE types shared by both groups, MRSA isolates predominated in
PFGE type 4, while MSSA were more prevalent in PFGE types 5 and
6.
Bioﬁlm level formed in anaerobiosis was signiﬁcantly lower than that
observed under aerobic and microaerophilic conditions (p< 0.001),
either comparing MRSA and MSSA or within MRSA strains. Overall,
MRSA did not differ from MSSA with regard to adhesion and bioﬁlm
levels, regardless of atmosphere tested. However, signiﬁcant differences
in bioﬁlm formation in aerobiosis was observed among speciﬁc PFGE
groups including MRSA strains. In particular, MRSA strains belonging
to PFGE type 4, comprising also MSSA isolates, formed signiﬁcantly
more bioﬁlm than that observed in MRSA isolates belonging to other
PFGE types and to MSSA strains of the same group. No difference in
adhesion levels was observed among pulsotypes.
Conclusion: Speciﬁc PFGE types represented by MSSA or MRSA were
found, thus suggesting that certain MRSA and MSSA isolates segregate
in different genetic lineages. Overall, MRSA and MSSA strains do not
differ in adhesion and bioﬁlm formation. Nevertheless, a clonal group of
MRSA, deﬁned by PFGE 4, exhibited a signiﬁcant increased ability in
forming bioﬁlm with respect to other PFGE groups comprising MRSA
as well as to all MSSA isolates.
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P1852 Comparison of various antimicrobial agents as catheter
lock solutions in an in vitro model of coagulase-negative
staphylococcal bioﬁlm
A. Pen˜a, R. Ga´lvez, C. Toma´s-Jime´nez, D. Parra, J. Herna´ndez-Quero,
J. Parra-Ruiz* (Granada, Murcia, Oviedo, ES)
Objectives: Coagulase-negative staphylococci (CoNS) are the main
causative agents of catheter-related bacteraemia (CRB). The antibiotic
lock technique (ALT) has been used to treat catheter colonization;
however, the optimum choice of antimicrobial agents and their
corresponding concentrations and exposure times have not been
determined. In addition bioﬁlm regrowth after ALT has not been
evaluated either, so our objective was to evaluate the efﬁcacy of different
ALT solutions using an in vitro model of central venous catheter (CVC)
infection.
Methods: The following lock solutions were evaluated: daptomycin
(DAP) 5mg/mL (reconstituted with lactated Ringer’s [LR]), teicoplanin
(TEC) 5mg/mL, both alone and combined with gentamicin (GM)
2,5mg/mL, levoﬂoxacin 2,5mg/mL, clarythromycin (CLA) 5mg/mL and
Ethanol 20%. PBS was used as control. Experiments were performed on
full introcan Safety® 14G catheters (Braun Medical, Spain) inoculated
with two clinical strains of methicillin resistant CoNS. AL solutions were
exchanged every 24h for 72h. After 72h, catheters were reincubated
another 24 h with fresh media. Catheters were drained, ﬂushed and
sonicated at 0,4,8,24,48,72 and 96h to assess CFU/ml. Scanning electron
microscopy was performed to evaluate persistence of bioﬁlm at 0, 72 and
96h.
Results: All antibiotic combinations resulted in signiﬁcant reductions
(p< 0.05) of log(10) cfu/mL at 72h for both organisms compared
with controls. DAP-LR resulted in signiﬁcant reductions of log(10) for
both organism versus TEC (p = 0,001). Only DAP was able ro reduce
logCFU below the limit of detection at 72h, however neither DAP
nor TEC prevent regrowth after 24h of ALT removal. SEM studies
showed persistence of bioﬁlm at 72 and 96h. DAP combinations were not
better that DAP alone, although they were signifcantly better than TEC
combinations. None of them were able to prevent regrowth at 24h after
ALT removal. TEC+GM resulted in improved efﬁcacy compared to TEC
alone at 72h. Ethanol alone reduce logCF/mL below the limit of detection
but did not prevent regrowth. DAP-Ethanol and TEC-ethanol eradicate
bioﬁlm at 72h, but only DAP-ethanol prevent regrowth at 24h after ALT.
Conclusion: Our CVC model demonstrated that ALT with 5mg/ml of
DAP-LR showed consistent better activity than ALT with 5mg/ml of
TEC, however both were unable to erradicate bioﬁlm after removal of
ALT.
DAP-Ethanol eradicates bioﬁlm and prevent regrowth so it should be
explored in clinical trials.
P1853 Application of Escherichia coli bioﬁlm supported on clinop-
tilolite for biosorption of cadmium from aqueous solution
A. Maleki*, E. Kalantar, B. Davari, A. Mahvi (Sanandaj, Tehran, IR)
Objectives: Bioﬁlms are microcosms consisting of microorganisms
distributed throughout a matrix of ﬁbrous and highly hydrated
extracellular polymeric substances (EPS). They play an important role
in natural aquatic environments. Since heavy metals pollution represents
a serious problem for human health and for life in general and bacterial
bioﬁlms to be able to concentrate metal species from dilute aqueous
solutions and to accumulate them within their cell structure the aim of
this study was to investigate the ability of a bioﬁlm of Escherichia coli,
an effective agent for metal adsorption, supported on clinoptilolite for
the removal of cadmium from aqueous solutions.
Methods: Adsorption experiments were carried out in a laboratory-scale
batch model with clinoptilolite and clinoptilolite covered by a bacterial
bioﬁlm. Escherichia coli were isolated from hospital environment. The
effect of initial heavy metal concentrations, pH, and agitation time on
the removal efﬁciency was studied. Finally, experimental results were
analysed using four isotherm equations.
Results: It was found that the clinoptilolite exhibits lower adsorption
to cadmium than clinoptilolite covered by bioﬁlm and adsorption of
the cadmium is inﬂuenced by several parameters such as cadmium
initial concentration, biosorption time and solution pH. The results
showed uptake values of 6.8mg/g and 9.6mg/g in the batch model with
clinoptilolite covered by bioﬁlm, respectively, for initial concentrations
of 10 and 100mg/L. It was also observed that as the initial cadmium
concentration increases, the uptake increases too, but the removal
percentage decreases. Maximum absorption efﬁciency was achieved
at pH value of 6. Among the models tested, namely the Langmuir,
Freundlich, and Sips isotherms, the biosorption equilibrium for cadmium
was best described by the Sips model.
Conclusion: It is concluded that the presence of bioﬁlm increased the
uptake efﬁciency of clinoptilolite and the bioﬁlm tested is very promising
for the removal of cadmium from aqueous solution.
P1854 Phenolic antioxidants that target the staphylococcal
membrane may have potential as bioﬁlm-eradicating agents
N. Ooi*, I. Chopra, J. Cove, A. Eady, A.J. O’Neill (Leeds, Bradford, UK)
Objectives: Bacterial bioﬁlms are refractory to the action of many
antibacterial agents currently in clinical use. Since approximately 80%
of bacterial infections in humans involve a bioﬁlm component, this
represents a signiﬁcant contributing factor to antibiotic treatment failure.
To address this problem, it is important to discover and develop novel
antibacterial agents which possess anti-bioﬁlm activity. Here we report
that a number of phenolic antioxidants show potent activity against
staphylococcal bioﬁlms in vitro, suggesting that these compounds, or
derivatives thereof, may represent candidates for the treatment of bioﬁlm
infections.
Methods: Susceptibility testing was performed by broth microdilution
according to British Society for Antimicrobial Chemotherapy (BSAC)
guidelines. The Calgary bioﬁlm device was used to establish Staphylo-
coccus aureus and Staphylococcus epidermidis bioﬁlm MICs (bMICs)
and minimum bioﬁlm eradication concentrations (MBECs). The effects
of antioxidants on the membrane of S. aureus SH1000 were assessed
using the BacLight™ assay and by monitoring K+ release via atomic
absorption spectroscopy.
Results: Of 15 phenolic antioxidants, 14 displayed antibacterial activity
against planktonic cultures (MIC 0.25−64mg/L) of S. aureus SH1000,
and the proliﬁc bioﬁlm-forming strains S. aureus UAMS-1 and S. epi-
dermidis RP62A. Eight of these compounds eradicated bioﬁlms formed
by all three test organisms, with bakuchiol and totarol demonstrating
the greatest potency (MIC 4mg/L, bMIC 8mg/L, MBEC 16mg/L
and MIC 4mg/L, bMIC 4mg/L, MBEC 16mg/L respectively). By
contrast, none of 16 established antibacterial agents tested were able to
eradicate staphylococcal bioﬁlms (MBEC >256mg/L). All compounds
displaying anti-bioﬁlm effects acted on the membrane, causing leakage
of intracellular K+ and/or >60% loss of membrane integrity.
Conclusion: In contrast to established antibacterial agents, several
phenolic antioxidants exhibited good anti-bioﬁlm activity, eradicating
staphylococcal bioﬁlms. All antioxidants that were able to eliminate
bioﬁlms displayed membrane-disrupting activity, suggesting that ac-
tivity against the membrane is necessary to sterilise staphylococcal
bioﬁlms. However, several established antibacterial agents and phenolic
antioxidants which disrupt the membrane failed to exhibit activity
against bioﬁlms, indicating that membrane-damaging activity alone is
not sufﬁcient for bioﬁlm eradication.
P1855 Multidrug-resistant Acinetobacter baumannii and
Pseudomonas aeruginosa bioﬁlm formation and the
destruction activity of macrolide antibiotics
S. Fujimura*, H. Takane, Y. Nakano, A. Watanabe (Sendai, JP)
Objectives: Acinetobacter baumannii and Pseudomonas aeruginosa are
the most common cause of nosocomial and bioﬁlm related infections.
Recently, Hospital infection by these strains acquired multidrug
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resistance (MDR) has been problem. The aim of the present study
is to evaluate the effect of mature bioﬁlm destruction activity of
macrolide antibiotics because macrolides indicate inhibitory effect of
bioﬁlm formation.
Methods: The total four clinical isolates of both A. baumannii and
P. aeruginosa, including for two each MDR strains were used in this
study. These strains were collected from 4 Japanese hospitals. Antibiotic
susceptibilities were determined using the micro dilution method. To
form bioﬁlm, 10 micro-L of each bacterial suspension of McFarland No.1
were added to 190 micro-L of TSB with 1% glucose in 96-well plates and
incubated at 37ºC for 24hr under anaerobic conditions. Mature bioﬁlms
washed twice with milli-Q water and added 200 micro-L of 1, 10, or
100mg/L of clarithromycin or azithromycin. After 24hr or 72hr of each
macrolide exposure, bioﬁlms were washed and stained by 1% crystal
violet. Absorbance at 595nm was used as a quantitative measurement of
the bioﬁlms.
Results: A. baumannii had less quantity of bioﬁlms formation than
P. aeruginosa. The bioﬁlm destruction effect by the exposure of 1
and 10mg/L macrolides 24 hr was not shown. However, the amounts
of bioﬁlms which drug-susceptible A. baumannii and P. aeruginosa
produced decreased to half by 72 hr exposure with 100mg/L of
macrolides. A difference of the bioﬁlm destruction effect was not found
between clarithromycin and azithromycin.
Conclusion: When it was treated clarithromycin or azithromycin at
100mg/L more than 72 hours, the bioﬁlm destruction effect was
conﬁrmed.
P1856 Improved antibiotic activity against Pseudomonas
aeruginosa bioﬁlms using a novel surface active lamellar
body mimetic LMS-611
R. Rajendran*, C. Williams, E. McCulloch, G. MacGregor, S. Bicknell,
G. Park, G. Ramage (Glasgow, UK)
Objectives: The opportunistic pathogen Pseudomonas aeruginosa grows
within the cystic ﬁbrosis (CF) lung as a bioﬁlm, which hinders antibiotic
activity due to the physical nature of the bioﬁlm. The aim of this study
was to assess the activity of a panel of antibiotics in the presence of
a novel surface active lamellar body mimetic LMS-611 to determine
whether it can potentiate antimicrobial activity against P. aeruginosa
bioﬁlms.
Methods: P. aeruginosa (PA01, PA14, H183 and two clinical CF strains)
bioﬁlms were grown on a Nunc Immunosorp peg plate model for 48 h on
a rocking platform. Bioﬁlms were tested in a checkerboard array using
LMS-611 in combination with piperacillin, aztreonam, meropenem,
gentamycin, tobramycin, erythromycin and ciproﬂoxacin. The effect of
pretreating bioﬁlms with LMS-611 at different time points (5 min, 1,
8 and 24 h) prior to challenging with piperacillin and gentamycin was
also investigated. Scanning electron microscopy was also performed on
treated bioﬁlms.
Results: LMS-611 demonstrated no antimicrobial activity on its own.
In combination studies it was shown to be most efﬁcacious at 50%
(v/v), signiﬁcantly reducing the sessile MIC’s of piperacillin (4−16
fold), gentamycin (4−32 fold) and ciproﬂoxacin (1−16 fold). Potentiation
of the antibiotics was also demonstrated with aztreonam (2−4 fold),
meropenem (1−4 fold) and tobramycin (1−16 fold). No effect was
observed for erthyromycin. It was also shown that short pretreatments
(5 min and 1 h) with LMS-611 did not reduce sessile MIC’s, but after
8 h a two-fold reduction was observed for piperacillin and gentamycin.
Scanning electron microscopy demonstrated that the bioﬁlm was scant
and dispersed following LMS-611 combinational treatment.
Conclusion: As the clinician’s ability to treat P. aeruginosa within
the CF environment diminishes, novel agents that potentiate existing
antimicrobial compounds are an attractive option. This study has shown
that LMS-611, a surface active agent with biophysical properties, can
reduce the sessile MIC’s of key CF antibiotics. Our data indicates
that disruption alters the biophysical properties of bioﬁlms, which may
improve access of the antibiotics into the bacterial cells.
P1857 Activity of daptomycin, levoﬂoxacin, clindamycin and
rifampicin against Propionibacterium acnes in planktonic
and bioﬁlm state
U. Furustrand*, W. Zimmerli, A. Trampuz (Lausanne, Liestal, CH)
Objectives: Propionibacterium acnes is a low-virulent, facultative
anaerobe organism, which causes delayed infections associated with
implants. These infections are often difﬁcult to eradicate due to per-
sistence and reduced antimicrobial susceptibility in bioﬁlms. Therefore,
we investigated the antimicrobial activity of daptomycin, levoﬂoxacin,
clindamycin and rifampicin against P. acnes in planktonic form by
conventional tests (minimal inhibitory and bactericidal concentration)
and in bioﬁlms on large-surface beads by measuring growth-related heat
production (microcalorimetry) on porous sintered glass beads.
Methods: The activity of daptomycin, levoﬂoxacin, clindamycin and
rifampicin against P. acnes (ATCC strain 11827) was tested. The minimal
inhibitory concentration (MIC) was determined by Etest, the minimal
bactericidal concentration (MBC) by macrobroth dilution (MBD) in
reduced Brain Heart Infusion (rBHI) at 48 h. P. acnes bioﬁlm was formed
on porous sintered glass beads (diameter 2mm, surface ~2.65 cm2)
in rBHI supplemented with 0.5% glucose (rBHI+g) at 37ºC under
anaerobic conditions without agitation. After 72 h, beads were washed
in sterile normal saline trice and incubated in rBHI+g containing serial
dilution of antimicrobials for 24 h. Beads were then washed as described
above and placed in 4ml rBHI+g. Recovering bacteria were detected
by measuring heat production at 37ºC for 72 h. The minimal bioﬁlm
inhibition concentration (MBIC) was deﬁned as the lowest antimicrobial
concentration inhibiting heat production during 72 h. All experiments
were repeated three times.
Results: Table shows the MIC, MBC and MBIC values of tested
antimicrobials. Against planktonic bacteria, rifampicin was the most
active antimicrobial, whereas clindamycin was not bactericidal. Against
bioﬁlm bacteria, considerably higher concentrations of daptomycin
(256x) and rifampicin (8000x) compared to MIC were required to
inhibit growth of P. acnes bioﬁlm during 72 h. Neither levoﬂoxacin nor
clindamycin were inhibiting P. acnes bioﬁlms up to 1024mg/L.
Conclusions: The activity of daptomycin and rifampicin was reduced in
P. acnes bioﬁlm, whereas levoﬂoxacin and clindamycin showed anti-
bioﬁlm activity only at very high concentrations. Microcalorimetry
allowed the investigation of most promising antibiotic agent eradicating
bioﬁlms for in vivo experiments in a foreign-body infection animal
model.
P1858 Ciproﬂoxacin or linezolid in combination with rifampicin
is effective against Enterococcus faecalis in bioﬁlm
A. Holmberg*, M. Mo¨rgelin, M. Rasmussen (Lund, SE)
Objectives: Enterococcus faecalis is increasingly recognized as an
important pathogen in infections of medical devices such as prosthetic
joints. Bacterial bioﬁlm formation is central in the pathogenesis
of infections related to foreign material, and E. faecalis can form
bioﬁlm. Treatment of E. faecalis infections is complicated both by
the antimicrobial resistance of the bacterium and by the ability of the
bacterium to form bioﬁlm. The aim of this study was to assess the
antibiotic susceptibility of E. faecalis isolates in bioﬁlm to suggest
improved treatments for infections of prosthetic joints.
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Methods: E. faecalis isolates were from infections of prosthetic hip
and knee joints. Minimal bioﬁlm eradication concentration (MBEC) for
ampicillin, vancomycin, linezolid, ciproﬂoxacin, and rifampicin alone
and in combinations was determined. E. faecalis bioﬁlms in microtiter
wells or on beads of bone cement were treated with the same antibiotics
for various times followed by plating to quantify surviving bacteria.
Results: The E. faecalis isolates displayed MBECs for the various
antibiotics in the 64–512mg/l range. When combined with 8mg/l
rifampicin, MBEC for ciproﬂoxacin and linezolid dropped to 16−32mg/l
for the four isolates tested. In bioﬁlms formed on plastic surfaces
signiﬁcant bacterial killing (>2−3 log decrease in colony forming units
(cfu)) was seen after an 8 hrs exposure to antibiotics. Thus we performed
time-kill experiments on bioﬁlms of four isolates formed on plastic
surfaces and on bone cement beads under these conditions. For all
isolates, the combination of ciproﬂoxacin and rifampicin, followed by
linezolid and rifampicin, was most potent in reducing the number
of cfu. E. faecalis resistance to rifampicin developed in our system
when bioﬁlms were subjected to this antibiotic alone. We observed no
resistance to rifampicin when bacteria were subjected to a combination
of ciproﬂoxacin and rifampicin.
Conclusions: Our data show that combinations of ciproﬂoxacin or
linezolid with rifampicin have good effect on E. faecalis bioﬁlms in
vitro. The use of such combinations should be considered for testing in
humans with for exemple joint prosthesis infections with E. faecalis.
P1859 The evaluation of lethal photosensitisation for
decontamination of implant surfaces in the treatment of
peri-implantitis in patients of Paschoal Dantas Dental
College, Sao Paulo, Brazil
E. Costa*, C. Costa, F.P. Varolli, M.F. Rodrigues, D. Cassiri (Sao
Paulo, BR)
Objective: Peri-implantitis is considered to be a multifactorial process
involving bacterial contamination of the implant surface. A previous
study demonstrated that a combination of toluidine blue O (100mg/ml)
and irradiation with a diode soft laser with a wavelength of 905 nm
results in an elimination of Porphyromonas gingivalis (P. gingivalis),
Prevotella intermedia (P. intermedia), and Actinobacillus actinomycetem-
comitans (A. actinomycetemcomitans) on different implant surfaces
(machined, plasma-ﬂame-sprayed, etched, hydroxyapatite-coated). The
aim of this study was to examine the laser effect in vivo.
Method: In 38 patients with TitaniumFix implants who showed clinical
and radiographic signs of peri-implantitis, toluidine blue O was applied
to the implant surface for 1 min and the surface was then irradiated
with a diode soft laser with a wavelength of 690 nm for 60 s. Bacterial
samples were taken before and after application of the dye and after
lasing.
Result: The cultures were evaluated semiquantitatively for A. actino-
mycetemcomitans, P. gingivalis, and P. intermedia. It was found that
the combined treatment reduced the bacterial counts by 2 log steps on
average.
Conclusion: The application of TBO and laser resulted in a signiﬁcant
reduction (P< 0.0001) of the initial values in all 3 groups of bacteria.
Complete elimination of bacteria was not achieved.
P1860 Antibioﬁlm activities of bismuth-thiol-biocides on bacteria
isolated from urinary catheter surfaces
G. Rahmany*, A. Abdi Ali, P. Mohammadi (Tehran, IR)
Objectives: The urinary catheters used in patients, can be colonized by
the microorganisms which produce bioﬁlm if they remain in their urinary
tract for a long period. This structure acts as an accumulating center for
infections; since prohibition of bioﬁlm formation in the urinary catheter
is essential. This study focus on inhibiting bioﬁlm production on the
catheter surfaces by use of bismuth ethanedithiol (BisEDT) and bismuth
propanedithiol (BisPDT).
Methods: In this study we used Escherichia coli, Acinetobacter bau-
mannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter
dissolvens, Staphylococcus aureus and Enterococcus faecalis which were
isolated from Foley catheters previously. We determined MICs of each
isolate in presence of BisEDT and BisPDT by microdilution technique
and bioﬁlm formation in presence of BTs was measured quantitatively
by microtiter plate and crystal violet methods.
Result: MICs and bioﬁlm inhibition percentage amounts of each
bacterium in presence of biocides are shown in table 1. Results
showed that BTs at MIC and sub-MIC concentrations inhibited bioﬁlm
production signiﬁcantly (P< 0.05).
Conclusion: The unique antibioﬁlm properties of BTs may be useful to
prevent or treat catheter associated urinary tract infections (CAUTI) due
to bacteria that can attach and produce bioﬁlm on catheter surfaces. It
seems that coating catheters with BTs can inhibit bioﬁlm formation on
their surfaces signiﬁcantly and prevent CAUTI in patients.
P1861 Bioﬁlm communities on urinary tract catheters
V. Hola*, F. Ruzicka (Brno, CZ)
Objectives: More than 40% of nosocomial infections belong to
infections of urinary tract; most of them are infections of catheterized
patients. Bacterial colonization of urinary tract and catheters causes not
only the particular infection, but also some complications, e.g. blockage
of catheters with crystallic deposits of bacterial origin, generation of
gravels and pyelonephritis. Adhesion of bacteria to the catheter depends
on many factors, e.g. surface charge, hydrophobicity or hydrophility of
the catheter and bacterial cell, on speciﬁc genes for adhesion etc. The
longer has the patient catheter, the higher diversity shows the bioﬁlm
microﬂora.
Methods: The aims of this study were to ﬁnd out the species composition
of the mixed bioﬁlm communities formed on the urinary catheters and
to discriminate particular causative agents of infections of urinary tract
and their importance as a bioﬁlm-formers in the microbial community.
We examined catheters from 535 patients. All catheters were sonicated
and the microbes were quantiﬁed. The quantiﬁcation of the microbes
was followed by their biochemical identiﬁcation.
Results and Conclusion: From the 535 catheters we isolated 1555
strains of microbes. Most of the catheters were colonized by three or
more microbes, only 12,5% showed mono-microbial colonization. We
isolated 39 different microbial taxa. Most often we isolated Enterococcus
faecalis (294 strains), Escherichia coli (213 strains), Pseudomonas
aeruginosa (148 strains) and Candida albicans (141 strains). Among
the microbes isolated from the urinary catheters, there were signiﬁcant
differences in the bioﬁlm-forming ability and therefore we conclude,
that some microbial species have greater potential to cause bioﬁlm-
based infection, where others can be only passive members of bioﬁlm
community. Differentiation of risk groups of bacteria in complex mixed-
species bioﬁlms of the urinary catheters enables to focus therapy of
these infections right way. The study took place on the Institute for
Microbiology, Faculty of Medicine, Masaryk University in Brno and
was supported by the Project IGA No. 9678−4.
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P1862 Coral-associated bacteria as a novel source for antibioﬁlm
and quorum quenching agents
D. Bakkiyaraj*, C. Siva Sankar, S. Karutha Pandian (Karaikudi, IN)
Objectives: Resistance to the drugs is more common today with
most of the bacterial pathogens, which limits the use of antibacterial
agents that directly implies pressure on the pathogens in turn resulting
in development of resistance. Hence an alternate target viz. quorum
sensing (QS) system of bacteria has been targeted. QS inhibition also
called quorum quenching is a promising method to combat multidrug
resistant pathogens since it inhibits the production of bioﬁlm & other
virulence factors of the bacterial pathogens without affecting the normal
growth, thus allowing no chance for the pathogen to gain resistance.
Coral ecosystem being an unexplored reserve for microorganisms,
are recently reported to have Actinomycetes as potential producers
of bioactive compounds. The likeliness of getting novel bioactive
compounds from these coral ecosystems is more prominent, since many
such microorganisms of this ecosystem are novel. Hence, coral associated
(CA) bacteria were screened for antibioﬁlm and quorum quenching
agents.
Methods: Bactericidal activity was tested against Staphylococcus aureus
ATCC 11632, methicillin resistant Staphylococcus aureus ATCC 33591,
S. aureus clinical isolates, Pseudomonas aeruginosa ATCC 10145 and
Serratia marcescens, since an ideal quorum quencher should not have
any antibiotic activity. The agents with no bactericidal activity were
subjected to a set of assays both quantitative and qualitative for revealing
their antibioﬁlm and quorum quenching activity. Bioﬁlm quantiﬁcation
using crystal violet stained quantiﬁcation method and its architecture in
treated as well as controls were visualized under CLSM.
Results: Out of 41 coral associated actinomycetes screened, 5 isolates
have shown antibioﬁlm and 13 isolates have shown quorum quenching
activity against both Gram positive and Gram negative pathogens. Isolate
CA-3 has shown complete inhibition of bioﬁlm formation by S. aureus
and its drug resistant counterparts. CA-21, 23, 27, 34 and 41 were
shown to inhibit the virulence factors like swarming, swimming, pigment
production, bioﬁlm formation and extracellular enzymes production that
are controlled by the QS system of P. aeruginosa and S. marcescens
signiﬁcantly.
Conclusion: Coral ecosystem thus proves to be an unexplored reserve
for novel anti-infectives. Puriﬁcation and characterization of these agents
will reveal a novel bioactive compound that is effective against multidrug
resistant pathogens.
P1863 Fluconazole susceptibility, oxidative stress response and
production of extracellular hydrolases in Candida glabrata
clinical isolates
N. Berila, P. Hyrossova, J. Subik* (Bratislava, SK)
Objectives: Candida glabrata is an opportunistic human pathogen
causing both mucosal and bloodstream infections. The understanding
of the factors contributing to virulence of this second most common
Candida pathogen after C. albicans is essential for a more efﬁcient
control of infections caused by this fungus. The aim of this study was
to determine the susceptibility of the C. glabrata clinical isolates to
ﬂuconazole and agents inducing oxidative stress as well as to assess
their factors of virulence.
Methods: Susceptibilities of isolates to ﬂuconazole were assayed by
the broth microdilution method in 96 well plates according to the
proposed CLSI (formerly NCCLS). The zone inhibition assay on YPGE
medium was used for determination of susceptibilities of isolates to
7-chlorotetrazolo[5,1-c]benzo[1,2,4]triazine (CTBT). Minimal inhibitory
concentrations to menadion and H2O2 were determined by spot assay.
Cell surface hydrophobicity was measured by the water-octane two-
phase assay). Bioﬁlm formation on untreated polystyrene 96-well plate
was quantiﬁed using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT) reduction assay or crystal violet (CV)
staining followed by measuring of absorbance using a microplate reader.
The proteinase production was detected on medium containing bovine
serum albumin. The phospholipase production was detected on medium
containing sterile egg yolk.
Results: Among 38 C. glabrata clinical isolates 28.9% were resistant to
ﬂuconazole. All isolates were susceptible to hydrogen peroxide, diamide
and 7-chlorotetrazolo[5,1-c]benzo[1,2,4]triazine (CTBT) inducing an
increased formation superoxide and other reactive oxygen species in
fungal cells. The mean relative cell surface hydrophobicity (CSH) of
isolates was 21.9. All isolates showed bioﬁlm formation. A high bioﬁlm
formation was observed among 60.5% of isolates. The 76.3% and 84.2%
of isolates displayed varying degrees of extracellular proteinase and
phospholipase activity, respectively. The ﬂuconazole resistant isolates
displayed a signiﬁcantly higher phospholipase production compared with
ﬂuconazole sensitive ones.
Conclusion: The results demonstrate a differential distribution of factors
contributing to virulence of C. glabrata clinical isolates and point to
the association of their resistance to ﬂuconazole with phospholipase
production.
P1864 A novel glycolipid biosurfactant from marine Serratia
marcescens disrupts pathogenic Candida albicans BH and
Pseudomonas aeruginosa PAO1 bioﬁlms
D. Dusane*, V. Pawar, Y. Nancharaiah, V. Venugopalan, A.R. Kumar,
S. Zinjarde (Pune, Chennai, IN)
Objectives: To study the anti-bioﬁlm activity of novel glycolipid
biosurfactant isolated from marine Serratia marcescens.
Methods: The marine strain was isolated from the surface of Symphyllia
sp., a coral obtained from the seashores of Mandapam, Bay of
Bengal, India. Morphological, biochemical and 16S rRNA analysis were
performed for identiﬁcation of the bacterial isolate. The culture was
identiﬁed as Serratia marcescens. Cell free supernatants of Serratia
marcescens grown in liquid medium were tested for antimicrobial
activity against the pathogenic Candida albicans BH and Pseudomonas
aeruginosa PAO1. Biosurfactant activity of S. marcescens was analyzed
by drop collapse, blood hemolysis and surface tension reduction
methods. The antimicrobial biosurfactant was puriﬁed by solvent
extraction and silicic acid column chromatography and characterized
by TLC, FTIR and GC-MS. Minimum inhibitory concentration (MIC)
against the planktonic cells of C. albicans BH and Ps. aeruginosa PAO1
was determined using standard broth microdilution assay. Preformed
bioﬁlm disruption and anti-adhesion ability of biosurfactant against
C. albicans and Ps. aeruginosa was studied in microtiter plates and on
glass surfaces. Confocal laser scanning microscopic analysis along with
IMARIS imaging technique was used to study the extent of bioﬁlm
disruption by the biosurfactant.
Results: The marine bacterium, identiﬁed as S. marcescens displayed
strong antimicrobial activity against Candida albicans BH and
Pseudomonas aeruginosa PAO1. Surface tension of the growth medium
decreased from 52.0 to 29.6 mN/m after 24h of growth. Characterization
of the biosurfactant showed presence of glycolipid as evident from
TLC, FTIR and fatty acid analysis. The novel glycolipid biosurfactant
contained glucose and palmitic acid moieties. The MIC against
C. albicans BH and Ps. aeruginosa PAO1 was >30mg/ml. Bioﬁlm
adhesion was inhibited and pre-established bioﬁlms of C. albicans
and Ps. aeruginosa were dispersed at sub-MIC concentrations of the
biosurfactant. Confocal laser scanning microscopic analysis showed
effective removal of preformed bioﬁlms of Ps. aeruginosa PAO1 and the
fungal, C. albicans bioﬁlms. The study shows antimicrobial biosurfactant
obtained from S. marcescens effective in controlling fungal and bacterial
bioﬁlms.
Conclusion: The results may provide a clue for the development of novel
natural strategy to control detrimental fungal and bacterial bioﬁlms.
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P1865 RT-PCR microarray detection of viral respiratory pathogens
in acute exacerbations of COPD in France
F. Renois*, J. Perotin, G. Deslee, F. Lebargy, L. Andreoletti (Reims, FR)
Objectives: Most of COPD acute exacerbations (AE-COPD) are
associated with bacterial or viral respiratory tract infections. The
relative importance of different respiratory pathogens and relevant
microbiological data in AE-COPD remains unclear. We assessed the
epidemiology of viral respiratory infections in AE-COPD using RT-
PCR microarray detection methods in Champagne-Ardenne (Northern
France).
Methods: 51 stage 2−3 COPD patients were included in a prospective 12
months follow-up study and followed monthly. At each AE-COPD and
one month later, clinical score (dyspnea, sputum volume and purulence),
respiratory functional tests, blood samples and induced sputum samples
were collected. Sputum samples were analyzed by a RT PCR microarray
detection system detecting 17 different viral respiratory pathogens and
by classical viral culture assays.
Results: 53 documented AE-COPD occured in 26 patients, whereas
25 patients did not exhibit any AE-COPD. Viral respiratory pathogens
were detected in 23 (43%) AE-COPD. The diagnostic yield of
viral identiﬁcation by PCR was 6.7 times higher than conventional
viral culture. Human metapneumovirus (hMPV) and human rhinovirus
(HRV) infection were detected in respectively 15% and 21% of AE-
COPD, whereas the other viruses identiﬁed were inﬂuenza A (6%),
inﬂuenza B (2%), parainﬂuenza III (2%) and respiratory syncytial virus
(2%). Demographic characteristics, including COPD severity, were not
associated with the risk of viral infection in AE-COPD. The clinical
severity of AE-COPD was not associated with respiratory viral pathogens
detection (P> 0.15 for all). Viral infection appeared to have no effect on
subsequent readmissions or mortality rate over a study period of 1 year.
Conclusion: Our study demonstrates that hMPV and HRV infections are
important pathogens in AE-COPD and may be considered as triggering
factor for AE-COPD.
P1866 Laboratory investigation of the Greek measles 2010 outbreak
A. Melidou*, G. Gioula, V. Pogka, M. Exindari, A. Moutoussi,
D. Sgouras, K. Papadakos, D. Chatzidimitriou, D. Karabaxoglou,
A. Mentis, N. Malisiovas (Thessaloniki, Athens, GR)
Objectives: In the prospect of measles virus elimination by 2010 a new
epidemic is currently ongoing in Greece and other European countries.
The purpose of this study is the laboratory investigation of the current
Greek measles outbreak.
Methods: Epidemiological information was collected from 24 sero-
logically tested measles patients during the 2010 measles outbreak in
Greece. Measles virus RNA, isolated from the clinical samples using
the Qiagen viral RNA mini kit, was used in RT-PCR to amplify the
nucleoprotein 450bp region, which was then sequenced and studied in
terms of nucleotide variation and phylogeny.
Results: 37.5% of the cases belonged to the Roma population
of Bulgarian nationality, 29% belonged to the Greek non-minority
population, 25% belonged to the Greek Roma population and 1 had
Albanian nationality. Of those cases, 21% were less than 1, 33% were
1−14, 25% were 15−29 and 21% were older than 30 years old. All of the
detected viruses were of the D4 genotype, which is currently circulating
in Greece among the above mentioned population groups. Phylogenetic
analysis revealed that the examined strains belonged to the 4th subgroup
of the D4 measles virus strains.
Conclusion: The same measles virus D4 group is also circulating in
other EU countries. The ﬁrst cases and clusters in Greece were among
persons of Bulgarian nationality, probably related to the measles outbreak
in Bulgaria which started in April 2009. The Greek 2010 outbreak,
which counts 126 patients until now, is epidemiologically linked to the
Bulgarian outbreak. The high proportion of Greek nationals, mainly
from Roma communities, underlines that despite the high national
immunisation coverage with measles-mumps-rubella vaccine, pockets
of unvaccinated populations still exist. It is essential to continue the
epidemiological surveillance of measles in Greece to monitor the
transmission pattern of the virus and the effectiveness of measles
immunization, which eventually will lead to the elimination of the virus
in our country.
Figure: Phylogenetic analysis of the sequences of the Greek measles strains based
on the 450 carboxy-terminal end of the N gene was achieved by MEGA 4.1
software. The dendrogram was constructed by comparison of the Greek D4
sequences with representative strains from the 4 proposed subgroups of the D4
genotype and currently circulating D4 strains from other countries. The tree was
built with the NJ algorithm and evaluated by 1000 bootstrap pseudoreplicates.
P1867 Respiratory viruses involved in acute respiratory infections
in a Greek paediatric population during the winter period
of the years 2005–2008
V. Pogka*, A. Kossivakis, M. Giannaki, A. Moutousi, D. Sgouras,
T. Panagiotopoulos, M. Theodoridou, V. Syriopoulou, A. Mentis
(Athens, GR)
Objectives: Viruses are the major cause of pediatric acute respiratory
infections (ARI) and yet many cases of illness remain uncharacterized.
Our aim was to reveal the distribution of several respiratory viruses
in children diagnosed as having an inﬂuenza-like illness (ILI) or other
respiratory tract infections, over the winter period of the years 2005–
2008.
Methods: Molecular assays including conventional and real time PCR
protocols were employed to screen respiratory specimens for the
identiﬁcation of common or recently identiﬁed respiratory viruses.
Specimens were collected by the clinicians or health care workers of
the National inﬂuenza sentinel system organized by the Hellenic Centre
for Disease Control and Prevention and of several pediatric clinics.
Results: Rhinopharyngeal or throat swabs from 3307 patients aged 0−18
yo, including 1856 males and 1451 females, were analyzed. A diagnosis
of ILI was made in 1272 of the above total cases of ARI. Viral presence
was conﬁrmed in 2268 (68.6%) samples and included 979 respiratory
syncytial viruses (hRSV), 660 inﬂuenza viruses (hINF), 537 rhinoviruses
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(hRV), 188 metapneumoviruses (hMPV), 183 bocaviruses (hBoV), 142
parainﬂuenza viruses (hPIV) and 73 coronaviruses (hCoV). Detection of
adenoviruses was performed only during the ﬁrst winter season, where
80 out of 943 samples were found positive. Simultaneous presence of
two or three viruses was established in 450 (19.4%) of the above positive
cases. Data on seasonality indicated that the majority of viral infections
occurred between January and February. In ILI positive cases, hINF was
the most prevalent virus accounting for nearly half of all viral infections,
followed by hRV and hRSV. In the remaining 2035 children with other
respiratory infections, hRSV predominated (54.5%) followed by hRV
and hINF. In children older than 1 yo hINF was the predominant virus,
with its prevalence increasing proportionally with age. In contrast, hRSV
prevailed in children younger than 2 yo and along with hMPV and hBoV,
detection rates decreased disproportionably to increasing age.
Conclusion: The application of molecular methods revealed that a wide
range of viral pathogens is implicated in 70% of ARI cases, establishing
the major contribution of hRSV, hINF and hRV to respiratory tract
infections in Greek children. Interestingly, the recently identiﬁed hMPV
and hBoV contributed to a proportion up to 11.5% of the total samples
examined.
P1868 In-house real-time PCRs are more sensitive than
RespiFinder Plus TwoStep, and xTAG RVP for detection of
respiratory viruses in nasopharyngeal ﬂocked swabs from
adult patients with lower respiratory tract infections
K. Loens*, A. Vanderstraeten, C. Lammens, H. Goossens, F. Coenjaerts,
E. Claas, A. van Loon, M. Ieven on behalf of the GRACE study group
Introduction: We investigated the viral aetiology in lower respiratory
tract infections (LRTI) in the European GRACE primary care network
(PCN) using mono- and small multiplex real-time nucleic acid
ampliﬁcation tests (NAATs). These had been shown to be more sensitive
than large multiplex (MX) assays on a GRACE proﬁciency panel, but
are more time-consuming and expensive due to the large diversity
of respiratory viruses. Large MX assays could be more convenient.
This study therefore compares the performance of the xTAG™ RVP
(Luminex) and the RespiFinder® Plus TwoStep (PathoFinder) kit to in-
house real-time PCRs on nasopharyngeal ﬂocked swabs (NPFSs).
Methods: 361 NPFSs, (COPAN) were collected prospectively in 11
PCNs in 8 European countries during the winter season of 2007/8.
They were sent to the local lab to be frozen until transport to the
central lab in Antwerp for subsequent nucleic acid (NA) extraction
by the NucliSens EasyMAG (bioMe´rieux). Aliquots of NA extracts
were sent to the LUMC and UMCU for detection of inﬂuenzaviruses
(INF) A/B, parainﬂuenzavirus (PIV) 1−4, human rhinoviruses (HRV),
human metapneumovirus (hMPV), respiratory syncytial virus (RSV),
adenoviruses (HAdV), and coronaviruses (HCoV) by in-house monoplex
and small MX real-time PCR. The xTAG RVP and RespiFinder TwoStep
kit were retrospectively applied in Antwerp on a selection of samples
found positive for any virus with the in-house PCRs. Sensitivity and
speciﬁcity were calculated against in-house PCRs.
Results: 366, 347, and 290 respiratory viruses were detected by the
real-time in-house PCRs, the RespiFinder TwoStep and the xTAG RVP
tests, respectively. Double infections were detected in 14, 6, and 2
samples by in-house PCR, RespiFinder TwoStep kit and xTAG RVP,
respectively. Sensitivity and speciﬁcity of the commercial assays are
shown in the table: INF was detected signiﬁcantly less frequently by both
RespiFinder and xTAG RVP compared to the in-house PCRs: P = 0.01
and P = 0.001 respectively; HCoV was detected less often by xTAG RVP
only: P = 0.001 compared to in-house PCRs. All other sensitivities were
not signiﬁcantly different. In general, samples found negative by the
commercial assays tended to have a low viral load (based on Ct-value).
Conclusions: In-house PCRs were more sensitive than both commercial
MX assays. The RespiFinder performed better than the xTAG RVP,
especially for HCoV where a low sensitivity was obtained with the xTAG
RVP.
P1869 Rapid killing of inﬂuenza virus and RNA preservation from
samples held at elevated temperatures for extended periods
L.T. Daum*, S.A. Worthy, Y.W. Choi, G.W. Fischer (San Antonio,
Columbus, US)
Background: Sensitive and speciﬁc molecular detection is an important
part of pathogen identiﬁcation and epidemiological surveillance during
pandemics and epidemics. Commercial collection and transport media,
commonly referred as VTM, that maintain viability of organisms
in specimens increase both infectious disease risk and RNA/DNA
degradation by nucleases, oxidation and hydrolysis. A speciﬁcally
designed molecular transport medium (MTM) for nucleic acid testing
(NAT) has been utilized to preserve labile inﬂuenza RNA and nucleic
acids from other pathogens. Speciﬁc Aim: We report the use of a MTM to
inactive/kill high titers of inﬂuenza A/Vietnam/1203/2004 (H5N1) and
pandemic A/Mexico/4108/2009 (H1N1) virus. Additionally, long-term
preservation of released viral RNA for 62 days at ambient temperature
and 37ºC was evaluated by real-time RT-PCR.
Methods: For viral killing studies, collection swabs were loaded with
0.1mL H5N1 (1.5×107 TCID50/mL) or viral storage buffer (negative
controls), placed into MTM and held for 10, 30, or 60 minutes at
ambient temperature. The samples were cultured using MDCK cells for
96 hours and visually examined for CPE with total TCID50 determined.
Preservation of H5N1 and H1N1 virus was analyzed using real-time RT-
PCR at 0, 1, 2, 5, 7, 14, 30, and 62 days post-inoculation. Additional RT-
PCR ampliﬁcation of large segments was performed to analyze integrity
of preserved inﬂuenza H1N1 RNA. For this experiment, aliquots were
placed into MTM, incubated at 37ºC for 2 weeks and tested by RT-PCR.
Results: High pathogenic H5N1 inﬂuenza virus placed into MTM
resulted in no detectable, viable virus and was equivalent to negative
controls. RNA from H5N1 and H1N1 viruses preserved in MTM for up
to 62 days at ambient temperature were detectable by real-time RT-PCR
analysis with only minimal degradation of target signal. Additionally,
inﬂuenza virus RNA was preserved for at least 2 weeks in MTM at
37ºC using real-time PCR detection.
Conclusion: MTM rapidly kills microbes by lysing lipid membranes,
and destroying proteins and enzymes (including nucleases). Further,
MTM stabilizes and preserves the released nucleic acids from viruses
and collected microbes. The ability to safely collect and ship clinical
specimens at ambient temperature and detect viral RNA with NAT weeks
later could be a valuable asset for tracking and surveillance of pandemic
inﬂuenza (H5N1, H1N1/09) viruses or other emerging pathogens.
P1870 Genomic extraction methods for detection of viral
respiratory infections
M. de On˜a*, P. Capo´n, L. Garrido, M.E. Alvarez, J. Boga, S. Melo´n
(Oviedo, ES)
Introduction: Semi-automated extraction of viral genome has improved
viral respiratory virus diagnosis. Semiautomated Magmax method
(Applied Biosystem, USA) processes 96 samples very fast, Hamilton-
kPCR method (Siemens, Sweden) include 96 puriﬁes extracts samples
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fully automatic, and Magnapure (Roche Diagnostic, Switzerland) process
PCR mix for 32 samples.
Objective: To compare the reliability of these methods to detect
respiratory viral infection, and to know the viability of stored samples
at 4ºC more than 1 week.
Individuals, Samples and Methods: 151 respiratory specimens
(67 pharyngeal swabs, 39 nasal washes, 27 nasopharyngeal swabs,
11 nasal swabs, 4 bronquial aspirates, and 3 broncoalveolar washes)
belonging to different individuals were collected in viral transport
media: 29 patients with lower respiratory infection (LRI), 106 with
upper respiratory infection (URI), and 16 with unknown symptoms. All
samples were processed for Hamilton method according manufacture’s
instructions, and two different “in-house” multiplex nested RT-PCRs
(one against inﬂuenzavirus A and B (IA, IB), respiratory syncytial virus
(RSV), and rhinovirus, and the other one against parainﬂuenzavirus,
metapneumovirus and coronavirus) were performed. The other two
genome puriﬁcation methods (Magmax and Roche) were developed in
those samples stored at 4ºC during one week at least.
Results: At least one virus was recovered in 61 (40.4%) samples (44
rhinovirus, 6 IB, 3 parainﬂuenzavirus, 4 RSV, 1 IA, 1 metapneumovirus,
2 mix infections) puriﬁed by Hamilton method. One week later, only
29 samples (19.2%) stored at 4ºC were positive (p< 0.0001). This
percentage was similar to the one observed performing Magmax method
(19.8%, 30 samples), and, at the same time, to the one observed using
Magnapure method (17.2%, 26 samples). The concordances were: 86.7%
between Hamilton-Magnapure, 84.1% between Hamilton-Magmax, and
84.8% between Magnapure-Magmax. According clinical symptoms, a
virus was detected in 16 (55%) patients of the LRIs, and in 41 (38%)
of the URIs. Once the samples were processed and PCR performed,
the percentage decreased signiﬁcantly to 27% (8 patients) and 17% (18
patients) after the following week.
Conclusions: Delays of more than one week in the genome puriﬁcation
affects sensitivity in samples stored at 4ºC. The three methods assayed
have the same sensitivity, although the concordance was not optimal.
The sensitivity decrease was not related to the respiratory symptoms.
P1871 Human rhinovirus species occurrence among adults with
respiratory tract infection and asymptomatic individuals
during two consecutive winter seasons
K. Zlateva*, S. van Nieuwkoop, F. Coenjaerts, N. Farzad, T. Verheij,
P. Little, M. Ieven, E. Claas on behalf of the GRACE Study Group
Objectives: Human rhinoviruses (HRVs) are classiﬁed into three species:
HRV-A, HRV-B and HRV-C and are the leading cause of respiratory tract
infections in humans. The disease outcomes associated with different
HRV species and genotypes are poorly established. Several studies have
documented high incidence and more severe illness caused by HRV-A
and HRV-C viruses, however most of them have focused mainly on
hospitalized pediatric patients during one season. The objective of this
study was to investigate the incidence and circulation patterns of HRV
species among adults with respiratory tract infection and asymptomatic
individuals during two winter seasons.
Methods: Nasopharyngeal swabs provided by 11 primary care networks
across 6 European countries, as part of the GRACE study (Genomics to
combat Resistance against Antibiotics in Community-acquired LRTI in
Europe) were included in this study. A total of 314 samples collected
during the winter seasons 2007/2008 and 2008/2009 and positive for
HRV as determined by real-time RT-PCR were selected for further
analyzes. The specimens were obtained from 290 adults with respiratory
illness during the ﬁrst (V1 = 253) or/and second visit (V2 = 44) to the
general practitioner and 17 (V0) matched controls. A semi-nested RT-
PCR targeting the VP1 capsid gene of all three HRV species was
developed with degenerate primers designed in conserved motifs in
VP3, VP1 and 2A HRV genes. HRV typing was performed by sequence
analysis of VP1 gene.
Results: 162 strains were characterized including, 112 (69%) HRV-A,
20 (12%) HRV-B, 26 HRV-C (16%), and 4 (3%) HEV isolates. Among
asymptomatic individuals HRV-A was detected in six cases, HRV-C in
three and one subject was positive for HEV. HRV species distributions
in the separate communities during the two seasons are presented in
Figure 1. HRV-A infections were dominating in all 11 communities
during both seasons, with the exceptions of Rotenburg/DE 2007/2008
and Bialystok/PL 2008/2007 with equal prevalence of HRV-A and
HRV-C, and Utrecht/NL 2008/2009 with no HRV-A identiﬁed.
Conclusion: HRV-A were the most frequently detected rhinoviruses
among adult outpatients and asymptomatic individuals during 2007/2008
and 2008/2009 winter seasons.
P1872 Comparison of the Abbott real-time high-risk HPV with
Genomica HPV clinical array for the detection of human
papillomavirus genotypes
C. Sias*, A.R. Garbuglia, D. Lapa, F. Del Nonno, S. Belladonna,
G. de Cunto, F.R. Pulvirenti, M.R. Capobianchi (Rome, IT)
Objectives: The development of highly sensitive DNA detection assays
over the past years has revolutionized the diagnosis of HPV infection.
Accurate HPV genotyping is essential for adequate classiﬁcation of
patients into low-risk or high-risk groups. However the diagnostic assays
do not provide fully comparable indications and results should be
interpreted with caution. We evaluated the genotyping accuracy of the
Abbott RealTime High Risk HPV assay (ABB), a newly fully automated
test able to detect 14 high risk types and to concurrently genotype HPV
16 and HPV 18. The Genomica HPV DNA Clinical Array (GEN) was
used as test of reference.
Methods: For GEN detection, swab samples were extracted by MDX
Biorobot (Qiagen). This assay is able to genotype 35 HPV types,
including 20 HR (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58,
59, 66, 68, 70, 73, 82, 85) and 15 LR (6, 11, 40, 42, 43, 44, 54, 61, 62,
71, 72, 81, 83, 84, 89) types. ABB reports results as HPV 16, HPV 18
and Other High Risk (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68).
Results: Results for both assays were available for 78 specimens: 63
cervical and 15 anal and urethral swabs. The age range of patients was
between 18 and 61 years (mean: 39). Among 19 cervical swabs with
single infection by GEN, the ABB assays showed 100% agreement,
based on the HPV types included in the kit. In 39 samples with mixed
infections, we noted only 4 discordant results: ABB missed one HPV-
31 and one HPV16 type, while reporting one additional HPV 18 and
one HPV HR in 2 samples. Agreement among cervical samples with
mixed infection was then 89,7%. In the anal and urethral swabs, we
found 5 discordant results: 3 HR samples with ABB were negative with
GEN. When GEN assay was performed on the ABB-extracted samples,
the results were in accordance to those provided by ABB (HPV-56 and
-58) pointing out at a better extraction efﬁciency of the Abbott system.
Two LR samples with GEN (conﬁrmed by PCR followed by phylogenetic
analysis of the MY09/11-L1 fragment), were identiﬁed as HR with ABB.
Conclusion: The overall agreement between the two assays was good
(68/78 = 87.2%) showing substantial genotyping accuracy of the Abbott
RealTime HR HPV. The results observed in rectal and urethral swabs
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underscore the importance of pre-analytical step (nucleic acid extraction)
to obtain reliable results in HPV DNA detection.
P1873 Human papillomavirus typing in a cohort of 200 women
in Greece
C. Trigoni*, A. Chrysagi, D. Chrysagi, J. Stamatiou, D. Karakalpakis,
E. Charvalos for the IASO group
Objectives: Prevention programs for cervical intraepithelial neoplasia,
which are mostly based on cytological examination have achieved a
22% reduction in incidence and mortality of invasive cervical cancer but
still with limitations due to low sensitivity and the false negative rates
reported by numerous studies. Human papilloma virus (HPV) detection
and typing seems to be an important test enhancing diagnosis and follow-
up of patients. The aim of this study was to evaluate the prevalence of
HPV high- and low-risk human papilloma virus in a cohort of women
by using molecular detection and typing.
Materials and Methods: Two hundred women aged from 19 to 59 years
have been tested for the presence of HPV in cervical samples, by using
the Linear Array method (ROCHE molecular diagnostics). The method
includes the detection of 13 high-risk and 24 low-risk HPV types. The
study was carried out during six months. When colposcopy was positive
and the test negative, cross checking was performed by home-made PCR
and RFLPs.
Results: Out of 200 cervical samples, 115 have been positive for HPV.
High-risk HPV types (HR-HPV) were detected in 28 women, Low-risk
HPV types (LR-HPV) in 39 and High+Low risk in 48 women samples.
Among the high-risk HPV group, 14 shared DNA sequences of the 16
and 2 shared the 18 subtypes. Typing of the low-risk subtypes detected
in 9 samples the G6, in 3 samples the G55, in 7 the G53, in 5 the
CP6108 and in one sample the G11 respectively. Co-infection with two
strains was detected in 29 samples, with three genotypes in 17 samples
and with four genotypes in 26 samples. Three samples with colposcopy
HSIL ﬁndings but negative for high-risk strains were re-tested by PCR.
One was positive and two had different low-risk HPV types.
Conclusions: This was a pilot study accomplished in our laboratory.
By using the linear array method we detected high- and low-risk HPV
types in women. The most prevalent HPV types were the low-risk ones
independently of colposcopy ﬁndings. Interestingly, in most of the cases,
high- and low-risk types have been detected in the same sample. This
typing proﬁle seems to be the most prevalent. We propose here a new
protocol taking in consideration both clinical and colposcopy ﬁndings
in order to elucidate in a next step whether co-infection with two or
more types is clinicaly important. Also, we aim to co-evaluate clinical,
cytological and colposcopy ﬁndings with the results of Linear Array
Method, performed in our laboratory, in the diagnosis of HSIL.
P1874 Implementation validation of the Qiagen Artus HCV
RT-PCR assay on the Rotorgene 6000 platform
G. Duson, B. Van Meensel, A. Smismans, I. Verstreken, J. Frans*
(Bonheiden, BE)
Objectives: To validate the Artus HCV RT-PCR kit (Qiagen), the ﬁrst
commercially available (CE-IVD) one-step HCV real-time PCR kit on
the Rotorgene platform (Qiagen), for diagnosis and follow-up of HCV
infections.
Methods: All validation experiments started with an extraction of
400ml of EDTA plasma using the Qiagen MinElute Virus Spin Kit.
Extraction was followed by a one-step RT-PCR on the Rotorgene
platform according to the manufacturers guidelines. The assay was
checked for analytical sensitivity, speciﬁcity, accuracy, precision and
linearity following international publications on molecular validation
methods (e.g. Rabenau, 2007).
Results:
1. Analytical sensitivity: To determine the limit of detection (LOD with
a 95% hit rate) of the HCV kit, the Acrometrix Optiquant HCV RNA
quantiﬁcation panel (genotype 1) was used. Twenty samples with a
concentration of 50 IU/ml were found positive and this with a mean
Ct of 37.8, meeting our clinical validation criterion of LOD 50
IU/ml (based on literature). In Belgium, HCV genotypes 1 en 3 are
the most common types. The Artus kit is developed to detect all HCV
genotypes (1−6). Positivity was conﬁrmed with genotypes 1a, 1b, 3,
4 and 5.
2. Speciﬁcity: According to previous validation guidelines, speciﬁcity
was sufﬁciently demonstrated by the manufacturer: the HCV assay
was tested on a broad range of viruses and bacteria and no cross-
reactivity was found with any of these organisms.
3. Accuracy: The 2009 QCMD panel for quantiﬁcation of HCV was
used to check the accuracy of the Artus HCV kit. All samples showed
a very good correlation with the QCMD results and were situated
within our validation criterion of±0,5 log of the expected results (log
IU/ml).
4. Precision: Two samples (10.000 IU/ml and 1000 IU/ml), were
extracted in triplicate on 3 different days. The standard deviation
(SD) (Ct) was 0.4 for both samples, meeting our validation criterion
of SD< 1 (Ct).
5. Linearity: Using the Optiquant HCV RNA quantiﬁcation panel, the
linearity of the HCV assay was assessed by testing 5 different
concentrations in triplicate (range 400–1 000 000 IU/ml). The HCV
assay fulﬁlled our validation criteria (SD< 0.5 per triplo and
0.99<R2 < 1) (see ﬁgure). Values within this range will be reported
in a quantitative way.
Conclusion: The Artus HCV RT-PCR assay met all our validation
criteria and was implemented in the daily routine both as a qualitative
(LOD 50 IU/ml) and as a quantitative assay (range 400–1 000 000 IU/ml).
P1875 Comparison of BD ProbeTec™ HSVQx assays, ELVIS viral
culture system, and TaqMan real-time HSV PCR assays in
herpes simplex virus detection of external anogenital lesions
M. Huang*, L. Corey, B. Van Der Pol, E. Hook, B. Body, M. Nye,
S. Taylor, M. Martens, P. Fine, S. Ginde, J. LeBed, L. Mena, T. Warren
(Seattle, Indianapolis, Birmingham, Burlington, New Orleans, Tulsa,
Houston, Denver, Philadelphia, Jackson, Portland, US)
Objectives: To evaluate the BD ProbeTec™ HSV1 and HSV2 Qx Assays
on the BD Viper System, a strand displacement ampliﬁcation (SDA)
system, with external anogenital lesion specimens vs. viral culture and
vs. TaqMan real-time PCR assays.
Methods: Two hundred and four subjects with external anogenital
lesions were enrolled from 9 geographically diverse clinical centers
between September 29, 2009 and December 14, 2009. Two swabs were
collected from each subject: the 1st swab was placed in BD™ Universal
Viral Transport (UVT) medium and the 2nd was placed in a Qx Swab
Diluent tube (data not presented). Each UVT swab specimen was tested
with the TaqMan real-time PCR assays and ELVIS viral culture. In
addition, a portion of each UVT specimen was transferred into a Qx
Swab Diluent tube and tested with the BD HSV Qx Assays. The PCR
assays provided the viral quantiﬁcation for each specimen in terms of
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copies/mL and all three methodologies provided HSV typing results for
specimens.
Results: Among 204 ELVIS culture results, three HSV culture positive
specimens were excluded from analysis due to the failure of typing
analysis. One PCR specimen was excluded from analysis due to
noncompliant specimen storage. The BD HSV Qx Assays results were
analyzed against the 201 ELVIS culture results and the 203 PCR results;
see table.
The detection frequency of both HSV1 and HSV2 were similar between
PCR and SDA at any viral titer tested. Both assays detected viral loads
less than 103 copies/mL. In comparison with the other two methods,
the ELVIS culture detection rate decreased at viral loads less than 104
copies/mL.
Conclusion: The percent agreement between the BD HSV Qx Assays
and the well characterized TaqMan real-time HSV PCR is excellent.
Both assays can detect positive specimens when the viral load is less
than 104 copies/mL, unlike the ELVIS test system. Both the BD HSV
Qx Assays and the TaqMan PCR assays are highly sensitive and speciﬁc
in detecting HSV infections in external anogenital lesions.
*Product not for sale, for investigational use only in the US.
P1876 Performance characteristics of GeneXpert FluA PCR in
comparison with real-time PCR in the current H1N1
inﬂuenza A pandemic
S. Al Johani* (Riyadh, SA)
Background: Although infections with the novel pandemic 2009
inﬂuenza A (H1N1) virus (A/H1N1/2009) appeared to be relatively
mild during the summer months of circulation (’off season’), and at
the current winter season, but there has been signiﬁcant morbidity
and hospitalization and several fatal cases. Thus, rapid detection of
A/H1N1/2009 is crucial for efﬁcient treatment and infection control
measures. In contrast to seasonal inﬂuenza, where point-of-care (POC)
rapid antigen tests and direct ﬂuorescent antibody (DFA) staining ensure
rapid detection, diagnosis of A/H1N1/2009 has so far been based on
RT-PCR.
Objectives: To determine the performance of Xpert FluA/H1N1 test
(Cepheid®) the ﬁrst molecular Point-Of-care test for inﬂuenza A virus
include A/H1N1/2009 for the detection of the recently emerged swine
inﬂuenza A (H1N1) and compare it with standard CDC qRT-PCR.
Method: A total of 43 respiratory samples were tested in parallel using
Cepheid Xpert FluA and compare it with qRT-PCR. Each tests performed
by different team, who are blinded for other team’s result. Data gathered
and we measure the analytical performance of the test.
Results: Xpert Flu A Panel detected A(H1N1) seasonal and 2009
pandemic, A(H3N2), A(H5N2), A(H5N1) and A(H7N7) viruses and
correctly subtyped A(H1N1) 2009 virus. Analytical sensitivity was
similar to qRT-PCR in the range of 400–5000 viral particles per
ml. However, of most subtypes some specimens with cycle threshold
values greater than 30 in qRT-PCR and A(H1N1) 2009 specimens with
inconsistent results in the qRT-PCR due to primer or probe mismatches
were not detected in the Xpert Flu A Panel. Analytical speciﬁcity was
100%.
Conclusions: The Xpert Flu A Panel is the ﬁrst commercially available
POC molecular test for detection of inﬂuenza A virus and determination
of the H1 2009 subtype and is analytically reasonable sensitive compared
with qRT-PCR and highly speciﬁc and therefore it represent an excellent
alternative to antigenic POC tests, but it is by far more expensive than
routine POC tests.
P1877 Evaluation of AdvanSure HPV screening real-time PCR,
Abbott real-time high-risk HPV test, and Hybrid Capture
2 HPV DNA test for the detection of human papillomavirus
Y. Hwang*, M. Lee (Seoul, KR)
Objectives: Various commercial molecular assays for the detection of
human papillomaviruses (HPV) are currently available. We compared the
AdvanSure HPV Screening real-time PCR test (AdvanSure PCR) (LG
Life Science, Korea) with RealTime High Risk HPV test (Abbott PCR)
(Abbott Molecular, USA) and Hybrid Capture 2 HPV DNA Test (hc2)
(Diagen Corporation, USA) for the detection of HPV.
Methods: The study population comprised 170 women who had been
referred to the hc2 test from July to September 2010. The 170
samples obtained from cervical swabs were tested with AdvanSure
PCR, Abbott PCR and hc2 tests, and 30 samples which showed any
discrepancy in three assays were tested with Inno-Lipa HPV Genotyping
(Innogenetics, Belgium). And the AdvanSure PCR and Abbott PCR tests
were compared for the detection of high-risk type 16 and/or 18.
The hc2 test detects high-risk groups of HPV types (HR) (16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) and low-risk groups of HPV
types (LR) (6, 11, 42, 43, and 44). The Abbott PCR detects HR type
66 including above HR types and can differentiate HPV type 16 and/or
18 from non-HPV type 16/18. The AdvanSure PCR assay detects above
types detected by hc2 test plus HR (53, 70, 73, 26, 67, 69, and 72) and
LR (34, 40, 54, 74, 3, 10, 27, 32, 55, 57, 61, 62, 71, 81, and 84) and
detects type 16 or 18 using additional probe.
Results: The clinical sensitivities of AdvanSure PCR, Abbott PCR, and
hc2 tests for cervical intraepithelial neoplasia grade 2 or worse were
83.3%, 83.3%, and 77.8%, respectively, and the clinical speciﬁcities of
those tests were 57.2%, 61.2%, and 50.0%, respectively. Comparing with
Inno-Lipa HPV Genotyping test, the analytical sensitivities of AdvanSure
PCR, Abbott PCR, and hc2 tests were 89.9%, 89.2%, and 97.7%,
respectively, and the analytical speciﬁcities of those tests were 100%,
100%, and 71.8%, respectively. For the detection of type 16 and/or
18, the sensitivity and speciﬁcity of AdvanSure PCR test were 100%
and 100%, respectively, and those of Abbott PCR test were 96.2% and
100%, respectively. And the kappa coefﬁcient between AdvanSure PCR
and Abbott PCR tests to detect type 16 and/or 18 was 0.9769, showing
almost perfect agreement.
Conclusions: The AdvanSure HPV Screening real-time PCR test for the
detection of HPV is comparable to Abbott RealTime high risk HPV test
and Hybrid Capture 2 HPV DNA Test and can concurrently differentiate
the HPV type 16 and/or 18 from other non-HPV type 16/18.
P1878 Quantiﬁcation of CMV DNA in plasma by real-time PCR
for monitoring allogeneic stem cell transplant recipients
L. Carden˜oso, A. Somodevilla*, A. Palmeiro, A. Garcia-Noblejas,
A. Figuera, R. de la Ca´mara (Madrid, ES)
The objective was to evaluate rt PCR QIACMV Abbott Diagnostics in
plasma samples for CMV monitoring for preemptive treatment of allo-
SCT patients.
Methods: 521 plasma samples obtained in 76 CMV infection episodes
from 47 allo SCT patients were studied between 2005 and 2009. All
patients were monitored post-SCT with antigenemia pp65 CINApool®,
Argene (AG) and quantitative PCR, COBAS® Amplicor® CMV
after automatic extraction COBAS® Ampliprep® TNAI kit, Roche
(CobasPCR). A positive sample was deﬁned by AG 2/4×105 PMNs
and/or CobasPCR 600 copies/mL. 41 out of 47 patients received one or
more course of preemptive therapy upon positive AG and/or CobasPCR
results and 6 (12.7%) developed CMV end-organ disease (4 colitis and
2 neumonitis). An episode was deﬁned as the period between the ﬁrst
positive sample by AG and/or CobasPCR, until the ﬁrst negative sample
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by both techniques. All samples were retrospectively tested using rt-
PCR QIACMV after automatic DNA extraction with m2000sp. Rt-PCR
positive results were deﬁned by 52 copies/mL.
Results: Plasma samples were positive in 29.2%, 34% and 40.7% by
AG, Cobas PCR and rt-PCR, respectively. Thirty-nine samples (7.5%)
were only positive by rt-PCR, of these 9 were ﬁrst and 15 last samples
in episodes. Concordance between PCR assays was 83.7% (k = 0.63),
Pearson 0.98 (p< 0.001) and rt-PCR vs AG&CobasPCR was 80.6%
(k = 0.66). ROC curve analysis was applied using the existing treatment
criteria based on AG and CobasPCR for triggering CMV preemptive
therapy and a viral load of >173 copies/ml by rt-PCR was established
as the optimal value (S 65%,E 73% AUC 0.728).
Episodes were detected in 71 (93%), 58 (76%) and 67 (88%) by AG,
CobasPCR and rt-PCR, respectively. Nine episodes (11.8%) were only
detected by AG (all PCRs negative) and 5 (6.6%) only by PCR assays.
For episode detection the ﬁrst positive technique was rt-PCR 51 (67%),
AG 50 (65.8%) and Cobas PCR 37 (48%). The range for rt-PCR was
52−3.9×104copies/ml vs 608−1.0×105 copies/ml for Cobas PCR. Bland
Altman Analyses CobasPCR vs rt-PCR difference is 0.76 log.
Conclusion: Rt PCR QIACMV detects earlier and more episodes than
the COBAS® AMPLICOR PCR CMV. Rt-PCR cuantitative results were
lower than end-point PCR (0.76 log). The threshold of 173 copies/mL is
the optimal rt-PCR CMV-DNA value for triggering preemptive treatment
in allo-SCT. Results from this study suggest that this rt-PCR assay is a
useful tool for the clinical management of CMV in allo SCT patients.
P1879 Evaluation of the extractor of nucleic acids incorporated
in the Versant kPCR molecular system to use with the
Trugene HIV-1 genotyping kit in plasma samples with viral
loads <1000 copies/ml
F. Ferna´ndez-Cuenca*, F.J. Va´zquez-Barbero, M.J. Rı´os,
J. Rodrı´guez-Ban˜o, A´. Pascual (Seville, ES)
Objective: Early detection of mutations associated with resistance (MR)
to antiretrovirals (AR) is recommended to anticipate and prevent the
therapeutic failure in HIV-infected patients receiving ARs. Many systems
used to detect these MR are based in the DNA sequencing of the protease
(PR) and the reverse transcriptase (RT) genes. One relevant limitation
of these assays is their reduced reliability (related with problems of
ampliﬁcation and/or sequencing) for samples with low viral loads
(<1000 copies/ml), due to the reduced amount of RNA presented in the
samples analysed. The aim of this study was to evaluate the reliability
of the semiautomatic extractor of nucleic acids (NA) included in the
VERSANT kPCR system (Siemens) in combination with the TRUGENE
HIV-1 Genotyping Kit (Siemens) in samples with plasmatic viral loads
<1000 copies/ml.
Methods: Forty eight plasma samples from different patients with
viral loads ranging from 87 to 795 copies/ml, as determined with the
VERSANT HIV-1 RNA 1.0 Assay (kPCR; Siemens), were studied.
Extraction of RNA was performed with the VERSANT kPCR extractor
module. DNA Sequencing of the RT and PR genes was performed
by the TRUGENE HIV-1 Genotyping Kit and the OpenGene DNA
Sequencing System (Siemens). The variables analysed were i) to get
or not ampliﬁcation and sequencing and ii) to detect major MR to AR
in samples with plasmatic viral loads <1000 copies/ml.
Result: Thirty-eight (79.2%) samples were successfully sequenced (PR
and RT genes). Thirty-three (86.8%) sequences belonged to subtype
B. MR to PR inhibitors (MR-PI) was detected in 3 samples (0.9%
of the PR sequences), whereas MR to nucleoside RT inhibitors (MR-
NRTIs) and non-nucleoside RT inhibitors (MR-NNRTIs) were detected
in 11 (28.9%) and 14 (36.8%) of the RT sequences, respectively. The
MR-PIs detected in the PR gene were L90M (n = 1), I54V + V82A
(n = 1), and D30N + L33F + V82A + N88D (n = 1). In the RT gene, the
most frequent MR-NRTI were V118I (n = 7), M184 I/V (n = 4), T215Y/F
(n = 4), and M41L (n = 3), whereas the MR-NNRTI were V90I (n = 3),
K103N/S (n = 2), G190A (n = 2), E138A (n = 2) and V108I (n = 2).
Conclusion: The extractor module of the VERSANT kPCR system is a
highly reliable and convenient device to use with the TRUGENE HIV-1
genotyping kit for samples with plasmatic viral loads <1000 copies/ml.
An elevated percentage of major mutations were detected with this
system, particularly in the RT gene, supporting evidence of its utility
in this type of samples.
P1880 Quantitative real-time PCR with automated viral DNA
extraction for diagnosis and monitoring of cytomegalovirus
in allogeneic bone marrow transplant recipients
K. Liopeta*, O. Dimitrakopoulos, M. Liga, A. Spyridonidis,
E.D. Anastassiou, F. Paliogianni (Patra, GR)
Objectives: Evaluation of the performance of a Real Time PCR (RT-
PCR) assay on whole blood samples or cell free plasma over a
Cytomegalovirus (CMV) antigenemia assay in diagnosis and monitoring
of CMV infection in bone marrow transplant (BMT) recipients.
Methods: 896 samples from 37 allogeneic BMT recipients hos-
pitalised at Patras’ University Hospital during a four-year-period
(02/2006−03/2010) were included in this study. Viral load was detected
either by RT-PCR on whole blood and cell free plasma, or CMV
antigenemia assay. Viral DNA was automatically extracted. RT-PCR was
performed using a commercially available kit that exploits the minor
groove binder technology. CMV lower matrix protein pp65 was detected
by indirect immunoﬂuorescence microscopy in 2×106 leucocytes/mL,
per sample. High risk for CMV disease patients were identiﬁed according
to the CDC guidelines1, depending on their viral load.
Results: Antigenemia assay was shown to be less sensitive in detecting
viral load (38.50%) than RT-PCR on whole blood (82.38%) or cell free
plasma samples (71.23%). All methods showed the same speciﬁcity
(96.45%-97.79%). Pairwise comparison of Roc Curves futher conﬁrmed
that the best method for CMV detection is RT-PCR on whole blood
(p< 0.001). Within the 4-year-period, 30 out of 37 BMT recipients (81%)
showed a ﬁrst incidence of CMV activation, as identiﬁed by RT-PCR
on whole blood. Twenty out of 30 (66.7%) were positive by all three
techniques (Table 1). CMV re-activation was detected in 22 out of the 30
(73,3%) by RT-PCR on whole blood, whereas, only 17 out of 22 (56.7%)
were positive by all three techniques (Table 1). Further statistical analysis
conﬁrmed that RT-PCR on whole blood samples is more sensitive for
CMV activation (p = 0.0196) than RT-PCR on cell free plasma and CMV
antigenemia assay. Finally, RT-PCR on whole blood detects re-activation
of CMV disease (231 days) earlier than RT-PCR on cell free plasma (238
days), (p> 0.05), and CMV antigenemia assay (281 days), (p = 0.0273).
Conclusion: Real-time PCR based on automatic viral DNA extraction
from whole blood samples is a quantitative, highly reproducible, more
sensitive and equally speciﬁc method for diagnosis of CMV activation,
as well as, monitoring of antiviral treatment in bone marrow transplant
recipients, as compared to either real-time PCR on cell free plasma or
the established CMV antigenemia assay.
Reference(s)
[1] MMWR Recomm Rep. 2000 Oct; 49(RR-10): 1–125, CE1−7.
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P1881 Could conjunctival swabs be useful to diagnose herpetic
keratitis?
L. Barrado*, E. Perez-Blazquez, M. Suarez, J.R. Otero, L. Folgueira
(Madrid, ES)
Objectives: Herpes simple virus (HSV) is a common cause of corneal
disease which ranges from superﬁcial infection to chronic inﬂammatory
herpetic stromal keratitis. The aim of this study was to asses if
conjunctival swabs samples were equivalent to corneal scrapings to
diagnose herpetic keratitis.
Methods: From June 2008 to May 2009, a total of 74 samples (37
conjunctival swabs and 37 corneal scrapings) collected from 37 patients
with clinical keratitis were studied. Samples were obtained from each
patient at the same time. Both types of samples were analyzed by real-
time PCR using EasyMag (BioMeriex) as DNA extractor; real-time
PCR was performed in a LightCycler (Roche) by using TaqMan probes.
Moreover, all samples were inoculated on A-549 and MRC-5 cell lines
and evaluated for cytopathic effect (CPE) development for 7 days. When
a CPE was observed, the viruses were typed by immunoﬂuorescence
(Microtrack).
Results: Real-time PCR was more sensitive than cell culture in both
type of samples. 15/37 (40.5%) corneal scraping samples were PCR
positive versus 9/37 (24.3%) conjunctival swabs. Cell culture allowed
to detect HSV in 11/37 (29.7%) corneal scraping specimens and in
7/37 (18.9%) conjunctival swabs. Sensitivity, speciﬁcity, positive and
negative predictive values and efﬁciency for cell culture performed
on conjunctival swabs were 77.77%, 100%, 93.33% and 94.59%,
respectively. For corneal samples these values were 73.33%, 100%,
84.61% and 89.18%, respectively. The agreement between both type
of samples was 89.17% for real-time PCR assay and 83.78% (31/37) for
cell culture detection.
Conclusion: These results showed that conjunctival swabs samples
allowed to detect HSV in 60% of patients with PCR positive corneal
scraping specimens, that are considered the optimal samples for herpetic
keratitis detection.
P1882 Molecular-genetic heterogeneity of tick-borne encephalitis
virus in Transbaikalie region
E. Sidorova*, E. Andaev, T. Borisova, A. Trukhina, L. Karan,
V. Pogodina, N. Kalyasnikova, O. Nagibina, S. Balakhonov (Irkutsk, RU)
Objectives: Tick-borne encephalitis (TBE) morbidity at Transbaikal
Region is 3,4 per 100.000 population and characterized by higher
lethality (from 22,5% in 2004 to 2,7% in 2009) in comparison with
lower, than in adjacent territories, morbidity indicators, high percent of
focal TBE forms (35,7%) and prevalence of rural population among
the patients (62,0%). Regional population of TBE virus is insufﬁciently
studied.
Materials and Methods: 37 strains of TBE virus isolated in 1995–2010
including 18 from patients with focal TBE forms with lethal outcome, 11
from Ixodes persulcatus ticks, 2 from Dermacentor silvarum and 6 from
wild rodents were studied.
Genotyping of strains was performed in real time by hybridization-
ﬂuorescent method with labelled genotype-speciﬁc ﬂuorescent probes,
restriction fragment length polymorphism (RFLP) assay, sequencing of
protein E gene fragment 211 bp containing a marker amino acid in 206
position, sequencing of full-size gene of protein E.
Main results: Among isolates from died humans four strains were
determined as a Siberian genotype of TBE virus, 13 − Far Eastern
genotype, one strain was genotyped as a mixed isolate containing genome
sites of Siberian and Far Eastern genotypes. Also, representatives of
Siberian (4) and Far Eastern (1) genotypes, “886-like” (2) isolates
and mixed-variants (4) were revealed among strains isolated from
I. persulcatus. Strains isolated from D. silvarum were genotypes as
TBE virus of the Far Eastern genotype. Strains from wild mammals
represented four Siberian and two Far Eastern genotypes.
Conclusions: The ﬁndings indicate uniqueness and genetic heterogeneity
of TBE virus circulating at the focal territories of Transbaikal region
presented by various genotypes (Siberian, Far Eastern), “886-like”
variants differed from all known genotypes of TBE virus at the genome
level and mixed-variants containing sites of Far Eastern and Siberian
genotype genomes. The role of different genotypes and variants in
formation of regional epidemiological and clinical manifestations of TBE
and the population immunostructures need further studying.
P1883 Investigation of potential relationship between BKV with
kidney and bladder cancers
Y. Bulut*, E. Ethem, N. Akpolat, F. Aker, Z.A. Toraman, A. Seyrek
(Elazig, Istanbul, TR)
Objectives: Despite some reports published on the relationship between
BK virus (BKV) and cancer, role of BKV in human cancers has not been
completely understood. Furthermore, there are conﬂicting data on this
subject. Objective of the present study was to determine the presence
of BKV DNA in formalin-ﬁxed parafﬁn-embedded kidney and bladder
tissues and to investigate the BKV mRNA levels in these tissues.
Materials and Methods: 90 cancer tissues (40 bladder and 50 kidney)
and 70 control tissues (25 bladder and 45 kidney) were included in this
study. For detection of the BKV DNA, the nested PCR was performed
from the tissues. Furthermore, real time RT-PCR was carried out for
investigation of the BKV mRNA levels.
Results: Results of the nested PCR indicated that 23 (14.37%) of
160 samples were positive for BKV DNA. There was, statistically, a
signiﬁcant relationship between the cancer and presence of BKV DNA
(p< 0.05). In the real-time PCR, BKV VP1 mRNA was detected in
69.5% of the BKV DNA positive samples. The levels of BKV mRNA
were signiﬁcantly higher in the cancer samples than non-cancer samples
(P< 0.05).
Conclusion: These results suggest that BKV may be associated with
development of bladder and kidney cancers. However, more extensive
studies are required to elucidate the role of BKV in pathogenesis of
cancer.
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P1884 A new method to inactivate genes on large conjugative
plasmids for investigation of their biological function
J.L. Cottell*, M.A. Webber, L.J. Piddock (Birmingham, UK)
Objectives: The study of large conjugative plasmids is of increasing
importance due to their role in the dissemination of antibiotic resistance
(eg. Extended spectrum b-lactamases) and virulence genes. As a result,
hundreds of complete plasmid DNA sequences have now been eluci-
dated. However, a lack of basic laboratory molecular methods to specif-
ically perturb functional genes on plasmids has meant little work has
investigated the biological properties of these plasmid borne genes. The
aim of this project was to devise a molecular method to rapidly inactivate
speciﬁc genes on plasmids, and to apply this method to the inactivation
of genes on a large epidemic plasmid that encodes blaCTX-M-14.
Methods: A PCR amplimer encoding either the aph kanamycin
resistance gene or an aph-green ﬂuorescent protein fusion (aph-
gfpmut2) with homologous ends to the target gene for inactivation was
generated. This PCR amplicon and the plasmid of interest were both
transformed into an E. coli strain carrying a chromosomally encoded
lamba red recombinase. Successful recombination between the plasmid
and PCR amplimer resulted in the removal of some of the DNA
from the gene of interest and insertion of aph or aph-gfp. Selection
of colonies on kanamycin containing agar allowed identiﬁcation of
plasmids where homologous recombination into the selected gene had
successfully occurred. This plasmid was transformed into E. coli DH5a
and Salmonella Typhimurium SL1344 and the effect on antibiotic
susceptibility, growth rates, conjugation frequencies and virulence was
measured.
Results: Five plasmid genes were successfully inactivated by insertion
of the aph and aph-gfp genes using this novel targeted recombination
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method. Insertional activation of blaCTX-M-14 with aph and aph-
gfpmut2 reduced the MIC of cefotaxime for host bacteria from 32 mg/ml
to 0.03mg/ml. However, in this plasmid, inactivation of genes or insertion
of gfp had no affect on bacterial host growth, virulence or conjugation
frequency of the plasmid.
Conclusion: This new method for rapid targeted inactivation of plasmid
genes will allow investigation of the function of selected genes and their
role in the biology of large conjugative plasmids. The easy insertion
of a gfp gene within selected regions in the plasmid allows potential
for study of the role of speciﬁc plasmid genes in the dissemination and
epidemiology of transferable elements.
P1885 Evaluation of a novel non-enzymatic method for enrichment
of pathogen DNA from whole blood
A.J. Loonen, B. van Meerbergen, S. Neerken, R. Penterman, I. Dobbelaer,
K. Schmidt, P. van de Wiel, A.J. van den Brule* (Eindhoven, NL)
Objectives: Bloodstream infections are a major clinical problem.
Blood culture is still the golden standard for identiﬁcation of
pathogens, however, this method is time-consuming. Rapid and sensitive
identiﬁcation of the causative pathogen is essential to select the most
effective treatment.
In this study, a novel non-enzymatic method was evaluated for isolation
of bacterial and fungal DNA from whole blood samples: Red and white
blood cells are selectively lysed and the leukocyte DNA is simultaneously
degraded, while pathogens remain intact. The performance of this novel
method was compared to the reference method to date, i.e. MolYsis
Complete5 kit (MolZym) based on enzymatic processes.
Methods: A 10-fold dilution series containing methicillin-resistant
Staphylococcus aureus, Candida albicans, and Pseudomonas aeruginosa
was spiked into 1 and 5ml whole blood. The puriﬁed pathogen DNA was
quantiﬁed by real-time PCR assays, while the remaining leukocyte DNA
was quantiﬁed using an RNaseP detection kit (Applied Biosystems).
Results: The new method and the MolYsis Complete5 kit revealed
comparable Ct values in qPCR for all species tested with the expected
linear relation between concentration and Ct value. 1−10 CFU spiked
into 1ml whole blood was detectable with all methods. Increase of the
input volume to 5ml resulted in a 5 times higher sensitivity. RNaseP
qPCR results for eluates from 1 and 5ml blood demonstrate effective
removal of leukocyte DNA by both methods which enables detection of
clinically relevant concentrations of pathogens from several milliliters of
blood. The pathogen DNA can be isolated within 30 minutes for 1ml
and within 40 minutes for 5ml blood, respectively, whereas the MolYsis
Complete5 kit takes 2−3 hours.
Conclusions: This novel method allows sensitive and fast DNA
enrichment from bacteria and fungi from whole blood. Starting from 5ml
blood, the lowest detectable concentration was 1 CFU/ml for the different
pathogens and similar Ct values were obtained for both methods.
However, at low pathogen concentrations increased detection rates were
observed for the new method. Furthermore, this non-enzymatic method
is less labour intensive and faster than the MolYsis Complete5 kit. It
can be carried out as manual procedure on the bench, but is at present
also integrated into a closed disposable cartridge for full automation.
P1886 Development of a rapid, fully automated method for
selective isolation of bacterial and fungal DNA from large
volumes of whole blood
S. Neerken*, R. Penterman, B. van Meerbergen, I. Dobbelaer,
K. Schmidt, P. van de Wiel (Eindhoven, NL)
Objectives: Rapid identiﬁcation of bacteria and fungi causing blood-
stream infections is crucial to increase the survival chances of sepsis
patients. Several attempts are made to replace traditional culture by
faster molecular tests. However, the sensitivity of standard molecular
tests is limited by the fact that at maximum 0.2−0.5ml blood can be
used, because larger amounts of leukocyte DNA will inhibit the PCR.
Our objective is to provide a rapid, fully automated isolation method that
increases the sensitivity by enabling the large sample volume.
Methods: We developed a method for selective isolation of pathogen
DNA from whole blood samples based on a non-enzymatic procedure.
The red and white blood cells are lysed, while keeping the pathogens
intact, simultaneously the leukocyte DNA is degraded and subsequently
removed by ﬁltration. Pathogens captured on the ﬁlter are chemically
lysed. Finally, the pathogen DNA is collected for downstream processing
with standard molecular techniques. The isolation procedure has been
completely automated by integration into a disposable cartridge actuated
by a table-top instrument.
Results: Different species of Gram-negative and Gram-positive bacteria
and fungi (P. aeruginosa, S. aureus, C. albicans) were spiked into 1 and
5ml human blood and bacterial and fungal DNA was isolated in the
cartridge; total processing time before PCR was 30 and 40 min for 1
and 5ml blood, respectively. Pathogen recovery and removal of inhibitors
were tested by comparing Ct values of spiked blood samples with
reference samples, the latter containing same amounts of bacteria spiked
into buffer, that were lysed directly. Similar Ct values were obtained,
demonstrating yields close to 100% and absence of PCR inhibition
by leukocyte DNA. PCR for a standard human gene demonstrated a
reduction of leukocyte DNA content by more than a factor 25. Increasing
the sample volume from 1 to 5ml revealed on average a gain of 2
Cts and higher hit rates at borderline concentrations (1−10 CFU/ml),
demonstrating a direct relation between sensitivity and sample volume.
Conclusion: Our method enables fully automated speciﬁc isolation of
pathogen DNA from up to 5ml blood within 40 min with high yield
and purity. Using 5ml blood, pathogens spiked in concentrations as low
as 1 CFU/ml were detectable. In combination with standard molecular
procedures this allows the rapid identiﬁcation of pathogens in blood at
clinically required sensitivity levels.
P1887 Comparison of six differentiation methods for identiﬁcation
of coagulase-negative staphylococci
A.J. Loonen*, A.R. Jansz, J.N. Bergland, P. Wolffs, A.J. van den Brule
(Eindhoven, Maastricht, NL)
Objectives: Coagulase-negative staphylococci (CNS) are a common
cause of nosocomial infections and therefore pose a great threat to
patients with an immunodeﬁciency. Rapid and reliable determination
of CNS is therefore clinically relevant.
In this study, we compared the conventional Kloos and Schleifer test,
the biochemical ID 32 Staph (bioMe´rieux), automated biochemical
identiﬁcation system Vitek2 (bioMe´rieux), partial 16S ribosomal DNA
sequencing (MicroSEQ, Applied Biosystems), partial TUF DNA se-
quencing, and the proteomics approach matrix-assisted laser desorption/
ionization-time of ﬂight mass spectrometry (MALDI-TOF-MS) to ﬁnd
the best method for accurate identiﬁcation of CNS strains.
Methods: Approximately 150 strains, representing 19 CNS species, were
included in this study. All CNS isolates were characterized by Vitek2
and when necessary partial 16S rDNA gene sequencing was performed.
Because this method does not give 100% correct identiﬁcation, due to
either incomplete database or discrimination problems, all methods were
used to analyze the included CNS strains. Data of all performed methods
were compared to obtain a reference name, as a “gold standard”.
Results: 16S rDNA sequencing, TUF sequencing and MALDI-TOF
seemed to have a correct identiﬁcation rate of 70.6%, 93% and 99.3%
respectively. For the Kloos & Schleifer test, ID 32 Staph and Vitek2
the correct identiﬁcation was 80.4%, 86%, and 92.3% consecutively. No
identiﬁcation could be given for 2.1%, 19.6% and 0.7% of the strains
when ID 32 Staph, Kloos and Schleifer or MALDI-TOF-MS was used
respectively. Incorrect identiﬁcation was given for 29.4%, 7%, 7.7%, and
11.9% of the strains when 16S sequencing, TUF sequencing, Vitek2 and
ID 32 Staph was used respectively.
Conclusions: MALDI-TOF-MS showed the best results for rapid CNS
differentiation (correct identity in 99.3%). In addition, this technique is
fast, cheap and suitable for high-throughput. The current gold standard
in many laboratories, a.o. our facility, is Vitek2 and partial 16S rDNA
sequencing. Therefore, in our opinion, the gold standard should be
replaced by MALDI-TOF-MS and TUF sequencing.
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P1888 Evaluation of PrimeStore® molecular transport medium
for use in the diagnosis of TB
N.A. Ismail*, A. Dreyer, S.V. Omar, L.T. Daum, G. Fischer, P.B. Fourie,
A.A. Hoosen (Pretoria, ZA; Bethesda, US)
Objective: To evaluate the safety of PrimeStore® Molecular Transport
Medium (PS MTM) in the diagnosis of TB and compatibility for use
with two commercial TB diagnostics assays.
Methods: To evaluate safety the following 3 studies were performed with
controls. 1) A 0.15ml and 0.5ml inocula of a known MDR strain was
placed into PS MTM for 2 and 10 minutes then vortexed and cultured
in the MGIT® liquid based system. 2) A known smear positive sputum
specimen (>10 AFB/hpf) was placed into PS MTM for 1min and 5
mins followed by Ziehl-Neelsen staining for morphological observation
of cell wall integrity. 3) A reference H37rv strain with a concentration
of 105−6 was used to perform a time kill assay. An inoculum of 0.5ml
of the strain was placed in the PS MTM for 5s, 10s, 20s, 40s, 80s and
160s and thereafter subcultured onto 7H11 agar for each time exposure.
To evaluate compatibility of the PS MTM with the two commercial
assays (LightCycler Mycobacterium Detection kit, Roche®, South Africa
and Genotype MTBDRplus, Hain LifeScience®, Germany) for TB
diagnosis the following was done. Fifteen smear positive and 15 smear
negative digested and decontaminated sputum specimens were processed
with the Hain LifeScience and Roche assays and 0.5ml of the remaining
sediment was then inoculated into PS MTM and stored overnight. The
2 assays were then repeated from the stored PS MTM.
Results: In the safety study using MGIT liquid culture no growth was
observed after 42 days incubation with both inocula in PS MTM whereas
the control unexposed to PS MTM was positive for growth after 9 days.
In the staining study, no AFB was observed after the 2 short exposure
times. For the time kill study, no growth was observed after 42 days
incubation at any of the time points, even at the 5s exposure to the PS
MTM whereas colony forming units were observable after 7 days on the
control plates. The compatibility studies for the Hain assay showed the
same results with and without exposure to the PS MTM (smear positives
were only tested). The Roche assay had the same results for the smear
positive specimens however an additional smear negative specimen was
detected after exposure to the PS MTM as compared to the control.
Conclusion: The PS MTM was safe in that it sterilized M. tuberculosis
in a very short time period. For clinical specimens the medium was
compatible with the 2 commercial assays and improved the diagnostic
yield. Hence this medium allows for safe and rapid point of care
diagnosis of TB.
P1889 Liquor protein proﬁling for the diagnostics of acute
bacterial meningitis using MALDI-TOF mass spectrometry
and ClinProt technology
L. Ikryannikova*, E. Ilina, E. Klimova, N. Yuschuk, M. Kostrzewa,
V. Govorun (Moscow, RU; Bremen, DE)
Objectives: Meningitis is a very serious, life threatening illness causing
different complications in many cases. The diagnosis of meningitis is
extremely important on the early stage of illness; however it may be
delayed because some symptoms may initially be assumed to be related
to another less serious condition. Meanwhile, acute meningitis, especially
acute bacterial (purulent) meningitis, can progress very rapidly and result
in death if it is not recognized and treated quickly. In our work, the
ClinProt technology followed by MALDI-ToF mass-spectrometry (MS)
analysis was applied to detect a combination of potential peptide markers
in human cerebrospinal ﬂuid (CSF) suitable for diagnostics of acute
bacterial meningitis.
Methods: 104 CSF samples (35 from patients with acute bacterial
meningitis, 38 from serous meningitis, and 31 from healthy controls)
were selected. Of these, 20 samples of each group formed the main
selections, while the rest ones − the additional (validation) groups.
CSF samples were fractionated using weak cation exchange magnetic
beads (MB-WCX kit, Bruker Daltonic, Germany) on a sample
preparation robot following the manufacturer’s protocol. Eluates were
applied onto a MTP 384 target plate polished steel; after drying at air a
solution of 2,5-dihydroxybenzoic acid and a-cyano-4-hydroxycinnamic
acid in a mixture of methanol/acetonitrile/water 5:4:1 was applied onto
the sample.
Mass spectra were collected by an Ultraﬂex MALDI-TOF MS and were
analyzed using ClinProTools 2.1 software (both from Bruker Daltonics).
Mathematical models for classiﬁcation of mass spectra obtained after
sample fractionation were generated using a genetic algorithm (GA) and
a Supervised Neural Network (SNN).
Results: Three diagnostic models were generated to classify the
bacterial/serous, bacterial/control and serous/control groups. Speciﬁcity
of the models generated by both GA and SNN algorithms were
100% both for bacterial/serous and bacterial/control groups, while the
sensitivity was no less than 80% in all cases. Only quite low values for
both sensitivity (no more than 41%) and speciﬁcity (no more than 76%)
were obtained for serous/control group differentiation.
Conclusion: The potential of CSF protein proﬁling for diagnosis of
acute bacterial meningitis could be demonstrated. The approach was not
appropriate to differentiate correctly the “serous meningitis” samples
from the CSF of control group.
P1890 The impact of thermocycler variability on IVD CE kit
validation
M. Span* (Landgraaf, NL)
Objectives: Thermocyclers are currently perceived by as black box
systems that are assumed to perform as speciﬁed by the manufacturer.
When combined with validated diagnostic CE IVD kits it is assumed
that validation of the assay, as required by the ISO 17025:2005 and ISO
15189:2007 norm is adequately covered.
The objective of this study is to determine what the thermal performance
is of a large population of thermocyclers, how big the variability is
within this population and if this does have any impact on CE IVD kit
validation.
Methods: 10.454 thermocyclers, both normal and real-time with both
standard and fast blocks, have been calibrated using the 16 sensor
dynamic MTAS system (CYCLERtest, NL).
All thermocyclers were measured with an identical temperature protocol,
being 30ºC 60s, 95ºC 180s, 30ºC 60s, 90ºC 180s, 50ºC 180s, 70ºC 180s,
60ºC 180s and 30ºC 60s to allow comparability. The parameters which
have been measured are accuracy, uniformity, heating rate, cooling rate,
overshoot, undershoot and plateau time.
Results: The thermocycler calibrations show that there is a large spread
in both the accuracy and uniformity between different brands (ﬁgure 1,
dots of different colors) and between different models of the same brand
(ﬁgure 1, dots of the same color).
When the calibration data are compared on individual serial number
level the spreads in both accuracy and uniformity are even bigger.
Conclusion: When comparing the accuracy and uniformity between and
within thermocyclers substantial differences can be observed. Practically
this leads to situations that (q)PCRs will give reliable results on a
particular thermocycler, but not on another thermocycler, even of the
same brand and model.
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Typically accredited labs consider CE IVD kits as sufﬁciently validated to
give reliable results on the thermocycler on which it has been validated.
However, CE IVD kit manufacturers typically validate their kits on
<5−10 individual thermocyclers, assuming they all function alike. In
the perspective of the large variability measured these small sample
populations are statistically not representative for the total populations
of thermocyclers.
Therefore it can be concluded that a validated CE IVD kit in combination
with a recommended thermocycler is no guarantee for reliable results
and that diagnostic labs currently run the risk to generate false negative
results or lower positive with all clinical consequences connected, due
to underestimated thermocycler variability.
P1891 Evaluation of automated DNA extraction devices for sepsis
diagnostics
S. Laakso*, M. Ma¨ki (Helsinki, FI)
Objective: Aim of this study was to compare two automated, In Vitro
diagnostic labeled DNA extraction devices. The performance of NorDiag
Arrow (Nordiag) was compared to that of NucliSENS® easyMAG®
(bioMe´rieux) using positive blood culture samples. Both devices utilize
magnetic particle based extraction technology, Arrow can process 1 to
12 samples simultaneously, whereas easyMAG® is a higher throughput
device capable of processing 1 to 24 samples. We analyzed the DNA
extracts with the PCR and microarray-based Prove-it™ Sepsis assay
(Mobidiag), which is designed to identify 60 Gram-negative and Gram-
positive bacterial species from positive blood cultures. In this study,
yields of DNA extracts were also studied using pure bacterial culture
samples.
Methods: A set of 91 positive blood cultures from patients with
suspected sepsis were randomly collected in HUSLAB, Finland. Blood
culture bottles of BacT/ALERT 3D (bioMe´rieux) were incubated until
ﬂagged as positive. 250ml of blood culture was used with the Arrow
VIRAL NA kit and Arrow, and the elution volume was 100ml. For
easyMAG®, 100ml of blood culture was used, and the elution volume
was 55ml. Prove-it™ Sepsis analysis was performed according to the
manufacturer’s instructions and the obtained results were compared to
those of conventional blood culture. DNA yields were studied using
various amounts of E. coli pure cultures and speciﬁc qPCR.
Results: Prove-it™ Sepsis assay reported bacterial ﬁndings from 77
blood culture samples. 14 samples were reported as negative, containing
bacteria not belonging to the pathogen panel of the assay. No difference
was observed between the performance of Arrow or easyMAG® with
regard to the result reporting of Prove-it™ Sepsis. Of note was that
Streptococcus dysgalactiae subsp. equisimilis was identiﬁed from two
samples by Prove-it™ Sepsis, but the conventional method reported
S. pyogenes ﬁndings. The DNA sequencing conﬁrmed S. dysgalactiae
subsp. equisimilis ﬁndings. Also, the difference was observed when the
DNA yields of these two devices were compared.
Conclusions: Use of automated and standardized sample preparation
methods together with rapid molecular assays can speed up the
diagnostics of septic patients. Both tested DNA extraction devices were
shown to be feasible for blood culture samples and the Prove-it™ Sepsis
assay, providing the identiﬁcation of pathogen in four hours.
P1892 Molecular versus conventional diagnosis of intestinal
parasitoses
A. Calderaro*, C. Gorrini, S. Montecchini, G. Piccolo, C. Chezzi
(Parma, IT)
Objectives: A ﬁeld comparison in the period 2003–2010 between
conventional and molecular methods for the diagnosis of infection by
Entamoeba histolytica, E. dispar, Giardia intestinalis, Dientamoeba
fragilis and Cryptosporidium spp. is reported analysing faecal samples
from patients with gastro-intestinal signs and symptoms related to a
clinical suspicion of intestinal parasitoses.
Methods: Two real-time PCR assays for the differentiation of
E. histolytica and E. dispar and for the detection of D. fragilis,
respectively, in faecal specimens were evaluated in comparison with
microscopy and culture.
Two real-time PCR assays for the detection of G. intestinalis and
Cryptosporidium spp., respectively, were evaluated in comparison with
the combination of microscopy, an immunocromatographic assay and an
immunoﬂuorescence assay.
Results: Conventional assays had a sensitivity of 88.4% for giardiasis,
43.5% for dientamoebiasis, 92.3% for cryptosporidiosis, 41.7% for
amoebiasis and a diagnostic speciﬁcity of 100% in all cases, whereas
molecular assays had 100% sensitivity and speciﬁcity in all cases.
G. intestinalis. On a total of 422 patients, 112 cases of giardiasis were
diagnosed by real-time PCR; only 99 cases were detected by microscopy
and/or antigen detection traducing in 13 missed diagnosis.
D. fragilis. On a total of 527 patients, 108 cases of dientamoebiasis were
diagnosed by real-time PCR; only 47 cases were detected by microscopy
and/or cultivation traducing in 61 missed diagnosis.
Cryptosporidium spp. On a total of 552 patients, 13 cases of
cryptosporidiosis were diagnosed by real-time PCR; only 12 cases were
detected by microscopy and/or antigen detection traducing in 1 missed
diagnosis.
E. histolytica and E. dispar. On a total of 1,108 patients, 12 cases
of amoebiasis and 79 cases of E. dispar infection were diagnosed
by real-time PCR. Only 64 cases of E. histolytica/E. dispar infection
were detected by microscopy and/or cultivation (5 E. histolytica and
59 E. dispar as determined by real-time PCR) traducing in a missed
diagnosis of 7 cases of amoebiasis (6 of whom extra-intestinal).
Conclusion: All the real-time PCR assays proved to be in our hand
a useful tool for the diagnosis of infections by protozoa showing a
higher sensitivity than conventional assays. Therefore, if available and
accessible, they would be the most accurate tool for the diagnosis of
intestinal parasitoses.
P1893 Use of PCR on urine samples for the diagnosis of
toxoplasmosis after allogeneic stem cell transplantation
V. Suybeng, H. Labussie`re, M. Wallon, M. Rabodonirina, F. Peyron*
(Lyon, FR)
Objective: Incidence of invasive toxoplasmosis among T. gondii
seropositive allogeneic stem cell transplantation patients is around 4%
and the estimated mortality rate is 60%-90%. Rapid diagnosis and
immediate onset of appropriate treatment are crucial for avoiding lethal
outcome. We investigated the performance of PCR on urine samples
for monitoring disseminated toxoplasmosis in 2 allogeneic stem cell
transplantation patients.
Methods: Analysis using the repetitive 529bp DNA fragment of T. gondii
(Genbank NoAF487550) through real-time PCR, was performed in
parallel on blood and urine and according to clinical signs on CSF and
bronchoalveolar lavage (BAL).
Two patients underwent an allogeneic stem cell transplantation for acute
lymphocytic leukaemia. Both were positive for toxoplasmosis serology
whereas donors were positive (for patient 1) or negative (for patient 2).
After they presented clinical and radiological manifestation of pulmonary
infection they were given a course of antibiotics and were systematically
monitored by PCR performed on blood, urine, BAL and CSF in one case
(patient 2).
Results: In patient 1, PCR in blood and urine were positive and induced
the onset of antiparasitic treatment. PCR in urine remained positive after
PCR in blood and turned negative few days later. After a 5 years follow
up the patient evolution remained favourable.
In patient 2, PCR in urine remained positive despite antiparasitic
treatment and negativation of PCR in blood. The patient died from fungal
co infection and cerebral manifestation of her leukaemia.
Conclusion: Recipients of stem cell transplantation, when positive
for toxoplasma serology, need to be systematically monitored for
toxoplasmosis as this potentially lethal disease can have a favourable
outcome when treated early. Generally, diagnosis relies on PCR on
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blood or on more invasive sampling like BAL. PCR in urine seems
an interesting alternative avoiding supplementary blood withdrawing.
Additionally, further studies are necessary to compare its sensitivity with
PCR on blood and to investigate if it correlates with the outcome of the
disease.
P1894 Two multiplexed nucleic acid tests for the detection of viral
and bacterial pathogens in cerebrospinal ﬂuid
A. Zoldowski*, S. McBride, F. Merante, H. Zhang, N. Krunic (Toronto,
CA)
Objectives: The diagnosis of central nervous system (CNS) infections
presents a challenge for clinicians, especially given the broad range
of bacterial and viral aetiologies. Delayed pathogen identiﬁcation and
treatment may lead to life-threatening conditions and can be associated
with high morbidity and mortality. Consequently, accurate and timely
identiﬁcation of the infectious agents is essential for patient management.
Here we present analytical study results of two qualititative, multiplex
PCR tests being developed for the detection of clinically important
pathogens targeting the CNS. Each panel detects and discriminates 7
pathogens in a single well: Panel A focuses on viral pathogens and
Panel B on bacterial pathogens as well as the mecA antibiotic resistance
gene.
Methods: Analytical reactivity and cross-reactivity were evaluated for
each panel using deidentiﬁed left-over human cerebral spinal ﬂuid (CSF)
spiked with serial dilutions of individual viral or bacterial cultures and an
internal control (to control for extraction efﬁciency and PCR inhibition).
Extracted nucleic acids evaluated were ampliﬁed by either one-step
reverse transcription (RT)-PCR (Panel A) or PCR (Panel B). Ampliﬁed
products were sorted on a bead-array incorporating the xTAG® Universal
Array coupled to magnetic microspheres. Detection was carried out on
the Luminex MAGPIX® instrument.
Results: Both panels assessed were able to detect relevant levels of
nucleic acids in CSF. Panel A identiﬁed viruses at around 100 copies/mL
and Panel B detected bacteria at 3 cfu/mL. Each multiplexed panel
showed good reactivity with the targeted pathogens and no cross
reactivity across probed analytes. The time-to-result from extraction was
less than 4 hours for each panel.
Conclusion: This study demonstrates that multiplexed detection of viral
and bacterial pathogens in CSF is readily achievable in an assay system
incorporating the xTAG® Universal Array and magnetic microspheres.
Findings also support the suitability of the MAGPIX® instrument for this
class of pathogen detection assay. The ability to simultaneously detect
multiple viral and bacterial targets reduces the need for large CSF ﬂuid
volumes. The short turnaround time of each assay, run either alone or in
tandem, is a key feature of this multiplexed system. Further development
is likely to conﬁrm that an assay system utilizing this approach will be
a valuable tool for an aetiological diagnosis of CNS infections.
P1895 Evaluation of a multiplex nucleic acid test for the detection
of gastrointestinal pathogens in faecal samples
C. O¨hrmalm*, S. Yaghoubian, L. Leyva, H. Zhang, J. Blomberg
(Uppsala, SE; Toronto, CA)
Objectives: Multiplex molecular diagnostics of infectious diseases are
often rapid and cost-effective. They also have the beneﬁt of detecting
co-infections. A qualitative, multiplex PCR test for detecting 19 of
the most common pathogens in faecal specimen being developed by
Luminex Molecular Diagnostics is designed to detect, in a single reaction
well, 4 viral (norovirus GI, GII, adenovirus, rotavirus), 12 bacteria/
bacterial toxins (Campylobacter, Salmonella, Shigella, E. coli O157,
V. cholerae and Y. enterocolitica, C. difﬁcile toxins A and B, Shiga
toxins 1 and 2, and ETEC toxins ST and LT) and 3 parasites (Giardia,
Cryptosporidium and E. histolytica). Here we describe preliminary
evaluation of this multiplex panel with clinical faeces samples from
patients with gastroenteritis at Clinical Microbiology in Uppsala,
Sweden.
Methods: Samples underwent a bead-beating pre-treatment step prior
to addition of an MS2 phage internal control and total nucleic acid
extraction. Reverse transcription and ampliﬁcation was performed in one-
step and ampliﬁed products were sorted on a bead-array incorporating the
xTAG® Universal Array coupled to magnetic microspheres. Detection
was carried out on a Luminex® 200™ xMAP® instrument. Total turn-
around-time was less than ﬁve hours.
Results: In this study 44 faecal samples from gastroenteritis patients
were tested with the multiplex panel. Thirty samples were qPCR
positive for Norovirus (Cq range12.85–29.54) and all were detected
by the xTAG® panel (MFI 488–6818). This panel also detected other
targets, some presented as co-infections, as conﬁrmed by bi-directional
sequencing. One sample was positive for Rotavirus A (MFI 5498).
One Y. enterocolitica positive sample (MFI 3254), was also positive for
Campylobacter concisus (MFI 4348) and Norovirus GII (MFI 6266, Cq
21.08). Another Y. enterocolitica positive sample (MFI 2189) was also
positive for toxin A (MFI 314) and toxin B (MFI 3831) of C. difﬁcile,
as well as for Norovirus GII (MFI 4961, Cq 26.14). A second sample
positive for C. difﬁcile toxins A (MFI 1804) and B (MFI 2861) was
co-infected with Norovirus GII (MFI 3894, Cq 19).
Conclusion: This preliminary evaluation suggests that multiplexed
nucleic acid detection using xTAG®/xMAP® is well suited for diagnostic
applications targeting viruses, bacteria, bacterial toxins and parasites.
This tool will enable further investigation on the clinical signiﬁcance of
co-infections which could be missed by other methods.
P1896 Development of a rapid method for Proteus spp. detection
in urine by peptide nucleic acid ﬂuorescence in situ
hybridisation (PNA)
C. Almeida*, N.F. Azevedo, J. Bento, M.J. Vieira, C.W. Keevil (Braga,
Porto, PT; Southampton, UK)
Objective: The need to avoid empirical treatment of patients, and the fact
that urine samples are among the most numerous of specimen types sent
for microbiology studies, have prompted many researchers to explore
methods to limit the time and expense of urine culture processing. The
aim of this work was to develop a new peptide nucleic acid ﬂuorescence
in situ hybridization (PNA FISH) method for the rapid detection of
Proteus spp., a genus related to the emergence of complicated urinary
tract infectios, especially for immuno-compromised patients.
Methods: The PNA probe was designed, optimized, tested on
representative strains of the genus and other related strains, and, ﬁnally,
a PNA FISH method was developed for application in urine samples.
Results: The PNA FISH method was optimized, and laboratory testing
on representative strains from the Proteus genus and several related
bacterial species, showed experimental speciﬁcity and sensitivity both of
100% (sensitivity, 95%CI, 81.5–100 and speciﬁcity, 95%CI, 91.4–100).
Then, the PNA FISH method was adapted to the detection of Proteus
in urine. Artiﬁcial urine samples were contaminated with decreasing
pathogen concentrations and the PNA FISH method was able to detect,
in approximately 2 hours, as low as 1×104 CFU/mL, a concentration
considered indicative of infection for catheter associated urinary tract
infections (CAUTI’s).
Conclusions: PNA FISH is a very sensitive, speciﬁc and rapid method
for Proteus detection in urine and it could be a reliable alternative to
the currently used culture-based techniques as it may avoid the need for
empirical antibiotic treatment.
P1897 Evaluation of the QIAsymphony® DSP pathogen complex
system: mid-throughput automation for diagnostic sample
extraction
T. Hanselle*, S. Hammerschmidt, Y. Kasper, C. Kupfer, K. Lindebaum,
M. Otte, M. Sprenger-Haussels (Hilden, DE)
Objectives: The QIAsymphony® DSP Virus/Pathogen Kit uses magnetic
bead technology on the QIAsymphony SP instrument (QSSP) for
isolation and puriﬁcation of viral nucleic acids and bacterial DNA
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from respiratory and urogenital samples. In this study, three veriﬁcation
parameters of the automated mid throughput QSSP DSP Pathogen
Complex system have been investigated: (i) stability of eluates,
(ii) repeatability, (iii) pretreatment for viscous samples and lysis of Gram-
positive bacteria.
Methods:
i. Urine samples spiked with HIV and CMV were extracted using
the QSSP Complex200 protocol. Eluates were incubated at 37ºC,
5ºC, and −20ºC for 0−24 h, 0−31 d and 0−6 months, respectively.
Eluates were analyzed using the artus® CMV RG PCR and the
artus HI Virus-1 RG RT-PCR Kits. Both kits are CE-IvD marked for
detection of the respective viruses from plasma; during development
of the QSSP DSP Pathogen Complex system these assays were used
for stability study with eluates generated from urine.
ii. Repeatability of the QSSP DSP Pathogen Complex system was
evaluated with urine samples spiked with Chlamydia trachomatis.
Three independent 96-sample runs were processed on different
days using QSSP Pathogen Complex protocols with 200, 400 and
800ml sample input (Complex200, Complex400, and Complex800).
Eluates were analyzed using the artus C. trachomatis TM PCR Kit.
iii. Sputum spiked with Mycobacterium tuberculosis were liqueﬁed
with DTT. Liqueﬁed samples were treated with lysozyme and
M. tuberculosis DNA was extracted using the Complex200 protocol
as well as the QIAamp® DNA Mini Kit as reference. Eluates were
analyzed with the artus M. tuberculosis RG PCR Kit.
Results:
i. Eluate stability was shown for 24 hours at 37ºC, 31 days at 5ºC,
and 6 month at −20ºC for both viruses.
ii. Inter-batch variation based on CT-values ranged from 1.43–
1.76%CV (Complex200), 0.64–0.98%CV (Complex400) and 1.67–
2.24%CV (Complex800). The inter-run variations based on the CT-
values were 1.84 (Complex200), 1.38 (Complex400) and 2.68%CV
(Complex800).
iii. Extraction with the Complex200 protocol was as efﬁcient as with
the QIAamp DNA Mini Kit. Use of different lots of lysozyme had
no inﬂuence on extraction of M. tuberculosis DNA.
Conclusion: Data shown are part of the veriﬁcation of the QIAsymphony
DSP Pathogen Complex system. The results show that the QSSP DSP
Pathogen Complex system serves as reliable tool for extraction of
viral RNA & DNA and bacterial DNA from urogenital and respiratory
samples.
P1898 Non-culture diagnosis of neonatal sepsis caused by
Streptococcus agalactiae
A. De Zoysa*, A. Vickers, K. Edwards, S. Gharbia, A. Underwood,
A. Bedford Russell, P. Heath, E. Galiza, I. Storey, A. Efstratiou
(London, Birmingham, UK)
Objectives: Streptococcus agalactiae (Lanceﬁeld Group B streptococci
(GBS) is a leading cause of sepsis, pneumonia and meningitis in
neonates The incidence of neonatal sepsis in the world ranges from
2−4 cases per thousand live births and early onset GBS infection occurs
in approximately 2.6/1000 live births. Diagnosis of GBS infection in the
newborn by conventional culture methods is slow and unreliable. Several
PCR methods for the detection of GBS from maternal swabs have been
developed. In this study we report the use of a real time PCR assay
for detection of GBS in blood, CSF and tissue samples of neonates.
The PCR targets the cylB gene and an internal processing control was
included to highlight ampliﬁcation failure due to inhibition.
Methods: Oligonucleotide primers targeting the cylB gene were used
to amplify a 264-bp fragment with the Roche Fast Start DNA Master
Hybridisation Probes Mix. Hybridisation probes targeting an internal
region of this product were used to conﬁrm the presence of this product.
An internal process control (IPC) in the form of a linearised plasmid
containing bacteriophage lambda DNA together with the cylB primer
binding sites was also included. A total number of 462 blood culture
negative clinical samples were analysed; including 112 clinical samples
from 29 babies who had suffered sudden unexpected death in infancy
(SUDI); 110 samples (35 EDTA bloods and 75 CSFs) from neonates with
probable GBS sepsis or meningitis submitted to the WHO Streptococcus
and Diphtheria Reference Unit (WHO SDRU) between 2006 and 2010
and 240 EDTA blood samples from neonates undergoing septic screens
submitted from two hospitals in the UK for a separate study in 2009.
Results: Amongst the 112 samples analysed from 29 SUDI babies, eight
were positive by PCR and amongst the 110 neonates with probable
sepsis or meningitis, 17 were positive by PCR (16 CSF samples and 1
EDTA blood) and amongst the 240 EDTA blood samples from neonates
undergoing septic screens, ﬁve were positive.
Conclusion: The RT PCR assay is superior to culture methods for
detection of GBS from clinical samples. The method is rapid, sensitive,
speciﬁc and reproducible. The use of a co-ampliﬁed IPC in the same
reaction tube with the same primers as the target increases throughput
and reduces cost. This is an invaluable tool in the rapid diagnosis of
neonatal sepsis.
P1899 Performance of Gen-Probe’s Aptima Combo 2® Assay on
the Panther™ system
C. Clark, M. Archer, J. Gilker, M. Hunsicker, S. Lang*, T. Le-Nguyen,
C. Motta, C. Nguyen, J.K. Pham, T. Trsic, M. Vi, L. Villegas,
B. Vinluan, C. Vu, A. Williams, A. Worlock (San Diego, US)
Objectives: The objective was to evaluate the analytical performance
of the Gen-Probe APTIMA COMBO 2 (AC2) Assay on the PANTHER
System, a new, fully automated molecular diagnostic analyzer that is CE
marked, but not yet cleared by the FDA in the U.S.
Methods: Sensitivity and speciﬁcity were assessed by percent agreement
to TIGRIS® DTS® Systems with individual negative urine specimens
spiked with various concentrations of Chlamydia trachomatis (CT)
and/or Neisseria gonorrhoeae (GC). A panel of 120 CT positives, 120
GC positives, 120 dual positives and 120 negatives were tested on three
TIGRIS DTS Systems and three PANTHER Systems using the AC2
Assay.
Precision was evaluated using panels spiked with CT and/or GC rRNA
into Swab Transport Media (STM). The panels were run in multiple
replicates on three PANTHER Systems over a period of 24 days.
Analytical sensitivity was tested with three sample matrices. These
were STM, urine processed with Urine Transport Medium (UTM), and
PreservCyt Liquid Pap solution diluted with STM. Matrices were spiked
with CT and GC rRNA to create panels at very low target concentrations
which were tested on three PANTHER Systems.
Results: Positive agreement between the PANTHER Systems and the
TIGRIS DTS Systems was 100%, with a lower 95% conﬁdence interval
of 99.5%. Negative percent agreement between the PANTHER Systems
and the TIGRIS DTS Systems was 99.9%, with a lower 95% conﬁdence
interval of 99.5%.
Total precision (%CV) for the AC2 Assay at the analytical sensitivity
claim for CT and GC respectively was 6.8% and 3.3% for STM panels,
11.5% and 5.6% for urine panels and 6.9% and 4% for PreservCyt Liquid
Pap solution panels.
Panels made at the analytical sensitivity claim for the TIGRIS DTS
Systems gave 100% positive results on the PANTHER Systems, with a
lower 95% conﬁdence interval of 96%. The analytical sensitivity for the
AC2 Assay on the PANTHER Systems was 5 fg/assay (2.5 IFU/mL) for
CT and 250 fg/assay (125 CFU/mL) for GC, which is equivalent to the
TIGRIS DTS Systems.
Conclusion: The fully automated PANTHER System from Gen-Probe
provides precise results comparable to the TIGRIS DTS System when
running the AC2 Assay.
Molecular diagnostics S555
P1900 Performance of Gen-Probe’s Aptima® Assays for Chlamydia
trachomatis and Neisseria gonorrhoeae on the Panther™
system
C. Clark, M. Archer, J. Gilker, M. Hunsicker, S. Lang*, T. Le-Nguyen,
C. Motta, C. Nguyen, J.K. Pham, T. Trsic, M. Vi, L. Villegas,
B. Vinluan, C. Vu, A. Williams, A. Worlock (San Diego, US)
Objectives: The objective was to evaluate the analytical performance of
the Gen-Probe APTIMA Chlamydia trachomatis (ACT) and Neisseria
gonorrhoeae (AGC) Assays on the PANTHER System, a new, fully
automated molecular diagnostic analyzer that is CE marked, but not
yet cleared by the FDA in the U.S.
Methods: Sensitivity and speciﬁcity were assessed by % agreement
to TIGRIS® DTS® Systems with individual negative urine specimens
spiked with various concentrations of Chlamydia trachomatis (CT) or
Neisseria gonorrhoeae (GC). A panel of 120 CT positives, 120 GC
positives and 120 negatives were tested on three TIGRIS DTS Systems
and three PANTHER Systems using Gen-Probe’s ACT and AGC Assays.
Precision was evaluated using panels spiked with CT or GC rRNA into
Swab Transport Media (STM). The panels were run in multiple replicates
on three PANTHER Systems over a period of 24 days. Analytical
sensitivity was tested with three sample matrices. These were STM,
urine processed with Urine Transport Medium (UTM), and PreservCyt
Liquid Pap solution diluted with STM. Matrices were spiked with CT
and GC rRNA to create panels at very low target concentrations which
were tested on three PANTHER Systems.
Results: Positive agreement between the PANTHER Systems and the
TIGRIS DTS Systems was 100%, with a lower 95% conﬁdence interval
of 98.9% for the ACT and AGC Assays. Negative percent agreement
between the PANTHER Systems and the TIGRIS DTS Systems was
100%, with a lower 95% conﬁdence interval of 98.8% for the ACT and
AGC Assays. Total precision (%CV) for the ACT Assay at the analytical
sensitivity claim was 5.1% for STM panels, 3.5% for urine panels and
4.8% for PreservCyt Liquid Pap solution panels. Total precision (%CV)
for the AGC Assay at the analytical sensitivity was 14.7% for STM
panels, 5.1% for urine panels and 15.5% for PreservCyt Liquid Pap
solution panels. Panels made at the analytical sensitivity claim for the
TIGRIS DTS Systems gave 100% positive results on the PANTHER
Systems, with a lower 95% conﬁdence interval of 96%. The analytical
sensitivity for the PANTHER Systems was 5 fg/assay (2.5 IFU/mL) for
the ACT Assay and 250 fg/assay (125 CFU/mL) for the AGC Assay,
which is equivalent to the TIGRIS DTS Systems.
Conclusion: The fully automated PANTHER System from Gen-Probe
provides precise results comparable to the TIGRIS DTS System when
running the ACT and AGC Assays.
P1901 A novel, automated DNA extraction method from cervical
SurePath® specimens
C. Kupfer*, K. Lindebaum, C. Papadopoulos, J. Giles, T. Hanselle,
M. Sprenger-Haussels (Hilden, DE; Gaithersburg, US)
Objectives: The digene HC2 High-Risk HPV DNA Test® (HC2 test) is
validated for use in Europe with cervical specimens collected in SurePath
liquid based cytology media. We developed a new automated protocol
(based on the QIAsymphony AXpH chemistry) to purify DNA from
cervical SurePath® specimens.
In our initial R&D study presented here we investigated the performance
of this protocol using (i) individual SurePath specimens and (ii) cell cul-
ture samples in SurePath medium spiked with potentially interfering
substances for subsequent downstream use with the HC2 test.
Methods:
i. Individual SurePath specimens: To compare manual and automated
sample preparation methods, DNA was isolated on the QIAsym-
phony using the newly developed AXpH SurePath protocol, which
included a Proteinase K digest with extended lysis and as a
reference, the established manual sample conversion method. The
QIAsymphony eluates and the corresponding manually converted
pellets were tested with HC2. Testing was conducted using 144
residual, de-identiﬁed, clinical SurePath samples. Cervical SurePath
post-gradient specimens, retained after cytology screening, were
used for this study.
ii. Interfering substances: The impact of potentially interfering
substances on the AXpH chemistry were tested by adding varying
amounts of blood, lubricating jelly, contraceptive jelly, spermicidal
gel, douche, feminine spray, and antifungal cream to low positive
cell culture samples in SurePath Medium.
Results:
i. Individual SurePath specimens: The newly developed QIAsym-
phony AXpH SurePath protocol resulted in 96% total agreement
with the manual conversion method (138 of the 144 results were
concordant, 6 were discordant).
ii. Interfering substances: Of the 7 potentially interfering substances,
no signiﬁcant impact on the performance of the SurePath AXpH
protocol has been observed. Mean RLU/co values of all low positive
samples stayed above the cut-off (>1).
Conclusion: The newly developed QIAsymphony AXpH SurePath
protocol demonstrates the feasibility of DNA extraction from cervical
SurePath specimens for use in hybrid capture based downstream
applications. The performance of the automated DNA extraction method
is not compromised by the presence of the tested potentially inhibitory
substances at the tested concentrations.
The QIAsymphony applications presented here are for research use only.
Not for use in diagnostic procedures.
P1902 Variability of ompC and ompF porin genes in multi-resistant
clinical isolates of E. coli
B. Ruiz del Castillo*, E. Roman, G. Moncalian, L. Martinez-Martinez
(Santander, ES)
Objectives: ompF and ompC code for the two major porins of E. coli
(Ec). Multiple reports on structure, regulation and function (including
their role in low level antibiotic resistance) of both porins in Ec-K12 are
available, but there is limited information when considering Ec isolates
from clinical sources. The aim of this study was to analyze the genetic
variability of both ompC and ompF from multirresistant Ec strains.
Methods: Clonally unrelated multirresistant Ec (as deﬁned by Rep-
PCR) isolated from diferent patients, producing extended-sprectrum
b-lactamases (EcESBL, n = 46) or lacking these enzymes (EcNonESBL,
n = 68) were studied. The complete ompC and ompF genes were
ampliﬁed using speciﬁc primers, and their sequences were compared
with those corresponding to Ec-K12 and to 24 other Ec strains deposited
in Genbank. The conformational changes due to mutations found in
our strains were studied by comparison with their corresponding crystal
structures (OmpC: PDB ID code 2J1N and OmpF: PDB ID code 20MP).
Results: All isolates included in this study expressed a complete copy
ompC. A full-length ompC two isolates presented a truncated ompF gene
with a stop codon at positions 127 and 122, respectively, that presumably
does not codify for a functional OmpF. Homology analysis showed that
the different Ec isolates deposited in Genbank presented 16 variations
of ompC and 7 variations ompF. Regarding the clinical isolates of this
study there are 46 EcESBL strains with 27 different ompC alleles and
15 ompF different alleles. The 68 EcNonESBL strains presented 16
different Omps and 11 OmpFs. Among the changes affecting the pore
structure of the porins, the more relevant were as follows: In OmpC,
K317E (1 strain), R37E (1 strain) A156V/S157R (1 strain) and S157D
(1 strain) mutations modify the inner constriction of the pore affecting
channel selection; In OmpF, the V337R and Q339P changes (1 strain),
located near the periplasmic end of the pore affect pore structure and
ion selectivity of the pore.
Conclusions: We have observed some variability in the sequences of
both ompF and ompC genes from multirresistant clinical isolates of
E. coli, in comparison with the corresponding genes in the K12 strain.
There was more variability in ompF than in ompC. Some of the observed
changes affect pore size and ion selectivity, which may be of importance
for antimicrobial resistance modulation.
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P1903 Cloning, soluble expression and immunoreactivity of HIV-1
CRF35_AD p24 protein in fusion with HP-thioredoxin from
an Iranian clinical isolate
M. Farajollahi*, Z. Shariﬁ, F. Gorgipor (Tehran, IR)
There are two distinguished types of HIV virus, HIV-1 and HIV-2, that
the ﬁrst one causes the most prevalent and also lethal cases of the disease.
As the p24 antigen is the most immunogenic protein of the virus and
appears in blood in the early stages of the disease, antibodies directed to
this antigen could be an important marker for early diagnosis of disease
in low income settings.
The purpose of this study was to isolate coding sequence of the p24
protein from the sera of clinical samples gathered from Iranian patients,
cloning and soluble expression of the p24 coding sequence of the
gag gene in E. coli, and also assessing the immunoreactivity of the
recombinant protein.
In this study the complete coding sequence of the Gag polyprotein
were isolated using the nested RT-PCR from the serum of an infected
individual and cloned in PTZ57R (T) vector and the resulting vector
named PTZ-gag53-IR and sequenced. Coding sequence of p24 protein
was isolated by PCR from the PTZ-gag53-IR vector and was inserted into
pET102/D-TOPO vector using TOPO directional cloning strategy, and
then expressed in E.Coli in fusion with thioredoxin. Immunoreactivity of
the expressed protein was tested using immunoblotting and ELISA using
blood samples of conﬁrmed seropositive patients and healthy controls.
Sequencing results showed that the cloned sequence belongs to
CRF35_AD subtype of HIV-1 virus which is highly prevalent in Iran
and Afghanistan. Western blot and protein assay data conﬁrmed that
pET102D/TOPO system effectively expressed recombinant p24 protein.
Antibody assay using recombinant p24 protein from this isolate showed
100% sensitivity and 100% speciﬁcity although more samples need to be
tested. This can be attributed to the native conformation of the antigen
produced by this method and possible similarity of the protein sequence
to those of infecting viruses in the tested population.
P1904 Campylobacter jejuni cmeA/B transcription in poultry and
human
M. Dzieciol*, M. Wagner, I. Hein (Vienna, AT)
Objectives: Campylobacter infections are amongst the leading causes
of foodborne bacterial gastroenteritis in the developed world. The
multidrug efﬂux pump CmeABC described in Campylobacter jejuni
has been shown to be important for bile resistance and for successful
colonization of chicken intestines and seems to be involved in resistance
to ﬂuoroquinolon and macrolide. The aim of the study was to develop
a real-time reverse transcriptase (RT)-PCR method to study transcript
levels of the multidrug efﬂux pump CmeABC in Campylobacter jejuni
and to apply it to compare bile salt dependent cmeABC transcription in
poultry and human C. jejuni strains.
Methods and Results: Ten poultry and eight human C. jejuni strains
were cultured microaerobically at 42ºC in Mueller-Hinton broth with
or without the addition of the bile salts cholate (CA) and taurocholate
(TCA). Normalization of real-time RT-PCR data to CFU revealed
inconsistent transcription of 16S rRNA and low level transcription of
cmeA and cmeB, which increased slightly but signiﬁcantly upon addition
of bile salts. Human C. jejuni strains had lower cmeA and cmeB
transcription levels but could be induced in a similar manner as poultry
strains.
Conclusion: Colony count normalized real-time RT-PCR was useful
for determination of the cmeA and cmeB transcription on a cellular
basis. The real-time RT-PCR method described is a valuable tool for
future studies regarding the activity of the cmeABC operon, provides
the opportunity to gather information about the transcript levels on a
cellular basis and could easily by adapted to investigate other targets.
P1905 The impact of rapid identiﬁcation with PNA FISH®
of selected bacteria and yeasts from blood cultures on
antibiotic treatment and clinical advice: a cross-sectional
study of 123 episodes of bacteraemia in 118 patients
S.H. Hartzen*, H. Colding (Hillerød, Copenhagen, DK)
Objectives and Background: Every laboratory is currently faced with a
tight budget and has to make priorities concerning which diagnostic tests
to use in order to maximize beneﬁts from resource spending. Therefore,
whenever a new diagnostic tool is assessed we have to ask the question:
are beneﬁts larger than the costs? In this study we tried to investigate
whether the results of the PNA FISH® hybridization of positive blood
cultures actually had any impact on 1) the antibiotic treatment of the
patients and 2) on the clinical advice given to the clinicians concerning
further diagnostic procedures and the origin of the infection.
Methods: PNA FISH®− short for peptide nucleic acid ﬂuorescence in
situ hybridization (AdvanDx, Boston, MA, USA) − uses ﬂuorescent-
labeled PNA probes in a 90 min. ﬂuorescence in situ hybridization.
Hybridization was performed according to the manufacturer’s manual.
The following PNA FISH® probes were used: S. aureus, coagulase-
negative staphylococci (CNS), E. faecalis, other enterococci, E. coli
(EC), K. pneumoniae, P. aeruginosa, C. albicans, and C. glabrata.
Design: Cross-sectional study of 123 episodes of bacteraemia in 118
patients observed in our laboratory during a two months’ period in the
autumn of 2010 where PNA FISH® technology was used.
Results: The most frequent isolated bacteria from the blood cultures
were CNS (34/123) and EC (23/123). PNA FISH® had been performed
in 123 out of 142 episodes of bacteraemia in 134 patients during this
2 months’ period. PNA FISH® had not been performed in 19 episodes
either because the Gram stain made the test irrelevant or because the
blood culture had become positive just before closure of the laboratory,
in which case only Gram stain had been performed. The PNA FISH®
result inﬂuenced the antibiotic treatment of the patient in 26 episodes
(21%) and the clinical advice given to clinicians in 24 episodes (20%).
Conclusion: In our study of the inﬂuence of rapid identiﬁcation using
PNA hybridization we found that the PNA FISH® result only inﬂuenced
antibiotic treatment and clinical advice in about 20% of the bacteraemia
episodes. This result might be explained by such factors as good coverage
of the empiric antibiotic treatment chosen, high a priori suspicion of the
focus of the infection based on the clinical examination and ﬁnally on
the distribution of microorganisms.
P1906 Characterisation of probiotic and antioxidative properties
of Nisin A producer L. lactis LL27 strain
D. Kaya Ozdogan, N. Akkoc*, P. Sanlibaba, M. Akcelik (Ankara, TR)
Objectives: The aim of this study was to evaluate the probiotic and
antioxidative properties of Nisin A producer L. lactis LL27 strain. To
determine the probiotic properties of LL27 strain; bile salt, pepsin,
pancreatin and acid tolerance were examined. Moreover the ability of
L. lactis to inhibit the adhesion of Escherichia coli ETEC and Salmonella
Typhimurium SL1344 to Caco-2 cells were identiﬁed.
Methods: L. lactis LL27 strain was grown in GM17 broth media for 18 h
at 30 ºC and cells were harvested by centrifugation. Cell pellets were
washed twice and resuspended in PBS. For acid tolerance experimet,
cells were inoculated in pH adjusted PBS and incubated at 30 ºC for 4 h.
The bacterial cells were inoculated in PBS adjusted to pH 2 and pH 3
containing 3% pepsin, PBS adjusted to pH 8 containing 1% pancreatin
and GM17 broth containing 0.3% (w/v) bile salt. Samples were collected
at 0 h, 1.5 h and 3 h of incubation for the pepsin treatment, and at 0 h
and 4 h of incubation for pancreatin and bile salt resistance assays. PBS
at pH 7.2 was used as control. Caco-2 cells were routinely cultured in
DMEM. Harvested ovenight LL27, E. coli ETEC and S. Typhimurium
SL1344 cells were diluted in PBS (pH 7.2) to achieve a population to
108 cfu/mL. For adhesion inhibiton assay, Caco-2 cells challenged with
LL27 before tested pathogens.
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Results: L. lactis LL27 exhibited high levels of resistance to low pH, bile
salts, pepsin and pancreatin, which are conditions characteristics of the
gastrointestinal tract environment. Moreover, L. lactis LL27 was found
to adhere to Caco-2 cells at a rate of 13±2.3%. Adhesion inhibition
assays showed that adhesion of Escherichia coli ETEC and Salmonella
Typhimurium SL1344 to Caco-2 cells was reduced to 73.6% and 29.5%,
respectively, when the cells were previously challenged with L. lactis
LL27. The hydrophobicity, DPPH radical-scavenging activity and iron
ion-chelating ability of the tested LL27 strain were found to be 83.48%,
75% and 29.5%, respectively. Scanning electron microscopy revead the
LL27 strain to be located inside Caco-2 cells.
Conclusion: The nisin A producer L. lactis subsp. lactis LL27 strain
of food origin possesses the ability to inhibit adhesion of pathogenic
microorganisms to Caco-2 cells and also was found to remain at a level
of 67.4% (viable count)after 4 hours incubation at pH 3, indicates that
this strain may survive in gastrointestinal tract conditions and can be
used as a probiotic strain.
P1907 CagA status and VacA subtypes of Helicobacter pylori in re-
lation to gastrointestinal complications in Iranian population
S. Saberi*, M. Douraghi, F. Ebrahimzadeh, Y. Talebkhan, S. Jahangiri,
P. Hassanpour, N. Mohajerani, E. Mostafavi, N. Rakhshani,
M. Mohagheghi, M. Eshagh Hosseini, M. Mohammadi (Tehran, IR)
Objectives: Gastric cancer is the most severe manifestation of chronic
H. pylori (Hp) infection. HP-induced carcinogenesis is mediated mostly
through two potent polymorphic toxins; vacA and cagA. The aim of
this study was to determine associations between different cagA/vacA
genotypes and functions with gastrointestinal complications and evaluate
whether there is correlation among genotyping, function and gastric
malignancy in Iranian patients.
Methods: Collectively, 88 Hp-infected patients were evaluated for the
presence and severity of gastric inﬂammation and atrophy according to
OLGA staging protocol. PCR genotyping of vacA s, m and i alleles plus
cagA 3′ region was performed. Concentrated Culture Filtrates (CCF) of
all of the studied strains were collected through liquid culture. HeLa
cell line was incubated with CCF up to 24 hours. These strains were
also co-cultured with AGS cells for 24 to 48 hours prior to analysis of
the hummingbird phenotype. The number of vacuolated cells and the
percentage of cells with hummingbird characteristics were determined
by inverted light microscopy. Statistical analysis of data was performed
using Kruskal-Wallis, Mann-Whitney U test and Bivariate correlations.
Results: Our results demonstrated that Hp strains with vacA s1m1i1
genotype and posses two or more EPIYA-C in their cagA 3′ region
in comparison with other genotypes were signiﬁcantly associated with
gastric atrophy and inﬂammation among Iranian population (P< 0.05).
The number of vacuolated cells incubated with s1i1m1 CCF was
signiﬁcantly greater than that of s1i2m2 strains (P< 0.001). The
hummingbird phenotype formation was signiﬁcantly prominent in AGS
cells incubated with strains having two or more EPIYA-C than all other
divergent subtypes (P< 0.05). Functional assays revealed a correlation
between hummingbird and vacuolation phenotypes in patients with
gastric atrophy (P = 0.01, K = 0.537), intestinal metaplasia (P = 0.02,
K = 0.608) and two or more premalignant lesions (P = 0.007,K = 0.894).
Conclusion: This analysis further recommends the application of cagA
and vacA genotyping in population screening approaches, identifying
high risk infections with functionally virulent strains, which may lead to
the development of gastric premalignant lesions and ultimately gastric
cancer.
P1908 The association of MDR1 gene C3435T polymorphism with
CMV reactivation in patients with multiple myeloma
N. Gorovenko*, N. Kostyukova, S. Vydyborets, S. Kyryachenko,
L. Gorenko, V. Mazurik, O. Popova, Z. Rossokha (Kiev, UA)
Objective: Cytomegalovirus is a common and worldwide virus. CMV
infection may reactivate in oncological patients who take chemotherapy.
A polymorphism C3435T in the human multi-drug resistance (MDR1)
gene is controlling toxicant excretion from the cells. The aim of this
study was detection the association of MDR1 gene polymorphism with
possible CMV reactivation to assess the individual risk for patients with
chemotherapy.
Method: We investigated 54 multiple myeloma (MM) patients who
took a course of chemotherapy. Polymorphism was detected by the
PCR method. PCR products were visualized after restriction in agarose
gel. The C3435T polymorphism in the MDR1 gene was compared in
patients of two groups depending on the presence or absence of CMV
reactivation. Differences in comparative groups were assessed by x2 (the
Pearson chi-square test).
Results: CMV reactivation was diagnosed in 25,92% patients. Analysis
of the polymorphic variants of MDR1 gene (Figure 1) showed that
genotype frequency CT+TT was signiﬁcantly increased (x2 = 5,42;
p< 0.05) in the patients with CMV reactivation (100%) as compared
with the patients without CMV reactivation (70%). Individuals with CC
genotype were not detected among the patients with CMV reactivation. It
means that the presence of allele polymorphism 3435T in homozygous or
heterozygous carriers increases the risk of CMV reactivation in patients
with MM during chemotherapy. Potential inﬂuence of the polymorphism
on CMV reactivation is connected with an increase of the toxic effect
during the treatment of patients with CT and TT genotypes who have
much worse toxicant excretion from the cells.
Conclusion: The presence of genotypes CT and TT in MDR1 gene
in patients with MM is associated with CMV reactivation during the
chemotherapy treatment. Genotype CC in patients may contribute with
protective effects to CMV reactivation. Genotyping of the MM patients
before treatment initiation allows to correct the dose of cytostatic drugs
or to choose medicinal agent with another mechanism of action.
Figure 1. The distribution of C3435T polymorphism in MDR1 gene among patients
depending on CMV reactivation
P1909 Integrated DNA extraction and puriﬁcation on an automated
microﬂuidic lab-on-chip from bacterial pathogens causing
community-acquired lower respiratory tract infections
L. Van Heirstraeten*, T. Roeser, P. Spang, B. Nieto, M. Camps,
B. Landgraf, C. Schwind, K. Drese, M. Ritzi-Lehnert, H. Goossens,
S. Malhotra-Kumar on behalf of the TheraEDGE (European
Commission, 7th Framework Programme) WP 2, 3 and 5 study groups
Objectives: Community-acquired lower respiratory tract infections (CA-
LRTI) can be caused by bacteria or viruses, however, clinical symptoms
cannot differentiate these etiologies. The overarching aim of the
TheraEDGE project is to develop a point-of-care test (POCT) that will
ensure a deﬁnitive etiological diagnosis of CA-LRTI within 30 minutes.
In this study, we tested the feasibility of automated DNA extraction
and puriﬁcation on an in-house developed lab-on-chip (LOC) prototype
utilizing the most common bacterial etiologic agents of CA-LRTI.
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Methods: The disposable polymeric LOC comprises multiple reservoirs
for buffer storage, two valves for ﬂuidic interactions and a membrane for
DNA puriﬁcation (Figure). 50 ml of 1E+08−09 colony forming units/ml
(cfu/ml) of reference strain cultures of Gram-positive (Staphylococcus
aureus ATCC 25923 and Streptococcus pneumoniae ATCC 49619) and
Gram-negative (Haemophilus inﬂuenzae ATCC 10211) bacteria were
added to the LOC in the presence of a swab. Broth cultures were pre-
treated with a constant and automated ﬂow of enzymatic buffer from its
reservoir with 3 minutes incubation at room temperature. Next, the pre-
treated culture was treated with a guanidium-based lysis buffer followed
by automated addition of ethanol to the lysate. Bacterial lysate was
puriﬁed by passing through a DNA-binding membrane and DNA was
eluted on-chip after a wash step. Experiments were done in quintuplicate
on the LOC, and manually replicated in triplicate at the macroscale. DNA
was quantiﬁed ﬂuorometrically (Qubit dsDNA HS, Invitrogen).
Results: S. aureus yielded signiﬁcantly higher amounts of DNA (average
of 5 experiments: 1.0mg/ml, 95%CI: 0.7−1.3) when undergoing LOC
lysis in comparison to macroscale DNA extractions (average of 3
experiments: 0.4mg/ml, 95%CI: 0.3−0.5) (P = 0.03, Mann Whitney U
test). Yields from S. pneumoniae were also higher when lysed on
LOC (average: 0.7mg/ml, 95%CI: 0.6−0.9) in comparison to macroscale
(average: 0.6mg/ml, 95%CI: 0.2−0.9) but the difference was not
signiﬁcant (P = 0.2). Similarly, DNA yields from H. inﬂuenzae were also
higher on the LOC (average: 0.5mg/ml, 0.4−0.6) compared to macroscale
(average: 0.3mg/ml, 95%CI: 0.2−0.4) but the difference was again non-
signiﬁcant (P = 0.05).
Conclusion: We obtained higher or similar concentrations of puriﬁed
bacterial DNA on an automated LOC device compared to manual
macroscale experiments, which is promising for its application on a
POCT.
P1910 Reduction of workload of microbial gastroenteritis
diagnostics by molecular pre-screening
W.A. van der Reijden*, C. Nguyen, T.G. Mank, R. Jansen (Haarlem, NL)
Introduction: Fecal samples from patients with diarrhea form a
substantial part of the workload in diagnostic microbiology laboratories.
The diagnosis of the bacterial and parasitic pathogens in gastrointestinal
infections is routinely performed by a combination of culture,
microscopy and antigen detection techniques. To reduce the workload
of this combined approach, we emphasized that molecular methods can
be used to screen the stool samples for positivity. PCR negative stool
samples can be discarded from further analysis, leading to a reduction
of workload and costs.
Objective: To determine the reduction of workload of gastrointestinal
diagnostics at the parasitology and bacteriology labs using a PCR
screening method.
Methods: A total of 267 stool samples from patients with gastroenteritis
were subjected to PCR screening. From these samples, 89 were send
in for parasitolgy, 97 were send in for bacteriology and 81 were
send in for both. A multiplex PCR was used for the gastroenteritis-
associated pathogens: Campylobacter (CA), Salmonella (SA), Shigella
(SH), Giardia lamblia (Gl), Dientamoeba fragilis (Df) Cryptosporidium
(CR), and Entamoeba histolytica (Eh). DNA extractions of the samples
were carried out on an EasyMag® DNA-extractor (bioMe´rieux) and three
multiplex PCRs per sample were performed on a LightCycler® 480II
(Roche Diagnostics).
Results: The prevalence of Gl, CR, Eh, SA, and SH by PCR were
low: 1.76%, 0.6%, 0%, 1.1% and 0.6% respectively. From a total of
170 samples send for parasitology, 33 samples (19.4%) were detected
by Df-PCR and microscopy/ELISA, 14 (8.2%) were detected by Df-
PCR only resulting in a prevalence of Df by PCR of 27.6%. From the
samples send for bacteriology (n = 178), 12 (6.7%) were positive by
CA-PCR and culture techniques, whereas 22 (12.4%) were positive by
CA-PCR only. The discrepancy between PCR and culture techniques
for Campylobacter was due to very low bacterial loads (P< 0.0001),
in contrast to the discrepancy between PCR and microscopy/ELISA for
Dientamoeba fragilis (p = 0.106).
Conclusion: Without speciﬁc anamnestic data, pre-screening of 267
stool samples by PCR resulted in a reduction to 29.4% positive
samples only that are eligible for conﬁrmation by microscopy/ELISA
for parasitology and a reduction to 19.7% positive samples only that
have to be cultured e.g. for antibiotic susceptibility.
P1911 Evaluation of the PNA FISH® technology for yeast
identiﬁcation directly from positive blood cultures. An
Italian experience
C. Farina*, S. Andreoni, C. Bonetti, P. Casella, M. Conte, P. Fazii,
G. Lombardi, F. Luzzaro, E. Manso, P. Marone, C. Morazzoni,
M. Passera, S. Perin, A. Rocchetti, S. Sanna, E. Vigano` on behalf
of the Medical Mycology Committee − Associazione Microbiologi
Clinici Italiani (AMCLI)
Objectives: Yeasts are responsible for the majority of fungemias. Non
albicans Candida spp. are frequently difﬁcult to treat because of their
sensitivity patterns. The PNA (peptide nucleic acid) FISH (ﬂuorescence
in situ hybridization) technology is designed to discriminate among
medically important yeasts in blood samples, allowing clinicians to begin
a proper empirical therapy.
Aim of the study was to evaluate the performance of PNA-FISH to
directly identify yeasts from blood cultures.
Methods: Centers: 14 Microbiology labs of Italian Public Hospitals
were included in a network coordinated by the Medical Mycology
Committee − Associazione Microbiologi Clinici Italiani.
Samples: 72 blood cultures positive for yeasts at direct Gram stain; 4
blood negative cultures as control.
Technology: Yeast Trafﬁc Light PNA FISH® AdvanDx, Woburn, USA
able to discriminate C. albicans/C. parapsilosis, C. tropicalis and
C. krusei/C. glabrata.
Reading: Lecture done in double by two different microbiologists and
supervision by a third one.
Control: In case of discrepancy, complete reprocessing of the samples.
Results: The agreement between the traditional and the FISH techniques
was 94,7% (72/76: 4 neg and 68 pos cultures). Complete agreement
was observed for 33 Candida albicans/parapsilosis (C. albicans, 27;
C. parapsilosis, 6); 17 Candida glabrata/krusei (C. glabrata, 16;
C. krusei, 1); 7 Candida tropicalis; 6 C. albicans + C. glabrata. The
test was negative in 5 cases of yeasts recognized by Gram staining but
not-included in the FISH pattern (C. lusitaniae 2; C. guilliermondii 1;
C. neoformans 1; G. capitatum 1).
Discrepancies occurred in 3 samples apparently positive only for
C. albicans but mixed (C. albicans + C. tropicalis, 2; C. albicans +
C. glabrata, 1). One case of a mixed culture (C. tropicalis + C. glabrata)
at the traditional identiﬁcation resulted caused by C. glabrata only.
Finally, sensitivity of the FISH technique evaluated for 5 Candida species
was 98,6%, and speciﬁcity 100%.
Conclusion: Distinguishing which yeast is causing fungemia, and
whether the infection is due to multiple species, is important for the
selection of antifungal therapy, particularly if results can be quickly
transmitted to clinicians. The PNA FISH® testing is a very useful
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approach because the test discriminates between groups of Candida
species with different susceptibility pattern, particularly against azoles
and echinocandins, and only 90 minutes are requested after the Gram
stain reading.
P1912 Comparison of culture with two different qPCR assays for
detection of rectovaginal carriage of Streptococcus agalactiae
N. El Aila*, I. Tency, G. Claeys, H. Verstraelen, P. Deschaght, E. Decat,
G. Santiago, P. Cools, M. Temmerman, M. Vaneechoutte (Ghent, BE)
Objectives: Comparison of culture with two different qPCR assays for
detection of Group B streptococci in pregnant women.
Methods: For a total of 100 pregnant women at 35−37 weeks of
gestation, one rectovaginal ESwab was collected. Eswab was inoculated
into Lim broth, incubated for 24 hours and plated onto chromID™
Strepto B agar (ChromAgar). DNA was extracted with the bioMe´rieux
easyMAG platform, either directly from the rectovaginal ESwab or from
the Lim broth enrichment culture. Two different qPCR formats were
compared, i.e. the hydrolysis probe format (Taqman, Roche), targeting
the sip gene and the hybridization probe format (Hybprobe, Roche),
targeting the cfb gene.
Results: Both qPCR techniques identiﬁed 33% of the women as GBS
positive. Only one culture-positive sample was qPCR-negative. qPCR,
directly on the sample, already signiﬁcantly increased the number of
women found to be GBS positive (27%), compared to culture (22%).
Moreover, the sensitivity of qPCR after Lim broth enrichment (33%)
was again signiﬁcantly higher than qPCR after DNA extraction directly
from the rectovaginal swabs (27%).
Conclusions: When detecting GBS from rectovaginal swabs, the
application of qPCR, irrespective of the target (sip or cfb) has increased
the number of GBS positive women in comparison with culture.
P1913 Rapid identiﬁcation of yeasts by PNA-FISH in patients
with candidaemia
S. van den Tempel, V. O¨zenci, L. Klingspor, M. Ullberg* (Stockholm, SE)
Objectives: To analyse the performance of PNA FISH in detection of
Candida spp. directly from positive blood culture bottles in a prospective
clinical study.
Methods: Peptide nucleic acid probe ﬂuorescence in situ hybridization
(PNA-FISH) was performed directly from blood culture bottles positive
for yeast growth documented by Gram staining. The Yeast Trafﬁc
Light probes for C. albicans/C. parapsilosis, C. tropicalis, and
C. glabrata/C. krusei were used in the study. Results were compared to
identiﬁcation by conventional methods including the VITEK 2 system.
Results: A total of 53 patients with positive blood cultures were tested
prospectively. Only one blood culture per patient was included in the
study. Using conventional methods 33 C. albicans, 11 C. glabrata, 2
C. tropicalis, 2 C. parapsilosis and one each of C. krusei, C. norvegensis,
C. dubliniensis, C. lusitaniae, and Saccharomyces cerevisiae were
detected. The PNA FISH Candida assay showed 100% sensitivity and
speciﬁcity for the Candida species included in Yeast Trafﬁc Light
kit. For two C. albicans tested in the beginning of the study, initial
assay results were negative. However, repeated staining of these samples
showed that both were positive for the C. albicans/C. parapsilosis
probes indicating that lack of experience in sample preparation was
the underlying factor for the negative result. Four Candida species
(C. norvegensis, C. dubliniensis, C. lusitaniae, and Saccharomyces
cerevisiae) not included in the Yeast Trafﬁc Light probes were negative
as expected. PNA-FISH was 24−48 h faster in identiﬁcation of Candida
spp. compared to conventional methods. With the help of PNA-FISH
12/53 (22,64%) (11 C. glabrata and 1 C. krusei) cases could have the
possibility to receive early effective treatment 24−48 h earlier with an
echinocandin instead of ﬂuconazole.
Conclusion: The present study shows that the Yeast Trafﬁc Light PNA
FISH assay can provide rapid and reliable identiﬁcation of ﬁve clinically
relevant Candida species from positive blood cultures. The signiﬁcantly
faster identiﬁcation of Candida spp. by PNA-FISH can be used as a
guidance for early, effective antifungal therapy.
P1914 Clinical consequences of using PNA-FISH
U.S. Jensen*, J. Knudsen (Copenhagen, DK)
Objectives: The clinical guidance from microbiologists following blood
cultures (BC) with Gram positive cocci in clusters depends on patient
history and the pathogen retrieved. If the patient is severely ill or
growth in all ﬂasks occurs, initially, Staphylococcus aureus and not
coagulase negative staphylococci (CoNS) is presumed which affects
the clinical guidance. PNA-FISH (peptide nucleic acid ﬂuorescence
in situ hybridization) identiﬁes pathogens within 90 min. The clinical
consequences of early species detection were studied.
Methods: In November 2009, PNA-FISH was implemented for routine
examination of Gram positive cocci in clusters directly from positive
BC. Records of BC containing Gram positive cocci in clusters from
August–October 2009 and 2010 were reviewed, and the guidance given
was recorded.
Results: We identiﬁed 348 BC with Gram positive cocci in clusters (77
S. aureus and 248 CoNS). PNA-FISH identiﬁed the pathogen of 116 BC;
19 S. aureus and 97 CoNS. S. aureus: Of 19 PNA-FISH identiﬁed BC,
6 (32%) patients had antimicrobial therapy changed from no appropriate
empirical coverage to speciﬁc narrow spectrum treatment; dicloxacillin.
In addition, for 11 (58%) patients the broad spectrum treatment could
be changed to speciﬁc S. aureus treatment at least one day earlier. All
patients were eligible for pursuing possible S. aureus foci one day ahead
of usual practice, e.g. performing echocardiography. Of 58 non-PNA-
FISH identiﬁed BC, appropriate empirical treatment could have been
given to 8 (14%) patients. Also, 36 (62%) patients could have had small
spectrum S. aureus treatment one day earlier.
CoNS: Of 97 PNA-FISH identiﬁed BC, 73 (75%) had clinical
consequences by stopping treatment of contaminants, but also by
identifying possible catheter-related foci and initiating glycopeptide
treatment and/or removal of the catheter one day ahead of usual practice.
Of 151 non-PNA-FISH identiﬁed BC, 27% could have beneﬁtted from
PNA-FISH. Two patients could have avoided being readmitted on the
presumption of S. aureus being grown.
Conclusions: In BC of 77 patients with S. aureus bacteremia and 248
patients with CoNS, PNA-FISH was able to improve guidance from
clinical microbiologist to clinical doctors in 80% and 46%, respectively.
The beneﬁts were early diagnosis, early appropriate treatment, faster
guidance to identify the infectious focus and avoiding unnecessary
readmissions. Obviously, these improvements in patients care also hold
economic beneﬁts.
P1915 Integration of affordable molecular detection of b-lactamase
genes with the CDS disc diffusion method of antibiotic
susceptibility testing
I.W. Carter*, J. Pham, S.M. Bell (Sydney, AU)
Objectives: To demonstrate integration of affordable molecular detection
of different classes of b-lactamase genes with the CDS disc diffusion
antimicrobial sensitivity test.
Methods: The methods employed are our frontline CDS test method
followed by a series of multiplex and single plex real-time PCR tests
on either the SmartCycler II or LC480 real-time PCR machines (both
available within our Department). The PCR methods employed can be
juggled to suit the typical b-lactamase resistance genes seen locally and
can include ESBL’s TEM, SHV, PER, VEB, GES, metallo b-lactamases
(IMP, VIM, SPM in multiplex format), NDM1, AIM, SIM, GIM, ampC
enzymes (Perez Perez & Hansen 2002), oxa genes, CTX-M-1, CTX-M-2,
CTX-M-9, CTX-M all groups except CTX-M-1 genes (can be multiplex
format) and other combinations of gene targets. Variations in assays
(and therefore the target genes) can be made with a simple change of
probe label to suit the instruments available. This can be aided by use
of real-time assay design software (Biosearch Technologies). A simple
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extraction procedure using Instagene matrix (Biorad Laboratories) is
used for nucleic acid isolation from cultures of the organism/colonies
to be tested.
Results: The combination of assay design (primer and probe), use
of multiplex assays and reduced assay volumes in the case of the
LC480 (12.5ul reaction volume in a 96 well plate format) allowed assay
consumable costs to be reduced to around $2.50 for a single-plex and
$3 for a triplex assay utilizing FAM, CAL Fluor Orange 560 and Cal
Fluor Red 610.
It was shown to be an affordable and fast method with master mixes
able to be made up as bulk mixes and held at 4C for up to 1 month until
required. This therefore made for a rapid one and a half hour turnaround
in gene detection in a 96-well format if and when required.
Conclusion: The successful use of affordable molecular detection of
targeted genes can be achieved with the use of readily available
real-time assay design software (in this case Biosearch Technologies)
and better affordable probe-dye combinations. Target gene sequences
are assembled, analysed and representative sequences used with free
software to derive appropriate targeted assays. The combination of these
molecular methods coupled with the CDS method is ideal for our
Laboratory.
However the variation and on-going diversity of the b-lactamase genes
(particularly the oxa genes) make for a continual ongoing challenge in
the diagnostic laboratory.
From molecular diagnosis to molecular
epidemiology
P1916 Full automation of nucleic acid extraction with the dual
STARlet (Hamilton)-MagNAPure 96 (Roche) system: a
preliminary experience
K. Jaton*, R. Brouillet (Lausanne, CH)
Objective: To increase the diagnostic efﬁciency of our molecular
diagnostic platform, where bacteria, viruses, parasites, fungi are detected
by real-time PCR (RT-PCR) in clinical samples, the extraction step was
fully automated with the STARlet liquid handling (Hamilton) followed
by a MagNAPure 96 (Roche) instrument which can extract 96 samples
in 1h. In order to assure correct and consistent extraction of DNA or
ARN of a variety of pathogens, this new extraction robot was validated
in our laboratory using clinical specimens.
Methods: Performance of the automated procedure was assessed by
means of i) efﬁcacy of the automation, i.e from the sample tube to DNA
elution ii) absence of cross-contamination tested with 4 blood samples
with high viral load (BKV, VZV, HSV and PB19 (109–1012 copies/mL);
and iii) the extraction efﬁciency compared with the MagNAPure LC
(Roche) for DNA, and with EasyMag (BioMe´rieux) for RNA. We tested
24 EDTA blood positive for CMV (n = 18), EBV (n = 3), B19 (n = 2)
and T. gondii (n = 1); 13 CSF positive for N. meningitidis (n = 2),
S. pneumoniae (n = 2), H. inﬂuenzae (n = 1),M. tuberculosis (n = 2), EBV
(n = 1), HSV (n = 1), JC (n = 1), VZV (n = 1), enterovirus (n = 1), T. gondii
(n = 1); 22 respiratory samples positive for ARN viruses and 11 positive
for bacteria (Mtbc (n = 8),M. pneumoniae (n = 1), C. pneumoniae (n = 1),
B. pertussis (n = 1); 6 urogenital specimens positive for C. trachomatis
(n = 3) or N. gonorrhoeae (n = 3); ﬁnally 14 difﬁcult to extract Gram
positive isolates and 1 C. albicans were tested. After extraction, nucleic
acids were ampliﬁed with their speciﬁc RT-PCR using the ABI 7900
(Applied Biosystems).
Results: (i) Automation was complete. (ii) No contamination resulted
from high copy number specimens. (iii) for 60% of specimens (54/91),
the agreement between the new and the previous extraction procedure
(difference of copies/ml) was <0.5 log, and for 90% of specimens
(78/91) <1 log. Discrepancies were found at the limit of detection due
to stochastic distribution.
Conclusions: A fully automated DNA/RNA extraction system was
highly effective for different types of specimens and various pathogens.
Although the determination of the diagnostic sensitivity and speciﬁcity
is both labour-intensive and expensive, it remains an essential step for
the validation of new instruments.
P1917 Recognition of positive urine samples by using a real-time
PCR-based semi-quantitative breakpoint
W.L. Hansen*, C. van der Donk, E. Stobberingh, P. Wolffs (Maastricht,
NL)
Objectives: Diagnosis of urinary tract infections is based on rapid testing
methods (Gram stain, latex agglutination tests) combined with urine
culture. However, molecular testing could be a more rapid approach.
Recently, we developed and successfully evaluated a multi-probe assay
using probes covering the most frequently found bacterial agents causing
bloodstream infections. The aim of this study was to broaden the
application ﬁeld of the multi-probe assay and therefore using it for the
rapid detection and identiﬁcation of bacterial pathogens in urine samples.
Furthermore, the rapid molecular recognition of infection could reduce
the amount of urine samples that need to be cultured.
Methods: Urine samples were collected and bacterial DNA was isolated
using the QIAamp DNA Mini Kit. A real-time PCR assay including one
universal probe and seven species- or genus-speciﬁc probes (Escherichia
coli, Pseudomonas species, Pseudomonas aeruginosa, Staphylococcus
species, Staphylococcus aureus, Enterococcus species and Streptococcus
species) was used for the detection of frequently found bacterial
pathogens. The designed probes were based on regions of identity within
the 16S rDNA gene. Results were compared with standard culturing.
Results: In a primary test collection, 97 samples were included. In
culture, the presence of at least 105 cfu/ml was deﬁned as a urinary tract
infection. We used this internationally accepted deﬁnition to determine
a breakpoint value in our multi-probe assay. Consequently, the universal
probe, of which a Ct-value of 25 was used as breakpoint, was used to
discriminate between positive and negative urine samples. Using this
threshold, a sensitivity and speciﬁcity of 97.8% and 80.8%, respectively,
could be reached. All primary causative agents detected by bacterial
culture, for which probes were included in our assay, were correctly
identiﬁed by the multi-probe assay.
Conclusion: The assay was able to identify the causative pathogen
rapidly and accurately in our primary test collection. Results could
be obtained within 4 hours, giving the opportunity to make adequate
therapy decisions within the same day. Moreover, the assay, using the
semi-quantitative breakpoint, was successfully employed resulting in a
sensitivity and speciﬁcity of 97.8% and 80.8%.
P1918 Description of an unusual N. meningitidis isolate containing
and expressing N. gonorrhoeae-speciﬁc 16S rDNA sequences
M. Walcher*, M. Montgomery-Fullerton, R. Skvoretz, V. Jonas,
S. Brentano (San Diego, US)
Objectives: An apparently rare Neisseria meningitidis isolate containing
one copy of the Neisseria gonorrhoeae 16S rDNA gene is described
herein. The isolate was identiﬁed as N. meningitidis by biochemical
identiﬁcation methods, but generated a positive signal with the Gen-
Probe APTIMA® Assays for the detection of Neisseria gonorrhoeae.
Since the APTIMA Assays detect areas within the 16S rRNA of
N. gonorrhoeae, the 16S rDNA gene was sequenced as part of this
study to investigate assay speciﬁcity as well as species afﬁliation of the
isolate.
Methods and Results: Direct 16S rDNA sequencing of PCR products
from whole genomic DNA of the puriﬁed isolate revealed ambiguous
bases at signature regions that allow for discrimination between
N. meningitidis and N. gonorrhoeae. The ambiguities were resolved
by sequencing a single genomic copy of the 16S rDNA gene. Whole
genomic DNA was fragmented by restriction digest with BbsI and
diluted to attain a maximum of one rDNA copy per PCR reaction. One
hundred twenty-one discreet sequences were obtained; 92 (76%) were
N. meningitidis and 29 (24%) were N. gonorrhoeae sequences, resulting
in a ratio of one gonococcal to three meningococcal genes.
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Fluorescence in situ hybridisation (FISH) probes speciﬁc for meningo-
coccal and gonococcal 16S rRNA were used to demonstrate the
expression of the different rRNA genes. Interestingly, the clinical isolate
described here expresses both N. meningitidis and N. gonorrhoeae 16S
rRNAs, as shown by positive FISH signals with both probes.
Over 800 published N. meningitidis 16S rDNA sequences were analysed
for intra-species variations as well as the presence of base ambiguities
that could point to variations within the four genomic operons of a
strain. No sequences with the same attributes as described above could
be found in the published 16S rDNA sequences, including the APTIMA
Assay binding regions.
Conclusions: Based on the results of this study, the speciﬁcity of the
Gen-Probe APTIMA Assays for the detection of N. gonorrhoeae is
conﬁrmed. The N. meningitidis isolate described must have obtained
N. gonorrhoeae-speciﬁc DNA containing 16S rDNA by interspecies
recombination. Based on the ratio of gonococcal to meningococcal
sequences, the N. meningitidis strain seems to have replaced one of
its four intrinsic 16S rDNA genes with the gonococcal gene. This is an
apparently rare example of lateral gene transfer between two species that
hardly ever coexist in the same body site.
P1919 Multicentre evaluation of PNA-FISH test for species
identiﬁcation of selected Gram-negative bacilli,
Gram-positive cocci and yeasts from blood cultures
A. Raglio, C. Venturelli, D. Barbarini, A. Grosini, E. Carretto*,
P. Marone, F. Rumpianesi, P. Serna Ortega, M. Passera, A. Goglio
(Bergamo, Modena, Pavia, IT)
Objective: Time is crucial for the diagnosis of sepsis. Recently, several
tools have been proposed to shorten the turn around time (TAT) for blood
cultures. The “peptide nucleic acid ﬂuorescence in situ hybridisation test”
(PNA FISH, AdvanDX) allows the identiﬁcation of some microrganisms
directly from the positive blood culture bottles in 90 minutes. Aim of this
multicenter study was to evaluate the performances of the PNA-FISH in
three different Italian hospitals (Bergamo, Modena and Pavia).
Methods: Two centers used the BacT/Alert system, one the Bactec
system. Four PNA-FISH assays were evaluated: one distinguishes
between Staphylococcus aureus and coagulase negative staphylococci
(CNS), one between Enterococcus faecalis and E. faecium, one among
Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa,
and one among Candida albicans/C. parapsilosis, C. glabrata/C. krusei
and C. tropicalis. A total of 384 isolates from different blood culture
samples were included in the study. According to the Gram stain results,
one drop of a positive blood culture was examined with the appropriate
PNA-FISH assay. PNA-FISH slides were read independently by different
test operators and blinded to the ﬁnal results with traditional techniques.
Results: Phenotypical tests allowed the identiﬁcation of 196 Gram
negative bacilli (GNB): 96 E. coli, 12 K. pneumoniae, 17 P. aeruginosa
and 71 GNB belonging to genus or species not detected by PNA-FISH;
114 Gram positive cocci in clusters (20 S. aureus and 94 CNS); 33
Gram positive cocci in pairs and chains (10 E. faecalis, 7 E faecium and
16 other genus or species); 41 yeasts: 24 C. albicans/C. parapsilosis
(respectively, 15 + 9), 11 C. glabrata/C. krusei (respectively, 10 + 1), 4
C. tropicalis, and 2 other genus or species. Except for one strain of CNS
not detected by PNA-FISH, all the isolates were correctly identiﬁed by
the PNA-FISH assays. In two cases PNA-FISH allowed the identiﬁcation
of mixed enterococcal cultures (E. faecium + E. faecalis) reported as
E. faecium infections.
Conclusion: This multicenter study conﬁrms the excellent agreement
between PNA-FISH and standard laboratory techniques in identifying
the microrganisms most frequently involved in bloodstream infections.
PNA-FISH is quick, reliable and easy to perform, reducing the TAT in
septic patients. In particular, genus and species identiﬁcation allows to
better ﬁnalize the empiric therapy in these patients.
P1920 Escherichia coli of the phylogenetic group B2 from
patients with inﬂammatory bowel disease compared with
uropathogenic B2 isolates
H. Mirsepasi*, J. Engberg, K. Krogfelt, A. Friis-Møller,
I. Nordgaard-Lassen, S. Wildt, A. Petersen (Copenhagen, Hvidovre, DK)
Background: Escherichia coli of the phylogenetic group B2 with
speciﬁc virulence genes known from uropathogenic E. coli are found
more frequently after faecal culture among ulcerative colitis patients
with active disease compared to patients with inactive disease. This study
aimed to charac-terize possible differences in extraintestinal pathogenic
E. coli (ExPEC) genes in faecal E. coli iso-lates from different groups
of IBD patients and controls compared to uropathogenic E. coli.
Methods: The presence of six ExPEC genes, papA, papC, afa, sfa/foc,
iut and kpsM was deter-mined. Disease activity was evaluated by disease
activity indexes (Harvey Bradshaw Index and Clinical Activity Index);
data were analyzed by chi-square test, two-sided.
Results: E. coli were isolated from 92 patients and from 18 healthy
controls and B2 IBD isolates were compared to 15 uropathogenic B2
isolates. E. coli strains of the phylogenetic group B2 were cultured from
56% of patients with ulcerative colitis, from 42% patients with Crohn’s
disease com-pared to 11% of healthy controls (p< 0.05). Furthermore,
when comparing B2 E. coli strains with at least one positive ExPEC
gene among different groups, 79% were found positive among active
UC, 86% among active CD patients, signiﬁcantly more than 25% among
inactive IBD patients (p< 0.05). When comparing B2 isolates with IBD
patients with active disease with positive ExPEC genes the distribution
was not different from uropathogenic isolates, in both groups the most
fre-quently detected ExPEC genes were PapC and KPSMII.
Conclusion: In conclusion, E. coli of the phylogenetic group B2
with ExPEC genes were found more frequently among IBD patients
with active disease compared to patients with inactive disease, and no
difference in ExPEC gene distribution could be determined compared to
uropathogenic isolates.
P1921 Evaluation of the new GNR Trafﬁc Light™ PNA FISH®
ﬂuorescence in situ hybridisation probes for rapid same-day
identiﬁcation of Gram-negative rods from positive blood
culture bottles
L. Leerbeck*, D.S. Hansen (Hillerød, DK)
Objectives: Early diagnosis of bloodstream infections is essential for
rational antibiotic therapy and minimizing morbidity and mortality.
Routine identiﬁcations of bloodstream organisms must await subculture
and are therefore not available on a same day basis. The PNA FISH®
(AdvanDx) assay is performed directly on smears from positive blood
cultures using ﬂuorescence labeled peptide nucleic acid (PNA) probes
targeting rRNA of the microorganisms, and takes 1 12 h for the whole
process. In a previous study on direct identiﬁcation of positive blood
cultures we evaluated ﬁve sets of PNA FISH® probes including two for
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Gram negative rods (GNR); the E. coli/P. aeruginosa and the EK (E. coli-
K. pneumoniae)/P. aeruginosa probes. The company have recently
developed a new GNR Trafﬁc Light™ probe set which differentiate
between E. coli (green), K. pneumoniae (yellow) and P. aeruginosa (red),
making the testing procedure easier. The purpose of this study was to
evaluate this new GNR Trafﬁc-Light™ probe set when used on positive
blood cultures.
Methods: During a 14 week period, September 1st–December 9th, 2010
all positive blood cultures with GNR detected in our BacT/ALERT®
system were included in the study. On all ﬂagged positive BCB
wet mount and Gram stain microscopy were done, and ﬂuorescence
microscopy of blood smears stained with the relevant PNA FISH®
probes were done; for GNR the GNR Trafﬁc Light™ probe set was
used. Patients usually have two aerobic and two anaerobic blood culture
bottles (BCB) taken. If more than one BCB from the same patient was
positive, but sample date and wet mount and Gram stain microscopy
was identical for all positive BCB, only one PNA FISH® microscopy
was done. Conventional identiﬁcation (Vitek 2 and MALDI-TOF) was
performed in parallel.
Results: In the study period 10,113 BCB from 1,924 patients were
cultured. 854 BCB (8.4%) were positive. The GNR Trafﬁc-Light™
probe set was used on 110 BCB from 97 patients. All E. coli
(N = 50), K. pneumoniae (N = 10), and P. aeruginosa (N = 5) were correct
identiﬁed. The other 45 BCB, with GNR on wet mount and Gram stain
microscopy, grew anaerobes (N= 11), other Enterobacteriaceae (N= 28)
and various mostly aerobes (N= 6).
Conclusion: The new GNR Trafﬁc-Light™ PNA FISH® probe set is
an accurate and reliable method for identiﬁcation of GNR directly from
positive blood culture bottles. The new tri-color probe set saves time for
the technologists and makes interpretation of the result simpler.
P1922 Diversity of emerging Acinetobacter species in a tertiary
university hospital in northern Spain
R. Cayoˆ*, M.E. Cano, J. Calvo, L. Martı´nez-Martı´nez (Santander, ES)
Objectives: We evaluated the diversity of Acinetobacter species in a
tertiary university hospital in northern Spain.
Methods: 86 clinical isolates, one of each being representative of a
different Rep-PCR pattern, were selected from a total of 603 isolates
reported as Acinetobacter baumannii-calcoaceticus complex during
2004–2008 period using MicroScan systems. A PCR screening using
primers for blaOXA-51-like was used for A. baumannii conﬁrmation. For
all clinical isolates, Acinetobacter species identiﬁcation was carried out
by ampliﬁed rRNA gene restriction analysis (ARDRA) using enzymes
CfoI, AluI, MboI, RsaI, MspI. To differentiate among isolates with
the same ARDRA proﬁle, a further restriction analysis was made with
enzymes BfaI and BsmI. PCR for blaOXA-23-like, blaOXA-24-like and
blaOXA-58-like followed by sequencing was also performed for all
isolates.
Results: Only 38 out of 86 isolates (44.2%) were positive for the
blaOXA-51-like, representing 515/603 isolates (85.4%). All blaOXA-
51-like-positive isolates were identiﬁed as A. baumannii (Acb) by
ARDRA, proﬁles 11121 (n = 20), 11123 (n = 15) and 11121+3 (n = 3).
The blaOXA-51 genes found were: blaOXA-64, blaOXA-65, blaOXA-
66, blaOXA-67, blaOXA-69, blaOXA-70, blaOXA-71, blaOXA-94,
blaOXA-98, blaOXA-106 and blaOXA-117. Other 8 new variants of
blaOXA-51-like were also identiﬁed. The carbapenem-resistant Acb
isolates harbored the gene blaOXA-24 or blaOXA-51-like + ISAba1. A
great diversity of Acinetobacter species has been found among blaOXA-
51-like-negative isolates: 41.8% (n = 36) were identiﬁed as A. genomic
species 3 (Ag3, proﬁle 21213), being the second most frequently
Acinetobacter species identiﬁed (70/603, 11.6%). The gene blaOXA-
58 was found in 19 out of 24 isolates of a carbapenem-susceptible Ag3
clone. Other 7 different species were also identiﬁed: A. calcoaceticus
(1 pattern/1 isolate, proﬁle 22113), A. phenon 3 (2 patterns/2 isolates,
proﬁle 14143), A. phenon 5 (2 patterns/2 isolates, proﬁle 25113),
A. genomic species 10 (3 patterns/9 isolates, proﬁle 42123 and BsmI
1), A. genomic species 13BJ (2 patterns/2 isolates, proﬁle 14122 and
BfaI 1+2), A. genomic species 13TU (1 pattern/1 isolate, proﬁle 21113)
and A. genomic species 16 (1 pattern/1isolate, proﬁle 12142).
Conclusion: Emerging Acinetobacter species have been identiﬁed in our
hospital and their actual incidence could be underestimated by using only
automated identiﬁcation systems.
P1923 Molecular epidemiology and clonal evolution of Brucella
melitensis in Spain
S. Gonza´lez Cabrero, F. Menegotto, A. Cubero Ribas, W. Cuervo,
V. de Santiago, M.P. Gutie´rrez Rodrı´guez, A. Ordun˜a, M.A. Bratos
Pe´rez* (Valladolid, ES)
Introduction: Brucellosis remains the commonest anthropozoonosis
worldwide and it was a very important health problem in Spain during
the past century. Even now the brucellosis still persists in some regions of
Spain with a human incidence higher as 3/100.000, where B. melitensis
causes more than 99% of the human cases. In these areas, molecular
epidemiology could be a very useful tool to know the origin and
evolution of Brucella epidemic.
Objective: The aim of this study is to know the genetic variability and
to assess the clonal evolution of Brucella melitensis strains isolates from
humans from 1974 till 2008 in Spanish.
Material and Methods: The genomic proﬁle of 172 strains of
Brucella melitensis was determined by Multiple Locus VNTR Analysis-
16 (MLVA-16). The most relevant genotypes characterized by MLVA
were selected for MLST analysis. The sequence type (STs) and their
alelic proﬁles were compared using the goeBURST algorithm, a globally
optimized implementation of the eBURST algorithm.
Results: We have identiﬁed ﬁve sequence type (ST): ST7, ST8,
ST11, ST28 and ST29; and the most prevalent was ST8. Using the
microsatellite MLVA analysis we found 7 different genotypes, two of
these, genotype 42 and genotype 60 were the most prevalent. The
strains corresponding to genotype 42 belong to the ST8 (described by
Whatmore et al.), the main group in this study. Among strains belonging
to genotype 60 we have detected the presence of two new alleles in the
glk and gyrB genes. Due to the emergence of these new alleles we have
described two new ST, ST28 and ST29. These two new allelic proﬁles
are related to the main ST found in this study (ST8). Using the algorithm
goeBURST, joined all the main clones in one clonal complex (Figure 1).
The ﬁgure shows that the ST7 belongs to the same clonal complex but
its evolutionary line was different.
Conclusions:MLST population analysis shows that all the strains belong
to a single clonal complex.
The new ST28 and ST29 belong to the same evolutionary line that ST8,
the majority in this study (Figure 1). these new STs therefore appear to
have evolved from ST8.
Both the ST8 as the new ST28 and ST29 have the same common
ancestor, ST11, connected to genotype 51.
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P1924 Molecular differentiation of H. inﬂuenzae and non-
haemolytic H. haemolyticus in bronchoalveolar lavage ﬂuids
of children with lower respiratory tract infections
I. Leroux-Roels*, I. De Schutter, F. Crokaert, C. Heymans, J. Debruyne,
J. Bouckaert, O. Soetens, D. Pie´rard (Brussels, BE)
Objectives: Classical microbiological methods do not reliably distin-
guish non-haemolytic Haemophilus haemolyticus from Haemophilus in-
ﬂuenzae. H. haemolyticus, a strict commensal, is frequently misidentiﬁed
as H. inﬂuenzae in upper respiratory tract (URT) samples and sputum. In
bronchoalveolar lavage ﬂuid (BALF) its presence has never been veriﬁed.
We used a PCR-based approach to assess the frequency of non-
haemolytic H. haemolyticus among routinely identiﬁed H. inﬂuenzae
isolates from BALF of children with lower respiratory tract infections
(LRTI). To enable comparison the misidentiﬁcation rate was also
evaluated among presumed H. inﬂuenzae strains isolated from tonsillar
smears.
Methods: We investigated presumed H. inﬂuenzae isolates from 152
quantitative BALF cultures obtained by ﬂexible bronchoscopy from
children with LRTI and from 33 tonsillar isolates. A 3-step algorithm
was used: ﬁrst, a PCR for the fuculokinase (fucK) gene was performed
as fucK is consistently present in H. inﬂuenzae and absent in
H. haemolyticus. The fucK-negative isolates underwent further study
with 2 PCR reactions using species speciﬁc 16S rRNA primers. In case
of equivocal results the complete 16S rRNA gene was ampliﬁed and
sequenced. Conﬁrmed H. inﬂuenzae isolates were serotyped according
to standard procedures.
Results: 145/152 (95.4%) BALF isolates and 25/33 (75.8%) tonsillar
isolates were identiﬁed as H. inﬂuenzae. The misidentiﬁcation rate was
signiﬁcantly higher in tonsillar isolates (24.2%) compared to BALF
isolates (4.6%) (P< 0.0001). Quantitative BALF culture did not reach
the cut-off level of 104 CFU/ml in 3/7 specimens for H. haemolyticus
and in 4/145 specimens for H. inﬂuenzae. Taking only signiﬁcant BALF
cultures into account, the misidentiﬁcation rate was even lower (4/145;
2.8%). All 145 and 25 conﬁrmed H. inﬂuenzae isolates from BALF and
tonsillar specimens, respectively, were shown to be nonencapsulated or
non-typeable H. inﬂuenzae (NTHi) strains.
Conclusion: Using a PCR-based algorithm we demonstrated that
the frequency of non-haemolytic H. haemolyticus among presumed
H. inﬂuenzae isolates in BALF is very low as compared to the frequency
in tonsillar smears. The low prevalence of H. haemolyticus in BALF
demonstrates the limited risk of contamination by URT secretions and
emphasizes its enhanced value as a diagnostic specimen for LRTI
compared to URT samples and sputum. It may also suggest a causal
relationship between NTHi and LRTI.
P1925 Diagnostic utility of BinaxNow for detection of
S. pneumoniae among children with suspected IPD
J. Picazo, J. Ruiz Contreras, E. Rı´os*, E. Culebras, I. Rodriguez-Avial,
C. Betriu, C. Mendez on behalf of Heracles Study Group
Objectives: The aim of this study was to evaluate the Binax
NOW inmunochromatographic pneumococcal antigen test (ICT) (Leti
Diagno´stico, Spain) for the identiﬁcation of S. pneumoniae in pleural
ﬂuids (PF) and cerebrospinal ﬂuids (CSF) from children with suspected
invasive pneumococcal disease (IPD). The results were compared with
those obtained by PCR.
Methods: A total of 219 samples (12 CSF and 207 PF) were collected
from May 2007 to May 2010 by 35 hospitals of Madrid, Spain. The
ICT was applied to these samples as recommended by manufacturer for
urine and CSF samples. Detection of pneumococcal DNA was performed
by real-time PCR assay targeting the autolysin gene (lytA). Those ICT
results didn’t agree with lytA PCR results, were conﬁrmed by ply PCR.
Results: A total of 200 samples were tested by both techniques, whereas
19 were not analyzed by ICT because of small sample volume. Results
are shown in table. Of the 200 samples, 131 were positive by both
ICT and lytA PCR and 37 samples were negative by both techniques.
Using the real-time PCR as the gold standard method for detection of
S. pneumoniae, the sensitivity and speciﬁcity of Binax NOW were 88%
and 72.5%, respectively.
Conclusions: Laboratory diagnosis of IPD relies on culture based-
methods, but detection of pneumococcal antigen by Binax Now is an
easy and fast method to identify S. pneumoniae in PF and CSF from
children with suspected IPD.
P1926 Implementation validation of a real-time Mycoplasma pneu-
moniae assay (Diagenode) on the Rotorgene 6000 platform
G. Duson, B. Van Meensel, A. Smismans, I. Verstreken, J. Frans*
(Bonheiden, BE)
Objectives: To validate the Diagenode Mycoplasma pneumoniae (MP)
real-time PCR assay (CE-IVD) on the Rotorgene platform (Qiagen) for
diagnosis of MP on nasopharyngeal eSwabs and BAL (BronchoAlveolar
Lavage) liquids.
Methods: All validation experiments started with a pre-treatment by
incubating a mixture of 250ml sample and 250ml of proteinase K
(Merck) for 1 hour at 56ºC (700rpm). The pre-treatment was followed by
an extraction on the Nuclisens EasyMAG (Biome´rieux) and afterwards
real-time PCR was performed on the Rotorgene using the Quantifast
Probe PCR Master Mix (Qiagen). The assay was checked for analytical
sensitivity, speciﬁcity, accuracy and precision following international
publications on molecular validation methods (e.g. Rabenau, 2007).
Results:
1. Analytical sensitivity: To determine the limit of detection (LOD with
a 95% hit rate) of the MP kit in combination with the Quantifast
Probe PCR Master Mix, a Vircell DNA control (MP type 2) was
used. Known concentrations of MP were spiked in eSwab medium
and BAL. For eSwabs, the lowest concentration with 20 positive
samples (=LOD) was 3000 copies/ml (mean Ct-value = 37,09). For
BAL, the LOD was 7500 copies/ml with a mean Ct-value of 36,59.
Based on literature (Nilson et al., 2010) there is a mean bacterial
load of 1600 geq/ml throat secretion for hospitalized patients and
170 geq/ml for non-hospitalized patients. The Diagenode assay meets
these speciﬁcations.
2. Speciﬁcity: According to previous validation papers, speciﬁcity was
sufﬁciently documented by the manufacturer: the assay was tested
on a broad range of viruses and bacteria that are causative agents of
respiratory diseases. No cross-reactivity was found with any of these
organisms.
3. Accuracy: The 2010 QCMD panel for detection of MP was used
to check the accuracy. All samples showed a perfect correlation
(see table). The Diagenode MP assay meets the accuracy validation
criterion of 100% agreement for positive samples and 90% agreement
for weak positive (LOD − 1 log) samples.
4. Precision: Four samples (2×BAL & 2× eSwab) were extracted
in triplicate on 3 different days. The standard deviations (SD) for
positive and weak positive samples (Ct) were 0,6 and 0,43 for eSwab
samples and 0,82 and 0,5 for BAL samples, meeting our validation
criterion of SD< 1 (Ct).
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Conclusion: The Diagenode MP assay met all our validation criteria and
was therefore implemented in our daily routine.
P1927 Detection rates of Haemophilus inﬂuenzae, Streptococcus
pneumoniae, Moraxella catarrhalis in children with otitis
media with effusion and comparison of the results obtained
by culture and PCR
M. Baysallar*, A. Uskudar Guclu, S. Yetiser, A. Kilic, C. Acikel
(Ankara, TR)
Objectives: To detect the rates of some common bacteria known as
pathogens in the middle ear effusions (MEE) of patients with otitis media
that underwent tympanostomy.
Methods: Standard and multiplex polymerase chain reaction techniques
have been applied to the detection of bacterial DNAs of these three
bacteria in MEE specimens and their diagnostic values were evaluated
in comparison to conventional culture method accepted as the “gold
standard”.
Results: A total of 67 samples from otitis media with effusion (OME)
suspected children were included. Two Haemophilus inﬂuenzae and two
Moraxella catarrhalis were isolated by conventional culture method
(6.0%; 4/67). PCR techniques detected DNAs of 3 S. pneumoniae, 6
H. inﬂuenzae, 8M. catarrhalis and 5 mix bacteria. Sensitivity, speciﬁcity,
positive predictive value and negative predictive value rates of PCR
techniques were 100.0%, 71.4%, 18.2% and 100.0%, respectively. The
results obtained by using Mc Nemar tests separately for each bacterium
showed that there is no signiﬁcant differences between culture and PCR
methods (p> 0.05). Kappa coefﬁcient was calculated as 0.230. So, the
aggrement between culture and PCR was inadequate.
Conclusion: Although the speciﬁcity and positive perdictive value are
low, at least for detecting the most common fastidious bacteria that
lead to OME, PCR methods could be considered as feasible and rapid
screening tests.
P1928 Weak mutators within ﬁrst positive Pseudomonas aeruginosa
isolates recovered from bronchial secretions of cystic
ﬁbrosis patients
A. Fernandez-Olmos*, L. Garcia-Garcia, M.C. Turrientes, F. Baquero,
J.C. Gala´n, R. Canto´n (Madrid, ES)
Objective: Hypermutation is a well-recognized mechanism facilitating
the development of multi-drug resistance in Pseudomonas aeruginosa
from cystic ﬁbrosis (CF) patients with chronic pathogenic colonization.
However, its prevalence is not well established in P. aeruginosa isolates
recovered during initial colonization stage. The aim of this study was to
establish the mutation frequencies of these ﬁrst positive culture isolates.
Material and Methods: A collection of 37 ﬁrst positive P. aeruginosa
isolates recovered from sputum samples of 23 CF-patients attended at
our CF-Unit in our Hospital along the past 15 years (1994–2009) were
studied. First colonizer isolates were each new colonizing P. aeruginosa
isolate and subsequent isolates with different PFGE from previous
ones. Isolates had non-mucoid morphotypes including 60% rough,
15% metallic, 13% enterobacteria-like and 12% small colony variant
(SCV). Genetic relationships were analyzed by PFGE-SpeI. Mutation
frequencies (MF) were determined using 300mg/l of rifampin as selector
agent.
Results: Although no strong mutators were detected, 7/37 (19%) isolates
showed increased MF and were classiﬁed as weak-mutator (MF range:
4,1×10−8–1,0×10−7) when compared with the rest of isolates (MF
range: 3,0×10−8–1,9×10−9). Interestingly, 6/23 CF-patients (26%) had
weak mutator strains in early colonization stage. No association between
increased MF and particular morphotypes could be established (3 rough,
2 SCV, and one each metallic and enterobacteria-like). PFGE studies
conﬁrmed different strains in each patient but also the presence of three
different mutator/non-mutator coexisting sub-populations in one patient
during ﬁrst colonization stage (MF: 1.34×10−8; 6.51×10−8; 1.04×10−7).
Conclusion: This study shows a high proportion of P. aeruginosa isolates
with increased MF during ﬁrst colonization state in CF-patients, which
represents the highest proportion (19% of weak mutators) described
until now. Most importantly, when considering the studied CF-patient
population, 26% of them were colonized with these weak mutators.
The ﬁnding suggests that colonization stress, and not only antibiotic
exposure or chronic conditions, favors the implantation of hyper-mutable
strains. This data are relevant for the accurate implementation of early
antimicrobial treatment since ﬁrst positive P. aeruginosa culture in CF-
patients.
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P1929 Identiﬁcation of bacteria by sequencing in routine
laboratory practice
E.P. Barantsevich*, N.E. Barantsevich, N.E. Pestova, M.O. Lubkina,
E.V. Schlyakhto (St. Petersburg, RU)
Objectives: Sequencing of 16s RNA gene (1540 pairs of nucleotides)
presents the valuable tool in identiﬁcation of most bacteria. The aim of
the present study was to investigate the efﬁciency of sequencing of 500
pairs of nucleotides and the use of MicroSeq ID 16s rDNA500 Library
v2.0 in identiﬁcation of bacteria in routine laboratory practice.
Methods: Bacterial strains, isolated from patients with nosocomial in-
fections in multidisciplinary medical center in Saint-Petersburg, Russia,
were identiﬁed routinely with phenotypic microbiological techniques and
sequencing (ABI Prism 3130, MicroSeq ID v2.0 Software, MicroSeq ID
16s rDNA500 Library v2.0, Applied Biosystems).
Results: Sequencing of 16sRNA gene was introduced in routine clinical
practice of microbiological laboratory in September, 2010. 229 strains,
included in the study, were isolated from blood (47), valves (5),
bronchoalveolar lavage (20), sputum (35), pleural exudates (5), lung
tissue (4), urine (45), wounds (33), oral swabs (23), endometrial brush-
biopsies (9), faeces (3).
Totally 19 species and 15 genera were registered by routine techniques
compared to 57 species of 27 genera, identiﬁed by sequencing.
S. aureus, S. pneumoniae, E. faecium, P. acnes, H. inﬂuenzae,
P. aeruginosa, and A. baumannii were the only species, correctly
identiﬁed by routine phenotypic methods in all cases. Errors in
identiﬁcation of E. faecalis occurred in 2.8%, E. coli in 5.9%,
S. epidermidis in 18.1%, P. mirabilis and S. maltophilia in 20%,
B. thuringiensis in 25.0%, K. pneumoniae in 28.5% of isolates.
Identiﬁcation by sequencing to species/subspecies with MicroSeq ID
16s rDNA500 Library v2.0 was successful in 97.9% cases. It failed in
3 (7.8%) Streptococcus strains, 1 Paenibacillus strain, and 1 bacterium
remained unidentiﬁed.
Conclusions:
1. Sequencing of 500 pairs of 16sRNA gene with MicroSeq ID v
2.0 Software, MicroSeq ID 16s rDNA 500 Library v 2.0, Applied
Biosystems, was effective in identiﬁcation of the majority of bacterial
isolates in multidisciplinary medical center
2. The method presents the valuable tool in routine identiﬁcation of
etiologic agents of bloodstream infections, nosocomial pneumonia,
infectious endocarditis, when exact data are of high value.
3. The perfect data on the diversity of microbial species, causing
nosocomial infections, can be obtained with sequencing, but not
routine microbiological methods.
P1930 Implementation of a novel multiple-target real-time assay
into a clinical microbiology laboratory
L. Thomas*, T. Olma, J. Iredell (New South Wales, AU)
Objectives: Real-time PCR provides clinically important results in a
timely manner, but considerable expertise in set-up and interpretation
potentially negates the effectiveness of rapid technology. Multiplexed
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Tandem-PCR (MT-PCR; AusDiagnostics, Australia)) is a real-time
assay that allows simultaneous detection and identiﬁcation of numerous
pathogens using a liquid handling robot and analysis software.
We incorporated and evaluated this technology within a clinical
microbiology laboratory.
Methods:
– The MRSA4 assay detects nuc, mecA and attBscc genes. Its suitability
as a screening assay for MRSA directly from patient swabs was
assessed and compared to enrichment/culture.
– The vancomycin-resistance 5 assay targets vanA, vanB, E. faecalis,
and E. faecium and was evaluated for detection of VRE from
enrichment broth.
– The Gram Positive 12 assay targets Gram-positive bacterial genes
of clinical signiﬁcance in blood cultures: pan-Staphylococcus, pan-
Streptococcus, pan-Enterococcus, nuc, mecA, lytA, gseA, vanA, vanB,
E. faecalis ddl, and E. faecium ddl; Blood cultures with Gram positive
cocci seen in Gram-stain were extracted and tested.
– The Faecal proﬁle 6 assay detects Campylobacter, Salmonella spp.,
Shigella spp., and Clostridium difﬁcile toxin B. Stool samples were
extracted and compared to either i) culture or ii) TECHLAB C
Diff Quick Chek Complete antigen and Toxins A/B kit (Princeton
NJ08540).
Conclusion: MT-PCR is a versatile, simple and robust assay which
required minimal training of inexperienced technicians. Minimal hands-
on-time was necessary post-extraction (<2 min/sample). All assays were
successfully incorporated into routine use and provided signiﬁcantly
more rapid results than culture.
P1931 Molecular-based methods for identiﬁcation of
microbiological aetiologies of bacteraemia
T.Y. Wolff*, C. Moser, T. Bjarnsholt, N. Høiby, J. Lorenzen, P. Nielsen,
T. Thomsen (Aarhus, Copenhagen, Aalborg, DK)
Objective: Direct sequencing based on the 16S rRNA gene is advancing
as a supplement to cultivation for identiﬁcation of the infectious
microorganisms in Danish hospitals. However, direct sequencing is being
reported not to be suitable for diagnosis of polymicrobial infections. The
aim of this study was to apply different molecular biological methods
for identiﬁcation of microorganisms in patients with bacteremia and
compare the ﬁndings with cultivation based results.
Methods: Aerobic and anaerobic blood cultivation was performed using
the BACTEC 9240 system. Culture-positive samples were subject to
further cultivation steps and subsequent cultivation-dependent colony
identiﬁcation as well as different molecular biological analyses. These
included direct 16S sequencing using the 3130xl Genetic Analyzer
and MicroSeq system (Applied Biosystems), construction of clone
libraries and subsequent sequencing and in some cases species speciﬁc
quantitative polymerase chain reaction (qPCR).
Results: Blood cultures from 36 patients were analyzed, and in 20
cases one single bacterium was identiﬁed by direct sequencing while
construction of clone libraries identiﬁed polymicrobial communities.
Direct sequencing failed for 10 patients where construction of clone
libraries identiﬁed polymicrobial communities for all. In 6 cases
concordant results were obtained with direct sequencing and the clone
library method (both techniques identiﬁed one single bacterium in 5
patients and 1 patient had negative results). In Table 1 data are illustrated.
Conclusion: Direct sequencing is a promising method for fast diagnosis
of patients with bacteremia, and in most polymicrobial samples
the technique was able to identify the dominant microorganism.
Establishment of clone libraries was most suitable for detection of
polymicrobial infections; however, it is too laborious to be used in routine
diagnosis. The results obtained will be compared with the use of the
new algorithm RipSeq (by Insentio) on failed direct sequencing results
to evaluate if the success rate can be further increased.
P1932 16S rDNA sequence analysis as supplement to traditional
blood culturing for improved detection of pathogens in
diagnostic setting
E. van Zanten*, A.V. Mo¨ller, A.M. Kooistra-Smid (Groningen, NL)
Objectives: Bloodstream infections may be life-threatening with
pathogenic bacteria as the most common causative agent. Blood
culture is the “golden standard” for microbiological diagnosis of these
pathogens. Although blood culturing is a sensitive detection method
it has limitations. Antibiotic use, fastidious-, anaerobic- or autolytic-
growing micro-organisms make detection and identiﬁcation difﬁcult.
Our laboratory supplements blood culturing with 16S rDNA sequence
analysis in case of a culture-positive result without bacterial growth or
fastidious growth or in case the blood culture remains negative and yet
strong clinical suspicion of bacteremia persists.
Methods: From January 2008 till September 2010, a total of 329
blood cultures, performed using BaCT/ALERT 3D (bioMe´rieux), were
requested for additional 16S rDNA sequence analysis. Of these, 140
yielded fastidious growths after blood culturing was detected culture-
positive and 189 yielded no growth or remained negative. DNA isolation
on blood cultures was performed using EasyMAG (bioMe´rieux) and for
bacterial isolates PrepMan Ultra (Applied Biosystems) was used. A 1500
bp ampliﬁcation of the 16S rDNA gene was carried out, of which 500
bp were sequenced.
Results: The 140 fastidious growing samples yielded 99 different
species belonging to 51 genera. The most prevalent genera were:
Streptococcus spp. (n = 31), Clostridium spp. (n = 7), Actinomyces
spp. (n = 6) and Acinetobacter spp. (n = 6) and the most prevalent
species: Fusobacterium nucleatum (n = 5), Streptococcus mitis (n = 5),
Streptococcus thermophilus (n = 4), Streptococcus sanguinis (n = 4).
In 57 of the 189 blood culture-negative samples 16S rDNA could
be detected and sequence analysis performed. Thirty-six different
species were identiﬁed belonging to 21 genera. The most prevalent
genera were: Streptococcus spp. (n = 13), Fusobacterium spp. (n = 8)
and Capnocytophaga spp. (n = 5) and the most prevalent species
were; Capnocytophaga canimorsus (n = 5), Streptococcus pneumoniae
(n = 4), Aggregatibacter aphrophilus (n = 4), Fusobacterium necropho-
rum (n = 4).
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Conclusion: False-negative blood culture results are under diagnosed
particularly among patients with bacteremia due to fastidious-, autolytic-
or anaerobic pathogens and therefore in case of clinical suspicion of
bacteraemia additional 16S rDNA sequential analysis is recommended
for improved microbiological diagnosis.
P1933 Molecular diagnosis of bacterial endocarditis by 16S rDNA
broad-range PCR and sequencing directly from valvular
tissue with vegetations
K. Ohkusu*, T. Ezaki (Gifu, JP)
Objectives: Infective endocarditis (IE) remains a major medical concern
with high morbidity and mortality. Culture-negative IE ranges between
10% and 30% of all IE cases and presents a diagnostic and therapeutic
challenge. The aim of this study was to evaluate broad-range PCR
ampliﬁcation followed by direct sequencing to identify bacterial DNA
from the resected heart valves of 38 patients with IE.
Methods: A prospective study was carried out from January 2006 to
December 2010 during which 40 excised cardiac valves from 38 patients
hospitalized at 15 hospitals in Japan were analyzed. DNA was extracted
from cardiac tissues with the MORA extract kit (AMR, Japan). PCR of
the 16S rRNA gene was performed using the universal primers 8UA and
1485B. The sequences obtained from ampliﬁed DNA were compared
with those available in the GenBank and EzTaxon databases.
Results: Forty excised heart valves with vegetations, including 24 mitral
valves, 8 aortic valves, and 3 tricuspid valves, were analyzed. From two
patients, both mitral and aortal valves were obtained. In addition, one
prosthetic aortal valve was studied. We detected bacterial DNA in all the
valves. Bacteria detected were as follows: 20 streptococci (5 S. mitis, 3
S. mutans, 3 S. sanguinis, 2 S. oralis, 2 S. gordonii, 2 S. agalactiae,
1 S. constellatus, 1 S. cristatus, 1 S. lutetiensis); 8 staphylococci (4
S. aureus, 2 S. lugdunensis, 1 S. caprae, 1 S. epidermidis); NVS
(2 A. defectiva, 1 G. adiacens); Bartonella spp. (2 B. quintana,
1 B. henselae); 1 HACEK group (Haemophilus parainﬂuenzae); 1
Aerococcus urinae; 1 Corynebacterium amycolatum; and 1 anaerobe
(Prevotella melaninogenica). Only one of 40 heart valves was positive by
culture. After prolonged culture incubation of 31 days, B. quintana was
isolated. All IE patients with negative heart valve cultures had received
prior antimicrobial therapy. Prior to surgical replacement, blood cultures
for 16 of the 38 patients (42%) were positive.
Conclusions: We conﬁrm that broad-range PCR ampliﬁcation followed
by direct sequencing is a reliable and accurate method when applied
to resected heart valves and that it can be an useful adjunct to culture
methods when blood culture are negative due to prior antibiotic therapy
or when the causative organism is fastidious or slow-growing. In addition
to implications for patient management, improved knowledge of real
spectrum of pathogens involved in IE might improve the basis for empiric
antimicrobial therapy in IE.
P1934 Multiplex PCR in sonication ﬂuid of removed implants for
diagnosis of prosthetic joint infection
M.E. Portillo*, S. Diaz, A. Alier, M.L. Sorli, S. Martinez, N. Sandoval,
L. Puig, J.P. Horcajada, M. Salvado´ (Barcelona, ES)
Objectives: Causes of failure of prosthetic joints include aseptic
loosening, infection, dislocation and fracture. It is important to accurately
diagnose prosthetic joint infection (PJI) because its management differs
from that of other causes of arthroplasty failure. The identiﬁcation of
the involved organisms is crucial for successful outcome. We compared
the cultures of sonication ﬂuid with a multiplex real-time PCR for
microbiologic diagnosis of PJI.
Methods: We consecutively included all explanted prosthesis from
8/2010 through 12/2010. Episodes of PJI and aseptic loosening were
included. PJI was deﬁned as visible purulence, acute inﬂammation on
histopathology, sinus tract or microbial growth in at least 2 periprosthetic
tissues. Aseptic loosening was deﬁned as failure of prosthesis in the
absence of any of these criteria. The patients with aseptic loosening
were used as control patients. The removed implants were sonicated (as
described in NEJM 2007;357:654) and the resulting sonication ﬂuids
were cultured aerobically and anaerobically. Aliquots of the ﬂuids were
also investigated using SeptiFast (Roche Diagnostics).
Results: 31 explanted prosthesis (21 aseptic loosening and 10 PJI)
from 30 patients were included (median age 69 y; range 27−86 y),
including hip (n = 20), knee (n = 9), elbow (n = 1) and shoulder (n = 1)
prosthesis. In sonication culture, the causative organism of PJI was
identiﬁed in 8 (80%) cases and by SeptiFast in 10 (100%) cases
(p< 0,001). In 2 false-negative cultures, the pathogens were identiﬁed
only by SeptiFast (S. aureus and coagulase-negative in one case
and Klebsiella pneumoniae/oxytoca in another). These 2 patients had
received antibiotics previously. SeptiFast identiﬁed more causative
organisms (20 vs 12) than culture. None of the 21 implants from control
patients showed growth in sonication ﬂuid culture, and all were negative
by SeptiFast.
Conclusions: SeptiFast in sonication ﬂuid has a high speciﬁcity (100%)
and higher sensitivity for diagnosis of PJI compared to sonication culture
(100% vs 80%). The SeptiFast has also a high positive predictive value
(100%) and higher negative predictive value (100% vs 93.9%) than
culture. SeptiFast identiﬁed more causative organisms than culture so,
this PCR allows a better adjust of antimicrobial therapy than other
microbiological procedures. SeptiFast is a promising test for the rapid
microbiologic diagnosis of PJI, especially in patients receiving antibiotic
therapy.
P1935 Application of PCR, FISH and culture methods in rapid
detection of bacterial joint ﬂuid infection
M. Bulanda*, T. Gosiewski, A. Chmielarczyk, D. Romaniszyn (Cracow,
PL)
Objectives: Aim of this project was checking of possibility of applying
PCR, FISH and culture methods in fast detection of bacterial joint ﬂuid
infection.
Methods: Twenty one joint ﬂuid samples were tested. The samples
origined from patients after joint orthopedic surgery who were
hospitalized in Cracow Rehabilitation Centre, Poland. The samples were
tested to presence of bacteria using PCR, FISH and blood culture method
in BACTEC machine. In PCR examination were applied two pair of
starters: DG74 and 143SA − for Gram positive bacteria; DG74 and
68dEC for Gram negative bacteria which enable detection of infection
in joint ﬂuid samples. To prevent from inhibition of DNA polymerase
during PCR ampliﬁcation special sample washing procedure was used
with solution of ammonium chloride.
FISH was carried out with special probes labelled by ﬂuorescein
and CY3 which were speciﬁc to all bacteria species (EUB338), and
Enterobacteriaceae (ENT183) and Staphylococci (STA). To remove from
joint ﬂuid samples any substance e.g. protein which may be the reason for
strong background autoﬂuorescence, special washing and centrifugation
was done.
Results: Percentage of positive joint ﬂuid samples was showed in table 1.
Sensitivity of PCR let indicate 6×101 CFU/ml bacteria cells in a sample.
For FISH method this level of detection was 6×103 CFU/ml. Moreover,
time needed to receive results of samples examination using PCR and
FISH was about 4−5 hours opposite to culture method when laboratory
needs even ﬁve days to conﬁrm infection.
Conclusions:
1. Molecular methods like PCR and FISH are much more sensitive than
culture method in BACTEC system.
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2. Applied methodology of preparation of samples lets on indication
bacteria cells in joint ﬂuid.
3. PCR and FISH allowed indicate bacteria in joint ﬂuid in a larger
number of samples compared to the culture method.
4. Application of PCR and FISH methods considerably shorten waiting
time for results even to few hours.
P1936 Molecular characterisation of the viable bacterial content
of ascitic ﬂuid from patients with cirrhosis
G.B. Rogers*, P. Marsh, L. Fraser, J. Collins, K.D. Bruce, M. Wright
(London, Southampton, UK)
Objectives: Spontaneous bacterial peritonitis (SBP) is a life threatening
development in advanced cirrhosis. Accurate diagnosis of SBP can be
difﬁcult, with the causative bacteria identiﬁed in only a minority of cases
using conventional microbiology. This inability to identify a causative
agent hinders rational antibiotic therapy and prophylaxis. A number
of recent studies have used molecular methods to detect bacteria in
ascites. Whilst this generally results in a greater detection of species, the
contribution of naked circulating DNA to positive PCR results has raised
concern about the clinical insight such approaches provide. We present
the application of a PCR-based approach that is speciﬁc to structurally
intact bacterial cells.
Methods: 106 time series ascites samples collected from 30 patients
with advanced cirrhosis were analysed by conventional diagnostic mi-
crobiology and culture-independent proﬁling. Diagnostic microbiology
was performed on ascites and blood samples in accordance with routine
practice. For molecular proﬁling, cell pellets were resuspended and
incubated with propidium monoazide for 30 min prior to exposure
to light. DNA was extracted from samples and a region of the 16S
ribosomal gene ampliﬁed using primers conserved for Bacteria, with
species resolved through 16S ribosomal Terminal Restriction Fragment
Length Polymorphism (T-RFLP) proﬁling. Data obtained through
culture-based microbiology and molecular analysis were compared.
Results: 104 of the samples were culture negative, with Gram positive
cocci isolated in two instances. In contrast, 60 of the samples were
PCR positive. T-RFLP analysis detected multiple bacterial species
present in all samples, with an average of 2.0 separate T-RF bands per
sample (± 2.6 std dev). Cell free ascites ﬂuid spiked with heat-killed
bacterial cells were PCR negative when PMA treatment was performed.
Signiﬁcant temporal stability was observed across time series samples,
with correlations made to clinical parameters and antibiotic therapy.
Conclusion: The combination of culture-independent molecular tech-
niques with propidium monoazide pre-treatment may offer a sensitive
and speciﬁc means to identify causative agents in SBP. The presence of
temporally stable bacterial assemblages in ascites ﬂuid suggests further
investigation into their potential role in the development of SBP is
warranted.
P1937 Contribution of molecular methods to diagnostics of
prosthetic joint infections
T. Freiberger*, B. Zaloudikova, J. Novak, M. Filipovic, J. Jurankova,
E. Nemcova, M. Stechova (Brno, CZ)
Objectives: Prosthetic joint replacement has shown great success in
restoring the function of joints in persons disabled by arthritis or
osteoarthritis. However, in a subgroup of patients, implantation of a
foreign body into the joint carries a high risk of bacterial infection
that may result in serious complications and even in the patient’s death.
Fast and accurate microbiological diagnostics are needed to detect the
infectious agent and initiate targeted antibiotic therapy as early as
possible. We aimed to compare sensitivity and speciﬁcity of molecular
and conventional methods of pathogen detection in prosthetic joint
infections (PJI).
Methods: One hundred and seventy-ﬁve synovial ﬂuids or periprosthetic
tissue samples from patients with prosthetic joint failure, examined in
our laboratory from 1.2.2004 to 31.5.2008, were included into the study.
Clinical and laboratory markers of infection were recorded. PJI was
diagnosed if at least one of the following criteria was present: visible
synovial ﬂuid purulence at the time of arthroscopy or during surgery;
acute inﬂammation on histopathologic examination of periprosthetic
tissue sections; or presence of a sinus tract communicating with the
prosthesis. Aseptic failure (AF) was deﬁned as prosthesis failure not
meeting the criteria for PJI. Microbiological diagnostics was performed
using routine conventional cultures and broad-range 16S rRNA PCR and
sequencing.
Results: Seventy-eight samples were classiﬁed as PJI and remaining 97
samples as AF. Mean CRP levels were 112.9 in PJI group and 23.0
in AF group. Forty-three (55.1%) and 23 (23.7%) samples were culture
positive, while 58 (74.4%) and 21 (21.6%) samples were PCR positive in
PJI and AF group, respectively. Thus, PCR showed sensitivity 74.4% and
speciﬁcity 78.4% compared to sensitivity 55.1% and speciﬁcity 76.3%
for conventional culture techniques. A discordance of both culture and
PCR positive results was present in 4/37 (10.9%) PJI and 1/11 (9.1%)
AF cases.
Conclusion: Broad-range 16S rRNA PCR followed by sequencing seems
to be a very useful tool for pathogen detection in PJI and should be
routinely used in addition to conventional microbiological techniques.
Discordant results of both methods need to be evaluated carefully with
respect to other clinical and laboratory signs of infection and possible
contamination.
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P1938 Aetiology of invasive fungal infections: results of a two-centre
study in tissue biopsies from patients with proven infection
M.J. Buitrago*, A. Ballen, J. Garcia-Rodriguez, L. Bernal-Martinez,
A. Garcia-Reyne, M. Prieto, J.M. Aguado, M. Cuenca-Estrella
(Majadahonda, Madrid, ES)
Objectives: The objectives of this work were to know the frequency
of fungal species as cause of IFI in two different Spanish hospitals,
a large onco-haematological reference centre (OHRC) and a tertiary
general hospital (TGH).
Methods: Hospitals sent all parafﬁn-embedded biopsies taken between
2004 and 2009 which were considered as proven IFI to the Spanish
Mycology Reference Laboratory for molecular analysis. Information
about results of microbiological cultures and microscopic examination
was also collected. A total of 85 biopsies were analyzed, 49 biopsies
were sent from the OHRC and 36 from the TGH. Samples were tested
by PCR-based methods. When Aspergillus or Zygomycetes species were
suspected, genus speciﬁc PCR-based techniques were used on tissues.
A panfungal PCR targeted the Internal Transcriber Spacer (ITS) regions
was performed when speciﬁc PCRs were negatives. Tests were done in
duplicate on different days.
Results: Microbiological cultures were done in 68 patients (80%).
Cultures were positive in 59% (40/68). The PCR techniques detected
fungal DNA in 89,5% (76/85) of biopsies analyzed. In nine cases PCRs
were not capable to detect DNA. Regarding species, 67% (51/76) of
tissue biopsies with PCR positive had species belonged to Aspergillus
genera followed by Candida 13% (10/76) and Zygomycetes 9% (7/76).
Rare fungi represented 11% (8/76). There were signiﬁcant differences in
frequency of species between OHRC and TGH. In OHRC, Aspergillus
were in 87% of samples (40/46), but Candida spp. (4%), Zygomycetes
(4%) and uncommon fungi (4%) were uncommonly identiﬁed, while in
TGH, Aspergillus represented 37% (11/30) of IFIs followed by Candida
27% (8/30), rare fungi 20% (6/30) and Zygomycetes 17% (5/30).
Conclusions: (1) The PCR-based techniques showed higher performance
than cultures to identify the IFI’s cause. (2) The PCR-based methods
could become reference technique for IFI identiﬁcation. (3) Aspergillus
spp. were the most common cause of IFI but the percentage of
Zygomycetes and rare fungi was around 20% (4) The etiological
proﬁle was different depending on the hospital and individualized
epidemiological surveys should be compulsory.
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P1939 Development of an inhalation model of invasive pulmonary
aspergillosis by Aspergillus fumigatus for evaluating the
efﬁcacy of detection of non-invasive markers for early
diagnosis of infection
Z. Khan*, A. Al-Shaikh, S. Ahmad (Safat, KW)
Objectives: Invasive pulmonary aspergillosis (IPA) caused by As-
pergillus fumigatus in immunocompromised patients is often fatal. Early
diagnosis of IPA is crucial for selection of appropriate antifungal therapy.
We developed an inhalation model of IPA for evaluating the efﬁcacy of
four non-invasive markers [(1→ 3)-b-D-glucan (BDG), galactomannan
(GM), A. fumigatus DNA and 18 kDa secreted antigen (mitogillin,
MIT)] in serum and bronchoalveolar lavage (BAL) specimens for early
diagnosis of IPA.
Methods: GM was detected by sandwich ELISA by using Platelia
Aspergillus kit while BDG was detected by using the Fungitell kit.
A. fumigatus DNA was detected by a sensitive PCR assay and rat
18S rRNA gene ampliﬁcation was used to rule out presence of PCR
inhibitors in clinical specimens. The MIT protein was obtained by
cloning A. fumigatus MIT gene in E. coli and puriﬁcation of expressed
protein to homogeneity. Polyclonal anti-MIT antibodies were raised in
rabbits by using puriﬁed MIT protein. The presence of MIT protein in
serum and BAL specimens was detected by using anti-MIT antibodies.
The expression of MIT protein was also studied at different time points
during in vitro growth of A. fumigatus in liquid cultures by blotting.
Results: Inhalation model of IPA was successfully developed and
animals were followed for up to ﬁve days post-infection. The lungs of all
animals yielded A. fumigatus in culture. The fungus was demonstrable
in KOH-calcoﬂuor mounts of lung tissues of 19 of 24 (79%) animals.
MIT protein was not detected in any of the serum or BAL specimen. The
BDG, GM and A. fumigatus DNA were detected in 100%, 88% and 54%
of serum samples, whereas positivity of these markers in BAL specimen
was 100%, 100% and 96%, respectively. Expression and secretion of
MIT protein increased progressively from 24 h to 96 h, however, delayed
secretion of MIT protein was noted in minimal medium during in vitro
growth of A. fumigatus.
Conclusions: Our data show that BAL is superior than serum and
combined detection of BDG, GM and A. fumigatus DNA provide a
sensitive diagnosis of IPA in a rat model. Although MIT protein was
readily detectable in culture ﬁltrate during in vitro growth of A. fumigatus
in three different media, it was not detected in any of the serum or BAL
specimens of infected rats. It appears that MIT is not a good marker for
the detection of IPA.
P1940 Metabolomics of Scedosporium and Aspergillus by mass
spectrometry
V. Havlicek*, M. Sulc, K. Peslova, M. Volny, P. Novak, J.-P. Bouchara,
M. Strohalm (Prague, CZ; Angers, FR)
Objectives: Small molecular weight fungal metabolites are used as
biomarkers of scedosporiosis and/or pseudallescheriasis.
Method: Mass spectrometry has already been recognized as an
indispensable molecular tool for clinical microbiologists particularly
useful in high-throughput bacterial, yeast and fungal strain identiﬁcation.
With the growth of microorganism database the major remaining
obstacle has been represented by strain mix analysis. In fungal analysis,
other obstacles have been the longer cultivation period mandatory for
sufﬁcient material production and visualization of fungal ribosomal
protein equipment by MALDI typing as well as the interfering presence
of signal scavenging molecules (melanin).
Results: We have introduced an alternative diagnostic molecular way
based on the knowledge of speciﬁc fungal metabolite structures. This
approach can be used in fungal mixture analysis and represents a
similar added value to that we know from proteomics: going from
peptide mapping to peptide sequencing gives better identiﬁcation rates.
Strain-speciﬁc fungal products of non-ribosomal origin have been
documented on a diverse Pseudallescheria boydii sensu lato complex
as well as Aspergillus genus. Fungal spores have been used as a
source of biomarkers useful for early stage diagnosis. Metabolites
were found at picogram quantities on the spores, hence within the
dynamic range of accurate-mass spectral analysis (FTICR) combined
with high performance liquid chromatography. With Scedosporium
apiospermum spores cyclic peptide pseudacyclin A, tyroscherin and
its analogue YM-193221 were detected. The same components have
been searched for in sera of patients suffering from scedosporiosis.
Pseudacyclin labelled with stable isotopes has been used as an
internal standard in the corresponding quantitation experiments. Lipid
structures have been found on the spores of Scedosporium proliﬁcans.
These were sphingolipids, monohexosylceramides and particularly
glycerophosphocholines. The assignment of the corresponding structures
has been based both on exact mass, isotopic proﬁle and aid of in-
house software Mmass (www.mmass.org) employing the Lipidmaps.org
database. Aspergillus fumigatus metabolome has also been explored.
Conclusion: Implementation of small molecules into current databases
could give higher identiﬁcation rates of pathogenic microbial strains even
in mixture strain analysis.
P1941 Comparison of MycAssay™ Aspergillus test with
galactomannan detection in bronchoalveolar lavage ﬂuid
samples of haematological and ICU patients
R. Torelli, B. Posteraro, E. De Carolis, G. De Pascale, M. Caira,
G. Bello, M. Antonelli, L. Pagano, G. Fadda, M. Sanguinetti* (Rome, IT)
Objectives: To assess the reliability of MycAssay™ Aspergillus
molecular diagnostic test for the detection of Aspergillus DNA in BAL
samples of patients with suspected invasive aspergillosis (IA).
Methods: BAL ﬂuid samples of consecutive patients with suspected
invasive fungal infection were collected for analysis using MycXtra™
DNA extraction and MycAssay™ Aspergillus real-time PCR. PCR
results were evaluated in comparison with clinical diagnosis and
conventional diagnostic tests such as culture and galactomannan (GM)
detection. Fungal infections were classiﬁed according to the EORTC
classiﬁcation on the basis of clinical, microbiological and radiological
ﬁndings.
Results: One hundred and twenty-two samples from 52 haematological
and 70 ICU patients were investigated for the presence of Aspergillus
DNA by the MycAssay™ Aspergillus test. Two and 11 patients had
proven and probable IA, respectively. All the 13 patients with IA
were PCR-assay positive, whereas all the remaining patients without
IA (n = 109) had a negative PCR result. Twelve of 13 patients with IA
and 3 of 109 patients without IA had a GM index value of BAL ﬂuid
>1. Interestingly, the last 3 patients were diagnosed with pulmonary
fusariosis.
Conclusions: The MycAssay™ Aspergillus molecular diagnostic test
was able to detect Aspergillus DNA in BAL ﬂuid samples from patients
with IA with high sensitivity and speciﬁcity rates and had a superior
performance to GM. MycAssay™ Aspergillus has the potential to
improve the diagnosis of aspergillosis in haematological and ICU patients
and warrants incorporation into routine work up to establish its role in
the management of these at risk patient groups.
P1942 Evaluation of MycAssay™ Aspergillus molecular diagnostic
test and automated EZ1 DNA extraction for detecting
Aspergillus spp. DNA in bronchoalveolar samples of patients
with risk factors for pulmonary invasive aspergillosis
E. Rosello´*, M. Culebras, J. de Gracia, G. Codina, A. Alvarez, I. Ruiz,
C. Figueras, A. Moreno, A. Torrent, C. Dı´az de Heredia, A. Andreu
(Barcelona, ES)
Objectives: Evaluation of a new real time PCR technique (MycAssay™,
Myconostica) combined with automated DNA extraction (EZ1, Qiagen)
to detect Aspergillus DNA in BAL samples of patients with pulmonary
Aspergillosis (PA) risk factors in comparison with the Aspergillus
galactomannan antigen (AGA) detection and conventional culture.
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Methods: 53 BAL samples belonging to 42 patients with PA risk factors
were analyzed: 29 solid organ transplants, 9 with haematologic diseases
and 4 with primary or secondary immunodeﬁciencies. After vortexing
the sample, three aliquots were prepared to perform: AGA detection
(Platelia Aspergillus®, Bio-Rad); conventional culture and automated
EZ1 DNA extraction (Qiagen®) following the 2.0 virus protocol with 400
microlitres of sample. All PCR (two per sample) were performed with
the same real time thermocycler (Cepheid SmartCycler system). The
PA criteria to classify cases of aspergillosis were those of the European
Organization for Research and Treatment of Cancer.
Results: Seven probable cases of PA were diagnosed in 5 lung
transplantation and 2 haematologic patients. Conventional culture was
positive in 75% of their samples. If detection of AGA in BAL is not taken
into account as a micological criterion, the sensitivity and speciﬁcity
of this technique − cut off for positive >1(OD) − was 85.7 and 91%
respectively. PCR technique with EZ1 DNA extraction system showed a
100% sensitivity and 93.3% speciﬁcity. The extraction method did not
include any steps for fungal cell wall lysis (for example bead beating) and
was rapid (45 mins) giving patient results in <3 hrs. In four false positive
AGA cases, the PCR was negative. During the study period one case
of zygomycosis and one of fusariosis were diagnosed by conventional
culture and no PCR cross reactions were detected.
Conclusion: The MycAssay™ Aspergillus molecular diagnostic test
performed in BAL samples combined with the EZ1 automated
DNA extraction system provides greater sensitivity and speciﬁcity in
diagnosing PA than AGA detection or conventional culture. Automated
EZ1 DNA extraction system is fast, simple and sensitive, despite not
including any fungal cell wall disruption step.
P1943 CandidaFinder: an innovative multiplex diagnostics for the
detection of Candida spp.
G. Dingemans, Y. Ozog, R. Boesten, C.H. Klaassen, M. Reijans*,
J. Meis, M. Vaneechoutte, T. Boekhout, G. Simons (Maastricht, Utrecht,
Nijmegen, NL; Ghent, BE)
Invasive fungal infections have become major causes of morbidity and
mortality in hospitalized patients and Candida species account for
70−80% of fungal bloodstream infections. Candida spp. are the fourth
most common cause of nosocomial bloodstream infections. Current tests
are mostly targeting regions of rRNA genes, or internal transcribed
spacer regions, which can give difﬁculties in discrimination and may
result in cross-reactivity in PCR assays. This results in an urgent need of
high discriminatory and accurate detection methods for clinical purposes
using novel probes.
The aim of this project is to improve molecular diagnostics of detection
of Candida spp. using the CandidaFinder assay.
The CandidaFinder can detect and differentiate 8 Candida species;
C. albicans, C. dubliniensis, C. krusei, C. tropicalis, C. parapsilosis,
C. glabrata, C. guilliermondii and C. lusitaniae. The speciﬁcity of the
CandidaFinder was tested by screening 95 Candida clinical isolates and
phylogenetically related species, including 31 Candida spp., 4 Pichia
spp. and S. cerevisiae. In addition, analytical sensitivity in blood was
tested by performing spiking experiments of twofold serial dilutions of
viable Candida cells to sterile blood and negative blood cultures. Two
different DNA extraction protocols were evaluated to identify the best
method for obtaining inhibitor-free nucleic acids from blood culture in
combination with the CandidaFinder assay.
The CandidaFinder showed 100% concordance with ITS region
sequencing results and AFLP ﬁngerprints. To determine the analytical
sensitivity in blood, MolYsis Complete5 (Molzym) and EasyMag
(Biomerieux) extraction methods were compared. For both methods 1ml
blood was used for extraction. The sensitivity of all targets could be
determined between 2 and 15 copies per reaction. This demonstrates
that the CandidaFinder matches the sensitivity of singleplex PCR.
We demonstrated that the CandidaFinder was able to identify 8.
Candida spp. in one reaction with a 100% concordance with ITS
sequencing and AFLP ﬁngerprinting. For all targets an analytical
sensitivity of 2−15 copies per reaction was determined, demonstrating
that the CandidaFinder shows equal sensitivity to singleplex PCR. This
corresponds with 40 to 600 copies per ml blood. As clinical relevant
Candida infections are estimated to even occur at concentrations <10
copies per ml the use of larger blood samples for further enrichment of
Candida DNA is required.
P1944 Candida mesorugosa sp. nov., a novel yeast species similar
to Candida rugosa, isolated from clinical samples in Brazil
G.M. Chaves, G.R. Terc¸arioli, A.C. Padovan*, R.C. Rosas, A.S. Melo,
A.L. Colombo (Natal, Sao Paulo, BR)
Candida rugosa is a yeast which is apparently emerging as a causative
agent of invasive infection, speciﬁcally in Latin America. This taxon
presents high genotypical heterogeneity and may be resistant to various
antifungal drugs.
Objective: To evaluate the genetic heterogeneity within a Brazilian
outbreak of C. rugosa bloodstream infection in ICU patients.
Methods: We analysed a total of 11 C. rugosa strains including:
5 clinical isolates, 3 environmental isolates and 3 reference strains
(C. rugosa ATCC 10571, C. rugosa CBS 1948 and C. pseudorugosa CBS
10433). All isolates were phenotypically identiﬁed with the ID32 C®
system. The clinical isolates were typed using RAPD and minisatelites
markers with primers B-14 and (GACA)4, respectively. Band patterns
were analysed with dendrogram constructions using Gel Compar II
version 4.0 Software. All strains were analysed by sequencing of the
ITS and D1/D2 regions. A Neighbor-joining phylogenetic tree was
constructed with Clustal W software.
Results: All clinical isolates used in this study were phenotypically
identiﬁed as C. rugosa. They were genotypically different from C. rugosa
ATCC10571 by RAPD and microsatelite analyses that revealed less
than 80% similarity between our clinical isolates and the type strain.
Comparing our isolates to the type strains C. rugosa ATCC10571 and
C. pseudorugosa CBS10433, ITS sequences showed identity ranging
from 89 to 91% and D1/D2 region ranging from 94% to 98%.
Surprisingly, very low similarity was observed among ITS and D1/D2
sequences from our clinical isolates and C. rugosa CBS1948. Further
BLAST analysis identiﬁed this type strain as C. pararugosa. The
ITS Neighbor-joining tree conﬁrmed lower relatedness of our strains
compared to the C. rugosa type strain ATCC10571 and other C. rugosa
and C. pseudorugosa sequences obtained from GenBank.
Conclusion: Therefore we propose the C. rugosa species complex,
including the recently described species C. pseudorugosa and C. mesoru-
gosa sp. nov., which comprises the clinical isolates from Brazil.
P1945 Resolution of C. albicans identiﬁcation discrepancies using
a C. dubliniensis speciﬁc PNA probe
S. Stevens*, J. Shepard, H. Stender, M. Fiandaca, K. Oliveira (Woburn,
US; Vedbaek, DK)
Objectives: Candida dubliniensis shares many phenotypic characteristics
with Candida albicans therefore it is often misidentiﬁed as C. albicans
by standard biochemical identiﬁcation methods. C. albicans PNA allows
for discrimination between the species however subsequent standard
methods may incorrectly identify a C. albicans FISH negative isolate
as C. albicans positive. Resolving this discrepancy can be difﬁcult
due to the lack of available methods for differentiation of the two
species. C. dubliniensis PNA is a molecular probe that allows for the
speciﬁc detection and identiﬁcation of C. dubliniensis from yeast positive
cultures.
Methods: Samples submitted to AdvanDx as part of routine investiga-
tions for false negative results with C. albicans PNA were subcultured
and tested with C. dubliniensis PNA. In addition, 33 yeast isolates,
including 10 C. albicans and 4 C. dubliniensis, were tested to determine
accuracy of the PNA probe. Brieﬂy, smears were made from subcultures,
hybridized with C. dubliniensis PNA for 30 min at 55ºC, washed for
30 min at 55ºC and then visualized with a ﬂuorescence microscope.
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C. dubliniensis was identiﬁed as bright green ﬂuorescent cells while
negatives were determined by an absence of ﬂuorescence.
Results: C. dubliniensis PNA FISH correctly resolved 18 reports of
C. albicans positive results by biochemical testing. All 18 isolates tested
produced a positive result with the C. dubliniensis PNA. Testing of
known yeast isolates with the C. dubliniensis PNA probe produced an
accuracy of 100%.
Conclusion: C. dubliniensis PNA FISH® is a rapid and accurate method
for the identiﬁcation of C. dubliniensis. This method allows for resolution
of identiﬁcation when standard laboratory methods cannot provide a
deﬁnitive identiﬁcation.
P1946 Rapid discrimination between Candida glabrata, Candida
nivariensis and Candida bracarensis using a simple-plex PCR
A. Enache-Angoulvant*, J. Guitard, F. Grenouillet, C. Fairhead,
C. Hennequin (Le Kremlin-Biceˆtre, Paris, Besanc¸on, Orsay, FR)
Within the Nakaseomyces clade, two new species, C. nivariensis
and C. bracarensis, closely related to C. glabrata, have recently
been described as emerging fungal pathogens. Differentiation between
these species and C. glabrata is important to better understand their
epidemiologic and clinical role in candidiases. The speciﬁcity of routine
identiﬁcation based on conventional (phenotypic) methods may be
insufﬁcient. In this work, we aimed at developing a simple molecular
method to differentiate C. glabrata, C. nivariensis and C. bracarensis
with no need of sequencing.
Among highly conserved genes between C. glabrata and Saccharomyces
cerevisiae that contain intron(s), we found RPL31, a gene coding for a
protein component of the large ribosomal subunit. A single primer pair
was designed to amplify a nucleotide fragment of 1136 and 780 bp
in C. glabrata and S. cerevisiae, respectively. A touch down protocol
using these primers was applied to a panel of 43 strains previously
identiﬁed using sequencing of the ITS region as C. glabrata (n = 5),
C. bracarensis (n = 6), C. nivariensis (n = 27) and, S. cerevisiae, Candida
albicans, Candida tropicalis, Candida parapsilosis and Candida krusei
(one each).
A PCR product differing by size according to the species was obtained
for C. glabrata (1100 bp), C. bracarensis (950 bp), C. nivariensis (740
bp) and S. cerevisiae (780 bp), while the ampliﬁcation failed for the
other Candida species tested.
The method appears reliable and fast making it a valuable tool for either
retrospectively investigating collection of strains previously identiﬁed as
C. glabrata or conﬁrmatory identiﬁcation.
P1947 Molecular investigation of Fusarium isolates from
keratomycosis
C.S. Shobana, L. Galgo´czy*, M. Homa, L. Kredics, K. Panneerselvam,
R. Rajendran, V. Narendran, C. Va´gvo¨lgyi, P. Manikandan (Coimbatore,
IN; Szeged, HU)
Objectives: Cases of keratomycosis caused by the members of the
genus Fusarium has increased signiﬁcantly over the past several years
in South India. This type of infection often results in blindness due
to inappropriate treatment and misidentiﬁcation of the causal agent.
Therefore, identiﬁcation of these Fusarium strains at species level would
be important for epidemiological and clinical purposes as the pathogenic
potential and clinical features vary between species, subspecies and
species complexes of the genus.
Methods: A total of 55 Fusarium isolates derived from human
keratomycosis (Tamil Nadu and Kerala States, India) was subjected for
molecular identiﬁcation and was compared with similar sequences of the
internal transcribed spacer region (ITS), b-tubulin (b-tub) and translation
elongation factor 1a gene (tef1) available in the NCBI and FUSARIUM-
ID databases. A combined phylogenetic tree was generated using the
maximum-likelihood and Bayesian method based on the tef1 and b-tub
sequence data. The in vitro antifungal susceptibilities of the isolates to
amphotericin B (AMB), itraconazole (ITZ) and terbinaﬁne (TBF) were
determined employing the standard Clinical and Laboratory Standards
Institute (CLSI) M38-A2 microbroth dilution method.
Results: Most of the isolates were conﬁrmed as F. solani (52; 94.5%)
followed by F. incarnatum (2; 3.6%), and F. sporotrichioides (1; 1.8%).
The minimal inhibitory concentrations (MICs) of AMB, ITZ and TBF
varied between 4 and >64mg/ml, and based on the susceptibility data,
TBF proved to be the most effective antifungal drug in vitro. Many of
the isolates examined were resistant or less susceptible to the antifungal
agents used in the present investigation. These isolates formed separate
clades on the phylogenetic tree.
Conclusion: Our results indicate that F. solani is the main causal agent
of human kertomycosis in South India and several strains of this species
show resistance or low susceptibility towards the conventional antifungal
agents. Based on the MIC data, TBF was found to be an effective drug
against Fusarium keratomycosis in South India.
This work is part of the INSA-HAS interacademic bilateral project.
L.G. holds a postdoctoral fellowship from the Hungarian Scientiﬁc
Research Fund (OTKA; grant reference number PD 83355).
P1948 MALDI-TOF mass spectrometry proteome proﬁling for
identiﬁcation of clinically relevant moulds
L. Putignani*, F. Del Chierico, E. Fiscarelli, M. Onori, L. Mancinelli,
G. Ricciotti, T. Franchin, A. Pompilio, L. Dimiziani, C. Russo,
A. Urbani, D. Menichella (Rome, Chieti, IT)
Objectives: Pediatric populations are currently at high risk for mould
opportunistic infections due to the high impact of changes in medical,
intensive care and organ transplantation practices. We designed and set-
up an analytical MALDI-TOF MS-based assay to identify the most
isolated (e.g. Aspergillus spp.) and emerging moulds (e.g. Scedosporium
spp; Geosmithia spp., Fusarium spp. and Penicillium spp.) from a
pediatric setting. The aim was achieved by generating a dedicated
customized library of reference spectra from solid media cultures which
are currently used in daily clinical mould identiﬁcation (ID).
Methods: Solid cultures of 230 isolates from 18 different mould
species (12 Aspergillus spp., Fusarium oxysporum, Penicillium chryso-
genum, Geosmithia argillacea, Scedosporium proliﬁcans, Scedosporium
apiospermum, Pseudallescheria boydii) were isolated during routine
diagnostic efforts. A growth time-course at 30ºC was run at 24, 48,
72, 96 and 120 hours for all 18 reference species to assess the best
quantity and quality of mould material collected from plate surface
and spot onto MALDI-TOF-MS target plate. Eight replicates for each
reference spectrum generation were collected for each species and
analyzed for reproducibility. Overlapping spectra were evaluated for
variance by principal component clustering analysis (PCA); a ﬁrst and
second derivative spectra generations were produced. ID concordance
analysis for the 230 isolates was assessed between MS and phenotypic
IDs. When discordant, the ID was achieved by gene sequencing at single
and multiple loci level (b-tubulin; ribosomal LSU D2 region; ITS).
Results: The time-course at 120 hours was selected for the highest
spectra reproducibility and quality. On visual inspection, similarity
of spectra produced by different species was recognized and spectra
differences between diverse genera were also registered. The spectra
reproducibility was proved by high similarity and PCA outcome for all
species. After customized database compilation and probing, only the
score range 1.74 ID 2.72 was used for reliable species ID for pattern
matching. Concordance between phenotypic and MT IDs was provided
for 200/230 clinical isolates.
Conclusion: Proteome proﬁling-based assay for mould IDs may be
an optimal diagnostic approach to overcome culture-based methods, to
encompass multiple fungal genera, to reﬂect the variety of morph types,
growth phase and fungal microenvironment.
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P1949 Fast and sensitive detection of the mycotoxin gliotoxin and
related compounds during human aspergillosis
M. Domingo, J. Pardo, L. Roc, M. Palacian, C. Colmenarejo, J. Meis,
N. Peyman-Fard, M. Revillo, E. Galvez, A. Rezusta* (Zaragoza, ES;
Nijmegen, NL)
Objectives: Invasive aspergillosis, a nosocomial opportunistic infection
caused by pathogens of the genus Aspergillus (mainly by Aspergillus
fumigatus), is associated with signiﬁcant mortality. This is due in
part to the absence of optimal diagnostic modalities, which hamper
early disease detection. Gliotoxin (GT) and bis-methylthio-gliotoxin
(mGT) are secondary metabollites produced by pathogens of the genus
Aspergillus. We have previously shown that GT is a virulence factor
during experimental aspergillosis induced by Aspergillus fumigatus that
helps mold to establish infection and survive within the host. Thus, we
hypothesise that GT and mGT should be produced during the ﬁrst stages
of infection, representing a potential early diagnosis marker to reveal
mold presence. A method to help with early diagnosis of aspergillosis
based on the detection of GT and mGT during invasive aspergillosis is
presented.
Methods: Our detection system is based on quantitative High
Performance Thin Layer Chromatography (HPTLC). In order to establish
the detection limit of this system, samples of serum from healthy
donors are spiked with known amounts of GT and mGT, extracted
with dichloromethane and separated on HPTLC plates. GT and mGT
are detected and quantiﬁed by using ﬂuorescence dyes or under UV
light exposure. Subsequently this method is used to analyse GT and
mGT presence in serum samples of patients with probable and proven
aspergillosis.
Results: A simple, accurate, fast and sensitive technique for simultane-
ous separation, detection and quantiﬁcation of GT and mGT in human
serum (detection limit lower than 5ng/ml) is achieved. Both GT and
mGT are found in real samples of serum from patients with probable
and proven aspergillosis.
Conclusions: Fast and sensitive detection methods of these mycotoxins
would be very useful in order to improve the protocols for early diagnosis
of aspergillosis in humans and to design therapies that target gliotoxin
activity. Our method has been used to detect and quantify gliotoxin
and bis(methylthio)gliotoxin presence in human samples (serum) from
probable and proven aspergillosis. Because of its simplicity, speed and
accuracy, it could be easily implemented in clinical diagnosis laboratories
and would complement or even improve current diagnosis methods of
aspergillosis.
P1950 Usefulness of the 1,3-b-D-glucan and antibody germ tube
C. albicans for early diagnosis of invasive candidiasis in
non-neutropenic critically ill adult patients
C. Castro*, A. Ubeda, T. Gonza´lez, P. Saavedra, J. Co´rdoba, A. Loza,
S. Ruiz-Santana, E. Martı´n-Mazuelos for the CAVA II Study Group
Objective: Candida colonization is a signiﬁcant risk for invasive
candidiasis. The value of serum levels of 1−3-b-D-glucan and the
antibody germ tube C. albicans (CAGTA) to diagnose invasive
candidiasis and to differentiate infection from Candida colonization was
evaluated.
Material and Methods: We studied 180 non-neutropenic critically
ill adult patients with complicated abdominal conditions admitted to
20 Spanish ICUs participating in a prospective study. The following
was performed twice a week: surveillance screening cultures, Candida
score, and measurement of serum levels of 1−3-b-D-glucan (Fungitell®
assay) and CAGTA (Vircell® Kit). Patients were grouped into invasive
candidiasis, Candida colonization, and neither colonized/nor infected.
Biomarkers were expressed as the maximum value either before the event
(invasive candidiasis) or across all observations. The discriminatory
ability of 1−3-b-D-glucan and CAGTA was assessed by the area under
the ROC curve (AUC). A prediction model of invasive candidiasis was
developed by CART (Classiﬁcation and Regression Trees) including
biomarkers, Candida score, and the patient’s clinical status. The
concomitant effect of biomarkers was determined by logistic regression
analysis.
Results: There were 31 (17.2%) patients with invasive candidiasis,
56 (31.1%) colonized, and 93 (51.6%) neither colonized/nor infected.
According to CART, the probabilities of invasive candidiasis were
82.3% for the terminal node of 1−3-b-D-glucan >253 pg/mL, 14.3%
for 1−3-b-D-glucan <253 pg/mL and CAGTA negative or limit NP, and
39.3% for 1−3-b-D-glucan <253 pg/mL and CAGTA positive. Using this
probability as cutoff, the predictive rule for invasive candidiasis showed
86.2% sensitivity and 54.5% speciﬁcity, with an AUC of 0.78 (95%CI
0.7−0.8).
Conclusions: Serum levels of 1−3-b-D-glucan >253 pg/mL associated
with positive CAGTA assay accurately differentiated Candida coloniza-
tion from invasive candidiasis.
Supported by Astellas S.A., Spain
P1951 Diversity of proteome proﬁles in neutropenic patients devel-
oping versus not developing invasive pulmonary aspergillosis
F. Dalle*, C. Truntzer, D. Pecqueur, A. Jeannin, S. Chabri, D. Caillot,
R. Herbrecht, V. Letscher-Bru, P. Ducoroy, A. Bonnin (Dijon,
Strasbourg, FR)
Objectives: Invasive Pulmonary Aspergillosis (IPA) in neutropenic
patients occurs in 5% to 25% of serial aplasia and remains a devastating
infection with attributable mortality of 40%. Early diagnosis is essential
to improve survival rates. Diagnosis of IPA generaly results from a
multiparametric approach bringing together clinical, radiological and
biological data. However, clinical signs are not speciﬁc and biological
diagnostic tools still lack sensitivity and speciﬁcity. A proteom proﬁling
approach was conducted to (1) study the proteom patterns of neutropenic
patients having (or not) developed IPA and (2) identify diagnostic, and
prognostic biomarkers for IPA.
Methods: For each patient enrolled in this study and for each period of
aplasia, sera and plasma were prospectively collected 5 days a week and
conserved in liquid nitrogen since 2005. A total of 330 patients were
included in two hematology units (Dijon and Strasbourg, France) among
whom 37 developed pulmonary invasive fungal infections in at least 1
period of aplasia. For each of these patients, serial sera and plasma were
processed for proteom proﬁling analyzes. A sub proteome was puriﬁed
from blood samples and analyzed by mass spectrometry (MALDI-TOF).
The proﬁles of peptides mass generated were pre-processed and analyzed
by statistical methods aimed at (1) studying the proteom variability in
patients during several periods of aplasia (including periods with versus
without ongoing aspergillosis), (2) identifying speciﬁc markers whose
kinetics correlated to the invasive fungal infection process.
Results: Preliminary descriptive analyses conducted on 10 patients
showed the capacity of peptidomics approaches combined with speciﬁc
statistical methods (like k-means clustering) to separate different groups
of samples in infected patients: (1) samples from the periods of aplasia:
without versus with ongoing aspergillosis; (2) in the period of aplasia
with ongoing aspergillosis: samples before versus after EORTC diagnosis
of aspergillosis.
Conclusions: The validation of these preliminary results will be
conducted on the remaining samples available.
P1952 Detection of galactomannan in serum and isolates of
Fusarium species from patients with proven invasive
Fusarium infection
M.P. Roiz*, M.S. Garcia, J. Agu¨ero, C. Ruiz de Alegria, I.C. Perez
del Molino Bernal, L. Martı´nez-Martı´nez (Santander, ES)
Objective: Cross-reactivity of Fusarium species and serum from
patients with invasive Fusarium infection (IFI) is rarely reported in the
Galactomannan enzyme immunoassay (GM-EIA). Isolates of Fusarium
spp. from 2 patients with proven IFI and their serum samples were
studied for their ability to produce positive results with GM-EIA.
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Methods: F. oxysporum was isolated from a dermic biopsy and a liver
necropsy from the same patient and F. proliferatum was cultured from
blood of another patient. Aspergillus spp were not isolated from any
sample of both patients. Identiﬁcation was based on morphology criteria
and sequencing the transcription elongation factor 1a gene. Serum
samples were tested under clinical demand. Isolates preparation was
done by two ways: (1) One loop of biomass grown on Sabouraud
cloramphenicol media for several days was suspended in 0.5ml of
sterile distilled water and (2) Preparation and dilutions (102-105) were
performed as described by Swanink C (J Clin Microbiol 1997) with
some modiﬁcations. GM-EIA assay was performed on serum and by
duplicate on both isolates preparation, according to the manufacturer’s
instructions (Platelia ™ Aspergillus GM EIA). A. fumigatus was used
as positive isolate control. Results were considered positive when serum
samples or duplicate isolates samples had a GM index value 0.5.
Results: Serum from patient with invasive F. oxysporum infection tested
repeatedly positive for galactomannan (0.54–9.50). F. oxysporum and
A. fumigatus isolates tested directly from sterile water suspension,
yielded positive results with GM-EIA (F. oxysporum:1.09 and 8.5;
A. fumigatus:11.5). None isolates but A. fumigatus, yielded positive
results with the dilution protocol (102 and 103). Blood isolate and serum
samples from patient with invasive F. proliferatum infection yielded
negative GM-EIA results.
Conclusions: Serum GM-EIA positive results caused by F. oxysporum
should be added to the list of possible invasive non-Aspergillus fungal
infection detected by this immunoassay. Differences in results obtained
with different in vitro exoantigens preparation make difﬁcult to establish
the clinical impact of these results and indicate the need for additional
studies.
P1953 Laboratory diagnosis of invasive aspergillosis
in haematological patients: comparison between
galactomannan, 1,3-b-D-glucan and Aspergillus IgG test
L. Persijn*, E. Steel, G. Claeys, A. Piette, S. Blot, K. Vandewoude,
P. Depuydt, D. Benoit, L. Noens, D. Vogelaers, E. Padalko (Ghent, BE)
Objectives: The diagnosis of invasive aspergillosis still remains
problematic and challenging despite the availability of different culture
and non-culture based tests. We compared the value of galactomannan
(GM), 1,3-b-D-glucan (BG) and Aspergillus IgG detection in a
haematological population.
Methods: In total 38 haematological patients were included. They
were divided in 4 groups according to clinical, microbiological and
radiological criteria. Group 1 consisted of 14 patients with positive
serum GM (1 proven, 9 probable and 4 clinically non-classiﬁable
according to the revised EORTC/MSG criteria 2008 for diagnosis of
invasive aspergillosis). In order to be able to compare the diagnostic
sensitivity of GM and BG, at least 3 consecutive samples per patient
were analyzed with both tests. Group 2 included 12 patients with only
BAL GM positivity (8 probable and 4 non-classiﬁable). In group 3
patients with suggestive clinical criteria, but negative serum and/or
BAL GM were included (n = 6). In group 4 patients on therapy but
without clear laboratory or radiological criteria were listed (n = 6). As
controls we selected 15 healthy donors and 10 haematological patients
without clinical and microbiological criteria of invasive aspergillosis.
GM (Platelia Aspergillus EIA, BioRad), BG (Fungitell®, Associates of
Cape Cod) and Aspergillus IgG (Platelia Aspergillus IgG, BioRad) were
performed according to manufacturer’s instructions.
Results: Results are summarized in Table 1.
No diagnostic advantage of GM or BG on consecutive clinical samples
was found. In case of negative serum GM results also all BG results were
negative. Remarkably, in 2 out of 6 patients with suggestive clinical
criteria but without any microbiological criteria, Aspergillus IgG was
positive.
Conclusion: In our study, serum galactomannan and 1,3-b-D-glucan
had a comparable sensitivity for diagnosis of invasive aspergillosis
in haematology patients. Due to the higher speciﬁcity, galactomannan
is preferred for routine screening. Aspergillus IgG is not a sensitive
diagnostic laboratory tool for the diagnosis of invasive aspergillosis as
compared to galactomannan and 1,3-b-D-glucan. In the group of patients
with suggestive clinical picture but negative serum galactomannan
values, Aspergillus IgG may represent an added value as the next
laboratory parameter to be tested prior more invasive methods of
diagnosis.
The study was supported by an unrestricted grant from MSD Belgium.
P1954 A clinical evaluation of two novel PCR-based analyses for
the diagnosis of dermatophytosis in skin and hair
R. Jensen*, M. Cavling Arendrup (Copenhagen, DK)
Objective: Classic diagnosis of dermatophytosis may require several
weeks due to the slow-growing nature of dermatophytes. We imple-
mented a multiplex PCR detecting any dermatophyte and Trichophyton
rubrum speciﬁcally in 2006 and subsequently developed and evaluated
species speciﬁc PCRs for the other common human pathogenic species
which were implemented in the spring 2010. Here we present the
performance of PCR-based analyses of skin and hair specimens
compared with traditional diagnostics.
Methods: Positive rates and species distribution were retrospectively
evaluated for samples received in the period from July 15th to October
1st in 2009 (before implementation of new PCR tests) and in 2010 (after
implementation of new tests). The diagnostic algorithms for PCR tests
were based on epidemiological statistics. Thus, skin samples (other than
from feet) were channelled to two speciﬁc PCR assays detecting all
Trichophyton sp., Microsporum canis/audouinii and all species within
the T. mentagrophytes complex (T. interdigitale, A. vanbreuseghemii,
A. benhamiae and T. erinacei). Hair/scalp samples were subjected to
Trichophyton sp., M. canis/audouinii, M. canis and T. violaceum speciﬁc
PCR assays. Samples negative for T. rubrum but positive in the pan-
dermatophyte PCR were subjected to the T. mentagrophytes complex
speciﬁc PCR.
Results: A total of 3148 and 3266 samples were collected in the
2009 and the 2010 periods respectively (Table). Overall, more than
75% of the samples were subjected to the previously described PCR
analysis detecting all dermatophytes and T. rubrum speciﬁcally and
no signiﬁcant changes between 2009 and 2010 in sample number or
species distribution were observed. Samples submitted to the two novel
PCR assays constituted 6.5% and a total number of 213 analyses were
ordered. Comparing again 2009 and 2010 we demonstrate that except an
increase in detected T. rubrum the species distribution statistically was
not different indicating that the performances of the novel analyses were
as intended.
Conclusion: Dermatophytosis is by far the most prevalent fungal
infection and many are affected by a fast and conﬁdent diagnosis of
such infections. Here we demonstrate that the implementation of two
novel PCR-based analyses for diagnosis of dermatophytosis in skin and
hair potentially can replace culturing and thereby reducing the diagnosis-
time from several weeks to a few days.
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P1955 The effect of antifungal treatments on laboratory diagnostic
assays for invasive fungal infections
E. McCulloch*, G. Ramage, R. Rajendran, D. Lappin, B. Jones,
P. Warn, R. Shrief, W. Kirkpatrick, T.F. Patterson, C. William (Glasgow,
Manchester, UK; San Antonio, US)
Objectives: Invasive aspergillosis (IA) remains a major concern in
the management of patients undergoing haematopoietic stem cell
transplantation. Due to the acknowledged risk of IA a number of
strategies have been developed for the use of antifungal agents ranging
from prophylaxis, via pre-emptive therapy to empiric therapy. However,
diagnosis of IA remains problematic with clinical symptoms that
are often non-speciﬁc and some radiological ﬁndings, such as the
presence of a halo sign or cavitating nodules in the lungs may being
strongly suggestive of aspergillosis also associated with other infections.
Diagnostic tests such as Galactomannan (GM) enzyme immunoassay and
qPCR have been widely employed. The aim of this study is to assess
laboratory based diagnostics and antifungal treatment as it is unclear
how this inﬂuences these tests.
Methods: This study utilises an animal model of IA infection to
examine the effect of antifungal treatment using the three main classes of
drugs; azoles (pozaconazole), echinocandins (caspofungin) and polyenes
(amphotericin B). Daily blood samples were collected for subsequent
analysis using a commercially available GM assay and an in house
qPCR assay. The effect on these diagnostic tests and how these tests
are impacted upon by the use of different classes of antifungal agents in
this in vivo model of IA was assessed.
Results: No signiﬁcant differences were observed in the fungal burden
of the lungs of any of the groups in this study. Examination of
the tests revealed qPCR was statistically more sensitive than GM for
both early detection of infected controls (p = 0.045) and for overall
detection (p = 0.018). However, antifungal treatment signiﬁcantly reduced
the overall sensitivity of qPCR (p = 0.020); these effects were due to
posaconazole and caspofungin. In the latter stages of infection (days 4
and 5) there were no signiﬁcant differences in the numbers of infections
detected by GM and qPCR. However, the antifungal class used caused
signiﬁcant qualitative differences (p = 0.041). GM showed improved
detection in posaconazole treated animals.
Conclusions: Our data provide insights into how diagnostic testing
strategies could be optimised. This raises an important issue that prior
exposure to antifungal therapy must be considered when interpreting
either qPCR or GM based IA diagnostics, as we have shown that
individual classes of antifungal agents impact upon the dynamics of
antigen and DNA release into the circulation.
P1956 Clinical relevance of a positive PCR assay to diagnose
Pneumocystis pneumonia in immunocompromised patients
F. Robert-Gangneux*, M. Revest, P. Tattevin, C. Guiguen,
J.-P. Gangneux (Rennes, FR)
Introduction: The biological diagnosis of Pneumocystis pneumonia
(PCP) is difﬁcult and mainly relies on microscopic demonstration
of cysts and/or trophozoites in bronchoalveolar lavage (BAL). More
recently, serum b1−3 D-glucan and PCR assays have emerged as new
diagnostic tools. PCR in BAL is reported to improve the sensitivity of
PCP diagnosis. However, the positive predictive value (PPV) of this test
when microscopic examination is negative is still under debate, since a
positive PCR can be related to an asymptomatic carriage.
Methods: Since the onset of a PCP PCR assay in our hospital in
April 2009, 225 patients beneﬁted from molecular and microscopic
Pneumocystis detection in BAL, on the basis of clinical and radiological
signs. We prospectively surveyed all cases of positive PCR results
and focused on the analysis of the clinical relevance of this PCR
positivity in case of discrepancy with microscopic examination (Giemsa
stained cytocentrifuged samples). All samples were also analyzed using
an immunoﬂuorescence (IF) assay for Pneumocystis cysts detection
(Biorad). PCR was performed using primers targeting the mitochondrial
long subunit (mtLSU) rRNA.
Results: Among the 225 patients, 49 had a positive PCR result (2
patients had 2 or more positive samples) with negative direct examination
on Giemsa-stained BAL samples. All of these 49 patients were
immunocompromised, with diverse etiologies for immunosuppression:
hematological malignancies (15), cancer (9), long-term treatment with
corticosteroids (14), transplantation (6), HIV (5). The diagnosis of PCP
was retained in 41/49 (84%) cases after review of the clinical and
radiological follow up. The diagnosis was excluded for 3 patients,
despite compatible radiological ﬁndings in 2 cases. In the 5 remaining
cases, the diagnosis of PCP was probable; 4 of them died soon after
biological diagnosis in a context of respiratory distress and hypoxemia
without having received any speciﬁc therapy and without other infectious
etiology. Sixteen samples were positive by IF also; in all 16 cases the
diagnosis of PCP was conﬁrmed. When including the 4 highly probable
cases, the PPV of PCR raised to 92% (45/49).
Conclusion: In our series, the PPV of a positive PCR when direct
examination was negative, was 92% when taking into account the
proven and probable cases, thus emphasizing the usefulness of molecular
diagnosis in immunocompromised patients, in particular in non-HIV
patients.
Clinical management challenges in hepatitis
in an era of changing treatment options
P1957 Hepatitis C virus genetic and amino acid diversity within
NS3 protease from 302 chronically-infected patients who
never received NS3 protease inhibitors in Marseille,
southeastern France
P. Colson*, A. Motte, N. Tivoli, C. Tamalet, R. Ge´rolami (Marseille, FR)
Objectives: Hepatitis C virus (HCV) displays considerable levels
of nucleotide and amino acid (aa) diversity. 7 genotypes and >80
subtypes have been described worldwide. Genotype and subtype-speciﬁc
natural polymorphisms were identiﬁed within HCV NS3 protease,
the target enzyme of future speciﬁcally-targeted antiviral therapy for
HCV (STAT-C), at aa sites associated with resistance to NS3 protease
inhibitors (NS3-PIs) or with compensatory mutations. We analyzed the
natural genetic and aa diversity of HCV NS3 protease from NS3-PIs-
naive patients (pts) monitored for their HCV chronic infection in public
hospitals of Marseille, southeastern France.
Methods: 328 serum samples collected in 2004–2010 from 302 pts
chronically-infected with HCV were analyzed. Ampliﬁcation/direct
sequencing of the HCV NS3 protease gene were performed using in
house protocols with primers designed using the SVARAP tool. HCV
NS3 protease genotypes were determined by phylogenetic analysis.
Divergent NS3 sequences were identiﬁed based on a nucleotide
identity <85% with their best BLAST hit in the NCBI GenBank
and/or the Timone sequence databases. Aa diversity at sites associated
with resistance to NS3-PIs, compensatory mutations, enhanced viral
replication, or corresponding to functionally and/or structurally-critical
aa residues was analyzed using Microsoft Excel.
Results: HCV NS3 genotype was 1a in 144 (48%) of 302 pts, 1b in
67 (22%) pts, 2 in 8 (2.6%) patients, 3a in 61 (20%) pts, 4a in 9
(3%) pts, 5 in 1 (0.3%) pt, and 6 in 2 (0.7%) pts. Divergent NS3
sequences were identiﬁed in 20 (7%) pts, and included sequences of
genotypes 2k and 3h. In NS3 protease from the 302 pts, 8 of the 11
aa positions implicated in resistance to NS3-PIs harbored 2 different
residues (mean±SD, 2.5±1.4). Drug resistance aa substitutions were
observed at 7 positions (V36L/M, T54S, V55A, Q80K, R155K, V158I,
D168E/Q) in a number of NS3 sequences ranging from 1 (R155K,
V36M) to 91 (V36L). Additionally, 2 (3.5±2.2) different aa residues
were observed at 13 other relevant positions of NS3 protease.
Conclusions: We identiﬁed substantial genetic and aa diversity within
NS3 protease from HCV chronically-infected pts followed-up in our
institution and who never received NS3-PIs. These data prompt to
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determine the relevance of these natural polymorphisms in view of future
NS3-PIs-based therapies and suggest that systematic HCV NS3 protease
sequencing may be of interest before initiating such STAT-C.
P1958 IL28B-gen polymorphic variants as pharmacogenetic
markers of HCV treatment response in HIV-infected patients
J. Guardiola*, J. Martin, K. Lamarca, C. Pacho, I. Ferna´ndez,
C. Cabeza, M. Sambeat, A. Fontanet, J. Mun˜oz, E. Martin, J. Salazar,
J. Cadafalch, M. Baiget, P. Domingo on behalf of the Sant Pau
Pharmacogenomic HCV-HIV Study Group
Background: HIV infection modiﬁes the natural history of chronic HCV,
thus promoting more rapid progression to cirrhosis and end-stage liver
disease. The combination of pegylated interferon plus ribavirin permits
to achieve sustained HCV clearance in no more than 40% of HIV-HCV
co-infected patients. Recent studies showed that genetic variation in
the IL28B gene, which encodes IFN-lambda, is associated with HCV
good treatment response in individuals infected with HCV genotype 1.
These studies heve been performed in HCV population, and no data are
available regarding HIV-HCV patients.
Methods: A prospective study of consecutive HIV-HCV adult patients
in a tertiary teaching hospital in Barcelona (Spain). Blood samples were
genotyped for IL28b SNP rs12979860 and rs12980275 using TaqMan
SNP Genotyping Assays (Applied Biosystems). All patients provided
consent for genetic studies. We studied two SNP’s in a HCV-HIV
population and correlated the demographic data and viral response.
Results: 173 HCV-HIV patients were included in demographic analysis.
63% men. Age 46 + 8,3 (24−65) year. HIV disease evolution 15+6
(0−26) ys. 70% were IDU. 95% follow treatment whit ARV drugs
actually, whit a mean of 4 different treatments during 10 a mean of
years. 82% with undetectable HIV viral load, mean CD4 count 606+321
(89–1843) cell/mm3. Mean basal HCV viral load: 4.200.000 UI/mL.
Mean basal ALT 56 U/L. Genotype 1 57%. Mean basal ﬁbrosacan were
8,8+5,7 (3,4−29) Kpa. 12% were in cirrhosis. SNP rs12979860 allelic
distribution were: CC, CT and TT in 45,5, (protective allele) 44,2 y
10% respectively. SNP rs12980275 Allelic distribution (AA, AG y GG)
shown the same percentages. Basal protective allele distribution was not
correlated whit hepatic cirrhosis and ﬁbroscan data (Mean of 9 Kpa
for protective allele carriers and no protective carriers). Protective allele
(CC) was correlated whit HCV genotype: (G1:30%, G3: 78,6%, G4
33,3%) (p = 0,007). 50 patients were treated whit peg interferon and
RBV, whit 43% of sustained viral response. High correlation between
CC protective allele and SVR was observed: 83% of patients whit SVR
were CC allele carriers (OR: 20.
Conclusions: Our ﬁndings suggest that the genetic variation of IL28B
have high inﬂuence whit SVR. Protective CC carriers was correlated
whit G3 HCV,but not whit ﬁbroscan data and cirrhosis stage.
P1959 Fulminant hepatitis E in southeastern France
P. Colson*, F. Raissouni, P. Borentain, A. Le Gofﬁc, J. Hardwigsen,
C. Nafati, Y.-P. Le Treut, R. Ge´rolami (Marseille, FR)
Objectives: Hepatitis E virus (HEV) is a major cause of acute hepatitis in
tropical and subtropical countries. Besides, HEV infection is an emerging
disease in developed industrialized countries where an increasing number
of autochthonous cases have been reported. In these countries, the
severity and mortality related to acute hepatitis E needs to be studied
more accurately. We report 3 cases of fulminant hepatitis E (FHE)
diagnosed in public hospitals of Marseille, southeastern France.
Methods: From April 2006 until September 2009 (42 months),
hepatitis E infections were diagnosed by anti-HEV IgM and IgG antibody
testing (using Adaltis assays) and HEV RNA detection and sequencing
in serum (using in house real-time PCR and ampliﬁcation/sequencing
protocols). FHE was deﬁned by an alanine transaminase level (ALT)
>10-fold upper normal value, a prothrombin index (PI)< 50%, clinical
signs of encephalopathy, and anti-HEV IgM and HEV RNA detection in
the serum. Other major cause of acute hepatitis were ruled out.
Results: 62 hepatitis E were diagnosed during the study period. Three
(4.8%) FHE occurred, and two patients died, despite liver transplantation
(LT) in one case. Patients were admitted 2−4 weeks after the onset
of clinical signs. Their mean age (±SD) was 43±17 years (range,
29−58). Mean ALT was 1716±1167 IU/l, mean bilirubinemia was
450±166 micromol/l, mean PI was 26±8%, and mean factor V level
was 0.32±0.12. Case no. 1 had non insulin-dependent diabetes mellitus
and was receiving azathioprine for Crohn disease. Transjugular liver
biopsy revealed preexisting ﬁbrosis. He developed encephalopathy and
acute respiratory deﬁciency syndrome then died. Cases no. 2 and no. 3
had no underlying chronic liver disease. Both received LT; case no. 3
died 36 days after surgery. All patients were infected with genotype 3f,
which is the most commonly found in autochthonous cases in France.
None had traveled abroad during the 2−9 weeks incubation period of
the disease. Consumption of pig or wild-boar meat was identiﬁed in 2
of the 3 patients.
Conclusion: Fulminant hepatitis occurred in about 5% of HEV
infections diagnosed in our lab and was fatal in 2 of 3 cases (3.2%).
Underlying chronic liver disease, which has been associated with poor
prognosis, was only evidenced in one patient. These data prompt to
improve prevention of HEV infection in our geographical area and raise
the question of treatment by ribavirin of such cases.
P1960 Seroepidemiology of hepatitis virus infections among men
who have sex with men aged between 18 to 40 years in Taiwan
Y. Tseng*, W. Liu, C. Hsieh, P. Wu, C. Wu, H. Sun, C. Hung (Taipei, TW)
Objective: Men who have sex with men (MSM) are reportedly at
increased risk for hepatitis A virus (HAV), hepatitis B virus (HBV),
and hepatitis C virus (HCV) infection than the general population. This
study aimed to compare the seroprevalence of hepatitis infections among
MSM with and without HIV infection who were aged less than 40 years
and to examine the associated factors with hepatitis virus infections.
Methods: From June 2009 to June 2010, clients aged 18−40 years
who were MSM and sought voluntary counseling and testing (VCT) for
HIV infection at the National Taiwan University Hospital were provided
serological tests for HAV, HBV, HCV, and syphilis that is diagnosed by
elevated Venereal Disease Research Laboratory/Rapid Plasma Reagin
(RPR) titers and positive for Treponema pallidum hemagglutination
antibody (TPHA). HIV-infected MSM of the same age group who sought
HIV care were tested for the same serological markers.
Results: During the 1-year study period, 690 VCT clients and
438 HIV-infected patients were tested for anti-HAV antibody, HBV
surface antigen (HBsAg), and anti-HCV antibody. HIV-infected patients
were signiﬁcantly older than HIV-negative VCT clients (30.5±5.4 vs
25.8±4.7, P< 0.01). The overall seroprevalence for HAV, HBsAg,
and HCV in VCT clients were 7.4% (51/690), 6.2% (43/690), 0.4%
(3/690), while that in HIV-infected MSM were 15.3% (67/438), 16.4%
(70/428), 5.5% (24/433), respectively. In multivariate analysis, age was
signiﬁcantly associated with seropositivity for HAV (OR, 1.15; 95%CI,
1.1−1.2), HBsAg (OR, 1.12; 95%CI, 1.1−1.2), and HCV (OR, 1.09;
95%CI, 1.0−1.2). HIV infection was independently associated with
HBsAg (OR, 1.75; 95%CI, 1.1−2.7), anti-HCV seropositivity (OR, 9.07;
95%CI, 2.6–32.0), and RPR/VDRL titers of 4 or greater within 1 year
of testing (OR, 7.03; 95%CI, 4.5–10.98).
Conclusions: Among MSM aged less than 40 years in Taiwan,
seroprevalence for HAV, HBsAg, and HCV increased with age, while,
because of sharing transmission routes, HIV infection was associated
with increased seroprevalence of HBV, HCV, and syphilis.
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P1961 Impact of the use of epoetin b on sustained virological
response in patients with hepatitis C virus treated with
pegylated interferon alfa-2a plus ribavirin
F. Lunel-Fabiani, D. Larrey, I. Fouchard-Hubert, M.T. Dao, P. Me´lin,
L. D’alteroche, P. Veillon* (Angers, Montpellier, Caen, Saint-Dizier,
Tours, FR)
Objectives: The aim of this pragmatic (a-risk = 100% and b-risk =
0%, with no test at the end), multicenter, randomized trial was to
demonstrate if epoetin b (EPO) could enhance sustained virological
response (SVR) by maintaining an optimal dose of ribavirin (R). Two
therapeutic strategies were compared: use or non-use of EPO in chronic
hepatitis C patients treated with pegylated interferon alfa-2a (IFN) plus
R.
Methods: HCV genotype 1, 4 or 5 infected patients on combination
therapy (IFN 180mg weekly and R 1000–1200mg daily during 48 weeks
(W)) were included with a randomization 1:2 in two groups: A, non-use
of EPO and B, use of EPO (30,000 U/W) when blood concentration of
Hb was below 12 g/dL in men and 11 g/dL in women (anemia and ITT
population deﬁnition in this study).
Results: 227 patients were randomized (group A: N= 78 and group
B: N= 149). Mean age was 48.8±12.4 years and sex repartition (male/
female) was 61.0% and 39.0%. Distribution of HCV genotypes 1, 4, 5
was 81.9%, 15.5%, 2.6%, respectively. 17.2% of patients had cirrhosis.
Baseline mean haemoglobin level was 14.7±1.4 and 14.6±1.3 g/L and
baseline mean HCV RNA was 6.0±0.7 and 6.0±0.8 log10 IU/mL in
groups A and B, respectively. Among the overall population, 164 (ITT
population) presented anaemia (63 in group A and 101 in group B).
Globally, the rate of SVR was 52.0% (118/227). Considering the ITT
population, the proportion of patients with undetectable HCV RNA was
74.6% and 80.2% at W48, and was 52.4% and 57.4% at W72, in groups
A and B, respectively. The rate of relapse six months after the end of
treatment was 29.8% and 28.4% in groups A and B, respectively.
Conclusion: The SVR rate in the standard group (non use EPO) is
consistent with those of the literature in this population. In this pragmatic
trial, the EPO group shows an increased rate of SVR with a g-risk at
27%. Further analyses are in process to reﬁne these results.
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P1962 Clostridium difﬁcile in Dutch animals: presence,
characteristics and comparison with human isolates
M.G. Koene*, D. Mevius, J.A. Wagenaar, C. Harmanus, M.P. Hensgens,
E. Kuijper (Lelystad, Utrecht, Leiden, NL)
Objectives: The aim of this study was to determine the presence and
molecular diversity of Clostridium difﬁcile isolated from Dutch animals
and to examine the genetic relatedness by multi-locus variable number
of tandem repeats analysis (MLVA) with those causing human infections
in the Netherlands.
Methods: Stool samples from various animal species (dogs, cats, horses,
pigs, cattle, sheep, and poultry) were examined for the presence of
C. difﬁcile. Samples were collected from apparently healthy animals
at abattoirs (n = 400) and from diarrheic animals (n = 439) which were
obtained from two Dutch veterinary microbiologic diagnostic labs.
After heat shock treatment, stool samples were directly inoculated onto
selective agar media (CCFA and Braziers medium) as well as after
enrichment and incubated for 7 days at 37ºC. Conﬁrmation of C. difﬁcile
suspected colonies was done by PCR for the presence of glutamate
dehydrogenase gene. Isolates were characterized by PCR ribotyping
and tested for the presence of toxin genes encoding enterotoxin A
(tcdA), cytotoxin B (tcdB), binary toxin A (cdtA) and binary toxin B
(cdtB). Genetic relatedness of 70 isolates was examined by MLVA. For
ribotype 012 and 014, MLVA patterns of animal and human strains were
compared.
Results: The mean prevalence of C. difﬁcile in animal samples was
11.4%, ranging from 1.0% (dairy cattle) to 25.0% (dogs). Of all isolates,
53% were toxinogenic.
Among 96 animal isolates, a total of 22 different ribotypes were
identiﬁed, the majority of which were shared by human isolates. Among
the toxinogenic ribotypes found in animals, 014 was most common
(13.5%), followed by, ribotype 012 (10.4%), and 078 (9.4%).
Minimum spanning trees based on MLVA patterns show that the
distribution of C. difﬁcile ribotypes is associated with, but not restricted
to distinct animal species.
MLVA results from ribotypes 012 and 014 showed no genetic relatedness
between human versus animal isolates.
Conclusions: The distribution of C. difﬁcile PCR ribotypes follows a
host species association, although an overlap is seen among various
animal species and human isolates. The limited genetic relatedness found
by MLVA of human and animal ribotype 012 and 014 indicate that
zoonotic transmission of these types is unlikely to occur on an extensive
scale.
P1963 Validation of the time and temperature relationships of
HSG (95) 18, for an extended panel of multi-resistant
healthcare infection-associated bacteria
J. Holton*, N. Lakdawalla (London, UK)
Objective: There is little current evidence that the recommended time/
temperature relationships for laundry as given in UK HSG(95)18 is
efﬁcacious for organisms of particular current concern in nosocomial
infection. As the guidance is under review and will be published as
HTM 01−04 a study was undertaken to deﬁne the laundry conditions
that lead to decontamination of contaminated linen.
Methods: Swatches of uniform fabric and bed linen were artiﬁcially con-
taminated with 107 cfu/ml of MRSA; multi-resistant Acinetobacter and
Klebsiella, E. coli, vancomycin-resistant Enterococcus and Clostridium
difﬁcile (CD) spores. The swatches were contaminated with 2mls of the
organism suspended in PBS with 3.5% bovine serum albumin, dried at
room temperature. The swatches were laundered in an Electrolux FOM
71 machine with a Claris controlled system providing control of the time
and temperature of each wash cycle. The wash load was 5Kg. The only
variables were the temperature and wash cycle time and the presence or
absence of a commercial detergent. The following temp(ºC)/time(min)
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conditions were tested: 90/3: 71/3; 65/10; 50/10; 40/20; 40/10; 30/20
and 30/10. Post laundry the swatches were massaged for 15 minutes in
10mls of PBS. Total viable counts were performed and the agar plates
were incubated at aerobically at 37 C and anaerobically for CD.
Results: Our study indicates the mechanical action of washing alone,
without detergent, reduced the organisms by a factor of 102−3 At 40ºC
the organisms were generally reduced by a factor of 103−4, at 65ºC
for 10 minutes no organisms were isolated. The only exception to this
was Cl. difﬁcile where temperature and detergent had no additional
effect over and above the mechanical washing action. In the presence of
either a biological or non-biological detergent even at a low temperature
wash (30ºC for 10 minutes) the Gram positive bacteria were eliminated
from the material but the Gram negative bacteria were more difﬁcult to
remove.
Conclusions: The laundry cycle conditions of time and temperature
relationships as given in HSG (95) 18 are sufﬁcient to eliminate hospital
pathogens with the exception of Clostridium difﬁcile spores. However,
the low numbers of Cl. difﬁcile spores remaining on the linen are unlikely
to present a pathogenic risk to patients. The addition of a detergent
allows a low temperature wash to effectively remove staphylococci and
enterococci.
P1964 Survival of Clostridium difﬁcile on bed linen after
processing in a commercial continuous batch (tunnel)
washer according to HSG(95)18
N. Lakdawalla, R. Morris, J. Holton* (London, UK)
Objectives: Clostridium difﬁcile (CD) is a major healthcare associated
problem causing Cl. difﬁcile-associated diarrhoea (CDAC) or life-
threatening pseudomembranous colitis. Patients may be colonized by
toxigenic CD yet not have symptoms and may act as a source of infection
for others. Sheets from these patients will normally be laundered in CBW
as the laundry will not be categorized as foul or infected. Therefore, it is
necessary to assess the efﬁcacy of CBWs in removing CD spores. Our
objective was to determine if Clostridium difﬁcile could be detected on
bed linen following a commercial washing process in a CBW satisfying
HSG(95)18 (71ºC, 3 minutes) followed by a steam press. HSG(95)18
is soon to be replaced by new guidance in the form of HTM 01−04,
however, the cleaning conditions described here remain relevant to the
revised work.
Methods: Six patients were identiﬁed as having CDAD with diarrhoea
and a positive stool toxin test. Naturally-contaminated linen was marked
and processed through a CBW All wash experiments were carried
out using a 14-compartment Voss CBW operating to HSG(95)18
requirements. Washed product was dewatered (hydraulic press) and
passed through a tumbler (without heating) to break up the compacted
linen. Linen was then dried/ironed by passage through a Kannegiesser
machine using a series of rollers operating at ~135ºC with a single
passage time of ~20 seconds before being automatically folded. Six
marked sections were removed from each of the laundered sheets and
soaked in PBS for 15 minutes with agitation in a stomacher for 15
minutes. All of the eluant was ﬁltered and the ﬁlter incubated at 37ºC in
an anaerobic environment on Braziers medium for 48 hours. Colonies
from faeces and post laundry linen were ribotyped.
Results: Our results demonstrated that we could detect 101–103
CFU/100cm2 from the bed linen. The ribotype of the patients’ isolates
matched the ribotype isolated post laundry. In one case an additional
ribotype was isolated.
Conclusion: These results suggested that a standard industrial washing
process and subsequent steam ironing did not fully eradicate CD spores
from bed linen. The low numbers of spores are unlikely to present
a pathogenic risk to patients. These results also suggested that cross
contamination of laundry may occur during the laundry process.
P1965 Epidemiologic study of Clostridium difﬁcile culture positive
cases using repetitive-sequence based PCR ﬁngerprinting
and PCR-ribotyping in 3 tertiary care hospitals in Korea
from 2004 to 2010
B. Shin*, S. Mun (Seoul, KR)
Object: Clostridium difﬁcile is a common pathogen of health
care associated Clostridium difﬁcile infection (HA-CDI). Community
associated CDI (CA-CDI) seems to be increasing as well. Therefore,
we need DNA typing techniques which are more discriminatory to
differentiate the origin of strains and to control of spreading of
C. difﬁcile. Repetive-sequence based PCR ﬁngerprinting (rep-PCR) is
a typing technique that uses primers that target noncoding repetitive
sequences interspersed throughout the bacterial genome. Semi-automated
rep-PCR (DiversiLab, bio-Merieux) could offer good standardization and
useful discrimination power.
Method: We performed C. difﬁcile culture and compared rep-PCR with
PCR-ribotyping using 378 C. difﬁcile strains isolated in 3 tertiary care
hospital in Korea from 2004 to 2010. We also ampliﬁed tcdA, tcdB and
tcdC genes in 378 C. difﬁcile strains.
Results: The number of tcdA+tcdB+, tcdA−tcdB+ and tcdA−tcdB−
strains were 246, 95 and 37. Among them, 20 (5.3%) tcd C negative
strains were found and 4 of them were tcdA−tcdB+ strains. In
tcdA+tcdB+, tcdA−tcdB+ and tcdA−tcdB− strains, 37, 10 and 15
patterns were identiﬁed with rep-PCR method and 11, 2 and 8 patterns
with PCR-ribotyping, respectively. We observed strain shift among
2004–2005 and 2009–2010 C. difﬁcile strains. Ribotype KS1 and KS2
were the major ribotype, but KS2 and KS3 were the major in 2009–
2010. There were common strains among 3 hospitals (KS2 and KS 4, 6
and 8).
Conclusion: We found C. difﬁcile strain shift from 2004/2005 to
2009/2010 and common strains distributied among 3 hospitals. This
results suggested that several major strains are distributed and major
strain shift were occured during 5 years in Korea. More diverse
patterns were observed in rep-PCR than in PCR-ribotyping and most
of tcdA−tcdB+ strains (97%) showed same pattern (PCR-ribotype 017)
in PCR-ribotype but more diverse patterns in rep-PCR, which could
be useful with the infection control in tcdA−tcdB+ strain prevalent
areas. This suggested rep-PCR is a reliable and valuable tool for the
discrimination and delineation of C. difﬁcile strains.
P1966 Molecular epidemiology of Clostridium difﬁcile at a
medical centre in Taiwan: an increasing prevalence of
toxin A-positive and toxin B-positive strains
J.H. Chia*, T.L. Wu, H.C. Lai, L. Su, A.J. Kuo, C.F. Sun (Taoyuan, TW)
Objectives: The incidence and severity of Clostridium difﬁcile infections
have been alarmingly increasing over the recent years world-widely.
However, the recent situation of C. difﬁcile infection in Taiwan was
not systematically studied. In the present study, we investigated the
prevalence of C. difﬁcile infection at Chang Gung Memorial Hospital
(CGMH), a 4,000-bed medical center in Taiwan. The genetic relatedness
and the antimicrobial susceptibility to metronidazole and vancomycin
were also examined.
Methods: A total of 181 non-repeat C. difﬁcile isolates were collected
at CGMH during 2002 and 2007. The presence of toxin genes (tcdA,
tcdB, cdtA and cdtB) was determined by PCR. Further characterization
of the toxigenic strains included antimicrobial susuceptibility testing by
the standard agar dilution method, genotyping by multilocus variable-
number tandem-repeat analysis (MLVA) and multilocus sequence typing,
tcdC genotyping by PCR and DNA sequencing, and toxinotyping by PCR
and restriction-fragment-length polymorphisms.
Results: The isolation rate of C. difﬁcile strains from stool samples
increased from 3% in the year 2002 to 11% in 2007, with an average
of 10%. Toxin gene was identiﬁed in 110 (60.8%) isolates, including
70 (38.7%) toxin A-positive/toxin B-positive (A+B+) and 40 (22.1%)
toxin A-negative/toxin B-positive (A-B+). The annual prevalence rate of
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the A+B+ strains increased signiﬁcantly over the study period (p< 0.05).
A total of 72 different genotypes were identiﬁed by MLVA and 24 isolates
(21.8%) formed a major cluster 1, varied by less than one allele. The
24 isolates were all A-B+ strains, toxinotype VIII/tcdC-sc7, sequence
type ST-45. Two isolates were found to be metronidazole-resistant and
were genetically related A+B+ strains. Another four were vancomycin-
resistant and two of them belonged to the major cluster 1 A-B+ strains.
Conclusion: C. difﬁcile infections are increasing in Taiwan, accom-
panied with the persistence of a MLVA cluster 1, A-B+ strains and
signiﬁcantly increased in A+B+ strains. Moreover, strains resistant to
metronidazole or vancomycin start to emerge. Continuous surveillance
is warranted to monitor the C. difﬁcile infections, especially among the
hospitalized patients.
P1967 Surveillance analysis of C. difﬁcile genotyps demonstrates
decreasing frequencies of 027 infections in a tertiary care
hospital
L. von Mu¨ller*, K. Speck, M. Herrmann (Homburg/Saar, DE)
Objective: Clostridium difﬁcile infections (CDI) have become an
emerging hazard in hospitals and also in the community. Since 2007
infections with a new “highly virulent” strain identiﬁed as ribotype 027,
toxinotyp III, PFGE NAP1 have been reported. New 027 outbreak strains
are characterised by Toxin A, B and binary toxin expression, mutations of
a potential toxin repressor gene (tcdC), and increased toxin production
in vitro. Severe infections with pandemic 027 strains were identiﬁed
in Germany for the ﬁrst time in 2007. Single locus sequence typing of
surface layer protein A (slpAST) is a new standardized method for typing
of C. difﬁcile outbreak strains which allows comprehensive identiﬁcation
of various outbreaks strains which is important for follow-up studies.
Methods: The University of Saarland Hospital is a 1300-bed (150 ICU-
beds) tertiary care facility. Consecutive C. difﬁcile isolates (n = 666) of
431 adult patients with diarrhoea were propagated by standard anaerobic
stool cultures using CCFA media (CLO-Agar). SlpAST was analyzed
as previously described (Kato et al., JMM 2005). The sequence data
were analysed by BLAST search and also by sequence alignment with a
growing institutional database. In the present single centre retrospective
study the appearance of different C. difﬁcile genotypes was analyzed
between March 2008 and June 2010.
Results: Fluctuating numbers of CDI were found without seasonal
clusters (Table 1). At the initial phase of follow-up (October 2008 and
June 2009) high numbers of 027 positive patients were identiﬁed in
our institution (up to 50%). The severe infections were found both in
groups with 027 and with other C. difﬁcile genotypes. Since July the
frequency of 027 is decreasing with signiﬁcant differences between the
plateau phase in 2008/2009 and the consecutive replacement phase in
2009/2010 (Fisher’s exact test).
Conclusion: 027 is a pandemic strain with fast worldwide spreading
and severe outbreaks. However, we could demonstrate in the present
single centre surveillance study that the frequency of infections may
also rapidly decrease again over time. Presumably also the morbidity
due to infections with epidemic outbreak strains may change. Changing
epidemiology of 027 reminds us to be aware of new C. difﬁcile outbreaks
requiring regular C. difﬁcile surveillance to early identify emerging
genotypes. A similar replacement of 027 by other strains was also found
in the Netherlands.
P1968 Clostridium difﬁcile recurrence, alcohol consumption, and
the effect of ﬁdaxomicin vs vancomycin
Y. Golan*, T. Louie, K. Weiss, K. Mullane, Y. Kean, A. Lentnek,
S. Gorbach, M. Miller (Boston, US; Calgary, Montreal, CA; Chicago,
San Diego, Georgia, US)
Objectives: Despite of successful therapy of the initial episode of
Clostridium difﬁcile infection (CDI), recurrence rates remain high and
represent a major unmet need in the management of CDI. While the
effect of alcoholism on the gut ﬂora is not well studied, alcohol abuse
(AA) may increase the risk of CDR. We examined the role of AA in
CDR.
Methods: We used data from 2 large, randomized phase 3 clinical trials
in which adults with CDI symptoms and a positive toxin test received
oral ﬁdaxomicin or vancomycin for 10 days. AA was deﬁned as the
regular consumption of >2 alcoholic drinks a day (>30g/day). CDR was
deﬁned as the reappearance of diarrhea and a positive stool toxin test
within 1 month following completion of therapy. Risk factors for CDR,
identiﬁed using univariate analyses, were used in a multivariate analysis
to adjust the effect of AA on CDR.
Results: Of the total of 737 patients in the per protocol population
who were cured of the initial CDI episode and had information on
alcohol consumption, 54 (7%) reported AA and 150 had CDR (19%).
CDI severity was similar among those with AA (57% with moderate or
severe CDI) and those without AA (66%). AA was associated with a
higher rate of overall CDR (32% vs 18%; p 0.015), and particularly early
CDR (days 1−15 of followup) (26% vs 13%; 0.008). Highest CDR was
observed among those who: are older than 64 years (AA: 41%, no AA:
20%; 0.015), infected by a none-BI/NAP1 strain (35% vs 12%; 0.002),
or had a prior CDI episode (AA: 40% vs 26%; 0.483). In multivariate
analysis, after adjustment for CDI treatment, albumin level, age, CDI
type, prior CDI occurrence, kidney disfunction and receipt of antibiotics
during the followup period, AA remained independently associated with
high CDI recurrence (adjusted OR 2.2, 96% CI 1.1−4.5). Compared
to vancomycin, ﬁdaxomicin therapy was associated with lower rates of
overall CDR (13% vs 25%; <0.001), CDR among those with and without
AA, and particularly, early CDR (AA: ﬁdaxomicin 10%, vancomycin
35%; 0.05, no AA: 6% vs 19%; <0.001).
Conclusion: Independent of other risk factors, AA is associated with
increased risk of CDR. Recurrence rates are especially high among
those with AA and other risk factors for CDR. Fidaxomicin therapy
is associated with a substantially lower rate of CDR regardless of AA.
P1969 Molecular epidemiology of Clostridium difﬁcile and
prevalence of the NAP-1 strain among patients admitted
to a general and a private hospital in Houston, Texas, USA
W. Santimaleeworagun*, J. Christensen, V. Singh, D. Shah, K.T. Chang,
V. Tam, K. Garey (Nakhon Pathom, TH; Houston, US)
Objective: To study the clonal relationships of Clostridium difﬁcile at
two neighboring hospitals and to investigate the prevalence of NAP-1
producing strains among these hospitals.
Material and Method: Repetitive extragenic palindromic sequence-
based PCR (rep-PCR) was performed on clinical C. difﬁcile isolates
cultured on CCFA from patients admitted to a private and public hospital
in the Texas Medical Center, Houston TX during January-November
2010. C. difﬁcile extracted DNA was ampliﬁed using a commercially
available typing Clostridium kit and web-based software (DiversiLab
version 3.4). A clonal strain was deﬁned as 90% similarity on the
dendogram.
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Results: Sixty-ﬁve clinical isolates were identiﬁed from the private
(n = 43) and public (n = 22) hospitals. At the private hospital, 32 different
REP-PCR patterns were identiﬁed among 43 clinical isolates and 19
different REP-PCR patterns were identiﬁed among 22 clinical isolates
at the public hospital. No single unique strain accounted for more than
10% of isolates at either hospital although 6 REP-PCR patterns from 14
isolates were identiﬁed at both hospitals. Eleven of 65 (17%) isolates
were a known toxinotype or PFGE pattern. Three of 65 (4.6%) isolates
were identiﬁed as the NAP-1 strain.
Conclusions: There was no evidence of a clonal epidemic strain at
these two hospitals although a number of C. difﬁcile strains were present
at both hospitals. These results could have signiﬁcant implications for
community-wide infection control measures to control CDI.
P1970 C. difﬁcile in patients with chronic heart failure
N.A. Bylova*, G.P. Arutyunov, L.I. Kafarskaya (Moscow, RU)
Patients with III-IV functional classes (FC) of chronic heart failure
(CHF) are usually hospitalized for pneumonia or pyelonephritis. This
group of patients commonly has 3 or more hospitalizations a year. In
all cases they receive a lot of different classes of antibiotics. It is well
known, that in case of treating with antibiotics we risk with growth
of Clostridium difﬁcile, which associated with a very poor prognosis.
Now, from literature we know that usually patients with co-morbidity,
who receive antibiotics, develop clostridial infection without morphology
changes corresponded to pseudomembranous colitis.
Aim: Analysis of changes of large intestinal microﬂora in patients with
III-IV FC of CHF hospitalized due to decompensation of heart failure.
Methods: Eighty-four patients with decompensation of III-IV FC CHF
of ischemic genesis (group 1) were enrolled in study. All of included
patients have more then 3 hospitalizations in previous 12 month. Also
forty patients with I-II FC of CHF (group 2) were included into the study.
All patients underwent of EF (echoCG); measurement of blood CRP
(EIA); endotoxin (LAL); faeces plating on growth media; colonoscopy
with cecal biopsy and sample plating on growth media.
Results: Patients of group 1 showed a signiﬁcant (p< 0.05) increase in
total number of enterobacteria (1010 CFU/g) as compared to the control
group (10 CFU/g). The pool of enterobacteria grew primarily due to
growth of E. coli, Klebsiella spp., citrate-assimilating enterobacteria
and citrobacters. Total number of Clostridium difﬁcile also were
signiﬁcantly increase in group 1 (107 CFU/g) as compared to the control
group (105 CFU/g), p< 0.05. Comparison of the cavity and parietal
microﬂora did not reveal signiﬁcant differences. Analyses of blood from
patients with III-IV FC CHF revealed signiﬁcantly (p< 0.05) higher
levels of endotoxin (LAL test) (1.2±0.02 EU/ml) and CRP (9.02±0.2
U/l), then in patients with I-II FC CHF: 0.46±0.02 EU/ml and in
healthy volunteers − 0.4±0.01 EU/ml; CRP levels were 2.9±0.11 and
2.2±0.09 U/l, respectively. Results of endoscopes show no sings of
pseudomembranous colitis.
Conclusions: The revealed alterations indicate the presence not only of
high levels of Gram-negative ﬂora in the large intestine of patients with
III-IV FC CHF, but also high levels of Clostridium difﬁcile, that may
cause a poor prognosis of these patients.
P1971 Demographic and clinical characteristics of patients with
Clostridium difﬁcile associated diarrhoea: a retrospective
study
B. Chazan*, N. Teitler, H. Edelstein, R. Raz (Afula, IL)
Background: Clostridium difﬁcile (CD) is responsible for up to 30% of
cases of diarrhea occurring after antibiotic (AB) treatment: Clostridium
difﬁcile associated diarrhea (CDAD). CD is the leading cause of hospital
acquired diarrhea (HA-CDAD), although recently there were reports
on an increased incidence of community acquired cases (CA-CDAD).
Studies aimed to detect risk factors for the development of CDAD
founded in addition to AB use, antiacids and chemotherapy treatment,
together with inﬂammatory bowel disease (IBD).
Objectives:
1. Identify risk factors for development of CA and HA-CDAD.
2. Compare clinical and demographic characteristics, of both groups.
3. Examine the rate of acquisition of CDAD during hospitalization.
Methods: All pts with positive CD tests in stool samples identiﬁed
at Ha’Emek Medical Centre between 1/1/2008 and 31/12/2009 were
included.
Demographic and clinical data (age, commorbidities, prior AB use,
hospitalization, 30 days mortality) were obtained from hospital and
community electronic medical records.
Pts were classiﬁed by acquisition place:
– CA-CDAD: pts without hospitalization within prior month.
– HA-CDAD: pts developing diarrhea 48 hours from admission until a
month after discharge.
Results: From 1/1/2008 to 31/12 2009, 1101 fecal samples were sent
to the microbiology lab; 115 (10.4%) were positive to CD toxin. Fifty
ﬁve (55.7%) were HA-CDAD (0.065/100 admissions) and 40 (44.3%)
CA-CDAD. Pts with HA-CDAD were older than those with CA-CDAD
(65.13 vs. 51.5y, p< 0.0006). Moreover, bed ridden pts had HA-CDAD
more frequently than CA-CDAD (35 vs. 19, p< 0.001). Fifteen pts
with HA-CDAD had a nasogastric feedeing tube (24.6%), but none of
those with CA-CDAD (p< 0.0001). Twenty two pts (19%) suffered from
IBD, 16 of them (72.7%) CA-CDAD and only 6 (27.3%) HA-CDAD
(p< 0.007). More pts in the HA-CDAD group received AB treatment
in the prior 3 months than pts in the CA-CDAD group (77.1% vs.
51.9%, p< 0.005). Mortality (30 days) was higher in the HA-CDAD
group (19.7%) than in the CA-CDAD group (5.6%; p< 0.02).
Conclusions:
1. Risk factors for HA-CDAD: age, bed ridden pts, feeding by
nasogastric tube and previous AB treatment.
2. Risk factors for CA-CDAD: IBD and previous AB treatment.
3. Higher mortality rate was found in HA-CDAD
4. About half of the cases were CD-CDAD. Community health teams
have to be aware of these ﬁndings.
5. IBD is a common commorbiﬁty in CA-CDAD. Diarrhea in these pts
could be miss-interpreted as a ﬂare-up of the disease.
P1972 Detection of Clostridium difﬁcile PCR ribotype 027 from
hospitalised patients in Sydney, Australia
P.G. Huntington*, A.A. Darbar, G. Kotsiou (St Leonards, AU)
Objectives: Clostridium difﬁcile is an anaerobic Gram positive rod
that is a recognised cause of antimicrobial-associated diarrhoea and
pseudomembranous colitis. Hypervirulent strains of C. difﬁcile with
deletions in the tcdC gene have been responsible for outbreaks in USA,
Canada and UK marked by severe disease and increased mortality.
C. difﬁcile BI/NAP1/027 was ﬁrst reported in Australia in Victoria in
2008 in a returned traveller. Further cases of hypervirulent C. difﬁcile
were reported in Victoria during 2010. There have been no previous
cases of C. difﬁcile 027 reported in New South Wales, Australia.
Methods: From March 2009 to December 2010 all faeces at Paciﬁc
Laboratory Medicine Services that requested C. difﬁcile were cultured
directly onto selective agar plates and incubated anaerobically for 48
hours. Plates were examined for growth of C. difﬁcile and isolates
were collected and stored frozen at −80ºC until required. Isolates
were characterised by PCR ribotyping using previously published
methods and capillary electrophoresis of PCR products. Electrophoresis
patterns were compared to known strains of C. difﬁcile ribotype 027.
Isolates of ribotype 027 were examined for deletions in the tcdC
gene by sequencing. Moxiﬂoxacin minimal inhibitory concentration was
determined by Etest.
Results: Of 413 isolates available for study, 22 were determined to be
ribotype 027. All 22 of these isolates showed an 18 bp deletion at position
330 in the tcdC gene and a single bp deletion at position 117. All ribotype
027 isolates also had moxiﬂoxacin MIC >32mg/mL. The 027 isolates
were obtained from 21 different patients across four different public
healthcare facilities during the 22 month period. The mean age of the
patients with ribotype 027 was 82 years old. Infection with C. difﬁcile
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ribotype 027 was associated with seven cases of colitis, including one
episode of toxic megacolon, but none of the cases required surgical
intervention. There was one ICU admission and two deaths, which may
have been related to the C. difﬁcile infection.
Conclusions: We report the ﬁrst cases of infection with C. difﬁcile
ribotype 027 in public healthcare facilities in Sydney, Australia.
Although hypervirulent C. difﬁcile has been associated with outbreaks
and increased mortality elsewhere in the world this has not yet been
reported in Sydney. The cases identiﬁed in this study suggest C. difﬁcile
ribotype 027 is probably already endemic in these facilities.
P1973 Microbial factors in recurrent Clostridium difﬁcile infections
in Stockholm, 2010
A. Weintraub, C. Jorup-Ro¨nstro¨m, S. Sandell, K. Ellstro¨m, M. Rashid,
Y. Chen, C.E. Nord* (Stockholm, SE)
Objectives: Clostridium difﬁcile is the major cause of nosocomial
diarrhoeal diseases in elderly patients after treatment with antimicrobial
agents. About 20% of the patients develop a recurrent infection after
the primary episode. The aim of this study was to investigate microbial
factors that may contribute to the recurrences of C. difﬁcile infection
(CDI).
Methods: Thirty-ﬁve patients with a primary CDI were enrolled in
this study. Faecal samples were collected at 1, 2, 4, 6 and 12 months
after the primary infection and analysed for the presence of C. difﬁcile
and toxin B. All isolates were investigated by PCR-ribotyping and
antimicrobial susceptibility.
Results: The mean age of the 35 patients was 74 years and 20 were
females and 15 males. Five of the patients died during the follow-
up period due to underlying diseases not directly attributed to CDI.
Seven patients harboured the same PCR-ribotype of C. difﬁcile up to
6 months after the initial episode without diarrhoea. However, from
four patients a new C. difﬁcile PCR-ribotype was isolated after a period
of negative samples. Patient 1 changed the ribotype from 001 to 020;
patient 2 changed from 014 to 026; patient 3 changed from 014 to
SE36, and patient 4 changed from 014 to 020 and then to 023. Four
patients had PCR-ribotype 078 in their initial samples and the same
isolate was also found in samples 2−4 months after the primary episode.
No PCR-ribotype 027 was found in any samples. Fifty-eight isolates
were analysed for antimicrobial susceptibility. All isolates were sensitive
to metronidazole, vancomycin, tigecycline, fusidic acid, linezolid and
ﬁdaxomicin. Two isolates were resistant to moxiﬂoxacin, tetracycline and
rifampicin. Eighteen C. difﬁcile isolates were resistant to clindamycin.
Conclusion: Among the 35 patients enrolled in this study, 11 were
positive for C. difﬁcile after the initial episode. During the study
period, 4/35 (11%) changed the PCR-ribotype. These patients were re-
infected with an other C. difﬁcile ribotype. The 078 PCR-ribotype was
isolated from four patients. No PCR-ribotype 027 was detected in any
samples. All tested strains were sensitive to metronidazole, vancomycin,
tigecycline, fusidic acid, linezolid and ﬁdaxomicin and 18 strains (30%)
were resistant to clindamycin.
P1974 Retrospective study of the epidemiology of Clostridium difﬁ-
cile infection in a district general hospital in United Kingdom
N. Virgincar*, S. Iyer, L. Downing, A. Stacey (Reading, UK)
Objective: Prevention and control of Clostridium difﬁcile infections
(CDI) is one of the key objectives for hospital infection and control
teams. A retrospective study was undertaken from April to June 2010 to
ascertain the local epidemiology in our health economy with the aim of
improving further management of patients with CDI.
Method: The study was undertaken in a 750-bed large acute NHS trust.
Patients with CDI were identiﬁed by the microbiology department using
our local 3-step CDI testing protocol. Patient demographic data, previous
admission and mortality data were obtained from laboratory reporting
system and hospital patient administration system. Data analysis was
undertaken using Excel. Laboratory conﬁrmed specimen taken up to
two days after the day of admission were attributed to the community.
Forty two positive stool samples from clinical areas with two or more
new cases of CDI in a 28-day period were sent to regional microbiology
laboratory for ribotyping.
Results: From April to June 2010, 89 CDI cases were identiﬁed. 56
were community acquired and 33 hospital acquired. Of the community
acquired ones, in 13/56 patient specimens were taken up to 2 days after
admission to the acute trust and remaining in the community setting.
25/89 (28%) patients were 45 years of age. In 8/89 (9%) of patients
we found a second enteric pathogen in addition to C. difﬁcile. Speciality
distribution of 46 cases who were in the hospital at the time of diagnosis
of CDI found that 22/46 (47.8%) of cases belonged to elderly care and
renal medicine.
Admission data showed that 6/13 (46%) patients who had specimen taken
up to 2 days after the day of admission to the acute trust, 10/33 (30%)
hospital acquired and 7/43 (16%) patients who had specimens taken in
community setting had been in-patients in the acute trust within 30 days
prior to the admission when CDI was diagnosed. 13/46 (28%) cases who
were in the hospital at the time of diagnosis of CDI died within 30 days
of diagnosis. 42/89 isolates were ribotyped, 17/42 (40%) and 8/42 (19%)
belonged to sporadic and 014 ribotypes respectively.
Conclusion: Although CDI is seen more in the elderly patients, we found
25/89 (28%) of our patients were 45 years of age. The crude 30 day
mortality rate of hospitalised patients with CDI was 28%. 23/89 (25.8%)
of CDI positive patients had been in-patients in the acute hospital 30 days
prior to developing CDI.
P1975 Molecular characterisation and antimicrobial susceptibility
in clinical isolates of Clostridium difﬁcile in a university
hospital, Split, Croatia
A. Novak*, P. Spigaglia, M. Tonkic, I. Goic Barisic, F. Barbanti,
V. Punda-Polic (Split, HR; Rome, IT)
Objective: Clostridium difﬁcile is the leading cause of nosocomial
diarrhoea. However, data on C. difﬁcile infection (CDI) in Croatia are
still scarce.
The aim of this study was to perform a phenotypic and molecular
characterization of toxigenic clinical isolates collected over six months.
Methods: The period of study was between January and June 2010. A
total of 97 faecal speciments from patients suspected of having CDI were
submitted to the laboratory and tested for C. difﬁcile toxins A and B by
Immunocard Toxins A/B, Meridian. All toxigenic samples were cultured
on commercial selective C. difﬁcile agar plates (CLO; bioMe´rieux) after
alcohol shock. Strains were identiﬁed according to cultural morphology
and conﬁrmed as C. difﬁcile by commercial biochemical identiﬁcation
system (RapID ANA; bioMe´rieux and Vitec 2 Compact ANA Card;
bioMe´rieux).
MIC values for moxiﬂoxacin (MX), ciproﬂoxacin (CI), gatiﬂoxacin
(GA), levoﬂoxacin (LE), erythromycin (EM), clindamycin (CM),
meropenem (MEM), metronidazole (MZ), vancomycin (VA) and
piperacillin/tazobactam (PTc) were determined by E test (AB biodisk) on
Brucella agar plates containing vitamin K, haemin and 5% deﬁbrinated
sheep red blood cells, according to the manufacturer’s instructions.
Isolates were characterized by PCR-ribotyping using the method of Bidet
et al. (FEMS Microbiol. Lett. 1999. 175: 261–266). DNA ﬁngerprinting
patterns produced by PCR-ribotyping were compared to a collection of
the predominant PCR-ribotypes circulating in Europe (gently provided
by ECDC).
Results: Among tested samples, 13.4% were toxins positive and 13
C. difﬁcile strains were isolated. All isolates were susceptible to MZ,
VA, MEM and PTc. One strain exhibited multiresistance (MR) to EM,
CM and to all tested ﬂuoroquinolones. Six strains were resistant and one
was intermediate to CI. Five strains were intermediate to LE.
The strains belonged to 8 different PCR ribotypes. Two strains were
ribotype 003, two ribotype 012, one ribotype 150, while eight strains
showed a pattern not comparable with the reference strains (including
the MR strain).
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Conclusion: The ﬁrst characterization of C. difﬁcile in South Croatia
shows the presence of an heterogeneous population and high resistance
to ﬂuoroquinolones. We found no clear association between antimicrobial
proﬁles and ribotyping. Further studies of incidence of CDI including
patients clinical data and antibiotic usage data in the hospital wards are
warranted.
P1976 Risk factors for recurrence of Clostridium difﬁcile infection:
impact of stool vancomycin-resistant enterococci colonisation
H.K. Choi*, S.J. Lee, K. Kim, S.H. Lee, Y.S. Park (Yangsan, Busan,
Ilsan, KR)
Objectives: Recurrent Clostridium difﬁcile infection (CDI) is one of the
most difﬁcult problems in healthcare infection control. We evaluated the
risk factors associated with recurrence in patients with CDI.
Methods: A retrospective cohort study was performed at Pusan
National University Yangsan Hospital from December 2008 through
October 2010. Variables associated with clinical ﬁndings, treatment and
laboratory ﬁndings were analyzed to identify risk factors related to CDI
recurrence.
Results: A total of 84 patients were included in this study. Recurrence
occurred 14.1% (11) cases. Stool vancomycin-resistant enterococci
(VRE) colonization (p = 0.006), number of exposed antibiotics 3
(p = 0.009), continued use of previous antibiotics (p = 0.05) and lower
hemoglobin level (p = 0.025) were more frequent in recurrent group.
On multivariate analysis, stool VRE colonization was independently
associated with recurrence of CDI (OR 14.519, 95%CI 1.157–182.229,
P = 0.038).
Conclusion: These data suggest that stool VRE colonization is a
signiﬁcant risk factor for CDI recurrence. Preventing the initial
acquisition of VRE and C. difﬁcile, both in terms of VRE and CDI
control, should be emphasized.
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P1977 Analytical comparison of the BD GenOhm Cdiff assay to
the Ridascreen C. difﬁcile toxin A/B ELISA for detection
of C. difﬁcile associated disease
I. Mu¨ller*, O. Coste, K. Schmidt, K.P. Hunfeld (Frankfurt/Main, DE)
Rapid detection of toxin producing Clostridium difﬁcile is essential
in CDAD patients. This study compares the performance of a new
PCR assay (BD GenOHM Cdiff Assay) and a conventional ELISA
(Ridascreen C. difﬁcile Toxin A/B) for rapid detection of toxin-producing
C. difﬁcile strains directly from stool.
531 stool samples obtained from 411 patients with suspected CDAD
from a single centre were analysed by real-time PCR and ELISA. Only
samples in accordance with the criteria for diarrheal stool (Bristol Score)
were eligible for the study. Anaerobic cultures were also performed
(George’s agar). The study was approved by the institutional review
board.
Using the ELISA as an analytical gold standard PCR yielded 106
concordant positive results (93,8%) and 352 concordant negative results
(84,2%). In 73 stool samples both assays showed discrepant results.
Including culture results into the discrepant analysis, PCR resulted in 165
(31,1%) true positives and 359 (67,1%) true negatives. One false positive
and 7 false negative PCR tests were observed yielding an analytical
sensitivity and speciﬁcity of 99,4 respective 98,1% compared to 64,5%
and 98,4% for the ELISA. Positive and negative predictive values for
PCR testing were 95,9% and 99,7%, respectively.
Although, studies dealing with cost effectiveness of PCR in the
management of CDAD patients are sparse, the BD GenOhm Cdiff assay
(PCR) has greater analytical sensitivity than a conventional toxin ELISA
maintaining comparable speciﬁcity in samples from CADA patients.
P1978 Development of a multiplexed LATE-PCR assay for
Clostridium difﬁcile identiﬁcation and characterisation
S. Goldenberg*, K. Pierce, H. Khan, R. Mistry, J. Lewington,
L. Wangh, G. French (London, UK; Waltham, US; Watford, UK)
Objectives: Clostridium difﬁcile (Cd) causes signiﬁcant morbidity &
mortality and its prevalence/severity has increased recently. This is
partly due to emergence of virulent strains which have potential to
spread rapidly causing outbreaks. Many laboratories use toxin Enzyme
Immunoassay for laboratory detection, however these are suboptimal.
Cell Cytotoxin Neutralisation is the gold standard but can take up to 72
hours and is labour intensive. Thus there is a need for a rapid, highly
sensitive/speciﬁc test that can detect Cd and identify potential clusters of
cases. LATE-PCR (Linear After The Exponential-PCR) is a molecular
method that can meet these requirements.
Methods: We have developed a multiplexed LATE-PCR assay for
Cd to be run on the Clinical Bio-Seeq® System, a Point-of-Care
(POC) PCR platform that provides “sample in, answer out” capability.
LATE-PCR is an advanced form of asymmetric PCR which is able
to give greater levels of multiplexing, strain level discrimination with
Mismatch Tolerant Probes, and quantitative endpoint detection. Single-
stranded PCR products from LATE-PCR allow probe hybridization at
endpoint, including at temperatures well below that used for primer
annealing. Probes are designed to bind at different temperatures
providing multiplex detection based on temperature, as well as colour.
Strain level discrimination can be achieved at each site using a single
probe which hybridises to target sequence with greater nucleotide
mismatches as the temperature is lowered.
Results: The assay has been tested on >300 clinical isolates of Cd
with a high degree of reproducibility. There was complete agreement
with resulted obtained for LATE-PCR targets and traditional PCR
using previously published primers. The assay is able to simultaneously
identify genes for toxins A, B and binary and distinguish >8 tcdC
variants. The assay has high speciﬁcity against non-Cd gastrointestinal
commensals and pathogens.
Conclusion: The test is highly sensitive and speciﬁc for tcdB (toxin B)
and can identify tcdA (toxin A) and cdtB (binary toxin), and
characterise strains according to multiple tcdC alleles. These additional
virulence factors may be associated with increased disease severity.
Strain characterisation may also aid epidemiological monitoring and
rapid identiﬁcation of transmission between patients. This information
can direct clinicians and infection prevention staff in the optimal
management of patients and rapid termination of outbreaks.
P1979 Development of a novel multiplexed molecular assay
for detection of the tcdA and tcdB genes in pathogenic
Clostridium difﬁcile using room temperature stable reagents
N. Nasser*, H. Liang, V. Armendarez, T. Ott, T. Pack, R. Lollar,
T. Ranalli, T. Stenzel (San Diego, US)
Background and Objectives: Cytotoxic C. difﬁcile is a Gram-positive,
anaerobic, spore forming bacillus capable of producing Clostridium
difﬁcile associated diarrhea (CDAD), or pseudomembranous colitis.
These symptoms are the result of the presence of either one or both
of two related cytotoxins − toxin A and toxin B. The genes for toxin A
and toxin B (tcdA and tcdB, respectively) are located together within
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the Pathogen Locus, or PaLoc. The presence or absence of the PaLoc,
therefore relates to the organism’s toxicity status.
Within those strains that contain a pathogen locus, there are signiﬁcant
genetic differences including point mutations, frame shifts, insertions
and several hundred base pair deletions. Of these genetic differences,
large deletions in tcdA are the most signiﬁcant as there is no functional
or antigenic toxin A expressed. Genetic variation occurs widely in the
tcdB gene as well, making it less suited for detection using standard
molecular techniques, requiring a high level of base pair concordance
for best performance.
Herein, we describe the initial studies performed with these newly
developed molecular reagents on both the Applied Biosystems® 7500
FastDx and the Cepheid® SmartCycler.
Methods and Results: To mitigate the risk of not detecting a cytotoxic
strain of C. difﬁcile, we describe here a two target approach for
C. difﬁcile detection using highly speciﬁc PCR primers and standard
Taqman® based chemistries. Our approach, the AmpliVue® C. difﬁcile
test, yields an assay with convenient, simpliﬁed workﬂow and room
temperature stable reagents. Testing on cultured isolates of 7 different
toxigenic C. difﬁcile strains, including the hypervirulent NAP-01 strain,
demonstrated that the assay is able to detect all toxinotypes tested (0, III,
IV, V, VIII, X, XXIII). Testing with non-pathogenic strains of C. difﬁcile
shows that the test does not amplify either the tcdA or tcdB target
sequences from non-toxigenic strains. Nucleic acid from representative
stool micro-organisms does not cross-react with the C. difﬁcile primers.
An LoD of 5 copies per reaction was measured in a variety of cultured
strains including 13682 and 9689. Clinical evaluation of this assay is
currently underway.
Conclusion: Our data indicate that the AmpliVue C. difﬁcile test is a
simple and speciﬁc molecular assay for detection of toxigenic C. difﬁcile.
P1980 Development of a rapid and simple isothermal molecular
assay for the qualitative detection of Clostridium difﬁcile
from faecal specimens in a non-instrumented platform with
room temperature stable reagents
W. Tang, M. Wilson, K. McCarthy, T. Pack, N. Nasser, T. Ranalli*,
R. Lollar, H. Kong, T. Stenzel (Beverly, San Diego, US)
Background and Objective: Clostridium difﬁcile (C.diff) is a Gram-
positive, anaerobic, spore-forming bacillus that produces two major
toxins, toxin A and toxin B, resulting in C. difﬁcile associated disease
(CDAD) which generates severe diarrhea and may lead to complications
such as toxic megacolon and death. Traditional methods that are currently
employed to diagnose CDAD include: cytotoxic cell culture, lateral ﬂow
assays, and enzyme immunoassays, however, the sensitivity of these tests
remains quite low, rendering them less useful diagnostically. Herein we
describe the development of a sensitive and speciﬁc molecular assay
for the detection of pathogenic C. difﬁcile using a novel isothermal
instrument-free platform with only two pipetting steps.
Methods and Results: Helicase dependent ampliﬁcation (HDA) is an
isothermal nucleic acid ampliﬁcation platform that utilizes a helicase
to separate strands of DNA or RNA, rather than heat, allowing for
efﬁcient ampliﬁcation of speciﬁc targets in the absence of thermocycling.
The C. difﬁcile assay combines HDA with a disposable self-contained
detection device (BESt™ cassette) that allows for the rapid detection of
labeled amplicons generated by primers and probes speciﬁc for a region
present in the tcd A gene found in all toxigenic strains of C.diff. A
swab from a patient sample is placed into a dilution tube, brieﬂy heated
to lyse the cells, and then transferred to a reaction tube containing the
lyophilized HDA reagents. The sample is then incubated in a heat block
at 64ºC for 45 minutes and transferred to the BESt™ cassette wherein
the result is read via a lateral ﬂow strip. The entire assay is performed in
less than 1.5hrs and can be performed “on-demand” without the need for
batching of samples. Initial analytical sensitivity testing has determined
that the C.diff assay can detect down to 20 copies of genomic DNA, does
not cross-react with any non-C.diff organisms that have been evaluated
(11/11), and is capable of detecting 6/6 of the toxinotypes. A preliminary
clinical study performed with previously frozen samples has found that
the assay correctly identiﬁed 9/9 positive samples and 10/10 negative
samples.
Conclusion: The HDA-based assay for the qualitative detection of
C. difﬁcile is a simple and sensitive assay that can be performed in a wide
variety of hospital settings without the need for costly instrumentation.
P1981 Loop-mediated isothermal ampliﬁcation technique for
routine detection of Clostridium difﬁcile
V. Zidaric, N. Oresic, M. Rupnik* (Maribor, SI)
Objectives: Rapid and accurate diagnosis of C. difﬁcile is crutial for
effective patient managment and infection control. Today, variety of
commerciall diagnostic tests is available, differentiating in turnaround
time, sensitivity, speciﬁcity, costs, workload and availability. Recently,
highly sensitive and speciﬁc molecular assays have been applied
directly to fecal sample and can represent a usefool tool in diagnosis
of C. difﬁcile. The aim of this study was to compare the novel
loop-mediated isothermal ampliﬁcation tehnique (LAMP; Illumigene,
Meridian Bioscience Inc.) to routine toxigenic culture.
Methods: Between October and December 2010, altogether 138 samples
sent for C. difﬁcile diagnosis have been tested in our routine laboratory.
Diagnosis included culturing on selective CLO agar plates (biMerieux)
after alcohol treatment, direct toxin testing by VIDAS CDAB assay
(bioMerieux) and Illumigene C. difﬁcile test (Meridian). Illumigene
C. difﬁcile test was performed additionally on all 31 known reference
toxinotypes, according to manufacturers instructions with an easy sample
processing and short turnaround time (<1 hour). Results were given as
Positive, Negative or Invalid.
Results: Of the 138 tested stool samples, 19 (13,8%) were toxigenic
culture C. difﬁcile positive, while one strain was nontoxigenic. Of 19
samples with toxigenic C. difﬁcile 18 were positive by new LAMP test
and 15 were positive with VIDAS toxin test. Three culture negative
samples had to be repeated in order to resolve the invalid result and
were ﬁnaly negative with Illumigene test. Using toxigenic culture as gold
standard, speciﬁcity, sensitivity, positive and negative predicitive value
for LAMP were 100,0%, 94,7%, 100,0% and 99,2%. Of 31 reference
toxinotypes only four (XIa, XIb (both toxin non-producers), XXX and
XXXI) were not detected by the molecular test, due to absence of
target sequence within tcdA region of the C. difﬁcile pathogenicity locus
(PaLoc).
Conclusions: New commerical molecular diagnostic kit is rapid and
sensitive also in the settings with low C. difﬁcile prevalence. It recognizes
all main known variant forms of C. difﬁcile except some rare types with
tcdB gene only.
P1982 Low variability of the surface layer proteins between two
high virulent Clostridium difﬁcile PCR-ribotypes
P. Spigaglia*, F. Barbanti, C. Galeotti, M. Scarselli, J. Van Broeck,
P. Mastrantonio (Rome, Siena, IT; Brussels, BE)
Objective: To analyze and compare the surface-layer (S-layer) proteins,
high and low-molecular weight (HMW and LMW), of predominant
Clostridium difﬁcile PCR-ribotypes involved in severe C. difﬁcile
infection (CDI) and outbreaks.
Methods: The slpA gene of C. difﬁcile strains belonging to different
PCR-ribotypes (001, 012, 014, 017, 027 and 078) were sequenced for the
slpA gene using different sets of primers, the DNAStar’s Lasergene v.8.0
software, the National Center for Biotechnology Information BLAST
server and the European Bioinformatics Institute Clustal W server.
Amino acidic sequences were analyzed using the SignalP 3.0 Server
and the ExPASy Proteomics Server. Amino acid comparisons were
accomplished using the European Bioinformatics Institute ClustalW
server and the output was used for the construction of the phylogenetic
tree by TreeView 1.6.6. Visualization of the LMW structure for the
identiﬁcation of surface exposed regions was performed using Swiss-Pdb
Viewer. The S-layer proteins of representative strains were obtained by a
low pH glycine extraction and separated by SDS-PAGE. Immunoblotting
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assays using sera from patients with severe C. difﬁcile 027 or 001
infection was also performed.
Results: In this study, all strains belonging to the same PCR-ribotype
showed an identical SlpA sequence and the sequence of each PCR-
ribotype, except 014, was identical to those previously found in
C. difﬁcile strains belonging to the same type. Phylogenetic analysis
showed that C. difﬁcile 027 SlpA was strongly related (identity 88%)
to that of the epidemic PCR-ribotype 001. Alignment of the LMW
amino acid sequences from all PCR-ribotypes has shown that there
are ten regions with sequence identity between the 001 and 027 PCR-
ribotype and low conservation with the other PCR-ribotypes. Two of
these regions correspond to areas of the LMW that are predicted to be
surface exposed. Immunoblotting results indicate cross-reaction of both
sera with synthetic peptides designed on the conserved region of both
PCR-ribotype 027 and 001.
Conclusions: In presence of a high variability of S-layer proteins among
the different PCR-ribotypes, the high identity found between the SlpA
of C. difﬁcile 027 and that of the PCR-ribotype 001, another type of
C. difﬁcile frequently responsible for severe CDI worldwide, intriguingly
suggests that the S-layers of these virulent strains present common
characteristics that could be an advantage during the infection process.
P1983 Evaluation of the RIDA™Gene Clostridium difﬁcile and
toxin A/B for molecular detection of toxigenic Clostridium
difﬁcile in diarrhoeal faeces
S. Petersdorf, H. Britt, D. Martens*, A. Simons, T. Hoppe (Bonn,
Cologne, Darmstadt, DE)
Objective: Clostridium difﬁcile is the primary cause of nosocomial
diarrhoea worldwide. Clinically symptomatic cases are caused by
toxigenic C. diff strains that produce toxin A and B. In recent years,
the incidence and severity of C. diff infection increased noticeably
worldwide. Health care costs associated with C. difﬁcile infection (CDI)
are estimated at around 3 billion euros per year in Europe and roughly
1.1 billion dollars per year in the USA. A rapid and accurate diagnosis
of CDI is important for patient management and also for timely infection
control measures. Real-time PCR is a rapid, highly sensitive and speciﬁc
alternative for screening for CDI. The aim of the study was to evaluate
the performance of the RIDA™GENE Clostridium difﬁcile & Toxin A/B
assay against cell cytotoxicity neutralization assay (CCNA) and culture.
Methods: From April to August 2010 a total of 502 stool specimens
from hospitalised patients suspected of having CDI were included in the
study. All samples were homogenized and tested freshly by CCNA and
culture while an aliquot for real-time PCR was frozen until extraction.
The DNA extraction was performed with the Promega Maxwell™16. The
RIDA™GENE Clostridium difﬁcile & Toxin A/B is a qualitative real-
time PCR assay targeting the C. diff (16s-rDNA), toxin A (tcdA) and
toxin B (tcdB) genes with ﬂuorogenic target-speciﬁc hydrolysis probes.
Inhibitory effects are monitored using an internal ampliﬁcation control.
The test can be run on the most commonly used real-time PCR cyclers.
Ampliﬁcations were performed using the LightCycler 480II. Results are
available in 1 hour.
Result: Among the 502 stool samples 68 (14%) were positive by
CCNA and 51 (12%) were positive by CCNA and culture. The overall
agreement between the RIDA™GENE and CCNA was 87% (436/502).
The sensitivity, speciﬁcity, PPV, NPV of RIDA™GENE were 96%, 85%,
51% and 99%, respectively. Compared to a deﬁned gold standard of
CCNA and culture the agreement, sensitivity, speciﬁcity, PPV and NPV
were 94%, 100%, 94%, 68% and 100% respectively.
Conclusion: The RIDA™GENE Clostridium difﬁcile & Toxin A/B is
a rapid, sensitive and speciﬁc method for the detection of C. difﬁcile
directly from stool specimens. Results are available in one hour. The
assay can be included in a diagnose algorithm to provide a rapid
diagnosis of CDI, followed by appropriate patient management and
timely infection control measures.
P1984 Evaluation of new real-time PCR assay using stool
specimens compared with conventional real-time PCR
assay, toxigenic culture and enzyme immunoassay for rapid
diagnosis of Clostridium difﬁcile infection
B. Shin*, S. Mun (Seoul, KR)
Objectives: The pathogenesis of C. difﬁcile infection (CDI) is mediated
by two toxins, enterotoxin A (TcdA) and cytotoxin B (TcdB), and
efﬁcient and effective identiﬁcation of these toxins is important. The
sensitivity of toxin EIAs is 50−90%, and CCNA is labor-intensive,
subjective and requires tissue culture facilities. Therefore, assays for the
rapid and sensitive tools for diagnosis of CDI are required. We evaluated
a new real time PCR assay using stool specimens that targets the tcdA
and tcdB genes and compared it with the commercially available BD
GeneOhm PCR and an EIA assay for TcdA and TcdB.
Methods: A total of 450 fecal specimens collected from patients
clinically suspected to have CDI. We performed C. difﬁcile culture and
an enzyme linked ﬂuorescent immunoassay and evaluated a real time
PCR assay that targets the tcdA and tcdB genes (AdvanSure CD real
time PCR; LG Life Science, Seoul, Korea) and compared it with the
commercially available BD GeneOhm PCR that target the tcdB gene
alone. We also ampliﬁed tcdA and tcdB genes in culture positive cases
to differentiate tcdA+tcdB+, tcdA−tcdB+ and tcdA−tcdB− strains.
Results: The number of culture positive and negative cases was 191
and 259, respectively. The concordance rate between BD GeneOhm
and LG AdvanSure was 92.2% (415/450). We placed tcdA+tcdB+ and
tcdA−tcdB+ strains among culture positive cases in a hypothetical toxin
positive group, and tcdA−tcdB− strains among culture positive cases and
culture negative cases in a hypothetical CDAB negative group. Based
on these criteria, the sensitivity and speciﬁcity, the positive predictive
value (PPV) and negative predictive value (NPV) of LG AdvanSure
were 80.1%, 96.2%, 95.5% and 83.9%, respectively. The sensitivity,
speciﬁcity, PPV and NPV of BD were 89.7%, 92.1%, 92.8% and 88.8%,
respectively. The sensitivity, speciﬁcity, PPV and NPV of EIA were
61.3%, 94.8%, 98.1% and 77.8%, respectively. Especially, LG Advansure
can differentiate tcdA-tcdB+ strains among toxigenic C. difﬁcile strains
(78.9% performance).
Conclusion: A new real time PCR assays (LG AdvanSure) represented
comparable or good performance compared with conventional real time
PCR assay (BD) and EIA. LG Advansure can differentiate tcdA−tcdB+
strains, in contrary with BD which detect tcdA alone, which can be used
as a new rapid diagnostic and epidemiologic tool for toxigenic CDI,
especially in areas where TcdA−TcdB+ variant C. difﬁcile strains are
prevalent.
P1985 Evaluation of a real-time PCR assay and conventional
methods for the detection of toxigenic Clostridium difﬁcile
in stool samples
M. Turan, B. Levent*, T. Demir, H. Bayrak, R. Gulesen, M. Akgeyik,
B. Esen (Ankara, Kirsehir, Mersin, TR)
Objectives: Clostridium difﬁcile is the major causative agent of
antibiotic associated diarrhea and the diagnosis of this pathogen became
important over the last years. Many assays are currently in use for
detection of C. difﬁcile and its toxins, toxin A and B, major virulence
factors for infection. The reference method for the diagnosis of
C. difﬁcile-associated infections (CDI) is the cytotoxicity neutralisation
assay in cell culture that may be neutralized by antitoxin. Also,
to improve the sensitivity of tests, some researchers recommended
the additional anaerobic culture of stool with conﬁrmation of toxin
production. Recently, a more rapid detection method, real-time PCR
(RT-PCR) assay have been developed. The aim of this study was to
evaluate and compare the test results of RT-PCR assay for toxin B gene
and glutamate dehydrogenase (GDH) test with the reference methods,
cytotoxicity assay and toxigenic culture.
Methods: Stool samples from both inpatients and outpatients with a
suspicion of CDI were analysed by RT-PCR for the detection of toxin B
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gene (ProGastro™ CD Assay, Prodesse, Waukesha, USA) and GDH
antigen test (C.Diff Quik Chek™, TechLab®, Blacksburg, USA). Test
results were compared with the reference methods, toxigenic culture
using CCFA and blood agar, and cytotoxicity neutralisation assay in
verocells using C. difﬁcile toxin-antitoxin kit (Techlab®, Blacksburg,
USA).
Results: C. difﬁcile was isolated 36 (27.3%) of the 132 stool
samples and 21 (15.9%) of these were conﬁrmed by toxigenic culture.
Using cytotoxicity neutralisation assay as a gold standard method, the
sensitivities, speciﬁcities, positive predictive values (PPV) and negative
predictive values (NPV) of the assays were 91.6%, 79.6%, 50.0% and
97.7% for RT-PCR, and 41.6%, 92.5%, 55.5% and 87.7% for GDH,
respectively. Also, using toxigenic culture as a gold standard method,
the sensitivities, speciﬁcities, PPV and NPV of the assays were 81.0%,
75.7%, 38.6% and 95.5% for RT-PCR, and 52.4%, 93.7%, 61.1%, and
91.2% for GDH, respectively.
Conclusion: Comparison of GDH with toxigenic culture and cytotoxicity
neutralisation assay showed that sensitivity of GDH test is low. RT-PCR
assay for the detection of C. difﬁcile toxin B gene is sensitive and speciﬁc
and thus, this assay can be used as rapid and useful screening method
for patients suspected of having CDI.
P1986 Correlation between Clostridium difﬁcile toxin genes and
the direct toxin detection assay results
L. Lindholm*, M. Kalluinen, E. Eerola, O. Meurman, A. Virolainen,
J. Jalava (Turku, Helsinki, FI)
Objectives: Direct enzyme immunoassays detecting toxin A and/or
toxin B are widely used for the rapid diagnosis of C. difﬁcile infection
as the rapid detection of toxin-producing strains is essential for optimal
management of patients with C. difﬁcile infection (CDI).
Our aim was to study in what extend C. difﬁcile isolates harbour toxin
genes, that is, their potential to produce toxins and how this compares
the results of the direct toxin detection assay.
Methods: This present study included a total of 2170 routine C. difﬁcile
culture positive faecal samples that had already been tested with the
direct toxin detection test (Vidas C. difﬁcile toxin A and B (CDAB)
assay, BioMerieux) as part of initial evaluation of a suspected case
of CDI. C. difﬁcile isolates were analysed with the in-house PaLoc-
CDT-multiplex-PCR detecting genes needed for toxin production and
regulation (tcdA, tcdB, cdtB, tcdC and cdu2). The results of the
multiplex-PCR and direct toxin detection assay were retrospectively
compared.
Results: In our 3-year clinical material, 2076 (95.7%) of the C. difﬁcile
isolates carried the toxin gene(s) and only 94 (4.3%) did not have the
genes needed for toxin production (only cdu2 was ampliﬁed). On the
contrary, the direct toxin detection assay had given negative results in
521 (24.0%) of the corresponding faecal samples and positive results
only in 1414 (65.2%) of the samples. By direct detection assay there
were also 235 (10.8%) equivocal results of which 228 (97.0%) harboured
toxin genes. By using the culture followed by toxin gene detection by
PCR as a standard, the sensitivity and speciﬁcity of the Vidas CDAB
was 67.9% and 88.3% respectively.
Conclusion: The use of enzyme-linked ﬂuorescence immunoassay alone
may lead to a substantial portion of toxigenic C. difﬁcile strains being
missed, leading possibly insufﬁcient treatment and spread of infection
as isolation procedures may not be imposed.
P1987 A new player on the market for detection of Clostridium
difﬁcile?
K. Flore´* (Bruges, BE)
Introduction: Clostridium difﬁcile (CD)-associated diarrhea (CDAD) is
a frequent cause of antibiotic associated nosocomial diarrhea. Recently
a new molecular technique for detection of toxigenic CD was launched.
The loop-mediated isothermal DNA ampliﬁcation (LAMP) targets the
pathogenicity locus of toxigenic CD strains.
In this study we evaluated the test both retrospectively and prospectively.
Materials and Methods: The LAMP test (Illumigene™ (ILL), Meridian
Bioscience Europe.) was ﬁrst validated on 30 selected stool samples,
in comparison with culture and a second molecular detection method
(GeneXpert (GX), Cepheid, Europe). During an outbreak of CDAD
on a geriatric ward we tested 90 consecutive faecal specimens. All
samples were processed within 8 h or kept at 4ºC until processing
(max 48 h). Samples were cultured on cycloserine-cefoxitin-fructose agar
plates (CLO, bioMe´rieux, France) and incubated for 72 h under anaerobic
conditions at 37ºC. Toxin detection was performed either directly from
faecal sample using the ImmunoCard® Toxins A and B (TOXA/B,
Meridian Bioscience Europe), or, if negative, from pure cultures.
Results: In the retrospective study 30 samples were compared with
GX:18 toxigenic strains, 5 atoxigenic strains and 7 negative samples. The
overall sensitivity of ILL compared with culture is 95% (1 false negative
result with ILL), with a speciﬁcity of 100%. The overall sensitivity and
speciﬁcity of GX was 100%.
In routine analysis we cultured 21 CD strains (21/90), among those
6 atoxigenic, resulting in a negative result with ILL. All 15 toxigenic
strains were positive both on culture and with ILL. No invalid results
were noticed. The overall sensitivity and speciﬁcity of Illumigene™
compared with culture and TOX A/B was 100%.
Conclusion: Although the preliminary results of the LAMP technology
are promising, this test is still expensive and no reimbursement for
molecular detection of CD in Belgium is provided. The high sensitivity
is comparable to other molecular tests such as GX. ILL proved to be
rapid (<1 h) and easy to perform, with 20 minutes hands on time. Strain
typing is not possible. Further testing with this promising molecular
technique is warranted.
P1988 Evaluation of three real-time PCR-methods for the
detection of C. difﬁcile in stool specimens
I. Fenner*, U. Eigner, C. Lensing, H. Petersen, A. Veldenzer, U. Wild,
M. Holfelder (Hamburg, Heidelberg, DE)
Objectives: Fast and reliable detection of Clostridium difﬁcile toxin
positive is crucial for the prevention of outbreaks of this serious
infectious agent.
We present our evaluation of three real-time PCR-tests (BD GeneOhm™
C diff., BD; RIDA® GENE C. diff Toxin A/B, R-biopharm; C. difﬁcile
PCR, Astra) for the detection of toxin-producing C. difﬁcile in stool
specimens.
Methods: 247 liquid or semi-liquid stool specimens for C. difﬁcile
analysis were examined in two microbiology laboratories. All stool
specimens were directly tested with the C. DIFF CHEKTM-60-EIA
(Techlab) for the detection of the GDH-antigen of C. difﬁcile and with an
EIA for the detection of C. difﬁcile toxins A and B (Premier™ TOXINS
A&B, Meridian; RIDASCREEN® Clostridium difﬁcile Toxin A/B,
R-Biopharm). Culture on CLO-agar (bioMe´rieux) was performed for all
stool specimens as reference method. Cultured C. difﬁcile-isolates were
S584 21st ECCMID/27th ICC, Posters
tested with the C. difﬁcile toxin A&B EIA and the PCR method. All
PCR-assays were performed according to manufacturer’s instructions.
Results: In total 247 stool specimens were analysed with the GeneOhm
PCR test. 40 were congruently positive with the GDH-test and the
Toxin A/B-EIA. 153 specimens were congruently negative. Discrepant
results (n = 54) between the tests were resolved by toxinogenic culture.
Performance of the GeneOhm PCR test was calculated with 99%
sensitivity, 97% speciﬁcity, 99% NPV and 94% PPV. Out of 247 stool
specimens, 105 were tested with the Astra PCR assay. 9 were congruently
positive with the GDH-test and the Toxin A/B-EIA. 60 specimens
were congruently negative. After resolution of discrepant results by
toxinogenic culture, performance of the Astra assay was calculated with
95% sensitivity, 95% speciﬁcity, 97% NPV and 93% PPV. For RIDA
GENE C. difﬁcile toxin A/B PCR test 79 stool specimens out of 247
in total were evaluated. 5 were congruently positive with the GDH-test
and the Toxin A/B-EIA. 45 specimens were congruently negative. In
comparison to toxinogenic culture the RIDA GENE assay showed 100%
sensitivity, 94% speciﬁcity, 100% NPV and 88% PPV.
Conclusions: The three Real-Time PCR-assays (GeneOhm C.diff, BD;
RIDA GENE C. diff, R-biopharm; C. difﬁcile PCR, Astra) evaluated
showed rapid, high sensitive and speciﬁc results for the detection of
C. difﬁcile toxin directly from stool specimens.
P1989 External quality assessment for laboratory detection of
Clostridium difﬁcile
C. Walton*, E. Fagan, A. Marwaha (London, UK)
Objectives: The United Kingdom National External Quality Assessment
Service (UK NEQAS) for Microbiology introduced a scheme for
Clostridium difﬁcile in April 2009 and provides participants with
the opportunity to assess the quality of culture, molecular and toxin
testing for C. difﬁcile. This study analysed the performance of clinical
laboratories participating in the Clostridium difﬁcile scheme from April
2009 to November 2010.
Methods: Fourteen simulated liquid faecal specimens were distributed
to between 177 and 276 participating laboratories in seven distributions.
Twelve specimens included toxigenic strains of C. difﬁcile ribotypes:
001, 002, 005 (x2), 014 (x2), 015, 016, 027 (x3) and one 078 (toxin A-
B+); one toxin negative strain (RT 010) and one negative for C. difﬁcile,
containing commensal organisms only. Results reported by participants
were analysed by method to determine their performance with these
specimens.
Results: For 9 of the 12 specimens containing a toxigenic strain of
C. difﬁcile 84% to 100% (average 94%) of participants reported correctly
on the detection of Clostridium difﬁcile and/or toxin. The remaining three
specimens contained weakly toxigenic strains (all conﬁrmed positive in
reference testing) and participants experienced a higher failure rate (27%,
18% and 25%). Ability to detect C. difﬁcile and/or toxin was higher
in culture (98.2%) than in EIA or membrane assays (mean 92%). The
non-toxigenic strain was successfully identiﬁed by 98% of participants
and 97% for the specimen containing only commensals. The number
of participants using culture increased from 14 to 50 but overall toxin
testing using an EIA and/or membrane assay was the most popular way
of examining. The number using kits detecting GDH has increased from
9 to 74 and the number using PCR toxin gene detection increased from
2 to 27. Results reported for both GDH and molecular tests were 98%
and 100% accurate respectively.
Conclusions: Many participants used a single assay and toxin levels
produced by some strains may have been at the lower limit of detection
for some assays thereby affecting participant performance. Current
opinion on performance of C. difﬁcile toxin detection assays indicates
that laboratories should not be using these assays in isolation. There were
no discrepancies with PCR test results. Results from the UK NEQAS
C. difﬁcile scheme will help participants monitor the performance of
their methods.
P1990 Evaluation of a novel loop-mediated ampliﬁcation system
(Illumi-pro10™ Meridian Bioscience Inc.), glutamate
dehydrogenase (Meridian and TechLab) and a rapid
immunoassay, Tox A/B Quik Chek (TechLab) for the
detection of C. difﬁcile toxin
F. Yazdani*, D. Gnanarajah, Y. Hussain (Derby, UK)
Objectives:
1. To prospectively evaluate 3 commercially available assays to improve
the laboratory diagnosis of Clostridium difﬁcile infection.
2. To determine whether to replace or supplement our current in-house
toxin detection method (Premiere toxin A/B − Meridian®).
Method: 260 liquid stool samples were prospectively tested using the
current in-house method, a 96 well ELISA for the detection of C. difﬁcile
toxin (Premiere Tox A/B-Meridian®).
All samples also underwent testing with the following commercially
available assays.
2X Glutamate dehydrogenase (GDH 96 well ELISA) (Meridian® and
Techlab®).
All positive GDH samples underwent testing with the following 2 toxin
detection assays.
Illumipro-10® a novel isothermal LOOP-mediated ampliﬁcation and
detection system for target nucleic acid sequence, for the detection of
C. difﬁcile toxin (Meridian®).
Tox A/B QUIK CHEK − Rapid immunoassay for the detection of
C. difﬁcile toxins A/B (Techlab®).
All assays were carried out according to the manufacturer’s instructions
and toxigenic culture (Gold standard) was performed using standard
techniques.
Results: The Illumipro-10 (Meridian®) assay had 3 false positives and
zero false negatives. The Tox A/B QUIK CHEK had 1 false negatives
and 2 false positives. Finally the Premiere EIA had 2 false positives and
2 false negatives.
Conclusion: Our current in-house ELISA has shown the lowest
sensitivity and has identiﬁed the need to review the way we test for
C. difﬁcile toxin. Interestingly the speciﬁcity value for all three assays
was similar. The GDH results for the Premiere kit is consistent with
several published studies. The Illumipro-10 was the best performing
assay, the fact that it had a low PPV may be down to its high sensitivity
because all three samples were positive two weeks prior to the study and
it may be that residual toxin has been detected.
Reliably detecting C. difﬁcile toxin cannot be underestimated, most
commercially available kits offer high speciﬁcities but low sensitivities.
Toxigenic culture is a Gold standard but it is labour intensive and time
consuming. 2-stage testing seems like a viable option i.e. screening
with GDH (high sensitivity and speciﬁcity) and if positive conﬁrm the
presence of toxin with the most cost effective and sensitive assay. We
have identiﬁed the need to replace our current ELISA, with a higher
sensitivity assay. The introduction of a more sensitive assay will have an
immediate impact on our hospital C. difﬁcile rates.
Diagnosis of C. difﬁcile infections S585
P1991 Evaluation of culture methods for isolation of Clostridium
difﬁcile and comparison of phenotypic identiﬁcation with
identiﬁcation by 16S ribosomal DNA sequencing and
matrix-assisted laser desorption ionisation − time-of-ﬂight
mass spectrometry
A. Jain*, C. Pope, M. Wilks, M. Pond, J. Haigh, T. Planche (London, UK)
Objectives: Stool culture is generally agreed to be the most sensitive
method for detection of Clostridium difﬁcile. It is essential for
epidemiological investigations and to monitor emerging resistance to
antibiotics. Identiﬁcation of C. difﬁcile in culture by phenotypic methods
is common but is time consuming.
We compared different culture methods for isolation of C. difﬁcile
from human stool samples in order to optimise laboratory diagnosis
of C. difﬁcile infection. Additionally, we evaluated identiﬁcation of
C. difﬁcile using phenotypic methods, 16S ribosomal DNA (rDNA)
sequencing and matrix-assisted laser desorption ionisation − time of
ﬂight mass spectrometry (MALDI-TOF MS).
Method: 163 faeces samples were analysed by simultaneously perform-
ing six culture methods over a one month period. Samples included 150
fresh stools and 13 stored C. difﬁcile positive stools.
Stools were alcohol-shocked and cultured on 2 different selective
media − cycloserine cefoxitin fructose agar (CCFA) and Brazier’s
cycloserine cefoxitin egg-yolk agar (CCEY) for 48 hours. Additionally,
samples were also enriched with brain heart infusion (BHI) broth for 24
hours either before or after alcohol shock followed by culture on these 2
media. Colonies were identiﬁed using standard phenotypic methods (UK
HPA BSOP10i1.3) for C. difﬁcile (colonial morphology, ﬂuorescence,
latex agglutination and lecithinase activity). Colonies were also identiﬁed
by 16S rDNA sequencing and MALDI-TOF MS.
Results: The methods of culturing alcohol-shocked stools with or
without enrichment on Brazier’s CCEY were best with sensitivity and
speciﬁcity being 100% (95% conﬁdence interval [CI] 79–100%) and
99% (95%CI 95–100%) respectively, with 16s rDNA sequencing as the
reference standard (Table).
C. difﬁcile was phenotypically identiﬁed in 29 samples out of 163. Only
16 out of these 29 samples (55%) were conﬁrmed as C. difﬁcile by both
sequencing and MALDI-TOF MS, both of which showed full agreement
on these 16 samples.
Conclusion: The additional step of enrichment of alcohol-shocked stool
did not signiﬁcantly increase the rate of isolation of C. difﬁcile on
Brazier’s CCEY media. This will need conﬁrmation using a larger
sample size. Phenotypic methods for identifying C. difﬁcile culture may
misidentify other clostridia species like C. bifermentans as C. difﬁcile.
P1992 Lack of impact of strain type on detection of Clostridium
difﬁcile using PCR and glutamate dehydrogenase
S. Goldenberg*, M. Gumba, A. Hall, A. Patel, G. French (London, UK)
Objectives: The poor performance of Toxin Enzyme Immunoassays
(EIAs) for the laboratory diagnosis of Clostridium difﬁcile (Cd) Infection
has resulted in a renewed interest in incorporating detection of Glutamate
Dehydrogenase (GDH) into two and three step testing algorithms.
Some recent work has suggested that the sensitivity of GDH may vary
according to ribotype, and speciﬁcally that GDH is less sensitive than
PCR in detecting PCR ribotypes 002, 027 and 106. We undertook a proof
of concept study to determine the effect of strain type on detection using
GDH (TechLab CDiff Chek-60) and PCR (Cepheid GeneXpert).
Methods: Suspensions of pure Cd of known ribotypes (n = 62) were
made to a 0.5 McFarland standard in nuclease free sterile water. This
was diluted 1:100, 1:200, 1:400 and 1:800 and tested by GDH (C Diff
Chek-60 using the automated Dynex 2 Platform) and Cepheid GeneXpert
PCR methods. It is important to note that the manufacturers recommend
using these assays with stool samples and not cultured isolates as we
have done. The mean optical dentisty (OD) (450/630 nm) for the GDH
and Cycle threshold (Ct) value for the PCR were compared for different
ribotypes (n = 62, 10 each of ribotypes 002, 005, 023, 078 and 106 and
12 of ribotype 027).
Results: All samples were positive by both methods in at least one
dilution using manufacturers’ cut off values. We found no signiﬁcant
difference amongst mean values obtained for GDH and PCR for different
PCR ribotypes (see table).
Conclusion: We did not ﬁnd any differences in the sensitivities of GDH
and PCR tests for different PCR Ribotypes. All samples were positive in
at least one dilution using the manufacturers’ cut-off values. All dilutions
for PCR were positive, however some of the higher dilutions for GDH
were negative, indicating that (as expected) PCR is more sensitive than
GDH. We tested isolates of Cd in pure culture, which is outside of the
manufacturers’ recommendations for these tests and results should be
interpreted with caution. A larger study using stool samples should be
conducted.
P1993 Evaluation of ﬁve methods for rapid detection of Clostridium
difﬁcile in diarrhoeal stool samples from paediatric patients
C. Burnham*, D. Tasler, R. Craven, L.F. Westblade, W.M. Dunne (St.
Louis, US)
Objectives: Many new methods, including molecular diagnostics, have
become commercially available to assist in making the diagnosis of
Clostridium difﬁcile-associated disease. Few studies have evaluated the
performance of these assays in samples submitted from paediatric
patients. The purpose of this study was to compare ﬁve methods for
the detection of C. difﬁcile (CD) in this patient population. Methods
amenable to small volume testing were selected for evaluation as CD is
typically a low-volume test for a stand-alone children’s hospital.
Methods: All samples included were diarrheal stools submitted to the
St. Louis Children’s Hospital Microbiology laboratory for CD testing.
Fresh samples were tested using the Wampole Tox A/B QuikCheck
rapid immunoassay as part of routine testing in our laboratory. Positive
specimens and an equal number of negative specimens were frozen at
−80ºC prior to subsequent testing. All samples were then analyzed using
the Techlab CDiff QuikChek GDH (Inverness Biomedical), TechLab
CDiff QuikChek Complete Tox A/B (Inverness Biomedical), Xpert
C. difﬁcile (Cepheid) and illumigene C. difﬁcile (Meridian Biosciences)
assays. Toxigenic culture was performed on all samples and was
considered the Gold Standard for comparison. Our historical CD
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positivity rate of 5.5% was used for positive and negative predictive
value (PPV and NPV) calculations. Typing was performed on all of
the CD isolates using a novel typing method combining ribotyping and
Diversilab bacterial barcodes analysis.
Results: The two molecular methods tested in this study (Xpert and
illumigene) demonstrated improved sensitivity and speciﬁcity compared
to rapid immunoassay-based detection of Toxins A and B. See Table 1
for sensitivity, speciﬁcity, PPV and NPV for each method. Molecular
typing of the isolates revealed six unique clusters, and six of the isolates
did not cluster, suggesting the study was not biased due to a clonal
population of isolates.
Conclusions: Rapid enzyme immunoassays for Toxin A/B detection are
less sensitive than nucleic acid-based methods or GDH antigen detection.
The ﬁndings of this study suggest that either a “two-step” algorithm of
screening samples with GDH followed by the Xpert C. difﬁcile assay,
or the Xpert C. difﬁcile assay alone, would be a sensitive and speciﬁc
approach for the detection of CD in the stool of paediatric patients.
P1994 Experience and consequences of using improved methods
for the diagnosis of Clostridium difﬁcile infection
S. Goldenberg*, N. Price, D. Tucker, P. Wade, G. French (London, UK)
Objectives: Widely used toxin Enzyme Immunoassays (EIAs) for
Clostridium difﬁcile (Cd) detection do not perform well enough for
use as single tests. Several molecular tests are now available promising
much improved sensitivity and speciﬁcity. We describe our experience of
changing from a toxin EIA to a two-step method comprising screening
with GDH (Glutamate Dehydrogenase) followed by conﬁrmation with
Cepheid GeneXpert PCR which detects toxin B gene.
Methods: We changed our laboratory methods for detecting toxigenic
Cd as described above on 1st September 2010. All samples positive by
the two-step algorithm were also tested by the gold standard Culture-
Cytotoxin Neutralisation Assay (CCNA). We monitored for changes in
disease prevalence, laboratory turnaround time, antibiotic prescribing
behaviour and environmental contamination with Cd for the following 3
months.
Results: Between 1st Sep. and 30th Nov. the two-step algorithm
identiﬁed 66 positives, 60 were conﬁrmed by CCNA (positive predictive
value = 91%). A number of repeat specimens which were initially
CCNA negative subsequently became positive, suggesting that PCR can
detect disease earlier. (These specimens were not excluded from the
performance analysis). All cultured isolates were Ribotyped: no 027
strains were identiﬁed during this period and typing did not reveal
any signiﬁcant transmission between patients. Mean turnaround time
was unaffected (6.3 hours for EIA and 6.5 hours for two-step). There
was no signiﬁcant change in antibiotic prescribing or environmental
contamination (9/120 samples = 7.5%). Reportable rates of Cd infection
have increased from 0.18 to 0.45 cases per 1000 occupied bed days.
Conclusion: Following a change to an improved testing method, our
reportable Cd rates increased signiﬁcantly. We excluded several factors
which might have contributed to this. We conclude that the increase in
rates was a consequence of using a better diagnostic method. Having
introduced a test which improves patient safety, we are now at risk of
ﬁnancial penalties from the UK Department of Health for exceeding
the reportable Cd infection target set for us in the upcoming year.
We believe this is unreasonable since the calculated targets were based
on the previous suboptimal, poorly sensitive EIA method. PCR allows
sensitive, robust and rapid detection of Cd but regulatory authorities
must recognise that a change to a more sensitive and accurate test will
increase reportable Cd infection.
P1995 Frozen human foreskin ﬁbroblasts provide a convenient
alternative to conventional cell lines for diagnosis of
Clostridium difﬁcile by cell cytotoxicity assay
N.K. Tan*, C. Pope, T. Planche (London, UK)
Objectives: Cell cytotoxicity assay (CCTA) is regarded as the ‘gold
standard’ method for the laboratory diagnosis of Clostridium difﬁcile
infection by detection of Toxin B. CCTA detects the presence/absence
of cytopathic effect (CPE) in a live cell culture that is neutralised by a
speciﬁc antitoxin. Many laboratories do not have cell culture facilities
or infrastucture to maintain cell lines normally required for CCTA,
which limits the use of this technique. A commercial cell line of human
foreskin ﬁbroblasts (HFF) (Diagnostic Hybrids, Ohio, USA) are available
in a convenient frozen form. This format consists of individual vials or
24 well plates which are shipped and stored frozen and thawed when
required ready for use in CCTA. Our aims were to conﬁrm the accuracy
of these frozen HFF in comparison with our in house CCTA using
Vero cells and determine the relative speed of these methods to detect
presence/absence of the CPE.
Methods: 177 stool samples (stored at 4ºC) were tested in parallel using
both frozen HFF and the in-house vero cells for CCTA. The frozen
HFF were used according to the manufacturer’s instructions. A positive
result was regarded as any sample detecting speciﬁc CPE by either assay.
Following incubation CPE was assessed at different time points (2, 4, 6,
24 and 48 hours). Inter-observer agreement was assessed in a subset of
47 samples read blind by two independent observers at both 24 and 48
hours.
Results: 47 of the 177 samples were positive by one or other CCTA
method; 46 were positive by the frozen HFF. This gives a sensitivity
for the Ready cells of 46/47 (98%, 95%CI 88–100%). 45 were positive
by the in house Vero cell method, giving a sensitivity for the in house
CCTA of 45/47 (96%, 95%CI 85−99%). Inter-observer agreement was
100% (kappa 1.0) for both methods at 24 and 48 hours. The average
time to positivity was 5.8 hours using the Fresh Frozen Cells compared
to 10.8 hours using the Vero cells. All positive samples demonstrated a
speciﬁc CPE by 24 hours.
Conclusion: There was excellent agreement between the frozen HFF
and in-house CCTA with the average time to positivity shorter for the
commercial frozen HFF CCTA than the Vero cell method. The use of
this commercial cell line in a vial format provides laboratories without
cell culture facilities the ability to perform CCTA with these convenient
commercially available alternative.
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P1996 Evaluation of a new molecular oligochromatographic assay
for direct mycobacterial detection in human respiratory
clinical specimens
M.J. Martı´nez-Lirola*, P. Mendoza Lo´pez, A. Ferna´ndez-Sa´nchez,
I. Toro-Peinado, M.P. Bermu´dez-Ruiz, B. Palop-Borra´s on behalf of
the IndalTB group
Objective: To evaluate a novel assay, namely “Speed-Oligo® Direct
Mycobacterium tuberculosis” (DirectMB), based on PCR method
attached to a dipstick, for detection of Mycobacterium spp. and speciﬁc
identiﬁcation of Mycobacterium tuberculosis complex (MTC) in human
respiratory clinical specimens.
Methods: A total of 382 N-acetylcysteine-4%NaOH decontaminated
specimens in 3 different sets were blindly tested with DirectMB:
Set A: 327 fresh, prospective respiratory specimens, from 270 patients
suspected of having a type of mycobacterial disease. Set B: To assess the
sensibility of the test, 44 selected respiratory smear positive specimens
with different load of acid-fast bacilli (AFB/ﬁeld 200×): 13 low (1)
and 31 heavy (>1) positives from 29 patients: 17 with TB (24 culture-
pos. and 3 neg. collected under healing) and 12 with NTM lung disease
(20 culture-pos. specimens). Set C: to investigate the cross-reactivity,
sputa artiﬁcially inoculated with 11 mycobacterium related organisms
(MrO) were assayed. The clinical specimens previously decontaminated
were microscopy examined for AFB and cultured in MGIT® or
Bact/Alert® and L-J. The isolates were identiﬁed by Mycob.CM®
assay or AccuProbe® hybridization probes. The DirectMB assay was
performed in 4 steps: mechanical DNA extraction (cell disruption for
5 min); ampliﬁcation (multiplex PCR). Targets: human gene RNAsaP
(control of ampliﬁcation and PCR inhibitors detection),16S rRNA
Mycobacterium genus-speciﬁc sequence and IS6110 fragment MTC-
speciﬁc). PCR detection: PCR product was added to a dipstick with
probes bound to colloidal gold and to the membrane (5 min incubation).
Reading of the result (visual or automatic): presence of visible lines.
Results: Culture of set A: 23 MTC; 6 NTM; 273 neg.; 5 and 1 neg.
with another specimen from the same patient MTC or NTM, respectively;
and 19 contaminated. The DirectMB showed no reactivity with all of the
MrO strains. No result (INV) could be obtained for 13 specimens culture-
neg. due to the absence of the ampliﬁcation control line (poor specimen
collection or presence of PCR inhibitors). The sensitivities (S) of the
DirectMB were: 0.92 for smear-pos. (0.76 for low-pos. and 0.97 for
heavy-pos.), 0.86 for MTC pos., 0.74 for NTM pos. and 0.46 for smear-
neg. specimens. The speciﬁcity was 0.99, the PPV 0.92, and the NPV
0.96 (prevalence 0.12). DirectMB produces reliable results, and may be
a valuable tool for rapid diagnosis of mycobacterium lung infection.
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P1997 Evaluation of the new GenoType MTBDRsl® assay for
rapid detection of resistance in Mycobacterium tuberculosis
isolates in a low-incidence community
F. Kontos, M. Zande, D. Mavromanolakis, S. Bazigos, A. Manidaki,
Z. Gitti* (Heraklion, GR)
Objectives: The new developed assay GenoType MTBDRsl (Hain
Lifescience, GmbH, Nehren, Germany), permits the identiﬁcation of
the M. tuberculosis (MTB) complex and the detection of speciﬁc
mutations in the genes gyrA, rrs and embB associated with resistance
to ﬂuoroquinolones, aminoglycosides/cyclic peptides and ethambutol
(EMB) respectively. In this study we examined with this molecular assay
all MTB strains, isolated in our laboratory for a period of nine-years.
Methods: M. tuberculosis isolates included in the study were collected
from 221 patients cared for or referred to the University Hospital of
Heraklion from January 2000 to May 2009. The conventional drug
susceptibility testing (DST) was routinely performed in every case of
a positive culture for M. tuberculosis with BacT/Alert 3D system for
initial screening of drug resistance and on LJ slants. For EMB, the
high- and low-level resistance were deﬁned by MIC >5mg/ml and
MIC = 2mg/ml, respectively. Shortly after isolation, the isolates had been
stored at −70ºC. All MTB isolates were retrospectively studied with the
GenoType®MTBDRls assay, according the manufacturer’s instructions.
Results: All the 221 MTB strains (100%) correctly identiﬁed by the
speciﬁc probe of the MTBDRls assay. Among the 221 MTB isolates
tested with the conventional DST for EMB, 208 were susceptible, 5
were high-level and 8 were low-level resistant. The MTBDRls assay
detected a mutation in the embB gene (mutation M306I) and a lack of a
wild type (embBWT) band in only one high-level EMB-resistant strain.
This is an MDR strain with mutations also in the rpoB and katG genes.
None of the other resistant and susceptible strains contained any embB
mutation. Furthermore, none of the isolates tested showed mutations in
the gyrA and rrs genes, associated with resistance to quinolones and
aminoglycosides.
Conclusions: Analyzing the mutations of the embB gene, the MTBDRls
assay does not appear sufﬁciently sensitive for use as a rapid screening
test for detection of resistant to EMB at 5mg/ml (sensitivity 20%). It is
likely that MTB isolates without an embB resistance-determining region
mutation likely represent the ﬁrst level on the multi-step phenomenon of
EMB resistance acquisition. There is a need for additional data pointing
on the association between EMB resistances, associated mutations and
MICs of the drug.
P1998 Could negative T Spot-TB exclude an active tuberculosis
suspect?
M. Arosio, G. Bargiggia, M. Rizzi, V. Ravasio, P. Serna Ortega,
F. Moioli, L. Trezzi, A. Raglio*, A. Goglio (Bergamo, IT)
Objective: Mycobacterium tuberculosis complex (MTC) infection
remains a problem for public health. There are commercial blood test
(IGRA: interferon-g release assay) based on the release of this cithochin
(IFN-g) after the antigenic stimulation with speciﬁc peptides (ESAT-6
and CFP-10) for the diagnosis of latent tuberculosis that are more
sensitive and speciﬁc than Mantoux test. The purpose of this study is to
evaluate the usefulness of the T SPOT-TB (Oxford Immunotec) for the
exclusion of active tuberculosis.
Methods: The dates were extracted from the our laboratory database by
the software Virtuoso Plus (Metaphora Computer Ltd.). We enrolled
all patients with negative T SPOT-TB and selected those with the
notiﬁcation of sospicious tuberculosis within one year from the execution
of IGRA test.
Results: Between November 2005 and December 2009, 1442 patients
were investigated and 760 (53%) with negative T SPOT-TB were
enclosed in this study. Tuberculosis was diagnosed in 8/760 (1%) by
microbiological isolation or clinical features only. Table 1.
Conclusion: Eight patients with negative T SPOT-TB and notiﬁcation of
tuberculosis should be considered as a failure of immunological test in
recognizing active infection. In these cases, it would be however required
further evaluation, considering additional factors that can weaken the
immune system as HIV infection, pregnancy and old age. From clinical
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data, our results show that the T SPOT-TB, which is normally used for
the diagnosis of latent tuberculosis, has a negative predictive value of
99,0% (760/760 + 8) and would therefore exclude a pulmonary or extra-
pulmonary tuberculosis in differential diagnosis with other pathological
forms.
P1999 Performance of the GenoType® MTBDRplus assay for
detection of Mycobacterium tuberculosis drug resistance in
routine settings: a multicentre study
S. Mironova, I. Kontsevaya*, E. Pimkina, V. Nikolayevskyy,
G. Skenders, T. Kummik, Y. Balabanova, F. Drobniewski (Samara,
RU; Vilnius, LT; London, UK; Riga, LV; Tartu, EE)
Objectives: Spread of multidrug resistant TB (MDR-TB) poses a major
public health problem in Eastern Europe. We conducted a retrospective
multicenter analysis of the performance of a commercial line-probe assay
(LPA) (GenoType® MTBDRplus, Hain Lifescience, Nehren) at four sites
in a non-trial context. The process of analysis and results were used to
support the development of a clinical/diagnostic trial network.
Methods: Analysis of retrospective (2008–2010) data comparing
molecular LPA and routine rifampicin (RIF) and isoniazid (INH)
resistance on 1045 consecutive primary specimens (Table 1) collected
at four TB reference laboratories (Samara, Russia; Tartu, Estonia;
Vilnius, Lithuania; and Riga, Latvia) was performed using a developed
electronic data collection forms. Decontamination, smear microscopy,
culture identiﬁcation and drug susceptibility tests (DST) were performed
using internationally established standard methods.
Results: Sputum specimens (N= 1024) comprised the majority (98.0%)
of all tested primary samples. Based on the acid-fast bacilli (AFB) smear
microscopy results, 22 specimens (2.1%) were graded negative, 107
specimens (10.4%) − scanty; 218 (21.1%) − “+”; 235 (22.8%) − “++”;
and 450 (43.6%) − “+++”.
Molecular assay readability was associated with smear positivity; with
the lowest (74.8%) in specimens having 1−9 AFB/100 ﬁelds and the
highest (96.7–97.0%) in specimens graded “++” and “+++”. Seventeen
smear-negative sputum specimens (77.3%) also produced readable result.
Performance characteristics of the MTBDRplus assay have been
calculated against phenotypical DST as the gold standard (Table 1).
Total agreement rates for the detection of RIF and INH resistance
exceeded 90% at all sites with the highest in Vilnius (96.0% and 100.0%)
respectively. Sensitivity and speciﬁcity values varied across sites (91.9–
100.0% and 80.2–100.0%) with sensitivity values being generally higher,
especially in Vilnius (100.0%) and Samara (95.8% and 96.1%) for RIF
and INH respectively.
Conclusion: Performance characteristics of the MTBDRplus assay when
used routinely on direct patient specimens at four sites located in medium
TB incidence countries with high TB drug resistance rates are close to
those previously published for validation studies. The current study has
formed the basis for the establishment of the integrated network of sites
for conducting clinical and diagnostic trials in Eastern Europe.
The study was funded by EU FP7 “TB PAN-NET” grant.
P2000 Clinical utility of immunochromatographic assay based
on mouse monoclonal anti-MPT64 antibody for simple
and rapid discrimination between M. tuberculosis complex
and non-tuberculous mycobacteria in clinical isolates of
extrapulmonary tuberculosis
A. Maurya*, S. Kant, V. Nag, R. Kushwaha, S. Jain, T.N. Dhole
(Lucknow, IN)
Objectives: Mycobacterium tuberculosis and nontuberculous mycobac-
teria (NTM) are different, therefore prompt detection, isolation, and
discrimination is necessary for suitable management. Conventional
methods are able to identify mycobacterial species; but they are
troublesome, time-consuming and laborious. Simple, quick and reliable
identiﬁcation of mycobacteria may provide patients with earlier and
proper treatments, and therefore may spare patients from unnecessary
treatments in cases of growth of environmental NTM. The aim
of study presented here was to investigate simple, rapid and easy
discrimination between Mycobacterium tuberculosis complex and Non
tuberculoses Mycobacteria by Mouse Monoclonal anti-MPT64 based
Immunochromatography Assay in clinical isolates of extra pulmonary
tuberculosis in Northern India.
Methods: A total of 250 BACTEC Culture (BACTEC 12 B vial), which
were positive in BD 460 TB System (Becton Dickinson, Sparks, MD,
USA) from clinical isolates during July 2009 to Nov 2010 has been
further evaluated on the ICA assay. BACTEC Media was subjected to SD
TB Ag MPT64 rapid detection kit (Standard Diagnostics). Brieﬂy, 100
ul aliquot of the Media were placed in to the ICA well, followed by 15
minutes to incubation. Results were read as positive for M. tuberculosis
complex by observing presence of line of precipitation in the control as
well the test well.
Results: Out of 250 BACTEC Culture positive isolates were tested
by ICA test; 165 (65%) were positives (M. tuberculosis complex) and
remains 85 (35%) were considered as Nontuberculous mycobacteria.
We have compare ICA test with the NAP Test for the detection
of M. tuberculosis. The sensitivity, speciﬁcity, and positive/negative
predictive values of ICT for identifying M. tuberculosis were 98.7%,
100%, 100%, and 97.7% respectively. ICA performance was excellent,
simple, easily disseminate, rapid and less time consuming.
Conclusion: ICA is of a new creation and is one of the simplest and
fastest tests to perform. Its methodology is simple and does not require
a high level of skill or equipment. The cost is approximately one third of
the price of the current molecular probe method, and the time required
to perform the assay is approximately 15 min, compared to 5 days for
the NAP Test. It can be easily discrimination between M. tuberculosis
complex and nontuberculous mycobacteria. It can help in early diagnosis
and appropriate management of tuberculosis.
P2001 Ambiguous Quantiferon-TB gold test results in Swiss
healthcare workers: analysis of IL-2/IFN-g ratios
D. Mayor*, A. Berger, P. Bittel, P. Iseli, F. Suter-Riniker, T. Bodmer
(Berne, CH)
Objectives: More and more occupational health programs use
Interferon-g (IFN-g) release assays (IGRA), such as the QuantiFERON-
TB Gold In-Tube test (QFT; Cellestis Inc., Australia), to screen
employees for latent Mycobacterium tuberculosis (MTB) infection
(LTBI). A correlation exists between the IFN-g plasma concentration
released upon MTB-speciﬁc stimulation and the risk of developing
active tuberculosis disease. However, data concerning the interpretation
of weak-positive IGRA results that, in our program, contribute >50%
of all positive IGRA results, are scarce. In analogy to viral infections,
where antigen clearance is associated with Interleukin-2 (IL-2) functional
T-cell signatures, we tested if in LTBI there was an inverse association
between the IFN-g plasma concentration and the relative proportion of
IL-2 released upon MTB-speciﬁc stimulation.
Methods: Plasma concentrations of IFN-g and IL-2 were assessed
in duplicates by ELISA (Mabtech AB, Germany) in QFT-plasma
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supernatants (kept at −20ºC) after MTB-speciﬁc stimulation of the
T-cells. QFT-positive healthcare workers were stratiﬁed into three
groups on the basis of the QFT screening test result (IU/ml): weak
responders, 0.35 to <1.0 (n = 23); intermediate responders, 1.0 to 5.0
(n = 32); strong responders, >5.0 (n = 21). Data were log-transformed and
analyzed statistically. Signiﬁcance was determined by one-sided ANOVA
and the Tukey-Kramer post test.
Results: We found a signiﬁcant inverse association of the QFT test
results and the corresponding IL-2/IFN-g ratios (see ﬁgure). Means
proved to be different (p< 0.001). Tukey-Kramer post test comparison
of all pairs of columns revealed signiﬁcant differences between group A
and B (p< 0.05) and group A and C (p< 0.001).
Conclusion: Screening a low prevalence population often generates
difﬁcult to interpret positive test results around the cut-off value.
IL-2/IFN-g ratios revealed indirect evidence of IL-2 dominant T-cell
signatures in weak responders, and were inversely correlated with the
QFT test results. This analysis of the data shows that, besides being false-
positive, QFT test results around the cut-off may indicate potential shifts
of the T-cell signature towards an IL-2 dominant response. However, the
clinical relevance of these ﬁndings needs to be further investigated by
analyzing more samples and by following patients over time.
P2002 MALDI-TOF Biotyper assay to test potential drug
susceptibility of non-tuberculous mycobacteria: the case of
Mycobacterium avium and clarithromycin resistance
L. Mancinelli*, L. Coltella, E. Tortoli, D. Menichella, C. Russo (Rome,
Florence, IT)
Objectives: Non Tuberculous Mycobacteria (NTM) are widespread in
the environment, otherwise they can also be responsible for a broad
range of diseases in humans.
Particularly the Mycobacterium avium complex (MAC) comprises
M. avium, which causes cervical lymphadenitis in children and dissem-
inated disease in immunocompromised patients. Species identiﬁcation
of NTM by molecular methods is often difﬁcult, time-consuming and
expensive.
In this study, we exploited the MALDI-ToF MS (Matrix-assisted
laser description ionization − time of ﬂight-mass spectrometry)
Biotyper in order to verify the capability of an accurate and rapid
identiﬁcation of M. avium from clinical specimens. Moreover we
evaluated clarithromycin (CLM) susceptibility because macrolide are
ﬁrst line drug used as NTM treatment.
Methods: 39 M. avium were collected from clinical samples, mostly
lymphonodal biopsy, of patients recovered at the Bambino Gesu` Children
Hospital and at the Mycobacterial Reference Center of the Tuscany
Region, while reference strains were provided from Prof. Bo¨ttger (Zurich
University). The whole set of strains were grown on 7H10 medium and
CLM susceptibility was assessed by broth diluition assay. Protein proﬁles
were provided by using MALDI-ToF MS Biotyper for both clinical and
reference strains. Since M. avium was not present in the MALDI-ToF
database, 20 spectra were collected from each strain in order to create
a reference database suitable for M. avium identiﬁcation. Spectra were
analysed even to detect differences in susceptible and resistant CLM
strains.
Results: Using MIC broth dilution assay 29 CLM susceptible M. avium
strains and 10 resistant strain were identiﬁed. MALDI-Tof MS provided
the correct M. avium identiﬁcation with a high sensitivity and speciﬁcity
showing a 99% of concordance compared to 16S rDNA based
sequencing analysis for all the analysed isolates.
Spectra analysis showed a speciﬁc peak, which could characterize and
distinguish susceptible from resistant strains.
Conclusion: This study provides the evidence that MALDI-ToF MS is a
fast and reliable method for the identiﬁcation of M. avium in clinical
samples and it could be useful for CLM evaluation. Broth diluition
assay is timeconsuming and end-point reading is somewhat subjective
and consequently open to variation in different settings. Given these
limitations, it’s necessary an equally robust methodology, with faster
turn-around times and where endpoints determination is objective.
P2003 Use of the genotype Mycobacterium assay for rapid
identiﬁcation of non-tuberculous mycobacteria in routine
clinical laboratory
F. Kontos, D. Mavromanolakis, M. Zande, G. Kosmadakis, A. Manidaki,
Z. Gitti* (Athens, GR)
Objectives: The incidence of Nontuberculous Mycobacteria (NTM),
as well as the number of mycobacteriosis patients is steadily rising.
The awareness of NTM as potential pathogen is increasing. While the
isolation and identiﬁcation of these organisms is difﬁcult. The aim of
this study is to assess the usefulness of GenoType Mycobacteria CM and
AS for the identiﬁcation of mycobacterial strains isolated from patients
living in Crete.
Methods: Over a 10-year period (2000–2010) 12971 samples from
inpatients and outpatients were collected. Recovery of NTM isolates
was accomplished using Lowenstein-Jensen slants and BactAlert 3D
(bioMerieux, Durham, NC) system. For identiﬁcation, the GenoType
Common Mycobacteria (GenoType CM) and GenoType Additional
Species assays (GenoType, Hain Lifescience, Nehren, Germany) were
performed, according to the manufacturer’s instructions. When necessary,
16S rRNA and/or hsp65 gene sequencing, PCR-RFLP analysis of the
hsp65 gene and the conventional culture identiﬁcation methods were
performed.
Results: During the study period 242 NTM isolates were recovered
from different patients, which belonged to 23 species. M. lentiﬂavum
(67/242, 27.7%) represents the most frequent species, probably due
to contamination of hospital water, followed by M. gordonae (53/242,
21.9%),M. fortuitum (32/242, 13.2%),M. avium (21/242, 8.6%). For one
culture with M. interjectum and M. bohemicum the PCR-RFLP analysis
of hsp65 detected these two species but the Genotype Mycobacterium
CM/AS identiﬁed only the M. interjectum. GenoType assay failed
to identify 24/242 (9,9%) of the strains, which belonged to new or
newly described species when compared with 16S rRNA or hsp65
gene sequencing. Apart from these isolates, all other identiﬁed by the
GenoType assay, were in concordance with the conventional methods
Conclusion: The results show that the GenoType mycobacterium system
is reliable, rapid, easy-to-perform and easy-to-interpret assay. Moreover it
appears to be suitable for use in our region, since it identiﬁed all but 9,9%
of the mycobacterial species. For the unidentiﬁed species sequencing
analysis is needed.
P2004 Lymphocyte subpopulations phenotyping in active tubercu-
losis: association with Quantiferon-TB gold in-tube® assay
and radiological/microbiological markers of severe disease
L. Guglielmetti*, M. Conti, R. Valentinotti, A. Cazzadori, A. Vella,
R. Ortolani, F. Boccafoglio, E. Concia (Verona, Trento, IT)
Objectives: The aim of this study was to evaluate the alterations of
lymphocyte subpopulations in tuberculosis (TB) patients compared to
healthy subjects, particularly related to IFN-g production in response
to a commercially available IFN-g-related assay and to radiological and
microbiological markers of advanced disease in pulmonary tuberculosis
(PTB) patients.
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Methods: We analysed 99 patients affected by active TB compared to
a control group of 93 healthy subjects; patients affected by HIV and
other immunosuppressive pathologies or treatments were excluded. All
TB patients had a positive cultural exam and underwent thoracic CT
scan and QuantiFERON-TB Gold In-Tube (QFT-IT) (®Cellestis Ltd).
Lymphocyte subpopulations were studied by using monoclonal antibod-
ies with six different ﬂuorochromes and subsequently by ﬂow cytometry
(®Becton-Dickinson).
Results: Total and relative lymphocyte counts showed statistically
signiﬁcant reductions in TB patients compared with healthy subjects;
CD8+ lymphocytes were more affected by this phenomenon than CD4+,
resulting in a signiﬁcant increase in CD4+/CD8+ ratio. Despite the
general lymphocyte decrease, activated (DR+) CD4+ and CD8+ cells
were more relevant in proportion and in total count in TB patients. In
the TB group we also found a signiﬁcant proportional increase of CD4+
CD57+ cells.
A positive QTF-IT result was related to a similar pattern of activated and
CD4+ CD57+ cells increase, together with a higher total and proportional
lymphocyte count.
Smear-positive PTB patients with extended (>2 lobes affected) and
cavitary pulmonary involvement showed lower IFN-g response to QFT-
IT and signiﬁcantly reduced NK cell and total lymphocyte counts,
with a trend towards higher levels of CD4+ lymphocytes and increased
CD4+/CD8+ ratio.
Conclusion: Our study reveals remarkable alterations in TB patients
lymphocyte subpopulations. Contrasting with a general lymphocyte
deﬁciency, we found an increase in activated and CD4+ 57+
lymphocytes. This subset of effector T lymphocytes is able to express
IFN-g and in our study was associated with QFT-IT positivity.
Severe, smear-positive pulmonary disease was associated to lower levels
of total lymphocytes and NK cells, with decreased IFN-g production
leading to higher rates of false-negative QTF-IT results. This ﬁnding
could reﬂect increased compartmentalization of the immune response to
the extensively affected lung parenchyma.
P2005 Direct detection of multiple drug-resistant Mycobacterium
tuberculosis in clinical specimens using real-time PCR,
multiplex allele-speciﬁc PCR and PCR-sequencing
W. Yam*, G. Siu, V. Cheng, P.L. Ho (Hong Kong, HK)
Objectives: The emergence of drug-resistant Mycobacterium tuberculo-
sis demands rapid diagnosis for better clinical management and public
health control.
Methods: A total of 838 respiratory specimens and 622 non-respiratory
specimens were collected for in-house single tube nested real-time
PCR and COBAS TaqMan (Roche Diagnostics) real-time PCR assays.
Samples positive for either PCR assay will be subjected to multiplex
allele-speciﬁc (MAS)-PCR for katG315 and maba-15; PCR-sequencing
for rpob and gyrA genes. Results were evaluated towards direct AFB
smear and mycobacterial culture. Susceptibility test of isolates for
isoniazid (INH), rifampicin (RIF), and oﬂoxacin (OFX) was performed
using agar proportional method.
Results: For respiratory and non-respiratory specimens, 231 and 25
were culture positive for M. tuberculosis among which 138 and 2
were also AFB smear-positive. Both in-house and Roche real time
PCR exhibited 100% sensitivity and speciﬁcity for AFB-smear positive
specimens. For culture positive but AFB smear-negative specimens,
diagnostic sensitivity of in-house and Roche PCR was 79% and 75%.
PCR inhibitors were detected at a rate of 1.5% and 5.5% for respiratory
and non-respiratory specimens. Subsequent MAS-PCR detected 83%
of INH resistant isolates whereas PCR-sequencing detected 96% RIF
resistant and 91% OFX resistant isolates among which 8 strains of MDR-
TB and 2 strains of XDR-TB were identiﬁed. All PCR results showed
complete concordance with mycobacterial culture and anti-mycobacterial
susceptibility test.
Conclusion: Both in-house and Roche PCR assays exhibited high
sensitivity and speciﬁcity suitable for rapid diagnosis of M. tuberculosis.
This study also evaluated a molecular strategy to detect multiple drug
resistant M. tuberculosis in respiratory specimens. A cost-effective and
cascade system will further shorten the turnaround time for identiﬁcation
and drug susceptibility testing of M. tuberculosis in clinical specimens
to around 5 days (Fig. 1) suitable for routine diagnostic services in areas
with high prevalence of drug-resistant tuberculosis.
P2006 Introduction of 24-loci MIRU-VNTR typing in a
region-wide scheme considerably reduces the number of
cases requiring epidemiological investigation
J.T. Evans*, A.L. Gibson, S. Khanom, C. Overton-Lewis, S. Gardiner,
E.G. Smith, P. Hawkey (Birmingham, UK)
Objective: In 2003, routine 15-loci Mycobacterial Interspersed Repeti-
tive Unit-Variable Number tandem Repeat (MIRU-VNTR) typing com-
menced at the West Midlands Public Health Laboratory, Birmingham,
UK. In January 2010, an additional 9 MIRU-VNTR loci were added to
the 15-loci panel to provide a routine prospective 24-loci typing service.
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The aim of the study was to determine if the implementation of 24-
loci typing reduced the level of clustering and therefore the amount of
epidemiological investigation required compared to the 15-loci typing
service.
Methods: All available culture conﬁrmed cases of M. tuberculosis
identiﬁed at the West Midlands Public Health Laboratory, in 2010 had
DNA extracted for 24-loci typing. All isolates with indistinguishable
MIRU-VNTR proﬁles were considered clustered. The level of clustering
observed using 15-loci was compared to that with all 24-loci. The
Hunter-Gaston Index (HGI) was used to determine the discriminatory
power of each typing method.
Results: A total of 850/893 (95.1%) culture-conﬁrmed cases had isolates
available for 24-loci typing. Using 15-loci typing, 60.0% (510/850) of
isolates were clustered compared to 35.2% (299/850) of isolates when
analysed with all 24-loci. Clusters ranged from 2−25 isolates and 2−18
isolates with 15-loci and 24-loci typing respectively. 24-loci typing
reduced the number of large clusters resulting in a greater proportion of
smaller clusters, 74% of clustered isolates were contained in clusters with
5 or less isolates compared to 50.2% of clustered isolates with 15-loci
typing. The HGI conﬁrmed that 24-loci was more discriminatory than
15-loci typing (0.968 and 0.957 respectively). Overall the addition of
9-loci to the original 15-loci resulted in 211 fewer clustered isolates and
ultimately reduced the number of cases requiring further investigation
by 41.4%.
Conclusion: The introduction of routine 24-loci typing reduces the
amount of cases that require epidemiological investigation and the
costs associated with contact tracing. This new typing service therefore
provides more accurate molecular epidemiological data for public health
teams to initiate cluster investigations.
P2007 Evaluation of Gene Xpert® MTB/RIF system for the direct
detection of rifampicin-resistant Mycobacterium tuberculosis
from pulmonary and extrapulmonary specimens in the
National Tuberculosis Reference Laboratory in Kuwait
E. Mokaddas*, S. Haneef, H. Saad Eldeen (Dasma, KW)
Introduction: Direct detection of Mycobacterium tuberculosis MTB
from clinical specimens and rapid testing of its antimicrobial suscep-
tibility helps the early treatment as well as prevention of spread among
contacts of patients with open pulmonary TB.
Objectives: This study was done to evaluate the Gene Xpert® MTB/RIF
system in the direct detection of MTB and their resistance to rifampicin
from clinical specimens.
Methods: A total of 236 specimens were included in the evaluation.
Sputum and other pulmonary specimens such as bronchoalveolar lavage
and endotracheal secretion comprised 196 specimens out of which
154 were smear negative. Extrapulmonary specimens such as pleural
ﬂuid, pus, ﬁne needle aspiration FNA, Cerebrospinal ﬂuid CSF and
urine comprised 40 specimens with 26 being smear negative. All the
specimens were processed for culture by MGIT960 and Gene Xpert®
MTB/RIF system. A total of 76 isolates of MTB were processed for
direct susceptibility testing using Bactec 460 and compared to the Gene
Xpert® MTB/RIF system. Twelve non tuberculous mycobacteria NTM
isolates were also tested by the Gene Xpert® MTB/RIF system to check
its speciﬁcity.
Results: The sensitivity, speciﬁcity, positive predictive value PPV
and negative predictive value NPV for smear-negative sputum were
60%, 100%, 100% and 97%, respectively while for smear positive
the sensitivity and speciﬁcity were 98% and 100%, respectively. For
smear-negative extrapulmonary specimens, sensitivity was 83% while
the speciﬁcity, PPV and NPV were all 95% and for smear positive the
sensitivity and speciﬁcity were 100%. The sensitivity, speciﬁcity, NPV
and PPV of rifampicin resitance by Gene Xpert® MTB/RIF system were
91%, 97%, 83% and 98%, respectively. An analysis of 12 NTM species
conﬁrmed 100% speciﬁcity.
Conclusion: Gene Xpert® MTB/RIF system is a rapid and reliable
technique for the detection of MTB and rifampicin resistance in both
pulmonary and extrapulmonary specimens.
P2008 Detection of Mycobacterium tuberculosis complex by
RT-PCR in non-respiratory clinical specimens in Health
Department 9, Valencia (Spain)
M.R. Guna*, N. Tormo, L. Villamayor, A. Jimenez, M.T. Fraile,
M.D. Ocete, M. Chanza´, C. Gimeno (Valencia, ES)
Objective: To compare sensitivity and speciﬁcity of two RT-PCR
commercial methods used for Mycobacterium tuberculosis complex
(MTBC) detection in non-respiratory samples, and to evaluate advan-
tages of molecular diagnostic tools compared to conventional methods
in paucibacillary samples.
Material and Methods: This study included 103 non-respiratory clinical
samples from Health Department 9 (Valencia, Spain) and processed
in the Microbiology Department of Hospital General Universitario
(Valencia). Samples were collected from March 2009 to March 2010
and were processed for mycobacterial culture in liquid Bactec® MGIT
960 (BD) and Lowenstein Jensen (BD). After sample decontamination,
MTBC genome detection using two different RT-PCR techniques was
conducted in parallel with: (a) Xpert® MTB/RIF in the GeneXpert®
System, (b) Extraction with BioRobot EZ1® workstation (Qiagen) after
heat shock treatment of samples (15min 95ºC) and ampliﬁcation in
SmartCycler® System (Cepheid) with RealAccurate™ Mycobacterium
tuberculosis PCR reagent kit (PathoFinder). In all cases manufacturer’s
instructions were followed. When a discrepant result occurred, the
process was repeated.
Results: We obtained a negative result by both RT-PCR methods in
86 of the 103 studied samples (83.5%). From those 86 PCR-negative
samples, only one (urine) had a MTBC positive culture. Fourteen samples
(13.6%) were positive by both RT-PCR methods; seven of them had a
positive smear (number of acid-fast bacilli showed strong correlation
with threshold cycle or Ct value) and eleven had a MTBC positive
culture. In three negative-culture cases, RT-PCR methods were discrepant
one to each other. The sensitivity for both sets of RT-PCR was 91.7%,
and the speciﬁcity was 95.6% for the Xpert® MTB/RIF and 94.5% for
the RealAccurate™ method (Table 1).
Conclusions: Both methods are useful tools for MTBC detection on
direct non-respiratory samples. They are fast, simple and little-handling
techniques, with high sensitivity and speciﬁcity (even in cases of
atypical mycobacterial infection they do not show false positive results),
exceeding the sensitivity of the smear and the slowness of the culture.
While covering a wide range of moderate VPP, the percentages of
agreement between RT-PCR negative results and culture were 98.9%,
which supports their use in non-respiratory samples.
P2009 New DNA microarray platform for detection of MDR
Mycobacterium tuberculosis and of drug-resistant malaria
A.M. Cabibbe*, P. Miotto, E. Lazzeri, J. Mugasa, F. Santoro,
V. Nikolayevskyy, L. Ranford-Cartwright, G. Pozzi, S. Niemann,
F. Drobniewski, D. Cirillo and the TM-REST Consortium (EU-FP7
project)
Objectives: The aim of the study is to develop a new rapid diagnostic
tool for MDR tuberculosis (TB) and for drug-resistant malaria using a
lab-on-chip (LoC) platform (In-Check™, ST Microelectronics).
Methods: The LoC provides an all-in-one device for fast-PCR
ampliﬁcation of target DNA followed by hybridization on a low-density
microarray.
TB: Most relevant mycobacterial species are identiﬁed by targeting
the 16S rDNA and IS6110 insertion sequence. Probes speciﬁc for
mycobacterial species were designed. A multiplex PCR was developed
to amplify rpoB, katG, and inhA as the most frequently mutated genes
involved in resistance to rifampin and isoniazid in species belonging the
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Mycobacterium tuberculosis complex. Speciﬁc probes targeting the hot-
spot region of rpoB, the codon 306 of katG, and nucleotides −15 and −8
in the promoter region of inhA were designed for drug resistance
detection.
Malaria: Detection of the ﬁve human malaria-causing Plasmodium
species (Plasmodium falciparum, P. vivax, P. ovale, P. knowlesi and
P. malariae) is performed using PCR based on 18S rRNA gene followed
by hybridization with species-speciﬁc probes on the LoC.
Results: TB: the performance of the In-Check™ platform was assessed
using DNA extracted from both isolates and clinical specimens. Selected
probes allowed identiﬁcation of M. tuberculosis complex, M. avium,
M. intracellulare, M. simiae, M. kansasii, M. scrofulaceum, M. ab-
scessus, M. chelonae, M. xenopi, M. haemophilum and M. fortuitum.
Concerning drug resistance detection, the assay detects mutations D516V,
S531L for rpoB, S315T for katG and c-15t, t-8c, t-8a for inhA. Mutations
at codon 533 and 526 in rpoB and other mutations at codon 315 of
katG are identiﬁed by a negative signal from wild-type probes. The
test sensitivity is 4000 cells/mL. Malaria: the LoC was tested on pure
species samples and patient samples and allowed correct identiﬁcation of
all human malaria parasite species. The accuracy of the test is 100% for
the identiﬁcation of all ﬁve Plasmodium species and shows a sensitivity
equivalent to microscopy and standard PCR assays.
Conclusions: This integrated PCR and microarray LoC tool represents
an innovation for its simplicity of use, rapidity and cost-effectiveness.
Moreover, the In-Check™ platform is particularly suitable for different
diagnostics purposes, making this assay indicated for the laboratory
routine.
P2010 Evaluation of GeneXPERT MTB/RIF assay in respiratory
and non-respiratory specimens for the rapid detection of
Mycobacterium tuberculosis
Z. Archontakis, C. Dimoulas, A. Charitakis*, S. Kanaki, S. Foyntoylakis,
E. Michailellis, K. Thymaki, V. Liakou (Herakleion, GR)
Objectives: The principle of the Xpert MTB/RIF test running on
GeneXpert system, is to detect M. tuberculosis complex (MTBC) and
mutations in the gene rpoB that cause resistance to rifampicin. The
aim of this study is to compare the detection sensitivity of pulmonary
and extrapulmonary MTBC using MTB/RIF assay and GenoType
MTBDRplus, (Hain Lifescience, Nehren, Germany) against liquid and
solid culture (Becton Dickinson BACTEC™X MGIT™, Lowenstein-
Jensen).
Methods: Each individual provided 3 sputum samples of sufﬁcient
quantity within 72 hours. Sputum samples for each patient were
processed using NALC (n-acetylcysteine)/NaOH decontamination, were
concentrated and tested using smear microscopy, culture, GenoType
MTBDRplus and XpertMTB/RIF (smear and Xpert MTB/RIF were done
from the same sediment as culture). Concentrated urine and gastric
samples were centrifuged and up to 500ml distilled water was added
in the sediment prior to decontamination and addition of lysis buffer.
Pleural ﬂuids were not decontaminated but were centrifuged and up to
500ml distilled water was added in the sediment before addition of lysis
buffer. For liquid culture 500ml of medium were centrifuged prior to
addition of lysis buffer.
Results: 250 specimens have been tested. Culture was positive
in 50 samples (Mean time of isolation 8.02 days). Twenty six
(10.4%) were identiﬁed as atypical mycobacterium. None of these
26 samples were positive by the Xpert test. MTBC was isolated
from 24 (9.6%) specimens, gastric ﬂuids (n = 8), pleural ﬂuids (n = 1),
respiratory samples (n = 14) and urine (n = 1). All of these were
positive by the Xpert MTB/RIF test. Twenty three specimens were
identiﬁed as Mycobacterium tuberculosis and 1 (urine) was identiﬁed
as Mycobacterium bovis (patient was known to be treated with M. bovis
as immunotherapy for bladder cancer).
Conclusions: The Xpert MTB/RIF provides rapid and speciﬁc detection
of MTBC compared with conventional laboratory tests, both in
respiratory and extrapulmonary samples. It can be used as an important
tool for early diagnosis of TB and efﬁcient patient management.
P2013 Clinical evaluation of the GenoType MTBDRsl for the
rapid diagnosis of second-line resistance in Mycobacterium
tuberculosis
I. Festoso*, P. Mantegani, P. Miotto, A.M. Cabibbe, I. Valente,
E. Borroni, D. Cirillo (Milan, IT)
Objectives: The aim of this study is to evaluate the performance of the
GenoType MTBDRsl (Hain Lifescience, Nehren, Germany) for the rapid
diagnosis of extensively drug-resistant (XDR) tuberculosis (TB) cases.
Methods: The GT-MTBDRsl is a molecular assay that allows rapid
detection of drug resistance to ﬂuoroquinolones (FQs), second-line
injectable drugs (AG/CP) and ethambutol (E) by identifying speciﬁc
mutations known to be responsible of resistant phenotype affecting
gyrA, rrs and embB genes, respectively. For the evaluation we compared
results obtained by the GT-MTBDRsl with sequencing data and culture
drug susceptibility testing (DST) on 105 multidrug resistant (MDR-TB)
clinical isolates and 26 sputum specimens from patients at risk of XDR-
TB. Sensitivity, speciﬁcity, positive and negative predictive values (PPV,
NPV) are reported.
Results: Table 1 summarizes data concerning evaluation of performance
of the GT-MTBDRsl on strains.
Concerning FQ-R, the concordance between the molecular test and the
DST is 95.2%; 1 phenotypically susceptible strain showed a double
pattern in sequencing. The concordance among FQ-S strains is 88.1%: 10
were FQ-R by phenotypic analysis. The agreement concerning AG/CP-R
strains between the GT-MTBDRsl and the DST is 100% whereas for
AG/CP-S strains is 81,4%: 13 cases were AG/CP-R by DST. The
concordance about E-R strains is 50%: in 24 cases the molecular test
identiﬁed mutations in strains resulted susceptible by DST. Concerning
E-S strains, observed concordance is 63,2%: 21 were resistant by DST.
Among the 26 sputum specimens, 2 identiﬁed as FQ-R by the molecular
test were also conﬁrmed by DST. Six cases (23,1%) resulted AG/CP-R;
5 of them showed a double pattern mutation + wild-type, and 1 didn’t
show wild-type signal. Only 2 cases were conﬁrmed by DST. Among 19
AG/CP-S strains by the GT-MTBDRsl, 1 resulted resistant by phenotypic
analysis. In 1 case the molecular test didn’t allow to obtain any result
for rrs gene. Three out of 11 samples (42,3%) identiﬁed E-R by the
presence of mutation were conﬁrmed as E-R in DST.
Conclusion: The speciﬁcity of the GT-MTBDRsl, comparing with
sequencing is very high.
This study shows that the GT-MTBDRsl is valid for the identiﬁcation
of XDR-TB with high PPV. Due to the low NPV, the use of the GT-
MTBDRsl would be justiﬁed for the screening of patients with MDR-TB
at high risk of progression to XDR-TB.
P2014 Evaluation of GeneXpert MTB/RIF assay for the diagnosis
of tuberculosis and rapid detection of rifampin resistance
in clinical specimens
A. Nazli*, C. Cavusoglu (Izmir, TR)
Objectives: The aim of this study was to determine the performance
of GeneXpert MTB/RIF (Xpert; Cepheid, Sunnyvale, CA) assay for the
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diagnosis of tuberculosis and rapid detection of rifampin resistance in
clinical specimens.
Materials and Methods: A total of 232 clinical specimens of 228
patients were included in the study. The GeneXpert MTB/RIF was
used according to the instructions of the manufacturer. The results
obtained by the GeneXpert MTB/RIF assay were then compared with
the results obtained by culture, clinical diagnosis and phenotypic drug
susceptibility testing (DST). Diagnosis of respiratory and nonrespiratory
tuberculosis were conﬁrmed by clinical (productive cough, hemoptysis,
weight loss), pathological and radiographic ﬁndings and/or positive
culture and microscopy tests. The ﬁnal diagnosis for the culture-negative
patients was established by the clinicians.
Results: A total of 232 clinical specimens which 28 smear-positive and
204 smear negative were included in the study. Among all culture positive
clinical specimens direct MTB/RIF test identiﬁed 56 of 69 specimens
(NPV: %92,4 PPV: %93,3). In 27 of 28 (26 culture positive) smear
positive specimens and 30 of 204 (42 culture positive)smear negative
clinical specimes were correctly identiﬁed by the test. GeneXpert
MTB/RIF assay detected 41 of 137 (40 culture positive) respiratory
specimen (NPV: %94,8, PPV: %97,6). In 19 of 95 (16 culture positive)
nonrepiratory specimens PCR was positive (NPV: %89,5, PPV: %84,2).
When we evaluate the performance of PCR for the diagnosis of clinically
diagnosed 83 tubercuosis cases (71 culture positive, 12 culture negative)
NPV: % 87,3 and PPV: % 100. It had lower sensivity in nonrespiratory
specimens (Table1). GeneXpert MTB/RIF assay did not detect any RIF
resistance and it was conﬁrmed by DST.
Discussion: In conclusion, GeneXpert MTB/RIF assay could be useful to
rapidly diagnose M. tuberculosis especially for smear negtive and smear
positive respiratory specimens. However, in nonrespiratory specimens it
has lower sensivity.
P2015 Speciﬁcity of urine PCR in diagnosing tuberculosis
M. Jamshidi*, A. Nejatizadeh, P. Davoodian, S. Zaare, H. Vahdat,
T. Eqbal eftekhaari, M. Baqer shiroodi, H. Dadvand, F. Fakhar
(Tehran, Bandar-Abbas, IR)
Objective: Sputum staining and culture is a standard method of
diagnosing tuberculosis. Because of long time elapsed in culture of
tuberculosis bacilli, a more rapid test is required for quick diagnosis
of tuberculosis to conﬁrm the clinical diagnosis and initiate the standard
antituberculosis regimen. Polymerase chain reaction (PCR) of urine
appears as the method of choice, particularly when tuberculosis gets
associated with HIV infection. Urine PCR seems to be helpful in
diagnosing pulmonay TB in patients who cannot expectorate sputum
and in patients with extrapulmonay TB.
Method: A prospective study was designed by collection of three early
morning urine specimens of 103 patients from Sep, 2008 to Sep 2009,
suffering from extrapulmonary and/or pulmonary tuberculosis. The three
samples were mixed, and a nested PCR was performed. Data analysis
was carried out by SPSS 16, using descriptive statistics.
Results: 28/103 (27.18%) had a positive urine PCR. 72.81% had
pulmonary TB. 48% were smear negative. 16.66% of smear negative
pulmonary TB, 30.76% of smear positive pulmonary TB and 37.03%
of patients with extrapulmonary TB had positive urine PCR. 21.35%
of studied population was HIV positive. 81.81% of HIV patients had
pulmonary TB. Urine PCR was positive in 38.88% of HIV positive
patients with pulmonary TB, and in 25% of HIV positive patients
with extrapulmonary TB. The most involved organ in extrapulmonary
tuberculosis was lymph node in 16 cases (15.5%) Sensitivity of PCR
in diagnosing pulmonary tuberculosis was 24%, speciﬁcity was 64%,
with a Positive predictive value (PPV) of 64%, negative predicting value
(NPV) of 24% and accuracy of 34%. Sensitivity of this test in diagnosing
smear positive TB was 30%, speciﬁcity was 73%, with a PPV of 42%,
NPV of 63% and accuracy of 78%. Sensitivity of this test in diagnosing
pulmonary Tb in HIV positive patients was 38%, speciﬁcity was 80%
with a PPV of 38%, NPV of 63% and accuracy of 70%. Sensitivity of
urine PCR in diagnosing extrapulmonary Tb in HIV positive patients is
25%, speciﬁcity is 62.5%, with a PPV of 10% and NPV of 83%, and
the accuracy is 57%.
Conclusion: Urine PCR is helpful in diagnosing tuberculosis especially
in HIV positive patients with extrapulmonay TB. This technique has high
speciﬁcity in diagnosing tuberculosis.
P2016 Evaluation of an induced sputum service for diagnosis of
pulmonary tuberculosis
P. Papineni*, R. Lever, A. Bello, J. Aspinall, M. Brown (London, UK)
Objectives: The diagnosis of pulmonary tuberculosis (TB) is usually
on sputum microscopy and culture. However, some patients are
unable to expectorate and alternatives include gastric lavage, ﬁbreoptic
bronchoscopy and sputum induction. We set up a service for sputum
induction (SI) at the Hospital for Tropical Diseases, London, and
conducted a retrospective analysis to consider if it is a useful tool for
diagnosing pulmonary TB in our patient group.
Methods: The study included patients with suspected pulmonary or
pleural TB (i.e. had clinical symptoms or a chest radiograph consistent
with TB) who were unable to expectorate. The patients excluded
were those with reduced consciousness, uncontrolled obstructive lung
diseases, hypoxia, pneumothorax or inability to consent. The technique
involves the patient receiving 30mls 3% hypertonic saline via nebuliser
in a negative pressure room, with the operator using standard respiratory
protection measures. We evaluated data over an 18-month period from
Dec 2008-July 2010.
Results: 69 patients were included in the study group. The median age
was 36 years (range 12−81 years) and 65% of patients were male. With
regards to HIV status, 34 patients were negative, 19 were HIV-positive
and 16 were not tested. 16 patients were referred from outpatient clinics;
the rest were inpatients.
In 6 patients SI was unsuccessful. The average number of sputum
samples sent was 2.4 (range1−4). 10 patients were smear positive for
acid-fast bacilli on SI (all Mycobacterium tuberculosis on culture). 3
patients were smear negative but culture positive for Mycobacterium
tuberculosis, and 3 patients were smear negative but isolated non-
tuberculous mycobacterium.
Of those patients who were smear negative on SI, 6 proceeded to
ﬁbreoptic bronchoscopy and 3 had endobronchial ultrasound. None
of these patients had a diagnosis of pulmonary TB made following
bronchoscopy (4 had a diagnosis of Pneumocystis jirovecii pneumonia
from bronchial washings and 2 patients had a diagnosis of lymph node
TB). Smear positive pulmonary TB diagnosed by SI had a prevalence of
20% in the study group. SI for diagnosis of smear positive pulmonary
TB had a sensitivity of 0.76 (95% conﬁdence interval 0.45–0.93).
Conclusions: SI is useful in the diagnosis of pulmonary TB in patients
who are unable to expectorate. Our service could be expanded to include
more outpatients, thus reducing costs with regards to length of hospital
stay and the need for invasive investigations.
P2017 Use of Quantiferon-TB gold assay for tuberculosis in
immunocompromised patients
M. Fomichev*, K. Levina, N. Fomicheva (Tallinn, EE)
Objectives: To evaluate the response to the Quantiferon-TB Gold Assay
(QFT) In Tube in immunocompromised patients.
Methods: 194 patients were routinely tested in QFT assay during the
period from August 2007 to October 2010. Patients were divided into
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following 3 groups: group 1) consisted of Intensive Care patients (39
subjects), group 2) consisted 39 hematology patients (both groups had
negative serological tests for HIV), and in group 3) 124 HIV patients
were included. QFT assay was performed according manufacturer’s
recommendations. The cut-off value for a positive result was 0,35
IU/ml interferon-g (IFN-g).
Results: Among of 194 immunocompromised patients positive value
was found in 23 (11.9%) patients, negative was in 150 (77.3%) and
indeterminate was in 21 (10.8%).
In group 1) 8 (20.5%, 95%CI 10−41%) demonstrated positive results and
22 (56.4%, 95%CI 55−87%) negative. In group 2) patients represented
the positive rates in 7 (17.9%, 95%CI 6−30%) cases and negative rates
in 25 (64.1%, 95%CI 49−79%). 8 patients (6.5%, 95%CI 2−11%) from
group 3) were QFT positive and 103 (83.1%, 95%CI 76−90%) were
negative.
However, 21 (10.8%) patients had an indeterminate QFT-TB result.
Indeterminate ﬁndings were not signiﬁcantly associated with distribution
of individuals between subgroups (Fisher’s p> 0.005). All of the QFT
indeterminate patients showed low response to phytohemagglutinin.
Active tuberculosis infection was found in 16 (8.3%) individuals. The
diagnosis of active TB was conﬁrmed by positive culture. Among of
them, 8 (50%) had a positive QFT results, 6 (37.5%) negative and
2 (12.5%) patients had indeterminate results. For active TB when
indeterminate results were excluded sensitivity was 50% (95%CI 22.5–
74.5%), speciﬁcity was 92.4% (95%CI 87−98%), positive predictive
value (PPV) was 40% (95%CI 20−64%), negative predictive value was
95% (95%CI 90−98%).
Conclusions: Sensitivity and PPV of QFT for diagnosing active TB in
immunocompromised patients were unsatisfactory. Usefulness of QFT
for these patients is limited. For the diagnosis of active TB infection
QFT must be used in combination with other tests.
P2018 Multicentre laboratory validation of the colorimetric
redox indicator assay for the rapid detection of extensively
drug-resistant Mycobacterium tuberculosis
A. Martin*, F. Paasch, S. Docx, K. Fissette, B. Imperiale, W. Ribon,
L. Gonzalez, W. Werngren, A. Engstrom, G. Skenders, P. Jureen,
S. Hoffner, P. Del Portillo, N. Morcillo, J.C. Palomino (Antwerp, BE;
Buenos Aires, AR; Bogota, CO; Solna, SE; Riga, LV)
Objective: To perform a multicenter study to validate the colorimetric
resazurin microtiter assay (REMA) for the rapid detection of resistance
to rifampicin, isoniazid, oﬂoxacin, kanamycin and capreomycin in
M. tuberculosis clinical isolates.
Methods: The study was carried out at 5 sites: the State Agency
LIC, Clinic of Tuberculosis and Lung Diseases, Riga, Latvia; the
Dr. Cetra´ngolo Hospital, Vicente Lo´pez, Buenos Aires, Argentina; the
Swedish Institute for Infectious Disease Control, Solna, Sweden, the
Instituto Nacional de Salud, Bogota, Colombia and the Institute of
Tropical Medicine in Antwerp, Belgium. In Phase I we tested 149
M. tuberculosis isolates and determined the MIC for each drug and
compared results with the conventional proportion method (PM). In
Phase II, a set of 30 strains, with different resistance patterns to second
line drugs were sent and tested blindly by the study sites to determine
the critical concentration of each drug.
Results: MICs were obtained after 8 days. Phase I: a strain was
considered resistant by the REMA if the MIC >0.5mg/L for rifampicin,
>0.25mg/L for isoniazid, >4.0mg/L for oﬂoxacin, and >5.0mg/L for
kanamycin and capreomycin. Sensitivity was 99.1% for isoniazid and
100% for the other drugs and speciﬁcity was 97.9% for capreomycin
and 100% for the other drugs. Phase II: the critical concentrations for
rifampicin was 0.5mg/L; for isoniazid 0.25mg/L; for oﬂoxacin 2.0mg/L;
and 2.5mg/L for kanamycin and capreomycin giving an overall accuracy
of 98.4%, 96.6%, 96.7%, 98.3% and 90% respectively.
Conclusion: Results demonstrate that REMA is an accurate method
for the rapid detection of XDR-TB in M. tuberculosis. A very good
correlation between results by the REMA and the PM was obtained.
REMA is faster that the conventional drug susceptibility testing method
using solid medium, has the same turnaround time that the BACTEC
MGIT 960 system but is less expensive and could be an adequate method
for low-income countries.
P2019 Prevalence of drug-resistant tuberculous meningitis in
real-time PCR-proven patients from Southern China: a
retrospective study based on the commercial molecular line
probe assays
D. Lina*, W. Lanlan, Y. Binwu (Chengdu, CN)
In the era of the globally increased prevalence of drug resistant
tuberculosis, the problem of multidrug-resistant tuberculosis (MDR TB)
has also been identiﬁed in patients with tuberculous meningitis (TM).
There are few reports on multidrug resistance in TM. Herein we report
the ﬁndings of a retrospective study using the Genotype MTBDRplus
line probe assay (Hain Lifescience GmbH, Nehren, Germany) in real-
time PCR-proven patients from the Chinese West China Hospital of
Sichuan University, which is a 4300-bed university-afﬁliated referral
hospital located in southwestern China, designed to collect regional
epidemiological information of drug resistant TM. In 2010, 30 acid-
fast bacillus smear-negative CSF samples from 16 male and 14 female
patients with the median age of 29 years (ranged from 18 to 73),
tested positive for TB DNA via real-time ﬂuorescence PCR (TB PCR
Fluorescence Diagnostic Kit, Qiagen) were analyzed by the GTplus
assay. Of them 8 had a history of previously treated pulmonary
tuberculosis, none was tested HIV seropositive and 10 patients were
ultimately culture conﬁrmed. Through the assay, the number of valid
tests obtained was 83.3% (25/30). Overall, 16 (53.3%) of the 30 patients
tested were found to be genotypically resistant to rifampin (RFP) and/or
isoniazid (INH), a much higher number than reports from South Africa
and India. Out of 30 tested samples,9 were genotypically resistant
to at least RFP (33.3%) and 14 were genotypically resistant to at
least INH (46.7%) in which 71.4% (10/14) were due to the high-
level INH resistance and 21.4% (3/14) to the low level INH resistance.
In addition, 7.1% (1/14) harbored both the high-level and the low-
leveling resistance mutation. MDR was identiﬁed in 23.3% (7/30) of
CSF samples, comprised of 4 (18.2%) in primary cases and 3 (37.5%)
in retreated cases. RMP-resistant mutations were concentrated in the
region of RpoB 530–533 and 66.7% (6/9) were the S531L mutation.
Notably 6 out of 7 patients deﬁned as monoresistant to INH displayed
katG mutation probe 1 but without wild probes missing suggesting the
mixture infections. In addition, compared with culture-positive patients,
the rates of drug resistance in culture-negative patients were signiﬁcantly
higher. This preliminary study suggested that drug resistance in TM is
likely to be more prevalent than previously recognized. Molecular tests
could be a rapid diagnostic method for drug resistant TM.
P2020 Incubation of whole blood at 39ºC augments IP-10 and
IFN-g responses to M. tuberculosis antigens
M.G. Aabye*, P. Ravn, I.S. Johansen, M. Ruhwald (Copenhagen,
Odense, DK)
Objectives: Cell mediated immune (CMI) assays are in-vitro tools
used to monitor antigen-speciﬁc immune responses. Sensitivity of the
CMI in cases with proven disease is often suboptimal and means to
improve performance are needed. A rarely challenged dogma in CMI
assays is the incubation at 37ºC. Fever aids the immune system in
combating microorganisms and increasing the in-vitro immune response
by simulating this in-vivo mechanism seems intuitively appealing. The
aim of this study was to explore whether incubation at fever-range
temperature could increase antigen-speciﬁc biomarker responses.
Methods: We compared CMI responses following incubation of whole
blood at 37ºC and 39ºC from
1. 34 healthy subjects incubated with the antigen TB10.4 present in the
Bacille Calmette Guerin and many environmental mycobacteria; or
2. 8 TB patients and 8 controls, using TB speciﬁc antigens in the
QuantiFERON-TB Gold test (QFT-IT); and
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3. from both groups using a T cell mitogen (PHA).
T-cell responses (IFN-g) and responses from antigen presenting cells (IP-
10) were determined. We further evaluated the effect of adding IL-7 and
blocking IL-10 during incubation.
Results: In TB patients TB antigen-speciﬁc IFN-g and IP-10 levels
were increased 4.1 and 3.4 fold at 39ºC compared to 37ºC incubation
(p< 0.001 for both) without an increase in the controls (ﬁgure 1). Similar
results were seen to mitogen stimulation. In controls responding to
TB10.4, the effects were less pronounced and only signiﬁcant for IP-
10.
Incubation at 39ºC converted one of two TB patients with an
indeterminate QFT-IT to a strong positive QFT-IT result (ﬁgure 1).
Adding IL-7 and blocking of IL-10 augmented the effects in synergy
with fever-range temperature.
Conclusions: Incubation at fever-range temperature and addition of IL7
and anti IL-10 vividly increases cell-mediated immune responsiveness to
antigen stimulation in-vitro in TB patients and may increase sensitivity
of CMI assays.
Advances in mycobacterial culture
P2021 Selective use of automated liquid mycobacterial culture in
an area of low tuberculosis incidence
J. Greig* (Plymouth, UK)
Objectives: Delays in mycobacteriological diagnosis may lead to the
avoidable transmission of tuberculosis (TB) and inappropriate treatment
of non-TB mycobacterial (NTM) infections. The use of techniques
such as automated liquid culture (CAMLiC) can reduce time needed
to isolate mycobacteria and is more sensitive than solid culture but the
cost of CAMLiC can be hard to justify in areas of low TB incidence.
Diagnostic standards such as TB identiﬁcation within 21 days and
ﬁrst line sensitivities within 30 days cannot be met using only solid
culture. An attempt to improve laboratory performance was made using a
protocol by which samples likely to yield a mycobacterium were referred
off site for CAMLiC.
Methods: Smear positive specimens, samples from patients with a
history of TB and invasive samples such as bronchial lavage or
cerebrospinal ﬂuid were referred off site for CAMLiC whilst all others
were cultured locally using existing solid media techniques. Fifty six
mycobacteria were isolated in the 34 months before the change in
methods and 128 in the following 47 months. The time to identify an
isolate as TB or NTM (time to useful speciation) and the proportion of
TB isolates identiﬁed within 21 days was measured.
Results: After the protocol change, time to useful speciation for all
mycobacteria fell (mean 37.3 to 33.3 days). For smear positive samples
the reduction was greater (mean 35 to 27.4 days). For all TB isolates the
protocol change had little impact on time to speciation though for smear
positive samples time to speciation fell appreciably (mean 25.8 to 20.8
days). After the protocol change the proportion of all TB identiﬁed within
21 days increased from 22% to 38%. The proportion of respiratory tract
TB and smear positive respiratory tract TB identiﬁed within 21 days
rose to 46% and 73% respectively.
Conclusions: The selective referral policy had a modest impact on
time to speciate mycobacteria and led to some signiﬁcant diagnostic
improvements. Patients with smear positive respiratory disease are those
most likely to transmit TB or for NTMs be treated inappropriately. Time
to identify an isolate as TB or NTM in smear positive samples was
reduced by over a week. The referral policy led to more TB isolates
being identiﬁed within 21 days but even for smear positive respiratory
specimens diagnostic targets were not met. A policy of CAMLiC for all
samples for which mycobacterial culture is indicated remains the ideal
diagnostic approach.
P2022 Enrichment of Mycobacterium spp. in sodium metasilicate
solution
S. Das* (Kolkata, IN)
Objectives: There is no enrichment technique for Mycobacteria spp so
far. Thus except PCR technique sometimes it is very difﬁcult to get
a positive detection result if the number of Mycobacteria spp. in the
clinical specimen is too low. Again PCR technique for detection of
Mycobacteria spp. in clinical materials often gives false positive results
particularly in developing countries. Thus this experiment was done to
study the efﬁcacy of sodium metasilicate solution for enrichment of
Mycobacteria spp. in general and in clinical samples.
Methods: Four concentrations of Sodium metasilicate solution − 0.5
g/dL, 1.0 g.dL, 2.0 g/dL, 4.0 g/dL were used in this study along with
normal saline and distilled water as controls. International strains of
Mycobacteria spp. − M. tuberculosis H37Rv, H37Ra; M. smegmatis were
used along with 22 wild strains of M. tuberculosis, 1 wild strain each of
M. marinum, M. scrofulaceum, M. ﬂavescens, M. gordonae, M. avium,
M. terrae, M. triviale, M. fortuitum were used in different concentrations
(cfu) in this study. 50 smear positive and 100 smear negative sputum
samples for AFB were also screened by this method. All the tests were
also compared with NALC and NaOH decontamination methods.
Results: Signiﬁcantly good enrichment along with decontamination of
AFB was found with 1g/dL sodium metasilicate solution. However, other
concentrations of sodium metasilicate which were used in this study
failed to show any signiﬁcant result.
Conclusion: Sodium metasilicate solution (1g/dL) may be used for
enrichment of Mycobacteria spp. present in clinical samples.
P2023 Bead-based specimen concentration for mycobacterial
culture
S. Mitarai*, H. Yamada, K. Mizuno, K. Chikamatsu, A. Aono,
T. Sugamoto, R. Karinaga, T. Hatano (Kiyose, Matsudo, JP)
Objectives: The centrifugation is a hazardous laboratory process.
Genetein Co. Ltd. has recently developed a beads-based M. tuberculosis
collection and concentration method, named TRICORE, to avoid
centrifugation process. The efﬁciency of TRICORE for the concentration
of M. tuberculosis from the sputum was evaluated.
Methods: A total of 30 sputum specimens were collected from the
patients with active tuberculosis. The specimens were mixed well with
same volume of NALC-NaOH for the digestion and decontamination,
and incubated at room temperature for 15 min followed by neutralisation
with phosphate buffer (PB: pH 6.8). To obtain various degrees of smear
positivity, 5ml of neutralised specimen was dispensed into two tubes,
and 0.5ml of the original was serially diluted with 4.5ml of PB into by
1/10 and 1/100. A total of 180 pre-treated specimens (30 specimens ×
3 dilutions, × 2 series) were prepared for the following experiments.
One series of specimens were centrifuged at 3,000g for 20 min at 4ºC.
The supernatant was discarded and the sediment was re-suspended with
1ml of PB. For the TRICORE method, 200 ml of bacteria capture beads,
100ml of capture sol, and 100 ml of co-precipitation beads were added
to each tube, and mixed by inversion rotation for 3 minutes. After 3
minutes’ incubation, the supernatant was removed remaining 1ml of
the specimen attracting the co-precipitated beads by magnet. 100 ml
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and 500ml of each residue were inoculated into 2% Ogawa and MGIT
(Becton Dickinson) media, respectively.
Results: Among 90 pre-treated sputum specimens, 51 (57.3%) and 55
(61.8%) strains were recovered by MGIT system with the centrifugation
and the TRICORE method, respectively (Chi square test: p = 0.5413).
The time to detection for centrifugation method was 359.3±117.0 hours,
while that of TRICORE method was 377.6±162.3 (p = 0.5637). However,
the numbers of colonies recovered on solid media were signiﬁcantly
higher in the TRICORE method (p = 0.003). Especially, among the
smear-negative specimens, the culture positivity of TRICORE method
was 39.6%, while the centrifugation method was 15.1% (p = 0.005).
Conclusion: The TRICORE is comparable to the conventional
centrifugation method, and considered to collect the tubercle bacilli more
efﬁciently than the centrifugation method especially in paucibacillary
specimens. The TRICORE, a new concentration method without using
centrifugation, will be safe and could yield more positive culture results.
P2024 Evaluation of a rapid identiﬁcation test for Mycobacterium
tuberculosis complex on mycobacteria growth indicator tube
S. Van den Wijngaert*, G. Stas, W. Chaker, A. Dediste (Brussels, BE)
Objectives: Identiﬁcation of a positive culture suspected for Mycobac-
terium tuberculosis complex (MTBc) relies on biochemical tests and
colony characteristics. Some centres have the privilege to use Nucleic
Acid Ampliﬁcation Techniques (NAT), but these are expensive and
are not performed on a daily base. Consequently, both methods delay
susceptibility testing.
The purpose of this study was to evaluate 2 rapid chromatographic im-
munoassays (CIA) on different mycobacteria, and one CIA prospectively
on successive positive cultures.
Methods: Twenty four different mycobacteria were tested with 2
CIA: the BD MGITTM TBc Identiﬁcation Test (BD) and the SD
TBAgMPT64 Rapid (BioLine; SDAg). Both tests detect the MPT64 Ag,
a mycobacterial protein fraction secreted by MTBc cells during culture.
Since results were comparable and costs were in favour of the SDAg,
a prospective evaluation between 17 May and 31 August 2010 on 84
successive positive culture media of 84 different patients was performed
with this CIA.
Results: Both CIA detected all MTBc strains with the exception of
2 BCG. Eleven different Non Tuberculous Mycobacteria (NTM) tested
negative with both CIA.
The prospective comparison of the SDAg with the COBAS Taqman
assay (Roche) is summarised in table 1. Seven (8.33%) cultures
gave an undetermined NAT result. The Belgian National Centre for
Mycobacteriaceae identiﬁed 3 of them as NTM and 2 as MTBc. The
remaining two had a positive NAT test directly on the sample, and were
considered as MTBc. One culture was probably false positive: doubtful
Auramine O smear performed on MGIT tube, negative Lo¨wenstein-
Jenssen after 10 weeks, re-culturing was negative. SDAg differentiated
the remaining 83 positive MGIT tubes correctly between MTBc and
NTM, giving it a sensitivity and speciﬁcity of 100%.
Both CIA were also tested directly on a respiratory sample with a strong
positive Auramine O smear but both remained negative.
Conclusion: Identiﬁcation of a positive mycobacterial culture is
time consuming and need experienced laboratory technicians. Some
manufacturers have developed a rapid immunoassay, which determines
the presence or absence of MTBc. The assay is easy to use, fast (less
than 15 minutes) and accelerates initiation of susceptibility testing.
This study shows a very high sensitivity and speciﬁcity of the CIA
compared to a NAT. In fact, the SD TB Ag MPT64 Rapid scored even
better than NAT, since 8.43% (7/83) of the NAT were undetermined,
probably due to inhibitors.
Antimicrobial activity against mycobacteria
P2025 Synergism of linezolid, levoﬂoxacin and amikacin
combination against multidrug-resistant and drug-
susceptible isolates of M. tuberculosis
E. Rey*, G. Tudo´, J. Gonza´lez-Martı´n (Barcelona, ES)
Objective: To evaluate the in vitro effectiveness of linezolid, levoﬂoxacin
and amikacin combination against multidrug-resistant and drug-
susceptible isolates of M. tuberculosis.
Methods: Clinical isolates were collected in the Hospital Clinic of
Barcelona: 9 multidrug-resistant, 10 drug-susceptible isolates and H37Rv
reference strain. The individual MICs of the isolates studied were
evaluated with the proportional method in 7H11 solid medium. The
linezolid, levoﬂoxacin and amikacin combination was studied crossing
3 concentrations of each antibiotic (corresponding to their MIC and two
lesser dilutions), with an adaptation to a three-antibiotic chequerboard
assay in 7H11 medium. The fractional inhibitory concentration (FIC) was
calculated as follows: FIC index = MICA in combination/MICA alone +
MICB in combination/MICB alone + MICC in combination/MICC alone
where A, B and C were the three respective antimicrobial agents tested.
The FIC index was interpreted as FIC index 0.75, synergistic activity,
FIC> 0.75−4, indifference and FIC> 4 antagonistic activity. As a control
a 1/100 inoculum was seeded in antibiotic-free medium. All the plates
were incubated at 37ºC, being read at the end of 3 and 4 weeks.
Results: Individual MIC of the studied isolates was 0.5mg/ml, 0.5mg/ml
and 2.5mg/ml for linezolid, levoﬂoxacin and amikacin respectively. All
the linezolid, levoﬂoxacin and linezolid MIC in combination of the
multidrug-resistant and drug-susceptible isolates decreased two dilutions
compared to their individual MIC displaying synergism of all the isolates
with FICs = 0.75.
Conclusion: The linezolid, levoﬂoxacin and amikacin combination is
synergistic against multidrug-resistant as well as susceptible isolates of
M. tuberculosis, suggesting that could be used as a multidrug-resistant
treatment.
P2026 Activity of drugs against Mycobacterium tuberculosis under
hypoxic plus acidic conditions
G. Piccaro, F. Giannoni, P. Filippini, L. Fattorini* (Rome, IT)
Objectives: Mycobacterium tuberculosis (Mtb) is the etiologic agent of
tuberculosis (TB), which causes 1.8 million deaths per year. Furthermore,
about 2 billion persons are latently infected with Mtb, with 10% of them
reactivating to active disease. TB comprises several types of lesions,
ranging from caseous granulomas with hypoxic centres (latent TB) to
non-necrotizing granulomas with pH values estimated to be between 5.5
and 6 (active TB). The aim of this study was to test the activity of drugs
under hypoxic plus acidic conditions.
Methods: Hypoxic Mtb H37Rv cultures were obtained through the self-
generated formation of an oxygen gradient in Dubos broth at pH= 5.8
(acidic Wayne model). Aerobic (A), replicating, bacilli were prepared
by incubation of the tubes with loosened screw caps for 5 days (A5).
Hypoxic (H), dormant, bacilli were obtained by incubation of the tubes
for 5, 12, 19 days (H5, H12, H19), and closing them with tight-
ﬁtting rubber caps under the screw caps. To determine drug activity,
rifampin (RMP), moxiﬂoxacin (MX), linezolid (LZ), metronidazole
(MZ), niclosamide (NC) (8, 4, 8, 8, 0.3mg/ml, respectively, for their
Cmax in serum), and 100 mg/ml of pyrazinamide (PZA), were added to
A5 and, by syringe, to H5, H12, H19 cultures. After 7, 14, 21 days, 1ml
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was withdrawn, washed, and inoculated in Middlebrook 7H10 agar for
CFU counts.
Results: CFUs of untreated cells increased up to day 8 then stabilized
up to day 26, followed by a drop, and a raise of pH to 5.9. RMP was
the most active drug, as shown by the fact that no CFU were found after
treatment of A5 and H19 cells for 7, 14, 21 days, in comparison with
untreated cultures; however, some H5 and H12 cells survived. On day
21, the log10 CFU decrease of A5, H5, H12, H19 cells were: RMP, >8,
5.7, 6.0, >6.3; MX, 8, 5.3, 1.3, 0.9; LZ, 5.0, 3.8, 0.4, 0.3; NC, 2.8, 0.5,
2.2, 2.6; PZA, 4.9, 0.5, 1.4, 2.6; MZ, 0.3, 2.9, 5.0, >6.3.
Conclusion: A differential activity of drugs was observed, with H5 and
H12 being more resistant than H5 and H19 cells to RMP. H12 and H19
cells were the most resistant to MX and LZ. H5 cells were the most
resistant to NC and PZA. MZ was inactive against A5 cells, however its
activity increased with dormancy, from H5 to H19. These observations
can be important to design new drug combinations active under hypoxic
plus acidic conditions for treatment of active and latent TB. (This work
was supported in part by the European Project StopLatent-TB, grant
agreement 200999.
P2027 Antimicrobial susceptibility testing of rapidly growing
mycobacteria by microdilution
C. Cavusoglu*, T. Gurpinar, T. Ecemis (Izmir, Manisa, TR)
Objectives: In this study, activities of amikacin, cefoxitin, ciproﬂoxacin,
clarithromycin, doxycycline, imipenem, linezolid, sulfamehoxazole and
tobramycin against 25 clinical isolates of rapidly growing mycobacteria
(RGM), including the common disease producing species Mycobac-
terium abscessus, M. chelonae, M. fortuitum and M. peregrinum were
tested by Sensititre RAPMYCO (Trek Diagnostic Systems Limited, UK).
Methods: The 25 clinical isolates of RGM belonging to 4 species were
included in the study. Organisms were identiﬁed to the species level
by PCR-reverse hybridization and DNA sequencing of the 441 bp of the
hsp65 gene. Sensititre RAPMYCO was used according to the instructions
of the manufacturer. Minimum inhibitory concentrations (MIC) were
determined by broth microdilution using Sensititre cation-adjusted
Mueller-Hinton broth (CAMHBT) with OADC according to the CLSI
guidelines. Quality control assay were performed with Staphylococcus
aureus ATCC 29213.
Results: Susceptibilities to amikacin, cefoxitin, ciproﬂoxacin, clar-
ithromycin, doxycycline, imipenem, linezolid, sulfamehoxazole and
tobramycin were determined for 25 clinical isolates of RGM belonging to
4 species (M. abscessus, M. chelonae, M. fortuitum and M. peregrinum)
by Sensititre RAPMYCO. The drug susceptibility patterns of the isolates
are shown in Table 1. M. fortuitum and M. peregrinum was much
less drug resistant than M. abscessus, M. chelonae. All isolates of
M. fortuitum and M. peregrinum were susceptible to amikacin and
ciproﬂoxacin. About 90% of isolates of M. fortuitum and M. peregrinum
were susceptible or intermediate to cefoxitin, clarithromycin, imipenem,
linezolid, sulfamehoxazole. All isolates ofM. abscessus andM. chelonae
were resistant or intermediate to ciproﬂoxacin. Isolates of M. abscessus
and M. chelonae were much less susceptible to amikacin than
M. fortuitum and M. peregrinum.
Conclusion: The treatment of serious infections with RGM is a problem
and limited by the small number of avaible drugs with activity at
clinically achievable levels in tissue or/and blood. In conclusion, a
variability in sensitivity to different antimicrobials exists in all strains;
therefore, each species and strain must be individually evaluated, and it
is advisable always to perform in vitro sensitivity tests before using the
drug for human therapy.
P2028 Antibiotic susceptibility testing of Mycobacterium avium
subspecies under iron starvation
R. Kopinc*, M. Ocepek, A. Lapanje (Ljubljana, SI)
Objectives: Mycobacterium avium ssp. are environmental opportunistic
pathogens, that infect a wide range of hosts, including humans. Upon
entry into macrophages they dwell and replicate inside phagosomes,
eventually killing the macrophage. Since macrophage environment is
known to be hostile to most of bacteria, especially by limiting available
iron, we wanted to test if susceptibility of Mycobacterium avium ssp.
to antibiotics is affected by iron concentrations. Previous extensive
genomic analysis of Mycobacterium avium ssp. paratuberculosis K-10
genome pointed to existence of potential antibiotic resistance genes
under regulation of iron responsive repressor IdeR.
Methods: MICs for different ﬁrst and second line anti-tuberculous
antibiotics under iron replete or deplete growth conditions were measured
for Mycobacterium avium strain 104 and several ﬁeld isolates of
Mycobacterium avium ssp. paratuberculosis with resazurin viability
assay. Strains were ﬁrst grown in Sauton’s medium with 100 uM iron to
late exponential phase. Cells were then washed and dilluted in Sauton’s
medium without iron (1 uM) to an OD600 of 0,010 and transferred
to 96-well plates. Antibiotic was added at different concentrations in
triplicates along with controls and plates were incubated for 6 days at
37ºC. Resazurin redox dye was then added to each well and the plates
incubated for 24 hours. Fluorescence was measured at 590 nm for each
well. MICs and growth inhibition were determined for each antibiotic in
iron deplete/replete medium.
Results: MICs for antibiotics tested were different between subspecies
and compared to MICs, determined for Mycobacterium tuberculosis.
However MICs were not signiﬁcantly different in iron replete compared
to iron deplete medium. Extent of growth inhibition showed different
patterns in presence of iron compared to growth without iron.
Subinhibitory concentrations of antibiotics have shown to increase
growth of bacteria in iron deplete compared to iron replete medium.
Conclusion: Growth conditions can signiﬁcantly affect antibiotic
susceptibility, therefore it is very important to closely mimic the
natural environment of pathogen. Current in vitro antibiotic susceptibility
testing for mycobacteria is carried out predominantely in nutrient rich
media, optimal for bacterial growth, which by no means resembles
host environments. This should be taken into consideration in future
development of antibiotics.
P2029 Change in ﬁrst-line anti-tuberculosis drug susceptibility
trends of Mycobacterium tuberculosis clinical isolates over
a period (30 years)
A. Alberte-Castin˜eiras*, M. Dominguez-Gil Gonzalez,
M. Gonzalez-Sagrado, P. Pe´rez-Pascual (Valladolid, ES)
Mycobacterium tuberculosis, remain one of the leading killers world-
wide. In several countries, a large number of multidrug-resistant (MDR)
and more recently, extremely drug-resistant (XDR) tuberculosis cases
have been reported.
Objectives: The assessment of resistance trends to ﬁrst line anti TB
drugs of M. tuberculosis isolates in a tertiary General Hospital serving
240.000 inhabitants.
Methods: Prospective analysis included all drug susceptibility test (DST)
performed on 1094 initial isolates of M. tuberculosis between 1981 and
September 2010, from newly treated human immunodeﬁciency virus
(HIV) negative patients, devised in ﬁve periods. DST was conducted by a
national reference laboratory (Dra M. Jime´nez, Instituto de Salud Carlos
III, Madrid, Spain) using the standardised proportion method, according
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to the guidelines of the external quality assurance programme. Resistance
was deﬁned as at least 1% colony growth at critical concentrations of the
drug (i.e., streptomycin [dihydrostreptomycin sulphate] 4mg/l, isoniazid
0.2mg/l, rifampicin 40mg/l and ethambutol 2mg/l).
Results: Antimycobacterial susceptibilities of M. tuberculosis complex
isolates, showed that 6.3% were resistant at least to one drug (Primary
resistance) in 1981−90 period; 4.7% in the 1991−95 period; 3.2% in
1996–2000 period; 1.7% in 2001−05 period and 8% in the last period,
2006 to November 2010.
More speciﬁcally, the resistance rate to streptomycin was 3%, 2.3%,
1%, 1.2% and 2% in the corresponding period. To isoniazid was 4.3%,
1.8%, 2.1%, 1.2% and 7%. To rifampicin was 0.3%, 0%, 0%, 0% and
0% respectively. Finally, to ethambutol was 0%, 1.5%, 0.5%, 0% and
0%. There was any MDR isolate.
Conclusion: In our study, resistant tuberculosis seems to be in an
acceptable level, with the resistance to ﬁrst line anti TB drugs in
an ascending trend, comparing to former results of ours previous
studies. Isoniazid was the less active drug. It is necessary study the
epidemiological impact of immigrant people in this new ﬁeld.
Mycobacterial disease, pathogenesis and
epidemiology
P2030 Epidemiology and clinical signiﬁcance of non-tuberculous
mycobacteria isolated from pulmonary specimens
E. Braun*, H. Sprecher, S. Davidson, I. Kassis (Haifa, IL)
Objectives: The growing awareness and the development of new
molecular tools for the diagnosis of nontuberculous mycobacteria (NTM)
have led to increased number of cases associated with these pathogens.
This study was designed to evaluate the clinical signiﬁcance of NTM
isolated from pulmonary specimens referred to the laboratory of clinical
microbiology of a large tertiary care medical center in Northern Israel.
Methods: Clinical specimens were collected from in-hospital population.
NTM isolated by standard microbiological cultures were further
identiﬁed by restriction enzyme pattern analysis of a PCR-ampliﬁed
439-bp fragment of the hsp-65 gene using DNA extracted from bacterial
colonies. Identiﬁcation was conﬁrmed by direct sequencing of a PCR
amplicon encompassing a 5′ region of 16S rRNA gene ﬂanked by
conserved sequences. Following identiﬁcation of NTM, patients were
followed or their records were reviewed. Cases were classiﬁed as
signiﬁcant, non-signiﬁcant and inconclusive, according to the 2007
ATS/IDSA Criteria for disease.
Results: Between January 2004 and December 2010, 215 cases of
respiratory isolations of NTM were identiﬁed in our hospital. Age range
was 11 to 98 years. Mycobacterium xenopi was the most common
species (85 isolates, 39.5%) followed by M. simiae (52 isolates, 24.2%).
M. simiae was the most common isolate in 2004−6, while M. xenopi
is the leading isolate since 2007. 167 of the 215 (77.7%) cases
were classiﬁed as non-signiﬁcant. 27 cases (12.6%) were considered
inconclusive. Only 21 (9.8%) cases were clinically signiﬁcant, the
majority being M. kansasii (7 isolates, 33% of signiﬁcant isolates) and
M. avium complex (6, 28%). Only one case of M. simiae and two
of M. xenopi were clinically relevant. Among patients with signiﬁcant
disease 6 had no underlying conditions. The rest had chronic obstructive
lung disaese (3), cardiac disease (6), HIV (3), malignancy (2) and CF (1).
Conclusions: M. xenopi and M. simiae are the most prevalent isolates
of NTM from respiratory samples in Northern Israel. However, most of
these isolates represent colonization. Of the relatively small number of
clinically signiﬁcant isolations, M. kansasii and M. avium complex are
the most common.
P2031 Multifocal tuberculous vertebral osteomyelitis:
a re-emerging infection
E. Arosemena*, M. Varela, V. Pascual, E. Calbo, C. Corbella, E. Ayats,
E. Cuchı´, J. Garau (Terrassa, ES)
Skeletal disease accounts for 5% of all cases of tuberculosis (TB) and
15% of extrapulmonary TB. Multifocal disease is rare and a low index
of suspicion leads to a delay in diagnosis and increased morbidity.
Methods: All cases of multifocal tuberculous vertebral osteomyelitis
(TBVO) seen in our institution since 2007 were reviewed. Data recorded
included demographic characteristics and comorbidities, clinical and
radiologic features, diagnostic methods (microbiologic and pathology),
treatment and outcomes.
Results: Since 2000, 77 cases of extrapulmonary tuberculosis were
diagnosed in our hospital; six (8%) had TBVO. We report on three
patients with multifocal spinal disease that have been diagnosed in the
last 4 years. All were men and median age was 33 years (21−35 y);
mean Charlson index was 0. All were immigrants from West Africa.
The number of affected vertebrae ranged 3 to16. Back pain and
weakness were the most frequent symptoms. All patients had neurologic
ﬁndings, 67% had visceromegalies and fever, and 33% had lymph node
enlargement. Two patients had pulmonary involvement and other extra-
axial manifestations. Magnetic resonance was the best radiologic method
in the diagnosis of TBVO as compared to other imaging techniques
(spine X-rays, bone scan, CT). Two patients underwent needle biopsy
of a localized abscess (spinal or other localization), and in one patient
a vertebral body biopsy was performed. Necrotizing granulomas were
present in all of them. Culture yielded Mycobacterium tuberculosis in
2 cases. Median time to diagnosis from onset of symptoms was 4
months (4−10), median duration of therapy was 12 months. Two patients
required surgery; all of them had spinal instability, epidural abscess and
compressive symptoms. Median time to surgery was 20 days (18−21)
from onset of therapy. At follow up, one case (33%) showed clinical
sequelae. Two are free of active disease, at 31 and 36 months of follow
up and the last one is still on therapy.
Conclusions: Tuberculous vertebral osteomyelitis presents frequently
with multifocal involvement in African immigrants. Early surgery is
safe and effective.
P2032 Risk factors of mortality among MDR-TB patients in Iran:
2002–2009
P. Tabarsi*, P. Baghaei, M. Marjani, M. Shamai, J. Soroush, M. Seyed
javadi, M. Masjedi (Tehran, IR)
Introduction: Multi-drug resistant Tuberculosis (MDR-TB) is a major
issue in control of TB. The aim of present study was to identify the risk
factors of mortality in MDR-TB.
Material and Method: During 2002–2009, all patients with documented
MDR-TB in only referral center, Tehran, Iran, who had at least 6 months
of follow up, were recruited. All patients received standard treatment
consisted of Oﬂoxacin, Prothionamide, Amikacin and Cycloserine. All
demographic and characteristic factors were studied, comparing between
the death group and the control group.
Results: 159 patients were included. 88 patients were male. The mean
age was 43.6±17.4 and 41.6±18.9 respectively in death and control
group. Outcome of treatment was: 118 (74.2%) cured, 4 (2.5%) failure,
21 (13.2%) dead and 16 (10.1%) interrupted of treatment. There was no
difference in sex, smoking, opium, co-disease, HIV status and cavitary
lesions between death group and the control group (P value >0.05).
In univariate analysis developing adverse effects and using Amikacin
less than 6 months were signiﬁcantly higher in death group. In logistic
regression analysis (multivariate), using Amikacin less than 6 month
retained the statistical signiﬁcance.
Conclusion: This study showed that using Amikacin less than 6 months
can raise mortality rate in MDR-TB patients.
Mycobacterial disease, pathogenesis and epidemiology S599
P2033 Variations in the occurrence of speciﬁc rpoB mutations
in rifampicin-resistant Mycobacterium tuberculosis strains
isolated from patients of different ethnic groups in Kuwait
S. Ahmad*, N. Al-Mutairi, E. Mokaddas (Safat, KW)
Objectives: Frequency of speciﬁc resistance-conferring mutations
in target genes varies among isoniazid- and ethambutol-resistant
Mycobacterium tuberculosis strains isolated from tuberculosis (TB)
patients of various ethnic groups within the same country. Similar studies
have not been carried out with rifampicin-resistant strains This study
determined the frequency of speciﬁc mutations in three rpoB gene
regions among rifampicin-resistant M. tuberculosis strains of different
genetic background isolated from TB patients belonging to three major
ethnic groups in Kuwait.
Methods: Rifampicin-resistant M. tuberculosis strains (n = 119) isolated
from South Asian (n = 55), Southeast Asian (n = 23), Middle Eastern
(n = 39) and other (n = 2) patients in Kuwait were analyzed. Rifampicin-
susceptible strains (n = 107) were also tested. Mutations in N-terminal,
hot-spot and cluster II regions of rpoB gene were detected by DNA
sequencing. Polymorphisms at katG463 and gyrA95 were detected by
PCR-RFLP for genetic group assignment.
Results: None of 107 rifampicin-susceptible but 116 of 119 (98%)
rifampicin-resistant isolates contained mutation(s) in rpoB gene. While
mutations at codon 516 (20%), 526 (24%) and 531 (27%) were evenly
distributed among isolates from South Asian patients, majority of
isolates from Southeast Asian (78%) and Middle Eastern (51%) patients
contained a mutated codon 531. All strains with N-terminal and cluster
II region mutations were isolated from Middle Eastern and South Asian
patients, respectively. Majority of M. tuberculosis strains isolated from
South Asian (84%) and Southeast Asian (70%) patients belonged to
genetic group I while nearly all remaining isolates from these two
ethnic groups belonged to genetic group II. Isolates from Middle Eastern
patients were distributed among genetic group I (46%), genetic group II
(33%) and genetic group III (21%).
Conclusion: The frequency of speciﬁc rpoB mutations varied in
rifampicin-resistant M. tuberculosis strains isolated from TB patients
belonging to different ethnic groups. Since rifampicin-resistant TB
mostly occurs among expatriates, due to reactivation of prior infection,
in Kuwait, the variations are likely due to genetic differences in
M. tuberculosis strains infecting different populations. The data are
also important for designing rapid methods for detecting majority of
rifampicin-resistant M. tuberculosis isolates recovered from patients of
various ethnic groups.
Supported by KURA grant YM03/06.
P2034 Genetic analysis of the host-pathogen interaction in
tuberculosis (“TB-EURO-GEN”) study − progress and
current tuberculosis epidemiology
O. Ignatyeva*, I. Kontsevaya, Y. Balabanova, V. Nikolaevskyy,
S. Mironova, A. Kovalev, A. Isaeva, Y. Chinkova, A. Rybkina, A. Kritskyy,
D. Gromova, M. Korobova, A. Shakhmistova, N. Malomanova,
I. Fedorin, S. Nejentsev, R. Horstmann, S. Hoffner, F. Drobniewski
(Samara, RU; London, UK; Cambridge, UK; Hamburg, DE; Solna, SE)
Objectives: “TB-EURO-GEN” (Genetic analysis of the host-pathogen
interaction in tuberculosis) is an FP 7 EU Framework project (2008–
2011) aiming to identify major host susceptibility genetic factors and
their interaction with Mycobacterium tuberculosis using a genome-
wide approach and state-of-the-art genotyping techniques. Functional
experiments of the role of identiﬁed mycobacterial factors and the effect
of this variation on aspects of innate immunity as inﬂuenced by newly-
identiﬁed TB-associated genes will be studied.
Methods: Biobanks of human DNA samples from culture-conﬁrmed TB
patients and matching healthy controls, along with matching TB strains
from the same patients combined with detailed clinical and demographic
information have been established at our ﬁeld site in Samara Oblast,
Russia. Further analyses will be performed on a combined collection
of Russian (established currently and during a previous pilot study) and
Ghanaian (established previously) biobanks.
Results: 2763 patients with culture conﬁrmed tuberculosis and 2500
healthy blood donors without active TB were enrolled as a control
group representing the general population (in addition to similar numbers
recruited from a prior pilot study). While genetic analysis is on-going, the
descriptive epidemiological analysis is complete reﬂecting the current TB
epidemiology in Samara. The median age of recruited TB patients was 40
years with over 80% of participants being ethnically Russians. A quarter
of patients had a history of imprisonment, 16% admitted recreational
drug use, 17% abused alcohol. Almost half of participants (46%) were
unemployed. In an earlier pilot study (2005) the rate of HIV-TB co-
infection in Samara population was 4%; however in the current cohort
17% of all recruited patients are HIV-positive. Rates of multidrug and
extensive drug resistant TB (MDR/XDR TB) were 50% and 9% for all
cases, 40% and 5% for new and 70% and 16% for re-treatment cases
respectively. Of note, the study of MDR TB conducted in 2002 in the
same region showed 0% rate of XDR TB.
Conclusion: This is the world’s largest study (5000 controls and 5275
patients) on the genetic susceptibility to TB in humans and host-
pathogen interaction. The recruited cohort of TB patients highlights
major obstacles in TB control in Russia including a worryingly high
proportion of multidrug and extensive drug resistant TB and of HIV
co-infection.
Funded by EU FP7 TB EUROGEN grant
P2035 Molecular epidemiology of multidrug-resistant (MDR)
Mycobacterium tuberculosis revealed by genotype MTBDR
assays in southern China
L. Zhang*, L. Duo, X. Lu, Y. Xie, X. Song, M. Kang, B. Ying, L. Wang
(Chengdu, CN)
Objectives: There are urgent needs called for clinical laboratories in
Mainland China to establish rapid diagnostic route for MDR TB and
serve local epidemiological surveillance, since the condition of lack of
laboratory diagnostic resources prevails in Mainland China, the second
highest TB burden country. This study investigated the epidemics of
MDR TB in a large-sized general hospital in southern China and
explored the feasibility of incorporation of Genotype MTBDRs into
routine conventional TB procedures for rapid laboratory diagnosis of
MDR TB.
Methods: The multiplex PCR-based reverse line probe hybridization
assays, Genotype MTBDRplus and MTBDRsl, were used to identify the
presence of mycobacterium tuberculosis complex and detect mutations
conferring resistance to most active ﬁrst-line and second-line drugs
against TB (rifampin [RMP], isoniazid [INH], ethambutol [EMB],
ﬂuoroquinolones [FLQ], amikacin [AMK], carpreomycin [CAP], kana-
mycin [KAN] and viomycin [VIO]) from clinical specimens and isolates.
238 smear-positive sputum specimens and 124 clinical isolates were
included in the study.
Results: Among conﬁrmed mycobacterium tuberculosis strains, MDR
TB occurred in an overall rate of 14.6% (49/336). Of 49 MDR TBs,
17 (34.7%) had ﬂuoroquinolone resistance-mediated mutations and 4
(8.2%) harbored mutations conferring cross resistance to AMK, CAP,
KAN or VIO. 6.1% (3/49) of MDR-TBs was identiﬁed as XDR TB
with additional resistance to ﬂuoroquinolones and to at least one of
the injectable second-line drugs (AMK, CAP, KAN). In addition, EMB
resistance was found in 44.9% (22/49) MDR TB, among which 20.4%
(10/49) were resistant to both EMB and FLQ and 4.1% (2/49) were
simultaneously resistant to EMB and one of the injectable second-line
drugs. Particularly, one super-resistant XDR TB has been found resistant
to all tested drugs. The new and retreated cases were, respectively, 38.8%
(19/49) and 61.2% (30/49) in MDR TB patients who all tested negative
for HIV.
Conclusions: The MDR TB epidemics uncovered by the Genotype
MTBDRs is of great importance and signiﬁcant support to local MDR
TB control, which indicates that improper and failed treatments are the
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main potential causes of local MDR TB. The situation may be under-
estimated since the incomplete coverage of the molecular mechanisms
underlying anti-TB drug resistance by Genotype MTBDRs. Additionally,
we proved that Genotype MTBDRs are valuable complements in
establishing rapid laboratory diagnosis of MDR TB.
P2036 Multidrug resistance proﬁles of pulmonary tuberculosis in
Georgia
N. Tadumadze*, N. Bablishvili, N. Shubladze, N. Lomtadze,
M. Akhalaia, R. Aspindzelashvili, M. Gegia (Tbilisi, GE)
Background: Multidrug-resistant tuberculosis (MDR TB) continues to
pose a signiﬁcant threat to public health in Georgia. Understanding the
MDR patterns is of a great importance for advancing TB treatment
and prevention efforts in this region. We studied MDR proﬁles of
Mycobacterium tuberculosis (MTB) isolates from new and retreatment
cases of pulmonary TB registered in Georgia in 2006–2008.
Design and Methods: A frequency distribution of rifampin (RIF),
isoniazid (INH), streptomycin (STR) and Ethambutol (EMB) resistance
proﬁles with the 95% conﬁdence interval (CI), in the MTB isolates from
new and retreatment MDR TB cases, was assessed using EpiInfo version
3.4 (CDC, Atlanta, GA, USA).
Results: The MTB isolates with either INH-RIF-STR or INH-RIF-
EMB-STR resistance proﬁles were predominant within both new and
retreatment MDR TB cases in 2006–2008. The frequencies of INH-
RIF-STR and INH-RIF-EMB-STR resistance proﬁles were respectively
40.3% (CI = 29.2–52.1)/46.5% (CI = 38.4–54.6) and 49.4% (CI = 37.8–
61.0)/49.7% (CI = 41.6–57.8) within new (n = 77)/retreatment (n = 155)
MDR TB cases in 2006. The frequency of INH-RIF-STR resistance
(being in a rage of 26.4–28.0%) markedly decreased, even though MDR
TB infections continued to increase steadily in the following years. In
contrast, the occurrences of the INH-RIF-EMB-STR resistance were
73.60% (CI = 63.0–82.4) and 70.3% (CI = 63.1–76.9) correspondingly
in 87 new and 182 retreatment MDR TB cases identiﬁed in 2007. In
2008, the frequencies of the INH-RIF-EMB-STR proﬁle were 68.9%
(CI = 61.8–75.4) and 70.6% (CI = 65.0–75.8) respectively within 190 new
and 289 retreatment MDR TB cases.
Conclusion and Recommendations: The TB burden reﬂects a strong
tendency for an increased selection of MDR MTB strains that are
resistant to almost all front-line drugs, which, along with other factors,
can be suggestive of high transmission rates of such strains in Georgia.
More effective strategies are needed for TB control and prevention in
this region.
P2037 Detection of gene mutations causing antibiotic resistance
in Mycobacterium tuberculosis complex by an array
T. Chan*, H. Huang, R. Jou, Y. Yang, P. Lu, S. Huang, T. Chang
(Tainan, Taipei, Kaohsiung, TW)
Objectives: This study aimed to develop an oligonucleotide array to
rapidly detect point mutations in seven genes that can cause antimicrobial
resistance in Mycobacterium tuberculosis complex (MTBC).
Methods: Antibiotic resistance in MTBC is associated with point
mutations in several genes including rpoB for rifampin (RIF), katG and
the mabA promoter for isoniazid (INH), embB for ethambutol (EMB),
rpsL and rrs for streptomycin (STR), and gyrA for ﬂuoroquinolone
(FQs). Oligonucleotide probes were designed from the respective genes
to detect these point mutations. The method consisted of multiplex
PCR ampliﬁcation of the seven genes, followed by hybridization
of the digoxigenin-labeled PCR products to oligonucleotide probes
immobilized on nylon membrane. A total of 195 clinical MTBC isolates
with known susceptibility patterns were tested. Among these strains, 50,
70, 52, 74, and 16 strains were resistant to RIF, INH, EMB, STR, and
OFX, respectively. After hybridization, alkaline phosphatase-conjugated
anti-digoxigenin antibodies were used to produce the hybridization
signals. The hybridized spots could be read by the naked eye.
Results: Single nucleotide mutations in genes of rpoB, katG, the mabA
promoter, embB, rpsL, rrs, and gyrA were successfully detected by the
array. The sensitivities of the array for different antibiotics were 98.0
(RIF), 88.6 (INH), 50 (EMB), 51.4 (SM) and 81.3% (FQs), respectively;
the speciﬁcities were 97.1 (RIF), 98.2 (INH), 100 (EMB), 100 (SM) and
100% (FQs), respectively; the positive predictive values were 92.5 (RIF),
96.9 (INH), 100 (EMB), 100 (SM) and 100% (FQs), respectively; and
the negative predictive values were 99.3 (RIF), 93.2 (INH), 82.6 (EMB),
73.7 (SM) and 97.7% (FQs), respectively.
Conclusion: The array could effectively detect point mutations in genes
associated with antibiotic resistance in MTBC. The test took about 5−6 h.
P2038 Combinations of TNF a/IL-10 polymorphisms affect active
tuberculosis development in Tunisia
W. Ben Selma, A. Ferjani, H. Harizi, M. Marzouk, I. Ben Kahla,
J. Boukadida* (Sousse, TN)
Tumor necrosis factor (TNF-a)/Interleukin 10 (IL-10) balance is
essential to control latent/reactivation stages of tuberculosis (TB). In
this study we focused on how association between combination of
cytokine gene single nucleotide polymorphism (SNP) linked to high
and low producer phenotypes [TNF-a −308Glow→Ahigh) and IL-10
(−1082Alow→Ghigh, −819Tlow&→Chigh and −592Alow→Chigh)]
can affect development risk of active TB in Tunisian population.
SNPs were investigated in population of 76 patients with active
pulmonary TB, 55 with active extrapulmonary TB and 95 healthy
subjects. We used Polymerase chain reaction-restriction fragment length
polymorphism method for genotyping study.
Mutant IL10 −1082G allele was statistically correlated with increased
risk development of active pulmonary TB and extrapulmonary TB
(P = 0.001, OR= 2.11; P = 0.0002, OR= 2.57). High producing IL10
−1082G/−819C/−592C (GCC) haplotype was over-represented among
pulmonary and extrapulmonary TB groups in comparison to control
group (P = 0.001, OR= 2.11; P = 0.0002, OR= 2.57). Mutant TNF-a;
−308A allele was signiﬁcantly associated with extrapulmonary TB when
compared to control group (P = 0.011, OR= 2.43).
Combinations of TNF-a −308 (A/A, A/G) (high TNF-a producer)/IL-10
(GCC/GCC, GCC/ACC, GCC/ATA) (high IL-10 producer) genotypes
were signiﬁcantly associated with increased risk development of
pulmonary TB (P = 0.03, OR= 2.37; P = 0.007, OR= 3.13, respectively).
However, combinations of TNF-a −308 (GG) (low TNF-a producer)/
IL-10 (ACC/ACC, ACC/ATA, ATA/ATA) (low IL-10 producer) were
associated with resistance against development of pulmonary TB
and extrapulmonary TB (P = 0.01, OR= 0.44; P = 0.0007, OR= 0.26,
respectively).
Our results demonstrate that genetic polymorphisms of TNF-a and IL-10
association may affect the functional balance Th1/Th2 contributing to the
development of active TB in Tunisian populations.
P2039 Host-pathogen relationship in tuberculosis: association
between the genetic diversity of M. tuberculosis strains and
the disease presentation in the State of Antioquia, Colombia
J.M. Hernandez Sarmiento*, E.M. Zapata, V. Gomez, G.I. Mejia,
N. Correa, M. Martinez, J. Robledo (Medellin, CO)
Objectives: Genotyping M. tuberculosis is useful to understand the host-
pathogen relationship as well as the transmission dynamics of the disease.
In the present work we analyzed the association between M. tuberculosis
genetic diversity and the clinical presentation of the disease in a cohort
of patients living in the state of Antioquia and who were all attended at
several health care institutions in the city of Medellı´n.
Materials and Methods: This prospective cohort study included 172 pa-
tients with pulmonary TB. All the patients were followed-up during their
treatment until the ﬁnal clinical outcome assessment. TheM. tuberculosis
isolates were genotyped using the RFLP IS6110 (Restriction Fragment
Length Polymorphism), Spoligotyping (Spacer Oligonucleotide Typing),
and MIRU (Mycobacterial Interspersed Units) methods. We identiﬁed
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associations between isolates genotypes, clinical presentation of the
disease and treatment outcome. Signiﬁcant associations were established
with a p< 0.05 using the SPSS v 15 program, and the relationships were
quantiﬁed using RR with IC 95%.
Results: The following signiﬁcant associations were found: LAM
genotype with moderate disease presentation (p = 0.03 RR 1.43 IC 1.02–
2.01) and treatment failure (p = 0.01 RR 0.12 IC 0.02–0.96). Haarlem
genotype was associated with mild presentation of the disease (p = 0.
05 RR 1.9 IC 1.04–3.47) and treatment failure (p< 0.001 RR 12.75 IC
1.64–99.33). T genotype was associated with moderate lung damage as
detected by X ray (p = 0, 02 RR 4, 9 IC 1, 29−18, 71) and X genotype
with paucibacillary infection (p = 0,04 RR 5,33 IC 2,15−13,24).
Conclusions: Our results suggest an inﬂuence of M. tuberculosis strains
genetic diversity on the disease clinical presentation. Patients infected
with Haarlem strains had a slight presentation of the disease but more
treatment failure, whilst patients infected with LAM M. tuberculosis had
a moderate disease presentation with a better treatment response.
P2040 The presence of viable Mycobacterium tuberculosis in tissue
specimens of lung surgery patients
N. Shubladze*, S. Vashakidze, S. Gogishvili, L. Kupreishvili,
M. Pochkhua, I. Kalandadze (Tbilisi, GE)
Background: Multidrug- and extensively-resistant tuberculosis (MDR-
and XDR-TB) is a serious health problem in Eastern European countries
including Georgia. The aim of this study was to reveal the viable
Mycobacterium tuberculosis (M.tb) in sputum and pulmonary surgery
specimens obtained from MDR-and XDR-TB patients at the National
Center of TB and Lung Diseases of Georgia.
Design and Methods: Standard sputum microscopy and cultural
analyses were performed for sputum and lung tissue samples from 15
MDR- and 7 XDR-TB patients treated with 2-nd-line drugs according
to DOTS+ standards prior to surgery from 8 to 16 months. 17 patients
had cavitary forms of tuberculosis; in 5 were observed patients strongly
pronounced residual morphological changes of lung tissue in the form
of ﬁbrosis and bronchiectasis. Lung tissue resectates were taken during
the surgery directly from tuberculous lesions. Susceptibility testing for
ﬁrst and second line drugs was performed before and after surgery.
Results: Out of 22 patients, 4 (18,1%) were sputum-smear and culture
positive, and 18 (81,9%) were sputum-smear and culture negative
immediately before the operation. A completely different picture was
observed in the lung tissue specimens: smear microscopy was positive
in 14 (63,6%) cases, and cultures showed the presence of M. tb in 12
cases (54.5%). Two patients had positive smear and negative culture.
Growth of M.tb cultures was detected in lung tissue specimens from
88,2% patients with cavitary forms of tuberculosis.
Conclusion and Recommendations: Regardless of the long-term
DOTS+ treatment, a large number of MDR- and XDR-TB patients caring
viable MTB in their lung tissues, still reﬂect sputum smear and culture
negativity prior to their surgery. This factor should be strongly considered
when developing the TB treatment strategies.
P2041 Mycobacterium tuberculosis replicates in human ﬁbroblasts
and interferes with their antigen presentation capacity
S. Mariotti*, V. Sargentini, M. Pardini, M. De Spirito, M.C. Gagliardi,
M. Fraziano, R. Nisini (Rome, IT)
Objectives: Mycobacterium tuberculosis (Mtb) is an intracellular
pathogen that causes tuberculosis (TB). The host immune response can
limit bacterial spreading, but does not kill all the bacilli, which can
persist for years causing latent TB infection and eventually active TB.
Persistent Mtb is conﬁned to granulomas in immune cells that prevent
spreading of bacilli. Mtb also infects other non-immune cells, including
adipocytes, endothelial cells and ﬁbroblasts (Fb), but data on the role of
these latter cells as possible reservoir of Mtb are not available.
Methods: A human Fb cell line (MRC5) and primary Fb were studied
for their possible permissive role to Mtb infection, replication and in
terms of antigen presenting capacity. In this context, the IFN-g dependent
expression of class I and class II MHC molecules was compared in
infected and non-infected Fb and correlated to their superantigen and
antigen presentation capacity, using autologous CD4+ T cell clones.
Infection of Fb was monitored by Mtb counts as well as by light and
confocal microscopy. Membrane expression of selected molecules was
measured by ﬂow cytometry and proliferation of T cell clones was
determined as 3H thymidine incorporation or IFN-g release.
Results: We demonstrate that Mtb infects Fb intracellularly, as shown
by confocal and light microscopy, and that Mtb actively replicates in
Fb. Moreover, we show that class I and class II MHC molecules are
respectively upregulated and de novo induced in IFN-g treated Fb.
However, Mtb infection inhibited the IFN-g induced upregulation of
class I as well as the expression of class II MHC molecules. We also
demonstrate that the functional consequences of reduced MHC class II
expression include a signiﬁcant reduction of T cell responsiveness to
the superantigen and an almost complete abrogation of antigen speciﬁc
presentation of soluble proteins to antigen speciﬁc T cell clones, when
Mtb infected Fb were used as APC.
Conclusion: The present results demonstrate that Mtb can actively
infect and replicate in Fb where it may inhibit the upregulation and
the expression of class I and class II MHC molecules, so preventing the
activation of antigen speciﬁc effector T cells. Altogether, these results
suggest that Fb may represent a possible privileged reservoir for live
Mtb outside the hostile environment of granuloma in TB patients.
P2042 Mycobacterium abscessus soft tissue infection in a
murine model: fast infection clearance but long lasting
pro-inﬂammatory cytokine production
A. D’Alessandro*, A. Rodrı´guez, D. Aguilar, Y. Tovar, D. Mata,
R. Herna´ndez-Pando, J. de Waard (Caracas, VE; Mexico City, MX)
Soft tissue infections caused by rapidly growing mycobacteria, especially
Mycobacterium abscessus, are being increasingly registered. This type of
infection causes considerable tissue damage and because inﬂammatory
processes last several weeks to months the infection is treated with
antibiotics for 6 months or more.
Objectives: To characterize the immunological responses of M. absces-
sus soft tissue infection in a murine model.
Methods: Balb/C and C57BL/6 mice were intradermal inoculated in the
footpads with approximately 250 thousand bacilli of severalM. abscessus
clinical isolates. Animals were euthanized at 3, 7, 14, 21, 28, 60 and 90
days after infection. Infected footpads were removed for histological
studies, determination of the number of viable bacteria and RT-PCR
analysis of cytokines expression.
Results: Bacteria were cleared from the footpads 14 days after the
infection but during the whole study period of 3 months the pro-
inﬂammatory cytokines IFN-g and TNF-a were overproduced. A low
expression of anti-inﬂammatory cytokines TGF-b and IL-4 was observed
during the time course of this experiment, indicating an inefﬁcient anti-
inﬂammatory mechanism and consequentially persistent inﬂammation,
tissue damage and ﬁbrosis.
Conclusion: Our model suggests that M. abscessus is easily eliminated
from soft tissue after infection but that pro-inﬂammatory response
continues because of a deﬁcient anti-inﬂammatory response. Our
experimental results suggest that treatment schemes based on only
antibiotics should be revised. Possibly these schemes can be shortened
and should include anti-inﬂammatory drugs to overcome continuing
tissue damage after the infection has been cleared.
P2043 Cutaneous infections of Mycobacterium marinum in human
aquarists and tracing of its possible sources
M. Slany*, M. Bodnarova, P. Jezek, V. Fiserova, J. Stork, I. Pavlik
(Brno, Prague, Pribram, CZ)
Objectives: The low frequency of non tuberculous mycobacterial
infections, non speciﬁc symptoms for individual mycobacteria and the
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lack of speciﬁc identiﬁcation methods could alter correct diagnosis.
Mycobacterium marinum is the most frequent non-tuberculous my-
cobacterial species in humans which usually causes various cutaneous
manifestations. This study presents four aquarists with cutaneous
M. marinum infection identiﬁed by combined microbiology and
molecular based approach. In addition, one case of systemic spread
of M. marinum from hand infection to the testis and epididymis is
presented. Simultaneously, screening for M. marinum presence in their
ﬁsh aquarium tanks was performed.
Methods: A total number of 43 mycobacterial isolates grown on
Lo¨wenstein-Jensen or Ogawa solid media originated from ﬁve human
patients (n = 23), aquarium animals (n = 15) and aquarium environment
(n = 5). Isolate identiﬁcation was carried out using growth characteristics,
biochemistry and sequence analysis of 16S rRNA and hsp65 genes.
Results: A microbiology based approach, followed by sequence
analysis was successfully used for detection of M. marinum in
all ﬁve patients. Animal and environmental samples from patients’
aquaria were simultaneously examined and a total number of eight
different mycobacterial species were isolated: M. chelonae, M. fortuitum,
M. gordonae, M. haemophilum, M. kansasii, M. mantenii, M. marinum
and M. peregrinum. The presence of M. marinum was proven in the
aquarium environments of four patients.
Conclusions: Correct identiﬁcation of the causative pathogen in the
case of skin mycobacteriosis still remains a challenge for clinicians. A
microbiology based approach, followed by the 16S rRNA and hsp65
sequence analysis is useful tool for identiﬁcation of mycobacteria.
The data, from sensitivity testing of M. marinum isolates were used
for selection of targeted mycobacterial therapy with ciproﬂoxacin and
ethambutol for one patient. The remaining patients were treated with
clarithromycin. Fish-tank exposure is the source of most cases of
cutaneous M. marinum infections and may be prevented by the use of
waterproof gloves by persons with acute or chronic open skin lesions.
Acknowledgement: This work was supported by grants Nos.
MZE0002716202 and QH91240 from the Ministry of Agriculture and
grant “AdmireVet” No. CZ 1.05/2.1.00/01.0006; ED0006/01/01 from the
Ministry of Education, Youth and Sports of the Czech Republic
P2044 Mycobacterium abscessus in cystic ﬁbrosis: what does it all
mean?
J.T. Evans*, N. Ratnaraja, S. Gardiner, P. Hawkey, E.G. Smith
(Birmingham, UK)
Aim: To estimate the prevalence of Mycobacterium abscessus in
patients with Cystic Fibrosis within the East and West Midlands and
Shefﬁeld regions and examine factors associated with the acquisition of
Mycobacterium abscessus.
Methods: The study included all patients with Cystic Fibrosis (CF)
within the East and West Midlands and Shefﬁeld area who had
Mycobacterium abscessus isolated from the respiratory tract between
January 2000 and August 2007. Data was collected by reviewing every
patient’s medical records where available.
Results: Twenty-eight patients (15 females, 13 males) were included
in the study. Notes regarding possible treatment for M. abscessus and
outcome were missing for two patients. The estimated prevalence of
Mycobacterium abscessus was 2.3%. The average age at ﬁrst isolation
of M. abscessus was 15.58 years, with the average number of years
between diagnosis of CF and ﬁrst isolation of this organism being 14.13
years.
Fifteen out of twenty-eight patients had received a diagnosis of ABPA,
and 21/28 patients had received oral steroids. All twenty-eight patients
had received prior antibiotics; 25/28 had received a ﬂouroquinolone,
27/28 an aminoglycoside, and 21/28 a macrolide (19 of whom had
received azithromycin).
Neither Burkholderia cepacia nor Mycobacterium avium intracellulare
was isolated from any patient. Sixteen of twenty-eight patients were
deemed to be colonised with P. aeruginosa, compared with nine patients
colonised with S. aureus. Eleven patients were also thought to be
colonised with other organisms.
Fourteen out of nineteen patients were thought to be colonised with
M. abscessus, compared with ﬁve patients thought to be infected. Of
the twenty-six patients for whom notes regarding management of this
organism were available, thirteen were given speciﬁc treatment for
M. abscessus.
Conclusions: The factors associated with the acquisition of Mycobac-
terium abscessus appear to be multifactorial. Prior antimicrobials,
especially macrolides and aminoglycosides, and oral steroid use all
appear to be potentially signiﬁcant risk factors. A larger, prospective
observational study is needed to see if any one risk factor is more
signiﬁcant than the others in the acquisition of this organism, and to see
what the implications are of isolating Mycobacterium abscessus from
the lungs of a patient with Cystic Fibrosis.
P2045 Updated meta-analysis on genetic predisposition of four
variants at NRAMP1 (SLC11A1) gene to tuberculosis
D. Li*, C. Tao, X. Hu, M.N. Zou, T. Wang, H. Ning, B. Ying (Chengdu,
CN)
Objective: A previous meta-analysis was performed to assess the
association between variations in NRAMP1 and tuberculosis (TB) risk,
but its limitations were that it did not report genotype comparative
results, and not discuss the association with extra-pulmonary TB (EPTB.
So, we carried out an updated meta-analysis to further investigate the
association between NRAMP1 and TB susceptibility.
Methods: We searched databases (PUBMED, EMBASE and ISI Web
of Knowledge) up to July 2010 using ”tuberculosis” “NRAMP1”
“SLC11A1” “solute carrier family 11 member 1” “natural resistance-
associated macrophage protein 1”, also performed a manual search
from relevant original studies. We extracted information on ﬁrst author,
publication year, country of origin, age of population, control sources
and genotype distribution. Summary ORs and corresponding 95%CIs
were estimated by ﬁxed effects or random effects model according to I2
value. To check for publication bias, a funnel plot, using Egger’s linear
regression method, was constructed. Chi-square goodness of ﬁt was used
to test deviation from Hardy-Weinberg equilibrium. We also performed
subgroup analysis based on the type of TB and ethnicity.
Results: A total of 31 case-control studies were included. Publication
bias was not found in the studies with four loci. The summary ORs
(95%CIs) for studies with polymorphisms of 3’ UTR, D543N, INT4
and 5′(GT)n loci of the NRAMPI gene were 1.20 (0.93–1.54), 1.17
(0.83–1.64), 1.48 (1.13–1.95), and 0.71 (0.57–0.88) respectively when
compared with their corresponding common homozygotes. And pooled
ORs for allele analysis showed TGTG-(3′ UTR), C(INT4), A(D543N)
and 5′(GT)3 were associated with TB. Except alleles in 3′ UTR, alleles
in the rest three loci failed to show statistically signiﬁcant association
with ETB or Mixed TB(P> 0.05). Summary of subgroup analysis based
on ethnicity showed that polymorphisms at four loci had statistically
association with TB in the Asia descendants (all P< 0.05),while only
variants at INT4 and 5′(GT)n were associated with TB risk in European
and Africa populations (P< 0.05.
Conclusion: Alleles at 3’ UTR, INT4, D543N and 5′(GT)n loci had
statistically signiﬁcant association between the NRAMP1 variants and
TB susceptibility, but only 5′(GT)3 decrease TB risk. Only variant
in the 3’ UTR locus showed signiﬁcant association with ETB risk.
Furthermore, different populations with different NRAMP1 variants had
different genetic predisposition to TB.
P2046 Outcome of Port Health referrals for new entrant screening
for tuberculosis in the United Kingdom
M. Healy, M.M. Raza* (Milton Keynes, UK)
Objectives: Screening of new entrants for tuberculosis (TB) in the
United Kingdom (UK) has been re-endorsed as a prevention and control
tool in the National Institute of Healthcare and Clinical Excellence
(NICE) guidance on TB published in 2006. Port of arrival identiﬁcation
of new entrants for TB screening has been in place in UK since 1971.
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We undertook an audit of Port Health referrals to our TB service and its
compliance with NICE guidance.
Methods: The audit was conducted in a UK district general hospital
which provides new entrant screening as part of the TB service. All port
health referrals to the TB service in the year 2009 were identiﬁed. Notes
were then reviewed to identify outcome of these referrals and compliance
of assessment with NICE guidance.
Results: 202 referrals were received from Port Heath in 2009. Nearly
half (46%) of the referrals were for new entrants from the Indian
subcontinent and one-third from sub-Saharan Africa. 168 (83%) were
less than 35 years of age. The TB nurse assessed 106 of these new
entrants. The assessment was in compliance with NICE guidance in 104
(98%) cases. In two cases assessment was considered non-compliant as
they not did not have a chest X-ray as part of the assessment.
The screening was negative for the majority and only 10 (9%) needed
referral to the physicians for further assessment. No case of active TB
was identiﬁed and only 4 cases of latent TB were diagnosed of which
only 2 accepted chemoprophylaxis. Of those screened negative only 2
qualiﬁed for BCG vaccination which was given. Therefore screening led
to preventive intervention in 4/106 (4%) of cases screened and 4/202
(2%) of total referrals.
96 (47.5%) referrals could not be assessed. In nearly half of them (42/96)
no contact could be made, a quarter (22/96) failed to attend appointments
and approximately one-ﬁfth (18/96) had moved to another area.
Conclusion: Assessment of referrals for new entrant screening for
tuberculosis by our TB service is highly compliant with current national
guidance. Physician involvement is required in less than 10% of those
screened. However screening led to preventive intervention in 2% of
referrals only and nearly half the referrals could not be assessed but
resources were spent in trying to contact these cases, referring them
onto appropriate authorities and wasted apointments. The results again
raise question marks over the cost-effectiveness of this port of arrival
new entrant screening strategy.
Molecular diagnosis of mycobacterial
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P2047 First report of molecular detection of ﬂuoroquinolone
resistance-associated gyrA mutations in multidrug-resistant
clinical Mycobacterium tuberculosis isolates in Kuwait
E. Mokaddas*, N. Al-Mutairi, S. Ahmad (Dasma, Jabrya, KW)
Objective: The extensively drug-resistant Mycobacterium tuberculosis
(XDR-TB) strains are deﬁned as multidrug-resistant M. tuberculosis
(MDR-TB) strains additionally resistant to a ﬂuoroquinolone and an
injectable agent and have been detected in >55 countries. Infections with
XDR-TB strains are extremely difﬁcult to treat in developing countries.
The aim of this study was to detect the occurrence of gyrA mutations
associated with ﬂuoroquinolone resistance among MDR-TB strains in
Kuwait.
Methods: A total of 85 MDR-TB strains isolated from 55 TB
patients and 25 pansusceptible M. tuberculosis strains were tested.
Fluoroquinolone resistance-associated mutations were detected by direct
DNA sequencing of quinolone resistance determining region of gyrA
gene. For isolates exhibiting gyrA mutations, 3′-end of rrs (16S rRNA),
three regions of rpoB, katG codon 315 and inhA regulatory region were
also sequenced. Further ﬁngerprinting of the isolates was achieved by
polymorphisms at gyrA codon 95 and katG codon 463 and by double-
repetitive element PCR.
Results: None of the pansusceptible but six of 85 MDR-TB strains
contained gyrA mutations. Only gyrA codon 94 was mutated in all six
(D94A in one and D94G in ﬁve) strains. Three of six mutant strains were
recovered from the same patient while the other three strains represented
individual patient isolates. Fingerprinting studies identiﬁed all individual
patient isolates as epidemiologically distinct strains. All six strains with
gyrA mutation contained wild-type rrs sequence.
Conclusion: Although ﬂuoroquinolones are not generally used for the
treatment of TB and drug susceptibility testing for second-line drugs
is not routinely carried out in Kuwait, four of 55 (7%) individual
patient MDR-TB strains contained ﬂuoroquinolone resistance-associated
mutations in gyrA gene. The data advocate routine drug susceptibility
testing for this important second-line drug for proper management of
MDR-TB in Kuwait. Lack of mutations in 3′-end of rrs gene that confer
resistance to injectable agents reduce the likelihood of the occurrence,
at least for now, of extensively drug-resistant tuberculosis in Kuwait.
P2048 Isothermal target and probe ampliﬁcation method for the
identiﬁcation of Mycobacterium tuberculosis complex from
broth cultures
M. Hur*, H. Moon, H. Kim, J.Y. Kim, Y. Yun (Seoul, KR)
Background: Variable methods are used to identify Mycobacterium
tuberculosis complex (MTC) from broth cultures, including im-
munochromatographic (ICT) and real-time PCR assays. Isothermal target
and probe ampliﬁcation (iTPA) method has been recently introduced
as a simple and cost-effective molecular assay. We wanted to evaluate
the diagnostic performance of iTPA method in comparison with
immunochromatographic (ICT) and real-time PCR assays.
Methods: A total of 175 specimens from MGIT 960 broth culture
system (BD Diagnostics, Sparks, MD, USA) were evaluated. ICT assay
(SD TB Ag MPT64 Rapid, Standard Diagnostics, Seoul, Korea) was
used to identify MTC in MGIT-positive specimens, and real-time PCR
assay (Advansure TB/NTM, LG Life Sciences, Seoul, Korea) was
additionally used for the specimens with MGIT-positive but ICT-negative
results. These results were compared with those of iPTA (RapidDx
Mycobacterium tuberculosis (TB) Test, RapleGene, Seoul, Korea).
Results: MTC was identiﬁed in 71 out of 131 MGIT-positive specimens
including 60 ICT-positive and 11 ICT-negative and PCR-positive
specimens. Sensitivity and speciﬁcity of ITC assay were 84.5% (74.0–
92.0%) and 100% (94.0–100.0%), respectively. These 71 specimens
were all MTC positive with iPTA method. Sixty specimens with
nontuberculous mycobacteria (NTM) and 44 MGIT-negative specimens
were all MTC negative with iPTA method.
Conclusions: Our data shows that the diagnostic performance of iPTA
method is superior to that of ICT assay and comparable to that of RT-
PCR assay. iPTA method could be a reliable and cost-effective option
for the identiﬁcation of MTC from broth culture.
P2049 Removal of PCR inhibitors in a real-time PCR of
Mycobacterium tuberculosis
H.S. Kim*, Y.K. Lee, J.S. Kim, H.Y. Yoon, W. Song, H.J. Kang,
K.M. Lee (Anyang, KR)
Background: The inhibition rates for nucleic acid tests of Mycobac-
terium tuberculosis ranging from less than 1% to more than 10% have
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been reported. Specimen dilution, boiling, addition of bovine serum
albumin (BSA), silica membrane can be used to override ampliﬁcation
inhibitors in nucleic acid tests of M. tuberculosis. The inhibition rate for
a real-time PCR of M. tuberculosis (COBAS TaqMan MTB test; Roche
Diagnostics, Mannheim, Germany) and effective strategies to override
PCR inhibitors were investigated in this study.
Methods: The inhibition rate for COBAS TaqMan MTB test were
investigated in 908 clinical specimens. The effectiveness of PCR
inhibitor removal by repeated run, dilution, boiling, addition of BSA,
and use of silica membrane were evaluated in the inhibited specimens.
Results: Inhibitory substances were present in 4.1% of specimens
(40/980). Among 40 inhibited specimens, inhibitory substances were
removed in 12 (30%), 30 (75%), 27 (67.5%), 25 (62.5%) and 12 (30%)
specimens with repeated run, dilution, addition of RBS, boiling and use
of silica membrane, respectively.
Conclusions: The overall inhibition rate for COBAS TaqMan MTB test
was 4.1%. Dilution, boiling and addition of BSA were shown to be more
effective than repeated run and use of silica membrane for removal of
PCR inhibitors. Combination of two methods might be useful.
P2050 Comparative evaluation of GeneXpert MTB/RIF assay
and Gen-Probe ampliﬁed Mycobacterium tuberculosis direct
test for detection of Mycobacterium tuberculosis complex in
smear-negative respiratory specimens
J.S. Lin*, C. Lin, R. Hsiao, L. Shih (Changhua, TW)
Background: The detection sensitivity of the Cepheid GeneXpert
MTB/RIF assay (GX) for rapid detection of Mycobacterium tuberculosis
complex (MTBC) in smear-negative respiratory specimens is rarely
mentioned. An evaluation was thus conducted to compare GX and
Gen-probe Ampliﬁed Mycobacterium tuberculosis Direct test (MTD) for
detection sensitivity.
Methods: A total of 21 unrelated smear-negative but MTBC culture-
positive respiratory specimens were submitted for GX assay and MTD
test. After inoculation onto Lowenstein-Jensen slants and liquid culture
media, all digested and decontaminated aliquots prepared from primary
specimens were kept frozen at −70ºC until molecular analysis.
Results: GX and MTD had been completed in each aliquot. Seven were
positive and nine were negative by GX and MTD. Four and one were
positive by GX only and MTD only, respectively. When using culture as
a gold standard, the detection sensitivity was 52.4% (11/24) and 38.1%
(8/21) for GX and MTD, respectively. The concordance rate between
GX and MTD was 76.2% (kappa value, 0.53).
Conclusion: This preliminary study suggests that the sensitivity of GX
in direct detection of MTBC in smear-negative respiratory samples is
superior to MTD test.
P2051 Detection of dnaA and dnaN reagents for identiﬁcation
Beijing strains of Mycobacterium tuberculosis in pulmonary
tuberculosis patients with culture-positive specimens
S. Jahani Sherafat*, H. Goudarzi, E. Mirsamadi (Tehran, IR)
Objective: The Beijing strain of Mycobacterium tuberculosis have
attracted special attention due to association with multi drug resistance
and rapid transmission. Spoligotyping is the gold standard for the
identiﬁcation and classiﬁcation of Beijing strains of MTB. This technique
however needs special equipment that there are not in clinical laboratory.
In this study we used of fast and cost-effective method for awareness to
doctors, patient to prevent of spread of this genotype in community.
Methods: Using CTAB method for extract DNA from positive
culture specimens in tuberculosis patients. Then with spoligotyping, we
determined different strain of MTB, then using PCR with dna_A &
dna_N primers.
Results: Total 200 MTB isolated we genotyped by both spoligotyping
and PCR, by spoligotyping 19 isolates we determined to be Beijing
strains and the remaining 181 isolated were non Beijing strains.
Detection of dna_A & dna_N reagents show the same result, and all
of Beijing strain had a insertion sequence in this reagent.
Conclusion: Considering the same detection power of two methods to
distinguish Beijing strain, and higher cost effectiveness in comparison to
spoligotyping, this method can be used in clinical laboratories settings.
P2052 Detection and differentiation of M. tuberculosis and
non-tuberculous mycobacteria by real-time PCR on the
BD MAX system targeting a region upstream of the 65 kDa
heat-shock protein gene
K. Egli*, C. Casanova, T. Bodmer, M. Altwegg (Lucerne, Berne, CH)
Objectives: To establish a real-time PCR assay for the differentiation of
M. tuberculosis (MTB) and non-tuberculous mycobacteria (NTM) from
positive liquid and solid cultures and to estimate its usefulness for the
direct detection and differentiation of mycobacteria in clinical specimens
using the BD MAX system (Becton Dickinson), a highly integrated,
automated device for the extraction, ampliﬁcation and detection of
nucleic acids from up to 24 specimens within about 2.5 hours.
Methods: A real-time PCR system targeting a variable region upstream
of the 65 kDa heat-shock protein gene (hsp) was designed. The assay
consists of a primer pair complementary to all mycobacteria and two
different probes, one for the detection of all mycobacteria (FAM-BHQ1),
the other speciﬁc for the MTB complex (Rox-BHQ2). PCR conditions
were optimized with regard to primer, probe and MgCl2 concentrations,
denaturation and annealing/extension temperatures and times and the
sensitivity was determined using a quantiﬁed MTB DNA standard.
Cultures and (spiked) NALC-decontaminated sputum specimens were
heat inactivated and mechanically disrupted. Sputa were processed both
with and without a BD MAX extraction step, respectively. Ampliﬁcation
was performed with two different enzymes on the BD MAX system.
Results: The analytical sensitivity was approx. 10 target copies per
PCR when using a hot start polymerase (Roche). All 10 MTB strains
were PCR positive with both the genus and the MTB-speciﬁc probe
whereas a genus signal only was observed for all 48 NTM representing
19 different species. No signal with either probe was observed for 7
Actinomyces, 5 Nocardia and 1 Gordonia species. However, the genus
but not the MTB probe gave a positive result for Gordonia sputi and
Rhodococcus equi. The assay detected MTB also in microscopy-negative
spiked sputum specimens irrespective of the extraction procedure applied
(mechanical disruption or full BD MAX extraction process). Similarly,
6/7 microscopy and culture negative sputum specimens were PCR-
negative with the remaining specimen being very weakly positive with
the genus probe only.
Conclusion: The target (upstream of the 65 kDa hsp gene) in
combination with the highly integrated analytical system (BD MAX)
looks very promising for the easy and rapid detection and/or
differentiation of MTB and NTM. Our results justify further validation.
P2053 Comparison of Advansure MDR-TB Genoblot assay kit
with Genotype HMDRTBplus and conventional drug
susceptibility test
S.B. Han*, J.K. Yu, K. Park, G.D. Lee, Y. Kim, Y.J. Park (Seoul, KR)
Introduction: Rifampin (RIF) and isoniazid (INH) are the most
important drugs in the treatment of tuberculosis, and resistance to
these antibiotics often results in incurable tuberculosis. Because of
the prolonged turnaround time for conventioanl susceptibility testing,
development of rapid methods for testing drug resistance is necessary.
Recently, Advansure MDR-TB Genoblot assay kit (LG life science,
Korea) using reverse hybridization line blot assay was developed. In
this study, we compared the kit with Genotype MTBDRplus (HAIN
lifescience, Germany) and conventional drug susceptiblity test (DST).
Materials and Methods: Of the DNAs preserved after the DST with
Genotype MTBDRplus, 150 samples with DST results by conventional
methods were selected. The experiments with both kits were performed
according to the manufacturer’s instructions. For discrepant results,
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sequencing was performed if the DNA was available. Conventional
DST was performed at Korean institute for tuberculosis using absolute
concentration method (RIF, 40mg/ml; INH, 0.2mgml).
Results: 140 specimens showed identical results by the three methods.
The discrepnat results for 10 specimes are described in Table 1. For
RIF, two molecular methods showed 100% agreement and the agreement
with the conventaional DST was 98.7% (148/150). One was very major
error and the other was major error. For INH, the agreement between
two molecular methods was 96.7% (145/150). The agreement with
conventional methods was 96.0% (144/150) and 95.3% (143/150) for
Advansure MDR-TB assay and Genotype MTBDRplus, respectively.
Of the six samples showing discrepancy with conventional method and
Advansure MDR-TB assay, ﬁve (no. 1,2,3,4,9) was very major error
and one (no. 10) was major error. In one (no. 9) sample, resistance was
detected by Genotype MTBDRplus due to loss of katG wild type. All the
seven specimens (no. 1,2,3,4,6,7,8) which showed discrepancy between
Genotype MTBDR plus and conventionnal DST, were very major error.
Of the seven specimens, resistance was detected in three by Advansure
MDR-TB assya, due to the mutaion in ahpC. One sample showed
resistance to INH by conventional method but showed susceptibility with
both molecular methods. By sequencing, there was a 1027dupC in katG
gene.
Conclusion: Advansure MDR-TB Genoblot assya was comparable to
Genotype MTBDRplus. It has the advantange in detecting INH resistance
due to additional target (ahpC).
Lyme borreliosis, toxoplasmosis
P2054 German Investigation of Lyme Borreliosis: Evaluation of
Therapeutic and Diagnostic Cost (GILEAD)
M. Freitag, I. Mu¨ller, G. Poggensee, E. Scharnetzki, J. Gensichen,
K.P. Hunfeld* (Jena, Frankfurt/Main, Berlin, Hamburg, DE)
Lyme borreliosis (LB) is a multisystem tick-borne disorder caused by
the spirochete Borrelia burgdorferi. In Germany alone the number of
incident cases is estimated to range between 40.000–60.000 annually.
LB diagnosis remains a primarily clinical diagnosis, but in most cases
laboratory support is essential because of the nonspeciﬁc nature of
many clinical manifestations. LB is generally responsive to antimicrobial
chemotherapy but the variable clinical picture, persisting symptoms
following treatment in some patients, and ongoing problems with the
quality and standardization of diagnostic tests actually complicate the
medical management of LB patients. Unfortunately, little is known on
the resulting economic impact of LB on the German health care system.
The GILEAD project is focused on a better characterization of the burden
of disease and the medical costs of LB in Germany. Here we analyzed
in- and outpatient data concerning diagnostics and laboratory testing as
provided by a German health insurance company covering healthcare
for approximately 6,6 million members. Medical, epidemiological, and
economic data (ICD- and EBM-codes) for 2007 are currently under
investigation to identify the total number of cases with deﬁnite or
suspected LB and to analyze the number of diagnostic tests and antibiotic
treatments in these patients. Initial results of this analysis suggest that
in 2007 alone the diagnosis LB was coded in 23.310 out of 6,6 million
insured members (0,35%). At the same time the number of hospitalized
patients with suspected or deﬁnite LB accounted for 762 cases. The
number of diagnostic tests ordered turned out to be 29.616 EIAs and
16.832 immunoblots. Moreover, a total number of 35.665 antibiotic
treatments were administered. Concerning the outpatient sector, our
investigations also revealed that for 2007 a total number of 203.871 EIAs
and 58.737 immunoblots were reimbursed to the health care providers.
Our study is the ﬁrst investigation into the medical and economical
burden of LB for the German healthcare system and suggests a high
amount of inappropriate healthcare services. The ﬁndings coming from
the GILEAD project will help assessing the economics of current and
future disease management and prevention programs.
P2055 Primary toxoplasmosis in pregnancy − results of a
multidisciplinary approach
K. Schreiter*, U. Dietz, A. Reich, I. Raila, E. Robel-Tillich, M. Borte,
F. Gebauer, S. Glasow, H.-J. Gottwald, C. Springer, C. Klein, A. Po¨ge,
B.R. Ruf, T. Gru¨newald (Leipzig, DE)
Objective: Primary toxoplasmosis in pregnancy is an immanent problem
for pregnant women and their caregivers. Despite of a low index
clinical manifestations can be severe and might lead to permanent
disabilities in children affected. Incidences are ranging from 0.12−2 per
1000 pregnancies. Evidence-based recommendations for management or
treatment are not available.
Goal: Prospective longitudinal evaluation of efﬁcacy, safety and
outcomes using short-term anti-protozoal treatment (21 to 28 days) for
primary toxoplasmosis in pregnant women.
Patients and Methods: All women attending an infectious diseases
outpatient clinic having serologically conﬁrmed primary toxoplasmosis
(documented seroconversion within four weeks, IgM antibody positivity
with low or absent IgG antibody avidity or positive Toxoplasma gondii-
PCR in plasma) between 2001 and 2009 were scheduled to treatment
in a standardized manner using pyrimethamine and sulfadiazine with
folinate rescue for three to four weeks. Postpartum newborn testing
was performed. If available, follow-up interviews of mothers as well
as children’s medical records were assessed at one to eight years after
birth.
Results: Information was available for 125/133 (94%) mother-child
pairs (mother’s median age 25 yrs, range 17−40 yrs). Diagnosis of
toxoplasmosis was established in pregnancy week 21 (range 6−35).
Treatment was either instituted immediately or week 12. In all
pregnancies no toxoplasmosis-related complication occurred (child
delivery in median week 38; child AGGAR score 10, range 6−10).
In 66/134 children (49.3%, one sibling birth) postnatal serologies were
available: 5 out of 67 children (7.5%) showed evidence of infection:
4/5 IgM antibody positive, one PCR positive (control PCR after one
week negative). No newborn was given pre-emptive treatment. All ﬁve
children are up to now without evidence for congenital toxoplasmosis
(follow up 1, 2, 3, 4, and ﬁve years, respectively).
Conclusions: In this prospectively evaluated large case series short-
term treatment of primary toxoplasmosis in pregnancy compares well
to continuous or intermittent treatment regimen with regard to childrens
and mothers outcomes. Short-term treatment is clearly superior regarding
patient comfort in comparison to regimes which have to be taken
permanently or intermittently during pregnancy.
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P2056 Unusual case of early stage Lyme borreliosis presenting as
acute anicteric hepatitis with splenomegaly
J. Nikolic*, N. Popovic, S. Stojakovic, G. Stevanovic, M. Pavlovic
(Belgrade, RS)
Lyme borreliosis is one of the most common vector-borne illnesses in
Eastern Europe, caused by Borrelia burgdorferi species transmitted via
ticks. In the early stage it may present with skin manifestations (ECM)
or a ﬂu-like disease, but there can also be other unexpected clinical and
biochemical ﬁndings.
This is a case report of a 29-year old, previously healthy, male from urban
surroundings, who presented at our Admission Ward with a history of
5-day low grade fever, malaise, sore throat and splenomegaly.
Laboratory investigations revealed leucopenia (WBC 3.4) with neutrope-
nia, lymphocytosis, and elevated liver enzymes (AST 98, ALT 98).
During a 6 month-follow-up liver enzymes peaked on the 14 th day
of illness, reaching AST 609, ALT 1092, with normal bilirubine and
preserved synthetic liver functions. Complete virology tests (hepatitis
A, B, C, HIV, CMV, Adenovirus, EBV, Parvo B19, Coxsackie B),
PPD, test for Brucellae, M. pneumoniae, stool and urine cultures
were negative, including an immunology tests panel (autoantibodies,
protein electrophoresis, RF, AST), but ELISA for B. burgdorferi was
positive, which was later conﬁrmed by western blot. After a 21-day
course treatment of doxycycline, patient was afebrile, with normal liver
enzymes, blood count and spleen size. Repeated virology markers for
hepatitis B, C were again negative, and also serology for B. burgdorferi
became negative after a 6 month follow up. During this whole
period, patient had no skin marks resembling ECM, was anicteric and
without any signs of hemorrhagic manifestations. Few days after being
diagnosed, he remembered a tick bite which occurred 12 days previous
to his illness.
According to a few articles on this particular subject, most of the similar
recorded cases were patients with ECM and only mild liver damage −
which occurred in approximately 15−20% of patients with early stage
Lyme borreliosis, and up to 66% of patients with disseminated disease.
This case shows an unusual possibility of an early stage borreliosis,
presenting as an acute anicteric hepatitis, with a complete recovery
after a standard course treatment, and therefore can be considered as
a diagnostic possibility in similar situations.
P2057 An unusual presentation of neuroborreliosis
J. Cortez*, M. Shamasna, J. Nunes, C. Valente, F. Pissarra (Coimbra, PT)
Introduction: Neurologic manifestations develop in approximately 15%
of untreated patients with Lyme disease. Meningitis, cranial neuritis
and radiculoneuritis are the classic triad of neurological abnormalities,
emerging within several weeks or months.
Clinical case: The authors describe a clinical case of a previously
healthy 25 year-old man that was admitted into our hospital due to
three separate episodes of generalized seizures. After the ﬁrst seizure he
had started carbamazepine and levetiracetam. Epidemiological data was
inconclusive. On admission’s day, neurological examination didn’t show
abnormalities and there wasn’t nuchal rigidity. Funduscopy and Mini-
Mental State Examination were normal. The levels of serum electrolytes,
calcium, thyroid hormones, folic acid and B12 vitamin, renal and hepatic
function and blood count were normal.
Electroencephalogram showed irregular and slowed base rhythm and
general paroxysmal activity.
The brain’s MRI revealed coronal T2-weighted and FLAIR high-
signal, T1 low-signal in anterior and lateral pons, symmetrically,
with upper extension and very thin leptomeningeal enhancement in
anterior pons without root or ganglion enhancement. No white or gray
matter involvement was found. The lumbar puncture revealed clear
cerebrospinal ﬂuid (CSF) containing 261 cells (98% mononuclear cells),
with a protein level of 2.8 g/L and a glucose level of 1.9mmol/L
with positive oligoclonal bands. VDRL, Gram’s and fungal staining
and PCR for Mycobacterium tuberculosis were negative; borrelia IgG
>240. Serological tests for rickettsia and brucella were negative and
borrelia IgG >240. ELISA and Western blot of Borrelia burgdorferi was
performed in the blood and CSF and the result was positive. Ceftriaxone
intravenous therapeutics was started and lumbar puncture performed 15
days later revealed improvement (50 cells mononuclear, protein level −
0.9 g/L and glucose level − 2.4mmol/L). There was a complete resolution
of symptoms.
Conclusion: In this case the authors didn’t ﬁnd the classic triad of
neuroborreliosis, not even the most typical MRI ﬁndings. When the
characteristic prodrome of erythema migrans, exposure history, arthritis
or MRI ﬁndings are absent, clinical suspicion and serological tests are
fundamental in diagnosis. We alert for high prevalence of Lyme disease
in Europe and the difﬁculties of diagnosis on the absence of this triad.
P2058 Correlation between clinical manifestation and reactive
Borrelia antigens in patients with Lyme disease
T. Gladnishka, E. Taseva*, I. Trifonova, V. Ivanova, I. Christova (Soﬁa,
BG)
Objectives: The aim of this study is to investigate prevalence of antibod-
ies against Borrelia-speciﬁc antigens in patients with early localized and
early disseminated Lyme borreliosis in order to characterize the antibody
patterns.
Methods: Serum samples from 47 patients with Lyme borreliosis (LB)
were studied − 9 patients with early localized LB and 38 patients
with early disseminated LB, including 20 patients with neuroborreliosis,
8 patients with Lyme arthritis, one with ophthalmic disorders and 9
patients with multiple system disorders. Western blot tests (Mikrogen,
Germany) coated with Borrelia speciﬁc antigens were used for IgM and
IgG analysis.
Results: In patients with early localized LB, IgM class antibodies were
most commonly detected against OspC in 6 (66,7%) cases, against
internal fragment of p41 (p41i) of Borrelia afzelii in 8 (88,9%) cases
and p41i of Borrelia garinii in 6 (66,7%) cases. Less frequently IgM
antibodies in these patients were found against p100, VlsE and p41 −
each in 2 (22,2%) cases. IgG class antibodies in these patients were most
frequently reactive with VlsE and p41 in 9 (100%) cases, followed by
p100 in 5 (55,6%) cases, BmpA, OspA, OspC and p41i of B. garinii in 3
(33,3%) cases and p41i of B. afzelii in 2 (22,2%) cases. Serum samples
from patients with early disseminated LB showed much higher reactivity
to all Borrelia antigens. IgM reactivity was shown against OspC in 30
(78,9%) cases, against p41 and p41i of B. garinii in 16 (42,1%) cases,
p41i of B. afzelii in 10 (26,3%), VlsE in 4 (10,5%), p100 and p18 in 2
(5,3%) cases. Most frequently reactive with IgG antibodies were VlsE
in 33 (86,8%) cases and p41 in 30 (78,9%), followed by p100 in 20
(52,6%), BmpA in 16 (42,1%), OspC, p41i of B. afzelii and p18 in 14
(36,8%), p41i of B. garinii in 8 (21,1%), and OspA in 5 (13,2%).
Conclusions: Most commonly reactive antigens with IgM class
antibodies in patients with early localized and early disseminated LB
were OspC, p41, p41i of B. garinii and p41i of B. afzelii. IgG class
antibodies reacted most frequently with VlsE, p41, p100, BmpA, OspC,
p18. Although infrequently, some IgM reactivity against VlsE and IgG
reactivity against OspC could be detected.
P2059 Congenital toxoplasmosis in the health area of Pontevedra,
Spain
M. Trigo*, A. Pallare´s, V. Pulia´n, P. A´lvarez, A. Moreno-Flores,
M. Garcı´a-Campello (Pontevedra, ES)
Objectives: Congenital toxoplasmosis continues to occur worldwide and
its potentially severe outcomes for the fetus and newborn remain one
of the major problems of pregnancy. The aim of this study was to
analyze serological patterns of toxoplasmosis in pregnant women and
to document the occurrence of possible congenital toxoplasmosis during
a three year period in the Health Area of Pontevedra (Spain).
Methods: 10,098 pregnancies were retrospectively studied from January
2008 to December 2010. 18,179 sera were analysed by ELISA IgG and
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IgM (Architect® Abbott 2007 to June 2009 and Liaison® June 2009 to
2010) All seroconversions and IgM positive samples were studied for
Toxo IgG avidity (Liaison®). Pregnant women under 17 weeks at the
time of diagnosis underwent amniocentesis. Serum, total blood and CFS
were taken from newborns to serology and PCR analysis.
Results: 3,625 women had IgG antibodies against T. gondii, representing
a seroprevalence of 35.9%. Ten of them presented acute toxoplasmosis
diagnosed by IgM antibodies and/or low or intermediate avidity.
Moreover eight of these women showed IgG seroconversion during
pregnancy. The overall prevalence of possible congenital toxoplasmosis
in the studied population was 0.99‰. The infection was acquired around
the time of conception in 2 cases, in the second trimester in 4 cases,
and in the third trimester in 4 cases. Additional data are shown in
table 1. Pregnancies follow-up with ultrasound techniques revealed no
abnormalities and infected mothers were treated until birth in attempt
to reduce the severity of fetal infection, although there is controversy
surrounding the beneﬁts of that measure.
Conclusion: The prevalence of T. gondii antibodies in our area has
been steadily falling as described worldwide. Therefore, women are more
susceptible to acute infection during pregnancy, and policies to prevent
the infection as well as serological controls should be emphasized.
Regardless of the time at which the mother became infected, none
of the newborns presented IgM or clinical manifestations at birth and
all the children negativized antibodies within the ﬁrst year of life.
However, clinical monitoring of children should continue until the second
or third decade of life in order to rule out chorioretinitis. Clinically
apparent congenital toxoplasmosis is rare, even though the high acute
toxoplasmosis prevalence in the studied population.
P2060 Susceptibility to Toxoplasma gondii infection in women of
childbearing age: a two-year study (2009–2010)
N. Terzi, A. Charalabopoulou*, A. Papanagiotou, A. Bliamou,
H. Chrysopoulou, D. Togas, T. Brouchos, K. Tzanetou (Athens, GR)
Background: Infection with T. gondii during pregnancy can cause severe
illness in the developing fetus.
Objective: To evaluate the susceptibility to Toxoplasma gondii infection
among women of childbearing age during a two-year period (2009–
2010).
Materials and Methods: From January 2009 to November 2010, a
total of 2609 women of childbearing age, who attended the department
of Obstetrics and Gynecology of “Alexandra” General Hospital of
Athens, were tested for anti-T. gondii IgG and IgM antibodies. Of these
2609 women, 1407 were Greek and 1202 were immigrants who came
from Africa, the Middle East and Eastern Europe. Detection of anti-
toxoplasma IgG antibodies was performed in the serum by indirect
immunoﬂuorescence antibody test (bioMerieux, Marcy l’Etoile, France)
and IgM by EIA (ABBOT, AxSYM Toxo IgM Microparticle Enzyme
Immunoassay) according to the manufacturers’ instructions.
Results: Anti-toxoplasma IgG and IgM antibodies were detected in
210 (14.925%) and 8 (0.57%) Greek women respectively out of 1407
examined, whereas IgG and IgM antibodies were detected in 358
(29.78%) and 7 (0.58%) out of 1202 immigrant women respectively.
The susceptibility to Toxoplasma gondii infection of Greek women of
childbearing age was estimated to 85.075%, while the susceptibility of
the immigrant women to 70.22% (P< 0.0001, odds ratio; 2.418, 95%
conﬁdence interval; 1.99–2.94).
Conclusions: (a) The prevalence of speciﬁc antibodies to T. gondii
in Greek women of childbearing age is low. (b) The seroprevalence
in immigrant women of childbearing age is higher (almost twice as
more) than that of Greek women, while the incidence of acute or
recently acquired infection remains very low in both groups. (c) The high
proportion of susceptibility to toxoplasma infection, especially in Greek
women of childbearing age requires raising awareness about prevention
of infection during pregnancy.
P2061 Multiparametric serological diagnosis in congenital
toxoplasmosis
C.M. Costanzo*, C. Franchina, C.I. Palermo, R. Russo, D. Zappala,
G. Scalia (Catania, IT)
Toxoplasma gondii shows the highest incidence of any human
pathogenic parasite in central Europe. As a rule, the course of the
infection is asymptomatic or mild and confers lifelong immunity to
immunocompetent people. Initial contact with the pathogen during
pregnancy can result in the transmission of the pathogens to the foetus,
resulting in severe damage. In order to obtain an early diagnosis
of congenital toxoplasmosis, the performance of the following were
retrospectively evaluated: i) IgG and IgM ELFA tests, ii) Western
Blot assay, by comparison of the mother’s and the newborn’s pattern
of antibody reactivity to Toxoplasma gondii IgG and IgM, and iii)
ISAGA IgM test. Fifty-seven serum specimens serially collected from 6
infants born to mothers in our centre and 61 sera from 4 congenitally
infected newborns born to mothers not in our centre, were tested. All
mothers suffered, or were strongly suspected of suffering, from primary
toxoplasmosis acquired during pregnancy. Results demonstrate that the
combination of Western Blot and ISAGA IgM assays represents a
useful tool for early postnatal diagnosis of congenital toxoplasmosis.
The gold standard still remains the follow-up of the newborn based on
the evaluation of the IgG decreasing up to negativity within 9−12 months
of life. Our results indicate that infants born to mothers who acquired the
primary infection early in pregnancy and who were adequately treated did
not present congenital infection. On the contrary, those born to mothers
who were not treated early or who acquired the infection after the 24th
week of pregnancy were congenitally infected but not symptomatic.
In conclusion, the use of comparative IgG and IgMWestern Blot together
with ISAGA IgM test seems to be extremely reliable as a diagnostic tool
of early diagnosis of congenital toxoplasmosis that leads to a prompt
speciﬁc therapy.
Sexually transmitted diseases
P2062 Prevalence of and factors associated with sexually
transmitted diseases in clients seeking anonymous
counselling and testing at a university hospital in Taiwan
P. Wu*, C. Wu, W. Liu, C. Hsieh, C. Hung (Taipei, TW)
Objectives: The aim of this study was to describe the prevalence
of and to analyze the factors associated with sexually-transmitted
diseases (STD) and HIV infection among persons who sought voluntary
counseling and testing (VCT) for HIV at a university hospital.
Methods: From April, 2006 to December, 2010, VCT clients were tested
for anti-HIV-1 antibody, Venereal Disease Research Laboratory/Rapid
Plasma Reagin (RPR) titers, indirect hemagglutination antibody (IHA)
for Entamoeba histolytica after integrated pre- and post-testing
counseling was provided. Those blood specimens tested positive for
anti-HIV antibody would be conﬁrmed by Western-Blot. Those persons
with elevated VDRL/RPR titers would be tested for Treponema pallidum
hemagglutination antibody (TPHA). Patients also provide 10-ml ﬁrst-
catch urine for detection of Chlamydia trachomatis and Neisseria
gonorrhoeae using PCR in two study periods, the ﬁrst from October
S608 21st ECCMID/27th ICC, Posters
2008 to February 2009, and the second from March 2010 to November
2010.
Results: Of the 9,908 persons seeking VCT services during the 4.5-
year study period, 8698 (87.7%) were male and 5,800 (58.5%) were
men who have sex with men (MSM). HIV infection was detected
in 352 (3.6%), VDRL/RPR titers of 4 or greater in 219 (2.2%),
and amoebiasis by serologies in 100 (1.0%). Of the 1,898 persons
who provided urine specimens for detection of N. gonorrhoeae and
C. trachomatis, 86 (4.5%) had Chlamydia infection and 19 (1.0%)
gonorrhea. Prevalences of HIV infection and syphilis were increasing
from 2008 to 2010, especially among MSM. In logistic regression model,
factors independently associated with HIV infection were MSM (odds
ratio [OR], 8.27; 95%CI, 4.03–16.98), non-injecting recreational drug
use (OR, 3.39; 95%CI, 2.43–4.72), having seropositive partners (OR,
1.60, 95%CI, 1.10–2.35). The factors independently associated with
syphilis were MSM (OR, 5.42; 95%CI,2.95–9.94) and non-injecting
recreational drug use (OR, 2.11; 95%CI, 1.47–3.03) Independent factors
associated with amoebiasis were MSM (OR, 7.20; 95%CI, 2.96–17.51)
and oral-anal sex practices (OR, 2.58; 95%CI, 1.66–4.01), while that
with chlamydia was oral-anal sex practices (OR, 1,95; 95%CI, 1.19–
3.21).
Conclusions: HIV infection, chlamydia, and syphilis were the three
leading STD among VCT clients seeking HIV anonymous testing.
Among those VCT clients, male homosexuality was consistently,
independently associated with STD that included syphilis, amoebiasis,
and HIV infection.
P2063 Epidemiological study of occurrence of urogenital
chlamydial infection in women from Slovakia
L. Cisla´kova´*, M. Hala´nova´, J. Mikulova´, Z. Szovenyiova´, P. Jarcusˇka
(Kosˇice, SK)
According to WHO estimate more than 340 million new cases
of curable, sexually transmitted infections, namely those due to
Treponema pallidum, Neisseria gonorrhoeae, Chlamydia trachomatis,
and Trichomonas vaginalis, occur throughout the world every year
in men and women aged 15−49 years. From this number about 92
million infections are caused by Chlamydia trachomatis with the largest
proportion in developing countries. In Slovakia, there is no speciﬁc law
establishing systematic screening of this infection and the disease is
not included in the category of notiﬁable diseases. Therefore the data
about prevalence of urogenital chlamydial infections differ signiﬁcantly
depending mainly on the diagnostic method used.
A total of 796 women were examined for the presence of bacterium
C. trachomatis by the method PCR. The women were tested at the 2nd
Department of Gynaecology and Obstetrics of Medical Faculty of P. J.
Sˇafa´rik University in Kosˇice and Gyncentrum, Ltd., in Kosˇice.
Out of 796 examined women, 723 women had various clinical symptoms
of inﬂammatory of urogenital tract. The control group consisted of 73
women before abortion without clinical signs of infection. The patients
were divided into 6 groups according to the age. In the ﬁrst group were
women between 15−20 years, in second group were 21−25 years old
women, in the third group women 26−30 years old, in fourth group
women aged 31−40 years, in ﬁfth group women between 41−50 years,
and in the last, sixth group were women older than 51 years.
Out of 723 examined women was positive result detected in 17 cases,
which represented 2.35% positivity. From 17 positive women were 15
with clinical signs and 2 coming from the control group. In examination
in relation to the age group the highest positivity was observed in the
group of 21−25 years old women.
This work was partially supported by the Agency of the Slovak Ministry
of Education for the Structural Funds of the EU, under project ITMS:
26220120058 (50%)and by VEGA MS SR No. 1/0418/09.
P2064 Chlamydia trachomatis infection among women in Italy:
data from a laboratory-based sentinel surveillance system
M.C. Salfa*, V. Regine, M. Raimondo, L. Camoni, B. Suligoi and
the Italian STI Laboratory-based Surveillance Working Group
Objective: To assess the prevalence and risk factors associated with
Chlamydia trachomatis (Ct) infection among Italian sexually active
women.
Methods: In 2009, the Istituto Superiore di Sanita` (Italy’s National
Institute of Health), in collaboration with the Association of Italian
Clinical Microbiologists (AMCLI), launched a programme for the
surveillance of Ct infection, gonorrhoea and Trichomonas vaginalis
infection. A sentinel network including 13 large clinical microbiology
laboratories, located in the main Italian cities throughout Italy, provide
monthly reporting of tested individuals. Ct infection is diagnosed
based on nucleic acid ampliﬁcation tests on samples from the genital
or anal area; individual socio-demographic, clinical, and behavioural
information are also collected.
Univariate and multivariate analyses (odds ratio, OR) were conducted to
identify associations between potential risk factors and Ct infection.
Results: Overall 19,106 women were tested for Ct, and 2.4% were
positive. About 40.0% of Ct positive women were asymptomatic.
At the multivariate analysis, the positivity for Ct was signiﬁcantly
associated with young age [15−24 years vs. >24 years of age, OR
3.3; 95% Conﬁdence Interval (CI) 2.6−4.2], presence of genito-urinary
symptoms (yes vs. no, OR 1.4; 95%CI 1.1−1.8), having had two or
more partners in the previous six months (2 vs. 0−1 partners, OR 4.7;
95%CI 3.3−6.7), and having used oral contraceptives in the previous six
months (yes vs. no, OR 1.5; 95%CI 1.1−1.9).
Conclusions: In Italy there do not exist screening programmes nor
guidelines for Ct testing. Our results suggest that testing for Ct should
be primarily offered to young women, women with multiple partners,
and women who use oral contraceptives, even if asymptomatic.
P2065 Remarkable increase of Neisseria gonorrhoeae with
decreased susceptibility to azithromycin in Japan
M. Yasuda*, K. Nakane, N. Hagiwara, S. Ishihara, S. Maeda, S. Ito,
T. Deguchi for the Gifu UTI·STI Research Group
Objective: We examined clinical strains of N. gonorrhoeae isolated
from men with gonococcal urethritis from 2000 to 2009 in Japan for
susceptibilities to antimicrobial agents.
Methods: A total of 1,034 clinical isolates of N. gonorrhoeae were
collected from 2000 to 2009. The CLSI agar dilution method was used
to measure their susceptibilities to penicillin G, tetracycline, ceﬁxime,
ceftriaxone, spectinomycin, azithromycin (measured from 2002), and
levoﬂoxacin.
Results: The MIC90s of penicillin G were 4mg/L from 2000 to 2001
and 8mg/L from 2002 to 2009, respectively. The MIC90s of tetracycline
were 2mg/L in 2000 and 8mg/L in 2009. The MIC90s of ceﬁxime were
0.5mg/L in 2000 and in 2009. Respective MIC90s of ceftriaxone were
0.125mg/L in 2000 and in 2009. The MIC90s of spectinomycin 32mg/L
in 2000 and in 2009. The MIC90s of azithromycin were 0.25mg/L in
2002 and 1mg/L from 2004 to 2009. The MIC90s of levoﬂoxacin were
8mg/L in 2000 and 16mg/L from 2001 to 2009.
Conclusions: Fluoroquinolones have not been recommended to
treat gonococcal infections anymore, because about 80−90% of
N. gonorrhoeae isolated from patients with gonococcal urethritis are
quinolone-resistant strain in Japan. Therefore the majority of clinical
N. gonorrhoeae isolates were resistant to penicillin G, tetracycline
and levoﬂoxacin. In place of ﬂuoroquinolones, oral cephalosporins
had been commonly used for the treatment of gonococcal infections.
However, oral cephalosporin treatment failure for gonococcal infection
was reported. Indeed, about 20−30% of the N. gonorrhoeae isolates
exhibited the decreased susceptibility to ceﬁxime in Japan. However, all
the clinical isolates were still sensitive to ceftriaxone and spectinomycin.
Therefore, only three drugs, spectinomycin, cefodizime and ceftriaxone,
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are recommended to treat for gonococcal infections in Japan. Recently,
azithromycin-resistant N. gonorrhoeae were reported around the world.
Regardless of having not an indication for gonococcal infections,
the susceptibility of N. gonorrhoeae against azithromycin had been
decreased in Japan. In 2009, azithromycin SR 2g, which have about the
same AUC on 1.5 g of azithromycin tablet, was licensed the indication
for gonococcal infections in Japan. Therefore, it will be necessary to
be careful the susceptibility of N. gonorrhoeae against azithromycin in
future.
P2066 Factors determining serological response to syphilis
treatment
D. Fro¨hlich Knaute, N. Graf, S. Lautenschlager, R. Weber,
P.P. Bosshard* (Zurich, CH)
Objectives: Serology is the mainstay for diagnosis of syphilis
and monitoring of treatment. There have been unusual reports in
serologic testing in HIV-positive patients, such as increased rate of
treatment failures for non-treponemal antibody tests and higher rate of
seroreversion to negative for speciﬁc treponemal test after therapy. We
aimed to compare the serological response to treatment between (1)
HIV-negative and HIV-positive persons, and (2) different clinical stages
of syphilis.
Methods: Data from syphilis patients who were treated and followed at
the University Hospital of Zurich and at the City Hospital Triemli in
Zurich between January 1999 and December 2008, and who had at least
one follow-up serology 20 to 375 days after treatment were analyzed
retrospectively. A total of 304 patients were included (98 primary, 150
secondary, 47 latent, and 9 tertiary cases of syphilis). The mean age
was 38 years; 92% of patients were men, and 45% were known to be
HIV-positive. The response of the Venereal Disease Research Laboratory
(VDRL) test and a speciﬁc IgM capture ELISA test (Pathozyme syphilis
M capture, Omega Diagnostics Ltd.) to treatment was assessed with a
Cox regression analysis. Endpoints were deﬁned as fourfold decrease in
VDRL titres or reversion to nonreactive and a drop of the Pathozyme-
IgM index below 0.9.
Results: The serological response to treatment was not inﬂuenced by
HIV co-infection (p = 0.26 for VDRL, p = 0.12 for Pathozyme-IgM) or
by the gender of the patient (p = 0.71 for VDRL, p = 0.82 for Pathozyme-
IgM). However, the clinical stage of syphilis and re-infection inﬂuenced
serological outcome: Compared with primary syphilis, secondary,
tertiary, and latent syphilis showed a slower serological response to
treatment; the hazard ratios (95% conﬁdence intervals) of VDRL
response in secondary, tertiary, and latent syphilis were 0.76 (0.55, 1.0),
0.46 (0.22, 0.94), and 0.45 (0.29, 0.68); and of Pathozyme-IgM response
0.51 (0.36, 0.70), 0.13 (0.02, 0.97), and 0.46 (0.27, 0.79), respectively.
Reinfected individuals also showed a slower response of the VDRL titre,
the hazard ratio was 0.69 (0.49, 0.97).
Conclusions: Serological treatment response in patients with syphilis is
not inﬂuenced by HIV co-infection. However, patients with secondary,
tertiary or latent syphilis respond slower to therapy than patients with
primary syphilis.
P2067 Inﬂammation on the cervical Papanikolaou smear: evidence
for infection in asymptomatic women?
S. Baka*, E. Elefteriou, S. Kotsali, A. Panopoulou, I. Patikas,
I. Tsouma, A. Spathi, A. Lykas, D. Makri, A. Kalantzi, G. Kaparos,
E. Kouskouni (Athens, GR)
Objectives: Most laboratories reporting the results of cervical Papaniko-
laou (Pap) smears tests comment on the possible presence of infection
based on cytological criteria. The clinical importance of these ﬁndings
is unknown especially in asymptomatic women. This study assessed
the possible association between inﬂammation on Pap smear with the
presence of pathogens in the genital tract.
Methods: Asymptomatic women with inﬂammatory changes on
routinely performed Pap smear and recalled for cultures in the last two
years were included in the study. Genital tract samples (vaginal and
cervical) were available for analysis. Clinical specimens collected from
patients were inoculated onto appropriate plates for standard aerobic and
anaerobic cultures and incubated at 370 C for 24h and 48h, respectively.
A wet mount as well as a Gram-stained smear were examined under
microscope to obtain valuable information about the microorganisms
present. The isolated pathogens were identiﬁed using the automated
system VITEK 2 (BioMerieux, Marcy l’Etoile, France). Furthermore, the
presence of Chlamydia trachomatis as well as Ureaplasma urealyticum
and Mycoplasma hominis, in the specimens studied, was determined
using the COBAS AMPLICOR Chlamydia trachomatis test (Roche
Diagnostics, USA) and Mycoplasma IST2 (BioMerieux, Marcy l’Etoile,
France), respectively.
Results: Out of the 280 women studied, 109 (38.9%) had negative
cultures (normal ﬂora present), in one case no microorganisms were
observed, while 170 (60.7%) women had positive cultures with different
pathogens. Gardnerella vaginalis and various anaerobes were isolated
from 87 (51.2%) women (in 46 G. vaginalis only, in 21 anaerobes
only and in 20, both). Ureaplasma urealyticum was isolated in 82
(48.2%) women, Mycoplasma hominis in 7 (4.1%) and only in one case
(0.6%) Chlamydia trachomatis was detected. Anaerobes together with
mycoplasmas were isolated in 33 (19.4%) cases, Candida species in 18
(10.6%), Streptococcus agalactiae in 15 (8.8%), Gram-negative rods in
6 (3.5%) and Staphylococcus aureus in 2 (1.2%) cases.
Conclusions: The results of our study suggest that a report of
inﬂammatory changes on the cervical Pap smear cannot be used to
reliably predict the presence of a genital tract infection, especially in
asymptomatic women. Nevertheless, the isolation of different pathogens
in about 60% of the women studied, in the absence of Lactobacillus
species, cannot be overlooked and must be regarded with concern.
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P2068 The prediction of positive stool culture in patients with
acute diarrhoea
S. Cho, J. Chung*, Y. Kwak (Seoul, Gyeonggi-do, KR)
Objectives: Acute diarrheal illness is a signiﬁcant clinical problem.
More than 90% of cases of acute diarrhea are caused by infectious agents
and the cornerstone of diagnosis is microbiologic analysis of the stool.
However, stool cultures have been shown to have poor yield and incur
high costs. Though several guidelines recommended the indications for
stool culture, it have been still inappropriately used for patients with
diarrhea. The aims of this study were to investigate the positive rates of
stool cultures and to determine the predictor of positive stool cultures in
patients with acute diarrhea.
Methods: From December 2004 to July 2009, we conducted a
retrospective study of patients who underwent stool culture in Chung-
Ang university hospital in Seoul, Korea. The patients who visited
the emergency department complaing of acute diarrhea and had acute
diarrhea among patients hospitalized with another illness were included
in the study. Stool samples were routinely examined for Salmonella spp.,
Shigella spp., and Vibrio spp. To investigate the predictors for positive
stool cultures, we compared the characteristics between the patients with
positive culture and those without.
Results: Of the patients who presented with acute diarrhea in the setting
of emergency department, and inpatient during the study period, 5647
patients underwent stool cultures. Among these patients, 115 patients
had positive results (2.0%). Salmonella spp. (73.0%) was detected
most frequently, followed by Vibrio spp. (27.0%). Out of the clinical
features, the frequency of diarrhea and fever were statistically associated
with positive cultures. Of the laboratory datas, C-reactive protein had
a signiﬁcant association with positive cultures. Multivariate logistic
regression analysis found that frequency of diarrhea and CRP were
the independent factors related with positive stool cultures. If the CRP
was more than 50mg/L, the odds ratio was 3.3 (95%CI, 2.12–5.08) for
positive stool cultures.
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Conclusion: Our study has suggested the frequency of diarrhea and
the high value of CRP may be the indepedant predictors of patient with
positive stool cultures in emergency and inpatient setting. These ﬁndings
will likely lead to more discerning and cost-effective utilization of stool
culture testing by clinician.
P2069 Outcomes of and predictors for colectomy in patients with
Clostridium difﬁcile associated diarrhoea
S. Rushworth*, V. Thomas, F. Miyajima, N. Beeching, M. Beadsworth
(Liverpool, UK)
Background: Clostridium difﬁcile associated diarrhoea (CDAD) has
been a major problem in the last 5 years. A small minority of patients
with CDAD have fulminant colitis requiring colectomy in addition to
anti-microbials and general support.
Objectives: To review the prognostic factors for and outcomes of
colectomy for CDAD in a large British Hospital.
Methods: A retrospective case note review of all patients with CDAD-
related colectomy in 2008–2009 inclusive. This was a case control study
using randomly selected CDAD patients admitted in the same period,
with roughly 4 controls:1 case.
Results: There were 654 CDAD cases in 2008–2009 at the Royal
Liverpool University Hospital. In total, 19 required colectomy. The
majority of these patients (13/19; 68%) developed CDAD in the
community. The median ages of colectomy and control groups were 72
and 74 years respectively. Seventy three percent of the colectomy group
and 64% of the non-colectomy group were female. All but one of the
surgical group had a sub-total colectomy. Median (range) time to surgery
was 2 (0−8) days, the primary indications being systemic toxicity (N = 6),
peritonitis (4), toxic megacolon (3), failure of medical treatment (2),
worsening symptoms (2) and pancolitis identiﬁed on CT (2). Mortality
in the colectomy group was 7/19 (36%) compared to 4/80 (5%) in the
controls. Radiological abdominal imaging revealed features of severe
CDAD in 13/19 (72%) of the colectomy group compared to 7/80 (7%)
of the control group. The colectomy group had an increased occurrence
of acute renal failure (9/19) compared to the controls (4/80), which
was not not signiﬁcantly associated with increased mortality within the
colectomy group (4/9; 44% mortality). Individuals in the colectomy
group also had considerably raised crp and peripheral white counts at
diagnosis compared to the control group. No differences were found in
liver function tests between the colectomy and non-colectomy group.
Summary: In this large series of patients with CDAD, 3% of patients
required urgent colectomy, with favourable mortality compared to other
published series. In addition to clinical & radiological indications, the
main associations with need for colectomy were ARF, and markedly
raised white cell count and CRP. Poor outcome following surgery related
to delay of presentation to hospital following development of CDAD
within the community, failure to review patients regularly within hospital
and delay between surgical review and surgery.
P2070 Enteroaggregative Escherichia coli in Danish children
attending daycare centres in greater Copenhagen
B.B. Roldgaard*, A. Munk Petersen, S. Schjørring, N. Boisen,
F. Scheutz, D. Ro¨ser, B. Utoft Andreassen, K.E. Olsen, K. Angeliki
Krogfelt (Copenhagen, Hvidovre, DK)
Objectives: Enteroaggregative Escherichia coli (EAEC) are suspected
to be a cause of child-hood diarrhoea. − Yet, epidemiology and severity
of disease is not assessed.
Therefore a large cohort study was established in order to investigate
the pres-ence of enteropathogenic bacteria in faecal samples from
children aged 1−6 years, who are attending daycare centers in greater
Copenhagen.
The aim of the study is to determine to which extend EAEC is present
in the gas-tro intestinal tract of Danish children and whether it has any
inﬂuence on their general health.
Methods: In this ongoing study we have enrolled 140 children from 24
daycare centers. The children are asked to deliver a faecal sample every
second month during a ten month period. When the sample was, taken
an online questionnaire were ﬁlled out and send to us.
The faecal samples were cultured at Statens Serum Institut by standard
operat-ing procedures for detection of enteric pathogens.
Results: So far we have received 276 samples, 5 of these were EAEC,
30 were Attaching and Effacing E. coli (A/EEC), 5 Entero Pathogenic
E. coli (EPEC), 1 Entero Inva-sive E. coli (EIEC) and 1 Salmonella
(S. muenchen).
None of the EAEC were collected from the same child or from children
in the same daycare center. However both EPEC and A/EEC were
isolated from chil-dren attending the same daycare center and in two
cases the same types were found in siblings attending the same center.
These types were also isolated from the same children at different time
points.
Conclusion: Preliminary results suggest that the children are mainly
colonised by E. coli strains containing the eae gene and these strains
seem to be transmitted from child to child. Only few children were
found to be colonised with EAEC strains.
P2071 Rotavirus G2P[4] and G2P[4]+[6] infections during
norovirus gastroenteritis outbreak in 2010 summer season
in the coastline area of Sa˜o Paulo State, Brazil
A. Luchs*, S. Morillo, A. Cilli, S. Calux, C. Ribeiro, R. Carmona,
M. Timenetsky (Sa˜o Paulo, BR)
Objective: A key characteristic on rotavirus (RV) epidemiology is
the distinct seasonal pattern. In Brazil, RV detection peaks during
the winter or dry season (from May to September) in central and
southern states who exhibit a temperate-like climate. During summer
2010 (December 2009 to February 2010), Sa˜o Paulo State (SP), southern
Brazil, experienced a large gastroenteritis outbreak due to Norovirus
(NoV). A particular event was observed in Guaruja´, a popular seashore
city, where occurred atypical RV infections by the side of the large
NoV outbreak. The aim of this study was to contribute to knowledge of
seasonality of RV infection in tropical countries, performed molecular
characterization of RV positive samples, and carried out sequence
analyses in order to provide additional sequence data and to gain insight
into the variability of Brazilian strains.
Methods: An epidemiological retrospective investigation was conducted,
and 28 stool samples were analysed from a total of 698 revised cases. RV
and NoV were detected using a commercial immunoenzymatic assay. RV-
positive stools samples were typed after reverse transcription followed
by nested PCR and sequenced.
Results: NoV and RV infection were detected in 35.7% (10/28) and
17.9% (5/28), respectively. RT-PCR assay identiﬁed G2P[4] genotype
in 4 samples, and a P mixed infection G2P[4]+P[6] in one sample.
Comparison of the SP G2 sequences showed 100% of similarity among
them, and a genetic relationship with RV strains from India. Comparison
of the SP P[4] sequences showed 99.9% to 100% of similarity among
them, and a genetic relationship with RV strains from Russia.
Conclusion: RV G2P[4] was recognized as the etiological agent of
this conﬁned gastroenteritis outbreak occurred during the summer.
RV outbreaks during the summer are very uncommon, and it seems
that is not an absolute temperature or humidity level that favors RV
transmission, but rather a relative change in climatic conditions. The
isolation of a Brazilian G2 strain exhibiting double P[4] and P[6]
speciﬁcity was not unexpected. The inclusion of alternative P types in
serotype G2 strain gene may provide a means of escaping protective
immunity, and an increase in RV diversity. Moreover, these results
suggested that was not the same strain circulating during this period,
and there was not a common source of RV contamination.
Solid organ transplant infections S611
Solid organ transplant infections
P2072 Optimal duration of selective antifungal prophylaxis in
heart transplant recipients
P. Mun˜oz, M. Valerio*, M. Giannella, J. Palomo, J. Ferna´ndez-Yan˜ez,
J. Guinea, A. Eworo, E. Bouza (Madrid, ES)
Background: Invasive aspergillosis (IA) is a major cause of infection
in heart transplant (HT) patients (pts) and universal prophylaxis with 3
months of itraconazole is effective and reduces mortality (Am J Transpl
2004; 4:636–643). However tolerance and interactions of itraconazole
are a limitation. Newer antifungals are tolerated better but long term use
may result in toxicity and they are expensive. In a previous study we
demonstrated that the time period of risk for developing IA is from the
onset of one or more risk factors (RF) − re-operation, CMV disease and
post-HT hemodialysis − until 30 days after their disappearance Targeted
antifungal prophylaxis (TP) in this setting is feasible.
Objective: To determine the efﬁcacy of TP in HT recipients given during
the risk period of developing IA (onset of RF/s until 30 days after their
disappearance).
Methods: From Jan 2003 to Nov 2010, TP was only administered to pts
with at least one of the mentioned risk factors (RF). The antifungal agent
was selected by the attending physician based on patient characteristics,
toxicity and interactions. Endpoints were: cases of IFI during the ﬁrst
year after HT and adverse effects related to TP.
Results: During the study, 133 pts received a HT and TP was only
administered to 15 (11.2% of the Tx population): caspofungin (10),
anidulafungin (3), micafungin (1), and voriconazole (1). TP failed in
1 patient who was receiving a low dose of caspofungin due to liver
failure (35mg/qd despite a 35 kg/m2 BMI). He developed pulmonary
aspergillosis (IPA) on day + 16 after HT and died. All the other high-risk
HT pts were successfully protected. All pts tolerated TP, except one who
developed leukopenia while receiving caspofungin.
Of the remaining 118 pts who did not receive TP, 3 (2.5%) developed IA
during an outbreak in our cardiac surgical ICU caused by an extremely
high environmental load of Aspergillus spores. The ﬁrst patient had one
RF (hemodialysis) and developed Aspergillus mediastinitis on day +44
after stopping hemodialysis. The other 2 pts did not have any RFs
and developed mediastinitis and IPA on days +31 and + 4 postHT,
respectively.
Conclusion: Prophylaxis for IA in HT patients should be provided only
to patients with one or more risk factors and should be maintained 30
days after their disappearance. In addition to this a high environmental
load of Aspergillus spores should be included as a risk factor and
prophylaxis should also be offered when present.
P2073 Primary toxoplasmosis after kidney transplantation: a rare
and potentially fatal complication, with very useful tools
to improve diagnosis and the outcome
B. Denis*, M.-N. Peraldi, J. Menotti, F. Derouin, J.-M. Molina (Paris, FR)
Objectives: Primary toxoplasmosis is a rare complication after kidney
transplantation. If initially negative, repeated serology is rarely done
during follow up. We report 2 cases with a review of literature and
stress on the usefulness of PCR for an early diagnosis.
Case 1: A 38 year old male received a renal transplant from a deceased
donor in 09/2007. His immunosuppressive regimen was rapamune and
mycophenolate mofetil (MMF). He went for vacation to Algeria from
09/08 to 12/08. Symptoms began on 01/01/2009 with headache, diarrhea,
and weight loss. At admission, he was febrile, had a dry cough, diffuse
enlarged lymphnodes, headache, a lymphopenia and anemia. Toxoplasma
(T) serology was negative on 01/14 and + on 01/20 (IgM: 6 UI,
IgG:33 UI),PCR for T. gondii was + at the same time on lymphnode
biopsy at 140 tachyzoit equivalent (tach), + on total blood at 22 tach
and on induced sputum (34 tach). Retrospectively, PCR was + at
8.8 tach on 01/06, thus being positive 15 days before serology. The
patient was successfully treated with atovaquone and clarithromycine
and negativation of PCR was seen on February 16.
Case 2: A 45 year old male received a renal transplant on 11/2005 in
Poland. His immunosuppressive regimen consisted of MMF, tacrolimus,
prednisone 15mg daily. In France, 17 days after transplantation he
started to have an isolated fever, then a dry cough, with lymphopenia
and anemia. T serology was + on 12/31 (IgG: 53 UI, IgM: 10UI,low
avidity: 0.1). PCR was + for T. gondii at 610 tach on total blood
on 01/07, and became negative after treatment by clindamycine and
pyrimethamine on 01/30 with a successful outcome.
Discussion: In the literature, 20 cases of primary toxoplasmosis after
kidney transplantation were previously described. Fever was present in
99% of cases, pneumonitis in 68%, hepatitis in 40%, headaches in
20%, seizures in 25%, chorioretinitis in 10%, and leucopenia and/or
thrombopenia in 70%. Diagnosis was made by autopsy in 35% of cases,
by serology in 45%, by a direct exam in 15%, by PCR in 15%. Mortality
rate was 60%. The two cases presented here had a favorable outcome
because of an early diagnosis and treatment, and PCR was positive two
weeks before serology in the ﬁrst case.
Conclusion: Primary toxoplasmosis is a rare complication after kidney
transplantation but detection of toxoplasmic DNA by PCR can lead
to early diagnosis and treatment, thus improving prognosis of this
potentially fatal opportunistic infection.
P2074 Histoplasmosis and blastomycosis in transplant patients in
Chicago
F. Lanternier*, M. Angarone, N. Theodoropoulos, K. Reed,
O. Lortholary, M.G. Ison (Paris, FR; Chicago, US)
Background: Blastomycosis and histoplasmosis are rare complications
of solid organ and stem cell transplantations in areas surrounding the
Mississippi and Ohio Rivers (USA).
Objective: We collected all cases of histoplasmosis and blastomycosis
in transplant recipients from bill records in Northwestern hospital,
Chicago, Illinois in order to describe the epidemiology and clinical
course of these endemic mycoses between 2000 and 2010. We describe
immunosuppressive agents used in patients, the incidence in different
transplant populations, clinical and radiological presentation, time
for diagnosis, diagnostic tools, patient and graft outcome, antifungal
treatment and maintenance therapy.
Results: See the table. 10 (71%) patients had a positive culture, 4 for
blastomycosis and 6 for histoplasmosis. Five patients had histological
conﬁrmation of diagnosis 52 for blastomycosis and 3 for histoplasmosis).
For patients with blastomycosis 3 out of 3 patients tested had positive
blastomycete antigen (rate 50±20) and 1 out of 2 tested had also a
positive histoplasmosis antigen (rate 3), blastomycosis diagnosis was
conﬁrmed with culture. For patients with histoplasmosis 3 out of 3
patients tested had positive blastomycete antigen (rate 61±34) and 6
out of 9 tested had a positive histoplasmosis antigen (23±20), one
patient had a negative histoplasmosis antigen and a positive blastomycete
antigen, but diagnosis was conﬁrmed with Histoplasma growing from
bronchoalveolar lavage and blood culture.
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Conclusion: Blastomycosis and histoplasmosis are rare but severe
infections in the transplant populations with no reliable serologic
markers.
P2075 Primary HHV8 infection with systemic inﬂammatory
syndrome and visceral Kaposi sarcoma after OLTx,
successfully treated with cidofovir, low-dose of steroids and
liposomal-doxorubicin: case report
V. Lamonaca*, G. Pietrosi, S. Gruttadauria, A. Provenzani, R. Di
Stefano, M.I. Minervini, P. Grossi, F. Cardinale, A. D’Antoni,
B. Gridelli (Palermo, IT)
Background: Primary post-transplant HHV8 infection has extremely
high mortality.
A 29 year-old woman with hemangio-endotelioma underwent liver
transplantation. Six months later she developed fever, weakness, severe
sinus tachycardia, maculo-papular skin rash. Bacterial cultures and
routine viral PCRs were negative. Donor/recipient HHV8 serology was
mismatched and HHV8-DNA, searched for on patient’s blood, came back
positive 1.500.000 copies/ml. On post-admission day 1 she was started
on cidofovir. Total body CT scan showed multiple lymphoadenopathies
on neck, chest and abdomen; no other abnormalities. On day 5, she had
continous fever (40.3ºC), severe sinus tachycardia (160/min), ARDS,
oligo-anuria, severe anemia and thrombocytopenia (5.000/ml); skin rash
turned violet. Blood pressure, WBC and graft function tests surprisingly
normal. HHV8-viral load was 19.000.000 copies/ml; 17.000.000/ml
on day 7. She had a second dose of cidofovir. Cervical lymph node
biopsy showed Kaposi’s sarcoma (KS) and positive latent HHV8-
Ag immunochemistry. Liposomal-doxorubicin (20mg/mq q2weeks) was
then administered. With clinical status approaching MOF, low dose of
steroid (methyl-prednisolone 0.5mg/Kg bid) was added. After 72 hrs
(day 11), patient had no fever, HR below 100/min, respiratory status
and urine output back to normal. Meanwhile, HHV8-viral load was
600.000/ml (day 11), 2.000/ml on day 13, undetectable on day 18. Patient
had two additional cidofovir and ﬁve liposomal-doxorubicin doses. In the
last 15 months of 18-month follow-up, viral load was persistently below
2.500 copies/ml; undetectable in the last 6 months. CT scan (days 22 and
62) showed progressive decreasing of lymph node size and was totally
normal on month 18. EGDS negative; colonoscopy refused. Data from
the acute phase were analyzed with Pearson’s test. We found signiﬁcant
correlation between viral load and both heart rate (p = 0.0246, r = 0.7725)
and platelet count (p = 0.0158, r = −0,8054); and between heart rate and
platelet count (p = 0.0003, r = −0.9515).
Conclusion: Primary HHV8 infection after liver transplantation was
associated with a systemic non-neoplastic life-threatening inﬂammatory
illness, in addition to KS. Sinus tachycardia and thrombocytopenia cor-
related with viral load. Cidofovir and liposomal-doxorubicin controlled
virus replication and neoplastic disease (KS) while low dose of steroids
seemed to have been crucial during the acute phase in controlling
inﬂammatory response.
P2076 Parvovirus B19 is a major cause of opportunistic viral
infection in the ﬁrst year after kidney transplantation
R. Porignaux, C. Barbe, A. Rauch, D. Talmud, F. Renois, V. Brodard,
T. Tabary, S. Daliphard, J. Lanc¸on, O. Toupance, S. Lavaud, P. Rieu,
L. Andreoletti, N. Leveque* (Reims, FR)
Background: Described for the ﬁrst time in 1986, the parvovirus B19
(B19V) infection in kidney transplant recipient remains little-known and
probably underestimated.
Objectives: (i) to establish the B19V infection incidence during the
ﬁrst year after kidney transplant; (ii) to compare demographic and
clinical characteristics of recipients presenting or not B19V infection to
determine speciﬁc patterns and predisposing factors to viral infection;
(iii) to characterize the clinical and biological manifestations due to the
B19V infection in renal transplant recipients.
Patients and Methods: The study included adults who underwent
kidney transplant at the Reims University Hospital Centre from January
2009 to June 2010. All patients included had been transplanted less
than a year before. B19V was detected and quantiﬁed by real-time
quantitative PCR assay in plasma samples collected every 15 days
during the ﬁrst three months and every month from 3 months to
one year following the kidney transplant. HCMV, EBV, HHV-6, BKV
and the adenovirus were simultaneously detected and quantiﬁed. B19V
serological test was performed in donors and recipients. Demographic,
clinical, biological data and immunosuppressive treatment taken by the
patient were recorded at each sampling date.
Results: A total of 381 samples obtained from 60 patients were
retrospectively investigated. Six patients (10%) presented B19V in-
fection, while 8 HCMV (13.3%), 7 EBV (11.7%), 5 HHV6 (8.3%),
5 BKV (8.3%), and 2 adenovirus (3.3%) infections were detected.
B19V viral loads ranged from 38 to 1800 UI/ml (median = 70±380
UI/ml). B19V infections were either reactivation or reinfection in
5 cases, while one case of primo-infection was observed. Induction
therapy with thymoglobulin infusion was signiﬁcantly associated with
opportunistic viral infections (P = 0.04), whereas basiliximab induction
treatment was not. As a consequence of infection an increase of
alanine aminotransferase activity was observed in B19V positive patients
by comparison to the B19V negative patients (34±16.3 IU/L versus
24±14.7 UI/L; P = 0.11).
Conclusion: These results rank the B19V third of opportunistic viral
infections occurring during the ﬁrst year after a kidney transplant. Even
if risk factors and biological consequences of the infection should be
assessed in larger studies, these preliminary data let open the question
of systematic screening and follow-up of B19V infection in the kidney
transplant recipient.
P2077 Monitoring of cell-mediated immune parameters identiﬁes
kidney transplant recipients at high risk of severe infection
M. Ferna´ndez-Ruiz*, F. Lo´pez-Medrano, L. Allende, A. Garcı´a-Reyne,
C. Lumbreras, R. San Juan, M. Lizasoain, A. Andre´s, J.M. Morales,
E. Paz, J.M. Aguado (Madrid, ES)
Objectives: Infection represents a signiﬁcant source of morbidity and
mortality after kidney transplantation (KT). End-stage renal disease
(ESRD) is associated with immunosuppression, as measured by low
absolute lymphocyte count and peripheral blood lymphocyte populations
(PBLPs). We aimed to assess if monitoring of these simple, broadly
available, surrogate parameters of the cell-mediated immune response
might predict the occurrence of infection in KT recipients.
Methods: ATALANTA is an ongoing, observational study in which
ESRD patients undergoing KT at our institution are enrolled in a
protocol including the evaluation of total lymphocyte count and PBLPs
(assessed by ﬂow cytometry) at baseline and at months 1 and 6 post-
transplant, with prospective surveillance of infectious and non-infectious
complications. For the present study we analyzed data from patients
included between November 2008 and November 2009. Risk factors for
severe infection occurring during the ﬁrst year post-transplant (deﬁned as
blood stream infection, pneumonia, cytomegalovirus [CMV] infection,
or invasive fungal infection) were analyzed by logistic regression.
Results:We included 143 KT recipients (89 males; mean age: 54.9±14.9
years). During the follow-up period (median: 349 days), 32 patients
(22.4%) had at least one episode of severe infection (including 24
episodes of blood stream infection, 12 episodes of pneumonia, 42
episodes of CMV infection, and 3 episodes of invasive fungal infection).
Recipients with low total CD3 (<1.125×103/mcL) and CD8 T-cell
counts (<0.375×103/mcL) at baseline developed a higher incidence of
severe infections (P = 0.037 and 0.008, respectively). Recipients with low
CD8 T-cell count (<0.165×103/mcL) at month 1 were at higher risk for
subsequently developing severe infection between months 2 and 6 post-
transplant (P = 0.002). After adjustment for other factors (including type
of induction therapy, long-term graft dysfunction and acute rejection),
low CD8 T-cell count at baseline emerged as an independent risk factor
for severe infection (OR= 6.01; 95%CI = 1.69–21.35; P = 0.006).
Conclusion: Low CD8 T-cell counts at baseline and at month 1 after
KT are associated with increased risk of severe infection. In our
Solid organ transplant infections S613
opinion, pre- and post-transplantation monitoring of simple parameters
of cell-mediated immunity may offer an opportunity for individualized
surveillance, prolonged prophylaxis, and preemptive therapy.
P2078 Identiﬁcation of patients at high risk for infections after
liver transplantation
S.H. van Olphen*, I.C. Konings, L.H. de Grim, G. Kazemier,
B.E. Hansen, R.A. de Man, X. Rogiers, C.A. Schurink, H.J. Metselaar
(Rotterdam, NL; Ghent, BE)
Objectives: Liver transplantation (LTx) is a successful therapy for
patients with end-stage liver disease. Infections are an important cause
of morbidity and mortality in the ﬁrst three months after transplantation
with a reported incidence up to 60%.
This study was conducted to develop a model for predicting both
bacterial and fungal infections.
Methods: Medical records of 200 LTx recipients transplanted between
2005 and 2009 at the Erasmus MC Rotterdam were reviewed. We
registered all infections according to CDC deﬁnitions during the ﬁrst
three months after LTx and noted potential risk factors for developing
infections. Multivariate logistic regression was used to create a predictive
model for infections in general. Subsequently, we validated this model
in another cohort of 94 LTx recipients transplanted between 2007 and
2009 at the Ghent University Hospital.
Results: The model consists the following parameters: (1) preoperative
haemodialysis; (2) preoperative Candida colonization; (3) history
of abdominal surgery; (4) Sodium <130mmol/l on day of LTx;
(5) intubation >3 days after LTx; (6) relaparotomy within 5 days for
intra-abdominal bleeding, anastomosis leakage, vascular insufﬁciency or
(7) retransplantation.
In high risk patients 2 or more conditions were present. In the Rotterdam
cohort 81% of high risk patients developed an infection versus 50% of
low risk patients [OR 4.273 (2.1−8.9)]. Surgical site infections were the
most frequent and 41 out of 109 bacterial infections (38%) were caused
by 41 Enterococcus species. In the Ghent cohort 80% of the high-risk
patients developed an infection compared to 48% of the low-risk patients
[OR 4.3 (CI 1.3–14.2)].
Conclusion: This model based on 7 clinical parameters identiﬁes
patients at high risk for bacterial and fungal infections in the
ﬁrst 3 months after liver transplantation. Close monitoring, starting
anti-bacterial and fungal prophylactic treatment and minimization of
immunosuppressive therapy should be considered in these high risk
patients.
P2079 Infections in patients with pancreas transplantation
G. Sanclemente*, L. Linares, C. Cervera, I. Hoyo, F. Marco,
M. Marcos, R. Garcı´a, M. Ricart, A. Moreno (Barcelona, ES)
Background: Pancreas transplantation has a high incidence of nosoco-
mial and opportunistic infectious complications.
Method: We performed an analysis of all pancreas transplant recipients
from July 2003 to December 2009 with at least one year of follow-
up. Multivariate logistic regression analysis was performed to identify
independent variables associated with post-transplant infections.
Results: We included 147 patients (18 isolated pancreas and 129
simultaneous kidney pancreas) with a median follow-up of 729.5 days.
All patients had enteric pancreas drainage. We diagnosed 151 episodes
of infection in 72 patients (49%). Out of 151 episodes, bacterial were
the most frequent (129, 85%), followed by viral (18, 12%), fungal
(3, 2%) and parasitic (1, 0.7%). By site, the most frequent locations were:
urinary tract (70, 46%), lung (17, 11%), surgical wound (15, 10%), intra-
abdominal (12, 8%), catheter (9, 6%), gastrointestinal (6, 4%), primary
bacteraemia (6, 4%), bone and joint infections (2, 1%) and others
(14, 9%). Isolated species were: Gram negative bacteria 62% (E. coli
19%, P. aeruginosa 12%, Enterobacter sp. 11%, Klebsiella pneumoniae
10%, Citrobacter 5%) and Gram positive 22% (Enterococcus sp.
8%, coagulase-negative staphylococci 5%, S. aureus 2%). Multidrug
resistant bacteria were found in 33% of the episodes of bacterial
infection. Nineteen episodes (15%) of bacterial infection episodes
coursed with bacteraemia. There were no differences in the incidence of
infections between isolated pancreas and simultaneous kidney-pancreas
transplantation. Forty-eight per cent of episodes occurred during the
ﬁrst month after SOT (65 bacterial infection, 3 CMV, 1 pneumonia by
inﬂuenza, 1 surgical wound infection and 1 intra-abdominal infection
by Candida sp., 1 Cryptosporidium-associated diarrhea). Independent
variables associated with infection after pancreas transplantation were:
Post-transplant dialysis (OR 15.7, 95%CI 1.9–128.2), post-transplant
surgery requirement (OR 3.5, 95%CI 1.6−7.7) and previous CMV
disease (OR 23.8, 95%CI 2.9–193.0). Three patients died during the
follow up of which 2 were deaths related to infection.
Conclusions: Infections are frequent after pancreas transplantation but
are accompanied with low mortality rates (<5%). More complicated
course of the transplant procedure is associated with higher risk of
infections.
P2080 Descriptive analysis of infections produced by respiratory
viruses in solid organ transplant recipients
J. Molina*, O.J. Ben-Marzouk, C. Milara, A. Martı´n, C. Martı´n,
V. Cabello, G. Sua´rez, M. Sobrino, P. Pe´rez-Romero, E. Cordero
(Seville, ES)
Objectives: Respiratory infections constitute a major cause of morbidity
and mortality in solid organ transplant recipients (SOTR). Published
data regarding infections by respiratory virus in these patients are
scarce, and their clinical features may be noticeably different from
those observed in general population. This study aims to describe
the etiology, epidemiology, clinical features and prognosis of viral
respiratory infections in non-pulmonar SOTR.
Methods: All patients receiving liver, kidney and/or heart transplant in
our center between January 1st and September 30th were prospectively
included. Nasopharingeal swabs were collected from each patient
at inclusion and when respiratory symptoms presented. Systematic
follow-up was programmed with one-month periodicity, and additional
clinical evaluation was performed whenever respiratory symptoms were
detected. Multiplex PCR was carried out on nasopharingeal swabs from
symptomatic patients.
Results: 97 cases were included. The nasopharingeal swab performed
at inclusion revealed positive PCR results in 23 patients (23.7%), 21
of which were asymptomatic. Up to 84.5% of patients had received
inﬂuenza vaccination by the time they were included. 20.6% cohabited
with children with ages bellow 3-years-old attending to nursery schools.
23 episodes of respiratory infections in 18 patients were included. The
most common symptoms were rhinorrhea (95.7%), cough (73.9%), sore
throat (73.9%) and fever (17.4%). The etiologic agent most frequently
isolated were inﬂuenza A (n = 8, 34.8%) − 3 of which corresponded
to H1N1 serotype, coronavirus (n = 3), and rhinovirus (n = 2). PCR
resulted negative in 5 patients. None of these episodes of infection
presented signs of severity nor required hospital admission. In up to
30.4% of cases, symptoms were not completely solved after 14 days
from the beginning of the clinical disease, although only 4,3% presented
secondary complications (bacterial sinusitis).
Conclusions: Infections produced by respiratory viruses is a frequent,
usually non-severe entity in SOTR, though the clinical course may
be more prolonged in this population. The inﬂuence of epidemiologic
factors like cohabitation with children attending to nursery schools, or
the immunization of close contacts constitute issues still not resolved.
Asymptomatic carriers of respiratory viruses detected by multiplex-PCR
techniques were prevalent in our sample, and the clinical value of this
ﬁnding needs to be stablished.
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P2081 Prevalence and clinical characteristics of mycobacterial
infection in a cohort of solid organ transplant recipients
over a 13-year period
N. Boillat Blanco*, K. Jaton, G. Nseir, P. Yerly, J.D. Aubert,
M. Pascual, O. Manuel (Lausanne, CH)
Objectives: Solid-organ transplant (SOT) recipients have an increased
susceptibility to mycobacteria, but the epidemiology of mycobacterial
infection in this population is not well characterized. We assessed the
prevalence and described the clinical characteristics of mycobacterial
infection in a large cohort of SOT recipients.
Methods: We included all consecutive patients who received a solid
organ transplant at our institution between 1997 and 2010. All positive
isolates for mycobacteria (either by culture or PCR) were identiﬁed
from the database of the microbiology laboratory. Medical records of
patients with a positive mycobacterial isolate were reviewed. Standard
ATS criteria were applied for the diagnosis of mycobacterial colonization
or disease.
Results: Overall 852 patients received a solid organ transplantation
between 1997–2010; 46% received a kidney, 25% a lung, 16% a heart
and 13% a liver transplant. 65% of patients were male and mean age at
the time of transplantation was 48.8 years. Two patients (1 heart and 1
kidney transplant recipients) presented with post transplant pulmonary
tuberculosis. Mycobacteria other than tuberculosis (MOTT) were isolated
in 9 patients: 6 were considered as having bronchial colonization (2 cases
ofM. gordonae, and 1 case each ofM. szulgai,M. hassiacum,M. xenopi,
and one non-identiﬁed rapidly-growing mycobacteria) and 3 patients
as having disease. Median time from transplantation was 24 months
(3.5, 45) for TB, 15 months (0−55) for MOTT colonization, and 0.2
months (0−5) for MOTT disease. The prevalence of tuberculosis, MOTT
colonization and MOTT disease was 0.2%, 1% and 0.4%, respectively.
Of the 3 patients with MOTT disease, 1 kidney transplant recipient had
urinary tract infection due toM. kansasii, and 2 lung transplant recipients
had pulmonary infection with M. arupense and M. avium intracellulare,
respectively. All 3 patients received antimycobaterial treatment with
azythromycin and ethambutol plus a third drug (either isoniazide,
ciproﬂoxacin or rifabutin). Median duration of treatment was 8.5 months
(3.5−12). No relapse or infection-associated mortality was observed.
Conclusions: In this cohort of SOT recipients, the prevalence of
mycobacterial infection after transplantation was very low. Most patients
with a positive isolate of MOTT were considered to be colonized
rather than infected. Larger cohorts are needed to better characterize
mycobacterial infection after organ transplantation.
P2082 Tuberculosis in solid organ transplant recipients: risk
factors and treatment outcome
Y.E. Ha*, E.J. Joo, M.K. Joung, S.Y. Park, S.J. Kang, C.I. Kang,
D.R. Chung, J.H. Song, K.R. Peck (Seoul, KR)
Objectives: Solid organ transplant (SOT) recipients are at increased
risk of tuberculosis (TB) than general population with few risk
factors established. Diagnosis and treatment of TB are further
complicated by immunosuppression, drug toxicity, interaction between
immunosuppressive agents and anti-TB drugs. Purpose of this study
was to investigate incidence, risk factors, and treatment outcome with
rifamycins of TB in SOT recipients.
Methods: By a retrospective cohort study, incidence density of TB was
calculated. Risk factors for TB were analyzed by a nested case-control
study among the 2144 SOT recipients. Treatment outcome and effect
on immunosuppressants and allograft were compared between patients
whose initial 2-month intensive regimen included rifampicin or not. Four
patients who received rifabutin were excluded from the analysis.
Results: From Feb 1995 to June 2010, a total of 2144 patients received
solid organ transplantation. The median duration of follow-up in these
patients was 1522 days (range, 1–5693 days). During the follow-up of
2144 SOT recipients, 40 cases of post-transplantation TB were found
(1.7%). The incidence density was 372 cases per 105 patient years
(95%CI, 270–503), which was higher than that for the general Korean
population (90 cases per 105 person years). The median time to the
development of TB was 234 days (range, 33–3940 days). TB developed
within 1 year of transplantation in 24 (60%) recipients. In a nested
case-control study, use of tacrolimus (OR 4.90; 95%CI, 1.74–13.80;
P = 0.003) and CMV infection within the prior 3 months (OR 4.62;
95%CI, 1.44–14.87; P = 0.01) were found to be risk factors for TB.
Patients whose intensive regimen included rifampicin were more likely to
increase the dose of calcineurin inhibitors than patients whose intensive
regimen spared rifampicin (13/15 (86.7%) vs. 3/14 (21.4%), P = 0.001).
However, graft rejection and mortality were not different between the
two groups.
Conclusions: Use of tacrolimus and CMV infection as risk factors for
TB in SOT recipients from this comparative study are novel ﬁndings
to our knowledge. Although patients with rifampicin needed to increase
the dose of immunosuppressants more frequently, either rifampicin-using
regimen or rifampicin-sparing regimen were used with similar efﬁcacy
and safety in terms of graft outcome and mortality.
P2083 Validation of a fungal infection prediction model in 2
European liver transplant centres
I.C. Konings*, S.H. van Olphen, L.H. de Grim, G. Kazemier,
B.E. Hansen, R.A. de Man, X. Rogiers, C.A. Schurink, H.J. Metselaar
(Rotterdam, NL; Ghent, BE)
Objectives: Liver transplantation (LTx) is a successful therapy for
patients with end-stage liver disease. Invasive fungal infections (IFI)
are an important cause of morbidity and mortality in the ﬁrst three
months after transplantation with a reported incidence up to 47%.
A recent described prediction model identiﬁed LTx patients who
were high risk for developing IFI. This model was based on the
presence of >1 of six following conditions: hepaticojejunostomy biliary
anastomosis; retransplantation; intra-operative administration of 40
units blood products; return to the operating room for intra-abdominal
bleeding, anastomotic leak or vascular insufﬁciency; preoperative serum
creatinine of 177mmol/l and perioperative Candida colonization
(Pappas et al., Am J Transplant. 2006;6:386−91). This retrospective
study was conducted to validate this American risk model in two
European transplant centers.
Methods: Medical records of 200 LTx recipients transplanted between
2005 and 2009 at the Erasmus MC Rotterdam and 94 LTx recipients
transplanted between 2007 and 2009 at the Ghent University Hospital
were reviewed. We registered invasive fungal infections for a period of
three months after LTx. All six risk factors were recorded from the
patient ﬁles.
Results: In Rotterdam 37 patients were deﬁned as high risk of which
14 (37.8%) developed IFI; 163 patients were at low risk, 17 (10.4%)
developed IFI (p< 0.001). Two (6,5%) IFI were due to A. fumigatus, 29
(93.5%) due to Candida spp. In the Ghent cohort, 25% of high risk and
2.9% of low risk patients developed IFI (p = 0.021).
Conclusion: This study in two European transplant centres conﬁrmed
the value of the so called Pappas risk model identifying ’high risk’
patients for developing IFI. As the numbers of IFI due to Aspergillus
spp are very low, ﬂuconazol as perioperative prophylaxis in these patients
is recommended.
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P2084 Risk factors for development of Pseudomonas aeruginosa
in non-neutropenic cancer patients with Gram-negative
bacteraemia: a case-control study
C.I. Kang, Y.E. Ha, J. Kim, S.J. Kang, S.Y. Park, D.R. Chung,
K.R. Peck, N. Lee, J.H. Song, E.J. Joo* (Seoul, KR)
Objective: Even though febrile neutropenia occurring after chemother-
apy in cancer patients has been identiﬁed as a strong risk factor for
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P. aeruginosa infections, few studies have speciﬁcally addressed ques-
tions concerning the clinical features and risk factors of P. aeruginosa
bacteremia in non-neutropenic cancer patients.
Methods: A case-control study was performed to indentify clinical
predictors for P. aeruginosa infection among non-neutropenic cancer
patients with Gram-negative bacteremia. One case of P. aeruginosa
bacteremia was matched to one or two controls covering E. coli,
Klebsiella species, Enterobacter or Citrobacter species in non-
neutropenic cancer patients.
Results: A total of 78 cases with P. aeruginosa bacteremia were
compared with 98 controls with other Gram-negative bacteremia. The
most common types of cancer were biliary tract cancer (49/176, 27.8%)
and hepatocellular carcinoma (38/176, 21.6%), followed by gastric and
bladder cancer. The univariate analysis showed that factors associated
with P. aeruginosa bacteremia were the presence of lung cancer,
indwelling percutaneous catheters, nosocomial acquisition, a receipt of
invasive procedure and a previous receipt of antimicrobial agents (all
P< 0.05). Among these, the presence of lung cancer and a previous
receipt of antimicrobial agents were found to be independent risk factors
for P. aeruginosa bacteremia (OR, 7.54; 95%CI, 1.39–40.96; P = 0.019
and OR, 4.29; 95%CI, 2.13–8.65; P< 0.001). In the subgroup analysis
including 90 patients with community-onset bacteremia, the prior receipt
of antimicrobial agents was the only factor signiﬁcantly associated with
P. aeruginosa bacteremia (OR, 6.10; 95%CI 2.25–16.54; P< 0.001).
Conclusions: P. aeruginosa should be considered to be a signiﬁcant
pathogen causing Gram-negative bacteremia, even in non-neutropenic
cancer patients. Underlying lung cancer and a prior receipt of
antimicrobial agents were signiﬁcantly associated with P. aeruginosa
bacteremia in non-neutropenic cancer patients.
P2085 Vancomycin-resistant enterococci control measures in a
haematologic and bone marrow transplant unit
A. Giannetti*, M. Vieira, F. Dulley, F. Rossi, G. Fonseca, T. Alves
Lima, J. Nobrega, T. Guimaraes, S. Costa (Sao Paulo, BR)
Introduction and Objectives: It’s known that healthcare associated
infections (HCAI) increases mortality, costs and hospitalization length,
and can be prevented by measures focused on patients care. Vancomycin-
resistant enterococci (VRE) is a nosocomial pathogen with increasing
concern in hematologic units. Our aim was to assess the VRE incidence
in a hematologic and bone marrow unit, featuring outbreaks and
analyzing employed control measures.
Methods: We analyzed oncohematologic and stem-cell transplanted
patients admitted on HC-FMUSP hematologic unit from 2002 to 2010.
VRE data was collected by active surveillance, with cultures obtained
weekly on all patients, except those known to be VRE positive. Incidence
density (cases/1000 patient-days) rates were calculated for colonization
(cID) and infection (iID), and graphical representations were built
to detect outbreaks. For outbreak periods a data ase was built and
analyzed with OpenEpi software, were 2-tail, P value0,05 was consider
signiﬁcant.
Results: We analyzed 4413 patients, 48470 patient-days and 775 HCAI.
VRE colonization and infection were diagnosed in 442 and 46 patients
respectively. There were two distinct periods, from 2002 to Oct-2005,
where only E. faecalis cases occurred, and from Nov-2005 to 2010,
where E. faecium was predominant. Only two outbreaks were identiﬁed
during the study period, caused one by E. faecalis and other by
E. faecium. The iID was signiﬁcant greater during outbreak period.
The most common infection was bloodstream infection (BSI) in both
outbreaks. The intervention measures used was staff education, hand
hygiene and contact precaution measures reinforcement. Since 2005
linezolid is used pre-emptively on VRE colonized febrile patients during
empirical antimicrobial coverage, and since 2009 all patients received
daily chlorhexidine bathing.
Discussion: VRE has become a true challenge to haematological
patients. As showed above and in other reports infection represents
only 10% of real VRE magnitude, and it control requires particular
techniques. Pre-emptive use of Linezolid is still a controversial issue.
Chlorhexidine bathing has shown helpful preventing BSI on critical
patients, and although more empowered assays are needed, it seems to
provide beneﬁcial effect in haematological patients too.
P2086 Respiratory viral infections after allogeneic haematopoietic
stem cell transplantation
M. Mikulska*, V. Del Bono, S. Dini, A. Raiola, A. Dominietto,
S. Bregante, M. Van Lint, A. Orsi, F. Ansaldi, A. Bacigalupo, C. Viscoli
(Genoa, IT)
Objectives: Viral respiratory tract infections (VRTI) contribute to
morbidity and mortality after hematopoietic stem cell transplant (HSCT).
Rapid and accurate diagnosis can be now obtained by molecular testing.
The aim of this study was to evaluate incidence, risk factors and outcome
of VRTI in allogeneic HSCT recipients.
Methods: VRTI were diagnosed by PCR in respiratory samples, in
the presence of signs or symptoms of respiratory infection. Data of
208 consecutive patients transplanted from 1/10/07 to 30/04/10 were
collected. Demographic and disease-related variables were analyzed as
potential risk factors for VRTI (chi-square test).
Results: Overall, 54 patients (26%) developed 70 VRTIs in median
183 days after HSCT (range:4–791). Almost half of VRTIs (46%) were
diagnosed within 100 days after HSCT. During the ﬁrst year after HSCT,
49 patients (24%) developed VRTI. Eleven patients had more than one
VRTI. The aetiology of 70 episodes was as follows: RSV (17, 24%),
inﬂuenza (12; 17%), rhinovirus (12; 17%), parainﬂuenza virus (PIV) (11;
16%), coronavirus (11; 16%), metapneumovirus (4;6%) and adenovirus
(3;4%). The seasonal distribution differed among viruses: RSV was more
frequent in spring and winter, PIV was equally present throughout the
year, while inﬂuenza virus was more frequent in winter (except for
H1N1 epidemic in fall). Isolated upper respiratory tract infection was
present in 39 patients (55.7%), while 31 (44.3%) had lower respiratory
tract infection (LRTI). In most of them (26/31, 83.9%) suspected or
proven coinfection was present. In univariate analysis, myeloablative
conditioning (p = 0.02) and type of donor (p = 0.07) were associated
with developing VRTI (tab. 1). Overall survival (OS) after a median
of 289 days of follow-up (range:1–1095) was 54.3%. Patients with
VRTI had better OS (64.8% vs 50.6%, p = 0.02), and they also had
signiﬁcantly longer follow-up than patients without VRTI (415 vs 253
days, p = 0.001).
Conclusions: VRTIs are common after HSCT, especially in the ﬁrst 100
days. The most frequently involved virus is RSV; followed by inﬂuenza
and PIV. Almost half of patients had LRTIs, but coinfections were
frequent. Preventive strategies are available, and given the high incidence
of VRTI due to viruses other than inﬂuenza, respiratory isolation is
crucial. It should be applied particularly during the ﬁrst year after HSCT
and in case of myeloablative conditioning or cord blood transplantation.
P2087 Severe infection is associated with lower M-ﬁcolin
concentration in patients with haematological cancer
undergoing chemotherapy
L. Ameye*, M. Paesmans, M. Aoun, J.C. Jensenius, S. Thiel (Brussels,
BE; Aarhus, DK)
Introduction: The pattern recognition molecules M-ﬁcolin, L-ﬁcolin
and H-ﬁcolin, members of the human innate immune system, bind
surface structures of different micro-organisms and activate the lectin
pathway of complement. We hypothesized that ﬁcolin deﬁciency could
be responsible for infections in haematological malignancies.
Materials and Methods: Plasma samples of 105 patients who underwent
chemotherapy for a hematological cancer and who were followed for the
development of infections in the context of an already published clinical
trial (Clin Infect Dis. 2007;44:1593) were retrieved. The samples were
obtained on the day of the start of chemotherapy or during the two
preceding days and used for assessment of several markers: M-ﬁcolin
(J Innate Immun. 2010;2:167), H-ﬁcolin, MASP-2 and MASP-3. In 93
patients one sample was used, in 12 patients two samples (two different
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chemotherapy cycles) could be used resulting in 117 samples. The
endpoints were febrile neutropenia, documented infections, bacteraemia
or severe infections during the chemotherapy cycle and the neutropenic
period.
Results: The median age of the patients was 54 years. 33% of the
patients had acute leukemia; 35% had lymphoma/HD. Patients developed
a severe infection during chemotherapy in 34 of the 117 chemotherapy
cycles. Lower M-ﬁcolin concentration was found in patients who
developed a severe infection: median 267 ng/ml compared to 473 ng/ml
in patients who did not develop a severe infection (P = 0.01). Signiﬁcant
association was also found for low M-ﬁcolin and the three other
endpoints.
Thirty-two of the 105 patients developed a severe infection. Considering
M-ﬁcolin <351 ng/ml as deﬁcient, the time to development of severe
infection was shorter in the M-ﬁcolin deﬁcient group: hazard ratio of
2.60 (95%CI, 1.23 to 5.49).
No statistically signiﬁcant associations between severe infection and
H-ﬁcolin or MASP-3 concentration were found. Higher MASP-2
concentration was present in patients who developed a severe infection:
median 535 ng/ml compared to 367 ng/ml in patients who did not develop
a severe infection (P< 0.01).
Conclusion: Patients with M-ﬁcolin deﬁciency who receives chemother-
apy are more likely to develop severe infection. This result needs to be
prospectively conﬁrmed with adjustment for other risk factors for the
development of severe infection.
P2088 Limited humoral responses of solid organ transplant recip-
ients to the AS03-adjuvanted pandemic inﬂuenza vaccine
J. Ambrosioni*, M. Bel, C. Combescure, K. Hadaya, P.Y. Martin,
P. Soccal, T. Berney, S. Noble, S. Meier, K. Posfay-Barbe, S. Grillet,
L. Kaiser, C.A. Siegrist, C. van Delden on behalf of the H1N1 study
group
Objectives: Solid organ transplant (SOT) recipients are considered a
priority group for inﬂuenza vaccination. However, immune responses
have been unsatisfactory and strategies enhancing immunogenicity,
including adjuvants, are needed. The objectives of our study were to
determine humoral immune responses to adjuvanted 2009-pandemic
inﬂuenza vaccines in SOT recipients compared to healthy controls.
Figure 1. Determination of anti-inﬂuenza H1N1 antibody levels in controls and
SOT recipients.
Methods: We determined immune responses to two doses of the AS03-
based adjuvanted inﬂuenza A/09/H1N1 vaccine in 216 SOT recipients
(lung: 25, liver: 45, kidney: 96, heart: 27 heart, pancreas: 23) and
to one dose in 138 controls. Antibody responses were measured by
hemagglutination inhibition (HAI) and conﬁrmed by microneutralisation
assays. Geometric mean titres (GMT) and seroprotection rates (GMT
40) were calculated. Uni and multivariate analyses were performed to
establish factors associated with weak responses.
Results: Baseline inﬂuenza A/09/H1N1 antibodies were low in patients
and controls (HAI seroprotection rates: 13.4% and 14.8% 1:40,
respectively). Seroprotection was achieved in 70.3% of SOT recipients,
compared to 87% of controls (p< 0.001). GMT remained 3-fold lower
(115 vs. 340) in SOT recipients than controls. The weakest responses
(seroprotection: 43.5%, GMT: 40) were elicited in lung transplant
recipients. Multivariate analyses identiﬁed increasing age, type of
transplant (lung and kidney) and mycophenolate mofetil treatment as
independently associated to weaker responses. Other immunosuppressive
drugs targeting mainly cellular responses (such as steroids or calcineurin
inhibitors) had no impact in antibody responses.
Conclusion: Two doses of AS03-adjuvanted vaccine elicited weaker
seroresponses in SOT patients than one dose in healthy individuals.
Lung transplant recipients, the more susceptible group to inﬂuenza-
related morbidity and mortality, showed the lowest responses. Additional
measures such as chemoprophylaxis may have to be considered to protect
these high-risk patients against inﬂuenza during high virus circulation
periods.
P2089 Primary cytomegalovirus infections in adult liver transplant
recipients receiving valganciclovir prophylaxis
I. Lautenschlager*, R. Loginov, K. Ho¨ckerstedt (Helsinki, FI)
Objectives: Cytomegalovirus (CMV) infections are signiﬁcant compli-
cations in liver allograft recipients, appearing usually within the ﬁrst 3
months after transplantation. In addition to fever, end-organ disease such
as colitis and hepatitis are the most common symptoms. To prevent CMV,
most transplant centers use antiviral prophylaxis for high risk patients
of CMV-seronegative recipients receiving an organ from a seropositive
donor (R-/D+). However, many patients develop primary CMV infection
after the cessation of prophylaxis. In this study, we investigated the
occurrence and outcome of the late primary CMV infections developing
after valgancyclovir prophylaxis in adult liver transplant patients.
Methods: Of 196 consecutive adult liver transplant patients 32 belonging
to the CMV high risk group received antiviral prophylaxis (valganciclovir
900mg daily and/or i.v. ganciclovir 5mg/kg/d) up to 3 months
after transplan-tation. The basic immunosuppression consisted of CN
inhibitors, azathioprine/MMF plus steroids. The patients were frequently
monitored for CMV by real-time quantitative plasma PCR. Tissue
invasive CMV infections were demonstrated in biopsy material by
immunohistochemistry.
Results: During antiviral prophylaxis, no break-through CMV infections
were recorded. After cessation of valgan-ciclovir prophylaxis 12/32
(37%) patients developed primary CMV infection mean 181 days (range
95–365 days) post transplantation. Two low level CMV infections were
asymptomatic and were not treated with antivirals, 6 primary infections
were successfully treated with valganciclovir, and 4 severe cases of
CMV disease with intrave-nous ganciclovir and secondary valganciclovir
prophylaxis. No intragaft CMV infection was found in these pa-tients,
but one developed gastrointestinal complication with a positive CMV
ﬁnding in ileum biopsy material. No patient or graft was lost due to
CMV.
Conclusions: No break-through CMV infections were recorded during
valganciclovir prophylaxis. Primary CMV infections were common
after cessation of prophylaxis. However, of these late-onset infections
only a few were severe, and all infections successfully treated with
valganciclovir or intravenous ganciclovir.
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P2090 Safety and clinical outcomes of high-dose daptomycin for
enterococcal infections
R. Kullar, M. Steed, S. Davis, S. Cosgrove, B. Potoski, D. Goff,
R. Hasbun, C. Crank, J. Segreti, G. Sakoulas, J. Zhao, D. Levine,
M. Rybak* (Detroit, Baltimore, Pittsburgh, Columbus, Houston,
Chicago, San Diego, US)
Objective: Few optimal agents are available to treat enterococcal in-
fection, including vancomycin-resistant enterococci (VRE). Daptomycin
(DAP), approved at dosages up to 6mg/kg/day for many clinically
signiﬁcant Gram-positive infections, may be beneﬁcial at higher dosages
due to its concentration-dependent activity. We evaluated the safety
and clinical outcomes of high-dose (HD) DAP (>6mg/kg/day) for
enterococcal infections.
Methods: A retrospective case series from 8 academic medical centres.
Consecutive patients (pts) treated for non-urinary enterococcal infection
with HD DAP for 72h, excluding dialysis pts, were collected from
2005–2010. Charts were reviewed for demographics, comorbidities,
antimicrobial therapy, microbiologic cultures, clinical outcomes, and
adverse events.
Results: 102 eligible pts were identiﬁed. Baseline characteristics:
Median (interquartile range (IQR)) age 57 yrs (46−66 yrs) and APACHE
II 10 (6−16), 87.3% prior hospitalization within 1 yr, 39.2% diabetes,
21.6% renal disease, 21.6% solid organ/bone marrow transplant,
15.7% liver disease. Infections: 46.1% complicated bacteremia, 26.5%
intra-abdominal, 26.5% catheter, 9.8% skin/wound. Organisms: 73.5%
E. faecium, 12.7% E. faecalis, 10.8% Enterococcal spp, with 83.3%
VRE. DAP MICs were tested in 57 isolates: 54% were 2mg/L,
9% = 3 and 37% = 4. Most common DAP dose: 8.0 (8−10) mg/kg/day,
duration of HD DAP: 12 days (6−16), length of hospital stay: 26
days (14−48), duration of bacteraemia: 3 days (1−8). 85.9% had a
favourable clinical outcome, deﬁned as clinically improved or cured, and
91.8% microbiological eradication. Safety: 81.4% pts had peak creatine
phosphokinase (CPK) levels 200 IU/L (29.8–121.3), and 89.1% had
end-of-therapy CPK levels 200 IU/L (22.5–82.3). No discontinuation
of HD DAP due to adverse events was observed.
Conclusion: HD DAP may prove to be a therapeutic option in pts with
VRE infections. Efﬁcacy and safety rates were favourable in these pts,
with no pts discontinued from therapy due to adverse events. Further
studies with a larger cohort are warranted in pts with VRE infections.
P2091 Results from the European Cubicin® outcomes registry
and experience: daptomycin is effective and safe in patients
with neutropenia and Gram-positive infections
A. Galloway*, N. Kro¨ger, F. Keil, A. Micozzi, T. Lejko-Zupanc,
M. Gutierrez, P. Gargalianos-Kakolyris, R. Parakh, M. Heep, Y. Yin,
R.L. Chaves (Newcastle upon Tyne, UK; Hamburg, DE; Leoben, AT;
Rome, IT; Ljubljana, SI; Zaragoza, ES; Athens, GR; Gurgaon, IN;
Basel, CH; East Hanover, US)
Objectives: The use of bactericidal agents is preferable in neutropenic
patients (pts). In comparison to other anti-MRSA agents, e.g. linezolid,
tigecycline, vancomycin, and teicoplanin, daptomycin (DAP) has the
most potent in-vitro and bactericidal activity against Gram positive (G+)
pathogens (Fuchs, 2002; Huang, 2008). The objective of this analysis
was to evaluate the efﬁcacy and safety of DAP in neutropenic pts with
G+ infections.
Methods: The European Cubicin® Outcomes Registry and Experience
(EU-CORE) is a retrospective, non-interventional, multicenter study
describing characteristics and outcomes of pts treated with DAP.
Outcomes (cured and improved = success, failure, non-evaluable) were
assessed at the end of DAP therapy by the investigators and safety data
collected up to 30 days after end of therapy. Among 3621 pts enrolled
from 2006 to 2010 all pts with neutropenia at baseline or during DAP
therapy were eligible. Subgroups were speciﬁed: Lowest neutrophil count
100, 100–499 and 500–1000 cells/mm3.
Results: 259 neutropenic pts were identiﬁed mostly with hematologic
malignancies or transplantation. 114 pts (46%) had severe neutropenia
(neutrophil 100 cells/mm3), 60% were male, 26% pts were 65 yrs
old, and 6% pts had CrCl <30mL/min. The most frequent reasons
for prior antibiotic discontinuation were clinical failure or resistance.
Bacteraemia was the most common diagnosis. Positive cultures were
reported in 159 pts (61%). Coagulase-neg staphylococcus was the most
common pathogen (72/159, 45%), mainly S. epidermidis. S. aureus was
isolated in 21% of cases (49% MRSA rate). Overall clinical success
was 76% (196/259) (Figure 1). Success rates were 86% for coagulase-
neg staphylococci, 73% for S. aureus (75% against MRSA) and 63% for
enterococci. DAP was well tolerated. CPK elevation of >5 to 10xULN
was reported in only one patient. DAP was discontinued in 6% of pts
due to adverse events, mostly infections.
Conclusion: Daptomycin was effective and safe in the treatment of
Gram-positive infections in pts with neutropenia regardless of severity.
P2092 Nosocomial Pneumocystis jirovecii pneumonia: lessons
learned from a case cluster in kidney transplant recipients
L. Phipps, S.C. Chen*, K. Kable, C. Patterson, C. Halliday,
C. Firacative, W. Meyer, B. Nankivell (Sydney, AU)
Objectives: Pneumocystis jirovecii pneumonia (PJP) is an important
infectious complication in kidney transplant recipients with an associated
mortality of approx. 48%. The risks for, and route of transmission of
infection in an outbreak setting are incompletely deﬁned. We describe
the epidemiology and risk factors during a case cluster of PJP.
Methods: PJP cases from March-October 2010 in renal transplant
patients, Westmead Hospital, Sydney, were reviewed for clinical,
microbiological and radiological data, and compared with those from
unaffected patients in a case control study. Investigations to determine
contact between patients identiﬁed a common clinic area where patients
had co-localized. Diagnosis was based on a combination of clinical
assessment, X Ray changes and positive PCR, targeting b-tubulin gene,
of induced sputum/BAL ﬂuid. Patients with typical clinical/X Ray
features where BAL ﬂuid/induced sputum specimens were not tested
by PCR but where there was no alternate cause of infection had
probable PJP. Oropharyngeal rinses from staff and samples of ambient
air were tested for P. jirovecii. P. jirovecii genotypes were determined by
sequencing of the ITS, DHPS, b-tubulin and mtLSU genes.
Results: 10 deﬁnite, and 2 probable, cases of PJP occurred (expected
rate 0.2±0.42 cases/yr). Of the PJP cohort, 9 (75%) were male (mean
age 46 yr [range 20−64]). The median time from transplant was 4
years. Multivariate analysis identiﬁed preexisting lung disease (OR
15.5; p< 0.001), prior/recent CMV infection (OR 92.3, p< 0.001) and
impaired eGFR (OR 9.6/10mls/min, p< 0.05) as independent predictors
of PJP vs. exposed unaffected patients. Prednisone use or greater
number of outpatient visits were not associated with increased PJP
risk. Identiﬁcation of a common source prompted extension of PJP
prophylaxis (Bactrim) till 12 mo. in recent recipients and reintroduction
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of Bactrim to all exposed patients. B-tubulin, DHPS and ITS genotypes
were identical for 8 patients tested but mtLSU genotypes differed in 2
patients. P. jirovecii was not detected in staff samples.
Conclusions: PJP clusters in kidney transplantation may result from
interhuman transmission. Underlying lung disease, CMV infection and
impaired graft function were risk factors. Early recognition of an
outbreak and prompt pre-emptive prophylaxis to exposed patients may
limit its escalation.
P2093 Orthotopic liver transplantation in HIV-infected patients:
experience in a cohort of 27 patients
M. Montejo, A. Mularoni*, M. Gastaca, J. Fernandez, A. Valdivieso,
M. Testillano, J. Gonzalez, J. Bustamante, A. Ventoso, M. Suarez,
P. Mun˜oz, J. Goikoetxea, E. Bereciartua, J. Ortiz de Urbina (Barakaldo,
ES)
Objective: We evaluated clinical, biological and immunovirological
outcomes of a prospective cohort of HIV infected liver transplant
recipients.
Methods: We evaluated 27 HIV positive patients who underwent 29
liver transplantations between September 2003 and October 2010 at our
center.
Results: Participants’ characteristics are described in Table1. Causes
of end stage liver disease were HCV related liver cirrhosis (n = 22),
HBV related cirrhosis (n = 4), and cryptogenic liver cirrhosis (n = 1). Ten
patients had hepatocellular carcinoma. At time of waiting list enrollment
all but one patient had a CD4 T cell count greater than 100 cells/mmc,
median CD4 count was 303 cells/mmc (range 49–836). Twenty-two
patients had undetectable viral load, the 5 patients with detectable viral
load had genotype predictive of viral suppression with HAART. Post
transplant HAART consisted of 2 NRTIs plus a third agent that was
NNRTI for 19 patients, PI for one patient, enfuvirtide for 2 patients
and raltegravir for 5 patients. The average CD4 count fell to 218
cells/mmc at 1 month post-transplant but then rose to 291 and to 316
cells/mmc at 6 and 12 months post transplant, respectively. At 1 month
after transplantation, six patients experienced an increase in HIV viral
load but all the 19 patients who reached one year follow up had HIV-
RNA below 50 copies/ml. After transplantation 20 patients presented
detectable HCV-RNA. Two-third of patients (12/20) received anti-HCV
therapy. Five patients developed a sustained virological response: three
had genotype 3 and two had genotype 2. Five patients with genotype 1
and one with genotype 3 were not responders. A patient with genotype
4 is still on treatment. Eight patients were not treated: ﬁve of them
died early on post-transplant period for HCV non related causes and 3
patients have a good liver function. Ten patients died: 4 due to a severe
recurrence of HCV infection, 3 due to metastatic cancer, 1 for severe
sepsis, 1 for a gastro-intestinal bleeding and 1 for a cerebral hemorrhage.
Survival rate were 93% at 1 year, 76% at 2 years and 67% at 3 years.
Conclusions: Immunosuppressive therapy had not deleterious impact
on immunovirological status and short-mid term survival was good.
Severe recurrence of HCV infection and de novo tumors were the most
important cause of death. Long term survival has still to be evaluated.
P2094 Evaluation of real-time PCR CMV, clinic correlation,
determination and validation of cut-off point for CMV
infection in low-risk CMV solid organ transplant recipients
C. Martı´n-Gandul*, M. Sa´nchez, V. Cabello, C. Bernal, E. Lage, J. Fijo,
M. Aguilar-Guisado, M.J. Rodrı´guez-Herna´ndez, E. Cordero on behalf
of the Spanish Network For Research in Infectious Diseases (REIPI)
Objectives: The aims of this study were: 1. To study the correlationship
between CMV viral load determined by RT-PCR and signs or symptoms
of CMV infection in low risk patients SOTR. 2. To set up a cutoff point
of CMV viral load to start preemptive therapy. 3. To validate this cutoff
point in a external cohort of these patients.
Methods: A prospective cohort study was performed (10/08−08/10).
All low risk CMV infection SOTR were included. CMV infection
and outcome was evaluated. A descriptive analysis was done. In the
derivation cohort (10/08−05/09), A cutoff point was determined using
G-Stat 2.0 for analysis by ROC curves of sensitivity and speciﬁcity in
the full spectrum of cutoff points in the over range of observed results.
Validation of the cutoff point was carried out with cases included from
06/09−08/10.
Results: In the derivation cohort 86 patients were included (51 kidney,
23 liver, 1 liver-kidney, 11 heart) and a total of 1381 CMV RT-PCR
were performed, of whom 346 (25.1%) were positive. Seven patients
(8,1%) of CMV disease were diagnosed: 4 viral syndrome and 3 CMV
organ-disease. In the remaining, 79 patients (94.2%), the diagnosis was
asyntomathic viremia. Twenty-nine patients (32.6%) received therapy for
CMV infection and the median viral load CMV at onset the treatment
was 6620 copies/ml (range 2755, 20800). After assessing the different
cutoff points by ROC curves, 2870 copies/ml was deﬁned as the best
cutoff point for early therapy initiation, with speciﬁcity 96%, sensitivy
85.7%, negative predictive value (NPV) 99.9% and positive predictive
value (PPV) 9.8%. The area under the ROC curve was 97.9%. In the
validation cohort 123 patients were included (72 kidney, 41 liver, 10
heart) and a total of 2508 CMV RT-PCR were performed, of whom
392 (15.6%) were positive. Were diagnosed 11 patients (8,9%) of CMV
organ-disease, no cases of viral syndrome. Fifty-six patients (45.5%)
received therapy for CMV infection and the median viral load CMV at
onset the treatment was 3620 copies/ml (2293, 5570). In plotting the
ROC curve in the validation cohort, 2870 copies/ml was associated with
a sensitivity, speciﬁcity, NPV and PPV of 70,0%, 96,6%, 99,8% and
12,3% respectively.
Conclusions: 1. Real time PCR CMV is an effective predictive dignostic
test to guide preemptive therapy. 2. A value of 2870 copies/ml is deﬁned
and validated as the best cutoff point for starting preemptive therapy in
low risk SOTR.
Molecular diagnosis of invasive fungal
infections: has the era of empirical
antifungals come to an end?
P2095 Clinical validation of a marketed real-time PCR assay
for diagnosis of invasive aspergillosis in patients without
haematological cancer
J. Guinea*, C. Padilla, S. Recio, P. Escribano, D. Garcı´a de Viedma,
T. Pela´ez, P. Mun˜oz, B. Padilla, P. Gijo´n, E. Bouza (Madrid, ES)
Background: Methods based on real-time PCR may anticipate the
diagnosis of invasive aspergillosis (IA) but are still limited by the
lack of standardization. We validated the standardized MycAssay™
Aspergillus (Myconostica, Ltd) for the IA diagnosis in patients without
hematological cancer, an emerging population at risk of IA.
Methods: We prospectively collected 394 samples (November 2009–
May 2010) from 207 patients with these IA predisposing conditions:
solid cancer (19%), cirrhosis (15%), corticosteroids use (60.4%),
HIV (12.6%), COPD (50%), solid organ transplantation (11%), or
none (8.2%). Specimens were obtained when clinically indicated and
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sourced mostly from the lower respiratory tract (97%). Specimens were
processed for microbiological culture; Aspergillus DNA was extracted
and ampliﬁed by means of MycXtra® and MycAssay™.
Results: According to the EORTC and Bulpa’s (for patients with
COPD) criteria, patients had proven/probable/possible IA (n = 2/11/5),
probable scedosporiosis (n = 1), or no invasive mold infection. The 13
patients with proven/probable IA had solid cancer (23%), cirrhosis
(23%), corticosteroids use (85%), HIV (15%), COPD (38%), or heart
transplantation (8%). Aspergillus spp. was isolated from 63 samples
(44 patients). The mean number of days from sample culture until
fungal growth visualization was 5 (range, 1−21; SD, 5). PCR results
(~4 hrs sample to result) were negative (n = 330), positive (n = 45),
or indeterminate (n = 18). Sensitivity (S), speciﬁcity (E), positive and
negative predictive values (PPV and NPV) of the assay for the diagnosis
of IA (ﬁrst sample/any sample) were: S (77/92), E (86/85), PPV (35/32),
NPV (98/99).
Conclusions: MycAssay™ Aspergillus showed a high sensitivity for
the diagnosis of IA in patients without hematological cancer, which
increased when multiple samples were used. PCR signiﬁcantly reduced
the time to diagnosis compare to fungal culture. Maria Alonso (UCAM)
was involved in the RT-PCR analysis.
P2096 A novel clinical diagnostic assay for the identiﬁcation of
multiple human fungal pathogens in a single sample
K. Dempsey*, A. Ricketts, K. Fitchett, J. Redden, P. White, M. Perry,
R. Barnes (Glasgow, Cardiff, UK)
Objectives: Surface-Enhanced Resonance Raman Scattering (SERRS)
is a highly sensitive and molecular-speciﬁc detection system which can
be used to detect multiple human pathogens in a single sample. The
objective of this study was to develop a screening assay for the multiplex
detection of fungal targets using PCR and SERRS.
Methods: The assay was designed to detect 23 species of fungi known to
cause invasive fungal disease (IFD). As Candida and Aspergillus species
account for >80% of all IFDs, one well of this assay was speciﬁcally
designed to detect a broad range of both genera and speciﬁcally identiﬁed
C. glabrata and C. krusei as these organisms may require alternative
antifungal therapy. A second well of this assay is being developed to
detect other causes of IFD.
A multiplex diagnostic assay was developed to detect targets at low copy
number in clinically relevant samples. Universal primers and speciﬁc
probes were designed to amplify and detect each target. One primer
from each primer set was biotinylated to allow capture of the ampliﬁed
DNA by streptavidin-coated beads. A labelled probe sequence speciﬁc
for each target was hybridised to the PCR products and captured on the
beads. The DNA/probe complex was washed, the probe released then
analysed by SERRS.
Results: Multiplex PCR for both genera ampliﬁed fungal species from
a single sample. Each was successfully identiﬁed by SERRS using the
probe’s unique molecular ﬁngerprint, conﬁrming the presence or absence
of each target.
The function of this multiplex assay is as diagnostic screening test to
exclude the presence of invasive fungal disease and requires excellent
analytical sensitivity. The analytical thresholds for the detection of
Candida and Aspergillus species are equivalent to real-time PCR assays.
The reproducible 100% detection limit for the targets of this assay is
20 input copies, which correlates to less than 1 genome per reaction
(Table 1).
Conclusions: This clinically relevant assay demonstrates excellent
sensitivity and speciﬁcity for the range of fungal species tested. The
reliably detection of common fungal species at 20 copies was clearly
demonstrated.
P2097 Evaluation of a panfungal PCR assay to detect and
identify fungal DNA in up to 7-year-old formalin-ﬁxed
parafﬁn-embedded tissue specimens
B. Babouee*, M. Weisser, S. Savic Prince, L. Bubendorf, M. Battegay,
R. Frei, D. Goldenberger (Basel, CH)
Objectives: Fungal cultures from intraoperatively resected biopsies of
patients with invasive fungal infections (IFI) often remain negative.
DNA-based test approaches might be promising alternatives for the
detection of the etiologic fungal organisms. In a retrospective study,
we applied a panfungal PCR assay on formalin-ﬁxed parafﬁn-embedded
(FFPE) tissue samples from patients with IFI.
Methods: We used a 45-cycle panfungal PCR test targeting the
ITS1-ITS2 and ITS2 rDNA region. Detection and identiﬁcation of
the ampliﬁed DNA was determined by agarose gel electrophoresis,
sequencing and the basic local alignment search tool (BLAST). In
addition we tested each extract using an inhibiton control and the quality
of the DNA was evaluated with multiplex b-globin PCR analysis. Results
were compared with culture, histology, and/or panfungal PCR from fresh
tissue.
Results: We investigated a total of 28 archived FFPE specimens stored
up to 7 years from 28 patients with IFI. The panfungal PCR identiﬁed
the correct fungal pathogen in 61% of culture-proven and in 33% of
histologically-proven or PCR-proven cases. The ITS2 PCR had a higher
sensitivity compared to ITS1-ITS2 PCR in 4 from 14 samples. The
fungal organisms found were: Aspergillus spp. (n = 9), Hormographiella
aspergillata (n = 3), Alternaria sp. (n = 1), and Rhizopus sp. (n = 1). Ten
FFPE control samples with no suspicion of IFI were included. All 10
samples were PCR-negative. A high amount of the extracted DNA from
FFPE samples showed degradation and partial inhibition.
Conclusions: The results support the complementary use of the
panfungal PCR approach applied on FFPE specimens in combination
with conventional laboratory test methods. Despite a reduced sensitivity,
our method provides accurate identiﬁcation of fungi on species level
in partially degraded tissue samples. Correct identiﬁcation can be
accomplished in samples stored up to 7 years.
P2098 Rapid identiﬁcation of yeast species by the PCR- and
microarray-based Prove-it™ sepsis assay
A. Aittakorpi, P. Kuusela, P. Koukila-Ka¨hko¨la¨, M. Vaara, M. Petrou,
V. Gant*, M. Ma¨ki (Helsinki, FI; London, UK)
Objective: Prove-it™ Sepsis, is a rapid PCR- and microarray-based
assay platform with proven excellent diagnostic performance for most
bacterial pathogens causing sepsis. We have extended this platform’s
diagnostic range to include 13 yeast species and evaluated its
performance against a large number of fungal isolates.
Methods: 159 classically speciated (Germ tube, growth on Corn Meal
Tween 80, API 20 AUX and API 32C as well as molecular when all
failed) clinical fungal isolates were tested. The isolates were cultured
on Sabouraud dextrose agar with penicillin for 48 h aerobically at 35 ºC
and blindly tested using the Prove-it™ Sepsis assay after DNA extracted
with an easyMAG (bioMe´rieux). Original routine identiﬁcations of the
clinical samples were revealed after the analysis.
Results: 151 out of 159 samples yielded a microarray-based result, all of
which were correct; 8 were negative. The microarray correctly identiﬁed
30% as Candida albicans, 19% as C. glabrata, 14% as C. parapsilosis,
9% as C. tropicalis, 4% as C. krusei, 3% as C. guilliermondii
and 1% as C. lusitaniae. 12% (19/159) of the organism panel were
correctly assigned to a pan-yeast group, designed to identify C. kefyr,
C. haemulonii, C. norvegensis, C. dubliniensis, and Saccharomyces
cerevisiae. Cryptococcus albidus, C. neoformans, Trichosporon asahii,
T. mycotoxinivorans, T. mucoides, and T. inkin were not identiﬁed by this
system.
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Conclusions: We have modiﬁed and extended the Prove-it Sepsis array
platform to detect almost all clinically relevant fungi. As previously
reported for over 50 bacterial species, the addition of rapid and accurate
yeast identiﬁcation to this diagnostic platform will now allow faster, more
evidence-based choice of antifungal agent and better patient outcomes.
P2099 DNA ﬁngerprinting for genotype assignment and molecular
genetic basis of 5-ﬂucytosine resistance among clinical
Candida dubliniensis isolates in Kuwait
S. Ahmad*, L. Joseph, A. Theyyathel, Z. Khan (Safat, KW)
Objective: Clinical Candida dubliniensis isolates have previously been
classiﬁed into four genotypes based on nucleotide sequences in internal
transcribed spacer (ITS)1 and ITS2 regions of rDNA. All genotype 3
and genotype 4 isolates from the Middle East were found to be resistant
to 5-ﬂucytosine (5FC). This study determined the signature nucleotides
within rDNA to deﬁne various genotypes and their association with
5FC resistance among clinical C. dubliniensis isolates in Kuwait.
The 5FC-resistant status of selected isolates was also explored by
direct sequencing of DNA region encompassing codon 29 of cytosine
deaminase.
Methods: A total of 103 C. dubliniensis isolates were studied. The
susceptibility of the isolates to anti-fungal agents including 5FC was
performed by Etest. Genotype assignment was carried out by rDNA
ampliﬁcation with genotype-speciﬁc primers. Direct DNA sequencing
of rDNA was performed to determine signature nucleotides to deﬁne
various genotypes and their association with resistance to 5FC. Direct
DNA sequencing of cytosine deaminase codon 29 region was also
performed to conﬁrm 5FC-resistant status of selected isolates.
Results: A total of 94 isolates yielded amplicons with only one
genotype-speciﬁc primer pair while 9 isolates yielded inconclusive
results. Seven different C. dubliniensis genotypes including 3 of the
original 4 and four new genotypes were identiﬁed based on rDNA
sequences. Majority (68 of 103, 66%) of isolates belonged to genotype
1. Of the remaining isolates, 1, 25, 6, 1, 1 and 1 strains belonged to
genotype 3, 4, 5, 6, 7 and 8, respectively, while no genotype 2 strains
were detected in Kuwait. All isolates of genotype 4 but none of the other
genotypes were resistant to 5FC and contained a ‘T’ signature residue at
ITS1 position 82. All genotype 4 isolates contained S29L mutation while
30 selected genotype 1 and all isolates belonging to other genotypes
contained wild-type codon 29 (S29) in cytosine deaminase.
Conclusions: Seven different genotypes based on sequences of ITS
region of rDNA were detected among C. dubliniensis isolates in Kuwait
with most of the isolates belonging to genotype 1 (66%) followed by
genotype 4 (24%). All 5FC-resistant strains belonged to genotype 4 and
contained a unique signature at ITS1 position 82 and S29L mutation in
cytosine deaminase.
Supported by KURA grant MI 01/08.
P2100 DiversiLab system, automated repetitive sequence-based
PCR, as typing method for Candida glabrata
R. Kofol*, T. Matos (Ljubljana, SI)
Objectives: The aim of this study was to explore the DiversiLab
(bioMe´rieux, Marcy l’Etoile, France) system as a genotyping method
for differentiation of Candida glabrata isolates heteroresistant to
ﬂuconazole.
Methods: Forty C. glabrata isolates, isolated from patients from
different departments of a tertiary hospital, were cultured on Sabouraud
agar (SABA) for 24−48 h at 35ºC (6 heteroresistant,10 resistant, 10
susceptible-dose dependent and 8 sensitive isolates). Heteroresistance
was determined with susceptibility testing with agar diffusion method,
E-test (bioMe´rieux, Marcy l’Etoile, France). Extraction of C. glabrata
DNA was made with the UltraClean microbial DNA isolaton kit (Mo
Bio Laboratories, Inc., Carlsbad, CA), quantiﬁed spectrophotomectricaly
and diluted to 35 ng/ml with molecular grade water. Repetitive sequence-
based PCR of extracted DNA was made using the DiversiLab
Candida ﬁngerprint kit (bioMe´rieux, Marcy l’Etoile, France). Ampliﬁed
fragments of various sizes and intensities were separated and detected
with DNA chip (bioMe´rieux, Marcy l’Etoile, France) on Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, California). Results were
demonstrated as dendrogram (with a Pearson correlation (98%) similarity
matrix) including a virtual gel image of the ﬁngerprint for each DNA
sample. Isolates were categorized as indistinguishable (0 difference),
similar (1−2 differences), or different (more than 3 differences).
Results: DiversiLab analysis demonstrated a high genetic diversity of
40 tested C. glabrata isolates of different resistance proﬁles (Figure 1).
We genotyped colonies outside and inside inhibition cone for all
six heteroresistant isolates and demonstrated that every heteroresistant
isolate included two different but related ﬁngerprint proﬁles.
Conclusion:With DiversiLab system which is simple to use and provides
rapid results we were able to genotype our isolates. Heteroresistant
isolates produce microcolonies inside the cone of inhibition. With
DiversiLab we have demonstrated that our heteroresistant strains
included two populations with different but related populations, which
could be the result of chromosomal mutation affecting the ﬁngerprint
proﬁle. For more detailed analysis we need a typing method based on
sequencing.
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P2101 Comparison of two Aspergillus real-time PCR methods and
clinical signiﬁcance of Aspergillus DNA detection in BAL
N. Renaud, L. Delhaes, V. Coiteux, S. Herwegh, I. Yakoub-Agha,
S. Nseir, E. Dei-Cas, E. Fre´alle* (Lille, FR)
Objectives: Aspergillus DNA detection in bronchoalveolar lavage (BAL)
could be useful for invasive pulmonary aspergillosis (IPA) diagnosis.
Many PCR methods are available, but no comparative studies have been
done. Here, we evaluated two home-made real-time PCR methods in
order to (i) determine their limit of detection (LOD) (ii) evaluate their
clinical utility for the diagnosis of aspergillosis.
Methods: First, we determined LOD using serial dilutions of
ASPERGILLUS FUMIGATUS DNA (105 to 100 fg/mL). Then, we
selected PCR and/or GM positive BAL ﬂuids sampled at Lille University
Hospital in 2009 (1st January to 31st December) using the results of
galactomannan (GM) detection and of the mitochondrial DNA targeting
PCR we perform routinely in our laboratory. DNA extracts which had
been obtained using the QIAamp DNA minikit (QIAGEN) were then
analyzed with a 28S targeting method. Finally, we collected mycological
data (microscopic examination and culture of BAL, serum GM, anti-A.
FUMIGATUS precipitins, results of respiratory samples), clinical and
radiological features.
Results: The mitochondrial DNA and 28S targeting methods LOD
reached 1−10 fg/mL and 1 fg/mL respectively. Fifty-two PCR and/or
GM positive BAL ﬂuid samples were collected. Among them, 16 were
both PCR and GM positive (Group 1), 29 were PCR positive but GM
negative (Group 2) and 7 were GM positive but PCR negative (Group 3).
In Group 1, 15 out of 16 BAL were positive using the 28S method. IPA
or semi-invasive aspergillosis (SIA) was diagnosed in 5 haematology (6
BAL), 1 heart transplant, and 6 intensive care patients. Three patients
were considered as colonized. In group 2, which mainly included BAL
with low amounts of DNA (Cp< 40), only 6 out of 29 BAL were positive
with the 28S method. In group 3, all the BAL were negative with both
methods. Clinical signiﬁcance of Aspergillus DNA or GM detection is
discussed in these two groups.
Conclusion: Both Aspergillus PCR methods were useful to conﬁrm IPA
or SIA diagnosis in immunocompromised or intensive care patients. Low
amounts of DNA failed to be detected in some BAL by the 28S method
(Group 2). Regarding the low LOD of the 28S method, this result could
be related to freeze-thaw DNA damage, but a higher speciﬁcity of the
28S method could also be hypothesized. In fact, further prospective
studies are needed to assess clinical signiﬁcance of low amounts of
DNA when GM is negative.
P2102 Molecular identiﬁcation and antifungal susceptibility of
clinical Aspergillus terreus complex isolates
P. Escribano, T. Pela´ez, S. Recio, B. Buendı´a, E. Bouza, J. Guinea*
(Madrid, ES)
Background: Although Aspergillus fumigatus is still the most frequent
species causing invasive aspergillosis (IA), other species of Aspergillus
are emerging. Molecular techniques are necessary to identify clinical
Aspergillus spp. isolates to species level and to provide a better
understanding of the epidemiology of IA. We identiﬁed a collection
of recent clinical Aspergillus terreus complex isolates using molecular
techniques. We also obtained their antifungal susceptibility to triazoles
and amphotericin B (AMB).
Methods: We studied 89 clinical A. terreus complex (morphological
identiﬁcation) isolates collected from October 2005 to March 2010.
Isolates were from 72 patients, 12 of whom had proven (n = 3) or
probable IA, according to EORTC criteria. Only 1 isolate per sample was
selected and subsequently identiﬁed by ampliﬁcation and sequencing of
the b-tubulin, and calmodulin genes. A BLAST search was performed
to identify the isolates. To avoid the presence of cryptic species
initially identiﬁed as A. terreus, a phylogenetic tree was obtained
using the two regions sequenced, including the reference sequences.
Antifungal susceptibility to itraconazole (ITRA), voriconazole (VORI),
posaconazole (POSA), and AMB was determined using the CLSI M38-A
procedure. The antifungal activity of AMB was also obtained using the
Etest.
Results: Molecular identiﬁcation proved that all isolates were A. terreus
sensu stricto. The antifungal susceptibility of the isolates (range of
MICs, MIC90, and geometric mean), in mg/ml, was as follows: ITRA
(0.25−2/2/1.097), VORI (0.125−2/2/1.176), POSA (0.25−1/1/0.836),
AMB CLSI (4−32/16/9.689), and AMB Etest (0.75−64/6/3.106). None
of the isolates showed an MIC for ITRA, VORI, or POSA greater than
2mg/ml. In contrast, the MICs for AMB were signiﬁcantly higher than
those found for the 3 triazoles (P< 0.001), regardless of the method
chosen.
Conclusions: No cryptic species of the A. terreus complex causing IA or
colonization were found in the isolates studied. A. terreus sensu stricto,
a species with a known lack of susceptibility to AMB, remains fully
susceptible to the triazoles.
P2103 One-step nested-multiplex real-time PCR for the detection
of Aspergillus fumigatus and Aspergillus lentulus based on
a single-locus target gene
M.J. Buitrago*, I. Cuesta, L. Bernal, J.L. Rodriguez-Tudela,
M. Cuenca-Estrella, E. Mellado (Majadahonda, Madrid, ES)
Objectives: Aspergillus lentulus, an species belonging to section
Fumigati, with remarkable high MICs to multiple antifungals, has been
reported as a cause of invasive aspergillosis (IA). A correct and early
diagnostic leading to a prompt antifungal therapy is the essential step
to improve clinical outcome. In section Fumigati, PCR misidentiﬁcation
can occur because very closely related strains can not be differentiated
on the bases of ITS sequences. Up to now, only single locus genes have
been able to discriminate between Aspergillus species included in section
Fumigati. The main objective of this work was the development of a
sensitive and speciﬁc one-step nested multiplex PCR using Molecular
Beacons (MB) probes for the detection and identiﬁcation of A. fumigatus
and A. lentulus. The technique is based in the azole target, 14-a sterol
demethylase (cyp51A), a single locus gene able to discriminate between
different species within Section Fumigati.
Methods: A multiplex quantitative one-step nested PCR assay was
developed. Primers and probes targeted the unique intron of the cyp51A
gene sequence. Different primers were designed for the ﬁrst and
second round of ampliﬁcation including two degenerated outer primers,
two speciﬁc inner primers and two Molecular Beacon probes labeled
with FAM and HEX. The probes were speciﬁc for A. fumigatus and
A. lentulus. Sensitivity, speciﬁcity and reproducibility were analyzed.
Twenty strains were tested to standardize the technique. The PCR has
been validated in an experimental model of invasive aspergillosis in
immunocompromised mice using both Aspergillus species (A. fumigatus
and A. lentulus).
Results: The detection limit of the PCR was calculated at 100 fg of
DNA. The PCR was validated in cultures and in an experimental model
of invasive aspergillosis. A total of 22 lung biopsy samples from infected
mice with A. fumigatus or A. lentulus were tested by PCR. The technique
was positive in 21 of 22 samples (95,5%) and was able to distinguish
between both species. No cross-reaction was detected in any sample.
Conclusions: The real-time PCR technology described here allows for
the use of single copy genes with enough sensibility to be used in clinical
specimens. The one-step nested PCR on cyp51A single copy gene shows
as a promising target for clinical detection of Aspergillus within section
Fumigati.
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Fungal infections: epidemiology, molecular
bases and management
P2104 SNPs associated with a high IL-6, low IL-10 cytokine
pattern predispose lung transplant recipients to pneumonia
due to moulds
C. Clancy*, D. Mitsani, A. Zeevi, Y. Toyoda, M. Nguyen (Pittsburgh, US)
Background: Host immunity is an important outcome determinant for
transplant patients (pts) with invasive fungal infections (IFI). In general,
Th1 responses are felt to be protective against IFI, and Th2 responses
deleterious. We determined if single nucleotide polymorphisms (SNPs)
associated with altered cytokine levels predisposed lung transplant (LT)
pts to invasive fungal pneumonia caused by moulds.
Methods:We retrospectively reviewed the records of 155 LT pts between
2003–2007 who received alemtuzumab induction and consented to
genetic studies. Only patients with proven or probable pneumonia due
to mould were included in the disease group. Genotypic analysis (SSP-
PCR) detected the presence of SNPs in genes encoding TNF-a, TGF-B1,
IL-4, IL-6, IL-10 and IFN-g.
Results: 25 had pneumonia due to moulds, and 130 pts did not develop
any fungal infection (controls). All were Caucasians. We excluded 5
patients with mould pneumonia who were treated for acute rejection
within 3 months of the diagnosis. No pts with mould pneumonia had
CMV infection within 3 months. 60% of pneumonias were caused by
Aspergillus, 15% Rhizopus, 15% dematiaceous fungi and 10% other
moulds. 55% were men. Mean and median ages were 53 and 56 yrs.
75% were double-LT, 20% single-LT and 5% heart-LT. 40% had COPD,
20% IPF and 10% CF. The time to pneumonia post-LT was <6 mo in
10%, 6−12 mo in 10%, 12−18 mo in 25%, 18−24 mo in 25%, 24−36 mo
in 15% and >36 mo in 15%. Genotypes were in HW equilibrium. There
was no signiﬁcant association between SNPs for individual genes and
fungal pneumonia. However, the combination of SNPs associated with
high level IL-6 and low level IL-10 was signiﬁcantly more common
among patients with pneumonia than controls (40% vs 14%, P< 0.01).
Conclusions: Surprisingly, LT pts with SNPs associated with a pro-
inﬂammatory cytokine proﬁle of high IL-6 and low IL-10 were at
increased risk of pneumonia due to moulds, independent of acute
rejection. Over-exuberant inﬂammatory responses might contribute to
the pathogenesis of late onset fungal pneumonia in pts receiving
alemtuzumab.
P2105 Cytokine proﬁle of patients with invasive aspergillosis:
initial results from the ﬁrst 100 patients recruited into the
Aspergillosis Study
M.M. Ceesay*, S. Kordasti, L. Berry, M. Smith, J. Wade, G.J. Mufti,
A. Pagliuca (London, UK)
Objectives: Invasive Aspergillosis (IA) is an important cause of morbid-
ity and mortality in haemato-oncology patients undergoing haematopoi-
etic stem cell transplantation (HSCT) or high-dose chemotherapy. We
set up an observational prospective cohort study in order to improve our
diagnostic and management strategies using the EORTC/MSG criteria as
a diagnostic tool. Here we assess the serial cytokine proﬁle of patients
to evaluate their potential role in the diagnosis and management of IA.
Methods: All study patients were prospectively recruited and followed
up for at least 4 months after chemotherapy or HSCT and had baseline
and fortnightly follow-up serum samples proﬁled for 30 inﬂammatory
cytokines using multiplex bead immunoassays by Luminex 100TM
instrument. The cytokines measured were: EGF, Eotaxin, FGF, G-CSF,
GM-CSF, HGF, IFN-a, IFN-g, IL-1RA, IL-1b, IL-2, IL-2R, IL-4, IL5,
IL6, IL7, IL-8, IL-10, IL-12p40/p70, IL-13, IL-15, IL-17, IP-10, MCP-1,
MIG, MIP-1a, MIP-1b, Rantes, TNF-a and VEGF. The ﬁrst hundred
patients enrolled with sufﬁcient follow up data were included in this
initial analysis. We used generalised logistic regression model for
binary outcome of proven/probable and no evidence of IA (R2 = 0.4355,
P< 0.001) adjusting for clustering, age, sex, underlying diagnosis and
treatment.
Results: The median (range) age was 52.5 (19−73) years and M/F ratio
was 58/42. The main diagnosis were AML/MDS (40), Myeloma (23),
NHL (17) and aplastic anaemia (9) treated by allogeneic HSCT (43),
autologous HSCT (32), chemotherapy (20), and immunosuppressive
therapy (5). The diagnosis of invasive fungal infection was based on
the revised 2008 EORTC/MSG criteria. The incidence of proven and
probable infection was 17% and possible infection accounted for 12%.
Eight patients were excluded from analysis because of lack of proper
baseline sample. Ten cytokines were found to be signiﬁcantly different.
Patients with IA were found to have lower IL-1b (P = 0.003), IL-10
(P< 0.001), IL-12 (P = 0.05), IL-17 (P = 0.016), IL-15 (P = 0.027), INF-a
(P = 0.05), and GMCSF (P = 0.023) but higher IL-6 (P = 0.08) and IP-10
(P = 0.022). Older age correlated with IA (P = 0.014).
Conclusion: Overall patients with invasive fungal infection have
signiﬁcantly lower pro-inﬂammatory cytokine proﬁle in the Th1 and
Th17 axis and therefore unable to effectively deal with infection. If this
proﬁle is validated in the larger cohort it may be used as a predictive
model for targeted anti-fungal prophylaxis.
P2106 Expression of immune genes by human macrophages
from healthy subjects and CCPA patients in response to
stimulation with Aspergillus fumigatus
N.L. Smith*, D.W. Denning, A. Simpson, P. Bowyer (Manchester, UK)
Objectives: Chronic cavitary pulmonary aspergillosis (CCPA) is a
progressive lung disease usually caused by the fungus Aspergillus
fumigatus. Macrophages are innate immune cells known to interact with
A. fumigatus. We investigated differences in the expression of immune
genes in response to A. fumigatus using macrophages from healthy
subjects and CCPA patients.
Methods: Monocyte-derived macrophages were generated from blood
from 10 healthy volunteers and 10 CCPA patients attending our clinic.
These were co-cultured with A. fumigatus spores (Af293 strain) and RNA
was extracted at various timepoints (0hr-9hr). RNA from the patients
and the healthy subjects was pooled. cDNA was generated and RT-
PCR was completed on 84 test genes using the Human Innate and
Adaptive Immune Responses RT2 Proﬁler PCR Array (SABiosciences).
Expression was normalised to HPRT1, RPL13A and GAPDH and
fold changes were generated compared to the Healthy 0hr (baseline)
expression level. Fold changes of >2-fold difference are described.
Results: Many differences in expression were seen. At baseline, 4
TLR genes had lower expression in the CCPA group, each with about
half the expression of that seen in the healthy group; TLR1 (0.46x),
TLR3 (0.43x), TLR8 (0.45x), TLR10 (0.38x). Other genes had higher
baseline expression in the CCPA patients, including CXCL7, a neutrophil
chemoattractant with almost 30-fold higher expression in CCPA. High
baseline expression in CCPA was also seen in PGLYRP3, TREM1 and
IL1B (all approx 2x). Expression of certain genes increased over time
in both groups, including MyD88, involved in signalling in response to
Aspergillus, and TNF, which is secreted by macrophages in response
to fungal infection. Interestingly, expression of many genes was similar
in both groups until 9hr, when expression increased or decreased in
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the healthy group but remained similar in the CCPA group. In some,
expression remained stable until 9hr, and in others expression increased
in both groups until 9hr. By 9hr most of the fungus present is in the
hyphal form, and differences at this timepoint may indicate a differing
response to the hyphal form of the fungus.
Conclusion: Differences are seen in both the baseline expression of
immune genes, in the change in expression over time, and in response to
different forms of the fungus. These differences demonstrate the response
of immune cells to A. fumigatus and may help to explain the genes and
pathways involved in susceptibility to CCPA.
P2107 Fungal pathogens secrete soluble factors that activate
thrombocytes
C. Speth*, G. Rambach, M. Hagleitner, C. Kupfahl, R. Wu¨rzner,
C. Lass-Flo¨rl (Innsbruck, AT; Heidelberg, DE)
Objective: The pathogenesis of invasive aspergillosis involves activation
of thrombocytes. Putative consequences are inﬂammation and throm-
bosis, but also antifungal defense. Since the mechanism of platelet
activation by Aspergillus is unknown we investigated the hypothesis that
fungal secretion products might be responsible for the stimulation of the
thrombocytes.
Methods: Human platelets were incubated with culture supernatant
derived from Aspergillus fumigatus. Activation of the thrombocytes was
quantiﬁed by FACS analysis using CD62P and microparticle formation
as markers. To identify the active components in the supernatant the
incubation was performed in some samples in the presence of protease
inhibitors or inhibitors of signal transduction molecules. Furthermore an
isolate of A. fumigatus which was defective for gliotoxin production was
included in the experiments.
Results: The culture supernatant of Aspergillus fumigatus was highly
active to induce activation of thrombocytes and fusion of secretory
vesicles with the plasma membrane. Even minimal amounts of the
fungal supernatant was able to upregulate the activation marker CD62P
on the platelet surface and to stimulate formation of platelet-derived
microparticles. Co-incubation experiments of thrombocytes and fungal
secretory products in the presence of different protease inhibitors showed
that a serine protease might be one relevant component for the activation.
Furthermore the DgliP mutant isolate of A. fumigatus which is defective
for the production of the mycotoxin gliotoxin was unable for secrete
molecules which stimulate platelets.
Conclusions: Fungal metabolites were identiﬁed as putatively potent
stimulators of thrombocytes. This mechanism might be responsible for
thrombosis and thrombocytopenia as visible in the course of invasive
aspergillosis. The secretion of the factors imply that this effect can occur
all through the body and not only in close vicinity to the hyphae. A
serine protease and the mycotoxin gliotoxin are amongst the secreted
compounds which efﬁciently stimulate the platelets and thus might
contribute to the pathogenesis of invasive aspergillosis.
P2108 Economic evaluation of voriconazole versus itraconazole
for primary prophylaxis of invasive fungal infection in
allogeneic haematopoietic stem cell transplantation
H. Schlamm, X. Gao, X. Ji, J. Stephens, M. Tarallo* (New York,
Bethesda, US; Rome, IT)
Objective: Voriconazole (VOR) has demonstrated better tolerability
with a longer treatment duration compared to itraconazole (ITR)
(IMPROVIT). This study assessed the association between drug
tolerability and economic impact for prophylaxis of invasive fungal
infection (IFI) after allogeneic hematopoietic stem cell transplant
(HSCT).
Methods: A prospective open label multicenter study for primary
IFI prophylaxis after HSCT included patients 12 years who were
randomized to receive oral VOR or oral ITR from the day of HSCT
for at least 100 and up to 180 days. Trial data on discontinuation
and medical resource utilization (MRU) for the ﬁrst 100 days were
analyzed. MRU endpoints included hospital days, day-hospital, ER visits,
outpatient visits, and other antifungal drugs besides study drug (con
AF), and were valued with 2010 UK costs. Univariate, multivariate,
and subgroup analyses by conditioning regimen and donor type were
conducted.
Results: 224 patients were in the VOR and 241 in the ITR group, with
similar age, sex, and race distributions (avg age 43 years, 59% male,
92% Caucasian). All-cause and study drug intolerance discontinuations
were less frequent with VOR than ITR (73% vs 82%, p = 0.02; 7%
vs 22%, p< 0.0001). VOR patients had longer study drug exposure
(median: 96 vs 68 days, p< 0.0001). Fewer VOR patients used other
con AF compared to ITR (25% vs 39%, p = 0.0014), with a shorter con
AF treatment duration (median: 15 vs 32 days, p = 0.0100). Multiple
logistic regression showed that ITR patients were 2 times more likely
to use con AF compared to VOR (p = 0.0032). No signiﬁcant difference
in hospital days, day-hospital and ER visits, and outpatient visits were
observed between VOR and ITR patients. Regression analyses showed
that prophylaxis duration is associated with all the key MRU while
controlling for treatment and key baseline variables: patients who stayed
on IFI prophylaxis longer tend to have fewer hospital days (p< 0.0001)
and special unit days (p = 0.0001), and are less likely to use con AF drugs
(p< 0.0001). Consequently, treatment exposure is negatively associated
with total cost (p< 0.0001) and con AF cost (p = 0.0035). Subgroup
analyses showed similar results especially for mismatched donor.
Conclusions: VOR was better tolerated, and better tolerability was
associated with lower MRU and costs. The ability of patients to tolerate
and continue their AF prophylaxis after HSCT appears to be associated
with signiﬁcant economic consequences.
P2109 Therapeutic drug monitoring of posaconazole in patients
with acute myeloid leukaemia or myelodysplastic syndrome:
a bi-centre study
M. Vaes, M. Hites*, A.M. Bourguignon, M. Csergo¨, C. Rasson, F. Cotton,
M. Paesmans, L. Ameye, D. Bron, F. Jacobs, M. Aoun (Brussels, BE)
Objectives: Posaconazole is a broad-spectrum triazole antifungal
available as an oral suspension. Pharmacokinetic data showed a high
variability of plasma posaconazole concentrations (PPCs) in patients,
suggesting the interest of drug monitoring.
The aim of our prospective study was to measure the PPCs in
prophylactically treated patients to evaluate the impact of different
factors on these concentrations.
Methods: All consenting patients hospitalised between February 2009
and June 2010 in Institute J. Bordet’s or Erasme hospitals’ Hematology
department for acute myeloid leukemia (AML) or myelodysplasic
syndrome (MDS) and treated prophylactically with posaconazole were
included in the study.
PPCs were measured after 7 days of treatment and then twice weekly.
The following information was collected and evaluated: demographic
data, clinical data (including gastrointestinal disorders, co-medications,
and treatment compliancy), caloric and fat intake, and biological data.
Results: 37 patients were included in the study. We obtained 259
measures of posaconazole with a median PPC of 520 ng/ml (range 0–
4500 ng/ml). PPCs were signiﬁcantly lower in patients with mucositis
(p = 0.001) and nausea (p = 0.02). PPCs were also lower in patients
with diarrhea (p = 0.05) or vomiting (p = 0.04). PPCs were higher in
patients with a higher caloric intake (p = 0.02) while the proportion of
fat intake had no inﬂuence on PPCs (p = 0.69). The concomitant use of
proton pump inhibitors decreased the PPCs (p = 0.007) while the use of
tacrolimus increased the PPCs (p = 0.04). We observed no correlation
between PPCs and liver enzymes, albumine or prealbumine.
The multivariate analysis revealed that the factors inﬂuencing the PPCs
independently were the concomitant use of proton pump inhibitors
(p = 0.03), the use of tacrolimus (p< 0.0001) and the food intake
(p = 0.026). 3% of patients interrupted their treatment for hepatotoxicity
and 10% for digestive intolerance. Only one patient developed probable
aspergillosis and his median PPC was 140 ng/ml (range 110–170 ng/ml).
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Conclusion: Our study conﬁrmed the high variability of posaconazole
bioavailability and showed the signiﬁcant inﬂuence of gastrointestinal
disorders, food intake and concomitant medication on the PPCs.
Therapeutic drug monitoring of posaconazole should be recommended
in the patient population at risk for low PPCs. The impact of intervention
measures could thus be evaluated.
P2110 Therapeutic drug monitoring among lung transplant
recipients receiving voriconazole prophylaxis: identiﬁcation
of preventive breakpoints
D. Mitsani, M. Nguyen, R. Shields, Y. Toyoda, C. Clancy* (Pittsburgh,
US)
Background: Voriconazole therapeutic drug monitoring (VOR TDM) is
advocated in patients (pts) treated for invasive fungal infections (IFI).
Associations between VOR levels and outcomes among lung transplant
(LTx) recipients receiving VOR prophylaxis (px) are unclear.
Methods: Prospective, observational study of LTx pts receiving VOR px
from Jan-Dec 2009 (2 doses IV (6mg/kg) then 200mg po BID). TDM
was performed by HPLC, beginning after 7 d of px.
Results: 93 LTx pts underwent TDM. Median age was 60 yrs (range:
20−74), 54% (50/93) were men, 91% (85/93) were white. Underlying
diseases were COPD 39% (36/93), IPF 32% (30/93), CF 13% (12/93),
others 16% (15/93). 438 VOR serum troughs were measured. 35% of pts
(33/93) had initial levels 1mg/mL (20 0.5, 13 between 0.5−1), 19%
(18/93) were 1−2, 30% (28/93) were 2−4 and 15% (14/93) were >4.
81% (72/89) of pts had signiﬁcant variation (>0.5) in levels upon serial
testing. Pts 60 yrs old were more likely to have signiﬁcant variation
in levels and levels >4 (both p = 0.02). CF pts were more likely to
have levels <1 and less likely to have levels >4 (p = 0.06 and 0.03,
respectively). IPF pts were more likely to have levels >4 (p = 0.01).
During VOR px, 12% (10/93) and 27% (25/93) of pts developed IFI
(anastomotic tracheobronchitis) or were colonized by fungi, respectively.
152 levels were drawn at time of respiratory cultures. 60% (6/10), 50%
(19/38) and 31% (32/104) of +IFI, +colonization and negative cultures,
respectively, were associated with levels 1 (p = 0.03). 56% (14/25) and
48% (10/21) of + cultures for yeasts and moulds, respectively, occurred
at levels 1. GI symptoms, hepato- or neurotoxicity occurred in 29%
(27/93) of pts, but there were no signiﬁcant associations with levels.
Conclusions: Our data support target VOR serum troughs >1mg/mL for
LTx pts receiving px. VOR TDM may be particularly useful for pts >60
and those with IPF who are at increased risk for higher levels, and CF
pts who are at increased risk of lower levels. Studies of dose adjustments
in response to VOR TDM are underway.
P2111 Risk factors for candidaemia-related death in
non-neutropenic critically ill patients
M. Lupse*, M. Flonta, A. Cioara, I. Filipescu, A. Moisuc, H. Kast,
N. Hagau, C. Mitre, C. Bodolea, I. Vlad, D. Nour, N. Todor
(Cluj-Napoca, RO)
Objective: To identify risk factors for death in non-neutropenic
patients admitted in ICU departments who developed candidemia during
hospitalization.
Material and Methods: A retrospective study based on patient records
for all non-neutropenic patients admitted in 6 ICU departments (4
surgery ICU, 1 medical ICU and 1 PICU) in our city between Jan 2007
and Oct 2010. We performed a statistical analysis using Kaplan-Meier
survival curves, ROC curves and univariate analysis regarding: age,
sex, morbidities (trauma, sepsis, recent surgery, gastrointestinal surgery,
solid cancer, acute renal failure), days of CVC, days of antibiotics,
days of corticotherapy, days of mechanical ventilation, use of parenteral
nutrition, days of fever before candidemia, etiology, fungal prophylaxis,
as risk factors for death in non-neutropenic patients with candidemia.
Results: 60 non-neutropenic patients with candidemia, 29 women,
median age 53 years (min 1 week, max 82 years, average 43.5 years),
75% with recent surgery (60% with gastrointestinal surgery), 22% with
solid cancers, 52% with bacterial sepsis, 8% with trauma. The etiology
was represented by Candida albicans in 27 cases (45%) and by non-
albicans Candida spp in 33 cases. The survival rate was 68% at 30
days and 40% at 120 days (CI 29−53). The risk factors associated with
death were: age over 69, mechanical ventilation, more than 14 days of
antibiotics and less than 3 days of fever before candidemia onset.
Conclusions: The incidence of candidemia in our ICU departments
is low in non-neutropenic critically ill patients. More than half of
cases are produced by non-albicans Candida spp. Old age, prolonged
antibiotic treatment, mechanical ventilation and short period of fever
before cnadidemia onset are associated with poor outcome.
P2112 A retrospective trial to evaluate the safety and efﬁcacy
of anidulafungin in individuals with hepatic dysfunction
including liver transplant recipients
M. Barron*, K. Richardson, A. Hilts, M. Levi (Aurora, US)
Objectives: Anidulafungin does not undergo hepatic metabolism but
is instead eliminated by slow, non-enzymatic degradation to inactive
moieties. Its levels may be more predictable compared to caspofungin in
patients with liver dysfunction and may be better tolerated; however,
this has not been formally evaluated. We evaluated the safety of
anidulafungin as empiric or directed treatment of invasive candidiasis
(IC) in patients with hepatic insufﬁciency and/or liver transplantation.
Methods: A retrospective chart review of 50 patients with hepatic
dysfunction (Child’s Class B or C) or liver transplantation who received
anidulafungin for empiric or directed treatment of IC from July 1, 2006
through January 31, 2010.
Results: 28 males and 22 females were enrolled with a median age
of 56 years. 96% of the subjects were Caucasian with 10% Hispanics.
50% of subjects were liver transplant recipients, 14% were other organ
transplant recipients, and 8% had hematologic malignancies. The median
hospital stay was 28 days. Hepatitis C was the most common cause of
initial liver dysfunction. The median MELD score was 20 (the mean
was 21) and 76% of subjects were Child Class B. Risk factors for
IC included: antibiotics >3 days (92%), vascular access device (82%),
immunosuppression (80%), steroids (68%), ICU stay >4 days (60%),
TPN (50%), renal failure (40%), & hemodialysis (24%). 33 subjects
(66%) received empiric therapy and 17 subjects (34%) received directed
therapy based on culture data. Intra-abdominal infection (peritonitis and
abdominal abscess) was the most common site of infection followed by
candidemia. C. albicans and C. glabrata were the most common yeast
species isolated. AST did not change from baseline in 28%, improved
or normalized in 42%, and worsened in 30% of subjects. ALT did
not change from baseline in 32%, improved or normalized in 48%,
and worsened in 20% of subjects. Total bilirubin did not change from
baseline in 26%, improved or normalized in 46%, and worsened in 28%
of subjects. Clinical symptoms (fever, elevated white blood cell count,
positive cultures) did not change in 8%, improved or resolved in 70%,
and worsened in 22% of subjects. 19 subjects (38%) died during their
hospitalization with 3 deaths attributable to IC despite treatment with
multiple antifungals.
Conclusion: Anidulafungin was well tolerated in patients with liver
dysfunction and/or liver transplantation with stable or improved liver
function tests in the majority of patients.
P2113 Efﬁcacy of intravenous itraconazole for the treatment of
invasive candidiasis in surgical department and acute care
medicine − a multicentre clinical study
Y. Takesue*, S. Oda, N. Aikawa, S. Fujishima, H. Mikamo (Hyogo,
Chiba, Tokyo, Aichi, JP)
Background: Although itraconazole (ITCZ) has potent activity against
Candida species, there are few data that examine the use of intravenous
(iv) ITCZ in the treatment of invasive candidiasis (IC). A nationwide
multi-center clinical study was conducted to evaluate the efﬁcacy and
safety of iv itraconazole in the management of IC including non-albicans
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Candida species in non-neutropenic patients of surgical department and
acute care medicine.
Methods: Between September 2007 and August 2009, patients with
proven and presumed IC were enrolled at 22 participating institutions.
Patients with presumed IC had a deep-body temperature of 37.8ºC
or higher, and were positive for serum b-D glucan or two or more
colonization sites of Candida species. Main exclusion criterion was
severe renal impairment (creatinine clearance <30mL/min). The primary
efﬁcacy analysis was based on clinical and microbiologic response 7−10
days after the end of treatment, assessed by an independent data-review
committee using the AKOTT algorithm (Aikawa N et al.: J Infect
Chemother 2009).
Results: Of a total of 60 patients enrolled, 49 were included in the
modiﬁed intention-to-treat population. Twenty-ﬁve patients received a
deﬁnite diagnosis and 24 patients a presumed diagnosis. Thirty-nine
patients were treated with iv ITCZ as the ﬁrst-line therapy and 10
patients as the second-line. The isolated species included C. albicans
(25 strains with deﬁnite diagnosis and 17 with presumed diagnosis) and
non-albicans species (16 and 10 respectively). Treatment was successful
in 61.5% of patients (65.5% in ﬁrst-line therapy and 50.5% in second-line
therapy). Sixty percent of proven IC patients were judged as a success
compared with 63.2% in presumed IC patients. The eradication rate
was 63.6% for C. albicans and 71.4% for C. glabrata. Adverse effects
occurred in 9 of 60 patients (15.0%), and impaired liver function was
common among them.
Conclusion: The clinical efﬁcacy and safety of iv ITCZ was suggested
in the management of proven and presumed IC including C. glabrata
in non-neutropenic patients. The position of iv ITCZ in the Japanese
guidelines warrants reconsideration.
P2114 Economic evaluation of micafungin versus liposomal
amphotericin B in the treatment of candidaemia and
invasive candidiasis
C.F. Neoh*, D. Liew, M. Slavin, D. Marriott, S.C. Chen, O. Morrissey,
K. Stewart, D. Kong (Melbourne, Sydney, AU)
Objective: Micafungin was as efﬁcacious as liposomal amphotericin B
(LAmB) for the treatment of candidaemia and invasive candidiasis in a
major randomised clinical trial. We performed an economic evaluation
of micafungin compared with LAmB for the treatment of candidaemia
and invasive candidiasis in the Australian setting.
Methods: A decision analytic model was constructed to capture
downstream consequences of using either micafungin or LAmB. The
main outcomes were treatment success and treatment failure due to
mycological persistence or death. Outcome probabilities and treatment
pathways were derived from a published randomised clinical trial (Lancet
2007;369:1519–1527) and literature. Resource use was estimated by an
expert panel and cost inputs were from the latest Australian resources.
The analysis was from an Australian hospital perspective. Sensitivity
analyses using Monte Carlo simulation were conducted.
Results: Micafungin (AU$61,425) had a lower total cost than LAmB
(AU$72,382), with a total net cost-saving of AU$10,957 per successfully
treated patient. This was primarily due to the lower cost associated with
initial antifungal treatment and shorter length of stay in the micafungin
arm. Hospitalisation was the main cost driver for both arms, followed by
drug acquisition costs. Results were robust over a wide range of variables
(±100.0% from the base case value). Uncertainty analysis demonstrated
micafungin had a 99.9% chance of being more cost-saving than LAmB.
Conclusion: Micafungin was associated with cost-saving relative to
LAmB in the treatment of candidaemia and invasive candidiasis in the
Australian hospital setting.
P2115 Fungiscope − a global rare fungal infection registry
M. Vehreschild, W. Heinz, A. Hamprecht, G. Fischer, S. De Hoog,
J. Vehreschild, O.A. Cornely* on behalf of the Fungiscope Working Group
Background: We are coordinating a global registry for cases of rare
invasive fungal diseases (IFD). Our objective is to broaden the knowledge
on epidemiology, to determine the clinical pattern of disease, to describe
and improve diagnostic procedures and therapeutic regimens, as well as
to facilitate exchange of clinical isolates among the contributors.
Methods: Fungiscope™ − A Global Rare Fungal Infection Registry uses
a web-based electronic case form accessible via www.fungiscope.net. For
inclusion in the registry we require positive cultures or histopathological,
antigen or molecular genetic evidence of IFD and the associated clinical
symptoms and signs of invasive infection. The data entered onto
the registry include demographics, underlying conditions, neutrophil
count, concomitant immunosuppressive medications, clinical signs and
symptoms of IFD, site of infection, diagnostic tests performed, pathogen
identiﬁcation, antifungal treatment, surgical procedures performed,
response to treatment, overall survival and attributable mortality.
Results: 209 cases have been registered. Zygomycetes (n = 71; 34%),
Fusarium spp. (n = 35; 17%), yeasts (n = 33; 16%) and Dematiaceae
(n = 28; 13%) were the most frequently registered pathogens. Chemother-
apy or allogeneic stem cell transplantation for a haematological
malignancy was the most predominant risk factor (n = 83; 40%), as well
as diabetes mellitus (n = 56; 27%), stay at an ICU (n = 43; 21%) and
chronic pulmonary disease (n = 26; 12%). In 77 patients (37%), the lung
was the organ of ﬁrst diagnosis, followed by blood stream infections
(n = 40; 19%), the sino-nasal region (n = 31, 15%) and deep soft tissues
(n = 27; 13%). For 110 (53%) patients, a favourable outcome, deﬁned
as a complete or partial response to treatment of IFD was documented.
Overall mortality and mortality attributable to IFD was 38% (n = 79) and
26% (n = 55), respectively.
Conclusion: The clinical relevance of rare IFD is increasing steadily. In
a short period of time, a wide variety of cases from Europe, Asia and
South America could be documented. Further investigators are cordially
invited to contribute to Fungiscope.
P2116 Epidemiology of fungaemia in Spain: preliminary results
of 1,177 episodes from a multicentre study (FUNGEMYCA)
in 2009
J. Pema´n*, E. Canto´n, C. Pazos, A. Garcı´a, S. Algarate, I. Campos,
D. Velasco, A. Sua´rez, J. Esperalba (Valencia, Caceres, Ca´diz,
Zaragoza, Las Palmas, La Corun˜a, Seville, Majadahonda, Madrid, ES)
Objectives: Candida albicans is the most common cause of noso-
comial fungal bloodstream infections (fungaemia). However, several
epidemiological surveillance studies have recently reported an increase in
fungaemia caused by non-C. albicans species in different proportions,
depending on the geographical area evaluated. The aim of this study
was to assess the changes in the epidemiology of fungaemia in
Spain comparing data from a new surveillance epidemiological study
conducted in 2009 with a previous study carried out from 1997–1999
(Pema´n J, et al. Eur J Clin Microbiol Infect Dis, 2005).
Methods: From January 2009 to December 2009, 43 Spanish hospitals
participated in the prospective multicenter fungaemia surveillance study.
Demographic and clinical data and the ﬁrst isolate of each episode
were gathered. Isolates were identiﬁed in the participating institution by
routine methods and sent to the central laboratory for posterior studies.
Results: A total of 1,177 fungaemia episodes were collected, 85%
from adult patients. The hospitalization Unit distribution (%) of patients
was: ICU 36.8; Surgery 16.6; Internal Medicine 12.8; Hematology 6.6;
Oncology 6.5; Neonatology 4.8 and Pediatrics 3.4%. C. albicans was
the most frequent species isolated (43%), followed by C. parapsilosis
(30%), C. glabrata (11%), C. tropicalis (8%), C. krusei (2%) and other
species (6%). In ICU settings, a reduction in C. parapsilosis frequency
was observed with increasing age (47% in children vs. 25% in adults)
and a parallel increase in C. glabrata and C. tropicalis (from 5% to
11% and from 2% to 10%, respectively). The most frequent risk factors
were intravascular catheter (61%), surgery (37%) and ICU stay (33%).
The species distribution of fungaemia is not regular for all hospitals and
depends on the hospital characteristics.
Conclusion: There has been an increase both in the number of
participating centres and the total number of isolates. The incidence of
fungaemia has not being yet analyzed. Fungaemia due to non-C. albicans
S626 21st ECCMID/27th ICC, Posters
has not increased in the last 10 years in Spain, in contrast with other
countries. Incidence of fungaemia in paediatric patients has decreased
54%.
P2117 Hospital contacts with Candida infections and risk of cancer
M. Nørgaard, D.F. Farkas, M.F. Mogensen, R.W. Thomsen*,
H.T. Sørensen (Aalborg, Aarhus, DK)
Objectives: To examine whether an inpatient or outpatient hospital
contact with a candida infection is a marker of increased cancer risk.
Methods: We conducted a nationwide population-based study using
linked data from the Danish National Registry of Patients and the Danish
Cancer Registry for the 1977–2003 period. We identiﬁed all patients with
a ﬁrst-time hospital contact with a candida infection (ICD-8 code: 112
candidiasis; ICD-10 codes: B37 (except B37.2 candida of skin/nails)
and G021A candidiasis), who had no previous cancer history. To assess
the data quality of candida diagnoses, we reviewed a random sample of
159 hospital records for presence of clinically and microbiologically
conﬁrmed candida infection. We followed all patients with candida
infection until a diagnosis of cancer, death, or 1 January 2004. We
computed the overall incidence of cancer and computed standardized
incidence ratios (SIRs) using Danish national cancer rates for the study
period. We stratiﬁed the SIRs by cancer type and follow-up interval (ﬁrst
year, more than one year).
Results: We identiﬁed 17,390 patients (11,199 women and 6,191 men)
with a ﬁrst-time hospital contact with candida infection. In the sample
of 159 cases for which we reviewed hospital records, 139 (87%) fulﬁlled
criteria for conﬁrmed candida infection. Among the 17,390 patients
with a diagnosis of candida, we identiﬁed 966 cancers during 138,364
person-years of follow-up (SIR= 1.5; 95% conﬁdence interval (CI):
1.4−1.6). Within the ﬁrst year following a candida diagnosis, the SIR
for all cancers was 3.1 (95%CI: 2.8−3.5). We found particularly high
SIRs during the ﬁrst year for cancer of the mouth [32.8 (95%CI:
19.1–52.5)], tongue [17.4 (95%CI: 4.7–44.6)], and oesophagus [12.3
(95%CI: 6.6–21.1)]. SIRs were also high for lymphomas and leukaemia.
Compared with the general population, the overall cancer risk after
one year of follow-up remained 20% higher than expected (SIR = 1.2;
95%CI: 1.1−1.3), while risk of cancer of the mouth, tongue, and pharynx
remained more than threefold higher than expected.
Conclusions: In the ﬁrst year after a hospital contact with candida, the
risk of any cancer is more than threefold higher than expected in the
general population. In subsequent years, a persistent 20% increase in
cancer risk remains.
P2118 Candidaemia after liver transplantation in the era of
ﬂuconazole prophylaxis: a prospective survey at one centre
over 10 years
C. Camus, J. Letheulle, A. Gacouin, S. Lavoue´, S. Marque, A. Gros,
L. Chimot, C. Guiguen, Y. Le Tulzo, J.-P. Gangneux* (Rennes, FR)
Objectives: Fluconazole (F) prophylaxis (P) in high risk liver transplant
recipients has been recommended to prevent invasive candidiasis. We
assessed the incidence, microbiological spectrum, characteristics and
outcome of candidemia (C) after liver transplantation (LTx) under a
prophylaxis protocol.
Methods: During a 10-year period (2000–2010), 845 patients underwent
914 LTx at Rennes Teaching Hospital. Over this period, antifungal P
in high risk patients with F 400mg/day during 6 weeks was in use
and remained unchanged. Immunosuppression was mostly based on
tacrolimus low dose, mycophenolate and steroid.
Results: C was observed in 12 pts (incidence rates of 1.4 per 100 pts, 3.7
per 1000 pt-year). Median (IQR) delay after LTx was 15 days (1−42).
C occurred during P for 9 patients (6/9 during the ﬁrst week), very
late after P for 1 patient or without P for 2 patients considered not at
risk. Reduced/non susceptibility to F was observed for 8 strains (67%)
(C. parapsilosis [5], C. krusei [2], C. valida [1]). Four strains (33%)
were F-susceptible (C. albicans [2], C. glabrata [1], C. dubliniensis [1]).
Three C. parapsilosis C were diagnosed over a 2-month period. Six pts
(50%) had septic shock. Other sites involved were: catheter (5; a central
venous catheter was the source of C in 4), bile (4) ascites (2) urine (2),
graft preservation solution (1) retina (1). No pt had endocarditis. In 5
pts, death was either directly (3) or possibly (2) related to C. Mortality
within 30 days of C was 63% (5/8) during F-resistant infections versus
0/4 during F-susceptible episodes. When compared to the 833 non C
pts, there was a difference in primary diagnosis (less non viral cirrhosis,
more acute liver failure in the C group). Cumulative mortality rate at all
time points were higher in the C group (Table).
Conclusion: With targeted F prophylaxis, the incidence of C remains
low after LTx, mostly involving F-nonS species (67%). However, C
remains associated with signiﬁcant direct or indirect mortality. Studies
investigating new agents for the prophylaxis of invasive fungal infections
but also for empirical therapy in the setting of LTx are warranted.
P2119 The value of the Candida Colonisation Index for predicting
Candida infections in a mixed intensive care unit
B. Ergu¨t Sezer, M. Dizbay, D. Arman* (Ankara, TR)
Objective: The aim of the investigation was to assess the usefulness
of “Candida colonisation index” (CCI) as an early microbiological
documentation for predicting candida infections.
Methods: A retrospective, cohort, observational study was performed
between January 2006 and July 2007 in Neurological and Reanimation
ICU’s of total 18 beds for medical and surgical patients. A total of 82
non-neutropenic adult intensive care unit patients admitted for at least
7 days are enrolled in the study. Clinical and demographic data of the
patients, APACHE II score, hospitalization during the last 6 months,
history of infection, antimicrobial treatment and invasive procedures
were recorded. Oral mucosa, axillae, rectal swab, enteral nutrition
catheter and urine samples were obrtained for culture on admission
and thrice weekly. The colonization index was considered as positive
if candida isolated sites over sampled sites rate was 0.5. The patients
were observed for candidemia, urinary candidiasis or other invasive
candidiasis lateron. Statistical analysis was performed by chi-square test,
Spearman’s correlation test and logistic regression analysis.
Results: Candida infections were diagnosed in 29 (35.4%) patients.
CCI was 0.5 in 27/29 (93,1%). CCI and candida infections are
shown in table 1. Among the advanced age, prolonged hospitalization
prior to ICU, extended spectrum cephalosporin use, renal insufﬁciency,
unconsciousness, preceding bacterial urinary infection, central venous
catheter, peripherial catheter use or intubation as risk factors for
candidiasis, CCI was the only independent risk factor (OR:701,553;
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95%CI; 28,310–17385,22; p< 0,001) in a multivariate logistic regression
analysis. Positive predictive value of CCI was 93.1%, susceptibility
93.1%, and speciﬁty 96.2% for candida infections.
Conclusions: Our results documented that CCI may be a good predictor
for candidasis in medical ICU patients. With limited patient population
and lack of investigation for value of preemptive treatment, our results
are only promising. Prospective trials with a large patient population on
preemptive treatment based on CCI would be useful.
P2120 Candida peritonitis: analysis of 81 episodes
A. Loza*, J. Gonzalez, A. Ubeda, C. Leo`n, C. Castro, P. Saavedra,
S. Ruiz on behalf of the Cava II study group
Objective: To describe the epidemiology and prognosis of Candida peri-
tonitis in non-neutropenic critically ill adult patients with complicated
abdominal surgery.
Material and Methods: In a prospective, observational and multicenter
study, the following cohorts were included: 1699 patients admitted to
73 ICUs in 1998/1999 (EPCAN database), 1107 patients admitted to 36
ICUs in 2006/2007 (CAVA I project), and 254 ICU patients admitted
in 2009/2010 (CAVA II project). Length of ICU stay for at least 7
days was an inclusion criterion. Patients with complicated abdominal
surgery were selected for the present analysis. Candida peritonitis was
deﬁned as isolation of Candida spp. in a peritoneal sample obtained by
laparotomy or percutaneous puncture in patients with associated clinical
ﬁndings. Variables independently associated with Candida peritonitis
were analyzed in a logistic regression model and the discriminating
capacity of the predictive variable selected was assessed with the area
under the ROC curve.
Results: There were 81 episodes of Candida peritonitis among 1120
patients undergoing abdominal surgery (incidence 72.32 episodes/1000
patients). Risk factors for Candida peritonitis were multifocal coloniza-
tion by Candida spp. (OR= 4.74, 95%CI 2.21–10.17), severe sepsis
or septic shock (OR= 3.54, 95%CI 1.77–7.07), extrarenal depuration
procedures (OR= 2.31, 95%CI 1.19–4.52), and days of ICU stay
(OR= 1.03, 95%CI 1.01–1.04). Pre-emptive antifungal treatment was
a protective factor (OR= 1.03, 95%CI 0.05–0.34) and showed a high
discriminating capacity (AUC= 0.842, P< 0.001). Crude mortality in
patients with and without Candida peritonitis was 39.5% and 25.4%
(P = 0.006).
Conclusions: Multifocal colonization, degree of sepsis, extrarenal
depuration procedures, and length of ICU stay allow identifying patients
with complicated abdominal surgery at risk for Candida peritonitis.
Candida peritonitis is associated with a high mortality. Pre-emptive
fungal therapy prevents intraabdominal Candida spp. invasion during
the postoperative period in ICU patients after complicated abdominal
surgery.
P2121 Trends in species distribution and antifungal susceptibility
in yeasts isolated from peritoneal ﬂuid in a general hospital:
an overview of a 16-year period
T. Pelaez*, B. Gama, A. Luis, E. Reigadas, R. Flores, J. Guinea,
P. Mun˜oz, E. Bouza (Madrid, ES)
Background: Yeasts may cause human peritonitis both alone or as part
of a polimicrobial infection. We assessed the evolution of peritoneal
ﬂuids (PF) with the isolation of yeasts over a 16 year period and the
activity of several antifungals against the available isolates.
Methods: From 1994 to 2009, the yeasts isolated from PF were
considered. The in vitro activities of amphotericin B (AB), ﬂuconazole
(FZ), itraconazole (IZ), voriconazole (VZ), posaconazole (POS),
caspofungin (CAS), anidulafungin (AND) and micafungin (MF) were
determined by the broth microdilution method following CLSI criteria.
Results: During the study period, a total of 394 peritoneal ﬂuids,
from 386 patients, showed positive yeast growth (425 isolates) and
the incidence of yeast peritonitis was 0,45 episodes/1.000 admissions.
Overall Candida albicans was the species more frequently isolated
(250; 58.8%) followed by C. glabrata (65; 15.3%), C. tropicalis (43;
10.1%), C. parapsilosis (37; 8.7%), C. krusei (12; 2.8%) and other (18;
4.2%). The MICs ranges and MICs 90 (mg/ml) of the 317 available
isolates tested were as follows: AMB (0.06−4/2), FZ (0.125–256/16), IZ
(0.015−32/0.5), VZ (0.015−32/0.25), POS (0.015−32/0.5), CAS (0.03−4/
0.5), AND (0.007−4/2) and MF (0.007−2/0.5). The geometric mean,
expressed in mg/ml were: AMB (0.353), FZ (4), IZ (0.088), VZ (0.043),
POS (0.062), CAS (0.25), AND (0.015) and MF (0.007).
Conclusions: In our hospital, the incidence of fungal peritonitis
has remained stable during the study period. However, the species
distribution was different between adult and paediatric population; and
the percentage of Candida non-albicans increased signiﬁcantly during
the last years. Candins exhibited an excellent in vitro activity against the
majority of isolates causing fungal peritonitis in adults and children.
P2122 Trends of candidaemia in Slovakia − a comparison of two
consecutive, prospective studies
L. Drgona*, D. Kotulova, J. Trupl, A. Kunova, M. Lisalova,
H. Hupkova, T. Marcek (Bratislava, SK; Paris, FR)
Objectives: To show and analyze the trends in epidemiology of
candidaemia in Slovakia during the recent period (2005–2009).
Methods: The results of two prospective, national studies were
compared. The 1. study (S1) was performed in 2005−7 (1) and
the 2. study in 2008−9 (S2). Both studies had the same design.
All bloodstream fungal isolates from participating sites (teaching and
regional hospitals) were collected for identiﬁcation and for sensitivity
testing in central study laboratory. Germ-tube tests, chromogenic media
(Chromagar, BBL), API 20C and YBC Vitek (bio´Me´rieux) were used
for identiﬁcation of yeasts. The CLSI M44-A method was used to test
all yeasts isolates. Quality control strains C. albicans ATCC 90028 and
C. parapsilosis ATCC 22019 were used. Breakpoints for ﬂuconazole
and voriconazole were based on CLSI-S2 standard. Basic clinical data
in both studies were obtained and compared.
Results: 171 (S1) and 239 (S2) episodes of candidaemia were
documented, analyzed and compared. The incidence of candidaemia in
Slovakia is increasing − from 2.2 to 3.0 (cases/100 000/year) in 2005−7
and 2008−9, respectively. Majority of patients with candidaemia were
from ICUs (38% in S1 and 64% in S2) and from hematology/oncology
departments (12% in S1 and 22% in S2). C. albicans was the pathogen
in 38% (65/171) of episodes in S1 and in 50% (12/239) of episodes
during S2. C. parapsilosis was the most common non-albicans strain
detected in both studies (29% in S1 and 26% in S2). Non-albicans
infections dominated at hemato/oncology and surgical wards. Resistance
of non-albicans Candida strains to ﬂuconazole were 21.6% (S1) and
24.3% (S2). Voriconazole resistance was 11.3% in S1 and 14.2% in
S2. Additional testing showed that 15 non-albicans strains, mainly
C. parapsilosis, were non-sensitive to anidulafungin.
Conclusion: Our consecutive, prospective studies documented the
increasing incidence of candideamia in Slovakia during the recent 5
years. The majority of population at risk were patients at ICUs and
hematology/oncology departments and the most common pathogen was
C. albicans in 38−50% of all episodes followed by C. parapsilosis
in 26−29%. The resistance to ﬂuconazole and voriconazole is slightly
increasing and we detected strains non sensitive to echinocandins.
Continual survey can help to identify the patients at risk and resistant
strains and should have the impact on therapy of candidaemia.
P2123 Nosocomial bloodstream infections due to Candida spp.
in the US − species distribution, clinical features and
susceptibilities
H. Wisplinghoff*, J. Ebbers, L. Geurtz, D. Stefanik, Y. Major,
M.B. Edmond, R.P. Wenzel, H. Seifert (Cologne, DE; Richmond, US)
Background: Candida species are among the most prevalent nosocomial
pathogens contributing signiﬁcantly to morbidity and mortality, mainly
among patients in the ICU setting. Even though several studies have
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analyzed the susceptibility of Candida spp. to newer agents and over
time in single institutions, comprehensive clinical and microbiological
data are still limited.
Methods: A total of 1338 episodes of Candida bloodstream infection
(BSI) prospectively collected from patients in 52 hospitals in the United
States between 1997 and 2005 were analyzed. Susceptibilities to ampho-
tericin B (AMB), ﬂucytosine (FLC), ﬂuconazole (FLU), posaconazole
(POS), voriconazole (VOR), anidulafungin (ANI), caspofungin (CAS),
and micafungin (MIC) were determined for a subset of 1062 Candida
isolates by the CLSI reference broth microdilution method.
Results: C. albicans was the most prevalent species accounting for 524
(45%) of all isolates, followed by C. parapsilosis (19%), C. glabrata
(18%), and C. tropicalis (10%). There was no trend in favour of
non-Candida albicans species over time. Patients had a mean age of
51 years (range 0−94 years) and their length of stay prior to BSI
averaged 22 days. The main underlying conditions were gastrointestinal
(20%), pulmonary (13%) and malignant (12%) diseases. IV catheters
(20%) and the urinary tract (9%) were the most frequently determined
sources of BSI, while in the majority of patients (59%) no source
could be identiﬁed. Overall mortality was 37%. MIC50/MIC90 values are
shown below. Resistance to ﬂuconazole occurred in <1% of C. albicans
isolates, 10% of C. glabrata isolates, and 3% of C. tropicalis isolates.
Resistance to ﬂuconazole was associated with resistance to voriconazole
and posaconazole. Nonsusceptibility to echinocandins was only found in
C. parapsilosis.
Conclusions: C. albicans and C. parapsilosis were the most prevalent
Candida species causing BSI in patients from US hospitals. Even though
all tested agents displayed good activity against most species decreased
activity of all azoles against C. glabrata and of echinocandins against
C. parapsilosis are important to consider in empirical therapy.
P2124 Epidemiology of candidaemia in two tertiary-care university
hospitals in Germany
A. Hamprecht*, S. Go¨ttig, H. Seifert, F. Knapp, H. Wisplinghoff,
G. Plum (Cologne, Frankfurt, DE)
Objectives: This study was initiated to assess the impact of candidemia
and to compare differences in species distribution and resistance at two
large University Hospitals in Germany. Currently, there is a lack of
studies about the epidemiology of candidemia and resistance rates in
Germany.
Methods: A retrospective analysis of all cases of candidemia from the
University Hospital Cologne (UHC) and University Hospital Frankfurt
(UHF) was carried out (UHC 2001−11/2010, UHF 2005−11/2010).
Results: A total of 542 cases of candidemia were identiﬁed at the two
centers, with an increasing number of cases over the study period (from
22 in 2001 to 50 until 11/2010 at UHC). C. albicans was the most
frequent species at UHC and UHF (62.4%), C. glabrata the most frequent
non-albicans species (18.6%), followed by C. tropicalis (7.0%) and
C. parapsilosis (6.6%). Non-albicans species increased at both centers,
from 35.6% in 2005 to 47.3% in 2010. This increase could be observed
earlier and more markedly at UHF with an almost even distribution of
C. albicans and non-albicans cases in 2007–2010.
155 isolates were susceptibility tested by E′test or Vitek-2 YST-01
card during the study period. C. albicans strains were susceptible to
ﬂuconazole in 100% at UHC and 97.6% at UHF. Amphotericin B
resistance was only reported at UHF (7.1% of all Candida species).
Susceptibility of C. glabrata isolates to ﬂuconazole was 66.7% (UHC)
and 62.9% (UHF). Echinocandin resistance was rare for species other
than C. parapsilosis. One case of clinical failure to caspofungin treatment
and in vitro caspofungin resistance (minimal inhibitory concentration
(MIC) >8mg/ml) was observed in 2010 at UHC.
Conclusion: The incidence of candidemia has markedly risen in the
study period at both study sites, with an increase of infections due to non-
albicans species. This change in the frequency of the different species
may be due to an increased use of antifungals. Use of azoles is known
to select for C. glabrata. Echinocandins select for C. parapsilosis, which
exhibits intrinsically high MIC to this drug class.
Resistance to echinocandins in other species is so far rarely reported in
Europe. Currently, susceptibility testing of echinocandins is therefore
not routinely performed in most laboratories. However, the case of
candidemia due to a caspofungin resistant C. glabrata strain with clinical
failure warrants a close monitoring of echinocandin resistance rates.
P2125 Phase IV, open-label study of intravenous anidulafungin
followed optionally by oral voriconazole for treatment of
candidaemia/invasive candidiasis in critically ill patients
M. Nucci*, M. Petti, M. Magana, P. Abreu, S. Sanchez (Rio de Janeiro,
Sa˜o Paulo, BR; San Luis Potosi, MX; New York, US)
Objectives: To evaluate the efﬁcacy, safety and impact on mortality of
short-course intravenous (IV) anidulafungin (ANID), followed optionally
by oral voriconazole (VORI), in critically ill patients with candidemia/
invasive candidiasis (C/IC).
Methods: Phase IV, multicentre, open-label, non-comparative trial.
Patients received ANID 200mg IV on Day 1 and 100mg IV ANID daily
thereafter. Oral VORI (400mg BID loading dose, 200mg BID thereafter)
was permitted if control of fungal infection was conﬁrmed at Day 5 of
IV treatment. The primary endpoint of the study was global response rate
(clinical + microbiological response) at end of therapy (EOT). Secondary
endpoints included: global response rate at end of IV treatment (EIVT),
30-day survival, C/IC-related mortality and species distribution. Safety
assessments included adverse events (AEs), and changes in clinical and
laboratory parameters.
Results: In total, 54 patients were enrolled from six countries across
Latin America (59.3% female, mean (SD) age 52.8 (17.4) years, mean
APACHE-II score 14.7), from a target sample size of 210 patients.
Median total duration of exposure (ANID±VORI) was 15 days (range 1
37); 16 patients (29.6%) were switched to oral VORI. The most common
species isolated was C. albicans (25/52 [48.1%]); C. parapsilosis was
isolated from 7/52 patients (13.5%) and C. glabrata from 5/52 (9.6%)
patients. Global response rate for the modiﬁed intent-to-treat population
(study drug + positive Candida within 96 h of study entry) at EOT was
59.1% (26/44 patients: 95%CI: 44.6, 73.6) for the primary endpoint
with missing/indeterminate set to failure, and 83.9% (26/31 patients;
95%CI: 70.9, 96.8) for a sensitivity analysis with missing/indeterminate
excluded. On day 30, the mortality rate was 43.2% (19/44). On the
last evaluation, 4 deaths (9.1% of patients [N = 44]) were attributed to
C/IC. The most common AE was septic shock (20.4%; all unrelated
to ANID). Only 17/204 AEs were considered ANID-related (12/54
patients [22.2%]). Two AEs with fatal outcome (hyperkalemia and drug
ineffective) were considered ANID-related.
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Conclusions: The safety of ANID in critically ill patients was
comparable to the known proﬁle of ANID. Initial results from this small
study suggest that short-course ANID, followed by optional oral VORI,
might be effective for the treatment of C/IC, including the reduction
of C/IC-associated mortality, in Latin America. Further studies are
warranted.
P2126 Invasive aspergillosis in haematologic patients: description
of 127 cases enrolled in a single-centre prospective
surveillance system, 2004–2009
T. Be´net*, M. Nicolle, A. Thiebaut, M. Piens, N. Voirin, A. Duclos,
X. Thomas, F. Nicolini, F. De Monbrison, M. Perraud, A. Bienvenu,
M. Michallet, P. Vanhems (Lyon, FR)
Objectives: Invasive aspergillosis (IA) is a major concern in hematology.
Incidence monitoring and clinical course of IA can enhance medical
support. The objectives were 1)to report a description of patients with
IA in an hematologic department, and 2)to estimate the incidence by
hematological diagnosis.
Methods: A prospective surveillance of IA cases has been implemented
between January, 1st 2004 and December, 31 2009 in the Hematology
Department (42 beds) of Edouard Herriot hospital (Lyon, France).
Multidisciplinary meetings with clinician, mycologist and infection
control practitioner were organized every 2 months to conﬁrm suspected
IA cases. Demographic characteristics, clinical and complementary
exams were prospectively collected. Hospital stays were extracted from
the hospital Information System. IA diagnosis followed the European
Organization for Research and Treatment of Cancer criteria, proven and
probable IA were retained. A descriptive analysis was done; temporal
trends of IA incidence were assessed by Poisson regression.
Results: Overall, 4 073 hospitalized patients counting for 78 360 patient-
days at risk were included. Totally, 127 (3.1%) patients had IA, the
global IA incidence was 1.6 per 1 000 patient-days (95%CI 1.4−1.9 per
1 000 patient-days). In patients with acute myeloid leukaemia (AML)
the incidence was 1.9 per 1 000 patient-days (95%CI 1.5−2.3 per 1 000
patient-days), in patients with acute lymphoid leukaemia (ALL) the
incidence was 1.3‰ per 1 000 patient-days (95%CI 0.8−2.0 per 1 000
patient-days). The IA incidence decrease was 16% per year (95%CI 1%-
28%) between 2004 and 2009. The IA incidence decrease in patients
with AML was 20% (95%CI 6%-36%). Serum Aspergillus antigen was
detected for 89 (71%) patients, 29 (23%) patients had positive culture,
118 (93%) had abnormal lung CT-scan. Three-month mortality was 42%.
Between 2004 and 2009, there was a trend for a decrease of 1-month
mortality (22% in 2004 vs. 14% in 2009) and 3-month mortality (50%
in 2004 vs. 29% in 2009) (P = 0.2 and P = 0.8 respectively).
Conclusions: A decrease of IA incidence and mortality was observed
between 2004 and 2009. The knowledge of characteristics and clinical
course of patients with IA should permit to improve the management of
these patients with severe disease. Observational data might complement
experimental studies for reporting effect of improvement of care.
P2127 The epidemiology of neutropenic patients with invasive
candidiasis using electronic data
E. Kuo, L. Puzniak, R. Reichley, J. Doherty, B. Camins* (Saint Louis, US)
Objective: Because of limited data, current treatment regimens for
invasive candidiasis (IC) in neutropenic patients are mainly based on
data from non-neutropenic patients. The objective of this study was to
identify and describe the epidemiology of neutropenic patients with IC
using an electronic clinical database.
Methods: Patients admitted to Barnes-Jewish Hospital (BJH), a 1250-
bed tertiary care center in the US, with either a positive candida culture
from blood or a normally sterile site and an ANC <500 at the time
of positive culture were included in the analyses. Electronic medical
data was collected from the Washington University and BJC Healthcare
Medical Informatics Database between the periods of 10/1/2004 and
12/31/2009.
Results: There were 81 patients included in the analysis. Mean age
was 53±16 years (0−67 years). Median modiﬁed APACHE II score
was 13 (0−28) and median Charlson Index of Co-morbidity was 4
(0−10). 29/81 (36%) were admitted to the ICU. 25/81 (31%) were treated
with anidulafungin; 22/81 (27%) with caspofungin, 17/81 (21%) with
ﬂuconazole, and 17/81 (21%) with other systemic antifungals. Crude in-
hospital mortality was 44% (36/81). The mean length of stay was 32±21
(0−85) days and the mean length of stay until the ﬁrst positive culture was
18±16 days (0−74). Co-morbid illnesses included heart disease (20%;
16/81), diabetes (17%; 14/81), and chronic lung disease (10%; 8/81).
The most common species isolated was C. albicans (42%) followed by
C. glabrata (16%), C. krusei (14%), C. parapsilosis (11%), C. tropicalis
(6%), and C. dubliniensis (6%).
Conclusions: The retrospective review of electronic clinical data
identiﬁed a considerable number of neutropenic patients with IC. Over
half of the study population were treated with an echinocandin, but a
signiﬁcant number of patients received ﬂuconazole and other systemic
antifungals. The in-hospital mortality rate and distribution of species
were consistent with previously reported studies in non-neutropenic
patients.
P2128 Respiratory aspergillosis in non-transplant, non-neutropenic
patients
E. Malmierca, D. Del Castillo, A. Fernandez-Villar, V. Villena,
G. Fernandez, F. Garcia-Perez, F. Garcia de la Llana, J. Barberan,
L. Aguilar, J.J. Granizo, M.J. Gimenez* on behalf of the ASP
Investigators Group
Objective: To analyse the signiﬁcance of lower respiratory tract cultures
yielding Aspergillus spp. growth in non-transplant/non-neutropenic
patients.
Methods: A multicenter (24 hospitals) retrospective review (2003–2010)
of clinical records corresponding to non-transplant/non-neutropenic
patients with at least 2 respiratory samples yielding Aspergillus spp. was
performed. Patients were assigned to 3 categories based on the criteria
by Bulpa et al. for patients with chronic obstructive pulmonary disease
(COPD): colonized, probable or proven aspergillosis.
Results: 200 patients were identiﬁed (mean age: 68.3±15.2 years; 72.0%
males). Most patients were admitted in Pneumology (50.5%), Internal
Medicine (20.5%) and Intensive Care Unit (11.0%), with 7.0% non-
hospitalized patients. COPD was present in 69.5% patients (of them
28.0% Gold IV, 36.9% Gold III and 24.5% Gold II), diabetes in
20.5%, malignancies in 16.5% and chronic renal impairment in 8.0%
patients. Hospital admission within the previous 3 months was recorded
in 26.0% patients. In the Rxs performed, 56.8% patients presented
inﬁltrates, 17.6% nodules, 10.0% pleural effusion and 9.6% cavitations.
Thoracic CT scan showed halo and air-crescent signs in 3.6% and
2.7%, respectively, of 112 (56.0%) patients with scan performed. Prior
to admission 41.0% patients had received corticosteroids (61.0% of
them with 20mg/day prednisone equivalent) and 35.5% antibiotics,
and during hospitalization, rates were 74.0% (89.2% patients with
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20mg/day) and 85.0%, respectively. Aspergillus fumigatus was the
most frequent species (65.0% patients). Fatal prognosis was recorded
for 40.0% patients (23.8% at short-term, <6 months). Distribution
by category: 46.0% colonized, 49.0% probable and 5.0% proven
aspergillosis. Pulmonary invasive aspergillosis represented 52.0% and
70.0% of probable and proven aspergillosis, respectively. Antifungal
treatment was initiated in 100%, 81.6% and 29.3% of proven, probable
and colonized patients, respectively. Voriconazole (as single or associated
antifungal treatment) was administered in 69.2% treated patients.
Mortality was 90.0%, 43.9% and 15.2% among proven, probable and
colonized patients, respectively.
Conclusion: Most non-transplant/non-neutropenic patients with prob-
able/proven aspergillosis presented advanced COPD and received
corticosteroids. Positive respiratory tract samples in these patients should
always prompt for further diagnostic assessment and subsequent therapy.
P2129 Chronic invasive pulmonary aspergillosis: diagnosis and
treatment
Y.V. Borzova, S.N. Khostelidi, M.O. Popova, R.M. Chernopyatova,
T.S. Bogomolova, S.M. Ignatyeva, O.A. Shurpitskaja, A.S. Kolbin,
I.S. Zjuzgin, N.V. Zubarovskaja, N.V. Vasilyeva*, N.N. Klimko (Saint
Petersburg, RU)
Objectives: To deﬁne demographic parameters, underlying diseases,
aetiology, clinical features and survival rate for patients with chronic
invasive pulmonary aspergillosis (CIPA).
Methods: Diagnosis of invasive pulmonary aspergillosis (IPA) was based
on EORTC/MSG 2008 criteria. Cases with a duration of the disease
longer than 3 months as well as cases of relapse within 6 months from
the onset of the disease were considered as CIPA.
Bronchoalveolar lavage (BAL) and sputum were examined by direct
microscopy with calcoﬂuor white and by culture.
Galactomannan (GM) in blood serum was determined by “Platelia
Aspergillus EIA” test (BioRad).
Results: The study included 262 patients with IPA, registered during
1998–2010 y.y. CIPA was diagnosed in 104 (40%) of patients. The ratio
of men and women was 1,5:1; median age − 39,8 years.
Main underlying diseases in patients with CIPA were hamatologic
malignancies (84%) and chronic pulmonary diseases (12%).
Risk factors for CIPA were: prolonged lymphocytopenia (median − 48
days), prolonged steroid therapy (median − 46 days) and long-lasting
chemotherapy (median − 6 courses).
Clinical manifestations of CIPA were: fever (91%), dyspnoea (57%),
cough (77%), haemoptysis (18%), broncho-obstructive syndrome (16%)
and chest pain (17%). On CT scan bilateral lung damage (85%) and
symptom “crescent sign” (31%) were characteristic for patients with
CIPA. Serum GM test was positive in 63% of patients.
Direct microscopic examinations of respiratory specimens were positive
for septate hyphae in 24% of patients. Aspergillus spp. have been isolated
from sputum or BAL in 25% of cases. The species distribution was
as follows: A. fumigatus − 43%, A. niger − 32%, A. ﬂavus − 13%,
A. nidulans − 3%, A. ochraceus − 3%, A. versicolor − 3%,
Aspergillus sp. − 3%.
Diagnosis of CIPA was regarded as proven in 12% of cases, probable in
67%, and possible in 21%.
Patients were treated with amphotericin B (64%), itraconazole (66%),
voriconazole (52%), posaconazole (10%), caspofungin (7%) and
amphotericin B lipid complex (5%); 84% of patients received combined
therapy with 2 or more antifungals.
Twelve months overall survival of patients with CIPA was 67%. Factors
associated with mortality were lymphocytopenia, neutropenia for 30 days
or more, and concomitant bacterial infection. Prognostically favourable
factor was “crescent sign” on CT scan.
Conclusions: (1) Chronic course of IPA developed in 40% of cases.
(2) Aspergillus non-fumigatus caused 57% of CIPA cases.
P2130 Consolidation and nodular inﬁltrates on CT scans of
patients with invasive pulmonary aspergillosis correlate
with elevated BAL galactomannan levels
C. Clancy*, J. Wingard, M. Nguyen (Pittsburgh, Gainesville, US)
Background: Invasive pulmonary aspergillosis (IPA) causes signiﬁcant
mortality and morbidity in hematopoietic stem cell (HSCT) and lung
transplant (LuTx) recipients. Galactomannan (GM) levels correlate well
with fungal burden in animal models. We studied the relationship
between BAL GM levels and CT scan ﬁndings among HSCT and LuTx
recipients with IPA.
Methods: Retrospective study of HSCT and LuTx recipients at
Universities of Florida and Pittsburgh, respectively, for whom BAL GM
and CT scans were performed within one day. CT scans were read by
two investigators who were blinded to clinical data.
Results: CT ﬁndings among the 16 HSCT patients were nodules (25%),
nodular inﬁltrates (50%) and consolidation (25%). CT ﬁndings among
the 13 lung transplant recipients were nodules (31%), nodular inﬁltrates
(15%) and consolidation (54%). There was a signiﬁcant association
between a ﬁnding of nodular inﬁltrates or consolidation and positive BAL
GM index (p = 0.02). Indeed, 100% (6/6) of patients with nodules had
BAL GM <1.0, whereas 78% (18/23) of patients with consolidation had
BAL GM >1.0. Moreover, BAL GM indices were signiﬁcantly higher
among patients with consolidation or nodular opaciﬁcation (median:
3.6±1.2) than among those with nodules (median: 0.5±3.3; p = 0.02).
Overall, 56% (9/16) of HSCT patients and 69% (9/13) of LuTx recipients
died. There was no association between BAL GM and outcome of
patients.
Conclusions: Consolidation on chest CT and positive BAL GM reﬂect
high burdens of Aspergillus. Lesions associated with earlier or localized
stages of IPA, such as nodules or nodular inﬁltrates, are likely to cause
lower burdens of Aspergillus and lower BAL GM indices. Our ﬁndings
are consistent with histopathologic studies of IPA demonstrating that
consolidation is airway-invasive, with fungi found deep in the vicinity
of the airway basement membrane.
P2131 Are community-acquired invasive aspergilloses preceded by
an increase of outdoor ﬁlamentous fungal load?
M.P. Brenier-Pinchart, B. Lebeau, J.L. Borel, J.L. Quesada,
M.R. Mallaret, F. Garban, J.-P. Brion, L. Molina, J.L. Bosson,
A. Tiebaut-Bertrand, R. Grillot, H. Pelloux* (Grenoble, FR)
A signiﬁcant relationship between the degree of fungal contamination
of air and surfaces in hematology wards and the incidence of invasive
nosocomial aspergillosis has been previously demonstrated. However,
numerous sporadic cases of invasive aspergillosis (IA) are acquired
outside the hospital setting.
Objectives: The objective was to prospectively study the outdoor daily
ﬁlamentous fungi (FF) spore load over a 31-month period and to compare
the FF load measured before community-acquired IA with the FF load
during days with no community-acquired IA diagnosed in our hospital.
Since the incubation period of IA is not known, three different periods
before diagnosis were analysed: 10, 20 and 30 days before IA.
Methods: During a 31-month period, the outdoor fungal spores were
daily sampled using a Burkard 7-day volumetric trap near hospital
and counted by optic microscopy. The Aspergillosis Committee of
the teaching hospital reviewed and classiﬁed IA cases using EORTC
criteria and determined the origin of acquisition; IA was considered
to be community-acquired if symptoms of IA were already present on
admission. Only patients living less than 20 kilometers from the hospital
were assessed. Mann-Whitney test was applied because of asymmetric
distribution.
Results: Twelve cases of community-acquired invasive aspergillosis were
diagnosed: 10 probable and 2 possible IA. The median of the daily
counts of fungal spores and the [25−75] range were 139 spores/day and
[33–567], respectively. The medians of the fungal load of the 95, 175,
251 days corresponding to the periods of 10, 20 and 30 days prior to IA
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occurrences were 303, 250, 217 spores/day and were signiﬁcant different
compared to 124 (p< 0,001), 124 (p< 0,01) and 123 (p< 0,01) spore/day
for the 848, 768 and 692 other days, respectively (table 1).
Conclusion: The level of outdoor FF spore load was higher before
community-acquired IA than during the periods without infections and
could potentially favor the Aspergillus contamination of immunocom-
promised patients at high risk for IA. This observation underlines the
importance of preventive measures to protect high-risk patients outside
the hospital: air control measures in a patient’s residence is not realistic
contrary to the common sense measures (using mask, avoiding places
with high-humidity and dust . . . ).
P2132 Imported AIDS-related histoplasmosis in metropolitan
France: a comparison of pre-HAART and HAART eras
V. Peigne*, F. Dromer, C. Elie, O. Lidove, O. Lortholary on behalf
of the French Mycosis Study Group
Objectives: Extrapulmonary Histoplasma capsulatum var. capsulatum
infection is rare outside endemic areas. Furthermore, clinical presenta-
tion and outcome of AIDS-related histoplasmosis are unknown in non-
endemic areas with wide access to highly active anti-retroviral therapy
(HAART).
Methods: Retrospective analysis of cases recorded at the French
National Reference Center for Mycoses and Antifungals during two
decades, pre-HAART (1st period, 1985–1994) and HAART (2nd period,
1997–2006). All adults with proven AIDS-related histoplasmosis were
included and relevant data collected. Clinical features and outcome were
compared between the 2 periods and risk factors for death were analyzed.
Results: One hundred and four patients were included (40 during the
pre-, 64 during the HAART era). Median CD4 cells count was 15/ml
(range, 1−97/ml). Diagnosis was established a mean of 62 days after onset
of symptoms, either by histopathology or direct examination (94%), or
by culture (80%). A higher proportion of patients native from Africa
(p< 0.001) with less frequent skin papules (p = 0.02) was observed at the
HAART era. Immune reconstitution inﬂammatory syndrome occurred
in 7 (11%) patients, including 2 with severe manifestations during the
2nd period. One-year overall mortality decreased from 53% during the
pre-HAART to 22% during the HAART era. Death was related to
histoplasmosis in 21 (51%) cases. Diagnosis during the pre-HAART
era and an older age were the only two independent factors associated
with death (Hazard ratio HR 0.19, 95%CI [0.01–0.39], p< 0.001 and
HR 1.72 per 10-years increase 95% conﬁdence interval CI [1.17–2.54],
p = 0.006, respectively).
Conclusion: Histoplasmosis is a rare invasive fungal infection outside
endemic areas. Its diagnosis is frequently delayed while its prognosis
improved signiﬁcantly at the HAART era.
P2133 Impact of liposomal amphotericin B on renal function in
ICU patients with increased serum creatinine level
M.C. Soriano*, M. Catala´n, A. Llorente, N. Vidart, M. Garitacelaya,
E. Maravı´, E. Ferna´ndez, F. Alvarado, M. Lo´pez, B. A´lvarez,
D. Granado, E. Quintana, P. Alvarez-Lerma (Madrid, Pamplona,
Oviedo, Santander, Alicante, Badajoz, Barcelona, ES)
Objective: To assess the effect of liposomal amphotericin B (L-AmB)
in ICU patients with increased serum creatinine (Cr) concentrations
(1.5mg/dL) at the beginning of L-AmB treatment.
Methods: A comparative retrospective and multicenter study was
conducted in two groups of critically ill patients according to serum
Cr values < or 1.5mg/dL at baseline and treated with L-AmB for at
least 3 days. Patients with renal replacement therapy before or within
48 h after starting L-AmB were excluded. The primary endpoint was
the difference in the mean Cr level at the end of L-AmB treatment
as compared with baseline. Secondary endpoints were risk factors
for nephrotoxicity and treatment-related withdrawals. Demographics,
underlying illness, APACHE II score, fungal infectious disease, risk
factors for nephrotoxicity, use of antifungals, and vital status at ICU
and hospital discharge were collected.
Results: A total of 122 patients recruited in 27 ICUs were included
(increased Cr, n = 16; normal Cr, n = 106). L-AmB was mainly selected
because of broad spectrum of the drug and hemodynamic instability of
the patients, and was given as ﬁrst-line antifungal treatment in 68.8%
and 52.8% of patients with elevated and normal Cr values, respectively.
The mean APACHE II score was 25 in patients with increased Cr
and 17 in those with normal Cr (P< 0.0010). Median duration of
L-AmB treatment was 16 and 12 days in patients with elevated and
normal Cr values, respectively, and mean dose 3.5 vs 3.9mg/kg/day.
Concomitant use of other nephrotoxic drugs, mortality rate, and length
of ICU and hospital stay were similar in both groups. Difference in
the mean serum Cr level at the end of L-AmB treatment as compared
with baseline was a reduction of 1.1mg/dl (P< 0.001). In none of the
patients (0.0%), L-AmB had to be stopped due to nephrotoxicity. In the
multivariable analysis, neutropenia was independently associated with
nephrotoxicity (odds ratio 8.6) and L-AmB doses 4mg/kg/day were
inversely associated with nephrotoxicity (odds ratio 0.5). Low number
of neutropenic patients (n = 16) make it difﬁcult to accurately estimate
risk factors of nephrotoxicity.
Conclusions: Treatment with L-AmB in critically ill patients with
impaired renal function had minimal impact on renal function
as measured by serum Cr concentration. Low doses of L-AmB
(4mg/kg/day) showed renal-protective effects.
P2134 Video-assisted thoracoscopic biopsy is feasible and safe
in adult haemato-oncology patients undergoing stem cell
transplantation or high-dose chemotherapy
M.M. Ceesay*, L. Berry, S.R. Desai, M. Marrinan, R. Deshpande,
D. Whitaker, S. Pomplun, A.G. Nicholson, H. Sikondari, J. Wade,
M. Smith, G.J. Mufti, A. Pagliuca (London, UK)
Objectives: Invasive Aspergillosis (IA) is a serious but difﬁcult diagnosis
in patients undergoing high dose chemotherapy or haematopoietic stem
cell transplantation (HSCT). For clinical trials the revised EORTC/MSG
criteria is a useful diagnostic tool but there is little data on its usefulness
in clinical practice. We set up an observational prospective cohort study
in order improve our diagnostic and management strategies using the
EORTC/MSG criteria as a diagnostic tool. We evaluated the feasibility,
safety and success of surgical biopsy in patients with suspected IA.
Methods: All study patients were prospectively recruited and followed
up for at least 4 months after chemotherapy or HSCT. During inpatient
admission twice weekly serodiagnostic surveillance was performed and
neutropenic sepsis unresponsive to second-line antimicrobials triggered
diagnostic work up for IA including computed tomography (CT). Patients
with suspected lesions on CT were referred for biopsy. Thirty one
patients underwent biopsy between 26/3/2009 and 26/11/2010.
Results: Thirty eight biopsies were performed on 31 patients (median
age 43 years [21−73y]; M/F ratio 17/14);one patient was excluded due
to specimen loss. The median duration of follow-up was 205 (115–476)
days. Fifteen patients (49%) had myeloid malignancies, 10 (32%) had
lymphoid malignancies and 6 (19%) had aplastic anaemia. At the time of
biopsy the treatment received was none in 1 (3%), immunosuppressive
therapy in 4 (11%), chemotherapy in 9 (24%), autologous HSCT in 5
(13%), and allogeneic HSCT in 18 (49%). The median (range) pre-
biopsy parameters were: platelets (supported in 78% of cases) 119 (41–
399) Hb 9.5 (6.9–13.1) and neutrophils 1.5 (0.02–7.35). The biopsy
was a video-assisted thoracoscopic (VATS) procedure in 32 (86%) cases
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(with pre-biopsy methylene-blue “targeting” in 4), palatal in 2, open
lung biopsy in 1, transbronchial in 1 and CT-guided in 1. Biopsy results,
reviewed by 2 thoracic pathologists were deﬁnitive in 14 (38%); proven
IA (4), alternative diagnosis (10). In the remaining 23 cases there were
non-speciﬁc inﬂammatory features in 20, wrong site biopsied in 2 and
procedure abandoned in 1 due to technical difﬁculties. The procedure
was well tolerated in all patients with no mortality and limited morbidity
(pain and minor pneumothorax) and no major bleeding.
Conclusion: Biopsy, especially VATS is a safe and useful diagnostic tool
which helps to guide clinical decision making and reduce unnecessary
treatment.
P2135 Diagnostic value of the 1,3-b-D-glucan test for detecting
candidaemia
L. Persijn*, A. Piette, S. Blot, K. Vandewoude, N. Brusselaers, P. Depuydt,
D. Benoit, J. Decruyenaere, D. Vogelaers, G. Claeys (Ghent, BE)
Objectives: Candidemia is a life-threatening disease, requiring early
diagnosis and treatment. Blood cultures are the golden standard for
diagnosis but may lack sensitivity. Therefore, we evaluated the diagnostic
value of the 1,3-b-D-glucan test (BG) in patients with proven candidemia.
Methods: 144 serum samples of 63 hospitalized patients with
candidemia (July 2007 till July 2009) were collected: on the ﬁrst
day of blood culture positivity for Candida species (= day 1) with
additional samples before diagnosis. As controls we selected 25 patients
with multisite Candida colonization, 25 patients with Gram-positive
bacteremia, 25 patients with Gram-negative bacteremia and 15 healthy
donors. BG measurement was performed in duplo with the Fungitell®
kit (Associates of Cape Cod).
Results:
– Results of BG in the different groups (expressed as % positive with
2 different cut-off levels) are shown in table 1.
– Sensitivity of BG for detecting candidemia was 81% for cut-off
80 pg/ml and 85,7% for cut-off 60 pg/ml. 8 patients with C. albicans
and 1 patient with C. glabrata infection had negative BG values. The
speciﬁcity was low with false-positive results ranging from 20 to 40%
in our control populations. Only in healthy donors no false-positive
results were observed.
– Considering the average epidemiologic proportion of nosocomial
Gram-positive bacteremia, Gram-negative bacteremia and candidemia,
PPV of BG for detecting candidemia was 21.9% and NPV 97.0% with
cut-off 80 pg/ml.
– In 11 patients with negative blood cultures prior to developing
candidemia, BG positivity (>80 pg/ml) preceded blood culture
positivity.
– There was no correlation between BG values and time-to-positivity of
blood cultures (Spearman’s rho = −0.094, p = 0.477).
Conclusion: Due to its low speciﬁcity BG lacks power to discriminate
between candidemia and bacteremia. Therefore its use cannot be
recommended in routine practice.
The study was supported by an unrestricted grant from MSD Belgium.
P2136 Contribution of the mannan antigen detection for the
diagnosis of invasive candidiasis in neonatal patients
L. Trovato*, P. Betta, M. Romeo, S. Oliveri (Catania, IT)
Objectives: We evaluate the use of the Platelia Candida antigen kit
for the diagnosis of invasive candidosis in pre-term infants admitted
to a neonatal intensive care unit (NICU) between January 2005 and
November 2010.
Methods: For all neonates at risk admitted to our NICU Platelia Candida
antigen kit (Bio-Rad, Segrate, Italy) has been used. The patients were
included in this study based on the availability of at least three mannan
antigen tests during their stay in the NICU. The mannan antigen test was
considered positive when at least two serum samples with mannan levels
of 0.5 ng/mL were obtained. Weekly surveillance cultures (pharyngeal
swab and faeces) from all neonates admitted over a 6-year period were
reviewed.
Results: Were included a total of 1541 patients. The overall colonization
rate was 15.3% (236/1541). Two hundred twenty-four patients were
included in this study according to the criteria used. Proven candidosis,
deﬁned in the present study as clinical signs of sepsis and positive
blood culture, was observed in 18 of 224 patients, i.e., a frequency
of 8%. Particularly, the frequency in the period 2005–2007 was 7.2%
and 9.3% in 2008–2010. Probable candidosis, deﬁned as alterations in
the laboratory parameters (quantitative C-reactive protein, leukocytosis,
neutrophilia), despite aggressive broad-spectrum antibiotic therapy for
at least 2 days and negative cultures for other microorganisms, was
observed in 26 patients. The sensitivity and speciﬁcity of the Platelia
Candida antigen test for all cases of proven and probable candidosis (44
patients) were 88.6% and 93.3%, respectively. The positive predictive
value and negative predictive value were 76.4% and 97.1%, respectively.
Particularly, during the two periods 2005–2007 and 2008–2010, the
sensibility of the Platelia Candida antigen was 92% and 84.2%
respectively. This is probably related to the increase of patients colonized
by Candida parapsilosis in the period 2008–2010 (36%) compared to
2005–2007 period (19.5%).
Conclusion: The Platelia Candida assay could be a good test for the
diagnosis of probable invasive candidosis in neonatal patients. This
is probably associated with an absence of circulating anti-mannan
antibodies, or a low concentration of circulating lectins (mannose-
binding protein). Nevertheless, it is important to note the low sensitivity
for the detection of C. parapsilosis infection.
P2137 The use of galactomannan detection in urine samples
from haemato-oncology patients at high risk of invasive
aspergillosis
L. Berry*, A. Junor, M.M. Ceesay, H. Sikondari, A. Pagliuca, J. Wade,
M. Smith (London, UK)
Objectives: Aspergillus fumigatus is a ubiquitous saprophytic fungus
capable of causing life-threatening lung infection in the immunocom-
promised, including recipients of haematopoietic stem cell or solid
organ transplants, and those with advanced HIV infection. Diagnosis
of invasive aspergillosis (IA) is problematic; delay is associated with
poor outcome. Symptoms of IA are non-speciﬁc, blood cultures usually
negative, and sputum culture has poor sensitivity and speciﬁcity; the
diagnostic yield of broncho-alveolar lavage is <30%. Galactomannan
is a cell wall component of Aspergillus spp. released during growth.
This antigen is detected in blood using the Platelia™ ELISA. It has
been proposed that screening for GM in urine may be clinically useful,
although there is little data addressing this. We studied the role of GM
testing of urine samples in a prospective cohort of haematology-oncology
patients at high risk of IA.
Methods: 405 urine samples from 49 haemato-oncology patients were
screened for the presence of GM, a mean of 8.3 samples were tested
per patient (range 1−35). Urine was tested using the Platelia ELISA
according to manufacturer’s instructions with amendments made to the
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pre-treatment stage: there were four pre-treatment conditions: 1) no pre-
treatment; 2) centrifuged at 3000rpm for 10m, followed by no pre-
treatment; 3) centrifuged and then treated as per the manufacturer’s
instructions for serum; 4) treated exactly as per manufacturer’s
instructions for serum.
Results: Pre-treatment conditions 1 and 2 gave results with higher
indices than methods 3 and 4. Applying EORTC/MSG criteria: 6, 10 and
5 patients had proven, probable and possible fungal disease, respectively,
and 28 had no evidence of fungal infection. Of 6 proven patients
2 had mould on histology but were culture-negative, 2 had invasive
aspergillosis, 1 had candidiasis and 1 fusariosis, these last 2 patients were
excluded from the analysis. From the 14 patients classiﬁed as having
proven or probable fungal disease only 5/14 (35.7%) tested positive for
the presence of GM in urine. Of the 28 patients that had no evidence of
fungal infection, 2/28 (7%) tested positive for the presence of GM. This
gives a sensitivity of 35.7% and speciﬁcity of 92.9%.
Conclusions: Although GM can be detected in urine this assay lacks
the sensitivity required to replace serum as the sample of choice for GM
detection.
P2138 Study of receptor expression and anti-Aspergillus functions
on phagocytes from healthy donors before monitoring
transplant patients
D. Aldebert, M. Hypolite, G. Bal, C. Dumestre-Perard, R. Bertini,
C. Rolland, J. Boutonnat, H. Pelloux, J.-P. Brion* (La Tronche,
Grenoble, FR)
Invasive aspergillosis is an infection for which the mortality rate is
extremely high in transplant patients (50–100%). The diagnosis is
difﬁcult and late, which often leads to delayed initiation of antifungal
treatment.
Objectives: For this reason, our objective is to follow innate immune
system rebuilding, targeted on key factors in anti-aspergillosis response,
in order to research one or more markers that could assist earlier
diagnoses of invasive aspergillosis and allow for rapid initiation of
antifungal treatment.
Phagocytes are the ﬁrst line of defense against Aspergillus. So, the
quality of phagocytic cells is important to evaluate the risk of invasive
aspergillosis in immunocompromised patients. However, the variability
in human phagocytic cell function or receptor expression which occurs
with age, gender or time is currently poorly characterized. A better
characterization of these parameters in healthy donors is essential before
a longitudinal study in patients.
This study determined the expression level of nine receptors involved in
Aspergillus immune response as well as the values of phagocytosis and
production of radical oxygen species after Aspergillus stimulation, in a
healthy adult population.
Materials: The study was conducted on 50 healthy subjects, ﬁve of
whom were followed for 1 year. For these donors, samples were collected
15 days and then 1, 2, 3, 6, 9, and 12 months after their ﬁrst sample
was taken. None of the donors had known disease or fever at the time of
the study. Thirty females and 20 males were included. Their age varied
from 22 to 64 years. This study was approved by the Ethics Committee
(CCPPRB).
Results: The expression values of the CD11b, CD11c, CD14, CD18,
CD35, CD181, CD182 and CD282 and CD284 receptors on peripheral
human monocytes and granulocytes was established (ﬁgure 1). A
heterogenous expression of the CD282 on granulocytes was observed
as CD181, CD182, CD284 on monocytes. Similarly, we observed
considerable variation in the expression of these receptors over time.
Only CD282 on granulocytes varied with sex. No variation with age
was observed. Consequently, the study of CD282 expression is delicate
for disease follow-up. Adherence of Aspergillus conidia to phagocytes
was dependent of individual, sex, age and time.
Conclusion: A better characterization of these innate immunity
parameters was necessary to develop in the future an immunologic
surveillance strategy for transplant recipients.
P2139 Cost-effectiveness analysis of two recommendations for
antifungal therapy indication in patients with persistent
febrile neutropenia
A. Martı´n-Pen˜a*, M.V. Gil Navarro, M. Aguilar-Guisado, I. Espigado,
E. Cordero, J. Pacho´n, J.M. Cisneros Herreros on behalf of the Spanish
Network for Research in Infectious Disease (REIPI)
Objective: To evaluate cost-effectiveness of antifungal therapy (AT)
indication in persistent febrile neutropenia (PFN) episodes in haema-
tological patients, selected by invasive fungal infection (IFI) risk proﬁle
and clinical criteria, recommended by Andalusian Society of Infectious
Diseases (ASID), Cisneros et al. EIMC 2005, vs. Infectious Diseases
Society of America (IDSA) recommendation, Hughes et al. CID 2002,
of universal empirical AT in all PFN episodes.
Methods: A cost-effectiveness analysis based on a decision making tree
with two different branches, each of them for a recommendation, was
performed through TreeAge Pro Suite 2009 program. In branch 1 (B1),
IDSA recommendation, probability data of indicating each AT were
taken from Lafaurie et al. CMI 2010, effectiveness and side effects (SE)
probability data for each AT were taken from clinical trial, Walsh et al.
NEJM 2004 (a). In branch 2 (B2), ASID recommendation, probability of
indicating each AT and effectiveness data, were taken from a prospective
patients serie Martı´n-Pen˜a et al. EBMT 2010. SE data was same as
in B1. The perspective of economic analysis was of Virgen del Rocı´o
Hospital (VRH) and time horizon was seven days after end of AT. Costs
considered were: purchase costs of AT for VRH, costs of SE treatment
Carnerero-Gomez et al. REES 2005. AT was considered effective when
fullﬁlled the criteria considered in clinical trial (a).
Results: In B1, 56 PFN episodes included, in all of them AT was
indicated. The effectiveness and average cost for each AT was: 0.049
and 7669€ amphotericin B deoxycholate (ABD), 0.05 and 3211€
amphotericin B liposomal (ABL), 0.34 and 5613€ caspofungin (C). In
B2, 85 NFP episodes were included, AT was indicated in 52 (61.2%). The
effectiveness and average cost of each AT was: 1 and 7660€ for ABD, 1
and 3117€ ABL, 0.5 and 4844€ for C, 0.87 and 8073€ voriconazole, 1
and 217€ ﬂuconazole. The average cost per PFN episode treated in B1
was 5403€ with a effectiveness of 38% vs. and 3723€ and 82% in B2.
Cost per unit of effectiveness in B1 was 14049€ vs. 4521€ in B2.
Conclusion: The indication of AT only in selected patients, ASID
recommendation is better cost-effective than the IDSA recommendation,
universal empirical AT in PFN episodes, avoiding over AT, saving direct
costs of AT and indirect costs of SE treatment, without a worse prognosis
in non treated patients.
Systemic antifungals: in vitro and in vivo
data
P2140 Functional characterisation of endogenous regulators of
calcineurin in Candida glabrata
T. Miyazaki*, Y. Nagayoshi, K. Izumikawa, M. Tashiro, S. Kohno
(Nagasaki, JP)
Objectives: Infections caused by the opportunistic fungal pathogen
Candida glabrata are often difﬁcult to treat due in part to its
intrinsic or rapidly acquired resistance to azole antifungals. We have
previously demonstrated that a C. glabrata mutant lacking the serine-
threonine-speciﬁc protein phosphatase calcineurin displays increased
azole susceptibility and reduced virulence, and these phenotypes are
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partially attributed to the inactivity of the downstream transcription factor
Crz1. In the present study, to further elucidate the calcineurin-signaling
pathway, we evaluated the potential roles of endogenous regulators of
calcineurin (RCN) in antifungal tolerance of C. glabrata.
Methods: The entire open reading frames of the RCN genes, RCN1
and RCN2, were deleted in C. glabrata and complemented strains were
made with a plasmid containing the corresponding wild-type gene.
Antifungal susceptibility was determined by a spot dilution assay. To
evaluate the activity of calcineurin-Crz1 signaling, the Vcx1-dependent
growth assay was performed using a Saccharomyces cerevisiae pmc1
mutant. Quantitative real-time PCR was performed to monitor the
expression level of YPS1, which is a Crz1 target gene encoding a GPI-
linked aspartyl protease, in the presence and absence of 0.03 mcg/ml
micafungin.
Results: S. cerevisiae pmc1 mutant is unable to grow under high-calcium
conditions unless calcineurin function is abolished. Overexpression
of CgRCN1, CgRCN2, ScRCN1 or ScRCN2 rescued growth of the
S. cerevisiae pmc1 mutant in the presence of 0.3 M calcium chloride,
suggesting that they have retained functional similarity regarding the
inhibitory activity on calcineurin signaling. While the C. glabrata rcn1
mutant exhibited decreased tolerance to micafungin and ﬂuconazole,
the rcn2 mutant did not display these phenotypes. In the presence of
micafungin, the expression level of YPS1 was increased approximately
fourfold in the wild-type and rcn2 strains but no induction was observed
in the rcn1 strain.
Conclusion: Rcn1 exerted both inhibitory and stimulatory effects
on calcineurin signaling, but Rcn2 displayed only inhibitory activity.
Phenotypic analyses of single and double mutants of calcineurin and
RCNs revealed that calcineurin requires Rcn1, but not Rcn2, for
antifungal tolerance in C. glabrata. Further elucidation of this important
signaling pathway will aid in the development of novel strategies for
antifungal therapy.
P2141 Functional characterisation of the Slt2-regulated
transcription factors, Rlm1 and SBF, in Candida glabrata
Y. Nagayoshi*, T. Miyazaki, K. Izumikawa, M. Tashiro, S. Kohno
(Nagasaki, JP)
Objectives: Candida glabrata has emerged as an important fungal
pathogen due to its intrinsically high tolerance to azole antifungals.
Fungal cell wall is an attractive target for new antifungal drug
development, however the molecular mechanisms of cell wall stress
response in C. glabrata are poorly understood. In Saccharomyces
cerevisiae, the Slt2 mitogen activated protein kinase (MAPK) pathway
plays crucial roles to maintain cell wall integrity, and two transcription
factors, Rlm1 and SBF (Swi4/Swi6), have been characterized as
downstream targets of the Slt2 MAPK. In this study, our objective
was to evaluate the potential roles of these molecules in environmental
stress response of C. glabrata through the characterization of mutant
phenotypes.
Methods: C. glabrata deletion strains of SLT2, RLM1, SWI4 and SWI6
were constructed using a one-step PCR-based technique. Antifungal
susceptibility was determined by a spot dilution assay. The level of Slt2
phosphorylation was assessed by Western blotting.
Results: It has been reported that loss of SLT2 results in decreased
tolerance to ﬂuconazole in S. cerevisiae and Candida albicans. The
C. glabrata slt2 mutant did not display this phenotype but exhibited
growth defects at elevated temperature and in the presence of cell wall
damaging agents (e.g. micafungin and Congo red). Although deletion
of RLM1 produced only an intermediate phenotype, overexpression of
RLM1 conferred increased tolerance to elevated growth temperature
and micafungin in the wild-type background. These results suggest
that the Slt2-Rlm1 pathway is important for tolerance to these stresses
in C. glabrata, although another downstream effector is also involved
in the slt2 phenotypes. Under the identical culture conditions, growth
of the swi6 mutant was comparable to that of the wild-type control,
and additional deletion of SWI6 in the rlm1 mutant had no additive
effect. However, Western blot analysis demonstrated that Slt2 was highly
phosphorylated in the SBF mutants even in the absence of external
stimuli, suggesting a feedback mechanism for Slt2 activation.
Conclusion: Although the regulatory mechanisms for maintenance of
cell wall integrity are complex, the results extend our understanding of
how the Slt2 signaling pathway is involved in cell wall stress response
in C. glabrata. Accumulation of these fundamental data will aid in the
development of novel antifungal therapy.
P2142 Flow cytometry: a faster method to assess the in vitro
activity of amphotericin B against Candida spp.
E.M. Gonza´lez Barbera´*, L. Cordo´n, E. Canto´n, A. Sempere, J. Pema´n,
I. Jarque (Valencia, ES)
Objective: To assess the incubation time to determine the minimum
inhibitory concentration (MIC) of amphotericin B (AMB) for Candida
species by ﬂow cytometry (FC) using FUN-1 as a metabolic marker.
Material and Methods: A total of 11 Candida albicans, 10
C. glabrata and 9 C. parapsilosis strains from blood cultures were
tested. C. parapsilosis ATCC 22019 was used as control. Dilution
method (DM) was performed according to M27-A3 document. The FC
method was based on a 4-h incubation of yeasts with two-fold dilutions
of AMB. Metabolic activity was measured with FUN-1, which binds
to nucleic acids and has a maximum ﬂuorescent emission after 30
minutes. While dead cells express diffuse yellow-green ﬂuorescence,
metabolically active cells (which incorporate FUN-1) have cilindric
intravacuolar structures that emit ﬂuorescence between 470 and 590 nm
(orange-red ﬂuorescence). Measures were performed every 30 or 60 min
depending on the strain analyzed.
MIC values were determined by the CLSI method, while the FC study
was done with comparable AMB concentrations and times. Percentage
of metabolically active cells obtained by FC was plotted versus time.
The 48-hour MIC value of CLSI was interpolated in the graphic. This
allowed to estimate the time-point at the MIC value which diminished
metabolic activity at least 90% for each strain. The average times for each
species were determined; these calculated times allowed to estimate for
each strain the value of minimum concentration of AMB that reduced
metabolic activity at least 90%. Finally, we compared this minimum
concentration with CLSI MIC.
Results: Average times were 64 (CI 95% [52−76]), 117 (CI 95% [98–
136]) and 97 (CI 95% [79–115]) minutes for C. albicans, C. glabrata
and C. parapsilosis, respectively. The same procedure was applied for
ATCC-22019 control in triplicate, providing MIC values within the range
of CLSI. All isolates were AMB susceptible by both methods. At most,
a difference in two dilutions was observed when CLSI and FC results
were compared.
Conclusions: 1) Calculated ﬂow cytometry average times allow a proper
classiﬁcation of the Candida strains as susceptible or resistant to AMB
in a shorter time compared with the CLSI method. 2) Different average
times were observed in a species-dependent pattern. 3) This study could
be the beginning to establish the ﬂow cytometry reading times, but larger
studies are warranted to assure its usefulness.
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P2143 Antifungal activity of echinocandins against isolates of
Candida parapsilosis, Candida metapsilosis and Candida
orthopsilosis
I. Miranda-Zapico*, E. Eraso, J.L. Herna´ndez Almaraz, A.J. Carrillo
Mun˜oz, J.M. Herna´ndez Molina, G. Quindo´s (Bilbao, Barakaldo,
Barcelona, Ma´laga, ES)
Candida parapsilosis forms a complex composed of three genetically
distinct groups that have been recognized as separate species:
C. parapsilosis sensu stricto and the two newly described species,
Candida metapsilosis and Candida orthopsilosis. C. parapsilosis is
usually susceptible to antifungal agents, but there are recent reports
of clinical isolates with decreased susceptibility to echinocandins, and
differences in antifungal susceptibility among the 3 species have been
observed. The antifungal susceptibility proﬁle of these new species is
of clinical relevance as may inﬂuence the therapeutic choices for these
infections.
Objective: To compare the in vitro activities of anidulafungin (ANF),
caspofungin (CAS) and micafungin (MIF) against clinical isolates of
C. parapsilosis, C. orthopsilosis and C. metapsilosis.
Methods: In vitro activities of 3 echinocandins were assessed by
Sensititre YeastOne 09 (Trek Diagnostics Systems, USA) against 117
C. parapsilosis (72 blood isolates and 45 isolates from other origins), 11
C. metapsilosis and 11 C. orthopsilosis from different anatomic origins.
Isolates were categorized as susceptible (S) and non susceptible (NS)
according to the CLSI M27-A3 and S3 supplement documents.
Results: ANF and MIF were more active against C. orthopsilosis and
C. metapsilosis than against C. parapsilosis (p< 0.001). ANF MIC90
values were 1, 0.5 and 2 mg/ml, and the mean values of MIC were
0.354, 0.182 and 1.245mg/ml for C. orthopsilosis, C. metapsilosis
and C. parapsilosis, respectively. MIF MIC90 values were 0.5, 0.5
and 2mg/ml, and the mean values of MIC were 0.193, 0.182 and
1.092mg/ml respectively. CAS was the most active echinocandin against
C. parapsilosis with MIC90 and mean MIC values of 1 and 0.455mg/ml.
CAS MIC90 was 0.5mg/ml for C. orthopsilosis and C. metapsilosis,
and the mean MIC values were of 0.249 and 0.170mg/ml, respectively.
However, 1 C. parapsilosis isolate from blood and other one from mouth
were NS to MIF (MICs = 4mg/ml). Moreover, 1 C. parapsilosis isolate
from skin was inhibited only by ANF MICs 4mg/ml.
Conclusion: Echinocandins were more active in vitro against C. metap-
silosis and C. orthopsilosis than against C. parapsilosis.
Funding: Projects GIC07 123-IT-222 and S-PR09UN01 (Gobierno
Vasco) and PI061895/2006 (FIS, Gobierno de Espan˜a).
P2144 Echinocandin susceptibility of Candida blood stream
isolates collected during a one-year period in Sweden
M. Axner-Elings, S. Botero-Kleiven, R. Jensen, V. Fernandez,
M. Cavling Arendrup* (Solna, SE; Copenhagen, DK)
Objectives: To investigate the susceptibility to echinocandins for
Swedish blood stream isolates.
Methods: Susceptibility to the echinocandins anidulafungin, caspofun-
gin and micafungin was determined using the Etest for 238 clinical
bloodstream isolates of Candida species collected between September
2005 and August 2006. The isolates represent approximately 95% of all
non-albicans Candida bloodstream infections and a third of C. albicans
bloodstream infections during this one year period in Sweden. Species
distribution was as follows: 81 (34.0%) C. albicans, 81 (34.0%)
C. glabrata, 36 (15.1%) C. parapsilosis, 14 (5.9%) C. dubliniensis, 8
(3.4%) C. tropicalis, 8 (3.4%) C. lusitaniae, 5 (2.1%) C. krusei, 2 (0.8%)
C. guilliermondii, 2 (0.8%) C. inconspicua and 1 (0.4%) C. pelliculosa
isolate. Sequencing of the FKS gene was done for isolates with elevated
MICs.
Results: The MICs were largely consistent with the global epidemiology
of bloodstream Candida isolates reported in the literature. All C. albi-
cans, C. glabrata and C. krusei isolates were susceptible according to the
revised CLSI breakpoints (S: MIC 0.25mg/l, R: MIC1mg/l for these
species, except for micafungin and C. glabrata: S: MIC 0.06mg/l,
R: MIC 0.25mg/l). Resistance (MIC 8mg/l) was observed for 4
(11.1%) of the C. parapsilosis isolates with anidulafungin (but not
caspofungin or micafungin). Decreased susceptibility to anidulafungin
(MIC24h values of 4 and 8mg/l and MIC48h values of 16 and 32mg/l)
was also observed for one of the two C. guilliermondii isolates but not
to caspofungin or micafungin. One of the eight C. tropicalis isolates
had MIC values that were suggestive of resistance (MIC 1mg/l) for
anidulafungin and caspofungin but 0.5mg/l for micafungin. This isolate
harbored a heterozygous FKS1 hot spot mutation (S80S/P) known to
confer echinocandin resistance.
Conclusion: Acquired echinocandin resistance is rare in Sweden but
has now been demonstrated for the ﬁrst time. Echinocandin Etest MICs
against C. parapsilosis and C. guilliermondii were lowest for micafungin.
P2145 Use of proposed species-speciﬁc CLSI breakpoints to
interpret anidulafungin MIC values. Results from three
regional clinical studies of anidulafungin for the treatment
of candidamia/invasive candidiasis
P. Hogan*, P. Biswas (New York, US)
Objectives: Pooled analyses of anidulafungin minimum inhibitory
concentration (MIC) and clinical response data for 403 patients from
three regional clinical trials were performed. These data provide a unique
opportunity to assess the ability of the proposed anidulafungin Clinical
Laboratory Standards Institute (CLSI) interpretive criteria to predict
clinical outcome.
Methods: MICs were determined by CLSI broth microdilution as
described in M27. Proposed CLSI interpretive criteria for anidulafungin
were applied to interpret susceptibility data for baseline isolates from
three open-label, non-comparative trials conducted in the US, Europe and
Asia. Neutropenic and non-neutropenic patients with albicans and non-
albicans Candida infections were treated with anidulafungin for at least
5 days followed by oral azole therapy with ﬂuconazole or voriconazole.
Clinical response was assessed by the investigator at the end of treatment
visit in the modiﬁed intent-to-treat population.
Results: The majority of anidulafungin MICs for non-C. parapsilosis
spp. were 0.25 mcg/mL. Clinical response data were available for 13
isolates with MICs above the susceptible species-speciﬁc breakpoint;
7/13 (54%) success, 4/13 (31%) failure and 2/13 (15%) unknown clinical
response compared to 287/390 (74%) success, 32/390 (8%) failure and
71/390 (18%) unknown clinical response for susceptible isolates.
Conclusions: For this collection of clinical isolates, clinical failure
occurred more frequently in patients infected with non-susceptible
isolates compared to patients with susceptible isolates as deﬁned by
proposed species-speciﬁc CLSI breakpoints for anidulafungin.
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P2146 In vitro activities of voriconazole, caspofungin and
amphotericin B against clinical Candida krusei isolates by
the time-kill method
N. Kiraz*, Y. O¨z (Istanbul, Eskisehir, TR)
Objectives: C. krusei is inherent resistant to ﬂuconazole and hence it
is an important problem especially for immunocompromised patients.
Amphotericin B (AMB) and voriconazole (VOR) act to the fungal
membrane ergosterol via different mechanisms, and caspogungin (CAS)
acts on the cell wall 1,3-b-D-glucan. We evaluated the in vitro antifungal
activity of clinical C. krusei isolates to voriconazole, caspofungin and
amphotericin B by time-kill method in the present study.
Methods: Thirty C. krusei isolates from various clinical samples were
included in this study. Minimal inhibitory concentration (MIC) values
of three antifungals were determined by reference CLSI M27-A2 broth
microdilution methods. The time-kill tests were performed at 1/4x MIC,
1x MIC ve 4x MIC for all isolates.
Results: MIC values were 0.25–0.50mg/ml for VOR, 1.0−2.0mg/ml
for AMB and 0.25−1.0mg/ml for CAS in broth microdilution tests.
VOR exhibited concentration-independent fungistatic activity against all
isolates in time-kill tests. AMB showed entirely dose-dependent activity;
it was fungistatic at 1/4−1 MICs for all isolates and fungicidal at 4x
MIC for 26 isolates (86.6%). Also efﬁciency of CAS was concentration-
dependent; it was fungistatic at 1/4x MIC (73.3%) and fungicidal at
1−4x MIC (86.8–96.6%, respectively) in general.
Conclusion: VOR, CAS and AMB were in vitro effective against
C. krusei isolates. Although VOR was concentration-independent
fungistatic effective, AMB and CAS exhibited entirely concentration-
dependent activity; CAS had the most performance among these three
antifungal agents.
P2147 Efﬁcacy of amphotericin B and caspofungin in a murine
model of disseminated candidiasis caused by Candida
albicans and Candida glabrata pre-exposed in vitro and in
vivo to ﬂuconazole
R. Lo´pez-Rojas*, J. Domı´nguez-Herrera, F. Docobo-Pe´rez,
M. McConnell, J.M. Cisneros Herreros, J. Garnacho Montero,
J. Pacho´n (Seville, ES)
Objectives: There are in vitro and in vivo data showing antagonism
between ﬂuconazole (FLU) and amphotericin B (AMB) when Candida
albicans is ﬁrst exposed to FLU, due to the depletion of membrane
ergosterol. Our objective is to study the effect of in vitro and in vivo pre-
exposure to FLU in C. albicans and C. glabrata on the efﬁcacy of AMB
or caspofungin (CAS), in a murine model of disseminated candidiasis.
Methods: We used C. albicans 0111 (Ca11) and C. glabrata
0112 (Cg12) clinical strains, AMB, FLU, and CAS antifungals, and
BALB/c mice. In vitro studies: minimum inhibitory and fungicidal
concentrations (MIC and MFC), and time-killing curves with and
without pre-incubation with FLU were performed. In vivo studies:
the minimum lethal dose (MLD) of each strain was calculated in a
murine model of disseminated candidiasis. In infected animals, we
performed pharmacokinetics/pharmacodynamics (PK/PD) of antifungals
to establish the treatment doses. Finally, we assessed the efﬁcacy of
treatment with AMB or CAS against Candida strains with or without
pre-incubation in vitro with FLU, or in animals that received a dose of
FLU previous to treatment.
Results: MICs (mg/L) for Ca11: AMB, 0.5 and CAS, 0.5; for Cg12:
AMB, 1 and CAS, 0.25. MFCs (99.9% inhibition, mg/L) for Ca11:
AMB, 1 and CAS, 1; for Cg12: AMB, 1 and CAS, 2. In time-kill curves,
when the strains were not pre-exposed to FLU, AMB showed fungicidal
activity with the three studied concentrations for Ca11. CAS showed a
concentration-dependant fungal decrease without reaching 3 logs. For
Cg12, the activity was similar but reaching fungicidal activity with
4xMIC of CAS. When the strains were pre-exposed to FLU, activities
of AMB and CAS were lower and delayed in time. MLD (Log CFU) of
Ca11 and Cg12 were 6.5 and 8.3, respectively. The PK/PD results showed
that the dose used in animals that resemble human parameters were 2
and 0.4mg/Kg for AMB and CAS, respectively. In treatment groups
without pre-incubation, both antifungals were effective decreasing kidney
concentrations of Ca11 and Cg12. Results were similar when strains
were pre-incubated in vitro with FLU. With the in vivo pre-incubation
with FLU (sequential treatment), both drugs were equally efﬁcacious,
although the decrease in tissue fungal concentrations was lower.
Conclusion: Treatment with AMB and CAS were effective against
C. albicans and C. glabrata in a murine model of systemic candidiasis,
regardless of the pre-exposure to FLU of the strains.
P2148 Antifungal susceptibilities of Aspergillus fumigatus and
sequence of the cyp51A gene of azole-resistant isolates in
Nagasaki, Japan
M. Tashiro*, K. Izumikawa, N. Hosogaya, T. Takazono, Y. Morinaga,
Y. Imamura, T. Miyazaki, M. Seki, H. Kakeya, Y. Yamamoto,
K. Yanagihara, T. Tashiro, S. Kohno (Nagasaki, JP)
Objectives: Azole resistance of Aspergillus fumigatus is one of the
concerns in treatment of aspergillosis. Epidemiology of azole resistance
has been reported in some countries in recently. We examined MIC
distributions for A. fumigatus and analyzed cyp51A gene mutations of
azole-resistant isolates in Nagasaki, Japan.
Methods: Between January 1994 and April 2010, a total of 212 isolates
of A. fumigatus were obtained from the Pneumology Department of
Nagasaki University Hospital. The isolates were identiﬁed based upon
macroscopic and microscopic morphological characteristics following
standard mycological procedures. All isolates were screened for growth
at 48ºC, thus conﬁrming A. fumigatus. The large-subunit RNA gene
(D1-D2 region) and internal transcribed spacers 1 and 2 (ITS1 and ITS2
regions) were sequenced for molecular identiﬁcation of all azole-resistant
A. fumigatus. The MICs of amphotericin B, micafungin, itraconazole
and voriconazole were determined by using the Clinical and Laboratory
Standards Institute M38-A2 reference method. The full sequence of the
cyp51A gene was determined.
Results: Of 212 clinical isolates, nearly all isolates (98.1%) had a
MIC 1mg/L to amphotericin B, and 98.6% had a MEC 0.015mg/L
to micafungin. The distribution of azole MICs were as follows:
itraconazole, <2mg/L, 177 (83.5%); = 2mg/L, 13 (6.1%); 4mg/L, 22
(10.3%); and voriconazole, <2mg/L, 184 (86.8%); = 2mg/L, 15 (7.1%);
4mg/L, 13 (6.1%). The frequency of azole resistance did not change
from1994 to 2010. Of the 22 itraconazole-resistant isolates, 10 (45.5%)
were cross-resistant to voriconazole. Of 23 azole-resistant isolates, 10
(43.5%) isolates had one or two point mutation and 13 (56.5%) isolates
had no mutation in cyp51A gene. The mutations G54E, G54R, G54W,
C239S, C239Y and I266N of cyp51A were found. Three azole-resistant
isolates had two mutations of G54 and I266N.
Conclusion: Azole-resistant A. fumigatus were exists in Nagasaki, Japan
same as other countries. However, the proﬁle of cyp51A mutations was
differed from other countries. The frequency of cyp51A mutation and
other unknown resistant mechanism may be different between regions.
P2149 Genotyping and cyp51A sequencing of consecutive
Aspergillus fumigatus isolates suggest in vivo as well as ex
vivo origin of azole resistance
R. Jensen*, K. Mortensen, S.J. Howard, H. Leatherbarrow,
E. Mellado, H.K. Johansen, M. Skov, T. Pressler, M. Cavling Arendrup
(Copenhagen, DK; Manchester, UK; Madrid, ES)
Objectives: We analysed the cyp51A gene and performed genotyping
of consecutive Aspergillus fumigatus isolates from cystic ﬁbrosis
patients (CF) harbouring azole resistant isolates in order to explore the
mechanism of resistance development.
Methods: A. fumigatus isolates were collected over a 2-year period from
CF patients. Itraconazole screening agar (4mg/L) was employed for the
detection of azole resistant isolates. Isolates growing on the screening
agar were susceptibility tested following the EUCAST methodology and
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the cyp51A gene was sequenced. Both susceptible and resistant isolates
from patients harbouring resistant isolates were genotyped by the short
tandem repeat assay (de Valk, H.A., JCM 2005).
Results: A total of 6/133 patients (4.5%) harboured azole resistant
A. fumigatus isolates (range, 1 to 9 resistant isolates per patient).
Five different mutations or combinations hereof were found in the
cyp51A gene (M220K, TR-L98H+S297T+F495I, M220I+V101F, and
Y431C, respectively) (Table). Genotyping of 29 isolates from these
patients revealed the following epidemiologically signiﬁcant trends: 1)
Microevolution in the short tandem repeat markers was observed for
A. fumigatus isolates received consecutively over a two year period;
2) Susceptible and resistant isolates (not involving the TR+L98H
combination) of identical or very closely related genotypes were found
in two patients. 3) Two related susceptible isolates and a third resistant
isolate with a unique genotype and the TRL98H resistance combination
were detected for one patient.
Conclusion: Genotyping of consecutive A. fumigatus isolates from
Danish CF patients demonstrated long-term carriage of the same isolate
as well as concomitant or sequential presence of several genotypes.
Molecular microevolution occurred not only in the short tandem repeat
markers but also in the cyp51A gene conferring azole-resistance
suggesting in vivo evolution of resistance, whereas no susceptible isolates
were found sharing genotype with any TR−L98H isolates suggesting ex-
vivo origin of this azole resistant A. fumigatus molecular type.
P2150 Posaconazole plasma concentrations in allogeneic
haematopoietic stem cell transplant recipients
J. Winterova*, Z. Racil, L. Malaskova, M. Toskova, M. Rolencova,
J. Mayer (Brno, CZ)
Objectives: Posaconazole (POSA) is a broad spectrum azol antifungal
used in treatment and prophylaxis of invasive fungal infection. POSA
exhibits variability in plasma concentration, due to its different
bioavailability and potential drug interactions.
Methods: POSA plasma concentrations were measured using a
high performance liquid chromatography assay. Retrospective analysis
of laboratory results and documentation from patients undergoing
allogeneic hematopoietic stem cell transplantation treated with POSA
from November 2006 to November 2010 in our institution was
performed.
Results: 81 plasma samples from 13 patients were analyzed, 1−17
samples per patient. POSA plasma concentration was monitored 3–
204 (median 43) days after start of POSA treatment. POSA was
administered in 68% as prophylaxis, in 24.5% as preemptive antifungal
treatment, in 2.5% as an empirical antifungal therapy and in 5% as a
treatment of invasive fungal infection. POSA was administered as an oral
suspension divided in 2−4 portions, the standard daily dose was 600 or
800mg, in 2 patients was an individal dosing 480mg and 960mg daily.
After 600mg daily the plasma concentration was 0.21−4.7mg/ml. The
POSA plasma levels varied between 0.21–2.86mg/ml and 0.2–1.14mg/ml
after 4x 200mg and 4x 200mg, respectively. In 27% (n = 22) of all
samples the POSA concentration did not achieved 0.5 mg/ml, which could
be ineffective and the the antifungal treatment could be insufﬁcient.
In this analysis there is no correlation between the daily dose and
achieved POSA plasma concentration. Low POSA plasma levels after
4x 200mg could be due to more frequently diarrhea and other lesion of
gastrointestinal tract. The results are in table 1.
Conclusion: Measurement of POSA plasma levels during its treatment
enables to optimize the individual dosing and improve the response to
antifungal treatment in high risk haematological patients after allogeneic
hematopoietic stem cell transplantation.
Supported by Grant of ministry of Health, Czech Republic,
NS/10441−3/2009
P2151 Chronic Aspergillus fumigatus colonisation of respiratory
tract in cystic ﬁbrosis: diagnosis, management and antifun-
gal resistance in a French cohort of cystic ﬁbrosis patients
L. Delhaes*, A. Jourdain, M. d’Almeida-Fourquet, E. Fre´alle,
S. Leroy, C. Pinel, B. Coltey, L. Favennec, S. Dominique, O. Vagner,
A.-L. Fanton, J.-P. Bouchara, C. Person, I. Durand-Joly, G. Loeuille,
P. Domblides, I. Accoceberry, A. Farce, P. Chavatte, B. Wallaert (Lille,
Bordeaux, Grenoble, Rouen, Dijon, Angers, Dunkerque, FR)
Introduction: Cystic ﬁbrosis (CF) is the major genetic inherited disease
in the European Caucasian population, with an average of 1 in 3000
living births in France. Prognostic depend essentially on the lung
impairments. While considerable attention therefore has been paid over
recent decades to prevent and treat bacterial respiratory infections,
we observed emergence of fungi colonization in CF respiratory tract.
In particular, Aspergillus fumigatus represents the most common
causative agent colonizing the airways of CF patients; it can be
responsible for Allergic Bronchopulmonary Aspergillosis (ABPA). Since
oral corticosteroids and itraconazole represent the mainstay of ABPA
treatment, long-term therapy may increase the risk of acquired resistance
to azoles that is mainly associated with amino acid substitutions in the
CYP51A gene of A. fumigatus.
Objective: Because CF patients are chronically exposed to itraconazole,
our study aimed to evaluate the prevalence of azole resistance in
isolates prospectively collected from CF patients followed-up in seven
French hospitals involved in our national prospective study (“MucoFong”
study − PHRC1902). To our knowledge, it is the ﬁrst multicenter study
focused on azole resistance of A. fumigatus in CF.
Methods: A total of 87 isolates of A. fumigatus was collected in 85
patients. The MICs of azole drugs were evaluated for each isolate using
the E-test® strips. Isolates were characterized at the molecular level by
targeting ITS, b-tubulin and MAT-A/a genes. The cyp51A gene as well
as its promoter was sequenced.
Results and Discussion: A majority of isolates (88.1%) were found
sensitive to itraconazole (MIC 2mg/ml), and 2 new mutations were
identiﬁed and localized within 3-dimensional Cyp51A protein model.
S638 21st ECCMID/27th ICC, Posters
To obtain insight into azole resistance of A. fumigatus, the results are
analyzed taking into account clinical data, itraconazole exposition, and
the potential correlation between the identiﬁed CYP5IA mutations and
azole resistance is discussed based on the Cyp51A protein homology
model.
Supported by: PHRC 1902 − Vaincre la mucoviscidose − Pﬁzer®
Conﬂict of interest: None to declare
P2152 Role of caspofungin in enhancing chronic haemodialysed
and kidney transplant patient PMN response against
Candida glabrata
V. Allizond, G. Banche, F. Giacchino, V. Tullio*, D. Scalas, C. Merlino,
N. Mandras, J. Roana, G. Garneri, R. Patti, A.M. Cufﬁni (Turin, Ivrea, IT)
Objectives: Taking into account that in immunocompromised patients
successful resolution of fungal infections is often related to the ability of
the patient’s immune system to cooperate with drugs, this study aimed to
evaluate the potential immunomodulating activity exerted by caspofungin
on polymorphonuclear cells (PMNs) from chronic hemodialyzed (HDs)
and renal transplant patients (RTRs) against Candida glabrata, the most
common life-threatening fungal pathogen in such immunocompromised
hosts.
Methods: PMNs were separated from venous blood samples of HDs and
RTRs. The effects of caspofungin on either phagocytosis of radiolabelled
C. glabrata ﬂuconazole and voriconazole resistant strain or intracellular
fungal killing by PMNs were investigated by incubating yeasts and
phagocytes for 30, 60, 90 minutes with caspofungin at MIC level.
Caspofungin-free controls were included.
Results: A diminished phagocytic efﬁciency was found in PMNs from
HDs and RTRs, with both reduced phagocytosis and fungicidal activity
towards intracellular C. glabrata, in comparison with that of healthy
donor PMNs. As the majority of systemically acting antifungal drugs,
caspofungin did not affect phagocytosis by granulocytes. Conversely,
the fungicidal activity of PMNs from HDs and RTRs was signiﬁcantly
(p< 0.01) improved by caspofungin, resulting in increased numbers of
killed yeasts for all three incubation times compared with those of
the drug-free controls: during the 90 minute period the intracellular
blastoconidial load was reduced by 56−68% for HDs and by 58−71%
for RTRs.
Conclusion: In neutropenic high risk patients an empirical use of
caspofungin has been described in literature. We previously demonstrated
that caspofungin had beneﬁcial properties in enhancing microbicidal
functions of PMNs from healthy subjects. The data of this study indicate
that caspofungin possesses interesting immunomodulating properties that
make it highly suitable for the treatment of C. glabrata multidrug-
resistant infections in patients with impaired components of the immune
system.
P2153 Development of amphotericin B deoxycholate-induced
nephrotoxicity is associated with induction of a net
pro-inﬂammatory cytokine proﬁle
L. Chai*, L. Khin, B. Tai, A. Vonk, H. Schlamm, R. Herbrecht, P. Troke,
M. Netea, B. Kullberg (Nijmegen, NL; Singapore, SG; Rotterdam,
NL; New York, US; Strasbourg, FR; Kent, UK)
Objectives: It has been postulated that the toxic proﬁles of ampho-
tericin B deoxycholate (AmBD), especially that of infusion related reac-
tion, might be related to the drug’s propensity to induce proinﬂammatory
cytokines through Toll-like receptor (TLR) 2. Recently, induction of
proinﬂammatory cytokine production through TLRs has been implicated
as an underlying mechanism for drug-induced nephrotoxicity. To date,
this has not been studied in the clinical setting.
Methods: Circulating concentrations of interleukin (IL)-6, IL-8 and
IL-10 were measured at baseline, weeks 1 and 2 of treatment, in a
cohort of patients enrolled in a clinical trial comparing AmBD versus
voriconazole for treatment of invasive aspergillosis. Serial cytokine
trends were correlated with development of renal impairment. Renal
impairment was deﬁned as an increase in the serum creatinine level to
double the base-line value, or more than 265 mmol/L if baseline value
was higher than 133mmol/L. Univariate and multivariate Cox regression
analysis was performed to predict time to renal event.
Results: From the study cohort, 87 patients had received AmBD as
the primary therapy, among which 35 patients (40.2%) developed renal
impairment during treatment. The median time to development of renal
event was 15 days. A progressive decline of proinﬂammatory serum IL-6
from baseline through week 2 of treatment was associated with decreased
likelihood of developing renal impairment (hazard ratio 0.20, 95%CI:
0.06–0.70; p = 0.012). Conversely, persistent decreasing concentrations
of the antiinﬂammatory cytokine IL-10 between baseline and week 2
was linked to an increased risk of nephrotoxicity (hazard ratio 5.72,
95%CI 2.5–12.9, p = 0.001).
Conclusions: We suggest in a clinical setting that a state of a
net proinﬂammatory cytokine proﬁle evoked by AmBD could be
an underlying mechanism which leads to the development of drug-
induced nephrotoxicity. Targeting immune modulation towards a net
antiinﬂammatory proﬁle may be a possible strategy to reduce AmBD-
associated adverse effects, which is a major limiting factor in use of this
otherwise efﬁcacious and economical antifungal agent.
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P2154 Time-dependent sensitivity of rapid antigen test in patients
with 2009 H1N1 inﬂuenza
C.S. Lee*, J.H. Lee, C.H. Kim, E.S. Kim, B.N. Kim (JeonJu, Jeonbuk,
Goyang, Busan, KR)
Objectives: Rapid antigen tests (RAT) are used to screen patients with
suspected infuenza and provide results timely. RAT can also help to
reduce unnecessay diagnostic testing, to facilitate antiviral treament,
and to decrease inappropriate use of antibiotics. However, the clinical
sensitivity of RAT was poor for 2009 H1N1 inﬂuenza, showing an
accuracy from 11.1% to 51%. Drexler et al. have suggested that the
viral concentraions in clinical samples inﬂuence the outcome of RAT.
Thus, the collection time of the samples may be an important factor for
the accuracy of RAT.
Methods: Retrospectively, we tested 637 clinical samples from 637
different patients. Samples were collected during the pandemic 2009
H1N1 season by nasopharyngeal swab and were kept frozen at −80ºC
until use. The 120 controls were taken from H1N1 negative febrile
subjects.
The 2009 H1N1 inﬂuenza was conﬁrmed by real time reverse
transcription-PCR. The RAT was done by SD Bioline Inﬂuenza
A/B/A(H1N1) pandemic (Standard Diagnostics, Yongin, Korea). The
RAT has 4 lines for the detection of 2009 H1N1, inﬂuenza A, inﬂuenza
B, and controls, and distinguishes between seasonal inﬂuenza virus and
2009 H1N1. Samples were classiﬁed by the hours elapsed after the ﬁrst
symptoms appeared when they were collected. They were classiﬁed into
24 hours (D1), 24 to 48 hours (D2), 48 to 72 hours (D3), 72 to 96
hours (D4), and 96 to 168 hours (D5). We calculated the sensitivity
and speciﬁcity of RAT. Data analysis was performed using SPSS, version
16.0. ANOVA test and Tukey’s post hoc test were used to compare the
mean log10 viral copy numbers. The study protocol was approved by
Institutional Review Board of the Chonbuk National University Hospital.
Results: The mean age of the subject was 23.4±12.81 (male 51.0%).
The control patients had a mean age of 34.6±20.8 (male 54.3%). The
overall sensitivity and speciﬁcity of the RAT was 75.6% and 99.3%,
respectively. The sensitivity of RAT at D1, D2, D3, D4, D5 was 75.0%,
76.8%, 79.9%, 77.4%, and 67.3%, respectively (Fig 1). The log quantity
of virus copy numbers at D1, D2, D3, D4, D5 was 3.35, 3.60, 3.68, 3.46,
and 3.17, respectively (p = 0.025). Only D3 and D5 showed signiﬁcant
difference by Tukey’s post hoc test (p = 0.026). The log10 virus copy
number was increased until D3 and then decreased.
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Conclusion: Our results may help to raise the sensitivity of RAT to be
used during the inﬂuenza seasons.
P2155 Clinical performance of a rapid antigen detection test for
pandemic inﬂuenza A/H1N1
M. Selleri*, S. Meschi, E. Lalle, F. Ferraro, V. Puro, F.N. Lauria,
M.R. Capobianchi (Rome, IT)
Objectives: Recently, the clinical performances of rapid inﬂuenza
antigen detection test (RIDT) have been evaluated during the inﬂuenza
pandemic A/H1N1 (A/H1N1pdm). In particular, according to several
studies, RIDT sensibility is highly variable (range 10−70%), while
speciﬁcity is generally high (range 86–100%).
The aim of the study was to evaluate the clinical performances of
BinaxNOW Inﬂuenza A&B for inﬂuenza A/H1N1pdm with respect to
the real-time RT-PCR method established by CDC during the inﬂuenza
A/h1N1pdm 2009 pandemic.
Methods: Between April-November 2009, nasopharyngeal swabs from
662 consecutive suspect cases of inﬂuenza A/H1N1pdm were tested
with BinaxNOW Inﬂuenza A&B rapid test. Nucleic acids were tested
with the CDC molecular method, using pan-inﬂuenza A, swine inﬂuenza
A-speciﬁc and A/H1N1pdm-speciﬁc primer/probe sets, targeting M, NP
and H genes, respectively. Samples positive only to pan-inﬂuenza A were
subtyped with H1N1 and H3N2 type-speciﬁc RT-PCR, as well as with
A/H1N1pdm NP-speciﬁc RT-PCR, followed by nucleotide sequencing.
Viral load (VL) in the pan-inﬂuenza A-RT-PCR-positive samples was
calculated by plotting the M gene cycle threshold values on a regression
curve, built on a standard inﬂuenza A/H1N1pdm preparation, containing
a known genome-equivalent concentration.
Results: 260/662 (39.3%) cases, resulted positive to the pan-inﬂuenza A
RT-PCR: 234 (90%) were typed as A/H1N1pdm, 6 (2.3%) as H3N2 and
20 (7.7%) remained untypable. Rapid test resulted positive in 47/260
pan-inﬂuenza A RT-PCR-positive cases and in one of 402 RT-PCR-
negative samples (overall sensitivity 18.1%, speciﬁcity 99.7%, PPV
97.9%, NPV 65.3%). Sensitivity for A/H1N1pdm conﬁrmed cases was
17.3% (44/254) and 50.0% (3/6) for H3N2. Median VL was 6.9 (IQR
6.3−7.3) and 5.1 (IQR 3.9−5.6) M gene Log cp/mL for RIDT-positive and
negative cases, respectively (p< 0.0001). among RIDT.positive samples,
92.1% showed VL values exceeding 6.0 M gene Log cp/mL.
Conclusions: The present study shows that RIDT has low sensibility and
high speciﬁcity for A/H1N1pdm, in agreement with previous reports. In
particular, A/H1N1pdm viral load seems to be the major determinant
for positive result in RIDT. Negative RIDT results should not be the
basis for excluding inﬂuenza A/H1N1pdm diagnosis, and samples from
suspect cases negative to RIDT should be analyzed with more accurate
methods.
P2156 Evaluation of a new rapid test for inﬂuenza A and B
viruses detection and pandemic A/H1N1 2009 inﬂuenza
virus subtyping in respiratory samples
N. Leveque*, D. Talmud, F. Renois, C. Barbe, L. Andreoletti (Reims, FR)
Background: Recent studies highlighted the poor performances of the
commercially available Rapid Inﬂuenza Diagnostic Tests (RIDT) for
the pandemic A(H1N1)2009 inﬂuenza virus detection and the lack of
subtyping of this emerging strain by this method.
Objectives: To assess the performances of a new RIDT (ONE
STEP Inﬂuenza virus A/B/A(H1N1) Pandemic RAPID TEST, Bioline,
Standard Diagnostics) for inﬂuenza A and B viruses detection in
association with pandemic A(H1N1)2009 inﬂuenza virus subtyping in
nasopharyngeal samples.
Study design: Fifty-six nasopharyngeal samples positive for the
pandemic A(H1N1)2009 inﬂuenza virus, 40 samples positive for
seasonal inﬂuenza A or B viruses and 10 negative respiratory samples
were retrospectively tested. Moreover the viral load was quantiﬁed for
each inﬂuenza A positive specimen by a M gene speciﬁc real-time RT-
PCR assay (rRT-PCR).
Results: For the pandemic A(H1N1)2009 inﬂuenza virus detection, this
new RIDT showed 39.3% sensitivity and 100% speciﬁcity comparatively
to rRT-PCR assay. The cut-off level of 2.4×104 copies/mL established
using receiver operating characteristics analysis demonstrated sensitivity
and speciﬁcity of 86.4% and 62.5%, respectively. Moreover the RIDT
performances appeared to be signiﬁcantly better for seasonal A and
B inﬂuenza viruses than for pandemic A(H1N1)2009 inﬂuenza virus
detection since the sensitivity was 53.3% and 50% for inﬂuenza A and
inﬂuenza B, respectively.
Conclusion: The low sensitivity of this new RIDT for pandemic
A(H1N1)2009 inﬂuenza virus diagnosis from clinical samples indicates
that negative or positive results for seasonal inﬂuenza A viruses should
be necessarily checked by a reference rRT-PCR assay for inﬂuenza A
virus detection and subtyping.
P2157 Performance evaluation of a new ELISA test detecting
inﬂuenza A/H1N1pdm-speciﬁc IgG and IgA
C. Castilletti, D. Lapa*, P. Marsella, M.R. Capobianchi (Rome, IT)
Objectives: Serological diagnosis of inﬂuenza A is mainly based on
inhibition of hemagglutination assay, this test shows strong variability,
depending on several technical issues. An IgG/IgA ELISA test, speciﬁc
for A/H1N1pdm, has been established whose performances have been
evaluated, in comparison with reference serological tests.
Methods: Paired acute and convalescent sera from patients (n = 20)
with RT-PCR conﬁrmed A/H1N1pdm infection were tested with this
assay produced by Genzyme Virotech GmbH and supplied by Grifols
Italia Spa. In addition, stored residual sera, collected in September 2008
(n = 24) and in February 2010 (n = 50), after the inﬂuenza peak in Italy,
were used.
In order to eliminate crossreacting antibodies, all the sera were pre-
adsorbed with the seasonal inﬂuenza strains. The results were classiﬁed
as positive, negative or borderline, and the borderline results were
combined with the negative ones.
As reference tests, HAI and Complement Fixation tests were used.
The antigen used in both HAI and CF assays was an UV-inactivated
A/H1N1pdm virus and sera were considered positive if both HAI and
CF titers were 1:10, or if either HAI or CF titers were 1:20.
Results: According to the results from HAI and CF tests, 95.0% of the
conﬁrmed infections were IgG positive, and 45.0% IgA positive in the
convalescent phase.
All conﬁrmed infections were IgG ELISA-positive, and 15.0% of the
baseline sera were IgG positive.
When considering the retrospective ’08 and ’10 sera collections, 16.6%
and 44.0% were reference tests-positive; 33.3% and 52.0% resulted
positive by IgG ELISA, with a concordance of 83.3% and 76.0%.
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Based on reference tests, IgG ELISA sensitivity was 93.0% and
speciﬁcity was 74.5%. Interestingly, 8.2% of post-pandemic sera, who
resulted positive by the reference criteria, yielded an IgG ELISA
borderline result.
Regarding IgA, 12.5% and 14.0% of samples resulted positive in ’08
and ’10 collections respectively.
Conclusions: These results suggest that the new IgG ELISA test is
very sensitive in detecting speciﬁc immune response in patients with
conﬁrmed infection, and may be useful for the serological diagnosis
of A/H1N1pdm infection, and to assess the individual response to
A/H1N1pdm vaccination.
Considering the retrospective groups, sensitivity and speciﬁcity of IgG
ELISA with respect to the reference tests are suboptimal, as expected.
The signiﬁcance of IgA in recent or remote infections, and in vaccine
response, remains to be established.
P2158 Study of norovirus infection from stool samples in transplant
recipients or intensive care unit patients from a children’s
hospital with an antigen detection enzyme immunoassay test
A.M. Mehlis*, Z. Rentero, S. Garcia-Bujalance (Madrid, ES)
Objective: The aim of this study was to evaluate the results obtained with
the commercial antigen detection enzyme immunoassay RIDA® QUICK
Norovirus, in comparison with the results obtained with conventional
reverse-transcriptase polymerase chain reaction (RT-PCR), regarded as
the gold standard, for detecting norovirus in stools samples from
transplant recipients or intensive care unit (UCI) patients in a children
hospital.
Methods: RIDA®QUICK Norovirus assay was performed on a total of
33 stool samples from 22 patients. The patients’ age ranged from 6
months to 3 years, 14 patients were males and 8 females. Samples were
collected from January to August of 2010. Each sample was prepared for
testing by RT-PCR (Kojima et al.,J Virol Methods, 2002, 100:107–114)
according to validated laboratory protocols.
Results: During the study period 16 samples from ﬁve patients with
norovirus were detected by RT-PCR. Of these samples, 10 were also
detected with the RIDA® QUICK Norovirus assay. Six cases of norovirus
infection were not detected by the RIDA® QUICK Norovirus. With these
results the calculated sensitivity of the RIDA®QUICK Norovirus, in this
study, was 63% and the speciﬁcity was 100%. As a consequence the
calculated negative predictive value was 74% and the positive predictive
value was 100%.
Conclusion: The RIDA®QUICK Norovirus can be used as a rapid
and simple ﬁrst test in cases with suspected norovirus aetiology of a
diarrhoeae in children transplant recipients or hospitalized in the ICU.
If the result is negative, the RT-PCR is recommended.
P2159 Comparison of Epstein-Barr virus tests on Immulite with
Enzygnost/Novagnost tests
I. Verstreken, K. Lagrou* (Louvain, BE)
Objectives: The aim of the study was to compare the performance
characteristics of different Epstein-Barr Virus (EBV) tests (EBV-VCA
IgG, EBV-VCA IgM, EBV-EBNA IgG) available on the random
access analyzer IMMULITE (Siemens, Germany) with Enzygnost Anti-
EBV/IgM II, Enzygnost Anti-EBV/IgG and Novagnost EBV-EBNA IgG
ELISA tests performed on BEPIII (Siemens).
Methods: A total of 400 sera, collected at the University Hospitals
Leuven, were evaluated on both analyzers. A ﬁrst group contained
200 sera from hospitalized patients. The majority had a past EBV
infection, sixteen were seronegative and none experienced a primary
EBV infection. To compare the sensitivity for the detection of primary
infection, 100 sera from patients with a primary EBV infection were
included. Finally to investigate cross reactivity, we selected 100 sera: 20
sera positive for CMV IgM, 20 sera positive for Toxoplasma IgM, 20
sera positive for rheumatoid factor and 40 sera of pregnant women. In
case of test discrepancies, additional Mikrogen recomLine EBV IgM/IgG
immunoblot (Mikrogen, Germany) was performed for ﬁnal classiﬁcation
of a specimen.
Results: In the ﬁrst group (n = 200) the speciﬁcity of the EBV-VCA IgM
test on IMMULITE was 97.5%, compared to 100% with the Enzygnost
Anti-EBV/IgM II kit. Sensitivity of the IMMULITE EBV VCA IgG test
was very good (98.5%) and excellent (100%) for the Enzygnost IgG test.
The correlation between the IMMULITE EBV-EBNA IgG, EBV VCA-
IgG and EBV VCA-IgM tests were respectively 98%, 98% and 94.5%
with the corresponding Novagnost and Enzygnost kits. The correlation
for positive sera was 94.2% for the EBNA-IgG and 95.1% for the VCA
IgG determination. Detection of a primary EBV infection was moderate
on IMMULITE with a sensitivity of 82.3%. There was no cross reactivity
due to CMV IgM, Toxoplasma IgM, rheumatoid factor and pregnancy.
Five samples showed a secondary reactivation which was only detected
on IMMULITE.
Conclusion: The different immunoassays on both analyzers have
acceptable and comparable performance characteristics with exception of
the IMMULITE IgM test which was less sensitive than the Enzygnost
IgM test. As such, sensitivity of IMMULITE for the detection of a
primary EBV infection was only moderate (82.3%).
P2160 Evaluation of new extremely rapid Epstein-Barr virus
VCA-IgG, EBNA-1-IgG and VCA-IgM assays using
immunoﬂuorescence as reference
B. Gaertner*, A. Halfmann, E. Heinzel (Homburg, DE)
Objectives: EBV speciﬁc serology is required to diagnose or exclude
an infectious mononucleosis (IM). It is mostly tested with time-
consuming methods often requiring speciﬁc instruments such as EIA,
immunoﬂuorescence (IFA) or blots.
The new Bio-Rad RDT EBV IgG and IgM Assays based on
immunoﬁltration are evaluated using an in-house IFA as reference
(German EBV Reference Center). The new assays provide results to
VCA IgG, EBNA-1 IgG and EBV IgM within 2 min and require no
speciﬁc instruments.
Methods: 340 clinical characterized samples were tested including 59
from patients with acute IM, 60 past EBV infection, 60 seronegative,
62 potential cross-reactive samples (CMV-, VZV-, HSV-IgM positive),
and samples from patients with immunosuppression due to rheumatic
disorders (51) or lung transplantation (48).
Results: The new rapid assays showed a high concordance with the
reference assay similar like conventional EIA or IFA (see table). The 10
out of 11 false positive VCA-IgM tests were found within the potential
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cross-reactive samples. However, most of these samples similarly had
a high positive EBNA-1 IgG and thus require further test methods.
Similarly, majority of false positive EBNA-1-IgG was extremely weak
and found within the primary infections in combination with a high
positive VCA-IgM.
Conclusion: Our results indicate that the Bio-Rad RDT EBV IgG and
IgM assays perform excellent comparable to gold standard IFA and many
other EIAs. Additionally, Bio-Rad RDT EBV IgG and IgM Assays
provide the practicability, ease-of-use and rapidity of Mononucleosis
devices and only 2 minutes are needed to report EBV accurate proﬁle
with high level of performance. These assays can be recommended for
EBV infection and IM detection.
P2161 Analysis of the results of the SEIMC external quality control
programme in the detection of gastrointestinal viruses
N. Orta*, M.R. Guna, M. Poveda, M. Ovies, E. Ruiz de Gopegui,
J.L. Perez, C. Gimeno (Valencia, ES)
Objective: To evaluate the results obtained by participants in the
Programme of External Quality Control launched by the Spanish Society
of Infectious Diseases and Clinical Microbiology (SEIMC) in detection
of gastrointestinal viruses.
Materials and Methods: From year 2004 to year 2010 four viral
controls were sent to an average of 80 participating centers, comparing
their results with those of a reference laboratory. In all cases, stool
samples were sent with a clinical history, and participants were asked to
operate the detection of gastrointestinal viruses. The samples submitted
were positive for the following viruses: Astrovirus (2004), Rotavirus
(2007), Adenovirus (2008) and Norovirus (2010).
Results: Participation rates were 73.2% (2004), 83.1% (2007), 85.1%
(2008) and 74.7% (2010). When virus was Rotavirus or Adenovirus
more than 97% of the centers performed the necessary tests to detect
them, but if virus was Astrovirus or Norovirus only 23.7% or 59.3%
of participants, respectively used appropriate techniques to detect them.
The success rates were: 83.3% (Astrovirus), 100% (Rotavirus), 88.5%
(Adenovirus) and 45.9% (Norovirus). The most common methods used
were the immunochromatography (IC), latex agglutination (LA) and
enzyme immunoassay (EIA). With EIA techniques the success rates
were of 100.0% (Rotavirus), of 81.8% (Astrovirus), 92.2% (Adenovirus)
and 20.0% (Norovirus). In case of IC techniques, the success rates
were of 100.0% (Rotavirus) and 80% (Adenovirus). LA techniques,
only were employed for Rotavirus (success rates of 100%) and for
Adenovirus (success rates of 33%). Thus, for Norovirus, the most
common techniques with better results were the molecular biology
methods (PCR/real time PCR − success rate 100%, and sequencing −
success rate 66,7%). Astrovirus just was detected by EIA and PCR.
Conclusions: (a) There’s an increase of centers that detected virus
in feces, especially in Rotavirus and Adenovirus control due to rapid
diagnostic techniques. Norovirus and Astrovirus are those with worse
detection rates. (b) EIA techniques are particularly successful in the
detection of all viruses with the exception of Norovirus and IC
techniques obtained good results with Rotavirus and Adenovirus. AL
techniques obtained acceptable results only in Rotavirus. PCR techniques
obtained good results for all viruses. (c) There are few laboratories of all
centers registered in virology control that are trained to detect Astrovirus
and Norovirus.
P2162 VZV glycoprotein E: a novel serological antigen for the
discrimination between VZV CNS infection and HSV-1
encephalitis
A. Grahn*, E. Thomsson, M. Studahl, T. Bergstro¨m (Gothenburg, SE)
Objectives: Herpes simplex virus type 1 (HSV-1) and varicella-zoster
virus (VZV) are the most common herpes viruses causing CNS infection
in Sweden. Both these viruses are diagnosed with PCR and/or intrathecal
antibody production. Cross-reactions between HSV-1 antibodies and
VZV antibodies have been reported frequently, mostly in patients with
herpes simplex encephalitis (HSE), which have hampered the serological
diagnosis of both these viruses. In this study we have evaluated VZV
glycoprotein E (gE) as a new antigen for serological diagnosis of VZV
CNS infection.
Methods: Paired samples of cerebrospinal ﬂuid (CSF) and serum from
29 patients with clinical diagnosis of VZV CNS infection (n = 15) or
HSE (n = 14), conﬁrmed by speciﬁc PCR, were analyzed. VZV gE and
VZV whole virus were compared as antigens in ELISAs. In addition,
each CSF/serum pair was diluted to identical total IgG concentration
and tested in serological assays using VZV gE and VZV whole virus
as antigens. The intrathecal antibody production of both viruses was
calculated.
Results: When the CSF and serum samples of the patients with HSE
(n = 14) were analyzed with ELISA using VZV gE antigen, 4/14 patients
revealed intrathecal synthesis of speciﬁc antibodies to VZV, compared to
11/14 patients when analyzed with VZV whole virus antigen (P = 0,021).
This difference was even more obvious when the CSF/serum pairs were
diluted to identical total IgG concentrations. In such dilution and using
the gE antigen none of the HSE patients revealed intrathecal antibodies
against VZV, as compared to 11/14 when using VZV whole virus antigen
(P 0.001). Furthermore, only 12/15 of the originally included patients
with VZV CNS infection showed intrathecal antibody production against
VZV using VZV gE antigen, which is in accordance with the higher
speciﬁcity of this antigen.
Conclusion: VZVgE is a sensitive antigen for serological diagnosis of
VZV infection in the CNS. This antigen was devoid of cross-reaction
with HSV-1 antibodies, as judged from patients with HSE. We propose
that VZV gE can be used for serological discrimination of VZV and
HSV-1 CNS infections.
P2163 Occurrence of immunoglobulin M antibodies against several
bacterial and viral pathogens in acute hantavirus infection
N. Wellinghausen*, A. Goetz, U. Weber (Ravensburg, DE)
Objectives: Elevated immunoglobulin M (IgM) antibodies against
Coxiella burnetii and enterovirus without concurrent IgG antibodies were
detected in a patient with acute hantavirus infection of serotype Puumala.
Thus, we questioned whether detection of IgM antibodies to hantavirus
non-related pathogens was a singular case in this patient or occurs more
frequently in acute hantavirus infection.
Methods: Serum samples from 48 patients with acute hantavirus
infection of serotype Puumala collected during the hantavirus epidemic
year 2010 in Germany were available. All patients had clinical suspicion
of hantavirus infection and were positive for hantavirus-speciﬁc IgM
and IgG antibodies by immunoblot analysis. IgM and IgG antibodies
against enterovirus, Epstein-Barr-Virus (EBV), cytomegalovirus (CMV),
Coxiella burnetii, Leptospira spp., and Borrelia burgdorferi were
determined by commercial immunoassay.
Results: IgM antibodies against one or more of the investigated
pathogens were detected in 16 of 48 patients (33.3%). In detail, IgM
antibodies were positive against Coxiella burnetii in 6 patients (12.5%),
enterovirus in 5 patients (10.4%), Leptospira spp. in 1 patient (2.1%),
and CMV in none of the patients. Isolated IgM antibodies against
Borrelia burgdorferi that were not conﬁrmed by immunoblot were found
in 2 patients (4.2%). IgM antibodies against EBV were detected in 11
patients (22.9%), of whom all patients showed serological evidence of
past EBV infection indicated by IgG antibodies against EBV nuclear
antigen. Concurrent borderline or positive IgM antibodies against two or
more of the investigated pathogens were observed in 10 of 48 patients
(20.8%). During serological follow-up isolated IgM antibodies against
Coxiella burnetii were detectable for more than 50 days in one patient.
Conclusion: IgM antibodies against several bacterial and viral
pathogens, possibly caused by polyclonal B cell stimulation, can be
detected quite frequently in acute hantavirus infection. This observation
should be taken into account to avoid misinterpretation of serological
test results.
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P2164 Evaluation of a rapid detection kit using
immunochromatography for adenovirus infection
G. Antonaki, M. Matsas*, F. Antonopoulou, P. Xenos, I. Paraskakis
(Athens, GR)
Objectives: A newly described rapid chromatographic immunoassay
was evaluated for adenovirus detection in nasopharyngeal aspirates of
children with respiratory illness, compared to an indirect immunoﬂuo-
rescense method (IFA).
Methods: During a four year period (2006–2009), we screened 2337
nasopharyngeal aspirates collected from children, aged <2 years,
hospitalized for acute lower respiratory infection, in a paediatric hospital
in Greece. The screening was performed for respiratory viruses detection
(respiratory syncytialvirus, adevovirus, inﬂuenza A and B, parainﬂuenza
1, 2 and 3) using IFA (Respiratory Virus Panel − Biotrin). Sixty-four
specimens were found to be positives only for adenovirus. Positives
specimens were divided, according to the number of ﬂuorescing cells
per optical ﬁeld (fc/pof) in low (0−2 fc/pof), medium (2−4 fc/pof)
and high positives (5 fc/pof). All adenovirus positives specimens,
16 specimens negatives for all the above respiratory viruses and
20 specimens positives for respiratory viruses other than adenovirus,
were evaluated for adenovirus detection by the new chromatographic
immunoassay (Adenovirus Resp. − CerTest).
Results: No false positives results were observed using the new assay.
The speciﬁcity and positive predictive value for adenovirus detection by
this new assay were100%, in comparison with IFA. No cross reaction
with the other respiratory viruses was detected. However the sensitivity
ranged from 0%, 35.5% and 100% in low, medium and high positives
specimens, respectively.
Conclusion: This new immunochromatographic assay is able to detect
adenovirus infection simply and rapidly, but his usefulness is limited in
early diagnosis when low or medium positives specimens are tested.
HIV/AIDS
P2165 HIV-1 is able to infect resting TCD4+ cells efﬁciently in a
short time of viral exposure
J.T. Maricato*, W. Alkmim, P. Fincatti, S. Nascimento-Brito,
J. Machado Jr., L. Janini (Sa˜o Paulo, BR)
HIV is the causative agent of the acquired immunodeﬁciency syndrome
(AIDS). According to UNAIDS there are roughly 33 million people
living with HIV. Several studies have addressed many aspects of HIV
infections but elements pertaining to the relationship between the virus
and target cells are still waiting for a better characterization. Most of the
studies on early steps of viral infection showed that cellular activation
is essential for HIV infection in TCD4+ lymphocytes and monocytes.
The objective of the this work was to determinate if HIV-1 is able
to infected resting TCD4+ lymphocytes puriﬁed from human peripheral
blood. The virus was able to infect resting TCD4+ lymphocytes on MOIs
ranging from 0,05 to 1,0. Our preliminary results showed that resting
TCD4+ lymphocytes can be infected by HIV-1 within 30 minutes after
the addition of virus to cell cultures. After infections, HIV-1 reverse
transcription was allowed to proceed for 36h under IL-2 and PHA
activation. Conventional PCR and RFLP of the protease gene showed
that viral DNA can be detected for all MOIs and in all time periods
from 30 minutes up to 180 minutes post-infection. Proviral load will
be measured by qPCR for each MOI and period infection. Our results
indicated that resting TCD4+ cells can be efﬁciently infected by HIV
when different MOIs are used and even when cells were exposed to virus
for only 30 minutes. Infection of resting cells does not represent a barrier
for HIV since virus could be recovered 36 hours post infection. Our
data may have some implications on how HIV can manage to establish
infection on new hosts.
P2166 Prevalence of primary resistance mutations and inﬂuence
of integrase polymorphism on virological outcome of
Raltegravir-containing anti-retroviral regimens
V. Guillot*, N. Chueca, M. Alvarez, A. Pen˜a, M.D. Merida,
J. Lopez-Bueno, J. Parra-Ruiz, J. Pasquau, J. de la Torre, F. Garcia
on behalf of RAL-CoRAO
Objective: To describe the prevalence of mutations conferring resistance
to Raltegravir in a cohort of patients starting salvage therapy with this
drug, and to evaluate the inﬂuence of polymorphisms in the integrase
gene on virological outcome.
Methods: We have studied 173 patients form Eastern Andalusia, South
of Spain, starting a Raltegravir containing regimen with at least 48
weeks of follow-up. Integrase from baseline and failure samples was
ampliﬁed and then sequenced using the Trugene platform and “in
house” procedures. Baseline characteristics of the study population were:
70.5% males; median viral load (Log): 3,8 (1.7−6.5); median CD4: 359
(10–111000) cell/mL; median no. of treatment lines: 8 (0−28); mean
genotypic susceptibility socre (GSS): 2.5; non-B subtypes 2.8%.
Results: No primary mutations to Raltegravir were found in the
baseline samples (n = 50); only one patient carried a secondary resistance
mutation (L74M, prevalence <1%). Most prevalent baseline integrase
polymorphisms were R127K, G123S (100%), N232D (83.3%), V72I
(65%), A124T (63.3%), V201I (41.7%). No association with any
baseline polymorphism and virological failure was observed. By week
48, 18 patients (10%) had virological failure to a Raltegravir, and
only 6 patients (24%) had detectable integrase mutations. No relation
with any baseline polymorphism and the detection of failure mutations
was observed. Most prevalent selected polymorphisms (not present at
baseline but detectable on failure) were K160R (11.1%), P145L (11.1%),
E85G (5.5%), K103R (11.1%), Q216R (16.6%), as well as other changes
near the catalytic site as K173E (5.5%), E138D/G (5.5), A179V (2.3%),
e I162M (2.3%). Non-B subtypes did not show differences in virological
failure compared to B subtypes.
Conclusion: The prevalence of resistance mutations in the integrase in
patients treated with Raltegravir in Southern Spain is low, and there
is no primary resistance to integrase inihibitors in our area. There is no
association between baseline polymorphisms in integrase and virological
failure to a Raltegravir containing regimen, or the selection of Raltegravir
associated mutations.
P2167 Regulation of APOBEC3G as therapeutic strategy to
control HIV-1 infection
L. Ferreira*, A. Ramos, J. Gonc¸alves, I. Soeiro (Lisbon, PT)
APOBEC3G (A3G) was one of the ﬁrst endogenous proteins reported
to be able to impair HIV-1 replication. Recent studies show that
A3G expression is raised in patients infected with HIV but presenting
a slow disease progression; other studies showed that it is possible
to enhance A3G expression through stimulation of speciﬁc cell
surface receptors. The molecular mechanisms responsible for this A3G
expression variations are still not clear, thus our aim is to characterize the
regulation of A3G expression upon speciﬁc T cell-receptor stimulation.
FoxO3a belongs to the Forkhead family of transcription factors, which
are involved in cell cycle arrest and apoptosis. Additionally, FoxO3a is
regulated by the PI3K/AKT pathway that is usually found downstream of
several T-cell receptors. In this context, the T-cell receptor stimulation
was achieved using HIV-1 gp120 protein that binds to the CD4 receptor.
Our results indicate that gp120 stimulation increases A3G expression
and leads to inactivation of FoxO3a.
To explore the A3G promoter region, bioinformatics tools were used
leading to the identiﬁcation of a sequence as the putative promoter
containing four putatives FoxO3a binding sites.
In order to validate this data, the putative A3G promoter was cloned into
a Luciferase-reporter vector. Zinc-ﬁnger technology was used to validate
this sequence and our preliminary results indicate that these zinc-ﬁngers
are able to trigger A3G expression.
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To identify the role of FoxO3a in the A3G promoter and also to clarify
the role of each putative FoxO3a binding site, all four sites were mutated
and cloned into Luciferase-reporter vectors.
Our results indicated that the A3G promoter has low activity, which
might be indicative of a promoter that is usually under repression. Three
of four mutants analyzed showed higher activity related to wt promoter
reinforcing that FoxO3a might be binding to these sites with a repressive
function.
To conﬁrm this, Chromatin Immunoprecipitation analysis was per-
formed, revealing the involvement of FoxO3a in this promoter.
In conclusion, gp120 stimulation appears to activate the PI3K pathway,
regulating FoxO3a activity. At the promoter level, preliminary results
using zinc-ﬁngers tools validate the sequence in study as a legitimate
sequence for A3G promoter. Moreover, three of four FoxO3a binding
sites appear to be equally crucial for FoxO3a-mediated A3G expression.
In this context, A3G expression appears to be under repression by
FoxO3a.
P2168 Cell entry to nuclear import: HIV cycle may be inﬂuenced
by phosphatases and kinases
A. Godinho Santos*, S. Rato, J. Gonc¸alves (Lisbon, PT)
Human Immunodeﬁciency Virus (HIV) depends on the host cell
machinery to complete its life cycle. Several host proteins may help viral
replication and others have the ability to suppress it. These helper and
restriction factors might be involved in many different pathways, where
regulation of protein activity by protein phosphorylation is essential.
Both kinases and phosphatases are required for this crucial process
that regulates many cellular processes in eukaryotes. Moreover, they
constitute the largest subset of the druggable genome, sustaining kinase/
phosphatase modulation as approach for the development of novel
therapeutic strategies. These features prompted this study, which was
designed to characterize kinases and phosphatases identiﬁed as helper
factors for HIV-1 replication in a previous shRNA screen. For this
purpose, we attempted to assess: 1) the effect of the 13 of the 14
identiﬁed proteins in HIV-2 replication cycle; and 2) the mechanism
by which two of the identiﬁed proteins, SGK and CIB2, affect the
early phase of HIV-1 life cycle, more precisely in viral fusion and in
post-reverse transcription pathways. To accomplish this, the constructed
shRNA clones were infected with HIV-2 particles to evaluate the effect
on HIV-2 replication. When we compared the amount of virus in all
tested shRNA clones challenged with HIV-1 and HIV-2, all proteins
exhibited a similar outcome from the one observed in HIV-1. This
evidence could indicate that HIV-1 and HIV-2 share cellular pathways
while hijacking these host factors to assure its survival. Since CIB2
potentially interacts with integrins, and both SGK and CIB2 are involved
in regulation of several ion channels, we inquired if these proteins could
affect virus-cell fusion and performed a virus-cell fusion assay. We
assessed that both SGK and CIB2 are important in HIV-1 entry, since
their knockdown reduces the number of fusion events. Furthermore, we
conducted the quantiﬁcation of 2-LTR circles by RealTime-PCR in SGK
and CIB2 shRNA clones infected with HIV-1, in order to establish if
SGK and CIB2 play a role in steps previous to integration. Preliminary
data suggests that SGK and CIB2 could lead to 2-LTR circles formation,
affecting HIV-1 replication. This study provides new insights for the
complex host-HIV interactions and proposes several mechanisms by
which some of these kinases and phosphatases affect HIV infection,
instigating further studies and new possibilities for antiviral strategies.
P2169 Antiviral drug resistance in HIV-1-infected individuals.
Results from a low-endemicity area in Germany, comparing
patients with primary HIV infection or antiretroviral naı¨ve
individuals to those with treatment failures or recurrent blips
T. Gru¨newald*, S. Weidemann, N. Schmidt, I. Raila, K. Schreiter,
T. Marcello, C. Klein, H. Mu¨ller, A. Po¨ge, B.R. Ruf (Leipzig, Hamburg,
DE)
Objective: Antiviral drug resistance is of rising concern in HIV-infected
patients undergoing antiretroviral therapy (ART). Primary resistance
in ART-naı¨ve individuals as well as transmission of resistant viruses
are increasingly reported especially in communities with high incident
HIV infections. Data regarding ART resistance in persons from low-
endemicity regions are still sparse.
This prospectively analysis was conducted to describe the extent and
level of genotypic resistance to antiretrovirals (HIV-GR) in a patient
group presenting within three months of serologically documented
seroconversion or clinically overt acute retrovirus syndrome (PHI) and
in those naı¨ve for ART scheduled for starting treatment (pre-ART) tested
in the setting of a low-endemicity region in Germany.
Patients and Methods: Between 2008–2010 ﬁfty individuals undergoing
HIV-GR for (non-nucleoside) RT inhibitors ((n)NRTI) and protease
inhibitors (PI) were capable for this prospective analysis. PHI or
seroconversion was diagnosed in 13, pre-treatment testing was done
in 20, and 17 individuals experiencing treatment failure served as
comparison group. Crude ART resistance was observed as well as
Stanford mutation score and compared between to either groups. HIV-GR
was performed using commercially available assays, Stanford mutation
score was calculated using published algorithms.
Results:Mutations (SNPs) in the reverse transcriptase (RT) and protease
(PR) genes were found in nearly all subjects. Median number of
mutations was 12 (range 4−29) for RT gene and 7 (range 3−14) for
PR gene. Signiﬁcant SNPs (both RT gene) were found in 2/13 PHI
individuals conferring resistance against both, NRTI and nNRTI. No PI
resistance could be detected. Stanford mutation score was 70 and 120 for
these individuals compared to mean scores of 15 (RT gene) and 0.7 (PI
gene) in all PHI patients. In the pre-ART group no evidence for RTI or PI
resistance was detectable. Mean Stanford mutation scores were 0.7 (RT
gene) and 0.6 (PI gene) in all 20 pre-ART patients. In those presenting
with ART failure 47.1% had detectable resistance which included two
(11.7%) with triple-class resistance. Mean Stanford mutation scores were
34.94 (RT gene) and 19.82 (PI gene) in ART-experienced individuals.
Conclusions: Primary ART resistance occurs rarely in ART non-exposed
patients presenting in low-endemicity regions. Risk of carrying resistant
viruses seems to be higher in those with recent virus transmission.
P2170 K103N minor variants in untreated and treated patients
from southern Spain
M. Alvarez*, V. Guillot, A. Pen˜a, N. Chueca, J. Lopez-Bueno,
M.D. Merida, M. Omar, V. Gutierrez-Rave, M.A. Martinez-Perez,
F. Garcia on behalf of CoRAO
Objective: To evaluate how the investigation of minority K103N
quasispecies (mutations below 10−20%) impacts the prevalence of
transmitted drug resistance mutations in newly diagnosed patients, and
how it affects the rate of resistance to non-nucleosides in pre-treated
patients.
Me´thods: We have investigated the presence of minority K103N using
an “in house” semiquantitative allele-speciﬁc RT-PCR (AS PCR),
able to recognize both AAC and AAT changes in K103 of the
retro-transcriptase gene of HIV-1. 802 samples from antiretroviral
naı¨ve patients and 1146 samples from treatment experienced patients
throughout the period 2005–2010 were investigated using population
sequencing (Trugene HIV-1 genotypic kit, Siemens NAD). 572 samples
from antiretroviral naı¨ve patients and 89 samples failing an efavirenz/
nevirapine antiretroviral regimen were analysed using AS-PCR. No
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differences in baseline viral load, CD4 count, age or gender were
observed between groups.
Results: For antiretroviral naı¨ve patients, the prevalence of K103N
using population sequencing was 3.5% (28/802). AS-PCR allowed to
detect K103N variants in another 1.7% (10/572), increasing the overall
prevalence of transmitted K103N to 5.2%. For treatment experienced
patients, K103N was detected in 25.2% (289/1146) of the patients
using population sequencing. For efavirenz or nevirpaine failing patients.
K103N could be additionally detected by AS-PCR in 15 of 89 patients
in whom this mutation was not present by population sequencing,
increasing the prevalence in 16.8%.
Conclusions: (a) The investigation of K103N by AS-PCR, in newly
diagnosed patients, increases the rate of transmitted drug resistance
to non-nucleosides in 1.7%, which, according to data published
using population sequencing, remains to be cost-effective. (b) K103N
minorities in patients failing non nucleoside regimens is relatively
frequent.
P2171 Regulation of Vif by phosphorylation during HIV-1 infection
A. Ramos*, A. Couto, F. Luı´s, J. Gonc¸alves, I. Soeiro (Lisbon, PT)
The Human Immunodeﬁciency virus (HIV) is the causative agent of
AIDS, a disease affecting around 33 million people worldwide. Current
anti-retroviral therapy, although efﬁcient in suppressing HIV-1 infection,
cannot provide a cure. For this reason, several studies turn to the dynamic
interplay of host-virus interaction as a tool for HIV eradication.
Viral Infectivity Factor (Vif) is an accessory protein codiﬁed in the
HIV-1 genome and synthesized during its late life cycle. It is essential in
infected cells for the formation of complexes (e.g. Vif-Cul5) that lead the
cellular defence factor APOBEC3G (A3G) to degradation, preventing its
inhibitory actions on HIV replication.
Previous studies reveal that several HIV-1 proteins are regulated by
phosphorylation, raising the question whether Vif phosphorylation by
host kinases could represent a valid option for novel antiviral therapy
solutions.
Five previously unpublished residues were identiﬁed on Vif as targets
for phosphorylation by cellular kinases, using 3 different bioinformatic
tools. Those sites were mutated by site-directed mutagenesis and both
bacterial and mammalian expression vectors constructed. The resulting
mutants were puriﬁed so that their speciﬁc phosphorylation patterns can
be conﬁrmed by in vitro kinase assays. HEK293T cells were transfected
with the mutant constructs and the expression levels of both Vif and
A3G evaluated by Western Blotting. In order to assess the ability of
the mutant proteins to bind to Cul5 and lead A3G to degradation, a co-
immunoprecipitation assay was performed. Preliminary results show that
the Vif mutants co-immunoprecipitate with Cul5, although with different
abilities, indicating that the mutations do not completely inﬂuence the
formation of the Vif-Cul5 complex required for A3G degradation.
Because Vif also bears A3G-unrelated functions, we inquired if the
infectivity of Vif-mutated viral particles was altered. Virions containing
the mutated proteins were produced in HEK293T cells and used to infect
HeLa-P4 cells. Viral production was evaluated by p24 ELISA assay and
preliminary data suggests, in accordance to previous studies, that the
replicative ability and infectivity of those virions was altered.
The identiﬁcation of these phosphorylations and their speciﬁc biological
role in regulating Vif activity may lead to a better understanding of the
complexity of HIV-1 replication and eventually provide a new direction
in antiviral research and development.
P2172 HIV integrase variability and genetic barrier in
antiretroviral naı¨ve and experienced patients
A. Piralla*, S. Paolucci, R. Gulminetti, F. Baldanti (Pavia, IT)
Objectives: To analyze the HIV-1 integrase variability in treatment
naive and treatment experienced patients infected with different HIV-1
subtypes.
Methods: The HIV-1 integrase variability was analyzed in 16 treatment
naı¨ve patients infected with subtype B strains and 25 with subtype non-B
strains. In addition, the effect of treatment with inhibitors of integrase
(INI), protease (PRI) and reverse-transcriptase (RTI) on the integrase
variability was analyzed in 19 INI naı¨ve patients with subtype B and 35
patients with subtype non-B. For comparison 13 patients infected with
subtype B strains and experienced of all classes of antiretroviral drugs
were analyzed. Moreover, the integrase variability was analyzed in 4
patients infected with HIV-2 naı¨ve for treatment with INI. Finally, the
genetic barrier for speciﬁc INI resistance mutations was calculated to
compare the rate of drug resistance development.
Results: Primary mutations associated with resistance to INI were
not detected in patients not previously treated with this class of
drugs. However, some secondary mutations which have been shown
to contribute to raltegravir resistance were found. In patients infected
with subtype B strains, a lower genetic barrier for the acquisition of
mutations G140S, S147G and V151I as compared with subtype non-B
was observed. HIV-2 strains from INI naı¨ve patients showed the presence
of both primary and secondary resistance mutations.
Conclusions: The overall efﬁcacy of INI do not appear to be reduced
by spontaneous emergence of resistance polymorphisms. However, the
lower genetic barrier in subtype B HIV-1 strains, and the natural
resistance of HIV-2 strains should be taken into consideration when
selecting INI-containing treatments.
P2173 Determination of drug resistance from HIV-1 RNA
stabilised at room temperature on solid matrix
M. Rossi de Gasperis*, L. Putignani, D. Caione, G. Pizzichemi,
G. Pontrelli, S. Bernardi, D. Menichella, F. Callea (Rome, IT)
Objectives: Analysis of HIV-1 genomic sequences, the kinetic
evaluation of high occurrence of nucleotide spontaneous mutations
and the appearance of resistance induced by drug treatment appear to
represent today the best index of clinical efﬁcacy of antiretroviral therapy
(HAART). The liability of the viral RNA requires the need to store or
transport biological samples at controlled temperature (60−80ºC) if not
processed immediately after harvesting, giving a substantial limit to the
current molecular methods for the determination of drug-resistance. The
objective of our work is to make stable at room temperature (RT) the viral
RNA on solid support for its safely transport to reference laboratories
distant from places where they are collected to test drug resistance.
Methods: From 45 samples whole blood was collected from viremic
patients either under drug treatment or not. Thirteen samples were
processed as follows: 9ml were used to perform, as routine procedure,
the monitoring of hematologic and chemical parameters and the
circulating lymphocyte subpopulation, viral-load and drug resistance;
residual 3ml were used to verify the stability and integrity of RNA
that, after a brief treatment, was adsorbed on solid support and kept
for 10 days at RT. Results from each fresh sample were compared with
those from stabilized RNA on solid matrix. Genome sequences were
analyzed by the HIV-1 genotyping TRUGENE and the DNA sequencing
OpenGene systems which are able to analyze and identify all genotypic
changes of the virus “naive” or the drug-induced gene “pol” mutations
in the region encoding the protease and reverse transcriptase.
Results: The same pol mutations associated to protease inhibitors
(IP) and to Nucleoside/Nucleotide Reverse Transcriptase (NRTI) and
not (NNRTI) inhibitors were highlighted both on fresh and stabilized
samples. Furthermore, the same missense and silent point mutations
were identiﬁed on both sample sets and were characterized as different
from HIV reference sequences. These sequences may be substantial for
HIV genotype phylogeny.
Conclusion: The purpose of this project is to develop a sampling
method suitable to conduct HIV-1 drug resistance tests in reference
laboratories even placed far from satellite centers, which are often located
in developing countries. The technique may allow, after RNA stabilizing,
to obtain the same characteristics of efﬁciency, sensitivity and speciﬁcity
of procedures used in peripheral points of care.
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P2174 Prevalence of cognitive impairment in an Irish HIV-positive
clinic population based on the use of surrogate markers for
cognitive impairment
P.H. McNamara*, C. Doherty, J. Redmond, C. Bergin (Dublin, IE)
Objectives: A retrospective chart review was carried out at the HIV
clinic in St. James’s Hospital, Dublin, Ireland to examine the rate of
cognitive impairment through the use of surrogate markers for cognitive
impairment. The surrogate markers for cognitive impairment chosen for
use in this chart review were subjective complaints from the patients
documented in the charts, a new psychiatric diagnosis since the diagnosis
of HIV seropositivity, neurological complications associated with HIV
and radiological evidence of brain atrophy.
Methods: 500 consecutive hospital charts were reviewed of patients who
were due to attend the outpatient clinics. All patients were included
except for patients whose charts were missing or unavailable. The paper
hospital charts were reviewed for the above surrogate markers and also
the electronic patient record system was reviewed for the results of
radiological investigations. Basic demographics including age, gender,
nationality, mode of transmission of HIV, nadir CD4 count, current CD4
count, viral load, co-morbidities, medication history and antiretroviral
history were all recorded.
Results: There were 306 men and 194 women included in the study.
Median age was 37. 5.6% were diagnosed within the last year, 39%
between 1 to 5 years ago and 33.4% 5 to 10 years ago. The most
common mode of transmission was heterosexual followed by the use of
intravenous drugs and then men who have sex with men. 45% had a nadir
CD4 count of less than 200. 58% were virally suppressed. 77% were on
antiretroviral therapy. Just under 30% were co-infected with hepatitis
B (22/500), C (121/500) or both (4/500). 13.8% of patients had one or
more positive surrogate markers for cognitive impairment. 9% had a new
onset of a psychiatric disorder after the diagnosis of HIV. 4.2% had a
neurological complication of HIV. Only 6 people had evidence of atrophy
on either CT or MRI brain. 94% of these patients with positive surrogate
markers for cognitive impairment were on antiretroviral therapy.
Conclusions: On univariate analysis signiﬁcant relationships were found
between the presence of positive surrogate markers for cognitive
impairment and female gender, older age, nadir CD4 <200, longer
duration of infection, Ireland as a country of birth, intravenous drug
use as a mode of transmission, being on ART and co-infection with
hepatitis B or C. Multivariate analysis using logistic regression showed
signiﬁcant relationships only with gender and year of diagnosis.
P2175 Late presentation of HIV infection in northern Greece:
prevalence and correlates, 2000–2010
S. Metallidis*, D. Pilalas, L. Skoura, Z.A. Antoniadou, O. Tsachouridou,
A.B. Haidich, T. Chrysanthidis, I. Bakaimi, E. Magaliou, A. Margariti,
I. Nikolaidis, P. Kollaras, N. Malisiovas, P. Nikolaidis (Thessaloniki, GR)
Objectives: To assess the extent of late presentation for HIV care in
North Greece during the period 2000–2010 and to explore correlations
aiming to provide guidance for future interventions.
Methods: HIV infected patients with no prior history of HIV care
at presentation and with a CD4 T-cell count within 3 months from
the ﬁrst conﬁrmatory Western blot result were eligible for this study.
Epidemiological and laboratory data were retrieved from the database of
the AHEPA University Hospital HIV clinic which provides healthcare for
the majority of HIV infected individuals in North Greece. Further clinical
information were pursued through review of medical ﬁles. Any patient
presenting with less than 350 CD4 T-cells or with an AIDS-deﬁning
event was classiﬁed as late presenter as deﬁned by the European Late
Presenter consensus working group. Advanced HIV disease was deﬁned
accordingly. Time trends in CD4 T-cell count at presentation during the
past decade were evaluated and logistic regression models were applied
in order to assess risk factors linked to late presentation and advanced
HIV disease.
Results: The status at presentation was evaluated for 631 eligible HIV
infected individuals. Overall, the proportion of late presentation was
estimated to be 52.5% (95%CI:48.6%-56.4%), while the proportion
of advanced HIV disease was 31.2% (95%CI:27.6%-34.8%). The
CD4 T-cell count at presentation improved over the past decade
(p< 0.001) and time trends were consistent with a reduction in
the incidence of late presentation and advanced HIV disease in
our study population (p< 0.001). Risk factors associated with late
presentation in multivariable logistic regression were: intravenous
drug use (OR: 2.2, 95%CI:0.98−4.9, p = 0.057), heterosexual HIV
transmission (OR:1.48 95%CI:0.95−2.3, p = 0.086), origin other than
greek (OR:1.65 95%CI:0.93–2.93, p = 0.088), age at diagnosis per 10
years increase (OR:1.34, 95%CI:1.16–1.55, p< 0.001) and year of
diagnosis (OR: 0.9, 95%CI:0.85–0.95, p< 0.001).
Conclusions: Despite the trend for improvement, a signiﬁcant proportion
of newly-diagnosed HIV infected patients presents late for care. Targeted
interventions with focus on social groups at risk such as the elderly, the
intravenous drug users and the immigrants are mandated.
P2176 Durable outbreak of syphilis in HIV-infected patients: data
from Northern Greece
S. Metallidis*, O. Tsachouridou, P. Kollaras, E. Sidiropoulou,
A.B. Haidich, D. Pilalas, L. Skoura, T. Chrysanthidis, I. Bakaimi,
A. Margariti, E. Diza, P. Nikolaidis (Thessaloniki, GR)
Objectives: To describe the prevalence of syphilis and other sexually
transmitted infections (STIs) and factors associated with HIV co-
infection.
Methods: A review of infectious syphilis cases in HIV patients in
Northern Greece during the period 2008–2010. Demographics of the
patients, results of diagnostic tests, concurrent infections, possible route
of acquisition for both infections and routine HIV screening tests were
recorded.
Results: Of 800 HIV patients treated in our hospital, 331 were screened
and 58 (17.5%) were syphilis positive, during a three year period. The
vast majority of syphilis patients were MSM (55 patients, 94.82%)
with a mean age of 38.4 years. The mean duration of HIV was 3.3
years and the way of transmission for all syphilis cases was sexual
contact. At time of syphilis seropositivity, mean CD4-cells count was
440.26/mm3 and mean plasmatic HIV RNA virus load was 3.85 log/mL.
Most patients with no syphilis infection were MSM with a mean age of
38.3 years. The mean duration of HIV was 3.01 years. At time of syphilis
screening, mean CD4-cells count was 493.11/mm3 and mean plasmatic
HIV RNA virus load was 3.7 log/mL There was no association between
gender and syphilis (P = 0.256). A signiﬁcantly greater proportion of
patients with syphilis were under HAART than no syphilis patients
(p = 0.026). A signiﬁcantly greater proportion of patients with syphilis
had co contaminant STIs than no syphilis patients (P< 0.001). There
was no association between syphilis and CD4 (p = 0.216),syphilis
and viral load (p = 0.609), syphilis and age (p = 0.943), syphilis and
mode of transmission (p = 0.484) or between syphilis and duration of
HIV (p = 0.693). Both ingestion of HAART and STIs existence were
independent predictors of syphilis, showing that the odds of syphilis
was 2.4 times higher in patients with HAART than in patients with no
HAART (95CI%: 1.26, 4.63, p = 0.008) and it was 9.4 times higher in
patients with STIs than in patients with no STIs (95%CI: 4.49, 19.64,
p< 0.001).
Discussion: Multiple sexual partners, unprotected sex, HAART intake
and co-infection with other STIs are risk factors for this syphilis epi-
demic record. The overall high rate of unprotected sex demonstrates an
increasing prevalence of unsafe sexual practices among MSM, probably
attributed to faith in antiretroviral therapy. Therefore, continuous alert,
prompt diagnosis, early treatment and contact tracing are essential in
order to control this important outbreak among HIV population.
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P2177 Late diagnosis of HIV infection in Ireland − a cause for
concern
A. Jackson*, M. Brenan, F. Mulcahy, W. Powderly, M. Codd,
S. McConkey (Dublin, IE)
Objectives: HIV outcomes improve with earlier diagnosis: antiretrovirals
can avert signiﬁcant immunocompromise and reduce transmissibility.
Unfortunately, many present late with low CD4 counts.
Using data from 2000–2009 from the Dublin City HIV Cohort we aim
to determine the proportion of people presenting with low CD4 counts
and to see if this changes with time, gender, country of origin and route
of transmission.
Methodology: The Dublin City HIV Cohort enrolled patients from 3
Dublin teaching hospitals from 2004 to 2009 collecting retrospective and
prospective information. A retrospective cohort study was performed,
reviewing cases diagnosed from 2000 to 2009 with a documented
CD4 count within 12 months of diagnosis. CD4 distribution was
approximately parametric data allowing use of parametric analyses with
SPSS software.
Results: 1021 patients were analysed. 48% were Irish-born, 42% from
SubSaharan Africa (SSA). 43% were female. Mean CD4 at diagnosis was
lower in 2009 (280 cells/uL) than in 2000 (409 cells/uL) and 2001 (395
cells/uL), but this difference was not statistically signiﬁcant. Mean CD4
was lower among those presenting from SSA (295 cells/uL), compared
to Irish-born patients (390 cells/uL) (p 0.001).
Considering CD4 <350 cells/uL at diagnosis as late presentation, 57%
of our cohort presented late overall. 48% of Irish-born people, and 69%
from SSA presented late. This did not change signiﬁcantly over time for
either subgroup. Men who have sex with men (MSM) were least likely
(41%), and those infected through heterosexual contact were most likely
(65%) to present late. 60% females were late presenters, and 55% men.
Among Irish-born, commonest modes of transmission were MSM (37%),
intravenous drug use (IVDU) (35%), and heterosexual contact (26%).
In this group the relative frequency of IVDU among this group has
declined: 13% from the past 2 years compared to 38% from the previous
8 years. Heterosexual transmission among Irish patients increased from
12% in 2000 to 38% in 2009.
Discussion: Late presentation of HIV is a problem both for individual
patients and national prevention programs. Our data shows that people
are not presenting earlier, despite current public health approaches.
It supports increased HIV testing among heterosexual, non-IVDU
population, as they are the most likely to present late and may have
less contact with health services.
P2178 Use of risk management as a tool for quality improvement
in a public HIV service
M. Brenan*, A. Jackson, H. Tuite, S. McConkey (Dublin, IE)
Risk assessment and risk management is an important process in
organisations ranging from corporations to public healthcare services.
The Health Services Executive (HSE) in Ireland has made this a
requirement to all its operational service areas. As a busy urban-based
HIV clinic in a large teaching hospital, we have evaluated and introduced
a risk management framework. The aim was to reduce the likelihood of
adverse events and to improve clinical outcomes by changing practice
and to educate staff regarding clinical and non-clinical risk and its
management.
Methods: The project began in December 2009 and ran for one
year, using a standardised tool developed by HSE to calculate risk,
incorporating both the potential impact of a problem and its likelihood.
Clinical staff, non clinical staff and patient representatives were involved.
Four workshops were held; Risk identiﬁcation: Members listed potential
problems in speciﬁc areas of the clinic with which they were familiar;
Risk analysis: The risks and current control measures were discussed in
depth; Risk evaluation and rating: Risks were stratiﬁed into categories
based on importance using a Risk Assessment Form; Identiﬁcation
of mitigating factors: For the highest risks a plan was developed to
implement changes.
Results: 14 risks were identiﬁed in total: 1 scored low, 6 medium, and
7 high risks. High risk items were drug dispensing errors, medication
prescription errors, serious drug interactions causing adverse events,
unsafe sex and lack of disclosure to sexual partners of HIV patients,
exposure to tuberculosis for staff and patients, patient non-attendance
and medical records unavailability. The following changes are being
implemented and pursued: additional pharmacy resources, simplify
guidelines for prescribers, increase education to prescribers and increase
stafﬁng to pharmacy, increase resources and stafﬁng for social work
department and co-ordinate a ‘buddy system’ among willing patients,
structural changes to clinic and early identiﬁcation of possible TB
patients, reminder letters and text messages to be sent before clinic and
a digital electronic patient record speciﬁcally for HIV patients.
Conclusion: Risk management is a useful tool to identify and to
prioritize areas where changes in clinical health care services should be
made. Due to the effectiveness, complexity, cost and dangers associated
with anti-retroviral therapy for people with HIV, areas related to therapy
were prominent.
P2179 Leprosy presenting as immune reconstitution inﬂammatory
syndrome in patients on highly active anti-retroviral
treatment. A case-series study from a tertiary care centre
in Kerala, South India
T. John*, C. Jacob, M. Sadeep, K. Shobhanakumary, A. Jacob,
A. George (Kottayam, Trivandrum, IN)
Objective: To ﬁnd out the incidence and clinical proﬁle of Leprosy
presenting as IRIS “Immune Reconstitution Inﬂammatory Syndrome”, in
HIV patients. IRIS is a unique syndrome which comprises of a collection
of inﬂammatory disorders, associated with paradoxical worsening of
preexisting infectious processes either previously diagnosed and treated
or subclinical and later unmasked following the initiation of highly active
antiretroviral therapy (HAART), in HIV-infected individuals. IRIS is
usually associated with a low pretreatment CD4 count (often less than
100 cells/microL). Although the most frequently reported associated
infections with IRIS are localized herpes zoster, M. tuberculosis,
M. avium complex, cytomegalovirus, and Cryptococcus, rarely leprosy
can also present in a similar fashion.
Methods and Materials: It was a prospective study where we evaluated
patients with HIV started on HAART for evidence of Leprosy, from May
2007 to June 2010.
Results: 4 patients treated with HAART were diagnosed to have Leprosy
(Incidence was 5.38/1000 HAART patients). Of these, 3 patients had
Borderline Tuberculoid and one had Borderline Lepromatous with type 1
lepra reaction. The pretreatment CD 4 counts were 25, 40,50 and 75 cells/
microL (mean-47.5±21) and CD4 count at the time of disease detection
was 198,159,245 and 230 respectively. All patients presented within 8
weeks of starting HAART. The clinical features were hypo pigmented
lesions, erythematous tender plaques and foot drop. Skin biopsy of these
patients showed granulomatous inﬂammation. These patients met the
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diagnostic criteria of IRIS and were successfully treated with Multi Drug
Treatment (MDT) along with continuation of HAART.
Conclusion: IRIS presenting as Leprosy is quite unusual. In patients
on HAART, who develop acute onset erythematous plaques or
paralysis, Leprosy should be ruled out especially in endemic areas.
Successful treatment depends on alleviation of patient’s symptoms
without compromising HAART.
P2180 Susac’s syndrome in a HIV-infected patient
E. Vryonis*, E. Kakalou, A. Baxevanakis, C. Linardi, K. Papanikolaou,
V. Papastamopoulos, I. Baraboutis, A. Skoutelis (Athens, GR)
Objective: To present a case of Susac syndrome in an HIV infected
patient.
Susac syndrome is a rare CNS vasculopathy characterized by the clinical
triad of encephalopathy, branch retinal artery occlusions and cochlear
hearing loss. Diagnosis is based on the clinical, laboratory and imaging
ﬁndings.
There are no deﬁnitive treatment guidelines and treatment consists
of corticosteroids, intravenous immunoglobulin, immunosuppressive
treatment and anticoagulant therapy.
Methods-results: A 38 year old male HIV(+) with a high CD4 count and
undetectable viral load without receiving antiretroviral therapy (ART)
presented with gradual hearing loss and mild cognitive impairment. He
was investigated for HIV related encephalopathy/dementia and was put
on ART. Cerebrospinal ﬂuid analysis was normal. Cerebrospinal ﬂuid
analysis was negative for CMV, EBV, JC and herpes viruses. Magnetic
resonance imaging revealed multiple small white matter lesions in the
corpus callosum and in the periventricular and supraventricular white
matter. Audiometry conﬁrmed severe hearing loss.
Four weeks later his conginitive function was further impaired. He
presented ataxia and visual impairement. Fundoscopy revealed retinal
vasculitis. Laboratory investigation failed to suggest any alternative
diagnosis, thus the diagnosis of Susac syndrome was made. The patient
was managed with iv immunoglobulin and pulse methyprednisolone.
Within four weeks, neurological focal symptoms, cognitive deﬁcits and
psychiatric disturbances disappeared. There was minimal improvement
of hearing loss and an improvement of visual loss. The result of re-
evaluation at two months was indicative of no further disease activity,
however hearing and visual mild improvement was considered residual
damage. Treatment was subsequently stopped trying to safeguard
immune status and avoid unnecessary toxicity bearing in mind the HIV
status of the patient.
Conclusions: To the best of our knowledge this is the ﬁrst report of
Susac syndrome in an HIV patient. Our patient was of good immune
status before he presented with Susac syndrome. Prompt diagnosis and
treatment are essential in reducing neurological and sensory sequalae.
Susac syndrome should be included in the differential diagnosis of
unexplained encepalopathies, even in the case of HIV infected patients.
P2181 Adverse effect of inﬂuenza A/H1N1 vaccination on
endothelial function of HIV infected patients
H. Sambatakou* (Athens, GR)
Background: Vaccination against the inﬂuenza A/H1N1 subtype had
been proposed as a mandatory precaution measure for HIV infected
patients during the 2009 pandemic. The immediate cardiovascular effects
of the novel vaccine have been largely unexplored. We investigated the
impact of vaccination on indices of endothelial function in a cohort of
HIV infected patients.
Methods: Twenty-four HIV infected patients were studied (mean age
37 years, all male) in a randomized, sham procedure-controlled design.
A monovalent, adjuvanted vaccine against inﬂuenza A/H1N1 was used
for patients in the vaccine arm (n = 16); the control group (n = 8) was
subjected to a sham procedure. Endothelial function and inﬂammatory
markers were assessed prior to, 8 and 48 hours post vaccination.
Results: Endothelial function, as assessed by FMD values, deteriorated
following vaccination (baseline: 6.2±1.1%, 8 hours: 2.0±1.3%, 48
hours: 1.5±1.4%, P< 0.05). White blood cell count increased at 8 hours
and remained elevated at 48 hours [baseline: 7060 (6385, 7385) cells/mL,
8 hours: 7650 (7275, 8925) cells/mL, 48 hours: 7615 (6653, 8216)
cells/mL, P< 0.01]; sICAM-1 levels decreased (baseline: 520±43 ng/mL,
8 hours: 388±35 ng/mL, 48 hours: 333±28 ng/mL, P< 0.001) and there
was a trend for increase in CRP levels (baseline: 1.32 (0.55, 3.65) mg/dL,
8 hours: 1.79 (0.54, 4.22) mg/dL, 48 hours: 2.53 (0.85, 5.13) mg/dL,
P = 0.057). IL-6 and ADMA levels did not change. Conversely, the sham
procedure did not induce signiﬁcant changes in endothelial function or
inﬂammatory markers, apart from a fall in white blood cell count at 48
hours.
Conclusions: Vaccination against the inﬂuenza A/H1N1 virus induces
endothelial dysfunction in HIV infected patients and this effect is
sustained for at least 48 hours. While our study provides a new model
for inﬂammation-induced endothelial dysfunction, our ﬁndings may have
additional important implications in view of the high cardiovascular
risk that HIV infection implies and should be weighed against the
immunological protection conferred by the novel vaccine.
P2182 Newly diagnosed HIV-infected patients in Romania −
late presentation
V. Arama, R. Mihailescu*, A. Streinu-Cercel, A. Hristea, A.M. Tudor,
S. Paraschiv, D. Otelea, M. Radulescu, D. Munteanu, L. Benea,
C. Tiliscan, S.S. Arama (Bucharest, RO)
Objectives: First presentation suggests the burden that is to be carried by
the patients and health systems. We evaluated the clinical, immunological
and virological features of Romanian newly-diagnosed HIV-infected
patients and short-term course of the disease.
Methods: Prospective Romanian grant (CNCSIS no. 848/2006) on
newly-diagnosed HIV-infected patients in a tertiary care hospital, over
a period of 3 years. Clinical, immunological and virological screening
was performed every 3 months. Chi-square tests and multiple logistic
regression were used when analyzing the data by means of SPSS
software.
Results: We included 105 newly-diagnosed HIV-infected subjects,
53.3% men, with overall average age of 30 years, who were followed-up
a mean period of 18 months. Clinical CDC stage was A, B, C in 15%,
40%, 45% of cases, respectively. At baseline, we found CMV replicative
disease in 19% of subjects, tuberculosis-14.2%, hepatitis B-12.3%
(including B+D 2%), hepatitis C-2%, Pneumocystis carinii pneumonia
PCP-7%, cerebral Toxoplasmosis-1%, syphilis-1%; also 3 lymphomas,
1 Kaposi sarcoma, 2 progressive multifocal leukoencephalopathies.
Among the 6 deaths, 4 occurred in the ﬁrst 6 months from diagnosis
in patients aged 28−47 years (leukoencephalopathy, lymphoma and 2
PCP). With a median CD4 cell count of 164.5/mmc, our patients were
mainly late-presenters: 68.6% had CD4 cell count <200/mmc (21% even
under 50/mmc). In logistic regression, late presentation was associated
with low educational level. Under HAART, median of CD4 cell count
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reached normal range after 21 months of follow-up. HIV viral load was
>100.000 copies/ml in 35.2% of the cases at enrollment and remained
so in less than 3% after 3 years. The reasons of HIV tests were: non-
speciﬁc symptoms or opportunistic infections in 73% of cases, HIV-
infected partner-14.5% and screening tests-12.5%.
Conclusions: In our study, more than two thirds of HIV-infected patients
were late presenters, despite their young age, letting their disease
progress and disseminating HIV for years. National programme for
serological screening should be implemented in order to discover HIV
seropositives before the disease has advanced.
P2183 High prevalence and incidence of oncogenic human
papillomavirus infection in a cohort of African HIV-positive
women in Belgium
D. Konopnicki*, Y. Manigart, C. Gilles, J. de Marchin, M. Delforge,
F. Feoli, P. Barlow, S. De Wit, N. Clumeck (Brussels, BE)
Objectives: HPV may induce different diseases according to its
genotype: high risk (HR) genotypes are associated with cervical cancer
(CC) and low-risk (LR) with benign condyloma. Worldwide, 12% of
women with normal cervical cytology are infected with HR HPV but
HIV positive women have higher rates: in a meta-analysis, prevalence of
infection by both LR and HR HPV was 31% in USA, 32% in Europe
and 57% in Africa. This leads more frequently to cervical precancerous
lesions (CPL) and CC than in HIV negative women. Most studies
performed in women with HIV have reported HPV rates mixing both LR
and HR HPV genotypes and very few have published incidence rates.
We aimed to deﬁne prevalence and incidence of HR HPV infection in a
cohort of HIV positive women in Belgium.
Methods: A prospective program of screening and follow-up of HR
HPV infection is systematically offered to all women followed for HIV-1
infection in our AIDS reference clinic since 2002. Women are seen by a
dedicated gynaecologist within the AIDS reference centre. At each visit,
Pap smear and HPV screen are performed by HC2 High-Risk HPV DNA
Test (Digene®, USA). A prospective cohort database collects all results
including surrogate markers of HIV infection.
Results: We enrolled 808 women in the HPV screening program: 142
were excluded because of previous CPL or CC and 74 because of non
oncologic hysterectomy leaving 592 for analysis. 85% of women were
from sub-Saharan Africa and 93% acquired HIV heterosexually. The
median number of HPV tests was 2 per women (IQ10−90:1−4) with
a median interval of 15.5 months. At time of ﬁrst screen, prevalence
of HR HPV infection was 41% (median age 38 years, median CD4
429/mL, 78% of women on highly active antiretroviral therapy (HAART)
for a median time of 25 months). The prevalence according to age is
67% for women <25 years (y), 58% (25−34 y), 31% (35−44 y), 27%
(45−54 y) and 29% after 55 y. Among the 151 patients with a ﬁrst
negative screening followed by at least another test, 51 women presented
a new HPV detection during 355 patients-years follow up leading to an
incidence of 14.7 per 100 patient-years.
Conclusion: We found a prevalence of high-risk oncogenic HPV of
41% and a yearly incidence of 15% in an HIV Belgian cohort mainly
composed of African women on HAART. These high rates should be
taken into account when designing screening and vaccination programs
for cervical cancer.
P2184 Pulmonary hypertension in HIV-infected patients: a
case-control study
S. Cicalini, P. Chinello, E. Grilli, M. Musso, R. Bellagamba,
C. Castilletti, N. Petrosillo* (Rome, IT)
Objective: Pulmonary hypertension (PH) is a rare but severe disease
which affects HIV positive patients with a prevalence of 0.5%. Its
pathogenesis is still unknown, and it is unclear whether the disease is
directly or indirectly inﬂuenced by HIV. Some observations suggest a
possible correlation between PH and herpetic human virus 8 (HHV-8),
whose prevalence is relatively high in HIV patients. We conducted a
case-control study to look for potential risk factors for the onset of PH
in HIV patients.
Methods: A matched case-control (1:2) study was performed. All HIV
patients with PH in our cohort were prospectively enrolled as cases. PH
was deﬁned by a value of pulmonary arterial systolic pressure (PAPS)
>30mmHg. Controls were selected among HIV patients with a PAPS
value 30mmHg. Matching criteria were sex, age and risk factor for
the acquisition of HIV.
The following data were obtained from each patient: age, sex, HIV risk
behavior, stage of HIV infection, antiretroviral therapy (ARV), T CD4+
count at enrollment and nadir, zenith HIV viremia, current or previous
drug addiction, cigarette smoking, HCV infection, hepatic cirrhosis,
HHV-8 seropositivity. Potential risk factors for PH were analysed by
univariate and multivariate analysis using conditional regression model.
A backward variable selection including potential explanatory variables
and those for which P was <0.05 at univariate analysis was performed
to deﬁne the best-ﬁtting model.
Results: 44 cases and 88 controls were included in the study. 70% of
patients were intravenous drug users and 30% reported heterosexual
contacts. No homosexual men with PH were included in our cohort.
Patients with PH had more frequently a nadir CD4 count less than
200/mmc (OR 2.95%CI 0.9−4.7; P = 0.05). 75% of PH patients and 98%
of controls were in ARV. Not taking ARV was signiﬁcantly associated
with PH (OR 14.95%CI 2.8–136.8; P< 0.0001). The proportion of
HHV-8 positive patients was 77% and 61% (OR 2.95%CI 0.8−5.2;
P = 0.09), respectively. Conditional regression analysis conﬁrmed not
taking ARV as independent risk factor for PH (OR 11, 95%CI 2.4–
49.6; P = 0.002).
Conclusions: Our study showed that the only variable signiﬁcantly
associated to the development of PH was the absence of ARV, suggesting
a protective effect of ARV against the development of PH. HHV8
positive patients had a double risk, compared to controls, of developing
PH, although this association did not reach statistical signiﬁcance.
P2185 Characteristics of women with a new HIV diagnosis in
Italy, 1985–2009
L. Camoni*, V. Regine, M.C. Salfa, M. Raimondo, S. Boros, B. Suligoi
and HIV Surveillance referents
Objective: To assess the incidence of new HIV diagnoses among women
over time and the characteristics of women with a newly diagnosed HIV
infection.
Method: Descriptive analysis of new diagnoses of HIV infection
among Italian women reported between 1985 and 2009 using regional
surveillance data from 15 Italian regions and provinces (which account
for approximately for 72% of the Italian population).
Results: Between 1985 and 2009, 45,201 new HIV diagnoses were
reported. Among these, 13,062 (28.9%) were women. Among women,
the median age at diagnosis progressively increased from 24 years
in 1985 to 35 years in 2009. Overall non-national women accounted
for 44.3% of the reported female cases. The proportion of new HIV
diagnoses among non-national women increased from 28.5% in 1992
(ﬁrst year of available data for non nationals) to 51.0% in 2009.
Overall almost three-fourth of women acquired HIV infection through
unprotected sexual contacts. The proportion of women that acquired HIV
infection through unprotected sexual contacts increased from 0.7% in
1985 to 87.7% in 2008. The incidence of new HIV diagnoses increased
among women (from 4.7 per 100,000 resident women in 1985 to 3.4
per 100,000 resident women in 2009) as well as among men. The male
to female incidence ratio (inc. M/inc. F) showed a decrease over time:
from 3.4 in 1985 to 2.1 in 1999, increasing subsequently and reaching
3.2 In 2009 (Figure).
During 2009, 5 cases of mother to child transmission were reported: 1/3
of HIV-infected mothers were non-national.
These data underline the need to encourage the adoption of safe sexual
behavior among women as well as the implementation of HIV testing,
especially among pregnant women.
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P2186 Prevalence and persistence of anal infection by oncogenic
human papillomavirus virus and co-infection with Chlamydia
trachomatis among HIV-infected homosexual males
J. Macı´as, M. Parra, J. Cabeza, C. Pablos, N. Sivianes, L. Perez,
E. Martı´n-Mazuelos, J.C. Palomares* (Seville, ES)
Objectives: The incidence of anal cancer among HIV-infected men who
have sex with men (MSM) is very high. The main risk factor associated
are the promiscuity, the tobacco, the immunosupression and HPV
infection. On the other hand, it have been reported the relation between
the HPV-C. trachomatis co-infection and progression to cervical cancer.
Our objective was to establish the prevalence and persistence of anal
infection by oncogenic HPV and the co-infection with C. trachomatis
among HIV-infected MSM.
Methods: We studied the presence of HPV and C. trachomatis
infections in samples of anal canal among a cohort of 62 HIV-infected
MSM. For HPV infections the samples were collected in ThinPrep
Preservcyt medium (Roche Diagnostics). We used the AMPLICOR
HPV Test (Roche Diagnostics) for HPV detection and the Linear
Array HPV Genotyping test (Roche Diagnostics) for genotype. For
C. trachomatis infection we used the CT/NG Ampliﬁcation test and
Detection tests (Roche Diagnostics). The patients were reclaimed for a
second determinations at six month.
Results: The median age was 40 years (range 21−78). The median of
CD4+ was 560/mcL (range 310–1230) and the percentage of patients
with undetectable HIV viral load was 70%. Fifty-one patients (82.8%)
harboured HPV infection. Of them, 41 (80.4%) had >1 oncogenic
genotype. The average of HPV genotype was 3 per patients (range
1−10). The more frequent genotypes detected were 16 (25 patients), 52
(22 patients), 51 (17 patients), 45 (14 patients) and 18 (13 patients). In
29 patients a second determination was available: there were 2 patients
(7%) that were HPV negative at ﬁrst and second determination; 25 (86%)
persisted HPV infected; and 2 patients (7%) HPV-positive initially were
HPV negative six month later. Six patients (10.3%) harboured HPV-
C. trachomatis co-infection. Of them, 2 persisted positive at six month,
2 reverted to negative and two patients were missed on study.
Conclusions: Prevalence of anal infection by oncogenic HPV genotypes
among HIV-positive MSM was very high and an elevated frequency of
HPV mixed infections (more than one genotype) was found.
Moreover, in this preliminary analysis a signiﬁcative number of anal co-
infection of HPV and C. trachomatis was detected, but more extensive
studies should be needed to elucidate their prognostic relevance.
P2187 Human herpesvirus 8 prevalence among HIV-1 infected
patients during 2007–2010
F. Lo´pez-Fabal*, A. Pe´rez-Rivilla, J.L. Go´mez-Garce´s (Madrid, ES)
Objective: Human herpesvirus 8 (HHV-8) infection is not always
associated with clinical manifestations. Kaposi’s sarcoma (KS) and
other consequences of HHV-8 are much more likely to arise in
immunosuppressed patients, especially those HIV-infected. HIV has an
unquestionable predisposing effect for the conversion from asymptomatic
HHV-8 infection into clinical manifestations. In addition, AIDS-KS is
more aggresive and resistant to treatment than other forms of KS. The
aim of this study was to determine the prevalence of concurrent HHV-8
in patients infected with HIV.
Methods: During the last 4 years serum samples from 1,273,932 patients
were tested for the detection of HIV by electrochemiluminiscence
immunoassay (ECLIA). Each HIV positive serum was tested ﬁr the
presence of HHV-8 using indirect immunoﬂuorescence (IIF).
Results: From all serum tested, 485 were HIV positive as follows: 101
in 2007, 168 in 2008, 121 in 2009 and 95 in 2010. Overall the IIF assay
to test HHV-8 was positive in 74 (15.3%) patients as follows: 7 (6.9%)
in 2007, 28 (17.3%) in 2008, 17 (14%) in 2009 and 22 (23.2%) in 2010.
The male/female ratio was 74/31 and the age range included 27−56 year
olds.
Conclusions:
1. In this study we report a signiﬁcant proportion of HIV infected
individuals who are seropositive for HHV-8.
2. The percentage of coinfected individuals has increased in the last
years, and in 2010 was the highest percentage.
3. Studies of prevalence of HHV-8 among HIV-infected patients are of
prime importance, as they can help to estimate the risks of future
coinfection-derived complications.
P2188 The inﬂuence of HAART on the incidence, clinical
presentation and prognosis of cryptosporidiosis
M. Korac*, J. Ranin, D. Salemovic, B. Brmbolic, D. Jevtovic (Belgrade,
RS)
Introduction: Cryptosporidium is the most frequent cause of diarrhea
among AIDS patients. Decreasing incidence of cryptosporidiosis has
been observed in the HAART era. The aim of this study was to analyze
the inﬂuence of HAART on the incidence, clinical presentation and
prognosis of cryptosporidiosis among AIDS patients in Serbia.
Methods: The study included patients with diarrheal illness due to
cryptosporidiosis treated in the Institute for Infectious and Tropical
Diseases in Belgrade, Serbia. Patients were stratiﬁed into two subgroups:
those in the pre-HAART era (1985–1996) and in the HAART era (1997–
2009). Demographic characteristics, immunological status, duration of
illness and prognosis were analyzed.
Results: Out of 1321 patients with AIDS, 50 (3.7%) had cryp-
tosporidiosis. The incidence of cryptosporidiosis did not change with
the introduction of HAART. However, the duration of illness was
signiﬁcantly shorter among HAART treated patients (p = 0.026). Patients
treated in the HAART era had signiﬁcantly longer survival after
cryptosporidiosis (p = 0.002).
Conclusion: Cryptosporidiosis is the most frequent cause of chronic
diarrhea among AIDS patients in Serbia. Even though the incidence
of cryptosporidiosis did not decrease with the introduction of HAART,
shorter duration of illness was observed with HAART, as well as
prolonged survival.
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P2189 Inﬂammatory markers and metabolic syndrome in
HIV-positive adults undergoing highly active anti-retroviral
therapy
D. Munteanu*, V. Arama, R. Mihailescu, A. Streinu Cercel, S.S. Arama,
I. Olaru, A. Hristea, C. Popescu, R. Moroti, D. Ion, C. Tiliscan,
L. Benea, M. Lazar (Bucharest, RO)
Background: HIV infection induce a chronic inﬂammatory status that is
frequently associated with metabolic syndrome. Although highly active
antiretroviral therapy reduces viral immune activation, inﬂammatory
markers can remain elevated in HIV positive patients, increasing the
cardiovascular disease risk. Our aim is to evaluate the inﬂammatory
markers in HIV positive patients undergoing HAART and to assess the
correlation with metabolic syndrome and cardiovascular risk.
Method: Preliminary results of an ongoing prospective Romanian
research grant (PNCDI2 no. 62077/2008) on HIV positive patients
undergoing HAART, recruited in a tertiary care hospital − INBIMB,
during18 months. Patients were monitored every 6 months on
clinical, anthropometric and laboratory grounds (including MPC1,
IL6, TNFa, hsPCR). Metabolic syndrome according to International
Diabetes Federation includes alteration of body mass index/central
obesity, triglycerids, HDL cholesterol, glycemia, blood pressure. The
cardiovascular risk was calculated using Framingham score.
Results: Up to date we included 106 patients with median age of
31 years; 59% men; 75% multiexperienced, 80% receiving a protease
inhibitor (PI) for a minimum of 6 months; median CD4 cell count
454/mmc; and HIV viremia undetectable in 70% of cases. The
inﬂammatory markers showed elevated values of TNFa (42%), high
sensitive PCR (36%), IL6 (12%) and MPC1 (6%). The prevalence of
metabolic syndrome was 14.3% and 20% of patients had a cardiovascular
risk more than 10% according to Framingham score. The presence of
metabolic syndrome was signiﬁcantly correlated only with increased
values of MPC1 (p = 0,026) in uni- and multivariate analisys. High
cardiovascular risk was not correlated with the presence of inﬂammation.
Conclusion: Despite antiretroviral therapy, we observed the presence of
chronic inﬂammation in up to 42% of patients and this was correlated
with the metabolic syndrome, but not with a high cardiovascular disease
risk.
P2190 Impaired antibody response to pandemic H1N1 inﬂuenza
vaccination in HIV-positive patients
C. Noah*, G. Mohrmann, G. Beckmann, H. Sahly, H.J. Stellbrink
(Hamburg, DE)
Objectives: A new strain of the H1N1 Inﬂuenza A virus emerged in
North America in April 2009 and spread around the world. Components
of the seasonal H1N1 inﬂuenza vaccine of 2009/2010 did not protect
against the pandemic variant, thus vaccination speciﬁc for the pandemic
(H1N1) inﬂuenza was recommended. Monitoring of as yet vaccinated
individuals showed no excess of serious adverse events. Vaccine induced
H1N1-speciﬁc antibodies in healthy persons are expected to protect
against infection. In contrast, little is known about the vaccine’s
immunogenicity in HIV-positive patients.
Individuals and Methods: Forty seven HIV-positive patients and 71
healthy individuals who received a single vaccination against pandemic
inﬂuenza (adjuvanted Pandemrix® vaccine) between Oct. and Dec.
2009 were included. Serum was available from HIV patients before
vaccination and pandemic outbreak and from patients and healthy
controls at least 4 weeks following vaccination. The Pandemic New
Inﬂuenza A IgG ELISA (Genzyme Virotech) was used to detect speciﬁc
antibodies and the magnitude of antibody response. The Virotech Unit
(VU=OD sample/OD cut-off X 10) is regarded as a measure of antibody
content of the sample, with a VU 11 indicating a positive response.
Results: Twelve of the 47 HIV patients but only 2 of the healthy
individuals (25.5% vs. 2,8% respectively) did not show sufﬁcient
antibody response after vaccination (p = 0.0003; OD 11.829; 95%CI
2.5–55.8). Responses 4 weeks following vaccination were signiﬁcantly
higher among healthy individuals (16.8±4.2 VU) as compared to HIV
patients (13.8±5.3 VU) (p = 0.0004; 95%CI 1.4−4.5). Antibodies were
detected in 8 HIV patients prior o the pandemic outbreak, with a
signiﬁcantly lower mean VU (13.45±2.3VU) than that of vaccinated
healthy individuals (p< 0.0001). There was no correlation of antibody
responses with current or nadir CD4 cell count, total IgG or plasma HIV
RNA (r 0.089; p 0.5).
Conclusions: Regardless of antiretroviral therapy, HIV-infected patients
showed a weaker antibody response to a single adjuvanted pandemic
H1N1 vaccination, indicating limited immunogenicity and protection
of the vaccine. The mechanisms of the impaired antibody responses,
as well as alternative vaccines or vaccination strategies require further
investigation. Some HIV-infected subjects apparently had cross-reactive
antibodies prior to the epidemic, indicating previous exposure to related
viral antigens.
P2191 Differences in serum levels of soluble Fas and FasL in
patients with human immunodeﬁciency virus, human
herpesvirus type 8 and herpes simplex virus type 2 infections
O. Dakovic Rode*, A. Markotic, M. Kujundzic Tiljak, S. Zidovec Lepej,
J. Begovac (Zagreb, HR)
Objectives: Fas mediated apoptosis is considered to be an important T
cells depletion mechanism in HIV-infection. Soluble Fas (sFas) prevents
apoptosis by inhibiting Fas binding with Fas ligand or soluble FasL
(sFasL). We investigated possible differences in sFas and sFasL serum
levels in HIV patients with herpes simplex type 2 (HSV-2) and human
herpesvirus type 8 (HHV-8) coinfection.
Methods: Levels of sFas and sFasL were measured by EIA in 136
HIV patients sera divided according to HHV-8 and HSV-2 antibody
status. Four HIV patients groups were studied: 1) without HHV-8 and
HSV-2 (n = 48), 2) with HHV-8 and HSV-2 (n = 21), 3) with only
HSV-2 (n = 61), 4) with only HHV-8 (n = 6). HIV-negative persons
(n = 39) without HHV-8 and HSV-2 and HIV-negative with HSV-2
antibodies (Ab) (n = 20) served as controls. In statistical analyses we used
the Kruskal-Wallis and Mann-Whitney-Wilcoxon tests. The Bonferroni
correction was applied for pairwise comparisons.
Results: The median concentrations of sFas and sFasL were: 589.3 pg/ml
and 47.8 pg/ml in HIV patients without HHV-8 and HSV-2; 892.3 pg/ml
and 72.2 pg/ml in HIV patients with HHV-8 and HSV-2; 717.6 pg/ml
and 40.9 pg/ml in HIV patients with only HSV-2; 1010.6 pg/ml and
70.9 pg/ml in HIV patients with only HHV-8; 678.9 pg/ml and 61.4 pg/ml
in HIV-negative controls; 695.2 pg/ml and 59.9 pg/ml in HIV-negative
controls with HSV-2. Higher sFas and sFasL levels were found in HIV
patients with HHV-8 and HSV-2 compared to HIV patients without
HHV-8 and HSV-2 Ab (P< 0.001; P = 0.001, respectively) and also
compared to HIV patients with only HSV-2 Ab (P 0.034; P< 0.001,
respectively). Higher sFas was also found in HIV patients with HHV-8
and HSV-2 Ab compared to HIV-negative controls without HHV-8 and
HSV-2 Ab (P = 0.046). HIV patients with only HHV-8 Ab had higher
sFas than HIV patients without HHV-8 and HSV-2 Ab (P = 0.006).
Lower sFasL levels were found in HIV patients with only HSV-2 Ab
than in HIV-negative controls with and without HSV-2 Ab (P = 0.001;
P< 0.001, respectively).
Conclusion: Our results suggest that HHV-8 and HSV-2 infections may
mediate apoptosis signalling molecules sFas and sFasL. The increased
sFas concentrations found in HIV patients with positive HHV-8 and
HSV-2 Ab suggest suppression of Fas mediated apoptosis. Our ﬁndings
need to be conﬁrmed by additional in vitro data and further studies are
necessary to deﬁne the clinical signiﬁcance of these ﬁndings.
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P2192 Disclosure of HIV serostatus and quality of life among
people living with HIV/AIDS in Thailand
N. Hiransuthikul*, Y. Leelukkanaveera, P. Sithisarankul, N. Buathong
(Bangkok, TH)
Background: HIV disclosure increases social support and avoid the
enhanced risk of transmission among sexual partners due to concealment.
However, it can impact the quality of life (QOL) of HIV-infected patients.
Objectives: To determine the rate of HIV disclosure and examine the
association between the HIV disclosure and QOL among HIV infected
patients in Thailand.
Methods: A cross-sectional study was conducted at the outpatient
departments of 16 community hospitals in Thailand during April 1−30,
2007. Sociodemographic characteristics, illness history, current health
status, HIV disclosure, and duration from knowing HIV infection to
disclosure were obtained by questionnaire interview. QOL was assessed
by participants’ rating score using visual analogue scale.
Results: There were totally 1,279 HIV-infected participants with the
mean age of 36.4 years and 53.9% female. We found that 82.5%
and 70.7% of participants disclosed their HIV serostatus to family
members and neighbors. For 796 married participants, 84.2% disclosed
the serostatus to their spouse. Among 580 clients who had coworkers,
46.9% disclosed the serostatus to their colleagues. The median duration
from knowing HIV infection to disclosure was 1 month. The mean
QOL scores among participants who did not disclose the serostatus to
family member, spouse, coworker, and neighbor were 82.0, 83.4, 85.5,
and 83.0 respectively compared to 78.9, 79.9, 79.2, and 78.9 among
participants who disclosed. Multivariate analysis showed that participants
who disclosed their serostatus to all family members or coworkers had
signiﬁcantly lower mean QOL scores than participants who did not.
Conclusion: HIV disclosure can have negative impact on QOL and
should be integrated into the overall counselling and psychosocial
support of people living with HIV. Comprehensive community education
for social support of the infected patients should also be implemented.
P2193 Evaluation of experienced patients treated with raltegravir
R.M. Tavares*, N. Luis, T. Baptista, I. Antunes, A.C. Miranda,
D. Fernandes, F. Borges, F. Ventura, K. Mansinho (Lisbon, PT)
Purpose of the study: In the past few years several new antiretroviral
drugs have been used for the treatment of HIV infected patients,
particularly in those with severe adverse events or on salvage regimens.
Evaluating drug performance in clinical settings is of the utmost
importance for the improvement of patient care. The aim of this study
was to identify the main reasons for raltegravir (RAL) prescription in a
cohort of heavily pre-treated HIV-infected patients followed in our centre
and to evaluate the safety, efﬁcacy and tolerability of RAL-containing
regimens.
Methods: We performed a retrospective analysis of all patient ﬁles,
between 1st January 2008 and 31st June 2010, which included raltegravir
in their therapeutic regimen. Demographic, epidemiologic and clinical
parameters were recorded and analyzed.
Summary of the results: 56 patients were on RAL-containing regimens;
5 patients were excluded due to insufﬁcient data. The average time since
prescription of Raltegravir was 14 months (2−26 months). Of the 51
patients analysed, 41 were male (80.4%). 46 were HIV-1 and 5 were
HIV-2 (9.8%) infected patients; 39 (76.5%) were born in Portugal, and
12 (23.5%) were from other countries. The mean patient age was 51
years (35−77 years). On average, HIV-infection had been diagnosed 15
years earlier, and most of the patients were heavily pre-treated, with a
median of 5 previous treatment regimens (1 to 14). At the time RAL
was prescribed, patients had a mean 332 (4–1147) and a median of 289
TCD4+ cells/mL. Main reasons behind RAL prescription were a failing
regimen in 41 patients (80.4%), a switch from enfuvirtide in 8 patients
(15.7%), or due to adverse events to the previous regimen in 2 patients
(3.9%). The new regimen was generally well tolerated. Most (94.1%)
of the patients are still on the same regimen, 2 (3.9%) discontinued
due to regimen failure, and 1 due to regimen-related toxicity. On those
kept on a RAL-containing regimen, there was a mean increase of 62.7
TCD4 cells/mL at 24 weeks (in those who were on the RAL-containing
regimen for less than 24 weeks, the last absolute T CD4 cell count was
considered).
Conclusions: The main reason behind RAL prescription in this
population was failure to ongoing treatment. There were no signiﬁcant
adverse events associated with RAL-containing regimens, which were
generally well tolerated. A trend towards an increase in T CD4 cell
count was observed, both in HIV-1 and HIV-2 infected patients.
P2194 Underreporting and non-adherence to post-exposure
prophylaxis among healthcare workers in Iranian university
hospitals
S. Shokouhi*, L. Gachkar, P. Youhanaee, M. Sajadi (Tehran, IR;
Baltimore, US)
Objectives: To determine the rate of non-adherence to post-exposure
guidelines in occupationally exposed healthcare workers (HCWs) in Iran.
Methods: Questionnaire study performed on a randomly selected sample
of HCWs (residents, interns, nurses, and nurse aides) in the teaching
hospitals of Shahid Beheshti University of Medical Sciences (Tehran,
Iran) during the years 2006–2007.
Results: Among 650 participant, 347 (53.4%) reported at least one
NSI, with 181 (27.8) reporting splash exposures. Of the 347 HCW
with NSI or splash exposure, 143 took no further action, 135 cared for
themselves, and 69 reported their exposures. 80.1% of persons (278 of
347) did not report exposures. Of the known total 75 HIV, HBV, and HCV
exposures, 40% adequately followed the guidelines. Those who presented
to physicians were no more likely to follow guidelines than those who
self-treated (p = 1.0). There were no cases of seroconversion among
these 75 known exposures. The total rate of non-adherence (number of
underreported and noncompliant with recommendations) in this study
was 88.2%.
Conclusion: This study highlights the problem of occupational exposure
to bloodborne pathogens in HCWs in the developing world. Although
none of the people in our study knowingly contracted an occupational
illness, the sheer number of under-reported exposures and inadequate
post-exposure care demonstrate the continuing risk of working in a health
care setting in developing countries. Continuing educational efforts
directed at HCWs and those who care for them are needed to address
this problem.
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P2195 Factors inﬂuencing the duration of illness in pandemic
H1N1/2009
J.H. Cho, J.H. Lee*, Y.H. Park (Seoul, KR)
In order to devise adequate public health plan for mitigating impacts of
the pandemic inﬂuenza, there is need to predict the potential longevity
of the disease. The auxiliary police (AP) are conscripted policemen of
Korea, healthy young men in their early 20s and living in barracks but
have frequent contact with general population unlike military personnel.
Therefore, they are vulnerable in the epidemic of infectious diseases.
During the pandemic of 2009 H1N1 all of them with inﬂuenza like
illness (ILI) around Seoul were admitted in our hospital for isolation
and treatment.
We performed real time RT-PCR (rRT-PCR), rapid inﬂuenza antigen
test (RIAT, BinaxNOW®), complete blood cell count, C-reactive protein
(CRP), chest X-ray (CXR) and got the histoty of symptoms and vital
signs of all admitted patients.
From 10th August 2009 to 14th January 2010 (prior to vaccination),
744 patients were presented with ILI among total 23,000 AP in
the target area. 317 were conﬁrmed 2009 H1N1 by rRT-PCR. The
estimated incidence rate of conﬁrmed 2009 H1N1 in AP was 596.6
cases per 100,000 person-years. The median age of patients was 21
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years old (interquartile range [IQR], 20.5–21.5). The median peak body
temperature (peak BT: the highest body temperature after onset of
illness) was 38.8º (IQR, 38.15–39.45). The median duration of fever
(interval from the onset of fever (BT 37.5º) to the time at which
BT <37.5º was attained and maintained for >24hrs) was 72 hours
(IQR, 54−90). Fever was a universal symptom in patients with H1N1.
Other symptoms included cough (presented in 96% of patients), sputum
(73.7%), headache (66.9%), sore throat (66.2%), rhinorrhea (61.2%)
and gastrointestinal symptoms (19%). 3 patients (0.9%) had pulmonary
inﬁltration in CXR. All acquired data were not distributed normally
and small number so analyzed nonparametrically with Mann-Whitney U
test (MWU) and Cox regression of defervescence. Patients adequately
treated with antivirals (begin within 48hrs after onset of symptoms) had
signiﬁcantly shorter duration of fever (p< 0.001 MWU and Cox). All
other symptoms, result of RIAT, peak BT and inadequate use of antiviral
agents had no signiﬁcant inﬂuence on the duration of fever.
The median duration of fever in 2009 H1N1 were 72 hours. Only
adequately administered antiviral agents can shorten the duration of
illness.
P2196 Secondary bacterial infections in patients with seasonal
inﬂuenza A and pandemic H1N1
K. Liderot*, M. Ahl, V. O¨zenci (Stockholm, SE)
Objectives: To analyse and compare the secondary bacterial infections
related to seasonal inﬂuenza A and pandemic H1N1.
Methods: The detection of inﬂuenza virus was made from nasopharynx
aspirate or nasopharynx swab samples by immunoﬂuorescence (IF)
and in some cases also in cell culture for seasonal inﬂuenza A and
by rRT-PCR for pandemic H1N1. Detection of bacteria from sputum,
bronchoalveolar lavage and blood samples were made by conventional
methods.
Results: A total of 352 patients with seasonal inﬂuenza A (between
2005–2008) and 742 patients with pandemic H1N1 (2009) were
included in the study. All patients were cross examined in the clinical
microbiology laboratory database of Karolinska University Hospital in
Huddinge for the presence of positive bacteria cultures from lower
airways or blood. Positive bacterial cultures were shown in 44/352
(12,5%) patients with seasonal inﬂuenza A and 38/742 (5,1%) patients
with pandemic H1N1. When patients who had positive bacterial cultures
were considered, the patients with pandemic H1N1 had longer hospital
stay than patients with seasonal inﬂuenza A (15,1 vs. 8,5 days,
respectively). Underlying diseases were common in both the seasonal
inﬂuenza A and the pandemic H1N1 group, 30/44 (68,2%) and 24/38
(63,2%) respectively. Numbers of culture positive lower airway samples
were higher in patients with seasonal inﬂuenza A than in patients with
pandemic H1N1 15/352 (4,3%) and 13/742 (1,8%) respectively. When
blood cultures were analyzed, 12/352 (3,4%) of the patients with seasonal
inﬂuenza A and 12/742 (1,6%) of the patients with pandemic H1N1
had positive cultures. The three most common bacteria isolated from
lower airway samples were S. pneumoniae, S. aureus and H. inﬂuenzae.
In blood cultures, S. pneumoniae, coagulase-negative staphylococci and
S. aureus were the most common isolates in both groups.
Conclusion: The present study shows that secondary bacterial infections
were more common in patients with seasonal inﬂuenza A than in patients
with pandemic H1N1. In both groups most of the patients with positive
bacterial cultures had underlying diseases. The bacterial proﬁles of the
positive cultures were similar in both groups.
P2197 Virological diagnosis of paediatric severe respiratory
infections during circulation of pandemic inﬂuenza A/H1N1
in Rome
A. Pierangeli, C. Scagnolari, C. Selvaggi, K. Monteleone, S. Trombetti,
E. Di Biase, C. Moretti, P. Papoff, F. Midulla, G. Antonelli* (Rome, IT)
Objectives: The emergence of A/H1N1 2009 pandemic inﬂuenza virus
pointed to the need of improving virological diagnosis to have better
data on disease impact caused by respiratory viruses.
Methods: A surveillance program was conducted from November 2009
to March 2010, in children attending pediatric Emergency Department
(ED) at the Sapienza University Hospital of Rome, for acute respiratory
infections. Exclusion criteria were underlying chronic diseases (including
cystic ﬁbrosis, chronic pulmonary disease, congenital heart disease, and
immunodeﬁciency). Detection of 14 different respiratory viruses was
performed with a panel of speciﬁc and sensitive RT-PCR assays.
Results: The majority of acute respiratory infections (58%) presented
a viral pathogen: the most common virus was respiratory syncytial
virus (RSV), being detected in 64% of the positive samples; pandemic
A/H1N1 inﬂuenza virus (pH1N1) was detected in 16% of the positives;
rhinovirus (RV) in 15%. Patient signs and symptoms at ED presentation,
epidemiological criteria and clinical data were not sufﬁcient to identify
the different viral respiratory infections.
Analysis of results of PCR tests performed in both nasal washings and
pharyngeal swabs indicated a higher sensitivity of swabs in inﬂuenza
virus detection, a substantial concordance of both specimens for RSV
and a signiﬁcant better detection of RV in nasal washings. Quantiﬁcation
of RSV, pH1N1 and RV genome by real-time PCR in respiratory samples
showed a clear concordance with qualitative PCR results but no clear-cut
association of viral loads with illness course was present.
Conclusions: Given that clinical and epidemiological criteria are not
sufﬁcient to identify viral respiratory infections, a timely virological
diagnosis aimed at detecting the major respiratory viruses could be
helpful to better manage infected patients. Interestingly, testing nasal
washings for RSV, inﬂuenza A, and RV would diagnose the majority of
pediatric severe acute respiratory infections.
P2198 Seasonal versus pandemic inﬂuenza: differences in severity,
course of illness and treatment
J.C. Rahamat-Langendoen*, A. Riezebos-Brilman, E.D. Tutuhatunewa,
E.H. Scho¨lvinck, H.G. Niesters (Groningen, NL)
Objectives: Pandemic Inﬂuenza A H1N1nv has been described as a
relatively mild disease. However, severe infections with Inﬂuenza A
H1N1nv in patients without underlying illness have occurred. In order to
determine the impact of Inﬂuenza A H1N1nv, we collected systematically
clinical information of all patients hospitalized because of pandemic
inﬂuenza, and compared this with previous seasonal inﬂuenza epidemics.
Methods: Clinical and virological data were collected from all patients
with Inﬂuenza A H1N1nv, hospitalized in the University Medical Centre
Groningen. In addition, data from patients admitted with seasonal
inﬂuenza during the years 2007–2009 were retrospectively gathered. Data
were analyzed using SPSS 18.0.
Results: 84 patients were hospitalized because of pandemic inﬂuenza,
compared to 60 with seasonal inﬂuenza (80% Inﬂuenza A, of which 67%
Inﬂuenza A H3). Age distribution was comparable between seasonal
and pandemic inﬂuenza (mean 22.6 vs 23.6 yrs). Patients hospitalized
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because of seasonal inﬂuenza had more underlying illness (85% vs
69%, not signiﬁcant). In both groups, admission at the Intensive Care
Unit (ICU) was necessary in approximately 30% of patients. Patients
admitted to the ICU with seasonal inﬂuenza were younger than those
admitted because of pandemic inﬂuenza (median age 4.5 vs 14 yrs).
Both groups were admitted to the ICU within 2 days after the ﬁrst day of
illness; both groups had equal amount of underlying illness. Duration of
hospitalization was longer in patients with pandemic inﬂuenza (median
23.5 days vs 9 days). The most striking difference was antiviral treatment
with oseltamivir: 10% of the patients with seasonal inﬂuenza were treated
with oseltamivir, compared to 81% in patients with pandemic inﬂuenza.
Similarly, patients admitted to the ICU with seasonal inﬂuenza were
less treated with oseltamivir (12.5% vs 84% in patients with pandemic
inﬂuenza). Seven patients (8%) died because of infection with Inﬂuenza
A H1N1nv, compared to three (5%) with seasonal inﬂuenza. Resistance
to oseltamivir was detected in four patients with pandemic inﬂuenza,
compared to 5 with seasonal inﬂuenza.
Conclusion: Comparison of seasonal with pandemic inﬂuenza in patients
hospitalized in our center shows similarities in severity and course
of illness. However, antiviral treatment was more frequently started in
pandemic inﬂuenza as compared to seasonal inﬂuenza.
P2199 Human parechovirus infections in a hospitalised patient
population in Northern Italy, 2008–2010
A. Piralla*, M. Furione, F. Rovida, F. Baldanti (Pavia, IT)
Objectives: Human parechoviruses (HPeVs) infection are associated
with a wide range of clinical syndromes such as respiratory,
gastrointestinal and neurologic disease. In particular, HPeV3 have been
associated with neonatal sepsis-like illness and neurological illness. The
aim of this study was to investigate the epidemiology and the clinical
manifestations of HPeVs infection in a hospitalized patient population.
Methods: Respiratory samples (n = 5288) from 3525 patients and
cerebrospinal ﬂuid samples (CSF; n = 356) from 345 patients collected
during a two years period (October 2008–October 2010) were
tested retrospectively by HPeV-speciﬁc real-time RT-PCR. Phylogenetic
analysis of VP3/VP1 region was applied to genotyping the positive
samples obtained. Clinical data were retrospectively analyzed to better
deﬁne the clinical impact of HPeV infection.
Results: Overall, 16/3525 (0.4%) patients had respiratory samples
positive for HPeV. Of these, 12 had a single positive sample, while 2
had multiple positive samples. 3/345 (0.9%) patients had positive CSF
samples. In 4/19 HPeV-positive patients multiple samples (e.g. stool,
plasma, CSF or respiratory samples) were available, and HPeV positivity
was showed in all specimens. Eleven patients (57.9%) were infected with
HPeV1 strain, 7 (36.8%) with HPeV3 and 1 (5.3%) with HPeV6 strains.
Ten of the 16 HPeV patients with positive respiratory samples were
found to be co-infected with other respiratory viruses (8 with rhinovirus
and 2 with coronavirus OC43) Five of HPeV3 infected patients were less
than 1 month of age and HPeV infections was associated with sepsis-like
illness.
Conclusion: HPeV does not circulate with high prevalence in
hospitalized patient population in northern Italy. HPeV is associated with
severe clinical syndromes in newborns. HPeVs should be enclosed in
diagnostic panels of virus detection in CSF and respiratory samples.
P2200 Type-speciﬁc human papillomavirus infection in female
anal and cervical brushings
A. Pierangeli*, F. Cannella, K. Monteleone, C. Selvaggi, S. Verzaro,
C. Scagnolari, O. Turriziani, M. Indinnimeo, G. D’ettorre,
A.M. Degener, G. Antonelli (Rome, IT)
Objectives: Despite the recognition of HPV anal infection as strongly
associated to progression to anal carcinoma, epidemiologic data have
shown no reduction in the incidence of this cancer so far, probably due
to an increase in high-risk sexual behaviours. Recent data showed that in
immuno-competent individuals HPV infection occurs in the anal canal
even in the absence of anal intercourse and, with a higher frequency,
in cervical HPV-positive women. However to date, the prevalence of
speciﬁc HPV genotype infection in anal infection in relation to genital
HPV have been only marginally addressed.
Methods: We here report preliminary results of a study on women
attending a colo-proctological clinic over the period 2006–2010, for
screening programs or referred by general physicians. The presence of
speciﬁc HPV genotypes in anal and cervical brushings was determined
by two PCR assays followed by sequencing; this method allows the
identiﬁcation of a wide range of mucosal HPV types.
Results: From a total of 145 anal brushings, HPV genotypes detected
in anal samples were: HPV 6 (13 cases), HPV 16 (8 cases), HPV 53,
HPV 66 and HPV 84 (3 cases each), HPV 31 (2 cases), and HPVs 11,
58, 61, 62, 74 and 87 (1 case each).
Considering 117 women for whom anal and cervical brushings were
concomitantly obtained, HPV was equally common in cervical and in
anal samples (25% vs. 24%). Despite the fact that HPV 6 was the most
frequent genotype in anal infections, percentage of high-risk HPVs in
anal samples were similar to the corresponding cervical samples (43%
vs. 40%).
Half patients presenting HPV positive anal samples (13/26) were HPV
negative at the cervical sample, and different HPV genotypes occurred
in 4/13 (31%) women positive at both anal and cervical samples.
These results suggest a different way of acquisition of the infection
or, alternatively, anal HPV may be acquired from vaginal/cervical HPV
infection but may be more persistent in infection.
Conclusion: Our results support the need of screening programs for
HPV anal infection directed not only to cervical HPV-positive women,
but also to general population with the aim to further evaluate anal
HPV genotypes distribution and to monitor their potential persistence
and progression to anal dysplastic lesions.
P2201 Antiviral effect of siRNA against Langat virus in cell
culture and organotypic hippocampal rat brain slices
C. Mafﬁoli*, S. Hofer, S. Leib, O. Engler (Berne, Spiez, CH)
Objectives: Tick borne encephalitis virus (TBEV) is the causative agent
of tick borne encephalitis (TBE), a potentially fatal neurological infection
affecting humans in Europe and Asia. TBEV, which belongs to the
mammalian group of tick-borne ﬂaviviruses, is transmitted by the bite
of infected ticks and despite the availability of a vaccine, approximately
2000 infections occur every year in Europe. To date there is no effective
antiviral therapy for TBE.
Methods: The antiviral effect of RNA mediated interference (RNAi)
by small interfering RNA (siRNA) was evaluated in cell culture and
organotypic rat hippocampal cultures (OHC). Langat virus (LGT), a
naturally attenuated ﬂavivirus strain closely related to TBEV exhibits
a low-pathogenicity for humans but retains neurovirulence for rodents.
LGT was used herein for the establishment of an in vitro model of TBE.
LGT productively infected both, dissociated HeLa cells and 400mm-
thick organotypic tissue slices of rat hippocampus cultured on a porous
membrane. Once infection was established, we analyzed the efﬁcacy of
19 different siRNA sequences targeting deﬁned regions of the Langat
genome to inhibit virus replication in the 2 in vitro systems.
Results: The most efﬁcient suppression of virus replication in both
in vitro systems was achieved by siRNA sequences targeting genes
within the envelope and the 3′ untranslated region (UTR). When siRNA
was administered to HeLa cells before infection with LGT, a 1000-
fold reduction of infectious virus particles was observed while delayed
treatment after infection decreased the viral replication by 90%. In OHC
the replication of LGT was reduced by up to 97% in the pretreatment
paradigm compared to OHC transfected with non-targeting siRNA used
as controls.
Conclusion: Organotypic rat hippocampal cultures represent a suitable in
vitro model to investigate neuronal infection mechanisms and treatment
strategies in preserved three-dimensional tissue- and cyto-architecture
and cellular composition of the brain. Our results demonstrate that
siRNA is an efﬁcient approach to limit LGT virus replication in vitro.
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P2202 May oysters favour zoonotic transmission of norovirus?
M. Pommepuy, H. Maalouf*, J.-C. Le Saux, N. Ruvoen-Couet, J. Le
Pendu, F.S. Le Guyader (Plouzane, Nantes, FR)
Shellﬁsh were identiﬁed as a vector for human enteric pathogen
transmission more than 150 years ago, as human pathogens may be
accumulated by shellﬁsh, during their ﬁlter-feeding activity. Contamina-
tion of shellﬁsh-growing waters with human sewage was recognized as a
contributing cause of such contaminations. Owing to the high densities of
cows bred in some coastal areas the hypothesis of seawater contamination
may be raised and thus the potential oyster contamination by bovine
pathogens. This is of special interest regarding norovirus (NoV) main
cause of acute gastroenteritis in human (genogroups (G)I and II) but
also present in cattle (GIII). A study was conducted to evaluate farm
and urban activities impact on shellﬁsh contamination in a coastal
area devoted both to intensive agriculture and shellﬁsh aquaculture
(Northern Brittany, France). Bovine stool collected in this area were
found contaminated by GIII NoV (18%). Environmental investigation
was conducted over a one year period. River and estuarine waters were
found contaminated by both human NoV (7% for NoV GI and 24%
for NoV GII) and bovine NoV (14%), whereas NoV GI were detected
in 4%, GII in 21% and GIII in 2% of oyster samples. However, more
interestingly, when comparing concentration detected in water and oyster
samples important differences were noticed with NoV GI being much
more efﬁciently concentrated than GII or GIII.
To explain such variations, we evaluated the binding speciﬁcity of these
NoV strains to oyster tissues. Clear difference were detected with NoV
GI.1 binding via an A-like Ag to digestive tissues, whereas GII.4 bounds
to digestive tissues, gills and mantle via two ligands. No ligand could be
identiﬁed for NoV GIII in oyster tissues nor to human, explaining the
low frequency of these strains in oyster samples. This suggest also that
the NoV GIII are unlikely to infect human.
P2203 Cerebrospinal ﬂuid ﬁndings in patients with different
clinical features of tick-borne encephalitis treated with
glucocorticoids
I. Vanaga*, I. Reinholde, A. Broduzˇa, J. Storozˇenko, B. Rozentale
(Riga, LV)
Objectives: Analysed cerebrospinal ﬂuid (CSF) ﬁndings in patients with
different clinical features of tick born encephalitis (TBE) and compared
them in regard to using glucocorticoids.
Methods: 367 medical records of patients, treated at the Infectology
Center of Latvia during 2000 to 2004, were analysed. Clinical features
of illness, CSF pleocytosis, neutrophils/lymphocytes (neu/ly) ratio and
protein level were compared. The case deﬁnition was conﬁrmed by
detecting speciﬁc antibodies (IgM Ab ELISA) in the blood and in the
CSF.
Results: 367 cases of TBE were reviewed. The patients ranged in age
from 14 to 80. The male/female ratio was 196/171. The speciﬁc IgM Ab
were detected in the blood − 94%, in the CSF − 56% of all cases and
in 51% cases Ab were detected in both.
Four different clinical forms of illness were observed. The most
frequent form was meningitis and it was determined in 68% of cases,
meningoencephilitis in 14% and meningoencephalomyelitis in 8%. The
median illness day at admission was 14. Different levels of altered
consciousness (scores of GCS 12) have been developed in 19% of
patients with encehalitis features. Acute CSF samples were obtained at
admission and convalescence samples 2 weeks later or at discharge.
The mean pleocytosis of CSF at admission was 265 and protein level
was 0,66 g/l. There were no differences regarded to clinical forms or
altered consciousness. Analysed neu/ly ratio, we had found that it was
higher in cases with focal brain damage features (p = 0,014) and with
altered consciousness (p = 0,018). Convalescence CSF ﬁndings had not
signiﬁcant differences regarding to clinical form.
76,6% of all patients had received glucocorticoids. The convalescence
CSF ﬁndings had not signiﬁcant differences with patients who had not
received them.
Conclusion: CSF ﬁndings have not been correlated with severity of tick
born encephalitis. Using corticosteroids did not impact CSF sanation in
TBE.
P2204 Lymphocytic choriomeningitis virus infection within
the same geographical area (southern Spain) during a
three-year period
M. Pe´rez-Ruiz*, J.M. Navarro-Marı´, M.P. Sa´nchez-Seco, M.I. Gegu´ndez,
G. Fedele, F. de Ory-Mancho´n (Granada, Majadahonda, Madrid,
Alcala´ de Henares, ES)
Objective: Lymphochoriomeningitis virus (LCMV) infection is trans-
mitted to humans by its reservoir (rodents) through contact by biting
or inhalation of contaminated stools and urine from these animals. We
describe clinicoepidemiological and virological data of two cases of
LCMV infection identiﬁed within the same geographical area during
a 3-year period.
Methods: Both cases presented with a clinical suspicion of viral
meningitis. Cerebrospinal ﬂuid (CSF) samples from the two cases were
processed by commercial and in-house real-time PCR assays for routine
investigation of viruses: enterovirus (Xpert EV, Cepheid), herpes simplex
1 and 2 viruses and varicella zoster virus (Roche Diagnostics) and
Toscana and mumps virus (in-house method). Another aliquot of the CSF
was used for culture in Vero, rhabdomyosarcoma and MRC-5 cell lines.
A third aliquot of the specimen as well as serum samples simultaneously
collected were frozen at −80ºC for further investigations of special viral
pathogens. Clinical and analytical data were recorded.
Results: All routine virological studies from the two cases were
negative. The presence of LCMV-speciﬁc IgM and IgG antibodies
(indirect ﬂuorescence assay) was observed in the serum samples of both
patients. Generic RT-PCR for detection of arenaviruses was negative.
The presence of LCMV was conﬁrmed by speciﬁc RT-PCR. Viral isolate
was only recovered from the ﬁrst case. A slight cytopathic effect was
suspected, although the slow progression of the virus in cell culture
made this effect indistinguishable from the effect due to ageing of cell
monolayers. The growth of LCMV was conﬁrmed by positive speciﬁc
RT-PCR in serial 10-fold dilutions from the Vero culture supernatant.
Case 1 (female, 24 years old) was detected in 2008, and case 2 (male,
39 years old) in 2010. Both individuals lived in the same neighbourhood
of Granada (southern Spain), characterized by its low socioeconomic
level.
Conclusion: 1. Serologic tests are especially useful for detecting less
frequent viruses, thus they should always be considered good tools in
suspected cases of viral meningitis without an etiologic diagnosis. 2.
Higher sensitivity is obtained with molecular methods for the recovery
of viral isolates. 3. An epidemiological study is being conducted to
investigate the presence of reservoirs of the virus and the mechanisms
of transmission involved in human LCMV cases.
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P2205 Sporadic detection in children during a 25-year surveillance
in Palermo, Italy, clariﬁes the zoonotic potential of G6
rotavirus strains
F. Bonura, V. Rotolo, M.A. Platia, A. Cascio*, C. Colomba,
G.M. Giammanco, S. De Grazia (Palermo, Messina, IT)
Objectives: G6 rotavirus is frequently isolated from cattle but has been
sporadically detected in humans. Emerging rotaviruses such as G8, G10
and G12 strains, are believed to have originated from animal rotaviruses
that were introduced into the human population through interspecies
transmission. In order to deﬁne the zoonotic capability of G6 rotaviruses
we conducted a retrospective study of the G6 strains circulation in
children hospitalised with diarrhea over 25 years.
Methods: 4,934 faecal samples were obtained from children, less than
ﬁve years, hospitalised for gastroenteritis in Palermo, Italy, at the “G.
Di Cristina” paediatric Hospital from 1989 to 2009. The samples
were screened for the presence of rotaviruses by EIA and/or RT-
PCR and positive specimens were G/P genotyped through multiplex
nested RT-PCR. G6 isolates were further characterised by sequence and
phylogenetic analysis of the VP6, NSP4 and NSP5 genes.
Results: During the 25-year surveillance only seven strains were
characterised as G6. The sequence analysis of the VP7, VP4, VP6,
NSP4 and NSP5 genes included the Italian G6 strains in either of
two genomic constellations: G6-P[9]-I2-E2-H3 and G6-P[14]-I2-E2-H3.
The phylogenetic analysis of the ﬁve genome segments revealed genetic
diversity at lineage or sub-lineage level for most of the isolates, but some
lineage/sublineage combinations were retained over time. Two G6P[9]
strains isolated in 2003 shared99.5% nt identity in all the ﬁve segments
analysed, which indicates a possible clonal origin. Genome segments of
human G6P[14] strains revealed closer relatedness to ovine and antelope
rotavirus strains, while the G6P[9] Italian rotaviruses were close to feline
or human/feline strains.
Conclusion: The data obtained in this study conﬁrm that G6 rotaviruses
can still be considered accidental human pathogens occasionally
transmitted from animal sources and some deﬁned genome constellations
may be required for transmission to humans. The ﬁnding of two
G6 isolates clonally related demonstrates that these strains have the
capability for human-to-human transmission. Circulation in children
even at low rates may provide a good opportunity for animal and
human rotaviruses to reassort and generate novel strains. Continuous
surveillance will be paramount to detect the eventual introduction in the
human population of unusual strains with high transmissibility among
humans that may escape immunity induced by the vaccines.
P2206 Human papillomavirus infection prevalence in Spain.
Preliminary results of a screening programme in Castilla
y Leo´n, Spain
M.L. Ferna´ndez Rueda, N. Calvo Sa´nchez, A.M. Bla´zquez de Castro,
M.N. Gutie´rrez Zuﬁaurre, S. Mun˜oz Criado, J.L. Mun˜oz Bellido*
(Salamanca, ES)
Objectives: Human papilomavirus (HPV) is the main cause of genital
cancer in women. The Castilla y Leo´n Autonomic Community (SPAIN)
is developing a program of genital cancer prevention in women, which
includes screening for HPV and genotype (GT) identiﬁcation. Here we
report HPV infection prevalence and features among >10,000 women
involved in this program during 2010.
Methods: The Genital Cancer Prevention Program includes 35−55 years
old women attending to our centers. We determined the presence and
GTs of HPV in cervical brushing samples obtained speciﬁcally for HPV
screening, from women attending to centers involved in this program,
between January 2010 and November 2010. HPV presence and GTs were
determined by PCR and microarray hybridization (Geno´mica, SPAIN).
Results: We studied 10,442 samples during 11 months. 806 (7.7%) were
positive for HPV. Among samples positive for HPV, 593 (73.6%) were
positive for one GT, and 213 samples (26,4%) were positive for between
2 and 7 GTs. 160 samples (19.9% of positive samples) were positive for
2 GTs, 29 (3.6%) for 3 GTs, 17 (2.1%) for 4 GTs, and 7 (0.9%) for
5−7 GTs. Among samples positive for 1 GT, 164 (27.7%) were positive
for low risk GTs (LRGT), and 429 (72.3%) for high risk GTs (HRGT).
Among samples positive for several GT, 110 (51.6%) were positive both
for LRGTs and HRGTs, 16 (7.6%) for LRGTs, and 87 (40.8%) only for
HRGTs. As whole, the most frequent LRGTs were GTs 61 (7.3%) and
6 (2.6%). GT 11 prevalence was low (0.6%). The most frequent HRGT
were GT 31 (11.4%), 16 (11.3%), 53 (9.1%), 51 (8.2%), and 66 (6.7%).
GT 18 prevalence was much lower (2.67%).
Conclusions: HPV infection prevalence is similar to prevalences
reported previously in other countries. There is a high GTs diversity.
GT 31 prevalence is similar to GT 16, and GT 18 frequency is low.
Infection by multiple genotypes is frequent, and >90% cases include
HRGTs.
P2207 Rubella susceptibility among women of childbearing age
N. Terzi, A. Papanagiotou, A. Charalabopoulou*, A. Bliamou,
H. Chrysopoulou, D. Togas, G. Iliopoulos, K. Tzanetou (Athens, GR)
Background: Although rubella is a mild exanthematous disease, an
infection during the ﬁrst trimester of pregnancy can cause the congenital
rubella syndrome.
Objective: To estimate the susceptibility to rubella virus infection of
women of childbearing age.
Materials and Methods: During a two-year period (from January
2009 to November 2010) 1840 women of childbearing age were
tested for rubella virus-speciﬁc IgG and IgM antibodies. Of the 1840
women, who attended the department of Obstetrics and Gynecology of
“Alexandra” General Hospital of Athens, the 991 were Greek and 849
were immigrants from Africa, the Middle East, and Eastern Europe.
Detection of rubella virus IgG and IgM antibodies was carried out by
EIA (ABBOT, AxSYM Rubella IgG and IgM Microparticle Enzyme
Immunoassay) according to the manufacturer’s instructions.
Results: Rubella virus-speciﬁc IgG antibodies were detected in 864
(87.19%) out of 991 Greek women examined, whereas they were not
detected in 127 (12.81%) women. Rubella virus IgG were detected in 735
(86.57%) out of 849 immigrant women, while 114 (13.43%) were found
negative for rubella virus IgG antibodies. Both groups were negative for
rubella virus-speciﬁc IgM antibodies.
Conclusions: (a) In spite of the widespread application of MMR
(measles, mumps and rubella) vaccination, a signiﬁcant proportion of
Greek women of childbearing age remain susceptible to rubella virus
infection. (b) The immigrants present almost the same proportion of
susceptibility to rubella virus infection, even though they come from
developing countries, where the MMR vaccination is restricted or
unavailable. (c) The non-interrupted transmission of rubella virus and
the natural rubella immunity may be responsible for high prevalence of
rubella virus-speciﬁc antibodies in immigrant women of childbearing
age.
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P2208 Selection of molecules disrupting protein-protein
interactions within the vaccinia virus replication complex
O. Flusin*, L. Saccucci, P. Colas, J.-M. Crance, F. Iseni (La Tronche,
Grenoble, Roscoff, FR)
Background: Variola virus (smallpox agent, Poxviridae family, Or-
thopoxvirus genus) can potentially be used as a biological weapon
(Category A pathogenic agent). We are actually searching for new active
molecules against this virus.
Vaccinia virus (VV), the prototypic member of the Orthopoxvirus genus,
shares around 90% similarity with variola virus; it is admitted that
a compound inhibiting VV would also inhibit Variola virus. Proteins
involved in poxvirus DNA replication are relevant targets to obtain
speciﬁc inhibitors of viral multiplication. The VV A20 protein interacts
with three essential proteins involved in DNA replication: the E9 protein
(replicative DNA polymerase), the D4 protein (uracil DNA glycosylase)
and the D5 protein (helicase/primase).
Methods: In order to screen for compounds able to speciﬁcally interrupt
interactions between A20/D4 and/or A20/D5, a yeast two-hybrid high-
throughput screen, based on the dual luciferase reporter system, was
performed. The interaction between A20 with either D4 or D5 is
detected independently by the sequential activity measurement of the
ﬁreﬂy and Renilla luciferase proteins, used as respective reporters for
each interaction. Thus, this test allows the selection of molecules able
to disrupt one of the two interactions in the same well. About 27000
compounds were screened from commercial chemical libraries.
Results: 33 molecules with good solubility and stability have been
identiﬁed as potential inhibitors. Among these compounds, we identiﬁed
two molecules that exhibit antiviral activity in VV or cowpox virus
infected Vero cell but not against herpes simplex virus type 1.
Conclusion: Thus, the screening of 27000 compounds from collections
of diverse commercial libraries led to the selection of 2 potent inhibitors
that display speciﬁcally antiorthopoxvirus effect in infected cell culture.
We are pursuing the characterization of these two compounds by testing
their activity against viral genome replication.
P2209 Systematic control of rubella virus infection in pregnancy in
the childbearing population in Emilia-Romagna region, Italy
P. Billi*, D. Marchetti, S. Semprini, E. Magrini, M. Della Strada,
S. Ghirelli, L. Morotti, S. Antonelli, C. Rovinetti, R. Dorizzi
(Pievesestina Cesena, Bologna, IT)
Objective: Prevention of congenital rubella syndrome is one of the
priorities set by the World Health Organization (WHO) Regional Ofﬁce
for Europe. In 1998, the target of one case of Congenital Rubella
Syndrome (CRS) per 100,000 live births by 2010 was approved as a goal
of immunisation programmes in the European Region. The objective is
to evaluate the rubella immunity coverage in Emilia Romagna region
and assess valuable criteria to prevent the risk of infection and offer
receptive women vaccination after delivery.
Methods: Between January and June 2010 more than 11.000 samples
have been received for rubella testing by two large regional Laboratories
located in Pievesestina di Cesena (FC) and in Bologna Maggiore
Hospital. These laboratories manage the workload relative to about
half of the population of the Emilia Romagna region. All sera were
screened for anti-rubella IgG and IgM with fully automated LIAISON®
chemiluminescent immunoassay analyzer (DiaSorin, Saluggia, Italy) in
use in both laboratories. All results were reported in International Units
for IgG and Arbitrary Units for IgM.
Results: The results have been assessed according to age, sex and
country of origin of the subject (the area hosts a huge community of
immigrated people coming both from Eastern European Union and from
Africa and Asia).
A total of 88.9% immune population was found in Italian people while
among immigrants the immunity was 83.5%. People of childbearing age
were much younger, if immigrants, than the Italians. Quite a relevant
percentage of non immune persons were found also in male Italian
population (16%) probably due to the fact that only female persons,
in the near past, were vaccinated.
Conclusion: The data workﬂow coming from the Laboratory observatory
can be a very useful tool in handling a correct vaccination policy in the
population.
Women should be aware of the risk connected with the receptive status
in pregnancy.
Vaccination should be offered to young persons and a sensibilization
campaign done in order to avoid the risk of rubella infection in
pregnancy.
P2210 Inter-a inhibitor proteins exhibit antiviral activity against
inﬂuenza virus strains in vitro
E. Christaki*, J.E. Palardy, N.A. Parejo, D. Lambrelli, Y.-P. Lim,
S. Opal (Providence, US; Thessaloniki, GR)
Objectives: Inter-a inhibitor proteins (IaIp) are a complex of endogenous
molecules consisting of inter a trypsin inhibitor, pre-a inhibitor and
bikunin (urinary trypsin inhibitor). Although it is found in high
concentrations in plasma, its role is still not fully understood. Research
work in anthrax and sepsis has showed that it may have anti-inﬂammatory
properties. Our hypothesis was that IaIp, as a serine protease, may
inhibit viral infection by inactivating furin which is necessary for the
cleavage and activation of certain envelope proteins critical in the cellular
attachment of dengue and inﬂuenza viruses to host cells.
Methods: We infected Madin Darby Canine Kidney (MDCK) cell
culture monolayers with laboratory strains of inﬂuenza A/H3N2 and
H1N1 virus. IaIp was then added at a dose of 250mcg/ml or 500mcg/ml
either at the same the time of viral inoculation, one hour prior or one
hour after infection. Cell viability of all cell culture monolayers was
measured at 4 hours and at 20 hours after infection with the alamar blue
reduction assay.
Results: When IaIp was added to the infected cells, they showed greater
viability compared to cells that were treated with H1N1 alone, whether
IaIp (500mcg/ml) was placed at the same time (p = 0.000, at 4hours
and p = 0.000 at 20 hours), before (p = 0.00 at 4 hours and p = 0.00 at
20 hours) or after (p = 0.00 at 4 hours and p = 0.00 at 20 hours) viral
inoculation. The protective effect of IaIp was present with both inﬂuenza
virus strains (H1N1 and H3N2) and its antiviral activity was sustained
when both doses of IaIp (500mcg/ml and 250mcg/ml) were used.
Conclusion: The addition of IaIp had an antiviral effect on MDCK cell
cultures infected with inﬂuenza virus H1N1 and H3N2. Hence, these
antiviral properties of IaIp reveal its promising therapeutic potential in
the ﬁght against inﬂuenza.
P2211 In vivo protection against Old World arenaviruses using
phosphorodiamidate morpholino oligomers with positionally
speciﬁc positive molecular charges added to monomers to
backbone
T. Warren, A. Shurtleff, J. Wells, F. Schnell, D. Mourich, S. Bavari,
P. Iversen* (Fredrick, Bothell, US)
Objectives: The Arenaviridae family represent severe threats to human
health not only from the possible use as weapons but also from the risks
to populations that live in endemic regions. At present, no vaccines or
therapeutic agents have been licensed for use against these viruses. We
explored the in vivo antiviral efﬁcacy of AVI-7012, a positively charged
phosphorodiamidate morpholino oligomer (PMOplus™) designed to
target conserved genetic sequences common to both L and S strands
of New World and Old World arenaviruses.
Methods: Mice were treated i.p. daily starting either 2 days before
initiation of lymphocytic choriomeningitis virus (LCMV) innoculation
with 60mg/mouse of scramble or AVI-7012 PMOplus™ or 2 days post
LCMV innoculation and treatment was continued until day 7 post-
innoculation. Mice were bled at day 8 post-innoculation and viral load
in kidney was quantiﬁed by qRT-PCR ampliﬁcation of viral GPC. Strain
13 guinea pigs were infected with Lassa virus (LASV) and AVI-7012
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was administered by daily i.p. injections at either 15, 30, or 60mg/kg
from the time of innoculation to day 21. Animal survival, weight, and
clinical index were recorded daily for 28 days and two animals from
each treatment group were sacriﬁced at day 15 post-innoculation for
assessment of viral burden by standard plaque assay.
Results: In mice, AVI-7012 reduced viral burden in kidney, brain, spleen
and liver by approximately 1 log when administered either prior to or
after innoculation with LCMV clone 13. Administration of AVI-7012 at
30 and 60mg/kg dose levels conferred a high degree of protection in
guinea pigs innoculated with LASV, with 92% (11 out of 12 animals,
cumulative) surviving infection, compared with 50% survival in saline-
treated animals. Moreover, administration of AVI-7012 at all dose levels
reduced blood and spleen viral burden and protected against LASV-
induced weight loss and clinical signs of disease relative to that observed
in saline-treated animals. In a separate evaluation, AVI-7012 conferred
no protective advantage against Junı´n virus (JUNV), a human pathogenic
New World arenavirus, in a lethal guinea pig model of infection.
Conclusions: Taken together, these results suggest that targeting
conserved genetic sequences using PMOplus™ therapeutics may be
a promising approach to counter Old World arenaviruses. Further
investigations will be required to determine whether this approach can
protect against New World arenaviruses besides JUNV.
P2212 Infection of human intestinal cells and mice with pepper
mild mottle virus, a plant virus
F. Balique, K. Al Moussawi, A. Ferretti, C. Nappez, H. Lecoq,
J.-L. Me`ge, D. Raoult, P. Colson* (Marseille, Montfavet, FR)
Objectives: Pepper mild mottle virus (PMMoV) is a plant RNA virus.
Recently, it was detected in fresh and processed peppers for human
consumption. Besides, it was identiﬁed as the most prevalent RNA virus
in human stools by metagenomics and its presence in patients’ stools
was signiﬁcantly associated with a speciﬁc immune response and clinical
symptoms (fever, abdominal pains and pruritus). Moreover, the virus was
viable in food products and stools. These ﬁndings question if PMMoV
may be pathogenic in humans. We studied PMMoV infection of human
intestinal cells and in an experimental mice model.
Methods: In the culture assay, 4.105 Caco2 cells (human epithelial
colorectal adenocarcinoma cells) were incubated during 12 days with
1010 infectious PMMoV recovered by culture on host plants. In the
experimental model, mice received orally 1011 infectious viruses with/
without pretreatment with capsaicin (the irritant pepper component;
0.2mg/mouse for 5 days before PMMoV ingestion). Four groups of mice
included controls (n = 9), capsaicin-treated (6), PMMoV-treated (10) and
capsaicin/PMMoV-treated (5). PMMoV detection was performed daily
in mice stools by in house real-time PCR. At day 7 and 14 after virus
ingestion, mice were sacriﬁced to detect PMMoV in organs (liver, spleen,
colon, small intestine). Weight of fresh/dried feces collected in colon was
measured to assess diarrhea. Viral infectivity was tested by culture on
plants. Anti-PMMoV antibody testing was performed using an in house
immuno-enzymatic assay.
Results: In Caco2 cells, PMMoV was detected until day 12 after
infection in culture medium and in washed cells. In the medium, a
3.5 Log(copies/ml) decrease of the viral titer was observed between
Day 0 and 6 (from 11.1 to 7.6 Log), then a 1.4 Log decrease was
observed between Day 6 and 12. In washed cells, a 2.2 Log decrease
was observed between Day 0 and 6 (from 8.4 to 6.2 Log), then viral titer
did not decrease between Day 6 and 12. In the experimental mice model,
PMMoV was detected in stools between day 1 and 7 after virus ingestion.
The viral titer decreased of 5 Log (from 1010 to 105 copies/ml). Stools
suspension remained infectious up to 2 days post-infection. PMMoV was
not detected in mice organs. No speciﬁc anti-PMMoV IgG antibodies
could be detected in mice sera with our assay. No diarrhea was observed.
Conclusion: These ﬁndings conﬁrm that PMMoV remain infectious after
their transit in the gut. PMMoV may infect vertebrate cells.
P2213 Kaposi sarcoma-associated herpesvirus saliva shedding in
children and mothers in Uganda
R. Romano*, F. Tabacchi, G. Russo, S. Gramolelli, S. Verzaro,
F. Marinucci, G.M. Paganotti, A. Gaeta, M. Coluzzi (Rome, IT;
Baltimore, US)
Objectives: Kaposi sarcoma-associated Herpesvirus (KSHV) seropreva-
lence rate in Ugandan children is elevated, ranging from 8% to 57%. This
suggests that KSHV infection can occur via horizontal nonsexual route
through saliva in which viral load is higher than in other body ﬂuids.
According to our hypothesis KSHV is transmitted from mother-to-child
through infected saliva, applied on child’s skin to relieve itching and
scratching following bloodsucking arthropod bite which induces a skin
inﬂammatory/immune response that could facilitate viral replication. We
investigated prevalence of viral DNA in mothers’ and children’s saliva
and how is spread the use of saliva.
Methods: Overall 270 saliva samples on Whatman® grade 1 ﬁlter papers
were collected in North-East Uganda (Karamoja: rural community, 76
women and 76 children) and in Central Uganda (Kampala and Entebbe:
urban community, 55 women and 63 children) to detect the presence
of KSHV DNA by Real Time PCR. Moreover, questionnaires directed
at 533 children (211 in rural and 322 in urban communities) were
administrated at schools and health centres. Yates-corrected chi square
test, odds ratios (OR) and conﬁdence intervals (CI) had been used to test
differences in KSHV DNA presence between rural and urban groups.
Results: KSHV DNA had been detected in 17.9% among rural
community (9.2% children, 26.7% mothers) and in 18.6% among urban
community (15.1% children, 22.4% mothers) (p> 0.05). The frequency
of saliva use was 20.4% and 57.1%. in rural and urban communities
respectively (p< 0.001).
Conclusions: Molecular data show that the higher viral load was among
rural mothers (26.7%), even though in the urban community the use
of saliva is more widespread than in rural one (57.1% and 20.4%
respectively). So we observe that in urban community could exist more
favourable conditions for a mother-to-child KSHV transmission. This
trend is conﬁrmed by preliminary molecular data of saliva KSHV DNA
detection which reveal an higher positivity rate among children from
urban community (15,1%).
P2214 Prevalence of anti-hepatitis E virus antibodies in HCV
chronically infected patients in southeastern France
R. Ge´rolami*, P. Borentain, A. Motte, P. Colson (Marseille, FR)
Objectives: Hepatitis E virus (HEV) infection was associated with a high
mortality rate in patients with liver diseases in developing and developed
industrialized countries. Patients chronically-infected with HCV could
be therefore at particular risk for severe outcome in case of HEV
superinfection. The aim of this study was to determine the prevalence
of anti-HEV antibodies and HEV RNA in HCV RNA positive patients.
Methods: Serum samples from 96 HCV RNA positive patients collected
in our institution in 2005 were tested for anti-HEV IgG and IgM
antibodies (Adaltis EIAGen kits) and HEV RNA (in-house real-time
PCR assay targeting the open-reading frame-2 region of HEV genome).
Detection of total anti-hepatitis A virus (HAV) antibodies (Axsym
Abbott) was concurrently performed.
Results: Mean age of patients was 48 (range, 21−73), 61 were male. A
total of 42 patients (44%) had cirrhosis of the liver. Ten patients (10.4%)
were positive for anti-HEV IgG antibodies. Mean test/cut off optical
density ratio was 2.4±2.2 (range, 1.14–8.12; ratios >1.1 were classiﬁed
as seropositive). The mean age of these patients was 41 (24−57). Four of
them had cirrhosis. Neither anti-HEV IgM nor HEV RNA were detected
in the serum of the 10 patients. No correlation between age or cirrhosis
and anti-HEV IgG prevalence was found. 67 of the 96 patients (70%)
were positive for anti-HAV total antibodies. Six (9%) of them were
positive for anti-HEV IgG. Conversely, six of the ten anti-HEV positive
patients were positive for anti-HAV total anibodies. The seroprevalence
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for anti-HAV antibodies increased statistically signiﬁcantly with age
(86% vs 59% in patients older or younger than 50, respectively; p< 0.01).
Conclusion: Our data suggest that the majority of HCV chronically-
infected patients in southeastern France are HEV seronegative, and
thus at risk for severe and fulminant hepatitis E. In comparison, a
majority of these patients are HAV seropositive, although vaccination
against HAV should be proposed to increase HAV seroprevalence. No
relationship between anti-HEV seropositivity and the severity of ﬁbrosis
could be noted. No case of concurrent HCV and HEV RNA detection
was observed in our population.
P2215 Increasing CD4+CD25hiFoxP3+ regulatory T-cells in
subjects after repeated booster doses of rabies vaccination
P. Vejpongsa*, P. Leelasinjaroen, P. Sodsai, N. Hirankarn,
T. Tantawichien (Bangkok, TH)
We have experience with subjects, who have had frequent rabies vaccine
boosters, have a decrease in their rabies neutralizing antibody (Nab)
response when given booster injections. Accumulating evidence indicates
a crucial role of CD4+CD25hiFoxP3+regulatory T cells (Tregs) in
inducing antigen-speciﬁc immunological tolerance. We hypothesized that
an increased frequency of Tregs could be involved in decreased antibody
response in subjects who received frequent booster vaccination.
We analyzed peripheral blood lymphocytes from subjects receiving
repeated doses of rabies vaccine for Tregs and correlated their levels
with rabies Nab. Forty-one subjects aged between 20−55 yrs, who
regularly donate serum for human RIG production, have received 2-site
intradermal booster doses of rabies vaccine every 3 months with 0.1mL
of PVRV more than 2 years were enrolled. Blood samples were obtained
before booster vaccination (day 0) and on day 14 after vaccination for
rabies Nab titers and Tregs. To determine Nab titers, we performed rapid
ﬂuorescent focus inhibition test for all serum samples individually. We
collected peripheral blood mononuclear cells (PBMCs) from ACD whole
blood by Ficoll separation then detected CD4+, CD25hi and intracellular
FoxP3 level by ﬂow cytometry.
Results: Thirty-seven subjects (low-responder group: age range,
20−55 yrs) had a poor or no Nab response after booster vaccination
[GMT of Nab titers = 8.36 (1.69–50.0) IU/mL on day 0 and GMT of
Nab titers= 9.7 (1.93–42.04) IU/mL on day14] while only 4 subjects
(responder group: age range, 22−55 yrs) have Nab titers increased more
than 2 fold [GMT of Nab titers = 3.87 (0.60–14.86) IU/mL on day
0 and GMT of Nab titers = 13.63 (6.25–31.05) IU/mL on day14].
The frequency of Tregs was increased signiﬁcantly in low-responder
group on 14 days (2.53±1.29% vs. 3.27±1.59%, p< 0.01). Tregs level
in responder group did not differ on day 0 and 14 days after booster
vaccination (3.21±0.75% vs. 3.61±0.9%, p> 0.05). There were no
signiﬁcantly statistical differences between two groups in terms of age,
numbers of previous booster doses, Nab titers and Tregs level on day 0.
Conclusion: We demonstrate that the frequency of Tregs increased
signiﬁcantly in subjects who had a poor Nab response after booster
vaccination but not in responder group. However, whether the up-
regulation of Tregs is involved in induction of immunologic tolerance
in subjects who received frequent booster vaccination need further
investigation.
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P2216 Premature stop codon in HBV S gene among several
patients groups from the Middle East
M. Vaezjalali*, S.M. Alavian, B. Behnava, T.M. Azad (Tehran, IR)
Objectives: We previously reported premature stop codon in S gene
among Iranian patients. This mutation can render HBV undetectable
by conventional Elisa methods. In this study we aimed to determine
the presence of premature stop codon in S gene from Middle Eastern
countries with predominant HBV genotype D.
Methods: Submitted HBV sequences to NCBI genome database from
Middle East countries (Iran, Iraq, Turkey, Pakistan, Afghanistan, UAE
and Yemen) were retrieved. The S gene of HBV submitted sequences
were analyzed by Bioedit ver. 7 software to evaluate the genotype and
premature stop codon in S gene.
Results: Premature stop codon in S gene was observed in all countries
with appropriate sequences for analysis. The frequency of mutated
sequences to total evaluated sequences were 17/884, 1/2, 4/110 and
1/30 for Iran, Iraq, Turkey and Yemen respectively. In other countries
(Pakistan, Afghanistan and UAE), there were no submitted sequences or
the submitted sequences were inappropriate for analysis.
All submitted sequences were from patients with positive HBsAg by
Elisa technique. The population of patients with premature stop codon
in S gene included blood donors.
Conclusion: Premature stop codon in S gene was observed in all
countries which had evaluable HBV genome sequences. These mutaions
were observed in patients positive for HBsAg however considering the
fact that premature stop codon in S gene can render HBsAg undetectable
by conventional Elisa technique, We face serious concerns about the
adequacy of screening blood donors for HBsAg by Elisa techniques.
P2217 Molecular epidemiology of HCV in Morocco
A. Benani*, W. Baha, N. Dersi, M. Ennaji, F. Lazaar, A. El Malki,
M. Hassar (Casablanca, MA)
Objectives: Hepatitis C is a major public health problem worldwide
and is a leading cause of liver disease that may silently progress
toward cirrhosis and hepatocellular carcinoma. The estimated worldwide
prevalence of HCV infection is 170 million, approximately 3% of the
world’s population. Genetic heterogeneity of HCV strains have led to
a consensus classiﬁcation of six major genotypes (1−6) and several
subtypes whose geographical distributions differ signiﬁcantly according
to transmission modes. HCV genotypes are clinically relevant in terms of
diagnostics, impact on natural history of liver disease, treatment regimen
required, and response to pegylated interferon treatment.
Methods: A large scale serology screening (24 646 individuals) was
made by ELISA HCV V4.0. Qualitative HCV RNA was detected in the
fully automated Cobas Ampliprep/Cobas Amplicor (Roche Diagnostics),
HCV viral load was measured by the Cobas Ampliprep/Cobas TaqMan
real-time PCR (Roche Diagnostics). HCV genotyping (1473 patients)
was tested with Versant LIPA HCV II (Siemens).
Results: We have found that HCV prevalence was about 1.1% and
increased with age. Genotype 2a/2c identiﬁed in total 41.5% was the
most prevalent. The genotype 1b identiﬁed in 40.33% was the second one
distributed. HCV genotypes 1a, 3a, 4, 2b and 5 were identiﬁed in 6.45%,
0.95%, 0.61%, 0.07% and 0.07% of cases respectively. Sequencing of
HCV NS5B region of 2a/2c and unclassiﬁed 2 genotype have permitted
us to analyze 16 samples. Surprisingly, 15 samples were assigned to
subtype 2i and one sample clustered with 2j/2k subtype. These ﬁndings
suggest that HCV subtype 2i infects also Moroccan patients as French
ones.
Conclusion: Preliminary results suggest that intermediate anti-HCV
prevalence was found in Moroccan population studied. Molecular data
have shown a predominance of genotypes 1 and 2 in Moroccan
patients while HCV genotypes 3, 4 and 5 are rarely found. Parenteral
transmission of HCV was observed in the population studied.
Nosocomial transmission of HCV was important, especially in high risk
groups such as hemodialysis patients where genotype 1b seems to be
homogenous (75%) and also genotype 4 that we have found in 4 patients
at the same dialysis center. HCV genotype 3 seems to be imported from
Europe by young Moroccan migrants while HCV genotype 4 was found
in patients who have been hospitalized in Saudi Arabia hospitals during
their pilgrimage.
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P2218 Evaluation of a novel quantitative HCV Core Ag
immunoassay for the study of chronic hepatitis C
C. Bartzavali*, S. Vamvakopoulou, E. Jelastopulu, E.D. Anastassiou,
M. Christoﬁdou (Patras, GR)
Objectives: To evaluate the performance of a novel automated
chemiluminance immunoassay (CLIA) for HCV core Ag in comparison
to quantitative determination of HCVRNA in patients with chronic
hepatitis C (CHC).
Methods: HCVAg was measured in sera of 121 patients with CHC
and six healthy individuals by using the new Architect HCVAg CLIA
(Abbott), an automated assay with a cut off value of 3.0 fmol/L and
a gray zone (GZ) of 3−10 fmol/L. Anti-HCV detection was performed
with CLIA (Architect, Abbott) and HCVRNA was quantiﬁed by bDNA
(Siemens) with detection limits of 615 IU/mL.
Results: Among 121 patients, 113 (93%) had anti-HCV (+), whereas,
HCVRNA values ranged between 4000 and >7690×103 IU/mL. All
HCV genotypes (1−4) and subtypes were detected. Values of HCValphag
(+) ranged between 15 and >20.000 fmol/L. Seven patients (6%) had
anti-HCV (+), HCVRNA 700–8000 IU/mL and HCValphag in GZ,
between 3.65 and 9 fmol/L. One patient (1%) with anti-HCV (+),
HCVRNA = 3000 IU/mL, and genotype 3a had HCValphag negative,
(0.65 fmol/L). The six healthy individuals had undetectable HCVAg
(0.06–2.52 fmol/L), anti-HCV (−) and HCVRNA (−).
Conclusions: The new CLIA HCVAg represents an easy to perform,
comparable to HCVRNA determination and useful method for the study
of CHC. It shows a high sensitivity (99%), and excellent correlation
(rho = 0.943) with viral load quantiﬁcation by bDNA method. HCVAg
CLIA represents also an alternative approach to routine diagnosis of
acute hepatitis C, as well as, in cases of CHC of immunocompromised
patients (haemodialysis or HIV +) that sometimes show undetectable
anti-HCV antibodies.
P2219 The prevalence of HCV infection among surgical nurses,
midwives, their patients and blood donors: a cross-sectional
sero-survey
M. Ganczak* (Szczecin, PL)
Surgical nurses and midwives might be considered at most risk of
accidental HCV infection due to their higher exposure to blood. One
of the most important risk factors of viral infection among the health
care workers is the prevalence of infection in the general population, or
more speciﬁcally, in patients.
Objectives: To compare the prevalence of HCV infection in surgical
nurses/midwives and in a control groups: consecutive surgical/
gynecological female patients from the same hospitals and female blood
donors in a cross-sectional sero-survey and to evaluate the alleged risk
factors for acquiring an occupational infection.
Methods: Serum samples from nurses/midwives (study group) and their
female patients (ﬁrst control group) were collected in 16 randomly
selected hospitals in West Pomeranian region of Poland, between
February 2008 and June 2009, assayed for anti-HCV antibodies using
third-generation testing methods. Serum samples obtained from blood
donors from the Regional Center for Blood Donation served as the
second control group.
Results: Of the 590 personnel eligible, 414 (70.2%) consented to
participate, all of them were female. Anti-HCV were found in 6
staff members (1.4%; 95%CI:0.7−3.1%). A stepwise multivariate
model indicated that for anti-HCV sero-positivity, only the length of
employment was associated with an increased odds of being infected
(p< 0.006). The prevalence of anti-HCV in 1118 female patients was
0.4% (4/1118; 95%CI:0.1−0.9%), while in 801 female blood donors
0% (0/801; 95%CI:0−1.1%). Comparison of anti-HCV prevalence with
blood donors from the region of Western Pomerania and the female
patients’ population indicated an increasing trend in this order: blood
donors, patients, nurses/midwives.
Conclusions: The prevalence of HCV-antibodies in surgical nurses and
midwives was more than three times higher than in the population of their
patients which may indicate an important occupational risk. Longer work
at a surgical/gynecologic ward may predispose to acquire an occupational
infection.
P2220 Viral hepatitis B and C among homeless people living in
south-eastern France
P. Colson*, E. Botelho-Nevers, H. Richet, S. Badiaga, D. Raoult,
P. Brouqui (Marseille, FR)
Objectives: Homeless people (HP), as a result of their lifestyle and
other social factors, are at risk for infectious diseases. Few data about
infections with hepatitis B and C viruses (HBV and HCV) in these
individuals are available. We studied HBV and HCV prevalence in HP
living in a large city of south-eastern France.
Methods: Sera were collected after individual consent from 190 HP
living in Marseille during a two-day survey in 2005. HBV and HCV
serologies were tested using Axsym Abbott assays. HBV-DNA and
HCV-RNA were tested in HBsAg-positive and HCV seropositive HP,
respectively, using in-house PCR ampliﬁcation/sequencing protocols.
The study has been reviewed and accepted by an ethical committee.
Results: Mean age of HP was 41±14 years, 182 were male, and 74
were born in France. Mean homeless life duration was 43±85 months.
17 and 39 HP reported piercing and tattooing, respectively. Excessive
alcohol intake was noted in 66% of HP. Only 6 (3.2%) HP reported past
or current intravenous drug use, and only 2 (1%) HP were HIV-infected.
Mean alanine aminotransferase level (ALT) was 35±44 IU/l (5–470).
ALT were >2x the upper normal value (UNV) in 9.8% of HP. HBsAg
was positive in 4.2% (n = 8) of HP. HBV genotype could be determined
from 4 sera, and was A, D (n = 2), or E. HBV serologies indicating past-
HBV infection were observed in 25% of HP. HBV serology indicating
vaccine immunization was observed in only 8.9% of HP. A total of
4.7% (n = 9) of HP were HCV-seropositive. HCV viremia was detected
in eight cases. One of them was co-infected with HIV. HCV genotype
was 1 (n = 4 HP), 3 (n = 3), or 4 (n = 1). HCV infection was signiﬁcantly
more frequent in HP with ALT >2× the UNV (22 vs 2.4%; p< 10−3).
Concurrent HBsAg and anti-HCV detection was not observed in any HP.
Conclusions: The present data underscore that HP are highly exposed to
infections with hepatitis B and C viruses. They prompt to extend the use
of HBV vaccine and the diagnosis of infections with hepatitis viruses in
this special population.
P2221 Hepatitis delta in Marseille, southeastern France
M. Plumelle, A. Motte, M. Henry, M.-H. Romera, C. Tourre`s,
A. Ferretti, C. Tamalet, P. Colson* (Marseille, FR)
Objectives: Hepatitis D virus (HDV) represents an additional clinical
concern for patients chronically-infected with hepatitis B virus (HBV).
Thus, it is considered to cause severe forms of viral hepatitis in humans
and sustained virologic response can be reached in only about 25%
of cases and only with interferon-a. Studies about hepatitis Delta are
rare in France, where chronic hepatitis B prevalence is about 0.65%
and HBV vaccine coverage is low, around 30−40%. We present the
prevalence and epidemiological and virologic features of hepatitis Delta
in HB surface antigen (HBsAg)-positive patients (pts) who were tested
in our microbiology lab in public hospitals of Marseille, southeastern
France.
Methods: The prevalence of anti-HDV antibodies and HDV RNA
detected in peripheral blood samples collected from 1998 to 2010
was analysed. Total and IgM antibodies to HDV were detected using
commercialized immune-enzymatic assays. HDV RNA was detected
using in house real-time PCR and ampliﬁcation/sequencing assays.
HDV genotype was determined by phylogenetic analysis. HDV chronic
infection was diagnosed by anti-HDV IgM or HDV RNA detection.
Results: HDV virologic results were available for 881 sera collected
from 772 pts. Total and IgM anti-HDV antibody testing were positive
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in 61 (7.9%) and 23 (3.0%) pts, respectively. The proportion of HIV-
positive pts was statistically signiﬁcantly greater for HDV seropositive
than seronegative pts (48 vs 19%; p< 10−6). Besides, the proportion of
men was statistically greater in HDV seropositive than seronegative pts
(82 vs 63%; p = 0.003), and HDV seropositive pts were statistically more
frequently in the 30−60 years group of age than HDV seronegative pts
(64 vs 41%; p< 10−3). One primary HDV infection could be documented
in 2008. HBV DNA was measured in 679 pts concurrently tested on
HDV virologic markers. No statistically signiﬁcantly difference was
observed regarding HBV load in total or IgM anti-HDV positive and
HDV seronegative pts. Overall, HDV RNA was detected by real-time
PCR and/or sequencing in serum samples from 24 pts. HDV RNA
sequences were available for 19 pts; HDV genotype was I in 18 cases
and V in one pt.
Conclusions: HDV infects 3% of HBV chronically-infected pts
monitored in public hospitals of Marseille, more predominantly those
co-infected with HIV. These ﬁndings prompt to study more accurately
the clinical impact on the progression of liver disease of hepatitis Delta.
P2222 Frequency and clinico-laboratory features of mix-infections,
caused by CMV and HSV (1/2) in pregnant women with
chronic HBV- and HCV-infection in Ukraine
V.A. Boyko*, T.A. Achkasova, G.V. Batsyura, M.T. Gafarova (Simferopol,
UA)
Objectives: To deﬁne frequency of mixt-infections, which caused by
Cytomegalovirus (CMV) and Herpes simplex virus (HSV) (1/2) in
pregnant woman with chronic HBV- and HCV-infection, to study its
clinico-laboratory features.
Methods: Clinical, biochemical, immunochromatographic test, reaction
of direct immunoﬂuorescent, ELISA, quantitative polymerase chain
reaction (PCR), ultrasonic research.
Results: Between January 2008 and December 2010 a total of 171
pregnant women were evaluated (the 1st group − 84 pregnant woman
with chronic HBV-infection, the 2nd group − 37 patients with chronic
HCV-infection, control group − 50 women with physiological course of
pregnancy without chronic HBV- and HCV-infection). All women in the
study were screened for HBsAg, HBeAg, antiHBe, HBcIgM, HBcIgG,
DNA of HBV and RNA of HCV, HSV IgM (1/2), HSV IgG (1/2), CMV
IgM, CMV IgG, CMV or HSV (1/2) DNA in blood, mucus of cervical
channel, urine and saliva. In 56 (66,7%) pregnant woman of the 1st group
were conﬁrmed reactivation of chronic HSV-infection (1/2) (n = 35) and
CMV-infection (n = 21), in the 2d group in 23 (62,2%) woman were
revealed reactivation of HSV-infection (1/2) (n = 14) and CMV (n = 9) in
replication stage. 3 (6%) women in control group had relapse of HSV-
infection (1/2), but CMV-infection had not revealed.
Conclusion: Frequency of detection of HSV- (1/2) and CMV-infection
in pregnant with chronic HBV- and HCV-infection is high (>60%).
Patients with mixt-infection have considerably more frequent speciﬁc
signs of chronic viral hepatitis (jaundice, hepatosplenomegaly, lesion of
hepatic structure on ultrasonic research, increase of markers of cytolytic
syndrome), then nonspeciﬁc syndromes (intoxication, astenovegetative,
dyspeptic and arthralgic). HSV (1/2) and CMV in replication stage
promote more prolonged lesions of liver functions (increase of ALT, AST
level and thymol test). Received results of study indicate hepatotropic
inﬂuence of CMV and HSV.
P2223 Acute and fulminant hepatitis B in public hospitals of
Marseille, southeastern France
L. Panassie´, P. Borentain, C. Nafati, G. Bernardin, B. Doudier,
V. Thibault, R. Ge´rolami, P. Colson* (Marseille, Nice, Paris, FR)
Objectives: Fulminant hepatitis has been shown to occur in about 1%
of acute hepatitis B virus (HBV) infections, and its mortality rate
is nearly 70%. Speciﬁc HBV genotypic features have been pointed
out in fulminant acute hepatitis B worldwide, but these associations
remain controversial. In France, hepatitis B remains a public health
concern with an estimated prevalence of HB surface antigen (HBsAg)-
carriage of 0.68% and a low vaccine coverage rate (around 33−41%). We
describe primary HBV infections diagnosed in 2008 in public hospitals
of Marseille, the main city of southern France.
Methods: HBV serologic status was assessed using Axsym Abbott
assays on all sera sent in 2008 to the virology lab of public hospitals
of Marseille. Primary HBV infections were diagnosed on the basis of
strongly elevated alanine aminotransferase level (ALT) (>20-fold the
upper normal value), HBV DNA positivity in serum, and strongly
elevated anti-HB core (HBc) IgM antibodies (>200 IU/mL) (Vidas
BioMe´rieux assay). Serum HBV DNA was quantiﬁed using the Cobas
TaqMan Roche assay. HBsAg encoding gene and the pre-core/core region
were ampliﬁed/sequenced using in house protocols.
Results: 18223 HBV serologies were performed in 2008 in our lab on
sera from 15774 patients. Serology indicating past HBV infection and
vaccine immunization were observed in 13.8% and 40.1% of sera tested,
respectively. HBsAg was positive in 427 cases (2.3%) and HBsAg-
positivity was newly-diagnosed in our lab in 146 cases (0.9%). 4 (2.7%)
of the 146 newly-diagnosed HBsAg-positive cases were acute hepatitis B.
Three were men; mean age was 38 years. Serum HBV DNA titres ranged
between 116−1,272,696 IU/mL. Fatal fulminant hepatitis B occurred in
2 cases, a 60-year-old woman and a 38-year-old man. Prothrombin index
was <20% at admission. Precore G1896A HBV mutants were detected
in both fatal fulminant cases. Mutation G1899A was detected from one
fulminant and one non-fulminant case. Nucleotides at positions 1762
and 1764 in the basal core promoter region were wild-type in the four
cases. HBV genotypes were D or E. HB e antigen was negative in the
two fatal cases, and hepatitis B surface antigen was negative in one fatal
observation, despite HBV DNA detection.
Conclusions: Acute hepatitis B remains a cause of death in France.
This prompts to extend the use of the HBV vaccine. The substantial
prevalence in France of G1896A precore HBV mutants suggests that
they may be frequently implicated in acute hepatitis B.
P2224 Liver damage in pandemic inﬂuenza A/H1N1
N. Papic, A. Pangercic, M. Vargovic, B. Barsic, A. Vince* (Zagreb, HR)
Objective: Although liver may not be primary target organ affected with
viral infection, it can be collaterally damaged in viral upper respiratory
tract infections. In these patients’ hepatic changes is a consequence of
immune response to viral antigens with a close topographic association
between the presence of viral antigens and the associated inﬂammatory
inﬁltrates in liver. In novel pandemic inﬂuenza A H1N1, it is still unclear
how large is liver damage in this new type of respiratory disease. The
aim of our study was to investigate collateral damage of the liver during
pandemic inﬂuenza A H1N1 infection.
Methods: This was a retrospective study conducted at the University
hospital for Infectious Diseases Zagreb. We included conﬁrmed cases
of pandemic inﬂuenza hospitalized during outbreak of inﬂuenza A
H1N1. Other group of patients were patients with seasonal inﬂuenza
hospitalized from 2007–2009. Patients younger than 15 years and with
previous liver diseases were excluded from the study. Statistical analysis
was performed by using the Fisher’s exact test and t-test as appropriate.
Results: We examined 97 patients with conﬁrmed pandemic H1N1
inﬂuenza and 86 patients with seasonal inﬂuenza. The pandemic group
consisted of 54 men and 43 women, mean age 46.79 years (range 17−75),
and the seasonal group included 52 men and 34 women, mean age 47.06
years (range 15−87). There was no signiﬁcant difference in age and sex
between the two groups. Serum levels of AST were in pandemic group
48.66±61.08, in seasonal 31.91±22.10 (p-value 0.0172); ALT were in
pandemic group 45.89±54.19, in seasonal 27.33±22.32 (p-value 0.0035)
and GGT were in pandemic group 71.79±130, in seasonal 34.52±32.76
(p-value 0.0115).
Conclusion: Liver damage is not tipicaly present in seasonal inﬂuenza.
According to our study serum levels of aspartate aminotransferaze, ala-
nine aminotransferaze and g-glutamyl transpeptidase were signiﬁcantly
higher in the pandemic inﬂuenza. Most of patients had mild hepatic
lesion, representing pattern of hepatocellular injury. Although platelets
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and D-dimer values were higher in pandemic inﬂuenza, suggesting
endothelial damage, the differences weren’t statistically signiﬁcant.
These ﬁndings support the concept of the pandemic H1N1 inﬂuenza
as a new illness with signiﬁcant immune response to infection leading
to hepatocelular injury, different clinical and laboratory features than in
previous seasonal epidemics.
P2225 Infectivity and pathogenicity of hepatitis A virus during an
outbreak in a communal living setting
J.H. Cho*, H.J. Hyun, J.H. Lee, Y.H. Park (Seoul, KR)
Objectives: Acute viral hepatitis A infection in adults is an emerging
public health problem in Korea. The infectivity and pathogenicity of
hepatitis A virus (HAV) in close contact have not been studied previously.
This study investigated the secondary attack rate and pathogenicity rate
of HAV during an outbreak among auxiliary police in a communal living.
Methods: A total of 70 people in close contact with a hepatitis A patient
(index case) were enrolled in the study, which included a thorough
oral history, physical examination, and laboratory testing. The subjects
were part of an auxiliary police unit living in a communal setting
(HAV contact group). Speciﬁc antibodies in the sera were determined
at the time when the last hepatitis patient was discharged from hospital
and at the end of the longest incubation periods. Subjects in another
auxiliary police unit without exposure to hepatitis A were examined as a
control group (HAV non-contact group). The secondary attack rate and
pathogenicity rate were calculated from the data.
Results: In the HAV non-contact group, none of the subjects had anti-
HAV antibodies. In the HAV contact group, three subjects had both
IgM and IgG anti-HAV antibodies, and two had only IgG anti-HAV
antibodies. Two of three (or ﬁve) HAV-infected subjects were treated for
hepatitis A.
Conclusion: The secondary attack rate (infectivity) of HAV was
4.3−7.1% (3~5/70) and the pathogenicity rate was 40.0~66.7% in the
group of young adults.
P2226 Hepatitis E virus infection in Bulgaria
G. Popov*, M. Baymakova, K. Plochev, I. Dikov on behalf of the
ESCMID Study Group for Viral Hepatitis (ESGVH)
Objectives: HEV infection is gaining global attention, not only because
of the increasing burden of the disease in low endemicity countries, but
also due to recent advances in the molecular virology and epidemiology
of this emerging pathogen. Several research teams are working on this
topic in Bulgaria.
Methods: In this retrospective study, 11 patients with acute viral
hepatitis type E were included. To describe the clinical and demographic
characteristic, we used information from cases recorded at the Clinic of
Infectious, Parasitic and Tropical Diseases, Military Medical Academy −
Soﬁa, between January 2004 to December 2010. The diagnosis of HEV
infection was conﬁrmed by the ﬁnding of anti-HEV antibodies of class
IgG and IgM (ELISA) in acute phase, and by dissappearing of IgM anti-
HEV in convalescent period. Statistical analysis was performed using the
chi-square test.
Results: The mean age of the patients was 49.82 years and 72.7%
were males. The most frequent clinical signs were mild to moderate
upper gastric symptoms (55%) and liver enlargement (91%). One of
the patients was with coinfection HEV+HBV with signs of threatening
acute hepatic failure. Another patient was a probable case of chronic
HEV infection. The cholestasis enzymes (ALP and GGT) were elevated
by all, but without clinical evidence of cholestasis.
Conclusions: Acute hepatitis E in Bulgaria emerges as an autochthonous
infection with a low incidence rate. At part of the patients there was
severe form of acute viral hepatitis E. Elevation of cholestasis enzymes
is an important parameter of the biochemical proﬁle of the disease. The
question of probable chronic form of HEV infection was discussed.
P2227 Hepatitis A in the area south of Gran Canaria, Spain
A. De Malet*, A. Herna´ndez-Betancor, C. Del Rosario-Quintana
(Las Palmas, ES)
Objectives: The seroprevalence of hepatitis A (HVA) has decreased in
recent years in developed countries. The subpopulation of adults less then
40 years has converted to a group susceptible to contagion. Recognising
the epidemiologic proﬁle of the infected population in our country is of
great interest to determine the population in risk, that will beneﬁt of a
program to vacunate for hepatitis A.
Methods: We analized retrospectively the cases diagnosed with acute
hepatitis A in the Microbiological department of ‘Hospital Universitario
Insular de Gran Canaria’ in the period from July 2007 to November 2010.
The microbiological diagnosis of HVA was realised using a qualitative
detection of IgM anti-VHA virus antibodies using enzyme immunoassay
(AXSYM) or using chemiluminescent microparticle immunoassay
(ARCHITECT, Abbott Laboratories) in human serum. In the patients
with suspected clinic we completed serologic research with markers of
hepatitis B virus, hepatitis C virus (HCV) and Human Immunodeﬁciency
Virus (HIV) with the tecniques previously described. Using a screening
for syphilis RPR, completing the positive results of the FTA-ABS test
(bioMe´rieux) and line immunoassay LIA (Innogenetics). The positive
results for HCV and HIV were conﬁrmed using line immunoassay LIA
(Innogenetics).
Results: We diagnosed 53 cases of acute hepatitis A, whose distribution
for gender was approximately 5:1, with a predominance for male (45
cases). The age range was from 18 to 80 years, with the most cases
between 20−40 years (75.47%). The coinfection with other hepatotropic
viruses, HIV or syphilis was not signiﬁcant. The detected cases in the
laboratory were communicated to Epidemiology and Prevention Section
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of Public Health, which realised a epidemiologic study to hepatitis A in
Gran Canaria from September 2007 to April 2009, noting that 45,7% of
the men declared to have partaken in homosexual relationship and 8,6%
had travelled to endemic areas.
Conclusion: The study shows the new cases of hepatitis A in male adult
with less than 40 years. The risk factor most notable was the percentage
of patients with homosexual contacts. This group, as well as travellers
to endemic areas and the patients affected with other hepatopathy, form
a population in risk which could beneﬁt from hepatitis A vacunation in
our area.
P2228 Hepatitis E virus in Italy: molecular analysis of
travel-related and autochthonous cases
G. La Rosa*, M. Muscillo, V. Spuri Vennarucci, A.R. Garbuglia, P. La
Scala, M.R. Capobianchi (Rome, IT)
Human hepatitis E virus (HEV) causes acute liver disease, and is a
major public health concern in non-industrialized countries where it
causes large outbreaks, signiﬁcant morbidity and deaths. In industrialized
countries, the disease is non-endemic, usually conﬁned to travelers
returning from endemic areas. Nevertheless, a growing number of
sporadic cases have been identiﬁed, involving also patients with no
travel history. The aim of the present study was to contribute to the
body of knowledge available on the molecular epidemiology of acute
hepatitis E in Italy. Three sets of HEV-speciﬁc primers targeting the
ORF1 and ORF2 regions were used to examine serum samples collected
from 43 acute hepatitis patients positive for anti-HEV IgG and/or IgM,
between 2007 and 2010. The following information was collected from
the patients’ hospital charts, where available: age, sex, symptoms and
diagnosis on admission, exposure history (food, water, travel, activities,
and recent contact with infected individuals). Seventeen patients (39.5%)
resulted HEV RNA-positive: 12 infections, due to genotype 1, were
associated to travel to endemic areas (Bangladesh, India and Pakistan),
while 5 infections, due to genotype 3, were presumably autochthonous,
whose risk factors included exposure to raw seafood, pork liver sausages,
and wild boar. Patients with genotype 3 tended to suffer less severe
symptoms, and none was hospitalized, while patients with genotype 1
were all hospitalized due to severe symptoms (jaundice, vomit and/or
fever), and had ALT levels signiﬁcantly above the normal.
Results from this study conﬁrm that human HEV infection in Italy is
due to different genotypes, depending on travel-related or autochthonous
origin. Further studies are necessary to gather information on the
occurrence and on the genetic diversity of the strains circulating
in humans, animals and the environment, in order to gain a better
understanding of the epidemiology of HEV, and to plan adequate
preventive measures.
P2229 Occult hepatitis B infection in couples, candidates for
assisted reproductive technology
N. Hannachi, M. Khammari, A. Ferjani, J. Boukadida* (Sousse, TN)
Objective: In Tunisia, identiﬁcation of hepatitis B virus (HBV) infection
in infertile couples candidates to Assisted reproductive technology (ART)
is based on HBs antigen (HBsAg) detection. However this marker can
be absent in case of occult hepatitis. The objective of this study is to
document the prevalence rate of occult hepatitis B in 808 infertile couples
candidates to ART.
Methods: All sera of the candidates to ART were prospectively screened
for HBsAg and anti-HBc antibody (anti-HBc). Negative HBsAg sera
were systematically tested for anti-HBs antibody (anti-HBs). Detection
of HBV-DNA was performed for “anti-HBc isolated” sera. The presence
of HBV genome was tested by a single-step PCR in Pre-S gene and two
nested PCR in X and C regions. The sensitivity of the PCR assays was
evaluated using samples with known viral load.
Results: Seroprevalence of positive HBsAg was 3,2%. Vaccinal
immunity was detected in only 3,3% of HBsAg negative sera. Anti-HBc
was detected in 22,3% of candidates and was signiﬁcatively higher in
men (<10−4). Anti-HBc was isolated in 5% of candidates sera. Detection
of HBV-DNA was performed in 77 cases (with anti-HBs lower than
5mUI/ml) and was positive in two cases (2,5%) by the three PCR assays.
Sensitivity of HBV-DNA detection was 103 copies/ml.
Conclusion: Occult hepatitis B can be misdiagnosed by selective HBsAg
screening in ART candidates. This can lead to a lack of appropriate
prophylaxis in couple and in newborns. Anti-HBc antibody should
be tested routinely before ART procedures especially in a country of
intermediate endemicity for HBV infection.
P2230 Thyroid dysfunction related to pegylated interferon-a and
ribavirin treatment for HCV hepatitis
C. Popescu*, V. Arama, R. Moroti, A. Hristea, V. Molagic,
G.A. Popescu, I. Olaru, R. Nastase, D. Munteanu, M. Radulescu,
R. Mihailescu, M. Ion, I. Niculescu, R. Geanta (Bucharest, RO)
Pegylated interferon-alfa (IFN) is well known to cause both hyper- and
hypothyroidism.
Objective: To evaluate the prevalence and predictive factors for the
development of thyroid dysfunction in patients treated with IFN and
ribavirin for HCV hepatitis.
Methods: Prospective cohort study in patients treated with IFN for HCV
hepatitis. All patients were monitored every three months for: thyrotropin
(TSH), free tetraiodothyronine (FT4), free triiodothyronine (FT3), anti
thyroperoxidase antibodies (ATPO) and anti thyroglobulin antibodies
until the completion of treatment and then at 3 and 6 months during the
follow-up period. The patients with previous positive ATPO antibodies
were monitored for TSH, monthly.
Results: 83 patients have met the inclusion criteria. 19 patients
developed thyroid dysfunction (22.89%). 8 patients developed hyperthy-
roidism and 11 developed hypothyroidism. The mean age was similar in
both groups of patients (with vs. without thyroid disorders: 43.35 years
vs 48.12 years). Sex ratio for patients with thyroid disorders was F:M −
8.5:1 (sex ratio in control group was F:M= 1.56:1). The relative risk
for female gender to develop thyroid disorders was 4.25 (1.06; 17.12).
ATPO antibodies were present before the initiation of antiviral treatment
in 8 patients (9.63%) and 7 of them developed hypothyroidism (pyates =
0.00003, RR= 5.47 (3.06; 9.78)). All the patients with hyperthyroidism
had previous negative ATPO antibodies (pyates = 0.04, RR= 2.40 (1.23;
4.69)); the hyperthyroidism seems to be caused by a non-autoimmune
destructive thyroiditis. 5 patients with hypothyroidism and 3 patients with
hyperthyroidism had severe clinical manifestations. For 2 patients with
hypothyroidism the IFN was temporary stopped. 6 patients developed
subclinical thyroiditis.
Conclusions: Female gender and positive ATPO antibodies are risk
factors for the development of thyroid dysfunction during interferon
therapy. TSH level should be monitored monthly especially in patients at
risk for thyroiditis Early detection and therapy of thyroiditis are important
in order to avoid discontinuation of IFN treatment.
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P2231 Hepatitis A and HIV co-infection
A. Infante*, E. Clavijo, A. Gutierrez, I. Viciana, M. Ortega,
M.A. Sanchez (Malaga, ES)
Objectives: To describe the clinical and epidemiological characteristics
of patients diagnosed with acute Hepatitis A and HIV coinfection in the
HCU Virgen de la Victoria in Malaga over a period of 5 years.
Methods: A retrospective study of cases of Hepatitis A from January
2006 to December 2010. Sex, age, health center of origin, nationality,
risk factor for transmission, coinfection with HIV and admission to
the hospital were analyzed:. The diagnosis was made by detection of
IgM anti-HAV and anti-HIV by ELISA (Dia Sorin®) and the statistical
analysis was performed using SPSS 15.0.
Results:We obtained a total of 419 positive (2.4%) of the 17163 samples
studied, with a reference population of 450,000 people; we estimated
that it has remained stable throughout the study period. 69% were men
with a mean age of 28.9±13.9 years (range 2−84). The patients came
from 4 health centers (11.9% of Alhaurin el Grande, 10% Tiro Picho´n,
10% Cruz Humilladero and 9.7% Torremolinos) varying the distribution
depending on the year (Table 1). 92,6% of patients were of Spanish
nationality. The main transmission factor risk were: contact with HAV-
infected (fecal-oral route) (17.2%), followed by travelling to endemic
areas (3.3%), sexual risk (3, 1%) and others (seafood consumption,
IVDU, piercing, . . . ) (2.8%). 24.3% needed to be hospitalized.
It was developed an intervention program on immunization of groups
with risk practices given the progressive increase in reported cases until
2009.
Conclusions:
– The infection predominates in men with a middle age of 29 years
been hospitalized a quarter of them.
– The increase in the number of cases of Hepatitis A until 2009 was
followed by a decrease in the last year, since the intervention program
was developed.
– In 2006–2009 a progressive increase in the number of cases coinfected
with HIV in Torremolinos was observed.
P2232 Quantitative determination of HCV core antigen: a marker
for monitoring hepatitis C viraemia
K. Ergunay, B. Sener*, A. Alp, J. Karakaya, G. Hascelik (Ankara, TR)
Objectives: Detection of Hepatitis C Virus (HCV) Core antigen (Ag)
has recently been suggested as a new marker of viral replication for
monitoring the efﬁciency of antiviral therapy. Furthermore, HCV Core
Ag assay has demonstrated the potential to be employed in blood donor
screening as well. In this study, the correlation of HCV RNA levels and
HCV core Ag has been evaluated in HCV-infected individuals at a major
university hospital in Ankara, Turkey.
Methods: A total of 207 plasma samples with detectable HCV RNA were
evaluated for HCV core Ag levels. HCV RNA levels were determined
via a commercial real-time PCR system (COBAS Ampliprep-COBAS
Taqman, Roche Diagnostics, Germany) and HCV Core Ag was
investigated quantitatively with a new generation commercial ELISA
assay (ARCHITECT HCV Core antigen assay, Abbott, USA). The
correlation of viral RNA and core Ag levels were evaluated via Pearson
correlation coefﬁcient.
Results: The distribution of HCV RNA levels in the samples were
given as follows: 18 (<102 IU/ml), 28 (102–103IU/ml), 19 (103–104
IU/ml), 142 (>104 IU/ml). Three samples (16.7%) were reactive for
core Ag in the <102 IU/ml group where core Ag detection rates of
25% (7/28), 63.2% (12/19) and 94.4% (134/142) were noted for viral
load levels of 102–103, 103–104 and >104 IU/ml groups, respectively.
After logarithmic conversion, the overall agreement between viral load
and core Ag levels were calculated to reveal a high correlation (r:0.937).
which was statistically signiﬁcant (p< 0.001). The scatter graph for HCV
RNA and core Ag were given in Figure.
Conclusion: In patients with active viral replication, as identiﬁed via
detectable viral RNA, HCV core Ag detection is a less labor-intensive
and cost-effective alternative to nucleic acid testing. The use of HCV
core Ag quantiﬁcation seems to constitute a new assay which will
enhance individual patient management and diagnostic decision-making.
P2233 Sero-prevalence study of HBsAg among pregnant women
in Albania
M. Goga*, A. Manaj, S. Leli, O. Hoxhaj, N. Pepi, A. Barbullushi,
A. Bulo, M. Dede, E. Shehu, A. Harxhi (Tirana, AL)
Objectives: This study aims to determine the sero-prevalence of
Hepatitis B surface antigen (HBsAg) among pregnant women in Tirana,
Albania and to identify the target group for perinatal post exposure
prophylaxis.
Methods: A total of 6000 pregnant women who attended the antenatal
clinic at Obstetric Gynecologic University Hospital, Tirana, Albania from
January till September 2010 were included in the study. The age range
was 15 till 43 years. Blood samples in gel tubes were drown, centrifuged
and worked with serum. HBsAg test was done using ELISA method with
SIRIUS.
Results: The overall prevalence of sero-positive HBsAg among pregnant
women was 6.8% (410 positive cases out of 6000 tested). According to
age group, the number and percentage of HBsAg positive cases were:
20 years, 12 out of 250 tested (4.8%), 21−30 years, 283 out of 3940
tested (7.2%), 31−40 years, 106 out of 1710 tested (6.2%), and >40
years, 9 positive out of 100 cases tested (9%).
Conclusions: Even that we can not generalize these ﬁndings to the
general population, these are consistent with data shown in other studies,
suggesting that Albania falls in the intermediate endemicity WHO
category for hepatitis B. Besides routine infant immunization which was
introduced in mid 90’ in the country, other preventive measures such as
targeted adult vaccination and screening of pregnant women should be
considered.
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P2234 Multicentre trial of the new Siemens HBsAgII assays for
qualitative detection of HBs antigen on the ADVIA Centaur
systems
E. Saxton, K. Schwarz, S. Froehlich, S. Patibandla, B. Weissbrich,
J. Verheyen* (Tarrytown, US; Marburg, DE; Wu¨rzburg, Cologne, DE)
Objectives: The ADVIA Centaur HBsAgII assay is an in vitro sandwich
chemiluminometric immunoassay for qualitative detection of hepatitis B
surface antigen (HBsAg) in human serum and plasma using the ADVIA
Centaur System. The assay may be used in conjunction with other
serological and clinical information to diagnose individuals with acute
or chronic hepatitis B infection, and as a screen for hepatitis B infection
in pregnant women to identify neonates at risk of acquiring hepatitis B
during the perinatal period. This study compared assay performance and
concordance to established commercial assays.
Methods: Assay sensitivity and speciﬁcity were evaluated at two
independent sites. Two kit lots were used at each site to test a total
of 5689 fresh and frozen samples from HBV-infected, blood donor, and
hospitalized patient populations. HBV+ samples comprised genotypes
A−E, multiple subtypes, and mutations. Twenty seroconversion panels
(202 individual samples) were evaluated between both sites and lots,
and compared to the Abbott Architect HBsAg assay. Ten additional
seroconversion panels were tested by Siemens Healthcare Diagnostics
and compared to supplier data for Abbott AxSYM and PRISM systems.
For all studies, ADVIA Centaur results 1.00 index are positive; <1.00
index are negative. Samples with discordant results between methods
were retested in duplicate and subjected to conﬁrmatory assays on both
systems.
Results: For donor and hospitalized patient samples, ﬁnal ADVIA
Centaur results were compared against disease classiﬁcation according
to the Abbott Architect, with retesting and conﬁrmatory testing where
needed (only two results were discordant). The assay detected all
genotypes, subtypes, and mutations tested. Overall sensitivity was 100%.
Speciﬁcity was 99.51% upon initial testing, 99.91% after retesting, and
100% after conﬁrmatory testing. Eleven of the 20 seroconversion panels
were reactive at the same bleed for the ADVIA Centaur and Architect
assays and 9 were reactive one bleed date earlier using the ADVIA
Centaur assay. For the remaining 10 panels, there was no difference in
reactivity between ADVIA Centaur and PRISM assays for 8/8 panels,
while for 5/8 panels, ADVIA Centaur was reactive 1 to 2 bleed dates
earlier than the AxSYM.
Conclusions: The ADVIA Centaur HBsAgII assay meets the common
technical speciﬁcations (CTS) requirements for sensitivity and speciﬁcity
and is comparable to several commercially available predicate assays.
P2235 The evaluation of the ELISA kit “DS-EIA-anti-HCV-
SPECTR-GM” as supplemental assay for conﬁrmation of
anti-HCV screening positive results
G. Bochkova*, S. Fomina, V. Puzyrev, A. Obriadina, A. Burkov,
T. Ulanova (Nizhny Novgorod, RU)
Introduction: The new kit “DS-EIA-anti-HCV-SPECTR-GM” for the
detection of antibodies to separate proteins of hepatits C virus in human
blood serum or plasma and for the conﬁrmation of anti-HCV screening
assay results was developed. The recombinant antigens comprising only
diagnostically relevant regions of different variants of native HCV
proteins were selected.
Aim: The evaluation of the ELISA kit “DS-EIA-anti-HCV-SPECTR-
GM”.
Objectives and Methods: The various sequences of recombinant
antigens comprising HCV Core, NS3, NS4, NS5 were separately
adsorbed on the plate. Diagnostic value of the assay was studied by
testing 1004 anti-HCV positive samples of patients with conﬁrmed
hepatitis C diagnosis, including 338 samples with determined genotype
1−6; samples of 18 commercial seroconversion panels (BBI Inc.,
ZeptoMetrix), samples of the “Anti-HCV Mixed Titer Performance Panel
BBI PHV 206” (BBI Inc.). Additionally sera samples of patients with
acute (n = 30) and chronic (n = 439) hepatitis C were studied for the
clinical efﬁciency assessment.
Diagnostic speciﬁcity was studied by testing samples of healthy blood
donor (n = 1657), clinical patients (n = 1225), pregnant women (n = 887).
Results: Out of 127 samples from 18 tested seroconversion panels
the “DS-EIA-ANTI-HCV-SPECTR GM” assay conﬁrmed 50 samples
(39.4%) as positive and 22 samples (17.3%) as indeterminate. The kit of
comparison (immunoblot “DECISCAN HCV Plus”, Bio-Rad) detected
35 (27.56%) seroconversion samples as positive and 37 (29.13%)
samples as indeterminate. In 21 samples with an indeterminate result
HCV-RNA was detected. The diagnostic sensitivity of the new kit at
testing anti-HCV positive samples from patients with acute and chronic
hepatitis C and samples with different genotypes was 100%. All samples
from “Anti-HCV Mixed Titer Performance Panel BBI PHV 206” were
detected by “DS-EIA-ANTI-HCV-SPECTR GM” in according to panel
data sheet. The study also showed high speciﬁcity of the kit “DS-EIA-
ANTI-HCV-SPECTR GM”.
Conclusion: The optimal selection of highly immunoreactive epitopes
of various HCV-proteins used in the kit allows signiﬁcantly reduce
indeterminate results and by that to increase the reliability of hepatitis C
diagnostics.
P2236 Assessment of a new Liaison® XL automated immunoassay
for the quantitative and highly speciﬁc detection of HBsAg
in human serum/plasma
F. Capuano*, V. Anro`, M. Petruzziello, S. Enrietti, L. Pallavicini
(Saluggia, IT)
Objective: The aim of the work was to develop and assess a highly
speciﬁc quantitative immunoassay for HBsAg detection in human serum/
plasma, capable of recognition of all mutants, to be used on the new
LIAISON® XL analyzer. Quantitative HBsAg determination has been
recently suggested as predictor of response to anti-HBV treatment.
Methods: The quantitative detection of Hepatitis B virus surface antigen
is a two-step sandwich chemiluminescence immunoassay (CLIA).
Comparable sensitivity for detection of different mutants and genotypes
is assured by mouse monoclonal antibodies directed to highly conserved
epitopes of HBsAg inner region that can detect HBsAg when used
in combination with a complex detergent mixture. Mouse monoclonal
antibodies are used for coating magnetic particles. A mixture of mouse
monoclonal antibodies recognizing different epitopes, labeled with an
isoluminol derivative, is used to detect HBsAg present in calibrators,
samples or controls. The analyzer automatically calculates the HBsAg
concentration (as IU/mL) and grades the results.
Results: 5,201 serum and plasma specimens collected in two blood
banks were run. The assay showed 99.88% diagnostic speciﬁcity at
screening and 99.98% after retest of initially reactive samples. 911
specimens from hospitalized patients, dialysis patients, pregnant women,
high-risk subjects, and another population of 2,000 specimens from a
laboratory routine, were also tested obtaining a diagnostic speciﬁcity
of 99.78% and 100% respectively. The assay showed 100% diagnostic
sensitivity by testing a panel of 10 recombinant mutants and 424
specimens from preselected HBsAg positive patients (86 of whom with
deﬁned HBsAg subtypes). 32 seroconversion panels were also evaluated
in comparison CE-marked HBsAg assays. The results show that the
LIAISON® XL Murex assay detected HBsAg one bleed earlier in ﬁve
out of 32 panels and one bleed later in two out of 32 panels. Both assays
exhibited equivalent HBsAg detection in 25 out of 32 panels.
Conclusions: The LIAISON® XL Murex HBsAg Quant assay shows
high analytical performance in the quantitative determination of HBsAg
in serum/plasma specimens. The test has to be performed on the
LIAISON® XL analyzers only. Additional investigations with clinical
samples should support algorithm deﬁnition with this quantitative
application.
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P2237 The serological proﬁle of the samples with HBsAg concentra-
tion below detection limit of best currently available EIA kits
N. Egorova*, S. Igolkina, I. Pyrenkova, I. Sharipova, V. Puzyrev,
A. Obriadina, A. Burkov, T. Ulanova (Nizhny Novgorod, RU)
Objectives: The aim of the study was to characterize the serological
proﬁle of the samples tested as HBsAg negative by the best available
tests with sensitivity 0.05−0.1 IU/ml (Second International Standard for
HBsAg subtype adw2, genotype A, NIBSC code number: 00/588). All
these samples were HBsAg-positive by the EIA with sensitivity 0.01
IU/ml DS-EIA-HBsAg-0.01.
Methods: Different samples cohorts (n = 307) tested as HBsAg negative
by the currently available assays with sensitivity 0.05−0.1 IU/ml were
analysed. The presence of HBsAg in these samples was estimated by
DS-EIA-HBsAg-0.01 and conﬁrmed by neutralization. All specimens
containing HBsAg were characterized for HBV-speciﬁc serological
markers.
Results: Among anti-HIV positive samples (n = 172) 14 were detected
as HBsAg positive by the EIA kit with sensitivity 0.01 IU/ml. Out of
14 specimens 12 contained HBV DNA. 1 HBV DNA-negative sample
shown presence of anti-HBc, anti-HBc-IgM and anti-HBe, another
contained anti-HBc.
Out of 72 isolated anti-HBc-positive specimens 12 were HBsAg-reactive
in EIA kit with sensitivity 0.01 IU/ml. Out of 12 samples 4 were anti-
HBc-IgM positive.
Other 63 samples from different cohorts (the primary asymptomatic
blood donors (accidental selection), clinical patients, pregnant women,
patients infected with various bacteria and viruses) previously detected
as HBsAg-negative were positive for HBsAg by DS-EIA-HBsAg-0.01.
21 samples of them were positive for anti-HBc. The serological proﬁle of
7 samples (anti-HBc and anti-HBe positive, anti-HBc-IgM and anti-HBs
negative) is compatible with that of an HBV carrier. 2 samples showed
the serological proﬁle of acute HBV infection (anti-HBc and anti-HBc-
IgM positive, anti-HBe, HBeAg and anti-HBs negative). The serological
markers of 1 sample was compatible with that of acute HBV infection
with active replication (anti-HBc, anti-HBc-IgM and HBeAg positive,
anti-HBe and anti-HBs negative). 2 samples showed the serological
proﬁle of an aggravation of a chronic HBV infection (anti-HBc, anti-
HBc-IgM and anti-HBe positive, HBeAg and anti-HBs negative). 9
samples from 31 tested for HBV DNA with HBsAg concentration below
0.05 IU/ml were HBV DNA positive.
Conclusion: The enhancement of sensitivity of the currently available
kits for HBsAg detection will allow to reveal HBsAg more effectively in
samples which tested negative now, will improve quality of blood donor
screening and reduce the risk of posttransfusional hepatitis B infection.
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P2238 Human rhinovirus-C: a frequently detected species in adult
haematopoietic stem cell transplant recipients with lower
respiratory tract infection
P. Ferguson*, N. Gilroy, I. Mackay, T. Sloots, M. Nissen, T. Sorrell
(Blacktown, Sydney, Brisbane, Westmead, AU)
A previously unidentiﬁed species of rhinovirus, HRV-C, was detected in
2006, in addition to the two known species A and B. While HRV-C is
associated with lower respiratory tract infection (LRTI) and wheezing
in children, few cases of HRV-C infection have been reported in adults,
and none associated with LRTI.
Objectives: To describe the clinical features of HRV-A, B and C in adult
haematopoietic stem cell transplant (HSCT) recipients.
Methods: A prospective cohort study of 193 adult HSCT recipients
(141 (73%) allogeneic, 52 (27%) autologous) admitted to Westmead
Hospital, Australia, over 27 months (July 1 2005 to September 30 2007)
was undertaken. Respiratory samples (596 nose/throat swabs, 40
bronchoalveolar lavage samples, two sputa) were tested for HRV and 15
other respiratory viruses (RV) by polymerase chain reaction followed by
HRV genotyping. Viral culture and immunoﬂuorescence for inﬂuenza
A&B, parainﬂuenza 1−3, adenovirus, respiratory syncytial virus and
human metapneumovirus were also performed.
Results: HRV was the virus most frequently detected in 32/435 (7.4%)
and 4/205 (2.0%) samples from symptomatic and asymptomatic patients
respectively, with 36 positive results from 23 clinical episodes. Sixteen
of 22 HRV viruses (73%) that were positive by PCR were speciated.
HRV-C was most frequent (nine, 56%), followed by A (ﬁve episodes)
and B (two episodes). All but the two episodes of HRV-B infection were
in allogeneic recipients. Pneumonia was diagnosed in 8/16 episodes (C:
5/9, A: 1/5, B: 2/2). Co-infection with another RV was most common
with HRV-C (C: 4/9, A: nil, B: 1/2). Polyomavirus KI and HRV-C
were present in 3 episodes; adenovirus and HRV-A were present in one.
Wheezing was noted in three episodes of LRTI (2/5 with HRV-C and
1/2 with HRV-B). Two of the patients with wheezing had a history of
asthma. Concomitant bacteraemia and/or candidaemia occurred in three
episodes of HRV-C infection; two of these episodes were fatal. HRV-Cs
were detected in 5/9 cases with LRTI, and were the sole pathogen in
two.
Conclusion: HRV-Cs were detected in adult HSCT recipients with
viral respiratory infection including LRTI, with the worst outcomes
occurring in the presence of co-pathogens. Further evidence is required
to clarify the clinical importance of speciating rhinoviruses in this patient
population.
P2239 Inﬂuenza A virus H1N1v in allogeneic haematopoietic
stem cell transplant recipients: comparison of the antibody
response to monovalent inﬂuenza A/H1N1 vaccine versus
the response in natural infection
P. Ribaud*, N. Le Corre, A. Krivine, B. Lioure, J. Bay, M. Coudert,
M. Rubio, P. Agape, A. Garnier, A. Faugeras, N. Kerbi-Hamimed,
A. Bergeron, J. Le Goff, G. Socie´, N. Milpied, B. Autran, N. Dhe´din
for the Socie´te´ Franc¸aise de Greffe de Moelle et de The´rapie Cellulaire
Background: Vaccination against inﬂuenza is less effective in
hematopoietic stem cell transplant (HSCT) recipients than in the
immunocompetent population. In addition, little is known about the
antibody response in natural infection. The presumed lack of background
antibody against inﬂuenza A (H1N1)v-virus was an opportunity to
compare the antibody response to illness with that observed after
vaccination.
Methods: This prospective study included 90 allogeneic HSCT
recipients aged from 18 to 65 years, either vaccinated with 2, 3-week
interval doses of monovalent inﬂuenza A(H1N1)v vaccine (GrI), or
with PCR positive inﬂuenza A(H1N1)v illness (GrII). H1N1v-speciﬁc
antibody titers were measured by a hemagglutination-inhibition assay, at
days 0, 21 and 42 after the ﬁrst vaccine dose of in GrI patients (pts),
and in both frozen pre-pandemic and post-infection serum in GrII.
Results: 70 pts were included in GrI and 20 in GrII. In GrI,
59 pts received an adjuvanted vaccine (GrIAdj+) and 11 a non-
adjuvanted vaccine (GrIAdj−). There were no signiﬁcant differences in
characteristics (pts) according to the group (sex, type of conditioning
regimen, source of stem cells, type of donor, incidence of acute- or
chronic graft-versus-host disease (GVHD)). GrII pts were younger. The
time interval between HSCT and infection was longer than between
HSCT and vaccination. The percentage of seroprotection (1/40) at day
42 after vaccine, or post infection, was similar in the 3 groups: 66%,
50% and 60% in GrIAdj+, GrIAdj− and GrII respectively (p = 0.59). The
ratio of geometric mean titers (RGMT) at day 42/day 0 of vaccination
or pre/post infection were 13.6, 3 and 9.1 in GrIAdj+, GrIAdj− and
GrII respectively, with a signiﬁcant difference between GrIAdj+ and
GrIAdj− (0.04). In the multivariate analysis, 3 factors were associated
with higher rate of post-infection/second vaccine seroprotection: a longer
time interval between HSCT and vaccination/infection, the absence of
chronic GVHD and a myeloablative conditioning regimen (p< 0.05).
RGMT were correlated with the same factors (p< 0.05).
Conclusions: (1) More than half of the HSCT recipients reach a sero-
protective hemaglutination titer after natural infection. (2) An equivalent
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response is obtained after 2 doses of vaccine. (3) Moreover, adding an
adjuvant improves the efﬁcacy of the vaccine.
P2240 Development of quinolone-resistant Escherichia coli bacter-
aemia in neutropenic cancer patients receiving quinolone
prophylaxis: data from a high-resistance prevalence setting
P. Zarakolu, S. Etgul, O. Kara, S. Ascioglu, Y. Buyukasik, M. Akova*
(Ankara, TR)
Objectives: Quinolone prophylaxis (QP) is commonly used in neu-
tropenic cancer patients (NCPs) to prevent bacteremia. However, this
practice has been criticized to increase colonization with quinolone-
resistant Escherichia coli (QREC). We recently showed in our institution
that the rate of quinolone resistance (QR) in E. coli bacteremia is 58%
in NCPs. Current study attempts to evaluate the role of QP on both
colonization and infection with QREC in such a high-resistance setting.
Methods: Between November 2009-December 2010 perirectal swab
specimens from 53 NCPs with 105 episodes of neutropenia were taken
at ﬁrst admission before QP and then repeated after QP, once weekly,
for 3 weeks. All patients received 500mg levoﬂoxacin, irrespective of
their colonization status. Quinolone prophylaxis was continued until
fever ensued or recovery of neutropenia. MacConkey agar (Oxoid,
UK) containing 1 microgr/ml ciproﬂoxacin was used for screening and
API 20E (BioMerieux, France) for identiﬁcation. Quinolone resistance
was determined by disk diffusion method according to CLSI criteria.
Blood cultures were taken to identify a presumable bacteremia in febrile
patients.
Results: Of the 53 patients, 24 (45%) had QREC colonization at ﬁrst
admission before QP. Among 29 patients that were not colonized initially,
16 (55%) developed QREC colonization after prophylaxis. Bacteremia
(all with QREC) was detected in 4 patients (7%), of whom 3 had been
colonised at ﬁrst admission and 1 after prophylaxis. None of the patients
without colonization developed bacteremia.
Conclusion: In this pilot study, we found a very high rate of colonization
in our patient population (75% in total) after QP. The low rate of
bacteremic episodes may indicate suppression of Gram-negatives by
QP. However, the fact that all these infections were by QREC and
signiﬁcant increase in colonization by this bacteria after prophylaxis
seem to counterbalance this protective effect.
P2241 Enterobacter bacteraemia in adult patients with solid
tumours at a tertiary care cancer centre in Japan
K. Okinaka*, Y. Hadano, J. Suzuki, I. Kawamura, H. Kurai, T. Sato,
N. Ohmagari (Shizuoka, Yamagata, JP)
Objectives: Very few studies have been carried out on the characteristics
of Enterobacter bacteraemia in adult patients with solid tumours. Based
on our experience, we reviewed the characteristics of Enterobacter
bacteraemia in adult patients with solid tumours as compared with those
in other populations reported previously.
Methods: We reviewed the hospital records of adult patients with
solid tumours whose blood cultures yielded Enterobacter species at
the Shizuoka Cancer Centre (569-bedded tertiary care cancer centre in
Japan) from September 1, 2002, through December 31, 2009.
Results: Seventy-six positive blood cultures were documented in 71
patients (Enterobacter aerogenes 25, E. cloacae 47, E. sakazakii 1,
Enterobacter sp. 3). Fifty episodes were associated with hepatobiliary
problems (related to biliary drainage in 22, hepatic metastasis in 14,
pancreatic tumour in 13, and cholangiocarcinoma in 12 episodes).
Among the 58 episodes for which the sites of infection could be
documented, the most common site was intra-abdominal (29 episodes
[cholangitis 19, hepatic abscess 6, abdominal abscess 4]). E. aerogenes
was associated more frequently with intra-abdominal infection than
E. cloacae (E. aerogenes 15 out of 25 [60.0%] vs. E. cloacae 13 out of 47
[27.7%], odds ratio, 3.92; 95% conﬁdence interval, 1.4–10.9; P< 0.01).
Isolates of Enterobacter species from 18 of the episodes were resistant
to b-lactams and/or quinolones. The 18 episodes included 16 of the
51 (31.4%) for which antimicrobials had been administered within the
previous 4 weeks and 2 of the 25 (8.0%) for which no antimicrobials had
been administered within the previous 4 weeks (odds ratio, 5.26; 95%
conﬁdence interval, 1.1–25.0; P = 0.02). Twenty-one out of 71 patients
(29.6%) died within 30 days (21 out of 76 episodes [27.6%]).
Conclusion: Enterobacter bacteraemia in adult patients with solid
tumours may be associated with problems in the hepatobiliary system.
Careful consideration is needed when selecting antimicrobials for
empiric therapy of Enterobacter bacteraemia, because of the high
frequency of drug resistance, especially in cases with recent exposure to
antimicrobials.
P2242 Healthcare-associated infection in haematopoietic stem
cell transplantation patients during a ten-year period
(2001–2010)
E. Mendes*, M. Vieira, F. Dulley, M. Basso, T. Guimaraes, S. Costa
(Sa˜o Paulo, BR)
Objectives: Infection remains a major cause of morbidity and mortality
in hematopoietic stem cell transplantation (HSCT) patients.
The aim of this study was to analyze the incidence of and risk factors
for healthcare-associated infection among HSCT patients and the impact
of such infections on mortality during hospitalization.
Methods: We conducted a 10 years (2001–2009) retrospective cohort
study of neutropenic patients submitted to HSCT at a reference Center in
Sa˜o Paulo/Brazil. A database was built using Epiinfo program, variables
with P< 0.01 were selected to multivariate analysis, Kaplan-Meier
Survival was performed to evaluate impact of infection on outcome.
Results: Over the 120-month period there were 476 neutropenic episodes
among 429 patients, with a total of 6,816 neutropenic-days. Of these
patients 358 (75.2%) had undergone allogenic HSCT. BSI (blood stream
infection) was the most frequent infection presented in 86 (18%)
followed by pneumonia in 55 (12%) of the cases. Invasive aspergilosis
was possible in 30 (6%), probable in 12 (3%) and deﬁnite in 6 (1%)
of cases. Most bacteremia were due to Gram-negative bacteria: 45
(52.3%), while 36 (41.9%) were caused by Gram-positive bacteria,
and 5 (5.81%) by fungal species. Among Gram-negative bacteria,
Pseudomonas aeruginosa (22.1%) accounted for the majority of cases.
Risk factors associated with healthcare-associated infection among
HSCT patients by multivariate analysis were prolonged neutropenia,
duration of fever (both with p 0.00001) and allogenic transplant
(p = 0.0001). Being submitted to an allogenic transplant, having a
microbiologic documented infection, invasive aspergilosis disease and
acute leukemias were related with death in multivariate analysis. The
intravascular catheter-related BSI was associated with decreased survival
of patients during hospitalization by Kaplan-Meier Survival (p = 0.01).
Conclusions: The type of the transplant, and the primary diagnoses
are able to select a higher risk population, and the microbiological
identiﬁcation is also an alarm signal. These ﬁndings may have important
clinical implications in decisions relating to treatment. Our results
showed that BSIs play an important hole on the post-transplant outcome,
and also that healthcare-related infections are closely related with
prolonged neutropenia and hospitalization.
P2243 18F-ﬂuorodeoxyglucose positron emission tomography/
computerised tomography (FDG-PET/CT) scanning in
persistent febrile neutropenia: a pilot study
S. Guy*, A. Tramontana, E. Lau, R. Hicks, J. Seymour, K. Thursky,
L. Worth, M. Slavin (Footscray, Melbourne, AU)
Objectives: Febrile neutropenia frequently complicates cancer care, with
evaluation often failing to identify the cause. It is not known whether
FDG-PET CT would be a useful addition to the routine investigations
performed for persistent febrile neutropenia. The aim of this study was
to evaluate the clinical utility of FDG-PET CT in patients with 5 or
more days of persistent fever and neutropenia despite broad spectrum
antibiotic therapy.
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Methods: Adult patients with a diagnosis of an underlying malignancy
and with persistent febrile neutropenia (temperature 38ºC and
neutrophil count <500 cells/ml for 5 days) underwent FDG-PET CT
as an adjunct to conventional evaluation (including clinical, laboratory,
microbiology, molecular and standard imaging tests). FDG-PET CT
results were made available to treating physicians and the impact of the
scan result on patient care was evaluated adapting previously published
criteria.
Results: Twenty highly immunocompromised patients (16 with acute
leukaemia, 4 with other malignancies) fulﬁlled eligibility criteria and
underwent FDG-PET CT scanning in addition to conventional evaluation.
The median neutrophil count on day 5 of the febrile neutropenia episode
was 30 cells/ml (range 0–370 cells/ml) and the median neutrophil
count on the day of the FDG-PET CT scan was 30 cells/ml (range
0–730 cells/ml). The median duration of the febrile neutropenia episode
at the time of FDG-PET CT scan was 7 days (range 5−14 days).
Fourteen distinct sites of infection were identiﬁed by conventional
evaluation and 22 infection sites by FDG-PET CT. Thirteen of 14
(93%) infections diagnosed by conventional evaluation were identiﬁed
by FDG-PET CT, including all deep tissue infections. Nine additional
sites of infection were identiﬁed by FDG-PET CT, 8 of which were
subsequently conﬁrmed “true positives” by further investigations. The
FDG-PET CT scan impacted on patient management for 15 of 20
(75%) patients, prompting surgical review of 3 patients and altering
antimicrobial management in 13 patients, including withholding of
empiric antifungal agents in 5 patients. No adverse events to FDG-PET
CT scanning occurred.
Conclusion: This study supports the usefulness of FDG-PET CT
scanning in severely immunocompromised patients with 5 or more days
of neutropenia and fever. Larger studies evaluating the contribution of
this technique for management of febrile neutropenia are indicated.
P2244 Bacteraemia due to Enterococcus faecium in cancer patients:
clinical features, antimicrobial susceptibility, and outcomes
M. Bodro*, J. Ayats, C. Gudiol, C. Garcia-Vidal, C. Ardanuy, M. Cisnal,
M. Cubero, G. Ortı´, M. Antonio, J. Carratala´ (Barcelona, ES)
Objectives: We aimed to ascertain the characteristics, antimicrobial
susceptibility, and outcomes of bacteremia due to E. faecium in cancer
patients.
Methods: All episodes of E. faecium bacteremia prospectively
documented in a university cancer center from Jan 2006 to November
2010 were included in the study. Antibiotic susceptibility was studied by
a microdilution method (MicroScan®).
Results: We documented a total of 907 episodes of bloodstream
infection. Among 370 episodes of Gram-positive bacteremia (41%),
60 episodes (16%) were caused by Enterococcus spp, and 29 of
them (48,3%) were due to E. faecium. Eighteen patients were male
(62%), mean age 57,8 yrs. (23−83 yrs). Underlying diseases were
hematological malignancies in 23 patients (79%) and solid tumors in
6. Nineteen episodes (65%) occurred in neutropenic patients. The most
common sources of bacteremia were endogenous/unknown origin in
48% of cases, followed by intravascular catheter (21%) and cholangitis
(17%). All patients had previously received two or more antimicrobial
agents, specially cephalosporines and carbapenems. All isolates were
vancomycin and teicoplanin susceptible. One strain was ampicillin
susceptible. All the others strains had high level resistance to ampicillin,
with MIC up to 256 mcg/mL. Rates of high level resistance to
gentamycin and streptomycin were 28.6% and 96.4%, respectively.
Twelve patients (41,%) received inadequate empirical antibiotic therapy,
with cephalosporines in 17 cases, and carbapenems in 17 cases.
Deﬁnitive antibiotic therapy consisted in vancomycin in 17 cases (59%),
teicoplanin in 7 cases (24%) and daptomycin in 3 cases (10%). Among
4 patients (14%) with persistent bacteremia, 3 had catheter-related
infection and 2 had received inadequate empirical antibiotic therapy.
ICU admission was needed in 4 patients. Early mortality (<48 hours)
was 14% and overall mortality (<30 days) was 38%.
Conclusions: E. faecium is a frequent cause of enterococcal bacteremia
in cancer patients, mainly among those with hematological malignancies
and neutropenia. In our institution, most E. faecium strains are highly
resistant to ampicillin but susceptible to glycopeptides. Cancer patients
with bacteremia receive frequently an inadequate empirical therapy and
the infection is associated with high mortality rates. Further studies are
needed to identify risk factors for E. faecium bloodstream infections.
P2245 Description of C. difﬁcile clinical characteristics in
onco-haematological and stem cell transplant patients
J. Gerhardt*, M. Vieira, F. Spada˜o, J. Nobrega, F. Dulley, G. Fonseca,
T. Guimaraes, S. Costa (Sa˜o Paulo, BR)
Objectives: Clostridium difﬁcile accounts for about 15−25% of cases of
antibiotic-associated diarrhea. Patients undergoing haematopoietic stem
cell transplantation (HSCT) appear to be a group at particularly high
risk.
The aim of this study was to evaluate the characteristics of patients
like those in our hospital, and from the suspected cases, the number of
conﬁrmed.
Methods: Evaluation of hospital records of patients with haematholog-
ical malignancies and/or HSCT who presented with clinical diarrhea
and a positive C. difﬁcile toxin stool test assay, from January 2009 to
September 2010.
Results: There were a total of 206 suspected cases of C. difﬁcile infection
(CDI), and 55 with a positive toxin test assay. The records of 40 patients
were reviewed. 67,5% were males, median age 35,5 years old (11−64).
The predominant baseline disease was myeloid leukemia (57,5%). 23
patients were submitted to HSCT: 8 autologous, 15 allogeneic. 12
patients (30%) did not receive large-spectrum antibiotics prior to the
diarrhea episode. 21 (53,5%) were on treatment for febrile neutropenia;
43,2% received carbapenemics, 29,7% piperacillin-tazobactam, 21,6%
colistimethate, 16,2% linezolidIt started within a mean of 11 days
of hospitalization (0−58). Other conditions: 76,9% Enterococcus sp.
vancomycin resistant colonization; 20,5% GVHD; 11% CMV infection;
11% rotavirus infection. Speciﬁc therapy was started in a mean of 2,6
days since the beginning of the diarrhea, and in 10 cases in the same day.
All patients received metronidazole as the ﬁst-line treatment, 2 received
it intravenously; no patient received vancomycin. Response to 7 days
of speciﬁc therapy was divided in 4 categories: resolution of symptoms
(21,4%), partial response (46,4%), no response (28,6%) and worsening
of diarrhea (3,6%). The median time of treatment was 10 days (5−30
days). 75% had resolution of the diarrhea at the end of treatment. Only
one patient had relapse between 30 days. 73% were discharged.
Conclusion: There are few reports of CDI occurring in the setting of
haemathological malignancies/HSCT despite the large antimicrobial’s
use in this population of patients. In the present report not all cases
were preceded by antibiotic therapy, reinforcing the importance of other
risk factors such as chemotherapy. Metronidazole is the only available
drug to treat C. difﬁcile in Brazil, our results show that it still is a useful
drug to treat CDI even in a high risk population such as HSCT.
P2246 The impact of microbiological factors on course and
outcome of febrile neutropenia in paediatric cancer patients
H. El-Mahallawy*, A. Abdulall, S. Lotfy, R. Abdel Hai, L. Shalaby
(Cairo, EG)
Objectives: Over the past decade, it has become evident that neutropenic
cancer patients are not a homogeneous group and practice guidelines
may vary on their risk status. Thus, we aimed in this study to evaluate
the signiﬁcance of a positive blood culture in febrile pediatric cancer
patients with chemotherapy induced febrile neutropenia, and to study
the impact of microbiological factors on clinical course and outcome of
these febrile episodes.
Methods: This prospective cohort study was carried out on febrile
episodes occurring in a large group of pediatric patients with
chemotherapy related neutropenia at National Cancer Institute in
S668 21st ECCMID/27th ICC, Posters
Egypt over a period of one year. The association between underlying
malignancies, age, absolute neutrophil count (ANC), clinical foci of
infection, microbiological documented infection, blood stream infection
(BSI) were analyzed in relation to duration and outcome of episodes.
Results: Among 1229 episodes of fever and neutropenia, bacteremia
was detected in 336 episodes. A lengthy episode was observed in 56
(37%), 90 (62%), 35 (94%) and 160 (18%) of Gram positive BSI,
Gram negative BSI, polymicrobial BSI and non-BSI episodes, with mean
values of 7.6±4.6, 9.4±5.0, 12.7±5.0, and 6.9±4.1days, respectively,
p-value 0.001. Coagulase negative staphylococci were associated with
the least complicated BSIs and Klebsiella spp was associated with the
most severe BSIs. A microbiological documented infection (MDI), other
than BSI, was signiﬁcantly associated with a long episode, p-value 0.001.
The overall mortality rate was 7.5% (n = 55) and was higher among
bacteremic (n = 37/336) patients than those who were not bacteremic
(18/893) (11% versus 2%, p 0.001). In addition, the mortality was
signiﬁcantly higher in Gram-negative and polymicrobial BSI than in
patients with Gram positive BSI, p 0.001. Among clinical foci of
infection, lower respiratory tract infection was signiﬁcantly associated
with BSI and an unfavorable outcome with a relative risk and 95%CI
of 2.8 (1.8−4.5) and 6.3 (3.5–11.4), respectively.
Conclusion: Microbiological factors profoundly inﬂuence the clinical
course and outcome of infection in pediatric cancer patients with
chemotherapy induced febrile neutropenia. Continuous multidisciplinary
surveillance of BSI is warranted in this group of patients in order to
develop strategies for antimicrobial resistance control and treatment of
infectious complications.
P2247 Outcome after a long-term intravenous catheter-related
bacterial infection in oncology: results from a prospective
monocentric study
D. Lebeaux*, V. Zarrouk, B. Larroque, V. Leﬂon-Guibout, C. Dreyer,
S. Bialek, A. Froissart, O. Hentic, C. Tessier, B. Fantin (Clichy, FR)
Objectives: Long term intravenous catheter (LTIVC)-related infections
in oncology are responsible for their own morbidity and mortality but
no prospective data are available to quantify them.
Methods: We conducted a prospective monocentric observational study
and included all patients with solid cancer who experienced a LTIVC-
related infection (deﬁned according to the Infectious Diseases Society
of America guidelines) between February 1st 2009 and February 1st
2010. Variables of interest were prospectively collected and patients
were prospectively followed during 12 weeks. Main endpoints were:
prevalence and factors associated with severe sepsis and septic shock,
mortality at week 12 and delay or cancellation of antineoplastic
chemotherapy.
Results: Forty-two episodes of LTIVC-related infections were included
(mean age, 59.7 years (± 13.6)). Mean Charlson comorbidity index
(CCI) and Karnofsky index were respectively 62.6 (± 17.6) and 6.8
(± 2.7). All but one patients were carrying a totally implantable
access port catheter. Among 48 microorganisms, 44% were coagulase
negative staphylococci (CoNS) (21/48), most of them being methicillin
resistant (62%). Eleven patients (11/42, 26%) exhibited local signs
with 5 complications leading to LTIVC removal (tunnel or port pocket
infection).
At diagnosis of infection, prevalence of complications were 19% for
severe sepsis or septic shock (8/42 patients), 38% for death at week
12 (16/42 patients) and 30% for deﬁnitive cancellation of antineoplastic
chemotherapy (8/27 patients). Mean delay of antineoplastic chemother-
apy was 14 days (± 7.7). Main factor associated with severe sepsis
or septic shock was an elevated C-reactive protein (CRP) level; three
episodes (3/8, 37.5%) were due to CoNS. Factors associated with death
at week 12 were a limited autonomy, an elevated CCI, the metastatic
evolution of cancer and an elevated CRP level. Among cases of catheter-
related bloodstream infections during wich catheters were removed,
sensibility of catheter tip and port cultures were comparable and similarly
inﬂuenced by antibiotic pretreatment.
Conclusion: Patients’ overall condition (co morbidities and autonomy)
and elevated CRP level were associated with an unfavourable clinical
outcome after an intravenous catheter-related infection. Co-NS, in this
setting, may be responsible for severe sepsis or septic shock.
P2248 Antibacterial prophylaxis for patients receiving high-dose
chemotherapy with autologous haematopoietic stem cell
transplantation: a randomised-placebo controlled trial on
the efﬁcacy and safety of moxiﬂoxacin
J. Vehreschild, G. Moritz, M.J. Vehreschild, D. Arenz, M. Mahne,
H. Bredenfeld, J. Chemnitz, F. Klein, B. Cremer, B. Bo¨ll, I. Kaul,
M. Hallek, C. Scheid, G. Wassmer, O.A. Cornely* (Cologne, DE)
Patients receiving high-dose chemotherapy with autologous peripheral
blood stem cell transplantation (PBSCT) are at a high risk of infections,
especially bacteremia.
We performed a prospective, double-blind, randomized, placebo-
controlled, single-centre pilot study on oral moxiﬂoxacin 400mg
versus placebo for preventing bacteremia in PBSCT recipients. Patients
received moxiﬂoxacin or placebo for the duration of neutropenia or
until emergence of fever or other infections necessitating intravenous
antibiotic treatment.
Of 68 patients included into the trial, two were removed from the
trial before taking their ﬁrst dose. The remaining 66 patients were
eligible for evaluation in the intention-to-treat analysis set. Neutropenia
with neutrophil counts <500/ml developed in 30 (88.2%) and 21
(65.6%), respectively (P< 0.03). Ten (29.4%) and 8 (25%) patients,
respectively, were prematurely discontinued from study treatment (NS).
Breakthrough bacteremia occurred in 3 (8.8%) and 9 (28.1%) of the
study patients, respectively (P = 0.042). The amount of days without fever
was 9.5 (95%CI: 8.06–10.94) and 7.69 (95%CI: 6.51–8.85), respectively
(P = 0.0499). There was no signiﬁcant increase of adverse events or
toxicities in the moxiﬂoxacin group.
Moxiﬂoxacin is a well-tolerated and effective drug for preventing
bacteremia and shortening febrile episodes in patients receiving
autologous PBSCT.
